gemcitabine has been researched along with deoxycytidine in 11568 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.01) | 18.7374 |
| 1990's | 543 (4.69) | 18.2507 |
| 2000's | 3950 (34.15) | 29.6817 |
| 2010's | 5745 (49.66) | 24.3611 |
| 2020's | 1329 (11.49) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, H; Furman, PA; McBrayer, TR; Micolochick Steuer, HM; Murakami, E; Obikhod, A; Otto, MJ; Ramesh, M; Schinazi, RF; Stuyver, LJ; Whitaker, T | 1 |
| Björck, L; Clausen, AR; Piskur, J; Sandrini, MP; Shannon, O | 1 |
| Singhal, RL; Szekeres, T; Weber, G; Yeh, YA | 1 |
| Fukuoka, M; Matsui, K | 1 |
| Ban, J; Weber, G | 1 |
| Baker, L; Corbett, T; Flaherty, L; Poplin, EA; Redman, BG; Tarasoff, P; Valdivieso, M | 1 |
| Plunkett, W; Xu, YZ | 1 |
| Abbruzzese, JL; Daugherty, K; Moore, DF; Pazdur, R; Tarassoff, P | 1 |
| Huang, P; Plunkett, W | 3 |
| Grindey, GB; Rockwell, S | 1 |
| Degen, D; Grindey, GB; Hanauske, AR; Hilsenbeck, SG; Marshall, MH; Von Hoff, DD | 1 |
| Fujita, H; Okamoto, M | 1 |
| Hertel, LW; Kroin, JS; Richardson, FC; Richardson, KK | 1 |
| Bhalla, K; Bullock, G; Holladay, C; Ibrado, AM; Jasiok, M; Lutzky, J; Singh, S | 1 |
| Nakamura, T; Ueda, T | 1 |
| Brown, TD; Burris, HA; Havlin, KA; O'Rourke, TJ; Rodriguez, GI; Wall, JG; Weiss, GR | 1 |
| Chubb, S; Grindey, GB; Hertel, LW; Huang, P; Plunkett, W | 1 |
| Chubb, S; Grindey, GB; Heinemann, V; Hertel, LW; Plunkett, W; Sen, A; Xu, YZ | 2 |
| Du, M; Faucher, K; Grunewald, R; Kantarjian, H; Plunkett, W; Tarassoff, P | 1 |
| Gandhi, V; Heinemann, V; Huang, P; Plunkett, W; Xu, YZ | 1 |
| Noordhuis, P; Peters, GJ; Ruiz van Haperen, VW; Veerman, G; Vermorken, JB | 1 |
| Bouffard, DY; Momparler, LF; Momparler, RL | 1 |
| Braakhuis, BJ; Snow, GB; van Dongen, GA; Vermorken, JB | 1 |
| Abbruzzese, JL; Grunewald, R; Plunkett, W; Tarassoff, P | 1 |
| Abbruzzese, JL; Adams, T; Gravel, D; Grunewald, R; Mineishi, S; Nowak, B; Raber, MN; Satterlee, W; Tarassoff, P; Weeks, EA | 1 |
| Abbruzzese, J; Grunewald, R; Kantarjian, H; Keating, MJ; Plunkett, W; Tarassoff, P | 1 |
| Gandhi, V; Plunkett, W | 1 |
| Boder, GB; Grindey, GB; Hertel, LW; Kroin, JS; Poore, GA; Rinzel, SM; Todd, GC | 1 |
| Grindey, GB; Hertel, LW; Plunkett, W | 1 |
| Grindey, GB; Heinemann, V; Hertel, LW; Plunkett, W | 1 |
| Heinemann, V; Issels, RD; Plunkett, W; Schulz, L | 1 |
| Cuddy, DP; Ross, DD | 2 |
| Gandhi, V; Grunewald, R; Heinemann, V; Huang, P; Plunkett, W; Xu, YZ | 1 |
| Eriksson, S; Peters, GJ; Ruiz van Haperen, VW; Stegmann, AP; Veerman, G | 1 |
| Boven, E; Braakhuis, BJ; Peters, GJ; Ruiz van Haperen, VW; Veerman, G | 1 |
| Csoka, K; Larsson, R; Liliemark, J; Nygren, P | 1 |
| Chapman, AJ; Chubb, S; Gandhi, V; Hertel, LW; Huang, P; Mineishi, S; Nowak, BJ; Plunkett, W; Yang, Y | 1 |
| Lawrence, TS; Shewach, DS | 4 |
| Bergman, AM; Braakhuis, BJ; Kuiper, CM; Peters, GJ; Ruiz van Haperen, VW; Veerman, G | 1 |
| Chapman, AJ; Chen, F; Chubb, S; Gandhi, V; Hertel, LW; Huang, P; Mineishi, S; Nowak, B; Plunkett, W; Yang, Y | 1 |
| Roth, BJ | 1 |
| Sørensen, JB | 1 |
| Ettinger, DS | 3 |
| Beykirch, M; Carmichael, J; Harris, AL; Kerr, H; Phillip, P; Possinger, K; Walling, J | 1 |
| Neijt, JP | 1 |
| Verweij, J | 1 |
| Esumi, Y; Gunji, S; Ishizaki, M; Kawai, M; Seki, H | 1 |
| Bergman, AM; Kuiper, CM; Peters, GJ; Ruiz van Haperen, VW; Veerman, G | 2 |
| Bakker, PJ; Geerdink, A; Haveman, J; Rietbroek, RC; Van Rijn, J | 1 |
| Klastersky, J | 1 |
| Niitani, H | 1 |
| Burris, HA; Eckardt, JR; Fields, S; O'Rourke, T; Rodriguez, GI; Rothenberg, ML; Weiss, GR | 1 |
| Grant, SC; Kris, MG; Miller, VA; Pisters, KM; Rigas, JR | 1 |
| Allerheiligen, SR; Anliker, S; Dhahir, PH; Freeman, KB; Hamilton, M; Nelson, R; Osborne, D | 1 |
| Fukuoka, M; Yoshikawa, A | 1 |
| Esumi, Y; Kawai, M; Mitsugi, K; Seki, H; Takao, A | 2 |
| Anderson, H; Dombernowsky, P; Lund, B; Petersen, PM; Ryberg, M; Thatcher, N | 1 |
| Bajorin, DF; Roth, BJ | 1 |
| Calabresi, F; Ceribelli, A; Crecco, M; Pollera, CF | 2 |
| Nightingale, SL | 1 |
| Eisenhauer, EA; Hansen, HH; Hansen, M; Neijt, JP; Piccart, MJ; Sessa, C; Thigpen, JT | 1 |
| Bruntsch, U; Catimel, G; Clavel, M; de Mulder, P; Judson, I; Piccart, M; Sessa, C; Vermorken, JB; Verweij, J; Wanders, J | 1 |
| Hansen, M; Hansen, OP; Lund, B; Neijt, JP; Theilade, K | 2 |
| Findenig, G; Fritzer, M; Lhotka, C; Schön, HJ; Szekeres, T | 1 |
| Boven, E; Noordhuis, P; Peters, GJ; Ruiz van Haperen, VW; Veerman, G; Vermorken, JB | 1 |
| Brown, TD; Casper, ES; Flombaum, CD; Green, MR; Heelan, RT; Kelsen, DP; Tarassoff, PG; Trochanowski, B | 1 |
| Altmann, A; Bellemann, ME; Blatter, J; Haberkorn, U; Kahn, B; Morr, I; Oberdorfer, F; van Kaick, G | 1 |
| Ariyoshi, Y; Sugiura, T | 1 |
| Fujita, F; Fujita, M; Sakamoto, Y | 2 |
| Bemis, K; Colbert, W; Heim, R; Helton, D; Rush, G; Shannon, H; Shetler, T; Todd, G; Turk, J; Wilson, B | 1 |
| Hata, Y; Prajda, N; Weber, G | 1 |
| Boven, E; Eriksson, S; Hermsen, M; Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; Stegmann, AP; Veerman, G; Vermorken, JB | 1 |
| Kaye, SB | 1 |
| Abratt, RP; Bezwoda, WR; Falkson, G; Goedhals, L; Hacking, D; Rugg, TA | 1 |
| Anliker, SL; Britton, TC; Cooke, GG; Maple, SR; McClure, MS; Stephan, EA | 1 |
| Aamdal, S; Eppelbaum, R; Franklin, H; Sessa, C; Smyth, JF; Sulkes, A; Ten Bokkel Huinink, W; Vermorken, J; Wanders, J; Wolff, I | 1 |
| Bianchi, V; Borella, S; Calderazzo, F; Chieco Bianchi, L; Ferraro, P; Reichard, P | 1 |
| Anderson, H; Bach, F; Hansen, HH; Lund, B; Thatcher, N; Walling, J | 1 |
| Andis, SL; Dudley, DE; Grindey, GB; Hertel, LW; Merriman, RL; Rutherford, PG; Schultz, RM; Tanzer, LR; Toth, JE; Zimmermann, JE | 1 |
| Fujita, F; Fujita, M; Inaba, H; Taguchi, T | 1 |
| Ayoub, J; Cormier, Y; Eisenhauer, E; Goss, G; Gregg, R; Muldal, A; Stewart, D; Tarasoff, P; Wong, D | 1 |
| Brown, TD; Burris, HA; Craig, JB; Havlin, K; Kuhn, JG; O'Rourke, TJ; Satterlee, WG; Tarassoff, PG; Von Hoff, DD | 1 |
| Chang, E; Hahn, TM; Hertel, LW; Lawrence, TS; Shewach, DS | 1 |
| Edzes, HT; Noordhuis, P; Peters, GJ; Vermorken, JB | 1 |
| Christman, K; Kelsen, D; Saltz, L; Tarassoff, PG | 1 |
| Eudaly, JA; Higdon, GL; Tizzano, JP; Todd, GC | 1 |
| Boven, E; Erkelens, CA; Hatty, SA; Pinedo, HM; Schipper, H | 1 |
| Abonyi, M; Hata, Y; Look, KY; Prajda, N; Singhal, RL; Szekeres, T; Weber, G; Yeh, A | 1 |
| Peters, GJ; Ruiz van Haperen, VW; Veerman, G; Vermorken, JB | 1 |
| Cory, AH; Cory, JG; Hertel, LW; Kroin, JS | 1 |
| Hansen, HH; Kristjansen, PE; Quistorff, B; Spang-Thomsen, M | 1 |
| Bloom, LB; Goodman, MF; Hertel, LW; Kroin, JS; Richardson, FC; Schy, WE | 1 |
| Hansen, HH; Kristjansen, PE; Lund, B | 1 |
| Bouffard, DY; Laliberté, J; Momparler, RL | 1 |
| Eisenhauer, EA; Mertens, WC; Moore, M; Muldal, A; Stewart, D; Venner, P; Wong, D | 1 |
| Bouffard, DY; Momparler, RL | 1 |
| Blatter, J; Carmichael, J; Fink, U; Harris, AL; Russell, RC; Spiessi, G; Spittle, MF | 1 |
| Chang, EY; Hahn, TM; Hertel, LW; Lawrence, TS; Shewach, DS | 1 |
| Edelman, MJ; Gandara, DR | 1 |
| Blatter, J; De Mulder, PH; Jakse, G; Osieka, R; Weissbach, L | 1 |
| Burkes, RL; Shepherd, FA | 1 |
| Gilbert, KS; Grindey, GB; Waud, WR; Worzalla, JF | 1 |
| Burkes, R; Cormier, Y; Crump, M; Feld, R; Schulz, M; Shepherd, FA; Strack, T | 1 |
| Chen, YM; Liu, JM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Macdonald, JS; Schnall, SF | 1 |
| Guchelaar, HJ; Richel, DJ; van Knapen, A | 1 |
| Bartsch, G; Böck, G; Cronauer, MV; Culig, Z; Geisen, FH; Hobisch, A; Klocker, H; Konwalinka, G; Radmayr, C; Reissigl, A; Schirmer, M; Talasz, H | 1 |
| Chang, KT; Chen, JY; Chen, MH; Chen, YM; Perng, RP; Tsai, CM | 1 |
| Bernabei, PA; D'Ippolito, G; Ermini, A; Rossi-Ferrini, P; Santini, V; Zoccolante, A | 1 |
| Fields, AL; Goldberg, GL; Runowicz, CD | 1 |
| Peters, G; Pinedo, HM; van Haperen, VW; Veerman, G; Vermorken, JB | 1 |
| Bamberger, U; Boven, E; Feller, N; Jansen, WJ; Pinedo, HM; van der Wilt, CL | 1 |
| Braakhuis, BJ; Peters, GJ; Ruiz van Haperen, VW; Welters, MJ | 1 |
| Burkes, RL; Cortes-Funes, H; Cottier, B; Gatzemeier, U; Gottfried, M; Groen, HJ; Le Chevalier, T; Mattson, K; Rosso, R; Shepherd, FA; Tonato, M; Voi, M; Weynants, P | 1 |
| Braakhuis, BJ; Noordhuis, P; Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; Veerman, G; Vermorken, JB | 1 |
| Moore, M | 1 |
| Lawrence, TS; Robertson, JM; Shewach, DS | 1 |
| Fukuoka, M; Furue, H; Furuse, K; Majima, H; Morimoto, K; Nakamura, T; Nakao, I; Niitani, H; Ohta, K; Shimoyama, T; Taguchi, T; Tsukagoshi, S; Wakui, A | 1 |
| Holzer, G; Karlseder, J; Orel, L; Simon, MM; Sliutz, G; Tempfer, C | 1 |
| Anderson, H; Hansen, H; Thatcher, N; Walling, J | 1 |
| Burkes, R; Cormier, Y; Crump, M; Feld, R; Shepherd, FA; Strack, T | 1 |
| Copley-Merriman, C; Corral, J; Dorr, FA; King, K; McDonald, RC; Voi, M; Whiteside, R | 1 |
| Abi-Aad, AS | 1 |
| Drengler, R; Eckardt, J; Eckhardt, G; Villalona-Calero, M; Von Hoff, D | 2 |
| Gandhi, V; Huang, P; Plunkett, W | 1 |
| Abratt, RP | 1 |
| Shepherd, FA | 3 |
| Martin, C; Mosconi, AM; Tonato, M | 1 |
| Cameron, C; Dabouis, G; Dunlop, DJ; Guerin, JC; Kleisbauer, JP; Perol, M; Sanson, C; Steward, WP; Talbot, DC; Thomas, P | 1 |
| Anderson, H; Betticher, DC; Ranson, M; Thatcher, N | 1 |
| Andersen, S; Blatter, J; Bosanquet, N; Copley-Merriman, K; Drings, P; Johnson, N; Koch, P; van Schaik, J | 1 |
| Possinger, K | 1 |
| Boeck, G; Egle, A; Geisen, F; Greil, R; Gruber, J; Konwalinka, G; Sgonc, R; Villunger, A | 1 |
| Giaccone, G; van Zandwijk, N | 1 |
| Pronk, LC; Schellens, JH; Verweij, J | 1 |
| Lawrence, TS; McGinn, CJ; Shewach, DS | 1 |
| Anderson, H; Lund, B; Martin, C; Thatcher, N | 1 |
| Deeter, JB; Hausheer, FH; Hertel, LW; Jones, ND; Kroin, JS; Seetharamulu, P; Singh, UC | 1 |
| Gelber, RD | 1 |
| Andersen, JS; Brown, TD; Burris, HA; Casper, ES; Cripps, MC; Green, MR; Moore, MJ; Portenoy, RK; Rothenberg, ML; Storniolo, AM; Tarassoff, PG; Von Hoff, DD | 1 |
| Chen, F; Gandhi, V; Hertel, LW; Legha, J; Plunkett, W | 1 |
| Cheson, BD; Phillips, PH; Sorensen, JM | 1 |
| Blau, CA; Neff, T | 1 |
| Hanauske, AR | 1 |
| Bokemeyer, C; Daikeler, T; Kanz, L; Maas, K | 1 |
| Rothenberg, ML | 1 |
| Sakata, Y; Suzuki, H; Takemori, H | 1 |
| Kurita, Y; Nakai, Y; Niitani, H; Taguchi, T; Yokoyama, A; Yoneda, S | 1 |
| Von Hoff, DD | 4 |
| Gandhi, V; Huang, P; Plunkett, W; Searcy, CE | 1 |
| Bergman, AM; Braakhuis, BJ; Kuiper, CM; Peters, GJ; Ruiz van Haperen, VW; Smitskamp-Wilms, E; van Moorsel, CJ; Veerman, G | 1 |
| Abbruzzese, JL | 4 |
| Green, MR | 3 |
| Le Chevalier, T | 3 |
| Dabouis, G; Dunlop, DJ; Lacroix, H; Steward, WP; Talbot, D | 1 |
| Burkes, RL; Cormier, Y; Crump, M; Feld, R; Schulz, M; Shepherd, FA; Strack, T | 1 |
| Allerheiligen, S; Carmichael, J; Walling, J | 1 |
| Lund, B; Neijt, JP | 1 |
| Carmichael, J; Walling, J | 2 |
| Evans, WK | 2 |
| Bosanquet, N; Copley-Merriman, C; Drings, PA; Johnson, N; Martin, C; Sacristan, JA | 1 |
| Francis, PA; Michael, M; Millward, MJ; Rischin, D; Shapiro, JD; Toner, GC; Walcher, V | 1 |
| Brandt, A; Palmer, AJ | 1 |
| Alvord, WG; Gazdar, AF; Gray-Goodrich, M; Koo, HM; McWilliams, MJ; Mikheev, A; Monks, A; Oie, HK; Paull, KD; Rubinstein, LV; Vande Woude, GF; Zarbl, H | 1 |
| Guchelaar, HJ | 1 |
| Eisenhauer, EA; Vermorken, JB | 1 |
| Fukuoka, M; Furuse, K; Hasegawa, K; Hirabayashi, K; Nakajima, H; Niitani, H; Noda, K; Ogura, T; Taguchi, T | 1 |
| Fukuoka, M; Furuse, K; Kamei, T; Kudo, S; Negoro, S; Niitani, H; Nishikawa, H; Taguchi, T; Takada, Y | 1 |
| Burris, HA | 2 |
| O'Brien, TE | 1 |
| Boder, GB; Grindey, GB; Hertel, LW; Houghton, JA; Houghton, PJ; Merriman, RL; Rutherford, PG; Schultz, RM; Tanzer, LR | 1 |
| Kennedy, MJ | 1 |
| Mani, S; Ratain, MJ | 1 |
| Wiley, JS | 1 |
| Adamo, V; Altavilla, G; Clerici, M; Crinò, L; Cruciani, G; De Marinis, F; Dogliotti, L; Figoli, F; Incoronato, P; Marangolo, M; Mosconi, AM; Oliva, C; Paccagnella, A; Pucci, F; Salvati, F; Santucci, A; Scagliotti, G; Sorbolini, S; Tonato, M; Trippetti, M | 1 |
| Calayag-Jung, M; Fossella, FV; Glisson, B; Hong, WK; Lee, JS; Lippman, SM; Murphy, WK; Perez-Soler, R; Rivera, E; Shin, DM; Tarassoff, P | 1 |
| Martin, C; Pollera, CF | 1 |
| Abratt, RP; Bezwoda, WR; Goedhals, L; Hacking, DJ | 2 |
| Christensen, IJ; Holm, B; Jensen, PB; Sehested, M; Sorensen, M | 1 |
| Hui, YF; Reitz, J | 1 |
| Chen, YM; Lin, WC; Ming-Liu, J; Perng, RP; Tsai, CM; Whang-Peng, J; Yang, KY | 1 |
| Pollera, CF | 1 |
| Anderson, H; Hopwood, P; Thatcher, N | 1 |
| Crinò, L; Mosconi, AM; Tonato, M | 2 |
| Burris, H; Storniolo, AM | 1 |
| Dorr, FA; Kuzel, TM; Levine, E; Raghavan, D; Roth, B; Stadler, WM; Vogelzang, NJ | 1 |
| Kaufmann, M; von Minckwitz, G | 1 |
| Tsukagoshi, S | 4 |
| Bunn, PA | 6 |
| Allerheiligen, SR; Pearce, HL; Storniolo, AM | 1 |
| Kanzawa, F; Saijo, N | 1 |
| Bergman, AM; Guechev, A; Peters, GJ; Postmus, PE; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
| Eisbruch, A; Lawrence, TS; Shewach, DS | 1 |
| Natale, RB | 4 |
| Hansen, HH; Sørensen, JB | 1 |
| Fukuoka, M; Kurita, Y; Niitani, H; Takada, M; Yokoyama, A | 1 |
| Gottfried, M; Le Chevalier, T | 1 |
| Abratt, RP; Anderson, H; Anglin, G; Gatzemeier, U; Iglesias, J; Shepherd, FA | 1 |
| Pedersen, AG | 1 |
| Blatter, J; Depenbrock, H; Gatzemeier, U; Hanauske, AR; Rassmann, I; Rastetter, J; Thödtmann, R | 1 |
| Andersen, J; Burris, HA; Cripps, MC; Dorr, FA; Green, MR; Modiano, MR; Moore, MJ; Nelson, R; Portenoy, RK; Rothenberg, ML; Stephens, CD; Storniolo, AM; Tarassoff, P; Von Hoff, DD | 1 |
| Sculier, JP | 1 |
| Boyer, MJ; Clarke, SJ | 1 |
| Anderson, H; Bradley, B; Jayson, G; Ranson, M; Thatcher, N | 1 |
| Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, P; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, P; ten Bokkel Huinink, W; van Walree, N; von Pawel, J; Wagenius, G | 1 |
| Einhorn, LH | 1 |
| Burkes, R; Cormier, Y; Evans, WK; Feld, R; Goss, G; Klimo, P; Shepherd, FA; Taylor, M | 1 |
| Blatter, J; Chomy, F; Chomy, P; Drings, P; Eberhard, W; Gatzemeier, U; Khayat, D; Manegold, C; Seeber, S; Wilke, HJ | 2 |
| Gregor, A | 1 |
| Huang, P; Iwasaki, H; Keating, MJ; Plunkett, W | 1 |
| Burkes, RL; Cortes-Funes, H; Cottier, B; Gatzemeier, U; Gottfried, M; Groen, HJ; Le Chevalier, T; Mattson, K; Ponzio, A; Rosso, R; Shepherd, F; Tonato, M; Voi, M; Weynants, P | 1 |
| Armand, JP | 1 |
| Fukuoka, M; Furuse, K; Kudoh, S; Kurita, Y; Niitani, H; Ohnoshi, T; Saijoh, N | 1 |
| Bell, DR; Levi, JA; Millward, MJ; Pavlakis, N | 1 |
| Calabresi, F; Ceribelli, A; Crecco, M; Oliva, C; Pollera, CF | 1 |
| Devriendt, D; Klastersky, J | 1 |
| Altmann, A; Bellemann, ME; Blatter, J; Brix, G; Doll, J; Gerlach, L; Haberkorn, U; Morr, I; Oberdorfer, F; van Kaick, G | 1 |
| Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, P; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, RA; ten Bokkel-Huinink, W; van Pawel, J; van Walree, N; Wagenius, G | 1 |
| Krajnik, G; Malayeri, R; Ohler, L; Pirker, R | 1 |
| Ballal, K; Huang, P; Plunkett, W | 1 |
| Goa, KL; Noble, S | 1 |
| Kurita, Y; Nakai, Y; Niitani, H; Yokoyama, A; Yoneda, S | 1 |
| Abratt, R; Cortes-Funes, H; Lund, B; Martin, C | 1 |
| Bokemeyer, C; Daikeler, T; Hartmann, JT; Kanz, L; Maas, K | 1 |
| Ball, DL; Groves, J; Joschko, MA; Millward, MJ; Palatsides, M; Webster, LK; Yuen, K | 1 |
| Matsuda, A | 1 |
| Halme, M; Jekunen, A; Mattson, K; Tamminen, K | 1 |
| Murray, N | 1 |
| Androulakis, N; Dimopoulos, MA; Georgoulias, V; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kourousis, C; Merambeliotakis, N; Papadakis, E; Vardakis, N | 1 |
| Aigner, K; Baumgartner, G; Forstner, B; Huber, H; Hubner, M; Krajnik, G; Krejcy, K; Kummer, F; Malayeri, R; Pirker, R; Ulsperger, E; Zöchbauer, S | 1 |
| Androulakis, N; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Hatzidaki, D; Heras, P; Kakolyris, S; Kalbakis, K; Kotsakis, T; Kourousis, C; Meramveliotakis, N; Papadimitriou, C; Vardakis, N | 1 |
| John, WJ; Mohiuddin, M; Regine, WF | 2 |
| Ozols, RF | 4 |
| Furuse, K | 2 |
| Auer, H; Glössl, J; Kowalski, H; Kucera, E; Lindner, R; Oehler, R; Orel, L; Simon, MM; Sliutz, G | 1 |
| Ardizzoni, A; Martin, C; Rosso, R | 1 |
| Dorr, FA; Kuzel, T; Raghavan, D; Roth, B; Stadler, WM | 1 |
| Masuda, N | 1 |
| Negoro, S | 1 |
| Beauduin, M; Bruniaux, M; De Coster, B; Grégoire, V; Octave-Prignot, M; Rosier, JF; Scalliet, P | 1 |
| Rosenberg, L | 1 |
| Michael, M; Moore, M | 1 |
| Ernst, DS; Huan, S; Moore, MJ; Murray, N; Tannock, IF | 1 |
| Clavel, MD; Guastalla, JP; Hatty, SR; McDaniels, C; Seitz, DE; Tanis, B; Vermorken, JB | 1 |
| Botti, G; Caputi, V; Comella, G; Comella, P; Frasci, G; Gravina, A; Natale, M; Nicolella, GP; Pacilio, C; Panza, N | 1 |
| Breiteneder, S; Brodowicz, T; Wiltschke, C; Zielinski, CC | 1 |
| Athanassiades, A; Bacoyiannis, C; Briassoulis, E; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Pavlidis, N; Samantas, E; Skarlos, D | 1 |
| Carmichael, J | 3 |
| Boyer, MJ | 1 |
| Ghaemmaghami, M; Jett, JR | 1 |
| Awada, A; Klastersky, J | 1 |
| Fukuoka, M; Furuse, K; Kamei, T; Kudo, S; Negoro, S; Niitani, H; Nishikawa, H; Takada, M; Takada, Y | 1 |
| Chaitchik, S; Merimsky, O | 1 |
| Caraceni, A; De Conno, F | 1 |
| Ballatori, E; Del Favero, A; Roila, F | 2 |
| Castro, MP | 1 |
| Cook, JA; Fisher, J; Liebmann, JE; Mitchell, JB; Russo, A; Teague, D; Theodossiou, C | 1 |
| Dormann, AJ; Grünewald, T; Huchzermeyer, H; Wigginghaus, B | 1 |
| Fagbemi, SO; Stadler, WM | 1 |
| Eda, H; F-Ouchi, K; Ishitsuka, H; Miwa, M; Tanaka, Y; Ura, M | 1 |
| Eda, H; Foley, LH; Ishitsuka, H; Keith, DD; Miwa, M; Ouchi, KF; Ura, M | 1 |
| Cartee, L; Kucera, GL | 1 |
| Eichinger, S; Gisslinger, H; Hattey, E; Knöbl, P; Mitterbauer, GJ; Mitterbauer, M; Speiser, W; Weltermann, A | 1 |
| Brand, R; Capadano, M; Tempero, M | 1 |
| Robins, MJ; Samano, V; Silva, DJ; Stubbe, J | 1 |
| Geisen, FH; Graziadei, I; Kelly, T; Konwalinka, G; Schirmer, M; Vogel, W | 1 |
| Chiodera, PL; Fiorenzano, G; Marruchella, A; Merizzi, A; Rossi, G | 1 |
| Kinsella, AR; Smith, D | 1 |
| Adsay, V; Al-Katib, A; Joshi, U; Majumdar, AP; Mohammad, RM; Pettit, GR; Sarkar, FH; Vaitkevicius, VK | 1 |
| Nori, D; Parikh, S | 1 |
| Pérez, L; Robins, MJ; Samano, V; Sanchez, RJ; Stubbe, J; van der Donk, WA; Yu, G | 1 |
| Bernell, P; Ohm, L | 1 |
| Brand, R; Tempero, MA | 1 |
| Blatter, J; Hayn, HK; Jakse, G; Rohde, D | 1 |
| Blatter, J; Goertz, M; Jakse, G; Rohde, D | 1 |
| Csapó, Z; Keszler, G; Noordhuis, P; Peters, GJ; Sasvári-Székely, M; Smid, K; Staub, M | 1 |
| Bergman, AM; Kroep, JR; Peters, GJ; Pinedo, HM; van Moorsel, CJ; Veerman, G; Vermorken, JB; Voorn, DA | 1 |
| Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; Veerman, G | 1 |
| Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; Veerman, G | 1 |
| Peters, GJ; Ruiz van Haperen, VW; van Moorsel, CJ; Veerman, G | 1 |
| Kroep, JR; Merriman, RL; Peters, GJ; Pinedo, HM; Schultz, RM; Tanzer, LR; van Moorsel, CJ; Veerman, G; Voorn, DA; Worzalla, JF | 1 |
| Bergman, AM; Jensen, PB; Peters, GJ; Ruiz van Haperen, VW; Sehested, M; van Moorsel, CJ; Veerman, G | 1 |
| Adjei, AA; Rajkumar, SV | 1 |
| Bunn, PA; Kelly, K | 1 |
| Marańda, E; Robak, T | 1 |
| Malayeri, R; Wein, W; Zielinski, C | 1 |
| Gietema, JA; Groen, HJ; Meijer, S; Smit, EF | 1 |
| Aapro, MS; Hatty, S; Martin, C | 1 |
| Calzas, J; Castellano, D; Cortés-Funes, H; Gómez, H; Gómez-Martín, C; Guerra, JA; Hidalgo, M; Lianes, P; Paz-Ares, L | 1 |
| Beauduin, M; Bruniaux, M; De Coster, B; Grégoire, V; Octave Prignot, M; Scalliet, P | 1 |
| Blatter, J; Eble, M; Fleckenstein, K; Latz, D; Wannenmacher, M; Weber, KJ | 1 |
| Cheson, BD | 1 |
| Dobbie, M; Herrmann, R; Hofer, S; Oberholzer, M | 1 |
| Rigas, JR | 2 |
| Loddenkemper, R; Schönfeld, N; Serke, M | 1 |
| Garcia, L; Goodwin, AL; Von Hoff, DD | 1 |
| Steward, WP | 1 |
| Chitambar, CR; Elford, HL; Myette, MS | 1 |
| Manegold, C | 4 |
| Calandri, C; Crinò, L; De Marinis, F; Della Giulia, M; Gridelli, C; Mosconi, AM; Noseda, M; Rinaldi, M; Scagliotti, GV; Selvaggi, G; Tonato, M | 1 |
| Rosell, R; Sandler, A; Tonato, M | 1 |
| Abratt, RP; Crinò, L; Green, MR; Nguyen, B; Peters, GJ; Sandler, A; Shepherd, FA; Steward, WP | 1 |
| Dombernowsky, P; Giaccone, G; Sandler, A; Schwartsmann, G | 1 |
| Calvert, P; Langer, CJ; Ozols, RF | 1 |
| Gregor, A; Turrisi, AT; Vokes, EE | 1 |
| Postmus, PE; Schramel, FM; Smit, EF | 1 |
| Carney, DN | 1 |
| Burke, T; Ferguson, PJ; Hammond, JR; Lee, S | 1 |
| Fey, V; Gazitt, Y; Hilsenbeck, SG; Montegomrey, W; Rothenberg, ML; Thomas, C | 1 |
| Aylesworth, C; Burris, HA; Eckardt, JR; Eckhardt, SG; Forral, K; Kraynak, MA; Nicol, SJ; Rinaldi, DA; Rodriguez, GI; Rothenberg, ML; Sharma, A; Stephens, CD; Villalona-Calero, MA; Von Hoff, DD; Weiss, GR | 1 |
| Abrams, RA; Regine, WF | 1 |
| Antoine, EC; Khayat, D | 1 |
| Belt, JA; Cass, CE; Crawford, CR; Mackey, JR; Mani, RS; Mowles, D; Selner, M; Young, JD | 1 |
| Cournoyer, D; Eliopoulos, N; Momparler, RL | 1 |
| Brandner, G; Hess, RD; Merlin, T | 1 |
| Augustine, K; Benjapibal, M; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Vasuratna, A; Verschraegen, CF | 1 |
| Fernberg, JO; Tennvall, GR | 1 |
| Blaszkowsky, L | 1 |
| Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; Smitskamp-Wilms, E; Veerman, G | 1 |
| Chang, EY; Hahn, TM; Lawrence, TS; Shewach, DS | 1 |
| Huang, P; Plunkett, W; Robertson, LE; Wright, S | 1 |
| Brown, TJ; Jain, RK; Kristjansen, PE; Shipley, LA | 1 |
| Abbruzzese, JL; Gravel, D; Plunkett, W; Raber, MN; Touroutoglou, N | 1 |
| Budman, DR; Calabro, A; Kreis, W | 1 |
| Grem, JL; Kao, V; Ren, Q | 1 |
| Akrivakis, C; Flath, B; Grunewald, R; Lüftner, D; Mergenthaler, HG; Possinger, K | 1 |
| Karlsson, G; Ragnarson Tennvall, G | 1 |
| Androulakis, N; Dimopoulou, I; Georgopoulou, T; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Souglakos, J; Tzannes, S; Vardakis, N | 1 |
| Fodor, M; Gallardo, J; Gamargo, C; Orlandi, L | 1 |
| Geisen, F; Konwalinka, G; Schirmer, M; Stegmann, AP | 1 |
| Akrivakis, C; Arning, M; Flath, B; Lüftner, D; Mergenthaler, HG; Ohnmacht, U; Possinger, K | 1 |
| Antimi, M; De Lena, M; Frassineti, GL; Gridelli, C; Lorusso, V; Luporini, G; Oliva, C; Pacini, M; Pollera, CF | 1 |
| Inbar, M; Kollender, Y; Meller, I; Merimsky, O | 1 |
| Jones, J; Laufman, LR; Nicol, S; Rhodes, VA; Spiridonidis, CH; Wallace, K | 1 |
| Miller, V; Vander Els, NJ | 1 |
| Glimelius, B | 2 |
| Ang, KK; Elshaikh, M; Fujii, T; Hittelman, W; Hunter, N; Mason, K; Milas, L; Plunkett, W | 1 |
| Borchmann, P; Diehl, V; Engert, A; Schnell, R | 1 |
| Steward, WP; Thomas, A | 1 |
| Bell, D; Bugat, R; Campbell, L; Friedlander, M; Harnett, P; Kayitalire, L; Millward, MJ; Moreno, JA; Ripoche, V; Varette, C | 1 |
| Alvarez Vincent, JJ; Brandariz, A; Castellano, D; Cortés-Funes, H; García-Carbonero, R; Hidalgo, M; Hitt, R; Millán, JM; Peña, M | 1 |
| Albertini, P; Bendandi, M; Gherlinzoni, F; Magagnoli, M; Orcioni, GF; Pileri, SA; Tura, S; Zinzani, PL | 1 |
| Daenen, M; Demedts, M; Nackaerts, K; Van Bleyenbergh, P; Vandevelde, A; Vansteenkiste, J | 1 |
| Bergman, AM; Brouwer, M; Eriksson, S; Jongsma, AP; Leyva, A; Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; Veerman, G | 1 |
| Guechev, A; Loves, WJ; Peters, GJ; Pinedo, HM; Postmus, PE; Smid, K; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
| Stadler, WM; Vogelzang, NJ | 1 |
| Amadori, D; Barzanti, F; Casadei Giunchi, D; Dal Susino, M; Frassineti, GL; Milandri, C; Ricotti, L; Zoli, W | 1 |
| Dichgans, J; Durka, S; Rieger, J; Streffer, J; Weller, M | 1 |
| Antón, A; Artal, A; Barneto, I; Díaz-Fernández, N; González Larriba, JL; Masutti, B; Montalar, J; Rosell, R; Vadell, C | 1 |
| Greil, R; Huber, H; Krajnik, G; Kummer, F; Malayeri, R; Marhold, F; Mohn-Staudner, A; Pirker, R; Wein, W; Zöchbauer-Müller, S | 1 |
| Ferguson, PJ; Hammond, JR; Lee, S | 1 |
| Chitambar, CR; Myette, MS; Wereley, JP; Wong, SJ | 1 |
| Cormier, Y; Earle, CC; Evans, WK; Gertler, SZ; Mihalcioiu, C; Stewart, DJ; Walde, PD | 1 |
| Chovan, L; Janko, C; Jassem, J; Kanitz, E; Krejcy, K; Krzakowski, M; Magyar, P; Pawlicki, M; Pesek, M; Petruzelka, L; Zatloukal, P | 1 |
| Hejna, M; Raderer, M; Valencak, J | 1 |
| Cartee, L; Kucera, GL; Nixon, JB | 1 |
| Böttcher, HD; Damrau, M; Jüling-Pohlit, L; Karapetian, M; Mose, S; Rahn, A; Ramm, U; Taborski, B | 1 |
| Adenis, A; Bugat, R; Dufour, P; Kayitalire, L; Kurtz, JE; Négrier, S; Ripoche, V; Trillet-Lenoir, V | 1 |
| Bergman, B; Dombernowsky, P; Hansen, HH; Krarup, M; Nielsen, AL; Sørensen, JB | 1 |
| Benedetti, F; Casper, ES; Erlandson, RA; Flombaum, CD; Mouradian, JA | 1 |
| Agelidou, A; Androulakis, N; Apostolopoulou, F; Bouros, D; Dimopoulos, MA; Georgoulias, V; Hatzakis, K; Kakolyris, S; Kalbakis, K; Kotsakis, A; Kouroussis, C; Papadakis, E; Papadimitriou, C; Vardakis, N; Vlachonicolis, J | 1 |
| Caponigro, F; Costagliola, G; De Marino, V; Dimitri, P; Facchini, G; Ferrante, G; Ferraro, A; Gentile, M; Gravina, A; Iaffaioli, RV; Illiano, A; Marzano, N; Tortoriello, A | 1 |
| Marañda, E; Robak, T; Szmigielska, A | 1 |
| Beauduin, M; Bruniaux, M; de Bast, M; de Coster, B; Grégoire, V; Octave-Prignot, M; Rosier, JF; Scalliet, P | 1 |
| Busi, C; Derenzini, M; Di Stefano, G; Fiume, L; Mattioli, A; Trerè, D | 1 |
| Cascinu, S; Catalano, G; Graziano, F | 1 |
| Einhorn, LH; Stender, MJ; Williams, SD | 1 |
| Beyer, J; Bokemeyer, C; Casper, J; Gerl, A; Harstrick, A; Kanz, L; Niederle, N; Schmoll, HJ; Schöffski, P | 1 |
| Alonso, S; Castellano, D; Cortes-Funes, H; Diaz-Puente, M; Gravalos, C; Hidalgo, M; Hitt, R; Paz-Ares, L | 1 |
| Agelaki, S; Alexopoulos, A; Apostolaki, F; Georgoulias, V; Giannakakis, T; Kakolyris, S; Kalbakis, K; Kosmas, C; Kourousis, C; Malamos, N; Mavroudis, D; Potamianou, A; Rigatos, G; Samonis, G; Sarra, E; Vlachonicolis, J | 1 |
| Cascinu, S; Cellerino, R; Cetto, GL; Giuliodori, L; Lippe, P; Mari, D; Monterubbianesi, MC; Pasini, F; Porfiri, E; Rossi, D; Santo, A; Silva, RR; Tummarello, D | 1 |
| Apostolopoulos, N; Giannios, J; Ginopoulos, P; Karana, A; Karvelas, F; Mastorakou, A; Mastronikolis, NS; Rathossis, S; Siabi, V | 1 |
| Cree, IA; Foss, AJ; Hungerford, JL; Kurbacher, CM; Myatt, N; Neale, MH; Plowman, PN | 1 |
| Huhn, D; Oettle, H; Riess, H; Serke, S | 1 |
| Brown, CA; Enas, NH; Rothenberg, ML; Schilsky, R; Storniolo, AM; Voi, M | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Meluch, AA; Morrissey, LH; Scullin, DC; Smith, SW | 1 |
| Bamberg, M; Brandes, A; Classen, J; Schott, U; Weinmann, M | 1 |
| Fujita, M; Higashino, K; Tsuchida, T | 1 |
| Coil, D; Davis, B; De Ipolyi, PD; Giovanella, BC; Natelson, EA; Stehlin, JS; Trojacek, A; Wallace, P; Wolk, D | 1 |
| Johnson, D; Tonato, M | 1 |
| Calvert, P; Edelman, MJ; Gandara, DR; Langer, CJ; Ozols, RF | 1 |
| Giaccone, G | 2 |
| Bareck, E; Brodowicz, T; Hejna, MH; Kornek, GV; Lang, F; Lenauer, J; Raderer, M; Scheithauer, W; Valencak, JB; Weinländer, GS | 1 |
| Arning, M; Coleman, R; Helsing, M; Kaufmann, M; Ohnmacht, U; Possinger, K; Stuart, NS | 1 |
| Barton-Burke, M | 1 |
| Brady, MF; McGuire, WP; Ozols, RF | 1 |
| Hansen, SW; Sessa, C; Tuxen, MK | 1 |
| Arning, M; Brookfield, W; Fung, MC; Nguyen, B; Storniolo, AM; Vigil, J | 1 |
| Bianco, A; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; De Cataldis, G; De Lena, M; Di Rienzo, G; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Natale, M; Nicolella, G; Pacilio, C; Panza, N | 1 |
| Liepa, AM; Minshall, ME | 1 |
| Ali, N; Li, Y; Sarkar, FH; Singh, B | 1 |
| Beauduin, M; Cvilic, S; De Coster, B; Grégoire, V; Gueulette, J; Octave-Prignot, M; Scalliet, P | 1 |
| Bergman, AM; Kuiper, CM; Peters, GJ; Pinedo, HM; van der Vijgh, WJ; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
| Kroep, JR; Peters, GJ; Pinedo, HM; Postmus, PE; van der Vijgh, WJ; van Groeningen, CJ; van Moorsel, CJ; Veerman, G; Vermorken, JB; Voorn, DA | 1 |
| Bacoyiannis, C; Daniilidis, J; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Kosmidis, P; Nicolaides, C; Nikolaou, A; Papadimitriou, C; Pavlidis, N; Samantas, E; Stathopoulos, G | 1 |
| Ardizzoni, A; Baas, P; Debruyne, C; Giaccone, G; Gridelli, C; Groen, HJ; Lentz, M; Manegold, C; van Marck, EA; van Meerbeeck, JP | 1 |
| Reeves, W; Tippin, DB; Vogelzang, NJ | 1 |
| Beauséjour, C; Eliopoulos, N; Momparler, RL | 1 |
| Ettinger, DS; Sandler, A | 1 |
| Edelman, MJ | 4 |
| Taguchi, T; Tsukagoshi, S | 1 |
| Asai, G; Fukuoka, M | 1 |
| Hara, N; Kurita, Y; Matsui, K; Nakai, Y; Niitani, H; Ohhashi, Y; Yokoyama, A | 1 |
| Yokoyama, A | 2 |
| Dent, P; Grant, S; Kramer, LB; Povirk, LF; Saunders, AM; Vrana, JA; Zhang, XF | 1 |
| Barni, S; Cascinu, S; Catalano, G; Cellerino, R; Frontini, L; Fusco, V; Giordani, P; Giuliodori, L; Labianca, R; Luporini, G; Pancera, G; Pessi, MA; Piazza, E; Silva, RR | 1 |
| Cvitkovic, E; Faivre, S; Raymond, E; Woynarowski, JM | 1 |
| Howell, SB; Lin, X | 1 |
| Ang, KK; Buchmiller, L; Elshaikh, M; Hittelman, K; Hunter, NR; Kishi, K; Mason, KA; Milas, L | 1 |
| van Oosterom, AT | 1 |
| Arlauskas, P; Ibrahim, D; Philip, PA; Shields, A; Zalupski, M | 1 |
| Biesma, B; Postmus, PE; Smit, EF | 1 |
| Callet Bauchu, E; Dumontet, C; Fabianowska-Majewska, K; Fang, X; Gandhi, V; Gazzo, S; Lepoivre, M; MacKey, J; Mantincic, D; Peters, GJ; Rolland, MO; Tigaud, I; Vanier-Viornery, A; Voorn, DA; Wyczechowska, D | 1 |
| Mendelsohn, LG; Teng, CH; Tonkinson, JL; Worzalla, JF | 1 |
| Jeekel, J; van der Schelling, GP | 1 |
| Stucky-Marshall, L | 1 |
| Rizvi, NA | 1 |
| Alberola, V; Antón, A; Artal, A; Barneto, I; Cardenal, F; Carrato, A; García, M; González-Larriba, JL; Lianes, P; Lomas, M; López-Cabrerizo, MP; Massuti, B; Montalar, J; Nguyen, B; Rosell, R; Vadell, C | 1 |
| Buck, M; Byrne, MJ; Davidson, JA; de Klerk, NH; Dewar, J; Musk, AW; Robinson, BW; van Hazel, G | 1 |
| Johansson, M; Karlsson, A; Van Rompay, AR | 1 |
| Bareck, E; Depisch, D; Funovics, J; Hejna, M; Kornek, GV; Kovats, E; Lang, F; Miholic, J; Raderer, M; Scheithauer, W; Valencak, J | 1 |
| Bauknecht, T; Neijt, JP; Visseren-Grul, CM; von Minckwitz, G | 1 |
| Beinert, T; Binder, D; Fleischhacker, M; Mergenthaler, HG; Oehm, C; Possinger, K; Priem, F; Schweigert, M; Sezer, O; Siebert, G; Stuschke, M; Werner, TG; Ziemer, S | 1 |
| Eady, A; Evans, WK; Gagliardi, A; Kocha, W; Newman, TE | 1 |
| Bergman, AM; Padrón, JM; Peters, GJ; Smitskamp-Wilms, E; van der Wilt, CL; van Moorsel, CJ | 1 |
| Magagnoli, M; Pellacani, A; Tosi, P; Tura, S; Visani, G; Zinzani, PL | 1 |
| Goan, YG; Hu, E; Mi, S; Yen, Y; Zhou, B | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Grossi, F; Loprevite, M; Merlo, F; Pirani, P | 1 |
| Khattab, J; Urba, SG | 1 |
| Bajorin, DF; Cozzi, PJ; Dalbagni, G; Heston, WD; Nguyen, H; Scott, J; Tong, W | 1 |
| Ferreira, CG; Giaccone, G; Peters, GJ; Pinedo, HM; Tolis, C | 1 |
| Peters, GJ; Pinedo, HM; Postmus, PE; van Moorsel, CJ; Veerman, G; Vermorken, JB | 1 |
| Akrivakis, K; Flath, B; Grosse, Y; Mergenthaler, HG; Possinger, K; Schmid, P; Sezer, O | 1 |
| Baxter, D; Govindarajan, R; Wilson, C; Zent, C | 1 |
| Bateman, AC; Cook, T; Dunsford, ML; Mead, GM; Tung, K | 1 |
| Belotti, G; Cantù, A; Ciotti, R; D'Amico, A; Facchi, E; Gatti, C | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Püribauer, F; Scheithauer, W; Valencak, J; Weinländer, G | 1 |
| Bailey, RD; Blaskovich, MA; Hamilton, AD; Knowles, D; Ohkanda, J; Qian, Y; Sebti, SM; Sun, J | 1 |
| Bauer, J; Kreil, A; Scheithauer, W | 1 |
| Piver, MS; Silver, DF | 1 |
| Brunet, R; Fonck, M | 1 |
| Barón, MG; Castro, J; De la Gándara, I; Espinosa, E; Espinosa, J; Feliu, J; Girón, CG; López Gómez, L; Madroñal, C; Martínez, B | 1 |
| Fracasso, PM; Grieff, M; Liapis, H; Rowinsky, EK; Stephenson, J; Tan, BR; Umbeck, NL; Von Hoff, DD | 1 |
| Choi, M; Göbel, U; Kettritz, R; Schneider, W; Woywodt, A | 1 |
| Endo, M; Machida, H; Miura, S; Sasaki, T; Satoh, H; Yoshimura, Y | 1 |
| Fischer, M; Geisen, F; Hittmair, A; Konwalinka, G; Margreiter, R; Roberts, K; Schirmer, M; Schmid, T; Tiefenthaler, M | 1 |
| Ragnarson-Tennvall, G; Wilking, N | 1 |
| Höffken, K; Kath, R; Sauer-Heilborn, A; Schneider, CP | 1 |
| Adsay, V; Al-Katib, AM; Li, Y; Mohamed, AN; Mohammad, RM; Pettit, GR; Sarkar, FH; Vaitkevicius, VK | 1 |
| Baldwin, SA; Cass, CE; Karpinski, E; Mackey, JR; Smith, KM; Yao, SY; Young, JD | 1 |
| Adamo, V; Barni, S; Bianco, R; Ceribelli, A; Crinò, L; Cruciani, G; De Marinis, F; Di Costanzo, F; Ferrara, G; Gozzelino, F; Gridelli, C; Marangolo, M; Masotti, A; Portalone, L; Ravaioli, A; Ricci, S; Rinaldi, M; Sassi, M; Scagliotti, GV; Tonato, M | 1 |
| Nanfro, JJ | 1 |
| Eisbruch, A; Fields, MT; Lawrence, TS; McGinn, CJ; Shewach, DS | 1 |
| Chakravarthy, A; Choy, H; Johnson, D | 1 |
| Comella, G; Frasci, G; Pacilio, G; Panza, N | 1 |
| Grant, S; Poplin, E; Roberts, J; Rubin, E; Tombs, M | 1 |
| Cazap, E; Cinat, G; Comba, AZ; Nievas, OR; Orlando, M; Sena, S; Traine, G; Van Kooten, M; Vicente, H | 1 |
| Kinikar, SA; Kolesar, JM | 1 |
| Marruchella, A; Tondini, M | 1 |
| Calandri, C; Crinò, L; De Marinis, F; Della Giulia, M; Gridelli, C; Mosconi, AM; Noseda, M; Novello, S; Rinaldi, M; Rossi, A; Scagliotti, G; Selvaggi, G; Tonato, M | 1 |
| Beijnen, JH; Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Postmus, PE; Rosing, H; Smit, EF; van Groeningen, CJ; van Moorsel, CJ; Voorn, DA | 1 |
| Bernard, SA; Blackstock, AW; Case, LD; Eagle, KS; Poole, ME; Richards, F; Savage, PD; Tepper, JE | 1 |
| Belli, M; Bilancia, D; Carpagnano, F; Cioffi, R; Comella, G; Comella, P; Contu, A; De Cataldis, G; De Lena, M; Frasci, G; Lorusso, V; Maiorino, L; Manzione, L; Mascia, V; Massidda, B; Micillo, E; Natale, M; Nicolella, GP; Panza, N; Pusceddu, G | 1 |
| Vogelzang, NJ | 5 |
| Horning, SJ; Horwitz, SM; Lucas, JB; Sayegh, A | 1 |
| Bennett, K; Huan, S; Moore, MJ; Murray, N; Seymour, L; Tannock, IF; Walsh, W; Winquist, EW | 1 |
| Bergman, B; Chemaissani, A; Dornoff, W; Drings, P; Kellokumpu-Lehtinen, PL; Liippo, K; Manegold, C; Mattson, K; Ricci, S; Sederholm, C; Stahel, RA; ten Bokkel Huinink, WW; von Pawel, J; Wagenius, G; Walree, NV | 1 |
| Dombernowsky, P; Hansen, HH; Stenbygaard, LE; Sørensen, JB | 1 |
| Halme, M; Isokangas, OP; Joensuu, H; Knuuttila, A; Lindström, I; Mäntylä, M; Mattson, K; Nikkanen, V; Viren, M | 1 |
| Aapro, MS; Gwyther, SJ; Hatty, SR; Postmus, PE; Smith, IE | 1 |
| Arning, M; Diebold, T; Hochmuth, K; Huhn, D; Langrehr, J; Neuhaus, P; Oettle, H; Pelzer, U; Riess, H; Schmidt, CA; Vogl, TJ | 1 |
| Amadori, D; Bacci, F; Barzanti, F; Dal Susino, M; Folli, S; Frassineti, GL; Ricotti, L; Tesei, A; Zoli, W | 1 |
| König, P; Kühr, T; Lhotta, K; Rumpelt, HJ; Thaler, J; Wöll, E | 1 |
| Bonadonna, G; Buksmaui, S; Fosså, A; Hiddemann, W; Niederle, N; Nowrousian, MR; Santoro, A; Seeber, S; Truemper, L | 1 |
| Antoniou, F; Aspropotamitis, A; Athanassiou, A; Batzios, S; Halikia, A; Kalantaridou, A; Karvounis, N; Pectasides, D; Visvikis, A | 1 |
| Balaña, C; Martin, C; Rosell, R | 1 |
| Nervi, AM; Ornstein, DL; Rigas, JR | 1 |
| Kelly, K | 3 |
| Cartei, G; Iop, A; Pella, N; Sacco, C; Sibau, A; Tabaro, G | 1 |
| Bengtson, EM; Rigas, JR | 1 |
| Bhargava, P; Dahut, W; Davis, TH; Figuera, M; Hawkins, MJ; Marshall, JL; Rizvi, NA; Spiridonidis, CH | 1 |
| Bahadori, HR; Eckardt, JR; Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Langer, CJ; Socinski, MA | 1 |
| Herbst, RS; Lilenbaum, R | 1 |
| Cianci, C; Conte, PF; Gadducci, A | 1 |
| Beyer, J; Bokemeyer, C; Casper, J; Gerl, A; Harstrick, A; Hartmann, JT; Kanz, L; Kollmannsberger, C; Metzner, B; Schmoll, HJ | 1 |
| Einhorn, LH; Ng, EW; Robinson, L; Sandler, AB | 1 |
| Adjei, AA; Erlichman, C | 1 |
| Kalapura, T; Krishnamurthy, M; Reddy, CV | 1 |
| Geisen, F; Konwalinka, G; Schirmer, M; Tiefenthaler, M | 1 |
| Baccala, P; Berg, D; Clark, JW; Finkelstein, D; Fuchs, CS; Grenon, N; Grossbard, ML; Lynch, TJ; Mayer, RJ; Ryan, DP; Seiden, MV | 1 |
| Brader, KR; Burnett, AF; Garcia, AA; Morrow, CP; Muderspach, LI; Roman, LD | 1 |
| Cormier, Y; Denham, C; Einhorn, LH; Gatzemeier, U; Gregor, A; Manegold, C; Mattson, K; Nemunaitis, J; Nguyen, B; Niyikiza, C; Palmer, MC; Sandler, AB; von Pawel, J | 1 |
| Cascinu, S; Catalano, G; Catalano, V; Gasparini, G; Gattuso, D; Giordani, P; Morabito, A; Pancera, G; Silva, RR | 1 |
| Blessing, JA; Mangan, CE; Morgan, M; Rader, JS; Schilder, RJ | 1 |
| Brunetti, C; Carpagnano, F; Cinieri, S; Cisternino, ML; De Lena, M; Di Rienzo, G; Frasci, G; Lorusso, V; Napoli, G; Orlando, S; Palazzo, S; Panza, N | 1 |
| Andersen, L; Crinò, L; Dogliotti, L; von der Maase, H; Weinknecht, S | 1 |
| Catik, A; Kroep, JR; Peters, GJ; Pinedo, HM; van Groeningen, CJ; van Moorsel, CJ; Vermorken, JB | 1 |
| Daniele, B; De Vivo, R | 1 |
| Aung, TT; Davis, MA; Ensminger, WD; Lawrence, TS | 1 |
| Barreras, L; Cano, R; Davila, E; Krill, E; Lewis, M; Lilenbaum, R; Lutzky, J; Schwartz, M; Siegel, L | 1 |
| Adenis, A; Conroy, T; Paillot, B | 1 |
| Burstein, HJ | 1 |
| Castellano, D; Cortés-Funes, H; Hitt, R; Rodriguez-Peralto, JL; Romero, A | 1 |
| Attar, EC; Deykin, A; Ervin, T; Godleski, J; Janicek, M | 1 |
| Ferreira, CG; Giaccone, G; Kummer, AJ; Peters, GJ; Pinedo, HM; Span, SW; Tolis, C; van Lopik, T | 1 |
| Atassi, G; Guilbaud, N; Jan, M; Kraus-Berthier, L; Naze, M; Pierré, A | 1 |
| Ariad, S; Fenig, E; Flusser, G; Inbar, M; Issakov, J; Kollender, Y; Meller, I; Merimsky, O; Neuman, G; Sapir, D; Weil-Ben-Arush, M | 1 |
| Camps, C; Herrero, CC; Jaime, AB; Martínez, EN | 1 |
| Bajorin, DF; Boyle, MG; Dodd, PM; Herr, H; Hilton, S; Icasiano, E; Kelly, WK; Mazumdar, M; McCaffrey, JA | 1 |
| Abbruzzese, JL; Crane, CH; Evans, DB; Hudec, WA; Janjan, NA; Lahoti, S; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA | 1 |
| De Filippis, S; Guerriero, G; Pompili, P; Rea, S; Recchia, F; Rosselli, M | 1 |
| André, T; Balosso, J | 1 |
| Davis, JR; Fernandes, C; Zalcberg, JR | 1 |
| Brierre, JE; Buller, EJ; Cole, JL; Fontenot, MF; Lormand, NA; Rainey, JM; Rinaldi, DA; Stagg, MP | 2 |
| Algeri, R; Antonuzzo, A; Bertuccelli, M; Bonifazi, V; Conte, PF; Fioretto, ML; Galli, L; Lopes Pegna, A; Orlandini, C; Petruzzelli, S; Ricci, S; Tibaldi, C | 1 |
| Armand, JP; Baudin, E; Boige, V; Chaouche, M; Chouaki, N; Delord, JP; Ducreux, M; Escudier, B; Faivre, S; Kayitalire, L; Le Chevalier, T; Pautier, P; Raymond, E; Rixe, O; Rodier, JM; Ruffie, P | 1 |
| Giaccone, G; Golding, RP; Laan, D; Pinedo, HM; Postmus, PE; Smit, EF; Splinter, T; van Meerbeeck, JP; van Tinteren, H | 1 |
| Dimitriadis, K; Dimopoulos, A; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Pavlidis, N; Samantas, E; Skarlos, D; Tsavdaridis, D | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Morrissey, LH; Scullin, DC; Smith, SW | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C | 1 |
| Alonso, S; Barnadas, A; Carañana, V; Colomer, R; De Paz, L; Fernández, Y; Guillem, V; Llombart, A; Lluch, A; Ojeda, B | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kourousis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N | 1 |
| Sternberg, CN | 2 |
| Bergman, AM; Kroep, JR; Peters, GJ; Pinedo, HM; Ruiz van Haperen, VW; van Moorsel, CJ; Veerman, G; Voorn, DA | 1 |
| Alberola, V; Antón, A; Cardenal, F; Carrato, A; Kennedy-Martin, T; Lomas, M; Massuti, B; Minshall, M; Rosell, R; Sacristán, JA | 1 |
| Brierre, JE; Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hon, JK; Litchy, S | 1 |
| de Leede, G; Eppinga, P; Erjavec, Z; Groen, HJ; Nabers, J; Smeets, JB; Th Sleijfer, D; van Putten, JW | 1 |
| Bilancia, D; Cioffi, R; Comella, G; Comella, P; De Cataldis, G; Di Nota, A; Di Rienzo, G; Filippelli, G; Frasci, G; Lamberti, A; Lorusso, V; Maiorino, L; Manzione, L; Micillo, E; Natale, M; Nicolella, G; Panza, N | 1 |
| Halm, U; Keim, V; Mössner, J; Schiefke, I; Schumann, T; Witzigmann, H | 1 |
| Akaza, H; Hattori, K | 1 |
| Jiang, H; Li, L; Plunkett, W; Shen, Y; Yang, LY | 1 |
| Abdel-Aziz, W; Hickey, RJ; Jiang, HY; Malkas, LH | 1 |
| Bamberg, M; Brandes, A; Plasswilm, L; Reichmann, U | 1 |
| Ardiet, CJ; Bernard, E; Droz, JP; Guillot, A; Peguy, M; Rebattu, P; Tranchand, B; Zanetta, S | 1 |
| Bauer, J; Bernhard, J; Borner, M; Fey, MF; Hanselmann, S; Hering, F; Hürny, C; Jacky, E; Maibach, R; Morant, R; Thürlimann, B; Trinkler, F; Zulian, G | 1 |
| Ely, G; Ferdinandi, ES; Joshi, SS; Liu, C | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Erlichman, C; Goldberg, RM; Hanson, LJ; Jett, J; Peethambaram, P; Pitot, HC; Reid, JM; Sloan, JA | 1 |
| Adak, S; Berlin, JD; Blaszkowsky, L; Flinker, D; Harris, JE; Vaughn, DJ | 1 |
| Jolivet, J; Locas, C; Marty, J; Von Hoff, DD; Weitman, S | 1 |
| Aisner, J; Carducci, M; Kaufman, D; Kuzel, T; Levine, EG; Murphy, B; Nicol, S; Oh, W; Raghavan, D; Stadler, W | 1 |
| Jekunen, A; Knuuttila, A; Linnainmaa, K; Mattson, K; Ollikainen, T; Suhonen, S; Taavitsainen, M | 1 |
| Asna, N; Greif, Y; Inbar, M; Mann, A; Merimsky, O; Paz, J; Schwartz, Y; Wigler, N | 1 |
| Allegra, CJ; Chabner, BA; Chu, E; Grem, JL; Johnston, PG; Multani, P; Ryan, D; Takimoto, CH | 1 |
| Chen, M; Hough, AM; Lawrence, TS | 1 |
| Calbó, J; Cascalló, M; Gelpí, JL; Mazo, A | 1 |
| Belanger, K; Forsyth, P; Fulton, D; Gertler, SZ; Goodyear, M; MacDonald, D; Perry, J; Seymour, L; Steward, W; Stewart, DJ; Wainman, N | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Elmo, M; Frasci, G; Lapenta, L; Petrillo, A; Thomas, R; Vallone, P | 1 |
| Achanta, G; Feng, L; Huang, P; Pelicano, H; Plunkett, W; Zhang, W | 1 |
| Banach, MJ; Williams, GA | 1 |
| Abbruzzese, JL; Bruns, CJ; Davis, DW; Evans, DB; Harbison, MT; Hicklin, DJ; McConkey, DJ; Portera, CA; Radinsky, R; Tsan, R | 1 |
| Bulankin, A; Grothey, A; Hoang-Vu, C; Müller, T; Schmoll, HJ; Schoeber, C; Voigt, W | 1 |
| Giaccone, G; Golding, RP; Linskens, RK; van Groeningen, CJ | 1 |
| Fukuoka, M | 1 |
| Blitzer, JB; Evans, SS; Forsthoff, C; Link, JS; Nagourney, RA | 1 |
| Blatter, J; Krejcy, K; Manegold, C; Zatloukal, P | 1 |
| Davis, MA; Eisbruch, A; Fields, MT; Lawrence, TS; Normolle, D; Orfali, A; Pu, AT | 1 |
| von der Maase, H | 7 |
| Bianco, AR; Damiano, V; De Lorenzo, S; Fabbrocini, A; Libroia, A; Matano, E; Tagliaferri, P | 1 |
| Antimi, M; De Lena, M; De Vita, F; Lorusso, V; Manzione, L; Selvaggi, FP | 1 |
| Flórez, A; Peteiro, C; Rosón, E; Sánchez-Aguilar, D; Toribio, J | 1 |
| Bishop, J; Boyer, M; Davison, J; Emmett, E; McClure, B; Michael, M; Millward, M; Rischin, D; Smith, J; Zalcberg, J | 1 |
| Abbate, A; Campisi, C; Di Cosimo, S; Di Sciascio, G; Gravante, G; Patti, G; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Agostara, B; Gebbia, V; Leonardi, V; Valenza, R | 1 |
| Braess, J; Hiddemann, W; Jahns-Streubel, G; Kern, W; Keye, S; Schleyer, E; Unterhalt, M; Wegendt, C | 1 |
| Abbruzzese, J; Bruns, CJ; Buchdunger, E; Fan, D; Fidler, IJ; Harbison, MT; Ozawa, S; Radinsky, R; Solorzano, CC; Traxler, P; Tsan, R | 1 |
| Barret, JM; Etiévant, C; Hill, BT | 1 |
| Lake, RA; McLaren, BR; Robinson, BW | 1 |
| Dumas, MC; Rini, BI; Stadler, WM; Taber, DA; Vogelzang, NJ; Wade, JL | 1 |
| Chen, YM; Liu, TW; Ming-Liu, J; Perng, RP; Tsai, CM; Whang-Peng, J; Yang, KY | 1 |
| Depisch, D; Funovics, J; Greul, R; Haider, K; Kornek, GV; Krauss, G; Kwasny, W; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Akers, MJ; Amos, RM; Baertschi, SW; Cooke, GG; Dorman, DE; Jansen, PJ; Kemp, CA; Maple, SR; McCune, KA | 1 |
| Haq, M; Rosemurgy, AS; Shafii, A; Zervos, EE | 1 |
| Korycka, A; Lech-Maranda, E; Robak, T | 2 |
| Albella, B; Bueren, JA; Keyes, KA; LoRusso, PM; Parchment, RE | 1 |
| D'Agostino, G; Genovesi, D; Greggi, S; Lorusso, D; Scambia, G; Smaniotto, D | 1 |
| Berghmans, T; Efremidis, A; Klastersky, J; Lafitte, JJ; Lecomte, J; Mommen, P; Ninane, V; Paesmans, M; Sculier, JP; Thiriaux, J | 1 |
| Akrivakis, K; Flath, B; Mergenthaler, HG; Possinger, K; Schmid, P; Schweigert, M; Sezer, O | 1 |
| Goldwasser, F; Gross, M; Hiesse, C; Kriaa, F | 1 |
| Belli, M; Bianco, A; Bilancia, D; Comella, G; Comella, P; De Cataldis, G; De Lena, M; Frasci, G; Iannelli, A; Lorusso, V; Massidda, B; Nicolella, G; Panza, N; Piantedosi, F | 1 |
| Alba, E; García-Conde, J; Khayat, D; Lluch, A; Moreno-Nogueira, JA; Palomero, M; Pérez-Manga, G; Rivelles, N | 1 |
| Ascani, S; Baliva, G; Bendandi, M; Gherlinzoni, F; Magagnoli, M; Modugno, G; Orcioni, GF; Pileri, SA; Simoni, R; Tura, S; Zinzani, PL | 1 |
| Benoehr, C; Bonadonna, G; Bonfante, V; Bredenfeld, H; Devizzi, L; Diehl, V; Fiedler, F; Pacini, M; Parra, HS; Santoro, A; Tesch, H; Viviani, S | 1 |
| Curran, D; Debruyne, C; Festen, J; Gans, S; Giaccone, G; Kramer, GW; Schlosser, NJ; Schramel, F; Smit, EF; Termeer, A; Van Zandwijk, N | 1 |
| Budman, D; Byrd, J; Egorin, MJ; Hawkins, M; Hohl, R; Hollis, D; Mani, S; Meropol, NJ; Ratain, MJ; Rosner, GL; Venook, AP | 1 |
| Mitchell, PL | 1 |
| Carles, J; Domènech, M; Guasch, I; Ibeas, R; Nogué, M; Pérez, C; Saigí, E; Villadiego, K | 1 |
| Au, E | 1 |
| Flamm, M; Garrett, TJ; Heitjan, D; Johnson, SA; Keohan, ML; Lee, RT; Oster, MW; Ruiz, J; Rule, SA; Savage, DG; Tighe, M | 1 |
| Casella, G; Costanzo, R; De Placido, G; De Vivo, R; Iodice, F; Perrone, F; Pignata, S; Ricchi, P; Tramontana, F; Tramontana, S; Varriale, E; Vernaglia, A | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; Carles, J; Cortés-Funes, H; González-Larriba, JL; Guillem, V; Paz-Ares, L; Tabernero, JM | 1 |
| Bajorin, DF | 1 |
| Burris, HS; Greco, FA; Hainsworth, JD; Meluch, AA | 1 |
| Gaafar, R; Hamza, MR; Khaled, HM; Mansour, O; Zaghloul, MS | 1 |
| Dietzmann, A; Genvresse, I; Grunewald, R; Koschuth, A; Possinger, K; Späth-Schwalbe, E | 1 |
| Andre, MH; Boaziz, C; Girard, T; Guillevin, L; Mouthon, L | 1 |
| Aravantinos, G; Bafaloukos, D; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Nicolaides, C; Pavlidis, N; Samelis, G | 1 |
| Fiebiger, WC; Greul, R; Hejna, M; Kornek, GV; Marosi, L; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Chan, AT; Johnson, P; Leung, SF; Leung, TW; Mok, TS; Nguyen, B; Yang, WT; Yeo, W; Yim, A; Zee, B | 1 |
| Demeaux, H; Dilhuydy, MS; Faure, I; Leng, B; Mercié, P; Pellegrin, JL; Viallard, JF | 1 |
| Belometti, MO; Beretta, GD; Gritti, G; Labianca, R; Michetti, G; Poletti, P; Quadri, A | 1 |
| Sone, S | 1 |
| Anderson, H; Bond, MG; Burt, PA; Carmichael, J; Connolly, CK; Cottier, B; Falk, SJ; Hopwood, P; Maughan, TS; McIllmurray, MB; Milroy, R; Nicholson, M; Stephens, RJ; Thatcher, N | 1 |
| Chen, JS; Lin, YC; Wang, CH; Wang, HM; Yang, TS | 1 |
| Bajetta, E; Bidoli, P; Chiara Stani, S; De Candis, D; Mariani, L; Pozzi, P; Procopio, G; Zilembo, N | 1 |
| Alabiso, O; Bortolini, M; Botta, M; Buosi, R; Chiappino, I; Clara, R; Grosso, M; Mussa, A; Satolli, A; Zai, S; Zanon, C | 1 |
| Glisson, BS; Hong, WK; Khuri, FR; Lippman, SM; Shin, DM | 1 |
| Castiglione, F; Cigolari, S; Farris, A; Felletti, R; Frontini, L; Gallo, C; Gasparini, G; Gridelli, C; Gulisano, M; Ianniello, GP; Locatelli, MC; Perrone, F; Piazza, E; Robbiati, SF | 1 |
| Czerniak, PM; Devenny, JJ; Gravallese, EM; Kerr, JS; Longtine, J; Slee, AM; Wexler, EJ; Wong, MK | 1 |
| Bhupalam, L; Fleming, DR; Glisson, SD; Goldsmith, GH; LaRocca, RV; Michelson, GD | 1 |
| Cappuzzo, F; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Scagliotti, GV | 2 |
| Choy, H | 2 |
| Edelman, MJ; Gandara, DR; Lara, PN; Lau, DH | 2 |
| Burris, HA; Greco, FA; Hainsworth, JD | 2 |
| Comella, P | 3 |
| Kosmidis, P | 1 |
| Altavista, P; Ceciarelli, F; Cividalli, A; Cruciani, G; Livdi, E; Mauro, F; Tirindelli Danesi, D | 1 |
| Colarian, J; Fowler, D; Poolos, S; Schor, J | 1 |
| Buccheri, G; Ferrigno, D | 2 |
| Eckel, F; Erdmann, J; Lersch, C; Schmidt, B; Schulte-Frohlinde, E | 1 |
| Geffen, DB; Horowitz, J | 1 |
| Albertini, P; Bendandi, M; Gherlinzoni, F; Piccaluga, PP; Stefoni, V; Tani, M; Tura, S; Zinzani, PL | 1 |
| Sandler, A | 2 |
| Albanell, J; Banús, JM; Baselga, J; Bastús, R; Batiste-Alentorn, E; Bellmunt, J; Carles, J; Climent, MA; Cortés-Funes, H; de la Cruz, JJ; Diaz-Rubio, E; Font, A; Gallardo, E; González-Larriba, JL; Guillem, V; López-Brea, M; Nogué, M; Paz-Ares, L; Sáenz, A | 1 |
| Giaccone, G; Groeningen, CJ; Kroep, JR; Loves, WJ; Peters, GJ; Pinedo, HM; Tolis, C; Voorn, DA | 1 |
| Johansson, M; Karlsson, A; Zheng, X | 1 |
| Casado, FJ; Inzillo, SM; Larrayoz, IM; Lostao, MP; Mata, JF; Pastor-Anglada, M | 1 |
| Catania, C; Cinieri, S; Curigliano, G; Danesi, R; de Braud, F; De Pas, T; del Tacca, M; Fogli, S; Goldhirsch, A; Marrocco, E; Milani, A; Rocca, A; Sbanotto, A; Sessa, C; Zampino, G | 1 |
| Bafaloukos, D; Dimopoulos, MA; Fountzilas, G; Kalofonos, C; Kosmidis, P; Nicolaides, C; Pavlidis, N; Razi, E; Samantas, E | 1 |
| Bunn, PA; Kelly, K; Mikhaeel-Kamel, N; Murphy, J; Pan, Z; Prindiville, S | 1 |
| Bergman, AM; Giaccone, G; Mauritz, R; Noordhuis, P; Peters, GJ; Pinedo, HM; van Moorsel, CJ | 1 |
| Albers, P; Bodrogi, I; Cleall, SP; Conte, PF; Dogliotti, L; Hansen, SW; Kerbrat, P; Knuth, A; Lippert, CM; Moore, MJ; Oliver, T; Roberts, JT; Roychowdhury, DF; Sanchez Rovira, P; Tomlin, I; Visseren-Grul, CM; von der Maase, H; Wersall, P | 1 |
| Barbarisi, A; Benassai, G; Carbone, I; Ciccarelli, PD; Crovella, F; De Rosa, P; Frattolillo, A; Iaffaioli, RV; Libutti, M; Santangelo, M; Tortoriello, A; Turitto, G | 1 |
| Beauchamp, RD; Benson, AB; Berlin, J; Catalano, PJ; Talamonti, MS; Vaughn, DJ; Whittington, R | 1 |
| Baldwin, AS; Broad, RM; Jones, DR; Madrid, LV; Mayo, MW | 1 |
| Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG | 1 |
| Chow, S; Hedley, DW; Tsao, MS | 1 |
| Beger, HG; Blatter, J; Butzer, U; Kornmann, M; Link, KH | 1 |
| Deutsch, J; Greil, R; Huber, H; Krajnik, G; Malayeri, R; Marhold, F; Mohn-Staudner, A; Pirker, R; Preiss, P; Schäfer-Prokop, C; Schmeikal, S; Thaler, J; Wein, W | 1 |
| Antonuzzo, A; Bertuccelli, M; Bonifazi, V; Franco Conte, P; Galli, L; Lopes Pegna, A; Orlandini, C; Petruzzelli, S; Ricci, S; Tibaldi, C | 1 |
| Boehrer, S; Chow, KU; Hoelzer, D; Mitrou, PS; Napieralski, S; Pourebrahim, F; Ries, J; Rummel, MJ; Stein, J; Stieler, M; Weidmann, E | 1 |
| Arita, K; Daido, K; Nakamura, K; Ohashi, N | 1 |
| Brandl, M; Massing, U; Moog, R; Schubert, R; Unger, C | 1 |
| Einhorn, LH; Kindler, HL; Kraut, M; Masters, G; Mitchell, E; Nicol, S; Raghavan, D; Sandler, AB | 1 |
| Barceló, R; Fernández, R; López-Vivanco, G; Mañé, JM; Muñoz, A; Rubio, I | 1 |
| Burman, KD; Chen, X; Greenberg, M; Hayre, N; Priebat, D; Ringel, MD; Saji, M; Suzuki, K | 1 |
| Brodowicz, T; Függer, R; Jakesz, R; Köstler, WJ; Steger, GG; Teleky, B; Tomek, S; Vaclavik, I; Wolfram, RM; Zielinski, CC | 1 |
| Firby, PS; Hedley, DW; Moore, MJ; Rauchwerger, DR | 1 |
| Ostruszka, LJ; Shewach, DS | 2 |
| Abratt, R; Anglin, G; Crino, L; Green, M; Iglesias, J; Sandler, A; Shepherd, FA; Steward, W | 1 |
| Arotçarena, R; Bénichou, M; Berthelémy, P; Calès, V; Dujols, JP; Pariente, A | 1 |
| Cox, G; Jeyapalan, K; Muller, S; O'Byrne, KJ; Sharma, RA; Shields, F; Steward, WP; Thomas, AL | 1 |
| Comijn, EM; Giaccone, G; Lakerveld, B; Peters, GJ; Pinedo, HM; Postmus, PE; Smid, K; Van der Vijgh, WJ; van Moorsel, CJ; Veerman, G; Voorn, DA | 1 |
| Drengler, RL; Eckhardt, SG; Felton, SA; Garner, AM; Hammond, LA; Hidalgo, M; Mallikaarjun, S; Patnaik, A; Rowinsky, EK; Siu, LL; Tammara, BK; Von Hoff, DD | 1 |
| Arning, M; Arnold, D; Herrenberger, J; Huhn, D; Kindler, M; Korsten, EW; Langrehr, J; Musch, R; Oettle, H; Pelzer, U; Reitzig, P; Riess, H; Stroszczynski, C | 1 |
| Bartolucci, R; Calandri, C; Cipri, A; Crinò, L; Darwish, S; De Marinis, F; Della Giulia, M; Gridelli, C; Mosconi, AM; Novello, S; Porrozzi, S; Rinaldi, M; Scagliotti, GV; Selvaggi, G; Tonato, M | 1 |
| Barni, S; Cascinu, S; Catalano, G; Catalano, V; Curti, C; Farinati, E; Frontini, L; Graiff, C; Labianca, R; Pessi, MA; Picone, G; Zonato, S | 1 |
| Centoni, PE; Ceretelli, S; Liumbruno, G; Sodini, ML | 1 |
| Akrivakis, K; Beinert, T; Flath, B; Genvresse, I; Possinger, K; Späth-Schwalbe, E | 1 |
| Lambrou, N; Trimble, EL | 1 |
| Langer, CJ | 3 |
| Ranson, MR; Thatcher, N; White, S | 1 |
| Briasoulis, E; Constantopoulos, S; Froudarakis, M; Milionis, HJ; Pavlidis, N; Peponis, I | 1 |
| Abruzzo, F; Di Leo, R; Mandina, P; Scarpulla, M; Verderame, F | 1 |
| Lehnert, T; Rudi, J; Stremmel, W; Teufel, A | 1 |
| Hunsucker, SA; Mitchell, BS; Spychala, J | 1 |
| Azinovic, I; Brugarolas, A; Calvo, E; Cortes, J; de Irala, J; Fernandez-Hildago, O; Garzon, C; Martinez-Aguillo, M; Martinez-Monge, R; Ramon Y Cajal, T; Rodriguez, J | 1 |
| Abu-Rustum, N; Barakat, RR; Brown, CL; Chi, DS; Curtin, JP; Hoskins, WJ; Husain, A; Poynor, EA; Prasad, M | 1 |
| Chen, YM; Lin, WC; Perng, RP; Tsai, CM; Whang-Peng, J; Wu, HW | 2 |
| Barbarisi, A; De Marino, V; Elia, S; Facchini, G; Fraioli, G; Frattolillo, A; Gentile, M; Gravina, A; Griffo, S; Iaffaioli, RV; Illiano, A; Libutti, M; Muto, P; Tortoriello, A; Turitto, G | 1 |
| Bonsignore, G; Bucchieri, F; Gjomarkaj, M; Melis, M; Pace, E; Profita, M; Siena, L; Vignola, AM | 1 |
| Lee, C; Tannock, IF | 1 |
| Gérinière, L; Souquet, PJ | 2 |
| Arnold, D; Oettle, H; Riess, H | 1 |
| Arning, M; Clemens, M; Fink, U; Heinemann, V; Illiger, HJ; König, H; Mergenthaler, HG; Possinger, K; Schalhorn, A; Wilke, H | 1 |
| Barbieri, F; Bearz, A; Ceresoli, GL; Favaretto, A; Frustaci, S; Ghiotto, C; Oniga, F; Paccagnella, A; Schiavon, S; Villa, E | 1 |
| Coeman, DC; Demedts, MG; Nackaerts, KL; Vansteenkiste, JF; Verbeken, EK | 1 |
| Arnold, D; Hempel, C; Oettle, H; Riess, H | 1 |
| Cree, IA; Hindley, A; Kurbacher, CM; Lamont, A; Neale, MH | 1 |
| Bartus, RT; Dean, RL; Emerich, DF; Lafreniere, D; Marsh, J; Pink, M; Snodgrass, P | 1 |
| Heinemann, V | 9 |
| D'Agostino, G; Ferrandina, G; Greggi, S; Lorusso, D; Mancuso, S; Manzione, L; Salerno, MG; Scambia, G | 1 |
| Aebi, S; Borner, MM; Büchler, MW; Friess, H; Ludwig, CU; Maurer, CA; Pampallona, S; Rauch, DP | 1 |
| Chang, JW; Chen, SC; Lee, CH; Lin, MC; Tsao, TC; Wang, SW | 1 |
| Carroll, J; Gurnani, M; Hajian, G; Johnson, RC; Mathis, JM; Nielsen, LL; Shi, B; Terracina, G | 1 |
| Ferreira, CG; Giaccone, G; Kruyt, FA; Peters, GJ; Span, SW | 1 |
| Bradford, CR; Chepeha, DB; Dawson, LA; Eisbruch, A; Hogikyan, ND; Lawrence, TS; Littles, JF; Marentette, LJ; Shewach, DS; Teknos, TN; Terrell, JE; Urba, S; Wolf, GT | 1 |
| Bomans, P; Demedts, MG; Nackaerts, KL; Vansteenkiste, JF; Verbeken, EK | 1 |
| Kornek, GV; Kraus, G; Pötter, R; Rogy, M; Scheithauer, W; Schratter, A; Selzer, E; Ulrich-Pur, H | 1 |
| Hojo, K; Maekawa, R; Maki, H; Matsumoto, M; Nishitani, Y; Takeda, Y; Wada, T; Yoshioka, T | 1 |
| Bamberg, M; Dichgans, J; Heiss, E; Kortmann, RD; Küker, W; Meyermann, R; Streffer, J; Weller, M; Wick, W | 1 |
| Alberola, V; Artal, A; Azagra, P; Camps, C; Carrato, A; Felip, E; González-Larriba, JL; Isla, D; Martin, C; Massutí, B; Rosell, R; Sánchez, JJ | 1 |
| Cohen, MH; Rothmann, M | 1 |
| Lilenbaum, R | 1 |
| Vokes, EE | 1 |
| Endo, M; Kadou, T; Kotani, Y; Ohbayashi, K; Satouchi, M; Takada, Y | 1 |
| Gershanovich, ML; Ignashov, AM; Ivanova, NE; Kokhanenko, NIu; Osipenko, SK; Rybakov, GV | 1 |
| Bregman, D; Manalo, J; Mani, S | 1 |
| Delpon, A; Dupuis, O; Ganem, G; Joffroy, A; Solal-Celigny, P; Tassy, D | 1 |
| Brescia, FJ; Green, MR; Rocha Lima, CM; Sherman, CA; Urbanic, JJ | 1 |
| Azuma, A; Huang, P; Li, YX; Plunkett, W; Sampath, D; Shi, Z | 1 |
| Bonomi, P; Shirazi, W | 1 |
| Belani, CP; Calvo, AR | 1 |
| Doyle, TH; McKenna, WG; Mornex, F | 1 |
| Davis, MA; Hough, A; Lawrence, TS; Rehemtulla, A | 1 |
| Al-Rikabi, AC; Najjar, TA; Noreddin, AM; Saad, SY | 1 |
| Kampinga, HH; Peters, GJ; Smid, K | 1 |
| Agelaki, S; Aravantinos, G; Georgoulias, V; Kakolyris, S; Karabekios, S; Kouroussis, C; Mavroudis, D; Rigatos, SK; Stathopoulos, GP; Tsavaris, N | 1 |
| Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Favre, C; Greco, F; Guarneri, V; Innocenti, F; Menconi, MC; Orlandini, C; Pazzagli, I | 1 |
| Blair, S; Carman, L; Colborn, D; George, C; Jones, J; Kuebler, JP; Laufman, LR; Moore, T; Patel, T; Roach, R; Rupert, R; Spiridonidis, CH; Zangmeister, J | 1 |
| Ryan, CW; Vogelzang, NJ | 1 |
| Bast, RC; Booser, D; Esteva, FJ; Esteva, FL; Hortobagyi, GN; Murray, JL; Rahman, Z; Rivera, E; Rosales, MM; Syrewicz, L; Theriault, RL; Valero, V | 1 |
| Seidman, AD | 4 |
| Hortobagyi, GN | 2 |
| Georgoulias, VA | 1 |
| Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini'Neto, AO | 1 |
| Nagourney, RA | 1 |
| Adjei, AA | 5 |
| Ansari, R; Gize, G; Miller, KD; Monaco, F; Nattam, S; Pennington, K; Sisk, J; Sledge, GW | 1 |
| Cetto, GL; Conte, P; Crino, L; Donati, S; Galligioni, E; Gennari, A; Mansutti, M; Mazzoni, F; Molino, A; Salvadori, B | 1 |
| Carrasco, E; Dueñas, R; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Löhr, JM | 1 |
| Furuse, J; Ikeda, M; Maru, Y; Okada, S; Okusaka, T; Ueno, H | 1 |
| Abbruzzese, JL; Breslin, TM; Cleary, KR; Crane, CH; Dackiw, AP; Evans, DB; Harbison, DB; Hess, KR; Janjan, NA; Jean, ME; Lee, JE; Pisters, PW; Vauthey, JN; Wolff, RA | 1 |
| Azuma, A; Huang, P; Matsuda, A; Plunkett, W | 1 |
| Fujita, A; Minase, T; Sekine, K; Tagaki, S; Takabatake, H | 1 |
| Albella, B; Bueren, JA; Keyes, KA; Parchment, RE; Segovia, JC | 1 |
| Fry, DW; Nelson, JM | 1 |
| Bergman, AM; Peters, GJ; Pinedo, HM | 2 |
| Douillard, JY; Eckardt, J; Georgoulias, V; Manegold, C; Miller, V; Scagliotti, G | 1 |
| Benk, J; Chemaissani, A; Dalhoff, K; Dürk, H; Edler, L; Hossfeld, DK; Laack, E; Lorenz, C; Mende, T; Müller, T; Niestroy, A; Scholtze, J; Walter, T | 1 |
| Gnant, MF; Jakesz, R; Locker, GJ; Marosi, C; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Kachnic, LA; Lauve, AD; Manning, MA; Neifeld, JP; Shaw, JE | 1 |
| Malkowicz, SB; Vaughn, DJ | 2 |
| Eucker, J; Jakob, C; Kaufmann, O; Possinger, K; Schmid, P; Sezer, O | 1 |
| Arends, J; Unger, C | 1 |
| Awwad, E; Cacayorin, ED; Dunphy, F; Nassif, AS; Perman, W; Russell, MT | 1 |
| Depisch, D; Fiebiger, W; Kornek, GV; Krauss, G; Lenauer, A; Penz, M; Raderer, M; Scheithauer, W; Schneeweiss, B; Ulrich-Pur, H | 1 |
| Brescia, FJ; Brunson, CY; Green, MR; Rocha Lima, CM; Sherman, CA | 1 |
| Johnson, DH | 1 |
| Calandri, C; Crinò, L; Maestri, A; Marrocolo, F | 1 |
| Choy, H; Curran, WJ | 1 |
| Krywicki, RF; Pipas, JM | 1 |
| Boneschi, V; Brambilla, L; Ferrucci, SM; Labianca, R; Taglioni, M | 1 |
| Rixe, O; Seigneur, J; Spano, JP | 1 |
| Culine, S | 4 |
| Geissler, M; Ness, T; Schmidt, D | 1 |
| Johnson, FM | 1 |
| Bianco, V; Di Girolamo, B; Florio, G; Gemma, D; Girolami, M; Marchei, P; Pignatelli, E; Speranza, I; Vietri, F | 1 |
| Pestieau, SR; Schnake, KJ; Stuart, OA; Sugarbaker, PH | 1 |
| Agelaki, S; Androulakis, N; Bania, E; Chainis, K; Georgoulias, V; Kakolyris, S; Kalofonos, C; Kouroussis, C; Papadakis, E; Rapti, A; Sarra, E; Toubis, M; Tsiafaki, X; Vardakis, N | 1 |
| Gajra, A; Graziano, SL; Kirshner, J; Mehdi, SA; Newman, N | 1 |
| Nguyen, NP; Sallah, S; Wan, JY | 1 |
| Bancalari, L; Canessa, P; Fiasella, L; Maggiani, R; Pensa, F; Pronzato, P; Tognoni, A; Vaira, F; Vigani, A | 1 |
| Bergman, AM; Jensen, PB; Munch-Petersen, B; Peters, GJ; Pinedo, HM; Sehested, M; Smid, K; Veerman, G; Voorn, DA | 1 |
| Du, W; Hussain, M; Redman, B; Smith, DC; Vaishampayan, U | 1 |
| de la Guerra, J; Dueñas-Gonzalez, A; Hinojosa-García, LM; López-Graniel, C; Maldonado, V; Meléndez-Zagla, J | 1 |
| Antonopoulos, M; Kalofonos, HP; Kosmas, C; Kourelis, T; Malamos, N; Panopoulos, C; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Cassidy, CA; Cirera, L; Peterson, P; Roychowdhury, DF | 1 |
| Assouline, D; Bennouna, J; Douillard, JY; Grau, B; Haller, AM; Lerouge, D; Monnier, A; Rivière, A; Sun, XS | 1 |
| Byrd, JC; Flinn, IW; Grever, MR; Shinn, CA; Waselenko, JK | 1 |
| Klausner, JY; Kluger, Y; Michowitz, M; Schreiber, L; Soffer, D; Sorid, D | 1 |
| Ahumada, M; Cortés, C; Gallardo, J; Rubio, B | 1 |
| Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A | 1 |
| Brátová, M; Kohout, P; Králícková, P; Melichar, B; Solichová, D; Zadák, Z | 1 |
| Altmann, A; Bellemann, ME; Blatter, J; Brix, G; Doll, J; Haberkorn, U; Kamencic, H; Kinscherf, R; Morr, I; Traut, U | 1 |
| Bontenbal, M; de Heus, G; de Wit, R; Seynaeve, C; Smorenburg, CH; van Zuylen, C; Verweij, J | 1 |
| Huber, H; Malayeri, R | 1 |
| Chansilpa, Y; Ieumwananontachai, N; Pattaranutaporn, P; Thephamongkhol, K; Therasakvichya, S; Thirapakawong, C | 1 |
| Cohen, EE; Stadler, WM | 1 |
| Azzadin, A; Chyczewski, L; Dadan, J; Dziecioł, J; Puchalski, Z; Sawicki, B; Wołczyński, S | 1 |
| Izuta, S; Miura, S; Satoh, H; Yoshimura, Y | 1 |
| Bandala, E; Espinosa, M; Maldonado, V; Meléndez-Zajgla, J | 1 |
| Alexopoulos, A; Georgoulias, V; Palamidas, P; Papadakis, E; Rapti, A; Tsiafaki, X; Veslemes, M; Vlachonikolis, I | 1 |
| Giaccone, G; Pinedo, HM; Savonije, JH; Spanier, BW; van Groeningen, CJ | 1 |
| Bouafia, F; Bourgeois, E; Coiffier, B; Dumontet, C; Hequet, O; Leleu, X; Morschhauser, F; Salles, G; Solal-Celigny, P; Thieblemont, C | 1 |
| Kokawa, Y; Matsuyama, K; Naito, Y; Nakamura, T; Oura, S; Sakurai, T; Tanino, H; Yoshimasu, T | 1 |
| Meyer, F; Ridwelski, K | 1 |
| Aleksic, A; Berg, SL; Blaney, S; Dauser, R; Egorin, MJ; Kerr, JZ; McGuffey, L; Nuchtern, J | 1 |
| Bengala, C; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Salvadori, B | 1 |
| Chanona, J; De la Garza, J; Dueñas-Gonzalez, A; Florentino, R; Gonzalez, A; Guadarrama, R; Hinojosa, LM; Lopez-Graniel, C; Maldonado, V; Meléndez, J; Mohar, A; Mota, A; Muñoz, D; Reyes, M; Robles, E; Solorza, G | 1 |
| Groen, HJ; Postmus, PE; Schlösser, NJ; Schramel, FM; Smit, EF; van der Lee, I; van Putten, JW | 1 |
| Aragão, BC; Garcia, R; Guimarães, RC; Murad, AM; Rodrigues, VH; Scalabrini-Neto, AO | 1 |
| Calandri, C; Chiara, S; Corgna, E; Crinò, L; Mosconi, AM; Nobili, MT; Porrozzi, S; Tonato, M | 1 |
| Bramham, J; Burris, HA; Calvert, SW; Greco, FA; Hainsworth, JD; Scullin, DC; Willcutt, NT | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Johnson, V; Meluch, AA; Morrissey, LH; O'Rourke, T; Ortega, G; Steis, RG | 1 |
| Cuvier, C; Diéras, V; Espié, M; Ferrero, JM; Fumoleau, P; Kalla, S; Kayitalire, L; Llombart-Cussac, A; Namer, M; Perrocheau, G; Ponzio, A; Pouillart, P; Spielmann, M | 1 |
| Fiebiger, W; Kornek, GV; Raderer, M; Scheithauer, W; Schüll, B; Ulrich-Pur, H | 1 |
| Fine, RL; Sherman, WH | 1 |
| Noordhuis, P; Peters, GJ; Smid, K; Van Moorsel, CJ; Voorn, DA | 1 |
| Dumontet, C; Galmarini, CM; Mackey, JR | 1 |
| Günzburg, WH; Salmons, B | 1 |
| Crane, CH; Evans, DB; Wolff, RA | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Erlichman, C; Goldberg, RM; Kaufmann, SH; Okuno, SH; Pitot, HC; Rubin, J; Sloan, J | 1 |
| André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F | 1 |
| Banzato, F; Cappella, P; D'Incalci, M; Faretta, M; Lupi, M; Montalenti, F; Tomasoni, D; Ubezio, P; Viale, F | 1 |
| Barón, F; Candamio, S; Cueva, J; Curiel, T; Graña, B; León, L; López, R; Vázquez, F | 1 |
| Farrugia, D; Lewis, R | 1 |
| Botwood, N | 1 |
| Mattson, K | 1 |
| Glimelius, B; Hafström, L; Nygren, P; Permert, J | 1 |
| Edelman, MJ; Gandara, DR; Lara, P; Lau, DH; Lauder, IJ; Tracy, D | 1 |
| Logothetis, CJ; Millikan, RE; Plunkett, WK; Smith, TL; Williams, DL | 1 |
| Ibrahim, SM; Koczan, D; Löhr, M; Müller, P; Ringel, B; Ringel, J; Schmidt, C; Thiesen, HJ | 1 |
| Kielb, SJ; Rubin, MA; Sanda, MG; Shah, NL | 1 |
| Soloway, MS | 1 |
| Barnes, B; Brierre, J; Buller, E; Cole, J; Fontenot, F; Lormand, N; Rainey, J; Rinaldi, D | 1 |
| Bruckner, HW; Evans, A; Kozuch, P; Petryk, M | 2 |
| Chewaskulyong, B; Pothirat, C; Thongprasert, S | 1 |
| Algazy, K; Gallagher, M; Giantonio, B; Haller, D; O'Dwyer, PJ; Raskay, BJ; Stevenson, JP; Sun, W; Vaughn, D | 1 |
| Baranov, E; Bouvet, M; Hoffma, RM; Jiang, P; Lee, NC; Moossa, AR; Nardin, S; Rashidi, B; Wang, X; Yang, M | 1 |
| Carpini, RD; Fedier, A; Fink, D; Haller, U; Schwarz, VA; Walt, H | 1 |
| Bowry, C; Bramhall, SR; Brown, PD; Buckels, JA; Rosemurgy, A | 1 |
| Benjamin, RS; Burgess, MA; Gandhi, V; Jenkins, J; Papadopolous, N; Patel, SR; Plager, C; Plunkett, W | 1 |
| Barth, RJ; Colacchio, TA; Lewis, LD; McDonnell, C; Meyer, LP; Mitchell, SE; Perez, RP; Pipas, JM; Rathmann, J; Vera-Gimon, R; Wagman, RS | 1 |
| Blatter, J; Bosquée, L; Gatzemeier, U; Hanauske, A; Manegold, C; Mansouri, K; Vansteenkiste, J; von Pawel, J; Weynants, P | 1 |
| Casali, A; Casali, M; Ferrone, C; Galante, E; Giuntini, T; Marcellini, M | 1 |
| Hansen, SW | 2 |
| Bookman, MA | 4 |
| Abbruzzese, JL; Charnsangavej, C; Evans, DB; Gravel, DM; Janjan, NA; Lee, JE; Lenzi, R; Pisters, PW; Wolff, RA | 1 |
| Jung, CP; Motwani, MV; Schwartz, GK | 1 |
| Baker, CH; Buchdunger, E; Cohen, P; Fidler, IJ; Killion, JJ; Solorzano, CC; Traxler, P; Tsan, R | 1 |
| Robinson, BW; Shewach, DS | 1 |
| Cole, DJ; Fraser, MM; Kelley, JR; Schweinfest, CW; Vournakis, JN; Watson, DK | 1 |
| Copeland, EM; Hebig, P; Hochwald, SN; Lind, DS; Mackay, S; Malaty, J; Mishra, G; Moldawer, LL; Rekkas, S | 1 |
| Albiol, S; Bellmunt, J | 1 |
| Murren, JR | 1 |
| Bunnell, CA; Burstein, HJ; Winer, EP | 1 |
| Alberts, SR; Jacobson, SD; O'Connell, MJ | 1 |
| Crowell, PL; Jung, SH; Marshall, MS; Sweeney, CJ; Yip-Schneider, MT | 1 |
| Adsay, V; Arlauskas, P; Chaplen, R; Heilbrun, LK; Philip, PA; Shields, AF; Vaitkevicius, VK; Weaver, D; Zalupski, MM | 1 |
| Casado, V; Castillo, M; Dómine, M; Estévez, LG; León, A; Lobo, F; Martin, JI; Rubio, G | 1 |
| Barroso, A; Conde, S; Guimarães, T; Parente, B; Seada, J | 1 |
| Steele, JP | 1 |
| Carles, J; Nogué, M | 1 |
| Abbruzzese, JL; Charnsangavej, C; Crane, CH; Evans, DB; Janjan, NA; Lahoti, S; Lee, JE; Lenzi, R; Mason, K; Milas, L; Pisters, PW; Vauthey, JN; Wolff, RA | 1 |
| Brunson, CY; Green, MR; Kneuper-Hall, R; Lal, A; Rocha Lima, CM; Urbanic, JJ | 1 |
| Abal, M; Agusto, S; Almira, E; Balbiani, L; Castilla, JL; Fein, L; Jovtis, S; Lewi, D; Marantz, A; Muiño, M; Pasccon, G; Pinckevicius, R; Reale, M; Uranga, G | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; De Rosa, V; Frasci, G; Thomas, R | 1 |
| de Mendoza, FH; Falcon, S; Gomez, H; Kahatt, C; Otero, J; Pen, DL; Santillana, S; Valdivia, S; Vallejos, C | 1 |
| Mandachain, M; Orlando, M | 1 |
| Bold, RJ; McConkey, DJ; Virudachalam, S | 1 |
| Inoue, A; Saijo, N | 1 |
| Chalas, E; Hindenburg, A; Jeyakumar, A | 1 |
| Brooks, A; Crombie, C; Drummond, M; Gurney, H; Lau, H; Shannon, C | 1 |
| Rixe, O | 1 |
| Ayoub, J; Cormier, Y; Hirsh, V; Iglésias, JL; Langleben, A; Pintos, J | 1 |
| Van Zandwijk, N | 1 |
| Cappuzzo, F; Crino, L | 2 |
| Accurso, V; Agostara, B; Carroccio, R; De Bella, MT; Di Vita, G; Faillú, G; Ferraù, F; Gebbia, V; Leonardi, V; Licata, G; Palmeri, S; Sciortino, G; Spatafora, M; Vaglica, M; Valenza, R; Vitello, S | 1 |
| Crane, CH; Janjan, NA; Mason, KA; Milas, L; Phan, TP; Vrdoljak, E | 1 |
| Abbruzzese, JL; Ballo, MT; Charnsangavej, C; Crane, CH; Evans, DB; Janjan, NA; Lee, JE; Lenzi, R; Mason, K; Milas, L; Nguyen, Q; Phan, T; Pisters, PW; Vauthey, JN; Wolff, RA; Wong, A | 1 |
| Ensley, JF; Giguere, JK; Gundacker, H; Kuebler, JP; Mills, GM; Samlowski, WE; Schuller, DE | 1 |
| Beryt, M; Felber, M; Hepp, H; Kahlert, S; Konecny, G; Langer, E; Lude, S; Pegram, M; Slamon, D; Untch, M | 1 |
| Edelman, MJ; Mullins, B; Quam, H | 1 |
| Anderson, I; Dang, NH; Elias, A; Herbst, RS; Leong, T; Lynch, C; Salgia, R; Skarin, AT; Strauss, G; Teicher, BA; Vasconcelles, M; Zacarola, P | 1 |
| Adams, AL; Gallo, JM; Guo, P; Guo, Z; Li, S; Ma, J | 1 |
| Bhargava, P; Dahut, W; Figuera, M; Fried, K; Gehan, E; Hanfelt, J; Hawkins, MJ; Lefebvre, P; Marshall, JL; Rizvi, NA; Williams, M | 1 |
| Sun, W; Vaughn, DJ | 1 |
| Coudray, AM; Faivre, S; Gespach, C; Louvet, C; Raymond, E | 1 |
| Gatzemeier, U | 1 |
| Blohmer, JU; du Bois, A; Kimmig, R; Lück, HJ; Moebus, V; Pfisterer, J; Quaas, J; Schroeder, W | 1 |
| Greif, J; Inbar, M; Mann, A; Marmor, S; Merimsky, O; Schwartz, Y; Staroselsky, A; Wigler, N | 1 |
| Cufer, T; Wein, W; Zwitter, M | 1 |
| Johnson, SA | 1 |
| Pützer, BM; Rödicker, F; Stiewe, T; Zimmermann, S | 1 |
| Cass, CE; Clarke, ML; Gourdeau, H; Jolivet, J; Lafrenière, RG; Lee, N; Mackey, JR; Mowles, D; Ouellet, F; Richard, A; Selner, M; Young, JD | 1 |
| Johansson, M; Karlsson, A; Sanda, A; Zhu, C | 1 |
| Colston, KW; Dalgleish, AG; Pettersson, F | 1 |
| Alonso, V; Antón, A; Artal, A; Herrero, A; Martinez-Trufero, J; Maurel, J; Puertas, MM; Puertolas, T; Zorrilla, M | 1 |
| Baron, A; Bunn, PA; Chan, DC; Franklin, WA; Helfrich, B; Hirsch, FR; Soriano, AF; Varella-Garcia, M; Zeng, C | 1 |
| Blackstock, AW; Case, LD; Hess, SM; Lightfoot, H; Mitchell, BS; Mukherji, SK; Swarts, SG; Tepper, JE | 1 |
| Hedley, DW; Ng, SS; Nicklee, T; Tsao, MS | 2 |
| Goulart, BH; Lynch, TJ; Martins, RG | 1 |
| Ahern, J; Carmichael, J; Dombernowsky, P; Hansen, H; Hansen, M; Harper, PG; Highley, MS; Hirsch, F; Lund, B; Parnis, FX; Underhill, CR; Williams, C | 1 |
| Aebi, S; Büchler, MW; Friess, H; Kleeff, J; Korc, M; Solioz, M; Xu, Z | 1 |
| Gandhi, V; Krett, N; Nabhan, C; Rosen, S | 1 |
| Satoh, H; Sekizawa, K | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; de Wit, R | 1 |
| Lawrence, TS; McGinn, CJ | 1 |
| Santini, M; Scarpati, MD; Vicidomini, G | 1 |
| Cabrera, E; Cortés, C; Gallardo, J; González, C; Rubio, B | 1 |
| Belle, E; Capellier, G; Caps, T; Carron, PL; Cousin, L; Neidhardt, A; Pernet, D | 1 |
| Baldini, E; Bengala, C; Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A; Orlandini, C; Pazzagli, I; Salvadori, B | 1 |
| Burstein, HJ; Winer, EP | 1 |
| De Vincenzo, R; Distefano, M; Ferlini, C; Gaggini, C; Mancuso, S; Scambia, G | 1 |
| Dams, NL; Devogelaere, RC; Humblet, YP; Marien, SA; Nackaerts, KL; Valcke, YJ; Vandebroek, JE; Vansteenkiste, JF; Verresen, DA; Weynants, P | 1 |
| Carman, L; Colborn, D; Gutterman, L; Jones, J; Kuebler, JP; Larrimer, N; Laufman, LR; Moore, T; Patel, T; Pritchard, J; Roach, R; Segal, M; Spiridonidis, CH; Zangmeister, J | 1 |
| Bansback, N; Calvert, N; Crellin, A; Forman, D; Larvin, M; Morris, E; Radstone, D; Ward, S | 1 |
| Calandri, C; Collina, G; Maestri, A; Marucci, G; Sgarbanti, E | 1 |
| Aydin, F; Ilis, E; Ozdemir, F; Yavuz, AA; Yavuz, MN | 1 |
| Brown, D; Eckhauser, FE; Hejna, G; Lawrence, TS; McGinn, CJ; Normolle, D; Robertson, JM; Shureiqi, I; Smith, DC; Strawderman, M; Zalupski, MM | 1 |
| Froehner, M; Gaertner, HJ; Manseck, A; Wirth, MP | 1 |
| Ardizzoni, A; Baldini, E; Boni, L; Cafferata, MA; Conte, PF; Neumaier, C; Prochilo, T; Rosso, R; Tibaldi, C | 1 |
| Monzo, M; Rosell, R; Taron, M | 1 |
| Bontenbal, M; Smorenburg, CH; Sparreboom, A; Verweij, J | 1 |
| Blackstock, AW; Case, LD; Fletcher-Steede, J; Lesser, GJ; Miller, A; Russo, SM; Tucker, RW; White, DR | 1 |
| du Bois, A | 1 |
| Calabrò, F; Cartei, G; Cetto, GL; Maiorino, A; Maluta, S; Molino, A; Oletti, MV; Panza, N; Pari, F; Pasini, F; Pedersini, R; Santo, A; Sibau, A; Terzi, A | 1 |
| Crinò, L; Rinaldi, M | 1 |
| Boccieri, MG; Bruschi, G; Lo Re, G; Saracchini, S; Toffoli, G; Tumolo, S | 1 |
| Alexopoulos, A; Georgoulias, V; Giannakakis, T; Grigoratou, T; Kakolyris, S; Kouroussis, C; Mavroudis, D; Palamidas, P; Papadakis, E; Rapti, A; Samonis, G; Tsiafaki, X; Veslemes, M; Vlachonikolis, J | 1 |
| Van Putten, JW | 1 |
| Belli, M; Bianco, A; Comella, G; Comella, P; De Lena, M; DeCataldis, G; Frasci, G; Iannelli, N; Lorusso, V; Mascia, V; Massidda, B; Nicolella, G; Panza, N | 1 |
| Caffo, O | 1 |
| le Chevalier, T; Novello, S | 1 |
| Araneo, M; Barzdins, A; Bruckner, HW; DeGregorio, P; Frager, D; Grossbard, ML; Homel, P; Kozuch, P; Marino, J; Robin, A | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, AB; Schiller, J; Sweeney, CJ; Zhu, J | 1 |
| Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ | 1 |
| Baker, M; Billings, FT; Bradof, JE; Burris, HA; Greco, FA; Hainsworth, JD | 1 |
| Jassem, J; Krawczyk, K; Krzakowski, M; Lis, J; Miracki, K; Mozejko-Pastewka, B; Ramlau, R; Roszkowski, K; Szczesna, A; Słomiński, JM | 1 |
| Achanta, G; Feng, L; Huang, P; Pelicano, H; Plunkett, W | 1 |
| Kalofonos, HP; Kosmas, C; Koutras, A; Malamos, N; Onyenadum, A; Polyzos, A; Rokana, S; Stavroyianni, N; Tsavaris, N; Vadiaka, M | 1 |
| Calabrò, F; Marini, L; Pizzocaro, G; Schnetzer, S; Sella, A; Sternberg, CN | 1 |
| Hribaschek, A; Kasper, U; Lippert, H; Meyer, F; Ridwelski, K | 1 |
| Ahumada, M; Fodor, M; Gallardo, JO; Gamargo, C; Orlandi, L; Rubio, B; Yáñez, M | 1 |
| Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N | 1 |
| De Stefano, V; Leone, G; Mario, AD; Mele, L; Pagano, L | 1 |
| Heinemann, V; Stoffregen, C; Wilkowski, R | 1 |
| Allegretto, M; Mackey, JR; Selkaly, H | 1 |
| Athanasiadis, I; Malamos, NA; Pergantas, N; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Tsavdarides, D | 1 |
| Blumenthal, R; Cardillo, TM; Gold, DV; Ying, Z | 1 |
| de Wit, R | 1 |
| Baker, CH; Bruns, CJ; Ellis, LM; Fidler, IJ; Killion, JJ; Solorzano, CC; Wood, J | 1 |
| Bethe, U; Cornely, OA; Pels, H; Ritzkowsky, A; Seibold, M; Soehngen, D; Toepelt, K | 1 |
| Alvarez, E; Bergman, AM; Eriksson, S; Kroep, JR; Loves, WJ; Peters, GJ; Pinedo, HM; Talianidis, I; van der Wilt, CL; van Groeningen, CJ | 1 |
| Belani, CP; Harrington, D; Johnson, DH; Krook, J; Langer, C; Sandler, A; Schiller, JH; Zhu, J | 1 |
| Bertucci, D; Kindler, HL; Ratain, MJ; Schilsky, RL; Vogelzang, NJ | 1 |
| Buscail, L; Escourrou, J; Faure, P; Moreau, J; Pages, P | 1 |
| Gmeiner, WH; James, TL; Konerding, D; Marky, LA; Soto, AM; Trump, E | 1 |
| Dueñas-Gonzalez, A; Hernández, P; Maldonado, V; Meléndez-Zajgla, J; Olivera, P; Pérez-Pastenes, MA; Zárate, A | 1 |
| Amadori, D; De Paola, F; Frassineti, GL; Ricotti, L; Tesei, A; Zoli, W | 1 |
| Artioli, F; Bandieri, E; Di Fabio, F; Guaraldi, M; Lelli, G; Martoni, A; Palomba, G; Piana, E; Preti, P; Ramini, R; Robustelli Della Cuna, G | 1 |
| Benasso, M; Corvò, R; Marchetti, G; Merlano, M; Numico, G; Pallestrini, E; Ricci, I; Rosso, R; Sanguineti, G; Santelli, A; Vitale, V | 1 |
| Clarke, ML; Dumontet, C; Falette, N; Galmarini, CM; Mackey, JR; Puisieux, A | 1 |
| Favaudon, V; Hennequin, C | 1 |
| Bonadonna, G; Brambilla, C; Demicheli, R; Gianni, L; Marchianò, A; Mariani, G; Tagliabue, P; Valagussa, P; Villa, E; Zucchinelli, P | 1 |
| Bergström, M; Borbath, I; Grégoire, V; Långström, B; Laryea, D; Pauwels, S | 1 |
| Clegg, A; Hewitson, P; Scott, DA; Sidhu, M; Waugh, N | 2 |
| Ambinder, R; Blackstein, M; Cowan, J; Iglesias, J; Melemed, A; Vogel, CL | 1 |
| Botti, G; Capasso, I; Comella, G; Comella, P; Cortino, GR; D'Aiuto, G; Di Bonito, M; Frasci, G; Rubulotta, R; Thomas, R; Vallone, P | 1 |
| Brugnatelli, S; Danova, M; De Bella, MT; Manuguerra, G; Palmeri, S; Riccardi, A; Vaglica, M | 1 |
| Clark, JW; Earle, CC; Fuchs, CS; Grossbard, ML; Grossman, SR; Kim, H; Kulke, MH; Mayer, RJ; Morgan, JA; Ryan, DP; Shivdasani, R | 1 |
| Milowsky, MI; Nanus, DM; Papanicolaou, N; Rosmarin, A; Tickoo, SK | 1 |
| Fukuda, M; Kato, K; Kawasaki, Y; Kobayashi, K; Miyata, M; Saito, S; Shimizu, E; Yano, S | 1 |
| Ayres, M; Du, M; Estey, EH; Gandhi, V; Plunkett, W | 1 |
| Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hurwitz, H; Jacobson, R; Laughlin, MJ; Moore, JO; Petros, WP; Rizzieri, DA; Rosner, GL | 1 |
| Cellini, N; Cesario, A; Corbo, GM; D'Angelillo, RM; Galetta, D; Granone, P; Gualano, G; Macis, G; Margaritora, S; Ramella, S; Trodella, L; Turriziani, A; Valente, S | 1 |
| Curigliano, G; Danesi, R; De Braud, F; De Pas, T; Del Tacca, M; Fogli, S; Giovannetti, G | 1 |
| Catania, C; Curigliano, G; de Braud, F; De Pas, T; Franceschelli, L; Spaggiari, L | 1 |
| Baraona, FJ; Kett, DH; Rosado, MF; Schein, RM; Sridhar, KS | 1 |
| Ahmed, I; Gupta, N; Mehrotra, B; Nissel-Horowitz, S; Patel, D; Steinberg, H | 1 |
| Adsay, NV; El-Rayes, BF; Philip, PA | 1 |
| Bagrova, SG | 1 |
| Broad, RM; Comeau, LD; Jones, DR; Mayo, MW; Parsons, SJ | 1 |
| Arcangeli, V; Drudi, G; Fochessati, F; Gianni, L; Mianulli, AM; Oliverio, G; Panzini, I; Pasini, G; Pasquini, E; Ravaioli, A; Sartori, S; Tassinari, D | 1 |
| Fujita, Y; Kunikane, H; Kurita, Y; Nakai, Y; Niitani, H; Noda, K; Watanabe, K; Yokoyama, A; Yoneda, S | 1 |
| Kindler, HL; van Meerbeeck, JP | 1 |
| Elad, G; Gana-Weisz, M; Haklai, R; Halaschek-Wiener, J; Jansen, B; Kloog, Y | 1 |
| Markman, M | 3 |
| Thigpen, T | 3 |
| Hossfeld, DK; Knuffmann, C; Laack, E; Mende, T | 1 |
| Ammaturo, MV; Ariganello, O; Belli, R; Cipri, A; De Marinis, F; Di Molfetta, M; Diana, F; Facciolo, F; Martelli, O; Migliorino, MR; Nelli, F | 1 |
| Chen, YM; Lee, CS; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Geoffroy, FJ; George, CM; Kollipara, P; Rini, BI; Stadler, WM; Vogelzang, NJ | 1 |
| Fong, KW; Foo, KF; Koh, L; Leong, SS; Lian, LG; Machin, D; Tai, BC; Tan, EH; Tan, T; Wee, JT | 1 |
| Bruckner, H; Compton, LD; Dudek, A; Eckardt, J; Elfring, GL; Green, MR; Hainsworth, J; Lester, E; Locker, PK; Miller, LL; Miller, W; Rocha Lima, CM; Savarese, D; Saville, W; Yunus, F | 1 |
| Chang, CJ; Chen, YM; Cheng, AL; Chiang, SC; Hsu, C; Huang, MH; Lee, YC; Liu, MY; Luh, KT; Lui, LT; Perng, RP; Tsai, CM; Wang, LS; Yang, CH; Yang, PC; Yen, SH | 1 |
| Blay, JY; Hermans, C; Hogendoorn, PC; Judson, IR; Keizer, HJ; le Cesne, A; Nielsen, OS; Svancárová, L; van Glabbeke, M; van Hoesel, QG; van Oosterom, AT; Verweij, J | 1 |
| Moore, MJ | 2 |
| Baas, P; Burgers, JA; de Bruin, HG; de Jonge, MJ; Manegold, Ch; Mooi, WJ; Schouwink, JH; van Haarst, JM; van Klaveren, RJ; van Meerbeeck, JP | 1 |
| Aparicio, M; De Precigout, V; Delclaux, C; Dilhuydy, MS; Pariente, A | 1 |
| Athanassiou, A; Bountouroglou, N; Glotsos, J; Karvounis, N; Kouloubinis, A; Mitakidis, N; Pectasides, D; Ziras, N | 1 |
| D'Aiuto, M; De Braud, F; Leo, F; Leon, ME; Pastorino, U; Pelosi, G; Solli, PG; Spaggiari, L; Veronesi, G | 1 |
| Gentile, A; Masotti, A; Morandini, G; Zannini, G | 1 |
| Albers, P; Blatter, J; Fallahi, M; Haeutle, D; Härtlein, M; Müller, SC; Perabo, FG; Siener, R; Steiner, G | 1 |
| Stadler, WM | 2 |
| Hussain, M; Smith, DC; Vaishampayan, U | 1 |
| Misset, JL | 1 |
| Alberola, V; Barnadas, A; Manzano, JL; Monzó, M; Rosell, R; Sanchez, JJ; Sánchez, JM; Taron, M | 1 |
| Cowan, DS; Egorin, MJ; Lee, CM; Tannock, IF; Tunggal, JK | 1 |
| Harper, P; Khayat, D; Marx, GM; Pavlakis, N; Rixe, O; Steer, CB | 1 |
| André, T; Bleiberg, H; Bouleuc, C; Cvitkovic, E; de Gramont, A; Flesch, M; Gamelin, E; Hammel, P; Lledo, G; Louvet, C | 1 |
| Barton, JH; Bradof, JE; Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Litchy, S; Morrissey, LH; Richards, P; Scullin, DC | 1 |
| Cropp, GF; Giaccone, G; Hoekman, K; Huisman, H; Kedde, MA; Kuenen, BC; Levi, M; Noordhuis, P; Parson, MR; Peters, GJ; Pinedo, HM; Rosen, L; Ruijter, R; Scigalla, P; Smit, EF; van der Vijgh, WJ | 1 |
| Salman, HS; Sparano, JA; Tanaka, K | 1 |
| Dueñas, MR; Fernández, M; González, E; Jaén, A; Lozano, A; Martos, M; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Conte, PF; Dani, D; Donati, S; Gennari, A; Giorgetti, A; Landucci, E; Mariani, G; Pisani, P; Poli, M; Puccini, G; Salvadori, B; Salvadori, PA; Sorace, O | 1 |
| Duan Xp, XP; Jia, SF; Kleinerman, ES; Turan, M; Worth, LL | 1 |
| Breidenbach, M; Kurbacher, CM; Mallmann, P; Rein, DT | 1 |
| Gunz, A; Joerger, M; Pestalozzi, BC; Speich, R | 1 |
| Assmann, G; Eckel, F; Lersch, C; Schulte-Frohlinde, E | 1 |
| Kato, Y; Saijo, N | 1 |
| Matranga, CB; Shapiro, GI | 1 |
| D'Agostino, G; Farnetano, MG; Ferrandina, G; Garganese, G; Lorusso, D; Mancuso, S; Salerno, MG; Scambia, G | 1 |
| Beger, HG; Cammerer, G; Gansauge, F; Gansauge, S; Leder, G; Muehling, B; Pressmar, J; Ramadani, M; Stecker, K | 1 |
| Okada, S | 1 |
| Bando, K; Hasegawa, Y; Hatachi, Y; Murayama, T; Nakata, M; Ohyama, S; Taniguchi, M; Ueda, T | 1 |
| Dickgreber, N; Dürk, H; Edler, L; Graeven, U; Hossfeld, DK; Jasiewicz, Y; Kneba, M; Laack, E; Mende, T; Müller, T; Scholtze, J; Welte, T | 1 |
| Catalano, P; Einhorn, LH; Hinton, S; Kuzel, T; Loehrer, PJ; Vaughn, D; Wilding, G | 1 |
| Biglietto, M; Cigolari, S; Colucci, G; Gebbia, V; Giuliani, F; Lopez, M; Maiello, E; Rabitti, P; Testa, A; Uomo, G | 1 |
| Riviere, A | 1 |
| Morere, JF | 2 |
| Mavroudis, D | 1 |
| Hisada, T; Ito, T; Masuda, S; Mochida, A; Morinari, H; Nakahara, K; Nishi, K; Saito, K; Sasaki, S; Tahara, M; Yakumaru, K | 1 |
| Baker, CH; Fidler, IJ; Solorzano, CC | 1 |
| Awada, A; Batter, V; Beex, L; Biganzoli, L; Cufer, T; Hamilton, A; Lohrisch, C; Nooij, M; Piccart, M | 1 |
| Böttcher, HD; Brady, LW; Class, R; Mose, S; Oszvald, A; Rahn, A; Weber, HW | 1 |
| Kelly, S; Nguyen, M; Sun, D; Urrabaz, R; Weitman, S | 1 |
| Akiyama, Y; Hotta, K; Inoue, A; Kodama, T; Kunitoh, H; Kusaba, H; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Shimoyama, T; Tamura, T; Ueda, Y; Yamamoto, N | 1 |
| Fu, D; Hua, Y; Ni, Q; Wang, L; Yu, X; Zhang, Q; Zhang, Y | 1 |
| Foo, KF; Machin, D; Tai, BC; Tan, EH; Tan, SB | 1 |
| Ferri-Dessens, RM; Gouva, S; Kleisbauer, JP; Léna, H; Robinet, G; Thomas, P; Vernejoux, JM | 1 |
| Schramel, FM; Seldenrijk, CA; Slee, PH; van Beek, FT; Voorburg, AM | 1 |
| Dediu, M | 1 |
| Abbruzzese, JL; Ballo, MT; Charnsangavej, C; Crane, CH; Delclos, M; Evans, DB; Janjan, NA; Lee, JE; Lenzi, R; Mason, K; Milas, L; Nguyen, Q; Phan, T; Pisters, PW; Vauthey, JN; Wolff, RA; Wong, AB | 1 |
| Lake, RA; Nowak, AK; Robinson, BW | 2 |
| Barbieri, L; Busi, C; Di Stefano, G; Fiume, L; Lanza, M | 1 |
| Bareck, E; Depisch, D; Ploner, M; Puhalla, H; Scheithauer, W; Stiglbauer, W | 1 |
| Brandl, M; Burger, AM; Fiebig, HH; Massing, U; Moog, R; Schubert, R; Schüler, J; Unger, C | 1 |
| Fujita, F; Fujita, M; Koike, M | 1 |
| Liu, X; Mo, X; Qiu, W; Yen, Y; Zhou, B | 1 |
| Hammerer, V; Pauli, G; Quoix, E; Schmitz, N | 1 |
| Aristides, M; Botwood, N; Lees, M; Maniadakis, N; McKendrick, J; Stephenson, D | 1 |
| Boehrer, S; Bojunga, J; Chow, KU; Fauth, F; Hoelzer, D; Martin, H; Mitrou, PS; Rummel, MJ; Schneider, B; Stieler, M; Weidmann, E | 1 |
| Barlogie, B; Crowley, JJ; Hussein, MA; Moore, DF; Weick, JK | 1 |
| Buesa, JM; Carrasco, J; Corral, N; Esteban, E; Estrada, E; Fra, J; Lacave, AJ; Palacio, I; Puerta, J; Sala, M; Valle, M; Vieitez, JM | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kovats, E; Kwasny, W; Lang, F; Payrits, T; Raderer, M; Scheithauer, W; Schüll, B | 1 |
| Robbins, KT | 1 |
| Bradford, CR; Chepeha, DB; Dawson, LA; Eisbruch, A; Haxer, MJ; Hogikyan, ND; Lyden, T; Miller, AE; Teknos, TN; Terrell, JE; Wolf, GT | 1 |
| Davis, M; Lawrence, TS; McGinn, CJ; Symon, Z; Zalupski, MM | 1 |
| Bamberg, M; Budach, W; Classen, J; Hehr, T; Paulsen, F | 1 |
| Fillet, G; Jerusalem, G; Polus, M; Sautois, B; Silvestre, RM | 1 |
| Azria, D; Culine, S; Dubois, JB; Jacot, W; Lemanski, C; Prost, P; Ychou, M | 1 |
| Fung, MC; Sakata, T | 1 |
| Brooks, S; Burstein, HJ; Devlin, PM; Fuchs, CS; Jänne, PA; Jeter, MD; Loeffler, JS; Salgia, R; Wen, P | 1 |
| Bernardo, A; Bernardo, G; Brunetti, G; Cuzzoni, Q; Jedrychowska, I; Palumbo, R; Pozzi, U; Strada, MR | 1 |
| Fujikawa, K; Fukuzawa, S; Iwamura, H; Matsui, Y; Oka, H; Takeuchi, H | 1 |
| Günzburg, WH; Löhr, M; Salmons, B | 1 |
| Algarra, I; Gaforio, JJ; Jaén, A; Lozano, A; Sánchez-Rovira, P; Serrano, MJ | 1 |
| Caliandro, R; Girard, P; Grunenwald, D; Lamer, C; Lenoir, S; Stern, JB; Théodore, C | 1 |
| Ardizzoni, A; Baldini, E; Boni, L; Cafferata, MA; Prochilo, T; Tibaldi, C | 1 |
| Smythe, WR | 1 |
| Cuesta, MA; de Lange, SM; Giaccone, G; Langendijk, JA; Meijer, OW; Meijer, S; Peters, GJ; Pinedo, HM; Slotman, BJ; van Groeningen, CJ; van Riel, JM | 1 |
| Berger, MR; Georgieva, MC; Konstantinov, SM; Topashka-Ancheva, M | 1 |
| Beauséjour, CM; Gagnon, J; Momparler, RL; Primeau, M | 1 |
| Alberts, SR; Cha, SS; Fitch, TR; Goldberg, RM; Krook, JE; Mailliard, JA; Moore, DF; Pitot, HC; Sargent, DJ; Townley, PM; Wiesenfeld, M | 2 |
| Tripathy, D | 2 |
| Bunn, PA; Chan, DC; Franklin, WA; Helfrich, B; Hirsch, FR; Varella-Garcia, M | 1 |
| Kimmel, G; Marsland, T; O'Shaughnessy, J; Pippen, J; Ratnam, S; Vukelja, SJ | 1 |
| Zielinski, CC | 2 |
| Dueñas, R; Fernández, M; Jaén, A; Lozano, A; Martínez, E; Medina, B; Mohedano, N; Porras, I; Sánchez-Rovira, P | 1 |
| Hensley, ML | 2 |
| Corlan, E; Draghici, IN; Grigorescu, AC; Gutulescu, N; Nitipir, C | 1 |
| Bruckner, HW; Kozuch, P; Petryk, M | 1 |
| Ryan, DP; Willett, CG | 1 |
| Aghajanian, C; Barakat, R; Geller, G; Hensley, ML; Lovegren, M; Maki, R; Sabbatini, P; Spriggs, DR; Tong, W; Venkatraman, E | 1 |
| Kalofonos, HP; Kosmas, C; Tsavaris, N | 1 |
| Rudi, J | 1 |
| Cortés-Funes, H | 1 |
| Ikeda, M; Okada, S; Okusaka, T; Tokuuye, K; Ueno, H | 1 |
| Asoh, H; Ichinose, Y; Semba, H; Seto, T; Yamamoto, H; Yoh, K | 1 |
| Gray, JR; Greco, FA; Hainsworth, JD; Hon, JK; Kalman, LA; Morrissey, LH | 1 |
| Daliani, D; Logothetis, CJ; Millikan, RE; Pagliaro, LC; Papandreou, CN; Tu, SM; Williams, D | 1 |
| Adams, DJ; Bass, AJ; Davis, P; DeCastro, CM; Foster, T; Gockerman, JP; Hammett, E; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL | 1 |
| Sederholm, C | 1 |
| Depierre, A; Jacoulet, P; Westeel, V | 2 |
| Takigawa, N | 1 |
| Takeda, K | 1 |
| Watanabe, H | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Büchler, MW; Friess, H; Solioz, M; Xu, ZW | 1 |
| Arbea, L; Calvo, E; Cambeiro, M; Cortes, J; Diaz-Gonzalez, JA; Garcia-Foncillas, J; Garzon, C; Gil-Bazo, I; Gurpide, A; Martin-Algarra, S; Navarro, V; Nicolas, AI; Rodriguez, J | 1 |
| Baillet, M; Bramhall, SR; Brown, PD; Buckels, JA; Nemunaitis, J; Schulz, J | 1 |
| Logothetis, C; Millikan, R | 1 |
| Green, MR; Leong, SS; Perkel, JA; Putman, T; Rocha Lima, CM; Safa, AR; Sherman, CA | 1 |
| Albertson, D; Blackstock, AW; Butler, JM; Howerton, R; Levine, E; Melin, SA; Patton, S; Pineau, B | 1 |
| Benson, A; Mulcahy, M; Musanti, R; Poplin, E; Rubin, E | 1 |
| Machin, D; Tan, SB | 1 |
| Alberola, V; Brabender, J; Camps, C; Cardenal, F; Danenberg, KD; Danenberg, PV; Domine, M; Gandara, D; Gumerlock, PH; Lord, RV; Rosell, R; Sánchez, JJ; Sánchez, JM; Tarón, M | 1 |
| Balis, FM; Berg, SL; Blaney, SM; Egorin, MJ; Kerr, JZ; McCully, CM; Zuhowski, EG | 1 |
| Clark, JW; Earle, CC; Fuchs, CS; Kim, H; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, KE; Vincitore, M | 1 |
| Buckner, JC; Edmonson, J; Frytak, S; Galanis, E; Mahoney, M; Okuno, S | 1 |
| Caness, P; Pensa, F; Pronzato, P; Sinaccio, G; Tognoni, A; Vaira, F; Vigani, A | 1 |
| Alexopoulos, CG; Berghmans, T; Efremidis, A; Florin, MC; Klastersky, J; Lafitte, JJ; Lecomte, J; Mommen, P; Ninane, V; Paesmans, M; Recloux, P; Sculier, JP; Thiriaux, J | 1 |
| Conte, PF; Danesi, R; Del Tacca, M; Donati, S; Fogli, S; Gennari, A | 1 |
| Cinatl, J; Doerr, HW; Gröschel, B; Höver, G; Kaufmann, A; Loves, WJ; Noordhuis, P; Peters, GJ | 1 |
| Blumenschein, G; Fossella, FV; Glisson, BS; Herbst, RS; Hong, WK; Jung, MS; Khuri, FR; Kies, MS; Kurie, JM; Lee, JJ; Lee, JS; Liu, DD; Lu, C; Lu, R; Munden, RF; Papadimitrakopoulou, VA; Pisters, KM; Shin, DM; Zinner, R | 1 |
| Chiu, HC; Chu, CY; Yang, CH | 1 |
| Asse, E; Kallwellis, G; Klebingat, KJ; Protzel, C; Zimmermann, U | 1 |
| Cottrell, W; Dranitsaris, G; Evans, WK | 1 |
| Fife, K; Ganjoo, KN; Gordon, MS; Loehrer, PJ; Poirier, S; Sandler, AB; Seshadri, R; Warner, RE | 1 |
| Büchler, MW; Friess, H; Kleeff, J; Liu, S; Shi, X | 1 |
| Perez, EA; Qu, G | 1 |
| Cesario, A; Corbo, GM; d'Angelillo, RM; Galetta, D; Granone, P; Macis, G; Mangiacotti, MG; Margaritora, S; Porziella, V; Ramella, S; Trodella, L; Valente, S | 1 |
| Barceló, R; Fernández, R; Fuente, N; López Vivanco, G; Mañé, JM; Muñoz, A; Rubio, I | 1 |
| Allott, CP; Boxall, FE; Kelland, LR; Rogers, P; Stephens, TC | 1 |
| Bruniaux, M; De Bast, M; De Coster, B; Grégoire, V; Octave-Prignot, M; Rosier, JF; Scalliet, P | 1 |
| Haba, T; Hyougotani, A; Katoh, K; Koyama, H; Miyazawa, M; Muramatsu, A; Ozawa, K | 1 |
| Czarnecki, A; Kilgour-Christie, J | 1 |
| Cynowska, B; Damps, I; Jassem, E; Mierzejewska, E; Słomiński, JM; Wolf, H | 1 |
| Colle, B; Debourdeau, P; Estival, JL; Pavic, M; Teixeira, L; Zammit, C | 1 |
| Grassin, F; Guigay, J; L'Her, P; Margery, J; Morel, V; Vaylet, F | 1 |
| Delbaldo, C; Faivre, S; Le Chevalier, T; Monnerat, C | 1 |
| Cognetti, F; Felici, A; Gelibter, A; Nardoni, C; Serrone, L | 1 |
| Crawford, ED | 1 |
| Bajorin, D; Dalbagni, G; dePalma, D; Donat, MS; Herr, HW; Mazumdar, M; Rabbani, F; Russo, P; Sheinfeld, J; Sogani, P; Tong, W | 1 |
| Benson, AB; Berlin, JD; Catalano, P; Haller, DG; Kugler, JW; Thomas, JP | 1 |
| Alesiani, F; Corvatta, L; Leoni, P; Malerba, L; Marconi, M; Mele, A; Offidani, M; Olivieri, A; Rupoli, S | 1 |
| Colantuoni, G; Gridelli, C; Maione, P; Rossi, A | 1 |
| Gioffre, C; Gmeiner, WH; Goldwasser, F; Hertel, LW; Kohlhagen, G; Pommier, Y; Pon, RT; Pourquier, P; Urasaki, Y; Yu, S | 1 |
| Hanel, EG; Karmali, S; Kilani, RT; Mackey, J; Moore, RB; Tamimi, Y; Wong, KK | 1 |
| de Boeck, G; de Bruijn, E; de Jonge, MJ; Dumez, H; Guetens, G; Highley, M; Louwerens, M; Mantel, M; Pawinsky, A; Planting, AS; Van Oosterom, AT; Verweij, J | 1 |
| Ryan, CW; Stadler, WM; Vogelzang, NJ | 1 |
| Casado, E; De Castro, J; Feliu, J; González Barón, M; Ordoñez, A | 1 |
| Alvarez Castelo, L; Blanco Díez, A; Fernández Rosado, E; González Martín, M; Rodríguez Gómez, I; Sánchez Rodríguez Losada, J; Suárez Pascual, G | 1 |
| Hojo, K; Maekawa, R; Matsumoto, M; Nishitani, Y; Takeda, Y; Wada, T; Yoshioka, T | 1 |
| Brendel, MD; Grimm, H; Jung, F; Korom, S; Maas, E; Wilker, S | 1 |
| Alloisio, M; Antonelli, G; Cavina, R; Dambrosio, M; Latteri, F; Morenghi, E; Ravasi, G; Sala, A; Santoro, A; Soto Parra, H | 1 |
| Chanona, G; De La Garza, J; Duenas-Gonzalez, A; Gonzalez-Enciso, A; Guadarrama, R; Lopez-Graniel, C; Mohar, A; Mota, A; Rivera, L | 1 |
| Au, SK; Chan, TM; Cheung, FY; Chiu, CY; Foo, W; Kwok, CH; Lau, WH; Law, CK; Ngan, RK; Tse, KC; Yau, S; Yiu, HH | 1 |
| Akerman, P; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Quirk, D; Ramdin, N; Rich, T; Safran, H; Shah, S | 1 |
| Castro Kreder, N; Franken, NA; Haveman, J; Loves, WJ; Peters, GJ; van Bree, C | 1 |
| Cini, G; Di Cello, V; Dominici, A; Doni, L; Fulignati, C; Gemelli, MT; Maleci, M; Mottola, A; Neri, B; Ponchietti, R; Raugei, A; Turrini, M; Valsuani, G | 1 |
| O'Brien, ME; Waters, JS | 1 |
| Byrne, MJ; Fielding, D; Mitchell, P; Musk, AW; Nowak, AK; Robinson, BW; Ryan, G; Segal, A; Williamson, R | 1 |
| Cini, G; De Luca Cardillo, C; Doni, L; Fioretto, LM; Fulignati, C; Mini, E; Moretti, R; Neri, B; Pantalone, D; Quattrone, A; Ribecco, AS; Scatizzi, M; Turrini, M; Zocchi, G | 1 |
| Aydogdu, I; Kaya, E; Kuku, I; Sevinc, A | 1 |
| Armand, JP; Faivre, S; Kayitalire, L; Le Chevalier, T; Lhommé, C; Lokiec, F; Monnerat, C; Novello, S; Pautier, P; Raymond, E; Ruffié, P; Taieb, J | 1 |
| Calabrò, F; Sternberg, CN | 2 |
| Belch, AR; Cass, CE; Coupland, R; Graham, KA; Mackey, JR; Reiman, T; Wong, J; Young, J | 1 |
| Arning, M; Cassidy, CA; Peterson, P; Roychowdhury, DF | 1 |
| Buesa, JM; Carrasco, J; Corral, N; Esteban, E; Estrada, E; Fra, J; Lacave, AJ; Palacio, I; Sala, M; Vieitez, JM | 1 |
| Eichelmann, K; Fahlke, J; Hribaschek, A; Kuhn, R; Ridwelski, K; Rudolph, S | 1 |
| Bacoyiannis, C; Boukovinas, J; Dimopoulos, M; Economopoulos, T; Fountzilas, G; Kalophonos, C; Kosmidis, P; Mylonakis, N; Nicolaides, C; Papakostas, P; Samantas, E; Skarlos, D; Tsavdaridis, D | 1 |
| Philip, PA | 6 |
| Oettle, H; Riess, H | 1 |
| Jacobs, AD | 1 |
| Kindler, HL | 6 |
| Lawrence, TS; McGinn, CJ; Zalupski, MM | 1 |
| Albanell, J; Baselga, J; Bellmunt, J; Carles, J; Climent, MA; Cortés-Funes, H; de la Cruz, JJ; Díaz-Rubio, E; González-Larriba, JL; Guillem, V; Paz-Ares, L | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Olencki, T; Peereboom, D; Perez-Zincer, F | 1 |
| Baker, CH; Bucana, CD; Fidler, IJ; Kedar, D; McCarty, MF; Tsan, R; Weber, KL | 1 |
| Barnes, BC; Brierre, JE; Buller, EJ; Cole, JL; Felicia Fontenot, M; Lormand, NA; Mills, G; Rainey, JM; Rinaldi, DA; Yadlapati, S | 1 |
| Barton, JH; Burris, HA; Butts, JA; Erland, JB; Gray, JR; Greco, FA; Hainsworth, JD; Houston, GA; Litchy, S; Scott, C; Thompson, DS; Webb, C | 1 |
| Fukui, I; Ishii, N; Maezawa, T; Tsukamoto, T; Yonese, J | 1 |
| Blagden, S; Blesing, C; Corrie, P; D'Ath, S; Mayer, A; Price, P; Shaw, J; Warner, N | 1 |
| Antonuzzo, A; Chioni, A; Conte, P; Francesca, F; Galli, L; Iannopollo, M; Orlandini, C; Ricci, S; Selli, C; Vocaturo, V | 1 |
| Bamberg, M; Dichgans, J; Duffner, F; Hermisson, M; Kortmann, RD; Küker, WM; Weller, M; Wick, W | 1 |
| Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M | 1 |
| Joerger, M; Pestalozzi, BC; Walter, RB | 1 |
| Adachi, S; Fung, MC; Ishiguro, H; Sakata, T | 1 |
| Ashamalla, H; Jiang, M; Rafla, S; Yang, SJ; Zhang, X | 1 |
| Cox, K; Faul, MM; Keyes, K; Mann, L; Shih, C; Teicher, BA; Treadway, P | 1 |
| Bianchi, L; Cantonetti, M; Chimenti, S; Fargnoli, MC; Muscardin, LM; Orlandi, A; Pagnanelli, G | 1 |
| Ansari, R; Desai, AA; Krauss, S; Rini, BI; Stadler, WM; Vogelzang, NJ | 1 |
| Popa, IE; Rizvi, NA; Smith, FP; Stewart, K | 1 |
| Ansari, R; Bhatia, S; Einhorn, L; Hanna, N; Ng, E; Pletcher, W; Sandler, A | 1 |
| Borsellino, N; Cazzato, C; Colucci, G; Durini, E; Galetta, D; Gebbia, V; Giotta, F; Pezzella, G; Romito, S | 1 |
| Joppert, MG; Rocha Lima, CM | 1 |
| Cook, J; Herscher, LL; Kroog, GS; Mitchell, JB; Muir, C; Poggi, MM; Russo, A; Smith, J | 1 |
| Berger, J; Dahlmann, N; Dierlamm, T; Fiedler, W; Hossfeld, DK; Knuffmann, C; Köhler, A; Kugler, C; Laack, E; Niestroy, A; Peters, A; Vohwinkel, G | 1 |
| Crawford, J; Green, MR; Herndon, JE; Leopold, KA; Miller, AA; Perry, MC; Vokes, EE | 1 |
| Curran, MP; Plosker, GL | 1 |
| Bruns, CJ; Ellis, LM; Harbison, MT; Hicklin, DJ; Jauch, KW; Portera, C; Radinsky, R; Shrader, M; Solorzano, CC | 1 |
| Duan, EY; Liu, AH; Wang, XS; Wu, YX; Zhou, Y | 1 |
| Abiko, M; Satoh, T | 1 |
| Kulke, MH | 3 |
| Fuxius, S; Mansouri, K; Mross, K; Unger, C | 1 |
| Arnold, D; Hoepffner, N; Kern, M; Neuhaus, P; Oettle, H; Riess, H; Settmacher, U | 1 |
| Arcusa, A; Balil, A; Batiste-Alentorn, E; Carrasco, EM; Cirera, L; Font, A; Nogué, M; Perez-Gracia, JL; Tusquets, I | 1 |
| Barsoum, J; Brickelmaier, M; Carmillo, A; Goelz, S; Qin, XQ | 1 |
| Bares, R; Bartusek, G; Dittmann, H; Dohmen, BM; Kehlbach, R; Pritzkow, M; Sarbia, M | 1 |
| Beijnen, JH; Crul, M; Schellens, JH; Sparidans, RW | 1 |
| Epelbaum, R; Faraggi, D; Gaitini, D; Kuten, A; Mizrahi, S; Nasrallah, S; Rosenblatt, E | 1 |
| Feng, F; Jin, M; Li, Z; Ni, Q; Wang, X; Wu, Y; Zhao, Y | 1 |
| Adamo, V; Altavilla, G; Boni, C; Ceribelli, A; Clerici, M; Crinò, L; De Marinis, F; Di Costanzo, F; Failla, G; Frontini, L; Gridelli, C; Marangolo, M; Matano, E; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M | 1 |
| Arquette, MA; Bartlett, NL; Blum, KA; Clark, RS; Fears, CL; Fracasso, PM; Tan, BR | 1 |
| Bohlen, P; Bonner, JA; Buchsbaum, DJ; Carpenter, M; Grizzle, WE; Hicklin, DJ; Raisch, KP; Stackhouse, MA | 1 |
| Blohmer, J; Camara, O; Elling, D; Heinrich, G; Hindenburg, HJ; Klare, P; Ledwon, P; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 1 |
| Bolaños, M; Borrega, P; Castro, J; Dorta, J; Escudero, P; Espinosa, E; Feliu, J; González Barón, M; López Gómez, L; Mel, R; Vázquez-Estévez, SE | 1 |
| Chen, JS; Fung, MC; Hsieh, RK; Wang, CH; Yang, TS | 1 |
| Arquette, MA; Denes, A; Fears, CL; Fracasso, PM; Goodner, SA; Govindan, R; Herzog, TJ; Mutch, DG; Picus, J; Rader, JS; Sun, SL; Tan, BR | 1 |
| Needle, MN | 1 |
| Baker, CH; Dinney, CP; Fidler, IJ; Kedar, D; Killion, JJ | 1 |
| Calandri, C; Crinò, L | 1 |
| Novello, S; Scagliotti, GV | 2 |
| Szczepura, A | 1 |
| Petruzelka, L; Zatloukal, P | 1 |
| Gridelli, C | 1 |
| Harper, P; Marx, G | 1 |
| Chau, I; Cunningham, D; Watkins, D | 1 |
| Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A | 1 |
| Chow, W; Doroshow, JH; Frankel, P; Gandara, D; Lenz, HJ; Leong, L; Longmate, J; Margolin, K; Morgan, R; Newman, EM; Raschko, J; Shibata, S; Somlo, G; Synold, T; Twardowski, P; Yen, Y | 1 |
| Bankhead, C | 1 |
| Donohue, CA; Kane, SE; Sadava, D; Schwarz, RE | 1 |
| Alberti, D; Arzoomanian, RZ; Bailey, H; Berlin, JD; Binger, K; Feierabend, C; Marrocha, R; Morgan-Meadows, S; Mulkerin, D; Thomas, JP; Volkman, J; Wilding, G | 1 |
| Bookman, MA; Garcia, AA; Look, KY; Mutch, DG; Rodriguez-Rodriguez, L | 1 |
| Bagnes, C; Chacón, RD; Morero, J; Orlando, M; Rojas, O; Rosenberg, M; Silva, C; Van Kooten, M; Vicente, H; Vilanova, M | 1 |
| Chamorey, AL; Milano, G; Thyss, A | 1 |
| Choma, D; Jacot, W; Pujol, JL; Quantin, X | 1 |
| Azria, D; Prost, P; Ychou, M | 1 |
| André, T; Artru, P; Louvet, C | 1 |
| Besse, B; Spano, JP | 1 |
| Gutierrez, M; Lhomme, C; Pautier, P | 1 |
| Clippe, C; Ligneau, B; Trillet-Lenoir, V | 1 |
| Dumontet, C | 1 |
| Mornex, F | 1 |
| André, T; Culine, S; Epaud, C; Gligorov, J | 1 |
| Durgam, S; Levin, M; Novetsky, A | 1 |
| Ash-Bernal, R; Browner, I; Erlich, R | 1 |
| Blackstock, AW; McMullen, KP | 1 |
| Carpagnano, F; Crucitta, E; De Lena, M; Guida, M; Lorusso, V; Mancarella, S; Panza, N; Sambiasi, D; Silvestris, N | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Matsumoto, T; Niho, S; Nishiwaki, Y; Ohmatsu, H | 2 |
| Chen, CW; Chen, HH; Chen, TY; Hsiue, TR; Huang, WT; Lai, WW; Su, WC; Tsao, CJ; Wang, NS | 1 |
| Aramendia, JM; Aristu, JJ; Bosch, A; Brugarolas, A; Calvo, E; Claver, A; Cortes, J; Garcia-Foncillas, J; Gurpide, A; Lopez-Picazo, JM; Martin-Algarra, S; Rodriguez, J; Salgado, E | 1 |
| Patel, SR | 1 |
| Terao, I | 1 |
| Hayashi, H; Hayashi, Y; Kamata, T; Kanno, M; Michiwa, Y; Minatoya, G; Onishi, I; Takeda, K; Takeda, T | 1 |
| Fujii, T; Maemura, M; Morishita, Y; Ohwada, S; Roppongi, T; Takeyoshi, I; Yamada, T | 1 |
| Edmonds, MR; Ma, BB; Pond, GR; Siu, LL; Tannock, IF | 1 |
| Crinò, L | 1 |
| Pirker, R | 1 |
| Choma, D; Jacot, W; Khial, F; Pujol, JL; Quantin, X | 1 |
| Thatcher, N | 1 |
| Bergman, AM; Peters, GJ; Pinedo, HM; Smid, K; Van Moorsel, CJ; Voorn, DA | 1 |
| Bonnaud, F; Sabria-Trias, J; Sioniac, M | 1 |
| Alvarez, E; Boven, E; Braakhuis, BJ; Kroep, JR; Loves, WJ; Peters, GJ; Pinedo, HM; Talianidis, I; van der Wilt, CL; van Groeningen, CJ | 1 |
| Gajria, D; Gandhi, V; Ghias, K; Krett, NL; Nabhan, C; Rosen, ST | 1 |
| Douillard, JY; Eckardt, J; Scagliotti, GV | 1 |
| Gridelli, C; Hainsworth, J | 1 |
| Baldwin, SA; Cass, CE; Clarke, ML; Mackey, JR; Young, JD | 1 |
| Ames, MM; Avramis, VI; Krailo, MD; Liu-Mares, W; Reaman, GH; Reid, JM; Safgren, SL; Seibel, NL; Steinherz, PG | 1 |
| Aoyagi, S; Fukuda, S; Hara, M; Hiraki, M; Horiuchi, H; Ishikawa, H; Kinoshita, H; Koganemaru, M; Ohdo, M; Okuda, K; Shirouzu, K; Tamae, T; Uchida, S; Yasunaga, M | 1 |
| Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H | 1 |
| Biggs, DD; Grubbs, SS; Guarino, MJ; Himelstein, AL; Hogaboom, K; Schneider, CJ; Tilak, S | 1 |
| Budd, GT; Bukowski, RM; Elson, P; Hutson, TE; Mekhail, T; Olencki, T; Peereboom, D; Pelley, R; Srkalovic, G | 1 |
| Adachi, M; Hirose, T; Horichi, N; Ohmori, T; Ohnishi, T; Shirai, T; Sohma, S; Yamaoka, T | 1 |
| Arcangeli, V; Fochessati, F; Panzini, I; Ravaioli, A; Sartori, S; Tassinari, D | 1 |
| Baum, U; Bautz, W; Brunner, TB; Grabenbauer, GG; Hohenberger, W; Klein, P; Papadopoulos, T; Sauer, R | 1 |
| Eaton, S; Fusco, N; Mossbruger, K; Rodriguez, M; Rose, PG; Smrekar, M | 1 |
| Brewer, CA; DiSaia, PJ; Evans, SS; Kidder, WA; Minor, DR; Nagourney, RA; Radecki, S; Sommers, BL | 1 |
| Beijnen, JH; Bocxe, S; Crul, M; Pluim, D; Schellens, JH; van Eijndhoven, MA; van Waardenburg, RC | 1 |
| Borner, M; Herrmann, R; Hess, V; Ludwig, C; Morant, R; Roth, AD; Salzberg, M | 1 |
| Hirai, I; Kokawa, Y; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T | 1 |
| Amano, H; Hanada, K; Hino, F; Hirota, Y; Kajiyama, G; Obayashi, M; Ooe, H; Sasao, S | 1 |
| Bouvet, M; Hoffman, RM; Moossa, AR; Nassirpour, R; Sun, FX; Tohgo, A; Yagi, S | 1 |
| Blackstock, AW; Lawrence, TS; McGinn, C | 1 |
| Apostolidou, E; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Thomas, D; Tsimberidou, A | 1 |
| Grem, JL; Keith, B; Xu, Y | 2 |
| Bonavida, B; Emmanouilides, C; Jazirehi, AR | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Dorr, FA; Dy, GK; Erlichman, C; Geary, RS; Goldberg, RM; Hanson, LJ; Holmlund, J; Pitot, HC; Reid, JM; Sloan, JA; Watanabe, T | 1 |
| Smit, EF | 1 |
| Ruffié, P | 1 |
| Fournel, P | 2 |
| Antolak, JA; Charnsangavej, C; Crane, CH; Evans, DB; Forster, KM; Janjan, NA; Lenzi, R; Papagikos, MA; Pisters, PW; Rosen, II; Wolff, RA | 1 |
| Boxberger, F; Brueckl, V; Brueckl, WM; Hahn, EG; Hautmann, M; Hohenberger, W; Jüngert, B; Wein, A | 1 |
| Adachi, S; Iijima, T; Ito, K; Kimura, T; Nakatsuji, Y; Nobunaga, T | 1 |
| Chiao, PJ; Evans, DB; Fan, Z; Fujioka, S; Schmidt, C; Sclabas, GM | 1 |
| Barni, S; Beretta, GD; Cascinu, S; Catalano, G; Catalano, V; Ferraù, F; Foa, P; Frontini, L; Graziano, F; Labianca, R; Mare, M; Pancera, G; Priolo, D | 1 |
| Aglione, S; Bajetta, E; Bidoli, P; Cortinovis, D; De Candis, D; Formisano, B; Mariani, L; Stani, SC; Zaffaroni, N; Zilembo, N | 1 |
| Agelaki, S; Androulakis, N; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Samonis, G; Souglakos, J; Vardakis, N | 1 |
| Barone, C; Basso, M; Battelli, C; Cassano, A; Corsi, DC; Longo, R; Pozzo, C; Quirino, M; Schinzari, G | 1 |
| Alonso, V; Antón, A; Artal-Cortés, A; Ceballos, C; Corral, M; Herrero, A; Martínez-Trufero, J; Maurel, J; Puértolas, T | 1 |
| Fukushima, M; Furuse, K; Harada, H; Hosoe, S; Iwamoto, Y; Kawahara, M; Komuta, K; Morioka, T; Ohsaki, Y; Origasa, H; Shibata, K | 1 |
| Albers, P; Lehmann, J; Lippert, C; Retz, M; Stöckle, M | 1 |
| Copeland, EM; Hochwald, SN; Lind, DS; MacKay, SL; Malaty, J; Moldawer, LL | 1 |
| Abbruzzese, JL; Bedford, R; Freeman, SM; Hecht, JR; Kirn, DH; Lahoti, S; Reid, TR; Soetikno, RM | 1 |
| Adams, DJ; Chao, NJ; DeCastro, CM; Foster, T; Gasparetto, C; Gockerman, JP; Ibom, VK; Long, GD; Moore, JO; Payne, N; Rizzieri, DA; Rosner, GL; Thompson, M; Vredenburgh, JJ | 1 |
| Amadori, D; De Paola, F; Frassineti, GL; Milandri, C; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W | 1 |
| Chanona, G; de la Garza, J; Dueñas-González, A; Gomez, E; González, A; López-Graniel, C; Mohar, A; Rivera, L; Trejo-Becerril, C | 1 |
| Böttcher, HD; Brady, LW; Class, R; Mose, S; Rahn, A; Weber, HW | 1 |
| Haller, DG | 4 |
| Scheithauer, W | 2 |
| Awasthy, BS; Doval, DC; Gupta, S; Gupta, SK; Sekhon, JS | 1 |
| Okusaka, T | 1 |
| Senzer, N | 1 |
| Borsellino, N; Caruso, M; Colucci, G; Durini, E; Galetta, D; Gebbia, N; Gebbia, V; Loizzi, M; Pandolfo, G; Pezzella, G; Rinaldi, M; Tirrito, ML; Valdesi, M; Valenza, R; Varvara, F; Verderame, F | 1 |
| Asmar, L; Garfield, DH; Gregurich, MA; Joppert, MG; Khandelwal, P; Marsland, TA; Nemunaitis, JJ | 1 |
| Arlt, A; Fölsch, UR; Gehrz, A; Grohmann, F; Haye, S; Kalthoff, H; March, C; Müerköster, S; Schäfer, H; Wegehenkel, K; Witt, M | 1 |
| Egorin, MJ; Eisenberger, MA; Haisfield-Wolf, ME; Laufer, M; Nativ, O; Ramalingam, S; Schoenberg, MP; Trueheart, IN; Zuhowski, EG | 1 |
| Castro, M | 1 |
| Akman, Y; Alper, M; Cam, K; Kavak, A | 1 |
| Dühmke, E; Heinemann, V; Rau, HG; Stoffregen, C; Thoma, M; Wagner, A; Wilkowski, R | 1 |
| Distel, L; Grabenbauer, GG; Sauer, R; Weiss, C | 1 |
| Calabrese, P; Caporusso, L; Catino, A; Crucitta, E; D'Amico, C; De Lena, M; Guida, M; Latorre, A; Lorusso, V; Mazzei, A; Sambiasi, D; Schittulli, F; Silvestris, N | 1 |
| Albers, P; Blatter, J; Fechner, G; Haase, L; Ludwig, E; Mller, SC; Perabo, FG; Schmidt, DH; Schueller, H | 1 |
| Agelaki, S; Androulakis, N; Aravantinos, G; Dimopoulos, MA; Foutzilas, G; Georgoulias, V; Giannakakis, T; Janninis, D; Kouroussis, C; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG | 1 |
| Colowick, AB; Fleishman, A; Glaspy, JA; Jadeja, JS; Justice, G; Rossi, G | 1 |
| Butzbach, D; Cairdella, M; Capanna, T; DiPaola, RS; Dvorzhinski, D; Eid, J; Goodin, S; Rubin, E; Shih, JW; Todd, MB; Toppmeyer, D | 1 |
| Adachi, Y; Fujita, Y; Fujiwara, M; Horiki, N; Imoto, I; Maruyama, M; Sasaki, H; Shimomura, M; Suzuki, K; Suzuki, Y; Tanaka, T; Tanigawa, K | 1 |
| Bellmunt, J; de Wit, R | 1 |
| Ariganello, O; Cipri, A; Cortesi, E; De Marinis, F; Gamucci, T; Gasperoni, S; Martelli, O; Migliorino, MR; Nelli, F; Paoluzzi, L; Portalone, L | 1 |
| Hiroi, M; Hojyo, T; Isobe, K; Kimura, K; Ryo, H; Sano, G; Sugino, K; Toyama, K; Yamada, H | 1 |
| Dono, K; Hayashi, N; Monden, M; Nagano, H; Nakamori, S; Nakazuru, S; Okami, J; Sakon, M; Tsujie, M; Umeshita, K | 1 |
| Accurso, V; Capaccetti, B; Cascinu, S; Catalano, V; Ferraù, F; Filippelli, G; Franciosi, V; Gasparini, G; Gattuso, D; Morabito, A; Palmeri, S; Scinto, F; Zagonel, V | 1 |
| Bunn, PA; Lilenbaum, R | 1 |
| Barbera, S; Bertetto, O; Castiglione, F; Cigolari, S; Clerici, M; Favaretto, A; Ferraù, F; Frontini, L; Galetta, D; Gallo, C; Gasparini, G; Gebbia, V; Gridelli, C; Iaffaioli, RV; Migliorino, MR; Novello, S; Perrone, F; Piantedosi, F; Piazza, E; Robbiati, SF; Rosetti, F; Rossi, A; Sacco, C | 1 |
| Inciūra, A; Juozaityte, E | 1 |
| Abramoff, R; Gansl, RC; Hoff, PM; Katz, A; Machado, MC; Saad, ED; Simon, SD; Tabacof, J; Wajsbrot, D | 1 |
| Kalofonos, HP; Kosmas, C; Mylonakis, N; Tsavaris, N | 1 |
| Chávez-Blanco, A; Dueñas-González, A; García-López, P; González-Fierro, A; Lizano-Soberon, M; Mariscal, I; Pérez-Cárdenas, E; Segura-Pacheco, B; Taja-Chayeb, L; Trejo-Becerril, C; Treviño-Cuevas, H; Wegman-Ostrosky, T | 1 |
| al-Jazayrly, G; Edelman, MJ; Gandara, DR; Houston, J; Lara, PN; Lau, DH; Lauder, I; Lim, N; Tanaka, M | 1 |
| el-Rayes, BF; Philip, PA; Shields, AF; Vaitkevicius, V | 1 |
| Bunn, PA; Simon, GR | 1 |
| De Bruijn, EA; Friedel, G; Guetens, G; Hendriks, JM; Pauwels, B; Romijn, S; Van Putte, BP; Van Schil, PE | 1 |
| Cullinane, C; Moufarij, MA; Phillips, DR | 1 |
| Büchler, MW; Dunn, JA; Friess, H; Ghaneh, P; Hickey, H; Neoptolemos, JP; Raraty, MG; Stocken, DD | 1 |
| Joo, KR; Min, YJ; Nah, YW; Nam, CW; Park, JH; Park, NH; Yun, TK | 1 |
| El-Rayes, BF; Philip, PA | 1 |
| Archer, CD; Catovsky, D; Chau, I; Cunningham, D; Gill, K; Harries, M; Hill, M; Koh, DM; Norman, AR; Prior, Y; Ross, PJ; Uzzell, M; Wotherspoon, A | 1 |
| Amant, F; Berteloot, P; D'Agostino, G; Scambia, G; Vergote, I | 1 |
| Aebi, S; Borner, MM; Büchler, MW; Friess, H; Kralidis, E | 1 |
| Grem, JL; Schuler, B; Szabo, E; Wright, MA | 1 |
| de Pooter, CM; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Pauwels, B; Vermorken, JB | 1 |
| Fitch, TR; Geeraerts, LH; Ghosh, C; Goldberg, RM; Haddock, MG; Keppen, MD; Martenson, JA; Pitot, HC; Sargent, DJ; Vigliotti, AP | 1 |
| Baay, MF; de Pooter, CM; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Pauwels, B; Vermorken, JB | 1 |
| Ehninger, G; Franz, T; Gross, P; Haufe, T; Kiani, A; Köhne, CH; Passauer, J; Schleyer, E | 1 |
| Albrecht, P; Elmer, A; Kortsik, C | 1 |
| Chen, MC; Chen, YM; Perng, RP; Tsai, CM | 1 |
| Bednarik, O; Bustova, I; Karasek, P; Kocakova, I; Melichar, B; Petruzelka, L; Skacel, T; Spurny, V; Trason, T | 1 |
| Li, A; Luo, R; Ma, S; Sheng, X | 1 |
| Berlin, JD; Rothenberg, ML | 1 |
| Blum, RH; Edmonson, JH; Okuno, S; Priebat, DA; Ryan, LM | 1 |
| Bacher, N; Hohla, F; Irschick, E; Konwalinka, G; Mühlmann, O; Strasser-Wozak, E; Tiefenthaler, M; Wein, W | 1 |
| Haigentz, M; Hamilton, A; Hochster, H; Kim, M; Lee, J; Macapinlac, M; Mirchandani, D; Muggia, FM; Pavlick, A; Sewak, S; Sorich, J; Volm, M | 1 |
| Colangelo, D; Mahboobi, H; Osella, D; Viarengo, A | 1 |
| Chow, KU; Hoelzer, D; Kim, SZ; Kriener, S; Mitrou, PS; Schui, DK; Sterry, W; Weidmann, E; Zollner, TM | 1 |
| Blanke, C; Declerck, L; DeVore, R; Johnson, D; Masters, GA; Miller, K; Sandler, A | 1 |
| Depisch, D; Haider, K; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H; Verena Kornek, G | 1 |
| Bilgin, T; Ozalp, S; Ozerkan, K; Vardar, MA; Yalçin, OT; Zorlu, G | 1 |
| Castellano, D; Ciruelos, E; Colomer, R; Cortés-Funes, H; Hitt, R | 1 |
| He, YJ; Liu, DG; Su, YS; Teng, XY; Zhou, NN; Zhou, ZM | 1 |
| Bosquée, L; D'Odemont, JP; Dams, N; Delobbe, A; Deman, R; Deschepper, K; Dooms, C; Galdermans, D; Nackaerts, K; Siemons, L; Van den Brande, P; Van Kerckhoven, W; Vandebroek, J; Vandeurzen, K; Vansteenkiste, J | 1 |
| Amenedo, M; Barón, FJ; Caeiro, M; Casal, J; Castellanos, J; Cueva-Banuelos, JF; Estévez, SV; Fírvida, JL; García Mata, J; Gómez, A; González, A; Grande, C; Huidobro, G; Lázaro, M; León, L; Rodríguez, MR; Romero, C | 1 |
| Chen, MC; Chen, YM; Ming-Liu, J; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Alonso, L; Arrivi, A; Carles, J; Font, A; Garrido, P; Juan, O; Mellado, B; Nogué-Aliguer, M; Sáenz, A | 1 |
| Ayoub, J; Charpentier, D; Desjardins, P; Hirsh, V; Langleben, A; Ofiara, L; Pintos, J; Small, D; Whittom, R | 1 |
| Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO | 1 |
| Aziz, Z; Malik, IA; Sethuraman, G; Zaidi, SH | 1 |
| Makhnova, EV | 1 |
| Arai, Y; Endo, M; Hagisawa, S; Hiramatu, M; Hoshi, S; Ohyama, C; Satoh, M; Watanabe, R | 1 |
| Faucette, SR; Gillenwater, HH; Hawke, RL; Lindley, C; Pescatore, SL; Shord, SS; Socinski, MA | 1 |
| Jassem, J | 1 |
| Fumoleau, P | 1 |
| Sledge, GW | 2 |
| O'shaughnessy, J | 2 |
| Kumazawa, K; Ogawa, K; Shiozawa, S; Tsuchiya, A | 1 |
| Hosoda, C; Ishikura, K; Izawa, M; Kawasaki, Y; Kikkawa, N; Koshohbu, T; Nakatani, S; Shimizu, E | 1 |
| Hamano, R; Kawamata, O; Mori, M; Oota, T; Uda, M; Urakubo, N | 1 |
| Herfarth, Ch | 1 |
| Bosquée, L; D'Orio, V; Mommens, V | 1 |
| Alonso Rodrigo, A; Barros Rodríguez, JM; Benavente Delgado, J; Domínguez Freire, F; González Piñeiro, A; López Bellido, D; Núñez López, A; Ojea Calvo, A; Otero García, M; Rodríguez Iglesias, B | 1 |
| Marchettini, P; Mohamed, F; Stuart, OA; Sugarbaker, PH; Urano, M | 1 |
| Collins, EJ; Frelinger, JA; Heath, WR; Lake, RA; Marzo, AL; Nowak, AK; Robinson, BW; Scott, B | 1 |
| Baker, CH; Bucana, CD; Evans, DB; Fidler, IJ; Hwang, R; Killion, JJ; Pisters, PW; Solorzano, CC | 1 |
| Aydemir, N; Bilaloğlu, R | 1 |
| Bacher, N; Hohla, F; Konwalinka, G; Mühlmann, O; Strasser-Wozak, E; Tiefenthaler, M; Wein, W | 1 |
| Balzer, JO; Berger, D; Eichler, K; Heller, M; Mack, MG; Schwarz, W; Vogl, TJ; Zangos, S | 1 |
| Baker, M; Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Scullin, DC; Shaffer, DW | 1 |
| Chen, WR; Ishmael, DR; Liu, H; Nordquist, JA; Nordquist, RE | 1 |
| Casado, V; Dómine, M; Dorta, FJ; Estévez, LG; Florián, J; Jiménez, E; Léon, A; Lobo, F; Lomas, M; López, P; Virizuela, JA | 1 |
| Bernacki, RJ; Chaudhary, ND; Greco, W; Hoffman, RM; Kobayashi, T; Mazurchuk, R; Pera, P; Spernyak, J; Veith, J; Wu, M | 1 |
| Goh, BC; Lee, HS; Lee, SC; Lehnert, M; Lim, HL; Millward, MJ; Soo, RA; Tok, LT; Wang, LZ | 1 |
| Agelaki, S; Alexopoulos, A; Ardavanis, A; Georgoulias, V; Kalbakis, K; Karyda, E; Kouroussis, Ch; Malamos, N; Malas, K; Tselepatiotis, E | 1 |
| Amabile, G; D'Aiuto, G; de Matteis, A; Di Maio, M; Gridelli, C; Labonia, V; Landi, G; Nuzzo, F; Perrone, F; Rossi, E | 1 |
| Arlt, A; Fölsch, UR; Gehrz, A; Kruse, ML; Müerköster, S; Schäfer, H; Vorndamm, J | 1 |
| Ardine, M; Bergnolo, P; Berruti, A; Bertetto, O; Coccorullo, Z; Comandone, A; Donadio, M; Fea, E; Mistrangelo, M; Ritorto, G | 1 |
| Dreicer, R; George, CS; Manola, J; Roth, BJ; Schneider, DJ; Schwerkoske, JF; Wilding, G | 1 |
| Aversa, SM; Bortolotti, L; Favaretto, AG; Loreggian, L; Manzini, Vde P; Monfardini, S; Oniga, F; Paccagnella, A; Palmisano, V; Rea, F; Stefani, M | 1 |
| Berkhof, J; Hoekman, K; Kakkar, AK; Kuenen, BC; Levi, M; Meijers, JC; Pinedo, HM; van Hinsbergh, VW | 1 |
| Akiyama, Y; Kanzawa, F; Nishio, K; Saijo, N | 1 |
| Corrie, PG; Cree, IA; Haass, N; Hengge, U; Kuwert, C; Neuber, K; Pföhler, C; Reinhold, U; Tilgen, W; Ugurel, S; Zutt, M | 1 |
| Bolaño, M; Casado, E; Castro, J; Checa, T; Feliu, J; González-Barón, M; Madroñal, C; Martín, G; Rodríguez, A; Rodríguez-Jaráiz, A | 1 |
| Delpassand, ES; Logothetis, CJ; Millikan, RE; Pagliaro, LC; Tu, SM; Williams, D | 1 |
| Clowse, ME; Wigley, FM | 1 |
| Ameye, G; Cedervall, B; Grégoire, V; Libouton, JM; Michaux, L; Octave-Prignot, M; Rosier, JF; Scalliet, P; Verellen-Dumoulin, C | 1 |
| Bepler, G; Boni, C; Cooc, J; Crinò, L; Danenberg, KD; De Marinis, F; Di Costanzo, F; Gozzelino, F; Lord, RV; Marangolo, M; Novello, S; Rinaldi, M; Rosell, R; Salonga, D; Sánchez, JJ; Scagliotti, G; Stephens, C; Taron, M; Tonato, M | 1 |
| Yeo, CJ | 1 |
| Nishiwaki, Y | 1 |
| Funayama, Y; Kagohashi, K; Satoh, H; Sekizawa, K | 1 |
| Azzoli, CG; Hensley, ML; Kris, MG; Krug, LM; Miller, VA; Muller, RJ; Ng, KK; O'Reilly, EM | 1 |
| Alberti, D; Arzoomanian, RZ; Bailey, HH; Binger, K; Feierabend, C; Liu, G; Marnocha, R; Thomas, JP; Volkman, J; Wilding, G | 1 |
| Aksoy, Y; Kadioğlu, YY; Yilmaz, B | 2 |
| Berghe, KV; Berkenblit, A; Cannistra, SA; Feyler, H; Kim, Y; Niloff, J; Tung, N | 1 |
| Bergman, AM; Loves, WJ; Peters, GJ; Pinedo, HM; Talianidis, I; van der Wilt, CL; Veerman, G | 1 |
| Belyanskaya, L; Belyanskya, L; Cathomas, R; Hopkins-Donaldson, S; Kurtz, S; Simões-Wüst, AP; Stahel, RA; Zangemeister-Wittke, U | 1 |
| Ali, S; Aranha, O; Li, Y; Pettit, GR; Philip, PA; Sarkar, FH | 1 |
| Flaherty, KT; Hahn, SM; O'Dwyer, PJ; Redlinger, M; Stevenson, JP | 1 |
| Schramm, H | 1 |
| Oettle, H | 2 |
| Chen, HH; Chen, JS; Lin, MH; Su, WC | 1 |
| Goff, BA; Greer, BE; Jacobs, A; Storer, B; Thompson, T | 1 |
| Heimans, JJ; Hoekman, K; Postma, TJ; Verstappen, CC | 1 |
| Gallagher, N; Smith, D | 1 |
| McGinn, CJ; Zalupski, MM | 1 |
| Hochster, HS | 1 |
| Abrams, RA; Regine, WF; Rich, TA; Safran, H; Willett, CG | 1 |
| Battelli, T; Bonsignori, M; Buzzi, F; Catanzani, S; De Signoribus, G; Di Lullo, L; Lippe, P; Massacesi, C; Mattioli, R; Mazzanti, P; Morale, D; Pilone, A; Rocchi, MB; Rossi, G; Sturba, F; Trivisonne, R; Tuveri, G | 1 |
| Aitini, E; Barbieri, R; Cacciani, GC; Camisa, R; Capra, R; Cascinu, S; Franciosi, V; Vasini, G | 1 |
| Bacoyiannis, C; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kiamouris, C; Klouvas, G; Kosmidis, P; Papakostas, P; Pavlidis, N; Samantas, E; Skarlos, DV | 1 |
| Closon, MT; Closset, J; Collette, M; Demols, A; Gastelblum, P; Gay, F; Gelin, M; Houbiers, G; Houtte, PV; Polus, M; Van Laethem, JL | 1 |
| Bartolini, S; Betti, M; Cappuzzo, F; Crinò, L; Darwish, S; De Angelis, V; De Marinis, F; Gregorc, V; Maestri, A; Mazzoni, F; Nelli, F; Novello, S; Rita Migliorino, M; Scagliotti, GV; Selvaggi, G; Tonato, M | 1 |
| Bresters, D; Broekhuizen, AJ; Faircloth, GT; Jimeno, J; Kaaijk, P; Kaspers, GJ | 1 |
| Barbera, S; Bezjak, A; Cigolari, S; Fava, S; Findlay, B; Frontini, L; Gallo, C; Gasparini, G; Gebbia, V; Gridelli, C; Hirsh, V; Ianniello, GP; Illiano, A; Manzione, L; Myers, R; Perrone, F; Piantedosi, F; Robbiati, SF; Seymour, L; Shepherd, FA; Veltri, E | 1 |
| Blohmer, J; Kaubitzsch, S; Lichtenegger, W; Oskay, G; Sehouli, J; Stengel, D | 2 |
| Camus, P | 1 |
| Barlési, F; Doddoli, C; Gimenez, C; Greillier, L; Kleisbauer, JP; Lima, G | 1 |
| Carini, M; Corvino, C; Lapini, A; Meliani, E; Serni, S | 1 |
| Bland, KI; Bonner, JA; Buchsbaum, DJ; Huang, ZQ; Raisch, KP; Vickers, SM | 1 |
| Sternberg, CN; Vogelzang, NJ | 1 |
| Kitchell, BE; Moore, AS | 1 |
| Araki, J; Nishio, K; Oda, T; Watanabe, M | 1 |
| Hitsuda, Y; Kawasaki, Y; Koshohbu, T; Matsumoto, S; Nakatani, S; Shimizu, E; Yasuda, K | 1 |
| Cerretani, D; Correale, P; Francini, G; Giorgi, G; Marsili, S; Messinese, S; Petrioli, R; Pinto, E; Pozzessere, D; Roviello, F; Sabatino, M | 1 |
| Gregor, A; Groen, HJ; Little, FA; Price, A; van der Leest, AH; van Putten, JW | 1 |
| Adjei, AA; Alberts, SR; Atherton, P; Bruzek, LM; Croghan, GA; Erlichman, C; Goldberg, RM; Hanson, LJ; Kaufmann, SH; Marks, RS; Palmer, PA; Pitot, HC; Reid, JM; Sloan, JA; Thibault, A | 1 |
| Duan, Y; Duan, Z; Lamendola, DE; Naeem, R; Penson, RT; Seiden, MV; Yusuf, RZ | 1 |
| Calvanese, A; Ceciarini, F; Cerretani, D; Correale, P; Di Palma, T; Francini, G; Giorgi, G; Marsili, S; Messinese, S; Neri, A; Pellegrini, M; Petrioli, R; Pinto, E; Pozzessere, D; Sabatino, M | 1 |
| Alberola, V; Felip, E; Massuti, B; Rosell, R; Taron, M | 1 |
| Johansson, R; Kataja, V; Pulkkanen, K | 1 |
| Antimi, M; Barduagni, M; Ceribelli, A; Cognetti, F; Cortesi, E; De Marinis, F; Fabi, A; Gamucci, T; Giannarelli, D; Gridelli, C; Maione, P; Migliorino, MR | 1 |
| Hsu, D; Lindgren, T; Tran, G; Wong, SF | 1 |
| Anderson, H; Ashcroft, L; Beresford, C; Burt, PA; Clemons, M; Danson, S; Dowd, I; Fairve-Finn, C; Hassan, J; Middleton, MR; O'Byrne, KJ; Ranson, M; Stout, R; Thatcher, N | 1 |
| Arroyo, G; Castagnino, R; Gonzalez Jazey, P; Jaremtchuk, AV; Keropian, M; Mina, C; Zarbá, JJ | 1 |
| Adsay, V; Day, J; El-Rayes, BF; Heilbrun, LK; Jain, V; Philip, PA; Shields, AF; Vaishampayan, U; Zalupski, MM | 1 |
| Abbruzzese, J; Hainsworth, J; Hochster, H; Lenzi, R; Plunkett, W; Ruiz Van Haperen, V; Tempero, M | 1 |
| Ardizzoni, A; de Cupis, A; Favoni, RE; Loprevite, M; Pirani, P; Semino, C | 1 |
| Eriguchi, N; Funakoshi, A; Ito, T; Migita, Y; Mizumoto, K; Muranaka, T; Niyahara, T; Sakai, T; Shinozaki, H; Sumii, T; Tanaka, M; Ueki, T; Yamaguchi, H | 1 |
| Behrns, K; Bernard, SA; Calvo, B; Cance, W; Churchel, MA; Detterbeck, FC; Koruda, M; Ollila, D; Poole, ME; Weissler, MC | 1 |
| Hussain, SA; James, ND | 1 |
| Crane, CH; Janjan, NA; Mason, K; Milas, L | 1 |
| Dueñas Garcia, R; Fernandez Flores, E; Fernandez Morales, M; Jaen Morago, A; Lozano Barriuso, A; Medina Magan, B; Mohedano Mohedano, N; Moreno Moreno, MA; Porras Quintela, I; Sánchez Rovira, P | 1 |
| Chan, WK; Chang, FY; Chao, Y; Chi, KH; Lee, RC; Lee, SD; Li, CP; Teng, HC; Yen, SH | 1 |
| Claude, L; Mornex, F | 1 |
| Harper, P | 1 |
| Alberola, V; Bepler, G; Camps, C; Crino, L; Danenberg, K; De Marinis, F; Peñas, R; Provencio, M; Rosell, R; Sanchez, JJ; Scagliotti, G; Taron, M | 1 |
| Economopoulos, T; Fountzilas, G; Raptis, S; Rontogianni, D; Valsami, S; Xiros, N | 1 |
| Clarke, ML; Cros, E; Dumontet, C; Galmarini, CM; Gosselin, G; Jordheim, L; Mackey, JR; Perigaud, C; Santos, CL | 1 |
| Bookman, M; Copeland, LJ; Trimble, E | 1 |
| Bloss, JD; Mutch, DG | 1 |
| Mutch, DG | 1 |
| Fowler, WC; Van Le, L | 1 |
| Fojtů, H; Grygárková, I; Havel, L; Horenková, E; Kolek, V; Kůta, M; Nováková, L; Pesek, M; Petruzelka, L; Průsa, P; Roubec, J; Sixtová, D; Skácel, T; Skricková, J; Zatloukal, P; Zemanová, M | 1 |
| Bolt, K; Lammers, JW; Maas, KW; Schramel, FM; van der Lee, I; Zanen, P | 1 |
| Bosse, U; Froeschle, P; Granetzny, A; Klinke, F; Koch, O; Striehn, E; Vogt, U; Wagner, W | 1 |
| Albain, KS; Cheng, C; Chiu, A; Doroshow, JH; Frankel, P; Gandara, D; Juhasz, A; Lenz, HJ; Longmate, J; Margolin, K; Newman, EM; Rivera, H; Synold, T; Vishwanath, R; Wilczynski, S; Yen, Y | 1 |
| Aikawa, I; Matsuda, T; Taniguchi, F; Tsuda, T | 1 |
| Bold, RJ; Fahy, BN; Schlieman, MG; Virudachalam, S | 2 |
| Bouvet, M; Hoffman, RM; Katz, MH; Moossa, AR; Spivack, D; Takimoto, S | 1 |
| Alberola, V; Artal, A; Azagra, P; Bover, I; Camps, C; Cardenal, F; Carrato, A; de las Peñas, R; Diz, P; Felip, E; González-Larriba, JL; Isla, D; Jiménez, U; López-Vivanco, G; Morales, S; Provencio, M; Rosell, R; Ruiz-Casado, A; Sanchez, JJ; Vadell, C | 1 |
| Adinin, R; Arun, B; Hoelzer, K; Hortobagyi, GN; Pusztai, L; Rivera, E; Royce, M; Valero, V; Wade, JL; Walters, R | 1 |
| Colwell, B; Dagenais, M; Dancey, J; Eisenberg, PD; Fields, A; Greenberg, B; Hagan, K; Hamm, J; Humphrey, R; Moore, MJ; Ottaway, J; Seymour, L; Tu, D; Zee, B | 1 |
| Alexander, RL; Fleming, RA; Ishaq, KS; Kucera, GL; Morris-Natschke, SL | 1 |
| Abad, A; Balaña, C; Cirauqui, B; Font, A; Manzano, JL; Mate, JL; Moreno, I; Rosell, R | 1 |
| Chen, A; Grem, JL; Hamilton, JM; Harold, N; Keith, B; Monahan, BP; Morrison, G; Nguyen, D; Pang, J; Quinn, MG; Rowedder, A; Takimoto, CH; Xu, Y | 1 |
| Groen, HJ; Kampinga, HH; Maring, JG; van Putten, JW; Wachters, FM; Zdzienicka, MZ | 1 |
| Adamo, V; Aiello, RA; Aitini, E; Altavilla, G; Angelini, V; Angiolillo, M; Anselmo, A; Ardizzoia, A; Aschelter, A; Azzarello, G; Barbera, S; Barletta, E; Barni, S; Bartolucci, R; Barzelloni, ML; Battiloro, C; Bearz, A; Belli, M; Bellia, V; Belloni, P; Belometti, MO; Bertetto, O; Bilancia, D; Bollina, R; Borsellino, N; Brancacio, L; Bretti, S; Bumma, C; Cabiddu, M; Caffo, O; Calandriello, A; Calcagno, A; Candido, P; Caprio, MG; Capuano, MA; Carrozza, F; Castiglione, F; Cazzaniga, M; Celano, A; Cigolari, S; Cioffi, A; Ciuffreda, L; Clerici, M; Colantuoni, G; Colucci, G; Corradini, GM; Cortesi, E; Crispino, C; Curcio, C; D'Aprile, M; D'Auria, G; Darwish, S; De Maio, E; De Marinis, F; Di Costanzo, F; Di Maio, M; Dinota, A; Esani, G; Esposito, M; Failla, G; Fava, S; Favaretto, A; Febbraro, A; Ferrario, S; Ferraù, F; Filipazzi, V; Foa, P; Frontini, L; Gaion, F; Galetta, D; Galligioni, E; Gallo, C; Gambaro, A; Gasparini, G; Gasperoni, S; Gattuso, D; Gebbia, N; Gebbia, V; Germano, D; Giotta, F; Gridelli, C; Grimi, E; Guardasole, V; Guidetti, G; Hopps, MR; Iaffaioli, RV; Ianniello, GP; Illiano, A; Isa, L; Labianca, R; Lamberti, A; Locatelli, MC; Luporini, G; Maione, P; Maiorino, L; Malaponte, E; Manzione, L; Martelli, O; Mattioli, R; Michetti, G; Migliorino, MR; Monfardini, S; Morabito, A; Nettis, G; Nisticò, C; Novello, S; Ostellino, O; Palazzolo, G; Parello, G; Pari, F; Pavia, G; Pedicini, T; Perrone, F; Piantedosi, FV; Piazza, E; Pistillucci, G; Pontillo, V; Porcile, G; Quadri, A; Raina, A; Renda, F; Robbiati, SF; Romano, F; Romito, S; Rosati, G; Rosetti, F; Rossi, A; Rossi, N; Sacco, C; Sannicolò, M; Santoro, A; Santoro, M; Scagliotti, G; Scalone, S; Scimone, A; Selvaggi, G; Sibau, A; Signoriello, G; Sollitto, F; Sorio, R; Spatafora, M; Stefani, M; Testa, A; Tinessa, V; Tonato, M; Tufano, G; Valerio, MR; Vasta, M; Veltri, E; Vinante, O; Volpintesta, A; Zollo, C; Zonato, S | 1 |
| Amberger, A; Gnaiger, E; Kofler, R; Konwalinka, G; Renner, K | 1 |
| Allouache, J; Bouzy, J; Bugat, R; Coudert, B; Culine, S; Douillard, JY; Fizazi, K; Goupil, A; Kaminsky, MC; Laplanche, A; Lesimple, T; Lortholary, A; Merrouche, Y; Négrier, S; Petrow, P; Pivot, X; Priou, F; Théodore, C; Viala, J; Voigt, JJ | 1 |
| Alfieri, S; Cellini, N; Costamagna, G; Doglietto, GB; Luzi, S; Macchia, G; Morganti, AG; Smaniotto, D; Trodella, L; Valentini, V | 1 |
| Ferenczi, E; Gergely-Farnos, E; Kovács, G; Magyar, P; Ostoros, G; Strausz, J; Szondy, K | 1 |
| Lénárt, T; Sárosi, V | 1 |
| Bodoky, G | 1 |
| Bodrogi, I | 1 |
| Belinson, J; Kulp, B; Markman, M; Peterson, G; Webster, K; Zanotti, K | 2 |
| Bui, DT; Fruehauf, JP; Holcombe, RF; Kong, KM; Sommers, KR | 1 |
| Castellano, D; Cortés-Funes, H; Hitt, R; Jimeno, A | 1 |
| Herchenhorn, D; Rabinowits, G; Rabinowits, M; Torres, W; Weatge, D | 1 |
| Debré, B; Oudard, S; Peyromaure, M; Scotté, F; Thiounn, N; Vieillefond, A | 1 |
| George, C; Huo, D; Karrison, T; Ryan, CW; Stadler, WM; Vogelzang, NJ; Yang, X; Zimmerman, TM | 1 |
| Baas, P; Beijnen, JH; Crul, M; Maliepaard, M; Pluim, D; Schellens, JH; Schoemaker, NE; Schot, M; Sparidans, RW; Underberg, RW; Van Zandwijk, N | 1 |
| Auditore-Hargreaves, K; Axworthy, D; Dearstyne, E; Graves, SS; Gray, D; Jones, HM; Lin, Y; Pantalias, A; Sanderson, J; Schultz, J; Zuo, Y | 1 |
| Cardillo, TM; Gold, DV; Modrak, D; Schutsky, K | 1 |
| Hanibuchi, M; Hirano, H; Ito, M; Maeda, H; Nakagawa, M; Okumura, Y; Sawabata, Y; Takeda, S; Uematsu, K | 1 |
| Ito, H; Katoh, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Shimamura, F; Shimizu, H; Togawa, A; Yoshidome, H | 1 |
| Goh, BC; Lee, HS; Noordhuis, P; Peters, GJ; Wang, LZ | 1 |
| Beatty, P; Hoang, T; Jaslowski, A; Kim, K; Koch, P; McGovern, J; Quisumbing, M; Schiller, JH; Shapiro, G; Witte, R | 1 |
| Kolb, EA; Steinherz, PG | 1 |
| Al-Mwalad, M; Albers, P; Becker, T; Brauers, A; Brkovic, D; Bub, P; Derigs, HG; Fassmann, C; Hamza, A; Hartlapp, J; Henss, H; Hertle, L; Jaeger, E; Jakse, G; Kälble, T; Kaldenbach, U; Knuth, A; Koser, M; Lehmann, J; Lippert, C; Loch, T; Melchior, H; Muschter, R; Otto, C; Piechota, HJ; Pomer, S; Potratz, C; Retz, M; Richter, AE; Roloff, J; Roth, S; Steiner, G; Stockamp, K; Stöckle, M; Tunn, U; Van Ahlen, H; Walz, P; Weinknecht, S; Weissbach, L; Winter, E; Wirth, M | 1 |
| Castro Kreder, N; Franken, NA; Haveman, J; Van Bree, C | 2 |
| Ge, Y; Jensen, TL; Matherly, LH; Taub, JW | 1 |
| Hirokawa, S; Masaki, T; Miyakawa, K; Ohkawa, S; Tamai, S; Tarao, K | 1 |
| Breda, E; D'Agostino, G; Ferrandina, G; Gbaguidi, N; Lorusso, D; Ludovisi, M; Mancuso, S; Scambia, G; Testa, A | 1 |
| Boezen, HM; de Leede, GP; de Vries, EG; Eppinga, P; Erjavec, Z; Groen, HJ; Kramer, H; Strijbos, JH; Van Putten, JW; Wachters, FM | 1 |
| Cooper, AJ; Johnson, CD; Whitehouse, PA | 1 |
| Beauduin, M; Belpomme, D; Canon, JL; De Pauw, A; Gauthier, S; Janssens, J; Kayitalire, L; Krakowski, I; Moreau, V; Petit, T | 1 |
| De Boeck, G; De Bruijn, E; Guetens, G; Hendriks, JM; Pauwels, B; Romijn, S; Van Putte, BP; Van Schil, PE | 1 |
| Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F | 1 |
| Cantor, R; Dabrow, MB; Francesco, MR; Gilman, PB; Meyer, TJ; Rose, L | 1 |
| Chen, WR; Hamilton, SA; Ishmael, DR; Liu, H; Nordquist, RE | 1 |
| Dundr, P; Dvorácek, J; Pesl, M; Povýsil, C; Vítková, I | 1 |
| Brancaccio, L; Cortesi, E; Crispino, C; De Marinis, F; Gridelli, C; Martelli, O; Migliorino, MR; Nelli, F; Portalone, L; Treggiari, S | 1 |
| Black, PC; Lange, PH; Takayama, TK | 1 |
| Hittmair, A; Jeske, HC; Klima, G; Margreiter, R; Oberladstätter, J; Obrist, P; Ollinger, R; Roberts, K; Schneeberger, S; Schubert, H; Steurer, W | 1 |
| Chao, Y; Hung, MC; Lee, SD; Lee, WP; Tai, DI; Tsai, SL; Yeh, CT | 1 |
| Lambiase, L; Li, J; Monteiro, C; Robinson, K; Schiff, M | 1 |
| Glasmacher, A; Gorschlüter, M; Mey, U; Sauerbruch, T; Schlie, C; Schmidt-Wolf, IG; Strehl, J; Ziske, C | 1 |
| Dowlati, A; Levitan, N | 1 |
| Haller, D; Sun, W | 1 |
| Bhargava, P; Jani, CR; O'Donnell, JL; Rocha Lima, CM; Savarese, DM; Stuart, KE | 1 |
| Arlander, SJ; Eapen, AK; Karnitz, LM; McDonald, RJ; Toft, DO; Vroman, BT | 1 |
| Peters, GJ; Schalken, JA; van der Heijden, AG; Vriesema, JL; Witjes, JA | 1 |
| Babarina, A; Kischkel, FC; Waldenmaier, DS | 1 |
| de Pooter, CM; Korst, AE; Lambrechts, HA; Lardon, F; Lenjou, M; Pattyn, GG; Pauwels, B; Van Bockstaele, DR; Vermeulen, K; Vermorken, JB | 1 |
| Atadja, P; Bali, P; Bhalla, K; Donapaty, S; Fuino, L; Guo, F; Wang, HG; Wittmann, S; Yamaguchi, H | 1 |
| Brasiūnas, V; Brasiūniene, B; Inciūra, A; Juozaityte, E | 1 |
| Bulgaru, A; Egorin, M; Goel, S; Harvey, E; Hochster, H; Ivy, P; Leibes, L; Lockwood, G; Mani, S; Muggia, F; Renshaw, G; Wadler, S; Zamboni, W | 1 |
| Eckhardt, SG; Gentner, L; Goetz, A; Hammond, LA; Izbicka, E; McCreery, H; Mori, M; Patnaik, A; Richards, H; Rowinsky, EK; Rybak, ME; Schwartz, G; Takimoto, CH; Terada, K; Tolcher, AA; Zhang, S | 1 |
| Casado, FJ; García-Manteiga, J; Mazo, A; Molina-Arcas, M; Pastor-Anglada, M | 1 |
| Biesma, B; Debruyne, C; Gaafar, R; Giaccone, G; Legrand, C; Lianes, P; Manegold, C; Neymark, N; Schramel, F; Smit, EF; Smit, H; van Meerbeeck, JP | 1 |
| Im, MM; Ljungman, M; Praz, F; Robinson, BW; Shewach, DS | 1 |
| Allen, HJ; Baker, C; Bosserman, LD; Chapman, Y; Figlin, RA; Gitlitz, BJ; Patel, R; Sanchez, JD; Shapiro, RM | 1 |
| D'Agostino, G; Ferrandina, G; Fruscella, E; Gallo, D; Scambia, G | 1 |
| Badalamenti, G; Fulfaro, F; Gebbia, N; Russo, A; Valerio, MR | 1 |
| Boni, C; Zanelli, F | 1 |
| Emoto, T; Kawamura, T; Matsumoto, T; Matsunaga, N; Miura, G; Tanaka, N | 1 |
| Coker, A; Kamer, E; Ozer, E; Ozkara, E; Ozzeybek, T; Sevinç, AI | 1 |
| Barton, JH; Bradof, JE; Erland, JB; Greco, EA; Hainsworth, JD; Stagg, MP; Thompson, DS; Twele, TW | 1 |
| Spiridonidis, CH | 1 |
| Genet, D; Labourey, JL; Ly, K; Martin, J; Szelag, JC; Tubiana-Mathieu, N; Vénat-Bouvet, L | 1 |
| Amadori, D; Fabbri, M; Frassineti, GL; Ibrahim, T; Monti, M; Ricotti, L; Zoli, W | 1 |
| Ariad, S; Cohen, AD; Grunwald, M; Lazarev, I; Mermershtain, W | 1 |
| Berkowitz, R; Campos, S; Colella, T; Duska, L; Fuller, A; Gore, S; Lee, H; Matulonis, U; Roche, M; Seiden, MV | 1 |
| Kennedy, AW; Khuntia, D; Markman, M; Schwartz, BM | 1 |
| Lee, SJ; Millikan, RE; Mueller, P; Thall, PF | 1 |
| Crucitta, E; De Lena, M; Fiore, M; Lorusso, V; Piscitelli, D; Silvestris, N | 1 |
| Garbrecht, M; Heinemann, V; Helmberger, T; Lamerz, R; Niebler, K; Schalhorn, A; Schermuly, MM; Stemmler, J; Stieber, P; Stoffregen, C; Szymala, AM; Wilkowski, R | 1 |
| Bremer, M; Dörk, T; Gross, M; Karstens, JH; Morlot, S; Schindler, D | 1 |
| Barten-van Rijbroek, A; Castro Kreder, N; Genç, M; Haveman, J; Stalpers, LJ | 1 |
| Bai, YR; Chen, Y; Guo, WJ; Lu, DQ; Wu, GH; Wu, XD; Yao, Y; Zhou, RH | 1 |
| Inoue, T; Kato, T; Kobashi, Y; Maeda, Y; Maniwa, K; Minakuchi, M; Noma, S; Sakuramoto, M; Taguchi, Y; Tanaka, E | 1 |
| Degen, JW; Lonser, RR; Oldfield, EH; Vortmeyer, AO; Walbridge, S | 1 |
| Chen, Z; Guan, Z; Kim, TW; Kim, WS; Lehnert, M; Maoleekoonpairoj, S; Ratanatharathorn, V; Reece, WH; Wang, Y | 1 |
| Aoyagi, S; Hara, M; Hayashi, K; Horiuchi, H; Ishikawa, H; Kinoshita, H; Kodama, T; Nishimura, K; Ogata, T; Ohdo, M; Okuda, K; Shirouzu, K; Uchida, S; Yasunaga, M | 1 |
| Matsumoto, G; Okamoto, A; Tsuruta, K | 1 |
| Arii, S; Baba, H; Endo, M | 1 |
| Barceló, R; Ferreiro, J; Fuente, N; López-Vivanco, G; Mañé, JM; Muñoz, A; Pérez-Hoyos, T; Rubio, I; Viteri, A | 1 |
| Ashley, SW; Benoit, E; Duxbury, MS; Ito, H; Whang, EE; Zinner, MJ | 2 |
| Gschwend, JE; Hautmann, RE; Simon, J; Volkmer, B | 1 |
| Eckel, F; Erdmann, J; Lersch, C; Mayr, M; Schmelz, R | 1 |
| Bolner, A; Caffo, O; Fellin, G; Galligioni, E; Graffer, U; Luciani, L; Tomio, L; Valduga, F | 1 |
| Boiron, C; Fouques Duparc, V; Jagot, JL; Lazzerini, C; Mathieu, M; Virally, J | 1 |
| Baltaci, S; Bedük, Y; Göğüş, C; Göğüş, O; Türkölmez, K | 1 |
| Albert, A; Bosch, C; Camps, C; Giner, V; Gómez, J; Gómez-Aldaraví, L; Llorca, C; Maestu, I; Oltra, A; Torregrosa, MD | 1 |
| Andruccetti, M; Bartolini, S; Benedetti, G; Calandri, C; Cappuzzo, F; Cortesi, E; Crinò, L; De Marinis, F; Maestri, A; Martelli, O; Migliorino, MR; Nelli, F; Rastelli, F | 1 |
| Abe, H; Akada, M; Egawa, S; Fukuyama, S; Matsuno, S; Motoi, F; Ottomo, S; Sunamura, M; Takeda, K | 1 |
| Furukawa, K; Kataba, H; Kato, H; Miura, T; Saito, M | 1 |
| Ahn, JH; Chang, HM; Kang, HJ; Kang, YK; Kim, TW; Lee, JS; Lee, K | 1 |
| Maeyama, R; Manabe, T; Matsuda, T; Okino, H; Tanaka, M | 1 |
| Chayama, K; Iiboshi, T; Kariya, K; Kobayashi, K; Kuwada, Y; Kuwahara, K; Miyata, H; Morinaka, K; Murakami, M; Noma, B; Sasaki, T; Serikawa, M; Yamasaki, S | 1 |
| Cornelio, GH; Gordon, EM; Hall, FL; Levy, JP; Liu, L; Lorenzo, CC; Reed, RA | 1 |
| Berardi, R; Carle, F; Cellerino, R; Lippe, P; Menichetti, ET; Nacciarriti, D; Piga, A; Porfiri, E; Scartozzi, M; Silva, RR; Tummarello, D | 1 |
| Calley, C; Fata, F; Ganjoo, KN; Loehrer, PJ; Picus, J; Schneider, BP; Seitz, DE; Stoner, C | 1 |
| Kurokawa, S; Matsuzaki, A; Morita, T; Tokue, A | 1 |
| Ashley, SW; Duxbury, MS; Ito, H; Whang, EE; Zinner, MJ | 3 |
| Chen, YM; Lee, CS; Lin, WC; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Brown, D; Hejna, G; Lawrence, T; McGinn, CJ; Muler, JH; Normolle, D; Zalupski, MM | 1 |
| Cable, CT; Mott, FE; Sharma, N | 1 |
| Camps, C; López-Vivanco, G; Rosell, R; Taron, M | 1 |
| Boige, V; Boleslawski, E; Bonyhay, L; de Baere, T; Delgado, MA; Ducreux, M; Golli, L; Hannoun, L; Mansourbakht, T; Poynard, T; Taïeb, J; Tigaud, JM | 1 |
| Dianzani, C; La Cesa, A; Landi, D; Santini, D; Tonini, G; Vincenzi, B | 1 |
| Battermann, JJ; El Sharouni, SY; Kal, HB | 1 |
| Addington-Hall, JM; Anderson, H; Keane, K; McKendrik, J; Peake, MD; Thatcher, N | 1 |
| Cree, IA; Di Nicolantonio, F; Knight, LA; Mercer, SJ; O'Callaghan, A; Whitehouse, PA | 1 |
| Balzarini, P; Bonora, A; Ennas, MG; Grigolato, P; Moore, PS; Sartoris, S; Scarpa, A; Sorio, C; Tecchio, C | 1 |
| Ardizzoni, A; Barton, C; Butts, C; Gatzemeier, U; Ghahramani, P; Groth, G; Hirsh, V; Shepherd, F; Van Zandwijk, N | 1 |
| Alexopoulos, A; Ardavanis, A; Georganta, C; Gerasimidis, G; Kandilis, K; Karamouzis, MV; Karydas, I; Rigatos, G; Stavrakakis, J; Stavrinides, H; Tryfonopoulos, D | 1 |
| Granov, DA; Pavlovskiĭ, AV; Tarazov, PG | 1 |
| Di, LJ; Gao, YJ; Li, L; Li, R; Liu, JW; Liu, SJ; Sun, H; Wang, J; Xu, GW; Yang, L; Zhang, MH | 1 |
| Gao, GQ; Mei, QD; Wang, LP | 1 |
| Dawson, NA; Edelman, MJ; Houston, J; Lara, PN; Lauder, I; Law, LY; Meyers, FJ | 1 |
| Bier, J; Gath, HJ; Oettle, H; Raguse, JD; Riess, H | 2 |
| Ariyoshi, Y; Katakami, N; Kodama, K; Nakano, T; Negoro, S; Nogami, T; Okamoto, N; Sugiura, T; Takada, Y; Yamamoto, H | 1 |
| Aristides, M; Bhalla, S; Kielhorn, A; Lees, M; Maniadakis, N; Schiller, J; Tilden, D | 1 |
| Beyer, J; Bokemeyer, C; Hartmann, JT; Hohloch, K; Kanz, L; Kollmannsberger, C; Liersch, R; Metzner, B; Rick, O; Schoeffski, P; Spott, C; Stengele, K | 1 |
| Comella, G; Comella, P; De Cataldis, G; De Rosa, V; Fiore, F; Frasci, G; Lapenta, L; Licenziato, M; Maiorino, L | 1 |
| Abbruzzese, JL; Benedetti, JK; Chansky, K; Macdonald, JS; Pluenneke, RE; Urba, SG; VanVeldhuizen, PJ | 1 |
| Chiba, H; Hirayama, Y; Sagawa, T; Sakamaki, S; Takayanagi, N; Tsuji, Y | 2 |
| Blackman, MR; Grem, J; Mansky, PJ; Monahan, BP; Wallerstedt, DB | 1 |
| Choi, BG; Han, JY; Hong, EK; Hong, YS; Jin, JY; Kang, JH; Kim, KW; Lee, KS; Park, JN; Park, SY | 1 |
| Cheong, K; Karapetis, CS; Li, J | 1 |
| Andreola, G; Crucitta, E; D'Aprile, M; De Lena, M; Locopo, N; Lorusso, V; Marini, L; Silvestris, N | 1 |
| Lawrence, TS | 1 |
| Arminio, D; Barbera, S; Colosimo, M; De Gregorio, P; De Sarro, GB; Gallelli, L; Maselli, R; Nardi, M; Pelaia, G; Pirritano, D; Prantera, T; Raffaele, M | 1 |
| Laan, A; Peters, GJ; Schalken, JA; van der Heijden, AG; Vriesema, JL; Witjes, JA | 1 |
| Clarke, NW; Cowan, R; Hendry, JH; Margison, GP; Sangar, VK | 1 |
| Anderson, N; Coco, F; Lokich, J | 1 |
| Ali, SA; Fareed, A; Mallick, JA; Siddiqui, N | 1 |
| Aglione, S; Bajetta, E; Bidoli, P; Cortinovis, D; De Candis, D; Formisano, B; Mariani, L; Stani, SC; Toffolatti, L; Zilembo, N | 1 |
| Gennatas, K; Gouveris, P; Karatzas, G; Kosmas, C; Margaris, H; Mouratidou, D; Papadoniou, N; Papalambros, E; Papastratis, G; Polyzos, A; Tsavaris, N; Tsipras, H; Tzima, E | 1 |
| Bickels, J; Inbar, M; Kollender, Y; Meller, I; Merimsky, O | 1 |
| Akar, S; Akkoc, N; Birlik, M; Kirkali, Z; Manisali, M; Onen, F; Ozer, E; Tuzel, E | 1 |
| Cortes, J; Giles, F; Kantarjian, H; Ravandi, F | 1 |
| Delecluse, HJ; Feng, WH; Hong, G; Kenney, SC | 1 |
| Barlési, F; Doddoli, C; Gimenez, C; Kleisbauer, JP; Villani, P | 1 |
| Christgen, M; Haye, S; Kalthoff, H; Kremer, B; Kurdow, R; Schniewind, B; Ungefroren, H | 1 |
| Dono, K; Maruhashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, Y; Tujie, M; Umeshita, K | 1 |
| Bookman, MA; Herzog, TJ; Look, KY; Rocereto, T; Schol, J; Vinters, J | 1 |
| Aravantinos, G; Briassoulis, E; Dimopoulos, MA; Fountzilas, G; Gika, D; Kalofonos, C; Moulopoulos, LA; Papadimitriou, CA | 1 |
| Brown, J; Martin, MC; Ramondetta, LM; Smith, JA; Wolf, JK | 1 |
| Boyer, M; Clarke, S; Fife, K; Hong, A; Rivory, L; Stevens, G; Zhang, M | 1 |
| Li, M; Rinehart, JJ; Wang, H; Zhang, R | 2 |
| Acquati, M; Ardizzoia, A; Casartelli, C; Fagnani, D; Fusco, O; Giordano, M; Malugani, F; Quattrone, A; Scanni, A; Tagliabue, P; Vergani, C; Visini, M | 1 |
| O'Shaughnessy, JA | 1 |
| Modi, S; Seidman, AD | 1 |
| Yardley, DA | 4 |
| Perez, EA | 1 |
| DeMichele, A; Domchek, S; Fox, K; Stein, S | 1 |
| Geyer, CE; Mamounas, EP; Swain, SM | 1 |
| Billiart, I; Bourgeois, H; Chabrun, V; Chieze, S; Daban, A; Ferrand, V; Germain, T; Lemerre, D; Meurice, JC; Tourani, JM | 1 |
| Alonso, S; Barnadas, A; Carañana, V; Colomer, R; Fernández, Y; García-Conde, J; Guillem, V; Hornedo, J; Llombart-Cussac, A; Lluch, A; Montero, S; Ojeda, B | 1 |
| Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N | 1 |
| Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Van Bochove, A; Van Groeningen, CJ | 1 |
| Aguilar-Ponce, J; Alvarado, A; Castillo-Henkel, C; De la Garza, J; Dueñas-González, A; Granados-García, M; Green, D; Herrera-Gómez, A; Luna-Ortiz, K; Martínez-Said, H; Poitevin-Chacón, A; Segura-Pacheco, B; Villavicencio, V | 1 |
| Berthaud, P; Faivre, S; Henriksson, R; Le Chevalier, T; Monnerat, C; Novello, S; Raymond, E | 1 |
| Blessing, JA; Look, KY; Lucci, JA; Rose, PG; Sandler, A | 1 |
| Geisler, JP; Manahan, KJ; Schraith, DF; Sorosky, JI | 1 |
| Fukuchi, Y; Hirama, M; Ohhashi, R; Sato, K; Seyama, K; Suzuki, K; Takagi, Y; Takahashi, K; Uekusa, T | 1 |
| Seidman, A | 1 |
| Balbiani, L; Brosio, C; Caccia, G; Delfino, C; Flores Morales, D; Mickiewicz, E; Riva Gonzáles, L; Rodger, J; Zori Comba, A | 1 |
| Murad, AM | 1 |
| Behrens, P; Lee, KM; Märten, A; Mühlradt, PF; Sauerbruch, T; Schmidt, J; Schmidt, T; Schmidt-Wolf, IG; Schneider, C; Tiemann, K; Uhlinsky, V; Ziske, C | 1 |
| Dühmke, E; Heinemann, V; Rau, HG; Thoma, M; Wilkowski, R | 1 |
| Crane, CH | 1 |
| Arita, Y; Hisano, T; Ito, T; Kawabe, K; Nawata, H | 1 |
| Balasubramanian, S; Chandraratna, RA; Eckert, RL | 1 |
| Alberola, V; Artal, A; Bepler, G; Camps, C; Danenberg, KD; Diz, P; Isla, D; Provencio, M; Rosell, R; Sanchez, JJ; Taron, M | 1 |
| Amadori, D; Fabbri, F; Frassineti, GL; Gasperi Campani, A; Gunelli, R; Ricotti, L; Tesei, A; Ulivi, P; Zoli, W | 1 |
| Belani, CP; Ramalingam, S | 2 |
| Averbuch, SD; Fandi, A; Gatzemeier, U; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Pluzanska, A; Rennie, P; Rosell, R; Scagliotti, G; Schiller, JH; Von Pawel, J; Wolf, MK | 1 |
| Cardillo, TM; Gold, DV; Modrak, DE; Schutsky, K | 1 |
| Fujimoto, S; Fukiya, E; Funatsu, E; Hata, K; Ikezawa, S; Kimura, H; Kutsumi, H; Masuda, K; Nakamura, H; Nishida, K; Nobutani, K; Okuyama, Y; Otsuka, H; Shiomi, H; Sugeta, N; Suyama, Y; Suzuki, T; Yagi, N; Yashiro, H | 1 |
| Crawford, J; Govindan, R; Green, MR; Herndon, JE; King, GW; Rizvi, NA; Rocha Lima, CM; Zhang, C | 1 |
| Addeo, A; Bellone, G; Bertelli, GF; Bertetto, O; Chiappino, I; Heouaine, A; Merlano, M; Novarino, A; Ritorto, G | 1 |
| Depisch, D; Gruenberger, T; Karall, K; Kornek, GV; Laengle, F; Lang, F; Penz, M; Scheithauer, W; Schuell, B | 1 |
| De Lange, SM; Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Snijders, JF; Van Bochove, A; van Groeningen, CJ | 1 |
| Aravantinos, G; Farmakis, D; Gaglia, A; Kostopoulou, V; Koumpou, M; Mylonakis, N; Nikolaou, M; Pectasides, D; Pectasides, M; Skarlos, D | 1 |
| Amsellem-Ouazana, D; Beuzeboc, P; Debre, B; Peyromaure, M; Viellefond, A; Zerbib, M | 1 |
| Habiro, A; Izawa, T; Kohgo, Y; Koizumi, K; Mizukami, Y; Nakano, Y; Okumura, T; Osanai, M; Tanno, S | 1 |
| Pfisterer, J | 1 |
| Antonini, G; Codacci-Pisanelli, G; De Berardinis, E; Di Silverio, F; Loves, WJ; Peters, GJ; Van der Born, K | 1 |
| Lees, DA; Pandian, Z; Seckl, MJ; Smith, R | 1 |
| Fossella, FV; Fritsche, HA; Glisson, BS; Herbst, RS; Kies, MS; Lee, PM; Mass, RD; Massarelli, E; Ordonez, NG; Pisters, KM; Ro, JY; Sabloff, B; Smith, TL; Tran, HT; Yang, Y; Zinner, RG | 1 |
| Dietrich, M; Grossbard, ML; Kozuch, P; Malamud, S; Mathew, S; Rachamalla, R | 1 |
| Ahmad, I; Dritschilo, A; Gokhale, PC; Kasid, UN; Pei, J; Rahman, A; Zhang, C | 1 |
| Dizdarević, Z; Lomigorić, J; Mehić, B; Zutić, H | 1 |
| Campione, A; Diciolla, F; Gotti, G; Luzzi, L; Voltolini, L | 1 |
| Becht, C; Culine, S; Cupissol, D; Fabbro, M; Pinguet, F; Pouessel, D; Romieu, G; Ychou, M | 1 |
| Láng, I | 1 |
| Beraldi, E; English, JC; Evans, K; Fazli, L; Gleave, ME; July, LV; So, A | 1 |
| Bar-Eli, M; Davis, DW; Dinney, CP; Kamat, AM; Karashima, T; Lashinger, L; McConkey, DJ; Millikan, R; Shen, Y | 1 |
| Balbiani, L; Brosio, C; Caccia, G; Comba, AZ; Delfino, C; Gonzáles, LR; Mickiewicz, E; Morales, DF; Rodger, J | 1 |
| Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, K; Kim, WS; Lee, J; Lee, JK; Lee, KT; Lee, MH; Lee, SI; Lim, DH; Park, JO; Park, K; Song, SY | 1 |
| Benasso, M; Corvò, R; Pallestrini, E; Ponzanelli, A; Ricci, I; Rosso, R; Sanguineti, G; Santelli, A; Vitale, V | 1 |
| Beauduin, M; Bruniaux, M; Grégoire, V; Husson, B; Octave-Prignot, M; Rosier, JF | 1 |
| Liu, X; Qiu, W; Shih, J; Xue, L; Yen, Y; Zheng, S; Zhou, B | 1 |
| Bruns, CJ; Geissler, EK; Guba, M; Hoehn, A; Jauch, KW; Koehl, GE; Schwend, A; Seeliger, H; Steinbauer, M; Yezhelyev, M | 1 |
| Aghajanian, C; Ben-Porat, L; Chi, DS; Hensley, ML; Hoppe, B; Prasad, M; Sabbatini, P | 1 |
| Abbruzzese, JL; Li, D; Wolff, R; Xie, K | 1 |
| De Gelder, V; De Ridder, L; Dierckx, RA; Lambert, B; Slegers, G; Thierens, H | 1 |
| Barlow, C; Fennell, D; Gallagher, C; Ismay, J; Nystrom, M; Oesterling, C | 1 |
| Besalduch, J; Galmes, B; Gines, J; Gutierrez, A; Ramos, R; Rodriguez, J; Sampol, A | 1 |
| Dong, M; Feng, FY; Fu, M; Liang, X; Lin, C; Lu, HY; Wu, M; Zha, YY; Zhang, XY | 2 |
| Abbruzzese, JL; McConkey, D; Pino, SM; Xiong, HQ | 2 |
| Berger, MR; Leible, M; Sänger, J; Seelig, MH | 1 |
| Fidler, IJ; Yokoi, K | 1 |
| Bagajevas, A; Cesas, A | 1 |
| Awasthy, BS; Doval, DC; Fuloria, J; Gupta, S; Gupta, SK; Sekhon, JS; Shukla, VK | 1 |
| MacLeod, P; Maziak, DE; Shamji, FM; Stewart, DJ; Tomiak, E | 1 |
| Humblet, Y; Karasek, P; Ma, Y; Neumann, H; Oettle, H; Perez Ruixo, J; Post, S; Safran, H; Schoffski, P; Szawlowski, A; Van Cutsem, E; van de Velde, H; Verslype, C; Vervenne, WL; Von Hoff, D | 1 |
| Bahador, A; Facio, G; Garcia, AA; Jeffers, S; Kim, DY; O'Meara, A; Roman, L | 1 |
| Arai, Y; Hoshi, S; Itoh, A; Ohyama, C; Okada, Y; Ono, K; Saito, S; Satoh, M; Sohma, F; Takeda, A; Yamashita, S; Yamato, T | 1 |
| Hedley, D; Knox, JJ; Moore, MJ; Oza, A; Pond, GR; Siu, LL | 1 |
| Alfonso, R; Averbuch, S; Fandi, A; Giaccone, G; González-Larriba, JL; Martens, M; Peters, GJ; Smit, EF; Smith, R; van der Vijgh, WJ; van Oosterom, AT | 1 |
| Bansal, R; Friedlander, PA; Kemeny, N; Posner, J; Schwartz, L; Wagman, R | 1 |
| Gadgeel, SM; Pass, HI | 1 |
| Baker, LH; Biermann, JS; Couwlier, C; Lee, JS; Leu, KM; Ostruszka, LJ; Palazzolo, K; Shewach, D; Sondak, V; Zalupski, M | 1 |
| Anliker, M; Bargetzi, M; Itin, P; Weder, P | 1 |
| Kadioğlu, Y; Yilmaz, B | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Yoh, K | 1 |
| Israel, V; Jeffers, S; Raghavan, D; Snyder, T; Tagawa, ST | 1 |
| Eto, H; Gleave, ME; Hara, I; Li, D; Miyake, H; So, A | 1 |
| Algazy, KM; Flaherty, KT; Giatonio, B; O'Dwyer, PJ; Redlinger, M; Stevenson, JP | 1 |
| Danesi, R; Del Tacca, M; Giovannetti, E; Mey, V; Mosca, I | 1 |
| Aghajanian, C; Anderson, S; Bloss, J; Chi, D; Dizon, D; Dupont, J; Leitao, M; O'Flaherty, C; Sabbatini, P; Spriggs, D; Venkatraman, E | 1 |
| Buyukcelik, A; Utkan, G; Yalcin, B | 1 |
| Ayres, M; Gandhi, V; Krett, NL; Ma, C; Nabhan, C; Nawrocki, S; Nowak, B; Rosen, ST | 1 |
| Costello, E; Ghaneh, P; Greenhalf, W; Halloran, CM; Neoptolemos, JP; Shore, S; Wilson, D; Zumstein, L | 1 |
| Bredenfeld, H; Diehl, V; Engert, A; Franklin, J; Fries, S; Josting, A; Mailänder, V; Nogova, L; Oertel, J | 1 |
| Bauer, S; Schütte, J; Seeber, S | 1 |
| Clementi, G; Costantino, G; Lempereur, L; Matera, M; Vasquez, E; Vasta, D | 1 |
| Fernandes, PA; Pereira, S; Ramos, MJ | 1 |
| Danova, M; Imarisio, I; Natalizi, A; Porta, C; Riccardi, A; Sartore-Bianchi, A; Zimatore, M | 1 |
| Agelaki, S; Bozionelou, V; Georgoulias, V; Kakolyris, S; Kalbakis, K; Kouroussis, C; Malas, K; Mavroudis, D; Souglakos, J; Voloudaki, A | 1 |
| Ben-Josef, E; Bossenberger, T; Burmeister, J; El-Rayes, BF; McDermott, P; Philip, PA; Shields, AF; Vaishampayan, U; Vaitkevicius, V | 1 |
| Chester, JD; Forster, M; Hall, GD; Protheroe, AS | 1 |
| Pérol, D; Pérol, M | 1 |
| Clairmont, C; Doroshow, J; Fishman, M; Johnson, B; Margolin, K; Sullivan, D; Sznol, M; Yen, Y | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Satoh, T; Tamura, K; Yamamoto, N | 1 |
| Chen, JS; Cheng, AL; Hsu, C; Hsu, CH; Li, CC; Liu, HT; Lu, YS; Shen, YC; Wu, CY; Yang, CH; Yeh, KH | 1 |
| Abbruzzese, A; Caraglia, M; Ceciarini, F; Correale, P; Francini, G; Giorgi, G; Guarnieri, A; Marsili, S; Messinese, S; Micheli, L; Nencini, C; Neri, A; Petrioli, R; Piccolomini, A; Prete, SD; Vuolo, G | 1 |
| Bettinelli, M; Minoia, C; Sottani, C; Zaffaroni, M; Zucchetti, M | 1 |
| Chen, LT; Chen, SC; Chuang, WL; Su, YC; Wu, WC | 1 |
| Boige, V; Ducreux, M; Malka, D | 2 |
| Clarke, ML; Cros, E; Dumontet, C; Galmarini, CM; Jordheim, L; Mackey, JR; Santos, CL | 1 |
| Becker, JC; Bröcker, EB; Terheyden, P | 1 |
| Carrell, D; Drengler, RL; Greco, FA; Hainsworth, JD; Scroggin, C | 1 |
| Jayabose, S; Ozkaynak, MF | 1 |
| Aguiar Bujanda, D; Aguiar Morales, J; Bohn Sarmiento, U | 1 |
| Agelaki, S; Georgoulias, V; Kentepozidis, N; Kouroussis, C; Milaki, G; Palamidas, F; Papakotoulas, P; Polyzos, A; Syrigos, K; Tzanakis, N; Vamvakas, L; Veslemes, M | 1 |
| Ferson, PF; Friberg, D; Gooding, WE; Kassem, B; Keenan, R; Landreneau, RJ; Levitt, ML; Lindberg, CA; Miketic, LM; Ponas, RS; Sabatine, JM; Tarasoff, P; Trenn, MR; Whiteside, TL; Yousem, SA | 1 |
| Adames, V; Beck, G; Birnboeck, H; Gand, L; Higgins, B; Hoffmann, G; Kolinsky, K; Linn, M; Rashed, M; Smith, M; Wheeldon, E | 1 |
| Delaloge, S; Di Palma, M; Forgue, ST; Le Chevalier, T; Llombart, A; Ni, L; Tourani, JM; Turpin, F | 1 |
| Le Cesne, A; Le Guen, Y | 1 |
| Adrian, TE; Ding, XZ; Hennig, R; Jovanovic, BD; Tong, WG; Witt, RC | 1 |
| Davidson, JD; Flagella, M; Geeganage, S; Gelbert, LM; Ma, L; Slapak, CA | 1 |
| Ashley, SW; Benoit, E; Duxbury, MS; Ito, H; Waseem, T; Whang, EE | 2 |
| Arai, Y; Habuchi, T; Horikawa, Y; Hoshi, S; Inoue, T; Kato, T; Matsuura, S; Ohyama, C; Saito, S; Sato, K; Satoh, S; Togashi, H; Tsuchiya, N | 1 |
| Aerts, R; Haustermans, K; Topal, B; Van Cutsem, E; Van Steenbergen, W; Verslype, C | 1 |
| Deng, XH; Kong, WM; Miao, JW; Niu, JW; Zhang, WH | 1 |
| Agustí, C; Casas, F; Gascón, P; Gimferrer, JM; Martin-Richard, M; Molina, R; Reguart, N; Sanchez-Reyes, A; Viñolas, N | 1 |
| Benk, J; Burk, M; Burkholder, I; Dalhoff, K; Dickgreber, N; Dierlamm, T; Dürk, H; Edler, L; Engel-Riedel, W; Gieseler, F; Graeven, U; Hossfeld, DK; Knuth, A; Kortsik, C; Laack, E; Lorenz, C; Müller, T; Welte, T | 1 |
| Ames, MM; Holcenberg, J; Krailo, MD; Kuttesch, J; Qu, W; Reid, JM; Safgren, SL; Seibel, NL | 1 |
| Bold, RJ; Mortenson, MM; Schlieman, MG; Virudachalam, S | 1 |
| Clark, JW; Henderson, JM; Humphreys, BD; Magee, CC; Marks, PW; Rennke, HG; Sharman, JP; Zhu, AX | 1 |
| Im, MM; Ostruszka, L; Robinson, BW; Shewach, DS | 1 |
| Brandi, M; Colucci, G; Gebbia, N; Giotta, F; Lopez, M; Schittulli, F; Valerio, MR; Vici, P | 1 |
| Antón, A; Arcusa, A; Bayo, JL; Calvo, L; Carrasco, E; Florián, J; Martn-Richard, M; Mayordomo, JI; Pelegrí, A; Vázquez, S; Virizuela, J | 1 |
| Alexopoulos, A; Karamouzis, MV; Rigatos, G | 1 |
| Calvo, I; Casado, V; Daz, M; Dómine, M; Estévez, LG; Jaén, A; León, A; Lobo, F; Miró, C; Rubio, G; Sánchez-Rovira, P | 1 |
| Castro Kreder, N; Franken, NA; Haveman, J; Peters, GJ; Rodermond, HM; Stalpers, LJ; van Bree, C; Zdzienicka, MZ | 1 |
| Hegewisch-Becker, S; Hossfeld, DK; Kehr, A; Schulz, J; Tuinmann, G; Zschaber, R | 1 |
| Ardavanis, A; Baziotis, N; Gerasimidis, G; Rigatos, G; Tryfonopoulos, D; Yiotis, I | 1 |
| Koizumi, M; Nishiyama, K; Yamazaki, H | 1 |
| Cerretani, D; Cetta, F; Clerici, M; Correale, P; Francini, G; Giorgi, G; Guarnieri, A; Marsili, S; Messinese, S; Petrioli, R; Pinto, E; Savelli, V | 1 |
| Alberola, V; Almenar, D; Artal, A; Barcelo, R; Bover, I; Camps, C; Cobo, M; de las Peñas, R; Diz, P; Garcia-Gomez, R; Gonzalez-Larria, JL; Insa, A; Isla, D; Massuti, B; Muñoz, MA; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Sarries, C; Taron, M; Terrasa, J | 1 |
| Felip, E; Maestre, J; Majo, J; Mendez, P; Queralt, C; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Taron, M | 1 |
| Aviles, V; Benson, AB; Berlin, JD; Harris, JE; Levy, DE; Shepard, RC; Stuart, K; Thomas, JP | 1 |
| Miles, D; Reichardt, P | 1 |
| Agelaki, S; Athanasiadis, A; Boukovinas, J; Christophylakis, C; Georgoulias, V; Kouroussis, C; Maltezakis, G; Milaki, G; Pavlakou, G; Syrigos, K; Vardakis, N; Varthalitis, J | 1 |
| Avilés, A; Fernández, R; Huerta-Guzmán, J; Neri, N | 1 |
| Doi, R; Fujimoto, K; Imamura, M; Inui, K; Okuda, M; Onoue, M; Terada, T | 1 |
| Akiyama, T; Doi, T; Hirata, K; Homma, H; Katsuki, S; Machida, T; Mezawa, S; Murakami, K; Sato, T; Takanashi, K | 1 |
| Jiang, R; Sairenji, T; Satoh, Y; Zhang, JL | 1 |
| Fujihara, M; Fujita, M; Furukawa, Y; Hattori, Y; Ishii, Y; Kuniki, H; Matsumoto, N; Yajima, T; Yamamoto, M; Yamaoka, Y | 1 |
| Hada, M; Mizutari, K | 1 |
| Alloisio, A; Bruzzi, P; Costa, R; Maineri, P; Ratto, GB; Vassallo, G | 1 |
| Edwards, JG; Martin-Ucar, A; O'Byrne, KJ; Pilling, JE; Stewart, DJ; Waller, DA | 1 |
| Fukunaga, AK; Hurley, TD; Marsh, S; McLeod, HL; Murry, DJ | 1 |
| Esper, P; Fardig, J; Herman, J; Kent, E; Lee, C; Montie, J; Sandler, H; Smith, DC | 1 |
| Abbruzzese, JL; Deutsch, J; LoBuglio, A; Needle, M; Rosenberg, A; Schmidt, W; Wolff, RA; Xiong, HQ | 1 |
| Ikeda, H; Ikeda, M; Ito, Y; Kagami, Y; Morizane, C; Okusaka, T; Takezako, Y; Ueno, H | 2 |
| Kim, CH; Kim, HT; Lee, JC; Park, YH; Ryoo, BY | 1 |
| A'Hern, R; Cole, C; Everard, M; Gibbens, I; Gore, M; Hall, G; Harries, M; Jenkins, A; Kaye, S; Moss, C; Perren, T; Pizzada, O; Shah, R | 1 |
| Agelidou, A; Ardavanis, A; Boukovinas, I; Georgoulias, V; Kouroussis, C; Palamidas, P; Polyzos, A; Stavrinidis, E; Syrigos, K; Toubis, M; Tselepatiotis, E; Veslemes, M; Vlachonikolis, I | 1 |
| Helke, C; Hoschke, B; May, M; Seehafer, M | 1 |
| Colovos, C; Emmanouilides, C; Hernandez, L; Pinter-Brown, L; Rosen, P; Schiller, G; Territo, M | 1 |
| Chahine, GY; Dagher, JE; Farhat, FS; Ghosn, MG; Kattan, JG; Mokaddem, WT; Nasr, FL; Tueni, EA | 1 |
| Kimmel, G; Marsland, T; O'Shaughnessy, JA; Pippen, JE; Ratnam, S; Vukelja, S | 1 |
| Esper, P; Griffith, KA; Hayman, JA; Herman, JM; Kent, E; Montie, J; Sandler, HM; Smith, DC; Sullivan, MA | 1 |
| Argiris, A; Kies, MS; LaCombe, M; Liptay, M; Marymont, M; Masters, G; Sundaresan, S | 1 |
| Carcas, A; Duque, B; Garcia-Ribas, I; Palou, J; Salvador, J; Segarra, J; Villavicencio, H | 1 |
| Ikehara, M; Noda, K; Oshita, F; Saitoh, H; Suzuki, R; Yamada, K | 1 |
| Piura, B | 1 |
| Buzzi, F; Carnicelli, P; Cioffi, R; Comella, P; Filippelli, G; Frasci, G; Guida, M; Maiorino, L; Mancarella, S; Massidda, B; Panza, N | 1 |
| Cheng, ZW; Zhang, L | 1 |
| Bachem, MG; Berberat, P; Büchler, MW; di Mola, FF; Esposito, I; Friess, H; Giese, NA; Giese, T; Köninger, J | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Sukthomya, V; Tonusin, A | 1 |
| Bengala, C; Campani, D; Collecchi, P; Conte, PF; Donati, S; Gennari, A; Guarneri, V; Maur, M; Orlandini, C | 1 |
| Barceló, JR; López-Vivanco, G; Muñoz, A | 1 |
| Allen, AM; Brown, D; Eckhauser, FE; Hejna, G; Lawrence, TS; McGinn, CJ; Normolle, D; Robertson, JM; Simone, D; Zalupski, MM | 1 |
| Al-Madhoun, AS; Eriksson, S; Loves, WJ; Padron, JM; Peters, GJ; Talianidis, I; van der Wilt, CL | 1 |
| Dafni, U; Dimopoulos, MA; Dimopoulou, I; Efstathiou, E; Kastritis, E; Lyberopoulos, P; Moulopoulos, LA; Papadimitriou, C; Roussos, C; Samakovli, A | 1 |
| Bessis, D; Guilhou, JJ; Guillot, B; Legouffe, E | 1 |
| Alakavuklar, M; Coker, A; Oztop, I; Sagol, O; Tarhan, O; Yaren, A; Yavuzsen, T; Yilmaz, U | 1 |
| Byrne, MJ; Nowak, AK; Stockler, MR | 1 |
| Piura, B; Rabinovich, A | 1 |
| Buksmaui, S; Hausmaninger, H; Heinrich, B; Höffken, K; Krejcy, K; Miller, MA; Morack, G; Possinger, K; Wallwiener, D | 1 |
| Burger, RA; Falkner, CA; Hunter, M; Monk, BJ; Tewari, D | 1 |
| Geh, JI; Hussain, SA; James, ND; Palmer, DH; Peake, DR; Riley, P; Spooner, D; Stocken, DD | 1 |
| König, J; Liu, L; Remberger, K; Rübe, C; Rübe, CE; Schuck, A; Uthe, D; Wilfert, F; Willich, N | 1 |
| Cesák, T; Kohlová, T; Melichar, B; Nová, M; Urminská, H | 1 |
| Ho, ES; Hung, MJ; Hwang, SF; Ke, YM; Liu, FS; Lu, CH | 1 |
| Argiris, A; Eng, C; Haraf, DJ; Kozloff, MF; Milano, MT; Mittal, BB; Pelzer, H; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Albain, K; Bhoopalam, N; Chansky, K; Clark, JI; Crowley, J; Edelman, MJ; Gandara, DR; Giguere, JK; Kelly, K; Weiss, GR | 1 |
| Hatayama, O; Hayasaka, M; Inou, H; Koizumi, T; Kubo, K; Sasabayashi, M; Tsushima, K; Yamamoto, H; Yoshiike, F | 1 |
| Chen, JH; Lan, SM; Luo, J; Peng, ZM; Wang, WB; Wang, XH | 1 |
| Chen, J; Deng, HX; Ding, ZY; Fu, CH; Gao, ZN; He, QM; Kan, B; Li, HL; Li, J; Li, Q; Liu, J; Luo, Y; Mao, YQ; Su, JM; Tan, GH; Tian, L; Wang, L; Wei, YQ; Wen, YJ; Wu, Y; Xiao, F; Xie, XJ; Yang, L; Yi, T; Zhao, X; Zou, CH | 1 |
| Casetta, G; Frea, B; Gontero, P; Maso, G; Pretti, G; Sogni, F; Tizzani, A; Zitella, A | 1 |
| Clarke, PA; Evans, SA; Gilliam, AD; Grabowska, AM; Harris, JC; McKenzie, AJ; McWilliams, DF; Watson, SA | 1 |
| Hedley, DW; Lau, JP; Skalski, V; Weatherdon, KL | 1 |
| Aoki, K; Matsumura, Y; Okusaka, T | 1 |
| Felip, E; Maestre, J; Majo, J; Mendez, P; Queralt, C; Ronco, MS; Rosell, R; Sanchez, JJ; Sanchez, JM; Souglakos, J; Taron, M | 1 |
| André, T; Avenin, D; de Gramont, A; Gayet, B; Hannoun, L; Houry, S; Lotz, JP; Louvet, C; Maindrault-Goebel, F; Paye, F; Provent, S; Rosmorduc, O; Selle, F; Tournigand, C | 1 |
| Abraham, NG; Gorschlüter, M; Märten, A; Nagaraj, S; Sauerbruch, T; Schmidt-Wolf, IG; Strehl, J; Ziske, C | 1 |
| Barón, MG; Belón, J; Casado, E; De Castro, J; Dorta, J; Feliu, J; Gallurt, PM; Lizón, J; Lorenzo, A; Madroñal, C; Morales, S | 1 |
| Codacci-Pisanelli, G; Kroep, JR; Loves, W; Peters, GJ; Sigmond, J | 1 |
| Bozec, L; Brahmer, J; Bunn, PA; Ettinger, DS; Kelly, K; Le Chevalier, T; Liepa, AM; Monnerat, C; Nakamura, T; Novello, S; Obasaju, CK | 1 |
| Cros, E; Dumontet, C; Galmarini, CM; Gouy, MH; Jordheim, LP; Mackey, J; Perigaud, C; Peyrottes, S | 1 |
| Clark, JW; Enzinger, PC; Fuchs, CS; Kim, H; Kulke, MH; Lynch, TJ; Michelini, A; Morgan, JA; Vincitore, M | 1 |
| Hatakeyama, K; Kurosaki, I; Shimizu, T; Tsuchiya, Y | 1 |
| Bodis, S; Jerman, M; Kestenholz, P; Lardinois, D; Stahel, RA; Taverna, C; Weder, W | 1 |
| Bunn, P | 1 |
| Onn, A; Thatcher, N; Tsuboi, M | 1 |
| Bojko, P; Hense, J; Moritz, T; Müller, S; Nowrousian, MR; Schütt, P; Seeber, S | 1 |
| Bechrakis, N; Foerster, MH; Keilholz, U; Schmittel, A; Schuster, R; Siehl, J; Thiel, E | 1 |
| Daugherty, CK; Huo, D; Janisch, L; Larson, RA; Odenike, OM; Ratain, MJ; Sobecks, RM; Zimmerman, TM | 1 |
| Birk, CL; Brown, JV; Goldstein, BH; Graham, C; Mattison, J; Micha, JP; Rettenmaier, MA | 1 |
| Bhalla, KN; Gillespie, TW; Harris, WB; Kooby, D; Landry, J; Meyers, M; Small, W; Staley, CA | 1 |
| Allendorf, JD; Chabot, JA; Chen, J; Ennis, RD; Fine, RL; Fogelman, DR; Schreibman, SM; Schrope, BA | 1 |
| Anagnostopoulos, A; Aravantinos, G; Athanasios Dimopoulos, M; Bafaloukos, D; Bamias, A; Deliveliotis, C; Efstathiou, E; Kalofonos, C; Linardou, H | 1 |
| deVere White, RW; Ellison, LM; Gandour-Edwards, R; Goldberg, Z; Karpman, E; Saffarian, A | 1 |
| Maehara, S; Maehara, Y; Saito, Y; Shimada, M; Shirabe, K; Takahashi, K; Tanaka, S | 1 |
| Duan, XN; Liu, YH; Shen, WJ; Wan, YL; Wang, DM; Yang, YM; Yu, SP; Zhou, G | 1 |
| Besalduch, J; Galmés, B; Gutierrez, A; Rodriguez, J; Sampol, A | 1 |
| Blackstock, AW; Hollis, DR; Mayer, RJ; Niedwiecki, D; Tempero, MA; Tepper, JE | 1 |
| Cooper, H; Eisenberg, BL; Freedman, G; Hoffman, JP; Meropol, NJ; Pingpank, JF; Ross, EA; Sasson, AR; Wetherington, RW | 1 |
| Arturi, F; Bulotta, S; Calvagno, MG; Celano, M; Filetti, S; Fresta, M; Paolino, D; Rotiroti, D; Russo, D | 1 |
| Bevilacqua, G; Bocci, G; Boggi, U; Boschi, E; Campani, D; Danesi, R; Del Tacca, M; Esposito, I; Fasciani, A; Fioravanti, A; Marangoni, G; Mosca, F | 1 |
| Barbone, F; Belvedere, O; Ceschia, T; Fasola, G; Follador, A; Grossi, F; Guglielmi, A; Morelli, A; Puglisi, F; Recchia, L; Rizzato, S; Sibau, A; Sobrero, AF; Talmassons, G; Vigevani, E | 1 |
| Desjardins, P; Hirsh, V; Laberge, F; Langleben, A; Latreille, J; Samson, B; Whittom, R | 1 |
| Cisar, LA; Green, MR; Gruia, G; Jeffrey, GM; Miller, LL; Miller, WH; Morganti, A; Orlando, N; Rocha Lima, CM; Rotche, R | 1 |
| Del Valle, J; Gómez, A; Ruiz, I | 1 |
| Hansen, SW; Larsen, FO | 1 |
| Hara, I; Kamidono, S; Kawabata, G; Miyake, H; Muramaki, M | 1 |
| Baker, JH; Huxham, LA; Kyle, AH; Minchinton, AI; Nykilchuk, LK | 1 |
| Dutcher, JP; Garino, A; Larkin, M; Milowsky, MI; Nanus, DM | 1 |
| Elomaa, I; Joensuu, TK; Kärkkäinen, P; Kiviluoto, T; Kivisaari, L; Tenhunen, M; Vento, P; Westberg, R | 1 |
| Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S | 1 |
| Hidaka, S; Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Masumoto, T; Moriwaki, T; Nasu, J; Nishina, T; Tanada, M; Tsubouchi, E; Tsuzuki, T; Yamauchi, Y | 1 |
| Airoldi, M; Cagliero, E; Cattel, L; Goffredo, F; Passera, R; Stella, B | 1 |
| Konwalinka, G; Kwon, HJ; Lee, S; Lutz, M; Schirmer, M; Sohn, S | 1 |
| Chen, YR; Li, H; Lu, YP; Sun, M; Wang, ZP; Wei, Q; Yang, YR; Yue, ZJ | 1 |
| Belt, R; Dow, E; Figueroa, JA; Geary, R; George, S; Holmlund, J; Leonardo, J; McCachren, S; Miller, GL; Modiano, M; Oliver, JW; Otterson, GA; Ritch, P; Valdivieso, M; Villalona-Calero, MA | 1 |
| Bansback, N; Karnon, J; Ward, S | 1 |
| Asmar, L; Boehm, KA; Di Bella, N; Flynn, TP; Vellek, MJ; Venkatesh, H | 1 |
| Camlica, H; Demir, C; Tas, F; Topuz, E; Ustuner, Z | 1 |
| Bertetto, O; Botta, M; Castagneto, B; Ferraris, V; Marenco, D; Mencoboni, M; Repetto, L; Scaltriti, L; Zai, S | 1 |
| Denlinger, CE; Jones, DR; Keller, MD; Rundall, BK | 1 |
| Hong, YS; Kang, JH; Lee, KS; Lee, MA; Woo, IS | 1 |
| Achiwa, H; Maeda, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 1 |
| Albain, KS; Doroshow, JH; Edelman, MJ; Frankel, P; Gandara, DR; Gandour-Edwards, R; Gumerlock, PH; Israel, V; Lara, PN; Lau, DH; Law, LY; Longmate, J; Mack, PC; Reddy, GP | 1 |
| Chang, GC; Chen, CY; Hsu, SL; Sheu, GT; Tsai, JR; Wu, WJ | 1 |
| Buesa, JM; Díaz, A; Esteban, E; Fernández, A; Fra, J; López-Pousa, A; Losa, R; Sierra, M | 1 |
| Davis, JJ; Fang, B; Jacob, D; Teraishi, F; Zhang, L; Zhu, H | 1 |
| Freiha, F; Morgan, K; Srinivas, S | 1 |
| Aronson, M; Dalal, E; Laufer, M; Nativ, O; Sabo, E | 1 |
| Merimsky, O | 1 |
| Adams, N; Cunningham, CC; MacEachern, JB; Nemunaitis, J; Paulson, AS; Rich, D; Ruxer, RL; Vukelja, S | 1 |
| Candelaria, M; Cetina, L; de la Garza, J; Dueñas-González, A; Rivera, L | 1 |
| Alcouffe, C; Boutonnat, J; Clément-Lacroix, J; Mousseau, M; Ronot, X | 1 |
| Chen, Y; Li, H; Lu, Y; Sun, M; Wang, Z; Wei, Q; Yang, Y; Yue, Z | 1 |
| Boutry, N; Brénuchon, C; Devulder, B; Hachulla, E; Hatron, PY; Lambert, M; Launay, D; Maurage, CA; N'Guyen, HD; Queyrel, V | 1 |
| Cass, C; Dabbagh, L; Dumontet, C; Glubrecht, D; Lai, R; Mackey, JR; Sangha, R; Spratlin, J; Young, JD | 1 |
| A'hern, R; Eisen, T; Gore, M; Hackett, S; James, M; Moss, C; Pyle, L; Waters, JS | 1 |
| Hirai, I; Kawago, M; Kokawa, Y; Nishida, M; Okamura, Y; Oura, S; Sakurai, T; Sasaki, R; Tanino, H; Yoshimasu, T; Yuzaki, M | 1 |
| Baba, Y; Ishikawa, T; Kamimura, T; Mizuno, K; Oota, H; Watanabe, K; Yoshida, T | 1 |
| Ishida, H; Miyake, M; Taki, T; Tomiyama, K | 1 |
| Hobbs, KB; Kroll, DJ; Seewaldt, VL; Shaw, HS | 1 |
| Akpek, G; Badros, A; Bolaños-Meade, J; Fenton, R; Gojo, I; Guo, C; Hakimian, R; Heyman, M; Kiggundu, E; Mannuel, H; Meisenberg, B; Natt, S; Phillips, GL; Rapoport, AP; Ratterree, B; Ruehle, K; Sarkodee-Adoo, C; Takebe, N; Tricot, G; Withers, T | 1 |
| Bastert, G; Beldermann, F; Hamerla, R; Huober, J; Krauss, K; Rudlowski, C; Schneeweiss, A; Sinn, HP; Solomayer, E; von Fournier, D; Wallwiener, D | 1 |
| Lordick, F | 1 |
| Bouafia, F; Dumontet, C; Facon, T; Leleu, X; Michallet, M; Troncy, J | 1 |
| Breton, JL; Gervais, R; Jacot, W; Pujol, JL; Quantin, X; Rebattu, P | 1 |
| Hermant, P; Jouveshomme, S; Patte, D | 1 |
| Asmar, L; Heaven, R; Ilegbodu, D; Neubauer, M; Olivares, J; Otsuka, A; Paschold, E; Sirridge, C; Tuttle, T | 1 |
| Buyukcelik, A; Demirkazik, A; Utkan, G; Yalcin, B | 1 |
| Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 2 |
| Barauskas, G; Brasiūnas, V; Brasiūniene, B; Juozaityte, E | 1 |
| Bendele, RA; Kuchta, RD; Moore, CL; Richardson, FC; Richardson, KA; Rohloff, JC; Tomkinson, B; Vega, TP | 1 |
| Cardillo, TM; Gold, DV; Goldenberg, DM; Modrak, DE; Newsome, GA | 1 |
| Dono, K; Hashimoto, K; Kubota, M; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakamori, S; Sakon, M; Takahashi, H; Umeshita, K; Yamamoto, S | 1 |
| Aoyagi, S; Hayashi, K; Horiuchi, H; Kinoshita, H; Koganemaru, M; Shirouzu, K; Toh, U; Uchida, S; Yamana, H | 1 |
| Funahashi, H; Manabe, T; Matsuo, Y; Okada, Y; Sakamoto, M; Sawai, H; Takahashi, H; Takeyama, H; Wakasugi, T; Yamamoto, M | 1 |
| Doi, M; Egawa, T; Hayashi, S; Kitano, M; Nagashima, A; Yoshii, H | 1 |
| Bobek, V; Boubelik, M; Hoffman, RM; Jiang, P; Kolostova, K; Pinterova, D; Plachy, J; Yang, M | 1 |
| Reddy, KG | 1 |
| Androulakis, N; Christophilakis, Ch; Georgoulias, V; Kalbakis, K; Kouroussis, Ch; Malamos, N; Mavroudis, D; Milaki, G; Polyzos, A; Varthalitis, I | 1 |
| Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Burris, HA; Erland, JB; Greco, FA; Hainsworth, JD; Hermann, R; Litchy, S; Morrissey, LH; Rodriguez, GI; Shaffer, DW; Yardley, DA | 1 |
| Aboulafia, DM; Jacobs, AD; Otero, H; Picozzi, VJ | 1 |
| Guan, ZZ; Li, N; Pan, ZK; Xu, F; Zhang, L; Zhang, Y | 1 |
| Han, H; Li, YH; Liu, ZW; Qin, ZK; Wang, B; Wang, H; Yu, SL; Zhou, FJ | 1 |
| Arpicco, S; Brusa, P; Cattel, L; Ceruti, M; Immordino, ML; Rocco, F | 1 |
| Fan, Y; Fang, L; Lin, NM; Ma, SL; Zeng, S; Zhong, HJ | 1 |
| Li, LY; Liang, HJ; Liao, ML; Liu, JW; Wan, HY; Wang, L; Xu, N | 1 |
| Herzog, TJ | 1 |
| Fujimori, Y; Furut, K; Hanazaki, K; Hasebe, O; Hayashi, K; Hisa, T; Hosokawa, K; Kajikawa, S; Kaneko, G; Kawa, S; Kiyosawa, K; Maejima, S; Matsuda, Y; Miwa, S; Miyagawa, S; Mukawa, K; Ochi, Y; Shikama, N; Tajiri, K; Takeuchi, N | 1 |
| Bergman, AM; Breistøl, K; Comijn, EM; Fodstad, O; Hendriks, HR; Kuiper, CM; Myhren, F; Noordhuis, P; Peters, GJ; Sandvold, ML; Smid, K; Voorn, DA | 1 |
| Cass, CE; Eriksson, S; Mani, RS; Usova, EV | 1 |
| Broekhuizen, AJ; Hubeek, I; Kaspers, GJ; Peters, GJ | 1 |
| Leen, R; Van Gennip, AH; Van Kuilenburg, AB; Verschuur, AC | 1 |
| Bergman, AM; Hendriks, HR; Kuiper, CM; Myhren, F; Peters, GJ; Sandvold, ML | 1 |
| Alvarez, JM; Byrne, MJ; Millward, MJ; Nowak, AK; Robinson, BW | 1 |
| Heinemann, V; Schauer, R; Thoma, M; Wagner, A; Wilkowski, R | 1 |
| Dai, L; Eng, C; Kindler, HL; Mani, S; Ramanathan, RK; Ramathan, RK; Remick, SC; Wade-Oliver, KT; Wong, MK | 1 |
| Hwang, TH; Jeong, JS; Kim, JM; Kim, JS; Kim, SE; Lee, JH; Park, BH; Rha, SH | 1 |
| Honsova, E; Kocik, M; Kriz, J; Kudla, M; Mergental, H; Pantoflicek, T; Ryska, M; Saudek, F; Tcherentsova, K | 1 |
| Aravantinos, G; Christodoulou, C; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Papakostas, P; Razis, E; Skarlos, D; Tsavdaridis, D | 1 |
| Goldstein, L; Hesketh, P; Hughes, TM; Iannitti, D; Kennedy, T; King, T; Maia, C; Nauman, C; Pasquariello, T; Ramanathan, R; Rathore, R; Safran, H; Schwartz, JD; Steinhoff, M; Tantravahi, U; Tsai, JY; Wolff, R | 1 |
| Berg, W; Olgac, S; Reuter, V; Scher, H; Slovin, SF | 1 |
| Cory, AH; Cory, JG | 1 |
| Driscoll, DL; Lele, S; Marchetti, D; Odunsi, K; Rodabaugh, K; Villella, J | 1 |
| Catalano, G; Catania, C; Curigliano, G; de Braud, F; De Pas, T; Jereczek-Fossa, B; Orecchia, R; Spaggiari, L; Veronesi, G | 1 |
| Arnoletti, JP; Buchsbaum, DJ; Hawkins, AE; Huang, ZQ; Khazaeli, MB; Kraus, MH; Vickers, SM | 1 |
| Callery, MP; Canete, JJ; Chandler, NM | 1 |
| Barge, A; Brabletz, T; Bruns, CJ; Fennell, M; Green, T; Guba, M; Jauch, KW; Koehl, G; Ryan, A; Yezhelyev, MV | 1 |
| Blessing, J; Cohn, DE; Schilder, RJ | 1 |
| Bader, K; Brown, JV; Goldstein, BH; Graham, C; Markman, M; Mattison, JA; Micha, JP; Rettenmaier, MA | 1 |
| Balm, AJ; Damen, E; Eisbruch, A; Marsh, R; Pameijer, FA; Rasch, C; Schwartz, M; Van As, CJ; Vineberg, K | 1 |
| Bang, SM; Chung, HW; Chung, JB; Kang, JK; Kim, JW; Lee, WJ; Park, SW; Seong, JS; Song, SY | 1 |
| Brunner, TB; Meyer, T; Sauer, R; Schwab, D | 1 |
| Aguiar, D; Aguiar, J; Bohn, U | 1 |
| Aieta, M; De Giorgi, U; Fochessati, F; Marangolo, M; Paoluzzi, L; Papiani, G; Rosti, G; Valduga, F | 1 |
| Gatzemeier, U; Groth, G; Nimmermann, C; Reck, M; von Pawel, J | 1 |
| Chen, CS; Chidiac, T; Lane, SR; Lilenbaum, RC; Schwarzenberger, PO; Thant, M; Versola, M | 1 |
| Chen, YT; Hong, GB; Jiang, RJ; Luo, JH; Xu, LF; Xu, LY; Zhou, JX | 1 |
| Han, H; Liu, ZW; Qin, ZK; Wu, ZG; Yang, GW; Zhou, FJ; Zhou, NN | 1 |
| Arceci, RJ; Loeb, DM; Mack, AK; Small, D; Spevak, M; Strouse, JJ | 1 |
| Aristides, M; Brown, A; Crino, L; Danson, S; Fitzgerald, P; Gridelli, C; Le Chevalier, T; Manegold, C; Natale, R; Pujol, JL; Rosell, R; Rudd, RM; Scagliotti, G; Schiller, JH; Stahel, R; Thatcher, N; Thomas, P; van Meerbeeck, JP; van Zandwijk, N; Vansteenkiste, J | 1 |
| Asmar, L; Boehm, KA; Garfield, DH; Khan, M; Kuerfler, PR; Lindquist, DL; Neubauer, MA; Raju, RN; Soo, EW | 1 |
| Hribaschek, A; Lippert, H; Lueck, A; Meyer, F; Ridwelski, K | 1 |
| Furuse, J; Ishii, H; Nagase, M; Yoshino, M | 1 |
| Alberts, SR; Erlichman, C; Fitch, TR; Foster, NR; Moore, DF; Nair, S; Rowland, KM; Schroeder, M; Steen, PD; Tschetter, LK | 1 |
| Foo, KF; Leong, SS; Lim, WT; Tan, EH; Tan, SB; Tan, T; Tay, MH; Thng, CH; Toh, CK; Wee, J | 1 |
| Rini, BI; Small, EJ; Weinberg, V | 1 |
| Blohmer, JU; Dieing, A; Eggemann, H; Elling, D; Heilmann, V; Krocker, J; Michniewicz, K; Possinger, K; Schmid, P; Schulz, CO; Sezer, O | 1 |
| Chow, KU; Engels, K; Kim, SZ; Kriener, S; Mitrou, PS; Trojan, J | 1 |
| Artioli, F; Di Fabio, F; Farris, A; Giaquinta, S; Guaraldi, M; Mantovani, L; Marino, A; Martoni, A; Melotti, B; Palomba, G; Petralia, A; Picece, V; Preti, P; Sperandi, F | 1 |
| Herrmann, R; Pless, M; Rochlitz, Ch; Stern, M; Wenger, C | 1 |
| Benimetskaya, L; Hua, E; Khvorova, A; Lai, JC; Miller, P; Stein, CA; Wu, S; Zhang, LM | 1 |
| Eisen, TG; Gower, NH; Gregory, WM; Harper, PG; Hatton, M; James, LE; Johnson, PW; Lee, SM; Littler, JA; Martin, WM; Qian, W; Rankin, EM; Rudd, RM; Spiro, SG | 1 |
| Maeyama, R; Manabe, T; Matsuda, T; Mizumoto, K; Okino, H; Tanaka, M | 1 |
| Cardaci, V; Cesario, A; Galetta, D; Granone, P; Margaritora, S; Onorati, D; Piraino, A; Porziella, V; Vita, L | 1 |
| Biswas, S; Corrie, PG; Nik, S | 1 |
| Korst, AE; Lardon, F; Pauwels, B; Vermorken, JB | 1 |
| Dorreen, M; Iscoe, N; Jonker, D; Wilson, JJ; Winquist, E; Wong, R | 1 |
| Crnogorac-Jurcevic, T; Donadelli, M; Lemoine, NR; Missiaglia, E; Palmieri, M; Scarpa, A | 1 |
| Huang, WG; Jia, L; Yuan, SZ; Zhang, MH | 1 |
| Amadori, D; Colantonio, I; Frassineti, GL; Ibrahim, T; Monti, M; Tesei, A; Zoli, W | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Ottaviani, D; Polimeni, MA | 1 |
| Autorino, R; Bianco, AR; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M | 1 |
| Altinoz, MA; Bilir, A; Guneri, AD | 1 |
| Barbera, S; Barni, S; Bertetto, O; De Marinis, F; Ferraú, F; Gridelli, C; Labianca, R; Lombardo, M; Michetti, G; Nelli, F | 1 |
| Comella, P; Crucitta, E; De Lena, M; Gebbia, V; Lorusso, V; Mancarella, S; Mangiameli, A; Manzione, L; Muci, D; Palmeri, S; Pezzella, G; Rosati, G; Silvestris, N; Sobrero, A | 1 |
| Amsterdam, A; Dantes, A; Hirsh, L; Land-Bracha, A; Merimsky, O; Suh, BS | 1 |
| Endou, M; Fujita, M; Hatano, M; Kuno, T; Mizuno, M; Nagata, T; Nakahara, N; Osawa, H; Tsukada, K; Tsuno, T; Yoshida, J | 1 |
| Matsuno, S | 1 |
| Dahan, L; Ries, P; Seitz, JF | 1 |
| Alberola, V; Besse, B; Isla, D; Massuti, B; Moran, T; Reguart, N; Rosell, R; Sanchez, JJ; Sanchez, JM; Taron, M | 1 |
| Berger, MR; Eyol, E; Rodenbach, M; Seelig, MH | 1 |
| Büyükçelik, A; Utkan, G; Yalçin, B; Yalçin, S | 1 |
| Choi, M; Fogoros, S; Griffith, KA; Hu, YY; Liu, JR; Lucas, PC; Williams, J | 1 |
| Beslija, S; Fitzthum, E; Hayden, A; Kose, MF; Krejcy, K; Melemed, A; Minarik, T; Saip, P; Sufliarsky, J; Tulunay, G | 1 |
| Belau, A; Burges, A; du Bois, A; Elser, G; Jackisch, C; Lueck, HJ; Olbricht, S; Pfisterer, J; Richter, B; Schmalfeldt, B; Schroeder, W; Staehle, A; Wagner, U | 1 |
| Bilancia, D; Dinota, A; Manzione, L; Romano, R | 1 |
| Colantonio, I; Di Costanzo, G; Dongiovanni, V; Fea, E; Garrone, O; Gasco, M; Granetto, C; Heouaine, A; Merlano, M; Numico, G; Occelli, M; Silvestris, N | 1 |
| Allegro, R; Galuffo, A; Pavone, C; Pavone-MacAluso, M; Serretta, V | 1 |
| Clarke, NW; Cowan, RA; Logue, JP; Lyons, J; McBain, CA; Ramani, VA; Sangar, VK; Wylie, JP | 1 |
| Charoentum, C; Moonprakan, S; Napapan, S; Thongprasert, S | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Hamilos, G; Kakoyiannis, C; Kastritis, E; Moulopoulos, LA; Papadimitriou, C; Zorzou, MP | 1 |
| Arends, JJ; de Jong, RS; Leys, MB; Nortier, JW; Sleeboom, HP; Smit, JM; Ten Bokkel Huinink, D; Tesselaar, ME | 1 |
| Amano, A; Masaki, T; Miyakawa, K; Ohkawa, S; Tarao, K; Ueno, M | 1 |
| Akita, H | 1 |
| Mikami, K; Miki, T; Mizutani, Y | 1 |
| Nishimoto, H; Ohara, T; Shimada, K | 1 |
| Fujii, Y; Yoneto, T; Yoshikawa, K | 1 |
| Klabatsa, A; Steele, JP | 1 |
| Claude, L; Flandin, I; Khodri, M; Kubas, A; Mazeron, R; Mornex, F; Partensky, C; Wautot, V | 1 |
| Azria, D; Coelho, M; Culine, S; Dubois, JB; Larbouret, C; Lemanski, C; Pèlegrin, A; Serre, A; Ychou, M | 1 |
| Normanno, N | 1 |
| Alexopoulos, A; Ardavanis, A; Kandylis, C; Lainakis, G; Rigatos, G; Tryfonopoulos, D | 1 |
| Colomer, R | 2 |
| Li, HC; Russell, CA | 1 |
| Poole, C | 1 |
| Bastert, G; Hamerla, R; Huober, J; Lichter, P; Schneeweiss, A; Wallwiener, D | 1 |
| Konecny, GE; Pegram, MD | 1 |
| Campbell, C; Harvey, H; Kerr, S; Legore, K; Lipton, A; Witters, L | 1 |
| Asmar, L; Ghaddar, H; Joppert, MG; Marsland, TA; Neubauer, MA; Reynolds, CH; Whitaker, T | 1 |
| Belani, CP; Eckardt, J | 1 |
| Barachini, S; Basolo, F; Danesi, R; Del Tacca, M; Deri, M; Giovannetti, E; Mey, V | 1 |
| Cree, IA; Kurbacher, CM; Neale, MH; Reinhold, U | 1 |
| Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rabbi, C; Rosati, G; Zamagni, D | 1 |
| Cronk, M; Thomson, D; Walpole, E | 1 |
| Cetina-Perez, L; de La Garza, J; Dueñas-González, A; Gómez-Gonzalez, E; Gonzalez-Enciso, A; Lopez-Graniel, C; Mohar, A; Montalvo-Esquivel, G; Muñoz-Gonzalez, D; Rivera-Rubi, L; Robles-Flores, J; Vazquez-Govea, E | 1 |
| Jin-Kim, H; Kim, JS; Kim, SH; Kim, YH; Kwon, HC; Oh, SY; Park, JS | 1 |
| Breton, JL; Depierre, A; Ducoloné, A; Germa, C; Lemarié, E; Mennecier, B; Moro-Sibilot, D; Neidhardt, AC; Quoix, E | 1 |
| Gillenwater, HH; Hensing, TA; Qaqish, BF; Socinski, MA; Stinchcombe, TE; Tyann, M | 1 |
| Anderson, H; Ashcroft, L; Baka, S; Burt, P; Dowd, I; Lind, M; Lorigan, P; Smith, D; Stout, R; Thatcher, N | 1 |
| Caenepeel, P; Demols, A; Houbiers, G; Leleux, A; Peeters, M; Polus, M; Van Cutsem, E; Van Laethem, JL; Van Maele, P; Vermaut, RR; Verslype, C | 1 |
| Ditto, A; Fontanelli, R; Grijuela, B; Hanozet, F; Kusamura, S; Raspagliesi, F; Scibilia, G; Scollo, P; Solima, E; Spatti, G; Vecchione, F; Zanaboni, F | 1 |
| Abdel-Hamid, AH; Holmes, M; Lind, M; Maraveyas, A; Sgouros, J; Upadhyay, S | 1 |
| Ansari, R; Einhorn, LH; Fisch, MJ; Fox, E; Juliar, B; Li, J; Sweeney, CJ; Yiannoutsos, C | 1 |
| Hou, M; Huang, XB; Yi, C | 1 |
| Dumontet, C; Sève, P | 1 |
| Hobrack, E; Jehle, P; Nagel, S; Schütte, W | 1 |
| Abbruzzese, JL; Du, M; Lenzi, R; Plunkett, W; Wolff, R; Xiong, HQ | 1 |
| Boehle, AS; Boenicke, L; Dohrmann, P; Kalthoff, H; Kurdow, R; Schniewind, B; Zoefelt, S | 1 |
| Bendix, N; Bernathova, M; Bodner, G; Glodny, B | 1 |
| Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K | 1 |
| Agelidou, A; Anagnostopoulou, O; Androulakis, N; Ardavanis, A; Chatzidaki, D; Christou, A; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mixalopoulou, P; Polyzos, A; Samaras, N; Samonis, G; Syrigos, K; Toubis, M; Tsiafaki, X; Ziotopoulos, P | 1 |
| Fukui, I; Hanada, E; Ishikawa, Y; Nakagawa, K; Okubo, Y; Satoh, Y; Tadokoro, M; Tsukamoto, T; Yonese, J | 1 |
| Corkery, LJ; Covey, TR; Pang, H; Schneider, BB; Siu, KW | 1 |
| Hedley, DW; Sutton, KL; Wheeler, JJ; Yau, CY | 1 |
| Argani, P; Brinker, DA; Haas, M; Montgomery, EA; Wu, J | 1 |
| Bustamante, Fde T; Maffuz, A; Silva, JA; Torres-Vargas, S | 1 |
| Braun, D; Breton, JL; Castéra, D; Clary, C; Debieuvre, D; Depierre, A; Gervais, R; Janicot, H; Kessler, R; Lemarié, E; Milleron, B; Morère, JF; Moro-Sibilot, D; Pujol, JL; Quantin, X; Rebattu, P; Souquet, PJ; Spaeth, D | 1 |
| Beinert, T; Flath, B; Possinger, K; Schmid, P; Schweigert, M; Sezer, O | 1 |
| Wu, BX; Wu, QL; Yao, H | 1 |
| Komut, K; Minami, S | 1 |
| Inoue, S; Kitamura, M; Maeshiro, T; Matsuo, S; Miyamoto, S; Ohkubo, T; Ohmura, T; Tanaka, S; Umekita, N | 1 |
| Akutsu, Y; Endo, M; Hoshino, T; Matsubara, H; Ochiai, T; Ota, Y; Tsunoda, Y; Yoshinaga, Y | 1 |
| Takeyama, O; Usui, Y | 1 |
| Funazaki, T; Nagasaki, N; Naitoh, N; Shiba, M; Watanabe, S | 1 |
| Argiris, A; Haraf, DJ; Kao, J; Milano, MT; Mittal, BB; Salama, JK; Stenson, KM; Vokes, EE; Weichselbaum, RR; Witt, ME | 1 |
| Allal, AS; Bernier, J; Bieri, S; Gertsch, P; Gervaz, P; Morel, P; Roth, AD | 1 |
| Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Dy, GK; Erlichman, C; Goldberg, RM; Hanson, LJ; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA; Suri, A | 1 |
| Baus, S; Bleck, J; Chavan, A; Frericks, B; Galanski, M; Kirchhoff, T; Kubicka, S; Malek, N; Manns, MP; Merkesdal, S; Zender, L | 1 |
| Debatin, KM; Dienemann, H; Gassler, N; Herr, I; Mattern, J; Schnabel, PA; Wenger, T; Zhang, C | 1 |
| Jansen, CF; Schalken, JA; van der Heijden, AG; Verhaegh, G; Witjes, JA | 1 |
| Bonsignori, M; Burattini, L; Marcucci, F; Massacesi, C | 1 |
| Ali, S; Aranha, O; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Chen, LH; Lü, YY; Yang, J | 1 |
| Algayres, JP; Artru, P; Béchade, D; Bredin, C; Brézault, C; Chaussade, S; Coutant, G; de Gramont, A; Defuentes, G; Desramé, J; Dourthe, LM; Duvic, C; Poirier, JM | 1 |
| Horai, T; Matsuda, M; Nakagawa, K; Nishio, M; Ohyanagi, F; Okumura, S; Sato, Y; Taguch, F | 1 |
| Bernardini, I; Chioni, A; Conte, PF; Fabbri, A; Falcone, A; Ferrari, K; Galli, L; Grosso, AM; Innocenti, F; Orlandini, C; Pegna, AL; Ricci, S; Russo, F; Tibaldi, C; Tognarini, L | 1 |
| Androulakis, N; Aravantinos, G; Georgoulis, V; Mallas, K; Polyzos, A; Stathopoulos, GP; Syrigos, K; Vamvakas, L; Ziras, N | 1 |
| Aydemir, N; Bilaloğlu, R; Celikler, S | 1 |
| Mai, M; Nishioka, K; Sawabu, N; Takahashi, Y | 1 |
| Chikamoto, A; Hiraoka, T; Ikeda, O; Imuta, M; Kanemitsu, K; Kudo, K; Nakahara, O; Takamori, H; Tanaka, H; Tsuji, T; Yamashita, Y | 1 |
| Bograd, S; Harris, JE; Plate, AE; Plate, JM; Shott, S | 1 |
| Alexander, RL; Greene, BT; Kucera, GL; Torti, SV | 1 |
| Herzog, TJ; Lewin, SN; Liapis, H; Mutch, DG; Whitcomb, BP | 1 |
| Danesi, R; Del Tacca, M; Giovannetti, E; Marini, L; Mey, V; Nannizzi, S; Pasqualetti, G | 1 |
| Castelli, F; Fresta, M; Raudino, A | 1 |
| Chen, E; Feld, R; Hedley, D; Knox, JJ; Moore, MJ; Nematollahi, M; Oza, A; Pond, GR; Siu, LL; Zhang, J | 1 |
| Chen, DT; Desmond, RA; Hemminki, A; Kanerva, A; Kangasniemi, L; Raki, M; Ranki, T; Ristimaki, A; Sarkioja, M | 1 |
| Kleinerman, ES; Koshkina, NV | 1 |
| Bafaloukos, D; Bamias, A; Economopoulos, T; Efstathiou, E; Gogas, H; Kalofonos, H; Kastritis, E; Kosmidis, P; Onyenadum, A; Papacostas, P; Samantas, E; Samelis, G; Skarlos, D; Xiros, N | 1 |
| Artz, A; Ryan, C; Stadler, WM; Vogelzang, NJ; Zimmerman, T | 1 |
| Guardino, AE; Srinivas, S | 1 |
| Larson, BJ; Lynch, JW; Mendenhall, NP; Pusateri, A; Waples, JM | 1 |
| Bufill, J; Cripe, LD; Fisher, W; Ganjoo, KN; Huh, SY; Jung, SH; McClean, J; Robertson, MJ; Williams, S | 1 |
| Burch, PA; Cannon, MW; Hillman, DW; Ingle, JN; Krook, JE; Mailliard, JA; Perez, EA; Rowland, KM; Veeder, MH | 1 |
| Catovsky, D; Chau, I; Cunningham, D; Hill, M; Horwich, A; Ng, M; Norman, AR; Waters, J; Wotherspoon, A | 1 |
| He, QM; Huang, MJ; Jiang, Y; Liu, JY; Luo, F; Peng, F; Wei, YQ; Zou, LQ | 1 |
| Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kikura-Hanajiri, R; Kim, SR; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yonemori, K; Yoshida, T | 1 |
| Deng, HX; Kan, B; Li, J; Mei, K; Tian, L; Wei, YQ; Wen, YJ | 1 |
| Dumontet, C; Galmarini, CM; Jordheim, LP | 2 |
| Advani, SH; Doval, DC; Ermisch, S; Feher, O; Jassem, J; Khoo, KS; Miller, MA; Morack, G; Roychowdhury, D; Vodvarka, P; von Minckwitz, G | 1 |
| Cai, J; Huang, MZ; Liu, J; Shentu, JZ; Wang, LR; Xu, N | 1 |
| Chung, HC; Jeung, HC; Kim, GE; Kim, YT; Moon, YH; Rha, SY; Roh, JK; Sohn, JH; Suh, CO; Yang, WI | 1 |
| Akada, M; Crnogorac-Jurcevic, T; Lattimore, S; Lemoine, NR; Lopes, R; Mahon, P; Matsuno, S; Sunamura, M | 1 |
| Filipski, E; Focan, C; Kayitalire, L; Lévi, F; Li, XM; Sun, J; Tanaka, K | 1 |
| Aristides, M; Bhalla, S; Brown, A; Kielhorn, A; Roberts, T; Von Der Maase, H | 1 |
| Felip, E; Maestre, J; Majo, J; Mendez, P; Queralt, C; Ronco, MS; Rosell, R; Sanchez, JJ; Sanchez, JM; Taron, M | 1 |
| Fukuoka, M; Furukawa, M; Hirashima, T; Kamoi, H; Kobayashi, M; Kudoh, S; Matsui, K; Mukohara, T; Nakagawa, K; Negoro, S; Nitta, T; Ogata, Y; Shiraishi, S; Takada, M; Takeda, K; Yamauchi, S; Yana, T; Yoshimura, N | 1 |
| Ding, ZY; Hu, B; Kan, B; Li, Q; Liu, JY; Luo, Y; Mao, YQ; Niu, T; Su, JM; Tian, L; Wei, YQ; Wen, YJ; Wu, Y; Xie, XJ; Yang, L | 1 |
| Chen, YM; Perng, RP; Tsai, CM | 1 |
| Habuchi, T; Hatakeyama, S; Horikawa, Y; Inoue, T; Matsuura, S; Ohyama, C; Sato, K; Satoh, S; Togashi, H; Tsuchiya, N | 1 |
| Büchler, MW; Erkan, M; Esposito, I; Friess, H; Giese, NA; Giese, T; Ketterer, K; Kleeff, J | 1 |
| Bearden, JD; Greco, FA; Hainsworth, JD; Litchy, S; Meluch, AA; Schnell, FM; Yost, K | 1 |
| Lertkhachonsuk, R; Sirisabya, N; Sittisomwong, T; Termrungruanglert, W; Tresukosol, D; Vasuratna, A | 1 |
| Ahmad, I; Ahmad, MU; Ali, SM; Chen, P; Khan, AR; Sheikh, S | 1 |
| Hori, H; Komada, Y; Miyahara, M; Ogawa, M; Ohta, T; Onozato, K | 1 |
| Canon, JL; John, W; Lahn, M; Mali, P; Peterson, P; Pirker, R; Riska, H; Vansteenkiste, J | 1 |
| Blankenberg, FG; Kuge, Y; Sato, M; Strauss, HW; Tait, JF; Takei, T; Tamaki, N; Zhao, S | 1 |
| Hlavatá, Z; Koza, I; Mardiak, J; Mego, M; Obertová, J; Recková, M; Sálek, T; Sycová-Milá, Z | 1 |
| Dühmke, E; Heinemann, V; Thoma, M; Weingandt, H; Wilkowski, R | 1 |
| Bulusu, R; Corrie, PG; Cree, IA; Hartley, JA; Jonson, A; Mayer, A; Sehmbi, R; Shaw, J; Spanswick, VJ | 1 |
| Buck, M; Byrne, MJ; Cameron, F; De Melker, Y; Dewar, J; Joseph, D; Lund, H; Newman, M; Phillips, M; Powell, A; Spry, N; Van Hazel, G | 1 |
| Crinò, L; De Marinis, F; Foggi, P; Kielhorn, A; Maestri, A; Migliorino, AM; Novello, S; Rinaldi, M; Scagliotti, GV; Selvaggi, G; Stynes, G; Tilden, D; Tonato, M | 1 |
| Chen, J; Ebert, MP; Gschaidmeier, H; Hosius, C; Kahl, S; Malfertheiner, P; Nitsche, B; Röcken, C | 1 |
| Arora, R; Awasthy, BS; Fuloria, J; Ganesh, N; Gupta, SK; John, S; Naik, R; Selvamani, B | 1 |
| Pfister, C | 1 |
| Bach, AM; Choi, J; Currie, VE; D'Andrea, GM; Hudis, CA; Lake, DE; Moasser, MM; Modi, S; Norton, L; Panageas, KS; Seidman, AD; Theodoulou, M | 1 |
| Fujioka, A; Fukushima, M; Kazuno, H; Matsuda, A; Sakamoto, K; Sasaki, T | 1 |
| Caron, HN; de Ruijter, AJ; Hoebink, J; Leen, R; van Kuilenburg, AB | 1 |
| Aitini, E; André, T; de Gramont, A; Ducreux, M; Faroux, R; Hammel, P; Labianca, R; Lepere, C; Lledo, G; Louvet, C; Taïeb, J; Zampino, MG; Zaniboni, A | 1 |
| Choi, SB; Kim, SR; Lee, HY; Yuh, YJ | 1 |
| Filatova, LV; Gershanovich, ML; Semiglazova, TIu | 1 |
| Caponigro, F; Chollet, P; de Balincourt, C; Fiedler, W; Fumoleau, P; Geoffrois, L; Lacombe, D; Peters, GJ; Ravaud, A; Theodore, C; Vermorken, JB | 1 |
| Barlési, F; Pujol, JL | 1 |
| Baumgart, J; Bechrakis, NE; Bornfeld, N; Foerster, MH; Keilholz, U; Scheulen, ME; Schmittel, A; Strumberg, D; Thiel, E | 1 |
| Abe, N; Atomi, Y; Sugiyama, M | 1 |
| Cass, C; Dumontet, C; Isaac, S; Mackey, JR; Pérol, M; Sève, P; Souquet, PJ; Trédan, O | 1 |
| De Marinis, F; De Petris, L; Gebbia, V | 1 |
| Botta, M; Bretti, S; Castagneto, B; Dongiovanni, D; Muzio, A; Numico, G; Sinaccio, G; Zai, S | 1 |
| Drebin, JA; Lin, LL; Linehan, DC; Myerson, R; Picus, J; Solis, J; Strasberg, SM; Tan, B; Thorstad, WL | 1 |
| Appeltants, H; Blaise, S; Carpentier, PH; Debru, JL | 1 |
| de Vos, J; Franken, NA; Haveman, J; Rodermond, HM; van Bree, C | 1 |
| Aldrighetti, L; Balzano, G; Bonetto, E; Bordonaro, R; Cordio, S; Di Carlo, V; Galli, L; Luppi, G; Milandri, C; Nicoletti, R; Oliani, C; Passardi, A; Passoni, P; Reni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
| Angiolillo, AL; Chen, Z; Krailo, M; Reaman, G; Whitlock, J | 1 |
| Adams, DJ; Colvin, OM; Flowers, JL; Rizzieri, DA; Shanks, RH | 1 |
| Czejka, M; Heinz, D; Muric, L; Ostermann, E; Schueller, J | 1 |
| Athanasiadis, A; Athanasiadou, DC; Papakostoulis, T; Roussos, G; Stathopoulos, GP | 1 |
| Ishihara, T; Kato, H; Kobayashi, A; Nakamura, K; Saisho, H; Sudo, K; Tadenuma, H; Yamaguchi, T | 1 |
| Bannowsky, A; Hamann, M; Hautmann, S; Jünemann, KP; Naumann, M; Wefer, B | 1 |
| Coleman, RE; El-Helw, L | 1 |
| Bang, YJ; Heo, DS; Kim, DW; Kim, DY; Kim, NK; Kim, TY; Lee, KW; Yun, T | 1 |
| Barauskas, G; Brasiūniene, B; Juozaityte, E | 1 |
| Förster, Y; Fuessel, S; Kotzsch, M; Kraemer, K; Krause, S; Meye, A; Schmidt, U; Schwenzer, B; Wirth, MP | 1 |
| Jaglowski, JR; Leure-Dupree, AE; McLaughlin, PJ; Smith, JP; Verderame, MF; Zagon, IS | 1 |
| Berdzik, J; Creaven, PJ; Hoffman, JL; Intengan, ME; Javle, MM; Khushalani, N; Litwin, AM; Pendyala, L; Ramnath, N; Rustum, YM; Slocum, HK; Smith, PF; Stewart, CC; Toth, K | 1 |
| Eckel, F; Lersch, C; Mayr, M; Schmid, RM; Schulte-Frohlinde, E; von Delius, S | 1 |
| Desjardins, P; Fox, S; Hirsh, V; Kreisman, H; Latreille, J; Ofiara, L; Palayew, MD; Pintos, J; Whittom, R | 1 |
| Stahel, R; Weder, W | 1 |
| Flores, RM | 1 |
| Hughes, DA | 1 |
| Ogretmen, B; Wooten, LG | 1 |
| Barbieri, F; Bartolini, S; Cappuzzo, F; Castaldini, L; Ceribelli, A; Crinò, L; Crucitta, E; De Marinis, F; Franciosi, V; Lorusso, V; Marini, L; Maur, M; Novello, S; Scagliotti, GV | 1 |
| Belcheva, A; Ellis, LM; Evans, DB; Fan, F; Gallick, GE; Gray, MJ; Klagsbrun, M; Liu, W; McCarty, MF; Somcio, R; Stoeltzing, O; Wey, JS | 1 |
| Thongprasert, S | 1 |
| du Manoir, J; Francia, G; Hicklin, DJ; Kerbel, RS; Ma, L; Rak, J; Viloria-Petit, A | 1 |
| Broggini, M; Kei Lee, M; Sabapathy, K; Siddique, MM; Vikhanskaya, F | 1 |
| Farmakis, D; Pectasides, D; Pectasides, M | 1 |
| Diot, P; Dubus, JC; Gagnadoux, F; Grimbert, D; Le Pape, A; Leblond, V; Lemarié, E; Montharu, J; Racineux, JL; Urban, T; Vecellio, L | 1 |
| Adrian, TE; Bell, RH; Ding, XZ; Hennig, R; Iwamura, T; Jovanovic, BD; Rao, SM; Segersvard, R; Talamonti, MS; Ventura, J; Ward, E | 1 |
| Adamo, V; Breda, E; D'Agostino, G; Ferrandina, G; Lorusso, D; Ludovisi, M; Paris, I; Pezzella, G; Pisconti, S; Scambia, G; Testa, A; Zanghi, M | 1 |
| Akazawa, Y; Isomoto, H; Kohno, S; Mizuta, Y; Nakagoe, T; Ohara, H; Ohba, K; Ohnita, K; Omagari, K; Shiozawa, K; Shirono, K; Takeshima, F; Tanaka, K; Yasutake, T | 1 |
| Ueoka, H | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Amano, R; Hirakawa, K; Inoue, M; Kosaka, K; Nakata, B; Nishino, H; Tendo, M; Yamada, N | 1 |
| Anadolu, RY; Birol, A; Erdem, C; Sanli, H; Türsen, U | 1 |
| Barletta, E; Carlini, P; Di Costanzo, F; Doni, L; Gasperoni, S; Iop, A; Massidda, B; Mattioli, R; Moscetti, L; Recchia, F; Tralongo, P | 1 |
| Balassy, C; Fakhrai, N; Haitel, A; Schmidinger, M; Zielinski, CC | 1 |
| Lutz, MP | 1 |
| Brachtel, EF; Brugge, WR; Fernandez-del Castillo, C; Ryan, DP; Sahani, D; Willett, CG | 1 |
| Crump, M; Lin, B; Shepherd, L | 1 |
| Achiwa, H; Bessho, Y; Maeda, H; Muramatsu, H; Niimi, T; Oguri, T; Sato, S; Ueda, R | 1 |
| Ben-Josef, E; Chang, AE; Colletti, LM; Hejna, GF; Lawrence, TS; McGinn, CJ; Normolle, DP; Schneider, BJ; Zalupski, MM | 1 |
| Newlands, ES; Partridge, WJ; Rangi, PS; Waldman, AD | 1 |
| Hendriks, JM; Pauwels, B; Romijn, S; Van Putte, BP; Van Schil, PE; Vermorken, JB | 1 |
| Abbruzzese, JL; Bergsland, EK; Hwang, J; Ko, AH; Tempero, MA; Venook, AP | 1 |
| Dimopoulos, M; Economopoulos, T; Fountzilas, G; Papageorgiou, ES; Papageorgiou, S; Pavlidis, N; Tsirigotis, P | 1 |
| Abacioglu, U; Caglar, H; Sengoz, M; Turhal, NS; Yumuk, PF | 1 |
| Byrne, MJ; Nowak, AK | 1 |
| Andres, R; Escudero, P; Isla, D; Lambea, J; Lara, R; Lastra, R; Mayordomo, JI; Ortega, E; Polo, E; Saenz-Cusi, A; Tres, A | 1 |
| Aquino, A; Bonmassar, E; Caraglia, M; Correale, P; Cusi, MG; Del Vecchio, MT; Formica, V; Francini, G; Giorgi, G; La Placa, M; Micheli, L; Montagnani, F; Nencini, C; Prete, S; Prete, SP; Terrosi, C; Tsang, KY | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 2 |
| Bobek, V; Boubelik, M; Douglas, J; Kolostova, K; Kovarik, J; Pavlasek, J; Pinterova, D; Teyssler, P | 1 |
| Aoki, Y; Asoh, H; Ichinose, Y; Ikeda, J; Maruyama, R; Miyake, T; Miyamoto, T; Nakamura, T; Okamoto, T; Shoji, F; Wataya, H | 1 |
| McGee, PJ; Saif, MW | 1 |
| Calbó, J; Capellà, G; Cascalló, M; Fillat, C; Mazo, A; Pastor-Anglada, M | 1 |
| Barceló, R; López-Vivanco, G; Muñoz, A | 1 |
| Dranitsaris, G; Evans, WK; Milliken, D; Zanke, B | 1 |
| Endo, S; Hashimoto, K; Higami, T; Itakura, M; Koike, M; Maruyama, R; Nio, Y; Tsuji, M; Yamaguchi, K; Yano, S | 1 |
| Akrivakis, K; Flath, B; Heilmann, V; Kreienberg, R; Mergenthaler, HG; Possinger, K; Schmid, P; Sezer, O | 1 |
| Felekouras, E; Gouveris, P; Kopterides, P; Kopteridis, P; Kosmas, C; Loukeris, D; Papalambros, E; Sigala, F; Skopelitis, H; Tsavaris, N; Zorbala-Sypsa, A | 1 |
| Lippman, AJ | 1 |
| Balzano, G; Bonetto, E; Di Carlo, V; Panucci, MG; Passoni, P; Reni, M; Ronzoni, M; Staudacher, C; Villa, E; Zerbi, A | 1 |
| Lopes, G; Rocha Lima, CM | 1 |
| Bubis, JA; Dragnev, KH; Rigas, JR | 1 |
| Antonia, S; Bepler, G; Chiappori, A; Haura, E; Rocha-Lima, C; Simon, G; Wagner, H; Williams, C | 1 |
| Cajozzo, M; Comella, G; Condemi, G; Danova, M; De Cataldis, G; Farris, A; Ferraù, F; Filippelli, G; Iannitto, E; Leonardi, V; Macaluso, MC; Mangiameli, A; Massidda, B; Misino, A; Palmeri, L; Palmeri, S; Spada, S; Vaglica, M | 1 |
| Chak, K; Chan, AT; Lam, KC; Lee, C; Mok, TS; Wong, H; Yeo, W; Yim, AP; Zee, B; Zhang, L | 1 |
| Aglietta, M; Capussotti, L; Faggiuolo, R; Gabriele, P; Gatti, M; Magnino, A; Massucco, P; Regge, D; Sperti, E | 1 |
| Kegel, T; Mueller, T; Schmoll, HJ; Simon, H; Voigt, W; Weiss, M | 1 |
| Abratt, R; Bertetto, O; Burillon, JP; Gatzemeier, U; Hui, R; Krzakowski, M; Macha, HN; Mattson, K; Parlier, Y; Pawel, JV; Pouget, JC; Reiterer, P; Szczesna, A; Tan, EH; Wernli, M | 1 |
| Agelidou, A; Agelidou, M; Chainis, K; Georgoulias, V; Kalykaki, A; Nikolakopoulos, I; Rapti, A; Stergiou, I; Tzanakis, N; Varthalitis, J | 1 |
| Ando, T; Hamada, Y; Ichikawa, J; Nakao, A; Okamoto, A; Tasaka, K | 1 |
| Cho, KH; Han, JY; Kim, HY; Lee, DH; Lee, JS; Pyo, HR; Yoon, SJ | 1 |
| Addis, A; Balsari, A; Belluco, S; Menard, S; Petrangolini, G; Pratesi, G; Rossini, A; Rumio, C; Selleri, S; Tortoreto, M | 1 |
| Abbruzzese, JL; Chiao, PJ; Fidler, IJ; Hamilton, SR; He, J; Kim, SJ; Nam, DH; Sasaki, T; Sclabas, GM; Thaker, P; Yazici, S; Yokoi, K | 1 |
| Cheng, AL; Shen, YC; Wan, JP; Yeh, KH; Yeh, SH | 1 |
| Boterberg, T; Closon, MT; Closset, J; Demols, A; Gay, F; Honoré, P; Peeters, M; Polus, M; Van Houtte, P; Van Laethem, JL | 1 |
| Dieing, A; Eggemann, H; Elling, D; Flath, B; Hauptmann, S; Heilmann, V; Jehn, C; Krocker, J; Kümmel, S; Lehenbauer-Dehm, S; Michniewicz, K; Possinger, K; Schmid, P; Schulz, CO; Wischnewsky, MB | 1 |
| Arning, M; Dogliotti, L; Moore, MJ; Oliver, T; Ricci, S; Roberts, JT; Sengelov, L; von der Maase, H; Zimmermann, A | 1 |
| Esteban-Gonzalez, E; Fernández, Y; Fra, J; Lacave, AJ; Mareque, B; Muñiz, I; Palacio, I; Uña, E; Vieitez, JM; Villanueva, N | 1 |
| Adsay, V; El-Rayes, BF; Ferris, AM; Heilbrun, LK; Philip, PA; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Arnaud, I; Blandin, S; Geriniere, L; Guibert, B; Mulsant, P; Perrot, E; Roy, P; Souquet, PJ | 1 |
| Dührsen, U; Kasper, C; Müller-Beissenhirtz, H; Nückel, H | 1 |
| Bajardi, E; Caraglia, M; Carli, AF; Cicero, G; Correale, P; Del Prete, S; Francini, G; Fulfaro, F; Gebbia, N; Greco, E; Intrivici, C; Marsili, S; Vuolo, G | 1 |
| Dieing, A; Flath, B; Heilmann, V; Jehn, C; Lehenbauer-Dehm, S; Possinger, K; Schmid, P; Schulz, CO; Sezer, O | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Okamura, Y; Oura, S; Tanino, H; Yoshimasu, T | 1 |
| Adamec, M; Girman, P; Honsová, E; Janotová, D; Kocík, M; Kríz, J; Kudla, M; Mergental, H | 1 |
| Bernardini, N; Bocci, G; Collecchi, P; Danesi, R; Del Tacca, M; Fioravanti, A; Orlandi, P | 1 |
| Wang, XP; Wu, K; Xu, G; Zhao, S | 1 |
| Lawrence, TS; Maybaum, J; Mesiwala, AK; Morgan, MA; Parsels, JD; Parsels, LA | 1 |
| Duquette, M; Galardi, E; Lawler, J; Parangi, S; Zhang, X | 1 |
| Aquino, A; Bonmassar, E; Correale, P; Cusi, MG; Del Vecchio, MT; Ferrari, F; Francini, G; Giorgi, G; Intrivici, C; Marsili, S; Micheli, L; Nencini, C; Placa, ML; Tsang, KY | 1 |
| Bearden, JD; Blackstock, AW; Butler, J; Case, LD; Ennever, PR; Ho, C; Howerton, R; Levine, E; Magrinat, GC; Melin, S; Minotto, DC; Mishra, G | 1 |
| Bahadur, S; Gibbs, J; Javle, M; Litwin, A; Melnyk, M; Nava, H; Shaukat, A | 1 |
| Ando, S; Iida, T; Kimura, H; Nakajima, T; Suzuki, M | 1 |
| Bria, E; Carboni, F; Carlini, P; Cognetti, F; Di Cosimo, S; Ettorre, GM; Gelibter, A; Giannarelli, D; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E | 1 |
| Chen, P; Hou, JM; Li, G; Tian, L; Wei, YQ; Yao, B; Zhang, L; Zhang, R | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Gill, S; Kim, GP; Kugler, J; Morton, RF; Schaefer, P; Steen, P; Wiesenfeld, M | 1 |
| Cao, CW; Gao, Y; Guo, J; Shi, ZQ; Zhu, CL | 1 |
| Chen, T; Chu, ZH; Liu, JP; Ou, QJ; Wang, J; Zhao, HY | 1 |
| Arning, M; Fuchs, M; John, W; Kindler, HL; Oettle, H; Peeters, M; Ramanathan, RK; Richards, D; van Laethem, JL; Von Hoff, D; Zimmermann, A | 1 |
| Deng, HX; Ding, ZY; Hou, JM; Kan, B; Li, J; Li, Q; Liu, JY; Lou, YY; Mao, YQ; Niu, T; Tan, GH; Tian, L; Wei, YQ; Wen, YJ; Wu, Y; Xiao, F; Yang, JL; Yang, L; Zhao, X | 1 |
| Dumontet, C; Galmarini, CM; Guittet, O; Jordheim, LP; Lepoivre, M | 1 |
| Böhle, A; Brocks, CP; Büttner, H | 1 |
| De Boeck, G; de Bruijn, EA; Dumez, H; Guetens, G; Highley, MS; Maes, RA; van Oosterom, AT | 1 |
| Buesa, JM; Corral, N; de Sande, JL; Esteban, E; Estrada, E; Fernández, JL; Fernández, Y; Fra, J; Lacave, AJ; Mareque, B; Muñiz, I; Palacio, I; Uña, E; Vieitez, JM; Villanueva, N | 1 |
| Dixon, B; Erridge, SC; Mohammed, N; Price, A | 1 |
| Baumann, KC; Burmeister, BH; Dauth, M; Fielding, DI; Ramsay, JR; Walpole, ET | 1 |
| Bhalla, KN; Swaby, RF | 1 |
| Boucher, PD; Shewach, DS | 1 |
| Jin, F; Joshi, I; Obasaju, C; Smith, MR | 1 |
| Carver, JR; Elstrom, R; Glatstein, E; Luger, S; Nasta, SD; Porter, DL; Schuster, SJ; Stadtmauer, EA; Tsai, DE; Vogl, DT | 1 |
| Bedor, M; Bisaccia, S; Doyle, LA; Edelman, MJ; Hausner, P; Kalra, K; Kendall, J; Smith, R | 1 |
| Caca, K; Kronberg, J; Mossner, J; Schoppmeyer, K; Tannapfel, A; Wittekind, C | 1 |
| Christgen, M; Jueschke, A; Kalthoff, H; Schniewind, B; Ungefroren, H | 1 |
| Banerjee, S; Biliran, H; Bollig, A; Heng, H; Liao, JD; Sarkar, FH; Thakur, A; Wang, Y; Xu, H | 1 |
| Ahuja, H; Bailey, H; Berlin, JD; Hansen, R; Jumonville, A; Kim, K; McFarland, T; Morgan-Meadows, S; Mulkerin, D; Saphner, T; Thomas, JP | 1 |
| Furuse, J; Gotohda, N; Ishii, H; Kinoshita, T; Konishi, M; Nakachi, K; Nakagohri, T; Suzuki, E; Takahashi, S; Yoshino, M | 1 |
| Fujimori, Y; Furuta, K; Hanazaki, K; Hasebe, O; Hayashi, K; Hisa, T; Hosokawa, K; Kajikawa, S; Kaneko, G; Kawa, S; Kiyosawa, K; Maejima, S; Matsuda, Y; Miwa, S; Miyagawa, S; Mukawa, K; Ochi, Y; Shikama, N; Tajiri, K; Takeuchi, N | 1 |
| Abbas, J; Al-Kutoubi, A; Bikhazi, AB; Chehal, AA; Habbal, MZ; Khalifeh, MJ; Malaeb, LA; Mourad, FH; Shamseddine, AI | 1 |
| Arlander, SJ; Baek, YU; Chen, J; Cliby, WA; Flatten, KS; Hackbarth, JS; Hopkins, KM; Karnitz, LM; Kaufmann, SH; Lieberman, HB; Loegering, D; Thomas, MB; Vroman, BT; Wagner, JM | 1 |
| Cho, JY; Lee, DK; Lee, SJ; Nam, JS; Paik, YH; Park, MS; Yoon, DS; Yu, JS | 1 |
| Greco, FA; Hainsworth, JD; Kommor, M; Kuzur, ME; Litchy, S; Raefsky, EL; Spigel, DR; Yost, K | 1 |
| Bartolini, S; Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L; Trisolini, R | 1 |
| Eklund, JW; Mulcahy, MF; Trifilio, S | 1 |
| Bierau, J; Caron, HN; Leen, R; Meinsma, R; van Gennip, AH; van Kuilenburg, AB | 1 |
| Azemar, M; Bokemeyer, C; Hartmann, JT; Horger, M; Huober, J; Jakob, A; Kanz, L; Oechsle, K | 1 |
| Akkoclu, A; Cakir, E; Cikrikicioglu, S; Firat, H; Goksel, T; Gorguner, M; Guzelant, A; Hatipoglu, ON; Itil, O; Kiyik, M; Ozturk, C; Sanal, S; Soyer, S; Tabakoglu, E; Tasbakan, S; Tutar, U; Yilmaz, U | 1 |
| Adjei, AA; Fitch, TR; Hillman, SL; Jett, JR; Ma, CX; Mandrekar, SJ; Nair, S; Nikcevich, DA; Obasaju, C; Rowland, KM; Schild, SE; Thomas, S; Windschitl, HE | 1 |
| Berghmans, T; Sculier, JP | 1 |
| Alenda-González, C; Campos-Mollo, E; Moya-Moya, MA; Pérez-González, LE | 1 |
| Boor, PJ; Coscio, AM; Das, GC; Goodwin, TJ; Logrono, R; Popov, VL; Vertrees, RA; Zwischenberger, JB | 1 |
| Hajder, J; Marisavljević, D; Ristić, B | 1 |
| Beckman, E; Carringer, M; Gårdmark, T; Malmström, PU | 1 |
| Broomfield, S; Brown, M; Currie, A; Lake, RA; Robinson, BW; van Bruggen, I; van der Most, RG | 1 |
| Büchler, MW; Büchler, P; Eibl, G; Friess, H; Hines, OJ; Isacoff, WH; Reber, HA; Roth, MA | 1 |
| Funakoshi, A; Ishii, H; Ohkawa, S; Okusaka, T; Saito, H; Saito, S; Tsuyuguchi, T; Yamao, K | 1 |
| Richards, DA | 1 |
| Alice Miller, M; Pearce, HL | 1 |
| Futagawa, T; Izumi, H; Miyamoto, H; Oh, T; Sonobe, S; Yamazaki, A | 1 |
| Cheng, XC; He, QM; Hou, JM; Hu, B; Jiang, Y; Kan, B; Li, G; Li, J; Tian, L; Wang, L; Wei, YQ; Wen, YJ; Xiao, F; Yao, B; Zhang, L; Zhang, R; Zhao, X; Zhou, Q | 1 |
| Chen, MD; Fleming, GF; Horowitz, I; Mitchell, S | 1 |
| Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Nodari, F; Rangoni, G; Simoncini, E; Strina, C; Tiberio, GA; Valcamonico, F; Vassalli, L | 1 |
| Denlinger, CE; Jones, DR; Rundall, BK | 1 |
| Blanco-Aparicio, C; Carnero, A; Fominaya, J; Leal, JF; Moneo, V; Pequeño, B; Romero, L; Velasco, J | 1 |
| Alexandre, J; Amsellem-Ouazana, D; Beuzeboc, P; Debré, B; Flam, T; Goldwasser, F; Guillevin, L; Mir, O; Ropert, S; Zerbib, M | 1 |
| Hahn, M; Lauschner, I; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; von Fournier, D | 1 |
| Baas, P; Beijnen, JH; Crul, M; Pluim, D; Rademaker-Lakhai, JM; Schellens, JH; Sparidans, RW; van Zandwijk, N | 1 |
| Berlin, JD | 1 |
| Bosse, D; Heinemann, V; Kahlert, S; Losem, C; Rauthe, G; Stemmler, HJ; Wohlrab, A | 1 |
| Carlini, P; Carpino, A; Cianciulli, AM; Ciccarese, M; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Giannarelli, D; Lorusso, V; Mottolese, M; Papaldo, P; Salesi, N; Sperduti, I | 1 |
| Iba, A; Kohjimoto, Y; Shinka, T; Shintani, Y; Uekado, Y | 1 |
| Albelda, SM; Jassar, AS; Kaiser, LR; Kapoor, V; Suzuki, E | 1 |
| Brodsky, I; Rosenbluth, JZ; Styler, MJ; Zak, D | 1 |
| Busby, EM; Carey, D; Divers, SG; Hyatt, MD; Robert, F; Spencer, SA | 1 |
| Brom, R; Candelaria, M; Cantu, D; Cetina, L; Chanona, J; de la Garza, J; Dolores, R; Duenas-Gonzalez, A; Gonzalez, A; Lopez-Graniel, C; Uribe, J | 1 |
| Duska, L; He, X; Klein, A; Mallett, A; Roche, M; Seiden, MV; Supko, JG | 1 |
| Büchler, MW; di Mola, FF; Di Sebastiano, P; Felix, K; Friess, H; Giese, NA; Hartel, M; Hinz, U; Mascetta, G; Selvaggi, F; Wente, MN | 1 |
| Araki, J; Ichinose, Y; Inoue, Y; Itoh, K; Iwamoto, N; Semba, H; Seto, T; Tamanoi, M; Tanaka, F; Yamamoto, H | 1 |
| Cunningham, D; Hill, A; Maisey, NR; Massey, A; Norman, AR; Oates, J | 1 |
| Agelidou, A; Agelidou, M; Androulakis, N; Athanasiadis, A; Georgoulias, V; Kalbakis, K; Mavroudis, D; Nikolakopoulos, J; Polyzos, A; Rapti, A; Samonis, G; Syrigos, K; Tselepatiotis, E | 1 |
| Blankenburg, T; Bork, I; Juergens, S; Nagel, S; Schaedlich, S; Schuette, W; Wollschlaeger, B | 1 |
| Bechrakis, NE; Foerster, MH; Keilholz, U; Schmittel, A; Schuster, R; Siehl, JM; Thiel, E | 1 |
| Ko, AH; Tempero, MA | 3 |
| Kuramoto, K; Terao, I | 1 |
| Baba, H; Matsumoto, G; Okamoto, A; Shimada, Y; Tsurta, K | 1 |
| Fujisaki, S; Kayashima, S; Nemoto, N; Oimuna, T; Takashina, M; Takayama, T; Tomita, R | 1 |
| Adamo, V; Altavilla, G; Angelini, V; Angiolillo, M; Annamaria, A; Ardizzoia, A; Azzarello, G; Barbera, S; Barletta, E; Barni, S; Barzelloni, ML; Bearz, A; Belli, M; Belloni, P; Bertetto, O; Bilancia, D; Bollina, R; Bordonaro, R; Borsellino, N; Brancaccio, L; Cabiddu, M; Caffo, O; Calandriello, A; Calcagno, A; Candido, P; Capuano, MA; Carrozza, F; Caruso, M; Castiglione, F; Cazzaniga, M; Celano, A; Chiodini, P; Cigolari, S; Cioffi, A; Ciuffreda, L; Clerici, M; Colantuoni, G; Colucci, G; Corradini, GM; Cortesi, E; Curcio, C; D'Aprile, M; D'Auria, G; Darwish, S; De Feo, G; De Maio, E; De Marinis, F; Di Costanzo, F; Di Maio, M; Di Negro, GB; Esani, G; Failla, G; Fava, S; Favaretto, A; Felletti, R; Ferraù, F; Foa, P; Frontini, L; Gaion, F; Galetta, D; Galligioni, E; Gallo, C; Gambaro, A; Gasparini, G; Gasperoni, S; Gattuso, D; Gebbia, N; Gebbia, V; Germano, D; Giotta, F; Gridelli, C; Guardasole, V; Hopps, MR; Iaffaioli, RV; Ianniello, GP; Illiano, A; Isa, L; Labianca, R; Lamberti, A; Locatelli, MC; Lopez, M; Luporini, G; Maione, P; Maiorino, L; Malaponte, E; Manzione, L; Martelli, O; Mattioli, R; Migliorino, MR; Monfardini, S; Morabito, A; Nettis, G; Novello, S; Ostellino, O; Palazzolo, G; Parello, G; Pavia, G; Perrone, F; Piantedosi, F; Piazza, E; Pontillo, V; Porcile, G; Quadri, A; Raucci, CA; Renda, F; Repetto, L; Rinaldi, M; Robbiati, SF; Romano, F; Romito, S; Rosetti, F; Rossi, A; Rossi, N; Sacco, C; Sannicolò, M; Scagliotti, G; Schiavon, S; Scimone, A; Selvaggi, G; Sibau, A; Sigoriello, G; Sollitto, F; Spatafora, M; Spazzapan, S; Stefani, M; Tartamella, F; Testa, A; Tinessa, V; Tirelli, U; Tonato, M; Tonini, G; Valerio, MR; Veltri, E; Vinante, O | 1 |
| Badger, J; Kang, S; Srinivas, S; Uzieblo, A | 1 |
| Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Gokgoz, S; Gonullu, G; Kanat, O; Kurt, E; Manavoglu, O; Saraydaroglu, O; Tasdelen, I; Tolunay, S; Topal, U | 1 |
| Arunabh, T; Davidoff, S; Shah, RD | 1 |
| Au, GK; Chua, DT; Sham, JS | 1 |
| Barceló, R; Fuente, N; López-Vivanco, G; Mañé, JM; Muñoz, A; Rubio, I; Viteri, A | 1 |
| Benimetskaya, L; Miller, P; Stein, CA | 1 |
| Albritton, K; Anderson, PM; Dubansky, SA; Erlandson, L; Rodriguez, V; Trotz, B; Wiseman, GA | 1 |
| Abbruzzese, J; Ali, S; Banerjee, S; Bhuiyan, M; Chiao, PJ; Philip, PA; Sarkar, FH; Wang, Z; Zhang, Y | 1 |
| Gagnadoux, F; Leblond, V; Lemarié, E; Lerondel, S; Pape, AL; Racineux, JL; Urban, T; Valo, I | 1 |
| Biroccio, A; D'Angelo, C; Leonetti, C; Lopez, M; Paoletti, G; Scarsella, M; Zupi, G | 1 |
| Abbruzzese, JL; Coombes, KR; Fidler, IJ; Hamilton, SR; Hawke, D; Kobayashi, R; Koomen, J; Li, D; Shih, LC; Yokoi, K | 1 |
| Hoshida, Y; Kawabe, T; Komatsu, Y; Nakai, Y; Omata, M; Otsuka, M; Tada, M | 1 |
| Chmura, SJ; Haraf, DJ; Kao, J; Milano, MT; Salama, JK; Stenson, KM; Vokes, EE; Witt, ME | 1 |
| Alinari, L; Baccarani, M; Bernengo, MG; Berti, E; Marchi, E; Pagano, L; Pileri, S; Pimpinelli, N; Rupoli, S; Stefoni, V; Tani, M; Zaja, F; Zinzani, PL | 1 |
| Montie, JE | 1 |
| Abdollahi, A; Buchler, MW; Buechler, P; Debus, J; Didinger, B; Friess, H; Heeger, S; Herfarth, KK; Huber, PE; Krempien, R; Muenter, MW; Nill, S; Timke, C | 1 |
| Brown, ER; Shepherd, FA | 1 |
| Forkert, R; Fronhoffs, S; Ko, Y; Koll, C; Neuhaus, T; Stier, S; Tuohimaa, A; Vetter, H | 1 |
| Kocijancic, I; Kovac, V; Segedin, B; Smrdel, U; Vrankar, M; Zwitter, M | 1 |
| Hada, M; Horiuchi, T | 1 |
| Amidon, GL; Landowski, CP; Lorenzi, PL; Song, X | 1 |
| Hatakeyama, K; Kurosaki, I | 1 |
| Haddad, R; Posner, MR | 1 |
| Frea, B; Gontero, P; Marini, L | 1 |
| Fujii, M; Goubaru, M; Makino, Y; Ogata, M; Ohta, T; Tanaka, S | 1 |
| Fukuda, Y; Ishimoto, T; Kagawa, N; Matsugu, Y; Nakahara, H; Tanaka, T | 1 |
| Bartoletti, R; Cai, T; Gacci, M; Ghezzi, P; Giubilei, G; Nerozzi, S; Repetti, F; Santelli, G; Sisani, M; Viggiani, F | 1 |
| Bergman, AM; Eijk, PP; Hubeek, I; Peters, GJ; Ruiz van Haperen, VW; Smid, K; van den Ijssel, P; Veerman, G; Ylstra, B | 1 |
| Barajas, O; Gallardo, J; Rubio, B; Villanueva, L | 1 |
| Aida, Y; Honma, K; Okura, M; Tanaka, N; Tanimura, S; Tsutsumi, K; Yamamoto, H | 1 |
| Andriessen, V; Baay, MF; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Pauwels, B; Pooter, CM; Vermorken, JB | 1 |
| Barge, A; Bruns, CJ; Friedrich, M; Jauch, KW; Kleespies, A; Köhl, G; Ryan, AJ | 1 |
| Brody, JR; Cunningham, SC; DeMarzo, AM; Dezentje, DA; Gallmeier, E; Hruban, RH; Isacoff, WH; Kern, SE; Offerhaus, GJ; Swartz, MJ; van der Heijden, MS | 1 |
| Cottler-Fox, M; Fassas, A; Fenton, R; French, T; Gojo, I; Guo, C; Heyman, M; Meisenberg, B; Murthy, A; Philips, GL; Rapoport, AP; Ruehle, K; Sarkodee-Adoo, C; Takebe, N; Tan, M; Tricot, G | 1 |
| Aurer, I; Bogdanić, V; Labar, B; Mrsić, M; Nemet, D; Radman, I; Sertić, D; Zupancić-Salek, S | 1 |
| Beijnen, JH; Crul, M; Howes, A; Pluim, D; Schellens, JH; Siegel-Lakhai, WS; Solanki, B; Sparidans, RW; Zhang, S | 1 |
| Barth, RJ; Bettmann, MA; Cates, JM; Colacchio, TA; Cole, BF; Gordon, SR; Marshall, JF; McDonnell, CE; Meyer, LP; Perez, RP; Pipas, JM; Redfield, N; Ripple, GH; Suriawinata, AA; Sutton, JE; Tsapakos, MJ; Zaki, B | 1 |
| Ashley, RA | 1 |
| Kiselyov, A | 1 |
| Dachman, A; Friberg, G; Karrison, T; Kindler, HL; Kozloff, M; Locker, G; Nattam, S; Singh, DA; Stadler, WM; Taber, DA; Vokes, EE | 1 |
| Batra, SK; Brand, RE; Mimeault, M; Sasson, AA | 1 |
| Ahmed, MM; Desimone, P; Halepota, M; Mohiuddin, M | 1 |
| Burdick, RK; Cunningham, SC; Cusnir, M; Moesinger, R; Van Echo, DA | 1 |
| An, CH; Bang, SM; Cho, EK; Jeong, SH; Kyung, SY; Lee, JH; Lee, SP; Lim, YH; Park, JW; Park, SH; Shin, DB | 1 |
| De Petris, L; Friesland, S; Lax, I; Sirzén, F | 1 |
| Hudson, MM | 1 |
| Govindan, R | 1 |
| Grénman, SE; Jalkanen, JT; Kuoppala, TA; Leminen, AO; Mäenpää, JU; Puistola, US; Vuolo-Merilä, PM; Yliskoski, MH | 1 |
| Leow, CH; Liam, CK | 1 |
| Adusumilli, PS; Chan, MK; Chou, TC; Eisenberg, DP; Fong, Y; Hendershott, KJ; Mullerad, M; Yu, Z | 1 |
| Blessing, JA; Brewer, CA; Lele, S; McMeekin, DS; Nagourney, RA; Zweizig, SL | 1 |
| Barata, F | 1 |
| Chen, G; Li, LJ; Niu, BZ; Wu, YD; Zhao, YP | 1 |
| Dexheimer, TS; Fellows, IM; Gleason-Guzman, M; Hurley, LH; Schwaebe, M; Vankayalapati, H; Whitten, JP | 1 |
| Lianes, P; Neymark, N; Smit, EF; van Meerbeeck, JP | 1 |
| Moreno-Aspitia, A; Perez, EA | 1 |
| Cameron, D; Dunlop, D; Eatock, M; McClory, B; Millar, J; Morrison, A; Philips, H; Price, A; Scullin, P; Wall, L | 1 |
| Bordonaro, R; Castorina, S; Giannitto, GC; Giuffrida, D; La Venia, G; Marletta, F; Pappalardo, A; Potenza, E; Russo, A; Saita, S; Vincenzi, B | 1 |
| Horio, Y; Mitsudomi, T; Shimizu, J | 1 |
| Hirata, N; Ishiguro, A; Munakata, M; Sakata, Y; Shitara, K; Wada, R; Yabu, K | 1 |
| Cleverly, A; de Lange, SM; Jensen, HA; Kroep, JR; Peters, GJ; Pfeiffer, P; van der Born, K; van Groeningen, CJ | 1 |
| Campodonico, F; Maffezzini, M | 1 |
| Simpson, A | 1 |
| Crausaz, S; Metcalfe, S | 1 |
| Bergman, AM; Costa, JL; Meijer, GA; Oudejans, CB; Peters, GJ; Smid, K; van de Wiel, MA; Ylstra, B | 1 |
| Abbruzzese, JL; Baker, CH; Bucana, CD; Fan, D; Fidler, IJ; Kitadai, Y; Kuwai, T; Sasaki, T; Yokoi, K | 1 |
| Aguiluz, M; Andrade, S; Erazo, M; Flores, C; Pineda, C; Santillana, S; Umanzor, J | 1 |
| Choy, H; Vokes, E | 1 |
| Bepler, G | 2 |
| Natale, R | 1 |
| Cullen, M | 1 |
| Treat, J | 1 |
| Goker, E; Goksel, G; Karabulut, B; Sanli, UA; Sezgin, C; Uslu, R; Yuzer, Y | 1 |
| Dufmats, M; Gawande, SR; Hillerdal, G; Kölbeck, K; Lamberg, K; Sederholm, C; Westberg, R | 1 |
| Chang, YS; Cho, JY; Chung, JB; Lee, DK; Lee, SJ; Paik, YH; Park, MS; Song, SY; Yoon, DS; Yu, JS | 1 |
| Caliceti, P; Cavallaro, G; Gaetano, G; Licciardi, M; Mariano, L; Salmaso, S | 1 |
| Blumenschein, G; Fossella, FV; Herbst, RS; Needle, M; Robert, F; Saleh, MN; Tseng, J | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H; Yoshino, M | 1 |
| Adjei, AA; Fitch, TR; Hillman, DW; Ingle, JN; Kugler, JW; Ma, CX; Niedringhaus, RD; Perez, EA; Rowland, KM; Steen, P | 1 |
| Bepler, G; Cantor, A; Nwogu, C; Ramnath, N; Robinson, L; Sharma, A; Sommers, E | 1 |
| Bardenheuer, W; Brueckner, A; Flasshove, M; Lehmberg, K; Moritz, T; Rattmann, I; Schneider, A; Seeber, S; Sorg, UR | 1 |
| Lokich, J | 1 |
| Barstis, JL; Black, AC | 1 |
| Davis, JJ; Dong, F; Fang, B; Guo, W; Lin, A; Teraishi, F; Zhang, L | 1 |
| Aguiar, J; Barón, MG; Chacón, JI; Colmenarejo, A; de Carpeño, JC; Feliu, J; García, MJ; Madroñal, C; Ordóñez, A; Sánchez, JJ | 1 |
| Baek, JH; Chae, YS; Chung, IJ; Joo, YD; Kim, DH; Kim, HJ; Kim, JG; Lee, JJ; Lee, KB; Lee, WS; Sohn, CH; Sohn, SK; Yang, DH | 1 |
| Berard, H; Bombaron, P; Fournel, P; Gouva, S; Kleisbauer, JP; Le Caer, H; Léna, H; Perol, M; Robinet, G; Thomas, P; Vergnenegre, A | 1 |
| Bissoli, S; Castoldi, G; Cavazzini, L; Chierichetti, F; Feggi, L; Fraulini, C; Mauro, E; Panareo, S; Rigolin, GM | 1 |
| Bavieri, M; Bigiani, N; Brambilla, E; Casali, C; Cavazza, A; Fabbri, LM; Facciolongo, N; Longo, L; Maiorana, A; Marchioni, A; Migaldi, M; Morandi, U; Rossi, G; Sartori, G; Schirosi, L | 1 |
| Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kinoshita, H; Sakai, T; Shirouzu, K; Uchida, S | 1 |
| Akiyama, T; Hirata, K; Homma, H; Kogawa, K; Koike, K; Mezawa, S; Takahashi, S | 1 |
| Arai, T; Baba, H; Ema, T; Hashimoto, T; Karasawa, K; Kawakami, M; Matsumoto, G; Nakanishi, C; Okamoto, A; Suzuki, Y; Tsuruta, K | 1 |
| Amano, M; Hayashida, H; Higaki, N; Itani, Y; Nakagawa, S; Niinobu, T; Nishikawa, Y; Sakon, M | 1 |
| Allouache, D; Bozec, L; Gawande, SR; Genot, JY; Mefti, F; Piperno-Neumann, S; Tubiana-Hulin, M; Tubiana-Mathieu, N | 1 |
| Bai, LY; Chen, PM; Poh, SB | 1 |
| Akerman, P; Barnett, JM; Cioffi, W; Cruff, D; Dipetrillo, T; Iannitti, D; Kennedy, T; Maia-Acuna, C; Martel, D; Miner, T; Remis, M; Safran, H | 1 |
| Carducci, M; Huie, M; Izquierda, M; Liu, G; Marnocha, R; Thomas, J; Wilding, G | 1 |
| Ahmad, I; Ahmad, MU; Ali, SM; Chen, P; Chien, PY; Khan, AR; Sheikh, S | 1 |
| Brown, S; Chen, EX; Chin, SF; Duran, I; Nottage, M; Oza, AM; Pond, GR; Siu, LL; Sturgeon, J | 1 |
| Russo, S; Saif, MW; Sellers, S | 1 |
| Adamo, B; Adamo, V; Alafaci, E; Garipoli, C; Magno, C; Maisano, C; Rossello, R; Scandurra, G; Scimone, A; Spitaleri, G | 1 |
| Furuse, J; Ikeda, M; Ishiguro, Y; Ishii, H; Matsubara, J; Morizane, C; Nagase, M; Nakachi, K; Okusaka, T; Ueno, H | 1 |
| Doi, R; Fujimoto, K; Hiraoka, M; Imamura, M; Mizowaki, T; Nagata, Y; Oya, N; Sakamoto, T; Shibuya, K | 1 |
| Bassi, P; Crucitta, E; Dal Moro, F; De Marco, V; Longo, F; Marini, L; Pinto, F; Tavolini, IM; Zucchetti, M | 1 |
| Comijn, EC; Lakerveld, B; Noordhuis, P; Peters, GJ; Pinedo, HM; Smid, K; Van der Vijgh, WJ; Van Moorsel, CJ; Voorn, D; Weaver, D; Willey, JC | 1 |
| Fehlauer, F; Muench, M; Richter, E; Slotman, B; Smid, EJ; Sminia, P; Van der Valk, P | 1 |
| Cebon, J; Davis, ID; de Souza, P; Galettis, P; Gan, HK; Links, M; Mitchell, PL | 1 |
| Boisdron-Celle, M; Diot, P; Fournier, J; Gagnadoux, F; Hureaux, J; Le Pape, A; Leblond, V; Lemarié, E; Majoral, C; Montharu, J; Racineux, JL; Urban, T; Vecellio, L | 1 |
| Crump, M; Keating, A; Kuruvilla, J; Nagy, T; Pintilie, M; Tsang, R | 1 |
| Käser, L; Kolyvanos Naumann, U; Vetter, W | 1 |
| Addeo, A; Barone, C; Berruti, A; Bertetto, O; Buffoni, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Grillo, R | 1 |
| Doi, R; Fujimoto, K; Ito, D; Kami, K; Kawaguchi, Y; Koizumi, M; Mori, T; Toyoda, E | 1 |
| Boos, J; Henze, G; von Stackelberg, A; Wagner-Bohn, A | 1 |
| Chang, JY; Hong, RL; Lin, CY; Liu, TW; Wang, CC; Yu, YC | 1 |
| Garcia, R; Goff, BA; Greer, B; Koh, WJ; Swensen, RE; Swisher, EM; Tamimi, H | 1 |
| Bang, S; Choo, YS; Chung, JB; Kim, HS; Park, SW; Song, SY | 1 |
| Airoldi, M; Cattel, L; Milla, P; Passera, R; Pedani, F; Zanon, C | 1 |
| Clayton, AJ; Hawkins, RE; Jones, ET; Mansoor, AW; Saunders, MP; Swindell, R; Valle, JW | 1 |
| Inadome, N; Maemondo, M; Matsumoto, K; Mizumoto, K; Murakami, M; Nagai, E; Nakamura, T; Nukiwa, T; Ogura, Y; Saimura, M; Tanaka, M | 1 |
| Brouwers, MC; Dingle, BH; Rumble, RB | 1 |
| Kakizaki, I; Kon, A; Kudo, D; Morohashi, H; Nakazawa, H; Sasaki, M; Takagaki, K; Yoshihara, S | 1 |
| Aravantinos, G; Bamias, A; Dimopoulos, MA; Fountzilas, G; Gika, D; Kalofonos, HP; Kastritis, E; Koutras, A; Linardou, H; Moulopoulos, LA; Pectasides, D; Skarlos, D | 1 |
| Neragi-Miandoab, S | 1 |
| Flores, AM; Rocha Lima, CM | 1 |
| Bergsland, EK; Dito, E; Ko, AH; Schillinger, B; Tempero, MA; Venook, AP | 2 |
| Gajewski, BJ; Mayo, MS | 1 |
| Hyodo, M; Koizumi, M; Kurihara, K; Nagai, H; Sata, N; Shimura, K; Tsukahara, M; Yasuda, Y; Yoshizawa, K | 1 |
| Barnett, CC; Beck, AW; Brekken, RA; Conner, CR; Fleming, JB; Holloway, SE; Luster, TA; Miller, AF; Thorpe, PE | 1 |
| Bloss, LP; Curiel, RE; Monberg, MJ; Obasaju, CK; Ye, Z | 1 |
| Dornof, W; Gatzemeier, U; Gosse, H; Hruska, D; Koschel, G; Manegold, C; Mezger, J; Pilz, LR; Romer, KS | 1 |
| Barnadas, A | 1 |
| Fumoleau, P; Levy, C | 1 |
| Poveda, A | 1 |
| Alberola, V; Camps, C; Catot, S; de Las Peñas, R; Massuti, B; Moran, T; Ramirez, JL; Rosell, R; Salazar, F; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M | 1 |
| Arnaud, JP; Debois, M; Ducreux, MP; El-Serafi, M; Etienne, PL; Gamelin, E; Genicot, B; Husseini, F; Koehne, CH; Lingenfelser, T; Lutz, MP; Mitry, E; Nordlinger, B; Praet, M; Reichardt, P; Van Cutsem, E; Van Laethem, JL; Vanhoefer, U; Wagener, T; Wils, JA | 1 |
| Folman, R; Khalid, T | 1 |
| Lehoczky, O | 1 |
| Beha, M; Brudler, O; Heinemann, V; Kahlert, S; Müller, S; Stauch, B; Stemmler, HJ | 1 |
| Aguilar, EA; Carbonero, AI; Delgado, FJ; Espinosa, JC; García López, JL; García Ribas, I; García, JJ; Guzmán, MC; Jericó, JF; Martos, CF; Mena, AC; Muñoz, ML; Plazas, JG; Rovira, PS; Santasusana, JM; Valera, JS | 1 |
| Ambrosino, N; Bernardini, I; Chella, A; Falcone, A; Malventi, M; Russo, F; Tempestini, F; Tibaldi, C; Toma, G; Vasile, E | 1 |
| Antón, A; Arcusa, A; Bayo, JL; Calvo, L; Carrasco, E; Florián, J; Martín-Richard, M; Mayordomo, JI; Pelegrí, A; Vásquez, S; Virizuela, J | 1 |
| Alvero, AB; Brown, D; Chen, W; Garg, M; Kelly, G; Mor, G; O'Malley, D; Rutherford, T | 1 |
| Chen, J; Chen, K; Guo, M; Nie, L; Yao, S; Yun, X | 1 |
| Altevogt, P; Debatin, KM; Edler, L; Gutwein, P; Herr, I; Marmé, A; Mattern, J; Rittgen, W; Wenger, T; Zhang, C | 1 |
| Brugiatelli, M; Cervetti, G; Di Renzo, N; Federico, M; Giglio, G; Liberati, AM; Luminari, S; Montanini, A; Spedini, P; Vigliotti, ML | 1 |
| Awada, A; Giannaris, T; Lathia, C; Moore, MJ; Petrenciuc, O; Piccart, M; Schwartz, B; Siu, LL; Takimoto, CH | 1 |
| Corti, A; Curnis, F; Gallo-Stampino, C; Gasparri, A; Sacchi, A; Toma, S | 1 |
| Archange, C; Barthet, M; Dagorn, JC; Gironella, M; Giroux, V; Iovanna, JL; Malicet, C; Vasseur, S | 1 |
| Atkinson, R; Coleman, R; Kaye, S; Lewsley, L; Osborne, R; Parkin, D; Paul, J; Reed, NS; Rustin, GJ; Symonds, R; Vasey, PA | 1 |
| Barón, MG; Casado, E; Castañón, C; Castro, J; Cruz, M; Feliu, J; Fonseca, E; Jara, C; Jaráiz, AR; León, A; Lomas, M; Sáenz, JG | 1 |
| Alberola, V; Botia, M; Camps, C; Cecere, F; Cobo, M; de las Peñas, R; Garcia-Carbonero, R; Garcia-Gomez, R; Isla, D; Massuti, B; Mendez, P; Queralt, C; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Santarpia, M; Taron, M | 1 |
| Bruns, C; Dühmke, E; Heinemann, V; Thoma, M; Wilkowski, R | 1 |
| Aithal, GP; Anagnostopoulos, GK; Kaye, P; Ragunath, K; Rowlands, BJ | 1 |
| Bassi, C; Boz, G; De Paoli, A; Falconi, M; Innocente, R; Pederzoli, P; Rossi, C; Tosolini, GC; Trovò, MG | 1 |
| Albers, P; Fechner, G; Kobalz, L; Reimann, M; Siener, R | 1 |
| Amaya, H; Aotake, T; Hirai, S; Ihaya, A; Ikeda, T; Kawabe, M; Sasaki, H; Sasaki, M; Tanaka, K; Uchinami, M; Yoshida, M | 1 |
| Fujita, S; Hirota, M; Inoue, Y; Nomura, M; Sakao, J; Souda, S | 1 |
| Lowy, AM | 1 |
| Guo, SS; Liang, HL; Wang, Y; Xie, de R | 1 |
| Ashoka, S; Ijare, OB; Jadegoud, Y; Kandagal, PB; Seetharamappa, J; Shaikh, SM | 1 |
| Fahlke, J; Florschuetz, A; Greiner, C; Hahnfeld, S; Hribaschek, A; Kettner, E; Klein, H; Kuhn, R; Lippert, H; Manger, T; Meyer, F; Ridwelski, K; Wilhelm, G | 1 |
| Baricević, D; Cucević, B; Jakopović, M; Redzepi, G; Samarzija, M; Samija, M | 1 |
| Habuchi, T; Higashi, S; Itoh, N; Kamoto, T; Kinoshita, H; Nakamura, E; Nishiyama, H; Ogawa, O; Segawa, T; Takahashi, T; Yamamoto, S | 1 |
| Ahn, YM; Cho, EH; Cho, KH; Choi, IS; Choi, JW; Kim, BS; Nam, SH; Roh, YH; Song, YB | 1 |
| Attaluri, V; Colletti, LM; Freedman, GM; Hoffman, JP; Kinsella, TJ; McGinn, CJ; Mulcahy, MF; Philip, PA; Small, W; Talamonti, MS; Wayne, JD; Zalupski, MM | 1 |
| Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Nyati, MK; Scheurer, AM | 1 |
| Hamada, S; Kanno, A; Kimura, K; Masamune, A; Satoh, K; Shimosegawa, T | 1 |
| Lorusso, V | 1 |
| Giannarelli, D; Moscetti, L; Nelli, F; Padalino, D; Pollera, CF; Sperduti, I | 1 |
| Amal, K; Fethi, el M; Habib, G; Imen, A; Ines, Z; Sameh, el F | 1 |
| Cardaci, V; Cesario, A; Corbo, GM; D'Angelillo, RM; Galetta, D; Gambacorta, MA; Granone, P; Macis, G; Margaritora, S; Mulè, A; Piraino, A; Porziella, V; Ramella, S; Russo, P; Sterzi, S; Trodella, L; Valente, S | 1 |
| Guo, Y; Hong, XN; Li, J; Tang, WY; Wang, JL | 1 |
| Friedrich, C; Krege, S; Pientka, L; Rübben, H | 1 |
| Angleitner-Boubenizek, L; Deibl, M; Marth, C; Petru, E; Reinthaller, A; Stempfl, A; Volgger, B; Zeimet, AG | 1 |
| Rudd, R; Saha, A | 1 |
| Barbieri, F; Bearz, A; Belloni, P; Biason, R; Ceresoli, G; Chella, A; Clerici, M; Favaretto, A; Ghi, MG; Nicoletto, MO; Oniga, F; Paccagnella, A; Riccardi, A; Ridolfi, R; Tirelli, U; Tumolo, S; Veglia, F | 1 |
| Chang, C; Endres, CJ; Fei, YJ; Ganapathy, V; Hu, H; Itagaki, S; Lee, EW; Swaan, PW; Umapathy, NS; Unadkat, JD | 1 |
| Bekaii-Saab, TS; Chen, CS; Li, J; Melvin, WS; Muscarella, P; Zhu, J | 1 |
| Nagata, T; Tsukada, K; Yoshino, T | 1 |
| Ohkawa, S | 1 |
| Akiyama, T; Homma, H; Mezawa, S; Takahashi, S | 1 |
| Nakao, A; Takeda, S | 1 |
| Takahashi, Y; Yamashita, K | 1 |
| Abe, H; Egawa, S; Motoi, F; Ohmura, N; Ottomo, S; Sunamura, M | 1 |
| Endoh, Y; Nagata, T; Ohnishi, Y; Tsukada, K; Yamagishi, F | 1 |
| Funakoshi, A; Iguchi, H; Sumii, T | 1 |
| Hasegawa, T; Hirayama, A; Nagakawa, T; Nishino, S; Suga, T | 1 |
| Ioka, T; Nakaizumi, A; Nishiyama, K; Tanaka, S; Yamazaki, H | 1 |
| Egawa, S; Fukuyama, S; Motoi, F; Sunamura, M; Unno, M | 1 |
| Izukura, M; Miyazaki, S; Nisijima, J | 1 |
| Kim, DH; Ogawa, K; Shiozawa, S; Tsuchiya, A | 1 |
| Funakoshi, A; Sumii, T | 2 |
| Arii, S; Nakamura, N; Teramoto, K | 1 |
| Canil, C; Chi, KN; Moore, M; Murray, RN; Tinker, A; Winquist, E | 1 |
| Borden, EC; Karen, A; Mills, GM; Rankin, C; Von Burton, G; Zalupski, MM | 1 |
| Eisele, L; Müller-Beissenhirtz, H; Seeber, S; Sheu, SY; Welt, A | 1 |
| Gardner, J; Gonen, M; Heaney, M; O'Connor, OA; Sirotnak, F; Smith, EA; Teruya-Feldstein, J; Toner, LE; Vrhovac, R | 1 |
| Braun, D; Breton, JL; Debieuvre, D; Depierre, A; Germa, C; Jacoulet, P; Kayitalire, L; Milleron, B; Quoix, E; Westeel, V | 1 |
| Chew, L; Foo, KF; Leong, SS; Poon, D; Tan, EH; Wee, J | 1 |
| Perez, E; Wirk, B | 1 |
| Choi, SH; Heo, JS; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KT; Park, JO; Park, K; Park, YS | 1 |
| Horan, G; Podd, TJ; Smith, SL | 1 |
| Baron, D; Kluger, Y; Mayo, A | 1 |
| Barlesi, F; Daurès, JP; Pujol, JL | 1 |
| Kubota, Y; Makiyama, K; Miyoshi, Y; Nakaigawa, N; Ogawa, T; Sugiura, S; Uemura, H; Umemoto, S; Yao, M; Yokomizo, Y | 1 |
| Julka, PK; Puri, T; Rath, GK | 1 |
| Dooms, CA; Lievens, YN; Vansteenkiste, JF | 1 |
| Cheng, YC; Lam, W; Leung, CH; Park, SY | 1 |
| Feng, FY; Fu, M; Liang, X; Lin, C; Yang, Y; Yao, J; Zhang, XY | 1 |
| Baas, P; Beijnen, JH; Crul, M; Rademaker-Lakhai, JM; Schellens, JH; Simis, YJ; van Zandwijk, N; Zuur, L | 1 |
| Koga, H; Naito, S | 1 |
| Kawauchi, A; Miki, T; Mizutani, Y; Nakamura, T; Nomoto, T | 1 |
| Abe, Y; Fujisawa, N; Fujisawa, T; Fujita, K; Inamori, M; Kawamura, H; Kirikoshi, H; Kobayashi, N; Kubota, K; Nakajima, A; Saito, S; Sakaguchi, T; Shimamura, T; Takahashi, H; Yoneda, M | 1 |
| Hada, M; Horiuchi, T; Shinji, H | 1 |
| Cho, EK; Heo, DS; Jung, KH; Kim, JH; Kim, SY; Kim, YH; Lim, HY; Park, BJ; Park, K; Ryoo, BY; Suh, CW | 1 |
| Aghajanian, C; Chi, DS; Correa, DD; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Thaler, H; Venkatraman, E; Wilton, A | 1 |
| Danquah, G; Jacobs, MJ; Mittal, VK; Ng, J; ReMine, SG; Saidi, RF; Williams, F | 1 |
| Bartoletti, R; Cai, T; Carini, M; Gacci, M; Ghezzi, P; Nerozzi, S; Nesi, G; Pinzi, N; Repetti, F; Viggiani, F | 1 |
| Kestenholz, P; Lardinois, D; Müller, M; Opitz, I; Rousson, V; Schneiter, D; Stahel, R; Weder, W | 1 |
| Bay, JO; Blay, JY; Brain, E; Bui, NB; Cherix, S; Chevreau, C; Cioffi, A; Coindre, JM; Emile, G; Fayette, J; Isambert, N; Kwiatkowski, F; Le Cesne, A; Leyvraz, S; Penel, N; Peyrade, F; Piperno-Neumann, S; Ray-Coquard, I | 1 |
| Amoh, Y; Bouvet, M; Hoffman, RM; Katsuoka, K; Li, L; Moossa, AR; Tsuji, K | 1 |
| Kitano, M; Kudo, M; Nakai, T; Ohyanagi, H; Sakamoto, H; Suetomi, Y; Takeyama, Y; Yasuda, C | 1 |
| Brundage, RC; Elmquist, WF; Guire, DE; Kirstein, MN; Marker, PH; Remmel, RP; Yee, D | 1 |
| Appleman, LJ; Demetri, GD; Desai, J; George, S; Manola, J; Paul Eder, J; Ryan, DP | 1 |
| Kose, MF; Meydanli, MM; Tulunay, G | 1 |
| Gasparro, S; La Cesa, A; Santini, D; Schiavon, G; Tonini, G; Vincenzi, A; Vincenzi, B | 1 |
| Parker, WB; Someya, H; Thottassery, JV; Westbrook, L | 1 |
| Muss, HB; Perez, E | 1 |
| Bitran, JD; Edelman, MJ; Irwin, D; John, WJ; Lilenbaum, R; Makalinao, A; Peterson, P; Ritch, P; Rudin, CM | 1 |
| Aprile, G; Balzano, G; Bonetto, E; Brandes, AA; Cordio, S; Dell'Oro, S; Di Carlo, V; Fugazza, C; Luppi, G; Milandri, C; Nicoletti, R; Pasetto, L; Passoni, P; Piemonti, L; Reni, M; Zerbi, A | 1 |
| Bielawska, A; Bielawski, J; Cobanoglu, B; Day, TA; Hannun, YA; Koybasi, S; Meyer, M; Obeid, LM; Ogretmen, B; Ponnusamy, S; Rossi, MJ; Senkal, CE; Sinha, D; Sundararaj, K; Szulc, Z | 1 |
| Bell, MD | 1 |
| Freise, KJ; Martín-Jiménez, T | 2 |
| Asadpour, B; Buell, U; Coenen, HH; Demirel, C; Eble, MJ; Gagel, B; Hamacher, K; Kaiser, HJ; Pinkawa, M; Piroth, M; Reinartz, P; Stanzel, S; Zimny, M | 1 |
| Abbruzzese, JL; Crane, CH; Evans, DB; Frazier, M; Hess, KR; Jiao, L; Li, D | 1 |
| Carbone, C; Codecà, C; Ferrari, D; Foa, P; Fumagalli, L; Gilardi, L; Marussi, D; Oldani, S; Tartaro, T; Zannier, F | 1 |
| Beijnen, JH; Giaccone, G; Kroep, JR; Peters, GJ; Pinedo, HM; Postmus, PE; Smit, EF; Van der Born, K; Van der Vijgh, WJ; Van Groeningen, CJ | 1 |
| Peterson, JA; Risley, DS; Yang, WQ | 1 |
| Ando, K; Kamata, T; Kitabayashi, H; Ochiai, T; Shimada, H; Tsujii, H; Yamada, S; Yasuda, S | 1 |
| Alexandre, J; Chapron, C; Chopin, N; Goldwasser, F; Moachon, L | 1 |
| Sleijfer, S | 1 |
| Ichinose, Y; Kamei, T; Maruyama, R; Nakamura, T; Nishiyama, K; Okamoto, T; Sakai, M; Suemitsu, R; Wataya, H | 1 |
| Fuchs, M; Schepp, W | 1 |
| Carvalho, FM; Carvalho, JP; Feher, O; Maluf, FC; Schütz, FA | 1 |
| Dealwis, C; Faber, C; Racca, J; Uchiki, T; Xu, H | 1 |
| De Greef, K; Hendriks, JM; Romijn, S; Van Putte, BP; Van Schil, PE | 1 |
| Bando, Y; Goto, H; Hamada, H; Kakiuchi, S; Kito, K; Matsumori, Y; Muguruma, H; Nakataki, E; Sone, S; Uehara, H; Yano, S; Yokoyama, A | 1 |
| Benedetti, G; De Pangher Manzini, V; Del Conte, G; dell'Amore, D; Galetta, D; Giaquinta, S; Lopez, M; Marino, A; Martoni, A; Mazzanti, P; Piana, E; Pinto, C | 1 |
| Haye, S; Kalthoff, H; Kapischke, M; Kremer, B; Kruse, ML; Sipos, B; Tepel, J | 1 |
| Ann, DK; Boo, LM; Chen, Y; Chung, V; Liu, X; Nguyen, HV; Song, J; Yen, Y; Zhou, B; Zhu, L | 1 |
| Canti, G; Chiaviello, A; Crescenzi, E; Palumbo, G; Reddi, E; Veneziani, BM | 1 |
| Hennemann, B | 1 |
| Chua, YJ; Cunningham, D | 1 |
| Crane, CH; Evans, DB; Pisters, PW; Varadhachary, G; Wolff, RA | 2 |
| Chang, GC; Douillard, JY; Gandara, DR; John, WJ; Koralewski, P; Lahn, M; Manegold, C; Obasaju, CK; Paz-Ares, L; Peterson, PM; Reyes, JM; Smit, EF | 1 |
| Amadori, D; Frassineti, GL; Gianni, L; Maltoni, R; Massa, I; Milandri, C; Nanni, O; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Ames, MM; Eckloff, BW; Gilbert, JA; Ji, Y; Pelleymounter, LL; Salavaggione, OE; Weinshilboum, RM; Wieben, ED | 1 |
| Du, W; Posner, M; Schmidt, H; Shafaee, Z; Weichselbaum, R | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Bartolini, S; Cappuzzo, F; Finocchiaro, G; Gioia, V; Toschi, L | 1 |
| Belani, CP | 1 |
| de Jager, J; Stebbing, J | 1 |
| Adachi, M; Ando, K; Hirose, T; Horichi, N; Hosaka, T; Ishida, H; Noda, M; Ohmori, T; Ohnishi, T; Okuda, K; Ozawa, T; Shirai, T | 1 |
| Algayres, JP; Béchade, D; Bredin, C; Defuentes, G; Desramé, J; Dourthe, LM; Duvic, C; Raynaud, JJ | 1 |
| Atkinson, T; Campos, S; Duska, L; Fuller, AF; Goodman, A; Krasner, CN; Matulonis, UA; Penson, RT; Seiden, MV; Verrill, C | 1 |
| Fujii, T; Habiro, A; Izawa, T; Kohgo, Y; Koizumi, K; Mizukami, Y; Nakano, Y; Okumura, T; Osanai, M; Tanno, S; Yanagawa, N | 1 |
| Belknap, SM; Bennett, CL; Kuzel, TM; Lyons, EA; Raisch, DW; Slimack, N; Yarnold, PR | 1 |
| Brodowicz, T; Ciuleanu, T; Cucevic, B; Ghilezan, N; Grgic, M; Gyurkovits, K; Jassem, J; Krzakowski, M; Oskina, N; Ramlau, R; Saip, P; Soldatenkova, V; Szilasi, M; Tzekova, V; Ulsperger, E; Wagnerova, M; Wenczl, M; Wiltschke, C; Zielinski, C; Zwitter, M | 1 |
| Jiang, PH; Minamoto, T; Motoo, Y; Sawabu, N | 1 |
| Chai, XS; Deng, H; Liu, WS; Long, SQ; Luo, HY; Wang, B; Wu, WY; Xue, XG; Zhang, HB | 1 |
| Dagit, JW; Fisher, JE; Guire, DE; Hassan, I; Kirstein, MN; Remmel, RP; Weller, DR | 1 |
| Beck, AM; Carrigan, PE; Hayes, GM; Miller, LJ | 1 |
| Bevilacqua, G; Boggi, U; Campani, D; Danesi, R; Del Chiaro, M; Del Tacca, M; Funel, N; Giovannetti, E; Iannopollo, M; Mey, V; Mosca, F; Nannizzi, S; Orlandini, C; Ricci, S | 1 |
| Asmar, L; Ilegbodu, D; Khandelwal, P; O'Shaughnessy, JA; Pluenneke, R; Sternberg, J | 1 |
| Boulikas, T; Rigatos, SK; Stathopoulos, GP; Stathopoulos, JG; Vougiouka, M | 1 |
| Dieringer, P; Jonasch, E; Mathew, P; Pagliaro, LC; Rodney, A; Tannir, N | 1 |
| Abdelatif, M; Bidault, F; Bouvet-Forteau, N; de Crevoisier, R; di Palma, M; Fizazi, K; Laplanche, A; Theodore, C; Wibault, P | 1 |
| Chellappan, S; Dasgupta, P; Decook, C; Haura, E; Joshi, B; Kinkade, R | 1 |
| Abbruzzese, JL; Atkins, JN; Blanke, CD; Dakhil, SR; Gandara, DR; McCoy, SA; Paradelo, JC; Williamson, SK; Yost, KJ | 1 |
| Jang, JS; Kang, JH; Kim, HG; Lee, GW; Lee, JS | 1 |
| Han, JY; Hong, EK; Kim, HY; Lee, DH; Lee, HG; Lee, JJ; Lee, JS; Yoon, SJ; Yoon, SM | 1 |
| Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M | 1 |
| Gridelli, C; Rossi, A | 1 |
| Bao, HY; Chen, J; Fang, WJ; Huang, S; Mou, HB; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC | 1 |
| Hirono, S; Ina, S; Kawai, M; Tani, M; Terasawa, H; Uchiyama, K; Yamaue, H | 1 |
| Garcia-Carbonero, R; Paz-Ares, L | 1 |
| Fukuchi, Y; Ito, J; Kajiyama, Y; Miura, K; Miyamoto, H; Nagashima, O; Sato, K; Shimanuki, Y; Suzuki, T; Tajima, K; Takahashi, K; Uekusa, T | 1 |
| Booker, AJ; Christensen, LA; Finch, RA; Vasquez, KM | 1 |
| Alter, MD; Avdulov, S; Bitterman, PB; Frizelle, SP; Jacobson, BA; Kratzke, MG; Kratzke, RA; Mohorn, RP; Peterson, MS; Polunovsky, VA; Whitson, BA; Zhang, Y | 1 |
| Benner, A; Brors, B; Eils, R; Hahn, M; Kramer, H; Lichter, P; Rudlowski, C; Schneeweiss, A; Schuetz, F; Sinn, HP; Sohn, C; Tews, B; Thuerigen, O; Toedt, G; Warnat, P | 1 |
| Bhargava, P; Blaszkowsky, LS; Clark, JW; Enzinger, PC; Hale, KE; Horgan, K; Muzikansky, A; Ryan, DP; Sheehan, S; Stuart, K; Zhu, AX | 1 |
| Graeven, U; Killing, B; Kremer, B; Rojo, F; Schmiegel, W; Südhoff, T; Tillner, J; Unal, C; Weber, D | 1 |
| Brueckl, WM; Brunner, TB; Grabenbauer, GG; Meyer, T; Sauer, R; Tinkl, D | 1 |
| Kalofonos, HP; Karabelis, A; Kosmas, C; Koutras, A; Makatsoris, T; Mylonakis, N; Stathopoulos, GP; Syrigos, K; Tsakonas, G; Tsavaris, N | 1 |
| Chen, Z; Jian, Z; Li, J; Li, X; Li, Y; Lv, X; Pei, H; Xia, K | 1 |
| Angelos, P; Sturgeon, C | 1 |
| Ikeda, M; Morizane, C; Okusaka, T; Ueno, H | 1 |
| Barbieri, F; Bartolini, S; Cappuzzo, F; Crinò, L; De Marinis, F; Marini, L; Maur, M; Novello, S; Papi, M; Pasquini, E; Scagliotti, GV; Selvaggi, G | 1 |
| Alcaide García, J; Alés Díaz, I; Benavides Orgaz, M; Cobo Dols, M; Gil Calle, S; Gutiérrez Calderón, V; Villar Chamorro, E | 1 |
| Arias de la Vega, F; Gómez Dorronsoro, ML; Jiménez, FJ | 1 |
| López Jiménez, A; Maestu Maiques, I; Oltra Ferrando, A; Pérez-Fidalgo, JA | 1 |
| Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T | 1 |
| Ausania, F; Borzomati, D; Caricato, M; Coppola, R; Garberini, A; Rabitti, C; Tonini, G | 1 |
| Chang, JY; Chao, Y; Chen, LT; Cheng, AL; Chuang, TR; Hsu, C; Hsu, CH; Jan, CM; Liu, TW; Shiah, HS; Whang-Peng, J; Yu, WL | 1 |
| Hidalgo, M; Iacobuzio-Donahue, CA; Klein, A; Kulesza, P; Laheru, D; Ricci, F; Rubio-Viqueira, B; Rubio-Viquiera, B; Sebastiani, V; Yeo, CJ | 1 |
| Büchler, P; Ganten, TM; Haas, TL; Koschny, R; Schader, MB; Schulze-Bergkamen, H; Stremmel, W; Sykora, J; Untergasser, A; Walczak, H | 1 |
| Boehm, KA; Clark, M; Dasse, KD; Grove, W; Gulyas, S; Krishnamurthi, SS; Macdonald, K; Richards, DA; Rosemurgy, A; Wagener, DJ; Waterhouse, DM | 1 |
| Egashira, A; Maehara, S; Maehara, Y; Oki, E; Taketomi, A; Tokunaga, E; Tsujita, E; Yamashita, Y; Yoshihiro, K | 1 |
| Cheong, KA; Chrystal, K; Galani, E; Gallagher, C; Harper, PG; Lofts, F; Marx, GM; Steer, CB; Strickland, AH; Thomas, H; Yip, D | 1 |
| Blessing, JA; Brewer, CA; Hanjani, P; Morgan, M; Nagourney, RA | 1 |
| Budman, DR; Calabro, A | 1 |
| Fukui, I; Ohkubo, Y; Tsukamoto, T; Yonese, J | 1 |
| Bhalla, S; Guerreiro, M; Laranjeira, L; Pimentel, FL | 1 |
| Beale, P; Boyer, M; Goh, BC; Lee, HS; Lee, SC; Liang, S; Lim, HL; Millward, M; Soo, RA; Tham, LS; Wang, LZ; Yong, WP | 1 |
| Ash, R; Passaperuma, K; Rodrigues, G; Venkatesan, V; Winquist, E | 1 |
| Asadpour, B; Breuer, C; Buell, U; Eble, MJ; Fischedik, K; Gagel, B; Pinkawa, M; Piroth, M; Reinartz, P; Schmachtenberg, A; Skobel, E; Stanzel, S; Zimny, M | 1 |
| Fakih, MG | 1 |
| Czarnecki, A; Voss, S | 1 |
| Giaccone, G; Voortman, J | 1 |
| Brown, J; Gaikwad, A; Ramondetta, LM; Smith, JA; Wolf, JK | 1 |
| Alloisio, M; Brambilla, G; Campagnoli, E; Cavina, R; Latteri, F; Morenghi, E; Parra, HS; Santoro, A; Torri, W | 1 |
| Capobianco, G; Corazzelli, G; Della Cioppa, P; Marcacci, G; Pinto, A; Russo, F | 1 |
| Aguirre, G; Alexander, F; Avila, E; Calderillo, G; Fuentes, H; Gallardo, D; Oñate-Ocaña, LF; Otero, J; Perez, L; Ramirez, M | 1 |
| Ch'ang, HJ; Chang, JY; Chang, MC; Chen, LT; Cheng, AL; Hsu, C; Lin, JT; Liu, TW; Lu, YS; Shiah, HS; Wang, CC; Wang, HP; Whang-Peng, J | 1 |
| Choi, YH; Chung, HC; Jeung, HC; Jung, JJ; Kim, TS; Kwon, WS; Lee, JO; Park, KH; Rha, SY | 1 |
| Ardizzoni, A; Barbieri, F; Benedetti, G; Berardi, R; Camisa, R; Campanini, N; Cascinu, S; Crinò, L; Franciosi, V; Rindi, G; Rossi, G; Santinelli, A; Scartozzi, M; Silva, RR | 1 |
| Ledermann, JA; Pfisterer, J | 1 |
| Odicino, F; Pasinetti, B; Pecorelli, S; Tisi, G | 1 |
| Krazkowski, M | 1 |
| Battiloro, C; Caponigro, F; Danilo, R; Formato, R; Iaffaioli, RV; Illiano, A; Tortoriello, A | 1 |
| Balañá, C; Buesa, JM; Casado, A; Esteban, E; Fra, J; García Del Muro, J; López-Pousa, A; Losa, R; Martín, J; Martínez-Trufero, J; Maurel, J; Poveda, A; Sierra, M | 1 |
| Eickhoff, A; Eickhoff, JC; Galle, PR; Hartmann, D; Jakobs, R; Martin, W; Möhler, M; Riemann, JF | 1 |
| Ishihara, T; Kato, H; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T | 1 |
| Chan, EW; Lee, AW; Ng, WT; Soong, IS; Tong, M; Wong, DH; Yau, TK; Yeung, RM | 1 |
| Economopoulos, T; Pectasides, D; Pectasides, M; Psyrri, A | 1 |
| Caprio, G; Di Seri, M; Frati, L; Romiti, A; Spinelli, GP; Terzoli, E; Tomao, F; Tomao, S | 1 |
| Berrios, M; Cordova, A; de Aretxabala, X; Gallardo, J; Hepp, J; Leon, J; Maluenda, F; Roa, I; Roa, JC | 1 |
| Bang, S; Choi, JS; Chung, JB; Kim, KS; Kim, YJ; Lee, WJ; Park, BK; Park, JY; Park, SW; Song, SY | 1 |
| Calabrò, F; Mancuso, A; Sternberg, CN | 1 |
| Buesa, JM; Esteban, E; Gión, MO; Losa, R; Sierra, MI | 1 |
| Carr, RA; de Vos, FY; Eskens, FA; Gietema, JA; Groen, HJ; Hoekstra, R; Humerickhouse, RA; Knight, RA; Loos, WJ; Uges, DR; van der Gaast, A | 1 |
| Bonomi, P; Chen, R; Christiansen, NP; McCleod, M; Mintzer, DM; Monberg, MJ; Obasaju, CK; Treat, J; Ye, Z | 1 |
| Al Refai, M; Brunelli, A; Marasco, R; Sabbatini, A; Salati, M; Xiume', F | 1 |
| De Pooter, CM; Kamphuis, JA; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Pauwels, B; Peters, GJ; Vermorken, JB | 1 |
| Buesa, JM; Del Muro, JG; Escudero, P; Esteban, E; Fra, J; Gión, M; Goitia, A; López-Pousa, A; Losa, R; Maurel, J; Nadal, R; Sierra, M; Uña, E | 1 |
| Gibb, RK; Hagemann, A; Mutch, DG; Norris, L; Powell, MA; Rader, JS; Viviano, D; Wright, JD | 1 |
| Aravantinos, G; Bacoyiannis, H; Bafaloukos, D; Fountzilas, G; Gogas, H; Kalofonos, HP; Kosmidis, P; Koutras, A; Makatsoris, T; Markopoulos, C; Onyenadum, A; Tzorakoelefterakis, E | 1 |
| Castelli, E; Casu, M; Conti, G; Cretarola, E; D'Urso, L; Ferrando, U; Francesca, F; Graziano, ME; Hurle, R; Lancini, V; Lissoni, G; Luporini, AC; Morabito, F; Muto, G; Razionale, P; Rossi, R; Simone, M; Sommariva, M | 1 |
| Albers, P | 1 |
| Aieta, M; Burattini, L; De Giorgi, U; Fornarini, G; Lo Re, G; Marangolo, M; Naglieri, E; Rosti, G; Testore, F; Zumaglini, F | 1 |
| Aragoncillo, P; Casado Herraez, A; Díaz-Rubio García, E; Gómez Díaz, R; Moreno Antón, F; Puente Vázquez, J | 1 |
| Boaz, M; Brenner, J; Golan, A; Grisaru, D; Hayat, H; Inbar, M; Levy, T; Menczer, J; Ron, I; Safra, T | 1 |
| Badalamenti, G; Cicero, G; Di Leo, R; Fulfaro, F; Gebbia, N; Gulotta, G; Russo, A; Santangelo, D; Tomasello, G; Valerio, MR; Verderame, F | 1 |
| Bajardi, E; Borsellino, N; Colucci, G; Gebbia, V; Giuliani, F; Maiello, E | 1 |
| Cavallo, D; Colombi, A; Giglio, M; Iavicoli, S; Marinaccio, A; Ursini, CL | 1 |
| Capomolla, E; Carpano, S; Cauchi, C; Conti, F; Foggi, P; Giacinti, L; Giannarelli, D; Leonetti, C; Lopez, M; Paoletti, G; Vici, P | 1 |
| Henson, R; Jiang, J; Lang, M; Maheshwari, S; Mendell, JT; Meng, F; Patel, T; Schmittgen, TD; Wehbe, H | 1 |
| Laurie, SA; Licitra, L | 1 |
| Choi, CW; Kim, AR; Kim, BS; Kim, JS; Kim, YH; Koo, BH; Lee, JB; Oh, SC; Seo, JH; Shin, SW | 1 |
| Girard, N; Mornex, F | 3 |
| Aitini, E; Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rosati, G; Zamagni, D | 1 |
| Antoniou, D; Chaimala, D; Chondrou, E; Dariotaki, F; Karydis, I; Papageorgiou, C; Pavlakou, G; Stathopoulos, GP; Veslemes, M | 1 |
| Mulholland, MW; Newman, EA; Simeone, DM | 1 |
| Ito, Y; Tokudome, N | 1 |
| Chitapanarux, I; Kamnerdsupaphon, P; Lorvidhaya, V; Somwangprasert, A; Srisukho, S; Sukthomya, V; Sumitsawan, S; Tharavichitkul, E; Trakultivakorn, H; Watcharachan, K | 1 |
| Doi, M; Fukuhara, K; Kuwabara, M; Maeda, H; Miyamoto, S; Sumiyoshi, H; Yamasaki, M | 1 |
| Kagaya, T; Kaneko, S; Kato, Y; Sunagozaka, H; Yamashita, T | 1 |
| Allerheiligen, SR; Callies, S; Forgue, ST; Ni, L; Peck, R; Sinha, V; Zhang, L | 1 |
| Baker, CH; Caron, A; Fidler, IJ; Gallick, GE; Nesbit, M; Summy, JM; Trevino, JG; Zhang, F | 1 |
| Bischoff, H; Giesel, FL; Kauczor, HU; Knopp, MV; von Tengg-Kobligk, H; Weber, MA; Zechmann, CM | 1 |
| Kunitoh, H; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Fan, Z; Glazer, RI; Li, X; Liang, K; Lu, Y; Mills, GB; Zeng, X | 1 |
| Bajorin, D; Ben-Porat, L; Bochner, B; Dalbagni, G; Donat, MS; Herr, HW; Russo, P; Sheinfeld, J; Sogani, P | 1 |
| Aschroft, L; Baka, S; Blackhall, F; Buchholz, E; Lorigan, P; Manegold, C; Nagel, S; Schott-von-Römer, K; Thatcher, N | 1 |
| Abbruzzese, JL; Abdelrahim, M; Baker, CH; Safe, S | 1 |
| Abbruzzese, JL; Carr, K; Xiong, HQ | 1 |
| Aisner, J; Guensch, L; Joyce, M; Lutzker, S; Schwartz, S; Sovak, MA; Wu, Y; Zheng, L | 1 |
| Carrato Mena, A; Gallego Plazas, J; Guillén Ponce, C; Maciá Escalante, S; Martínez Ortiz, MJ; Rodríguez Lescure, A | 1 |
| Angouridakis, N; Aravantinos, G; Bafaloukos, D; Bamias, A; Christodoulou, C; Dafni, U; Daniilidis, J; Economopoulos, T; Fountzilas, G; Kalofonos, H; Kalogera-Fountzila, A; Karina, M; Makatsoris, T; Maniadakis, N; Nikolaou, A; Papakostas, P; Pavlidis, N; Stathopoulos, G; Syrigos, K | 1 |
| Smith, IE | 1 |
| Davies, AM; Gandara, DR; Gumerlock, PH; Ho, C; Lara, PN; Mack, P | 1 |
| A-Hon, K; Kamiyama, Y; Komiyama, Y; Satoi, S; Takahashi, H; Takahashi, K; Takai, S; Terakawa, N; Yanagimoto, H | 1 |
| Fukuoka, M; Kashii, T; Kato, T; Matsui, K; Nakagawa, K; Nakanishi, Y; Negoro, S; Sugiura, T; Takada, M; Takada, Y; Uejima, H; Yamamoto, N | 1 |
| Case, AS; Estes, JM; Partridge, EE; Rocconi, RP; Straughn, JM | 1 |
| Campos, S; Duska, LR; Falke, R; Krasner, CN; Lee, H; Matulonis, UA; Penson, RT; Roche, M; Seiden, MV; Smith, LM | 1 |
| Albiol, S; Bellmunt, J; de Olano, AR; Maroto, P; Pujadas, J | 1 |
| Arning, M; Conte, PF; Dogliotti, L; Moore, MJ; Oliver, T; Roberts, JT; Sengeløv, L; von der Maase, H; Zimmermann, A | 1 |
| Frea, B; Gontero, P | 1 |
| Camps, C; Cobo, M; Isla, D; Massuti, B; Rosell, R | 1 |
| Artioli, G; Binato, S; Cartei, G; Ceravolo, R; Cingarlini, S; Dal Bianco, M; De Zorzi, L; Pastorelli, D; Salmaso, F; Zovato, S; Zustovich, F | 1 |
| Airoldi, M; Cattel, L; Delprino, L; Milla, P; Passera, R; Pedani, F | 1 |
| Artioli, G; Binato, S; Cartei, G; Ceravolo, R; Cillo, U; Cingarlini, S; Farinati, F; Marchese, F; Mattiazzi, M; Pastorelli, D; Salmaso, F; Sanavio, C; Zanus, G; Zovato, S; Zustovich, F | 1 |
| Ferrazzi, E; Stievano, L | 1 |
| Danesi, R; Del Tacca, M; Giovannetti, E; Mey, V; Nannizzi, S; Pasqualetti, G | 1 |
| Amadori, D; Cecconetto, L | 1 |
| Morandi, P | 1 |
| Di Stefano, A; Fanfani, F; Lorusso, D; Scambia, G | 1 |
| Arcuri, C; Galligioni, E; Griso, C; Sorio, R | 1 |
| Barzon, L; Cartei, G; Nadai, M; Palù, G; Palumbo, M; Richter, SN; Trestin, A | 1 |
| Barzon, L; Cartei, G; Colombrino, E; Nadai, M; Palù, G; Palumbo, M; Richter, SN; Trestin, A | 1 |
| Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L | 1 |
| Bearz, A; Binato, S; Cartei, G; Ceravolo, R; Cingarlini, S; Colombrino, E; Fantoni, U; Iop, A; Palamidese, A; Sacco, C; Scalone, S | 1 |
| Cellini, F; Cesario, A; Ciresa, M; D'Angelillo, RM; Granone, P; Ramella, S; Trodella, L | 1 |
| Cauchi, C; Gridelli, C; Rinaldi, M | 1 |
| Caciagli, B; Landini, I; Mazzei, T; Mini, E; Nobili, S | 1 |
| Ambroggi, M; Bologna, A; Boni, C; Zanelli, F | 1 |
| Favaretto, AG | 1 |
| Le Chevalier, T; Monnerat, C | 1 |
| Balzano, G; Bonetto, E; Cereda, S; Di Carlo, V; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Viganò, MG; Zerbi, A | 2 |
| Gemma, A; Kawakami, A; Kosaihira, S; Kudoh, S; Li, C; Matsuda, K; Minegishi, Y; Nara, M; Noro, R; Ogawa, N; Seike, M; Seike, Y; Shionoya, A; Sugiyama, Y; Uesaka, H; Yoshimura, A | 1 |
| Adam, R; Bellin, MF; Bralet, MP; Guettier, C; Paule, B | 1 |
| Galmarini, CM | 1 |
| Campo, E; Casado, FJ; Colomer, D; Marcé, S; Molina-Arcas, M; Pastor-Anglada, M; Villamor, N | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, TY; Lee, KH; Oh, DY | 1 |
| Agrawal, S; Kandimalla, ER; Rayburn, ER; Wang, H; Wang, W; Zhang, R | 1 |
| Götz, C; Harlozinska, A; Kartarius, S; Montenarh, M; Touma, R | 1 |
| Amici, S; Bonginelli, P; Bonsignori, M; Carillio, G; De Sio, L; Fanelli, M; Gasparini, G; Gattuso, D; Longo, R; Mariani, L; Massaccesi, C; Morabito, A; Torino, F | 1 |
| Kopchak, KV; Kopchak, VM; Romaniv, IaV | 1 |
| Akbulut, H; Büyükçelik, A; Demirkazik, A; Dinçol, D; Gören, D; Içli, F; Mousa, U; Onur, H; Senler, FC; Utkan, G; Yalçin, B | 1 |
| Fujimoto, S; Hotta, A; Koma, M; Nagai, K; Nagasawa, K | 1 |
| Maekawa, M; Okusaka, T; Yamada, T | 1 |
| Saif, MW | 14 |
| Bruns, C; Heinemann, V; Thoma, M; Wagner, A; Wilkowski, R | 1 |
| Bardenheuer, W; Brueckner, A; Flasshove, M; Hilger, RA; Kleff, V; Moritz, T; Opalka, B; Rattmann, I; Seeber, S; Sorg, UR | 1 |
| Endo, I; Fujii, Y; Ichikawa, Y; Kubota, T; Miura, Y; Shimada, H; Tanaka, K; Togo, S; Ueda, M | 1 |
| Cartei, G; Pavei, P; Zustovich, F | 1 |
| Azzoni, P; Cetto, GL; Genestreti, G; Manno, P; Micciolo, R; Molino, A; Pattaro, C; Santo, A; Sava, T; Terzi, A | 1 |
| Galle, PR; Kanzler, S; Moehler, M; Schadmand-Fischer, S; Schimanski, CC; Sprinzl, MF | 1 |
| Bustam, A; Khoo, KS; Lehnert, M; Manzoor Zaidi, SH; Nair, R; Ngelangel, CA; Reece, WH; Song, S; Srimuninnimit, V | 1 |
| Bonetto, E; Bordonaro, R; Cereda, S; Cordio, S; Di Carlo, V; Galli, L; Johnson, CD; Milandri, C; Passoni, P; Reni, M; Spreafico, A; Staudacher, C | 1 |
| Adorini, L; Daniel, KC; Penna, G | 1 |
| Fan, W; Kraft, AS; Sui, M; Xiong, X | 1 |
| Goldstein, D; Karapetis, C; Steer, CB; Strickland, A; Yip, D | 1 |
| Ishikawa, N; Mizumoto, K; Murakami, M; Nagai, E; Ogura, Y; Ohuchida, K; Tanaka, M; Yamada, D | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Kamatani, N; Kaniwa, N; Kim, SR; Maekawa, K; Minami, H; Morizane, C; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yoshida, T | 1 |
| Eichler, K; Hammerstingl, R; Heller, M; Hochmuth, K; Jacob, U; Scheller, A; Schwarz, W; Vogl, TJ; Zangos, S | 1 |
| Aimpun, P; Jarruwale, P; Tanapat, Y | 1 |
| Hirakawa, K; Ren, J; Yashiro, M; Zhang, X | 1 |
| Aikawa, I; Matsuda, T; Minato, H; Nomura, H; Taniguchi, F; Tsuda, T | 1 |
| Büchler, MW; Friess, H; Kleeff, J; Michalski, C | 1 |
| Dono, K; Hayashi, N; Monden, M; Nagano, H; Nakahira, S; Nakamori, S; Okami, J; Sakon, M; Takahashi, Y; Takeda, S; Tsujie, M; Umeshita, K | 1 |
| Blackstock, AW; Case, LD; Descos, L; Kachnic, LA; Levine, EA; Limentani, SA; Melin, SA; Mishra, G; Mornex, F; Partensky, C; Tepper, JE | 1 |
| Curigliano, G; Danesi, R; De Braud, F; De Cobelli, O; Del Tacca, M; Giovannetti, E; Mey, V; Nannizzi, S; Pece, S; Verweij, F | 1 |
| Horai, T; Kasahara, K; Nishio, M; Ohyanagi, F; Shibata, K; Shirosaki, H; Taguchi, F; Takeda, Y | 1 |
| Funakoshi, A; Furuse, J; Ishii, H; Okusaka, T; Sumii, T; Ueno, H | 1 |
| Neoptolemos, JP; Smith, DB | 1 |
| Haam, S; Huh, YM; Park, SB; Yang, J; Yoon, HG | 1 |
| Chen, G; Geertsen, PF; Gough, J; Gravis, G; Joensuu, H; Kania, M; Lehmann, J; von der Maase, H | 1 |
| Cai, LZ; Fu, YW; Liang, QL; Liu, GX; Pan, DC; Xie, JR; Yang, Q; Yin, ZM | 1 |
| Akerley, W; Kennedy, T; Mega, T; Ready, N; Safran, H; Zaner, K | 1 |
| Apisarnthanarax, N; David, CL; Duvic, M; Kurzrock, R; Talpur, R; Wen, S | 1 |
| Lehmann, J; Retz, M; Schreier, U; Siemer, S; Stöckle, M; Zwergel, U | 1 |
| Ahn, JS; Jung, JY; Kim, HJ; Kim, JH; Kwon, JH; Lee, DH; Lee, JA; Lee, KS; Park, YL; Shin, HC; Song, HH; Zang, DY | 1 |
| Smith, S | 1 |
| Achiwa, H; Bessho, Y; Maeda, H; Miyazaki, M; Muramatsu, H; Niimi, T; Oguri, T; Sato, S; Takano, Y; Ueda, R | 1 |
| Schultze, JL | 1 |
| Ishihara, T; Nakamura, K; Saisho, H; Sudo, K; Yamaguchi, T | 1 |
| Altiok, S; Amador, ML; Bouraoud, N; Cusatis, G; Danenberg, K; Danenberg, PV; Eshleman, J; Hidalgo, M; Hruban, RH; Iacobuzio-Donahue, C; Jimeno, A; Karikari, C; Kulesza, P; Kuramochi, H; Maitra, A; Messersmith, W; Rubio-Viqueira, B; Salimi-Moosavi, H; Shi, C; Singh, S; Tanaka, K; Yeo, C; Zhang, X | 1 |
| Greer, K; McGinness, J | 1 |
| Hendricksen, K; Witjes, JA | 1 |
| Androulakis, N; Aravantinos, G; Boukovinas, J; Fountzilas, G; Georgoulias, V; Kotsakis, A; Papakotoulas, P; Polyzos, A; Potamianou, A; Samonis, G; Stathopoulos, GP; Syrigos, K; Varthalitis, J; Ziras, N | 1 |
| Barrier, R; Davila, E; Ernstoff, MS; Halabi, S; Picus, J; Rini, B; Small, EJ; Stadler, WM | 1 |
| Kaira, K; Mori, M | 1 |
| Hirakawa, K; Inoue, M; Kimura, K; Komatsu, M; Muguruma, K; Nishihara, T; Ohira, M; Sawada, T; Yamada, N; Yamashita, Y | 1 |
| Akel, A; Bachmann, C; Dreischer, P; Eisele, K; Gulbins, E; Huober, J; Kempe, DS; Klarl, BA; Lang, F; Lang, PA; Niemoeller, OM; Sobiesiak, M; Wieder, T | 1 |
| Arnaud, P; Bordier, V; Couturier, J; Decaudin, D; Lantz, O; Marszak, FB; Martin, A; Mathiot, C; Némati, F; Poupon, MF; Santo, Jd; Vincent-Salomon, A | 1 |
| Beuzeboc, P; Chevreau, C; Culine, S; Fizazi, K; Fléchon, A; Geoffrois, L; Gourgou-Bourgade, S; Mottet, N; Théodore, C | 1 |
| Clemens, M; Einsele, H; Fleckenstein, D; Fuchs, M; Gesierich, W; Gieseler, F; Gonnermann, M; Haag, C; Heinemann, V; Heinrich, B; Hinke, A; Holstege, A; Neuhaus, H; Quietzsch, D; Rost, A; Schalhorn, A; Schönekäs, H; Uthgenannt, D; Vehling-Kaiser, U; Wilkowski, R | 1 |
| Boos, J; Gerss, J; Paulussen, M; Stoffregen, C; Vieira Pinheiro, JP; Wagner-Bohn, A | 1 |
| Li, M; Rayburn, ER; Wang, H; Wang, W; Zhang, R; Zhang, Z | 1 |
| de Boeck, G; de Bruijn, EA; Folkerts, G; Guetens, G; Hendriks, JM; van Putte, BP; van Schil, PE | 1 |
| Hoffmann, D; Wildner, O | 1 |
| Bellone, G; Bertetto, O; Buffolino, A; Busso, V; Carbone, A; Emanuelli, G; Novarino, A; Scirelli, T; Smirne, C; Tosetti, L | 1 |
| Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA | 1 |
| Angelov, CA; Cavell, R; El-Mabhouh, AA; Mercer, JR | 1 |
| Cecere, F; Cuello, M; Felip, E; Reguart, N; Rosell, R; Santarpia, M; Taron, M | 1 |
| Brahmer, J; Ettinger, D; Juergens, R | 1 |
| Löhr, M; Müller, H; Nakchbandi, IA; Nakchbandi, W; Singer, MV | 1 |
| Funahashi, H; Manabe, T; Okada, Y; Sawai, H; Takeyama, H; Tanaka, M; Yamamoto, M | 1 |
| Dinney, CP; Highshaw, R; Kamat, AM; Kassouf, W; Nelkin, GM | 1 |
| Mountzios, G; Soria, JC | 1 |
| Li, L; Liu, L; Wang, XW; Yu, XJ; Zhang, WD; Zhang, X | 1 |
| Guo, YL; Lian, HY; Luo, H; Qiu, F; Xiong, JP; Zhang, L; Zhong, LX | 1 |
| Huang, HB; Lin, PL; Lin, ZC; Liu, T; Zhong, JT | 1 |
| Augé, JM; Ayuso, C; Cajal, R; Conill, C; Fernández-Cruz, L; Gallego, R; Gascón, P; Ginès, A; Marmol, M; Martin-Richard, M; Maurel, J; Miquel, R; Nadal, C; Navarro, S; Petriz, L; Sánchez, M | 1 |
| Bepler, G; Cantor, A; Gautam, A; Kusmartseva, I; Sharma, A; Sharma, S; Simon, G | 1 |
| Bentley, J; du Bois, A; Eisenhauer, E; Emerich, J; Hirte, H; Jackisch, C; Kimmig, R; Kuhn, W; Lacave, AJ; Le, T; Lück, HJ; Olbricht, S; Pfisterer, J; Plante, M; Rochon, J; Stähle, A; Stuart, G; Vergote, I; Wagner, U; Zimmermann, AH | 1 |
| Billemont, B; Bourry, E; Brocheriou, I; Casimir, N; Deray, G; Isnard-Bagnis, C; Izzedine, H; Karie, S; Launay-Vacher, V; Mercadal, L; Rixe, O; Saeb, S; Tostivint, I | 1 |
| Androulakis, N; Boukovinas, I; Georgoulias, V; Gioulmbasanis, I; Kalykaki, A; Kotsakis, A; Mavroudis, D; Papakotoulas, P; Polyzos, A; Vamvakas, L; Xenidis, N; Ziras, N | 1 |
| Nakano, T | 1 |
| Nagaoka, S; Okabe, Y; Ono, N; Saito, F; Sata, M; Suga, H; Toyonaga, A; Tsuruta, O | 1 |
| Fujimori, N; Funakoshi, A; Horikawa, Y; Nakamura, T; Senju, T; Sumii, T | 1 |
| Baba, Y; Ishikawa, N; Ishikawa, T; Kamimura, T; Mafune, Y; Mizuno, K; Ohta, H; Seki, K; Togashi, T; Ushiki, T; Watanabe, K; Yoshida, T | 1 |
| Machida, H; Suzuki, K; Toda, H; Ushida, S | 1 |
| Geissler, M; Harder, J; Henss, H; Kummer, O; Lohrmann, C; Opitz, O; Otto, F; Riecken, B; Usadel, H | 1 |
| Gazitt, Y; Rothenberg, ML; Shaughnessy, P | 1 |
| Griep, C; Lelie, B; Pinson, PJ; Sanders, WH | 1 |
| Bechrakis, NE; Foerster, MH; Keilholz, U; Martus, P; Schmidt-Hieber, M; Schmittel, A; Schuster, R; Siehl, JM; Thiel, E | 1 |
| Jackisch, C | 1 |
| Tu, LF; Wang, LH; Wang, XF; Zhou, JY | 1 |
| Lehoczky, O; Pulay, T | 1 |
| Calogero, R; Cambieri, A; Ceppi, P; Danenberg, KD; Danenberg, PV; Novello, S; Papotti, M; Rapa, I; Saviozzi, S; Scagliotti, GV; Selvaggi, G; Volante, M | 1 |
| Henson, R; Lang, M; Meng, F; Patel, T; Wehbe, H | 1 |
| Abou-Alfa, GK; Ackerman, J; De Jager, RL; Eckhardt, SG; Feit, K; Harker, G; Hurwitz, H; Letourneau, R; Modiano, M; O'Reilly, EM; Tchekmedyian, NS | 1 |
| Aoki, H; Arai, Y; Endoh, M; Ishidoya, S; Ito, A; Shimazui, T | 1 |
| Fangusaro, J; Finlay, J; Rook, J; Rosser, T | 1 |
| Buscail, L; Cordelier, P; Drocourt, D; Ghénassia, L; Lulka, H; Pradayrol, L; Pyronnet, S; Souque, A; Tiraby, G; Vernejoul, F | 1 |
| Delorme, S; Hauschild, A; Kaatz, M; Neuber, K; Pföhler, C; Reinhold, U; Rittgen, W; Schadendorf, D; Spieth, K; Thoelke, A; Tilgen, W; Ugurel, S; Ulrich, J | 1 |
| Boeck, S; Fahrig, R; Hänel, M; Heinemann, V; Heinrich, JC; Krupitza, G; Liebert, A; Praha, C; Quietzsch, D; Schmid, RM; Sonntag, D | 1 |
| Helke, C; Hoschke, B; May, M | 1 |
| Gemba, K; Harita, S; Hiraki, S; Kishino, D; Kiura, K; Kozuki, T; Segawa, Y; Shibayama, T; Tabata, M; Tada, A; Tada, S; Takigawa, N; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Bonassi, S; Cellini, F; Cesario, A; Ciresa, M; Corbo, GM; Cortesi, E; D'Angelillo, RM; De Marinis, F; Granone, P; Margaritora, S; Migliorino, MR; Nelli, F; Porziella, V; Ramella, S; Russo, P; Trodella, L; Valente, S | 1 |
| Cipolat, M; Colantonio, I; Di Costanzo, G; Fea, E; Garrone, O; Gasco, M; Granetto, C; Merlano, M; Numico, G; Occelli, M; Pelissero, A; Russi, EG; Sorrentino, R; Taglianti, RV; Vitiello, R | 1 |
| Dagorn, JC; Giroux, V; Iovanna, J | 1 |
| Bodo, J; Duraj, J; Rauko, P; Sedlak, J; Sulikova, M | 1 |
| Goldberg, G; Hopkins, U; Rajdev, L; Sparano, JA | 1 |
| Balzarotti, M; Bramanti, S; Castagna, L; Magagnoli, M; Mazza, R; Nozza, A; Russo, F; Santoro, A; Sarina, B; Siracusano, L; Timofeeva, I; Todisco, E | 1 |
| Airoldi, M; Cattel, L; Delprino, L; Micari, C; Passera, R; Pedani, F | 1 |
| Boronovskaia, LE; Korman, DB; Maslova, IA | 1 |
| Hamada, H; Ikeda, T; Miyauchi, Y; Ochi, T; Ozawa, A; Shimamoto, K; Sugawara, T; Tanji, N; Toshino, A; Yanagaki, T; Yanagihara, Y; Yokoyama, M | 1 |
| Huo, D; Jin, JO; Lehmann, J; Stadler, WM; Steinberg, G; Stöckle, M; Taxy, J; Vogelzang, NJ | 1 |
| Blankenburg, T; Chemaissani, A; Guetz, S; Laier-Groeneveld, G; Reck, M; Schneider, CP; Schuette, W; Virchow, JC; von Weikersthal, LF | 1 |
| Campodonico, F; Canepa, G; Capponi, G; Fontana, V; Maffezzini, M | 1 |
| Boselli, S; Catania, C; Curigliano, G; de Braud, F; De Pas, T; Milani, A; Noberasco, C; Orlando, L; Putzu, C; Sabrina, B; Spaggiari, L | 1 |
| Basso, U; Brunello, A; De Salvo, GL; Fratino, L; Ghiotto, C; Koussis, H; Lonardi, S; Lumachi, F; Monfardini, S; Pasetto, LM | 1 |
| Behrens, R; Buechner-Steudel, P; Fleig, WE; Kleber, G; Kuss, O; Lindig, U; Moehler, M; Schmalenberg, H; Wagner, AD; Wein, A | 1 |
| Beinert, T; Binder, D; Grah, C; Schäper, C; Schweisfurth, H; Siebert, G; Suttorp, N; Temmesfeld-Wollbrück, B | 1 |
| Chatani, K; Kametani, T; Masuda, S; Shibata, K; Takase, M | 1 |
| Kondo, T; Matsuo, R; Moon, Y; Ohkohchi, N; Ohshiro, Y; Takeshima, T; Todoroki, T; Yamamoto, Y | 1 |
| Boku, N; Fukutomi, A; Yoshino, T | 1 |
| Nishi, R; Ueda, T; Yamauchi, T | 1 |
| Appleman, LJ; Clark, JW; Cusack, J; Eder, JP; Enzinger, PC; Fidias, P; Fishman, M; Kashala, O; Lynch, T; Ryan, DP; Supko, JG; Zhu, AX | 1 |
| Antón, A; Cuevas, C; Hernández-Vargas, H; Julián-Tendero, M; Moreno-Bueno, G; Palacios, J; Ríos, MJ; Rodríguez-Pinilla, SM; Sánchez-Rovira, P | 1 |
| Fujioka, H; Hatano, K; Honda, M; Matsumiya, K; Satoh, M; Takada, T; Tsujimoto, Y | 1 |
| Furukawa, K; Ito, T; Kitsukawa, S; Noda, K; Saito, M; Samejimai, T | 1 |
| Eckel, F; Schmid, RM; Schneider, G | 1 |
| Belani, CP; Clark, RH; Dakhil, S; Desch, CE; Monberg, MJ; Obasaju, CK; Rooney, DK; Waterhouse, DM; Ye, Z | 1 |
| Bozec, L; Campone, M; Diéras, V; Espié, M; Fumoleau, P; Kayitalire, L; Petit, T; Pouillart, P; Pujade-Lauraine, E; Serin, D; Viens, P | 1 |
| Amarantidis, K; Christophillakis, C; Georgoulias, V; Giassas, S; Kakolyris, S; Kalbakis, K; Malamos, N; Mavroudis, D; Mavrousis, D; Potamianou, A; Tselepatiotis, E; Vamvakas, L | 1 |
| Baum, U; Brunner, TB; Grabenbauer, GG; Lambrecht, U; Sauer, R | 1 |
| Altorki, NK; Bonomi, P; Fayyad, R; Hariharan, S; Hart, LL; Keresztes, RS; Lilenbaum, R; Morrison, ME; Socinski, MA | 1 |
| Chow, W; Doroshow, J; Frankel, P; Gandara, D; Juhasz, A; Lenz, HJ; Leong, L; Lim, D; Margolin, K; Morgan, R; Newman, E; Shibata, S; Somlo, G; Synold, T; Yen, Y | 1 |
| Clenton, SJ; Ferguson, CJ; Kirkbride, P | 1 |
| Bamias, A; Bozas, G; Dimopoulos, MA; Efstathiou, E; Gika, D; Koutsoukou, V; Papadimitriou, CA | 1 |
| Chen, G; Chen, H; Friess, H; Greenblatt, DY; Guo, J; Kleeff, J; Leung, PS; Liao, Q; Shen, S; Zhao, Y | 1 |
| Giaccone, G; Honeywell, R; Laan, AC; Peters, GJ; Ruiter, R; Strocchi, E; van Groeningen, CJ | 2 |
| Bains, MS; Carlson, DL; Halpern, NA; Hmidi, A; Maki, RG; Pastores, SM; Voigt, LP | 1 |
| Li, JH; Luo, XG | 1 |
| Adema, AD; Albertoni, F; Floor, K; Hubeek, I; Kaspers, GJ; Peters, GJ; Zuurbier, L | 1 |
| Bergman, AM; Eijk, PP; Peters, GJ; Smid, K; van den Ijssel, P; van Haperen, VW; Veerman, G; Ylstra, B | 1 |
| Franken, NA; Haveman, J; Kreder, NC; Loves, WJ; Peters, GJ; Sigmond, J; van Bree, C | 1 |
| Atkins, JN; Green, MR; Herndon, JE; Lee, ME; Mauer, A; Rocha-Lima, CM; Vokes, E | 1 |
| Chen, G; Guo, JC; Jiang, H; Niu, BZ; Wu, WW; Zhang, LY; Zhao, YP | 1 |
| Aigner, T; Hueber, AJ; Kalden, JR; Kallert, S; Rech, J; Rösler, W; Schulze-Koops, H | 1 |
| Bleeker, G; Henson, R; Meng, F; Naus, PJ; Patel, T; Wehbe, H | 1 |
| Buesa, JM; Capellan, M; Corral, N; de Sande, JL; Esteban, E; Estrada, E; Fernandez, JL; Fernández, Y; Fra, J; Jimenez, P; Lacave, AJ; Luque, M; Mareque, B; Muñiz, I; Vieitez, JM; Villanueva, N | 1 |
| Barceló, R; Díaz-Aguirregoitia, J; Fernández, R; López-Vivanco, G; Mañé, JM; Muñoz, A; Saiz, M | 1 |
| Bianco, M; Buzzi, F; Cioffi, R; Comella, P; De Cataldis, G; Filippelli, G; Frasci, G; Gambardella, A; Ghiani, M; Maiorino, L; Mancarella, S; Massidda, B; Masullo, P; Milia, V; Natale, D; Palmeri, S; Putzu, C; Roselli, M | 1 |
| Alcalde García, J; Alés Díaz, I; Benavides Orgaz, M; Bretón García, JJ; Carabantes Ocón, F; Cobo Dols, M; Gil Calle, S; Gutiérrez Calderón, V; Montesa Pino, A; Villar Chamorro, E | 1 |
| Albanell, J; Carles, J; Doménech, M; Fabregat, X; Font, A; Gallén, M; Mesía, C; Nogué, M; Suárez, C; Suárez, M; Tusquets, I | 1 |
| Bauters, F; Bouabdallah, R; Chouaki, N; Coiffier, B; Depil, S; Dumontet, C; Jourdan, E; Marit, G; Morschhauser, F; Sebban, C; Solal-Céligny, P; Wetterwald, M | 1 |
| Georgoulias, V; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P | 1 |
| André, M; Bayle, S; Bideau, K; Labat, JP; Lagarde, N; Metges, JP; Robaszkiewicz, M | 1 |
| Dobbelstein, M; Kranz, D | 1 |
| Fok, JY; Kumar, R; Manavathi, B; Mann, AP; Mehta, K; Verma, A; Wang, H | 1 |
| Abbruzzese, J; Ali, IF; Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
| Ariyoshi, Y; Fukuoka, M; Kubota, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Ohashi, Y; Ohe, Y; Saijo, N; Tamura, T | 1 |
| Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB | 1 |
| Ilanchadran, A; Tan, TY; Tay, SK | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Guha, S; Janjan, NA; Krishnan, S; Palla, S; Rana, V; Varadhachary, G; Wolff, RA | 1 |
| Boswell, JS; Flam, MS; Tashjian, DN; Tschang, TP | 1 |
| Karapetis, CS; Keefe, DM; Koczwara, B; Kotasek, D; Moldovan, S; Olver, IN; Parnis, FX; Patterson, WK; Pittman, KB; Price, TJ; Yeend, SJ | 1 |
| Furuya, T; Iizuka, N; Kawauchi, S; Oga, A; Oka, M; Sasaki, K; Toshimitsu, H; Yamamoto, K | 1 |
| Bartel, P; Ecke, TH; Koch, S; Ruttloff, J; Theissig, F | 1 |
| Aleknavicius, E; Asadauskiene, J; Jankevicius, F; Zelviene, TP | 1 |
| Brasiūnas, V; Brasiūniene, B; Juozaityte, E | 1 |
| Kamiyama, Y; Kano, Y; Kodama, T; Kondo, T; Mori, K | 1 |
| Ameshima, S; Chiba, Y; Demura, Y; Ishizaki, T; Miyamori, I; Nakanishi, M; Umeda, Y | 1 |
| Bleichrodt, RP; Boerman, OC; Goldenberg, DM; Koppe, MJ; Oyen, WJ; Verhofstad, AA | 1 |
| Owen, OG | 1 |
| Aikou, T; Kitazono, M; Kubo, F; Maemura, K; Noma, H; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Hibi, T; Higuchi, H; Hisamatsu, T; Iizuka, H; Iwasaki, E; Izumiya, M; Masaoka, T; Nagata, H; Nishizawa, T; Suzuki, H; Takaishi, H; Yamagishi, Y | 1 |
| Comella, G; Danova, M; Ferraú, F; Lorusso, V; Massidda, B; Nortilli, R; Palmeri, L; Palmeri, S; Porta, C; Vaglica, M | 1 |
| Guo, SS; Liang, HL; Wang, Y; Xie, DR; Yang, Q | 1 |
| Aitini, E; Bajetta, E; Bidoli, P; Cortinovis, D; Cullurà, D; Formisano, B; Isa, L; Mancin, M; Mariani, L; Nova, P; Pari, F; Zilembo, N | 1 |
| Schmid, RM | 1 |
| Ashley, SW; Liau, SS; Whang, EE | 1 |
| Buchsbaum, DJ; DeRosier, LC; Huang, ZQ; Sellers, JC; Vickers, SM | 1 |
| Beijnen, JH; Hillebrand, MJ; Jansen, RS; Perkins, EJ; Rosing, H; Schellens, JH; Veltkamp, SA; Wickremsinhe, ER | 1 |
| Dranitsaris, G; Gascon, P; Lau, C; Ludwig, H; Van Belle, S; Verma, S; Vincent, M | 1 |
| Cai, J; Huang, M; Liu, J; Wang, L; Wu, X; Xu, N | 1 |
| Admirand, JH; Bueso-Ramos, CE; Ford, RJ; Jiang, L; Moran, C | 1 |
| Arcara, C; Badalamenti, G; Caraceni, A; Cicero, G; Fulfaro, F; Gebbia, N; Intrivici, C | 1 |
| Dono, K; Marubashi, S; Miyamoto, A; Monden, M; Nagano, H; Nakahira, S; Nakamori, S; Okami, J; Sakon, M; Takahashi, Y; Takeda, Y; Takemasa, I; Tsujie, M; Umeshita, K; Yamasaki, M; Yoshioka, S | 1 |
| DeVita, VT | 1 |
| Eguchi, K; Hada, E; Izumi, Y; Kawamura, M; Kobayashi, K; Koike, T; Sakaguchi, H; Yamato, Y | 1 |
| Fujita, N; Horaguchi, J; Ito, K; Kobayashi, G; Noda, Y; Takasawa, O | 1 |
| Lee, AW; Ng, WT; Pang, ES; Soong, IS; Wong, DH; Yau, TK; Yeung, RM | 1 |
| El-Rayes, BF; Gadgeel, S; Lorusso, P; Manza, S; Philip, PA; Shields, AF | 1 |
| Bianco, C; Ciardiello, F; Cionini, L; Danesi, R; de Liguoro, M; Del Tacca, M; Eckhardt, G; Giovannetti, E; Mey, V; Nannizzi, S; Pasqualetti, F; Raben, D; Ricciardi, S; Tortora, G; Troiani, T | 1 |
| Aoyagi, Y; Enomoto, T; Nakajima, M; Noguchi, M; Oda, T; Ohkohchi, N; Satake, M; Sugiura, S | 1 |
| Chinnaiyan, AM; Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Li, X; Lopez, CA; Nyati, MK; Tomlins, SA; Varambally, S | 1 |
| Ahmad, SA; Firdaus, I; Howington, JA; James, L; Jazieh, AR; Lowy, AM; Redmond, K; Reed, MF; Rose, P; Roychowdhury, D; Safa, M; Sussman, JJ | 1 |
| Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H | 1 |
| Chan, M; Feller, E; Gold, R; Mega, A; Squire, S | 1 |
| Dragovich, T; Hage, G; Hamilton, M; Huberman, M; Nadler, P; Patnaik, A; Rowinsky, EK; Von Hoff, DD; Wolf, J; Wood, D | 1 |
| Balcke, P; Castellano, D; Davidson, N; Dittrich, C; Dobrowolski, F; Esteve, AA; Friess, H; Hawkins, R; Herzog, P; Hossfeld, DK; Katz, F; Kleeff, J; Kovar, A; Langrehr, JM; Neyns, B; Niedergethmann, M; Nippgen, J; Oettle, H; Piedbois, P; Raedle, J; Scheithauer, W; Stöger, H; Tempia-Caliera, AA; van Belle, S; Vermorken, J | 1 |
| D'Andrea, MR; Falci, C; Monfardini, S; Pasetto, LM | 1 |
| Leoni, V; Rocci, L; Santini, D; Tonini, G; Vincenzi, B; Virzí, V | 1 |
| Bang, S; Chung, JB; Jeon, TJ; Kim, MH; Park, JY; Park, SW; Song, SY | 1 |
| Aglianò, AM; Frati, L; Gandini, O; Gazzaniga, P; Gianni, W; Gradilone, A; Morrone, S; Scarpa, S; Silvestri, I | 1 |
| Aerts, R; De Boeck, G; De Bruijn, EA; Dumez, H; Guetens, G; Maes, RA; Martens, M; Selleslach, J; van Oosterom, AT | 1 |
| Alberola, V; De las Peñas, R; Gupta, J; Ramírez, JL; Salazar, MF; Sánchez, JM; Sanchez-Ronco, M; Taron, M | 1 |
| Becht, C; Culine, S; de Champfleur, NM; Pouessel, D; Vieillot, S | 1 |
| Ammerpohl, O; Griep, U; Grutzmann, R; Janssen, O; Kalthoff, H; Kloppel, G; Pilarsky, C; Saeger, HD; Schniewind, B; Sipos, B; Trauzold, A | 1 |
| Ciruelos, E; Colomer, R; Cortés-Funes, H; Hornedo, J; Llombart-Cussac, A; Mayordomo, JI; Ojeda, B; Rifà, J; Tusquets, I; Vicente, D | 1 |
| Alés, I; Baena, V; Benavides, M; Bretón, JJ; Carabante, F; Cobo, M; Contreras, J; Del Rosal, JM; Delgado, R; Fuentes, C; García, E; Gil, S; Herruzo, I; Moreno, P; Ruiz, JL; Villar, E | 1 |
| Cengel, KA; Plastaras, JP | 1 |
| Arumugam, T; Logsdon, CD; Ramachandran, V | 1 |
| Doi, E; Doi, R; Fukushima, M; Hatano, E; Ikai, I; Ishiguro, H; Kiba, T; Kitano, T; Matsumoto, S; Mori, A; Nishimura, T; Teramukai, S; Yanagihara, K; Yasumi, S; Yoshikawa, K | 1 |
| Siefker-Radtke, A | 2 |
| Kasman, L; Lu, P; Voelkel-Johnson, C | 1 |
| Earle, CC; Krzyzanowska, MK; Kuntz, KM; Weeks, JC | 1 |
| Neifeld, JP | 1 |
| Akbulut, H; Büyükcelik, A; Cay, F; Demirkazik, A; Dincol, D; Icli, F; Isikdogan, A; Onur, H; Utkan, G; Yalcin, B | 1 |
| Furuse, J; Hasegawa, R; Ishii, H; Kamatani, N; Kaniwa, N; Kikura-Hanajiri, R; Kim, SR; Maekawa, K; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yoshida, T | 1 |
| Fischer, JR; Lahm, H; Manegold, C; Ohnmacht, U; Rieger, N; Stoffregen, C; Zemaitis, M | 1 |
| Brade, A; Brezden-Masley, C; Brierley, J; Cummings, B; Gallinger, S; Hedley, D; Maclean, M; Moore, M; Oza, A; Pond, GR; Townsley, C; Wong, S | 1 |
| Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H | 1 |
| Ozawa, A; Shimamoto, K; Shirato, A; Tanji, N; Yokoyama, M | 1 |
| Hoshi, S; Kobayashi, T; Muto, A; Ono, K; Sasaki, M; Saso, S; Sugano, O; Suzuki, K; Tukigi, M | 1 |
| Cheng, WW; Cho, WC; Law, SC; Ma, VW; Ngan, RK; Podust, VN; Yip, C; Yip, TT; Yip, V; Yiu, HH | 1 |
| Arkus, N; Arnold, NB; Gunn, J; Korc, M | 1 |
| Bajorin, DF; Boyle, MG; Galsky, MD; Iasonos, A; Mironov, S; Scattergood, J | 1 |
| Boye, K; Bras-Gonçalves, RA; Chapelier, A; de Cremoux, P; Defrance, R; Judde, JG; Livartowski, A; Poupon, MF; Rebucci, M; Tran-Perennou, C; Vogt, N | 1 |
| Amadori, D; Bertetto, O; Bono, A; Cartenì, G; Dogliotti, L; Marini, L; Martoni, A; Onat, H; Siena, S | 1 |
| Bowerman, NA; Fu, YX; Kranz, DM; Rowley, DA; Salama, JK; Schietinger, A; Schmidt, H; Schreiber, H; Spiotto, MT; Weichselbaum, RR; Yu, P; Zhang, B | 1 |
| Baba, H; Karasawa, K; Kurata, M; Okamoto, A; Tsuruta, K | 1 |
| Fujiwara, T; Gochi, A; Kagawa, S; Tanaka, N; Teraishi, F; Uno, F | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| de Gelder, V; De Ridder, L; De Vos, F; Lambert, B; Slegers, G; Thierens, H; Van de Wiele, C | 1 |
| Meerum Terwogt, JM; Rodenhuis, S; Schellens, JH; van Boven, HH; van den Heuvel, MM; Veltkamp, SA | 1 |
| Izawa, T; Kohgo, Y; Koizumi, K; Minoguchi, M; Mizukami, Y; Nakamura, K; Nakano, Y; Nishikawa, T; Okumura, T; Tanno, S | 1 |
| Bechstein, WO; Burkart, C; Doerken, B; Fahlke, J; Gellert, K; Gutberlet, K; Kettner, E; Langrehr, J; Neuhaus, P; Niedergethmann, M; Oettle, H; Post, S; Ridwelski, K; Riess, H; Roll, L; Schmalenberg, H; Schmidt-Wolf, I; Schramm, H; Weigang-Koehler, K; Zuelke, C | 1 |
| Benson, AB | 1 |
| Balzarotti, M; Castagna, L; Magagnoli, M; Michieli, M; Morenghi, E; Nozza, A; Pinotti, G; Santoro, A; Sarina, B; Siracusano, L; Spina, M; Tirelli, U | 1 |
| Boeck, S; Depenbrock, H; Fuchs, M; Heinemann, V; Kettner, E; Köhne, CH; Kröning, H; Lordick, F; Quietzsch, D; Steinmetz, T; Stötzer, O; Trojan, J; Weigang-Köhler, K; Zeuzem, S | 1 |
| Albiol, S; Baselga, J; Bellmunt, J; Carles, J; Cecere, FL; Cuello, M; de la Cruz, JJ; Gallardo, E; Guillem, V; Mendez, P; Paz-Ares, L; Rosell, R; Taron, M | 1 |
| Ajiki, T; Fujimori, T; Fujita, T; Hirata, K; Hori, H; Horiuchi, H; Kamigaki, T; Kuroda, Y; Mita, Y; Okazaki, T | 1 |
| Caterino, M; Cecere, FL; Ceribelli, A; Cognetti, F; Facciolo, F; Gelibter, AJ; Milella, M; Mirri, A; Pino, MS | 1 |
| Imamura, F; Uchida, J; Ueno, K; Yoshimura, M | 1 |
| Bornheim, L; Chen, J; Clary, DO; Karnitz, LM; Kim, YD; Matthews, DJ; Miller, N; Murray, L; Robertson, S; Tadano, M; Tai, A; Wagner, JM; Yakes, FM | 1 |
| Buettner, H; Kaur, H; Marks, RS; Salomao, DR | 1 |
| Furukawa, T; Hata, K; Hirai, I; Kawago, M; Kokawa, Y; Nakamura, R; Ohta, F; Okamura, Y; Oura, S; Tamaki, T; Tanino, H; Yoshimasu, T | 1 |
| d'Amato, TA; Huang, W; Landreneau, RJ; Luketich, JD; Mechetner, E; Parker, R; Ricketts, W; Yu, IR | 1 |
| Johnson, DH; Langer, C; Li, S; Rapoport, BL; Schiller, J; Tester, W | 1 |
| Benninger-Döring, G; Boos, J; Ripkens-Reinhard, A; Wagner-Bohn, A | 1 |
| Boeck, S; Heinemann, V; Holdenrieder, S; Schulz, C; Stieber, P; Weckbach, S | 1 |
| Dietrich, M; Goel, A; Grossbard, ML; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Rodriguez, T | 1 |
| Calvagno, MG; Castelli, F; Celia, C; Cosco, D; Doldo, P; Frest, M; Iannone, M; Paolino, D | 1 |
| Furuse, J; Ishii, H; Nakachi, K; Suzuki, E; Yoshino, M | 1 |
| Amenedo, M; Antón, LM; Casal, J; Castellanos, J; Constenla, M; González-Ageitos, A; López-López, R; Mel, JR; Rodríguez-López, R; Tisaire, JL | 1 |
| Konduri, S; Schwarz, RE | 1 |
| Alcaide, J; Alés, I; Benavides, M; Bretón, JJ; Carabantes, F; Cobo, M; Durán, G; Gil, S; Gutiérrez, V; Martínez, J; Villar, E | 1 |
| Banerjee, S; Chiritescu, G; Dahrouge, S; Stewart, DJ; Tomiak, EM | 1 |
| Arnold, S; Doyle, A; Garofalo, MC; Hanna, N; Kataria, R; Mohiuddin, M; Regine, WF; Sims, J; Tan, M | 1 |
| Brames, MJ; Einhorn, LH; Juliar, B; Williams, SD | 1 |
| Barsanti, G; Danesi, R; Del Tacca, M; Giovannetti, E; Loni, L; Mey, V; Nannizzi, S; Ricciardi, S; Savarino, G | 1 |
| Arkenau, HT; Chau, I; Chong, G; Cunningham, D; Horwich, A; Matutes, E; Norman, A; Sirohi, B; Watkins, D; Wotherspoon, A | 1 |
| Avallone, A; Barbato, E; Comella, P; Condemi, G; De Cataldis, G; Franco, L; Gambardella, A; Massidda, B; Putzu, C | 1 |
| Araya, T; Fujimura, M; Hara, J; Kasahara, K; Kimura, H; Kita, T; Nakao, S; Nishi, K; Nobata, K; Oribe, Y; Shibata, K; Shirasaki, H; Sone, T; Yoshimi, Y | 1 |
| Araya, T; Fujimura, M; Kasahara, K; Nakao, S; Sone, T; Tambo, Y; Tamori, S | 1 |
| Adelstein, D; Davis, M; Kalmadi, S; McNeill, G; Mekhail, T; Peereboom, D | 1 |
| Cho, H; Conaway, M; Hampton, G; Havaleshko, DM; Lee, JK; Owens, CR; Theodorescu, D | 1 |
| Bialewski, J; Hannun, YA; Jazwinski, SM; Jiang, JC; Ogretmen, B; Ponnusamy, S; Rossi, MJ; Senkal, CE; Sinha, D | 1 |
| Honma, S; Itoh, K; Kamiyama, Y; Mine, T; Mizoguchi, J; Nakahara, K; Oka, M; Satoi, S; Takahashi, K; Takai, S; Tanaka, M; Terakawa, N; Yamada, A; Yamamoto, K; Yanagimoto, H | 1 |
| Hruska, D; Koschel, G; Manegold, C; Mezger, J; Pilz, LR; Scott-von-Römer, K | 1 |
| Barbone, D; Bertino, P; Busacca, S; Favoni, R; Gaudino, G; Germano, S; Mutti, L; Pinato, S; Porta, C; Tassi, G | 1 |
| Astoul, P; Auquier, P; Barlési, F; Barrau, K; Doddoli, C; Morange, S; Thirion, X; Thomas, P | 1 |
| Beddy, P; Connolly, RM; Doherty, CP; O'Byrne, K | 1 |
| Anile, M; Coloni, GF; De Giacomo, T; Diso, D; Ibrahim, M; Liparulo, V; Rolla, M; Venuta, F | 1 |
| Chow, W; Chu, D; Doroshow, JH; Frankel, P; Koczywas, M; Leong, L; Lim, D; Lin, P; Margolin, K; Morgan, RJ; Paz, B; Schwarz, RE; Shibata, S; Somlo, G; Stalter, S; Synold, TW; Tetef, M; Twardowski, P; Wagman, L; Xi, B; Yen, Y | 1 |
| Altieri, V; Autorino, R; Benincasa, G; D'Armiento, M; De Placido, S; Di Lorenzo, G; Giordano, A; Giuliano, M; Morelli, E; Napodano, G; Russo, A | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK | 1 |
| Bergman, AM; Hoebe, EK; Kamphuis, JA; Laan, AC; Peters, GJ; Sigmond, J | 1 |
| Eckel, F; Schmid, RM | 2 |
| Antonia, S; Chiappori, A; de Lima Lopes, G; Haura, E; Langevin, M; Lush, R; Rocha-Lima, CM; Simon, G; Sullivan, D | 1 |
| Adrover, E; Balil, A; Calvo, L; Carrasco, E; Casado, A; Escudero, MJ; García-Mata, J; García-Saenz, JA; Guillem, V; Jara, C; Mahillo, E; Martín, M; Mel, JR; Morales-Vasquez, F; Muñoz, M; Ribelles, N; Rodríguez, CA; Ruiz, A; Salas, F; Soto, C | 1 |
| Esquerdo, G; Gómez-Aldaraví, L; Maestu, I; Muñoz, J; Romero, R; Torregrosa, MD; Yubero, A | 1 |
| Asnacios, A; Boige, V; Bonyhay, L; de Baere, T; Ducreux, M; Hannoun, L; Louafi, S; Mansourbakht, T; Poynard, T; Taïeb, J | 1 |
| Alvarez, H; Beaty, R; Bedja, D; Dhara, S; Feldmann, G; Fendrich, V; Gabrielson, KL; Iacobuzio-Donahue, C; Jimeno, A; Karikari, C; Maitra, A; Matsui, W; Mullendore, M | 1 |
| Magee, CC; Mendez, GP; Rennke, HG; Schlondorff, JS | 1 |
| De Grève, J; De Mey, J; Fontaine, C; Meysman, M; Neyns, B; Schallier, D; Steene, JV | 1 |
| Courtellemont, C; Esposito, L; Guitard, J; Kamar, N; Mehrenberger, M; Modesto, A; Pontier, S; Ribes, D; Rostaing, L | 1 |
| Armour, EP; Feldmann, G; Herman, J; Karikari, CA; Maitra, A; Pinilla, C; Rakheja, D; Reed, JC; Roy, I; Tryggestad, E; Welsh, K; Wong, J | 1 |
| Habuchi, T; Inoue, T; Kakinuma, H; Kanzaki, M; Kumazawa, T; Narita, S; Saito, M; Tsuchiya, N; Yuasa, T | 1 |
| Zalatnai, A | 1 |
| Cusimano, L; Li, M; Saif, MW; Sellers, S; Wang, H; Wang, W; Zhang, R | 1 |
| Altug, S; Chu, DT; Damyanov, D; Kim, SW; Krishnamurthy, S; Kuo, HP; Ozacar, R; Reece, WH; Salajka, F; Wang, L | 1 |
| Atmatzidis, K; Chrysogelou, E; Harlaftis, N; Livanis, J; Moschidis, A; Moschidis, E; Mourelatos, D; Papageorgiou, A; Tsalis, K; Tsavdaridis, D | 1 |
| Lahans, T | 1 |
| Barbera, S; Barone, C; Bruzzi, P; Buosi, R; Crinò, L; Dongiovanni, V; Fioretti, M; Garetto, L; Masotti, A; Mazzanti, P; Michetti, G; Novello, S; Scagliotti, GV; Selvaggi, G; Spatafora, M | 1 |
| Cheng, AL; Hsu, CH; Huang, CY; Huang, KH; Keng, HY; Lin, CC; Pu, YS; Tsai, YC | 1 |
| Dalgleish, A; Hill, M; Lofts, F; Maraveyas, A; Michael, A | 1 |
| González, C; Morís, G; Ribacoba, R | 1 |
| Bergsland, EK; Dito, E; Ko, AH; Quivey, JM; Schillinger, B; Tempero, MA; Venook, AP | 1 |
| Aggarwal, BB; Kamat, AM; Sethi, G | 1 |
| Abdulla, A; Albert, PS; Brady, ED; Brechbiel, MW; Flynn, J; Garmestani, K; Milenic, DE | 1 |
| Ahn, MJ; Kim, HK; Kim, JS; Kim, TY; Lee, J; Lee, MA; Lee, NS; Lim, HY; Park, BJ | 1 |
| Aghajanian, C; Chi, DS; Colevas, AD; Derosa, F; Dizon, D; Dupont, J; Hensley, ML; Sabbatini, P; Spriggs, D; Venkatraman, E | 1 |
| Alberts, SR; McWilliams, RR | 1 |
| Brown, JV; Goldstein, BH; Graham, C; Hu, JC; Markman, M; Micha, JP; Rettenmaier, MA | 1 |
| Bae, DS; Choi, CH; Huh, SJ; Kim, BG; Kim, TJ; Kim, WY; Lee, JH; Lee, JW; Nam, HR | 1 |
| Adusumilli, S; Ben-Josef, E; Griffith, KA; Lawrence, TS; Murphy, JD; Ray, ME; Zalupski, MM | 1 |
| Als, AB; Sengelov, L; von der Maase, H | 2 |
| Gschwend, JE | 1 |
| Bruchertseifer, F; Chatal, JF; Chérel, M; Davodeau, F; Gouard, S; Mahé, MA; Morgenstern, A; Rio, E; Supiot, S; Thillays, F | 1 |
| Demetri, GD; Desai, J; Dileo, P; George, S; Harmon, DC; Morgan, JA; Polson, K; Quigley, MT; Salesi, JM; Zahrieh, D | 1 |
| Danenberg, PV; Endo, I; Fujii, Y; Ichikawa, Y; Ishikawa, T; Matsuyama, R; Mori, R; Shimada, H; Taniguchi, K; Togo, S; Ueda, M | 1 |
| Bauer, C; Bauernfeind, F; Dauer, M; Eigler, A; Endres, S; Lehr, HA; Orban, M; Schnurr, M; Sterzik, A | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kang, WK; Lee, HR; Lee, J; Lee, JK; Lee, KT; Lim, DH; Lim, HY; Park, BB; Park, JO; Park, K; Park, YS | 1 |
| Bortolotti, L; Breda, C; Favaretto, AG; Loreggian, L; Marulli, G; Rea, F; Sartori, F | 1 |
| Akahori, T; Azuma, M; Enomoto, K; Hamada, K; Kanehiro, H; Kubo, A; Nakajima, Y; Nakamura, S; Nomi, T; Sho, M; Yagita, H | 1 |
| Alexopoulos, CG; Berchier, MC; Berghmans, T; Collon, T; Efremidis, A; Giner, V; Lafitte, JJ; Lecomte, J; Meert, AP; Ninane, V; Paesmans, M; Scherpereel, A; Sculier, JP; Van Cutsem, O | 1 |
| Coskun, U; Kaya, AO; Ozturk, B; Yaman, E; Yildiz, R | 1 |
| Ewald, B; Plunkett, W; Sampath, D | 1 |
| Bremer, M; Karstens, JH; Schwarte, S; Wagner, K | 1 |
| Egberts, JH; Fändrich, F; Kalthoff, H; Kruse, ML; Schafmayer, C; Schniewind, B; Sipos, B; Tepel, J | 1 |
| Baggstrom, MQ; Govindan, R; Subramanian, J; Velcheti, V | 1 |
| Mandrekar, SJ; Sargent, DJ | 1 |
| Argiris, AE; Beck, JT; Bloss, LP; Curiel, RE; Hahn, EA; Masters, GA; Monberg, MJ; Obasaju, CK; Rausch, PG; Ye, Z | 1 |
| Abratt, RP; Boyer, M; Brnabic, AJ; Han, JY; Kim, SW; Lee, JS; Lehnert, M; Mok, T; Reece, WH; Tsai, CM | 1 |
| Ahuja, HG; Hensing, TA; Hoang, T; Kim, K; Larson, M; McGovern, J; Merchant, J; Oettel, KR; Sanchez, FA; Schiller, JH; Traynor, AM | 1 |
| Akhurst, T; Flores, RM; Heelan, R; Krug, LM; Rosenzweig, KE; Rusch, VW; Venkatraman, E; Vincent, A | 1 |
| Erridge, S; Jackson, S; Law, A; Rae, P | 1 |
| Blackstock, AW; Butler, J; Case, LD; Fletcher-Steede, J; Hinson, W; Ho, C; Miller, AA | 1 |
| Bessho, A; Isobe, H; Katakami, N; Niitani, H; Takiguchi, Y; Yoshimori, K; Yoshimura, A | 1 |
| Aerts, JG; Hoogsteden, HC; Senan, S; Surmont, V; Tan, KY; van Klaveren, RJ; van Meerbeeck, JP; van Wijhe, G; Verhoeven, GT; Vernhout, R | 1 |
| Kovac, V; Smrdel, U; Strojan, P; Zwitter, M | 1 |
| Dowlati, A; Johnson, D; Langer, C; Li, S; Madajewicz, S; Masters, GA; Schiller, J | 1 |
| Aravantinos, G; Bacoyiannis, C; Bafaloukos, D; Boukovinas, I; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Nicolaides, C; Pectasides, D; Syrigos, K | 1 |
| Blackstock, AW; Capellari, J; Knight, SN; Lovato, J; Miller, AA; Miller, MS; Mosley, L; Petty, WJ; Tucker, R | 1 |
| Caffo, O; Favaretto, A; Gregorc, V; Gridelli, C; Kaukel, E; Manegold, C; Martoni, A; Migliorino, MR; Müller, TR; Muñoz, M; Peterson, P; Reck, M; Rossi, A; Russo, F; Schmittel, A | 1 |
| Foo, KF; Ho, J; Leong, SS; Lim, WT; Lin, X; Poon, D; Tan, EH; Tan, SB; Tay, MH; Toh, CK | 1 |
| Chella, A; Dini, P; Fontanini, G; Lucchi, M; Melfi, F; Mussi, A; Tibaldi, C | 1 |
| Butman, JA; Lonser, RR; Morrison, PF; Murad, GJ; Oldfield, EH; Szerlip, N; Walbridge, S | 1 |
| Ajiki, T; Fujino, Y; Kamigaki, T; Kamoda, Y; Kuroda, Y; Matsumoto, I; Takase, S; Ueda, T; Yasuda, T | 1 |
| Goto, H; Ishiguro, H; Ito, M; Ko, SB; Kondo, T; Naruse, S; Yamamoto, A; Yoshikawa, T | 1 |
| El-Rayes, BF; LoRusso, P; Manza, SG; Philip, PA; Shields, AF; Zalupski, M | 1 |
| Barge, A; Bruns, CJ; Conrad, C; Geissler, EK; Guba, M; Ischenko, I; Jauch, KW; Köhl, G; Ryan, AJ; Wedge, SR; Wiegand, U; Yezhelyev, M | 1 |
| Akca, S; Bozcuk, H; Burgucu, D; Ekinci, D; Ozdogan, M; Ozturk, OH; Yildiz, M | 1 |
| Bartlett, NL; Canellos, GP; Cheson, BD; Friedberg, JW; Johnson, JL; Johnson, KB; Niedzwiecki, D; van Besien, K; Zelenetz, AD | 1 |
| Adler, G; Seufferlein, T; von Wichert, G | 1 |
| Boeck, S; Heinemann, V; Moosmann, N; Stemmler, HJ | 1 |
| Chau, J; Lee, J; Liu, X; Mi, S; Shih, J; Un, F; Xue, L; Yen, Y; Zhou, B | 1 |
| Ballabeni, P; Bernhard, J; Betticher, D; Bodis, S; Jermann, M; Lardinois, D; Mingrone, W; Ris, HB; Roth, AD; Schmid, R; Spiliopoulos, A; Stahel, RA; Stupp, R; Vogt, P; Weder, W | 1 |
| Corrado, G; Ferrandina, G; Legge, F; Mey, V; Nannizzi, S; Petrillo, M; Ricciardi, S; Scambia, G | 1 |
| Brundage, RC; Dagit, JW; Fisher, JE; Hillman, LA; Kirstein, MN; Kratzke, RA; Marker, PH; Moore, MM; Williams, BW; Yee, D | 1 |
| Cheng, B; Liu, K; Qiu, DB; Wang, GB | 1 |
| Hosomi, Y; Shibuya, M | 1 |
| Yoneda, S | 1 |
| Clavel, M; Edzes, HT; Geyssen, GJ; Guastalla, J; Laan, AC; Noordhuis, P; Peters, GJ; Vermorken, JB | 1 |
| Arakelyan, N; Banu, A; Banu, E; Culine, S; Duclos, B; Escudier, B; Fournier, L; Medioni, J; Oudard, S; Priou, F; Rolland, F; Vieillefond, A | 1 |
| Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Li, X; Lopez, CA; Normolle, DP; Nyati, MK; Varambally, S | 1 |
| Huang, YJ; Huang, YS; Liao, RQ; Wu, YL; Xie, SX; Yang, JJ | 1 |
| Aggarwal, BB; Diagaradjane, P; Gelovani, J; Guha, S; Krishnan, S; Kunnumakkara, AB | 1 |
| Lévi, F; Li, XM | 1 |
| Andrade, R; Chabot, J; Desai, M; Fine, RL; Fogelman, DR; Guba, S; Schreibman, SM; Sherman, W; Strauss, J | 1 |
| Fok, JY; Mehta, K | 1 |
| De Rosa, F; Gatzemeier, U; Janaskova, T; Karnicka-Mlodkowski, H; Kaukel, E; Manikhas, GM; Milanowski, J; Pesek, M; Pluzanska, A; Ramlau, R; Roubec, J; Serwatowski, P; Strausz, J; Szczesna, A; Vansteenkiste, J; Von Pawel, J | 1 |
| Ikemoto, T; Imura, S; Miyake, K; Morine, Y; Shimada, M; Yoshizumi, T | 1 |
| Apparaju, SK; Desai, PB; Gudelsky, GA | 1 |
| Bahra, M; Boas-Knoop, S; Davis, J; Jacob, DA; Langrehr, JM; Lippert, S; Neumann, UP; Schumacher, G; Stefaniak, R | 1 |
| Akaza, H; Miki, T; Miyanaga, N; Naito, S; Taniai, H; Usami, M | 1 |
| Au, HJ; Campos, D; Clark, G; Ding, K; Figer, A; Gallinger, S; Goldstein, D; Hamm, J; Hecht, JR; Lim, R; Moore, MJ; Murawa, P; Parulekar, W; Ptasynski, M; Voskoglou-Nomikos, T; Walde, D; Wolff, RA | 1 |
| Bramhall, SR; Buckels, JA; Hassan, AB; Hewitt, H; Johnson, PJ; Markham, CE; Palmer, DH; Stocken, DD | 1 |
| Depisch, D; Dworan, N; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Payrits, T; Scheithauer, W; Ulrich-Pur, H; Vormittag, L | 1 |
| Chau, I; Chong, G; Cunningham, D; Horwich, A; Last, K; Norman, A; Oates, J; Sirohi, B; Wotherspoon, A | 1 |
| Ariganello, O; Belli, R; Cipri, A; Condò, S; de Marinis, F; De Santis, S; Di Molfetta, M; Migliorino, MR; Tedesco, B; Treggiari, S | 1 |
| Arslan, U; Boyaci, B; Okyay, K; Sen, N; Tavil, Y | 1 |
| Clegg, AJ; Jones, J; Loveman, E; Takeda, AL; Tan, SC | 1 |
| Basson, BR; Ciuleanu, T; Firoiu, E; Grigorescu, A; Muresan, DR; Teodorescu, G | 1 |
| Brunetti, E; Bucci, B; Michienzi, S; Misiti, S; Panacchia, L; Patriarca, V; Stigliano, A; Toscano, V; Verga Falzacappa, C | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Crino, L; Finocchiaro, G; Hirsch, FR; Ligorio, C; Magrini, E; Paioli, D; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Chansky, K; Crowley, JJ; Gandara, DR; Grapski, RT; Hesketh, PJ; Israel, V; Kelly, K; Mekhail, TM; Mills, GM; Spiridonidis, CH | 1 |
| Alexopoulos, CG; Berchier, MC; Berghmans, T; Collon, T; Efremidis, A; Giner, V; Lafitte, JJ; Leclercq, N; Lecomte, J; Meert, AP; Ninane, V; Paesmans, M; Scherpereel, A; Sculier, JP; Van Cutsem, O | 1 |
| Amarantidis, K; Chatzaki, E; Houhouli, K; Kakolyris, S; Lyrantzopoulos, N; Matthaios, D; Miloussis, A; Papatheodorou, K; Tentes, A; Tsaroucha, A | 1 |
| Brunetti, E; Bucci, B; Cannizzaro, A; Martinelli, M; Misiti, S; Verga Falzacappa, CV | 1 |
| Hermann, TW; Negro-Vilar, A; Ng, SC; Tooker, P; Yen, WC | 1 |
| Horai, T; Horiike, A; Ishikawa, Y; Nakagawa, K; Nishio, M; Ohyanagi, F; Okano, Y; Okumura, S; Satoh, Y | 1 |
| Castelli, F; Cattel, L; Ceruti, M; Rocco, F; Sarpietro, MG | 1 |
| Aprahamian, M; Hajri, A; Réjiba, S; Wack, S | 1 |
| Onodera, R; Sato, T; Seki, Y; Shimizu, K; Tai, H | 1 |
| Bartoletti, R; Cai, T; Farina, U; Mazzoli, S; Melone, F; Mondaini, N | 1 |
| Conti, G | 1 |
| Gontero, P | 1 |
| Huang, WT; Kuo, CY; Li, SH | 1 |
| Alberts, SR; Chari, ST; Gores, GJ; Kendrick, ML; Kim, GP; Martenson, JA; Roberts, LR; Rosen, CB | 1 |
| Kim, R; Saif, MW | 2 |
| Belhadj, K; Copie-Bergman, C; Diviné, M; Dupuis, J; El Gnaoui, T; Gaillard, I; Haioun, C; Jais, JP; Rahmouni, A; Reyes, F; Tabah-Fisch, I | 1 |
| Aikou, T; Kitazono, M; Maemura, K; Mataki, Y; Noma, H; Shinchi, H; Takao, S | 1 |
| Arnadottir, M; Benediktsson, T; Hrafnkelsson, J | 1 |
| Motoo, Y | 1 |
| Barbera, S; Carozza, F; Ceribelli, A; Ciardiello, F; Cognetti, F; Daniele, B; Di Maio, M; Favaretto, A; Galetta, D; Gallo, C; Gamucci, T; Gebbia, V; Gridelli, C; Maione, P; Morabito, A; Perrone, F; Rosetti, F; Rossi, A; Testa, A | 1 |
| Iishi, H; Ioka, T; Ishikawa, O; Koizumi, M; Nakaizumi, A; Nishiyama, K; Ohigashi, H; Tanaka, E; Uehara, H; Yamazaki, H | 1 |
| Calvo, I; Carrasco, E; Casado, V; Casillas, M; Díaz, M; Dómine, M; Estévez, LG; Jaén, A; León, A; Lobo, F; Miró, C; Rubio, G; San Antonio, B; Sánchez-Rovira, P | 1 |
| Fukushima, N; Itoi, T; Itokawa, F; Kasuya, K; Kurihara, T; Moriyasu, F; Sofuni, A; Tsuchida, A; Tsuchiya, T | 1 |
| Dent, S; Messersmith, H; Trudeau, M | 1 |
| Adams, E; Dragovic, S; Haghedooren, E; Hoogmartens, J; Kóczián, K; Noszál, B | 1 |
| Henson, R; Meng, F; Patel, T | 1 |
| Moore, MJ; Welch, SA | 1 |
| Vaughn, DJ | 1 |
| Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Cina, S; Dietrich, D; Figer, A; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, B; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K | 1 |
| Chatta, GS; Chen, H; Dunn, RL; Glode, LM; Hussain, MH; Lara, PN; MacVicar, GR; Nanus, DM; Petrylak, DP; Smith, DC; Trump, DL; Vaishampayan, U | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Janjan, NA; Krishnan, S; Rana, V; Varadhachary, GR; Wolff, RA | 1 |
| Huang, MZ; Liu, J; Wang, LR; Xu, N | 1 |
| Arthur, C; Reed, K; Spencer, A | 1 |
| Akerley, W; Atkins, JN; Bearden, JD; Chansky, K; Crowley, JJ; Gandara, DR; Goodwin, JW; Hesketh, PJ; McCoy, J | 1 |
| Fukushima, M; Maruyama, R; Nio, Y; Toga, T | 1 |
| Gorzalczany, Y; Merimsky, O; Sagi-Eisenberg, R | 1 |
| Huang, MZ; Wang, LR; Wu, XH; Xu, N; Zhang, GB | 1 |
| Borel, C; Calais, G; Cupissol, D; Eymard, JC; Germann, N; Kohser, F; Labourey, JL; Tourani, JM; Tubiana-Mathieu, N | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Giassas, S; Kalykaki, A; Kentepozidis, N; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Vamvakas, L | 1 |
| Huang, FY; Jiao, CL; Wu, RL; Zheng, SJ; Zheng, SP | 1 |
| Adam, U; Bornmann, C; Esser, N; Graeser, R; Hopt, UT; Jantscheff, P; Keck, T; Massing, U; Schaechtele, C; Unger, C; von Dobschuetz, E; Ziroli, V | 1 |
| Burtness, B | 1 |
| Beghelli, S; Bonora, A; Budillon, A; Caraglia, M; Costanzo, C; Dandrea, M; Donadelli, M; Palmieri, M; Piacentini, P; Scarpa, A; Scupoli, MT | 1 |
| Fang, WJ; Qian, J; Xiong, JP; Xu, N; Yu, LF; Zhang, L; Zhang, XC | 1 |
| Cafasso, D; Konduri, S; Schwarz, MA; Schwarz, RE | 1 |
| Cereda, S; Galli, L; Reni, M | 1 |
| Belzer, K; Gadgeel, S; Heilbrun, LK; Kalemkerian, GP; Kraut, MJ; Kucuk, O; Venkatramanamoorthy, R; Wozniak, AJ | 1 |
| Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A | 1 |
| Bussom, S; Cheng, YC; Lam, W; Leung, CH | 1 |
| Hariharan, S; Welsh, CH | 1 |
| Kusano, F; Nagayama, K; Nitta, S; Sakai, Y; Tazawa, J | 1 |
| Branscheid, D; Droemann, D; Goldmann, T; Lang, DS; Martin, C; Ressmeyer, AR; Schultz, H; Vollmer, E; Zabel, P | 1 |
| Charoentum, C; Chewaskulyong, B; Munprakan, S; Thongprasert, S | 1 |
| Flanagan, SA; Krokosky, CM; Robinson, BW; Shewach, DS | 1 |
| Giaccone, G; Honeywell, R; Kuenen, BC; Peters, GJ; Smit, EF; van de Velde, H; Voortman, J | 1 |
| Carpinteiro, A; Grammatikos, G; Gulbins, E; Hengge, UR; Teichgräber, V; Trarbach, T; Weller, M | 1 |
| Komiyama, S; Kurahashi, T; Kuwabara, Y; Mikami, M; Murakami, I; Nakamura, M; Tanaka, K | 1 |
| Burgers, S; Kartachova, M; Valdés Olmos, RA; van Tinteren, H; van Zandwijk, N; Verheij, M | 1 |
| Alberts, SR; Camoriano, JK; Foster, NR; Haddock, MG; Hauge, MD; Martenson, JA; Moore, DF; Schaefer, PL; Stella, PJ; Swaminathan, R; Tenglin, RC | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Smith, CT; Starling, N; Sultana, A | 2 |
| Bria, E; Carlini, P; Cognetti, F; Cuppone, F; Gelibter, A; Giannarelli, D; Milella, M; Nisticò, C; Pino, MS; Ruggeri, EM; Terzoli, E | 1 |
| Beijnen, JH; Rosing, H; Schellens, JH; Thijssen, B; Vainchtein, LD | 1 |
| Shivnani, AT | 1 |
| Lowenfels, AB; Maisonneuve, P | 1 |
| Albelda, SM; Jassar, AS; Kapoor, V; Sun, J; Suzuki, E | 1 |
| Hirte, H; Johnson, C; Low, J; Mackenzie, MJ; Moore, MJ; Pond, G; Saltman, D | 1 |
| Blajman, CR; Del Giglio, A; Fein, L; Hall, BJ; Orlando, M; Pereira, JR; Richardet, E; Schwartsmann, G; van Kooten, M; West, TM | 1 |
| Joensuu, T; Kärkkäinen, P; Kivilaakso, E; Kiviluoto, T; Mustonen, H; Vento, P | 1 |
| Kubota, Y; Makiyama, K; Nakaigawa, N; Oshiro, H; Sugiura, S; Yao, M | 1 |
| El-Rayes, B; Griffith, KA; Kalemkerian, GP; Muler, JH; Philip, PA; Schneider, BJ; Zalupski, MM | 1 |
| Aasebø, U; Bailey, A; Bremnes, RM; Brunsvig, PF; Garpestad, OK; Helbekkmo, N; Hjelde, HH; Sundstrøm, SH; von Plessen, C | 1 |
| Kaniwa, N; Kiyosawa, K; Ueno, H | 1 |
| Azim, HA; Elsedewy, E | 1 |
| Bhargava, P; Blaszkowsky, L; Earle, CC; Fuchs, CS; Kulke, MH; Lehman, N; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX | 1 |
| Asadpour, B; Breuer, C; Eble, MJ; Gagel, B; Kaiser, HJ; Krohn, T; Pinkawa, M; Piroth, M; Reinartz, P; Schmachtenberg, A; Stanzel, S | 1 |
| Fukuda, M; Kinoshita, A; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Oka, M; Soda, H; Soejima, Y; Takatani, H | 1 |
| Choi, YH; Chung, HC; Jeung, HC; Kim, BS; Rha, SY; Roh, JK; Yang, WI; Yoo, JH | 1 |
| Baker, LH; Benjamin, RS; Fanucchi, M; Harmon, DC; Hensley, ML; Maki, RG; Okuno, SH; Patel, SR; Priebat, DA; Reinke, D; Samuels, B; Schuetze, SM; Thall, PF; Wathen, JK | 1 |
| Gordon, AN; Goss, T; Marciniack, M; McMeekin, SD; Mutch, DG; Naumann, RW; Orlando, M; Scribner, DR; Secord, AA; Teneriello, MG; Wang, Y | 1 |
| Borch, RF; Peters, GJ; Sigmond, J; Wu, W | 1 |
| Cagnoni, PJ; Clark, G; Nagrani, T; Wacker, B; Weinberg, J; Witt, K | 1 |
| Bouffard, DY; Cass, CE; Clarke, ML; Damaraju, VL; Gourdeau, H; Grey, M; Leblond, L; Mackey, JR; Wong, CK | 1 |
| Shah, PC; Shah-Khan, F; Zupancic, M | 1 |
| Choi, EH; Gang, J; Haam, S; Hyung, W; Kim, HS; Park, SB; Shul, YG; Song, SY; Wen, J | 1 |
| Aarestrup, FM; Clausen, AR; Munch-Petersen, B; On, SL; Piskur, J; Sandrini, MP | 1 |
| Füessl, HS | 1 |
| Fenoglio-Preiser, C; Hingorani, SR; Lowy, AM; Revelo-Penafiel, MP; Thomas, RM; Toney, K; Tuveson, DA; Waltz, SE | 1 |
| Brausi, MA | 1 |
| Cornfeld, D; Saif, MW; Shahrokni, A | 1 |
| Gemma, A; Kawakami, A; Kudoh, S; Li, C; Matsuda, K; Minegishi, Y; Noro, R; Ogawa, N; Seike, Y; Shionoya, A | 1 |
| Chin, SN; Knox, JJ; Pond, GR; Riechelmann, RP; Townsley, CA | 1 |
| Irisawa, A; Kanazawa, M; Ogata, T; Ohira, H; Ohto, H; Sato, Y; Takagi, T; Takenoshita, S | 1 |
| Gabata, T; Kayahara, M; Kitagawa, H; Matsui, O; Minato, H; Nakagawara, H; Nakamura, M; Ohnishi, I; Ohta, T; Tajima, H; Takamura, H; Tani, T; Zen, Y | 1 |
| Cerqueira, NM; Fernandes, PA; Ramos, MJ | 1 |
| Nimura, Y | 1 |
| Furuse, J; Ishii, H; Nakachi, K; Shimizu, S; Suzuki, E | 1 |
| Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Niwano, M; Ogasahara, K; Okabe, M; Paku, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y | 1 |
| Benhadji, K; Calvo, F; Chiao, J; Cvitkovic, E; Faivre, S; Galmarini, CM; Ghoul, A; Green, SR; Le Tourneau, C; Raymond, E; Serova, M | 1 |
| Cerny, T; Früh, M; Lanz, C; Lauterburg, BH; Thormann, W | 1 |
| Baril, P; Bhakta, V; Caulee, K; Chelala, C; Harada, T; Lemoine, NR; Mahon, PC | 1 |
| Bianco, A; Campbell, S; Caputo, F; D'Agostino, D; Gilli, M; Marsico, SA; Mazzarella, G; Piantedosi, FV; Pontillo, A | 1 |
| Agelaki, S; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kalykaki, A; Karabeazis, A; Karampeazis, A; Mavroudis, D; Saridaki, Z; Sfakiotaki, G; Vamvakas, L; Vardakis, N | 1 |
| Christophylakis, C; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kotsakis, A; Polyzos, A; Potamianou, A; Stathopoulos, GP; Tselepatiotis, E; Vamvakas, L | 1 |
| Chen, GY; Hong, X; Lu, L; Wang, M; Yang, ZY; Zhang, CH | 1 |
| Fisher, JE; Kirstein, MN; Kratzke, RA; Le, CT; Marker, PH; Wieman, KM; Williams, BW; Yee, D | 1 |
| Arpicco, S; Cattel, L; Couvreur, P; Marsaud, V; Renoir, JM; Rocco, F; Stella, B | 1 |
| Alés-Martínez, JE; Aramburo González, PM; Sánchez-Escribano Morcuende, R | 1 |
| Davies, T; Goldstein, D; Harvey, J; Kotasek, D; Michael, M; Reece, W; Shapiro, J; Spry, N; Underhill, C; Van Hazel, G; Walpole, E | 1 |
| Jones, DV; Klementich, FJ; Ravindranathan, M | 1 |
| Achiwa, H; Eimoto, T; Muramatsu, H; Oguri, T; Ozasa, H; Sato, S; Shimizu, S; Ueda, R; Yamazaki, H | 1 |
| Darro, F; Dewelle, J; Dumont, P; El Yazidi, M; Gaussin, JF; Kiss, R; Lefranc, F; Mahieu, T; Mijatovic, T; Ribaucour, F; Sauvage, S; Simon, G; Tuti, J; Van Quaquebeke, E; Van Vynckt, F | 1 |
| Heinemann, V; Hinke, A; Labianca, R; Louvet, C | 1 |
| Géczi, L | 1 |
| Chiorean, EG; Colowick, AB; Dragovich, T; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GF | 1 |
| Brand, RE; Carneiro, BA; Fine, E; Khandekar, JD; Knop, RH; Locker, GY; Uhlig, W | 1 |
| Kibble, A | 1 |
| Büchler, MW; Jäger, D; Märten, A; Mühlradt, PF; Schmidt, J; Welsch, T | 1 |
| Chouaid, C; Fournel, P; Gimenez, C; Jullian, H; LeCaer, H; Letreut, J; Paillotin, D; Perol, M; Thomas, P; Vergnenegre, A | 1 |
| Beerepoot, LV; Beijnen, JH; Enas, N; Mehra, N; Musib, L; Radema, SA; Rademaker-Lakhai, JM; Schellens, JH; van Hal, G; van Maanen, R; Vermaat, JS; Visseren-Grul, CM; Voest, EE; Witteveen, EO | 1 |
| Gordon, N; Jia, SF; Khanna, C; Kleinerman, ES; Koshkina, NV; Mendoza, A; Worth, LL | 1 |
| Chang, SY; Chang, WS; Kang, CY; Kim, YJ; Kim, YS; Ko, HJ; Ko, SY; Sakaguchi, S | 1 |
| El Khodary, AI; El Serafi, MM; El Zawahry, HR; Gaballa, HE; Mansour, OM | 1 |
| Gahr, S; Ganslmayer, M; Hahn, EG; Hartl, A; Herold, C; Leitner, S; Ocker, M; Okamoto, K; Zopf, S | 1 |
| Chaudhari, AA; Kang, HS; Kim, IS; Kim, NS; Kim, TH; Lee, YJ; Park, JH; Park, SY; Seol, DW; Seol, JW | 1 |
| Chen, W; Dang, C; Lee, W; Liu, D; Ma, Q; Zhang, Y | 1 |
| Blackstock, AW; Butler, J; Ove, R; Russo, S | 1 |
| Abou-Alfa, GK; O'Reilly, EM | 1 |
| Hagihara, A; Ikeda, M; Morizane, C; Ogura, T; Okusaka, T; Tanaka, T; Ueno, H | 1 |
| Iwata, H; Yamashita, T | 1 |
| Bunce, PE; Gold, WL; Liles, WC; Tan, DH | 1 |
| Aydiner, A; Cakan, A; Cikrikcioglu, S; Dilege, S; Goksel, T; Gurses, A; Kiyik, M; Kosar, F; Turna, A; Yazar, A | 1 |
| Akasaka, H; Hara, Y; Hashimoto, H; Hayashi, K; Inokuchi, M; Kasahara, K; Miyamoto, K; Nakamura, M; Nishigami, J; Nishimura, G; Shimizu, M; Suga, Y; Yonejima, M | 1 |
| Degeest, K; Fusco, N; McMeekin, S; Rose, PG | 1 |
| Kim, CH; Kim, HS; Kim, JH; Kim, KJ; Lee, KY; Sung, CW | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, A; Prezerakos, P | 1 |
| Alexopoulos, CG; Berchier, MC; Berghmans, T; Collon, T; Efremidis, A; Giner, V; Koumakis, G; Lafitte, JJ; Leclercq, N; Lecomte, J; Meert, AP; Ninane, V; Paesmans, M; Scherpereel, A; Sculier, JP; Van Cutsem, O; Vaslamatzis, MM | 1 |
| Albanell, J; Bellmunt, J; Berrocal, A; Carles, J; Climent, M; Esteban, E; Fabregat, X; Font, A; Garcia-Ribas, I; Gonzalez-Larriba, JL; Marfa, X | 1 |
| Chen, Q; Chen, TG; Hao, MZ; Lin, HL; Wu, H; Yu, WC | 1 |
| Di, LJ; Gong, JF; Jin, ML; Li, J; Shen, L; Zhang, XD | 1 |
| Guo, SS; Jiang, ZM; Liang, HL; Xie, DR; Yang, Q | 1 |
| Dillmann, S; Henne-Bruns, D; Keller, F; Klug, F; Mayer, JM; Stracke, S; Tuncyurek, P | 1 |
| Egberts, JH; Hinz, S; Kalthoff, H; Schniewind, B; Sipos, B; Tepel, J | 1 |
| Ito, H; Kato, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Sawada, S; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H | 1 |
| Aoki, K; Ikeda, T; Kikugawa, T; Ochi, T; Ozawa, A; Shimamoto, K; Tanji, N; Toshino, A; Yamaguchi, A; Yanagihara, Y; Yokoyama, M | 1 |
| Inui, K; Ito, N; Jiko, M; Kamoto, T; Masuda, S; Motohashi, H; Nakamura, E; Ogawa, O; Okuda, M; Sato, E; Segawa, T; Takahashi, K; Yano, I | 1 |
| Amato, RJ; Khan, M | 1 |
| Avallone, A; Comella, P; Costanzo, R; Frasci, G; Gambardella, A | 1 |
| Klöppel, G; Kolb-van Harten, P; Layer, P; Rosien, U | 1 |
| Boeck, S; Hausmann, A; Heinemann, V; Reibke, R; Schulz, C | 1 |
| Fakih, M; Gibbs, J; Iyer, RV; Javle, MM; Kepner, J; Kuvshinoff, B; Lawrence, D; Soehnlein, N | 1 |
| Gao, SL; Shen, HW; Tang, ZY; Wu, YL | 1 |
| Huang, MZ; Wang, LR; Zhang, GB | 1 |
| Cao, LM; Huang, FY; Jiao, CL; Wu, RL; Zheng, SJ; Zheng, SP | 1 |
| Bréchot, JM; Morère, JF; Pailler, M | 1 |
| Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D | 1 |
| Lohman, GJ; Stubbe, J; Wang, J | 1 |
| Kanazumi, N; Kasuya, H; Nakao, A; Nomoto, S; Nomura, N; Shikano, T; Shirota, T; Sugimoto, H; Takeda, S; Watanabe, I | 1 |
| Fujii, N; Takemura, N; Tanaka, T | 1 |
| Bluethner, T; Caca, K; Moebius, C; Mossner, J; Niederhagen, M; Serr, F; Wiedmann, M; Witzigmann, H | 1 |
| Akada, M; Egawa, S; Fujimura, H; Furukawa, T; Horii, A; Ishida, M; Shibuya, E; Sunamura, M; Unno, M | 1 |
| Xu, BH | 1 |
| Li, Y; Sun, Y; Zhang, XR | 1 |
| Burks, T; Chaudhary, UB; Curry, N; Sawhney, R | 1 |
| Thachil, J | 1 |
| Castelli, F; Cattel, L; Micieli, D; Rocco, F; Sarpietro, MG; Stella, B | 1 |
| Agelidou, A; Agelidou, M; Androulakis, N; Boukovinas, I; Chandrinos, V; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kotsakis, A; Mavroudis, D; Polyzos, A; Syrigos, K; Vamvakas, L; Varthalitis, I; Ziras, N | 1 |
| Maki, RG | 1 |
| Agelaki, S; Georgoulias, V; Gioulbasanis, I; Ignatiadis, M; Karampeazis, A; Kentepozidis, N; Mavroudis, D; Papadimitraki, E; Vamvakas, L; Vardakis, N | 1 |
| Ammons, WS; Hoffman, RM; Tidmarsh, GF; Wang, JW; Yang, Z | 1 |
| Allendorf, JD; Bill, A; Chabot, JA; DiGiorgi, M; Fine, RL; Goetz, N; Hall, M; Lauerman, M; Remotti, H; Schrope, B; Sherman, W; Vakiani, E | 1 |
| Baggstrom, MQ; Fried, DB; Hensing, TA; Poole, C; Socinski, MA; Stinchcombe, TE | 1 |
| Buesa, JM; Capelan, M; Esteban, E; Estrada, E; Fernández, Y; Fra, J; Jiménez, P; Jiménez-Lacave, A; Llorente, B; Luque, M; Muñiz, I; Vieitez, JM; Villanueva, N | 1 |
| Dyck, J; Huizing, MT; Schrijvers, D; Specenier, PM; Van den Brande, J; Van den Weyngaert, D; Van Laer, C; Vermorken, JB; Weyler, J | 1 |
| Ann Houston, G; Anthony Greco, F; Bearden, JD; Farley, C; Gandhi, J; Hainsworth, JD; Shipley, DL; Spigel, DR | 1 |
| Gu, Y; Guo, Y; Hong, X; Hu, X; Li, J; Tang, W; Wang, B; Wang, J | 1 |
| Bay, JO; Spano, JP | 1 |
| Lansiaux, A; Lokiec, F | 1 |
| Abbas, F; Gligorov, J; Khalil, A; Lotz, JP; Namer, M; Selle, F | 1 |
| Besse, B; Vignot, S | 1 |
| André, T; Blanchard, P; Huguet, F | 1 |
| Fléchon, A | 1 |
| Bailly, C; Bay, JO; Cabrespine, A; Gilliot, O; Gimbergues, P; Mishellany, F; Vincent, C | 1 |
| El Maalouf, G; Faivre, S; Le Tourneau, C; Raymond, E; Sablin, MP | 1 |
| Seto, T | 1 |
| Atahan, IL; Cengiz, M; Gullu, IH; Gurkaynak, M; Yalcin, S; Zorlu, F | 1 |
| Hashmi, S; Saif, MW | 1 |
| Ho, CC; Huang, HY; Huang, PH; Kuo, SH; Yang, CH; Yang, PC | 1 |
| Couvreur, P; Deroussent, A; Khoury, H; Paci, A; Reddy, LH; Vassal, G | 1 |
| Chan, AT; Goh, BC; Lam, KC; Leong, SS; Ma, B; Mo, F; Mok, T; Soo, R; Tan, EH; Wang, LZ; Zee, B | 1 |
| Balaa, FK; Carr, BI; Gamblin, TC; Geller, DA; Gusani, NJ; Marsh, JW; Steel, JL; Zajko, AB | 1 |
| Bredenfeld, H; Diehl, V; Eich, HT; Engert, A; Macann, A; Müller, RP | 1 |
| Charpidou, A; Dannos, I; Dilana, K; Dionellis, G; Georgatou, N; Karapanagiotou, E; Rigopoulou, A; Roussos, C; Syrigos, KN | 1 |
| Havrilesky, LJ; Kulasingam, S; Myers, E; Secord, AA | 1 |
| Doi, T; Fujimi, A; Izumi, K; Kanisawa, Y; Kikuchi, S; Kitahara, T; Ohta, H; Okuda, T; Sato, Y | 1 |
| Capanu, M; Duffy, A; Kelsen, DP; Kortmansky, J; Minsky, B; O'Reilly, EM; Puleio, S; Saltz, L; Schwartz, GK | 1 |
| Aderka, D; Ashkenazy-Voghera, M; Ben-Yosef, R; Greif, J; Lev-Ari, S; Starr, A; Vexler, A | 1 |
| Blesius, A; Ciccolini, J; Dahan, L; Duluc, M; Dupuis, C; Evrard, A; Favre, R; Franceschini, F; Giacometti, S; Mercier, C; Milano, G; Ortiz, A; Raynal, C; Salas, S; Seitz, JF | 1 |
| Anderes, K; Blasina, A; Chen, E; Chen, P; Deng, Y; Grant, S; Hu, Q; Johnson, MD; Kania, RS; Kornmann, J; Lundgren, K; Ninkovic, S; Peng, Z; Register, J; Rogers, C; Teng, M; Zhu, J | 1 |
| Baldazzi, V; Carini, M; Crisci, A; Giordano, C; Grifoni, R; Lapini, A; Neri, B; Pantaleo, P; Raugei, A; Vannini, L | 1 |
| Alberici, F; Bongiovanni, C; Brighenti, M; Buti, S; Buzio, C; Chiesa, MD; Passalacqua, R | 1 |
| Cao, P; Hedley, DW; Pham, NA; Tsao, MS | 1 |
| Hayashi, H; Igarashi, H; Ito, T; Kawabe, K; Kodama, M; Sakai, H; Takayanagi, R; Yoshinaga, M | 1 |
| Babcock, TA; Dekoj, TR; Espat, NJ; Garrean, S; Hering, J; Razzak, A; Saied, A; Trevino, J | 1 |
| Andrieu, JM; Banu, A; Banu, E; Chatellier, G; Fodor, A; Landi, B; Oudard, S; Rougier, P | 1 |
| Palmer, DH | 1 |
| Emori, Y; Eta, R; Hamano, H; Iino, Y; Kawasaki, D; Takei, M; Tanaka, T; Watson, SA; Yoshinaga, K | 1 |
| Dong, P; Jiang, AC; Li, L; Wan, Y; Yu, ZW | 1 |
| Faerber, GJ; Weizer, AZ; Wolf, JS | 1 |
| Balani, JP; Mohanty, SK; Parwani, AV | 1 |
| Goldstein, M; Miksad, RA; Schnipper, L | 1 |
| Balzarotti, M; Capizzuto, R; Castagna, L; Isa, L; Magagnoli, M; Michieli, M; Morenghi, E; Santoro, A; Spina, M; Timofeeva, I; Tirelli, U | 1 |
| Casallo Blanco, S; Celdrán Gil, J; de Matías Salces, L; Marcos Sánchez, F; Núñez Cuerda, E; Viana Alonso, A | 1 |
| Fornier, MN; Hudis, C; Kelsen, DP; Lefkowitz, R; O'Reilly, E; Patil, S; Rathkopf, D; Schwartz, GK; Shah, M; Tse, AN | 1 |
| Ali, Y; Egorin, MJ; Gharibo, MM; Gounder, MK; Lagattuta, TF; Lin, Y; Poplin, EA; Rubin, EH; Stein, MN | 1 |
| Ayoub, JP; Charpentier, D; Del Vecchio, P; Duclos, M; Faria, S; Gruber, J; Hirsh, V; Ofiara, L; Portelance, L; Souhami, L; Soulieres, D | 1 |
| Cucherat, M; Douillard, JY; Fossella, F; Georgoulias, V; Kubota, K; Kudoh, S; Laporte, S; Monnier, A; Pujol, JL; Rubio, JE | 1 |
| Aikin, A; Balis, FM; Berg, SL; Bernardi, RJ; Blaney, SM; Bomgaars, L; Egorin, MJ; Fox, E; Lagattuta, TF; Lieberman, FS; Renbarger, J; Whitcomb, P | 1 |
| Guan, ZZ; Huang, PY; Peng, PJ; Xu, F; Zhang, L; Zhang, Y | 1 |
| Egozi, Y; Elad-Sfadia, G; Haklai, R; Kloog, Y | 1 |
| Gallick, GE; Parikh, NU; Park, SI; Shah, AN; Summy, JM; Zhang, J | 1 |
| Gluck, S; Lobo, C; Lopes, G; Silva, O | 1 |
| Aravantinos, G; Economopoulos, T; Gaglia, A; Gouveris, P; Koumarianou, A; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Sykiotis, C; Xiros, N | 1 |
| Albertsson, M; Friesland, S; Frykholm, G; Johansson, B; Kadar, L; Letocha, H; Wagenius, G | 1 |
| Chen, HH; Cheng, YC; Lim, KH; Lin, CJ; Wu, CJ | 1 |
| Dudek, AZ; Keshtgarpour, M; Kumar, P; Larson, T | 1 |
| Aoki, H; Iijima, H; Imai, H; Inoue, T; Ishida, E; Ishihara, S; Iwasaki, Y; Kawashima, O; Kobayashi, G; Mori, M; Saito, R; Sato, K; Tomizawa, Y; Watanabe, S; Yamada, H; Yatomi, M | 1 |
| Antognoli, S; Berardi, R; Carbonari, G; Cascinu, S; Giampieri, R; Mariani, C; Pierantoni, C; Scartozzi, M; Silva, RR; Squadroni, M; Verdecchia, L | 1 |
| Miletzki, A | 1 |
| Bajorin, D; Halabi, S; Philips, GK; Sanford, BL; Small, EJ | 2 |
| Burris, HA; Gandhi, JG; Gray, JR; Greco, FA; Hainsworth, JD; Kuzur, ME; Pati, A; Shipley, D; Spigel, DR; Thompson, DS; Webb, CD; Yardley, DA | 1 |
| Ben-Josef, E; Chang, AE; Colletti, LM; Desai, SP; Francis, IR; Greenson, JK; Lawrence, TS; Normolle, DP; Simeone, DM; Zalupski, MM | 1 |
| Bearz, A; Carrozza, F; Favaretto, A; Filipazzi, V; Gallo, C; Gridelli, C; Iaffaioli, RV; Illiano, A; Lorusso, V; Maione, P; Manzione, L; Morabito, A; Perrone, F; Piantedosi, FV; Robbiati, SF | 1 |
| Kad, R; Kalra, N; Osama, S | 1 |
| Fu, de L; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yu, XJ | 1 |
| Blum, HE; Harder, J; Kummer, O; Olschewski, M; Opitz, O; Otto, F | 1 |
| Haller, DG; Hershock, D; Hewitt, MR; Sun, W; Theobald, MR | 1 |
| Alexandru, A; Dediu, M; Gal, C; Median, D; Vremes, G | 1 |
| Ghaneh, P; Neoptolemos, JP; Raraty, M; Smith, R; Tudor-Smith, C | 1 |
| Akbunar, T; Evrensel, T; Kanat, O; Kurt, E; Manavoglu, O; Yalcinkaya, U | 1 |
| Bafaloukos, D; Bakogiannis, C; Bamias, A; Boukovinas, I; Christodoulou, C; Dimopoulos, MA; Fountzilas, G; Kalofonos, HP; Kosmidis, PA; Makatsoris, T; Nicolaides, C; Samantas, E; Skarlos, D; Syrigos, K; Xiros, N | 1 |
| Bauer, RW; Eichler, K; Selby, JB; Vogl, TJ; Zangos, S | 1 |
| Caffo, O; D'Incalci, M; Galligioni, E; Marangon, E; Sala, F; Zucchetti, M | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Nagase, M; Ohkawa, S; Okusaka, T; Saisho, H; Sato, T; Tanaka, K; Yamao, K; Yonemoto, N | 1 |
| Husain, SR; Kioi, M; Nakajima, A; Puri, RK; Royal, RE; Shimamura, T | 1 |
| Ahn, E; Flores, A; Lopes, G; Quesada, J; Ribeiro, A; Rocha-Lima, CM | 1 |
| Chang, AY; Fong, FK; Hsin, KW; Lim, R; Lopes, G; Wong, J | 1 |
| Aguilo, R; Artal, A; Astudillo, J; Barcelo, JR; Cardenal, F; Domine, M; Garrido, P; González-Larriba, JL; Hernando-Trancho, F; Insa, A; Isla, D; Massuti, B; Muguruza, I; Provencio, M; Rosell, R; Sanchez, JM; Sanchez-Ronco, M; Tarrazona, V; Torres, A; Varela, A | 1 |
| Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Ciccolini, J; Evrard, A; Mercier, C | 1 |
| Bauer, RW; Böcher, E; Hammerstingl, RM; Heller, M; Jacob, U; Vogl, TJ; Zangos, S | 1 |
| Bützow, R; Chen, DT; Desmond, RA; Hemminki, A; Kanerva, A; Raki, M; Särkioja, M | 1 |
| Aldaz, A; Aramendía, JM; Aristu, J; Centeno, C; Hernández, M; Moreno, M; Nieto, Y; Pérez-Calvo, J; Rifón, J; Sayar, O; Viteri, S; Viúdez, A; Zafra, A; Zufia, L | 1 |
| Baba, S; Irie, A; Iwamura, M; Matsumoto, K; Okazaki, M; Satoh, T | 1 |
| Galettis, P; Jiang, X; Links, M; McLachlan, AJ; Mitchell, PL | 1 |
| Boeck, HP; Boeck, S; Geissler, M; Golf, A; Heinemann, V; Hochhaus, A; Hoehler, T; Kettner, E; Ko, Y; Kojouharoff, G; Lordick, F; Mahlberg, R; Neugebauer, S; Schmid, B; Schoppmeyer, K; Seipelt, G; Stauch, M; Wein, A | 1 |
| Huang, HF; Lang, JH; Pan, LY; Peng, P; Shen, K; Wu, M; Yang, JX | 1 |
| Cordes, T; Fischer, D; Friedrich, M; Lüdders, D; Maass, N; Schroer, A; Villena-Heinsen, C | 1 |
| Kim, YT; Lee, KY; Lee, SH; Park, JK; Ryu, JK; Woo, SM; Yoo, JW; Yoon, YB | 1 |
| Atzpodien, J; Fluck, M; Reitz, M; Terfloth, K | 3 |
| Raj Pandey, K | 1 |
| Gemma, A; Kudoh, S; Matsuda, K; Minegishi, Y; Nara, M; Noro, R; Okano, T; Shibuya, M; Takemura, A; Yoshimura, A | 1 |
| Fujimoto, M; Kuramitsu, Y; Maehara, S; Maehara, Y; Mikuria, K; Mori-Iwamoto, S; Nakamura, K; Okita, K; Ryozawa, S; Sakaida, I | 1 |
| Aprahamian, M; Hajri, A; Parmentier, C; Rejiba, S; Wack, S | 1 |
| Brasiūniene, B; Juozaityte, E | 1 |
| Ballardini, M; Bercovich, E; Fiori, M; Frassineti, GL; Giovannini, N; Gunelli, R; Nanni, O; Pappagallo, GL; Pasquini, E; Silvestrini, R; Ulivi, P; Zoli, W | 1 |
| Arcangeli, G; Carapella, CM; Carosi, MA; Cognetti, F; Fabi, A; Felici, A; Iandolo, B; Metro, G; Mirri, A; Occhipinti, E; Pace, A; Vidiri, A | 1 |
| Alarcón, J; Blancas, I; Caballero, MD; De Mattos, SF; Gines, J; Gutierrez, A; Lopez, A; Martínez, J; Navarrete, M; Palacios, A; Rodríguez, J | 1 |
| Diasio, R; Johnson, M; Kang, SP; Ledbetter, L; Saif, MW; Steg, A | 1 |
| Camsari, T; Cavdar, C; Cokmert, S; Oztop, I; Secil, M; Toprak, O | 1 |
| Alarcón, J; Blancas, I; Gutiérrez, A; López, A; Martínez, J; Morey, M; Navarrete, M; Palacios, A; Perelló, A; Rodríguez, J | 1 |
| Adelstein, DJ; Borden, EC; Jacobs, AD; Kalmadi, SR; Keohan, ML; Kraut, MJ; Petrylak, DP; Rankin, C; Taub, RN | 1 |
| Ahn, JJ; Baek, JH; Cha, HJ; Jegal, Y; Jeong, AK; Jung, JP; Kim, H; Kim, JW; Kwon, WJ; Min, YJ; Noh, YJ; Park, CR; Park, JH; Seo, KW; Shin, JK; Shin, SJ | 1 |
| Böhlke, I; Bokemeyer, C; Hartmann, JT; Honecker, F; Kollmannsberger, C; Mayer, F; Oechsle, K; Waller, CF | 1 |
| Abe, H; Endo, Y; Kurumi, Y; Kushima, R; Mekata, E; Miyake, T; Murata, S; Shimizu, T; Tani, T | 1 |
| Chang, YC; Cheng, AL; Hsu, C; Hsu, CH; Lin, CC; Lin, ZZ; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Alken, RG; Bader, Y; Fritzer-Szekeres, M; Grusch, M; Hartmann, J; Heller, N; Horvath, Z; Krupitza, G; Madlener, S; Maier, S; Oehler, L; Saiko, P; Szekeres, T | 1 |
| Feng, M; Gong, WY; Ma, XT; Qiu, F; Tao, QS; Xiang, XJ; Xiong, JP; Xu, J; Yu, F; Zhang, L; Zhong, LX | 1 |
| Chen, ZL; Duan, G; Huang, LS; Wan, J; Wang, CX; Yan, XQ | 1 |
| Chumworathayi, B; Krusun, S; Luanratanakorn, S; Pattamadilok, J; Tangvorapongchai, V; Yuenyao, P | 1 |
| Fukuyama, T; Hachiya, Y; Hirano, Y; Ishikawa, N; Maeyama, R; Morimatsu, K; Sako, T; Tamura, T | 1 |
| El Karak, F; Flechon, A | 1 |
| Blackhall, F; Califano, R; Nagel, S; Thatcher, N | 1 |
| Hashimoto, Y; Kato, T; Kohri, K; Okada, S; Takahashi, S; Tozawa, K | 1 |
| Cinieri, S; La Torre, I; Lorusso, V; Numico, G; Orlando, L; Pezzella, G; Silvestris, N | 1 |
| Alexander, HR; Bartlett, DL; Dedrick, RL; Egorin, MJ; Gamblin, TC; Herscher, LL; Lagattuta, TF; Libutti, SK; Russo, A; Zuhowski, EG | 1 |
| Dixon, J; Holcomb, B; Kennard, J; Mahomed, J; Matos, JM; Schmidt, CM; Sebolt-Leopold, J; Shanmugam, R; Yip-Schneider, MT | 1 |
| Ansiaux, R; Beghein, N; Cron, GO; Feron, O; Gallez, B; Martinive, P | 1 |
| Arnoletti, JP; Ben-Josef, E; Bhargava, P; Casper, ES; Kim, P; Malafa, MP; Nakakura, EK; Shibata, S; Talamonti, M; Tempero, M; Wang, H; Willett, C | 1 |
| Bergmann, F; Büchler, MW; Friess, H; Gaida, MM; Giese, NA; Giese, T; Mayer, C; Michalski, CW; Wente, MN | 1 |
| George, TJ; Rajasekhar, A | 1 |
| Broaddus, VC; Hassan, R; Liewehr, DJ; Wilson, S; Zhang, J | 1 |
| Basche, M; Chow, LQ; Eckhardt, SG; Gore, L; Grolnic, S; Morrow, M; O'Bryant, CL; Schultz, MK | 1 |
| Ceribelli, A; Cognetti, F; Fariello, AM; Gamucci, T; Giampaolo, MA; Mansueto, G; Narducci, F; Pino, MS; Sperduti, I; Trapasso, T | 1 |
| Germano, D; Manzione, L; Rosati, G | 1 |
| Miller, JD | 1 |
| Bang, SJ; Joo, KR; Kim, H; Kim, MJ; Min, YJ; Nah, YW; Nam, CW; Park, JH; Park, NH; Shin, SJ | 1 |
| Cupelli, L; de Fabritis, P; Dentamaro, T; Giovannini, M; Niscola, P; Palombi, M; Perrotti, AP; Piccioni, D; Scaramucci, L; Tendas, A | 1 |
| Saito, Y; Sawada, J | 1 |
| Jiang, WQ; Liu, DG; Teng, XY; Zhou, NN | 1 |
| Li, GZ; Wang, RL; Zhang, SH; Zhang, Z | 1 |
| Aitini, E; Artale, S; Barni, S; Berardi, R; Cascinu, S; Dapretto, E; Di Costanzo, F; Falcone, A; Floriani, I; Labianca, R; Pierantoni, C; Rota, S; Scartozzi, M; Siena, S; Tonini, G; Zaniboni, A | 1 |
| Bjerregaard, JK; Pfeiffer, P | 1 |
| Ichihara, N; Kitanaka, A; Kubota, Y; Taminato, T; Tanaka, T | 1 |
| Iguch, M; Kiba, T; Motoo, Y; Nishio, K; Saitou, Y; Takahashi, Y; Yamaguchi, K | 1 |
| Fujiwara, S; Ino, K; Kajiyama, H; Kato, S; Kikkawa, F; Nakamura, S; Nawa, A; Shibata, K; Suzuki, K | 1 |
| Heinemann, V; Wilkowski, R; Wolf, M | 1 |
| Fayad, LE; Goy, A; Hagemeister, F; McLaughlin, P; Neelapu, S; Oki, Y; Pro, B; Romaguera, J; Samaniego, F; Younes, A | 1 |
| Aglianò, AM; Gazzaniga, P; Gradilone, A; Silvestri, I | 1 |
| Chung, J; Han, KS; Jeong, IG; Joung, JY; Kim, TS; Lee, KH; Seo, HK | 1 |
| Bakirtas, H; Eroglu, M; Guvence, N; Ozok, HU; Ure, M | 1 |
| Arnoletti, P; Buchsbaum, DJ; Derosier, LC; Grizzle, WE; Huang, Z; Lobuglio, AF; Oliver, PG; Sellers, J; Stockard, CR; Vickers, SM; Wang, W; Zhou, T; Zinn, KR | 1 |
| Gandhi, V | 1 |
| de Souza, PL; Galettis, P; Grimison, P; Jelinek, M; Liauw, W; Links, MJ; Manners, S; Metharom, E | 1 |
| Alam, Y; Bodkin, D; Butts, CA; Ellis, PM; Ellison, D; Englund, CW; Graze, P; Kaplan, E; Kreisman, H; Maher, J; McNulty, W; Middleman, EL; Pautret, V; Ross, HJ; Shepherd, FA; Weber, MR | 1 |
| Betticher, DC; Bihl, M; Bubendorf, L; D'Addario, G; Jost, L; Lerch, S; Mach, N; Mayer, M; Pless, M; Rauch, D; Ribi, K; Stahel, R; Stupp, R; Tapia, C; Widmer, L | 1 |
| Kim, YT; Lee, SH; Park, JK; Ryu, JK; Yoon, WJ; Yoon, YB | 1 |
| Brunet, J; Colomer, R; De Llorens, R; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A | 1 |
| De Smet, D; Jochmans, K; Neyns, B | 1 |
| Borg, M; Carroll, S; Davies, T; Goldstein, D; Graham, P; Harvey, J; Iacopetta, B; Kneebone, A; Macleod, C; Millar, JL; Ngan, SY; Reece, WH; Spry, N; Zissiadis, Y | 1 |
| Aydiner, A; Camlica, H; Derin, D; Guney, N; Tas, F; Topuz, E | 1 |
| Chou, SJ; Chu, CH; Chu, HC; Hsieh, CB; Shih, ML; Yao, NS; Yu, JC | 1 |
| Detterbeck, FC; Edelman, MJ; Govindan, R; Gralla, RJ; Jahan, TM; Limentani, SA; Loesch, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Ye, Z; Zaman, MB | 1 |
| Bold, R; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Lau, DH; Lenz, HJ; Ruel, C; Schenkein, DP; Shibata, S | 1 |
| Ayedi, L; Ayoub, A; Jlidi, R; Ketata, W; Msaad, S; Sellami, T; Yangui, I | 1 |
| Aletti, M; Bauduceau, O; Bonnichon, A; Borne, M; Ceccaldi, B; Fayolle, M; Le Moulec, S; Margery, J; Vedrine, L | 1 |
| Rödel, C; Sauer, R; Weiss, C | 2 |
| Chang, HM; Cho, JY; Do, YR; Hong, DS; Kim, SY; Kim, YH; Lee, KE; Lee, KH; Ryu, MH; Song, HS | 1 |
| Alberti, D; Bailey, H; Brandon, H; Eickhoff, J; Holen, K; Morgan-Meadows, S; Oliver, K; Schelman, W; Thomas, JP; Wilding, G | 1 |
| Berardi, R; Cantore, M; Cascinu, S; Cereda, S; Ferrari, VD; Grisanti, S; Mambrini, A; Mazza, E; Pasetto, L; Reni, M | 1 |
| Braguer, D; Cournede, A; Dahan, L; Duluc, M; Laquiere, A; Laugier, R; Ressiot, E; Ries, P; Seitz, JF | 1 |
| Benson, AB; Small, W; Wahl, AO; Wisinski, KB | 1 |
| Behringer, D; Gelos, M; Mann, B; Philippou, S | 1 |
| Davies, AM; Gandara, DR; Sangha, R | 1 |
| De Boeck, G; Folkerts, G; Grootenboers, M; Guetens, G; Hendriks, JM; Pasterkamp, G; Schramel, F; van Boven, WJ; van Putte, BP; van Schil, PE | 1 |
| Endlicher, E; Golder, S; Grossmann, J; Herfarth, H; Herold, T; Kullmann, A; Kullmann, F; Schlottmann, K; Troppmann, M | 1 |
| Désaknai, S; Esik, O; Huszty, G; Lumniczky, K; Sáfrány, G; Sasvári-Székely, M; Spasokoukotskaja, T; Staub, M; Szatmári, T | 1 |
| Berster, J; Beuers, U; Böck, S; Graeb, C; Heinemann, V; Jacobs, T; Kolligs, FT; Schäfer, C; Schirra, J; Schönberg, SO; Thasler, W; Wilkowski, R; Zech, CJ | 1 |
| Araki, H; Kamiyama, Y; Matsui, Y; Satoi, S; Sohgawa, M; Takahashi, K; Takai, S; Terakawa, N; Toyokawa, H; Yanagimoto, H | 1 |
| Antonelli, A; Barani, L; Berti, P; Fallahi, P; Ferrannini, E; Ferrari, SM; Marchetti, I; Materazzi, G; Miccoli, P | 1 |
| Hatakeyama, K; Muneoka, K; Sakata, J; Sasaki, M; Shirai, Y; Toshima, M; Wakai, T | 1 |
| Hagisawa, S; Hatakeyama, S; Imai, A; Ishimura, D; Iwabuchi, I; Koie, T; Mori, K; Ohyama, C; Okamoto, A; Yamato, T; Yoneyama, T | 1 |
| Aizawa, M; Ho Kim, D; Inose, S; Katsube, T; Naritaka, Y; Ogawa, K; Shiozawa, S; Tsuchiya, A; Usui, T; Yoshimatsu, K | 1 |
| Hashimoto, M; Matsuda, M; Watanabe, G | 1 |
| Hashimoto, M; Matsuda, M; Mine, S; Watanabe, G | 1 |
| Alkis, N; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Er, O; Uner, A; Yamac, D; Yildiz, R | 1 |
| Bedor, M; Brahmer, J; Bridges, BB; Doyle, LA; Edelman, MJ; Hausner, PF; Smith, R; Thomas, L | 1 |
| Ammerpohl, O; Bohm, B; Brockschmidt, C; Eismann, T; Giamas, G; Henne-Bruns, D; Hillenbrand, A; Hirner, H; Huber, N; Kalthoff, H; Knippschild, U; Leithäuser, F; Radunsky, B; Trauzold, A | 1 |
| Kimura, F; Miyazaki, M; Ohtsuka, M; Seki, N; Shimizu, H; Sugimoto, T; Washiro, M; Yoshidome, H | 1 |
| Charpidou, A; Dilana, K; Karapanagiotou, EM; Kosmas, E; Kotteas, E; Provata, A; Syrigos, K; Tourkantonis, I; Tzannou, I | 1 |
| Huang, F; Liang, ZY; Xiong, ZP; Zhang, YD | 1 |
| Morizane, C | 1 |
| Amoroso, D; Andreuccetti, M; Antonuzzo, A; Di Marsico, R; Fabbri, A; Falcone, A; Innocenti, F; Lo Dico, M; Tartarelli, G; Tibaldi, C; Vasile, E | 1 |
| Drömann, D; Goldmann, T; Lang, DS; Marwitz, S; Radtke, J; Schultz, H; Vollmer, E | 1 |
| Berlin, J; Chan, E; Holen, KD; Lockhart, AC; Mulkerin, D; Rothenberg, M; Thomas, J | 1 |
| Hayashida, H; Higaki, N; Hiura, Y; Ichihara, T; Kan, K; Murakami, M; Nakano, K; Sakon, M; Yamashita, S | 1 |
| Doi, K; Kudoh, K; Matsuo, A; Muranaka, T; Ogata, K; Ohchi, T; Ohtao, R | 1 |
| Bertino, P; Cilli, M; Favoni, R; Gaudino, G; Mutti, L; Piccardi, F; Porta, C | 1 |
| Adjei, AA; Aubry, MC; Delaune, R; Foster, NR; Kardinal, CG; Maurer, MJ; Nikcevich, DA; Northfelt, DW; Okuno, SH; Rowland, KM; Sloan, JA; Soori, GS | 1 |
| Estes, LA; Kelner, MJ; McMorris, TC; Rojas, RJ; Suthipinijtham, P | 1 |
| Atienza, D; Awasthi, S; Berry, W; Delaune, R; Deutsch, M; Dien, PY; Gregory, TF; Hood, K; Hutson, TE; Ilegbodu, D; Kolodziej, MJ; Mull, S; Muscato, JJ; Nicol, S; Raju, RN; Ruxer, RL; Vukelja, S | 1 |
| Gou, SM; Liu, T; Tao, J; Wang, CY; Wu, B; Wu, HS; Xiong, JX; Yang, M; Zhao, G; Zhou, F; Zhou, J | 1 |
| Boeck, S; Heinemann, V | 2 |
| Begum, M; Bepler, G; Simon, GR | 1 |
| Brown, RK; Glaros, S; Michael, C; Reisman, D; Wilson, R | 1 |
| Amos, KD; Arumugam, T; Evans, DB; Hwang, RF; Ji, B; Logsdon, CD; Moore, T; Ramachandran, V; Rivera, A | 1 |
| Johnson, JR; Justice, R; Pazdur, R; Senderowicz, AM; Sridhara, R; Zimmerman, P | 1 |
| Amenitsch, H; Bourgaux, C; Couvreur, P; Desmaële, D; Lepêtre-Mouelhi, S; Mangenot, S; Ollivon, M; Pili, B; Poupaert, JH; Reddy, LH | 1 |
| Bajetta, E; Bodoky, G; Dietrich, D; Figer, A; Glimelius, B; Grawe, P; Herrmann, R; Hess, V; Ruhstaller, T; Saletti, P; Scheithauer, W | 1 |
| Marik, PE; Vahid, B | 1 |
| Altorjai, G; Bartsch, R; Dubsky, P; Gampenrieder, SP; Gnant, M; Mader, RM; Pluschnig, U; Rottenfusser, A; Rudas, M; Steger, GG; Wenzel, C; Zielinski, CC | 1 |
| Arseneau, J; Caprioni, F; Corringham, R; De Boer, C; DeWitte, M; Friess, H; Lu, JD; Malfertheiner, P; Mantovani, G; Prabhakar, U; Qi, M; Richel, D; Ritch, P; Robinson, D; Van Cutsem, E; Von Hoff, D; Wiedenmann, B; Zhong, B | 1 |
| Couvreur, P; Desmaële, D; Dubernet, C; Marque, PE; Mouelhi, SL; Reddy, LH | 1 |
| Jing, Q; Rougcheng, L; Xinyu, Q | 1 |
| Belani, C; Ramalingam, S | 1 |
| Ishikawa, T; Kamimura, H; Kamimura, T; Ohta, H; Seki, K; Takeda, K; Togashi, T; Tsuchiya, A; Watanabe, K; Yoshida, T | 1 |
| El-Mabhouh, AA; Mercer, JR | 1 |
| Dai, C; Du, Q; Gardner, K; Guo, X; Jacobs, JL; Jiang, K; Li, H; Li, QQ; Miao, Y; Qian, Z; Sun, G; Xu, Z; You, Y; Yu, C; Yuan, D; Zhang, X; Zhu, Y | 1 |
| Sleijfer, S; Verweij, J | 1 |
| Bauer, S; Ebeling, P; Eisele, L; Flasshove, M; Moritz, T; Schuett, P; Schuette, J; Seeber, S | 1 |
| Hirobe, M; Itoh, T; Kunishima, Y; Masumori, N; Takayanagi, A; Takeuchi, M; Tsukamoto, T | 1 |
| Boku, N; Fukutomi, A; Kinoshita, T; Kondo, S; Maeda, A; Nagino, M; Uesaka, K | 1 |
| Klein, F | 1 |
| Attia, S; Eickhoff, J; Erlichman, C; Heun, J; Holen, KD; Huang, W; Kolesar, J; Laheru, D; Mahoney, MR; Pitot, HC | 1 |
| Bedor, M; Edelman, MJ; Gajra, A; Green, MJ; Hodgson, L; Jewell, S; Kratzke, RA; Masters, GA; Mauer, AM; Morrison, C; Vokes, EE; Wang, X; Watson, D | 1 |
| Breda, E; Del Medico, P; Ferrandina, G; Katsaros, D; Lorusso, D; Ludovisi, M; Pignata, S; Priolo, D; Savarese, A; Scaltriti, L; Scambia, G | 1 |
| Benson, AB; Berlin, J; Chakravarthy, AB; Freedman, GM; Gill, JF; Hoffman, JP; Kinsella, TJ; Konski, AA; Lawrence, T; McGinn, CJ; Merchant, NB; Mulcahy, MF; Nicol, S; Philip, PA; Small, W; Talamonti, MS; Xu, RM; Zalupski, MM | 1 |
| Ikeda, H; Kobayashi, M; Morita, T; Nakano, K; Nukui, A; Sugaya, Y; Suzuki, K; Yuzawa, M | 1 |
| Epstein, RJ; Leung, TW | 1 |
| Bull, JM; Deng, W; Jenkins, GN; Rowe, RW; Strebel, FR | 1 |
| Campagnoli, E; Cappuzzo, F; Cavina, R; Ceresoli, GL; De Vincenzo, F; Garassino, I; Salamina, S; Santoro, A; Soto Parra, HJ; Zucali, PA | 1 |
| Adams, E; Dragovic, S; Haghedooren, E; Hoogmartens, J; Németh, T; Noszál, B | 1 |
| Dong, K; Li, B; Lin, F; Shen, JJ; Wang, R; Wang, X; Wei, SH; Zhang, HZ; Zhang, Q | 1 |
| Fujii, M; Fukatsu, H; Harada, R; Ishida, E; Kawamoto, H; Kurihara, N; Mizuno, O; Nakanishi, T; Ogawa, T; Okada, H; Sakaguchi, K; Tsutsumi, K | 1 |
| Bang, S; Chung, JB; Hong, SP; Jeon, TJ; Lee, WJ; Park, JY; Park, MS; Park, SW; Seong, J; Song, SY | 1 |
| Fukushima, M; Hamada, C; Hosoe, S; Kawahara, M; Matsui, S; Tada, H | 1 |
| Fujiwara, K; Ichikawa, K; Ishida, S; Kurakata, S; Yada, A; Yazawa, M; Yoshida, H | 1 |
| Holalkere, NS; Horgan, K; Muzikansky, A; Sahani, DV; Zhu, AX | 1 |
| Arkenau, HT; Ethell, M; Hiwarkar, P; Morgan, G; Potter, M; Treleaven, J | 1 |
| Choi, B; Mehta, M; Robins, HI; Schiller, J | 1 |
| Goh, BC; Holford, NH; Lee, HS; Lee, SC; Soo, RA; Tham, LS; Wang, LZ | 1 |
| Cavallaro, G; Cosco, D; Fresta, M; Giammona, G; Licciardi, M; Paolino, D | 1 |
| Ackermann, H; Gruber, T; Nabil, M; Vogl, TJ; Yakoub, D; Zangos, S | 1 |
| Cartei, G; Labianca, R | 1 |
| Afchain, P; André, T; Balosso, J; Dupuis, O; Huguet, F; Lledo, G; Louvet, C; Mineur, L; Moureau-Zabotto, L; Phélip, JM; Touboul, E; Vendrely, V | 1 |
| Gallick, GE; Kim, MP | 1 |
| Liau, SS; Whang, E | 1 |
| Abrams, RA; Benson, AB; Fromm, ML; Haddock, MG; Hoffman, JP; Konski, A; Kudrimoti, MR; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Schaefer, P; Willett, CG; Winter, KA | 1 |
| Fukuoka, J; Hori, T; Hosokawa, A; Ishizawa, S; Kitano, H; Kudo, T; Kuroda, K; Sugiyama, T; Tanaka, T; Tsukada, K; Uotani, H | 1 |
| Kang, SP; Saif, MW | 2 |
| Aysan, T; Cok, G; Göksel, T; Soyer, S | 1 |
| Briollais, L; Ibrahim-Zada, I; Jarjanazi, H; Kiefer, J; Mousses, S; Ozcelik, H; Pabalan, N; Savas, S; Tuzmen, S | 1 |
| Kang, SP; Lacy, J; McLennan, B; Taddei, T | 1 |
| Arai, K; Honda, M; Iida, H; Kagaya, T; Kakinoki, K; Kaneko, S; Kitamura, K; Mizukosi, E; Nakamoto, Y; Sakai, A; Sakai, Y; Terashima, T; Yamashita, T | 1 |
| Adam, P; Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Quinkler, M; Ritte, C; Ritter, C; Strasburger, C; Wortmann, S | 1 |
| Arvanitaki, M; De Maertelaere, V; Demols, A; Gay, F; Hendlisz, A; Maréchal, R; Van Laethem, JL | 1 |
| Awar, O; Duvic, M | 1 |
| Ames, MM; Bhattacharya, R; Buhrow, SA; Dutta, S; Katarya, A; Lau, JS; Muders, M; Mukherjee, P; Mukhopadhyay, D; Patra, CR; Reid, JM; Safgren, SL; Wang, E; Wang, S; Yaszemski, MJ | 1 |
| Baconnier, M; Bedenne, L; Boucher, E; Girault, C; Phelip, JM; Roblin, X | 1 |
| An, CH; Cho, EK; Hong, J; Jeong, SH; Kim, Y; Kim, YS; Kyung, SY; Lee, JH; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB | 1 |
| Carone, V; Corrado, G; Ferrandina, G; Ludovisi, M; Petrillo, M; Scambia, G | 1 |
| Correale, P; Francini, G; Miano, S; Montagnani, F; Pascucci, A; Petrioli, R; Sciandivasci, A; Tanzini, G; Testi, W | 1 |
| Arpicco, S; Canal, F; Dalla Via, L; Pasut, G; Schiavon, O; Veronese, FM | 1 |
| Capellà, G; Casanovas, O; Figueras, A; Galán, M; Germà, JR; Ginestà, MM; Lacasa, C; Laquente, B; Ribas, IG; Viñals, F | 1 |
| Antonuzzo, A; Danesi, R; Del Tacca, M; Di Marsico, R; Falcone, A; Giovannetti, E; Laan, AC; Mey, V; Nannizzi, S; Orlandini, C; Peters, GJ; Ricciardi, S; Tibaldi, C; Vasile, E | 1 |
| Kameda, A; Minami, K; Miyahara, E; Noso, Y; Suzuki, T; Tsutani, Y | 1 |
| Chen, XJ; Qu, X; Xiao, W; Zhou, SY | 1 |
| Dowlati, A; Fidias, P; Jänne, PA; Kindler, H; Langer, CJ; Monberg, M; Obasaju, C; Simon, GR; Taub, RN | 1 |
| Chie, EK | 1 |
| Kim, YT | 1 |
| Leen, R; Medema, J; Rodermond, H; van Bree, C; van Kuilenburg, A | 1 |
| Persaud, R | 1 |
| Cercato, MC; Ciccarese, M; Cognetti, F; Di Filippo, F; Ferraresi, V; Giannarelli, D; Nuzzo, C; Zeuli, M | 1 |
| Alemany, R; Amat, JC; Besalduch, J; Galmés, A; Ginés, J; Gutiérrez, A; Martín, J; Navarro, M; Ros, T; Sampol, A; Saus, C; Serra, JM; Serra-Moisés, L; Vögler, O | 1 |
| Bastos Oreiro, M; López Rodríguez, M; Monedero Martín, MC; Plasencia Rodríguez, C | 1 |
| Arvanitaki, M; de Maertelaer, V; Demols, A; Gay, F; Hendlisz, A; Maréchal, R; Van Laethem, JL | 1 |
| Chiba, T; Doi, R; Fukushima, M; Ishiguro, H; Kami, K; Kanai, M; Kawaguchi, Y; Kitano, T; Matsumoto, S; Misawa, A; Nishimura, T; Yamauchi, J; Yanagihara, K; Yasuda, H; Yazumi, S; Yoshikawa, K | 1 |
| Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakagawa, N; Ohge, H; Sudo, T; Sueda, T; Uemura, K | 1 |
| Behne, MJ; Brüllke, N; Hauswirth, U; Menz, A; Moll, I; Müllerleile, U | 1 |
| Kamio, Y; Mori, N; Murakami, T; Yokooji, T | 1 |
| Fujino, Y; Kuroda, Y; Sakai, T | 1 |
| Boeck, S; Heinemann, V; Hinke, A; Labianca, R; Louvet, C | 1 |
| Hayashi, T; Homma, H; Ihara, H; Ishiwatari, H; Kato, J; Kawano, Y; Matsunaga, T; Miyanishi, K; Niitsu, Y; Okuda, T; Sato, Y; Takada, K; Takahashi, M; Takahashi, S; Takanashi, K | 1 |
| Armand, R; Kintner, J; Lewis, LD; Perez, R; Yeo, TK | 1 |
| Clarenbach, R; Märten, A; Nagaraj, S; Sauerbruch, T; Schmidt, T; Schmidt-Wolf, IG; Schmitz, V; Tiemann, K; Ziske, C | 1 |
| Beijnen, JH; Schellens, JH; Veltkamp, SA | 1 |
| Burris, H; Rocha-Lima, C | 1 |
| Brown, JA; Fowler, JD; Johnson, KA; Suo, Z | 1 |
| Banerjee, TK; Bromund, JL; Chen, R; Dowell, JE; Dudek, AZ; Larson, T; McCleod, MJ; Monberg, MJ; Obasaju, CK; Pandya, KJ; Schneider, DJ | 1 |
| Chereddy, S; Dudek, AZ; Maddaus, M; Nguyen, S; Wagner, JE | 1 |
| Crinò, L; Della Fazia, MA; Flacco, A; Gori, S; Ludovini, V; Piobbico, D; Pistola, L; Scuderi, C; Servillo, G | 1 |
| Bergsland, EK; Dito, E; Hwang, J; Ko, AH; Schillinger, B; Scott, J; Tempero, MA; Venook, AP; Wong, D; Xu, Z | 1 |
| Brahmer, J; Donehower, RC; Elsayed, Y; Ettinger, D; Hidalgo, M; Jimeno, A; Khan, Y; Laheru, D; Lansey, D; Messersmith, WA; Zannikos, P | 1 |
| Chua, YJ; Zalcberg, JR | 1 |
| Abbruzzese, JL; Chang, P; Evans, DB; Jiao, L; Li, D; Okazaki, T | 1 |
| Awasthy, B; Chacko, RT; Dawar, R; Dhindsa, N; Hu, Z; Julka, PK; Koppiker, CB; Lin, B; Ma, D; Miller, ID; Nag, S; Nair, A; Nair, S; Oh, DS; Parshad, R; Perou, CM | 1 |
| Fulga, C; Fulga, I; Zugravu, A | 1 |
| Alberts, SR; Carlson, SK; Foster, NR; Galanis, E; Grothey, A; Jatoi, A; Lowe, V; McWilliams, RR; Quevedo, F; Rubin, J | 1 |
| Van Laethem, JL | 1 |
| Dipetrillo, T; Evans, D; Gutman, N; Joseph, P; Kennedy, T; McNulty, B; Millis, R; Miner, T; Plette, A; Resnick, M; Safran, H; Sears, D | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Zerbi, A | 1 |
| Alvarez, I; Burris, H; Chow, S; Dragovich, T; Gordon, M; Green, S; Loehrer, P; Obregon, Y; Stratton, S; Von Hoff, DD | 1 |
| Abulafia, O; Blessing, JA; Degeest, K; Hensley, ML; Homesley, HD; Rose, PG | 1 |
| De Grève, J; De Mey, J; Decoster, L; Everaert, H; Meysman, M; Neyns, B; Nieboer, K; Schallier, D | 1 |
| Chang, S; Desser, TS; Fisher, GA; Ford, JM; Goodman, KA; Greco, R; Koong, AC; Kuo, T; Lee, F; Norton, J; Quon, A; Schellenberg, D; Yang, GP | 1 |
| Chadda, SK; Hossain, MT; Kane, CT; Risbood, PA; Vadapalli, S | 1 |
| Maples, PB; Nemunaitis, JJ; Wallraven, G | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Morizane, C; Najima, M; Nakachi, K; Ogura, T; Okusaka, T; Suzuki, E; Ueno, H | 1 |
| Adams, DJ; Giles, F; Jacobsen, TF; Myhren, F; Rizzieri, DA; Sandvold, ML | 1 |
| Hilbig, A; Oettle, H | 1 |
| Dunlop, D; Graham, J; McLaren, V; Paul, J | 1 |
| Arita, Y; Eriguchi, N; Funakoshi, A; Igarashi, H; Ito, T; Miyahara, T; Mizumoto, K; Muranaka, T; Sakai, T; Shinozaki, H; Sumii, T; Tanaka, M; Ueki, T; Yamaguchi, H | 1 |
| Nagai, T; Ohgaki, K; Sugie, T | 1 |
| Dean-Colomb, W; Esteva, FJ | 1 |
| Artru, P; Asnacios, A; Fartoux, L; Hebbar, M; Louafi S, S; Mansoubakht, T; Poynard, T; Romano, O; Rosmorduc, O; Taieb, J; Tesmoingt, C | 1 |
| Abbruzzese, JL; Chiao, PJ; Fleming, JB; Ishiyama, S; Melisi, D; Sclabas, GM; Tortora, G; Xia, Q | 1 |
| Boukovinas, I; Georgoulias, V; Hatzidaki, D; Koutsopoulos, A; Mavroudis, D; Mendez, P; Rosell, R; Souglakos, J; Stathopoulos, E; Taron, M; Tripaki, M | 1 |
| Aasebø, U; Bremnes, RM; Brunsvig, PF; Helbekkmo, N; Sundstrøm, SH; von Plessen, C | 1 |
| Rocha-Lima, CM | 1 |
| Bacigalupo, A; Benasso, M; Corvò, R; Marcenaro, M; Margarino, G; Ponzanelli, A; Vigo, V | 1 |
| Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R | 1 |
| Caca, K; Helmchen, U; Schmidt, A; Schwella, N; von Renteln, D | 1 |
| Ahmad, A; Azmi, AS; Banerjee, S; Mohammad, RM; Rangnekar, VM; Sarkar, FH | 1 |
| Chen, J; Ou-Yang, ZG; Wu, SY; Zhen, YS | 1 |
| Celia, C; Cosco, D; Fresta, M; Malara, N; Paolino, D; Savino, R; Terracciano, R | 1 |
| Du, J; Guo, J; Li, T; Lu, WL; Min, R; Zhang, Y | 1 |
| Advani, RH; Chen, AI | 1 |
| Alexandrova, EN; Istomin, YP; Petrovich, SV; Sergeyeva, OP; Zhavrid, EA | 1 |
| Algara, M; Bastus, R; Blanco, R; Bover, I; Domenech, M; Gay, M; Mesía, C; Montesinos, J; Nogué, M; Solé, J; Terrassa, J; Vadell, C | 1 |
| Aikata, H; Chayama, K; Ito, K; Kawaoka, T; Miki, D; Saneto, H; Takahashi, S; Takaki, S; Toyota, N; Uka, K | 1 |
| Choi, SH; Han, SS; Kang, SB; Kim, JW; Lee, HP; Lee, YK; Park, NH; Song, YS | 1 |
| Hezel, AF; Zhu, AX | 2 |
| Agelaki, S; Agelidou, A; Agelidou, M; Androulakis, N; Boukovinas, I; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Kakolyris, S; Kentepozidis, N; Lamvakas, L; Pallis, AG; Pavlakou, G; Polyzos, A; Tsiafaki, X | 1 |
| Davila, E; Lilenbaum, R; Raez, L; Seigel, L; Tseng, J | 1 |
| Dees, EC; Goldberg, RM; Hayes, DN; Lee, CB; Moore, DT; Socinski, MA; Stinchcombe, TE | 1 |
| Cho, HA; Kim, IY; Kim, JS; Kim, MJ; Lee, HJ; Lee, IA; Lim, SK | 1 |
| Cheng, AL; Hsu, C; Hu, FC; Huang, TC; Kuo, SH; Lin, CC; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Bartlett, NL; Cass, CE; Cheson, B; Cook, JR; Hsi, ED; Johnson, JL; Jones, D; Jung, SH; Lai, R; Mackey, JR; Said, J; Young, JD | 1 |
| Oki, Y; Younes, A | 1 |
| Kang, WK; Yang, L | 1 |
| Fujiwara, Y; Gemba, K; Hotta, K; Kiura, K; Omori, M; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S | 1 |
| Gillani, JA; Iqbal, M; Khan, A; Nasreen, S; Samad, A | 1 |
| Cooney, MM; Dreicer, R; Li, H; Roth, BJ; Wilding, G | 1 |
| Ben-Josef, E; Lawrence, TS | 2 |
| Furuse, J; Ioka, T; Ishii, H; Ito, Y; Okusaka, T; Shibuya, K; Shinchi, H; Yamada, S | 1 |
| Aydiner, A; Derin, D; Guney, N; Tas, F; Topuz, E | 1 |
| Bertoldi, I; Correale, P; Fioravanti, A; Francini, G; Miracco, C; Montagnani, F | 1 |
| Aparicio, T; Azzedine, A; Bedenne, L; Bonnetain, F; Bosset, JF; Bouché, O; Butel, J; Chauffert, B; Hammel, P; Maingon, P; Mariette, C; Mineur, L; Mornex, F; Rougier, P; Stremsdoerfer, N | 1 |
| Dhabhar, B; Hazarika, N; Saikia, TK | 1 |
| Couvreur, P; Reddy, LH | 1 |
| Gerson, R; Serrano, A | 1 |
| Besnard, M; Chacun, H; Cintrat, JC; Couvreur, P; Declèves, X; Deroussent, A; Desmaële, D; Dubernet, C; Ferreira, H; Khoury, H; Laugier, C; Lepêtre-Mouelhi, S; Paci, A; Reddy, LH; Rousseau, B; Vassal, G | 1 |
| Gerber, HP; Grewal, IS; Kissler, KM; Oflazoglu, E; Sievers, EL | 1 |
| Alivizatos, G; Antoniou, N; Bamias, A; Chrisofos, M; Dimopoulos, MA; Karayiotis, E; Kastritis, E; Koureas, A; Lainakis, G; Skolarikos, A | 1 |
| Cho, HJ; Jeong, JY; Ju, JY; Kim, KS; Kim, MR; Kim, SO; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Oh, IJ | 1 |
| Aravantinos, G; Bafaloukos, D; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Karina, M; Kosmidis, P; Koutras, A; Maniadakis, N; Matsiakou, F; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Skarlos, D | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Lee, SY; Song, JE | 1 |
| Daw, NC; Furman, W; McCarville, MB; Navid, F; Roberts, W; Watkins, A; Willert, JR | 1 |
| Cerny, T; D'Addario, G; Demmer, R; Früh, M; Gillessen, S | 1 |
| Blackstock, AW; Bogart, JA; Green, M; Gu, L; Masters, GA; Miller, AA; Munley, M; Rosenman, J; Sleeper, A; Socinski, MA; Ungaro, P; Vokes, EE; Wang, X | 1 |
| Bauerfeind, P; Clavien, PA; Heinrich, S; Knuth, A; Pestalozzi, BC; Schäfer, M; Weber, A | 1 |
| Kuwahara, A; Masuda, T | 1 |
| Kurosaki, I; Nakadaira, K; Ueki, H | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Dikilitas, M; Kaya, AO; Ozkan, S; Ozturk, B; Uner, A; Yamac, D; Yaman, E; Yildiz, R | 1 |
| Beijnen, JH; Pluim, D; Schellens, JH; van Tellingen, O; Veltkamp, SA | 1 |
| Bevilacqua, G; Boggi, U; Campani, D; Danesi, R; Del Chiaro, M; Del Tacca, M; Funel, N; Giovannetti, E; Mey, V; Mosca, F; Nannizzi, S; Pollina, LE; Ricciardi, S | 1 |
| Germano, D; Manzione, L; Romano, R | 1 |
| Adamo, B; Adamo, V; Condemi, G; Di Lullo, L; Ferrandina, G; Ferraro, G; Lorusso, D; Lorusso, V; Paglia, A; Pisconti, S; Priolo, D; Rossello, R; Scambia, G | 1 |
| Hasegawa, Y; Hida, T; Horio, Y; Osada, H; Sekido, Y; Shimizu, J; Shimokata, K; Takahashi, T; Yatabe, Y | 1 |
| Abel, U; Herrmann, C; Herrmann, T; Jaeger, D; Stremmel, W | 1 |
| Erovic, BM; Heiduschka, G; Kloimstein, P; Martinek, H; Selzer, E; Skoda, C; Thurnher, D; Vormittag, L; Wachek, V; Wrba, F | 1 |
| Danese, MD; Lin, CY; Lubeck, D; Northridge, K; O'Connor, P; Reyes, C | 1 |
| Cloud, G; Davidson, S; deShazo, M; Kuo, KL; Leggas, M; Li, M; Rinehart, J; Robert, F; Wang, H; Zhang, R | 1 |
| Agarwal, M; Beer, TM; Crawford, ED; Goldman, B; Nichols, CR; Petrylak, DP; Ryan, CW | 1 |
| Agelaki, S; Agelidou, A; Agelidou, M; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Papakotoulas, P; Vardakis, N | 1 |
| Ang, PC; Chowbay, B; Khoo, KS; See, HT; Wong, NS; Wong, ZW | 1 |
| Bernstein, SH; Fisher, RI; Friedberg, JW; Jordan, CT; Kelly, J; Liesveld, J; Marquis, D; Mendler, JH; Rich, L; Rossi, RM; Voci, S | 1 |
| Alschuler, L; Block, KI; Gyllenhaal, C; Kranz, S; Roddy, GD; Rubin, D | 1 |
| Biesma, B; de Marinis, F; Digumarti, R; Gandara, D; Gatzemeier, U; Goksel, T; Lee, JS; Manegold, C; Mellemgaard, A; Parikh, P; Park, K; Patil, S; Rolski, J; Scagliotti, GV; Serwatowski, P; Simms, L; Sugarman, KP; Vansteenkiste, J; von Pawel, J; Zukin, M | 1 |
| Agelaki, S; Agelidou, A; Boukovinas, I; Georgoulias, V; Geroyianni, A; Hatzidaki, D; Kakolyris, S; Kalbakis, K; Kotsakis, A; Mavroudis, D; Polyzos, A; Souglakos, J; Vamvakas, L; Ziras, N | 1 |
| Chao, Y; Chi, KH; Huang, PI; Lee, RC; Li, CP; Shiau, CY; Wang, LW; Yen, SH | 1 |
| Ames, MM; Dai, NT; Flatten, KS; Gálvez-Peralta, M; Karnitz, LM; Kaufmann, SH; Loegering, DA; Safgren, SL; Wagner, JM | 1 |
| Brunner, TB; Cavallaro, A; Geiger, M; Grabenbauer, GG; Hohenberger, W; Lang-Welzenbach, M; Mantoni, TS; McKenna, WG; Sauer, R | 1 |
| Aoki, H; Hisada, T; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Shimizu, Y; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
| Bouabdallah, K; Brice, P; Carde, P; Chaoui, D; Decaudin, D; Diviné, M; Fermé, C; Fitoussi, O; Gabarre, J; Pacquement, H; Salhi, R; Soussain, C; Validire, P; Zanni, M | 1 |
| Cavalli, F; Mazzucchelli, L; Mora, O; Soldini, D; Zucca, E | 1 |
| Deray, G; Isnard-Bagnis, C; Janus, N; Karie, S; Launay-Vacher, V | 1 |
| Barbone, D; Broaddus, VC; Bueno, R; Gordon, GJ; Jablons, DM; Nishimura, SL; Sugarbaker, DJ; Wilson, SM; Yang, TM | 1 |
| Bajetta, E; Barone, C; Bycott, P; Chodkiewicz, C; Kim, S; Létourneau, R; Liau, K; Maurel, J; Pithavala, Y; Ricart, AD; Rixe, O; Spano, JP; Trask, P; Wasan, H; Wong, R | 1 |
| Grossbard, ML; Kozuch, P; Nieto, J | 1 |
| Fasching, PA; Heinemann, V; Kalischefski, B; Kolbl, H; Laessig, D; Maubach, P; Meerpohl, H; Melchert, F; Morack, G; Scharl, A; Stauch, M; Stemmler, HJ; Vehling-Kaiser, U; Weber, B | 1 |
| Vose, JM | 1 |
| Andre, VA; Beijnen, JH; Callies, S; Jansen, RS; Kloeker-Rhoades, S; Pluim, D; Rosing, H; Schellens, JH; Slapak, CA; Veltkamp, SA; Visseren-Grul, CM | 1 |
| Beumer, JH; Covey, JM; Egorin, MJ; Eiseman, JL; Joseph, E; Parise, RA | 1 |
| Wakelee, H | 1 |
| Argiana, E; Froudarakis, ME; Karpathiou, G; Koutsopoulos, A | 1 |
| Bertolini, F; Codeluppi, M; Conte, PF; De Matteis, E; Frassoldati, A; Malavasi, N; Rossi, G; Venturelli, C | 1 |
| Beijnen, JH; Brouwers, EE; Huitema, AD; Schellens, JH | 1 |
| Rocha-Lima, C; Vulfovich, M | 1 |
| Fleming, G | 1 |
| Blessing, JA; Hensley, ML; Mannel, R; Rose, PG | 1 |
| Brenner, WS; Fournier, C; Fracasso, PM; Gao, F; James, J; Marsh, S; McLeod, HL; Picus, J; Tan, BR; Yen-Revollo, JL | 1 |
| Chong, PY; Choo, TB; Goh, BC; Lee, HS; Lee, SC; Liu, JJ; Ng, SS; Soo, RA; Soong, R; Tham, LS; Wang, LZ; Yong, WP | 1 |
| Goff, BA; Holmberg, LA; Kurland, BF; Veljovich, D | 1 |
| Arias, JL; Couvreur, P; Reddy, LH | 3 |
| Barbarot, V; Courant-Menanteau, M; Lewden-Bernadac, B; Perrocheau, G; Thomare, P | 1 |
| Eley, HL; McDonald, PS; Russell, ST; Tisdale, MJ | 1 |
| Cox, JD; Fossella, FV; Glisson, BS; Herbst, RS; Hong, WK; Kies, M; Komaki, R; Liao, Z; Pisters, KM; Zinner, RG | 1 |
| Aksoy, P; Ames, MM; Eckloff, BW; Gilbert, JA; Kocabas, NA; Moon, I; Pelleymounter, LL; Ryu, JS; Salavaggione, OE; Weinshilboum, RM; Wieben, ED; Yee, V | 1 |
| Bourquin, V; Delouche, D; Dettwiler, S; Giovannini, M; Guinand, A; Haenni, C; Moll, S | 1 |
| Ceballos, J; García-Foncillas, J; Pérez-Gracia, JL; Santisteban, M; Vivas, I | 1 |
| Nagai, S; Sonobe, M; Takenaka, K; Tanaka, F; Wada, H | 1 |
| Friess, H; Kleeff, J | 1 |
| Cappellacci, L; Franchetti, P; Grifantini, M; Petrelli, R; Vita, P | 1 |
| Bulotta, S; Calvagno, MG; Celia, C; Fresta, M; Paolino, D; Russo, D; Ventura, CA | 1 |
| Brown, C; Chetiyawardana, AD; Cullen, MH; Draycott, C; El-Modir, A; Hussain, SA; Palmer, DH; Peake, DR; Rea, DW; Riley, P; Swinson, DE; Wills, A | 1 |
| Aiura, K; Ito, Y; Kitagawa, Y; Kitajima, M; Ueda, M | 1 |
| Desauw, C; Rose, C; Tran, TH | 1 |
| Vikram, B | 1 |
| Fujita, T | 1 |
| Cunningham, D; Ghaneh, P; Neoptolemos, JP; Starling, N; Sultana, A; Tudur Smith, C | 1 |
| Lebret, T | 1 |
| Buclin, T; Chassot, PG; Decosterd, LA; Kuemmerle, A; Lejeune, F; Liénard, D; Mosimann, F; Stupp, R | 1 |
| Carbó, N; Casado, FJ; García-Manteiga, J; Mazo, A; Mercadé, E; Pastor-Anglada, M; Pérez-Torras, S | 1 |
| Camara, O; Keil, E; Klare, P; Lichtenegger, W; Oskay-Oezcelik, G; Paulenz, A; Sehouli, J; Sommer, H; Stauch, M; Stengel, D; Zeimet, AG | 1 |
| Correale, P; Cusi, MG; Del Vecchio, MT; Fioravanti, A; Francini, E; Francini, G; Ginanneschi, C; Martellucci, I; Montagnani, F; Remondo, C; Rotundo, MS; Tagliaferri, P; Tassone, P | 1 |
| Goh, BC; Holford, NH; Lee, HS; Lee, SC; Soo, RA; Tham, LS; Wang, L; Yong, WP | 1 |
| Creaven, PJ; Gottlieb, RH; Iyer, RV; Khushalani, NI; Ramnath, N; Rustum, YM; Schwarz, JK; Yu, J | 1 |
| Bandstra, B; Bilynsky, BT; Bondarenko, IN; Eisenfeld, AJ; Ganul, VL; Hotko, YS; Kostinsky, IY; O'Brien, ME; Oldham, FB; Popovich, AY; Sandalic, L; Sandler, AB; Singer, JW; Socinski, MA; Tomova, A | 1 |
| Jiang, JX; Liu, WS; Qin, RY; Shen, M; Shi, CJ; Tian, R; Wang, M; Yan, HJ | 1 |
| Bluethner, T; Caca, K; Haefner, M; Moebius, C; Mossner, J; Niederhagen, M; Wiedmann, M; Wittekind, C | 1 |
| Danesi, R; Falcone, A; Giovannetti, E; Laan, AC; Nannizzi, S; Peters, GJ; Ricciardi, S; Tibaldi, C; Vasile, E | 1 |
| Graves, LM; Jones, SZ; Leisewitz, AV; Yang, J; Zimmerman, EI | 1 |
| Ko, SK; Lim, JY; Min, SH | 1 |
| Dorr, RT; Landowski, TH; Samulitis, BK | 1 |
| Ahn, CW; Bull, JM; Koch, SM; Nagle, VL; Oliver, D; Redwine, M; Rowe, RW; Scott, GL; Strebel, FR | 1 |
| Goodman, A; Ko, E; Lee, S | 1 |
| Hee, SW; Leong, SS; Lim, WT; Poon, D; Rajan, S; Tan, EH; Tay, MH; Toh, CK; Wee, J | 1 |
| Asmar, L; Boehm, KA; Doane, L; Loesch, D; McIntyre, K; Monticelli, M; O'Shaughnessy, JA; Orlando, M; Paul, D; Vaughn, LG; Vukelja, S; Zhan, F | 1 |
| Eisenkop, SM; McAlpine, JN; Spirtos, NM | 1 |
| Kamiyama, Y; Kodama, T; Kondoh, T; Mori, K | 1 |
| Hayama, M; Konishi, Y; Kubo, M; Maeda, H; Mizuta, M; Shirakawa, K; Sogabe, O; Udaka, T; Waki, N | 1 |
| Fujimori, N; Fujimoto, C; Funakoshi, A; Maruyama, Y; Niina, Y; Sumii, T | 1 |
| Saijyo, N | 1 |
| Furuiye, M; Inase, N; Ishiwata, N; Jin, Y; Miyake, S; Miyashita, Y; Takano, S; Yoshizawa, M; Yoshizawa, Y | 1 |
| Aizawa, M; Inose, S; Katsube, T; Kim, DH; Naritaka, Y; Ogawa, K; Shiozawa, S; Tsuchiya, A; Usui, T; Yoshimatsu, K | 1 |
| Fujimoto, K; Hara, T; Kurahashi, T; Muraki, Y; Nagata, M; Yamashita, Y; Yasuda, Y | 1 |
| Hirata, K; Kawasaki, H; Kukita, K; Mizushima, Y | 1 |
| Jonasch, E; Mathew, P; Ng, CS; Pagliaro, L; Siefker-Radtke, A; Tannir, NM; Thall, PF; Wang, X; Wood, C; Wooten, L | 1 |
| Alexandre, J; Becht, C; Bekradda, M; Chomy, F; Culine, S; De Cremoux, H; Szyldergemajn, S; Trédaniel, J; Yataghene, Y | 1 |
| Ide, T; Kitajima, Y; Kohya, N; Mitsuno, M; Miyazaki, K; Ohtaka, K; Sato, K | 1 |
| Abbruzzese, JL; Abdalla, E; Bhosale, PR; Crane, CH; Das, P; Evans, DB; Ho, L; Krishnan, S; Lee, JE; Lee, JH; Pisters, PW; Ross, WA; Staerkel, GA; Sun, CC; Tamm, EP; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA; Xiong, H | 1 |
| Abbruzzese, JL; Charnsangavej, C; Cleary, KR; Crane, CH; Evans, DB; Ho, L; Lano, EA; Lee, JE; Lenzi, R; Pisters, PW; Staerkel, GA; Sun, CC; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Dowlati, A; Gadgeel, SM; Gill, J; Jänne, PA; Kalemkerian, GP; Kelly, K; Kindler, HL; Langer, CJ; Obasaju, CK; Peng, G; Simon, GR; Traynor, AM; Verschraegen, CF | 1 |
| Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY | 1 |
| Hampton, T | 1 |
| Gout, PW; Ling, V; Lo, M; Wang, YZ | 1 |
| Ammerpohl, O; Fölsch, UR; Kalthoff, H; Koch, D; Müerköster, SS; Schäfer, H; Sipos, B; Tsao, MS; Werbing, V | 1 |
| Ansari, R; Geyer, CE; Hamm, JT; Kardinal, CG; Kim, W; Lembersky, BC; Paik, S; Rastogi, P; Raymond, JM; Robidoux, A; Shalaby, IA; Song, YK; Tseng, GC; Wilson, JW; Wolmark, N | 1 |
| Butts, C; Ciardiello, F; Feld, R; Gallo, C; Gridelli, C; Perrone, F | 1 |
| Drebin, JA; Hawkins, WG; Hull, M; Linehan, DC; Malyapa, RS; Myerson, RJ; Picus, J; Strasberg, SM; Tan, BR; Tan, MC; Trinkaus, K | 1 |
| Bartlett, NL; Cashen, AF | 1 |
| De Wit, PE; Folkerts, G; Grootenboers, MJ; Hendriks, JM; Pasterkamp, G; Schramel, FM; van Boven, WJ; van Putte, BP; van Schil, PE | 1 |
| Christiansen, H; Hermann, RM; Lucke, EM; Nitsche, M; Peters, K; Pradier, O; Rave-Frank, M; Schmidberger, H | 1 |
| Bowman, A; Coleman, RE; Dunn, JA; Earl, HM; Fernando, IN; Hiller, L; Howard, HC; Poole, CJ; Ritchie, DM; Wardley, AM | 1 |
| Akhmedjanova, V; Aubert, C; Ciccolini, J; Ea, S; Giacometti, S | 1 |
| Bajetta, E; Bauer, J; Bernhard, J; Bodoky, G; Dietrich, D; Figer, A; Gerber, D; Glimelius, B; Herrmann, R; Koeberle, D; Köhne, CH; Kornek, GV; Mingrone, W; Pestalozzi, BC; Ruhstaller, T; Saletti, P; Scheithauer, W; Schüller, J; Stemmer, SM; Tàmas, K | 1 |
| Beretta, K; Borner, M; Caspar, CB; Dietrich, D; Gerber, D; Herrmann, R; Koeberle, D; Mingrone, W; Mora, O; Ruhstaller, T; Saletti, P; Strasser, F | 1 |
| Besenval, M; Bosquee, L; Brain, E; Dansin, E; Dohollou, N; Gervais, R; Quoix, E; Sessa, C; Urban, T; Vansteenkiste, J; Zatloukal, P | 1 |
| Auroux, J; Brunetti, F; Delchier, JC; Fabre-Guillevin, E; Locher, C; Piedbois, P; Zelek, L | 1 |
| Cereda, S; Reni, M | 1 |
| Corsini, MM; Iott, MJ; Miller, RC | 1 |
| Atcher, RW; Nayak, TK; Norenberg, JP; Prossnitz, ER | 1 |
| Barbera, S; Brancaccio, L; De Maio, E; Gridelli, C; Maione, P; Morabito, A; Perrone, F; Piantedosi, F; Piazza, E; Renda, F; Sannicolo, M; Signoriello, G | 1 |
| Lin, CS; Tsai, CM; Wang, LS; Wei, YH | 1 |
| Cheng, T | 1 |
| Arizumi, M; Arizumi, T; Hirano, K; Isayama, H; Kawabe, T; Kogure, H; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T | 1 |
| Andriani, F; Bajetta, E; Bidoli, P; Cortinovis, DL; Fabbri, A; Livio, A; Marcomini, B; Mariani, L; Perrone, F; Pilotti, S; Roz, L; Sozzi, G | 1 |
| Chia, WK; Choo, SP; Foo, KF; Hee, SW; Koo, WH; Ong, S; Poon, DY; Tan, CK; Tay, MH; Toh, HC | 1 |
| Abe, K; Fujiwara, J; Hayashi, I; Ishida, H; Kawauchi, A; Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Okada, K; Toiyama, D; Yamamoto, K; Yoshida, J | 1 |
| Dabanaka, K; Hanazaki, K; Kobayashi, M; Kohsaki, T; Maeda, H; Nishimori, I; Nishioka, A; Ogawa, Y; Okabayashi, T; Onishi, S; Sugimoto, T; Yamashita, K | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Kollar, LE; Lawrence, TS; Maybaum, J; Morgan, MA; Normolle, DP; Parsels, LA | 1 |
| Ioka, T; Kanemitsu, Y; Mizuno, N; Nakaizumi, A; Nakamura, T; Salem, AA; Sawaki, A; Takahashi, K; Tanaka, S; Ueda, R; Yamao, K | 1 |
| Baayen, JC; Bergman, AM; de Lange, SM; Dirven, CM; Giaccone, G; Honeywell, RJ; Laan, AC; Peters, GJ; Postma, TJ; Sigmond, J; van der Born, K; Van Groeningen, CJ | 1 |
| Arai, M; Fujita, Y; Fujitani, S; Fukuda, K; Horiki, N; Iizuka, Y; Ishii, N; Suzuki, S; Tsukamoto, M | 1 |
| Hokkoku, K; Kiba, T; Mizuno, T; Mori, M; Nakagawa, T; Nakai, M; Oikawa, M; Sakuma, H; Shintaku, K; Ueda, H; Watanabe, Y; Yoshimitsu, Y | 1 |
| Hashimoto, Y; Hayashidani, Y; Murakami, Y; Ohge, H; Sudo, T; Sueda, T; Uemura, K | 1 |
| Etoh, T; Hoshiai, H; Koike, E; Nakai, H; Watanabe, Y | 1 |
| Hall, B; Li, LY; Liao, ML; Wan, HY; Wang, L; West, T; Yu, SY; Zhu, YZ | 1 |
| O'Leary, HM; Savage, KJ | 1 |
| Albain, KS; Calderillo-Ruiz, G; Jordaan, JP; Llombart, AC; Melemed, AS; Nag, SM; O'Shaughnessy, J; Pluzanska, A; Reyes-Vidal, JM; Rolski, J; Sekhon, JS; Simms, L | 1 |
| Kato, A; Kimura, F; Miyazaki, M; Nomura, F; Ohtsuka, M; Shida, T; Shimizu, H; Takano, S; Togawa, A; Tomonaga, T; Yoshidome, H; Yoshitomi, H | 1 |
| Bouche, O; Bugat, R; De Porre, P; Eckhardt, SG; Maurel, J; Michiels, B; Smith, D; Steward, WP; van de Velde, H | 1 |
| Anderes, K; Arango, ME; Blasina, A; Chen, E; Chen, P; Grant, S; Hallin, J; Kraynov, E; Nichols, T; Ninkovic, S; O'Connor, P; Register, J | 1 |
| Beijnen, JH; Bolijn, MJ; Govindarajan, R; Ong, FH; Pluim, D; Schellens, JH; Unadkat, JD; van Eijndhoven, MA; Veltkamp, SA | 1 |
| Erkan, M; Friess, H; Giese, NA; Giese, T; Kleeff, J; Michalski, CW; Sartori, C; Sauliunaite, D; Stratmann, R | 1 |
| Brooks, KJ; Coleman, EJ; Vitetta, ES | 1 |
| Dobrila Dintinjana, R; Guina, T; Krznarić, Z | 1 |
| Ames, M; Batzler, A; Fridley, B; Hildebrandt, M; Jenkins, G; Kalari, K; Li, L; Safgren, S; Schaid, D; Wang, L | 1 |
| Borghaei, H; Cohen, RB; Huang, CH; Langer, CJ; Millenson, MM; Mintzer, DM; Ruth, KJ; Seldomridge, J; Sherman, EJ; Staddon, AP; Treat, OJ; Tuttle, H | 1 |
| Aggarwal, AN; Singh, N | 1 |
| Amendt, C; Bruns, CJ; Eichhorn, ME; Ischenko, I; Jauch, KW; Kleespies, A; Mantell, O; Seeliger, H | 1 |
| Bang, S; Chung, JB; Kim, YJ; Park, JY; Park, SW; Song, SY | 1 |
| Adams, DJ; Decastro, CM; Gockerman, JP; Moore, JO; Peterson, BL; Petros, WP; Rao, AV; Rizzieri, DA; Sand, GJ; Spasojevic, I; Younis, IR | 1 |
| Catane, R; Kundel, Y; Mendlovic, S; Pfeffer, R; Rabin, T; Symon, Z | 1 |
| Benezra, R; Bertolini, F; Colleoni, M; Daenen, LG; Emmenegger, U; Henke, E; Kerbel, RS; Langenberg, MH; Man, S; Mancuso, P; Roodhart, JM; Shaked, Y; Strieter, RM; Tang, T; Voest, EE; Witte, L; Xu, P; Zhu, Z | 1 |
| Choi, H; Choi, JH; Han, JH; Hwang, SC; Jeong, SH; Jung, YM; Kang, SY; Kim, JH; Lee, HW; Lim, HY; Oh, YJ; Oh, YT; Park, KJ; Sheen, SS | 1 |
| Pan, BR; Qin, TJ; Ruan, ZP; Yun, J; Zhang, LX; Zhao, XH | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawabe, T; Kogure, H; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yashima, Y | 1 |
| Arita, Y; Hisano, T; Igarashi, H; Ito, T; Kaku, T; Kawabe, K; Takayanagi, R | 1 |
| Eisen, T; Ferry, DR; Gilligan, D; Gower, NH; Harper, PG; Hocking, M; James, LE; Lee, SM; Prendiville, J; Qian, W; Rudd, RM; Spiro, S | 1 |
| Moriwaki, H; Nakagawa, T; Shimizu, M; Shirakami, Y; Tatebe, H; Tsurumi, H; Yasuda, I | 1 |
| Azmi, AS; Burikhanov, R; Chen, J; Mohammad, RM; Rangnekar, VM; Sarkar, FH; Wang, G; Wang, S; Wang, Z | 1 |
| Ashwell, S; Caleb, BL; Deng, C; Green, S; Grondine, MR; Haye, HR; Horn, CL; Janetka, JW; Liu, D; Mouchet, E; Queva, C; Ready, S; Rosenthal, JL; Schwartz, GK; Sheehy, AM; Taylor, KJ; Tse, AN; Walker, GE; White, AM; Zabludoff, SD | 1 |
| Chohnabayashi, N; Horinouchi, H; Nishimura, N; Ono, H; Sugiura, R; Uchiyama, N; Ueda, H | 1 |
| Aono, T; Hatakeyama, K; Kawachi, Y; Kurosaki, I; Nihei, K; Shimizu, T; Tsuchiya, Y; Yokoyama, N | 1 |
| Bafaloukos, D; Bobos, M; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalogera-Fountzila, A; Kalogeras, KT; Karayannopoulou, G; Kosmidis, P; Koutras, AK; Linardou, H; Murray, S; Samantas, E; Xiros, N | 1 |
| Bloom, C | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Shimizu, Y; Sunaga, N; Tsuchiya, T; Utsugi, M; Yanagitani, N | 1 |
| Abou-Alfa, GK; Blumgart, LH; Capanu, M; D'Angelica, M; Dematteo, RP; Duffy, A; Fong, Y; Huitzil, D; Jarnagin, W; O'Reilly, EM | 1 |
| Fabi, A; Metro, G; Mottolese, M | 1 |
| Alard, S; Berghmans, T; Giner, V; Holbrechts, S; Koumakis, G; Leclercq, N; Lecomte, J; Meert, AP; Paesmans, M; Richez, M; Roelandts, M; Sculier, JP; Van Houtte, P | 1 |
| Bolling, C; Depenbrock, H; Endler, C; Fleeth, J; Graefe, T; Hanauske, AR; Lüdtke, FE; Müller-Hagen, S; Ohnmacht, U; von Scheel, J | 1 |
| Klipin, M; Omoshoro-Jones, J; Smith, MD; Sparaco, A | 1 |
| Aerts, R; Bielen, D; Budiharto, T; Ectors, N; Goethals, L; Haustermans, K; Topal, B; Van Cutsem, E; Van Steenbergen, W; Vanbeckevoort, D; Verslype, C | 1 |
| Azim, H; Azim, HA; Elattar, I; Ganti, AK; Loberiza, FR; Mok, T | 1 |
| Akita, H; Hokari, M; Iwasaki, Y; Kamoshima, Y; Sawamura, Y | 1 |
| Hoffe, SE; Springett, GM | 1 |
| Boehm, KA; Cartwright, T; Richards, DA | 1 |
| Matsumoto, K; Murawaki, Y; Nagahara, T; Okano, J | 1 |
| Bergsland, EK; Hwang, J; Ko, AH; Tempero, MA; Venook, AP; Wong, D | 1 |
| Awada, A; Bernier, J; Bogaerts, J; Buter, J; de Mulder, P; Lacombe, D; Licitra, L; Locati, LD; Thomas, J; van Herpen, CM; Vermorken, JB | 1 |
| Debus, J; Jensen, A; Weber, KJ | 1 |
| Furukawa, K; Ito, H; Kato, A; Kimura, F; Miyazaki, M; Nozawa, S; Otsuka, M; Shimizu, H; Togawa, A; Yoshidome, H; Yoshitomi, H | 1 |
| Nielsen, ME | 1 |
| Bajorin, DF; Bochner, BH; Boyle, MG; Dalbagni, G; Dash, A; Donat, SM; Herr, HW; Milowsky, MI; Pettus, JA; Russo, P | 1 |
| Choi, J; Gump, J; Lacevic, M; Lee, JH; Lush, R; Minton, S; Moulder, S; Munster, P; Neuger, A; Sullivan, D; Valkov, N | 1 |
| Anevlavis, S; Argiana, E; Bouros, D; Froudarakis, ME; Kouliatis, G; Marselos, M; Nikolaidou, M; Pappas, P; Pataka, A; Pozova, S | 1 |
| Dyer, C | 1 |
| Couvreur, P; Desmaele, D; Dubernet, C; Ferreira, H; Mouelhi, SL; Reddy, LH; Rousseau, B | 1 |
| Antonia, S; Bepler, G; Cantor, A; Chiappori, A; Haura, E; Li, X; Obasaju, C; Robinson, LA; Sharma, A; Simon, G; Sommers, KE; Tanvetyanon, T; Williams, C | 1 |
| Ardman, B; Fidias, P; Heist, RS; Huberman, M; Lynch, TJ; Sequist, LV; Temel, JS | 1 |
| Backes, FJ; Cohn, DE; Copeland, LJ; Fowler, JM; O'Malley, DM; Richardson, DL; Seamon, LG; Zanagnolo, V | 1 |
| Aghajanian, CA; Fury, M; Gerst, S; Goss, TL; Hensley, ML; Konner, J; Larkin, J; Orlando, M; Sabbatini, P; Tai, DF | 1 |
| Arumugam, T; Logsdon, CD; Ramachandran, V; Wang, H | 1 |
| Donahue, B; Hiotis, SP; Hochster, HS; Marti, JL; Newman, E; Ryan, T | 1 |
| Harris, P; Hartwell, D; Loveman, E; Takeda, A; Welch, K | 1 |
| Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Sakamoto, T; Shiba, H; Uwagawa, T; Wakiyama, S; Yanaga, K | 1 |
| Lohr, JM; Müller, H; Nakchbandi, IA; Nakchbandi, W; Singer, MV | 1 |
| Bandiera, A; Carretta, A; Ciriaco, P; Ferla, L; Melloni, G; Puglisi, A; Sayed, I; Zannini, P | 1 |
| Furuse, J | 2 |
| Adrover Cebrian, E; Alonso Carrion, L; Arcusa Lanza, A; Bover Barcelo, I; Calvo Garcia, E; Casado Herraez, A; Churruca Galaz, C; Fabregat i Mayol, X; Gonzalez Martin, A; Herrero Ibañez, A; Mellado, B; Ojeda Gonzalez, B; Poveda Velasco, A; Rubio Perez, MJ | 1 |
| Kayahara, M; Kitagawa, S; Minato, H; Mouri, H; Ohta, T; Ohtsubo, K; Tsuchiyama, T; Watanabe, H | 1 |
| Bernhaus, A; Erker, T; Fritzer-Szekeres, M; Grusch, M; Handler, N; Horvath, Z; Jaeger, W; Jaschke, M; Krupitza, G; Lackner, A; Madlener, S; Ozsvar-Kozma, M; Saiko, P; Szekeres, T | 1 |
| Alberti, DB; Attia, S; Bailey, HH; Campbell, TC; Cleary, JF; Eickhoff, JC; Holen, KD; Huie, MS; Liu, G; McFarland, TA; Morgan-Meadows, S; Mulkerin, DL; Schelman, WR; Tevaarwerk, AJ; Traynor, AM; Wilding, G | 1 |
| Dafni, U; Fountzilas, G; Fragkoulidi, A; Fragoulakis, V; Galani, E; Grimani, I; Maniadakis, N | 1 |
| Hagihara, A; Ikeda, M; Iwasa, S; Kojima, Y; Morizane, C; Okusaka, T; Tanaka, T; Ueno, H | 1 |
| Galmarini, CM; Kohli, E; Mitin, A; Vinogradov, SV; Warren, G; Zeman, A | 1 |
| Buchsbaum, DJ; Forero, A; Grizzle, WE; Kim, H; Long, JW; McNally, LR; Morgan, DE; Sellers, JC; Stockard, CR; Warram, JM; Zeng, H; Zinn, KR | 1 |
| Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R | 1 |
| Beekman, K; Dunn, RL; Hussain, M; Lee, CT; Mackler, NJ; Montie, JE; Petrylak, DP; Quinn, DI; Sanda, M; Smith, DC; Vaishampayan, U; Wood, D | 1 |
| Chan, CY; Chen, Y; He, ML; Jiang, L; Kung, HF; Li, JC; Lin, L; Lin, MC; Sung, JJ; Wang, X; Yew, DT | 1 |
| Aikawa, I; Matsuda, T; Minato, H; Shikata, S | 1 |
| Arthur, C; Catalano, J; D'Rozario, J; Grigg, A; Leahy, M; Lowenthal, R; Pasricha, SR; Reed, K; Spencer, A; Underhill, C | 1 |
| Almhanna, K; Kim, R | 1 |
| Bird, B; Janku, F | 1 |
| Kamiyama, Y; Kano, Y; Kobayashi, H; Kodama, T; Mori, K | 1 |
| Adrover, E; Calvo, L; Colomer, R; De la Haba, J; Del Barco, S; Rifà, J; Sánchez, P; Tusquets, I; Virizuela, JA | 1 |
| Granov, DA; Gulo, AS; Pavlovskiĭ, AV; Popov, SA; Shapoval, SV; Suvorova, IuV; Tlostanova, MS | 1 |
| Doval, DC; Jena, A; Pande, SB; Pavithran, K; Sharma, JB; Vaid, AK | 1 |
| Levien, TL; Reynolds, JK | 1 |
| Barton, JH; Burris, HA; Drosick, D; Greco, FA; Hainsworth, JD; Shipley, D; Simons, L; Spigel, DR; Yardley, DA | 1 |
| Blitzer, J; Evans, S; Flam, M; Hager, S; Link, J; Lyons, W; Nagourney, RA; Sommers, BL | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawabe, T; Kogure, H; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yoshida, H | 1 |
| Flynn, PJ; Garbo, LE; Kolibaba, KS; MacRae, MA; Rauch, MA; Wang, Y | 1 |
| Lipton, L; McCoy, S; McGreivy, J; Price, TJ; Rosenthal, MA; Sun, YN | 1 |
| Ishihara, T; Kobayashi, A; Matsuyama, M; Tawada, K; Tsuyuguchi, T; Yamaguchi, T; Yokosuka, O | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Kamatani, N; Kaniwa, N; Kim, SR; Maekawa, K; Morizane, C; Okusaka, T; Ozawa, S; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yamamoto, N; Yoshida, T | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Narita, S; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Yuasa, T | 1 |
| Amadori, D; Cecconetto, L; Dall'agata, M; Dazzi, C; Frassineti, GL; Milandri, C; Nanni, O; Oliverio, G; Pasquini, E; Passardi, A; Zoli, W; Zumaglini, F | 1 |
| Lee, CT; Montie, JE; Oh, KS; Sandler, HM; Smith, DC; Soto, DE | 1 |
| Hillerdal, G; Hjerpe, A; Riska, H; Sorensen, JB; Sundström, S; Vikström, A | 1 |
| Babineaux, S; Buesching, D; Earle, C; Faries, D; Lang, K; Marciniak, MD; Morissette, N; Stokes, M; Thompson, D; Treat, J | 1 |
| Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, LA | 1 |
| Cornfeld, D; Lansigan, F; Saif, MW; Shaib, W; Syrigos, K | 1 |
| Saif, MW; Wasif, N | 1 |
| Knisely, J; Ramos, J; Saif, MW | 1 |
| Dasanu, CA | 1 |
| Mei, K; Tian, L; Wang, L; Wei, Y; Yu, J; Zhang, Z | 1 |
| Cha, SW; Chung, JB; Kim, KW; Kim, MJ; Klotz, E; Lim, JS; Park, MS; Park, SW; Seong, J; Song, SY | 1 |
| Ajiki, T; Fujino, Y; Fujita, T; Ku, Y; Kuroda, Y; Matsumoto, I; Matsumoto, T; Mita, Y; Morimoto, H; Suzuki, Y; Takase, S | 1 |
| Maniwa, Y; Nishimura, Y; Ohno, Y; Takata, M; Yoshimura, M | 1 |
| Abrams, R; Ammar, A; Benson, AB; Cass, CE; Dicker, AP; Elsaleh, H; Farrell, JJ; Garcia, M; Lai, R; Macdonald, J; Mackey, JR; Regine, WF | 1 |
| Kijima, H; Kusumi, T; Nakamura, M; Nishime, C; Ohnishi, Y; Sato, F; Suemizu, H; Tamaoki, N; Ueyama, Y; Yamazaki, H | 1 |
| Cai, CL; Kang, JB; Li, JG; Nie, Q; Qi, WJ; Wang, B; Zhang, LP | 1 |
| Märten, A; Mehrle, S; Schmidt, J; Serba, S; von Lilienfeld-Toal, M; Zeiss, N | 1 |
| Boukovinas, I; Georgoulias, V; Koutsopoulos, A; Mavroudis, D; Mendez, P; Papadaki, C; Rosell, R; Sanchez, JJ; Sanchez-Ronco, M; Souglakos, J; Staphopoulos, E; Taron, M; Trypaki, M | 1 |
| Anderson, H; Bishop, W; Lee, CW; Murray, N; Rao, SC | 1 |
| Fujisawa, M; Gleave, ME; Hayashi, N; Miyake, H; Muramaki, M; So, A; Sowery, R | 1 |
| Bosch-Barrera, J; Ferrer, M; García-Foncillas, J; Gil-Bazo, I; López-Picazo, JM; Montero, A; Yuste, JR | 1 |
| Hamada, K; Horiuchi, R; Igarashi, R; Obayashi, K; Ohwada, S; Sunose, Y; Takeyoshi, I; Yamamoto, K | 1 |
| Boku, N; Fukutomi, A; Hashimoto, T; Hironaka, S; Nishimura, T; Onozawa, Y; Taira, K; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
| Boersma, L; Bootsma, G; Borger, J; De Ruysscher, D; Dehing, C; Dekker, A; Dingemans, AM; Geraedts, W; Hochstenbag, M; Lambin, P; Ollers, M; Pitz, C; Simons, J; Wanders, R; Yu, S | 1 |
| Fujita, Y; Fukushima, M; Furuse, K; Kawahara, M; Komuta, K; Kubota, K; Minato, K; Nishiwaki, Y; Ogawara, M; Teramukai, S | 1 |
| Cardenal Escarcena, A; Fernández Sarabia, MT; García Bernardo, L; Rodríguez García, JM; Serrano Vicente, J | 1 |
| Dorff, TB; Miranda, G; Quinn, DI; Skinner, DG; Stein, JP; Tsao-Wei, D | 1 |
| Abbruzzese, JL; Amos, CI; Chen, J; Evans, DB; Frazier, ML; Killary, AM; Li, D; Sen, S | 1 |
| Alberts, SR; Fitch, TR; Foster, NR; Jaslowski, AJ; Kugler, JW; McWilliams, RR; Quevedo, FJ; Sande, JR | 1 |
| Chan, A; Chan, F; Cosenza, SC; Cusatis, G; Donehower, RC; Hidalgo, M; Jimeno, A; Kulesza, P; Ramana Reddy, MV; Reddy, EP; Rudek, MA; Solomon, A; Wheelhouse, J; Zhang, X; Zhao, M | 1 |
| Twombly, R | 2 |
| Höhler, T; Oettle, H; Staib, L | 1 |
| El-Baradie, M; Ismail, HM; Khorshid, O; Moneer, M; Touny, A | 1 |
| Chang, HM; Cho, JY; Im, SA; Kim, BS; Kim, HK; Kim, JS; Kim, MK; Kim, YH; Lee, KH; Lee, MA; Lim, HY; Ryoo, BY; Song, HS; Zang, DY | 1 |
| Galmarini, CM; Myhren, F; Sandvold, ML | 1 |
| Beck, AW; Brekken, RA; Carbon, JG; Dineen, SP; Mamluk, R; Miller, AF; Sullivan, LA; Wong, H | 1 |
| Altug, T; Atalar, B; Dinçbaş, FO; Gedik, N; Ilvan, S; Koca, S; Oksüz, DC; Ozel, S | 1 |
| Arnold, A; Crabb, SJ; Ellis, PM; Goss, G; Laurie, SA; Leighl, NB; Patsios, D; Powers, J; Sauerbrei, E; Seymour, L; Shepherd, FA | 1 |
| Abrams, T; Allen, B; Blaszkowsky, LS; Chan, JA; Clark, JW; Enzinger, PC; Fuchs, CS; Hezel, AF; Meyerhardt, JA; Ryan, DP; Wolpin, BM | 1 |
| Currie, AJ; Darabi, A; Lake, RA; Mahendran, S; Nowak, AK; Prosser, A; Robinson, BW; van der Most, RG | 1 |
| Bramlage, P; Dörken, B; Hilbig, A; Kauschat-Brüning, D; Oettle, H; Opitz, B; Pelzer, U; Riess, H; Scholten, T; Stieler, J | 1 |
| Izuishi, K; Kakinoki, K; Maeba, T; Okamoto, Y; Okano, K; Suzuki, Y; Usuki, H; Wakabayashi, H | 1 |
| Bae, SH; Eun, JR; Hyun, MS; Jang, BI; Kim, MK; Kim, TN; Lee, KH; Lee, SA; Ryoo, HM | 1 |
| Benekli, M; Buyukberber, S; Coskun, U; Kaya, AO; Ozdemir, M; Ozturk, B; Sahin, G; Tacoy, G; Topal, S; Yaman, E; Yildiz, R | 1 |
| Aklilu, M; Kindler, HL; Nattam, S; Vokes, EE | 1 |
| Huang, KH; Jia, L; Li, H; Li, YY; Shuai, XT; Zheng, JJ | 1 |
| Ioannidis, JP; Mauri, D; Pavlidis, N; Polyzos, NP; Salanti, G | 1 |
| Al-Batran, SE; Aldaoud, A; Bernhard, H; Burkart, C; Folprecht, G; Hoffmann, M; Huebner, G; Jahn, A; Kaiser, U; Kohne, CH; Kretzschmar, A; Kullmann, F; Link, H; Menges, M; Otremba, B; Schoffski, P; Stahl, M; Steinbach, S | 1 |
| Fujii, Y; Kawakami, S; Kihara, K; Kobayashi, T; Koga, F; Masuda, H; Nakayama, T; Saito, K; Yoshida, S | 1 |
| Lebret, T; Méjean, A | 1 |
| Haseke, N; Ihrler, S; Karl, A; Schöppler, G; Siebels, M; Stadler, T; Staehler, M; Stief, CG | 2 |
| Bromund, JL; Chen, R; Dakhil, SR; Fidias, PM; Gill, J; Hristova-Kazmierski, M; Loesch, DM; Lyss, AP; Marciniak, M; Obasaju, CK; Schiller, JH; Treat, J; Waterhouse, DM | 1 |
| Alomar, A; Corella, F; Dalmau, J; García-Navarro, X; Roé, E | 1 |
| Kim, YT; Lee, JL | 1 |
| Ikeuchi, N; Ishii, K; Itoi, T; Itokawa, F; Kurihara, T; Moriyasu, F; Sofuni, A; Tsuchiya, T; Tsuji, S | 1 |
| Bane, CL; Gross, GG; LaPlant, BR; Palmieri, FM; Roy, V | 1 |
| Arumugam, T; Ji, B; Levin, PA; Logsdon, CD; Lopez-Berestein, G; McConkey, DJ; Pan, X; Ramachandran, V; Sood, AK; Vivas-Mejia, PE; Yamamoto, T | 1 |
| Dilulio, J; Ganju, V; Khamly, K; Leong, T; Matera, A; Michael, M; Milner, AD; Muller, A; Ngan, SY; Price, T; Strickland, AH; Zalcberg, JR | 1 |
| Adamson, DJ; Ali, CW; Highley, MS; Kaye, TF; Polignano, FM; Tait, IS | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, MJ; Kim, TY; Lee, SH; Oh, DY | 1 |
| Chen, E; Feld, R; Gauthier, I; Goss, G; Laurie, S; Leighl, N; Powers, J; Seymour, L; Shepherd, FA | 1 |
| Balzer, JO; Eichler, K; Gruber, T; Hammerstingl, R; Vogl, TJ; Zangos, S | 1 |
| Bhure, U; Clavien, PA; Hany, TF; Heinrich, S; Pestalozzi, BC; Schäfer, M; Weber, A | 1 |
| Kanai, K; Kikuchi, E; Miyajima, A; Nakagawa, K; Nakashima, J; Ohigashi, T; Oya, M | 1 |
| Doiuchi, T; Inoue, T; Ito, K; Niwa, T; Ohkawa, S; Ueno, M; Yoshida, T | 1 |
| Choy, H; Curran, W; Demas, WF; Ettinger, DS; Jain, AK; Moughan, J; Whipple, G | 1 |
| Albain, KS; Chansky, K; Crowley, J; Davies, AM; Gandara, DR; Gumerlock, PH; Lara, PN; Vogel, SJ | 1 |
| Folkerts, G; Grootenboers, M; Pasterkamp, G; Schramel, F; van Boven, WJ; van Oosterhout, M; van Putte, BP | 1 |
| Aiba, T; Aoyagi, Y; Baba, Y; Ban-Nai, H; Furukawa, K; Iiri, T; Ishizuka, K; Isokawa, O; Maruyama, Y; Mori, S; Motoyama, N; Nakamura, A; Natsui, M; Ohta, H; Seki, K; Shioji, K; Suzuki, Y; Watanabe, K; Yanagi, M | 1 |
| Hirota, M; Ichihara, T; Okamoto, K; Sato, T; Yagi, Y; Yamashita, K | 1 |
| Agelaki, S; Agelidou, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Gerogianni, A; Pallis, AG; Papakotoulas, P; Pavlakou, G; Rapti, A; Varthalitis, I | 1 |
| Chen, X; Deng, H; Hou, S; Wang, Y; Wei, Y; Yan, F; Zhao, Z | 1 |
| Altavilla, G; Danesi, R; Giovannetti, E; Rosell, R | 1 |
| Cho, YJ; Hwang, YS; Jeong, YY; Kang, JH; Kang, MH; Kim, HC; Kim, HG; Kim, HJ; Kim, SH; Lee, GW; Lee, JD; Lee, JS | 1 |
| Ebuchi, M; Koide, A; Koike, T; Maruyama, M; Maruyama, S; Ohinata, R; Sakoma, T; Sanada, T; Satoh, E; Shima, Y | 1 |
| Aoki, T; Hamada, H; Kenno, S; Oba, G; Okuda, K; Shimada, S; Shimokuni, T; Takada, J | 1 |
| Iida, M; Tokairin, Y; Yamazaki, S | 1 |
| Kim, DH; Nakamura, Y; Ogawa, K; Otani, T; Shiozawa, S; Tsunoda, T; Usui, T; Yoshimatsu, K | 1 |
| Arefayene, M; Basu, GD; Bradley, JM; De Petris, G; Mukherjee, P; Skaar, T; Subramani, DB; Tinder, TL | 1 |
| Anbarasu, A; Bhide, A; Gurumurthy, M; Hocking, M; Koh, P; Satodia, P; Singh, R; Wood, LE | 1 |
| Becker, J; Bharthuar, A; Deeb, G; Egloff, L; George, M; Iyer, RV; Lohr, JW | 1 |
| Chen, ZS; Hopper-Borge, E; Kruh, GD; Shen, T; Shi, Z; Xu, X | 1 |
| Campbell, SC; Dreicer, R; Fergany, AF; Garcia, JA; Gong, MC; Hansel, DE; Jones, JS; Klein, EA; Stephenson, AJ; Weight, CJ | 1 |
| López-Tarruella, S; Rivera, F; Salcedo, M; Vega-Villegas, ME | 1 |
| Imada, H; Korogi, Y; Morioka, T; Nakano, K; Narisada, H; Ohguri, T; Yahara, K | 1 |
| Abrams, RA; Leslie, WT; Mahon, B; Shah, A; Shah, AP; Strauss, JB | 1 |
| Hollender, J; Kovalova, L; McArdell, CS | 1 |
| Abu-Rustum, N; Aghajanian, CA; Hensley, ML; Ishill, N; Konner, J; Larkin, J; Sabbatini, P; Soslow, R; Spriggs, D; Tew, W | 1 |
| Booth, RJ; Canman, CE; Denny, WA; Kraker, AJ; Lawrence, TS; Maybaum, J; Morgan, MA; Palmer, BD; Parsels, JD; Parsels, LA; Tanska, DM | 1 |
| Chen, N; Fong, Y; Galanis, C; Szalay, AA; Woo, Y; Yu, YA; Zhang, Q | 1 |
| Alonso, G; Alvarez, E; Amenedo, M; Fernández, I; Fírvida, JL; Huidobro, G; Lázaro, M; Mel, JR; Rubio, JC; Vázquez, F; Vázquez, S | 1 |
| Kitade, H; Kwon, AH; Matsui, Y; Mergental, H; Satoi, S; Takahashi, K; Takai, S; Tanigawa, N; Toyokawa, H; Yanagimoto, H | 1 |
| Bornmann, C; Esser, N; Graeser, R; Hopt, UT; Jantscheff, P; Massing, U; Schaechtele, C; Unger, C; von Dobschuetz, E; Ziroli, V | 1 |
| Bentrem, DJ; Ding, XZ; McGill, JJ; Melstrom, LG; Milam, BM; Salabat, MR; Strouch, MJ; Ujiki, MB | 1 |
| Bae, SB; Cheon, YG; Cho, YD; Hong, DS; Kim, CK; Kim, HJ; Kim, YS; Lee, KT; Lee, NS; Lee, SC; Moon, JH; Park, HS; Park, SH; Park, SK; Won, JH | 1 |
| Chu, Z; Gao, G; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Angelova, AL; Aprahamian, M; Balboni, G; Dinsart, C; Giese, NA; Grekova, SP; Hajri, A; Herrmann, A; Leuchs, B; Raykov, Z; Rommelaere, J | 1 |
| Esser, N; Fichtner, I; Graeser, R; Kratz, F; Unger, C; Unger, H; Zhu, A | 1 |
| Choi, JH; Choi, YW; Han, JH; Hwang, SC; Jeong, SH; Jung, JH; Kang, SY; Kim, JH; Lee, HW; Oh, YT; Park, KJ; Sheen, SS | 1 |
| Belt, RJ; Chen, R; Obasaju, C; Perry, MC; Wakelee, HA; West, HL | 1 |
| Fukui, T; Hatooka, S; Ishiguro, F; Kobayashi, R; Mitsudomi, T; Mori, S; Ogawa, S; Okuda, K; Shinoda, M | 1 |
| Jeong, CY; Ju, JH; Kang, JH; Kim, HG; Kim, HJ; Kim, SH; Kim, TH; Lee, GW | 1 |
| Alberola Candel, V; Esteban González, E; Gasent Blesa, JM; Martín Algarra, S; Provencio Pulla, M | 1 |
| Barlési, F; Berard, H; Chouaïd, C; Corre, R; Fournel, P; Le Caer, H; Marin, B; Tillon, J; Vergnenègre, A; Vernejoux, JM | 1 |
| Hazra, S; Konrad, M; Lavie, A; Ort, S; Sabini, E | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Kalbakis, K; Kalykaki, A; Mavroudis, D; Vamvakas, L | 1 |
| Ando, M; Kudoh, S; Matsui, K; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Semba, H; Shibata, T; Takada, Y; Takeda, K; Tamura, T; Yokota, S | 1 |
| Blakely, LJ; Epperson, A; Henry, D; Keaton, M; Schnell, F; Schwartzberg, L; Walker, MS | 1 |
| Crane, CH; Evans, DB; Fleming, JB; Settle, SH; Varadhachary, G; Wolff, RA | 1 |
| Gao, HJ; Liu, XQ; Tang, CH; Yang, SF; Zhu, B | 1 |
| Feldmann, G; García-García, E; Hidalgo, M; Jimeno, A; López-Ríos, F; Maitra, A; Matsui, W; Rasheed, Z; Rubio-Viqueira, B; Solomon, A; Suárez-Gauthier, A; Zou, GM | 1 |
| Mayo, MS; Smith, HJ; Watkins, JF; Williamson, SK | 1 |
| Abramo, F; Lorenzo, RM; Marconato, L; Ratto, A; Zini, E | 1 |
| Azuma, H; Inamoto, T; Katsuoka, Y | 1 |
| Bodoky, G; Ciuleanu, TE; Garin, AM; Kroll, S; Langmuir, VK; Pavlovsky, AV; Tidmarsh, GT | 1 |
| Ansari, RH; Detterbeck, FC; Edelman, MJ; Gralla, RJ; Jahan, TM; Luketich, JD; Monberg, M; Moore, DT; Obasaju, CK; Peng, G; Rivera, MP; Socinski, MA | 1 |
| Archer, V; Gorbounova, V; Hirsh, V; Leighl, N; Manegold, C; Mezger, J; Moore, N; Ramlau, R; Reck, M; von Pawel, J; Zatloukal, P | 2 |
| Agostini, C; Aleba, A; Cretin, J; Dohollou, N; Ferrero, JM; Fric, D; Geay, JF; Gouttebel, MC; Haddad-Guichard, Z; Hardy-Bessard, AC; Lévy, E; Orfeuvre, H; Paraiso, D; Provencal, J; Pujade-Lauraine, E; Ray-Coquard, I; Salvat, J; Weber, B | 1 |
| Hong, WK; Khuri, FR; Kim, ES; Lee, JJ; Lee, JL; Lippman, SM; Liu, S; Shin, DM; William, WN | 1 |
| Campbell, DO; Czernin, J; Herschman, HR; Laing, RE; Phelps, ME; Radu, CG; Satyamurthy, N; Walter, MA; Witte, ON | 1 |
| Flombaum, CD; Glezerman, I; Kris, MG; Miller, V; Seshan, S | 1 |
| Bussom, S; Cheng, YC; Lam, W | 1 |
| Akashi, K; Arita, S; Baba, E; Hirano, G; Isobe, T; Kusaba, H; Makiyama, A; Nakano, S; Qin, B; Shibata, Y; Uchino, K | 1 |
| Egoshi, K; Fukasawa, S; Hamano, M; Ichikawa, T; Imamura, Y; Maruoka, M; Miyasaka, K; Nakamura, K; Nihei, N; Sazuka, T; Suyama, T; Ueda, T | 1 |
| Barten-Van Rijbroek, AD; Kal, HB; Leen, R; Rodermond, HM; Van Bree, C; Van Kuilenburg, AB | 1 |
| Aho, U; Andersson, R; Nilsson, BI; Pastor-Anglada, M; Peters, GJ; Rasch, W; Sandvold, ML | 1 |
| Arcamone, M; Ballerini, PF; Becchimanzi, C; Capobianco, G; Corazzelli, G; De Chiara, A; Frigeri, F; Iannitto, E; Marcacci, G; Pinto, A; Russo, F | 1 |
| Bazan-Perkins, B; Candelaria, M; Cantú, D; Cetina, L; Coronel, J; Dueñas-González, A; Flores, V; Garcia-Arias, A; Gonzalez, A; Rivera, L | 1 |
| Blatter, J; Fossella, F; Hanna, N; Peterson, P; Scagliotti, G; Shepherd, FA; Simms, L; Sugarman, K | 1 |
| Haviland, D; Kemeny, N; Patel, D; Tse, AN; Wu, N | 1 |
| Jia, L; Liu, YH; Wei, CG; Xie, Q | 1 |
| Davies, D; Halldén, G; Leitner, S; Lemoine, NR; Miranda, E; Oberg, D; Sweeney, K | 1 |
| Hirohata, S; Horita, K; Niki, T; Nishisaki, H; Tsuda, M; Yamamoto, Y | 1 |
| Hisada, T; Imai, H; Ishizuka, T; Kaira, K; Kawata, T; Mori, M; Shimizu, K; Sunaga, N; Utsugi, M; Yanagitani, N | 1 |
| Miki, H; Nakahira, S; Nakata, K; Okada, K; Okamura, S; Sugimoto, K; Suzuki, R; Tamura, S; Uji, K; Yoshida, A; Yoshimura, M | 1 |
| Foo, KF; Wang, ML | 1 |
| Hoskins, PJ | 1 |
| Chen, L; Cole, PD; de Alarcon, PA; Drachtman, RA; Schwartz, CL; Trippett, TM | 1 |
| Accario-Winslow, C; Alberts, DS; Argenta, PA; Bookman, MA; Brady, MF; Burger, RA; Colombo, N; De Geest, K; Fowler, JM; Friedlander, M; Harper, PG; McGuire, WP; Mutch, DG; Roth, LM; Swart, AM; Trimble, EL | 1 |
| Anraku, M; Bezjak, A; Burkes, R; Cho, BC; de Perrot, M; Feld, R; Johnston, MR; Keshavjee, S; Leighl, N; Roberts, H; Tsao, MS | 1 |
| Braconi, C; Henson, R; Lang, M; Patel, T | 1 |
| Kang, HS; Kim, EA; Kim, SW; Kwon, Y; Lee, ES; Lee, KS; Nam, BH; Ro, J; Shin, KH | 1 |
| Lluís, F | 1 |
| Adamo, V; Carreca, I; Fulfaro, F; Gebbia, N; Rizzo, S; Russo, A; Santini, D; Vincenzi, B | 1 |
| Fiorito, C; Gontero, P; Lucca, I; Tizzani, A; Valentino, F | 1 |
| Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ | 1 |
| Beijnen, JH; Jansen, RS; Rosing, H; Schellens, JH | 2 |
| Apte, S; Boren, T; Chan, G; Chen, DT; Dressman, H; Hakam, A; Kamath, SG; Lancaster, JM; Wenham, R; Xiong, Y | 1 |
| Kuramitsu, Y; Maehara, S; Maehara, Y; Mori-Iwamoto, S; Nakamura, K; Okita, K; Ryozawa, S; Sakaida, I; Taba, K; Tanaka, T | 1 |
| Bayer, GK; Graham, DL; Kolesar, JM; Lee, JW; Mazurczak, M; Schiller, JH; Tate, JM; Thomas, SP; Traynor, AM | 1 |
| Debus, J; Heilmann, M; Hennink, WE; Huber, PE; Kiessling, F; Kühnlein, R; Lammers, T; Peschke, P; Storm, G; Subr, V; Ulbrich, K | 1 |
| Biasoni, D; Gianni, L; Milani, A; Necchi, A; Nicolai, N; Piva, L; Pizzocaro, G; Salvioni, R; Stagni, S; Torelli, T | 1 |
| Caraglia, M; Correale, P; Francini, G; Gotti, G; Macrì, P; Migali, C; Remondo, C; Rotundo, MS; Tagliaferri, P; Tindara Miano, S | 1 |
| Belderbos, J; Borst, GR; Burgers, S; Lebesque, J; Sonke, JJ | 1 |
| Al-Ejeh, F; Brown, MP; Darby, JM | 1 |
| Brell, JM; Dranko, S; Evans, T; Kiefer, GJ; Lenzner, D; Matin, K; Ramanathan, RK; Rath, L; Schlesselman, JJ; Schmotzer, A; Volkin, RL | 1 |
| Bhatt, A; Farooq, MU; Kassab, M; Majid, A | 1 |
| Bulotta, A; Calimeri, T; Celia, C; Cosco, D; Costa, N; Fresta, M; Neri, P; Paolino, D; Perri, G; Tagliaferri, P; Tassone, P; Ventura, M | 1 |
| Altug, S; Chu, DT; Cok, G; Damyanov, D; Hall, B; Hsu, HK; Kim, SW; Patil, S; Roubec, J; West, T | 1 |
| Cho, GJ; Chung, JS; Joo, YD; Kim, KH; Kim, YS; Lee, WS; Shin, HJ; Shin, SH; Sohn, CH | 1 |
| Citro, G; Cognetti, F; Colantonio, S; Contestabile, M; Di Segni, S; Felici, A; Milella, M; Nuvoli, B; Sacconi, A; Sperduti, I; Zaratti, M | 1 |
| Antón, A; Carrasco, E; Chan, S; Delozier, T; du Bois, A; Frimodt-Moller, B; Fumoleau, P; Harrison, M; Huober, J; Jones, A; Kreienberg, R; Llombart, A; Lluch, A; Mayordomo, JI; Romieu, G; Schneeweiss, A; Tubiana-Hulin, M; Vaury, AT | 1 |
| Aasebø, U; Bremnes, RM; Helbekkmo, N; Strøm, HH; Sundstrøm, SH; Von Plessen, C | 1 |
| Bertoni, F; Cogliatti, SB; Ghielmini, M; Hitz, F; Martinelli, G; Mingrone, W; Peterson, J; Simcock, M; von Moos, R; Zimmermann, DR; Zucca, E | 1 |
| Abbruzzese, JL; Ahmad, A; Ali, S; Azmi, AS; Banerjee, S; Gallick, GE; Kong, D; Li, Y; Sarkar, FH; Wang, Z | 1 |
| Goto, H; Hara, K; Hirooka, Y; Ishigami, M; Ishikawa, T; Itoh, A; Kaneko, T; Kasugai, T; Katano, Y; Kawashima, H; Matsubara, H; Nieda, M; Niwa, Y; Nonogaki, K; Ohmiya, N; Ohno, E; Yamamoto, K; Yokokawa, K | 1 |
| Bitzer, M; Fend, F; Finkenwirth, P; Gregor, M; Horger, MS; Lauer, UM; Schick, D | 1 |
| Clausen, AR; Eklund, H; Gojković, Z; Knecht, W; Mikkelsen, NE; Piskur, J; Willer, M | 1 |
| Hoimes, C; Saif, MW; Strimpakos, AS | 1 |
| Li, J; Saif, MW | 3 |
| Hoimes, CJ; Saif, MW; Strimpakos, AS | 1 |
| Antonuzzo, A; Arcabasso, G; D'Incecco, A; Falcone, A; Mazzoni, E; Menconi, G; Tibaldi, C | 1 |
| Chiba, T; Furuse, J; Furuta, K; Hirohashi, S; Honda, K; Kaniwa, N; Matsubara, J; Negishi, A; Okusaka, T; Ono, M; Saijo, N; Saito, Y; Sakuma, T; Sawada, J; Sugiyama, E; Ueno, H; Yamada, T | 1 |
| Clark, JW; Goulart, BH; Grenon, N; Lauwers, GY; Muzikansky, A; Ryan, DP; Zhu, AX | 1 |
| Dollinger, MM; Endlicher, E; Fuchs, M; Gäbele, E; Harder, J; Hinke, A; Hollerbach, C; Hollerbach, S; Kullmann, F; Messmann, H; Trojan, J | 1 |
| Hasegawa, R; Ikeda, M; Kaniwa, N; Kim, SR; Kondo, S; Morizane, C; Okusaka, T; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Ueno, H; Yoshida, T | 1 |
| Dörken, B; Hilbig, A; Oettle, H; Pelzer, U; Riess, H; Roll, L; Stieler, J | 1 |
| Han, H; Li, YH; Liu, ZW; Qin, ZK; Wu, PH; Xiong, YH; Yu, SL; Zhou, FJ | 1 |
| Hennink, WE; Huber, PE; Lammers, T; Peschke, P; Storm, G; Subr, V; Ulbrich, K | 1 |
| Bennouna, J; Cosaert, J; Gill, S; Humblet, Y; Moore, MJ; Scheithauer, W; Shang, A; Van Cutsem, E; Van Laethem, JL; Verslype, C; Vervenne, WL | 1 |
| Albain, KS; Bayer, R; Chew, HK; Doroshow, JH; Frankel, P; Gandara, DR; Gordon, M; Hantel, A; Lenz, HJ; Margolin, KA; Russell, C; Somlo, G; Spicer, D; Stiff, PJ; Synold, T; Tetef, ML; Yang, D; Zhang, W | 1 |
| Bekaii-Saab, TS; Fortune, BE; Kosuri, KV; Li, X; Thomas, JP; Weatherby, LM | 1 |
| Favaudon, V; Hennequin, C; Quero, L | 1 |
| Cass, CE; Demetter, P; Devière, J; Lai, R; Mackey, JR; Maréchal, R; Peeters, M; Polus, M; Salmon, I; Van Laethem, JL; Young, J | 1 |
| Fujimoto, T; Koshiji, M; Nambu, Y; Yamamoto, N | 1 |
| Ch'ang, HJ; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Huang, CL; Hwang, TL; Jan, CM; Lin, JT; Shiah, HS; Tien, YW; Wang, HP; Whang-Peng, J | 1 |
| Bao, QL; Chen, P; Dai, CH; Li, J; Li, XQ | 1 |
| Chang, K; Goedegebuure, PS; Hawkins, WG; Hotchkiss, RS; Kashiwagi, H; Mach, RH; McDunn, JE; Simon, PO; Vangveravong, S | 1 |
| Crinò, L; De Marinis, F; Falcone, A; Grassivaro, N; Nardi, M; Novello, S; Rinaldi, M; Russo, F; Scagliotti, GV; Tibaldi, C; Tinazzi, A; Tonato, M | 1 |
| Hirata, K; Ishikawa, O; Kimura, W; Kinoshita, H; Kurashina, K; Nagai, H; Nagakawa, T; Nakao, A; Ohta, T; Oka, M; Sata, N; Shimada, H; Tanaka, M; Yasuda, H | 1 |
| Bear, HD; Cha, E; Graham, L; Le, HK; Manjili, MH; Morales, JK | 1 |
| Asanuma, F; Atsuda, K; Hiraku, O; Inoue, G; Morimoto, Y; Sasaki, K; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoshizawa, J | 1 |
| Hartmann, JT; Horger, M; Kanz, L; Mayer, F; Meisinger, I; Pintoffl, J; von Weyhern, C | 1 |
| Hannun, YA; Wu, BX; Zeidan, YH | 1 |
| Aoshima, K; Kadowaki, T; Oda, Y; Tanaka, M; Tanaka, S; Uehara, T; Yokoi, A | 1 |
| Allen-Auerbach, MS; Benz, MR; Chow, K; Czernin, J; Dry, SM; Eckardt, JJ; Eilber, FC; Elashoff, D; Evilevitch, V; Phelps, ME; Tap, WD; Weber, WA | 1 |
| Koczywas, M; Leong, L; Raubitschek, A; Shibata, S; Williams, L; Wong, JY; Zhan, J | 1 |
| Chauhan, A; Manocha, KK; Sharma, T; Singh, H | 1 |
| Bilici, A; Eren, M; Gumus, M; Karabulut, SG; Kocak, M; Mayadagli, A; Oruc, F; Oven Ustaalioglu, BB; Ozkan, A; Parlak, C; Seker, M | 1 |
| Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS | 1 |
| Baserga, R; Belmontes, B; Beltran, PJ; Cajulis, E; Calzone, FJ; Chung, YA; Ho, J; Kendall, R; Lu, J; Mitchell, P; Radinsky, R; Tsai, MM; Vonderfecht, S; Zhu, M | 1 |
| Altman, RB; Brunak, S; Hansen, NT | 1 |
| Crawford, ED; deVere White, RW; Goldman, B; Hussain, MH; Lara, PN; Smith, DC; Tangen, CM; Wood, DP | 1 |
| Bousquet, C; Brizuela, L; Cuvillier, O; Davenne, L; Delisle, MB; Guilbeau-Frugier, C; Guillermet-Guibert, J; Pchejetski, D; Saint-Laurent, N; Susini, C | 1 |
| Fujiwara, T; Hashimoto, Y; Kojima, T; Kuroda, S; Liu, D; Onimatsu, H; Ouchi, M; Urata, Y; Watanabe, Y | 1 |
| Chang, PY; Chen, JH; Yao, NS | 2 |
| Ardizzoni, A; Bartolotti, M; Gelsomino, F; Tiseo, M | 1 |
| Finn, RS; Zhu, AX | 1 |
| Gorlick, R; O'Day, K | 1 |
| Bollina, R; Carrozza, F; Cascone, T; Ciardiello, F; Di Maio, M; Gallo, C; Gebbia, V; Gridelli, C; Maione, P; Mattioli, R; Mencoboni, M; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Rossi, A; Valerio, MR; Valmadre, G; Verusio, C; Viganò, MG | 1 |
| Ishibashi, Y; Ito, Y | 1 |
| Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A | 1 |
| Ceresa, C; Giaccone, G; Giovannetti, E; Honeywell, R; Laan, AC; Peters, GJ; Voortman, J | 1 |
| Jacobs, MJ; Saidi, RF | 1 |
| Alacacioglu, A; Erten, C; Meydan, N; Somali, I; Tarhan, MO; Usalp, S; Yilmaz, U | 1 |
| Buchsbaum, DJ; Grizzle, WE; Li, J; Oelschlager, DK; Tian, DA; Wan, M; Wang, P; Wang, Y; Yang, C; Zheng, Y | 1 |
| Choong, NW; Connor, TB; George, B; Wirostko, WJ | 1 |
| Brown, JV; Goldstein, BH; John, CR; Markman, M; Micha, JP; Rettenmaier, MA | 1 |
| Bantleon, R; Farkas, E; Kehlbach, R; Werner, M; Wiesinger, B; Wiskirchen, J | 1 |
| Alonso, S; Calabrò, F; Di Paula, ED; Frassineti, L; Lorusso, V; Manzione, L; Rosati, G; Sava, T; Sternberg, CN | 1 |
| Esser, N; Graeser, R; Jantscheff, P; Kluth, J; Massing, U; Unger, C; Ziroli, V | 1 |
| Chen, ZL; Hou, LB; Huang, LS; Jiang, L; Wang, CX; Wang, YL; Yan, ZT | 1 |
| Ding, L; Duan, LN; Liu, J; Wang, HX; Wang, ZD; Xue, M; Yan, HM; Zhu, L | 1 |
| Bral, S; De Grève, J; De Mey, J; Decoster, L; Fontaine, C; Ilsen, B; Meysman, M; Neyns, B; Schallier, D | 1 |
| Chang, K; Goedegebuure, PS; Hawkins, WG; Hotchkiss, RS; Kashiwagi, H; McDunn, JE; Simon, PO | 1 |
| Cruz, O; de Torres, C; Mora, J; Parareda, A; Sola, T | 1 |
| Hedley, DW; Mamaghani, S; Patel, S | 1 |
| Barthet, M; Calvo, EL; Dagorn, JC; Delpero, JR; Iovanna, JL; Legoffic, A | 1 |
| Chen, DD; Li, WY; Lu, XM; Shu, XG; Tao, KX; Tong, Q; Wang, GB | 1 |
| Ben-Josef, E; Chang, AE; Colletti, L; Desai, S; Francis, IR; Greenson, JK; Griffith, KA; Hampton, J; Lawrence, TS; Simeone, D; Zalupski, MM | 1 |
| Barneto, I; Blanco, R; Catot, S; Chaib, I; Cobo, M; de Las Peñas, R; Diz, P; Domine, M; Ibeas, R; Isla, D; Jimenez, U; Lopez-Vivanco, G; Macias, JA; Mendez, P; Moran, T; Oramas, J; Perez-Roca, L; Provencio, M; Reguart, N; Rosell, R; Sala, MA; Sanchez, JJ; Sanchez, JM; Taron, M | 1 |
| Georgoulias, V; Kotsakis, A; Marselos, M; Mavroudis, D; Nikolaidou, M; Pappas, P; Saridaki, Z; Souglakos, J; Vardakis, N | 1 |
| Elzawawy, A | 1 |
| Bartel, P; Ecke, TH; Gerullis, H; Koch, S; Ruttloff, J | 1 |
| Bulusu, R; Camilleri, D; Follows, G; Marcus, R; Raj, S; Stafford, G; Todd, T; Williams, M | 1 |
| Davies, AM; Gandara, DR; Gautschi, O; Jablons, DM; Mack, PC; Rosell, R | 1 |
| Cunha, JE; Fernandes, Gdos S; Freitas, D; Hoff, PM | 1 |
| Chun, SG; Yee, NS; Zhou, W | 1 |
| Choi, YJ; Chung, JS; Kang, HJ; Kim, HJ; Kim, SH; Kim, SJ; Kim, WS; Lee, DH; Oh, SY; Ryoo, BY; Suh, C | 1 |
| Hashimoto, Y; Hayashidani, Y; Murakami, Y; Nakamura, H; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 2 |
| Addeo, A; Bellone, G; Brondino, G; Campra, D; Ciuffreda, L; Fronda, GR; Giacobino, A; Novarino, A; Prati, A; Vizio, B | 1 |
| Chekerov, R; Fotopoulou, C; Karavas, A; Lichtenegger, W; Sehouli, J; Trappe, R | 1 |
| Alfieri, S; Antinori, A; Cellini, N; Crucitti, A; D'Agostino, GR; Di Lullo, L; Doglietto, GB; Ippolito, E; Luzi, S; Mantini, G; Mattiucci, GC; Morganti, AG; Smaniotto, D; Valentini, V | 1 |
| Chen, Y; Guo, Q; Kang, M; Wu, Y; Xie, Q; Zhang, B | 1 |
| Cao, Y; Chen, B; Cheng, H; Cheng, L; Feng, J; Ji, J; Li, F; Lu, Z; Ma, J; Qin, S; Sun, N; Sun, X; Zhou, Y | 1 |
| Bernard, C; Grushka, JR; Laberge, JM; Mueller, C; Nguyen, VH; Puligandla, PS; Roessingh, Ade B; Ryckman, J; St Vil, D; Walton, JM | 1 |
| Aasebø, U; Amundsen, T; Bremnes, RM; Brunsvig, PF; Fløtten, O; Grønberg, BH; Hjelde, HH; Kaasa, S; Stornes, F; Sundstrøm, S; Tollåli, T; von Plessen, C; Wammer, F | 1 |
| Ece, F; Hanta, I; Hasturk, S; Hatabay, N; Karatasli, M | 1 |
| Dalgleish, AG; Liu, WM; Nizar, S | 1 |
| Georgoulias, V; Hatzidaki, D; Koutsopoulos, A; Mavroudis, D; Papadaki, C; Souglakos, J; Stathopoulos, E; Trypaki, M; Tsakalaki, E | 1 |
| Mizumoto, K; Moriyama, T; Nabae, T; Nagai, E; Ohuchida, K; Sato, N; Takahata, S; Tanaka, M; Toma, H; Yu, J | 1 |
| Chu, Z; Mao, L; Ren, H | 1 |
| Adachi, S; Handa, O; Ishikawa, T; Kokura, S; Naito, Y; Okayama, T; Takagi, T; Yoshikawa, T | 1 |
| Frumovitz, M; Han, LY; Rashid, A; Ricks, AM | 1 |
| Bachelez, H; Beylot-Barry, M; Chaoui, D; Dubertret, L; Ingen-Housz-Oro, S; Jidar, K; Morel, P; Paul, C; Sigal-Grinberg, M | 1 |
| Freeman, JW; Giles, FJ; Wang, Y | 1 |
| Pawlega, J; Zygulska, AL | 1 |
| Chang, JJ; Chi, RM; Frethem, CD; Kirstein, MN; Kratzke, RA; Le, CT; Marker, PH; Williams, BW | 1 |
| Gedanken, A; Grinberg, O; Mukherjee, P; Mukhopadhyay, D; Patra, CR; Patra, S | 1 |
| Adachi, S; Akiyama, M; Fujita, H; Hosokawa, K; Itani, Y; Ito, K; Tabata, T; Takeuchi, S; Tsubamoto, H | 1 |
| Cantore, M; Del Freo, A; Mambrini, A; Orlandi, M; Pacetti, P; Pezzuolo, D; Seta, RD; Tartarini, R; Torri, T | 1 |
| Brandi, M; Colucci, G; Corsetti, S; DI Lauro, L; Fattoruso, SI; Foggi, P; Gebbia, V; Giannarelli, D; Giotta, F; Lopez, M; Lorusso, V; Sergi, D; Vici, P; Viola, G; Vitucci, C | 1 |
| Fairweather, WR; King, CR; Murugesan, SR; O'Reilly, EM; Osborn, R; Thornton, MO; Wei, LL | 1 |
| Jeong, CY; Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY | 1 |
| Sorscher, SM | 1 |
| Alla, P; Bounolleau, P; Faivre, A; Lafolie, T; Legodec, J; Pasqualini, C | 1 |
| Arima, K; Hasegawa, Y; Kise, H; Nishikawa, K; Soga, N; Sugimura, Y; Yamada, Y | 1 |
| Borbath, I; Boterberg, T; de Hemptinne, B; Demols, A; Hendlisz, A; Laurent, S; Mahin, C; Monsaert, E; Peeters, M; Polus, M; Scalliet, P; Van Laethem, JL | 1 |
| Doi, R; Fukushima, M; Hatano, E; Ikai, I; Ishiguro, H; Kanai, M; Kitano, T; Matsumoto, S; Misawa, A; Morita, S; Nishimura, T; Sasaki, T; Yanagihara, K; Yasuda, H; Yazumi, S | 1 |
| Fushiki, H; Hayakawa, Y; Jiang, J; Kanoh-Azuma, T; Katoh, M; Kawabata, K; Satow, A; Tamai, Y; Tsuchiya, N | 1 |
| Adams, J; Allard, D; Caldwell, ME; Chang, A; Combs, C; Davidson, CJ; Davies, SE; Denicola, G; Dhara, M; Egorin, M; Feig, C; Frese, KK; Goldgraben, MA; Gopinathan, A; Griffiths, J; Grützmann, R; Hingorani, SR; Honess, D; Howat, WJ; Hruban, RH; Huang, P; Iacobuzio-Donahue, C; Ireland-Zecchini, H; Izeradjene, K; Jacobetz, MA; Madhu, B; McGovern, K; McIntyre, D; Olive, KP; Pilarsky, C; Plunkett, W; Reichelt, S; Rückert, F; Tuveson, DA; Wang, L; Whitebread, N; Winter, SP | 1 |
| Amitani, R; Hatano, K; Ikeda, A; Kawakami, H; Kimura, T; Kita, R; Maruo, T; Matsuo, H; Nakatsuji, M; Nishijima, N; Nishikawa, H; Okabe, Y; Osaki, Y; Saito, S; Tsumura, T | 1 |
| Chang, PM; Chang, SY; Chen, PM; Chu, PY; Huang, JL; Tai, SK; Tsai, TL; Tzeng, CH; Wang, HM; Wang, YF; Yang, MH | 1 |
| Batra, SK; Davis, JS; Davis, TL; Hauke, R; Lin, FF; Lin, MF; Schutte, R; Zelivianski, S; Zhang, L | 1 |
| Chovanec, J; Dorr, A; Habetinek, V; Helpianska, L; Horvathova, D; Jancokova, I; Koza, I; Kroslakova, D; Lalabova, R; Laluha, A; Magdin, D; Malec, V; Minarik, T; Packan, T; Rakicka, G; Sevcik, L; Spacek, J; Stresko, M; Sufliarsky, J; Svetlovska, D; Tkacova, V | 1 |
| Gans, SJ; Goksel, T; Martins, R; Park, K; Patil, S; Peterson, P; Rolski, J; Scagliotti, GV; Visseren-Grul, C | 1 |
| Bonomo, G; Chilosi, M; Leo, F; Pelosi, G; Sonzogni, A; Spaggiari, L | 1 |
| Fong, KW; Hee, SW; Leong, SS; Lim, WT; Tan, EH; Toh, CK; Yap, SP | 1 |
| de la Peña, FA; Garcia-Martinez, E; Vicente, E; Zafra, M | 1 |
| Cheng, AL; Kuo, SH; Lin, ZZ; Yang, SH | 1 |
| Brody, JR; Costantino, CL; Cozzitorto, JA; Dasgupta, A; Gorospe, M; Keen, JC; Kennedy, EP; Kuwano, Y; Witkiewicz, AK; Yeo, CJ | 1 |
| Clark, JI; Crawford, DE; Gandour-Edwards, R; Hussey, M; Lange, MK; Lara, PN; Mack, PC; Van Veldhuizen, PJ | 1 |
| Bonomi, P; Langer, C; Lilenbaum, R; O'Brien, M; O'Byrne, K; Oldham, FB; Ross, HJ; Sandilac, L; Singer, JW; Socinski, M; Villaflor, VM | 1 |
| Arrieta, O; Astorga-Ramos, AM; de la Garza, J; Gallardo-Rincón, D; Martínez-Barrera, L; Michel, RM; Villarreal-Garza, C | 1 |
| Bätge, R; Egberts, EH; Holstein, A | 1 |
| Garrett, C; Gibbs, J; Iyer, R; Javle, M; Kuvshinoff, B; Litwin, A; Pande, A; Phelan, J; Yu, J | 1 |
| Chan, F; Hidalgo, M; Jimeno, A; Lin, SH; Rajeshkumar, NV; Rubio-Viqueira, B; Solomon, A; Tan, AC; Wheelhouse, J | 1 |
| Patel, SR; Shord, SS | 1 |
| Arai, T; Hirai, H; Itadani, H; Kotani, H; Mizuarai, S; Nishibata, T; Yamanaka, K | 1 |
| Bartenstein, P; Berger, F; D'Haese, JG; Ellwart, JW; Heeschen, C; Hermann, PC; Hidalgo, M; Huber, S; Jauch, KW; Leicht, SF; Mueller, MT; Mustafa, M; Rubio-Viqueira, B; Schoenberg, MH; Witthauer, J | 1 |
| Bliziotis, I; Makrilia, N; Saif, MW; Syrigos, K; Xyla, V | 1 |
| Aspe, JR; Galloway, NR; Sellers, C; Wall, NR | 1 |
| Emerich, J; Gołka, KA; Kobierski, J; Milczek, T | 1 |
| Jian, W; Lerner, SP; Levitt, JM; Sonpavde, G; Yamashita, H | 1 |
| Boterberg, T; Casneuf, VF; Delrue, L; Demetter, P; Peeters, M; Van Damme, N | 1 |
| Takahashi, T; Tanaka, A | 1 |
| Innocenti, F; Soo, RA; Wong, A; Yong, WP | 1 |
| Bijelic, L; Kamath, A; Stuart, OA; Sugarbaker, PH; Yoo, D | 1 |
| Arora, S; Azorsa, DO; Basu, GD; Bisanz, KM; Choudhary, A; Gonzales, IM; Henderson, MC; Kiefer, JA; Mousses, S; Trent, JM; Von Hoff, DD | 1 |
| Goto, K; Kim, YH; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Hanahan, D; Olson, P | 1 |
| Alexandrescu, DT; Dasanu, CA; Herzog, TJ | 1 |
| Ko, CJ; Li, J; Saif, MW | 1 |
| Arakawa, T; Ashida, R; Hirakawa, K; Mizuno, N; Nakata, B; Sawaki, A; Shigekawa, M; Yamao, K | 1 |
| Antúnez, A; García-Mata, J; Mellado, JM; Villar, JL; Zambrana, F | 1 |
| Gold, DV; Goldenberg, DM; Leon, E; Modrak, DE | 1 |
| Banerjee, S; Kong, D; Sarkar, FH; Wang, Z | 1 |
| Bisegna, R; Bonfili, P; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F; Sica, G; Tombolini, V | 1 |
| Abiko, M; Sato, T; Shiono, S; Tamura, G | 1 |
| Mistafa, O; Stenius, U | 1 |
| Abe, T; Ikeda, K; Koeda, K; Minakawa, Y; Nitta, H; Obuchi, T; Otsuka, K; Sasaki, A; Shimooki, O; Wakabayashi, G | 1 |
| Aono, T; Fushimi, H; Iwase, K; Koma, M; Matsuda, C; Nishikawa, K; Nomura, M; Shimada, K; Takeda, S; Tamagawa, H; Tanaka, Y; Yoshida, H | 1 |
| Endo, M; Hasegawa, I; Kato, A; Koguchi, H; Matsunaga, S; Miura, A; Ohno, T; Sakakibara, K; Tanaka, Y; Tokuda, Y | 1 |
| Akita, H; Bepler, G; Doki, Y; Dono, K; Kim, C; Kittaka, N; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Takemasa, I; Zheng, Z | 1 |
| Avallone, A; Chiuri, VE; Cioffi, R; Comella, P; Costanzo, R; De Cataldis, G; Filippelli, G; Franco, L; Greco, E; Maiorino, L; Mancarella, S; Palmeri, L; Putzu, C; Vessia, G | 1 |
| Bowen, C; Licea-Perez, H; Wang, S | 1 |
| Kovac, V; Smrdel, U; Vrankar, M; Zadnik, V; Zwitter, M | 1 |
| Choo, SP; Leong, SS; Li, HH; Lim, WT; Tan, EH; Tan, SH; Tham, CK; Toh, CK | 1 |
| Eguchi, H; Ishikawa, O; Nakagawa, H; Nakamura, Y; Nishiyama, K; Ohigashi, H; Takahashi, H; Takehara, A; Tomita, Y; Uehara, R; Yano, M | 1 |
| Amano, A; Masaki, T; Miyakawa, K; Niwa, T; Ohkawa, S; Ueno, M; Yoshida, T | 1 |
| Banerjee, S; Kaseb, AO; Kong, D; Mohammad, M; Mohammad, RM; Padhye, S; Sarkar, FH; Wang, Z | 1 |
| Blackstock, AW; Lally, B; Urbanic, JJ | 1 |
| Giaccone, G; Honeywell, RJ; Laan, AC; Mammatas, LH; Peters, GJ; Ruyter, R; van den Berg, FG; van Groeningen, CJ; van Riel, JM | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Sargent, M; Schafer, C; Seufferlein, T | 1 |
| Estephan, F; Esteva, FJ; Frye, DK; Ibrahim, NK; Mejia, JA; Valero, V | 1 |
| Böhle, A; Büttner, H; Frei, C; Helsberg, K; Knispel, HH; Kühn, M; Leyh, H; Lübben, B; Pottek, T; Soldatenkova, V; Stoffregen, C; Tschada, R; von Pokrzywnitzki, W; Wagner, W; Zorlu, F | 1 |
| Eguchi, H; Gotoh, K; Ishikawa, O; Nakaizumi, A; Nishiyama, K; Ohigashi, H; Takahashi, H; Tomita, Y; Uehara, H; Yamada, T; Yano, M | 2 |
| Adema, AD; Honeywell, RJ; Peters, GJ; van der Born, K | 1 |
| Bigand, C; Hajri, A; Parmentier, C; Réjiba, S | 1 |
| Funai, K; Itaya, T; Mochizuki, T; Momiki, S; Nakamura, T; Neyatani, H; Sasaki, K; Suzuki, K; Takahashi, T; Takamochi, K; Toyoda, F; Yong-Il, K | 1 |
| Cance, WG; Golubovskaya, VM; Hochwald, SN; Magis, A; Massoll, NA; Nyberg, C; Ostrov, D; Wood, C; Zheng, D; Zheng, M | 1 |
| Fridley, BL; Jenkins, G; Schaid, DJ; Wang, L | 1 |
| Kim, SN; Lee, KS; Nam, BH; Park, IH; Ro, J; Yun, YH | 1 |
| DattaGupta, S; Deo, S; Dwary, A; Garg, P; Mohanti, B; Pal, S; Raina, V; Rath, G; Sahni, P; Sharma, A; Shukla, N; Thulkar, S | 1 |
| Delpero, JR; Giovannini, M; Guiramand, J; Lelong, B; Moureau-Zabotto, L; Moutardier, V; Turrini, O; Viret, F | 1 |
| de Marinis, F; Gridelli, C; Maione, P; Ricciardi, S; Rossi, A | 1 |
| Fukui, H; Ikenaka, Y; Kaji, K; Kawaratani, H; Kitade, M; Namisaki, T; Noguchi, R; Tsujimoto, T; Yamazaki, M; Yanase, K; Yoshii, J; Yoshiji, H | 1 |
| Bang, YJ; Cha, Y; Choi, IK; Choi, IS; Kim, CD; Kim, JH; Kim, JS; Kim, YH; Oh, DY; Oh, SC; Yoon, SY | 1 |
| Alberts, S; Benson, AB; Berlin, J; Catalano, P; Cella, D; Feng, Y; Haller, D; Hochster, H; Mitchell, E; O'Dwyer, P; Poplin, E; Rothenberg, ML | 1 |
| Saif, MW; Strimpakos, AS; Syrigos, KN | 4 |
| Sherman, WH | 1 |
| Choi, DW; Choi, SH; Heo, JS; Lee, HG; You, DD | 1 |
| Abbruzzese, JL; Arumugam, T; Choi, W; Fournier, KF; Gallick, GE; Logsdon, CD; Marquis, L; McConkey, DJ; Ramachandran, V; Wang, H | 1 |
| Alvarado-Miranda, A; Arrieta, O; Bargallo-Rocha, E; Gamboa-Vignolle, C; Lara-Medina, F; Morales-Barrera, R; Perez-Sanchez, V; Ramirez-Ugalde, T; Saavedra-Perez, D; Zinser-Sierra, J | 1 |
| Dreisbach, L; Kristedja, T; Kurtin, S; Mahadevan, D; Obregon, Y; Von Hoff, DD; Williams, D | 1 |
| Canil, C; Dent, SF; Gertler, S; Goel, R; Iscoe, N; Keller, O; Segal, R; Verma, S; Young, V | 1 |
| Ebi, M; Hirata, Y; Joh, T; Kamiya, T; Kataoka, H; Kubota, E; Mabuchi, M; Mizoshita, T; Mizushima, T; Mori, Y; Murakami, K; Ogasawara, N; Okamoto, Y; Sasaki, M; Shimura, T; Takahashi, S; Tanaka, M; Tanida, S; Wada, T | 1 |
| Coffey, MC; Mussio, JK; Nagashima, K; Parchment, RE; Sei, S; Shoemaker, RH; Tomaszewski, JE; Yang, QE | 1 |
| Felekouras, E; Giannakopoulos, K; Giannopoulos, A; Gogas, H; Karatzas, T; Lagadas, A; Papadopoulos, O; Polyzos, A; Polyzos, K; Tsavaris, N; Tsigris, C | 1 |
| Fu, D; Hu, J; Long, J; Ni, Q; Wang, C; Yang, D; Yang, F | 1 |
| Bang, S; Hong, SP; Park, S; Song, SY; Wen, J | 1 |
| Abbassi, S; Doan, NB; Iwanski, GB; Koeffler, HP; Lin, P; Okamoto, R; Said, JW; Song, JH; Thoennissen, NH; Toh, M; Xie, WD; Yin, D | 1 |
| Böll, B; Borchmann, P; Engert, A; Gossmann, A; Reiners, KS; von Strandmann, EP | 1 |
| Choi, EK; Kang, YS; Kim, IY; Kim, JS; Lee, DS; Oh, YK; Park, HJ; Son, HJ | 1 |
| An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Lin, XB; Wang, FH; Xu, RH | 1 |
| Agatsuma, T; Fujimoto, K; Hanaoka, M; Koizumi, T; Kubo, K; Urushihata, K; Yamamoto, H; Yasuo, M | 1 |
| Fushida, S; Kimura, H; Mukawa, A | 1 |
| Aksoy, P; Eckloff, BW; Kalari, KR; Moon, I; Pelleymounter, LL; Wang, L; Weinshilboum, RM; Wieben, ED; Yee, VC; Zhu, MJ | 1 |
| Cui, DD; Huang, XB; Huang, Y; Ji, LL; Liu, TG; Mao, SH; Song, HB; Yi, C | 1 |
| Awasthi, N; Cafasso, D; Konduri, S; Schwarz, MA; Schwarz, RE | 2 |
| Angel, J; Athanasiou, A; Karanikas, C; Kosmas, C; Lampaki, S; Mylonakis, N; Politis, N; Rapti, A; Ziras, N | 1 |
| Dragnev, K; Dudek, AZ; Gupta, V; Isaksson, R; Kratzke, RA; Larson, T; Lesniewski-Kmak, K; Maddaus, MA | 1 |
| Abu-Baker, SO | 1 |
| Crane, CH; Curran, W; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, K; Wolff, RA | 1 |
| Bajorin, DF; Iasonos, A; Maluf, FC; Milowsky, MI; Mironov, S; Nanus, DM; Regazzi, A; Riches, J; Shi, W | 1 |
| Danesi, R; Del Tacca, M; Ferlini, C; Ferrandina, G; Mey, V; Nannizzi, S; Petrillo, M; Ricciardi, S; Scambia, G | 1 |
| Byun, JH; Hwang, IG; Jang, JS; Kim, BS; Kim, SY; Kim, YH; Lee, KH; Lee, MA; Lee, SJ; Lim, HY; Oh, SC; Oh, SJ; Park, E; Song, HS; Yoo, N; Yoon, S | 1 |
| Ali, S; Kong, D; Li, Y; Philip, PA; Sarkar, FH; VandenBoom, TG; Wang, Z | 1 |
| Eichler, K; Gruber-Rouh, T; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S | 1 |
| Altintas, S; Huizing, MT; Specenier, PM; Van den Brande, J; Van den Weyngaert, D; Van Laer, C; Vermorken, JB; Weyler, J | 1 |
| Cass, CE; Damaraju, S; Damaraju, VL; Mowles, D; Sawyer, MB | 1 |
| Barton, J; Burris, HA; Greco, FA; Hainsworth, JD; Hanson, S; Spigel, DR; Yardley, DA | 1 |
| Bakshandeh-Bath, A; Homann, N; Peters, SO; Stölting, S; Stoltz, AS; Wagner, T | 1 |
| Chiao, PJ; Gocho, T; Hirohara, S; Misawa, T; Uwagawa, T; Yanaga, K | 1 |
| Endo, S; Hashimoto, K; Iguchi, C; Itakura, M; Koike, M; Nio, Y; Nishi, T; Omori, H; Sato, Y; Takamura, M; Takeda, H | 1 |
| Gkini, E; Gkiozos, I; Katirtzoglou, N; Kotteas, E; Makrilia, N; Ralli, M; Syrigos, K; Tourkantonis, I | 1 |
| Belderbos, JS; Burgers, SA; Kappers, I; Klomp, HM; van Sandick, JW; van Zandwijk, N | 1 |
| Ikeda, M; Morizane, C; Okusaka, T; Seki, Y; Ueno, H | 1 |
| Holm, B; Mellemgaard, A; Skov, BG; Skov, T | 1 |
| Guan, Y; He, J; Jiang, M; Shao, W; Tucker, S; Wang, D; Wu, Y; Xu, X; Yang, H; Ying, W; Zhong, B; Zhong, N | 1 |
| Anthoney, A; Baka, S; Bridgewater, J; Corrie, P; Dixon, L; Evans, L; Falk, S; Gollins, S; Highley, M; Iveson, T; Johnson, P; Jones, E; Lofts, F; Maraveyas, A; Meyer, T; Osborne, R; Swindell, R; Valle, JW; Wasan, H | 1 |
| Ides, J; Lambrechts, HA; Lardon, F; Meijnders, P; Pattyn, GG; Pauwels, B; Van Laere, S; Vermeulen, K; Vermorken, JB; Wouters, A | 1 |
| Aubert, S; Fauquette, V; Huet, G; Jonckheere, N; Pigny, P; Porchet, N; Saint-Laurent, N; Stechly, L; Susini, C; Van Seuningen, I | 1 |
| Hollender, J; Kovalova, L; Mcardell, CS; Moser, R; Ort, C; Pazhepurackel, V; Siegrist, H; Weissbrodt, D | 1 |
| Bang, YJ; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sun, JM | 1 |
| Hoimes, C; Merl, M; Pham, T; Saif, MW | 1 |
| Aggarwal, BB; Inamoto, T; Kamat, AM; Sung, B; Tharakan, ST | 1 |
| Lee, HJ; Lim, JS; Yang, YJ | 1 |
| Antman, KA; Chabot, JA; Chen, C; Fine, RL; Grann, VR; Kumah, CK; Tsai, WY | 1 |
| Barrios, CH; Chiorean, EG; Dragovich, T; Gorini, CF; Hamm, J; Jung, DT; Kroll, S; Langmuir, VK; Loehrer, PJ; Tidmarsh, GT | 1 |
| Catania, C; De Braud, F; De Pas, TM; Noberasco, C; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| de Vries, EG; Eskens, FA; Fox, NL; Gietema, JA; Loos, WJ; Miceli, R; Mom, CH; Oldenhuis, CN; Sleijfer, S; Verweij, J | 1 |
| Doi, R; Egawa, S; Hatori, T; Kanemitsu, K; Kosuge, T; Matsuyama, Y; Monden, M; Nakao, A; Shimada, M; Tanaka, M; Ueno, H; Yamamoto, J | 1 |
| Hirotsune, H; Inoue, A; Komori, K; Matsuyama, K; Miyamoto, A; Nakamori, S; Oike, M; Satomi, E; Sekiyama, R; Sueta, K; Todaka, K; Tsujinaka, T; Ueno, H; Yoshida, T | 1 |
| Bohnenkamp, H; Bruns, CJ; Dellian, M; Eichhorn, ME; Guenzi, E; Ischenko, I; Jauch, KW; Luedemann, S; Michaelis, U; Papyan, A; Preissler, G; Strieth, S; Werner, A | 1 |
| Fidias, P; Heist, RS; Lynch, TJ; Muzikansky, A; Ostler, P; Sequist, LV | 1 |
| Hara, K; Hoki, N; Ito, S; Kawai, H; Kobayashi, Y; Matsumoto, K; Mizuno, N; Nakamura, T; Sawai, Y; Sawaki, A; Tajika, M; Takagi, T; Yamao, K | 1 |
| Chan, D; Chuah, B; Goh, BC; Lee, SC; Lim, SE; Soo, R; Tan, SH; Tiemsim Cordero, M; Wong, CI; Yeo, WL | 1 |
| Hasebe, O; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Maetani, I; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yasuda, I | 1 |
| Dumitru, CA; Gulbins, E; Weller, M | 1 |
| Hsiao, PJ; Hung, WW; Ou-Yang, F; Shin, SJ; Tsai, KB; Wang, CS | 1 |
| Asmar, L; Becerra, C; Boehm, KA; Gersh, RH; Gill, JF; Hozak, RR; Kuefler, PR; Mullaney, BP; Myrand, SP; Nicol, SJ; Obasaju, CK; Richards, DA; Wilfong, LS; Zhan, F; Zhao, L | 1 |
| Alkis, N; Aslan, UY; Benekli, M; Buyukberber, S; Camci, C; Celenkoglu, G; Coskun, U; Er, O; Ozkan, M; Ozturk, B; Sevinc, A; Tokluoglu, S; Uner, A; Yildiz, R | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, DE; McMeekin, DS; Monk, BJ; Ramondetta, LM; Sill, MW | 1 |
| Barone, C; Chodkiewicz, C; Kim, S; Maurel, J; Ricart, AD; Rosbrook, B; Spano, JP; Springett, GM; Wasan, HS; Wong, R | 1 |
| Chen, Y; Smith, BJ | 1 |
| Beijnen, JH; Huitema, AD; Jansen, RS; Koolen, SL; Schellens, JH; Smit, WM; van Voorthuizen, T | 1 |
| Cruz, CO; de Torres, C; Mora, J; Parareda, A | 1 |
| Amatu, A; Bernardo, G; Minoia, C; Montagna, B; Poggi, G; Pozzi, E; Quaretti, P; Riccardi, A; Rossi, O; Sottani, C; Sottotetti, F; Tagliaferri, B; Villani, L; Zappoli, F | 1 |
| Bozas, G; Dimopoulos, MA; Fountzilas, G; Kalofonos, H; Makatsoris, T; Papadimitriou, CA; Papakostas, P; Zagouri, F | 1 |
| Hagihara, A; Hashimoto, K; Ikeda, M; Kojima, Y; Kondo, S; Morizane, C; Okusaka, T; Ueno, H | 1 |
| Esau, C; Lee, EJ; Park, JK; Schmittgen, TD | 1 |
| Chen, W; Cui, L; Fu, DL; Hou, HM; Jin, C; Li, JM; Lu, WY; Ni, QX; Wang, H; Yu, XJ | 1 |
| Alberola, V; Camps, C; Carcereny, E; Cobo, M; de Aguirre, I; Domine, M; Isla, D; Lopez-Vivanco, G; Massuti, B; Mendez, P; Moran, T; Okamoto, T; Provencio, M; Ramirez, JL; Rosell, R; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Wei, J | 1 |
| Bharthuar, A; Iyer, R; Kuvshinoff, B; LeVea, C; Litwin, A; Pearce, L | 1 |
| Kaley, K; Peccerillo, J; Saadati, H; Saif, MW; Schilsky, ML | 1 |
| Bockisch, A; Dralle, H; Kegel, T; Mann, K; Matuszczyk, A; Petersenn, S; Schmoll, HJ; Voigt, W | 1 |
| Cohen, MH; Justice, R; Pazdur, R | 1 |
| Boyer, MJ; Chen, YM; Chua-Tan, M; Chui, W; Ignacio, J; Jin, K; Johnston, M; Lee, JS; Liao, M; Mok, TS; Srimuninnimit, V; Sriuranpong, V; Sudoyo, AW; Wu, YL; Yu, CJ; Zhang, L; Zhou, C | 1 |
| Bafna, S; Batra, SK; Kaur, S; Momi, N | 1 |
| Baulieux, J; Bossard, N; de la Roche, E; Gamondes, JP; Geriniere, L; Guibert, B; Mulsant, P; Remontet, L; Souquet, PJ; Thibout, Y; Tiffet, O; Tronc, F | 1 |
| Alvarez Sánchez, MV; Alvarez, M; Baltar Arias, R; Gómez Martínez, P; Soto Iglesias, S; Vázquez Astray, E; Vázquez Rodríguez, S | 1 |
| Ikeda, H; Mouri, H; Nakanuma, Y; Ohtsubo, K; Tsuchiyama, T; Watanabe, H; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Eom, HS; Kim, JS; Kim, WS; Lee, DH; Lee, YY; Oh, SJ; Park, BB; Suh, C | 1 |
| Custodio, A; Díaz-Rubio, E; Puente, J; Sastre, J | 1 |
| Dumitru, CA; Gulbins, E; Sandalcioglu, IE; Wagner, M; Weller, M | 1 |
| Alamara, C; Chatzidarellis, E; Georgiadis, E; Giza, L; Makrilia, N; Syrigos, KN | 1 |
| Bartsch, R; Brodowicz, T; Gerges, DA; Inbar, M; Pawlega, J; Spanik, S; Timcheva, C; Tomova, A; Tzekova, V; Wiltschke, C; Zielinski, CC | 1 |
| Gion, T; Harimoto, N; Itoh, S; Maehara, Y; Sugimachi, K; Taketomi, A; Tsujita, E; Yamashita, Y | 1 |
| Gruber, T; Hammerstingl, R; Naguib, NN; Nour-Eldin, NE; Vogl, TJ | 1 |
| Gilligan, D; Gower, N; Hackshaw, A; Jitlal, M; Lee, SM; Ottensmeier, C; Price, A; Rudd, R; Spiro, S; Woll, PJ | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, T; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Märten, A; Neugebauer, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Campodonico, F; Maffezzini, M; Martelli, A; Mattioli, F; Puntoni, M | 1 |
| Bourgeois, H; Chevalier-Place, A; Delva, R; Guardiola, E; Henry-Amar, M; Joly, F; Mayer, F; Pautier, P; Petit, T; Sevin, E | 1 |
| Bartel, P; Ecke, TD; Gerullis, H; Koch, S; Ruttloff, J | 1 |
| Che, G; Gong, Y; Hou, M; Huang, M; Li, L; Li, T; Li, W; Liu, L; Liu, Y; Lu, Y; Ren, L; Tang, B; Wang, J; Xu, Y; Zhou, L; Zhu, J; Zou, B | 1 |
| Aogi, K; Fujiwara, Y; Iwata, H; Nambu, Y; Saeki, T; Saji, S; Sasaki, Y; Suri, A; Suzuki, Y; Takashima, S; Tokuda, Y | 1 |
| Kim, IH; Kim, SH; Kim, SW; Lee, SO | 1 |
| Armesilla, AL; Brown, J; Darling, JL; Goessl, E; Guo, X; Pandey, S; Wang, W; Xu, B | 1 |
| Arimoto, T; Hiramatsu, A; Hosogi, S; Iwasaki, Y; Kohno, Y; Koyama, Y; Marunaka, Y; Nakanishi, M; Tamiya, N; Ueda, M | 1 |
| Esser, N; Graeser, R; Jantscheff, P; Kluth, J; Massing, U; Sukolinskaya, A; Taylor, LA; Unger, C; Ziroli, V | 1 |
| Halldén, G | 1 |
| Bellmunt, J; De Santis, M; de Wit, R; Kerst, JM; Leahy, M; Maroto, P; Marreaud, S; Mead, G; Skoneczna, I; Sylvester, R | 1 |
| Cass, CE; Paproski, RJ; Young, JD | 1 |
| Ekerbicer, N; Inan, S; Karakaya, J; Muftuoglu, SF; Vatansever, HS; Zeybek, ND | 1 |
| Heike, Y; Hyodo, I; Ikeda, M; Makiyama, H; Morita-Hoshi, Y; Morizane, C; Okusaka, T; Soeda, A; Takahashi, N; Takaue, Y; Ueno, H; Yamagata, S | 1 |
| Draux, F; Dumas, P; Gobinet, C; Jeannesson, P; Manfait, M; Pijanka, J; Sandt, C; Sockalingum, GD; Sule-Suso, J | 1 |
| Alvarez, RD; Gallion, HH; García, AA; Kilgore, LC; Lucci, J; Mannel, R; Numnum, TM; Orlando, M; Tai, DF; Zou, SX | 1 |
| Apohan, E; Baatz, JE; Davies, C; Demarse, NA; Ogretmen, B; Ponnusamy, S; Spicer, EK | 1 |
| Anderson, PM; Cannan, VA; Crabbs, TA; Gordon, N; Kleinerman, E; Koshkina, N; Rodriguez, CO; Skorupski, KA; Wilson, DW | 1 |
| Clegg, A; Cooper, K; Jones, J; Loveman, E; Takeda, A; Tan, SC | 1 |
| Bechi, P; Cipriani, G; Grifoni, R; Molinara, E; Neri, B; Pantaleo, P; Pantalone, D; Rangan, S; Taddei, A; Tonelli, P; Valeri, A; Vannini, A | 1 |
| Matsuzawa, H; Suemitsu, R; Takeo, S; Yamaguchi, M | 1 |
| Larsen, CJ | 1 |
| Liew, A; Magee, C; Phelan, PJ | 1 |
| Qian, C; Yao, J | 1 |
| Gore, EM; Jones, BS; Marques, MB | 1 |
| Alanko, T; Asola, R; Bono, P; Hahka-Kemppinen, M; Huuhtanen, R; Joensuu, H; Kellokumpu-Lehtinen, P; Kokko, R; Leinonen, M; Pyrhönen, S; Sailas, L; Sunela, K; Turpeenniemi-Hujanen, T; Utriainen, M; Wigren, T | 1 |
| Abe, K; Furuhashi, S; Maebayashi, T; Sakaguchi, M; Shizukuishi, T; Sugitani, M; Takahashi, M; Tanaka, Y; Uematsu, A | 1 |
| Rajebi, MR; Saif, MW; Shahrokni, A | 1 |
| Aboukameel, A; Banerjee, S; Chen, J; Choi, M; Mohammad, M; Mohammad, RM; Sarkar, FH; Wang, Z; Yang, D | 1 |
| Blackwelder, WC; Chawla, SP; Chua, VS; Fernandez, L; Gordon, EM; Hall, FL; Quon, D | 1 |
| Han, DJ; Hwang, JY; Kim, JE; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, JS; Lee, SK; Lee, SS; Park, DH; Seo, DW; Yoo, C | 1 |
| Maréchal, R; Van Laethem, JL | 2 |
| Mackenzie, RP; McCollum, AD | 1 |
| Manegold, C; Martins, RG; Parikh, P; Scagliotti, GV; Simms, L; Sugarman, KP; Syrigos, KN; Vansteenkiste, J; Visseren-Grul, C; von Pawel, J | 1 |
| Abdel Karim, N; Flora, D; Gupta, A; Issa, M; Jazieh, AR; Knapp, M; Komrokji, R; Patil, S | 1 |
| Ansari, R; Belani, CP; Catalano, RB; Comis, RL; Edelman, MJ; Gillenwater, HH; Gonin, R; Marinucci, DM; Obasaju, CK; Rowland, KM; Socinski, MA; Treat, JA | 1 |
| Barthet, M; Calvo, E; Cano, C; Closa, D; Dagorn, JC; Delpero, JR; Ferrés-Masó, M; Folch-Puy, E; Iovanna, J; Legoffic, A | 1 |
| Chiba, A; Fujii, T; Habiro, A; Kohgo, Y; Koizumi, K; Mizukami, Y; Nakamura, K; Nakano, Y; Nishikawa, T; Okumura, T; Sasajima, J; Sugiyama, Y; Tanno, S | 1 |
| Fukada, I; Ikeda, H; Imai, S; Ito, T; Kawamoto, K; Morimoto, Y; Ogasahara, K; Okabe, M; Paku, T; Sano, K; Tsuruta, A; Yamaguchi, K; Yoshida, Y | 1 |
| Hashiguchi, K; Kitahara, K; Kohya, N; Miyazaki, K; Miyoshi, A; Ohtsuka, T; Yakabe, T | 1 |
| Miura, T; Nakamura, J; Ozeki, Y; Sato, K; Suzuki, N; Takahashi, T; Yamada, S; Yanagi, M | 1 |
| Ahlgren, J; Ahlin, C; Carlsson, L; Hansen, J; Jansson, T; Malmberg, L; Malmström, A; Svensson, JH; Westberg, R | 1 |
| Ngeow, J; Toh, CK | 1 |
| Abbruzzese, A; Addeo, R; Bellini, S; Caraglia, M; Cennamo, G; Del Prete, S; Faiola, V; Guarrasi, R; Lanna, M; Miragliuolo, A; Montella, L; Vincenzi, B | 1 |
| Carapella, CM; Carosi, M; Cognetti, F; Fabi, A; Giannarelli, D; Maschio, M; Metro, G; Mirri, MA; Pace, A; Pellegrini, D; Pompili, A; Russillo, M; Vidiri, A | 1 |
| Kanter, J; Strasberg, S; Wilson, DB | 1 |
| Boytim, ML; Cohen, SJ; Conkling, P; Davis, P; Dorr, RT; Hersh, EM; Modiano, MR; Patt, YZ; Zalupski, MM | 1 |
| Kawauchi, A; Mikami, K; Miki, T; Nakamura, T; Shiraishi, T; Takaha, N | 1 |
| Bender, GP; Masellis, AM; Sielaff, TD | 1 |
| Bertsch, HP; Buhl, T; Kaune, KM; Kretschmer, L; Mitteldorf, C; Schön, MP | 1 |
| Andreu, J; Carles, J; Serrano, C; Suárez, C | 1 |
| Booth, CM; Eisenhauer, EA; Ohorodnyk, P | 1 |
| Adab, F; Chau, I; Crellin, A; Cunningham, D; Dunn, J; Eatock, M; Falk, S; Harper, PG; Herrmann, R; Leonard, P; Neoptolemos, JP; Ostrowski, J; Scheithauer, W; Smith, D; Steward, W; Stocken, DD; Thompson, J; Tudur-Smith, C; Valle, JW; West, J | 1 |
| Puglisi, F | 1 |
| Macarulla, T; Tabernero, J | 1 |
| Cusnir, M; Enzinger, PC; Goldberg, RM; Gorsch, SM; Hollis, DR; Kindler, HL; Kulke, MH; Mayer, RJ; Niedzwiecki, D; Tempero, MA | 1 |
| Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Autorino, R; Bruni, G; Cantiello, F; Damiano, R; De Sio, M; Di Lorenzo, G; Federico, P; Gallo, L; Masala, D; Perdonà, S; Pizzuti, M; Quattrone, C | 1 |
| Bao, J; Bender, DM; Dantzig, AH; Diseroad, WD; Law, KL; Magnus, NA; McCarthy, JR; Perkins, EJ; Peterson, JA; Pu, YJ; Remick, DM; Reutzel-Edens, SM; Starling, JJ; Stephenson, GA; Vaid, RK; Zhang, D | 1 |
| Cellini, F; Cesario, A; Ciresa, M; D'Angelillo, RM; Fiore, M; Granone, P; Greco, C; Mineo, TC; Paleari, L; Pompeo, E; Ramella, S; Trodella, L | 1 |
| Hagmann, W; Jesnowski, R; Matthias Löhr, J | 1 |
| Amour, E; Beckendorf, V; Bossard, N; Douillard, JY; Girard, N; Grunenwald, D; Milleron, B; Mornex, F; Quoix, E | 1 |
| Ito, Y; Karasawa, K; Kazumoto, T; Nemoto, K; Nishimura, Y; Nishino, S; Ogawa, K; Ogawa, Y; Ogo, E; Okuno, Y; Onishi, H; Shibuya, H; Shibuya, K; Uchida, N | 1 |
| Chen, H; Jiang, H; Kong, R; Krissansen, GW; Pan, S; Sun, B; Sun, X; Wang, S | 1 |
| Bergaglio, M; Ceribelli, A; De Placido, S; Del Prete, S; Di Lorenzo, G; Federico, P; Lalle, M; Marino, M; Merola, C; Merola, G; Milella, M; Montella, L; Palmieri, G; Petillo, L | 1 |
| Bentzen, L; Buch-Hansen, TZ; Hansen, S; Hoeyer, M; Jensen, NV; Saxe, C; Sengeloev, L | 1 |
| Berglund, RK | 1 |
| Asmar, L; Bepler, G; Boehm, KA; Boulware, D; Bromund, J; Caton, JR; Demarco, LC; Li, X; Monberg, MJ; O'Rourke, MA; Obasaju, C; Peng, G; Reynolds, C; Schell, MJ; Shaw Wright, G; Zheng, Z | 1 |
| Chyi Lee, F; Fekrazad, HM; Rabinowitz, I; Royce, M; Smith, HO; Verschraegen, CF | 1 |
| Cormier, JN; Du, XL; Hardy, D; Liu, CC; Xia, R; Xing, Y | 1 |
| Dalphin, JC; Depierre, A; Elleuch, R; Gainet, M; Girard, N; Jacoulet, P; Pernet, D; Westeel, V | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Derenzini, E; Fina, M; Gandolfi, L; Pellegrini, C; Pileri, S; Quirini, F; Stefoni, V; Venturini, F; Zinzani, PL | 1 |
| Chau, WK; Chung, CL; Hsieh, CC; Hsu, CH; Tai, CJ; Wang, FJ | 1 |
| Azria, D; Bascoul-Mollevi, C; Ho-Pun-Cheung, A; Larbouret, C; Mach, JP; Morisseau, S; Navarro-Teulon, I; Pèlegrin, A; Penault-Llorca, F; Robert, B | 1 |
| Chiba, T; Hatano, E; Ishiguro, H; Kanai, M; Kawaguchi, Y; Kitano, T; Masui, T; Matsumoto, S; Matsumura, Y; Mori, A; Nakamura, E; Nishimura, T; Tada, S; Yanagihara, K | 1 |
| Abe, K; Kanno, Y; Katsushima, F; Monoe, K; Ohira, H; Takahashi, A; Wakatsuki, T; Yokokawa, J | 1 |
| Furukawa, K; Kato, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Shimizu, H; Suda, K; Takano, S; Takayashiki, T; Takeuchi, D; Yoshidome, H; Yoshitomi, H | 1 |
| Boku, N; Endo, M; Igawa, S; Murakami, H; Nakamura, Y; Shukuya, T; Takahashi, T; Tamiya, A; Tsuya, A; Yamamoto, N | 1 |
| Brewster, AE; Crosby, TD; Hudson, E; Hurt, C; Iqbal, N; Joseph, G; Mort, D; Mukherjee, S | 1 |
| Batzler, A; Fridley, BL; Jenkins, G; Kalari, K; Li, L; Wang, L; Weinshilboum, RM | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Konífrová, E; Móciková, H; Stríteský, J | 1 |
| Kennedy, AM; Nam, KH; Rapoport, N; Scaife, CL; Shea, JE | 1 |
| Amler, LC; Dizon, DS; Glenn, D; Gold, MA; Januario, T; Kelsey, S; Lin, CY; Makhija, S; Matulonis, U; Ng, K; Paton, V; Sliwkowski, MX; Strauss, A; Ueland, FR | 1 |
| Boselli, S; Catania, C; Danesi, R; de Braud, F; De Pas, T; Giovannetti, E; Manzotti, M; Minocci, D; Noberasco, C; Pelosi, G; Radice, D; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| Atanassow, V; Braumann, C; Caldenas, S; Hartmann, J; Kilian, M; Makareinis, A; Raue, W; Schwenk, W | 1 |
| Candelaria, M; de la Cruz-Hernández, E; Dueñas-González, A; Gutiérrez-Hernández, O; Pérez-Cárdenas, E; Trejo-Becerril, C | 1 |
| Behl, S; Behrens, R; Buechner-Steudel, P; Fahlke, J; Fleig, WE; Kleber, G; Kuss, O; Moehler, M; Schmalenberg, H; Wagner, AD; Wein, A | 1 |
| Boeck, S; Boettcher, HD; Bruns, CJ; Fietkau, R; Flentje, M; Heinemann, V; Herbst, M; Hinke, A; Miethe, S; Ostermaier, S; Rau, HG; Sauer, R; Scholten, T; Wilkowski, R | 1 |
| Capelozzi, VL; Galvão, FH; Pestana, JO | 1 |
| Aggarwal, BB; Anand, P; Diagaradjane, P; Gelovani, J; Guha, S; Harikumar, KB; Krishnan, S; Kunnumakkara, AB; Pandey, MK; Sethi, G | 1 |
| Hudson, E; Lester, JF | 1 |
| Fan, QX; Huang, JY; Sun, Y; Zhang, YQ | 1 |
| Matsuda, A; Matsushita, A; Matsutani, T; Sasajima, K; Uchida, E; Yokoyama, T | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Ikeda, K; Iwata, K; Kobayashi, N; Kurihara, E; Nakamura, T; Okusawa, S; Sagae, S; Saito, J | 1 |
| Auner, V; Horvat, R; Oskay-Oezcelik, G; Sehouli, J; Speiser, P; Zeillinger, R | 1 |
| Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kawabe, T; Kawakubo, K; Kogure, H; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Harnett, EL; Laurie, SA; Maksymiuk, A; Parulekar, WR; Siu, LL; Tu, D; Walsh, W; Winquist, E | 1 |
| Hirono, S; Kawai, M; Miyazawa, M; Nakamura, Y; Ohsawa, R; Tani, M; Tsunoda, T; Yamaue, H | 1 |
| André, N; Blesius, A; Brunet, C; Ciccolini, J; Dahan, L; Duffaud, F; Duluc, M; Evrard, A; Frances, N; Giacometti, S; Iliadis, A; Mercier, C; Ortiz, A; Raynal, C; Seitz, JF; Yang, C | 1 |
| Gao, F; Leong, SS; Lim, WT; Ngeow, J; Poon, D; Tan, EH; Toh, CK | 1 |
| Andrés, R; Baselga, J; Bermejo, B; Ciruelos, EM; Cortés, J; Cortés-Funes, H; García, E; Gómez, P; Lluch, A; Manso, L; Mayordomo, JI; Mendiola, C; Muñoz, M; Ojeda, B; Rodríguez, CA; Saura, C | 1 |
| Gu, YH; Guo, RH; Lin, QF; Liu, LX; Shu, YQ; Wang, RS | 1 |
| Chang, CH; Gold, DV; Goldenberg, DM; Karacay, H; McBride, WJ; Ragland, DR; Rossi, EA; Sharkey, RM | 1 |
| Carrasco, E; Chacón, I; de la Torre-Cabrera, C; Dueñas, B; Dueñas-García, R; Fernández-Navarro, M; García-Tapiador, AM; Jaén-Morago, A; Martín-Salvago, MD; Martínez, J; Martínez-Ortega, E; Ortega-Granados, AL; Ribelles, N; Rueda, AI; Sánchez-Muñoz, A; Sánchez-Rovira, P; Tortosa, CR | 1 |
| Daniele, A; Ferrero, A; Fuso, L; Logrippo, V; Perotto, S; Spanu, PG; Zola, P | 1 |
| Hirono, S; Ina, S; Noda, T; Yamaue, H | 1 |
| Araújo, A; Catarino, R; Coelho, A; Gomes, M; Medeiros, R; Nogueira, A | 1 |
| He, SM; Huang, YJ; Leng, TD; Li, Y; Ou, YQ; Qiu, PX; Xie, J; Xu, D; Yan, GM; Zheng, XK; Zhu, Wb | 1 |
| Clark, WF; Robinson, A | 1 |
| Furuse, J; Ikeda, M; Ishii, H; Kawashima, M; Kinoshita, T; Mitsunaga, S; Nakachi, K; Shimizu, S | 1 |
| Antoniani, B; Bepler, G; Boulware, D; Cognetti, F; Fabi, A; Lara Rivera, S; Metro, G; Monteiro, AN; Mottolese, M; Schell, M; Vici, P; Zheng, Z | 1 |
| Dalgleish, AG; Fowler, DW; Liu, WM; Smith, P | 1 |
| Borbath, I; Caplin, ME; Coxon, F; Kato, H; Larvin, M; Meyer, T; Nagano, E; Palmer, DH; Peeters, M; Valle, JW; Waters, JS | 1 |
| Fujimura, M; Fukushima, W; Hayase, H; Hirosawa, H; Ishida, Y; Ishikawa, M; Ishiura, Y; Izumi, R; Kasahara, K; Maruyama, K; Obata, C; Tanikawa, F; Terasaki, Y; Yamamoto, H | 1 |
| Adachi, S; Kimura, M; Matsumoto, R; Matsuoka, T; Nakao, T; Okada, K; Tanaka, Y; Usami, E; Yasuda, T; Yoshimura, T | 1 |
| Groe, R; Grothey, A; Kantelhardt, EJ; Kegel, T; Koelbl, H; Mueller, LP; Schmoll, HJ; Seliger, G; Strauss, HG; Thomssen, C | 1 |
| Crinò, L; De Marinis, F; Gridelli, C; Liepa, AM; Peterson, P; Ricci, S; Rinaldi, M; Scagliotti, GV; Tonato, M; Zhao, YD | 1 |
| Boyer, JC; Brouillet, JP; Ciccolini, J; Evrard, A; Lallemant, B; Lumbroso, S; Mercier, C; Mouzat, K; Polge, A; Raynal, C | 1 |
| Liu, B; Qu, Y; Xiao, W; Yang, Y | 1 |
| Grützmann, R; Joensson, P; Pilarsky, C; Rückert, F; Saeger, HD | 1 |
| Koga, Y; Kuroda, J; Matsumura, Y; Saito, Y; Yasunaga, M | 1 |
| Fragoulakis, V; Georgoulias, V; Maniadakis, N; Pallis, AG; Simou, E | 1 |
| Besova, NS; Borisov, VI; Bychkov, MB; Chitiia, LV; Filatova, LV; Garin, AM; Gershanovich, ML; Gorbunova, VA; Gurov, SN; Makhnova, EV; Nebol'sin, VE; Raĭkhlin, NT; Sitdikova, SM; Topchieva, SV; Treshchalina, EM; Verebnikova, NV | 1 |
| Huanwen, W; Kai, W; Tonghua, L; Xiaohua, S; Xinyu, R; Zhiyong, L | 1 |
| Wang, ZY | 1 |
| Feng, FY; Fu, M; Liang, X; Lin, C; Luo, Y; Zhang, XY | 1 |
| Baker, MK; Branch, KD; Gluck, S; Goldsberry, GT; Montero, AJ; Talebi, TN; Zhu, Y | 1 |
| Abbruzzese, JL; Javle, M; Li, D; Okazaki, T; Tanaka, M | 1 |
| Ansari, RH; Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Katayose, Y; Nakagawa, K; Okaue, A; Rikiyama, T; Unno, M | 1 |
| Akahori, T; Doh, J; Hasegawa, M; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Nomi, T; Sho, M; Tamamoto, T; Tanaka, T; Yamada, T; Yamato, I | 1 |
| Doki, Y; Eguchi, H; Hatano, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Ohmura, Y; Takeda, Y; Takiuchi, D; Tanemura, M; Tomokuni, A | 1 |
| Kametaka, H; Koyama, T; Makino, H; Seike, K; Yasuno, K | 1 |
| Doki, Y; Eguchi, H; Hoshino, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Tanemura, M; Umeshita, K | 1 |
| Egawa, T; Hayashi, S; Ito, Y; Mihara, K; Nagashima, A; Ohashi, M; Takahashi, T | 1 |
| Ami, K; Ando, M; Fukuda, A; Ganno, H; Hataji, K; Maruyama, M; Nagahama, T; Ohara, T | 1 |
| Doki, Y; Eguchi, H; Kitagawa, T; Kobayashi, S; Marubashi, S; Monden, M; Mori, M; Nagano, H; Nakamori, S; Ohmura, Y; Takeda, Y; Tanemura, M | 1 |
| Funada, N; Honda, G; Kurata, M; Tokashiki, T; Tsuruta, K; Watanabe, F | 1 |
| Fukunaga, M; Furukawa, H; Ikeda, H; Mabuchi, E; Matsumura, T; Miwa, H; Ohzato, H; Ota, K; Yamamoto, T | 1 |
| Heller, G; Panageas, KS; Schrag, D; Sima, CS | 1 |
| Feng, J; Liu, B; Shi, ZL; Tao, HM; Yan, XB; Zhang, B | 1 |
| Favaretto, AG; Magro, C; Pasello, G | 1 |
| Hashiguchi, K; Hiraki, M; Kai, K; Kitajima, Y; Mitsuno, M; Miyazaki, K; Nakamura, J; Noshiro, H; Ohtaka, K | 1 |
| Funamizu, N; Gocho, T; Kamata, Y; Manome, Y; Misawa, T; Okamoto, A; Uwagawa, T; Yanaga, K | 1 |
| Blobe, GC; Dugan, E; Fernando, NH; Gockerman, JP; Hurwitz, HI; Meadows, KL; Morse, MA; Petros, WP; Truax, R | 1 |
| Ardavanis, A; Doufexis, D; Karagiannis, A; Kountourakis, P; Rigatos, G; Tzovaras, AA | 1 |
| Hasegawa, R; Kamatani, N; Kaniwa, N; Kawamoto, M; Kim, SR; Kim, WY; Lee, SJ; Lee, SS; Okuda, H; Saito, Y; Sawada, J; Shin, JG; Sugiyama, E; Tohkin, M | 1 |
| Arrieta, O; Astorga, A; Flores-Estrada, D; Martinez-Barrera, L; Michel Ortega, RM; Pachuca, D; Villarreal-Garza, C | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, A; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Raynaud, FI; Reader, JC; Valenti, M; Walton, MI; Williams, DH | 1 |
| Chang, DT; Fisher, GA; Ford, JM; Goodman, KA; Graves, EE; Koong, AC; Kunz, P; Minn, AY; Quon, A; Schellenberg, D | 1 |
| Bossard, N; Chauffert, B; Girard, N; Mornex, F; Wautot, V; Ychou, M | 1 |
| Lillemoe, KD; Nakeeb, A; Simianu, VV; Zyromski, NJ | 1 |
| Chiba, T; Furuse, J; Furuta, K; Hirohashi, S; Honda, K; Kaniwa, N; Matsubara, J; Negishi, A; Okusaka, T; Ono, M; Saijo, N; Saito, Y; Sakuma, T; Sawada, J; Shoji, A; Sugiyama, E; Ueno, H; Yamada, T | 1 |
| Doi, R; Fujii, T; Hiraoka, M; Matsuo, Y; Mitsumori, M; Nakamura, A; Oya, N; Shibuya, K | 1 |
| Adema, AD; Balzarini, J; Bergman, AM; Bruheim, S; Fichtner, I; Fodstad, O; Hendriks, HR; Myhren, F; Noordhuis, P; Peters, GJ; Sandvold, ML | 1 |
| Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S | 1 |
| Ceraulo, D; Cereda, S; Fugazza, C; Mazza, E; Reni, M; Rognone, A; Villa, E | 1 |
| Brandl, M | 1 |
| Gerhardt, T; Heller, J; Höblinger, A; Rings, D; Sauerbruch, T; Schepke, M | 1 |
| Aziz, F; Ji, Y; Wang, D; Yang, G; Yang, Z; Yu, X; Zhang, Y; Zhao, H; Zhao, W; Zhong, B; Zhu, J | 1 |
| Adham, M; Boschetti, G; Cassier, P; Dumortier, J; Hervieu, V; Lombard-Bohas, C; Scoazec, JY; Walter, T | 1 |
| Archambault, J; Bullock, PA; Fradet-Turcotte, A; Lehoux, M; Morin, G | 1 |
| Batzel, G; Erlichman, C; Felten, S; Haluska, P; Hubbard, J; Ivy, SP; Qin, R; Stensgard, BA; Ten Eyck, C; Toft, DO | 1 |
| Abdel Wahab, M; Dorgham, Y; Hamouda, W; Yosry, A | 1 |
| Esaki, M; Hiraoka, N; Hirohashi, S; Ino, Y; Kanai, Y; Kokubu, A; Kondo, T; Kosuge, T; Miyamoto, M; Morofuji, N; Nara, S; Ojima, H; Okusaka, T; Onaya, H; Sakamoto, Y; Shibata, T; Shimada, K; Shimizu, H; Yoshikawa, D | 1 |
| Gridelli, C; Pallis, AG | 1 |
| Lai, JI; Lin, PC; Tzeng, CH; Wang, WS | 1 |
| Gupta, S; Mallik, S; Munshi, A | 1 |
| Chan, A; Hidalgo, M; Jimeno, A; Rajeshkumar, NV; Rubio-Viqueira, B; Solomon, A | 1 |
| Aronow, B; French, R; Hoffman, RM; Jaquish, D; Logan-Collins, J; Lowy, AM; McClaine, R; Mose, E; Stuart, W; Thomas, RM; Waltz, SE; Yu, P | 1 |
| Hirai, T; Ichikawa, Y; Kishikawa, H; Kobayashi, Y; Nishimura, K; Soda, T; Yamanaka, K | 1 |
| Au, JL; Bekaii-Saab, T; Chen, L; Grever, M; Guillaume Wientjes, M; Jensen, RR; Lam, ET; Li, X; Murgo, AJ; Otterson, GA; Shen, T; Villalona-Calero, MA; Wei, Y | 1 |
| Abbruzzese, JL; El-Rayes, BF; Ferris, AM; Hess, K; Javle, MM; Kaseb, AO; Philip, PA; Sarkar, FH; Shields, AF; Varadhachary, GR; Wolff, RA | 1 |
| Aprile, G; Berardi, R; Cereda, S; Cordio, S; Falconi, M; Mambrini, A; Milella, M; Pasetto, LM; Passardi, A; Pederzoli, P; Reni, M; Rognone, A; Sartori, N; Tronconi, MC | 2 |
| Boulon, C; Conri, C; Constans, J; Solanilla, A; Viguier, JB | 1 |
| Jia, G; Zhang, WM; Zhou, J; Zhu, ZX | 1 |
| Hamano, H; Kobayashi, N; Orikawa, Y; Seto, K; Takei, M; Yoshinaga, K | 1 |
| Gourley, BL; Gupta, P; Mesa, H | 1 |
| Liu, LS; Shi, ZM; Tian, JH; Wang, L; Zhou, ZY | 1 |
| Bergsland, EK; Dito, E; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Schillinger, B; Scott, J; Tempero, MA; Venook, AP | 1 |
| Chandrasekhar, R; Fakih, M; Gibbs, JF; Iyer, RV; Khushalani, NI; May, KS; McCloskey, SA; Thomas, CR; Wilding, GE; Yang, GY; Yendamuri, SS | 1 |
| Bayraktar, S; Bayraktar, UD; Rocha-Lima, CM | 1 |
| Hu, YD; Kong, YZ; Li, P; Ling, Y; Liu, YP; Wang, F | 1 |
| Bai, XW; Chen, H; Gao, Y; Jiang, HC; Kong, R; Pan, SH; Sun, B; Wang, SJ; Xue, DB | 1 |
| Caffo, O; Cassetta, MI; Fallani, S; Galligioni, E; Marangon, E; Mini, E; Murgia, V; Nobili, S; Novelli, A; Sala, F; Zucchetti, M | 1 |
| Cheung-Lau, G; Dawson, DW; Dawson, NA; Farrell, J; Guha, C; Hines, OJ; Horvath, S; Kurdistani, SK; Manuyakorn, A; Paulus, R; Reber, H; Seligson, DB; Tze, S | 1 |
| Alamara, C; Charpidou, A; Kotanidou, A; Makrilia, N; Nikolaidis, I; Ralli, M; Syrigos, K; Tourkantonis, I; Tsimpoukis, S | 1 |
| Bi, ZF; Chen, DL; Jiang, ZM; Ma, W; Xie, DR; Yang, Q; Zhang, YD | 1 |
| Ando, M; Funada, Y; Hata, A; Katakami, N; Kotani, Y; Negoro, S; Satouchi, M; Shimada, T; Urata, Y; Yoshimura, S | 1 |
| Chen, R; Liu, E; Liu, X; Niu, J; Niu, W; Peng, C; Wang, J; Xu, K; Zhang, Z | 1 |
| Chow, W; Cristea, M; Doroshow, JH; Frankel, P; Gaur, S; Koczywas, M; Lim, D; Luu, T; Margolin, K; Morgan, RJ; Somlo, G; Yen, Y | 1 |
| Lee, JS; Orlando, M; Park, K; Scagliotti, G; Simms, L; Yang, CH | 1 |
| Eguchi, K; Ichinose, Y; Masuda, N; Ogura, T; Okamoto, H; Seki, N; Seto, T; Shibuya, M; Shinkai, T; Takiguchi, Y; Wasada, I; Watanabe, K; Yamanaka, T | 1 |
| Majumdar, AP; Patel, BB | 1 |
| Christians, K; Evans, DB; Lal, A | 1 |
| Backlund, DC; Berlin, JD; Parikh, AA | 1 |
| Conti, C; McNeely, S; Patel, H; Pommier, Y; Schwartz, G; Sheikh, T; Tse, A; Zabludoff, S | 1 |
| Ascierto, P; Autorino, R; Cantiello, F; Damiano, R; De Sio, M; Di Lorenzo, G; Faiella, A; Perdonà, S; Pignata, S; Simeone, E | 1 |
| Doi, H; Imai, T; Nakajim, T; Uemura, Y; Urata, T | 1 |
| Cui, L; Egami, T; Hashizume, M; Mizumoto, K; Nagai, E; Ohuchida, K; Onimaru, M; Sato, N; Takayama, K; Tanaka, M; Uchino, J | 1 |
| Albanell, J; Bellmunt, J; Calvo, E; Carles, J; Lázaro, M; López, R; Pérez-Gracia, JL; Rubió, J; Trigo, JM; Virizuela, JA | 1 |
| Chang, PY; Cheng, MF; Hsieh, CB; Lee, HS; Yao, NS | 1 |
| Brennan, D; Callery, M; Goldstein, M; Jain, S; Mahadevan, A; Miksad, R; Pleskow, D; Sawhney, M; Vollmer, C | 1 |
| Bini, V; Costantini, E; Del Zingaro, M; Giannantoni, A; Lazzeri, M; Mearini, L; Porena, M | 1 |
| Bircan, HA; Ceyhan, AM; Karayigit, DZ; Yildirim, M | 1 |
| Anai, H; Arai, Y; Aramaki, T; Ikeda, M; Inaba, Y; Kumada, T; Najima, M; Sato, Y; Sone, M; Tanigawa, N; Yamaura, H; Yoshioka, T | 1 |
| Dong, X; English, JC; Evans, K; Flint, J; Gout, PW; Guan, J; Lam, S; Lam, WL; Laskin, J; Ling, V; Macaulay, C; Murray, N; Ng, RT; Wang, Y; Yee, J | 1 |
| Huang, KH; Jia, L; Jiang, SM; Zheng, JJ | 1 |
| Amano, R; Hirakawa, K; Hirakawa, T; Nakao, S; Nakata, B; Okita, Y; Shinto, O; Tamura, T; Yamada, N | 1 |
| Cao, Y; Gao, F; Liao, C; Liu, L; Tan, A; Wu, L | 1 |
| Clausen, AR; Cros-Perrial, E; Dumontet, C; Hébrard, C; Jordheim, LP; Piskur, J | 1 |
| Celia, C; Cosco, D; Costante, G; Filetti, S; Fresta, M; Iannone, M; Paolino, D; Puxeddu, E; Racanicchi, L; Russo, D; Trapasso, E | 1 |
| Boku, N; Fukuda, H; Fukutomi, A; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Nakamura, K; Ohkawa, S; Okusaka, T | 1 |
| Aldrighetti, L; Cereda, S; Nicoletti, R; Passoni, P; Reni, M; Viganò, MG; Villa, E | 1 |
| Cedres, S; Chao, R; Felip, E; Frickhofen, N; Fuhr, HG; Gatzemeier, U; Heigener, D; Lanzalone, S; Reck, M; Ruiz-Garcia, A; Stephenson, P; Thall, A | 1 |
| Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Sakamoto, T; Taku, K; Todaka, A; Tomita, H; Yamazaki, K; Yasui, H | 1 |
| Bossone, G; Cognetti, F; Gelibter, AJ; Marolla, P; Milella, M; Pino, MS; Sperduti, I | 1 |
| Albrecht, H; Boxberger, F; Hahn, EG; Hohenberger, W; Konturek, PC; Männlein, G; Ostermeier, N; Reulbach, U; Roehrig, S; Wein, A; Wolff, K | 1 |
| Benson, AB; Berlin, J | 1 |
| Ha, MW; Li, JP; Liu, XM; Wu, Q; Xing, YD; Yu, YL; Zhu, ZT | 1 |
| Cartenì, G; Cavanna, L; Ciaparrone, M; Colucci, G; Dapretto, E; Di Costanzo, F; Di Maio, M; Falconi, M; Gallo, C; Gebbia, V; Giuliani, F; Labianca, R; Maiello, E; Manzione, L; Massidda, B; Pederzoli, P; Perrone, F; Piazza, E; Sannicolò, M; Testa, A | 1 |
| Arai, S; Blume, KG; Horning, SJ; Johnston, LJ; Laport, GG; Lavori, PW; Letsinger, R; Lowsky, R; Miklos, DB; Negrin, RS; Shizuru, JA; Weng, WK; Wong, RM | 1 |
| Hendzel, MJ; Kaufmann, SH; Patel, A; Poirier, GG; Rouleau, M | 1 |
| Rouprêt, M; Yates, DR | 1 |
| Adachi, S; Itoh, F; Izawa, N; Katakura, Y; Kobayashi, M; Nakahara, K; Nakatsu, S; Noguchi, Y; Sato, Y; Takagi, R | 1 |
| André, N; Ciccolini, J; Coze, C; Mercier, C; Moreau, E; Padovani, L | 1 |
| Cercueil, JP; Chauffert, B; Ghiringhelli, F; Guiu, B; Guiu, S; Ladoire, S; Ortega-Deballon, P; Vincent, J | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Ghilardi, M; Petrelli, F | 1 |
| Corrie, P; Gounaris, I; Zaki, K | 1 |
| Richter, J; Saif, MW | 1 |
| Hiraya, D; Kagohashi, K; Kondo, T; Sakamoto, N; Satoh, H | 1 |
| Bader, T; Bertucci, F; Castéran, N; Dubreuil, P; Finetti, P; Hanssens, K; Hermine, O; Humbert, M; Iovanna, J; Letard, S; Mansfield, CD; Moussy, A | 1 |
| Lin, L; Liu, XQ; Song, ST; Wang, WX | 1 |
| Boezen, HM; de Vries, EG; Groen, HJ; Maring, JG; Maurer, JM; Slijfer, M; Uges, DR; Wachters, FM | 1 |
| Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH; Schaffert, JM | 1 |
| Conrad, S; Heer-Sonderhoff, A; Schmorl, P; Vosshenrich, R | 1 |
| Cheong, SK; Chung, LY; Kiew, LV; Sidik, K | 1 |
| Busakhala, N; Gregory, KM; Jakait, B; Loehrer, PJ; Pastakia, SD; Rosmarin, AG; Schellhase, EM; Strother, RM; Tenge, C; Were, P | 1 |
| Ali, S; Campbell-Baird, C; Harvey, H; Lipton, A; Witters, L | 1 |
| Amarantidis, K; Chamalidou, E; Chatzaki, E; Dimopoulos, P; Kakolyris, S; Karakitsos, P; Neanidis, K; Pitsiava, D; Tentes, A; Xenidis, N | 1 |
| Ambrosino, G; Casamassima, F; Costantin, G; Febbraro, A; Francescon, P; Guglielmi, R; Panizzoni, G; Polistina, F | 1 |
| Chen, ZH; Cheng, H; Dong, S; Guo, AL; Huang, Y; Wang, Z; Wu, YL; Xie, Z; Yan, HH; Zhang, XC | 1 |
| Burton, GV; Koshy, N; Mansour, R; Quispe, D; Shi, R | 1 |
| Ashley, S; Hubner, R; Myerson, J; O'Brien, ME; Popat, S; Puglisi, M; Sheri, A; Trani, L; Young, K | 1 |
| Abdelhamid, T; El-Mesidi, S; Elzawhri, H; Goda, Y; Kandeel, A; Koheil, H; Meshref, M; Saad, E; Shehata, S; Zaki, M | 1 |
| Hall, PD; Teusink, AC | 1 |
| Cho, JS; Cho, KS; Chung, BH; Doo, SH; Hong, SJ; Kim, CI; Kim, SJ; Song, KH; Song, YS; Yang, WJ | 1 |
| Dash, AK; Khurana, J; Nagvekar, AA; Trickler, WJ | 1 |
| Elias, AD; Gralow, J; Muscato, J; Neubauer, M; O'Shaughnessy, JA; Orlando, M; Pippen, J; Shonukan, O; Stokoe, C; Vaughn, LG; Wang, Y | 1 |
| Alvarez, EM; Archange, C; Gonzalez, CD; Iovanna, JL; Lo Ré, A; Papademetrio, DL; Pardo, R; Ropolo, A; Vaccaro, MI | 1 |
| Isik, M; Kos, FT; Odabas, H; Seker, MM; Uncu, D; Zengin, N | 1 |
| Chen, H; Jiang, HC; Kong, R; Pan, SH; Sun, B; Wang, G; Wang, SJ; Xue, DB | 1 |
| Batra, SK; Chakraborty, S; Johansson, SL; Mimeault, M; Momi, N; Senapati, S | 1 |
| Baker, SD; Donehower, RC; Hidalgo, M; Jimeno, A; Laheru, D; Messersmith, WA; Murphy, KM; Nallapareddy, S; Norris-Kirby, A; Rudek, MA; Weekes, CD | 1 |
| Levine, MN | 1 |
| Santoni-Rugiu, E; Sørensen, JB; Vilmar, AC | 1 |
| Bardeesy, N; Brekken, RA; Carbon, JG; Dineen, SP; Greer, R; Gupta, P; Minna, JD; Roland, CL; Sun, H; Toombs, JE; Williams, N | 1 |
| Hayashi, N; Hayashi, Y; Iijima, H; Inoue, T; Kitagawa, T; Konishi, K; Nishida, T; Takeda, Y; Tsujii, M; Tsutsui, S; Yamamoto, K; Yoshioka, Y | 1 |
| Komori, E; Nogami, H; Ogino, A; Sawada, S; Segawa, Y; Shinkai, T; Suehiro, H; Yamashita, M | 1 |
| Hirose, K; Ikeda, T; Imai, N; Ishikawa, T; Kawata, N; Mizutani, Y; Taga, M; Takeda, K; Utsunomiya, S; Yoshida, S | 1 |
| Arima, K; Kise, H; Soga, N; Sugimura, Y | 1 |
| de Vries, EG; Groen, HJ; Maring, JG; Maurer, M; Uges, DR; Wachters, FM | 1 |
| Garber, K | 1 |
| Dorr, RT; Landowski, TH; Roman, NO; Samulitis, BK; Wisner, L | 1 |
| Aoki, K; Ikeda, T; Kikugawa, T; Miura, N; Nishida, T; Ochi, T; Ozawa, A; Sasaki, T; Shimamoto, K; Tanji, N; Yanagihara, Y; Yokoyama, M | 1 |
| Belani, CP; Chen, R; Edelman, MJ; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Chou, KM; Garcia-Diaz, M; Kunkel, TA; Murray, MS | 1 |
| Advani, RH; Fisher, GA; Francisco, B; Galatin, PS; Julian, T; Losa, R; Sierra, MI; Sikic, BI | 1 |
| Edina, M; László, L; Tamás, N | 1 |
| Danesi, R; Falcone, A; Giovannetti, E; Peters, GJ; Tibaldi, C | 1 |
| Denda, T; Hara, T; Ishihara, T; Nakamura, K; Sudo, K; Yamaguchi, T; Yokosuka, O | 1 |
| Fujiwara, H; Hagiuda, J; Hoshino, H; Kikuchi, E; Maeda, T; Matsumoto, K; Miyajima, A; Nakagawa, K; Oya, M; Yazawa, S | 1 |
| Feigenberg, S; Huang, CH; Jotte, RM; Langer, CJ; Monberg, MJ; Movsas, B; Obasaju, CK; Ross, HJ; Wang, L; Xu, F | 1 |
| Gu, CP; Hong, D; Li, T; Lou, GY; Zhang, YP | 1 |
| Ha, CY; Hong, SC; Hwang, IG; Jang, JS; Jeong, CY; Kang, JH; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY | 1 |
| Grossgoupil, M; Ravaud, A | 1 |
| McIntosh, D; Shaukat, A | 1 |
| Nugent, FW; Stuart, K | 1 |
| Cooke, EW; Hazard, L | 1 |
| Mehta, SP | 1 |
| Kato, Y; Katori, M; Koga, R; Kokudo, N; Saiura, A; Sakamoto, Y; Seki, M; Yamaguchi, T; Yamamoto, J | 1 |
| Deplanque, G; Hammel, P; Hermine, O; Kinet, JP; Levy, P; Mitry, E; Mornex, F; Moussy, A; Raymond, E; Rougier, P; Seitz, JF | 1 |
| Bollard, CM; Cruz, CR; Foster, AE; Heslop, HE; Ku, S; Leen, AM; Lu, A; Rooney, CM; Rousseau, A; Shafer, JA | 1 |
| Betta, PG; Boidi, CD; Lingua, G; Monti, E; Orecchia, S; Osella, D; Zanellato, I | 1 |
| Aboukameel, A; Almhanna, K; Azmi, AS; Banerjee, S; Goustin, AS; Mohammad, RM; Philip, PA; Sarkar, FH; Wang, Z; Yang, D; Zafar, SF | 1 |
| Biasco, G; Brandi, G; Di Cicilia, R; Di Marco, M; Macchini, M; Nobili, E; Vecchiarelli, S | 1 |
| An, Y; Cai, HH; Chen, P; Dai, CC; Ji, ZL; Jiang, KR; Lu, ZP; Miao, Y; Qian, ZY; Wei, JS; Wu, JL; Xu, ZK; Yao, J | 1 |
| Anthoney, A; Bridgewater, J; Cunningham, D; Hughes, S; Iveson, T; Madhusudan, S; Maraveyas, A; Palmer, DH; Pereira, SP; Roughton, M; Valle, J; Wasan, H | 1 |
| Mayer, RJ; Wolpin, BM | 1 |
| Hamaguchi, M; Ito, S; Kokuryo, T; Nagino, M; Senga, T; Takayama, Y; Yokoyama, Y | 1 |
| Dumontet, C; Hage-Sleiman, R; Herveau, S; Laurier, JF; Matera, EL | 2 |
| Adham, M; Bancel, B; Baulieux, J; Cassier, PA; Lombard-Bohas, C; Ponchon, T; Scoazec, JY; Souquet, JC; Thevenet, C; Walter, T | 1 |
| Correale, P; Del Vecchio, MT; Francini, G; Ginanneschi, C; Licchetta, A; Loiacono, L; Mannucci, S; Migali, C; Remondo, C; Rotundo, MS; Tagliaferri, P; Tassone, P; Tsang, KY | 1 |
| Giacalone, N; Haar, L; James, L; Noel, G; Ogle, C; Osterburg, A; Schwemberger, S; Thomas, I; Wang, Q | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Ardavanis, A; Arnogiannaki, N; Doufexis, D; Kountourakis, P; Maliou, S; Missitzis, I; Pissakas, G; Sotiropoulou, A; Zobolas, V | 1 |
| Agatsuma, T; Ichiyama, T; Koizumi, T; Kubo, K; Tanabe, T; Yamamoto, H | 1 |
| Ahmad, A; Ali, S; Banerjee, S; Dominiak, K; Padhye, S; Philip, PA; Sarkar, FH; Schaffert, JM; Wang, Z | 1 |
| Apetoh, L; Bruchard, M; Chalmin, F; Chevriaux, A; Ghiringhelli, F; Ladoire, S; Martin, F; Mignot, G; Rébé, C; Vincent, J | 1 |
| Cen, Y; Sauve, AA | 1 |
| Hirakawa, K; Matsuzaki, T; Nishii, T; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Agarwal, R; Carty, K; Gabra, H; Gore, ME; Gourley, C; Kaye, SB; Parkin, DE; Paul, J; Perren, TJ; Reed, N; Rustin, GJ | 1 |
| Santoni-Rugiu, E; Sørensen, JB; Vilmar, A | 1 |
| Chung, EK; Hahn, OM; Karrison, T; Kasza, K; Manchen, E; Posadas, EM; Stadler, WM | 1 |
| Cui, L; Egami, T; Hashizume, M; Matsumoto, K; Mizumoto, K; Nagai, E; Ohuchida, K; Onimaru, M; Tanaka, M; Toma, H | 1 |
| Daugaard, G; Gothelf, A; Møller, AK; Pedersen, KD | 1 |
| Moore, M; Renouf, D | 1 |
| Alexander, R; David, V; Garofalo, M; Hanna, N; Jabbour, S; Pandya, N; Poppe, M; Regine, WF; Yovino, S | 1 |
| Abbruzzese, A; Arcuri, FP; Caraglia, M; Carducci, A; Correale, P; Del Vecchio, MT; Loiacono, L; Marra, M; Migali, C; Misso, G; Remondo, C; Tagliaferri, P; Tassone, P | 1 |
| Barlési, F; Baudrin, L; Bréchot, JM; Debieuvre, D; Gounant, V; Lebeau, B; Milleron, B; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Athanasas, G; Economopoulos, T; Koumarianou, A; Macheras, A; Papaxoinis, G; Pectasides, D; Pectasides, E; Pliarchopoulou, K; Psyrri, A; Xiros, N | 1 |
| Davis, TH; Dragnev, KH; Hardin, SB; Pipas, JM; Rigas, JR | 1 |
| Bernstein, SA; Edison, JD; Hamilton, CA; Ramsay, LB; Schlegal, KE; Stany, MP | 1 |
| Angeli, A; Badalamenti, G; Berruti, A; Daffara, F; De Francia, S; Del Buono, S; Dogliotti, L; Ferrero, A; Intrivici, C; Kalomirakis, E; Papotti, M; Priola, A; Ratti, R; Santini, D; Sperone, P; Terzolo, M; Vincenzi, B; Volante, M; Zaggia, B | 1 |
| Ansari, RH; Belani, CP; Catalano, RB; Chen, R; Comis, RL; Edelman, MJ; Gonin, R; Marinucci, DM; Monberg, MJ; Obasaju, CK; Socinski, MA; Treat, J | 1 |
| Imawari, M; Ito, N; Kiuchi, Y; Kobayashi, M; Kogo, M; Konishi, K; Kurihara, T; Sunaga, T; Tobe, T; Yoneyama, K | 1 |
| Gong, HT; Han, XF; Liu, L; Ren, XJ; Sun, L | 1 |
| Barton, JH; Burris, HA; Greco, FA; Griner, P; Hainsworth, JD; Patton, JF; Simons, L; Spigel, DR; Zubkus, JD | 1 |
| Azmi, AS; Banerjee, S; Baruah, JB; Mohammad, RM; Padhye, S; Philip, PA; Sarkar, FH; Singh, MW | 1 |
| Chen, X; Jiang, H; Liu, L; Lu, Z; Meng, X; Song, X; Wang, J; Zheng, T | 1 |
| Bartlett, NL; Blum, KA; Byrd, JC; Cheson, BD; Hsi, ED; Johnson, JL; Jung, SH; Lin, TS; Lucas, DM | 1 |
| Hidalgo, M | 1 |
| Aviram, A; Escalon, E; Melnick, SJ; Ramachandran, C; Resek, AP | 1 |
| Beddy, P; Collins, IM; O'Byrne, KJ | 1 |
| Fietkau, R; Heinemann, V; Knoefel, WT; Oettle, H; Tannapfel, A | 1 |
| Amenitsch, H; Bourgaux, C; Couvreur, P; Desmaële, D; Keller, G; Lepêtre-Mouelhi, S; Ollivon, M; Pili, B | 1 |
| Bergman, AM; Hoebe, EK; Leon, LG; Loves, WJ; Peters, GJ; Sigmond, J | 1 |
| Dougherty, DW; Friedberg, JW | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Inhorn, RC; Lane, CM; Reeves, J; Rubinsak, J; Spigel, DR; Thompson, DS; Vazquez, ER; Webb, C | 1 |
| Brand, RE; Singh, SV; Stan, SD | 1 |
| Chakerian, P; Kaley, K; Lamb, L; Saif, MW | 1 |
| Ames, MM; Bai, L; Beumer, JH; Clausen, DM; Covey, JM; D'Argenio, DZ; Egorin, MJ; Eiseman, JL; Gilbert, JA; Hershberger, PA; Holleran, JL; Parise, RA; Yellow-Duke, AE | 1 |
| Cappuzzo, F; Toschi, L | 1 |
| Jensen, BV; Ladekarl, M; Pfeiffer, P | 1 |
| Cescato, C; Herrmann, R; Hess, V; Jost, L; Lee, L; Lohri, A; Pestalozzi, B; Potthast, S; Pratsch, S; Stillhart, P; Widmer, L; Winterhalder, R | 1 |
| Findlay, MP; Han, CH | 1 |
| Abulafia, O; Blessing, JA; Miller, BE; Richards, WE; Secord, AA; Shahin, MS; Stehman, FB; Van Le, L; Warshal, DP; Yamada, SD | 1 |
| Kovac, V; Rajer, M; Smrdel, U; Vrankar, M; Zwitter, M | 1 |
| Bock, PR; Friedel, WE; Matthes, H; Zänker, KS | 1 |
| Chen, J; Feng, YH; Gully, C; Lee, MH; Velazquez-Torres, G; Yeung, SC | 1 |
| Alpaugh, RK; Astsaturov, IA; Burtness, BA; Cheng, JD; Cohen, SJ; McLaughlin, S; Meropol, NJ; Rogatko, A; Watson, JC; Weiner, LM; Xu, Z | 1 |
| DeMorrow, S; Frampton, GA; Lazcano, EA; Li, H; Mohamad, A | 1 |
| Eckert, KA; Polizzi, JM; Prakasha Gowda, AS; Spratt, TE | 1 |
| Boggi, U; Campani, D; Danesi, R; Del Chiaro, M; Erozenci, LA; Falcone, A; Funel, N; Giovannetti, E; Groen, A; Leon, LG; Peters, GJ; Pollina, LE; Vasile, E; Verheul, HM | 1 |
| Chaudhary, RT; Kleynberg, RL; Sofi, AA | 1 |
| Abdi, E; Ackland, SP; Brown, C; Gainford, MC; Gebski, V; Goldstein, D; Jefford, M; Miller, D; Selva-Nayagam, S; Shannon, J; Tebbutt, N; van Hazel, G | 1 |
| Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M | 1 |
| Abbruzzese, J; Baker, AF; Dragovich, T; Green, S; Guillen, JM; Kirkpatrick, L; Pestano, LA; Ramanathan, RK; Von Hoff, DD | 1 |
| Benson, AB; Catalano, PJ; Cooper, H; Harris, W; Hoffman, J; Landry, J; Staley, C; Talamonti, M; Xu, N | 1 |
| Pineda de la Losa, F; Prieto García, A | 1 |
| Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Tsujino, T | 1 |
| Bonfill Abella, T; Dalmau Pórtulas, E; Gallardo-Díaz, E; Moya-Horno, I; Pericay Pijaume, C; Querol Niñerola, R; Saigí Grau, E | 1 |
| Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Chen, YG; Hu, JM; Huang, Q; Qu, QX; Xie, F; Zhang, XG | 1 |
| Chini, EN; Escande, C; Hartman, WR; Kalari, K; Liu, M; Moon, I; Nin, V; Pelleymounter, LL; Weinshilboum, RM; Wu, TY | 1 |
| Amundsen, T; Bremnes, RM; Fløtten, O; Grønberg, BH; Hjelde, HH; Jordhøy, M; Kaasa, S; Plessen, Cv; Sundstrøm, S | 1 |
| Fujisawa, T; Joshi, BH; Nakajima, A; Nakashima, H; Puri, RK | 1 |
| Buranrat, B; Kongpetch, S; Kukongviriyapan, U; Kukongviriyapan, V; Prawan, A | 1 |
| Bui-Nguyen, B; Italiano, A; Toulmonde, M | 1 |
| Doroshow, JH; Kummar, S; Speranza, G | 1 |
| Chan, WC; Dalgleish, AG; Gravett, AM; Haynes, RK; Krishna, S; Liu, WM; Wilson, NL | 1 |
| Eguchi, K; Hasegawa, S; Misuta, K; Mori, R; Murakami, T; Nakano, A; Sasaki, M; Tokuhisa, M | 1 |
| Awasthi, N; Schwarz, MA; Schwarz, RE | 2 |
| Bou Reslan, H; Cao, TC; Carano, RA; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, WF; Fuh, G; Hamilton, P; Ho, CC; Johnson, L; Koeppen, H; Lee, CV; Lima, A; Molina, R; Nannini, MA; Plowman, GD; Singh, M; Thompson, JD; Yu, RX | 1 |
| Dickson, NR; Foust, JT; Grapski, R; Hainsworth, JD; Hendricks, LK; Peacock, NW; Scott, WL; Vázquez, ER; White, MB; Yardley, DA | 1 |
| Arumugarajah, S; Canman, CE; Davis, MA; Hassan, MC; Hylander-Gans, L; Lawrence, TS; Maybaum, J; Morgan, MA; Morosini, D; Normolle, DP; Parsels, JD; Parsels, LA; Simeone, DM; Zabludoff, SD; Zhao, L | 1 |
| Lv, M; Ren, S; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Bagust, A; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Green, J; Greenhalgh, J; McLeod, C; Pearson, M; Tudur Smith, C | 1 |
| Eastwood, A; Manca, A; Misso, K; Palmer, S; Paton, F; Paulden, M; Saramago, P | 1 |
| Sun, WZ; Zhang, QY; Zhao, S | 1 |
| Bepler, G; Cognetti, F; Conti, F; Di Lauro, L; Fabi, A; Giannarelli, D; Lopez, M; Metro, G; Sergi, D; Tomao, F; Vici, P | 1 |
| Fajkic, A; Mekic-Abazovic, A; Music, M; Zerem, E | 1 |
| Fukuoka, M; Komiya, T; Kurata, T; Miyazaki, M; Nakagawa, K; Takeda, K; Tamura, K; Tsurutani, J; Yamamoto, N | 1 |
| Aerts, JG; Hoogsteden, HC; Legrand, C; Schmitz, PI; Surmont, V; Tan, KY; Tournoy, K; van Klaveren, RJ; van Meerbeeck, JP; Vernhout, RM | 1 |
| Ai, KX; He, ML; Huang, XY; Li, A; Qin, HL; Wang, HC; Yuan, Z; Zheng, Q | 1 |
| Fan, Y; Fang, L; Huang, ZY; Lin, NM; Luo, LH; Ma, SL; Wu, FQ; Yu, HF | 1 |
| Chai, HS; Hebbring, SJ; Kalari, KR; Kocher, JP; Li, L; Wang, L; Weinshilboum, RM | 1 |
| Choi, YH; Jung, JW; Kim, HS; Lee, HJ; Lee, JC; Nam, SB; Park, KY | 1 |
| Bifulco, G; Carlomagno, C; De Placido, S; Insabato, L; Lauria, R | 1 |
| Gordon, N; Kleinerman, ES | 1 |
| Bustinza-Linares, E; Kurzrock, R; Tsimberidou, AM | 1 |
| Baker, JH; Buczkowski, AK; Cham, KK; Chang, CW; Chu, EM; Chung, SW; Flexman, JA; Kozlowski, P; Minchinton, AI; Ng, SS; Owen, DA; Reinsberg, SA; Scudamore, CH; Takhar, KS; Wong, MQ; Yapp, DT; Yung, A | 1 |
| Kang, WK; Kim, ST; Lee, J; Lim, HY; Park, JO; Park, JY; Park, SH; Park, YS | 1 |
| Chaudhary, RT; Li, G; Saikumar, J | 1 |
| Caruso, M; Cottin, S; de Campos-Lima, PO; Ghani, K | 1 |
| Al Meani, SA; Clausen, AR; Piskur, J | 1 |
| Adema, AD; Kathmann, I; Losekoot, N; Myhren, F; Peters, GJ; Sandvold, ML; Smid, K | 1 |
| Alecci, C; Bertini, S; Danesi, R; Funel, N; Giancola, F; Giovannetti, E; Leon, LG; Macchia, M; Minutolo, F; Peters, GJ | 1 |
| Andersson, K; Hillerdal, G; Sederholm, C | 1 |
| Adachi, M; Hibi, T; Higuchi, H; Hozawa, S; Iizuka, H; Izumiya, M; Nakamura, S; Sakai, G; Takaishi, H; Yamagishi, Y | 1 |
| Fridley, BL; Jenkins, GD | 1 |
| da Silva Passos Júnior, GA; da Silva, GN; de Camargo, EA; de Castro Marcondes, JP; Sakamoto-Hojo, ET; Salvadori, DM | 1 |
| André, N; Ciccolini, J; Dahan, L; Mercier, C; Ouafik, L | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Aryal, S; Hu, CM; Zhang, L | 1 |
| Johnson, CS; Ma, Y; Trump, DL; Yu, WD | 1 |
| Kasman, I; Plowman, GD; Roy Choudhury, K | 1 |
| El-Rayes, BF; Hammad, N; Heilbrun, LK; Philip, PA; Shields, AF; Venkatramanamoorthy, R; Zalupski, MM | 1 |
| Bandera, M; Dominioni, L; Imperatori, A; La Salvia, D; Nardecchia, E; Rotolo, N; Spanevello, A; Toungoussova, O | 1 |
| Miyagawa, K; Sagara, Y; Yamaoka, N; Yata, Y | 1 |
| Kameda, R; Kobayashi, S; Miyagawa, K; Morinaga, S; Okawa, S; Ueno, M | 1 |
| Harrington, C; James, M; Wynne, C | 1 |
| Dünschede, F; Galle, PR; Junginger, T; Möhler, M; Otto, G; Vahl, CF; von Langsdorf, C; Will, L | 1 |
| Brody, JR; Dasgupta, A; Kleer, CG; Potoczek, M; Toll, AD; Witkiewicz, AK; Yeo, CJ | 1 |
| Bekaii-Saab, T; Kraut, EH; Serna, DS | 1 |
| Cho, SY; Han, SS; Kim, SH; Kim, TH; Kim, YK; Lee, KW; Lee, WJ; Park, SJ; Woo, SM | 1 |
| Daniels, JT; Garrison, MA; Gjerset, GF; Gooley, TA; Gopal, AK; Lonergan, M; Murphy, AE; Pagel, JM; Petersdorf, SH; Press, OW; Shustov, AR; Smith, JC | 1 |
| Baldi, GG; Caraglia, M; Cass, CE; Catalano, V; Chiusa, L; Falcone, A; Giacobino, A; Lai, R; Mackey, J; Manazza, AD; Rizzo, S; Russo, A; Santini, D; Schiavon, G; Tonini, G; Vasile, E; Vincenzi, B | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Kogure, H; Koike, K; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yashima, Y | 1 |
| Galmarini, CM; Senanayake, MT; Vinogradov, SV; Warren, G | 1 |
| Jin, X; Koniaris, LG; Montero, AJ; Zimmers, TA | 1 |
| Eppinga, W; Lagerwaard, F; Senan, S; Slotman, B; Verbakel, W | 1 |
| Baez, O; Castrellon, A; Ferrell, A; Glück, S; Higgins, C; Hurley, E; Hurley, J; Lobo, C; Lopes, G; Reis, I; Richman, S; Seo, P; Silva, O; Slingerland, J; Tukia, K; Welsh, C | 1 |
| Arnoletti, JP; Buchsbaum, DJ; Christein, J; Eloubeidi, M; Frolov, A; Greeno, E; Jhala, N; Keene, K; Oster, R; Posey, J; Russo, S; Varadarajulu, S; Vickers, SM; Wood, T | 1 |
| Hasse, J; Henke, M; Kaden, M; Momm, F; Schumacher, M; Tannock, I | 1 |
| Berta, G; Carbone, F; Cattel, L; Fiorito, C; Gontero, P; Medana, C; Milla, P; Paone, TC; Tizzani, A | 1 |
| Bokemeyer, C; Castor, B; Doan, NB; En-Gal, S; Iwanski, GB; Koeffler, HP; Lee, DH; Said, JW; Thoennissen, NH; Toh, M; Vogt, M | 1 |
| Kadish, SP; McDade, TP; Piperdi, B; Piperdi, M; Shim, JK; Sullivan, ME; Tseng, JF; Whalen, GF | 1 |
| Ansari, RH; Catalano, RB; Chen, R; Comis, RL; Liles, DK; Marinucci, DM; Monberg, MJ; Obasaju, CK; Ribeiro, MJ; Socinski, MA; Treat, J | 1 |
| Bear, MD; Kulp, SK; London, CA; McMahon, MB; Pennell, ML | 1 |
| Frings, V; Maassen van den Brink, KI; Melissant, CF; Phernambucq, ECJ; Postmus, PE; Senan, S; Smit, EF; Spoelstra, FOB; van de Ven, PM; Verbakel, WFAR | 1 |
| Fujii, Y; Iino, Y; Isayama, H; Kamimura, H; Kihara, K | 1 |
| Benson, AB; Bentrem, DJ; Mulcahy, MF; Rademaker, A; Small, W; Talamonti, MS; Weitner, BB | 1 |
| Ahmad, A; Azmi, AS; Banerjee, S; Kong, D; Li, Y; Sarkar, FH; Wang, Z | 1 |
| An, X; Ding, PR; He, YJ; Jiang, WQ; Li, YH; Shi, YX; Wang, FH; Wang, ZQ; Xu, RH | 1 |
| Agatsuma, T; Fukushima, M; Hanaoka, M; Honda, T; Koizumi, T; Kubo, K; Tsushima, K; Urushihata, K; Yamamoto, H; Yasuo, M | 1 |
| Araki, H; Denda, T; Hara, T; Hatano, K; Imagumbai, T; Ishihara, T; Ito, H; Kawakami, H; Nakamura, K; Sakai, M; Sudo, K; Tawada, K; Uno, T; Yamaguchi, T; Yokosuka, O | 1 |
| Blackman, G; Bridgewater, J; Collis, C; Gillmore, R; Goodchild, K; Laurence, V; Meyer, T; Raouf, S; Tobias, J | 1 |
| Bouvet, M; Fruehauf, J; Hoffman, RM; Imagawa, DK; Katz, MH; Kaushal, S; Keleman, A; Kim, G; Romney, E; Tran Cao, HS | 1 |
| Bhargava, P; Goldberg, RM; Hollis, D; Hurwitz, H; Innocenti, F; Kindler, HL; Mayer, RJ; Mulcahy, MF; Niedzwiecki, D; O'Reilly, E; Picus, J; Schilsky, RL; Schrag, D; Sutherland, S; Wozniak, TF | 1 |
| Abbruzzese, JL; Atkins, JN; Benedetti, J; Blanke, CD; Corless, CL; Fenoglio-Preiser, CM; Flynn, PJ; Goldman, B; Khorana, AA; Mirtsching, BC; O'Reilly, EM; Philip, PA; Rivkin, SE; Rowland, KM; Wong, R | 1 |
| Benedetti, J; Blanke, CD; Flynn, PJ; Goldman, B; Lippman, SM; Millwood, B; Moinpour, CM; O'Reilly, EM; Philip, PA; Redman, MW; Rowland, KM; Seay, TE; Vaught, NL; Wong, RP | 1 |
| Hirano, K; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Furuse, J; Hasegawa, R; Ikeda, M; Ishii, H; Kaniwa, N; Kim, SR; Kondo, S; Morizane, C; Okusaka, T; Saijo, N; Saito, Y; Sawada, J; Sugiyama, E; Tamura, T; Ueno, H; Yamamoto, N; Yoshida, T | 1 |
| Cavallaro, G; Celia, C; Fresta, M; Giammona, G; Licciardi, M; Paolino, D | 2 |
| Clouser, CL; Mansky, LM; Patterson, SE | 1 |
| Lavi, S; Leitner, O; Lindzen, M; Yarden, Y | 1 |
| Lemoine, NR; Wong, HH | 1 |
| Blaha, L; Dott, W; Kovalova, L; Zounkova, R | 1 |
| Fukutomi, A; Funai, J; Funakoshi, A; Furuse, J; Kondo, S; Koshiji, M; Miyazaki, M; Mizuno, N; Nagaoka, S; Nagino, M; Nakachi, K; Nambu, Y; Nimura, Y; Ohkawa, S; Okusaka, T | 1 |
| Aogi, K; Fujimoto, T; Funai, J; Kamigaki, S; Okazaki, M; Saeki, T; Sagara, Y; Takashima, S; Toi, M; Yoshida, M | 1 |
| Fukuda, H; Furuse, J; Ishii, H; Morizane, C; Nakamura, K; Okusaka, T; Takashima, A | 1 |
| Gocho, T; Hirohara, S; Iida, T; Misawa, T; Sakamoto, T; Uwagawa, T; Wakiyama, S; Yanaga, K | 1 |
| Bertelsen, K; Christensen, RD; Keldsen, N; Lindegaard, JC; Lund, B; Mellemgaard, A; Mirza, MR | 1 |
| Ashley, S; Brunetto, AT; Carden, CP; Faria, AL; Myerson, J; O'Brien, ME; Popat, S | 1 |
| Bai, XW; Chen, H; Jiang, HC; Kong, R; Li, J; Pan, SH; Sun, B; Wang, SJ; Xue, DB | 1 |
| Cariati, A | 1 |
| Bisht, S; Chenna, V; Feldmann, G; Goggins, MG; Hong, SM; Karikari, C; Maitra, A; Mizuma, M; Ottenhof, NA; Pramanik, D; Ravi, R; Rudek, MA; Sharma, R | 1 |
| Arakawa, A; Hisama, S; Kimura, M; Matsushita, H; Nishimura, T; Okamura, S; Saitoh, S; Shimokawa, Y; Tanaka, Y; Toyama, H | 1 |
| Mo, JZ; Sun, HL; Wu, SM; Xiong, GS | 1 |
| Hou, J; Ji, Y; Jin, DY; Lou, WH; Niu, GM; Wang, DS | 1 |
| Anai, S; Fujimoto, K; Hirao, Y; Ikeda, T; Inoue, T; Matsumura, Y; Miyake, M; Nakai, Y; Ohnishi, S; Okajima, E; Tanaka, N; Tomioka, A | 1 |
| Adjei, AA; Dy, GK; Endo, C; Mandrekar, SJ; Molina, JR; Salavaggione, OE; Schild, SE; Ziegler, KL | 1 |
| Hall, FM | 1 |
| Bueno, R; Mujoomdar, AA; Richards, WG; Sugarbaker, DJ; Tilleman, TR | 1 |
| Abbou, CC; De La Taille, A; Diao, B; Esquivel, S; Paule, B; Salomon, L | 1 |
| Heike, Y; Ikeda, M; Kaida, M; Kojima, Y; Kondo, S; Morita-Hoshi, Y; Morizane, C; Okusaka, T; Soeda, A; Ueno, H; Wakeda, T; Yamaki, Y | 1 |
| Boku, N; Fukutomi, A; Kojima, T; Machida, N; Onozawa, Y; Shukuya, T; Taku, K; Yamazaki, K; Yasui, H | 1 |
| Czernin, J; Hacke, K; Hildebrandt, IJ; Kelly, O; Kesner, AL; Lawson, GW; Phelps, ME; Schiestl, RH; Walter, MA; Weber, WA | 1 |
| Fujiwara, K; García-García, E; Hidalgo, M; López-Ríos, F; Matsui, WH; Rajeshkumar, NV; Rasheed, ZA | 1 |
| Blackhall, FH; Kennedy, SJ; Milenkova, T; Nicolson, M; O'brien, M; Schmid, P; Taylor, P; Thatcher, N | 1 |
| Kim, YH; Mishima, M; Yoshizawa, A | 1 |
| Leaw, SJ; Luo, J; Xu, Y; Zheng, D | 1 |
| Fournier, CC; James, JS; Picus, J; Suresh, R; Tan, BR; Trinkhaus, K; Williams, KJ | 1 |
| Buti, S; Caminiti, C; Chiesa, MD; Donini, M; Lazzarelli, S; Lheshi, A; Mattioli, R; Mazza, G; Passalacqua, R; Re, GL; Simon, S; Simonelli, C | 1 |
| Brown, DB; Carr, BI; Gonsalves, CF; Witkiewicz, AK; Yeo, CJ | 1 |
| Itoh, K; Komatsu, N; Kwon, AH; Mine, T; Noguchi, M; Satoi, S; Shiomi, H; Tani, T; Toyokawa, H; Yamada, A; Yamamoto, T; Yanagimoto, H | 1 |
| Abbruzzese, JL; Dong, X; Eng, C; Javle, M; Li, D; Tanaka, M | 1 |
| Brown, J; Coleman, RL; Jung, M; Levenback, CF; Munsell, MF; Ramirez, PT; Ramondetta, LM; Smith, JA; Sood, AK; Wolf, JK | 1 |
| Cass, CE; Demetter, P; Devière, J; Lai, R; Mackey, JR; Maréchal, R; Peeters, M; Polus, M; Salmon, I; Van Laethem, JL | 1 |
| Jakobsen, A; Jensen, LH; Lassen, U; Rohrberg, KS; Sorensen, M; Ujmajuridze, Z | 1 |
| Burris, HA; Daniel, B; Hainsworth, JD; Inhorn, R; Lane, CM; Naot, Y; Vazquez, ER; Yardley, DA; Zubkus, J | 1 |
| Gou, Y; Guo, H; Jiang, L; Tian, J; Yang, K; Yang, Q; Zhang, L; Zhang, R | 1 |
| Chen, CW; Cheng, AL; Chiang, CT; Feng, WC; Gao, M; Hsu, CH; Kuo, SH; Lu, YS; Yeh, LC; Yeh, PY | 1 |
| Aleknavicius, E; Asadauskiene, J; Jankevicius, F; Pipiriene-Zelviene, T | 1 |
| Albers, P; Fechner, G; Fimmers, R; Heidenreich, A; Heimbach, D; Lehmann, J; Niegisch, G; Park, SI; Siener, R; Steiner, U | 1 |
| Bassett, MR; Bedolla, G; Campbell, AD; Davis, AT; Koo, HM; Luttenton, CR; Melnik, MK; Monroe, TJ; O'Rourke, TJ; Richardson, PJ; Stein, P; Szczepanek, CM; Truszkowski, KJ; Van Brocklin, MW; Vande Woude, GF; Webb, CP; Yost, KJ | 1 |
| Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Ryozawa, S; Sakaida, I; Taba, K; Tanaka, T; Yoshida, K | 1 |
| Kaley, K; Penney, R; Saif, MW; Syrigos, K | 1 |
| Isufi, I; Kaley, K; Saif, MW; Syrigos, K | 1 |
| Arcuri, C; Arisi, E; Caffo, O; Caldara, A; Ferro, A; Galligioni, E; Griso, C; Murgia, V; Scalone, S; Sorio, R | 1 |
| Albelda, SM; Cheng, G; Fridlender, ZG; Kapoor, V; Singhal, S; Sun, J; Suzuki, E | 1 |
| Du, Z; Peng, C; Qin, R; Shi, C; Tian, R; Wang, M; Wei, C | 1 |
| Cantore, M; Del Freo, A; Mambrini, A; Orlandi, M; Pacetti, P; Pennucci, MC; Pezzuolo, D; Tartarini, R | 1 |
| Gong, XG; Li, XQ; Lv, YF; Ma, QY; Xu, FG | 1 |
| Bénech, H; Bildstein, L; Chacun, H; Couvreur, P; Desmaële, D; Dubernet, C; Gueutin, C; Lepêtre-Mouelhi, S; Marsaud, V; Nicolas, V; Sarasin, A | 1 |
| Fässler-Weibel, P; Gartner, V | 1 |
| Bader, M; Haseke, N; Karl, A; Roosen, A; Siebels, M; Stadler, T; Staehler, M; Stief, CG | 1 |
| Baker, LH; Chenevert, T; Chugh, R; Karantza, V; Mehnert, J; Moss, RA; Poplin, EA; Saraiya, B; Savkina, N; Stein, MN | 1 |
| Araki, M; Hasegawa, H; Itoh, M; Kodama, Y; Kuzushita, N; Mano, M; Mita, E; Morita, K; Nakazuru, S; Ohta, M; Ohta, T; Suemura, S; Sueyoshi, Y; Toyama, T; Yoshio, T; Yoshioka, C | 1 |
| Ackermann, BL; Bones, AM; Freeman, AB; Jones, BR; Lutzke, BS; Pratt, SE; Schultz, GA; Wickremsinhe, ER | 1 |
| Flynn, G; Johnson, CS; Kong, RX; Ma, Y; Muindi, JR; Trump, DL; Yu, WD | 1 |
| Cree, IA; Gabriel, FG; Glaysher, S; Johnson, P; Knight, LA; Narayanan, A; Parker, K; Polak, M; Poole, M | 1 |
| Chen, H; Li, C; Pan, Y; Sun, Y; Wang, Q; Yang, S | 1 |
| Drukker, L; Epstein, A; Gabizon, A; Isacson, R; Keinan, A; Kelsen, D; Lowery, M; O'Reilly, EM; Rachkiman, M; Reissman, P; Rosengarten, O; Segal, A; Shah, MA; Smyth, E | 1 |
| Crea, F; Danesi, R; Del Tacca, M; Mey, V; Nannizzi, S; Pasqualetti, G; Ricciardi, S | 1 |
| Hasegawa, Y; Imaizumi, K; Kondo, M; Shimokata, K; Shindo, J; Suzuki, R; Taniguchi, H; Usami, N; Yamamoto, M; Yokoi, K | 1 |
| Ito, T; Kawashima, H; Nakatani, T; Omachi, T; Tamada, S | 1 |
| Hashimoto, H; Obara, K; Oshika, Y; Shimizu, E; Tanaka, Y | 1 |
| Akiyama, N; Ayata, S; Maruyama, Y; Tsukada, Y | 1 |
| Fujiwara, M; Inoue, K; Ito, N; Kubo, N; Maruyama, A; Nakayama, A; Ogiwara, H; Rokuhara, T; Shirozaki, T; Takasu, K; Takeuchi, N; Tsujimoto, K | 1 |
| Dutcher, JP; Nanus, D | 1 |
| Barron, G; Cass, CE; Damaraju, VL; Mowles, D; Peng, Y; Robins, MJ; Tackaberry, T; Young, JD | 1 |
| Guerra, B; Kreutzer, JN; Ruzzene, M | 1 |
| Gabra, H; Hartley, JA; James, LE; Jayson, GC; Jitlal, M; Ledermann, JA; Rustin, GJ; Spanswick, VJ | 1 |
| Baay, M; Lambrechts, HA; Lardon, F; Meijnders, P; Pattyn, GG; Pauwels, B; Vermorken, JB; Wouters, A | 1 |
| Chen, HT; Peng, PJ; Zhang, HY | 1 |
| Fukami, T; Funakoshi, A; Kuroki, M; Miyamoto, S; Yagi, H; Yoshizato, T; Yotsumoto, F | 1 |
| de Marinis, F; Giuliani, G; Grossi, F; Walzer, S | 1 |
| Bischoff, HG; Heigener, DF; Nuijten, M; Walzer, S | 1 |
| Bischoff, HG; Chouaid, C; de Castro Carpeño, J; Heigener, DF; Mueller, E; Schmidt, E; Stanisic, S; Vergnenègre, A; Walzer, S | 1 |
| Aultman, R; Bischoff, HG; Chouaid, C; de Castro Carpeño, J; Heigener, DF; Nuijten, M; Siebert, U; Vergnenègre, A; Walzer, S | 1 |
| Avall-Lundqvist, E; Burges, A; du Bois, A; Gropp, M; Hardy-Bessard, AC; Harter, P; Herrstedt, J; Huober, J; Jackisch, C; Jelic, S; Joly, F; Kristensen, G; Kurzeder, C; Müller, HH; Pfisterer, J; Pujade-Lauraine, E; Sehouli, J; Staehle, A; Weber, B; Wimberger, P | 1 |
| Jiang, WG; Lane, J; Martin, TA; Mason, MD; McGuigan, C | 1 |
| Brigulová, K; Cervinka, M; Sedláková, I; Tošner, J | 1 |
| Brody, JR; Cozzitorto, JA; Freydin, B; Gonye, G; Grenda, D; Kennedy, EP; Richards, NG; Rittenhouse, DW; Rui, H; Witkiewicz, AK; Yeo, CJ | 1 |
| Alli, E; Ford, JM; Hastak, K | 1 |
| Bult, P; van Herpen, CM; van Laarhoven, HW; Wesseling, P; Willemsen, AE | 1 |
| Bureau, C; Buscail, L; Cordelier, P; Diab, T; Dusetti, N; Gayet, O; Hanoun, N; Selves, J; Torrisani, J; Vinel, JP | 1 |
| Agamah, E; Hall, MJ; Kindler, HL; Locker, G; Nattam, S; Stadler, WM; Vokes, EE; Wallace, JA; Wroblewski, K | 1 |
| Engineer, R; Kishore Shrivastava, S; Mahantshetty, U; Mehta, S; Purandare, N; Rangarajan, V; Wadasadawala, T | 1 |
| Douillard, JY; Eckardt, J; Liepa, AM; Novello, S; O'Brien, M; Paz-Ares, L; Pimentel, FL; Simms, L; Visseren-Grul, C; von Pawel, J | 1 |
| Azuma, H; Ibuki, N; Inamoto, T; Katsuoka, Y; Kiyama, S; Komura, K; Kotake, Y; Narumi, Y; Nomi, H; Takahara, K; Ubai, T; Uehara, H; Yamamoto, K | 2 |
| Ku, Y; Mukubou, H; Sasaki, R; Tsujimura, T | 1 |
| Hashiguchi, K; Hiraki, M; Kai, K; Kitajima, Y; Kohya, N; Miyazaki, K; Nakamura, J; Noshiro, H; Ohtaka, K; Tokunaga, O | 1 |
| Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K | 1 |
| Lin, YG; Matsuo, K; Roman, LD; Sood, AK | 1 |
| Akan, B; Ba'ssalamah, A; Eisenhut, A; Gnant, M; Goetzinger, P; Jakesz, R; Koellblinger, C; Kuehrer, I; Peck-Radosavljevic, M; Sahora, K; Teleky, B; Zielinski, C | 1 |
| Hu, Y; Liao, Q; Zhang, Q; Zhao, YP; Zhou, T | 1 |
| Bourgaux, C; Couvreur, P; Desmaële, D; Lepêtre-Mouelhi, S; Pili, B; Reddy, LH | 1 |
| Alba, L; Antinori, A; Bibas, M; Del Nonno, F; Grisetti, S; Picchi, G | 1 |
| Bassi, C; Büchler, MW; Buckels, JA; Butturini, G; Cunningham, D; Dervenis, C; Doi, R; Friess, H; Gallinger, S; Ghaneh, P; Goldstein, D; Izbicki, JR; Lerch, MM; Lind, PA; Mariette, C; McKay, CJ; Moore, MJ; Neoptolemos, JP; Oláh, A; Padbury, R; Palmer, DH; Rawcliffe, CL; Smith, D; Stocken, DD; Thompson, J; Valle, JW; Wente, MN | 1 |
| Van Dyke, T | 1 |
| Hagmann, W; Jesnowski, R; Löhr, JM | 1 |
| Ahmad, A; Azmi, AS; Banerjee, S; Kong, D; Sarkar, FH; Sethi, S; Wang, Z | 1 |
| Chin, K; da Cunha Santos, G; Dhani, N; Kamel-Reid, S; Ludkovski, O; Moore, MJ; Parulekar, W; Squire, J; Tsao, MS; Tu, D | 1 |
| Fan, Y; Iovanna, JL; Peng, L; Qu, F; Rocchi, P; Wang, M; Xia, Y | 1 |
| Benda, J; Boardman, CH; Cella, D; Cohn, D; Huang, HQ; McMeekin, DS; Monk, BJ; Ramondetta, L; Wenzel, L | 1 |
| Azria, D; Budach, V; Collette, L; Hammel, P; Haustermans, K; Lutz, M; Mauer, M; Mornex, F; Peeters, M; Polus, M; Praet, M; Van Cutsem, E; Van Laethem, JL; Van Tienhoven, G; Vergauwe, P | 1 |
| Burkhard, FC; Gautschi, O; Ghadjar, P; Studer, UE; Thalmann, GN | 1 |
| Hunabiki, K; Iwadou, H; Kamikawa, Y; Matsuda, T; Watanabe, T; Yoshida, R | 1 |
| Fukui, H; Kou, C; Matsumoto, M; Matsumoto, T | 1 |
| Abe, S; Akaboshi, S; Baba, H; Beppu, T; Eto, S; Furuhashi, S; Horino, K; Ida, S; Nakahara, O; Ozaki, N; Takamori, H; Tanaka, H | 1 |
| Huang, XE; Tang, JH; Xu, HX; Yao, CY | 1 |
| Ebina, A; Imai, T; Kishimoto, K; Nakamura, Y; Sato, N | 1 |
| Elit, L; Hirte, HW; Macalpine, K; Oza, AM; Schilder, RJ; Wang, L; Welch, SA; Wright, JJ | 1 |
| Berthillot, C; Gaertner, S; Miréa, C; Stephan, D; Welsch, M | 1 |
| Sahoo, SK; Vandana, M | 2 |
| Cass, CE; Damaraju, VL; Karpinski, E; Mowles, D; Nowak, I; Robins, MJ; Smith, KM; Young, JD | 1 |
| Chiu, YF; Kuo, YH; Lin, YW; Su, YC; Tsai, MS | 1 |
| Billaud, EM; Bobin-Dubigeon, C; Boisdron-Celle, M; Boyer, JC; Chatelut, E; Concordet, D; Durdux, C; Etienne-Grimaldi, MC; Evrard, A; Floquet, A; Gladieff, L; Laffont, CM; Lafont, T; Lansiaux, A; Le Guellec, C; Mazières, J; Mousseau, M; Ollivier, F; Pinguet, F; Schmitt, A | 1 |
| Li, XD; Shen, H; Shu, YQ; Wang, RS; Wu, CP; Yin, YM | 1 |
| Galettis, P; Manners, S; Souza, Pd | 1 |
| Aggarwal, BB; Asada, M; Chiba, T; Guha, S; Imaizumi, A; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mori, Y; Nishimura, T; Suzuki, C; Yanagihara, K; Yazumi, S; Yoshimura, K | 1 |
| Alarcon, Pd; Chen, L; Cole, PD; Drachtman, RA; McCarten, KM; Schwartz, CL; Trippett, TM | 1 |
| Erkan, M; Friess, H; Kleeff, J; Michalski, CW; Quan, L; Raggi, MC; Reiser-Erkan, C; Wang, W; Yupei, Z | 1 |
| Aggarwal, BB; Deorukhkar, A; Dey, S; Diagaradjane, P; Gelovani, JG; Guha, S; Koca, C; Krishnan, S; Kunnumakkara, AB; Ravindran, J; Sung, B; Tong, Z; Yadav, VR | 1 |
| Bai, CM; Cheng, YJ; Zhang, ZJ | 1 |
| Chen, ZH; Ishigaki, Y; Motoo, Y; Nakagawa, H; Nakajima, H; Shimasaki, T; Takegami, T; Xia, QS; Zhao, X | 1 |
| Armand, P; Di Salvo, D; Hwang, DG; Kelly, PJ; Nishino, M; O'Regan, KN | 1 |
| Bafaloukos, D; Bakogiannis, C; Boukovinas, J; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Kalofonos, HP; Katirtzoglou, N; Kosmidis, PA; Lambaki, S; Pectasides, D; Pentheroudakis, G; Samantas, E; Skarlos, D; Syrigos, KN | 1 |
| Cardenes, HR; Chiorean, EG; Helft, P; Howard, TJ; Johnson, CS; Loehrer, PJ; Moore, AM; Stephens, AW; Tai, DF; Vinson, J; Yu, M | 1 |
| Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ | 1 |
| Clément-Duchêne, C; Colevas, AD; Ganjoo, K; Krupitskaya, Y; Kumar, A; Lavori, P; McMillan, A; Padda, S; Pedro-Salcedo, MS; Wakelee, HA; Zhao, G; Zhou, L | 1 |
| Aelbrecht, K; De Boeck, G; Dyck, J; Guetens, G; Specenier, P; Van den Weyngaert, D; Vermorken, JB; Weyler, J | 1 |
| Barzilai, A; Davidovici, B; Wolf, R | 1 |
| Dalgleish, AG; Gravett, AM; Liu, WM | 1 |
| Brandt, R; Lane, HA; Lassota, P; McSheehy, PM; O'Reilly, T; Wartmann, M | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Carlson, D; Fury, MG; Haque, S; Pfister, D; Shen, R; Stambuk, H | 1 |
| Dreicer, R; Elson, P; Garcia, JA; Hutson, TE; Shepard, D | 1 |
| Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Ishii, H; Kamei, A; Kuraoka, K; Matsuyama, M; Ozaka, M; Takano, K; Yukisawa, S | 1 |
| Amarantidis, K; Chamalidou, E; Chatzaki, E; Chelis, L; Kakolyris, S; Karakitsos, P; Mikroulis, D; Neanidis, K; Prassopoulos, P; Xenidis, N | 1 |
| Backer, JM; Backer, MV; Buhr, HJ; Hotz, B; Hotz, HG | 1 |
| Fujita, H; Itaba, S; Ito, T; Kayashima, T; Manabe, T; Mizumoto, K; Nakata, K; Ohtsuka, T; Ohuchida, K; Souzaki, R; Tajiri, T; Tanaka, M; Yu, J | 1 |
| Barriuso, J; Belda-Iniesta, C; Borrega, P; Castro, J; Feliu, J; González-Barón, M; León, A; López, M; López-Gómez, L; Martínez, V | 1 |
| Grendys, EC; Holloway, RW; Lefebvre, P; McMeekin, S; Vekeman, F | 1 |
| Abolhassani, M; Baronzio, G; Behzadi, M; Campion, F; Fiorentini, G; Guais, A; Mainini, C; Montagnani, F; Sanders, E; Schwartz, L | 1 |
| Besse, B; Ferrand, FR; Le Floch, H; Mairovitz, A; Margery, J; Planchard, D; Rivière, F; Ruffié, P; Vaylet, F | 1 |
| Baba, N; Inaba, T; Ishikawa, H; Ishikawa, S; Kawai, K; Miyoshi, M; Nagano, T; Senoh, T; Takaguchi, K; Watanabe, S; Wato, M | 1 |
| Fukuhara, H; Inoue, K; Kamada, M; Matumoto, M; Nishikawa, H; Shuin, T; Tamura, K; Yamasaki, I | 1 |
| Hayashi, T; Kakuta, Y; Nakai, Y; Nakao, A; Nakayama, M; Nonomura, N; Okumi, M; Takayama, H | 1 |
| Abajo, A; Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Ponz, M; Rodriguez, J; Zarate, R | 1 |
| Clynes, M; McDermott, R; O'Connor, R; Sheikh, R; Walsh, N | 1 |
| Aurer, I; Baila, L; Eghbali, H; Fortpied, C; Khaled, HM; Raemaekers, J; van der Maazen, RW | 1 |
| Aerts, I; Boos, J; Cesare, C; Chisholm, J; Couanet, D; Devos, A; Dias, N; Frappaz, D; Gentet, JC; Geoerger, B; Hain, S; Jaspan, T; Le Deley, MC; Leblond, P; Mc Hugh, K; Riccardi, R; Vassal, G; Zwaan, CM | 1 |
| Gupta, P; Khanna, AK; Khanna, R; Singh, S | 1 |
| Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Ryozawa, S; Sakaida, I; Taba, K; Tanaka, T; Yoshida, K; Zhang, X | 1 |
| Galettis, P; Links, M; Manners, S; Metharom, E | 1 |
| Alberto, M; Alessandro, C; Artioli, G; Borgato, L; Bozza, F; Cappetta, A; Davide, P; Fernando, B; Giorgio, Z; Grazia, A; Lucia, B; Marchet, A; Mocellin, S; Pastorelli, D; Simone, M; Stefania, Z; Zavagno, G; Zovato, S | 1 |
| Aoki, K; Azuma, K; Fukumoto, T; Kikugawa, T; Miura, N; Nishida, T; Sasaki, T; Shimamoto, K; Tanji, N; Yanagihara, Y; Yokoyama, M | 1 |
| Komori, S; Matsui, S; Mori, R; Osada, S; Sanada, Y; Takahashi, T; Tokuyama, Y; Tomita, H; Yamaguchi, K; Yoshida, K | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakashima, A; Ohge, H; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
| Bedenne, L; Bonnetain, F; Cattan, S; Chauffert, B; Dahan, L; Gasmi, M; Hammel, P; Legoux, JL; Michel, P; Mitry, E; Phelip, JM; Raoul, JL; Rougier, P; Seitz, JF; Ychou, M | 1 |
| Enoki, Y; Fujimoto, S; Fukui, A; Okuyama, Y; Tanaka, M; Tomie, A; Yoshida, N | 1 |
| Nakamoto, Y; Ogata, M; Yamamoto, M | 1 |
| Gong, W; He, Z; Jiang, J; Li, X; Qin, R; Shi, C; Tian, R; Wang, M; Wang, X; Zhang, Z | 1 |
| Bellone, G; Brondino, G; Ciuffreda, L; Cristiano, C; Giacobino, A; Novarino, A; Prati, A; Vizio, B | 1 |
| Ahmed, M; Hassan, AH; Hussain, A; Priyani, A; Sadrieh, L; Sharma, C | 1 |
| Diamond, DJ; Ellenhorn, JD; Ishizaki, H; Manuel, ER; Song, GY; Srivastava, T; Sun, S | 1 |
| Caffo, O; Fellin, G; Galligioni, E; Graffer, U; Mussari, S; Tomio, L | 1 |
| Frank, RC; Lincer, R; Mody, K; Strauss, E | 1 |
| Balboa, L; Bruzzo, J; Chiarella, P; Fernández, GC; Isturiz, MA; Laborde, EA; Landoni, VI; Maglioco, A; Rearte, B; Ruggiero, RA | 1 |
| Horneber, M | 1 |
| Meier, JJ; Ritter, PR; Schmidt, WE; Tischoff, I; Uhl, W | 1 |
| Leighl, NB; Manegold, C; Mezger, J; Moore, N; Ramlau, R; Reck, M; Zatloukal, P | 1 |
| Arizumi, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yashima, Y | 1 |
| Cohen, DJ; Hochster, HS; Levinson, B; Love, E; Nicol, SJ; Yaw, M; Yuan, Y | 1 |
| Friedman, GK; Hilliard, LM; Kelly, DR; Vaid, YN; Walsh, A | 1 |
| Christos, P; Espinoza-Delgado, I; Hamel, N; Kaubish, A; Lane, ME; Matulich, D; Ocean, AJ; Siegel, A; Sparano, JA; Sung, M; Ward, MM; Yen, Y | 1 |
| de Vere White, R; Henderson, P; Lara, PN; Malfatti, M; Pan, CX; Turteltaub, K; Wang, S; Zhang, H | 1 |
| Gordian, E; Miller, H; Ramachandran, K; Rocha-Lima, C; Singal, R | 1 |
| Barbarat, A; Houlgatte, R; Raharijaona, M; Rolland, D; Thieblemont, C | 1 |
| Agelaki, S; Androulakis, N; Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kalykaki, A; Kotsakis, A; Saridaki, Z; Vamvakas, L; Vardakis, N | 1 |
| Alvarez, PJ; Aranega, A; Burgos, M; Hita, F; Melguizo, C; Ortiz, R; Prados, J; Rama, AR; Ramos, JL; Rodríguez-Serrano, F | 1 |
| Cao, L; Liu, D; Que, R; Wang, G; Wang, L; Xie, D; Yu, J | 1 |
| Fleming, JB; Katz, MH; Lee, JE; Pisters, PW | 1 |
| Bhardwaj, A; Owen, LB; Singh, AP; Singh, S; Srivastava, SK | 1 |
| Baba, H; Beppu, T; Hirota, M; Ikeda, O; Kanemitsu, K; Oya, N; Takamori, H; Tanaka, H; Yamashita, Y | 1 |
| Chang, JS; Hsieh, YH; Huang, CT; Huang, YB; Tsai, YH; Wu, PC | 1 |
| Assi, C; Bedenne, L; Jouve, JL; Lepage, C; Sgro, C | 1 |
| Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, SF; Messersmith, WA; Spigel, DR; Weekes, CD; Yardley, DA | 1 |
| An, Y; Cai, HH; Dai, CC; Lu, ZP; Miao, Y; Qian, ZY; Wei, JS; Xu, ZK; Yao, J | 1 |
| Asakura, H; Deguchi, N; Fukuyama, R; Horinaga, M; Iida, M; Nakahira, Y; Nonaka, S; Yanaihara, H | 1 |
| Badmaev, V; Bar-Sela, G; Epelbaum, R; Schaffer, M; Vizel, B | 1 |
| Cillo, U; Donach, M; Farina, M; Farinati, F; Lombardi, G; Pastorelli, D; Vitale, A; Zanus, G; Zovato, S; Zustovich, F | 1 |
| Mohelníková-Duchonová, B; Soucek, P | 1 |
| Ebrahim, MA; Halim, A; Saleh, Y | 1 |
| Furuse, J; Hagihara, A; Ikeda, M; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Shimizu, S; Suzuki, E; Ueno, H | 1 |
| Ahad, A; Jacobs, MJ; Nalbantoglu, I; Saidi, RF; Tilak, J | 1 |
| Giaccone, G; Rajan, A | 1 |
| Freimann-Pircher, S; Gruenberger, B; Gruenberger, T; Heubrandtner, U; Kaczirek, K; Roka, R; Schueller, J; Tamandl, D; Wrba, F | 1 |
| Akı, ŞZ; Özkurt, ZN; Sucak, GT; Suyanı, E; Yağcı, M; Yeğin, ZA | 1 |
| Abahssain, H; Afchain, P; Errihani, H; Ismaili, N; Melas, N; Rabti, HM; Rahali, R | 1 |
| Arlt, A; Müerköster, SS; Schäfer, H | 1 |
| Liu, F; Liu, H; Ning, K; Wang, F; Wang, Y; Yu, J; Yuan, S; Zhang, J | 1 |
| Boadle, R; Hills, K; Mahajan, H; Nankivell, B; P'ng, CH; Yong, JL | 1 |
| Hong, BJ; Lee, SM; MacRenaris, KW; Mastarone, DJ; Meade, TJ; Nguyen, ST; O'Halloran, TV; Song, Y | 1 |
| Ansari, RH; Brufsky, A; Cavalheiro, J; Chen, SC; De La Cruz Vargas, JA; Fein, LE; Gill, JF; Hart, LL; Kim, SB; Obasaju, CK; Orlando, M; Russell, CA; Schwartzberg, LS; Seidman, AD; Stein, RS; Stewart, JF; Tai, DF; Zhao, L | 1 |
| Azuma, S; Hashimoto, Y; Hirata, R; Katsuragawa, M; Kobayashi, R; Matsunami, J; Meguro, K; Miyakawa, H; Okamura, K; Sato, Y; Shibanami, A; Taniguchi, R; Tokutome, A; Tsumaki, R | 1 |
| Chen, L; Jiao, SC; Li, J; Lv, YL; Shi, Y; Sun, Q; Wang, LX | 1 |
| Aglietta, M; Bardelli, A; Casorzo, L; Cavalloni, G; Chiorino, G; Leone, F; Migliardi, G; Penachioni, JY; Peraldo-Neia, C; Pignochino, Y; Risio, M; Sarotto, I | 1 |
| Goedegebuure, P; Hawkins, WG; Hornick, JR; Mach, RH; Mitchem, JB; Spitzer, D; Tu, Z; Vangveravong, S; Xu, J | 1 |
| Bridgewater, J; Furuse, J; Koshiji, M; Okusaka, T; Taketsuna, M; Valle, J; Wasan, H | 1 |
| Katoh, M; Kita, J; Kubota, K; Sawada, T; Shimoda, M | 1 |
| Bahary, N; Bao, PQ; Bartlett, DL; Hughes, SJ; Krasinkas, A; Lee, KK; Lembersky, BC; Moser, AJ; Ramanathan, RK; Zeh, HJ | 1 |
| Arkenau, HT; Coffey, M; de Bono, JS; Evans, TR; Gill, G; Harrington, K; Lolkema, MP; Mettinger, K; Morrison, R; Roulstone, V; Roxburgh, P; Twigger, K | 1 |
| Eguchi, K; Ichinose, Y; Kishi, K; Minato, K; Nishikawa, M; Nogami, N; Okamoto, H; Seki, N; Seto, T; Shinkai, T; Takiguchi, Y; Watanabe, K | 1 |
| Karoopongse, E; Pattanaprichakul, P; Siriphukpong, S; Sitthinamsuwan, P | 1 |
| Guan, Z; Jiang, Z; Shen, Z; Xu, B; Zhang, X | 1 |
| Fujita, S; Fukuhara, A; Hata, A; Hatachi, Y; Kaji, R; Katakami, N; Kim, YH; Masago, K; Mio, T; Mishima, M | 1 |
| Azzi, GR; Choueiri, TK; Je, Y; Nguyen, PL; Schutz, FAB | 1 |
| Büchler, MW; Franz, C; Hoffmann, K; Mohr, E; Schemmer, P; Serba, S; Xiao, Z | 1 |
| Cheng, L; Evans, C; Pan, CX; Wang, S; Zhang, H | 1 |
| Baumunk, D; Fotopoulou, C; Schmidt, SC; Schumacher, G | 1 |
| Inoue, M; Nagashima, A; Nakanishi, K; Nakanishi, R; Osaki, T; Sakata, H; Uchiyama, A; Uramoto, H; Yasumoto, K; Yoshimatsu, T | 1 |
| Ayuso, D; Becht, C; Culine, S; Huguet, H; Iborra, F; Pouessel, D; Rebillard, X | 1 |
| Balzano, G; Belli, C; Brioschi, M; Cereda, S; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E | 1 |
| Lesnaya, NA; Pokrovsky, VS; Romanenko, VI; Treshalina, EM | 1 |
| Belani, CP; Brodowicz, T; Fossella, F; Manegold, C; Scagliotti, G; Shepherd, FA; Simms, L; Sugarman, K; Vansteenkiste, J; Zielinski, C | 1 |
| Fan, XW; Shan, L; Yang, SF; Zhang, GQ | 1 |
| Meriggi, F; Zaniboni, A | 1 |
| Kuramitsu, Y; Maehara, S; Maehara, Y; Mori-Iwamoto, S; Nakamura, K; Ryozawa, S; Sakaida, I; Taba, K; Tanaka, T; Yoshida, K | 1 |
| Barreto, G; Döderlein, G; Niehrs, C; Schäfer, A; Schomacher, L | 1 |
| Bommakanti, SV; Dudek, AZ; Gada, PD; Khatri, A; Kirstein, MN | 1 |
| Han, XF; Ling, Z; Liu, D; Liu, LX; Liu, YF; Sun, L; Wang, F | 1 |
| Lawrence, TS; Maybaum, J; Morgan, MA; Normolle, D; Parsels, LA; Zhao, L | 1 |
| Goto, H; Hara, K; Hashimoto, S; Hirai, T; Hirooka, Y; Itoh, A; Itoh, T; Kanamori, A; Kawashima, H; Miyahara, R; Nakamura, M; Ohmiya, N; Ohno, E; Takeda, K; Taki, T | 1 |
| Huang, XE; Jiang, Y; Li, Y; Xiang, J; Yan, PW | 1 |
| Arenas, DR; Arvelo, F; Kouznetsov, VV; Muñoz, A; Sojo, F | 1 |
| De Jesus-Acosta, A; Donehower, R; Eshleman, JR; Garrido-Laguna, I; Hidalgo, M; Hruban, RH; Jones, S; Klein, A; Laheru, D; Maitra, A; Rajeshkumar, NV; Villarroel, MC | 1 |
| Holzman, DC | 1 |
| Ishihara, T; Miyakawa, K; Sakai, Y; Sugiyama, H; Tomizawa, M; Tsuyuguchi, T; Yokosuka, O | 1 |
| Chewaproug, D; Khanmoradi, K; Kung, SC; Melin, A; Ortiz, J; Pontinen, T; Varadi, G; Zaki, R | 1 |
| Airoldi, M; Amoroso, D; Ardizzoia, A; Aurilio, G; Bajetta, E; Ballardini, P; Balzelloni, ML; Banna, GL; Barbieri, F; Barletta, E; Basso, U; Bernardini, I; Boni, C; Bordin, V; Bretti, S; Bria, E; Bronte, G; Brunetti, C; Buti, S; Capanna, L; Collovà, E; Colombo, A; Condemi, G; Cortinovis, D; Dambrosio, M; Di Fonzo, C; Di Lucca, G; Di Maio, M; Dima, G; Falzetta, A; Favaretto, A; Ferraù, F; Follador, A; Garetto, L; Gebbia, V; Genestreti, G; Gentile, AL; Giovanardi, F; Labianca, R; Lorusso, V; Mantovani, G; Martelli, O; Massari, F; Mazzoli, M; Menis, J; Michetti, G; Mordenti, P; Mucciarini, C; Munao, S; Nacci, A; Novello, S; Pogliani, C; Procopio, G; Riccardi, F; Rizzato, S; Rossi, A; Rosti, G; Russo, P; Saladino, T; Salesi, N; Santangelo, D; Sava, T; Savarino, A; Spinnato, F; Tiseo, M; Tomassi, O; Tondulli, L; Tonini, G; Turano, S; Valerio, MR; Verderame, F; Zanelli, F; Zanon, E | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Barron, MR; Bentrem, DJ; Dangi-Garimella, S; Grippo, PJ; Heiferman, MJ; Krantz, SB; Munshi, HG; Shields, MA | 1 |
| Fukuda, M; Kasai, T; Kinoshita, A; Kohno, S; Masuda, N; Nagashima, S; Nakamura, Y; Nakatomi, K; Oka, M; Soda, H; Soejima, Y; Takatani, H; Tsukamoto, K | 1 |
| Heike, Y; Ikeda, M; Kaida, M; Kojima, Y; Kondo, S; Morita-Hoshi, Y; Morizane, C; Okusaka, T; Soeda, A; Takaue, Y; Ueno, H; Wakeda, T; Yamaki, Y | 1 |
| Bildzukewicz, NA; Brody, JR; Costantino, CL; Cozzitorto, JA; Dasgupta, A; Einstein, L; Gonye, GE; Gorospe, M; Keen, JC; Richards, NG; Rittenhouse, DW; Williams, TK; Witkiewicz, AK; Yeo, CJ | 1 |
| Ikeda, R; Jiang, Z; Kolesar, JM; Lau, E; Sachidanandam, K; Vermeulen, LC; Yamada, K | 1 |
| Cheung, IY; Cheung, NK; Gao, X; Tran, H; Wei, XX; Xu, H | 1 |
| Advani, AS; Ali-Osman, F; Barker, A; Beaven, A; Copelan, E; de Castro, CM; Diehl, LF; Kalaycio, M; Moore, JO; Rizzieri, DA; Rybicki, L; Sekeres, MA; Shadman, M; Sobecks, R; Talea, P | 1 |
| Blessing, JA; Hoffman, JS; Lachance, JA; Miller, DS; Moore, KN; Rotmensch, J; Spirtos, NM; Tait, DL | 1 |
| Daum, S; Epple, HJ; Grozdanovic, Z; Kunkel, J; Loddenkemper, C; Schmittel, A; Schulze, K; Zeitz, M | 1 |
| Branson, KR; Dhand, R; Essman, S; Guntur, VP; Henry, CJ; Kim, DY; Owen, N; Reinero, C; Selting, K; Waldrep, JC | 1 |
| Hara, I; Inagaki, T; Kohjimoto, Y; Matsumura, N; Nakamura, Y; Nanpo, Y; Ohashi, Y; Yasuoka, H | 1 |
| Arsawang, U; Hannongbua, S; Remsungnen, T; Rungrotmongkol, T; Saengsawang, O; Sornmee, P; Wittayanarakul, K | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Coyne, CP; Jones, T; Pharr, T | 1 |
| Chen, E; Gauthier, I; Gill, S; Goel, R; Hedley, D; Jonker, D; McIntosh, L; Moore, MJ; Renouf, DJ; Seymour, L; Southwood, B; Walde, D; Walsh, W | 1 |
| Balandra, A; Bergey, MR; Canter, DJ; Guzzo, TJ; Magerfleisch, L; Malkowicz, SB; Resnick, MJ; Tomaszewski, JE; Vaughn, DJ | 1 |
| Jonasch, E; Lim, ZD; Ng, C; Richey, SL; Tannir, NM | 1 |
| Fujii, Y; Kawakami, S; Kihara, K; Koga, F; Masuda, H; Saito, K; Tatokoro, M; Yasuda, Y; Yokoyama, M | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Iguchi, H; Ioka, T; Ito, T; Komatsu, Y; Nakachi, K; Nakagawa, K; Nakamori, S; Ohkawa, S; Okusaka, T; Yamao, K | 1 |
| Abskharon, JE; Jost, A; Mack, MG; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S | 1 |
| Clamp, AR; Evans, S; Griffiths, RW; Hasan, J; Jayson, GC; Kumaran, GC; Mitchell, CL; Welch, RS; Zee, YK | 1 |
| Braconi, C; Huang, N; Kogure, T; Patel, T; Swenson, E | 1 |
| Hilpert, F; Jonat, W; Kuemper, C; Mundhenke, C; Schaefer, F; Strauss, A | 1 |
| He, A; Ma, S; Sun, Z; Xu, H; Zhao, L; Zheng, X; Zhu, Z | 1 |
| Davis, C; Haefele, A; Hammons, G; Lyn-Cook, BD; Mohammed, SI; Wang, H; Word, B | 1 |
| Chen, SM; Chen, YY; Huang, CH; Li, SH; Rau, KM; Tang, Y; Wu, SC | 1 |
| de Lima Araújo, LH; Gomes, CA; Moitinho, MV; Noronha Júnior, H; Silva, AM | 1 |
| Boggi, U; Campani, D; Del Chiaro, M; Falcone, A; Funel, N; Giovannetti, E; Scarpa, A; Vasile, E | 1 |
| Hisatome, I; Kanki, K; Kurimasa, A; Matsuura, S; Nishio, R; Shiota, G; Tsuchiya, H; Yasui, T | 1 |
| Bottomley, I; Choudhury, A; Clarke, NW; Cowan, RA; Elliott, PA; Kiltie, AE; Livsey, JE; Logue, JP; Lyons, J; McCaul, D; Ramani, V; Sangar, V; Swindell, R; Symonds, P; Wise, M; Wylie, JP | 1 |
| d'Adhemar, C; Kelly, ME; Kinsella, J; Ridgway, PF; Swan, N | 1 |
| Corinaldesi, R; Morselli-Labate, AM; Pezzilli, R | 1 |
| Asmar, L; Kobina, S; Neubauer, MA; Pritchard, S; Reynolds, CH; Weissman, CH | 1 |
| Bradley, C; Koo, IC; O'Shaughnessy, J; Osborne, C; Patt, D; Pippen, JE; Rocha, C; Sherman, BM; Yoffe, M | 1 |
| Chu, P; DU, XL; Li, DP; Liu, NF; Lu, CH; Sheng, XG; Zhou, CX | 1 |
| Chen, B; Liu, S; Wang, D; Wang, Y; Wu, J; Zhao, W | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Jiang, J; Li, L; Lin, Q; Tian, J; Wang, Q; Wang, X | 1 |
| Bandres, E; Bitarte, N; Boni, V; Chopitea, A; Garcia-Foncillas, J; Hernández, A; Ponz-Sarvisé, M; Rodriguez, J; Zarate, R | 1 |
| Fisher, WE | 1 |
| Chang, QY; Li, M; Li, XG; Li, YF; Liu, J; Song, PP; Tian, HM; Wang, XB; Wu, LY; Zhang, W; Zhao, D | 1 |
| Wang, XY; Zhao, YL | 1 |
| Anai, H; Hasegawa, M; Kichikawa, K; Maeda, S; Masada, T; Morimoto, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T; Yamamoto, K | 1 |
| Baba, H; Goseki, N; Kuwabara, H; Nakajima, K; Ohba, A; Sanada, T; Tanaka, K; Tsubomoto, T; Wakabayashi, M | 1 |
| Aoki, H; Choda, Y; Fujiwara, Y; Harano, M; Matsukawa, H; Ninomiya, M; Nishizaki, M; Ohno, S; Ojima, Y; Shiozaki, S; Takakura, N | 1 |
| Murata, K; Nagase, H; Ota, H | 1 |
| Amano, R; Doi, Y; Hirakawa, K; Iwauchi, T; Nakamoto, K; Ohira, G; Ohira, M; Yamada, N | 1 |
| Akagi, K; Dono, K; Fujino, S; Fujita, J; Hata, T; Ikeda, K; Iwazawa, T; Kawanishi, K; Kitada, M; Kitahara, T; Miyake, M; Munakata, K; Nagai, K; Shimano, T; Shimizu, J; Takamoto, K; Watanabe, N; Yanagawa, T | 1 |
| Kametaka, H; Koyama, T; Makino, H; Seike, K | 1 |
| Mizuyama, Y; Nakagawa, H; Nishihara, T; Ono, Y; Shinto, O; Tamura, T | 1 |
| Bai, Z; Guo, W; Ma, X; Tang, K; Wang, Y; Zhang, Z | 1 |
| Cai, X; Chen, J; Li, Q; Mei, K; Yu, J; Zhao, X; Zhou, C | 1 |
| Chakrabarti, D; Khanna, A; Mahalingam, K; Periyasamy, G | 1 |
| Farid, M; Koo, GC; Lim, ST; Loong, S; Quek, R; Tao, M; Tay, K; Yau, YW | 1 |
| Awasthi, N; Brekken, RA; Kirane, A; Schwarz, MA; Schwarz, RE; Toombs, JE | 1 |
| Carron, MA; Kucuk, O; Lin, HS; Shkoukani, MA; Tulunay, O | 1 |
| Carlson, JJ; Roth, JA | 1 |
| Arpicco, S; Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Franchini, M; Palmieri, M; Scarpa, A; Zaniboni, T | 1 |
| Alfaro Gamero, J; Bastús Piulats, R; Campos Cervera, JM; Dotor Navarro, E; Escudero Emperador, P; Esquerdo Galiana, G; Gallén Castillo, M; Guasch Jordán, I; Pericay Pijaume, C; Pisa Gatell, A; Saigí Grau, E | 1 |
| Sun, Q; Yu, J; Zhang, L; Zheng, X | 1 |
| Fujita, H; Hayashi, A; Itaba, S; Ito, T; Kayashima, T; Manabe, T; Mizumoto, K; Nakata, K; Ohtsuka, T; Ohuchida, K; Onimaru, M; Souzaki, R; Tajiri, T; Tanaka, M; Yu, J | 1 |
| Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J | 1 |
| Biesma, B; Dalesio, O; Groen, HJM; Slaets, JPJ; Smit, EF; Smit, HJM; Stigt, JA; van Felius, CL; van Putten, JWG; Vincent, A; Wymenga, ANM | 1 |
| Beham, A; Bodo, K; Lackner, K; Liegl, B; Martin, D; Tsybrovskyy, O | 1 |
| Chen, YG; Lin, GM; Lin, JC; Lin, TY | 1 |
| Briggs, JE; Chauhan, J; Clouser, CL; Crankshaw, DL; Holtz, CM; Mansky, LM; Mullett, M; Patterson, SE; VanHoutan, IM | 1 |
| Jiang, Z; Lu, X; Shen, G; Song, S; Wang, T; Wu, S; Zeng, M; Zhang, S | 1 |
| Liu, TG; Zhu, H; Zhu, WY | 1 |
| Brito, LG; de Andrade, JM; Lins-Almeida, T; Marana, HR; Peria, FM; Pinheiro, MN; Tiezzi, DG; Zola, FE | 1 |
| Bar-Sela, G; Haim, N; Nasrallah, H | 1 |
| Jiang, J; Kim, R; Lai, KK; Liu, X; Rybicki, LA; Tan, A; Wang, Y | 1 |
| Merchant, NB; Nagaraj, NS; Washington, MK | 1 |
| Egloff, AM; Grandis, JR | 1 |
| Fukuda, S; Guo, Z; Kathuria, H; Milani, M; Mitra, R; Pelus, LM; Potter, DA; Rizzardi, A; Rodriguez, M; Schmechel, S; Skalnik, DG; Srirangam, A | 1 |
| Arias, JL; Couvreur, P; Desmaële, D; Dosio, F; Gillet, B; Gref, R; Othman, M; Reddy, LH; Zouhiri, F | 1 |
| Galettis, P; Links, M; Luk, PP | 1 |
| Abrams, RA; Benson, AB; Hoffman, JP; Konski, AA; Lustig, R; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA | 1 |
| Chaigneau, L; Chargari, C; Clavreul, G; Dumanoir, C; Jacquin, JP; Magné, N; Mélis, A; Merrouche, Y; Mille, D; Nourissat, A; Orfeuvre, H; Savary, J; Thorin, J | 1 |
| Abo-Elyazeed, A; El-Hadaad, HA; Halim, AA; Wahba, HA | 1 |
| Benyumov, A; Gurvich, VJ; Kirstein, MN; Lis, LG; Williams, BW | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morita, S; Morizane, C; Nakachi, K; Okusaka, T; Tanaka, K; Ueno, H | 1 |
| Barile, C; Bolzonella, C; Bononi, A; Crepaldi, G; Gusella, M; Meneghetti, S; Menon, D; Modena, Y; Padrini, R; Pasini, F; Stievano, L; Toso, S | 1 |
| Eichbaum, MH; Sohn, C | 1 |
| Hattori, H; Russell, P; Skoulidis, F; Venkitaraman, AR | 1 |
| Bepler, G; Chen, DT; Chiappori, A; Dilling, TJ; Greenberg, H; Haura, E; Hazelton, T; Simon, G; Stevens, C; Tanvetyanon, T; Wagner, H; Walsh, F; Williams, C | 1 |
| Hodge, LS; Taub, ME; Tracy, TS | 2 |
| Ando, M; Fukuoka, M; Iwamoto, Y; Katakami, N; Kurata, T; Maeda, M; Nakagawa, K; Nakano, T; Saito, H; Takeda, K | 1 |
| Bonanno, L; Carli, P; Favaretto, A; Jirillo, A; Magro, C; Marulli, G; Nicotra, S; Pasello, G; Rea, F | 1 |
| Saito, Y | 1 |
| Dutcher, J; Haas, NB; Heath, E; Lin, X; Liu, G; Manola, J; McDermott, D; Nanus, D; Pins, M; Wilding, G | 1 |
| Blomfield, P; Bohmer, R; Chan, WS; McIntosh, R | 1 |
| André, N; Ciccolini, J; Dahan, L; Mercier, C | 1 |
| Azzariti, A; Bocci, G; Chiarappa, P; Del Bufalo, D; Del Tacca, M; Fioravanti, A; Mangia, A; Paradiso, A; Porcelli, L; Quatrale, AE; Sebastian, S; Simone, GM; Sini, P | 1 |
| Chen, H; Guo, Y; Lin, S; Liu, A; Liu, J; Tan, W; Tong, H; Wang, Z; Wei, W | 1 |
| Bennouna, J; Bycott, P; Funakoshi, A; Furuse, J; Ioka, T; Kim, S; Kindler, HL; Létourneau, R; Ohkawa, S; Okusaka, T; Park, YS; Ricart, AD; Richel, DJ; Springett, GM; Trask, PC; Van Cutsem, E; Wasan, HS | 1 |
| Nam, KH; Rapoport, N; Scaife, CL; Shea, JE | 1 |
| Goto, H; Ko, SB | 1 |
| Barbara, C; Barni, S; Cabiddu, M; Petrelli, F | 1 |
| Rexer, H | 3 |
| Aparicio, T; Azzedine, A; Barhoumi, M; Bedenne, L; Bonnetain, F; Bosset, JF; Bouché, O; Butel, J; Chauffert, B; Hammel, P; Maingon, P; Mariette, C; Mineur, L; Mornex, F; Rougier, P; Stremsdoerfer, N | 1 |
| Chang, D; Du, HZ; You, L; Zhao, YP | 1 |
| Dowaki, S; Hirabayashi, K; Imaizumi, T; Makuuchi, H; Matsuyama, M; Okada, K; Tobita, K; Yazawa, N | 1 |
| Cho, DC; McDermott, DF; Mier, JW; Pandya, SS | 1 |
| Bhagwat, B; Davis, N; Dwyer, MP; Gu, D; Guzi, TJ; Hsieh, Y; Labroli, M; Lee, S; Liu, M; Parry, D; Paruch, K; Penaflor, E; Seghezzi, W; Shanahan, F; Taricani, L; Wang, W; Wiswell, D | 1 |
| Assouline, S; Buckstein, R; Chua, NS; Crump, M; Eisenhauer, E; Fernandez, LA; Gascoyne, RD; Klasa, RJ; Kouroukis, CT; Powers, J; Turner, R; Walsh, W | 1 |
| Aguilar Ponce, JL; Cabrera Aquino, G; Chilaca Rosas, MF; Frías Mendivil, M; Granados García, M; Lavín Lozano, AJ; Maldonado Magos, F; Montes Luis, MM; Olvera Caraza, D; Segura Pacheco, BA | 1 |
| Baldi, A; Bazzano, S; D'Anna, S; Orlando, F; Palmieri, A; Tenaglia, S; Valentinis, L | 1 |
| Ballestrero, A; Bergaglio, M; Bertolotti, F; Brema, F; Canobbio, L; Cinzia, N; Folco, U; Mencoboni, M; Murialdo, R; Parodi, M; Pastorino, G; Simoni, C; Vaira, F | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, TY; Lee, KH; Lim, KH; Oh, DY | 1 |
| Baracos, VE; Chu, QS; Mazurak, VC; Mourtzakis, M; Murphy, RA; Reiman, T | 1 |
| Araki, K; Kobayashi, T; Kubo, N; Kuwano, H; Raz, A; Shimura, T; Suzuki, H; Tsutsumi, S; Wada, W; Yajima, T | 1 |
| Hikichi, T; Ikeda, T; Imamura, H; Irisawa, A; Obara, K; Ohira, H; Sato, A; Sato, M; Shibukawa, G; Suzuki, R; Takagi, T; Takahashi, Y; Terashima, M; Wakatsuki, T | 1 |
| Gondo, T; Hamada, R; Hatano, T; Nakashima, J; Ohori, M; Satake, N; Tachibana, M; Takeuchi, H; Tanaka, A | 1 |
| de Souza, PL; Galettis, P; Hoskins, JM; Jelinek, M; Liauw, W; Links, M; Manners, S; Metharom, E | 1 |
| Dubreuil, P; Hermine, O; Humbert, M; Kow, K; Mansfield, CD; Moussy, A; Rose, B; Thamm, DH | 1 |
| Moon, S; Na, K; Yang, SG | 1 |
| Angeli, I; Calamai, G; Catania, C; Danesi, R; De Braud, F; De Pas, TM; Giovannetti, E; Milani, A; Noberasco, C; Pelosi, G; Radice, D; Russo, F; Spitaleri, G; Toffalorio, F | 1 |
| Arriví, A; Company, M; Cuadrado, A; Dolz, C; Falcó, E; García Bonafe, M; González de Cabo, M; Morales, R; Noguera, JF; Riera, J; Socías, A; Vicens, JC; Vilella, A | 1 |
| Contreras Ibáñez, JA; Díaz Gómez, L; Navas García, N | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H | 1 |
| Fujita, H; Hashizume, M; Kayashima, T; Mizumoto, K; Moriyama, T; Nagai, E; Ohtsuka, T; Ohuchida, K; Tanaka, M; Ueda, J | 1 |
| Halim, A; Wahba, H | 1 |
| Bartlett, NL; Canellos, GP; Cheson, BD; Hall, NC; Hsi, ED; Johnson, JL; Jung, SH; Juweid, ME; Kostakoglu, L; LaCasce, AS; Schöder, H; Schwartz, LH; Straus, DJ; Takvorian, RW | 1 |
| Atkinson, BJ; Byfield, SD; Feng, C; Jonasch, E; Lal, LS; Miller, LA; Pagliaro, LC; Tannir, NM | 1 |
| Paglino, C; Porta, C | 1 |
| Bharadwaj, RR; Chen, EX; Jarvi, A; Kamel-Reid, S; Le Tourneau, C; Mann, V; Perez-Ordonez, B; Siu, LL; Wang, L; You, B | 1 |
| Gill, S; Kim, C; Owen, D | 1 |
| Coban, I; El-Rayes, BF; Kauh, JS; Kneuertz, PJ; Kooby, DA; Maithel, SK; Sarmiento, J; Staley, CA; Volkan Adsay, N | 1 |
| Hu, Y; Liao, Q; Si, S; You, LL; Zhang, Q; Zhao, YP | 1 |
| Hasegawa, S; Hayashi, T; Hirayama, K; Ikematsu, Y; Kageyama, S; Kanai, T; Mori, H; Nakata, Y; Nishiwaki, Y; Okawada, T; Ozawa, T; Sugimura, H; Tamura, H | 1 |
| Hanyu, F; Harada, N; Hayashi, T; Kaji, S; Koike, N; Morishita, K; Suzuki, M; Suzuki, S; Takeo, Y | 1 |
| Hatata, T; Ikeguchi, M; Kondo, A; Naka, T; Takaya, S; Taniguchi, K | 1 |
| Hamamoto, Y; Kamimura, M; Takano, N; Yamada, K | 1 |
| Hatano, E; Ikeda, K; Kamo, N; Mitsuyoshi, H; Mori, A; Nitta, T; Uemoto, S | 1 |
| Fukuoka, J; Hosokawa, A; Ishizawa, S; Itaya, Y; Kajiura, S; Kawai, K; Minemura, M; Nakayama, Y; Nishimizu, T; Sawasaki, T; Shimizu, S; Sugiyama, T; Tajiri, K; Takahara, T; Tokimitsu, Y; Yamawaki, H; Yanagisawa, A; Yasumura, S | 1 |
| Chen, J; Li, J; Li, MW; Shen Tu, JZ; Wang, LR; Wang, Y; Xu, N; Zhang, GB | 1 |
| Chung, WG; Cui, Z; DiGiovanni, J; Kiguchi, K; Lansakara-P, DS; Li, D; Proteau, PJ; Sandoval, MA; Sloat, BR | 1 |
| Brady, H; Heise, C; Kelter, G; Maier, A; Richard, N; Sung, V | 1 |
| Chen, G; Dong, J; Zhang, TP; Zhao, YP; Zhou, L | 1 |
| Arranz, EM; Arranz, MD; Bellido, EC; Cabral, JM; García, AB; Juberías, LA; Kreilinger, JJ; Parga, JM; Prianes, LA; Robledo, JP; Sanz, RR; Sanz-Agero, PG; Serrano, EM | 1 |
| Hedley, DW; Khanna, M; Wong, KM; Wu, RC | 1 |
| Baay, M; Ides, J; Lambrechts, HA; Lardon, F; Meijnders, P; Pattyn, GG; Pauwels, B; Peeters, M; Vermorken, JB; Wouters, A | 1 |
| Akladios, CY; Aprahamian, M; Balboni, G; Bour, G; Marescaux, J; Mutter, D | 1 |
| Ahmed, M; Brahmbhatt, K; Hussain, A; Priyani, A; Sadrieh, L; Sharma, C | 1 |
| Beniwal, P; Blair, EA; Cohen, EEW; Dekker, AJ; Gomez-Abuin, G; Haraf, D; Kocherginsky, M; Langerman, A; Portugal, L; Salama, JK; Seiwert, T; Stenson, KM; Villaflor, VM; Vokes, EE; Williams, RD; Witt, ME | 1 |
| Oberstein, PE; Saif, MW | 1 |
| Chang, BW; Saif, MW | 1 |
| Makrilia, N; Saif, MW; Syrigos, KN | 2 |
| Dimou, AT; Saif, MW; Syrigos, KN | 1 |
| Jiang, ZM; Ma, W; Xie, DR; Yang, Q; Zhang, YD; Zhou, SW | 1 |
| Gu, FY; Hu, XY; Li, MD; Shen, H; Yuan, Y; Zhong, X | 1 |
| Ducoloné, A; Fraisse, P; Mennecier, B; Quoix, E | 1 |
| Carrió, M; Cascante, A; Fillat, C; García-Ribas, I; Garcia-Rodríguez, L; Mazo, A; Pérez-Torras, S | 1 |
| Brooks, D; De Oliveira, E; Demuth, T; Hidalgo, M; Hirai, H; Maitra, A; Mizuarai, S; Ottenhof, N; Rajeshkumar, NV; Shumway, SD; Watters, J | 1 |
| Chen, C; Cubas, R; Li, M; Yao, Q; Zhang, S | 1 |
| Bozionelou, V; Georgoulias, V; Hatzidaki, D; Kalykaki, A; Karampeazis, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Vamvakas, L; Vardakis, N | 1 |
| Arnold, D; Dörken, B; Herrenberger, J; Kindler, M; Korsten, FW; Oettle, H; Pelzer, U; Reitzig, P; Riess, H; Stieler, J | 1 |
| Chalmers, B; Chen, P; Chen, Q; Drisko, J; Espey, MG; Levine, M; Sun, AY | 1 |
| Akino, H; Aoki, Y; Ito, H; Miwa, Y; Oyama, N; Yokoyama, O | 1 |
| Bang, YJ; Kang, HJ; Kim, BS; Kim, JS; Lee, KH; Lee, KW; Oh, DY; Park, YS; Ryoo, HM; Sohn, CH; Song, HS; Zang, DY | 1 |
| Abenhardt, W; Brudler, O; Brugger, W; diGioia, D; Freier, W; Gitsch, G; Heinemann, V; Hurtz, HJ; Jonat, W; Kettner, E; Rösel, S; Stemmler, HJ; Tesch, H; Tessen, HW | 1 |
| Aboukameel, A; Ali, S; Banerjee, S; Bao, B; Kong, D; Padhye, S; Philip, PA; Sarkar, FH; Sarkar, SH; Wang, Z | 1 |
| Norby, SM; Sethi, S; Thomas, JG | 1 |
| Ashikari, A; Ashimine, S; Haranaga, S; Machida, N; Matsumura, E; Oshiro, Y; Saito, S; Tasaki, S; Toyosato, T | 1 |
| Ambike, A; Couvreur, P; Lepêtre-Mouelhi, S; Rosilio, V; Stella, B | 1 |
| Bigand, C; Couvreur, P; Hajri, A; Parmentier, C; Reddy, LH; Réjiba, S | 1 |
| Ch'ang, HJ; Chang, JY; Chang, MC; Chen, JS; Chen, LT; Cheng, AL; Chiu, YF; Hsieh, RK; Hsu, CH; Hwang, TL; Lin, PW; Lin, YL; Shan, YS; Tien, YW; Wang, HP; Whang-Peng, J | 1 |
| Hahn, NM; Johnson, CS; Nattam, S; Perkins, SM; Picus, J; Stadler, WM; Sweeney, CJ; Waddell, MJ; Waterhouse, D; Zon, RT | 1 |
| Bridgewater, J; Vazquez, I | 1 |
| Bieblová, J; Bubeník, J; Indrová, M; Mikyšková, R; Reiniš, M; Símová, J | 1 |
| El-Khoueiry, AB; Gandara, D; Lenz, HJ; Ramanathan, RK; Shibata, S; Wright, JJ; Yang, DY; Zhang, W | 1 |
| Liu, Y; Shi, Y; Sun, Y; Wang, L; Wang, Y; Yu, S; Zhang, X | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Maita, S; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Bapiro, TE; Cook, N; Frese, KK; Goldgraben, MA; Griffiths, JR; Jacobetz, MA; Jodrell, DI; Madhu, B; Olive, KP; Richards, FM; Smith, DM; Tuveson, DA | 1 |
| Bachet, JB; Boussaha, T; Dubreuil, O; Landi, B; Lepère, C; Taieb, J; Trouilloud, I; Zaanan, A | 1 |
| Beatty, GL; Chiorean, EG; Fishman, MP; Huhn, RD; Li, D; O'Dwyer, PJ; Saboury, B; Sharp, LL; Song, W; Sun, W; Teitelbaum, UR; Torigian, DA; Vonderheide, RH | 1 |
| Al-Leswas, D; Al-Taan, O; Arshad, A; Dennison, AR; Metcalfe, M; Stephenson, J; Steward, WP | 1 |
| Berros, JP; Blay, P; Crespo, G; Esteban, E; Fernández, Y; Fonseca, PJ; Fra, J; Lacave, AJ; Losa, R; Luque, M; Muriel, C; Sanmamed, M; Sierra, M; Villanueva, N | 1 |
| Chen, H; Guo, H; Guo, Y; Lin, S; Liu, D; Wei, W | 1 |
| Hu, J; Ma, Y; Tang, L; Wang, HX; Xu, YC; Zhang, FC; Zhao, G | 1 |
| Thomas, G | 1 |
| Alcedo, JC; Barraclough, H; Beslija, S; Blair, JM; Casanova, L; Dueñas-González, A; Hameed, S; Orlando, M; Patel, F; Pattaranutaporn, P; Zarbá, JJ | 1 |
| Hernández-Fernández, C; Herranz-Amo, F; Husillos, A; Lledó, E; Molina-Escudero, R; Subirá, D | 1 |
| Anazawa, T; Gotoh, M; Kenjo, A; Kimura, T; Saito, T; Sato, J; Sato, Y; Tsuchiya, T | 1 |
| Fernández Domínguez, J; García Rodríguez, R; Mateos Marcos, V; Valle Pereda, M | 1 |
| Brioschi, M; Ceraulo, D; Cereda, S; Fugazza, C; Ghidini, M; Nicoletti, R; Reni, M; Rognone, A; Villa, E | 1 |
| Egawa, S; Katayose, Y; Maeda, S; Morikawa, T; Motoi, F; Naitoh, T; Onogawa, T; Rikiyama, T; Sakata, N; Shigeru, O; Takadate, T; Unno, M | 1 |
| Berlin, JD; Cardin, DB; Castellanos, EH | 1 |
| Buettner, GR; Cullen, JJ; Spitz, DR | 1 |
| Collisson, EA; Cooc, J; Danenberg, KL; Feiler, HS; Gibb, WJ; Gray, JW; Gu, S; Hanahan, D; Jakkula, L; Kim, GE; Ko, AH; Olshen, AB; Olson, P; Sadanandam, A; Spellman, PT; Tempero, MA; Truitt, M; Weinkle, J | 1 |
| Pazos Arias, B; Peteiro Cancelo, A; Romero Reinoso, C; Samprón Rodríguez, M; Vello Román, A | 1 |
| Al-Barrak, J; Gilks, CB; Hoskins, P; Lau, H; Santos, JL; Swenerton, KD; Tinker, A | 1 |
| Au, JSK; Benner, RJ; Blasinska-Morawiec, M; Ingrosso, A; Jassem, J; Krzakowski, M; Manegold, C; Meech, SJ; Readett, D; Serwatowski, P; Szczesna, A; Tan, EH; Thatcher, N; van Zandwijk, N; Zatloukal, P | 1 |
| Arena, MG; Bochicchio, AM; Casali, PG; De Rosa, P; Dei Tos, AP; Morosi, C; Nuzzo, A; Palassini, E; Pilotti, S; Sanfilippo, R; Stacchiotti, S; Turano, S; Vincenzi, B | 1 |
| Arnoletti, JP; Chen, Y; Jhala, NC; Jing, G; McDonald, JM; Turk, AN; Yuan, K; Zhang, K | 1 |
| Chung, HC; Del Giglio, A; Feng, J; Jiang, Z; Kim, SB; Malzyner, A; Pen, DL; Shen, LJ; Xu, B; Yu, S | 1 |
| Agrogiannis, G; Gamaletsou, MN; Kechagias, G; Papageorgiou, A; Syrios, J; Tsavaris, N; Xynos, ID | 1 |
| Bendell, JC; Burris, HA; Greco, FA; Infante, JR; Jones, SF; Murphy, PB; Spigel, DR; Thompson, DS; Yardley, DA | 1 |
| Chao, SY; Chou, CH; Hour, TC; Hu, HT; Huang, AM; Kao, YT; Lin, PY; Liou, JY; Lu, CY; Pu, YS; Toh, S | 1 |
| Imbriani, M; Minoia, C; Porro, B; Sottani, C | 1 |
| Blackstock, AW; Bogart, JA; Crawford, JC; Gu, L; Morano, K; Salama, JK; Socinski, MA; Stinchcombe, TE; Vokes, EE; Wang, X | 1 |
| Chiba, T; Ishikawa, S; Kanai, M; Kawaguchi, Y; Masui, T; Matsumoto, S; Mimori, T; Mori, Y; Nishimura, T; Yanagihara, K; Zaima, C | 1 |
| Abbruzzese, JL; Bennett, B; Bullock, S; Cunningham, P; Fogelman, D; Jafari, M; Lin, E; Morris, J; Ozer, H; Varadhachary, GR; Wolff, RA; Xiong, H | 1 |
| Tanji, N; Yokoyama, M | 1 |
| Abacioğlu, U; Atasoy, BM; Cağlar, H; Cıngı, A; Dane, F; Turhal, NS; Uçüncü Kefelı, A; Yeğen, C | 1 |
| Li, J; Yao, W; Yuan, Y; Zhang, L; Zhang, R; Zhou, L | 1 |
| Hirakawa, K; Miwa, A; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Azzarello, D; Bottari, M; Maisano, M; Maisano, R; Nardi, M; Raffaele, M; Zavettieri, M | 1 |
| Arumugarajah, S; Brown, JL; Gross, M; Hassan, MC; Hylander-Gans, L; Lawrence, TS; Maybaum, J; Morgan, MA; Morosini, D; Parsels, JD; Parsels, LA; Qian, Y; Simeone, DM; Tanska, DM; Zabludoff, SD; Zhao, L | 1 |
| Aggarwal, S; Gupta, S; Yadav, S | 1 |
| Brodowicz, T; Loibl, S; Lück, HJ; Nekljudova, V; Schwenkglenks, M; Skacel, T; von Minckwitz, G; Zielinski, C | 1 |
| Li, B; Li, J; Zhong, M | 1 |
| Brichkova, OY; Davidov, MI; Karaseva, VV; Lazarev, AF; Marenich, AF; Orlov, SV; Pavlushkov, EV; Polotzky, BE; Semenchenya, VA; Skryabina, LS | 1 |
| Jeong, KS; Kim, YT; Lee, JK; Lee, SH; Park, JK; Ryu, JK; Woo, SM; Yang, KY; Yoon, WJ; Yoon, YB | 1 |
| Bertz, S; Birkenkamp-Demtroder, K; Bødker, JS; Dyrskjøt, L; Hartmann, A; Lehmann, J; Nordentoft, I; Orntoft, TF; Wild, PJ | 1 |
| Berlin, J; Cardin, DB; Castellanos, E | 1 |
| Cleves, A; Mason, M; Shelley, M; Wilt, TJ | 1 |
| Jeglum, AK; Lindner, D; Marconato, L; Nelson, V; Suslak-Brown, L; Zini, E | 1 |
| Di, Y; Fu, D; Hu, J; Jiang, Y; Jin, C; Li, J; Ni, Q; Wang, C; Yang, D; Yang, F | 1 |
| Fineberg, N; Grizzle, WE; Kim, H; Knowles, JA; Rosenthal, EL; Shah, N; Stockard, CR; Zhai, G; Zhou, T; Zinn, KR | 1 |
| Gao, Z; Gu, A; Han, B; Shen, J; Zhong, H | 1 |
| Ambrosone, CB; Bookman, M; Darcy, KM; Deloia, JA; Gallion, H; Krivak, TC; Tian, C | 1 |
| Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA | 1 |
| Fukayama, M; Goto, A; Maeda, E; Morita, S; Murakawa, T; Nakajima, J; Ota, S; Sakatani, T | 1 |
| Collins, IM; Thomas, DM | 1 |
| Adenis, A; Conroy, T; Gavoille, C | 1 |
| Cui, L; Egami, T; Fujita, H; Matsumoto, K; Mizumoto, K; Ohtsuka, T; Ohuchida, K; Onimaru, M; Tanaka, M; Yasui, T; Zhao, M | 1 |
| Eller, J; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Molnár, J; Pálföldi, R; Szántó, E; Thurzó, L; Tiszlavicz, L | 1 |
| Park, JY | 1 |
| Fujii, M; Harada, R; Hirao, K; Ishida, E; Kato, H; Kawamoto, H; Kurihara, N; Mizuno, O; Noma, Y; Ogawa, T; Sakakihara, I; Tsutsumi, K; Yamamoto, K; Yamamoto, N | 1 |
| Centeno, B; Helm, J; Hodul, P; Hoffe, S; Kim, J; Klapman, J; Malafa, M; Patel, M; Springett, G; Valone, T | 1 |
| Gnant, M; Goetzinger, P; Koelblinger, C; Kuehrer, I; Sahora, K; Schindl, M | 1 |
| Anne, PR; Berger, AC; Chervoneva, I; Kennedy, EP; Mitchell, EP; Rosato, EL; Showalter, TN; Yeo, CJ; Zhan, T | 1 |
| Abbruzzese, A; Bifulco, M; Caraglia, M; Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Marra, M; Palmieri, M; Scarpa, A; Scupoli, MT; Zaniboni, T; Zappavigna, S | 1 |
| Dhesy-Thind, B; Doyle, L; Goffin, JR; Hedley, D; Krzyzanowska, MK; Major, P; Moore, MJ; Renouf, DJ; Tang, PA; Wang, L | 1 |
| Baas, P; Beijnen, JH; Burgers, JA; Burylo, A; deJong, D; Huitema, AD; Joerger, M; Schellens, JH | 1 |
| Danesi, R; Del Tacca, M; Mey, V; Pasqualetti, G; Ricciardi, S | 1 |
| Brostjan, C; Brugger, P; Gnant, M; Kuehrer, I; Schauer, D; Schoppmann, SF; Sommerfeldt, S; Starlinger, P; Tamandl, D | 1 |
| Arora, S; Azorsa, DO; Choudhary, A; Gonzales, IM; Henderson, MC; Mousses, S; Trent, JM; Von Hoff, DD | 1 |
| Mak, AL; Moibi, JA; Moore, RB; Sun, B | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H | 1 |
| Hu, YS; Ke, PY; Lin, SZ; Liu, A; Tang, LL; Wang, ZH | 1 |
| Cao, YD; Cheng, HY; Deng, YX; Ge, XL; Huang, PL; Jin, ZL; Li, F; Ma, J; Qin, SK; Sun, XC; Xu, RZ | 1 |
| Arai, Y; Chen, GP; Hamada, H; Li, DC; Satoh, M; Wang, H | 1 |
| Brümmer, F; Gebhard, MM; Gross, W; Herr, I; Kallifatidis, G; Klöppel, A; Liu, L; Ottinger, S; Rausch, V | 1 |
| Binder, D; Hübner, RH; Schlattmann, P; Temmesfeld-Wollbrück, B | 1 |
| Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Nakashima, A; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
| Balaraman, S; Ballouz, S; Boxwala, IG; Cotant, MB; Hardy-Carlson, M; Jaiyesimi, IA; Jury, RP; Margolis, J; Marvin, KS; Nadeau, L; Robertson, JM; Wallace, M; Ye, H | 1 |
| Chang, DT; Christman-Skieller, C; Chun, CL; Columbo, LA; Desser, TS; Fisher, GA; Ford, JM; Goodman, KA; Hsu, A; Kim, J; Koong, AC; Kunz, PL; Maxim, PG; Norton, J; Quon, A; Schellenberg, D; Van Dam, J; Xing, L | 1 |
| Balaraman, B; Conley, JA; Sheinbein, DM | 1 |
| Acharya, S; Arya, G; Sahoo, SK; Vandana, M | 1 |
| Agelaki, S; Ardavanis, A; Chandrinos, V; Christophyllakis, C; Georgoulias, V; Giassas, S; Karachaliou, N; Kotsakis, A; Pallis, AG; Polyzos, A; Samonis, G; Saridaki, Z; Syrigos, K; Vamvakas, L; Vardakis, N; Varthalitis, I | 1 |
| Brausi, M; Fiorito, C; Gontero, P; Oderda, M; Pappagallo, G | 1 |
| Jenks, S | 1 |
| Ciombor, KK; Ferrell, A; Flores, A; Levi, J; Lopes, G; Macintyre, J; Merchan, JR; Ribeiro, A; Rocha-Lima, CM; Sleeman, D | 1 |
| Bergsland, EK; Coakley, FV; Dito, E; Espinoza, AM; Hanover, CS; Jones, KA; Kelley, RK; Ko, AH; Ong, A; Tempero, MA; Venook, AP | 1 |
| Ishiguro, M; Kamio, Y; Mori, N; Murakami, T; Shimomukai, Y; Yokooji, T | 1 |
| Alberts, SR; Camoriano, JK; Enger, JR; Farr, GH; Johnson, DB; Kim, GP; Morlan, BW; Reid, JM; Seay, TE | 1 |
| Chang, Y; Littman, SJ; Mbeo, G | 1 |
| Ahmad, SA; Blanke, CD; El-Khoueiry, AB; Gold, PJ; Holcombe, RF; Iqbal, S; Lenz, HJ; Messino, MJ; Rankin, C | 1 |
| Hanaoka, J; Ikemoto, T; Imura, S; Iwahashi, S; Mori, H; Morine, Y; Saito, Y; Shimada, M; Sugimoto, K; Utsunomiya, T | 1 |
| Adenis, A; Assenat, E; Bachet, JB; Bécouarn, Y; Bennouna, J; Bouché, O; Chauffert, B; Conroy, T; de la Fouchardière, C; Delbaldo, C; Desseigne, F; Ducreux, M; Gourgou-Bourgade, S; Guimbaud, R; Khemissa-Akouz, F; Michel, P; Montoto-Grillot, C; Péré-Vergé, D; Raoul, JL; Ychou, M | 1 |
| Bassi, C; Cantore, M; Fiorentini, G; Mambrini, A; Orlandi, M; Torri, T | 1 |
| Draux, F; Gobinet, C; Jeannesson, P; Manfait, M; Sockalingum, GD; Sulé-Suso, J | 1 |
| Johansson, M; Karlsson, A; Xu, Y | 1 |
| Adler, M; Dörken, B; Oettle, H; Pelzer, U; Riess, H; Schwaner, I; Seraphin, J; Stieler, J | 1 |
| Cai, TY; Dong, XW; He, QJ; Hu, YZ; Jiang, H; Lin, NM; Yang, B; Yang, LQ; Zhang, C; Zhu, H | 1 |
| Doki, Y; Endo, W; Hasuike, Y; Masutani, S; Monden, M; Mori, M; Morimoto, T; Nakamori, S; Ozato, H; Shibata, T; Takeda, Y; Tohno, K | 1 |
| Kenno, S; Kobayashi, T; Kuji, M; Tani, C; Yamamoto, Y | 1 |
| Chen, Y; Liu, B; Qian, X | 1 |
| Galizia, MS; Miller, FH; Mulcahy, MF; Rezai, P; Small, W; Tochetto, SM; Yaghmai, V | 1 |
| Afonso, SL; da Silva, LG; Stefano, EJ; Tavares, VC; Viani, GA | 1 |
| Guo, K; Liu, H; Ma, Q; Shan, T; Wang, F; Wu, E; Zhang, D | 1 |
| Chen, YX; Lin, Y; Shi, J; Xie, WF; Zhu, CP | 1 |
| Grigull, L; Hartmann, C; Linderkamp, C; Reinhardt, D; Sander, A; Schmid, H; Weinel, P; Welte, K | 1 |
| Che, L; DI, LJ; Fang, J; Jiang, HF; Ren, J; Song, GH; Yu, J; Zhu, YL | 1 |
| Liu, T; Zhang, JQ; Zhang, L | 1 |
| Sai, K; Saito, Y | 1 |
| Dasanu, CA; Majumder, S; Trikudanathan, G | 1 |
| Chang, GC; Chang, JW; Chua, DT; Hsia, TC; Manegold, C; Mok, TS; Moore, N; Sirisinha, T; Sriuranpong, V; Thitiya, S; Thongprasert, S; Tsai, CM; Tsang, K | 1 |
| Ahn, MJ; Chang, JW; Kang, JH; Kim, HT; Kim, JH; Kim, SW; Thongprasert, S; Tsang, K; Walzer, S; Wright, E | 1 |
| Hara, I; Matsumura, N | 1 |
| Baas, P; Beijnen, JH; Burgers, JA; Doodeman, VD; Huitema, AD; Jansen, RS; Joerger, M; Rosing, H; Schellens, JH; Smits, PH; Vainchtein, LD | 1 |
| Adamo, V; Alabiso, O; Ardizzoni, A; Barbera, S; Barni, S; Buscarino, C; Caprioli, A; Crinò, L; De Marinis, F; Filippelli, G; Gebbia, V; Gridelli, C; Lorusso, V; Maione, P; Marangolo, M; Morena, R; Pela, R; Piazza, E; Venturino, P; Zilembo, N | 1 |
| Bodoky, G; Ciuleanu, TE; La Stella, PJ; Pover, G; Spigel, DR; Tebbutt, NC; Timcheva, C | 1 |
| Avital, I; Davis, JL; Langan, RC; Levy, E; Pandalai, P; Ripley, RT; Steinberg, SM; Toomey, MA; Walker, M | 1 |
| Bang, S; Chung, JB; Chung, MJ; Kim, YJ; Park, JY; Park, SW; Song, SY | 1 |
| Gattuso, P; Groh, V; Kaufman, HL; Plate, J; Prinz, RA; Rao, GS; Spies, T; Xu, X | 1 |
| Buesa, JM; Carrasco, JA; Casado, A; Cruz, J; Cubedo, R; de Andrés, R; De Juan, A; Fra, J; García-Del-Muro, X; Gómez-España, A; Laínez, N; López-Pousa, A; Martín, J; Martínez-Trufero, J; Maurel, J; Meana, A; Pericay, C; Poveda, A; Rubió, J | 1 |
| Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, HC; Park, JO; Park, SH; Park, YS | 1 |
| Ahn, JB; Hong, YS; Kim, SH; Kim, SY; Kim, TW; Lee, KH; Lee, SH; Park, SH; Park, YS; Shin, SJ | 1 |
| Fujiwara, H; Homma, S; Ito, M; Iwamoto, T; Koido, S; Komita, H; Mineno, J; Nagasaki, E; Nishida, S; Ochi, T; Sagawa, Y; Shiku, H; Sugiyama, H; Tajiri, H; Takahara, A; Yasukawa, M | 1 |
| Cannavà, C; Cosco, D; La Mantia, A; Paolino, D; Pignatello, R; Stancanelli, R; Tommasini, S; Ventura, CA | 1 |
| Liu, A; Tong, HF; Zeng, Y | 1 |
| Cao, W; Chen, Q; Liu, X; Wang, Y; Wang, Z; Xia, C; Yan, B; Zhang, K; Zhang, L; Zhang, S | 1 |
| Eastwood, A; Epstein, D; Fox, D; Rodgers, M; Soares, M; Yang, H | 1 |
| Copur, MS; Obermiller, A | 1 |
| Bennouna, J; Favrel, S; Lemarie, E; Pinel, MC; Pouget, JC; Senellart, H; Tourani, JM; Tournoux-Facon, C | 1 |
| Appelbaum, L; Goldberg, Y; Hubert, A; Kadouri, L; Peretz, T; Sagi, M; Sonnenblick, A | 1 |
| Gunn, JR; Korc, M; Sempere, LF | 1 |
| Colaço, A; Lopes, C; Oliveira, PA; Palomino, LF; Santos, L; Vala, H; Vasconcelos-Nóbrega, C | 1 |
| Bergerat, JP; Delpeuch, A; Leveque, D; Rob, L | 1 |
| Fujita, H; Kurata, N; Mahawithitwong, P; Manabe, T; Mizumoto, K; Ohtsuka, T; Ohuchida, K; Onimaru, M; Sakai, H; Tanaka, M | 1 |
| Hassan, R; Kelly, RJ; Sharon, E | 1 |
| Ambrosino, G; Baiocchi, C; Costantin, G; Febbraro, A; Francescon, P; Guglielmi, R; Polistina, FA; Scalchi, P | 1 |
| Donders, AR; Oostendorp, LJ; Ottevanger, PB; Stalmeier, PF; van der Graaf, WT | 1 |
| Balaraman, S; Gustafson, G; Huang, J; Jury, R; Khilanani, P; Margolis, J; McIntosh, B; Nadeau, L; Robertson, JM | 1 |
| Bang, YJ; Bergethon, K; Camidge, DR; Christensen, J; Clark, JW; Dy, J; Iafrate, AJ; Kim, DW; Kwak, EL; Maki, RG; Ou, SH; Salgia, R; Siwak-Tapp, C; Solomon, BJ; Tan, W; Wilner, KD | 1 |
| Bae, K; Dicker, AP; Elsaleh, H; Farrell, JJ; Guha, C; Wong, J | 1 |
| Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E | 1 |
| Huang, XE; Jin, GF; Li, Y; Shen, HB; Xu, L | 1 |
| Ellinger, S; Henne-Bruns, D; Klapperstueck, T; Knippschild, U; Kreyes, A; Landfester, K; Udelnow, A; Walther, P; Wohlrab, J; Würl, P | 1 |
| Ballal, S; Dicke, K; Gurtler, J; Katz, T; Kayaleh, O; Keaton, M; Ko, AH; Lenz, HJ; Rowinsky, EK; Youssoufian, H | 1 |
| Cheng, CY; Cherng, SH; Huang, XY; Liao, FT; Sheu, GT; Wu, MF; Wu, WJ; Yang, TY | 1 |
| An, Y; Chen, P; Ji, ZL; Jiang, KR; Lu, ZP; Miao, Y; Wie, JS; Wu, JL; Xu, ZK; Yao, J | 1 |
| Bockhorn, M; Effenberger, KE; Güngör, C; Izbicki, JR; Kalinina, T; Vashist, YK; Yekebas, E; Zander, H | 1 |
| Cabarcas, SM; Farrar, WL; Hurt, EM; Jaffee, EM; Mathews, LA; Zhang, X | 1 |
| Belghiti, J; Botti, M; Boussaha, T; Dubreuil, O; Housset, M; Landi, B; Rougier, P; Taieb, J; Trouilloud, I; Williet, N | 1 |
| Aakre, JA; Aubry, MC; Croghan, GA; Cunningham, JM; Johnson, C; Li, Y; Molina, J; Pankratz, VS; Sun, Z; Wampfler, JA; Wang, L; Wu, D; Yang, P | 1 |
| Bornschein, J; Kuester, D; Mönkemüller, K | 1 |
| Cho, JH; Kim, CS; Kim, HJ; Lee, JE; Nam, HS; Ryu, JS; Shin, ES; Yi, HG | 1 |
| He, J; Yang, H; Zhao, M | 1 |
| Burlando, B; Martinotti, S; Ranzato, E | 1 |
| Aoki, D; Bartholomeusz, C; Ishihara, H; Itamochi, H; Kigawa, J; Suzuki, N; Terakawa, N; Ueno, NT; Walker, CL; Yoshida, T | 1 |
| Ardizzoni, A; Bartolotti, M; Cappuzzo, F; D'Incecco, A; Giovannetti, E; Honeywell, R; Leon, LG; Loosekoot, N; Peters, GJ; Tibaldi, C; Tiseo, M | 1 |
| Blackstock, AW; Fuchs, CS; Goldberg, RM; Hollis, D; Mamon, HJ; Mayer, RJ; Niedzwiecki, D; Tan, BR; Tepper, JE | 1 |
| Buchbinder, E; Bullock, A; Callery, M; Goldstein, M; Kent, T; Mahadevan, A; Miksad, R; Pleskow, D; Sawhney, M; Sullivan, R; Vollmer, C | 1 |
| Conversano, A; D'Abbicco, D; Epifania, BR; Indellicato, R; Margari, A | 1 |
| Favaudon, V; Fernet, M; Huguet, F; Monnier, L; Touboul, E | 1 |
| Kaneko, G; Kikuchi, E; Matsumoto, K; Miyajima, A; Nakamura, S; Obata, J; Oya, M | 1 |
| Alvero, AB; Brown, DM; Husband, AJ; Kim, KH; McKernan, R; Mor, G; Saif, MW; Thompson, JA; Tytler, EM; Wang, X; Whiting, A | 1 |
| Straus, DJ | 1 |
| Kim, S; Moore, MJ; Pithavala, YK; Ricart, AD; Rixe, O; Spano, JP | 1 |
| Anzai, N; Azuma, S; Goto, H; Ishiguro, H; Kamimura, K; Ko, SB; Mizuno, N; Yamamoto, A | 1 |
| Gou, S; Shi, P; Wang, C; Wei, H; Yang, Z; Yin, T; Zhao, G | 1 |
| Li, X; Lv, M; Ren, S; Wu, F; Xu, J; Zhang, J; Zhang, L; Zhou, C; Zhou, S | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kawakubo, K; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Togawa, O; Tsujino, T; Yagioka, H; Yamamoto, K; Yamamoto, N; Yashima, Y | 1 |
| Andrieu, JM; Bats, AS; Eme, D; Hofmann, H; Huchon, C; Le Frere-Belda, MA; Lecuru, F; Levy, E; Medioni, J; Oudard, S | 1 |
| Blasco, A; Cabrera, A; Camps, C; Carrato, A; Gil, M; Gómez-Aldaraví, L; González-Larriba, JL; Guijarro, R; Iranzo, V; Jantus, E; Massuti, B; Provencio, M; Rossell, R; Sanmartín, E; Sirera, R; Velasco, A | 1 |
| Benninger, K; Carson, WE; Chaudhury, AR; Guenterberg, K; Guttridge, DC; Jaime-Ramirez, AC; Khan, M; Kondadasula, SV; Kreiner, M; Kuppusamy, P; La Perle, KM; Lesinski, GB; Mundy-Bosse, BL; Young, G | 1 |
| Hashimoto, S; Hirai, Y; Kawago, M; Naito, K; Nakamura, R; Nishiguchi, H; Ohta, F; Okamura, Y; Oura, S; Yoshimasu, T | 1 |
| Bando, E; Kanemoto, H; Kinugasa, Y; Mizuno, T; Sugiura, T; Terashima, M; Uesaka, K | 1 |
| Choi, DW; Choi, SH; Heo, JS; Kang, WK; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, DH; Lim, HY; Park, JO; Park, K; Park, SH; Park, YS; Yi, JH | 1 |
| Bonnabry, P; Fleury-Souverain, S; Geiser, L; Hochstrasser, D; Nussbaumer, S; Sadeghipour, F; Veuthey, JL | 1 |
| Battistella, M; Sassolas, B | 1 |
| Boehlke, I; Bokemeyer, C; Hartmann, JT; Honecker, F; Kollmannsberger, C; Mayer, F; Oechsle, K; Waller, CF | 1 |
| Bi, F; Chen, Y; Cheng, K; Ge, J; Gong, FM; Li, Q; Liu, JY; Peng, XC; Qiu, M; Tan, BX; Wei, M; Wu, Y; Xu, F; Zhao, Y; Zhou, Y | 1 |
| He, X; Hu, C; Liu, T; Ou, D; Xiayun, H; Ying, H; Zhu, G | 1 |
| Chen, CY; Huang, AM; Li, JH; Liu, CH | 1 |
| Abbruzzese, JL; Crane, CH; Das, P; Fleming, JB; Haque, W; Hobbs, BD; Javle, MM; Krishnan, S; Lee, JE; Safran, H; Staerkel, GA; Varadhachary, GR; Wolff, RA; Yordy, JS | 1 |
| Hoshino, K; Ide, H; Masuda, T; Satou, A; Tasaka, Y; Uchida, Y; Yasumizu, Y | 1 |
| Curioni, A; Knuth, A; Parvanova, I; Pascolo, S; Rettig, L; Samaras, P; Seidenberg, S | 1 |
| Boku, N; Funakoshi, A; Furuse, J; Moriyasu, F; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Tanaka, K; Ueno, H; Yamao, K; Yokosuka, O | 1 |
| Bakri, K; Beaumont, JL; Bradford, DS; Crane, JM; Harper, HD; Hensing, TA; Lee, CB; McElroy, E; Moore, DT; Niell, HB; Pal, S; Peterman, AH; Schwartz, G; Socinski, MA; Stinchcombe, TE; Taylor, M | 1 |
| Cleves, A; Mason, MD; Shelley, MD; Wilt, TJ | 1 |
| de Clermont, H; Dilhuydy, MS; Gross-Goupil, M; Ravaud, A; Roubaud, G; Wallerand, H | 1 |
| Arora, S; Bhardwaj, A; McClellan, S; Singh, AP; Singh, S; Srivastava, SK; Wang, B | 1 |
| Bertetto, O; Dall'agata, M; Fumagalli, L; Galliano, M; Lissoni, P; Lopez, M; Maglie, M; Naglieri, E; Porta, C; Recchia, F; Ridolfi, L; Ridolfi, R; Santo, A; Testore, F | 1 |
| Fisher, SG; Golijanin, D; Messing, EM; Peterson, DR; Sahasrabudhe, D; Scosyrev, E; van Wijngaarden, E | 1 |
| Chan, S; Davidson, SE; Harden, S; McMahon, T; Paul, J; Rai, D; Reed, NS; Symonds, RP | 1 |
| Beck, T; Bromund, J; Brufsky, A; Frontiera, M; Hainsworth, J; Hoelzer, K; Keaton, M; Krill-Jackson, E; Kroener, J; Marciniak, MD; Middleman, E; Nadella, P; Obasaju, C; Orlando, M; Panella, T; Paul, D; Tai, F; Whorf, R; Zhao, L | 1 |
| Cortesi, E; Frati, L; Gandini, O; Gazzaniga, P; Gradilone, A; Naso, G; Nicolazzo, C; Palazzo, A; Petracca, A; Raimondi, C | 1 |
| Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W | 1 |
| Shariat, SF; Sonpavde, G | 1 |
| Bruzzone, M; Centurioni, MG; Cosso, M; Cristoforoni, P; Ferrarini, M; Giannelli, F; Giglione, P; Gualco, M; Merlo, DF; Miglietta, L | 1 |
| Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M | 1 |
| Kanetake, H; Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H | 1 |
| Handa, K; Hatogai, K; Hibi, T; Higuchi, H; Iwasaki, E; Izumiya, M; Kishino, R; Maeda, N; Mizuki, A; Mukai, K; Nakazawa, A; Seki, E; Shimoyama, Y; Takaishi, H; Takita, M; Tsukada, N | 1 |
| Deslattes Mays, A; Kim, SE; LaConti, JJ; Marshall, JL; Peran, I; Preet, A; Riegel, AT; Shivapurkar, N; Wellstein, A | 1 |
| Armstrong, DK; Bristow, RE; Diaz-Montes, TP; Giuntoli, RL | 1 |
| de Oliveira, E; Garrido-Laguna, I; Hidalgo, M; Hruban, RH; Jimeno, A; Karikari, C; Laheru, D; Maitra, A; Rajeshkumar, NV; Rubio-Viqueira, B; Salomon, A; Sharma, R; Tan, AC; Taylor, G; Uson, M; Villaroel, MC | 1 |
| Abbruzzese, JL; Budillon, A; Carbone, C; Chiao, PJ; Ling, J; Melisi, D; Moccia, T; Paradiso, G; Xia, Q | 1 |
| Chen, H; Guo, HC; Lin, SZ; Liu, HB; Liu, JX; Ni, ZL; Tan, W; Tong, HF; Wang, ZH; Wei, WT | 1 |
| Deng, AM; Liang, AB; Qu, YQ; Wang, H; Xiu, B; Zeng, HZ; Zhang, WJ | 1 |
| Arias-Pulido, H; Bocklage, T; Cerilli, LA; Eberhardt, S; Lee, SJ; Movva, S; Muller, CY; Purdy, M; Quinn, R; Rabinowitz, I; Schmit, B; Snyder, D; Verschraegen, CF | 1 |
| Androulakis, N; Boukovinas, I; Constantinides, CA; Georgoulias, V; Karampeazis, A; Kentepozidis, N; Kostakopoulos, A; Kotsakis, A; Markos, V; Mavroudis, D; Papakotoulas, P; Polyzos, A; Samonis, G; Vardakis, N; Ziras, N | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Hawkes, EA; Oates, J; Starling, N; Thomas, J; Thomas, K; Watkins, D; Webb, J | 1 |
| Funai, J; Ishii, M; Saeki, T; Takao, S; Takashima, S; Tokuda, Y | 1 |
| Beijnen, JH; Benhadji, KA; Callies, S; Garcia-Ribas, I; Jansen, RS; Koolen, SL; Kronemeijer, RH; Langenberg, MH; Nol, A; Schellens, JH; Slapak, CA; Voest, EE; Witteveen, PO | 1 |
| Abraham, R; Clarke, S; Cullen, M; Davey, R; Harvie, R; Kao, SC; Kerestes, Z; Marx, G; Paturi, F; Pavlakis, N; Taylor, R | 1 |
| Butera, JN; Mega, AE; Nadeem, A; Reagan, JL; Rosmarin, A; Schiffman, FJ; Sikov, WM; Winer, E | 1 |
| Hou, M; Li, Z; Wang, H; Wang, Z | 1 |
| Bollard, CM; Buglio, D; Derenzini, E; Illés, A; Ji, Y; Jóna, A; Khaskhely, N; Medeiros, LJ; Shafer, JA; Younes, A | 1 |
| Alvarez, H; Bannerji, R; Bisht, S; Brossart, P; Dadon, T; Feldmann, G; Fendrich, V; Garrido-Laguna, I; Hidalgo, M; Karikari, C; Maitra, A; Matsui, W; Mishra, A; Nelkin, BD; Ottenhof, NA; Rajeshkumar, NV; Rasheed, Z | 1 |
| Obeid, KM; Venugopal, AA | 1 |
| Alli, E; Ford, JM; Hartman, AR; Lin, PS; McPherson, L; Sharma, VB | 1 |
| Abelson, J; Chang, DT; Daly, ME; Koong, AC; Murphy, JD; Nelson, LM; Yeung, HN | 1 |
| Giannini, OH; González, ME; González, P; Saldaña, B | 1 |
| Chen, H; Li, H; Li, W; Lu, X; Shu, X; Tong, Q; Wang, G | 1 |
| Abele, JT; El-Mabhouh, AA; McEwan, AJ; Mercer, JR; Nation, PN; Postema, E; Riauka, T | 1 |
| Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M | 1 |
| Aerts, HJ; Bussink, J; De Ruysscher, D; Emans, D; Folgering, AM; Lambin, P; Oyen, WJ; van Elmpt, W; Velders, M | 1 |
| Chen, G; Chen, L; Feng, J; Hu, C; Huang, J; Liu, XQ; Lu, S; Luo, Y; Ma, J; Ren, S; Wang, C; Wang, J; Wu, YL; Xiu, Q; Ye, M; You, C; Zhang, L; Zhang, S; Zhang, Y; Zhi, X; Zhou, C; Zhou, S | 2 |
| Adewoye, AH; Desai, J; Johnson, J; Kotasek, D; McCoy, S; Price, T; Siu, LL; Sun, YN; Tebbutt, N; Welch, S | 1 |
| Afrin, LB; Bielawski, J; Bostick, R; Chaudhary, U; Day, TA; Garrett-Mayer, E; Gillespie, MB; Hannun, YA; O'Brien, PE; Ogretmen, B; Saddoughi, SA; Senkal, CE; Sharma, AK; Shirai, K; Simon, GR; Wilhoit, CS | 1 |
| Homma, S; Imai, K; Kimura, Y; Koido, S; Okamoto, M; Shimamura, K; Shimodaira, S; Sunamura, M; Takahashi, H; Tomoda, T; Tsukada, J; Yonemitsu, Y | 1 |
| Boidron-Celle, M; Diot, P; el Houfia, A; Gagnadoux, F; Giraudeau, B; Grimbert, D; Hureaux, J; le Pape, A; Lemarie, E; Pichon, E; Prunier, C; Valat, C; Vecellio, L | 1 |
| Chung, JB; Chung, MJ; Kim, H; Kim, KS; Park, S; Park, SW | 1 |
| Brunner, TB; Fietkau, R; Sauer, R | 1 |
| Barth, BM; Cabot, MC; Cheng, H; DiVittore, NA; Fox, TE; Fritz, JL; Heakal, Y; Jiang, Y; Kaiser, JM; Kester, M; Shanmugavelandy, SS; Staveley-O'Carroll, KF; Tagaram, HR; Tran, MA | 1 |
| Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L | 1 |
| Barraclough, H; Pavlakis, N; Standfield, L; Van Kooten, M; Weston, AR | 1 |
| Bertucci, F; Cauvin, C; Chetaille, B; Denoux, Y; Guiramand, J; Hilgers, W; Jacquemier, J; Moureau-Zabotto, L; Sarran, A | 1 |
| Cetto, GL; Cingarlini, S; Frizziero, M; Genestreti, G; Giovannini, N; Maglie, M; Molino, AM; Piciucchi, S; Sanna, S; Santo, A | 1 |
| Hanaoka, J; Ikemoto, T; Imura, S; Iwahashi, S; Mori, H; Morine, Y; Saito, Y; Shimada, M; Utsunomiya, T | 1 |
| Filatova, LV; Gershanovich, ML; Latipova, DKh; Semiglazova, TIu | 1 |
| Filatova, LV; Gershanovich, ML; Latipova, DKh; Semiglazova, TIu; Stukov, AN; Tarasenkova, AA; Vershinina, SF | 1 |
| Chen, X; Hormigo, A; Liu, A; O'Reilly, E; Pentsova, E; Rosenblum, M | 1 |
| Lowery, MA; O'Reilly, EM | 1 |
| Kamei, H; Katoh, T; Kiura, K; Shiote, Y; Suwaki, T; Takigawa, N; Umemura, S; Yamane, H; Yano, T | 1 |
| Bachellier, P; Berrevoet, F; Clavien, PA; Delpero, JR; Dufour, P; Heinrich, S; Lang, H; Laurent, S; Lesurtel, M; Moehler, M; Pestalozzi, B; Raoul, JL; Rogiers, X; Weber, A | 1 |
| Baudrin, L; Bennouna, J; Bigay-Game, L; Dansin, E; Dauba, J; Debieuvre, D; Ducoloné, A; Herman, D; Laporte, S; Lavolé, A; Lebitasy, MP; Milleron, B; Molinier, O; Moro-Sibilot, D; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Tredaniel, J; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Reckamp, KL | 1 |
| Hanna, N; Langer, C; Monberg, M; Ortuzar, W; Peng, G; Pennella, E; Scagliotti, G | 1 |
| Chiba, S; Habuchi, T; Inoue, T; Kanda, S; Kumazawa, T; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Boni, L; Caffo, O; de Marinis, F; Dondi, D; Ferraù, F; Galligioni, E; Gamucci, T; Gebbia, V; Grossi, F; Moscetti, L; Nardi, M; Riccardi, F | 1 |
| Cerullo, V; Hemminki, A; Jalonen, H; Jokinen, M; Kanerva, A; Kangasniemi, A; Kangasniemi, L; Kiviluoto, T; Koski, A; Koskinen, M; Parviainen, S; Pesonen, S; Pisto, T | 1 |
| Bhattacharyya, M; Eddouadi, A; Francis, J; Halldén, G; Lemoine, NR | 1 |
| Albers, P; Fimmers, R; Niegisch, G; Park, SI; Siener, R | 1 |
| Kato, H; Kobayashi, N; Meyer, T; Seto, K; Takei, M; Yoshinaga, K | 1 |
| Couvreur, P; Desmaële, D; Gref, R | 1 |
| Ando, M; Hasegawa, Y; Isa, S; Kawaguchi, T; Kubo, A; Nakagawa, K; Ou, SH; Shiraishi, J; Takada, M; Tsuji, T; Tsujino, K | 1 |
| Jiang, PY; Kantorowitz, D; Yanke, R | 1 |
| Choi, DH; Choi, Y; Jeon, YK; Kim, CW; Kim, MK; Kim, YH; Woo, JK | 1 |
| Baladandayuthapani, V; Fayad, LE; Jones, RJ; Neelapu, S; Orlowski, RZ; Romaguera, JE; Sharma, R; Wang, M; Yang, D | 1 |
| Fukushima, M; Furuse, K; Kawahara, M; Kubota, K; Origasa, H; Shinkai, T; Tada, H; Teramukai, S; Tokoro, A | 1 |
| Abbruzzese, JL; Carlson, PJ; Dakik, HK; Fogelman, DR; Moskovic, DJ; Qiao, W; Tamm, EP; Wolff, RA | 1 |
| Chung, WG; Cui, Z; Lansakara-P, DS; Sandoval, MA; Sloat, BR | 1 |
| Jensen, JB; Jensen, KM; Ulhøi, BP | 1 |
| Amarantidis, K; Chamalidou, E; Chelis, L; Chiotis, A; Courcoutsakis, N; Dimopoulos, P; Kakolyris, S; Prassopoulos, P; Tentes, A; Xenidis, N | 1 |
| Acholonu, S; Alousi, AM; Anderlini, P; Champlin, RE; Chancoco, C; Ciurea, S; Fanale, MA; Hosing, CM; Khouri, IF; Ledesma, C; Nieto, Y; Popat, UR; Saliba, RM; Shpall, EJ; Valverde, R; Younes, A | 1 |
| Boccardo, F; Cognetti, F; Felici, A; Gallucci, M; Giannarelli, D; Massidda, B; Muto, G; Pollera, CF; Rubagotti, A; Ruggeri, EM | 1 |
| Ando, M; Hirohata, M; Imagawa, A; Kato, H; Kawamoto, H; Matsumoto, K; Miyake, Y; Nakatsu, M; Toyokawa, T; Yamamoto, K | 1 |
| Baek, KK; Choi, YL; Jang, HL; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lim, DH; Lim, HY; Lim, T; Park, JO; Park, SH; Park, YS; Yi, JH | 1 |
| Milella, M; Sperduti, I; Vaccaro, V | 1 |
| Dosch, J; Hynes, M; Li, C; Pasca di Magliano, M; Sarkar, B; Simeone, DM; Welling, TH; Wu, JJ | 1 |
| Hotchkiss, S; Kaley, K; Penney, R; Saif, MW; Strimpakos, AS; Syrigos, KN | 1 |
| Batzler, A; Fridley, BL; Jenkins, GD; Ji, Y; Li, F; Li, L; Matimba, A; Wang, L; Weinshilboum, RM | 1 |
| Cui, Z; Digiovanni, J; Kiguchi, K; Kumar, A; Lansakara-P, DS; Rodriguez, BL; Sandoval, MA; Sloat, BR | 1 |
| Katano, M; Kiyota, A; Koya, N; Morisaki, T; Nagamatsu, I; Ogino, T; Onishi, H; Tanaka, H; Umebayashi, M | 1 |
| Cao, M; Chen, HG; Ma, CK; Ma, J; Xue, W | 1 |
| Chen, ZW; Cheng, BJ; Jian, H; Lu, S; Xu, YH; Ye, XY; Zhou, Z | 1 |
| Boylan, JF; Deng, X; Ewton, DZ; Friedman, EA; Hoffman, AF; Hu, J; Luk, KC; Polonskaia, A; Vilenchik, M; Zipf, K | 1 |
| Lagerstedt, E; Mäenpää, J; Seppänen, J; Staff, S | 1 |
| Chen, L; Dong, J; Du, Y; Gong, W; Jin, H; Li, L; Lv, Y; Sun, J; Wei, X; Wu, J; Zhang, X | 1 |
| Borut, K; Lijana, ZK | 1 |
| Ball, D; Burmeister, BH; Burmeister, E; Cox, S; Forouzesh, B; Horwood, K; Lehman, M; Michael, M; Sasso, G; Wirth, A | 1 |
| Bepler, G; Chen, Z; Zhang, Y; Zhou, J | 1 |
| Milleron, B; Quoix, E; Westeel, V; Zalcman, G | 1 |
| Dollinger, MM; Endlicher, E; Fuchs, M; Harder, J; Hartmann, A; Hollerbach, S; Kullmann, F; Kutscheidt, A; Messmann, H; Stöhr, R; Trojan, J; Troppmann, M | 1 |
| Chan, HL; Chen, JY; Chen, YH; Chen, YW; Chou, HC; Fan, CY; Huang, PC; Huang, SH; Kuo, CC; Law, CH; Li, JM; Lin, ST; Liu, JY; Lu, YC; Lyu, PC; Wu, CL; Wu, JY | 1 |
| Bechstein, WO; Bodoky, G; Cwiertka, K; Fischbach, W; Fölsch, UR; Haas, SL; Jäger, D; Löhr, JM; Lutz, MP; Osinsky, D; Prausova, J; Schmidt, WE | 1 |
| Ko, AH | 2 |
| Burris, HA; Ervin, TJ; Greco, FA; Hainsworth, JD; Kohler, PC; Lubiner, ET; Peyton, JD; Shipley, DL; Spigel, DR; Waterhouse, DM | 1 |
| Baba, S; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Minamida, S; Satoh, T; Tabata, K | 1 |
| Omueti-Ayoade, K; Yang, M; Zemtsov, A; Zemtsov, R | 1 |
| Horai, T; Ikeda, N; Imamura, F; Inoue, A; Kimura, Y; Nishino, K; Nishio, M; Noro, R; Ohsaki, Y; Tsuboi, M; Uchida, J | 1 |
| Akaike, M; Kameda, Y; Mikayama, H; Miyagi, Y; Morinaga, S; Nakamura, Y; Ohkawa, S; Shiozawa, M; Tamagawa, H; Watanabe, T; Yamamoto, N | 1 |
| Böll, B; Borchmann, P; Bredenfeld, H; Eich, HT; Eichenauer, DA; Engert, A; Fuchs, M; Geissler, M; Görgen, H; Graeven, U; Halbsguth, T; Keller, U; Kremers, S; Markova, J; Soekler, M; Trenn, G; von Tresckow, B | 1 |
| Hirata, T; Kobashikawa, K; Nakamura, M; Uchima, N | 1 |
| Cerny, T; De Dosso, S; Koeberle, D; Renggli, V; Saletti, P; Sessa, C | 1 |
| Abe, Y; Aoki, T; Itoi, T; Kasuya, K; Nagakawa, Y; Nagao, T; Serizawa, H; Shimazu, M; Suzuki, M; Tsuchida, A | 1 |
| Albain, KS; Donaldson, GW; Liepa, AM; Melemed, AS; Moinpour, CM; O'Shaughnessy, J | 1 |
| Gao, Y; Lv, Y; Xie, X; Yu, F; Yu, P; Zhang, Q; Zhang, S; Zheng, Y | 1 |
| Funamizu, N; Kamata, Y; Lacy, CR; Manome, Y; Misawa, T; Uwagawa, T; Yanaga, K | 1 |
| Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Sato, T; Sato, Y; Sonoda, T; Takimoto, R; Yoshida, M | 1 |
| Culine, S; Demery, ME; Pouessel, D; Thézenas, S | 1 |
| Barlesi, F; Bota, S; Chouaid, C; Corre, R; Delhoume, JY; Dujon, C; Falchero, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Aggarwal, BB; Deorukhkar, A; Dey, S; Diagaradjane, P; Gelovani, JG; Guha, S; Koca, C; Krishnan, S; Kunnumakkara, AB; Ravindran, J; Sung, B; Tong, Z | 1 |
| Ardavanis, A; Boukovinas, I; Georgoulias, V; Malamos, N; Mavroudis, D; Pallis, AG; Varthalitis, I | 1 |
| Ahmed, M; Brahmbhatt, K; Hussain, A; Priyani, A; Rizvi, TA; Sharma, C | 1 |
| Dreyer, C; Hammel, P; Hentic, O; Lévy, P; Raymond, E; Rebours, V; Ruszniewski, P; Zappa, M | 1 |
| Byun, SS; Hong, SK; Jeon, HG; Jeong, SJ; Lee, JE; Lee, SE; Park, MJ; Yoon, CY; Yu, JH | 1 |
| Adachi, S; Itani, M; Kawaguchi, J; Kozawa, O; Moriwaki, H; Nakamura, M; Nakashima, M; Yamauchi, T; Yasuda, I; Yoshioka, T | 1 |
| Beger, C; Buurman, R; Focken, T; Heyn, H; Schlegelberger, B; Schreek, S | 1 |
| Brody, JR; Witkiewicz, AK; Yeo, CJ | 1 |
| Cui, L; Fujita, H; Kozono, S; Maeyama, R; Mizumoto, K; Ohuchida, K; Tanaka, M; Toma, H; Tominaga, Y; Zhao, M | 1 |
| Cetina, L; Coronel, J; Dueñas-Gonzalez, A | 1 |
| Ahn, JH; Lee, EM; Lee, J; Park, KH; Rha, SY | 1 |
| Chen, CP; Jablons, DM; Jahan, TM; Weinberg, VK; Yom, SS | 1 |
| Christenson, R; Edelman, MJ; Hodgson, L; Jewell, S; Kratzke, R; Vokes, E; Wang, X | 1 |
| Lyn-Cook, BD; Wang, H; Word, BR | 1 |
| Lorenz, J; Mössner, J; Thrum, S; Wiedmann, M | 1 |
| Alberts, SR; Benson, AB; Brell, JM; Cardenes, H; Cella, D; Crane, CH; Feng, Y; Flynn, P; Loehrer, PJ; Ramanathan, RK; Wagner, L | 1 |
| Borad, MJ; Desai, N; Hidalgo, M; Iglesias, JL; Korn, RL; Laheru, DA; Maitra, A; Rajeshkumar, NV; Ramanathan, RK; Shi, T; Smith, LS; Soon-Shiong, P; Trieu, V; Von Hoff, DD; Wood, TE; Zhang, H | 1 |
| Francois, RA; Husain, K; Malafa, MP; Perez, M; Sebti, SM; Yamauchi, T | 1 |
| Murakami, Y; Sudo, T; Uemura, K | 1 |
| Kosuge, T | 1 |
| Azizi, A; Emami, AH; Farshid, P; Mbalisike, E; Naguib, NN; Vogl, TJ | 1 |
| Bryant, A; Gaitskell, K; Haldar, K; Kehoe, S; Morrison, J; Nicum, S | 1 |
| Bechstein, WO; Gruber-Rouh, T; Naguib, NN; Nour-Eldin, NE; Trojan, J; Vogl, TJ; Zeuzem, S | 1 |
| Burkholder, TL; Chen, MD; Gill, JF; Gordon, AN; Hines, J; Homesley, HD; Janicek, MF; Lim, PC; McMeekin, S; Obasaju, CK; Orlando, M; Tai, DF; Teneriello, M; Vaccarello, L; Wang, Y; Zhao, L | 1 |
| Bu, HJ; Chen, Y; Liu, QH; Ni, CY; Yu, DH; Zhang, J; Zhao, CY; Zhu, MH | 1 |
| Chen, J; Gu, YM; Ma, YH; Zhao, WG | 1 |
| Bae, I; Duong, HQ; Kang, HJ; Kim, HJ; Seong, YS | 1 |
| Adachi, S; Hirose, Y; Itani, M; Kawaguchi, J; Kozawa, O; Matsushima-Nishiwaki, R; Moriwaki, H; Nakashima, M; Yamauchi, T; Yasuda, I; Yoshioka, T | 1 |
| Adema, AD; Honeywell, RJ; Losekoot, N; Myhren, F; Peters, GJ; Sandvold, ML; Smid, K; Verheul, HM | 1 |
| Chikaraishi, T; Kimura, K; Kudo, H; Miyano, S; Nakazawa, R; Sasaki, H | 1 |
| Assmann, G; Bader, DC; Bruns, C; Buchner, D; De Toni, EN; Gallmeier, E; Göke, B; Guo, Y; Jung, A; Kirchner, T; Laubender, RP; Ochs, S; Palagyi, A; Schäfer, C; Seeliger, H; Ziesch, A | 1 |
| Ito, H; Kawahara, T; Kubota, Y; Makiyama, K; Oshiro, H; Sekiguchi, Z; Uemura, H | 1 |
| Jung, SY; Kang, HS; Kim, SW; Ko, K; Kwon, Y; Lee, KS; Lee, S; Nam, BH; Park, IH; Ro, J; Shin, KH | 1 |
| Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Werner, J | 1 |
| Adjei, AA; Cutler, DL; Hurwitz, HI; Kaufmann, SH; Meadows, KL; Meyers, ML; Morse, MA; Petros, WP; Rosen, LS; Statkevich, P; Wong, NS; Zhu, Y | 1 |
| Ahn, H; Ahn, JH; Ahn, S; Hong, JH; Kim, CS; Kwon, JH; Lee, JL; Lim, HY; Park, SH; Song, C | 1 |
| Andriulli, A; Bassi, C; Botteri, E; Festa, V; Koch, M; Maisonneuve, P; Sebastiano, PD; Valvano, MR | 1 |
| Acunzo, J; Andrieu, C; Baylot, V; Garcia, S; Garrido, C; Giusiano, S; Gleave, M; Iovanna, J; Katsogiannou, M; Rocchi, P; Taieb, D | 1 |
| Ohlmann, CH; Stöckle, M | 1 |
| Hirokawa, N; Ito, Y; Karasawa, K; Kokubo, M; Nemoto, K; Nishimura, Y; Ogawa, K; Ogo, E; Onishi, H; Saito, T; Shibuya, H; Shibuya, K | 1 |
| Acres, B; Bastien, B; Bizouarne, N; Bonnefoy, JY; Braun, D; Breton, JL; Buyse, M; Chenard, MP; Debieuvre, D; Koralewski, P; Lacoste, G; Lena, H; Limacher, JM; Madroszyk, A; Papai, Z; Quoix, E; Ramlau, R; Riviere, A; Stoelben, E; Tavernaro, A; Westeel, V | 1 |
| Awasthi, N; Schwarz, MA; Schwarz, RE; Yen, PL | 1 |
| Allen, JN; Arvold, ND; Blaszkowsky, LS; Clark, JW; Fernandez-Del Castillo, C; Hong, TS; Kwak, EL; Niemierko, A; Ryan, DP; Wadlow, RC; Wo, JY; Zhu, AX | 1 |
| Koga, H; Sata, M; Selvendiran, K; Sivakumar, R; Torimura, T; Ueno, T; Yoshida, T | 1 |
| Dovzhanskiy, DI; Felix, K; Giese, NA; Krysko, DV; Welsch, L; Welsch, T; Werner, J | 1 |
| Ikegami, A; Imawari, M; Inoue, K; Katsumoto, E; Kiuchi, Y; Kogo, M; Kurihara, T; Shimada, K; Yoneyama, K; Yoshikumi, H | 1 |
| Cheng, AL; Hsu, C; Hsu, CH; Kuo, SH; Kuo, YH; Tien, YW; Yang, SH | 1 |
| Debeljak, A; Kovac, V; Marin, A; Rajer, M; Smrdel, U; Vrankar, M; Zwitter, M | 1 |
| Aftab, BT; Campbell, NR; Chenna, V; Hong, SM; Hu, C; Karikari, C; Khan, SR; Maitra, A; Pramanik, D; Rudek, MA; Rudin, CM; Zhao, M | 1 |
| Brostjan, C; Brugger, P; Gnant, M; Kuehrer, I; Reiter, C; Schauer, D; Schoppmann, SF; Sommerfeldt, S; Starlinger, P; Tamandl, D | 1 |
| Chen, G; Chen, SP; Kang, T; Liang, Y; Zhang, GN; Zhang, TP; Zhao, YP; Zhou, LJ | 1 |
| Barbera, S; Barletta, E; Ceribelli, A; De Maio, E; Di Maio, M; Favaretto, A; Filipazzi, V; Gallo, C; Gamucci, T; Gridelli, C; Iaffaioli, RV; Isa, L; Maione, P; Morabito, A; Perrone, F; Piccirillo, MC; Rocco, G; Rossi, A; Signoriello, S; Vecchione, A | 1 |
| Baas, P; Bard, MP; Beijnen, JH; Burgers, SA; Doodeman, VD; Haitjema, TJ; Huitema, AD; Joerger, M; Schellens, JH; Smit, EF; Smits, PH; Vincent, A | 1 |
| Movva, S; Verschraegen, C | 1 |
| Balasubramaniam, A; Cho, J; Kennedy, MA; Lewis, KB; Sheriff, S; Tinch, SL; Watanabe, M | 1 |
| Aizawa, K; Fukunaga, E; Hamada, A; Iwata, K; Jingami, S; Saito, H; Sakai, S; Yoshida, M | 1 |
| Ishigaki, Y; Kawakami, K; Kitano, A; Minamoto, T; Motoo, Y; Nakajima, H; Nakamura, Y; Nakaya, N; Sato, I; Shimasaki, T; Takata, T; Takegami, T; Tanaka, T; Tomosugi, N; Zhao, X | 1 |
| Choi, DW; Choi, SH; Heo, JS; Jang, KT; Kim, EJ; Kim, JO; Lee, EM; Lee, JK; Lee, KH; Lee, KT; Min, SY; Park, YG | 1 |
| Camoriano, JK; Colon-Otero, G; Erlichman, C; Glaser, G; Haluska, P; Hendrickson, AE; Ivy, SP; Karnitz, LM; Kaufmann, SH; Oberg, AL; Peethambaram, PP | 1 |
| Brekken, RA; Gazdar, AF; Girard, L; Greer, RM; Harran, P; Larsen, JE; Minna, JD; Peyton, M; Wang, L; Wang, X; Xie, Y | 1 |
| Baldelli, E; Chiari, R; Crinò, L; Flacco, A; Floriani, I; Garavaglia, D; Ludovini, V; Meacci, M; Minotti, V; Pistola, L; Siggillino, A; Tofanetti, FR; Tonato, M | 1 |
| Abbruzzese, A; Altieri, V; Buonerba, C; Caraglia, M; Di Lorenzo, G; Facchini, G; Ferro, M; Giuberti, G; Perdonà, S; Porto, S; Sperlongano, P; Zappavigna, S | 1 |
| Dudek, AZ; Liu, SV; Ramanathan, RK; Truskinovsky, AM | 1 |
| Fukunaga, K; Hirata, Y; Iida, H; Kakuno, A; Morita, M; Murata, S; Nishigami, T; Tamura, M; Tani, S; Yamanaka, N | 1 |
| Bahleda, R; Bosq, J; Hartl, DM; Hollebecque, A; Massard, C; Soria, JC | 1 |
| Celli, JP; Hasan, T; Liang, A; Pereira, SP; Solban, N | 1 |
| Belfiglio, M; Cioffi, P; Grappasonni, I; Laudadio, L; Nuzzo, A; Petrelli, F | 1 |
| Abbruzzese, J; Abdalla, EK; Balachandran, A; Bhosale, P; Charnsangavej, C; Chopin-Laly, X; Crane, CH; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Varadhachary, G; Vauthey, JN; Wang, H; Wang, X; Wolff, R | 1 |
| Aggarwal, BB; Park, B; Prasad, S; Sung, B; Yadav, V | 1 |
| Kreitman, RJ; Pastan, I; Singh, R; Zhang, Y | 1 |
| Hamada, T; Isaji, S; Kishiwada, M; Mizuno, S; Ohsawa, I; Sakurai, H; Tabata, M; Usui, M | 1 |
| Kotek, A; Parlak, C; Pehlivan, B; Topkan, E; Yapar, AF | 1 |
| Bahra, M; Boas-Knoop, S; Esendik, U; Hartmann, W; Heppner, F; Kamphues, C; Koch, A; Lippert, S; Neuhaus, P; Pietsch, T; Schüller, U; Waha, A | 1 |
| Han, S; Hu, G; Jiang, Z; Li, F; Ouyang, K; Qin, X; Tang, X; Wang, K; Wen, D; Xie, F; Zhang, L; Zhu, M | 1 |
| Brodsky, EM; Elpiner, AK; Hazzah, TN; Post, GS | 1 |
| Celia, C; Cosco, D; Fresta, M; Paolino, D | 1 |
| Eichler, K; Gruber-Rouh, T; Lehnert, T; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S | 1 |
| Dees, EC | 1 |
| Andersson, M; Bjerre, KD; Cold, S; Jakobsen, EH; Jørgensen, CL; Kamby, C; Møller, S; Nielsen, DL; Stenbygaard, L; Sørensen, PG | 1 |
| Abdelraheem, AG; Ali, EM | 1 |
| Altieri, V; Bono, AV; Brausi, MA; Colombo, R; Conti, I; Gontero, P | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
| Ahmad, A; Ali, S; Azmi, AS; Banerjee, S; Bao, B; Kong, D; Li, Y; Sarkar, FH; Sarkar, SH; Thakur, S; Wang, Z | 1 |
| Black, ME; Brown, MN; Johnson, AJ | 1 |
| Casale, F; Cilurzo, F; Cosco, D; Fresta, M; Paolino, D | 1 |
| Colucci, G; D'Amico, C; Di Lauro, L; Giannarelli, D; Giotta, F; Latorre, A; Mariani, L; Pizzuti, L; Sergi, D; Vici, P; Vizza, E | 1 |
| Ahn, JH; Ahn, JS; Ha, SW; Im, SA; Im, YH; Kang, HS; Kim, JH; Kim, SB; Kwon, Y; Lee, ES; Lee, KS; Noh, DY; Park, IA; Ro, J; Shin, KH | 1 |
| Huang, J; Margolis, J; Nadeau, L; Robertson, JM; Yan, D; Ye, H | 1 |
| Bozas, G; Ettelaie, C; Fyfe, D; Gardiner, E; Lofts, F; Maraveyas, A; Propper, D; Roy, R; Sgouros, J; Waters, J; Wedgwood, K | 1 |
| Brundage, RC; Hull, JM; Khatri, A; Kirstein, MN; Williams, BW; Yee, D | 1 |
| Chougule, MB; Jackson, T; Patel, A; Sachdeva, P; Singh, M | 1 |
| Alkis, N; Benekli, M; Berk, V; Bilici, A; Colak, D; Coskun, U; Dane, F; Dikilitas, M; Gumus, M; Kaplan, MA; Ozdemir, NY; Ozkan, M | 1 |
| Archer, L; Basch, E; Kindler, HL; Niedzwiecki, D; Romanus, D; Schrag, D; Weeks, J | 1 |
| Barlett, B; Dalgleish, AG; Fryer, RA; Galustian, C | 1 |
| Anai, H; Hasegawa, M; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T | 1 |
| Ambrosone, CB; Armstrong, DK; Bookman, MA; Darcy, KM; Davis, W; DeLoia, JA; Gallion, H; Krivak, TC; Moysich, K; Tian, C; Zhao, H | 1 |
| Aragno, M; Canuto, RA; Catalano, MG; Fadda, M; Finocchiaro, C; Fortunati, N; Maggiora, M; Monge, T; Muzio, G; Oraldi, M; Pugliese, M; Schena, M; Scigliano, M; Segre, O; Tinivella, M; Tiozzo, E | 1 |
| Monberg, MJ; Obasaju, CK; Peng, G; Scagliotti, GV; Socinski, MA; Treat, J | 1 |
| Bartucci, M; Biffoni, M; Dattilo, R; De Maria, R; Duranti, E; Eramo, A; Lotti, F; Martinelli, S; Maugeri-Saccà, M; Navarra, S; Patrizii, M; Pilozzi, E; Rinaldo, C; Romania, P; Signore, M; Svensson, S; Zeuner, A | 1 |
| Chen, F; Liu, Y; Sun, Y; Wu, X | 1 |
| Asmis, TR; Hilton, JF; Jonker, DJ; Moore, MJ; O'Callaghan, CJ; Parulekar, W; Powell, ED; Tu, D; Vickers, MM | 1 |
| Furuse, J; Ikeda, M; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Shinichi, O; Suzuki, E; Ueno, H; Ueno, M; Yamaguchi, T | 1 |
| Adachi, M; Hirose, T; Ishida, K; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Ohnishi, T; Oki, Y; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Doki, Y; Eguchi, H; Gotoh, K; Ishikawa, O; Nagata, S; Ohigashi, H; Takahashi, H; Tomita, Y; Yamada, T; Yano, M | 1 |
| Facciolo, F; Hetzel, M; Leschinger, M; Maiorino, L; Orlowski, TM; Pastorino, U; Scagliotti, GV; Spaggiari, L; Torri, V; Vansteenkiste, JF; Visseren-Grul, C | 1 |
| Costantini, C; Millard, F | 1 |
| Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH | 1 |
| Fritzer-Szekeres, M; Golakoti, T; Graser, G; Jaeger, W; Krupitza, G; Madlener, S; Saiko, P; Schwarz, S; Somepalli, V; Szekeres, T | 1 |
| Giovannetti, E; Honeywell, RJ; Peters, GJ | 1 |
| Adema, AD; Calvo, BD; Diosdado, B; Giovannetti, E; Hodzic, J; Peters, GJ | 1 |
| Conroy, T; Mitry, E | 1 |
| Dodič-Fikfak, M; Dolžan, V; Erčulj, N; Franko, A; Hmeljak, J; Kovač, V | 2 |
| Ackland, SP; Borg, M; Brown, C; Bydder, S; Carroll, S; Cummins, MM; Gebski, VJ; Goldstein, D; Harvey, J; Horvath, L; Hruby, G; Porter, IW; Selva-Nayagam, S; Shapiro, J; Spry, N; Underhill, C; van Hazel, GA; Wratten, C | 1 |
| Borbath, I; Gigot, JF; Humblet, Y; Lai, R; Piessevaux, H; Sempoux, C; Verbrugghe, L | 1 |
| Asagi, A; Hori, S; Iguchi, H; Ikeda, Y; Kajiwara, T; Matsumoto, T; Nadano, S; Nishina, T; Takeji, S | 1 |
| Cox, NL; Evans, P; Friedman, P; Giacomini, KM; Glubb, D; Goldberg, RM; Hollis, D; Hurwitz, H; Innocenti, F; Jiang, C; Kindler, HL; Kubo, M; Li, L; McLeod, HL; Mushiroda, T; Nakamura, Y; Owzar, K; Ratain, MJ; Schilsky, RL; Wang, L; Zembutsu, H | 1 |
| Apetoh, L; Ghiringhelli, F; Martin, F | 1 |
| Abraham, R; Broad, A; Burns, I; Clarke, S; Diiulio, J; Galettis, P; Links, M; Milner, A; Mitchell, PL; Rosenthal, MA | 1 |
| Arazi, L; Bittan, H; Cooks, T; Efrati, M; Horev-Drori, G; Keisari, Y; Kelson, I; Lazarov, E; Schmidt, M | 1 |
| Asahina, D; Esaki, M; Hiraoka, N; Kondo, T; Kosuge, T; Morofuji, N; Nagino, M; Nara, S; Ojima, H; Okusaka, T; Onaya, H; Sakamoto, Y; Shimada, K; Ushigome, M | 1 |
| Aranda, E; Arrivi, A; Díaz-Rubio, E; Galán, M; Irigoyen, A; Manzano, JL; Mendez, MJ; Pericay, C; Rivera, F; Safont, MJ; Sastre, J; Valladares-Ayerbes, M | 1 |
| Gocho, T; Hirohara, S; Ito, R; Misawa, T; Sadaoka, S; Tsutsui, N; Uwagawa, T; Yanaga, K | 1 |
| Baker, JH; Kyle, AH; Minchinton, AI | 1 |
| Bu, H; Chen, H; Guo, HC; Li, H; Lin, SZ; Liu, DL; Liu, HB; Ni, ZL; Tong, HF; Wang, ZH | 1 |
| Enomoto, T; Fujita, M; Kimura, T; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Inoue, K; Kamata, M; Kitade, H; Kwon, AH; Matsui, Y; Ohe, C; Sakaida, N; Satoi, S; Tanigawa, N; Toyokawa, H; Uemura, Y; Yamamoto, T; Yanagimoto, H | 1 |
| Chen, Y; Kong, D; Liu, R; Wang, G; Xu, Y; Yang, K; Zhang, Z; Zhao, W | 1 |
| Bellmunt, J; Collette, S; Daugaard, G; De Santis, M; de Wit, R; Gil, T; Kerst, JM; Leahy, M; Lorent, J; Maroto, P; Marreaud, S; Mead, G; Skoneczna, I; Sylvester, R | 1 |
| Lee, M; Yee, NS; Yee, RK; Zhou, W | 1 |
| Aydemir, I; Inan, S; Ozbilgin, K; Uluer, ET; Vatansever, HS | 1 |
| Bjerregaard, JK; Jensen, HA; Mortensen, MB; Nielsen, M; Pfeiffer, P | 1 |
| Abo, RP; Batzler, A; Eckloff, BW; Fridley, BL; Jenkins, GD; Kalari, KR; Li, L; Moon, I; Pelleymounter, L; Schaid, DJ; Sun, Z; Wang, L; Wieben, ED; Yang, P | 1 |
| Li, B; Song, K; Sun, WJ | 1 |
| Bauknecht, T; Benhadji, KA; Davidson, N; Gümüş, M; Soldatenkova, V | 1 |
| Moran, SL; Peethambaram, PP; Reynolds, C; Shon, W; Swapp, RE | 1 |
| Besançon, OG; Caron, HN; Hoebink, J; Jaehde, U; Kalayda, GV; Leen, R; Meinsma, R; Tytgat, GA; van Kuilenburg, AB | 1 |
| Jiang, G; Li, J; Li, X; Li, Y; Liu, J; Wang, J; Yang, F; Zhao, H | 1 |
| Cesta, C; Dantzig, AH; Foster, FS; Francia, G; Hackl, C; Hashimoto, K; Kerbel, RS; Man, S; Shaked, Y; Stewart, J; Sun, J; Uhlik, M; Xu, P; Yin, M | 1 |
| Lau, PC; Ng, WT; Yu, SC; Zheng, SF | 1 |
| Ishii, M; Kitagawa, N; Maeda, K; Nagaoka, S; Okubo, S; Taketsuna, M; Takeuchi, K; Tatsumi, M | 1 |
| Orlova, RV; Protasova, AE | 1 |
| Fukuta, F; Kunishima, Y; Kyoda, Y | 1 |
| Jensen, LH | 1 |
| Chang, HM; Chang, JS; Choi, HJ; Jang, JS; Jeung, HC; Kang, HJ; Kang, JH; Kang, WK; Kim, JS; Lee, HW; Lee, J; Lee, MA; Lim, HY; Park, JO; Park, SH; Park, YS; Shin, DB; Sun, JM | 1 |
| Ahn, JJ; Baek, JH; Cha, HJ; Jegal, Y; Jung, JP; Kim, H; Kim, JW; Kwon, WJ; Lee, YJ; Min, YJ; Noh, YJ; Oh, S; Park, CR; Park, JH; Ra, SW; Seo, KW | 1 |
| Badalato, GM; Benson, MC; Hruby, G; McKiernan, JM; Petrylak, DP; RoyChoudhury, A; Wosnitzer, MS; Yeshchina, O | 1 |
| Abelson, JA; Chang, DT; Chung, M; Fisher, GA; Ford, JM; Koong, AC; Kunz, P; Minn, AY; Murphy, JD; Norton, JA; Poultsides, GA; Visser, BC | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HP; Kim, TY; Min, AR; Nam, HJ; Oh, DY; Song, SH; Yoon, YK | 1 |
| Cormier, Y; Gitlitz, B; Gleave, ME; Hao, D; Laskin, JJ; Lee, C; Murray, N; Nemunaitis, J; Nicholas, G; Nugent, F; Pressnail, B; Sanborn, R; Stephenson, J; Ung, Y; Vincent, M | 1 |
| Hashimoto, Y; Hatakeyama, S; Imanishi, K; Kamimura, N; Koie, T; Ohyama, C; Okamoto, A; Okamoto, T; Tokui, N; Yoneyama, T | 1 |
| Matsuo, T; Miyata, Y; Ohba, K; Sagara, Y; Sakai, H; Takahashi, H; Watanabe, S | 1 |
| Chen, LH; Ding, Y; Guan, J; Ling, ZH; Sun, QQ; Zhang, YW | 1 |
| Funakoshi, A; Ikeda, N; Kawanami, T; Takiguchi, S | 1 |
| Ge, Y; Guo, Y; Qi, W; Wang, G; Xie, C; Xu, X; Zhang, A | 1 |
| Akashi, M; Akasu, G; Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kawashima, Y; Kinoshita, H; Kitazato, Y; Mikagi, K; Nogita, H; Okabe, Y; Shirouzu, K | 1 |
| Aoyagi, H; Hasegawa, K; Iwata, N; Kaneko, J; Katsuta, E; Maejima, S; Takahata, T; Yoshida, T | 2 |
| Akashi, M; Akasu, G; Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kawashima, Y; Kinoshita, H; Kitasato, Y; Mikagi, K; Nogita, H; Shirouzu, K | 1 |
| Akasu, G; Hisaka, T; Horiuchi, H; Ishikawa, H; Kawahara, R; Kinoshita, H; Kitasato, Y; Mikagi, K; Nakayama, M; Okabe, Y; Yasunaga, M; Yoshitomi, M | 1 |
| Kikuchi, I; Kurosumi, M; Nishida, K; Nishimura, Y; Sakai, H; Sakamoto, H; Tanaka, Y; Yatsuoka, T | 1 |
| Baba, H; Goseki, N; Kuwabara, H; Nakajima, K; Nakamura, H; Sanada, T; Wakabayashi, M | 1 |
| Hasegawa, Y; Ikeda, M; Ito, N; Matsuo, T; Nishizuka, S; Nitta, H; Sugitachi, A; Takahara, T; Takahashi, M; Wakabayashi, G | 1 |
| Danno, K; Imaoka, S; Inadome, J; Kagara, N; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakamura, H; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Watanabe, A | 1 |
| Doki, Y; Eguchi, H; Iwagami, Y; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H | 1 |
| Akagi, K; Dono, K; Fujita, J; Hata, T; Ikeda, K; Iwazawa, T; Kawanishi, K; Kitada, M; Miyake, M; Nagai, K; Shimano, T; Shimizu, J | 1 |
| Chung, I; Eastman, A; Garner, KM; Montano, R; Parry, D | 1 |
| Duvic, M; Falchook, GS; Hong, DS; Kurzrock, R; Lim, J; Naing, A; Wheler, J | 1 |
| Hasegawa, Y; Itou, N; Nishizuka, S; Nitta, H; Takahara, T; Takahashi, M; Wakabayashi, G | 1 |
| Ben-Josef, E; Desai, S; Feng, FY; Francis, IR; Griffith, KA; Hunter, KU; Lawrence, TS; Murphy, JD; Zalupski, MM | 1 |
| Fujimoto-Ouchi, K; Iwai, T; Mori, K; Moriya, Y; Shirane, M | 1 |
| Altevogt, P; Dieckmann, C; Kiefel, H; Korniienko, O; Krüger, A; Moldenhauer, G; Salnikov, A; Schäfer, H; Sebens, S | 1 |
| Chen, H; Guo, HC; Lin, SZ; Liu, DL; Liu, HB; Ni, ZL; Tong, HF; Wang, ZH; Wei, WT | 1 |
| Ben-Ami, T; Gosiengfiao, Y; Reichek, J; Walterhouse, D; Woodman, J | 1 |
| Bordeleau, L; Kim, S; Seki, J; Sridhar, S; Tannock, I | 1 |
| Carlson, H; Lenzi, R; Raber, MN; Varadhachary, GR | 1 |
| Camp, ER; Cole, DJ; Little, EC; Wang, C; Watson, DK; Watson, PM | 1 |
| Li, S; Liu, J; McFadden, G; Mona, M; Rahman, MM; Wennier, ST | 1 |
| Blenc, AM; Boxwala, I; Chisti, MM; Jaiyesimi, I; Micale, MA; Muslimani, A | 1 |
| Fan, Y; Huang, Z; Lin, N; Luo, L; Miao, L; Yu, H | 1 |
| Aprile, G; Balzano, G; Cereda, S; Di Carlo, V; Di Muzio, N; Fugazza, C; Magli, A; Milandri, C; Passoni, P; Reni, M; Rognone, A; Saletti, P; Tronconi, MC; Villa, E; Zerbi, A | 1 |
| Ajiki, T; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Nagano, H; Sakai, D | 1 |
| Ardizzoni, A; Bagnulo, A; Baldini, E; Barone, C; Boni, C; Boni, L; Cafferata, MA; Caroti, C; Di Costanzo, F; Germano, D; Grossi, F; Labianca, R; Marini, G; Matano, E; Mencoboni, M; Pennucci, C; Prochilo, T; Recchia, F; Tiseo, M; Zanelli, F | 1 |
| Aoki, H; Arata, T; Fujiwara, Y; Kanazawa, T; Morihiro, T; Nakagawa, H; Ohara, T; Seita, M; Takehara, K; Takeuchi, H; Tanakaya, K | 1 |
| Iizawa, H; Kakizaki, Y; Motoi, F; Okada, T; Sakurai, N; Tamura, G; Unno, M; Yamamoto, K | 1 |
| Abhari, BA; Cristofanon, S; Debatin, KM; Deshayes, K; Fulda, S; Stadel, D; Vucic, D; Zobel, K | 1 |
| Ausseil, F; Cordelier, P; Dedieu, L; Ducommun, B; Dufau, I; Frongia, C; Sicard, F; Valette, A | 1 |
| Bourhis, J; Casagrande, AS; Chargari, C; Clémenson, C; Désiré, L; Deutsch, E | 1 |
| Egawa, N; Hanada, K; Hijioka, S; Hirose, Y; Ikari, T; Ikeda, T; Ishii, H; Itoi, T; Kimura, Y; Maetani, I; Matsumura, Y; Mouri, H; Nakajima, T; Ohoka, S; Okabe, Y; Omuro, Y; Ozaka, M; Sofuni, A; Suyama, M; Tani, M; Watanabe, R | 1 |
| Cerqueira, NM; Fernandes, PA; Gesto, DS; Ramos, MJ | 1 |
| Chang, YJ; Hung, CS; Kuo, LJ; Li, LT; Liew, PL; Lin, FY; Lin, SF; Liu, DZ; Liu, HH; Su, HY; Wei, PL | 1 |
| Abdalla, EK; Balachandran, A; Crane, CH; Fleming, JB; Fogelman, DR; Katz, MH; Lee, JE; Pisters, PW; Tzeng, CW; Varadhachary, GR; Vauthey, JN; Wolff, RA; Xiao, L | 1 |
| Clouser, CL; Greggs, WM; Mansky, LM; Patterson, SE | 1 |
| Cleves, A; Jones, G; Kynaston, HG; Mason, M; Shelley, M; Wilt, TJ | 1 |
| Blum, HE; Breidert, M; Euringer, W; Fischer, R; Harder, J; Kuhlmann, JB; Spangenberg, HC | 1 |
| Konishi, M | 1 |
| Lai, J; Li, H; Liang, C; Liu, B; Shen, C; Shi, Z; Tao, HM | 1 |
| de Ávila Lucas, AI; Domingo, E; Grande-Pérez, A; Gutiérrez-Rivas, M; López-Galíndez, C; Lorenzo-Redondo, R; Olivares, I; Sánchez-Jiménez, C; Toledano, V | 1 |
| Engels, KS; Farshid, P; Gruber-Rouh, T; Lehnert, T; Naguib, NN; Nour-Eldin, NE; Vogl, TJ | 1 |
| Hahn, EG; Kalden, JR; Meister, S; Ocker, M; Voll, R; Wissniowski, TT | 1 |
| Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
| Pan, SH; Sun, B; Wang, SJ; Wang, YW; Zhou, YN | 1 |
| Briggs, JE; Clouser, CL; Crankshaw, DL; Holtz, CM; Mansky, LM; Mullett, M; O'Sullivan, MG; Patterson, SE | 1 |
| Bazzan, AJ; Deshmukh, S; Levine, M; Littman, S; Mitchell, E; Monti, DA; Newberg, AB; Pillai, MV; Yeo, CJ; Zabrecky, G | 1 |
| Heike, Y; Okusaka, T; Sato, T; Ueno, M | 1 |
| Adams, PT; Atkins, JN; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Mamounas, EP; Margolese, RG; Mehta, RS; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Alexander, R; Goloubeva, O; Hanna, N; Herman, JM; Laheru, D; Maidment, BW; Pandya, N; Regine, WF; Schulick, R; Wolfgang, C; Yovino, S | 1 |
| Brons, S; Combs, SE; Debus, J; Haberer, T; Habermehl, D; Rieken, S; Weber, KJ; Winter, M; Zipp, L | 1 |
| Altavilla, G; Artal, A; Baize, N; Bearz, A; Bernabe, R; Bombaron, P; Bover, I; Carcereny, E; Cobo, M; Corre, R; Cortesi, E; Dansin, E; de Aguirre, I; de Castro, J; De Marinis, F; Domine, M; Drozdowskyj, A; Felip, E; Ferrera-Delgado, L; Garcia-Campelo, R; Garcia-Gomez, R; Garrido, P; Gebbia, V; Gervais, R; Illiano, A; Insa, A; Isla, D; Jimenez, U; Longo, F; Lopez-Vivanco, G; Massuti, B; Mazieres, J; Milella, M; Molina, MA; Molinier, O; Moran, T; Moreno, MA; Muñoz-Langa, J; Pallares, C; Palmero, R; Paz-Ares, L; Porta, R; Provencio, M; Queralt, C; Ramirez, JL; Reguart, N; Robinet, G; Rodriguez-Abreu, D; Rolfo, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Terrasa, J; Valdivia, J; Vergnenegre, A | 1 |
| Chang, JS; Chung, Y; Koom, WS; Seong, J; Song, SY; Wang, ML; Yoon, HI | 1 |
| Dorigo, O; Eng, C; Fekete, M; Santiskulvong, C | 1 |
| Guo, F; Luo, F; Mao, X; Wang, J; Wang, Z | 1 |
| Hirata, K; Ina, S; Kihara, C; Kimura, Y; Kiyotani, K; Kubo, M; Mitsuhata, N; Mushiroda, T; Nakamura, Y; Takahashi, A; Uno, S; Yamaue, H; Zembutsu, H | 1 |
| Du, Z; Shi, M; Xu, X; Yu, Y | 1 |
| Chen, Y; Shi, Y; Wang, C; Yang, Y | 1 |
| Abe, M; Demizu, Y; Fujii, O; Hashimoto, N; Hishikawa, Y; Jin, D; Kitajima, N; Mima, M; Murakami, M; Niwa, Y; Sasaki, R; Sirakawa, S; Sugimura, K; Takatori, K; Terashima, K; Yonson, K | 1 |
| Belmont, LD; Fairbrother, WJ; Peale, FV; Tan, N; Wong, M; Yue, P; Zha, J | 1 |
| Cha, YJ; Go, S; Hwang, IG; Jang, JS; Kang, JH; Kang, MH; Kwon, HC; Lee, GW; Lee, S; Oh, SY | 1 |
| Chen, J; Li, J; Li, MW; Shentu, JZ; Wang, LR; Wang, Y; Xu, N; Zhang, GB | 1 |
| Alazraki, A; Brill, P; Clark, D; George, BA; Katzenstein, HM; Martin, M; Olson, TA; Qayed, M; Rapkin, L; Wasilewski-Masker, K | 1 |
| Campbell, DO; Czernin, J; Lee, JT; Radu, CG; Satyamurthy, N | 1 |
| Aoki, T; Fukuoka, M; Hirashima, T; Ikeda, N; Ishiguro, T; Iwamoto, Y; Kawaguchi, T; Kotani, Y; Kurata, T; Nakagawa, K; Sawa, T; Tsuboi, M | 1 |
| Cui, Y; Dong, N; Guo, Q; Li, H; Wang, M | 1 |
| Bernard, A; Chauffert, B; Facy, O; Ladoire, S; Magnin, G; Ortega-Deballon, P; Pages, PB; Royer, B | 1 |
| Chen, D; Jiao, X; Liang, J; Niu, M; Zhang, D; Zhang, K | 1 |
| Cleves, A; Jones, G; Kynaston, HG; Mason, MD; Shelley, MD; Wilt, TJ | 1 |
| Blot, E; Bouzy, J; Chaigneau, L; Culine, S; Fizazi, K; Fourcade, A; Gross-Goupil, M; Kaminsky, MC; Laplanche, A; Lesimple, T; Lortholary, A; Négrier, S; Penel, N; Priou, F; Provencal, J; Voog, E | 1 |
| Ding, Q; Hayashi, T; Kuwahata, T; Maeda, K; Matsubara, S; Miyazaki, Y; Natsugoe, S; Obara, T; Takao, S | 1 |
| Burt, AD; Dasari, BV; Kelly, PJ; Loughrey, MB; Spence, R; Taylor, M | 1 |
| Cui, K; Li, L; Li, S; Niu, ZX; Sun, ZQ; Tian, H; Wang, AL; Wang, CL; Xue, Y; Zhang, B; Zhao, B; Zhou, WY | 1 |
| Hashimoto, Y; Hiyama, E; Kondo, N; Murakami, Y; Nakashima, A; Ohge, H; Sakabe, R; Sudo, T; Sueda, T; Uemura, K | 1 |
| Guo, J; Hu, G; Jiang, Z; Li, F; Liang, J; Ouyang, K; Qin, X; Wang, K; Wen, D; Zhang, L; Zhu, M | 1 |
| Ajiki, T; Connolly, K; DiGiovanni, J; Kiguchi, K; Kitamura, T; Lueckgen, A; Ruffino, L | 1 |
| Bronte, G; Catalano, V; Falcone, A; Graziano, F; Masi, G; Russo, A; Santini, D; Tonini, G; Vasile, E; Vincenzi, B; Virzi, V | 1 |
| Algin, E; Balakan, O; Benekli, M; Buyukberber, S; Colak, D; Dane, F; Dikiltas, M; Durnali, AG; Elkiran, ET; Geredeli, C; Goksel, G; Gumus, M; Harputoglu, H; Helvaci, K; Inal, A; Isikdogan, A; Kaplan, MA; Kos, FT; Kucukoner, M; Ozdemir, N; Ozkan, M; Uncu, D; Unek, IT; Yildiz, R | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Nakashima, A; Sudo, T; Sueda, T; Uemura, K | 1 |
| Hirai, K; Katoh, R; Ogawa, H; Sunose, Y; Takeyoshi, I; Totsuka, O; Toya, H; Yoshinari, D | 1 |
| Dakeshita, H; Kinoshita, M; Morita, A; Nomata, K; Ogawa, M; Ozeki, A; Tsuruta, T; Yoshioka, H | 1 |
| Asanuma, F; Atsuda, K; Morimoto, Y; Suzuki, Y; Takeuchi, O; Takizawa, A; Yamada, Y; Yoneyama, H | 1 |
| Gao, Q; Wang, FY; Yu, H | 1 |
| Jafari, M; Kislukhin, G; Long, AD; Murphy, ML | 1 |
| Adjei, AA; Dy, GK; Eckhardt, SG; Jimeno, A; Ma, WW; Maniar, M; Messersmith, WA; Ren, C; Weekes, CD; Whitworth, A; Wilhelm, F | 1 |
| Cai, RG; Chen, L; Fan, QX; Hao, XZ; Huang, J; Liu, AN; Sun, Y; Wang, JW | 1 |
| De Pooter, C; den Hengst, W; Hendriks, J; Pauwels, P; Van den Weyngaert, D; Van Schil, P; Van Thielen, J; Wittock, A | 1 |
| Fu, J; Shankar, S; Srivastava, RK; Tang, SN | 1 |
| Georgoulias, V; Kalbakis, K; Karachaliou, N; Kouroussis, Ch; Mavroudis, D; Papakotoulas, P; Poppis, E; Tryfonidis, K; Vardakis, N | 1 |
| Chilelli, M; D'Auria, G; Fabbri, MA; Frittelli, P; Massari, A; Moscetti, L; Natoli, G; Nelli, F; Ruggeri, EM | 1 |
| Bapiro, TE; Cook, N; Demuth, T; Frese, KK; Gopinathan, A; Howat, WJ; Jacobetz, MA; Jodrell, DI; Miller, JL; Rao, SS; Tuveson, DA | 1 |
| Abou-Tarboush, FM; Al-Buhairi, M; Al-Harbi, N; Al-Qadasi, WD; Alhazza, I; Alsbeih, G; Farah, MA; Saeed, NM; Salem, SD | 1 |
| Brown, NJ; Jitlal, M; Lee, SM; Tin, AW; Woll, PJ; Young, RJ | 1 |
| Engehausen, DG; Giedl, J; Goebell, PJ; Hartmann, A; Keck, B; Kunath, F; Wullich, B | 1 |
| Barraclough, H; Chacko, RT; Dhindsa, N; Julka, PK; Koppiker, CB; Majumdar, A; Nag, S; Nair, A; Parshad, R; Puri, T; Seth, A; Xue, FC | 1 |
| Cass, CE; Damaraju, VL; Mowles, D; Ng, A; Tong, Z; Yao, S; Young, JD | 1 |
| Audrain, O; Boucher, E; Crouzet, L; Edeline, J; Le Du, F; Raoul, JL | 1 |
| Colantonio, I; Comino, A; Crook, T; Denaro, N; Gasco, M; Lattanzio, L; Lo Nigro, C; Merlano, M; Monteverde, M; Natoli, G; Russi, E; Syed, N; Vivenza, D | 1 |
| Benjamin, RS; Chawla, S; Chugh, R; Fox, E; Harmon, D; Helman, LJ; Patel, S; Reinke, D; Schuetze, S; Wathen, JK | 1 |
| Alexander, HR; Funamizu, N; Gaedcke, J; Ghadimi, BM; Hanna, N; Hassan, R; He, P; Hussain, SP; Lacy, C; Lee, DH; Maitra, A; Ried, T; Schetter, A; Yfantis, HG; Zhang, G | 1 |
| Albiges, L; Blesius, A; Culine, S; Edeline, J; Escudier, B; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Lee, JW; Na, K; Yang, SG | 1 |
| Hansen, TF; Jakobsen, A; Jensen, LH; Lindebjerg, J; Ploen, J | 1 |
| Hashmi, A; Masood, R; Qayyum, A; Rafi, M; Tunio, MA | 1 |
| Au-Yeung, G; Davis, ID; Liew, MS | 1 |
| Ahn, JS; Ahn, MJ; Han, JH; Han, JY; Jo, SJ; Kim, HT; Kim, HY; Kim, SW; Lee, DH; Lee, JS; Lee, JW; Park, K; Suh, C; Yoon, SJ; Yun, T | 1 |
| Bellmunt, J; Boehle, A; Chevreau, C; Collette, S; Daugaard, G; De Santis, M; de Wit, R; Laufman, LR; Marreaud, S; Mead, GM; Paz-Ares, L; Raghavan, D; Skoneczna, I; Sylvester, R; von der Maase, H; Winquist, E | 1 |
| Fu, L; Gao, Y; Hong, D; Hong, W; Hu, L; Kou, JY; Su, D; Xie, FJ; Zhang, YP; Zhao, P | 1 |
| Carter, CA; Figg, WD; Giaccone, G; Gutierrez, M; Ji, J; Kelly, RJ; Kummar, S; Mannargudi, B; Rajan, A; Spencer, S; Szabo, E; Woo, S; Yancey, MA | 1 |
| Liu, BX; Ying, JE; Zhu, LM | 1 |
| Kamiyama, Y; Kasai, H; Kodama, T; Mori, K | 1 |
| Bu, HQ; Chen, H; Guo, HC; Li, HH; Li, W; Lin, SZ; Liu, DL; Luo, J; Tong, HF; Wang, ZH; Wei, WT; Wu, HY; Zuo, MM | 1 |
| Hiraoka, M; Matsuo, Y; Mizowaki, T; Nakamura, A; Nakamura, M; Shibuya, K; Shiinoki, T | 1 |
| Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y | 1 |
| Abdollahi, A; Bergmann, F; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Hof, H; Kessel, K; Rieken, S; Schirmacher, P; Weitz, J; Welzel, T; Werner, J | 1 |
| Elnaggar, M; Giovannetti, E; Peters, GJ | 1 |
| Chahine, G; Farhat, F; Ghosn, M; Kattan, J; Nasr, F; Saroufim, A | 1 |
| Aiba, T; Furukawa, K; Hayashi, M; Igarashi, K; Sato, M; Shibuya, H; Sugimura, K; Waguri, N; Yoneyama, O | 1 |
| Bae, I; Hong, YB; Hwang, JS; Kim, YJ; Seong, YS | 1 |
| Cao, Q; Dudek, AZ; Wang, H | 1 |
| Diaz, I; Muggia, F; Peters, GJ | 1 |
| Fukutomi, A; Furuse, J; Koshiji, M; Miyazaki, M; Nimura, Y; Okusaka, T; Taketsuna, M | 1 |
| Eltawil, KM; Molinari, M; Renfrew, PD | 1 |
| Berard, H; Chouaid, C; Corre, R; Crequit, J; Dujon, C; Falchero, L; Greillier, L; Jullian, H; LeCaer, H; Vergnenegre, A | 1 |
| Choi, M; Kim, R; Saif, MW | 2 |
| Inoue, T; Kamba, T; Matsui, Y; Nishiyama, H; Ogawa, O; Saito, R; Sumiyoshi, T; Xing, ND; Yoshimura, K | 1 |
| Chen, SW; Chu, PH; Huang, YK; Lu, MS; Shen, WC; Shih, LG | 1 |
| Bae, I; Hong, YB; Kim, JS; Seong, YS; Yi, YW | 1 |
| Bespalov, VG; Filatova, LV; Gershanovich, ML; Kon'kov, SA; Krylova, IM; Latipova, DKh; Murazov, IaG; Panchenko, AV; Semiglazova, TIu; Stukov, AN; Tarasenkova, AA; Vershinina, SF | 1 |
| Egawa, S; Kawaguchi, K; Motoi, F; Ohmine, K; Ohtsuki, S; Terasaki, T; Unno, M | 1 |
| Baschnagel, A; Jury, R; Margolis, J; Nadeau, L; Robertson, JM; Shah, C; Stein, J | 1 |
| Hiraki, Y; Iino, S; Kurahara, H; Maemura, K; Mataki, Y; Natsugoe, S; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Cook, L; Hughes, G; Kanfer, EJ; Karadimitris, A; Macdonald, DH; Marks, AJ; Matthey, F; Naresh, KN; Sivam, V; Szydlo, RM; Yarranton, H | 1 |
| Cui, Z; Lansakara-P, DS; Rodriguez, BL | 1 |
| Govindarajan, R; Hung, SW; Mody, HR | 1 |
| Ishikawa, O; Katayama, K; Kawada, N; Nagata, S; Nakamura, S; Ohigashi, H; Takahashi, H; Tomita, Y; Uehara, H | 1 |
| Bao, Q; He, B; Pan, Y; Song, G; Tang, Z; Tian, F; Wang, S | 1 |
| Boudou-Rouquette, P; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mallet, V; Mir, O; Pol, S; Ropert, S; Sogni, P | 1 |
| Candelaria, M; Chavez-Blanco, A; de la Cruz-Hernandez, E; Diaz-Chavez, J; Dominguez, G; Duenas-Gonzalez, A; Gonzalez-Fierro, A; Perez-Cardenas, E; Soto-Reyes, E; Taja-Chayeb, L; Trejo-Becerril, C; Trujillo, JE | 1 |
| Fan, X; Liu, L; Zhang, D; Zhou, Q | 2 |
| DeMichele, A; Gogineni, K | 1 |
| Antoine, M; Beau-Faller, M; Bergot, E; Brambilla, E; Braun, D; Creveuil, C; de Fraipont, F; Debieuvre, D; Favrot, MC; Hainaut, P; Levallet, G; Milleron, B; Morin, F; Moro-Sibilot, D; Mounawar, M; Quoix, E; Richard, N; Rouquette, I; Westeel, V; Zalcman, G | 1 |
| Brody, JR; Holdbrook, T; Leiby, BE; Littman, SJ; Pequignot, E; Valsecchi, ME; Witkiewicz, AK; Yeo, CJ | 1 |
| Chang, AE; Cuevas, C; Goel, VK; Hingorani, SR; Provenzano, PP; Von Hoff, DD | 1 |
| Chalasani, P; Jolivet, J; Kurtin, S; Mahadevan, D; Pretzinger, C; Ramanathan, RK; Rensvold, D; Von Hoff, DD; Weiss, GJ | 1 |
| Ben Larbi, S; Bergeron, E; Doléans-Jordheim, A; Ducrot, C; Dumontet, C; Fendrich, O; Freney, J; Jordheim, LP | 1 |
| Abdullah, M; Al Khodary, A; Barsoum, M; El Nowieam, S; El Zawahry, H; Gaafar, R; Gouda, Y; Halim, IA; Hamada, E; Hamid, TA; Kohail, H; Mansour, O; Meshref, M; Shehata, S; Taleb, FA; Wareth, AA | 1 |
| Baudrin, L; Belmont, L; Cadranel, J; Danel, S; Epaud, C; Gounant, V; Lavolé, A; Milleron, B; Rosencher, L; Ruppert, AM | 1 |
| He, AN; Lin, F; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 2 |
| Arbea, L; Aristu, J; Gil-Bazo, I; Moreno-Jimenez, M; Perez-Gracia, JL; Rodríguez-Ruiz, ME; San Miguel, I | 1 |
| Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Takasu, A | 1 |
| Wolff, RA | 1 |
| Colucci, G; Di Maio, M; Giuliani, F; Perrone, F | 1 |
| Innocenti, F; Soo, RA; Yong, WP | 1 |
| Fridley, BL; Jenkins, GD; Lund, S; Wang, L | 1 |
| Bapiro, TE; Caldwell, ME; Chan, DS; Cook, N; Feig, C; Frese, KK; Frost, GI; Jacobetz, MA; Jiang, P; Jodrell, DI; Kultti, A; Lolkema, MP; Maneval, DC; Nakagawa, T; Neesse, A; Shepard, HM; Skepper, JN; Thompson, CB; Tuveson, DA; Zecchini, HI | 1 |
| Abe, S; Harada, M; Hiura, M; Kihara, Y; Miyagawa, K; Shimajiri, S; Taguchi, M; Yamamoto, M | 1 |
| Facio, G; Garcia, AA; Muderspach, L; Pham, H; Roman, L; Yessaian, A | 1 |
| Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H | 1 |
| Fukuoka, J; Hori, R; Moriyama, M; Nagata, T; Okumura, T; Omura, T; Sawada, S; Sekine, S; Shimada, Y; Tsukada, K; Watanabe, T; Yoshioka, I | 1 |
| Cui, Z; Lansakara-P, DS; Li, X; Zhu, S | 1 |
| Iyoda, A; Jiang, SX; Kageyama, T; Masuda, N; Matsumoto, T; Nagashio, R; Ryuge, S; Saegusa, M; Sato, Y; Satoh, Y | 1 |
| Botteri, E; Calabrese, L; Cocorocchio, E; Martinelli, G; Peccatori, F; Piperno, G; Preda, L; Travaini, L; Vanazzi, A | 1 |
| Ba, Y; Hou, Y; Wang, HQ | 1 |
| Behrens, C; Correa, AM; Erasmus, JJ; Kalhor, N; Kim, ES; Lee, JJ; Pataer, A; Raso, MG; Roth, JA; Stewart, DJ; Swisher, SG; Vaporciyan, AA; Wistuba, II | 1 |
| Aracil, M; Arguelaguet, E; Hernández-Losa, J; Jimeno, J; Marés, R; Pons, B; Ramón Y Cajal, S; Somoza, R; Teixidó, C | 1 |
| Iwasaki, H; Kai, M; Katano, M; Morifuji, Y; Onishi, H; Suyama, K | 1 |
| Cao, K; Dai, J; Li, L; Li, MY; Lin, C; Nie, CL; Wang, BN; Yang, J; Yang, Y; Yuan, Z; Zhang, J | 1 |
| Chen, N; Egawa, S; Fujimura, H; Fujiwara, S; Fukushige, S; Horii, A; Ishida, M; Jin, G; Kudo, Y; Lee, Y; Manabe, T; Mano, N; Motoi, F; Nakano, T; Nezhad, ZK; Oba, S; Saiki, Y; Shimada, M; Shimizu, H; Shimizu, S; Sunamura, M; Unno, M; Yoshino, Y | 1 |
| Amsailale, R; Arts, A; Bontemps, F; Smal, C; Starczewska, E; Van Den Neste, E | 1 |
| Chen, J; Gui, YZ; Long, HX; Sun, Y; Zhang, WH; Zhang, XY; Zhong, GC; Zhu, B | 1 |
| Hatakeyama, K; Kawachi, Y; Kitami, CE; Kurosaki, I; Minagawa, M; Nihei, K; Nomura, T; Takano, K; Tsuchiya, Y | 1 |
| Altwegg, R; Assenat, E; Caillo, L; Faure, S; Flori, N; Guillaumon, V; Mazard, T; Samalin, E; Senesse, P; Thezenas, S; Ychou, M | 1 |
| Batzler, A; Breheny, P; Chalise, P; Fridley, BL; Wang, L | 1 |
| Baba, S; Hirai, S; Ishkawa, W; Iwamura, M; Maru, N; Nishi, M; Shimizu, T; Sugita, Y; Yokota, S | 1 |
| Cook, N; Davies, S; Halford, S; Jaki, T; Jodrell, D; Thygesen, H; Turner, H; Whitehead, J | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Lee, SC; Ling, W; Sachdeva, P; Wong, AS; Zee, YK | 1 |
| Abe, T; Akada, T; Dendo, M; Ito, Y; Kato, H; Muto, R; Nakanishi, C; Ozawa, Y; Sakashita, K; Sato, K | 1 |
| Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M | 1 |
| Ahn, DW; Hwang, JH; Kim, YT; Lee, JK; Lee, SH; Ryu, JK; Seo, JK; Yoon, YB | 1 |
| Buranrat, B; Kongpetch, S; Kukongviriyapan, U; Kukongviriyapan, V; Prawan, A; Senggunprai, L | 1 |
| Akasbi, Y; Arifi, S; Boutayeb, F; El Idrissi, M; El Mesbahi, O; El Mrini, A; Shimi, M | 1 |
| Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mouri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Yagioka, H; Yamamoto, K; Yamamoto, N | 1 |
| Chang, YC; Chen, CM; Chih-Hsin Yang, J; Hsu, HH; Hu, FC; Ting-Fang Shih, T; Tseng, WY; Yang, PC; Yu, CJ | 1 |
| Fukui, I; Kitsukawa, S; Komai, Y; Kubo, Y; Okubo, Y; Saito, K; Urakami, S; Yamamoto, S; Yasuda, Y; Yonese, J | 1 |
| Alici, S; Alkiş, N; Benekli, M; Berk, V; Büyükberber, S; Camci, C; Coskun, U; Esbah, O; Kaya, AO; Ozdemir, NY; Ozkan, M; Sevinc, A; Ulas, A | 1 |
| Cheewakriangkrai, C; Manopunya, M; Suprasert, P | 1 |
| Joshi, KV; Menon, SK; Mistry, BR; Patel, RV; Sutariya, PG | 1 |
| Chen, Y; Guo, Q; Kang, M; Lu, W; Wu, Y; Xie, Q; Zhang, B | 1 |
| Adamo, B; Adamo, V; Agostino, RM; Caristi, N; Franchina, T; Proto, C; Ricciardi, GR | 1 |
| Alexander, A; Anlauf, M; Knoefel, WT; Rehders, A; Riediger, R; Schmitt, M | 1 |
| Anant, S; Balakrishnan, A; Chakrabarti, D; Padigaru, M; Periyasamy, G; Ponnurangam, S; Sharma, S; Subramaniam, D; Sugumar, A; Weir, SJ | 1 |
| He, A; Huang, Y; Qi, W; Shen, Z; Sun, Y; Yang, Y; Yao, Y; Zhao, H | 1 |
| Akinfenwa, PY; Anderson, ML; Creighton, CJ; Kolomeyevskaya, N; Laucirica, R; Lev, DC; Odunsi, K; Savannah, KB; Shan, W; Thomas, DG | 1 |
| Chenevert, TL; Galbán, CJ; Galbán, S; Heist, KA; Holland, EC; Johnson, TD; Lawrence, TS; Lemasson, B; Leopold, JS; Li, F; Mikkelsen, T; Rehemtulla, A; Ross, BD; Williams, TM | 1 |
| Burris, HA; Greco, FA; Infante, JR; Jones, SF; McCulloch, W; Peacock, NW; Spigel, DR; Thompson, DS | 1 |
| Cariello, A; Casanova, C; Cruciani, G; Dazzi, C; Freier, E; Gamboni, A; Leoni, M; Mazza, V; Milandri, C; Montanari, M; Papi, M; Papiani, G; Verlicchi, A; Vertogen, B | 1 |
| Eskander, RN; Guo, Y; Hoang, B; Randall, LM; Sakai, T; Zi, X | 1 |
| Borg, M; Goldstein, D; Halkett, G; Kneebone, A; Reece, W; Short, M; Spry, N; Zissiadis, Y | 1 |
| Abrams, R; Ben-Josef, E; Francis, IR; Hadley, S; Khan, G; Lawrence, T; Leslie, W; Normolle, D; Schipper, M; Simeone, DM; Sonnenday, C; Ten-Haken, R; Zalupski, MM | 1 |
| DeSimone, JM; Finniss, M; Gullapalli, A; Luft, JC; Napier, ME; Pandya, A; Parrott, MC | 1 |
| Cai, W; Chen, Y; Liu, T; Xu, J; Zhang, J; Zhou, Y; Zhuang, R | 1 |
| Aklilu, M; Bernard, SA; Blackstock, AW; Davies, JM; Goldberg, RM; Ivanova, A; O'Neil, BH; Raftery, L; Tepper, JE | 1 |
| Donehower, R; Goldsweig, H; Hidalgo, M; Jimeno, A; Laheru, D; Le, DT; Linden, S; McAllister, F; Rajeshkumar, NV; Rudek, MA; Shah, P; Song, D; Taylor, G; Zhao, M | 1 |
| Almeida, L; Ashwell, S; Brassil, P; Breed, J; Deng, C; Gero, T; Grondine, M; Horn, C; Ioannidis, S; Janetka, J; Liu, D; Lyne, P; Newcombe, N; Oza, V; Pass, M; Read, J; Ready, S; Rowsell, S; Su, M; Toader, D; Vasbinder, M; Xue, Y; Yu, D; Yu, Y; Zabludoff, S | 1 |
| Chang, GC; Chen, YM; Cheng, YK; Liao, WY; Shih, JY; Yang, JC; Yu, CJ | 1 |
| Chen, LH; Leung, PS; Liang, J; Lin, ZX; Liu, L; Zhao, M | 1 |
| Apte, SM; Bicaku, E; Bou Zgheib, N; Chen, DT; Chon, HS; Cubitt, CL; Gonzalez-Bosquet, J; Hakam, A; Judson, PL; Lancaster, JM; Marchion, DC; Sawah, EA; Stickles, XB; Wenham, RM; Xiong, Y | 1 |
| Arizumi, T; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Toda, N; Togawa, O; Tsujino, T | 1 |
| Ahn, S; Kang, MJ; Kim, MH; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Seo, DW | 1 |
| Guo, J; He, L; Hu, G; Jiang, Z; Li, F; Qin, X; Sun, L; Tang, X; Wang, K; Wang, T; Wen, D; Yao, J; Zhang, L | 1 |
| Cho, K; Ganbold, EO; Joo, SW; Lee, SY; Ock, KS; Park, J | 1 |
| Bekaii-Saab, T; Gold, DV; Goldenberg, DM; Goldsmith, SJ; Guarino, MJ; Gulec, SA; Hall, N; Holt, M; Horne, H; Kauh, J; Lee, D; Manzone, T; Montero, AJ; O'Neil, BH; Ocean, AJ; Pennington, KL; Serafini, AN; Sheikh, A; Sung, MW; Wegener, WA | 1 |
| Barth, RJ; Colacchio, TA; Davis, TH; Gardner, TB; Gordon, SR; Korc, M; MacKenzie, TA; McGowan, MM; Pipas, JM; Preis, M; Ripple, GH; Smith, KD; Srivastava, A; Suriawinata, AA; Sutton, JE; Tarczewski, SM; Tsapakos, MJ; Tsongalis, GJ; Zaki, BI | 1 |
| Audrain, O; Boucher, E; Boudjema, K; Le Roux, G; Manfredi, S; Mesbah, H; Pracht, M; Raoul, JL; Sulpice, L | 1 |
| Gu, WJ; Li, Y; Liu, HL | 1 |
| Askoxylakis, J; de Bree, E; Melissas, J; Metaxari, M; Michalakis, J; Romanos, J; Tsiftsis, DD; Tsogkas, J; Volakakis, E | 1 |
| Abbruzzese, A; Apollinari, S; Bestoso, E; Botta, C; Caraglia, M; Correale, P; Cusi, MG; Misso, G; Pastina, P; Sperlongano, P; Tagliaferri, P; Tassone, P | 1 |
| Basu, S; Ghosh, AK | 1 |
| Duchêne, B; Hebbar, M; Jonckheere, N; Leteurtre, E; Skrypek, N; van Seuningen, I | 1 |
| Hashimoto, Y; Kobayashi, H; Kondo, N; Murakami, Y; Sudo, T; Sueda, T; Uemura, K | 1 |
| Atsumi, I; Fujita, T; Miki, Y; Nakamichi, H; Nakamura, H; Shiokawa, M; Suzuki, R; Tomita, K; Totsuka, K; Tsuji, D | 1 |
| Clark, JW | 1 |
| Bapiro, TE; Cook, N; Frese, KK; Jodrell, DI; Lolkema, MP; Neesse, A; Tuveson, DA | 1 |
| Hou, J; Wang, L | 1 |
| Hong, SW; Hong, YS; Jin, DH; Jung, KA; Kim, KP; Kim, SM; Kim, TW; Lee, JL; Lee, JS; Shin, JS; Suh, C; Yoon, DH | 1 |
| Bahlo, M; Klapdor, R; Klapdor, S | 1 |
| Bellmunt, J; Carles, J; Gallén, M; Guix, M; Morales-Barrera, R; Serrano, C; Suárez, C; Valverde, C | 1 |
| Atyabi, F; Dinarvand, R; Hosseinzadeh, H; Ostad, SN | 1 |
| Gu, MF; He, LJ; Li, JJ; Liu, LZ; Luo, GY; Xu, GL; Yan, CX; Yuan, WX; Zhang, HM; Zhang, R | 1 |
| Arsenijevic, L; Atanackovic, J; Jeftovic, M; Jeremic, K; Stefanovic, A; Stojnic, J; Zecevic, N | 1 |
| Cañueto, J; Fernández-López, E; Mir-Bonafé, JM; Román-Curto, C; Santos-Briz, A; Unamuno, P | 1 |
| Li, Z; Lu, S; Ren, Z; Yu, Y; Zhang, L; Zhao, J | 1 |
| Guo, Z; Li, J | 1 |
| Aznar Oroval, E; García-Lozano, T; Juan Bañón, JL; Lorente Alegre, P | 1 |
| Downward, J; Hancock, DC; Howell, M; Kelly, G; Kuznetsov, H; Marani, M; Molina-Arcas, M; Saunders, B; Steckel, M; Warne, PH; Weigelt, B | 1 |
| Hong, TH; Jeon, EK; Ko, YH; Lee, IS; Lee, MA; Won, HS; You, YK | 1 |
| Fujita, K; Funamizu, N; Furukawa, K; Lacy, CR; Manome, Y; Misawa, T; Yanaga, K | 1 |
| Gradishar, WJ | 1 |
| Li, W; Liu, H; Qu, X; Sun, C; Yue, B; Zhao, C | 1 |
| Hu, H; Le, L; Li, J; Li, S; Qiu, P; Su, X; Wu, S; Yan, G; Zhu, W | 1 |
| Chen, Y; Liang, X; Lin, C; Luan, Q; Ma, F; Meng, X; Pei, W; Qian, H; Wang, H; Zhan, Q; Zhang, X; Zhao, P; Zhao, Z; Zhou, S | 1 |
| Beane, JD; Crooks, PA; Holcomb, BK; Schmidt, CM; Waters, JA; Yip-Schneider, MT | 1 |
| Barash, I; Baumgartner, R; Blank, S; Curtin, JP; Gabizon, A; Kopolovic, J; Kwa, M; Michael, J; Muggia, F; Puzanov, I; Rosengarten, O; Shavit, L | 1 |
| Avan, A; Crea, F; Danesi, R; Funel, N; Galvani, E; Giovannetti, E; Honeywell, RJ; Marquez, VE; Paolicchi, E; Peters, GJ | 1 |
| Inaba, Y; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Tanaka, T | 1 |
| Ahmed, S; Bhatt, H; Lee-Ying, R; Lim, J; Shahid, RK | 1 |
| Aarts, M; Ashworth, A; Garcia-Murillas, I; Gevensleben, H; Hurd, MS; Sharpe, R; Shumway, SD; Toniatti, C; Turner, NC | 1 |
| Antón, A; Barnadas, A; Carrasco, E; Castellá, E; García-Andrade, C; Lomas, M; Palacios, JL; Ramírez, C; Ramírez, JL; Ríos, MJ; Rodríguez-Pinilla, M; San Antonio, B; Sánchez-Rovira, P; Velasco, A | 1 |
| Adaniel, C; Aghajanian, C; Grisham, RN; Hyman, DM; Iasonos, A; Konner, J; Ma, W | 1 |
| Chen, H; Chen, J; Jin, G; Ma, H; Shao, Z; Wang, Y; Xu, X | 1 |
| Casagrande, A; Fantaccini, G; Lecca, P; Morpurgo, D; Priami, C | 1 |
| Li, J; Liang, X; Yang, X | 1 |
| Kaino, S; Kuramitsu, Y; Nakamura, K; Ryozawa, S; Sakaida, I; Suenaga, S; Taba, K; Wang, Y | 1 |
| Li, G; Li, W; Qu, X; Sun, C; Xue, X; Zhao, C | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Bashir, Q; Bassett, R; Champlin, R; Chancoco, C; Ciurea, S; Frazier, E; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Khouri, I; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Rondon, G; Shah, N; Shpall, EJ; Thall, P; Valdez, B; Worth, L | 1 |
| El-Rayes, BF; Zafar, SF | 1 |
| Choi, MK | 1 |
| Auriemma, A; Bassi, C; Boz, G; Cantore, M; Frigerio, I; Giardino, A; Girelli, R; Mambrini, A; Orlandi, M; Salvia, R | 1 |
| Kitamura, H; Masuko, K; Narita, Y; Nishimura, T; Satoh, T; Sumida, K; Terada, S; Wakita, D; Watanabe, K | 1 |
| Comans, EF; Hartemink, KJ; Paul, MA; Phernambucq, EC; Postmus, PE; Senan, S; Smit, EF | 1 |
| Gress, TM; Michl, P | 1 |
| Baek, JS; Cho, CW; Hwang, CJ; Lim, JH; Na, YG; Shin, SC; You, SK | 2 |
| Basile, S; Bellati, F; Benedetti-Panici, P; Di Donato, V; Donfrancesco, C; Graziano, M; Marchetti, C; Palaia, I; Pernice, M; Perniola, G; Tomao, F | 1 |
| Albain, KS; Armato, SG; Brahmer, JR; Chen, HX; Gandara, DR; Jänne, PA; Karrison, TG; Kindler, HL; Koczywas, MN; Krug, LM; Lu, C; Quinn, DI; Stadler, WM; Stevenson, JP; Taber, DA; Vogelzang, NJ; Vokes, EE | 1 |
| Jiang, W; Lin, J; Liu, X; Thomas, DG; Xie, H | 1 |
| Erridge, S; Faivre-Finn, C; Gilligan, D; Hatton, M; Keerie, C; Mohammed, N; Price, A; Russell, S; Skailes, G; Snee, M; Yellowlees, A | 1 |
| Katsenos, S; Nikolopoulou, M | 1 |
| Barlev, A; Bray, S; Butt, Z; Cella, D; Fuchs, CS; Kindler, HL; Oglesby, A | 1 |
| El Deen, DA; El Morsy, SM; Toson, EA | 1 |
| Liu, A; Luo, J; Zhang, JH | 1 |
| Arnold, SM; Dovzhanskiy, DI; Felix, K; Giese, N; Hackert, T; Oehme, I; Werner, J; Witt, O | 1 |
| Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH | 1 |
| Abrams, RA; Benson, AB; Berger, AC; Freedman, GM; Hoffman, JP; Macdonald, J; Regine, WF; Safran, H; Willett, CG; Winter, K | 1 |
| Cai, XY; Cai, YC; Cao, Y; Hu, WH; Jiang, WQ; Jin, Y; Shi, YX; Xia, XY; Zhang, WD | 1 |
| Hirano, T; Iseki, K; Itagaki, S; Kobayashi, M; Sugawara, M; Takahashi, N; Takekuma, Y | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Valdez, BC; Wang, G | 1 |
| Anupindi, SA; Cantor, J; Lin, H; Matthews, RP; Rutstein, R | 1 |
| Cocco, A; Daw, HA; Kawsar, HI; Spiro, TP | 1 |
| Barraclough, H; Dueňas-González, A; Orlando, M; Quinlivan, M; Zhou, Y | 1 |
| Hu, ZH; Huang, Y; Xue, C; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY | 1 |
| Bae, I; Cho, CH; Hong, YB; Kim, YJ; Seong, YS | 1 |
| Hampole, H; Singh, A | 1 |
| Houts, AC; Leon, L; Miller, PJ; Reyes, C; Satram-Hoang, S; Schwartzberg, LS; Stepanski, EJ; Walker, MS; Wojtowicz-Praga, S | 1 |
| Lee, JK; Lee, KH; Lee, KT; Moon, IH; Rhee, JC; Yang, MH; Yang, S | 1 |
| Boudou-Rouquette, P; Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Durand, JP; Goldwasser, F; Mir, O; Perkins, G; Ropert, S | 1 |
| Bray, SL; Chan, D; Feigal, EG; Fuchs, CS; Galimi, F; Garbo, LE; Garon, EB; Hei, Y; Kindler, HL; Kocs, DM; Loh, E; McGreivy, J; Richards, DA; Rocha-Lima, CM; Safran, H; Stephenson, JJ | 1 |
| Chao, Y; Chu, WC; Lan, KH; Lee, SD; Lee, WP; Li, CP; Lin, HC; Su, CH; Tsai, YC | 1 |
| Berchier, MC; Berghmans, T; Bosschaerts, T; Giner, V; Lafitte, JJ; Leclercq, N; Lewin, D; Meert, AP; Paesmans, M; Scherpereel, A; Sculier, JP | 1 |
| André, T; Bachet, JB; Bardier-Dupas, A; Cass, CE; Closset, J; Couvelard, A; Dalban, C; Demetter, P; Devière, J; Dumontet, C; Emile, JF; Graham, K; Hammel, P; Jordheim, LP; Louvet, C; Mackey, JR; Maréchal, R; Matera, EL; Paye, F; Penna, C; Rougier, P; Salmon, I; Sauvanet, A; Svrcek, M; Van Laethem, JL | 1 |
| Chida, K; Inui, N; Karayama, M; Kuroishi, S; Kusagaya, H; Masuda, M; Nakamura, Y; Shirai, T; Suda, T; Toyoshima, M; Yamada, T; Yasuda, K; Yokomura, K | 1 |
| Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Fiorini, C; Menegazzi, M; Palmieri, M; Sgarbossa, A | 1 |
| Araujo, JC; Jonasch, E; Lim, ZD; Lin, E; Ng, CS; Pagliaro, LC; Richey, SL; Sharma, P; Tamboli, P; Tannir, NM | 1 |
| Gu, M; Ma, S; Zhang, N; Zhao, L; Zheng, X | 1 |
| Clarke, S; Clingan, P; De Boer, R; Johnston, M; Michael, M; Pavlakis, N | 1 |
| Bae, I; Duong, HQ; Hwang, JS; Kang, HJ; Kim, HJ; Seong, YS | 1 |
| Bu, HQ; Chen, H; Guo, HC; Li, HH; Lin, SZ; Luo, J; Wang, ZH; Zhang, JH | 1 |
| Fox, SA; Jackaman, C; Majewski, D; Nelson, DJ; Nowak, AK | 1 |
| Jia, L; Jiang, SM; Wu, JH | 1 |
| Hoshina, A; Onishi, T; Sasaki, T | 1 |
| Ishida, T; Tsubouchi, K; Yoshioka, H | 1 |
| Awasthi, N; Ruan, W; Schwarz, MA; Schwarz, RE; Zhang, C | 2 |
| Furukawa, K; Kagawa, S; Kato, A; Kimura, F; Matsushita, K; Miyazaki, M; Nomura, F; Ohtsuka, M; Satoh, M; Shimizu, H; Takano, S; Yoshidome, H; Yoshitomi, H | 1 |
| Feng, Q; Gao, SY; Tao, XM; Wang, JB; Wang, JC; Zhang, LR; Zhang, Q | 1 |
| Hashimoto, J; Koizumi, F; Kondo, S; Morizane, C; Okusaka, T; Tamura, K; Ueno, H | 1 |
| Costello, E; Greenhalf, W; Neoptolemos, JP | 1 |
| Hosokawa, A; Kiba, T; Kozawa, K; Nakashima, T; Ogawa, Y | 1 |
| Loke, MM; Mann, S; Stellman, A | 1 |
| Jiang, J; Jiang, W; Kim, R; Liu, X; Wang, Y; Xie, H | 1 |
| Jiang, C; Li, YX; Shen, H; Yi, XP | 1 |
| Liu, XJ; Nowak, B; Plunkett, W; Wang, YQ | 1 |
| An, X; Chen, C; Chen, YC; Li, YH; Luo, HY; Wang, FH; Wang, ZQ; Xu, RH; Zhang, L | 1 |
| Campbell, NR; De Oliveira, E; de Wilde, RF; Hidalgo, M; Maitra, A; Matsui, W; Mizuma, M; Omura, N; Puig, O; Rajeshkumar, NV; Rasheed, ZA; Yabuuchi, S; Zhang, Q | 1 |
| Tan, J; Zhou, X; Zhu, H | 1 |
| Aasebø, U; Amundsen, T; Bremnes, R; Fløtten, Ø; Grønberg, BH; Hornslien, K; Rolke, H; Sundstrøm, S; von Plessen, C; Wentzel-Larsen, T | 1 |
| Chen, J; He, J; Jiang, L; Li, B; Sun, G; Wang, L; Xiu, Q; Yu, H; Zhao, L | 1 |
| Gupta, MK; Madabhavi, I; Rastogi, M; Revannasiddaiah, S | 1 |
| de Boer, JP; Greijer, AE; Huitema, AD; Juwana, H; Middeldorp, JM; Novalic, Z; Tan, IB; Verkuijlen, SA; Wildeman, MA | 1 |
| Akahori, T; Enomonoto, Y; Hasegawa, M; Hokuto, D; Kasai, T; Kawaguchi, C; Kichikawa, K; Kinoshita, S; Marugami, N; Nakajima, Y; Nishiofuku, H; Nomi, T; Sho, M; Tamamoto, T; Tanaka, T; Yamato, I; Yasuda, S | 1 |
| Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
| Amoroso, D; Camerini, A; Cappuzzo, F; D'Incecco, A; Fabbri, A; Tibaldi, C; Vasile, E | 1 |
| Bekaii-Saab, TS; Bloomston, M; Ellison, EC; Kleiber, B; Li, X; Martin, LK; Zalupski, M | 1 |
| Cogdill, AP; Cooper, ZA; Ferrone, CR; Fiedler, A; Frederick, DT; Garber, HR; Rosenberg, L; Thayer, SP; Wargo, JA; Warshaw, AL | 1 |
| Dahan, L; Delpero, JR; Esterni, B; François, E; Gasmi, M; Genre, D; Gilabert, M; Giovannini, M; Gonçalves, A; Lamy, R; Largillier, R; Moureau-Zabotto, L; Perrier, H; Raoul, JL; Re, D; Seitz, JF; Tchiknavorian, X; Turrini, O; Viens, P | 1 |
| Korniyenko, A; Lozada, J; Ranade, A; Sandhu, G | 1 |
| Han, JY; Kim, HT; Kim, SH; Lee, JS; Lee, Y; Yun, T | 1 |
| Baake, G; Boeck, S; Clemens, MR; Gauler, TC; Geissler, M; Greten, TF; Hegewisch-Becker, S; Heinemann, V; Höhler, T; Jung, A; Kettner, E; Klein, S; Ko, YD; Kojouharoff, G; Märten, A; Neugebauer, S; Rubanov, O; Vehling-Kaiser, U; von Weikersthal, LF; Waldschmidt, D; Winkelmann, C | 1 |
| Bartlett, N; Beaven, A; Drachman, JG; Forero-Torres, A; Lobuglio, AF; Moskowitz, CH; Myint, H; Nasta, S; Northfelt, DW; Whiting, NC | 1 |
| Aglietta, M; Campanella, D; Capussotti, L; Colombi, F; Gabriele, P; Gatti, M; Leone, F; Massucco, P; Regge, D; Sperti, E | 1 |
| Alam, Y; Butts, C; Cantile, F; Ciardiello, F; Cinieri, S; da Cunha Santos, G; Di Maio, M; Favaretto, A; Feld, R; Felletti, R; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, N; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rossi, A; Saieg, M; Siena, S; Tortora, G; Tsao, MS; Wierzbicki, R | 1 |
| Bertetto, O; Ceccarelli, M; Chiappino, I; Ciccone, G; Ciuffreda, L; Giacobino, A; Napoletano, R; Novarino, AM; Satolli, MA; Schena, M | 1 |
| Chang, DZ; Cohen, L; Garrett, CR; Huo, Y; Liu, L; Meng, Z; Ng, CS; Shen, Y; Spelman, AR; Yang, P; Zhao, Q | 1 |
| Anthoney, A; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Cox, TF; Dervenis, C; Ghaneh, P; Glimelius, B; Halloran, CM; Lacaine, F; Lerch, MM; McDonald, AC; Middleton, MR; Moore, MJ; Neoptolemos, JP; Oláh, A; Palmer, DH; Rawcliffe, CL; Scarfe, AG; Smith, D; Tebbutt, NC; Valle, JW; Verbeke, CS | 1 |
| Hagihara, A; Kido, H; Kondo, S; Morizane, C; Okusaka, T; Tamura, T; Ueno, H | 1 |
| Ruan, JD; Sun, WJ; Wu, W; Xiong, Y; Zeng, J; Zhang, LB | 1 |
| Brody, JR; Burkhart, RA; Cozzitorto, JA; Gorospe, M; Leiby, B; Londin, ER; Pineda, DM; Rigoutsos, I; Rittenhouse, DW; Sachs, JN; Valley, CC; Weber, MC; Winter, JM; Witkiewicz, AK; Yeo, CJ | 1 |
| Chung, WG; Cui, Z; Digiovanni, J; Kiguchi, K; Wonganan, P; Zhu, S | 1 |
| Bauer, TM; Bekaii-Saab, T; El-Rayes, BF; Hammad, N; Li, X; Philip, PA; Shields, AF; Zalupski, MM | 1 |
| Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Simeone, DM; Venkatesha, VA; Zabludoff, SD; Zhao, L | 1 |
| Arantes-Rodrigues, R; Cardoso, ML; Colaço, A; Gaivão, I; Oliveira, P; Palmeira, C; Pinto-Leite, R; Santos, L | 1 |
| Chen, Q; Huang, JZ; Liang, JG; Shi, CM; Zhong, DT | 1 |
| Hirakata, A; Makino, H; Maruyama, H; Matsushita, A; Matsutani, T; Sasajima, K; Suzuki, S; Uchida, E; Yokoyama, T; Yoshida, H | 1 |
| Callery, PS; Chura, JC; Downs, LS; Hodge, LS; Kramer, P; Soisson, AP; Thomas, SG; Tracy, TS; Wolfe, SS | 1 |
| Adesso, L; Barbagallo, F; Calabretta, S; Capurso, G; Delle Fave, G; Geremia, R; Pilozzi, E; Sette, C | 1 |
| Chang, YS; Cho, SH; Kang, SY; Kim, JH; Kim, MH; Kim, MY; Kim, SH; Kim, YJ; Lee, JS; Lee, KW; Lee, SY; Min, KU; Song, WJ; Yang, MS | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Hwang, JH; Im, SA; Kim, JH; Kim, JS; Kim, TY; Lim, JH; Yoon, YB | 1 |
| Chen, XQ; Li, YJ; Wang, KF; Wang, L; Wang, ZH; Xia, YF; Xia, ZJ | 1 |
| Aprelikova, O; Bennett, CN; Caplen, NJ; Chu, IM; Green, JE; Hollingshead, MG; Luger, D; Michalowski, AM; Mittereder, LR; Piwinica-Worms, H; Shou, J; Tomlinson, CC | 1 |
| Ames, MM; Behrens, RJ; Erlichman, C; Foster, NR; Goetz, MP; Graham, DL; Holtan, SG; Medeiros, F; Safgren, SL; Steen, PD | 1 |
| Auliac, JB; Chouaid, C; Dujon, C; Le Caer, H; Locher, C; Monnet, I; Thomas, P; Vergnenegre, A | 1 |
| Arslan, M; Ceylan, Y; Degirmenci, T; Gunlusoy, B; Kara, C; Kozacıoğlu, Z; Vardar, E | 1 |
| Casini, M; Cavattoni, IM; Cortelazzo, S; Deola, S; Farsad, M; Mian, M; Pescosta, N | 1 |
| Alexander, HR; Back, TC; Chan, T; Funamizu, N; Gaedcke, J; Ghadimi, MB; Hanna, N; He, P; Hu, C; Hussain, SP; Lacy, C; Lee, DH; Maitra, A; Ried, T; Schetter, A; Subleski, J; Weiss, JM; Yanaga, K; Yfantis, HG; Zhang, G | 1 |
| Brunner, TB; Charlton, PA; Fokas, E; McKenna, WG; Muschel, RJ; Pollard, JR; Prevo, R; Reaper, PM | 1 |
| Ashley, S; Yim, KL | 1 |
| Andou, T; Kameda, R; Kobayashi, S; Morinaga, S; Ohkawa, S; Ueno, M; Yamamoto, N | 1 |
| Dalgleish, AG; Liu, WM | 1 |
| Fisher, RI; LeBlanc, M; Mahadevan, D; Miller, TP; Persky, DO; Spier, CM; Unger, JM; Young, F | 1 |
| Abo, T; Isomoto, H; Nagayasu, T; Nanashima, A; Nonaka, T; Nonaka, Y; Uehara, M | 1 |
| Chyczewska, E; Korniluk, M; Mroz, RM; Ossolinska, M; Panek, B | 1 |
| Ando, T; Handa, O; Hattori, T; Imamoto, E; Ishikawa, T; Kamada, K; Katada, K; Kitagawa, K; Kokura, S; Konishi, H; Naito, Y; Okumura, Y; Oyamada, H; Sakagami, J; Sakamoto, M; Sakamoto, N; Takagi, T; Uchiyama, K; Yagi, N; Yasuda, H; Yoshida, N; Yoshikawa, T; Yoshinami, N | 1 |
| Frampton, AE; Jiao, LR; Krell, J; Stebbing, J | 1 |
| Dudek, AZ; Greeno, EW; Khatri, A; Kirstein, MN; Kratzke, RA; Lamba, JK; Mitra, AK; Skubitz, KM | 1 |
| Choi, H; Jang, KT; Kim, KK; Kim, S; Lee, SY; Park, JO; Park, YS; Woo, HI; Yi, JH | 1 |
| De Pas, T; Giovannetti, E; Peters, GJ; Toffalorio, F | 1 |
| Alami, M; Giessrigl, B; Gollinger, M; Hengstschläger, M; Huttary, N; Jäger, W; Kazlauskas, E; Kopf, S; Krieger, S; Krupitza, G; Maciuk, A; Matulis, D; Mazal, P; Messaoudi, S; Peyrat, JF; Rosner, M; Saiko, P; Szekeres, T | 1 |
| Hwang, EC; Hwang, IS; Hwang, JE; Jung, SI; Kang, TW; Kim, SO; Kwon, DD; Park, K; Ryu, SB; Yu, HS | 1 |
| Bekaii-Saab, T; Deam, D; Grever, MR; Harper, EJ; Hicks, WJ; Ivy, SP; Ling, Y; Liu, X; Liu, Z; Martin, LK; Monk, JP; Mortazavi, A; Otterson, GA; Phelps, MA; Wei, L; Wu, X; Yen, Y; Zhou, BS | 1 |
| Chew, DJ; de Brito Galvao, JF; Inpanbutr, N; Kisseberth, WC; Murahari, S; Sutayatram, S | 1 |
| Alberola, V; Bennouna, J; Biesma, B; Eisen, T; Gans, S; Gottfried, M; Heigener, D; Le Marie, E; Liao, M; Montegriffo, E; Ong, TJ; Paz-Ares, LG; Santoro, A; Strauss, UP; Sun, Y; Syrigos, K; Vansteenkiste, J; von Pawel, J; Zhang, L | 1 |
| Duan, W; Li, X; Liu, H; Ma, Q; Wu, E; Xu, H | 1 |
| Chen, Y; Gao, L; Liu, QH; Ni, CY; Zhang, J; Zhao, CY; Zhu, MH | 1 |
| Bailey, JM; Bunt, SK; Grandgenett, PM; Hollingsworth, MA; Mohr, AM | 1 |
| Goedegebuure, P; Hawkins, WG; Hornick, JR; Lockhart, AC; Mitchem, JB; Picus, J; Plambeck-Suess, S; Simon, PO; Sorscher, S; Suresh, R; Tan, B; Wang-Gillam, A | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 2 |
| Kanetake, H; Matsuo, T; Miyata, Y; Nomata, K; Ohba, K; Sagara, Y; Sakai, H | 1 |
| Bokar, JA; Brell, JM; Cooney, MM; Dowlati, A; Gibbons, J; Ivy, P; Krishnamurthi, SS; Meropol, NJ; Rath, L; Savvides, P | 1 |
| Bachet, JB; Demetter, P; Maréchal, R; Salmon, I; Van Laethem, JL; Verset, L | 1 |
| Issels, RD; Lindner, LH | 1 |
| Joshi, K; Joshi, KS; Khanwalkar, H; Manohar, SM; Rathos, MJ | 1 |
| Kagohashi, K; Kurishima, K; Nakazawa, K; Satoh, H; Tamura, T | 1 |
| He, J; Li, H; Lu, J; Ma, P; Qin, Y; Wang, J; Wei, L; Xu, J; Zhang, X | 1 |
| O'Reilly, EM | 2 |
| Filatova, LV; Gershanovich, ML; Latinova, DKh; Semiglazova, TIu; Stukov, AN; Tarasenkova, AA; Vershinina, SF; Zargarova, NI | 1 |
| Barnett, JC; Chino, JP; Havrilesky, LJ; Jewell, EL; Leath, CA; Phippen, NT | 1 |
| Andoh, H; Nakagawa, Y; Nanjo, H; Takahashi, T; Uchinami, H; Watanabe, G; Yamamoto, Y; Yoshioka, M; Yoshioka, T | 1 |
| Li, D; Liu, M; Lou, Y; Ren, Y; Sun, X; Zhang, C; Zhou, J | 1 |
| Gremeaux, L; Topal, B; Van den Broeck, A; Vankelecom, H | 1 |
| Choi, M; Kim, R; Razzaque, S | 1 |
| Abotouk, N; Halim, A | 1 |
| Inal, A; Isikdogan, A; Kaplan, MA; Karakus, A; Kucukoner, M; Urakci, Z | 1 |
| Berk, V; Buyukberber, S; Ciltas, A; Colak, D; Dane, F; Gumus, M; Inal, A; Isikdogan, A; Kos, FT; Ozdemir, NY; Ozkan, M; Unek, IT; Yildiz, R | 1 |
| Chen, LK; Liang, Y; Liu, GZ; Wei, WD; Xu, F; Xu, GC; Yang, QY; Zhou, NN | 1 |
| Cao, WM; Wang, BH; Wang, XL; Yu, J | 1 |
| Hu, LM; Hu, ZB; Huang, MD; Shen, HB; Shu, YQ; Wang, ZW; Xu, JL; Yin, ZQ | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Cao, N; Li, Z; Ma, B; Mi, D; Tian, J; Yang, K | 1 |
| Abe, T; Fujikawa, T; Kawashima, T; Maekawa, H; Shimoike, N; Shiraishi, K; Tada, S; Tanaka, A; Tanaka, H; Yoshimoto, Y | 1 |
| Byun, HJ; Kim, BR; Park, SY; Rho, SB; Yoo, R | 1 |
| Akhisaroglu, M; Beckhove, P; Buchler, MW; Ge, Y; Grenacher, L; Haefeli, WE; Hohmann, N; Knebel, P; Koch, M; Leowardi, C; Lubenau, H; Mikus, G; Niethammer, AG; Schmitz-Winnenthal, FH; Springer, M; Weitz, J | 1 |
| Blay, JY; Bompas, E; Cioffi, A; Collin, F; Cupissol, D; Delcambre, C; Duffaud, F; Floquet, A; Isambert, N; Jimenez, M; Pautier, P; Penel, N; Piperno-Neumann, S; Rey, A | 1 |
| Derakhshandeh, K; Fathi, S | 1 |
| Ahola, T; Aittokallio, T; De Brabander, JK; Denisova, OV; Elliott, RM; Feng, L; Hukkanen, V; Julkunen, I; Kainov, DE; Kakkola, L; Kallio-Kokko, H; Kantele, A; Kaukinen, P; Kuivanen, S; Lampe, J; Nagaraj, A; Paavilainen, H; Saelens, X; Stenman, J; Tynell, J; Vapalahti, O; Yadav, B | 1 |
| Dinney, CP; Grossman, HB; Kamat, AM; Millikan, RE; Shen, Y; Siefker-Radtke, AO; Williams, DL | 1 |
| Baker, LH; Crowley, JJ; Maki, RG | 1 |
| Burnside, N; MacGowan, SW | 1 |
| Harada, M; Harashima, N; Inao, T; Kawauchi, H; Monma, H; Tongu, M; Yamada, T | 1 |
| Gallois-Montbrun, S; Negroni, M; Rossolillo, P; Simon-Loriere, E; Winter, F | 1 |
| Beebe, SJ; Feng, H; Guo, J; Pan, J; Sun, S; Wang, J; Wu, S; Zhang, J | 1 |
| Bekaert, S; Cataldo, D; Chiap, P; Coia, I; Evrard, B; Foidart, JM; Gueders, M; Noel, A; Paulissen, G; Rocks, N; Van Heugen, JC | 1 |
| Arcand, SL; Caceres, KY; Cyr, L; de Ladurantaye, M; Delvoye, N; Létourneau, IJ; Mes-Masson, AM; Meunier, L; Portelance, L; Provencher, DM; Quinn, MC; Shen, Z; Tonin, PN; Wang, LL | 1 |
| Bourgaux, C; Couvreur, P; Desmaële, D; Lepeltier, E; Lepêtre, S; Maksimenko, A; Mougin, J; Mura, S; Sliwinski, E; Zouhiri, F | 1 |
| Azuma, K; Fukumoto, T; Kikugawa, T; Miura, N; Miyauchi, Y; Shimamoto, K; Shirato, A; Tanji, N; Yanagihara, Y; Yokoyama, M | 1 |
| Hong, GB; Li, CY; Song, LQ; Sun, HB; Zhou, JX | 1 |
| Cui, X; Li, M; Liu, C; Long, J; Luo, G; Ni, Q; Satoh, K; Xiao, Z; Xu, J; Yu, X; Zhang, B | 1 |
| Kimura, Y; Morikawa, N; Murakami, K; Nagano, Y; Tabata, T; Yanagisawa, S | 1 |
| Bersani, S; Dalla Pozza, E; Dando, I; De Laurenzi, V; De Marco, M; di Mola, FF; di Sebastiano, P; Dijk, F; Donadelli, M; Fontana, A; Franco, R; Medema, JP; Palaia, R; Palmieri, M; Pezzilli, R; Rosati, A; Scarpa, A; Scognamiglio, G; Tavano, F; Turco, MC; Welling, L | 1 |
| Barlési, F; Chouaid, C; Crequit, J; Devouassoux-Shisheboran, M; Falchero, L; Fournel, P; Gervais, R; Le Caer, H; Léna, H; Milleron, B; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Ségura-Ferlay, C; Taron, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Esaki, S; Goshima, F; Kimura, H; Murakami, S; Nishiyama, Y | 1 |
| Beviglia, L; Fischer, MM; Gurney, A; Hoey, T; Hynes, M; Kapoun, AM; Kim, E; Lewicki, J; Simeone, DM; Song, X; Wu, J; Yen, WC; Yeung, VP | 1 |
| Cheng, Z; Han, B; Jia, G; Jiang, H; Liu, J; Pan, S; Sun, B; Wang, Y; Zhou, H; Zhou, Y | 1 |
| Ding, Y; Liao, Y; Peng, RQ; Zhang, X; Zhang, XS; Zheng, LM | 1 |
| Huang, ZL; Huang, ZM; Li, W; Pan, CC; Wu, PH; Yi, RY; Zhao, M | 1 |
| Akaike, M; Kameda, Y; Miyagi, Y; Morinaga, S; Nakamura, Y; Numata, M; Ohkawa, S; Shiozawa, M; Tamagawa, H; Watanabe, T; Yamamoto, N | 1 |
| Hayashi, A; Ishigaki, Y; Motoo, Y; Shimasaki, T; Takata, T; Tomosugi, N; Tsuchida, H | 1 |
| Jiang, Y; Liu, F; Sun, S; Tang, Y; Zheng, C | 1 |
| Belli, C; Cereda, S; Reni, M | 1 |
| Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P | 1 |
| Avan, A; Frampton, AE; Funel, N; Giovannetti, E; Maftouh, M; Nicolini, F; Pelliccioni, S; Peters, GJ; Quint, K; Schuurhuis, GJ | 1 |
| Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ | 1 |
| Bastiat, G; Benoit, JP; Moysan, E | 1 |
| Pal, SK; Ruel, NH; Wilson, TG; Yuh, BE | 1 |
| Gores, GJ; Razumilava, N | 1 |
| Alken, S; Breathnach, OS; El-Helali, A; Greene, J; Grogan, L; Korpanty, G; Smyth, L | 1 |
| Labianca, R; Merelli, B; Mosconi, S | 1 |
| Chen, G; Lu, S; Yu, Y; Zhang, L; Zhao, Q | 1 |
| Botta, C; Caraglia, M; Ciliberto, D; Correale, P; Rossi, M; Tagliaferri, P; Tassone, P | 1 |
| Enomoto, T; Fujita, M; Hiramatsu, K; Kimura, T; Kiyohara, Y; Kobayashi, E; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V | 1 |
| Brogan, F; Chi, DC; Saif, MW; Schwartz, L; Turenne, I; Zelonis, S | 1 |
| Barcenas, J; Bohac, GC; Conlon, K; Davis, M; Deng, Y; Lamzabi, I; Leslie, W; Li, Y; Plate, JM; Watkins, L | 1 |
| Bachet, JB; Rougier, P; Seufferlein, T; Van Cutsem, E | 1 |
| Banerjee, D; Basu, S; Harfouche, R; Papa, AL; Sengupta, P; Sengupta, S | 1 |
| Barrière, J; Falk, AT; Ghalloussi, H; Otto, J; Poudenx, M | 1 |
| Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Tateishi, K; Yamamoto, N | 1 |
| Angst, E; Chen, M; Eibl, G; Go, VL; Hines, OJ; King, J; Li, G; Lu, QY; Lu, X; Moro, A; Park, JL; Reber, HA | 1 |
| Ji, M; Jiang, JT; Liu, WS; Sun, WH; Wang, Q; Wu, CP; Wu, J; Yan, HJ; Zheng, X | 1 |
| Andersson, R; Ansari, D; Sun, C; Wu, DQ | 1 |
| Gilbert, KS; Scoggins, JW; Stackhouse, MA; Waud, WR | 1 |
| Eshun, F; Hingorani, P; Watanabe, M; White-Collins, A | 1 |
| Almgren, M; Baird, AM; Dockry, E; Ekström, TJ; Gray, SG; Hollywood, D; Meunier, A; Nikolaidis, G; O'Byrne, KJ; O'Kelly, F; Perry, AS | 1 |
| Drebin, JA; Pippin, JA; Singla, S | 1 |
| Forssell, H; Krona, H; Pröh, K; Wester, M | 1 |
| Hashimoto, Y; Hatakeyama, S; Kamimura, N; Koie, T; Ohyama, C; Yamamoto, H; Yoneyama, T | 1 |
| Bussink, J; Soetekouw, PM; Timmer-Bonte, JN; Tjan-Heijnen, VC; van der Drift, MA; van Die, L; van Leeuwen, F; Wagenaar, M | 1 |
| Alexandrescu, S; Becheanu, G; Buica, F; Croitoru, A; Diculescu, M; Dinu, I; Gheorghe, L; Gramaticu, I; Herlea, V; Hrehoret, D; Luca, I; Lupescu, I; Popescu, I; Simionov, I | 1 |
| Casado, FJ; Molina-Arcas, M; Pastor-Anglada, M; Pérez-Torras, S; Trigueros-Motos, L | 1 |
| Anderson, MA; Gorospe, EC; Leggett, CL; Levy, M; Lutzke, LS; Sun, G; Wang, KK; Wong Kee Song, LM | 1 |
| Deng, LC; Shen, WS; Shu, ZQ | 1 |
| Bagnobianchi, A; Bingham, JP; Craddock, C; Hartley, JA; Hochhauser, D; Kiakos, K; Ledermann, JA; Lowe, HL; Newton, C; Spanswick, VJ | 1 |
| Czyz, A; Dytfeld, D; Gil, L; Hellmann, A; Knopinska-Posluszny, W; Komarnicki, M; Lojko-Dankowska, A; Nowicki, A; Romejko-Jarosinska, J; Walewski, J | 1 |
| Alinger, B; Di Fazio, P; Lingelbach, S; Montalbano, R; Neureiter, D; Ocker, M; Quint, K; Rückert, F; Tonigold, M | 1 |
| Basu, B; Jodrell, D | 1 |
| Cheek, MA; Ellington, AD; Li, N; Ray, P; Sharaf, ML; Shaw, BR; Sullenger, BA; White, RR | 1 |
| Armesilla, AL; Bian, X; Brown, S; Channathodiyil, P; Darling, JL; Goktug, T; Guichet, PO; Hugnot, JP; Kannappan, V; Liu, P; Wang, W | 1 |
| Cho, JH; Kim, HJ; Lee, JE; Nam, HS; Ryu, JS; Shin, ES | 1 |
| Liu, Y; Shen, H; Su, Z; Wang, D; Yin, R; Zhang, Z; Zhu, H; Zhu, Y | 1 |
| Alici, S; Berk, V; Camcı, C; Coskun, U; Degerli, H; Gumus, M; Kaya, AO; Kefeli, U; Oner, MK; Ozdemir, NY; Ozkan, M; Ozturk, C; Sevinc, A; Unal, OU; Yilmaz, AU | 1 |
| Santoni-Rugiu, E; Sorensen, JB; Vilmar, AC | 1 |
| Arrowsmith, E; Beck, T; Borson, R; Bromund, J; Hager, S; Harker, G; Harrer, G; Horvath, W; Jones, M; Kornberg, LJ; Kudrik, FJ; Malamud, SC; Obasaju, C; Orlando, M; Reeves, J; Tai, DF; Tillinghast, G; Yardley, DA; Zeigler, H | 1 |
| Chen, X; Guo, R; Jin, S; Liu, Y; Ping, G; Røe, OD; Shu, Y; Yan, K; Yin, Y | 1 |
| Campbell, C; Dwivedi, P; Garg, NK; Tyagi, RK | 1 |
| Conney, AH; Cui, XX; Gao, Z; Huang, MT; Liu, Y; Rabson, AB; Verano, M; Zheng, X | 1 |
| Belletrutti, MJ; Bhargava, R; Bigam, D; Grundy, P | 1 |
| Kobayashi, N; Nishiuma, S; Okubo, S; Taketsuna, M; Taniai, H | 1 |
| Chen, S; Cheng, YL; Gu, B; Li, ST; Ni, YJ | 1 |
| Aguilar-Ponce, JL; Alvarez-Avitia, MA; Arrieta, O; Castillo-Hernández, C; Cruz López, JC; De la Garza-Salazar, J; González-Ramírez, I; Granados-García, M; Lara-Cruz, G; Maldonado-Magos, F; Martinez-Juárez, I; Medina-Santillan, R | 1 |
| Kitamura, H; Masumori, N; Shindo, T; Tsukamoto, T | 1 |
| Ashimine, S; Kimura, R; Machida, N; Matsumura, E; Miyagi, R; Miyazato, M; Oshiro, Y; Saito, S | 1 |
| Ding, XX; Hu, JW; Qiu, MT; Tian, HY; Xu, L; Yin, R | 1 |
| Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kawakubo, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Satoh, Y; Tada, M; Takahara, N; Takai, D; Uchino, R; Yamamoto, N; Yatomi, Y | 1 |
| da Silva, GN; de Camargo, EA; Salvadori, DM | 1 |
| Pereira, S | 1 |
| Bandarchi, B; Leung, L; Organ, S; Panchal, D; Pintilie, M; Radulovich, N; To, C; Tsao, MS; Zhu, CQ | 1 |
| Cha, BH; Hwang, JH; Jeong, SH; Kim, JE; Kim, JW; Kim, N; Lee, DH; Lee, SH; Park, YS; Yoo, JY | 1 |
| Cheng, YM; Tang, Y; Wang, L; Yao, YY; Zhu, Q; Zhuang, Y; Zou, LF | 1 |
| O'Malley, DM; Salani, R | 1 |
| Ball, HA; Botbyl, J; Gibson, DM; Jeffels, M; Madi, A; Nokay, B; Plummer, R; Richly, H; Rubin, S; Scheulen, ME; Weller, S | 1 |
| Ding, X; Fan, M; Huang, W; Li, B; Sun, H; Yi, Y; Zhang, J; Zhou, T | 1 |
| Behrman, SW; Chitkara, D; Kumar, V; Mahato, RI; Singh, S | 1 |
| Cheng, G; Hu, C; Hu, X; Huang, C; Jiao, S; Li, K; Luo, R; Lv, W; Ouyang, X; Sun, Y; Wang, J; Wang, M; Wang, Y; Wang, Z; Zhang, S; Zheng, R | 1 |
| Chang, J; Fang, J; Hu, Z; Huang, C; Huang, Y; Li, B; Li, K; Liang, H; Liu, W; Liu, X; Liu, Y; Lu, Y; Wang, M; Wang, S; Wang, Y; Wang, Z; Wu, G; Xu, N; Yu, S; Zhang, L; Zhang, Y; Zhou, J | 1 |
| Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S | 1 |
| Beckham, TH; Beeson, CC; Beeson, G; Bielawska, A; Bielawski, J; Cheng, JC; Drake, RR; Jones, EE; Lewis, CS; Liu, X; Lu, P; Marrison, T; Norris, JS; Ogretmen, B; Ramshesh, VK; Szulc, ZM | 1 |
| Caffo, O; Fellin, G; Galligioni, E; Mussari, S; Russo, L; Veccia, A | 1 |
| Endo, I; Ichikawa, Y; Kumamoto, T; Matsuyama, R; Mori, R; Nagashima, Y; Nojiri, K; Sugita, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M | 1 |
| Cao, P; Chen, E; Green, DE; Hedley, DW; Ibrahimov, E; Knox, JJ; McNamara, MG; Metran-Nascente, C; Serra, S; Tsao, M; Vines, D; Xu, J | 1 |
| Capobianco, G; Cherchi, PL; Fadda, GM; Miolo, GM; Re, GL; Santeufemia, DA; Tumolo, S | 1 |
| Celano, M; Cosco, D; Fresta, M; Moretti, S; Paolino, D; Puxeddu, E; Russo, D | 1 |
| Lecca, P; Morpurgo, D | 1 |
| Cheng, S; He, Y; Song, MM; Yuan, HS; Zhong, ZQ | 1 |
| Gu, J; Li, YM; Wang, HX; Wang, M; Wang, YJ; Wu, MH | 1 |
| Gu, Y; Jameson, MB; McKeage, MJ; Melink, TJ; Rajendran, J; Ramanathan, RK; Tchekmedyian, NS; Wilson, WR | 1 |
| Pascolo, S | 1 |
| Bahleda, R; Blay, JY; Dieras, V; LoRusso, P; Macaulay, VM; Mery-Mignard, D; Middleton, MR; Protheroe, AS; Sessa, C; Soria, JC; Tolcher, A | 1 |
| Ahn, HK; Hwang, DW; Kim, SJ; Kim, WS; Ko, YH; Lim, ST; Tang, T | 1 |
| Chen, SP; Fu, MY; Jiang, CP; Liu, F; Wang, BQ; Wu, BH; Yang, M | 1 |
| Cao, Q; Dudek, AZ; H Thaw, SS; Kumar, P; Larson, T; Pawloski, P | 1 |
| Aiura, K; Itano, O; Kitagawa, Y; Matsuda, S; Suzuki, K; Takeuchi, O; Umezawa, K | 1 |
| Algül, H; Conradt, L; Henrich, A; Krämer, OH; Lesina, M; Reichert, M; Saur, D; Schmid, RM; Schneider, G; Wirth, M | 1 |
| Baird, AM; Gray, SG; Kilmartin, L; Leonard, J; Naicker, KM; O'Byrne, KJ | 1 |
| Motoshige, H; Oyama, K; Sakurai, K; Takahashi, K | 1 |
| Pal, SK; Ruel, N; Vogelzang, N; Wilson, TG; Yuh, BE | 1 |
| Jiang, W; Liu, X; Xiao, SY; Xie, H | 1 |
| Hwang, YI; Jang, SH; Jung, KS; Kim, DG; Kim, JH; Kim, SY; Park, S | 1 |
| Itoh, K; Matsubara, N; Mukai, H; Naito, Y; Nezu, M | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Bashir, Q; Champlin, R; Hosing, C; Jones, RB; Kebriaei, P; Khouri, I; Liu, P; Nieto, Y; Parmar, S; Popat, U; Qazilbash, M; Rondon, G; Shah, N; Shpall, EJ; Valdez, B | 1 |
| Bustamante-Montalvo, M; Fernández-Pérez, A; Lesquereux-Martínez, L | 1 |
| Albarello, L; Balzano, G; Braga, M; Capretti, G; Castoldi, R; Cereda, S; Di Carlo, V; Doglioni, C; Pecorelli, N; Reni, M | 1 |
| Carboni, GL; Fahrner, R; Ochsenbein, A; Schmid, RA | 1 |
| Aravantinos, G; Bamias, A; Chrisophos, M; Constantinidis, C; Dafni, U; Deliveliotis, C; Dimopoulos, MA; Eleftheraki, A; Fountzilas, G; Hatzimouratidis, C; Karadimou, A; Koutoulidis, V; Pectasides, D; Psyrri, A; Samantas, E; Stravodimos, K; Timotheadou, E; Tsiatas, M; Visvikis, A; Xanthakis, I | 1 |
| Britti, D; Cosco, D; Federico, C; Morittu, VM; Trapasso, E | 1 |
| Cai, J; Daneshmand, S; Dorff, T; Dorin, R; Fairey, AS; Lieskovsky, G; Miranda, G; Quinn, D; Schuckman, A; Skinner, EC | 1 |
| Chen, G; You, L; Zhang, J; Zhang, TP; Zhao, YP; Zhou, B | 1 |
| Chang, LC; Hao, WH; Hsu, CS; Hsu, KY; Hsu, PJ; Hsueh, SP; Wang, JJ | 1 |
| Armato, SG; Dignam, JJ; Kindler, HL; Labby, ZE; Nowak, AK; Straus, C | 1 |
| Al-Wadei, HA; Banerjee, J; Schuller, HM | 1 |
| Azzariti, A; Carioggia, E; Leo, MG; Lioce, M; Mantuano, P; Paradiso, A; Porcelli, L; Quatrale, AE; Rolland, JF; Silvestris, N | 1 |
| Furukawa, K; Kato, A; Kimura, F; Miyazaki, M; Ohtsuka, M; Shimizu, H; Takayashiki, T; Takeuchi, D; Yoshidome, H; Yoshitomi, H | 1 |
| Gurung, J; Lindemayr, S; Mbalisike, EC; Naguib, NN; Nour-Eldin, NE; Vogl, TJ; Zangos, S | 1 |
| Fujioka, M; Fukui, H; Kou, C | 1 |
| Boettcher, M; Eisen, C; Fredebohm, J; Gaida, MM; Giese, NA; Greulich-Bode, KM; Heller, A; Hoheisel, JD; Hotz-Wagenblatt, A; Keleg, S; Lathrop, M; Tost, J | 1 |
| Deng, HX; Liang, SF; Nie, CL; Wei, YQ; Yuan, Z; Zhao, XY | 1 |
| Antoine, M; Belmont, L; Cadranel, J; Duruisseaux, M; Giroux Leprieur, E; Gounant, V; Lacave, R; Lavolé, A; Milleron, B; Poulot, V; Rabbe, N; Vieira, T; Wislez, M | 1 |
| Alam, Y; Bianco, R; Butts, C; Ciardiello, F; Cinieri, S; Di Maio, M; Fasano, M; Favaretto, A; Feld, R; Felletti, R; Fregoni, V; Gallo, C; Gebbia, V; Genestreti, G; Gridelli, C; Leighl, NB; Maione, P; Mancuso, G; Morabito, A; Morgillo, F; Perrone, F; Ravaioli, A; Riccardi, F; Rossi, A; Siena, S; Signoriello, S; Spatafora, M; Tsao, MS; Wierzbicki, R | 1 |
| Fujiwara, Y; Furukawa, K; Gocho, T; Haruki, K; Iwase, R; Misawa, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Katsumata, N; Maejima, A | 1 |
| Kitao, A; Matsumoto, K | 1 |
| Bocchia, M; Cencini, E; Defina, M; Fabbri, A; Fontanelli, G; Gozzetti, A; Mazzei, MA; Pietrini, A; Volterrani, L | 1 |
| Alvarez, R; Aribi, A; Chan, KT; Doan, NB; Gery, S; Ho, Q; Koeffler, HP; Lee, DH; Lee, K; Said, JW; Thoennissen, GB; Thoennissen, NH; Toh, M | 1 |
| Hassali, MA; Hassan, BA; Othman, SB; Weiderpass, E; Yusoff, ZB | 1 |
| Dong, HX; Ke, HG; Li, J; Liu, JH; Shen, Y; Shen, ZY; Yan, Y; You, QS | 1 |
| Barner, M; Boeck, S; Clemens, MR; Egg, R; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Goritschan, C; Greten, TF; Heinemann, V; Jung, A; Kirchner, T; Klein, S; Kojouharoff, G; Laubender, RP; Mansmann, U; Märten, A; Neumann, J; Vehling-Kaiser, U; Winkelmann, C | 1 |
| Bottiglieri, S; Mehdi, S; Mo, JH; Patel, R; Tierson, N | 1 |
| Cameron, RB; Hou, D | 1 |
| Akasaka, H; Mizushina, Y; Sasaki, R; Takayama, I; Yamaguchi, T; Yoshida, H; Yoshida, K | 1 |
| Ai, ZH; Guo, JZ; Liu, WC; Wang, Y; Wen, L; Zhao, SH | 1 |
| Chen, H; Chen, Z; Fan, J; Liu, L; Luo, J; Meng, Z; Wang, K; Wang, P; Zhang, J; Zhuang, L | 1 |
| An, Y; Cai, B; Chen, J; Gao, W; Jiang, K; Li, Q; Lv, N; Miao, Y; Tang, D; Tu, M; Wei, J; Wu, J; Xue, X; Yao, J | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K | 2 |
| Choe, JH; Choe, JM; Falchook, GS; Gallick, GE; George, GC; Hong, DS; Kurzrock, R; Moulder, SL; Naing, A; Piha-Paul, S; Strauss, LC; Wheler, JJ | 1 |
| Hirooka, S; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H | 1 |
| Baldissareli, J; Cardoso, AM; Chiesa, J; da Costa, P; do Carmo Araújo, M; Leal, DB; Martins, CC; Morsch, VM; Oliveira, L; Pelinson, LP; Pimentel, VC; Schetinger, CC; Schetinger, MR; Schmatz, R; Zanini, D | 1 |
| Chiorean, EG; Elzey, BD; Hazbun, T; Konieczny, SF; Kuang, S; Liu, X; Liu, XS; Ratliff, TL; Rice, SJ; Song, B | 1 |
| Lim, YL; Tay, EY | 1 |
| Hirose, T; Ishida, H; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Ohnishi, T; Oki, Y; Okuda, K; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Baidoo, KE; Brechbiel, MW; Milenic, DE; Yong, KJ | 2 |
| Boursier, C; Bylicki, O; Dot, JM; Peloni, JM | 1 |
| Apetoh, L; Boireau, W; Bruchard, M; Chalmin, F; Chevriaux, A; Connat, JL; Derangère, V; Ghiringhelli, F; Kanellopoulos, J; Martin, F; Mignot, G; Rébé, C; Ryffel, B; Simon, B; Végran, F | 1 |
| Krug, S; Michl, P | 1 |
| Bischoff, S; Caca, K; Kubicka, S; Nehls, O; Pelzer, U; Riess, H; Sinn, M; Stieler, JM; von Weizsäcker, F | 1 |
| Alfieri, S; Antinori, A; Balducci, M; Crucitti, A; D'Agostino, GR; Deodato, F; Ippolito, E; Luzi, S; Macchia, G; Mattiucci, GC; Morganti, AG; Smaniotto, D; Valentini, V | 1 |
| Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ | 1 |
| Cella, D; Ko, AH | 1 |
| Adenis, A; Bascoul-Mollevi, C; Bécouarn, Y; Bérille, J; Boige, V; Bouché, O; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Guimbaud, R; Raoul, JL; Ychou, M | 1 |
| Fujita, T; Imataki, O; Matsunaga, T; Nishiuchi, T; Ohnishi, H; Okutani, Y; Shimizu, H; Shimizu, T; Yamagishi, Y | 1 |
| Fujiwara, Y; Furukawa, K; Haruki, K; Iwase, R; Misawa, T; Ohashi, T; Shiba, H; Uwagawa, T; Yanaga, K | 2 |
| Knox, JJ; Zhu, AX | 1 |
| Belaygorod, L; Belt, BA; Brennan, DJ; Carpenter, D; Collins, L; DeNardo, DG; Gallagher, WM; Goedegebuure, P; Hewitt, S; Knolhoff, BL; Linehan, DC; Mitchem, JB; Piwnica-Worms, D; Sanford, DE; Udupi, GM; Wang-Gillam, A; Wegner, C; West, BL; Zhu, Y | 1 |
| Horiguchi, N; Kakizaki, S; Mori, M; Nakajima, Y; Sato, K; Sunaga, N; Takagi, H | 1 |
| Hazama, S; Homma, S; Inoue, Y; Kan, S; Koido, S; Maeda, K; Oka, M; Okamoto, M | 1 |
| Liem, N; Wang, L; Wong, FY; Wong, WC; Xie, C; Yan, FL; Yong, WP | 1 |
| Asmar, L; Galsky, MD; Gardner, TA; Hahn, NM; Hellerstedt, BA; Hutson, TE; Kocs, D; Lerner, SP; McKenney, SA; Melnyk, AM; O'Rourke, M; Powles, T; Rauch, M; Sonpavde, G; Vogelzang, NJ; Wang, Y; Yu, M | 1 |
| Chiorean, EG; Hardacre, JM; Krishnamurthi, S; Lenz, HJ; Mulcahy, M; Obel, J; Rocha-Lima, CS; Safran, H; Small, W; Talamonti, M | 1 |
| Baker, JA; Dantzig, AH; Guo, Y; Hall, SD; Li, CH; Oluyedun, OA; Qian, YW; Ring, BJ; Wickremsinhe, ER; Wrighton, SA | 1 |
| Ahler, E; Benz, MR; Braas, D; Christofk, HR; Eilber, FC; Nathanson, D; Riedinger, M; Smith, KB; Tam, B; Tap, WD; Witte, ON; Wu, H | 1 |
| Adjei, AA; Ansari, RH; Dy, GK; Lyss, AP; Mandrekar, SJ; Meyers, JP; Molina, JR; Nelson, GD; Ross, HJ; Schild, SE; Stella, PJ | 1 |
| Bayry, J; Bazhin, AV; Karakhanova, S; Link, J; Shevchenko, I; Soltek, S; Umansky, V; Werner, J | 1 |
| Bennouna, J; Chamorey, E; Douillard, JY; Etienne-Grimaldi, MC; Follana, P; Francois, E; Mari, V; Michel, C; Milano, G; Renée, N; Senellart, H | 1 |
| Acharya, AP; Dasari, M; Kim, D; Lee, S; Molinaro, R; Murthy, N; Rhea, J | 1 |
| Fantaccini, G; Kahramanoğullari, O; Lecca, P; Morpurgo, D; Priami, C | 1 |
| Chaudhary, UB; Gudena, V; Keane, T; Verma, N | 1 |
| Andersson, R; Ansari, D; Tingstedt, B | 1 |
| Fang, H; Shen, J; Wu, A; Xu, C; Xu, L; Ye, J; Zhu, H | 1 |
| Abdel-Rahman, S; Berger, F; Dieterle, N; Issels, RD; Milani, V; Salat, C; Tschoep-Lechner, KE | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sudo, T; Sueda, T; Uemura, K | 1 |
| Bui, DT; Couvreur, P; Harrisson, S; Maksimenko, A; Mougin, J; Nicolas, J | 1 |
| Itami, J; Ito, Y; Kondo, S; Mayahara, H; Morizane, C; Morota, M; Murakami, N; Okusaka, T; Sumi, M; Ueno, H | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Gu, Z; Jian, K; Qi, J; Shen, H | 1 |
| Abrams, R; Ben-Josef, E; Francis, IR; Khan, G; Lawrence, TS; Leslie, W; Schipper, M; Vainshtein, JM; Zalupski, MM | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Laubender, RP; Parhofer, KG; Schulz, C; Zeiss, K | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Hayakumo, T; Kido, M; Ku, Y; Matsumoto, I; Murakami, S; Ohtsubo, I; Okazaki, T; Sawa, H; Shinozaki, K; Shinzeki, M; Shirakawa, S; Tanaka, M; Toyama, H; Ueno, K; Yoshida, Y | 1 |
| Hasuike, Y; Hirao, S; Iwagami, Y; Kira, T | 1 |
| Akahori, T; Hokutoh, D; Kinoshita, S; Nakajima, Y; Nomi, T; Sho, M; Yamato, I; Yasuda, S | 1 |
| Kakimoto, M; Kawashima, H; Koshiishi, H; Miyamoto, H; Okamura, T | 1 |
| Egawa, C; Hamanaka, M; Kanemura, T; Kato, T; Kawashima, H; Miki, H; Mukai, Y; Nakahira, S; Nakata, K; Okishiro, M; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H; Uchiyama, C | 1 |
| Ajiki, T; Fukumoto, T; Kido, M; Ku, Y; Matsumoto, I; Murakami, S; Ohtsubo, I; Okazaki, T; Shinozaki, K; Shinzeki, M; Yoshida, Y | 1 |
| Fukuda, S; Fukushima, Y; Hashimoto, K; Ide, Y; Kodama, K; Matsumoto, S; Matsuyama, J; Morimoto, T; Naito, A; Nomura, T; Sasaki, Y; Shiba, I; Takeda, M; Tokuoka, M; Toshiyama, R; Yokoyama, S | 1 |
| Baba, H; Goseki, N; Kuwabara, H; Mitsuoka, A; Nakamura, H; Sanada, T; Watanabe, S; Yamamoto, Y | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Ku, Y; Matsumoto, I; Sawa, H; Shinzeki, M; Shirakawa, S; Takahashi, M; Tanaka, M; Toyama, H; Tsuchida, S; Ueno, K; Yamashita, H | 1 |
| Dong, M; Gui, L; He, XH; Liu, P; Qin, Y; Shi, YK; Yang, JL; Yang, S; Zhang, CG; Zhou, LQ; Zhou, SY | 1 |
| Bean, A; Eckardt, MA; Federman, N; Selch, MT | 1 |
| Chen, GY; Ding, YB; Liu, JL; Xia, JG; Zhang, DC | 1 |
| Ashida, R; Ioka, T; Katayama, K; Kobayashi, N; Takakura, R; Tanaka, S; Taniai, H | 1 |
| Fujioka, T; Iwasaki, K; Kato, Y; Obara, W; Takata, R; Tanji, S | 1 |
| Bhattacharyya, J; Chilkoti, A; Hammer, DA; Hassouneh, W; McDaniel, JR; Vargo, KB | 1 |
| Hirashima, T; Imamura, F; Kawase, I; Kijima, T; Komuta, K; Minami, S; Nakatani, T; Namba, Y; Ogata, Y; Okafuji, K; Osaki, T; Otsuka, T; Shiroyama, T; Tachibana, I; Uchida, J; Yamamoto, S | 1 |
| Aspillaga M, A; Buttinghausen, V; Chandía C, M; Orellana, M | 1 |
| Bitterman, PB; Jacobson, B; Jia, Y; Kratzke, R; Li, S; McCauley, J; Wagner, CR | 1 |
| Boggi, U; Campani, D; Caparello, C; Caponi, S; Cappelli, C; Costa, F; De Lio, N; Falcone, A; Funel, N; Ginocchi, L; Lencioni, M; Lucchesi, M; Mosca, F; Pollina, L; Ricci, S; Vasile, E | 1 |
| Chen, DY; Zhao, WY | 1 |
| Hannongbua, S; Okumura, H; Rungnim, C; Rungrotmongkol, T | 1 |
| Ishigatsubo, Y; Kaneko, T; Klinman, DM; Sato, T; Shimosato, T; Takahashi, R | 1 |
| Ali, S; Banerjee, S; Deryavoush, T; Gupta, S; Parasramka, MA; Sarkar, FH | 1 |
| Chandran, S; Chennazhi, K; Lakshmanan, VK; Nair, SV; Pavithran, K; Praveen, G; Snima, KS | 1 |
| Shurin, MR | 1 |
| Doki, Y; Eguchi, H; Ishii, H; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Wada, H; Yamada, D | 1 |
| Arias, JL; Durán-Lobato, MM; Holgado, MÁ; Martín-Banderas, L; Melguizo, C; Prados, JC; Sáez-Fernández, E | 1 |
| Fang, X; Liang, W; Lou, C; Yang, M; Zeng, W; Zhang, C; Zhang, F; Zhang, Y; Zhao, J | 1 |
| Brullé, L; Le Pape, A; Lerondel, S; Martel, E; Pouvesle, JM; Richard, S; Riès, D; Robert, E; Trichet, V; Vandamme, M | 1 |
| Ito, R; Kitamura, H; Miyake, R; Nojiri, T; Okui, N; Saito, R; Son, K; Toyama, Y; Usuba, T; Yanaga, K; Yoshida, S | 1 |
| Haruta, J | 1 |
| Centeno, BA; Chellappan, SP; Fulp, WJ; Kunigal, S; Pillai, S; Singh, S; Treviño, JG | 1 |
| Duan, X; Mao, X; Sun, W | 1 |
| Açikalin, M; Başeskioglu, B; Can, C; Duman, BB; Kara, IO; Yildirim, M | 1 |
| Alba-Conejo, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Llácer, C; Lomas-Garrido, M; Navarro-Perez, V; Plata-Fernández, YM; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Chirita, D; Dumitrascu, T; Ionescu, M; Popescu, I | 1 |
| Calvani, N; Cinefra, M; Cinieri, S; D'Amico, M; Fedele, P; Marino, A; Nacci, A; Orlando, L; Rizzo, P; Schiavone, P; Sponziello, F | 1 |
| Dantzig, AH; Durland-Busbice, S; Heinz-Taheny, K; Iversen, PW; Pratt, SE; Shepard, RL | 1 |
| Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Mizuno, S; Nakai, Y; Omata, M; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N | 1 |
| Failla, CM; Gallinari, P; Orecchia, A; Paolini, C; Steinkühler, C; Zambruno, G | 1 |
| Bai, B; Bu, Q; Cai, QC; Cai, QQ; Gao, Y; Guo, Y; Huang, HQ; Lin, ZX; Wang, XX; Xia, Y | 1 |
| Ji, S; Liu, C; Long, J; Ni, Q; Xu, J; Xu, W; Xu, Y; Yao, W; Yu, X; Zhang, B; Zhu, W | 1 |
| Agarwal, N; Boucher, KM; Galsky, MD; Hussain, SA; Kaufman, DS; Lorusso, V; Maughan, BL; Moore, MJ; Sonpavde, G; Von Der Maase, H | 1 |
| Araujo, DM; Baker, LH; George, S; Hensley, ML; Maki, RG; Priebat, DA; Soslow, RA; Sutton, G; Wathen, JK | 1 |
| Bhutia, YD; Govindarajan, R; Hung, SW; Krentz, M; Lovin, D; Manoharan, R; Patel, D; Thomson, JM | 1 |
| He, LH; Niu, LZ; Xu, KC; Yang, ZZ; Zhou, L; Zuo, JS | 1 |
| Cui, X; Li, M; Liu, C; Liu, L; Liu, Z; Long, J; Luo, G; Shi, S; Xiao, Z; Xu, J; Yu, X | 1 |
| Huang, H; Jiao, Z; Kong, X; Li, L; Liu, Z; Xu, M; Xu, P; Zhang, Y | 1 |
| Lecca, P | 2 |
| Apolo, AB; Bajorin, DF; Balar, AV; Gallagher, DJ; Garcia-Grossman, IR; Iasonos, A; Milowsky, MI; Mironov, S; Ostrovnaya, I; Regazzi, AM; Trout, A | 1 |
| Cai, H; Canto, MI; Chang, KJ; Donehower, RC; Herman, JM; Hoffe, SE; Klapman, J; Laheru, DA; Pawlik, TM; Reid, T; Rosemurgy, A; Savage, DT; Shah, RJ; Taylor, GE; Tran, PT; Wang, H; Wild, AT; Wolfgang, CL; Ziegler, MA | 1 |
| Demolin, G; Focan, C; Graas, MP; Houbiers, G; Stultiens, A | 1 |
| Babu, R; Byrne, AT; Devocelle, M; Gallagher, WM; Kenny, ST; Nikodinovic-Runic, J; O'Connor, A; O'Connor, KE; O'Connor, S; O'Donovan, N; Szwej, E; Zinn, M; Zulian, QR | 1 |
| Cheng, X; Li, H; Li, L; Li, M; Lu, W; Wang, X; Zhou, T | 1 |
| Awada, A; Bergeland, T; Hals, PA; Hendlisz, A; Rasch, W; Schellens, JH; Stuurman, FE; Voest, EE; Witteveen, PO | 1 |
| Batra, S; Sharma, N; Vaid, AK; Wadhwa, J | 1 |
| Cui, L; Eguchi, D; Fujiwara, K; Ikenaga, N; Kozono, S; Mizumoto, K; Ohuchida, K; Tanaka, M | 1 |
| Cao, LP; Li, YX; Song, JL; Yi, XP | 1 |
| Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Kogure, H; Koike, K; Maetani, I; Maguchi, H; Mukai, T; Nakai, Y; Okabe, Y; Sasahira, N; Sasaki, T; Toda, N; Yasuda, I | 1 |
| Blackhurst, DW; Gill, SE; Puls, LE; Shrum, KJ; Thompson, LK | 1 |
| Arkenau, HT; Bendell, JC; Burris, HA; Hainsworth, JD; Infante, JR; Jones, GT; Lane, CM; Rubin, MS; Spigel, DR; Waterhouse, D | 1 |
| Blando, JM; Cui, Z; De Angel, RE; Dunlap, SM; Hogan, MG; Hursting, SD; Lansakara-P, DS; Sandoval, MA | 1 |
| Ahmadzadeh, A; Babaei, M; Elahi, F; Hassanpour, K; Yadollahzadeh, M | 1 |
| Bergmann, F; Brecht, IC; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Rieken, S; Schirmacher, P; Welzel, T; Werner, J | 1 |
| Chua, M; Coleman, A; Collins, M; Corry, J; D'Costa, I; Hicks, RJ; Lim, AM; Peters, L; Rischin, D; Solomon, B | 1 |
| Grigorieva, J; Lee, CB; Moore, DT; Peterman, AH; Roder, J; Socinski, MA; Stinchcombe, TE | 1 |
| Cruickshank, S; Delmore, JE; diZerega, GS; Drummond, L; Peterson, KJ; Pham, H; Reed, E; Rodgers, KE; Schwartz, BM | 1 |
| Cheon, J; Choi, IK; Kang, SG; Kang, SH; Kim, HS; Kim, JS; Kim, ST; Kim, YH; Ko, YH; Lee, SW; Oh, SC; Park, JH; Park, KH; Park, YJ; Seo, JH; Sung, DJ | 1 |
| Dantzig, AH; Donoho, GP; Durland-Busbice, S; Perkins, EJ; Pratt, SE; Shepard, RL; Starling, JJ; Wickremsinhe, ER | 1 |
| Hess, KR; Hong, D; Naing, A; Nwosu, U; Tsimberidou, AM; Wheler, J; Wolff, RA; Ye, Y | 1 |
| Barlow, LJ; Benson, MC | 1 |
| Asaoka, Y; Ijichi, H; Ikenoue, T; Isayama, H; Koike, K; Miyabayashi, K; Mohri, D; Morishita, Y; Moses, HL; Nakai, Y; Omata, M; Tada, M; Tateishi, K; Yamamoto, K | 1 |
| Borghero, Y; Cassina, JC; Gabrielli, M; Galindo, J; Garrido, M; Guerra, JF; Jarufe, N; Madrid, J; Martínez, J; Roa, JC; Zoroquiain, P | 1 |
| Berg, DJ; Bodeker, KL; Buettner, GR; Cullen, JJ; Drisko, J; Du, J; Halfdanarson, TR; Levine, M; Roberts, LJ; van't Erve, TJ; Wagner, BA; Welsh, JL; Yee, NS; Zehr, PS | 1 |
| Buscail, L; Cordelier, P; Delpu, Y; Hanoun, N; Lopez, F; Lulka, H; Saint-Laurent, N; Sicard, F; Torrisani, J | 1 |
| Arpicco, S; Beghelli, S; Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Fattal, E; Lerda, C; Palmieri, M; Scarpa, A; Scupoli, MT; Zoratti, E | 1 |
| Senanayake, TH; Vinogradov, SV; Warren, G; Wei, X | 1 |
| Avan, A; Cantore, M; Caponi, S; Cereda, S; Giovannetti, E; Mambrini, A; Milella, M; Pacetti, P; Peters, GJ; Reni, M; Vaccaro, V; Vasile, E | 1 |
| Ke, XY; Liu, ZQ; Wang, Y; Xie, ZQ; Yang, DL; Zhang, CF; Zhao, Q | 1 |
| Dai, L; Hoffman, RM; Lin, Y; Liu, Y; Qi, M; Shi, Y; Sun, Y; Tian, Y; Tong, M; Wang, Z; Wu, Y; Yang, Z; Zhang, Y | 1 |
| Ciccolini, J; Evrard, A; Lacarelle, B | 1 |
| Cazales, M; Ducommun, B; Frongia, C; Laurent, J; Lobjois, V; Mondesert, O | 1 |
| Chen, H; Fan, B; Fang, S; Lu, Q; Sun, Y; Tang, D; Wei, Y; Yin, J; Yin, X; Zhang, B; Zhang, F | 1 |
| Aigner, J; Jäger, D; Lorenzo Bermejo, J; Marmé, F; Schneeweiss, A; Sinn, P; Sohn, C | 1 |
| Lee, GY; Mao, H; Nie, S; Qian, WP; Satpathy, M; Staley, CA; Wang, L; Wang, YA; Yang, L | 1 |
| Campbell, NR; De Oliveira, E; de Wilde, RF; Hidalgo, M; Korangath, P; Maitra, A; Pai, SG; Rajeshkumar, NV; Rasheed, ZA; Streppel, MM; Yabuuchi, S | 1 |
| Almasan, A; Dreicer, R; Ecsedy, JA; Hansel, DE; Lindner, D; Mir, MC; Parker, Y; Singh, K; Teh, BT; Zhang, Z; Zhou, N | 1 |
| Constantinidou, A; Jones, RL; Loggers, E; Pollack, S; Rodler, E | 1 |
| Fahmy, ES; Habib, EE | 1 |
| Chikano, Y; Endo, Y; Higashi, T; Hirose, M; Ishigaki, Y; Kawakami, K; Kitano, A; Minamoto, T; Miyamoto, K; Motoo, Y; Nakada, M; Sai, Y; Sato, H; Shimasaki, T; Takino, T | 1 |
| Apolo, AB; Bajorin, DF; Halabi, S; Iasonos, A; Milowsky, MI; Ostrovnaya, I; Philips, GK; Riches, J; Rosenberg, JE; Small, EJ | 1 |
| Ayaki, M; Horie, S; Kashiwagi, R; Mitsuda, A; Tanaka, H | 1 |
| Kano, M; Nakau, M; Suzaki, S; Tachibana, T; Yamamoto, T; Yanagibashi, K | 1 |
| Bevan, P; Boeck, S; Ebert, MP; Heinemann, V; Laubender, RP; Mala, C | 1 |
| Kawakita, M; Matsumoto, K; Muguruma, K; Segawa, T; Sumiyoshi, T; Utsunomiya, N | 1 |
| Bingjing, Z; Hu, L; Liang, G; Rufu, X; Xiangdong, Z; Yuliang, W | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HJ; Kim, HP; Kim, MS; Kim, TY; Lee, GS; Oh, DY; Yoon, YK | 1 |
| Arshad, A; Chung, W; Dennison, A; Isherwood, J; Metcalfe, M; Steward, W | 1 |
| Budman, DR; Calabro, A; Lesser, M; Rosen, L | 1 |
| Bekaii-Saab, TS; Chidiac, TA; Criswell, T; Fernandez, SA; Guttridge, D; Villalona-Calero, M; Wu, C | 1 |
| Bardutzky, J; Dechent, F; Dersch, R; Doostkam, S; Goller, K; Meckel, S; Stich, O; Weiller, C | 1 |
| Bednar, F; Heidt, DG; Lee, CJ; Li, C; Proctor, E; Simeone, DM; Waghray, M; Yalamanchili, M | 1 |
| An, Y; Cai, B; Chen, J; Jiang, K; Lv, N; Miao, Y; Sun, J; Tu, M; Wei, J; Wu, P | 1 |
| Chen, H; Chen, KJ; Li, H; Li, Y; Lin, SZ; Liu, DL; Luo, J; Tong, HF; Zhang, JH; Zhang, W | 1 |
| Cass, CE; Evans, D; Favis, N; Paproski, RJ; Yao, SY; Young, JD; Zemp, RJ | 1 |
| Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W | 1 |
| Blaszkowsky, LS; Chan, E; Hartford, A; Hidalgo, M; Jackson, L; Ko, YJ; Lichinitser, M; Macarulla, T; McWhirter, E; Morrison, K; O'Reilly, EM; Pezet, D; Rarick, M; Reyno, L; Ritch, P; Rocha-Lima, CM; Roman, L; Spratlin, J; Vincent, M; Wolpin, BM | 1 |
| Berzcel, L; Charabaty, A; Collins, SP; Gurka, MK; Haddad, N; Jackson, P; Jha, R; Johnson, CD; Lei, S; Ley, L; Marshall, JL; Pishvaian, MJ; Slack, R; Suy, S; Tse, G | 1 |
| Kamata, K; Katou, S; Matsuki, M; Takagi, Y; Takahashi, A; Takayanagi, A | 1 |
| Arshad, A; Chung, WY; Dennison, AR; Metcalfe, MS; Steward, W | 1 |
| Calvo, EL; Dusetti, N; Fernandez-Zapico, ME; Garcia, S; Gilabert, M; Iovanna, JL; Lomberk, G; Moutardier, V; Secq, V; Turrini, O; Urrutia, R; Vaccaro, MI | 1 |
| Bhuniya, S; Han, JH; Jeon, HM; Kang, C; Kim, JS; Lee, JH; Maiti, S; Park, N | 1 |
| Chau, I; Cunningham, D; Hubner, RA; Worsnop, F | 1 |
| Chen, X; Li, J; Ouyang, X; Wang, W; Xie, F; Xue, Z; Yu, Z; Zheng, P | 1 |
| Hong, D; Hong, W; Kou, JY; Mao, WM; Su, D; Wang, K; Wang, XJ; Xie, FJ; Yu, XM; Zhang, YP | 1 |
| Gul, A; Karli, R | 1 |
| Camp, ER; Chang, EH; Cole, DJ; Little, EC; Pirollo, KF; Rait, A; Wang, C; Watson, DK; Watson, PM | 1 |
| Chen, JZ; Di, MY; Ding, H; Huang, YF; Mao, C; Tang, JL; Wu, XY; Yang, ZY; Yuan, JQ; Zheng, DY | 1 |
| Abrams, RA; Bridgewater, J; Crosby, T; Cummins, S; Falk, S; Griffiths, G; Hurt, CN; Jephcott, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Radhakrishna, G; Ray, R; Roy, R; Staffurth, J; Wasan, H | 1 |
| Büchler, MW; Combs, SE; Diener, MK | 1 |
| Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN | 1 |
| Kim, R; Kothari, N; Saif, MW | 1 |
| Arnold, S; Baeker, T; Brooks, M; Carloss, H; Croley, J; Kloecker, G; Kvale, E; Leggas, M; Lim, A; Maheshwari, JG; Rinehart, J; Shelton, B; Slone, S; Zaydan, MA | 1 |
| Harada, N; Hayashi, T; Kaji, S; Koike, N; Ozaki, Y; Saida, S; Suzuki, M; Suzuki, S | 1 |
| Asami, K; Atagi, S; Fujita, Y; Kawaguchi, T; Minomo, S; Okishio, K; Saitou, R; Takata, S; Tamura, A | 1 |
| Li, YH; Luo, HY; Qiu, MZ; Wang, DS; Wang, F; Wang, FH; Wang, ZQ; Xu, RH; Zhang, DS | 1 |
| Bhattacharya, R; Khan, JA; Kudgus, RA; Mukherjee, P; Reid, JM; Robertson, JD; Szabolcs, A; Walden, CA | 1 |
| Bepler, G; Chen, Z; Li, X; Malysa, A; Oliveira, P; Zhang, Y; Zhou, J | 1 |
| Jain, NK; Jain, V; Mehra, NK; Singh, R | 1 |
| Einsele, H; Germer, CT; Hartlapp, I; Isbert, C; Kenn, W; Kunzmann, V; Müller, J; Scheurlen, M; Steger, U | 1 |
| Abe, Y; Asaka, M; Eto, K; Fukuoka, M; Kawahata, S; Kawakami, H; Kudo, T; Kuwatani, M; Matsuno, Y; Sakamoto, N; Takasawa, A | 1 |
| Awasthi, N; Hinz, S; Schwarz, MA; Schwarz, RE; Zhang, C | 1 |
| du Bois, A; Harter, P; Heitz, F; Kurzeder, C; Lubbe, D; Pfisterer, J; Plante, M; Vergote, I | 1 |
| Dohrmann, T; Izbicki, JR; Jaenicke, F; Kutup, A; Mahner, S; Müller, V; Vashist, YK | 1 |
| Breyer, BN; Erickson, BA; Konety, BR; Lightfoot, AJ; O'Donnell, MA; Rosevear, HM | 1 |
| Daneker, GW; Kim, B; McDonald, JF; Mezencev, R; Sulchek, TA; Wang, L; Xu, W | 1 |
| Chen, I; McDermott, DF; Michaelson, MD; Patyna, S; Ruiz-Garcia, A; Ryan, DP; Schwarzberg, AB; Shapiro, GI; Stephenson, P; Tye, L; Zhu, AX | 1 |
| Altevogt, P; Bretz, NP; Fogel, M; Hazin, J; Herr, I; Keller, S; Moldenhauer, G; Perne, C; Salnikov, AV; Schlange, T | 1 |
| Banna, GL; Basile, A; Fraggetta, F; Ippolito, M; Lipari, H; Marletta, F; Nicolosi, M; Saita, S; Terminella, A; Urso, OE; Vaglica, M | 1 |
| Fang, J; Li, S; Lv, C; Ma, Y; Sun, Y; Wu, N; Yan, S; Yang, Y; Zheng, Q | 1 |
| Bessard, R; Bourgeois, H; Douillard, JY; Gamelin, E; Grudé, F; Metges, JP; Riché, C; Vidal, AM | 1 |
| Li, J; Lu, Q; Ouyang, L; Peng, L; Tan, C; Wang, S; Zeng, X | 1 |
| Altiok, S; Bui, MM; Foroutan, P; Gillies, RJ; Kreahling, JM; Letson, D; Martinez, G; Raghavan, M; Razabdouski, T; Reed, D | 1 |
| Cheng, J; Gao, J; Liu, X; Wang, J; Wang, L; Xiong, L | 1 |
| Boku, N; Furuse, J; Ikeda, M; Nagakawa, T; Nakamori, S; Ohkawa, S; Okusaka, T; Sato, T; Suzuki, E; Yanagimoto, H | 1 |
| Biffo, S; Burlando, B; Gallo, S; Martinotti, S; Mutti, L; Ranzato, E; Russo, MV; Volta, V | 1 |
| Bernard, A; Facy, O; Ghiringhelli, F; Ladoire, S; Lokiec, F; Magnin, G; Mordant, P; Pagès, PB | 1 |
| Drebin, JA; Feldman, MD; Giantonio, BJ; Ginsberg, G; Harlacker, K; Heitjan, DF; Kochman, ML; Metz, JM; O'Dwyer, PJ; Plastaras, JP; Sohal, DP; Sun, W; Teitelbaum, UR | 1 |
| Han, JC; Li, HB; Li, XD; Wu, XY; Zhang, YJ | 1 |
| Arslan, ÜY; Bulut, E; Cangir, AK; İçli, F; Kavukçu, Ş; Kılıç, D; Koçer, M; Özdemir, NY; Oztuna, DG; Ürün, Y; Utkan, G | 1 |
| Barzotti, E; Drudi, F; Fantini, M; Gianni, L; Giuliani, J; Lotti, N; Ravaioli, A; Ridolfi, C; Santelmo, C; Tamburini, E; Tassinari, D | 1 |
| Boy, D; Bruzzi, P; Ceccarelli, M; Cognetti, F; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Fabi, A; Kazeem, G; La Torre, I; Mansutti, M; Marchi, P; Merlo, DF; Venturini, M | 1 |
| Alexandre, J; Awada, A; Besse-Hammer, T; Faivre, S; Gianella-Borradori, A; Goldwasser, F; Jego, V; Raymond, E; Rejeb, N; Trandafir, L | 1 |
| Angspatt, A; Sriussadaporn, S | 1 |
| Johnson, DC; Pruthi, RS; Woods, ME | 1 |
| Ahn, JJ; McKiernan, JM | 1 |
| Huang, CH; Huang, CN; Lee, MH; Li, CC; Li, WM; Tsai, CC; Wu, WJ; Yeh, HC | 1 |
| Ge, Y; Guo, Y; He, M; He, Y; Li, W; Qiao, Z; Ren, S; Sun, L; Wang, X; Yu, Q | 1 |
| Chun, F; Gontero, P; Gurioli, A; Kluth, LA; Lucca, I; Marson, F; Martorana, G; Mehnert, A; Oderda, M; Pappagallo, G; Rink, M; Sanguedolce, F; Schiavina, R; Schmid, M; Shariat, SF; Sogni, F | 1 |
| Amadori, D; Bauknecht, T; Carrasco, E; Desaiah, D; Labianca, R; Martin, M; Moreau, V; Roesel, S; Soldatenkova, V; Uziely, B | 1 |
| Chan, KS; Lim, KH; Lim, WT; Lynette, O; Montoya, J; Ng, QS; Sakktee Krisna, S; Takano, A; Tan, DS; Tan, EH | 1 |
| Angelini, C; Arosio, P; Bertuzzi, A; Colombo, P; Cucchiari, D; De Sanctis, R; Faucher, E; Fusco, N; Pellegrinelli, A | 1 |
| Baba, H; Boku, N; Chen, JS; Cheng, AL; Egawa, S; Fukutomi, A; Funakoshi, A; Furuse, J; Hatori, T; Ikeda, M; Ioka, T; Kitano, M; Mizumoto, K; Ohashi, Y; Ohkawa, S; Okusaka, T; Sato, A; Shimamura, T; Sho, M; Sugimori, K; Tanaka, M; Ueno, H; Yamaguchi, T; Yamao, K; Yanagimoto, H | 1 |
| Flatten, KS; Huehls, AM; Huntoon, CJ; Karnitz, LM; Kaufmann, SH; Sutor, SL; Wahner Hendrickson, AE | 1 |
| Ardizzoni, A; Azzoni, C; Baldini, E; Boni, C; Boni, L; Bordi, C; Bordi, P; Bortesi, B; Campanini, N; Fontanini, G; Grossi, F; Naldi, N; Recchia, F; Tiseo, M; Zanelli, F | 1 |
| Endo, I; Hosono, K; Kobayashi, N; Kubota, K; Matsuyama, R; Mori, R; Nakajima, A; Sato, T; Taniguchi, K; Watanabe, S | 1 |
| Bouvet, M; Hoffman, RM; Liu, F; Wu, C; Zhang, L; Zhang, Y; Zhao, M | 1 |
| Endoh, T; Ikeda, K; Iwata, N; Minami, T; Sasano, H; Sugawara, N; Yoshida, Y | 1 |
| Chatzaki, E; Constantinidis, TC; Darwiche, K; Domvri, K; Kakolyris, S; Karamanos, NK; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Fujii, Y; Fukui, I; Kitsukawa, S; Masuda, H; Saito, K; Sakura, M; Urakami, S; Yamamoto, S; Yano, A; Yonese, J; Yuasa, T | 1 |
| Abate-Shen, C; Benson, M; Delto, JC; Kobayashi, T; McKiernan, J | 1 |
| Li, G; Li, W; Li, Y; Qin, Y; Qu, X; Sun, C; Wang, R; Zhao, C | 1 |
| Chen, AB; Johnson, BE; Schrag, D; Sharma, DB; Weeks, JC; Zhu, J | 1 |
| Hwang, JH; Kim, HR; Lee, SH; Paik, WH; Park, JK; Song, BJ | 1 |
| Borzási, E; Együd, Z; Fodor, E; Furák, J; Hideghéty, K; Kahán, Z; Maráz, A; Pálföldi, R; Tiszlavicz, L; Varga, Z | 1 |
| Annereau, JP; Bailly, C; Bonnet, D; Brel, V; Créancier, L; Currie, E; Fournier, E; Gomes, B; Guilbaud, N; Guminski, Y; Kruczynski, A; Pillon, A; Vandenberghe, I | 1 |
| Chen, G; Cui, QC; Du, X; Shi, J; Shu, H; Wang, TX; You, L; Zhang, TP; Zhao, YP; Zhou, L | 1 |
| Jiang, Y; Jiao, X; Sun, S; Zheng, C | 1 |
| Ahn, JH; Ahn, JS; Han, SW; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, JH; Kim, SB; Lee, KS; Lee, MH; Lee, S; Nam, BH; Oh, DY; Park, HS; Park, IH; Park, YH; Ro, J; Sohn, JH | 1 |
| Abonyi-Tóth, Z; Katona, L; Kovács, G; Moldvay, J; Rokszin, G | 1 |
| Scheithauer, W; Van Cutsem, E | 1 |
| Byun, HJ; Kim, BR; Park, SY; Rho, SB; Yoo, HJ | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Ajiki, T; Fukumoto, T; Ku, Y; Matsumoto, I; Murakami, S; Okazaki, T; Otsubo, I; Sawa, H; Shinozaki, K; Tsuchida, S; Ueno, K; Yoshida, Y | 1 |
| Bellew, KM; Bendell, JC; Burris, HA; Cox, DS; Durante, M; Infante, JR; Jones, SF; Le, NT; Papadopoulos, KP; Park, JJ; Patnaik, A; Rasco, D; Smith, L; Tolcher, AW | 1 |
| Anile, M; Ciccone, AM; D'Andrilli, A; Ibrahim, M; Maurizi, G; Rendina, EA; Venuta, F | 1 |
| Gabor, F; Kählig, H; Neutsch, L; Pichl, C; Spijker, S; Wirth, EM; Wirth, M | 1 |
| Alvarez, E; Campos, MD; Cavaliere, V; Costantino, S; Kaiser, CM; Lombardo, T; Papademetrio, DL; Simunovich, T | 1 |
| Hao, K; Qin, C; Tian, X; Xie, K; Xie, X; Yang, Y | 1 |
| Ikeda, Y; Kikuchi, Y; Kita, T; Kudoh, K; Sasaki, N; Takano, M | 1 |
| Akewanlop, C; Ithimakin, S; O-Charoenrat, P; Prasarttong-Osoth, P; Ratanawichitrasin, A; Rojananin, S; Soparattanapaisarn, N; Srimuninnimit, V; Veerasarn, V | 1 |
| Agaram, N; Crooks, PA; Schmidt, CM; Stantz, K; Wu, H; Yip-Schneider, MT | 1 |
| Barlési, F; Bylicki, O; Chouaid, C; Corre, R; Créquit, J; Dubos, C; Falchero, L; Ferlay, C; Fournel, P; Lavolé, A; Le Caer, H; Linard, P; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenègre, A; Westeel, V; Zalcman, G | 1 |
| Furuse, J; Higashi, S; Ikeda, M; Inagaki, M; Kato, H; Mitsunaga, S; Ochiai, A; Ohno, I; Shimizu, S; Terao, K | 1 |
| patel, J | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Bauer, D; Biassoni, V; Casanova, M; Catania, S; De Pava, MV; Gandola, L; Indini, A; Massimino, M; Modena, P; Pecori, E; Podda, M; Polastri, D; Rampini, P; Schiavello, E | 1 |
| Benson, M; Goldman, B; Lee, CT; Lenz, HJ; Lerner, SP; Petrylak, DP; Sakr, WA; Skinner, EC; Tangen, CM; Thompson, IM; Wilson, SS | 1 |
| Dolgikh, SD; Gapbarov, ACh; Polysalov, VN; Veriasova, NN | 1 |
| Bondarev, GN; Filatov, MV; Ibatulin, FM; Kovalëv, RA; Stam, TA | 1 |
| Ghansah, T; Kinney, K; Kodumudi, K; Pilon-Thomas, S; Sarnaik, AA; Springett, G; Vohra, N; Weber, A | 1 |
| El-Hadaad, HA; Wahba, HA | 1 |
| Cantú, D; Cetina, L; Chanona, J; Coronel, J; de la Garza, J; Dueñas-González, A; González-Enciso, A; Hinojosa, J; Jiménez-Lima, R; Montalvo, G; Mota, A; Muñoz, D; Pérez-Montiel, D; Poitevin, A; Rivera, L; Robles-Flores, J; Serrano, A; Trejo, E; Wegman, T | 1 |
| Appelbaum, L; Breuer, S; Hubert, A; Maimon, O; Peretz, T | 1 |
| Dahlberg, SE; Hoang, T; Johnson, DH; Schiller, JH | 1 |
| Andreu, F; Arellano, A; Arnaiz, Mdel M; Calvo, F; Cardenal, F; Cobo, M; Delgado, R; Dómine, M; García-Gómez, R; Garrido, P; Isla, D; Massutí, B; Morán, T; Morera, R; Perez-Casas, A; Ramos, A; Rosell, R; Valencia, J; Zamora, J | 1 |
| Abrao, FG; Gross, JL; Naim Younes, R; Rodrigues Pereira, J | 1 |
| Chabot, JA; Hershman, DL; Insel, BJ; Khanna, LG; Neugut, AI; Oberstein, PE | 1 |
| Choi, MH; Kim, JS; Lim, SK; Shin, DH | 1 |
| Abacioglu, U; Alsan Cetin, I; Atasoy, BM; Dane, F; Ibrahimov, R; Ozgen, Z; Turhal, NS; Turkeri, L; Ucuncu Kefeli, A | 1 |
| Benhadji, KA; Makiuchi, T; Nokihara, H; Sekiguchi, R; Slapak, CA; Tamura, T; Uenaka, K; Yamada, Y; Yamamoto, N | 1 |
| Chen, B; Cheng, H; Cheng, L; Li, F; Lu, Z; Qin, Q; Sun, N; Sun, X | 1 |
| Ando, T; Kameda, R; Kobayashi, S; Ohkawa, S; Ueno, M | 1 |
| Lv, M; Ren, JC; Sun, J; Wang, B; Wang, X; Zhang, L; Zhang, T | 1 |
| Abou-Elela, E; Darwish, D; Ibrahim, N | 1 |
| Fang, JY; Sun, TT; Wang, JL | 1 |
| De, D; George, J; Kanwar, AJ; Mahajan, R; Saikia, UN | 1 |
| Bai, H; Chen, J; Fang, F; Fang, J; Feng, Q; Feng, Y; Li, S; Lv, C; Ma, Y; Pei, Y; Wang, J; Wang, Y; Wu, N; Yan, S; Yang, Y; Zhao, B; Zheng, Q | 1 |
| Beeharry, N; Caviston, JP; Rattner, JB; Yen, T | 1 |
| Abe, H; Azuma, H; Inamoto, T; Kiyama, S; Komura, K; Kotake, Y; Kouno, J; Minami, K; Narumi, Y; Nomi, H; Takagi, S; Takahara, K; Uehara, H; Yamamoto, K | 1 |
| Cheng, X; Ji, Z; Lu, M; Mei, F; Ou, Y; Peng, Z | 1 |
| Dick, IM; Harken, JA; Khong, A; Lake, RA; Lesterhuis, WJ; Nowak, AK; Robinson, BW; Rozali, EN; Salmons, J | 1 |
| Gabor, F; Kählig, H; Neutsch, L; Spijker, S; Wambacher, M; Wirth, EM; Wirth, M | 1 |
| Morishita, F; Okazawa, H; Orisaka, M; Tsuyoshi, H; Yoshida, Y | 1 |
| Assadourian, S; Barone, C; Hatteville, L; Humblet, Y; Karasek, P; Manges, R; Philip, PA; Riess, H; Rougier, P; Santoro, A | 1 |
| Barbera, S; Bianco, R; Cavanna, L; Cinieri, S; Costanzo, R; Daniele, G; De Marinis, F; Di Maio, M; Gallo, C; Gebbia, V; Giordano, P; Gridelli, C; Mancuso, G; Montanino, A; Montesarchio, V; Morabito, A; Nacci, A; Perrone, F; Piccirillo, MC; Rocco, G; Russo, P; Sandomenico, C; Viganò, MG | 1 |
| Altuntaş, F; Bozdağ, SC; Demiriz, IŞ; Durgun, G; Koçubaba, S; Sarıca, A; Tekgündüz, E | 1 |
| Abbruzzese, JL; Carlson, P; Fogelman, DR; George, B; Javle, M; Khalil, MA; Overman, M; Qiao, W; Varadhachary, G; Wolff, RA | 1 |
| Bedard, PL; Chen, EX; Chen, Z; Clarke, BA; Cohen, B; Hirte, HW; Hotte, SJ; Ivy, SP; McWhirter, E; Moore, MJ; Oza, AM; Razak, AR; Reedijk, M; Richter, S; Siu, LL; Stathis, A; Tran, B; Wang, L; Zhang, WJ | 1 |
| Wang, J; Xu, Q; Xu, S; Zhang, L; Zhang, N; Zhou, J | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Murray, D; Nieto, Y; Qazilbash, MH; Shah, J; Turturro, F; Valdez, BC; Wang, G; Wang, M; Weber, DM | 1 |
| Ji, M; Li, J; Zhu, LN | 1 |
| Capellà, G; Casanovas, O; Ginestà, MM; Gracova, K; Graupera, M; Laquente, B; Serrano, T; Viñals, F; Vives, M | 1 |
| Fu, Z; Han, B; Han, H; He, Q; Tang, K; Wang, X; Xu, J; Yin, H; Zhang, X | 1 |
| Giese, N; Giese, T; Gladkich, J; Hage, C; Herr, I; Labsch, S; Mattern, J; Nwaeburu, C; Rausch, V; Schönsiegel, F | 1 |
| Horiguchi, S; Ichimura, K; Iwamuro, M; Kataoka, J; Kato, H; Matsubara, M; Nagahara, T; Nishina, S; Nouso, K; Shiraha, H; Takaki, A; Tanaka, T; Yagi, T; Yamamoto, K | 1 |
| Conter, HJ; Lim, ZD; Millikan, RE; Ng, CS; Tannir, NM | 1 |
| Bochner, BH; Chen, LY; Dalbagni, G; Donat, SM; Herr, HW; Sternberg, IA | 1 |
| Beijnen, JH; Huitema, AD; Leijen, S; Schellens, JH; van Werkhoven, E; Veltkamp, SA | 1 |
| Dua, V; Goyal, H | 1 |
| Han, H; Li, YH; Liu, JY; Liu, ZW; Qin, ZK; Yao, K; Ye, YL; Zhang, ZL; Zhou, FJ | 1 |
| Duffy, A; Greten, TF; Liewehr, DJ; Rahma, OE; Steinberg, SM | 1 |
| Chen, Q; Drisko, J; Yu, J | 1 |
| Artru, P; Bachet, JB; Bidard, FC; Bouché, O; Chibaudel, B; Desseigne, F; Hammel, P; Huguet, F; Louvet, C; Mathiot, C; Mineur, L; Pierga, JY | 1 |
| Fujimura, Y; Himeno, A; Hirata, H; Inoue, K; Kida, H; Kijima, T; Kumanogoh, A; Matsumoto, M; Nagatomo, I; Nishijima, Y; Otani, Y; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Lv, X; Pan, ZH; Su, A; Zhang, J; Zhou, QM | 1 |
| Boulware, SB; Christensen, LA; Coghlan, L; Finch, RA; Thames, H; Vasquez, KM | 1 |
| Ciombor, KK; Goff, LW | 1 |
| Armbrecht, N; Fleischmann-Mundt, B; Gürlevik, E; Hoffmann, D; Kloos, A; Kubicka, S; Kühnel, F; Longerich, T; Manns, MP; Schambach, A; Wirth, TC; Woller, N; Zender, L | 1 |
| Boettcher, M; Fredebohm, J; Hoheisel, JD; Wolf, J | 1 |
| Cabella, C; Canapè, C; Catanzaro, G; Colombo Serra, S; Jensen, PR; Karlsson, M; Lerche, MH; Miragoli, L; Poggi, L; Tedoldi, F; Uggeri, F; Venturi, L | 1 |
| Cho, YJ; Hwang, YS; Jeong, YY; Kim, HC; Kim, IS; Kim, MJ; Kim, SH; Lee, GW; Lee, JD; Lee, S; Ling, H; Oh, SY | 1 |
| Arizumi, T; Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Miyabayashi, K; Mizuno, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Yagioka, H; Yamamoto, K; Yamamoto, N | 1 |
| Antonia, S; Bepler, G; Brahmer, J; Chen, W; Chiappori, A; Fischer, JR; Gadgeel, S; Gray, J; Haura, E; Pinder-Schenck, M; Schell, MJ; Schreiber, F; Simon, G; Tanvetyanon, T; Williams, C; Zhao, X; Zheng, Z | 1 |
| Akiba, J; Arinaga-Hino, T; Kage, M; Kawaguchi, T; Nakashima, O; Niizeki, T; Sata, M; Takenaka, M; Yano, H | 1 |
| Hiraoka, N; Ikeda, M; Kondo, S; Kosuge, T; Morizane, C; Nara, S; Okusaka, T; Otsuka, T; Shimada, K; Ueno, H | 1 |
| Ai, Y; Brody, JR; Burkhart, RA; Cozzitorto, JA; Gehrmann, M; Lal, S; Liang, Q; Miller, K; Napper, A; Norris, ZA; Peng, Y; Sawicki, JA; Talbott, VA; Tholey, RM; Winter, JM; Witkiewicz, AK; Yeo, CJ; Zhuang, Z | 1 |
| Dangi-Garimella, S; Ebine, K; Kumar, K; Munshi, HG; Sahai, V | 1 |
| Abu-Rustum, NR; Andikyan, V; Barakat, RR; Chi, DS; Khoury-Collado, F; Konner, JA; O'Cearbhaill, RE; Sandadi, S; Sonoda, Y; Tew, WP | 1 |
| Fleming, J; Jiang, ZQ; Katz, M; Kopetz, S; Lee, JE; Overman, MJ; Shroff, R; Varadhachary, G; Wang, H; Wang, X; Wolff, RA | 1 |
| Singer, A; Tresley, J; Velazquez-Vega, J; Yepes, M | 1 |
| Alva, A; Daignault-Newton, S; Grivas, PD; Hafez, K; Hollenbeck, B; Hussain, M; Lee, CT; Montgomery, JS; Montie, JE; Smith, DC; Weizer, A; Wood, D | 1 |
| Adam, J; Pinilla-Dominguez, P; Richardson, J; Robertson, J | 1 |
| Li, R; Li, W; Shi, L; Shuai, X; Tao, K; Wang, G; Wu, K; Yin, Y; Zhang, P; Zhao, E | 1 |
| Gschwend, JE; Horn, T; Kübler, HR; Ladwein, B; Maurer, T; Redlin, J; Retz, M; Seitz, AK | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Murata, A; Nakata, B; Yamada, N; Yashiro, M | 1 |
| Chauffert, B; Ghiringhelli, F; Wiazzane, N | 1 |
| Tang, Y; Teng, X; Wang, Y | 1 |
| Clements, A; Cohn, DE; Smith, B; Straughn, JM; Tierney, BJ | 1 |
| Kawamura, N; Matsushita, M; Nin, M; Okada, T; Tsujihata, M; Ujike, T | 1 |
| Matsuzaki, K; Nakazawa, S; Nonomura, N; Takao, T; Tsujimura, A; Uemura, M; Yoshida, T | 1 |
| Bekaii-Saab, T; Ben-Josef, E; Bloomston, M; Dawson, LA; Francis, IR; Greenson, JK; Griffith, KA; Herman, JM; Kim, EJ; Laheru, D; Lawrence, TS; Moore, MJ; Simeone, DM; Wei, A; Williams, T; Wolfgang, CL; Zalupski, MM | 1 |
| Bansal, SS; Celia, C; Ferrari, M; Ferrati, S; Grattoni, A; Palapattu, G; Zabre, E | 1 |
| Khunnarong, J; Manusirivithaya, S; Pataradool, K; Pitakkarnkul, S; Prutthiphongsit, W; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
| Bigay-Game, L; Braun, D; David, P; Debieuvre, D; Depierre, A; Douillard, JY; Laporte, S; Lavolé, A; Lebeau, B; Lemarié, E; Milleron, B; Molinier, O; Morin, F; Ozenne, G; Poudenx, M; Pujol, JL; Puyraveau, M; Quoix, E; Rivière, A; Westeel, V; Zalcman, G | 1 |
| Bajpayee, A; Chaudhary, RK; Dubey, A; Verma, A | 1 |
| Arora, S; Bhardwaj, A; Grizzle, WE; McClellan, S; Nirodi, CS; Owen, LB; Piazza, GA; Singh, AP; Singh, S; Srivastava, SK | 1 |
| Badola, S; Chen, L; Deng, H; Fuchs, CS; Gansert, JL; Kindler, HL; Loh, E; McCaffery, I; Patterson, SD; Suzuki, S; Tang, R; Tudor, Y | 1 |
| Fu, Z; Wang, X; Yin, H; Zhang, X | 1 |
| Ando, R; Etani, T; Hashimoto, Y; Kawai, N; Kohri, K; Naiki, T; Okada, A; Okamura, T; Tozawa, K; Yasui, T | 1 |
| Beaussart, P; Bologna, S; Canioni, D; Casasnovas, RO; Castaigne, S; Delarue, R; El Gnaoui, T; Gaulard, P; Haioun, C; Mounier, N; Petrella, T; Rahmouni, A; Salles, G; Sebban, C; Sonet, A; Tilly, H | 1 |
| Chitkara, D; Kumar, N | 1 |
| Behrman, SW; Chitkara, D; Kumar, N; Mahato, RI; Mittal, A | 1 |
| An, G; Chen, W; Wei, P; Yan, D | 1 |
| Baines, AT; Baldwin, AS; Bednarski, BK; Cobb, MG; Gavilano, L; Kim, HJ; Taverna, P; White, CD; Williams, D; Witherspoon, SM; Xu, D | 1 |
| Fan, KX; Guo, YJ; Huang, A; Wang, B; Zhang, B; Zhang, F | 1 |
| Takeuchi, K; Tamura, T | 1 |
| Boku, N; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Mizusawa, J; Morizane, C; Okusaka, T; Takashima, A; Ueno, M | 1 |
| Ahmad, S; Khattak, J; Naqi, N; Shah, I | 1 |
| Hatano, E; Ishii, T; Kanai, M; Machimoto, T; Nagata, H; Narita, M; Tanaka, S; Taura, K; Uemoto, S; Yamamoto, K; Yamanaka, K | 1 |
| Chen, KZ; Jiang, GC; Li, X; Wang, J; Yang, F | 1 |
| Darwiche, K; Freitag, L; Goldberg, EP; Huang, H; Li, Q; Petridis, D; Ritzoulis, C; Spyratos, D; Yarmus, L; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Ahn, YO; Heo, DS; Kim, DW; Kim, S; Kim, TM; Lee, SH | 1 |
| Blackford, AL; Cameron, JL; Choti, MA; De Jesus-Acosta, A; Donehower, RC; Edil, BH; Ellsworth, S; Fan, KY; Hacker-Prietz, A; Herman, JM; Hidalgo, M; Hruban, RH; Laheru, DA; Le, DT; Pawlik, TM; Schulick, RD; Wild, AT; Wolfgang, CL; Wood, LD; Zheng, L | 1 |
| Fujikawa, T; Maekawa, H; Shimoike, N; Tanaka, A | 1 |
| Huang, L; Kim, WY; Rogers, AB; Schwerbrock, NM; Zhang, Y | 1 |
| Akagi, Y; Ishikawa, H; Kinugasa, T; Mizobe, T; Ohshima, K; Oka, Y; Setojima, K; Shiratsuchi, I; Shirouzu, K | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| Ishihara, Y; Itoh, K; Komatsu, N; Matsueda, S; Mine, T; Noguchi, M; Sasada, T; Yamada, A; Yonemoto, K; Yoshitomi, M; Yutani, S | 1 |
| Ball, D; Collins, M; Francis, H; Franco, M; Kofoed, S; Mileshkin, L; Paramanathan, A; Solomon, B | 1 |
| Choi, W; Jinesh G, G; Kamat, AM; Laing, NM; Lee, EK; McConkey, DJ | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Muto, T; Nakagawa, N; Sasaki, H; Sudo, T; Sueda, T; Uemura, K; Urabe, K | 1 |
| Chen, YJ; Hu, JB; Li, HB; Wang, B; Yang, R; Zou, SQ | 1 |
| Gotoh, K; Ioka, T; Ishikawa, O; Marubashi, S; Murata, M; Ohigashi, H; Takahashi, H; Uehara, H; Yamada, T; Yano, M | 1 |
| Akita, H; Doki, Y; Eguchi, H; Hama, N; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Alongi, F; Clerici, E; Comito, T; Cozzi, L; Fogliata, A; Iftode, C; Mancosu, P; Navarria, P; Reggiori, G; Rimassa, L; Scorsetti, M; Tomatis, S; Tozzi, A; Zerbi, A | 1 |
| Jin, X; Liu, G; Miao, X; Sun, J; Zhong, D | 1 |
| Asthana, S; Chourasia, MK; Gupta, A; Konwar, R | 1 |
| Awasthi, N; Hinz, S; Schwarz, AM; Schwarz, MA; Schwarz, RE; Wang, C; Williams, NS; Zhang, C | 1 |
| Davis, MA; Engelke, CG; Greenson, JK; Karnak, D; Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Qian, Y; Robertson, JR; Tanska, DM; Wei, D; Zhang, Q; Zhao, L | 1 |
| Del Bene, F; Germani, M; Magni, P; Terranova, N | 1 |
| Hiratsuka, Y; Ishii, T; Matsubara, T; Taira, H | 1 |
| Bingham, J; Blasina, A; Cao, J; Fang, DD; Gu, Y; Hostomsky, Z; Jani, JP; Jirout, Z; Kornmann, J; Lira, ME; Los, G; Tsaparikos, K; Vanarsdale, T; Wang, J; Zhu, Z | 1 |
| Dimcevski, G; Gilja, OH; Hoem, D; Kotopoulis, S; Postema, M | 1 |
| Brons, S; Combs, SE; Debus, J; El Shafie, RA; Haberer, T; Habermehl, D; Mairani, A; Orschiedt, L; Rieken, S; Weber, KJ | 1 |
| Bakker, A; Balic, A; Garcia, E; Hahn, SA; Heeschen, C; Hermann, PC; Hidalgo, M; Sahoo, SK; Sainz, B; Trabulo, SM; Tunici, P; Vandana, M | 1 |
| Carazo, A; Delgado, AV; Gómez-Sotomayor, R; Munoz-Gamez, JA; Rudzka, K; Ruiz-Extremera, A; Salmerón, J; Viota, JL | 1 |
| Cheney, DL; Ghandehari, H; Kopeček, J; Larson, N; Ray, A; Yang, J | 1 |
| Hashimoto, J; Hosoi, H; Koizumi, F; Kondo, S; Morizane, C; Okusaka, T; Tamura, K; Ueno, H | 1 |
| Chindaprasirt, J; Khuntikeo, N; Ngamprasertchai, T; Pakkhem, A; Sookprasert, A; Ungarereevittaya, P; Wirasorn, K | 1 |
| Couvreur, P; Desmaële, D; Harrisson, S; Maksimenko, A; Nicolas, J; Trung Bui, D; Vauthier, C | 1 |
| Lee, LB; Ruterbories, KJ; Schmalz, CA; Torchia, J; Wickremsinhe, ER | 1 |
| Bhuniya, S; Han, JH; Jeon, HM; Kang, C; Kim, JS; Lee, JH; Lee, MH; Maiti, S; Park, N | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, Y; Yun, T | 1 |
| Lin, F; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
| Hamed, SS; Jusko, WJ; Straubinger, RM | 1 |
| Beasley, TM; Boothman, DA; Buchsbaum, DJ; Kim, H; Lee, SK; Li, LS; Martin, A; Rigell, CJ; Samuel, SL; Stockard, CR; Umphrey, HR; Zhai, G; Zinn, KR | 1 |
| Bapiro, TE; Frese, KK; Jodrell, DI; Nakagawa, T; Neesse, A; Pilarsky, C; Seeley, TW; Spong, SM; Sternlicht, MD; Tuveson, DA | 1 |
| Ciccolini, J; Dahan, L; Duluc, M; Fina, F; Lacarelle, B; Norguet, E; Ouafik, L; Seitz, JF; Serdjebi, C | 1 |
| Akada, M; Egawa, S; Fujishima, F; Ishida, K; Katayose, Y; Motoi, F; Nakagawa, K; Oikawa, M; Okada, T; Ono, F; Ottomo, S; Shimamura, H; Takemura, S; Unno, M | 1 |
| Dobra, K; Hjerpe, A; Mundt, F; Nilsonne, G; Souri, P; Szulkin, A; Wasik, AM | 1 |
| Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Jodrell, DI; Krippendorff, BF; Neesse, A; Richards, FM; Tuveson, DA | 1 |
| Choi, JN; Subtil, A; Wiznia, LE | 1 |
| Callen, JP | 1 |
| Bajorin, DF; Bochner, BH; Dalbagni, G; Kent, M; Kim, PH; Sfakianos, JP; Zhao, P | 1 |
| Bao, GQ; Pan, CP; Peng, CH; Shen, BY; Shi, MM; Zhang, YJ | 1 |
| Demizu, Y; Fuwa, N; Horai, A; Kinoshita, Y; Kitajima, N; Ose, T; Satake, S; Takatori, K; Terashima, K; Yoshida, R | 1 |
| Chaulagain, CP; Rothschild, J; Saif, MW | 1 |
| Huber, KE; Saif, MW; Savir, G | 1 |
| Jarboe, J; Saif, MW | 1 |
| Saif, MW; Strimpakos, AS | 1 |
| Saif, MW; Skoura, E; Syrigos, KN | 1 |
| Saif, MW; Sarris, EG; Syrigos, KN | 1 |
| Ducreux, M; Heinemann, V; Macarulla, T; Reni, M; Richel, DJ; Ychou, M | 1 |
| Cass, CE; El-Gehani, F; Ghosh, S; Lai, R; Mackey, JR; North, S; Santos, C | 1 |
| Boeck, S; Haas, M; Heinemann, V | 1 |
| Hamada, C; Nagashima, K; Noma, H; Sato, Y | 1 |
| Bae, I; Cho, CH; Duong, HQ; Hong, YB; Kim, JS; Kim, YJ; Lee, HS; Seong, YS; Wang, A; Yi, YW; Zhao, W | 1 |
| Cheng, AL; Hsu, CH; Kuo, SH; Lee, JC; Tien, YW; Yang, SH | 1 |
| Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K | 1 |
| Fujita, S; Katagata, N; Matsuzaki, M; Nomizu, T; Saito, M; Sakuma, T; Takenoshita, S; Watanabe, F | 1 |
| Araki, K; Hachisuka, H; Iwamura, Y; Kushima, A; Nagano, K; Nakajima, T; Nakamoto, T; Nunomura, M; Takahashi, K; Takahashi, M; Wakata, M | 1 |
| Ohkawa, S; Sakamoto, Y; Ueno, M | 1 |
| Asuthkar, S; Cines, DB; Estes, N; Gondi, CS; Holterman, AL; Lebedeva, T; Rao, JS; Stepanova, V | 1 |
| Han, JH; He, Y; Hong, KS; Jeon, HM; Kang, C; Kim, JS; Lee, H; Lee, JH; Park, N; Yang, Z | 1 |
| Ajiki, T; Awane, M; Furuyama, H; Ikai, I; Ikezawa, K; Ioka, T; Kanai, M; Kou, T; Kume, M; Kuroda, N; Miyamoto, A; Nagano, H; Ochiai, T; Ogawa, M; Taira, K; Takeda, Y; Takemura, S; Terajima, H; Toyokawa, H; Tsukamoto, T; Yazumi, S | 1 |
| Contreras-Steyls, M; Estrada, D; Gallego, E; Herrera, E; López-Navarro, N; Moyano, B | 1 |
| Gonzalez de Mejia, E; Johnson, JL | 1 |
| Chang, X; Fan, X; Guo, Q; Huang, Y; Li, X; Lu, J; Lu, Y; Shan, H; Wang, L; Wang, Y; Wang, Z; Zhu, H; Zhu, M; Zhu, S | 1 |
| Dito, G; Girit, E; Humphrey, R; Hunt, JT; Jure-Kunkel, M; Lee, F; Masters, G | 1 |
| Ahuja, N; Azad, NS; Danilova, L; Delmas, A; Herman, JG; Pelosof, L; Yerram, SR | 1 |
| Blackwood, E; Cain, G; Choi, J; Epler, J; Evangelista, M; Flagella, M; Gazzard, L; Halladay, J; Jackson, PK; Jakubiak, D; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Schmidt, S; Williams, K; Wong, K; Xiao, Y; Yee, S; Yen, I | 1 |
| Fang, J; Jiang, G; Li, D; Tao, H; Yang, Y; Zhang, J; Zhou, S | 1 |
| Delalande, A; Dimcevski, G; Gilja, OH; Gjertsen, BT; Kotopoulis, S; Mamaeva, V; McCormack, E; Popa, M; Postema, M | 1 |
| Kakudo, Y; Kameno, K; Kanai, M; Kim, YH; Kitano, T; Matsumoto, S; Mishima, M; Mori, Y; Nagai, H; Nakata, K; Nishimura, T; Sato, H; Takashima, S; Yamaguchi, T; Yanagihara, K; Yasuda, H | 1 |
| Shi, X; Yu, XM; Zhang, YP; Zhao, J | 1 |
| Kimura, S; Kitahara, K; Komiya, K; Noshiro, H; Sueoka-Aragane, N; Sugioka, T; Yakabe, T | 1 |
| Butthongkomvong, K; Jhankumpha, S; Kumdang, S; Sirachainan, E; Sukhontharot, OU | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, V; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Somali, I; Tarhan, MO | 1 |
| Akca, Z; Aksahin, A; Aslan, T; Berk, V; Buyukcelik, A; Erden, A; Karaca, H; Mutlu, H; Ozkan, M | 1 |
| Ariyoshi, K; Eto, T; Okadome, M; Saito, T; Shimamoto, K; Tomita, Y | 1 |
| Agbo, F; Arita, S; Esaki, T; Fujimoto, C; Hamatake, M; Hirai, F; Kometani, T; Makiyama, A; Nosaki, K; Seto, T; Shi, X; Takeoka, H | 1 |
| Barth, PJ; Bartsch, DK; Brendel, C; Ebert, MP; Endlicher, E; Fass, J; Fensterer, H; Gress, TM; Hofheinz, R; Kornmann, M; Lindig, U; Märten, A; Michl, P; Müller, HH; Schade-Brittinger, C; Schmidt, WE; Settmacher, U; Tebbe, S | 1 |
| Akada, J; Kitagawa, T; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Suenaga, S; Tanaka, T; Tokuda, K; Wang, Y | 1 |
| Gong, DJ; Guo, QQ; Yu, M; Zhang, JM; Zhuang, B | 1 |
| Li, WB; Li, YY; Qin, YZ; Qu, XJ; Wang, RQ | 1 |
| Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH | 1 |
| Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tomimaru, Y; Wada, H | 1 |
| Bria, E; Cognetti, F; Gamucci, T; Gelibter, A; Mansueto, G; Milella, M; Moscetti, L; Ruggeri, EM; Sperduti, I; Vaccaro, V | 1 |
| Aleksandrova, LN; Bezborodova, OA; Iakubovskaia, RI; Kovalenko, AL; Nemtsova, ER; Venediktova, IuB | 1 |
| Hu, Y; Liao, Q; Wen, Z; You, L; Zhao, Y; Zhou, L | 1 |
| Abood, GJ; Bahary, N; Bartlett, DL; Krasinskas, AM; Lembersky, BC; Moser, AJ; Potter, DM; Ramanathan, RK; Shuai, Y; Smith, RP; Van Buren, G; Zeh, HJ; Zureikat, AH | 1 |
| Dumontet, C; Jordheim, LP | 1 |
| Dong, S; Li, WT; Peng, WJ; Ye, XD; Yuan, Z | 1 |
| Alvarez, R; Barbacid, M; Cubillo, A; de Vicente, E; Garcia-Garcia, E; Guerra, C; Hidalgo, M; Lopez-Casas, PP; Lopez-Rios, F; Megias, D; Muñoz, M; Musteanu, M; Plaza, C; Prados, S; Quijano, Y; Rodriguez-Pascual, J; Tabernero, S | 1 |
| Dong, X; Du, J; Hao, Y; Wei, Y; Yin, Q; Zhao, X | 2 |
| Ikeda, M; Morizane, C; Okusaka, T | 1 |
| Chao, Y; Lee, RC; Lee, WP; Li, CP; Wang, JP; Wu, CY | 1 |
| Hiramatsu, Y; Shibahara, H | 1 |
| Castiglioni, V; Cesca, M; Decio, A; Giavazzi, R; Rovida, A; Scanziani, E; Scarlato, V | 1 |
| Kok, VC; Li, MC; Ruan, CW; Tsai, HJ | 1 |
| Egerer, G; Ho, AD; Kosely, F; Schmier, JW; Schmitt, T; Wuchter, P | 1 |
| Colvin, J; Evens, AM; Gordon, LI; Helenowski, I; Kline, J; Larsen, A; Rosen, ST; Smith, SM; van Besien, KM; Winter, JN | 1 |
| Li, W; Li, X; Wang, H | 1 |
| Arena, MG; Barba, M; Corrado, G; Di Lauro, L; Giannarelli, D; Mariani, L; Maugeri-Saccà, M; Paoletti, G; Pizzuti, L; Sergi, D; Tomao, F; Tomao, S; Vici, P; Vincenzoni, C; Vizza, E | 1 |
| Eberhart, C; Goldberg, MF; Hsu, AW; Montaner, S; Sodhi, A | 1 |
| Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Komoto, M; Murata, A; Nakata, B | 1 |
| Gog, C; Heinrich, S; Kraft, D; Lorenz, M; Schwarz, W; Staib-Sebler, E; Vogl, T | 1 |
| Tan, ZM; Wang, LY; Yu, Z; Yuan, YH; Zhong, W | 1 |
| Abe, H; Azuma, H; Hirano, H; Ibuki, N; Inamoto, T; Kiyama, S; Komura, K; Kotake, Y; Kouno, J; Minami, K; Narumi, Y; Nomi, H; Takagi, S; Takahara, K; Uehara, H; Yamamoto, K | 1 |
| Brisbin, A; Fridley, BL | 1 |
| Abo, R; Bamlet, W; Brisbin, A; Carlson, E; Eckloff, BW; Ellsworth, KA; Fridley, BL; Jenkins, GD; Li, L; Moon, I; Petersen, G; Wang, L; Wieben, ED | 1 |
| Manson, SC; Penel, N; Powell, S; Sharma, S; Takyar, S | 1 |
| Atkins, JN; Azar, CA; Biggs, DD; Brufsky, AM; Costantino, JP; Donnellan, PP; Fehrenbacher, L; Geyer, CE; Levine, EA; Mamounas, EP; Northfelt, DW; Paik, S; Polikoff, JA; Provencher, L; Rastogi, P; Robidoux, A; Swain, SM; Tang, G; Wolmark, N; Zapas, JL | 1 |
| Bhutia, YD; Cho, JH; Chu, CK; Davis, F; Dhar, S; Govindarajan, R; Hung, SW; Marrache, S; Mody, H; Zastre, J | 1 |
| da Silva, EM; de Castria, TB; Gois, AF; Riera, R | 1 |
| Chen, MC; Eibl, G; Hines, OJ; Ishiguro, H; Matsuo, Y; Pham, H; Reber, HA; Takahashi, H; Takeyama, H | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Kolek, V | 1 |
| Bradbury, PA; Coyle, D; Di Maio, M; Evans, WK; Graham, B; Gridelli, C; Hirsh, V; Leighl, NB; Mittmann, N; Perrone, F; Reaume, MN; Seymour, L; Shepherd, FA; Tu, D | 1 |
| Centeno, BA; Chen, DT; Hingorani, SR; Husain, K; Malafa, MP; Sebti, SM | 1 |
| Mangone, M; Marchi, E; O'Connor, OA; Zullo, K | 1 |
| Choi, BI; Choi, Y; Han, JK; Kim, H; Lee, ES; Lee, JY; Park, J | 1 |
| Abel, G; Barthelmes, J; Dueregger, A; Guggenberger, F; Haunschild, J; Intelmann, D; Klocker, H; Ramoner, R; Sampson, N; Schuh, M; Stecher, G | 1 |
| Borbath, I; Ceratti, A; Delaunoit, T; Deleporte, A; Demols, A; Laurent, S; Sempoux, C; Van Cutsem, E; Van Laethem, JL; Van Maanen, A; Vergauwe, P; Verslype, C | 1 |
| Lopes, Gde L | 1 |
| Choi, DR; Han, B; Jang, G; Jeon, JY; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, IG; Kim, JH; Kwon, JH; Park, CK; Song, H; Zang, DY | 1 |
| Campbell, L; Eakin, RL; Hanna, GG; Hussain, A; Khan, K; McAleese, J; Scullin, P | 1 |
| Chudziak, D; Ciesielka, M; Homa, I; Kalinka-Warzocha, E; Kozioł, P; Krawczyk, P; Kucharczyk, T; Milanowski, J; Mlak, R; Ramlau, R; Wasylecka-Morawiec, M; Wojas-Krawczyk, K | 1 |
| Alavi, A; Beatty, GL; Brothers, A; Chiorean, EG; O'Dwyer, PJ; Saboury, B; Sun, W; Teitelbaum, UR; Torigian, DA; Troxel, AB; Vonderheide, RH | 1 |
| Inaba, M; Kojima, I; Matsuura, H; Matsuzu, K; Mukaibashi, T; Nakayama, H; Nishiyama, S; Shimizu, S; Yamanaka, A; Yamanaka, T; Yoshida, A | 1 |
| Bartsch, DK; Buchholz, M; Fendrich, V; Fichtner-Feigl, S; Kesselring, R; Knoop, R; Plassmeier, L; Waldmann, J | 1 |
| Bai, J; Fu, S; Guan, R; Huang, Y; Ji, W; Jin, Y; Meng, X; Quan, C; Sun, D; Sun, W; Yu, L; Yu, Y; Zhang, C; Zhao, Y; Zhu, J | 1 |
| Chen, RX; Jiang, ZD; Jin, FS; Wang, EF; Wang, YN; Zhang, LG; Zhang, X; Zhao, JH | 1 |
| Bonnac, L; Clouser, CL; Mansky, LM; Patterson, SE | 1 |
| Ichioka, D; Kawai, K; Kimura, T; Miyazaki, J; Nagata, C; Nagumo, Y; Nishiyama, H; Oikawa, T; Suetomi, T; Uchida, M | 1 |
| Amit, M; Binenbaum, Y; Gil, Z; Krelin, Y; Shabtay-Orbach, A; Weizman, N; Wong, RJ | 1 |
| Stinchcombe, TE | 1 |
| Budai, B; Ganofszky, E; Hitre, E; Horváth, Z; Juhos, E; Láng, I; Nagy, T; Rubovszky, G; Szabó, E; Szentirmay, Z | 1 |
| Clements, D; Giacomantonio, CA; Gujar, SA; Hill, R; Lee, PW; Madureira, PA; Rabb, M; Waisman, DM | 1 |
| Fan, X; Ge, S; Jia, R; Song, X; Wang, J; Xu, X; Zhang, H; Zhang, Y; Zhou, Y | 1 |
| Celano, P; Eisenhauer, E; Fader, AN; Frasure, H; Gehrig, PA; Giuntoli, RL; Havrilesky, LJ; Krill, L; Levinson, K; Lopez, MA; Ricci, S; Secord, AA; Tanner, EJ | 1 |
| Berruti, A; Carturan, S; Germano, A; Lo Buono, N; Papotti, M; Rapa, I; Terzolo, M; Volante, M | 1 |
| Padmanabhan, J; Woods, NK | 1 |
| Alonso, MÁ; Jorge, M; Mendez, JC; Montes, AF; Pellón, ML; Quintero, G; Ramos, M; Reboredo, M; Romero, C; Salgado, M; Valladares-Ayerbes, M; Varela, S | 1 |
| Du, QH; He, CY; Xu, YB; Yun, P; Zhang, MY | 1 |
| Cao, L; Freeman, JW; Hill, P; Nawrocki, ST; Peterson, L; Venkatasubbarao, K; Zhao, S; Zhou, Q | 1 |
| Bartholin, L; Calvo, E; Cano, CE; Dusetti, N; Garcia, MN; Garcia, S; Grasso, D; Hamidi, T; Iovanna, JL; Lomberk, G; Loncle, C; Urrutia, R | 1 |
| Akiyama, D; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Toda, N; Yagioka, H; Yamamoto, N | 1 |
| Ichioka, D; Inai, H; Kawai, K; Miyazaki, J; Nishiyama, H | 1 |
| Hatakeyama, S; Koie, T; Ohyama, C; Yoneyama, T | 1 |
| Büchler, MW; Combs, SE; Debus, J; Dreher, C; Habermehl, D; Haselmann, R; Jäger, D; Jäkel, O; Kieser, M; Werner, J | 1 |
| Arantes-Rodrigues, R; Colaço, A; Ferreira, R; Lara Santos, L; Moreira da Silva, V; Oliveira, P; Palmeira, C; Pinto-Leite, R | 1 |
| Blackwood, E; Del Nagro, C; Evangelista, M; Jackson, PK; Kowanetz, K; Malek, S; O'Brien, T; Ramiscal, J; Xiao, Y | 1 |
| Bahra, M; Bischoff, S; Denkert, C; Dörken, B; Neuhaus, P; Oettle, H; Pelzer, U; Riess, H; Sallmon, D; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Buckway, B; Ghandehari, H; Ray, A; Wang, Y | 1 |
| Hilger, RA; Hoheisel, JD; Holtrup, F; Werner, J; Wolf, RJ | 1 |
| Che, CL; Mei, YF; Shi, YZ; Zhang, HH; Zhang, ZY | 1 |
| Amoroso, D; Boni, L; Camerini, A; Cecere, FL; Di Costanzo, F; Giuliani, C; Lucchesi, S; Lucherini, E; Martella, F; Mazzoni, F; Meoni, G; Torricelli, F | 1 |
| Berrevoet, F; De Bosschere, K; Ferdinande, L; Geboes, K; Hav, M; Ky, V; Laurent, S; Monsaert, E; Troisi, RI; Van Damme, N; Vanderstraeten, E | 1 |
| Aiba, K; Fujiwara, Y; Furukawa, K; Futagawa, Y; Kitamura, H; Misawa, T; Shiba, H; Tsutsui, N; Uwagawa, T; Yanaga, K | 1 |
| Albers, P; de Geeter, P; Fenner, M; Feyerabend, S; Hakenberg, O; Heidenreich, A; Heinzer, H; Kamradt, J; Klotz, T; Krege, S; Kühn, M; Retz, M; Rexer, H; Roigas, J; Schrader, M; vom Dorp, F; Wülfing, C; Zastrow, S | 1 |
| Chen, M; Zhang, J; Zhou, CC; Zhu, J | 1 |
| Eichler, K; Gruber-Rouh, T; Hammerstingl, R; Jakobi, S; Vogl, TJ; Zangos, S | 1 |
| Chen, Q; Hu, H; Jiao, D; Song, J; Wu, L; Xu, LQ; Yan, J | 1 |
| England, CG; Frieboes, HB; Huang, J; Lee, JJ; McNally, LR | 1 |
| Dong, J; He, S; Liu, L; Shen, J; Sun, X | 1 |
| Gaur, S; Horne, D; Hu, S; Hu, W; Smith, DL; Su, L; Synold, TW; Wu, J; Yen, Y; Yip, ML; Yuan, YC; Zhou, B | 1 |
| Cai, QC; Guan, HH; Lin, ZX; Wu, ZY; Yang, HK; Zhou, L | 1 |
| Chen, Y; Deng, M; Feng, X; Liu, D; Liu, Q; Wang, J; Xie, G; Yuan, P; Zhang, L | 1 |
| Abe, T; Fuga, M; Hasegawa, Y; Irie, K; Kawamura, D; Tanaka, T; Tochigi, S; Yanagisawa, T | 1 |
| Guo, JC; Yang, SH | 1 |
| Bellmunt, J; Blais, N; Castellano, D; Cerbone, L; Le-Guennec, S; Machiels, JP; Peters, F; Risse, ML; Skoneczna, IA; Sternberg, CN; Theodore, C; Voog, E | 1 |
| Daignault, S; Healy, P; O'Malley, M; Ramnath, N | 1 |
| Balasubramanian, SU; Harfouche, R; Luchette, M; Papa, AL; Sarangi, S; Sengupta, S; Sidiqui, A | 1 |
| Bierwirth, C; Dobbelstein, M; Elvers, I; Gaestel, M; Helleday, T; Köpper, F; Kranz, D; Kunze, M; Menon, MB; Saini, P; Schön, M; Schön, MP; Sørensen, CS; Walter, D | 1 |
| Jiao, SC; Wu, JJ | 1 |
| Gansauge, F; Kleef, R; Poch, B; Schwarz, M | 1 |
| Jamil, K; Naidu Madireddy, UR; Natukula, K; Pingali, UR; Suresh Attili, VS | 1 |
| Alba, E; de la Torre-Cabrera, C; Fernández, M; Fernández-Navarro, M; Jaén-Morago, A; Pascual, J; Plata-Fernández, Y; Ramirez-Tortosa, C; Sánchez-Muñoz, A; Sánchez-Rovira, P | 1 |
| Avan, A; Boggi, U; Campani, D; Caretti, V; Fuchs, D; Funel, N; Galvani, E; Giovannetti, E; Honeywell, RJ; Lagerweij, T; Maftouh, M; Peters, GJ; Schuurhuis, GJ; Van Tellingen, O; Verheul, HM; Würdinger, T | 1 |
| Deshane, JS; Grant, SC; Jin, TH; Ponnazhagan, S; Roth, J; Sawant, A; Schafer, CC; Siegal, GP; Sun, Z; Thannickal, VJ; Tse, HM; Zmijewski, J | 1 |
| Cheng, Y; Dong, W; Hu, Y; Li, R; Sun, J; Tao, H; Wang, J; Wu, B | 1 |
| Bonetti, A; Durante, E; Furini, L; Giuliani, J; Greco, F; Mercanti, A; Moratello, G; Piacentini, P; Tognetto, M; Trolese, AR | 1 |
| Carvalheira, JB; Leal, F; Macedo, LT | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Kim, KS; Kim, YC; Kim, YI; Kwon, YS; Lim, SC; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| diZerega, GS; Espinoza, TB; Meeks, CJ; Roda, N; Rodgers, KE | 1 |
| Bertagnolli, MM; Friedman, PN; Goldberg, RM; Hurwitz, HI; Kindler, HL; Nixon, AB; Pang, H; Starr, MD; Venook, AP | 1 |
| Arning, MB; Fahlke, J; Gellert, K; Hartmann, JT; Hinke, A; Hochhaus, A; Neuhaus, P; Niedergethmann, M; Oettle, H; Ridwelski, K; Riess, H; Sinn, M; Zülke, C | 1 |
| Aogi, K; Hara, F; Kiyoto, S; Ohsumi, S; Takabatake, D; Takahashi, M; Takashima, S; Watanabe, M | 1 |
| Centeno, BA; Chellappan, SP; Lawrence, NJ; Pernazza, D; Pillai, S; Sebti, SM; Singh, S; Treviño, JG; Verma, M; Zhang, D | 1 |
| Barda, D; Barnard, D; Blosser, W; Clawson, D; Cox, K; Diaz, H; Guo, S; King, C; Marshall, M | 1 |
| Dwinell, MB; Hauser, AD; Roy, I; Williams, CL; Wilson, JM; Zimmerman, NP | 1 |
| Desai, PB; Genter, MB; Gudelsky, GA; Krishan, M | 1 |
| Chen, GP; Li, DC; Li, FY; Liu, Z; Wang, H; Wang, ZP; Zhao, Y | 1 |
| Goecke, H; Méndez, GP; Parodi, C; Vega, J | 1 |
| Qi, JL; Shi, SB; Tang, XY; Tian, J; Wang, M | 1 |
| Inagaki, A; Iwao, H; Izumi, Y; Miura, K; Nagayama, K; Shiota, M; Takahashi, K; Tanaka, M; Wanibuchi, H | 1 |
| Azad, A; Bolton, D; Davis, ID; Eapen, R; Liew, MS; Sengupta, S; Tafreshi, A | 1 |
| Di Sano, C; Ferraro, M; Gjomarkaj, M; Melis, M; Pace, E; Profita, M; Siena, L; Spatafora, M | 1 |
| Arena, FP; Bahary, N; Chiorean, EG; Dowden, S; Ervin, T; Goldstein, D; Harris, M; Hidalgo, M; Iglesias, J; Infante, J; Laheru, D; Ma, WW; Moore, M; Ramanathan, RK; Reni, M; Renschler, MF; Saleh, MN; Seay, T; Tabernero, J; Tjulandin, SA; Van Cutsem, E; Von Hoff, DD; Wei, X | 1 |
| Arakawa, K; Ide, M; Ishioka, NS; Itoh, H; Kaira, K; Kanai, Y; Mori, M; Nagamori, S; Ogawa, T; Ohshima, Y; Oriuchi, N; Oyama, T; Segawa, A; Shimizu, K; Sunaga, N; Sunose, Y; Takeyoshi, I; Tominaga, H; Yamaguchi, A | 1 |
| Chan, C; Counsell, N; Cowan, R; Gilson, D; Illidge, T; Morris, S; Patrick, P; Popova, B; Scarisbrick, J; Smith, P; Whittaker, S | 1 |
| Al-Leswas, D; Arshad, A; Chung, WY; Dennison, AR; Isherwood, J; Mann, CD; Metcalfe, MS; Steward, WP | 1 |
| Alfred Witjes, J; Arentsen, HC; Falke, J; Høgset, A; Oosterwijk, E | 1 |
| Fillat, C; Mato-Berciano, A; Mazo, A; Sobrevals, L; Urtasun, N | 1 |
| Bai, L; Jiao, SC; Li, J; Long, YY; Shi, WW; Su, D; Wang, LJ | 1 |
| Brinker, CJ; Chang, CH; Dong, J; Ji, Z; Lin, YS; Mai, WX; Meng, H; Nel, AE; Xue, M; Zhang, H; Zhao, Y; Zink, JI | 1 |
| Carberry, M; Damjanov, N; Giantonio, BJ; Jacobs-Small, M; Mykulowycz, K; O'Dwyer, PJ; Sepulveda, A; Sohal, DP; Sun, W; Teitelbaum, UR; Uehara, T; Wissel, P | 1 |
| Miyoshi, K; Murawaki, Y; Okamoto, K | 1 |
| Brahmbhatt, H; Cheng, YY; Edelman, JJ; Kirschner, MB; Klebe, S; MacDiarmid, JA; McCaughan, BC; Mugridge, N; Pel, ME; Reid, G; Vallely, MP; van Zandwijk, N; Weiss, J; Williams, M; Wright, C | 1 |
| Ito, K; Kaiho-Sakuma, M; Kurosawa, H; Nagai, T; Nagase, S; Niikura, H; Otsuki, A; Otsuki, T; Shiga, N; Shigeta, S; Takano, T; Tanaka, S; Tokunaga, H; Toyoshima, M; Tsuji, K; Utsunomiya, H; Yaegashi, N; Yamaguchi, T | 1 |
| Ernsting, MJ; Li, SD; May, JP; Undzys, E | 1 |
| Donahue, TR; Elashoff, DA; Farrell, JJ; Gorgan, TR; Hines, OJ; Wei, CH | 1 |
| Chen, JH; Ma, GY; Meng, L; Wang, L; Wang, XW | 1 |
| Berger, W; Berta, J; Döme, B; Grusch, M; Hegedűs, B; Hoda, MA; Horváth, LZ; Kenessey, I; Keszthelyi, M; Klepetko, W; László, V; Rényi-Vámos, F; Rojkó, L; Rózsás, A; Török, S; Tóvári, J | 1 |
| Balza, E; Borsi, L; Carnemolla, B; Castellani, P; Mortara, L; Orecchia, P | 1 |
| Barton, S; Chau, I; Chua, S; Cunningham, D; Dearden, C; Ethel, M; Hawkes, EA; Horwich, A; Peckitt, C; Potter, M; Wotherspoon, A | 1 |
| Chen, C; Chen, S; Chen, Y; Hou, X; Hou, Y; Miele, L; Sarkar, FH; Wang, R; Wang, Z; Wu, Q; Yang, Q; Yang, Y | 1 |
| Hirai, F; Ichinose, Y; Inamasu, E; Kojo, M; Morodomi, Y; Seto, T; Shimokawa, M; Shiraishi, Y; Takenaka, T; Takenoyama, M; Toyokawa, G; Toyozawa, R; Yamaguchi, M | 1 |
| Biasoni, D; Catanzaro, M; Farè, E; Giannatempo, P; Gianni, AM; Lo Vullo, S; Mariani, L; Milani, A; Necchi, A; Nicolai, N; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Torelli, T | 1 |
| Choi, SH; Heo, JS; Hong, JY; Kang, WK; Lee, J; Lee, SC; Lim, HY; Nam, EM; Park, JO; Park, SH; Park, YS; Song, SY | 1 |
| Coe, IR; Naydenova, Z; Ramadan, A; Rose, JB; Stevanovic, K | 1 |
| Beijnen, JH; Cerny, T; Gillessen, S; Hitz, F; Huitema, AD; Joerger, M; Koeberle, D; Rosing, H; Schellens, JH | 1 |
| Day, KC; Day, ML; Grivas, PD; Hussain, M; Karatsinides, A; Kunju, LP; Liebert, M; Owainati, I; Paul, A; Shakir, N; Thomas, D | 1 |
| Clark, JI; Kucuk, O; Malhotra, B; Moon, J; Urba, SG; Wolf, GT; Worden, FP | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Ryan, AJ; Sawyer, MB; Scriver, T | 1 |
| Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU | 1 |
| Akbari, EH; Esmati, E; Hashemi, FA; Kalaghchi, B | 1 |
| Chi, HD; Liu, Z; Orlando, M; Quinlivan, M; Xu, B; Zhang, XQ | 1 |
| Bahary, N; Brand, R; Burton, SA; Heron, DE; Krasinskas, AM; Lembersky, B; Moser, AJ; Quinn, AE; Rajagopalan, MS; Wegner, RE; Zeh, HJ | 1 |
| Avan, A; Boggi, U; Funel, N; Giovannetti, E; Granchi, C; Honeywell, R; Leon, LG; Maftouh, M; Minutolo, F; Peters, GJ; Rani, R; Sciarrillo, R; Smid, K | 1 |
| Wang, W; Wang, Y; Zhang, P; Zhang, XD | 1 |
| Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H | 1 |
| Asna, N; Grisaru, D; Inbar, M; Matcejevsky, D; Safra, T; Shpigel, S; Veizman, A | 1 |
| Bui, DT; Couvreur, P; Desmaële, D; Maksimenko, A; Nicolas, J | 1 |
| Kondo, T; Ohkohchi, N; Oshiro, Y; Sakashita, S; Sasaki, R; Takahashi, K | 1 |
| Ashley, CE; Brinker, CJ; Brocato, TA; Butner, JD; Carnes, EC; Cristini, V; Koay, EJ; Pascal, J; Wang, Z | 1 |
| Momeni, M; Veras, L; Zakashansky, K | 1 |
| Aitini, E; Barni, S; Berardi, R; Bidoli, P; Boni, C; Caprioni, F; Cascinu, S; Cinquini, M; Conte, P; Di Costanzo, F; Faloppi, L; Ferrari, D; Labianca, R; Mosconi, S; Siena, S; Sobrero, A; Tonini, G; Villa, F; Zagonel, V | 1 |
| Albiges, L; Allory, Y; Bigot, F; Escudier, B; Gachet, J; Massard, C; Méjean, A; Oudard, S; Pécuchet, N; Teghom, C | 1 |
| Brons, S; Combs, SE; Debus, J; Haberer, T; Schlaich, F; Weber, KJ | 1 |
| Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
| Chung, C; Kim, H; Kim, SK; Kim, T; Kim, TS; Koh, GY; Lee, DH; Lim, DS | 1 |
| Burlando, B; Martinotti, S; Parodi, M; Ranzato, E; Vitale, M | 1 |
| Felder, MA; Perez Horta, Z; Qu, X; Rakhmilevich, AL; Sondel, PM | 1 |
| Biasco, G; Brandi, G; De Rosa, F; Di Girolamo, S; Di Marco, M; Guarnieri, T; Macchini, M; Papi, A; Paterini, P; Tavolari, S | 1 |
| Duffy, AG; Greten, TF | 1 |
| Cha, H; Cho, WJ; Dung, le TK; Lee, HY; Lee, SJ; Min, YJ; Moon, CH; Park, JW | 1 |
| Kim, S; Li, X; Lin, L; Liu, C; Okunieff, P; Su, Y; Sun, W; Wang, W; Yang, S; Zhang, H; Zhang, L; Zhang, M; Zhang, Z | 1 |
| Chen, MY; Guo, L; Hong, MH; Huang, HQ; Jiang, R; Liu, Q; Mai, HQ; Qian, CN; Qiu, F; Sun, R; Xia, ZJ; Zhang, L; Zou, X | 1 |
| Aprahamian, M; Bour, G; Giese, NA; Grekova, SP; Lehn, JM; Nicolau, C; Raykov, Z | 1 |
| Balslev, E; Bjerre, KD; Ejlertsen, B; Jørgensen, CL; Nielsen, DL; Nielsen, KV | 1 |
| Amadori, D; Aquilina, M; Burgio, MA; Carloni, S; Casadei Gardini, A; Frassineti, GL; Lucchesi, A; Oboldi, D; Tenti, E | 1 |
| John, P; McConnell, K; Saif, MW | 1 |
| Hamada, S; Masamune, A; Miura, S; Satoh, K; Shimosegawa, T | 1 |
| Forgeson, G; Prince, SK | 1 |
| Gisbert, R; Gómez-Codina, J; Juan, O; Maciá, S; Muñoz, J; Vidal, J | 1 |
| Allen, A; Andersson, R; Bassi, C; Boeck, S; Bondar, V; Bondarenko, I; Davidenko, I; Dicker, A; Evans, TR; Garin, A; Hahn, H; Heinemann, V; Ikdahl, T; Isaacson, J; Kaur, P; Mann, E; Ormanns, S; Picozzi, V; Poplin, E; Raponi, M; Rolfe, L; Voong, C; Wasan, H | 1 |
| Counsell, N; Cunnningham, D; El-Mehidi, N; Fields, PA; Jack, A; Johnson, PW; Linch, DC; Pocock, C; Radford, J; Smith, P; Townsend, W; Webb, A | 1 |
| Akada, J; Baron, B; Kaino, S; Kitagawa, T; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Sakaida, I; Suenaga, S; Tokuda, K; Wang, Y | 1 |
| Bassi, C; Bosco, G; Bosio, C; Camporesi, E; Cannato, M; Casarotto, A; Chen, C; Garetto, G; Guizzon, L; Mangar, D; Nasole, E; Toniolo, L; Yang, Z | 1 |
| Kaniwa, N; Knights, J; Ramanathan, M; Saito, Y; Sato, Y; Ueno, H | 1 |
| Asou, H; Kiyosawa, K; Maeda, K; Takeuchi, K; Taniai, H | 1 |
| Hattori, M; Iwata, H; Kaise, H; Kawaguchi Ushio, A; Kohno, N | 1 |
| Abro, E; Gilbar, P; Richmond, J | 1 |
| Abbott, DE; Abbruzzese, JL; Aloia, TA; Crane, CH; Evans, DB; Fleming, JB; Katz, MH; Lee, JE; Pisters, PW; Tran Cao, HS; Tzeng, CW; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Aljumaily, R; Gay, HA; Parent, T; Russo, S; Walker, PR; Zhang, J | 1 |
| Fujisawa, M; Inoue, T; Miyake, H; Miyazaki, A; Tanaka, H; Terakawa, T; Yokoyama, N | 1 |
| Da, L; Hu, Y | 1 |
| Choi, J; Del Nagro, CJ; Jackson, PK; Mohan, S; O'Brien, T; Pandita, A; Rangell, L; Xiao, Y; Zha, J | 1 |
| Abe, M; Azemoto, N; Furukawa, S; Hiasa, Y; Hirooka, M; Ikeda, Y; Imai, Y; Imamine, S; Inada, N; Koizumi, M; Kumagi, T; Kuroda, T; Matsuura, B; Miyaike, J; Miyake, T; Nishiyama, M; Ohno, Y; Okada, S; Onji, M; Seike, H; Shibata, N; Tanaka, Y; Tatsukawa, H; Utsunomiya, H; Yamanishi, H; Yokota, T | 1 |
| Akita, H; Doki, Y; Eguchi, H; Hama, N; Isohashi, F; Kawamoto, K; Kobayashi, S; Kudo, T; Mori, M; Nagano, H; Sakai, D; Satoh, T; Tomimaru, Y; Wada, H | 1 |
| Dubear Kroening, K; Etchison, RG; Graff, JR; Jacobson, BA; Jay-Dixon, J; Konicek, BW; Kratzke, MG; Kratzke, RA; Patel, MR; Thumma, SC | 1 |
| Fukawa, T; Fukumori, T; Izaki, H; Kagawa, J; Kanayama, HO; Komori, M; Oi, H; Oyama, T; Sasaki, Y; Senzaki, T; Takahashi, H; Takahashi, M; Takemura, M; Yamaguchi, K; Yamamoto, Y | 1 |
| Colbert, LE; Curran, WJ; El-Rayes, BF; Fisher, SB; Gandhi, K; Hall, WA; Hardy, CW; Kooby, DA; Kowalski, J; Landry, JC; Maithel, SK; Pantazides, BG; Petrova, AV; Saka, B; Shelton, JW; Staley, CA; Volkan Adsay, N; Warren, MD; Yu, DS | 1 |
| Chen, KT; Cohen, SJ; Cooper, HS; Denlinger, C; Devarajan, K; Hoffman, JP; Meyer, JE; Milestone, BN | 1 |
| Anota, A; Auquier, P; Bascoul-Mollevi, C; Bonnetain, F; Borg, C; Chibaudel, B; Fiteni, F; Hamidou, Z; Paget-Bailly, S; Westeel, V | 1 |
| Bessler, M; Engert, A; Hansen, HP; Henke, A; Klein, JM; Reiners, KS; Sauer, M; von Strandmann, EP | 1 |
| Chiba, S; Hori, Y; Shimizu, K | 1 |
| Clements, D; Dielschneider, R; Gujar, SA; Helson, E; Lee, PW; Marcato, P | 1 |
| Adams, S; Baum, J; Fitzgerald, JB; Harms, BD; Iadevaia, S; Jiao, Y; Johnson, BW; Kohli, N; Lugovskoy, AA; Nielsen, UB; Olivier, KJ; Razlog, M; Rennard, R; Rimkunas, V; Schoeberl, B; Tang, J; Xu, L | 1 |
| Dandagi, PM; Doijad, RC; Nandini, PT; Shivakumar, HN | 1 |
| Cleland, LG; Graf, SW; Limaye, VS | 1 |
| Begum, S; Harish, G; Hussain, A; Javed, E; Khan, MA; Mohsin, J; Nusri, Qel-A; Prabhu, SA; Sharma, C | 1 |
| Camargo, EA; da Silva, GN; Gobette, CP; Marcondes, JP; Salvadori, DM | 1 |
| Annels, NE; Billingham, L; Corrie, P; Cunningham, D; Eatock, M; Gabitass, RF; Middleton, G; Neoptolemos, JP; Pandha, H; Shaw, VE; Smith, D; Valle, J; Wadsley, J | 1 |
| Chan, JK; Chan, KH; Kwong, YL; Pang, AW; So, JC | 1 |
| Carafa, M; Celia, C; Cilurzo, F; Di Marzio, L; Gentile, E; Paolino, D; Ventura, CA; Wolfram, J | 1 |
| Cheng, CC; Chiu, TH; Huang, YT; Lai, PC; Lin, TC | 1 |
| Chang, Y; Fu, XR; Li, L; Li, X; Qiu, YJ; Sun, ZC; Wang, R; Wang, XH; Wu, JJ; Zhang, C; Zhang, L; Zhang, MZ | 1 |
| Brundage, RC; Dudek, AZ; Fisher, J; Greeno, EW; Gurvich, VJ; Khatri, A; Kirstein, MN; Kratzke, RA; Lamba, JK; Lis, LG; Skubitz, KM; Williams, BW | 1 |
| Anthoney, A; Bassi, C; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Costello, E; Cox, TF; Deakin, M; Dervenis, C; Garner, E; Ghaneh, P; Glimelius, B; Goldstein, D; Greenhalf, W; Halloran, CM; Jackson, R; Lacaine, F; Lamb, RF; Mackey, JR; Mayerle, J; McDonald, AC; Middleton, MR; Moore, MJ; Neoptolemos, JP; Oláh, A; Palmer, DH; Rawcliffe, CL; Scarfe, AG; Scarpa, A; Shannon, J; Tebbutt, NC; Valle, JW | 1 |
| Apetoh, L; Ghiringhelli, F | 1 |
| Endo, I; Homma, Y; Ichikawa, Y; Matsuyama, R; Mori, R; Murakami, T; Nakagawa, K; Nakazawa, M; Takeda, K; Tanaka, K; Taniguchi, K; Ueda, M | 1 |
| Chun, HJ; Hyun, JJ; Jeen, YT; Keum, B; Kim, CD; Lee, HS; Seo, YS; Um, SH | 1 |
| Chen, G; Du, X; Shu, H; Wang, TX; You, L; Zhang, TP; Zhao, YP; Zhou, L | 1 |
| Duangjai, A; Kopeček, J; Luo, K; Yang, J; Zhou, Y | 1 |
| Bestoso, E; Bianco, MT; Botta, C; Caraglia, M; Ciliberto, D; Conca, R; Correale, P; Cusi, MG; Fioravanti, A; Guglielmo, A; Guidelli, GM; Licchetta, A; Mantovani, G; Martino, E; Mini, E; Misso, G; Pastina, P; Pirtoli, L; Ridolfi, R; Rotundo, MS; Tagliaferri, P; Tassone, P | 1 |
| Hazama, S; Iida, M; Matsui, H; Oka, M; Shindo, Y; Suzuki, N; Takeda, K; Ueno, T; Yoshimura, K; Yoshino, S | 1 |
| Alva, A; Daignault, S; Hussain, M; Smith, DC | 1 |
| Bang, SM; Chung, JB; Kang, DR; Kim, KS; Park, JY; Park, MS; Park, SW; Seong, J; Song, SY; Yi, SW | 1 |
| Azemoto, R; Hara, T; Hirata, N; Ishihara, T; Mikata, R; Nakagawa, A; Nakaji, S; Nakamura, K; Nihei, T; Nishino, T; Ohshima, T; Ozawa, F; Shimura, K; Sudo, K; Tada, M; Tawada, K; Yamaguchi, T; Yokosuka, O | 1 |
| Enomoto, H; Imai, H; Kise, H; Kobayashi, M; Nomura, Y; Wakita, T; Yamamoto, I | 1 |
| Horibe, K; Maeda, N; Moritani, S; Sekimizu, M; Ueki, H; Yamashita, Y | 1 |
| Ferro, A; Toso, S; Zustovich, F | 1 |
| Arra, C; Barbieri, A; Bimonte, S; Luciano, A; Palma, G; Rea, D | 1 |
| Hong, SK; Yang, KX; Yang, SY; Yin, SH | 1 |
| Braghiroli, MI; da Costa Miranda, V; Faria, LD; Hoff, PM; Riechelmann, RP; Sabbaga, J; Siqueira, SA | 1 |
| Chen, Y; Ouyang, J; Ouyang, L; Yang, J | 1 |
| Ahmad, S; Khattak, J; Murad, S; Naqi, N | 1 |
| Baba, H; Beppu, T; Hashimoto, D; Hayashi, H; Kuroki, H; Mima, K; Nakagawa, S; Okabe, H; Sakamoto, K; Sakamoto, Y; Tokunaga, R; Yokoyama, N | 1 |
| Chen, T; Gao, W; Zhao, C | 1 |
| Abu-Taleb, F; Elbolkainy, T; Farag, K; Haggag, R; Khaled, H; Shamaa, S; Zekri, AR | 1 |
| Balzarini, J; Pulido, J; Sobczak, AJ; Wnuk, SF | 1 |
| Lee, HY; Lim, KH; Song, SY | 1 |
| Brail, L; Enas, N; Eschbach, C; Hirsh, V; Jänne, PA; Oh, Y; Paz-Ares, L; von Pawel, J | 1 |
| Beare, S; Bridgewater, J; Furuse, J; Jitlal, M; Mizuno, N; Okusaka, T; Valle, JW; Wasan, H | 1 |
| Azad, N; Blackford, A; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, R; Edil, BH; Faisal, F; Fishman, EK; Herman, J; Hruban, RH; Laheru, D; Le, DT; Olino, K; Rasheed, Z; Schulick, R; Tsai, HL; Wolfgang, C; Xia, C; Zheng, L | 1 |
| Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM | 1 |
| Berger, AK; Jäger, D; Springfeld, C; Weber, TF | 1 |
| Altiok, S; Foroutan, P; Gillies, RJ; Grove, O; Kreahling, JM; Lloyd, MC; Martinez, GV; Morse, DL; Raghavan, M; Reed, D | 1 |
| Chung, I; Eastman, A; Hou, H; Khan, N; Montano, R; Thompson, R | 1 |
| Balslev, E; Bjerre, KD; Ejlertsen, B; Jørgensen, CL; Liu, S; Nielsen, DL; Nielsen, TO; Wallden, B | 1 |
| Abraham, J; Caldas, C; Chan, S; Dean, S; Dunn, J; Earl, HM; Fenwick, N; Gallagher, C; Gounaris, I; Harries, M; Hickish, T; Hiller, L; Houston, S; Hughes-Davies, L; Iddawela, M; Laing, R; McAdam, K; Provenzano, E; Ritchie, D; Skene, A; Vallier, AL; Wishart, G; Young, J | 1 |
| Ahn, JS; Chang, W; Choi, MK; Im, SA; Im, YH; Kim, S; Lee, SY; Park, YH; Woo, SY | 1 |
| Amidon, GL; Hilfinger, JM; Incecayir, T; Song, X; Tsume, Y | 1 |
| Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS | 1 |
| Atxner, J; Buchwald, D; Happe, A; Kröz, M; Matthes, H; Popp, S; Schad, F | 1 |
| Bae, I; Duong, HQ; Hong, YB; Kang, HJ; Seong, YS; Tang, W; Wang, A; Yi, YW | 1 |
| Azria, D; Culine, S; Fenoglietto, P; Pouessel, D; Rebillard, X; Riou, O; Thezenas, S; Thuret, R | 1 |
| Fang, L; Hu, H; Li, F; Liu, L; Mao, Y; Zhu, H | 1 |
| Horiguchi, S; Iwamuro, M; Kataoka, J; Kato, H; Kumon, H; Nagahara, T; Nasu, Y; Nouso, K; Shiraha, H; Takaki, A; Uchida, D; Watanabe, M; Yagi, T; Yamamoto, K | 1 |
| Chen, YW; Chou, KM; Chu, P; Liu, X; Loria, S; Wang, Y; Yen, Y; Zhou, W | 1 |
| Bauer, C; Bauernfeind, F; Conrad, C; Dauer, M; Duewell, P; Eigler, A; Endres, S; Kiefl, R; Schnurr, M; Sterzik, A | 1 |
| Jiang, Y; Yang, L; Yuan, Z; Zhang, Y; Zhao, Q | 1 |
| Etienne, E; Geny, B; Gottenberg, JE; Lannes, B; Messer, L; Meyer, A; Meyer, C; Moreau, P; Sibilia, J; Spielmann, L | 1 |
| Ding, X; Liu, W; Luo, H; Lv, Y; Pan, J; Pei, Q; Zhu, H; Zou, X | 1 |
| Antoine, M; Bonnette, P; Cadranel, J; Cazes, A; Duruisseaux, M; Girard, N; Mazieres, J; Monnet, I; Ung, M; Vieira, T; Wislez, M | 1 |
| Abdi, E; Badger, HD; Boyle, F; Bull, J; Chirgwin, J; Forbes, JF; Francis, PA; Gebski, V; Kannourakis, G; Leong, E; Lindsay, DF; McCarthy, N; Reaby, L; Simpson, A; Veillard, AS; Wilcken, N; Zannino, D; Zdenkowski, N | 1 |
| Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Nakagawara, H; Nakanuma, S; Ohta, T; Sakai, S; Shoji, M; Tajima, H; Takamura, H | 1 |
| Desaki, R; Higashi, M; Iino, S; Kawasaki, Y; Kurahara, H; Maemura, K; Mataki, Y; Natsugoe, S; Sakoda, M; Shinchi, H; Takao, S; Ueno, S | 1 |
| Gabata, T; Hayashi, H; Kinoshita, J; Kitagawa, H; Koda, W; Makino, I; Minami, T; Miyashita, T; Nakagawara, H; Nakamura, K; Nakanuma, S; Ohta, T; Okamoto, K; Oyama, K; Sai, Y; Sakai, S; Sanada, J; Shoji, M; Tajima, H; Takamura, H | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Ku, Y; Matsumoto, I; Murakami, S; Ohtsubo, I; Okazaki, T; Shinozaki, K; Shinzeki, M; Yoshida, Y | 1 |
| Kaiho, T; Kobayashi, S; Nishimura, M; Okamoto, R; Okaniwa, A; Shimizu, W; Shinmura, K; Tsuchiya, S; Yanagisawa, S | 1 |
| Hakamada, K; Ishido, K; Ishiguro, A; Kimura, N; Kudo, D; Sato, A; Takahata, T; Toyoki, Y; Wakiya, T; Yakoshi, Y | 1 |
| Kaiho, T; Kobayashi, S; Miyazaki, M; Nishimura, M; Nomura, S; Okamoto, R; Okaniwa, A; Shinmura, K; Tsuchiya, S; Yanagisawa, S | 1 |
| Fukushima, Y; Hashimoto, K; Ide, Y; Kodama, K; Matsuyama, J; Morimoto, T; Nomura, T; Sasaki, Y; Takeda, M; Tokuoka, M; Toshiyama, R; Yokoyama, S | 1 |
| Amano, R; Hirakawa, K; Hirata, K; Kimura, K; Kubo, N; Maeda, K; Muguruma, K; Murata, A; Nagahara, H; Ohira, M; Otani, H; Tanaka, H; Toyokawa, T | 1 |
| Aoki, S; Egawa, S; Fukase, K; Hayashi, H; Katayose, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Okada, T; Sakata, N; Unno, M; Yoshida, H | 1 |
| Akita, H; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Nagano, H; Tanizaki, K; Tomimaru, Y; Wada, H | 1 |
| Doi, T; Fujishima, F; Kawaguchi, K; Kuroda, F; Motoi, F; Nozawa, Y; Takemura, S; Unno, M; Yokoyama, S | 1 |
| Hakamada, K; Ishido, K; Kimura, N; Kudo, D; Sakuraba, S; Toyoki, Y; Wakiya, T | 1 |
| Aoki, T; Chohno, T; Hyuga, S; Kobayashi, K; Matsumoto, T; Nishioka, K; Takachi, K; Takemoto, H; Uemura, Y; Watanabe, R | 1 |
| Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Nakahira, S; Okishiro, M; Sakisaka, H; Suzuki, R; Takeda, Y; Takeno, A; Tamura, S; Taniguchi, H | 1 |
| Jinno, H; Kitagawa, Y; Kitasato, K; Murai, S; Nakadai, J; Oto, I; Shimizu, H; Yabe, N; Yoshikawa, T | 1 |
| Alexandre, J; Coronado, C; Dios, JL; Faivre, S; Fernández-García, EM; Goldwasser, F; Kahatt, CM; Miguel-Lillo, B; Paramio, PG; Raymond, E | 1 |
| Baumgartner, S; Kunz, M; Urech, K; Weissenstein, U | 1 |
| Funamizu, N; Hiyoshi, Y; Lacy, CR; Parpart, ST; Takai, A; Yanaga, K | 1 |
| Baillet-Guffroy, A; Caudron, E; Eveleigh, L; Lê, LM | 1 |
| Bar-Sela, G; Miller, RC; Novotny, PJ; Sio, TT; Sohawon, S; Thariat, J; Van Houtte, P; Vu, CC | 1 |
| Bhuvaneshwar, K; Deeken, J; Filice, R; Harris, M; Madhavan, S; Natarajan, T; Pishvaian, MJ; Sheahan, L; Shoulson, I; Steadman, K; Tadesse, MG; Wang, D | 1 |
| Sinha, G | 1 |
| Arrowsmith, E; Austin, T; Beckman, R; Forero-Torres, A; Greenberg, J; Hart, L; He, AR; Infante, JR; Jin, X; Rosen, M; Saleh, M; Trent, D; Vickers, S; von Roemeling, R; Wade, J; Wang, Q; Waterhouse, D; Wong, L | 1 |
| Kaino, S; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Sakaida, I; Suenaga, S | 1 |
| Avan, A; Giovannetti, E; Orsini, V; Peters, GJ; Ruiz, MG; Smit, EF | 1 |
| Bhardwaj, TR; Malhotra, M; Rawal, RK; Sharma, AK; Sharma, R | 1 |
| Adams, DJ; Grace, L; Jia, J; Murphy, SK; Nixon, AB; Secord, AA; Teoh, D | 1 |
| Gore, AJ; Korc, M; Liu, F; Wilson, JL | 1 |
| Cury, FL; Duclos, M; Faria, SL; Kassouf, W; Souhami, L; Sturgeon, J; Turgeon, GA | 1 |
| Alcolea, V; Aparicio, J; Corbellas, M; Diaz Beveridge, R; Fonfría, M; García, J; Giménez, A; Montalar, J; Segura, Á | 1 |
| Garcon, MC; Kaley, K; Rodriguez, T; Saif, MW | 1 |
| Aparicio, J; Ayuso, JR; Conill, C; Feliu, J; Fuster, D; García-Mora, C; Martín, M; Maurel, J; Petriz, ML; Sánchez-Santos, ME | 1 |
| Beer, DG; Bergeron, EJ; Chen, G; Giordano, TJ; Grabauskiene, S; Morgan, MA; Reddy, RM; Thomas, DG | 1 |
| Bianco, R; Bordonaro, R; Burgio, MA; Cavanna, L; Ciardiello, F; Cinieri, S; Costanzo, R; Di Maio, M; Favaretto, AG; Filipazzi, V; Gallo, C; Gridelli, C; Leo, S; Morabito, A; Perrone, F; Rossi, A; Sandomenico, C | 1 |
| Anthoney, A; Bassi, C; Büchler, MW; Butturini, G; Carter, R; Cox, T; Cunningham, D; Dervenis, C; Ghaneh, P; Goldstein, D; Izbicki, JR; Jackson, R; Karapetis, C; Lacaine, F; Lind, PA; Mayerle, J; Middleton, MR; Neoptolemos, JP; O'Reilly, D; Oláh, A; Palmer, D; Rawcliffe, CL; Robinson, BA; Sand, J; Scarfe, A; Stocken, DD; Sumpter, K; Valle, JW | 1 |
| Allo, G; Bitanihirwe, BK; de Perrot, M; Felley-Bosco, E; Friess, M; Frischknecht, L; Meerang, M; Moch, H; Opitz, I; Seifert, B; Soltermann, A; Stahel, R; Thies, S; Tsao, MS; Weder, W | 1 |
| Adikrisna, R; Arii, S; Irie, T; Matsumura, S; Nakamura, N; Tanaka, S | 1 |
| Jiang, L; Li, P; Ma, J; Qi, L; Xu, X; Zhou, L; Zhou, P | 1 |
| Alemany, R; Cascalló, M; Laborda, E; Moreno, R; Puig-Saus, C; Rodríguez-García, A | 1 |
| Bouvet, M; Chishima, T; Endo, I; Fleming, JB; Hiroshima, Y; Hoffman, RM; Katz, MH; Maawy, A; Miwa, S; Momiyama, M; Suetsugu, A; Tanaka, K; Uehara, F; Yano, S; Zhang, Y; Zhao, M | 1 |
| Aberson, HL; Duitman, J; Queiroz, KC; Richel, DJ; Shi, K; Spek, CA; van Noesel, CJ; Wilmink, JW | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Kim, M; Lee, KY; Li, W; Lu, S; Massey, D; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Agbo, F; Azad, N; Barker, P; Carducci, M; Carter, J; Cosgrove, D; Knight, R; Lorusso, P; Malburg, L; Oakes, P; Quinn, MF; Sausville, E; Senderowicz, A; Zabludoff, S | 1 |
| Han, Z; Peng, Z; Sun, H; Wu, J | 1 |
| Li, J; Shi, R; Yu, P | 1 |
| Brustugun, OT; Grønberg, BH; Lund-Iversen, M; Scott, H; Strøm, EH | 1 |
| Hwang, JH; Kim, DU; Kim, YT; Lee, MG; Lee, SH; Lee, SJ; Lee, YS; Ryu, JK; Woo, SM | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY | 1 |
| Cai, X; Cui, JJ; Huang, WY; Song, WF; Wang, L; Wang, LW | 1 |
| Kukongviriyapan, V; Prawan, A; Senggunprai, L; Sripa, B; Zeekpudsa, P | 1 |
| Brade, A; Brierley, J; Cummings, B; Dawson, LA; Gallinger, S; Hashem, S; Hedley, D; Jiang, H; Kim, J; Krzyzanowska, MK; Ringash, J; Wong, R; Youl, M | 1 |
| Adem, A; Adrian, TE; Al Shemaili, J; Attoub, S; Collin, P; Hellman, B; Mensah-Brown, E; Nyberg, F; Parekh, K; Thomas, SA | 1 |
| Goldberg, SN | 1 |
| Kolokythas, O; Le, T; Meng, Y; Soriano, SS; Wang, H; Wei, B; Willis, P; Wu, X; Yang, X; Zhang, F; Zhang, T | 1 |
| Balzarini, J; Blagden, S; Ghazaly, E; Jiang, WG; Lopez, MH; Mason, M; McGuigan, C; Slusarczyk, M; Thompson, E | 1 |
| Jaiyesimi, I; Kizilbash, SH; Liang, JJ; Lipscomb, J; Ward, KC | 1 |
| Chan, EH; Chan, SL; Chan, ST; He, ZX | 1 |
| Madlon-Kay, R; Patel, M; Raza, A; Skubitz, K; Vakil, K; Zakharova, M | 1 |
| Chen, YJ; Chu, L; Fang, JM; Han, YC; Liu, ZQ; Xu, Q; Zhang, X; Zhao, HX | 1 |
| Aoyama, F; Hiyoshi, M; Kataoka, H; Sawaguchi, A; Takahashi, N | 1 |
| Lu, Y; Wang, L; Wang, WD; Xia, ZJ; Xiang, J; Zhang, YJ | 1 |
| Abo, RP; Batzler, A; Fridley, BL; Jenkins, G; Kalari, K; Li, L; Niu, N; Schaid, D; Wang, L | 1 |
| Cheng, J; Hong, DF; Liu, JW; Shen, GL; Shi, Y; Sun, XD; Wang, CY; Wang, ZF; Zhang, CW; Zhang, JG; Zhang, YB; Zhao, G | 1 |
| Baldwin, GS; Beutler, JA; Christophi, C; He, H; Huynh, N; Nikfarjam, M; Shulkes, A; Yeo, D | 1 |
| Alexander, DC; Johnson, SP; Lythgoe, MF; Panagiotaki, E; Pedley, RB; Rajkumar, V; Siow, B; Walker-Samuel, S | 1 |
| Elsamany, S; Elsirafy, M; Farooq, MU; Sakr, M; Shamaa, S | 1 |
| Briggs, K; Curley, SA; Koshkina, NV; Palalon, F | 1 |
| Bläuer, M; Hashimoto, D; Hirota, M; Ikonen, NH; Laukkarinen, J; Sand, J | 1 |
| Ahn, KO; Jeong, KC; Jung, NR; Lee, KH; Lee, SJ; Park, WS; Seo, HK; Shin, JS | 1 |
| Agrawal, AK; Das, M; Jain, R; Jain, S; Thanki, K | 1 |
| Driessen, W; Jiang, X; Wu, W | 1 |
| Amiji, MM; Singh, A; Xu, J | 1 |
| Aghajanian, C; Blank, S; Goff, B; Husain, A; Nycum, LR; Wang, Y | 1 |
| Andersen, RF; Jakobsen, A; Pallisgaard, N; Ploen, J; Spindler, KL | 1 |
| Choi, H; Choi, YJ; Chung, MJ; Han, SH; Kang, H; Kim, JS; Lee, HW; Lee, KJ; Lee, SW; Song, SY | 1 |
| Fujimura, Y; Hashizume, M; Ikenaga, N; Irie, M; Miura, D; Mizumoto, K; Murata, M; Ohuchida, K; Setoyama, D; Tanaka, M; Wariishi, H | 1 |
| Chen, B; Cheng, L; Hong, DF; Shen, XD; Xin, Y | 1 |
| Chiba, T; Kanai, M; Kawaguchi, Y; Kodama, Y; Matsumoto, S; Mori, Y; Nishimura, T; Takaori, K; Uemoto, S; Uza, N; Xue, P | 1 |
| Chen, YH; Marcus, KJ; Michaelson, EM; Ng, AK; Silver, B; Stevenson, MA; Tishler, RB | 1 |
| Han, B; Ji, L; Jia, G; Jiang, H; Li, Y; Liu, J; Lv, J; Pan, S; Song, Z; Sun, B; Teng, Y; Wang, Y; Zhou, Y | 1 |
| Chen, X; Gao, G; He, Y; Li, W; Li, X; Ren, S; Zhang, L; Zhou, C; Zhou, F | 1 |
| Chen, T; He, M; Ji, F; Li, F; Shen, HJ; Shi, WJ; Wang, J; Xu, M; Yang, C; Zhu, HY | 1 |
| Alami, M; Boissenot, T; Brion, JD; Couvreur, P; Desmaële, D; Hamze, A; Maksimenko, A; Mougin, J; Provot, O; Pruvost, A; Zouhiri, F | 1 |
| Akashi, Y; Enomoto, T; Hashimoto, S; Kurokawa, T; Miyamoto, R; Oda, T; Ohara, Y; Ohkohchi, N; Satake, M; Yamada, K | 1 |
| Bierwirth, C; Binkowski, AM; Dobbelstein, M; Köpper, F | 1 |
| Colussi, O; Landi, B; Lepère, C; Pernot, S; Portal, A; Rougier, P; Siauve, N; Taieb, J; Verrière, B; Zaanan, A | 1 |
| Bahra, M; Bischoff, S; Bläker, H; Denkert, C; Dietel, M; Dörken, B; Lindner, JL; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Bayraktar, S; Blaya, M; Green, MR; Levi, J; Lopes, G; Macintyre, J; Mayo, C; Merchan, J; Rocha-Lima, CM; Silva, O; Soares, HP; Walker, G | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Ghilardi, M; Petrelli, F | 1 |
| Cai, L; Li, CH; Li, DD; Liu, MY; Liu, W | 1 |
| Hussain, R; Iqbal, H; Jamshed, A | 1 |
| Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L | 1 |
| Boudaya, MS; Brahem, E; Charmiti, F; Kilani, T; Marghli, A; Mestiri, T; Mohamed, J; Ouerghi, S; Smadhi, H; Smati, B | 1 |
| Guo, Y; Kim, DH; Larson, AC; Nicolai, J; Omary, RA; Procissi, D; Zhang, Z | 1 |
| Angelova, AL; Aprahamian, M; Bour, G; Cziepluch, C; Daeffler, L; Giese, NA; Giese, T; Grekova, SP; Heller, A; Kuhlmann, O; Raykov, Z; Rommelaere, J; Rüffer, S; Soyka, E; Werner, J | 1 |
| Abdi, E; Button, P; Clarke, S; Clingan, P; Do, H; Dobrovic, A; Gregory, D; Michael, M; Nott, L; Solomon, B; White, SC; Zimet, A | 1 |
| Cheng, L; Wang, R; Wang, Z; Wu, Q; Xia, J | 1 |
| Dai, X; Fan, W; Katragadda, U; Mckinley, D; Tan, C; Teng, Q; Wang, Y | 1 |
| Arai, N; Fuse, H; Heshiki, W; Nakamori, K; Noguchi, M; Takei, R; Tomihara, K; Zhang, B | 1 |
| Kondratska, K; Kondratskyi, A; Lemonnier, L; Lepage, G; Morabito, A; Prevarskaya, N; Skryma, R; Yassine, M | 1 |
| Banno, S; Imai, H; Kawai, H; Miura, N; Nobata, H; Suzuki, K; Wakamatsu, R; Yamada, Y | 1 |
| Collins, GP; Eyre, TA; Gooding, S; Hatton, C; Moore, N; Patel, I | 1 |
| Barrett, D; Beaumont, M; Davis, N; Dwyer, MP; Guzi, TJ; Labroli, MA; Malinao, MC; McCoy, M; Parry, D; Popovici-Muller, J; Pu, Q; Seghezzi, W; Shanahan, F; Shen, R; Taricani, L; Wyss, D | 1 |
| Chen, J; Li, Y; Lou, Y; Wang, LR; Zhang, GB | 1 |
| Khaira, R; Saini, V; Sharma, J | 1 |
| Ai, B; Cheng, G; Nie, X; Zhang, S | 1 |
| Burcoveanu, D; Chevreau, C; Culine, S; Delva, R; Eymard, JC; Fizazi, K; Flechon, A; Geoffrois, L; Gravis, G; Houede, N; Laguerre, B; Laplanche, A; Rolland, F | 1 |
| Fan, JX; Guo, KY; Hung, YX; Wang, J; Xu, XJ; Ye, YB; Zhang, MW | 1 |
| Hiraoka, M; Itasaka, S; Kawaguchi, Y; Matsuo, Y; Mizowaki, T; Nakamura, A; Shibuya, K; Takaori, K; Uemoto, S; Yoshimura, M | 1 |
| Eibl, H; Hahn, J; Hossann, M; Issels, RD; Lechner, K; Limmer, S; Lindner, LH; Schmidt, R; Wachholz, K; Zengerle, A | 1 |
| Chen, X; Dai, H; Qian, Z; Wang, Y; Xu, X; Zhao, Y | 1 |
| Abramovitch, R; Corchia, N; Dery, E; Fried, I; Gross, E; Komar-Stossel, C; Meir, K | 1 |
| Chen, J; Fan, L; Li, L; Li, W; Mao, L; Nai, L; Wang, J; Wen, R; Yang, C; Zheng, J | 1 |
| Ko, AH; Walker, EJ | 1 |
| Camp, ER; Chaudhary, UB; Cole, DJ; Esnaola, NF; Garrett-Mayer, E; Hoffman, BJ; Marshall, DT; Montero, AJ; O'Brien, P; Orwat, KP; Romagnuolo, J; Thomas, MB | 1 |
| Fujisawa, T; Han, J; Husain, SR; Puri, RK | 1 |
| Barbachano, Y; Brown, G; Chau, I; Cunningham, D; Oates, J; Starling, N; Thomas, J; Watkins, DJ; Webb, J | 1 |
| Becker, G; Gaertner, J | 1 |
| Bernhard, J; Bodoky, G; Dietrich, D; Glimelius, B; Herrmann, R; Scheithauer, W | 1 |
| Abbruzzese, JL; Bhosale, PR; Chatterjee, D; Chen, R; Chen, Y; Crane, CH; Cristini, V; Ferrari, M; Fleming, JB; Gottumukkala, VN; Javle, M; Kang, Y; Katz, MH; Koay, EJ; Lee, JE; Plunkett, W; Rozner, MA; Shen, H; Tamm, EP; Thomas, RM; Truty, MJ; Varadhachary, GR; Wang, H; Wolff, RA | 1 |
| Bepler, G; Chen, Z; Li, X; Zhang, Y | 1 |
| Ajiki, T; Fujiwara, Y; Hatano, E; Ikoma, H; Ioka, T; Kaihara, S; Kanai, M; Kobayashi, S; Miyamoto, A; Morita, S; Nagano, H; Nakamori, S; Sakai, D; Takemura, S; Terajima, H; Toyoda, M; Toyokawa, H; Tsuji, A | 1 |
| Jia, Y; Marks, E; Saif, MW | 1 |
| Abdelmohsen, K; Acosta, Ade J; Brody, JR; Burkhart, RA; Gorospe, M; Iacobuzio-Donahue, CA; Jimbo, M; Laheru, D; Lal, S; Lankapalli, RH; McAllister, F; Moughan, J; Pineda, DM; Winter, JM; Winter, KA; Witkiewicz, AK; Yeo, CJ | 1 |
| Jin, X; Wu, Y | 1 |
| Beegle, N; Blau, S; Cox, D; Dranitsaris, G; Faria, C; Kalberer, T | 1 |
| Kajihara, M; Koido, S; Matsudaira, H; Matsumoto, K; Mitobe, J; Nagatsuma, K; Odahara, S; Ohkusa, T; Tajiri, H; Takahara, A; Takakura, K; Tsukinaga, S; Uchiyama, K; Yukawa, T | 1 |
| Bekaii-Saab, T; Espinoza, AM; Fogelman, DR; Foster, NR; Iyer, RV; Javle, MM; Kim, GP; Ko, AH; Martin, LK; Picozzi, VJ; Tempero, MA; Van Loon, K; Wolff, RA | 1 |
| Ii, N; Inoue, H; Isaji, S; Kishiwada, M; Kobayashi, M; Mizuno, S; Murata, Y; Sakurai, H; Shiraishi, T; Tabata, M; Usui, M; Yamada, T; Yamakado, K | 1 |
| Di, XY; Guo, JM; Jiang, HT; Yu, Q; Yu, YP; Zhu, Y | 1 |
| Bai, G; Hua, L; Lao, L; Qi, M; Wang, W; Zhu, Y | 1 |
| Adsay, NV; Colbert, LE; Curran, WJ; El-Rayes, BF; Fisher, SB; Gandhi, K; Hall, WA; Hardy, CW; Kooby, DA; Kowalski, J; Landry, JC; Liu, EA; Madden, MZ; Maithel, SK; Nagaraju, GP; Pan, Y; Pantazides, BG; Pauly, R; Petrova, AV; Saka, B; Shelton, JW; Staley, CA; Warren, MD; Yu, DS | 1 |
| Baraniak, J; Cieslak, M; Kaczmarek, R; Krakowiak, A; Krolewska, K; Kulik, K; Nawrot, B; Pietkiewicz, A; Radzikowska, E | 1 |
| Dohmen, T; Goto, T; Kamada, K; Mashima, H; Ohnishi, H; Sakai, T; Sato, W; Uchinami, H; Yamada, Y; Yamamoto, Y; Yoshioka, M | 1 |
| Greten, TF | 1 |
| Bekaii-Saab, T; Fogelman, D; Geyer, S; Iyer, R; Ko, AH; Martin, LK; Pant, S; Sommovilla, N; Van Loon, K; Wei, L; Zalupski, M | 2 |
| Akamatsu, H; Endo, M; Imai, H; Kenmotsu, H; Murakami, H; Naito, T; Ono, A; Shukuya, T; Taira, T; Takahashi, T; Tokito, T; Yamamoto, N | 1 |
| Brown, K; Dixey, M; Linclau, B; Weymouth-Wilson, A | 1 |
| Guo, S; Huang, L; Kim, WY; Miao, L; Satterlee, A; Zhang, J; Zhang, L; Zhang, Y | 1 |
| Duxfield, L; Li, Y; Lim, J; Paxton, J; Wu, Z; Xu, H; Zhang, W | 1 |
| Bahra, M; Dörken, B; Gebauer, B; Hilbig, A; Pelzer, U; Riess, H; Sinn, M; Stieler, JM | 1 |
| Arizumi, T; Hamada, T; Hirano, K; Isayama, H; Ito, Y; Kogure, H; Koike, K; Matsui, H; Nakai, Y; Sasaki, T; Tada, M; Takagi, K; Takahara, N; Tsujino, T; Watanabe, T; Yagioka, H; Yamamoto, N; Yasunaga, H | 1 |
| Blanco Codesido, M; García Alfonso, P; Martín Jiménez, M; Muñoz Martín, AJ; Pérez Ramírez, S; Rupérez Blanco, AB | 1 |
| Ichioka, D; Kawai, K; Kimura, T; Miyazaki, J; Nishiyama, H; Suetomi, T; Takaoka, E; Uchida, M | 1 |
| Ciftci, R; Disci, R; Duranyildiz, D; Karabulut, S; Sakar, B; Sen, F; Tas, F | 1 |
| Cisneros, BT; Corr, SJ; Curley, SA; Kaluarachchi, WD; Phounsavath, S; Raoof, M; Wilson, LJ; Zhu, C | 1 |
| da Silva, GN; de Camargo, EA; Salvadori, DM; Sávio, AL | 1 |
| Altimari, A; Di Tullio, P; Fiorentino, M; Giunchi, F; Gruppioni, E; Martorana, G; Pinto, C | 1 |
| Bastiat, G; Béjaud, J; Benoit, JP; González-Fernández, Y; Lautram, N; Moysan, E | 1 |
| Botteman, M; Ji, X; Reni, M; Solem, C; Wan, Y; Whiting, S | 1 |
| Audebert, S; Baudelet, E; Bidaut, G; Bonacci, T; Borg, JP; Camoin, L; Garcia, M; Iovanna, JL; Perkins, ND; Soubeyran, P; Witzel, II | 1 |
| Argyros, O; Fokas, D; Karampelas, T; Kolios, G; Liapakis, G; Millar, RP; Morgan, K; Pappas, C; Sayyad, N; Spyridaki, K; Tamvakopoulos, C; Tzakos, AG | 1 |
| Arce-Lara, C; Kelley, MJ; Santana-Davila, R; Szabo, A; Whittle, J; Williams, CD | 1 |
| Brunetti, O; Dei Tos, AP; Gesualdo, L; Silvestris, F; Stucci, S; Tucci, M; Vallarelli, S | 1 |
| Shu, H; Wang, TX; Xu, JW; You, L; Zhang, TP; Zhao, YP; Zheng, LF | 1 |
| Balzarini, J; Fieuws, S; Hofer, A; Liekens, S; Noppen, S; Ranjbarian, F; Sabuncuoğlu, S; Vande Voorde, J | 1 |
| Li, J; Li, T; Li, Z; Liu, F; Sun, X; Xiu, P; Xu, Z; Zou, F | 1 |
| Bae, I; Duong, HQ; Jang, YJ; Kang, HJ; Kwak, SJ; Seong, YS; Yi, YW | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Ishigami, H; Kawakubo, K; Kitayama, J; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Sasahira, N; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Uchino, R; Watanabe, T; Yamaguchi, H; Yamamoto, N; Yamashita, H | 1 |
| Chang, H; Chen, X; Dai, Y; Dong, T; He, C; Ji, J; Li, J; Liu, T; Liu, W; Xiang, B | 1 |
| Raucher, D; Ryu, JS | 1 |
| Berlin, JD; Pauff, JM; Thota, R | 1 |
| Ayrault, O; Bihannic, L; Finkelstein, D; Freeman, BB; Gajjar, A; Guy, RK; Jacus, M; Li, XN; Morfouace, M; Olson, JM; Puget, S; Robinson, GW; Robinson, S; Roussel, MF; Shelat, A; Stewart, CF; Turner, D; Wang, YD; Zindy, F | 1 |
| Arrieta, O; Bacon-Fonseca, L; Blake-Cerda, M; Corona-Cruz, JF; López-Macías, D; Macedo-Pérez, EO; Mendoza-García, VO; Muñiz-Hernández, S; Muñoz-Montaño, W | 1 |
| Liu, Q; Liu, Y; Su, Z; Wang, D; Xie, X; Zhang, L; Zhang, Z; Zhou, Y; Zhu, H; Zhu, Y | 1 |
| Ginsberg, MS; Kass, SL; Krug, LM; Sima, CS; Woo, K; Zauderer, MG | 1 |
| Kim, DH; Lee, JA; Lim, JS; Seo, J; Song, BS; Yoo, JY | 1 |
| Ayuk, F; Bokemeyer, C; Brammer, I; Kröger, N; Mina, S; Nitsch, E; Pace, A; Schuch, G; Zander, A | 1 |
| Harada, N; Ikeda, T; Ikegami, T; Kawanaka, H; Maehara, Y; Matsuura, H; Morita, M; Okadome, K; Oki, E; Saeki, H; Shirabe, K; Soejima, Y; Uchiyama, H; Yamashita, Y; Yoshizumi, T | 1 |
| Ahn, JS; Ahn, MJ; Chang, W; Choi, MK; Chung, MP; Hong, JY; Jung, HA; Kim, M; Kim, S; Lee, SJ; Park, K; Park, S; Sun, JM | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 3 |
| Chan, S; Seidman, AD; Wang, J; Xu, B; Xu, C; Zhu, C | 1 |
| Dong, P; Han, H; Jiang, L; Li, Y; Liu, Z; Qin, Z; Yao, K; Yao, M; Zhang, Z; Zhou, F | 1 |
| Ashihara, K; Fujiwara, S; Kanemura, M; Kawaguchi, H; Ohmichi, M; Sasaki, H; Takai, M; Tanabe, A; Tanaka, T; Tanaka, Y; Terai, Y; Tsunetoh, S | 1 |
| Haeusler, GM; Lingaratnam, SM; Rischin, D; Seymour, JF; Slavin, MA; Teh, BW; Thursky, KA; Worth, LJ | 1 |
| Hirooka, S; Inoue, K; Kim, S; Kwon, AH; Matsui, Y; Satoi, S; Toyokawa, H; Yamaki, S; Yamamoto, T; Yamao, J; Yanagimoto, H | 1 |
| Bootsma, G; Brans, B; Das, M; de Ruysscher, D; Dingemans, AM; Hochstenbag, M; Houben, R; Lambin, P; Reymen, B; van Baardwijk, A; van Belle, A; Wanders, R | 1 |
| Barni, S; Brandes, AA; Caffo, O; Cerea, G; Ciardiello, F; Crinò, L; Cruciani, G; De Marinis, F; Fasola, G; Favaretto, AG; Ferrari, S; Ferraù, F; Galetta, D; Genestreti, G; Gridelli, C; Grossi, F; Iannacone, C; Luciani, A; Novello, S; Zilembo, N | 1 |
| Akisik, FM; Anderson, S; Bu, G; Cardenes, HR; Chiorean, EG; Clark, R; Deluca, J; DeWitt, J; Helft, P; Johnson, CS; Johnston, EL; Loehrer, PJ; Perkins, SM; Sandrasegaran, K; Schneider, BP; Shahda, S; Spittler, AJ | 1 |
| Azuma, H; Hirano, H; Ibuki, N; Inamoto, T; Kiyama, S; Komura, K; Minami, K; Narumi, Y; Nomi, H; Saito, K; Takahara, K; Takai, T; Tanda, N; Uchimoto, T; Uehara, H; Yamamoto, K | 2 |
| Chen, EY; Eastman, A; Hodge, S; Hou, H; Khan, N; Kuppusamy, M; Kuppusamy, P; Swartz, HM | 1 |
| Cheng, Y; Cun, Y; Li, M; Li, Z; Peng, Y; Qian, C; Ren, T; Wang, D; Xia, L; Xiong, Y; Zhang, S | 1 |
| Chen, SH; Jiang, Y; Li, DL; Wu, Z; Yang, F; Zhao, YY | 1 |
| Ahn, H; Ahn, JH; Choi, MK; Hong, BS; Hong, JH; Hong, SW; Jeong, IG; Kim, Y; Lee, JL; Lee, KH; Song, C | 1 |
| Abbadessa, G; Bendell, J; Camacho, LH; Chen, Y; Infante, JR; Jones, S; Kazakin, J; Kurkjian, CD; Moore, KM; Pant, S; Saleh, M; Schwartz, B; Wang, Y | 1 |
| Alberts, SR; Borad, MJ; Costello, BA; Erlichman, C; Kim, GP; Northfelt, DW; Qi, Y | 1 |
| Forster, T; Gebhard, MM; Gerhauser, C; Giese, N; Gladkich, J; Gross, W; Heilmann, K; Herr, I; Isayev, O; Labsch, S; Liu, L; Mattern, J; Nessling, M; Nwaeburu, CC; Rausch, V; Richter, K; Schaefer, M; Schemmer, P; Schoensiegel, F; Werner, J; Zhang, Y | 1 |
| Bottomley, A; Coens, C; Ediebah, DE; Flechtner, H; Gotay, C; Greimel, E; King, MT; Quinten, C; Reeve, BB; Ringash, J; Schmucker von Koch, J; Smit, EF; Taphoorn, MJ; Weis, J; Zikos, E | 1 |
| Aguirre, E; Benhadji, KA; Callies, S; Garcia, M; Gil-Martín, M; Llombart, A; Morales, S; Oaknin, A; Salazar, R; Wickremsinhe, ER | 1 |
| Chen, L; Huang, MJ; Lu, Y; Song, LL; Wang, YS; Xiong, WJ; Xue, JX; Zhang, XX | 1 |
| Chang, DT; Chaudhry, M; Dholakia, AS; Griffith, ME; Hacker-Prietz, A; Herman, JM; Koong, AC; Laheru, DA; Leal, JP; Oteiza, KE; Pai, J; Pawlik, T; Raman, SP; Su, Z; Tryggestad, E; Wahl, RL; Wolfgang, CL | 1 |
| Furukawa, H; Furuse, J; Ojima, H; Shibata, T; Shimizu, H; Takahashi, H | 1 |
| Anderson, E; Bahary, N; Charpentier, K; Clark, A; Kennedy, T; Lopez, CD; McNulty, B; Miner, T; Safran, H; Schumacher, A; Shipley, J; Sio, T; Sun, W; Vakharia, J; Whiting, S | 1 |
| Chen, Q; Yu, J | 1 |
| Arumugam, T; Elmetwally, AM; Lin, HY; Mousa, SA; Nazeer, T; Phillips, P; Sudha, T; Yalcin, M | 1 |
| Bockorny, B; Dasanu, CA | 1 |
| Botkjaer, KA; Huang, Y; Kwok, HF; McCafferty, J; Murphy, G; Tape, CJ | 1 |
| Bellei, M; Biasoli, I; Bonacorsi, G; Cesaretti, M; Federico, M; Luminari, S; Maiorana, A; Quaresima, M; Salati, M | 1 |
| Ba'ssalamah, A; Brostjan, C; Eisenhut, A; Gnant, M; Kuehrer, I; Sahora, K; Schindl, M; Schoppmann, SF; Stift, J; Telek, B; Werba, G | 1 |
| Iida, T; Nakabayashi, Y; Okui, N; Otsuka, M; Shiba, H; Yanaga, K | 1 |
| Blazar, BR; Chandler, P; Ding, ZC; Huang, L; Krasinski, A; Lemos, H; Liu, K; Lu, X; Mack, M; Mellor, AL; Munn, DH; Walters, M; Yu, M; Zhou, G | 1 |
| Fukutomi, A; Gansert, J; Ikeda, M; Kobayashi, Y; Okusaka, T; Shibayama, K; Takubo, T | 1 |
| Chi, Y; Song, Y; Wang, J; Yang, L; Zhou, A | 1 |
| Baradia, D; Khatri, N; Misra, A; Rathi, M | 1 |
| Ambre, AH; Gange, KN; Haldar, MK; Katti, KS; Layek, B; Mallik, S; Meghnani, V; Nahire, R; Paul, S; Sarkar, K; Singh, J | 1 |
| Avan, A; Boggi, U; Campani, D; Cantore, M; Caponi, S; Faviana, P; Funel, N; Giovannetti, E; Maftouh, M; Mambrini, A; Milella, M; Pacetti, P; Paolicchi, E; Peters, GJ; Reni, M; Vaccaro, V; Vasile, E | 1 |
| Barni, S; Blasi, L; Cinieri, S; Colucci, G; De Vita, F; Fedele, P; Filippelli, G; Gebbia, N; Giotta, F; Lorusso, V; Maiello, E; Orlando, L; Pappagallo, GL; Pisconti, S; Riccardi, F; Verderame, F | 1 |
| Chen, Y; Cheng, JM; Gong, GQ; Li, CY; Li, GP; Liu, LX; Wang, JH; Wang, XL; Yan, ZP | 1 |
| Agarwal, N; Al-Hawary, M; Daignault, S; Dawsey, S; Day, KC; Day, ML; Eisenberger, MA; Grivas, PD; Hussain, M; Levine, EG; MacVicar, GR; Puzanov, I; Quinn, DI; Siefker-Radtke, AO; Smith, DC; Srinivas, S; Twardowski, P; Vaishampayan, UN; Yu, EY | 1 |
| Ah Lee, S; Gwe Ahn, S; Jeong, J; Min Lee, H; Woo Lee, H | 1 |
| Chen, L; Chen, M; Dai, F; He, M; Shen, P; Song, Y; Wan, X; Xiao, P | 1 |
| Archer, V; Burdaeva, O; Delmar, P; Gorbunova, V; Hilton, M; Juhasz, E; Mok, T; Orlov, S; Pallaud, C; Reck, M; Szima, B; Yu, CJ | 1 |
| Gao, RJ; Li, L; Li, Y; Liu, XJ; Qin, Y; Shao, RG; Zhen, YS | 1 |
| Alam, N; Dubey, RD; Gupta, AP; Gupta, PN; Khare, V; Koul, M; Kour, S; Saneja, A; Saxena, AK; Singh, D; Singh, SK | 1 |
| Joshi, G; Kumar, A; Sawant, K | 1 |
| Srimuninnimit, V; Sriuranpong, V; Suwanvecho, S | 1 |
| Ambike, A; Bekkara-Aounallah, F; Couvreur, P; Gref, R; Rosilio, V | 1 |
| Gulbis, A; Hart, JW; Nieto, Y; Wang, E | 1 |
| Cui, L; Ji, SL; Xiong, L; Zhang, CY; Zheng, HL; Zhu, MH | 1 |
| Fang, Z; Hong, S; Hong, SS; Jung, KH; Lee, H; Son, MK; Yan, HH | 1 |
| Hasegawa, Y; Kitamura, C; Kobayashi, K; Miura, D; Sato, N; Suzuki, T | 1 |
| Ghiringhelli, F; Guiu, B; Ladoire, S; Lorgis, V; Vincent, J | 1 |
| Di, G; Hu, X; Hu, Z; Liu, G; Liu, Y; Shao, Z; Wang, B; Wang, L; Wang, Z; Wu, J; Yang, W; Zhang, J | 1 |
| Cheon, YK; Hong, MJ; Lee, EJ; Lee, TY; Shim, CS | 1 |
| Ambre, AH; Borowicz, PP; Guo, B; Haldar, MK; Katti, KS; Katti, P; Kulkarni, PS; Mallik, S; Muhonen, WW; Nahire, RR; Padi, SK; Reindl, K; Shabb, JB; Shrivastava, DK; Singh, RK | 1 |
| Chen, L; Cress, WD; Kurtyka, CA | 1 |
| Andergassen, U; Beckmann, MW; Fasching, PA; Fehm, T; Friedl, TW; Friese, K; Hepp, P; Janni, W; Jückstock, J; Lichtenegger, W; Lorenz, R; Pantel, K; Rack, B; Schindlbeck, C; Schneeweiss, A; Tesch, H; Zwingers, T | 1 |
| Bourgaux, C; Couvreur, P; Desmaële, D; Lepeltier, E; Maksimenko, A; Meneau, F; Rosilio, V; Sliwinski, E; Zouhiri, F | 1 |
| Celano, M; Celia, C; Cosco, D; Ferrari, M; Filetti, S; Fresta, M; Gaspari, M; Paolino, D; Puxeddu, E; Russo, D; Voce, P; Wolfram, J | 1 |
| Behrman, SW; Chitkara, D; Mahato, RI; Mittal, A | 1 |
| Bansal, AK; Munjal, B; Patel, M | 1 |
| Al-Ejeh, F; Biankin, AV; Brown, MP; Chou, A; Grimmond, SM; Kalimutho, M; Khanna, KK; Miranda, M; Nagrial, AM; Pajic, M; Shi, W | 1 |
| Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G | 1 |
| Ding, YJ; Feng, Y; Wan, HY; Xiang, Y; Zhang, QR; Zhou, M | 1 |
| Cinque, G; Dumas, P; Filik, J; Rutter, AV; Sandt, C; Siddique, MR; Sockalingum, GD; Sulé-Suso, J; Yang, Y | 1 |
| André, T; Assenat, E; Blanc, JF; Boucher, E; Cervera, P; de la Fouchardière, C; Dollinger, M; Ducreux, M; Faivre, S; Fartoux, L; Foulon, S; Grenier, J; Greten, TF; Hahn, P; Hammel, P; Heinemann, V; Herrmann, T; Malka, D; Pignon, JP; Rosmorduc, O; Rousseau, V; Seufferlein, T; Trarbach, T; Viret, F; Wendum, D | 1 |
| Antunes Soares, FA; Araújo, Mdo C; Baldissareli, J; Belmonte Pereira, L; Bitencourt Rosa Leal, D; Brenner Reetz, LG; Chiesa, J; Curry Martins, C; Morsch, VM; Pelinson, LP; Pires Amaral, G; Schetinger, MR; Schmatz, R; Zanini, D | 1 |
| Aloia, TA; Cooper, AB; des Bordes, JK; Fleming, JB; Fogelman, D; Holmes, HM; Katz, MH; Lee, JE; Parker, NH; Vauthey, JN | 1 |
| Bartosiewicz, M; Boeck, S; Haas, M; Heinemann, V; Isaacson, J; Kirchner, T; Kleespies, A; Kruger, S; Laubender, RP; Mann, E; Ormanns, S; Raponi, M | 1 |
| Au, HJ; Chen, E; Dhani, N; Gill, S; Hedley, D; Kamel-Reid, S; Moore, MJ; Renouf, DJ; Tang, PA; Tran-Thanh, D; Tsao, MS; Wang, L | 1 |
| Cui, J; Du, Y; Huang, S; Jia, Z; Jiang, W; Kong, X; Li, L; Li, Z; Wei, D; Xie, D; Xie, K | 1 |
| Guo, YH; Liao, ZJ; Nan, KJ; Xu, R; Yao, JT; Zhao, Z | 1 |
| Bradley, M; Carragher, NO; Dawson, JC; Fraser, C; Patton, EE; Rybski, W; Torres-Sánchez, C; Unciti-Broceta, A; Weiss, JT | 1 |
| Cheng, G; Dwinell, MB; Kalyanaraman, B; McAllister, D; Tsai, S; Zielonka, J | 1 |
| Li, LQ; Li, Q; Li, YQ; Liang, CY; Liang, R; Liao, SN; Liao, XL; Lin, Y; Liu, ZH; Yuan, CL; Zhang, YM | 1 |
| Bapiro, TE; Bramhall, JL; Cook, N; Courtin, A; Frese, KK; Griffiths, JR; Jodrell, DI; Madhu, B; Neesse, A; Richards, FM; Tuveson, DA | 1 |
| Bekaii-Saab, T; Bloomston, M; Chen, CS; Chou, CC; Fang, CS; Kulp, SK; Lai, IL; Lai, PT; Mo, X; Shirley, LA; Yan, R | 1 |
| Borazanci, E; Von Hoff, DD | 1 |
| Balslev, E; Bartels, A; Bjerre, C; Bjerre, KD; Brünner, N; Ejlertsen, B; Jørgensen, CL; Nielsen, DL | 1 |
| Badran, A; Enein, HA; Ghoneim, M; Kalawee, ME; Khaled, HM; Mahran, TZ; Manie, M; Mansur, O; Megeed, HA; Ramadan, SM; Saber, RA; Shafik, HE; Sherbini, ME; Zabhloul, MS | 1 |
| Akiyama, N; Akiyoshi, K; Fujioka, K; Funamizu, N; Ikeda, K; Kamada, M; Manome, Y; Watanabe, M | 1 |
| Chung, N; Park, SH; Sung, JH | 1 |
| Szalontai, B; Zimányi, L | 1 |
| Bruchard, M; Ghiringhelli, F | 1 |
| Abou-Alfa, GK; Allen, PJ; Brennan, MF; Capanu, M; Coit, DG; DeMatteo, RP; DʼAngelica, M; Gerdes, H; Jarnagin, WR; Kingham, TP; Klimstra, DS; Kurtz, RC; LaValle, J; Lowery, MA; OʼReilly, EM; Perelshteyn, A; Reidy, DL; Schattner, M; Tang, LH; Winston, C | 1 |
| Canseven, AG; Esmekaya, MA; Kayhan, H; Seyhan, N; Tuysuz, MZ | 1 |
| Feng, J; Huang, X; Huang, Z; Li, Y | 1 |
| Ahn, HK; Cho, EK; Jeong, SH; Jung, M; Kang, SM; Kyung, SY; Park, JW; Shin, DB; Sym, SJ | 1 |
| Aglietta, M; Bagalà, C; Barone, C; Cagnazzo, C; Colombi, F; Fly, KD; Gioeni, L; Huang, B; Leone, F; Miller, WH; Moore, MJ; Sawyer, MB; Wang, E | 1 |
| Argnani, L; Casadei, B; Maglie, R; Pellegrini, C; Stefoni, V; Zinzani, PL | 1 |
| Abe, H; Kondo, Y; Miura, T; Nemoto, K; Nomura, S; Shioji, G; Tsuboi, N | 1 |
| Choi, DW; Choi, JY; Choi, MK; Choi, SH; Heo, JS; Lee, J; Lee, JK; Lee, KH; Lee, KT; Lim, HY; Park, JO; Park, YS | 1 |
| Callahan, MJ; Cobb, B; Cohn, DE; Copeland, LJ; Eisenhauer, EL; Fowler, JM; O'Malley, DM; Salani, R; Sutton, G; Zanagnolo, V | 1 |
| Adhikaree, J; Madhusudan, S | 1 |
| Infante, JR; Kasubhai, SM; Le, N; Li, CP; Liu, Y; Oh, DY; Park, JO; Redhu, S; Scheulen, ME; Somer, BG; Steplewski, K | 1 |
| Booth, CM; Mackillop, WJ; Peng, Y; Siemens, DR; Tannock, IF | 1 |
| Bang, S; Chung, MJ; Park, JY; Park, SW; Song, SY | 1 |
| Araki, N; Fukuda, H; Hiraga, H; Iwamoto, Y; Kataoka, K; Kawai, A; Kimura, A; Matsumine, A; Matsunobu, T; Mizusawa, J; Oda, Y; Tanaka, K | 1 |
| Bergmann, F; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Kessel, KA; Naumann, P; Werner, J | 1 |
| Busman, T; Cleary, JM; Franklin, C; Graham, A; Holen, K; Hurwitz, HI; Lima, CM; Mabry, M; Montero, AJ; Shapiro, GI; Uronis, H; Yang, J | 1 |
| Ide, T; Kitahara, K; Koga, H; Miyoshi, A; Nakamura, J; Noshiro, H | 1 |
| Katsuno, A; Matsushita, A; Nakamura, Y; Sumiyoshi, H; Uchida, E; Yamahatsu, K | 1 |
| Frödin, JE; Liljefors, M; Mellstedt, H; Mozaffari, F; Staff, C | 1 |
| Ajamie, RT; Cai, S; Chan, EM; Cronier, D; de Dios, A; Del Prado, M; Flack, RS; Gelbert, LM; Iversen, P; Kreklau, E; Lallena, MJ; Lin, X; Neubauer, BL; Sanchez-Martinez, C; Torres, R; Wishart, GN; Young, J | 1 |
| Cheung, SS; Hasman, D; Tai, J | 1 |
| Abe, T; Ensako, T; Hino, K; Nakamura, M; Nakashima, H; Yoshida, K | 1 |
| Chang, Y; Chen, C; Fu, X; Li, L; Li, X; Li, Z; Lu, L; Ma, W; Qin, B; Sun, Z; Wang, X; Wen, J; Wu, J; Yan, J; Zhang, L; Zhang, M; Zhang, X; Zhou, Z | 1 |
| Gordon, N; O'Farrill, JS | 1 |
| Huang, G; Kleinerman, ES; Nishimoto, K; Yang, Y | 1 |
| Rodriguez, CO | 1 |
| Chiu, CC; Hour, TC; Hsu, SH; Hsu, WC; Hu, HT; Huang, AM; Kao, YT; Lin, CS; Lu, CY; Pu, YS | 1 |
| Ikari, T; Ioka, T; Isayama, H; Ishii, H; Koike, K; Kwon, AH; Nakai, Y; Okusaka, T; Ozaka, M; Satoi, S; Shimokawa, T; Sho, M; Tanaka, M; Ueno, H; Yanagimoto, H | 1 |
| Conte, M; Ellingrod, VL; King, AN; O'Malley, M; Ramnath, N | 1 |
| Aires, A; Cortajarena, AL; Couleaud, P; Latorre, A; Somoza, Á | 1 |
| Brana, I; Calles, A; Calvo, E; de Boer, CJ; LoRusso, PM; Puchalski, TA; Seetharam, S; Tabernero, J; Yee, LK; Zhong, B | 1 |
| Christopoulou, A; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katopodis, O; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Polyzos, A; Souglakos, J; Stathopoulos, E | 1 |
| Hoegdall, DT; Jensen, LH; Larsen, FO; Mellergaard, AH | 1 |
| Arslan, A; Baran, M; Cihan, YB; Deniz, K; Karaca, H; Ozturk, A | 1 |
| Cai, LT; Liu, NN; Qu, QR; Wu, GQ; Xue, XL; Yan, XJ; Zhang, C | 1 |
| Elity, MM; Sad, LM; Younis, SG | 1 |
| Bachner, M; Cerveny, M; De Santis, M; Dittrich, C; Kametriser, G; Königsberg, R; Schratter-Sehn, A; Sedlmayer, F; Steininger, T | 1 |
| Brkic, S; Dedic, S; Jamakosmanovic, S; Osmic, M; Ramic, N; Umihanic, S | 1 |
| Baker, AF; Bolejack, V; Burris, H; Crowley, J; Dayyani, F; Dragovich, T; Hidalgo, M; Laheru, D; Raghunand, N; Ritch, P; Rosen, P; Seng, J; Smith, L; Von Hoff, DD | 1 |
| Hebraud, B; Houyau, P; Laurent, G; Oberic, L; Recher, C; Suc, E; Vaillant, W; Ysebaert, L | 1 |
| Avan, A; Castellano, L; Fiuji, H; Frampton, AE; Funel, N; Galla, V; Giovannetti, E; Maftouh, M; Pelliccioni, S; Peters, GJ | 1 |
| Ciccolini, J; Etienne-Grimaldi, MC; Giovannetti, E; Honeywell, RJ; Losekoot, N; Maulandi, M; Milano, G; Peters, GJ; Serdjebi, C | 1 |
| Du, QG; Guo, XY; Han, S; Hao, ZM; Liu, GS; Lv, YF; Wang, P; Zhu, SM | 1 |
| Han, ZF; Hong, J; Jiang, Y; Liu, LS; Shen, LP | 1 |
| Hazama, S; Hinoda, Y; Iida, M; Maeda, Y; Matsui, H; Oka, M; Sakai, K; Shindo, Y; Suehiro, Y; Suzuki, N; Ueno, T; Yamasaki, T; Yoshimura, K; Yoshino, S | 1 |
| Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, TY; Kim, YJ; Lee, KH; Lee, KW; Oh, DY | 1 |
| Blum, H; Bruns, CJ; Camaj, P; Ellwart, JW; Ischenko, I; Jäckel, C; Jauch, KW; Krebs, S; Mysliwietz, J; Nelson, PJ; Niess, H; Renner, A; Zhao, Y | 1 |
| Beardo Villar, P; Gamaza Martínez, R; Gavira Moreno, R | 1 |
| Chien, W; Ding, LW; Garg, M; Gery, S; Kitajima, S; Koeffler, PH; Lee, KL; Leong, WZ; Lim, SL; Poellinger, L; Sun, H; Sun, QY; Takao, S; Tan, SZ; Tokatly, I; Torres-Fernandez, LA; Xiao, J | 1 |
| Kornmann, M; Liu, X; Ma, Y; Tian, X; Wang, F; Yang, Y | 1 |
| Bartsch, DK; Fendrich, V; Hudemann, C; Knoop, RF; Lauth, M; Plassmeier, L; Sparn, M; Waldmann, J | 1 |
| Anthoney, A; Archer, C; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Eatock, M; Evans, J; Falk, S; Garcia-Alonso, A; Greenhalf, W; Harrison, M; Hickish, T; Iveson, T; Madhusudan, S; McAdam, K; Middleton, G; Naisbitt, D; Nanson, G; Neoptolemos, J; Nicolson, M; Propper, D; Rawcliffe, C; Robinson, A; Roques, T; Ross, P; Shaw, V; Silcocks, P; Steward, W; Valle, J; Wadd, N; Wadsley, J | 1 |
| Andrake, M; Astsaturov, I; Banina, E; Beeharry, N; Deacon, S; Egleston, BL; Hittle, J; Khazak, V; Peterson, JR; Skobeleva, N; Yen, TJ | 1 |
| Alishekevitz, D; Bril, R; Fremder, E; Gingis-Veltski, S; Hasnis, E; Karban, A; Raviv, Z; Shaked, Y; Voloshin, T | 1 |
| Boyella, R; Gottesman, S; Juneman, E; Khan, MF | 1 |
| Akca, Z; Büyükçelik, A; Cihan, YB; Coşkun, HS; Erden, A; Gündüz, S; Karaca, H; Mutlu, H | 1 |
| Abrams, TA; Allen, JN; Baran, A; Blaszkowsky, LS; Borger, DR; Clark, JW; Connolly, GC; Faris, JE; Fuchs, C; Goyal, L; Harris, DJ; Herr, M; Hezel, AF; Hyrien, O; Iafrate, AJ; Khorana, AA; Murphy, JE; Ng, K; Noel, MS; Regan, E; Ryan, DP; Sheehan, S; Yurgelun, M; Zheng, H; Zhu, AX | 1 |
| Arai, Y; Ito, A; Kaiho, Y; Mitsuzuka, K; Nakagawa, H; Namiki, S; Saito, H; Sato, K; Yamada, S; Yamashita, S | 1 |
| Brunner, TB; Chu, KY; Hawkins, M; Mukherjee, S; Partridge, M; Wilson, JM | 1 |
| Choi, BI; Han, JK; Kim, H; Kim, JH; Kim, YJ; Lee, JY | 1 |
| Carbone, A; Di Cristofano, C; Evangelista, S; Palleschi, G; Pastore, AL; Petrozza, V; Porta, N; Rossi, L; Silvestri, L; Tomao, S | 1 |
| Goda, Y; Irie, K; Kobayashi, S; Morimoto, M; Ohkawa, S; Ueno, M | 1 |
| Chen, B; Liu, LL; Lou, HZ; Pan, HM; Pan, Q; Sun, P; Weng, XC | 1 |
| Hirano, S; Kuroda, A; Kuwatani, T; Kyogoku, N; Maki, T; Miyauchi, K; Shichinohe, T; Takeuchi, S; Tsuchikawa, T; Wada, M; Yamamura, Y | 1 |
| Hernandez, F; Jaksa, R; Klanova, M; Klener, P; Kulvait, V; Lateckova, L; Lorkova, L; Maswabi, B; Mavis, C; Molinsky, J; Petrak, J; Pospisilova, J; Trneny, M; Vejmelkova, D; Vit, O; Vockova, P; Vokurka, M | 1 |
| Boku, N; Furuse, J; Ishido, K; Kasuga, A; Machida, N; Morizane, C; Nishina, T; Okusaka, T; Sudo, K; Takahashi, H; Tobimatsu, K; Yamaguchi, T | 1 |
| Aghajanian, C; DeLair, D; Grisham, RN; Hyman, DM; Iasonos, A; Iyer, G; Sala, E; Zhou, Q | 1 |
| Eskander, RN; Tewari, KS | 1 |
| Alejandre, MJ; Aránega, A; Caba, O; Delgado, JR; Iglesias, J; Irigoyen, A; Linares, A; Martin, M; Ortuño, FM; Palomino, RJ; Perales, S; Prados, JC; Rojas, I; Torres, C | 1 |
| Inoue, K; Sonoda, T; Tsubamoto, H | 1 |
| Bischoff, S; Dörken, B; Görner, M; Greten, TF; Heil, G; Lakner, V; Mölle, M; Oettle, H; Pelzer, U; Riess, H; Schwaner, I; Seraphin, J; Sinn, M; Stieler, JM | 1 |
| Cattel, L; Couvreur, P; Desmaële, D; Giraudo, E; Maione, F; Mura, S; Noiray, M; Stella, B; Valetti, S; Vauthier, C; Vergnaud, J | 1 |
| Buoro, RM; Diculescu, VC; Lemos, L; Lopes, IC; Oliveira-Brett, AM; Serrano, SH | 1 |
| Cao, B; Li, Q; Wen, Z; Yan, H; Yuan, Z; Zhang, R | 1 |
| Chen, X; Li, S; Lu, Y; Wang, H; Wang, KF; Wang, Z; Wuxiao, ZJ; Xia, ZJ; Zhu, J | 1 |
| Bang, S; Chung, JB; Chung, MJ; Jo, JH; Park, JY; Park, SW; Song, SY | 1 |
| Beyer, M; Erdmann, R; Humme, D; Nast, A; Vandersee, S | 1 |
| Chen, ZX; Cheng, Z; Du, X; Hu, JK; Li, Y; Wang, YH; Wang, ZQ; Zhou, ZG | 1 |
| Li, Y; Lim, J; Paxton, J; Wu, Z; Xu, H | 1 |
| Benson, MC; Danzig, MR; Decastro, GJ; Deibert, CM; Ghandour, RA; McKiernan, JM; Stevenson, SM | 1 |
| Barth, RJ; Colacchio, TA; Gardner, TB; Gordon, SR; Hessami, N; Klibansky, DA; Mody, K; Pipas, JM; Putra, J; Ripple, GH; Smith, KD; Suriawinata, AA; Tsapakos, MJ; Tsongalis, GJ; Zaki, B | 1 |
| Colom, H; García del Muro, X; Gil-Martín, M; Gonzalo, N; Martin-Liberal, J; Muñoz, C; Rigo, R; Sáinz-Jaspeado, M; Tirado, OM | 1 |
| Batra, SK; Dey, P; Ganti, AK; Ponnusamy, MP; Rachagani, S; Vaz, AP | 1 |
| Cao, J; Chen, H; Chen, WR; Fida, G; Gu, Y; Li, S; Qian, Z; Qin, J; Tian, C; Wang, Z | 1 |
| Akaihata, M; Hosoya, M; Kikuta, A; Kobayashi, S; Mochizuki, K; Ohara, Y; Sano, H; Waragai, T | 1 |
| Andreou, D; Busemann, C; Ehninger, G; Gerdes, S; Pink, D; Reichardt, P; Richter, S; Schuler, MK; Tunn, PU | 1 |
| Bauer, N; Bazhin, AV; Fan, P; Gladkich, J; Gross, W; Haberkorn, U; Herr, I; Isayev, O; Liu, L; Mattern, J; Mollenhauer, M; Nwaeburu, CC; Rausch, V; Rückert, F; Schönsiegel, F; Zach, S; Zhang, Y | 1 |
| Chen, J; Chen, T; Gao, W; Li, T; Liu, H; Qin, G; Wu, S; Xi, G; Zhao, C | 1 |
| Galsky, MD; Gimpel-Tetra, K; Godbold, J; Holcombe, RF; Lee, KM; Lowe, N; Misiukiewicz, K; Oh, WK; Posner, M; Soto, R; Tsao, CK | 1 |
| Andersson, R; Ansari, D; Nordh, S | 1 |
| Jeong, KS; Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ; Yoon, YB | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Joka, M; Krause, A; Licht, T; Seufferlein, T; Wichert, Gv; Zech, CJ | 1 |
| Fan, X; Jiang, H; Liu, Y; Mao, Z; Wang, X; Wang, Y; Zhang, J | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Sasaki, H; Sudo, T; Sueda, T; Uemura, K | 1 |
| Al-Massarani, G; Alali, A; Alammar, M; Almalla, N; Altahan, M; Bachour, M; Najjar, F | 1 |
| Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I | 1 |
| Attygalle, A; Barton, S; Chau, I; Chua, S; Cunningham, D; Dearden, C; Ethell, M; Gleeson, M; Hawkes, EA; Horwich, A; Peckitt, C; Potter, M; Wotherspoon, A | 1 |
| Chanpanitkitchot, S; Khunnarong, J; Pataradool, K; Srijaipracharoen, S; Tangjitgamol, S; Thavaramara, T | 1 |
| Benedetti, JK; Blanke, CD; Gaur, R; Goldman, B; Iqbal, S; Lenz, HJ; Lowy, AM; Philip, PA; Ramanathan, RK; Wakatsuki, T; Whitehead, RP | 1 |
| Hong, DF; Hu, ZM; Huang, DS; Shang, MJ; Wu, WD; Zhang, CW; Zhao, DJ | 1 |
| Agarwal, N; Apolo, AB; Galsky, MD; Gimpel-Tetra, K; Godbold, JH; Lee, KM; Lowe, N; Oh, WK; Poole, A; Soto, R; Tsao, CK | 1 |
| Groth, P; Jones, RM; Kotsantis, P; Petermann, E; Stewart, GS | 1 |
| Arakawa, H; Gong, J; Hayashi, K; Homma, S; Ikegami, M; Imazu, H; Ishidao, T; Ito, M; Kajihara, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Koyama, S; Misawa, T; Mori, M; Odahara, S; Ohkusa, T; Okamoto, M; Shimodaira, S; Sugiyama, H; Tajiri, H; Takakura, K; Toyama, Y; Tsukinaga, S; Uchiyama, K; Yanagisawa, S; Yoshizaki, S; Yusa, S | 1 |
| Brekken, RA; Carroll, KD; Cenik, BK; Hagopian, MM; Nugent, D; Ostapoff, KT; Rivera, LB; Topalovski, M; Wang, M; Xu, X; Ye, R | 1 |
| Guo, Z; Hu, H; Jiao, F; Jin, Z; Wang, L; Yuan, C | 1 |
| Ajiki, T; Eguchi, H; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kubo, S; Morita, S; Nagano, H; Sakai, D; Seo, S; Takemura, S; Taura, K; Terajima, H; Toyokawa, H; Tsuji, A; Yanagimoto, H | 1 |
| Hirano, T; Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M | 1 |
| Haager, B; Osei-Agyemang, T; Passlick, B; Wiesemann, S | 1 |
| Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN | 1 |
| Huber, K; Saif, MW; Yu, E | 1 |
| Chang, BW; Johung, KL; Saif, MW | 1 |
| Peponi, E; Saif, MW; Syrigos, KN; Tourkantonis, IS | 1 |
| Bhalla, A; Saif, MW | 1 |
| Kaddis, N; Saif, MW | 1 |
| Daoud, V; Goodman, M; Saif, MW | 1 |
| Gao, XD; Ge, LH; Jin, ZY; Liang, JG; Te, MR; Wang, CL | 1 |
| Cao, J; Huang, XE; Qian, ZY; Shi, L; Wu, XY; Xu, X | 1 |
| Hong, J; Johnson, ZL; Kwon, DY; Lee, JH; Lee, K; Lee, M; Lee, SY | 1 |
| Barraclough, H; Cheng, Y; Chi, H; Lu, S; Lu, Y; Orlando, M; Qin, S; Song, X; Wang, M; Wang, X; Wu, YL; Zhang, X; Zhang, Y; Zhou, C; Zhu, Y | 1 |
| DeNardo, DG; Goedegebuure, SP; Knolhoff, BL; Linehan, DC; Luo, J; Meyer, MA; Nywening, TM; Wang-Gillam, A; West, BL; Zhu, Y | 1 |
| Lemstrová, R; Melichar, B; Mohelnikova-Duchonova, B; Souček, P | 1 |
| de Sousa Cavalcante, L; Monteiro, G | 1 |
| Barzi, A; Beckett, L; Burich, RA; Gong, IY; Holland, W; Hutchins, IM; Kim, EJ; Lara, PN; Lenz, HJ; Mack, P; Semrad, T; Snyder-Solis, L; Tanaka, M | 1 |
| Kopeček, J; Sima, M; Yang, J; Zhang, R; Zhou, Y | 1 |
| Cao, B; Li, Q; Liu, W; Yan, H; Yang, Y; Zhen, H | 1 |
| Fuchs, C; Innocenti, F; Jiang, C; Kindler, HL; Mulcahy, MF; Niedzwiecki, D; O'Reilly, EM; Owzar, K; Van Loon, K; Venook, AP | 1 |
| Braddock, M; Chen, YP; Lin, YQ; Shi, KQ; Wang, LR; You, J; Zheng, MH; Zhu, GQ; Zou, H | 1 |
| Bekaii-Saab, TS; Ben-Josef, E; Dawson, LA; Griffith, KA; Herman, JM; Kim, EJ; Ringash, J; Serrano, PE; Wei, AC; Zalupski, MM | 1 |
| Bai, C; Chen, H; Gao, Z; Han, B; Jin, L; Li, Q; Li, X; Lu, D; Qian, J; Shao, M; Song, X; Wang, J; Wang, S; Wu, J; Zhao, X | 1 |
| Bryant, C; Massey, AJ; Rawlinson, R | 1 |
| Hanazaki, K; Iiyama, T; Iwata, J; Kobayashi, M; Kosaki, T; Kozuki, A; Morita, S; Okabayashi, T; Shima, Y; Sumiyoshi, T; Tokumaru, T | 1 |
| Ahn, JB; Chon, HJ; Chung, HC; Hong, MH; Jeung, HC; Kang, B; Lim, S; Nam, CM; Park, JS; Rha, SY; Yang, WI | 1 |
| Erkan, M; Gündüz, U; Kleeff, J; Parsian, M; Ünsoy, G; Yalçin, S | 1 |
| Bonnetain, F; Borg, C; Demarchi, M; Fein, F; Fiteni, F; Kim, S; Nguyen, T; Paillard, MJ; Pivot, X; Vernerey, D | 1 |
| Du, G; Eastman, A; Gimi, B; Hou, H; Khan, N; Krishnamurthy Nemani, V; Montano, R; Song, R; Swartz, HM | 1 |
| Cheung, TT; Chiu, JW; Fan, ST; Leung, R; Pang, R; Poon, R; Wong, H; Yau, T | 1 |
| Beohou, E; Bonnetain, F; Borg, C; Cleau, D; Demarchi, M; Dobi, E; Fein, F; Fiteni, F; Fratté, S; Jary, M; Kim, S; Monnien, F; Nerich, V; Nguyen, T; Pivot, X | 1 |
| Doki, Y; Eguchi, H; Gotoh, N; Hama, N; Hasegawa, S; Ishii, H; Kawamoto, K; Kobayashi, S; Konno, M; Koseki, J; Mori, M; Nagano, H; Nishida, N; Nishimura, T; Nojima, H; Ohno, S; Tomimaru, Y; Wada, H; Yabuta, N | 1 |
| Huang, J; Lin, Y; Sun, S; Zhang, L; Zhang, Q; Zhu, X | 1 |
| Baena, JM; Bayo, J; Blancas, I; Casal, J; Ciruelos, E; de la Haba, J; de Villena, MC; Galan, A; Gil, M; Jaen, A; Jara, C; Manso, L; Mel, JR; Murias, A; Salvador, J; Sanchez Rvira, P | 1 |
| Burns, M; Cardenes, HR; Chiorean, EG; Howard, T; Khawaja, MR; Kleyman, S; Loehrer, PJ; Nakeeb, A; Yu, Z | 1 |
| Ak, G; Akcay, M; Bayman, E; Etiz, D | 1 |
| Aggarwal, S; Alkharfy, KM; Baral, A; Chowdhury, S; Dutta, SK; Krishnaswamy, S; Mukhopadhyay, D; Pal, K; Pletnev, AA; Spaller, MR; Wang, E; Yadav, VK; Zhao, R | 1 |
| Baay, M; Burrows, N; Deschoolmeester, V; Lardon, F; Laukens, K; Meijnders, P; Pauwels, B; Pauwels, P; Peeters, M; Van den Weyngaert, D; Van Gestel, D; Vermorken, JB; Vu, TN; Williams, KJ; Wouters, A | 1 |
| Cisneros, BT; Corr, SJ; Curley, SA; Liu, H; Raoof, M; Wilson, LJ; Zhu, C | 1 |
| Chen, L; Luo, S; Zhang, M | 1 |
| Chen, X; Li, W; Li, X; Liu, L; Ren, S; Zhou, C; Zhou, F | 1 |
| Adachi, T; Goto, A; Hirata, T; Ishimine, Y; Kasai, K; Kondo, Y; Naito, T; Yabana, T | 1 |
| Chang, FY; Chang, KC; Chang, YT; Chen, MH; Huang, JY; Liang, PC; Lin, FH; Wong, JM | 1 |
| Barlesi, F; Besse, B; Cappuzzo, F; Carcereny, E; Felip, E; Ferry, D; Garcia-Ribas, I; Mazieres, J; Novello, S; Reck, M; Santoro, A; Scagliotti, G; Soria, JC; von Pawel, J; Zalcman, G | 1 |
| Albanell, J; Bellmunt, J; Beltran, M; Bonfill, T; Carles, J; Gallardo, E; Galtes, S; Moya, I; Pons, F; Rodon, J; Suarez, C | 1 |
| Hamada, T; Hirano, K; Ijichi, H; Isayama, H; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N | 1 |
| Gu, Y; Hu, B; Hu, H; Li, J; Qian, Y; Wang, G; Zhu, C | 1 |
| Guo, B; Liu, J; Song, L; Wu, J; Zhao, DY | 1 |
| Chen, Y; Jiang, T; Jin, C; Mao, A; Sun, X | 1 |
| Bruchertseifer, F; Bryan, RA; Dadachova, E; Epstein, AL; Jandl, T; Jiang, Z; Koba, W; Morgenstern, A; Onyedika, C; Strauss, J | 1 |
| Belgum, H; Drees, J; Etchison, R; Federspiel, MJ; Jacobson, BA; Jay-Dixon, J; Kratzke, RA; Patel, MR; Raza, A; Russell, SJ; Sadiq, A; Wang, H | 1 |
| Ho, C; Laskin, J; Melosky, B; Murray, N; Ramsden, K; Sun, S; Zhai, Y | 1 |
| Barattin, M; Bersani, S; Brazzale, C; Salmaso, S; Vila-Caballer, M | 1 |
| Fujikawa, A; Kohno, M; Moriyama, M; Namura, K; Ota, J; Sawada, T; Yamada, Y | 1 |
| Held-Warmkessel, J | 1 |
| Diaz-Griffero, F; Hollenbaugh, JA; Kim, B; Kim, DH; Lenzi, GM; Ryu, S; Schinazi, RF; Tao, S | 1 |
| Altman, RB; Alvarellos, ML; Klein, DJ; Klein, TE; Lamba, J; Sangkuhl, K; Thorn, CF; Wang, L | 1 |
| Al Husaini, H; ALHusaini, H; Aparisi, F; Arriola, E; Baize, N; Ballesteros, I; Barneto, I; Berchem, G; Bernabé, R; Blasco, A; Bombaron, P; Bosch-Barrera, J; Botia-Castillo, M; Bover, I; Calvo de Juan, V; Camps, C; Carcereny, E; Catot, S; Chaib, I; Chen, H; Chen, X; Chouaid, C; Cobo, M; Colinet, B; Dansin, E; De Grève, J; de Las Peñas, R; Domine, M; Drozdowskyj, A; Du, J; Felip, E; Fournel, P; Fraboulet, G; Gao, Y; García-Campelo, MR; García-Girón, C; García-Gómez, R; Garcia-Sevila, R; Garde, J; Gasco, A; Germonpre, P; Gervais, R; Gil, J; González-Larriba, JL; Hernando-Polo, S; Hominal, S; Hu, J; Hu, W; Insa, A; Isla, D; Jantus, E; Jiménez, B; Kahlout, S; Karachaliou, N; Kong, W; Lecaer, H; Lena, H; LeTreut, J; Li, L; Li, R; Li, X; Lianes, P; Liu, B; Liu, J; Locher, C; López-López, R; López-Martín, A; Lopez-Vivanco, G; Lu, H; Macias, JA; Majem, M; Marti-Ciriquian, JL; Massuti, B; Mate, JL; Mijangos, E; Molinier, O; Monnet, I; Montoyo, R; Morales-Espinosa, D; Moran, T; Moreno, MA; O'Brate, R; Ocaña, J; Oliviero, G; Pallares, C; Parera, M; Pereira, E; Perez-Cano, M; Pérez-Carrión, R; Porta, R; Provencio, M; Qian, X; Ramirez, JL; Rauh, S; Reguart, N; Ren, W; Robinet, G; Rosell, R; Rosillo, F; Sala, MA; Sanchez, JJ; Sanchez, JM; Sanchez-Rodriguez, B; Sanchez-Ronco, M; Schoot, R; Shao, J; Song, Y; Sullivan, I; Sun, X; Taron, M; Terrasa, J; Thomas, P; Tierno-Garcia, M; Trigo, JM; Valdivia, J; Vergnenegre, A; Viñolas, N; Viteri, S; Wang, L; Wei, J; Wen, L; Wu, Q; Xiao, X; Xu, X; Yan, J; Yang, J; Yang, M; Yang, Y; Yin, J; You, C; Yu, L; Yue, X; Zhang, F; Zhang, J; Zhou, Y; Zhu, L; Zou, Z | 1 |
| Forget, F; Hartner, L; Johnson, BM; Karaszewska, B; Kumar, K; Mayer, B; Messam, CA; Mostafa Kamel, Y; Ramlau, R; Richards, DA; Safran, H; Winer, ES | 1 |
| Chilakapati, DR; Chilakapati, SR; Kanala, JR; Manikonda, PK; Serasanambati, M | 1 |
| Blokzijl, E; Driever, EM; Groen, HJ; Hiltermann, TJ; Kerner, GS; Liesker, JJ; Mertens, MJ; Pieterman, RM; Renkema, TE; van Dullemen, LF; van Putten, JW; Widder, J; Wiegman, EM | 1 |
| Allory, Y; Bouquot, M; Comperat, E; de la Taille, A; Masson-Lecomte, A; Rouprêt, M; Sibony, M; Xylinas, E; Zerbib, M | 1 |
| Addanki, S; Bollu, LR; Candelaria, NR; Dey, P; Fisher, WE; Gabbi, C; Gustafsson, JÅ; Hodges, SE; Issazadeh, MA; Ittmann, MM; Jonsson, PK; Karaboga, H; Lin, CY; Lin, JZ; Liu, K; McElhany, AL; Nguyen-Vu, T; Steffensen, KR; Su, F; Vedin, LL; Wu, W; Zheng, J | 1 |
| Bera, A; Freeman, JW; Hill, P; Manoharan, MS; VenkataSubbaRao, K | 1 |
| Kwong, YL | 1 |
| Asanuma, F; Atsuda, K; Suzuki, Y; Takeuchi, O; Takizawa-Hashimoto, A; Watanabe, Y; Yamada, Y; Yoneyama, H | 1 |
| Dong, Z; Qin, L; Zhang, JT | 2 |
| Chino, JP; Delavan, JA; Vinson, EN | 1 |
| Bamezai, RN; Kumar, B; Manvati, S; Pandita, A; Singh, SK; Vaishnavi, S | 1 |
| Chen, XZ; Jin, T; Li, B | 1 |
| Andriulli, A; Burbaci, FP; Cappello, F; Copetti, M; di Mola, FF; di Sebastiano, P; Fontana, A; Graziano, P; Lombardi, L; Maiello, E; Pazienza, V; Pellegrini, F; Rappa, F; Tavano, F; Vinciguerra, M | 1 |
| Oguchi, K; Oyamada, H; Sasaki, A; Tsuchiya, H; Tsuji, M; Tsunoda, Y; Udaka, Y | 1 |
| Papadatos-Pastos, D; Rabbie, R; Ross, P; Sarker, D; Thillai, K | 1 |
| Beijnen, JH; Crombag, MR; de Vries Schultink, AH; Huitema, AD; Schellens, JH | 1 |
| Ehdaivand, S; Hardy, CW; Liang, D; Liu, EA; Madden, MZ; Pan, Y; Petrova, AV; Robinson, MH; Rudra, S; Smith, SC; Torres, MA; Wang, H; Wang, J; Wang, Y; Warren, MD; Yu, DS | 1 |
| Groselj, B; Karaszi, K; Kerr, M; Kiltie, AE; Scott, HE; Sharma, NL; Stratford, MR | 1 |
| Amundsen, T; Grønberg, BH; Helbostad, JL; Hjelde, H; Kaasa, S; Stene, GB; Sørhaug, S | 1 |
| Able, SL; Bowman, L; Brown, J; Cui, ZL; DeLozier, AM; Hess, LM; Natanegara, F; Treat, J; Zhao, L | 1 |
| Akyol, M; Alacacioglu, A; Bayoglu, IV; Cokmert, S; Demir, L; Dirican, A; Karabulut, B; Kucukzeybek, Y; Muslu, U; Tarhan, MO; Uslu, R; Varol, U; Yildiz, I; Yildiz, Y | 1 |
| Wang, WM; Wei, MY; Zhuang, YF | 1 |
| Qiu, ZQ; Zhao, K | 1 |
| Bearz, A; Bozzetti, R; Buti, S; Caminiti, C; Camisaschi, C; Castelli, C; Donini, M; Lazzarelli, S; Lo Re, G; Mattioli, R; Passalacqua, R; Rivoltini, L; Simonelli, C | 1 |
| Cooper, AJ; Keshavarz, S; Lwaleed, BA; Rooprai, HK; Thani, NA | 1 |
| Georgoulias, V; Giagkas, G; Ioannidis, G; Koutsopoulos, A; Lagoudaki, E; Mavroudis, D; Papadaki, C; Sfakianaki, M; Souglakos, J; Trypaki, M; Tsakalaki, E; Voutsina, A | 1 |
| King, EG; Kislukhin, G; Long, AD; Walters, KN | 1 |
| Abi-Jaoudeh, N; Avital, I; Beane, JD; Beresnev, T; Griffin, KF; Levy, EB; Pandalai, P; Rudloff, U; Shutack, Y; Webb, CC; Wood, B | 1 |
| Dia, VP; Gonzalez de Mejia, E; Johnson, JL; Wallig, M | 1 |
| Chen, GY; Cheng, Y; Huang, C; Song, Y; Wu, YL; Yan, HH; Yang, JJ; Zhou, Q | 1 |
| Han, L; Li, W; Liu, J; Ma, J; Ma, Q; Reindl, KM; Wang, F; Wu, E; Wu, Z; Zhang, D | 1 |
| Bennouna, J; Bonnet, I; Chauffert, B; Fauchart, JP; Gasmi, M; Jouve, JL; Le Malicot, K; Lepage, C; Maingon, P; Martin, P; Michel, P; Morin, T; Phelip, JM; Rostain, F; Seitz, JF; Smith, D; Subtil, F; Vendrely, V | 1 |
| Bu, HQ; Huang, H; Jin, HM; Li, Y; Liu, DL; Zhao, JF | 1 |
| Hu, N; Liu, Y; Wang, H; Wu, F; Xu, T; Zhang, J; Zheng, Y | 1 |
| Aprile, G; Ciuleanu, T; Csutor, Z; Federowicz, I; Fittipaldo, A; Hsu, C; Klughammer, B; Li, CP; Lipp, R; Meng, X; Moore, M; Nowara, E; Stemmer, SM; Tham, CK; Van Cutsem, E; Van Laethem, JL; Zeaiter, A | 1 |
| Chen, XS; Garfield, DH; Huang, O; Shen, KW; Wu, JY; Yuan, Y | 1 |
| Aizawa, M; Nashimoto, A; Nomura, T; Sato, Y; Tsuchiya, Y | 1 |
| Chen, K; Gumireddy, K; Huang, Q; Li, A; Li, H; Tang, K; Wang, J; Xiao, H; Xiao, W; Xu, H; Yao, W; Ye, Z; Yu, G | 1 |
| Asano, E; Funasaka, K; Goto, H; Hamaguchi, M; Hirooka, Y; Hyodo, T; Miyahara, R; Senga, T; Wong, M | 1 |
| Bechstein, WO; Brunner, TB; Bruns, C; Fietkau, R; Golcher, H; Grabenbauer, GG; Hohenberger, W; Jungnickel, H; Marti, L; Merkel, S; Meyer, T; Schreiber, S; Witzigmann, H | 1 |
| Alborzinia, H; Can, S; Cheng, X; Holenya, P; Ott, I; Rubbiani, R; Wölfl, S | 1 |
| Cheung, DY; Jeong, M; Kang, CS; Kim, HS; Kim, IK; Kim, JI; Kim, TJ; Seo, JH | 1 |
| Aning, J; Barocas, DA; Bivalacqua, TJ; Black, PC; Campain, NJ; Cookson, MS; Dall'Era, MA; Daneshmand, S; Dinney, CP; Ercole, CE; Espiritu, PN; Fairey, AS; Gandhi, NM; Garcia, JA; Griffin, J; Holzbeierlein, JM; Horenblas, S; Jacobsen, NE; Kassouf, W; Krabbe, LM; Lotan, Y; McGrath, JS; Mertens, LS; Mir, MC; Montgomery, JS; Morgan, TM; North, S; Seah, JA; Shah, JB; Shariat, SF; Spiess, PE; Sridhar, SS; Stephenson, AJ; Thorpe, AC; van Rhijn, BW; Vasdev, N; Wright, JL; Xylinas, E; Youssef, D; Yu, EY; Zargar, H | 1 |
| Distler, AM; Hill, EG; Lemasters, JJ; Manevich, Y; Mieyal, JJ; Nieminen, AL; Qanungo, S; Shaner, B; Townsend, DM; Uys, JD | 1 |
| Chao, YJ; Hsu, HP; Shan, YS; Sy, ED | 1 |
| Becerra, CR; Braiteh, F; Chen, J; Chow, KH; Conkling, PR; Garbo, L; Ilaria, R; Jotte, RM; Richards, DA; Robert-Vizcarrondo, F; Smith, DA; Stephenson, J; Tai, DF; Turner, PK; Von Hoff, DD | 1 |
| Al-Wadei, HA; Al-Wadei, MH; Banerjee, J; Dagnon, K; Schuller, HM | 1 |
| Bouvet, M; Fujimura, K; Kaushal, S; Kelber, JA; Klemke, RL; Lowy, AM; Metildi, C; Strnadel, J; Wright, T | 1 |
| Bynoe, MS; Kim, DG | 1 |
| de la Fuente, M; Jones, MC; Marimuthu, P; Mirenska, A; Santander-Ortega, MJ; Schätzlein, A; Uchegbu, I | 1 |
| Hu, W; Jiang, YH; Ma, N; Sui, CG; Zheng, RR | 1 |
| Akada, J; Baron, B; Kitagawa, T; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Tokuda, K; Wang, Y | 1 |
| Ba, Y; Bai, Y; Ge, F; Jia, R; Li, F; Lin, L; Wang, Y; Xu, H; Xu, J; Xu, N; Zhang, Y | 1 |
| Andersson, R; Ansari, D; Bauden, MP; Ek, F; Hilmersson, KS; Olsson, R; Urey, C | 1 |
| Abel, EV; Balis, UG; Blau, JL; Craig, R; Greenson, JK; Griffith, KA; Khan, GN; Kim, EJ; Sahai, V; Simeone, DM; Takebe, N; Zalupski, MM | 1 |
| Chan, K; Coyle, D; Ko, YJ; Lam, H; Lien, K; Shah, K | 1 |
| Azim, HA; de Azambuja, E; Piccart, M; Sonnenblick, A | 1 |
| el Aziz, LM | 1 |
| Adhikary, A; Hindi, RM; Kumar, A; Rayala, R; Sevilla, MD; Wnuk, SF | 1 |
| Bachet, JB; Cros, J; Demetter, P; Fléjou, JF; Maréchal, R; Svrcek, M | 1 |
| Hong, WD; Huang, QK; Liu, Y; Sun, XC; Wu, JM | 1 |
| Bradley, JD; Curran, WJ; Machtay, M | 1 |
| Li, HY; Li, N; Li, Q; Li, X; Shen, XH; Sun, HH; Wei, W | 1 |
| Blandino, G; Cordani, M; Di Agostino, S; Donadelli, M; Fiorini, C; Padroni, C | 1 |
| Arpicco, S; Couvreur, P; Desmaële, D; Dosio, F; Mura, S; Noiray, M; Stella, B; Valetti, S; Vergnaud, J | 1 |
| Bahra, M; Denkert, C; Dörken, B; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Currie, AJ; Khong, A; Lake, RA; Lesterhuis, WJ; McDonnell, AM; Nowak, AK; Robinson, BW | 1 |
| Grewal, P; Karvat, A; Kohli, K; Liu, J; Parameswaran, A; Schellenberg, D; Thomas, S | 1 |
| Du, W; Ke, QH; Lei, Y; Liang, G; Luo, F; Yang, JY; Zhou, SQ | 1 |
| Hwang, IG; Jang, JS; Lee, KH; Lee, KT; Lee, MA; Lim, J; Nam, EM; Song, HS; Zang, DY | 1 |
| Azam, S; Batra, U; Choudhury, KD; Doval, DC; Kumar, K; Mehta, A; Pruthi, A | 1 |
| Guo, Y; Li, E; Ma, K; Shao, G; Sun, H; Wang, X | 1 |
| Guo, H; Liu, Y; Yang, S; Yao, S; Yao, Z; Zhao, Y | 1 |
| Wang, GS | 1 |
| De Toni, EN; Gallmeier, E; Göke, B; Guo, Y; Hocke, S; Kampmann, E; Ochs, S; Ziesch, A | 1 |
| Liu, GL; Luo, HY; Wang, DS; Wang, ZQ; Xu, RH; Zeng, ZL; Zhang, Y | 1 |
| Ke, Y; Li, XN; Ruan, J; Yi, SY; Zhao, L | 1 |
| Alessio, E; Baas, P; Beijnen, JH; Burgers, SA; Leijen, S; Pluim, D; Sava, G; Schellens, JH; Tibben, M; van Werkhoven, E | 1 |
| George, TJ; Liu, C; Lu, Z; Ostrov, DA; Puszyk, WM; Robertson, KD; Zhao, X | 1 |
| Li, HY; Liao, Y; Mu, GG; Yu, HG; Zhang, LL | 1 |
| Alexander, DB; Fukamachi, K; Futakuchi, M; Hagiwara, Y; Hino, O; Iigo, M; Shibata, K; Suzui, M; Tsuda, H | 1 |
| Dawson, DW; Donahue, TR; Kadera, BE; Li, L; Nguyen, AH; Toste, PA; Wu, N | 1 |
| Carlson, RW; Charpentier, E; Danso, MA; Finn, RS; Garcia-Ribas, I; Hellerstedt, B; Miller, KD; Neubauer, M; O'Shaughnessy, J; Richards, P; Robert, N; Rugo, HS; Saleh, M; Schwartzberg, L; Specht, JM; Winer, EP; Yardley, DA | 1 |
| Kwiatkowski, DJ; Liu, Y | 1 |
| Feng, J; Gu, J; Huang, J; Ni, S; Wang, H; Xu, L; Zhang, S; Zhang, W; Zhu, H | 1 |
| Bekaii-Saab, T; Blazer, M; Bloomston, M; Ellison, EC; Goldberg, RM; Muscarella, P; Phillips, G; Reardon, J; Schmidt, C; Williams, TM; Wu, C; Wuthrick, E | 1 |
| Chen, L; Harada, M; Harashima, N; Tamada, K; Tongu, M | 1 |
| Ide, T; Ide, Y; Kai, K; Kitahara, K; Koga, H; Miyoshi, A; Nakamura, H; Nakamura, J; Noshiro, H; Okumura, T | 1 |
| Garrido-Laguna, I; Patel, S; Reese, Z; Stenehjem, DD | 1 |
| Gong, J; Homma, S; Ito, M; Kajihara, M; Kan, S; Koido, S; Namiki, Y; Odahara, S; Ohkusa, T; Okamoto, M; Sugiyama, H; Tajiri, H; Takakura, K; Tsukinaga, S; Yoshida, K; Yoshizaki, S; Yusa, S | 1 |
| Chen, JS; Chou, WC; Hsu, HC; Huang, WK; Kuo, YC; Shen, WC; Tsang, NM; Yang, TS | 1 |
| Freund, KB; Pahk, PJ; Sheyman, AT; Wald, KJ | 1 |
| Liu, LH; Liu, YH; Xu, L; Yang, H | 1 |
| Bou-Reslan, H; Cao, T; Carano, R; Castillo, J; Chan, E; Cheng, JH; Clermont, AC; Devasthali, V; Forrest, W; French, D; Hoeflich, KP; Junttila, MR; Merchant, M; Metcalfe, C; Nannini, MA; Otter, DD; Singh, M | 1 |
| Grąt, M; Kornasiewicz, O; Krasnodębski, M; Krawczyk, M; Patkowski, W; Stankiewicz, R | 1 |
| Bitzer, M; Maier-Stocker, C; Malek, NP; Plentz, RR | 1 |
| Wang, W; Wang, Z; Xiao, X | 1 |
| Bansal, AK; Munjal, B | 2 |
| Bouvet, M; Endo, I; Fleming, JB; Hiroshima, Y; Hoffman, RM; Katz, MH; Maawy, AA | 1 |
| Fu, M; Huang, H; Wang, C; Xie, J; Yang, A; Zhang, W | 1 |
| Hamada, T; Ijichi, H; Isayama, H; Ishigaki, K; Kogure, H; Koike, K; Miyabayashi, K; Mizuno, S; Mohri, D; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Tateishi, K; Yamamoto, K; Yamamoto, N | 1 |
| Agelaki, S; Boukovinas, I; Christophyllakis, Ch; Georgoulias, V; Kalbakis, K; Kalykaki, A; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Mavroudis, D; Vamvakas, L; Vardakis, N | 1 |
| Asami, K; Atagi, S; Isa, S; Kawaguchi, T; Kitaichi, M; Kubo, A; Matsumura, A; Okishio, K; Shimizu, S; Takada, M; Tamiya, A | 1 |
| Burkhart, C; Commane, M; Fleyshman, D; Garrigan, J; Gurova, KV; Kohrn, R; Kurbatov, V; Martello, L; Ramachandran, R; Toshkov, I | 1 |
| Bosetti, R; Ferrandina, G; Marneffe, W; Scambia, G; Vereeck, L | 1 |
| Bernard, A; Bouchot, O; Charon-Barra, C; Derangere, V; Ghiringhelli, F; Lokiec, F; Magnin, G; Pagès, PB | 1 |
| Lu, L; Xie, J; Yuan, J | 1 |
| Abe, K; Aiba, K; Futagawa, Y; Hata, D; Okui, N; Sakamoto, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Yang, F; Zheng, H | 1 |
| Béjot, JL; Berthommé, H; Biollay, C; Buscail, L; Cordelier, P; Epstein, AL; Gayral, M; Hanoun, N; Lulka, H; Sèlves, J; Trempat, P; Vignolle-Vidoni, A | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Konishi, K; Marubashi, S; Mori, M; Nagano, H; Nakamori, S; Takeda, Y; Tanemura, M; Umeshita, K; Yoshioka, Y | 1 |
| Ferrari, M; Koay, EJ | 1 |
| Abbruzzese, JL; Baio, FE; Bhosale, PR; Chatterjee, D; Chen, R; Chen, Y; Court, L; Crane, CH; Cristini, V; Ferrari, M; Fleming, JB; Gottumukkala, VN; Javle, M; Kang, Y; Katz, MH; Koay, EJ; Lee, JE; Maitra, A; Ondari, A; Plunkett, W; Qayyum, A; Rozner, MA; Shen, H; Tamm, EP; Thomas, RM; Truty, MJ; Varadhachary, GR; Wang, H; Wolff, RA; Zhang, J | 1 |
| Lee, JL; Park, JH | 1 |
| Faez, L; Garrido, M; Jiménez-Fonseca, P; Menendez, MD; Rodriguez, D; Ruiz, AL; Sanchez Lorenzo, ML; Solis, MP; Uriol, E; Viéitez, JM | 1 |
| Ai, Z; Lu, B; Sun, L; Xu, J; Yan, X | 1 |
| Billadeau, DD; Deng, ZH; Gomez, TS; Osborne, DG; Phillips-Krawczak, CA; Zhang, JS | 1 |
| Li, QH; Liu, P; Sun, L; Zhang, P; Zhou, DS | 1 |
| Cox, D; Dranitsaris, G; Faria, C; Gluck, S; Rugo, H | 1 |
| Sun, M; Wu, B; Xie, Q; Zhan, Y; Zhao, W | 1 |
| Adaire, B; Cescon, TP; Choi, M; Cohen, SJ; Duncan, G; Hall, MJ; Joiner, M; Konski, A; McSpadden, E; Meropol, NJ; Meyer, JE; Philip, P; Shields, A | 1 |
| Akita, H; Fujiwara, Y; Gotoh, K; Ishikawa, O; Kishi, K; Kobayashi, S; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
| Berie, L; Denzer, U; Distelrath, A; Dollinger, MM; Duerr, EM; Ebert, MP; Galle, PR; Geissler, M; Kaiser, AK; Kanzler, S; Kolligs, FT; Lammert, F; Lindig, U; Lohse, A; Lubomierski, N; Maderer, A; Moehler, M; Sauvigny, C; Schadmand-Fischer, S; Schimanski, C; Schütz, M; Trojan, J; Wachtlin, D; Woerns, M; Zimmermann, S | 1 |
| Caron, J; Couvreur, P; Desmaële, D; Maksimenko, A; Mougin, J | 1 |
| Agarwal, N; Bellmunt, J; Di Lorenzo, G; Eigl, BJ; Giannatempo, P; Hussain, SA; Locke, J; Necchi, A; Niegisch, G; Pal, SK; Pond, GR; Poole, A; Singh, P; Sonpavde, G; Vaishampayan, UN | 1 |
| Chang, S; Chung, YH; Hwang, Y; Kim, NY; Kim, S; Kim, SJ; Koh, SS; Lee, Y; Min, HJ; Park, EH; Park, YW; Yoo, KS | 1 |
| Chaturvedi, P; Gilkes, DM; Samanta, D; Semenza, GL; Xiang, L | 1 |
| Appleton, B; Chapman, K; Chen, H; Clark, K; Drobnick, J; Gazzard, L; Goodacre, S; Halladay, J; Lyssikatos, J; Malek, S; Schmidt, S; Sideris, S; Wiesmann, C; Williams, K; Wu, P; Yen, I | 1 |
| Aparicio, T; Artru, P; Asnacios, A; Bonnetain, F; Dubreuil, O; Dupont-Gossard, AC; Fein, F; Gauthier, M; Landi, B; Lecomte, T; Lobry, C; Malka, D; Manet-Lacombe, S; Taïeb, J; Thirot-Bidault, A; Trouilloud, I; Zaanan, A | 1 |
| Banu, E; Bay, JO; Beuzeboc, P; Culine, S; Deplanque, G; Elaidi, R; Goldwasser, F; Gravis, G; Machiels, JP; Muracciole, X; Nguyen, T; Oudard, S; Pichon, MF; Priou, F; Radvanyi, F; Ravaud, A; Teghom, C; Théodore, C; Vannetzel, JM; Vano, Y; Vieillefond, A; Voog, E | 1 |
| Aulitzky, WE; Bergmann, L; Burkholder, I; Edler, L; Fuxius, S; Hartung, G; Heil, G; Köberle, D; Maute, L; Moritz, B; Richly, H; Rüssel, J; Scheulen, ME; Weidmann, E; Weigang-Köhler, K; Wörmann, B | 1 |
| Celia, C; Cilurzo, F; Cosco, D; De Angelis, F; Di Marzio, L; Fattal, E; Fresta, M; Paolino, D; Russo, D; Tsapis, N | 1 |
| Byun, JH; Hong, SH; Jung, KH; Kim, HG; Kim, HY; Kim, KH; Lee, HJ; Lee, NR; Lee, S; Lee, SC; Park, KH; Rha, SY; Woo, IS; Yun, J | 1 |
| Barber, J; Casbard, A; Chester, J; Cowles, R; Crabb, S; Elliott, T; Evans, J; Geldart, T; Griffiths, G; Huddart, RA; Jones, RJ; Mead, G; Protheroe, A; Smith, J | 1 |
| Alkharfy, KM; Bhattacharya, S; Chari, ST; Dutta, SK; Elkhanany, A; Lau, JS; Mukhopadhyay, D; Pal, K; Patel, TC; Sanyal, A; Sharma, AK; Spaller, MR; Wang, E; Yan, IK | 1 |
| Katanyoo, K; Laopaiboon, M; Lumbiganon, P; Manusirivithaya, S; Supawattanabodee, B; Tangjitgamol, S | 1 |
| Bergaglio, M; Buonerba, C; Calabrese, F; Damiano, V; De Maio, AP; Di Lorenzo, G; Federico, P; Lalle, M; Marino, M; Merola, C; Milella, M; Montella, L; Ottaviano, M; Palmieri, G; Von Arx, C | 1 |
| Kitanaka, C; Okada, M; Sato, A; Seino, M; Seino, S; Shibuya, K; Suzuki, S; Takeda, H; Yoshioka, T | 1 |
| Addington, C; Cartwright, C; Gagea, M; Kim, SJ; Kundra, V; Lee, HJ; Newman, RA; Pan, Y; Ravoori, MK; Rhea, P; Tan, L; Yang, P | 1 |
| Ajiki, T; Fujiwara, Y; Hatano, E; Ikoma, H; Ikuta, S; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Kubo, S; Marubashi, S; Miyamoto, A; Morita, S; Nagano, H; Sakai, D; Seo, S; Shiomi, H; Terajima, H; Yanagimoto, H | 1 |
| Cardwell, J; Chatterjee, D; Fleming, JB; Kang, Y; Katz, MH; Li, SQ; Roife, D; Suzuki, R; Thomas, RM; Truty, MJ; Wang, H; Wang, Y; Zhang, R | 1 |
| Cress, AE; Dorr, RT; Landowski, TH; Patel, C; Patel, H; Pond, E; Pond, KW; Samulitis, BK; Wisner, L | 1 |
| Addeo, G; Allendorf, J; Chabot, J; Chu, K; Fine, RL; Hecht, E; Jin, B; Leung, D; Postolov, I; Remotti, H; Schrope, BA; Sherman, WH; Tsai, W | 1 |
| Jaidev, LR; Krishnan, UM; Sethuraman, S | 1 |
| Chovanec, M; Mardiak, J; Mego, M; Obertova, J; Palacka, P; Sycova-Mila, Z | 1 |
| Affandi, AM; Blumetti, TP; Fernandez-Peñas, P; Hertzberg, M; Wells, J | 1 |
| Belaiche, S; Couraud, S; Moro-Sibilot, D; Sakhri, L; Toffart, AC | 1 |
| Agerbaek, M; Albers, P; Charpentier, D; Chester, JD; Collette, L; Daugaard, G; de Santis, M; de Wit, R; Dumez, H; Fossa, SD; Geoffrois, L; Graham, J; Joly, F; Kerst, JM; Leahy, MG; Marreaud, S; Mignot, L; Rolland, F; Sengelov, L; Skoneczna, I; Sternberg, CN; Sundar, S; Sylvester, R; Symonds, P; Thalmann, G; Théodore, C; Verbaeys, A; Witjes, JA; Wood, L | 1 |
| Bold, RJ; Daylami, R; Muilenburg, DJ; Virudachalam, S | 1 |
| Gao, H; Han, M; Han, Y; Jiang, Q; Peng, J; Wang, C; Xie, J | 1 |
| Ajiki, T; Eguchi, K; Furuse, J; Hakamada, K; Ichikawa, W; Ikeda, M; Ioka, T; Ishii, H; Maguchi, H; Matsuyama, M; Miyazaki, M; Mizuno, N; Ohashi, Y; Ohkawa, S; Sasaki, Y; Yamaguchi, T; Yamamoto, M; Yamaue, H | 1 |
| Ahn, CH; Fine, T; Kashi, R; Kaye, J; Kim, DJ; Lee, YB; Ohne, O; Peters, GJ; Smid, K; Yang, MY | 1 |
| Butler, H; John, P; Saif, MW | 1 |
| Maneechawakajorn, J; Suksuperm, J | 1 |
| Adshead, J; Boustead, G; Green, JS; Hughes, S; Lamb, BW; Lane, T; Payne, H; Tan, WS; Vasdev, N | 1 |
| Duchêne, B; Jonckheere, N; Tréhoux, S; Van Seuningen, I | 1 |
| Borget, I; Chabaud, S; Chouaïd, C; Crequit, J; Dô, P; Falchero, L; Fournel, P; Greillier, L; Lavolé, A; Le Caer, H; Léna, H; Monnet, I; Pérol, D; Pérol, M; Poudenx, M; Vaylet, F; Vergnenegre, A; Westeel, V; Zalcman, G | 1 |
| Bahary, N; Borad, MJ; Chiorean, EG; Cohn, AL; Del Prete, SA; Dragovich, T; Eng, C; Kroll, S; Rarick, M; Reddy, SG; Rosen, PJ; Ryan, DP; Schelman, WR; Sigal, D; Stephenson, J; Ulrich, B; Uronis, HE | 1 |
| Cai, QP; Feng, D; Huang, HJ; Wang, CM; Yang, DJ; Zhang, X | 1 |
| Chung, N; Kim, EJ; Park, SH; Sung, JH | 1 |
| Han, D; Jin, J; Kim, Y; Min, H; Yi, EC | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Sawyer, MB | 1 |
| Aloia, T; Balachandran, A; Conrad, C; Cooper, AB; Evans, DB; Fleming, JB; Fogelman, D; Garg, N; Holmes, HM; Katz, MH; Lee, JE; Ngo-Huang, A; Parker, N; Petzel, M; Slack, R; Varadhachary, G; Vauthey, JN | 1 |
| Aktas, B; Balakan, O; Berk, V; Cinkir, Hy; Demirci, U; Helvaci, K; Kos, T; Kucukoner, M; Oztop, I; Sevinc, A; Tonyali, O; Turan, N; Unal, OU; Yildiz, R; Yilmaz, AU | 1 |
| Adhikari, S; Eisenhaber, F; Feng, M; Kuralmani, V; Li, N; Liem, N; Limviphuvadh, V; Mah, TL; Maurer-Stroh, S; Soo, RA; Sridharan, S; Tong, JC; Yap, XN; Yong, WP | 1 |
| Bae, KS; Cho, JM; Choi, HJ; Go, SI; Kang, MH; Kim, DC; Kim, HG; Kim, MJ; Lee, JH; Lee, US; Lee, WS | 1 |
| Awasthi, N; Brekken, RA; Hinz, S; Schwarz, MA; Schwarz, RE | 1 |
| Aguilar, M; Chiao, PJ; Fu, J; Gocho, T; Huang, P; Ju, HQ; Wu, M; Yanaga, K; Zhuang, ZN | 1 |
| An, SG; Jang, AL; Kim, DU; Song, GA | 1 |
| Aydin, S; Gizzi, M; Machiels, JP | 1 |
| Deng, Y; Li, J; Qin, S; Zhang, Z | 1 |
| Cordani, M; Donadelli, M; Fiorini, C; Gotte, G; Picone, D | 1 |
| Aquino, JB; Malvicini, M; Mazzolini, G | 1 |
| Chang, DT; Columbo, LA; Dholakia, AS; Fisher, GA; Goodman, KA; Griffith, ME; Hacker-Prietz, A; Herman, JM; Iacobuzio-Donahue, CA; Koong, AC; Laheru, DA; O'Reilly, E; Pai, JS; Pawlik, TM; Raman, SP; Rosati, LM; Sugar, EA; Wild, AT; Wolfgang, CL; Zheng, L | 1 |
| Arrivas Bajardi, E; Barone, C; Bencardino, K; Buonadonna, A; Cartenì, G; Comandone, A; Ferrari, D; Ferrari, S; Foa, P; Gebbia, V; Milella, M; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Testa, A; Tronconi, MC; Zaniboni, A | 1 |
| Chen, J; Gao, S; Hao, J; Huang, C; Jia, L; Li, J; Qian, D; Ren, H; Wang, X; Xin, W; Yan, F; Zhao, T | 1 |
| Furuse, J; Kasuga, A; Kitamura, H; Nagashima, F; Naruge, D; Okano, N; Takasu, A | 1 |
| Li, ZH; Liu, H; Lu, LG; Zhang, QD; Zhang, QQ | 1 |
| Lee, JK; Lee, KH; Lee, KT; Rhee, JC; Yang, MH; Yang, S | 1 |
| Hirano, Y; Homma, S; Ito, Z; Kajihara, M; Kan, S; Kobayashi, H; Koido, S; Matsumoto, Y; Misawa, T; Mori, M; Ohkusa, T; Okamoto, M; Sugiyama, H; Tajiri, H; Takakura, K; Takami, S; Yoshida, K | 1 |
| Bhattacharjee, V; Yen, TJ; Zhou, Y | 1 |
| Dong, H; Fu, S; Gao, W; Guan, R; Jia, X; Liu, P; Meng, X; Sun, W; Wang, G; Wu, J; Yu, J; Yu, Y | 1 |
| Hanada, K; Hasebe, O; Isayama, H; Ito, Y; Kamada, H; Koike, K; Maetani, I; Maguchi, H; Matsubara, S; Mukai, T; Nakai, Y; Okabe, Y; Sasaki, T; Toda, N; Yagioka, H; Yasuda, I | 1 |
| Honeywell, RJ; Peters, GJ; Ruiz van Haperen, VW; Smid, K; Veerman, G | 1 |
| Dong, M; Gui, L; He, X; Liu, P; Qin, Y; Shi, Y; Sun, Y; Yang, J; Yang, S; Zhang, C; Zhou, S | 1 |
| Ackroyd, JJ; Flanagan, SA; Im, MM; Shewach, DS | 1 |
| Boroujerdi, M; Kohan, HG | 1 |
| Guo, Z; Li, X; Su, B; Xie, F; Zhang, M; Zhang, X; Zhou, L | 1 |
| de Lima, VA; Sørensen, JB | 1 |
| Cafferata, EG; Curiel, DT; Gidekel, M; Haab, GA; Podhajcer, OL; Rotondaro, C; Salvatierra, E; Sganga, L; Weber, HL; Werbajh, S | 1 |
| Bendell, J; Burke, W; Burris, H; Chau, I; Fielding, A; Hochster, H; Middleton, MR; O'Reilly, EM | 1 |
| Chiorean, EG; Ferrara, S; Ganju, V; Goldstein, D; Hingorani, SR; Infante, JR; Penenberg, DN; Ramanathan, RK; Romano, A; Scheithauer, W; Tabernero, J; Von Hoff, DD; Weekes, C | 1 |
| Chen, W; Ding, X; Fan, H; Zhu, B | 1 |
| Bridges, E; Harris, AL | 1 |
| Alrawashdeh, W; Cereser, B; Crnogorac-Jurcevic, T; Demircioglu, F; Elia, G; Ghazaly, E; Hagemann, T; Hodivala-Dilke, KM; Kocher, HM; McDonald, S; Scudamore, CL; Stratford, MR; Wong, PP | 1 |
| García del Muro, X; Martin-Liberal, J; Tirado, OM | 1 |
| Baidoo, KE; Brechbiel, MW; Kim, YS; Milenic, DE | 1 |
| Bennouna, J; Boyer, M; Feng, J; Geater, SL; Gorbunova, V; Hirsh, V; Hu, CP; Huang, Y; Kato, T; Lee, KH; Lee, KY; Lu, S; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Popat, S; Schuler, M; Sebastian, M; Sequist, LV; Shahidi, M; Su, WC; Tsai, CM; Wu, YL; Yamamoto, N; Yang, JC; Zazulina, V; Zhou, C | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Marubashi, S; Mori, M; Nagano, H; Ogawa, K; Satoh, T; Takehara, T; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Hohenberger, P; Kasper, B; Mathew, M; Pink, D; Rauch, G; Reichardt, P; Sommer, M | 1 |
| Dobbelstein, M; Kunze, M; Loock, AC; Schmidt, F | 1 |
| Gao, HQ; Liu, P; Yang, YM; Zhuang, Y | 1 |
| Shibata, Y | 1 |
| Aota, Y; Gotoh, A; Komatu, N; Tanaka, M; Tomomatu, J; Watanabe, N | 1 |
| Bhutia, YD; Cummins, S; Dhar, S; Govindarajan, R; Hooks, SB; Hung, SW; Marrache, S; Mody, H | 1 |
| Chowdhury, EH; Mozar, FS | 2 |
| Beuzeboc, P; Chevreau, C; Culine, S; Dupuy, L; Filleron, T; Fléchon, A; Gravis, G; Houédé, N; Laguerre, B; Théodore, C | 1 |
| Lan, H; Li, Y; Lin, CY | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Ashworth, MT; Daud, AI; Freshwater, T; Goldman, JW; Grabowsky, JA; Isaacs, R; Kang, SP; Loechner, S; Mendelson, D; Munster, PN; Parry, D; Rosen, LS; Shanahan, F; Shumway, S; Sorge, C; Springett, G; Strosberg, J; Venook, AP | 1 |
| Guan, J; Liang, Z; Liu, T; Ren, X; Shi, X; Wang, L; Wu, H; Zhang, H | 1 |
| Azevedo, S; Bach, BA; Bodoky, G; Carrato, A; Fuchs, CS; Gansert, JL; Haddad, V; Ikeda, M; Lipton, LR; Loberg, R; Melichar, B; Moore, MJ; Nemecek, R; Ohkawa, S; Okusaka, T; Peeters, M; Riess, H; Świeboda-Sadlej, A; Szczylik, C; Tjulandin, SA; Van Cutsem, E; Van Laethem, JL | 1 |
| Bae, KH; Han, BS; Jung, H; Kim, DS; Kim, JM; Kim, JS; Kim, WK; Lee, HJ; Lee, SC; Oh, KJ; Park, SG; Seo, YS | 1 |
| He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB | 1 |
| Aiura, K; Fujita, T; Hamamoto, Y; Higuchi, H; Itano, O; Kawakami, Y; Kitagawa, Y; Kitago, M; Matsuda, T; Mayanagi, S; Okamoto, M; Sakurai, T; Sunamura, M; Taguchi, J; Takaishi, H; Takeuchi, H | 1 |
| Hirata, T; Ishikawa, O; Kawaguchi, Y; Konishi, K; Nishiyama, K; Ogawa, K; Ohigashi, H; Otani, K; Takahashi, H; Teshima, T; Tomita, Y | 1 |
| Choi, HJ; Han, Z; Hwang, YS; Je, S; Kang, D; Kang, S; Kim, JH; Kim, SY; Song, JJ | 1 |
| Abdulhayoglu, M; Ak, G; Cihnioglu, AO; Hamarat Sanlıer, S; Yasa, M; Yılmaz, H | 1 |
| Fiaschi, AI; Francini, E; Laera, L; Marrelli, D; Petrioli, R; Roviello, F; Roviello, G | 2 |
| He, C; Lin, W; Liu, D; Lu, K; Poon, C | 1 |
| Chau, C; Crabb, SJ; Geldart, T; Wheater, M | 1 |
| Barton, S; Edwards, SJ; Thurgar, E; Trevor, N | 1 |
| Cutrera, J; Gumpel, E; Jones, P; Kicenuik, K; King, G; Li, S; Xia, X | 1 |
| Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY | 1 |
| Cai, H; Gu, M; Xu, T; Xu, Z; Yu, B; Zhou, J; Zou, Q | 1 |
| Jiang, X; Li, B; Wang, J; Xia, N; Yu, Y | 1 |
| Cheng, L; Fang, B; Ma, C; Ma, J; Pang, H; Shi, Y; Wang, H; Wang, Z; Xia, J; Yin, B; Zeng, F | 1 |
| El-Maraghi, RH; Goldstein, D; Hammel, P; Heinemann, V; Kunzmann, V; Lu, B; Penenberg, DN; Romano, A; Sastre, J; Scheithauer, W; Siena, S; Tabernero, J; Teixeira, L; Tortora, G; Van Laethem, JL; Von Hoff, DD; Young, R | 1 |
| Aster, RH; Bougie, DW; Curtis, BR; George, JN; Reese, JA; Terrell, DR; Vesely, SK | 1 |
| Hotta, K; Ishii, T; Kita, K; Kusano, K; Mano, Y; Sakamaki, K; Ueno, T | 1 |
| Cao, ZG; Chen, DN; Chen, L; Hu, X; Li, S; Ling, H; Qiao, F; Shao, ZM; Song, CG; Xia, C; Yao, L; Ye, FG | 1 |
| Wang, JF; Wu, DP; Ye, WL | 1 |
| Baba, T; Furukawa, K; Li, YY; Matsugo, S; Mukaida, N; Sasaki, S; Song, Y; Tanabe, Y | 1 |
| Sui, YN; Wang, F; Wang, LS; Wang, YH; Yan, K; Zhou, JH | 1 |
| Boku, N; Bycott, P; Fujii, Y; Furuse, J; Ioka, T; Kamei, Y; Namazu, K; Ohkawa, S; Okusaka, T; Sawaki, A; Takahashi, S; Umeyama, Y | 1 |
| Ichimaru, N; Kojima, Y; Nonomura, N; Okumi, M; Takahara, S; Takahi, Y | 1 |
| Anders, CK; Bickford, LR; Brooks, CR; Byrne, JD; Darr, D; Deal, A; DeSimone, JM; Hyder, N; Jajja, MR; Keeler, AW; Lee, W; Little, RE; Luft, JC; Moffitt, RA; Napier, ME; Nelson, M; O'Neill, AT; Stack, C; Stack, R; Tepper, JE; Wagner, K; Wang, AZ; Yeh, JJ; Zamboni, WC | 1 |
| Erkan, M; Esposito, I; Friess, H; Hong, X; Jäger, C; Kleeff, J; Kong, B; Michalski, CW; Nitsche, U; Valkovska, N; Wu, W | 1 |
| Chen, C; Chen, D; Chen, Z; Le, H; Wang, Z; Zhang, B | 1 |
| Agelaki, S; Agelidou, A; Chandrinos, V; Emmanouilidis, Ch; Georgoulias, V; Hatzidaki, D; Kalbakis, K; Katsaounis, P; Kentepozidis, N; Kotsakis, A; Mavroudis, D; Nintos, G; Polyzos, A; Stoltidis, D; Vamvakas, L; Vaslamatzis, M; Vetsika, EK | 1 |
| Paxton, JW; Wu, Z; Xu, H | 2 |
| Culine, S; Gauthier, H; Le Maignan, C; Pouessel, D; Serrate, C; Teixeira, L | 1 |
| Dredge, K; Hammond, E; Jung, DB; Jung, JH; Kim, B; Kim, EO; Kim, J; Kim, SH; Mukhopadhyay, D; Shridhar, V; Wang, E; Yun, M | 1 |
| Agarwal, C; Agarwal, R; Deep, G; Patel, M; Shrotriya, S; Somasagara, RR | 1 |
| Cao, F; Cui, Y; Li, F; Li, J; Liu, S; Sun, H | 1 |
| Uwagawa, T; Yanaga, K | 1 |
| Aboagye, EO; Barwick, T; Challapalli, A; Howell, EC; Mauri, F; Maxwell, RJ; Merchant, S; Pearson, RA; Sharma, R; Sumpter, K | 1 |
| Brais, RJ; Chatzizacharias, NA; Corrie, P; Davies, S; Elias, A; Harper, SJF; Huguet, E; Jah, A; Jamieson, NV; Praseedom, RK; Xanthis, A | 1 |
| Bidaut, G; Borge, L; Calvo, E; Garcia, S; Gayet, O; Gouirand, V; Guillaumond, F; Guimaraes, C; Iovanna, JL; Lac, S; Lavaut, MN; Loncle, C; Nigri, J; Olivares, O; Ouaissi, M; Pinault, M; Roques, J; Servais, S; Staels, B; Tailleux, A; Tomasini, R; Vasseur, S | 1 |
| Lee, KH | 1 |
| Chi, KC; Hwang, IG; Jang, JS; Jun, HJ; Lee, HR; Lee, S; Nam, EM; Oh, SY; Park, JO; Park, YS; Rho, MH | 1 |
| Chen, J; Hao, J; Li, F; Li, Y; Nie, G; Ren, H; Wang, H; Zhao, X | 1 |
| Bajor, DL; Byrne, KT; Clendenin, C; Evans, RA; Furth, EE; Meyer, AR; Odorizzi, PM; Stanger, BZ; Vonderheide, RH; Wherry, EJ; Winograd, R | 1 |
| Ahluwalia, D; Bhupathi, D; Hart, CP; Li, W; Liu, Q; Meng, F; Ruprell, AS; Sun, JD; Wang, Y | 1 |
| André, T; Aparicio, T; Bachet, JB; Berger, A; Bonnetain, F; Cojean Zeleck, D; Colussi, O; Coriat, R; Dousset, B; Hammel, P; Locher, C; Malka, D; Nordlinger, B; Paye, F; Pozet, A; Rougier, P; Sauvanet, A; Taieb, J; Tchinou, L; Vaillant, JC; Voron, T | 1 |
| Brown, K; Linclau, B; Weymouth-Wilson, A | 1 |
| Cockerill, PA; Frank, I; Karnes, RJ; Knoedler, JJ; Tarrell, R | 1 |
| Babacan, NA; Deveci, K; Kacan, T; Sancakdar, E; Seker, A; Seker, MM; Turesin, AK; Yilmaz, A | 1 |
| Gao, S; Hua, YQ; Liu, LM; Pan, Y | 1 |
| O'Reilly, EM; Yang, A | 1 |
| Atyabi, F; Badiei, A; Bahrami, Z; Darabi, HR; Mehravi, B | 1 |
| Cong, C; Dou, Y; Duan, L; Gao, A; Lai, Q; Sun, Y; Zheng, Y | 1 |
| Funazaki, H; Ichida, Y; Ikeda, M; Kobayashi, M; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Saitoh, S; Shimizu, S; Shinohara, A; Takahashi, H; Takahashi, K | 1 |
| Hayashi, T; Ishiwatari, H; Kato, J; Kobune, M; Miyanishi, K; Ono, M; Sato, T; Sato, Y; Takimoto, R; Yoshida, M | 1 |
| Buyse, M; Ding, K; Parulekar, WR; Péron, J; Roche, L; Roy, P | 1 |
| Eastman, A; Sakurikar, N | 1 |
| Fujiwara, Y; Futagawa, Y; Misawa, T; Shiba, H; Uwagawa, T; Yanaga, K | 1 |
| Mahdi, H; Rizzo, A; Rose, PG | 1 |
| Barlesi, F; Braun, D; Debieuvre, D; Des Guetz, G; Fraboulet, G; Landre, T; Milleron, B; Molinier, O; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Uzzan, B; Vaylet, F; Westeel, V | 1 |
| Kukongviriyapan, V; Prawan, A; Samatiwat, P; Senggunprai, L | 1 |
| Bakkum-Gamez, JN; Behbakht, K; Hensley, ML; Mannel, RS; Michael, H; Miller, A; O'Malley, DM | 1 |
| Abali, H; Köse, F; Mertsoylu, H; Muallaoğlu, S; Ozyilkan, O; Sezer, A; Sümbül, AT | 1 |
| Cioffi, M; Costello, E; Erkan, M; Greenhalf, W; Heeschen, C; Hidalgo, M; Kleeff, J; Sainz, B; Trabulo, S | 1 |
| Bansal, SS; Celia, C; Cosco, D; Ferrari, M; Fresta, M; Kirui, DK; Molinaro, R; Shen, H | 1 |
| Borders, EB; Cherry, MA; Herman, T; Holter, J; Selby, GB; Srour, SA | 1 |
| Chen, H; Chen, L; Chen, Z; Liu, L; Meng, Z; Pan, Y; Shen, Y; Xu, L | 1 |
| Buettner, GR; Button, A; Cieslak, JA; Cullen, JJ; Doskey, CM; Du, J; Rawal, M; Schroeder, SR; Strother, RK; Wagner, BA | 1 |
| Abe, H; Horie, S; Ide, H; Isotani, S; Kamai, T; Kitamura, K; Muto, S; Noguchi, T; Sugiura, S; Yamaguchi, R | 1 |
| Aoki, Y; Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Miyazaki, M; Ohtsuka, M; Okamura, D; Sakai, N; Shimizu, H; Suzuki, D; Suzuki, T; Takano, S; Takayashiki, T; Yoshitomi, H | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Ohashi, T; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Karasawa, H; Katagiri, M; Katayose, Y; Morikawa, T; Motoi, F; Naito, T; Sato, J; Unno, M; Yabuuchi, S | 1 |
| Katayose, Y; Morikawa, T; Otsuka, H; Shirasaki, K; Unno, M | 1 |
| Ajiki, T; Fukumoto, T; Ku, Y; Matsumoto, I; Matsumoto, T; Murakami, S; Okazaki, T; Shinozaki, K; Shinzeki, M; Yoshida, Y | 1 |
| Fujie, Y; Fujita, J; Fujita, S; Hashimoto, K; Imaoka, S; Monden, T; Nishida, K; Nonaka, R; Ohnishi, T; Tono, T; Tsunashima, R; Yoshida, T | 1 |
| Araki, H; Choda, Y; Harano, M; Idani, H; Kanazawa, T; Kato, T; Matsukawa, H; Mimura, N; Miyake, S; Miyoshi, H; Ninomiya, M; Ojima, Y; Okajima, M; Satoh, D; Shiozaki, S; Taguchi, K; Takahashi, K; Tokumoto, N; Toshima, T; Yamaguchi, K; Yoshida, K | 1 |
| Deguchi, S; Goto, W; Inoue, T; Ishikawa, A; Kanazawa, A; Kotsuka, M; Kurihara, S; Mori, Y; Nakajima, T; Nishiguchi, Y; Ohira, G; Sakae, M; Shimizu, S; Tachimori, A; Tamamori, Y; Tashima, T; Tsukamoto, T; Yamamoto, A; Yamashita, Y; Yoshii, M | 1 |
| Ishii, J; Kaneko, H; Katagiri, T; Koda, T; Kubota, Y; Maeda, T; Otsuka, Y; Shibuya, K; Tamura, A; Tsuchiya, M | 1 |
| Matsui, K; Moriyama, M; Nagata, T; Osawa, S; Sawada, S; Shibuya, K; Tsukada, K; Yoshida, T; Yoshioka, I | 1 |
| Abe, T; Egawa, S; Fukase, K; Hayashi, H; Karasawa, H; Katayose, Y; Kawaguchi, K; Masuda, K; Mizuma, M; Morikawa, T; Motoi, F; Naito, T; Nakagawa, K; Okada, R; Okada, T; Sakata, N; Taniguchi, H; Unno, M; Yabuuchi, S; Yoshida, H | 1 |
| Aisu, Y; Andoh, Y; Asao, Y; Furuyama, H; Honda, K; Kadokawa, Y; Kato, S; Machimoto, T; Nishino, H; Nishiuchi, A; Yoshimura, T | 1 |
| Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Nakagawara, H; Nakanuma, S; Nakayama, A; Ohta, T; Shoji, M; Tajima, H; Takamura, H | 1 |
| Fukui, H; Ito, M; Maegawa, Y; Miyoshi, K; Nakamura, M; Suemura, S; Tanaka, E; Tatsumi, O; Terabe, F; Ueda, T | 1 |
| Branden, E; Hillerdal, G; Kolbeck, K; Koyi, H | 1 |
| Deng, QH; He, JX; He, YW; Yang, XY; Zeng, J; Zhao, ML | 1 |
| Hu, Y; Xu, X; Ye, W; Ying, K; Zhang, R | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Nakashima, S; Tomimaru, Y; Tomokuni, A; Wada, H | 1 |
| Hamakawa, H; Iwamoto, K; Nakashiro, K; Tanaka, H; Tokuzen, N | 1 |
| Hirai, K; Igarashi, T; Ogawa, H; Sunose, Y; Takahashi, K; Takahashi, N; Takeyoshi, I; Tanaka, K; Tsukagoshi, H; Yamazaki, H; Yokoo, H; Yoshinari, D | 1 |
| Itagaki, T; Kameda, A; Kegoya, Y; Miyahara, E; Nitta, Y; Oue, N | 1 |
| Alanazi, KM | 1 |
| Du, F; Fang, Y; Huang, J; Liu, S; Lu, W; Meng, H; Xu, Y; Yu, J; Zhang, X | 1 |
| Aerts, J; de Castro Carpeño, J; Dyachkova, Y; Girvan, AC; Kraaij, K; Lesniewski-Kmak, K; Moro-Sibilot, D; Nacerddine, K; Schnabel, PA; Smit, E; Smith, KT; Taipale, K; Villatoro, R; Visseren-Grul, C | 1 |
| Böhlandt, A; Fischer, E; Groeneveld, S; Schierl, R | 1 |
| Bauer, C; Bauernfeind, F; Dauer, M; Duewell, P; Endres, S; Hees, C; Lehr, HA; Mak'Anyengo, R; Noessner, E; Schnurr, M; Sterzik, A; Trauzold, A; Wank, R | 1 |
| Ma, GF; Wang, D; Ying, KJ; Zhang, RF | 1 |
| Du, Q; Han, C; Tu, M; Wang, Q; Xu, D; Xu, L; Zhang, J; Zhu, Y | 1 |
| Chen, C; Chen, S; Hou, Y; Li, Y; Wang, R; Wang, X; Wang, Z; Wu, Q; Yang, Q; Yang, Y | 1 |
| Matsumoto, K; Onda, T; Yaegashi, N | 1 |
| Auquier, P; Barlesi, F; Chouaid, C; Crequit, J; Fabre-Guillevin, E; Le Caer, H; Le Treut, J; Legodec, J; Loundou, A; Pujol, JL; Simeoni, MC; Thomas, PA; Vergnenegre, A | 1 |
| Collins, DC; Morris, PG | 1 |
| Wang, XB; Zhou, HY | 1 |
| Chang, CH; Ji, Z; Liu, H; Liu, X; Meng, H; Nel, AE; Situ, A; Wang, M; Wu, B | 1 |
| Basso, SM; Bidoli, E; Foltran, L; Lo Re, G; Lumachi, F; Santeufemia, DA | 1 |
| Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE | 1 |
| Du, Z; He, X; Li, Q; Tang, R; Wen, F; Zhang, J; Zhang, P; Zhao, R; Zhou, J | 1 |
| Jiang, Z; Li, Y; Liu, G; Sun, J; Zhang, L | 1 |
| Bastiat, G; Benoit, JP; Cieślak, A; Hureaux, J; Kondo, K; Moal, V; Moysan, E; Rousselet, MC; Wauthoz, N; Zandecki, M | 1 |
| Abraham, I; Bootman, JL; Gharaibeh, M; McBride, A | 1 |
| Chen, D; Hu, J; Huang, W; Li, N; Wan, Z; Wang, L; Xue, P; Yang, H; Zhu, L | 1 |
| Acker, T; Andreas, S; Fischer, J; Grah, C; Kollmeier, J; Kortsik, C; Müller, E; Penzel, R; Reinmuth, N; Reuss, A; Schenk, M; Schnabel, P; Schröder, M; Serke, M; Thomas, M; Villalobos, M; von Eiff, M; Witt, C; Wolf, M | 1 |
| Galluzzo, A; Hayano, K; Sahani, DV; Zhu, AX | 1 |
| Bergqvist, M; Bergström, S; Brandén, E; Ekman, S; Harmenberg, J; Holgersson, G; Jerling, M; Klockare, M; Koyi, H; Larsson, O; Lundström, KL; Ringbom, M | 1 |
| Cai, L; Feng, JF; Gu, YJ; Hu, XC; Jiang, ZF; Liu, DG; Lou, GY; Luo, JF; Pan, YY; Ragaz, J; Shao, ZM; Sun, K; Teng, YE; Tong, ZS; Wang, BY; Wang, XJ; Wang, ZH; Wu, CP; Wu, J; Xu, BH; Yin, YM; Zhang, J | 1 |
| Bianco, V; Fiaschi, AI; Francini, E; Ghiribelli, C; Laera, L; Luzzi, L; Paladini, P; Petrioli, R; Roviello, G; Voltolini, L | 1 |
| Duconseil, P; Dusetti, N; Garcia, S; Gasmi, M; Gayet, O; Gilabert, M; Iovanna, J; Loncle, C; Lopez-Millan, MB; Molejon, MI; Moutardier, V; Ouaissi, M; Poizat, F; Tellechea, JI; Turrini, O | 1 |
| Cho, M; Fournier, C; Gao, F; Linehan, D; Myerson, R; Nagaraj, G; Parikh, P; Picus, J; Sorscher, S; Strasberg, S; Suresh, R; Tan, BR; Wang-Gillam, A | 1 |
| Hu, HG; Huang, JJ; Shen, H; Zhao, J | 1 |
| Dong, YZ; Liao, Y | 1 |
| Funazaki, H; Ikeda, M; Katayama, S; Kobayashi, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Tanaka, H; Ueno, H | 1 |
| Baras, A; Berman, D; Bivalacqua, TJ; Eisenberger, M; Faraj, S; Gandhi, NM; Hahn, NM; Hoque, MO; Kates, M; Liu, JJ; Munari, E; Netto, GJ; Reis, LO; Schoenberg, MP | 1 |
| Choi, MG; Jeong, D; Min, D; Na, K | 1 |
| Ding, T; Liu, XH; Lv, QY; Song, J; Wang, SH; Wang, Y; Wei, MH; Wu, MD; Yang, QH; Zhou, J; Zhou, YF | 1 |
| Li, Y; Shang, YM; Yang, Y; Zheng, H | 1 |
| Boeck, S; Bruns, CJ; Heinemann, V; Jauch, KW; Kleespies, A; Neumann, J; Niess, H; Renz, BW; Reu, S; Schiergens, TS | 1 |
| Bain, BJ; Erblich, T; Hill, PD; Tomlinson, J | 1 |
| Fu, BH; Fu, ZZ; Gu, T; Meng, W; Sun, XD; Zhang, Z | 1 |
| Ishii, H; Osumi, H; Ozaka, M; Sasahira, N | 1 |
| Kord Valeshabad, A; Mieler, WF; Setlur, V; Shahidi, M; Thomas, M | 1 |
| Aittomäki, K; Andrulis, IL; Blomqvist, C; Chang-Claude, J; Chenevix-Trench, G; Couch, FJ; Czene, K; Easton, DF; Eccles, D; Fagerholm, R; Fasching, PA; Figueroa, J; García-Closas, M; Greco, D; Hall, P; Hamann, U; Heikkinen, T; Hooning, MJ; Hopper, JL; Jager, A; Janni, W; Kabisch, M; Kataja, V; Keeman, R; Khan, S; Knight, JA; Lambrechts, D; Lindblom, A; Liu, J; Loehberg, CR; Luben, R; Mannermaa, A; Margolin, S; Muranen, TA; Nevanlinna, H; Olson, JE; Perkins, BJ; Pharoah, PD; Rafiq, S; Schmidt, MK; Seibold, P; Shah, M; Southey, MC; Tapper, W; Weinshilboum, R; Wildiers, H | 1 |
| Bai, C; Cao, S; Chen, H; Chen, J; Dai, J; Han, B; Hu, Z; Jin, G; Li, Q; Lu, D; Ma, H; Shen, H; Shu, Y; Song, X; Sun, C; Tang, S; Wang, C; Wang, S; Wu, J; Xu, L; Yin, R | 1 |
| Bang, S; Chang, JS; Chung, JB; Chung, MJ; Kang, H; Oh, TG; Park, JY; Park, SW; Seong, J; Song, SY | 1 |
| Fujita, T; Hirayama, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mochizuki, K; Nishi, M; Okazaki, M; Tabata, K; Taoka, Y | 1 |
| Bal, CK; Chatrath, BS; Longacre, TA; Poultsides, GA; Schaberg, K; Tran, TB | 1 |
| Ettrich, TJ; Perkhofer, L; Seufferlein, T | 1 |
| Chang, CJ; Chang, TC; Chen, CH; Chou, HH; Hong, JH; Huang, EY; Huang, HJ; Huang, KG; Lai, CH; Lin, H; Liou, JD; Liou, WS; Liu, FY; Tseng, CW; Wang, CC; Yang, LY | 1 |
| Fuerte, F; Klughammer, B; Ladrera, G; Lee, JS; Liao, M; Margono, B; Mok, T; Sandoval-Tan, J; Shames, DS; Srimuninnimit, V; Sriuranpong, V; Thongprasert, S; Truman, M; Tsai, J; Wen, W; Wu, L; Wu, YL; Yu, CJ; Zhou, C; Zhu, Y | 1 |
| Terui, Y | 1 |
| Furuse, J; Naruge, D | 1 |
| Kato, R; Kato, Y; Obara, W; Sato, J; Takata, R | 1 |
| Ang, MK; Cheah, SL; Fong, KW; Lim, WT; Ng, QS; Ong, WS; Quah, D; Soo, KC; Soong, YL; Tan, D; Tan, SH; Tan, T; Wee, J; Yip, C | 1 |
| Dawood, S; Kulkarni, S; Ramadwar, M; Rastogi, S; Sheth, V; Shrikhande, SV; Singh, A; Sirohi, B; Talole, S | 1 |
| Iida, M; Miyazawa, H; Nanjo, H; Shibata, S; Uchinami, H; Watanabe, G; Yamamoto, Y; Yoshida, M; Yoshioka, M; Yoshioka, T | 1 |
| Katoh, M; Kubota, K; Shimizu, T; Shimoda, M | 1 |
| Papadopoulos, EI; Scorilas, A; Yousef, GM | 1 |
| Bousquet, C; Bousquet-Dubouch, MP; Breibach, F; Chalabi-Dchar, M; Cordelier, P; Delisle, MB; Duluc, C; Gayral, M; Martineau, Y; Mathonnet, M; Moatassim-Billah, S; Perraud, A; Pyronnet, S; Samain, R; Schmid, H; Tomasini, R | 1 |
| Liljefors, M; Rossmann, E; Ullenhag, GJ | 1 |
| Akiyama, S; Chijiiwa, K; Furukawa, T; Ikeda, R; Kawahara, K; Minami, K; Nishizawa, Y; Pastor-Anglada, M; Pérez-Torras, S; Shinsato, Y; Tabata, S; Takahashi, H; Tsujikawa, K; Yamada, K; Yamamoto, M; Yasuo, T; Zhang, S | 1 |
| Amorin, S; Brice, P; Deau, B; Guillermin, Y; Harel, S; Lebras, L; Michallet, AS; Reynes, C; Salles, G; Subtil, F | 1 |
| Frischknecht, L; Meerang, M; Moch, H; Opitz, I; Seifert, B; Soltermann, A; Stahel, R; Weder, W | 1 |
| Behrman, SW; Chauhan, N; Chauhan, SC; Ebeling, MC; Ganju, A; Gara, RK; Jaggi, M; Khan, S; Singh, MM; Thompson, PA; Yallapu, MM; Zafar, N; Zhao, H | 1 |
| Bamezai, RN; Manvati, S; Pandita, A; Singh, SK; Vaishnavi, S | 1 |
| Oon, CE; Östman, A; Prakash, J; Strell, C; Yeong, KY | 1 |
| Anthony, S; Babiker, HM; Borad, MJ; Buchbinder, A; Grem, J; Keilani, T; Mita, M | 1 |
| Cheung, WY; Gill, S; Ho, M; Lim, HJ; Peixoto, RD; Renouf, DJ; Ruan, JY | 1 |
| Dawson, DW; Donahue, TR; Kadera, BE; Li, L; Madnick, DL; Nguyen, AH; Patel, SG; Toste, PA; Tran, LM; Wu, N | 1 |
| Berr, F; Kiesslich, T; Mayr, C; Namberger, K; Neureiter, D; Pichler, M; Wagner, A | 1 |
| Bauer, N; Bazhin, AV; Fan, P; Fortunato, F; Giese, NA; Gladkich, J; Gross, W; Hackert, T; Herr, I; Hinz, U; Liu, L; Ryschich, E; Strobel, O; Zhang, Y | 1 |
| Abkevich, V; Carlson, RW; Chang, PJ; Dakhil, SR; Flaherty, PJ; Ford, JM; Goldstein, LJ; Haley, B; Hartman, AR; Head, B; Jensen, KC; Kurian, AW; Lipson, JA; Manola, J; Reid, JE; Schackmann, EA; Sparano, JA; Telli, ML; Timms, K; Vinayak, S; Wapnir, IL | 1 |
| An, Y; Ding, F; Gao, Q; Liang, C; Wang, L; Yuan, C; Zhang, D; Zhang, H | 1 |
| Chang, C; Guo, H; Huang, X; Li, M; Lu, Q; Xie, B; Yan, J; Yan, X; Yao, X; Ye, C; Zhang, Z; Zhao, W; Zhou, J; Zhuang, J | 1 |
| Kamada, T; Kamijo, T; Sai, S; Shirai, T; Vares, G; Wakai, T; Yamada, S | 1 |
| Berda, Y; Ciccolini, J; Costello, R; Fanciullino, R; Fina, F; Lacarelle, B; Mercier, C; Ouafik, L; Serdjebi, C | 1 |
| Kamada, Y; Minehira, T; Miyoshi, E; Nakayama, K; Sobajima, T; Takamatsu, S; Terao, N | 1 |
| Bae, SJ; Kim, JK; Kim, SY; Kwon, K; Lee, YS; Noh, YH; Ryu, SW | 1 |
| Motoi, F; Unno, M | 1 |
| Shimizu, S | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Murata, A; Yamazoe, S | 1 |
| Morizane, C; Okusaka, T | 1 |
| Allegrini, S; Camici, M; Cividini, F; Filoni, DN; Pesi, R; Tozzi, MG | 1 |
| Acin, Y; Atkins, J; Demarchi, M; Deplanque, G; Dubreuil, P; Flynn, P; Hammel, P; Hebbar, M; Hermine, O; Mansfield, CD; Melichar, B; Moussy, A; Moyé, L; Nowara, E; Piquemal, D; Ritter, D | 1 |
| Buchbinder, N; Jaffray, M; Lutun, A; Piquenot, JM; Schneider, P; Vannier, JP | 1 |
| Baron, B; Kuramitsu, Y; Maehara, S; Maehara, Y; Nakamura, K; Wang, Y | 1 |
| Bessueille, F; Cristea, C; Dzyadevych, S; Florea, A; Goutaland, F; Guo, Z; Jaffrezic-Renault, N; Săndulescu, R; Vocanson, F | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Coinu, A; Petrelli, F | 1 |
| Faure, R; Forestier, J; Hubault, M; Lombard-Bohas, C; Pivot, C; Walter, T | 1 |
| Qian, Z; Song, Z; Wang, H; Wang, X; Zhang, H; Zhao, J | 1 |
| Boku, N; Fukutomi, A; Furukawa, M; Ikeda, M; Ishii, H; Maguchi, H; Miyazawa, M; Mizuno, N; Nishio, K; Ohashi, Y; Ohkawa, S; Okusaka, T; Tani, M; Togashi, Y; Tsunoda, T; Ueno, H; Yamao, K; Yamaue, H | 1 |
| Baetz, T; Chen, BE; Cheung, MC; Couban, S; Crump, M; Desjardins, P; Hassan, S; Hay, AE; Imrie, KR; Kouroukis, CT; Kukreti, V; Le, A; MacDonald, D; Meyer, RM; Mittmann, N; Risebrough, N; Shepherd, L; Song, Y; Sussman, J; Szwajcer, D | 1 |
| Agarwal, N; Bellmunt, J; Berthold, D; Chowdhury, S; Crabb, SJ; Galsky, MD; Harshman, LC; Hussain, SA; Ladoire, S; Milowsky, MI; Moshier, EL; Necchi, A; Pal, SK; Powles, T; Recine, F; Rosenberg, JE; Theodore, C; Vaishampayan, UN; Wong, YN; Yu, EY | 1 |
| Chatzikonstantinou, AV; Geromichalou, E; Giannopoulou, E; Kalofonos, HP; Kyriakou, E; Sayyad, N; Stamatis, H; Tzakos, AG; Vrbjar, N | 1 |
| Amano, M; Asada, H; Ikeda, F; Kato, H; Kinugasa, H; Kuwaki, K; Miura, Y; Miyahara, K; Morimoto, Y; Nakahara, T; Nakamura, S; Nishimura, S; Nouso, K; Onishi, H; Shiraha, H; Takaki, A; Tsutsumi, K; Yamamoto, K; Yamamoto, N | 1 |
| Bobustuc, GC; Frick, J; Konduri, SD; Patel, A; Srivenugopal, KS; Thompson, M; Weese, J | 1 |
| Araki, M; Endo, S; Hamano, Y; Hasegawa, N; Hyodo, I; Imanishi, M; Ishida, H; Ito, Y; Kobayashi, M; Moriwaki, T; Sato, D; Shimoyamada, M; Sugaya, A; Yoshida, S | 1 |
| Baba, H; Egawa, N; Fukutomi, A; Funakoshi, A; Hamada, C; Hamamoto, Y; Hosotani, R; Hyodo, I; Ichikawa, Y; Ikeda, M; Isayama, H; Ishii, H; Matsumoto, S; Nagase, M; Nakamori, S; Ohkawa, S; Okusaka, T; Omuro, Y; Sho, M; Takahashi, S; Tsuchiya, Y; Tsuda, M; Unno, M; Wakabayashi, G; Watanabe, G; Yamada, N; Yamaguchi, K; Yanagimoto, H | 1 |
| Chen, D; Dong, X; Hao, F; Liu, Z; Lu, X; Ni, G; Wang, M | 1 |
| Abeni, C; Aroldi, F; Bertocchi, P; Di Biasi, B; Meriggi, F; Ogliosi, C; Rizzi, A; Rosso, E; Rota, L; Savelli, G; Zaniboni, A | 1 |
| Brandes, F; Geissler, EK; Lang, SA; Redekopf, J; Schlitt, HJ; Schmidt, K; Wagner, C | 1 |
| Antonietti, P; Bartsch, G; Blaheta, R; Cinatl, J; Gessler, F; Haferkamp, A; Kögel, D; Mani, J; Michaelis, M; Rakel, S; Vallo, S | 1 |
| Bouvet, M; Hoffman, RM | 1 |
| Aicher, A; Cioffi, M; Dorado, J; Hahn, S; Heeschen, C; Hidalgo, M; Lonardo, E; Miranda-Lorenzo, I; Ramirez, JC; Reis Vieira, C; Sainz, B; Sanchez-Ripoll, Y; Trabulo, SM | 1 |
| Beatty, GL; Clendenin, C; Evans, RA; Gladney, WL; Guirnalda, PD; Knoblock, DM; Lee, JW; Long, KB; Luque, SL; Vonderheide, RH; Winograd, R | 1 |
| Chen, H; Chen, R; Fu, Z; Gao, W; Li, H; Li, W; Li, Z; Liu, Y; Song, Y; Wang, Y; Ye, H; Zeng, J; Zhao, X; Zheng, S; Zhou, Q; Zhou, Y; Zhuang, B | 1 |
| Bergmann, F; Brecht, IC; Büchler, MW; Combs, SE; Debus, J; Habermehl, D; Jäger, D; Rieken, S; Springfeld, C; Werner, J | 1 |
| Duchêne, B; Jonckheere, N; Skrypek, N; Van Seuningen, I; Vasseur, R; Vincent, A | 1 |
| Choi, J; Choi, Y; Haam, S; Huh, YM; Kim, HO; Lee, DK; Noh, I | 1 |
| Ahn, HK; Ahn, MJ; Hwang, IG; Jung, HA; Jung, KS; Kim, HS; Kim, M; Kim, SM; Lee, J; Lee, JY; Lee, MY; Lee, SC; Lee, SI; Lim, DH; Lim, SH; Park, KW; Park, SH; Sun, JM; Yi, SY | 1 |
| Amano, R; Hirakawa, K; Kimura, K; Motomura, H; Nakata, B; Tanaka, S; Yamamoto, A; Yamazoe, S | 1 |
| Bahary, N; Bao, P; Bartlett, DL; Boone, BA; Espina, V; Liotta, LA; Lotze, MT; Loughran, P; Moser, AJ; Normolle, DP; Singhi, AD; Wu, WC; Zeh, HJ; Zureikat, AH | 1 |
| André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN | 1 |
| Bonetti, A; Giuliani, J; Piacentini, P | 1 |
| Cheng, S; Eliaz, I; McClintick, JN; Sandusky, GE; Sliva, D; Swanson, K | 1 |
| Assenat, E; Azria, D; Bibeau, F; Bleuse, JP; Crapez, E; Delord, JP; Guimbaud, R; Larbouret, C; Mollevi, C; Pèlegrin, A; Portales, F; Robert, B; Samalin, E; Smith, D; Tubiana-Mathieu, N; Ychou, M | 1 |
| de Boer, JP; Greijer, AE; Huitema, AD; Juwana, H; Middeldorp, JM; Novalić, Z; Stoker, SD; Tan, IB; Verkuijlen, SA; Wildeman, MA | 1 |
| Chatzitheoklitos, E; Lambropoulou, M; Pitiakoudis, M; Polychronidis, A; Romanidis, K; Simopoulos, C; Tsaroucha, AK; Tsiaousidou, A | 1 |
| Boeck, S; Clemens, MR; Fischer von Weikersthal, L; Gauler, TC; Geissler, M; Greten, TF; Haas, M; Hegewisch-Becker, S; Heinemann, V; Kettner, E; Klein, S; Kojouharoff, G; Kruger, S; Laubender, RP; Märten, A; Modest, DP; Stintzing, S; Vehling-Kaiser, U; Waldschmidt, D; Winkelmann, C | 1 |
| Aspberg, A; Broberg, BS; Hoffmann, EK; Klausen, TK; Lambert, IH; Rasmussen, LJ; Sauter, DP; Sørensen, BH | 1 |
| Choi, HJ; Go, SI; Kang, JH; Kang, MH; Kim, HG; Lee, A; Lee, GW; Lee, US; Lee, WS; Song, HN | 1 |
| Bondarenko, IM; Bycott, P; Cebotaru, CL; Ingrosso, A; Kim, S | 1 |
| Akahori, T; Hasegawa, M; Kichikawa, K; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiofuku, H; Nishiwada, S; Ohbayashi, C; Sho, M; Tamamoto, T; Tanaka, T | 1 |
| Bahra, M; Boas-Knoop, S; Denecke, T; Klein, F; Neuhaus, P; Pelzer, U; Pratschke, J; Puhl, G; Pullankavumkal, JR; Riess, H; Sinn, M | 1 |
| Feng, J; Geater, SL; Hou, M; Hu, CP; Huang, Y; Lee, KY; Li, W; Lu, S; Lungershausen, J; Palmer, M; Shi, JH; Shi, Y; Wu, YL; Xu, CR; Zhou, C | 1 |
| Ampie, L; Bade, NA; Hartley, ML; Marshall, JL; Prins, PA | 1 |
| Julka, PK; Mallick, S; Singh, A; Venkatesulu, BP | 1 |
| Coppola, D; Crochiere, M; Husain, K; Kashyap, T; Kazim, S; Landesman, Y; Mahipal, A; Malafa, MP; Rashal, T; Sullivan, DM; Zibadi, S | 1 |
| Belderbos, J; De Ruysscher, D; Deasy, JO; Din, S; Dingemans, AM; Houben, R; Lambin, P; Oberije, C; Rimner, A; Uyterlinde, W; van de Heuvel, M | 1 |
| Honma, Y; Kato, N; Miyake, T; Suzumiya, J; Urano, T | 1 |
| Atanackovic, D; Barlesi, F; Bennouna, J; Feurer, M; Germonpre, P; Goekkurt, E; Gridelli, C; Hicking, C; Krzakowski, M; Lena, H; Milanowski, J; O'Byrne, K; Picard, M; Schuette, W; Straub, J; Szczesna, A; Vansteenkiste, J; Verhoeven, D; Waller, CF | 1 |
| Akada, J; Baron, B; Kitagawa, T; Kuramitsu, Y; Nakamura, K; Tokuda, K; Wang, Y | 1 |
| Izzedine, H; Perazella, MA | 1 |
| Bria, E; Cognetti, F; Garufi, C; Melisi, D; Milella, M; Nuzzo, C; Reni, M; Scarpa, A; Sperduti, I; Tortora, G; Vaccaro, V; Vari, S | 1 |
| Dai, X; Jiang, Y; Tan, C | 1 |
| Chen, BL; Liu, L; Qin, SH; Tan, QL; Zhao, Z | 1 |
| Kaniwa, N | 1 |
| Erlichman, C; Foster, NR; Kim, GP; McWilliams, RR; Pedersen, KS; Wang-Gillam, A | 1 |
| Kuter, DJ | 1 |
| Abe, H; Baghdadi, M; Higuchi, K; Hirano, S; Inoko, K; Nakamura, T; Nakanishi, S; Sato, S; Seino, K; Shichinohe, T; Takahashi, M; Takano, H; Takeuchi, S; Tsuchikawa, T; Usui, Y; Wada, H | 1 |
| Bi, XW; Huang, JJ; Jiang, WQ; Li, ZM; Liu, PP; Sun, P; Wang, Y; Xia, Y; Zhang, WW | 1 |
| Jamil, K; Jayaraman, A; Subhani, S | 1 |
| Alberts, SR; Ben-Josef, E; Blanke, CD; Corless, CL; Dawson, LA; El-Khoueiry, AB; Guthrie, KA; Lowy, AM; Micetich, KC; Siegel, AB; Thomas, CR; Thomas, MB; Zalupski, MM | 1 |
| Kashino, G; Kobashigawa, S; Mori, H; Morikawa, K | 1 |
| Aishima, S; Baba, H; Harimoto, N; Hualin, W; Itoh, S; Maehara, Y; Shirabe, K; Takeishi, K; Uchihara, T; Yamashita, Y; Yoshizumi, T | 1 |
| Dobbelstein, M; Li, Y; Saini, P | 1 |
| Ali-El-Dein, B; Babjuk, M; Burger, M; Chang, SS; Clayman, RH; Daneshmand, S; Efstathiou, JA; Fritsche, HM; Gakis, G; Galland, S; Hrbacek, J; Keegan, KA; Mischinger, J; Morgan, TM; Olugbade, K; Rink, M; Schubert, T; Stenzl, A; Thalmann, GN; Todenhöfer, T; Zaid, HB | 1 |
| Arora, S; Bhardwaj, A; Carter, JE; Khan, MA; Singh, AP; Singh, S; Srivastava, SK; Zubair, H | 1 |
| Guo, XZ; Li, HY; Li, YY; Liang, C; Mukaida, N; Ni, QX; Song, Y; Sun, MH; Wang, Z; Yu, XJ | 1 |
| Costa, JM; Cotta, RM; da Cunha Neto, SH; de Pinho, ST; Dulikravich, GS; Orlande, HR; Velho, HF | 1 |
| Gao, H; Guo, W; Li, J; Li, X; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Xu, J; Yang, H; Yang, L | 1 |
| Hayashi, K; Homma, S; Ishidao, T; Ito, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Nagasaki, E; Okamoto, M | 1 |
| Fujino, Y; Goto, H; Hasegawa, H; Kakinoki, K; Katsura, M; Ohara, T; Oshikiri, T; Oyama, M; Sendo, H; Sugimoto, T; Sugiyama, H; Tominaga, M; Ueda, Y; Yamashita, H; Yasuda, T | 1 |
| Bracci, L; Brunetti, J; Carini, M; Depau, L; Falciani, C; Lelli, B; Menichetti, S; Minervini, A; Pini, A; Ravenni, N; Siena, G; Tenori, E | 1 |
| Gao, C; Han, B; Li, Y; Meng, L; Shan, D; Wu, X; Yan, Y | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Benedit, P; Carrato, A; García, P; Gostkorzewicz, J; López, R; Macarulla, T; Pérez-Alcántara, F; Rivera, F; Sastre, J | 1 |
| Abesada-Terk, G; Alemany, C; Brown, RH; Cartwright, TH; Faig, D; Fulp, WJ; Jacobsen, PB; Kim, GP; Lee, JH; Levine, RM; Malafa, M; Markham, MJ; Schreiber, F; Sharp, PV; Tanvetyanon, T | 1 |
| Tempero, MA | 1 |
| Ding, Q; Matsubara, S; Miyazaki, Y; Takao, S; Tsukasa, K; Yoshimitsu, M | 1 |
| Boonmars, T; Hahnvajanawong, C; Jearanaikoon, P; Kanchanawat, S; Leelayuwat, C; Namwat, N; Seubwai, W; Techasen, A; Wattanawongdon, W | 1 |
| Ahn, H; Hong, B; Hong, JH; Jeong, IG; Kim, YR; Lee, JL; Song, C; You, D | 1 |
| Baba, E; Iguchi, A; Kusaba, H; Sagara, K; Sakamoto, N; Takayoshi, K; Uchino, K | 1 |
| Chen, J; He, LJ; Li, Y; Li, YY; Lou, Y; Wang, LR; Wang, Y; Zhang, GB | 1 |
| Cerezuela Fuentes, P; Ferris Villanueva, E; García Márquez, A; Guerrero Bautista, R; Martínez Penella, M; Mira Sirvent, Mdel C | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Ohyama, C; Yoneyama, T | 1 |
| Dancour, A; David, EB; Domb, A; Eliakim, R; Gabai, RM; Galun, E; Golan, T; Goldes, Y; Goldin, E; Harari, G; Hen, N; Hubert, A; Khvalevsky, EZ; Kopleman, Y; Lahav, M; Raskin, S; Segal, A; Shemi, A | 1 |
| Anota, A; Artru, P; Bonnetain, F; Dubreuil, O; Dupont-Gossart, AC; Fein, F; Gauthier, M; Lecomte, T; Mouillet, G; Paget-Bailly, S; Taieb, J; Trouilloud, I; Zaanan, A | 1 |
| Basson, MD; Ito, H; Ono, H | 2 |
| Imaizumi, H; Iwai, T; Kaneko, T; Kida, M; Koizumi, W; Miyazawa, S; Okuwaki, K; Takezawa, M; Watanabe, A; Yamauchi, H | 1 |
| Bai, C; Gao, Z; Han, B; Li, H; Li, Q; Li, X; Liu, W; Lu, D; Ma, K; Qian, J; Wang, H; Wang, J; Wang, S; Wang, X; Wu, J; Wu, W; Zhao, X | 1 |
| Cohen, RB; Doroumian, S; LoRusso, PM; Morris, JC; Olowokure, OO; Olszanski, AJ; Puzanov, I; Rixe, O; Shen, L; Yin, JY | 1 |
| Bartolotti, M; Brandes, AA; Cavallo, G; Di Battista, M; Genestreti, G | 1 |
| Jiang, Y; Stenzel, MH; Utama, RH; Zetterlund, PB | 1 |
| He, Y; Liu, W; Luo, Y; Su, J; Wu, BP; Wu, W; Yang, S; Yuan, ZJ; Zhao, J; Zhou, WW | 1 |
| Lin, ZQ; Luo, RJ; Wu, W; Xia, Q; Xue, P | 1 |
| Huang, CB; Huang, LL; Lin, SJ; Pan, JJ; Qiu, SF; Xu, YJ; Zheng, W; Zong, JF | 1 |
| Deng, J; Deng, JH; Niu, PG; Ouyang, XN; Shi, DH | 1 |
| Ahn, JH; Ahn, JS; Han, SW; Im, SA; Im, YH; Jung, KH; Jung, SH; Kang, SY; Kim, JH; Kim, SB; Lee, KS; Lee, MH; Lee, S; Nam, BH; Oh, DY; Park, HS; Park, IH; Park, YH; Ro, J; Sohn, JH; Woo, SY | 1 |
| Antoch, G; Graf, D; Häussinger, D; Knoefel, WT; Kröpil, P; Riemer, J; Schneitler, S | 1 |
| Bujanda, L; Er, TK; Herreros-Villanueva, M | 1 |
| Kitagawa, H; Miyamoto, K; Nakanishi, T; Ohta, T; Sai, Y; Sawamoto, K; Shimada, T; Tajima, H; Takabayashi, M; Tamai, I; Yamazaki, M; Yokono, R | 1 |
| Bridgewater, J; Furuse, J; Grenader, T; Mizuno, N; Nash, S; Okusaka, T; Plotkin, Y; Valle, J; Wasan, H | 1 |
| Baba, J; Ichikawa, K; Igarashi, N; Ishikawa, D; Kagamu, H; Kondo, R; Koshio, J; Koya, T; Miura, S; Nakata, K; Narita, I; Nozaki, K; Okajima, M; Saida, Y; Sato, K; Shoji, S; Tanaka, J; Tanaka, T; Watanabe, S; Yoshizawa, H | 1 |
| Artal, A; Barneto, I; De Castro, J; Esteban, E; Gascó, P; Gasent, JM; Montalar, J; Muñoz-Langa, J; Sanchez, A; Vidal, S | 1 |
| Grignani, G; Martín-Broto, J; Reichardt, P; Schuler, M | 1 |
| Amjad-Iranagh, S; Modarress, H; Razmimanesh, F | 1 |
| Chao, Y; Chen, MH; Hung, YP; Kuo, CY; Lee, WP; Li, CP; Luo, JC; Shyr, YM; Wang, JP; Wu, CY; Wu, YY; Yeh, YC | 1 |
| Bahra, M; Bläker, H; Denkert, C; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Stieler, JM; Striefler, JK | 1 |
| Hur, GY; In, KH; Kang, KH; Kim, JH; Lee, EJ; Lee, SH; Lee, SY; Min, KH; Shim, JJ; Shin, C | 1 |
| Bachet, JB; Boussaha, T; Brieau, B; Cacheux, W; Claudez, P; Coriat, R; Dahan, L; De Rycke, Y; Desrame, J; Lecomte, T; Lièvre, A; Marthey, L; Mary, F; Soibinet, P; Taieb, J; Thirot-Bidault, A; Tougeron, D; Trouilloud, I; Vasseur, P; Zaanan, A | 1 |
| Chang, YF; Chen, SY; Hsiao, CH; Hsieh, JC; Hsieh, RK; Hsu, CL; Lee, KD; Lu, CH; Ng, SH; Shiau, CY; Wang, CH; Wang, HM; Yeh, KH | 1 |
| Ichioka, D; Inoue, T; Kageyama, S; Kikuchi, E; Kinoshita, H; Matsui, Y; Mitsuzuka, K; Miyazaki, J; Nishiyama, H; Nomoto, T; Shiraishi, Y; Sugimoto, M; Wakeda, H | 1 |
| Bruynzeel, AM; Giovannetti, E; Jacobs, MA; Kazemier, G; Meijer, OW; Meijerink, MR; van der Vliet, HJ; van Tienhoven, G; van Zweeden, AA; Verheul, HM; Wilmink, JW | 1 |
| Chen, C; Fei, K; Hou, L; Jiao, Y; Liu, D; Lu, D; Qian, J; Su, B; Wu, C; Zheng, H | 1 |
| Atkins, MB; Choueiri, TK; McDermott, DF; McKay, RR; Michaelson, MD; Olivier, KM; Signoretti, S; Song, J; Van Allen, EM; Werner, L | 1 |
| Dussol, AS; Forestier, J; Hervieu, V; Joly, MO; Lombard-Bohas, C; Scoazec, JY; Vercherat, C; Walter, T | 1 |
| Alexandrow, MG; Bryant, VL; Elias, RM; McCarthy, SM; Yeatman, TJ | 1 |
| Li, H; Li, K; Wang, H; Zhang, Q; Zhang, Y; Zheng, J | 1 |
| Benafif, S; Bridgewater, J; Lamarca, A; Ross, P; Valle, JW | 1 |
| Baker, LH; Biermann, JS; Chugh, R; Davis, EJ; Feng, M; Jacobson, J; Lucas, DR; Metko, G; Reinke, D; Schuetze, SM; Wong, SL; Zalupski, MM; Zhao, L; Zyczynski, L | 1 |
| Beeker, A; Kordes, S; Mathôt, RA; Pollak, MN; Punt, CJ; Richel, DJ; Weterman, MJ; Wilmink, JW; Zwinderman, AH | 1 |
| Miller, K; Morant, R; Stenzl, A; Wirth, M; Zuna, I | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hagemeister, F; Hosing, C; Jones, RB; Liu, Y; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC | 1 |
| El-Rayes, B; Landry, J; Maithel, SK; Nanda, RH | 1 |
| Bhatti, AB; Hameed, N; Hussain, R; Illyas, A; Iqbal, H; Irfan, M; Jamshed, A; Jamshed, S | 1 |
| Anderson, K; Au, A; Bailey, P; Biankin, A; Carter, CR; Chang, D; Erler, JT; Evans, TR; Jamieson, NB; Karim, S; Leach, J; Marais, R; McGarry, L; McGhee, E; McKay, C; Miller, BW; Morton, JP; Oien, K; Pinese, M; Sansom, OJ; Saturno, G; Shanks, E; Springer, C; Steele, C; Timpson, P | 1 |
| Alfredsson, J; Björklund, U; Bykov, VJ; Byström, S; Fransson, Å; Gullbo, J; Hallberg, A; Mohell, N; Uustalu, M; Wiman, KG | 1 |
| Di Cresce, C; Ferguson, PJ; Figueredo, R; Koropatnick, J; Maleki Vareki, S; Rytelewski, M; Vincent, MD; Way, C | 1 |
| Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM | 1 |
| Abduloeva, NKh; Alexandrov, VA; Belyaeva, OA; Bespalov, VG; Chubenko, VA; Filatova, LV; Kireeva, GS; Latipova, DKh; Maidin, MA; Markochev, AB; Semenov, AL; Semiglazova, TY; Stukov, AN; Vasilieva, IN; Vershinina, SF | 1 |
| Horita, H; Hotta, H; Kato, R; Kitamura, H; Kunishima, Y; Masumori, N; Takahashi, A; Takei, F | 1 |
| Aisner, DL; Bajaj, R; Baranda, JC; Bathini, V; Berlin, J; Boles, J; Cho, JK; Cohen, DJ; Cohen, SJ; Coveler, L; Cusnir, M; Fanta, P; Fehrenbacher, L; Gomes, CL; Granfortuna, J; Jimeno, A; Ma, WW; Maguire, R; Maniar, M; McRee, AJ; Menter, AR; Messersmith, WA; Nazemzadeh, R; O'Neil, BH; Olowokure, OO; Phillip, P; Radford, J; Rarick, M; Scott, AJ; Tejani, MA; Wilhelm, F | 1 |
| Fan, W; Zeng, C; Zhang, X | 1 |
| Kulhari, H; Panyaram, S; Pooja, D; Rachamalla, SS; Reddy, B; Sistla, R | 1 |
| Gu, MF; Li, JJ; Li, Y; Li, YQ; Liu, LZ; Pan, K; Shen, WX; Xia, JC; Zhang, H | 1 |
| Chen, L; Cheng, Y; Fernando, MCL; Han, B; How, SH; Huang, C; Jiang, G; Li, E; Liam, CK; Liang, H; Liu, X; Lu, S; Pan, H; Qin, S; Wu, G; Wu, YL; Xia, F; Zhang, Y; Zhong, Z; Zhou, C; Zhu, Y; Zuo, Y | 1 |
| Hu, YP; Jiang, W; Liu, CC; Wang, WD; Xia, ZJ; Zhang, J | 1 |
| Alamoudi, S; Anglin, P; Baetz, T; Chen, BE; Cheung, M; Couban, S; Crump, M; Djurfeldt, MS; Hay, AE; Ismail, WS; Kouroukis, CT; Kuruvilla, J; Luminari, S; MacDonald, DA; Meyer, RM; Olney, HJ; Seftel, M; Shepherd, L; Turner, AR | 1 |
| Al-Massarani, G; Alammar, M; Banat, I; Najjar, F | 1 |
| Hoshino, T; Kodama, R; Mizushima, T; Moritomo, S; Namba, T | 1 |
| Hong, SM; Jang, JJ; Jung, Y; Kang, MG; Kim, DJ; Kim, JA; Kim, MJ; Koo, H; Lee, KB; Park, KC; Park, YS; Yeom, YI; You, YM | 1 |
| Li, HY; Li, YY; Liang, C; Wang, Z; Yu, BH; Zhang, F | 1 |
| Belfiore, G; Belfiore, MP; De Lucia, G; Di Gennaro, TL; Gallo, C; Ianniello, GP; Marsicano, C; Romano, F; Ronza, FM | 1 |
| Bendaoud, S; de Mestier, L; Hammel, P; Hentic, O; Lekhal, C; Neuzillet, C | 1 |
| Berlin, S; Campos, S; Horowitz, N; Krasner, C; Lee, H; Liu, J; Matulonis, U; Obermayer, E; Penson, R; Whalen, C | 1 |
| Hirano, K; Nagata, T; Okumura, T; Shimada, Y; Tsukada, K; Watanabe, T; Yamaguchi, T | 1 |
| Akada, J; Kitagawa, T; Kuramitsu, Y; Nakamura, K; Tokuda, K; Tokunaga, M; Wang, Y | 1 |
| Ikuta, S; Inoue, K; Sonoda, T; Tani, S; Tsubamoto, H; Yamanaka, N | 1 |
| Furukawa, K; Sakamoto, T; Shiba, H; Tsutsumi, J; Uwagawa, T; Yanaga, K | 1 |
| Ahn, JS; Ahn, MJ; Ha, SY; Han, J; Jung, SH; Park, K; Sun, J; Sun, JM | 1 |
| Fulp, WJ; Jump, H; Kim, R; Mahipal, A; Shibata, D; Siegel, EM; Springett, GM; Suleiman, Y | 1 |
| Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ | 1 |
| de Prado-Otero, DS; Poves-Alvarez, R; Trueba-Arguiñarena, FJ | 1 |
| Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M | 1 |
| Che, J; Cheng, R; Giroux-Leprieur, E; Hao, X; He, B; Jablons, DM; Jin, JQ; Li, H; Luh, TW; Mo, M; Tolani, B; Tseng, HH; Wang, C; Woodard, GA; Yang, C; Yang, Y; Yue, D; Zhang, H; Zhang, Y; Zheng, Q | 1 |
| Gow, CH; Liao, WY; Liu, YN; Shih, JY | 1 |
| Amano, H; Ikeda, Y; Ito, H; Kainuma, M; Miura, F; Sano, K; Shibuya, M; Takada, T; Toyota, N; Wada, K | 1 |
| Boyce, RJ; Boyle, RG; Courtin, A; Jodrell, DI; Koh, SB; Richards, FM | 1 |
| Du, L; Jin, Y; Wang, S; Yao, W | 1 |
| Bevis, KS; Blansit, K; Chan, JK; ElNaggar, A; Fuh, KC; Huh, W; Kapp, DS; Previs, R; Secord, AA; Tillmanns, T | 1 |
| Han, BH; Jin, B; Lou, YQ; Ren, ZH; Xu, JL; Yang, QZ; Zhou, ZR | 1 |
| Aksoy, A; Aliustaoglu, M; Alkis, N; Aydin, K; Dane, F; Demirci, NS; Ekinci, AS; Gumus, M; Inal, A; Inanc, M; Odabas, H; Sevinc, A; Turkeli, M; Ulas, A; Uysal, M; Yazilitas, D; Yuksel, S | 1 |
| Li, H; Qiao, JO; Wang, F | 1 |
| Coffey, M; Gill, G; Mahalingam, D; Nawrocki, ST; Nuovo, G; Patel, S; Selvaggi, G | 1 |
| Ak, G; Akarsu, M; Metintas, M; Metintas, S | 1 |
| Eagle, T; Fang, CX; Feng, M; Hart, D; Kimmel, GW; Lawrence, TS; Minter, RM; Schipper, MJ; Shen, J; Simeone, DM; Vainshtein, J; Zalupski, MM; Zhou, J | 1 |
| Alam, N; Dubey, RD; Gupta, PN; Khare, V; Kumar, A; Mahajan, G; Mondhe, DM; Saneja, A; Sharma, PR; Singh, SK; Vaidh, S | 1 |
| Lv, W; Wu, XZ; Yan, T; Zhang, JH; Zhang, WL | 1 |
| Brachmann, CB; Heise, C; Hidalgo, M; Illei, P; Lopez-Casas, PP; Lopez-Rios, F; Menendez, C; Musteanu, M; Pierce, D; Plaza, C; Romano, A; Tabernero, J; Von Hoff, DD; Wei, X | 1 |
| Diniz, AL; Forsmark, CE; Zhu, AX | 1 |
| Hasegawa, Y; Nitta, H; Sasaki, A; Takahara, T; Umemura, A; Wakabayashi, G | 1 |
| Akiyama, T; Doi, T; Hirano, S; Hirata, K; Homma, H; Kogawa, K; Mezawa, S; Morii, K; Ohi, M; Takahashi, M; Takeuchi, M; Tanaka, S | 1 |
| D'Aronzo, M; Graziano, P; Mazza, T; Panebianco, C; Pazienza, V; Pereira, SP; Saracino, C; Vinciguerra, M | 1 |
| Ballo, MT; Cormier, JN; Feig, BW; Hunt, KK; Lazar, AJ; Lewis, VO; Lin, PP; Patel, S; Pisters, PW; Pollock, RE; Thall, PF; To, CA; Tseng, WW; Zhou, S | 1 |
| Anthoney, DA; Backen, AC; Beare, S; Bridgewater, JA; Corrie, P; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; Morris, K; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS | 1 |
| Bianco, T; Borgida, A; Bristow, RG; Cao, P; Cheung, M; Gallinger, S; Hedley, DW; Holter, S; Ibrahimov, E; Kumareswaran, R; Lohse, I; Pintilie, M; Tsao, MS | 1 |
| Cao, M; Chen, YC; Fan, ZF; Hu, SY; Li, WX; Liu, L; Sun, XM; Wang, LX; Yang, ZF; Zhou, JY; Zhu, XJ | 1 |
| Dong, J; Liu, J; Xu, K; Yu, G | 1 |
| Bergman, AM; Bex, A; Horenblas, S; Kerst, JM; Meijer, RP; Mertens, LS; van de Putte, EE; van der Heijden, MS; van der Poel, HG; van Rhijn, BW | 1 |
| Bahary, N; Braiteh, FS; Bridges, BB; Cohen, SJ; Conkling, PR; Dragovich, T; Frank, RC; Goldenberg, DM; Goldsmith, SJ; Gribbin, TE; Guarino, MJ; Horne, H; Intenzo, CM; Korn, RL; Lee, FC; Lee, M; Lowery, MA; Manzone, TC; Mitchel, EP; O'Neil, BH; O'Reilly, EM; Ocean, AJ; Pandit-Taskar, N; Picozzi, VJ; Ramanathan, RK; Richards, DA; Sharkey, RM; Sheikh, A; Starodub, AN; Von Hoff, DD; Wegener, WA | 1 |
| Bassa, B; Chinnia, J; Fletcher, H | 1 |
| Jang, HL; Jang, KT; Kang, WK; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| Li, H; Li, J; Sun, W; Wang, X; Wei, H; Yi, Z | 1 |
| Barthélémy, C; Décaudin, B; Hebbar, M; Lemahieu, N; Michel, P; Odou, P; Pinçon, C; Romano, O; Simon, N; Vasseur, M | 1 |
| Baretton, GB; Froehner, M; Hakenberg, OW; Heberling, U; Hübler, M; Koch, R; Novotny, V; Oehlschlaeger, S; Wirth, MP | 1 |
| Fujiwara, S; Hirayama, A; Horii, A; Kudo, C; Matsumura, N; Mizuguchi, Y; Motoi, F; Nakano, T; Saiki, Y; Soga, T; Sunamura, M; Unno, M | 1 |
| Chu, GC; Chung, LW; Li, Q; Shi, C; Wu, JB; Xu, Q; Yu, JS; Zhang, Y; Zhau, HE | 1 |
| Asami, Y; Iiba, M; Kitagawa, R; Kondo, K; Sato, N; Sugita, M; Tadauchi, K; Tsunoda, H; Uenoyama, A | 1 |
| Aass, N; Baracos, VE; Benth, JŠ; Fløtten, Ø; Grønberg, BH; Hjermstad, MJ; Jordhøy, M; Sjøblom, B | 1 |
| Chan, A; De Guzman Langit, MR; Fong, W; Lim, ST; Lim, TA; Song, M; Tang, T; Tay, K | 1 |
| Bassett, R; Champlin, R; Gulbis, AM; Holmberg, L; Jones, RB; Kingham, A; Ledesma, C; Margolin, K; Nieto, Y; Pagliaro, L; Tannir, N; Tu, SM | 1 |
| Besse, B; Gazzah, A; Remon, J; Soria, JC | 1 |
| Heo, DS; Keam, B; Kim, HH; Kim, M; Kim, TM; Ku, JH; Kwak, C; Lee, E; Lee, SH; Moon, KC | 1 |
| Cieslak, JA; Cullen, JJ | 1 |
| Chen, B; He, A; Tang, M; Wang, W; Zheng, X; Zu, C | 1 |
| Humm, JL; Kramer, RM; Russell, J | 1 |
| Brekken, RA; Dellinger, MT; Dineen, SP; Haaland, G; Kirane, A; Lorens, JB; Ludwig, KF; Micklem, D; Ranaweera, R; Sandal, T; Sorrelle, N; Toombs, JE; Wang, M | 1 |
| Anota, A; Bastien, B; Bonnetain, F; Lacoste, G; Limacher, JM; Mercier, M; Quoix, E; Rotonda, C | 1 |
| Aguilar-Saavedra, JR; Beane, JD; Crean, CD; Dumas, RP; Matos, J; Schmidt, CM; Suvannasankha, A; Waters, JA; Yip-Schneider, M | 1 |
| Bai, X; Chen, BW; Chen, W; Hu, L; Liang, C; Liang, T; Shen, J; Wen, L; Xue, F; Zhi, X; Zhou, Y | 1 |
| Brames, MJ; Einhorn, LH; Mulherin, BP | 1 |
| Arshad, A; Cooke, J; Dennison, A; Isherwood, J; Mann, C; Metcalfe, M; Morgan, B; Pollard, C; Runau, F; Steward, W | 1 |
| Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Paik, WH; Ryu, JK; Son, JH | 1 |
| Fujikawa, K; Fujino, Y; Goji, T; Ikushima, H; Kagemoto, K; Kimura, M; Kimura, T; Kitamura, S; Matsumoto, S; Mitsui, Y; Miyamoto, H; Miyamoto, Y; Muguruma, N; Okada, Y; Okahisa, T; Okamoto, K; Okazaki, J; Sagawa, T; Sato, Y; Sogabe, M; Sueuchi, T; Takaoka, T; Takaoka, Y; Takayama, T; Takehara, M; Tanaka, K | 1 |
| Cheung, SS; Hasman, D; Ou, D; Tai, J; Warnock, GL | 1 |
| Fillat, C; José, A; Maliandi, MV; Mato-Berciano, A; Roué, G; Sobrevals, L | 1 |
| De, A; Franklin, MJ; Graff, JR; Jacobson, BA; Jay-Dixon, J; Konicek, BW; Kratzke, RA; Patel, MR; Sadiq, A; Thumma, SC | 1 |
| Amini, M; Azizi, M; Daman, Z; Gilani, K; Montazeri, H; Ostad, SN; Rezaie, F | 1 |
| Goodstal, S; Hagemann, T; Hartley, JA; Hochhauser, D; Li Causi, E; Rodriguez-Justo, M; Vena, F | 1 |
| Arnold, D; Bridgewater, J; Goldstein, D; Jensen, LH; Klümpen, HJ; Lohse, AW; Nashan, B; Primrose, J; Schrum, S; Shannon, J; Stein, A; Vettorazzi, E; Wege, H | 1 |
| Baras, AS; Berman, D; Bivalacqua, TJ; Faraj, S; Gandhi, N; Hahn, N; Hoque, M; Hoque, MO; Marchionni, L; Munari, E; Netto, G; Schoenberg, M; Shultz, L | 1 |
| Asano, T; Cho, A; Furukawa, D; Kainuma, O; Miura, F; Nakagohri, T; Sano, K; Yamamoto, H | 1 |
| Bielli, P; Calabretta, S; Capurso, G; Fave, GD; Fendrich, V; Passacantilli, I; Pilozzi, E; Sette, C | 1 |
| Bouvet, M; Chishima, T; Endo, I; Hiroshima, Y; Hoffman, RM; Ichikawa, Y; Maawy, A; Matsuyama, R; Mii, S; Miwa, S; Momiyama, M; Mori, R; Murakami, T; Tanaka, K; Uehara, F; Yamamoto, M; Yano, S; Zhang, N; Zhang, Y; Zhao, M | 1 |
| Furukawa, K; Kato, A; Kishimoto, T; Miyazaki, M; Nakadai, E; Nakatani, Y; Ohtsuka, M; Shimizu, H; Takayashiki, T; Yoshidome, H; Yoshitomi, H | 1 |
| Liu, F; Ouyang, HQ; Pan, ZY; Xie, GR; Yan, ZC | 1 |
| Gall, TM; Jiao, LR; Tsakok, M; Wasan, H | 1 |
| Chung, KH; Jang, DK; Kim, YT; Lee, BS; Lee, SH; Ryu, JK | 1 |
| Bang, SM; Choi, JY; Choi, SH; Hwang, HK; Kang, CM; Lee, JH; Lee, WJ; Seong, JS | 1 |
| Fujimori, T; Fujita, K; Fujiwara, S; Iwama, H; Kamada, H; Kato, K; Katsura, A; Kobayashi, K; Masaki, T; Mimura, S; Miyata, M; Miyoshi, H; Morishita, A; Nomura, T; Okano, K; Okura, R; Sakamoto, T; Suzuki, Y; Tadokoro, T; Tani, J; Toyota, Y; Yoneyama, H | 1 |
| Jusko, WJ; Straubinger, RM; Zhu, X | 1 |
| Husain, K; Kim, R; Malafa, M; Sebti, S; Yamauchi, T | 1 |
| Aoyama, T; Higuchi, A; Kanazawa, A; Katayama, Y; Kobayashi, S; Morimoto, M; Morinaga, S; Murakawa, M; Shiozawa, M; Ueno, M; Yamaoku, K | 1 |
| Chen, YY; Chiang, PH; Hsieh, MC; Huang, CH; Rau, KM; Su, YL | 1 |
| Go, T; Huang, CL; Liu, D; Nakano, J; Nii, K; Tokunaga, Y; Yokomise, H; Zhang, X | 1 |
| Beesetty, Y; Caprioli, R; Castellanos, JA; Chen, X; Merchant, NB; Moses, HL; Nagathihalli, NS; Reyzer, ML; Shi, C; Skala, MC; Walsh, AJ | 1 |
| Fujisaka, Y; Furuse, J; Kasuga, A; Kitamura, H; Kurata, T; Matsushita, H; Mukaiyama, A; Nagashima, F; Nakagawa, K; Naruge, D; Nishimura, Y; Nishina, S; Okamoto, W; Shimizu, T; Takasu, A | 1 |
| Ding, YC; Huang, T; Luo, SX; Ma, C; Meng, B; Wang, Q; Yu, W | 1 |
| Aguayo, G; Bizama, C; Espinoza, JA; García, P; Leal, JL; Macanas, P; Nervi, B; Riquelme, I; Roa, JC; Viñuela, E; Weber, H | 1 |
| Arriaga, Y; Courtney, K; Krabbe, LM; Lotan, Y; Margulis, V; Raj, GV; Sagalowsky, AI; Westerman, ME | 1 |
| Aghajanian, C; Blank, SV; Goff, B; Husain, A; Nycum, LR; Wang, YV | 1 |
| Adams, PT; Baez-Diaz, L; Bear, HD; Brufsky, AM; Costantino, JP; Fehrenbacher, L; Gaur, R; Geyer, CE; Gross, HM; Liu, Q; Mamounas, EP; Margolese, RG; Mehta, RS; Paik, S; Rastogi, P; Robidoux, A; Senecal, FM; Swain, SM; Tang, G; Wolmark, N; Young, JA | 1 |
| Abe, T; Kamiie, J; Kawaguchi, K; Motoi, F; Ohmine, K; Ohtsuka, H; Ohtsuki, S; Terasaki, T; Unno, M | 1 |
| Bjånes, T; Eide, T; Kamčeva, T; Riedel, B; Schjøtt, J; Svardal, A | 2 |
| Chen, B; Tang, JY; Tang, QH; Wang, XJ; Xu, M; Xu, MZ; Zhang, H | 1 |
| Cao, C; Luo, J; Mo, W; Ran, Y; Sun, L; Yang, Z | 1 |
| Doi, T; Fuse, N; Hynes, SM; Lin, AB; Matsubara, N; Naito, Y; Nakamura, T; Shitara, K; Uenaka, K; Yoshino, T | 1 |
| Betticher, D; Egger, T; Keller, S; Mansouri Taleghani, B; Mueller, BU; Pabst, T; Rauch, D; Seipel, K | 1 |
| Aherne, GW; Box, G; Boxall, KJ; Collins, I; De Haven Brandon, AK; Eccles, SA; Eve, PD; Garrett, MD; Hayes, A; Henley, AT; Hunter, JE; Lainchbury, M; Matthews, TP; McHardy, T; Osborne, J; Perkins, ND; Raynaud, FI; Reader, JC; Swales, K; Tall, M; Valenti, MR; Walton, MI | 1 |
| Bassi, N; Brivio, S; Cadamuro, M; Fabris, L; Floreani, A; Furlanetto, A; Joplin, RE; Massani, M; Morton, SD; Stecca, T; Strazzabosco, M; Vismara, M | 1 |
| Fukushima, S; Ihn, H; Izumi, K; Jinnin, M; Kajihara, I; Maeda, S; Masuguchi, S; Yamada, S | 1 |
| Bluhme, H; Farr, KP; Grau, C; Kallehauge, JF; Khalil, AA; Kramer, S; Morsing, A; Møller, DS | 1 |
| Abakar-Mahamat, A; André, T; Arsene, D; Ciccolini, J; Dahan, L; Deplanque, G; Desramé, J; Fein, F; François, E; Gagnière, J; Guerin-Meyer, V; Guillet, P; Guimbaud, R; Lecomte, T; Legoux, JL; Lepage, C; Montérymard, C; Seitz, JF; Serdjebi, C; Volet, J | 1 |
| Asai, A; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K; Sakai, H | 1 |
| Chen, Z; Ku, TC; Seley-Radtke, KL | 1 |
| Li, YY; Qian, KQ; Tu, C; Wang, JY; Zheng, F | 1 |
| Yang, S | 1 |
| Dai, Y; Ishibashi, O; Kondo, T; Maeda, M; Ohkohchi, N; Watanabe, M | 1 |
| Jinesh, GG; Kamat, AM; Mmeje, CO; Takeuchi, H; Taoka, R | 1 |
| Burki, M; Cohen, SJ; Egleston, B; Hoffman, JP; Meyer, JE; Shaikh, T; Wang, LS | 1 |
| Daemen, TA; Dijkgraaf, EM; Goedemans, R; Kroep, JR; Melief, CJ; Nijman, HW; Reyners, AK; Santegoets, SJ; Smit, VT; van der Burg, SH; van der Hoeven, JJ; van Erkel, AR; van Poelgeest, MI; Welters, MJ | 1 |
| Bi, Z; Chen, C; Chen, R; Fan, X; Li, D; Li, Z; Liu, Y; Zhou, Y | 1 |
| Arai, T; Ishiwata, T; Matsuda, Y; Ushijima, T; Yamashita, S; Yoshimura, H | 1 |
| Andersson, R; Ansari, D; Sasor, A; Vaz, J | 1 |
| Beachy, SH; Fetterly, GJ; Gibbs, JF; Hylander, BL; Pitoniak, R; Prey, JD; Qiu, J; Repasky, EA; Sen, A; Ullas, S | 1 |
| Fan, M; Li, Z; Liang, X; Shi, B; Wang, H; Yang, D | 1 |
| Hua, M; Ji, S; Li, L; Lu, W; Ren, Y; Wang, L; Yuan, Y; Zhou, S; Zhou, T; Zhou, X | 1 |
| Fu, J; Sun, G; Wang, M; Wang, T; Zhou, B | 1 |
| Chen, M; Ding, XW; Huang, SL; Lv, Y; Shen, SS; Zhang, S; Zhang, XQ; Zou, XP | 1 |
| Tao, ZZ; Xu, B | 1 |
| Beck, JT; Bendell, JC; Clark, J; Garrett, WM; Hunter, DS; Hurwitz, HI; Leopold, L; Levy, RS; Manges, R; Nemunaitis, JJ; Pipas, JM; Sandor, V; Stella, PJ; Uppal, N; Wade, SM; Wagner, SA; Wainberg, ZA | 1 |
| Fallon, JK; Lin, Z; Liu, D; Liu, F; Ma, Y; Wang, Y; Zhao, Q | 1 |
| Akahori, T; Kawaguchi, C; Kichikawa, K; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiofuku, H; Nishiwada, S; Sho, M; Tanaka, T; Yasuda, S | 1 |
| Cui, L; Dang, S; Fan, X; Lv, L; Ma, X; Mao, Z; Qu, J; Wang, X; Zhang, J | 1 |
| Dosch, JS; Rehemtulla, A; Sebolt-Leopold, JS; Shettigar, A; Ziemke, EK | 1 |
| Dumas, G; Goldwasser, F; Rodrigues, MJ; Rousseau, B; Tlemsani, C | 1 |
| Beijnen, JH; Boss, DS; Grob, M; Huitema, AD; Keessen, M; Rehorst, H; Rosing, H; Schellens, JH; Smit, WM; Tibben, MM; van der Noll, R; Wymenga, AN | 1 |
| Acharyya, S; Bilger, M; Haaland, B; Lopes, G; Tan, PS | 1 |
| Hoegdall, E; Nielsen, D; Ole Larsen, F; Taksony Solyom Hoegdall, D | 1 |
| Chen, G; Svirskis, D; Wen, J | 1 |
| Baranova, K; Carcangiu, ML; Dorman, SN; Knoll, JH; Mariani, G; Rogan, PK; Urquhart, BL | 1 |
| Arbaud, C; Bachet, JB; Bidault, AT; Bonnetain, F; Coriat, R; Dahan, L; de la Fouchardière, C; Dréanic, J; Dubreuil, O; Hammel, P; Lecomte, T; Lepère, C; Locher, C; Marthey, L; Pernot, S; Portal, A; Taieb, J; Tchoundjeu, B; Tougeron, D | 1 |
| Gao, S; Hedrick, JL; Krishnamurthy, S; Ng, VW; Tan, MH; Yang, YY | 1 |
| Benhadji, KA; Callies, S; Cohen, RB; Faivre, SJ; Horn, CL; Myrand, SP; Olszanski, AJ; Ouyang, H; Raymond, E; Riess, H; Wang, X; Weigang-Köhler, K; Wickremsinhe, ER | 1 |
| Besse, B; Blackhall, F; Brandén, E; de Petris, L; Edsgärd, D; Gréen, H; Hasmats, J; Koyi, H; Kupershmidt, I; Lewensohn, R; Lindgren, A; Lundeberg, J; Peterson, C; Vikingsson, S | 1 |
| Bradley, WH; Eng, KH; Hanlon, BM; Szender, JB | 1 |
| Andergassen, U; Beckmann, MW; Bekes, I; DeGregorio, N; Deniz, M; Fasching, PA; Friedl, TW; Jaeger, B; Janni, W; Jueckstock, J; Kost, B; Lato, K; Neugebauer, J; Rack, B; Schneeweiss, A; Scholz, C; Schrader, I; Schramm, A; Schwentner, L; Trapp, E; Weissenbacher, T; Widschwendter, P | 1 |
| Ryu, JK | 1 |
| Chai, X; Chu, H; Gou, S; Meng, Y; Shi, P; Yang, X | 1 |
| Geyer, AI; Kelly, DW; O'Reilly, EM; Sahin, IH | 1 |
| Guo, Q; Qin, W | 1 |
| Barreca, GS; Costa, C; Donato, G; Focà, A; Giancotti, A; La Boria, A; Liberto, MC; Pisani, V; Roveda, L; Strazzulla, A; Torti, C; Tucci, L; Zicca, E | 1 |
| El-Rayes, BF; Murata, T; Shoji, M; Yamaguchi, M | 1 |
| Cheng, CC; Chiu, TH; Huang, YT; Lai, PC | 1 |
| Gong, FR; Li, W; Liu, ZY; Shen, M; Tao, M; Wang, WJ; Wu, MY; Zhi, Q | 1 |
| Hashimoto, K; Itoh, N; Shindo, T | 1 |
| Bokemeyer, C; Oechsle, K; Oing, C; Rink, M; Seidel, C; von Amsberg, G | 1 |
| Du, F; Huang, J; Liu, S; Lu, W; Meng, H; Xu, Y; Yu, J | 1 |
| Aerts, JG; Dingemans, AM; Goosens, MJ; Haitjema, TJ; Hendriks, LE; Herder, GJ; Krouwels, FH; Masen-Poos, L; Mellema, WW; Pouw, E; Smit, EF; Smit, HJ; Staal-Van den Brekel, AJ; Stigt, JA; Termeer, A; van den Borne, BE; van den Heuvel, MM; van der Wekken, AJ; van Heemst, RC | 1 |
| Chang, KP; Chang, YS; Fan, HC; Hsieh, CH; Hsu, CL; Huang, Y; Huang, YC; Kuo, YC; Lee, LY; Li, HP; Lin, AC; Lin, TL; Lui, KW; Wang, HM | 1 |
| Byrne, WL; Cummins, J; Lehouritis, P; McCarthy, FO; Murphy, CT; Reid, G; Stanton, M; Tangney, M; Urbaniak, C | 1 |
| Bae, K; Han, SS; Hong, EK; Jung, MK; Kim, TH; Koh, YH; Lee, WJ; Park, SJ; Park, WS; Woo, SM; Yoon, KA | 1 |
| Inoue, A; Kamada, S; Kitoh, H; Miyazaki, K; Nagata, M; Nozumi, K; Okatoh, A | 1 |
| Inatsu, H; Kondo, Y; Murata, T; Nyomura, S; Takahashi, N; Tokunaga, M; Tomita, K | 1 |
| Crowder, C; Hamner, JB; Singh, G; White, M | 1 |
| Felley-Bosco, E; Friess, M; Frischknecht, L; Korol, D; Opitz, I; Soltermann, A; Stahel, R; Thies, S; Vrugt, B; Weder, W | 1 |
| Behrns, KE; Delitto, D; George, TJ; Gonzalo, DH; Graves, CL; Han, S; Hughes, SJ; Knowlton, AE; Liu, C; Moldawer, LL; Perez, C; Pham, K; Thomas, RM; Trevino, JG; Wallet, SM | 1 |
| Dykoski, R; Gruenberg, J; Gupta, P; Manivel, JC; Mesa, H | 1 |
| Ambinder, RF; Chen, J; Choi, TH; Chong, CR; Dong, SM; Hayward, SD; Kim, EJ; Kim, H; Lee, HG; Lee, JM; Liu, JO; Park, JH; Park, PG | 1 |
| Feng, YH; Huang, KH; Li, CF; Lin, KL; Shen, KH; Tzeng, WS | 1 |
| Dobbelstein, M; Li, Y; Saini, P; Sriraman, A | 1 |
| Chalasani, V; Gunaratne, DA; Krieger, LE; Maclean, F; Vaux, KJ | 1 |
| Badary, O; El Wakeel, L; Elkholy, E; Saad, AS; Sayed, R | 1 |
| Chen, SQ; Cui, FB; Gao, EY; Jiang, BQ; Li, M; Shu, RB; Sun, P; Tang, W; Wang, H; Zhang, FL; Zhang, Y | 1 |
| Bian, Q; Hu, XG; Jin, G; Jing, W; Li, G; Liu, AA; Liu, R; Shao, CH; Song, B; Zhang, YJ; Zhou, YQ | 1 |
| Moghanaki, AA; Pourjavadi, A; Tehrani, ZM | 1 |
| Artyukhin, AB; Brekken, RA; Christie, AL; Cruz, VH; Hale, MA; Heath, BR; Kollipara, RK; Lorens, JB; Ocal, O; Pashkov, V; Swift, GH; Tsoulfas, P; Wilkie, TM; Zolghadri, Y | 1 |
| Kiessling, R; Lundqvist, A; Maeda, A; Nakata, M; Nakayama, E; Oka, M; Okita, R; Saisho, S; Seliger, B; Shimizu, K; Wolf, D; Yamaguchi, Y; Yasuda, K; Yukawa, T | 1 |
| Bai, L; Chen, LZ; Chiao, PJ; Deng, W; Ju, HQ; Li, H; Lu, YX; Mo, HY; Sheng, H; Tian, T; Xu, RH; Zeng, JB | 1 |
| André, T; Bachet, JB; Bonnetain, F; Chibaudel, B; Hammel, P; Louvet, C; Validire, P | 1 |
| Alevizos, L; Daskalou, T; Eleftheriadis, S; Iatrou, C; Korakianitis, O; Mavroudis, C; Stamou, K; Tentes, AA; Vogiatzaki, T | 1 |
| Agulnik, M; Carvajal, RD; Chi, P; Chmielowski, B; Crago, AM; D'Angelo, SP; Dickson, MA; Ezeoke, MO; Gounder, MM; Hameed, M; Healey, JH; Keohan, ML; Landa, J; Luke, JJ; Munhoz, RR; Qin, LX; Schwartz, GK; Singer, S; Singh, AS; Tap, WD; Van Tine, BA | 1 |
| Ahmed, AK; Duncan, MD; Fushida, S; Harmon, JW; Kamigaki, T; Kitagawa, H; Makino, I; Miki, K; Miyashita, T; Nakagawara, H; Ohta, T; Tajima, H; Takamura, H | 1 |
| Bazhin, AV; Brecht, R; Fritz, J; Karakhanova, S; Nachtigall, I; Werner, J | 1 |
| Agostoni, V; Anand, R; Couvreur, P; Gref, R; Lampropoulou, M; Maksimenko, A; Monti, S; Rodriguez-Ruiz, V; Yannakopoulou, K | 1 |
| Gandhi, M; Gandhi, R; Mashru, R; Misra, A; Pandya, T; Patel, S; Tandel, H | 1 |
| Eils, R; Giese, N; Krammer, PH; Lavrik, IN; Pietkiewicz, S | 1 |
| Castañon, E; Rolfo, C | 1 |
| Chiu, TJ; Hou, YC; Shan, YS; Tung, HL; Wang, HC; Yang, MC | 1 |
| Balzano, G; Belli, C; Ceraulo, D; Cereda, S; Di Terlizzi, G; Doglioni, C; Dugnani, E; Falconi, M; Lampasona, V; Liberati, D; Maggiora, P; Nicoletti, R; Pasquale, V; Piemonti, L; Reni, M; Scavini, M; Sordi, V | 1 |
| Actis, ML; Evison, BJ; Fujii, N; Inoue, A | 1 |
| Dolan, DE; Gupta, S; Jan, AS; Lombardi, K | 1 |
| He, P; Jiang, Y; Yang, K; Zheng, L; Zhong, H | 1 |
| Bode, AM; Byun, S; Cho, YY; Dong, Z; Farrand, L; Jung, SK; Kwon, YJ; Lee, E; Lee, HJ; Lee, J; Lee, KW; Lee, SY; Shin, SH; Sin, HS; Tsang, BK; Um, SJ; Zhang, C | 1 |
| Andersson, R; Ansari, D; Kölby, D; Sasor, A; Thilén, J | 1 |
| Akin, N; Aksoy, S; Arvas, M; Balaban, B; Bildik, G; Eryılmaz, B; Guzel, Y; Ince, U; Iwase, A; Karanfil, I; Kilic, Y; Oktem, O; Ozkanbaş, C; Senbabaoglu, F; Taskiran, C; Unal, F; Urman, B; Yilmaz, P; Yuksel, A | 1 |
| Chen, Y; Han, H; Ji, J; Jin, Q; Wang, Y | 1 |
| Agerbaek, M; Cerbone, L; Collette, S; Daugaard, G; Marreaud, S; Sengeløv, L; Sternberg, CN; Van Herpen, C; Zhang, J | 1 |
| Craven, KE; Gore, J; Korc, M; Palam, LR; Wilson, JL | 1 |
| Fujiwara, K; Hiraoka, K; Nagase, H; Nakamura, M; Ozaki, T; Sang, M; Shimozato, O; Shinohara, K; Sugimoto, H; Yoda, H | 1 |
| Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Koido, S; Komita, H; Nagasaki, E; Okamoto, M | 1 |
| Alessandri, G; Bondiolotti, G; Bonomi, A; Cavicchini, L; Ceserani, V; Ciusani, E; Coccè, V; Dossena, M; Dugnani, E; Parati, E; Pascucci, L; Pessina, A; Piemonti, L; Piovani, G; Sisto, F; Sordi, V | 1 |
| Brayé, M; Coulibaly, ST; Kretzschmar, FK; Lener, D; Martin, DP; Negroni, M; Rossolillo, P; Winter, F | 1 |
| Akiyama, T; Fujimori, N; Funakosi, A; Hisano, T; Horiuchi, H; Ito, T; Kawabe, K; Okabe, Y; Sirabe, K; Suga, H; Ueki, T; Yamaguchi, H; Yamashita, Y | 1 |
| Chang, YJ; Huang, CY; Huang, MT; Lin, FY; Luo, SD; Tai, CJ; Uyanga, B | 1 |
| Choi, EK; Hong, SW; Hong, YS; Hwang, IY; Jin, DH; Kim, JE; Kim, JH; Kim, KP; Kim, SM; Kim, TW; Lee, DH; Lee, EY; Lee, JS; Lee, WK; Moon, JH; Park, SJ; Shin, JS; Shin, YJ | 1 |
| Arakawa, H; Ito, Z; Kajihara, M; Kanai, T; Kobayashi, H; Koido, S; Matsumoto, Y; Odahara, S; Ohkusa, T; Okamoto, M; Saito, K; Sugiyama, H; Sumiyama, K; Takakura, K; Takami, S; Tsukinaga, S; Uchiyama, K | 1 |
| Alejandre, MJ; Delgado, JR; Linares, A; Palomino-Morales, RJ; Perales, S; Torres, C | 1 |
| Bellmunt, J; Galsky, MD; Giannatempo, P; Naik, G; Necchi, A; Pond, GR; Raggi, D; Sonpavde, G | 1 |
| Guo, J; Tang, N; Wang, Y; Wang, Z; Zhang, Q | 1 |
| Li, CZ; Liu, Z; Song, Z; Sun, FL; Sun, J; Sun, JZ; Xu, LY | 1 |
| Aguilar, M; Chiao, PJ; Fan, X; Fleming, JB; Fu, J; Gocho, T; Iida, T; Iwakura, Y; Ju, HQ; Lee, H; Li, H; Li, M; Li, Z; Ling, J; Melisi, D; Wu, M; Xu, K; Zhou, H; Zhuang, Z | 1 |
| Arrowsmith, C; BeGora, M; Cleary, S; Connor, AA; Crawford, HC; Gallinger, S; Holtzinger, A; Huang, L; Jagan, I; Kalloger, SE; Keller, G; Lohse, I; Muthuswamy, LB; Muthuswamy, SK; Ngai, N; Nostro, C; Renouf, DJ; Roehrl, M; Schaeffer, DF; Tsao, MS; Wang, R | 1 |
| Chen, IC; Hsieh, MJ; Hung, MS; Jablons, DM; Li, YC; Lin, YC; Liu, ST; Mao, JH; Tsai, YH; Xu, Z; Yang, CT; You, L | 1 |
| Jeong, CW; Kim, HH; Kim, HS; Ku, JH; Kwak, C | 1 |
| Baron, B; Kitagawa, T; Kuramitsu, Y; Tokuda, K; Tokunaga, M | 1 |
| Hirajima, S; Ichikawa, D; Ikoma, H; Imamura, T; Kawaguchi, T; Komatsu, S; Konishi, H; Miyamae, M; Morimura, R; Ochiai, T; Ohashi, T; Okajima, W; Okamoto, K; Otsuji, E; Shiozaki, A; Taniguchi, H | 1 |
| Han, KS; Hong, SJ; Kim, KH | 1 |
| Baloğlu, E; Bernkop-Schnürch, A; Çalışkan, Ç; İlem-Özdemir, D; Karavana, SY; Şen, S; Şenyiğit, ZA; Waldner, C | 1 |
| Chang, J; Hong, X; Luo, Z; Peng, W; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, X | 1 |
| Bakkenist, CJ; Conrads, TP; Lau, A; O'Connor, MJ; Schamus, S; Vendetti, FP | 1 |
| Hur, GY; Kang, EJ; Kang, KH; Kim, JS; Lee, SY; Min, KH; Oh, SC; Seo, JH; Shim, JJ | 1 |
| Cao, C; Chen, J; Kuang, M; Tang, C; Xu, W; Zhang, X | 1 |
| Lariño Noia, J | 1 |
| Ceresoli, GL; Zucali, PA | 1 |
| Cho, S; Choi, K; Choi, M; Han, SB; Kang, H; Kang, M; Kim, C; Kim, DE; Kim, HS; Kim, J; Kim, M; Ko, HJ; Lee, CK; Lee, K; Lee, MY; Lee, SU; Shin, JS; Song, JH; van Kuppeveld, FJ | 1 |
| Bahary, N; Catenacci, DV; Cohen, D; de Sauvage, FJ; Henderson, L; Horiba, MN; Junttila, MR; Karrison, T; Kindler, HL; Kozloff, M; Kumar, P; Lenz, HJ; Marsh, R; Nattam, SR; Rajdev, L; Salgia, R; Sleckman, B; Stadler, WM; Stiff, P; Takebe, N; Wade, J; Wallace, J; Wang, X; Xu, P | 1 |
| Abrams, RA; Blazeby, JM; Bridges, S; Bridgewater, J; Crosby, T; Dutton, P; Falk, S; Griffiths, G; Hurt, CN; Johnson, C; Joseph, G; Maughan, T; McDonald, A; Mukherjee, S; Staffurth, J | 1 |
| Ali, HR; Bentley, D; Caldas, C; Chin, SF; Contente-Cuomo, T; Dawson, SJ; Farahani, H; Gale, D; Grant, J; Humphray, S; Kingsbury, Z; Marass, F; Murtaza, M; Pogrebniak, K; Provenzano, E; Rosenfeld, N; Rueda, OM; Shah, P; Shah, SP; Shumansky, K; Tsui, DWY; Wallis, M | 1 |
| Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM | 1 |
| Aglietta, M; Amatu, A; Aprile, G; Belli, C; Cagnazzo, C; Cereda, S; Ciuffreda, L; Fasola, G; Filippi, R; Leone, F; Marino, D; Montano, M; Nasti, G; Reni, M; Siena, S; Spadi, R | 1 |
| Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
| Akita, H; Gotoh, K; Ishikawa, O; Kobayashi, S; Marubashi, S; Nishiyama, K; Ohigashi, H; Sakon, M; Takahashi, H; Teshima, T; Tomokuni, A; Yamada, T; Yano, M | 1 |
| Kim, JS; Lee, SJ; Ryu, JH; Shin, DH | 1 |
| Bourade, V; Chen, E; Doyle, L; Goel, R; Halford, R; Jonker, D; Keller, D; Laurie, SA; Lheureux, S; Oza, AM; Siu, LL; Wang, L | 1 |
| Cousin, S; Ducoulombier, A; Kotecki, N; Penel, N | 1 |
| Gu, M; Li, F; Liu, J; Sun, Y; Wei, Y; Xiong, Y; Zhu, L | 1 |
| Carstens, JL; Kalluri, R; Kaye, J; Kim, J; LeBleu, VS; Scheible, M; Sugimoto, H; Wu, CC; Zheng, X | 1 |
| Ishii, M; Kitamura, K; Kiuchi, Y; Kogo, M; Kurihara, T; Shimada, K; Shimizu, S; Yoneyama, K; Yoshida, H | 1 |
| Ishitoya, S; Onishi, H; Takeuchi, E; Terashima, T; Uemura, Y; Ushida, H | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ochiai, A; Ohno, I; Okusaka, T; Okuyama, H; Sakamoto, Y; Shimizu, S; Takahashi, H; Ueno, H | 1 |
| Kitaoka, H; Kubo, T; Nakashima, Y; Syuin, T; Tanioka, K; Yamasaki, I; Yamasaki, N | 1 |
| Alvaro, D; Bragazzi, MC; Cardinale, V; Carpino, G; Costantini, D; De Rose, AM; Di Matteo, S; Fraveto, A; Gaudio, E; Giuliante, F; Grazi, GL; Lustri, AM; Napoletano, C; Nevi, L; Renzi, A; Semeraro, R | 1 |
| Alexandrov, VA; Belyaev, AM; Belyaeva, OA; Bespalov, VG; Kireeva, GS; Kopteva, OS; Krasilnikova, LA; Maidin, MA; Semenov, AL; Stukov, AN; Vasilieva, IN; Vyshinskaya, EA | 1 |
| Dong, Y; Li, D; Li, H; Tian, G; Wang, L; Yuan, Y | 1 |
| Chen, D; Di Cresce, C; Ferguson, PJ; Figueredo, R; Koropatnick, J; Maleki Vareki, S; Min, W; Pampillo, M; Rytelewski, M; Vincent, M; Zheng, X | 1 |
| Chiarelli, M; Cioffi, U; De Simone, M; Gabrielli, F; Gerosa, M; Guttadauro, A; Marando, A | 1 |
| Chen, N; Cui, J; Guo, R; Hu, JF; Jin, H; Li, W; Wang, G; Wang, H; Yin, H | 1 |
| Davis, MA; Karnak, D; Kausar, T; Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Schreiber, JS; Zhao, L | 1 |
| Di, Y; Fu, D; He, H; Jin, C; Li, H; Lu, W; Pu, X; Song, Y; Xie, C; Yu, X | 1 |
| Hour, TC; Huang, CN; Huang, HS; Kang, WY; Li, CC; Li, WM; Liu, ZM; Wu, WJ; Yeh, BW | 1 |
| Ahn, SJ; Ban, HJ; Chung, WK; Jeong, JU; Kim, KS; Kim, YC; Kim, YH; Nam, TK; Oh, IJ; Song, JY; Yoon, MS | 1 |
| Al Yaghchi, C; Alusi, G; Lemoine, NR; Wang, Y; Zhang, Z | 1 |
| Ando, Y; Ebata, T; Fujita, K; Maeda, O; Mitsuma, A; Nagino, M; Sasaki, Y; Shibata, T; Shimokata, T | 1 |
| Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M | 1 |
| Al-Batran, SE; Kullmann, F; Kunzmann, V; Oettle, H; Plentz, R; Riess, H; Siveke, J; Springfeld, C; Vogel, A | 1 |
| Furukawa, H; Kofunato, Y; Koyama, Y; Kumamoto, K; Shimura, T; Takenoshita, S; Yashima, R | 1 |
| Dennison, AR; Garcea, G; Haqq, J; Howells, LM | 1 |
| Dodagoudar, C; Doval, DC; Goel, V; Goyal, P; John, MC; Mahanta, A; Patnaik, N; Singh, S; Talwar, V; Tiwari, S; Upadhyay, A | 1 |
| Jusko, WJ; Koch, G; Miao, X; Straubinger, RM | 1 |
| Dhayat, SA; Haier, J; Hummel, R; Mardin, WA; Matuszcak, C; Mees, ST; Seggewiß, J; Senninger, N; Ströse, AJ | 1 |
| Chen, Y; Han, H; Ji, J; Jin, Q; Li, Z; Wang, H; Wang, Y | 1 |
| Barda, D; Barnard, D; Beckmann, R; Burke, T; Diaz, HB; Donoho, G; Jones, B; King, C; Marshall, M | 1 |
| Bayever, E; Belanger, B; Blanc, JF; Bodoky, G; Braiteh, F; Chen, LT; Chiu, CF; Cunningham, D; Dean, A; Dhindsa, N; Hubner, RA; Jameson, G; Lee, KH; Li, CP; Macarulla, T; Moyo, V; Schwartsmann, G; Shan, YS; Siveke, JT; Von Hoff, DD; Wang-Gillam, A | 1 |
| Apolo, AB; Bajorin, DF; Furberg, HF; Ostrovnaya, I; Regazzi, AM; Rosenberg, JE; Tully, CM; Zabor, EC | 1 |
| Baha, A; Ozturk, C; Yıldırım, F; Yurdakul, AS | 1 |
| Kumar, V; Mahato, RI; Mondal, G; Shukla, SK; Singh, PK | 1 |
| Ajiki, T; Fujiwara, Y; Hamada, A; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Minami, H; Nagano, H; Takashima, Y; Toyoda, M; Yoshimura, K | 1 |
| Arai, Y; Ito, A; Kaiho, Y; Kamiyama, Y; Kawamorita, N; Mitsuzuka, K; Nakagawa, H; Watanabe, M; Yamada, S | 1 |
| Li, B; Shen, ZT; Wang, L; Wu, XH; Zhu, XX | 1 |
| Kmietowicz, Z | 1 |
| Duvic, M | 1 |
| Ashida, R; Ioka, T; Katayama, K; Sakon, M; Takahashi, H; Teshima, T | 1 |
| Guzzo, T; Keefe, S; Malkowicz, SB; Mamtani, R; Narayan, V; Vaughn, DJ | 1 |
| Bai, R; Ding, T; Lan, X; Liu, S; Yin, L; Yu, Y; Zhang, L; Zhao, J | 1 |
| An, G; Ma, Y; Wang, J; Wang, Q; Xu, F; Yang, L | 1 |
| Jiang, Y; Lin, Z; Liu, G; Ren, N; Shi, Y; Xu, W | 1 |
| Barrios, CH; Bines, J; Blajman, C; Capó, A; Fanelli, M; Fein, L; Gómez, HL; Ismael, G; Lerzo, G; Mano, M; Martínez-Mesa, J; Neciosup, S; Nerón, Y; Pinczowski, H; Sampaio, C; Santi, PX; Tosello, C; Varela, MS; Werutsky, G; Zarba, JJ | 1 |
| Barone, C; Basso, M; Cassano, A; Cerchiaro, E; D'Argento, E; Dadduzio, V; Martini, M; Rossi, S; Strippoli, A | 1 |
| Hishima, T; Hosomi, Y; Okamura, T; Okuma, Y; Takahashi, S; Watanabe, K | 1 |
| Ciesielka, M; Homa, I; Kozioł, P; Krawczyk, P; Małecka-Massalska, T; Milanowski, J; Mlak, R; Powrózek, T; Prendecka, M | 1 |
| Ferrara, S; Goldstein, D; Greeno, E; Liu, H; Lu, B; Macarulla, T; Moore, M; Pilot, R; Ramanathan, RK; Tortora, G; Von Hoff, DD | 1 |
| Billadeau, DD; Chini, CC; Chini, EN; Escande, C; Espindola-Netto, JM; Guerrico, AM; Mondal, G; Nin, V; Sola-Penna, M; Zhang, JS | 1 |
| Amiji, M; Mattheolabakis, G; Singh, A; Xu, J | 1 |
| Hagiwara, M; Hanai, K; Ichioka, D; Inoue, T; Kageyama, S; Kikuchi, E; Kinoshita, H; Matsui, Y; Mitsuzuka, K; Miyazaki, J; Nishiyama, H; Sugimoto, M; Wakeda, H; Yamamoto, S; Yuge, K | 1 |
| Bi, D; Ding, K; Ding, S; Li, J; Liu, S; Lu, J; Niu, Z; Sun, L; Wu, F; Zhang, H; Zhao, Z | 1 |
| Jha, V; Ojha, R; Singh, SK | 1 |
| Armstrong, PA; Centeno, BA; Chen, DT; Fulp, WJ; Gamenthaler, AW; Ha, TT; Hodul, PJ; Hoffe, S; Hutchinson, T; Illig, K; Johnson, BL; Malafa, MP; Nguyen, P; Pimiento, JM; Rashid, OM; Shridhar, R; Springett, G | 1 |
| Allavena, P; Belli, C; Cangi, MG; Cappio, S; Ceraulo, D; D'Incalci, M; Doglioni, C; Dugnani, E; Garassini, G; Maggiora, P; Piemonti, L; Porcu, L; Reni, M; Zucchetti, M | 1 |
| Hu, XC; Li, T; Ni, C; Tao, ZH; Wu, ZH; Xie, J; Zhang, J; Zhang, JF | 1 |
| Kim, ES | 1 |
| Jiang, H; Pan, S; Sun, B; Wang, Y; Wu, X; Zhou, Y | 1 |
| Behrns, KE; Black, BS; Delitto, D; George, TJ; Han, S; Hughes, SJ; Knowlton, AE; Liu, C; Lu, X; Sarosi, GA; Thomas, RM; Trevino, JG; Vlada, AC; Wallet, SM; Zhang, D | 1 |
| Borzomati, D; Coppola, R; D'Angelillo, RM; Fiore, M; Floreno, B; Ippolito, E; Ramella, S; Trecca, P; Trodella, L; Trodella, LE; Valeri, S | 1 |
| Li, SD; May, JP; Roy, A; Undzys, E | 1 |
| Albiges, L; Bellmunt, J; Culine, S; De Santis, M; Flechon, A; Lin, CC; Loidl, WC; Lucas, C; Mourey, L; Necchi, A; Retz, MM; Senkus-Konefka, E; Su, WC; Vaissière, N; Wiechno, PJ | 1 |
| Barton, D; Beck, RM; Brufsky, A; Coleman, RE; Conte, PF; Cortes, J; Glück, S; Harbeck, N; Ko, A; Nabholtz, JM; O'Shaughnessy, J; Renschler, MF; Yardley, DA | 1 |
| Dambrauskas, Z; Gulbinas, A; Jakstaite, A; Kmieliute, K; Maziukiene, A; Silkuniene, G | 1 |
| Deng, M; Evans, D; Fang, Y; Gao, B; Kim, J; Lee, S; Liu, T; Lou, W; Lou, Z; Niu, N; Qin, B; Wang, L; Xie, F; Yu, J; Zhang, H | 1 |
| Choi, HJ; Eom, CY; Han, Z; Je, S; Kim, JH; Lee, S; Song, JJ | 1 |
| Baba, H; Boku, N; Fukutomi, A; Fukuzawa, K; Furukawa, M; Furuse, J; Hyodo, I; Iguchi, H; Ikeda, M; Ioka, T; Isayama, H; Komatsu, Y; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Shimada, K; Sugimori, K; Takeuchi, M; Ueno, M | 1 |
| Cui, YQ; Gao, CC; Gong, BG; Jiang, H; Li, F; Liu, S; Sun, HC; Xu, PY; Xu, XL; Zheng, YM | 1 |
| Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Sakamoto, Y; Shimizu, S; Shoji, H; Takahashi, H; Ueno, H | 1 |
| Kim, DH; Kim, MS; Lee, JA; Lim, JS; Paik, EK; Seo, J; Yoo, JY | 1 |
| Binenbaum, Y; Gil, Z; Na'ara, S | 1 |
| Aprile, G; Brandi, G; Caparello, C; Cereda, S; Falcone, A; Fornaro, L; Leone, F; Lonardi, S; Milella, M; Musettini, G; Pasquini, G; Santini, D; Silvestris, N; Sperduti, I; Vasile, E; Vivaldi, C | 1 |
| Allen, PJ; D'Angelica, MI; DeMatteo, RP; Do, RK; Fong, Y; Gönen, M; Groot Koerkamp, B; Jarnagin, WR; Kemeny, NE; Kingham, TP; Klimstra, DS; Konstantinidis, IT | 1 |
| Bekaii-Saab, T; Blazer, M; Lundberg, J; Phillips, G; Reardon, J | 1 |
| Bokemeyer, C; Cathomas, R; de Wit, M; Dieing, A; Grünwald, V; Hentrich, M; Hornig, M; Lorch, A; Meiler, J; Oechsle, K; Seidel, C | 1 |
| Dobelbower, MC; Dreicer, R; George, A; Heney, NM; Kaufman, DS; Mitin, T; Sandler, HM; Shipley, WU; Souhami, L; Uzzo, RG; Wallace, HJ; Zietman, AL | 1 |
| Cohen, SJ; Conkling, P; Hersh, E; Lee, FC; Ma, WW; Modiano, M; Nugent, F; Pascual, R; Wong, L; Zalupski, MM | 1 |
| Arumugam, T; Cao, J; Deng, D; Li, Z; Logsdon, CD; Ramachandran, V; Xu, L; Yang, J | 1 |
| Iwata, T; Nakajima, T; Suzuki, H; Tagawa, T; Yoshida, S; Yoshino, I | 1 |
| Benasso, M; Merlano, MC; Peeters, M; Specenier, P; Szturz, P; Van den Weyngaert, D; Van Gestel, D; Van Laer, C; Vanderveken, OM; Vermorken, J; Wouters, K | 1 |
| Dong, M; Gui, L; He, X; Hu, S; Jia, B; Liu, P; Qin, Y; Yang, J; Yang, S; Zhang, C; Zhou, S | 1 |
| Debus, J; Hoffmann, H; Huber, PE; Nicolay, NH; Roeder, F; Safi, S; Sterzing, F; Thieke, C | 1 |
| Bradshaw-Pierce, EL; Eckhardt, SG; Eppers, S; Freas, E; Kane, MA; Kessler, ER; Leong, S; Lieu, CH; Messersmith, WA; Nallapreddy, S; O'byrant, CL; Pitts, TM; Spratlin, J; Weekes, C | 1 |
| Asao, T; Fujii, T; Kato, T; Kuwano, H; Osone, K; Suto, T; Takada, T; Takahashi, R; Tatsuki, H; Tsutsumi, S; Yajima, R; Yokobori, T | 1 |
| Hwang, HK; Kang, CM; Kim, H; Kim, MJ; Lee, SH; Lee, WJ; Seong, J; Song, SY | 1 |
| Natsui, M; Seino, S; Tsuchiya, A | 1 |
| Dong, SX; Han, P; Qi, J; Ren, ZG | 1 |
| Fu, S; Ma, G; Sun, Y | 1 |
| Campbell, MT; Carolla, RL; Harris, DR; Munsell, MF; Pagliaro, LC; Siefker-Radtke, AO | 1 |
| Abbruzzese, JL; Abrams, RA; Chang, P; Crane, C; Freedman, GM; Guha, C; Hoffman, JP; Li, D; Liu, C; Moughan, J; Regine, WF; Safran, H; Winter, KA | 1 |
| Chan-On, W; Khuntikeo, N; Kongpetch, S; Kukongviriyapan, U; Kukongviriyapan, V; Ong, CK; Prawan, A; Puapairoj, A; Senggunprai, L; Siew, EY; Teh, BT | 1 |
| Adam, J; Bastien, B; Beck, JT; Chouaid, C; Debieuvre, D; Felip, E; Forget, F; Gervais, R; Halluard, C; Kazarnowicz, A; Lacoste, G; Lena, H; Limacher, JM; Losonczy, G; Madroszyk, A; Ottensmeier, C; Palanché, T; Papai, Z; Quoix, E; Szczesna, A; Tavernaro, A; Westeel, V | 1 |
| Garnock-Jones, KP | 1 |
| Buscail, L; Cordelier, P; Gayral, M; Hanoun, N; Pointreau, A | 1 |
| Anastasina, M; Bamford, DH; De Brabander, JK; Islam, MM; Julkunen, I; Kainov, D; Matikainen, S; Nyman, TA; Poranen, MM; Saelens, X; Šaulienė, I; Söderholm, S; Stenman, J; Tynell, J | 1 |
| Egawa, S; Hara, K; Hijioka, S; Imaoka, H; Kou, T; Mizuno, N; Shimizu, Y; Tanaka, M; Yamao, K; Yazumi, S | 1 |
| Bagalà, C; Barone, C; Basso, M; Calegari, MA; Cassano, A; Cocomazzi, A; Indellicati, G; Larocca, LM; Martini, M; Orlandi, A; Zurlo, V | 1 |
| Jones, RB; Li, D; Nieto, Y; Shinozuka, K; Tang, H | 1 |
| Ahmadloo, N; Askarian, M; Hatam, N; Javan-Noghabi, J; Mohammadianpanah, M | 1 |
| Adeberg, S; Debus, J; Haberer, T; Harrabi, SB; Weber, KJ; Winter, M | 1 |
| Atyabi, F; Dinarvand, R; Kazemi, B; Razzazan, A | 2 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Shintakuya, R; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Aires, A; Cadenas, JF; Carrascosa, JL; Clarke, RB; Cortajarena, AL; Couleaud, P; Josefa Rodríguez, M; Latorre, A; Miranda, R; Ocampo, SM; Simões, BM; Somoza, Á; Spence, K | 1 |
| Li, Z; Qian, J; Wang, X; Xu, P; Yao, J; Zhao, L | 1 |
| Chuong, P; Fouts, BL; Gurka, MK; McNally, LR; McNally, MW; Mezera, M; Pender, D; Sobelov, A; Woo, SY | 1 |
| Doherty, M; Hedley, D; Knox, JJ; McNamara, MG; Mian, M; Serra, S | 1 |
| Apte, MV; Biankin, AV; Goldstein, D; Pirola, RC; Pothula, SP; Wilson, JS; Xu, Z | 1 |
| Baldwin, GS; He, H; Lowy, AM; Nikfarjam, M; Patel, O; Yeo, D | 1 |
| Fushimi, K; Hamada, T; Isayama, H; Koike, K; Matsui, H; Nakai, Y; Yasunaga, H | 1 |
| Colloca, G; Guarneri, D; Venturino, A | 1 |
| Desco, M; Hernández-Agudo, E; Hidalgo, M; Lopez-Casas, PP; Megías, D; Mondejar, T; Mouron, S; Mulero, F; Quintela-Fandino, M; Sanchez, J; Soto-Montenegro, ML | 1 |
| Bolenz, C; Budjan, J; Erben, P; Gaiser, T; Michel, MS; von Hardenberg, J; Wezel, F | 1 |
| Boegemann, M; Krabbe, LM; Schlack, K; Schrader, AJ; Steinestel, J | 1 |
| Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM; Solca, F | 1 |
| Kim, JS; Koo, MJ; Shin, DH | 1 |
| He, X; Shen, X; Shi, M; Wang, J; Wei, W; Xin, B; Zhang, T | 1 |
| Gordetsky, JB; Lockhart, ME; Nix, JW; Sonpavde, G | 1 |
| Chekerov, R; Ismaeel, F; Richter, R; Roots, I; Sehouli, J; Siepmann, T; Woopen, H | 1 |
| Aftimos, P; Awada, A; Bahleda, R; Bourbouloux, E; Campone, M; Frenel, JS; Gombos, A; Soria, JC; Varga, A | 1 |
| Chain, P; Cimino, G; de Vere White, R; Gleasner, C; Henderson, PT; Hu, B; Lin, TY; Malfatti, M; Mcmurry, K; Pan, AW; Pan, CX; Scharadin, TM; Turteltaub, K; Vinall, R; Vuyisich, M; Wang, S; Zhang, H; Zimmermann, M | 1 |
| Arena, F; Goldstein, D; Korn, RL; Liu, H; Lu, B; McGovern, D; Moore, M; Ramanathan, RK; Siena, S; Tabernero, J; Teixeira, L; Van Laethem, JL; Von Hoff, DD | 1 |
| Arena, FP; Bathini, VG; Chiorean, EG; Clingan, PR; Goldstein, D; Infante, JR; Ko, A; Kunzmann, V; Lu, B; Mainwaring, PN; McGovern, D; Muldoon, RT; Ramanathan, RK; Reni, M; Tabernero, J; Von Hoff, DD; Wood, TE | 1 |
| Asano, T; Kanomata, H; Matsuoka, Y; Miyamoto, Y; Murayama, M; Seyama, Y; Takahashi, M; Tani, K; Tanizawa, T; Umekita, N; Warabi, M | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Kinoshita, H; Ku, Y; Matsumoto, T; Murakami, S; Shinozaki, K; Toyama, H | 1 |
| Abe, T; Aoki, S; Hayashi, H; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Okada, R; Okada, Y; Oyauchi, M; Sakata, N; Unno, M; Yoshida, H | 1 |
| Hiratsuka, M; Ishibashi, Y; Ito, Y; Morita, A; Omori, K; Saito, H; Suda, H; Suematsu, Y; Takahashi, M; Wakabayashi, K | 2 |
| Fukada, T; Hasegawa, A; Kametaka, H; Koyama, T; Makino, H; Seike, K | 1 |
| Furukawa, T; Muto, T; Takahashi, H; Tanaka, K | 1 |
| Chiba, R; Kaiho, T; Kobayashi, S; Mun, Y; Nishimura, M; Okamoto, R; Okaniwa, A; Shinmura, K; Tsuchiya, S; Yanagisawa, S | 1 |
| Hasegawa, J; Kobayashi, T; Naito, T; Sakata, J; Shimada, T; Shimakage, N; Tani, T; Usui, K; Wakai, T; Yamamoto, J | 1 |
| Amano, K; Ebihara, T; Hiraki, Y; Hoshino, H; Ikeda, N; Inoue, T; Kamigaki, S; Kato, F; Kawada, M; Kimura, Y; Makari, Y; Mikami, J; Munakata, S; Nakata, K; Nakata, Y; Nishi, H; Ohzato, H; Sasamatsu, S; Shimizu, K; Tsujie, M; Yamamoto, T; Yamamura, J; Yoshimura, J | 1 |
| Egawa, C; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Matsushita, K; Morimoto, Y; Motoyama, Y; Murakami, K; Naito, A; Ohmura, Y; Okishiro, M; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Furukawa, K; Kagawa, S; Kato, A; Kuboki, S; Maeda, S; Miyazaki, M; Ohtsuka, M; Sakai, N; Shimizu, H; Suzuki, D; Takano, S; Takayashiki, T; Yoshitomi, H | 1 |
| Hashimoto, M; Hayashi, H; Ikeda, Y; Ishii, T; Katayama, T; Kawasaki, Y; Ohtsuru, M; Okubo, Y; Senba, H; Shinozaki, K; Tono, T; Yasuda, S | 1 |
| Fujiwara, H; Hatakeyama, T; Ichikawa, D; Ikoma, H; Imamura, T; Komatsu, S; Konishi, H; Kosuga, T; Kuriu, Y; Morimura, R; Murayama, Y; Nakanishi, M; Ochiai, T; Okamoto, K; Otsuji, E; Shiozaki, A | 1 |
| Hirose, Y; Kameyama, H; Kobayashi, T; Kosugi, S; Minagawa, M; Miura, K; Morimoto, Y; Nagahashi, M; Sakata, J; Sato, R; Soma, D; Takano, K; Takizawa, K; Wakai, T; Yuza, K | 1 |
| Ajiki, T; Asari, S; Fukumoto, T; Goto, T; Kido, M; Kinoshita, H; Ku, Y; Kuramitsu, K; Matsumoto, I; Matsumoto, T; Takebe, A; Tanaka, M; Terai, S; Toyama, H | 1 |
| Adachi, S; Kozawa, O; Okuno, M; Shimizu, M; Yasuda, I | 1 |
| Araki, N; Ishikawa, O; Ito, Y; Kawaguchi, Y; Konishi, K; Nishiyama, K; Ohigashi, H; Oshima, K; Otani, K; Takahashi, H; Teshima, T | 1 |
| Aldayel, AM; Cui, Z; Hursting, SD; Lansakara-P, D; Lashinger, LM; Naguib, YW; Niu, M; Peng, L; Rodriguez, BL; Valdes, S | 1 |
| du Bois, A; Grabowski, JP; Harter, P; Heitz, F; Heitz, J; Kristensen, G; Pfisterer, J; Pujade-Lauraine, E; Ray-Coquard, I; Reuss, A; Traut, A | 1 |
| Fujiwara, K; Hanaoka, T; Hasegawa, K; Iwasa, N; Kurosaki, A; Nagao, S; Nishikawa, T | 1 |
| Gehrig, PA; Kim, KH; Milam, B; Palisoul, M; Raker, C; Robison, K; Roque, DR; Taylor, KN; Wysham, WZ | 1 |
| Chang, DT; Chiu, W; Heestand, G; Hellendag, MG; Koong, AC; Moore, MJ; Ng, K; Pai, J; Parulekar, WR; Shultz, DB; Tu, D | 1 |
| Amoh, Y; Masuzawa, M; Takasu, H | 1 |
| Cho, BC; Heo, SJ; Jeong, J; Jung, I; Kim, HR; Kim, JH; Lee, CK; Lim, SM; Moon, YW; Shim, HS | 1 |
| Beck, JT; Berdov, BA; Devoe, CE; Dychter, S; Gladkov, OA; Harris, WP; Hingorani, SR; Holcombe, RF; Jiang, P; Korn, R; Pshevlotsky, EM; Raghunand, N; Shepard, HM; Tjulandin, SA; Wagner, SA | 1 |
| Büning, C; Jürgensen, C; Mitroshkin, A; Prager, M; Schachschal, G; Voderholzer, W; Wentrup, R; Winkelmann, N | 1 |
| Li, Y; Liu, J; Liu, Y; Qin, S; Su, F; Wang, R; Wang, Z; Wu, Q; Yang, Y; Zhao, F | 1 |
| Kim, JH; Kim, SJ; Lee, J | 1 |
| Cavalcante, LC; Domingues, RZ; Fabris, JD; Ferreira, RV; Goes, AM; Martins, TM; Outon, LE | 1 |
| Kohane, DS; Li, L; Li, M; Tong, R | 1 |
| Abramovici, O; Carlos Molano, L; Cuvelier, A; Darmon, A; Duval-Modeste, AB; Louvel, JP; Muir, JF; Piton, N | 1 |
| Abukiwan, A; Amponsah, PS; Bauer, N; Fan, P; Gao, C; Gladkich, J; Gross, W; Herr, I; Liu, L; Nwaeburu, CC; Schemmer, P; Xiao, X; Yin, Y; Zhang, Y; Zhao, Z | 1 |
| Bastiancich, C; Bastiat, G; Danhier, F; Lagarce, F; Pitorre, M; Préat, V; Ucakar, B; Vanvarenberg, K | 1 |
| Itoi, T; Kamisawa, T; Takaori, K; Wood, LD | 1 |
| Buchsbaum, D; Grizzle, W; Hidalgo, M; Kim, H; Kovar, J; Lopez-Casas, P; Oelschlager, D; Samuel, S; Warram, J; Zinn, K | 1 |
| Broussolle, C; Gerfaud-Valentin, M; Guillet, M; Noel, A; Pouteil-Noble, C; Rogier, T; Sève, P; Taleb, A | 1 |
| Cassano, R; Loizzo, MR; Mellace, S; Menichini, F; Picci, N; Trombino, S; Tundis, R | 1 |
| Chan, KW; Chen, H; Li, Y; Liu, G; Luo, L; McMahon, MT; van Zijl, PC; Vogelstein, B; Xu, J; Yadav, NN; Zhou, S | 1 |
| Pourjavadi, A; Tehrani, ZM | 1 |
| Cong, M; Li, H; Liu, B; Lu, A; Wang, C; Xu, W; Xu, X; Yin, J; Zhuang, B | 1 |
| Furuse, J; Ikeda, M; Ioka, T; Mizuno, N; Nakajima, TE; Omuro, Y; Ueno, H; Ueno, M | 1 |
| Hirooka, S; Inoue, K; Kon, M; Kotsuka, M; Matsui, Y; Michiura, T; Ryota, H; Satoi, S; Tsuta, K; Yamaki, S; Yamamoto, T; Yanagimoto, H | 1 |
| Anajafi, T; Choi, Y; Mallik, S; Qian, SY; Scott, MD; Yang, X; You, S | 1 |
| Hasumi, K; Imaizumi, A; Kawamoto, M; Morisaki, T; Onishi, H; Umebayashi, M; Yamasaki, A | 1 |
| Ardito, F; Autorino, R; Balducci, M; Deodato, F; Gambacorta, MA; Giuliante, F; Macchia, G; Mantini, G; Mattiucci, GC; Morganti, AG; Perri, V; Tagliaferri, L; Tringali, A; Valentini, V | 1 |
| Betz, BL; Camelo-Piragua, S; Cao, Y; Heth, J; Junck, L; Kim, CJ; Kim, MM; Lawrence, TS; Mammoser, A; Normolle, D; Sagher, O; Schipper, M; Tao, Y; Tsien, CI | 1 |
| Atallah, JP; Garcia, G | 1 |
| Cao, L; Chen, L; Hu, X; Liu, M; Yao, G; Ye, C | 1 |
| Bockhorn, M; Brockmöller, J; Gaedcke, J; Ghadimi, BM; Güngör, C; Hackert, T; Hank, T; Haubrock, M; Izbicki, JR; Johnsen, SA; Lüske, CM; Pflüger, R; Rapp, J; Roppel, S; Schaudinn, A; Schirmer, MA; Strobel, O; Werner, J; Zimmer, C | 1 |
| Afghani, R; Azarhoush, R; Hajimohammadi, A; Kazemi-Nejad, V; Rezapour Esfahani, M; Yari, B | 1 |
| Bhagwandin, VJ; Bishop, JM; Shay, JW; Wright, WE | 1 |
| Anazawa, T; Doi, R; Ito, T; Kawaguchi, Y; Masui, T; Nakano, K; Sato, A; Takaori, K; Uemoto, S | 1 |
| Barton, S; Begum, R; Braconi, C; Chau, I; Cunningham, D; Fassan, M; Guzzardo, V; Hawkins, M; Khan, K; Oates, J; Peckitt, C; Rao, S; Starling, N; Tait, D; Thomas, J; Watkins, D | 1 |
| Fahmy, O; Fend, F; Feyerabend, S; Gakis, G; Scharpf, M; Schubert, T; Schwentner, C; Stenzl, A | 1 |
| Aljarah, AK; Han, B; Ide, H; Inoue, S; Kashiwagi, E; Kawahara, T; Li, Y; Miyamoto, H; Patterson, JD; Shareef, HK; Zheng, Y | 1 |
| Benepal, T; Cadranel, J; Christoph, DC; Das, M; Fennell, DA; Ferry, D; Lal, R; Maxwell, F; Summers, Y; Visseren-Grul, C | 1 |
| Haddock, MG; Hallemeier, CL; Harmsen, WS; Kendrick, ML; Merrell, KW; Miller, RC; Quevedo, JF | 1 |
| Assadi, RK; Dholakia, AS; Ellsworth, SG; Ford, E; Grossman, SA; Hacker-Prietz, A; Herman, JM; Jaffee, EM; Laheru, DA; Lu, Y; Moningi, S; Pawlik, TM; Rosati, LM; Saeed, AM; Tran, PT; Weiss, MJ; Wild, AT; Wolfgang, CL; Ye, X | 1 |
| Gao, X; Liao, Q; Liu, Q; Niu, Z; Wang, M; Yao, L; Zhao, Y; Zhou, L | 1 |
| Dong, M; Gui, L; He, XH; Li, YX; Liu, P; Shi, YK; Wang, JJ; Wang, WH; Yang, JL; Yang, S; Zhang, CG; Zhou, SY | 1 |
| Cherubini, G; Halldén, G; Lemoine, NR; Pantelidou, C | 1 |
| Chen, CC; Teng, CL; Yeh, SP | 1 |
| Dai, B; Fleming, JB; Kang, Y; Li, X; Pratt, M; Roife, D | 1 |
| Anastasia, A; Angelucci, E; Annechini, G; Balzarotti, M; Bonfichi, M; Botto, B; Brusamolino, E; Carella, AM; Congiu, A; Giordano, L; Gotti, M; Magagnoli, M; Massidda, S; Mazza, R; Merli, F; Murru, R; Re, A; Rodari, M; Russo, E; Salvi, F; Santoro, A; Spina, M; Stelitano, C; Vitolo, U; Zilioli, VR | 1 |
| Li, Y; Liao, Q; Liu, Q; Lu, Z; Niu, Z; Wang, M; Yao, L; Zhao, Y; Zong, Y | 1 |
| Honda, H; Kamada, T; Saisho, H; Shinoto, M; Shioyama, Y; Terashima, K; Tsujii, H; Yamada, S; Yasuda, S | 1 |
| Audigier-Valette, C; Auliac, JB; Baize, N; Bérard, H; Bota, S; Chouaïd, C; Corre, R; Dansin, E; Daurès, JP; Decroisette, C; Descourt, R; Dujon, C; Falchero, L; Greillier, L; Lamy, R; Le Caër, H; Léna, H; Marcq, M; Massuti, B; Monnet, I; Pérol, M; Plassot, C; Vergnenègre, A | 1 |
| Ames, P; Berlin, J; Catalano, PM; Cohen, SJ; Davies, A; Horan, J; Leichman, L; McKinley, M; O'Neil, BH; Weekes, CD | 1 |
| Fuchs, JR; He, F; Highfill, CA; Ji, M; Li, K; Li, L; Lian, J; Lin, J; Marquez, RT; Tang, W; Wu, X; Xu, L | 1 |
| Alborzinia, H; Cheng, X; Duvaci, T; Eisenbrand, G; Fredebohm, J; Ghafoory, S; Hafezi, M; Hoheisel, JD; Holenya, P; Kim, JY; Mehrabi, A; Merz, KH; Rafiee, R; Saffari, A; Theobald, J; Wölfl, S | 1 |
| Cuneo, KC; Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Tanska, DM; Zabludoff, SD | 1 |
| Ahmad, N; Karki, A; Kong, Y; Konieczny, SF; Li, J; Liu, X; Schweickert, PG; Wang, R; Yang, Y | 1 |
| He, J; Li, Z; Qian, J; Wang, X; Xu, P; Yao, J; Zhao, L | 1 |
| Adachi, S; Doi, S; Hirose, Y; Iwashita, T; Kawaguchi, J; Kozawa, O; Moriwaki, H; Nakashima, M; Okuno, M; Shimizu, M; Yasuda, I; Yoshimi, N | 1 |
| Alvarez, R; Caruso, R; Diaz, E; Duran, H; Fabra, I; Ferri, V; Hidalgo, M; Ielpo, B; Malavé, L; Plaza, C; Quijano, Y; Vicente, E | 1 |
| Chang, T; Egawa, N; Honda, G; Kamisawa, T; Karasawa, K; Kobayashi, S; Kurata, M; Okuda, Y; Omuro, Y; Sakamoto, K; Tsuruta, K | 1 |
| Aggarwal, BB; Gupta, SC; Prasad, S; Sung, B; Tyagi, AK; Yadav, VR | 1 |
| Carrassa, L; Falcetta, F; Lupi, M; Ubezio, P | 1 |
| Beare, S; Bridgewater, J; Duggan, M; Lee, D; Lopes, A; McEntee, D; Ricamara, M; Sukumaran, A; Valle, JW; Wasan, H | 1 |
| Aiba, K; Hayashi, K; Homma, S; Ito, M; Kamata, Y; Kan, S; Nagasaki, E | 1 |
| Ahn, DW; Chai, JW; Chun, JY; Kim, YA; Lee, JM; Shin, K | 1 |
| Gan, ZH; Han, K; Hu, HY; Li, KP; Lin, SC; Liu, Y; Lu, ZG; Min, DL; Tseng, KF; Zhao, RH; Zhou, Y | 1 |
| Hanvoravongchai, P; Havanond, P; Khempech, N; Luealon, P; Vasuratna, A | 1 |
| Huang, S; Li, Q; Liu, Z; Miao, X; Ouyang, G; Wen, Y; Xiong, L | 1 |
| Ben Shem, E; Ben Zvi, M; Levy, T; Menczer, J; Peled, O; Schreiber, L; Vaknine, H | 1 |
| Adams, DJ; Bansal, V; Kota, R; Kulhari, H; Pooja, D; Reddy, TS; Shukla, R; Sistla, R; Tabor, RF | 1 |
| Costello, E; Cox, T; Ghaneh, P; Greenhalf, W; Middleton, G; Neoptolemos, JP; Palmer, DH; Shaw, V | 1 |
| Chen, X; Duan, X; He, J; He, K; Huang, R; Xia, Z; Xiang, G; Xiao, J; Zhang, J; Zhou, W | 1 |
| Ezaki, T; Kikuchi, E; Matsumoto, K; Mizuno, R; Morita, S; Oya, M; Shinoda, K | 1 |
| Donahue, TR; Gifford, JB; Hill, R; Hindoyan, A; Huang, W; Wu, H; Zeleniak, AE | 1 |
| Mantripragada, KC; Safran, H | 1 |
| Aarons, L; Mistry, H; Ogungbenro, K; Wendling, T | 1 |
| Bakirhan, K; Cheng, H; Perez-Soler, R; Sharma, J | 1 |
| Borowa-Mazgaj, B | 1 |
| Brody, JR; Daum, GS; DuHadaway, JB; Dunton, CJ; Furuuchi, N; Huang, YH; Jimbo, M; Leiby, BE; Peng, W; Pirritano, A; Sawicki, JA | 1 |
| Epperla, N; Strouse, C | 1 |
| Culine, S; Kránitz, N; Kullmann, T; Pintér, T; Szepesvári, Z | 1 |
| Hattori, Y; Inayama, Y; Ishida, H; Kawahara, T; Kondo, T; Kumano, Y; Maeda, Y; Miyoshi, Y; Mochizuki, T; Ohtaka, M; Teranishi, J; Uemura, H; Yao, M; Yumura, Y | 1 |
| Feng, X; Fu, X; Guo, C; He, W; Hu, X; Pu, K; Wen, S | 1 |
| Besselink, MG; Boerma, D; Bonsing, BA; Busch, OR; de Hingh, IH; de Vos-Geelen, J; Dohmen, MA; Erdmann, JI; Festen, S; Groothuis, KB; Klaase, JM; Molenaar, IQ; Patijn, GA; Punt, CJ; Rasch, CR; Suker, M; Ten Tije, AJ; van der Harst, E; van der Kolk, MB; van Eijck, CH; van Tienhoven, G; Versteijne, E; Zwinderman, AH | 1 |
| Bae, SH; Baek, JH; Choi, Y; Jo, JC; Joo, YD; Kim, DY; Kim, H; Lee, JH; Lee, JL; Lee, KH; Lee, WS; Ryoo, HM | 1 |
| Hou, W; Lin, HS; Liu, J; Wang, XQ | 1 |
| Barile, E; Das, SK; De, SK; Emdad, L; Fisher, PB; Morvaridi, SK; Pandol, SJ; Pellecchia, M; Quinn, BA; Sarkar, D; Stebbins, JL; Wang, S | 1 |
| Buczkowski, AK; Chung, SW; Kozlowski, P; Kyle, AH; Minchinton, AI; Ng, SS; Owen, DA; Scudamore, CH; Tso, J; Valdez, SM; Wong, MQ; Yapp, DT; Yung, A | 1 |
| Berns, A; Bianchi, ME; Boldorini, R; Ceriotti, C; Crippa, L; Crippa, MP; D'Incalci, M; de Vries, H; Doglioni, C; Frapolli, R; Frenquelli, M; Gatti, E; Marchis, FD; Mezzapelle, R; Moresco, RM; Pecciarini, L; Perani, L; Preti, A; Recordati, C; Rrapaj, E; Scanziani, E; Spinelli, AE; Valtorta, S; Venturini, M | 1 |
| Costantini, M; Di Leone, A; Ferrucci, M; Franceschini, G; Masetti, R; Mulè, A; Sanchez, AM; Scaldaferri, A | 1 |
| Altaf, K; He, D; Ke, N; Li, A; Liu, X; Tan, C; Tang, J; Wang, Y; Xiong, J; Zhang, H | 1 |
| Nepple, KG; O'Donnell, MA; Steinberg, RL; Thomas, LJ; Velaer, KN | 1 |
| Chen, IC; Hung, MS; Jablons, DM; Li, YC; Liu, ST; Lung, JH; Mao, JH; Xu, Z; Yang, CT; You, L | 1 |
| Chapuy, CI; Kozyreva, ON; Sahai, I; Sharma, R; Zhu, AX | 1 |
| Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Nieto, Y; Teo, EC; Valdez, BC | 1 |
| Aoyama, T; Atsumi, Y; Kobayashi, S; Miyagi, Y; Morimoto, M; Morinaga, S; Murakawa, M; Nakamura, Y; Ueno, M; Yamaoku, K; Yokose, T | 1 |
| Bikhchandani, M; Dawson, DW; Donahue, TR; Duong, M; Gawlas, I; Kadera, BE; Li, L; Nguyen, AH; Patel, SG; Toste, PA; Tran, LM; Wu, N | 1 |
| Andersson, BS; Brammer, JE; Champlin, RE; Hosing, C; Ji, J; Li, Y; Liu, Y; Nieto, Y; Teo, EC; Valdez, BC | 1 |
| Bonomi, P; Brown, J; Chouaki, N; Dediu, M; Gralla, RJ; Losonczy, G; Luft, A; Molinier, O; Obasaju, C; Peterson, P; Ramlau, R; Reck, M; Schumann, C; Socinski, MA; Soldatenkova, V; Szczęsna, A; Thatcher, N | 1 |
| Dutta, R; Karaca, M; Mahato, RI; Ozsoy, Y | 1 |
| Chen, Y; Li, C; Liu, X; Wang, X; Yang, X; Zhou, G | 1 |
| Kim, JK; Park, JS; Yoon, DS | 1 |
| Li, J; Lu, J; Qi, H; Wang, M; Wang, Y; Xu, Y; Zhang, H | 1 |
| Agelaki, S; Filippa, G; Georgoulias, V; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Mala, A; Mavroudis, D; Moutsos, M; Syrigos, K; Vamvakas, L; Ziras, N | 1 |
| Chio-Srichan, S; Hahnvajanawong, C; Heraud, P; Jearanaikoon, P; Leelayuwat, C; Limpaiboon, T; Tippayawat, P; Wongwattanakul, M | 1 |
| Augustyn, M; Grys, I; Iwaniec-Karlikowska, E | 1 |
| Ai, J; Algül, H; Barenboim, M; Campbell, A; Demir, IE; Diakopoulos, KN; Doglioni, C; Görgülü, K; Hagemann, T; Jodrell, D; Karpathaki, AP; Kurkowski, MU; Lesina, M; Neesse, A; Protti, MP; Rose-John, S; Ruess, D; Sansom, O; Schmid, RM; Song, L; Wörmann, SM | 1 |
| Ciccolini, J; Giovannetti, E; Peters, GJ; Serdjebi, C | 1 |
| Hu, XC; Li, T; Tao, ZH; Wu, ZH; Xie, J; Zhang, J; Zhang, JF; Zhao, J | 1 |
| Chen, N; Fang, W; Hu, Z; Huang, J; Quan, R; Zhan, J; Zhang, H; Zhang, L; Zhou, T | 1 |
| Li, D; O'Reilly, EM | 1 |
| Cheng, S; Coakley, N; Ellis, PM; Gregg, R; Kulkarni, S; Ung, YC; Vella, ET | 1 |
| Bowman, L; John, W; Liepa, AM; Melemed, A; Peterson, P; Shen, W; Smyth, EN | 1 |
| AlMalik, AM; Alsaiari, S; Croissant, JG; Deng, L; Khashab, NM; Lu, J; Tamanoi, F; Zhang, D; Zink, JI | 1 |
| Chen, Y; Cheng, K; Li, ZK; Li, ZP; Liu, JY; Yang, Y | 1 |
| Li, Z; Lu, L; Sun, Z; Wang, Y; Zhang, M; Zhang, X; Zhou, Z | 1 |
| Fukuda, H; Furuse, J; Ishii, H; Katayama, H; Mizusawa, J; Morizane, C; Okusaka, T | 1 |
| Dearnaley, D; Hafeez, S; Hansen, VN; Harris, V; Horwich, A; Huddart, R; Jones, K; Khan, A; Kumar, P; Lalondrelle, S; McDonald, F; McNair, HA; Mohammed, K; Tan, M; Thomas, K; Thompson, A; Warren-Oseni, K | 1 |
| Aglietta, M; Calogero, R; De Simone, M; Di Renzo, MF; Erriquez, J; Katsaros, D; Mittica, G; Olivero, M; Ponzone, R; Scalzo, MS; Vaira, M; Valabrega, G | 1 |
| Baldwin, GS; Beutler, JA; He, H; Huynh, N; Nikfarjam, M; Yeo, D | 1 |
| Endo, S; Gosho, M; Hyodo, I; Kobayashi, M; Moriwaki, T; Sugaya, A; Yamada, T; Yamamoto, Y | 1 |
| Barbera, MA; Biasco, G; Brandi, G; Cescon, M; Cucchetti, A; D'Errico-Grigioni, A; de Lorenzo, S; Degiovanni, A; Deserti, M; Di Marco, M; Ercolani, G; Farioli, A; Frega, G; Garajova, I; Palloni, A; Pantaleo, MA; Pinna, AD; Tavolari, S; Vasuri, F | 1 |
| Fan, Y; Gan, Y; Gu, J; Li, G; Tu, H; Wang, Q; Wu, Y; Yao, M; Yuan, H; Zhang, J | 1 |
| Chan, AL; Leung, HW; Muo, CH | 1 |
| Ahn, HK; Cho, EK; Choi, SJ; Hong, J; Kim, YS; Lee, JH; Park, I; Park, J; Shin, DB; Shin, YJ; Sym, SJ | 1 |
| Ishiwata, T; Matsuda, Y; Matsushita, A; Naito, Z; Nakamura, Y; Sumiyoshi, H; Uchida, E | 1 |
| Ding, X; Li, H; Zhang, Z; Zhou, G; Zhou, Z | 1 |
| Abnous, K; Alibolandi, M; Hadizadeh, F; Ramezani, M | 1 |
| Akise, Y; Hashimoto, S; Kutsuki, S; Miyazawa, M; Nishimoto, K; Uchida, A | 1 |
| Du, L; Jin, Y; Lei, Y; Wang, S; Zhang, B | 1 |
| Alothman, S; Alqunaibit, D; Avanzi, A; Barilla, R; Daley, D; Engle, D; Giao Ly, NN; Greco, SH; Hajdu, C; Hundeyin, M; Mani, VR; Miller, G; Ochi, A; Pansari, M; Pergamo, M; Rendon, M; Seifert, L; Tippens, D; Tiwari, S; Torres-Hernandez, A; Werba, G; Zambirinis, CP | 1 |
| Azzi, L; Bachet, JB; Bartholin, L; Bernard, D; Cros, J; de la Fouchardière, C; Dubus, P; Gout, J; Griveau, A; Guitton, J; Le Calvé, B; Maréchal, R; Payen, L; Svrcek, M; Vindrieux, D; Wiel, C | 1 |
| Chen, H; Li, Q; Tang, R; Wen, F; Wu, Y; Zhang, J; Zhang, P; Zhao, R; Zhou, J | 1 |
| Guan, J; Li, H; Tong, DN; Zhang, ZY; Zhou, GW; Zhou, ZQ | 1 |
| Frank, H; Kitzwögerer, M; Moser, M; Wiedemann, D | 1 |
| Chang, Y; Cui, Y; Fu, X; Li, L; Li, W; Li, X; Ma, W; Nan, F; Su, L; Sun, Z; Wang, J; Wang, X; Wu, J; Xue, H; Zhang, L; Zhang, M; Zhang, X | 1 |
| Arumugam, P; Bapiro, TE; Carapuça, EF; Delvecchio, FR; Feig, C; Gemenetzidis, E; Grose, RP; Kocher, HM; Lemoine, NR; Richards, FM; Williams, MD; Wilson, AS | 1 |
| Andrikou, K; Bianconi, M; Bittoni, A; Brunetti, O; Casadei Gardini, A; Cascinu, S; Del Prete, M; Dessì, A; Faloppi, L; Giampieri, R; Lai, E; Santini, D; Scartozzi, M; Silvestris, N; Valgiusti, M | 1 |
| Alousi, AM; Anderlini, P; Champlin, RE; Fanale, MA; Hagemeister, FB; Hosing, CM; Khouri, IF; Ledesma, C; Neelapu, S; Nieto, Y; Oki, Y; Plair, T; Popat, UR; Romaguera, JE; Saliba, RM; Shpall, EJ; Younes, A | 1 |
| Bekaii-Saab, T; El-Rayes, BF; Flowers, CR; Goldstein, DA; Krishna, K; Noonan, AM | 1 |
| Endou, M; Nagamori, S; Takada, S; Tamaki, S | 1 |
| Hori, K; Ito, K; Miyagi, K; Murakami, J; Nakagawa, M; Okubo, R; Shiomi, M; Tashima, R; Tsuruta, T; Uragami, K; Yoshioka, E | 1 |
| Kinoshita, A; Koike, K; Koyama, M; Nishino, H; Tanaka, K | 1 |
| Abramian, A; Arden, JM; Ayub, TH; Doeser, A; Hecking, T; Hoeller, T; Kaiser, C; Keyver-Paik, MD; Kuhn, W; Lüders, C; Thiesler, T | 1 |
| Asai, K; Asayama, Y; Honda, H; Matsumoto, K; Nakamura, K; Nishie, A; Ohga, S; Sasaki, T; Shinoto, M; Shioyama, Y; Terashima, K; Yoshitake, T | 1 |
| Boeck, S; Haas, M; Heinemann, V; Kruger, S; Westphalen, CB | 1 |
| Argnani, L; Chiappella, A; Corradini, P; Degl'Innocenti, D; Dodero, A; Monaco, F; Pellegrini, C; Salvi, F; Vitolo, U; Zinzani, PL | 1 |
| Huang, HQ; Jiang, WQ; Lu, Y; Wang, H; Wang, JH; Wang, YJ; Xia, ZJ | 1 |
| Chang, MH; Chen, MH; Cheng, CT; Chiang, KC; Chung, YH; Huang, SC; Liu, CY; Su, Y; Weng, JJ; Wu, CE; Wu, RC; Yeh, CN; Yeh, TS | 1 |
| Dong, M; Gui, L; He, X; Hu, S; Jia, B; Lin, H; Liu, P; Qin, Y; Shi, Y; Sun, Y; Wang, L; Xing, P; Yang, J; Yang, S; Zhang, C; Zhou, L; Zhou, S | 1 |
| Couture, F; Dowden, S; El-Maraghi, R; Kennecke, H; Lesperance, B; Letourneau, R; Liu, H; Romano, A; Tehfe, M | 1 |
| Grimes, DR; Harris, A; Kannan, P; Kavanagh, A; McIntyre, A; Partridge, M; Siddiky, A; Wigfield, S | 1 |
| Endlicher, E; Gelbmann, C; Klebl, F; Kullmann, F; Messmann, H; Rogler, G; Schnoy, E; Troppmann, M | 1 |
| Anderlini, P; Cheah, CY; Chihara, D; Fanale, MA; Fayad, LE; Fowler, NH; Hagemeister, FB; Horowitz, S; Nastoupil, LJ; Neelapu, SS; Nieto, Y; Oki, Y; Rodriguez, MA; Romaguera, JE; Samaniego, F; Sevin, A; Turturro, F; Wang, M; Westin, JR; Zhou, S | 1 |
| Huang, HQ; Jiang, WQ; Lin, TY; Liu, CC; Lu, Y; Wang, JH; Wang, L; Xia, ZJ | 1 |
| Apers, S; Capistrano, R; Dockx, Y; Lardon, F; Pauwels, P; Pieters, L; Staelens, S; Stroobants, S; Vangestel, C; Wouters, A | 1 |
| Andorsky, D; Beck, JT; Belada, D; Dakhil, S; Daly, R; Dean, JP; Failloux, N; Georgiev, P; Hübel, K; Inhorn, LF; Pavlyuk, M; Pettengell, R; Quick, D | 1 |
| Asaftei, S; Cesari, M; Coccoli, L; Fagioli, F; Ferrari, S; Grignani, G; Jones, RL; Longhi, A; Marchesi, E; Meazza, C; Paioli, A; Palmerini, E; Picci, P; Pollack, SM; Tamburini, A | 1 |
| Fang, W; Tian, Y; Xue, C; Zhan, J; Zhang, J; Zhang, L; Zhao, Y | 1 |
| Chayahara, N; Imamura, Y; Kiyota, N; Kotake, T; Minami, H; Mukohara, T; Nishimura, M; Saito, K; Saito, Y; Takenaka, K; Toyoda, M; Tsuji, A | 1 |
| Han, NK; Jang, CY; Kim, JS; Shin, DH; Weon, KY | 1 |
| Chong, S; Han, YH; Kim, HJ; Kim, JW; Kim, MH; Lee, HR; Shin, SH; Sohn, KY; Yoo, N; Yoon, SY | 1 |
| Chan-On, W; Huyen, NT; Prachayasittikul, V | 1 |
| Arpicco, S; Berlier, G; Blandino, G; Bottinelli, E; Malfanti, A; Miletto, I; Zonari, D | 1 |
| Blake, A; Hayes, JP; Helenowski, I; Huang, J; Kim, T; McGinn, CJ; Mulcahy, M; Rakhra, S; Robertson, J; Small, W; Strauss, JB | 1 |
| Lee, HS; Park, SW | 1 |
| Beesetti, S; Bhoopalan, H; Biswal, J; Chidambaram, S; Jagadeeshan, S; Jeyaraman, J; Malathi, R; Mavuluri, J; Nair, AS; Pitani, RS; Raghavan, S; Rayala, SK; Singhal, M; Subramanian, A; Sundaram, S; Surabhi, RP; Tentu, S; Venkatraman, G | 1 |
| Caparello, C; Falcone, A; Fornaro, L; Vasile, E; Vivaldi, C | 1 |
| Bachet, JB; Pernot, S; Portal, A; Taieb, J | 1 |
| Fimiani, M; Garosi, G; Rongioletti, F; Rubegni, P; Tognetti, L | 1 |
| Katata, Y; Okawaki, M; Sawaki, A; Yamaguchi, Y; Yamamura, M | 1 |
| Akaike, M; Godai, T; Higuchi, A; Katayama, Y; Masuda, M; Morinaga, S; Numata, K; Numata, M; Rino, Y; Sawazaki, S; Shiozawa, M | 1 |
| Bastiat, G; Benoit, JP; Bronte, V; Lollo, G; Mandruzzato, S; Marigo, I; Pinton, L; Pitorre, M; Sasso, MS; Solito, S; Valpione, S | 1 |
| Enas, NH; Friberg, LE; Gueorguieva, I; Zecchin, C | 1 |
| Chao, Y; Chen, JS; Chen, LT; Chen, MH; Chiang, NJ; Hsu, C; Huang, SF; Shan, YS; Shen, YY; Tsou, HH; Yeh, TS | 1 |
| André, T; Artru, P; Bonnetain, F; Borbath, I; Bouché, O; Chibaudel, B; Glimelius, B; Goldstein, D; Hammel, P; Huguet, F; Louvet, C; Mineur, L; Shannon, J; van Laethem, JL | 1 |
| Pekyardımcı, Ş; Tığ, GA; Zeybek, B | 1 |
| Einecke, D | 1 |
| Allen, P; Beumer, BR; Chau, I; Conroy, T; El-Rayes, BF; Faris, JE; Hohla, F; Hong, TS; Hosein, PJ; Koerkamp, BG; Lacy, J; Marthey, L; Mellon, EA; Moorcraft, SY; Sadot, E; Shridhar, R; Suker, M; Taieb, J; van Eijck, CH; Wang-Gillam, A | 1 |
| Koide, S; Matsuo, Y; Morimoto, M; Saito, K; Sato, T; Shamoto, T; Takahashi, H; Takeyama, H; Tsuboi, K | 1 |
| Giese, T; Klein, K; Schenk, M; Teske, C; Weitz, J; Welsch, T; Werner, K | 1 |
| Camara, SN; Cao, B; Duan, Q; Shen, Q; Shi, P; Wang, C; Yin, T; Zhang, Z; Zhao, H | 1 |
| Avan, A; Boggi, U; Funel, N; Giovannetti, E; Leon, LG; Peters, GJ; Vistoli, F | 1 |
| Hartley, JA; Hochhauser, D; Vena, F | 1 |
| Gunduz, U; Mutlu, P; Parsian, M; Tezcaner, A; Unsoy, G; Yalcin, S | 1 |
| Ahmad, A; AlKharfy, KM; Banerjee, R; Dutta, SK; Jinka, S; Mondal, SK; Mukhopadhyay, D; Nelli, S; Pal, K; Wang, E | 1 |
| Chin, AI; Huang, J; Lee, J; Li, G; Peek, EM; Pellegrini, M; Prado, K; Wang, X; Zhang, H; Zhang, KX | 1 |
| Ebata, T; Igami, T; Mizuno, T; Nagino, M; Sugawara, G; Yamaguchi, J; Yokoyama, Y | 1 |
| Ahn, HS; Baek, HJ; Cho, WH; Choi, HS; Im, HJ; Jeon, DG; Kang, HJ; Koh, KN; Koo, HH; Kook, H; Lee, JA; Lee, JW; Lim, YJ; Park, BK; Park, HJ; Park, KD; Seo, JJ; Shin, HY; Song, WS; Sung, KW; Yoo, KH; Yoon, HS | 1 |
| Alexander, HR; Bergmann, F; Bernhardt, M; Funamizu, N; Gaedcke, J; Gaida, MM; Ghadimi, BM; Hanna, N; He, P; Hussain, SP; Ried, T; Satoskar, AR; Schetter, A; Tang, W; Uwagawa, T; Wang, J; Werner, J; Yanaga, K; Yang, S | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Bashir, Q; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shah, N; Shpall, EJ; Thall, PF; Valdez, BC; Wei, W | 1 |
| Bastiere-Truchot, L; Berton-Rigaud, D; Colombo, N; Del Campo, JM; du Bois, A; Gadducci, A; García, Y; González-Martín, A; Kiermaier, A; Kurzeder, C; Mahner, S; Marmé, F; Martin, N; Ortega, E; Ottevanger, P; Pautier, P; Rau, J; Selle, F | 1 |
| Hirsch, FR; Hozak, RR; Kurek, R; Paz-Ares, L; Shahidi, J; Socinski, MA; Soldatenkova, V; Thatcher, N; Varella-Garcia, M | 1 |
| Chan, DE; Freeman, JW; Ghosh, R; Gong, J; Kumar, AP; Muñoz, AR; Payton-Stewart, F; Pingali, S | 1 |
| Wang, BZ; Yu, ZG | 1 |
| Armbrecht, N; Brooks, J; Calvisi, DF; Ceyhan, GO; Demir, IE; Dombrowski, F; Esposito, I; Fleischmann-Mundt, B; Gürlevik, E; Kleine, M; Kloos, A; Kubicka, S; Kühnel, F; Manns, MP; Oettle, H; Ostroumov, D; Ribback, S; Saborowski, M; Steiger, K; Wirth, TC; Woller, N; Yevsa, T | 1 |
| Goel, M; Gupta, S; Jandyal, S; Ostwal, V; Pande, N; Patkar, S; Ramadwar, M; Ramaswamy, A; Sahu, A; Shetty, N | 1 |
| Higa, T; Hyakuna, N; Iraha, S; Kinjyo, T; Kuroda, N; Matsuda, T; Miyazato, Y; Nakama, T; Nakazato, I; Oshiro, K | 1 |
| Grapsa, D; Passero, FC; Saif, MW; Syrigos, KN | 1 |
| Higuchi, Y; Kato, H; Kinoshita, T; Nakamura, S; Saito, T; Taji, H; Yamamoto, H; Yamamoto, K; Yatabe, Y | 1 |
| Chiao, PJ; Fan, XQ; Ju, HQ; Li, H; Lu, YX; Mo, HY; Sheng, H; Tian, T; Xu, RH; Zhou, HJ; Zhuang, ZN | 1 |
| Almorsy, W; Elshebeiny, M | 1 |
| Jing, XM; Li, L; Luo, L; Ren, YR; Wei, W; Wu, P; Xiong, ZJ; Zhang, SC; Zhang, ZH | 1 |
| Akahoshi, K; Ban, D; Kirimura, S; Kudo, A; Matsumura, S; Minoru, T; Mitsunori, Y; Oba, A; Ochiai, T; Tanaka, S | 1 |
| Chen, K; Lin, W; Liu, J; Tong, J; Ye, H; Zhang, C; Zhao, J; Zhu, W | 1 |
| Bauer, N; Fan, P; Gao, C; Gladkich, J; Gross, W; Herr, I; Liu, L; Mattern, J; Schemmer, P; Xiao, X; Yin, Y; Zhang, Y; Zhao, Z | 1 |
| Albany, C; Bihrle, R; Cary, KC; Cheng, L; Cho, JS; Foster, RS; Gellhaus, PT; Hahn, NM; Kaimakliotis, HZ; Koch, MO; Masterson, TA; Monn, MF; Pedrosa, JA | 1 |
| Dai, B; Fleming, JB; Kang, Y; Li, X; Perez, MVR; Pratt, M; Roife, D | 1 |
| Cuderman, A; Doma, A; Grmek, M; Kern, I; Kovac, V; Rajer, M; Stanic, K; Vrankar, M; Zwitter, M | 1 |
| Hirooka, S; Inoue, K; Kon, M; Matsui, Y; Michiura, T; Miyasaka, C; Ohe, C; Ryota, H; Satoi, S; Tanigawa, N; Uemura, Y; Yamaki, S; Yamamoto, T; Yanagimoto, H | 1 |
| Futamata, Y; Noguchi, J; Okabe, M; Yoshida, A | 1 |
| Boku, N; Fukutomi, A; Hirano, S; Hishinuma, S; Imai, K; Kainuma, O; Kaneoka, Y; Konishi, M; Matsumoto, I; Morinaga, S; Nakamori, S; Ohashi, Y; Ojima, H; Okamura, Y; Sakamoto, H; Sata, N; Shimizu, Y; Sudo, T; Uesaka, K; Yamaguchi, R | 1 |
| Bailey, P; Balkwill, F; Barry, ST; Biankin, AV; Bryson, S; Candido, JB; Carter, CR; Chang, DK; Clarke, M; Connelly, J; Eberlein, C; Evans, TRJ; Foth, M; Jamieson, N; Karim, SA; Leach, JDG; McDaid, K; Morton, JP; Nibbs, RJB; Nixon, C; Rishi, L; Sansom, OJ; Steele, CW; Strathdee, D; Upstill-Goddard, R; Wilson, Z | 1 |
| Chang, K; Chen, C; Freeman, JW; Jagirdar, J; Karnad, A; Kumar, AP; Zhao, S | 1 |
| Hoang, NT; Kadonosono, T; Kizaka-Kondoh, S; Kuchimaru, T | 1 |
| Green, JE; He, S; Min, DJ | 1 |
| Date, K; Fujimoto, T; Kimura, H; Matsunaga, T; Miyasaka, Y; Mochidome, N; Mori, Y; Nakamura, M; Oda, Y; Ohtsuka, T | 1 |
| Cavallaro, G; Celia, C; Cosco, D; Fresta, M; Giammona, G; Licciardi, M; Mauro, N; Paolino, D | 1 |
| Arber, N; Kazanov, D; Pleban, S; Shapira, S; Tirosh, P | 1 |
| Buchsbaum, DJ; Christein, JD; Cooper, SJ; Davis, NS; Gertz, J; Greeno, EW; Grizzle, WE; Heslin, MJ; Johnston, BE; Kirby, MK; Myers, RM; Oliver, PG; Posey, JA; Ramaker, RC; Sexton, KC; Vickers, SM | 1 |
| Aroldi, F; Bertocchi, P; Fraccon, AP; Mutti, S; Prochilo, T; Rizzi, A; Savelli, G; Zaniboni, A | 1 |
| Cai, Q; Fu, H; Hu, Z; Shi, J; Wei, Z; Xu, J; Yan, R; Yang, D; Zhang, Y | 1 |
| Byrne, KT; Vonderheide, RH | 1 |
| Han, SM; Han, Y; Shi, SB; Tian, J; Wang, YS | 1 |
| Fujibayashi, S; Fujiya, M; Goto, T; Kawamoto, T; Kohgo, Y; Koizumi, K; Moriichi, K; Sasajima, J; Sugiyama, Y; Yamada, M | 1 |
| Chen, J; Cui, Y; Han, J; Jing, H; Sha, D; Wang, C; Wang, W | 1 |
| Goda, Y; Hara, H; Irie, K; Kobayashi, S; Morimoto, M; Moriya, S; Ohkawa, S; Okusaka, T; Tanaka, M; Tezuka, S; Ueno, M | 1 |
| Choi, Y; Haldar, MK; Kulkarni, P; Mallik, S; You, S | 1 |
| Cochran, JR; Cox, N; Grant, GA; Kintzing, JR; Smith, M | 1 |
| Fukuda, S; Kuga, Y; Moriya, T; Nishida, T | 1 |
| Bajor, J; Balázs, A; Czakó, L; Czimmer, J; Farkas, G; Gódi, S; Halász, A; Hegyi, P; Izbéki, F; Kahán, Z; Kelemen, D; Kui, B; Lakatos, G; Leindler, L; Papp, R; Pár, G; Szabó, I; Szentesi, A; Szentkereszty, Z; Szepes, Z; Szmola, R; Szücs, Á; Takács, T; Vincze, Á | 1 |
| Baba, T; Mukaida, N; Song, Y | 1 |
| Doihara, H; Iwamoto, T; Matsuoka, J; Mitsuhashi, T; Mizoo, T; Motoki, T; Nogami, T; Ogasawara, Y; Shien, T; Taira, N; Tsuji, H; Yoshitomi, S | 1 |
| Kitawaki, J; Kokabu, T; Konishi, E; Mori, T; Tsukasaki, N; Yasukawa, S | 1 |
| Bellmunt, J; Galsky, MD; Giannatempo, P; Grivas, P; Necchi, A; Pond, GR; Raggi, D; Sonpavde, G; Vogelzang, NJ | 1 |
| Aiken, C; Cronk, M; Ferraro, D; Gebski, VJ; Goldstein, D; Grimison, P; Karapetis, CS; Lipton, LL; McLachlan, S; Ng, S; O'Connell, RL; Shannon, J; Sjoquist, KM; Tebbutt, NC; Vasey, P; Zalcberg, JR | 1 |
| Anota, A; Bigay-Game, L; Bonnetain, F; Dansin, E; Dauba, J; Debieuvre, D; Fiteni, F; Milleron, B; Molinier, O; Morin, F; Oster, JP; Pichon, E; Poudenx, M; Quoix, E; Souquet, PJ; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Isayama, H; Ishigami, H; Kitayama, J; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Satoi, S; Tada, M; Takahara, N; Watanabe, T; Yamaguchi, H; Yamamoto, N | 1 |
| Daniel, BR; Eakle, JF; Hainsworth, JD; Lamar, RE; Lane, CM; Ward, PJ; Yardley, DA | 1 |
| Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
| Furukawa, D; Hirabayashi, K; Izumi, H; Mashiko, T; Nakagohri, T; Ozawa, S; Sadahiro, S; Tomioku, M; Yasuda, S; Yazawa, N | 1 |
| Leone, JP | 1 |
| Fan, Y; Lin, NM; Tong, YH; Wang, LL; Weng, X; Yan, YY; Zeng, JM | 1 |
| Connors, JM; Gascoyne, RD; Hitz, F; Hoskins, P; Klasa, R; Moccia, AA; Power, MM; Savage, KJ; Sehn, LH; Shenkier, T; Shepherd, JD; Slack, GW; Song, KW | 1 |
| Carter, K; Grant, MH; Henderson, CJ; Khalaf, AI; Puig-Sellart, M; Scott, FJ; Suckling, CJ; Watson, DG; Westrop, G | 1 |
| Fujie, K; Inoue, T; Ishitsuka, R; Kageyama, S; Keino, N; Kikuchi, E; Kinoshita, H; Matsui, Y; Mitsuzuka, K; Miyazaki, J; Nishiyama, H; Nomoto, T; Ogawa, O; Shiraishi, Y; Sugimoto, M; Wakeda, H | 1 |
| Chiorean, EG; El-Maraghi, R; Goldstein, D; Harris, M; Li, JS; Liu, H; Lu, B; Ma, WW; Manax, V; Reni, M; Romano, A; Tabernero, J; Von Hoff, DD; Whorf, R | 1 |
| Gakis, G | 1 |
| Antonia, S; Borghaei, H; Brahmer, JR; Chen, AC; Chow, LQ; Gerber, DE; Gettinger, S; Goldman, JW; Harbison, CT; Hellmann, MD; Juergens, RA; Laurie, SA; Nathan, FE; Rizvi, NA; Shen, Y; Shepherd, FA | 1 |
| Amitani, H; Inui, T; Kubo, K; Kuchiike, D; Mette, M; Nishikata, T; Uto, Y | 1 |
| Büchler, MW; Hackert, T; Hinz, U; Jäger, D; Michalski, CW; Sachsenmaier, M; Schneider, L; Springfeld, C; Strobel, O; Ulrich, A | 1 |
| Guo, J; Han, X; Hu, GF; Liu, LY; Tang, N; Wang, X; Wang, Y; Wang, ZH; Zhang, QQ | 1 |
| Carrasco, N; De, A; Do, J; Foster, D; Jeffrey, SS; Renier, C; Reyna-Neyra, A; Tse, V; Vogel, H; Wapnir, I | 1 |
| Amantini, C; Cardinali, C; Gismondi, A; Morelli, MB; Nabissi, M; Santoni, G; Santoni, M | 1 |
| Brooks, A; Guo, B; Miskimins, KW; Qian, SY; Xu, Y; Yang, X | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Dawson, DW; Fernandez-Zapico, ME | 1 |
| DeNardo, DG; Hawkins, WG; Hegde, S; Herndon, JM; Jiang, H; Knolhoff, BL; Meyer, MA; Nywening, TM; Pachter, JA; Shapiro, IM; Wang-Gillam, A; Weaver, DT; Zhu, Y | 1 |
| Anamalai, M; Julka, PK; Kumaran, D; Nambirajan, A; Velu, U | 1 |
| Anastasia, A; Annechini, G; Bonfichi, M; Carlo-Stella, C; Castagna, L; Di Renzo, N; Giordano, L; Gotti, M; Liberati, AM; Luminari, S; Mazza, R; Merli, F; Peli, A; Pulsoni, A; Re, A; Salvi, F; Santoro, A; Zilioli, VR | 1 |
| Chen, L; Chen, M; Dai, F; He, M; Pan, T; Shen, P; Song, Y; Wan, X; Wang, Q; Xiao, P | 1 |
| Chang, Y; Fu, X; Jia, S; Li, L; Li, W; Li, X; Li, Z; Ma, W; Ma, Y; Nan, F; Qin, Y; Su, L; Sun, Z; Wang, G; Wang, J; Wang, X; Wu, J; Xue, H; Yan, J; Young, KH; Zhang, D; Zhang, L; Zhang, M; Zhang, X | 1 |
| Asimakopoulos, AG; Boroujerdi, M; Davis, PJ; Kannan, K; Kohan, HG; Mousa, SA; Muralidharan-Chari, V; Sell, S; Sudha, T | 1 |
| Allorge, D; Barthelemy, C; Bonnabry, P; Décaudin, B; Humbert, L; Lebecque, M; Odou, P; Pinturaud, M; Richeval, C; Sidikou, O; Simon, N; Soichot, M; Vasseur, M | 1 |
| Fuerte, F; Klughammer, B; Ladrera, G; Lee, JS; Mok, T; Perez-Moreno, P; Sandoval-Tan, J; Shames, DS; Srimuninnimit, V; Sriuranpong, V; Thongprasert, S; Truman, M; Wu, YL; Yu, CJ | 1 |
| Agle, S; Bhutiani, N; Li, S; Li, Y; Martin, RC | 1 |
| Alberti-Violetti, S; Berti, E; Corti, L; Fanoni, D; Merlo, V; Reseghetti, A; Venegoni, L; Vezzoli, P | 1 |
| Chen, H; Deng, X; Gu, J; Li, Y; Peng, C; Shen, B; Shi, M; Wang, D; Wang, X; Wei, G; Zhan, Q; Zhang, J; Zhu, Y | 1 |
| Kwon, H; Lee, KH; Park, CM; Shin, S | 1 |
| Alexander, HR; Gaedcke, J; Gaida, MM; Ghadimi, BM; Hanna, N; He, P; Hussain, SP; Lee, DH; Ried, T; Schetter, AJ; Wang, J; Yang, S; Yfantis, HG | 1 |
| Bang, S; Chung, JB; Chung, MJ; Lee, HS; Lee, YI; Moon, do C; Park, JY; Park, SW; Song, SY | 1 |
| Bendas, G; Bisht, S; Brossart, P; Feldmann, G; Holdenrieder, S; Nolting, J; Rupp, A; Schlesinger, M; Schubert, R; Wenzel, J | 1 |
| Arcidiacono, PG; Balzano, G; Ceraulo, D; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Nicoletti, R; Passoni, P; Pepe, G; Reni, M; Zanon, S | 1 |
| Alam, N; Gupta, M; Gupta, PN; Khare, V; Kour, S; Kumar, A; Mahajan, G; Mondhe, DM; Saxena, AK; Singh, A; Singh, G; Singh, SK | 1 |
| Biederman, L; Blanco, F; Brody, JR; Jimbo, M; Jing, Y; Londin, E; Rigoutsos, I; Telonis, AG; Xia, NL; Zhou, H | 1 |
| Ding, ZY; Liu, ZL; Ren, YN; Zeng, TT; Zhang, L; Zhang, XX; Zhou, XJ | 1 |
| Bernier, M; Singh, NS; Wainer, IW | 1 |
| Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Long, J; Ma, X; Nie, J; Tian, G; Wang, Y; Wu, D; Zhang, J | 1 |
| Li, Y; Liu, J; Liu, Y; Ou, W; Su, F; Wang, R; Wang, X; Wu, Q; Zheng, J | 1 |
| Li, Y; Meng, Z; Ning, Z; Wang, H; Zhu, X | 1 |
| Azuma, T; Matayoshi, Y; Nagase, Y; Oshi, M; Sato, Y | 1 |
| Cen, Y; Lin, X; Wang, J; Wu, Q; Zhang, X | 1 |
| Ellenrieder, V; König, A; Seufferlein, T | 1 |
| Aristizabal-Alzate, A; Florez-Vargas, AA; Galvez-Cárdenas, KM; Higuita, LM; Nieto-Ríos, JF; Ocampo-Kohn, C; Rincón, CI; Zuluaga-Quintero, M; Zuluaga-Valencia, GA | 1 |
| Akin, O; Arslan, A; Deniz, E; Ozcakir-Tomruk, C | 1 |
| Camphausen, K; Griffith, KA; Kim, EJ; Ruch, JM; Sahai, V; Savage, JE; Simeone, DM; Zalupski, MM; Zhen, DB | 1 |
| Bateman, S; Heise, C; Hidalgo, M; Hou, S; Maitra, A; Pai, SG; Pierce, DW; Rajeshkumar, NV; Tong, Z; Von Hoff, DD; Yabuuchi, S | 1 |
| Cassarino, D; Nguyen, CM | 1 |
| Bi, D; Ding, S; Gao, D; Han, L; Li, C; Li, W; Liu, S; Liu, Z; Lu, J; Niu, Z; Yin, L | 1 |
| Chen, QW; Cheng, CS; Meng, ZQ; Ning, ZY; Shi, WD; Song, LB; Wang, K; Wang, P; Xie, J; Xu, LT; Zhang, CY; Zhu, XY; Zhuang, LP | 1 |
| Chen, YM; Fu, PF; Liu, Y; Lv, KZ; Wei, HY | 1 |
| Alsdorf, WH; Bokemeyer, C; Oechsle, K; Oing, C; von Amsberg, G | 1 |
| Kesharwani, P; Maheshwari, R; Pandey, H; Soni, N; Tekade, RK | 1 |
| Gu, M; Qian, Y; Xiong, Y; Yang, B | 1 |
| Bahra, M; Bläker, H; Denkert, C; Dörken, B; Jühling, A; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Striefler, JK; Wislocka, L | 1 |
| Akita, H; Fijiwara, Y; Ishikawa, O; Kobayashi, S; Ohigashi, H; Sakon, M; Takahashi, H; Tomokuni, A; Yano, M | 1 |
| Chllamma, MK; Cook, N; Dhani, NC; Dodd, A; Giby, K; Hedley, DW; Knox, JJ; Moore, MJ; Wang, L | 1 |
| Ishii, M; Kikuta, J; Naito, Y; Ogawa, K; Otani, K; Sakaguchi, Y; Seo, Y; Takahashi, Y | 1 |
| Bak, YT; Choi, SJ; Kim, HJ; Kim, JS | 1 |
| Arya, N; Christensen, J; Kohler, E; Lamichhane, SP; Shastri, VP; Xiang, S | 1 |
| Albert, AC; Bürtin, F; Graffunder, J; Jaster, R; Kumstel, S; Müller, S; Radecke, T; Schönrogge, M; Shih, HY; Vollmar, B; Zechner, D; Zhang, X | 1 |
| Lopez, CD; Vaccaro, G | 1 |
| Ahn, CW; Ahn, DH; Bekaii-Saab, T; Chen, JL; Ciombor, K; Jain, A; Javle, M; Mikhail, S; Noonan, AM; Shroff, RT; Wu, C | 1 |
| Fernando, M; Goldstein, D; Ritchie, GE | 1 |
| Azakami, T; Eguchi, N; Hayashi, H; Matsumoto, K; Shimamoto, F; Sumida, T; Sumii, M; Sumimoto, K; Tamura, T; Uraoka, N | 1 |
| Iida, T; Kaneto, H; Kon, S; Konishi, Y; Murakami, K; Sasaki, K; Satoh, S; Shimizu, H; Yamamoto, I; Yokoyama, Y | 1 |
| He, Z; Jia, Z; Shi, Y; Xu, C | 1 |
| Adsay, V; Brutcher, E; Chen, Z; El-Rayes, B; Ethun, CG; Kooby, DA; Maithel, SK; Postlewait, LM; Sarmiento, JM; Staley, CA | 1 |
| Olaussen, KA; Postel-Vinay, S | 1 |
| Şahin, B; Yalçin Balçik, P | 1 |
| Di, Y; Fu, D; He, H; Jin, C; Song, Y; Yu, X | 1 |
| Cao, J; Fan, S; Jia, S; Li, S; Li, Z; Nan, F; Su, L; Wang, J; Xue, H; Zhang, C; Zhang, L; Zhang, M | 1 |
| Lewis, CS; Smith, CD; Voelkel-Johnson, C | 1 |
| Askin, G; Buchy, E; Cayre, F; Couvreur, P; Desmaele, D; Gouazou, S; Mougin, J; Mura, S; Sobot, D; Stella, B; Valetti, S | 1 |
| Bindra, R; Couvreur, P; Desmaële, D; Gaudin, A; King, AR; Saltzman, WM; Saucier-Sawyer, JK; Song, E | 1 |
| Huguet, F; Mornex, F; Orthuon, A | 1 |
| Allbritton, NL; Brandt, AT; DiSalvo, M; Jones, CD; Marayati, R; Prins, JF; Sims, CE; Welch, JD; Williams, LA; Yeh, JJ | 1 |
| Dubey, RD; Gupta, PK; Gupta, PN; Saneja, A | 1 |
| Adiseshaiah, PP; Crist, RM; Hook, SS; McNeil, SE | 1 |
| Chen, LT; Hsu, MC; Hung, WC; Luo, CW; Pan, MR; Shan, YS | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Iwabuchi, I; Kawaguchi, T; Koie, T; Murasawa, H; Ogasawara, M; Ohyama, C; Yamamoto, H; Yoneyama, T | 1 |
| Anghinolfi, M; Casalini, AG; Gnetti, L; Majori, M | 1 |
| DeCaire, X; Streu, E | 1 |
| Andre, V; Enas, N; Gueorguieva, I; Ribba, B; Tate, SC | 1 |
| Domingo-Domenech, J; Ferket, BS; Galsky, MD; Sfakianos, JP | 1 |
| Li, Z; Lu, Z; Su, J; Ye, D; Zhan, Y | 1 |
| Allory, Y; Bastuji-Garin, S; Beuzeboc, P; Chevreau, C; Culine, S; Houédé, N; Le Thuaut, A; Loriot, Y; Pouessel, D; Sevin, E; Taille, A; Vordos, D | 1 |
| Borsky, M; Brychtova, Y; Bryja, V; Collakova, J; Dzimkova, M; Hylse, O; Janovska, P; Jaskova, Z; Kasparkova, M; Kohoutek, J; Oltova, A; Paruch, K; Trbusek, M; Verner, J; Vesely, P; Zaprazna, K; Zemanova, J | 1 |
| Chen, ZN; Fu, ZG; Jiang, JL; Li, L; Meng, Y; Wu, B; Wu, XQ; Xu, BQ; Xu, L | 1 |
| Gordon, DJ; Goss, KL | 1 |
| Coyne, CP; Narayanan, L | 2 |
| Hagiwara, M; Iwamura, M; Kobayashi, K; Matsumoto, K; Nagi, S; Tachibana, T; Tsumura, H; Yoshida, K | 1 |
| Chyczewska, E; Naumnik, B; Naumnik, W; Niklińska, W; Ossolińska, M | 1 |
| Duan, Q; Liu, T; Shen, Q; Wang, C; Wu, H; Yin, T; Zhang, Z; Zhao, H | 1 |
| Chang, X; Dai, M; Shi, N; Xing, C; Zhao, Y | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomihara, H; Wada, H; Yamada, D | 1 |
| Büchler, MW; Strobel, O | 3 |
| Bang, S; Cha, J; Kim, HM; Lee, KJ; Park, SW; Seong, J; Song, SY; Yi, SW | 1 |
| Chen, J; Liu, JY; Liu, ZQ; Qian, CY; Wang, Y; Yin, JY; Zheng, Y; Zhou, HH | 1 |
| Ciardiello, F; Conzo, G; De Vita, F; Diana, A; Fabozzi, A; Febbraro, A; Galizia, G; Giordano, G; Laterza, MM; Orditura, M; Petrillo, A; Savastano, B; Troiani, T; Ventriglia, J | 1 |
| Chen, W; Hou, H; Li, X; Pan, J; Wu, W; Xue, M; Zhai, W | 1 |
| Astorgues-Xerri, L; Bekradda, M; Bello, E; Cvitkovic, E; D'Incalci, M; Erba, E; Frapolli, R; Grosso, F; Lettera, E; Libener, R; Licandro, SA; Orecchia, S; Panini, N; Riveiro, ME; Romano, M; Ubezio, P; Vázquez, R | 1 |
| Cao, Z; Hu, Y; Huang, H; Wang, T; Xiong, G; Xu, J; You, L; Zhang, T; Zhao, Y; Zheng, L; Zhou, L | 1 |
| Becerra, C; Bence Lin, A; Braiteh, F; Calvo, E; Galsky, MD; Hurt, K; Hynes, SM; Jameson, G; Lin, J; McKane, S; McWilliams, R; Richards, D; Von Hoff, D; Wickremsinhe, ER | 1 |
| Adamson, DJ; Arif, SS; Bidoli, P; Carroll, KJ; Chang, D; Cheeseman, S; Dalgleish, AG; Diaz-Beveridge, R; Fernandez-Martos, C; Gaya, A; Glynne-Jones, R; Granetto, C; Martín, AJ; Massuti, B; McAdam, K; McDermott, R; Mudan, SS; Papamichael, D; Pazo-Cid, R; Stebbing, J; Vieitez, JM; Wagle, S; Zaniboni, A | 1 |
| Huang, M; Huang, Q; Lin, X; Xie, F; Yang, J; Zhou, H | 1 |
| Jiang, ZF; Liu, RY; Shao, LJ; Wu, HM | 1 |
| Bahary, N; Hogg, ME; Poruk, KE; Steve, J; Weiss, MJ; Wolfgang, CL; Wright, GP; Zeh, HJ; Zenati, MS; Zuriekat, AH | 1 |
| Bernanke, AG; Blobe, GC; Hesler, RA; Huang, JJ; McCall, SJ; Nixon, AB; Starr, MD; Treboschi, VM; White, RR | 1 |
| Chisaki, Y; Terada, T; Yano, Y | 1 |
| Cao, YQ; Jing, K; Liang, TJ; Ma, MZ; Wang, XJ; Zhou, ZM | 1 |
| Brown, J; Depenbrock, H; Krause, T; Kropf-Sanchen, C; Mezger, J; Reck, M; Socinski, MA; Soldatenkova, V; Thatcher, N; Thomas, M | 1 |
| Akladios, C; Aprahamian, M; Ignat, M; Mutter, D | 1 |
| Beaudoin, A; Cano, P; Cripps, C; Dhesy-Thind, S; Do, T; Dowden, S; Gill, S; Grassin, H; Ko, YJ; Lam, WYH; Moore, M; Stewart, J; Zalewski, P; Zulfiqar, M | 1 |
| Dan, G; Deng, D; Jiang, J; Li, W; Zheng, X; Zheng, Y | 1 |
| Gharios, J; Kattan, J; Kourie, HR | 1 |
| Korc, M; Kota, J; Kwon, JJ; Quirin, KA; Wek, RC; Willy, JA; Yin, XM | 1 |
| Hanai, K; Higure, T; Hoshi, A; Kawamura, Y; Nakajima, N; Nitta, M; Shimizu, Y; Terachi, T | 1 |
| Andersson, R; Ansari, D; Bauden, M; Cebrián, MJ; Holdenrieder, S | 1 |
| Alunni-Fabbroni, M; Andergassen, U; Fasching, P; Fehm, T; Friedl, TW; Hecker, N; Hepp, P; Jäger, B; Janni, W; Lorenz, R; Rack, B; Schneeweiss, A; Trapp, E | 1 |
| Cheah, SL; Chua, ML; Fong, KW; Kusumawidjaja, G; Shwe, MT; Soong, YL; Tan, SH; Tan, TW; Wee, JT | 1 |
| Feuz, L; Gee, ME; Krajewski, KC; Kurtzhalts, K | 1 |
| Hwnag, YI; Jeon, J; Kang, JS; Kim, H; Kim, TW; Kim, Y; Lee, WJ; Park, JH; Park, JK | 1 |
| Cimino, GD; de Vere White, R; Henderson, PT; Malfatti, MA; Pan, CX; Scharadin, TM; Turteltaub, K; Wang, S; Zhang, H; Zimmermann, M | 1 |
| Cai, WJ; Dong, YY; Liu, Y; Zhuang, YH; Zou, WB | 1 |
| Feduska, JM; Gilbert, SR; Hensel, JA; Levy, S; Ponnazhagan, S; Sawant, A | 1 |
| Arpino, G; De Placido, S; Giuliano, M; Schettini, F | 1 |
| He, J; Liu, L; Xiang, Z; Xiao, H; Xiao, J | 1 |
| Chen, K; Chen, X; Duan, W; Gao, L; Jiang, Z; Lei, M; Ma, J; Ma, Q; Sun, L; Wang, Z; Zhou, C | 1 |
| Fishel, ML; Hill, R; Littlepage, LE; Richards, KE; Wu, J; Zeleniak, AE | 1 |
| Hou, J; Huang, Y; Jiang, Y; Li, X; Wang, X; Wu, J; Xu, W; Zhang, J; Zhang, Y | 1 |
| Blanc, JF; Carrato, A; Ciardiello, F; de Jong, FA; Ektare, V; Gill, S; Hubner, RA; Patel, DA; Vogel, A; Yang, Y | 1 |
| Esumi, H; Fujioka, R; Hasegawa, H; Hashimoto, Y; Ikeda, M; Kishino, S; Mitsunaga, S; Miyoshi, C; Mochizuki, N; Nomura, S; Ohno, I; Sato, A; Takahashi, H; Takahashi, R; Toyosaki, K; Tsuchihara, K; Yomoda, S | 1 |
| Msaouel, P; Tu, SM; Zhang, M | 1 |
| Bally, MB; Corcoran, JA; Franco, OL; Hancock, REW; Haney, EF; Hilchie, AL; Hoskin, DW; Sharon, AJ | 1 |
| Du, L; Gao, F; Li, F; Liang, X; Lin, L; Liu, Y; Qiao, X; Qin, P; Xing, L; Zhang, J; Zhao, Q | 1 |
| Chan, C; Duan, X; Han, W; Lin, W; Poon, C | 1 |
| Penel, N | 1 |
| Hiraoka, K; Nakamura, M; Ogata, T; Ozaki, T; Sang, M; Shimozato, O; Yoda, H | 1 |
| Azria, D; Caffo, O; Choudhury, A; De Santis, M; Fellin, G; Galligioni, E; Hamstra, DA; Kragelj, B; Pappagallo, GL; Thompson, C | 1 |
| Bastuji-Garin, S; Brureau, L; Canoui-Poitrine, F; Carvahlo-Verlinde, M; Culine, S; Demery, ME; Fléchon, A; Laurent, M; Paillaud, E; Thuaut, AL | 1 |
| Fan, Z; Guo-Fang, T; Xiao-Huan, L; Yong-Xian, G | 1 |
| Fang, J; Huang, D; Luo, G | 1 |
| Bohle, W; Egger, J; Hann, A; Zoller, WG | 1 |
| Hu, M; Huang, P; Huang, W; Wang, Y; Yan, D; Zhu, X | 1 |
| Gunduz, U; Mutlu, P; Parsian, M; Tezcaner, A; Yalcin, S | 1 |
| Kataoka, K; Maeda, M; Matsubara, H; Okamura, S; Urano, F | 1 |
| Chen, CY; Chen, ZW; Cheng, H; Hu, C; Huang, D; Rong, L; Shen, H; Shen, L; Vignuzzi, M; Wang, R; Yang, E; Zhang, Z; Zhao, Y | 1 |
| Aglietta, M; Campanella, D; Depetris, I; Fenocchio, E; Galizia, D; Garetto, L; Grignani, G; Leone, F; Schianca, FC | 1 |
| Ackroyd, JJ; Flanagan, SA; Im, MM; Knapp, B; Kramer, A; Shewach, DS | 1 |
| Allen, JN; Blaszkowsky, LS; Clark, JW; Fernandez-Del Castillo, C; Ferrone, CR; Hong, TS; Keane, FK; Kwak, EL; Lillemoe, KD; Ryan, DP; Wo, JY | 1 |
| Biermann, M; Bjånes, T; Dimcevski, G; Gilja, OH; Gjertsen, BT; Hoem, D; Kotopoulis, S; McCormack, E; Molven, A; Postema, M; Schjøtt, J; Sorbye, H | 1 |
| Benson, AB; Bepler, G; Elsaleh, H; Farrell, JJ; Guha, C; Lai, R; Liu, X; Macdonald, JS; Moughan, J; Regine, WF; Schaefer, P; Wong, JL; Yen, Y; Zheng, Z | 1 |
| Li, L; Li, X; Liu, Y; Miao, L; Ni, R; Wang, J; Wang, X; Zhang, H | 1 |
| Bamlet, WR; Carlson, EE; Fridley, BL; Jenkins, G; Li, L; McWilliams, RR; Petersen, GM; Wang, L; Xie, F; Zhang, JW | 1 |
| Bachet, JB; Calomme, A; Demetter, P; Drouillard, A; Maréchal, R; Ouazzani, S; Puleo, F; Van Laethem, JL; Verset, G | 1 |
| Altundag, K; Barnadas, A; Botha, M; Chan, A; Cinieri, S; Coskun, U; Dodyk, P; Lazzarelli, S; Rauch, D; Tubiana-Mathieu, N; Vandebroek, A; Villanova, G | 1 |
| Brunner, T; Fokas, E | 1 |
| Keating, GM | 1 |
| Andley, M; Maharshi, V; Nagar, P; Rehan, HS | 1 |
| Cho, MH; Chung, J; Joung, JY; Kim, SH; Lee, KH; Park, WS; Seo, HK | 1 |
| Apers, S; Capistrano I, R; Fransen, E; Pieters, L; Staelens, S; Vangestel, C; Vanpachtenbeke, H | 1 |
| Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N | 1 |
| Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M | 1 |
| Chen, QD; Ge, X; Jiang, BH; Lin, Y; Liu, LZ; Lu, Y; Shi, ZM; Wang, M; Wen, Y | 1 |
| Li, JS; McGovern, D; Romano, A; Römmler-Zehrer, J; Stahl, M; Vogel, A | 1 |
| Chang, HM; Kim, KP; Park, K; Park, S | 1 |
| Chen, K; Chen, X; Duan, W; Han, L; Jiang, Z; Lei, J; Li, J; Li, X; Ma, J; Ma, Q; Ma, Z; Sun, L; Wang, F; Wang, Z; Wu, E; Wu, Z; Xu, Q | 1 |
| Aoki, H; Kanaya, N; Morihiro, T; Takeuchi, H; Yamasaki, R | 1 |
| Chang, H; Gao, HJ; Li, HG; Liu, FF; Lu, J; Ma, CQ; Ma, JB; Song, X; Zhou, X; Zhu, HQ | 1 |
| Álamo, P; Allavena, P; Avilés, P; Céspedes, MV; Cuevas, C; Gallardo, A; Galmarini, CM; Guillén, MJ; Hidalgo, M; López-Casas, PP; Mangues, R; Sarno, F | 1 |
| Arima, H; Aruga, A; Fujiwara, T; Furukawa, H; Hatori, T; Hayashi, H; Hazama, S; Hirakawa, K; Iguchi, H; Iida, M; Ikemoto, T; Ishizaki, H; Koki, Y; Matsui, H; Nagano, H; Nakamura, Y; Oka, M; Sakata, K; Shimada, M; Shimizu, R; Shindo, Y; Suzuki, N; Takenouchi, H; Tanaka, H; Ueno, T; Uesugi, K; Umeda, Y; Yoshimatsu, K; Yoshino, S | 1 |
| Faber, C; Griffiths, JR; Heinzmann, K; Held, A; Hermann, S; Honess, DJ; Jacobs, AH; Schelhaas, S; Smith, DM; Wachsmuth, L | 1 |
| Li, C; Liu, R; Zhao, Z; Zhou, Z | 1 |
| Arakawa, I; Ejiri, M; Inoue, T; Matsuura, K; Nakao, H; Saito, H; Tsukiyama, I; Yamamoto, Y; Yoneda, M | 1 |
| Cui, H; Jiang, R; Li, X; Lin, X; Liu, C; Tao, R; Tian, S; Zhuang, H; Zhuo, C | 1 |
| Belau, AK; Bover-Barcelo, I; Canzler, U; Chekerov, R; Gonzalez-Martin, A; Hanker, LC; Harter, P; Hilpert, F; Keil, E; Klare, P; Kurzeder, C; Mahner, S; Meier, W; Petru, E; Reinthaller, A; Richter, R; Sehouli, J; Wimberger, P; Woopen, H; Zeimet, A | 1 |
| Caperell-Grant, A; Cardenas, H; Fishel, M; Ivan, C; Jones, DR; Lee, J; Matei, D; Yakubov, B | 1 |
| Hanazaki, K; Kitagawa, H; Koyama, T; Maeda, H; Munekage, E; Munekage, M; Namikawa, T; Takezaki, Y | 1 |
| Kang, MJ; Kim, BH; Kim, N; Kim, YT; Lee, JM; Lee, JS; Lee, SH; Ryu, JK; Son, JH | 1 |
| Areepium, N; Kumpiro, S; Sriuranpong, V | 1 |
| Giovannetti, E; Kazemier, G; Meijer, LL; Peters, GJ; Puik, JR | 1 |
| Lu, H; Lu, M; Stenzel, MH; Wang, YK; Xiao, P; Zhao, J | 1 |
| Hu, Z; Ju, B; Lu, S; Wang, W; Xie, H; Yang, Q; Zhang, Y; Zhao, X; Zheng, S; Zhou, D; Zhou, L; Zhou, X | 1 |
| Chen, H; Fan, W; He, Y; Hu, H; Tang, S; Wang, P; Xu, P; Xu, Z; Yang, G; Yu, M; Zhang, Z; Zhao, X | 1 |
| Lin, Y; Qin, C; Su, Z; Xian, G; Zhang, Z; Zhao, J | 1 |
| Ferrara, S; Goldstein, D; Kunzmann, V; Liu, H; Lu, B; Ramanathan, RK; Renschler, MF; Von Hoff, DD | 1 |
| Chang, ZF; Chen, QQ; Guo, JR; Lam, CW; Wang, CY; Wong, VK; Zhang, W | 1 |
| An, Y; Duan, J; Fan, S; Li, X; Pan, Y; Tie, L; Wang, X; Xiaokaiti, Y; Yang, H; Ye, M | 1 |
| Grande, C; Groman, A; Iancu, DM; Iyer, RV; Ma, WW; Malhotra, U; Pokuri, VK; Saab, TB | 1 |
| Dong, M; Gui, L; He, X; Li, Y; Liu, P; Qi, F; Shi, Y; Wang, W; Yang, J; Yang, S; Zhang, C; Zhou, S | 1 |
| Lian, B; Mo, Q; Qin, Q; Tan, Q; Wei, C; Yang, W | 1 |
| Hirono, S; Imaoka, H; Ishii, H; Katanuma, A; Katsuda, M; Kawai, M; Maguchi, H; Miyazawa, M; Okada, KI; Ozaka, M; Yamao, K; Yamaue, H | 1 |
| Hu, J; Liu, G; Liu, S; Wang, C; Zhang, G | 1 |
| Gao, D; Guo, Q; Han, B; Li, C; Sun, W; Wang, Q; Wei, X; Xie, X; Zhang, Z; Zhao, P; Zhu, D | 1 |
| Funt, SA; Rosenberg, JE | 1 |
| Chen, Y; He, Q; Zhang, H | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Sudo, T; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Dibbern, JL; Ghadban, T; Güngör, C; Izbicki, JR; Miro, JT; Reeh, M; Tsui, TY; Vashist, YK; Wellner, U | 1 |
| Cabezuelo, B; de la Vara Inesta, L; Illescas, ML; Jimeno García, L; López Rubio, ME; Lucas Guillén, E; Martinez Díaz, M; Mateo Bosch, E; Morales Albuja, ME; Rodado Martínez, R | 1 |
| Hirano, M; Iizuka, M; Kameda, M; Kikuchi, A; Kuromitsu, S; Nakayama, A; Nakazawa, T; Ozawa, T; Shindoh, N; Suzuki, T; Terasaka, T | 1 |
| Plimack, ER; Ramamurthy, C; Zibelman, M | 1 |
| Alberts, SR; Bamlet, WR; Burch, PA; Chari, ST; Farnell, MB; Gleeson, FC; Haddock, MG; Kendrick, ML; Levy, MJ; Oberg, AL; Petersen, GM; Takahashi, N | 1 |
| Bekaii-Saab, T; Chen, CS; Ding, LY; Henderson, SE; Huang, PH; Kulp, SK; Mo, X | 1 |
| Brody, JR; Buchler, M; Costello, E; Dabbish, N; Ghaneh, P; Greenhalf, W; Grigoli, A; Halloran, C; Jiang, W; Jimbo, M; Leiby, BE; Neoptolemos, JP; Palmer, D; Tatarian, T; Winter, JM; Yeo, CJ | 1 |
| Cao, Y; Ma, Q; Wang, F; Wang, Y; Yu, B | 1 |
| Juszczak, M; Paschke, L; Slupski, M | 1 |
| Bahary, N; Bednar, F; Hogg, ME; Ocuin, LM; Steve, J; Winters, S; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Costello, JC; Kanigel Winner, KR | 1 |
| Handa, K; Kaida, H; Nagano, H; Sato, M; Tomita, A; Watanabe, R; Yoshioka, S | 1 |
| Chen, L; Feng, J; Gong, Q; Li, J; Li, L; Li, N; Li, X; Tang, F; Tang, X; Wang, C; Xiao, Z | 1 |
| Airhart, S; Chamie, K; Cimino, GD; de Vere White, R; Drakaki, A; Haack, K; Henderson, PT; Lin, TY; Malfatti, M; Ognibene, T; Pan, CX; Tepper, CG; Turteltaub, KW; Wang, SS; Yang, H; Zhang, H; Zimmermann, M | 1 |
| Honeywell, RJ; Kathmann, I; Kristensen, MH; Peters, GJ; Sarkisjan, D | 1 |
| Coe, IR; Naydenova, Z; Zafar, M | 1 |
| Giovannetti, E; Gómez, VE; Leon, LG; Minutolo, F; Peters, GJ; Zucali, PA | 1 |
| Blanco, R; Camps, C; de Aguirre, I; Garrido, P; Gonzalez-Larriba, JL; Insa, A; Isla, D; Moran, T; Pérez Cano, M; Provencio, M; Queralt, C; Ramirez, JL; Rosell, R; Santarpia, M | 1 |
| Deguchi, T; Fujita, Y; Horie, K; Ito, M; Kameyama, K; Kato, T; Kawakami, K; Kojima, T; Miyazaki, T; Mizutani, K | 1 |
| Haruki, K; Horiuchi, T; Iwase, R; Ohashi, T; Saito, N; Shiba, H; Shirai, Y; Uwagawa, T; Yanaga, K | 1 |
| Li, L; Wei, W; Wu, P; Zhang, ZH | 1 |
| Abraham, I; Bootman, JL; Gharaibeh, M; McBride, A; Patel, H | 1 |
| Kitanaka, C; Kuramoto, K; Okada, M; Sakaki, H; Sanomachi, T; Seino, S; Suzuki, S; Takeda, H; Watarai, H; Yoshioka, T | 1 |
| Chuman, H; Hatano, H; Hiraga, H; Hosaka, M; Iwamoto, Y; Joyama, S; Kaya, M; Kubo, T; Morioka, H; Nagano, A; Nishida, Y; Takahashi, M; Tanaka, K; Toguchida, J; Tsumura, H; Yoshikawa, H | 1 |
| Azad, A; D'Costa, Z; Diana, A; Dushek, O; Fokas, E; Jones, K; Kruger, P; Liu, S; McKenna, WG; Muschel, RJ; Sansom, OJ; Yin Lim, S | 1 |
| Fukushi, K; Hashimoto, Y; Hatakeyama, S; Imai, A; Koie, T; Matsumoto, T; Narita, T; Ohyama, C; Soma, O; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Fujiwara, H; Machida, S; Matsubara, S; Morisawa, H; Nagashima, T; Saga, Y; Takahashi, S; Takahashi, Y; Takei, Y; Taneichi, A | 1 |
| Aguila, FN; Chambers, LW; Hu, H; Huang, X; Knoble, JL; Liu, H; Patel, T; Zeng, M | 1 |
| Amponsah, PS; Bauer, N; Fan, P; Fellenberg, J; Gladkich, J; Herr, I; Zhao, Z | 1 |
| Devulapally, R; Foygel, K; Paulmurugan, R; Sekar, TV; Willmann, JK | 1 |
| Çalış, S; Esendağlı, G; Gürbüz, MU; Öztürk, K; Tülü, M | 1 |
| Bridgewater, J; Cascinu, S; Childs, BH; Dueland, S; Garosi, VL; Giurescu, M; Haas, M; Jassem, J; Martens, UM; Melichar, B; Michl, P; Peeters, M; Rajagopalan, P; Riess, H; Ross, P; Roth, K; Saramak, P; Schmiegel, W; Schulz, A; Seidel, H; Teufel, M; Van Brummelen, D; Van Laethem, JL; Weekes, C; Zaniboni, A | 1 |
| Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M | 1 |
| He, J; Li, T; Liu, P; Luo, L; Yang, J; Yu, M | 1 |
| Chang, CL; Chen, JH; Chen, TM; Lai, MT; Lee, FP; Lin, KC; Wu, CC; Wu, SY; Yen, YC; Yuan, KS | 1 |
| Chen, W; Gu, Y; He, Y; Hu, B; Hu, H; Wang, Y | 1 |
| Fujita, H; Kadono, T; Kimura, T; Masui, Y; Miyagaki, T; Miyagawa, T; Saigusa, R; Sato, S; Yamada, D; Yoshizaki, A | 1 |
| Gajra, A | 1 |
| Bazin, IS; Bodoky, G; Deplanque, G; Elekes, A; Evans, TRJ; Harrison, M; Lin, C; Melichar, B; Moore, MJ; O'Dwyer, PJ; Pezet, D; Rock, E; Rosemurgy, A; Strauss, L; Van Cutsem, E | 1 |
| Biankin, A; Goldstein, D; Johns, A; Mawson, A; McCarroll, J; Nunez, A; Phillips, P; Sharbeen, G; Youkhana, J | 1 |
| Agarwal, N; Alva, A; Bamias, A; Bellmunt, J; Casey, MF; Crabb, SJ; De Giorgi, U; Galsky, MD; Harshman, LC; Ladoire, S; Necchi, A; Niegisch, G; Pal, SK; Powles, T; Ramos, JD; Recine, F; Rosenberg, JE; Vaishampayan, UN; Wong, YN; Yu, EY | 1 |
| Akada, J; Baron, B; Kitagawa, T; Kuramitsu, Y; Maehara, SI; Maehara, Y; Nakamura, K; Tokuda, K; Wang, Y | 1 |
| Du, X; Li, X; Liu, N; Sheng, X; Wang, F; Yu, H | 1 |
| Hong, S; Zhang, L | 1 |
| Chess-Williams, R; Farr, SE; McDermott, CM | 1 |
| Abbate, MI; Agustoni, F; Bianchini, G; Bidoli, P; Canova, S; Cicchiello, F; Cortinovis, DL | 1 |
| Agarwal, N; Agarwal, P; Baisre, A; Goldstein, IM; Hansberry, DR; Kavi, A | 1 |
| Arigami, T; Iino, S; Kawasaki, Y; Kurahara, H; Maemura, K; Mataki, Y; Mori, S; Natsugoe, S; Sakoda, M; Shinchi, H; Uchikado, Y; Ueno, S; Uenosono, Y | 1 |
| Park, K | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR | 1 |
| Cai, H; Duan, Z; Gong, Q; Gu, Z; Li, B; Luo, K; Sun, L; Zhang, Y; Zhu, H | 1 |
| Beyer, G; Javed, MA; Kohlmann, T; Krug, S; Le, N; Neesse, A; Schober, M; Sund, M; Vinci, A | 1 |
| Chen, Y; Gao, L; Hong, C; Hong, Y; Jin, Y; Lu, L; Mao, G; Qin, Z; Su, D; Wei, Y; Wu, G; Ye, X; Yuan, G; Zhao, T; Zhou, H; Zhou, Y | 1 |
| Shen, B; Shi, M; Tang, X; Wen, C; Zhang, Y | 1 |
| Jiang, W; Luo, S; Pan, H; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L; Zhou, Y | 1 |
| Hu, XC; Lin, C; Liu, MM; Tao, ZH; Wu, ZH; Zhang, J | 1 |
| Bo, JJ; Duan, XH; Huang, YR; Liu, Q; Wang, ZL; Yang, GL; Zhang, LH | 2 |
| Chang, JI; Huang, BZ; Li, E; Wu, BU; Xiang, AH | 1 |
| Bespalov, MM; De Brabander, JK; Ianevski, A; Kainov, DE; Kuivanen, S; Nandania, J; Vapalahti, O; Velagapudi, V | 1 |
| Cinatl, J; Hoffmann, MJ; Isono, M; Michaelis, M; Niegisch, G; Pinkerneil, M; Sato, A; Schulz, WA | 1 |
| Chisaki, Y; Nakamura, N; Yano, Y | 1 |
| Alazraki, A; Carden, MA; Meany, H; Rapkin, LB; Smith, S; Yin, H | 1 |
| Diao, T; Feng, F; Hou, R; Huhe, M; Liu, S; Nan, G; Sun, X; Tang, H; Wang, B; Wang, L; Wu, B; Zhang, Y; Zhang, Z; Zhu, Y | 1 |
| Hori, Y; Nishiyama, T; Shimizu, K | 1 |
| Aicher, B; Avan, A; Boggi, U; Funel, N; Giovannetti, E; Granchi, C; Leon, LG; Maftouh, M; Massihnia, D; Minutolo, F; Peters, GJ; Raktoe, R; Russo, A; van Krieken, A | 1 |
| Aboukameel, A; Azmi, AS; Baloglu, E; Kauffman, M; Landesman, Y; Mohammad, RM; Muqbil, I; Philip, PA; Senapedis, W; Shacham, S | 1 |
| Hara, I; Iba, A; Kikkawa, K; Kodama, Y; Kohjimoto, Y; Matsumura, N; Nakamura, Y; Nishizawa, S | 1 |
| Han, H; Ji, J; Jin, Q; Li, Z; Parak, WJ; Pelaz, B; Valdepérez, D; Wu, Y; Yang, B | 1 |
| Bang, S; Cheon, YK; Cho, CM; Cho, KB; Choi, HS; Chung, MJ; Kang, DH; Kim, CD; Kim, DU; Kim, HG; Kim, HJ; Kim, JK; Kim, TH; Kim, YT; Lee, DK; Lee, HS; Lee, SH; Moon, J; Moon, JH; Noh, MH; Park, JY; Park, SW; Shin, HJ; Song, SY | 1 |
| Leung, J; St-Onge, P; Stagg, J; Suh, WK | 1 |
| Alarcón Cano, D; Andrade G, A; Barajas, O; Butte, JM; Caglevic, C; Calderillo Ruiz, G; Carballido, M; Cuartero, V; De La Fuente, H; de la Torre, M; Díaz Romero, C; Gallardo, J; González M, P; Hoefler, S; Kon Jara, X; Lembach, H; Lingua, A; Lobatón, J; Mahave, M; Marsiglia, H; Mas López, L; Montenegro B, P; Morillas G, L; Moscoso, Y; Müller, B; O'Connor, JM; Padilla Rosciano, A; Pérez Encalada, V; Roa, JC; Roca, E; Rolfo, C; Schwartsmann, G; Solé, S; Torres, J; Ubillos, L; Yepes, A | 1 |
| Bapiro, TE; Chen, N; Ellenrieder, V; Frese, KK; Gopinathan, A; Gress, TM; Hessmann, E; Heuchel, R; Jodrell, DI; Johnsen, SA; Kari, V; Klein, L; Li, X; Löhr, JM; Neesse, A; Patzak, MS; Ramu, I; Richards, FM; Verbeke, C | 1 |
| Eguchi, K; Furuse, J; Hamada, C; Iguchi, H; Ioka, T; Ishiguro, A; Ito, T; Itoi, T; Kida, M; Kitano, M; Komatsu, Y; Mizuno, N; Munakata, M; Ohkawa, S; Sakata, Y; Satoh, T; Takeda, K; Tanaka, M; Tsuji, A; Yamaguchi, T | 1 |
| Alis, H; Dagoglu, N; Gonenc, M; Karabulut, M; Karabulut, S; Serilmez, M; Tas, F; Usul Afsar, Ç | 1 |
| Chao, Y; Hou, MC; Lan, KH; Lee, SD; Lee, WP; Li, CP; Lin, HC | 1 |
| Are, C; Bhirud, AR; Lazenby, AJ; Lin, C; Ly, QP; Sasson, AR; Verma, V; Zheng, D | 1 |
| Bedel, A; Brillac, A; Buscail, E; Dabernat, S; de Verneuil, H; Moranvillier, I; Moreau-Gaudry, F; Peuchant, E; Rousseau, B; Vendrely, V | 1 |
| Bowcock, S; De Lord, C; Devereux, S; Dhanapal, V; Fields, P; Gunasekara, M; Kassam, S; Lianwea, C; Marcus, R; Patten, P; Wrench, D; Yallop, D | 1 |
| Arenare, L; Bergamini, A; Cecere, SC; Della Pepa, C; Di Napoli, M; Facchini, G; Gargiulo, P; Mangili, G; Pignata, S; Pisano, C; Rossetti, S; Tambaro, R | 1 |
| Fang, Y; Kopeček, J; Li, Y; Pan, H; Yang, J; Zhang, L; Zhang, R | 1 |
| Binder, PS; Goedegebuure, SP; Hashim, YM; Hawkins, WG; Liu, J; Mach, RH; Sankpal, NV; Spitzer, D; Vangveravong, S | 1 |
| Broberg, M; Liljefors, M; Mellstedt, H; Mozaffari, F; Ullenhag, GJ | 1 |
| Argyros, O; Fokas, D; Karampelas, T; Skavatsou, E; Tamvakopoulos, C | 1 |
| Akita, H; Fujiwara, Y; Fukui, K; Gotoh, K; Kobayashi, S; Marubashi, S; Sakon, M; Takahashi, H; Teshima, T; Tomokuni, A; Yamada, T | 1 |
| Abbott, DE; Ahmad, SA; Al Humaidi, AH; Choe, KA; Dhar, VK; Fu, B; Habib, DA; Hanseman, DJ; Kharofa, J; Kim, Y; Levinsky, NC; Olowokure, OO; Smith, M; Wang, J; Wilson, GC; Xia, BT | 1 |
| Avan, A; Fayazbakhsh, H; Hassanian, SM; Hosseini, M; Khazaei, M; Maftouh, M; Mohammadzadeh, E; ShahidSales, S | 1 |
| Han, SS; Hong, EK; Joo, J; Kim, MK; Kim, TH; Kim, YH; Kong, SY; Lee, JH; Lee, WJ; Moon, H; Park, B; Park, SJ; Woo, SM; Yoon, KA | 1 |
| Ahn, MJ; Bello, M; Cho, EK; Depenbrock, H; Orlando, M; Park, K; Puri, T; Soldatenkova, V; Song, EK; Thongprasert, S | 1 |
| Arkenau, HT; Moschetta, M; Uccello, M | 1 |
| Han, X; Lu, N; Pan, Y; Xu, J | 1 |
| Booth, CM; Mackillop, WJ; Robinson, AG; Vera-Badillo, FE; Wei, X | 1 |
| Amundsen, T; Grønberg, BH; Hjelde, HH; Kaasa, S; Kristensen, A; Solheim, TS; Sørhaug, S | 1 |
| Asmann, Y; Foye, C; Maji, S; Matsuda, A; Nguyen, P; Parasramka, M; Patel, T; Wang, X; Yan, IK | 1 |
| Akiyama, D; Isayama, H; Ishigaki, K; Ito, Y; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Sasaki, T; Tada, M; Takahara, N; Toda, N; Togawa, O; Uchino, R; Yagioka, H | 1 |
| Kaura, S; Khan, ZM; MacEwan, JP; Yin, W | 1 |
| Kang, R; Lotze, MT; Sun, X; Tang, D; Zeh, HJ; Zhang, Q; Zhu, S | 1 |
| Fujii, Y; Fujita, H; Fujita, J; Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Miura, S; Nakano, Y; Ohnishi, T; Tomita, Y; Ueda, N | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Nagaoka, S; Noda, T; Umeshita, K; Wada, H; Yamada, D | 1 |
| Hanazaki, K; Kitagwa, H; Munekage, M; Namikawa, T; Sugimura, K; Takezaki, Y | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Goto, K; Kawamoto, K; Mori, M; Noda, T; Ueno, G; Wada, H; Yamada, D | 1 |
| Hagino, S; Nakayama, A; Sakamoto, K | 1 |
| Akiyama, Y; Ishida, T; Kagawa, Y; Kato, T; Katsura, Y; Kuwahara, R; Morimoto, Y; Murakami, K; Naito, A; Ohmura, Y; Oneda, Y; Sakamoto, T; Takeda, Y; Takeno, A; Tamura, S | 1 |
| Fukabori, M; Itoh, Y; Morita, A; Nakayama, M; Saito, H; Suematsu, Y; Takahashi, M; Wakabayashi, K; Yamagishi, S | 1 |
| Endo, K; Hirose, Y; Kameyama, H; Kido, T; Kobayashi, T; Miura, K; Morimoto, Y; Otani, A; Otani, T; Sakata, J; Tamura, H; Wakai, T; Yoshino, K | 1 |
| Abe, T; Fukase, K; Hayashi, H; Kanno, A; Kyakumoto, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Otsuka, H; Sakata, N; Shimosegawa, T; Takadate, T; Unno, M | 1 |
| Fujimoto, T; Hazama, S; Iida, M; Kanekiyo, S; Matsui, H; Matsukuma, S; Nagano, H; Sakamoto, K; Shindo, Y; Suzuki, N; Takeda, S; Tokuhisa, Y; Tokumitsu, Y; Ueno, T; Yoshino, S | 1 |
| Ando, S; Kamei, R; Kitamura, Y; Tokunou, K; Yamamoto, H; Yamamoto, T | 1 |
| Fukada, T; Hasegawa, A; Isozaki, M; Kametaka, H; Makino, H; Seike, K | 1 |
| Hoshino, H; Hosoda, Y; Kakita, N; Kawada, J; Kim, Y; Nishino, M; Okano, M; Okuyama, M; Tsujinaka, T; Yamasaki, M | 1 |
| Fujita, S; Hayashi, N; Michiura, T; Miyazaki, Y; Nagaoka, M; Nakagawa, T; Okubo, K; Yamabe, K | 1 |
| Fukuda, S; Harada, T; Hiraki, S; Kanesada, K; Tada, K | 1 |
| Araki, H; Choda, Y; Harano, M; Idani, H; Ishida, M; Kanazawa, T; Matsukawa, H; Mimura, N; Ninomiya, M; Ogawa, T; Ojima, Y; Okajima, M; Satoh, D; Shiozaki, S; Sumitani, D | 1 |
| Asai, K; Fukunaga, H; Hiratsuka, M; Murata, M; Saso, K; Sawami, H; Suzuki, R; Tanaka, N; Yamada, M; Yamamoto, M | 1 |
| Inose, S; Karikomi, K; Kitamura, K; Koyama, M; Masamura, S; Matsumura, T; Nakamura, N; Okada, K; Suwa, T; Totsuka, E | 1 |
| Ito, F; Kaneta, A; Miura, J; Otani, S; Saito, T; Tsuchiya, T | 1 |
| Akiyama, Y; Hasuike, Y; Higuchi, I; Hosomi, S; Ishikawa, A; Miyamoto, M; Tanigawa, T | 1 |
| Fukumoto, K; Kobayashi, H; Koizumi, N; Nakase, Y; Takagi, T | 1 |
| Hama, N; Hirao, M; Ikeda, M; Maeda, S; Miyake, K; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Uemura, M; Yamamoto, K | 1 |
| Cha, H; Cho, JM; Kim, SA; Kwon, SK; Lee, DY; Lee, HS; Park, SB; Ro, S; Song, SY | 1 |
| Blackwood, E; Cao, Y; Evangelista, M; Klijn, C; Lee, HJ; Pham, V; Settleman, J; Stokoe, D; Wilson, C | 1 |
| Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
| Del-Barrio-Díaz-Aldagalan, A; Garrido-Abad, P; López-Elzaurdia, C; Méndez-Rubio, S; Platas-Sancho, A; Rodríguez-Cabello, MA; Saenz-Medina, J; Sanz-Miguelañez, JL | 1 |
| Birhanu, G; Javar, HA; Seyedjafari, E; Zandi-Karimi, A | 1 |
| Hepel, M; Kurzątkowska, K; Santiago, T | 1 |
| Alsdorf, WH; Avilov, SA; Bokemeyer, C; Dyshlovoy, SA; Hauschild, J; Honecker, F; Kalinin, VI; Madanchi, R; Otte, K; Schumacher, U; Silchenko, AS; Stonik, VA; von Amsberg, G | 1 |
| Bhardwaj, A; Khan, MA; Khushman, M; Patel, GK; Patton, MC; Singh, AP; Singh, S; Srivastava, SK; Zubair, H | 1 |
| Hui, P; Ma, J; Meng, W; Wang, N; Xiang, S | 1 |
| Koh, V; Kwan, HY; Mah, TL; Tan, WL; Yong, WP | 1 |
| Atkins, MB; Choueiri, TK; Jay, R; McDermott, DF; McKay, RR; Olivier, KM; Signoretti, S; Song, J; Van Allen, EM; Werner, L | 1 |
| Aicher, A; Aires, A; Cortajarena, AL; Heeschen, C; Trabulo, S | 1 |
| Darko, KO; He, C; Huang, Y; Liu, Z; Peng, M; Su, Q; Tao, T; Yang, X; Yin, T | 1 |
| Fields, RC; Hawkins, WG; Linehan, DC; Liu, J; Ohman, KA; Strasberg, SM; Tan, BR; Tan, MC | 1 |
| Hagiwara, M; Hara, M; Hirayasu, K; Kojima, T; Nishiyama, H; Usui, J; Yamagata, K; Yokoyama, C; Yoshino, T | 1 |
| Dou, QP; Peng, T | 1 |
| Cho, S; Hong, HJ; Hwang, H; Jeong, MS; Kang, SG; Kim, AR; Kim, H; Lee, TS; Lee, YJ; Song, IH | 1 |
| Guan, X; Song, W; Tang, L; Wang, S; Xie, H; Xu, J; Xu, Y; Zhang, W | 1 |
| Alanee, SR; Bajorin, DF; Garcia-Grossman, IR; Littman, J; Offit, K; Ostrovnaya, I; Pendse, DV; Regazzi, AM; Shah, S; Vijai, J; Zabor, EC | 1 |
| Agaimy, A; Akdemir, KC; Amin, S; Carugo, A; Chin, L; Colla, S; Corti, D; DePinho, RA; Dey, P; Draetta, GF; Fleming, JB; Garvey, J; Genovese, G; Ghosh, P; Giuliani, V; Goggins, MG; Gutschner, T; Heffernan, TP; Jiang, S; Kwong, LN; Leo, E; Li, L; Liu, CG; Maitra, A; Minelli, R; Molin, MD; Muller, F; Nezi, L; Pettazzoni, P; Roberts, CW; Robinson, FS; Seth, S; Sgambato, A; Svelto, M; Takahashi, K; Tepper, J; Toniatti, C; Viale, A; Wang, H; Wood, LD; Wu, CC; Ying, H; Zhang, J | 1 |
| Altan, B; Araki, K; Hosouchi, Y; Ishii, N; Kubo, N; Kuwano, H; Nishiyama, M; Shirabe, K; Suzuki, H; Tsukagoshi, M; Watanabe, A; Yokobori, T | 1 |
| Nanjappa, S; Pabbathi, S; Singh, V; Uttamchandani, S | 1 |
| Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Miyazawa, M; Okada, KI; Shimizu, A; Ueno, M; Yamaue, H | 1 |
| Arima, S; Furuse, J; Kasuga, A; Kawai, K; Kitamura, H; Kobayashi, T; Nagashima, F; Naruge, D; Okamoto, T; Okano, N; Shimizu, K; Sugiyama, M; Suzuki, Y; Takasu, A; Toki, M | 1 |
| Guru Murthy, GS; Hamadani, M; Jethava, Y | 1 |
| Alemany, R; Fillat, C; Maliandi, MV; Mato-Berciano, A; Montoliu, L; Raimondi, G | 1 |
| Du, L; Jin, Y; Tong, L; Yang, M; Zuo, J | 1 |
| Aoki, T; Hasegawa, K; Hoshikawa, M; Kakimi, K; Kokudo, N; Matsushita, H | 1 |
| Hayasaka, T; Honda, T; Imai, N; Kagabu, S; Kin, S; Matsui, T; Nishigori, H; Oishi, T; Otsuki, T; Sato, H; Sato, K; Shimokawa, H; Shoji, T; Sugiyama, T; Takahashi, F; Tando, T; Tokunaga, H; Wagatsuma, S; Watanabe, T; Watanabe, Y; Yaegashi, N; Yamada, H; Yamamoto, H; Yokoyama, Y; Yoshida, Y; Yoshinaga, K | 1 |
| Albrecht, T; Michalik, K; Nolte-Ernsting, C; Pereira, PL; Pützler, M; Schicho, A; Stroszczynski, C; Wiggermann, P | 1 |
| Abrahams, L; Ahmad, GT; Ajakaiye, AM; Alatsatianos, M; AlHumaidi, AS; Ashmore-Harris, C; Bahsoun, B; Baines, AJ; Blackburn, E; Cinatl, J; Clark, I; Dura, UK; Fixmer, CN; Garrett, MD; Gourlay, CW; Griffin, DK; Gullick, WJ; Hargreaves, E; Hogwood, CE; Howard, MJ; Ike-Morris, C; Lithgow, PE; Lloyd, DR; Mato Prado, M; Mccullough, D; Michaelis, M; Mishra, S; Rossman, JS; Rothweiler, F; Rowe, M; Saintas, E; Schöler, KM; Smales, CM; Timur, H; Tsaousis, AD; von der Haar, T; Wass, MN; Williamson, MD; Yiangou, L; Zehner, R | 1 |
| Banavali, S; Bhargava, P; Kannan, S; Mirani, J; Nashikkar, C; Ostwal, V; Pinninti, R; Ramaswamy, A | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Hasegawa, S; Kawamoto, K; Kishimoto, T; Mikamori, M; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Wada, H; Yamada, D | 1 |
| Bird, NT; Dodd, J; Elmasry, M; Ghaneh, P; Greenhalf, W; Jones, R; Kitteringham, N; Malik, H; Neoptolemos, JP; Palmer, D; Psarelli, E | 1 |
| Fader, AN; Ricci, S; Stone, RL | 1 |
| Baker, SD; Blum, W; Drenberg, CD; Du, G; Gibson, AA; Gruber, TA; Hu, S; Li, L; Nies, AT; Pabla, N; Pounds, SB; Rhinehart, DP; Schwab, M; Shi, L; Sparreboom, A | 1 |
| Boku, N; Chen, JS; Cheng, AL; Egawa, S; Fujii, H; Funakoshi, A; Furuse, J; Hamamoto, Y; Hatori, T; Ioka, T; Ito, T; Maguchi, H; Matsumoto, S; Miyakawa, H; Mizumoto, K; Nakamori, S; Ohashi, Y; Ohkawa, S; Okusaka, T; Sato, A; Satoh, T; Tanaka, M; Ueno, H; Yamaguchi, T; Yamao, K | 1 |
| Altendorf-Hofmann, A; Betzler, C; Bruns, C; Camaj, P; Däberitz, T; Jauch, KW; Knösel, T; Niess, H; Popp, F; Pozios, I; Seeliger, H; Settmacher, U; Wang, X; Zhao, Y | 1 |
| Assi, T; El Karak, F; El Rassy, E; Ghosn, M; Kattan, J | 1 |
| Inoue, K; Kuroda, H; Ohtsuka, H; Ohtsuki, S; Tachikawa, M; Terasaki, T; Uchida, Y; Unno, M | 1 |
| Hara, A; Ichinoe, M; Imaizumi, H; Iwai, T; Kaizu, T; Kaneda, T; Kawamata, H; Kida, M; Kumamoto, Y; Nakamoto, S; Nishiyama, R; Okuwaki, K; Suzuki, E; Tajima, H; Watanabe, M; Yamauchi, H; Yokota, M | 1 |
| Becker, PS; Cassaday, RD; De Padova, N; Lindstrom, S; Puri, A; Ulrickson, ML | 1 |
| Cherniawsky, H; Ho, M; Merchant, N; Sawyer, M | 1 |
| Feng, B; Fu, JT; Hu, Y; Shi, D; Shi, Z | 1 |
| Gao, G; Yu, H; Yue, Q; Zheng, X; Zou, G | 1 |
| Arigami, T; Kijima, Y; Kurahara, H; Maemura, K; Mataki, Y; Matsushita, D; Natsugoe, S; Okubo, K; Sakoda, M; Uenosono, Y; Yanagita, S | 1 |
| Alexandre, J; Blanchet, B; Goldwasser, F; Henon, C; Huillard, O; Preta, LH | 1 |
| Chen, H; Ding, D; Dong, J; He, Z; Kou, L; Liu, X; Luo, C; Sun, J; Sun, M; Wang, G; Wang, J; Yi, X; Zhang, D; Zhao, D | 1 |
| Fuks, Z; Haimovitz-Friedman, A; Kolesnick, R; Tap, WD; van Hell, AJ | 1 |
| Kusuhara, M; Sasaki, K; Serizawa, M; Todaka, A; Umehara, R; Urakami, K; Yamaguchi, K; Yasui, H | 1 |
| Anandadas, C; Choudhury, A; Elliott, T; Joseph, N; Logue, J; Lyons, J; Sanderson, B; Thompson, C; Wylie, J | 1 |
| Duan, Q; Li, H; Shen, Q; Wang, C; Wu, H; Yin, T; Zhang, Z; Zhao, H | 2 |
| Bendell, J; Benson, AB; Dong, H; Hecht, JR; Kudrik, F; Vyushkov, D; Wainberg, ZA | 1 |
| Artru, P; Bodère, A; Brac, C; Edeline, J; Le Pabic, E; Le Sourd, S; Leconte, B; Lièvre, A; Pracht, M; Viaud, J | 1 |
| Avallone, A; Botti, G; Capozzi, M; De Divitiis, C; De Stefano, A; Ottaiano, A; Tafuto, S | 1 |
| Fukushi, K; Hashimoto, Y; Hatakeyama, S; Koie, T; Narita, T; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Campbell, F; Corrie, P; Costello, E; Cox, T; Coxon, F; Cunningham, D; Evans, A; Falk, S; Ghaneh, P; Greenhalf, W; Hickish, T; Jackson, R; Madhusudan, S; Middleton, G; Neoptolemos, JP; Palmer, DH; Propper, D; Rawcliffe, C; Ross, P; Shaw, VE; Valle, JW; Wadd, N; Wadsley, J; Wasan, H | 1 |
| Bains, A; Gong, Q; Gu, Z; Guys, N; Hu, J; Li, J; Li, X; Luo, K; Pan, D; Zhang, C; Zhu, H | 1 |
| Chen, S; Dong, MS; Wang, Y; Zhang, JH; Zhang, WL | 1 |
| Andersson, B; Andersson, R; Ansari, D; Nilsson, J; Said-Hilmersson, K; Sasor, A; Urey, C | 1 |
| Cross, WE | 1 |
| Anoopkumar-Dukie, S; Arora, D; Desbrow, B; Grant, GD; Hall, S; Hong, Y; Lai, R | 1 |
| Barrett, EG; Chougule, MB; Forest, MG; Hill, DB; Hoffmann, PR; Morris, KR; Youngren-Ortiz, SR | 1 |
| Han, Y; Ni, S; Qiu, L; Zhang, G; Zhou, H | 1 |
| Han, J; Li, K; Liang, Y; Tian, B; Wang, L; Wu, Z; Zhang, J | 1 |
| Belk, KW; Kim, GP; Parisi, MF; Patel, MB; Pelletier, CL | 1 |
| Saborowski, A; Vogel, A | 1 |
| Marasini, B; Sahu, RP | 1 |
| Avan, A; Funel, N; Giovannetti, E; Gomez, VE; Griffioen, AW; Leon, LG; Rovithi, M; Verheul, HM; Wurdinger, T | 1 |
| Janssen, S; Manig, L; Rades, D; Schild, SE | 1 |
| Benz, D; Chen, S; Cruise, GM; Lopez-Benitez, R; Wu, X; Wu, Y | 1 |
| Fischer, M; Kirstein, MM; Kratzel, AM; Lehner, F; Manns, MP; Reineke-Plaaß, T; Schweitzer, N; Vogel, A; Weber, T | 1 |
| Hashimoto, Y; Kondo, N; Murakami, Y; Nakagawa, N; Okada, K; Sudo, T; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Ahn, HM; Choi, IK; Hong, J; Hong, SS; Jung, KH; Lee, HS; Son, MK; Yan, HH; Yun, CO | 1 |
| Li, M; Li, X; Liu, N; Meng, F; Song, S; Wu, X | 1 |
| Chourasia, MK; Dyawanapelly, S; Kumar, A | 1 |
| Cruz-Vallejo, V; Morales-Ramírez, P; Vallarino-Kelly, T | 1 |
| Idage, BB; Idage, SB; Munot, NM; Surwase, SS | 1 |
| Chen, J; Gao, W; Guo, F; Jiang, K; Li, H; Lu, Z; Lv, N; Miao, Y; Song, G; Tu, M; Wei, J; Xi, C | 1 |
| Duvic, M; Oki, Y; Wilmas, K | 1 |
| Woo, SM | 1 |
| Ariyoshi, K; Matsushita, S; Okadome, M; Saito, T; Shimada, T; Shimamoto, K; Shimokawa, M; Yamaguchi, S | 1 |
| Bel, A; Buijsen, J; Ebrahimi, G; Gurney-Champion, OJ; Kolff, MW; Lens, E; Neelis, KJ; Rasch, CR; Stoker, J; van der Horst, A; van Herk, M; van Tienhoven, G; Versteijne, E | 1 |
| Kondo, N; Murakami, Y; Nakagawa, N; Sueda, T; Takahashi, S; Toyota, K; Uemura, K | 2 |
| Chen, H; Chen, Z; Geng, YW; Meng, ZQ; Qi, Q; Wang, P; Xu, LT; Yu, SL | 1 |
| Abakar-Mahamat, A; Ciccolini, J; Dahan, L; Deplanque, G; Fein, F; François, E; Gagnière, J; Gattacceca, F; Lacarelle, B; Rachid, M; Seitz, JF; Serdjebi, C | 1 |
| Beg, MS; Bolluyt, J; Boothman, DA; Deberardinis, RJ; Fattah, F; Gerber, DE; Huang, X; Laheru, D; Leff, R; Merritt, ME; Sarode, V; Silvers, MA; Xie, XJ | 1 |
| Desai, P; Haimovitz-Friedman, A; Humm, JL; Kramer, RM; Lowery, MA; Pillarsetty, N; Romesser, PB; Russell, J | 1 |
| Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y | 1 |
| Huang, J; Li, Z; Shen, X; Wang, Y; Zhi, Q; Zhou, J | 1 |
| Baze, WB; Cui, Z; Finch, RA; Jolly, CA; Naguib, YW; Valdes, S | 1 |
| Cao, YB; Li, Q; Ma, YX; Sun, Y; Xu, CA; Zhang, XW | 1 |
| Alessandri, G; Balducci, L; Brini, AT; Cabeza, L; Ciusani, E; Cocce, V; Falchetti, ML; Parati, E; Pascucci, L; Pessina, A; Piovani, G; Sisto, F | 1 |
| Ahn, JS; Awada, A; Cortés, J; Diéras, V; Gómez-Pardo, P; Hannah, AL; Hoch, U; Im, SA; Mailliez, A; Moreno-Aspitia, A; O'Shaughnessy, J; Perez, EA; Potter, DA; Rugo, HS; Schwartzberg, LS; Tagliaferri, M; Twelves, C; Yardley, DA; Zhao, C | 1 |
| Ahn, JH; An, H; Choi, Y; Kim, YH; Kim, YJ; Lee, J; Lim, HY; Lim, SH; Park, KH; Park, YS; Suh, DC; Yun, MS | 1 |
| Chen, Y; Hu, Q; Li, L; Li, Y; Lou, Z; Luo, K; Nowsheen, S; Wu, C; Yin, Y; Yuan, J; Zhang, L | 1 |
| Bugde, P; Hawkins, BC; Li, Y; Paxton, JW; Revalde, JL; Rosengren, RJ; Wijeratne, TS | 1 |
| Xiao, J; Yu, H | 1 |
| Cruz-Monserrate, Z; Govindarajan, R; Griffin, J; Hung, SW; Mody, HR; Pathak, RK | 1 |
| Chen, CS; Cheng, CL; Chiu, KY; Ho, HC; Hung, SC; Li, JR; Ou, YC; Wang, SS; Yang, CK | 1 |
| Avallone, A; Capozzi, M; Cavalcanti, E; DE Divitiis, C; DI Girolamo, E; Nasti, G; Ottaiano, A; Romano, G; Tafuto, S; Tatangelo, F; VON Arx, C | 1 |
| Aguilar-Bonavides, C; Behrens, C; Çeliktas, M; Delgado, O; Dennison, JB; Dhillon, D; Do, KA; Fahrmann, JF; Gazdar, AF; Hanash, SM; Ostrin, EJ; Taguchi, A; Tanaka, I; Tripathi, SC; Villalobos, P; Wang, H | 1 |
| Hijikata, Y; Hosokawa, Y; Kasuya, K; Katsumata, K; Nagakawa, Y; Nakajima, T; Nakayama, H; Sahara, Y; Takishita, C; Tokuuye, K; Tsuchida, A | 1 |
| Caputo, D; Coppola, R; D'Angelillo, RM; Fiore, M; Floreno, B; Ramella, S; Trecca, P; Trodella, L; Trodella, LE; Valeri, S | 1 |
| Adam, AA; Allam, AH; Anderson, KI; Biankin, AV; Boulghourjian, A; Burgess, A; Chantrill, L; Chin, VT; Chou, A; Conway, JR; Cox, TR; Currey, N; Del Monte-Nieto, G; Drury, A; Evans, TR; Froio, D; Gallego-Ortega, D; Gill, AJ; Giry-Laterriere, M; Grey, ST; Harris, NL; Harvey, RP; Herrmann, D; Heu, C; Jain, R; Johns, AL; Kohonen-Corish, M; Lucas, MC; Magenau, A; McCloy, RA; McGhee, EJ; Melenec, P; Morton, JP; Nagrial, AM; Nobis, M; Ormandy, CJ; Pajic, M; Phan, T; Pinese, M; Samra, JS; Samuel, MS; Sansom, OJ; Steinmann, A; Timpson, P; Vennin, C; Walters, SN; Wang, Y; Warren, SC; Weninger, W; Whan, R; Zaratzian, A | 1 |
| Beinse, G; Bonnetain, F; Borg, C; Bouché, O; Cleau, D; d'Engremont, C; de Mestier, L; Dupont-Gossart, AC; Fein, F; Heyd, B; Lakkis, Z; Louvet, C; Meurisse, A; Neuzillet, C; Rousseau, B; Tournigand, C; Vernerey, D; Vienot, A | 1 |
| Chiang, S; George, S; Hemming, ML; Hensley, ML; Nucci, MR; Wagner, AJ; Wang, L | 1 |
| Ando, R; Hotta, Y; Kimura, K; Kondo, M; Yasui, T | 1 |
| Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Murray, D; Nieto, Y; Valdez, BC | 1 |
| Cao, Q; Duan, HX; Qu, GF; Tan, LH; Wang, LT; Xiao, S; Xiao, YP; Zhuang, X | 1 |
| Berlin, J; Engebretson, A; Hong, TS; Katz, MHG; Khorana, AA; Maitra, A; Mangu, PB; Mohile, SG; Mumber, M; Schulick, R; Shapiro, M; Urba, S; Zeh, HJ | 1 |
| Böhm, R; Grünberger, B; Kraischits, N; Kudlacek, S; Kunit, T; Lamche, M; Loidl, W; Meran, JG; Niedersüss-Beke, D; Puntus, T; Schramek, P | 1 |
| Lamb, YN; Scott, LJ | 1 |
| Fujimoto, K; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, JY; Kim, TM; Lee, SH; Park, S; Suh, B | 1 |
| Abe, T; Endo, S; Hashizume, M; Iwamoto, C; Koikawa, K; Manabe, T; Miura, D; Miyasaka, Y; Mizumoto, K; Mizuuchi, Y; Moriyama, T; Nagai, E; Nakamura, M; Nakata, K; Oda, Y; Ohtsuka, T; Ohuchida, K; Okumura, T; Sada, M | 1 |
| Chen, W; Gao, S; Gong, X; Liang, Y; Liu, K; Yang, L; Zhang, F | 1 |
| Azria, D; Fléchon, A; Lapierre, A; Mottet, N; Riou, O | 1 |
| Gujral, TS; Kirschner, MW | 1 |
| Dolžan, V; Goričar, K; Kovač, V | 1 |
| Batist, G; Chanez, B; Gilabert, M; Giovanini, M; Kavan, P; Raoul, JL; Rho, YS; Turrini, O | 1 |
| Eken, A; Katırcıbaşı, MT | 1 |
| Chmielowski, B; Dry, SM; Eilber, FC; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Murakami, T; Nelson, SD; Russell, TA; Singh, AS; Unno, M | 1 |
| Chen, H; Deng, X; Fang, Y; Huo, Z; Li, H; Lu, X; Peng, C; Shen, B; Shi, M; Tang, X; Wang, X; Wen, C; Xie, J | 1 |
| Amada, K; Itoh, H; Nakahara, R; Ono, H; Sato, Y | 1 |
| Dong, XY; Gou, X; He, WY; Huang, XL; Lin, Y; Xie, XY; Yang, XY; Yin, HB; Zhang, H | 1 |
| Aspeslagh, S; Douchet, G | 1 |
| Galvez-Silva, J; Hernandez, F; Liu, D; Maher, OM; Nieto, Y; Park, M; Tewari, P | 1 |
| Edwards, H; Ge, Y; Jiang, Y; Liu, S; Quan, C; Ren, Q; Wang, G; Wang, T | 1 |
| Cinar Ciftci, G; Guler, MO; Hamsici, S; Sardan Ekiz, M; Tekinay, AB | 1 |
| Chen, S; Chen, Y; Huang, C; Huang, K; Li, J; Li, Y; Lian, G; Lin, Y; Wang, L; Yang, K; Zeng, L; Zhang, Z | 1 |
| Chung, JI; Hwang, H; Kim, TS; Noh, GH | 1 |
| Baechmann, S; Boeck, S; Clemens, MR; Esposito, I; Haas, M; Heinemann, V; Jung, A; Kettner, E; Kirchner, T; Kruger, S; Laubender, RP; Ormanns, S; Quietzsch, D; Remold, A; Schlitter, AM; Siveke, JT; Wenzel, P; Westphalen, CB | 1 |
| Benhadji, KA; Fujii, H; Ikeda, M; Kondo, S; Lahn, MMF; Ogasawara, K; Takahashi, H; Ueno, H | 1 |
| Li, J; Liu, B; Liu, F; Ma, Z; Qian, J; Wu, G | 1 |
| Lee, SH; Nilofar Danishmalik, S; Sin, JI | 1 |
| Andersen, JB; Burmeister, K; Fusco, A; Karamitopoulou, E; Matter, MS; Pallante, P; Piscuoglio, S; Quagliata, L; Quintavalle, C; Sepe, R; Terracciano, LM | 1 |
| Li, J; Liu, Y; Wang, Z; Yang, L; Zhai, X; Zheng, Q; Zhu, Y | 1 |
| Do, C; Han, Y; Smith, GS; Zhang, Z | 1 |
| Akita, T; Kiuchi, Y; Kogo, M; Kurihara, T; Nakajima, H; Nakamura, S; Shikama, Y; Sunaga, T; Tobe, T; Yoneyama, K | 1 |
| Furuse, J; Hamada, C; Ikari, T; Imai, S; Isayama, H; Ishii, H; Nakai, Y; Okamura, S; Okusaka, T | 1 |
| Endo, I; Kubota, K; Kumamoto, T; Matsuyama, R; Mori, R; Sakamaki, K; Taniguchi, K; Yabushita, Y | 1 |
| Abrams, TA; Fuchs, CS; Meyer, G; Meyerhardt, JA; Schrag, D; Wolpin, BM | 1 |
| Li, W; Yao, J; Zhang, C; Zhang, L | 1 |
| Hirai, K; Inoue, K; Itoh, K; Kawasaki, Y; Matsumoto, M; Nakamori, H; Osada, M; Otake, A; Taku, K; Tsuji, D; Yokoi, M | 1 |
| Endo, I; Goto, A; Ichikawa, Y; Kobayashi, N; Shimamura, T; Tokuhisa, M | 1 |
| Chiba, N; Imai, H; Ishioka, C; Komine, K; Mori, T; Ohori, H; Okada, Y; Saijo, K; Shimodaira, H; Shirota, H; Takahashi, M; Takahashi, S | 1 |
| Baburina, I; Barrett, M; Beumer, JH; Courtney, JB; Harney, RL; Holleran, JL; Honeywell, RJ; Jarrah, J; Kozo, D; Peters, GJ; Ross, MW; Salamone, SJ | 1 |
| Chen, W; Liu, Q; Long, MM; Mohan, M; Shi, YH; Wang, H; Wang, J; Xu, SW; Zhan, M | 1 |
| Daste, A; Dousset, V; Gross-Goupil, M; Hoepffner, JL; Ravaud, A; Teyssonneau, D | 1 |
| Alves, C; Araújo, MJ; Fernandes, I; Ferreira, A; Gomes, P; Mateus, N; Vale, N | 1 |
| Cassier, P; Charmetant, X; Fournier, T; Jolivot, A; Juillard, L; Lemoine, S; Puthet, JC | 1 |
| Chen, BE; Crump, M; Djurfeldt, M; Good, D; Hay, AE; Kuruvilla, J; Laferriere, N; LeBrun, D; Luminari, S; Meyer, RM; Reiman, T; Savage, KJ; Sehn, LH; Shepherd, LE; Skamene, T; Soulières, D; Stakiw, J; Zhu, L | 1 |
| Abou-Khalil, J; Rocha, FG | 1 |
| Bjerregaard, JK; Detlefsen, S; Graversen, M; Mortensen, MB; Pfeiffer, P | 1 |
| Gahrton, G | 1 |
| Azemoto, N; Hasebe, A; Hiasa, Y; Imai, Y; Imamura, Y; Inada, N; Kawamura, T; Koizumi, M; Kumagi, T; Kuroda, T; Miyata, H; Nishiyama, M; Ohno, Y; Seike, H; Shibata, N; Tanaka, Y; Terao, T; Ueno-Toshimori, A; Yamanishi, H; Yokota, T | 1 |
| An, X; Deng, YF; Jiang, WQ; Li, LR; Shao, C; Shi, YX; Sun, P; Thomas, R; Xue, C; Yang, W | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kirchner, T; Kruger, S; Ormanns, S; Remold, A | 1 |
| Jia, L; Li, H; Li, L; Liu, X; Sun, Y; Wu, J; Zhao, L; Zhou, W | 1 |
| Chaudhary, AK; Kattel, K; Kumar, V; Mahato, RI; Mondal, G | 1 |
| Bouvet, M; Clary, BM; Delong, JC; Hoffman, RM; Hwang, HK; Igarashi, K; Kawaguchi, K; Kiyuna, T; Lwin, TM; Murakami, T; Unno, M | 1 |
| Hao, YP; Sun, L; Wang, HY; Wang, L; Zhang, J; Zhu, YP; Zhuang, YP | 1 |
| Furuse, J; Gemma, A; Ichikawa, W; Ishii, T; Okusaka, T; Seki, A | 1 |
| Mahdi, H; Maurer, K; Michener, C; Rose, PG | 1 |
| Baechmann, S; Boeck, S; Haas, M; Heinemann, V; Jung, A; Kirchner, T; Kruger, S; Modest, DP; Ormanns, S; Remold, A; Werner, J | 1 |
| Andreiuk, B; Bort, G; Cayre, F; Couvreur, P; Dalbin, L; Desmaële, D; Klymchenko, AS; Lepetre-Mouelhi, S; Mougin, J; Mura, S; Paul, JL; Pieters, G; Ramseyer, C; Sobot, D; Yesylevskyy, SO | 1 |
| Bergsland, CH; Bruun, J; Danielsen, SA; Eilertsen, IA; Høland, M; Kallioniemi, O; Kolberg, M; Lothe, RA; Mpindi, JP; Murumägi, A | 1 |
| Besselink, MG; Busch, OR; de Rooij, T; Dijkgraaf, MG; Martin, RC; Rombouts, SJ; Schoorlemmer, A; van Delden, OM; van Gulik, TM; van Hooft, JE; van Laarhoven, HW; van Lienden, KP; Vogel, JA; Wilmink, JW | 1 |
| Asai, A; Asaoka, T; Asukai, K; Doki, Y; Eguchi, H; Gotoh, K; Ishii, H; Iwagami, Y; Kawamoto, K; Konno, M; Mori, M; Nishida, N; Noda, T; Satoh, T; Wada, H; Yamada, D | 1 |
| Chigutsa, E; Long, AJ; Wallin, JE | 1 |
| Damhuis, RA; den Bakker, MA; Derks, JL; Dingemans, AC; Groen, HJ; Smit, EF; Speel, EM; Thunnissen, E; van den Broek, EC; van Suylen, RJ | 1 |
| da Silva, GN; Filoni, LT; Salvadori, DMF; Salvadori, MC | 1 |
| Malkoski, SP; Nolan, K; Patil, T; Tippimanchai, D; Ziemke, M | 1 |
| Fong, KW; Hussain, A; Ong, WS; Sommat, K; Soong, YL; Tan, T; Wee, J | 1 |
| Abu-Suboh, M; Allende, E; Arribas, J; Balsells, J; Bernadó Morales, C; Bilal, F; Carreras, MJ; Macarulla, T; Massó-Vallés, D; Mohan, V; Pedersen, K; Sagi, I; Salcedo, MT; Serres, X; Soucek, L; Tabernero, J; Vivancos, A | 1 |
| Blaydorn, L; Coats, J; Farley, JH; Khemka, V; Lynch, CA; McGahey, K; Niu, J; Sangal, A; Waypa, J; Weiss, GJ | 1 |
| Ghazaly, E; Peters, GJ; Rizzuto, I | 1 |
| Hara, R; Kita, E; Nakamura, K; Sudo, K; Tsujimoto, A; Yamaguchi, T | 1 |
| Chang, HM; Cho, H; Hyung, J; Kim, BJ; Kim, KP; Kim, MH; Lee, SK; Lee, SS; Park, DH; Park, JH; Park, SJ; Ryoo, BY; Seo, DW; Song, TJ; Yoo, C | 1 |
| Chang, Y; Duan, W; Fu, X; Li, L; Li, X; Li, Z; Nan, F; Sun, Z; Wang, X; Wu, J; Yan, J; Young, KH; Zhang, L; Zhang, M; Zhang, X | 1 |
| Abbott, DE; Ahmad, SA; Al Humaidi, AH; Bentrem, DJ; Cho, CS; Ethun, CG; Hanseman, DJ; Kooby, DA; Maithel, SK; Salem, A; Stocker, SJ; Talamonti, MS; Weber, SM; Xia, BT | 1 |
| Du, C; Guo, H; Kornmann, M; Liu, X; Ma, L; Tian, X; Wang, F; Yang, Y; Zhang, Z | 1 |
| Fan, ZK; Jin, LM; Jin, SF; Pan, L | 1 |
| Aono, T; Masuda, N; Matsunami, N; Mizutani, M; Nakayama, T; Nishida, Y; Ooe, A; Tanaka, S; Tanino, H; Tokunaga, S; Tsurutani, J; Tsuyuki, S; Yamaguchi, M; Yamamoto, D; Yamamura, J; Yasojima, H; Yoshidome, K | 1 |
| Buchy, E; Cayre, F; Couvreur, P; Desmaële, D; Garcia-Argote, S; Mura, S; Pieters, G; Rouquette, M; Sobot, D; Vukosavljevic, B; Windbergs, M | 1 |
| Anton-Pascual, B; Calzas-Rodriguez, J; Guerra-Martinez, JA; Malon-Gimenez, D; Olmo-Sanchez, A; Sanchez-Cendra, C | 1 |
| Colleselli, D; Löbig, N; Martini, T; Mitterberger, MJ; Wezel, F | 1 |
| Corr, SJ; Curley, SA; Curtis, LT; Frieboes, HB; Godin, B; Ho, JC; Ware, MJ; Wu, M | 1 |
| Dağli, AF; Karataş, A; Koca, SS; Orhan, C; Özgen, M; Şahin, K; Tuzcu, M | 1 |
| Bonnetain, F; de la Motte Rouge, T; Kalbacher, E; Lesoin, A; Pautier, P | 1 |
| Abu-Fayyad, A; Nazzal, S | 1 |
| Feygenzon, V; Klausner, JM; Lahat, G; Loewenstein, S; Lubezky, N; Pasmanic-Chor, M; Sher, O | 1 |
| Barni, S; Ghidini, A; Inno, A; Labianca, R; Petrelli, F; Rimassa, L; Tomasello, G | 1 |
| Arai, D; Chen, LT; Furuse, J; Ichikawa, W; Ikeda, M; Ioka, T; Ishii, H; Li, CP; Matsuyama, Y; Mizuno, N; Oh, DY; Okusaka, T; Park, YS; Ueno, M; Yamaguchi, T | 1 |
| Hiramoto, H; Ichikawa, D; Inazawa, J; Muramatsu, T; Otsuji, E; Tanimoto, K; Yasukawa, S | 1 |
| Díaz-Paniagua, L; Diez-Fernández, R; Enrech-Frances, S; López-Esteban, L; Martín Martínez, JM; Molina-García, T; Sánchez-Peña, AM; Soria-Tristán, M; Vázquez-Sánchez, R | 1 |
| Adamska, A; Domenichini, A; Falasca, M | 1 |
| Amini, M; Atyabi, F; Dinarvand, R; Mirzaie, ZH; Mirzazadeh Tekie, FS; Mottaghitalab, F; Norouzi, P | 1 |
| Badalamenti, G; Baldi, A; Casali, P; Collini, P; Dei Tos, AP; Gronchi, A; Iuliani, M; Muda, AO; Pantano, F; Perrone, G; Rabitti, C; Sanfilippo, R; Santini, D; Stacchiotti, S; Tonini, G; Vincenzi, B | 1 |
| Alexander, PM; Caudell, DL; Kucera, GL; Pardee, TS; Pladna, KM | 1 |
| Blanco, FF; Brody, JR; Chand, SN; Cozzitorto, JA; Dukleska, K; Jiang, W; Jimbo, M; Lal, S; Londin, ER; Mambelli-Lisboa, NC; Metallo, CM; Moffat, C; Nevler, A; Parker, SJ; Seifert, EL; Vaziri-Gohar, A; Winter, JM; Yeo, CJ; Zarei, M | 1 |
| Chen, F; Hu, Y; Li, H; Liu, H; Tao, H; Wang, Y | 1 |
| Andronescu, E; Boldeiu, A; Grumezescu, AM; Mogoantă, L; Mogoșanu, GD; Popescu, RC; Radu, M; Savu, D; Temelie, M; Truşcă, R; Vasile, BȘ | 1 |
| Crane, CH; Cuaron, JJ; Goodman, KA; Hajj, C; Lowery, MA; O'Reilly, EM; Park, JJ; Reyngold, M; Shi, W; Wu, AJ; Yu, KH; Zhang, Z | 1 |
| Maloney, A; Relias, V; Saif, MW; Smith, MH | 1 |
| Furuse, J; Kasuga, A; Kawai, K; Kobayashi, T; Nagashima, F; Naruge, D; Okano, N | 1 |
| Anile, G; Banna, GL; Castaing, M; Conte, P; Dieci, MV; Guarneri, V; Lal, R; Marletta, F; Nicolosi, M; Parra, HJS; Strano, S | 1 |
| Abraham, T; Adair, JH; Butler, PJ; Clawson, GA; Fox, T; Gigliotti, CM; Kester, M; Linton, SS; Loc, WS; Martin, JA; Matters, GL; McGovern, CO; Smith, JP; Tabakovic, A; Tang, X; Wilczynski, ZR | 1 |
| Jiang, S; Ni, J; Zhang, HP; Zhu, J | 1 |
| Cheng, AL; Guo, JC; Kuo, SH; Kuo, TC; Lee, JC; Tien, YW; Yang, SH; Yeh, KH | 1 |
| Achiwa, K; Fujita, M; Kataoka, K; Matsubara, H; Minami, Y; Naitoh, T; Urano, F; Yamada, M; Yamamoto, H | 1 |
| Bahary, N; Epelboym, I; Hamad, A; Hogg, ME; Lee, KK; Steve, J; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Bai, S; Gao, YE; Hou, M; Kang, Y; Ma, X; Xu, Z; Xue, P | 1 |
| Huang, WF; Jiang, JH; Nie, J; Tan, DW; Wang, XF; Zhou, Y | 1 |
| Alexander, JF; Borsoi, C; Elganainy, D; Ferrari, M; Godin, B; Kai, M; Kang, Y; Koay, EJ; Lee, Y; Leonard, F; Liu, X; Liu, YT; Yokoi, K; Zaid, M | 1 |
| Arena, J; Bergamin, S; Chua, TC; Clarke, S; Diakos, C; Gibbs, E; Gill, AJ; Hruby, G; Itchins, M; Kim, S; Kneebone, A; Maher, R; Mittal, A; Nahm, CB; Pavlakis, N; Rabindran, J; Samra, J; Wong, M | 1 |
| Carlan, SJ; Guzman, A; Holloman, C; Madruga, M; Sundharkrishnan, L | 1 |
| Hazama, S; Iida, M; Kanekiyo, S; Matsui, H; Matsukuma, S; Nagano, H; Nakashima, M; Oka, M; Sakamoto, K; Shindo, Y; Suzuki, N; Takeda, S; Tokuhisa, Y; Ueno, T; Yoshimura, K; Yoshino, S | 1 |
| Abrego, J; Asara, JM; Attri, KS; Augustine, JJ; Berim, L; Cantley, LC; Chaika, NV; Dai, B; Dasgupta, A; Fleming, JB; Gebregiworgis, T; Goode, GD; Grandgenett, PM; Grem, JL; Gunda, V; Hankins, JH; Hollingsworth, MA; Illies, AL; Kim, JW; King, RJ; Lazenby, AJ; Ly, QP; Lyssiotis, CA; Mashadova, O; Matés, JM; Mehla, K; Murthy, D; Oliveto, JM; Powers, R; Purohit, V; Sasson, AR; Serkova, NJ; Shukla, SK; Singh, PK; Vernucci, E; Weekes, C; Yu, F | 1 |
| Aloia, TA; Cloyd, JM; Das, P; Egger, ME; Fleming, JB; Fogelman, D; Herman, JM; Javle, M; Katz, MHG; Kim, MP; Koay, EJ; Lee, JE; Maitra, A; Overman, MJ; Prakash, LR; Shroff, R; Tzeng, CD; Varadhachary, GR; Vauthey, JN; Wang, H; Wolff, RA | 1 |
| Ding, M; Gao, Y; Gong, L; Hong, C; Huang, X; Li, K; Yang, H; Yang, Q; Zhang, Z | 1 |
| Sohal, DPS | 1 |
| Chang, SY; Cho, S; Heo, EY; Kim, DE; Kim, SR; Ko, HJ; Lee, JY; Seong, J; Song, JH; Yoon, BI | 1 |
| Boggi, U; Cernusco, NLV; Coppola, M; Falcone, A; Gonnelli, A; Montrone, S; Morganti, R; Paiar, F; Panichi, M; Pasqualetti, F; Sainato, A; Vasile, E | 1 |
| Ilic, D; Ilic, I; Radojkovic, M | 1 |
| Gill, D; Kelly, M; Martinez, F; Schrader, J; Syed, W; Wright, J | 1 |
| Higashi, M; Momose, S; Morozumi, M; Tamaru, JI; Yamashita, T | 1 |
| Cheng, H; Guo, M; Jin, K; Liu, C; Lu, Y; Luo, G; Ni, Q; Yu, X | 1 |
| Bayerl, C; Breitenstein, S; Frei, L; Staerkle, RF; Stieger, R | 1 |
| Almawash, S; Chaudhary, AK; Mahato, RI; Mondal, G | 1 |
| Doi, M; Eguchi, H; Hirono, S; Kawai, M; Matsumoto, I; Murakami, Y; Okada, KI; Satoi, S; Shimokawa, T; Sho, M; Yamada, S; Yamaue, H | 1 |
| Billadeau, DD; Huang, H; Jin, X; Ma, T; Pan, Y; Tang, AH; Wang, L; Wu, H; Zhang, L | 1 |
| Asada, H; Miyagawa, F; Sho, M; Sugano, Y | 1 |
| Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB | 1 |
| Ark, M; Ibisoglu, B; Ilbasmis-Tamer, S; Özdemir, A; Takka, S; Yalcin, TE | 1 |
| Aldrighetti, L; Alexandrescu, S; Bagante, F; Bauer, TW; Ejaz, A; Guglielmi, A; Itaru, E; Koerkamp, BG; Maithel, SK; Marques, HP; Martel, G; Pawlik, TM; Poultsides, GA; Pulitano, C; Reames, BN; Ruzzenente, A; Shen, F; Soubrane, O; Spolverato, G; Weiss, M | 1 |
| Dou, J; Fan, H; Guo, J; Li, J; Shen, B; Wang, X; Xie, X; Zhou, C; Zhou, Y | 1 |
| Dora, CP; Jain, S; Katiyar, SS; Kumar, P; Kushwah, V; Pillay, V; Suresh, S | 1 |
| Hori, Y; Kuki, K; Shiomi, Y; Tanaka, T; Yoshimura, M | 1 |
| Ding, L; Dong, X; Geng, L; Li, N; Li, Y; Liu, Y; Luo, Q; Ma, C; Wei, F; Zhang, L; Zhang, Y; Zhou, T | 1 |
| Ge, L; Qie, S; Wang, Z; Yan, Q; Yang, L; Zhong, S | 1 |
| de Martino, M; Facchini, L; Farina, S; Lucchesi, M; Materassi, M; Melosi, F; Roperto, RM; Sardi, I; Stival, A; Tintori, V | 1 |
| Embry-Schubert, J; Lentz, SE; Littell, RD; Neugebauer, R; Palen, TE; Raine-Bennett, T; Tucker, LY; Zaritsky, E | 1 |
| Angevin, E; Cassier, PA; Drubay, D; Gazzah, A; Gonçalves, A; Gravis, G; Hollebecque, A; Italiano, A; Paci, A; Parlavecchio, C; Poinsignon, V; Soria, JC; Terret, C; Toulmonde, M; Varga, A | 1 |
| Fujita, N; Hamano, I; Hashimoto, Y; Hatakeyama, S; Hosogoe, S; Iwamura, H; Koie, T; Kusaka, A; Ohyama, C; Tobisawa, Y; Yamamoto, H; Yoneyama, T | 1 |
| Benes, C; Gao, P; Gray, NS; Li, F; Li, Y; Liu, F; Liu, Q; Liu, Y; Merlino, AA; Quinn, MM; Wang, X; Wong, KK | 1 |
| Fernandes Junior, HJ; Graziani, SR; Kalil Filho, R; Maranhão, RC; Morikawa, AT; Van Eyll, BM; Vital, CG | 1 |
| Chen, L; Cui, Y; Deng, Y; Feng, R; Li, T; Liu, X; Shi, J; Song, Y; Zhao, X | 1 |
| Hu, Q; Ji, S; Liang, C; Liang, D; Ni, Q; Qin, Y; Shi, S; Xiang, J; Xu, J; Xu, W; Yu, X; Zhang, B | 1 |
| Chen, T; Han, H; Ji, J; Jin, Q; Qin, Z; Teng, W; Zhao, J | 1 |
| Assaf, C; Nicolay, JP | 1 |
| Almokadem, S; Appleman, L; Belani, CP; Beumer, JH; Carneiro, BA; Chen, A; Chu, E; Ding, F; Hershberger, PA; Holleran, J; Jiang, Y; Ken Czambel, R; Kiesel, BF; Kontopodis, E; Lin, Y; Petro, D; Puhalla, S; Rachid, M; Schmitz, JC; Stoller, R | 1 |
| Bahra, M; Bischoff, S; Bläker, H; Denkert, C; Jöhrens, K; Jühling, A; Lohneis, P; Oettle, H; Pelzer, U; Riess, H; Sinn, BV; Sinn, M; Striefler, JK; Wislocka, L | 1 |
| Danishmalik, SN; Sin, JI | 1 |
| Inatsu, H; Kitamura, K; Nakashima, K | 1 |
| Castañeda, A; Cruz, J; Cruz, O; de Alava, E; de Torres, C; Garcia Del Muro, X; Lopez-Pousa, A; Maradiegue, E; Martin-Broto, J; Martinez-Trufero, J; Maurel, J; Mora, J; Perez-Jaume, S; Valverde, C; Vaz, MA | 1 |
| Algül, H; Azoitei, N; Bohnenberger, H; Frappart, PO; Gaedcke, J; Gieldon, L; Hampp, S; Hessmann, E; Hohwieler, M; Ihle, M; Kleger, A; Lechel, A; Lesina, M; Liebau, S; Lin, Q; Perkhofer, L; Reinhardt, HC; Romero Carrasco, MC; Ruess, DA; Russell, R; Schmitt, A; Schröck, E; Seufferlein, T; Sipos, B; Wagner, M; Wiesmüller, L | 1 |
| Agrawal, AK; Dora, CP; Gupta, RC; Jain, S; Kushwah, V; Lamprou, DA; Mallinson, D | 1 |
| Bonafede, M; Cai, Q; McBride, A; Parisi, M; Patel, M; Pelletier, C; Princic, N; Tran, O | 1 |
| Amidon, GL; Drelich, AJ; Smith, DE; Tsume, Y | 1 |
| Huang, X; Meng, Q; Song, Z; Wang, H; Xia, G | 1 |
| Hadian, K; Kirchner, M; Schneider, S; Schorpp, K | 1 |
| Chen, T; Han, H; Ji, J; Jin, Q; Wang, J; Yin, L | 1 |
| Brentnall, TA; Chen, R; Jung, L; Lai, LA; Pan, S; Pillarisetty, VG; Riddell, J; Sullivan, Y; Wang, L; Wong, M | 1 |
| Bansal, P; Baron, AD; Bedrick, E; Boumber, Y; Du, R; Fekrazad, MH; Lee, FC; Lee, SJ; Murad, W; Patt, YZ; Steinberg, K | 1 |
| Ancrile, BB; Birkholz, JH; Blandford, JT; Dye, CE; Gusani, NJ; Headlee, BD; Heisey, HD; Levenick, JM; Maranki, JL; Mathew, A; McGarrity, TJ; Moyer, MT; Sharzehi, S | 1 |
| Cai, R; Hao, J; Ji, T; Lang, J; Nie, G; Qi, F; Qin, Z; Wang, J; Wu, W; Zhang, L; Zhang, Y; Zhao, X; Zhao, Y | 1 |
| Miller, PJE; Ravelo, A; Schwartzberg, LS; Walker, MS; Wong, W | 1 |
| Abrego, J; Berim, L; Chaika, NV; Grem, J; Gunda, V; King, RJ; Lazenby, AJ; Sasson, AR; Shukla, SK; Singh, PK; Tadros, S; Vernucci, E; Yu, F | 1 |
| Bai, C; Feng, J; Gao, B; Hua, D; Huang, J; Jian, H; Li, W; Lu, S; Ma, S; Ma, Z; Pan, H; Qin, S; Song, Y; Tao, M; Yu, Y; Zhu, H | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Dörken, B; Gellert, K; Ghadimi, M; Grützmann, R; Jacobasch, L; Liersch, T; Maschmeyer, G; Messmann, H; Oettle, H; Pelzer, U; Rau, BM; Riess, H; Sinn, M; Stieler, JM; Striefler, JK; Waldschmidt, D; Weinmann, A; Wilhelm, M | 1 |
| Barajas, A; Evans, MA; Helgeson, ME; Krishnan, V; Menegatti, S; Mitragotri, S; Nowak, M; Pusuluri, A; Squires, TM; Vogus, DR; Zhang, M | 1 |
| Arenare, L; Bergamini, A; Bologna, A; Breda, E; Bryce, J; Cecere, SC; Cinieri, S; Cormio, G; Daniele, G; Di Napoli, M; Ferrandina, G; Gallo, C; Lorusso, D; Mangili, G; Murgia, V; Natale, D; Perrone, F; Piccirillo, MC; Pignata, S; Pisano, C; Raspagliesi, F; Sacco, C; Salutari, V; Scambia, G; Signoriello, S; Sorio, R; Vergote, IB; Wagner, U | 1 |
| Agostoni, V; Couvreur, P; Gref, R; Lampropoulou, M; Lazarou, YG; Maksimenko, A; Rodriguez-Ruiz, V; Salzano, G; Yannakopoulou, K | 1 |
| Bastiancich, C; Bastiat, G; Bianco, J; Danhier, F; Gallez, B; Joudiou, N; Lagarce, F; Préat, V; Ucakar, B; Vanvarenberg, K | 1 |
| Behera, UC; Modi, RR; Sheth, J; Singh, A | 1 |
| Atyabi, F; Bardania, H; Beiki, D; Dinarvand, R; Farokhi, M; Geramifar, P; Gholami, M; Kiani, M; Kundu, SC; Mottaghitalab, F; Reis, RL | 1 |
| Cui, Y; Guo, H; Huang, R; Huang, X; Lu, Q; Shen, L; Yan, J; Yang, L; Zhang, D; Zhao, X; Zheng, X; Zhuang, J | 1 |
| Dhande, R; Sharma, RK; Thakkar, H; Tyagi, A | 1 |
| Chen, Y; Cui, X; Lin, Y; Qin, C; Wang, X; Wang, Z; Xian, G; Zhang, Z | 1 |
| de Greeuw, I; Eersels, JLH; Greijer, AE; Middeldorp, JM; Molthoff, CFM; Novalić, Z; Verkuijlen, SAWM; Verlaan, M | 1 |
| Chen, Y; Tian, B; Wang, L; Wang, W; Zhang, Y; Zhu, Y | 1 |
| Bajwa, R; Daily, K; Starr, J | 1 |
| Adamian, Y; Brambilla, D; Gharibi, A; Hong, J; Hoover, M; Kelber, JA; La Kim, S; Lin, J; Molnar, J; Wolfenden, L | 1 |
| Ding, T; Fan, Y; Gu, Z; Lin, G; Shi, Y; Wang, Q | 1 |
| Kai, M; Kubo, M; Nakamura, M; Yamada, M; Yamamoto, H | 1 |
| Anders, RA; Che, X; Chen, J; Jaffee, EM; Kleponis, J; Muth, S; Rucki, AA; Sharma, R; Xiao, Q; Zheng, L | 1 |
| Bauer, S; Burgess, P; Doerfel, S; Forget, F; Kalambakas, S; Karaszewska, B; Khan, D; Mostafa Kamel, Y; Safran, H; Winer, ES | 1 |
| Fan, L; Song, C; Tan, J; Wu, H; Yang, Q; Zhao, S | 1 |
| Das, T; Dash, A; Ghosh, S; Sarma, HD | 1 |
| Bai, CM; Cheng, YJ; Gao, X; Li, NN; Meng, CT; Shao, YJ; Yan, XY; Zhou, JF; Zhou, N | 1 |
| Boroujerdi, M; Gilzad-Kohan, H; Sani, S | 1 |
| Afgar, A; Mahmoodzadeh, H; Radfar, JE; Rajabpour, A; Rajaei, F; Teimoori-Toolabi, L | 1 |
| Gilabert, M; Raoul, JL; Rousseau, F | 1 |
| Bulitta, JB; Jeong, SW; Joo, SH; Kim, S; Kim, TH; Kwon, DR; Lee, DY; Ma, E; Park, GY; Shin, BS; Shin, S; Weon, KY; Yoo, SD | 1 |
| Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA | 1 |
| Guo, X; Ingale, SA; Leonard, P; Seela, F | 1 |
| Fu, XB; He, JP; Jiao, H; Li, CL; Li, W; Liao, ZY; Liu, XR; Yang, B; Yi, C; You, X; Yuan, ML; Zhao, J | 1 |
| Biasoni, D; Busico, A; Calareso, G; Catanzaro, M; Colecchia, M; Giannatempo, P; Lo Vullo, S; Mariani, L; Necchi, A; Nicolai, N; Pennati, M; Perrone, F; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Togliardi, E; Torelli, T; Zaffaroni, N | 1 |
| Avraham, R; Barshack, I; Barzily-Rokni, M; Bhatia, SN; Brandis, A; Bu, J; Chatman, K; Cooper, ZA; Danino, T; Ferrone, CR; Flaherty, KT; Fleming, J; Frederick, DT; Fuks, G; Garrett, WS; Gavert, N; Geller, LT; Gevers, D; Golan, T; Golub, TR; Gopalakrishnan, V; Gurbatri, C; Hurd, MW; Huttenhower, C; Johnston, SE; Jonas, OH; Katz, M; Kim, M; Ligorio, M; Livny, J; Maitra, A; Mandinova, A; Michaud, M; Mosher, CM; Nejman, D; Reuben, A; Sandbank, J; Shee, K; Shental, N; Skalak, M; Smith, DA; Straussman, R; Thaiss, CA; Thayer, SP; Trauger, SA; Wargo, JA; Zwang, Y | 1 |
| Choi, HG; Gupta, B; Jeong, JH; Kim, JO; Oh, KT; Pathak, S; Poudel, BK; Ramasamy, T; Thapa, RK; Yong, CS | 1 |
| Gao, Y; Li, J; Mao, S; Ru, Y; Zhang, R | 1 |
| Gurunathan, S; Peng, QL; Yuan, YG | 1 |
| Fan, L; Jin, X; Song, C; Wu, H; Zhang, Y; Zhao, S | 1 |
| Li, XF; Liu, GF; Liu, L; Yu, SN; Zhang, SH | 1 |
| Cavaliere, A; Probst, KC; Slusarczyk, M; Westwell, AD | 1 |
| Diness, LV; Larsen, FO; Markussen, A; Nielsen, D | 1 |
| Conroy, T; Gourgou Bourgade, S; Jarlier, M; Lambert, A | 1 |
| Coppola, L; D'Andrea, MR; Di Raimo, T; Giordano, G; Olivieri, N; Pancione, M; Parcesepe, P; Toffoli, G; Velocci, M | 1 |
| Affram, K; Agyare, E; Krishnan, S; Reams, R; Rosenberg, J; Singh, M; Udofot, O | 1 |
| Al-Hazzouri, A; Bendell, JC; DeBusk, LM; Earwood, C; Guo, S; Ko, AH; Lane, CM; Murphy, PB; Peyton, JD; Rodriguez, FA; Shipley, DL; Tempero, MA; Waterhouse, DM; Womack, MS; Xiong, HQ | 1 |
| He, X; Hu, C; Ou, D; Wu, M | 1 |
| Saung, MT; Zheng, L | 1 |
| Bittar, PG; Nickolich, MS; Onwuemene, OA | 1 |
| Kim, JH; Kuh, HJ; Lee, J; Park, WS; Shin, BC | 1 |
| Al-Shakarchi, W; Albusair, MK; Aldebasi, MH; Curtis, ADM; Elsini, RS; Haxton, KJ; Hoskins, C; Manzur, A; Oluwasanmi, A | 1 |
| Bianco, C; Bianco, R; Marciano, R; Servetto, A | 1 |
| Chen, L; Hu, Z; Ju, B; Song, W; Sun, Q; Wang, W; Xie, H; Yang, Q; Yao, H; Zhang, L; Zheng, S; Zhou, D; Zhou, L | 1 |
| Arkenau, HT; Blackhall, F; Califano, R; Dean, E; Dymond, AW; Ghiorghiu, D; Greystoke, A; Hossack, S; Lindsay, CR; Md Haris, N; Plummer, R; So, K; Steele, N; Summers, Y; Voskoboynik, M | 1 |
| Aguilar, M; Chiao, PJ; Fu, J; Gocho, T; Iida, T; Ju, H; Lee, H; Li, H; Ling, J; Lu, Y; Sun, Y; Wu, M; Zhuang, Z | 1 |
| Anand, S; Badhe, B; Chandrasekar, S; Pottakkat, B; Rajagopal, MD | 1 |
| Wang, X; Xiao, G; Yu, Y | 1 |
| Wang, J; Wang, M; Wang, Z; Yang, Y; Zheng, R; Zou, W | 1 |
| Jun, E; Kim, SC; Lee, CM; Lee, S; Oh, J; Shim, IK | 1 |
| Furukawa, K; Kagawa, S; Miyazaki, M; Nishino, H; Ohtsuka, M; Shimazaki, R; Shimizu, H; Suzuki, K; Takano, S; Yoshitomi, H | 1 |
| Jhaj, G; Jhaj, R; Shrier, EM | 1 |
| Behringer, DM; Berdel, WE; Bulitta, M; De Dosso, S; Dommach, M; Ebert, MP; Goker, E; Hofheinz, R; Kerkhoff, A; Kneba, M; Overkamp, F; Reuter, D; Rohrberg, R; Schlegel, F; Schmidt, WE; Schultheis, B; Siveke, J; Steinmetz, T; Strumberg, D; Yalcin, S | 1 |
| Bellmunt, J; Blais, N; Blumenstein, B; Castellano, D; Eigl, BJ; Jacobs, C; Loriot, Y; Pal, S; Petrylak, DP; Retz, M; Senkus, E; Sridhar, SS; Sternberg, CN; Stewart, PS; Twardowski, P | 1 |
| Liu, Y; Tamam, H; Yeo, Y | 1 |
| Ahn, C; Cheedella, N; Choy, H; Dowell, JE; Gerber, DE; Hughes, RS; Iyengar, P; Nedzi, L; Pulipparacharuvil, S; Timmerman, RD; Tumati, V; Wardak, Z; Westover, KD | 1 |
| Bonetti, A; Giuliani, J | 1 |
| Guo, Y; Hu, Y; Huang, Y; Liu, D; Lu, B; Wang, X; Zhu, Z | 1 |
| Andolfi, M; Balloni, S; Bellezza, G; Bodo, M; Cagini, L; Ludovini, V; Marinucci, L; Matricardi, A; Potenza, R; Puma, F; Siggillino, A; Tofanetti, FR; Vannucci, J | 1 |
| Di, Y; Fu, D; Gu, J; Guo, Z; Jin, C; Li, H; Yu, X; Zhu, W | 1 |
| Bachmann, H; Knuth, A; Nguyen-Kim, TDL; Pascolo, S; Samaras, P; Seifert, B; Tusup, M; von Moos, R | 1 |
| Bennouna, J; Bouché, O; Conroy, T; Desseigne, F; Gourgou, S; Jarlier, M; Juzyna, B; Robert, M; Ychou, M | 1 |
| Chang, A; Gao, S; Hao, J; Huang, C; Li, N; Li, Y; Li, Z; Ren, H; Wang, H; Wang, X; Yang, S; Zhao, T | 1 |
| Al-Suraih, F; Bhattacharya, S; Caulfield, TR; Coffer, JL; Dutta, SK; Gonzalez-Rodriguez, R; Kwak, HS; Pal, K; Wang, E | 1 |
| Ji, S; Liang, C; Liang, D; Meng, Q; Ni, Q; Qin, Y; Shi, S; Xu, J; Yu, X; Zhang, B | 2 |
| Ishimoto, U; Kondo, S; Morizane, C; Ohba, A; Okusaka, T; Sakamoto, Y; Sasaki, M; Ueno, H | 1 |
| Thomas, H | 1 |
| Fei, S; He, H; Liang, Y; Tang, X; Wang, X; Yin, T; Zhang, Y | 1 |
| Beeharry, N; Bhattacharjee, V; Fink, L; Fraenkel, E; Gosline, SJC; Huang, SC; Ursu, O; Yen, T; Zhou, Y | 1 |
| An, MJ; Cha, YH; Gee, HY; Han, JW; Jeung, HC; Jun, I; Jung, J; Lee, MG; Park, HS; Park, JS; Piao, H; Shin, YK; Yook, JI; Yoon, DS; Yun, BG; Zhang, X | 1 |
| Cottica, D; Dezza, B; Grignani, E; Negri, S; Oddone, E; Sottani, C; Villani, S | 1 |
| Goto, A; Horita, N; Ito, K; Kaneko, T; Nagashima, A; Nakashima, K; Shibata, Y; Yamanaka, T | 1 |
| Chen, H; Ji, W; Jin, X; Lin, X; Pan, B; Song, H; Xiao, J; Yu, H | 1 |
| Chen, W; Feng, J; Huang, X; Liu, P; Shao, L; Sun, M; Sun, Q; Xiao, R; Xiong, J; Xiong, M; Yu, X; Yuan, W; Zhang, Q; Zhao, X | 1 |
| Fang, Y; Qin, YX; Shen, BY; Shi, MM; Tang, XM; Wen, CL; Zhang, YJ | 1 |
| Abbruzzese, JL; Benson, AB; Berlin, JD; Blackstock, AW; Catalano, P; Feng, Y; Lowy, AM; McWilliams, RR; Philip, PA | 1 |
| Carnero, A; Carranza, A; Cruz, J; Diaz-Beveridge, R; Encinas, V; Garcia Del Muro, X; Gutierrez, A; Hindi, N; Lopez-Pousa, A; Luna, P; Marcilla, D; Martin-Broto, J; Martinez-Trufero, J; Mora, J; Moura, DS; Redondo, A; Sancho, P; Taron, M; Tous, C; Valverde, C; Vaz, MA | 1 |
| Juang, GD; Lai, HC; Wu, CK | 1 |
| Chen, W; Huang, S; Liu, Q; Long, MM; Wang, J; Xu, SW; Yang, LH; Yang, RM; Zhan, M; Zhou, J; Zhu, J | 1 |
| Goel, A; Han, H; Ravindranathan, P; Toden, S; Yoshida, K | 1 |
| Hamano, K; Harada, E; Hosoyama, T; Kawamura, D; Kugimiya, N; Nishimoto, A; Shirasawa, B; Takemoto, Y; Tanaka, T; Ueno, K | 1 |
| Abdel-Wahab, M; Berriochoa, CA; Khorana, A; Kumar, AMS; Leyrer, CM; Matthew Walsh, R | 1 |
| Andersson, B; Andersson, R; Ansari, D; Hilmersson, KS; Urey, C | 1 |
| Arakawa, Y; Ikemoto, T; Imura, S; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Yamada, S | 1 |
| Chang, JW; Chang, YH; Chuang, CK; Juan, YH; Liao, TY; Liaw, CC | 1 |
| Barone, C; Bassi, P; Cassano, A; Marandino, L; Monterisi, S; Nazzicone, G; Orlandi, A; Pierconti, F; Racioppi, M; Rossi, E; Schinzari, G | 1 |
| Buckstein, M; Ghiassi-Nejad, Z; Moshier, E; Ru, M; Schwartz, M; Tabrizian, P; Tarchi, P | 1 |
| Anthoney, A; Büchler, MW; Campbell, F; Carter, R; Cox, TF; Deakin, M; Dervenis, C; Ghaneh, P; Glimelius, B; Goldstein, D; Halloran, CM; Izbicki, JR; Jackson, R; Jones, O; Kleeff, J; Lerch, MM; Mayerle, J; McDonald, AC; Melling, J; Neoptolemos, JP; O'Reilly, DA; Oláh, A; Padbury, R; Palmer, DH; Raraty, M; Rawcliffe, CL; Scarfe, AG; Shannon, J; Smith, CJ; Strobel, O; Tebbutt, NC; Valle, JW | 1 |
| Allen, BG; Bradley, MD; Buettner, GR; Mapuskar, KA; Milhem, M; Monga, V; Schoenfeld, JD; Sibenaller, ZA; Spitz, DR; Wagner, BA | 1 |
| Qiu, C; Wang, L | 1 |
| Bastiancich, C; Bastiat, G; Lagarce, F | 1 |
| Fujii, Y; Hamada, T; Hiyoshi, M; Imamura, N; Nanashima, A; Tsuchimochi, Y; Wada, T; Yano, K | 1 |
| Altieri, B; Berruti, A; Deutschbein, T; Fassnacht, M; Henning, JEK; Kircher, S; Kroiss, M; Perotti, P; Ronchi, CL; Rosenwald, A; Sbiera, S; Schlötelburg, W; Steinhauer, S; Wild, V | 1 |
| Arai, R; Masatsugu, A; Okuda, H; Sijimaya, T | 1 |
| Dhayat, SA; Mardin, WA; Senninger, N | 1 |
| Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Lennartsson, J; Sooman, L | 1 |
| Abe, H; Kamai, T; Kobayashi, M; Mizuno, T; Nishihara, D; Nukui, A; Sakamoto, K; Suzuki, I; Takei, K; Tokura, Y; Uematsu, T; Yamaguchi, Y | 1 |
| Ahn, JH; Chae, YS; Han, HS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Lee, SJ; Park, IH; Park, YH; Sohn, JH | 1 |
| Bojko, P; Hentrich, M; Jäger, H; Schipek-Voigt, K; Schmid, P; Schulz, S; Stötzer, O | 1 |
| Attwood, K; Balachandar, S; Chandra, D; Chaudhary, AK; Hochwald, S; Inigo, JR; Kumar, R; Kumar, S; O'Malley, J; Wang, J; Wang, X; Yadav, N | 1 |
| Alvarez, R; Caruso, R; Cubillo, A; Diaz, E; Duran, H; Fabra, I; Ferri, V; Ielpo, B; Kalivaci, D; Lazzaro, S; Malavé, L; Plaza, C; Quijano, Y; Vicente, E | 1 |
| Baldwin, G; He, H; Huynh, N; Nikfarjam, M; Wang, K; Wang, X | 1 |
| Che, X; Hou, K; Jing, W; Liu, Y; Qu, X; Song, N; Yang, X | 1 |
| De, A; Jacobson, BA; Jay-Dixon, J; Kratzke, MG; Kratzke, RA; Patel, MR; Peterson, MS; Sadiq, AA | 1 |
| Chen, P; Dai, CH; Jiang, Q; Lan, T; Li, J; Li, MY; Su, JY; Wang, Y; Wu, Y | 1 |
| Beck, J; Blaydorn, L; Bornemann-Kolatzki, K; Khemka, V; Schütz, E; Urnovitz, H; Weiss, GJ | 1 |
| Bielli, P; Capurso, G; Farini, D; Fave, GD; Panzeri, V; Passacantilli, I; Pilozzi, E; Sette, C | 1 |
| DeVaux, RS; Espinal, R; Hepel, M; Herschkowitz, JI; Kurzatkowska, K; Santiago, T | 1 |
| Hisada, T; Kaira, K; Kawashima, O; Miura, Y; Saito, R; Sakurai, R; Sunaga, N; Tomizawa, Y; Tsurumaki, H; Yamada, M; Yoshii, A | 1 |
| Audebert, S; Baudelet, E; Betzi, S; Casteran, N; Combes, S; De Sepulveda, P; Dubreuil, P; Gros, L; Hajem, B; Hammam, K; Humbert, M; Letard, S; Lopez, S; Lugari, A; Mansfield, C; Morelli, X; Moussy, A; Rebuffet, E; Saez-Ayala, M | 1 |
| Itai, R; Yamashita, Y; Yokode, M; Zen, Y | 1 |
| Ma, Z; Xue, X | 1 |
| Deshmukh, SP; Epstein, JD; Keith, SW; Kozak, GM; Lavu, H; Scott, BB; Winter, JM; Yeo, CJ | 1 |
| Camateros, P; Cheung, WY; Wang, Y | 1 |
| Li, SY; Lin, XQ; Liu, YQ; Ouyang, M; Qin, YY; Xie, ZH; Zhang, DH; Zhang, JX; Zhou, CZ | 1 |
| Fujii, K; Natori, Y; Saeki, S; Sakata, S; Terasaki, Y | 1 |
| Bao, YT; Li, CM; Liu, ZC; Sun, XD; Wang, LL | 1 |
| Inui, M; Ishiguro, S; Kawabata, A; Monson, K; Ohta, N; Pappas, CG; Tamura, M; Tzakos, AG; Uppalapati, D; Zulbaran-Rojas, A | 1 |
| Bálint, B; Ciuleanu, T; Depenbrock, H; Luft, AV; Molinier, O; Nanda, S; Obasaju, C; Paz-Ares, L; Ramlau, R; Socinski, MA; Szafrański, W; Szczesna, A; Thatcher, N | 1 |
| Bodis, S; Clavien, PA; Datta, NR; Khan, S; Knuchel, J; Mamot, C; Pestalozzi, B; Puric, E; Reiner, CS; Riesterer, O; Siebenhüner, A | 1 |
| Bennouna, J; Caulet, M; Gournay, J; Hautefeuille, V; Lecomte, T; Matysiak-Budnik, T; Prieux-Klotz, C; Salimon, M; Tiako Meyo, M; Touchefeu, Y; Tougeron, D; Zaanan, A | 1 |
| Allen-Petersen, BL; Amery, TS; Crawford, HC; Egbukichi, N; Farrell, AS; Heiser, LM; Hoffman, MT; Jenny, ZP; Joly, MM; Kendsersky, ND; Lanciault, C; Link, J; Manning, SL; Morton, JP; Murphy, DJ; Muthalagu, N; Pelz, C; Pratt, ED; Rhim, AD; Sansom, OJ; Sauer, D; Sears, RC; Sheppard, BC; Thoma, MC; Worth, PJ | 1 |
| Fukuda, M; Hosokawa, M; Iwakawa, S; Masuda, A; Tanaka, S; Ueda, K | 1 |
| Begum, A; Del Carmen Rodriguez Pena, M; Dinalankara, W; Hahn, NM; Hoque, MO; Mao, S; Marchionni, L; Netto, GJ; Ooki, A; Rasheed, ZA; Sidransky, D; VandenBussche, CJ | 1 |
| Brekken, RA; Cruz, VH; Du, W; Lorens, JB; Ludwig, KF; Maitra, A; Rajeshkumar, NV; Sorrelle, NB; Toombs, JE; Topalovski, M; Wnuk-Lipinska, K; Yabuuchi, S | 1 |
| Armbrecht, N; Bernhardt, G; Brooks, J; Calvisi, DF; Ceyhan, GO; Demir, IE; Fleischmann-Mundt, B; Gürlevik, E; Kubicka, S; Kühnel, F; Manns, MP; Niemann, J; Peters, K; Ribback, S; Smyth, MJ; Wirth, TC; Woller, N | 1 |
| Batte, K; Bid, HK; Braggio, D; Casadei, L; Choy, E; Iwenofu, OH; Koller, D; Lev, D; Lopez, G; Pollock, R; Strohecker, A; Yu, P; Zewdu, A | 1 |
| Fujii, H; Hamamichi, S; Hori, Y; Ito, K; Matsui, J; Ozawa, Y; Umeda, IO | 1 |
| Abdallah, A; Baumann, BC; Christodouleas, JP; Hwang, WT; Khaled, HM; Smith, A; William, H; Zaghloul, MS | 1 |
| Puls, TJ; Tan, X; Voytik-Harbin, SL; Whittington, CF | 1 |
| Bellis, SL; Bonner, JA; Buchsbaum, DJ; Chakraborty, A; Dorsett, KA; Oliver, PG; Trummell, HQ; Yang, ES | 1 |
| Chang, HM; Cho, H; Hwang, S; Jeong, JH; Kang, J; Kim, KM; Kim, KP; Kim, MH; Lee, HC; Lee, JH; Lee, SK; Lee, SS; Lee, YJ; Lim, YS; Moon, DB; Park, DH; Ryoo, BY; Shim, JH; Song, GW; Song, TJ; Yoo, C | 1 |
| He, JQ; Huang, LJ; Li, J; Li, JW; Li, KL; Li, YJ; Liu, XL; Liu, XY; OuYang, Z; Sun, ZY; Yi, PY; Zhong, MZ; Zhou, F; Zhou, H | 1 |
| Alkaff, SMF; Chan, CY; Chan, ECY; Goh, S; Kam, JH; Leow, WQ; Lim, TKH; Phua, LC; Tai, DWM | 1 |
| Jensen, AB; Knoop, A; Langkjer, ST; Rosvig, LH | 1 |
| Caffrey, TC; Grunkemeyer, JA; Hollingsworth, MA; Madiyalakan, R; Mehla, K; Nicodemus, CF; O'Connell, KA; Schultes, BC; Singh, PK; Steele, MM; Tremayne, J; Yu, F; Zhu, X | 1 |
| Dai, GH; Han, QL; Lyu, Y; Yan, H; Zhou, YH | 1 |
| Li, X; Niu, Q; Song, W; Tian, Z; Wu, J; Xie, M; Xu, Y; Yang, L; Zhang, C; Zhang, Q; Zhao, X; Zhou, B | 1 |
| Chen, P; Chen, Q; Dong, R; Drisko, JA; Fan, F; Godwin, AK; Levine, M; Pessetto, Z; Polireddy, K; Reed, G; Violet, PC; Williamson, S; Yu, J | 1 |
| Abdol Razak, NB; Adamska, A; Elaskalani, O; Emmanouilidi, A; Falasca, M; Kim, M; Metharom, P | 1 |
| Aktas, B; Bangemann, N; Braun, M; Christgen, M; Clemens, M; Forstbauer, H; Gluz, O; Grischke, EM; Hackmann, J; Harbeck, N; Kates, R; Kohls, A; Kreipe, HH; Kuemmel, S; Liedtke, C; Lindner, C; Nitz, U; Potenberg, J; Schumacher, C; Schumacher, J; Staib, P; Uleer, C; von Schumann, R; Warm, M; Wuerstlein, R | 1 |
| Aldrich, C; Bahary, N; Braiteh, F; Bullock, AJ; Chondros, D; Harris, WP; Hendifar, AE; Hingorani, SR; Jiang, P; Khelifa, S; Oberstein, PE; Pu, J; Ritch, PS; Seery, TE; Sigal, DS; Wang-Gillam, A; Wu, W; Zalupski, MM; Zheng, L | 1 |
| Adiseshiah, C; Buckley, RJ; Clemens, MJ; Elia, A; Henry-Grant, R; Marboeuf, C; Mudan, S; Pyronnet, S | 1 |
| Corrie, PG; Doherty, GJ; Tempero, M | 1 |
| Klang, E; Lawson, P; Michal Amitai, M; Yonat, H | 1 |
| Alcindor, T; Chan, E; Chao, R; Chiorean, EG; Gabrail, NY; Hurwitz, H; O'Dwyer, PJ; Potvin, D | 1 |
| Liang, J; Ma, Y; Tian, X; Wang, F; Xie, X; Yang, C; Yang, Y; Zhang, Z | 1 |
| Hamada, S; Masamune, A; Shimosegawa, T; Taguchi, K; Yamamoto, M | 1 |
| Akers, N; Albany, C; Bhardwaj, N; Chen, R; Domingo-Domenech, J; Donovan, MJ; Fleming, MT; Galsky, MD; Gnjatic, S; Hahn, NM; Hauke, RJ; Kim-Schulze, S; Losic, B; Oh, WK; Pal, SK; Patel, VG; Schadt, EE; Sfakianos, JP; Sonpavde, G; Starodub, A; Twardowski, P; Uzilov, AV; Wang, H; Yu, M; Zhao, Q | 1 |
| Casadei, R; Chen, X; Chu, T; Dantes, Z; Di Marco, M; Friedman, RA; Habenicht, AJR; Hayakawa, Y; Ilmer, M; Iuga, AC; Jiang, Z; Kleespies, A; Macchini, M; Maurer, HC; Middelhoff, M; Mohanta, SK; Nagar, K; Neumann, J; Olive, KP; Reichert, M; Remotti, H; Renz, BW; Tailor, Y; Takahashi, R; Tanaka, T; Valenti, G; Wang, TC; Werner, J; Westphalen, CB; Worthley, DL | 1 |
| Belkouz, A; Coelen, RJS; de Groot, JWB; Dierks, J; Gaspersz, MP; Groot Koerkamp, B; Klümpen, H; Meijer, WG; Otten, HM; Pruijt, JFM; Rentinck, M; Smit, JM; Ten Oever, D; Ten Tije, AJ; van Gulik, TM; van Spronsen, DJ; van Voorthuizen, T; van Vugt, JLA; Wilmink, JW | 1 |
| Cho, SW; Choi, CK; Lee, HP; Lee, JS; Ryu, W; Yang, D | 1 |
| Glynn, P; Price, L; Zarkar, A | 1 |
| Glenn, JD; Whartenby, KA; Xue, P | 1 |
| Cheng, K; Han, X; Hao, J; Lang, J; Lin, Y; Miao, QR; Nie, G; Qin, H; Ren, H; Shi, J; Sun, W; Wang, X; Wang, Y; Zhao, R; Zhao, X; Zhao, Y; Zheng, X | 1 |
| Gourd, E | 1 |
| Fushida, S; Harmon, JW; Hayashi, H; Kishimoto, K; Makino, I; Miyashita, T; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okazaki, M; Tajima, H; Takamura, H; Yamaguchi, T | 1 |
| Bartscht, T; Hakim, SG; Idel, C; Rades, D | 1 |
| Bruckner, HW; Gurell, D; Hirschfeld, A | 1 |
| Guo, Y; Liang, M; Ma, L; Zhao, T | 1 |
| Beijnen, JH; Burgers, JA; Hillebrand, MJX; Rosing, H; Schellens, JHM; van Nuland, M | 1 |
| Kondo, N; Murakami, Y; Nakagawa, N; Okano, K; Shintakuya, R; Sueda, T; Takahashi, S; Uemura, K | 1 |
| Thoma, C | 2 |
| Couvreur, P; Mura, S; Ramseyer, C; Savenko, M; Yesylevskyy, SO | 1 |
| Altomare, DA; Copik, AJ; Gitto, SB; Hogan, FC; Oyer, JL; Pandey, V; Phanstiel, O | 1 |
| Benguigui, M; Beyar-Katz, O; Bronshtein, T; Kotsofruk, R; Letko-Khait, N; Machluf, M; Rachman-Tzemah, C; Raviv, Z; Shaked, Y; Timaner, M | 1 |
| Chung, V; Cristea, M; Diamond, DJ; Ellenhorn, JDI; Eng, M; Frankel, P; Hardwick, NR; Kaltcheva, T; Kilpatrick, J; Kos, F; Leong, L; Morgan, R; Ruel, C; Tinsley, R; Tsai, W; Wilczynski, S | 1 |
| Bianski, B; Boulos, N; Calabrese, C; Dapper, J; DeCuypere, M; Freeman, BB; Gajjar, A; Gilbertson, RJ; Guy, RK; Merchant, TE; Nimmervoll, BV; Onar-Thomas, A; Patel, YT; Roussel, MF; Shelat, A; Stewart, CF; Terhune, HE; Terranova, S; Wright, KD | 1 |
| Baiu, I; Charville, GW; Visser, BC | 1 |
| He, J; Jia, B; Yan, J; Yang, J | 1 |
| Bivalacqua, TJ; Gupta, M; Hahn, NM; Johnson, MH; Kates, M; Liao, RS; McConkey, D; Patel, HD; Pierorazio, PM; Schwen, ZR | 1 |
| Du, C; Gao, H; Guo, H; Kornmann, M; Ma, L; Tian, X; Wang, F; Xie, X; Yang, Y; Zhang, Z; Zhuang, Y | 1 |
| Chen, L; Chen, Z; Guo, Y; Huang, X; Kang, Y; Liu, Q; Liu, Z; Sun, C; Zhou, D; Zhu, H | 1 |
| Di, GH; Hong, Q; Kuang, XY; Shao, ZM; Yang, L; Yu, SJ | 1 |
| Bivalacqua, TJ; Black, PC; Daneshmand, S; Kassouf, W; Shah, JB; Spiess, PE; van Rhijn, BW; Zargar, H | 1 |
| Cai, H; Chen, J; Chen, Q; Guo, Q; Huang, S; Jiang, B; Kang, M; Li, P; Lu, W; Qin, W; Rao, J; Wan, D; Wang, L; Wu, Y; Zheng, W; Zhou, Y | 1 |
| Friess, H; Goess, R | 1 |
| Brenner, R; Capanu, M; Chen, AP; Dhani, N; Do, RK; Epstein, AS; Estrella, H; Golan, T; Kelsen, DP; Kindler, HL; Lee, JW; Lowery, MA; Maynard, H; Moore, MJ; O'Reilly, EM; Salo-Mullen, EE; Segal, A; Segal, M; Stadler, ZK; Tang, LH; Yu, KH | 1 |
| Hayashi, K; Inoue, T; Joh, T; Kato, A; Kondo, H; Naiki-Ito, A; Naitoh, I; Nakazawa, T; Nishi, Y; Okumura, F; Shimizu, S; Takada, H; Takahashi, S; Yoshida, M | 1 |
| Chen, S; Chen, Y; Huang, K; Li, J; Li, Y; Lian, G; Yang, K; Zeng, L | 1 |
| Eshima, K; Fukushima, M; Iizuka, K; Jin, C; Zhang, C | 1 |
| Bao, Y; Guo, H; Lu, Y; Qiu, L; Shi, Q; Sun, X; Wang, X; Yan, B | 1 |
| Alseidi, A; Badiozamani, K; Biehl, TR; Edwards, AM; Helton, WS; Kanji, ZS; Kozarek, RA; Lin, BS; Mandelson, MT; Picozzi, VJ; Rocha, FG; Sahar, N; Song, G | 1 |
| Asai, A; Doki, Y; Ishii, H; Konno, M; Koseki, J; Mori, M; Ogawa, K; Satoh, T; Taketo, K; Toratani, M | 1 |
| Ajavon-Hartmann, A; Alberts, SR; Genvresse, I; Grilley-Olson, JE; Kelly, A; Kim, RD; Peña, C; Xia, C | 1 |
| Aglietta, M; Aprile, G; Avallone, A; Cagnazzo, C; Cavalloni, G; Cereda, S; Doglioni, C; Fenocchio, E; Frattini, M; Gammaitoni, L; Leone, F; Martin, V; Nasti, G; Peraldo-Neia, C; Reni, M; Satolli, MA; Spadi, R; Venesio, T | 1 |
| Bell-McGuinn, K; Cristea, M; Fleming, GF; Gray, HJ; Luo, Y; Martin, LP; McKee, MD; Munasinghe, W; Sullivan, D; Xiong, H | 1 |
| Liang, C; Liang, D; Meng, Q; Ni, Q; Shi, S; Xu, J; Yu, X; Zhang, B | 1 |
| Chen, D; Jing, FC; Liu, HQ; Yan, X; Yang, XH; Zhang, QA; Zhang, R | 1 |
| Ahmed, AA; Andrade, ACG; Balasubramanian, S; Besser, RJ; Di Vita, G; Diocou, S; Evans, TRJ; Gunaratnam, M; Haider, SM; Laughlin-Toth, S; Marchetti, C; Marsico, G; Morton, JP; Neidle, S; Ohnmacht, SA; Pazitna, I; Pedley, RB; Pike, JA; Robson, M; Tannahill, D; Vo, T; Wilson, WD; Zyner, KG | 1 |
| Egawa, S; Eguchi, H; Fujiki, F; Homma, S; Ishii, J; Ishikawa, T; Ito, K; Kanno, Y; Koido, S; Kokura, S; Kon, M; Kumanogoh, A; Morimoto, S; Morita, S; Nagano, H; Nishida, S; Oba, MS; Oka, Y; Sato, M; Shimada, H; Sugiyama, H; Unno, M; Yanagimoto, H; Yasuda, H | 1 |
| Head, R; Jiang, H; Li, L; Li, Q; Lim, KH; Liu, J; Ruzinova, MB; Wang-Gillam, A; Yu, J; Zhang, D | 1 |
| Danter, WR; Koropatnick, J; Maleki Vareki, S; Salim, KY | 1 |
| Garcia-Cremades, M; Iversen, PW; Pitou, C; Troconiz, IF | 2 |
| Cai, MH; Sun, Z; Tu, YX; Wang, BK; Xu, XG; Yan, SL; Ying, Y | 1 |
| Arun, B; Buzdar, AU; Hortobagyi, GN; Moulder, SL; Murray, JL; Murthy, RK; Shroff, GS; Stalzer, CJ; Szklaruk, J; Valero, V; Yam, C; Yang, W | 1 |
| Hu, C; Hui, K; Jiang, X; Liang, L; Qiao, Y; Ren, Y; Wang, L; Xia, Y; Zhu, P | 1 |
| Jiang, L; Lee, SC; Ng, TC | 1 |
| Fujioka, T; Hayama, T; Nakashima, M; Nohta, H; Todoroki, K; Tomita, R; Yamaguchi, M; Yoshida, H | 1 |
| Bjerregaard, JK; Ejlsmark, MW; Jensen, HA; Krogh, M; Pfeiffer, P; Schonnemann, KR; Winther, SB | 1 |
| Church, KJ; Fagnan, M; Harding, JW; Harris, PH; LeValley, JC; Mateo-Victoriano, B; Riggers, RR; Vanderwerff, BR | 1 |
| Chen, Z; Cui, Z; Shi, Y; Zheng, Y | 1 |
| Capurso, G; Delle Fave, G; Panzeri, V; Passacantilli, I; Sette, C; Terracciano, F | 1 |
| Hakamada, K; Ishido, K; Kimura, N; Kudo, D; Mitsuhashi, Y; Toyoki, Y; Wakiya, T; Yakoshi, Y | 1 |
| Ariake, K; Fukase, K; Hayashi, H; Ishida, M; Maeda, S; Masuda, K; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Sakata, N; Takadate, T; Unno, M | 1 |
| Hasuo, K; Jin, Y; Kakazu, A; Komori, K; Masuda, M; Mikayama, Y; Watanabe, T | 1 |
| Fujii, Y; Fujita, H; Fujita, J; Kinami, S; Kosaka, T; Miura, S; Motoo, Y; Nakano, Y; Ohnishi, T; Omote, K; Tomita, Y; Ueda, N | 1 |
| Deguchi, M; Ishida, M; Kaizaki, Y; Kitajima, T; Ohnishi, K; Ohno, N; Sawai, K; Tabata, S | 1 |
| Fujiyama, J; Hiramoto, H; Kawamura, Y; Masuyama, M; Nakashima, S; Nishida, M; Ochi, F; Shibamoto, J; Takashima, Y; Tsujiura, M | 1 |
| Hosoda, Y; Katayama, H; Katsushima, U; Kawai, J; Kiyochi, H; Komoto, I; Nishiyama, K; Ogura, N; Okabe, A; Oshima, Y; Sasaki, Y; Sugimoto, T; Taki, Y; Tsunekawa, S; Yanagihara, K | 1 |
| Hata, T; Hayashi, H; Iseki, M; Kanno, A; Kyakumoto, Y; Mizuma, M; Morikawa, T; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Sakata, N; Shimosegawa, T; Takadate, T; Unno, M | 1 |
| Hori, T; Kaizaki, R; Kanazawa, A; Kodai, S; Komatsu, R; Takahama, M; Takatsuka, S; Tsukamoto, T | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Ichikawa, Y; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Takeyari, M; Tatsumi, M; Wada, H; Yamada, D | 1 |
| Chen, T; Fu, Y; Gong, T; Huang, T; Li, W; Liu, X; Yang, Q; Zhang, Z | 1 |
| Barbour, M; Bujold, KE; Jassim, AD; Tjarks, BJ | 1 |
| Ambo, Y; Ando, M; Ebata, T; Fukutomi, A; Hirano, S; Kaneoka, Y; Konishi, M; Nagino, M; Nimura, Y; Ohtsuka, M; Ozawa, F; Shimizu, Y; Tsuchiya, Y; Uesaka, K; Yamamoto, M | 1 |
| Algéo, MP; Bourdon, A; Chaire, V; Cousin, S; Italiano, A; Laroche-Clary, A; Le Loarer, F; Lucchesi, C; Rey, C; Savina, A; Shutzman, J; Toulmonde, M; Vélasco, V; Verbeke, S | 1 |
| Chang, JS; Chung, SY; Lee, BM; Lee, KJ; Seong, J | 1 |
| Colby, AH; Grinstaff, MW; Liu, K; Lu, C; Oberlies, NH; Pearce, C; Sabbatini, ME; Yang, D | 1 |
| Fuse, T; Ozeki, T; Tagami, T; Tane, M | 1 |
| Hirai, M; Kume, M; Makimoto, H; Minami, H; Mizuta, N; Nakagawa, T; Nishioka, T; Yamamoto, K; Yano, I | 1 |
| Bruno, A; Cipollina, C; Di Vincenzo, S; Ferraro, M; Gjomarkaj, M; Pace, E; Siena, L | 1 |
| Patel, JA; Piper, JB; Wang, BG | 1 |
| Anthoney, DA; Basu, B; Cook, N; Evans, J; Farmer-Hall, H; Gopinathan, A; Halford, S; Hampson, LV; Hategan, M; Jodrell, D; McLeod, R; Nebozhyn, M; Palmer, D; Propper, D; Smith, DM; Steward, WP; Turner, H; Tuveson, D; Venugopal, B | 1 |
| Leblanc, RM; Pardo, J; Peng, Z | 1 |
| Beijnen, JH; Derissen, EJB; Huitema, ADR; Rosing, H; Schellens, JHM | 1 |
| Chen, L; Cheng, X; Feng, H; Fu, Z; Jin, Z; Kuang, J; Liang, J; Peng, C; Qiu, W; Shen, B; Shen, X; Yuen, S | 1 |
| Cao, Y; Dong, P; Fan, W; Guo, S; Han, H; Jiang, L; Li, X; Li, Y; Liu, Z; Qin, Z; Shi, Y; Yao, K; Ye, Y; Zhou, F | 1 |
| Chie, EK; Choi, SH; Han, Y; Heo, JS; Jang, JY; Kim, SH; Kim, SW; Koh, YH; Kwon, W; Lee, H; Lee, IJ; Lee, JM; Lee, KH; Lee, WJ; Lim, DH; Oh, DY; Park, JO; Park, JS; Park, SJ; Yoon, DS | 1 |
| Agrawal, N; Arora, A; Baghmar, S; Bihari, C; Chattopadhyay, TK; Kumar, G; Kumar, S; Pamecha, V; Panda, D; Patidar, Y | 1 |
| Bomba, H; Dotti, G; Gu, Z; Hu, Q; Hu, X; Liu, Z; Wang, C; Wang, J; Wen, D; Ye, Y; Yu, S; Zhang, X | 1 |
| Alejandro Barbieri, M; Collins, J; Gonzalez, C; Lee, JT; Lisova, K; Michael van Dam, R; Ramachandran, C; Sanchez, A; Wnuk, SF | 1 |
| Adamberg, K; Adamberg, S; Andriulli, A; Copetti, M; Fontana, A; Jaagura, M; Kolk, K; Panebianco, C; Pazienza, V; Vilu, R | 1 |
| Ojima, H; Okusaka, T; Sakamoto, Y; Tajimi, M; Tanizawa, Y; Yamagishi, S | 1 |
| Boku, N; Fukutomi, A; Hagiwara, Y; Hirano, S; Hishinuma, S; Imai, K; Kainuma, O; Kaneoka, Y; Konishi, M; Matsumoto, I; Morinaga, S; Nakamori, S; Ohashi, Y; Ojima, H; Okamura, Y; Sakamoto, H; Sata, N; Shimizu, Y; Sudo, T; Uesaka, K; Yamaguchi, R | 1 |
| Brade, A; Dawson, LA; Gallinger, S; Greig, PD; Horgan, AM; Knox, JJ; Loveday, BPT; Metser, U; Moulton, CA | 1 |
| Ajioka, Y; Aoki, M; Fukunari, H; Hayashi, T; Kawai, Y; Nishikura, K; Saito, T; Shitara, K; Umebayashi, Y; Watanabe, A; Watanabe, G | 1 |
| Cheng, JX; Li, J; Qu, X; Tian, J; Zhang, JT | 1 |
| Furuse, J; Kasuga, A; Kawai, K; Kobayashi, T; Nagashima, F; Naruge, D; Okano, N; Yamauchi, Y | 1 |
| An, M; Cuneo, KC; Lubman, DM; Wu, J; Zhu, J | 1 |
| Bastos, BR; Brahmer, JR; Chai, F; Dietrich, MF; Gerber, DE; Hesketh, PJ; Huang, C; Johnson, ML; Kazakin, J; Kelly, RJ; Lilenbaum, RC; Neal, JW; Rosovsky, RP; Schiller, JH; Schwartz, B; Sequist, LV; Shirai, K; Socinski, MA; Subramaniam, DS; Wakelee, HA; Wang, Y | 1 |
| Maithel, SK; Zaidi, MY | 1 |
| Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Ma, J; Milgrom, S; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Timmons, M; Valdez, BC | 1 |
| Alberts, SR; Hartgers, ML; Hassan, M; Jin, Z; Mahipal, A; Muppa, P; Nagorney, DM; Sanhueza, CT; Shubert, CR; Smyrk, TC; Truty, MJ | 1 |
| Borgmann, H; Cebulla, A; Dogan, S; Frank, T; Hennig, M; Hofbauer, SL; Klatte, T; Kramer, M; Merseburger, AS; Salem, J; Struck, JP | 1 |
| Anthoney, A; Aughton, K; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Costello, E; Cox, TF; Deakin, M; Dervenis, C; Elander, NO; Ghaneh, P; Glimelius, B; Goldstein, D; Greenhalf, W; Halloran, CM; Lerch, MM; Mackey, JR; Mayerle, J; McDonald, AC; Neoptolemos, JP; Oláh, A; Palmer, DH; Scarfe, AG; Shannon, J; Tebbutt, NC; Valle, JW | 1 |
| Chen, H; Chen, Z; Hua, YQ; Huang, L; Meng, ZQ; Ming, LL; Na, L; Wang, F; Wang, L; Yu, J | 1 |
| Balmaña, J; Cedrés, S; Cruz, C; Felip, E; Llop-Guevara, A; Mancuso, F; Martinez de Castro, A; Martinez-Marti, A; Miquel, JM; Navarro, A; Nuciforo, P; Pardo, N; Remon, J; Sansano, I; Serra, V; Vivancos, A; Zeron-Medina, J | 1 |
| Hu, HJ; Li, FY; Liu, F; Wang, JK; Zhou, RX | 1 |
| Chen, G; Huang, Y; Lu, W; Svirskis, D; Wen, J; Ying, M | 1 |
| Boeck, S; Caca, K; Ettrich, TJ; Fischer von Weikersthal, L; Freiberg-Richter, J; Fuchs, M; Haas, M; Heinemann, V; Held, S; Kanzler, S; Kruger, S; Kullmann, F; Kunzmann, V; Lerch, MM; Reinacher-Schick, A; Schenk, M; Siveke, JT; Westphalen, CB | 1 |
| Chang, Q; Peng, Y; Sun, J; Wang, G; Wang, W; Zhang, X; Zhou, F; Zhou, Y | 1 |
| Biankin, AV; Chantrill, L; Chin, V; Nagrial, A; O'Connor, CA; Scholten, RJ; Sjoquist, K; Yip, D | 1 |
| Aa, L; Fei, F; Hao, K; Jiang, W; Liu, J; Lu, L; Pei, X; Peng, Y; Sun, Y; Wang, G; Wang, J; Zhen, L | 1 |
| Bu, Y; Ozaki, T; Sang, M; Sun, D; Yin, D; Yu, M; Zhu, Y | 1 |
| Dehua, Z; Jisheng, W; Mingming, C | 1 |
| Bo, X; Li, M; Liu, H; Ni, X; Shen, S; Suo, T; Wang, J; Wang, Y; Xu, J | 1 |
| Jin, J; Li, T; Teng, C | 1 |
| Engineer, R; Goel, M; Kumar, S; Majumdar, S; Mandavkar, S; Mehta, S; Ostwal, V; Patkar, S; Ramaswamy, A; Swami, R | 1 |
| Jin, H; Ma, S; Yang, J; Zhang, S; Zhang, X; Zhao, Y | 1 |
| El Khalifi, M; Gharbi, T; Mlaouah, M; Picaud, F; Tangour, B | 1 |
| Ashford, M; Bradshaw, TD; Burroughs, L; Kellam, B; Marlow, M; Skilling, KJ; Stocks, MJ | 1 |
| Aoki, Y; Hamamoto, Y; Hirata, K; Kanai, T; Kasuga, A; Kawasaki, K; Okano, N; Sukawa, Y; Suzuki, T; Takaishi, H; Takeuchi, A; Togasaki, K | 1 |
| Chen, Y; Ji, Y; Jin, Y; Yu, Y; Zhang, X; Zhou, J; Zhu, J | 1 |
| Egger, J; Hann, A; Hermann, PC; Keller, F; Nosalski, E; Seufferlein, T | 1 |
| Fang, J; Ge, C; Hou, Y; Li, J; Li, X; Ma, H; Meng, X | 1 |
| Best, LM; Bussières, JF; Gurusamy, KS; Korva, M; Lennan, E; Tanguay, C | 1 |
| Blair, AB; Burkhart, RA; Cameron, JL; Fishman, EK; Gemenetzis, G; Groot, VP; He, J; Hruban, RH; Laheru, DA; Narang, AK; Weiss, MJ; Wolfgang, CL; Yu, J; Zheng, L | 1 |
| Boichard, A; Bush, KT; Tsigelny, IF | 1 |
| Kobayashi, M; Koido, S; Koizumi, T; Koya, T; Nagai, K; Okamoto, M; Sano, K; Shimodaira, S; Sugiyama, H; Yanagisawa, R | 1 |
| Brustugun, OT; Grønberg, BH; Lund-Iversen, M; Scott, H; Strøm, EH; Theiss, N | 1 |
| Abe, K; Gocho, T; Haruki, K; Onda, S; Sakamoto, T; Takano, Y; Uwagawa, T; Yanaga, K | 1 |
| Bagust, A; Banks, L; Beale, S; Boland, A; Duarte, R; Greenhalgh, J; Kotas, E; Palmer, D; Richardson, M; Stainthorpe, A | 1 |
| Chen, H; Cohen, HJ; Edelman, MJ; Feliciano, JL; Gajra, A; Hurria, A; Jatoi, A; Lafky, J; Le-Rademacher, JG; Lilenbaum, R; Maggiore, R; McMurray, RP; Muss, HB; Wong, ML; Zemla, TJ | 1 |
| Curtis, LT; Frieboes, HB; van Berkel, VH | 1 |
| Bardini, R; Buda, A; D'Ippolito, S; Da Dalt, G; Fabricio, ASC; Fiduccia, P; Gion, M; Giovanis, P; Pastorelli, D; Rainato, G; Soldà, C; Sperti, C; Ursini, F | 1 |
| Feng, M; Hu, Y; Huang, H; Xiong, G; Yang, G; You, L; Zhang, T; Zhao, Y; Zheng, L; Zheng, S | 1 |
| Chang, HM; Hong, SM; Hwang, DW; Hwang, I; Jeong, JH; Kang, J; Kim, KP; Kim, MH; Kim, SC; Lee, JH; Lee, SK; Lee, SS; Park, DH; Ryoo, BY; Seo, DW; Shin, SH; Song, KB; Song, TJ; Yoo, C | 1 |
| Bhatnagar, S; Kumari, P; Pattarabhiran, SP; Venuganti, VVK | 1 |
| Han, L; Jiang, J; Ma, Q; Wang, Z; Wu, Z | 1 |
| Nakamura, M; Nikaido, T; Ogata, T; Ozaki, T; Sang, M; Shimozato, O; Sun, D | 1 |
| Brezault, C; Coriat, R; Guillaumot, MA; Léandri, C; Ribiere, SC | 1 |
| Bouvet, M; Han, Q; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, S; Lwin, TM; Miyake, K; Miyake, M; Oshiro, H; Tan, Y; Unno, M | 1 |
| Abdel-Rahman, O; Elhalawani, H; Elsayed, Z | 1 |
| Bauer, N; Gladkich, J; Gretz, N; Gross, W; Hackert, T; Herr, I; Liu, L; Nwaeburu, CC; Sticht, C; Strobel, O; Yin, L; Yin, Y; Zhao, Z | 1 |
| Kellett, C; Kim, CA; Lambert, P; Zhang, H | 1 |
| Dora, CP; Gupta, RC; Jain, S; Katiyar, SS; Kumar Agrawal, A; Kushwah, V; Lamprou, DA | 1 |
| Einama, T; Kamachi, H; Kamiyama, T; Nagatsu, A; Ohmura, T; Orimo, T; Shimada, S; Sugiyama, K; Taketomi, A; Wakayama, K; Yokoo, H | 1 |
| Izumiya, Y; Kawakami, S; Kimura, Y; Kin, S; Komiyama, S; Nakashima, S | 1 |
| Endo, T; Hasegawa, K; Isogai, J; Kamiya, A; Kaneko, J; Kobayashi, K; Kondoh, I; Maejima, K; Maejima, S; Takatsuno, Y | 1 |
| Guo, J; Lam, CWK; Li, Y; Wang, C; Yao, M; Zhang, W | 1 |
| Beguin, E; Callan, B; Callan, JF; Kamila, S; Kelly, P; Logan, K; Love, M; McHale, AP; Nesbitt, H; O'Rourke, D; Sheng, Y; Stride, E; Taylor, MA; Thomas, K | 1 |
| Barrios, CH; Boyer, M; Chih-Hsin Yang, J; Geater, SL; Hirsh, V; Kato, T; Lee, KH; Märten, A; Mok, T; O'Byrne, K; Orlov, S; Park, K; Paz-Ares, L; Peil, B; Schuler, M; Sequist, LV; Tan, EH; Tsai, CM; Wu, YL; Yamamoto, N; Zhang, L | 1 |
| Fujiwara, H; Higuchi, T; Ishino, M; Iwamura, H; Kakinuma, C; Kito, N; Kuniyoshi, H; Matsumoto, T; Mima, S; Nishikawa, H; Paradiso, LJ; Saeki, K; Shimada, Y; Uematsu, R; Yamada, T | 1 |
| Dorjee, P; Long, ZW | 1 |
| Chen, TC; Lin, G; Lin, KJ; Wang, F; Yeh, TS; Yen, TC | 1 |
| Katz, MH; Kim, MP; Lee, JE; Tzeng, CW | 1 |
| An, Q; Xu, N; Zhou, L | 1 |
| Ebara, S; Edamura, K; Hanamoto, M; Hayashi, N; Hirata, T; Ogura, K; Saika, T; Takamura, K | 1 |
| Agócs, L; Döme, B; Fábián, K; Fillinger, J; Kajdácsi, Z; Moldvay, J; Pipek, O; Reiniger, L; Rojkó, L; Szállási, Z; Téglási, V; Tímár, J; Vágvölgyi, A | 1 |
| Cho, S; Kim, C; Shin, HJ | 1 |
| Abdelrheem, AM; Elnaggar, MS; Gabr, A; Mohamed, HAH; Salem, MA | 1 |
| Kwon, WA; Lee, JW; Oh, TH; Park, SC; Seo, IY | 1 |
| Akashita, G; Hioki, M; Miyamoto, KI; Nakanishi, T; Ohta, T; Sai, Y; Sawamoto, K; Shimada, T; Tajima, H; Takabayashi, M; Tamai, I; Yamazaki, M; Yokono, R; Yuan, T | 1 |
| Agrawal, AK; Gupta, RC; Jain, S; Katiyar, SS; Kushwah, V | 1 |
| Endo, T; Ikeda, A; Kandori, S; Kawai, K; Kojima, T; Kurobe, M; Miyagawa, T; Nishiyama, H; Tsutsumi, M; Uchida, M | 1 |
| Kim, DU | 1 |
| Adham, M; Boschetti, G; Castel-Kremer, E; Charlois, AL; Chopin-Laly, X; Comte, B; De Talhouet, S; Graillot, E; Lombard-Bohas, C; Walter, T | 1 |
| Albrecht, MH; Gruber-Rouh, T; Hammerstingl, R; Lahrsow, M; Thompson, ZM; Vogl, TJ | 1 |
| Nguyen, BD | 1 |
| Hu, H; Huang, CX; Li, D; Tong, MT; Wang, J; Xing, HB; Zhai, CY | 1 |
| He, W; Li, X; Tong, H; Wang, Q; Yang, X; Yin, H; Zeng, Y; Zhang, Y | 1 |
| Eichbaum, C; Eichbaum, M | 1 |
| Hu, Q; Ji, S; Liu, J; Liu, W; Ni, Q; Qin, Y; Sun, Q; Xiang, J; Xu, J; Xu, W; Yu, X; Zhang, B; Zhang, Z | 1 |
| Dobbelstein, M; Köpper, F; Li, Y | 1 |
| Chansriniyom, C; Iempridee, T; Khongkow, M; Khumkhrong, P; Piboonprai, K; Ruangrungsi, N; Yata, T | 1 |
| Kawabe, K; Kawamoto, M; Koya, N; Morisaki, T; Nakagawa, S; Nakamura, M; Onishi, H; Tanaka, H; Umebayashi, M | 1 |
| Gangangari, KK; Humm, JL; Larson, SM; Pillarsetty, NVK | 1 |
| Fan, Y; Feng, Y; Guo, X; Liu, T; Lou, W; Wang, D; Wang, Y; Wu, L; Wu, W; Xu, B; Xu, Y; Zhou, Y | 1 |
| Gao, H; Itkin-Ansari, P; Jakubison, BL; Konieczny, SF; Liu, Y; Moser, SE; Schweickert, PG; Scully, K; Yang, Y | 1 |
| Arafat, K; Attoub, S; Iratni, R; Khalaf, T; Sulaiman, S | 1 |
| Cassoni, A; Di Benedetto, G; Fadda, MT; Raponi, I; Terenzi, V; Valentini, V | 1 |
| Barney, C; Diaz, DA; Dillhoff, M; Grieco, C; Manilchuk, A; Pawlik, TM; Salloum, J; Schmidt, C; Walston, S; Williams, TM; Wuthrick, E | 1 |
| Chen, B; Chen, Z; Shi, K; Zhao, L | 1 |
| Chung, FF; Er, JL; Goh, PN; Hii, LW; Lee, CY; Leong, CO; Mai, CW; Tan, YJ | 1 |
| Cronin, M; Fox, JD; Gonzalez, AM; Kirsner, RS; Mackrides, N; Nichols, AJ; Zito, PM | 1 |
| Axtman, AD; Baines, AT; East, MP; Gilbert, TSK; Golitz, BT; Graves, LM; Herring, LE; Johnson, GL; Kireev, D; Krulikas, LJ; Lee, B; McDonald, IM; Okumu, DO; Wells, CI; Willson, TM; Yeh, JJ; Zuercher, WJ | 1 |
| Martínez-Piñeiro, L; Rios González, E | 1 |
| Singh, B | 1 |
| Cai, S; Chen, X; Lao, Y; Li, Y; Liang, C; Tan, H; Wang, Z; Xi, Z; Xu, H | 1 |
| Hou, XF; Li, K; Li, S; Wang, JF; Wu, C; Xu, SN | 1 |
| Eisenhaber, F; Jenjaroenpun, P; Konishi, F; Kremenska, Y; Lee, SC; Limviphuvadh, V; Maurer-Stroh, S; Mu, YS; Soo, RA; Syn, N; Tan, CS; Xiang, JS; Yong, WP | 1 |
| Chen, L; Chu, Z; Huang, C; Huang, Y; Jia, N; Wang, Z | 1 |
| Hu, Q; Liu, H; Xu, Y; Yang, W; Zhong, L | 1 |
| Kawamata, O; Murata, T; Uda, M | 1 |
| Bazin, I; Canon, JL; Cubillo, A; Hammel, P; Hidalgo, M; Macarulla, T; Manojlovic, N; Poddubskaya, E; Radenkovic, D; Raymond, E; Schueler, A; Van Cutsem, E; Verslype, C; Zhao, C | 1 |
| Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Kirouac, DC | 1 |
| Cao, J; Chen, K; Cheng, L; Jiang, Z; Li, J; Ma, J; Ma, Q; Qian, W; Sha, H; Sun, L; Yan, B; Zhou, C | 1 |
| Hinoshita, F; Katagiri, D | 1 |
| Ji, M; Lee, EJ; Park, SM; Wang, JH | 1 |
| Farley, J; Kundranda, MN; Markman, M; Niu, J | 1 |
| Ding, H; He, Z; Kan, Q; Kou, L; Li, D; Li, Z; Luo, C; Na, K; Sun, J; Wang, K; Wang, M; Zhang, H; Zhao, D; Zhong, L | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Yamada, D | 1 |
| Alazraki, AL; Amankwah, EK; Cash, T; Clark, D; George, BA; Metts, JL; Olson, TA; Wasilewski-Masker, KJ | 1 |
| Cao, J; Jiang, T; Luo, G; Qiu, Z; Wang, X; Xia, X; Zhang, K; Zhao, Q | 1 |
| Cheng, I; Li, Y; Lu, J; Qi, H; Wang, Y; Zhang, H | 1 |
| Chen, H; He, Z; Li, L; Li, N; Sun, J; Sun, Z; Tan, X; Wang, K; Zhang, H | 1 |
| Coe, IR; Karshafian, R; Mariglia, J; Momin, S | 1 |
| Ding, F; Xu, C; Yu, Y | 1 |
| Cheng, CS; Du, T; Guo, J; Hu, BD; Jiang, Q; Liu, RN; Ye, YZ; Zhang, YB | 1 |
| Li, D; Liu, J; Lu, Y; Wang, S; Wang, Y | 1 |
| Beatson, R; Burchell, JM; Graham, R; Taylor-Papadimitriou, J | 1 |
| Iguchi, T; Kato, M; Kuratsukuri, K; Nakatani, T; Nishihara, C; Takeyama, Y; Tamada, S; Yamasaki, T | 1 |
| Blackwood, EM; Cousin, S; DuPree, K; Epler, J; Hamilton, E; Hollebecque, A; Infante, JR; Italiano, A; Lauchle, JO; LoRusso, PM; Lu, X; Mahrus, S; Moein, A; Moore, KN; Murray, ER; Peale, FV; Postel-Vinay, S; Schutzman, JL; Shapiro, GI; Soria, JC; Tagen, M; Tolaney, S; Toulmonde, M | 1 |
| Devasahayam, N; Gillies, RJ; Hart, CP; Kishimoto, S; Krishna, MC; Matsumoto, S; Mitchell, JB; Munasinghe, JP; Saito, K; Takakusagi, Y | 1 |
| Baric, RS; Go, YY; Jung, E; Kim, M; Shin, JS | 1 |
| Bly, CA; Brown, J; Carter, GC; Cinfio, FN; Klein, RW; Molife, C; Tawney, MK | 1 |
| Anurova, O; Asano, N; Ben-Ami, E; Benjamin, RS; Blay, JY; Boye, K; Brahmi, M; Broto, JM; Brunello, A; Casali, PG; Collini, P; Dei Tos, AP; Desar, IME; Fedenko, A; Flucke, U; Frezza, AM; Gelderblom, H; Grignani, G; Gronchi, A; Hall, KS; Hornick, JL; Jones, RL; Kawai, A; Lo Vullo, S; Lobmaier, I; Lucibello, F; Mariani, L; Mir, O; Palmerini, E; Philippe, T; Picci, P; Ranchere, D; Ratan, R; Renne, SL; Rutkowski, P; Sbaraglia, M; Stacchiotti, S; Teterycz, P; Thway, K; Vincenzi, B; Wagner, AJ; Wagrodzki, M; Wang, WL; Yoshida, A | 1 |
| Brand, TC; Culkin, DJ; Evans, CP; Hafez, KS; Holzbeierlein, JM; Karsh, LI; Koppie, TM; Lerner, SP; Mack, PC; Messing, EM; Plets, M; Sahasrabudhe, DM; Svatek, RS; Tangen, CM; Thompson, IM; Vogelzang, NJ; Wilson, SS; Wood, DP; Wu, G | 1 |
| Goto, H; Hirooka, Y; Ichinose, T; Ishikawa, T; Kasuya, H; Kawashima, H; Kodera, Y; Koyama, N; Naoe, Y; Ohno, E; Tanaka, M; Villalobos, IB | 1 |
| Huang, M; Huang, Q; Lin, X; Liu, C; Liu, Z; Meng, F; Wang, C; Xie, F | 1 |
| Balasubramanian, A; Davis, JW; Dinney, CP; Kamat, AM; Karam, JA; Matin, SF; Metcalfe, MJ; Navai, N; Papadopoulos, J; Wagenheim, G; Wood, CG; Xiao, L | 1 |
| Duran, H; Ielpo, B; Quijano, Y; Vicente, E | 1 |
| Cao, H; Chen, H; Hu, C; Huang, L; Li, H; Lu, H; Wang, R; Wu, X | 1 |
| Abdel-Wahab, R; Bhosale, PR; Fogelman, DR; Javle, M; Overman, MJ; Shroff, RT; Varadhachary, GR; Wang, X; Wolff, RA | 1 |
| Dong, S; Duan, Y; Guo, Y; Li, Z; Ma, M; Niu, L; Shi, Y; Wang, C; Wang, N; Zhang, M | 1 |
| Akao, J; Otsuka, N; Shimizu, K; Tahara, J; Takayama, Y; Tokushige, K | 1 |
| Chen, H; Cohen, HJ; Edelman, MJ; Feliciano, JL; Gajra, A; Hurria, A; Jatoi, A; Le-Rademacher, JG; Lilenbaum, R; McMurray, R; Muss, H; Zemla, T | 1 |
| Kang, MJ; Kim, N; Kim, YT; Lee, JE; Lee, SH; Paik, WH; Ryu, JK; Son, JH | 1 |
| Stone, L | 1 |
| Chen, K; Chen, P; Chen, YJ; Li, J; Li, XQ; Ren, J; Wu, M; Wu, Y | 1 |
| Chen, B; Chen, H; Deng, T; Huang, C; Lou, B; Shi, K; Xiang, Y; Ye, W; Yu, D; Zhang, F; Zhang, J; Zhou, M | 1 |
| Chen, CG; Chen, K; Chen, P; Jiang, HG; Lan, T; Li, J; Qian, H; Shu, Y; Wu, JN; Zhao, XH | 1 |
| Esumi, H; Fujioka, R; Ikeda, M; Kishino, S; Mochizuki, N; Nomura, S; Owada, S; Sato, A; Tsuchihara, K; Yomoda, S | 1 |
| Bouvet, M; Clary, B; Delong, JC; Hoffman, RM; Hwang, HK; Igarashi, K; Kawaguchi, K; Kiyuna, T; Lwin, TM; Miyake, K; Miyake, M; Murakami, T; Singh, SR; Unno, M | 1 |
| Absil, J; Bali, MA; Chao, SL; Marechal, R; Matos, C; Metens, T; Peerboccus, BM; Pullini, S; Van Laethem, JL | 1 |
| Burt, HM; Jackson, JK; Liggins, R; Mugabe, C; Pandey, R | 1 |
| Chouaib, S; Foucher, ED; Galon, J; Ghigo, C; Iovanna, J; Olive, D | 1 |
| Choudhury, A; Christodoulou, M; Henry, A; Hodgson, C; Hoskin, PJ; Kennedy, J; Reeves, KJ; Slevin, F; Zeniou, A | 1 |
| Hou, J; Jin, W; Yang, Q; Yi, W; Yoo, S; Zhang, P | 1 |
| Chae, H; Chang, HM; Cho, H; Hwang, S; Jeong, JH; Kang, J; Kim, KM; Kim, KP; Lee, HC; Lee, JH; Lee, SS; Lee, YJ; Lim, YS; Moon, DB; Park, DH; Ryoo, BY; Shim, JH; Song, GW; Song, TJ; Yoo, C | 1 |
| Ali, H; Barton, D; Bengala, C; Brufsky, A; Coleman, R; Conte, P; Cortes, J; de la Cruz-Merino, L; Eakel, J; Glück, S; Harbeck, N; Li, H; Miller, J; O'Shaughnessy, J; Schneeweiss, A; Shtivelband, M; Wilks, S; Yardley, DA; Young, R | 1 |
| Huang, KW; Kim, MD; Li, SP; Liang, PC; Pua, U; Qiu, YD; Song, TQ; Yang, PC | 1 |
| Bianchi, G; Capri, G; Cona, MS; de Braud, F; Ferrari, B; Huber, V; Maggi, C; Manoukian, S; Mariani, G; Mennitto, A; Milano, M; Prisciandaro, M; Rinaldi, L; Rivoltini, L; Vernieri, C | 1 |
| Bernaldo de Quirós Fernández, S; Dunlop, CR; Fornari, C; Jodrell, DI; Johnson, TI; Koh, SB; Lau, A; Richards, FM; Wallez, Y; Yates, JWT | 1 |
| Lawrence, TS; Maybaum, J; Morgan, MA; Parsels, JD; Parsels, LA; Tanska, DM | 1 |
| Fung, KP; Han, QB; Lau, CBS; Leung, PC; Leung, PS; Li, L; Pu, JX; Sun, HD; Wong, TP; Yue, GGL; Zhao, SL | 1 |
| Cao, J; Hu, XC; Lin, Y; Luo, JF; Shao, ZM; Sun, XJ; Tao, ZH; Wang, BY; Wang, LP; Wang, ZH; Wu, J; Yang, WT; Zhang, J; Zhang, S | 1 |
| Andreas, S; Czapiewski, P; Fischer, JR; Kortsik, C; Neuser, P; Reinmuth, N; Reuss, A; Schnabel, PA; Serke, M; Thomas, M; Villalobos, M; Wolf, M | 1 |
| Qi, Y; Qian, S; Wu, X; Xing, K; Zhang, L; Zhang, P | 1 |
| Wang, Y; Xu, F; Xu, H; Ying, J; Zhu, W | 1 |
| Anthoney, A; Backen, AC; Beare, S; Bridgewater, JA; Corrie, PG; Cunningham, D; Dive, C; Duggan, M; Lopes, A; Madhusudan, S; Maraveyas, A; McNamara, MG; Palmer, DH; Rees, C; Ross, PJ; Steward, WP; Valle, JW; Wasan, H; Waters, JS | 1 |
| Bouvet, M; Han, Q; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, S; Miyake, K; Miyake, M; Oshiro, H; Razmjooei, S; Singh, SR; Tan, Y; Unno, M; Wangsiricharoen, S; Zhang, Z | 1 |
| Chen, S; Guo, Y; Sun, C; Yu, C | 1 |
| Che, X; Cheng, X; Du, Z; Huang, X; Li, J; Lin, D; Shao, M; Tan, W; Wang, C; Wu, C; Zhao, Y; Zheng, J | 1 |
| Aly, A; Asghari, G; Beale, P; Botteman, M; Clingan, P; Ferrara, S; Harris, M; Mainwaring, P; Margunato-Debay, S; Parnis, FX; Romano, A; Young, R | 1 |
| An, C; Bang, S; Cho, IR; Chung, JB; Chung, MJ; Jo, JH; Jung, SY; Kang, H; Lee, HS; Park, JY; Park, MS; Park, SW; Song, SY | 1 |
| De Haes, P; Morren, MA; Noë, E; Van Cutsem, E; Van den Oord, JJ; Verhulst, L; Verslype, C | 1 |
| Chen, LH; Feng, L; Hu, CY; Mostofa, AGM; Suthe, SR; Wang, MH; Wang, WL; Weng, TH; Wu, ZG; Yao, HP | 1 |
| Abraham, I; Alberts, DS; Alsaid, N; Bootman, JL; Erstad, B; Gharaibeh, M; McBride, A; Slack, M | 2 |
| Li, XQ; Ni, D; Teng, JP; Yang, ZY; Zhu, YM; Zhu, ZJ | 1 |
| Jusko, WJ; Molins, EAG | 1 |
| Chen, GP; Chen, YQ; Hu, JL; Liu, NF; Sun, HY; Yang, Y; Yu, H; Zhu, JQ; Zhu, T | 1 |
| Huang, C; Kwon, GS; Poellmann, M; Tam, YT | 1 |
| Cheng, L; Li, X; Yang, F; Zhang, L | 1 |
| Gwynne, SH; Quinton, AE; Yim, KL | 1 |
| Borowicz, P; Confeld, M; Gange, K; Haldar, MK; Hossain, R; Karandish, F; Kulkarni, P; Mallik, S; Sarkar, K; Xia, L | 1 |
| Ilbasmis-Tamer, S; Takka, S; Yalcin, TE | 2 |
| Chandimali, N; Huynh, DL; Jin, WY; Kwon, T | 1 |
| Anthony, L; Desimone, P; Dineen, S; Goel, G; Hosein, PJ; Husnain, M; Kudrimoti, M; Loaiza-Bonilla, A; Peterson, SL; Pimentel, A; Pollack, T; Ratermann, K; Tzeng, CD; Westendorf-Overley, C | 1 |
| Canale, TD; Cheung, WY; Cho, H | 1 |
| Gaffney, K; Louie, S; Rodgers, K; Soto, M; Weinberg, M | 1 |
| Abrams, SL; Candido, S; Cervello, M; Cocco, L; Falasca, M; Lertpiriyapong, K; Libra, M; Lombardi, P; Martelli, AM; McCubrey, JA; Montalto, G; Murata, RM; Ratti, S; Rosalen, PL; Steelman, LS; Yang, LV | 1 |
| Hua, J; Liang, C; Liang, D; Meng, Q; Shi, S; Xu, J; Yu, X; Zhang, B | 1 |
| Thanh, VH | 2 |
| Agrawal, AK; Gupta, RC; Jain, S; Katiyar, SS; Kushwah, V; Lamprou, DA; Saraf, I; Singh, IP | 1 |
| Kim, HO; Lee, SR; Shin, JH | 1 |
| Halldén, G; Nattress, CB | 1 |
| Robson, M | 1 |
| Abe, M; Chiba, T; Iino, Y; Kato, N; Mikata, R; Ogawa, Y; Ohyama, H; Suzuki, E; Tsuyuguchi, T; Yasui, S | 1 |
| Bahary, N; Matsuda, R; Miller-Ocuin, JL; Nguyen, K; Singhi, AD; Thakur, PC; Zeh, HJ | 1 |
| Ji, L; Ke, M; Li, Y; Liu, G; Ou, Z; Tang, N | 1 |
| Celia, C; Cilurzo, F; Cosco, D; Costa, N; Di Marzio, L; Di Tullio, A; Fresta, M; Locatelli, M; Malatesta, L; Paolino, D | 1 |
| Basset, V; Cortesse, A; Culine, S; de la Taille, A; Desgrandchamps, F; Dumont, C; Gaudez, F; Masson-Lecomte, A; Meria, P; Meyer, F; Michel, C; Mongiat-Artus, P; Vordos, D | 1 |
| Baloğlu, E; Çalışkan, Ç; Erzurumlu, Y; Karavana, SY; Özdemir, Dİ; Şen, S; Şenyiğit, ZA; Sevin, G | 1 |
| Álvarez, R; Carrato, A; Díaz, R; García, A; Hidalgo, M; Laquente, B; Macarulla, T; Muñoz, A; Sastre, J | 1 |
| Chan, MW; Chang, CC; Chen, HJ; Chen, LY; Huang, RL; Lai, HC; Liew, PL; Su, PH; Wang, YC; Weng, YC | 1 |
| Guo, P; Han, Z; Jiang, H; Peng, L; Shang, W; Tian, J; Wang, H; Wang, K; Wang, L; Xu, W | 1 |
| Bahra, M; Denecke, T; Jühling, A; Klein, F; Pelzer, U; Riess, H; Roemmler-Zehrer, J; Sinn, M; Striefler, J; Wislocka, L | 1 |
| Chen, W; He, M; Liu, Q; Long, MM; Wang, H; Wang, J; Xu, SW; Yang, LH; Yang, RM; Zhan, M | 1 |
| Chen, Y; Ma, L; Sun, Y; Wang, X; Xiong, M; Zhang, X; Zhao, Y | 1 |
| Hu, W; Liu, Q; Pan, J; Sui, Z | 1 |
| Belle, S; Betge, J; Burgermeister, E; Chi-Kern, J; Ebert, MP; Gutting, T; Haertel, N; Jesenofsky, R; Maenz, M; Schulte, N; Wedding, U | 1 |
| Delpero, JR; Ewald, J; Gilabert, M; Marchese, U; Turrini, O | 1 |
| Nishibuchi, I; Wadasaki, K | 1 |
| Saito, K; Sato, A; Takahata, T; Yu, C | 1 |
| Artioli, F; Bianco, R; Bilancia, D; Bonanno, L; Bordonaro, R; Burgio, MA; Cavanna, L; Ciardiello, F; Cinieri, S; Cortinovis, D; Costanzo, R; Daniele, G; di Isernia, G; Filipazzi, V; Fregoni, V; Gallo, C; Gebbia, V; Gridelli, C; Leo, S; Luciani, A; Maione, P; Mencoboni, M; Morabito, A; Nelli, F; Perrone, F; Piccirillo, MC; Riccardi, F; Rocco, G; Rosetti, F; Signoriello, S | 1 |
| Chevalier, H; Neuzillet, C; Turpin, A | 1 |
| Ahn, S; Jang, JS; Kim, JH; Kim, SH; Kim, YJ; Lee, H; Lee, JH; Lee, JS; Lee, YG | 1 |
| Bakhtiari, A; Moradnia, H; Raissi, H | 1 |
| Huang, WW; McGregor, S; Nyckowski, T | 1 |
| Ben David, G; Binenbaum, Y; Fridman, E; Gil, Z; Milman, N; Schroeder, A; Shlomi, T; Yaari, Z | 1 |
| Buscemi, G; Chan, SY; Delia, D; Magni, M; Maita, L; Montecucco, A; Peng, L; Zannini, L | 1 |
| Cao, J; Chen, K; Cheng, L; Duan, W; Jiang, Z; Li, J; Ma, Q; Qian, W; Yan, B; Zhou, C | 1 |
| Chang, S; Choi, EA; Choi, YS; Kim, I; Kim, SC; Lee, EJ; Park, S; Rhee, JK; Song, JH | 1 |
| Ichimiya, S; Imaizumi, A; Morisaki, T; Murahashi, M; Nagai, S; Nakamura, K; Ogata, H; Onishi, H; Umebayashi, M; Yamasaki, A; Yanai, K | 1 |
| Cheng, R; Cui, W; Deng, L; Huang, X; Santos, HA; Song, Z; Wang, H; Xia, G; Zhang, H | 1 |
| Aiken, T; Anderson, A; Avital, I; Li, D; Mullinax, JE; Rudloff, U; Thorgeirsson, S; Wiegand, G; Xin, H | 1 |
| Ciesielka, M; Homa-Mlak, I; Kozioł, P; Krawczyk, P; Małecka-Massalska, T; Milanowski, J; Mlak, R; Powrózek, T | 1 |
| Hankinson, O; Yamaguchi, M | 1 |
| Jusko, WJ; Straubinger, RM; Trueman, S; Zhu, X | 1 |
| Hasanov, M; Hernandez, CMR; Konoplev, SN | 1 |
| Fløtten, Ø; Grønberg, BH; Kristensen, A; Solheim, TS | 1 |
| Einama, T; Kamachi, H; Kamiyama, T; Katoh, N; Mitsuhashi, T; Orimo, T; Sakamoto, Y; Sakata, T; Shibuya, K; Shimada, S; Taketomi, A; Tsuruga, Y; Uchinami, Y; Wakayama, K; Yokoo, H | 1 |
| Bria, E; Caccese, M; D'Argento, E; di Noia, V; Grizzi, G; Iacovelli, R; Pilotto, S; Tortora, G | 1 |
| Fukuda, H; Fukutomi, A; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Katayama, H; Mizuno, N; Mizusawa, J; Okusaka, T; Ozaka, M; Ueno, H; Ueno, M | 1 |
| Jusko, WJ; Qu, J; Shen, X; Straubinger, RM; Zhu, X | 1 |
| Dai, H; Huang, J; Shen, H; Yao, D; Yuan, Y | 1 |
| Bilalis, P; Dimas, K; Iatrou, H; Karatzas, A; Marakis, J; Sereti, E; Skoulas, D; Stamogiannos, A; Stratikos, E; Tsimblouli, C; Vlassopoulos, D | 1 |
| Al-Ghadhban, A; Carter, JE; Deshmukh, SK; Dugger, K; Khan, MA; Singh, AP; Singh, S; Srivastava, SK; Tyagi, N | 1 |
| Couvreur, P; Denis, S; Guillaneuf, Y; Jacobs, M; Mougin, J; Mura, S; Nicolas, J; Vinciguerra, D | 1 |
| Chen, B; Dong, M; Fang, H; Gui, L; He, XH; Li, YX; Liu, P; Qi, F; Qi, SN; Song, YW; Wang, SL; Wang, WH; Yang, JL; Yang, S; Zhou, SY | 1 |
| Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kawamoto, K; Kobayashi, S; Mori, M; Noda, T; Okumura, Y; Sakamoto, T; Takeda, Y; Tanemura, M; Umeshita, K; Wada, H; Yamada, D | 1 |
| Barbie, D; Chaves, J; Fuchs, CS; Hahn, WC; Hendifar, A; Koh, B; Ng, K; Starodub, A; Yang, Y | 1 |
| Bamlet, WR; Bentrem, DJ; Etheridge, AS; Glubb, D; Gordân, R; Innocenti, F; Jiang, C; Kindler, HL; Kubo, M; McLeod, H; McWilliams, RR; Mulkey, F; Nakamura, Y; Neel, N; Niedzwiecki, D; Owzar, K; Petersen, GM; Ratain, MJ; Seiser, E; Sibley, AB; Talamonti, MS; Van Loon, K; Venook, AP; Yeh, JJ | 1 |
| Li, D; Li, Z; Qian, J; Qian, X; Wang, X; Xu, P; Yao, J | 1 |
| Hu, C; Li, Y; Lu, X; Qian, W; Xu, T | 1 |
| Bowers, M; Cozens, K; Cross, N; Hennig, IM; Huddart, R; McKenzie, HS; Mead, G; Rustin, GJS; Wheater, MJ; White, JD | 1 |
| Cho, NH; Hyun, YM; Jun, CD; Lee, SH; Lee, WJ; Park, SA; Seo, SU; Zou, Y | 1 |
| Cao, J; Li, S; Wang, Q; Wu, G | 1 |
| Chen, BW; Chen, W; Hu, L; Li, H; Liang, T; Liu, H; Ma, T; Shen, J; Zhang, B; Zhang, S; Zheng, X; Zhi, X; Zhou, Y | 1 |
| Bai, XG; Ding, M; Jin, ZL; Xu, HJ; Yang, Y; Zhang, LJ | 1 |
| Chiappella, A; Vitolo, U | 1 |
| Blaney, SM; Bush, R; Cole, PD; Drachtman, RA; Horton, TM; Kelly, KM; McCarten, KM; Metzger, ML; Pei, Q; Spira, M; Weigel, BJ | 1 |
| Berlin, J; Cardin, D; Das, S | 1 |
| Al-Muderis, O; Benson, C; Chauhan, D; Davis, EJ; Fisher, C; Jones, RL; Judson, I; Keedy, VL; Messiou, C; Miah, A; Pender, A; Thway, K; van der Graaf, W; Zaidi, S | 1 |
| Akita, H; Asukai, K; Ioka, T; Ishikawa, O; Ohue, M; Takahashi, H; Tomokoni, A; Wada, H; Yano, M | 1 |
| Cabeza-Morales, M; Garcia-Carbonero, N; Garcia-Foncillas, J; Li, W; Martinez-Useros, J | 1 |
| Huang, Y; Liu, S; Lu, W; Xu, Y; Yu, J; Zhang, X | 1 |
| Chen, X; Deng, M; Gu, J; Shen, N; Song, W; Tang, Z; Yang, C; Yin, L; Yu, H; Zhang, D | 1 |
| Cong, X; Dong, X; Fan, J; Fang, S; Tang, Y; Wang, S; Yuan, Y | 1 |
| Bhowmick, NA; Boros, LG; Chheda, C; Edderkaoui, M; Habtezion, A; Hu, RW; Lewis, M; Madhav, A; Murali, R; Pan, X; Pandol, SJ; Ramanujan, VK; Soufi, B; Tajbakhsh, J; Tuli, R; Wang, Q; Zayou, F | 1 |
| Akita, H; Asukai, K; Ishikawa, O; Matsunaga, T; Miyata, H; Nakanishi, M; Nishimura, J; Ohue, M; Omori, T; Sakon, M; Shirayanagi, M; Sugimura, K; Takahashi, H; Takahashi, Y; Tomokuni, A; Wada, H; Yamamoto, K; Yamamoto, T; Yamasaki, T; Yanagimoto, Y; Yano, M; Yasui, M | 1 |
| Arcidiacono, PG; Balzano, G; Castoldi, R; Ceraulo, D; Chiaravalli, M; Doglioni, C; Falconi, M; Fugazza, C; Gianni, L; Macchini, M; Nicoletti, R; Partelli, S; Passoni, P; Peretti, U; Pircher, C; Reni, M; Zanon, S | 1 |
| Dai, H; Guo, S; Jiang, Y; Li, Y; Lin, SY; McGrail, DJ; Yin, J | 1 |
| Bode, B; Britschgi, C; Cecconi, V; Curioni-Fontecedro, A; Felley-Bosco, E; Friess, M; Hiltbrunner, S; Opitz, I; Soldini, D; Stahel, RA; Stolzmann, P; Tallón de Lara, P; Tischler, V; van den Broek, M; Vrugt, B; Weder, W; Yagita, H | 1 |
| Liu, H; Tang, W; Xue, R; Zhang, S; Zhou, Y | 1 |
| Goto, R; Hattori, M; Iwata, H; Kashiwaba, M; Kondo, N | 1 |
| Aujla, PK; Beckett, LA; Lara, PN; Li, Y; Pan, CX; Parikh, M; Robles, DA | 1 |
| Hashimoto, K; Itoh, N; Maehana, T; Masumori, N; Nishiyama, N; Okabe, K; Shindo, T; Tachiki, H; Taguchi, K; Takahashi, A; Tanaka, T | 1 |
| Hwang, HS; Im, BN; Kim, DH; Na, K | 1 |
| Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC | 1 |
| Deshpande, H; Donadio, A; Hurwitz, ME; Kelly, WK; Markowski, P; Mehnert, JM; Mortazavi, A; Patel, J; Petrylak, DP; Stein, MN; Yao, X | 1 |
| Benson, AB; Catalano, PJ; Lubner, SJ; Menge, MR; Munshi, HG; Nimeiri, HS; O'Dwyer, PJ; Sahai, V; Zalupski, MM | 1 |
| Bharti, JN; Soni, SC; Sureka, B; Varshney, VK | 1 |
| Kim, HS; Seo, HK | 1 |
| Honda, G; Matsumoto, I; Motoi, F; Satoi, S; Shinchi, H; Sho, M; Tsuchida, A; Unno, M; Wada, K | 1 |
| Assi, H; Charafeddine, M; Hammoud, MS; Makki, I; Mukherji, D; Nassif, S; Shamseddine, A; Temraz, S; Tfayli, A | 1 |
| Martins, A; Neves, NM; Oliveira, C; Reis, RL; Silva, TH | 1 |
| Hack, E; Karanth, N; Thachil, T | 1 |
| Abou-Tarboush, FM; Ahmad, A; Al-Anazi, KM; Farah, MA; Hailan, WAQ; Qasem, A | 1 |
| Bastiancich, C; Bastiat, G; Bianco, J; Danhier, F; Franconi, F; Lagarce, F; Lemaire, L; Préat, V | 1 |
| Cai, H; Cao, X; Chen, M; Duan, M; Han, B; Li, J; Zhang, W; Zhang, Y; Zhou, D; Zhu, T; Zhuang, J | 1 |
| Kim, S; Marshall, JL; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Ung, B; Xiang, CQ; Yang, H | 1 |
| Fuse, K; Kawamoto, K; Kiryu, M; Masuko, M; Mitobe, M; Miyoshi, H; Nanba, A; Ohshima, K; Shibasaki, Y; Sone, H; Suwabe, T; Suzuki, T; Takizawa, J; Tamura, S; Tanaka, T | 1 |
| Kwong, DLW | 1 |
| Berkowitz, RS; Bonventre, JV; Crum, CP; D'Andrea, AD; Decker, B; Do, KT; Feltmate, CM; Hill, SJ; Horowitz, NS; Kochupurakkal, BS; Konstantinopoulos, PA; Liu, JF; Matulonis, UA; Morizane, R; Muto, MG; Nguyen, H; Nucci, MR; Roberts, EA; Shapiro, GI; Swisher, EM; Worley, MJ; Yang, C | 1 |
| Di, Y; Fu, D; Guo, Z; Jin, C; Li, J; Wang, F; Yao, L; Yu, X | 1 |
| Borbath, I; Conroy, T; Malka, D | 1 |
| Cheon, MJ; Fang, Z; Han, B; Hong, SS; Jung, KH; Kang, YW; Kim, SJ; Kim, YS; Lee, JE; Lim, JH; Park, JH; Shin, SM; Son, MK; Woo, MG; Yan, HH | 1 |
| Hu, M; Nijampatnam, B; Qin, JJ; Ruan, KH; Velu, SE; Voruganti, S; Wang, W; Zhang, R; Zhou, J | 1 |
| Han, BS; Jang, HY; Kwon, B; Sin, JI | 1 |
| Chiou, SH; Dorsch, M; Grüner, BM; Koong, AC; Kozak, MM; Kusch, E; Naranjo, S; Winslow, MM | 1 |
| Babazono, A; Fujita, T; Harano, Y; Jiang, P | 1 |
| Apolo, AB; Chowdhury, S; Galsky, MD; Hahn, NM; Merseburger, AS; Milowsky, MI; Petrylak, D; Powles, T; Quinn, DI; Rosenberg, JE; Siefker-Radtke, A; Sonpavde, G; Sternberg, CN | 1 |
| Bartolazzi, A; D'Arino, A; Federico, A; Magri, F; Muscianese, M; Pigliacelli, F; Pranteda, G | 1 |
| Cai, Q; Fu, H; Hu, Z; Tang, Y; Xu, J; Yang, D; Zhang, Y | 1 |
| Bahra, M; Neumann, CCM; Pratschke, J; Reutzel-Selke, A; Sauer, IM; Schmuck, RB; Seidel, E; von Hörschelmann, E | 1 |
| Cai, XJ; Chen, LY; Cheng, B; Lei, L; Lin, NM; Shi, L; Wang, Z; Ye, LQ | 1 |
| Arroyo-Conde, C; Casanova-Martinez, C; González-Costas, S; Piñeiro-Corrales, G; Romero-Ventosa, EY | 1 |
| Alexander, MS; Allen, BG; Berg, DJ; Bodeker, KL; Brown, HA; Buatti, JM; Buettner, GR; Cullen, JJ; Du, J; Gibson-Corley, K; O'Leary, BR; Schroeder, SR; Spitz, DR; Vollstedt, S; Wagner, BA; Wilkes, JG | 1 |
| Chen, K; Dai, Y; Gong, Q; Luo, K; Ma, X; Tang, JZ; Zhang, Y | 1 |
| Chen, X; Shen, N; Tang, Z; Wang, G; Yang, S; Zhang, D | 1 |
| Chavez-MacGregor, M; Giordano, SH; Kehl, KL; Niu, J | 1 |
| Bajpai, P; Pandey, P; Pathak, N; Sayyed, U; Siddiqui, MH; Tiwari, RK | 1 |
| Ge, C; Ge, J | 1 |
| Akhtar, S; David, D; Geamanu, A; Goja, A; Gupta, SV; Razalli, NH; Saadat, N; Shen, Y | 1 |
| Higashi, T; Koizumi, M; Kurosawa, G; Kurosawa, Y; Saga, T; Sudo, H; Sugyo, A; Tsuji, AB; Ukai, Y | 1 |
| Chang, HM; Hyung, J; Jeong, JH; Kim, B; Kim, KP; Ryoo, BY; Yoo, C | 1 |
| Gordon, DJ; Goss, KL; Koppenhafer, SL; Terry, WW | 1 |
| Bansal, R; Mardhian, DF; Prakash, J; Storm, G | 1 |
| Chang, HC; Chow, PM; Hong, JY; Hsu, FS; Huang, KH; Kuo, KL; Kuo, Y; Liao, SM; Lin, MC; Lin, WC; Liu, SH; Shi, CS; Shun, CT; Tsai, YC; Wu, JT; Yang, SP | 1 |
| Chen, C; Meng, X; Qin, Z; Song, N; Wang, Y; Xia, J; Xu, L; Zhang, Q; Zhou, X | 1 |
| Bruno, S; Butera, G; Conti, P; Donadelli, M; Margiotta, M; Mullappilly, N; Pacchiana, R; Riganti, C | 1 |
| Akahori, T; Hasegawa, M; Ikeda, N; Kichikawa, K; Mitoro, A; Nagai, M; Nakagawa, K; Nakamura, K; Nishiwada, S; Sho, M; Tamamoto, T; Tanaka, T; Yoshiji, H | 1 |
| Copolla, D; Goyal, G; Kim, J; Kim, R; Kommalapati, A; Mahipal, A; Neuger, A; Soares, H; Tella, SH | 1 |
| Dhir, M; Zureikat, AH | 1 |
| Hashimoto, Y; Ikeda, M; Imaoka, H; Kan, M; Kimura, G; Mitsunaga, S; Ohno, I; Sasaki, M; Suzuki, Y; Takahashi, H; Umemoto, K; Watanabe, K | 1 |
| Fetterly, G; Fountzilas, C; Iyer, R; Javle, M; Johnson, C; Ma, Y; Tan, W | 1 |
| Arlt, A; Deisinger, F; Helm, O; Hesse, L; Kha, ML; Röcken, C; Schäfer, H; Sebens, S; Sipos, B | 1 |
| Chang, YY; Gao, YJ; Gong, YW; Guo, Q; Wang, YH; Wang, ZP; Zhang, S; Zhao, YL | 1 |
| Bonior, J; Góralska, M; Jastrzębska, M; Jaworek, J; Leja-Szpak, A; Link-Lenczowski, P; Nawrot-Porąbka, K; Pierzchalski, P | 1 |
| Gou, H; Yi, C; Zhao, Y; Zhu, H | 1 |
| Fang, Z; Hong, S; Hong, SS; Jung, HY; Maeng, HJ; Yoon, JH | 1 |
| Alhebshi, H; Bakker, E; Demonacos, C; Guazzelli, A; Hussain, M; Krstic-Demonacos, M; Meysami, P; Mutti, L; Schwartz, JM; Tian, K | 1 |
| Gong, Y; Hao, W; He, B; He, Z; Hu, G; Li, W; Liu, J; Liu, Y; Yu, Q | 1 |
| Jin, R; Wang, GJ; Yan, L; Zhang, M | 1 |
| Benhadji, KA; Blunt, A; Cleverly, A; Deplanque, G; Estrem, ST; Fuchs, M; Garcia-Carbonero, R; Gueorguieva, I; Kozloff, M; Lahn, MMF; Macarulla, T; Melisi, D; Oettle, H; Pezet, D; Smith, C; Tabernero, J; Trojan, J | 1 |
| Bing, X; Haijun, Z; Lian, Y; Manman, D; Silei, B; Xiufeng, Z; Yong, Z; Zhihong, F | 1 |
| Franch-Sarto, M; López, L; Moreno, M; Ribera, JM; Sancho, JM; Sorigue, M | 1 |
| Chang, HM; Hwang, I; Ip, HNN; Jeong, JH; Kang, J; Kim, KP; Ryoo, BY; Yoo, C | 1 |
| Bhosale, P; Fogelman, D; Gulhati, P; Javle, M; Katz, MHG; Koay, EJ; Lee, JE; Lee, JH; Maitra, A; Prakash, L; Shroff, R; Tamm, E; Tzeng, CD; Varadhachary, GR; Wang, H; Wang, X; Weston, B; Wolff, RA | 1 |
| Eskens, FALM; Groot Koerkamp, B; Heijmen, BJM; Koedijk, MS; Méndez Romero, A; Poley, JW; Sprengers, D; van der Holt, B; van der Laan, LJW; van Gent, DC; Willemssen, FEJA | 1 |
| Cai, Q; Chu, W; Ding, N; Gou, J; He, H; Li, J; Tang, X; Tang, Z; Tian, P; Yin, T; Zhang, Y; Zhuo, X | 1 |
| Biondi, M; Botti, G; Fusco, S; Iaffaioli, RV; Mayol, L; Quagliariello, V; Serri, C | 1 |
| Ahn, JB; Choi, YD; Chung, HC; Han, JW; Heo, SJ; Hur, H; Kim, HS; Kim, JH; Kim, KS; Kim, S; Kim, SH; Kim, SK; Lee, YH; Noh, SH; Park, HS; Rha, SY; Shin, KH; Suh, JS | 1 |
| Chen, R; Li, G; Li, Z; Lin, Q; Liu, Y; Lu, Y; Wei, L; Ye, H; Zheng, S; Zhou, Q | 1 |
| Ajiki, T; Gotoh, K; Hatano, E; Hirose, T; Ikai, I; Ioka, T; Kamei, K; Kobayashi, S; Morita, S; Nagano, H; Sakai, D; Satake, H; Seo, S; Terajima, H; Tohyama, T; Tomokuni, A; Uchida, Y | 1 |
| Cao, J; Cheng, L; Duan, W; Jiang, Z; Li, J; Li, X; Ma, J; Ma, Q; Qian, W; Sun, L; Wang, F; Wu, E; Wu, Z; Yan, B; Zhou, C | 1 |
| Liang, Z; Liu, C; Liu, Z; Wang, H; Yang, G; You, L; Zhang, J; Zhang, T; Zhao, F; Zhao, Y | 1 |
| Hajatdoost, L; Kosari, S; Sedaghat, K; Thomas, J; Walker, EJ | 1 |
| Boeck, S; Diehl, F; Haas, M; Heinemann, V; Holdenrieder, S; Jung, A; Kirchner, T; Kruger, S; Liebmann, S; Nagel, D; Ormanns, S; Prinz-Bravin, I; Ross, C; von Bergwelt-Baildon, M; Westphalen, CB | 1 |
| Bahl, C; Behera, D; Sharma, S; Singh, N | 1 |
| Han, Z; Hao, W; Jiang, Y; Wang, Y | 1 |
| Chen, H; He, R; Qin, R; Shi, X; Zhang, H; Zhao, C; Zhou, M | 1 |
| Araki, K; Gantumur, D; Hagiwara, K; Handa, T; Harimoto, N; Igarashi, T; Ishii, N; Kubo, N; Kuwano, H; Masamune, A; Shirabe, K; Tsukagoshi, M; Umezawa, K; Watanabe, A; Yamanaka, T; Yokobori, T | 1 |
| Connelly, JW; Doroshow, JH; Fang, J; Fogli, LK; Hamed, H; Harris, E; Hose, C; Konaté, MM; Krushkal, J; Li, MC; Miller, SB; Monks, A; Palmisano, A; Polley, EC; Rapisarda, A; Simon, R; Simpson, MA; Sonkin, D; Teicher, BA; Voth, AR; Wu, X; Zhao, Y | 1 |
| Arumugam, T; Chiao, P; Curran, MA; Deng, D; Hung, MC; Husted, H; Hwang, RF; Lee, JE; Ling, J; Liu, Y; Logsdon, CD; Lu, M; Maitra, A; Moore, T; Niehrs, C; Ramachandran, V; Wang, H; Zhou, L | 1 |
| Cao, JZ; Chen, B; He, X; Hou, XR; Lan, SM; Li, YX; Liu, X; Qi, SN; Qian, LT; Qu, BL; Shi, M; Su, H; Wang, Y; Wu, G; Wu, JX; Wu, T; Xu, LM; Yang, Y; Yuan, ZY; Zhang, FQ; Zhang, LL; Zhang, YJ; Zhu, SY; Zhu, Y | 1 |
| Choi, YJ; Kang, EJ; Kim, DS; Kim, HJ; Kim, JS; Lee, SY; Oh, SC; Seo, JH | 1 |
| Muddana Eswara, BR; Panduragaiah, VM; Sidramappa, MA; Unnam, S | 1 |
| Chen, W; Fan, W; Huang, F; Lu, X; Mou, X; Ru, G; Wang, S; Zhang, X | 1 |
| Guo, K; Liu, Z; Ma, G; Song, S; Wu, X | 1 |
| Balachandar, V; Devi, SM; Kaavya, J; Mahalaxmi, I; Santhy, KS | 1 |
| Gupta, N; Jangid, AK; Kulhari, H; Pooja, D; Singh, M | 1 |
| Goodwin, ML; Simeone, DM; Urs, SK | 1 |
| Chiorean, EG; Gu, D; Jia, Y; Wan, J; Wang, Y; Xie, J; Yu, B; Zhang, X | 1 |
| Gao, D; Qian, SY; Xu, Y; Yang, L; Yang, X | 1 |
| Azuma, H; Ibuki, N; Inamoto, T; Komura, K; Minami, K; Narumi, Y; Nomi, H; Takahara, K; Uehara, H; Yamamoto, K | 1 |
| Bush, X; Chen, JA; Yan, B; Zhang, Y | 1 |
| Bi, H; Bold, RJ; Gonzalez, FJ; Ho, PY; Jian, C; Kim, EJ; Qiu, JX; Tu, MJ; Yu, AM; Zhang, QY | 1 |
| Dhaliwal, A; Gray, DS; Moghe, PV; Pelka, S | 1 |
| Babjuk, M | 2 |
| Carnevale, I; Choy, ATF; Coppola, S; Deng, D; Giovannetti, E; Kazemier, G; Meijer, LL; Zaura, E | 1 |
| Burtey, S; Coppo, P; Daviet, F; Duffaud, F; Frémeaux-Bacchi, V; Grandvuillemin, A; Grange, S; Jourde-Chiche, N; Mancini, J; Micallef, J; Moussi-Francès, J; Poullin, P; Pourroy, B; Rouby, F; Sabatier, R; Sallée, M | 1 |
| Hung, WS; Lee, IC; Wu, YC | 1 |
| Baron, B; Hamada, JI; Harada, K; Kitagawa, T; Kobayashi, M; Kuhara, K; Kuramitsu, Y; Nagayasu, H; Ohta, T; Shimo, T; Takai, R; Terasaki, M; Tokuda, K; Tokunaga, M; Uehara, O | 1 |
| Rao, M; Soni, SC; Sureka, B; Varshney, VK | 1 |
| Liu, C; Lou, C; Lu, H; Ma, Z; Zhang, Y | 1 |
| Choi, JH; Choi, YH; Huh, G; Kim, YT; Lee, SH; Paik, WH; Ryu, JK; You, MS | 1 |
| Tian, Q; Wang, Y; Zhang, F | 1 |
| Benigno, BB; Clayton, EA; Huang, C; Matyunina, LV; McDonald, JF; McDonald, LD; Vannberg, F | 1 |
| Fu, J; Jin, Y; Li, X; Liang, X; Luo, Y; Zhang, J; Zhang, P; Zou, Q | 1 |
| Baldini, E; Barbieri, F; Boni, L; Brighenti, M; Camerini, A; Chartoire, M; Gilli, A; Giovannetti, E; Honeywell, R; Mazzoni, F; Peters, GJ; Tibaldi, C; Tiseo, M; Vittimberga, I | 1 |
| An, N; Cheng, D | 1 |
| Li, B; Liao, W; Wen, H; Xu, P; Zhang, S; Zheng, L | 1 |
| Anderson, GJ; Du, C; Han, X; Lang, J; Min, H; Nie, G; Qi, Y; Qin, H; Shi, Q; Tian, X; Wang, Y; Yang, Y; Zhang, Y; Zhang, Z; Zhao, X; Zhao, Y | 1 |
| D'Haese, JG; Friess, H; Gloor, B; Hartmann, D; Kaufmann, B; Radenkovic, D; Stupakov, P | 1 |
| Hakuta, R; Hamada, T; Ijichi, H; Isayama, H; Ishigaki, K; Kishikawa, T; Kogure, H; Koike, K; Matsubara, S; Mizuno, S; Nakai, Y; Saito, K; Saito, T; Sasaki, T; Tada, M; Takahara, N; Takeda, T; Tateishi, K; Uchino, R; Yamamoto, N | 1 |
| Brunner, TB; Willich, C | 1 |
| Asleh, K; Balslev, E; Burugu, S; Ejlertsen, B; Gao, D; Jensen, MB; Laenkholm, AV; Lyck Carstensen, S; Nielsen, DL; Nielsen, TO; Tykjaer Jørgensen, CL; Won, JR | 1 |
| Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Long, J; Ma, X; Nie, J; Tian, G; Wang, Y; Zhang, Z | 1 |
| Belanger, B; Blanc, JF; Bodoky, G; Braiteh, FS; Chen, LT; Chiu, CF; Cunningham, D; de Jong, FA; Dean, AP; Hubner, RA; Jameson, GS; Lee, KH; Li, CP; Macarulla, T; Mamlouk, K; Schwartsmann, G; Shan, YS; Siveke, JT; Wang-Gillam, A | 1 |
| Adjei, AA; Boland, P; Brady, W; Dy, GK; Fetterly, G; Iyer, R; LeVea, C; Ma, WW; Mantione, K; Pitzonka, L; Schihl, S; Straubinger, RM; Tan, W; Whitworth, A; Wilton, J; Xie, H | 1 |
| Cao, XY; Hu, LP; Huo, YM; Jiang, SH; Jiang, YS; Li, J; Li, Q; Sun, YW; Tao, LY; Tian, GA; Wang, YH; Xiao, GG; Yang, MW; Yang, Q; Yang, XM; Zhang, XX; Zhang, YL; Zhang, ZG; Zhu, LL | 1 |
| Bergeat, D; Coulouarn, C; De La Torre, C; Dooley, S; Ebert, MPA; Gretz, N; Li, J; Liebe, R; Lin, T; Sulpice, L; Weng, HL; Yuan, X | 1 |
| Adamowicz, K; Janiszewska, J; Lichodziejewska-Niemierko, M | 1 |
| Kumar, L; Tiwari, A | 1 |
| Gupta, S; Nayak, L; Ostwal, V; Ramaswamy, A; Sahu, A; Shetty, N; Shrikhande, SV; Zanwar, S | 1 |
| Ji, Z; Xu, C; Xu, R; Zhu, J | 1 |
| Coen, JJ; Efstathiou, JA; Jani, AB; Kucuk, O; Lautenschlaeger, T; Lee, CT; Parker, W; Rodgers, JP; Sandler, HM; Saylor, PJ; Shipley, WU; Souhami, L; Wu, CL; Zhang, P; Zietman, AL | 1 |
| Jain, A; Jain, AK; Prajapati, SK; Shrivastava, C | 1 |
| Borowicz, P; Confeld, M; Mallik, S; Quadir, M; Ray, P; Wang, T | 1 |
| Hashimoto, A; Ichikawa, H; Inui, Y; Ito, M; Kakiuchi, S; Kawamoto, S; Kurata, K; Matsuoka, H; Minami, H; Miyata, Y; Mizutani, Y; Nagao, S; Okuni, M; Saito, Y; Sakai, R; Shinzato, I; Suto, H; Tanaka, Y; Uehara, K; Yakushijin, K; Yamamoto, K | 1 |
| Ma, S; Yang, D; Yang, Y; Zhao, Y | 1 |
| Akce, M; Alese, OB; El-Rayes, BF; Kane, SR; Kooby, DA; Maithel, SK; Narayan, AS; Patel, PR; Sarmiento, JM; Shaib, WL; Switchenko, JM; Wu, C | 1 |
| Kopeček, J; Li, L; Opanasopit, P; Soodvilai, S; Wang, J; Yang, J | 1 |
| Amundadottir, L; Clarke, WR; James, MA | 1 |
| Boku, N; Chang, HM; Chung, IJ; Fukuzawa, K; Furukawa, M; Furuse, J; Hara, H; Hyodo, I; Ikeda, M; Ioka, T; Kanai, M; Kim, JS; Maguchi, H; Mizuno, N; Nakamori, S; Okusaka, T; Omuro, Y; Park, JO; Sasahira, N; Sugimori, K; Takeuchi, M; Ueno, H; Ueno, M; Yamaguchi, T; Yukisawa, S | 1 |
| Lv, C; Wang, J; Wu, N; Yan, S; Yang, Y | 1 |
| Guo, Z; He, S; Hu, Z; Jiang, K; Lin, C; Su, H; Yuan, G; Zeng, Y; Zhong, F | 1 |
| Han, H; Rong, Y; Tang, Z; Tao, J; Xiong, C; Zhang, Z; Zhu, K; Zhu, Z | 1 |
| Adeva, J; Alés-Díaz, I; Buxò, E; Cañabate, M; Carmona-Bayonas, A; De la Cámara, J; Fernández, A; Gallardo, E; Gallego, J; García, A; González, P; Guillén, C; Jiménez-Fonseca, P; Llorca, C; López, C; López, LJ; Muñoz, A; Navarro-Pérez, V; Pazo-Cid, RA; Quintero, G; Ramírez, P; Reboredo, M; Ruiz-Miravet, N; Salgado, M; Sanchez-Cánovas, M; Vera, R | 1 |
| Huang, P; Li, Y; Shi, L; Tong, B; Wang, Z; Xing, W; Xu, G; Yu, T; Zheng, Y; Zhou, C; Zhou, J | 1 |
| Kim, DH; McCaw, ZR; Tian, L; Wei, LJ | 1 |
| Díaz-Serrano, A; Paz-Ares, L; Sánchez-Torre, A | 1 |
| Chen, H; Chen, J; Gou, F; Liu, J; Lu, H; Lv, X; Shen, Y; Yu, D; Zhang, X | 1 |
| Liu, W; Liu, X; Song, Y; Wu, M; Xie, Y; Yang, M; Zheng, W; Zhu, J | 1 |
| Arima, K; Baba, H; Chikamoto, A; Fukuzawa, K; Hashimoto, D; Hirata, T; Hirota, M; Inomata, M; Maehara, Y; Nakagawa, S; Negoro, Y; Ohga, T; Oki, E; Saeki, H; Yamashita, YI | 1 |
| Appius, A; Button, P; Hooper, G; Lee, V; Liam, CK; Lu, S; Mok, T; Palma, JF; Park, K; Schulze, K; Scudder, S; Shames, DS; Srimuninnimit, V; Wang, J; Wu, YL; Yin, AY; Zhang, G; Zhou, C | 1 |
| Abraham, RG; Dedi, B; Krucher, NA; Thomas, NA | 1 |
| Avola, R; Cardile, V; Eleonora Graziano, AC; Pistarà, V; Rescifina, A; Stancanelli, R; Surdo, E; Tommasini, S; Ventura, CA | 1 |
| Ding, GS; Fu, H; Guo, WY; Liu, C; Mao, JX; Sun, KY; Teng, F; Yuan, H | 1 |
| Bartsch, JW; Bronsert, P; Conrad, C; Hoeppner, J; Kulemann, B; Lopatta, P; Maurer, J; Nyström, A; Oria, VO; Preca, BT; Schilling, O; Schmitz, T | 1 |
| Cai, YL; Li, J; Shen, ZP; Song, Y; Wu, XD; Zou, L | 1 |
| Hwang, JH; Kim, H; Kim, J; Kim, JW; Kim, YT; Lee, JC; Lee, SH; Paik, WH; Ryu, JK | 1 |
| Choi, YJ; Kang, EJ; Kim, DS; Kim, HJ; Kim, JS; Lee, SY; Seo, HY | 1 |
| Cao, D; Chen, X; Feng, Y; Gong, C; Haydon, RC; He, TC; Huang, B; Huang, S; Lei, Y; Liu, B; Liu, W; Liu, X; Luo, W; Luu, HH; Ma, C; Peng, B; Shen, Y; Tang, S; Wang, X; Wu, T; Wu, X; Yang, L; Ye, Z; Yuan, C; Zeng, Z; Zhang, B; Zhang, L; Zhang, Z; Zhao, L | 1 |
| Cao, S; Han, B; Teng, J; Xu, J; Zhong, H | 1 |
| Abou-Alfa, GK; Berger, M; Bradley, M; Capanu, M; Cercek, A; Chou, JF; Dika, IE; Gerst, S; Harding, JJ; Hollywood, E; Lowery, MA; Morgono, E; O'Reilly, EM; Ptashkin, R; Rasalan-Ho, T; Salehi, E; Valentino, E; Wong, P; Yu, KH; Zehir, A | 1 |
| Caplan, A; Chu, DH; Rosenbach, M; Svoboda, J | 1 |
| Kitagawa, Y; Suzuki, K; Suzuki, Y; Takeuchi, O | 1 |
| Beltran, BE; Conlon, K; Cook, L; Dwyer, K; Feldman, T; Fields, PA; Gonsky, J; Hermine, O; Horwitz, SM; Humphrey, J; Kurman, M; Leoni, M; Moriya, J; Pereira, J; Phillips, AA; Ramos, JC; Sawas, A; Taylor, GP; Wandroo, F | 1 |
| Eastman, A; Warren, NJH | 1 |
| Artru, P; Assenat, E; Bachet, JB; Ben Abdelghani, M; Biagi, JJ; Bouhier-Leporrier, K; Breysacher, G; Castan, F; Choné, L; Conroy, T; Cripps, C; Di Fiore, F; Faroux, R; Francois, E; Gourgou, S; Hammel, P; Hebbar, M; Jouffroy-Zeller, C; Juzyna, B; Kavan, P; Khemissa-Akouz, F; Lecomte, T; Legoux, JL; Malka, D; O'Callaghan, CJ; Raoul, JL; Rat, P; Sauvanet, A; Texereau, P; Volet, J; Wei, AC; Ychou, M | 1 |
| Batra, SK; Ju, J; Junker, WM; Kalaga, M; Mallapragada, S; Pothuraju, R; Rachagani, S; Uz, M | 1 |
| Chen, Y; Kadam, SM; Kelly, LE; Liu, L; Rapp, CM; Sahu, RP; Thyagarajan, A | 1 |
| Chen, J; Hu, P; Wu, G; Zhou, H | 1 |
| Barbier, E; Blanc, JF; Bourgeois, V; Desrame, J; Edeline, J; Malka, D; Manfredi, S; Michel, P; Neuzillet, C; Phelip, JM | 1 |
| Cao, K; Dai, LX; Huang, S; Li, H; Li, MY; Liu, JM; Wang, BN; Yang, J; Zhao, ZY | 1 |
| Caliskan, Y; Dalgic, AD; Gerekci, S; Gulec, EA; Keskin, D; Ozen, C; Tezcaner, A | 1 |
| Desai, N; Goff, HW; Rizvi, S; Stewart, JR; Zhu, H | 1 |
| Al-Muderis, O; Antoniou, G; Benson, C; Constantinidou, A; Jones, RL; Messiou, C; Miah, A; Petruckevitch, A; Sebio, A; Thway, K; VAN DER Graaf, WT; Zaidi, S | 1 |
| Kim, NR; Kim, YJ | 1 |
| Algül, H; Atzpodien, J; Berger, AW; Daum, S; Dickhut, A; Ettrich, TJ; Gallmeier, E; Geissler, M; König, A; Kornmann, M; Muche, R; Perkhofer, L; Prasnikar, N; Reinacher-Schick, A; Seufferlein, T; Tannapfel, A; Uhl, W; Wille, K; Wittel, U | 1 |
| Abou Ali, E; Batteux, F; Bordacahar, B; Camus, M; Lafon, C; Mestas, JL; Prat, F | 1 |
| Aldrich, JD; Overman, MJ; Raghav, KPS; Varadhachary, GR; Wolff, RA | 1 |
| Hashemi Sadraei, N; Patil, PD; Pennell, NA; Shapiro, M | 1 |
| Furuse, J; Honda, G; Kosuge, T; Matsumoto, I; Matsuyama, Y; Motoi, F; Satoi, S; Sho, M; Ueno, H; Unno, M; Wada, K; Yamaue, H | 1 |
| Shi, S; Yu, X | 1 |
| Couvreur, P; Denis, S; Guillaneuf, Y; Jacobs, M; Lazzari, G; Mougin, J; Mura, S; Nicolas, J; Vinciguerra, D; Zhu, C | 1 |
| Bang, S; Chung, MJ; Jo, JH; Kang, H; Lee, HS; Park, JY; Park, SW; Song, SY | 1 |
| Bernard, PW; Fan, J; Han, H; Hu, Y; Katz, MH; Koay, EJ; Liu, Y; Ning, B; Wei, Q; Zhang, N; Zhao, Z | 1 |
| Chawla, SP; Dry, SM; Eilber, FC; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Li, Y; Miwa, S; Miyake, K; Nelson, SD; Oshiro, H; Razmjooei, S; Singh, SR; Tsuchiya, H; Wangsiricharoen, S; Yamamoto, N; Zhang, Z | 1 |
| Blomstrand, H; Bratthäll, C; Elander, NO; Green, H; Scheibling, U | 1 |
| Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T | 1 |
| Ahmmed, B; Faqeer, A; Kampo, S; Khan, M; Kumar, SP; Liu, JW; Yan, Q; Yulin, L | 1 |
| Funamizu, N; Kamada, M; Lacy, CR; Manome, Y; Yanaga, K | 1 |
| Azumi, Y; Fujii, T; Hayasaki, A; Iizawa, Y; Isaji, S; Kato, H; Kishiwada, M; Kuriyama, N; Mizuno, S; Murata, Y; Sakurai, H; Takeuchi, T; Tanemura, A; Usui, M | 1 |
| Buyse, M; Giai, J; Maucort-Boulch, D; Péron, J | 1 |
| Smith, SD | 1 |
| Avigdor, A; Kedmi, M; Nagler, A; Ribakovsky, E; Zlotnick, M | 1 |
| Junghanss, C; Maletzki, C; Nassar, I; Stenzel, J; Wiegele, L | 1 |
| Bates, SE; Chabot, JA; Manji, GA; Raufi, AG | 1 |
| Aamir Mirza, M; Alshahrani, SM; Alshetaili, AS; Anwer, MK; Iqbal, Z; Jamil, A; Panda, AK; Telegaonkar, S; Thakur, PS | 1 |
| Ehrlich, A; Foerster, F; Galle, PR; Maderer, A; Marquardt, JU; Moehler, M; Nickolay, T; Ruckes, C; Schad, A; Sivanathan, V; Thomaidis, T; Weinmann, A; Woerns, M | 1 |
| Bryant, M; Davis, MJ; Hendifar, A; Hoffman, D; Jamil, L; Kim, S; Klempner, SJ; Lo, S; Nissen, N; Noe, P; Osipov, A; Piantadosi, S; Placencio-Hickok, V; Ristow, L; Rokhsar, S; Sandler, H; Scher, K; Shiao, SL; Tighiouart, M; Tuli, R; Wachsman, A | 1 |
| Bolch, M; Branchi, V; Gonzalez-Carmona, MA; Jansen, C; Kalff, JC; Mahn, R; Manekeller, S; Matthaei, H; Mohr, RU; Nattermann, J; Praktiknjo, M; Sampels, M; Strassburg, CP; Trebicka, J; van Beekum, K; Vogt, A; Weismüller, TJ | 1 |
| Argnani, L; Broccoli, A; Casadei, B; Cavo, M; Morigi, A; Nanni, L; Stefoni, V; Zinzani, PL | 1 |
| Boige, V; Conroy, T; Ducreux, M; Hollebecque, A; Laurent-Puig, P; Malka, D; Seufferlein, T; Smolenschi, C; Van Laethem, JL | 1 |
| Du, G; Fan, Z; Ma, L; Wang, H | 1 |
| Clair, PM; Deininger, MW; Glenn, MJ; Kopeček, J; Kosak, KM; Li, L; Radford, DC; Shami, PJ; Stephens, DM; Wang, J; Yang, J | 1 |
| Ao, Z; Chen, Y; Danehy, R; Guo, F; Tu, H; Xu, J | 1 |
| Du, S; Lu, Y; Xiong, H; Xu, C; Yao, J | 1 |
| Trent, JC; Van Tine, BA | 1 |
| Abdalla, MY; Ahmad, IM; Bailey, KL; Banerjee, K; Britigan, BE; Kumar, S; Maurer, HC; Olive, KP; Rachagani, S; Thompson, CM | 1 |
| Ho, TTB; Honda, M; Kaneko, S; Kawaguchi, K; Komura, T; Miyazawa, M; Mizukoshi, E; Nasti, A; Okuzono, M; Sakai, Y; Takabatake, H; Wada, T; Yamada, T; Yamashita, T; Yamato, M; Yoshida, K | 1 |
| Romero, D | 1 |
| Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Kawaguchi, K; Kiyuna, T; Kumamoto, T; Li, Y; Matsuyama, R; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Oshiro, H; Razmjooei, S; Singh, SR; Wangsiricharoen, S; Zhang, Z | 1 |
| Jian, YK; Li, B; Sun, ZY; Zhu, HY | 1 |
| Galsky, MD; Gore, JL; Holt, SK; Ramos, JD; Schade, GR; Wright, JL; Yu, EY | 1 |
| Bakker, E; Demonacos, C; Giordano, A; Guazzelli, A; Krstic-Demonacos, M; Meysami, P; Mutti, L | 1 |
| Cui, SH; Fu, Y; Sun, J; Wang, JC; Yang, D; Zhang, HT; Zhang, Q | 1 |
| Gandara, DR; Knollmann, FD; Lim, S; Narayanan, A; Riess, JW; Walby, JAS | 1 |
| Fang, W; Jiang, W; Liu, L; Ma, R; Peng, L; Tong, Z; Wang, K; Wang, L; Wu, L; Wu, W; Yao, M; Zhang, H; Zhao, P; Zheng, Y | 1 |
| Soefje, SA | 1 |
| Baillet Guffroy, A; Berge, M; Caudron, E; Dowek, A; Lê, L; Prognon, P; Tfayli, A | 1 |
| Bronich, TK; Caffrey, T; Hollingsworth, MA; Lei, F; Lele, SM; Mehla, K; O'Connell, KA; Radhakrishnan, P; Sagar, S; Soni, KS; Thomas, D | 1 |
| Bi, T; Gao, Q; Liu, L; Liu, Y; Qin, L; Shen, G | 1 |
| Cao, F; Cao, Y; Fang, F; Jia, Z; Ju, X; Qing, S; Shen, Y; Zhang, H; Zhu, X | 1 |
| Higashi, Y; Hirayama, K; Maruo, H; Nakamura, K; Shibasaki, Y; Shimizu, Y; Shoji, T; Tsuyuki, H; Yamazaki, M | 1 |
| Fushida, S; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okamoto, K; Okazaki, M; Sakai, S; Tajima, H; Takamura, H; Terai, S | 1 |
| Hakamada, K; Ishido, K; Kimura, N; Kudo, D; Sakuraba, S; Yachi, T | 1 |
| Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A | 1 |
| Amagasa, H; Ami, K; Andou, M; Fukuda, A; Ganno, H; Iida, S; Imai, K; Kajiyama, D; Kakuta, R; Kawaguchi, M; Maeda, S; Motoyama, K; Shibuya, G; Yamada, A | 1 |
| Chang, HL; Chong, IW; Hsu, JF; Lee, YL; Li, CY; Lin, CM; Shen, YT; Wei, PJ; Yang, CJ | 1 |
| Abuelgasim, KA; Alahmari, B; Alaskar, A; Alhejazi, A; Ali, O; Alsharhan, Y; Alzahrani, M; Damlaj, M; Gmati, G; Hommady, M; Khairi, M; Masuadi, EM; Salama, H | 1 |
| Alexandre, J; Bellesoeur, A; Blanchet, B; Cessot, A; Cohen, R; Curis, E; Desaulle, D; Goldwasser, F; Huillard, O; Joste, V; Jouinot, A; Narjoz, C; Nicolis, I; Preta, LH; Quilichini, J; Thomas-Schoemann, A; Tiako Meyo, M; Vidal, M | 1 |
| Bastiancich, C; Bastiat, G; Bozzato, E; Danhier, F; Luyten, U; Préat, V | 1 |
| Laczkó, D; Marchand, B; Pitarresi, JR; Reichert, M; Rustgi, AK; Suzuki, K | 1 |
| Ahmadi, N; Amini, E; Bazargani, ST; Cai, J; Clifford, TG; Daneshmand, S; Djaladat, H; Hugen, CM; Miranda, G; Sherrod, AE | 1 |
| Brunner, M; Ellenrieder, V; Gaedcke, J; Goetze, RG; Gruetzmann, R; Hamdan, FH; Hessmann, E; Jodrell, DI; Johnsen, SA; Kari, V; Kitz, J; Knösel, T; Neesse, A; Patil, S; Patzak, MS; Pilarsky, C; Richards, FM; Rümmele, P | 1 |
| Fischer, M; Kirstein, MM; Kratzel, AM; Manns, MP; Mederacke, YS; Schweitzer, N; Vogel, A | 1 |
| Chatzigiannis, CM; Karampelas, T; Liapakis, G; Sayyad, N; Spyridaki, K; Tamvakopoulos, C; Tzakos, AG; Vrettos, EI | 1 |
| Jiménez Gordo, AM; López Gómez, M | 1 |
| Chang, YJ; Chen, HA; Huang, CY; Huang, MT; Makondi, PT; Wang, JW; Wei, PL | 1 |
| Bian, WG; Chen, HT; Chen, P; Shen, Y; Song, S; Zhou, XN | 1 |
| Dede, I; Demirci, NS; Engin, H; Eren, T; Ergun, Y; Esin, E; Guner, EK; Koksoy, EB; Oksuzoglu, B; Ozdemir, NY; Sendur, MA; Sezer, A; Urun, Y; Utkan, G; Yalcin, B; Zengin, N | 1 |
| Dong, M; Li, X; Sheng, W; Shi, X; Wang, G; Zhou, J | 1 |
| Carugo, A; Corti, D; Deem, AK; Del Poggetto, E; Draetta, GF; Fleming, J; Futreal, A; Genovese, G; Giuliani, V; Heffernan, TP; Ho, IL; Jiang, S; Kang, Y; Karpinets, T; Kim, M; Kumar, T; Li, CY; Loponte, S; Maitra, A; Peoples, M; Robinson, FS; Sapio, L; Seth, S; Song, X; Viale, A; Yen, EY; Zhang, J | 1 |
| Georgoulias, V; Hatzidaki, D; Kalbakis, K; Kentepozidis, N; Kontopodis, E; Kotsakis, A; Kouroussis, C; Polyzos, A; Syrios, J; Vardakis, N | 1 |
| Chen, L; Chen, Z; Hua, Y; Li, Y; Liu, L; Meng, Z; Ning, Z; Shi, W; Zhang, C | 1 |
| Chen, H; Ding, Y; Hu, A; Li, B; Li, J; Liu, R; Wang, Y; Wu, Y; Zhang, M | 1 |
| Copier, J; Dalgleish, AG; Gravett, AM | 1 |
| Ishizuka, Y; Nakamichi, H; Sasano, T; Shiokawa, M; Tokou, U; Tsuji, D; Yabe, K; Yamamoto, K; Yoneda, T | 1 |
| Hu, R; Jin, C; Liu, Y; Wang, K; Wang, R; Yang, M; Yang, Y; Zhang, M; Zhou, Y | 1 |
| Wang, C; Xin, B; Zhang, X; Zhao, P | 1 |
| Ben, XS; Chen, GY; Chen, HJ; Cheng, Y; Huang, C; Jiang, BY; Song, Y; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhou, Q | 1 |
| Chang, SS | 3 |
| Han, L; Jiang, J; Qin, T; Wang, Z; Xiao, Y | 1 |
| Chandler, D; Grossman, A; Hanau, A; Hatfield, M; Lonshteyn, A; Sharma, A; Weycker, D | 1 |
| Akiyama, T; Fukada, T; Kametaka, H; Makino, H; Miyazaki, M; Okura, R; Oya, M; Saitou, M; Seike, K; Tabe, S; Yoshitomi, H | 1 |
| Ahn, DH; Bekaii-Saab, T; Goldstein, D; Li, CP; Macarulla, T; O'Neil, B; Okusaka, T; Reni, M; Sonbol, MB; Tabernero, J; Van Cutsem, E | 1 |
| Bai, Z; Chen, G; Chen, Y; Guo, W; Ma, X; Pei, H; Peng, Y; Wang, T; Yang, Y; Zhang, Z | 1 |
| Hu, W; Li, M; Lu, H; Lu, S; Yang, D; Ye, J; Zhang, L | 1 |
| Fang, L; Guan, X; Li, Q; Li, Z; Lian, J; Liu, C; Lou, C; Shi, J; Wang, B; Wang, Y; Yao, Y; Zhan, F; Zhang, Y; Zhao, Q; Zhou, B; Zhu, Y | 1 |
| Bai, J; Cheng, Y; Li, H; Meng, F; Shi, G; Wang, C; Xu, S; Ye, H; Zhang, L; Zhang, P; Zhang, Z; Zhong, L | 1 |
| Choi, HJ; Hong, JH; Jang, JS; Kang, JH; Kim, MJ; Kim, S; Kim, ST; Lee, HW; Lee, J; Lee, MA; Lim, HY; Oh, SY; Park, JO; Park, YS; Sohn, BS; Yoon, SY | 1 |
| Dabke, IR; Gao, J; Hennig, MJ; Hoy, JJ; Kallifatidis, G; Kuczyk, MA; Li, J; Lokeshwar, BL; Lokeshwar, VB; Merseburger, AS; Morera, DS; Pearce, RF; Smith, DK | 1 |
| Araujo-Gutierrez, R; Bryan, NS; Fernandez-Moure, JS; Fleming, JB; Kang, Y; Kirui, D; Van Eps, JL | 1 |
| Albiges, L; Arfi-Rouche, J; Baciarello, G; Cojean-Zelek, I; Fizazi, K; Loriot, Y; Massard, C; Vicier, C | 1 |
| Barrett, AM; Chen, A; Doroshow, JH; Dull, AB; Hollingshead, MG; Kinders, RJ; Kummar, S; Lawrence, SM; Parchment, RE; Wilsker, DF | 1 |
| Blasi, E; Buetow, B; Chunyk, AG; Costa, MJ; Delaria, K; Dorywalska, M; Ho, WH; Holz, C; Kudaravalli, J; Lindquist, K; Liu, SH; Ma, JT; Rajpal, A; Shelton, DL; Stauffer, A; Strop, P; Tran, TT; Zong, Q | 1 |
| Cheng, R; Cui, W; Dai, Y; Liu, H; Ni, Q; Wu, W; Ye, T | 1 |
| Bekaii-Saab, T | 2 |
| Benedetti Panici, P; Tomao, F; Tomao, S | 1 |
| Enserro, D; Hensley, ML; Miller, DS | 1 |
| Dubey, RD; Gupta, PN; Kumar, R; Mintoo, MJ; Mondhe, DM; Panda, AK; Saneja, A; Sangwan, PL | 1 |
| Bosch, R; Brú, A; Brú, I; Carmona-Güedes, S; Céspedes, MV; Pascual, E; Souto, JC | 1 |
| Hasegawa, K; Inagaki, Y; Kamiya, M; Kaneko, J; Kokudo, N; Kokudo, T; Sato, M; Uno, SN; Urano, Y | 1 |
| Witjes, JA | 2 |
| Deng, Z; Li, X; Liu, Y; Lu, Y; Ma, C; Tian, L; Wang, J; Xu, L; Yang, T; Yao, W; Zhang, J | 1 |
| Le Tourneau, C; Ricci, F | 1 |
| Are, C; Grem, JL; Hahn, SM; Lazenby, A; Li, S; Lin, C; Ly, QP; Meza, JL; Sasson, A; Schwarz, JK; Verma, V; Wang, S | 1 |
| Biankin, A; Chang, D; Crawford, HC; Dreyer, S; Frankel, TL; Halbrook, CJ; Hong, HS; Kemp, S; Kovalenko, I; Kremer, DM; Lapienyte, L; Lazarus, J; Lee, HJ; Lyssiotis, CA; Morton, JP; Nelson, BS; Pasca di Magliano, M; Pontious, C; Sajjakulnukit, P; Shi, J; Thurston, G; Zhang, L; Zhang, Y | 1 |
| Bhinderwala, F; Chaika, NV; Gebregiworgis, T; Powers, R; Purohit, V; Singh, PK | 1 |
| Birnbaum, A; Cohen, RB; Denlinger, CS; Giles, J; He, AR; Hwang, J; Lewis, N; Moser, B; Mynderse, M; Niland, M; Plimack, ER; Sama, A; Sato, T; Walgren, R; Wallin, J; Zhang, W | 1 |
| Gutierrez, A | 1 |
| Bordon, Y | 1 |
| Conroy, T; Van Laethem, JL | 1 |
| Baldwin, GS; He, H; Nikfarjam, M; Wang, K | 1 |
| Cole, G; Gabrail, NY; James, D; Khorana, AA; Ramanathan, RK; Shah, S; Thomas, GW; Wong, S; Zhou, C | 1 |
| Lubgan, D; Semrau, S | 1 |
| Higashi, T; Matsumoto, H; Nagatsu, K; Oe, Y; Sugyo, A; Tsuji, AB; Yoshii, Y; Yoshimoto, M; Zhang, MR | 1 |
| Guo, JC; Li, BQ; Liang, ZY; Liu, QF; Seery, S; You, L; Zhang, TP; Zhao, YP | 1 |
| Davlouros, P; Hahalis, G; Koniari, I; Kounis, NG; Plotas, P; Soufras, GD; Tsigkas, G | 1 |
| Bachini, M; Bekaii-Saab, T; Crane, C; Edeline, J; El-Khoueiry, A; Feng, M; Katz, MHG; Kennedy, EB; Maithel, SK; Primrose, J; Shroff, RT; Soares, HP; Valle, J | 1 |
| Ciccolini, J; Giovannetti, E; Honeywell, RJ; Peters, GJ | 1 |
| Lin, J; Ma, L; Su, GH; Wei, J | 1 |
| Fujimori, N; Kakihara, D; Kimura, R; Matsuda, R; Miyasaka, Y; Mori, Y; Nakamura, M; Nakata, K; Oda, Y; Ohno, T; Ohtsuka, T | 1 |
| Balboni, B; Benaim, E; El Hassouni, B; Giovannetti, E; Heaton, C; Honeywell, RJ; Kim, DJ; Lee, YB; Peters, GJ; Peterson, C; Poore, J; Sarkisjan, D | 1 |
| Chen, L; Cheng, Y; Han, B; Huang, C; Jiang, G; Li, E; Liang, H; Liu, X; Lu, S; Pan, H; Qin, S; Wu, G; Wu, YL; Zhong, Z; Zhou, C; Zhu, Y | 1 |
| Billig, AM; Jordan, VC; Medarova, Z; Pantazopoulos, P; Ross, A; Sheedy, P; Yoo, B | 1 |
| Benhadji, KA; Cleverly, A; Deplanque, G; Driscoll, KE; Estrem, ST; Fuchs, M; Garcia-Carbonero, R; Kozloff, M; Lahn, MMF; Macarulla, T; Man, M; Melisi, D; Pezet, D; Simionato, F; Smith, C; Tabernero, J; Trojan, J; Wang, S | 1 |
| Crona, DJ; Denning, S; Etheridge, AS; Furukawa, Y; Hatch, AJ; Hurwitz, HI; Innocenti, F; Jiang, C; Kindler, HL; Kubo, M; McLeod, HL; Niedzwiecki, D; Nixon, AB; Owzar, K; Ratain, MJ; Sibley, AB; Watson, D | 1 |
| Gao, F; He, M; Jiang, X; Kuai, Q; Nie, G; Pan, Y; Ren, S; Shi, W; Wang, Y; Yu, Q; Zhao, X | 1 |
| Adeva, J; Berardi, R; Bittoni, A; Bruix, J; Edeline, J; La Casta, A; Salati, M; Sangro, B; Valle, JW | 1 |
| Fornaro, L; Vasile, E; Vivaldi, C | 1 |
| Kumar, S; Narain, TA; Sharma, G; Tyagi, S | 1 |
| Bekes, I; Cámara, RJA; Deniz, M; Fink, V; Friedl, TWP; Janni, W; Lato, K; Rack, B; Schwentner, L; Singer, S; Widschwendter, P | 1 |
| Ali, M; Batool, F; Fatima, M; Iqbal Ahmed, MM; Munch-Petersen, B; Mutahir, Z; Riaz, A | 1 |
| Choi, CM; Ji, W; Kim, S; Kim, WS; Kwon, BS; Lee, JC; Park, JH; Park, S; Park, YR | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Hatano, E; Higashiguchi, M; Ioka, T; Iwagami, Y; Kobayashi, S; Mori, M; Noda, T; Sakai, D; Yamada, D | 1 |
| Hata, T; Imamoto, H; Kawada, J; Kim, Y; Miwa, H; Murakami, M; Okano, M; Okuyama, M; Shimizu, J; Tanizaki, K; Tsujinaka, T; Yamasaki, M | 1 |
| Shan, Y; Sun, Y; Wang, P; Wu, H; Yang, W; Zhang, Q | 1 |
| Bian, Y; Cao, K; Gao, S; Guo, S; Jiang, H; Jin, G; Shi, X; Wang, K; Zhang, H; Zhu, X | 1 |
| Chen, D; Cheng, M; Gao, Q; Jiang, Y; Li, J; Li, Y; Liang, Y; Lin, S; Liu, Z; Sheng, L; Wu, M; Zhang, H; Zhang, X; Zhang, Y; Zhu, F | 1 |
| Hu, Y; Li, C; Xie, Y; Zeng, Q | 1 |
| Ray, K | 1 |
| Cao, L; Chen, Y; Ding, G; Jia, S; Wang, W; Wu, Z; Yu, W; Zhang, M; Zhou, L | 1 |
| Cheng, SH; Cheng, YJ; Jin, ZY; Xue, HD | 1 |
| Bouvet, M; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Razmjooei, S; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N; Zhang, Z | 1 |
| Burges, A; Colomban, O; Du Bois, A; Freyer, G; Hardy-Bessard, AC; Kurzeder, C; Leary, A; Lortholary, A; Péron, J; Pfisterer, J; Ray-Coquard, I; Tod, M; You, B | 1 |
| Alcalá, S; Alonso-Nocelo, M; Carrato, A; Cassiano, C; D'Errico, G; Earl, J; Feliu, J; García, CP; García-Bermejo, L; Hermann, PC; Lombardia, L; Martin-Hijano, L; Martinelli, P; Monti, MC; Sainz, B; Seufferlein, T; Valle, S; Vallespinos, M | 1 |
| Aires, A; Cortajarena, AL; Couleaud, P; Courty, J; Göring, J; Hilger, I; Latorre, A; Ludwig, R; Miranda, R; Prina-Mello, A; Sanhaji, M; Somoza, Á; Stapf, M; Volkov, Y | 1 |
| Adachi, K; Hasegawa, R; Imaizumi, H; Iwai, T; Kaneko, T; Kida, M; Koizumi, W; Kumamoto, Y; Miyata, E; Nishiyama, R; Okuwaki, K; Yamauchi, H | 1 |
| Bauernhofer, T; Gerger, A; Kasparek, AK; Moik, F; Pichler, M; Posch, F; Prinz, F; Reicher, A; Riedl, JM; Rossmann, CH; Schaberl-Moser, R; Stöger, H; Stotz, M; Szkandera, J; Terbuch, A; Winder, T | 1 |
| Arteta, B; Benedicto, A; Hernandez-Unzueta, I; Herrero, A; Márquez, J; Olaso, E; Romayor, I; Sanz, E | 1 |
| Fan, J; Jiang, JT; Liu, ZH; Mu, XY; Sun, F; Tan, MY; Wang, RJ; Wang, X; Wu, K; Yao, ZX; Zheng, JH; Zheng, Z | 1 |
| Fukumitsu, K; Ishii, T; Kaido, T; Morino, K; Nishino, H; Okajima, H; Seo, S; Taura, K; Uemoto, S; Yamanaka, K; Yoh, T | 1 |
| Chen, J; Li, Z; Pan, Z; Yao, J; Yao, Z; Zhang, Y | 1 |
| Lai, ZY; Li, Y; Mu, JB; Xie, J; Xu, J; Yang, MD; Yang, WH; Zhang, GH | 1 |
| Clay, T; Das, A; Dean, A | 1 |
| Apisarnthanarax, S; Hallemeier, CL; Huguet, F; Jabbour, SK; Murphy, JD; Olsen, JR; Tait, D | 1 |
| Chen, Q; Fu, Y; Shi, W; Tang, L; Yao, N | 1 |
| Angelini, G; Ciferri, E; Cornacchia, C; Filauro, M; Rutigliani, M; Serventi, A | 1 |
| Bellmunt, J; Rodriguez-Vida, A | 1 |
| Liang, TS; Ma, SL; Yang, CL; Yang, DK; Yang, Y; Zhao, ZJ; Zuo, XX | 1 |
| André, F; Cortés, J; Dent, R; Deurloo, R; Easton, V; Gonçalves, A; Kümmel, S; Martín, M; Pollex, E; Schmid, P; Schuetz, F; Swain, SM | 1 |
| Fukushima, T; Kaneko, T; Maeda, S; Oka, H; Okada, K; Okazaki, H; Sugimori, K; Tozuka, Y | 1 |
| Conroy, T; Ducreux, M | 1 |
| Ahn, DH; Bekaii-Saab, TS; Borad, MJ; Iwasaki, M; Javle, MM; Kaseb, AO; Masci, P; Raghav, KPS; Ramanathan, RK; Shroff, RT; Varadhachary, GR; Wolff, RA; Xiao, L | 1 |
| Goff, LW; Roth, MT | 1 |
| Alabkaa, A; Behrman, S; Chauhan, SC; Dan, N; Ganju, A; Hafeez, BB; Jaggi, M; Khan, S; Kumari, S; Massey, A; Setua, S; Stiles, ZE; Yallapu, MM; Yue, J | 1 |
| Hara, M; Hayashi, Y; Imafuji, H; Koide, S; Matsuo, Y; Morimoto, M; Ogawa, R; Omi, K; Saito, K; Takahashi, H; Takiguchi, S; Tsuboi, K; Ueda, G | 1 |
| Chen, L; Fang, K; Fang, Z; Liu, T; Wang, L | 1 |
| Li, PW; Luo, S; Tian, BL; Wang, L; Xiao, LY; Zeng, YC; Zhang, ZR | 1 |
| Choi, HY; Jeon, HG; Jeon, SS; Jeong, JY; Lee, HM; Seo, SI; Song, W; Sung, HH | 1 |
| Awasthi, A; Bill, KLJ; Brock, GN; Bupathi, M; Chen, JL; Demoret, B; Duggan, MC; Hays, JL; Millis, SZ; Pollock, RE; Seligson, ND; Shakya, R; Stets, CW; Timmers, CD; Wakely, PE | 1 |
| Hu, Z; Huang, Y; Sun, Q; Wang, W; Yang, Q; Zhang, L; Zhang, Y; Zheng, H | 1 |
| Asakuma, M; Gonen, M; Haeno, H; Hur, C; Inoue, Y; Kartoun, U; Kong, CY; Liu, LL; Michor, F; Nakamura, A; Shimizu, T; Stein, S; Tramontano, AC; Uchiyama, K; Yamamoto, KN | 1 |
| Ghalali, A; Raasmaja, A; Stenius, U | 1 |
| Abuzaid, H; Alonso, MJ; Bradshaw, TD; Cadete, A; Marlow, M; Štaka, I; Surikutchi, BT | 1 |
| Cai, X; Chen, W; Gu, X; Guo, M; He, J; He, P; Li, C; Liang, H; Liang, W; Pan, Z; Sun, J; Wang, Z; Xu, C; Yang, H; Yang, X; Yin, W; Zhao, Y | 1 |
| Bumberová, M; Dolinský, J; Janega, P; Jurišová, S; Kašperová, B; Macúch, J; Mego, M | 1 |
| Bradbury, PA; Chan, KK; Chen, BE; Cheung, M; Cheung, WY; Ding, K; Hay, AE; Kornelsen, EA; Leighl, NB; Mittmann, N; Ng, RCH; Pater, JL; Tu, D | 1 |
| Chi, KN; Eigl, BJ; Forbes, C; Parimi, S; Tsang, ES | 1 |
| Bonazzi, V; Daignault, SM; Fernando, M; Gabrielli, B; Haass, NK; Lanagan, C; Larsen, JE; Nazareth, D; Oo, ZY; Proctor, M; Škalamera, D; Snell, C; Stevenson, AJ; Walpole, S | 1 |
| Furuhashi, S; Hiraide, T; Kikuchi, H; Kitajima, R; Kiuchi, R; Konno, H; Morita, Y; Sakaguchi, T; Shibasaki, Y; Takeda, M; Takeuchi, H | 1 |
| Dart, A | 1 |
| Chen, Q; Chen, X; Guo, Q; Jiang, C; Li, C; Liang, C; Lu, Y; Shi, S; Sun, T; Yu, X; Zhang, Y; Zhou, W | 1 |
| Harrison, MR; Inman, BA; Meleis, L; Moore, R | 1 |
| Fan, JF; Jiang, W; Kong, XY; Liao, SF; Lu, JX; Mi, JL; Qin, XL; Tang, HY; Xu, QL; Yao, DC; Yu, XW; Zhang, J; Zhang, RJ | 1 |
| Kanamala, M; Leung, E; Svirskis, D; Tang, M; Wang, H; Wu, Z | 1 |
| Baker, SD; Buelow, DR; Cotton, A; Dang, J; Drenberg, CD; Fu, Q; Gruber, TA; Guy, RK; Hu, S; Inaba, H; Jeon, JY; Li, M; Orwick, SJ; Pioso, M; Ribeiro, RC; Rubnitz, JE; Shelat, A | 1 |
| Alhothali, M; Chellappan, S; Iyer, G; Lawrence, HR; Mathew, M; Padmanabhan, J; Yang, S | 1 |
| Bynon, JS; Cen, P; Dinh, BC; Gonzalez, A; Mohlere, V; Thosani, NC; Wray, CJ; Zhang, S | 1 |
| Liang, T; Liu, Z; Yang, C; Yang, D; Zheng, Y | 1 |
| Chen, C; Chen, H; Chen, Y; Lu, Y; Luo, Z; Peng, J; Wang, Z; Xu, D; Yin, P; Zheng, M | 1 |
| Franses, JW; Hong, TS; Zhu, AX | 1 |
| Chang, SF; Godec, A; Hawkins, WG; Hirbe, AC; Prudner, BC; Rathore, R; Robinson, AM; Van Tine, BA | 1 |
| Bré, J; Chan, TH; Harrison, DJ; Mullen, P; Reynolds, PA; Sarr, A; Um, IH | 1 |
| Choi, DW; Choi, SH; Han, IW; Han, S; Heo, JS; Park, DJ; Ryu, Y | 1 |
| Li, B; Xie, D; Zhang, H | 1 |
| Gao, J; Gao, W; Ma, J | 1 |
| Feng, J; Jin, X; Ma, Y; Mou, Q; Su, Y; Yan, D; Zhang, C; Zhu, L; Zhu, X | 1 |
| Amaravadi, RK; Borazanci, E; Burrell, JA; De Jesus-Acosta, A; Drebin, JA; Karasic, TB; Laheru, DA; Loaiza-Bonilla, A; O'Dwyer, PJ; O'Hara, MH; Redlinger, C; Reiss, KA; Teitelbaum, UR; Von Hoff, DD | 1 |
| Bai, J; Chen, YS; Hou, PF; Liu, QH; Yong, HM; Zhang, XP; Zhu, MH; Zhuang, QX | 1 |
| Chen, X; Ji, J; Jin, Q; Teng, W | 1 |
| Chen, Y; Cheng, T; Guan, R; Hang, T; Jin, R; Song, M; Sun, X; Wang, Y; Xu, X | 1 |
| Jin, HB; Lu, L; Ma, SL; Xie, L; Yang, JF; Zhang, XF | 1 |
| Chang, S; Khawar, IA; Kuh, HJ; Nam, S; Park, JK | 1 |
| Kim, HS; Kim, K; Lee, JK; Lee, KH; Lee, KT; Park, JK; Song, BG | 1 |
| Abdel-Aleem, JA; Abdelrahman, AA; Abdelrahman, SI; Gadalla, HH; Lyle, LT; Masters, AR; Park, J; Tamam, H; Yeo, Y | 1 |
| Ahn, JH; Chae, YS; Han, HS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Lee, SJ; Park, IH; Park, S; Park, YH; Sohn, J | 1 |
| Allegrini, V; Aversa, J; Ball, CG; Barrows, CE; Behrman, SW; Berger, AC; Cagigas, MN; Christein, JD; Dickson, PV; Dixon, E; Ecker, BL; Fisher, WE; Freedman-Weiss, M; Guzman-Pruneda, F; Hollis, RH; House, MG; Kent, TS; Kowalsky, SJ; Malleo, G; Salem, RR; Salvia, R; Schmidt, CR; Seykora, TF; Vollmer, CM; Zheng, R; Zureikat, AH | 1 |
| Chen, P; Wang, C; Wang, M | 1 |
| Couvreur, P; Degrassi, A; Mancini, L; Mougin, J; Mura, S; Nicolas, J; Vinciguerra, D | 1 |
| Chen, L; Chen, YP; Cheng, ZB; Chua, MLK; Du, XJ; Guo, R; Guo, Y; Han, F; Hu, GQ; Hu, WH; Huang, J; Jin, F; Li, JG; Li, L; Li, WF; Li, YH; Li, YQ; Liang, SQ; Liu, N; Liu, QD; Liu, X; Long, GX; Long, JH; Lv, JW; Ma, J; Mao, YP; Mo, HY; Shi, M; Su, QF; Sun, R; Sun, Y; Tang, LL; Tian, Y; Wang, SY; Wang, XC; Xiao, Y; Xie, FY; Xu, C; Yang, KY; Zang, J; Zhang, N; Zhang, Y; Zheng, BM; Zhou, GQ; Zhu, XD; Zou, L | 1 |
| Awasthi, N; Hassan, MS; Kronenberger, D; Schwarz, MA; Schwarz, RE; Stefaniak, A; von Holzen, U | 1 |
| Ishigaki, A; Kainuma, O; Kato, M; Kuwayama, N; Maruyama, T; Matsumoto, Y; Miyazaki, A; Mizumoto, H; Natsume, T; Note, H; Oshima, S; Sato, Y; Shimizu, S; Suzuki, K; Tanaka, H; Yoshioka, T | 1 |
| Chae, JS; Choi, YS; Kang, H; Lee, S; Shin, H; Song, Y; Yeom, CH | 1 |
| Alba, E; Awada, A; Bonnefoi, H; Charpentier, E; Coudert, B; Diéras, V; Emmons, GT; Garcia-Ribas, I; Gligorov, J; Jager, A; Lindeman, GJ; Paridaens, R; Pivot, X; Verweij, J; Zambelli, S | 1 |
| Branstrom, A; Cao, L; Decker, AR; Eberle-Singh, JA; Hu, J; Kim, MJ; Maurer, HC; Mollin, A; Olive, KP; Palermo, CF; Sagalovskiy, I; Sastra, SA; Sheedy, J; Weetall, M | 1 |
| Autorino, R; Bisello, S; Brandi, G; Buwenge, M; Cammelli, S; Cellini, F; Cilla, S; Deodato, F; Macchia, G; Mattiucci, GC; Morganti, AG; Palloni, A; Tagliaferri, L; Valentini, V | 1 |
| Chen, X; Jiang, J; Liang, W; Wan, N; Yang, Y; Zhang, L; Zhang, T | 1 |
| Hashimoto, Y; Iizumi, S; Ikeda, M; Imaoka, H; Kondo, S; Kuchiba, A; Mitsunaga, S; Morizane, C; Ohashi, K; Ohno, I; Okusaka, T; Osame, K; Sakamoto, Y; Sasaki, M; Takahashi, H; Ueno, H | 1 |
| Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A | 1 |
| Ferraro, M; Haag, R; Quadir, M; Ray, P | 1 |
| Eid, R; Haddad, FG; Hajjar, AH; Kourie, HR | 1 |
| Hidalgo, M; Macarulla, T | 1 |
| Catanese, S; Fornaro, L; Pecora, I; Salani, F; Vasile, E; Vivaldi, C | 1 |
| Sidaway, P | 2 |
| Assenat, E; Cassinotto, C; Kellil, T; Leon, P; Navarro, F; Panaro, F; Piardi, T; Rosso, E; Sega, V; Souche, R; Vendrell, J | 1 |
| Barangi, M; Bouvet, M; Chawla, SP; Endo, I; Higuchi, T; Hiroshima, Y; Hoffman, RM; Homma, Y; Katsuya, Y; Li, Y; Matsuyama, R; Miyake, K; Murakami, T; Nelson, SD; Oshiro, H; Park, JH; Razmjooei, S; Singh, SR; Sugisawa, N; Zhang, Z | 1 |
| Akita, H; Asai, A; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Ishii, H; Iwagami, Y; Kasahara, Y; Kawamoto, K; Kobayashi, S; Konno, M; Koseki, J; Matsushita, K; Mori, M; Mori, S; Morihiro, K; Noda, T; Obika, S; Okuda, T; Satoh, T; Yamada, D | 1 |
| Hu, Y; Smith, DE; Thompson, BR | 1 |
| Aasrum, M; Amrutkar, M; Gladhaug, IP; Verbeke, CS | 1 |
| Aloia, TA; Fogelman, DR; Ho, L; Javadi, S; Katz, MHG; Kim, MP; Lee, JE; McAllister, F; Prakash, LR; Tzeng, CD; Varadhachary, G; Vauthey, JN; Vreeland, TJ | 1 |
| Ahn, KS; Allotey, LK; Borad, MJ; Kang, KJ; Kang, YN; Kim, TS; Kim, YH; Kocher, JA; Mounajjed, T; O'Brien, D; Roberts, LR | 1 |
| Antoniou, G; Bertulli, R; Blay, JY; Brahmi, M; Casali, PG; Collini, P; Dei Tos, AP; Dufresne, A; Fucà, G; Fumagalli, E; Gronchi, A; Grosso, F; Hindi, N; Jones, RL; Le Cesne, A; Mir, O; Provenzano, S; Sanfilippo, R; Sbaraglia, M; Stacchiotti, S | 1 |
| Asanuma, H; Hayashi, H; Hirata, K; Hirohashi, Y; Imai, K; Ito, YM; Kanaseki, T; Kimura, Y; Kubo, T; Kutomi, G; Miyakoshi, T; Mizuguchi, T; Murai, A; Nakae, Y; Nakatsugawa, M; Ota, Y; Sato, N; Shima, H; Sugita, O; Takemasa, I; Tokita, S; Torigoe, T; Tsukahara, T; Tsurita, G; Wada, S; Watanabe, K; Yasui, H | 1 |
| Booth, S; Bosworth, J; Browning, JA; Collins, GP; Djebbari, F; Eyre, TA; Hatton, CSR; Hildyard, C; Stanton, L; Vora, SM; Willan, J | 1 |
| Hirose, Y; Ishii, A; Ishimoto, U; Iwaku, A; Kinoshita, A; Koike, K; Mizuno, Y; Saruta, M; Shibata, K; Shoji, R; Yokota, T | 1 |
| Bae, WK; Lee, HJ; Lee, JL; Park, I; Yoon, S | 1 |
| Ma, J; Sun, Y; Zhang, Y | 1 |
| Cianflone, E; Cilurzo, F; Cristiano, MC; Da Pian, M; Paolino, D; Pasut, G; Quintieri, L | 1 |
| Kocher, HM; North, B; Sasieni, P | 1 |
| Furuse, J; Ikeda, M; Ioka, T; Mizuno, N; Nagashima, F; Nakajima, TE; Ohkawa, S; Omuro, Y; Ueno, H; Ueno, M | 1 |
| Fu, DL; Jin, C; Warshaw, AL; Yang, F | 1 |
| Burge, M; Cohen, J; Cooray, P; Gibbs, P; Goldstein, D; Harris, M; Haydon, A; Javed, AA; Kinzler, KW; Lawrence, B; Lee, B; Lennon, AM; Li, L; Lipton, L; Nagrial, A; Nikfarjam, M; Papadopoulos, N; Simons, K; Tai, DWM; Tebbutt, NC; Thomson, B; Tie, J; Tomasetti, C; Vogelstein, B; Wolfgang, CL | 1 |
| Ahmad, M; Akhlaq, M; Danish, Z; Saeed, H; Saleem, Z; Sattar, S | 1 |
| He, H; Hu, J; Li, G; Ma, B; Su, X; Wang, Y; Yu, T; Zhuang, W | 1 |
| Castellanos, K; Cordoba-Chacon, J; Dawson, D; Dorman, MJ; Grimaldo, S; Grippo, PJ; Hirsch, E; Kumar, S; Mancinelli, G; McKinney, R; Munshi, HG; Principe, D; Rana, A; Torres, C; Viswakarma, N | 1 |
| Diaz, CL; Hwang, J; Johns, C; Kerridge, WD; Ko, AH; Tempero, MA | 1 |
| Gong, K; Gong, ZJ; Liu, H; Liu, HB; Lu, PX; Ni, XL; Shen, S; Suo, T; Wang, JW; Zhang, DX | 1 |
| Asao, T; Hagiwara, S; Higuchi, T; Kakinuma, C; Kitahara, H; Kuwano, H; Matsumoto, T; Naito, T; Shirabe, K; Takahashi, R; Yokobori, T | 1 |
| Abbott, DE; Ahmad, SA; Dudeja, V; Fields, RC; Franceschi, D; Hawkins, WG; Kim, HJ; Kooby, DA; Lee, RM; Livingstone, AS; Macedo, FI; Maduekwe, U; Maithel, SK; Martin, RCG; Merchant, NB; Patel, SH; Ryon, E; Schwartz, P; Scoggins, CR; Weber, SM; Williams, G | 1 |
| Levy, BP; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Xiang, CQ; Yang, H | 1 |
| Bang, K; Chang, HM; Hwang, I; Jeong, JH; Kim, KP; Kim, MH; Lee, K; Lee, SK; Lee, SS; Oh, D; Park, DH; Park, JH; Ryoo, BY; Song, TJ; Yoo, C | 1 |
| Bhattacharya, S; Caplette, JR; Dutta, SK; Gong, X; Mukhopadhyay, D; Nguyen, FT; Son, M; Strano, MS; Wang, E | 1 |
| Collisson, EA; Fer, N; Galeas, J; Kim, SE; McCormick, F; Sharib, J; Wang, MT | 1 |
| Chen, Q; Qiu, J; Tao, M; Xie, Y; Yu, D; Zhao, Y | 1 |
| Chen, B; Dong, M; Fang, H; Gui, L; Li, Y; Lin, X; Liu, P; Qi, F; Qi, S; Song, Y; Wang, J; Wang, S; Yang, J; Yang, S; Zhou, S | 1 |
| Baikoghli, M; Borowsky, AD; Cheng, RH; Ferrara, KW; Foiret, J; Hubbard, NE; Ingham, ES; Kheirolomoom, A; Mahakian, LM; Tam, SM; Tucci, ST | 1 |
| Chae, SH; Chang, M; Choi, AY; Kang, GG; Kim, SN; Lee, SJ; Shim, SH | 1 |
| Hasegawa, R; Imaizumi, H; Iwai, T; Kaneko, T; Kawaguchi, Y; Kida, M; Koizumi, W; Kurosu, T; Matsumoto, T; Miyata, E; Ohno, T; Okuwaki, K; Uehara, K; Watanabe, M; Yamauchi, H | 1 |
| Grafmüller, A; Hall, CK; Lilova, RL; Menegatti, S; Schneible, JD; Singhal, A | 1 |
| Anota, A; Aparicio, T; Bachet, JB; Bonnetain, F; Charton, E; Chibaudel, B; Cohen, R; Dauba, J; Debourdeau, P; Desramé, J; Guerin-Meyer, V; Hammel, P; Lecomte, T; Louvet, C; Seitz, JF; Taieb, J; Tournigand, C; Volet, J | 1 |
| Alfaro-Olea, A; Casajús-Navasal, A; Marín-Gorricho, R; Nebot-Villacampa, MJ; Uriarte-Pinto, M; Zafra-Morales, R | 1 |
| Bie, Z; Li, B; Li, L; Li, X; Li, Y; Wang, D | 1 |
| Dhanushkodi, M; Ganesan, P; Ganesan, TS; Joel, A; Kannan, K; Mehra, N; Perumal Kalayarasi, J; Radhakrishnan, V; Sagar, TG | 1 |
| Maslov, DV; Matrana, M; Thomas, K | 1 |
| Aerts, J; Biesma, B; Dingemans, AC; Groen, HJM; Hoekstra, O; Klinkenberg, TJ; Kloosterziel, C; Pieterman, R; Schramel, FMNH; Smit, EF; Smit, HJM; van den Borne, B; van der Heijden, EHFM; van der Noort, V; van Tinteren, H; Verhagen, A | 1 |
| Berlin, J; Cardin, DB; Cohen, SJ; Davis, SL; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, WA; O'Neil, BH; Shahda, S; Stagg, RJ | 1 |
| Auriemma, A; Bassi, C; Binco, A; Bonamini, D; Casciani, F; Casetti, L; Ciprani, D; D'Onofrio, M; Esposito, A; Landoni, L; Maggino, L; Malleo, G; Marchegiani, G; Melisi, D; Merz, V; Nessi, C; Paiella, S; Salvia, R; Secchettin, E; Sereni, E; Simionato, F; Tuveri, M; Viviani, E; Zecchetto, C | 1 |
| Fang, Z; Fu, B; Hao, P; Xu, J; Yang, Z; Zhou, L | 1 |
| Bendell, JC; Bullock, A; Dupont, J; Firdaus, I; Hatoum, H; Holmgren, E; Hool, H; Hu, ZI; Kapoun, AM; Leach, JW; LoConte, NK; O'Reilly, EM; Patel, R; Picozzi, V; Ritch, P; Sahai, V; Sanchez, J; Sohal, DPS; Strickler, J; Wang-Gillam, A; Yu, KH; Zhou, L | 1 |
| Dong, S; He, J; Li, D; Li, L; Ni, P; Sun, Y; Zhang, M | 1 |
| van der Heijden, MS; van Rhijn, BWG; Voskuilen, CS | 1 |
| Corfiotti, F; Corvaisier, M; Deshorgues, AC; El Amrani, M; Fulbert, M; Gnemmi, V; Huet, G; Lahdaoui, F; Pruvot, FR; Skrzypczyk, C; Truant, S; Tulasne, D; Van Seuningen, I; Vasseur, R; Vincent, A | 1 |
| Endo, I; Hata, M; Homma, Y; Ito, E; Kaizu, H; Koike, I; Kumamoto, T; Matsuyama, R; Mukai, Y; Sato, M; Sawada, Y; Sugiura, M; Takano, S; Yabushita, Y | 1 |
| Fang, Y; Kuang, T; Lou, W; Rong, Y; Wang, D; Wu, W; Xu, X; Zhou, W | 1 |
| Büchler, MW; Hackert, T; Heger, U; Hinz, U; Klaiber, U; Liu, B; Michalski, CW; Sachsenmaier, M; Springfeld, C; Sun, H; Tanaka, M | 1 |
| Dvorak, P; Ehrlichova, M; Flasarova, D; Hlavac, V; Kocik, M; Mohelnikova-Duchonova, B; Ojima, I; Oliverius, M; Soucek, P; Strouhal, O | 1 |
| Altinoz, MA; Bilir, A; Elmaci, İ; Ozpinar, A | 1 |
| Anai, S; Fujii, T; Fujimoto, K; Gotoh, D; Hori, S; Itami, Y; Miyake, M; Morizawa, Y; Nakai, Y; Ohnishi, S; Owari, T; Shimizu, T; Tanaka, N; Torimoto, K; Toritsuka, M | 1 |
| Chang, CF; Chang, PH; Chen, JS; Chen, YY; Chou, WC; Hsueh, SW; Huang, PW; Hung, CY; Hung, YS; Lu, CH; Yeh, KY | 1 |
| Cao, Z; Ding, X; Lin, G; Liu, D; Su, B; Wang, N; Wu, C; Xu, W; Zhou, X | 1 |
| Al-Hawaray, M; Cho, CS; Cuneo, KC; Devasia, T; Lawrence, TS; Maybaum, J; Morgan, MA; Nathan, H; Parsels, JD; Parsels, LA; Sahai, V; Schipper, MJ; Zalupski, MM | 1 |
| Celewicz, L; Kleczewska, N; Liberska, J; Ruszkowski, P; Singh, A; Trznadel, R | 1 |
| Hackman, RM; Mackenzie, GG; Penso, NEC; Wang, Y; Wei, R | 1 |
| Bal, M; Bhandare, M; Chaudhari, V; Chavan, N; Kataria, P; Majumdar, S; Mandavkar, S; Ostwal, V; Ramaswamy, A; Rohila, J; Shrikhande, SV; Shrirangwar, S; Swami, R | 1 |
| Chae, YS; Im, SA; Jung, KH; Kim, JH; Kim, JY; Kim, TY; Lee, E; Lee, KS; Park, K; Park, YH; Sohn, J | 1 |
| Batteson, R; de Wit, R; Grivas, P; Keefe, S; Li, H; Meng, Y; Patterson, K; Pellissier, J; Prabhu, V; Xu, R; Zarabi, N; Zhong, Y | 1 |
| Chen, Y; Huang, Y; Liu, J; Liu, Y | 1 |
| Hasegawa, Y; Hirabayashi, M; Hirai, T; Ikeda, S; Ishida, T; Kaneda, T; Komaki, C; Morita, M; Nakano, Y; Niwa, T; Noguchi, T; Sakaguchi, C; Sone, N; Tomioka, H; Yokoyama, T; Yoshimura, K; Yoshioka, H | 1 |
| Berlin, J; Carrero, X; Deshpande, V; Evans, DB; Goff, LW; Kindler, HL; Merchant, N; Meyerhardt, J; Misdraji, J; Moore, M; Newman, E; O'Reilly, EM; Ou, FS; Pisters, P; Posner, MC; Sahani, D; Shi, Q; Tamm, E; Wei, AC; Wolff, RA | 1 |
| Chen, X; Luan, Y; Miao, H | 1 |
| Bastière-Truchot, L; Berger, R; Berton-Rigaud, D; Cardona, A; Colombo, N; du Bois, A; González Martin, A; Greimel, E; Grischke, EM; Hilpert, F; Kroep, JR; Kurzeder, C; Lorusso, D; Lück, HJ; Martinez-Garcia, J; Mirza, MR; Ottevanger, P; Pardo, B; Rau, J; Redondo, A; Selle, F; Vergote, I | 1 |
| Ai, P; Chen, N; Duan, B; Li, Y; Shi, H; Tian, J; Zhu, J | 1 |
| Cheng, H; Fan, K; Fan, Z; Huang, Q; Jin, K; Liu, C; Luo, G; Yang, C; Yu, X | 1 |
| Debus, J; Grosu, AL; Huber, PE; Lopez Perez, R; Münz, F; Nicolay, NH; Rühle, A; Saffrich, R; Sisombath, S; Trinh, T; Vidoni, D; Wuchter, P; Zou, B | 1 |
| Schwartz, PB; Uboha, NV; Weber, SM | 1 |
| Doki, Y; Eguchi, H; Isohashi, F; Kashiwazaki, M; Mori, M; Nagano, H; Nakahira, S; Sakai, D; Shimizu, J; Takahashi, H; Takeda, Y | 1 |
| Parvathaneni, S; Sharma, S | 1 |
| Biglietto, M; Calabrese, F; Caterino, M; Ciardiello, F; Conzo, G; De Vita, F; Laterza, MM; Molino, C; Orditura, M; Pappalardo, A; Petrillo, A; Pompella, L; Tirino, G; Ventriglia, A | 1 |
| He, H; Jiang, S; Ling, G; Peng, F; Qin, L; Yang, D; Zhang, F; Zhang, P | 1 |
| Abdo Filho, E; Aranha, AS; Bonadio, RC; Carvalho, HA; da Costa, SCS; de Freitas, D; Dias Genta, MLN; Estevez-Diz, MDP; Ferreira, PAO; Gabrielli, FCG; Machado, KK; Miranda, VC; Scaranti, M | 1 |
| Boccia, R; Buresti, G; Carbonari, D; Cavallo, D; Chiarella, P; Ciervo, A; Colosio, C; Delrio, P; Fresegna, AM; Iavicoli, S; Jemos, C; Maiello, R; Maiolino, P; Mandić-Rajčević, S; Marchetti, P; Omodeo Salè, E; Rubino, FM; Ursini, CL | 1 |
| Burgess, K; Jiang, Z; Kuai, D; Pflug, K; Sitcheran, R; Usama, SM; Yan, X | 1 |
| Byers, LA; Cardnell, RJ; Della Corte, CM; Diao, L; Fan, Y; Gay, CM; Hansen, RJ; Hassig, CA; Hedrick, MP; Heymach, JV; Milutinovic, S; Ramkumar, K; Sen, T; Shen, L; Stewart, CA; Strouse, B; Wang, J | 1 |
| Barry, E; Bivalacqua, TJ; Daniels, MJ; Kates, M; Milbar, N; Sankin, A; Schoenberg, M | 1 |
| Cao, Z; Feng, M; Liu, Y; Luan, J; Luo, W; Qiu, J; Yang, G; You, L; Zhang, T; Zhang, Y; Zhao, F; Zhao, Y; Zheng, L | 1 |
| Benhadji, KA; Cleverly, A; Gueorguieva, I; Lahn, MM; Macarulla, T; Melisi, D; Merz, V; Miles, C; Tabernero, J; Waterhouse, TH | 1 |
| Anthoney, A; Borg, D; Büchler, MW; Campbell, F; Crosby, T; Cummins, S; Cunningham, D; Darby, S; Falk, S; Faluyi, O; Ghaneh, P; Gillmore, R; Glimelius, B; Hackert, T; Halloran, CM; Hammel, P; Izbicki, JR; Jackson, R; Jones, RP; Lerch, MM; Lind, P; Mayerle, J; McDonald, A; Meyer, T; Middleton, GW; Neoptolemos, JP; O'Reilly, DA; Palmer, DH; Patel, K; Psarelli, EE; Ross, PJ; Sherriff, D; Soomal, R; Sothi, S; Strobel, O; Ting, Y; Tjaden, C; Valle, JW; Wadsley, J; Wasan, H | 1 |
| Ojima, H; Okusaka, T; Sakamoto, Y; Yamagishi, S | 1 |
| Dalin, S; Fenoglio, S; Grauman-Boss, B; Hemann, MT; Kreidl, E; Lau, AN; Lauffenburger, DA; Lees, JA; Luengo, A; Mueller, HS; Sullivan, MR; Vander Heiden, MG | 1 |
| Banáth, JP; Bennewith, KL; Bosiljcic, M; Cederberg, RA; Collier, JL; Franks, SE; Halvorsen, EC; Hamer, M; Hamilton, MJ; Harbourne, BT; Kim, AY; LePard, NE; Rossi, FM; Shi, R | 1 |
| Cao, H; Liu, G; Shao, F; Yan, L; Zhang, H | 1 |
| Cho, CS; Cuneo, KC; Griffith, KA; Kaza, R; Kim, E; Lawrence, TS; Nathan, H; Sahai, V; Shi, J; Sonnenday, CJ; Tran, NH; Zalupski, MM | 1 |
| Jones, RL | 1 |
| Blay, JY | 1 |
| Hindi, N; Martin-Broto, J; Moura, DS | 1 |
| Chen, J; Vermolen, FJ; Weihs, D | 1 |
| Bracco, OL; Frenkl, T; Freshwater, T; Keefe, S; Li, H; Li, M; Perini, R; Valiathan, C | 1 |
| Jarearnrat, A; Khuntikeo, N; Klanrit, P; Loilome, W; Namwat, N; Phetcharaburanin, J; Sa-Ngiamwibool, P; Suksawat, M; Techasen, A; Titapun, A | 1 |
| Alimoghaddam, K; Alishahi, Z; Esmaeili, F; Eyvani, H; Ghaffari, P; Ghaffari, SH; Ghavamzadeh, A; Momeny, M; Tavakkoly-Bazzaz, J; Zaghal, A | 1 |
| Grützmann, R; Lan, B; Pilarsky, C; Pöttler, M; Yang, H; Zeng, S | 1 |
| Feng, M; Hu, Y; Liu, C; Wang, X; Xiong, G; Xu, J; Yang, G; You, L; Zhang, T; Zhao, F; Zhao, Y; Zheng, L; Zhou, L | 1 |
| Costa-Silva, TA; de Sousa Cavalcante, L; Ienne, S; Monteiro, G; Souza, TA | 1 |
| Bansal, R; Bijlsma, MF; De Geus, SWL; Kuninty, PR; Kuppen, PJK; Mardhian, DF; Metselaar, JM; Östman, A; Prakash, J; Schnittert, J; Sier, CFM; Storm, G; Vahrmeijer, AL; van Baarlen, J; van Laarhoven, HW | 1 |
| Acramel, A; Chouquet, T; Goldwirt, L; Jouenne, F; Mourah, S; Plé, A; Sauvageon, H | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kimura, Y; Morizane, S; Nishikawa, R; Takenaka, A; Teraoka, S; Yumioka, T | 1 |
| Chin, SY; Hii, LW; Lai, KS; Leong, CO; Lim, SE; Mai, CW; Tan, NP | 1 |
| Dou, J; Ma, L; Shen, B; Shen, W; Xie, X; Xu, D; Zhou, C; Zhou, Y | 1 |
| Guo, Y; Li, X; Liu, W; Liu, X; Shen, L; Sun, X; Wang, J; Yang, X; Yao, L; Yuan, J; Zhou, X | 1 |
| Li, B; Liu, X; Liu, Y; Wang, J; Zhang, Y | 1 |
| Iyikesici, MS | 1 |
| Ando, K; Iwata, T; Mishima, H | 1 |
| Alekhina, O; Billadeau, DD; Ding, L; Dube, J; Dutta, SK; Giles, FJ; Kiers, S; Kozikowski, AP; Madamsetty, VS; Mazar, AP; Mukhopadhyay, D; Schmitt, DM; Ugolkov, A; Wang, E; Zhang, JS; Zhang, Y | 1 |
| Bai, Y; Du, L; Gao, F; Jin, L; Li, F; Lin, L; Niu, S; Shi, Q; Sun, T; Wu, J; Zhu, LM | 1 |
| Adam, J; Assi, T; Baldi, GG; Barisella, M; Ben-Ami, E; Benjamin, RS; Blay, JY; Casali, PG; Czarnecka, AM; Desar, I; Duffaud, F; Dufresne, A; Fedenko, A; Ferraro, R; Frezza, AM; Gelderblom, H; Gounder, M; Gronchi, A; Hornick, JL; Jones, RL; Kawai, A; Le Cesne, A; Lo Vullo, S; Maki, RG; Mariani, L; Meurgey, A; Mir, O; Noguchi, E; Pantaleo, MA; Ravi, V; Sbaraglia, M; Schuetze, S; Siontis, B; Stacchiotti, S; Teterycz, P; Thornton, K; Vincenzi, B; Wagner, AJ; Yonemori, K | 1 |
| Miyasaka, Y; Nakamura, M | 1 |
| Chen, M; Fu, G; Guan, Y; Guo, Z; Jiang, H; Jiang, X; Liang, J; Lu, T; Niu, X; Sun, R; Sun, S; Sun, X; Tang, J; Wang, H; Wang, X; Wu, K; Wu, X; Yang, C; Zheng, S; Zhong, B | 1 |
| Blanco-Prieto, MJ; Couvreur, P; Desmaële, D; Irusta, S; Rodríguez-Nogales, C; Sebastián, V | 1 |
| Choi, JS; Doh, KO; Joshi, M; Park, JW | 1 |
| Haan, L; Hankemeier, T; Joore, J; Kramer, B; Lanz, HL; Olivier, T; Vermeer, M; Vulto, P | 1 |
| Aglietta, M; Aimar, G; Fenocchio, E; Filippi, R; Leone, F; Lombardi, P; Milanesio, M; Quarà, V | 1 |
| Adhami, S; Ghodsi, J; Karimzadeh, F; Kermanpur, A; Rafati, AA; Shoja, Y | 1 |
| Li, P; Li, Y; Liu, B; Wang, W; Wang, Y | 1 |
| Choodetwattana, P; Jearanaikoon, P; Limpaiboon, T; Proungvitaya, S | 1 |
| Alexandrov, VA; Baranenko, DA; Bespalov, VG; Filatova, LV; Kireeva, GS; Semenov, AL; Semiglazova, TY; Stukov, AN | 1 |
| Huang, Y; Liu, S; Lu, W; Xiao, Y; Xu, Y; Yu, J | 1 |
| Grimberg, DC; Inman, BA; Shah, A | 1 |
| Cardoso, ACF; Florez Bedoya, CA; Fogelman, D; Katz, MHG; Kim, MP; Ngo-Huang, A; Park, M; Parker, N; Petzel, MQ; Romero, SG; Schadler, KL; Wang, H | 1 |
| Asagi, A; Fukutomi, A; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Iwai, T; Kamata, K; Katayama, H; Kato, N; Kawabe, K; Kawamoto, Y; Kojima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nakamori, S; Nakamura, K; Okano, N; Okusaka, T; Ozaka, M; Shimizu, K; Shioji, K; Sugimori, K; Sugimoto, R; Tobimatsu, K; Ueno, M; Wada, K; Yamaguchi, H; Yamashita, T; Yanagimoto, H; Yane, K; Yukisawa, S | 1 |
| Berkenstam, A; Dai, B; DiLorenzo, S; Fleming, J; Hases, L; Ibrahim, A; Jafferali, MH; Jose Augustine, J; Kang, Y; Kim, M; Lin, CY; Mesmar, F; Wang, J; Williams, C; Zhao, Y | 1 |
| Chen, C; Chen, T; Fu, S; He, LN; Hong, S; Li, H; Lin, Z; Wang, Y; Zhang, L; Zhang, X; Zhou, Y | 1 |
| Chen, HY; Chou, CJ; Hsieh, YY; Lee, KH; Liu, TP; Yang, PM | 1 |
| Bouvet, M; Chawla, SP; Higuchi, T; Hoffman, RM; Kawaguchi, K; Miyake, K; Oshiro, H; Park, JH; Singh, SR; Sugisawa, N; Unno, M; Zhang, Z | 1 |
| Fushida, S; Gabata, R; Harmon, JW; Hayashi, H; Kinoshita, J; Makino, I; Miyashita, T; Nakamura, K; Nakanuma, S; Ninomiya, I; Ohbatake, Y; Ohta, T; Okamoto, K; Okazaki, M; Sakai, S; Shimbashi, H; Tajima, H; Takamura, H | 1 |
| Feng, W; Tang, Z; Wang, Q; Yang, Y | 1 |
| An, T; Chen, H; Dong, Z; Jia, B; Li, J; Shi, A; Wang, Y; Wang, Z; Wu, M; Yang, S; Yang, X; Zhao, J; Zhong, J; Zhuo, M | 1 |
| Algül, H; Braren, R; Friess, H; Kaissis, G; Lohöfer, F; Muckenhuber, A; Rummeny, E; Schmid, R; Siveke, JT; Steiger, K; Weichert, W; Yen, HY; Ziegelmayer, S | 1 |
| Banerjee, RK; Caulfield, TR; Dutta, SK; Huang, HS; Madamsetty, VS; Mody, K; Mukhopadhyay, D; Pal, K; Thompson, JR; Wang, E; Yen, Y | 1 |
| Digiovanni, MG; Lacomb, JF; Luo, D; Mackenzie, GG; Rigas, B; Wei, R; Williams, JL | 1 |
| Chen, ZM; Huang, H; Ji, B; Jiang, CX; Mukaida, N; Song, Y; Yao, NH | 1 |
| Bai, X; Chen, Q; Chen, Y; Dang, X; Fu, Q; Liang, T; Lou, Y; Wang, J; Wei, T; Yang, J; Ye, M; Zhang, J; Zhang, Q; Zhang, X | 1 |
| Gou, H; Huang, J; Li, Q; Liao, W; Wang, X; Wen, F; Wu, Q; Zhang, P; Zhou, J; Zhou, K; Zhu, G | 1 |
| Babu, T; Gandin, V; Gibson, D; Ishan, M; Karmakar, S; Nemirovski, A; Yempala, T | 1 |
| Chen, D; Shen, W; Tan, X; Xu, T | 1 |
| Chen, J; Chen, ZH; Huang, JL; Ma, XK; Wei, L; Wen, JY; Wu, DH | 1 |
| Ding, F; Guo, Y; Huang, X; Li, Q; Ma, Y; Mou, Q; Pan, G; Zhang, C; Zhang, J; Zhu, X | 1 |
| Dubray, B; Ganem, J; Gouel, P; Salaun, M; Texte, E; Thureau, S; Vera, P | 1 |
| Berg, T; Nøttrup, TJ; Roed, H | 1 |
| Kato, T; Kiyokawa, T; Kohno, T; Kuroda, T; Ogiwara, H; Okamoto, A; Sasaki, M; Sudo, K; Takahashi, K; Tamura, K; Yoshida, H | 1 |
| Nazari, M; Rosenblum, JS; Trumbo, S | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Kubo, M; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y | 1 |
| Arcieri, M; Ergasti, R; Fagotti, A; Marchetti, C; Palluzzi, E; Pietragalla, A; Rosati, A; Scaletta, G; Scambia, G | 1 |
| Guan, H; Liu, G; Sheng, Y; Shi, L; Xie, F | 1 |
| Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N | 1 |
| Diao, WL; Guo, HQ; Wang, TW; Yang, R; Yuan, H; Zhao, XZ | 1 |
| Apellániz-Ruiz, M; Björn, N; Brandén, E; de Petris, L; Gréen, H; Koyi, H; Lewensohn, R; Lundeberg, J; Pradhananga, S; Rodríguez-Antona, C; Sigurgeirsson, B; Svedberg, A | 2 |
| Fang, C; Hu, WW; Ji, M; Wu, J; Zhang, C; Zhao, WQ | 1 |
| Chen, H; Chen, Z; Hua, YQ; Liu, LM; Meng, ZQ; Ning, ZY; Sheng, J; Xie, GQ; Zhang, K; Zhu, YD; Zhu, ZF | 1 |
| Li, Y; Wang, Q; Xie, S; Xu, M; Zhang, H; Zhou, L | 1 |
| Cai, JX; Hu, XB; Li, YJ; Wang, JM; Wu, JY; Xiang, DX | 1 |
| Furukawa, K; Kagawa, S; Kuboki, S; Mishima, T; Miyazaki, M; Nakadai, E; Ohtsuka, M; Sakai, N; Suzuki, D; Takano, S; Takayashiki, T; Yoshitomi, H | 1 |
| Bandyopadhyaya, R; Prabhuraj, RS; Saini, K | 1 |
| Bridgewater, J | 1 |
| Boeck, S; Crispin, A; D'Haese, JG; Gebauer, L; Haas, M; Heinemann, V; Ilmer, M; Kirchner, T; Kobold, S; Kruger, S; Kunz, WG; Mayerle, J; Ormanns, S; Ricke, J; Schirle, K; Schirra, J; von Bergwelt-Baildon, M; Werner, J; Westphalen, CB | 1 |
| Choi, I; Iwasaki, H; Kada, A; Nagai, H; Saito, AM; Yamasaki, S; Yoshida, I | 1 |
| Chen, L; Feng, D; Gu, M; Qian, Y; Wu, Y; Xiong, Y; Zhang, X | 1 |
| Kee, JY; Kim, M; Lee, HJ; Lee, MJ; Mun, JG; Son, SR | 1 |
| Akita, H; Ando, R; Chaya, R; Etani, T; Iida, K; Kobayashi, D; Moritoki, Y; Nagai, T; Naiki, T; Nozaki, S; Okamura, T; Sugiyama, Y; Yanase, T; Yasui, T | 1 |
| Eguchi, H; Kubo, M | 1 |
| Johnson, J; Li, L; Sharick, JT; Skala, MC | 1 |
| Huang, GC; Ji, XQ; Jiang, CC; Li, AM; Li, B; Shen, ZT; Yuan, X; Zhou, H; Zhu, XX | 1 |
| Allen, PJ; Balachandran, VP; Boerner, T; Boucher, TM; Cercek, A; Chapman, WC; Chou, JF; D'Angelica, MI; DeMatteo, RP; Diaz, LA; Do, RKG; Drebin, JA; Fields, RC; Gönen, M; Harding, JJ; Hauser, HF; Hawkins, WG; Jarnagin, WR; Kemeny, NE; Kingham, TP; Lim, KH; Lowery, MA; Majella Doyle, MB; Reidy-Lagunes, D; Saltz, L; Sanchez-Vega, F; Schultz, N; Strasberg, SM; Tan, BR; Vachharajani, N; Varghese, AM | 1 |
| Georgikou, C; Gladkich, J; Gretz, N; Gross, W; Herr, I; Karakhanova, S; Schäfer, M; Sticht, C; Torre, C; Xiao, X; Yin, L | 1 |
| Ahmad, S; Hasan, B; Hussain, I; Jain, AG; Jehanzeb, S; Khan, AK; Khetpal, N; Rahman, AU; Rashid, MU; Sarvepalli, D; Ullah, W | 1 |
| Eyre, TA | 1 |
| Hussein, A; Razavi, M; Ren, G; Rezaee, M; Thakor, AS; Ullah, M; Wang, J; Zheng, F | 1 |
| Liu, W; Mao, Y; Peng, S; Wang, Y; Wu, J; Zhang, X; Zhao, M; Zhao, S | 1 |
| Abdul Rahman, MB; Ashari, SE; Salim, N; Wahgiman, NA | 1 |
| Chen, Q; Dai, S; Hou, C; Liu, T; Miao, Y; Peng, Y; Wu, J; Xu, D; Xu, W; Zhu, F; Zhu, X; Zhu, Y | 1 |
| Ferreira, A; Lapa, R; Vale, N | 2 |
| Hashimoto, M; Hikichi, T; Irie, H; Konno, N; Nakamura, J; Ohira, H; Sato, Y; Sugimoto, M; Suzuki, R; Takagi, T | 1 |
| Cheung, WY; Gill, S; Kim, CA; Kong, S; Spratlin, J; Tsang, ES; Xu, Y | 1 |
| Cai, Q; Hu, Z; Tang, Y; Wang, Y; Xu, J; Yang, D; Zhu, Z | 1 |
| Arora, SP; Cheetham, K; Coffey, M; Eng, KH; Fields, P; Fountzilas, C; Kalinski, P; Mahalingam, D; Moseley, JL; Nuovo, G; Raber, P; Wilkinson, GA; Zhang, B | 1 |
| Abbas, HA; An, T; Chang, L; Chen, H; Chen, R; Chen, W; Dong, Z; Futreal, PA; Glisson, BS; Gong, Y; Guan, Y; Heymach, JV; Hong, L; Kalhor, N; Lee, JJ; Lewis, J; Li, J; Li, Z; Rinsurongkawong, W; Roarty, EB; Roth, JA; Swisher, SG; Wang, J; Wang, Y; Wang, Z; Wistuba, II; Wu, M; Wu, N; Xia, X; Yang, L; Yang, X; Yi, X; Zhang, J; Zhao, J; Zhong, J; Zhu, X; Zhuo, M | 1 |
| Hara, R; Ishii, H; Kita, E; Nakamura, K; Sudo, K; Takayama, W; Tsujimoto, A; Yamaguchi, T | 1 |
| Daunys, S; Matulis, D; Petrikaitė, V | 1 |
| Chikhladze, S; Fichtner-Feigl, S; Kousoulas, L; Lederer, AK; Reinmuth, M; Sick, O; Wittel, UA | 1 |
| Bhatnagar, S; Deo, SV; Iyer, VK; Kalyan Mohanti, B; Kumar Sahoo, R; Kumar Shukla, N; Kumar, R; Kumar, S; Mishra, S; Pal Chaudhary, S; Pal, S; Pathy, S; Raina, V; Ranjan Dash, N; Sahni, P; Sharma, A; Sreenivas, V; Thulkar, S | 1 |
| Bami, H; Boldt, G; Goodman, C; Vincent, M | 1 |
| Brabletz, T; Bronze, MS; Cui, X; Ding, K; Edil, BH; Fernandez-Zapico, ME; Fung, KA; Houchen, CW; Li, M; Li, YP; Liu, M; Postier, RG; Stemmler, MP; Tian, X; Yang, J; Yang, Z; Zhan, H; Zhang, Y; Zhou, Z | 1 |
| Cui, J; Peng, T; Wu, H; Xiong, J; Yang, Z; Zhao, N | 1 |
| Jin, C; Wen, F; Xu, T; Zhan, M; Zheng, H | 1 |
| Arias, J; Beca, JM; Berry, SR; Biagi, JJ; Chan, KKW; Cheng, S; Coburn, N; Dai, WF; Earle, C; Gavura, S; Guo, H; Isaranuwatchai, W; Kennedy, ED; McLeod, R; Meyers, BM; Mittmann, N; Qiao, L; Redmond-Misner, R; Schwartz, D; Welch, S | 1 |
| Lassaletta, A; Madero, L; Moreno-Tejero, ML; Pelaez, I; Perez-Somarriba, M; Rozas, MI | 1 |
| Forssell-Aronsson, E; Montelius, M; Nilsson, O; Sandblom, V; Shubbar, E; Spetz, J; Ståhl, I; Swanpalmer, J | 1 |
| Furukawa, K; Kuboki, S; Miyazaki, M; Ohtsuka, M; Takayashiki, T; Yoshitomi, H | 1 |
| Chen, X; Cui, SH; Ding, JS; Qian, HG; Qiu, C; Sun, J; Wang, CH; Wang, H; Wang, JC; Yan, Y; Zhang, HT; Zhang, Q | 1 |
| Ghanem, NB; Jamshed, MB; Li, X; Muhammad, SA; Munir, F; Sadiq, U; Shahid, N; Zhang, Q; Zhong, H | 1 |
| Kaur, H; Lee, YS; Ong, SY; Phipps, C; Tan, L | 1 |
| Benson, A; Fought, AJ; Kalyan, A; Kamath, SD; Kircher, S; Mulcahy, M; Nimeiri, H | 1 |
| Fu, CX; Li, HM; Liu, W; Peng, WJ; Tang, W; Wang, QF; Wang, XH; Zhou, LP | 1 |
| Knudsen, ES; Kumarasamy, V; Nambiar, R; Ruiz, A; Witkiewicz, AK | 1 |
| Ramseyer, C; Rivel, T; Yesylevskyy, S | 1 |
| Ariake, K; Mitachi, K; Motoi, F; Unno, M | 1 |
| Chen, H; He, Z; Jian, W; Liu, X; Sun, J; Sun, M; Sun, Y; Wang, G; Wang, Y | 1 |
| Haas, CR; McKiernan, JM | 1 |
| Brooks, NA; O'Donnell, MA | 1 |
| Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C | 1 |
| Bazhin, AV; Gasimov, E; Isayev, O; Werner, J; Zhu, Y | 1 |
| Dong, D; Dong, X; Fan, Y; Geng, Q; Hu, Y; Jing, J; Li, E; Shi, Y; Wang, C; Wu, Y | 1 |
| Desmaële, D; Gref, R; Lacombe, S; Li, X; Menendez-Miranda, M; Pastor, A; Porcel, E; Qiu, J; Serre, C; Yang, X | 1 |
| Abe, R; Izumi, H; Makuuchi, H; Mukai, M; Nomura, E; Tajiri, T; Yoshii, H | 1 |
| Shi, DM; Xu, HF; Zhu, XQ | 1 |
| Dang, CT; DeFusco, P; Fornier, MN; Goldfarb, S; Gucalp, A; Hudis, CA; Iyengar, NM; Jhaveri, K; Jochelson, M; Lake, D; Modi, S; Norton, L; Patil, S; Singh, JC; Smyth, LM; Traina, TA; Troso-Sandoval, T; Ulaner, GA | 1 |
| Ding, C; Hu, X; Tan, X; Wu, C; Yan, J; Zhou, M | 1 |
| Ardeshna, KM; Barton, S; Begum, R; Chau, I; Cunningham, D; Du, Y; Johnson, R; Kühnl, A; Macheta, MP; Paneesha, S; Patel, B; Peckitt, C; Radford, J; Valeri, N; Wotherspoon, A; Zerizer, I | 1 |
| Bi, PD; Duan, WJ; Liu, NQ; Ma, Y; Zhen, X | 1 |
| Junking, M; Panya, A; Poungvarin, N; Sawasdee, N; Sujjitjoon, J; Thepmalee, C; Yenchitsomanus, PT; Yongpitakwattana, P | 1 |
| Cao, M; Chen, Y; Hu, R; Li, T; Wang, K; Wang, R; Yang, M; Zhou, Y | 1 |
| Bai, XL; Chen, W; Chen, YW; Fu, QH; Gao, SL; Guo, CX; Huang, DB; Li, X; Liang, TB; Ma, T; Que, RS; Su, W; Tang, TY; Zhang, Q; Zhang, XC | 1 |
| Choi, I; Iwasaki, H; Kada, A; Miyata, Y; Miyazawa, Y; Nagai, H; Saito, A; Yamasaki, S; Yoshida, I | 1 |
| Inamura, A; Muraoka-Hirayama, S; Sakurai, K | 1 |
| Asch, D; Beatty, GL; Domchek, SM; Nathanson, KL; O'Dwyer, PJ; Reiss, KA; Rosen, MA; Siegelman, ES; Wattenberg, MM; Yu, S | 1 |
| Hamamoto, T; Hirohara, M; Masuda, Y; Morimoto, Y; Takada, K; Takagi, A; Takeuchi, O; Watanabe, K | 1 |
| Bell, R; Bell-McGuinn, K; Buderath, P; Campbell, R; Farrington, DL; Fiorica, J; Golden, L; Hamilton, A; Heitz, F; Lee, CM; Moore, KN; Pitou, C; Powell, M; Sehouli, J; Teneriello, M; Vergote, I; Wenham, RM; Zhang, W | 1 |
| Chen, W; He, M; Huang, S; Huang, X; Jiang, C; Lin, R; Liu, Q; Mohan, M; Shen, H; Shi, Y; Wang, J; Xu, S; Yang, L; Zhan, M | 1 |
| Li, F; Li, W; Liu, Y; Shi, C; Wang, X; Yang, J; Zang, R; Zhao, J; Zhong, L | 1 |
| Ishiki, H; Kubo, E; Satomi, E; Tateishi, A | 1 |
| Wu, YL; Yan, HH; Zhong, WZ | 1 |
| Qin, G; Xu, Q; Xue, Z; Yang, B; Zhu, X | 1 |
| Lin, W; Lu, B; Shi, L; Yu, J; Zhao, Y | 1 |
| El Hassouni, B; Giovannetti, E; Immordino, B; Mantini, G; Peters, GJ | 1 |
| Bivalacqua, TJ; Brooks, N; Crump, T; Daniels, MJ; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nagaraju, S; Nepple, KG; O'Donnell, MA; Rao, MY; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J | 1 |
| Ding, Y; Ge, W; Huang, Y; Kong, Y; Wang, W; Yan, Y; Zhang, L; Zheng, H; Zhou, J; Zhou, X; Zhu, W | 1 |
| He, Z; Li, Y; Liu, Y; Niu, Y; Shi, H; Xu, M; Xu, Q; Zhang, Y; Zhu, J | 1 |
| Alvarez Secord, A; Armstrong, DK; Azab, M; Banerjee, S; Basu, B; Birrer, MJ; Blagden, SP; Braly, P; Fleming, GF; Ghamande, S; Hall, GD; Hao, Y; Hirte, HW; Jueliger, S; Keer, H; Kristeleit, R; Markham, MJ; Matei, D; Matulonis, UA; McGuire, WP; Naim, S; Nemunaitis, J; Nephew, KP; Oganesian, A; Oza, AM; Provencher, DM; Roman, LD; Schwartz, B | 1 |
| Abou Ali, E; Batteux, F; Bordacahar, B; Camus, M; Chouzenoux, S; Jeljeli, M; Lafon, C; Leenhardt, R; Mestas, JL; Nicco, C; Prat, F | 1 |
| Akita, H; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Mori, M; Nagano, H; Noda, T; Tomimaru, Y | 1 |
| Bay, JO; Bertucci, F; Bompas, E; Bozec, L; Chenuc, G; Chevreau, C; Cupissol, D; Delaye, J; Delcambre, C; Duffaud, F; Eymard, JC; Guillemet, C; Isambert, N; Italiano, A; Pautier, P; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Rios, M; Saada, E | 1 |
| Huang, KW; Kim, MD; Li, SP; Li, XY; Liang, PC; Pua, U; Yang, PC | 1 |
| Chen, XD; Qiao, ZG; Tang, JM; Wu, XY; Yao, XM; Zhou, HY | 1 |
| Chen, Y; Cheng, L; Cui, X; Du, X; Sheng, L | 1 |
| Aburatani, H; Masoudi, M; Seki, M; Yachie, N; Yazdanparast, R | 1 |
| Al-Dhubiab, BE; Attimarad, M; Chavda, V; Jacob, S; Morsy, MA; Nair, AB; Patel, SS; Patel, V; Shah, J; Shinu, P; Sreeharsha, N; Venugopala, KN | 1 |
| Caffrey, TC; Clement, EJ; Cook, LM; Costanzo-Garvey, D; DiMaio, DJ; Fisher, KW; Grandgenett, PM; Grem, JL; Hollingsworth, MA; Krieger, KL; Lagundžin, D; Law, HC; Qiao, F; Wagner, ZS; Woods, NT; Yu, F | 1 |
| Biasoni, D; Bisogno, G; Boldrini, R; Conte, M; Crocoli, A; D'Angelo, P; Dall'Igna, P; De Pasquale, MD; Inserra, A; Miele, E; Siracusa, F; Spreafico, F; Terenziani, M | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Goto, K; Gotoh, K; Hayashi, K; Iwagami, Y; Kinoshita, M; Kobayashi, S; Kubo, M; Maekawa, K; Mori, M; Noda, T; Takeda, Y; Tanemura, M; Urakawa, S; Wada, H; Yamada, D | 1 |
| Conforti, C; Corneli, P; Di Meo, N; Magaton-Rizzi, G; Retrosi, C; Vezzoni, R; Zalaudek, I | 1 |
| Deng, LD; Hu, LJ; Jiang, X; Ren, ZP; Wang, YP; Yang, L; Zhao, HJ | 1 |
| Belanger, B; Blanc, JF; Bodoky, G; Chen, LT; Cunningham, D; Dean, A; Lee, KH; Li, CP; Macarulla Mercadé, T; Siveke, JT; Wang-Gillam, A | 1 |
| Frank, RC; Lee, R; Levy, G; Lo, T; Lobo, S; Martino, C; Pandya, D | 1 |
| Brunetti, O; Silvestris, N | 1 |
| Anders, R; Batukbhai, B; Begum, A; De Jesus-Acosta, A; de Wilde, RF; Laheru, DA; Maitra, A; McAllister, F; O'Dwyer, PJ; Rajeshkumar, NV; Ramanathan, RK; Rasheed, Z; Sahin, I; Sugar, EA; Von Hoff, DD; Yabuuchi, S; Zheng, L | 1 |
| Li, G; Li, H; Peng, C; Shi, L; Zhou, C | 1 |
| de Santibañes, E; de Santibañes, M; Mazza, O; Pekolj, J; Sanchez Clariá, R | 1 |
| Odoi, A; Pattarawat, P; Pfisterer, B; Wallace, S; Wang, HR | 1 |
| Choi, BS; Choi, MS; Kim, DE; Kim, HG; Kim, K; Park, CM; Shin, Y; Yoon, CH | 1 |
| Cabezas-Camarero, S; Cabrera-Martín, MN; Pérez-Alfayate, R; Pérez-Segura, P; Puebla, F | 1 |
| Abdel Karim, N; Aljohani, HM; Bahassi, EM; Eldessouki, I; Gaber, O; Morris, J | 1 |
| Blanco, A; Li, J; Norgard, RJ; Stanger, BZ; Yamazoe, T; Yan, F; Yuan, S | 1 |
| Bjånes, TK; Cros-Perrial, E; Jordheim, LP; Kamceva, T; Kotopoulis, S; Langer, A; McCormack, E; Riedel, B; Ruiz de Garibay, G; Schjøtt, J | 1 |
| Chen, X; Li, T; Wan, J; Wang, H; Wang, Y; Wu, L; Zhang, F | 1 |
| Chang, J; Chen, T; He, M; Hong, W; Li, F; Li, H; Li, J; Liu, L; Luo, D; Ran, L; Shan, L; Song, Y; Wang, B; Wang, H | 1 |
| Alvaro, D; Begum, R; Boulter, L; Braconi, C; Cardinale, V; Carotenuto, P; Carpino, G; Cascione, L; Cillo, U; Clarke, P; Costantini, D; Cunningham, D; Fassan, M; Forbes, SJ; Ghidini, M; Guest, RV; Guzzardo, V; Hahne, JC; Hedayat, S; Kirkin, V; Lampis, A; Michalarea, V; Rimassa, L; Roncalli, M; Said-Huntingford, I; Salati, M; Santoro, A; Scarpa, A; Smyth, E; Te Poele, R; Trevisani, F; Valeri, N; Ventura, S; Vicentini, C; Vlachogiannis, G; Workman, P | 1 |
| Fang, T; Lu, Q | 1 |
| Chen, L; Chen, Z; Cheng, CS; Liu, W; Meng, Z; Tang, W; Zhong, A; Zhou, L | 1 |
| Chen, T; Choy, E; Cote, GM; Demetri, G; George, S; Marino-Enriquez, A; Merriam, P; Morgan, J; Nathenson, MJ; Thornton, K; Wagner, AJ | 1 |
| Kawashiri, T; Kobayashi, D; Shimazoe, T; Tokunaga, A | 1 |
| Chauhan, B; Chauhan, N; Chauhan, SC; Halaweish, FT; Jaggi, M; Khan, P; Khan, S; Kumari, S; Malik, S; Sikander, M; Yallapu, MM | 1 |
| Gong, JH; Liu, XJ; Miao, QF; Wang, RH; Wang, YX; Yang, SQ; Zhang, MR; Zhen, YS; Zheng, YB | 1 |
| Adiseshaiah, PP; Burgan, W; Goswami, D; Guerin, TM; Kozlov, SV; McCormick, F; Mukhopadhyay, S; Nissley, DV; Yi, M | 1 |
| Gowda, PS; Javed, A; Li, J; Lu, Y; Ponnazhagan, S; Trotter, TN; Xu, X; Yang, Y; Zhang, C | 1 |
| Bansal, R; Mardhian, DF; Prakash, J; Storm, G; Vrynas, A | 1 |
| Ahn, ER; Algül, H; Askoxylakis, V; Bendell, J; Charu, V; Gracian, AC; Ko, AH; Kuesters, G; Kundranda, M; Meiri, E; Pelzer, U; Pipas, JM; Rivera, F; Santillana, S; Watkins, D; Zafar, SF; Zalutskaya, A | 1 |
| Akara-Amornthum, P; Choksi, S; Jitkaew, S; Lomphithak, T; Tohtong, R | 1 |
| Belkouz, A; de Vos-Geelen, J; Eskens, FALM; Klümpen, HJ; Mathôt, RAA; Punt, CJA; van Gulik, TM; van Oijen, MGH; Wilmink, JW | 1 |
| Arora, R; Hildebrandt, GC; Munker, R; Qasrawi, A; Ramlal, R | 1 |
| Abu Hilal, M; Alseidi, A; Bassi, C; Besselink, MG; Bolm, L; Busch, OR; De Pastena, M; Del Chiaro, M; Gill, AJ; Groen, JV; Groot Koerkamp, B; Groot, VP; Halimi, A; He, J; Jang, JY; Keck, T; Malleo, G; Marchegiani, G; Mieog, JS; Mittal, A; Samra, JS; Steyerberg, EW; Strijker, M; Suhool, A; van Eijck, CH; van Roessel, S; Wolfgang, CL; Zarantonello, L | 1 |
| Davis, JH; Deyell, RJ; Douglas, K; Gershony, S; Marr, K; Nadel, H; Ronsley, R; Strahlendorf, C | 1 |
| Bo, X; Gao, Z; Li, M; Liu, H; Lu, P; Nan, L; Ni, X; Shen, S; Suo, T; Wang, C; Wang, J; Wang, Y; Xin, Y; Zhang, D | 1 |
| Cheng, Y; Dang, Q; Huang, J; Shi, W; Yang, L; Zhang, Y; Zhou, H | 1 |
| Anastasia, A; Annechini, G; Bonfichi, M; Carlo-Stella, C; Castagna, L; Di Renzo, N; Giordano, L; Gotti, M; Liberati, AM; Luminari, S; Mazza, R; Merli, F; Peli, A; Pulsoni, A; Re, A; Ricci, F; Santoro, A; Zanni, M; Zilioli, VR | 1 |
| Beh, I; Brais, R; Connell, CM; Corrie, P; Janowitz, T; Jodrell, DI; Risdall, J; Upponi, S; Whitaker, H | 1 |
| Abakumova, TO; Antipina, MN; Brichkina, AI; Brzozowska, AM; Gorin, DA; Kakran, M; Ketkar, A; Lau, HH; Loh, HM; Novoselova, MV; Trushina, DB; Zatsepin, TS | 1 |
| Caprioli, R; Dai, X; Dosch, AR; Kashikar, N; Kwon, D; Mehra, S; Merchant, NB; Nagathihalli, NS; Reyzer, ML; Srinivasan, S; Willobee, BA | 1 |
| Segar, J; Shroff, RT | 1 |
| Andersson, BS; Bashir, Q; Li, Y; Liu, Y; Murray, D; Nieto, Y; Qazilbash, MH; Valdez, BC | 1 |
| Moradnia, H; Raissi, H; Shahabi, M | 1 |
| Choe, JW; Kim, HJ; Kim, JS | 1 |
| Chen, T; Jin, Y; Xiao, Z; Zhuang, B | 1 |
| Edeline, J | 1 |
| Harano, K; Motohashi, T; Nakanishi, T; Saito, T; Susumu, N; Takehara, K; Teramoto, N; Tokunaga, H; Tsuda, H; Ueda, Y; Watanabe, R; Yamashita, N; Yokoyama, Y | 1 |
| Abrams, RA; Berger, AC; Corn, BW; Crane, CH; DiPetrillo, TA; Fisher, BJ; Gillin, MT; Goodman, KA; Haddock, MG; Jiang, Y; Katz, AW; Lowy, AM; Mehta, S; Philip, PA; Regine, WF; Safran, H; Seaward, SA; Song, S; Willett, CG; Winter, KA; Wu, A | 1 |
| Jia, Y; Liu, B; Ma, J; Mao, A; Shang, M; Wang, Z; Weng, L; Wu, S; Xue, L; Yin, X | 1 |
| Honda, Y; Inaba, T; Kim, J; Liu, X; Matsui, M; Nishiyama, N; Nomoto, T; Takemoto, H; Taniwaki, K; Tomoda, K; Toyoda, M; Yamada, N | 1 |
| Du, Y; Guo, S; Mu, J; Xu, Y; Xu, Z; Yu, N; Zhang, S; Zhong, H | 1 |
| Fukuchi, T; Fukuda, T; Igarashi, R; Inoue, K; Kanki, T; Yamashita, SI; Yamashita, T | 1 |
| Beumer, JH; Chen, Y; Diao, D; Li, S; Lu, B; Luo, Z; Parise, RA; Ren, P; Sun, J; Wan, Z; Xu, J | 1 |
| Bergonzini, C; Carbone, D; Cascioferro, S; Cirrincione, G; Dekker, H; Diana, P; Funel, N; Geerke, D; Giovannetti, E; Mantini, G; Parrino, B; Peters, GJ; Petri, GL | 1 |
| Fukushima, T; Hashimoto, Y; Hirotani, A; Ikeda, M; Imaoka, H; Kobayashi, S; Mitsunaga, S; Morimoto, M; Moriya, S; Ohno, I; Ozaka, M; Sano, Y; Sasahira, N; Sasaki, M; Sasaki, T; Tezuka, S; Tozuka, Y; Ueno, M; Umemoto, K; Watanabe, K; Yamada, I | 1 |
| Cao, W; Hu, X; Li, H; Liang, L; Liu, J; Wang, W; Wang, Z; Xiao, X; Yang, Q; Yuan, Z; Zhang, B; Zhou, P | 1 |
| Sridhar, SS | 1 |
| Georgoulias, V; Ioannidis, G; Lagoudaki, E; Mavroudis, D; Papadaki, C; Souglakos, J; Stathopoulos, E; Trypaki, M; Tzardi, M | 1 |
| Aravantinos, G; Demiri, S; Fountzilas, G; Koliou, GA; Lampropoulou, DI; Pectasides, D; Pentheroudakis, G; Psyrri, A; Razis, E; Samantas, E; Sgouros, J; Zagouri, F | 1 |
| Beauregard, J; Collins, L; Dostie, S; Guindon, Y; Labbé, MO; Lefebvre, CA; Maharsy, W; Nemer, M; Prévost, M | 1 |
| Berg, M; Cinatl, J; Michaelis, M; Rothweiler, F; Stege, H; Vallo, S; Winkelmann, R | 1 |
| Kohno, T; Kuroda, T | 1 |
| Bi, J; Chen, S; Diao, C; Dong, Y; Fan, H; Fan, W; Feng, Q; Geng, D; Han, X; Huang, G; Li, F; Li, G; Li, P; Li, Q; Li, T; Li, W; Li, Y; Liu, B; Meng, M; Meng, Q; Ni, Y; Ren, H; Sheng, L; Sun, D; Sun, L; Sun, W; Sun, Y; Tian, H; Wang, C; Wang, J; Wei, Z; Xu, X; Xu, Y; Xue, G; Yang, X; Ye, X; Yu, G; Zhang, B; Zhang, K; Zhang, L; Zheng, A; Zou, Z | 1 |
| Cai, W; Chen, B; Geng, C; Jiang, L; Lu, H; Sun, J; Yang, B; Zhou, Y | 1 |
| Jimi, T; Kitai, M; Kogiku, A; Matsuoka, K; Nagao, S; Shibutani, T; Shiozaki, T; Suzuki, K; Yamaguchi, S; Yamamoto, K | 1 |
| Arslan, FB; Calis, S; Esendagli, G; Ozturk, K; Tavukcuoglu, E | 1 |
| Calvisi, DF; Chen, X; Cigliano, A; Dituri, F; Giannelli, G; Mancarella, S; Ribback, S; Serino, G; Wang, J | 1 |
| Garcia-Cremades, M; Magni, P; Melillo, N; Troconiz, IF | 1 |
| Beringer, A; Groschek, M; Heinemann, V; Hoeffkes, HG; Marschner, N; Schulze, M; Tessen, HW; Waldschmidt, D; Westphalen, CB | 1 |
| Besselink, MG; Creemers, GJ; de Groot, JWB; de Vos-Geelen, J; Haj Mohammad, N; Homs, MYV; Latenstein, AEJ; Mackay, TM; Molenaar, IQ; Ten Tije, BJ; van der Geest, LGM; van Eijck, CHJ; van Laarhoven, HWM; Wilmink, JW | 1 |
| Al-Batran, SE; Bankstahl, US; Bechstein, WO; Goetze, TO; Keck, T; Königsrainer, A; Lang, SA; Pauligk, C; Piso, P; Vogel, A | 1 |
| Aksnes, AK; Amund Eriksen, J; Dueland, S; Faluyi, O; Iversen, B; Jensen Gjertsen, T; Ma, YT; Miller, R; Møller, AS; Neoptolemos, JP; Palmer, DH; Valle, JW | 1 |
| Benoit, JP; Bronte, V; Della Puppa, A; Ingangi, V; Lollo, G; Magri, S; Mandruzzato, S; Marigo, I; Masetto, E; Matha, K; Pinton, L; Schibuola, I; Vettore, M | 1 |
| Chen, X; Gao, M; Han, H; Hou, Y; Ji, J; Jin, Q; Kang, M; Zhang, P | 1 |
| Bender, L; Gantzer, J; Kurtz, JE; Somme, F; Weingertner, N | 1 |
| Huang, J; Li, Q; Liao, W; Wu, Q; Zhang, N; Zhang, P | 1 |
| Debnath, MC; Ganguly, S; Kazi, J; Mukhopadhyay, R; Paul, B; Sen, R | 1 |
| Chen, J; Fan, Y; He, T; Li, W; Liu, Y; Wang, Q; Wang, Y; Wang, Z | 1 |
| Comlek, S | 1 |
| Hsu, CH; Jakfar, S; Lin, FH; Lin, TC; Ling, TY; Liu, L; Sun, YJ; Young, IC | 1 |
| Beringer, A; Fuchs, M; Garlipp, B; Hahn, L; Heinemann, V; Kukiolka, T; Kütting, F; Malfertheiner, P; Reiser, M; Waldschmidt, DT; Westphalen, CB | 1 |
| Gibbs, SL; King, D; Solanki, A; Thibault, G; Wang, L | 1 |
| Altuntaş, F; Bakırtaş, M; Başçı, S; Batgi, H; Dal, MS; Darçın, T; İskender, D; Kızıl Çakar, M; Merdin, A; Şahin, D; Tetik, A; Uncu Ulu, B; Yiğenoğlu, TN; Yıldız, J | 1 |
| Ding, X; Huang, W; Jiang, C; Li, F; Sun, T; Wang, Q; Wang, Z; Wu, Z; Zhu, X | 1 |
| Cordua, N; D'Antonio, F; De Vincenzo, F; Giordano, L; Perrino, M; Santoro, A; Zucali, PA | 1 |
| Han, J; Liang, Y; Svirskis, D; Tian, B; Wu, Z; Zhang, J | 1 |
| Bhattacharya, R; Elechalawar, CK; Figg, WD; Hossen, MN; Mukherjee, P; Peer, CJ; Robertson, JD; Shankarappa, P | 1 |
| Fei, Z; Liang, X; Su, H; Zou, C; Zou, J | 1 |
| Akkermans-Vogelaar, JM; Besselink, MG; Bonsing, BA; Buijsen, J; Busch, OR; Creemers, GM; de Groot, JWB; de Hingh, IH; de Vos-Geelen, J; Eskens, FALM; Festen, S; Groot Koerkamp, B; Groothuis, K; Homs, MYV; Kerver, ED; Luelmo, SAC; Neelis, KJ; Nuyttens, J; Paardekooper, GMRM; Patijn, GA; Punt, CJ; Suker, M; van Dam, RM; van der Sangen, MJC; van Eijck, CH; van Hooft, JE; van Tienhoven, G; Versteijne, E; Wilmink, JW; Zwinderman, AH | 1 |
| Drevinskaite, M; Kevlicius, L; Mickys, U; Patasius, A; Smailyte, G | 1 |
| Baek, YY; Fang, S; Jang, SI; Lee, DH; Lee, DK; Lee, SY; Na, K | 1 |
| Abate-Shen, CT; Anderson, CB; DeCastro, GJ; Drake, CG; Holder, D; James, B; Kates, MM; Lee, SM; McKiernan, JM; Pak, JS; Sui, W; Virk, RK | 1 |
| Hwang, JH; Kim, J; Kim, MJ; Lee, JC; Lee, KH; Lee, WJ; Shin, DW; Woo, SM | 1 |
| Li, W; Lin, H; Peng, Y; Sun, J; Wu, W; Yu, X; Zhang, K; Zhu, Y | 1 |
| Bartlett, DW; Desai, D; Guerrero, YA; Kindt, E; Maurer, TS; Solomon, DE; Spilker, ME; Sullivan, C | 1 |
| Crane, CH; Gusani, NJ; Lehrer, EJ; Sharma, NK; Tchelebi, LT; Trifiletti, DM; Zaorsky, NG | 1 |
| Fukui, I; Inoue, T; Masuda, H; Numao, N; Ogawa, M; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Dahabreh, IJ; García-Albéniz, X; Hernán, MA; Howlader, N; Logan, RW; Mariotto, AB; Petito, LC | 1 |
| Jeong, KC; Kwon, WA; Lee, SJ; Seo, HK | 1 |
| Garcia, PL; Miller, AL; Yoon, KJ | 1 |
| Griffin, JI; Ho, RJY; McConnachie, LA; Mu, Q; Wu, Y; Yu, J; Zhu, L | 1 |
| Chen, H; Li, J; Liang, X; Pu, X; Shen, T; Song, Z; Wang, L; Wang, W; Xu, C; Yu, Z; Zhang, Y | 1 |
| Bun, S; Kato, MK; Kato, T; Miyasaka, N; Shimoi, T; Tamura, K; Yonemori, K; Yunokawa, M | 1 |
| Dijk, SN; Elpidorou, M; Kroon, AM; Protasoni, M; Taanman, JW | 1 |
| Basch, E; Dueck, A; Johansen, C; Lindberg, H; Pappot, H; Taarnhøj, GA | 1 |
| Gunduz, U; Mutlu, P; Parsian, M; Yalcin, S | 1 |
| Amaravadi, RK; Bahary, N; Bartlett, DL; Boone, BA; Espina, V; Hogg, ME; Lee, KK; Liotta, L; Lotze, MT; Marsh, JW; Miller-Ocuin, JL; Murthy, P; Normolle, DP; Seiser, N; Singhi, AD; Tang, D; Tsung, A; Zeh, HJ; Zureikat, AH | 1 |
| Egawa, C; Haruna, K; Hata, T; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Murakami, K; Murata, K; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A; Yanagawa, T; Yanai, A | 1 |
| Ido, S; Kawazoe, H; Matsuo, M; Mori, N; Nakai, M; Nakamura, T; Sumikawa, S; Takeuchi, A; Tsuneoka, K; Uozumi, R; Yakushijin, Y; Yamauchi, M | 1 |
| Cong, J; Jiao, D; Jin, L; Li, Z; Wang, D; Xu, L; Zhang, X; Zheng, X | 1 |
| Akamine, S; Ebi, N; Ichiki, M; Matsumoto, T; Nakanishi, Y; Takayama, K; Tokunaga, S; Uchino, J; Yamada, T | 1 |
| Delpero, JR; Ewald, J; Garnier, J; Gilabert, M; Giovannini, M; Launay, S; Marchese, U; Moureau-Zabotto, L; Poizat, F; Turrini, O | 1 |
| Hata, M; Kawana, K; Maebayashi, A; Nagaishi, M; Nakajima, T; Xiaoyan, T | 1 |
| Kubo, S; Tomita, N; Yamano, T | 1 |
| Li, J; Li, W; Liang, L; Liu, Z; Wang, Y; Xu, F; Xu, H; Yang, G; Yang, L; Ying, J; Zhang, Q; Zhang, S | 1 |
| Balasubramaniam, DK; Gregory, M; Hariharan, S; Karuppaiah, A; Rajan, R; Sankar, V | 1 |
| Balakrishnan, I; Desisto, J; Eberhardt, CG; Foreman, NK; Green, A; Griesinger, A; Moreira, DC; Pierce, A; Prince, E; Subramanian, A; Venkataraman, S; Vibhakar, R | 1 |
| Buse, JB; Corty, RW; Fine, JP; Langworthy, BW; Lund, JL; Sanoff, HK | 1 |
| Azim, N; Bhattacharya, S; Catarata, R; Zhai, L | 1 |
| Hou, J; Li, H; Ma, W; Tian, Z; Wang, S; Zheng, X | 1 |
| Li, B; Li, T; Liu, MF; Xi, Y; Yuan, P; Zhang, M | 1 |
| Drexler, R; Feyerabend, B; Kleine, M; Küchler, M; Oldhafer, KJ; Wagner, KC | 1 |
| Montgomery, RB; Ruplin, AT; Spengler, AMZ; Wright, JL | 1 |
| Bi, M; Hong, S; Li, S; Song, Y; Yan, Z | 1 |
| Apte, MV; Goldstein, D; Liu, AC; Mekapogu, AR; Murakami, T; Pang, TCY; Perera, CJ; Pirola, RC; Pothula, SP; Wilson, JS; Xu, Z | 1 |
| Abdelrahman, L; Banerjee, S; Kesh, K; Mendez, R | 1 |
| D'Haese, JG; Maisonneuve, P; Miksch, RC; Weniger, M; Werner, J | 1 |
| Hamada, Y; Hattori, A; Kawabata, H | 1 |
| Antico, G; Blauer-Petersen, C; Doleh, Y; Lal, LS; Pishvaian, M | 1 |
| Bacher, U; Betticher, D; Farag, S; Farese, S; Jeker, B; Li, Q; Luethi, JM; Mueller, BU; Novak, U; Pabst, T; Ruefer, A; Taleghani, BM | 1 |
| Barcinska, E; Inkielewicz-Stepniak, I; Sobczak, K; Steckiewicz, KP; Tomczyk, E; Wojcik, M | 1 |
| Gao, S; Hao, J; Huang, C; Jin, F; Liu, J; Wang, H; Wang, X; Xiao, D; Yang, S; Zhao, T | 1 |
| Akbulut, H; Aykan, F; Coskun, HS; Dane, F; Demirag, GG; Evrensel, T; Hayran, M; Isikdogan, A; Karabulut, B; Kilickap, S; Oksuzoglu, B; Ozdemir, F; Ozdemir, NY; Ozkan, M; Sevinc, A; Turna, H; Ustaoglu, MA; Yalcin, S; Yavuzsen, T; Yuce, D | 1 |
| Al-Youbi, AO; Bashammakh, AS; El-Shahawi, MS; Graham, RM; Leblanc, RM; Liyanage, PY; Vanni, S; Zhou, Y | 1 |
| Chiaradonna, F; De Vitto, H; Gang, Y; Giampà, M; Gu, J; Guan, W; La Ferla, B; Li, Q; Palorini, R; Ricciardiello, F; You, L; Zhang, T; Zhao, F; Zhao, Y | 1 |
| Sinn, M; Stein, A; Wege, H | 1 |
| Dorman, MJ; Fishel, ML; Grippo, PJ; Hwang, RF; Kamath, SD; Kumar, S; Munshi, HG; Narbutis, M; Park, A; Principe, DR; Rana, A; Thummuri, D; Trevino, JG; Underwood, PW; Viswakarma, N | 1 |
| Fu, X; Mao, L; Qiu, YD; Tang, N; Xie, WQ | 1 |
| Barroilhet, LM; Brown, J; Darus, C; Duska, LR; Jelovac, D; McGuire, WP; Moore, KN; Petroni, GR; Secord, AA; Varhegyi, N | 1 |
| Damarla, V; Dobrosotskaya, I; Khan, G; Kwon, D; Li, J; Raoufi, M; Seixas, T; Siddiqui, F; Thanikachalam, K; Winters, K; Wollner, I | 1 |
| Cao, J; Guo, Z; Li, Q; Wang, Q; Zhang, J; Zhu, S; Zhu, WH | 1 |
| Abu Hilal, M; Al-Sarireh, B; Alseidi, A; Bassi, C; Besselink, MG; Boggi, U; Bolm, L; Bonds, M; Dreyer, SB; Ferraro, D; Fontana, M; Fusai, GK; Halimi, A; Harris, S; Jamieson, NB; Khalil, K; Malleo, G; Mavroeidis, VK; Moekotte, AL; Mortimer, MC; Napoli, N; Primrose, JN; Roberts, KJ; Robinson, S; Salvia, R; Shablak, A; Soonawalla, Z; van Roessel, S; Wellner, UF; White, SA; Wilmink, JW; Zarantonello, L | 1 |
| Chiba, M; Honma, S; Imazu, H; Ito, M; Shimamoto, N; Sumiyama, K | 1 |
| Pan, J; Yang, X; Zhao, H | 1 |
| Cercek, A; Jarnagin, WR | 1 |
| Bajorin, DF; Bochner, BH; Dalbagni, G; Donat, SM; Herr, HW; Iyer, G; Milowsky, MI; Ostrovnaya, I; Regazzi, AM; Rosenberg, JE; Russo, P; Tully, CM; Zabor, EC | 1 |
| Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N; Yamamoto, T | 1 |
| Hada, T; Ishibashi, H; Iwahashi, H; Kakimoto, S; Matsuura, H; Miyamoto, M; Sakamoto, T; Soyama, H; Suminokura, J; Takano, M | 1 |
| Cheng, X; Hu, X; Jia, Z; Liang, X; Yang, J; Zhai, Y | 1 |
| Gao, LF; Han, J; Li, XL; Liu, QY; Liu, ZJ; Wang, XH; Xu, W | 1 |
| Kimura, S; Kurioka, Y; Matsumoto, T; Matsuo, Y; Miura, K; Morishita, H; Okazaki, U; Takagi, S; Takatani, M; Tsuduki, T | 1 |
| Cui, M; Dai, M; Gao, J; Guo, J; Kleeff, J; Li, T; Li, Y; Liao, Q; Liu, J; Liu, Q; Lu, Z; Pan, B; Wang, W; Wu, H; Wu, W; Zhang, R; Zhang, T; Zhang, X; Zhao, Y; Zhou, L | 1 |
| Abbasnezhad, A; Abd El-Ghafar, OA; Abhilash, L; Abouzid, KAM; Achberger, AM; Ackerman, S; Akhatayeva, Z; Akin, D; Al-Kaysi, RO; Alakhdar, AA; Alame, M; Aleksic Sabo, V; Alinezhadbalalami, N; Allen, JD; Alonso, JM; Alqatani, S; Alsayed, B; Álvarez Larraondo, M; Alvarez, M; Amini, SB; An, Z; Anasir, MI; Anderson, GH; Andremont, A; Andrés, S; Angel, S; Anigboro, AA; Anini, Y; Antonides, CFJ; Arafa, K; Arafa, RK; Aryal, UK; Asbaghi, O; Assefa, MK; Atyah, M; Avwioroko, OJ; Ayora-Talavera, G; Azpilikueta, A; Azyazov, VN; Ba, YF; Bachmann, KF; Badoual, J; Bae, SJ; Baek, SH; Bahrami, B; Bai, J; Baid-Agrawal, S; Bailey, MR; Baillie, JK; Balani, N; Balcar, VJ; Banica, T; Banks, L; Barb, J; Bardeen, CJ; Barrett, HE; Bartnikowski, N; Bashir, R; Battaglia, M; Bautista-Hernández, V; Becker, B; Beekman, FJ; Benidir, M; Benjelloun, M; Bentley, RF; Bergé, J; Berger, D; Bernsen, MR; Berraondo, P; Bhattacharya, R; Bhayani, SB; Bi, W; Bi, X; Bi, YL; Bi, Z; Bian, K; Biesecker, LG; Billadeau, DD; Blaszczyk, R; Blum, JL; Boachie, R; Boelte, K; Bogers, AJJC; Boileau, I; Bonduelle, C; Bonny, O; Bonsu, JM; Boos, LA; Borges-Argáez, R; Bouchard, PA; Boudot, C; Bourgeade-Delmas, S; Boutet-Robinet, E; Boyle, AJ; Branigan, D; Briones, S; Broniowska, KA; Brossas, JY; Brown, WA; Brzezinska, J; Buitron, G; Burnier, M; Bursulaya, B; Burton, PR; Bush, AA; Busuttil, RW; Cabello-Aguilar, S; Cáceres-Farfán, M; Cacheux, V; Caffrey, PJ; Cai, B; Cai, Q; Cai, S; Cai, Y; Calders, P; Cammarota, G; Campbell, DA; Cancelli, C; Cao, Q; Cao, WH; Cao, X; Capet, M; Capoluongo, E; Carey, ME; Carnero, M; Carrasco, LI; Carreno, J; Carrillo-Reyes, J; Casini, I; Cassar, M; Catalan, G; Cattamanchi, A; Cazares-Granillo, M; Celie, B; Cen, YK; Cena, H; Cerbo, RM; Ceron, E; Cetina-Montejo, L; Chaâbane-Banaoues, R; Chabanet, C; Chace-Donahue, F; Chalfun-Júnior, A; Chan-Balan, R; Chang, CS; Chen, CS; Chen, D; Chen, J; Chen, L; Chen, PN; Chen, Q; Chen, S; Chen, W; Chen, WP; Chen, X; Chen, Z; Cheng, H; Cheng, J; Cheng, Q; Cheng, T; Chi, T; Chianelli, D; Chieppa, M; Child, CJ; Cho, JH; Cho, JY; Chogtu, B; Choi, GH; Choi, J; Choi, M; Choi, NG; Cholu, CO; Chow, ES; Chowdhury, AH; Chu, PC; Chu, Q; Chu, S; Chua, H; Chung, T; Chunyan, L; Church, JS; Civardi, E; Cobiella, J; Colinge, J; Collado, CJ; Collins, TJ; Cong, LM; Conkrite, KL; Cope, SJ; Corbett, JA; Cornet, M; Cornillot, E; Corvaisier, S; Costes-Martineau, V; Courtioux, B; Coussens, M; Covino, M; Criado, A; Cui, J; Cui, Y; Cunitz, BW; Curry, AE; Cussó, L; D'Urzo, AD; D'Urzo, KA; Dabbous, S; Dahlgren, RA; Dai, H; Dai, T; Dai, W; Dalinghaus, M; Dang, S; Davalos, RV; Davidson, H; de Andrea, CE; De Angelis, M; de Blois, E; de Carvalho, PA; De Clercq, E; De Giuseppe, R; de Jong, M; De Langhe, S; De Oliveira, L; de Souza Pinto Lemgruber, R; de Souza, LB; de Swart, J; De Wandele, I; de Woestijne, PCV; Delaney, S; Delorme, M; Delvenne, P; Deng, L; Deng, Z; Denkinger, CM; der Meulen, MHV; Deraeve, C; Desco, M; DeSilva, S; Destere, A; Dhali, A; Di Ciano, P; Dias-Santagata, D; Diskin, SJ; Djè, MK; Doddipatla, S; Doerr, AJ; Dokla, EME; Domiciano, D; Domingo, N; Dong, C; Dong, J; Dong, Q; Dong, S; Dong, X; Dong, Z; Douair, I; Douglas, TA; Doyle, SM; Drain, PK; Du, K; Du, L; Du, Q; Du, S; Duan, C; Duan, H; Duan, J; Duan, S; Duan, W; Dueluzeau, R; Dukic, L; Dunmire, BL; Duvauchelle, T; Dymek, B; Dzwonek, K; Earnest, A; Eckardt, KU; El Ghadraoui, L; El Massoudi, S; Elloumi, F; Elnour, IE; Embarak, S; Ende, M; England, K; Enikeev, D; Enyedy, I; Epple, R; Erickson, GE; Eriksson, J; Erndt-Marino, J; Errachidi, F; Etxeberria, I; Evan, AP; Fairlamb, AH; Falahi, E; Fan, CC; Fan, H; Fan, M; Fan, MZ; Fan, S; Fan, Y; Fang, CS; Fang, J; Fang, X; Fang, Z; Farmany, A; Farooqi, A; Farouk, HO; Fazelipour, S; Feng, D; Feng, J; Feng, JX; Feng, YL; Ferraz, SL; Ferreira, CR; Figenshau, RS; Finn, AV; Fiseha, T; Fleischer, AS; Fogleman, AD; Fontaine, O; Ford, CR; Fouladvand, F; Four, M; Fousteri, G; Francis, JR; Fraser, JF; Frazier, RP; Fu, H; Fu, P; Fu, YJ; Fujishima, A; Fuster, V; Gabilan, JC; Gagliani, N; Gai, QY; Galán-Arriola, C; Gale, P; Galimova, GR; Galkin, A; Gallo, A; Gallo, AA; Gang, DD; Ganschow, S; Gao, C; Gao, F; Gao, GP; Gao, H; Gao, K; Gao, M; Gao, MY; Gao, P; Gao, R; Gao, S; Gao, WJ; Gao, Y; Garbacz, P; García Ruiz, L; Garcia, EM; Garofoli, F; Gasbarrini, A; Gattinoni, L; Gaudig, M; Gbureck, U; Ge, X; Genko, N; Gentile, GL; George, MW; Gerety, GF; Gestwicki, JE; Geusens, PP; Ghassemi, M; Giardina, JD; Giebultowicz, JM; Gifford, CA; Gijsen, FJH; Gilfillan, R; Gilson, E; Gingl, K; Giuliano, C; Glybochko, P; Goessler, W; Gofflot, S; Golab, J; Goldstein, A; Golebiowski, A; Gómez, L; Gómez-Carballo, J; Gonçalves, PEO; Gonzales, R; Gonzalez-Cotto, M; González-Fernández, D; Gonzalez-Lopez de Turiso, F; Goodman, JM; Govinda Raju, S; Grimm, J; Gross, AJ; Gruenheid, S; Gu, C; Gu, FF; Gu, S; Gu, Z; Guest, RL; Gui, C; Gui, J; Guillem, A; Guo, G; Guo, L; Guo, Q; Guo, S; Guo, SW; Guo, W; Guo, Y; Guo, YG; Guo, Z; Guretzky, JA; Haenggi, M; Hahn, MS; Hakkola, J; Halim, AA; Hampel, D; Han, B; Han, BH; Han, D; Han, G; Han, J; Han, LZ; Han, R; Han, S; Han, X; Han, Z; Handley, MA; Hanke, I; Hannongbua, S; Hao, P; Happ, JT; Hara, M; Haraux, F; Hare, JL; Harper, JD; Hartley, AM; Harvey, E; Hashimoto, K; Hassan, HM; Hautajärvi, H; Hayton, TW; He, C; He, H; He, HJ; He, WP; He, Y; He, Z; Hedrick, V; Heffernan, JK; Hegrová, J; Heidarimoghadam, R; Helms, K; Hengphasatporn, K; Henry, D; Herrmann, TRW; Hesson, T; Himmelbauer, MK; Hindle, A; Hoffmann, R; Hogg, N; Hong, KB; Hong, SK; Honjol, Y; Hood, C; Hsi, RS; Hsu, JL; Hu, B; Hu, BC; Hu, D; Hu, H; Hu, J; Hu, K; Hu, M; Hu, MK; Hu, T; Hu, W; Hu, Y; Hu, Z; Hua, S; Huang, H; Huang, J; Huang, L; Huang, M; Huang, P; Huang, X; Huang, Y; Huang, Z; Hukkanen, J; Hung, MC; Huo, X; Hyötyläinen, T; Ianiro, G; Ibanez, B; Imran, M; Ireland, S; Irwin, MS; Ishiguro, H; Jackowski, K; Jackson, C; Jacob, SI; Jahromy, MH; Jakob, SM; Jang, J; Javvaji, PK; Jefferson, KK; Jena, P; Ji, H; Jiang, F; Jiang, GH; Jiang, H; Jiang, J; Jiang, X; Jiang, Z; Jiao, J; Jiménez, A; Jin, X; Jincai, W; Jintao, X; Jo, K; Jofra, T; Johari, Y; Johnson, ACM; Jones, JH; Josephine Fauci, A; Juhl, AK; Jun, S; Kaiser, RI; Kajioka, J; Kajiyama, H; Kalliyil, A; Kalthur, SG; Kamalanathan, M; Kamaldinov, T; Kanaani, L; Kang, D; Kang, J; Kang, S; Känsäkoski, P; Kaplan, DL; Karwan, M; Kasibhatla, S; Kaur, A; Kawazoe, Y; Ke, C; Keyser, J; Khalique, A; Khan, IT; Kharshoum, RM; Kher, R; Kherani, J; Ki, KK; Kikkawa, F; Kikkawa, R; Kim, BT; Kim, EH; Kim, GA; Kim, GD; Kim, HB; Kim, HG; Kim, JS; Kim, MJ; Kim, SI; Kim, SJ; Kim, Y; King, K; Kinyamu-Akunda, J; Kirkkala, T; Kjaer-Sorensen, K; Kleppinger, EL; Kloner, RA; Klopfenstein, TJ; Knappe, D; Knezevic, P; Kobos, LM; Kohli, M; Kolano, L; Kolodgie, FD; Kolte, AP; Koneru, B; Kong, D; Kong, F; Kong, X; Konggidinata, MI; Köpke, M; Koski, KG; Kotsis, F; Köttgen, A; Kouakou-Kouamé, CA; Kraemer, US; Krane, V; Krehbiel, CR; Krenning, BJ; Kretzschmar, D; Ku, KB; Kubota, Y; Kulich, P; Kumar, NG; Kupiec-Weglinski, JW; Lalani, SS; Lan, X; Landfeldt, E; Langenberg, E; Lapauw, B; Larkin, J; Lassoued, MA; Laukhtina, E; Laura Martinez, J; Laveillé, A; Lavela, P; Law, AD; Lazraq, A; Le Foll, B; Lee, BK; Lee, C; Lee, CS; Lee, EJ; Lee, EY; Lee, G; Lee, HY; Lee, JH; Lee, JJ; Lee, JO; Lee, JS; Lee, R; Lei, H; Lei, P; Lellouche, F; Lennerz, JK; Leong, W; Leslie, I; Lessem, E; Levin, M; Levinger, I; Li, C; Li, CW; Li, CX; Li, CY; Li, D; Li, H; Li, HM; Li, J; Li, L; Li, LM; Li, N; Li, S; Li, W; Li, X; Li, XX; Li, Y; Li, Z; Li, ZL; Li, ZX; Lian, Q; Liang, C; Liang, GH; Liang, H; Liang, J; Liang, X; Liao, CX; Liao, R; Ličbinský, R; Lim, YS; Lima, HK; Lin, JG; Lin, L; Lin, S; Lin, WP; Lin, Z; Liso, M; Liu, BX; Liu, C; Liu, H; Liu, J; Liu, M; Liu, Q; Liu, S; Liu, SF; Liu, SL; Liu, T; Liu, W; Liu, X; Liu, XB; Liu, Y; Liu, YY; Liu, Z; Liu, ZQ; Lobo, M; Loitzenbauer, M; López, F; Lopez, G; López, GJ; Lou, Z; Lu, IC; Lu, J; Lu, M; Lu, W; Lu, X; Lu, Y; Luhovyy, BL; Luna-Abanto, J; Luo, J; Luo, K; Luo, L; Luo, M; Luo, W; Luo, X; Luo, XM; Lv, Y; Lv, YQ; Lyu, HD; Lyu, J; Ma, C; Ma, G; Ma, L; Ma, Q; Ma, X; Ma, Y; Macha, SJ; MacLean, E; Mahalapbutr, P; Maina, T; Malfait, F; Malfertheiner, MV; Malzert-Fréon, A; Mansouri, E; Mao, C; Marcellin, E; Marchiori, PER; Marcotte, DJ; Maréchal, A; Maric, N; Maris, JM; Maron, L; Marti, CN; Martínez-Milla, J; Mateo, J; Mather, K; Mathison, CJN; Matthay, MA; Maxwell, CL; Mazier, D; Mazumder, D; Mazurkiewicz, M; Mazzucchelli, TG; McAuley, DF; Mccoy, K; McVicar, DW; Mebel, AM; Mech, A; Meester, EJ; Meiselbach, H; Melero, I; Ménard, G; Meng, X; Mengya, Y; Merle, G; Meunier, B; Mfarrej, B; Mi, K; Migueliz, I; Mikuška, P; Miladi, K; Miletich, R; Millar, JE; Mills, MR; Milne, R; Minute, L; Misiak, M; Mo, F; Modi, A; Mok, F; Molina, C; Mollen, CJ; Molteni, V; Montalto, M; Montet, D; Monti, MC; Moor, MB; Moravec, P; Morsiani, C; Murillo, E; Murugan, P; Muslem, R; Myers, RK; N'guessan, FK; Nabil, H; Nadal, J; Nadeem, M; Nafady, MM; Nafie, MS; Nair, HP; Nakano, R; Nance, J; Naren, N; Neil, CJ; Nelson, J; Nery, FC; Netsch, C; Nguyen, TH; Ni, L; Ni, YX; Nie, W; Nielsen, LK; Nigam, K; Nikolayev, AA; Nishiyama, M; Niu, LL; Niu, PP; Nock, BA; Noer, PR; Noll, G; Noll, S; Norenberg, JP; Nowicka, J; Nutho, B; O'Connor, M; Obonyo, NG; Ochiai, T; Ochoa, MC; Oh, BL; Oh, S; Olczak, J; Olivares, X; Ommurugan, B; Oosthuizen, MC; Operario, D; Orešič, M; Oshima, K; Otano, I; Ou, Y; Owen, TW; Oxvig, C; Pacey, V; Pai, M; Paik, H; Paiva, R; Palmieri, EM; Palpant, N; Pan, L; Pan, Q; Panahi, S; Pang, B; Pang, ZC; Pannecouque, C; Paris, L; Park, D; Park, DJ; Park, E; Park, EC; Park, IH; Park, JH; Park, JI; Park, S; Passmore, MR; Pattaranggoon, NC; Paun, M; Pedersen, S; Pedron, J; Peng, M; Peng, X; Penzhorn, BL; Pérez-Camargo, D; Perez-Maldonado, R; Pérez-Vicente, C; Pham, TD; Pickering, L; Pickersgill, NA; Pinault, E; Pinotsis, N; Plan, M; Pocino, K; Poh, CL; Pons, EDC; Popoff, MR; Porri, D; Pourmand, A; Pratviel, G; Prudente, DO; Qi, H; Qi, N; Qian, LY; Qiao, L; Qiao, Q; Qin, QP; Qiu, N; Qiu, SW; Qu, F; Quan, M; Quigg, A; Raee, E; Raibaud, P; Ramanitrahasimbola, D; Rapoport, L; Rasby, RJ; Rasoanirina, BNV; Raspini, B; Ratner, JR; Razafindrakoto, Z; Redd, MA; Ren, H; Ren, N; Rey, J; Reynolds, CP; Rich, PR; Richards, CJ; Rigol, M; Rimoldi, S; Robert, P; Rodrigues, AE; Roe, JH; Rohde, S; Rokita, JL; Roland, J; Rombaut, L; Ronkainen, J; Rothenberg, SM; Roy, SC; Ruan, Z; Rucker, PV; Rueda, D; Ruhwald, M; Rungrotmongkol, T; Rupert, AS; Rusjan, P; Ryabov, AD; Rysä, J; Saad, NES; Sabioni, P; Sadow, PM; Sahai, N; Salem, HF; Salinas, B; Salonurmi, T; Samé Guerra, D; Sánchez, J; Sanchez-González, J; Sanmamed, MF; Sansores-Peraza, P; Santoro, JC; Santschi, PH; Saritas, T; Sarkisova, Y; Savolainen, MJ; Scherberich, JE; Schlom, DG; Schmelz, EM; Schmid, MC; Schneider, MP; Schumacher, S; Schwartz, JC; Schwartzer, JJ; Schwehr, K; Schweitzer, DH; Scott, ME; Sedky, NK; See Hoe, L; Sejian, V; Selvaraju, S; Sen, SK; Seo, G; Šerý, O; Settles, JA; Sfar, S; Shaffer, J; Shan, GL; Shang, Q; Shannahan, JH; Shao, B; Shao, H; Shao, J; Shao, ZH; Shasha, Y; Shaw, K; Sheeba, V; Shekar, K; Shen, G; Shen, H; Shen, XD; Shen, Y; Sherrell, PC; Shete, PB; Shi, AX; Shi, J; Shi, JH; Shi, S; Shi, X; Shigeta, Y; Shimbo, A; Shin, E; Sikka, N; Silhavy, TJ; Simanon, N; Simard, S; Simon, J; Simon, M; Simpson, SD; Simundic, AM; Since, M; Singh, B; Singhroy, DN; Sinisterra, OT; Smith, EH; Sobreira, TJP; Solanes, N; Somasundar, Y; Sommerer, C; Sonei, A; Song, B; Song, E; Song, J; Song, M; Song, Y; Soo Lee, M; Sorensen, MD; Sournia-Saquet, A; Spaepen, E; Spirk, D; Srivastava, S; Stancill, JS; Stanczak, PS; Starenki, D; Starr, F; Step, DL; Steubl, D; Stigliani, JL; Stráská, J; Sträter, N; Su, ZZ; Sudano, I; Suen, JY; Suh, HJ; Sui, ZY; Suico, JG; Suleiman, K; Sumon, K; Sun, HB; Sun, J; Sun, L; Sun, LL; Sun, M; Sun, Q; Sun, W; Sun, X; Sun, XF; Sun, Y; Sun, YB; Sun, YH; Sun, YN; Sun, Z; Sunada, K; Suzuki, S; Sylvan, JB; Takala, J; Talla, D; Tamir, Z; Tan, SJ; Tanda, S; Tang, H; Tang, J; Tang, LF; Tang, SJ; Tang, Y; Tao, FB; Tappel, R; Taratkin, M; Teijeira, Á; Tellew, JE; Thomas, AM; Thomas, SG; Thomson, SR; Tian, J; Tie, Y; Tirado, JL; Tolonen, A; Tosato, G; Tronnet, A; Tsai, S; Turtoi, A; Turtoi, E; Tvrdoňová, M; Tyagi, A; Tzou, DT; Uddin Ahmad, Z; Urias, E; Usawachintachit, M; Ustriyana, P; Utsumi, F; Vacca, M; Vaculovič, T; Vaidya, SS; Valentin, A; Valgepea, K; van den Berg, P; van den Bergh, JP; van der Heiden, K; van Gaalen, K; Van Gemert, W; van Haard, PMM; van Hest, JCM; Vecchiarelli, E; Večeřa, Z; Venkatesh, R; Verhaeghe, P; Verhagen, HJ; Vetter, JM; Vieira, D; Vilchez-Tschischke, JP; Villena-Gutierrez, R; Villoslada Terrones, V; Vital-Jacome, M; Voelkl, J; Vogel, K; Vogrin, S; Volke, D; von Bahr, V; Vysloužil, J; Wade, TL; Wagner-Gillespie, M; Walsh, SW; Wan, LJ; Wan, SP; Wang, AL; Wang, B; Wang, BY; Wang, C; Wang, D; Wang, F; Wang, H; Wang, HR; Wang, HY; Wang, J; Wang, JY; Wang, K; Wang, L; Wang, LF; Wang, P; Wang, Q; Wang, R; Wang, SF; Wang, SP; Wang, SR; Wang, T; Wang, W; Wang, WP; Wang, X; Wang, XJ; Wang, Y; Wang, YL; Wang, YN; Wáng, YXJ; Wang, Z; Wang, ZF; Wang, ZY; Waning, B; Warner, JM; Washington, SL; Watson, AK; Wei, B; Wei, C; Wei, F; Wei, X; Wei, Y; Wemhoff, AP; Wen, Z; Weng, TT; Wesdemiotis, C; Wheeler, DA; Wildner, M; Wilson, BK; Wirth, LJ; Wissler, M; Wu, F; Wu, G; Wu, J; Wu, KH; Wu, MC; Wu, P; Wu, PK; Wu, S; Wu, W; Wu, X; Wu, XP; Wu, Y; Wyatt, E; Wyllie, S; Xia, Y; Xiao, BH; Xiao, SZ; Xiao, W; Xiao, X; Xiao, Z; Xie, D; Xie, K; Xie, X; Xie, Y; Xie, YF; Xin, S; Xin, Z; Xing, Q; Xing, WQ; Xiong, D; Xiong, X; Xu, C; Xu, D; Xu, F; Xu, G; Xu, H; Xu, J; Xu, JY; Xu, L; Xu, N; Xu, W; Xu, X; Xu, Y; Xu, YM; Xue, H; Xue, J; Xue, Z; Yan, R; Yan, SQ; Yan, W; Yan, X; Yan, Z; Yang, C; Yang, D; Yang, F; Yang, FC; Yang, G; Yang, J; Yang, M; Yang, P; Yang, Q; Yang, R; Yang, S; Yang, SJ; Yang, TWW; Yang, X; Yang, Y; Yang, Z; Yao, C; Yao, L; Yao, LP; Yao, M; Yao, T; Yao, W; Yao, Y; Yaseen, T; Yazdani, V; Ye, J; Ye, S; Yerys, BE; Yi, HWL; Yi, JL; Yin, F; Yin, J; Yin, Y; Yin, Z; Yong, ZP; Yongli, S; Yoo, JS; Yoshikawa, N; You, Q; Yu, B; Yu, CQ; Yu, H; Yu, HG; Yu, J; Yu, L; Yu, Q; Yu, X; Yu, Y; Yu, YK; Yu, Z; Yuan, Q; Yuan, R; Yuan, W; Yuan, X; Yuan, Y; Zager, RA; Zagozdzon, A; Zaller, N; Zang, YP; Zappi, ME; Zelikoff, JT; Zeman, T; Zhai, X; Zhan, P; Zhang, B; Zhang, C; Zhang, G; Zhang, H; Zhang, HB; Zhang, J; Zhang, JS; Zhang, L; Zhang, M; Zhang, Q; Zhang, RX; Zhang, S; Zhang, T; Zhang, W; Zhang, WH; Zhang, X; Zhang, XX; Zhang, Y; Zhang, YQ; Zhang, YW; Zhang, Z; Zhang, ZH; Zhao, D; Zhao, FL; Zhao, K; Zhao, L; Zhao, M; Zhao, R; Zhao, S; Zhao, W; Zhao, WG; Zhao, X; Zhao, Y; Zheng, G; Zheng, J; Zheng, S; Zheng, W; Zheng, Y; Zheng, YG; Zhong, Z; Zhou, C; Zhou, D; Zhou, H; Zhou, HY; Zhou, L; Zhou, Q; Zhou, X; Zhou, Y; Zhou, YL; Zhou, Z; Zhu, J; Zhu, L; Zhu, N; Zhu, X; Zhu, XF; Zhu, Y; Zhu, Z | 1 |
| Endo, I; Kumamoto, T; Matsuyama, R; Murakami, T; Sawada, Y; Tsuchiya, N; Yabushita, Y | 1 |
| Alfaro, F; Bizama, C; Boekstegers, F; Cerda-Infante, J; Dávila-López, M; Espinoza, JA; García, P; Kato, S; Lagos, M; Leal, P; Leiva-Acevedo, C; Lorenzo-Bermejo, J; Montecinos, VP; Parra, Z; Roa, JC; Romero, D; Rosa, L; Sánchez, M; Weber, H | 1 |
| Bäsecke, J; Schoel, G; Schrader, J | 1 |
| Fanchon, LM; Gangangari, K; Humm, JL; O'Donoghue, I; Pillarsetty, N; Russell, J; Yu, KH | 1 |
| Buczkowski, A; Gorzkiewicz, M; Ionov, M; Klajnert-Maculewicz, B; Malinowska-Michalak, M; Palecz, B; Stepniak, A; Tokarz, P; Urbaniak, P | 1 |
| Farzad, F; Hashemzadeh, H | 1 |
| Blasi, M; Bozorgmehr, F; Hommertgen, A; Kieser, M; Krisam, J; Kuon, J; Lasitschka, F; Maenz, M; Schneider, M; Stenzinger, A; Thomas, M | 1 |
| Bonadio, R; da Costa, S; de Bock, GH; Del Pilar Estevez Diz, M; Dornellas, A; Nunes de Arruda, F; Pereira, D | 1 |
| Cheng, Q; Feng, F; Han, M; Jiang, X; Li, B; Li, F; Li, JY; Li, Z; Liu, C; Qin, H; Qiu, Z; Xiong, L; Xu, C; Yi, B; Yu, Y; Zhang, D | 1 |
| Bottinor, W; Das, S; Nunnery, S | 1 |
| Peard, L; Saltzman, AF; Stark, T; Ziada, A | 1 |
| Birtle, A; Casbard, A; Chester, J; Crabb, S; Elliott, T; Evans, L; Griffiths, G; Huang, C; Huddart, R; Jagdev, S; Jones, R; Lester, J; Madden, TA | 1 |
| Anthoney, A; Arif, S; Basu, B; Bax, L; Brais, R; Bridgewater, J; Bundi, P; Chhabra, A; Corrie, PG; Cummins, S; Dalchau, K; Dayim, A; Ellis, R; Evans, J; Falk, S; Gillmore, R; Gopinathan, A; Isherwood, C; Jodrell, DI; Lwuji, C; Ma, YT; Machin, A; McAdam, K; Neesse, A; Palmer, D; Propper, D; Qian, W; Scott-Brown, M; Skells, R; Tuveson, D; Valle, JW; Wadsley, J; Wall, L; Wasan, H | 1 |
| Heneghan, M; Kitagawa, M; Prachalias, A; Srinivasan, P; Suzuki, K; Zen, Y | 1 |
| Ichedef, C; Karatay, KB; Teksöz, S; Yilmaz, S | 1 |
| Arora, S; Carter, JE; Gorman, GS; Khan, MA; Khushman, M; Patel, GK; Singh, AP; Singh, S; Srivastava, SK; Zubair, H | 1 |
| Barone, D; Bekaii-Saab, T; Flaherty, KT; Krause, S; Mahalingam, D; O'Reilly, EM; Richards, DA; Roach, JM; Rosano, M; Ryan, DP; Shao, SH; Wolf, J; Yu, KH | 1 |
| Li, C; Luo, S; Shi, M; Wang, J; Xu, M; Zang, J; Zhao, L | 1 |
| Jin, Y; Li, S; Li, Y; Ma, Z; Sun, R; Yan, H; Zhao, K; Zhao, W | 1 |
| Chen, SY; Hsu, YH; Lin, JA; Wang, SY; Yen, GC | 1 |
| Dwarkasing, RS; Eskens, FALM; Groot Koerkamp, B; Homs, MYV; Nuyttens, JJ; Suker, M; van Eijck, CHJ | 1 |
| Bhutia, YD; Cai, A; Chen, R; Chen, Z; Ganapathy, V; Kou, L; Li, C; Lin, X; Yao, Q; Zheng, H | 1 |
| Fujita, M; Harada, T; Ichiki, M; Inoue, K; Shiraishi, Y; Sugio, K; Takayama, K; Takeshita, M; Tokunaga, S; Uchino, J; Wataya, H; Yamada, T | 1 |
| Enokida, H; Kuroshima, K; Nakagawa, M; Nohata, N; Osako, Y; Sugita, S; Tatarano, S; Tsuruda, M; Yonemori, M; Yoshino, H | 1 |
| Donnell, R; Hong, T; Hu, Y; Pattarawat, P; Tsai, CL; Wallace, S; Wang, HR; Wang, J; Wang, TH | 1 |
| Esim, O; Ozkan, CK; Ozkan, Y; Sarper, M; Savaser, A | 1 |
| Cai, H; Cao, X; Chen, M; Feng, J; Mao, Y; Wang, W; Wei, C; Yang, C; Zhang, L; Zhang, W; Zhang, Y; Zhou, D | 1 |
| Foroughi, J; Kim, SC; Shim, IK; Spinks, GM; Talebian, S; Vine, KL | 1 |
| Fazio, N | 1 |
| Kelsen, DP; O'Reilly, EM; Park, W | 1 |
| Tang, J; Zhao, J; Zheng, F | 1 |
| Chang, JW; Chen, JS; Chou, WC; Hsieh, CH; Lin, CY; Wu, CE; Yeh, CN | 1 |
| Abushahin, L; Alexandra Diaz, D; Chen, W; Cloyd, JM; Dillhoff, M; Frankel, WL; Miller, ED; Noonan, A; Prabhakar, D; Williams, TM; Wolfe, AR; Yildiz, VO | 1 |
| Björn, N; Gréen, H; Jakobsen, I; Lotfi, K | 1 |
| Ahn, HM; Kim, DG; Kim, YJ | 1 |
| Chu, JJH; Inoue, M; Kaur, P; Lee, RCH; Sun, J; Tan, YW; Yogarajah, T | 1 |
| Aceti, M; Bayle, S; Duckett, D; Frydman, SM; Grant, W; McDonald, P; Monastyrskyi, A; Nieto, A; Quereda, V; Roush, WR; Sansil, SS; Teng, M; Vena, F | 1 |
| Deng, CL; Li, XD; Wang, Z; Wei, HP; Xiao, SQ; Xiong, J; Yang, XL; Ye, HQ; Yuan, ZM; Zhang, B; Zhang, QY; Zhang, YN; Zhang, ZR | 1 |
| Abdelrahman, A; Arora, M; Barrett, MT; Bogenberger, JM; Borad, MJ; Braggio, E; Chen, X; Egan, JB; Kasimsetty, A; Kosiorek, HE; Leiting, JL; Lenkiewicz, E; Malasi, S; Nagalo, BM; Salomao, MA; Truty, MJ; Uson, PLS; Zhou, Y | 1 |
| Chen, L; Hu, C; Li, G; Liang, Z; Wang, Y; Yu, T; Zhuang, W | 1 |
| Ajmal, M; Bhatti, MH; Chaudhry, GE; Muhammad, TST; Sung, YY; Yunus, U; Zulfiqar, MA | 1 |
| Feng, Y; Wang, L; Wu, Y; Zhang, Y; Zhou, Y | 1 |
| André, T; Bekaii-Saab, T; Bridgewater, J; Cunningham, D; Goldstein, D; Jensen, LH; Knox, JJ; Koeberle, D; Lopes, A; Malka, D; McNamara, MG; Moehler, M; Okusaka, T; Shannon, J; Valle, JW; Wagner, AD; Wasan, H | 1 |
| Hayama, T; Hiraki, R; Miyata, Y; Nakamura, N; Nakashima, M; Nakashima, MN; Ohyama, K; Sakai, H; Wang, M; Yasuda, T | 1 |
| Fujimoto, D; Goi, T; Iida, A; Ishida, M; Kimura, T; Sato, Y; Togawa, T | 1 |
| Andrade, CF; Figueiró, F; Filippi-Chiela, E; Gonzalez, EA; Klamt, F; Nunes, V; Pilar, ES; Solari, JIG | 1 |
| Chen, ZN; Jiang, JL; Liu, Z; Tang, J; Yang, H; Zheng, M; Zhou, Y; Zhu, P | 1 |
| Cheng, L; Liu, L; Sun, YJ | 1 |
| Gontero, P; Soria, F | 1 |
| Borbath, I; Delaunoit, T; Demols, A; Goemine, JC; Holbrechts, S; Houbiers, G; Laurent, S; Marechal, R; Paesmans, M; Peeters, M; Van den Eynde, M; Van Laethem, JL | 1 |
| Cho, DH; Kim, KM; Lee, DH; Lee, NR; Yim, CY | 1 |
| Kim, JH; Lee, J | 1 |
| Arima, K; Kanda, H; Kato, M; Kitano, G; Masui, S; Nishikawa, K; Nishikawa, T; Owa, S; Sasaki, T; Sugimura, Y; Sugino, Y; Uchida, K; Yoshio, Y | 1 |
| Bijvelds, MJ; Chen, S; de Jonge, HR; Kainov, DE; Li, P; Pan, Q; Peppelenbosch, MP; Wang, Y; Yin, Y | 1 |
| Ando, R; Etani, T; Hamamoto, S; Iida, K; Kawai, N; Nagai, T; Naiki, T; Nozaki, S; Sugiyama, Y; Tasaki, Y; Yasui, T | 1 |
| Arentsen-Peters, STCJM; Castro, PG; Cheung, LC; Chua, GA; Dolman, MEM; Jones, L; Kerstjens, M; Koopmans, B; Kotecha, RS; Molenaar, JJ; Pieters, R; Pinhanҫos, SS; Schneider, P; Singh, S; Stam, RW; Wander, P; Zwaan, CM | 1 |
| Abdul-Rahim, O; Khushman, M; Phung, T; Surinach, A | 1 |
| Assaraf, YG; Avan, A; Braczko, A; Cascioferro, S; Cloos, J; Deraco, M; Diana, P; El Hassouni, B; Funel, N; Giovannetti, E; Granchi, C; Jansen, G; Lagerweij, T; Li Petri, G; Mantini, G; Matherly, LH; Minutolo, F; Parrino, B; Peters, GJ; Sciarrillo, R; Smid, K; Smolenski, RT; Zaffaroni, N; Zeeuw van der Laan, EA; Zucali, PA | 1 |
| Buyuksimsek, M; Kidi, MM; Ogul, A | 1 |
| Chen, D; Chen, J; Hao, Q; Huag, Y; Jiang, L; Kong, Y; Li, W; Liu, R; Lu, Y; Tang, Y; Tao, W; Yang, X; Yu, H; Zhang, H; Zhang, Y; Zhu, X; Zou, H | 1 |
| Bartoli, L; Messori, A; Trippoli, S | 1 |
| Cao, Z; de Vere White, R; Guo, J; Lin, TY; Long, Q; Ma, AH; Pan, CX; Sonpavde, GP; Xia, R; Zhang, H | 1 |
| Borsellino, N; Cipolla, C; Galanti, D; Gebbia, V; Pardo, S; Serretta, V; Valerio, MR; Vecchia, M | 1 |
| Huang, Q; Qin, G; Tang, T; Ye, W | 1 |
| Ahmad, SA; Bogdanov, VY; Chu, Z; Davis, HW; Franco, RS; Lewis, CS; N'Guessan, KF; Olowokure, O; Qi, X; Vallabhapurapu, SD; Yeh, JJ | 1 |
| Chen, S; Chen, Y; Huang, K; Li, X; Lian, G; Tan, Y; Tian, Z; Zou, J | 1 |
| Beardmore, R; Boeckemeier, L; Chaplin, D; Gasasira, MU; Gollins, S; Hartsuiker, E; Keszthelyi, A; Kraehenbuehl, R; Krokan, HE; Lambert, SAE; Paizs, B; Vågbø, CB; Vernon, EG | 1 |
| Luttke, M; Marschner, S; Späth, R; Walter, F | 1 |
| Courcelle, M; Djaker, N; Palama, T; Sahli, F; Savarin, P; Spadavecchia, J | 1 |
| Cui, Y; Huang, P; Ji, D; Kang, P; Leng, K; Wang, Z; Xu, Y; Zheng, W; Zhong, X | 1 |
| Blagden, SP; Kapacee, ZA; Knox, JJ; Lamarca, A; McNamara, MG; Palmer, D; Valle, JW | 1 |
| Bodea, R; Mercea, V; Nemes, A; Vidra, R | 1 |
| Bazan, D; Cavaliere, A; Deiana, M; Fedele, V; Lonardi, S; Mangiameli, D; Melisi, D; Merz, V; Piro, G; Sabbadini, F; Santoro, R; Simionato, F; Valenti, MT; Zecchetto, C | 1 |
| Babu, S; Biankin, AV; Chang, DK; Escobar-Hoyos, LF; K Bai, JD; Kawalerski, RR; Leiton, CV; Otsuka, Y; Pan, CH; Scampavia, L; Shroyer, KR; Spicer, T; Sridharan, B; Torrente Gonçalves, M; Woo, M | 1 |
| Liu, JM; Wang, WJ; Ye, CY; Zhao, FC | 1 |
| Chen, L; Hu, C; Li, G; Liang, Z; Su, X; Wang, Y; Yu, T; Zhuang, W | 1 |
| Alsyouf, M; Groegler, J; Hu, B; Pierorazio, P | 1 |
| Bachet, JB; Mas, L; Schwarz, L | 1 |
| Akhoundova Sanoyan, D; Lamarca, A; McNamara, MG; Valle, JW | 1 |
| Aly, A; Botteman, M; Chiorean, EG; Goldstein, D; Lee, CK; Louis, CU; Lu, B; Margunato-Debay, S; McGovern, D; Ramanathan, RK; Reni, M; Tabernero, J; Von Hoff, DD | 1 |
| Bean, PA; Bulanadi, JC; de Campo, L; Gong, X; Julovi, SM; Moghaddam, MJ; Smith, RC; Xue, A | 1 |
| Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K | 1 |
| Kasi, A; Paluri, RK; Posey, JA; Young, C | 1 |
| Casey, PJ; Chai, TF; Manu, KA; Wang, M | 1 |
| Asukai, K; Hara, H; Haraguchi, N; Hasegawa, S; Ishikawa, O; Miyata, H; Nishimura, J; Ohue, M; Omori, T; Sakon, M; Shinno, N; Sugimura, K; Takahashi, H; Ushigome, H; Wada, H; Yamada, D; Yamamoto, K; Yano, M; Yasui, M | 1 |
| Akie, K; Amano, T; Dosaka-Akita, H; Fujita, Y; Fuke, S; Fukumoto, SI; Harada, M; Harada, T; Isobe, H; Ito, K; Kinoshita, I; Nakano, K; Nishigaki, Y; Nishimura, M; Oizumi, S; Sakakibara-Konishi, J; Sukoh, N; Takamura, K | 1 |
| Chen, HB; Gu, DN; Jiang, MJ; Mei, Z; Ye, ZQ; Zou, CL | 1 |
| Lamarca, A; Valle, JW | 1 |
| Du, B; Lai, J; Lin, M; Wang, Y; Wen, X | 1 |
| Bao, M; Das, M; Huang, L; Li, J | 1 |
| Li, PC; Lin, GH; Wang, BC; Xiao, BY | 1 |
| Ibusuki, M; Inoue, T; Ito, K; Kimoto, S; Kitano, R; Kobayashi, Y; Nakade, Y; Ohashi, T; Sakamoto, K; Sumida, Y; Yoneda, M | 2 |
| Cai, Y; Yao, D; Zheng, Q; Zhou, T | 1 |
| Búzová, D; Červený, J; Culig, Z; Drápela, S; Fedr, R; Hampl, A; Khirsariya, P; Krejčí, L; Paruch, K; Puhr, M; Souček, K; Suchánková, T; van Weerden, WM; Watson, WR | 1 |
| Bullock, A; Chiorean, EG; Oestreicher, N; Rowan, CG; Yeganegi, H | 1 |
| Cai, R; Chen, S; Chen, X; Chen, Y; Fan, Y; Guan, Y; Lan, B; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Zhang, P; Zhao, W | 1 |
| Chen, M; Goodin, S; Li, D; Liu, W; Ma, Y; Sheng, Z; Wang, X; Wu, P; Xu, X; Zhang, K; Zheng, X; Zhou, R | 1 |
| Balourdas, DI; Berger, BT; Cheung, PF; Hahn, SA; Hamdan, FH; Joerger, AC; Johnsen, SA; Knapp, S; Ladigan, S; Liffers, ST; Lucas, R; Scheffler, B; Siveke, JT; Trajkovic-Arsic, M; Weiser, T; Zegar, T; Zhang, X | 1 |
| Shi, J; Smith, DE; Thompson, BR; Zhu, HJ | 1 |
| Fukushima, T; Gomi, D; Hara, H; Kobayashi, T; Koizumi, T; Noguchi, T; Ozawa, T; Sekiguchi, N | 1 |
| Ichikura, D; Ichimura, T; Kawashima, W; Minemura, A; Murakami, K; Nawata, S; Sasaki, T; Usuda, M | 1 |
| Chen, R; Chen, Y; Feng, H; Fung, FKC; Li, CH; Li, G; To, KF; Tong, JH; Wong, CH; Xia, T; Zhu, YX | 1 |
| Hsiao, CY; Huang, KW; Li, X; Yang, PC | 1 |
| Capacio, BA; Carr, MJ; Chai, LF; Cox, BF; Erdem, S; Jaroch, DB; Katz, SC; Ray, P; Shankara Narayanan, JS; Vicente, DA; White, RR | 1 |
| Brunn, M; Frost, N; Grohé, C; Klauschen, F; Ochsenreither, S; Raspe, M; Ruwwe-Glösenkamp, C; Suttorp, N; Temmesfeld-Wollbrück, B; von Laffert, M; Witzenrath, M; Zhamurashvili, T | 1 |
| Begg, SKS; Birnbaum, DJ; Castillo, CF; Clark, JW; Lillemoe, KD; Liss, AS; Mino-Kenudson, M; Schilling, O; Warshaw, AL; Wellner, UF | 1 |
| Akagi, N; Burns, ST; Damon, L; Ko, AH; Laszik, Z | 1 |
| Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J | 1 |
| Kumar, T; Pandey, M; Soni, K | 1 |
| Bachet, JB; Bouhier Leporrier, K; Coriat, R; Gouttebel, MC; Gratet, A; Khemissa Akouz, F; Laharie, H; Le Malicot, K; Lepage, C; Louafi, S; Malka, D; Miglianico, L; Pointet, AL; Rinaldi, Y; Taieb, J; Terrebonne, E; Texereau, P; Thirot Bidault, A; Wahiba, B | 1 |
| Chen, Y; Di, YS; He, L; Lam, LM; Liang, ST; Liao, Y; Tsang, YS; Xia, Q | 1 |
| Jin, J; Zhang, Y; Zheng, T; Zhou, L | 1 |
| Eguchi, H; Goda, K; Hashimoto, Y; Ikeda, M; Imaoka, H; Kan, M; Kimura, G; Mitsunaga, S; Ohno, I; Otsuru, T; Sasaki, M; Suzuki, Y; Takahashi, H; Umemoto, K; Watanabe, K | 1 |
| Albino, V; Granata, V; Izzo, F; Palaia, R; Petrillo, A; Piccirillo, M; Venanzio Setola, S | 1 |
| Fujiwara, M; Fukui, I; Hayashi, T; Komai, Y; Kouno, T; Numao, N; Takeda, H; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
| Cao, D; Cheng, K; Guo, F; Li, J; Li, S; Li, X; Peng, Y; Shui, L; Shui, P; Yi, C | 1 |
| Abolmaali, N; Baumann, M; Blum, S; Distler, M; Folprecht, G; Grützmann, R; Jentsch, C; Polster, H; Saeger, HD; Troost, EGC; Weitz, J; Zimmermann, C; Zöphel, K | 1 |
| Moir, JAG; Severs, GR; Tingle, SJ; White, SA | 1 |
| Bendell, J; Feeney, K; Gracián, AC; Hecht, JR; Hung, A; Lee, MA; Lin, Y; Lonardi, S; Muñoz, A; Ryoo, BY; Wainberg, ZA | 1 |
| Li, H; Meng, R; Rui, M; Shang, Y; Shi, F | 1 |
| Berjon, A; Brenes, J; Casado, G; Castelo, B; Espinosa, E; Feliu, J; Gallego, A; Hardisson, D; Hernandez, A; Mendiola, M; Ramon-Patino, J; Redondo, A | 1 |
| Fan, YZ; Li, XP; Pan, MS; Sun, W; Wang, FT; Wang, H; Wang, QW | 1 |
| Boggio, V; Catrinacio, C; Gonzalez, CD; Orquera, T; Renna, FJ; Ropolo, A; Vaccaro, MI | 1 |
| Evans, DB | 1 |
| Ahmad, S; Barrord, M; Choe, K; Esslinger, H; Kharofa, J; Latif, T; Olowokure, O; Patel, S; Poreddy, S; Smith, M; Sussman, J | 1 |
| Chen, K; Ding, Y; Dong, Z; Gao, K; Li, R; Li, W; Li, Y; Ma, X; Song, J; Wang, Y; Wang, Z; Yang, X | 1 |
| Daniele, MA; Menegatti, S; Schneible, JD; Young, AT | 1 |
| Dalgleish, AG; Kasow, S; Samad, M; Smith, PL; Yogaratnam, Y | 1 |
| Li, J; Liu, TT; Xu, BW; Zhu, GH | 1 |
| Hines, OJ; Ye, L | 1 |
| Fogelman, D; Herman, J; Ikoma, N; Javle, M; Katz, MHG; Kim, M; Koay, EJ; Lee, JE; Overman, M; Pant, S; Perri, G; Prakash, L; Qiao, W; Tzeng, CW; Varadhachary, GR; Wolff, R | 1 |
| Fujimiya, T; Kurihara, T; Nagatani, A; Ogawa, Y; Sasaki, H; Sasaki, T; Sunaga, T; Takahashi, N; Watanabe, T; Yamagishi, M | 1 |
| Anani, M; Attia, F; Elazab, M; Fathy, S; Hassan, A; Ibrahim, G | 1 |
| Iede, K; Ikenaga, M; Kato, R; Matsuyama, J; Nakashima, S; Ohta, K; Tominaga, S; Tsuda, Y; Ueda, M; Yamada, T | 3 |
| Gui, W; Han, Q; Li, W; Liu, C; Liu, H; Yang, X; Zhu, C | 1 |
| Du, J; Gu, J; Li, J | 1 |
| Bhutiani, N; Chen, Y; Li, Y; Martin, RCG; Pandit, H; Pulliam, ZR; Shi, X; Tan, M; Yu, Y; Zheng, Q | 1 |
| Chen, C; Chen, X; Kuang, Y; Lei, L; Li, J; Liu, P; Peng, C; Tan, L; Zhu, W | 1 |
| Astsaturov, I; Brachmann, RK; Cardin, DB; Cohen, SJ; Denlinger, CS; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, W; O'Neil, B; Shahda, S; Stagg, RJ; Uttamsingh, S; Weekes, C | 1 |
| Ahmed, AA; Marchetti, C; Neidle, S; Ohnmacht, SA | 1 |
| Cordelier, P; Lumeau, A | 1 |
| Cao, J; Chen, J; Diao, F; Huang, P; Qiu, F | 1 |
| Arshad, A; Dennison, AR; Isherwood, JD; Jones, DJL; Ng, LL; Runau, F; Sandhu, JK | 1 |
| Chan, W; Chu, SKP; Lee, KCE; Mui, WH; Wong, CSF | 1 |
| Han, Y; Ma, J; Qian, J; Shi, Y; Wang, Y; Yan, X; Yao, N | 1 |
| Cheng, J; Feldman, R; Fuks, Z; Fuller, J; Kolesnick, R; Owa, T; Tap, W | 1 |
| Li, P; Tian, Z; Wang, J; Wang, X; Yang, J; Yao, W; Zhang, F; Zhang, P | 1 |
| Ali, DW; Chen, XZ; Dong, X; Huang, Y; Michalak, M; Qin, W; Tang, J; Wei, J; Yan, Y; Yi, C; Yi, Y; Zhang, R; Zhang, X; Zhou, C | 1 |
| Bao, C; Cai, S; Chen, Q; Kong, J; Liu, S; Lu, H; Luo, J; Xie, X | 1 |
| Ceyhan, GO; Damm, M; Kordes, M; Maggino, L; Moir, J; Rosendahl, J; Schorn, S; Weniger, M | 2 |
| Ahmad, SA; Beg, MS; Chiorean, EG; Duong, M; Gandhi, NS; Guthrie, KA; Hochster, HS; Lowy, AM; Philip, PA; Sohal, DPS; Wade, JL; Wang-Gillam, A | 1 |
| Jin, CR; Xuan, YZ; Yang, KJ | 1 |
| Bernaldo de Quirós Fernández, S; Cadogan, EB; Dunlop, CR; Durant, ST; Jodrell, DI; Johnson, TI; Lau, A; Richards, FM; Wallez, Y | 1 |
| Chen, WP; Huang, YM; Li, SL; Lu, L; Qi, CH; Qiao, SQ | 1 |
| Fu, J; McGrath, NA; Monge Bonilla, C; Xie, C | 1 |
| Andrikou, K; Bernardini, L; Casadei-Gardini, A; Catanese, S; Falcone, A; Formica, V; Fornaro, L; Lencioni, M; Massa, V; Pecora, I; Rapposelli, GI; Riggi, L; Rovesti, G; Salani, F; Vasile, E; Vivaldi, C | 1 |
| Carpenter, ES; Pasca di Magliano, M; Steele, NG | 1 |
| Lam, LL; Levingston, R; O'Neill, RS; Solanki, P; Thomas, D | 1 |
| Dash, AK; Deodhar, S; Hulce, M; North, EJ | 1 |
| Chie, EK; Jang, JY; Kim, BH; Kim, H; Kim, K; Kwon, W; Lee, KB; Lee, KH; Oh, DY | 1 |
| Huang, G; Huang, J; Liu, Y; Xue, C; Zhang, Z | 1 |
| Chauhan, SC; Hatami, E; Jaggi, M; Nagesh, PKB; Yallapu, MM | 1 |
| Amini, M; Arefian, E; Atyabi, F; Dinarvand, R; Norouzi, P; Seyedjafari, E | 1 |
| Chatterjee, D; Hauser, R; Kaufman, PA; Kazmi, S; Raju, D | 1 |
| Bendell, J; Berlin, J; Bhargava, P; Brachmann, CB; Chaves, J; Gordon, M; Khan, SA; Liu, J; Patel, MR; Shah, MA; Sharma, S; Starodub, A; Thai, D; Wainberg, ZA; Windsor, KS; Zavodovskaya, M | 1 |
| Agarwal, C; Agarwal, R; Bagby, SM; Dhar, D; Kumar, D; Messersmith, WA; Orlicky, DJ; Pitts, TM; Raina, K; Wempe, MF | 1 |
| Chan, GHJ; Chong, SM; Chong, WQ; Goh, BC; Goh, RM; Ho, FCH; Huang, Y; Jeyasekharan, AD; Kong, LR; Kumarakulasinghe, NB; Lau, JA; Lee, SC; Lim, CM; Lim, YC; Loh, KS; Loh, WS; Sinha, AK; Soo, RA; Soon, YY; Sundar, R; Tai, BC; Tan, CS; Tay, JK; Wang, L; Wong, AL; Yadav, K | 1 |
| Alseidi, A; Carney, M; Carrier, E; Glaspy, J; Kouchakji, E; Larson, T; Matrana, M; Mody, K; Picozzi, V; Pishvaian, M; Porter, S; Rocha, F; Winter, J | 1 |
| He, L; Huang, X; Li, Y; Lou, Y; Wang, L; Yang, H; Zhang, Y | 1 |
| Chan Chae, Y; Jang, DK; Kim, YT; Lee, JK; Lee, SH; Lee, YG; Paik, WH; Ryu, JK | 1 |
| Bai, Z; Cheng, X; Hu, M; Huang, H; Kang, G; Li, R; Wang, J; Yang, D | 1 |
| Bullock, TNJ; Price, RJ; Sheybani, ND; Thim, EA; Witter, AR; Yagita, H | 1 |
| Cui, C; Feng, Y; Hao, C; Kong, D; Su, H; Tian, X; Xue, J; Yan, L; Yao, Q; Yao, Y; Zhou, T | 1 |
| Arpicco, S; Chegaev, K; Donadelli, M; Fruttero, R; Gazzano, E; Masetto, F; Mullappilly, N; Riganti, C; Rolando, B | 1 |
| Hatano, H; Imura, S; Johira, H; Kagajo, Y; Kashu, N; Kawata, N; Kimura, M; Tamura, S; Tomomatsu, M; Umeoka, T; Watanabe, R; Yunoki, S | 1 |
| Bakhtiyari, S; Gheysarzadeh, A; Mofid, MR | 1 |
| Boeck, S; Guenther, M; Haas, M; Heinemann, V; Kirchner, T; Kruger, S; Mayerle, J; Ormanns, S; von Bergwelt-Baildon, M; Werner, J; Westphalen, CB | 1 |
| Byun, Y; Chie, EK; Choi, YJ; Han, Y; Jang, JY; Kang, JS; Kim, H; Kim, HS; Kim, YT; Kwon, W; Lee, K; Lee, SH; Oh, DY; Paik, WH; Ryu, JK | 1 |
| Badam, TVS; Björn, N; Brandén, E; De Petris, L; Gréen, H; Gustafsson, M; Koyi, H; Lewensohn, R; Lubovac-Pilav, Z; Lundeberg, J; Sahlén, P; Spalinskas, R | 1 |
| Choi, SJ; Hwang, HW; Jeong, S; Lee, DH; Park, JS | 1 |
| Camara, JC; Franco, F; Gutiérrez-Abad, D; Juez, I; León, A; López-Alfonso, A; Marrupe, D; Martín-Valadés, JI; Martínez-Amores, B; Pérez, M; Royuela, A; Ruiz-Casado, A | 1 |
| Allory, Y; Culine, S; Fléchon, A; Gravis, G; Guy, L; Harter, V; Joly, F; Laguerre, B; Mottet, N; Pfister, C; Soulié, M | 1 |
| Jiang, WD; Qiu, L; Wang, HY; Wu, JC; Zhang, GF | 1 |
| Hirabayashi, K; Kikuta, K; Kondo, T; Noguchi, R; Ono, T; Ozawa, I; Sei, A; Yoshimatsu, Y | 2 |
| Carbone, D; Cascioferro, SM; Cavazzoni, A; Cirrincione, G; Diana, P; El Hassouni, B; Giovannetti, E; Li Petri, G; Parrino, B; Pecoraro, C; Peters, GJ; Randazzo, O; Zaffaroni, N; Zoppi, S | 1 |
| Hoffman, RM; Huang, J; Shen, L; Sun, YU; Tong, Z; Yang, H | 1 |
| Deng, GL; Hu, YY; Wan, XJ; Weng, JY; Xiao, JB | 1 |
| Cha, HS; Hwang, JH; Kim, J; Kim, JW; Kim, MJ; Lee, JC; Lee, WJ; Park, P; Shin, DW; Woo, SM; Yang, SY | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Bitzer, M; Denzlinger, C; Gellert, K; Ghadimi, M; Hinke, A; Hofheinz, R; Lammert, F; Liersch, T; Lindig, U; Maschmeyer, G; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Stübs, P; Waldschmidt, D | 1 |
| Fukami, N; Fukaya, K; Ichino, M; Kusaka, M; Nukaya, T; Sasaki, H; Shiroki, R; Sumitomo, M; Takahara, K; Takenaka, M; Zennami, K | 1 |
| Li, J; Liu, J; Liu, Y; Qi, Z; Shen, Y; Tian, W; Yang, L; Yang, Y; Zhang, Q; Zhu, M | 1 |
| Ding, J; He, L; Pang, S; Shen, B; Xie, X; Xu, D; Zhou, C; Zhou, Y | 1 |
| Adler, W; Bechstein, WO; Boeck, S; Croner, RS; Fietkau, R; Ghadimi, M; Golcher, H; Grützmann, R; Hohenberger, WM; Imhoff, D; Jacobasch, L; Keilholz, L; Lubgan, D; Neumann, UP; Oettle, H; Pirkl, A; Reinacher-Schick, A; Rutzner, S; Semrau, S; Uhl, W; Wittel, UA | 1 |
| Ferrara, KW; Ingham, ES; Kakwere, H; Tumbale, SK | 1 |
| Chen, F; Gou, S; Wang, X | 2 |
| Abubakar, M; Jan, MRU; Saeed, H; Wali, RM | 1 |
| Aoe, K; Atagi, S; Ebiana, V; Fukuhara, T; Han, SR; Hida, T; Horiike, A; Horinouchi, H; Hotta, K; Katakami, N; Kishi, K; Kurata, T; Nakagawa, K; Noguchi, K; Nosaki, K; Ohira, T; Okamoto, H; Okamoto, I; Saka, H; Sakai, H; Satouchi, M; Sekine, A; Sugawara, S; Takahashi, T; Umemura, S; Yamamoto, N | 1 |
| Covey, TR; Liu, C; Olah, TV; Shou, WZ; Wagner, A; Weller, HBN; Zhang, J | 1 |
| Ge, C; Shen, F; Yuan, P | 1 |
| Andersen, JB; Boisen, MK; Dang, H; Dehlendorff, C; Factor, VM; Grunnet, M; Høgdall, D; Jensen, LH; Johansen, AZ; Johansen, JS; Larsen, OF; Linnemann, D; Mau-Sørensen, M; O'Rourke, CJ; Oliveira, DVNP; Wang, XW | 1 |
| Bu, LP; Li, XY; Liu, H; Liu, P; Shao, L; Ying, Q; Yu, SQ | 1 |
| Chen, Q; Dong, M; Wu, S; Yang, Z; Zhang, M; Zhang, X | 1 |
| Aragon-Ching, JB; Bellmunt, J; Blake-Haskins, JA; Caserta, C; Costa, N; Davis, C; Demey, W; di Pietro, A; Fowst, C; Grivas, P; Gurney, H; Huang, B; Kalofonos, H; Kopyltsov, E; Laliberte, R; Loriot, Y; Park, SH; Petrylak, DP; Powles, T; Radulović, S; Sridhar, SS; Sternberg, CN; Tsuchiya, N; Ullén, A; Valderrama, BP; Voog, E; Wang, J | 1 |
| Cui, M; Guo, C; Liu, Z; Tang, J; Wang, C; Xie, G; Ye, X | 1 |
| Beumer, JH; Christner, S; Chu, E; Guo, J; Holleran, JL; Ivy, SP; Joshi, A; Kiesel, B; Miller, BM; Parise, RA; Taylor, S; Venkataramanan, R | 1 |
| Bulanadi, JC; Gill, AJ; Gong, X; Hugh, T; Julovi, SM; Moghaddam, MJ; Phillips, L; Proschogo, N; Rye, KA; Smith, RC; Smith, SF; Xue, A | 1 |
| Baltatzis, M; De Liguori Carino, N; Rodriquenz, MG; Siriwardena, AK | 1 |
| Cao, T; Fan, D; Gao, X; Gao, Z; Guo, F; Luo, X; Xing, Q; Yang, F; Zhang, L; Zhang, S | 1 |
| Catalano, M; Conca, R; D'Angelo, A; Ianza, A; Mini, E; Nobili, S; Palmieri, VE; Panella, B; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Bardia, A; Elhence, PA; Nag, P; Pareek, P | 1 |
| Cho, IR; Chun, JW; Huh, G; Kim, JS; Kim, YT; Lee, SH; Paik, WH; Park, N; Ryu, JK | 2 |
| Blaauboer, A; Booy, S; Dogan, F; Hofland, LJ; Karels, B; van Eijck, CHJ; van Koetsveld, PM; van Zwienen, S | 1 |
| Antico, G; Cole, A; Doleh, Y; Malangone-Monaco, E; Noxon, V; Pishvaian, MJ | 1 |
| Song, JX; Yuan, BS; Yuan, Y; Zhang, MN | 1 |
| Griffin, JI; Ho, RJ; McConnachie, LA; Mu, Q; Perazzolo, S; Shen, DD; Yu, J; Zhu, L | 1 |
| Cui, J; Qu, S; Wang, L; Zhang, X | 1 |
| Liu, W; Peng, S; Wang, Y; Wu, J; Zhang, J; Zhang, X; Zhao, M; Zhao, S | 1 |
| Barocas, DA; Bivalacqua, TJ; Black, PC; Cookson, MS; D'Andrea, D; Dall'Era, MA; Daneshmand, S; Dinney, CP; Holzbeierlein, JM; Kassouf, W; Lotan, Y; Matin, S; McGrath, JS; Morgan, TM; North, S; Petros, FG; Shariat, SF; Spiess, PE; Sridhar, SS; Stephenson, AJ; Thorpe, AC; van Rhijn, BW; Wright, JL; Zargar, H | 1 |
| Bolidong, D; Domoto, T; Minamoto, T; Miyashita, T; Takenaka, S; Takeuchi, O; Uehara, M | 1 |
| Bouvet, M; Higuchi, T; Hoffman, RM; Kawaguchi, K; Nishino, H; Park, JH; Sugisawa, N; Tashiro, Y; Unno, M; Yamamoto, J | 1 |
| Adachi, T; Eguchi, S; Harada, H; Miyazaki, Y; Nagai, K; Sugiyama, H | 1 |
| Fitzpatrick, FC; Sabile, JMG; Skelton, MR; Stump, MS | 1 |
| Ito, K; Kawamoto, Y; Komatsu, Y; Nakano, S; Nakatsumi, H; Saito, R; Sakamoto, N; Yuki, S | 1 |
| Câmara, AS; Faria, RC; Materon, EM; Nascimento, GF; Oliveira, ON; Sandrino, B; Shimizu, FM | 1 |
| Andric, Z; Barrios, CH; de Marinis, F; Deng, Y; Enquist, I; Felip, E; Geater, S; Giaccone, G; Herbst, RS; Jassem, J; Komatsubara, K; Kuriki, H; McCleland, M; Mocci, S; Morise, M; Özgüroğlu, M; Reinmuth, N; Sandler, A; Spigel, DR; Vergnenegre, A; Wen, X; Zou, W | 1 |
| Clayton, EA; McDonald, JF; Pujol, TA; Qiu, P | 1 |
| Aghmesheh, M; Foroughi, J; Moulton, SE; Piper, AK; Sahin, Z; Talebian, S; Vine, KL; Wade, SJ; Wallace, GG | 1 |
| Boldrini, L; Buwenge, M; Cellini, F; D'Aviero, A; Deodato, F; Dinapoli, N; Frascino, V; Macchia, G; Mattiucci, GC; Morganti, AG; Nardangeli, A; Valentini, V | 1 |
| Gong, Y; Minuk, GY; Sontag, D; Yang, J | 1 |
| Abe, Y; Ashida, R; Fukutake, N; Ikezawa, K; Imai, T; Katayama, K; Kato, K; Kiyota, R; Kukita, Y; Nawa, T; Ohkawa, K; Takada, R; Yamai, T | 1 |
| Furuse, J; Ikeda, M; Imaoka, H; Inoue, H; Kawamoto, Y; Kobayashi, S; Maehara, K; Morizane, C; Nagano, H; Okamura, K; Ozaka, M; Sakaguchi, C; Shioji, K; Shirakawa, H; Suzuki, R; Terashima, T; Tsuji, K; Ueno, M; Umemoto, K | 1 |
| Cheng, X; Li, Y; Tian, Y | 1 |
| Huang, WK; Yeh, CN | 1 |
| Björnsson, B; Blomstrand, H; Elander, NO; Fredrikson, M; Gränsmark, E; Green, H | 1 |
| Furuse, J; Hosoi, H; Ikeda, M; Kobayashi, S; Maeno, S; Morimoto, M; Morizane, C; Nagashima, F; Nakai, Y; Ojima, H; Okano, N; Okusaka, T; Ozaka, M; Sasaki, M; Takahara, N; Ueno, M; Yamanaka, T | 1 |
| El-Husseiny, AA; El-Mahdy, HA; Gamal El-Din, AM; Kandil, YI | 1 |
| Hussain, SA; Riaz, IB | 1 |
| Arcucci, S; Barentin, C; Ben-Mériem, Z; Delanoë-Ayari, H; Delarue, M; Guillermet-Guibert, J; Hatzikirou, H; Mascheroni, P; Prunet, A; Rivière, C; Rizzuti, IF | 1 |
| Atari, M; Imai, K; Matsuo, T; Minamiya, Y; Motoyama, S; Nakayama, K; Nomura, K; Sato, Y; Shibata, H; Takashima, S | 1 |
| Parks, RJ; Saha, B | 1 |
| Chang, Y; Fu, X; Li, L; Li, W; Li, X; Nan, F; Sun, Z; Wang, G; Wang, X; Wang, Y; Wu, J; Wu, X; Yan, J; Yu, H; Zhang, L; Zhang, M; Zhang, X; Zhou, Z | 1 |
| Ban, D; Esaki, M; Furuse, J; Ioka, T; Ishii, H; Nara, S; Okusaka, T; Shimada, K; Takamoto, T | 1 |
| Al-Batran, SE; Aldaoud, A; Behringer, DM; Bildat, S; Blau, W; Büchner-Steudel, P; Däßler, KU; Dörfel, S; Eschenburg, H; Ettrich, TJ; Feustel, HP; Fietz, T; Forstbauer, H; Gallmeier, E; Götze, TO; Groschek, M; Hahn, L; Harich, HD; Hausen, GZ; Höffkes, HG; Hofheinz, RD; Homann, N; Jacobasch, L; Koenigsmann, M; Kretzschmar, A; Kunzmann, V; Mahlmann, S; Messmann, H; Papke, J; Pauligk, C; Peters, U; Pink, D; Reichart, A; Schaaf, M; Schlag, R; Schönherr, C; Schubert, J; Schuch, G; Schulz, H; Schwindel, U; Siegler, G; Springfeld, C; Stauch, M; Trojan, J; Uhlig, J; Vehling-Kaiser, U; Vogel, A; von Weikersthal, LF; Waibel, K; Waidmann, O; Wehmeyer, J; Weniger, J; Wierecky, J; Wolf, M; Wörns, MA; Zahn, MO | 1 |
| Cao, S; Liu, S; Xu, J; Yang, X; Zhou, Y | 1 |
| Chiang, KY; Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
| Jiang, W; Li, H; Li, T; Liu, L; Liu, X; Yu, X; Zhang, J; Zhang, W | 1 |
| Benkirane-Jessel, N; Chalhoub, S; Fuhrmann, G; Hassan, S; Idoux Gillet, Y; Peluso, J; Rochel, N; Ubeaud-Sequier, G | 1 |
| Doi, H; Ishigaki, H; Kijima, T; Kitajima, K; Koda, Y; Kuribayashi, K; Minami, T; Nakajima, Y; Nakamura, A; Takahashi, R; Yokoi, T | 1 |
| Cha, J; Hsu, S; Huang, S; Jennings, E; Lee, JB | 1 |
| Chung, H; Kim, HS; Kim, JW; Kim, SI; Lee, EJ; Lee, M; Park, NH; Song, YS | 1 |
| Inoue, Y; Ito, H; Mise, Y; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Takahashi, Y | 1 |
| Beijnen, JH; Derissen, EJB | 1 |
| Akahane, T; Kaji, K; Kitagawa, K; Mitoro, A; Moriya, K; Namisaki, T; Nishimura, N; Saikawa, S; Sato, S; Yoshiji, H | 1 |
| Gultekin, M; Yildiz, F; Yuce Sari, S | 1 |
| Mell, LK; Saenz, CC; Xu, R | 1 |
| Björn, N; Gréen, H; Pellé, L; Schimek, V; Svedberg, A | 1 |
| Gauthier, M; Laurent, C; Mouchel, PL; Syrykh, C; Tavitian, S | 1 |
| Belkouz, A; Erdmann, JI; Franken, LC; Klümpen, HJ; Nooijen, LE; Punt, CJA; Riady, H; van Oijen, MGH | 1 |
| Cheng, WC; Chiang, CM; Hsu, KW; Liu, YH; Peng, PH; Tsai, LH; Wu, HH; Yang, HJ; Yang, SF | 1 |
| Abushahin, L; Chakravarti, A; Cruz-Monserrate, Z; Hegazi, A; Jacob, JR; Palanichamy, K; Robb, R; Shyu, DL; Trevino, JG; Williams, TM; Wolfe, AR; Yang, L | 1 |
| Andergassen, U; Bauer, E; Beckmann, MW; Bekes, I; Blohmer, JU; Brucker, SY; de Gregorio, A; de Gregorio, N; Deniz, M; Fasching, PA; Fehm, TN; Fink, V; Forstbauer, H; Friedl, TWP; Häberle, L; Heinrich, G; Janni, W; Lato, K; Lorenz, R; Mahner, S; Müller, V; Rack, B; Schneeweiss, A; Schrader, I; Tesch, H | 1 |
| Adair, SJ; Adli, M; Bauer, TW; Demirlenk, YM; Dutta, A; Habieb, AH; Kane, WJ; Kuscu, C; Lee, KY; Liu, D; O'Hara, PE; Ozturk, H; Wei, X; Yang, J; Yilmaz, E | 1 |
| Chugh, P; Furukawa, M; Furuse, J; Ikeda, M; Ioka, T; Ishii, H; Kanai, M; Kawabe, K; Komatsu, Y; Nakamori, S; Okusaka, T; Ozaka, M; Sato, A; Shimizu, S; Sugimori, K; Tang, R; Ueno, M | 1 |
| Deng, Z; Gao, Y; Li, F; Xiao, Y | 1 |
| Cui, H; Dai, G; Deng, G; Guan, J; Lou, C; Yuan, J; Zhang, W; Zhang, Y; Zhou, A; Zhou, J | 1 |
| Abraham, AG; Cox, CM; Hughes, DLI; Hurt, CN; Jones, CM; Maughan, T; Mukherjee, S; O'Neill, EE; Owens, R; Parkes, EE; Sabbagh, A; Wilhelm-Benartzi, CS; Willenbrock, F | 1 |
| Kobayashi, M; Komatsu, Y; Saito, Y; Sugawara, M; Takekuma, Y | 1 |
| Arai, T; Fukumura, Y; Hirabayashi, K; Kawanishi, A; Kojima, M; Matsuda, Y; Mino-Kenudson, M; Nakano-Narusawa, Y; Ohkubo, S; Sahara, Y; Takahashi, S; Yamaguchi, H | 1 |
| Angelis De, V; Chovanec, M; Hlavčák, P; Janega, P; Jurišová, S; Macák, D; Makovník, M; Mardiak, J; Mego, M; Pinďák, D; Rejleková, K | 1 |
| Batra, SK; C Caffrey, T; Chhonker, YS; Chirravuri, R; Chugh, S; Grandgenett, PM; Gupta, R; Hollingsworth, MA; L Grem, J; Lele, SM; Leon, F; Mallya, K; Marimuthu, S; Murry, DJ; Nallasamy, P; Nimmakayala, RK; Ponnusamy, MP; Prajapati, DR; Rachagani, S; Rauth, S; Shailendra, GK | 1 |
| Lunec, J; Pan, YR; Wu, CE; Yeh, CN | 1 |
| Bezrookove, V; Dar, AA; de Semir, D; Ice, RJ; Kashani-Sabet, M; McAllister, S; Nosrati, M; Osorio, R; Proetsch-Gugerbauer, H; Saqub, H; Soroceanu, L; Vaquero, EM | 1 |
| Lv, X; Yin, N; Yu, H; Zhang, X | 1 |
| Canonge, JM; Claraz, P; Cretu, Y; Grand, A; Hennebelle, I; Perriat, S; Puisset, F; Riff, I; Vert, C; Wolff, E | 1 |
| El Shazely, B; Kim, JJ; Kuropka, B; Nath, A; Rodríguez-Rojas, A; Rolff, J; Santi, G; Weise, C | 1 |
| de Man, RA; Kainov, DE; Li, P; Li, Y; Ma, Z; Pan, Q; Peppelenbosch, MP; Yu, P; Zhang, R | 1 |
| Kawai, S; Kikuchi, S; Lin, Y; Suzuki, T; Ueno, M | 1 |
| Fujiwara, H; Koyanagi, T; Machida, S; Saga, Y; Takahashi, S; Takahashi, Y; Takei, Y; Tamura, K; Taneichi, A; Yoshiba, T | 1 |
| Huang, Z; Li, C; Li, N; Luo, D; Tang, S; Yang, S | 1 |
| Bapat, RA; Dewangan, RP; Dubey, RD; Kesharwani, P; Molugulu, N; Paroha, S; Sahoo, PK; Verma, J | 1 |
| Beck, A; Gravekamp, C; Lara, O; Meena, K; Meheus, L; Rooman, I; Selvanesan, BC | 1 |
| Cui, JX; Qin, Y; Xu, J; Xu, Y | 1 |
| Huang, CP; Shyr, CR; Wu, CC | 1 |
| Boras, B; Chen, W; D'Argenio, DZ; Hu, W; Spilker, ME; Sung, T | 1 |
| Aieta, M; Catalano, M; Conca, R; D'Angelo, A; Dreoni, L; Gasperoni, S; Ianza, A; Mini, E; Nobili, S; Petrioli, R; Ramello, M; Roviello, G | 1 |
| Capone, A; Capurso, G; de Latouliere, L; Di Agostino, S; Manni, I; Montori, A; Naro, C; Panzeri, V; Piaggio, G; Pilozzi, E; Sacconi, A; Sette, C | 1 |
| Fukutomi, A; Furuse, J; Hara, H; Hiraoka, N; Hosokawa, A; Ikeda, M; Ioka, T; Ishii, H; Ito, Y; Katayama, H; Kawashima, Y; Miyakawa, H; Mizuno, N; Mizusawa, J; Nakamori, S; Nakamura, S; Okano, N; Okusaka, T; Ozaka, M; Sata, N; Shimizu, K; Sugimori, K; Tobimatsu, K; Todaka, A; Ueno, M; Yamaguchi, T; Yanagimoto, H | 1 |
| Fukuda, K; Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 2 |
| Asagi, A; Hashine, K; Iuchi, S; Nakasya, A; Tohyama, M | 1 |
| Pan, YR; Wu, CE; Yeh, CN | 1 |
| Chen, HA; Chiu, CF; Chuang, TH; Hsieh, CL; Hsu, TW; Huang, MT; Leo Su, J; Su, CM; Su, YH | 1 |
| Kato, K; Matsuoka, A; Nishikimi, K; Otsuka, S; Shozu, M; Takahashi, Y; Tate, S | 1 |
| Canu, L; De Filpo, G; Mannelli, M | 1 |
| Ho, TTB; Honda, M; Inui, H; Kaneko, S; Kawaguchi, K; Kitamura, Y; Komura, T; Kozaka, T; Mizukoshi, E; Nasti, A; Sakai, Y; Seki, A; Shiba, K; Wada, T; Yamashita, T | 1 |
| Armenoult, L; Arsenijevic, T; Augustin, J; Ayadi, M; Bachet, JB; Bigonnet, M; Blum, Y; Cros, J; Dahan, L; de Reyniès, A; Duconseil, P; Dusetti, NJ; Elarouci, N; Emile, JF; Gayet, O; Gilabert, M; Giovannini, M; Grandval, P; Hammel, P; Iovanna, J; Moutardier, V; Nicolle, R; Puleo, F; Roques, J; Svrcek, M; Van Laethem, JL; Vanbrugghe, C | 1 |
| Akdogan, B; Akyol, F; Esen, CSB; Hurmuz, P; Kilickap, S; Ozen, H; Ozyigit, G | 1 |
| Lu, M; Peng, Z; Shen, L; Wang, X; Yuan, J; Zhou, J; Zong, Y | 1 |
| Anevlavis, S; Bouros, D; Froudarakis, ME; Karpathiou, G; Kotsianidis, I; Kouliatsis, G; Mihailidis, V; Nakou, E; Ntolios, P; Tzouvelekis, A | 1 |
| Gao, S; Xu, Y; Zhang, Z; Zhao, C | 1 |
| Almuqbil, RM; da Rocha, SRP; Fines, CB; Heyder, RS; Sunbul, FS | 1 |
| Caires, HR; Castro, I; Cavadas, B; Ferreira, D; Oliveira, MJ; Pereira, L; Santos, LL; Vasconcelos, MH; Xavier, CPR | 1 |
| Becerra, CHR; Boyd, TE; Casero, RA; Conkling, PR; Fitzgerald, M; Garbo, LE; Jotte, RM; Marton, LJ; Murray Stewart, T; Richards, DA; Smith, DA; Stephenson, JJ; Vogelzang, NJ; Von Hoff, D; Wu, HH | 1 |
| Wang, F; Zhang, Z | 1 |
| Real, FX; Siveke, JT | 1 |
| Ahmed, AA; Neidle, S | 1 |
| Ahmad, Z; Cambron, DA; Chen, S; Dillenburg, M; Jacobson, BA; Kratzke, RA; Patel, AJ; Patel, MR; Stoian, E; Wagner, CR; Waldusky, G | 1 |
| Deng, D; El Hassouni, B; Giovannetti, E; Gregori, A; Kazemier, G; Puik, JR | 1 |
| Banerjee, S; Banerjee, SK; Dutta, D; Haque, I; Jain, P; Kale, N; Kambhampati, S; Mallik, S; Mohammed, J; Nair, G; Orr, M; Parmer, M; Quadir, M; Ray, P; Reindl, KM | 1 |
| Garri, DD; Karamysheva, АF; Moiseeva, NI; Saakyan, SV; Tsygankov, АY | 1 |
| Du, W; Hu, C | 1 |
| Ammori, JB; Bingmer, K; Hardacre, JM; Hue, JJ; Sugumar, K; Winter, JM | 1 |
| Altuntaş, F; Bakırtaş, M; Başcı, S; Batgi, H; Baysal, NA; Dal, MS; Darçın, T; İskender, D; Kılınç, A; Kızıl Çakar, M; Merdin, A; Özcan, N; Şahin, D; Uncu Ulu, B; Yiğenoğlu, TN; Yıldız, J | 1 |
| Azevedo-Pouly, AC; Brekken, RA; Girard, L; Huang, H; Kantheti, HS; Layeghi-Ghalehsoukhteh, S; MacDonald, RJ; Niederstrasser, H; Ocal, O; Pal Choudhuri, S; Pashkov, V; Posner, BA; Wilkie, TM; Zolghadri, Y | 1 |
| Alcaraz-Sanabria, A; Burgos, M; Corrales-Sanchez, V; Galan-Moya, EM; Martinez-Canales, S; Montero, JC; Nieto-Jimenez, C; Nuncia-Cantarero, M; Ocaña, A; Pandiella, A | 1 |
| Buffi, N; Casale, P; Colombo, P; Contieri, R; Fasulo, V; Frego, N; Guazzoni, G; Hurle, R; Lazzeri, M; Lughezzani, G; Morenghi, E; Paciotti, M; Saita, A | 1 |
| Fujiwara, H; Ijichi, H; Isayama, H; Kim, J; Kimura, G; Koike, K; Kudo, Y; Miyabayashi, K; Mohri, D; Morishita, Y; Moses, HL; Nakai, Y; Nakatsuka, T; Sano, M; Soma, K; Takahashi, R; Takeda, N; Tanaka, Y; Tateishi, K; Yamamoto, K | 1 |
| Cui, L; Desar, S; Diggs, LP; Gores, G; Greten, TF; Heinrich, B; Heinrich, S; Kleiner, D; Lai, W; Longerich, T; Loosen, SH; Luedde, T; Ma, C; McVey, JC; Neumann, UP; Rosato, U; Ruf, B; Subramanyam, V; Wabitsch, S; Wang, XW; Zhang, Q | 1 |
| Hsia, RC; Kambhampati, SP; Kannan, RM; Kokkoli, E; Shabana, AM | 1 |
| Cho, CJ; Ho, JY; Wu, CL; Yang, CW; Yu, CP; Yu, DS | 1 |
| Besselink, MG; Blomjous, JG; Bollen, TL; Bosscha, K; Brada, LJ; Bruijnen, RC; Busch, OR; Creemers, GJ; Daams, F; de Hingh, IH; de Meijer, VE; de Vos-Geelen, J; de Vries, JJJ; Festen, S; Hermans, JJ; Jan de Groot, D; Kerver, ED; Liem, MS; Los, M; Meijerink, MR; Mekenkamp, LJ; Mohammad, NH; Molenaar, IQ; Nederend, J; Nio, CY; Patijn, GA; Patuleia, SIS; Polée, MB; Pruijt, JF; Renken, NS; Rombouts, SJ; Schouten, TJ; Stommel, MWJ; van Dam, R; van der Leij, C; van Leeuwen, MS; van Lienden, KP; van Santvoort, HC; Verweij, ME; Vulink, A; Walma, MS; Wessels, FJ; Willem de Groot, J; Wilmink, JW | 1 |
| Chiu, CH; Huang, CY; Huang, GY; Huang, IC; Kuo, WW; Liu, JS; Mahalakshmi, B; Wen, SY; Yeh, CA | 1 |
| Li, J; Liu, Z; Mi, M; Wang, Y; Zhang, C; Zhang, L | 1 |
| Benson, C; Cojocaru, E; Fisher, C; Gennatas, S; Huang, P; Jones, RL; Messiou, C; Miah, AB; Thway, K; Zaidi, S | 1 |
| Batra, SK; Chirravuri-Venkata, R; Foster, JM; Jain, M; Kaushik, G; Lele, SM; Ly, QP; Malafa, MP; Mallya, K; Nallasamy, P; Nimmakayala, RK; Ponnusamy, MP; Rachagani, S; Rauth, S; Seshacharyulu, P; Singh, AB; Smith, LM; Vengoji, R | 1 |
| Al-Toubah, TE; Cao, B; Centeno, BA; Kim, J; Kim, RD; Mehta, R; Tan, ES | 1 |
| Abdel Hadi, N; Borge, L; Carrier, A; Cormareche, L; Diémé, B; Dou, S; Dusetti, N; El Kaoutari, A; Garcia, J; Gayet, O; Gicquel, T; Iovanna, J; Lac, S; Masoud, R; Pasquier, E; Reyes-Castellanos, G; Shintu, L; Tranchida, F | 1 |
| Abdelhamid, AH; Agarwal, S; Bobbili, PJ; Chugh, R; Demetri, GD; Duh, MS; Gounder, MM; Huynh, L; Lax, AK; Merriam, P; Patel, SR; Rajarethinam, A; Ratan, R; Thornton, M; Totev, TI; Van Tine, BA; Villalobos, VM; Whalen, J; Yang, J | 1 |
| Andel, J; Arnold-Schrauf, C; Djanani, A; Eisterer, W; Gerger, A; Gruenberger, B; Heibl, S; Hubmann, E; Korger, M; Laengle, F; Mlineritsch, B; Neumann, HJ; Oehler, L; Pecherstorfer, M; Petzer, A; Philipp-Abbrederis, K; Pichler, P; Prager, GW; Sliwa, T; Trondl, R; Wilthoner, K; Winder, T; Wöll, E | 1 |
| Campbell, MJ; Chen, W; Govindarajan, R; Hung, SW; Li, J; Nayak, D; Persaud, AK; Raj, R; Weadick, B; Williams, TM | 1 |
| Jiang, Z; Liu, Y; Tao, L; Zhao, Y | 1 |
| Inoue, Y; Ito, H; Mise, Y; Oba, A; Ono, Y; Saiura, A; Sato, T; Takahashi, Y; Ushida, Y | 1 |
| Hirokawa, T; Masutani, T; Sakamoto, K | 1 |
| Chen, Y; Huang, C; Kong, X; Liu, C; Meng, Q; Meng, YM; Qiu, X; Su, L; Wang, M; Wong, PP; Wu, S; Zhao, X | 1 |
| Andrés, I; Arconada-Luque, E; Belandia, B; Bossi, G; Fernández-Aroca, DM; Garcia-Flores, N; Ortega-Muelas, M; Pascual-Serra, R; Roche, O; Ruiz-Hidalgo, MJ; Sabater, S; Sánchez-Prieto, R | 1 |
| Ando, M; Ando, Y; Ebata, T; Inada-Inoue, M; Maeda, O; Matsuoka, A; Mitsuma, A; Miyai, Y; Mizuno, T; Morita, S; Nagino, M; Shimokata, T; Sugishita, M; Takano, Y; Urakawa, H | 1 |
| Karaca, M; Kayahan, N; Özet, A; Satış, H; Yapar, D | 1 |
| Cao, Y; Chu, C; Liu, Z; Lu, J; Wu, C; Zhang, Y | 1 |
| Bartholomeusz, C; Devi, GR; Lee, J; Liu, H; Lu, AY; Pearson, T; Tripathy, D; Ueno, NT; Xie, X | 1 |
| Arumugam, T; Fujii, T; Huang, H; Ji, B; Jiang, H; Jin, Z; Li, Z; Lin, K; Logsdon, C; Peng, L; Sun, L; Yao, Y; Zhang, Y; Zhuang, L | 1 |
| Cao, D; Hu, Q; Wang, X; Xu, H; Zhou, S | 1 |
| Kim, JS; Kim, SJ; Kim, T; Kim, WS; Koh, Y; Moon, JH; Park, GS; Park, J; Shin, HJ; Yang, DH; Yhim, HY | 1 |
| Crysandt, M; Cygon, F; Egerer, G; Eigendorff, E; Heißner, K; Kasper, B; Kessler, T; Kopp, HG; Kunitz, A; Lindner, LH; Mayer-Steinacker, R; Meinert, F; Niederwieser, D; Petersen, I; Reichardt, P; Rüssel, J; Schmoll, HJ; Steighardt, J; Stein, A | 1 |
| Hua, YQ; Meng, ZQ; Ning, ZY; Shen, YH; Sheng, J; Wang, P; Xu, LT; Yan, X; Zhu, ZF; Zhuang, LP | 1 |
| Che, G; Chen, Y; Huang, C; Li, T; Li, Y; Lin, Y; Luo, L; Peng, S; Ren, T; Yang, P; Zeng, L | 1 |
| Gan, Y; Jiang, W; Li, X; Zhou, W | 1 |
| Fukutomi, A; Furuse, J; Hashimoto, Y; Honda, G; Ioka, T; Miyamoto, A; Mizuno, N; Morinaga, S; Nakamori, S; Okusaka, T; Saiura, A; Sasahira, N; Seyama, Y; Shimizu, S; Shimizu, Y; Sugiyama, M; Takadate, T; Takahashi, H; Ueno, H; Ueno, M; Umemoto, K; Unno, M | 1 |
| Anjarwalla, S; Lakshmaiah, S; Marzouk, O | 1 |
| Bai, LY; Chen, CY; Chen, LT; Chiang, NJ; Chiu, CF; Liang, SH; Su, YY; Wang, HC | 1 |
| Dash, A; Diamontopoulos, LN; Gore, JL; Grivas, P; Holt, SK; Lin, DW; Nyame, YA; Psutka, SP; Schade, GR; Winters, BR; Wright, JL; Yu, EY | 1 |
| Aoyama, T; Kamiya, M; Kobayashi, S; Masuda, M; Morimoto, M; Morinaga, S; Murakawa, M; Numata, M; Oshima, T; Rino, Y; Sawazaki, S; Shiozawa, M; Tamagawa, H; Ueno, M; Yamamoto, N; Yoshikawa, T; Yukawa, N | 1 |
| Gao, Y; Han, X; Hao, M; Hou, S; Kang, Z; Li, Y; Tong, Y; Wang, B; Wang, C; Wang, Q; Zhang, C | 1 |
| Gürses, E; Kemal, HS; Kültürsay, H; Özbay, B; Şimşek, E | 1 |
| Chen, G; Chen, K; Cui, J; Dong, X; Fan, Y; Fang, L; Gu, K; Guo, Q; He, J; Hu, C; Hu, X; Jiang, D; Jiang, L; Jiang, T; Li, J; Li, Y; Liang, D; Liu, J; Pan, Y; Peng, M; Ren, S; Shi, Q; Song, Y; Tan, W; Wang, G; Wang, H; Wang, Z; Wu, L; Wu, X; Xie, W; Xiong, J; Yang, N; Yao, W; Yi, T; Yu, G; Yue, L; Zang, A; Zhang, G; Zhang, H; Zhang, X; Zhao, G; Zhao, W; Zhao, Y; Zhou, C | 1 |
| Slater, H | 1 |
| Ak, H; Atay, S; Aydin, HH; Rüstem, DG | 1 |
| Assenat, E; Boissière-Michot, F; de Forges, H; Dupuy, M; Ho-Pun-Cheung, A; Lombard-Bohas, C; Lopez-Crapez, E; Mazard, T; Mineur, L; Mollevi, C; Portales, F; Samalin, E; Walter, T; Ychou, M | 1 |
| Dehdashti, F; Detering, L; Greco, S; Grierson, PM; Heo, GS; Laforest, R; Li, L; Lim, KH; Liu, Y; Lou, L; Luehmann, H; Ruzinova, M; Sultan, D; Zhang, X | 1 |
| Deng, ZH; Hong, X; Hou, J; Li, ZX; Pang, LH; Sun, H; Wang, T; Zhang, CY; Zhang, HY; Zhang, J | 1 |
| Bang, YJ; Chie, EK; Ha, SW; Han, SW; Im, SA; Jang, JY; Kim, JH; Kim, JS; Kim, SW; Kim, TY; Kwon, J; Lee, KH; Oh, DY | 1 |
| Lu, Y; Ruan, Y; Wang, L | 1 |
| Dehghanian, A; Firouzabadi, D; Mahmoudi, L; Rezvani, A; Talei, A | 1 |
| Aoki, Y; Hirose, Y; Ishimoto, U; Kinoshita, A; Koike, K; Mizuno, Y; Ohsawa, A; Saruta, M; Satou, N; Satou, Y | 1 |
| Huang, Z; Lin, J; Shen, R; Wang, S; Wang, X; Wei, H; Wu, Z | 1 |
| Bogeski, I; Ellenrieder, V; Gaedcke, J; Gibhardt, CS; Hamdan, FH; Hessmann, E; Johnsen, SA; Kopp, W; Kutschat, AP; Najafova, Z; Ströbel, P; Wang, X; Wixom, AQ | 1 |
| Geng, X; Li, G; Liu, Z; Lu, M; Qin, X; Yue, H; Zhou, Y | 1 |
| Kaneko, T; Kobayashi, S; Miwa, H; Morimoto, M; Ohkawa, S; Sugimori, K; Taguri, M; Ueno, M; Yamanaka, T | 1 |
| Deep, A; Kaur, M; Kim, KH; Kumar, P; Kush, P; Madan, J; Sharma, M | 1 |
| Hawryłkiewicz, A; Ptaszyńska, N | 1 |
| Chen, LT; Chen, MH; Chiang, NJ; Shan, YS; Yeh, CN | 1 |
| Betancourt, O; Cazes, A; Esparza, E; Gymnopoulos, M; Jaquish, D; Lowy, AM; Mose, ES; Tiriac, H; Wascher, AA; Wong, E | 1 |
| Chen, L; Ju, L; Luo, Y; Peng, T; Wang, G; Wang, X; Xiao, Y; Xiong, Y; Xu, H; Yuan, L | 1 |
| Cao, S; Stephenson, AA; Suo, Z; Taggart, DJ; Vyavahare, VP | 1 |
| Choi, MH; Hong, TH; Kim, IH; Lee, IS; Lee, MA | 1 |
| Arrigoni, E; Catanese, S; Crucitta, S; Cucchiara, F; Danesi, R; Del Re, M; Fornaro, L; Massa, V; Morganti, R; Pecora, I; Rofi, E; Salani, F; Vasile, E; Vivaldi, C | 1 |
| Akaike, H; Amemiya, H; Furuya, S; Higuchi, Y; Hosomura, N; Ichikawa, D; Kawaguchi, Y; Kawaida, H; Kono, H; Nakata, Y; Nakayama, T; Saito, R; Shoda, K; Sudo, M; Tsukahara, I | 1 |
| Funakoshi, S; Hirose, S; Kouno, T; Machino, C; Oikawa, H; Sato, T | 1 |
| Aoyama, Y; Hayashi, K; Hayashi, Y; Imafuji, H; Kato, T; Matsuo, Y; Morimoto, M; Naitoh, I; Ogawa, R; Omi, K; Saito, K; Takahashi, H; Takiguchi, S; Tsuboi, K; Ueda, G | 1 |
| Hayashi, H; Ishida, M; Kamei, T; Miyazaki, K; Mizuma, M; Morikawa, T; Motoi, F; Nakagawa, K; Ohtsuka, H; Shinoto, M; Takiyama, H; Unno, M; Yamada, S | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Fu, S; Leng, Q; Li, Y; Lu, Y; Luo, J; Wang, B; Wang, J; Wen, Q; Wu, Z; Xiong, K | 1 |
| Blagden, SP; Nicum, S | 1 |
| Bowering, V; Bruce, JP; Cabanero, M; Chen, E; Cristea, MC; Dhani, NC; Ellard, SL; Fleming, GF; Garg, S; Jenkins, S; Jones, GN; Karakasis, K; Kunos, CA; Lheureux, S; Mantia-Smaldone, G; Olawaiye, AB; Oza, AM; Pugh, TJ; Rath, P; Rodriguez-Canales, J; Stockley, T; Tan, Q; Tracy, M; Udagani, S; Wahner Hendrickson, AE; Wang, L; Weberpals, JI; Welch, S | 1 |
| Caffrey, TC; Clausen, H; Hollingsworth, MA; Leiphrakpam, PD; McAndrews, KL; Radhakrishnan, P; Sagar, S; Swanson, BJ; Thomas, D; Wandall, HH | 1 |
| Sardar, M; Shroff, RT | 1 |
| Beatty, GL; Carpenter, EL; Giannone, MA; Gladney, WL; Herrera, VM; Wattenberg, MM | 1 |
| Cheng, K; Li, G; Li, Y; Lin, CY; Liu, Y; Staveley-OCarroll, KF; Zhao, Z | 1 |
| Chan, SK; Chan, SY; Choi, HC; Kwong, DL; Lam, KO; Lee, AW; Lee, VH; Leung, TW; Luk, MY; Tong, CC | 1 |
| Aerts, JG; Baas, P; Biesma, B; Bootsma, GP; Buikhuisen, WA; Burgers, JA; Cornelissen, R; Dammeijer, F; de Gooijer, CJ; den Brekel, AJS; Groen, HJM; Lalezari, F; Soud, MY; Stigt, JA; van der Noort, V; van Heemst, RC; van Tinteren, H; van Walree, N | 1 |
| Nowak, AK | 1 |
| Aerts, JG; Baas, P; Biesma, B; Bootsma, GP; Burgers, JA; Cornelissen, R; Dammeijer, F; De Gooijer, CJ; Jebbink, M; Kaijen-Lambers, MEH; Klaase, L; Lievense, LA; Lukkes, M; Mankor, J; Stigt, JA; Van der Noort, V; van Gulijk, M; Vroman, H; Waasdorp, C | 1 |
| Atias, D; Berger, R; Borgida, A; Cuggia, A; Denroche, RE; Dodd, A; Fischer, SE; Gallinger, S; Glick, Y; Golan, T; Grant, RC; Halperin, S; Holter, S; Jang, GH; Knox, JJ; Notta, F; O'Kane, GM; Park, JP; Raitses-Gurevich, M; Renouf, DJ; Schaeffer, DF; Stossel, C; Wang, Y; Williamson, L; Wilson, JM; Wong, HL; Zhang, A; Zogopoulos, G | 1 |
| Bjånes, TK; Riedel, B; Schjøtt, J | 1 |
| Hupe, MC; Kramer, M; Matzen, M; Merseburger, AS; Offermann, A; Perner, S; Tharun, L | 1 |
| Eleraky, NE; Hasan, OA; Omar, MM; Zaki, RM | 1 |
| Bosch-Barrera, J; Cedrés, S; Coves, J; de Castro-Carpeño, J; García-Campelo, R; Guirado, M; López-Castro, R; Nadal, E; Ortega, AL; Vicente, D | 1 |
| Di Benedetto, L; Gozzi, E; Lazzeroni, R; Pietranera, M; Raimondi, FM; Raimondi, L; Rossi, L; Spinelli, GP | 1 |
| Akahori, T; Ikeda, N; Kunishige, T; Nagai, M; Nakagawa, K; Nakamura, K; Nishiwada, S; Sho, M; Takagi, T; Terai, T | 1 |
| Fu, JY; Mai, CW; Maniam, G; Zulkefeli, M | 1 |
| Chawsheen, MA; Dash, PR | 1 |
| Killock, D | 1 |
| Abdul Rahman, MB; Abdulmalek, E; Cordova, KE; Fakurazi, S; Kamal, NAMA | 1 |
| Bendell, J; Greil, R; Gueorguieva, I; Hecht, JR; Hozak, RR; Lin, Y; Lonardi, S; Lopez, CD; Macarulla, T; Muñoz Martin, AJ; Park, JO; Rao, S; Ryoo, BY; Sim, HW; Van Cutsem, E; Wang, H | 1 |
| Higa, N; Hirano, H; Kitanaka, C; Okada, M; Sanomachi, T; Seino, S; Sonoda, Y; Sugai, A; Suzuki, S; Takajo, T; Togashi, K; Uchida, H; Yamada, Y; Yamamoto, M; Yonezawa, H; Yoshimoto, K | 1 |
| An, T; Jang, Y; Jung, E; Kim, K; Kim, M; Kim, UI; Lee, MK; Shin, JS | 1 |
| Alcindor, T; Elkrief, A; Kazandjian, S | 1 |
| Li, X; Li, ZQ; Liu, YF; Luo, D; Yu, X; Zhu, HW | 1 |
| Ding, J; Gao, L; Shao, T; Zheng, W | 1 |
| Hua, YQ; Li, Y; Liu, LM; Ning, ZY; Sheng, J; Shi, WD; Zhang, K | 1 |
| Cepero, A; Martin-Guerrero, SM; Martin-Oliva, D; Melguizo, C; Munoz-Gamez, JA; Ortiz, R; Prados, J; Quinonero, F; Urbano, D | 1 |
| Gao, W; Li, X; Liu, Y; Luo, D; Yu, L; Yu, X; Zhu, H | 1 |
| Furukawa, T; Higuchi, R; Izumo, W; Matsunaga, Y; Shiihara, M; Uemura, S; Yamamoto, M; Yazawa, T | 1 |
| Bentsion, D; Bondarenko, I; Chen, CI; Cicin, I; Clingan, P; Gao, B; Gladkov, O; Gogishvili, M; Gullo, G; Gümüş, M; Kilickap, S; Lee, S; Li, S; Lowy, I; Makharadze, T; McGuire, K; Nechaeva, M; Özgüroğlu, M; Paydas, S; Rietschel, P; Rizvi, N; Seebach, F; Sezer, A; Sriuranpong, V; Turk, HM; Weinreich, DM; Yancopoulos, GD | 1 |
| Abdul-Ahad, A; Boeck, S; Dechow, T; Fischer von Weikersthal, L; Freiberg-Richter, J; Frickhofen, N; Haas, M; Heinemann, V; Held, S; Illerhaus, G; Kaiser, F; Kanzler, S; Kruger, S; Kubicka, S; Mahlberg, R; Malfertheiner, P; Reinacher-Schick, A; Seufferlein, T; Snijder, R; Stahl, M; von Bergwelt-Baildon, M; Waldschmidt, DT; Westphalen, CB | 1 |
| Chen, K; Du, Z; Feng, R; Li, R; Qi, L; Ye, J; Yu, L; Zhai, W | 1 |
| Bai, H; Bi, X; Cao, C; Chen, Y; Feng, X; Guan, K; Guan, Y; Hu, L; Hu, Z; Jiang, W; Li, C; Li, Y; Liu, Y; Ma, J; Shi, H; Shou, J; Tian, J; Wang, D; Xiao, Z; Zhang, J; Zhang, W; Zheng, S; Zhou, A | 1 |
| Brandi, G; Rizzo, A | 2 |
| Hu, X; Li, P; Liu, D; Wang, Y; Wei, X; Wu, J; Zhou, H | 1 |
| Ergözen, S; Gümüş, T | 1 |
| Baba, H; Goel, A; Nishiwada, S; Okada, Y; Sho, M; Takayama, T; Yamamura, K | 1 |
| Jaeger, M; Klassen, MD; Reinders, LMH; Schmidt, TC; Teutenberg, T; Tuerk, J; Vom Eyser, C | 1 |
| Goel, A; Okada, Y; Takahashi, N; Takayama, T | 1 |
| Curiel, TJ; Deng, Y; Gupta, HB; Kancharla, A; Kari, S; Kornepati, AVR; Li, R; Osta, E; Padron, AS; Reyes, RM; Sun, X; Svatek, RS; Vadlamudi, R; Wu, B; Zhang, D | 1 |
| Albores-Saavedra, J; Álvarez-Hilario, LG; Ávila-López, PA; Cedillo-Barrón, L; Guerrero, G; Hernández-Montes, G; Hernández-Rivas, R; Herrera-Goepfert, R; Montes-Gómez, AE; Nuñez-Martínez, HN; Peralta-Alvarez, CA; Recillas-Targa, F; Schnoor, M; Vargas, M; Villegas-Sepúlveda, N | 1 |
| Liu, B; Mao, A; Shang, M; Wang, Z; Weng, L; Wu, S; Xu, G; Yin, X; Zou, X | 1 |
| Al-Rajabi, R; Balducci, L; Banks, J; Brenner, W; Coveler, AL; Elquza, E; George, TJ; Hatoum, H; Hewitt, DB; Kennedy, E; Lavu, H; Leiby, B; Link, C; LoConte, N; Musher, B; Nissen, N; Rossi, G; Seng, J; Vaccaro, G; Vahanian, N; Yeo, CJ | 1 |
| Arora, S; Brown, L; Cai, EY; Corey, E; Garcia, J; Hsieh, AC; Lakely, B; Lam, HM; Lee, JK; Liu, Y; Montgomery, B; Nguyen, HM; Vakar-Lopez, F; Wong, A; Wright, JL | 1 |
| Fukutomi, A; Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Kajiwara, T; Katanuma, A; Kobayashi, S; Komatsu, Y; Makino, K; Mizuno, N; Moriwaki, T; Morizane, C; Muto, M; Nakai, Y; Negoro, Y; Nemoto, N; Ozaka, M; Sakai, D; Shimizu, S; Tsuda, M; Tsuji, A; Ueno, M | 1 |
| Einama, T; Fujii, Y; Fukai, M; Hatanaka, Y; Kamachi, H; Kawamata, F; Kobayashi, N; Matsuzawa, F; Mizukami, T; Taketomi, A | 1 |
| Chang, M; Hang, T; Hu, Z; Liu, Y; Ning, M; Song, M; Wu, W; Xu, X | 1 |
| Cho, SK; Ediriweera, MK; Kim, HY; Moon, JY; Ryu, JY | 1 |
| Fujimura, A; Ichimiya, S; Imaizumi, A; Koga, S; Nagao, S; Nakamura, M; Nakayama, K; Oda, Y; Onishi, H; Oyama, Y; Sakihama, K | 1 |
| Akhoundova, D; Bachmann, H; Breitenstein, S; Clavien, PA; Knuth, A; Nguyen-Kim, TDL; Pestalozzi, B; Petrowsky, H; Pietge, H; Samaras, P; Sánchez-Velázquez, P; Siebenhüner, A; Winder, T | 1 |
| Choi, KY; Han, G; Lee, SH; Ryu, WJ | 1 |
| Atlı Şekeroğlu, Z; Aydın, B; Işık, S; Şekeroğlu, V | 1 |
| Cao, Z; Feng, M; Gu, J; Guan, W; Guo, W; Liu, Y; Qiu, J; Xiong, G; Yang, G; You, L; Zhang, MQ; Zhang, T; Zhao, F; Zhao, Y | 1 |
| Im, HS; Jeong, H; Kim, HD; Kim, JH; Lee, JL; Park, I; Yoon, SK | 1 |
| Gao, Q; Guo, H; Jia, W; Liu, Q; Sun, J; Tan, F; Yu, J; Zhu, H | 1 |
| Fan, F; Jin, L; Yang, L | 1 |
| Chen, X; Guo, G; He, W; Quan, Q; Wang, F; Wang, Y; Zhang, B; Zhang, D | 1 |
| Billingsley, KG; Dewey, EN; Enestvedt, CK; Mayo, SC; Orloff, SL; Sutton, TL; Walker, BS | 1 |
| Bau, L; Browning, RJ; Callan, JF; Folkes, L; Gray, MD; Hampson, A; Kamila, S; Kiltie, AE; McHale, AP; Ruan, JL; Stride, E; Vojnovic, B; Yildiz, YO | 1 |
| Ariake, K; Douchi, D; Fukase, K; Hayashi, H; Kawasaki, S; Masuda, K; Mizuma, M; Morikawa, T; Motoi, F; Nakagawa, K; Ohtsuka, H; Sato, M; Sato, Y; Unno, M | 1 |
| Becker, D; Kendre, G; Kühnel, F; Lorz, G; Marhenke, S; Marquardt, JU; Murugesan, K; Pich, A; Poth, T; Reineke-Plaaß, T; Saborowski, A; Saborowski, M; Vogel, A; Wirtz, RM; Woller, N | 1 |
| Cordoba, R; Eyre, TA; Luminari, S | 1 |
| Bau, L; Browning, RJ; Callan, JF; Elliott, A; Gray, M; Kamila, S; Kiltie, AE; McHale, AP; Ruan, JL; Smart, S; Stride, E; Thompson, J; Vojnovic, B; Yildiz, YO | 1 |
| Bates, SE; Conroy, T; Fojo, T; Juzyna, B; Mutetwa, T; Nadkarni, G; Park, YA; Polak, P; Sigel, C; Sigel, K; Wisnivesky, JP; Ychou, M; Yeh, C; Zhou, M | 1 |
| Cho, YM; Hong, B; Kim, YS; Lee, JL; Lee, Y | 1 |
| Ambrosini, R; Berruti, A; Cosentini, D; Ferrari, L; Ferrari, VD; Grisanti, S; Laganà, M; Lazzari, B; Morandi, A; Sigala, S; Volta, AD | 1 |
| Gao, C; Hu, L; Li, C; Lv, D; Mao, X; Wang, T; Xu, Y | 1 |
| Byeon, S; Hong, JY; Jang, KT; Kang, WK; Kim, H; Kim, J; Kim, ST; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
| He, Y; Wei, X; Weng, Z; Xu, C; Zhao, Y; Zhou, X | 1 |
| Brooks, T; Massey, AJ; Wayne, J | 1 |
| Cheon, MJ; Fang, Z; Han, B; Hong, SS; Jung, KH; Kang, YW; Kim, JS; Kim, SJ; Kim, YS; Lee, JE; Lim, JH; Park, JH; Seo, MS; Shin, SM; Son, MK; Woo, MG; Yan, HH; Yoon, YC | 1 |
| Davis, A; Gibson, EG; Roussel, MF; Stewart, CF; Zhong, B | 1 |
| Jusko, WJ; Lin, Q; Ma, WW; Mager, DE; Qian, Z; Straubinger, RM | 1 |
| Besselink, MG; Bonsing, BA; Bos, H; Bosscha, KP; Coene, PPLO; de Hingh, IHJT; de Vos-Geelen, J; Groot Koerkamp, B; Homs, MYV; Janssen, QP; Karsten, TM; Liem, MSL; Loosveld, OJL; Patijn, GA; van Dam, JL; van der Kolk, MB; van Eijck, CHJ; van Santvoort, HC; van Tienhoven, G; Wilmink, JW; Zonderhuis, BM | 1 |
| Chung, N; Han, TY; Jung, SH; Lee, DG; Pak, PJ; Park, SH; Sung, JH | 1 |
| Becker, S; Belhadj, K; Camus, V; Carvalho, M; Cazelles, C; Dupuis, J; El Gnaoui, T; Gaulard, P; Haioun, C; Itti, E; Jardin, F; Le Bras, F; Lemonnier, F; Mounier, N; Poullot, E; Roulin, L; Tilly, H; Vellemans, H; Veresezan, L | 1 |
| Chen, X; Gao, G; Guo, Y; Liang, G; Liu, J; Wang, D; Wu, FG; Wu, Y; Zhang, X; Zhao, Y | 1 |
| Aviñó, A; Cabrero, C; Eritja, R; Gargallo, R; González, C; Martín-Pintado, N; Mazzini, S | 1 |
| Araki, M; Edamura, K; Iwata, T; Katayama, S; Kobayashi, Y; Nasu, Y; Nishimura, S; Sadahira, T; Sako, T; Takamoto, A; Wada, K; Watanabe, M; Watanabe, T | 1 |
| Goodwin, A; Im, SA; Kim, SB; Lanzalone, S; Lee, KH; Sohn, J; Usari, T | 1 |
| Chen, R; Fu, Z; Huang, L; Li, G; Lin, Q; Lu, Y; Wei, L; Zhou, Q | 1 |
| Gavriatopoulou, M; Kyriazoglou, A; Liontos, M; Ntanasis-Stathopoulos, I | 1 |
| Dedonyte, V; Kurlinkus, B; Schemmer, P; Sileikis, A; Valius, M; Zalyte, E | 1 |
| Adachi, S; Chishima, T; Doi, T; Endo, I; Hasegawa, S; Ichikawa, Y; Ishikawa, T; Kito, A; Morita, S; Morita, T; Narui, K; Oba, M; Shimada, K; Shimizu, D; Sugae, S; Tanabe, M; Yamada, A; Yamamoto, S | 1 |
| Goto, M; Hori, K; Ito, K; Nakagawa, M; Ono, H; Onoue, M; Shimoji, K; Shiomi, M; Suzuki, J; Tashima, L; Uragami, K; Yamashita, M; Yoshioka, E | 1 |
| Han, HS; Hwang, JH; Kim, H; Kim, J; Lee, JC; Shin, DW; Yoon, YS | 1 |
| Coppens, E; Couvreur, P; Desmaële, D; Mougin, J; Mura, S; Tusseau-Nenez, S | 1 |
| Beg, MS; Brekken, RA; Du, W; Huang, H; Lorens, JB; Phinney, NZ; Toombs, JE; Wang, Z; Westcott, J; Wilkie, TM; Zhang, Y | 1 |
| Astaras, C; Borner, M; De Dosso, S; Fritsch, R; Meisel, A; Siebenhüner, AR; Szturz, P; Winder, T | 1 |
| MacCuaig, WM; McNally, LR | 1 |
| Aoki, T; Iso, Y; Kubota, K; Matsumoto, T; Mori, S; Park, KH; Sakuraoka, Y; Shimizu, T; Shiraki, T; Yamaguchi, T | 2 |
| Bao, PT; Lin, H; Liu, XF; Mu, M; Pan, P; Tian, FF; Wang, Q; Zhang, R; Zhao, WG | 1 |
| Amini, A; Attiyeh, MA; Chung, V; Melstrom, LG | 1 |
| Brown, ZJ; Cloyd, JM | 1 |
| Chen, HB; Chen, SW; Fei, Q; He, X; Xu, JJ; Zhang, CM | 1 |
| Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Berger, AK; Bougatf, N; Busch, E; Hackert, T; Jäger, D; Springfeld, C; Werft, W | 1 |
| Furukawa, K; Gocho, T; Onda, S; Sakamoto, T; Shiba, H; Shiozaki, H; Uwagawa, T; Yanaga, K; Yasuda, J | 1 |
| Burdio-Pinilla, F; Casasola-Sánchez, LE; Pereira-Rodríguez, JA; Radosevic, A; Sánchez-Velázquez, P; Visa, L | 1 |
| Cui, J; Guo, Y; Peng, T; Wu, H; Xiong, J | 1 |
| Li, F; Liang, S; Liu, H; Wu, H; Xu, Y | 1 |
| Al-Lohedan, HA; Ali, MS; Subbarao, N; Waseem, M | 1 |
| Bischoff, S; Blau, O; Briest, F; Bullinger, L; Christen, F; Damm, F; Hablesreiter, R; Hoyer, K; Hummel, M; Inoue, Y; Kakiuchi, N; Keilholz, U; Lohneis, P; Ogawa, S; Pelzer, U; Putter, H; Riess, H; Shiozawa, Y; Shiraishi, Y; Sinn, M; Striefler, JK; Yoshida, K; Yoshizato, T | 1 |
| Honeywell, RJ; Opperman, RCM; Peters, GJ; Poel, D; van der Vliet, HJ; van Zweeden, AA; Verheul, HMW | 1 |
| Custodio, A; Feliu, J; Garcia-Cuesta, JA; Ghanem, I; Gutierrez-Sainz, L; Martinez-Perez, D; Villamayor, J; Viñal, D | 1 |
| Liu, D; Liu, X; Qiu, R; Zhang, W | 1 |
| Duan, Z; Gong, Q; Gu, Z; Guo, C; Li, N; Luo, K; Wang, L; Zhang, H | 1 |
| Alig, S; Bararia, D; Boeck, S; Haas, M; Haebe, S; Heinemann, V; Kobold, S; Kruger, S; Metzger, P; Ormanns, S; Rataj, F; Sams, L; von Bergwelt-Baildon, M; Weigert, O; Werner, J; Westphalen, CB; Zhang, D | 1 |
| Cui, R; Ji, M; Jin, SY; Li, H | 1 |
| Chu, W; Gou, J; He, H; Liu, Z; Sun, Q; Tan, X; Tang, X; Yin, T; Zhang, Y; Zhao, L | 1 |
| Schaub, JR; Tang, SC | 1 |
| Fujii, Y; Fukai, M; Kamachi, H; Kobayashi, N; Matsuzawa, F; Mizukami, T; Taketomi, A | 1 |
| Alva, A; Bandini, M; Curran, C; Diamantopoulos, LN; Gallina, A; Grivas, P; Grunewald, CM; Gupta, S; Jain, RK; Lee, JL; McGregor, BA; Mossanen, M; Necchi, A; Niegisch, G; Olson, KM; Pond, GR; Ravi, P; Singh, P; Skelton, WP; Sonpavde, GP; Su, C; Tward, JD | 1 |
| Caffrey, TC; Crawford, A; Grunkemeyer, J; Hollingsworth, MA; Leclerc, E; Neville, T; O'Connell, KA; Patil, P; Radhakrishnan, P; Shin, S; Swami, P; Thiyagarajan, S; Vetter, SW | 1 |
| Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS | 1 |
| Kakehi, Y; Liu, D; Matsuoka, Y; Sugimoto, M; Taoka, R; Tohi, Y; Zhang, X | 1 |
| Dahl, E; Eschenbruch, J; Gaisa, NT; Gan, L; Kistermann, J; Knüchel, R; Noetzel, E; Rose, M; Rushrush, S | 1 |
| Binda, E; Latiano, TP; Panebianco, C; Pazienza, V; Perri, F; Potenza, A; Terracciano, F; Trivieri, N; Villani, A | 1 |
| Emamzadeh, M; Pasparakis, G | 1 |
| Hamura, R; Horiuchi, T; Ikegami, T; Kanegae, Y; Ohashi, T; Saito, N; Shimada, Y; Shirai, Y; Takada, N; Taniai, T; Yanaga, K | 1 |
| Leung, E; Lozano Hernandez, L; Reginald-Opara, JN; Svirskis, D; Tang, M; Wang, H; Wu, Z | 1 |
| Bahra, M; Bischoff, S; Kruger, S; Kurreck, A; Modest, DP; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Weckwerth, J | 1 |
| Agopsowicz, K; Burlot, C; Cardinal, O; Craig, M; Crosley, P; Farkkila, A; Fu, Y; Heikinheimo, M; Hitt, MM; Jenner, AL; Pihlajoki, M; Potts, KG | 1 |
| Barrios-Anderson, A; Radhakrishnan, R; Shimanovsky, A; Yu, E | 1 |
| Bhol, CS; Bhutia, SK; Mohapatra, S; Panda, S | 1 |
| Barth, DA; Djanani, A; Gantschnigg, A; Gerger, A; Greil, R; Horvath, L; Moik, F; Pichler, M; Posch, F; Renneberg, F; Riedl, JM; Rossmann, CH; Schaberl-Moser, R; Schlick, K; Schwarzenbacher, E; Stöger, H; Stotz, M | 1 |
| Ashrafi-Zadeh, A; Chan, DL; Chua, TC; Clarke, S; Diakos, C; Gill, A; Hruby, G; Jamieson, NB; Kneebone, A; Maloney, S; Mittal, A; Nahm, CB; Pavlakis, N; Samra, JS; Wijetunga, AR | 1 |
| Hagiwara, S; Higuchi, T; Hori, R; Ioroi, T; Kano, M; Kato, Y; Kitahara, H; Kitahashi, T; Komori, T; Kori, H; Matsumoto, T; Ono, K; Sakabe, M; Yoshino, Y | 1 |
| Awaya, Y; Fujitaka, K; Furutama, J; Hamai, K; Hattori, N; Horimasu, Y; Ishikawa, N; Kitaguchi, S; Kondo, T; Masuda, T; Miyamoto, S; Nishida, A; Shoda, H; Takao, S; Tamamoto, S; Yamasaki, M | 1 |
| Eurola, A; Haglund, C; Hagström, J; Mustonen, H; Nurmi, AM; Ristimäki, A; Seppänen, H | 1 |
| Chen, B; Li, J; Xi, WQ; Yang, C; Zhang, WX | 1 |
| Fujisaki, H; Hara, J; Hira, K; Ishii, Y; Matsubara, K; Nitani, C; Okada, K; Okuhiro, Y; Tanimura, K; Yamasaki, K | 1 |
| Hara, S; Hiramoto, N; Ishikawa, T; Nishikubo, M; Sawamura, N; Shimomura, Y; Yamaguchi, T | 1 |
| Asano, T; Isono, M; Okubo, K; Sato, A | 2 |
| Atherton, PJ; Bajorin, D; Ballman, KA; Dreicer, R; Flaig, TW; Hahn, O; Halabi, S; Hoimes, C; Katragadda, S; Misleh, J; Morris, MJ; Mortazavi, A; Picus, J; Plimack, ER; Rosenberg, JE; Small, EJ; Stadler, WM; Sweeney, C; Tagawa, ST; Teply, BA; Vaena, D | 1 |
| Gou, S; Liao, Z; Xu, Z; Zhang, B | 1 |
| Liu, A; Tang, X; Xu, J; Zhao, T; Zhou, B; Zhou, Y | 1 |
| Aoki, T; Hayakawa, F; Hikita, T; Iwamoto, E; Kagaya, Y; Kiyoi, H; Kunou, S; Oneyama, C; Sakamoto, A; Sanada, M; Shimada, K; Shimada, S; Takai, M | 1 |
| Dieudé, P; Forien, M; Gounant, V; Jelin, G; Ottaviani, S; Palazzo, E; Pina Vegas, L | 1 |
| Fukahori, M; Kakuma, T; Miwa, K; Murotani, K; Nagasu, S; Naito, Y; Okabe, Y; Sakaue, T; Suga, H; Tanaka, T; Torimura, T; Ushijima, T | 1 |
| Chung, V; Fakih, M; Franko, J; Le, VH; Paz, BI; Singh, G | 1 |
| Asleh, K; Balslev, E; Gao, D; Jensen, MB; Leung, S; Lænkholm, AV; Nielsen, D; Nielsen, LB; Nielsen, TO; Riaz, N; Stovgaard, ES | 1 |
| Azih, I; Escudero, DO; Ghosh, S; Hasanali, SL; Hennig, M; Hupe, MC; Jordan, AR; Kuczyk, MA; Lokeshwar, VB; Lopez, LE; Merseburger, AS; Morera, DS; Racine, RR; Sarcan, S; Terris, MK; Wang, J; Zhou, M; Zhu, H | 1 |
| Cui, J; Pan, LX; Tan, HF; Xiao, Z; Zhang, LL | 1 |
| Callan, B; Callan, JF; Gao, J; Logan, KA; Love, M; McHale, AP; McKaig, T; Nesbitt, H; Taylor, M | 1 |
| Archibald, CJ; Hunt, JT; Pattarawat, P; Poloway, J; Wang, HR | 1 |
| Elloumi, F; Jo, U; Kim, SH; Murai, Y; Pommier, Y; Rajapakse, VN; Saha, LK; Schultz, CW; Senatorov, IS; Takahashi, N; Thomas, A; Zenke, FT; Zimmermann, A | 1 |
| Bhutkar, S; Dukhande, V; Patel, K; Patki, M; Saraswat, A | 1 |
| Cang, S; Chen, G; Cui, J; Du, Y; Fan, M; Fan, Y; Fang, J; Hu, C; Huang, D; Li, B; Li, J; Li, Y; Liu, L; Sun, P; Wang, S; Wang, Z; Wu, L; Xue, J; Yang, Z; Zhang, L; Zhang, W; Zhao, H; Zhou, C; Zhou, H; Zhou, J | 1 |
| Carnevalli, LS; Dunlop, CR; Fernández, SBQ; Jodrell, DI; Johnson, TI; Kottmann, D; Lau, A; Minteer, CJ; Richards, FM; Wallez, Y | 1 |
| Chovanec, M; Kalavska, K; Mardiak, J; Mego, M; Obertova, J; Palacka, P; Reckova, M; Rejlekova, K; Svetlovska, D; Sycova-Mila, Z | 1 |
| Aoyama, T; Fujita, M; Harada, T; Hirano, R; Igata, F; Inoue, H; Nakao, A; Osaki, Y | 1 |
| Amin, S; K Pandey, M; Karelia, DN; Kim, S; Lu, J; Plano, D; Sharma, AK | 1 |
| Bartolini, G; Bernardini, L; Casadei-Gardini, A; Cucchetti, A; Frassineti, GL; Massa, V; Passardi, A; Rapposelli, IG; Vivaldi, C | 1 |
| Chen, G; Deng, T; Ding, X; Li, J; Wang, Y; Wu, L; Xie, X; Yang, Z; Ye, L; Yu, H; Yu, Z; Zheng, Y; Zhu, Q | 1 |
| Cass, I; Kamrava, M; Karlan, B; Kim, S; Li, A; Rimel, BJ; Rogatko, A; Walsh, CS | 1 |
| Brody, JR; Brown, D; Delaney, LJ; Eisenbrey, JR; Forsberg, F; Jimbo, M; Liu, JB; Oeffinger, BE; Stanczak, M; Wheatley, MA | 1 |
| Hashimoto, D; Hirooka, S; Inoue, K; Ishida, M; Ryota, H; Sakaguchi, T; Satoi, S; Sekimoto, M; Yamaki, S; Yamamoto, T | 1 |
| Ando, M; Ebata, T; Igami, T; Maeda, O; Mizuno, T; Onoe, S; Takahashi, D; Watanabe, N; Yamaguchi, J; Yokoyama, Y | 1 |
| Shang, H; Sun, L; Wu, Y; Xin, X | 1 |
| Bivalacqua, TJ; Brooks, N; Crump, T; DeWolf, WC; Hyndman, ME; Kamat, AM; Kates, M; Lamm, DL; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Steinberg, RL; Thomas, LJ; Vitale, A; Wang, J | 1 |
| Ebadi, M; Gordon, DJ; Gordon, PM; Jonart, LM; Koppenhafer, SL; Ostergaard, J | 1 |
| Cheng, C; Lovell, JF; Sun, H; Wu, Y; Yan, L; Zhang, R | 1 |
| Minomi, K; Tamura, Y; Yoneda, A | 1 |
| Akahoshi, K; Ban, D; Fujii, M; Kato, T; Kudo, A; Ogawa, K; Ogura, T; Ono, H; Tanabe, M; Tanaka, S | 1 |
| Cai, X; Chao, H; Chen, M; Jiang, Y; Lu, X | 1 |
| Cleves, A; Dahm, P; Han, MA; Hwang, EC; Hwang, JE; Jung, JH; Maisch, P; Narayan, V | 2 |
| Cao, M; Chen, C; Chen, G; Chen, Y; Fan, J; Feng, Q; Guo, Y; Lai, C; Lin, S; Mi, J; Tian, J; Tian, L; Xi, N; Yu, L; Zhang, F; Zhang, Y | 1 |
| Adachi, H; Hotta, H; Ito, N; Kato, R; Kunishima, Y; Maehana, T; Masumori, N; Matsukawa, M; Shindo, T; Tachiki, H; Taguchi, K; Takahashi, A; Tanaka, T | 1 |
| Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Kobayashi, R; Miyazawa, M; Okada, KI; Ueno, M; Yamaue, H | 1 |
| Furukawa, T; Kasuga, A; Matsuyama, M; Mie, T; Mori, C; Okamoto, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, Y | 1 |
| Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Iwai, T; Kamata, K; Katanuma, A; Kataoka, T; Kato, N; Kawamoto, Y; Kojima, Y; Miyakawa, H; Miyamoto, A; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nishina, T; Okano, N; Okusaka, T; Oono, T; Ozaka, M; Sano, K; Shimizu, K; Shimizu, S; Shioji, K; Shirakawa, H; Sudo, K; Sugimori, K; Takahashi, H; Tobimatsu, K; Todaka, A; Ueno, M; Yamaguchi, H; Yamamoto, T; Yamashita, T; Yasuda, I | 1 |
| Gotoda, T; Hemmi, A; Iwatsuka, K; Kikuta, D; Moriyama, M; Nakagawara, H; Ogawa, M; Shibuya, H; Yamao, K | 1 |
| Chu, PY; Lai, HY; Liang, HY; Liu, YB; Shen, WJ; Wang, JM; Wang, WJ; Zhang, F | 1 |
| Li, S; Liu, X; Zhang, X | 1 |
| Curran, C; Dranitsaris, G; Kilbridge, KL; Mantia, C; McGregor, BA; Montazeri, K; Mossanen, M; Preston, MA; Ravi, P; Sonpavde, G; Steele, GS; Thomas, JD | 1 |
| Wu, Y; Xu, W; Yang, Y; Zhang, Z | 1 |
| Bian, W; Liu, JH; Liu, SG; Lv, HT; Wang, WB; Xing, L; Zhang, TF | 1 |
| Asby, S; Beatty, M; Blauvelt, J; Innamarato, P; Kidd, S; Mackay, A; Morse, J; Mullinax, JE; Pilon-Thomas, S; Sarnaik, AA | 1 |
| Li, Y; Paxton, JW; Wu, Z; Xu, H | 1 |
| Chen, H; Cheng, T; Cheng, Z; Wang, L; Xie, P; Yang, Y; Zhou, J | 1 |
| Farrow, JM; Gryzinski, GM; Kern, SQ; Sundaram, CP | 1 |
| Amé, JC; Burckel, H; Mura, C; Noël, G; Waissi, W | 1 |
| Bokas, A; Felekouras, E; Karamouzis, MV; Koustas, E; Papadimitropoulou, A; Papakotoulas, P; Papalampros, A; Papavassiliou, AG; Sarantis, P; Schizas, D; Theocharis, S | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Kawaguchi, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Murayama, K; Nakashita, S; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Oza, N; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Takahashi, H; Ueda, Y; Ureshino, N | 1 |
| Brede, CM; Broekhuizen, HT; Busman, RD; Kuipers, SK; Kuperus, JM; Lane, BR; Noyes, SL; Tobert, CM | 1 |
| Arima, S; Fukahori, M; Hashimoto, S; Honda, T; Ide, Y; Ido, A; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Fujii, H; Iihara, H; Iwashita, T; Kato-Hayashi, H; Kobayashi, R; Ohata, K; Sadaka, S; Shimizu, M; Suzuki, A; Uemura, S | 1 |
| Beilhack, A; Caruana, I; Miele, E; Mokhtari, Z; Schlegel, PG; Schneider, T; Schwinn, S; Sirén, AL; Thusek, S; Tiemeyer, N; Wölfl, M | 1 |
| Chang, YH; Huang, HS; Lu, MC; Tam, HL | 1 |
| Cao, Y; Jiang, L; Jin, G; Ju, X; Liu, W; Ye, Y; Zhang, H; Zhao, X; Zhu, X | 2 |
| Cao, J; Du, Y; Hu, X; Li, T; Liu, X; Tao, Z; Wang, B; Wang, L; Zhang, J; Zhu, Y | 1 |
| Fujimoto, N; Harada, M; Inatomi, H; Minato, A; Onishi, R; Terado, M; Tomisaki, I | 1 |
| Yuasa, T | 1 |
| Adachi, T; Doi, S; Katsukura, N; Kikuchi, K; Kikuyama, T; Matsui, K; Matsumoto, K; Namura, Y; Okamoto, K; Saito, G; Tsujikawa, T; Tsunashima, H; Watanabe, A | 1 |
| Attri, KS; Auwerx, J; Chaika, NV; Chaudhary, S; Fu, X; He, C; High, RR; Hu, T; Jha, K; King, RJ; Lan, P; Lazenby, A; Mai, A; Mehla, K; Mulder, SE; Mullen, NJ; Murthy, D; Pacheco, CG; Rotili, D; Shukla, SK; Siddhanta, K; Singh, PK; Steegborn, C; Tafani, M; Thakur, R; Tuveson, D; Valente, S; Verdin, E; Vernucci, E; Wang, D; Yu, F | 1 |
| Esmaeili, E; Karami, C; Moradi, S; Shahlaei, M; Shekarbeygi, Z | 1 |
| Baydogan, S; Dong, W; Fogelman, DR; Hasanov, M; Javle, MM; Katz, MHG; Kim, MP; Lotze, MT; McAllister, F; Mizrahi, JD; Mohindroo, C; Overman, MJ; Pant, S; Prakash, LR; Rogers, JE; Tzeng, CD; Varadhachary, GR; Wolff, RA | 1 |
| Furukawa, T; Kasuga, A; Kawano, F; Matsuyama, M; Mie, T; Mori, C; Okamoto, T; Ono, Y; Ozaka, M; Sasahira, N; Sasaki, T; Takahashi, Y; Takamatsu, M; Takeda, T; Yamada, Y | 1 |
| Ay, C; Barth, DA; Djanani, A; Fandler-Höfler, S; Gantschnigg, A; Gary, T; Gerger, A; Greil, R; Gressenberger, P; Hatzl, S; Horvath, L; Jost, PJ; Moik, F; Pichler, M; Posch, F; Renneberg, F; Riedl, JM; Schlick, K; Schwarzenbacher, E; Stotz, M | 1 |
| Babu, D; Gautam, M; Karuppaiah, A; Natrajan, T; Nesamony, J; Rajan, R; Ranganathan, H; Sankar, V; Selvaraj, D; Siram, K | 1 |
| Jia, Z; Tang, M; Zhang, J | 1 |
| Han, L; Jiang, S; Kuerban, K; Li, S; Pan, S; Wang, R; Ye, L; Yuan, Y | 1 |
| Aoyama, T; Hama, T; Hashiguchi, M; Hori, S; Ito, G; Kawakami, K; Kizaki, H; Nakamura, M; Ozaka, M; Sasahira, N; Yokokawa, T | 1 |
| Cui, J; Cui, X; Gong, W; Han, X; Lau, WY; Li, H; Li, M; Li, X; Liu, Y; Ren, T; Song, X; Wang, L; Wang, X; Wu, W; Wu, X; Zhu, Y; Zou, L | 1 |
| Bao, JM; Chen, MK; Chen, ZJ; Duan, HF; Guo, WB; Huang, ZP; Liang, ZJ; Liao, DY; Liu, CD; Liu, Y; Qin, ZK; Wang, HY; Wang, P; Xia, M; Xie, X; Xue, KY; Yang, C; Yang, JK; Ye, YL; Zhou, JH; Zhou, JW; Zhou, QZ | 1 |
| Burns, G; Greystoke, A; Iqbal, MS; Robinson, M; Rodriguez, CN | 1 |
| Guleria, A; Jain, P; Jangid, AK; Kulhari, H; Patel, K; Patel, S; Pooja, D | 1 |
| Hayuka, K; Murakami, A; Nishiuchi, T; Okano, K; Okita, Y; Okuyama, H; Suzuki, Y; Tsuji, A | 1 |
| Ando, R; Etani, T; Hamamoto, S; Iida, K; Isobe, T; Kawai, N; Kubota, H; Matsumoto, D; Nagai, T; Naiki, T; Noda, Y; Nozaki, S; Shimizu, N; Sugiyama, Y; Yasui, T | 1 |
| Benhamou, Y; Chiche, NJ; Coindre, JP; Coppo, P; Daviet, F; François, A; Frémeaux-Bacchi, V; Grall, M; Grangé, S; Guerrot, D; Karras, A; Pouteil-Noble, C; Presne, C; Provot, F; Veyradier, A | 1 |
| Bartos, P; Bartunkova, J; Chovanec, J; Cibula, D; Fucikova, J; Galluzzi, L; Hassan, HIB; Hein, A; Hraska, M; Hrnciarova, T; Kieszko, D; Klat, J; Knapp, P; Madry, R; Mallmann, P; Markowska, J; Melichar, B; Minar, L; Pecen, L; Pluta, M; Rob, L; Spacek, J; Spisek, R; Streb, J; Valha, P; Wimberger, P | 1 |
| Bae, SB; Kim, CK; Kim, HJ; Kim, KH; Kim, SH; Lee, KT; Lee, MY; Lee, N; Lee, SC; Lee, YN; Lim, SH; Moon, JH; Park, SK; Yun, J | 1 |
| David, KI; Krishnan, UM; Ravikumar, TS; Sethuraman, S | 1 |
| Correia, C; Ferreira, A; Lapa, R; Santos, J; Urtti, A; Vale, N; Yliperttula, M | 1 |
| Chen, J; Hua, Q; Lin, Z; Pi, G; Wang, H; Yu, D; Zhang, D; Zhang, T; Zhao, L | 1 |
| Gao, S; Hao, J; Huang, C; Li, X; Liu, J; Liu, W; Ma, Y; Wang, H; Wang, X; Wang, Z; Wu, L; Yang, S; Yu, X; Zhao, T | 1 |
| Choi, IS; Kim, JH; Kim, JS; Kim, JW; Kim, KH; Kim, YJ; Lee, JH; Park, JH; Suh, KJ | 1 |
| Arscott, WT; Bear, A; Ben-Josef, E; Drebin, J; Lee, MK; Loaiza-Bonilla, A; Lukens, JN; Metz, J; Nead, KT; O'Hara, M; Plastaras, JP; Reiss, KA; Shabason, J; Shroff, SG; Teitelbaum, U; Venigalla, S; Wojcieszynski, A | 1 |
| Ata, FK; Yalcin, S | 1 |
| Adjei, A; Attwood, K; Bshara, W; Evans, R; Fountzilas, C; Ghasemi, M; Goey, A; Groman, A; Iyer, R; Ma, WW; Opyrchal, M; Wilton, J | 1 |
| Bai, Y; Chen, D; Deng, J; Guo, H; Guo, Y; Lan, J; Liu, X; Wang, J; Xiao, Y; Zhang, Q; Zhu, H | 1 |
| Hamada, S; Masamune, A; Matsumoto, R; Taguchi, K; Tanaka, Y; Yamamoto, M | 1 |
| Hua, J; Liang, C; Liu, J; Lu, SY; Meng, QC; Shi, S; Wang, W; Wei, MY; Xu, J; Yu, XJ; Zhang, B | 1 |
| Chung, H; Han, J; Jeong, H; Kim, J; Lee, Y; Woo, YA | 1 |
| Barman, S; Batra, SK; Chauhan, S; Dhawan, P; Fatima, I; Ponnusamy, MP; Rachagani, S; Rauth, S; Singh, AB; Smith, L; Talmon, G; Uppada, J | 1 |
| Hamada, S; Kadowaki, D; Miyamura, S; Nishimura, F; Oniki, K; Saruwatari, J; Ushijima, T | 1 |
| Chen, D; Chen, QY; Chen, X; Chen, Y; Feng, H; He, X; Hsieh, CY; Hu, C; Jiang, Y; Jin, F; Jing, S; Keegan, P; Li, J; Li, P; Li, Q; Liao, W; Lim, WT; Lin, X; Liu, YC; Liu, Z; Lu, Y; Mai, HQ; Pan, J; Qu, S; Samol, J; Shi, YR; Wang, HM; Wen, J; Xu, R; Xu, RH; Yang, K; Yang, MH; Yao, S; Yen, CJ; Yuan, X | 1 |
| Baron, MK; Garrido-Laguna, I; Haaland, B; Moser, JC; Nevala-Plagemann, C; Wang, X | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Ido, A; Kawahira, M; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Abuelafia, AM; Bigonnet, M; Chuluyan, E; Cros, J; Dusetti, N; Fraunhoffer, NA; Gayet, O; Iovanna, J; Nicolle, R; Palazzo, L; Teyssedou, C | 1 |
| Han, BR; Jung, HA; Jung, JY; Kim, HJ; Kim, HY; Zang, DY | 1 |
| Bogdanov, AA; Chubenko, VA; Klimenko, VV; Knyazev, NA; Moiseyenko, VM; Terterov, IN | 1 |
| Cao, JX; Lu, FT; Luo, F; Luo, M; Luo, QY; Ma, WJ; Pan, WT; Qiu, MZ; Xia, ZF; Yang, DJ; Zeng, KM; Zhang, L; Zhang, ZH; Zhao, HY; Zhou, T | 1 |
| Abou-Alfa, GK; Bekaii-Saab, TS; Bitzer, M; Borad, MJ; Borbath, I; El-Khoueiry, A; Goyal, L; Javle, M; Kelley, RK; Li, A; Macarulla, T; Moran, S; Pande, A; Philip, PA; Roychowdhury, S; Sadeghi, S; Shepherd, SP; Soifer, HS; Tanasanvimon, S; Waldschmidt, DT; Weiss, KH; Yong, WP; Zhu, AX | 1 |
| Chambers, C; Chen, A; Eurich, DT; Ha, V; McCall, M; Sawyer, MB; Youn, S | 1 |
| Cavaletti, G; Celio, L; Damian, S; Malacrida, A; Mazzaferro, V; Miloso, M; Rigolio, R | 1 |
| Aps, LRMM; Bitencourt Rodrigues, K; Cestari Moreno, N; de Oliveira Diniz, M; de Oliveira Silva, M; de Souza Ferreira, LC; Menck, CFM; Porchia, BFMM; Ramos da Silva, J; Ramos Moreno, AC; Silva Sales, N; Venceslau-Carvalho, AA | 1 |
| Bi, R; Li, L; Wang, L; Yin, H; Zhou, K | 1 |
| Bapiro, TE; Bautista, W; Chen, V; Gilbert, DJ; Guerin, TM; Jodrell, DI; Kim, SJ; Kozlov, S; Kumar, P; Li, D; Mehta, M; Ock, CY; Palena, C; Pate, N; Richards, FM; Rudloff, U; Schaub, N; Schlomer, JJ; Sorber, R; Talsania, K; Teper, Y; Zhao, Y | 1 |
| Abdallah, IB; Balti, M; Chourabi, C; Fehri, W; Haddaoui, A; Nasr, SB; Zribi, A | 1 |
| Arango-Bravo, E; Brau-Figueroa, H; Castro-Eguiluz, D; Cetina-Pérez, L; Cruz-Bautista, I; Galicia-Carmona, T; Jiménez-Lima, R; Lugo-Alferez, LA | 1 |
| Akshinthala, D; Clohessy, JG; Gaglia, G; Gray, NS; Hidalgo, M; Ke, S; Kibe, S; Kim, N; Koikawa, K; Lee, TH; London, N; Lu, KP; Manz, TD; Muthuswamy, SK; Nakamura, M; Nezu, Y; Oda, Y; Ohuchida, K; Pinch, BJ; Qiu, C; Santagata, S; Sekino, N; Suizu, F; Verma, A; Wegiel, B; Wulf, GM; Zhou, XZ | 1 |
| Chen, X; Dong, T; Ji, J; Kuang, P; Li, J; Liu, J; Liu, T; Liu, Z; Shen, K; Zhang, C; Zhang, L | 1 |
| Croagh, D; Deswaerte, V; Gao, H; Gearing, LJ; Hertzog, PJ; Jenkins, BJ; Lundy, J; McLeod, L; Pajic, M; Porazinski, S; West, AC; Yu, L | 1 |
| Abdelrahman, AM; Ahn, DH; Alva-Ruiz, R; Arora, M; Baker, AT; Barrett, MT; Bekaii-Saab, TS; Bogenberger, JM; Borad, MJ; Braggio, E; Buetow, KH; Chen, X; Dumbauld, CR; Egan, JB; Eskelinen, EL; Gamb, SI; Kosiorek, HE; Leiting, JL; Mansfield, AS; Meurice, N; Nagalo, BM; Roberts, LR; Salomao, MA; Serrano Uson Junior, PL; Sonbol, MB; Truty, MJ; Yonkus, J; Zhou, Y | 1 |
| Kang, W; Li, Y; Liao, J; Xiao, L | 1 |
| Guo, J; Shang, Y; Song, J; Wang, J; Wang, T; Xu, J | 1 |
| Dong, A; Li, X; Wang, H; Xu, S | 1 |
| Cui, Y; Dreicer, R; Emamekhoo, H; Frankel, PH; Hoimes, C; Kim, WY; Lara, PN; Lyou, Y; Michaelson, D; Milowsky, M; Mortazavi, A; Newman, E; Pal, SK; Parikh, M; Parikh, R; Srinivas, S; Teply, B; Vaishampayan, U; Weng, P; Zhang, T | 1 |
| Ahn, JH; Chae, YS; Cho, EH; Im, SA; Jang, JH; Jung, KH; Kim, JH; Kim, JY; Lee, KH; Lee, KS; Lee, SY; Park, MS; Park, YH; Sohn, J | 1 |
| Carvalho, T; Castillo Martin, M; Costa, B; Couto, N; Fior, R; Rebelo de Almeida, C; Tavares Barroso, M | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Hama, N; Hashimoto, K; Kim, Y; Kobayashi, S; Morimoto, O; Murakami, M; Nakahira, S; Shimizu, J; Sugimoto, K; Takahashi, H; Takeda, Y; Tanemura, M; Tomokuni, A; Tsujie, M; Yamada, D; Yamada, T; Yokoyama, S | 1 |
| Al-Radhi, M; Awsh, M; Baldi, S; Chu, P; Fang, J; Jia, J; Li, X; Ma, X; Peng, J; Safi, M; Shopit, A; Shu, X; Tang, Z; Wang, F; Wang, S | 1 |
| Fan, G; Hu, Q; Ji, S; Liu, M; Liu, W; Qin, Y; Xu, W; Xu, X; Ye, Z; Yu, X; Zhang, Z; Zhuo, Q | 1 |
| An, G; Fan, S; Fan, X; Gao, T; Ge, Y; Liu, H; Liu, J; Xiao, Z; Yan, R | 1 |
| Chiba, Y; Fukuoka, M; Higashiyama, M; Iked, N; Katakami, N; Mitsudomi, T; Nakagawa, K; Nakanishi, Y; Negoro, S; Nomori, H; Oda, M; Ohta, M; Saka, H; Sawa, T; Semba, H; Seto, T; Shimokawa, M; Tada, H; Yamaguchi, M; Yamashita, M; Yokoi, K | 1 |
| Belkouz, A; Besselink, MG; Busch, OR; Erdmann, JI; Franken, LC; Klümpen, HJ; Nooijen, LE; Oulad Abdennabi, I; Swijnenburg, RJ | 1 |
| Assaf, C; Blazejak, C; Gambichler, T; Gosman, J; Klemke, CD; Nicolay, JP; Olk, J; Stadler, R; Stendel, S; Stranzenbach, R; Wehkamp, U; Weyermann, M; Wobser, M | 1 |
| Chen, L; Chen, Y; He, QM; He, SW; Huang, SY; Li, XM; Li, YQ; Liu, N; Luo, WJ; Ma, J; Yang, XJ; Zhang, Y; Zhao, Y | 1 |
| Cailleau, C; Coppens, E; Couvreur, P; Desmaële, D; Feuillastre, S; Garcia-Argote, S; Michel, JP; Mura, S; Naret, T; Noiray, M; Paul, JL; Pieters, G; Prost, B; Solgadi, A | 1 |
| Athul, KK; Bhuniya, S; Cha, Y; Lee, MH; Maiti, M; Yoon, SA | 1 |
| Bonelli, C; Boni, L; Bonomi, M; Cappuzzo, F; Ceresoli, GL; de Marinis, F; Frega, S; Garassino, MC; Gervasi, E; Gianoncelli, L; Grossi, F; Grosso, F; Maconi, A; Pagano, M; Pasello, G; Pedrazzoli, P; Perrino, M; Pinto, C; Santoro, A; Soto Parra, H; Tiseo, M; Zanelli, F; Zucali, PA | 1 |
| Fukushima, K; Hayashi, H; Hosoda, K; Kobayashi, R; Kubota, K; Motoyama, H; Notake, T; Shimizu, A; Soejima, Y; Sugenoya, S; Yasukawa, K | 1 |
| Dotan, E; Handorf, E; Winer, A | 1 |
| Atri, P; Batra, SK; Bhatia, R; Cox, JL; Ganguly, K; Kaur, S; Kisling, A; Kumar, S; Mallya, K; Ram Krishn, S; Rauth, S; Shinde, D; Thomas, V; Thompson, C; Vengoji, R | 1 |
| Cai, J; Cai, Q; Fang, Y; Huang, H; Li, Z; Liu, P; Ma, S; Su, N; Tian, X; Wang, J; Xia, Y; Zhang, Y | 1 |
| Chen, X; Guo, S; Li, Y; Meng, M; Mo, G; Su, H; Xi, J | 1 |
| Grobet-Jeandin, E; Pinar, U; Rouprêt, M | 1 |
| Fan, D; Fang, J; Feng, C; He, L; Liang, W; Qin, X; Wang, Q | 1 |
| Chen, D; Chen, F; Dong, L; Liu, D; Long, J; Wan, F; Wang, Y | 1 |
| Cheng, SC; Chowdhury, D; Curtis, J; D'Andrea, AD; da Costa, AABA; Färkkilä, A; Gulhan, D; Hendrickson, AEW; Kochupurakkal, B; Kohn, EC; Kolin, DL; Konstantinopoulos, PA; Lee, EK; Liu, JF; Matulonis, UA; Polak, M; Shapiro, GI; Stover, EH; Tayob, N | 1 |
| AlMasri, SS; Bahary, N; Bartlett, DL; Boone, BA; Desilva, A; Espina, V; Liotta, LA; Lotze, MT; Loughran, P; Nassour, I; Paniccia, A; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH | 1 |
| Chen, G; Li, H; Liu, M; Lu, W; Svirskis, D; Wen, J; Ying, M | 1 |
| Jin, X; Ren, D; Shen, J; Sun, Y; Wu, H; Zhou, Y | 1 |
| Deng, L; Deng, Q; He, X; Lei, QY; Liu, C; Liu, S; Liu, Y; Lv, J; Qiang, J; Shao, ZM; Wang, D; Xia, J; Yu, Z; Zhang, L; Zhang, XY; Zhao, B; Zhou, L | 1 |
| Blanco-Prieto, MJ; Couvreur, P; Desmaële, D; Rodríguez-Nogales, C; Sebastián, V | 1 |
| Black, PC; Roumiguié, M | 1 |
| Chen, D; Chen, Q; He, C; Hu, P; Hu, Y; Huang, K; Huang, M; Niu, Y; Tang, J; Wang, C; Wang, F; Xu, F; Zeng, Z; Zhao, G; Zhao, Y | 1 |
| Au, T; Biskupiak, J; Kharat, AA; Nelson, R | 1 |
| Bai, J; Guo, H; Lei, J; Li, S; Yang, J; Zhang, S | 1 |
| Chambers, CR; Chen, A; Ghosh, S; Ha, VH; Sawyer, MB | 1 |
| Adelantado, EZ; Beck, JT; Campone, M; Chan, A; Couillebault, XM; De Laurentiis, M; Duhoux, FP; Fan, L; Greil, R; Guerreiro, N; Im, SA; Kim, SB; Kuemmel, S; Kuter, I; Kwong, A; Loirat, D; Lopez, RL; Lu, YS; Mataraza, J; Özgüroğlu, M; Sand-Dejmek, J; Scholz, CW; Singer, CF; Steger, GG; Tibau, A; Vega, E; Wimberger, P; Zamagni, C | 1 |
| Cai, J; Cai, QQ; Huang, H; Huang, HQ; Li, ZM; Liu, PP; Ma, SY; Su, N; Wang, JN; Xia, Y; Xia, ZJ; Zhang, YC | 1 |
| Chen, C; Cui, F; Lin, K; Peng, L; Sun, L; Yao, Y; Yu, Q; Zhang, Y; Zhuang, L | 1 |
| Huang, H; Wang, C | 1 |
| Chassagnon, G; Ginestet, C; Sabat, C | 1 |
| Amundsen, T; Doyle, J; Hall, JA; Raiyani, C; Wong, L | 1 |
| Ando, R; Banno, R; Etani, T; Hamamoto, S; Iida, K; Isobe, T; Kawai, N; Kubota, H; Nagai, T; Naiki, T; Naiki-Ito, A; Noda, Y; Nozaki, S; Shimizu, N; Sugiyama, Y; Tomiyama, N; Yasui, T | 1 |
| Hwang, JH; Kim, J; Kim, JH; Lee, JC; Lee, YS | 1 |
| Gao, P; Ha-Duong, T; Nicolas, J | 1 |
| Jensen, E; Nalluri, H; Staley, C | 1 |
| Gong, Y; Hou, B; Huang, B; Huang, S; Li, Z; Liu, C; Ma, Z; Yang, L; Zhang, C; Zheng, Z; Zhou, Q; Zhou, Z; Zhuang, H; Zou, Y | 1 |
| Akouz, FK; Barbier, E; Bourgeois, V; Coriat, R; Dahan, L; Desrame, J; Edeline, J; Ghiringhelli, F; Lecomte, T; Louafi, S; Ly, VL; Malka, D; Manfredi, S; Michel, P; Molin, Y; Neuzillet, C; Perrier, H; Phelip, JM; Soularue, E; Terrebonne, E | 1 |
| Wang, Q; Xie, S; Xu, M; Yang, C; Zhang, D; Zhang, J; Zhong, W; Zhou, L | 1 |
| Hua, J; Liang, C; Liu, J; Meng, Q; Shi, S; Tan, Z; Wang, W; Xu, J; Yang, J; Yu, X; Zhang, B | 1 |
| Bohorquez, MA; Carr, ZJ; Yan, L | 1 |
| Chan, J; Lucero, MY | 1 |
| Ding, L; Hang, Y; Oupický, D; Sil, D; Tang, S; Tang, W; Xie, Y; Yu, A; Zhang, C | 1 |
| Bai, J; Chen, G; Chen, K; Cui, J; Dong, X; Fan, Y; Gu, K; Guo, Q; He, J; Hu, C; Hu, X; Jiang, D; Jiang, L; Li, J; Li, Y; Liu, J; Pan, Y; Peng, M; Shi, Q; Song, Y; Tan, W; Wang, G; Wang, H; Wang, Z; Wu, L; Wu, X; Xie, W; Xiong, J; Yang, N; Yao, W; Yi, T; Yu, G; Yue, L; Zang, A; Zhang, G; Zhang, J; Zhang, X; Zhao, G; Zhao, W; Zhou, C | 1 |
| Fujii, T; Gyoten, K; Hayasaki, A; Iizawa, Y; Isaji, S; Kishiwada, M; Komatsubara, H; Kuriyama, N; Maeda, K; Mizuno, S; Murata, Y; Nakagawa, Y; Noguchi, D; Sakurai, H; Shinkai, T; Tanemura, A | 1 |
| Chen, QY; Du, CC; Guo, SS; Liu, LT; Liu, T; Mai, HQ; Yang, ZC | 1 |
| Hong, TH; Kim, H; Lee, MA; Park, SJ; Shin, K; Suh, JH | 1 |
| Hikita, K; Honda, M; Iwamoto, H; Kawamoto, B; Morizane, S; Shimizu, R; Takenaka, A; Teraoka, S; Yamaguchi, N; Yumioka, T | 1 |
| Ebata, T; Mizuno, T; Takahashi, D | 1 |
| Mungmungpuntipantip, R; Wiwanitkit, V | 1 |
| Gong, R; Hu, L; Li, J; Ping, Q; Qin, Y; Wang, Y; Yang, Y; Zhang, G | 1 |
| Holmes, B; Hossain, MA; Mukherjee, P; Tarannum, M; Vivero-Escoto, JL; Yan, S | 1 |
| Chao, Y; Lee, CY; Li, CP; Lin, LG; Yu, HY | 1 |
| Arias, J; Beca, J; Biagi, JJ; Chan, KKW; Dai, WF; Earle, CC; Forbes, L; Gavura, S; Habbous, S; Raphael, MJ; Raskin, W; Tai, X | 1 |
| Abd Al-Jabbar, S; Atiroğlu, A; Atiroğlu, V; Deveci Ozkan, A; Guney Eskiler, G; Hameed, RM; Özacar, M | 1 |
| Dai, GH; Deng, GC; Han, QL; Lv, Y; Pan, YT; Qu, TT; Sun, DC; Yan, H | 1 |
| Dong, Z; Feng, Q; Gong, J; Liu, Q; Zhang, H | 1 |
| Hwang, HK; Kang, CM; Lee, SH; Lee, WJ | 1 |
| Kaneyasu, T; Morimoto, K; Moriwaki, K; Nakayama, H; Shimozuma, K | 1 |
| Hino, T; Honda, A; Kurokawa, M; Masamoto, Y; Shimura, A | 1 |
| Furukawa, M; Hisano, T; Lee, L; Miki, M; Sugimoto, R | 1 |
| Chen, T; Chen, W; Chen, X; Hu, X; Jiang, C; Lin, R; Wang, X; Xu, S | 1 |
| Wu, CE; Yeh, CN | 1 |
| Guo, X; Qin, R; Wang, M; Yu, S; Zhang, H | 1 |
| Assenat, E; de la Fouchardière, C; Debourdeau, A; Desseigne, F; Fiess, C; Iltache, S; Mazard, T; Mollevi, C; Portales, F; Ychou, M | 1 |
| Andolfo, A; Federici, F; Latiano, TP; Laura, M; Panebianco, C; Pazienza, V; Perri, F; Pisati, F; Potenza, A; Rizzi, E; Tripodo, C; Ulaszewska, M; Villani, A | 1 |
| Albisinni, S; Awada, A; Barthelemy, P; Caparica, R; Carnot, A; Casert, V; Culine, S; Fantoni, JC; Gil, T; Gizzi, M; Martinez Chanza, N; Paesmans, M; Roumeguere, T; Sautois, B; Seront, E; Soukane, L; Staudacher, L; Tricard, T; Van den Brande, J; Vanhaudenarde, V | 1 |
| Chen, Q; Gao, G; Go, VLW; Guo, J; Li, K; Li, N; Liu, J; Pan, Y; Tao, X; Xiao, GG; Zhao, Y | 1 |
| Barrera, LN; Brumskill, S; Calcraft, P; Costello, E; Phillips, C | 1 |
| Elango, S; Finkelmeier, F; Koch, C; Pession, U; Queck, A; Schmidt, J; Trebicka, J; Trojan, J; Waidmann, O; Walter, D | 1 |
| Mo, DC; Ren, T | 1 |
| Benatti, S; Brandi, G; Carotenuto, P; De Lorenzo, S; Dominici, M; Francesco, C; Frega, G; Gelsomino, F; Luppi, G; Melisi, D; Merz, V; Messina, C; Palloni, A; Pettorelli, E; Ricci, AD; Rizzo, A; Salati, M; Spallanzani, A | 1 |
| Ding, N; Gou, J; He, H; Tang, X; Wang, Y; Xu, Y; Yin, N; Yin, T; Zhang, Y; Zhao, Z | 1 |
| Gao, Y; Maharjan, S; Mitragotri, S; Pan, DC; Singh, B; Zhang, YS; Zhao, Z | 1 |
| Bauer, K; Henne-Bruns, D; Manzini, G | 1 |
| Anai, S; Aoki, K; Fujimoto, K; Gotoh, D; Hori, S; Ichikawa, K; Kiba, K; Maesaka, F; Matsumura, Y; Miyake, M; Mizobuchi, S; Morizawa, Y; Nakai, Y; Nishimura, N; Oda, Y; Ohmori, C; Shimizu, T; Tachibana, A; Tanaka, N; Tomizawa, M; Torimoto, K; Yoshikawa, T | 1 |
| Che, JX; Dong, XW; Gu, YQ; Lin, NM; Lin, X; Teng, F; Yan, YY; Zhang, B; Zhou, LX; Zhou, XL | 1 |
| Chen, X; Fang, D; Guan, J; He, X; Shi, ZW; Wang, H; Wang, X | 1 |
| Fan, D; Fan, Y; Fang, Z; Gao, X; Li, X; Liu, J; Yan, K | 1 |
| Besselink, MG; Bonsing, BA; Bouwense, SAW; de Jong, EJM; de Meijer, VE; de Vos-Geelen, J; Geurts, SME; Homs, MYV; Janssen, QP; Koerkamp, BG; Simons, TFA; Tjan-Heijnen, VCG; Valkenburg-van Iersel, LBJ; van der Geest, LG; van Laarhoven, HWM; Wilmink, JW | 1 |
| Bai, C; Fan, H; Ji, Y; Wang, Z; Yang, M; Yang, W | 1 |
| Gong, H; Xu, H; Zhang, G | 1 |
| Bai, L; Li, H; Li, S; Tong, R; Yu, D; Zhang, Q | 1 |
| Bianchini, F; Chatzisideri, T; Karampelas, T; Leonidis, G; Sarli, V; Skavatsou, E; Tamvakopoulos, C; Velentza-Almpani, A | 1 |
| Komatsu, Y; Saito, Y; Sakamoto, T; Sugawara, M; Takekuma, Y; Uchiyama, K | 1 |
| Deng, L; Gao, Y; Gu, Y; Han, S; Li, X; Li, Z; Wang, D; Wang, X; Yang, R; Yin, A; Yu, Y | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Du, C; Hu, C; Jiang, J; Kong, F; Lv, Y; Ni, M; Ying, H; Zhai, R | 1 |
| Fang, J; Ge, C; Jin, N; Li, X; Li, Y; Liu, Z; Shang, C; Song, G; Sun, L; Xiu, Z; Yang, X; Zhu, Y | 1 |
| Katsuda, T; Matsukuma, K; Nasu, H; Nishio, S; Park, J; Tasaki, K; Terada, A; Tsuda, N; Ushijima, K; Yoshimitsu, T | 1 |
| Kiyozuka, K; Kohei, N; Suzuki, R | 1 |
| Endo, I; Hiratani, S; Homma, Y; Kumamoto, T; Matsuyama, R; Miyake, K; Mori, R; Murakami, T; Ota, Y; Sawada, Y; Shimizu, Y; Yabusita, Y | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Mitsufuji, S; Mori, M; Noda, T; Tomimaru, Y; Ueno, G; Yamada, D | 2 |
| Deng, H; Shen, Y; Shen, Z; Tang, M; Wei, Z; Zhou, C | 1 |
| Cox, V; Javle, M; Kang, HC; Kawaguchi, Y; Kim, BJ; Maki, H; Mizuno, T; Panettieri, E; Pant, S; Vauthey, JN; Vega, EA | 1 |
| Hwang, JH; Jung, JH; Jung, K; Kim, J; Lee, JC; Park, J | 1 |
| Gu, HY; Hu, C; Huang, ZD; Lin, LL; Liu, ZZ; Wei, RX | 1 |
| Andrén, PE; Atkinson, J; Barnes, J; Barry, ST; Brais, R; Bunch, J; Dunlop, CR; Goodwin, RJA; Gopinathan, A; Hamm, G; Jodrell, DI; Johnson, TI; Kaistha, BP; Lau, A; Ling, S; Maglennon, G; Nilsson, A; Race, AM; Richards, FM; Sansom, OJ; Serra, MP; Smith, A; Strittmatter, N; Sutton, D; Takats, Z; Wallez, Y; Wilson, J; Wong, E | 1 |
| Pereira, M; Vale, N | 1 |
| Bao, G; Chaohong, H; Shiming, Z; Tiejun, Y; Yin, H; Yongkang, M | 1 |
| Ashida, R; Emori, T; Hatamaru, K; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Koike, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y | 1 |
| Chen, R; He, R; Hu, C; Li, G; Li, T; Li, Z; Lin, Q; Xia, R; Ye, Y; Zhang, X; Zheng, S | 1 |
| Bartels, A; Bolch, M; Branchi, V; Dold, L; Gonzalez-Carmona, MA; Heling, DJ; Kaczmarek, DJ; Kalff, JC; Mahn, R; Manekeller, S; Matthaei, H; Mohr, RU; Möhring, C; Nattermann, J; Sadeghlar, F; Strassburg, CP; Vogt, A; Weismüller, TJ; Zhou, T | 1 |
| Furukawa, M; Furuse, J; Ikeda, M; Ishii, H; Iwai, T; Kamata, K; Kataoka, T; Kato, N; Kawamoto, Y; Kojima, Y; Mizuno, N; Mizusawa, J; Morizane, C; Nakagohri, T; Nishina, T; Okamura, K; Okano, N; Okusaka, T; Oono, T; Sekimoto, M; Shimizu, K; Shimizu, S; Shioji, K; Shirakawa, H; Sudo, K; Tobimatsu, K; Todaka, A; Ueno, M; Yamada, I; Yamaguchi, H; Yamashita, T | 1 |
| Hao, S; Li, S; Liu, Z; Lu, W; Ouyang, G; Pan, G; Wu, Y | 1 |
| Blaheta, RA; Chun, FK; Juengel, E; Maxeiner, S; Rutz, J; Tsaur, I | 1 |
| Bai, O; Guo, W; Liu, Z; Song, W; Tang, Z; Wang, S; Yu, H; Zhang, D | 1 |
| Banerjee, N; Basu, S; Bhattacharya, R; Chatterjee, K; Chattopadhyay, S; Choudhury, P; Mukhopadhyay, A; Mukhopadhyay, S; Nandi, SK; Roychowdhury, T; Saha, P | 1 |
| Han, S; Liang, D; Liu, D; Liu, Q; Ma, J; Yan, C; Yang, Z | 1 |
| Dawe, DE; Kim, CA; Lambert, P; McAndrew, EN; Rittberg, R; Zhang, H | 1 |
| Aggen, D; Al-Ahmadie, H; Apollo, A; Bajorin, DF; Balar, AV; Bochner, BH; Boswell, A; Cha, EK; Donahue, TF; Donat, SM; Durdin, TD; Folefac, E; Francese, K; Funt, SA; Goh, AC; Herr, HW; Hettich, G; Huang, WC; Iyer, G; Jihad, M; Kamradt, J; Khalil, M; Lash, B; Lattanzi, M; Lee, CH; McCoy, AS; McHugh, D; Mortazavi, A; Ostrovnaya, I; Pietzak, E; Quinlan, C; Ratna, N; Regazzi, A; Rosenberg, JE; Teo, MY; Truong, H; Whiting, K; Yang, Y; Zimmerman, D | 1 |
| Asagi, A; Furuse, J; Higuchi, R; Konishi, M; Mizuno, N; Morinaga, S; Motoi, F; Nagano, H; Nara, S; Okuyama, H; Shioji, K; Shirakawa, H; Sugimachi, K; Todaka, A; Toshiyama, R; Tsumura, H | 1 |
| Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S | 1 |
| Akazawa, M; Narimatsu, H; Sasahara, Y; Takumoto, Y | 1 |
| Imada, K; Kaneko, H; Mizutani, C; Nagata, O; Naka, R; Tada, K; Tashima, M | 1 |
| Ohata, C; Shimizu, Y | 1 |
| Bai, Y; Guo, H; Guo, Y; Huang, Y; Lin, M; Xiao, Y; Yang, X; Yuan, Z; Zhang, Q; Zhu, H | 1 |
| Bates, SE; Hur, C; Ingram, MA; Kastrinos, F; Kong, CY; Lauren, BN; Lim, F; Manji, GA; Park, J; Pumpalova, Y | 1 |
| Fujii, T; Hashimoto, D; Hirano, S; Honda, G; Kitayama, J; Kodera, Y; Miura, F; Motoi, F; Satoi, S; Sekimoto, M; Shimokawa, T; Uemura, K; Ueno, H; Unno, M; Yamaki, S; Yamamoto, T; Yamaue, H; Yoshitomi, H | 1 |
| Ahmad, M; Alharbi, H; Aloahd, MS; Alrashed, MM; Alshehry, AS | 1 |
| Björn, N; Brandén, E; De Petris, L; Gréen, H; Jakobsen, I; Koyi, H; Lewensohn, R; Udagawa, C; Zembutsu, H | 1 |
| Fukumoto, T; Matsuo, Y; Nanno, Y; Ogura, Y; Okimoto, T; Park, S; Suga, M; Sulaiman, NS; Takahashi, D; Terashima, K; Tokumaru, S; Toyama, H | 1 |
| Abduljabbar, A; Alashwah, A; Alhomoud, S; Aljubran, A; Almanea, H; Alsanea, N; Alsuhaibani, A; Alzahrani, A; Ashari, L; Badran, A; Bazarbashi, S; Elhassan, T; Elshenawy, MA; Ghebeh, H; Mohiuddin, M; Neimatallah, M | 1 |
| Enokida, H; Fukumoto, W; Kawakami, I; Nakagawa, M; Okamura, S; Osako, Y; Sakaguchi, T; Sugita, S; Tamai, M; Tatarano, S; Yamada, Y; Yonemori, M; Yoshino, H | 1 |
| Alemany, R; Álvarez, R; Bazan-Peregrino, M; Blasco, C; Blasi, E; Capella, G; Cascallo, M; Garcia-Carbonero, R; Gimenez-Alejandre, M; Ginestà, MM; Gornals, JB; Hidalgo, M; Laquente, B; Maliandi, MV; Mato-Berciano, A; Moreno, R; Morgado, S; Perea, S; Perez-Carreras, M; Prados, S; Riesco, MC; Rodríguez-García, A; Salazar, R | 1 |
| Li, N; Qi, Y; Yu, D; Zhan, J; Zhang, G; Zhao, Q | 1 |
| Chen, K; Chen, Z; Li, J; Ma, J; Ma, Q; Qian, W; Qin, T; Wang, Z; Wu, E; Wu, Z; Xiao, Y | 1 |
| Cai, C; Dong, P; Gong, W; Li, ML; Liang, HB; Liu, SL; Wu, XS; Wu, ZY; Yang, ZY; Zheng, L | 1 |
| Abdul Majid, AMS; Asif, M; Oon, CE; Yehya, AHS | 1 |
| Chang, WC; Chiu, CF; Hsieh, CY; Hua, CH; Lien, MY; Lin, CC; Lin, CY; Lo, WJ | 1 |
| Abi Jaoude, J; Delahoussaye, AM; Feng, N; Fowlkes, N; Fujimoto, TN; Garcia Garcia, CJ; Gay, JP; Green, M; Marszalek, J; Molkentine, J; Taniguchi, CM | 1 |
| Ambo, Y; Ando, M; Benabdelghani, M; Bertaut, A; Ebata, T; Edeline, J; Hammel, P; Hirano, S; Joly, JP; Kaneoka, Y; Konishi, M; Louvet, C; Malka, D; Monard, L; Nagino, M; Ohtsuka, M; Phelip, JM; Uesaka, K; Watelet, J; Yamamoto, M | 1 |
| Iede, K; Ikenaga, M; Koh, M; Matsuyama, J; Nakashima, S; Ohta, K; Tanida, T; Tominaga, S; Tsuda, Y; Ueda, M; Yamada, T | 2 |
| Enomoto, A; Fujishiro, M; Iida, T; Imai, M; Ishikawa, T; Kawashima, H; Kinoshita, F; Kuwatsuka, Y; Mizutani, Y; Ohno, E; Shimizu, S; Tsuruta, T | 1 |
| Jaidee, R; Jusakul, A; Kongpetch, S; Kukongviriyapan, V; Laphanuwat, P; Prawan, A; Senggunprai, L | 1 |
| Jarearnrat, A; Khuntikeo, N; Klanrit, P; Li, JV; Loilome, W; Mahalapbutr, P; Namwat, N; Phetcharaburanin, J; Sa-Ngiamwibool, P; Suksawat, M; Techasen, A; Titapun, A; Vilayhong, V; Wangwiwatsin, A | 1 |
| Fu, L; Huo, J; Jin, M; Li, Z; Zhang, M | 1 |
| Abe, Y; Daiku, K; Fujita, M; Fukutake, N; Higashi, S; Hiraga, E; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Maeda, S; Nakabori, T; Ohkawa, K; Takada, R; Uehara, H; Urabe, M; Yamai, T | 1 |
| Hong, SS; Kang, CM; Kim, D; Kim, S; Lee, J; Lee, JH; Lee, S; Lee, SH; Park, H | 1 |
| Jeong, BC; Kim, CK; Kim, H; Kim, R; Kwon, GY; Park, SH; Park, W; Song, W; Sung, HH | 1 |
| Allory, Y; Chevreau, C; Culine, S; Fléchon, A; Gravis, G; Guillot, A; Harter, V; Joly, F; Laguerre, B; Mahammedi, H; Pfister, C; Soulié, M | 1 |
| Alyahya, MY; Bhadra, S; Khan, S; Samuel, RE; Xu, YJ | 1 |
| Kashima, H; Kimura, Y; Kusumi, F; Matsumoto, A; Minami, R; Ohana, M; Okano, A; Ozawa, T; Takeda, Y; Ueo, T | 1 |
| Cheuk, W; Cho, WCS; Huang, QH; Li, Y; Lin, ZX; Xian, YF; Xu, HX; Yang, W; Zhang, J | 1 |
| Chen, P; Guo, N; Li, J; Li, S; Liu, B; Tang, J; Zhang, W; Zhao, Y | 1 |
| Inoue, Y; Ito, H; Mie, T; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Ushida, Y | 2 |
| Bhosale, P; Danner De Armas, A; Javle, M; Lee, S; Makawita, S; Pant, S; Raghav, K; Reddy, K; Shalaby, A; Shroff, RT; Wolff, RA; Xiao, L | 1 |
| Carson, JA; Chaib, M; Glazer, ES; Hayes, DN; Kansal, R; Makowski, L; Morrrison, M; Rana, M; Shibata, D; Stanfill, AG; Teng, B | 1 |
| Pandit, B; Royzen, M | 1 |
| Duan, X; Fang, Y; Fang, Z; Lin, D; Liu, H; Luo, M; Miao, C; Wu, J; Zhang, X; Zhong, W | 1 |
| Baker, K; Buhtoiarov, IN; Bush, R; Cole, PD; Kelly, KM; Mba, NI; McCarten, KM; Metzger, ML; Pei, Q; Santos, CDL | 1 |
| He, Y; Huang, M; Yi, C; Zhang, L | 1 |
| Niu, X; Wang, T; Zhong, B | 1 |
| Cutillas, PR; de Luxán-Delgado, B; Dormann, C; Drake, RJG; Géraud, C; Gómez-Escudero, J; Hodivala-Dilke, K; Maiques, O; Meng, YM; Newport, E; Rajeeve, V; Reynolds, LE; Richards, FM; Roy-Luzarraga, M; Sanz-Moreno, V; Saur, D; Vermeulen, PB; Weller, C; Wisniewski, L; Wong, PP | 1 |
| Chen, L; Jiang, N; Li, JY; Li, WF; Li, XM; Li, YQ; Liu, N; Ma, J; Mao, YP; Tang, LL; Zhang, XM; Zhang, Y; Zhou, GQ | 1 |
| Anjum, MM; Bhattacharya, S; Patel, KK | 1 |
| Chen, W; Fang, Z; Tan, X; Xu, Y; Yang, Q | 1 |
| Bianchi, L; Cantonetti, M; Di Raimondo, C; Meconi, F; Monopoli, A; Narducci, MG; Nunzi, A; Rapisarda, V; Scala, E; Tesei, C; Vaccarini, S; Zizzari, A | 1 |
| Hou, Y; Li, C; Liu, H; Zhang, L; Zhu, J | 1 |
| Cheng, XR; Liu, RF; Zou, MJ | 1 |
| Bran, DM; Fuks, D; Gallois, C; Karoui, M; Lahlou, W; Lansier, A; Taieb, J | 1 |
| An, G; Deng, S; Fu, M; Huang, W; Jiao, Y; Li, R; Liu, H; Liu, W; Lv, R; Qiu, L; Sui, W; Wang, T; Yi, S; Zhao, Y; Zou, D | 1 |
| Hindson, J | 1 |
| Akasaka, E; Fukui, T; Hamaya, T; Nakajima, K; Nakano, H; Sawamura, D; Yamashita, A | 1 |
| Asama, H; Fukushima, T; Kawano, K; Kobayashi, S; Maeda, S; Morimoto, M; Nagashima, S; Ohira, H; Sano, Y; Tanaka, S; Ueno, M | 1 |
| Aboueisha, SS; Khamis, AA; Salim, EI | 1 |
| Balbarrey, M; Grigera, JD; Loscalzo, F | 1 |
| Chiawpanit, C; Chieochansin, T; Junking, M; Lee, VS; Luangwattananun, P; Nimmanpipug, P; Panya, A; Phanthaphol, N; Rotarayanont, S; Sangsuwannukul, T; Sawasdee, N; Somboonpatarakun, C; Sujjitjoon, J; Tragoolpua, Y; Wathikthinnakon, M; Wutti-In, Y; Yenchitsomanus, PT | 1 |
| Beijnen, JH; Boosman, RJ; Crombag, MBS; Huitema, ADR; Steeghs, N; van Erp, NP | 1 |
| Horino, T; Inotani, S; Ishihara, M; Terada, Y | 1 |
| Guo, B; Meng, F; Sun, Y; Wang, J; Wei, J; Yuan, J; Zhong, Z | 1 |
| Aron, M; Brummelhuis, ISG; Chau, A; Cutie, CJ; Daneshmand, S; Keegan, KA; Maffeo, JC; Pohar, KS; Raybold, B; Reynolds, DL; Steinberg, GD; Witjes, JA | 1 |
| Kawano, R; Kondo, N; Murakami, Y; Okada, K; Otsuka, H; Seo, S; Sumiyoshi, T; Takahashi, S; Uemura, K | 1 |
| Ashida, R; Emori, T; Hatamaru, K; Higashino, N; Ikoma, A; Itonaga, M; Kawai, M; Kawaji, Y; Kitano, M; Shimokawa, T; Sonomura, T; Tamura, T; Yamashita, Y | 1 |
| Arasawa, S; Fukunaga, T; Goda, K; Hoshi, S; Hoshi, T; Inamoto, O; Kajimura, K; Miyajima, S; Takaya, H; Takeda, S; Tanaka, Y | 1 |
| Ibusuki, M; Inoue, T; Ito, K; Kitano, R; Kobayashi, Y; Naitoh, I; Nakade, Y; Sumida, Y; Yoneda, M | 1 |
| Abe, Y; Daiku, K; Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Maeda, S; Nakabori, T; Ohkawa, K; Takada, R; Uehara, H; Urabe, M; Yamai, T | 1 |
| Ishii, M; Itano, O; Itano, S; Morinaga, J; Shirakawa, H | 1 |
| Chen, S; Chen, ZW; Hu, JF; Huang, L; Huang, Y; Kang, FP; Liao, CY; Lin, CF; Tian, YF; Wang, ZW | 1 |
| Aissa, AF; Benevolenskaya, EV; Ke, R; Kumar, S; Munshi, HG; Nair, R; Pham, TND; Principe, DR; Rana, A; Rana, B; Trevino, JG; Underwood, PW | 1 |
| Cai, L; Chen, S; Li, J; Wang, J; Zhao, Q | 1 |
| Li, X; Lu, W; Tang, K; Wang, L | 1 |
| Bajor, D; Bauer, T; Davar, D; Holland, A; Luke, JJ; Merghoub, T; Naik, GS; Newman, W; Piper, D; Qi, J; Rixe, O; Sato, T; Sifferlen, L; Sirard, CA; Wang, H; Wolchok, JD; Wong, P; Zappasodi, R | 1 |
| Laukhtina, E; Shariat, SF | 1 |
| Cai, MB; Li, ZM; Nie, YH; Tan, YR; Yang, Q; Zhu, HB | 1 |
| Cao, C; Han, S; Hu, C; Li, M; Liu, R; Pan, L; Xu, M; Yuan, Y; Zhang, X | 1 |
| Spek, A | 1 |
| Allard, J; Bonnet, M; Bouattour, M; Gagaille, MP; Laurent, L; Leclerc, V | 1 |
| Cai, CY; Chen, ZS; Fan, Y; Gu, J; Huang, W; Li, J; Liu, S; Tao, T; Wang, H; Wang, X; Yang, J; Zhang, J; Zheng, Y | 1 |
| Furukawa, K; Gocho, T; Hamura, R; Ikegami, T; Onda, S; Sakamoto, T; Shiba, H; Shirai, Y; Uwagawa, T; Yanaga, K; Yasuda, J | 1 |
| Chen, S; Chen, ZW; Hu, JF; Huang, L; Huang, Y; Liao, CY; Pan, JJ; Shen, BY; Tian, YF; Wang, YD; Wang, ZW; Yang, C; Zhang, JQ | 1 |
| Clark, PE; Meeks, JJ; Sexton, WJ | 1 |
| Aprile, G; Catalano, M; Conca, R; Petrioli, R; Ramello, M; Roviello, G | 2 |
| Ahn, JH; Baek, W; Han, YD; Jung, I; Kim, CG; Kim, HS; Kim, JE; Kim, JH; Kim, SH; Kim, SK; Koh, YW; Lee, YH; Rha, SY; Shin, SJ; Sim, NS; Yun, KH | 1 |
| Boeck, S; Engel, J; Gil, L; Guenther, M; Heinemann, V; Mayerle, J; Ormanns, S; Palm, MA; Surendran, SA; von Bergwelt-Baildon, M; Werner, J | 1 |
| Black, PC; Contreras-Sanz, A; Eto, M; Hayashi, T; Inokuchi, J; Kang, D; Kiyokoba, R; Kohashi, K; Matsumoto, S; Matsumoto, T; Nagakawa, S; Noda, N; Oda, Y; Setoyama, D; Shiota, M; Takamatsu, D; Tsukahara, S; Uchiumi, T; Yagi, M | 1 |
| Feng, M; Gu, Z; He, Y; Kong, X; Mao, H; Wu, L | 1 |
| Bu, F; Chen, L; Hu, Z; Li, Q; Lin, K; Luo, C; Peng, X; Wang, K; Yu, X; Yuan, R; Zhang, W; Zhao, J; Zhu, J; Zhu, X; Zhu, Z | 1 |
| Costantini, A; Fabre, L; Giroux-Leprieur, E; Magdelaine, P | 1 |
| Bryant, HE; Bucklain, FA; Ciani, B; Ginn, L; Grant, E; Laity, P | 1 |
| Andolfo, A; Latiano, TP; Orsenigo, F; Panebianco, C; Pazienza, V; Perri, F; Pisati, F; Potenza, A; Terracciano, F; Tripodo, C; Ulaszewska, M; Villani, A | 1 |
| Abdelrahim, M; Abudayyeh, A; Al Najjar, E; Al-Rawi, H; Al-Rawi, M; Bugazia, D; Esmail, A; Ghobrial, RM; Ibnshamsah, F; McMillan, R; Saharia, A; Umoru, G; Victor, D; Xu, J | 1 |
| Behera, C; Behl, A; Chhillar, AK; Datta, TK; Gupta, PN; Kumar, S; Mintoo, MJ; Sarwalia, P | 1 |
| Li, R; Pan, S; Tao, L | 1 |
| Brown, K; Dennany, L; Hoskins, C; Oluwasanmi, A | 1 |
| Kumar, S; Pareek, T; Parmar, K; Sharma, AP | 1 |
| Hashimoto, K; Hinotsu, S; Hotta, H; Ito, N; Kato, R; Kobayashi, K; Kunishima, Y; Maehana, T; Masumori, N; Matsukawa, M; Miyamoto, S; Shindo, T; Tachiki, H; Taguchi, K; Takahashi, A; Tanaka, T | 1 |
| Crocenzi, TS; Driscoll, M; Hansen, P; Kelly, LR; Martin, RCG; McMasters, KM; Philips, P; Rocha, F; Scoggins, CR; Sharma, VR; Simo, KA; Tatum, CM | 1 |
| Du, H; Gong, Y; Lan, J; Na, F; Shao, B; Wang, Y; Wu, S; Xiang, L; Xie, G | 1 |
| Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G | 1 |
| Dechêne, A; Finnesand, L; Hoffmeister, A; Høgset, A; Jakobs, R; Jürgensen, C; Kasper, S; Neu, B; Olivecrona, H; Palmer, D; Schirra, J; Selbo, PK; Sturgess, R; Trojan, J; Walday, P | 1 |
| Hirata, H; Ito, H; Kobayashi, K; Matsumoto, H; Matsuyama, H; Misumi, T; Nagao, K | 1 |
| Chen, Y; Liu, M; Lu, P; Niu, N; Shen, X; Shi, J; Sun, Y; Tang, Y; Xu, D; Xue, J; Yang, X; Yao, H | 1 |
| Kong, R; Qian, X; Ying, W | 1 |
| Fujita, Y; Hayashi, K; Hirano, A; Hori, Y; Inoue, T; Kataoka, H; Kato, A; Kato, H; Miyabe, K; Naiki-Ito, A; Naitoh, I; Natsume, M; Nishi, Y; Okumura, F; Sano, H; Takada, H; Takahashi, S; Yoshida, M | 1 |
| Chen, SY; Li, ZY; Weng, MH; Yen, GC | 1 |
| Huang, B; Li, C; Yan, Y; Yang, X | 1 |
| Campagne, O; Jonchere, B; Liu, J; Northcott, PA; Onar-Thomas, A; Patel, Y; Pribnow, A; Robinson, GW; Robinson, S; Roussel, MF; Smith, KS; Stewart, CF; Wu, G; Xu, K; Yu, J | 1 |
| Banjare, N; Behera, C; Gupta, PN; Kumar, A; Kumar, R; Malik, SB; Mondhe, DM; Sandha, KK; Tabassum, M | 1 |
| Fu, L; Jiang, J; Li, J; Liu, M; Liu, Q; Song, C; Zeng, Z; Zhu, H | 1 |
| Hu, X; Li, Y; Tong, S | 1 |
| Komatsu, Y; Saito, Y; Sugawara, M; Takekuma, Y | 1 |
| Arciero, V; Arias, J; Beca, JM; Biagi, JJ; Chan, KKW; Dai, WF; Earle, CC; Gavura, S; Habbous, S; Isaranuwatchai, W; Luo, J; Mittmann, N; Parmar, A; Raphael, MJ; Tadrous, M | 1 |
| Chen, G; Liu, Y; Qiu, J; Su, D; Tao, J; Yang, G; You, L; Zhang, T; Zhao, F; Zhao, Y; Zheng, L | 1 |
| Takahashi, T | 1 |
| Furuse, J; Gondo, K; Kogure, M; Matsuki, R; Nagashima, F; Ochiai, K; Okano, N; Sakamoto, Y; Shibahara, J; Sugiyama, M; Suzuki, Y; Tateishi, H; Toki, M; Watanabe, S | 1 |
| Acar, R; Akcan, E; Aykan, MB; Erturk, I; Karadurmus, N; Yildiran, GS | 1 |
| Chen, T; Geng, Y; Gu, Y; Li, Y; Liu, K; Sun, L; Wang, L; Wu, S; Xu, F; Xu, H; Zhao, Z; Zou, M | 1 |
| Chen, Y; Li, Y; Liu, Y; Luan, Y; Wang, K | 1 |
| Aydin, AM; Cheriyan, SK; Gilbert, SM; Hajiran, A; Jain, R; Li, R; Peyton, CC; Poch, MA; Reich, R; Sexton, WJ; Spiess, PE; Yu, A; Zemp, L; Zhang, J | 1 |
| An, HJ; Cho, S; Hong, MH; Jung, HA; Keam, B; Lee, KW; Lim, J; Ock, CY; Park, KU; Park, WY; Pereira, S; Yun, T | 1 |
| Cai, L; Guo, X; Hu, X; Jiang, Z; Luo, J; Pan, Y; Shao, Z; Sun, T; Teng, YE; Wang, B; Wang, S; Wang, X; Wang, Z; Wu, J; Yan, M; Zhang, J; Zhao, Y | 1 |
| Ananda, S; Burge, M; Chee, CE; Clarke, K; Cooray, P; Fox, A; Gibbs, P; Harris, M; Knowles, B; Lee, B; Lipton, L; Mclachlan, SA; Nagrial, A; Nikfarjam, M; Pattison, S; Shapiro, J; Tebbutt, N; Thomson, B; Usatoff, V; Walpole, I; Wong, R; Zielinski, R | 1 |
| Hernandez-Guerrero, T; Moreno, V | 1 |
| Das, B; Minz, AP; Mishra, S; Mohapatra, D; Senapati, S; Suresh, V | 1 |
| Bai, LY; Chao, Y; Chen, LT; Chen, MH; Chen, SC; Chen, SJ; Chiang, NJ; Hsiao, CF; Huang, CJ; Huang, CY; Huang, YH; Hung, YP; Lee, IC; Lee, PC; Shan, YS; Su, YY; Tan, KT; Yeh, CN | 1 |
| Fukasawa, M; Fukushima, M; Imamura, M; Kumagai, M; Muraoka, K; Shiraishi, Y; Ueda, M; Yabusaki, R; Yoshimura, K | 1 |
| Chen, E; DeLuca, S; Dhani, N; Doherty, MK; Hedley, D; Jang, R; Knox, JJ; McNamara, MG; O'Kane, GM; Pedutem, T; Sim, HW; Tam, VC; Tang, P; Wang, L | 1 |
| Chen, Y; Feng, W; Feng, Y; Li, H; Liu, H; You, H; Zheng, Q | 1 |
| Abe, S; Akisue, T; Asanuma, K; Emori, M; Fukuda, H; Furuta, T; Hatano, H; Hiraga, H; Hiraoka, K; Hiruma, T; Iwamoto, Y; Katagiri, H; Kataoka, T; Kawai, A; Kawano, M; Kawashima, H; Machida, R; Matsumoto, Y; Morii, T; Nagano, A; Nakayama, R; Nishida, Y; Okuma, T; Outani, H; Ozaki, T; Suehara, Y; Takenaka, S; Takeyama, M; Tanaka, K; Toguchida, J; Tsukushi, S; Watanuki, M; Yamamoto, T; Yonemoto, T | 1 |
| Esposito, F; Font, C; Garcia de Herreros, M; Sauri, T | 1 |
| Elia, A; Kraev, I; Miralles, F; Rashid, S; Rimmer, E | 1 |
| Fujii, K; Fujiwara-Tani, R; Kishi, S; Kuniyasu, H; Mori, S; Nishiguchi, Y; Ohmori, H; Sasaki, T; Takagi, T | 1 |
| Gellhaus, PT; Martin, AC; McElree, IM; Mott, SL; Nepple, KG; O'Donnell, MA; Packiam, VT; Richards, J; Steinberg, RL | 1 |
| Beg, MS; Deming, DA; Griffith, KA; Mahalingam, D; Sahai, V; Shaib, WL; Zalupski, MM; Zhen, DB | 1 |
| Chen, C; Chen, H; Chen, X; Jian, Y; Xiu, Z; Yang, S; Yin, L; Yu, Q; Zeng, W; Zhou, J | 1 |
| Hattori, N; Hayashi, M; Inokawa, Y; Kanda, M; Kodera, Y; Kurimoto, K; Nakayama, G; Otsu, T; Shimizu, D; Takami, H; Tanaka, C; Tanaka, H; Tanaka, N | 1 |
| Hamauchi, S; Kawakami, T; Nakase, H; Ohwada, S; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
| Chen, JA; Gandara, DR; Huynh, JC; Kelly, KL; Kim, EJ; Li, T; Mack, PC; Mahaffey, N; Martinez, A; Matsukuma, K; Riess, JW; Semrad, TJ; Tam, K; Wu, CY; Yu, AM | 1 |
| Asagi, A; Hiasa, Y; Hino, K; Hyodo, I; Imamura, Y; Inoue, T; Kajiwara, T; Kanemitsu, K; Koizumi, M; Kokubu, M; Kumagi, T; Marui, K; Nadano, S; Nakasya, A; Nishide, N; Nishina, T; Numata, Y; Okujima, Y; Sakaguchi, C; Terao, T; Yoshimatsu, M | 1 |
| Chen, L; Fu, X; Gao, Q; Han, L; Huang, H; Li, H; Li, T; Liu, Y; Peng, L; Qin, P; Till, BG; Wang, W; Wang, Z; Yan, X; Yang, Y; Ye, Z; Zhang, B; Zhang, X; Zhao, L | 1 |
| Chen, L; Gong, Q; Li, H; Tang, Z; Tao, J; Zhang, Z; Zhao, C | 1 |
| Al-Mutairi, AA; Alkhatib, MH | 1 |
| Kates, M; Rodriguez, KM | 1 |
| Chen, JY; Jiang, JL; Ma, T; Qi, WX; Xu, HP | 1 |
| Cong, M; Li, C; Li, F; Pang, H; Wang, Y; Xu, G; Yang, S; Zhao, W | 1 |
| Arslan, O; Gokgoz, Z; Gokmen, A; Ilhan, O; Okcu, MK; Ozan, U; Ozcan, M; Sahin, U; Soydan, E | 1 |
| Shen, R; Sun, C; Tang, C; Tang, Z; Ying, X | 1 |
| He, J; Kong, W; Liang, M; Liu, P; Ren, P; Tang, S; Wei, D; Xu, L; Yang, H; Zhang, T | 1 |
| Cao, L; Chen, C; Freeman, JW; Karnad, A; Kumar, AP; Zhao, S; Zhao, X | 1 |
| Bai, X; Chen, W; Gao, S; Huang, B; Lao, M; Liang, T; Ma, T; Que, R; Shui, Y; Wang, J; Wei, Q; Zhang, Y | 1 |
| Arima, S; Doi, K; Furuse, J; Hayashi, H; Higuchi, H; Hisano, T; Imaoka, H; Ishii, H; Ishii, S; Kawabe, K; Kitano, Y; Kobayashi, S; Kojima, Y; Maruki, Y; Misumi, T; Miwa, H; Nagano, H; Naganuma, A; Nakashima, K; Okano, N; Ozaka, M; Shioji, K; Suzuki, M; Suzuki, R; Tanaka, K; Todaka, A; Tsuji, K; Tsumura, H; Ueno, M; Umemoto, K; Yamaguchi, H; Yamashita, T | 1 |
| Chen, X; Li, Y; Qian, Y; Qiao, L; Shi, C; Tang, L; Wu, D; Xie, F; Yang, C; Yang, J; Zheng, Y | 1 |
| Adam, J; Bahleda, R; Briand, S; Cavalcanti, A; Cesne, AL; Chamseddine, AN; Court, C; Fadel, E; Faron, M; Haddag-Miliani, L; Henon, C; Honoré, C; Levy, A; Mercier, O; Mir, O; Ngo, C; Pechoux, CL; Ropert, S; Verret, B; Watson, S | 1 |
| Chang, A; Gao, S; Ge, Y; Hao, J; Huang, C; Li, H; Liu, J; Sun, H; Wang, X; Wang, Y; Wu, L; Xu, C; Yuan, Y; Zhao, T | 1 |
| Ananda, S; Burge, M; Clarke, K; Gibbs, P; Jennens, R; Lee, B; Lipton, L; Michael, M; Nikfarjam, M; Pattison, S; Santucci, J; Shapiro, J; Tacey, M; Thomson, B; Wong, R; Zielinski, R | 1 |
| Jarearnrat, A; Khuntikeo, N; Klanrit, P; Loilome, W; Namwat, N; Phetcharaburanin, J; Sangkhamanon, S; Sitthirak, S; Suksawat, M; Titapun, A; Wangwiwatsin, A | 1 |
| Chang, JS; Chen, HA; Chiu, CF; Hsu, TW; Lin, CY; Park, JM; Peng, JM; Saengboonmee, C; Shan, YS; Shen, YS; Su, YH | 1 |
| Aucoin, N; Couture, F; Du, P; Gill, S; Harb, M; Jia, S; Jonker, D; Kavan, P; Kim, CA; Knox, JJ; Ko, YJ; Lemay, F; Loree, JM; Meyers, BM; O'Callaghan, CJ; Ramjeesingh, R; Renouf, DJ; Schaeffer, DF; Tang, PA; Tehfe, M; Topham, JT; Tu, D; Welch, S | 1 |
| Anderson, B; Azaro, A; Benhadji, KA; Cassier, PA; Massard, C; Oakley, G; Pant, S; Yu, D; Yuen, E | 1 |
| Chen, MY; Ding, X; Duan, CY; Gu, CM; Hua, YJ; Huang, PY; Liu, YL; Liu, YP; Ouyang, YF; Wang, X; Wang, ZQ; Xu, HS; You, R; Zhang, MX; Zhang, WJ; Zou, X | 1 |
| Bai, L; Dong, X; Gao, S; Huang, L; Li, H; Li, N; Liu, Z; Luo, T; Zhang, Y | 1 |
| Funahara, H; Hiraki, K; Kikkawa, A; Matsumoto, S; Nakai, M | 1 |
| Chen, L; Chen, WJ; Chen, WQ; Hong, RQ; Wang, HP; Yu, Y; Zou, YF | 1 |
| Bertram, M; Binninger, A; Chiabudini, M; Hegewisch-Becker, S; Hollerbach, SH; Jänicke, M; Kaiser-Osterhues, A; Kreher, S; Marschner, N; Reiser, M; von der Heyde, E; Wolf, T | 1 |
| Hu, W; Li, K; Liu, K; Qu, L | 1 |
| Brown, J; Correa Ordonez, I; Davis, M; Vanenkevort, E; Varun, S; Wojtowicz, M; Young, A | 1 |
| Ho, TJ; Huang, CY; Kuo, CH; Kuo, WW; Lai, SC; Lin, PY; Lin, SZ; Lin, YJ; Shih, CY; Su, SH; Sundhar, N | 1 |
| Adachi, T; Azuma, H; Egawa, S; Fukuokaya, W; Fukushima, T; Hashimoto, T; Inamoto, T; Iwatani, K; Kimura, T; Komura, K; Miki, J; Mori, K; Nakamori, K; Nakamura, K; Nishimura, K; Nishio, K; Ohno, Y; Shiroki, R; Takahara, K; Tsuduki, S; Uchimoto, T; Urabe, F; Yamamoto, S; Yanagisawa, T; Yano, Y; Yoshizawa, A | 1 |
| Chiao, PJ; Glorieux, C; Han, Y; Huang, P; Li, SP; Li, X; Ling, J; Meester, C; Noppe, G; Robert, A; Wang, H; Wang, Z; Xia, X; Yang, J; You, X; Zhang, H; Zhang, L | 1 |
| Chang, Q; Chen, Q; Huang, X; Jiang, H; Li, K; Li, R; Liu, G; Liu, X; Shi, P; Tu, Q; Xu, G; Yao, X; Zhao, B; Zhu, H | 1 |
| Du, S; Fan, L; Li, Y; Liu, Y; Wang, J | 1 |
| Dong, LP; Liu, YM; Lu, WJ; Tang, KZ | 1 |
| Cao, R; Chen, H; Li, L; Li, R; Li, Y; Liu, X; Shao, R; Shi, Y; Song, W; Wang, J; Yao, H; Ye, C; Zhang, L; Zhou, X | 1 |
| Huitema, ADR; Otten, HM; Verkerk, K | 1 |
| Jiang, Y; Sohal, DPS | 1 |
| Bao, Y; Cai, M; Chen, M; Chen, Z; Fu, C; Guo, J; Hu, H; Huang, J; Huang, Z; Jiang, S; Li, C; Su, R; Wang, Z; Wei, Q; Xue, W; Yuan, Y; Zheng, B | 1 |
| Ahn, D; Bai, LY; Bayat, A; Borad, MJ; Davis, SL; Hubbard, J; McCormick, D; Mody, K; O'Brien, D; Oh, DY; Park, JO; Rha, SY; Richards, D; Soong, J; Tse, E | 1 |
| Abdul Majid, AMS; Asif, M; Kaur, G; Oon, CE; Subramaniam, AV; Yehya, AHS | 1 |
| Chakraborty, G; Gadly, T; Patro, BS | 1 |
| Abuelafia, AM; Bigonnet, M; Chanez, B; Chuluyan, E; Dusetti, N; Fraunhoffer, NA; Gayet, O; Iovanna, J; Roques, J | 1 |
| Goršić, I; Kekez, D; Librenjak, N; Pleština, S; Prejac, J; Tomek Hamzić, D | 1 |
| Chiao, PJ; Fu, J; Furukawa, K; Ling, J; Lu, YU; Marukuchi, R; Sun, Y | 1 |
| Chen, Q; Gao, W; Li, W; Zeng, H | 1 |
| Fantinel, E; Manduca, S; Merler, S; Milella, M; Pafumi, S; Zacchi, F; Zampiva, I; Zivi, A | 1 |
| Deng, J; Du, J; Fu, D; Gu, J; Guo, Y; Hu, X; Kong, L; Li, J; Tao, B; Ying, T | 1 |
| Feng, W; Hong, H; Huang, X; Jiang, W; Li, Z; Liang, J; Liang, L; Liu, Q; Liu, Y; Liu, ZG; Peng, Y; Xian, S; Yang, S; Zhang, Y; Zhang, Z; Zhong, G; Zhou, Y | 1 |
| Abdiannia, M; Acharya, A; Aranha, O; Belle, JI; Bogner, SJ; Boice, N; Breden, M; Brown, A; DeNardo, DG; Gao, F; Hawkins, WG; Herndon, J; Herzog, BH; Lim, KH; Lockhart, AC; McWilliams, R; Pedersen, K; Ratner, L; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A; Yoon, HH; Zhu, M | 1 |
| Hong, J; Hong, JY; Jeong, BC; Kim, CK; Kim, H; Kwon, GY; Park, SH; Park, W; Pyo, H; Song, W; Sung, HH | 1 |
| Blaheta, RA; Chun, FK; Cinatl, J; Grein, T; Haferkamp, A; Khadir, SE; Makhatelashvili, N; Mann, J; Maxeiner, S; Rutz, J; Sonnenburg, M; Thomas, A; Tsaur, I; Xie, H | 1 |
| Kuraoka, K; Onoe, T; Shibata, Y; Shimizu, Y; Sudo, T; Suzuki, T; Takahashi, S; Tashiro, H; Tazawa, H; Tazuma, S | 1 |
| Bai, C; Cheng, Y; Dai, M; Guo, J; Lu, J; Qiao, C; Tang, H; Wang, Y; Zhang, T | 1 |
| Dutta, M; Mohapatra, AP; Mohapatra, D; Roychowdhury, A; Senapati, S | 1 |
| Hiratsuka, M; Inoue, Y; Ito, H; Matsueda, K; Oba, A; Ono, Y; Ozaka, M; Saiura, A; Sasahira, N; Sasaki, T; Sato, T; Takahashi, Y; Takeda, T | 1 |
| Arjyal, L; Khan, AM; Shamaileh, L; Simon, M | 1 |
| Hu, Z; Jing, W; Liu, J; Lu, H; Wang, T | 1 |
| Anzengruber, M; Gabor, F; Skoll, K; Szuchar, R; Wimmer, L; Wirth, M | 1 |
| Huang, CS; Lai, JM; Liu, Q; Liu, ZD; Shi, YH; Su, Q; Wang, JQ; Wang, XY; Xu, QC; Xu, X; Yin, XY; Zhao, GY; Zhu, YQ | 1 |
| Chen, Y; Lin, L; Lin, X; Ou, G; Pan, L; Su, M; Tan, Y; Tian, Z | 1 |
| Amin, MA; Der, CJ; Grierson, PM; Knoerzer, D; Kreider, B; Lim, KH; Liu, J; Park, H; Pedersen, KS; Reddy, A; Suresh, R; Tan, B; Trikalinos, NA; Wang-Gillam, A | 1 |
| Cheon, J; Choi, SH; Chon, HJ; Kang, B; Kang, I; Kim, DJ; Kim, G; Ko, KH; Kwon, CI; Lee, SH | 1 |
| Banciu, M; Berindan-Neagoe, I; Jurj, A; Rus, L; Sesarman, A; Stiufiuc, R; Tefas, LR; Toma, I; Tomuta, I | 1 |
| Banavath, HN; Gupta, S; Tejavath, KK | 1 |
| Balconi, F; Berardi, R; Cimbro, E; Donisi, C; Giampieri, R; Lai, E; Lupi, A; Murgia, S; Pecci, F; Persano, M; Pozzari, M; Pretta, A; Pusceddu, V; Puzzoni, M; Scartozzi, M; Spanu, D; Ziranu, P | 1 |
| Ding, DY; Ding, WB; Gan, XJ; Hou, GJ; Li, W; Liu, L; Sun, DP; Tao, QF; Yang, F; Yang, Y; Yu, J; Yuan, SX; Zhang, JN; Zhou, WP | 1 |
| Gao, J; Li, Y; Luan, Y; Wang, R | 1 |
| Assenat, E; Boleslawski, E; Camus, M; Delaye, M; Edeline, J; Henriques, J; Herrero, A; Lièvre, A; Malka, D; Neuzillet, C; Turpin, A; Vernerey, D | 1 |
| Artru, P; Auvray Kuentz, M; Coutzac, C; de Mestier, L; Drouillard, A; Hammel, P; Hautefeuille, V; Lecomte, T; Lièvre, A; Malka, D; Nardon, V; Pernot, S; Taieb, J; Touchefeu, Y; Tran-Minh, ML; Trouilloud, I; Turpin, A; Williet, N; Zaanan, A | 1 |
| Arora, P; Boyne, DJ; Brenner, DR; Cheung, WY; Gupta, A; Hernán, MA; Mackay, E; Wasiak, R | 1 |
| Beutel, AK; Halbrook, CJ | 1 |
| Chen, Q; Li, S; Shen, L | 1 |
| Kamitani, N; Kato, JY; Nakamae, I; Sho, M; Yoneda-Kato, N | 1 |
| Cheng, W; Chu, X; Huang, S; Zheng, H; Zheng, X; Zhou, Y | 1 |
| Chu, C; Geng, S; Gong, P; Jiang, M; Luo, T; Wu, L; Zhang, X; Zhou, W | 1 |
| Ahn, E; Ahn, T; Bang, S; Choi, J; Han, JM; Hwang, GS; Kim, K; Kim, Y; Lee, HS; Luo, E; Min, DS; Park, SJ; Sung, Y; Yoo, HC; Yu, YC | 1 |
| Bianchi, GV; Cantarelli, B; Capri, G; de Braud, F; Depretto, C; Fucà, G; Leporati, R; Ligorio, F; Lobefaro, R; Manoukian, S; Mariani, L; Peverelli, G; Presti, D; Pruneri, G; Rametta, A; Scaperrotta, G; Vernieri, C; Vingiani, A; Zattarin, E | 1 |
| Fan, J; Gan, Y; Han, Y; Li, B; Peng, F; Rao, M; Su, S; Tang, H; Wang, R; Yang, X; Zhang, J; Zhang, X | 1 |
| Albers, D; Herold, T; Kasper, S; Linden, G; Markus, P; Prasnikar, N; Radunz, S; Schmidt, H; Schuler, M; Schumacher, B; Siveke, J; Ting, S; Treckmann, JW; Virchow, I; Wiesweg, M | 1 |
| Hu, Q; Huang, Y; Li, B; Liang, T; Ping, Y; Shao, S; Tang, H; Wang, M; Yao, Z; Zhang, F | 1 |
| Baba, H; Eguchi, H; Hatano, E; Ioka, T; Kamachi, H; Kanai, M; Kobayashi, S; Nagano, H; Nakagami, Y; Sakai, D; Shindo, Y; Takahashi, M; Takayama, T; Ueno, M; Wada, H; Yoshimura, K | 1 |
| Araujo, R; Dallaston, M; Jenner, AL; Kelly, W; Kim, PS; Parfitt, I; Pooladvand, P; Steinitz, D; Vine, KL; Wade, SJ | 1 |
| Fujimori, N; Fukuda, H; Furukawa, M; Furuse, J; Ikeda, M; Imaoka, H; Ishii, H; Kamata, K; Katanuma, A; Kataoka, T; Katayama, H; Kobayashi, S; Komatsu, Y; Miwa, H; Mizukoshi, E; Mizuno, N; Mizusawa, J; Nakachi, K; Ohba, A; Okano, N; Okusaka, T; Ozaka, M; Sasahira, N; Takayama, Y; Terashima, T; Todaka, A; Tsumura, H; Ueno, M; Yamamoto, T | 1 |
| Guo, W; Huang, JH; Liu, Z | 1 |
| Su, J; Wang, W; Yang, L; Zhou, F | 1 |
| Bender, JD; Mizukawa, B; Perentesis, JP; Pommert, L; Rubinstein, JD | 1 |
| Chen, XP; Luo, C; Zhang, BX; Zhang, W; Zhang, ZY | 1 |
| Cao, L; Ding, K; Fan, L; Li, J; Liu, H; Ma, J; Peng, H; Shi, W; Wang, H; Wu, W; Yang, H; Zhao, X; Zhu, H | 1 |
| Abo Elkasem, F; Bahnassy, A; Gaafer, R; Khorshid, O; Wahba, NI | 1 |
| Atri, P; Batra, SK; Bessho, M; Bessho, T; Chirravuri, R; Cox, JL; Foster, JM; Ganguly, K; Ganti, AK; Lakshmanan, I; Nallasamy, P; Nimmakayala, RK; Ogunleye, AO; Parte, S; Ponnusamy, MP; Rauth, S; Talmon, GA; Varadharaj, V; Vengoji, R | 1 |
| Cheng, HH; Dash, A; Garcia, J; Gore, JL; Holt, SK; Lam, HM; Lin, D; Makrakis, D; Montgomery, B; Mostaghel, E; Nelson, P; Porter, MP; Roudier, MP; Schade, G; Schweizer, M; Vakar-Lopez, F; Wang, Y; Winters, B; Wright, JL; Yu, EY; Zhang, X | 1 |
| Albers, D; Kasper, S; Kostbade, K; Laue, K; Liffers, ST; Markus, M; Markus, P; Maßmann, M; Mende, B; Pogorzelski, M; Reissig, TM; Roehrle, J; Rosery, V; Schildhaus, HU; Schmid, K; Schuler, M; Schumacher, B; Siveke, JT; Ting, S; Treckmann, JW; Virchow, I; Wendling, J; Wiesweg, M; Zaun, G | 1 |
| Arakawa, A; Goto, M; Hori, K; Ito, K; Kaneda, M; Kawabata, A; Kaya, R; Kondo, E; Motohashi, T; Nagasawa, T; Nakagawa, M; Nasu, H; Nishio, S; Park, J; Shimokawa, M; Suzuki, J; Tashima, L; Tsubamoto, H; Yamada, K; Yanagida, S | 1 |
| Aprile, G; Bergamo, F; Bernardini, I; Bozzarelli, S; Cardellino, GG; Cavanna, L; Cordio, S; De Simone, I; Di Marco, MC; Ghidini, M; Giommoni, E; Macchini, M; Maiello, E; Milella, M; Orsi, G; Pinto, C; Porcu, L; Reni, M; Rulli, E; Spada, M; Torri, V | 1 |
| Funakoshi, S; Harada, H; Hayashi, T; Hirose, S; Hoshino, M; Odaira, M; Ogura, N | 1 |
| Ho, B; Li, CG; Mitchell, A; Ponomarova, O; Rosener, B; Sayin, S; Walhout, AJM; Ward, DV | 1 |
| Doolin, JW; Paredes de la Fuente, R; Peters, ML | 1 |
| Huang, X; Jin, C; Li, H; Wang, W; Yang, C; Yu, X | 1 |
| Amano, H; Dash, S; Honda, M; Kawazu, M; Komuro, A; Okada, H; Ueda, T | 1 |
| Aldakkak, M; Christians, KK; Clarke, CN; Erickson, BA; Evans, DB; George, B; Hall, WA; Kamgar, M; Smith, ZL; Thalji, SZ; Tolat, PP; Tsai, S | 1 |
| Hasegawa, R; Imaizumi, H; Ishizaki, A; Ishizaki, J; Iwai, T; Kaneko, T; Kida, M; Kurosu, T; Kusano, C; Okuwaki, K; Watanabe, M; Yamauchi, H | 1 |
| Furukawa, T; Ishitsuka, T; Kasuga, A; Matsuyama, M; Mie, T; Nakagawa, H; Okamoto, T; Ozaka, M; Sasahira, N; Sasaki, T; Takeda, T; Yamada, M | 1 |
| Azzouqa, AG; Colon-Otero, G; Kase, AM; Kochuveettil, S | 1 |
| Aoyama, S; Hata, T; Hiraki, M; Ikeshima, R; Katsura, Y; Katsuyama, S; Kihara, Y; Kinoshita, M; Masuzawa, T; Muneta, M; Murata, K; Ohmura, Y; Shinke, G; Sugimura, K; Takeda, Y | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Marukawa, D; Noda, T; Sasaki, K; Takahashi, H; Tanemura, M; Tomimaru, Y; Yamada, D | 1 |
| Arias, J; Beca, JM; Biagi, JJ; Chan, KKW; Coburn, N; Dai, WF; Earle, CC; Gavura, S; Habbous, S; Raphael, M; Saluja, R | 1 |
| Bramwell, LG; Cheung, K; Falchook, GS; Janku, F; Javle, MM; Johansen, MJ; Madden, T; Maier, G; Pant, S; Saeki, K; Sen, S; Subach, RA; Subbiah, V; Suzuki, T; Wages, DS; Way, T; Wheeler, CA | 1 |
| Chen, DS; Chen, XY; Cheng, Z; Deng, WL; Dong, YL; Guo, LP; Han, Q; Lou, C; Qi, C; Shang, PP; Song, YJ; Tao, CJ; Wei, W; Xu, HM; Yang, G; Yuan, ZG; Zeng, TM | 1 |
| Akamune, A; Johira, H; Kagajo, Y; Kawata, N; Kimura, M; Tamura, S; Tomomatsu, M; Umeoka, T; Yunoki, S | 1 |
| Aronson, A; Cohen, DJ; Fulop, DJ; Labiner, AJ; Lucas, AL; Sigel, KM; Wisnivesky, J; Wu, YL; Zylberberg, HM | 1 |
| Hu, Q; Huang, J; Liang, T; Shao, S; Wang, M; Yao, Z; Zhang, F; Zhao, X | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shinohara, Y; Shirakawa, T; Taguchi, H; Ueda, Y; Ueno, S; Ureshino, N | 1 |
| Chen, Y; Hu, Q; Jin, P; Liang, T; Que, R; Xu, M; Yao, Z; Zhang, F | 1 |
| O'Donnell, MA; Packiam, VT; Steinberg, RL | 1 |
| Gao, S; Jiang, CF; Wang, W; Yin, HS; Yu, BP | 1 |
| Bai, Y; Dal, E; Li, K; Li, X; Lin, R; Liu, N; Liu, Z; Qi, R; Shi, B; Wang, H; Wang, X; Wang, Y; Xu, Y | 1 |
| Bhargava, P; Das, S; Kannan, S; Ostwal, V; Ramaswamy, A; Shah, D; Shah, M; Srinivas, S; Suman, M; Trikha, M | 1 |
| Bhambhvani, H; Collisson, EA; Fountzilas, C; Hendifar, A; Johansen, JS; Joshi, A; Krishna, V; Makawita, S; Mehta, A; Musher, B; Nimgaonkar, V; Rajpurkar, P; Singhi, A; Smith, K; Sohal, D; Tiu, E; Vrabac, D; Wainberg, Z | 1 |
| Brender, JR; Chandramouli, GVR; Devasahayam, N; Kishimoto, S; Krishna, MC; Mitchell, JB; Otowa, Y; Saida, Y; Yamamoto, K; Yamashita, K | 1 |
| Chon, HJ; Hwang, DW; Jeong, H; Jeong, JH; Kim, KH; Kim, KP; Lee, JH; Lee, JS; Lee, MA; Moon, DB; Park, JH; Park, SJ; Ryoo, BY; Yoo, C | 1 |
| Akdeniz, N; Beşiroğlu, M; Demirci, A; Ergün, Y; İnanç, M; Işikdoğan, A; Kaplan, MA; Kiliçkap, S; Küçüköner, M; Şendur, MAN; Topçu, A; Uncu, D; Urakçi, Z; Yerlikaya, H | 1 |
| Enokida, H; Iizasa, S; Inoguchi, S; Matsushita, R; Nakagawa, M; Okamura, S; Osako, Y; Sakaguchi, T; Tamai, M; Tanimoto, A; Tatarano, S; Yamada, Y; Yokoyama, S; Yoshino, H | 1 |
| Kashiwa, M; Matsushita, R | 1 |
| Cho, YJ; Han, BS; Hong, SS; Jung, KH; Kim, DK; Kim, SE; Ko, S; Lee, JE; Lee, P; Lee, YJ; Lim, JH; Park, MS; Ryu, JK; Shim, S; Yoon, YC | 1 |
| Bizama, C; Buchegger, K; Espinoza, K; García, P; Ili, C; Leal, P; Obreque, J; Repetto, G; Roa, JC; Rosa, L; Suárez, F; Vergara-Gómez, L; Weber, H; Zhong, J | 1 |
| Hsu, CP; Hwang, TL; Kou, HW; Kuo, YC; Lo, CH | 1 |
| Bhawal, UK; Fujiwara-Tani, R; Ikemoto, A; Kishi, S; Kuniyasu, H; Luo, Y; Mori, S; Nishiguchi, Y; Ogata, R; Ohmori, H; Sasaki, R; Sasaki, T; Sho, M; Takagi, T | 1 |
| Achreja, A; Animasahun, O; Chinnaiyan, AM; Choppara, S; Crysler, O; Dippman, D; Enzler, T; Griffith, KA; Gunchick, V; Hsiehchen, D; Kumar-Sinha, C; Mohan, A; Nagrath, D; Nenwani, M; Sahai, V; Wuchu, F; Zalupski, MM; Zhen, DB | 1 |
| Cheon, J; Choi, HJ; Choi, SH; Chon, HJ; Jung, S; Kang, B; Kim, C; Lee, CK; Lee, S; Lee, SH; Park, YN; Shim, HS | 1 |
| Horenblas, S; Los, M; Reesink, DJ; van de Garde, EMW; van der Nat, PB; van Melick, HHE | 1 |
| Amador, Y; Arguelles, O; Concepción, ML; Guerra, PP; Leblanch, L; Leyva, A; Martorell, B; Moret, S; Piriz, A; Rabassa, R; Rivero, G; Sánchez, L; Sánchez, Y; Saumell, Y; Valls, AR; Vasallo, AL | 1 |
| Aquilini Mummolo, A; Bruno, G; Cincione, RI; Conteduca, V; Giordano, G; Landriscina, M; Lizzi, V; Losavio, F; Pacilli, M; Piscazzi, A; Senia, T | 1 |
| Cappetta, A; Catalano, M; Conca, R; D'Angelo, A; Petrioli, R; Ramello, M; Roviello, G; Siminonato, F | 1 |
| Agyare, E; Bulusu, R; Frimpong, E; Han, B; Inkoom, A; Ndemazie, NB; Poku, R; Smith, T; Trevino, J; Zhu, X | 1 |
| Fu, X; Hao, Z; Hua, X; Jiao, A; Li, S; Wang, K | 1 |
| Fu, L; Han, W; Lv, K; Tian, Y; Zhou, X | 1 |
| Akazawa, M; Asami, H; Shibahara, R; Takumoto, Y | 1 |
| Arima, S; Fukahori, M; Honda, T; Ide, Y; Koga, F; Komori, A; Makiyama, A; Mitsugi, K; Mizuta, T; Nakazawa, J; Nio, K; Okabe, Y; Otsu, S; Otsuka, T; Shibuki, T; Shimokawa, M; Shirakawa, T; Taguchi, H; Ueda, Y; Ureshino, N | 1 |
| Berres, ML; Gonzalez-Carmona, M; Kehmann, L; Keitel, V; Luedde, T; Modest, DP; Mohr, R; Roderburg, C; Strassburg, C; Trautwein, C; Venerito, M; Wree, A | 1 |
| Mellema, JJ; van der Heijden, MS; van Rhijn, BWG | 1 |
| Bhoopathi, P; Das, SK; Emdad, L; Fisher, PB; Mannangatti, P | 1 |
| Chen, YP; Guan, JL; Guo, R; He, QM; He, SW; Huang, ZL; Jin, X; Kuang, DM; Li, GB; Li, JY; Li, WF; Li, XM; Liang, XY; Liu, N; Lv, J; Ma, J; Mao, YP; Shen, JY; Sun, R; Sun, Y; Tang, LL; Wang, SQ; Wei, C; Wei, Y; Xiong, KX; Yin, JH; Zhang, CJ; Zhang, Y; Zheng, YH; Zhou, GQ; Zhou, WW | 1 |
| Cooper, SJ; Gordon, ER; James, M; Wright, CA | 1 |
| Bajwa, A; Bisunke, B; Fang, J; Glazer, ES; Kansal, RG; Rana, M; Shibata, D; Yang, J | 1 |
| Doğan, M; Kurtuluş, A; Özdemir, M; Türkel, A | 1 |
| Beebe, J; Dong, Z; Hao, Y; He, Z; Huang, C; Liu, H; Liu, JY; Liu, Y; Qin, L; Subramaniyan, B; Zhang, JT | 1 |
| Chang, YC; Chen, MH; Chou, WC; Huang, SC; Huang, WK; Hung, TH; Jung, SM; Lin, SH; Pan, YR; Wu, CE; Yeh, CN; Yu, AL | 1 |
| Chen, IM; Christensen, S; Detlefsen, S; Egendal, I; Johansen, JS; Ladekarl, M; Liposits, G; Pfeiffer, P; Rasmussen, LS; Shim, S; Ventzel, L; Weber, B; Winther, SB | 1 |
| Alameda, M; Espinosa, E; Feliu, J; Gallego, A; Gutierrez-Sainz, L; Martinez-Fdez, S; Martinez-Marin, V; Martinez-Recio, S; Mendiola, M; Pedregosa-Barbas, J; Peña, J; Perez-Wert, P; Pertejo-Fernandez, A; Redondo, A; Villamayor, J; Viñal, D; Zamora, P | 1 |
| Minchom, A; Popat, S | 1 |
| Choi, JK; Han, JH; Lee, KJ; Park, BK; Seo, JH; Son, KJ | 1 |
| Bhardwaj, N; Chen, KT; Ebot, E; Fabrizio, D; Fleischmann, Z; Frampton, G; He, J; Hegde, P; Jin, D; Lofgren, KT; Madison, R; Moore, J; Newberg, J; Pishvaian, MJ; Schrock, A; Singhi, A; Sokol, E | 1 |
| Abbey, L; Abdelghany, TM; Abdellatif, MH; Abdelmohsen, UR; Abduljaleel Alzawar, NS; Abid, MF; Abu Kasim, AFB; Abu Saad, H; Adolpho, LF; Agostini, F; Agrizii, AP; Ahmed, S; Akce, M; Åkesson, D; Al-Awaadh, AM; Al-Mutar, DMK; Al-Odayni, AB; Al-Rajhi, AMH; Alaaeldin, R; Alam, M; Alam, MM; Alanazi, MA; Alattar, H; Alawlaqi, MM; Aldebis, HK; Algehainy, NA; Almeida, AA; Aloisi, F; Alrahlah, A; Alsenani, F; Alshabib, A; Altemani, FH; Althagafi, A; Amari, A; Andronesi, AG; Antonyuk, M; Arantes, TD; Araújo, R; Arrotti, S; Asakura, T; Asib, N; Atlaskin, AA; Aung, MS; Axiaq, A; Azekawa, S; Bacon, S; Bagalagel, A; Balbinot, GS; Barnet, LS; Baroyi, SAHM; Barreto, F; Barth, Y; Barysheva, AV; Bassa, E; Basu, R; Basu, S; Bates, C; Bautista, LS; Beitl, K; Beloti, MM; Benatti, G; Benavent-Celma, C; Bentaher, A; Bergsland, N; Bernardino, AF; Bernhardt, A; Bhandari, RK; Bhaskaran, K; Bhate, K; Bhattacharjee, A; Bian, X; Bien, EM; Birch, M; Bishara, K; Biswas, JP; Bleha, R; Bocale, R; Bona, S; Boriani, G; Bouyssi, A; Bradley, D; Bravo-Sánchez, MG; Bressan, GC; Brik, A; Brizuela, A; Brockbank, KGM; Buchner, F; Bunc, M; Buscombe, JR; Butler, AJ; Buzaleh, AM; Buzin, MI; Cabrera-Capetillo, CA; Calvo, AM; Camerota, A; Campagna, G; Campisi, M; Cano, K; Cao, HST; Cardellini, S; Carvalho, AP; Carvalho, BCR; Castillo-Baltazar, OS; Cataldo, P; Chai, P; Chakraborty, S; Chalo, DM; Chan, MY; Chander, S; Changbunjong, T; Chappuis, CJF; Chee, RCH; Chen, C; Chen, CJ; Chen, E; Chen, M; Chen, X; Chen, Y; Cheng, HT; Cheng, MC; Cheow, HK; Chi, Y; Chirikova, NK; Chiu, SH; Cho, G; Cho, HR; Cho, S; Cho, SJ; Choe, A; Choe, YH; Chun, BS; Chun, Z; Cinque, A; Ciopec, M; Cladas, Y; Cleary, SP; Clermont, O; Cléroux, M; Cockburn, J; Collares, FM; Colombini-Ishikiriama, BL; Conn, BN; Cortina, JL; Cox, DRA; Crini, G; Croker, R; Cursaru, DL; Curtis, HJ; da Silva, KJG; Dalla Costa, T; Davy, S; de Araújo, BV; de Cassia Ribeiro Gonçalves, R; de Gaetano, F; de Gregorio, C; de Oliveira, MG; De Vera, MAT; de Vos, M; de-la-Fuente, I; Dell'Oca, I; Delles, M; Déméautis, T; Dempster, M; Deng, YH; Denisenko, Y; Descombes, C; Desideri, G; Devarbhavi, H; Devouassoux, G; Di Bella, G; Di Marco, F; Diao, Y; Dias, BB; Dilgin, Y; Dimopoulou, I; Dionísio, TJ; Dobrovic, A; Dokin, ES; Dolby, T; Dong, X; Dong, Y; Dou, SX; Douglas, IJ; Dousset, S; Du, Z; Duan, M; Duan, SB; Duke-Williams, O; Duteanu, N; Dutertre, S; Dutta, S; Dwyer, MG; Ebenbauer, J; Eggo, RM; El-Mordy, FMA; Elbhnsawi, NA; Elrehany, MA; Elshewemi, SS; Elwakil, BH; Emadzadeh, D; Eraso, E; Ermolenko, E; Erten, K; Ettorre, E; Evans, D; Evans, SJ; Faheem, M; Fallanza, M; Faramarzi, M; Faria, FAC; Faro, DC; Fatma, YS; Fazil, S; Feng, Y; Ferguson, J; Fernandes, MH; Fernández-Domínguez, M; Ferrari, LAL; Ferraz, EP; Ferreira, LC; Ferri, C; Fikry, M; Floris, M; Forbes, H; Fotouh, B; Franke, K; Freitas, AC; Freitas, GP; Frieboes, HB; Fu, B; Fu, Y; Fukina, DG; Fukuda, DH; Fukunaga, K; Fulham, GJ; Furlan, L; Furtado Mesa, M; Furtunescu, FL; Gabbieri, D; Ganash, M; Gebers, JC; Gehman, V; Ghaedi, A; Ghazali, NSM; Ghebrekristos, Y; Gil, J; Gilbert, NM; Gimenes, R; Giordano, L; Glehen, O; Godeau, C; Goh, SK; Goldacre, B; Gomes, AM; Gomes, MPO; Gomes, PS; Gomes, RMODS; Gómez-Coma, L; Grenho, L; Gu, Q; Gu, T; Gu, YC; Guiducci, V; Guillemin, JP; Guo, W; Guo, YW; Gur, E; Guridi, A; Guzmán-López, A; Gvozdenko, T; H Elmaidomy, A; Hagar, M; Haider, S; Han, JM; Hanratty, J; Hans, R; Haque, N; Harharah, HN; Harharah, RH; Harper, S; Hasegawa, N; Hassanin, AH; Hastuti, YP; Hatem, AE; He, R; He, Y; Heinemann, C; Heinmaa, I; Heinzl, F; Helfer, VE; Hester, F; Hickman, G; Hill, MA; Hill, WG; Hintze, V; Ho, JSY; Ho, LY; Hoang, T; Holzer, I; Houbraken, J; Hsu, CN; Hu, J; Hu, X; Hu, Y; Hua, T; Huang, Z; Hulme, WJ; Hunter, A; Ianăşi, C; Ibañez, R; Iezzi, R; Iliuță, L; Im, YM; Imran, M; Inglesby, P; Inguimbert, N; Iqbal, A; Izawa, N; Jahaj, E; Jain, S; Jakimovski, D; Jalal, MM; Jaroszuk-Ściseł, J; Jasim, DJ; Jauregizar, N; Javle, MM; Jędryczka, M; Ji, H; Jiang, Y; Jin, J; Johnson, NT; Joshi, S; Jullok, N; Kachapulula, PW; Kaczmarek, J; Kaczmarek-Szczepańska, B; Kadota, K; Kaji, M; Kakeji, Y; Kakizoe, S; Kakudidi, E; Kalitukha, L; Kamata, H; Kang, YJ; Kapinos, AA; Karakaya, S; Kashchenko, NI; Kasyanov, S; Kataky, R; Katati, B; Kato, G; Katsina, AU; Kaya, A; Kaya, H; Kazarina, OV; Ke, Y; Keenan, C; Keilson, JM; Keshavan, A; Keskinidou, C; Khalifa, MA; Khan, R; Khan, S; Kim, D; Kim, K; Kim, MS; Kim, SM; Kim, WH; Kim, Y; Kim, YJ; Kishimura, H; Kitagawa, RR; Klemenkova, ZS; Kloss, F; Kobayashi, N; Kohlhoff, M; Kong, WKF; Konsek, H; Kornaros, M; Kotanidou, A; Kovacs, S; Kraska, J; Kruppke, B; Kumagai, Y; Kumar, S; Kumari, R; Kuruva, V; Kuster, RM; Kusumoto, T; Kutyła, M; Kwon, JH; Kwon, SH; Kwong, KY; Kyser, AJ; Lackner, M; Lass-Flörl, C; Lauri, C; Lavandera, JV; Lee, BH; Lee, ECY; Lee, HJ; Lee, J; Lee, PS; Lee, S; Lee, SE; Lee, SY; Lefort, F; Leite, JPV; Leo, G; Leonard, R; Leow, AST; Lepori, N; Leyden, K; Leys, L; Ležaić, L; Li, D; Li, H; Li, J; Li, S; Li, TYW; Li, X; Li, XH; Li, Y; Li, Z; Li, ZH; Liao, S; Liaqat, K; Lim, H; Lin, BS; Lin, MY; Lin, NH; Lin, X; Lin, Y; Liu, C; Liu, H; Liu, HK; Liu, HX; Liu, P; Liu, R; Liu, T; Liu, X; Liu, Y; Lock, GA; Lokaj, G; Lopes, HB; Losi, V; Lotsios, NS; Low, KE; Lu, Z; Luhana, S; Luo, X; Luo, XQ; Lutz, MB; Lysova, AA; Lyssenko, KA; Macit, M; MacIver, B; MacKenna, B; Magalhães, GAP; Magnavacchi, P; Mahadevan, J; Mahboubi, A; Maher, SA; Mahipal, A; Mahmoud, MY; Maithel, SK; Makhtar, MMZ; Makurat-Kasprolewicz, B; Malysheva, YB; Mansourizadeh, A; Marek, EJ; Maresca-Fichter, H; Martin, JT; Maslov, AA; Mastora, Z; Mastroiacovo, D; Mastropetros, SG; Matei, D; Mathur, R; Matos, AO; Matsuda, Y; Maurya, SK; Mayor, Á; Mayrhofer, D; Mazzuco, AC; McCaffrey, J; McClure, T; McDonald, HI; Mchunu, NP; McLaggan, D; Mehrkar, A; Meilik, B; Melito, VA; Mellem, J; Mengozzi, A; Menotti, J; Mesquita, V; Miao, Z; Mihai, S; Miller, S; Minassian, C; Mirabile, A; Mitra, S; Mladin, G; Mo, Z; Moawad, H; Mohamed, EM; Mohammed, TJ; Mohanlall, V; Mohyeldin, RH; Moldovan, H; Monneret, G; Monopoli, DE; Monte, IP; Monteiro, JRB; Morgante, V; Mori, M; Morin-Crini, N; Morita, A; Morton, CE; Mrak, M; Muhammed, AP; Mulick, A; Muralidharan, V; Murthy, P; Muselli, M; Mustafa, S; Mysore Visweswariah, A; Nagao, G; Naicker, S; Nakagawara, K; Namgoong, B; Namkoong, H; Namukobe, J; Nasir, AA; Nasreen, SA; Natarajan, P; Nchiozem-Ngnitedem, VA; Necozione, S; Negrea, A; Negrea, P; Ngubane, S; Nguyen, TT; Nicke, A; Nightingale, E; Nistor, CL; Nitsch, D; Njapau, H; Noman, M; Novgorodtseva, T; Nowak, A; O'Connor, SR; Ofoe, R; Oh, K; Oh, TH; Oki, E; Olama, ZA; Olennikov, DN; Oliveira, GM; Omar, D; Ong, SJ; Orfanos, SE; Origa-Oryem, H; Orita, H; Ortiz, I; Ota, M; Ott, J; Otvagina, KV; Pacheco, N; Pacheco, RR; Padmanabhan, D; Pagan, JD; Pagnotta, PA; Palangi, V; Palanisamy, G; Palanisamy, K; Palanisamy, S; Pan, SG; Panaitescu, E; Pang, X; Panoutsakopoulos, V; Parera, VE; Park, JI; Park, JS; Park, SW; Park, Y; Park, YS; Parkash, O; Parry, J; Parry, JP; Paul, SK; Pavšič, N; Pałubicka, A; Persat, F; Petriz-Prieto, MA; Petukhov, AN; Pham, T; Pillay, S; Poh, KK; Ponomarev, II; Pontons-Melo, JC; Posa, A; Powell, E; Priya, AK; Punekar, R; Puppin Rontani, RM; Purushottam, M; Pusphanathan, K; Qi, JY; Qin, J; Qin, Z; Qiu, B; Qiu, X; Quattrini, G; Quindós, G; Qureshi, F; Rabbany, MA; Rac-Albu, M; Rac-Albu, ME; Rădulescu, BC; Rafatullah, M; Rajab, TK; Rajna, S; Ramanathan, M; Rao, D; Raviglione, D; Razorenov, DY; Redd, MJ; Rehman, W; Reig, M; Rentsch, CT; Ribeiro, LMS; Robles, D; Rocchi, S; Rocha, FG; Rodrigues, C; Rodrigues, LA; Rodrigues, RP; Roh, GH; Ronowska, A; Root, A; Rosa, AL; Rossi, R; Roy, S; Roy, VC; Rupji, M; Saber, EA; Sadarat, F; Saed, Y; Saeed, WS; Saeki, H; Saha, B; Saiwichai, T; Sakowicz-Burkiewicz, M; Sampedro, T; Sands, K; Santos, CF; Sari, M; Sathi, FA; Sauro, S; Sazanova, TS; Scafa-Udriște, A; Schoustra, SE; Schultze, A; Seo, DJ; Sevillano, E; Sezmis, G; Sgura, FA; Shah, NNAK; Shani, N; Shankarappa, B; Sharkey, LM; Sharma, VK; Sharp, C; Shehata, N; Shelton, N; Shieh, PB; Shimokawa, M; Shin, J; Shin, SH; Shin, YN; Shin, YR; Shipilova, A; Shoparwe, NF; Shukor, H; Sia, CH; Siddiqui, MH; Siddiqui, MR; Siena, V; Signore, A; Silwane, B; Siqueira-Sandrin, VS; Siregar, A; Sirignano, P; Sit, NW; Skidmore, S; Skupov, KM; Smeeth, L; Smoczer, C; Smolyanskiy, E; Sohn, H; Solodeev, I; Solovyev, A; Şomoghi, R; Song, F; Song, H; Song, Z; Souf, YM; Sousa, SC; Souza, MT; Steinbach-Rankins, JM; Stockton, J; Stout, JR; Su, K; Su, MZ; Suarez-Lopez, YA; Sukkurd, R; Sultanov, R; Sun, Y; Sun, Z; Supernak, M; Supriyono, E; Suroshe, SS; Suvorov, SS; Svera M Ianăşi, P; Switchenko, JM; Syarif, NY; Synytsya, A; Taherzadeh, MJ; Tain, YL; Tamburino, C; Tammam, OY; Tan, BYQ; Tan, H; Tan, S; Tanaka, H; Tang, R; Tang, X; Tang, Z; Taurino, M; Tazare, J; Teresi, L; Testro, A; Thanasoponkul, W; Thangarasu, S; Thavaselvam, D; Theodoro, RC; Theron, G; Thomas, RH; Thomson, JJ; Tian, X; Tian, Y; Tomaszewski, CA; Tomlinson, LA; Torres, CMME; Tóth, M; Trecourt, A; Trevisani, F; Trimarchi, G; Tristán, C; Truong, VK; Tsigkou, K; Tsutsumi, S; Ubukata, Y; Uehara, H; Uwamino, Y; Vahedi-Shahandashti, R; Valberg, SJ; Valderrama, C; Valdovinos-García, EM; Valsecchi, D; van Diepeningen, AD; van West, P; Vargas-Osuna, E; Vassall, M; Vassilaki, N; Vassiliou, AG; Vecino, X; Velez-Irizarry, D; Venkatesh, YN; Vignali, L; Virdis, A; Viswanath, B; Voisin, AS; Volkova, YA; Vorotyntsev, AV; Vorotyntsev, IV; Vtyurina, ES; Vu, DH; Waldridge, B; Walker, AJ; Wallon, M; Wang, B; Wang, G; Wang, H; Wang, J; Wang, LJ; Wang, S; Wang, T; Wang, X; Wang, Z; Warren, RM; Warren-Gash, C; Wei, SH; Weinstock-Guttman, B; Wekwejt, M; Wessjohann, LA; Wiesmann, HP; Williams, ZJ; Williamson, EJ; Wilson, M; Wing, K; Wong, AY; Wong, BKL; Woodward, S; Wozniak, KL; Wu, C; Wu, K; Wu, S; Wu, Y; Xiang, D; Xie, H; Xiong, X; Xu, C; Xu, H; Xu, J; Xu, WH; Xu, Y; Xun, T; Yamaguchi, S; Yan, P; Yan, W; Yan, Z; Yang, B; Yang, F; Yang, L; Yao, XB; Yasui, H; Yenesew, A; Yeo, LLL; Yeo, TC; Yi, S; Yin, F; Yip, JWL; Yoon, SH; Yoon, SJ; Yoshida, M; Yoshizumi, T; Young, LA; Yu, C; Yu, DD; Yu, F; Yu, H; Yu, JD; Yu, NJ; Yu, X; Yuan, Y; Yurenko, A; Yusof, YA; Zahedipoor, A; Zahran, EM; Zainuddin, NI; Zanatta, AC; Zanotto, ED; Zanozin, ID; Zavascki, AP; Zenke, M; Zhang, F; Zhang, G; Zhang, H; Zhang, J; Zhang, L; Zhang, MX; Zhang, NY; Zhang, Q; Zhang, W; Zhang, X; Zhang, XM; Zhao, F; Zhao, Q; Zhao, R; Zhao, Y; Zheng, J; Zheng, S; Zhou, L; Zhou, X; Zhu, H; Zivadinov, R; Žižek, D; Zuccoli, JR; Zwaan, BJ | 1 |
| Cogen, AL; Kovacs, LD; O'Donoghue, M | 1 |
| Chang, A; Ding, J; Feng, Y; Fu, D; Gao, C; Gao, S; Hao, J; Huang, C; Liu, J; Liu, Y; Ma, X; Ma, Y; Tang, B; Wang, H; Wang, X; Yan, J; Yang, S; Zhang, Z; Zhao, R; Zhao, T | 1 |
| Agirman, F; Arsenijevic, T; Azurmendi Senar, O; Bellahcène, A; Crake, R; D'Haene, N; Dehaye, J; Gasmi, I; Koopmansch, B; Lambert, F; Lardinois, F; Maloujahmoum, N; Peiffer, R; Peulen, O; Van Laethem, JL | 1 |
| Barwad, A; Bhatnagar, S; Bhoriwal, S; Dhamija, E; Kumar, A; Mridha, AR; Rastogi, S; Shamim, SA; Tansir, G | 1 |
| Jiang, X; Lee, MJ; Lin, W; Luo, T; Tillman, L | 1 |
| Jingu, K; Kishida, K; Mizuma, M; Nakagawa, K; Omata, S; Suzuki, Y; Takahashi, N; Umezawa, R; Unno, M; Yamamoto, T | 1 |
| Gu, HF; Hu, YF; Jin, YW; Li, FY | 1 |
| Jeong, H; Yoo, C | 1 |
| Akita, H; Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Iwagami, Y; Kobayashi, S; Nishi, H; Noda, T; Sasaki, K; Takahashi, H; Tanemura, M; Tomimaru, Y; Yamada, D | 1 |
| Bai, Y; Chen, C; Chen, J; Gao, Y; Guo, H; Guo, Y; Hu, Z; Xie, L; Yang, X; Yuan, Z | 1 |
| Gallinger, S; Grant, R; Grunwald, B; Jang, GH; Knox, JJ; Notta, F; O'Kane, GM; Perera, S | 1 |
| Daiku, K; Higashi, S; Hirao, T; Ikezawa, K; Kai, Y; Kawamoto, Y; Miyashiro, I; Morishima, T; Mukai, K; Nakabori, T; Ohkawa, K; Seiki, Y; Takada, R; Uehara, H; Urabe, M; Watsuji, K; Yamai, T | 1 |
| Small, EJ | 1 |
| Chen, B; Cheng, H; Deng, T; Gong, P; He, Z; Jiang, S; Liu, W; Ma, L; Shi, D; Wang, W; Yuan, J; Zhang, X | 1 |
| Alves, F; Feldmann, C; Ischyropoulou, M; Napp, J; Niemeyer, CM; Sabljo, K; Schneider, L | 1 |
| Bai, C; Cheng, Y; Tang, H; Wang, X; Wang, Y; Ying, J; Zhu, Z | 1 |
| Bai, X; Bai, Y; Chen, D; Chen, J; Chen, Z; Cheng, Y; Fu, D; Hao, C; Li, J; Liu, T; Pan, H; Qin, B; Qin, S; Shen, L; Wang, Q; Wang, Z; Xu, J; Xu, R; Yang, J; Yang, L; Yuan, Y; Zhang, H; Zhang, J; Zheng, Q; Zhong, H | 1 |
| Abbaspour, A; Dehghani, M; Firuzi, O; Ghorbani, M; Moosavi, F; Omidvari, S; Ramzi, M; Rostamipour, HA; Setayesh, M; Tavakkoli, M | 1 |
| Hayashi, H; Kubota, K; Masuo, H; Miyazaki, S; Notake, T; Sakai, H; Shimizu, A; Soejima, Y; Yoshizawa, T | 1 |
| Cheong, JH; Hong, WC; Kang, HW; Kim, HJ; Kim, HS; Kim, JH; Kim, M; Kim, MJ; Lee, DE; Lee, YS; Park, JS | 1 |
| Avallone, A; Bouattour, M; Burris, H; Chen, JS; Chen, LT; Cohen, G; Cundom, J; He, AR; Ikeda, M; Kim, JW; Kitano, M; Kurland, JF; Lee, CK; Lee, MA; Makowsky, M; McNamara, MG; Oh, DY; Okusaka, T; Qin, S; Rokutanda, N; Suksombooncharoen, T; Takahashi, H; Tan, B; Tanasanvimon, S; Valle, JW; Vogel, A; Wang, J; Zaucha, R; Żotkiewicz, M | 1 |
| Du, J; Hou, G; Li, M; Liang, J; Shao, Y; Silli, EK; Wang, Y; Zhang, Y | 1 |
| Dai, C; Gong, T; Guo, Y; Huang, Y; Pan, H; Wu, D; Yan, J; Yang, Y; Zhao, Y; Zhu, S | 1 |
| Achkar, BE; Bhardwaj, N; Brody, R; Cabal, R; Cetnar, JP; Chan, KG; D'Souza, A; Daneshmand, S; Dorff, TB; Ellis, E; Galsky, MD; Gnjatic, S; Gogerly-Moragoda, M; Gonzalez-Kozlova, E; Haines, GK; Horwitz, A; Ioannou, G; Izadmehr, S; Jun, T; Kelly, G; Kim-Schulze, S; Kinoshita, Y; Kyriakopoulos, C; Lewis, S; Mamtani, R; Mehrazin, R; Mouw, KW; Neil, BO; Nie, K; Nose, Y; Pal, SK; Samstein, RM; Sebra, R; Sfakianos, J; Wang, L; Xie, H; Yu, M; Zhao, Q; Zhu, J | 1 |
| Balachandran, VP; Cercek, A; D'Angelica, MI; Drebin, JA; Franssen, S; Groot Koerkamp, B; Harding, JJ; Holster, JJ; Homs, MYV; Jarnagin, WR; Jolissaint, JS; Kemeny, NE; Kingham, TP; Klümpen, HJ; Mostert, B; Nooijen, LE; Soares, KC; Swijnenburg, RJ; Wei, AC | 1 |
| Bouchekioua-Bouzaghou, K; Chen, J; Griera, JB; Jiang, X; Kong, X; Meng, YM; Qin, H; Wang, M; Wong, PP; Xu, Q | 1 |
| Alhalabi, O; Campbell, MT; Corn, PG; Czerniak, B; Dinney, CPN; Gao, J; Goswami, S; Guo, C; Hansel, DE; Holla, V; Kamat, AM; Khandelwal, J; Kovitz, C; Lin, Y; Logothetis, C; Matin, S; Moussa, MJ; Msaouel, P; Navai, N; Pilie, P; Shah, AY; Siefker-Radtke, AO; Tannir, NM; Wilson, N; Xiao, L | 1 |
| Cheong, JH; Hong, WC; Kang, HW; Kim, HJ; Kim, HS; Kim, JH; Kim, M; Kim, MJ; Lee, DE; Park, JS | 1 |
| Abrahams, D; Ali, J; Bazargan, S; Beatty, MS; Blauvelt, J; Bunch, B; Cox, C; Hall, AM; Landin, A; Ojwang', AME; Pilon-Thomas, S; Poch, M; Rejniak, KA | 1 |
| Chen, M; Gan, L; Hong, P; Jin, J; Li, D; Liu, W; Wei, X; Wong, W; Wu, M; Wu, P; Wu, R; Xu, X; Zhang, K; Zheng, X | 1 |
| Chen, X; Liu, X; Liu, Z; Lu, J; Song, W; Yang, Y | 1 |
| Fung, S; Syed, YY | 1 |
| Biswas, R; Bugde, P; He, J; Li, J; Li, S; Li, Y; Tian, F; Wu, Z; Yang, X | 1 |
| Augustinus, S; Besselink, MG; Bonsing, BA; Bruno, MJ; Busch, OR; de Groot, JWB; Groot Koerkamp, B; Intven, MPW; Köhler, F; Molenaar, Q; Wilmink, JW | 1 |
| Busch, OR; de Wilde, RF; Molenaar, IQ; Seelen, LWF; van Santvoort, HC; Wilmink, JW | 1 |
| Dong, X; Hou, F; Li, C; Wang, S; Wang, Y; Zhang, M | 1 |
| Asagi, A; Gotoh, K; Ikeda, M; Imaoka, H; Mizuno, N; Morizane, C; Nakamura, K; Nomura, S; Okano, N; Okusaka, T; Ozaka, M; Sano, K; Satoi, S; Shimizu, S; Shirakawa, H; Sugimori, K; Sugimoto, R; Ueno, M; Yamaguchi, H; Yamazaki, K | 1 |
1295 review(s) available for gemcitabine and deoxycytidine
| Article | Year |
|---|---|
[New antitumor antimetabolites--gemcitabine and DMDC].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male | 1992 |
New anticancer agents.
Topics: Alkaloids; Animals; Antineoplastic Agents; Azacitidine; Biphenyl Compounds; Chrysenes; Deoxycytidine; Echinomycin; Epirubicin; Etanidazole; Flavonoids; Gemcitabine; Guanidines; Humans; Idarubicin; Menogaril; Mitoguazone; Neoplasms; Nitroimidazoles; Nogalamycin; Organoplatinum Compounds; Paclitaxel; Pentostatin; Polymers; Propylene Glycols; Ribavirin; Sulfonylurea Compounds; Trimetrexate; Vidarabine Phosphate | 1991 |
Gemcitabine: metabolism, mechanisms of action, and self-potentiation.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Death; Cytidine Deaminase; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Gemcitabine; Half-Life; Humans; Prodrugs; Ribonucleotide Reductases; Substrate Specificity; Tumor Cells, Cultured | 1995 |
Palliative chemotherapy in advanced bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Paclitaxel; Palliative Care; Urinary Bladder Neoplasms; Vinblastine | 1995 |
Gemcitabine in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms | 1995 |
New drugs for treating small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan | 1995 |
New drug for therapy of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
[Phase II study].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Practice Guidelines as Topic; Taxoids | 1995 |
New anticancer agents.
Topics: Adenine; Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Imides; Indoles; Irinotecan; Isoquinolines; Naphthalimides; Organophosphonates; Pyridines; Topotecan; Vinblastine; Vinorelbine | 1994 |
New chemotherapeutic agents for non-small cell lung cancer.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Quinoxalines; Sulfanilamides; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1995 |
[Therapeutic strategy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1995 |
Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Staging; Paclitaxel; Pyrimidines; Trimetrexate; Urinary Bladder Neoplasms; Vinblastine | 1995 |
New cytostatic drugs in ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 1993 |
[New promising anticancer drugs for lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Organoplatinum Compounds; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1994 |
Role of differentiation induction in action of purine antimetabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Differentiation; Deoxycytidine; Gemcitabine; Humans; Leukemia; Oncogenes; Ribavirin | 1994 |
Clinical and preclinical activity of 2',2'-difluorodeoxycytidine (gemcitabine).
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Drug Evaluation; Drug Evaluation, Preclinical; Gemcitabine; Humans; Neoplasms; Neoplasms, Experimental | 1993 |
Promising new agents in the treatment of non-small cell lung cancer.
Topics: Aminopterin; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1996 |
Chemotherapy of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Growth Substances; Humans; Immunologic Factors; Octreotide; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Taxoids | 1996 |
Clinical, toxicological and pharmacological aspects of gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans | 1996 |
Promising new therapies in the treatment of advanced ovarian cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topotecan | 1995 |
Activity of gemcitabine in patients with advanced pancreatic carcinoma. A review.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 1996 |
Preclinical studies of chemotherapy and radiation therapy for pancreatic carcinoma.
Topics: Antimetabolites, Antineoplastic; Bromodeoxyuridine; Combined Modality Therapy; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Idoxuridine; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1996 |
Chemotherapy for advanced bladder carcinoma: new molecules and regimens.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Folic Acid Antagonists; Gallium; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Methotrexate; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 1996 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; DNA Topoisomerases, Type I; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Paclitaxel; Prodrugs; Taxoids; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1995 |
Preclinical characteristics of gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Cell Line; Deoxycytidine; DNA Repair; DNA Replication; Enzyme Inhibitors; Gemcitabine; Humans; Tumor Cells, Cultured | 1995 |
Current chemotherapy of advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Quality of Life; Survival Rate | 1995 |
Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; North America; South Africa | 1995 |
Safety profile of gemcitabine.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blood Cell Count; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Edema; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms | 1995 |
Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate | 1995 |
Emerging drug treatments for solid tumours.
Topics: Amifostine; Antineoplastic Agents; Aziridines; Deoxycytidine; Gemcitabine; Humans; Indolequinones; Indoles; Neoplasms; Organoplatinum Compounds; Paclitaxel; Protein Kinase C; Topoisomerase I Inhibitors | 1996 |
New anticancer agents in clinical development.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Neoplasms; Polysaccharides, Bacterial; Prodrugs; Quinazolines; Tegafur; Thiophenes; Thymidylate Synthase; Uracil | 1995 |
Radiosensitizing nucleosides.
Topics: Animals; Deoxycytidine; Gemcitabine; Humans; Hydroxyurea; Nucleosides; Pyrimidines; Radiation-Sensitizing Agents; Thymidine; Vidarabine | 1996 |
Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Kidney Diseases; Lung Neoplasms; Neoplasms; Thrombocytopenia | 1996 |
The development of new chemotherapeutic agents.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasms; Pemetrexed; Quinazolines; Thiophenes; Trimetrexate | 1996 |
New developments in chemotherapy for patients with advanced pancreatic cancer.
Topics: Analgesics; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pain; Pancreatic Neoplasms | 1996 |
[Chemotherapy for pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Irinotecan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Taxoids | 1996 |
Gemcitabine: preclinical pharmacology and mechanisms of action.
Topics: Animals; Antimetabolites, Antineoplastic; DCMP Deaminase; Deoxycytidine; DNA; Gemcitabine; Humans; Ribonucleotide Reductases | 1996 |
Preclinical combination therapy with gemcitabine and mechanisms of resistance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; DNA Damage; Drug Resistance; Gemcitabine; Humans | 1996 |
Phase I studies with the novel nucleoside analog gemcitabine.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Neoplasms | 1996 |
Gemcitabine safety overview.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 1996 |
Single-agent activity of gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
Radiosensitization of human solid tumor cell lines with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1996 |
Gemcitabine in cisplatin-resistant ovarian cancer.
Topics: Antineoplastic Agents; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Ovarian Neoplasms | 1996 |
Economic value of gemcitabine in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms | 1996 |
The cost-effectiveness of four cisplatin-containing chemotherapy regimens in the treatment of stages III B and IV non-small cell lung cancer: an Italian perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Etoposide; Gemcitabine; Health Care Costs; Humans; Ifosfamide; Insurance, Health, Reimbursement; Italy; Lung Neoplasms; Mitomycin; Ribonucleotide Reductases; Vinblastine; Vinorelbine | 1996 |
New drugs in gynecologic oncology.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Ovarian Neoplasms; Platinum Compounds; Uterine Cervical Neoplasms | 1996 |
Gemcitabine and radiosensitization in human tumor cells.
Topics: Antimetabolites, Antineoplastic; Cell Survival; Clinical Trials as Topic; Deoxycytidine; Deoxyribonucleotides; DNA; Gemcitabine; Humans; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1996 |
Metastatic breast cancer.
Topics: Adenine; Antibodies, Monoclonal; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Diphosphonates; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imides; Intercalating Agents; Isoquinolines; Naphthalimides; Neoplasm Metastasis; Neoplasm Proteins; Organophosphonates; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Topoisomerase II Inhibitors; Treatment Outcome | 1996 |
Promising new agents in oncologic treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Mice; Microtubules; Neoplasm Proteins; Neoplasms; Paclitaxel; Thymidylate Synthase; Topoisomerase I Inhibitors; Topotecan | 1996 |
Gemcitabine: a cytidine analogue active against solid tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Neoplasms, Experimental | 1997 |
Improving quality of life in patients with non-small cell lung cancer: research experience with gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life | 1997 |
Combination therapy with gemcitabine in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 1997 |
Metastatic bladder cancer: advances in treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Urinary Bladder Neoplasms | 1997 |
Advanced breast cancer: investigational role of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans | 1997 |
Gemcitabine in ovarian cancer: an overview of safety and efficacy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms | 1997 |
[Recent development of antitumor antimetabolites in Japan--cytosine arabinoside analogues].
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleotides; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cytarabine; Cytidine Monophosphate; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mice; Neoplasm Transplantation | 1997 |
Preclinical, pharmacologic, and phase I studies of gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; DNA Replication; DNA, Neoplasm; Drug Evaluation, Preclinical; Gemcitabine; Half-Life; Humans; Lung Neoplasms; Ribonucleotide Reductases; Safety | 1997 |
Combination chemotherapy studies with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Deoxycytidine; Drug Synergism; Etoposide; Gemcitabine; Humans; Mitomycin; Neoplasms; Ribonucleotide Reductases; Tumor Cells, Cultured | 1997 |
Gemcitabine-mediated radiosensitization.
Topics: Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colonic Neoplasms; Deoxycytidine; Gemcitabine; Head and Neck Neoplasms; Humans; Radiation-Sensitizing Agents; Research Design; Tumor Cells, Cultured | 1997 |
Overview of current and future chemotherapeutic agents in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Forecasting; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 1997 |
Efficacy of single-agent gemcitabine in advanced non-small cell lung cancer: a review.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Ribonucleotide Reductases | 1997 |
Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleotide Reductases; Survival Rate | 1997 |
[New wave of chemotherapeutic agents: update in pulmonary oncology].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1997 |
Gemcitabine: symptomatic benefit in advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Ribonucleotide Reductases; Treatment Outcome | 1997 |
New anticancer drugs in Europe.
Topics: Aminopterin; Anthraquinones; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Aziridines; Bridged-Ring Compounds; Bryostatins; Camptothecin; Dacarbazine; Deoxycytidine; Distamycins; Doxorubicin; Europe; Gemcitabine; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Nitrogen Mustard Compounds; Nitrosourea Compounds; Pyrazoles; Quinazolines; Taxoids; Temozolomide; Thiophenes; Vinca Alkaloids | 1997 |
New cytostatic agents for the treatment of head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids | 1997 |
Gemcitabine. A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms | 1997 |
Safety profile of gemcitabine, a novel anticancer agent, in non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Alopecia; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Dyspnea; Edema; Fever; Gemcitabine; Heart; Humans; Kidney; Liver; Lung Neoplasms; Middle Aged; Nausea; Vomiting | 1997 |
[Nucleoside kinases and new types of antitumor nucleosides].
Topics: Antimetabolites, Antineoplastic; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Nucleic Acid Synthesis Inhibitors; Phosphotransferases | 1997 |
Current and emerging treatments for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 1997 |
Future directions in the chemotherapy of ovarian cancer.
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Europe; Female; Forecasting; Gemcitabine; Humans; Injections, Intraperitoneal; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Time Factors; Topotecan; Vinblastine; Vinorelbine | 1997 |
[Lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1997 |
[Combination chemotherapy in the treatment of inoperable non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Meta-Analysis as Topic; Mitomycin; Paclitaxel; Survival Rate; Vinblastine; Vindesine; Vinorelbine | 1997 |
["State-of-the-art" chemotherapy for small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vincristine | 1997 |
Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Forecasting; Gemcitabine; Hormone Antagonists; Humans; Pancreatic Neoplasms; Somatostatin; Tamoxifen | 1997 |
Clinical experience with gemcitabine in pancreatic carcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Evaluation; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Safety; Survival Rate; Treatment Outcome | 1997 |
Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 1997 |
New chemotherapeutic agents in the treatment of non-small cell lung cancer: the Australian experience.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Australia; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
Experience with new chemotherapeutic agents in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 1998 |
New agents in the treatment of small cell lung cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Menogaril; Paclitaxel; Taxoids; Teniposide; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 1998 |
[Gemcitabine: a new chemotherapy agent for solid cancers].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 1997 |
[Gemzar (gemcitabine)--a new chemotherapeutic agent for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 1997 |
New chemotherapy regimens for advanced bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Folic Acid Antagonists; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Urinary Bladder Neoplasms; Vinblastine | 1998 |
Tumor resistance to antimetabolites.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Proteins; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Amplification; Humans; Methotrexate; Mutation; Neoplasms; Quinazolines; Thiophenes | 1998 |
A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer.
Topics: Alkaloids; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Survival Rate; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1998 |
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
Gemcitabine--a safety review.
Topics: Alopecia; Antimetabolites, Antineoplastic; Blood Cell Count; Bone Marrow; Deoxycytidine; Digestive System; Gemcitabine; Hematuria; Humans; Nausea; Neoplasms; Vomiting | 1998 |
Do newer chemotherapeutic agents improve survival in non-small cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 1998 |
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Male; Pancreatic Neoplasms; Pemetrexed | 1998 |
Combination studies with gemcitabine in the treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Middle Aged; Vinblastine; Vinorelbine | 1998 |
The role of gemcitabine in the treatment of other tumours.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasms | 1998 |
The activity of gemcitabine plus cisplatin in randomized trials in untreated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic | 1998 |
Gemcitabine and paclitaxel combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 1998 |
Gemcitabine and carboplatin in combination: phase I and phase II studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 1998 |
Gemcitabine and radiation therapy for non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Evaluation Studies as Topic; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents | 1998 |
Evaluation of new drugs in small cell lung cancer: the activity of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 1998 |
New agents in the management of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1998 |
[The role of new drugs in the treatment of locally advanced urothelial tumors of the bladder].
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 1998 |
Treatment of advanced and metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Mitomycin; Neoplasm Metastasis; Nitrosourea Compounds; Pancreatic Neoplasms | 1998 |
Adjuvant therapy for pancreatic cancer: current status.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Postoperative Care; Preoperative Care; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate | 1998 |
Gemcitabine for palliative treatment in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Palliative Care | 1998 |
Chemotherapy in the treatment of cancer of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Ribonucleotide Reductases | 1998 |
New drugs in the treatment of Hodgkin's disease.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bendamustine Hydrochloride; Deoxycytidine; Drug Therapy; Gemcitabine; Hodgkin Disease; Humans; Idarubicin; Immunotoxins; Nitrogen Mustard Compounds; Vinblastine; Vinorelbine | 1998 |
Hemolytic-uremic syndrome caused by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fatal Outcome; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Lung Neoplasms; Male; Middle Aged; Vindesine | 1998 |
Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 1999 |
Chemotherapy for advanced pancreatic cancer: it may no longer be ignored.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 1999 |
Chemotherapy for non-small cell lung cancer: have we reached a new plateau?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 1999 |
Gemcitabine and carboplatin in combination: an update of phase I and phase II studies in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms | 1999 |
Gemcitabine plus taxane combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds | 1999 |
Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Gemcitabine: a pharmacologic and clinical overview.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Nursing Care; Oncology Nursing; Pancreatic Neoplasms | 1999 |
Gemcitabine in the treatment of ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1999 |
Review of the pharmacoeconomic research on gemcitabine in the treatment of advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Europe; Gemcitabine; Humans; Lung Neoplasms; Models, Econometric; United States | 1998 |
Chemoprotection against cytosine nucleoside analogs using the human cytidine deaminase gene.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; Drug Resistance; Gemcitabine; Humans | 1999 |
Gemcitabine: single-agent and combination therapy in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Survival Analysis; Treatment Outcome | 1999 |
[Clinical development in gemcitabine and its clinical pharmacological profile].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Half-Life; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 1999 |
[Gemcitabine hydrochloride is a new anti-cancer agent which will be available in the patients with non-small cell lung cancer (NSCLC) in Japan].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Gemcitabine; Humans; Lung Neoplasms; Middle Aged | 1999 |
Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Palliative chemotherapy and radiotherapy for pancreatic cancer: is It worthwhile?
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Survival Analysis | 1999 |
New agents in gastrointestinal malignancies: Part 2: Gemcitabine in clinical practice.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Oncology Nursing; Pancreatic Neoplasms | 1999 |
Docetaxel (Taxotere) and gemcitabine in combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Docetaxel (Taxotere) in non-small cell lung cancer: ongoing studies in Heidelberg and future plans.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Palliative Care; Radiotherapy, Adjuvant; Taxoids | 1999 |
The use of gemcitabine in non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group. Provincial Systemic Treatment Disease Site Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Neutropenia; Odds Ratio; Randomized Controlled Trials as Topic; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 1999 |
Chemotherapy in head and neck cancer. Overview of newer agents.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Organoplatinum Compounds; Paclitaxel; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Topotecan; Vinblastine; Vinorelbine | 1999 |
Radiosensitization by gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Combined Modality Therapy; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Ribonucleotide Reductases | 1999 |
The role of radiation, with or without chemotherapy, in the management of NSCLC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Topotecan; Vinblastine; Vinorelbine | 1999 |
Ifosfamide in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel | 1999 |
Docetaxel (Taxotere) in combination chemotherapy and in association with thoracic radiotherapy for the treatment of non-small-cell lung cancer. Thoracic Oncology Program.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neutropenia; Patient Selection; Thrombocytopenia; Treatment Outcome | 1999 |
Cisplatin and gemcitabine in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Lung Neoplasms; Treatment Outcome | 1999 |
Docetaxel and gemcitabine combinations in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 1999 |
Single-agent gemcitabine and gemcitabine/irinotecan combination (irimogem) in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms | 1999 |
Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Vinblastine; Vinorelbine | 1999 |
Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Survival Analysis; Vinblastine; Vinorelbine | 1999 |
Up date in the management of advanced ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Topotecan | 1999 |
[New drugs in gastrointestinal oncology. Current status and future directions].
Topics: Antineoplastic Agents; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Taxoids; Tegafur; Thiophenes; Vinblastine; Vinorelbine | 1999 |
[Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Multicenter Studies as Topic; Palliative Care; Pancreatic Neoplasms; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors | 1999 |
Gemcitabine in bladder cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Prognosis; Urinary Bladder Neoplasms | 2000 |
The role of gemcitabine in the treatment of ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Prognosis | 2000 |
[New combination chemotherapy in urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2000 |
New chemotherapy agents for small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2000 |
Antimetabolites.
Topics: Animals; Antimetabolites, Antineoplastic; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Methotrexate | 1999 |
[Current perspectives of new agents in lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Gemcitabine in non-small cell lung cancer (NSCLC).
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2000 |
Gemcitabine in locally advanced and/or metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Urinary Bladder Neoplasms; Urothelium | 2000 |
Clinical update of gemcitabine in pancreas cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Analysis | 2000 |
Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urologic Neoplasms | 2000 |
[Clinical development of new molecular targeted therapeutics for cancer therapy].
Topics: Angiogenesis Inhibitors; Apoptosis; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Hydroxamic Acids; Neoplasms | 2000 |
[Current status and future directions of gemcitabine in the treatment of non-small cell lung cancer and pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Etoposide; Forecasting; Gemcitabine; Lung Neoplasms; Pancreatic Neoplasms | 2000 |
Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Vinblastine; Vinorelbine | 2000 |
Gemcitabine/cisplatin as induction therapy for stage IIIA N2 non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Preoperative Care; Randomized Controlled Trials as Topic; Remission Induction; Tomography, Emission-Computed | 2000 |
Combination chemoradiotherapy with gemcitabine: potential applications.
Topics: Agranulocytosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Thrombocytopenia | 2000 |
Gemcitabine/carboplatin combination regimens: importance of dose schedule.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Palliative Care; Randomized Controlled Trials as Topic; Thrombocytopenia | 2000 |
Second-line chemotherapy for recurrent non-small cell lung cancer: do new agents make a difference?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drugs, Investigational; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2000 |
[A 42-year-old patient with the hemolytic-uremic syndrome under gemcitabine therapy for an adenocarcinoma of the liver. The hemolytic-uremic syndrome and gemcitabine].
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Liver Neoplasms; Male | 2000 |
Chemotherapy in metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Mitomycin; Paclitaxel; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2000 |
Extensive small-cell lung cancer: a treatment overview.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2000 |
Dose-intensive approaches to ovarian cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Prognosis; Survival Analysis; Topotecan | 1999 |
The role of new agents in advanced non-small-cell lung carcinoma.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immunologic Factors; Irinotecan; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Prognosis; Quality of Life; Survival Analysis; Taxoids; Tomography, X-Ray Computed; Vinblastine; Vinorelbine | 2000 |
Management of elderly patients with lung cancer.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Combined Modality Therapy; Decision Making; Deoxycytidine; Gemcitabine; Geriatrics; Humans; Lung Neoplasms; Prognosis; Quality of Life; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2000 |
New approaches to treatment of metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gallium; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Metastasis; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2000 |
[Chemotherapy of stage IV non-small-cell lung cancer: contribution of gemcitabine].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mitomycin; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2000 |
[Adjuvant therapy of pancreatic carcinoma].
Topics: Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2000 |
The role of gemcitabine alone and in combination in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2000 |
Gemcitabine: progress in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Irinotecan; Matrix Metalloproteinase Inhibitors; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Options in advanced non-small cell lung cancer: a review and report on a phase II study of vinorelbine plus gemcitabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Novel combinations with oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2000 |
Docetaxel followed by gemcitabine and irinotecan in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Survival Rate; Taxoids | 2001 |
Chemoradiation in locally advanced non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Forecasting; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Treatment of extensive stage small cell lung cancer.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Genes, Dominant; Growth Substances; Humans; Irinotecan; Lung Neoplasms; Metalloendopeptidases; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasm Staging; Oncogenes; Paclitaxel; Palliative Care; Protease Inhibitors; Randomized Controlled Trials as Topic; Salvage Therapy; Signal Transduction; Taxoids; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Gemcitabine in the treatment of bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2000 |
Gemcitabine as single-agent therapy in the management of advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Palliative Care | 2001 |
Treatment of advanced breast cancer with gemcitabine and vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2001 |
Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 2001 |
Gemcitabine and Pemetrexed disodium in treating breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Neoplasm Metastasis; Pemetrexed | 2001 |
[Palliative therapy of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Palliative Care; Pancreatic Neoplasms | 2001 |
Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Recent advances in bladder cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Urinary Bladder Neoplasms | 2001 |
Irinotecan/gemcitabine combination chemotherapy in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms | 2001 |
Gemcitabine in combination with new platinum compounds: an update.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Platinum Compounds | 2001 |
Gemcitabine and nonplatinum combinations in non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Platinum Compounds; Treatment Outcome | 2001 |
Gemcitabine for the treatment of non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Multicenter Studies as Topic; Treatment Outcome | 2001 |
Gemcitabine and cisplatin combination in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Treatment Outcome | 2001 |
Optimizing chemoradiation in locally advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2001 |
[Gemcitabine + Cisplatin combinations in advanced non-small cell lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2000 |
[Chemotherapy of non-small cell lung cancer: non-cisplatin based combinations].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2000 |
[Gemcitabine and urothelial tumours].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Urologic Neoplasms | 2000 |
Alterations in taste sensation: a case presentation of a patient with end-stage pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dysgeusia; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Taste Disorders | 2001 |
Incidence of thrombocytopenia with gemcitabine-based therapy and influence of dosing and schedule.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Comorbidity; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Hemorrhage; Humans; Incidence; Platelet Transfusion; Retrospective Studies; Thrombocytopenia | 2001 |
The evolving role of gemcitabine in the management of breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans | 2001 |
Gemcitabine in advanced bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Urinary Bladder Neoplasms; Vinblastine | 2001 |
The current role of gemcitabine in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms | 2001 |
Treatment of metastatic urothelial cancer in the post-MVAC era.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Muscle Neoplasms; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2001 |
Current options for palliative treatment in patients with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Analysis | 2001 |
New combinations with epirubicin in advanced breast cancer.
Topics: Adult; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Survival Rate; Time Factors | 2001 |
Nucleoside analogues: mechanisms of drug resistance and reversal strategies.
Topics: 2-Chloroadenosine; 5'-Nucleotidase; Acute Disease; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Leukemia, Myeloid; Lymphoproliferative Disorders; Neoplastic Stem Cells; Nucleosides; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Remission Induction; Ribonucleotide Reductases; Vidarabine | 2001 |
Novel clinical strategies for the treatment of pancreatic carcinoma.
Topics: Adjuvants, Immunologic; Antibodies, Monoclonal; Antineoplastic Agents; Bile; Biotransformation; Cancer Vaccines; Carcinoma; Clinical Trials as Topic; Cytochrome P-450 CYP2B1; Cytosine; Deoxycytidine; Dioxolanes; DNA, Antisense; Endopeptidases; Enzyme Inhibitors; Gemcitabine; Genes, p53; Genes, ras; Genetic Therapy; Heat-Shock Proteins; Humans; Ifosfamide; Multicenter Studies as Topic; Neoplasm Proteins; Neoplastic Stem Cells; Pancreatic Neoplasms; Pectins; Pilot Projects; Polyamines; Prospective Studies; Prostheses and Implants; Sesquiterpenes; Spiro Compounds; Tissue Extracts; Topoisomerase I Inhibitors | 2001 |
Neoadjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2001 |
Recent developments in chemotherapy for bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2001 |
Non-platinum based combination chemotherapy: phase I and II trials of docetaxel plus gemcitabine, vinorelbine, or irinotecan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Taxoids | 2001 |
A systematic overview of chemotherapy effects in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis | 2001 |
Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Methotrexate; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2001 |
Therapy for regionally unresectable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2001 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; DNA Adducts; Female; Gemcitabine; Humans; Immunologic Factors; Liposomes; Ovarian Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Topoisomerase I Inhibitors; Topotecan | 2001 |
New chemotherapy combinations for advanced bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Combinations; Female; Gemcitabine; Humans; Male; Methotrexate; Neoplasm Metastasis; Platinum; Prognosis; Severity of Illness Index; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2001 |
Second-line treatment of advanced transitional cell carcinoma of the urothelial tract.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Severity of Illness Index; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium; Vinblastine | 2001 |
Rationale for non-platinum chemotherapy in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2001 |
New cytotoxic agents and schedules for advanced breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Humans; Liposomes; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Trastuzumab; Vinblastine; Vinorelbine | 2001 |
Pancreatic cancer in the older patient.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Cholestasis; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pain; Pain Management; Palliative Care; Pancreatic Neoplasms | 2001 |
Gemcitabine-containing regimens in bladder cancer: A new standard of care.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2001 |
Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2001 |
Gemcitabine/carboplatin in advanced urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2001 |
Combining gemcitabine with radiation in pancreatic cancer: understanding important variables influencing the therapeutic index.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2001 |
Beyond pancreatic cancer: irinotecan and gemcitabine in solid tumors and hematologic malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Hematologic Neoplasms; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Pancreatic Neoplasms | 2001 |
Gemcitabine in ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms | 2001 |
Recent advances in the chemotherapy of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
[Therapeutic strategies in neoadjuvant therapy of non-small cell lung cancer: benefits of gemcitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Survival Rate | 2001 |
[Role of gemcitabine in the treatment of advanced non-small cell lung cancer: review of the main phase II and phase III trials].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Multicenter Studies as Topic | 2001 |
Adjuvant chemotherapy for muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2001 |
[Preclinical studies of oxaliplatin in combination chemotherapy].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Mice; Models, Biological; Organoplatinum Compounds; Oxaliplatin; Tumor Cells, Cultured | 2001 |
Indications for chemotherapy in stage IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Tirapazamine; Triazines; Vinblastine; Vinorelbine | 2001 |
Nucleoside analogues in the treatment of haematological malignancies.
Topics: Antimetabolites, Antineoplastic; Arabinonucleosides; Biological Transport; Cladribine; Clinical Trials as Topic; Cytarabine; Cytosine; Deoxycytidine; Dioxolanes; Economics, Pharmaceutical; Gemcitabine; Guidelines as Topic; Hematologic Neoplasms; Humans; Molecular Structure; Nucleosides; Pentostatin; Vidarabine | 2001 |
Gemcitabine in hematologic malignancies.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; DNA; Gemcitabine; Hodgkin Disease; Humans; Leukemia; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Tumor Cells, Cultured | 2001 |
Recent advances in the use of radiosensitizing nucleosides.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents | 2001 |
[Gemcitabine in the treatment of 4 patients with cholangiocarcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2001 |
[Results of gemcitabine hydrochloride in the treatment for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 2001 |
New combinations with Herceptin in metastatic breast cancer.
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Drug Synergism; Epirubicin; Female; Fluorouracil; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Nitriles; Organoplatinum Compounds; Paclitaxel; Tamoxifen; Thiotepa; Trastuzumab; Treatment Outcome; Triazoles; Vinblastine; Vinorelbine | 2001 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life | 2001 |
Treatment of advanced ovarian cancer.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Topotecan | 2001 |
Induction chemotherapy with gemcitabine and cisplatin in stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy | 2001 |
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2001 |
Radiosensitization with chemotherapeutic agents.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Platinum Compounds; Radiation-Sensitizing Agents; Taxoids; Vinblastine; Vinorelbine | 2001 |
Gemcitabine and pemetrexed disodium combinations in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2001 |
ALIMTA (pemetrexed disodium, LY231514, MTA): clinical experience in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2001 |
A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life | 2002 |
[New developments in chemotherapy for metastasized bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Methotrexate; Paclitaxel; Palliative Care; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms; Vinblastine | 2001 |
Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost of Illness; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Active chemotherapy for collecting duct carcinoma of the kidney: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 2002 |
Gemcitabine-induced pulmonary toxicity: case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dyspnea; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged | 2002 |
Pancreatic cancer: the evolving role of systemic therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2001 |
The role of gemcitabine in the treatment of malignant mesothelioma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Mesothelioma | 2002 |
Second-line treatment of ovarian cancer with single-agent gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2002 |
The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Vinblastine; Vinorelbine | 2002 |
Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel | 2002 |
Developmental chemotherapy in advanced ovarian cancer: incorporation of newer cytotoxic agents in a phase III randomized trial of the Gynecologic Oncology Group (GOG-0182).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan | 2002 |
Pancreatic cancer: what the oncologist can offer for palliation.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Mutation; Neoplasm Recurrence, Local; Organophosphonates; Palliative Care; Pancreatic Neoplasms | 2002 |
[Hemolytic-uremic syndrome complicating a long-term treatment with gemcitabine. Report of a case and review of the literature].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Time Factors | 2002 |
Current and future perspectives in advanced bladder cancer: is there a new standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Metastasis; Paclitaxel; Patient Selection; Practice Guidelines as Topic; Research Design; Risk Factors; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Gemcitabine doublets in advanced urothelial cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Renal Insufficiency; Survival Analysis; Trastuzumab; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Novel gemcitabine-containing triplets in the management of urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Forecasting; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Gemcitabine-based combination treatment of pancreatic cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2002 |
Future directions for gemcitabine in the treatment of genitourinary cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Forecasting; Gemcitabine; Humans; Kidney Neoplasms; Male; Morbidity; Prostatic Neoplasms; Survival Analysis; Testicular Neoplasms; Treatment Outcome; United States; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2002 |
Determinants of response and resistance to cytotoxics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Damage; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Loss of Heterozygosity; Lung Neoplasms; Predictive Value of Tests; Signal Transduction | 2002 |
[Developed new agents for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2002 |
[Radiotherapy and chemotherapy for unresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycin; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage | 2002 |
[Does treatment for malignant pleural mesothelioma exist?].
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Interferons; Male; Mesothelioma; Middle Aged; Mitomycin; Multivariate Analysis; Paclitaxel; Palliative Care; Pemetrexed; Pleural Neoplasms; Pneumonectomy; Postoperative Care; Radiotherapy Dosage; Time Factors | 2001 |
[New therapeutic approaches in non-small-cell lung carcinoma (NSCLC), stages IV].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
[Combined radiotherapy and gemcitabine. Evaluation of clinical data based on experimental knowledge].
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Neoplasms; Radiography; Radiotherapy, Adjuvant; Treatment Outcome | 2002 |
[How I treat ... An advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis | 2002 |
[Gemcitabine and ionizing radiations: radiosensitization or radio-chemotherapy combination].
Topics: Adenosine Triphosphate; Cell Cycle; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2002 |
What's new in pancreatic cancer treatment?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Survival Analysis | 2002 |
Gemcitabine-induced radiation recall.
Topics: Adult; Aged; Deoxycytidine; Drug Administration Schedule; Drug Eruptions; Female; Gemcitabine; Humans; Male; Middle Aged; Radiation Injuries; Radiation-Sensitizing Agents; Retrospective Studies | 2002 |
Gemcitabine in non-small cell lung cancer.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Radiotherapy, Adjuvant | 2002 |
Novel treatments and therapies in development for pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Genetic Therapy; Hormones; Humans; Immunotherapy; Pancreatic Neoplasms | 2002 |
[Acute respiratory failure due to Gemcitabine-induced pulmonary toxicity].
Topics: Acute Disease; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Respiratory Hypersensitivity; Respiratory Insufficiency | 2002 |
Gemcitabine, ifosfamide and Navelbine (GIN): a platinum-free combination in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mesna; Middle Aged; Protective Agents; Vinblastine; Vinorelbine | 2002 |
Current therapy for malignant mesothelioma.
Topics: Antimetabolites, Antineoplastic; Asbestosis; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Mesothelioma; Pleural Neoplasms; Prognosis; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome | 2002 |
Overview: gemcitabine as single-agent therapy for advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Ribonucleotide Reductases; Survival Analysis; Treatment Outcome | 2002 |
Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Drug Evaluation, Preclinical; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lung Neoplasms; Ribonucleotide Reductases; Trastuzumab; Tumor Cells, Cultured | 2002 |
Pemetrexed (Alimta) and gemcitabine in breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Glutamates; Guanine; Humans; Pemetrexed; Taxoids; Treatment Failure; Treatment Outcome | 2002 |
Gemcitabine plus cisplatin for the treatment of metastatic breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids; Trastuzumab; Treatment Failure; Treatment Outcome | 2002 |
Gemcitabine/anthracycline combinations in metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Neoadjuvant gemcitabine therapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome | 2002 |
Gemcitabine in breast cancer: future directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Ribonucleotide Reductases | 2002 |
Epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Practice Guidelines as Topic; Tamoxifen; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2002 |
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Interferon alpha-2; Interferon-alpha; Irinotecan; Leucovorin; Multicenter Studies as Topic; Organoplatinum Compounds; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Respiratory Distress Syndrome; Taxoids; Treatment Outcome | 2002 |
Management of locally advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycins; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioisotope Teletherapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies; Streptozocin | 2002 |
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; England; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Wales | 2001 |
New treatment approaches for lung cancer and impact on survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Incidence; Lung Neoplasms; Paclitaxel; Survival Rate | 2002 |
Incorporation of pemetrexed (Alimta) into the treatment of non-small cell lung cancer (thoracic tumors).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Folic Acid; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed; Pleural Neoplasms; Thymidylate Synthase; Vitamin B 12 | 2002 |
Present and future treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids | 2002 |
The present and future of combination chemotherapy in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Methotrexate; Paclitaxel; Pemetrexed; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Gemcitabine and pemetrexed (Alimta) in thoracic cancers: present and future perspectives. Introduction and current controversies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2002 |
Gemcitabine induction chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Randomized Controlled Trials as Topic | 2002 |
[Docetaxel].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2002 |
[Gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Carboplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Chemotherapy for elderly patients with lung cancer].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2002 |
Docetaxel in the management of advanced or metastatic urothelial tract cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Taxoids; Urologic Neoplasms | 2002 |
Gemcitabine and radiotherapy in the treatment of brain metastases from transitional cell carcinoma of the bladder: a case report.
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Urinary Bladder Neoplasms | 2002 |
Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).
Topics: Animals; Antiviral Agents; Apoptosis; Cell Membrane; Deoxycytidine; Drug Resistance, Viral; Gemcitabine; Genome, Viral; Humans; Phosphorylation | 2002 |
Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Economics, Pharmaceutical; Gemcitabine; Health Policy; Humans; Lung Neoplasms; Policy Making; Quality of Life; Survival; Vinblastine; Vinorelbine | 2002 |
Gemcitabine and targeted therapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2002 |
[Gemcitabine-induced thrombotic microangiopathy].
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Metastasis; Thrombosis; Urologic Neoplasms; Vascular Diseases | 2002 |
[New drugs in bronchial cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy; Gemcitabine; Humans; Lung Neoplasms; Vinblastine; Vinorelbine | 2002 |
Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
Chemotherapy of non-small cell lung cancer in elderly patients.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Risk Factors; Vinblastine; Vinorelbine | 2002 |
The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Europe; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom; Vinblastine; Vinorelbine | 2002 |
New drugs and new approaches for the treatment of metastatic urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Doxorubicin; Drug Therapy; Gemcitabine; Humans; Methotrexate; Taxoids; Urologic Neoplasms; Urothelium; Vinblastine | 2002 |
Gemcitabine and platinum combinations in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia | 2002 |
Gemcitabine in combination with 5-fluorouracil with or without folinic acid in the treatment of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Trastuzumab | 2002 |
The pemetrexed/gemcitabine combination in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Pancreatic Neoplasms; Pemetrexed; Survival Analysis | 2002 |
On the development of gemcitabine-based chemoradiotherapy regimens in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2002 |
New applications of gemcitabine and future directions in the management of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Transformation, Neoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Signal Transduction | 2002 |
Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Palliative Care; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2002 |
Gemcitabine-associated hemolytic-uremic syndrome.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Ovarian Neoplasms; Ribonucleotide Reductases | 2002 |
[Gemcitabine-based chemotherapy for non-small cell lung cancer (NSCLC)--a review of 30 randomized trials].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2002 |
Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Topoisomerase I Inhibitors | 2002 |
Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Injections, Intravenous; Liver Diseases; Lung Neoplasms; Vinblastine; Vinorelbine | 2002 |
Metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Autonomic Nerve Block; Celiac Plexus; Cholestasis; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Digestive System Diseases; Fluorouracil; Gastric Outlet Obstruction; Gemcitabine; Humans; Neoplasm Metastasis; Neuralgia; Palliative Care; Pancreatic Neoplasms; Risk Factors; Stents | 2002 |
Safety experience with IMC-C225, an anti-epidermal growth factor receptor antibody.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Eruptions; Drug Hypersensitivity; Drug Interactions; Gemcitabine; Head and Neck Neoplasms; Humans; Irinotecan; Pancreatic Neoplasms | 2002 |
Gemzar platinum combinations: phase III trials in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Survival | 2002 |
Gemcitabine (Gemzar)-based induction chemotherapy in non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Gemcitabine/carboplatin in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
Past, present, and future of gemcitabine and carboplatin regimens in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Outpatients; Randomized Controlled Trials as Topic; Steroids; Taxoids | 2002 |
Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer?
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Palliative Care; Quality of Life; Survival | 2002 |
Non-platinum gemcitabine combinations in non-small cell lung cancer.
Topics: Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Gemcitabine and its combinations in the treatment of malignant lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Random Allocation; Recurrence; Rituximab; Transplantation, Autologous; Treatment Outcome | 2002 |
[Clinical pharmacology of nucleoside analogues].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Biotransformation; Cytarabine; Cytidine Deaminase; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Half-Life; Humans; Male; Metabolic Clearance Rate; Neoplasm Proteins; Phosphorylation; Prodrugs; Vidarabine | 2002 |
[New neoadjuvant approaches using gemcitabine in non-small-cell lung cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome | 2002 |
[Combinations of platinum salts and gemcitabine in the treatment of non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Randomized Controlled Trials as Topic; Remission Induction; Reproducibility of Results; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Platinum-free gemcitabine-based combinations: an alternative to conventional chemotherapy of non-small-cell lung cancers?].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Neoadjuvant Therapy; Paclitaxel; Pneumonectomy; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Gemcitabine and pancreatic cancer].
Topics: Adenocarcinoma; Analgesia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Europe; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States | 2002 |
[Gemcitabine-based combinations in inoperable pancreatic cancers].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Routes; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Multicenter Studies as Topic; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2002 |
[Gemcitabine and urogenital tumors].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Germinoma; Hematologic Diseases; Humans; Kidney Neoplasms; Male; Methotrexate; Organoplatinum Compounds; Patient Selection; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms; Urogenital Neoplasms; Vinblastine | 2002 |
[Gemcitabine and breast cancer].
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Gemicitabine in the treatment of epithelial ovarian cancer].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Multicenter Studies as Topic; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Palliative Care; Prodrugs; Remission Induction; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[Role of gemcitabine in the treatment of other malignant tumors].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Melanoma; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome; Uterine Cervical Neoplasms | 2002 |
[The role of gemcitabine in hematology].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Design; Gemcitabine; Hematologic Neoplasms; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Cutaneous; Multiple Myeloma; Neoplasm Proteins; Nucleotides; Ribonucleotide Reductases; Salvage Therapy; Treatment Outcome | 2002 |
[Combined gemcitabine and radiotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasms; Neoplasms, Experimental; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Prodrugs; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy; Tumor Cells, Cultured | 2002 |
Chemoradiation with novel agents for rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclooxygenase Inhibitors; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Rectal Neoplasms | 2002 |
Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Developing therapeutic pharmaceuticals for the treatment of soft-tissue sarcomas.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Imatinib Mesylate; Irinotecan; Isoquinolines; Piperazines; Pyrimidines; Sarcoma; Temozolomide; Tetrahydroisoquinolines; Trabectedin | 2002 |
Chemotherapy for advanced non-small cell lung cancer (NSCLC).
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Palliative Care; Randomized Controlled Trials as Topic; Survival Rate | 2002 |
Two- versus three-drug combinations in the chemotherapy of advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Survival Rate; Vinblastine; Vinorelbine | 2002 |
Combination chemotherapy without cisplatin in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Quality of Life; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2002 |
Challenging the platinum combinations in the chemotherapy of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Taxoids | 2002 |
Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Health Status; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Survival; Taxoids; Vinblastine; Vinorelbine | 2002 |
The role of membrane transporters in cellular resistance to anticancer nucleoside drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Transport; Capecitabine; Cell Membrane; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Tumor Cells, Cultured; Vidarabine | 2002 |
The mechanism of action of radiosensitization of conventional chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Risk Factors | 2003 |
Preclinical and clinical studies with combinations of pemetrexed and gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Thymidylate Synthase | 2002 |
Emerging insights into the biology and therapy of malignant mesothelioma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Quinazolines; Thiophenes; Thymidylate Synthase | 2002 |
Pemetrexed in the treatment of non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Thymidylate Synthase | 2002 |
Pemetrexed in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Folic Acid; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Pancreatic Neoplasms; Pemetrexed; Thymidylate Synthase; Vitamin B 12 | 2002 |
[Gemcitabine in advanced bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Neoplasm Staging; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2003 |
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Paclitaxel; Pancreatic Neoplasms; Signal Transduction; Taxoids; Transcription Factors; Treatment Failure | 2002 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
Future directions in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2002 |
Review of gemcitabine in biliary tract carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans | 2002 |
Chemotherapy in biliary tract carcinomas: results in India.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; India | 2002 |
Chemotherapy for biliary tract cancer in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Japan | 2002 |
Gemcitabine in transitional cell carcinoma of the urothelium.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Urologic Neoplasms; Urothelium | 2003 |
[Gemcitabine treatment of pancreatic cancer peritonitis].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Peritonitis | 2003 |
Overview of gemcitabine triplets in metastatic bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2003 |
Chemotherapy for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
An overview of current results with the gemcitabine and docetaxel combination as initial and salvage chemotherapy regimen in advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Developments in the systemic therapy of pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Neoplasm Proteins; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Signal Transduction; Topoisomerase I Inhibitors; United States | 2003 |
Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): recent developments.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Microtubules; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Palliative Care; Podophyllotoxin; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Teniposide; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[Adjuvant and additive therapy for cancer of the pancreas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Controlled Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Folic Acid; Gemcitabine; Hematinics; Humans; Leucovorin; Male; Mitoxantrone; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Retrospective Studies; Surveys and Questionnaires; Time Factors | 2003 |
Systemic therapy for advanced pancreatic cancer.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Signal Transduction; Topoisomerase I Inhibitors | 2002 |
Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study.
Topics: Adult; Aged; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2003 |
Chemotherapeutic advances in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2003 |
CD4+ CD56+ neoplasia: clinical and biological features with emphasis on cytotoxic drug-induced apoptosis and expression of sialyl Lewis X.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; CD4 Antigens; CD56 Antigen; Cladribine; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Hematologic Neoplasms; Humans; Immunophenotyping; Lewis X Antigen; Oligosaccharides; Sialyl Lewis X Antigen | 2003 |
Role of gemcitabine in the treatment of advanced and metastatic breast cancer.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Epirubicin; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vindesine; Vinorelbine | 2003 |
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Pain; Quality of Life; Time Factors; Treatment Outcome; Vindesine | 2003 |
Active chemotherapy for bone metastasis in sarcomatoid renal cell carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carboplatin; Carcinoma, Renal Cell; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Paclitaxel; Sarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Monotherapy options in the management of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
Gemcitabine and anthracyclines in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Humans | 2003 |
Gemcitabine combined with docetaxel in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
Gemcitabine combined with paclitaxel or paclitaxel/trastuzumab in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Trastuzumab | 2003 |
[Mucinous adenocarcinoma of the urachus].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Intermediate Filament Proteins; Keratin-20; Keratin-7; Keratins; Male; Middle Aged; Neoplasm Proteins; Radiotherapy, Adjuvant; Urachus; Urinary Bladder Neoplasms | 2003 |
[Malignant pleural mesothelioma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Pemetrexed; Pleural Neoplasms; Randomized Controlled Trials as Topic | 2003 |
Gemcitabine-induced peripheral edema: report on 15 cases and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Edema; Female; Gemcitabine; Humans; Leg; Male; Middle Aged; Risk | 2003 |
[Adjuvant treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Intraoperative Care; Metalloendopeptidases; Neoplasm Metastasis; Neoplasm Recurrence, Local; Organic Chemicals; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Phenylbutyrates; Postoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Time Factors | 2003 |
Radiation therapy with once-weekly gemcitabine in pancreatic cancer: current status of clinical trials.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Time Factors | 2003 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Random Allocation; Treatment Outcome | 2003 |
Newer approaches to gemcitabine-based therapy of pancreatic cancer: fixed-dose-rate infusion and novel agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; DNA Damage; DNA Repair; Dose-Response Relationship, Drug; Gemcitabine; Humans; Pancreatic Neoplasms; Random Allocation; Time Factors | 2003 |
Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Enzyme Inhibitors; Gastrointestinal Neoplasms; Gemcitabine; Humans; Paclitaxel; Quinolones; Radiotherapy, Conformal; Treatment Outcome | 2003 |
[Asbestos--gemcitabin. Combined risk for pulmonary toxicity?].
Topics: Antimetabolites, Antineoplastic; Asbestos; Deoxycytidine; Gemcitabine; Humans; Incidence; Lung Diseases; Occupational Exposure; Risk Factors | 2003 |
Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Glutamates; Guanine; Humans; Kidney Neoplasms; Paclitaxel; Pemetrexed; Urogenital Neoplasms; Urothelium | 2003 |
New chemotherapy agents in veterinary medicine.
Topics: Animals; Antineoplastic Agents; Cat Diseases; Cats; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine; Ifosfamide; Lomustine; Mesna; Neoplasms; Streptozocin; Veterinary Drugs | 2003 |
Genetic testing for chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; DNA Adducts; DNA Damage; DNA Helicases; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Genetic Testing; Humans; Lung Neoplasms; Polymorphism, Genetic; Protein Biosynthesis; Repressor Proteins; RNA, Messenger; Survival Analysis; Taxoids; Transcription Factors; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2003 |
The global role of irinotecan in the treatment of lung cancer: 2003 update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Multicenter Studies as Topic; Neoplasm Staging; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; United States; Vindesine | 2003 |
The systemic treatment of advanced and metastatic bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2003 |
Initial experience combining cyclooxygenase-2 inhibition with chemoradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Gemcitabine; Humans; Isoenzymes; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Radiation-Sensitizing Agents; Sulfonamides | 2003 |
[Chemoradiation in pancreatic carcinoma].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2003 |
Update on gemcitabine/carboplatin in patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Quality of Life; Randomized Controlled Trials as Topic | 2003 |
Efficacy of neoadjuvant strategies with gemcitabine and other chemotherapy in resectable non-small cell lung cancer: a combined modality approach.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Randomized Controlled Trials as Topic | 2003 |
Targeted therapy in combination with gemcitabine in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Polymorphism, Genetic; Ribonucleotide Reductases; Survival Rate | 2003 |
Gemcitabine in cervical cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 2003 |
Gemcitabine combination chemotherapy of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 2003 |
Gemcitabine as a single-agent treatment for ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms | 2003 |
The emerging role of pemetrexed (Alimta) and gemcitabine in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed; Thymidylate Synthase | 2003 |
Pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2003 |
[Role of gemcitabine/cisplatin in the treatment of advanced and metastatic bladder cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
New perspectives in the management of pancreas cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Taxoids | 2003 |
Localized pleural malignant mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Mesothelioma; Neoplasm Recurrence, Local; Paclitaxel; Pleural Neoplasms; Radiography, Thoracic; Tomography, X-Ray Computed | 2003 |
[The update on pancreatic cancer chemotherapy].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Infusions, Intra-Arterial; Irinotecan; Male; Mitomycin; Multicenter Studies as Topic; Pancreatic Neoplasms; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Taxoids; Time Factors | 2003 |
Gemcitabine: current role and future options in the treatment of ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Treatment Outcome | 2003 |
Antiblastic drug combinations with ifosfamide: an update.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Ifosfamide; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Ifosfamide in non-small cell lung cancer.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Vinblastine; Vinorelbine | 2003 |
Advanced pancreatic cancer: is there a role for combination therapy?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cysteine Endopeptidases; Deoxycytidine; Fluorouracil; Gemcitabine; Genes, ras; Glutamates; Guanine; Humans; Multienzyme Complexes; Pancreatic Neoplasms; Pemetrexed; Protease Inhibitors; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; Sesquiterpenes | 2003 |
An autopsy case of acute pulmonary toxicity associated with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Respiratory Distress Syndrome | 2003 |
[Chemotherapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Radiography; Radiotherapy Dosage; Survival Rate | 2003 |
Influence of genetic markers on survival in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; DNA Adducts; DNA Helicases; DNA Repair; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gemcitabine; Genetic Markers; Humans; Lung Neoplasms; Polymorphism, Genetic; Proteins; Ribonucleotide Reductases; Survival Rate; Transcription Factors; Xeroderma Pigmentosum Group D Protein | 2003 |
Dramatic improvement of psoriasis with gemcitabine monotherapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Psoriasis; T-Lymphocytes | 2003 |
Rationale for the use of gemcitabine in breast cancer (Review).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Glutamates; Guanine; Humans; Pemetrexed; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2004 |
Radiation sensitizers and targeted therapies.
Topics: Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents | 2003 |
Palliative treatment for advanced or metastatic osteosarcoma.
Topics: Amputation, Surgical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Recurrence, Local; Osteosarcoma; Palliative Care; Pneumonectomy; Prognosis; Radiotherapy, Adjuvant; Severity of Illness Index; Survival Rate; Treatment Outcome | 2004 |
New agents in acute myeloid leukemia and other myeloid disorders.
Topics: Antineoplastic Agents; Cyclosporine; Cytosine; Deoxycytidine; Dioxolanes; Female; Gemcitabine; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Myeloid, Acute; Male; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine-induced severe pulmonary toxicity.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diagnosis, Differential; Disease Progression; Drug Interactions; Dyspnea; Gemcitabine; Humans; Lung; Lung Diseases; Lung Neoplasms; Radiography, Thoracic; Risk Factors | 2004 |
Single-agent gemcitabine in the treatment of advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Quality of Life; Treatment Outcome | 2004 |
Gemcitabine and taxanes as a new standard of care in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2004 |
Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2004 |
Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab | 2004 |
Rationale and clinical trial design for evaluating gemcitabine as neoadjuvant and adjuvant therapy for breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Research Design | 2004 |
[A case of primary squamous cell carcinoma of the lung with a metastatic thyroid tumor improved following chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Thyroid Neoplasms | 2004 |
Introduction. Single-agent or combination chemotherapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
Gemcitabine combination chemotherapy in metastatic breast cancer: phase II experience.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2003 |
Gemcitabine, anthracycline, and taxane combinations for advanced breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Severity of Illness Index; Taxoids | 2003 |
[Conservative therapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Peripheral Blood Stem Cell Transplantation | 2004 |
State-of-the-art chemotherapy for advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Treatment Outcome | 2004 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
[Chemotherapy in pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Palliative Care; Pancreatic Neoplasms | 2004 |
Pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Risk Factors | 2004 |
Novel therapies for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclooxygenase Inhibitors; Deoxycytidine; Farnesyltranstransferase; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Matrix Metalloproteinase Inhibitors; Oligonucleotides, Antisense; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Protein-Tyrosine Kinases; Treatment Outcome | 2004 |
[Combined treatment of esophageal cancer: a review].
Topics: Adenocarcinoma; Alcohol Drinking; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Brachytherapy; Camptothecin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Diet; Dihematoporphyrin Ether; Esophageal Neoplasms; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Palliative Care; Photochemotherapy; Platinum Compounds; Postoperative Care; Prospective Studies; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Taxoids; Time Factors | 2004 |
Gemcitabine-related radiation recall preferentially involves internal tissue and organs.
Topics: Adenocarcinoma; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Myositis; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Radiation Dosage; Radiation Injuries; Risk Assessment; Steroids | 2004 |
Novel combinations using pemetrexed in malignant mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Organoplatinum Compounds; Pemetrexed; Pleural Neoplasms | 2004 |
Gemcitabine in the treatment of soft tissue sarcomas.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Treatment Outcome | 2004 |
Systemic chemotherapy for patients with bladder cancer--current controversies and future directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Genes, p53; Genetic Therapy; Humans; Immunologic Factors; Neoadjuvant Therapy; Phenotype; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
[The role of meta-analysis in assessing the treatment of advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Practice Guidelines as Topic | 2004 |
Emerging drugs in pancreatic cancer.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Growth Inhibitors; Humans; Immunotherapy; Male; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Proteins; Organoplatinum Compounds; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Receptors, Growth Factor; Risk Factors; Survival Rate; Treatment Outcome | 2004 |
Gemcitabine (Gemzar) in non-small cell lung cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Ribonucleotide Reductases | 2004 |
[Docetaxel and non-small cell lung cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2004 |
Novel therapies for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cysteine Endopeptidases; Deoxycytidine; Epidermal Growth Factor; Gemcitabine; Humans; Hydroxamic Acids; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Multienzyme Complexes; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Protein-Tyrosine Kinases; RNA, Antisense | 2004 |
Systemic treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Duodenal Obstruction; Gemcitabine; Humans; Neoplasm Recurrence, Local; Palliative Care; Pancreatic Neoplasms; Postoperative Care; Treatment Outcome | 2004 |
In vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer: general concepts and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Synergism; Female; Gemcitabine; Humans; Taxoids | 2004 |
Gemcitabine and docetaxel in metastatic and neoadjuvant treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Epirubicin; Gemcitabine; Humans; Neoadjuvant Therapy; Taxoids | 2004 |
Twelve-year experience with left atrial resection in the treatment of non-small cell lung cancer.
Topics: Aged; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Heart Atria; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Postoperative Complications; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
[Chemotherapy of the elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Retrospective Studies; Signal Transduction; Taxoids | 2004 |
Brain metastases of epithelial ovarian carcinoma responding to cisplatin and gemcitabine combination chemotherapy: a case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Deoxycytidine; Epithelial Cells; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2004 |
New approaches for pancreatic cancer in Japan.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Infusions, Intra-Arterial; Japan; Pancreatic Neoplasms; Stem Cell Transplantation | 2004 |
New investigative regimens and cytotoxic agents in thoracic cancers: gemcitabine and pemetrexed.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed; Ribonucleotide Reductases; Thymidylate Synthase | 2004 |
Carboplatin/gemcitabine combination in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic | 2004 |
Gemcitabine-containing regimens vs others in first-line treatment of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2004 |
Chemoradiation in NSCLC: focus on the role of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Radiotherapy, Adjuvant; Ribonucleotide Reductases | 2004 |
Treatment of non-small-cell lung cancer: a perspective on the recent advances and the experience with gefitinib.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Health Status; Humans; Lung Neoplasms; Middle Aged | 2004 |
The evolution of adjuvant and neoadjuvant chemotherapy and radiation for advanced pancreatic cancer: from 5-fluorouracil to GTX.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Preoperative Care; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2004 |
Analysis of treatment for small cell cancer of the bladder and report of three cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Biomarkers, Tumor; Bone Neoplasms; Carboplatin; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease Progression; Etoposide; Gemcitabine; Humans; Life Tables; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms, Second Primary; Prostatectomy; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urinary Diversion | 2004 |
[Do combinations without cisplatin represent an alternative to conventional chemotherapy in non-small cell lung cancers?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Recurrent ovarian cancer: how important is it to treat to disease progression?
Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Recurrence; Risk; Taxoids; Time Factors; Topotecan | 2004 |
Current chemotherapeutic treatment of malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Therapy; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Pleural Neoplasms | 2004 |
Significant responses to platinum-based chemotherapy in renal medullary carcinoma.
Topics: Adolescent; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Carboplatin; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Medulla; Kidney Neoplasms; Male; Paclitaxel; Treatment Outcome | 2005 |
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Treatment Outcome | 2005 |
Combined modality therapy of gemcitabine and radiation.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; DNA; DNA Damage; DNA Repair; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents; Rodentia; Tumor Cells, Cultured | 2005 |
[New horizon of the treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Pancreatectomy; Pancreatic Neoplasms; Registries; Survival Rate | 2004 |
Pemetrexed in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Pancreatic Neoplasms; Pemetrexed; Survival Analysis; Thymidylate Synthase | 2004 |
Pemetrexed in transitional cell carcinoma of the urothelium.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Pemetrexed; Thymidylate Synthase; Urologic Neoplasms; Urothelium | 2004 |
The promise of pharmacogenomics: gemcitabine and pemetrexed.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Pharmacogenetics; Thymidylate Synthase | 2004 |
[Second-line treatment for advanced non-small-cell lung cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2005 |
[The second-line chemotherapy for urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Male; Methotrexate; Paclitaxel; Survival Rate; Testicular Neoplasms; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2005 |
Chemotherapy options and new advances in malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Palliative Care; Pemetrexed; Pleural Neoplasms; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Thiophenes | 2005 |
[Chemoradiation for pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Time Factors | 2004 |
[Concomitant use of radiotherapy and gemcitabine: preclinical findings and clinical practice].
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Neoplasms; Otorhinolaryngologic Neoplasms; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Rats; Time Factors; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 2004 |
Gemcitabine and paclitaxel in metastatic breast cancer: a review.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Paclitaxel; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Gemcitabine and docetaxel in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Taxoids; Time Factors; Treatment Outcome | 2004 |
Gemcitabine and platinum-based chemotherapy in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Treatment Outcome | 2004 |
Adjuvant chemotherapy for early-stage breast cancer: the tAnGo trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Research Design; Survival Analysis | 2004 |
Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Antagonism; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Heart Failure; Humans; Platinum Compounds; Receptor, ErbB-2; Time Factors; Trastuzumab; Treatment Outcome | 2004 |
Integrating gemcitabine into breast cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Time Factors; Trastuzumab; Treatment Outcome | 2004 |
Development of docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2004 |
Chemoresistance in non-small cell lung cancer.
Topics: Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2005 |
Recent updates in the clinical use of platinum compounds for the treatment of gastrointestinal cancers.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Esophageal Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Stomach Neoplasms | 2004 |
[Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Neoplasms; Prognosis; Retrospective Studies | 2005 |
[Metabolism, mechanism of action and resistance to cytotoxic nucleoside analogues].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nucleoside Transport Proteins; Nucleosides; Phosphorylation; Vidarabine | 2005 |
Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal | 2005 |
Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: a systematic review of phase III trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Quality Control; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
[Recent important insights into treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Intraoperative Care; Lymph Node Excision; Lymphatic Metastasis; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pyridines; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Treatment Outcome | 2005 |
Neoadjuvant chemotherapy for stage IIIA-N2 non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Taxoids | 2005 |
[Digital ischaemia and gemcitabine. Two new cases].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fingers; Gemcitabine; Humans; Ischemia; Male; Middle Aged | 2005 |
Salvage, dose intense and high-dose chemotherapy for the treatment of poor prognosis or recurrent germ cell tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Salvage Therapy | 2005 |
The role of chemotherapy in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin | 2005 |
Recent advances in conventional-dose salvage chemotherapy in patients with cisplatin-resistant or refractory testicular germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Ifosfamide; Irinotecan; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Salvage Therapy; Testicular Neoplasms; Vinblastine | 2005 |
Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Pancreatic Ductal; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Hyperthermia, Induced; Infusions, Parenteral; Male; Middle Aged; Mitomycin; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Peritoneal Neoplasms; Pseudomyxoma Peritonei | 2005 |
[Chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Gemcitabine in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; DNA Damage; DNA Repair; Female; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2005 |
Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Pancreatic Neoplasms | 2005 |
Docetaxel in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids; Thalidomide | 2005 |
Experience with docetaxel in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Stomach Neoplasms; Taxoids | 2005 |
Docetaxel in the treatment of esophageal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Irinotecan; Neoadjuvant Therapy; Taxoids | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Perspectives on salvage therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Chemotherapy dosing in the setting of liver dysfunction.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Liver; Liver Diseases; Liver Function Tests; Male; Maximum Tolerated Dose; Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Topotecan | 2005 |
Recent updates on the role of chemotherapy in pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines | 2005 |
Gemcitabine and carboplatin in second-line ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Survival Rate | 2005 |
Chemotherapeutic gemcitabine doublets in pancreatic carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2005 |
Gemcitabine plus paclitaxel in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Survival Rate | 2005 |
Second-line chemotherapy and beyond for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Forecasting; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Pneumonectomy; Quinazolines; Salvage Therapy; Survival Rate; Taxoids; Time Factors | 2004 |
Combination of gemcitabine and irinotecan for recurrent metastatic osteogenic sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Femoral Neoplasms; Gemcitabine; Head and Neck Neoplasms; Humans; Ifosfamide; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Osteosarcoma; Palliative Care; Salvage Therapy; Scalp; Skin Neoplasms; Thoracotomy | 2005 |
Systemic therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pemetrexed; Quinazolines | 2005 |
Treatment of metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis | 2005 |
Erlotinib in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2005 |
Palliative chemotherapy in patients with salivary gland neoplasms and preliminary reports of 2 recent phase II studies with trastuzumab and gemcitabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Palliative Care; Salivary Gland Neoplasms; Trastuzumab | 2003 |
Intravesical gemcitabine for superficial bladder cancer: rationale for a new treatment option.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Patient Selection; Urinary Bladder Neoplasms | 2005 |
[Successful removal of T4 lung cancer with left atrial invasion after induction chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cardiac Surgical Procedures; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Heart Atria; Heart Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pneumonectomy | 2005 |
Recent advances on the molecular mechanisms involved in pancreatic cancer progression and therapies.
Topics: Apoptosis; Biomarkers, Tumor; Cyclic AMP-Dependent Protein Kinases; Deoxycytidine; ErbB Receptors; Gemcitabine; Gene Expression Profiling; Hedgehog Proteins; Humans; Mucin-1; Mucin-4; Mucins; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptors, Notch; Signal Transduction; Trans-Activators; Wnt Proteins | 2005 |
[First-line non-small-cell lung cancer: role of gemcitabine].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2005 |
[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Rate | 2005 |
A ten-year review of progress in the treatment of non-small-cell lung cancer with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Survival Analysis; Treatment Outcome | 2005 |
[Pancreatic carcinoma (ductal adenocarcinoma)].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Ductal, Breast; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Radiography, Abdominal; Tomography, X-Ray Computed | 2005 |
The role of gemcitabine in the treatment of cholangiocarcinoma and gallbladder cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2005 |
Multimodality approach in management of malignant pleural mesothelioma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Mesothelioma; Palliative Care; Pleural Neoplasms; Thoracic Surgical Procedures; Treatment Outcome | 2006 |
Gemcitabine-taxane experience in the treatment of metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Remission Induction; Taxoids; Treatment Outcome | 2005 |
What is the best schedule for administration of gemcitabine-taxane?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Receptor, ErbB-2; Remission Induction; Taxoids; Trastuzumab | 2005 |
Gemcitabine in patients with ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Quality of Life; Remission Induction | 2005 |
[Review of effectiveness of chemotherapy with gemcitabine in ovarian cancer].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2005 |
Front-line therapy of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2005 |
Meta-analysis of inoperable pancreatic cancer: gemcitabine combined with cisplatin versus gemcitabine alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
What news in urological cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Palliative Care; Patient Selection; Survival Rate; Taxoids; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2005 |
[Geriatric urology -- tumour diseases].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Hematopoietic Cell Growth Factors; Humans; Male; Middle Aged; Patient Care Team; Prostatic Neoplasms; Taxoids; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2006 |
Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Prognosis; Quality of Life; Survival Analysis | 2006 |
[Management of pancreatic cancer: current therapy and continued development].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Immunotherapy; Lymph Node Excision; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2006 |
[Gemcitabine chemotherapy for patients with advanced or relapsed pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2006 |
[Combination chemotherapy in unresectable pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2006 |
[Adjuvant chemotherapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2006 |
[IMRD therapy for patients with metastatic pancreas cancer].
Topics: Antimetabolites, Antineoplastic; Contraindications; Deoxycytidine; Gemcitabine; Humans; Maximum Tolerated Dose; Pancreatic Neoplasms; Quality of Life | 2006 |
[Therapeutics with replication--selective virus (RSV) for pancreatic cancer].
Topics: Adenoviridae; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Genetic Therapy; Humans; Pancreatic Neoplasms; Viral Vaccines | 2006 |
[Gene therapy of human pancreatic cancer cells by human interferon-beta gene].
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Interferon-beta; Liposomes; Pancreatic Neoplasms; Signal Transduction | 2006 |
[Multimodal therapy for advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Therapy; Gemcitabine; Humans; Liver Neoplasms; Palliative Care; Pancreatic Neoplasms; Peripheral Blood Stem Cell Transplantation; Radiation-Sensitizing Agents; Radiotherapy; Radiotherapy Dosage | 2006 |
[Concurrent chemoradiation therapy with gemcitabine for advanced or relapsed pancreatic tumors].
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 2006 |
[Chemoradiation therapy and immunotherapy for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Intraoperative Care; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2006 |
[Significance of thermo-chemotherapy for the patients with unresectable pancreas cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; Mitomycin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2006 |
[Prognostic significance of CA19-9 levels in patients with pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis | 2006 |
[Chemotherapy for biliary tract cancers: general remarks].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Clinical Trials as Topic; Cytarabine; Deoxycytidine; Doxorubicin; Drug Therapy; Gemcitabine; Humans; Tegafur; Treatment Outcome | 2006 |
[Systemic chemotherapy with gemcitabine for advanced biliary tract carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fatal Outcome; Female; Fluorouracil; Gemcitabine; Humans; Treatment Outcome | 2006 |
Role of Gemcitabine in Breast Cancer Management: An Update.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Paclitaxel; Receptor, ErbB-2 | 2006 |
Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2006 |
[Recent progress in the treatment for urothelial cancer].
Topics: Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Doxorubicin; Endoscopy, Gastrointestinal; Evidence-Based Medicine; Gemcitabine; Humans; Laparoscopy; Laser Therapy; Methotrexate; Neoadjuvant Therapy; Taxoids; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2006 |
[Progress in therapy for testicular tumors].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Irinotecan; Lymph Node Excision; Male; Paclitaxel; Taxoids; Testicular Neoplasms | 2006 |
Gemcitabine plus carboplatin in platinum-sensitive recurrent ovarian carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Quality of Life; Survival | 2006 |
Optimizing adjuvant chemotherapy in early-stage breast cancer.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
[Palliative chemotherapy of head and neck cancer: present status and future development].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; ErbB Receptors; Forecasting; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
What's new in pancreatic cancer treatment pipeline?
Topics: Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cancer Vaccines; Cetuximab; Cyclic N-Oxides; Deoxycytidine; Drug Combinations; Gastrins; Gemcitabine; Humans; Niacinamide; Oxonic Acid; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Tegafur; Tumor Necrosis Factor-alpha | 2006 |
Chemotherapy for advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Organoplatinum Compounds; Palliative Care; Pancreatic Neoplasms; Pemetrexed; Taxoids; Topoisomerase I Inhibitors | 2006 |
The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Patient Selection; Postoperative Complications; Radiotherapy Dosage | 2006 |
Role of gemcitabine in cancer therapy.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Urinary Bladder Neoplasms | 2005 |
Optimizing chemotherapy for advanced non-small cell lung cancer: focus on docetaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Survival Rate; Taxoids | 2005 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colorectal Neoplasms; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Lung Neoplasms; Lymphoma, Non-Hodgkin; Mucositis; Neoplasms; Prednisone; Radiotherapy; Severity of Illness Index; Stomatitis; Taxoids; Vinblastine; Vincristine; Vinorelbine | 2006 |
Chemotherapy of advanced non-small cell lung cancer in elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Platinum Compounds; Taxoids; Vinblastine; Vinorelbine | 2006 |
Systemic chemotherapy in the management of malignant peritoneal mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Peritoneal Neoplasms; Quinazolines; Thiophenes; Vinblastine; Vinorelbine | 2006 |
Identification and treatment of aggressive thyroid cancers. Part 1: subtypes.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Paclitaxel; Prognosis; Risk Assessment; Risk Factors; Thyroid Neoplasms | 2006 |
[Non-surgical treatment for pancreatic cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Tegafur | 2006 |
[Development of a molecular target therapy on the basis of global gene analyses of gastrointestinal carcinoma].
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Base Pair Mismatch; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Microsatellite Repeats; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Protein-Tyrosine Kinases; Signal Transduction | 2006 |
Management of platinum-sensitive recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel | 2006 |
Optimizing gemcitabine regimens in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Decision Trees; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
The role of gemcitabine in first-line treatment of advanced ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2006 |
Optimal therapy for platinum-resistant recurrent ovarian cancer: doxorubicin, gemcitabine or topotecan?
Topics: Antineoplastic Agents; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Topotecan | 2006 |
Chemoradiotherapy in gallbladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Palliative Care; Survival Analysis | 2006 |
Current therapies and advances in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Incidence; Neoplasm Metastasis; Pancreatic Neoplasms; Remission Induction; Vascular Endothelial Growth Factor A | 2006 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Gemcitabine and radiation therapy in non-small cell lung cancer: state of the art.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2006 |
Adjuvant treatment strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cholangiopancreatography, Endoscopic Retrograde; Cholangiopancreatography, Magnetic Resonance; Deoxycytidine; Diagnostic Imaging; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
[Chemotherapy for metastatic breast cancer].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diphosphonates; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Meta-Analysis as Topic; Quality of Life; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms | 2006 |
Overview of gemcitabine activity in advanced breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Taxoids | 2006 |
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2006 |
Gemcitabine in the treatment of advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Comorbidity; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Pharmacogenetics; Prognosis; Renal Insufficiency; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2006 |
Actual experience and future development of gemcitabine in superficial bladder cancer.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2006 |
Pharmacogenomics and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Genes, BRCA1; Humans; Lung Neoplasms; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2006 |
A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Topotecan | 2006 |
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2006 |
Gemcitabine: monochemotherapy of breast cancer.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Metastasis; Taxoids | 2006 |
In vitro studies on gemcitabine combinations with other antiblastics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Evaluation, Preclinical; Drug Interactions; Gemcitabine; Humans; Models, Biological; Neoplasms; Prodrugs; Tumor Cells, Cultured | 2006 |
Gemcitabine and taxanes in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2006 |
Biological agents and gemcitabine in the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Breast Neoplasms; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Farnesyltranstransferase; Gemcitabine; Humans; Protein-Tyrosine Kinases; Ribonucleotide Reductases | 2006 |
Role of gemcitabine in ovarian cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Survival Analysis; Treatment Outcome | 2006 |
Clinical studies of pemetrexed and gemcitabine combinations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Biological; Neoplasms; Pancreatic Neoplasms; Pemetrexed | 2006 |
Development of gemcitabine in non-small cell lung cancer: the Italian contribution.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Drug Administration Routes; Gemcitabine; Humans; Italy; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic | 2006 |
Chemo-radiotherapy in non-small cell lung cancer: the role of gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Radiation-Sensitizing Agents | 2006 |
First line chemotherapy in advanced or metastatic NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoadjuvant Therapy; Neoplasm Metastasis | 2006 |
Cellular pharmacology of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Deoxycytidine; Gemcitabine; Humans; Models, Biological; Neoplasms | 2006 |
Non-small-cell lung cancer: which platinum for gemcitabine?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Platinum Compounds; Survival Analysis | 2006 |
Non-platinum combination of gemcitabine in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Platinum Compounds; Taxoids; Vinblastine; Vinorelbine | 2006 |
Review of the pemetrexed and gemcitabine combination in patients with advanced-stage non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Pemetrexed | 2006 |
Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic | 2006 |
Pancreatic cancer: from bench to 5-year survival.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticojejunostomy; Prognosis; Randomized Controlled Trials as Topic; Survival Rate | 2006 |
Capecitabine in carcinoma of the pancreas.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prodrugs; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
[Requirements for the development of molecularly defined targeted therapy in oncology].
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Bevacizumab; Biomedical Research; Biotechnology; Breast Neoplasms; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Computational Biology; Controlled Clinical Trials as Topic; Deoxycytidine; Drug Industry; Female; Gemcitabine; Genome, Human; Humans; Imatinib Mesylate; Medical Oncology; Molecular Biology; Multicenter Studies as Topic; Neoplasms; Phenotype; Piperazines; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Risk Assessment; Trastuzumab; Treatment Outcome | 2006 |
Intravesical gemcitabine: an update of clinical results.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Recurrence; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Usefulness of predictive tests for cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; ErbB Receptors; Gemcitabine; Genes, ras; Humans; Lung Neoplasms; Membrane Glycoproteins; Polymorphism, Single Nucleotide; Predictive Value of Tests; Randomized Controlled Trials as Topic; RNA, Messenger; Semaphorins; Taxoids; Ubiquitin-Protein Ligases | 2006 |
Gemcitabine-induced thrombotic microangiopathy: a systematic review.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Kidney; Microcirculation; Retrospective Studies; Syndrome; Thrombosis | 2006 |
[Malignant mesothelioma--diagnosis and treatment strategies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asbestos; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Interleukin-6; Irinotecan; Mediastinal Neoplasms; Mesothelioma; Pleural Neoplasms; Tomography, X-Ray Computed | 2006 |
[Arterial infusion chemotherapy for patients with advanced pancreatic cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Administration Schedule; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Mesenteric Artery, Superior; Mitomycin; Pancreatic Neoplasms; Quality of Life; Radiography; Survival Rate | 2006 |
[Gemcitabine is an effective single agent for the treatment of advanced biliary tract cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Survival Rate | 2006 |
HER-2-positive metastatic breast cancer: optimizing trastuzumab-based therapy.
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2006 |
State-of-the-art management of metastatic disease at initial presentation or recurrence.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Taxoids; Urinary Bladder Neoplasms | 2006 |
Pancreatic cancer: a review of recent advances.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Cancer Vaccines; Clinical Trials as Topic; Deoxycytidine; Drugs, Investigational; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2006 |
[Bladder preservation possibilities in the treatment of muscle-invasive bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Taxoids; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2006 |
Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2006 |
Gemcitabine in advanced biliary tract cancers.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Clinical Trials as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Neoplasm Staging; Palliative Care; Radiotherapy, Adjuvant | 2007 |
Methylation patterns and chemosensitivity in NSCLC.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Methylation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms | 2006 |
Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Urachal carcinoma: surgical and chemotherapeutic options.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; Gemcitabine; Hematuria; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Risk Factors; Umbilicus; Urachal Cyst; Urachus; Urinary Bladder Neoplasms | 2006 |
Case of carcinosarcoma of urinary bladder obtained a pathologically complete response by neoadjuvant chemoradiotherapy.
Topics: Antineoplastic Agents; Carboplatin; Carcinosarcoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Remission Induction; Urinary Bladder Neoplasms | 2007 |
Implementing Good Clinical Practice in two noncommercial phase II studies in children with cancer.
Topics: Child; Clinical Trials, Phase II as Topic; Deoxycytidine; European Union; Financing, Government; Gemcitabine; Germany; Humans; Informed Consent; Medical Oncology; Neoplasms; Pediatrics; Practice Guidelines as Topic; Practice Patterns, Physicians' | 2007 |
Chemotherapy dose--response relationships in non-small cell lung cancer and implied resistance mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Clinical Trials as Topic; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Farnesyltranstransferase; Gemcitabine; Hormone Antagonists; Hormones; Humans; Pancreatic Neoplasms; Prognosis | 2007 |
[Palliative treatment of pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Incidence; Nutrition Therapy; Pain Management; Palliative Care; Pancreatic Neoplasms; Quality of Life | 2007 |
[Molecular-based treatment concepts in advanced pancreatic cancer].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Metalloproteases; Molecular Biology; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Pancreatic cancer: an update.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2007 |
[Non-cisplatin based chemotherapy in advanced non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
Treatment of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Survival Rate | 2007 |
Role of induction chemotherapy in resectable N2 non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2007 |
The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors | 2007 |
Treatment options for hepatobiliary and pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Ethanol; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis | 2007 |
Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2007 |
[Diagnosis of and therapy for pancreatic neoplasms].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Diabetes Complications; Drug Combinations; Early Diagnosis; Gemcitabine; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Tegafur | 2007 |
Gemcitabine in the management of metastatic breast cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Taxoids | 2008 |
Her signaling in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Epidermal Growth Factor; Erlotinib Hydrochloride; Gemcitabine; Humans; Lapatinib; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2007 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2007 |
Gemcitabine-based combinations for inoperable pancreatic cancer: have we made real progress? A meta-analysis of 20 phase 3 trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2007 |
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Enzymes; Gemcitabine; Genomics; Humans; Nucleoside Transport Proteins; Polymorphism, Single Nucleotide | 2007 |
Imatinib in the treatment of follicular dendritic sarcoma: a case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cisplatin; Dendritic Cells, Follicular; Deoxycytidine; Follow-Up Studies; Gemcitabine; Head and Neck Neoplasms; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Sarcoma; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
[Gemcitabine and radiotherapy for the future].
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Forecasting; Gemcitabine; Humans; Lung Neoplasms | 2007 |
Gemcitabine-associated thrombotic thrombocytopenic purpura.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Purpura, Thrombotic Thrombocytopenic; Ribonucleotide Reductases | 2007 |
New strategies in the treatment of Ta-T1 transitional cell carcinoma (TCC) of the bladder.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Genetic Therapy; Humans; Hyperthermia, Induced; Immunotherapy; Medical Oncology; Microwaves; Urinary Bladder Neoplasms; Urology | 2006 |
[Treatment of pancreatic cancer--surgical point of view].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Pancreatectomy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2007 |
[Treatments of pancreatic cancer from the standpoint of medical oncology].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Quinazolines; Survival Rate; Tegafur | 2007 |
[Modern chemotherapy of invasive bladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Lymphatic Metastasis; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Locally advanced pancreatic cancer: a review.
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2007 |
Future chemoradiation strategies in pancreatic cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Forecasting; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Patient Selection; Radiotherapy, Adjuvant | 2007 |
Cytotoxic therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids | 2007 |
[Current situation and features of chemotherapy for breast neoplasms].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Practice Guidelines as Topic; Taxoids; Trastuzumab | 2007 |
Gemcitabine-related "pseudocellulitis": report of 2 cases and review of the literature.
Topics: Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Diagnostic Errors; Erythema; Female; Gemcitabine; Humans; Male; Middle Aged; Radiodermatitis; Radiotherapy, Adjuvant | 2007 |
[Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
Topics: Adenocarcinoma; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Neutropenia; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2007 |
[Strategy in the treatment of anthracycline-resistant breast cancer].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Taxoids; Vinblastine; Vinorelbine | 2007 |
Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Humans; Sarcoma; Taxoids | 2007 |
Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
[Gemcitabine: from preclinic to clinic passing by pharmacokinetics].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Deoxycytidine; Gemcitabine | 2007 |
[Updates on gemcitabine on metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Trastuzumab; Vinblastine; Vinorelbine | 2007 |
[Gemcitabine and non small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic | 2007 |
[Gemcitabine and digestive carcinomas].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Deoxycytidine; Digestive System Neoplasms; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Stomach Neoplasms | 2007 |
[Gemcitabine and pemetrexed in genito-urinary tumors treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Gemcitabine; Glutamates; Guanine; Humans; Kidney Neoplasms; Methotrexate; Pemetrexed; Urologic Neoplasms; Vinblastine | 2007 |
[Docetaxel and gemcitabine combination in soft-tissue sarcomas treatment].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Sarcoma; Taxoids | 2007 |
[Gemcitabine and radiotherapy in non-small cell lung cancer: dolce vita at last!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation-Sensitizing Agents; Remission Induction | 2007 |
[Gemcitabine and pemetrexed: novel associations and mechanisms of resistance].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamates; Guanine; Humans; Pemetrexed | 2007 |
[Chemotherapy in lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Survival Rate | 2007 |
Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2007 |
Pleomorphic leiomyosarcoma of the adrenal gland: case report and review of the literature.
Topics: Abdominal Pain; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyoma; Leiomyosarcoma; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Nephrectomy; Radiotherapy, Adjuvant; Taxoids; Thrombophlebitis; Uterine Neoplasms | 2007 |
Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vindesine; Vinorelbine | 2007 |
Tyrosine kinase inhibitors in non-small cell lung and pancreatic cancer: the emerging role of erlotinib.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pancreatic Neoplasms; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Treatment Outcome | 2007 |
Neoadjuvant and adjuvant strategies for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis | 2008 |
Role of platinum agents in the management of advanced pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Pancreatic Neoplasms | 2007 |
Gemcitabine in bladder cancer.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2007 |
Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Quality of Life; Survival Rate | 2007 |
Role of gemcitabine in metastatic breast cancer patients: a short review.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
Topics: Adenocarcinoma; Algorithms; Antigens, Tumor-Associated, Carbohydrate; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cholestasis; Deoxycytidine; Disease Management; Drainage; Gastric Outlet Obstruction; Gemcitabine; Humans; Lymph Node Excision; Neoplasm Staging; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Radiotherapy, Adjuvant; Treatment Outcome | 2007 |
[Prediction of adverse drug reactions based on genomic information].
Topics: Anti-Infective Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Arylamine N-Acetyltransferase; Asian People; Azathioprine; Camptothecin; Cytidine Deaminase; Deoxycytidine; Forecasting; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Mercaptopurine; Methyltransferases; Polymorphism, Genetic; Prodrugs; Sulfamethoxazole | 2007 |
[Chemotherapy and radiotherapy for inoperable pancreatic cancer. A survey of a Cochrane review].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Survival Rate | 2007 |
Primary advanced unresectable pancreatic cancer.
Topics: Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2008 |
Pancreatic carcinosarcoma. Case report of multimodal therapy and review of the literature.
Topics: Antimetabolites, Antineoplastic; Carcinosarcoma; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2008 |
[Interdisciplinary diagnosis of and therapy for cholangiocarcinoma].
Topics: Algorithms; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Drainage; Endosonography; Gemcitabine; Hepatic Duct, Common; Humans; Klatskin Tumor; Liver Transplantation; Magnetic Resonance Imaging; Tomography, X-Ray Computed | 2008 |
The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Salvage Therapy; Survival Analysis; Treatment Failure | 2008 |
Setting the stage for tailored chemotherapy in the management of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Humans; Lung Neoplasms; Predictive Value of Tests; Ribonucleoside Diphosphate Reductase; Survival Analysis; Taxoids; Tumor Suppressor Proteins | 2008 |
Pulmonary complications of novel antineoplastic agents for solid tumors.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Everolimus; Gemcitabine; Humans; Lung; Lung Diseases; Mitoxantrone; Neoplasms; Pneumonia; Pyrimidines; Risk Factors; Sirolimus; Teniposide; Trastuzumab | 2008 |
Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Optimal second line treatment options for gemcitabine refractory advanced pancreatic cancer patients. Can we establish standard of care with available data?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biological Products; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Salvage Therapy; Treatment Failure | 2008 |
Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Infusions, Intravenous; Male; Mycosis Fungoides; Skin Neoplasms; Treatment Outcome | 2007 |
[Radiation therapy in pancreatic cancer].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2008 |
[Chemotherapy for pancreatic cancer].
Topics: Antimetabolites; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
Topics: Aminoacridines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Neoplasms; Time Factors | 2008 |
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Benzenesulfonates; Bevacizumab; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2008 |
[Radiochemotherapeutic options for bladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Radiography; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk Factors; Salvage Therapy; Taxoids; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 2008 |
Pancreatic cancer--is the wall crumbling?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Fluorouracil; Forecasting; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
[Pancreatic cancer: ten years of systemic therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines | 2008 |
Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Liver; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Gemcitabine in the treatment of metastatic pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Neoplasm Metastasis; Pancreatic Neoplasms | 2008 |
Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Dioxoles; Diphtheria Toxin; Drug Resistance, Neoplasm; Drugs, Investigational; Epothilones; Female; Furans; Gemcitabine; Glutamates; Guanine; Humans; Interleukin-2; Ketones; Lapatinib; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Quinazolines; Recombinant Fusion Proteins; Tetrahydroisoquinolines; Trabectedin; Vinblastine; Vinorelbine | 2008 |
New directions in the management of advanced pancreatic cancer: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Quinazolines | 2008 |
Systemic therapy for biliary tract cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2008 |
Current role of gemcitabine in the treatment of Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Treatment Outcome | 2008 |
Chemoradiotherapy for unresectable pancreatic cancer.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Forecasting; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Technology, Radiologic | 2008 |
Current status of chemoradiotherapy for locally advanced pancreatic cancer in Japan.
Topics: Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Japan; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2008 |
Novel approaches to deliver gemcitabine to cancers.
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplasms | 2008 |
Chemotherapy with gemcitabine in advanced biliary tract carcinoma.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Gemcitabine; Humans | 2008 |
Metastatic pancreatic cancer 2008: is the glass less empty?
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Disease-Free Survival; Gemcitabine; Heparin, Low-Molecular-Weight; Humans; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2008 |
Update on T-cell lymphoma.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cohort Studies; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Geography; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Survival Analysis; World Health Organization | 2008 |
Antibodies to vascular endothelial growth factor in non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Sex Factors; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Novel advances in pancreatic cancer treatment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Delivery Systems; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2008 |
Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer: results of secondary end points analyses.
Topics: Antineoplastic Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis | 2008 |
[Nonmuscle-invasive bladder cancer (NMIBC): when to perform cystectomy?].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Cystectomy; Cystoscopy; Deoxycytidine; Disease Progression; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Risk Factors; Time Factors; Urinary Bladder Neoplasms | 2008 |
Salvage regimens for Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous | 2008 |
Evidence-based guidelines for adjuvant therapy for resected adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Cause of Death; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Evidence-Based Medicine; Gemcitabine; Humans; Oncology Nursing; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Postoperative Care; Practice Guidelines as Topic; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Research Design; Survival Rate; Treatment Outcome | 2008 |
Systemic therapy for unresectable and metastatic transitional cell carcinoma of the urothelium: first-line and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Urologic Neoplasms; Urothelium | 2008 |
Novel therapies in peripheral T-cell lymphomas.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Diphtheria Toxin; Enzyme Inhibitors; Gemcitabine; Humans; Immunotherapy; Interleukin-2; Lymphoma, T-Cell, Peripheral; Medical Oncology; Prognosis; Recombinant Fusion Proteins; Treatment Outcome | 2008 |
HER-2-positive metastatic breast cancer: trastuzumab and beyond.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Neoplasm Metastasis; Nitriles; Receptor, ErbB-2; Trastuzumab; Triazoles; Vinblastine; Vinorelbine | 2008 |
Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: a systematic overview.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2009 |
Borderline resectable pancreatic cancer: on the edge of survival.
Topics: Deoxycytidine; Gemcitabine; Genetic Therapy; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Radiotherapy, Intensity-Modulated; Tomography, X-Ray Computed | 2008 |
Cancer of the pancreas: are we making progress? A review of studies in the US Oncology Research Network.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2008 |
Time to full publication of studies of anti-cancer medicines for breast cancer and the potential for publication bias: a short systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Consensus Development Conferences as Topic; Databases, Bibliographic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lapatinib; Paclitaxel; Publication Bias; Publishing; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Technology Assessment, Biomedical; Time; Trastuzumab | 2008 |
Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms | 2008 |
Quality-of-life assessment in phase III clinical trials of gemcitabine in non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Patient Compliance; Quality of Life | 2008 |
Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Gemcitabine; Humans; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Radiation-Sensitizing Agents | 2008 |
Gemcitabine: vascular toxicity and prothrombotic potential.
Topics: Animals; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Risk Factors; Thrombosis; Vascular Diseases | 2008 |
[Treatment of advanced pancreatic carcinoma].
Topics: Antineoplastic Agents; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Platinum; Quinazolines; Terminal Care | 2008 |
[Medical-oncological aspects in the treatment of pancreatic cancer].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Survival Rate | 2009 |
Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Data Interpretation, Statistical; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Odds Ratio; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Pharmacogenomics of gemcitabine in non-small-cell lung cancer and other solid tumors.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Monitoring; Gemcitabine; Humans; Pharmacogenetics; Prognosis | 2009 |
Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2009 |
Management of a patient with borderline resectable pancreatic cancer. Case report and review.
Topics: Adenocarcinoma; Adult; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Care; Preoperative Care; Radiotherapy, Adjuvant; Treatment Outcome | 2008 |
A meta-analysis of platinum plus gemcitabine or vinorelbine in the treatment of advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Databases, Bibliographic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Platinum; Vinblastine; Vinorelbine | 2009 |
The integration of chemoradiation in the care of patient with localized pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Capecitabine; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2009 |
Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms | 2009 |
Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2009 |
New drugs currently available in non-muscle invasive bladder cancer: update on gemcitabine studies.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2008 |
[Biological basis of chemo-radiotherapy associations].
Topics: Cell Proliferation; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; DNA Damage; DNA Repair; Fluorouracil; Gemcitabine; Humans; Neoplasms; Oxygen Consumption; Radiation Tolerance; Temozolomide | 2009 |
First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Disease Management; Gemcitabine; Glutamates; Guanine; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Multicenter Studies as Topic; Organoplatinum Compounds; Palliative Care; Pemetrexed; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Cytotoxins; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Proteins; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Purines; Quinazolines; RNA, Small Interfering; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Novel therapeutic agents for osteosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy, Adjuvant; Child; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Docetaxel; Dogs; Drug Delivery Systems; Folic Acid Antagonists; Gemcitabine; Humans; Immunologic Factors; Neoadjuvant Therapy; Neoplasm Proteins; Osteosarcoma; Protein Kinase Inhibitors; Radiopharmaceuticals; Signal Transduction; Survival Rate; Taxoids; Xenograft Model Antitumor Assays; Young Adult | 2009 |
Pharmacogenomic approaches to individualizing chemotherapy for non-small-cell lung cancer: current status and new directions.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Genes, BRCA1; Humans; Lung Neoplasms; Pharmacogenetics; Prognosis; Taxoids | 2008 |
Medical management of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Agents; Black People; Capecitabine; Deoxycytidine; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; DNA Mismatch Repair; Female; Fluorouracil; Gemcitabine; Helicobacter Infections; Helicobacter pylori; Humans; Male; Overweight; Palliative Care; Pancreatic Neoplasms; Risk Factors; Smoking | 2009 |
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Child; Child, Preschool; Choristoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Diagnostic Errors; Doxorubicin; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Pyrazoles; Radiography; Sulfonamides; Teratoma; Thalidomide; Thymus Gland; Thyroid Neoplasms; Thyroidectomy | 2009 |
Clinical pharmacology and pharmacogenetics of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Ethnicity; Gemcitabine; Humans; Nucleoside Transport Proteins; Nucleotidases; Pharmacogenetics; Polymorphism, Genetic; Ribonucleotide Reductases | 2009 |
Rationale for an intraperitoneal gemcitabine chemotherapy treatment for patients with resected pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; Injections, Intraperitoneal; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2009 |
Pemetrexed in the treatment of advanced non-squamous lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Small Cell Lung Carcinoma | 2009 |
Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2009 |
Is there a palliative benefit of gemcitabine plus fluoropyrimidines in patients with refractory colorectal cancer? A review of the literature previously presented: poster at the 2008 Gastrointestinal Cancer Symposium (Abstract No. 512).
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Maximum Tolerated Dose; Palliative Care; Treatment Outcome | 2009 |
Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Nephrectomy; Palliative Care; Renal Dialysis; Urologic Neoplasms | 2009 |
[Virchow's node as the form of onset of squamous cell carcinoma of the pancreas].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Palliative Care; Pancreatic Neoplasms; Radiography; Spinal Neoplasms; Vinblastine; Vinorelbine | 2009 |
Second-line therapy for advanced pancreatic cancer: a review of the literature and future directions.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum Compounds; Predictive Value of Tests; Prognosis; Research Design; Risk Assessment; Risk Factors; Salvage Therapy; Survival Analysis | 2009 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Male; Mitoxantrone; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids; Virus Replication | 2009 |
Gemcitabine for the treatment of metastatic breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Comparative Effectiveness Research; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Quality-Adjusted Life Years; Survival Analysis | 2009 |
Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Plasma Exchange | 2009 |
Novel agents for the treatment of adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Pancreatic Neoplasms; Risk Factors; Survival Rate | 2009 |
[A case of interstitial pneumonia induced by gemcitabine hydrochloride for unresectable bile duct cancer].
Topics: Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bilirubin; Deoxycytidine; Diuretics; Gemcitabine; Humans; Jaundice, Obstructive; Lung Diseases, Interstitial; Male; Pulse Therapy, Drug; Steroids; Tomography, X-Ray Computed | 2009 |
The role of pemetrexed combined with gemcitabine for non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2010 |
[Complementary treatment for pancreas cancer].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Pancreatic Neoplasms; Prognosis | 2009 |
Pharmacogenetics and pharmacoepigenetics of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Epigenomics; Gemcitabine; Humans; Neoplasms; Pharmacogenetics | 2010 |
Gemcitabine and carboplatin in the treatment of transitional cell carcinoma of the urothelium: a single centre experience and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Urinary Bladder Neoplasms | 2010 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
[A case of postoperative brain metastasis originated from pancreatic cancer which was successfully treated by resection and postoperative irradiation].
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2009 |
Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?
Topics: Age Factors; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Global Health; Humans; Immunosuppressive Agents; Lung Neoplasms; Neoplasm Metastasis; Prognosis; Radiation-Sensitizing Agents; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; Drug Therapy; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms | 2010 |
Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2010 |
Synergistic role of curcumin with current therapeutics in colorectal cancer: minireview.
Topics: Adenoma; Animals; Anticarcinogenic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colorectal Neoplasms; Curcumin; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2009 |
Meta-analysis of randomized trials: evaluation of benefit of gemcitabine-based molecular targeted therapy for inoperable pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Evidence-Based Medicine; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
PARP inhibition: PARP1 and beyond.
Topics: Animals; Antineoplastic Agents; Cell Death; Dacarbazine; Deoxycytidine; DNA Damage; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Mice; Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Substrate Specificity; Temozolomide | 2010 |
Failure of bacille Calmette-Guérin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: an update of available treatment options.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Mitomycin; Neoplasm Invasiveness; Risk Factors; Treatment Failure; Urinary Bladder Neoplasms | 2010 |
What else in gemcitabine-pretreated advanced pancreatic cancer? An update of second line therapies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Survival Rate | 2010 |
Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Choice Behavior; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pyrimidines | 2010 |
Updates in adjuvant therapy in pancreatic cancer: gemcitabine and beyond. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Congresses as Topic; Deoxycytidine; Gastrointestinal Neoplasms; Gemcitabine; Humans; Pancreatic Neoplasms; Retrospective Studies | 2010 |
[Treatment possibilities in breast cancer progressing after anthracyclines and/or taxanes].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Doxorubicin; Epothilones; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2010 |
Adjuvant and neoadjuvant therapy in curable pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis | 2010 |
Curative radiation therapy for pancreatic malignancies.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis | 2010 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Protein Kinase Inhibitors; Radiotherapy, Adjuvant; Signal Transduction; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Evolution of systemic therapy for advanced pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Delivery Systems; Drug Design; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Survival | 2010 |
Pancreatic cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Risk Factors; Smoking | 2010 |
[New data on pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2010 |
Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Lenalidomide; Nitrogen Mustard Compounds; Rituximab; Thalidomide; Vinblastine; Vinorelbine | 2010 |
Chemoprevention strategies for pancreatic cancer.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; beta Carotene; Camellia sinensis; Celecoxib; Cell Transformation, Neoplastic; Chemoprevention; Curcumin; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Models, Animal; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Isothiocyanates; Pancreatic Neoplasms; Phototherapy; Pyrazoles; Sulfonamides; Tea; Vitamin D; Vitamin E | 2010 |
Impact of biomarkers on non-small cell lung cancer treatment.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Taxoids; Tubulin; Tumor Suppressor Proteins | 2010 |
[Chemotherapy options for patients with advanced soft-tissue sarcoma beyond anthracyclines].
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Docetaxel; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Liposarcoma; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; Trabectedin | 2010 |
Adenocarcinoma of the small bowel: changes in the landscape?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Intestine, Small; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2010 |
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Glutamates; Guanine; Humans; Immunosuppressive Agents; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Taxoids; United Kingdom | 2010 |
Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cost-Benefit Analysis; Cross-Linking Reagents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Quality of Life; Quality-Adjusted Life Years; Radiation-Sensitizing Agents; Topotecan; Treatment Outcome; United Kingdom; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2010 |
Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Sarcoma; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2010 |
Aerosol therapy for the treatment of osteosarcoma lung metastases: targeting the Fas/FasL pathway and rationale for the use of gemcitabine.
Topics: Aerosols; Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Fas Ligand Protein; fas Receptor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Osteosarcoma | 2010 |
Salirasib in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Membrane; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Farnesol; Farnesyltranstransferase; Galectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Proteins; Neoplasms; Pancreatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Salicylates; Signal Transduction | 2010 |
Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC).
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Immunohistochemistry | 2011 |
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Neoplasms; Paclitaxel; Receptors, Notch; Signal Transduction; Tamoxifen; Taxoids; Trastuzumab | 2010 |
[Renal medullary carcinoma: remission with gemcitabine-cisplatin and review of therapeutic perspectives].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Remission Induction | 2010 |
One year survival with poorly differentiated metastatic pancreatic carcinoma following chemoembolization with gemcitabine and cisplatin.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Differentiation; Chemoembolization, Therapeutic; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
[A meta analysis of gemcitabine plus platinum chemotherapy compared with single-agent chemotherapy in the treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Platinum; Treatment Outcome | 2010 |
Gemcitabine plus paclitaxel versus carboplatin plus either gemcitabine or paclitaxel in advanced non-small-cell lung cancer: a literature-based meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2010 |
Overcoming platinum resistance in ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms | 2010 |
Sonographic features of pectoralis muscle necrosis secondary to gemcitabine-induced radiation recall: case report and review of current literature.
Topics: Adult; Antimetabolites, Antineoplastic; Biopsy, Needle; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Male; Necrosis; Pectoralis Muscles; Radiodermatitis; Tomography, X-Ray Computed; Ultrasonography, Doppler, Color | 2010 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols | 2010 |
[A case of hemolytic uremic syndrome after adjuvant chemotherapy with gemcitabine in a patient with pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2010 |
[Granulocyte-colony stimulating factor producing squamous cell carcinoma of the renal pelvis: a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Kidney Pelvis; Organoplatinum Compounds | 2010 |
Challenges of drug resistance in the management of pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Microenvironment | 2010 |
[The role of membrane transporters in cellular resistance of pancreatic carcinoma to gemcitabine].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Membrane Transport Proteins; Pancreatic Neoplasms | 2010 |
Chemotherapy for thymic tumors: induction, consolidation, palliation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Methotrexate; Neoadjuvant Therapy; Palliative Care; Procarbazine; Thymoma; Thymus Neoplasms; Vincristine | 2011 |
[Chemotherapy in gallbladder carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
Targeting apoptosis pathways in pancreatic cancer.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Histone Deacetylases; Humans; MAP Kinase Signaling System; MicroRNAs; NF-kappa B; Pancreatic Neoplasms; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; ras Proteins; TOR Serine-Threonine Kinases | 2013 |
Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Kaplan-Meier Estimate; Treatment Outcome | 2011 |
Gemox: a widely useful therapy against solid tumors-review and personal experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2010 |
Cutaneous metastasis of pancreatic adenocarcinoma after kidney transplant: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Kidney Transplantation; Pancreatic Neoplasms; Skin Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2010 |
The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2011 |
[A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Platinum; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2011 |
Long-term recurrence-free survival in a patient with pancreatic carcinosarcoma: a case report with a literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence | 2012 |
Development of molecularly targeted therapies in biliary tract cancers: reassessing the challenges and opportunities.
Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2011 |
[Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].
Topics: Antineoplastic Agents; Camptothecin; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Neutropenia; Pharmacogenetics; Polymorphism, Genetic | 2011 |
Integrating pharmacogenetics into gemcitabine dosing--time for a change?
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Pharmacogenetics; Precision Medicine; Prognosis | 2011 |
A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Nasal Septum; Nose Diseases; Vinblastine; Vinorelbine | 2011 |
[Signet ring cell carcinoma of the ampulla of Vater].
Topics: Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Gemcitabine; Humans; Jaundice, Obstructive; Jejunum; Liver; Lymphoma, Follicular; Male; Neoplasm Invasiveness; Neoplasms, Second Primary; Pancreatectomy; Pancreaticoduodenectomy; Splenectomy; Urinary Bladder Neoplasms | 2011 |
[Metastatic non-small cell lung cancer: Systemic treatment of patients aged 70 and over].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Long-Term Care; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Prognosis; Vinblastine; Vinorelbine | 2011 |
Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2011 |
[Combination chemotherapy of paclitaxel, carboplatin and gemcitabine in patients who have received prior cisplatin-based chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Salvage Therapy; Urologic Neoplasms; Urothelium | 2011 |
[A case of interstitial pneumonia during gemcitabine and cisplatin chemotherapy for locally advanced bladder cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Urinary Bladder Neoplasms | 2011 |
Nonsurgical therapy of biliary tract cancer.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Photochemotherapy | 2011 |
Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2011 |
Pooled survival and response data from phase III randomized controlled trials for gemcitabine-based regimes in the treatment of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2011 |
Treatment of early-stage pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2011 |
Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Everolimus; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2011 |
Current treatment options for pancreatic carcinoma.
Topics: Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography | 2011 |
Gemcitabine for unresectable, locally advanced or metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Paclitaxel; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Metastatic pancreatic cancer: old drugs, new paradigms.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Heparin; Humans; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Platinum; Quinazolines | 2011 |
[Second line chemotherapy for pancreatic cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Camptothecin; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Taxoids | 2011 |
Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung; Neoplasms; Regression Analysis; Taxoids | 2011 |
Evaluation of cutaneous angioimmunoblastic T-cell lymphoma.
Topics: Aged; Arthralgia; Cyclophosphamide; Deoxycytidine; Diphtheria Toxin; Doxorubicin; Epstein-Barr Virus Infections; Gemcitabine; Gene Rearrangement, T-Lymphocyte; Humans; Immunoblastic Lymphadenopathy; Interleukin-2; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Prednisolone; Pruritus; Recombinant Fusion Proteins; Retrospective Studies; Skin Neoplasms; Stem Cell Transplantation; Vinblastine; Vincristine; Vinorelbine | 2011 |
[Advances of drug resistance marker of gemcitabine for non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genetic Markers; Humans; Lung Neoplasms | 2011 |
Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2011 |
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Ethnicity; Gemcitabine; Genetic Markers; Genotype; Haplotypes; Humans; Irinotecan; Multidrug Resistance-Associated Protein 2; Pharmacogenetics; Polymorphism, Single Nucleotide; Tamoxifen | 2011 |
Emerging pharmacotherapeutic strategies for cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans | 2011 |
Bevacizumab in combination with a taxane for the first-line treatment of HER2-negative metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Taxoids | 2011 |
Chemotherapy and targeted therapies for unresectable malignant mesothelioma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Therapy; Folic Acid Antagonists; Gemcitabine; Genetic Therapy; Glutamates; Guanine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Immunotherapy; Mesothelioma; Molecular Targeted Therapy; Pemetrexed; Vascular Endothelial Growth Factor A; Vinblastine; Vinorelbine; Vorinostat | 2011 |
Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Increased expression of DNA repair genes in invasive human pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Databases, Factual; Deoxycytidine; DNA Repair; DNA, Neoplasm; Gemcitabine; Gene Dosage; Gene Expression; Genes, BRCA1; Genomic Instability; Humans; Neoplasm Invasiveness; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Rad51 Recombinase; Spheroids, Cellular | 2011 |
Splenic localization of the peritoneal mesothelioma: case report and literature revue.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Laparoscopy; Male; Mesothelioma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Peritoneal Neoplasms; Radiography; Splenectomy; Splenic Neoplasms; Time Factors; Treatment Failure | 2012 |
[New perspectives for radiosensitization in pancreatic carcinoma: a review of mechanisms involved in pancreatic tumorigenesis].
Topics: Antimetabolites, Antineoplastic; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cystadenoma, Mucinous; Delayed Diagnosis; Deoxycytidine; Disease Progression; Gemcitabine; Genes, Tumor Suppressor; Humans; Intercellular Signaling Peptides and Proteins; Mutation; Neoplasm Proteins; Oncogenes; Pancreatic Neoplasms; Precancerous Conditions; Radiation Tolerance; Signal Transduction | 2011 |
Chemotherapy only for localized Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachial Plexus; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Deoxycytidine; Doxorubicin; Etoposide; Fibrosis; Gemcitabine; Heart; Hodgkin Disease; Humans; Hypothyroidism; Lung; Lymphedema; Neoplasm Staging; Positron-Emission Tomography; Prednisone; Procarbazine; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Risk Assessment; Secondary Prevention; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vincristine | 2011 |
Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Updates on treatment of gemcitabine-refractory pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Topics: Adenocarcinoma; Antineoplastic Agents; Chicago; Congresses as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Medical Oncology; Models, Biological; Pancreatic Neoplasms; Societies, Medical; United States | 2011 |
Gemcitabine-associated "pseudocellulitis" and "pseudosepsis": a case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Diagnosis, Differential; Edema; Female; Fever; Gemcitabine; Humans; Pancreatic Neoplasms; Sepsis; Skin Diseases; Tachycardia | 2013 |
Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Randomized Controlled Trials as Topic; Reproducibility of Results; Taxoids | 2011 |
Primary leiomyosarcoma of the seminal vesicle: case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Genital Neoplasms, Male; Humans; Leiomyosarcoma; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Middle Aged; Prostatectomy; Radiotherapy, Adjuvant; Seminal Vesicles; Taxoids; Treatment Outcome | 2011 |
[Role of gemcitabine in treatment of metastatic breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Molecular Targeted Therapy; Paclitaxel; Trastuzumab; Treatment Outcome | 2011 |
Squalenoylation: a generic platform for nanoparticular drug delivery.
Topics: Animals; Antineoplastic Agents; Antiviral Agents; Deoxycytidine; Didanosine; Drug Delivery Systems; Gemcitabine; Humans; Nanoparticles; Squalene; Zalcitabine | 2012 |
RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Lung Neoplasms; Odds Ratio; Predictive Value of Tests; Ribonucleoside Diphosphate Reductase; Time Factors; Tumor Suppressor Proteins | 2012 |
Chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Therapy; Gemcitabine; Humans; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2011 |
Systemic chemotherapy in patients with advanced transitional cell carcinoma of the urothelium and impaired renal function.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Kidney; Kidney Function Tests; Neoplasm Invasiveness; Paclitaxel; Randomized Controlled Trials as Topic; Urologic Neoplasms; Urothelium | 2012 |
The past, present, and future of biomarkers: a need for molecular beacons for the clinical management of pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Prognosis; Sensitivity and Specificity | 2011 |
Pharmacokinetic evaluation of gemcitabine hydrochloride for the treatment of cervical cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Survival Rate; Topotecan; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2011 |
[Adjuvant gemcitabine plus S-1 chemotherapy for pancreatic cancer after surgical resection - outcomes and future perspectives].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2011 |
[Evidences for adjuvant therapy of resected pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms | 2011 |
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic | 2011 |
[Strategies for preoperative downsizing in patients with local nonresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Cooperative Behavior; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Interdisciplinary Communication; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Particle Accelerators; Prognosis; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Intensity-Modulated | 2011 |
Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Premedication; Survival Rate; Treatment Outcome | 2012 |
[When should systemic chemotherapy be used for urinary bladder carcinoma?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Guideline Adherence; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2012 |
Systemic management strategies for metastatic soft tissue sarcoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dioxoles; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Lysine; Paclitaxel; Randomized Controlled Trials as Topic; Sarcoma; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2011 |
Gemcitabine-loaded innovative nanocarriers vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Liposomes; Nanoparticles; Neoplasms; Polymers; Squalene; Tissue Distribution | 2011 |
Update on chemotherapy in the treatment of urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Urinary Bladder Neoplasms | 2011 |
[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Role of myeloid-derived suppressor cells in tumor immunotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Myeloid Cells; Neoplasms; T-Lymphocytes, Regulatory | 2012 |
[Meta-analysis of the efficacy between gemcitabine-alone and gemcitabine-based chemotherapy applied in advanced pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: case report and topic review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Ultrasonic Therapy | 2012 |
[A case of intrahepatic cholangiocarcinoma with invasion to right adrenal gland].
Topics: Adrenal Glands; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Tomography, X-Ray Computed | 2011 |
Chemotherapy-induced infiltrative pneumonitis cases in breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Paclitaxel; Taxoids | 2012 |
Gemcitabine: a critical nucleoside for cancer therapy.
Topics: Antimetabolites, Antineoplastic; Catalytic Domain; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Humans; Models, Molecular; Neoplasms; Nucleosides; Phosphorylation | 2012 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Mitomycin; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2012 |
Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Prognosis; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Treatment Failure; Urinary Bladder Neoplasms | 2012 |
Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Rate | 2012 |
Primary hepatocellular carcinoma of the pancreas: a case report and review of the heterogeneous group of pancreatic hepatoid carcinomas.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms | 2012 |
First-line chemotherapy in epithelial ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Poly(ADP-ribose) Polymerase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Topotecan; Vascular Endothelial Growth Factor A | 2012 |
A rational approach to the management of recurrent or persistent ovarian carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Decision Making; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovary; Paclitaxel; Polyethylene Glycols; Quality of Life; Randomized Controlled Trials as Topic | 2012 |
Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib | 2012 |
Molecular targets of gemcitabine action: rationale for development of novel drugs and drug combinations.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Design; Drug Therapy, Combination; Gemcitabine; Humans; Pharmacogenetics | 2012 |
[A case of malignant peritoneal mesothelioma successfully treated with systemic chemothrapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Paclitaxel; Pemetrexed; Peritoneal Neoplasms | 2012 |
Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Evidence-Based Medicine; Gemcitabine; Humans; Molecular Targeted Therapy; Odds Ratio; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; Treatment Outcome | 2012 |
What options are available for refractory pancreatic cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms | 2012 |
Novel agents in early phase clinical studies on refractory pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Ipilimumab; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2012 |
Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.
Topics: Antimetabolites, Antineoplastic; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Molecular Targeted Therapy; Mutation; Pancreatic Neoplasms; Signal Transduction | 2012 |
Current approaches to the management of Her2-negative metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Deoxycytidine; Doxorubicin; Estradiol; Female; Fulvestrant; Gemcitabine; Humans; Megestrol; Ovary; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases | 2012 |
Pathological vertebral fracture after stereotactic body radiation therapy for lung metastases. Case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Carboplatin; Carcinoma, Transitional Cell; Cervical Vertebrae; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fractures, Spontaneous; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Osteoporosis, Postmenopausal; Pemetrexed; Radiosurgery; Radiotherapy, Conformal; Rib Fractures; Ribs; Spinal Fractures; Thoracic Vertebrae; Urinary Bladder Neoplasms | 2012 |
Role of chemotherapy in treatments for biliary tract cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Systemic therapies for pancreatic cancer--the role of pharmacogenetics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Pharmacogenetics; Precision Medicine; Survival Rate | 2012 |
[Successful gemcitabine-nedaplatin therapy in a hemodialysis patient with ureteral carcinoma after bilateral nephroureterectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Nephrectomy; Organoplatinum Compounds; Renal Dialysis; Ureter; Ureteral Neoplasms | 2012 |
Soft-tissue metastasis revealing a pancreatic adenocarcinoma: one case report and a review of literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Soft Tissue Neoplasms; Thigh | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Pancreatic Neoplasms; Proteomics | 2012 |
Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Pyrimidines | 2014 |
Doublet versus single cytotoxic agent as first-line treatment for elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Biological; Neutropenia; Platinum Compounds; Randomized Controlled Trials as Topic; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2012 |
New biomarkers and targets in pancreatic cancer and their application to treatment.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; CD40 Antigens; Computational Biology; Deoxycytidine; Drug Therapy, Combination; Equilibrative Nucleoside Transport Proteins; Fluorouracil; Gemcitabine; Gene Rearrangement; Hedgehog Proteins; Humans; MicroRNAs; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction; Treatment Outcome | 2012 |
Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Prospective Studies; ROC Curve; Treatment Outcome | 2013 |
Pharmacogenetics of conventional chemotherapy in non-small-cell lung cancer: a changing landscape?
Topics: Biomarkers, Pharmacological; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Pharmacogenetics; Polymorphism, Single Nucleotide; Taxoids | 2012 |
Paracrine sonic hedgehog signaling derived from tumor epithelial cells: a key regulator in the pancreatic tumor microenvironment.
Topics: Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Fibroblasts; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplasm Metastasis; Neovascularization, Pathologic; Neuronal Plasticity; Paracrine Communication; Tumor Microenvironment | 2012 |
Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Odds Ratio; Paclitaxel; Platinum Compounds; Publication Bias; Research Report; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Molecular changes in pancreatic cancer: implications for molecular targeting therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemokine CXCL12; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, CXCR4 | 2012 |
[Soft-tissue sarcoma: recent developments].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Gemcitabine; Humans; Hyperthermia, Induced; Indazoles; Multimodal Imaging; Neoadjuvant Therapy; Positron-Emission Tomography; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sirolimus; Soft Tissue Neoplasms; Sulfonamides; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Survival Analysis; Treatment Outcome | 2013 |
Adjuvant therapy for pancreas adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2013 |
Systemic therapy of advanced pancreatic cancer: has the landscape changed?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Nausea; Neutropenia; Salvage Therapy; Stomatitis; Survival Analysis; Taxoids; Thrombocytopenia; Vomiting; Young Adult | 2013 |
[Thermo-chemotherapy of GP or TP for advanced non-small cell lung cancer: a systematic review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms; Paclitaxel; Safety; Taxoids | 2012 |
Malignant primary cardiac tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cardiac Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Myxoma; Neoplasm Recurrence, Local; Reoperation; Sarcoma; Taxoids; Time Factors; Treatment Outcome | 2012 |
Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Kaplan-Meier Estimate; Models, Biological; Phosphorylation; Prodrugs | 2013 |
Classification, diagnosis, and management of cholangiocarcinoma.
Topics: Antineoplastic Agents; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Therapy; Gemcitabine; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Severity of Illness Index; Surgical Procedures, Operative | 2013 |
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2013 |
Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Odds Ratio; Pancreatic Neoplasms; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2012 |
Fixed-dose rate infusion and standard rate infusion of gemcitabine in patients with advanced non-small-cell lung cancer: a meta-analysis of six trials.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature.
Topics: Antineoplastic Agents; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Quality of Life; Radiation-Sensitizing Agents; Urinary Bladder; Urinary Bladder Neoplasms | 2013 |
Pooled analysis of clinical outcomes with neoadjuvant cisplatin and gemcitabine chemotherapy for muscle invasive bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Forecasting; Gemcitabine; Humans; Liposomes; Nanocapsules; Nanomedicine; Neoplasms | 2012 |
New developments in pancreatic cancer treatment.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
[Long-surviving patient with hilar cholangiocarcinoma by gemcitabine monotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Staging; Time Factors | 2012 |
Experience with newer intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Humans; Mitomycin; Paclitaxel; Taxoids; Thiotepa; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
Chemoradiation in the management of cervix cancer: current status and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Uterine Cervical Neoplasms | 2013 |
The evolution of systemic therapy in sarcoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chordoma; Deoxycytidine; Dermatofibrosarcoma; Dioxoles; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Hemangiosarcoma; Humans; Osteosarcoma; Proteasome Inhibitors; Receptor, IGF Type 1; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tetrahydroisoquinolines; TOR Serine-Threonine Kinases; Trabectedin | 2013 |
Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Invasiveness; Organoplatinum Compounds; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2013 |
First-line treatment for advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
[Radically resected pancreatic cancer and adjuvant treatment. A review of the literature].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Mitomycin; Multicenter Studies as Topic; Pancreatectomy; Pancreatic Neoplasms; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
Primary angiosarcoma of the breast: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Developing Countries; Docetaxel; Female; Gemcitabine; Hemangiosarcoma; Humans; Lymph Node Excision; Magnetic Resonance Imaging; Mammaplasty; Mastectomy, Radical; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Surgical Flaps; Taxoids; Thailand | 2013 |
Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology.
Topics: Administration, Inhalation; Adsorption; Aerosols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; Humans; Lung; Lung Neoplasms; Particle Size; Platinum Compounds; Small Cell Lung Carcinoma; Taxoids | 2013 |
The role of oxaliplatin in the management of upper gastrointestinal tract malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms; Survival Rate | 2003 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
Impact of adjuvant chemotherapy in completely resected stage IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Evaluation; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2013 |
Gemcitabine alone or in combination with Cisplatin for advanced biliary tract carcinomas: an overview of clinical evidence.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Survival | 2013 |
Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Survival; Taxoids | 2013 |
Unusual aggressive breast cancer: metastatic malignant phyllodes tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Female; Fibroadenoma; Gemcitabine; Humans; Ifosfamide; Muscle Neoplasms; Naphthacenes; Neoplasm Invasiveness; Palliative Care; Phyllodes Tumor; Prognosis | 2013 |
Efficacy of gemcitabine plus platinum agents for biliary tract cancers: a meta-analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Evidence-Based Medicine; Female; Gemcitabine; Humans; Male; Middle Aged; Odds Ratio; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome | 2013 |
Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis.
Topics: Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Deoxycytidine; Gemcitabine; Humans; Incidence; Neoplasms; Randomized Controlled Trials as Topic; Risk; Venous Thromboembolism | 2013 |
Subacute cutaneous lupus erythematosus induced by chemotherapy: gemcitabine as a causative agent.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Drug Eruptions; Female; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous | 2013 |
Tumour-stroma interactions in pancreatic ductal adenocarcinoma: rationale and current evidence for new therapeutic strategies.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Signal Transduction; Treatment Outcome; Tumor Microenvironment | 2014 |
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Survival; Treatment Outcome | 2013 |
Do hENT1 and RRM1 predict the clinical benefit of gemcitabine in pancreatic cancer?
Topics: Animals; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
[Chemotherapy for gallbladder cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Molecular Targeted Therapy | 2013 |
Efficacy of gemcitabine-based chemotherapy in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Treatment Outcome | 2013 |
Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A Meta-analysis.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2015 |
Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
Topics: Antineoplastic Agents; Dacarbazine; Deoxycytidine; Dioxoles; Gemcitabine; Humans; Indazoles; Pyrimidines; Randomized Controlled Trials as Topic; Sarcoma; Sulfonamides; Tetrahydroisoquinolines; Trabectedin; Treatment Failure | 2013 |
Cisplatin versus carboplatin in combination with third-generation drugs for advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic | 2013 |
[Contemporary trends of the adjutant chemotherapy in non-small cell lung cancer].
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Evidence-Based Medicine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Prognosis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
[A case of gastric metastasis and carcinomatous peritonitis of breast cancer with improved QOL by stent implantation and gemcitabine].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Peritonitis; Quality of Life; Stents; Stomach Neoplasms | 2013 |
Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2013 |
Assessment and management of renal impairment in chemotherapy for urogenital cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Glomerular Filtration Rate; Humans; Incidence; Kidney; Male; Renal Insufficiency, Chronic; Survival Rate; Testicular Neoplasms; Urogenital Neoplasms; Urothelium | 2013 |
Slow progression of calcified cerebellar metastasis from ovarian cancer: a case report and review of the literature.
Topics: Adenocarcinoma, Mucinous; Adult; Antimetabolites, Antineoplastic; Calcinosis; Cerebellar Neoplasms; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Deoxycytidine; Disease Progression; Encephalocele; Female; Gemcitabine; Humans; Hydrocephalus; Hysterectomy; Magnetic Resonance Imaging; Ovarian Neoplasms; Ovariectomy; Tomography, X-Ray Computed | 2013 |
Increased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trials.
Topics: Deoxycytidine; Gemcitabine; Hemorrhage; Humans; Incidence; Neoplasms; Publication Bias; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2013 |
A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2013 |
Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: a retrospective comparison of East Asian and global studies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Asia, Western; Breast Neoplasms; China; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Middle Aged; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic | 2014 |
[Medical treatment of bladder carcinoma].
Topics: Aminolevulinic Acid; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma; Cisplatin; Cystoscopy; Deoxycytidine; Doxorubicin; Fluorescence; Gemcitabine; Humans; Methotrexate; Mitomycin; Photosensitizing Agents; Urinary Bladder Neoplasms; Vinblastine | 2013 |
Immunological off-target effects of standard treatments in gastrointestinal cancers.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cytotoxicity, Immunologic; Deoxycytidine; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Taxoids; Tumor Escape; Tumor Microenvironment | 2014 |
Methods of biological network inference for reverse engineering cancer chemoresistance mechanisms.
Topics: Antineoplastic Agents; Bayes Theorem; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Stochastic Processes | 2014 |
[Chemotherapy using gemcitabine hydrochloride for malignant lymphoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Lymphoma; Practice Guidelines as Topic | 2013 |
Liposomal chemotherapeutics.
Topics: Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Female; Gemcitabine; Humans; Liposomes; Multiple Myeloma; Paclitaxel; Pancreatic Neoplasms; Thyroid Neoplasms | 2013 |
[Current status and future directions of chemotherapy for pancreatic cancer].
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Tegafur | 2013 |
The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunity, Cellular; Immunologic Factors; Interleukin-1beta; Neoplasms; Th17 Cells | 2014 |
Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
[A case of unresectable biliary tract cancer with liver metastasis that exhibited an effective response to chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Stents | 2013 |
[Pancreatic cancer showing complete pathological response to preoperative chemoradiotherapy-a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[Study of unresectable pancreatic cancer - successful resections after gemcitabine-based chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Practice Guidelines as Topic; Tegafur; Treatment Outcome | 2013 |
Predictive role of repair enzymes in the efficacy of Cisplatin combinations in pancreatic and lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cisplatin; Deoxycytidine; DNA Repair Enzymes; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms; Prognosis | 2014 |
[Curative resection of stage IV advanced gallbladder cancer following combined treatment with gemcitabine and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymph Node Excision; Lymphatic Metastasis; Neoplasm Staging; Oxonic Acid | 2014 |
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2014 |
Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models | 2014 |
Gemcitabine-induced hemolytic uremic syndrome in pancreatic cancer: a case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Platinum Compounds; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2014 |
Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Signal Transduction; Time Factors; Treatment Outcome | 2014 |
Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2014 |
Myeloid-derived suppressor cells in pancreatic cancer: more than a hidden barrier for antitumour immunity?
Topics: Animals; Deoxycytidine; Gemcitabine; Humans; Immunosuppressive Agents; Immunotherapy; Myeloid Cells; Pancreatic Neoplasms | 2014 |
Treatment of metastatic pancreatic adenocarcinoma: a review.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2014 |
Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Paclitaxel; Pancreatic Neoplasms; Product Surveillance, Postmarketing; Survival Rate; Treatment Outcome | 2014 |
[Impact of chemotherapies on immunosuppression and discovery of new therapeutic targets].
Topics: Animals; Carrier Proteins; CD4-Positive T-Lymphocytes; Deoxycytidine; Epoxy Compounds; Fluorouracil; Gemcitabine; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Inflammasomes; Interleukin-17; Interleukin-1beta; Mice; Myeloid Cells; Neoplasms; Neovascularization, Pathologic; NLR Family, Pyrin Domain-Containing 3 Protein; Tyrosine | 2014 |
[A case of effective treatment with S-1/gemcitabine chemotherapy and resection for advanced pancreatic cancer with peritoneal dissemination].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur; Treatment Outcome | 2014 |
Autophagy in osteosarcoma.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hydroxychloroquine; Lung; Lung Neoplasms; Mice; Osteosarcoma; Species Specificity | 2014 |
Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases.
Topics: Animals; Antineoplastic Agents; Benzamides; Bone Neoplasms; Deoxycytidine; Epigenesis, Genetic; Fas Ligand Protein; fas Receptor; Gemcitabine; Humans; Lung Neoplasms; Mice; MicroRNAs; Osteosarcoma; Pyridines; RNA, Long Noncoding; Signal Transduction; Tumor Microenvironment | 2014 |
Using canine osteosarcoma as a model to assess efficacy of novel therapies: can old dogs teach us new tricks?
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Aerosols; Animals; Antineoplastic Agents; Bone Neoplasms; Child; Deoxycytidine; Dog Diseases; Dogs; Gemcitabine; Humans; Interleukin-2; Lung Neoplasms; Molybdenum; Osteosarcoma; Phosphatidylethanolamines; Signal Transduction | 2014 |
Effects of cigarette smoking on metabolism and effectiveness of systemic therapy for lung cancer.
Topics: Antineoplastic Agents; Camptothecin; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Deoxycytidine; Docetaxel; Enzyme Induction; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Nicotine; Paclitaxel; Polycyclic Aromatic Hydrocarbons; Quinazolines; Smoking; Taxoids | 2014 |
Gemcitabine-induced cardiomyopathy: a case report and review of the literature.
Topics: Antimetabolites, Antineoplastic; Cardiomyopathies; Cardiotoxicity; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Ultrasonography; Ventricular Dysfunction, Left | 2014 |
Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mass Screening; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Taxoids; Topotecan; Uterine Cervical Neoplasms | 2014 |
Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Databases, Bibliographic; Deoxycytidine; Gemcitabine; Humans; Male; Meta-Analysis as Topic; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2014 |
Systematic review of combination therapies for mycosis fungoides.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Combined Modality Therapy; Deoxycytidine; Ficusin; Gemcitabine; Humans; Hydroxamic Acids; Interferon-alpha; Methotrexate; Mycosis Fungoides; Phototherapy; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes; Vorinostat | 2014 |
hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Role of solute carrier transporters in pancreatic cancer: a review.
Topics: Adenocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Membrane Transport Proteins; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Genetic | 2014 |
Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inflammation Mediators; Pancreatic Neoplasms | 2014 |
Progress in the knowledge and treatment of advanced pancreatic cancer: from benchside to bedside.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Mast Cells; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Treatment Outcome; Tumor Microenvironment | 2014 |
Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans | 2014 |
Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic | 2014 |
Outcome of gemcitabine plus molecular targeted agent for treatment of pancreatic cancer: a meta-analysis of prospective phase III studies.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Protein Kinases | 2014 |
[Gallbladder cancer with elevated serum α-fetoprotein, α-fetoprotein-L3, and human chorionic gonadotropin levels].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Middle Aged | 2014 |
Gemcitabine-induced radiation recall myositis.
Topics: Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Myositis; Radiation Injuries; Radiation Tolerance; Radiography; Radiotherapy; Treatment Outcome | 2015 |
FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Study protocol: systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Survival Rate; Systematic Reviews as Topic | 2014 |
Gemcitabine for the treatment of patients with osteosarcoma.
Topics: Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Osteosarcoma; Treatment Outcome | 2014 |
Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carboplatin; Carcinoma, Ductal, Breast; Deoxycytidine; Epothilones; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Pancreatic adenocarcinosarcoma of monoclonal origin: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; CA-19-9 Antigen; Cell Differentiation; Deoxycytidine; DNA Mutational Analysis; Exons; Gemcitabine; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasms, Complex and Mixed; Pancreatic Neoplasms; Phenotype; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sarcoma; Tomography, X-Ray Computed; Up-Regulation | 2014 |
A Bayesian meta-analysis of multiple treatment comparisons of systemic regimens for advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Survival Analysis | 2014 |
An update on PARP inhibitors--moving to the adjuvant setting.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Benzamides; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Carboplatin; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Breaks, Single-Stranded; DNA Repair; Female; Gemcitabine; Humans; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors | 2015 |
The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tegafur | 2015 |
The role of chemotherapy for metastatic, relapsed and refractory osteosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Deoxycytidine; Docetaxel; Etoposide; Gemcitabine; Humans; Ifosfamide; Methotrexate; Neoplasm Recurrence, Local; Osteosarcoma; Taxoids | 2014 |
Gemcitabine fixed-dose rate infusion for the treatment of pancreatic carcinoma: a meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chi-Square Distribution; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Infusions, Parenteral; Odds Ratio; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Gemcitabine in treating patients with refractory or relapsed multiple myeloma.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Multiple Myeloma; Recurrence; Salvage Therapy | 2014 |
Lentinan reduces tumor progression by enhancing gemcitabine chemotherapy in urothelial bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Lentinan; Urinary Bladder Neoplasms; Urothelium | 2015 |
Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Mitomycin; Neoplasm Staging; Randomized Controlled Trials as Topic; Uterine Cervical Neoplasms | 2014 |
[Impact of lung cancer treatments on renal function].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Diphosphonates; Gemcitabine; Glutamates; Guanine; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Lung Neoplasms; Pemetrexed | 2014 |
Is concomitant radiotherapy necessary with gemcitabine-based chemotherapy in pancreatic cancer?
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chi-Square Distribution; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Pancreatic Neoplasms; Risk Factors; Time Factors; Treatment Outcome | 2014 |
Combined therapy for gastrointestinal carcinomas: exploiting synergies between gene therapy and classical chemo-radiotherapy.
Topics: Antineoplastic Agents; Carcinoma; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Gastrointestinal Neoplasms; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Paclitaxel | 2015 |
Efficacy and safety of gemcitabine-based chemotherapies in biliary tract cancer: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Odds Ratio; Risk Factors; Survival Analysis; Time Factors; Treatment Outcome | 2014 |
Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Topics: Alleles; Antimetabolites, Antineoplastic; Chemotherapy-Induced Febrile Neutropenia; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Genetic Markers; Humans; Male; MEDLINE; Neoplasm Proteins; Neoplasms; Polymorphism, Genetic; Survival Rate | 2015 |
Locally advanced undifferentiated carcinoma with osteoclast-like giant cells of the pancreas.
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Giant Cell; Cell Differentiation; Chemotherapy, Adjuvant; Colectomy; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Mesenteric Vascular Occlusion; Mesenteric Veins; Neoplasm Invasiveness; Osteoclasts; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2015 |
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Health Care Costs; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Tetrahydroisoquinolines; Topotecan; Trabectedin; Treatment Outcome; United Kingdom | 2015 |
Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biliary Tract Neoplasms; Bortezomib; Camptothecin; Curcumin; Deoxycytidine; Ditiocarb; Drug Resistance, Neoplasm; Gemcitabine; Guanidines; Humans; Irinotecan; Molecular Targeted Therapy; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Pregnenediones; Treatment Outcome | 2015 |
Novel directions in neoadjuvant therapy for pancreas adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Using chemo-drugs or irradiation to break immune tolerance and facilitate immunotherapy in solid cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Cyclophosphamide; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Killer Cells, Natural; Neoplasms; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Escape; Tumor Microenvironment | 2015 |
[A case of pancreatic cancer with distant metastasis successfully resected after neoadjuvant chemotherapy with a combination of S-1 and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Oxonic Acid; Pancreatic Neoplasms; Pleural Neoplasms; Stomach Neoplasms; Tegafur | 2014 |
[A case of pancreatic cancer with local recurrence and liver metastases eight years after surgery].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence; Time Factors | 2014 |
Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Everolimus; Female; Folic Acid; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Nivolumab; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Glycols; Pyrimidines; Quinazolines; Recombinant Fusion Proteins; Sirolimus; Sulfonamides; Topotecan; TOR Serine-Threonine Kinases; Vinca Alkaloids | 2015 |
Systemic therapy for advanced pancreatic cancer: individualising cytotoxic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Receptors, Vascular Endothelial Growth Factor | 2015 |
Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Risk; Survival Rate; Tegafur; Treatment Outcome | 2015 |
Integrative meta-analysis of multiple gene expression profiles in acquired gemcitabine-resistant cancer cell lines to identify novel therapeutic biomarkers.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Interaction Maps | 2015 |
Progression-free survival as surrogate endpoint in advanced pancreatic cancer: meta-analysis of 30 randomized first-line trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival | 2015 |
Pancreatic cancer, treatment options, and GI-4000.
Topics: Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2015 |
Thrombotic microangiopathy, cancer, and cancer drugs.
Topics: Adrenal Cortex Hormones; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Immunosuppressive Agents; Kidney; Male; Neoplasms; Pancreatic Neoplasms; Plasmapheresis; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A | 2015 |
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Maintenance Chemotherapy; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Risk Factors; Treatment Outcome | 2015 |
[Utilization of Genomic Biomarkers for Post-marketing Safety of Drugs].
Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Camptothecin; Deoxycytidine; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Genomics; Glucuronosyltransferase; HLA Antigens; Humans; International Cooperation; Irinotecan; Japan; Pharmacogenetics; Precision Medicine; Prodrugs; Product Surveillance, Postmarketing | 2015 |
Managing thrombocytopenia associated with cancer chemotherapy.
Topics: Antineoplastic Agents; Benzoates; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Evidence-Based Medicine; Gemcitabine; Humans; Hydrazines; Neoplasms; Platelet Count; Platelet Transfusion; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thrombocytopenia; Thrombopoiesis; Thrombopoietin; Treatment Outcome | 2015 |
Maintenance therapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2015 |
RRM1 expression is associated with the outcome of gemcitabine-based treatment of non-small cell lung cancer patients--a short report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
[Pancreatic adenocarcinoma: 10 years of progress].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Paclitaxel; Pancreatic Neoplasms; Precancerous Conditions | 2015 |
Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Publication Bias; Randomized Controlled Trials as Topic; Smoking; Treatment Outcome; Young Adult | 2015 |
Treatment of Pancreatic Cancer with Pharmacological Ascorbate.
Topics: Animals; Antioxidants; Ascorbic Acid; Deoxycytidine; Gemcitabine; Humans; Hydrogen Peroxide; Oxidative Stress; Pancreatic Neoplasms | 2015 |
Pancreatic cancer: current management and treatment strategies.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Pancreatic Neoplasms; Pancreaticoduodenectomy; Practice Guidelines as Topic; Prognosis; Treatment Outcome | 2015 |
An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Pyrimidines; Survival Analysis | 2015 |
Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2015 |
SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Methylation; Gemcitabine; Humans; Osteonectin; Pancreatic Neoplasms; Prognosis; Signal Transduction; Treatment Outcome | 2015 |
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, hi
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Substitution; ErbB Receptors; Gemcitabine; Genetic Predisposition to Disease; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Markov Chains; Monte Carlo Method; Mutation; Neoplasm Staging; Pemetrexed; Phenotype; Protein Kinase Inhibitors; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
[Recent Advances in Palliative Chemotherapy for Unresectable Pancreatic Cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2015 |
Nasopharyngeal carcinoma: review of the literature with a focus on therapeutical implications.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Valproic Acid | 2015 |
Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biological Factors; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indazoles; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Pyrimidines; Salvage Therapy; Sulfonamides; Urinary Bladder Neoplasms; Vinblastine | 2016 |
[LEIOMYOSARCOMA ARISING FROM OVARIAN VEIN WITH RIGHT HYDRONEPHROSIS: A CASE REPORT].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Hydronephrosis; Leiomyosarcoma; Ovarian Neoplasms; Taxoids; Tomography, X-Ray Computed; Vena Cava, Inferior | 2015 |
Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Plasmacytoid Urothelial Bladder Cancer: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Treatment Outcome; Ultrasonography; Urinary Bladder Neoplasms | 2016 |
Multifocal intraductal tubulopapillary neoplasm of the pancreas with total pancreatectomy: report of a case and review of literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatectomy; Pancreatic Ducts; Pancreatic Neoplasms | 2015 |
The Impact of Adding Taxanes to Gemcitabine and Platinum Chemotherapy for the First-Line Therapy of Advanced or Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Multivariate Analysis; Platinum Compounds; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2016 |
Pathological T0 Following Cisplatin-Based Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Network Meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Gemcitabine plus S-1: a hopeful frontline treatment for Asian patients with unresectable advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Odds Ratio; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Randomized Controlled Trials as Topic; Research Report; Tegafur; Treatment Outcome | 2015 |
[Latest advances in pancreatic tumours].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contrast Media; Deoxycytidine; Diagnosis, Differential; Disease Progression; Early Detection of Cancer; Elasticity Imaging Techniques; Endosonography; Gemcitabine; Humans; Paclitaxel; Pancreatectomy; Pancreatic Cyst; Pancreatic Neoplasms; Pancreatitis, Alcoholic; Prognosis; Risk | 2015 |
Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Pleural Neoplasms; Vinblastine; Vinca Alkaloids; Vinorelbine | 2015 |
Gemcitabine-based chemotherapy in sarcomas: A systematic review of published trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Leiomyosarcoma; Osteosarcoma; Sarcoma | 2016 |
Vaccinia virus, a promising new therapeutic agent for pancreatic cancer.
Topics: Antineoplastic Agents; Cancer Vaccines; Deoxycytidine; Gemcitabine; Genetic Vectors; Humans; Immunotherapy, Active; Membrane Glycoproteins; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Vaccinia virus; Virus Replication | 2015 |
Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Evidence-Based Medicine; Expert Testimony; Gemcitabine; Germany; Humans; Hyperbilirubinemia; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Chemotherapy Resistance in Lung Cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Pemetrexed; Taxoids; Vinblastine; Vinorelbine | 2016 |
Gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Proteins; Pancreatic Neoplasms; Ribonucleotide Reductases; Signal Transduction; Survival Analysis; Tumor Microenvironment | 2015 |
Gemcitabine-Based Chemoradiation in the Treatment of Locally Advanced Head and Neck Cancer: Systematic Review of Literature and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Recurrence, Local; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Squamous Cell Carcinoma of Head and Neck | 2016 |
Necitumumab: First Global Approval.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms | 2016 |
The safety and efficacy of gemcitabine for the treatment of bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Urinary Bladder Neoplasms | 2016 |
Chemotherapy for Muscle-Invasive Bladder Cancer: Better Late Than Never?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Urinary Bladder Neoplasms; Vinblastine | 2016 |
The influence of polypharmacy on grade III/IV toxicity, prior discontinuation of chemotherapy and overall survival in ovarian cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polypharmacy; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Withholding Treatment; Young Adult | 2016 |
The Clinical Significance of Phosphorylated Heat Shock Protein 27 (HSPB1) in Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Molecular Chaperones; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Prognosis; Protein Serine-Threonine Kinases | 2016 |
[Gemcitabine Monotherapy for Advanced Mycosis Fungoides--Two Case Reports and a Literature Review].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Male; Mycosis Fungoides; Prednisone; Skin Neoplasms; Vincristine | 2015 |
Pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Fluorouracil; Gemcitabine; Genes, p16; Humans; Irinotecan; Leucovorin; Neoplasms, Cystic, Mucinous, and Serous; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Smad4 Protein; Tumor Suppressor Protein p53 | 2016 |
Antineoplastic agents and thrombotic microangiopathy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Immunologic Factors; Incidence; Interferon-alpha; Mitomycin; Molecular Targeted Therapy; Neoplasms; Proteasome Inhibitors; Signal Transduction; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A | 2017 |
Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Discovery; Gemcitabine; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Lung Neoplasms; Paclitaxel; Taxoids | 2016 |
Relapsed and refractory subcutaneous panniculitis-like T-cell lymphoma with excellent response to cyclosporine: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclosporine; Cytarabine; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Immunosuppressive Agents; Lymphoma, T-Cell, Cutaneous; Male; Methylprednisolone; Multimodal Imaging; Panniculitis; Positron-Emission Tomography; Recurrence; Remission Induction; Salvage Therapy; Skin Neoplasms; Subcutaneous Fat; Tomography, X-Ray Computed | 2016 |
Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2016 |
Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Geriatric Assessment; Humans; Molecular Targeted Therapy; Neoplasm Staging; Pemetrexed; Programmed Cell Death 1 Receptor; Taxoids; Vinblastine; Vinorelbine | 2016 |
[Pancreatic cancer--mechanisms of chemoresistance].
Topics: Antineoplastic Agents; Apoptosis; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Pancreatic Neoplasms; Signal Transduction; Tumor Microenvironment | 2016 |
Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Pemetrexed; Randomized Controlled Trials as Topic; Survival Rate | 2016 |
Experience with Sequential Intravesical Gemcitabine and Docetaxel as Salvage Therapy for Non-Muscle Invasive Bladder Cancer.
Topics: Administration, Intravesical; Cystectomy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Salvage Therapy; Taxoids; Urinary Bladder Neoplasms | 2016 |
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective.
Topics: Adult; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Precision Medicine | 2016 |
Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Neoadjuvant Therapy; Pancreatic Neoplasms | 2016 |
The Use of Systemic Treatment in the Maintenance of Patients with Non-Small Cell Lung Cancer: A Systematic Review.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Pemetrexed; Taxoids | 2016 |
Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Safety of palliative chemotherapy in advanced pancreatic cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Systemic Chemotherapy in Advanced Pancreatic Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2016 |
The safety and efficacy of Onivyde (irinotecan liposome injection) for the treatment of metastatic pancreatic cancer following gemcitabine-based therapy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Prognosis | 2016 |
A case of ectopic pancreatic cancer in the mesentery of the jejunum.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Jejunum; Male; Pancreatic Neoplasms | 2016 |
HBV-associated intrahepatic cholangiocarcinoma with high serum alpha-fetoprotein: a case report with review of literature.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; DNA, Viral; Gemcitabine; Guanine; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Immunohistochemistry; Liver; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Risk Factors; Tomography, X-Ray Computed | 2016 |
Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Survival Analysis; Taxoids; Treatment Outcome; Urologic Neoplasms | 2017 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2016 |
Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2016 |
Primary Cutaneous Interdigitating Dendritic Cell Sarcoma: A Case Report and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Dendritic Cell Sarcoma, Interdigitating; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Skin Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2016 |
Platinum-refractory germ cell tumors: an update on current treatment options and developments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Salvage Therapy; Testicular Neoplasms | 2017 |
Rituximab to treat gemcitabine-induced hemolytic-uremic syndrome (HUS) in pancreatic adenocarcinoma: a case series and literature review.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Pancreatic Neoplasms; Retrospective Studies; Rituximab | 2017 |
Autopsy of anaplastic carcinoma of the pancreas producing granulocyte colony-stimulating factor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biopsy; Carcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2016 |
A case of adenosquamous carcinoma of the lower bile duct diagnosed preoperatively via transpapillary biopsy.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biopsy; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Gemcitabine; Humans; Male; Pancreaticoduodenectomy | 2016 |
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Gemcitabine; Humans; Pemetrexed; Poly-ADP-Ribose Binding Proteins; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2016 |
Recent advances in drug delivery strategies for improved therapeutic efficacy of gemcitabine.
Topics: Deoxycytidine; Drug Delivery Systems; Gemcitabine | 2016 |
Nanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Delivery Systems; Extracellular Matrix; Gemcitabine; Hedgehog Proteins; Humans; Nanomedicine; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2016 |
Definitive Management of Primary Bladder Tumors in the Context of Metastatic Disease: Who, How, When, and Why?
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Lymphatic Metastasis; Male; Pelvis; Radiotherapy; Retroperitoneal Space; Urinary Bladder Neoplasms | 2016 |
[Combined Chemotherapy with Radiation was Tolerable and Effective Treatment in Female Octogenarian Patients with Urethral Cancer -Two Case Reports].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Organoplatinum Compounds; Proton Therapy; Tomography, X-Ray Computed; Treatment Outcome; Urethral Neoplasms | 2016 |
Pancreatic carcinoma masked as fever of unknown origin: A case report and comprehensive review of literature.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fever of Unknown Origin; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2016 |
Paradoxical Role of HMGB1 in Pancreatic Cancer: Tumor Suppressor or Tumor Promoter?
Topics: Animals; Apoptosis; Autophagy; Biomarkers, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genes, Tumor Suppressor; HMGB1 Protein; Humans; Mice; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic | 2016 |
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2016 |
Post-gemcitabine therapy for patients with advanced pancreatic cancer - A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma.
Topics: Adult; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Isoquinolines; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Rituximab | 2016 |
Bladder chondrosarcoma plus urothelial carcinoma in recurred transitional cell carcinoma of the upper urinary tract: a case report and literature review.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Chondrosarcoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Tomography, X-Ray Computed; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2016 |
Evaluating the efficacy and safety of intravesical chemotherapies for non-muscle invasive bladder cancer: a network meta-analysis.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; BCG Vaccine; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Humans; Isoniazid; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Odds Ratio; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Therapeutic efficacy and safety of S-1-based combination therapy compare with S-1 monotherapy following gemcitabine failure in pancreatic cancer: a meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur; Treatment Outcome | 2016 |
Systemic, perioperative management of muscle-invasive bladder cancer and future horizons.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; DNA Repair; Evidence-Based Medicine; Gemcitabine; Humans; Immunotherapy; Lymphatic Metastasis; Muscle Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Organ Sparing Treatments; Preoperative Care; Randomized Controlled Trials as Topic; Time Factors; Urinary Bladder Neoplasms | 2017 |
Emerging role of immunotherapy in urothelial carcinoma-Advanced disease.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; CTLA-4 Antigen; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Ipilimumab; Molecular Targeted Therapy; Neoplasm Proteins; Nivolumab; Oncolytic Virotherapy; Programmed Cell Death 1 Receptor; Therapies, Investigational; Urinary Bladder Neoplasms | 2016 |
Surgical treatment of recurrent urachal carcinoma with liver metastasis: a case report and literature review.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hepatectomy; Humans; Hysterectomy; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Neoplasms; Salvage Therapy; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2016 |
Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Synergism; Drugs, Chinese Herbal; Gemcitabine; Humans; Injections; Lung Neoplasms; Randomized Controlled Trials as Topic | 2017 |
The efficacy and safety of platinum plus gemcitabine (PG) chemotherapy with or without molecular targeted agent (MTA) in first-line treatment of non-small cell lung cancer (NSCLC).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Platinum Compounds; Survival Analysis; Treatment Outcome | 2016 |
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2016 |
Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Curcumin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Lymphoepithelioma-Like Bladder Carcinoma: A Diagnostic and Therapeutic Challenge. Contribution Using a New Case and Review of the Literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Urinary Bladder Neoplasms | 2017 |
Nanotechnology for delivery of gemcitabine to treat pancreatic cancer.
Topics: Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Nanotechnology; Pancreatic Neoplasms | 2017 |
Combination of metformin with chemotherapeutic drugs via different molecular mechanisms.
Topics: Androgen Antagonists; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Estrogen Receptor Modulators; Fluorouracil; Gemcitabine; Humans; Metformin; Methotrexate; Neoplasms; Paclitaxel; Tubulin Modulators | 2017 |
Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?
Topics: Adult; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunotherapy; Middle Aged; Neoplasm Recurrence, Local; Risk Factors; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult | 2017 |
Immunohistochemical hENT1 expression as a prognostic biomarker in patients with resected pancreatic ductal adenocarcinoma undergoing adjuvant gemcitabine-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis | 2017 |
Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Chemotherapy, Adjuvant; Deoxycytidine; Diagnostic Errors; Dioxoles; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Hysterectomy; Indazoles; Laparoscopy; Leiomyoma; Leiomyosarcoma; Morcellation; Neoplasm Staging; Pyrimidines; Sulfonamides; Taxoids; Tetrahydroisoquinolines; Trabectedin; Uterine Myomectomy; Uterine Neoplasms | 2017 |
Natural Products as Adjunctive Treatment for Pancreatic Cancer: Recent Trends and Advancements.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Piperidines; Pyridines; Randomized Controlled Trials as Topic; Survival Analysis; Thiazoles | 2017 |
Natural Anti-Cancer Agents: Implications in Gemcitabine-Resistant Pancreatic Cancer Treatment.
Topics: Antineoplastic Agents; Biological Products; Combined Modality Therapy; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Neoplasms | 2017 |
[Chemotherapy for Biliary Tract Cancer].
Topics: Antineoplastic Agents; Bevacizumab; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin | 2017 |
Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2017 |
Efficacy and safety of chemotherapy with or without targeted therapy in biliary tract cancer: A meta-analysis of 7 randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2017 |
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
[What is the place of the combinations for immunotherapy with chemotherapy or with other immune checkpoint inhibitors?]
Topics: Anthracyclines; Antigens, Neoplasm; Antineoplastic Agents; Combined Modality Therapy; CTLA-4 Antigen; Cyclophosphamide; Deoxycytidine; Gemcitabine; Humans; Immune Tolerance; Immunotherapy; Neoplasms; Platinum Compounds; Programmed Cell Death 1 Receptor; Taxoids | 2017 |
Surgical strategies and novel therapies for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arteries; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Digestive System Surgical Procedures; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Veins | 2017 |
Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2017 |
Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cytidine Triphosphate; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2017 |
Gemcitabine-based combination therapy compared with gemcitabine alone for advanced pancreatic cancer: a meta-analysis of nine randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Odds Ratio; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Treatment Outcome | 2017 |
[Systematic review on conservative treatment options in non-muscle-invasive bladder cancer patients refractory to Bacillus Calmette-Guérin instillation therapy].
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; BCG Vaccine; Conservative Treatment; Deoxycytidine; Drug Resistance, Viral; Gemcitabine; Humans; Immunotherapy; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2017 |
Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy | 2017 |
Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasm Metastasis; Pancreatic Ducts; Pancreatic Neoplasms; Signal Transduction | 2017 |
A case of a patient with granulocyte-colony stimulating factor-producing pancreatic cancer who responded to nab-paclitaxel plus gemcitabine.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2017 |
Toxicity of chemotherapy regimens in advanced and metastatic pancreatic cancer therapy: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms | 2018 |
Primary signet ring cell carcinoma of the pancreas with a good response to chemotherapy: case report and literature review.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2017 |
S-1 monotherapy versus S-1 combination therapy in gemcitabine-refractory advanced pancreatic cancer: A meta-analysis (PRISMA) of randomized control trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Tegafur | 2017 |
[Treatment of mycosis fungoides and Sézary syndrome].
Topics: Adrenal Cortex Hormones; Bexarotene; Brentuximab Vedotin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Immunoconjugates; Interferon-alpha; Mycosis Fungoides; Neoplasm Recurrence, Local; Neoplasm Staging; Phototherapy; Polyethylene Glycols; PUVA Therapy; Sezary Syndrome; Skin Neoplasms; World Health Organization | 2017 |
How to treat pancreatic adenocarcinoma in elderly: How far can we go in 2017?
Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Frailty; Gemcitabine; Geriatric Assessment; Humans; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy | 2017 |
Efficacy of different chemotherapy regimens in treatment of advanced or metastatic pancreatic cancer: A network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Network Meta-Analysis; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2018 |
Fluorinated nucleosides as an important class of anticancer and antiviral agents.
Topics: Antineoplastic Agents; Antiviral Agents; Deoxycytidine; Fluorine; Fluorouracil; Gemcitabine; HIV; Neoplasms; Nucleoside Transport Proteins; Nucleosides; Positron-Emission Tomography | 2017 |
Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
Topics: Albumins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Neoplasm Staging; Osteonectin; Paclitaxel; Pancreas; Pancreatic Neoplasms; Permeability; Treatment Outcome | 2017 |
Current Standards of Chemotherapy for Pancreatic Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Do anti-stroma therapies improve extrinsic resistance to increase the efficacy of gemcitabine in pancreatic cancer?
Topics: Albumins; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronic Acid; Osteonectin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pyridines; Stromal Cells; Survival Analysis; Treatment Outcome | 2018 |
The best platinum regimens for chemo-naive incurable non-small cell lung cancer: network meta-analysis.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Network Meta-Analysis; Paclitaxel; Platinum | 2017 |
Gemcitabine and glioblastoma: challenges and current perspectives.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Deoxycytidine; Gemcitabine; Glioblastoma; Humans; Nanomedicine; Radiation-Sensitizing Agents | 2018 |
Extraordinary response of metastatic pancreatic cancer to apatinib after failed chemotherapy: A case report and literature review.
Topics: Angiogenesis Inhibitors; Antigens, Tumor-Associated, Carbohydrate; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Pleural Effusion, Malignant; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Tomography, X-Ray Computed; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2018 |
Molecular and cellular mechanisms of chemoresistance in pancreatic cancer.
Topics: Animals; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2018 |
A look at the progress of treating pancreatic cancer over the past 20 years.
Topics: Antineoplastic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Palliative Care; Pancreatic Neoplasms; Survival Rate | 2018 |
Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
Topics: Antineoplastic Agents; Deoxycytidine; Drug Carriers; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lipids; Lysosomes; Nanomedicine; Nanoparticles; Neoplasms | 2018 |
[Cystic Duct Cancer with Postoperative Liver Metastasis That Achieved Complete Response after Gemcitabine Treatment - A Case Report].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cholecystectomy; Cystic Duct; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Staging | 2017 |
[A Case of Pathological Complete Response Following Neoadjuvant Chemotherapy with Gemcitabine plus Nab-Paclitaxel in Borderline Resectable Pancreatic Cancer].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms | 2017 |
Cancer Targeting and Drug Delivery Using Carbon-Based Quantum Dots and Nanotubes.
Topics: Antineoplastic Agents; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Liberation; Fluorescent Dyes; Folic Acid; Gemcitabine; Humans; Hyaluronic Acid; Molecular Targeted Therapy; Nanotubes, Carbon; Neoplasms; Quantum Dots; Surface Properties; Transferrin | 2018 |
Updates on Gallbladder Cancer Management.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Laparoscopy | 2018 |
Chemotherapy and radiotherapy for advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome | 2018 |
Impact of RUNX2 on drug-resistant human pancreatic cancer cells with p53 mutations.
Topics: Antimetabolites, Antineoplastic; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Prognosis; Tumor Suppressor Protein p53 | 2018 |
Meta-analysis of gemcitabine in brief versus prolonged low-dose infusion for advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Time Factors | 2018 |
Combination therapy versus gemcitabine monotherapy in the treatment of elderly pancreatic cancer: a meta-analysis of randomized controlled trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Molecular Structure; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Structure-Activity Relationship; Survival Rate | 2018 |
Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis | 2018 |
Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kidney Failure, Chronic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Renal Dialysis; Taxoids | 2018 |
Closed-system drug-transfer devices plus safe handling of hazardous drugs versus safe handling alone for reducing exposure to infusional hazardous drugs in healthcare staff.
Topics: Adult; Antineoplastic Agents; Chemical Safety; Cyclophosphamide; Deoxycytidine; Endocrine Disruptors; Fluorouracil; Gemcitabine; Hazardous Substances; Humans; Ifosfamide; Nursing Staff, Hospital; Observational Studies as Topic; Occupational Exposure; Pharmacists; Pharmacy Technicians | 2018 |
Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Models, Economic; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Technology Assessment, Biomedical | 2018 |
Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going.
Topics: Animals; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
[Therapeutic advances in the management of biliary tract carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; France; Gemcitabine; Humans; Medical Oncology | 2018 |
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Tegafur | 2018 |
[A Distal Bile Duct Carcinoma Patient Who Underwent Surgical Resection for Liver Metastasis].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreaticoduodenectomy; Tegafur | 2018 |
Gemcitabine and Nucleos(t)ide Synthesis Inhibitors Are Broad-Spectrum Antiviral Drugs that Activate Innate Immunity.
Topics: Animals; Antiviral Agents; Deoxycytidine; Gemcitabine; Gene Expression; Humans; Immunity, Innate; Interferon Regulatory Factors; Metabolic Networks and Pathways; Nucleosides; Nucleotides | 2018 |
[Metastases of Urothelial Carcinoma with Trophoblastic Differentiation that Responded to Combination Chemotherapy with Gemcitabine and Oxaliplatin : A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Neoplasm Metastasis; Oxaliplatin; Urinary Bladder Neoplasms | 2018 |
[New endovesical chemotherapy drugs and application vehicles.]
Topics: Administration, Intravesical; Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2018 |
Latest developments in MUC1 immunotherapy.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Glycosylation; Humans; Immunotherapy; Mucin-1; Neoplasms; Tumor Microenvironment | 2018 |
Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hypoxia; Immunotherapy; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2018 |
Scleroderma-like cutaneous lesions during treatment with paclitaxel and gemcitabine in a patient with pancreatic adenocarcinoma. Review of literature.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Scleroderma, Localized | 2018 |
Advances in oncolytic adenovirus therapy for pancreatic cancer.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms | 2018 |
Management and supportive treatment of frail patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Frail Elderly; Frailty; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Associations between hematologic toxicity and health-related quality of life during first-line chemotherapy in advanced non-small-cell lung cancer: a pooled analysis of two randomized trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Quality of Life; Randomized Controlled Trials as Topic; Vinorelbine | 2018 |
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Treatment Outcome | 2018 |
Harnessing the Immune System in Pancreatic Cancer.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Microsatellite Instability; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2018 |
New Hope for Pancreatic Ductal Adenocarcinoma Treatment Targeting Endoplasmic Reticulum Stress Response: A Systematic Review.
Topics: Activating Transcription Factor 6; Animals; Antibodies; Carcinoma, Pancreatic Ductal; Communicable Diseases; Deoxycytidine; Diabetes Complications; Disease Models, Animal; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Endoribonucleases; Gemcitabine; Gene Expression Regulation; Heat-Shock Proteins; Humans; Pancreatic Neoplasms; Pancreatitis, Chronic; Protein Serine-Threonine Kinases; Risk Factors; RNA, Small Interfering; Sulfones | 2018 |
Immune checkpoint inhibitors for urothelial carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Nivolumab; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2018 |
SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Liver Neoplasms; Methotrexate; Nivolumab; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2019 |
The management of pseudomyogenic hemangioendothelioma of the foot: A case report and review of the literature.
Topics: Adolescent; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy; Deoxycytidine; Foot; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Soft Tissue Neoplasms; Treatment Outcome | 2018 |
Factors potentially associated with gemcitabine-based chemotherapy-induced thrombocytopenia in Chinese patients with nonsmall cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Medical Records; Middle Aged; Neoplasm Staging; Risk Factors; Thrombocytopenia; Treatment Outcome | 2018 |
Different Chemotherapy Regimens in the Management of Advanced or Metastatic Urothelial Cancer: a Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Blood Platelet Disorders; Cisplatin; Databases, Factual; Deoxycytidine; Disease-Free Survival; Doxorubicin; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Urologic Neoplasms | 2018 |
Chemotherapy in Pancreatic Cancer: A Systematic Review.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Progression-Free Survival; Randomized Controlled Trials as Topic | 2018 |
Targeting phosphoinositide-3-kinase pathway in biliary tract cancers: A remedial route?
Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; Gemcitabine; Humans; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Signal Transduction | 2019 |
Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Tumor Burden | 2019 |
The clinical value of using chloroquine or hydroxychloroquine as autophagy inhibitors in the treatment of cancers: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Dacarbazine; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Hydroxychloroquine; Neoplasms; Risk; Temozolomide; Treatment Outcome | 2018 |
Necitumumab for the treatment of advanced non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms | 2019 |
Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.
Topics: Alemtuzumab; Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Deoxycytidine; Folic Acid Antagonists; Gemcitabine; Humans; Mycosis Fungoides; Retreatment; Sezary Syndrome; Skin Neoplasms | 2018 |
Selecting chemotherapy for pancreatic cancer: Far away or so close?
Topics: Albumins; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Margins of Excision; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2019 |
Neoadjuvant Treatment for Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms | 2019 |
Systemic treatment of pancreatic cancer revisited.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2019 |
Managing the economic impact of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost Control; Cost-Benefit Analysis; Deoxycytidine; Early Detection of Cancer; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Microsatellite Instability; Oxaliplatin; Pancreatic Neoplasms; Terminal Care | 2019 |
Nowadays pancreatic cancer prognosis.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Diabetes Mellitus; Diet; Drug Resistance, Neoplasm; Early Detection of Cancer; Fluorouracil; Gemcitabine; Genetic Predisposition to Disease; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Metastasis; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Radiosurgery; Risk Factors; Spain | 2019 |
Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Oxaliplatin; Practice Guidelines as Topic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Retrospective Studies | 2019 |
RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Biological Availability; Cytidine; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Patient Selection | 2019 |
Medical treatment for cholangiocarcinoma.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Hepatocyte Growth Factor; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Isocitrate Dehydrogenase; Molecular Targeted Therapy; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-met; Randomized Controlled Trials as Topic; Receptors, Fibroblast Growth Factor | 2019 |
Pancreatic Ductal Adenocarcinoma Derived From an Intraductal Papillary Neoplasm With Synchronous Incidental Glucagonoma: A Case Report and Literature Review.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Glucagonoma; Humans; Incidental Findings; Male; Middle Aged; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Treatment Outcome | 2019 |
Adjuvant treatment of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Pancreatic Neoplasms | 2019 |
Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Observational Studies as Topic; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Uterine Neoplasms | 2019 |
Small Molecular Gemcitabine Prodrugs for Cancer Therapy.
Topics: Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Prodrugs | 2020 |
Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Histone Deacetylases; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; RNA, Untranslated; Signal Transduction; Tumor Microenvironment | 2019 |
Population pharmacokinetics and exposure-overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Quinolines; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2019 |
Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Eligibility Determination; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2019 |
Chemoresistance in Pancreatic Cancer.
Topics: Animals; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genome; Humans; Pancreatic Neoplasms; Treatment Outcome; Tumor Microenvironment | 2019 |
Pharmacotherapeutic options for biliary tract cancer: current standard of care and new perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Neoplasm Staging; Receptor, Fibroblast Growth Factor, Type 2 | 2019 |
Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Gemcitabine: A Review of Chemoresistance in Pancreatic Cancer.
Topics: Albumin-Bound Paclitaxel; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome | 2019 |
Gemcitabine-induced pseudocellulitis: a case report and review of the literature.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms | 2019 |
Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Invasiveness; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Combination Intravesical Therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Humans; Neoplasm Invasiveness; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
[New progress in the treatment of locally advance pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2019 |
[Adjuvant treatment of biliary tract cancers: Who and how?]
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Intention to Treat Analysis; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Precision medicine for ovarian clear cell carcinoma based on gene alterations.
Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Dosage; Glutathione; Humans; Molecular Targeted Therapy; Mutation; Ovarian Neoplasms; Precision Medicine; Transcription Factors | 2020 |
Malignant mesothelioma of the tunica vaginalis testis: a rare case and review of literature.
Topics: Aged; Antineoplastic Agents; Biopsy; Cisplatin; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Lymphadenopathy; Male; Mesothelioma; Mesothelioma, Malignant; Orchiectomy; Pemetrexed; Prognosis; Testicular Hydrocele; Testicular Neoplasms | 2020 |
Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.
Topics: Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Pancreatic Neoplasms; Prospective Studies; Radiosurgery; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
Developing effective combination therapy for pancreatic cancer: An overview.
Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; DNA Damage; Gemcitabine; Histones; Humans; Pancreatic Neoplasms; Proteins | 2020 |
Successful surgical treatment of cardiac metastasis from uterine leiomyosarcoma: A case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Heart Neoplasms; Humans; Hysterectomy; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Uterine Neoplasms | 2020 |
Complete regression of pulmonary squamous carcinoma in IPF following gemcitabine plus cisplatin: a case report and literature review.
Topics: Aged; Antineoplastic Agents; Bronchoscopy; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Idiopathic Pulmonary Fibrosis; Lung Neoplasms; Male; Mycobacterium tuberculosis; Tomography, X-Ray Computed; Treatment Outcome; Tuberculosis, Pulmonary | 2020 |
Considering gemcitabine-based combination chemotherapy as a potential treatment for advanced oesophageal cancer: A meta-analysis of randomised trials.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Primary transitional cell carcinoma of the fallopian tube: A case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Hysterectomy; Magnetic Resonance Imaging; Neoplasm Recurrence, Local; Palliative Care; Salpingo-oophorectomy | 2020 |
NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Chemoablation in Urothelial Carcinoma: A Systematic Review and Future Perspectives.
Topics: Administration, Intravesical; Antineoplastic Agents; Aziridines; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Cystoscopy; Deoxycytidine; Epirubicin; Ethanol; Forecasting; Gemcitabine; Humans; Indolequinones; Injections, Intralesional; Interferon-alpha; Interleukin-2; Mitomycin; Urinary Bladder Neoplasms; Urothelium | 2020 |
Adjuvant chemotherapy in pancreatic cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Multicenter Studies as Topic; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Tegafur | 2020 |
Second-line treatment for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Efficacy and safety of gemcitabine plus capecitabine in the treatment of advanced or metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Giant paratesticular liposarcoma with lung metastases: a case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Humans; Liposarcoma; Lung Neoplasms; Male; Orchiectomy; Testicular Neoplasms | 2020 |
Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature.
Topics: Adult; Albumins; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Complement Inactivating Agents; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Thrombotic Microangiopathies | 2020 |
Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Oxaliplatin; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2020 |
Comparison between Fluoropyrimidine-Cisplatin and Gemcitabine-Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2020 |
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with oth
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Survival Analysis; Treatment Outcome | 2020 |
Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Mitomycin; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2020 |
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Molecular Targeted Therapy; Mutation; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Survival Rate; Treatment Outcome; Tumor Microenvironment | 2020 |
Systemic treatment options for advanced biliary tract carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Molecular Targeted Therapy; Mutation; Prognosis | 2020 |
Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma: a case report and literature review.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Nivolumab; Treatment Outcome | 2020 |
Contemporary management of pancreas cancer in older people.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Enhanced Recovery After Surgery; Fluorouracil; Gemcitabine; Geriatric Assessment; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2021 |
The Emerging Role of MicroRNAs in Regulating the Drug Response of Cholangiocarcinoma.
Topics: Apoptosis; Biomarkers, Pharmacological; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs | 2020 |
Adjuvant and neoadjuvant therapy for biliary tract cancer: a review of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Tegafur | 2020 |
Intracellular Pharmacokinetics of Pyrimidine Analogues used in Oncology and the Correlation with Drug Action.
Topics: Cytarabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasms; Phosphorylation; Prodrugs; Pyrimidines | 2020 |
Efficacy and safety of systemic induction therapy in initially unresectable locally advanced intrahepatic and perihilar cholangiocarcinoma: A systematic review.
Topics: Aged; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Klatskin Tumor; Male; Middle Aged; Treatment Outcome | 2020 |
Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Tumor Suppressor Protein p53 | 2020 |
Recent advances and prospects in gemcitabine drug delivery systems.
Topics: Antineoplastic Agents; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Gold; Metal Nanoparticles; Nanoparticles | 2021 |
Adrenocortical carcinoma: current treatment options.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Mitotane; Randomized Controlled Trials as Topic | 2021 |
The Application of Exosomal MicroRNAs in the Treatment of Pancreatic Cancer and Its Research Progress.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Genetic Therapy; Humans; MicroRNAs; Pancreatic Neoplasms | 2021 |
Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy.
Topics: Animals; Cell-Penetrating Peptides; Deoxycytidine; Gemcitabine; Humans; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Peptides | 2021 |
Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials.
Topics: Biliary Tract Neoplasms; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Molecular Targeted Therapy | 2021 |
Biliary cancer: gateway to comprehensive molecular profiling.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Leucovorin; Mutation; Oncogene Proteins, Fusion; Organoplatinum Compounds; Survival Rate | 2021 |
SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020).
Topics: Antineoplastic Agents; Asbestos; Carcinogens; Combined Modality Therapy; Cytoreduction Surgical Procedures; Deoxycytidine; Gemcitabine; Genetic Testing; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Medical Oncology; Mesothelioma, Malignant; Neoplasm Staging; Pemetrexed; Platinum Compounds; Pleural Neoplasms; Radiotherapy; Societies, Medical; Spain; Vinorelbine | 2021 |
Gemcitabine-induced dilated-cardiomyopathy in patient with platinum-refractory ovarian-cancer: A case report and literature review.
Topics: Adult; Cardiomyopathy, Dilated; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Stroke Volume; Ventricular Function, Left | 2021 |
First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!"
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Neoplasm Staging; Progression-Free Survival; Randomized Controlled Trials as Topic | 2021 |
Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Review Literature as Topic; Standard of Care | 2021 |
The use of frailty assessments in treating older adults with aggressive lymphomas.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Disease Management; Doxorubicin; Frailty; Gemcitabine; Geriatric Assessment; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Prednisone; Prognosis; Rituximab; Vincristine | 2021 |
The systemic treatment of uterine leiomyosarcomas: A systematic review. No news is good news?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunotherapy; Leiomyosarcoma; Molecular Targeted Therapy; Treatment Outcome; Uterine Neoplasms | 2021 |
Treatment landscape of metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Multidisciplinary management of locally advanced pancreatic adenocarcinoma: Biology is King.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease Management; Evidence-Based Medicine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Precision Medicine | 2021 |
Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
The efficacy and safety of gemcitabine-based induction chemotherapy for locally advanced nasopharyngeal carcinoma treated with concurrent chemoradiation: A meta-analysis.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Case-Control Studies; Chemoradiotherapy; China; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Observational Studies as Topic; Progression-Free Survival; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2021 |
Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Delayed Gemcitabine-Induced Posterior Reversible Encephalopathy Syndrome.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Middle Aged; Posterior Leukoencephalopathy Syndrome; Time Factors | 2021 |
Paraspinal radiation recall myositis after gemcitabine for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Myositis; Paclitaxel; Pancreatic Neoplasms | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; BCG Vaccine; Bias; Cause of Death; Confidence Intervals; Deoxycytidine; Disease Progression; Drug Administration Schedule; Gemcitabine; Humans; Mitomycin; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic; Saline Solution; Urinary Bladder Neoplasms | 2021 |
Nephron-sparing management of upper tract urothelial carcinoma.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Mitomycin; Neoplasm Staging; Nephrectomy; Nephrons; Organ Sparing Treatments; Ureteral Neoplasms; Ureteroscopy | 2021 |
The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Publication Bias; Treatment Outcome | 2021 |
Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions.
Topics: Animals; Antimetabolites, Antineoplastic; Bacteria; Carcinogenesis; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Oncolytic Viruses; Pancreatic Neoplasms | 2021 |
Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Nasopharyngeal Neoplasms | 2022 |
A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Aidi injection as adjunctive treatment to gemcitabine-based chemotherapy for advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Humans; Lung Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Encouraging long-term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for high-risk patients with resectable pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Deoxycytidine; Female; Gemcitabine; Humans; Hydroxychloroquine; Male; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival; Risk Factors; Survival Analysis; Survivors | 2021 |
Pharmacoethnicity of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Ethnicity; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Ferroptosis; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase; Reactive Oxygen Species; Signal Transduction | 2021 |
Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Comparative Effectiveness Research; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Outcome Assessment, Health Care; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Loss of adipose tissue or skeletal muscle during first-line gemcitabine/nab-paclitaxel therapy is associated with worse survival after second-line therapy of advanced pancreatic cancer.
Topics: Adipose Tissue; Albumins; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Cachexia; Deoxycytidine; Gemcitabine; Humans; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms | 2022 |
Two Possible Strategies for Drug Modification of Gemcitabine and Future Contributions to Personalized Medicine.
Topics: Antineoplastic Agents; Cell-Penetrating Peptides; Deoxycytidine; Drug Repositioning; Gemcitabine; Humans; Molecular Structure; Phosphorylation; Precision Medicine | 2022 |
Efficacy and safety of gemcitabine-capecitabine combination therapy for pancreatic cancer: A systematic review and meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Comparative Effectiveness Research; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Pyridines; Survival Rate; Tegafur; Treatment Outcome | 2022 |
Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Randomized Controlled Trials as Topic | 2022 |
Recent Development of Prodrugs of Gemcitabine.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Prodrugs | 2022 |
Systematic Evaluation Meta-Analysis of the Efficacy of Recombinant Human Endostatin Combined with Gemcitabine and Cisplatin in Non-Small-Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Endostatins; Gemcitabine; Humans; Lung Neoplasms | 2022 |
Efficacy and safety of FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine-based therapy: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2022 |
Efficacy and safety of neoadjuvant Folfirinox and Gemcitabine plus Nab-Paclitaxel for borderline resectable and locally advanced pancreatic cancer: a systematic review and meta-analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
Pancreatic Adenocarcinoma Management.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2022 |
Barriers and opportunities for gemcitabine in pancreatic cancer therapy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Effect of intravesical mitomycin compared with gemcitabine on the treatment non-muscle invasive bladder cancer: A meta-analysis.
Topics: Administration, Intravesical; Cystitis; Deoxycytidine; Gemcitabine; Hematuria; Humans; Mitomycin; Non-Muscle Invasive Bladder Neoplasms; Urinary Bladder Neoplasms | 2023 |
Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Conversion therapy for advanced intrahepatic cholangiocarcinoma with lenvatinib and pembrolizumab combined with gemcitabine plus cisplatin: A case report and literature review.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged | 2022 |
[A Case of Pathological Complete Response Induced by Preoperative Gemcitabine plus S-1 with Concurrent Radiation Therapy Followed by Gemcitabine plus S-1 Therapy in Borderline Resectable Pancreatic Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms | 2023 |
Recent developments in perioperative combination therapy in muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Urinary Bladder Neoplasms | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
Chemotherapy-Induced Pseudocellulitis Without Prior Radiation Exposure: A Systematic Review.
Topics: Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male | 2023 |
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
Liposomal nanostructures for Gemcitabine and Paclitaxel delivery in pancreatic cancer.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liposomes; Nanostructures; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Durvalumab: A Review in Advanced Biliary Tract Cancer.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Treatment Outcome | 2023 |
3021 trial(s) available for gemcitabine and deoxycytidine
| Article | Year |
|---|---|
Difluorodeoxycytidine (dFdC)--gemcitabine: a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms | 1992 |
Phase II study of gemcitabine in advanced colorectal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged | 1992 |
Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Evaluation; Gemcitabine; Humans; Leukemia; Middle Aged | 1992 |
Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Evaluation; Gemcitabine; Humans; Leukocytes, Mononuclear; Neoplasms | 1991 |
A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Evaluation; Gemcitabine; Half-Life; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasms | 1991 |
Advanced breast cancer: a phase II trial with gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Remission Induction; Vomiting | 1995 |
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate | 1994 |
Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms | 1994 |
A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group.
Topics: Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Carcinoma, Squamous Cell; Deoxycytidine; Europe; Fatigue; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Liver; Male; Middle Aged; Neutropenia; Remission Induction | 1994 |
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Survival Analysis; Treatment Outcome | 1994 |
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Evaluation; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Pancreatic Neoplasms | 1994 |
Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1994 |
Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Europe; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Neutropenia; Stomach Neoplasms | 1994 |
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Remission Induction; Survival Rate; Vomiting | 1994 |
Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 1994 |
Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC). A study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1994 |
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Male; Middle Aged; Neoplasms | 1994 |
Phase II trial of gemcitabine in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Remission Induction; Stomach Neoplasms | 1994 |
Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local | 1993 |
Phase II study of gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1996 |
Gemcitabine: a phase II study in patients with advanced renal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged | 1996 |
Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Theoretical | 1996 |
Maculopapular rashes secondary to gemcitabine injection for non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Parapsoriasis | 1996 |
Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Time Factors | 1996 |
[LY188011 phase I study. Research Group of Gemcitabine (LY188011)].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Bone Marrow; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fever; Gastrointestinal Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Nausea; Vomiting | 1996 |
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Middle Aged | 1996 |
Phase I trial of gemcitabine and cisplatin in advanced non-small cell lung cancer: a preliminary report.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis | 1996 |
Economic value of gemcitabine compared to cisplatin and etoposide in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost Savings; Deoxycytidine; Direct Service Costs; Drug Costs; Etoposide; Female; Gemcitabine; Health Services Research; Hospital Costs; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Models, Economic; Monte Carlo Method; Oncology Service, Hospital; Sensitivity and Specificity; United States | 1996 |
Combination chemotherapy with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results of an ongoing phase I/II study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1995 |
Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Platinum Compounds; Survival Rate; Time Factors | 1995 |
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Body Weight; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Retreatment; Survival Rate; Treatment Outcome | 1996 |
[A late phase II study of LY188011 (Gemcitabine hydrochloride) in patients with non-small-cell lung cancer. Gemcitabine Cooperative Study Group B for Late Phase II].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hemoglobins; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Vomiting | 1996 |
Phase I/II study of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer: preliminary results.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
A phase I study of gemcitabine and carboplatin in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1996 |
Phase II activity of gemcitabine in advanced breast cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged | 1996 |
Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Platinum; Treatment Outcome | 1996 |
[An early phase II study of gemcitabine hydrochloride (LY 188011). Gemcitabine Cooperative Study Group for Early Phase II].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Stomach Neoplasms; Uterine Cervical Neoplasms | 1996 |
[Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Fever; Gemcitabine; Hemoglobins; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Vomiting | 1996 |
Objective outcome measures of quality of life.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Pain; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 1996 |
Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prospective Studies | 1997 |
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 1997 |
Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia | 1997 |
Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Treatment Outcome | 1997 |
Phase II studies of gemcitabine for non-small cell lung cancer in Japan.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Japan; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases | 1997 |
Single-agent gemcitabine in non-small cell lung cancer: the French experience.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases; Survival Rate | 1997 |
Phase I studies of gemcitabine combined with carboplatin or paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Ovarian Neoplasms; Paclitaxel; Ribonucleotide Reductases | 1997 |
Gemcitabine and etoposide in small cell lung cancer: phase I and II trials.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases | 1997 |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps; Male; Middle Aged; Morphine; Narcotics; Pain; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 1997 |
A randomized study of gemcitabine monotherapy versus etoposide/cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Ribonucleotide Reductases; Treatment Outcome; Vomiting | 1997 |
Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma.
Topics: Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 1997 |
Phase II trial of gemcitabine plus cisplatin in non-small cell lung cancer: a Hoosier Oncology Group study.
Topics: Adult; Aged; Agranulocytosis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Eruptions; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ribonucleotide Reductases; Thrombocytopenia; Treatment Outcome | 1997 |
Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mitomycin; Ribonucleotide Reductases | 1997 |
A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ribonucleotide Reductases; Treatment Outcome | 1997 |
Gemcitabine plus radiotherapy for non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Ribonucleotide Reductases | 1997 |
[A phase II multicenter study of gemcitabine in non small cell lung cancers].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 1997 |
Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 1997 |
Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis | 1997 |
Activity of gemcitabine in the treatment of patients with non-small cell lung cancer: a multicenter phase II study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Survival Rate; Thrombocytopenia; Treatment Outcome | 1997 |
Phase II study of weekly gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 1997 |
Second-line treatment of advanced non-small cell lung cancer with paclitaxel and gemcitabine: a preliminary report on an active regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Salvage Therapy; Survival Analysis | 1997 |
Phase II trial of gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Austria; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Treatment Outcome | 1997 |
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids | 1997 |
Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 1997 |
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms | 1997 |
Phase I study of gemcitabine using a once every 2 weeks schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged | 1997 |
Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Vinblastine; Vinorelbine | 1997 |
Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Immunosuppression Therapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel | 1997 |
Clinical response benefit in patients with advanced pancreatic cancer. Role of gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 1997 |
Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1998 |
Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 1998 |
A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Blood Cell Count; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pancreatic Neoplasms; Survival Analysis | 1997 |
Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Treatment Outcome | 1998 |
Mechanisms of synergism between gemcitabine and cisplatin.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; RNA, Neoplasm; Tumor Cells, Cultured | 1998 |
A phase II study of a novel gemcitabine plus cisplatin regimen administered every three weeks for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 1998 |
Advances in the treatment of patients with pancreatic cancer: improvement in symptoms and survival time. The San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Male; Pancreatic Neoplasms; Pemetrexed | 1998 |
Single-agent gemcitabine versus cisplatin/etoposide in patients with inoperable, locally advanced, or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1998 |
Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1998 |
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel | 1998 |
Adjuvant therapy for pancreatic cancer: back to the future.
Topics: Antimetabolites, Antineoplastic; Clinical Protocols; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiotherapy Dosage | 1998 |
Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Treatment Outcome | 1998 |
Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis | 1998 |
Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Gemcitabine; Humans; Injections, Intravenous; Middle Aged; Neoplasm Staging | 1998 |
A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer.
Topics: Adult; Aged; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Influenza, Human; Infusions, Intravenous; Male; Middle Aged; Treatment Outcome; Urologic Neoplasms | 1998 |
Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1998 |
A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fever; Gemcitabine; Humans; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Quality of Life; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 1998 |
Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bone Marrow Diseases; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Treatment Outcome | 1998 |
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Mycosis Fungoides; Neutropenia; PUVA Therapy; Remission Induction; Safety; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 1998 |
Phase II trial assessing the combination of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life | 1998 |
Vinorelbine/gemcitabine in advanced non-small cell lung cancer (NSCLC): a phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 1998 |
A phase I study of gemcitabine/cisplatin/etoposide in the treatment of small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1998 |
Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 1998 |
Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Vindesine | 1999 |
Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Paclitaxel; Survival Analysis; Taxoids | 1999 |
Phase I-II study of gemcitabine and carboplatin in stage IIIB-IV non-small-cell lung cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Thrombocytopenia | 1999 |
Phase II trial of gemcitabine in refractory germ cell tumors.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Germinoma; Humans; Male; Middle Aged; Ovarian Neoplasms; Testicular Neoplasms | 1999 |
Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Germinoma; Humans; Infusions, Intravenous; Male; Middle Aged; Testicular Neoplasms | 1999 |
Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms | 1999 |
Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Greek Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Taxoids | 1999 |
Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1999 |
A phase II study with vinorelbine, gemcitabine and cisplatin in the treatment of patients with stage IIIb-IV non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 1999 |
A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Pancreatic Neoplasms; Patient Selection; Quality of Life; Survival Analysis; Tomography, X-Ray Computed | 1999 |
Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Survival Analysis; Treatment Outcome | 1999 |
Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Quality of Life; Treatment Outcome | 1999 |
Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quality of Life; Vinblastine; Vindesine; Vinorelbine | 1999 |
Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Deoxycytidine; DNA Adducts; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukocytes; Linear Models; Male; Middle Aged; Neoplasms; Statistics, Nonparametric; Treatment Outcome | 1999 |
Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Greece; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate | 1999 |
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Survival Analysis; Treatment Outcome | 1999 |
[Phase II studies of gemcitabine for non-small cell lung cancer in Japan].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged | 1999 |
[Gemcitabine in the treatment of non-small cell lung cancer for elderly patients].
Topics: Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Evaluation; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Nausea; Survival Rate; Vomiting, Anticipatory | 1999 |
[Phase I study of gemcitabine hydrochloride (LY 188011) combination therapy with cisplatin in the patients with non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Vomiting, Anticipatory | 1999 |
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 1999 |
Gemcitabine and UFT plus oral calcium folinate: phase I study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; DNA, Neoplasm; Drug Administration Routes; Female; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Ribonucleotide Reductases; Tegafur; Treatment Outcome; Uracil | 1999 |
A dose and schedule finding study of gemcitabine and etoposide in patients with progressive non-small cell lung cancer after platinum containing chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nucleic Acid Synthesis Inhibitors; Platinum Compounds; Salvage Therapy; Survival Rate | 1999 |
Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Rate | 1999 |
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Survival Rate; Tomography, X-Ray Computed | 1999 |
Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Survival Rate; Time Factors | 1999 |
Phase II study of gemcitabine in ovarian cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Quality of Life | 1999 |
Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis | 1999 |
Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Dyspnea; Fatal Outcome; Gemcitabine; Humans; Lung; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Severity of Illness Index; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 1999 |
Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine | 1999 |
Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin. Oncopaz Cooperative Group.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Contraindications; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Peripheral Nervous System Diseases; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
Treatment of locally advanced pancreatic carcinoma in Sweden. A health economic comparison of palliative treatment with best supportive care versus palliative treatment with gemcitabine in combination with best supportive care.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Sweden | 1999 |
Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ifosfamide; Italy; Lung Neoplasms; Male; Middle Aged; Mitomycin; Quality of Life; Sample Size; Survival Rate | 1999 |
Phase I trial dosing of gemcitabine and concurrent involved field irradiation in patients with localized pancreatic carcinomas.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Administration Schedule; Gemcitabine; Humans; Pancreatic Neoplasms | 1999 |
Is there any impact of new drugs on the outcome of advanced NSCLC? An overview of the Southern Italy Cooperative Oncology Group trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 1999 |
Leucovorin, 5-fluorouracil, and gemcitabine: a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Time Factors; Treatment Outcome | 1999 |
Single-agent gemcitabine in pretreated patients with non-small-cell lung cancer: results of an Argentinean multicentre phase II trial.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 1999 |
Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: A phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Analysis | 1999 |
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cells, Cultured; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; In Vitro Techniques; Infusions, Intravenous; Leukocytes, Mononuclear; Linear Models; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Statistics, Nonparametric | 1999 |
Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms | 1999 |
Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Vomiting | 1999 |
Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Thrombocytopenia; Ureteral Neoplasms; Urinary Bladder Neoplasms | 1999 |
Single-agent gemcitabine: an active and better tolerated alternative to standard cisplatin-based chemotherapy in locally advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1999 |
Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Time Factors | 1999 |
Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Time Factors; Vinblastine; Vinorelbine | 1999 |
Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Professional Staff Committees; Treatment Outcome | 1999 |
Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 1999 |
Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Treatment Outcome | 1999 |
Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 1999 |
A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a hoosier oncology group study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Enzyme Inhibitors; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neutropenia; Remission Induction; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia | 1999 |
A phase I trial of MTA and gemcitabine in patients with locally advanced or metastatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gallbladder Neoplasms; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Pemetrexed | 1999 |
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome | 2000 |
A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Uterine Cervical Neoplasms | 2000 |
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Survival Analysis; Time Factors | 2000 |
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Severity of Illness Index; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: a Phase II study of the gynecologic oncology group.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Uterine Cervical Neoplasms | 2000 |
Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Urologic Neoplasms | 1999 |
Gemcitabine-cisplatin: a schedule finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Leukopenia; Linear Models; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Thrombocytopenia | 1999 |
Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: a phase II study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pleural Effusion, Malignant; Remission Induction; Survival Rate; Thrombocytopenia; Vinblastine; Vinorelbine | 2000 |
Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: a phase II study.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2000 |
Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer (NSCLC) cisplatin failures: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pilot Projects; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Topics: Aged; Agranulocytosis; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Male; Middle Aged; Nausea; Paclitaxel; Remission Induction; Urologic Neoplasms; Vomiting | 2000 |
Ifosfamide, vinorelbine and gemcitabine in advanced non-small cell lung cancer. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 1999 |
A phase I trial of gemcitabine and infusional 5-fluorouracil (5-FU) in patients with refractory solid tumors: Louisiana Oncology Associates protocol no. 1 (LOA-1).
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 2000 |
Gemcitabine monotherapy in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Survival Analysis; Treatment Outcome | 2000 |
A dose-finding study of gemcitabine and vinorelbine in advanced previously treated malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Platelet Count; Vinblastine; Vinorelbine | 2000 |
A phase I-II study of gemcitabine and paclitaxel in advanced non-small-cell lung cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel | 2000 |
Combination chemotherapy with paclitaxel plus carboplatin versus paclitaxel plus gemcitabine in inoperable non-small cell lung cancer: a phase III randomized study. Preliminary results. Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2000 |
Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin in the treatment of patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis | 2000 |
The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Tomography, Emission-Computed | 2000 |
Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction | 2000 |
Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: a preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2000 |
Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Costs and Cost Analysis; Deoxycytidine; Etoposide; Female; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Randomized Controlled Trials as Topic | 2000 |
Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung carcinoma patients: a minnie pearl cancer research network phase II trial.
Topics: Actuarial Analysis; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Fever; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Platinum Compounds; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia; Vinblastine; Vinorelbine | 2000 |
Activity of high-dose epirubicin combined with gemcitabine in advanced non-small-cell lung cancer: a multicenter phase I and II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Quality of Life | 2000 |
Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
A sensitive docetaxel assay in plasma by solid-phase extraction and high performance liquid chromatography-UV detection: validation and suitability in phase I clinical trial pharmacokinetics.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calibration; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Methotrexate; Paclitaxel; Reproducibility of Results; Solvents; Spectrophotometry, Ultraviolet; Taxoids | 1999 |
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Hormones; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pain Measurement; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 2000 |
Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasms; Pemetrexed; Tumor Cells, Cultured | 2000 |
A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; New England; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2000 |
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2000 |
Monthly gemcitabine (days 1, 8 and 15) plus cisplatin (days 1-3) in advanced non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Israel; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2000 |
NCIC-CTG phase II study of gemcitabine in patients with malignant glioma (IND.94).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Deoxycytidine; Female; Gemcitabine; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Steroids | 2000 |
Weekly docetaxel plus gemcitabine or vinorelbine in refractory advanced breast cancer patients: a parallel dose-finding study. Southern Italy Cooperative Oncology Group (SICOG).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Taxoids; Treatment Failure; Vinblastine; Vinorelbine | 2000 |
Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms | 2000 |
Gemcitabine plus cisplatin for advanced transitional cell carcinoma of the urinary tract: a phase II multicenter trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Urologic Neoplasms | 2000 |
A phase I trial of docetaxel and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2000 |
Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Treatment Outcome | 2000 |
A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Palliative Care; Vinblastine; Vinorelbine | 2000 |
A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2000 |
Gemcitabine is ineffective in recurrent, preirradiated cervical cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Uterine Cervical Neoplasms | 2000 |
A phase II trial testing gemcitabine as second-line chemotherapy for non small cell lung cancer. The European Lung Cancer Working Party. 101473.1044@compuserve.com.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Analysis; Treatment Outcome | 2000 |
Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Lymphangioma; Middle Aged | 1999 |
Gemcitabine plus vinorelbine versus vinorelbine alone in elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2000 |
Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Survival Rate | 2000 |
Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms; Survival Rate | 2000 |
Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged | 2000 |
Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 2000 |
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
Topics: Aged; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bilirubin; Creatinine; Deoxycytidine; Female; Gemcitabine; Humans; Liver Diseases; Liver Function Tests; Male; Middle Aged; Models, Biological; Neoplasms; Renal Insufficiency | 2000 |
Carboplatin-gemcitabine treatment of patients with transitional cell carcinoma of the bladder and impaired renal function.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Diseases; Male; Middle Aged; Survival Analysis; Urinary Bladder Neoplasms | 2000 |
Gemcitabine for relapsed or resistant lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Treatment Outcome | 2000 |
A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Treatment Outcome | 2000 |
Exploring sequenced chemotherapy regimens in the treatment of transitional cell carcinoma of the urothelial tract.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Ifosfamide; Methotrexate; Paclitaxel; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2000 |
A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Schistosomiasis; Treatment Outcome; Urinary Bladder Neoplasms | 2000 |
Phase II trial of gemcitabine in patients with pretreated advanced soft tissue sarcomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Female; Gemcitabine; Humans; Ifosfamide; Infusions, Intravenous; Male; Middle Aged; Prospective Studies; Safety; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 2000 |
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Patient Compliance; Survival Rate; Taxoids | 2000 |
Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Taxoids | 2000 |
A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Prospective Studies; Survival Analysis | 2000 |
Gemcitabine plus vinorelbine in elderly or unfit patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Patient Compliance; Quality of Life; Survival Analysis | 2000 |
Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2000 |
Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine | 2000 |
Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Gem Vin Investigators.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Phase I study of paclitaxel and day 1/day 8 gemcitabine in patients with solid malignancies.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Deoxycytidine; Diarrhea; Esophageal Neoplasms; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neoplasms, Unknown Primary; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Paresthesia; Urinary Bladder Neoplasms; Vomiting | 2000 |
Gemcitabine, paclitaxel, and carboplatin for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukocyte Count; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Platelet Count | 2000 |
Interim analysis of a phase III trial. Triple- vs double-agent chemotherapy for advanced non-small-cell lung cancer. Southern Italy Cooperative Oncology Group.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Patient Compliance; Proportional Hazards Models; Research Design; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
Interim results of a phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Gemcitabine/Alimta in locally advanced or metastatic non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Staging; Neutropenia; Pemetrexed | 2000 |
Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Evaluation; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Neutropenia; Recurrence; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2000 |
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Analysis; Urologic Neoplasms | 2000 |
Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2000 |
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Vinblastine; Vinorelbine | 2000 |
A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia | 2000 |
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hospitalization; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Quality of Life; Survival Analysis; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Phase I dose escalation study of gemcitabine and paclitaxel plus colony-stimulating factors in previously treated patients with advanced breast and ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Thrombocytopenia | 2000 |
Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Survival Analysis | 2000 |
Vinorelbine-gemcitabine in advanced non-small-cell lung cancer (NSCLC): an AASLC phase II trial. Austrian Association for the Study of Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2000 |
A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 2000 |
Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis | 2000 |
Phase II study of gemcitabine in combination with cisplatin in patients with locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2000 |
Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Allowable Concentration; Middle Aged; Paclitaxel; Pneumonia | 2000 |
Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasms; Neutropenia; Pyrazines; Quinolines; Thrombocytopenia; Vomiting | 2000 |
A phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2000 |
A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2000 |
Biliary tract cancer: our experience with gemcitabine treatment.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged | 2000 |
Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome; Vomiting | 2000 |
Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2000 |
Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIB-IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome | 2000 |
Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Male; Middle Aged; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Patient Acceptance of Health Care; Quality of Life; Survival Analysis; Treatment Outcome | 2000 |
Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fever; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Remission Induction; Survival Analysis; Treatment Outcome | 2000 |
Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Recurrence; Topotecan; Treatment Outcome | 2001 |
Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venous; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2001 |
Phase II study of regimen of gemcitabine and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis | 2000 |
Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Combined Modality Therapy; Cytosine Nucleotides; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy | 2001 |
Combined radiochemotherapy of locally advanced unresectable pancreatic adenocarcinoma with mitomycin C plus 24-hour continuous infusional gemcitabine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Mitomycin; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia | 2001 |
Preirradiation gemcitabine chemotherapy for newly diagnosed glioblastoma. A phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Deoxycytidine; Female; Gemcitabine; Glioblastoma; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Thrombocytopenia | 2001 |
Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
Options in advanced non-small cell lung cancer: a review and report on a phase II study of vinorelbine plus gemcitabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Induction chemotherapy followed by concomitant chemoradiotherapy for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Taxoids; Treatment Outcome | 2001 |
High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Epirubicin; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Paclitaxel; Survival Analysis; Thiotepa; Treatment Outcome | 2001 |
Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Female; Fever; Gemcitabine; Humans; Liposomes; Middle Aged; Neutropenia | 2001 |
Gemcitabine and paclitaxel as salvage therapy in metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2001 |
Gemcitabine plus cisplatin in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis | 2001 |
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Trastuzumab | 2001 |
The gemcitabine/epirubicin/paclitaxel trials in advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2001 |
Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heart; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Thrombocytopenia | 2001 |
Phase I trial of gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2001 |
Gemcitabine and vinorelbine as first-line chemotherapy for advanced non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome | 2001 |
Phase II trial of two-weekly gemcitabine in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2001 |
Gemcitabine for the treatment of non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Multicenter Studies as Topic; Treatment Outcome | 2001 |
Optimizing chemoradiation in locally advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2001 |
Treatment of classical Kaposi's sarcoma with gemcitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma, Kaposi; Skin Neoplasms | 2001 |
Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Life Tables; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Recombinant Proteins; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2001 |
Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Hyponatremia; Life Tables; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Staging; Nervous System Diseases; Neutropenia; Remission Induction; Survival Analysis; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2001 |
Treatment of refractory T-cell malignancies using gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukemia, Prolymphocytic; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Recurrence; Salvage Therapy; Treatment Outcome | 2001 |
Weekly cisplatin/low-dose gemcitabine combination for advanced and recurrent cervical carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Uterine Cervical Neoplasms | 2001 |
Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Patient Compliance; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Combined paclitaxel and gemcitabine as first-line treatment in metastatic non-small cell lung cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Peripheral Nervous System Diseases; Survival Analysis; Treatment Outcome | 2001 |
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2001 |
Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Palliative Care; Taxoids; Treatment Failure | 2001 |
Phase II study of concurrent gemcitabine and radiotherapy in locally advanced stage IIIB cervical carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Brachytherapy; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Radiation-Sensitizing Agents; Radiotherapy; Uterine Cervical Neoplasms | 2001 |
Phase III trial of cisplatin/gemcitabine with or without vinorelbine or paclitaxel in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2001 |
[Decline in the need for blood transfusions in cancer patients due to the use of epoietin alfa during cisplatin based chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Epoetin Alfa; Erythropoietin; Female; Gemcitabine; Hematinics; Humans; Male; Middle Aged; Neoplasms; Recombinant Proteins; Treatment Outcome | 2001 |
Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antimetabolites; Capillary Leak Syndrome; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Middle Aged; Myocardial Infarction; Pulmonary Veno-Occlusive Disease; Recurrence; Renal Insufficiency; Survival Rate; Thrombocytopenia; Time Factors | 2001 |
A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2001 |
Single-agent gemcitabine in patients with resistant small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2001 |
Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy | 2001 |
Gemcitabine in advanced pancreatic cancer: a phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Pancreatic Neoplasms | 2001 |
Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neoplasms, Unknown Primary; Salvage Therapy; Thrombocytopenia; Treatment Outcome | 2001 |
Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms; Urothelium | 2001 |
Single-agent gemcitabine is active in previously treated metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Remission Induction; Safety; Vomiting | 2001 |
Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Neutropenia; Thrombocytopenia | 2001 |
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2001 |
Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pilot Projects; Treatment Outcome | 2001 |
Gemcitabine modulation of alkylator therapy: a phase I trial of escalating gemcitabine added to fixed doses of ifosfamide and doxorubicin.
Topics: Adult; Aged; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Pelvic Neoplasms; Treatment Outcome; Urinary Bladder Neoplasms | 2001 |
A phase I-II trial of topotecan and gemcitabine in patients with previously treated, advanced non-small cell lung cancer (LOA-3).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
Combination of gemcitabine and cisplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies | 2001 |
A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Thrombocytopenia; Topotecan; Treatment Outcome | 2001 |
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Humans; Hydroxamic Acids; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2001 |
Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Leiomyosarcoma; Leukocytes, Mononuclear; Male; Middle Aged; Phosphates; Sarcoma; Soft Tissue Neoplasms | 2001 |
Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Treatment Outcome | 2001 |
Gemcitabine plus etoposide in chemonaive extensive disease small-cell lung cancer: a multi-centre phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2001 |
Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2001 |
Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2001 |
A prospective study of gemcitabine and carboplatin as first-line therapy in advanced non-small cell lung cancer: toxicity of a three- versus a four-week schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis | 2001 |
Gemcitabine/carboplatin versus cisplatin/etoposide for patients with poor-prognosis small cell lung cancer: a phase III randomized trial with quality-of-life evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis | 2001 |
Phase II study of gemcitabine, 5-fluorouracil, and leucovorin in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Survival Analysis | 2001 |
Gemcitabine/cyclophosphamide/5-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients: a Southern Italy Cooperative Oncology Group phase I/II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2001 |
A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy | 2001 |
Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: a phase II multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): a multicentre phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
Evaluation of gemcitabine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Southwest Oncology Group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Deoxycytidine; Drug Evaluation; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Ribonucleotide Reductases; Survival Rate | 2001 |
Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Vinblastine; Vinorelbine | 2001 |
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2001 |
Gemcitabine and vincristine: an effective outpatient regimen with low myelotoxicity for stage IV non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Thrombocytosis; Treatment Outcome; Vincristine | 2001 |
Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms | 2001 |
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Remission Induction | 2001 |
Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2001 |
A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2001 |
Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Tissue Distribution; Treatment Outcome | 2001 |
Clinical-benefit response in advanced non-small-cell lung cancer: A multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Treatment Outcome; Vindesine | 2001 |
Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Radiation therapy and concurrent fixed dose amifostine with escalating doses of twice-weekly gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Amifostine; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Radiation-Protective Agents; Radiation-Sensitizing Agents; Survival Analysis; Thrombocytopenia; Vomiting | 2001 |
Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Gemcitabine, Ifosfamide and Navelbine (GIN): activity and safety of a non-platinum-based triplet in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vinblastine; Vinorelbine | 2001 |
Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Thorax | 2001 |
A phase II study of induction chemotherapy with gemcitabine (G) and cisplatin (P) in locally advanced non-small cell lung cancer: interim analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2001 |
Comparison of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Taxoids | 2001 |
Activity of the combination of high-dose epirubicin with gemcitabine in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2001 |
Gemcitabine plus vinorelbine yields better survival outcome than vinorelbine alone in elderly patients with advanced non-small cell lung cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase III trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Quality of Life; Survival Analysis; Vinblastine; Vinorelbine | 2001 |
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma .
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Prognosis; Risk Factors; Severity of Illness Index; Survival Analysis; Taxoids | 2001 |
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2001 |
Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2001 |
A phase II study of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer: clinical outcomes and quality of life.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life | 2002 |
Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Platinum; Survival Analysis; Taxoids; Treatment Outcome | 2001 |
Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2001 |
A phase II study of gemcitabine in gallbladder carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Fever; Gallbladder Neoplasms; Gemcitabine; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Treatment Outcome | 2001 |
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Hematuria; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Urination Disorders; Urologic Neoplasms | 2001 |
Use of gemcitabine (GEM) in advanced myelodysplastic syndromes.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Myelodysplastic Syndromes; Survival Analysis; Treatment Outcome | 2001 |
Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Greece; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Vinblastine; Vinorelbine | 2002 |
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids | 2002 |
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Stomatitis; Treatment Outcome | 2002 |
Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Analysis | 2001 |
Gemcitabine, cisplatin, and radiation in advanced, unresectable squamous cell carcinoma of the head and neck: a feasibility study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Remission Induction; Survival Analysis | 2001 |
Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer.
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Menopause; Middle Aged; Vinblastine; Vinorelbine | 2001 |
Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Pain Measurement; Receptors, Estrogen; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
A phase I-II study on a gemcitabine-cyclophosphamide-fluorouracil/folinic acid triplet combination in anthracycline- and taxane-refractory breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Rate; Taxoids | 2002 |
Weekly administration of gemcitabine plus docetaxel in patients with advanced breast cancer: a phase 1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Outcome; World Health Organization | 2002 |
A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2002 |
Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; DNA; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male | 2002 |
Phase I evaluation of prolonged-infusion gemcitabine with mitoxantrone for relapsed or refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Mitoxantrone; Neural Tube Defects | 2002 |
Phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with inoperable non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Treatment Outcome | 2002 |
Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Middle Aged; Paclitaxel | 2001 |
[Results of phase II clinical trial of cycloplatam in refractory solid tumors].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Organoplatinum Compounds; Pleural Neoplasms; Pleurisy; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2001 |
Combination chemotherapy of carboplatin and gemcitabine against solid tumors: a phase I trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Hematologic Diseases; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Treatment Outcome | 2001 |
A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in non-small-cell lung cancer: 3-week schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Incidence; Japan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Survival Rate; Treatment Outcome | 2001 |
A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Recurrence; Survival Rate; Time Factors | 2002 |
Paclitaxel plus carboplatin, compared with paclitaxel plus gemcitabine, shows similar efficacy while more cost-effective: a randomized phase II study of combination chemotherapy against inoperable non-small-cell lung cancer previously untreated.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Time Factors | 2002 |
A phase II trial of weekly intravenous gemcitabine and cisplatin with continuous infusion fluorouracil in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2002 |
Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type.
Topics: Adult; Aged; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Survival Rate; Time Factors | 2002 |
Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Radiography; Safety; Survival Rate; Treatment Outcome | 2002 |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Sarcoma; Survival Analysis | 2002 |
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Survival Rate | 2002 |
Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urinary Bladder Neoplasms | 2002 |
Low morbidity of bronchoplastic procedures after chemotherapy for lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymph Node Excision; Male; Mediastinum; Middle Aged; Neoplasm Staging; Pneumonectomy; Prospective Studies; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2002 |
Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2002 |
Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life.
Topics: Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Prospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2002 |
Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Survival Rate; Treatment Outcome | 2002 |
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pyrroles; Thromboembolism; Treatment Outcome | 2002 |
Phase I/II trial of gemcitabine plus cyclophosphamide in patients with metastatic breast carcinoma previously treated with taxanes.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bilirubin; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Heart; Humans; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Treatment Outcome | 2000 |
Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prostatic Neoplasms | 2002 |
Phase I study of gemcitabine and liposomal doxorubicin in relapsed ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Hemoglobins; Humans; Infusions, Intravenous; Leukocytes; Liposomes; Middle Aged; Ovarian Neoplasms; Treatment Outcome | 2002 |
NSC-631570 (Ukrain) in the palliative treatment of pancreatic cancer. Results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Berberine Alkaloids; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Phenanthridines; Prospective Studies; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Germinoma; Humans; Infusions, Intravenous; Male; Ovarian Neoplasms; Paclitaxel; Seminoma; Testicular Neoplasms; Treatment Outcome; United States | 2002 |
Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2002 |
An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Taxoids | 2002 |
Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia | 2002 |
A Bayesian re-assessment of two Phase II trials of gemcitabine in metastatic nasopharyngeal cancer.
Topics: Antimetabolites, Antineoplastic; Bayes Theorem; Deoxycytidine; Gemcitabine; Humans; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2002 |
Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fever; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Platelet Count; Thrombocytopenia; Vomiting | 2002 |
Economic evaluation of gemcitabine alone and in combination with cisplatin in the treatment of nonsmall cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Gemcitabine; Humans; Lung Neoplasms; Treatment Outcome | 2002 |
The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: a Southwest Oncology Group study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local | 2002 |
Phase I/II study of gemcitabine plus vinorelbine in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Vinblastine; Vinorelbine | 2002 |
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Middle Aged; Nausea; Nervous System Diseases; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome | 2002 |
Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer.
Topics: Combined Modality Therapy; Deglutition; Deglutition Disorders; Deoxycytidine; Fluoroscopy; Gemcitabine; Head and Neck Neoplasms; Humans; Pneumonia, Aspiration; Prospective Studies; Radiation-Sensitizing Agents | 2002 |
First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Infections; Infusions, Intravenous; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Vomiting | 2002 |
Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Genes, erbB-2; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis; Trastuzumab; Treatment Failure; Treatment Outcome | 2002 |
Gemcitabine (GEM) and carboplatin (CBDCA) versus cisplatin (CDDP) and vinblastine (VLB) in advanced non-small-cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival; Treatment Outcome; Vinblastine | 2002 |
Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Leiomyosarcoma; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Thrombocytopenia; Treatment Outcome; Uterine Neoplasms | 2002 |
Chemotherapy with gemcitabine in patients with gall-bladder carcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoplasm Staging; Pilot Projects; Prognosis; Survival Analysis; Treatment Outcome | 2002 |
A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Palliative Care; Pancreatic Neoplasms; Radiotherapy, High-Energy; Treatment Outcome | 2002 |
A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fever; Gemcitabine; Hematologic Diseases; Humans; Kidney; Liver; Lung Neoplasms; Nausea; Neoplasm Staging; Tegafur; Uracil | 2002 |
Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network.
Topics: Actuarial Analysis; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Pilot Projects; Salvage Therapy; Treatment Outcome; Urologic Neoplasms | 2002 |
Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Deoxycytidine; Drug Administration Schedule; Esophagitis; Evaluation Studies as Topic; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukemia; Lymphoma; Male; Middle Aged; Nausea; Neutropenia; Recurrence; Stomatitis; Treatment Outcome; Vomiting | 2002 |
Early results of a randomized phase III trial of platinum-containing doublets versus a nonplatinum doublet in the treatment of advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer 08975.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quality of Life; Survival Rate | 2002 |
Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Survival Rate | 2002 |
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Hydroxamic Acids; Life Tables; Male; Matrix Metalloproteinase Inhibitors; Middle Aged; Musculoskeletal Diseases; Neoplasm Proteins; Pancreatic Neoplasms; Protease Inhibitors; Quality of Life; Safety; Survival Analysis | 2002 |
Irinotecan and gemcitabine in patients with solid tumors: phase I trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Maximum Tolerated Dose; Nausea; Neoplasms; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Vomiting | 2002 |
Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Irinotecan; Neutropenia; Pancreatic Neoplasms | 2002 |
Pilot study of gemcitabine (10 mg/m(2) per min) and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pilot Projects | 2002 |
Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Treatment Outcome | 2002 |
Phase II trial of gemcitabine in advanced sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Survival Rate | 2002 |
A dose finding study of carboplatin and gemcitabine in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2002 |
A three-arm phase III randomised trial comparing combinations of platinum derivatives, ifosfamide and/or gemcitabine in stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Belgium; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Probability; Reference Values; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Treatment Outcome | 2002 |
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biological Therapy; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Vinblastine; Vinorelbine | 2002 |
A phase I study of weekly gemcitabine and docetaxel in patients with advanced cancer: a Hoosier Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome | 2002 |
Incidental surgical findings of a phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with unresectable non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pneumonectomy; Radiotherapy Dosage; Treatment Outcome | 2002 |
Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2002 |
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2002 |
Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Life Tables; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome | 2002 |
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Area Under Curve; Biotransformation; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Drug Interactions; Female; Gemcitabine; Half-Life; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Taxoids | 2002 |
A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2002 |
Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Reference Values; Survival Analysis; Treatment Outcome | 2002 |
Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2002 |
Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2002 |
Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic cancer: a Phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2002 |
Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Infusions, Intravenous; Injections, Intramuscular; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged | 2002 |
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Quality of Life; Respiratory Function Tests; Survival Analysis; Treatment Outcome | 2002 |
Weekly gemcitabine plus Epirubicin as effective chemotherapy for advanced pancreatic cancer: a multicenter phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; DNA Damage; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2002 |
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Probability; Prognosis; Risk Assessment; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2002 |
Phase I/II study of gemcitabine and vinorelbine plus cisplatin in non-small cell lung cancer.
Topics: Adult; Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Hematologic Diseases; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Survival; Vinblastine; Vinorelbine | 2002 |
Outpatient therapy with gemcitabine and docetaxel for gallbladder, biliary, and cholangio-carcinomas.
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Survival Analysis; Taxoids | 2002 |
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: a phase III randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Greece; Health Care Costs; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Retrospective Studies; Survival Rate | 2002 |
Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2002 |
A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Recombinant Proteins | 2002 |
A Phase II trial of topotecan and gemcitabine in patients with previously treated, advanced nonsmall cell lung carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan | 2002 |
Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flutamide; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Kidney Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Neoadjuvant gemcitabine/treosulfan chemotherapy for newly diagnosed glioblastoma: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Glioblastoma; Hematologic Diseases; Humans; Male; Middle Aged; Neoadjuvant Therapy; Venous Thrombosis | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2002 |
A high rate of venous thromboembolism in a multi-institutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Heart Arrest; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Thalidomide; Thromboembolism | 2002 |
A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2002 |
A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pneumonia; Thrombocytopenia; Treatment Outcome | 2002 |
Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost Control; Deoxycytidine; Disease Progression; Docetaxel; Drug Costs; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival; Taxoids; Treatment Outcome | 2002 |
Phase I study of weekly gemcitabine as a radiation sensitizer for unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis | 2002 |
Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Endothelial Growth Factors; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Health Status; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Male; Matrix Metalloproteinase 9; Middle Aged; Neoplasm Staging; Prognosis; Survival; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vinblastine; Vinorelbine | 2002 |
Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Radiotherapy Dosage; Survival Analysis; Vinblastine; Vinorelbine | 2002 |
Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Paclitaxel; Quality of Life; Salvage Therapy; Survival Analysis; Taxoids | 2002 |
Phase I trial of gemcitabine, administered as a standard and constant dose-rate infusion, in combination with paclitaxel in patients with advanced solid tumors (LOA-2).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Urologic Neoplasms | 2002 |
Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Interferon alpha-2; Interferon-alpha; Karnofsky Performance Status; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Ovarian Neoplasms; Pancreatic Neoplasms; Recombinant Proteins; Treatment Outcome | 2002 |
Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged | 2002 |
Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2002 |
Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, High-Energy | 2002 |
Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2002 |
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Humans; Liposomes; Male; Middle Aged; Neoplasms; Neutropenia; Stomatitis; Treatment Outcome | 2002 |
A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Probability; Survival Analysis; Topotecan; Treatment Failure; Treatment Outcome | 2002 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Statistics, Nonparametric; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2002 |
Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Hepatocellular; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Analysis; Taiwan; Treatment Outcome | 2002 |
Phase I study of rubitecan and gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptothecin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome | 2002 |
Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; California; Chemical and Drug Induced Liver Injury; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Hydroxyurea; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2002 |
Phase I study of eniluracil, oral 5-fluororacil and gemcitabine in patients with advanced malignancy.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Patients; Uracil | 2002 |
Phase I escalation of gemcitabine combined with protracted oral etoposide in gynecologic malignancies: A Gynecologic Oncology Group study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged | 2002 |
Neoadjuvant chemotherapy with gemcitabine and cisplatin in stage IIIA/B non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging | 2002 |
Cyclophosphamide, doxorubicin, and gemcitabine combination chemotherapy for treatment of metastatic and locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2002 |
Phase I/II study of paclitaxel, gemcitabine and vinorelbine as first-line chemotherapy of non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Risk Assessment; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Triplet chemotherapy with vinorelbine, gemcitabine, and cisplatin for advanced non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Combined intrapleural and intravenous chemotherapy, and pulmonary irradiation, for treatment of patients with lung cancer presenting with malignant pleural effusion. A pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intralesional; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Pleural Effusion, Malignant; Pleurodesis; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome | 2003 |
[Phase I study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non-small-cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids | 2002 |
Phase I study of gemcitabine (difluorodeoxycytidine) in children with relapsed or refractory leukemia (CCG-0955): a report from the Children's Cancer Group.
Topics: Adolescent; Biotransformation; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Gemcitabine; Half-Life; Humans; Infant; Leukemia; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Salvage Therapy | 2002 |
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Hand, Foot and Mouth Disease; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Syndrome; Treatment Outcome | 2003 |
A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Analysis; Thrombocytopenia; Topotecan; Treatment Outcome | 2002 |
Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Paclitaxel; Taxoids; Treatment Outcome | 2003 |
Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Carboplatin and gemcitabine in stage IV non small cell lung cancer: beyond cisplatin in palliative chemotherapy.
Topics: Aged; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Palliative Care; Survival Rate; Treatment Outcome | 2003 |
Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Cisplatin; Combined Modality Therapy; Deoxycytidine; Digestive System; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Radiotherapy Dosage | 2003 |
Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms | 2003 |
Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Receptor, ErbB-2 | 2003 |
Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma: a phase I/II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Switzerland | 2003 |
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Infusions, Parenteral; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Mouth Mucosa; Pilot Projects; Remission Induction; Salvage Therapy; Sepsis; Stomatitis; Treatment Outcome | 2003 |
A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Transplantation; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides; ras Proteins; Signal Transduction; Time Factors | 2003 |
Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms | 2001 |
Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Palliative Care; Pancreatic Neoplasms; Survival; Thrombocytopenia; Treatment Outcome | 2003 |
Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival; Thrombocytopenia; Treatment Outcome; Tumor Cells, Cultured | 2003 |
A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin | 2003 |
Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2003 |
A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Adenoviridae; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; In Situ Hybridization; Injections, Intralesional; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Selection; Safety; Treatment Outcome; Ultrasonography; Viral Vaccines | 2003 |
Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidine; Esophagitis; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leukemia, Myeloid, Acute; Metabolic Clearance Rate; Middle Aged; Recurrence; Stomatitis; Vidarabine | 2003 |
Induction chemotherapy with gemcitabine and oxaliplatin for locally advanced cervical carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Uterine Cervical Neoplasms | 2003 |
A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cytoprotection; Deoxycytidine; Esophagitis; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Radiation Injuries; Radiation-Protective Agents | 2002 |
Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospe
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Topotecan; Treatment Outcome | 2003 |
Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: a phase I and pharmacokinetic study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 2003 |
Phase I/II study of gemcitabine plus mitoxantrone as salvage chemotherapy in metastatic breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Heart Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Salvage Therapy; Soft Tissue Neoplasms | 2003 |
Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pain; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2003 |
A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Darbepoetin alfa; Deoxycytidine; Docetaxel; Erythropoietin; Fatigue; Female; Gemcitabine; Humans; Injections, Subcutaneous; Male; Middle Aged; Neoplasms; Paclitaxel; Pilot Projects; Taxoids; Treatment Outcome | 2003 |
Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cell Survival; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2003 |
Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival; Treatment Outcome | 2003 |
[A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Thrombocytopenia | 2003 |
The combination of gemcitabine and vinorelbine is an active regimen as second-line therapy in patients with metastatic breast cancer pretreated with taxanes and/or anthracyclines: a phase I-II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Taxoids; Vinblastine; Vinorelbine | 2003 |
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Surveys and Questionnaires; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Prospective Studies; Thrombocytopenia; Treatment Outcome | 2003 |
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hodgkin Disease; Humans; Lymphoma; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, T-Cell; Male; Methylprednisolone; Middle Aged; Recurrence; Survival Rate | 2003 |
Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy | 2003 |
Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Thiophenes; Treatment Outcome; Vomiting | 2003 |
Gemcitabine and oxaliplatin for metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival; Treatment Outcome | 2003 |
A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome; Vomiting | 2003 |
Gemcitabine and carboplatin in patients with locally advanced or metastatic non-small cell lung cancer: a prospective phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate; Time Factors | 2003 |
Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Survival Rate; Treatment Outcome | 2003 |
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Cytoprotection; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms | 2003 |
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Treatment Outcome | 2003 |
Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Time Factors; Treatment Outcome | 2003 |
Biweekly vinorelbine and gemcitabine: a phase I dose-finding study in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Vinblastine; Vinorelbine | 2003 |
[Comparison of cisplatin combined with gemcitabine versus cisplatin combined with vinorelbine regimen for treatment of patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Influence of cisplatin-use, age, performance status and duration of chemotherapy on symptom control in advanced non-small cell lung cancer: detailed symptom analysis of a randomised study comparing cisplatin-vindesine to gemcitabine.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Pain; Quality of Life; Time Factors; Treatment Outcome; Vindesine | 2003 |
A phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIb/IV) non-small-cell lung cancer patients aged 80 or older.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Palliative Care; Vinblastine; Vinorelbine | 2003 |
Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Survival Analysis; Taxoids | 2003 |
Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Survival Rate; Urologic Neoplasms | 2003 |
Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): a dose-optimizing phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2003 |
Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Analysis | 2003 |
Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Remission Induction; Survival Analysis | 2003 |
Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Gemcitabine and trastuzumab in metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab | 2003 |
[Usefulness of gemcitabine in the treatment of advanced pancreatic cancer in terms of its clinical benefits].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2003 |
[Transarterial chemoperfusion of inoperable pancreas carcinoma and local recurrence].
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Quality of Life; Survival Rate; Tomography, X-Ray Computed | 2003 |
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Actuarial Analysis; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Patient Selection; Recurrence; Survival Rate; Thrombocytopenia; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Gemcitabine/vinorelbine in metastatic breast cancer patients previously treated with anthracyclines: results of a phase II trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Prognosis; Vinblastine; Vinorelbine | 2003 |
Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Treatment Outcome | 2003 |
Gemcitabine plus irinotecan in breast cancer patients pretreated with taxanes and anthracyclines: a multicenter phase II study.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Middle Aged; Treatment Outcome | 2003 |
Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? a single-center phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2003 |
Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Taxoids; Urologic Neoplasms; Urothelium | 2003 |
Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Survival Rate | 2003 |
Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Cisplatin; Deoxycytidine; E-Selectin; Endothelial Growth Factors; Endothelium, Vascular; Female; Gemcitabine; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Middle Aged; Multivariate Analysis; Platelet Count; Pyrroles; Regression Analysis; Thromboembolism; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Melanoma; Middle Aged; Pilot Projects; Survival Analysis; Uveal Neoplasms | 2003 |
Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Treatment Outcome | 2003 |
A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases.
Topics: Aged; Bone Neoplasms; Carcinoma; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation-Sensitizing Agents; Strontium; Strontium Radioisotopes; Testosterone | 2003 |
Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutathione S-Transferase pi; Glutathione Transferase; Humans; Isoenzymes; Lung Neoplasms; Male; Membrane Proteins; Microtubule Proteins; Middle Aged; Paclitaxel; Phosphoproteins; Predictive Value of Tests; Prostaglandin-Endoperoxide Synthases; Randomized Controlled Trials as Topic; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Stathmin; Survival Rate; Transcription, Genetic; Tubulin; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2003 |
Gemcitabine, Paclitaxel, and piritrexim: a phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Folic Acid Antagonists; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pyrimidines | 2003 |
Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Mullerian Ducts; Ovarian Neoplasms; Paclitaxel; Taxoids | 2003 |
Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Thrombocytopenia; Treatment Outcome | 2003 |
A phase II trial of gemcitabine in the treatment of advanced bile duct and periampullary carcinomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Ribonucleotide Reductases; Treatment Outcome | 2003 |
Treatment of recurrent platinum resistant ovarian or peritoneal cancer with gemcitabine and doxorubicin: A phase I/II trial of the Puget Sound Oncology Consortium (PSOC 1602).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Platinum; Prospective Studies; Quality of Life; Survival Analysis; Treatment Outcome; Washington | 2003 |
A phase II/III study comparing intravenous ZD9331 with gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis | 2003 |
Randomized, multicenter, phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2003 |
Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Treatment Outcome | 2003 |
Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2003 |
Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Postoperative Care; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant | 2003 |
Gemcitabine and cisplatin as induction chemotherapy for patients with unresectable Stage IIIA-bulky N2 and Stage IIIB nonsmall cell lung carcinoma: an Italian Lung Cancer Project Observational Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2003 |
Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Vinblastine; Vinorelbine | 2003 |
Gemcitabine plus cisplatin in adjuvant regimen for bladder cancer. Toxicity evaluation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasms | 2003 |
A Phase I study of gemcitabine with concurrent radiotherapy in stage III, locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Time Factors; Treatment Outcome | 2003 |
A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Electrolytes; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Maximum Tolerated Dose; Middle Aged; Mouth Mucosa; Neoplasms; Quinolones; Time Factors | 2003 |
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Prolonged gemcitabine infusion in advanced non-small cell lung carcinoma: a randomized phase II study of two different schedules in combination with cisplatin.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases; Treatment Outcome | 2003 |
Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Quality of Life; Survival Rate; Time Factors; Vinblastine | 2003 |
A phase I-II study of weekly cisplatin and gemcitabine with concurrent radiotherapy in locally advanced cervical carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome; Uterine Cervical Neoplasms | 2003 |
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Failure | 2003 |
[Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Exanthema; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Survival Rate; Vomiting, Anticipatory | 2003 |
A phase I study of gemcitabine and docetaxel for advanced stage solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Patient Selection; Taxoids | 2003 |
Triplet chemotherapy combination with gemcitabine, cisplatin and ifosfamide in patients with advanced non-small-cell lung cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Remission Induction; Survival Analysis | 2003 |
Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taiwan; Treatment Outcome | 2003 |
Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liposomes; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Topotecan | 2003 |
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2003 |
Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast; Breast Neoplasms; Cisplatin; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; DNA-Binding Proteins; DNA, Complementary; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Sensitivity and Specificity; Sequence Analysis, DNA; Tumor Suppressor Proteins | 2003 |
Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Spain; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Liposomes; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2003 |
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biphenyl Compounds; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Organic Chemicals; Pancreatic Neoplasms; Phenylbutyrates; Proportional Hazards Models; Quality of Life; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2003 |
A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Unknown Primary | 2003 |
A phase I and pharmacologic study of weekly gemcitabine in combination with infusional 5-fluorodeoxyuridine and oral calcium leucovorin.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Floxuridine; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Ribonucleotide Reductases; Thrombocytopenia | 2003 |
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary | 2003 |
Concomitant gemcitabine (Gemzar) and extended nodes irradiation in the treatment of pancreatic and biliary carcinoma: a phase I study.
Topics: Aged; Bile Duct Neoplasms; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hepatic Duct, Common; Humans; Infusions, Intravenous; Klatskin Tumor; Lymphatic Irradiation; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant | 2003 |
[Effectiveness of Gemzar-Cisplatin therapy in stage IIIA-N2, IIIB and IV non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Survival Analysis; Treatment Outcome | 2003 |
[Experience with the treatment of advanced pancreatic cancer in Hungary].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Treatment Outcome | 2003 |
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel | 2003 |
Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Male; Prognosis; Survival Rate | 2003 |
Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Time Factors | 2003 |
Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2003 |
A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Dexamethasone; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukemia; Male; Recurrence; Thiotepa; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Palliative Care; Prospective Studies; Survival Rate; Urologic Neoplasms; Vinblastine | 2003 |
Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Liposomes; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Treatment Outcome | 2003 |
First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Gemcitabine combined with cisplatin as first-line treatment in patients with epithelial ovarian cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Survival Rate | 2003 |
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis; Topotecan; Treatment Outcome | 2003 |
A phase I human trial of mitoguazone and gemcitabine sequential bi-weekly treatment of cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Mitoguazone; Neoplasms | 2003 |
Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Kinetics; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome | 2003 |
Irinotecan and fixed-dose-rate gemcitabine in advanced pancreatic and biliary cancer: phase I study.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Pancreatic Neoplasms; Research Design | 2003 |
Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Treatment Outcome | 2003 |
Phase I clinical study of infusional 5-fluorouracil with oxaliplatin and gemcitabine (FOG regimen) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2003 |
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gemcitabine; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Models, Chemical; Neoplasms; Protein Prenylation; Quinolones; ras Proteins; Time Factors; Treatment Outcome | 2003 |
Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2003 |
A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Severity of Illness Index; Taxoids; Treatment Outcome | 2003 |
Doxorubicin, paclitaxel and gemcitabine: a Phase I study of a new sequential treatment in stage III B - IV breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2003 |
A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2003 |
Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Treatment Outcome | 2003 |
Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2003 |
Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quality of Life; Thrombocytopenia; Treatment Outcome | 2003 |
Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer.
Topics: Aged; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quality of Life; Radiation-Sensitizing Agents; Treatment Outcome; Urinary Bladder Neoplasms | 2003 |
Gemcitabine plus vinorelbine chemotherapy in patients with advanced bladder carcinoma who are medically unsuitable for or who have failed cisplatin-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Risk Assessment; Survival Analysis; Terminally Ill; Treatment Failure; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2003 |
Gemcitabine and low dose carboplatin in the treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Survival Analysis; Survival Rate; Treatment Outcome | 2003 |
Phase II study of gemcitabine-cisplatin-paclitaxel triplet as induction chemotherapy in inoperable, locally-advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2003 |
Phase II study of gemcitabine, UFT and leucovorin in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2002 |
First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclin G; Cyclin G1; Cyclins; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Hemodynamics; Humans; Infusions, Intravenous; Kidney Function Tests; Liver Function Tests; Male; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Retroviridae; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Elderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Prospective Studies; Treatment Outcome | 2003 |
Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: a Hoosier Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Taxoids; Time Factors | 2003 |
Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Survival Analysis; Vinblastine; Vinorelbine | 2003 |
Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Endpoint Determination; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Conformal; Survival Analysis; Time Factors; Treatment Outcome | 2004 |
Phase II study of an alternate carboplatin and gemcitabine dosing schedule in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Analysis; Time Factors; Treatment Outcome | 2003 |
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Random Allocation; Receptor, ErbB-2; Trastuzumab | 2004 |
Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids | 2004 |
[Phase II clinical trial on gemcitabine in the treatment of stage IIIB-IV non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging | 2003 |
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neutropenia; Paclitaxel; Urologic Neoplasms | 2004 |
Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Testicular Neoplasms; Treatment Outcome | 2004 |
Taxol plus gemcitabine and vinorelbine given every other week in advanced chemo-naïve non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Gemcitabine and cisplatin for patients with metastatic or recurrent esophageal carcinoma: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Rate | 2004 |
Death receptor 5 and Bcl-2 protein expression as predictors of tumor response to gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Proto-Oncogene Proteins c-bcl-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Survival Rate | 2003 |
Intravesical gemcitabine: a phase 1 and pharmacokinetic study.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Time Factors; Urinary Bladder Neoplasms | 2004 |
Alternating doublets: establishing the optimal multifractionated dosing schedule to administer docetaxel, cisplatin, gemcitabine, and vinorelbine in combination.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Fever; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Impact of Gemcitabine and Cisplatin with radiotherapy in locally advanced or metastatic transitional cell carcinoma of urinary bladder.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Urinary Bladder Neoplasms | 2003 |
Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Thrombocytopenia | 2004 |
Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer.
Topics: Aged; Biliary Tract Neoplasms; Cholangiocarcinoma; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hematologic Diseases; Humans; Karnofsky Performance Status; Male; Middle Aged; Survival Rate | 2004 |
[Phase I study of gemcitabine (GEM) and UFT combination chemotherapy for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pancreatic Neoplasms; Tegafur; Uracil | 2004 |
Phase I feasibility trial of carboplatin, paclitaxel, and gemcitabine in patients with previously untreated epithelial ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms | 2004 |
Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prospective Studies | 2004 |
Second line therapy with weekly low-dose docetaxel for pretreated non-small-cell lung carcinoma patients: a multicenter Italian phase II study.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophagitis; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neurotoxicity Syndromes; Premedication; Remission Induction; Stomatitis; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged | 2004 |
Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Genes, erbB-2; Humans; Infusions, Intravenous; Middle Aged; Paclitaxel; Predictive Value of Tests; Prognosis; Treatment Outcome | 2004 |
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Weight Gain | 2004 |
Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Radiation Injuries; Ribonucleotide Reductases; Treatment Outcome | 2004 |
Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Enzyme Inhibitors; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase C; Staurosporine | 2004 |
Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Uterine Neoplasms | 2004 |
Gemcitabine/paclitaxel as first-line treatment of advanced breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Selection; Survival Rate; Treatment Outcome; World Health Organization | 2003 |
Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Patient Selection; Salvage Therapy; Survival Analysis; Trastuzumab; Treatment Outcome; World Health Organization | 2003 |
Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Trastuzumab; Treatment Outcome | 2003 |
Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies | 2004 |
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Quinazolines; Reference Values; Survival Analysis; Treatment Outcome | 2004 |
Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2004 |
Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2004 |
Mitomycin C in combination with capecitabine or biweekly high-dose gemcitabine in patients with advanced biliary tract cancer: a randomised phase II trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Treatment Outcome | 2004 |
Phase II trial of cisplatin and gemcitabine in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2004 |
Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germinoma; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Gonadal Tissue; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Salvage Therapy; Treatment Outcome | 2004 |
Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Intravesical administration of gemcitabine in superficial bladder cancer: a phase I study with pharmacodynamic evaluation.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 2004 |
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing d
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Up-Regulation | 2004 |
Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with advanced pancreatic cancer or other solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2004 |
[Effectiveness of gemcitabine in combination with cisplatin in a randomized study of untreated patients with advanced non-small-cell lung carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2004 |
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasms, Unknown Primary; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2004 |
Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2004 |
Alternating gemcitabine and cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fever; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Squamous Cell; Neutropenia; Survival Analysis; Survival Rate; Thrombocytopenia; Treatment Outcome | 2004 |
Dose intense triplet chemotherapy with gemcitabine, carboplatin, paclitaxel with peripheral blood progenitor cell support for six cycles in advanced epithelial ovarian cancer.
Topics: Adolescent; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Transplantation, Autologous | 2004 |
A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2004 |
Phase II study of alternating chemotherapy regimens for advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Placebos; Prognosis; Quinolones | 2004 |
Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel | 2004 |
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Treatment Outcome | 2004 |
Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Taxoids; Treatment Outcome | 2004 |
A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasms; Organoplatinum Compounds | 2004 |
Intraperitoneal cisplatin with intraperitoneal gemcitabine in patients with epithelial ovarian cancer: results of a phase I/II Trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intraperitoneal; Middle Aged; Nausea; Neutropenia; Ovarian Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vomiting | 2004 |
Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination o
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Etoposide; Feasibility Studies; Female; Gemcitabine; Hodgkin Disease; Humans; Lung Diseases; Male; Middle Aged; Prednisone; Procarbazine; Vincristine | 2004 |
Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Carcinoma, Renal Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Sarcoma; Survival Rate; Therapeutics; Treatment Outcome | 2004 |
A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Methemoglobinemia; Middle Aged; Neoplasms; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones | 2004 |
Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Thrombocytopenia | 2004 |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Survival Analysis; Treatment Outcome | 2004 |
A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2004 |
Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Melanoma; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Failure; Treatment Outcome; Uveal Neoplasms | 2004 |
Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Severity of Illness Index; Taxoids; Treatment Outcome | 2004 |
A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Taxoids | 2004 |
Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cytokines; Deoxycytidine; Female; Gemcitabine; Granulocytes; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Superoxides | 2004 |
Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Renal Insufficiency | 2004 |
Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Randomized phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine, and cisplatin in the treatment of advanced non-small-cell lung cancer: from the German and Swiss Lung Cancer Study Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Middle Aged; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2004 |
Phase I trial and pharmacokinetics of gemcitabine in children with advanced solid tumors.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Child, Preschool; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Half-Life; Humans; Male; Maximum Tolerated Dose; Neoplasms | 2004 |
Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Salvage Therapy; Survival Analysis; Taxoids | 2004 |
Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Taxoids | 2004 |
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: preliminary results of a phase II and pharmacogenomic study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Taxoids | 2004 |
Gemcitabine and mitomycin C in advanced pancreatic cancer: a single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Drug Administration Schedule; Dyspnea; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Hospitals, University; Humans; Injections, Intravenous; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Pneumonia; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2004 |
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Digestive System Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2004 |
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on patients with cisplatin/gemcitabine-treated stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; DNA Methylation; Female; Gemcitabine; Genes, Tumor Suppressor; Genotype; Homocysteine; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome | 2004 |
Gene expression as a predictive marker of outcome in stage IIB-IIIA-IIIB non-small cell lung cancer after induction gemcitabine-based chemotherapy followed by resectional surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Helicases; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2004 |
Phase II study of gemcitabine in combination with docetaxel in patients with advanced pancreatic carcinoma (E1298). A trial of the eastern cooperative oncology group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Failure; United States | 2004 |
A multicenter phase II study of the combination of irinotecan and gemcitabine in previously treated patients with small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2004 |
Gemcitabine and cisplatin in refractory malignant lymphoma.
Topics: Actuarial Analysis; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Pilot Projects; Prospective Studies; Survival Analysis; Treatment Outcome | 2004 |
Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2004 |
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2004 |
Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2004 |
Gemcitabine and vinorelbine as second-line therapy for non-small cell lung cancer after treatment with paclitaxel plus platinum.
Topics: Adult; Aftercare; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Platinum; Survival Rate; Vinblastine; Vinorelbine | 2004 |
A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lung; Middle Aged; Neutropenia; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Treatment Outcome | 2004 |
Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicentre, randomised, phase II study.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Survival Analysis; Taxoids | 2004 |
Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hodgkin Disease; Humans; Infusions, Intravenous; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Pilot Projects; Racial Groups; Recurrence | 2004 |
Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Breast Neoplasms; Chemotherapy, Adjuvant; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Mastectomy; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Probability; Risk Factors; Survival Analysis; Trastuzumab; Treatment Outcome | 2004 |
Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Prospective Studies; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Planning, Computer-Assisted; Surveys and Questionnaires; Thrombocytopenia; Urinary Bladder Neoplasms | 2004 |
A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase I pharmacokinetic study of a single intravesical instillation of gemcitabine administered immediately after transurethral resection plus multiple random biopsies in patients with superficial bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 2004 |
Irinotecan in advanced lung cancer: focus on North American trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; North America; Radiotherapy, Adjuvant; Ribonucleotide Reductases; Survival Rate; Taxoids; Topoisomerase I Inhibitors; Vindesine | 2004 |
Phase II study of OK-432 intrapleural administration followed by systemic cisplatin and gemcitabine for non-small cell lung cancer with pleuritis carcinomatosa.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Middle Aged; Picibanil; Pleural Neoplasms; Survival Rate; Treatment Outcome | 2004 |
Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2004 |
Cisplatin and gemcitabine in patients with metastatic cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Survival Rate; Thrombocytopenia; Uterine Cervical Neoplasms | 2004 |
Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Conformal | 2004 |
A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Male; Middle Aged; Neoplasms; Prospective Studies; Pulmonary Diffusing Capacity | 2004 |
Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2004 |
Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2004 |
A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Kidney Function Tests; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Outpatients; Treatment Outcome; Urinary Bladder Neoplasms; Viscera | 2004 |
Triplet combination of gemcitabine, carboplatin, and paclitaxel in previously treated, relapsed ovarian and peritoneal carcinoma: an experience in Taiwan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Salvage Therapy | 2004 |
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, gemcitabine, and twice-daily radiation in patients with poor-prognosis cancer of the head and neck.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Radiometry; Time Factors; Treatment Outcome | 2004 |
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel | 2004 |
Front-line weekly chemotherapy with gemcitabine for unfit patients with non-small cell lung cancer (NSCLC).
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2004 |
Phase II study to investigate the ablative efficacy of intravesical administration of gemcitabine in intermediate-risk superficial bladder cancer (SBC).
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Thrombocytopenia; Treatment Outcome; Vomiting | 2004 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids | 2005 |
Phase II study of pemetrexed-gemcitabine combination in patients with advanced-stage non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dietary Supplements; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Analysis; Time Factors; Vitamins | 2004 |
A Phase II trial of gemcitabine for metastatic neuroendocrine tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neuroendocrine Tumors; Prognosis; Survival Rate; Treatment Outcome | 2004 |
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Neoadjuvant Therapy; Pleural Neoplasms; Pneumonectomy; Survival Rate | 2004 |
A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Treatment Outcome; Uveal Neoplasms | 2004 |
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Administration Schedule; Fatigue; Feasibility Studies; Female; Gemcitabine; Hematologic Neoplasms; Humans; Male; Middle Aged; Neutropenia; Thrombocytopenia | 2004 |
Pilot study of outpatient paclitaxel, carboplatin and gemcitabine for advanced stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Pilot Projects | 2004 |
Neoadjuvant induction chemotherapy followed by chemoradiation: a phase I trial of gemcitabine, cisplatin, and 5-fluorouracil for advanced pancreatic/gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Prognosis; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Carcinoma, Transitional Cell; Cisplatin; Contraindications; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Kidney Function Tests; Life Tables; Male; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
[Intraoperative 125I brachytherapy combined with chemotherapy for pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Intraoperative Period; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Survival Rate | 2004 |
Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Survival Analysis | 2003 |
Sequential chemotherapy with paclitaxel plus cisplatin, followed by vinorelbine, followed by gemcitabine in advanced non-small cell lung cancer: an Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 001).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Taxoids | 2004 |
Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2004 |
Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lymph Node Excision; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2004 |
Gemcitabine plus vinorelbine chemotherapy regimens: a pharmacokinetic study of alternate administration sequences.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Forecasting; Gemcitabine; Half-Life; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Italy; Kinetics; Lymphoma, Non-Hodgkin; Vinblastine; Vinorelbine | 2004 |
A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Deoxycytidine; Enzyme Inhibitors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oligodeoxyribonucleotides, Antisense; Oligonucleotides; Oligonucleotides, Antisense; Protein Kinase C; Protein Kinase C-alpha; Thionucleotides; Treatment Outcome | 2004 |
Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow Transplantation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Recurrence; Time Factors; Treatment Outcome | 2004 |
Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2004 |
Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Geriatric Assessment; Humans; Male; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
Gemcitabine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II California cancer consortium trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome | 2004 |
Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Gemcitabine; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Maximum Tolerated Dose; Middle Aged; Sarcoma; Treatment Outcome | 2004 |
Phase I trial of topotecan in combination with gemcitabine in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prospective Studies; Topotecan; Treatment Outcome | 2004 |
Chemoradiation with gemcitabine for cervical cancer in patients with renal failure.
Topics: Brachytherapy; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Creatinine; Deoxycytidine; Drug Administration Schedule; Drug Evaluation; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Kidney Function Tests; Mexico; Middle Aged; Neoplasm Staging; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Renal Insufficiency; Time Factors; Treatment Outcome; Urethral Obstruction; Uterine Cervical Neoplasms | 2004 |
Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Survival Analysis; Treatment Outcome | 2004 |
Autologous stem cell transplantation followed by consolidation chemotherapy for relapsed or refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Dexamethasone; Etoposide; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Salvage Therapy; Secondary Prevention; Survival Analysis; Transplantation, Autologous | 2004 |
Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Taxoids; Treatment Outcome | 2004 |
Evaluation of gemcitabine in relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Multiple Myeloma | 2004 |
[Evaluation of advanced non-small-cell lung cancer (ANSCLC) chemotherapy in routine practice].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Fever; France; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Primary Health Care; Prospective Studies; Vinblastine; Vinorelbine | 2004 |
Results of a Phase II study of carboplatin plus gemcitabine in patients with untreated extensive small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Thrombocytopenia | 2004 |
Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Survival Analysis | 2005 |
Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Treatment Outcome | 2004 |
Gemcitabine combined with docetaxel for the treatment of unresectable pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids | 2004 |
[Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in treatment of advanced non-small cell lung cancer (NSCLC)].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 2004 |
A Phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis | 2004 |
Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: a phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Greece; Humans; Middle Aged; Neutropenia; Paclitaxel; Trastuzumab; Treatment Outcome | 2004 |
Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Pancreatic Neoplasms; Prognosis; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2004 |
Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Remission Induction; Survival Analysis | 2004 |
Evaluation of gemcitabine in previously treated patients with non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Adenosquamous; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Uterine Cervical Neoplasms | 2005 |
Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2005 |
Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT?
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deglutition; Deglutition Disorders; Deoxycytidine; Gemcitabine; Head and Neck Neoplasms; Humans; Hypopharynx; Image Processing, Computer-Assisted; Palatine Tonsil; Pharyngeal Muscles; Pneumonia, Aspiration; Prospective Studies; Radiotherapy, Conformal; Tongue | 2004 |
A prospective randomized study of gemcitabine with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiotherapy Dosage | 2004 |
Alternating weekly administration of paclitaxel and gemcitabine: a phase II study in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate | 2005 |
Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Germinoma; Humans; Male; Mediastinal Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Survival Analysis; Testicular Neoplasms | 2004 |
[Phase II-trial of tirapazamine in combination with cisplatin and gemcitabine in patients with advanced non-small-cell-lung-cancer (NSCLC)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Survival Analysis; Thrombocytopenia; Tirapazamine; Triazines | 2004 |
Phase II randomized trial of vinorelbine and gemcitabine versus carboplatin and paclitaxel in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids | 2005 |
Phase I trial using weekly administration of gemcitabine and docetaxel in patients with advanced pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain Measurement; Pancreatic Neoplasms; Quality of Life; Severity of Illness Index; Taxoids | 2004 |
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Oligonucleotides, Antisense; Pancreatic Neoplasms; Phosphorothioate Oligonucleotides; Survival Analysis | 2004 |
Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neutropenia; Paclitaxel; Severity of Illness Index; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Hematologic Diseases; Humans; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Severity of Illness Index; Treatment Outcome | 2005 |
Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids; Treatment Outcome | 2005 |
Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2005 |
Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma?
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Deoxycytidine; Drug Therapy, Combination; Female; Frail Elderly; Gemcitabine; Humans; Immunotherapy; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Rituximab; Survival Rate | 2005 |
Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small-cell lung cancer: a phase III randomized study of the London Lung Cancer Group.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Quality of Life; Survival Rate; Treatment Outcome | 2005 |
A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Outpatients; Treatment Outcome; Urologic Neoplasms | 2004 |
Innovative sequence of docetaxel-gemcitabine based on preclinical data in the treatment of advanced non small cell lung cancer: a phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Taxoids; Tumor Cells, Cultured | 2005 |
Sequential chemotherapy of cisplatin and vinorelbine followed by paclitaxel and gemcitabine in advanced non-small-cell lung cancer. A single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
A multicenter, randomized, Phase II study of cisplatin, etoposide, and gemcitabine or cisplatin plus gemcitabine as first-line treatment in patients with poor-prognosis small cell lung carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Paclitaxel; Time Factors; Urinary Bladder Neoplasms; Urothelium | 2005 |
A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2005 |
A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel | 2005 |
Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of bladder: Phase I-II study on marker lesions.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prodrugs; Remission Induction; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Urinary Bladder Neoplasms | 2005 |
Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Treatment Outcome | 2005 |
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infections; Male; Methotrexate; Middle Aged; Neutropenia; Prognosis; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2005 |
A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Survival Rate; Thiophenes | 2005 |
Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium | 2005 |
Neoadjuvant therapy with gemcitabine in breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Recombinant Proteins; Taxoids; Time Factors; Treatment Outcome | 2004 |
Gemcitabine/Irinotecan/celecoxib in pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Time Factors; Treatment Outcome | 2004 |
Results of a phase II trial of gemcitabine in patients with non-small-cell lung cancer and a performance status of 2.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases; Treatment Outcome | 2005 |
Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: a randomized Phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy Dosage; Uterine Cervical Neoplasms | 2005 |
Single-agent gemcitabine in the treatment of advanced biliary tract cancers: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia | 2005 |
First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week schedule.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Treatment Outcome | 2005 |
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Belgium; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome | 2004 |
Gemcitabine combined with oxaliplatin (GEMOX) as second-line chemotherapy in patients with advanced ovarian cancer refractory or resistant to platinum and taxane.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum Compounds; Severity of Illness Index; Taxoids; Thrombocytopenia; Treatment Outcome | 2004 |
Gemcitabine twice weekly as a radiosensitiser for the treatment of brain metastases in patients with carcinoma: a phase I study.
Topics: Adult; Aged; Brain Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Radiation-Sensitizing Agents; Remission Induction | 2005 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2005 |
A pharmacological study of celecoxib and gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Treatment Outcome | 2005 |
Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2005 |
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2005 |
Prolonged infusion of gemcitabine in advanced solid tumors: a phase-I-study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms | 2005 |
Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Paclitaxel; Radiotherapy Dosage | 2005 |
A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Pemetrexed | 2005 |
Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Embolization, Therapeutic; Female; Gemcitabine; Humans; Male; Middle Aged; Quality of Life; Treatment Outcome | 2005 |
Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged | 2005 |
Increased dose-intensity of gemcitabine in advanced non small cell lung cancer (NSCLC): a multicenter phase II study in elderly patients from the "polmone toscano group" (POLTO).
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neutropenia; Survival Analysis; Thrombocytopenia | 2005 |
Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2005 |
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients with metastatic pancreas cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Survival Rate; Treatment Failure | 2005 |
5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Prognosis; Survival Analysis | 2005 |
Carboplatin plus gemcitabine in patients with inoperable or metastatic pancreatic cancer: a phase II multicenter study by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Greece; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Prognosis; Quality of Life; Risk Assessment; Survival Analysis; Terminally Ill; Treatment Outcome | 2005 |
A phase II trial of sequential chemotherapy with docetaxel and methotrexate followed by gemcitabine and cisplatin for metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Methotrexate; Middle Aged; Survival Analysis; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2005 |
A nonplatinum combination in metastatic transitional cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms | 2005 |
A phase II study of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged | 2005 |
A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Middle Aged | 2005 |
Phase II study of gemcitabine plus cisplatin in patients with metastatic breast cancer: a North Central Cancer Treatment Group Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2005 |
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma; Methylprednisolone; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine and cisplatin in advanced nasopharyngeal carcinoma: a pilot study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Nasopharyngeal Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Topics: Aged; Amino Acid Substitution; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cisplatin; Cytidine Deaminase; Deoxycytidine; DNA Mutational Analysis; DNA, Neoplasm; Exanthema; Fatigue; Floxuridine; Gemcitabine; Genotype; Humans; Japan; Male; Middle Aged; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Stomatitis; Thrombocytopenia; Treatment Outcome | 2005 |
First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study.
Topics: Aged; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Postmenopause | 2005 |
Pharmacokinetics of gemcitabine in Chinese patients with non-small-cell lung cancer.
Topics: Adolescent; Adult; Aged; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Time Factors | 2005 |
Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Gene Expression; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nuclear Proteins; Pneumonectomy; RNA, Messenger; Survival Analysis; Transcription Factors; Treatment Outcome | 2005 |
A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Hemoglobins; Humans; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids | 2005 |
Clinical experience with single-agent gemcitabine chemotherapy in patients with non-small-cell lung cancer in whom previous chemotherapy has failed.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Uterine Cervical Neoplasms | 2005 |
Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides | 2005 |
Gemcitabine plus cisplatine and paclitaxel (GCP) in second-line treatment of germ cell tumors (GCT): a phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Germinoma; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Testicular Neoplasms; Treatment Outcome | 2005 |
Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Comet Assay; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Skin Neoplasms; Uveal Neoplasms | 2005 |
Cost-minimisation analysis comparing gemcitabine/cisplatin, paclitaxel/carboplatin and vinorelbine/cisplatin in the treatment of advanced non-small cell lung cancer in Italy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost Control; Deoxycytidine; Gemcitabine; Health Care Costs; Health Services; Humans; Italy; Lung Neoplasms; Paclitaxel; Retrospective Studies; Vinblastine; Vinorelbine | 2005 |
The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Benzamides; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Imatinib Mesylate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Quality of Life; Receptors, Platelet-Derived Growth Factor; Surveys and Questionnaires; Survival Rate | 2006 |
A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel | 2005 |
A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Salvage Therapy; Skin Neoplasms; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2005 |
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
[A phase II study of combination chemotherapy with gemcitabine, 5-fluorouracil, and cisplatin for advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2005 |
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
Topics: Adult; Aged; Aged, 80 and over; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Farnesyltranstransferase; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Piperidines; Pyridines; Salvage Therapy; Survival Analysis; Urologic Neoplasms | 2005 |
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leukopenia; Male; Melanoma; Middle Aged; Survival Analysis; Thrombocytopenia; Uveal Neoplasms | 2005 |
Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Neutropenia; Pleural Neoplasms; Survival Analysis; Thrombocytosis; Treatment Outcome | 2005 |
A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Carcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intestine, Small; Life Tables; Lymphatic Irradiation; Male; Middle Aged; Neoadjuvant Therapy; Palliative Care; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Radiation Injuries; Radiation-Sensitizing Agents; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Italy; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Phase II study of gemcitabine in children with relapsed acute lymphoblastic leukemia or acute myelogenous leukemia (ADVL0022): a Children's Oncology Group Report.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Failure | 2006 |
Pharmacokinetics of gemcitabine combined with trastuzumab in patients with advanced breast cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Deoxycytidine; Female; Gemcitabine; Humans; Metabolic Clearance Rate; Middle Aged; Severity of Illness Index; Tissue Distribution; Trastuzumab | 2005 |
Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Outpatients; Paclitaxel; Survival Rate | 2005 |
Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Tegafur; Treatment Outcome | 2005 |
Efficacy of platinum-based chemotherapy after cranial radiation in patients with brain metastasis from non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclin A; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Respiratory Tract Neoplasms; S Phase | 2005 |
Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Models, Statistical; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Sequential therapy with Vinorelbine followed by Gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities--a multicenter phase II trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Drug Administration Schedule; Female; Frail Elderly; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Palliative Care; Risk Factors; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2005 |
Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Survival Rate | 2005 |
[Changes in tumor marker levels as a predictor of gemcitabine effect on patients with unresectable or recurrent pancreatic cancer].
Topics: Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2005 |
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2005 |
A randomized phase III study of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin as salvage chemotherapy followed by posttransplantation rituximab maintenance therapy versus observation for treatment of aggressive
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cytarabine; Deoxycytidine; Dexamethasone; Gemcitabine; Humans; Lymphoma, B-Cell; Lymphoma, T-Cell; Rituximab | 2005 |
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Endpoint Determination; Gemcitabine; Humans; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2005 |
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: a phase-II trial by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Analysis; Vinblastine; Vinorelbine | 2005 |
Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2005 |
Phase II study on low dose gemcitabine plus oral chemotherapy with uracil-tegafur and cyclophosphamide in combination with radiotherapy against recurrent and advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Constipation; Cyclophosphamide; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Fever; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy; Survival Rate; Tegafur; Thrombocytopenia; Treatment Outcome; Uracil | 2005 |
Gemcitabine and mitoxantrone in metastatic breast cancer: a phase-I-study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neutropenia | 2005 |
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Analysis; Thrombocytopenia | 2005 |
Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2005 |
Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Phase II randomized study comparing the toxicity profile of gemcitabine plus cisplatin with gemcitabine plus oral etoposide in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Rate; Treatment Outcome | 2005 |
Phase II trial of primary radiation therapy and concurrent chemotherapy for patients with locally advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy Dosage; Ribonucleotide Reductases; Survival Rate | 2005 |
Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; International Agencies; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Combination of vinorelbine plus gemcitabine in previously treated patients with small cell lung cancer: a multicentre phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Remission Induction; Vinblastine; Vinorelbine | 2005 |
Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: a multicenter Belgian Phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 2005 |
Primary chemotherapy with gemcitabine as prolonged infusion, non-pegylated liposomal doxorubicin and docetaxel in patients with early breast cancer: final results of a phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Liposomes; Mastectomy, Segmental; Middle Aged; Taxoids; Treatment Outcome | 2005 |
Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Activity of carboplatin in patients with advanced non-small cell lung cancer pre-treated with a non-platinum combination.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cisplatin; Cyclooxygenase Inhibitors; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis | 2005 |
Gemcitabine, vinorelbine and prednisone for refractory or relapsed aggressive lymphoma, results of a phase II single center study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Graft vs Host Disease; Humans; Infections; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Prospective Studies; Recurrence; Remission Induction; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neurotoxicity Syndromes; Organoplatinum Compounds; Stomach Neoplasms; Survival Rate | 2005 |
Gemcitabine as prolonged infusion and vinorelbine in anthracycline and/or taxane pretreated metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Neoplasms; Colorectal Neoplasms; Cytotoxicity, Immunologic; Deoxycytidine; Disease Progression; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Infusions, Intravenous; Interleukin-2; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; T-Lymphocytes, Regulatory; Thymidylate Synthase; Treatment Outcome | 2005 |
Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Thrombocytopenia; Vomiting | 2005 |
Phase I study of vinorelbine plus gemcitabine as third-line chemotherapy for refractory non-small cell lung cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree.
Topics: Adenocarcinoma; Biliary Tract Neoplasms; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Survival Rate | 2005 |
PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrazines; Survival Analysis; Treatment Outcome | 2005 |
[A randomized trial of docetaxol plus cisplatin versus gemzar plus cisplatin in treating advanced non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids; Thrombocytopenia | 2005 |
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Pemetrexed; Survival Analysis; Treatment Outcome | 2005 |
Gemcitabine and vinorelbine (GV) versus cisplatin, gemcitabine and vinorelbine (CGV) as first-line treatment in advanced non small cell lung cancer: results of a prospective randomized phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
GRiN: a trial and tribulation in respiratory radiotherapy research.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2005 |
Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bexarotene; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome | 2005 |
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2005 |
Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Injections, Intra-Arterial; Injections, Intravenous; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
A Phase II study of capecitabine combined with gemcitabine in patients with advanced gallbladder carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Rate | 2005 |
Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Analysis; Treatment Outcome | 2005 |
An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 2006 |
A prospective, multicentre clinical trial comparing cisplatin plus gemcitabine with cisplatin plus etoposide in patients with locally advanced and metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome; Turkey | 2005 |
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Survival Analysis; Treatment Outcome | 2005 |
Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Urinary Bladder Neoplasms | 2005 |
Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Ribonucleotide Reductases; Survival Rate | 2006 |
Gemcitabine in the treatment of advanced head and neck cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Radiotherapy; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
A phase I trial of gemcitabine and topotecan in previously treated ovarian or peritoneal cancer: a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Topotecan | 2006 |
Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Outcome | 2006 |
Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Creatinine; Deoxycytidine; Female; Gemcitabine; Heart Diseases; Humans; Kidney Failure, Chronic; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2005 |
Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Darbepoetin alfa; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Erythropoietin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Ki-67 Antigen; Middle Aged; Neutropenia; Polyethylene Glycols; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Taxoids; Treatment Outcome | 2005 |
Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Adducts; Dose-Response Relationship, Drug; Floxuridine; Gemcitabine; Humans; Leukocytes; Male; Middle Aged; Platinum; Treatment Outcome | 2005 |
High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Salvage Therapy; Taxoids; Time Factors | 2006 |
Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Polyethylene Glycols; Quality of Life; Survival Rate; Treatment Outcome | 2006 |
Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis | 2005 |
UFT plus gemcitabine combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2005 |
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2005 |
Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Prospective Studies; Survival Analysis | 2005 |
Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors; Treatment Outcome | 2005 |
A two-cohort phase II clinical trial of gemcitabine plus treosulfan in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome; Uveal Neoplasms | 2005 |
[Phase II study of gemcitabine (GEM) and docetaxel (TXT) combination chemotherapy for unresectable non small cell lung cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids | 2005 |
Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2005 |
Biweekly administration of cisplatin/gemcitabine in advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Rate | 2005 |
Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2005 |
Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a Phase II Hoosier Oncology Group Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiotherapy, Intensity-Modulated; Time Factors; Treatment Outcome | 2005 |
Gemcitabine and paclitaxel in metastatic or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel | 2005 |
Phase I-II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Heart Ventricles; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Thrombocytosis | 2005 |
Adjuvant systemic chemotherapy with gemcitabine for stage IV pancreatic cancer: a preliminary report of initial experience.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2005 |
Intravesical gemcitabine therapy for superficial transitional cell carcinoma: results of a Phase II prospective multicenter study.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Risk Factors; Urinary Bladder Neoplasms | 2005 |
Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Croatia; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Risk Assessment; Risk Factors; Survival Rate; Treatment Failure; Treatment Outcome | 2005 |
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones | 2005 |
Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Conformal; Taxoids | 2005 |
Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Chemotherapy for metastatic NSCLC: current status and future direction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mitomycin; Quality of Life; Survival Analysis; Treatment Outcome | 2005 |
Sequential gemcitabine-carboplatin followed by paclitaxel-carboplatin in the first-line treatment of advanced ovarian cancer: A phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Paclitaxel | 2006 |
Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Uterine Cervical Neoplasms | 2006 |
Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer.
Topics: Adult; Aged; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Survival Rate | 2005 |
Paclitaxel, carboplatin and gemcitabine combination as induction chemotherapy for stage IIIA N2 bulky non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Remission Induction; Survival Analysis; Treatment Outcome | 2005 |
No evidence of gemcitabine accumulation during weekly administration.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms | 2005 |
Concurrent cisplatin/gemcitabine chemotherapy along with radiotherapy in locally advanced cervical carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Uterine Cervical Neoplasms | 2006 |
Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quality of Life; Statistics, Nonparametric; Survival Analysis; Sweden | 2005 |
Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Needle; Bone Neoplasms; Capecitabine; Carcinoma, Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Phase I study of fixed dose rate infusion of gemcitabine in patients with unresectable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2005 |
A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Pemetrexed; Survival Analysis | 2006 |
Phase II study of neoadjuvant chemotherapy with gemcitabine and vinorelbine in resectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Radiography; Vinblastine; Vinorelbine | 2005 |
Same-day pegfilgrastim and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Lung Neoplasms; Neutropenia; Polyethylene Glycols; Recombinant Proteins; Taxoids; Vinblastine; Vinorelbine | 2005 |
CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prednisone; Survival Rate; Vincristine | 2006 |
Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Ribonucleotide Reductases; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
First-line therapy with gemcitabine and paclitaxel in locally, recurrent or metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prognosis; Recurrence; Remission Induction; Time Factors; Treatment Outcome | 2005 |
Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Doxorubicin; Fatigue; Female; Fluorouracil; Gemcitabine; Hepatitis B, Chronic; Humans; Liposomes; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Proteins; Paresthesia; Polyethylene Glycols; Salvage Therapy; Survival Analysis; Treatment Outcome | 2005 |
Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Life Tables; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2005 |
Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Female; Folic Acid Antagonists; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kidney; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrimidines; Salvage Therapy; Treatment Outcome | 2005 |
Phase I trial of gemcitabine, doxorubicin and cisplatin (GAP) in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasms; Ovarian Neoplasms | 2006 |
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Odds Ratio; Remission Induction; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Pyridines; Tegafur; Time Factors; Treatment Outcome | 2005 |
Chemoradiotherapy in patients with pancreatic carcinoma: phase-I study with a fixed radiation dose and escalating doses of weekly gemcitabine.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Blood Cell Count; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival | 2006 |
Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Biopsy; Carcinoma in Situ; Chromatography, High Pressure Liquid; Cystoscopy; Deoxycytidine; Disease-Free Survival; Drug Resistance; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Ribonucleotide Reductases; Treatment Outcome; Urinary Bladder Neoplasms | 2005 |
A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2006 |
Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2006 |
Phase II study of gemcitabine in children with relapsed leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Child, Preschool; Deoxycytidine; Female; Gemcitabine; Humans; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2006 |
Phase II study of gemcitabine plus vinorelbine in the treatment of cisplatin-resistant nasopharyngeal carcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Weekly gemcitabine and cisplatin in combination with pelvic radiation in the primary therapy of cervical cancer: a phase I trial of the Puget Sound Oncology Consortium.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Uterine Cervical Neoplasms | 2006 |
Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytotoxicity, Immunologic; Deoxycytidine; Female; Gemcitabine; Humans; Immunity, Cellular; Interleukin-10; Killer Cells, Natural; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Reference Values; Vascular Endothelial Growth Factor A | 2006 |
Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
A phase II study of weekly cisplatin and gemcitabine in patients with advanced pancreatic cancer: is this a strategy still worth pursuing?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Time Factors | 2006 |
The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2006 |
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Research Design; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Gemcitabine/carboplatin in patients with metastatic non-small-cell lung cancer: phase II study of 28-day and 21-day schedules.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2005 |
Randomized multicenter phase II study of gemcitabine versus docetaxel as first-line therapy with second-line crossover in advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Brief communication: a new combination in the treatment of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Survival Rate | 2005 |
Gemcitabine plus docetaxel: a new treatment option for anthracycline pretreated metastatic breast cancer patients?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Prodrugs; Prospective Studies; Remission Induction; Taxoids | 2005 |
Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2005 |
High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab | 2005 |
A phase II trial of gemcitabine and weekly high-dose 5-fluorouracil in a 48-hour continuous-infusion schedule in patients with advanced pancreatic carcinoma. A study of the Spanish Cooperative Group for Gastrointestinal Tumour Therapy (TTD).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Hyperbilirubinemia; Infusions, Intravenous; Male; Middle Aged; Mucositis; Neutropenia; Pancreatic Neoplasms; Patient Compliance; Quality of Life; Spain; Survival Analysis; Treatment Outcome | 2005 |
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: final results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Taxoids | 2005 |
Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Procarbazine; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
SCOTROC 2A: carboplatin followed by docetaxel or docetaxel-gemcitabine as first-line chemotherapy for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Dyspnea; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Tegafur; Treatment Outcome; Uracil | 2006 |
Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Ribonucleotide Reductases; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urologic Neoplasms; Urothelium | 2006 |
A phase II study of single-agent gemcitabine as a second-line treatment in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Prognosis; Remission Induction; Survival Analysis; Vomiting, Anticipatory | 2006 |
A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy Dosage; Safety; Survival Rate; Treatment Outcome | 2006 |
Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Prospective Studies | 2005 |
Multimodality treatment of unresectable stage III non-small cell lung cancer: interim analysis of a phase II trial with preoperative gemcitabine and concurrent radiotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2006 |
Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life | 2006 |
Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Paclitaxel; Prognosis; Risk Factors; Survival Rate; Thrombocytopenia; Treatment Outcome | 2006 |
A phase I dose finding study of cisplatin, gemcitabine, and weekly docetaxel for patients with advanced transitional cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Taxoids; Urinary Bladder Neoplasms | 2006 |
Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Sarcoma; Survival Analysis; Treatment Outcome | 2006 |
Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: a multicenter phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II trial of gemcitabine and cisplatin sequentially administered in Asian patients with unresectable or metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Singapore | 2006 |
A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Rate; Treatment Outcome | 2006 |
A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2006 |
Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Korea; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2006 |
Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cognition; Cognition Disorders; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Longitudinal Studies; Middle Aged; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2006 |
Intravesical gemcitabine in BCG-refractory T1G3 transitional cell carcinoma of the bladder: a pilot study.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Treatment Failure; Urinary Bladder Neoplasms | 2006 |
Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Nausea; Neutropenia; Retrospective Studies; Sarcoma; Survival Analysis; Taxoids; Thrombocytopenia; Treatment Outcome | 2006 |
Comparison of standard-dose and low-dose gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Time Factors | 2006 |
Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides; Protein Kinase C; Retrospective Studies; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Salvage Therapy; Survival Analysis; Thiophenes | 2006 |
[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Misonidazole; Positron-Emission Tomography; Prospective Studies; Pulmonary Embolism; Radiopharmaceuticals; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer.
Topics: Adenosine Triphosphatases; Adult; Aged; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Deoxycytidine; DNA Helicases; DNA Repair; DNA-Binding Proteins; Female; Gemcitabine; Genotype; Humans; Male; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; RecQ Helicases; Tumor Suppressor Proteins | 2006 |
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel | 2006 |
Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Italy; Male; Mesothelioma; Methotrexate; Middle Aged; Mitomycin; Mitoxantrone; Neoplasm Staging; Pleural Neoplasms; Retrospective Studies; Treatment Outcome | 2006 |
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Oligonucleotides, Antisense; Phosphorothioate Oligonucleotides; Survival Analysis | 2006 |
Phase II study of gemcitabine, doxorubicin and paclitaxel (GAT) as first-line chemotherapy for metastatic breast cancer: a translational research experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur | 2006 |
Phase II study of the combination of gemcitabine and nedaplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome | 2006 |
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Uterine Cervical Neoplasms | 2006 |
A phase I study of oral uracil-tegafur prior to weekly intravenous gemcitabine in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prodrugs; Tegafur; Uracil | 2006 |
Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome | 2006 |
Improvement of quality of life with Shenfu injection in non small cell lung cancer patients treated with gemcitabine plus cisplatin regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cross-Over Studies; Deoxycytidine; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life | 2006 |
Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liposomes; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Rate | 2006 |
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes.
Topics: Administration, Oral; Aged; Androgens; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Probability; Prognosis; Prostatic Neoplasms; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Gemcitabine; Humans; Infusions, Intravenous; Organoplatinum Compounds; Oxaliplatin; Pain; Pain Measurement; Placebos; Treatment Outcome; Urologic Neoplasms | 2006 |
Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Esophageal Neoplasms; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2006 |
Combination chemotherapy with gemcitabine and cisplatin as first-line treatment for immunohistochemically proven cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Infusions, Intravenous; Male; Middle Aged; Survival Analysis | 2006 |
A pilot trial of gemcitabine and vinorelbine plus capecitabine in locally advanced or metastatic nonsmall cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pneumonia; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Endpoint Determination; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2007 |
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Vascular Endothelial Growth Factor A | 2006 |
Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Signal Transduction; Treatment Outcome | 2006 |
A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Patient Compliance; Quality of Life; Survival Analysis; Taxoids | 2007 |
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2006 |
Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms | 2006 |
Phase I-II trial of weekly gemcitabine plus high-dose 5-fluorouracil and leucovorin in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phenylenediamines; Prognosis; Survival Rate | 2006 |
Gemcitabine and oxaliplatin followed by paclitaxel and carboplatin as first line therapy for patients with suboptimally debulked, advanced epithelial ovarian cancer. A phase II trial of sequential doublets. The GO-First Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Survival Rate | 2006 |
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms | 2006 |
Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Rate; Urologic Neoplasms | 2006 |
A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life | 2006 |
Gemcitabine concurrent with thoracic radiotherapy after induction chemotherapy with gemcitabine/vinorelbine in locally advanced non-small cell lung cancer: a phase I study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Remission Induction; Respiratory Function Tests; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Cisplatin plus gemcitabine on days 1 and 4 every 21 days for solid tumors: result of a dose-intensity study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome | 2007 |
Phase II study of gemcitabine plus cisplatin in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2006 |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Vitamin B Complex | 2006 |
Phase I/II study of gemcitabine and epirubicine in stage IIIB-IV non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Treatment Outcome | 2006 |
Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 2006 |
A phase I/II multicentric trial of gemcitabine and epirubicin in patients with advanced pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Gemcitabine; Hemoglobins; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Platelet Count | 2006 |
Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.
Topics: Aged; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur; Time Factors | 2006 |
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2006 |
Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome | 2006 |
A phase I study assessing the safety and pharmacokinetics of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with gemcitabine and cisplatin in patients with solid tumors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Oligopeptides; Thrombospondin 1 | 2006 |
Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Survival Rate; Treatment Outcome | 2006 |
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aspartate Aminotransferases; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Hematologic Diseases; Humans; Ifosfamide; Infusions, Intravenous; Liver; Lung; Male; Middle Aged; Remission Induction; Sarcoma; Temozolomide; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Mitoxantrone plus gemcitabine in pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Mitoxantrone; Remission Induction; Salvage Therapy; Survival Rate | 2006 |
Multicenter study on the use of gemcitabine to prevent recurrence of multiple-recurring superficial bladder tumors following intravesical antiblastic agents and/or BCG: evaluation of tolerance.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2006 |
Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2006 |
Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2006 |
Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged | 2006 |
Evaluation of early DNA damage in healthcare workers handling antineoplastic drugs.
Topics: Adult; Analysis of Variance; Antineoplastic Agents; Biomarkers; Cancer Care Facilities; Comet Assay; Cyclophosphamide; Cytarabine; Deoxycytidine; DNA Damage; Environmental Monitoring; Epidemiological Monitoring; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Italy; Lymphocytes; Male; Middle Aged; Mouth Mucosa; Nursing Staff, Hospital; Occupational Exposure; Pharmacy Service, Hospital | 2006 |
Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anemia; Antimetabolites, Antineoplastic; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Middle Aged; Neoplasm Metastasis; Recurrence; Severity of Illness Index; Stomatitis; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome | 2007 |
Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
[Carboplatin plus gemcitabine therapy versus carboplatin plus weekly paclitaxel therapy for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia | 2006 |
Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
Topics: Aged; Antimetabolites, Antineoplastic; Contrast Media; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gadolinium DTPA; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Predictive Value of Tests; Treatment Outcome | 2006 |
Phase II trial of intravesical gemcitabine in bacille Calmette-Guérin-refractory transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Remission Induction; Urinary Bladder Neoplasms | 2006 |
Rational drug sequencing of paclitaxel, gemcitabine and carboplatin in patients with untreated stage IV and select stage IIIB non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pleural Effusion; Survival Analysis; Treatment Outcome | 2006 |
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Greece; Head and Neck Neoplasms; Humans; Male; Middle Aged; Paclitaxel; Patient Compliance; Polyethylene Glycols; Survival Analysis; Treatment Outcome | 2006 |
Clinical monitoring of innate cellular immunity of monocytes/macrophages by tumor necrosis factor alpha productivity in whole blood stimulated by lipopolysaccharide in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunity, Cellular; Lipopolysaccharides; Liver Neoplasms; Macrophages; Male; Middle Aged; Monocytes; Pancreatectomy; Pancreatic Neoplasms; Survival Analysis; Tumor Necrosis Factor-alpha | 2006 |
Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced nonsmall cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Survival; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Mixed Tumor, Mullerian; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Topotecan | 2006 |
Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Survival Analysis; Time Factors; Urinary Bladder Neoplasms; Vinblastine | 2006 |
A phase II study of gemcitabine and immunotherapy in renal cancer: preliminary results and review of the literature.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Topotecan | 2006 |
Pharmacokinetic evaluation of gemcitabine and 2',2'-difluorodeoxycytidine-5'-triphosphate after prolonged infusion in patients affected by different solid tumors.
Topics: Adult; Aged; Cytidine Triphosphate; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2006 |
Gemcitabine and anthracyclines in platinum-resistant ovarian cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Treatment Outcome | 2006 |
Topoisomerase I, II alpha and II beta mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Deoxycytidine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Administration Schedule; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Middle Aged; Neoplasms; RNA, Messenger; Time Factors; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2006 |
Simplified gemcitabine and platin regimen in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to be proposed as neoadjuvant therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Quality of Life | 2006 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2007 |
Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab; Up-Regulation; Vinblastine; Vinorelbine | 2006 |
[Modern possibilities of chemotherapy in patients with ductal pancreatic adenocarcinoma].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2006 |
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Time Factors; Treatment Outcome | 2006 |
Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Gemcitabine (GEM) and vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): a phase II study in elderly or poor performance status patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pain; Time Factors; Treatment Outcome; Vindesine | 2006 |
Gemcitabine and split-dose paclitaxel or docetaxel in metastatic breast cancer: a randomised phase II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Treatment Failure | 2006 |
Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life | 2006 |
Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Recurrence; Survival Rate; Treatment Outcome | 2006 |
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.
Topics: Administration, Intravesical; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Dipyridamole; Dose-Response Relationship, Drug; Drug Synergism; Equilibrative Nucleoside Transporter 1; Excitatory Amino Acid Antagonists; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Phosphoribosylglycinamide Formyltransferase; Phosphorylation; Proto-Oncogene Proteins c-akt; S Phase; Thioinosine; Thymidylate Synthase; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Phase II study of combination chemotherapy with gemcitabine and irinotecan in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Platinum; Survival Rate | 2006 |
A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatic Neoplasms; Survival Rate | 2006 |
A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Survival Analysis; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium | 2006 |
Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Salvage Therapy; Survival Rate | 2006 |
Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Mycosis Fungoides; Receptors, Interleukin-2; Sezary Syndrome; Skin Neoplasms; Treatment Outcome | 2006 |
A phase II study with gemcitabine and split-dose cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Treatment Outcome | 2006 |
[Combination chemotherapy with gemcitabine and S-1 for advanced pancreatic cancer].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Thrombocytopenia | 2006 |
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Compliance | 2006 |
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Treatment Outcome | 2006 |
Stimulation of erythrocyte phosphatidylserine exposure by paclitaxel.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Calcium; Carboplatin; Cell Size; Ceramides; Deoxycytidine; Endometrial Neoplasms; Erythrocytes; Female; Gemcitabine; Hematocrit; Humans; Mice; Mice, Inbred C57BL; Osmotic Pressure; Ovarian Neoplasms; Paclitaxel; Phosphatidylserines; Protein Binding; Sphingomyelin Phosphodiesterase; Time Factors | 2006 |
Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Quality of Life; Risk Factors; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of gemcitabine in children with solid tumors of mesenchymal and embryonic origin.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Child; Child, Preschool; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasms; Prospective Studies; Sample Size | 2006 |
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neutropenia; Vinblastine; Vinorelbine | 2007 |
[A randomized comparative trial of three combined regimens containing cisplatin for treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Paclitaxel; Prospective Studies; Remission Induction; Survival Rate; Vinblastine; Vinorelbine | 2006 |
[Phase II trial of prolonged infusion of low-dose gemcitabine in advanced non-small cell lung cancer treatment].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Remission Induction; Survival Rate | 2006 |
Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gefitinib; Gemcitabine; Humans; Interleukin-8; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Vascular Endothelial Growth Factor A | 2006 |
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2006 |
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Quality of Life; Survival Analysis; Treatment Outcome | 2006 |
Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Taxoids; Treatment Outcome; Urologic Neoplasms | 2006 |
Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Home Infusion Therapy; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome | 2006 |
A phase II trial with gemcitabine and paclitaxel for the treatment of refractory and relapsed multiple myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Multiple Myeloma; Paclitaxel; Recurrence; Time Factors; Treatment Outcome | 2006 |
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Survival Analysis; Uveal Neoplasms | 2006 |
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Paclitaxel; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
[Gemcitabine and carboplatin chemotherapy in advanced transitional cell carcinoma in regard to patients with impaired renal function].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Function Tests; Kidney Pelvis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Survival Rate; Ureter; Ureteral Neoplasms; Urinary Bladder; Urinary Bladder Neoplasms | 2006 |
A triplet chemotherapy with cisplatin, docetaxel and gemcitabine in patients with advanced non-small-cell lung cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplasm Staging; Pregnancy; Survival Analysis; Taxoids; Treatment Outcome; Vomiting | 2007 |
Induction cisplatin-gemcitabine-paclitaxel plus concurrent radiotherapy and gemcitabine in the multimodality treatment of unresectable stage IIIB non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2006 |
A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lymphoma; Male; Middle Aged; Time Factors; Treatment Outcome | 2006 |
Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Taxoids | 2006 |
Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pilot Projects; Retinoblastoma Protein; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2006 |
Randomized, multicenter, open-label phase II study of gemcitabine plus single-dose versus split-dose carboplatin in the treatment of patients with advanced-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 2006 |
Short-schedule intravesical gemcitabine with ablative intent in recurrent Ta-T1, G1-G2, low- or intermediate-risk, transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Risk Factors; Urinary Bladder Neoplasms | 2007 |
Which benefit from adding gemcitabine to vinorelbine in elderly (>or=70 years) women with metastatic breast cancer? Early interruption of a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Taxoids; Treatment Outcome; Vomiting | 2007 |
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Treatment Outcome | 2006 |
Randomized phase II trial of gemcitabine plus weekly versus three-weekly paclitaxel in previously untreated advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Gemcitabine and epirubicin in patients with metastatic breast cancer: a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; France; Gemcitabine; Humans; Infusions, Intravenous; Menopause; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2006 |
Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: a multicenter phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Survival Analysis; Treatment Outcome | 2006 |
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase Inhibitors; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Pyrazoles; Sulfonamides; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Ribonucleoside Diphosphate Reductase; RNA, Messenger | 2007 |
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prospective Studies | 2007 |
Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate | 2007 |
Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative On
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2006 |
Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome | 2007 |
Coadministration of oxaliplatin does not influence the pharmacokinetics of gemcitabine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Platinum; Treatment Outcome | 2006 |
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate; Vinblastine; Vinorelbine | 2007 |
First-line gemcitabine and carboplatin in advanced ovarian carcinoma: a phase II study.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2006 |
Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Australia; Carboplatin; Carcinoma, Large Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Unknown Primary; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2006 |
Chemotherapy with gemcitabine, paclitaxel, and cisplatin in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2006 |
[Effect of combined treatment methods on quality of life in patients with pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Data Interpretation, Statistical; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Status; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy Dosage; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2006 |
Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Rate | 2007 |
Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intravenous; Italy; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Vinblastine; Vinorelbine | 2006 |
Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Taxoids; Time Factors; Treatment Outcome | 2007 |
The efficacy and relationship between peak concentration and toxicity profile of fixed-dose-rate gemcitabine plus carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2007 |
Phase II trial of gemcitabine and docetaxel in patients with completely resected stage IIA-IIIA non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Survival Rate; Taxoids | 2007 |
Treatment of Stage IV(A-B) nasopharyngeal carcinoma by induction-concurrent chemoradiotherapy and accelerated fractionation: impact of chemotherapy schemes.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Radiotherapy, Conformal; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
Phase I study of bryostatin 1 and gemcitabine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2006 |
A phase II study of sequential neoadjuvant gemcitabine and paclitaxel, radiation therapy with cisplatin and 5-fluorouracil and surgery in locally advanced esophageal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Analysis; Treatment Outcome | 2006 |
Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome | 2006 |
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer.
Topics: Adult; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Snake Venoms; Surveys and Questionnaires; Survival Rate | 2006 |
A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Treatment Outcome | 2007 |
Phase II study of cisplatin combined with weekly gemcitabine in the treatment of patients with metastatic pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Intravenous; Korea; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2006 |
Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Survival; Deoxycytidine; Docetaxel; Erythrocytes; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Urothelium | 2007 |
Biweekly gemcitabine plus vinorelbine in first-line metastatic breast cancer: efficacy and correlation with HER2 extracellular domain.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Receptor, ErbB-2; Vinblastine; Vinorelbine | 2006 |
Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2-3 transitional bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Radiotherapy; Urinary Bladder Neoplasms; Urologic Surgical Procedures; Vinblastine | 2006 |
Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Survival Rate; Thromboembolism; Vomiting, Anticipatory | 2007 |
Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Analysis | 2007 |
Phase II trial of dose-dense doxorubicin plus gemcitabine followed by paclitaxel plus carboplatin in patients with advanced urothelial carcinoma and impaired renal function.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Kidney Diseases; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2007 |
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Turkey; Urinary Bladder Neoplasms; Urothelium | 2007 |
Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life | 2007 |
Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Male; Middle Aged; Recurrence; Stem Cell Transplantation; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial.
Topics: Adult; Aged; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pemetrexed; Survival Rate; Treatment Failure | 2007 |
Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2007 |
Gemcitabine/carboplatin in a modified 21-day administration schedule for advanced-stage non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Thrombocytopenia; Treatment Outcome | 2006 |
Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis | 2007 |
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2007 |
Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Evaluation; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Survival Rate; Taxoids | 2007 |
A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Taxoids | 2007 |
Low-dose radiotherapy as a chemopotentiator of gemcitabine in tumors of the pancreas or small bowel: a phase I study exploring a new treatment paradigm.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Humans; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents | 2007 |
Phase II study of paclitaxel plus gemcitabine salvage chemotherapy for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Indiana; Kaplan-Meier Estimate; Male; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Salvage Therapy; Testicular Neoplasms; Time Factors; Treatment Failure; Treatment Outcome | 2007 |
Intra-patient alternated dose escalation of paclitaxel and gemcitabine versus paclitaxel followed by fixed dose rate infusion of gemcitabine in fit elderly non-small cell lung cancer patients. A Southern Italy Cooperative Oncology Group randomised phase I
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Paclitaxel; Survival Analysis; Survival Rate | 2007 |
Bi-weekly administration of gemcitabine plus vinorelbine in elderly patients with advanced non-small-cell lung cancer: multicenter phase II trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Japan; Lung Neoplasms; Male; Neoplasm Staging; Radiation-Sensitizing Agents; Retrospective Studies; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunoglobulin G; Male; Middle Aged; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Vaccination; Vaccines, Subunit | 2007 |
Open, randomized, phase II study of single-agent gemcitabine and docetaxel as first- and second-line treatment in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids | 2007 |
[Phase III randomised trial of adjuvant chemotherapy with cisplatin plus docetaxel versus cisplatin plus gemcitabine in resected non-small cell bronchial carcinoma with quality of life as the primary objective].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; France; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Surveys and Questionnaires; Survival Rate; Taxoids | 2006 |
Phase I trial of intraperitoneal gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Parenteral; Male; Middle Aged; Peritoneal Neoplasms | 2007 |
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Gemcitabine; Humans; Imidazoles; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Pain Measurement; Palliative Care; Prednisone; Probability; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid | 2007 |
Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms | 2007 |
Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Taxoids; Vinblastine; Vinorelbine | 2007 |
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome | 2007 |
A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Survival Rate | 2007 |
A phase I study of bi-weekly administration of 24-h gemcitabine followed by 24-h irinotecan in patients with solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Carcinoma, Small Cell; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Female; Gastrointestinal Hemorrhage; Gemcitabine; Half-Life; Humans; Infusions, Intravenous; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms | 2007 |
Phase III study in stage IV non-small-cell lung cancer patients treated with two courses of cisplatin/gemcitabine followed by a randomization to three additional courses of the same combination or gemcitabine alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Diseases; Humans; Ifosfamide; Male; Neoplasm Metastasis; Survival Analysis; Urinary Bladder Neoplasms; Urothelium | 2007 |
13-cis-Retinoic acid in combination with gemcitabine in the treatment of locally advanced and metastatic pancreatic cancer--report of a pilot phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Isotretinoin; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Palliative Care; Pancreatic Neoplasms; Pilot Projects; Prognosis; Ribonucleotide Reductases; Survival Rate; Treatment Outcome | 2007 |
A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; California; Cisplatin; Comorbidity; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2007 |
Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Treatment Outcome; Vomiting | 2008 |
A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Gemcitabine; Humans; Kidney Neoplasms; Leukopenia; Lung Neoplasms; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Sarcoma; Urinary Bladder Neoplasms; Uterine Neoplasms; Water-Electrolyte Imbalance | 2007 |
Phase II study of consolidation chemotherapy after concurrent chemoradiation in cervical cancer: preliminary results.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Comorbidity; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Korea; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2007 |
Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Comorbidity; Deoxycytidine; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Male; Michigan; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2007 |
Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; History, 16th Century; History, 17th Century; Humans; Male; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2007 |
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Pleural Neoplasms; Pneumonectomy; Radiation Dosage; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Time Factors | 2007 |
A phase III randomised trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome | 2007 |
A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; United States | 2006 |
Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate | 2006 |
Phase I/II study of gemcitabine and exisulind as second-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Sulindac; Survival Analysis; Treatment Outcome; Vomiting | 2006 |
Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Pneumonectomy; Prospective Studies | 2006 |
Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Esophagus; Female; Forced Expiratory Volume; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy; Radiotherapy Dosage; Thorax | 2006 |
Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids | 2006 |
A phase II study of induction therapy with carboplatin and gemcitabine among patients with locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Denmark; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome | 2006 |
Gemcitabine, cisplatin, and hyperfractionated accelerated radiotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Radiation Injuries; Radiation-Sensitizing Agents; Survival Rate | 2006 |
A phase II trial of carboplatin and gemcitabine with exisulind (IND #65,056) in patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (E1501).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Sulindac; Survival Rate | 2006 |
Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Severity of Illness Index; Treatment Outcome | 2007 |
A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Genetic; Taxoids | 2007 |
Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed | 2007 |
A randomized phase II trial of single-agent gemcitabine, vinorelbine, or docetaxel in patients with advanced non-small cell lung cancer who have poor performance status and/or are elderly.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2007 |
Four-modality therapy in malignant pleural mesothelioma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Epirubicin; Feasibility Studies; Female; Gemcitabine; Humans; Interleukin-2; Male; Mesothelioma; Middle Aged; Pleura; Pleural Neoplasms; Radiotherapy, Adjuvant | 2007 |
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasms; Tegafur; Uracil | 2007 |
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Hodgkin Disease; Humans; Middle Aged; Neutropenia; Patient Selection; Polyethylene Glycols; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Mesothelioma; Middle Aged; Neoadjuvant Therapy; Pleural Neoplasms; Pneumonectomy; Quality of Life; Radiotherapy | 2007 |
[Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction | 2007 |
Clinical phase I and pharmacology study of gemcitabine (2', 2'-difluorodeoxycytidine) administered in a two-weekly schedule.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Metabolic Clearance Rate; Middle Aged; Neoplasms | 2007 |
Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d'Etudes des Tumeurs Uro-Génitales) study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome | 2007 |
Weekly gemcitabine as a radiosensitiser for the treatment of brain metastases in patients with non-small cell lung cancer: phase I trial.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Radiation-Sensitizing Agents | 2007 |
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Prognosis; Quinazolines; Risk Assessment; Statistics, Nonparametric; Survival Analysis | 2007 |
Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urologic Neoplasms; Urothelium | 2007 |
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; International Agencies; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms | 2007 |
Phase II trial of pegylated liposomal doxorubicin (Caelyx) plus Gemcitabine in chemotherapeutically pretreated patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Polyethylene Glycols; Survival; Treatment Outcome | 2007 |
A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Phase II study of gemcitabine and cisplatin in patients with previously untreated extensive stage small cell lung cancer: Southwest Oncology Group Study 9718.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2007 |
Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Failure | 2007 |
A dose escalation study of docetaxel plus capecitabine in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Patient Compliance; Stomach Neoplasms; Taxoids; Treatment Outcome | 2006 |
Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2008 |
Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Rituximab; Salvage Therapy; Survival Rate | 2007 |
Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lactones; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Sulfones; Survival Rate | 2007 |
Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Taxoids | 2007 |
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2007 |
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Trastuzumab; Urinary Bladder Neoplasms | 2007 |
Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Asian People; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2007 |
Gemcitabine and irinotecan for patients with untreated extensive stage small cell lung cancer: SWOG 0119.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2007 |
Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis | 2007 |
Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Pharyngeal Neoplasms; Recurrence; Taxoids; Treatment Outcome | 2007 |
A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Survival Rate | 2007 |
A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urothelium.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms; Urothelium | 2007 |
Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2007 |
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2007 |
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazines | 2007 |
Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2007 |
A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret hospital Phase II consortium.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones; Treatment Failure | 2007 |
Gemcitabine administered as a short infusion versus a fixed dose rate in combination with cisplatin for the treatment of patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2007 |
Impact of preoperative chemoradiotherapy on survival in patients with resectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Female; Gemcitabine; Hospital Mortality; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Survival Rate | 2007 |
Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.
Topics: Abdominal Neoplasms; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Carcinoembryonic Antigen; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Neutropenia; Treatment Outcome | 2007 |
Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis | 2008 |
Sequential (gemcitabine/vinorelbine) and concurrent (gemcitabine) radiochemotherapy with FDG-PET-based target volume definition in locally advanced non-small cell lung cancer: first results of a phase I/II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Probability; Prognosis; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome; Tumor Burden; Vinblastine; Vinorelbine | 2007 |
Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Treatment Outcome | 2007 |
Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Taxoids; Treatment Outcome | 2007 |
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Treatment Outcome | 2007 |
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2007 |
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2007 |
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed | 2006 |
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2006 |
Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Salvage Therapy; Secondary Prevention; Survival Analysis; Taxoids | 2007 |
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2007 |
A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Female; Gemcitabine; Glucose; Half-Life; Hematologic Diseases; Humans; Ifosfamide; Male; Middle Aged; Pancreatic Neoplasms; Phosphoramide Mustards | 2008 |
Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2007 |
Intratumoural injection of the toll-like receptor-2/6 agonist 'macrophage-activating lipopeptide-2' in patients with pancreatic carcinoma: a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Combined Modality Therapy; Cytokines; Cytotoxicity, Immunologic; Deoxycytidine; Female; Gemcitabine; Granzymes; Humans; Injections, Intralesional; Killer Cells, Natural; Lipopeptides; Male; Middle Aged; Myocardial Infarction; Oligopeptides; Pancreatic Neoplasms; Survival Analysis; Time Factors; Toll-Like Receptor 2; Toll-Like Receptor 6; Treatment Outcome | 2007 |
An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a study.
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Staging; Patient Selection; Pleural Neoplasms; Severity of Illness Index; Taxoids; Treatment Outcome | 2007 |
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cisplatin; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Glycoproteins; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms; Peptides; Prognosis; Protein Kinase C; Protein Kinase C beta; RNA, Messenger; Survival Rate | 2007 |
Gemcitabine plus doxorubicin as first-line treatment in advanced or metastatic breast cancer (MBC), a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Treatment Outcome | 2006 |
Phase II study of combination chemotherapy with gemcitabine and cisplatin for patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Demography; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2007 |
A phase I study of gemcitabine followed by cisplatin concurrent with whole pelvic radiation therapy in locally advanced cervical cancer: a Gynecologic Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Pelvis; Radiotherapy, Adjuvant; United States; Uterine Cervical Neoplasms | 2007 |
Economic evaluation of docetaxel/gemcitabine versus docetaxel as frontline treatment of patients with advanced/metastatic non-small cell lung cancer in Greece.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Greece; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids | 2007 |
Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Kidney Function Tests; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Urinary Bladder Neoplasms | 2007 |
[Efficacy of transcatheter arterial chemoembolization combined thalidomide on hepatocellular carcinoma: a controlled randomized trial].
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Deoxycytidine; Exanthema; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Thalidomide; Young Adult | 2007 |
Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Survival Analysis; Tegafur; Treatment Failure; Treatment Outcome | 2007 |
A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Neoplasm Metastasis; Recombinant Proteins; Thalidomide | 2008 |
Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Rate | 2008 |
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Survival Rate; Treatment Outcome | 2007 |
Docetaxel versus docetaxel plus gemcitabine as front-line treatment of patients with advanced non-small cell lung cancer: a randomized, multicenter phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids | 2008 |
A dose escalation study of biweekly oral vinorelbine and gemcitabine in patients with solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Female; Gemcitabine; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prospective Studies; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: long-term follow up data.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Time Factors | 2007 |
Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2007 |
Concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy; Survival Rate | 2007 |
A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gemcitabine; Humans; Hypoxia; Leukocytes, Mononuclear; Lung Neoplasms; Male; Methemoglobinemia; Middle Aged; Pyridines; Thiosemicarbazones; Treatment Outcome | 2008 |
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2007 |
Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin's lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin's Lymphoma Stud
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Interactions; Etoposide; Female; Gemcitabine; Germany; Hodgkin Disease; Humans; Lung; Male; Middle Aged; Pilot Projects; Prednisone; Procarbazine; Remission Induction; Vincristine | 2008 |
Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Taxoids; Treatment Outcome | 2007 |
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2008 |
Gemcitabine plus docetaxel as first-line biweekly therapy in locally advanced and/or metastatic urothelial carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Urologic Neoplasms; Urothelium | 2007 |
IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Deoxycytidine; Gemcitabine; Graft Survival; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Ifosfamide; Lenograstim; Middle Aged; Recombinant Proteins; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Female; Flavonoids; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Piperidines; Taxoids; Treatment Outcome | 2007 |
Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperazines; Pyrimidines; Treatment Outcome | 2007 |
Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis.
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Child; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Injections, Spinal; Male; Meningeal Neoplasms; Middle Aged | 2008 |
Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Platinum Compounds; Survival Rate; Treatment Outcome | 2008 |
Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2008 |
Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Treatment Outcome | 2007 |
Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Neoplasms; Patient Selection | 2007 |
A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Leukopenia; Life Expectancy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia | 2007 |
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Selection; Predictive Value of Tests; Pyrazoles; Sulfonamides; Treatment Outcome | 2007 |
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Quinazolines; Treatment Outcome; Urologic Neoplasms; Urothelium | 2008 |
Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2007 |
Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2007 |
Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
A phase 1 study of fixed dose rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2007 |
Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cimetidine; Deoxycytidine; Dexamethasone; Diphenhydramine; Female; Gemcitabine; Heart Diseases; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Ondansetron; Paclitaxel; Premedication; Proportional Hazards Models | 2008 |
Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Cisplatin; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Lung Neoplasms; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2008 |
Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pyridines; Salvage Therapy; Survival Analysis | 2007 |
Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis | 2007 |
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Taxoids | 2007 |
Phase II pharmacogenomics-based adjuvant therapy trial in patients with non-small-cell lung cancer: Southwest Oncology Group Trial 0720.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Patient Selection; Pharmacogenetics; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2007 |
Phase I and pharmacokinetic study of gemcitabine administered at fixed-dose rate, combined with docetaxel/melphalan/carboplatin, with autologous hematopoietic progenitor-cell support, in patients with advanced refractory tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Male; Maximum Tolerated Dose; Melphalan; Middle Aged; Neoplasms; Taxoids; Transplantation, Autologous | 2007 |
Gemcitabine and paclitaxel chemotherapy as a second-line treatment for advanced or metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2007 |
Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Probability; Risk Assessment; Single-Blind Method; Survival Analysis; Treatment Outcome | 2008 |
Phase II study of gemcitabine combined with platinum chemotherapy for recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds | 2007 |
Feasibility and efficacy of chemotherapy with gemcitabine mono and with paclitaxel/mitoxantron in gynaecological cancers.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Mitoxantrone; Paclitaxel; Palliative Care; Survival Analysis | 2007 |
Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Neoplasms, Unknown Primary; Recurrence; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome | 2007 |
The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prospective Studies; Radiotherapy; Radiotherapy Dosage; Time Factors | 2007 |
Activity of endovesical gemcitabine in BCG-refractory bladder cancer patients: a translational study.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Apoptosis; BCG Vaccine; Carcinoma, Transitional Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Humans; Male; Middle Aged; Survival Analysis; Technology Transfer; Urinary Bladder Neoplasms | 2007 |
Fixed dose-rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma: a dose-finding study.
Topics: Adult; Aged; Brain Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Radiation-Sensitizing Agents; Survival Analysis; Survival Rate | 2008 |
Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Treatment Failure; Treatment Outcome | 2007 |
GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Recurrence; Rituximab; Salvage Therapy; Treatment Outcome | 2008 |
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms | 2008 |
Prospective phase II trial of a combination of fixed dose rate infusion of gemcitabine with cisplatin and UFT as a first-line treatment in patients with advanced non-small-cell lung carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Tegafur; Uracil | 2008 |
Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group.
Topics: Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Feasibility Studies; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Testicular Neoplasms; Thrombocytopenia; Treatment Outcome | 2008 |
Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel | 2008 |
Phase II trial of low-dose gemcitabine in prolonged infusion and cisplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged | 2008 |
Weekly gemcitabine and cisplatin concurrent with pelvic irradiation for primary therapy of cervical cancer: report of the first seven cases in Thai women.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Thailand; Treatment Outcome; Uterine Cervical Neoplasms | 2007 |
Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Ascitic Fluid; Chromatography, High Pressure Liquid; Combined Modality Therapy; Deoxycytidine; Dialysis Solutions; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Dialysis; Pilot Projects; Survival Rate | 2008 |
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Farnesyltranstransferase; Fatigue; Female; Gemcitabine; HSP40 Heat-Shock Proteins; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Piperidines; Pyridines; Treatment Outcome; Vomiting | 2008 |
A phase II study of biweekly paclitaxel (P) and gemcitabine (G), followed by maintenance weekly paclitaxel in elderly patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel | 2008 |
Gemcitabine combined with oxaliplatin (GEMOX) as salvage treatment in elderly patients with advanced ovarian cancer refractory or resistant to platinum: a single institution experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum Compounds; Salvage Therapy | 2007 |
Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Remission Induction; Survival Analysis; Treatment Outcome | 2008 |
[Efficacy and toxicity of gemcitabine combined vinorelbine on metastatic breast cancer: a report of 34 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Remission Induction; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 2007 |
[Efficacy of gemcitabine with concurrent radiotherapy on stage III,inoperable non-small cell lung cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Esophagitis; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Radiotherapy, High-Energy; Remission Induction; Survival Rate | 2007 |
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2008 |
Study supports activity of gemcitabine in treatment of early-stage breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging | 2007 |
Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Pain; Rituximab; Survival Analysis; Treatment Outcome | 2008 |
Randomized crossover study evaluating the effect of gemcitabine infusion dose rate: evidence of auto-induction of gemcitabine accumulation.
Topics: Antimetabolites, Antineoplastic; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Neoplasms | 2007 |
Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2007 |
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; Radiography; ras Proteins; Risk Assessment; Risk Factors; Smoking; Surveys and Questionnaires; Switzerland; Treatment Outcome | 2008 |
3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome | 2008 |
Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Preliminary experience with gemcitabine and cisplatin adjuvant chemotherapy after liver transplantation for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Treatment Outcome | 2008 |
Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Survival Analysis; Time Factors; Treatment Outcome | 2008 |
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; California; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Neutropenia; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome | 2008 |
A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Compliance; Survival Analysis | 2008 |
A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Epothilones; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2008 |
Improving treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Taxoids | 2008 |
Irinotecan plus gemcitabine and 5-fluorouracil in advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2007 |
Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Female; Gemcitabine; HIV Infections; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organ Transplantation; Paclitaxel | 2008 |
A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2008 |
First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Survival Analysis; Taxoids | 2008 |
A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Female; Furans; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2008 |
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Leukopenia; Male; Mesothelioma; Middle Aged; Neutropenia; Pleural Neoplasms; Quality of Life; Remission Induction; Ribonucleotide Reductases; Survival Rate; Thrombocytopenia; Treatment Outcome | 2008 |
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Folic Acid; Gemcitabine; Glutamates; Guanine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pemetrexed; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium; Vitamin B 12; Vitamin B Complex | 2008 |
Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Infliximab; Liver Neoplasms; Male; Pancreatic Neoplasms; Placebos; Prognosis; Survival Rate | 2008 |
Randomized phase III trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01).
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Injections, Intravenous; Japan; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Survival Rate; Tegafur | 2008 |
A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, MDR; Humans; Leukopenia; Male; Middle Aged; Mouth Mucosa; Pancreatic Neoplasms; Polymorphism, Genetic; Pyridines; Ribonucleoside Diphosphate Reductase; Survival Rate; Thiosemicarbazones; Treatment Outcome | 2008 |
Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Eicosanoids; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Immunohistochemistry; Lipoxygenase Inhibitors; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Up-Regulation | 2008 |
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Quality of Life; Treatment Outcome | 2008 |
Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Survival Analysis; Treatment Outcome; Vomiting | 2008 |
[A pilot clinical trial of gemcitabine and capecitabine chemotherapy for the treatment of advanced renal cell carcinoma failing immunotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Salvage Therapy; Survival Rate | 2008 |
Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Pemetrexed; Pleural Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine, followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small-cell lung cancer: single-institution experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Hepatocellular; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prognosis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
A phase I study of gemcitabine plus palliative radiation therapy for advanced lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Esophagitis; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Palliative Care; Radiation-Sensitizing Agents; Treatment Outcome | 2008 |
Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en O
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2008 |
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2008 |
Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Routes; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Salvage Therapy; Treatment Outcome | 2008 |
Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids | 2008 |
Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-125 Antigen; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Survival Analysis | 2008 |
Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies | 2008 |
Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Pemetrexed; Pleural Neoplasms; Survival Analysis; Treatment Outcome | 2008 |
Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms | 2008 |
Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Drug Tolerance; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome | 2008 |
A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Patient Selection; Survival Analysis; Treatment Outcome | 2008 |
Phase 1/2 dose escalating study of twice-monthly pemetrexed and gemcitabine in patients with advanced cancer and non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome | 2008 |
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Vascular Endothelial Growth Factor A | 2008 |
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Deoxycytidine; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2008 |
Single-nucleotide polymorphisms of DNA damage response genes are associated with overall survival in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; DNA Damage; Gemcitabine; Genotype; Humans; Kaplan-Meier Estimate; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Radiotherapy | 2008 |
A phase II study of sequential neoadjuvant gemcitabine plus doxorubicin followed by gemcitabine plus cisplatin in patients with operable breast cancer: prediction of response using molecular profiling.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Prognosis | 2008 |
Phase I trial of a pathotropic retroviral vector expressing a cytocidal cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer.
Topics: Adult; Aged; CA-19-9 Antigen; Cyclin G; Cyclin G1; Cyclins; Deoxycytidine; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retroviridae; Stem Cells; Treatment Outcome | 2008 |
Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Quinazolines; Survival Analysis | 2008 |
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Survival Analysis | 2008 |
Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: results of a phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Survival Analysis; Vascular Endothelial Growth Factor A | 2008 |
Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Uterine Neoplasms | 2008 |
Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiography; Radiosurgery; Radiotherapy Dosage; Survival Analysis; Survivors | 2008 |
A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2009 |
[Phase I/II study of combination chemotherapy with gemcitabine and UFT for advanced pancreatic cancer in a multi-center trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Tegafur; Uracil | 2008 |
Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cetuximab; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin | 2008 |
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Research Design; Ribonucleoside Diphosphate Reductase; Taxoids; Tumor Suppressor Proteins | 2008 |
Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Quality of Life; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
A phase II trial of low-dose gemcitabine and radiation alternated to cisplatin and 5-fluorouracil: an active and manageable regimen for stage IV squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2008 |
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Survival Rate | 2007 |
Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: final results of a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy | 2008 |
Efficacy and safety of oxaliplatin and gemcitabine with bevacizumab in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Outcome | 2008 |
Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Paclitaxel; Survival Rate; Treatment Outcome | 2008 |
Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Endonucleases; Epirubicin; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2008 |
Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802): a trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Middle Aged; Neutropenia; Pemetrexed; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Radiotherapy Dosage; Radiotherapy, Adjuvant; Remission Induction; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids; Trastuzumab | 2009 |
Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cross-Over Studies; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Vinblastine; Vinorelbine | 2008 |
Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2008 |
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Prognosis; Radiography; Radiotherapy Dosage; Radiotherapy, Conformal; Remission Induction; Survival Rate; Thoracic Neoplasms | 2008 |
Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2008 |
Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Tomography, X-Ray Computed | 2007 |
Pegylated liposomal doxorubicin and gemcitabine in the front-line treatment of recurrent/metastatic breast cancer: a multicentre phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Polyethylene Glycols; Recurrence; Treatment Outcome | 2008 |
Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Tissue Distribution; Treatment Outcome | 2009 |
Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Prospective Studies; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome; Urologic Neoplasms | 2008 |
Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in Asian women with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Polyethylene Glycols; Treatment Outcome | 2008 |
Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines | 2008 |
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed | 2008 |
Docetaxel plus gemcitabine as front-line chemotherapy in elderly patients with lung adenocarcinomas: a multicenter phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Prospective Studies; Taxoids; Time Factors; Treatment Outcome | 2009 |
Efficacy and factors affecting outcome of gemcitabine concurrent chemoradiotherapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Survival Analysis; Survival Rate; Taiwan; Treatment Outcome | 2009 |
Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nelfinavir; Pancreatic Neoplasms; Treatment Outcome | 2008 |
Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gemcitabine; Humans; Hyperglycemia; Leukopenia; Lung Neoplasms; Male; Maximum Tolerated Dose; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome | 2008 |
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Axitinib; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2008 |
Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Thrombocytopenia | 2007 |
Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Cell Proliferation; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; T-Lymphocytes | 2008 |
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Taxoids; Uterine Neoplasms | 2008 |
Phase I study of biweekly oxaliplatin, gemcitabine and capecitabine in patients with advanced upper gastrointestinal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2008 |
Treatment of recurrent or persistent platinum-refractory ovarian, fallopian tube or primary peritoneal cancer with gemcitabine and topotecan: a phase II trial of the Puget Sound Oncology Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Fallopian Tube Neoplasms; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Quality of Life; Topotecan | 2008 |
Dose escalation of gemcitabine is possible with concurrent chest three-dimensional rather than two-dimensional radiotherapy: a phase I trial in patients with stage III non-small-cell lung cancer.
Topics: Abdomen; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Treatment Outcome | 2009 |
A phase II clinical trial of gemcitabine and split dose cisplatin in advanced non-small cell lung cancer in an outpatient setting.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2008 |
A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
Topics: Abdominal Cavity; Aged; Antimetabolites, Antineoplastic; Ascites; Blood Gas Analysis; Deoxycytidine; Drug Administration Schedule; Drug Delivery Systems; Extracorporeal Circulation; Female; Gemcitabine; Humans; Hypoxia; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Perfusion | 2009 |
Nonplatinum topotecan combinations versus topotecan alone for recurrent ovarian cancer: results of a phase III study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Deoxycytidine; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Proportional Hazards Models; Quality of Life; Survival Rate; Topotecan; Treatment Outcome | 2008 |
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Injections, Subcutaneous; Interleukin-2; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Recombinant Proteins; Treatment Outcome | 2008 |
A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in non-small cell lung cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Kinetics; Lung Neoplasms; Male; Middle Aged; Neoplasms; Time Factors | 2008 |
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2008 |
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polyglutamic Acid; Survival Rate | 2008 |
Fever-range whole-body thermal therapy combined with cisplatin, gemcitabine, and daily interferon-alpha: a description of a phase I-II protocol.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Hyperthermia, Induced; Interferon-alpha; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quality of Life | 2008 |
Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Trastuzumab | 2008 |
[Phase II study of combination of gemcitabine and carboplatin in advanced non-small cell lung cancer (an interim report)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging | 2008 |
[Randomized phase II study of carboplatin/paclitaxel followed by gemcitabine versus carboplatin/gemcitabine followed by docetaxel in patients with advanced nonsmall cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids | 2008 |
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy; Infusions, Intravenous; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Survival Analysis; Treatment Outcome | 2008 |
An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Vinblastine; Vinorelbine | 2009 |
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Preoperative Care; Radiotherapy | 2008 |
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Preoperative Care; Radiotherapy, Adjuvant | 2008 |
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Male; Mesothelioma; Middle Aged; Pemetrexed; Pleural Neoplasms | 2008 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Remission Induction; Survival Rate | 2008 |
Gemcitabine/epirubicin/paclitaxel as neoadjuvant chemotherapy in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Patient Compliance | 2008 |
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rat
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Research Design | 2008 |
Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Radiotherapy, Adjuvant; Risk Assessment; Survival Analysis; Time Factors | 2008 |
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Heart; Heart Function Tests; Humans; Liver; Liver Function Tests; Lung; Paclitaxel; Prospective Studies; Respiratory Function Tests; Survival Rate | 2008 |
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Capecitabine; Deoxycytidine; Drug Administration Schedule; Europe; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Parenteral; Karnofsky Performance Status; Male; Middle Aged; Pain; Pain Measurement; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Time Factors; Treatment Failure | 2008 |
Patient-reported outcomes of patients with advanced biliary tract cancers receiving gemcitabine plus capecitabine: a multicenter, phase II trial of the Swiss Group for Clinical Cancer Research.
Topics: Administration, Oral; Adult; Aged; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Staging; Pain; Pain Measurement; Palliative Care; Quality of Life; Switzerland; Time Factors; Treatment Outcome | 2008 |
Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Taxoids | 2008 |
Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Male; Palliative Care; Pancreatic Neoplasms | 2008 |
The MILES-2G phase 2 study of single-agent gemcitabine with prolonged constant infusion in advanced non-small cell lung cancer elderly patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male | 2008 |
Phase II trial of gemcitabine in combination with cisplatin in inoperable or advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Time Factors; Treatment Outcome | 2008 |
Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biological Availability; Biopsy; Brain Neoplasms; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Female; Floxuridine; Gemcitabine; Glioblastoma; Humans; Male; Middle Aged; Nucleoside Deaminases; Radiation-Sensitizing Agents | 2009 |
Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Salvage Therapy | 2008 |
Gemcitabine and cisplatin treatment over a 3-week versus a 4-week dosing schedule: a randomized trial conducted in Chinese patients with nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2008 |
Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel | 2008 |
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Double-Blind Method; Europe; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Pain Measurement; Pancreatic Neoplasms; Patient Satisfaction; Placebo Effect; Quinolones; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; United States | 2009 |
Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2009 |
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Half-Life; Humans; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Salvage Therapy; Tissue Distribution; Vidarabine | 2008 |
Efficacy and safety of gemcitabine-oxaliplatin combined with huachansu in patients with advanced gallbladder carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bufanolides; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quality of Life; Severity of Illness Index | 2008 |
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies | 2008 |
Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cause of Death; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Hospitalization; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Small Cell Lung Carcinoma; Treatment Outcome | 2009 |
Liver perfusion chemotherapy with 5-Fluorouracil followed by systemic gemcitabine administration for resected pancreatic cancer: preliminary results of a prospective phase 2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Survival Rate | 2009 |
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Diseases; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Genes, ras; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Receptor, ErbB-2; Survival Analysis | 2008 |
A phase III randomised study comparing concomitant radiochemotherapy as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy; Vinblastine; Vinorelbine | 2009 |
Phase-I-study of four different schedules of pemetrexed, gemcitabine and cisplatin in patients with locally advanced or metastatic solid tumours.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pemetrexed; Treatment Outcome; Young Adult | 2008 |
A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Radiotherapy | 2008 |
Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenoid Cystic; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Compliance; Treatment Outcome | 2008 |
A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Tegafur; Uracil | 2008 |
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Camptothecin; Chromatography, High Pressure Liquid; Deoxycytidine; DNA Topoisomerases, Type I; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged | 2008 |
Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Salvage Therapy | 2008 |
Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pemetrexed; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Rate | 2008 |
A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate | 2008 |
A phase I trial of pemetrexed plus gemcitabine given biweekly with B-vitamin support in solid tumor malignancies or advanced epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dietary Supplements; Drug Administration Schedule; Female; Folic Acid; Gemcitabine; Glutamates; Guanine; Humans; Maximum Tolerated Dose; Neoplasms; Neutropenia; Ovarian Neoplasms; Pemetrexed; Treatment Outcome; Vitamin B Complex | 2008 |
Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate; Treatment Outcome | 2008 |
A phase I study of full-dose gemcitabine and regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Guanidines; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Molecular Structure; Pancreatic Neoplasms; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
A phase II trial of fixed-dosed rate gemcitabine in platinum-resistant ovarian cancer: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) Trial.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Ribonucleotide Reductases; Survival Rate | 2008 |
Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Treatment Outcome | 2009 |
Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Neoplasm Metastasis; Paclitaxel; Quality of Life; Quality-Adjusted Life Years; Survival Rate; Taxoids | 2009 |
Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Urinary Bladder Neoplasms | 2008 |
A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Recurrence; Risk; Salvage Therapy; Survival Analysis; Vinblastine; Vinorelbine | 2008 |
A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Rate; Thrombocytopenia; Treatment Outcome | 2009 |
Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Humans; Kaplan-Meier Estimate; Liposomes; Middle Aged; Neoplasm Staging; Treatment Outcome | 2009 |
A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Receptor, ErbB-2; Trastuzumab | 2008 |
Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local | 2008 |
Results of a Phase II trial of gemcitabine, mitoxantrone, and rituximab in relapsed or refractory mantle cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Oligonucleotides | 2008 |
Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Taxoids | 2008 |
Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Salvage Therapy; Survival Analysis; Urinary Bladder Neoplasms | 2009 |
Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Carboplatin; Deoxycytidine; Disease Progression; Doxorubicin; Female; Gemcitabine; Humans; Liposomes; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Effusion, Malignant; Prognosis; Survival Rate; Time Factors | 2008 |
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; RNA, Messenger; Treatment Outcome | 2009 |
Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Smoking; Taxoids; Vinblastine; Vinorelbine | 2008 |
Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Nuclear Proteins; Pancreatic Neoplasms; Pancreaticoduodenectomy; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-mdm2; Radiotherapy, Adjuvant; Survival Rate; Time Factors; Tumor Protein p73; Tumor Suppressor Proteins | 2009 |
Pemetrexed and gemcitabine for biliary tract and gallbladder carcinomas: a North Central Cancer Treatment Group (NCCTG) phase I and II Trial, N9943.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome | 2007 |
Clinicopathologic and prognostic significance of overexpression of her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gastrectomy; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Protein p53; Young Adult | 2007 |
Gemcitabine and oxaliplatin combination as first-line treatment for advanced pancreatic cancer: a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Female; Gemcitabine; Humans; Male; Middle Aged; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2009 |
Rationale and design of PROSPECT-CONKO 004: a prospective, randomized trial of simultaneous pancreatic cancer treatment with enoxaparin and chemotherapy).
Topics: Adolescent; Adult; Animals; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Deoxycytidine; Drug Interactions; Enoxaparin; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Pancreatic Neoplasms; Prospective Studies; Research Design; Survival Analysis; Swine; Venous Thromboembolism | 2008 |
Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxides; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome | 2008 |
Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Proportional Hazards Models; Prospective Studies; Vinblastine; Vinorelbine | 2009 |
Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Taxoids; Treatment Outcome | 2009 |
Usefulness of contrast-enhanced ultrasonography in determining treatment efficacy and outcome after pancreatic cancer chemotherapy.
Topics: Antineoplastic Agents; Biopsy, Fine-Needle; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Regional Blood Flow; Treatment Outcome; Ultrasonography, Doppler, Color | 2008 |
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2009 |
A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National C
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Treatment Outcome | 2009 |
Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Morbidity; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Positron-Emission Tomography; Prospective Studies | 2008 |
RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy ("ping-pong trial") followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Treatment Outcome | 2009 |
Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazines; Survival Rate; Treatment Outcome | 2009 |
A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Small Cell Lung Carcinoma | 2009 |
[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer].
Topics: Aged; Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epitopes; Female; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Peptides; Receptors, Vascular Endothelial Growth Factor | 2008 |
Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Staging; Prospective Studies; Taxoids; Uterine Neoplasms | 2009 |
A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
A phase II study of gemcitabine in combination with oxaliplatin as first-line chemotherapy in patients with inoperable biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2009 |
Gemcitabine and pemetrexed administered in rapid sequence as front-line chemotherapy for advanced non-small-cell lung cancer: a phase II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Time Factors; Treatment Outcome; United States | 2009 |
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Survival Analysis; Tegafur | 2009 |
Management of platinum-resistant ovarian cancer with the combination of pemetrexed and gemcitabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Pemetrexed; Platinum Compounds; Salvage Therapy; Survival Analysis; Treatment Outcome | 2009 |
A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quality of Life; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2009 |
A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Taxoids | 2009 |
Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Taxoids; Time Factors; Treatment Outcome | 2009 |
A phase II trial of pemetrexed and gemcitabine as first line therapy for poor performance status and/or elderly patients with stage IIIB/IV non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Demography; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Treatment Outcome | 2009 |
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Quinazolines; Urologic Neoplasms | 2009 |
Gemcitabine, irinotecan and celecoxib in patients with biliary cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Celecoxib; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Pyrazoles; Sulfonamides; Thrombocytopenia; Treatment Outcome | 2009 |
A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Deoxycytidine; Female; Gemcitabine; Glucose; Humans; Ifosfamide; Male; Middle Aged; Pancreatic Neoplasms; Phosphoramide Mustards; Survival Analysis; Treatment Outcome | 2009 |
Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Confidence Intervals; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Preoperative Care; Probability; Respiratory Function Tests; Risk Assessment; Survival Analysis | 2009 |
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2009 |
Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum; Taxoids | 2009 |
Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Prognosis; Salvage Therapy; Topotecan; Treatment Outcome | 2009 |
Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Eruptions; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Peripheral Nervous System Diseases; Prognosis; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms | 2009 |
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Randomized Controlled Trials as Topic; Taxoids | 2009 |
A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusion Pumps, Implantable; Liver; Liver Neoplasms; Male; Middle Aged; Treatment Outcome | 2009 |
Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polyethylene Glycols; Topotecan | 2009 |
Primary systemic therapy with intermittent weekly paclitaxel plus gemcitabine in patients with stage II and III breast cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel | 2010 |
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2009 |
A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Cooperative Behavior; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Pyridines; Survival Analysis; Thiosemicarbazones; Time Factors; Treatment Outcome | 2010 |
Second-line treatment of non small cell lung cancer by biweekly gemcitabine and docetaxel +/- granulocyte-macrophage colony stimulating factor and low dose aldesleukine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Interleukin-2; Lung Neoplasms; Macrophage Colony-Stimulating Factor; Male; Middle Aged; Recombinant Proteins; Taxoids; Treatment Outcome | 2009 |
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Taxoids | 2009 |
Gemcitabine, etoposide, cisplatin, and dexamethasone in patients with refractory or relapsed non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Deoxycytidine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Gemcitabine; Glucocorticoids; Humans; Immunosuppressive Agents; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Stem Cell Transplantation; Treatment Outcome; Young Adult | 2009 |
Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Survival Analysis; Taxoids | 2009 |
Chemotherapy and quality of life in NSCLC PS 2 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Karnofsky Performance Status; Life Expectancy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Quality of Life; Surveys and Questionnaires; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Recurrence; Remission Induction | 2009 |
A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Killer Cells, Lymphokine-Activated; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Severity of Illness Index; T-Lymphocytes, Cytotoxic; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Cisplatin plus gemcitabine as adjuvant chemotherapy for radically resected non-small-cell lung cancer: a pilot study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Pneumonectomy | 2009 |
Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2009 |
Second-line therapy in refractory pancreatic cancer. results of a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Failure; Treatment Outcome | 2009 |
Intra-arterial chemotherapy with gemcitabine and cisplatin for patients with recurrence of transitional cell carcinoma confined to the pelvis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pelvic Neoplasms; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2009 |
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2009 |
Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Middle Aged; Neoplasm Metastasis; Polymorphism, Genetic | 2009 |
Fixed-dose-rate gemcitabine in combination with oxaliplatin in patients with metastatic pancreatic cancer refractory to standard-dose-rate gemcitabine: a single-institute study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
A landmark point analysis with cytotoxic agents for advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2009 |
Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2009 |
Randomised multicenter phase II study of two schedules of docetaxel and gemcitabine or cisplatin/gemcitabine followed by docetaxel as first line treatment for advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids | 2009 |
A phase I study of a combination of yttrium-90-labeled anti-carcinoembryonic antigen (CEA) antibody and gemcitabine in patients with CEA-producing advanced malignancies.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Deoxycytidine; Female; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organometallic Compounds; Treatment Outcome | 2009 |
Gemcitabine concurrent with radiation therapy for locally advanced head and neck carcinomas.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Treatment Outcome | 2008 |
Induction chemotherapy and chemoradiation therapy for inoperable locally advanced non-small-cell lung cancer: a single-institution review of two different regimens.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chi-Square Distribution; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Remission Induction; Risk Assessment; Survival Analysis | 2009 |
A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Treatment Outcome; Young Adult | 2010 |
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Failure; Treatment Outcome | 2009 |
Bortezomib induces schedule-dependent modulation of gemcitabine pharmacokinetics and pharmacodynamics in non-small cell lung cancer and blood mononuclear cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Pyrazines | 2009 |
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Urinary Bladder Neoplasms | 2009 |
Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.
Topics: Adult; Aged; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Dosage Calculations; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gemcitabine; Histone Chaperones; Humans; Male; Middle Aged; Mutation; Nuclear Proteins; Pharmacogenetics; RNA, Messenger; RNA, Neoplasm; Survival Rate; Taxoids; Treatment Outcome | 2009 |
A dose escalation and pharmacokinetic study of the biweekly administration of paclitaxel, gemcitabine and oxaliplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Fever; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2009 |
Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cooperative Behavior; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Neoplasm Staging; Recurrence; Survival Analysis; Time Factors; Treatment Outcome | 2010 |
Venous thromboembolism in recurrent ovarian cancer-patients: A systematic evaluation of the North-Eastern German Society of Gynaecologic Oncology Ovarian Cancer Study Group (NOGGO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Germany; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Venous Thromboembolism | 2009 |
External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage | 2010 |
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quality of Life | 2009 |
Gemcitabine, vinorelbine, and Cisplatin in the treatment of advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
[Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cisplatin; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate | 2008 |
A phase I/II study of docetaxel and gemcitabine combination for chemotherapy-resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Taxoids | 2009 |
Gemcitabine-capecitabine plus intra-arterial epirubicin-cisplatin in pretreated pancreatic cancer patients: a phase I study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Maximum Tolerated Dose; Pancreatic Neoplasms | 2009 |
Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Taxoids | 2009 |
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Pilot Projects; Salvage Therapy; Survival Analysis | 2010 |
Gemcitabine and capecitabine chemotherapy in Japanese patients with immunotherapy-resistant renal cell carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Japan; Kidney Diseases; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2009 |
Feasibility of radiotherapy with concomitant gemcitabine and oxaliplatin in locally advanced pancreatic cancer and distal cholangiocarcinoma: a prospective dose finding phase I-II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2009 |
Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis | 2010 |
Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Practice Guidelines as Topic; Prognosis; Risk Assessment; Survival Analysis | 2009 |
A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Vinblastine; Vinorelbine | 2010 |
A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kidney Neoplasms; Male; Middle Aged; Prognosis; PTEN Phosphohydrolase; Thymidylate Synthase; Treatment Outcome; Von Hippel-Lindau Tumor Suppressor Protein | 2009 |
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interleukin-2; Isotretinoin; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Gemcitabine combined with either pemetrexed or paclitaxel in the treatment of advanced non-small cell lung cancer: a randomized phase II SICOG trial.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pemetrexed; Peripheral Nervous System Diseases; Survival Analysis | 2010 |
Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Quality of Life | 2009 |
Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Survival; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Flow Cytometry; Gamma Rays; Gemcitabine; Humans; Lectins, C-Type; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreatitis-Associated Proteins; Predictive Value of Tests; Radiotherapy, Adjuvant; Transfection | 2009 |
A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Thrombocytopenia; Treatment Outcome | 2009 |
Phase I study of prolonged-infusion gemcitabine combined with cyclophosphamide in patients with metastatic carcinoma of the breast: tolerability of an optimal dose schedule.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Postoperative Care; Urinary Bladder Neoplasms | 2009 |
Feasibility study of adjuvant chemotherapy with gemcitabine and split-dose cisplatin for completely resected non-small-cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Dosage Calculations; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Patient Compliance; Pneumonectomy; Prospective Studies; Thrombocytopenia | 2010 |
Phase II study of gemcitabine in combination with vinorelbine versus gemcitabine followed by vinorelbine for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Quality of Life; Survival Analysis; Time Factors; Treatment Failure; Vinblastine; Vinorelbine | 2010 |
A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Mucositis; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Treatment Outcome; Vomiting | 2010 |
A multicenter phase II study of gemcitabine and S-1 combination chemotherapy in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2010 |
Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome; United States | 2009 |
Phase I study of fixed dose gemcitabine plus epirubicin in patients with advanced solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome | 2009 |
A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Exanthema; Fatigue; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Metastasis; Pemetrexed; Pneumonia; Treatment Outcome | 2010 |
Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia | 2010 |
Phase II trial of neoadjuvant therapy with carboplatin, gemcitabine plus thalidomide for stages IIB and III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pneumonectomy; Prognosis; Prospective Studies; Survival Rate; Thalidomide; Treatment Outcome | 2009 |
Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome | 2009 |
Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2009 |
Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2010 |
Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoembolization, Therapeutic; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Liver Neoplasms; Middle Aged; Mitomycin; Prevalence; Survival Analysis; Survival Rate; Treatment Outcome | 2010 |
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2009 |
Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Prognosis; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Gemcitabine plus cisplatin chemotherapy with concurrent para-toluenesulfonamide local injection therapy for peripherally advanced nonsmall cell lung cancer larger than 3 cm in the greatest dimension.
Topics: Administration, Cutaneous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Sulfonamides; Toluene; Treatment Outcome | 2009 |
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged | 2009 |
Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Complementary Therapies; Deoxycytidine; Dietary Supplements; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Pancreatic Neoplasms; Peptide Hydrolases; Proportional Hazards Models; Quality of Life; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
A phase 2 trial of glufosfamide in combination with gemcitabine in chemotherapy-naive pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glucose; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Phosphoramide Mustards; Safety; Survival Rate; Treatment Outcome | 2010 |
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor | 2009 |
A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2009 |
Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed | 2009 |
Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome | 2010 |
Multicenter, phase II study of gemcitabine and S-1 combination chemotherapy in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Gemcitabine plus enzastaurin or single-agent gemcitabine in locally advanced or metastatic pancreatic cancer: results of a phase II, randomized, noncomparative study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Indoles; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2011 |
Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Quality of Life; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine; Young Adult | 2009 |
CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Diastole; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Outpatients; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Ewing; Sarcoma, Synovial; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Taxoids | 2009 |
Blood-based CHRNA3 single nucleotide polymorphism and outcome in advanced non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Precision Medicine; Receptors, Nicotinic; Survival Analysis; Taxoids | 2010 |
Chemotherapy with paclitaxel and gemcitabine in progressive medullary and thyroid carcinoma of the follicular epithelium.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Carcinoma, Medullary; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Thyroid Neoplasms | 2010 |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Concomitant docetaxel plus gemcitabine versus sequential docetaxel followed by gemcitabine in anthracycline-pretreated metastatic or locally recurrent inoperable breast cancer patients: a prospective multicentre trial of the Central European Cooperati
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Recurrence; Taxoids; Time Factors | 2010 |
Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2010 |
Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and Carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Placebos; Thalidomide; Treatment Outcome | 2009 |
Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas, Exocrine; Pancreatic Neoplasms; Prospective Studies; Quinazolines | 2010 |
Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Ovarian Neoplasms; Quality of Life; Topotecan; Treatment Outcome | 2009 |
Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatment.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Salvage Therapy; Taxoids; Treatment Outcome | 2009 |
Phase II trial of weekly gemcitabine and split-dose cisplatin for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mortality; Neoplasm Staging; Neutropenia; Survival Rate | 2009 |
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium; Vinblastine | 2009 |
Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms | 2009 |
Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms | 2009 |
Feasibility study for biweekly administration of cisplatin plus gemcitabine as adjuvant-chemotherapy for completely resected non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Patient Compliance; Treatment Outcome | 2010 |
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer.
Topics: Cyclin G1; Deoxycytidine; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Retroviridae | 2010 |
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II trial of thalidomide, irinotecan and gemcitabine in chemonaive patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Thalidomide; Time Factors; Treatment Outcome | 2009 |
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
Gemcitabine and capecitabine in combination for advanced anthracycline and taxane pre-treated breast cancer patients: A phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Salvage Therapy; Taxoids | 2010 |
Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
Phase II study of fixed dose rate gemcitabine as radiosensitizer for newly diagnosed glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Deoxycytidine; DNA Modification Methylases; DNA Repair Enzymes; Female; Gemcitabine; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Methylation; Middle Aged; Promoter Regions, Genetic; Radiation-Sensitizing Agents; Tumor Suppressor Proteins | 2010 |
A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Cystine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Half-Life; Hexanones; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sulfhydryl Compounds; Tomography, X-Ray Computed | 2010 |
Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Catheter Ablation; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Radiosurgery; Radiotherapy, Adjuvant; Salvage Therapy; Time Factors; Treatment Outcome; Young Adult | 2009 |
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Proportional Hazards Models; Quality of Life; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Time Factors; Treatment Outcome; United Kingdom | 2009 |
Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome; United States | 2009 |
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Probability; Quinazolines; Risk Assessment; Survival Analysis; Time Factors; Treatment Outcome | 2009 |
Is gemcitabine an option in BCG-refractory nonmuscle-invasive bladder cancer? A single-arm prospective trial.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms | 2010 |
Multimodality treatment of stage III non-small cell lung cancer: analysis of a phase II trial using preoperative cisplatin and gemcitabine with concurrent radiotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Treatment Outcome | 2009 |
Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Survival Analysis; Vinblastine; Vinorelbine | 2010 |
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Glandular and Epithelial; Pilot Projects; Salvage Therapy; Survival Analysis; Thymus Neoplasms | 2010 |
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Endpoint Determination; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Survival Analysis; Taxoids | 2010 |
Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2009 |
A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Flavonoids; Gemcitabine; Humans; Irinotecan; Life Expectancy; Male; Middle Aged; Neoplasm Metastasis; Patient Selection; Piperidines | 2010 |
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mycosis Fungoides; Recurrence; Skin Neoplasms; Time Factors; Treatment Outcome | 2010 |
Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Fallopian Tube Neoplasms; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Peritoneal Neoplasms; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger | 2010 |
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomis
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Young Adult | 2009 |
[Efficacy of Shenyi Capsule combined with gemcitabine plus cisplatin in treatment of advanced esophageal cancer: a randomized controlled trial].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capsules; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Ginsenosides; Humans; Male; Middle Aged; Panax; Phytotherapy; Quality of Life; Survival Rate; Vascular Endothelial Growth Factor A | 2009 |
A phase 2 study of platinum and gemcitabine in patients with advanced salivary gland cancer: a trial of the NCIC Clinical Trials Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Rate; Time Factors | 2010 |
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.
Topics: Adult; Aged; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: a multicenter phase II study (SOLTI 0301 trial).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination?: results from a phase II Trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Survival Analysis; Trastuzumab | 2010 |
Gemcitabine and vinorelbine combination in platinum-sensitive recurrent ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Recurrence; Survival Analysis; Vinblastine; Vinorelbine | 2009 |
Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Repair; Female; Gemcitabine; Genetic Variation; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Polymerase Chain Reaction; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Rad51 Recombinase; Smoking; Survival Rate; Taxoids; Treatment Outcome | 2010 |
A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2010 |
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Deoxycytidine; Female; Gastrins; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Receptor, Cholecystokinin B; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2010 |
Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and paclitaxel-pretreated epithelial ovarian cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Prognosis; Prospective Studies; Risk Factors; Taxoids; Treatment Outcome; Young Adult | 2009 |
The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2010 |
[Final results of cooperative studies of dicarbamine used as a hemoprotector in combination chemotherapy for cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Caproates; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hematinics; Humans; Imidazoles; Leukopenia; Middle Aged; Neutropenia; Ovarian Neoplasms; Treatment Outcome | 2009 |
Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Prognosis; Survival Rate | 2009 |
Estimating optimal dose of twice-weekly gemcitabine for concurrent chemoradiotherapy in unresectable pancreatic carcinoma: mature results of GEMRT-01 Phase I trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiotherapy Dosage; Survival Rate; Thrombocytopenia; Tumor Burden; Young Adult | 2010 |
Phase II study of radiation therapy combined with weekly low-dose gemcitabine for locally advanced, unresectable pancreatic cancer.
Topics: Adult; Aged; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Safety; Survival Analysis | 2011 |
Weekly epirubicin as salvage therapy in patients with gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Salvage Therapy | 2009 |
Concurrent gemcitabine and high-intensity focused ultrasound therapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biomarkers, Tumor; Cisplatin; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Middle Aged; Neoplasms; Protein Serine-Threonine Kinases; Treatment Outcome | 2011 |
Neoadjuvant chemotherapy in locally advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Remission Induction; Survival Rate; Treatment Outcome | 2007 |
Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Nomograms; Radiotherapy, Adjuvant; Suramin; Taxoids; Treatment Outcome | 2010 |
A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Isoflavones; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2011 |
A randomized controlled pilot trial of "Feiji Recipe" on quality of life of non-small cell lung cancer patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Health Surveys; Humans; Lung Neoplasms; Middle Aged; Phytotherapy; Pilot Projects; Plants, Medicinal; Quality of Life; Surveys and Questionnaires; Vinblastine; Vinorelbine; Young Adult | 2010 |
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2010 |
Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pleural Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Safety; Survival Rate; Tegafur; Treatment Outcome | 2010 |
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Placebos; Prognosis; Survival Rate | 2010 |
Phase I trial of fixed-dose rate gemcitabine in combination with bortezomib in advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Middle Aged; Neoplasms; Pyrazines | 2010 |
Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Retrospective Studies; Safety; Survival Rate; Treatment Outcome | 2010 |
Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Follow-Up Studies; Gemcitabine; Humans; Infections; Lung Neoplasms; Maximum Tolerated Dose; Neoplasm Staging; Silicates; Survival Analysis; Titanium | 2010 |
Gemcitabine versus bacille Calmette-Guérin after initial bacille Calmette-Guérin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Retreatment; Treatment Failure; Urinary Bladder Neoplasms | 2010 |
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2010 |
Bacillus Calmette-Guérin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Deoxycytidine; Disease Progression; Endoscopy; Gemcitabine; Humans; Immunotherapy; Recurrence; Reproducibility of Results; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2011 |
Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Adenosquamous; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pain Measurement; Pancreatic Neoplasms; Survival Rate | 2010 |
Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Female; Gemcitabine; Humans; Indoles; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pyrroles; Sunitinib | 2010 |
Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome | 2010 |
Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Prognosis; Time Factors; Treatment Outcome; United States | 2010 |
[The effect of thalidomide in preventing delayed nausea and vomiting induced by GP regimen of chemotherapy for non-small cell lung cancer].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Prospective Studies; Thalidomide; Vomiting | 2009 |
Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2010 |
Phase I/II trial of GN-BVC, a gemcitabine and vinorelbine-containing conditioning regimen for autologous hematopoietic cell transplantation in recurrent and refractory hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous; Vinblastine; Vinorelbine; Young Adult | 2010 |
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cytidine Deaminase; Deoxycytidine; Female; Floxuridine; Gemcitabine; Gene Frequency; Genotype; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Polymorphism, Single Nucleotide | 2010 |
Phase II trial of gemcitabine, irinotecan, and celecoxib in patients with advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Celecoxib; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Pyrazoles; Sulfonamides; Treatment Outcome | 2010 |
Biweekly vinorelbine and gemcitabine as second-line and beyond treatment in ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Prospective Studies; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
A phase II study of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Salvage Therapy; Taxoids; Treatment Outcome | 2010 |
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Demography; Deoxycytidine; Enhancer Elements, Genetic; Female; Fluorouracil; Gemcitabine; Genotype; Homozygote; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Survival Analysis; Thymidylate Synthase; Treatment Outcome | 2011 |
ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2010 |
Phase I trial of gemcitabine dose escalation with concurrent radiotherapy for patients with locally advanced pancreatic cancer.
Topics: Aged; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2010 |
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis | 2010 |
Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Genes, bcl-2; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Oligonucleotides, Antisense; Thionucleotides; Treatment Outcome | 2011 |
Phase II study of S-1 in patients with gemcitabine-resistant advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2011 |
Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Etoposide; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2010 |
[Efficacy study of single-agent gemcitabine versus gemcitabine plus carboplatin in untreated elderly patients with stage IIIb/IV non-small-cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging | 2010 |
Phase II study of second line gemcitabine single chemotherapy for biliary tract cancer patients with 5-fluorouracil refractoriness.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
Chemotherapy followed by chemoradiotherapy for locally advanced non-metastatic pancreatic cancer - a new paradigm?
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Radiotherapy | 2010 |
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Endpoint Determination; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Pancreatic Neoplasms; Piperidines; Pyridines; Survival Analysis; Thiazoles | 2010 |
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Patient Compliance; Proportional Hazards Models | 2010 |
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Forkhead Transcription Factors; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunohistochemistry; Immunotherapy; Leucovorin; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Recombinant Proteins; Survival Analysis; T-Lymphocytes, Regulatory | 2010 |
Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Neoadjuvant Therapy; Patient Selection; Radiotherapy, Adjuvant; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 2010 |
ERCC1, toxicity and quality of life in advanced NSCLC patients randomized in a large multicentre phase III trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Young Adult | 2010 |
A phase II trial of gemcitabine, capecitabine, and bevacizumab in metastatic renal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chicago; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Survival Analysis | 2011 |
Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Paclitaxel; Risk Factors; Treatment Outcome | 2010 |
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2010 |
Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Squamous Cell; Organoplatinum Compounds; Survival Analysis; Treatment Outcome | 2011 |
Carboplatin/gemcitabine alternating with carboplatin/pegylated liposomal doxorubicin and carboplatin/cyclophosphamide in platinum-refractory/resistant paclitaxel - pretreated ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Prospective Studies; Survival Rate | 2010 |
A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols; Recombinant Proteins; Taxoids | 2010 |
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Mucositis; Thrombocytopenia; Treatment Outcome | 2010 |
Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed | 2010 |
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Doxorubicin; Female; Gemcitabine; Hodgkin Disease; Humans; Lung Diseases; Male; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Polymorphism, Single Nucleotide; Receptors, IgG; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2010 |
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Tennessee; Treatment Outcome | 2010 |
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
A phase II evaluation of weekly gemcitabine and docetaxel for second-line treatment of recurrent carcinosarcoma of the uterus: a gynecologic oncology group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Uterine Neoplasms | 2010 |
Two schedules of chemotherapy for patients with non-small cell lung cancer in poor performance status: a phase II randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged | 2010 |
Molecular mistletoe therapy: friend or foe in established anti-tumor protocols? A multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Clinical Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Plant Proteins; Retrospective Studies; Survival Analysis; Viscum album | 2010 |
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Blood Coagulation Factors; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Survival; Treatment Outcome | 2011 |
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival; Taxoids | 2011 |
A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Disulfides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Mas; Survival; Thioredoxins; Treatment Outcome | 2011 |
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy; Safety; Survival Analysis | 2010 |
Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2010 |
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Quality of Life; Surveys and Questionnaires; Thrombocytopenia; Young Adult | 2010 |
A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Treatment Outcome | 2010 |
High-level mRNA of excision repair cross-complementation group 1 gene is associated with poor outcome of platinum-based doublet chemotherapy of advanced nonsmall cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Phase I-II trial of prolonged gemcitabine infusion plus paclitaxel as a biweekly schedule for advanced breast cancer patients pretreated with anthracyclines.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ribonucleoside Diphosphate Reductase; Survival; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Young Adult | 2011 |
A phase I study of gemcitabine plus irinotecan for advanced NSCLC: Japan Clinical Oncology Group Trial (JCOG9904).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome | 2010 |
A randomized phase II study comparing two schedules of the 21-day regimen of gemcitabine and carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2010 |
Phase II trial of gemcitabine plus cisplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Young Adult | 2010 |
Randomized phase II study of gemcitabine and carboplatin +/- sequential docetaxel in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2010 |
A phase I study of topotecan and gemcitabine in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Topotecan; Treatment Outcome | 2011 |
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Breast Neoplasms, Male; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Florida; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Proportional Hazards Models; Receptor, ErbB-2; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2010 |
A phase I study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Cadherins; Cetuximab; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; ErbB Receptors; Feasibility Studies; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Vimentin | 2011 |
Dose escalation of gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer: a phase 1-2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Recurrence; Survival Analysis | 2010 |
Pharmacokinetic study to optimize the intravesical administration of gemcitabine.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Hydrogen-Ion Concentration; Neoplasm Invasiveness; Tissue Distribution; Urinary Bladder Neoplasms | 2010 |
A Comparison of white and African American outcomes from a three-arm, randomized, phase III multicenter trial of advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; White People | 2010 |
Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Pancreatic Neoplasms; Radiotherapy, Conformal; Remission Induction | 2011 |
Phase II study of oral S-1 and concurrent radiotherapy in patients with unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Tegafur | 2011 |
Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Placebos | 2010 |
Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2010 |
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Attitude to Health; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mental Health; Middle Aged; Pain; Pancreatic Neoplasms; Quality of Life | 2010 |
Feasibility study of gemcitabine and cisplatin combination chemotherapy for patients with refractory biliary tract cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Survival Rate; Treatment Outcome | 2011 |
Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Treatment Outcome | 2010 |
The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Phenotype; Receptor, ErbB-2 | 2011 |
Randomized phase II study of gemcitabine plus S-1 combination therapy vs. S-1 in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG0805).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Japan; Male; Middle Aged; Oxonic Acid; Patient Selection; Sample Size; Survival Analysis; Tegafur; Treatment Outcome | 2010 |
Proton-pump inhibitor as palliative care for chemotherapy-induced gastroesophageal reflux disease in pancreatic cancer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gastroesophageal Reflux; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Tegafur | 2010 |
A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Polyethylene Glycols; Survival Rate | 2010 |
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Genotype; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Reduced Folate Carrier Protein; Survival Rate | 2010 |
Weekly Paclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ascites; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Quality of Life; Retrospective Studies; Treatment Failure; Treatment Outcome | 2010 |
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Piperidines; Quinazolines; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Missouri; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy; Intention to Treat Analysis; Interferon-alpha; Interleukin-2; Italy; Kidney Neoplasms; Male; Maximum Tolerated Dose; Medical Oncology; Middle Aged; Neoplasm Metastasis; Survival Analysis | 2010 |
A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cancer Vaccines; Deoxycytidine; Female; Gemcitabine; HLA Antigens; Humans; Immunity, Cellular; Immunity, Humoral; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Time Factors; Treatment Outcome; Vaccines, Subunit | 2010 |
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Endometrial Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Recurrence | 2010 |
A Phase I-II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2011 |
A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Polyethylene Glycols; Recombinant Proteins | 2010 |
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prognosis; Urinary Bladder Neoplasms | 2011 |
Phase II trial to evaluate gemcitabine and etoposide for locally advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis | 2010 |
Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Italy; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Remission Induction; Survival Analysis; Treatment Outcome | 2010 |
Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sorafenib | 2010 |
Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Michigan; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; New Jersey; Perfusion Imaging; Piperazines; Pyrimidines; Taxoids; Time Factors; Treatment Outcome | 2012 |
Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Deoxycytidine; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Time Factors; Treatment Outcome | 2010 |
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2010 |
Phase III trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Proportional Hazards Models; Prospective Studies; Quality of Life; Time Factors; Treatment Outcome; Young Adult | 2010 |
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Chicago; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Outcome; Universities | 2012 |
Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Health Resources; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate; Treatment Outcome | 2010 |
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2011 |
NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2010 |
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Canada; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Dosage; Humans; Mutation; Pancreatic Neoplasms; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2010 |
Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Topotecan; Treatment Outcome; Uterine Cervical Neoplasms; Vinblastine; Vinorelbine | 2010 |
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Administration Schedule; Fatigue; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2010 |
[A phase II study of gemcitabine and carboplatin bi-weekly combination chemotherapy for complete resected non-small-cell lung cancer patients].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2010 |
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
The regimen of gemcitabine and cisplatin combined with radio frequency hyperthermia for advanced non-small cell lung cancer: a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms; Male; Middle Aged; Quality of Life; Radio Waves; Remission Induction | 2011 |
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Curcumin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur | 2011 |
Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Greece; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 2011 |
A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Brachytherapy; Carcinoma, Adenosquamous; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2011 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2010 |
A phase 2 study of pemetrexed plus gemcitabine every 2 weeks for patients with recurrent or metastatic head and neck squamous cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Squamous Cell; Pemetrexed; Recurrence; Squamous Cell Carcinoma of Head and Neck | 2011 |
Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2011 |
Multicenter phase II study of S-1 monotherapy as second-line chemotherapy for advanced biliary tract cancer refractory to gemcitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2012 |
Biweekly vinorelbine and gemcitabine as second-line treatment and beyond in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Taxoids; Vinblastine; Vinorelbine | 2010 |
Phase II study of a fixed dose-rate infusion of gemcitabine associated with erlotinib in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival; Treatment Outcome | 2011 |
Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma--EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Doxorubicin; Europe; Female; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prednisolone; Prognosis; Time Factors; Treatment Outcome; Vincristine | 2011 |
Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infant; Male; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Young Adult | 2011 |
Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Polyethylene Glycols; Taxoids | 2010 |
Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; France; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer: Long-term cumulative results of 2 prospective single-institution studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Survival Rate; Time Factors; Urinary Bladder Neoplasms | 2011 |
Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging | 2010 |
Phase I dose-escalating study of biweekly fixed-dose rate gemcitabine plus pemetrexed in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Disease Progression; Female; Fever; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Neutropenia; Patient Dropouts; Pemetrexed; Pyrimidines; Renal Insufficiency; Severity of Illness Index; Young Adult | 2011 |
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biopsy, Fine-Needle; Cell Cycle Proteins; Cohort Studies; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hepatic Insufficiency; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Neutropenia; Pyridines; Ribonucleotide Reductases; RNA, Messenger; Survival Analysis; Thiosemicarbazones | 2011 |
A phase I, dose-escalation study of pomalidomide (CC-4047) in combination with gemcitabine in metastatic pancreas cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Thalidomide; Treatment Outcome | 2011 |
Curcumin and gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Curcumin; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Pancreatic Neoplasms; Severity of Illness Index; Survival Analysis | 2010 |
Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Polyethylene Glycols | 2011 |
A phase II study of outpatient biweekly gemcitabine-oxaliplatin in advanced biliary tract carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Egypt; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2011 |
Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cetuximab; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2010 |
Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cross-Over Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Taxoids | 2011 |
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intravenous; Male; Mammalian orthoreovirus 3; Maximum Tolerated Dose; Middle Aged; Neoplasms; Oncolytic Virotherapy | 2011 |
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Platinum; Salvage Therapy; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2011 |
A phase II study of gemcitabine plus paclitaxel in patients with metastatic breast cancer and prior anthracycline treatment.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2010 |
A randomized phase II trial of adjuvant chemotherapy with bi-weekly carboplatin plus paclitaxel versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Survival Rate; Treatment Outcome | 2010 |
[Efficacy and safety of chemotherapy combined with interstitial (125)I seed implantation brachytherapy in unresectable stage IIIa/IIIb non-small cell lung cancer].
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Diarrhea; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vinblastine; Vinorelbine; Vomiting | 2010 |
Phase 1 trial of gemcitabine with bortezomib in elderly patients with advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasms; Pyrazines | 2011 |
Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Endostatins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Recombinant Proteins; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer.
Topics: Animals; Deoxycytidine; Disease Progression; DNA Breaks, Double-Stranded; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group N Protein; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitomycin; Mutation; Nuclear Proteins; Pancreatic Neoplasms; Precision Medicine; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2011 |
Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Paclitaxel; Polymorphism, Genetic; Risk Factors; Survival Rate; Treatment Outcome | 2011 |
Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cancer Vaccines; Cell Cycle Proteins; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; RNA Splicing Factors; Vaccines, Subunit | 2011 |
A Phase II trial of gemcitabine and mitoxantrone for patients with acute myeloid leukemia in first relapse.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidine; Drug Resistance, Multiple; Equilibrative-Nucleoside Transporter 2; Female; Fever; Gemcitabine; Gene Expression Regulation, Leukemic; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Infusions, Intravenous; K562 Cells; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Multidrug Resistance-Associated Proteins; Recurrence; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; U937 Cells | 2010 |
A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Deoxycytidine; Endometrial Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local | 2011 |
A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Canada; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Treatment Outcome; Tumor Burden | 2012 |
Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Adenosquamous; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscle Neoplasms; Neoplasm Invasiveness; Neoplasm Staging; Radiotherapy, Conformal; Urinary Bladder Neoplasms | 2011 |
A phase III randomized trial of gemcitabine-oxaliplatin versus carboplatin-paclitaxel as first-line therapy in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
Iniparib plus chemotherapy in metastatic triple-negative breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Carboplatin; Cross-Over Studies; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Survival Analysis | 2011 |
[Gemcitabine based combination chemotherapy, a new salvage regimen for recurrent platinum resistant epithelial ovarian cancer].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Ovarian Neoplasms; Platinum Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2010 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Association of RRM1 -37A>C polymorphism with clinical outcome in colorectal cancer patients treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blotting, Western; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genotype; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2011 |
[Clinical efficacy and adverse effects of taxol plus carboplatin or gemcitabine plus carboplatin in patients with advanced non-small-cell lung carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2010 |
A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Endostatins; Female; Gemcitabine; Humans; Male; Middle Aged; Recombinant Proteins | 2012 |
Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2011 |
Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2012 |
Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Guideline Adherence; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Survival Analysis | 2012 |
Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Injections, Intravenous; Middle Aged; Neutropenia; Polyethylene Glycols; Stomatitis; Thrombocytopenia; Treatment Outcome | 2012 |
Concomitant chemoradiotherapy using low-dose weekly gemcitabine versus low-dose weekly paclitaxel in locally advanced head and neck squamous cell carcinoma: a phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Young Adult | 2012 |
Combination of gemcitabine and cisplatin is highly active in women with endometrial carcinoma: results of a prospective phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Endometrial Neoplasms; Female; Gemcitabine; Humans | 2011 |
Phase II trial of induction gemcitabine and carboplatin followed by conformal thoracic radiation to 74 Gy with weekly paclitaxel and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gamma Rays; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prospective Studies; Radiography, Thoracic; Radiotherapy Dosage; Standard of Care; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of carboplatin-paclitaxel or gemcitabine-vinorelbine in patients with advanced nonsmall cell lung cancer and a performance status of 2: West Japan Thoracic Oncology Group 0004.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infections; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate | 2012 |
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2011 |
[AUO-study AB34/09: an open-label, randomised, multicentre, phase II study to evaluate the efficacy of chemotherapy with gemcitabine and cisplatin in combination with the EGF receptor antibody panitumumab (GemCisP) versus GemCis in the first-line therapy
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Panitumumab; Randomized Controlled Trials as Topic; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
[Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Conformal; Remission Induction | 2011 |
A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Canada; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Medical Oncology; Middle Aged; National Health Programs; Pyrazines; Recurrence; Societies, Medical | 2011 |
Cetuximab concomitant with gemcitabine and radiotherapy in advanced squamous cell carcinomas of upper aerodigestive tract: a pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2011 |
Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Gemcitabine; Health Status Indicators; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dietary Supplements; Docosahexaenoic Acids; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2011 |
The efficacy and safety of gemcitabine plus cisplatin regimen for patients with advanced urothelial carcinoma after failure of M-VAC regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Failure; Treatment Outcome; Urologic Neoplasms; Urothelium; Vinblastine | 2011 |
The pharmacological advantage of prolonged dose rate gemcitabine is restricted to patients with variant alleles of cytidine deaminase c.79A>C.
Topics: Alleles; Antimetabolites, Antineoplastic; Cross-Over Studies; Cytidine Deaminase; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Genotype; Humans; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Time Factors | 2011 |
Second-line neoadjuvant vinorelbine and gemcitabine combination in locally advanced breast cancer showing no early response to TAC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prognosis; Prospective Studies; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2012 |
Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Prognosis; Remission Induction; Vinblastine; Young Adult | 2011 |
A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Phase II trial of pemetrexed-based induction chemotherapy followed by concomitant chemoradiotherapy in previously irradiated patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Prospective Studies; Radiotherapy; Squamous Cell Carcinoma of Head and Neck | 2011 |
First-line treatment of pancreatic cancer patients with the combination of 5-fluorouracil/folinic acid plus gemcitabine: a multicenter phase II trial by the CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis | 2011 |
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Gene Amplification; Genes, ras; Humans; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2012 |
Randomised phase II trial of gemcitabine plus vinorelbine vs gemcitabine plus cisplatin vs gemcitabine plus capecitabine in patients with pretreated metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Vinblastine; Vinorelbine | 2011 |
Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate; Taiwan | 2011 |
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; United States; Urinary Bladder Neoplasms; Urothelium | 2011 |
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cyclooxygenase 2; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Nucleoside Deaminases; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; Ribonucleoside Diphosphate Reductase; Sorafenib; Tumor Suppressor Proteins | 2012 |
[Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Sorafenib | 2011 |
Combination therapy consisting of gemcitabine, carboplatin, and docetaxel as an active treatment for advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Taxoids; Urologic Neoplasms; Vinblastine | 2011 |
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD40 Antigens; Deoxycytidine; Disease Models, Animal; Disease-Free Survival; Female; Gemcitabine; Humans; Immunologic Surveillance; Macrophage Activation; Macrophages; Male; Mice; Middle Aged; Pancreatic Neoplasms; T-Lymphocytes; Tumor Microenvironment; Young Adult | 2011 |
Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: a phase Ib study.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Polyethylene Glycols; Survival Rate; Tissue Distribution; Treatment Outcome | 2011 |
Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infant; Infant, Newborn; Uterine Cervical Neoplasms | 2011 |
Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Salvage Therapy | 2011 |
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oligodeoxyribonucleotides; Proportional Hazards Models | 2012 |
Biweekly gemcitabine-paclitaxel, gemcitabine-carboplatin, or gemcitabine-cisplatin as first-line treatment in metastatic breast cancer after anthracycline failure: a phase II randomized selection trial.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome | 2011 |
A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Neoplasms; Panobinostat; Treatment Outcome | 2011 |
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Grou
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Male; Middle Aged; Organs at Risk; Paclitaxel; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal | 2011 |
Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neutropenia; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Watchful Waiting | 2011 |
Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Treatment Outcome; Young Adult | 2011 |
Toxic effects and antitumor response of gemcitabine in combination with piroxicam treatment in dogs with transitional cell carcinoma of the urinary bladder.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Gemcitabine; Male; Piroxicam; Urinary Bladder Neoplasms | 2011 |
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2011 |
A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2011 |
NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Taxoids | 2011 |
A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Drug Resistance, Neoplasm; Ethers, Cyclic; Female; Furans; Gemcitabine; Humans; Ketones; Macrolides; Male; Middle Aged; Pancreatic Neoplasms; Tubulin Modulators | 2012 |
Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with erlotinib for unresected pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infections; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Pancreatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Time Factors; Tumor Burden; Vomiting | 2012 |
Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiosurgery; Radiotherapy Dosage | 2011 |
Second-line paclitaxel/carboplatin versus vinorelbine/carboplatin in patients who have advanced non-small-cell lung cancer pretreated with non-platinum-based chemotherapy: a multicenter randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Phase II study of biweekly gemcitabine as first line therapy in CIS of the bladder: what does an aborted trial tell us?
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma in Situ; Cystitis; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Remission Induction; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Phase II study of gemcitabine, oxaliplatin, and cetuximab in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2012 |
Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2012 |
Gemcitabine and docetaxel for hepatocellular carcinoma: a phase II North Central Cancer Treatment Group clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Taxoids; Tissue Distribution; Treatment Outcome | 2012 |
A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Thymidylate Synthase | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quality of Life; Severity of Illness Index; Survival Analysis | 2011 |
Systemic gemcitabine and capecitabine plus intra-arterial epirubicin and cisplatin as second-line chemotherapy in gemcitabine-failure pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Failure | 2011 |
Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Germany; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
[Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Tegafur; Uracil | 2011 |
Change in the growth rate of localized pancreatic adenocarcinoma in response to gemcitabine, bevacizumab, and radiation therapy on MDCT.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Guideline Adherence; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome; Tumor Burden | 2011 |
Weekly gemcitabine and cisplatin in combination with radiotherapy in patients with locally advanced head-and-neck cancer: Phase I study.
Topics: Aged; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy, Conformal; Remission Induction; Stomatitis | 2011 |
[Concurrent versus sequential systemic chemotherapy and whole brain radiation therapy for brain matastases in non-small-cell lung cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2011 |
Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging | 2011 |
An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Analysis; Treatment Outcome | 2011 |
Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: results from the Italian observational "SUN" (Survey on the lUng cancer maNagement) study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Italy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Practice Guidelines as Topic; Survival Analysis | 2011 |
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Benzimidazoles; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Treatment Outcome; Young Adult | 2012 |
Regional chemotherapy in locally advanced pancreatic cancer: RECLAP trial.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Embolization, Therapeutic; Gemcitabine; Humans; Maryland; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Research Design; Treatment Outcome | 2011 |
Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Alanine Transaminase; Anemia; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Positron-Emission Tomography; Survival Rate; Thrombocytopenia; Tomography, X-Ray Computed | 2011 |
Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Spain; Treatment Outcome; Young Adult | 2011 |
Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Combining capecitabine, oxaliplatin, and gemcitabine (XELOXGEM) for colorectal carcinoma patients pretreated with irinotecan: a multicenter phase I/II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Survival Rate; Thrombocytopenia | 2012 |
Brief commentary: largest randomized trial of biliary tract cancer treatment with cisplatin plus gemcitabine versus gemcitabine alone: an excellent opportunity to evaluate the prognostic value of tumor marker CA 19-9.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Prognosis | 2011 |
Phase I and pharmacokinetic study of IV vinflunine in combination with gemcitabine for treatment of advanced non-small cell lung cancer in Chemonaive patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Tissue Distribution; Treatment Outcome; Vinblastine | 2011 |
Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2012 |
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Pancreatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2012 |
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2011 |
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms | 2012 |
Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prospective Studies; Survival Rate; Treatment Outcome | 2011 |
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
Phase II clinical trial with gemcitabine and paclitaxel sequential monotherapy as first-line treatment for advanced non-small-cell lung cancer (SLCG 01-04).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Treatment Outcome | 2011 |
Experience with combination of cisplatin plus gemcitabine chemotherapy and intensity-modulated radiotherapy for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Chemotherapy, Adjuvant; China; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome | 2012 |
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Patient Selection; Radiotherapy, Adjuvant; Remission Induction; Research Design; Smad4 Protein; Treatment Outcome | 2011 |
Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Thrombocytopenia; Treatment Outcome | 2011 |
A randomized phase II trial of first-line treatment with gemcitabine, erlotinib, or gemcitabine and erlotinib in elderly patients (age ≥70 years) with stage IIIB/IV non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Interleukin-2; Lung Neoplasms; Maintenance Chemotherapy; Male; Medication Adherence; Middle Aged; Neoplasm Staging | 2011 |
SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Quality of Life; Taxoids; Uterine Cervical Neoplasms | 2011 |
A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Quality of Life; Survival Rate; Treatment Outcome | 2011 |
Second-line treatment with intravenous gemcitabine and oral etoposide in platinum-resistant advanced ovarian cancer patients: results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Survival Analysis; Treatment Outcome | 2011 |
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Treatment Outcome | 2012 |
Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Docetaxel; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Proportional Hazards Models; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Taxoids; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscles; Nausea; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Taxoids; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Piperazines; Pyrimidines; Thrombocytopenia; Treatment Outcome | 2012 |
Long-term gemcitabine administration in heavily pretreated Japanese patients with metastatic breast cancer: additional safety analysis of a phase II study.
Topics: Adult; Aged; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Heart Failure; Humans; Middle Aged; Taxoids; Unconsciousness | 2012 |
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; Prodrugs; Quinazolines; Treatment Outcome; Young Adult | 2011 |
Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL.
Topics: Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Maximum Tolerated Dose; Middle Aged; Prednisone; Rituximab; Survival Rate; Treatment Outcome; Vincristine | 2011 |
[A randomized study of gemcitabine plus oxaliplatin versus gemcitabine plus cisplatin as the 1st line chemotherapy for advanced non-small cell lung cancer in elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Male; Organoplatinum Compounds; Treatment Outcome | 2011 |
[First line therapy for local advanced or metastatic urothelial cell carcinoma: randomized phase II study to investigate the combination of vinflunine with gemcitabine and vinflunine with carboplatin in patients unfit for cisplatin therapy with advanced o
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hypertension; Indoles; Male; Metabolic Clearance Rate; Middle Aged; Nausea; Neoplasms; Niacinamide; Oligonucleotides; Quinazolines; Treatment Outcome; Venous Thrombosis; Vomiting; Young Adult | 2011 |
Results of a phase II trial of gemcitabine plus doxorubicin in patients with recurrent head and neck cancers: serum C₁₈-ceramide as a novel biomarker for monitoring response.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Squamous Cell; Ceramides; Deoxycytidine; Doxorubicin; Gemcitabine; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Middle Aged; Recurrence; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2011 |
Carboplatin and gemcitabine in first-line treatment of elderly patients with advanced non-small cell lung cancer: data from a retrospective study.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2011 |
Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Prospective Studies; Tomography, X-Ray Computed; Translational Research, Biomedical | 2011 |
Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Survival Rate; Vinblastine; Vinorelbine | 2011 |
Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Taxoids; Treatment Outcome | 2012 |
Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Decision Support Techniques; Deoxycytidine; Female; Gemcitabine; Germany; Hemoglobins; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Patient Selection; Regression Analysis; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium; Vinblastine | 2011 |
Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Self-Assessment; Surveys and Questionnaires; Taxoids; Vinblastine; Vinorelbine | 2011 |
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2012 |
Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Recurrence; Urinary Bladder Neoplasms | 2012 |
Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Genes, ras; Humans; Middle Aged; Mutation; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2011 |
[Evaluation of the efficacy and safety of intravesical instillation with gemcitabine after first-line intravesical chemotherapy failure in the treatment of non-muscle-invasive bladder cancer].
Topics: Administration, Intravesical; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2011 |
[Short-term intermittent prophylactic administration of recombinant human thrombopoietin attenuates chemotherapy-induced thrombocytopenia in lung cancer patients].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Deoxycytidine; Dizziness; Female; Fever; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platelet Count; Recombinant Proteins; Thrombocytopenia; Thrombopoietin | 2011 |
Phase I study of radiochemotherapy with gemcitabine in invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2012 |
A randomized phase II trial of two regimens of moderate dose chemoradiation therapy for patients with non-small cell lung cancer not suitable for curative therapy: Trans Tasman Radiation Oncology Study TROG 03.07.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Dyspnea; Fatigue; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Quality of Life; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cations; Deoxycytidine; Disease Progression; Dosage Forms; Female; Gemcitabine; Humans; Liposomes; Male; Middle Aged; Models, Biological; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2012 |
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Fatigue; Female; Gemcitabine; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neutropenia; Pemetrexed; Thrombocytopenia; Thromboembolism; Time Factors; Treatment Outcome | 2012 |
Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2011 |
Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study).
Topics: Adult; Aged; Alanine Transaminase; Alkaline Phosphatase; Anemia; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Thrombocytopenia | 2011 |
Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Patient Dropouts; Prednisone; Prognosis; Recurrence; Remission Induction; Survival Analysis; Vinblastine | 2011 |
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Piperidines; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monothe
Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Data Collection; Deoxycytidine; Female; Gemcitabine; Health Status Indicators; Humans; Internationality; Middle Aged; Paclitaxel; Pain Measurement; Psychometrics; Quality of Life; Stress, Psychological; Treatment Outcome | 2012 |
The combined treatment of CT-guided percutaneous 125I seed implantation and chemotherapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Radiosurgery; Radiotherapy Dosage; Radiotherapy, Image-Guided; Tomography, X-Ray Computed | 2011 |
A phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Parenteral; Male; Middle Aged; Treatment Outcome | 2012 |
A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFP
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2011 |
A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine | 2012 |
Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Sarcoma; Taxoids; Young Adult | 2012 |
Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arachidonate 5-Lipoxygenase; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2011 |
Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2011 |
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Retreatment; Treatment Outcome | 2011 |
Phase III trial of induction gemcitabine or paclitaxel plus carboplatin followed by paclitaxel consolidation in ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Induction Chemotherapy; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Survival Rate; Young Adult | 2011 |
A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2 positive early breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Lapatinib; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Quinazolines; Receptor, ErbB-2 | 2012 |
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Piperidines; Pyridines | 2011 |
Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemistry, Pharmaceutical; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Micelles; Middle Aged; Organoplatinum Compounds; Paclitaxel; Polyethylene Glycols; Polymers; Prognosis; Urologic Neoplasms | 2012 |
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Europe; Female; Gemcitabine; Humans; Interleukin-2; Kaplan-Meier Estimate; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neoplasm Staging; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vaccines, Synthetic; Vaccinia virus | 2011 |
A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Quality of Life; Slovenia | 2012 |
Discrimination between circulating endothelial cells and blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in cancer therapy.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Agents; Bevacizumab; Blood Platelets; CD146 Antigen; Deoxycytidine; Drug Administration Schedule; Endothelial Cells; Female; Flow Cytometry; Gemcitabine; Humans; Immunophenotyping; Leukocyte Common Antigens; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Regression Analysis; T-Lymphocytes; Treatment Outcome | 2011 |
Phase I-II trial of gemcitabine-based first-line chemotherapies for small cell lung cancer in elderly patients with performance status 0-2: the G-STEP trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Germ Cells; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Treatment Outcome | 2012 |
A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Biomarkers, Tumor; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cohort Studies; Deoxycytidine; Female; Gemcitabine; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Survival Rate | 2012 |
Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: a randomized, phase III study by the Danish Breast Cancer Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Receptor, ErbB-2; Taxoids | 2011 |
Concurrent radiotherapy and chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Prospective Studies; Radiation-Sensitizing Agents; Young Adult | 2011 |
Can gemcitabine instillation ablate solitary low-risk non-muscle-invasive bladder cancer? Results of a phase II marker lesion study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Endoscopy; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoplasm Invasiveness; Time Factors; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms; Urine | 2011 |
A multicenter phase II randomized trial of docetaxel/gemcitabine versus docetaxel/capecitabine as first-line treatment for advanced breast cancer: a Gruppo Oncologico Italia Meridionale study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Intention to Treat Analysis; Middle Aged | 2011 |
Phase II trial of preoperative paclitaxel, gemcitabine, and trastuzumab combination therapy in HER2 positive stage II/III breast cancer: the Korean Cancer Study Group BR 07-01.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Receptor, ErbB-2; Republic of Korea; Risk Assessment; Risk Factors; Time Factors; Trastuzumab; Treatment Outcome | 2012 |
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; Dalteparin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Survival Rate; Venous Thromboembolism | 2012 |
Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303).
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Pain; Palliative Care; Pancreatic Neoplasms; Prevalence; Quality of Life; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; United States | 2012 |
Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Paclitaxel; Polymorphism, Genetic; Topotecan; Young Adult | 2012 |
Effect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Docosahexaenoic Acids; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Gemcitabine; Humans; Interleukin-6; Lung Neoplasms; Male; Oxidative Stress; Patient Dropouts; Weight Gain | 2012 |
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Vinblastine; Vinorelbine | 2012 |
Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Placebos; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk | 2012 |
Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2012 |
Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Peripheral Nerves; Prognosis; Prospective Studies; Risk Factors | 2012 |
Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging | 2012 |
The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3-D conformal radiotherapy for the treatment of localised pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2012 |
Randomized phase 2 sequencing and pharmacokinetic study of gemcitabine and oxaliplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Survival Analysis | 2011 |
Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Mice; Mice, SCID; Microfilament Proteins; Middle Aged; Neoplasm Proteins; Neoplasm Transplantation; Nuclear Proteins; Survival Rate; Transplantation, Heterologous | 2012 |
Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: relationship between skin rash and survival (Pantar study).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Phase II study of gemcitabine in combination with regional arterial infusion of nafamostat mesilate for advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Guanidines; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
[First line therapy for local advanced or metastasized urothelial carcinoma: randomized double-blind phase II study to compare gemcitabin and cisplatin in combination with OGX-427 or placebo for advanced transitional cell carcinoma of the bladder (OGX-427
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Placebo Effect; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Contraindications; Deoxycytidine; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Quality of Life; Surveys and Questionnaires; Survival Rate; Urologic Neoplasms; Vinblastine | 2012 |
Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
Prospective phase II trial of a combination of gemcitabine and UFT as first-line treatment in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Survival Analysis; Tegafur; Treatment Outcome; Uracil | 2012 |
Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligonucleotides, Antisense; Survival Rate; Thionucleotides; Treatment Outcome | 2012 |
[A pilot study of intraperitoneal gemcitabine for reduction of peritoneal dissemination in advanced pancreatic cancer].
Topics: Aged; Deoxycytidine; Gemcitabine; Humans; Infusions, Parenteral; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pilot Projects | 2011 |
Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pyrazines; Treatment Outcome; Young Adult | 2012 |
A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur | 2012 |
Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Retreatment; Tumor Burden | 2012 |
A phase II study to evaluate the efficacy and toxicity of oxaliplatin in combination with gemcitabine in carcinoma of unknown primary.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Unknown Primary; Organoplatinum Compounds; Oxaliplatin | 2013 |
[Phase II trial of improved regimen with gemcitabine in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2012 |
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate; Young Adult | 2012 |
Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2012 |
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Vinblastine; Vinorelbine | 2012 |
Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2012 |
Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Deoxycytidine; Epidemiologic Methods; Female; Gelatin Sponge, Absorbable; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2012 |
Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Pulmonary Embolism; Quinazolines; Treatment Outcome | 2012 |
Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplat
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biliary Tract Neoplasms; Cancer Vaccines; Cell Cycle Proteins; Cisplatin; Combined Modality Therapy; Deoxycytidine; Digestive System Neoplasms; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Nuclear Proteins; Pancreatic Neoplasms; Research Design; RNA Splicing Factors; Treatment Outcome; Vaccines, Subunit | 2012 |
Bevacizumab added to neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Logistic Models; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Taxoids; Treatment Outcome | 2012 |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Europe; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Treatment Outcome | 2012 |
Gemcitabine adsorbed onto carbon particles increases drug concentrations at the injection site and in the regional lymph nodes in an animal experiment and a clinical study.
Topics: Adsorption; Animals; Antimetabolites, Antineoplastic; Carbon; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Injections; Lymph Nodes; Pancreatic Neoplasms; Rats; Rats, Sprague-Dawley; Temperature; Time Factors; Tissue Distribution | 2011 |
A phase I/II study of gemcitabine-concurrent proton radiotherapy for locally advanced pancreatic cancer without distant metastasis.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Proton Therapy | 2012 |
A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2012 |
RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Regression Analysis; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins; Young Adult | 2012 |
Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hematologic Diseases; Humans; Infant; Male; Neoplasm Grading; Recurrence; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Time Factors | 2012 |
A phase I/II study of carboplatin plus gemcitabine for elderly patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group Trial (WJTOG) 2905.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Treatment Outcome | 2012 |
Gemcitabine in combination with vinorelbine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Prognosis; Prospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Survival Rate | 2012 |
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging | 2012 |
Long-term results of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2012 |
[A randomized controlled trial of the efficacy of combination of gemcitabine and carboplatin or paclitaxel and combination of paclitaxel and carboplatin in the treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Remission Induction; Survival Rate; Thrombocytopenia | 2011 |
Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Cycle Proteins; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gemcitabine; Glycine; Humans; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Sulfones; Survival Analysis; Treatment Outcome | 2012 |
Long-term outcomes of gemcitabine and cisplatin in patients with recurrent or metastatic esophageal squamous cell carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged | 2011 |
A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
A phase 2 study of sequential neoadjuvant chemotherapy with gemcitabine and doxorubicin followed by gemcitabine and cisplatin in patients with large or locally advanced operable breast cancer: results from long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Survival Rate | 2013 |
Phase II study of sequential gemcitabine followed by docetaxel for recurrent Ewing sarcoma, osteosarcoma, or unresectable or locally recurrent chondrosarcoma: results of Sarcoma Alliance for Research Through Collaboration Study 003.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Chondrosarcoma; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Osteosarcoma; Sarcoma, Ewing; Taxoids | 2012 |
Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Capecitabine; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Statistics, Nonparametric; Treatment Outcome | 2012 |
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Treatment Failure | 2012 |
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Hemorrhage; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Survival Analysis; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms; Urothelium | 2012 |
A phase I combination study of olaparib with cisplatin and gemcitabine in adults with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2012 |
A phase II study of first-line chemotherapy with weekly carboplatin plus gemcitabine in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Thrombocytopenia; Treatment Outcome | 2012 |
Sequential FOLFOX-6 and gemcitabine for locally advanced and/or metastatic pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Prospective Studies | 2012 |
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines | 2012 |
A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Treatment Outcome | 2012 |
An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Calcium-Calmodulin-Dependent Protein Kinases; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytoskeleton; Death-Associated Protein Kinases; Deoxycytidine; Disease-Free Survival; DNA Methylation; ErbB Receptors; Female; Gemcitabine; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Phase I trial of AEG35156 an antisense oligonucleotide to XIAP plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oligonucleotides; Pancreatic Neoplasms; Survival Rate; Treatment Outcome; X-Linked Inhibitor of Apoptosis Protein | 2013 |
A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Salvage Therapy | 2012 |
Phase II study of gemcitabine and docetaxel in recurrent platinum resistant ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids | 2012 |
[Efficacy evaluation of high intensity focused ultrasound combined with intra-arterial infusion of gemcitabine in the treatment of pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Staging; Pain Management; Pancreatic Neoplasms; Quality of Life; Remission Induction; Survival Rate; Ultrasonography | 2012 |
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, IGF Type 1; Sorafenib | 2012 |
Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1.
Topics: Adult; Aged; Antihypertensive Agents; Antimetabolites, Antineoplastic; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Tetrazoles | 2012 |
Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatin.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Contrast Media; Deoxycytidine; Female; Gadolinium DTPA; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Treatment Outcome | 2012 |
Phase 1 results from a study of romidepsin in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2012 |
Gemcitabine and paclitaxel combination as second-line chemotherapy in patients with small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nervous System Diseases; Neutropenia; Paclitaxel; Small Cell Lung Carcinoma | 2013 |
Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Surveys and Questionnaires; Treatment Outcome | 2013 |
A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Cause of Death; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Organs at Risk; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Thrombocytopenia; Time Factors | 2012 |
A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2013 |
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Farnesol; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); ras Proteins; Salicylates; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2012 |
Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Severity of Illness Index; Tegafur; Thrombocytopenia; Treatment Outcome | 2012 |
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes | 2012 |
Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Treatment Outcome | 2012 |
Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Dendritic Cells; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Gemcitabine; Humans; Immunomodulation; Immunotherapy; Interleukin-2; Irinotecan; Killer Cells, Natural; Male; Middle Aged; Recombinant Proteins; T-Lymphocyte Subsets | 2012 |
Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kidney Diseases; Male; Middle Aged; Urinary Bladder Neoplasms | 2012 |
Sequential chemoradiotherapy with gemcitabine and cisplatin for locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Young Adult | 2013 |
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM/2002-01 phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Extracellular Signal-Regulated MAP Kinases; Female; Gemcitabine; Humans; Immunohistochemistry; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Polymorphism, Single Nucleotide; Receptors, Estrogen; Survivin | 2012 |
Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Patient Compliance; Pilot Projects; Prospective Studies; Ultrasonography, Interventional | 2012 |
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Placebos; Pleural Neoplasms | 2012 |
Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents; Treatment Outcome | 2012 |
Gemcitabine-based induction chemotherapy and concurrent with radiation in advanced head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging | 2012 |
Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Prospective Studies; Republic of Korea | 2012 |
Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial.
Topics: Antimetabolites, Antineoplastic; CA-19-9 Antigen; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Survival Rate | 2012 |
Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: prognostic and predictive factors and the impact of disease stage on outcomes from a prospective
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymph Nodes; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Tumor Burden; Uterine Cervical Neoplasms | 2012 |
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Placebos; Receptor, IGF Type 1; Survival Rate; Treatment Outcome | 2012 |
Final results and pharmacoeconomic analysis of a trial comparing two neoadjuvant chemotherapy (CT) regimens followed by surgery in patients with resectable non-small cell lung cancer (NSCLC): a phase II randomised study by the European Lung Cancer Working
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Costs and Cost Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitomycin; Multivariate Analysis; Neoadjuvant Therapy; Proportional Hazards Models; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a randomized, phase-II study.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Neoplasm Staging; Treatment Outcome | 2012 |
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Infusions, Intravenous; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Prognosis; Survival Rate; Young Adult | 2013 |
A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Early Termination of Clinical Trials; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2012 |
Intermittent chemotherapy is a treatment choice for advanced urothelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Prospective Studies; Quality of Life; Serum Albumin; Survival Rate; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2012 |
Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inducing Agents; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Deoxycytidine; Endothelial Cells; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis | 2012 |
Salvage gemcitabine-vinorelbine chemotherapy in patients with metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Risk Factors; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Vinorelbine and gemcitabine vs vinorelbine and carboplatin as first-line treatment of advanced NSCLC. A phase III randomised controlled trial by the Norwegian Lung Cancer Study Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Quality of Life; Vinblastine; Vinorelbine | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
First-line chemotherapy with planned sequential administration of cisplatin/gemcitabine followed by docetaxel in elderly 'unfrail' patients with advanced non-small-cell lung cancer: a multicenter phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Survival Rate; Taxoids; Treatment Outcome | 2012 |
VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2012 |
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Ribonucleotide Reductases; Sorafenib | 2012 |
Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Early Detection of Cancer; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prospective Studies; Quinazolines; Treatment Outcome; Young Adult | 2012 |
Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104).
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2013 |
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2012 |
FOLFOX-4 regimen or single-agent gemcitabine as first-line chemotherapy in advanced biliary tract cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bone Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Prospective randomised evaluation of traditional Chinese medicine combined with chemotherapy: a randomised phase II study of wild toad extract plus gemcitabine in patients with advanced pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Amphibian Venoms; Animals; Antineoplastic Combined Chemotherapy Protocols; Anura; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Medicine, Chinese Traditional; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Single-Blind Method | 2012 |
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Prognosis; Survival Analysis; Watchful Waiting | 2012 |
Efficacy and safety of gemcitabine monotherapy for patients with advanced biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2012 |
Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2012 |
Gemcitabine and irinotecan as first-line therapy for carcinoma of unknown primary: results of a multicenter phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Unknown Primary; Treatment Outcome | 2012 |
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Docetaxel; Erlotinib Hydrochloride; France; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Monte Carlo Method; Multivariate Analysis; Prospective Studies; Quinazolines; Taxoids | 2012 |
[The efficacy and toxicity of gemcitabine and cisplatin chemotherapy in advanced/metastatic bladder urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neutropenia; Salvage Therapy; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
Phase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Middle Aged; Neoplasm Staging; Treatment Outcome; Young Adult | 2013 |
Phase II trial of combined regional hyperthermia and gemcitabine for locally advanced or metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2012 |
A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyridines; Ribonucleoside Diphosphate Reductase; Thiosemicarbazones; Thrombocytopenia | 2013 |
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2012 |
A phase I study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphocyte Activation Gene 3 Protein; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2013 |
Phase I trial of sunitinib and gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2012 |
Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Survival Analysis; Treatment Outcome | 2013 |
Cost effectiveness of concurrent gemcitabine and cisplatin with radiation followed by adjuvant gemcitabine and cisplatin in patients with stages IIB to IVA carcinoma of the cervix.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Middle Aged; Models, Statistical; Neoplasm Staging; Quality of Life; Quality-Adjusted Life Years; Survival Analysis; Treatment Outcome; United States; Uterine Cervical Neoplasms | 2012 |
Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2013 |
Cisplatin-based therapy for the treatment of elderly patients with non-small-cell lung cancer: a retrospective analysis of a single institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2012 |
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Antimetabolites, Antineoplastic; Cancer Vaccines; Clinical Trials, Phase I as Topic; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Neovascularization, Pathologic; Pancreatic Neoplasms; Placebos; Randomized Controlled Trials as Topic; Salmonella typhi; Vaccines, DNA; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; France; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leiomyosarcoma; Lenograstim; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Recombinant Proteins; Taxoids; Uterine Neoplasms | 2012 |
A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2013 |
Continuous transarterial infusion chemotherapy with gemcitabine and 5-Fluorouracil for advanced pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Survival; Survival Rate; Treatment Outcome | 2012 |
Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Survival Rate; Treatment Outcome | 2012 |
[Gemcitabine combined with vinorelbine in the treatment of refractory patients with advanced non-small cell lung cancer: a multi-center retrospective study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas.
Topics: Adaptive Immunity; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; B7 Antigens; CD8-Positive T-Lymphocytes; Cytotoxicity, Immunologic; Deoxycytidine; Female; Follow-Up Studies; Forkhead Transcription Factors; Gemcitabine; Glutamates; Guanine; Humans; Immunity, Innate; Immunologic Memory; Interferon-gamma; Interleukin-2; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Pancreatic Neoplasms; Pemetrexed; Survival Analysis; T-Lymphocyte Subsets | 2012 |
Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Safety and efficacy of sequential chemotherapy with carboplatin plus gemcitabine followed by weekly paclitaxel in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2013 |
[Curative effect of 3D-CRT combined with gemcitabine concurrently with addition of Kanglaite Injection in treatment of locally advanced pancreatic].
Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phytotherapy; Radiotherapy, Conformal; Young Adult | 2012 |
Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Radiation-Sensitizing Agents; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins; Vinblastine; Vinorelbine; Young Adult | 2013 |
Phase II study of gemcitabine and bevacizumab as first-line treatment in taxane-pretreated, HER2-negative, locally recurrent or metastatic breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Bridged-Ring Compounds; Deoxycytidine; Female; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Survival Rate; Taxoids | 2012 |
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Polymorphism, Genetic; Prospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2013 |
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; Indazoles; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrimidines; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
[Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Quality of Life; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
[A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Pemetrexed; Treatment Outcome | 2012 |
PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Hypoxia; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Taxoids | 2012 |
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Melanoma; Middle Aged; Quinazolines; Receptor, IGF Type 1; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Treatment Outcome | 2013 |
High COL4A3 expression correlates with poor prognosis after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer.
Topics: Actins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Collagen Type IV; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; RNA, Messenger; Treatment Outcome | 2013 |
Phase II study of biweekly carboplatin, gemcitabine, and bevacizumab as first-line treatment in patients with stage IIIB/IV NSCLC.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2014 |
Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Radionuclide Imaging; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2013 |
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2013 |
Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Research Design; Salvage Therapy; Surveys and Questionnaires | 2012 |
Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Guanidines; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2012 |
EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins | 2013 |
A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Dasatinib; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Interleukin-8; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Neoplastic Cells, Circulating; Pyrimidines; Thiazoles; Young Adult | 2013 |
Long-term analysis of gemcitabine-based chemoradiation after surgical resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2013 |
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 2013 |
Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pyrroles; Sunitinib; Survival Rate; Urinary Bladder Neoplasms; Urothelium | 2013 |
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunotherapy, Active; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Analysis; Treatment Outcome; Trisaccharides | 2013 |
A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Dyspnea; Fatigue; Female; Gemcitabine; Humans; Hypothyroidism; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Proportional Hazards Models; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Stomatitis; Vascular Endothelial Growth Factor Receptor-3 | 2013 |
Phase I trial of gemcitabine combined with capecitabine and erlotinib in advanced pancreatic cancer: a clinical and pharmacological study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Quinazolines; Stomatitis; Vomiting | 2012 |
A phase II study of gemcitabine and irinotecan in patients with locally advanced or metastatic bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Nausea; Neutropenia; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Prognostic significance of carbohydrate antigen 19-9 in unresectable locally advanced pancreatic cancer treated with dose-escalated intensity modulated radiation therapy and concurrent full-dose gemcitabine: analysis of a prospective phase 1/2 dose escala
Topics: Adenocarcinoma; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Prospective Studies; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Sex Factors; Tumor Burden | 2013 |
Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung can
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel | 2013 |
[A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Remission Induction; Survival Rate; Thrombocytopenia | 2012 |
The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2013 |
When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient population with advanced non-small-cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome | 2013 |
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Urologic Neoplasms; Urothelium | 2013 |
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prospective Studies; Taxoids; Treatment Outcome; Uterine Neoplasms | 2013 |
Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Constipation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Treatment Outcome; Urologic Neoplasms; Urothelium | 2013 |
Randomized phase III multi-institutional study of TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer: final results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Treatment Failure | 2013 |
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Demography; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms | 2013 |
A randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine monotherapy for advanced biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Patient Compliance; Tegafur | 2013 |
New-onset congestive heart failure with gemcitabine in ovarian and other solid cancers.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Pancreatic Neoplasms; Retrospective Studies; Urinary Bladder Neoplasms | 2014 |
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Rate; Thalidomide | 2013 |
A phase II study of induction carboplatin and gemcitabine followed by chemoradiotherapy for the treatment of locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Radiotherapy, Intensity-Modulated; Remission Induction; Ribonucleotide Reductases; Survival Rate; Young Adult | 2013 |
A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age 70 years or older) with stage IIIB/IV non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Predictive Value of Tests; Proteomics; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Angiotensin I; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peptide Fragments; Thrombocytopenia | 2013 |
A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms; Paclitaxel | 2013 |
Pharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Ascorbic Acid; Chromatography, High Pressure Liquid; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glutathione; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Patient Compliance; Patient Safety; Sentinel Lymph Node Biopsy | 2013 |
Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: long-term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Prognosis; Survival Analysis; Taxoids | 2013 |
Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome | 2013 |
Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Proteins; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Oximes; Pancreatic Neoplasms; Piperazines; Sulfonamides | 2013 |
Assessing the effectiveness and safety of liposomal paclitaxel in combination with cisplatin as first-line chemotherapy for patients with advanced NSCLC with regional lymph-node metastasis: study protocol for a randomized controlled trial (PLC-GC trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemistry, Pharmaceutical; China; Cisplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Liposomes; Lung Neoplasms; Lymphatic Metastasis; Neoplasm Staging; Paclitaxel; Prospective Studies; Research Design; Time Factors; Treatment Outcome | 2013 |
Restoration of mannose-binding lectin complement activity is associated with improved outcome in patients with advanced pancreatic cancer treated with gemcitabine and intravenous ω-3 fish oil.
Topics: Administration, Intravenous; Adult; Aged; Complement System Proteins; Cytokines; Deoxycytidine; Fatty Acids, Omega-3; Female; Fish Oils; Gemcitabine; Humans; Male; Mannose-Binding Lectin; Middle Aged; Pancreatic Neoplasms | 2014 |
Disrupting cytokine signaling in pancreatic cancer: a phase I/II study of etanercept in combination with gemcitabine in patients with advanced disease.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Etanercept; Fatigue; Female; Gemcitabine; Humans; Immunoglobulin G; Interferon-gamma; Interleukin-10; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Receptors, Tumor Necrosis Factor; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Treatment Outcome; Tumor Necrosis Factor-alpha | 2013 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
Global, multicenter, randomized, phase II trial of gemcitabine and gemcitabine plus AGS-1C4D4 in patients with previously untreated, metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; GPI-Linked Proteins; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Proportional Hazards Models; Treatment Outcome | 2013 |
Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Quality of Life; Radiosurgery; Treatment Outcome | 2013 |
Reduction in circulating pro-angiogenic and pro-inflammatory factors is related to improved outcomes in patients with advanced pancreatic cancer treated with gemcitabine and intravenous omega-3 fish oil.
Topics: Administration, Intravenous; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cytokines; Deoxycytidine; Disease-Free Survival; Down-Regulation; England; Fatty Acids, Omega-3; Fibroblast Growth Factors; Gemcitabine; Humans; Inflammation Mediators; Interleukin-6; Interleukin-8; Kaplan-Meier Estimate; Linear Models; Pancreatic Neoplasms; Platelet-Derived Growth Factor; Time Factors; Treatment Outcome | 2013 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Phase II randomized trial of carboplatin and gemcitabine with or without dexamethasone pre-treatment in patients with Stage IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dexamethasone; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Serum Albumin; Survival Rate; Treatment Outcome | 2013 |
Phase II study of triplet chemotherapy using Tegafur-Uracil, Vinorelbine, Gemcitabine for advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Tegafur; Uracil; Vinblastine; Vinorelbine | 2013 |
Phase I/II study of albumin-bound nab-paclitaxel plus gemcitabine administered to Chinese patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2013 |
Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Young Adult | 2013 |
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrroles; Sunitinib | 2013 |
A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Carboplatin; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Economic; Quinazolines; Time Factors | 2013 |
Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas.
Topics: Adolescent; Adult; Animals; Antimetabolites, Antineoplastic; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line, Tumor; Child; Child, Preschool; Deoxycytidine; Drug Synergism; Female; Femoral Neoplasms; Gemcitabine; Humans; Male; Mice; Mice, SCID; Middle Aged; Neoplasm Transplantation; Nuclear Proteins; Osteosarcoma; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pilot Projects; Radiotherapy | 2013 |
Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Medical Futility; Middle Aged; Neoplasm Metastasis; Paclitaxel; Patient Compliance; Taxoids; Treatment Outcome | 2013 |
A phase I schedule dependency study of the aurora kinase inhibitor MSC1992371A in combination with gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Norbornanes; Protein Kinase Inhibitors; Pyrimidines; Young Adult | 2014 |
The impact of intravesical gemcitabine and 1/3 dose Bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: results of a prospective, randomized, phase II trial.
Topics: Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prospective Studies; Quality of Life; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
A randomized phase II non-comparative study of pemetrexed‑carboplatin and gemcitabine‑vinorelbine in anthracycline- and taxane-pretreated advanced breast cancer patients.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glutamates; Guanine; Humans; Middle Aged; Neoplasm Staging; Pemetrexed; Taxoids; Vinblastine; Vinorelbine | 2013 |
Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Survival Analysis; Taiwan; Tegafur; Treatment Outcome | 2013 |
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Ifosfamide; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Vinblastine; Vinorelbine | 2013 |
Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Treatment Outcome; Urologic Neoplasms; Urothelium | 2014 |
Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Republic of Korea; Treatment Outcome; Watchful Waiting | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Neutropenia; Pyridones; Pyrimidinones; Thrombocytopenia; Treatment Outcome | 2013 |
A phase II study of the combination of gemcitabine plus carboplatin as the neoadjuvant treatment in locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy | 2013 |
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2013 |
Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2013 |
SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2013 |
Oxaliplatin plus 5-fluorouracil and folinic acid (OFF) in gemcitabine-pretreated advanced pancreatic cancer: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Survival Rate | 2013 |
Brachytherapy versus radical hysterectomy after external beam chemoradiation with gemcitabine plus cisplatin: a randomized, phase III study in IB2-IIB cervical cancer patients.
Topics: Adult; Aged; Brachytherapy; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Hysterectomy; Middle Aged; Radiation-Sensitizing Agents; Survival; Treatment Outcome; Uterine Cervical Neoplasms; Young Adult | 2013 |
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Neoplasms, Squamous Cell; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Randomized phase II trial of non-platinum induction or consolidation chemotherapy plus concomitant chemoradiation in stage III NSCLC patients: mature results of the Spanish Lung Cancer Group 0008 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Consolidation Chemotherapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome | 2013 |
Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Carboxylesterase; Deoxycytidine; Deoxyuridine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Polymorphism, Single Nucleotide; Prodrugs | 2013 |
A retrospective study of chemotherapy with cisplatin plus gemcitabine after the failure of gemcitabine monotherapy for biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Survival Rate; Thrombocytopenia; Treatment Failure; Treatment Outcome | 2013 |
Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Proteinuria; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Treatment Outcome | 2013 |
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Treatment Outcome; Young Adult | 2013 |
A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575).
Topics: Adult; Aged; Amyloid Precursor Protein Secretases; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Calcium-Binding Proteins; Deoxycytidine; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Male; Membrane Proteins; Middle Aged; Neoplasms; Receptor, Notch1; Receptor, Notch3; Receptors, Notch; Serrate-Jagged Proteins | 2014 |
[Cisplatin-based chronotherapy for advanced none-small cell lung cancer: a randomized controlled study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Chronotherapy; Female; Gemcitabine; Humans; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Remission Induction; Taxoids | 2013 |
Phase I dose-escalation study and population pharmacokinetic analysis of fixed dose rate gemcitabine plus carboplatin as second-line therapy in patients with ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Thrombocytopenia | 2013 |
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Pancreatic Neoplasms; Prospective Studies; Survival; Young Adult | 2013 |
A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biphenyl Compounds; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Tetrazoles; Treatment Outcome | 2013 |
Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Docetaxel; Endonucleases; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; International Cooperation; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neutropenia; Paclitaxel; Thrombocytopenia; Urinary Bladder Neoplasms | 2013 |
A multi-institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2013 |
Treatment outcomes of paclitaxel for refractory or recurrent epithelial ovarian cancer patients in Thailand.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Survival Rate | 2013 |
A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Paclitaxel; Perioperative Care; Preoperative Care; Quality of Life; Treatment Outcome; Vomiting | 2013 |
Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an IGF1R inhibitor.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Deoxycytidine; Gemcitabine; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; ras Proteins; Receptor, IGF Type 1; Survival Analysis | 2013 |
Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neutropenia; Taxoids; Thrombocytopenia; Treatment Outcome; Urologic Neoplasms; Urothelium; Young Adult | 2014 |
Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Rituximab; Secondary Prevention; Survival Rate | 2013 |
Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Flow Cytometry; Gemcitabine; Glutamates; Guanine; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Lung Neoplasms; Male; Middle Aged; Myeloid Cells; Pemetrexed; Taxoids | 2013 |
Randomized phase II study of gemcitabine plus S-1 versus S-1 in advanced biliary tract cancer: a Japan Clinical Oncology Group trial (JCOG 0805).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Tegafur | 2013 |
A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisolone; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2013 |
A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Male; Neoplasm Recurrence, Local; Treatment Outcome | 2014 |
Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quality of Life; Quinazolines; Radiotherapy, Intensity-Modulated | 2013 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; HLA Antigens; Humans; Immunoglobulins; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Peptide Fragments; Precision Medicine; Prognosis; Survival Rate; Tegafur; Vaccination; Young Adult | 2013 |
Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Topics: Aged; Algorithms; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Preoperative Care; Prospective Studies | 2013 |
Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiotherapy Dosage; Remission Induction; Survival Rate; Tegafur | 2013 |
Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: a double-blind randomized crossover study.
Topics: Adult; Antimetabolites, Antineoplastic; Cross-Over Studies; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Glucose; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplasms; Pain; Pain Measurement; Vascular Diseases | 2013 |
[Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Nausea; Neoplasm Staging; Neutropenia; Pemetrexed; Quality of Life; Survival Rate; Thrombocytopenia; Vomiting | 2013 |
Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Thiophenes; Urea | 2013 |
Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP).
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Survival Rate | 2013 |
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Patient Selection; Proportional Hazards Models; Prospective Studies; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Laparoscopy; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Prognosis; Radiotherapy Dosage; Remission Induction; Survival Rate | 2013 |
Intra-arterial infusion chemotherapy for advanced non-small-cell lung cancer: preliminary experience on the safety, efficacy, and clinical outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Prevalence; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hospitalization; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Quality-Adjusted Life Years; Survival Rate; Time Factors; Treatment Outcome | 2013 |
Gemcitabine and docetaxel for metastatic soft tissue sarcoma - a single center experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma; Soft Tissue Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2013 |
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Pyrazines; Recurrence; Treatment Outcome | 2013 |
Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Salvage Therapy | 2013 |
Phase II study on combined intravenous and intra-arterial chemotherapy with gemcitabine and mitomycin C in patients with advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Prospective Studies | 2013 |
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prognosis; Survival Rate; Taxoids | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Pralatrexate pharmacology and clinical development.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Depsipeptides; Disease-Free Survival; Drug Approval; Drug Synergism; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
Combination of gemcitabine and cetuximab in patients with advanced cholangiocarcinoma: a phase II study of the Belgian Group of Digestive Oncology.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cetuximab; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins | 2013 |
Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
A phase I study of an agonist CD40 monoclonal antibody (CP-870,893) in combination with gemcitabine in patients with advanced pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Carcinoma, Pancreatic Ductal; CD40 Antigens; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Macrophages; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Positron-Emission Tomography; Survival; Treatment Outcome | 2013 |
Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cetuximab; Deoxycytidine; DNA Mutational Analysis; Drug Administration Schedule; Exanthema; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Regression Analysis; Treatment Outcome | 2013 |
Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Prospective Studies; Time Factors; Urinary Bladder Neoplasms | 2014 |
Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial.
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Clinical Protocols; Deoxycytidine; Gemcitabine; Heavy Ion Radiotherapy; Humans; Neoplasm Staging; Pancreatic Neoplasms; Radiation Dosage; Treatment Outcome | 2013 |
Does long-term survival in patients with pancreatic cancer really exist? Results from the CONKO-001 study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Risk Factors; Time Factors | 2013 |
Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Treatment Outcome; Urologic Neoplasms | 2014 |
Transarterial chemoembolisation (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Chemoembolization, Therapeutic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Prospective Studies; Treatment Outcome; Young Adult | 2013 |
A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine/cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged | 2014 |
Combination of low-dose gemcitabine in 6-hour infusion and carboplatin is a favorable option for patients in poor performance status with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2014 |
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2013 |
Tumor histological subtyping determined by hormone receptors and HER2 status defines different pathological complete response and outcome to dose-dense neoadjuvant chemotherapy in breast cancer patients.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Remission Induction; Survival Rate; Trastuzumab | 2014 |
A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Injuries; Radiotherapy, Conformal; Survival Rate; Taxoids; Treatment Outcome | 2013 |
Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Survival Analysis | 2013 |
S-1 plus CIK as second-line treatment for advanced pancreatic cancer.
Topics: Adult; Aged; Cytokine-Induced Killer Cells; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2013 |
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2013 |
Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Remission Induction; Skin Neoplasms; Tetrahydronaphthalenes; Treatment Outcome; United Kingdom | 2013 |
Cellular and plasma uptake of parenteral omega-3 rich lipid emulsion fatty acids in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Deoxycytidine; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Eicosapentaenoic Acid; Emulsions; Gemcitabine; Humans; Pancreatic Neoplasms | 2014 |
Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2014 |
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2013 |
Combination of paclitaxel, cisplatin, and gemcitabine (TPG) for multiple relapses or platinum-resistant germ cell tumors: long-term outcomes.
Topics: Adult; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival; Treatment Outcome | 2014 |
Randomized double-blinded, placebo-controlled phase II trial of simvastatin and gemcitabine in advanced pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; ErbB Receptors; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mutation; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Simvastatin | 2014 |
Phase II trial of biweekly gemcitabine and paclitaxel with recurrent or metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group study S0329.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2014 |
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; Taxoids | 2014 |
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; In Vitro Techniques; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2013 |
De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Heart Diseases; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisolone; Rituximab; Severity of Illness Index; Stroke Volume; Treatment Outcome; United Kingdom; Vincristine | 2014 |
Phase II study of low-dose paclitaxel with timed thoracic radiotherapy followed by adjuvant gemcitabine and carboplatin in unresectable stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy; Thorax | 2014 |
A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2014 |
Low CHD5 expression activates the DNA damage response and predicts poor outcome in patients undergoing adjuvant therapy for resected pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; DNA Damage; DNA Helicases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nerve Tissue Proteins; Pancreatic Neoplasms; Prognosis; Treatment Outcome; Tumor Cells, Cultured | 2014 |
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Europe; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-2; Leucovorin; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
A phase I clinical trial of vaccination with KIF20A-derived peptide in combination with gemcitabine for patients with advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kinesins; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocyte Subsets; Tomography, X-Ray Computed; Treatment Outcome; Vaccines, Subunit | 2014 |
Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Demography; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Survival Analysis; Treatment Outcome; Urologic Neoplasms; Urothelium | 2014 |
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur; Treatment Outcome | 2014 |
Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Demography; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Low-dose versus standard-dose gemcitabine infusion and cisplatin for patients with advanced bladder cancer: a randomized phase II trial-an update.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Randomized, double-blind, phase II trial comparing gemcitabine-cisplatin plus the LTB4 antagonist LY293111 versus gemcitabine-cisplatin plus placebo in first-line non-small-cell lung cancer.
Topics: Adiponectin; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Leukotriene B4; Lung Neoplasms; Male; Middle Aged | 2014 |
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom | 2014 |
Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Membrane Transport Proteins; Middle Aged; Neoplasm Metastasis; Paclitaxel; Polymorphism, Genetic; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
Combined chemoradiation therapy with twice-weekly gemcitabine and cisplatin for organ preservation in muscle-invasive bladder cancer: long-term results of a phase 1 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Organ Sparing Treatments; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
[ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Neoplasm Recurrence, Local; Paclitaxel; Survival Rate; Uterine Cervical Neoplasms; Vincristine | 2013 |
Neoadjuvant chemotherapy with sequential anthracycline-docetaxel with gemcitabine for large operable or locally advanced breast cancer: ANZ 0502 (NeoGem).
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Taxoids; Trastuzumab; Treatment Outcome | 2014 |
Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Depsipeptides; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms | 2014 |
Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.
Topics: Antimetabolites, Antineoplastic; ATP-Binding Cassette Transporters; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Markers; Genetic Variation; Genome-Wide Association Study; Genotype; Humans; Linkage Disequilibrium; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Precision Medicine; Signal Transduction; Sulfotransferases | 2014 |
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand | 2013 |
A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Tomography, X-Ray Computed | 2014 |
Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Pemetrexed; Prognosis; Prospective Studies; Quality of Life; Research Design; Survival Rate | 2014 |
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Analysis; Survival Rate | 2014 |
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Risk Factors; Thailand; Time Factors; Treatment Outcome | 2014 |
Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Protein Kinases; Thiophenes; Urea | 2014 |
Associations between TS, TTF-1, FR-α, FPGS, and overall survival in patients with advanced non-small-cell lung cancer receiving pemetrexed plus carboplatin or gemcitabine plus carboplatin as first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; DNA-Binding Proteins; Female; Folate Receptor 1; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Peptide Synthases; Prognosis; Retrospective Studies; Survival Rate; Thymidylate Synthase; Tissue Array Analysis; Transcription Factors | 2013 |
Induction gemcitabine plus concurrent gemcitabine and radiotherapy for locally advanced unresectable or resected pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis | 2014 |
Phase II study of low-dose fixed-rate infusion of gemcitabine combined with cisplatin and dexamethasone in resistant non-Hodgkin lymphoma and correlation with Bcl-2 and MDR expression.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cisplatin; Cohort Studies; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Infusions, Intravenous; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins c-bcl-2; Remission Induction; Salvage Therapy; Survival Rate; Young Adult | 2014 |
Independent radiologic review: bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer.
Topics: Adult; Advisory Committees; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Radiology; Tomography, X-Ray Computed | 2014 |
Gemcitabine and capecitabine for heavily pre-treated metastatic colorectal cancer patients--a phase II and translational research study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Translational Research, Biomedical | 2014 |
SPARC expression in resected pancreatic cancer patients treated with gemcitabine: results from the CONKO-001 study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Osteonectin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Treatment Outcome | 2014 |
A phase II study of capecitabine plus docetaxel in gemcitabine-pretreated metastatic pancreatic cancer patients: CapTere.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Taxoids | 2014 |
Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2014 |
Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate | 2015 |
First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Treatment Outcome; Tumor Suppressor Proteins | 2014 |
The tailored chemotherapy based on RRM1 immunohistochemical expression in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Precision Medicine; Prognosis; Prospective Studies; Ribonucleoside Diphosphate Reductase; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Prospective Studies; Salvage Therapy; Testicular Neoplasms; Treatment Outcome; Young Adult | 2014 |
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated | 2014 |
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2014 |
Clinical benefit response in pancreatic cancer trials revisited.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Causality; Comorbidity; Deoxycytidine; Disease-Free Survival; Drug Therapy; Female; Fluorouracil; Gemcitabine; Humans; Incidence; Karnofsky Performance Status; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Palliative Care; Pancreatic Neoplasms; Quality of Life; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2014 |
Transport properties of pancreatic cancer describe gemcitabine delivery and response.
Topics: Aged; Antimetabolites, Antineoplastic; Biological Transport, Active; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Adducts; DNA, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Models, Biological; Pancreatic Neoplasms; Prognosis; Prospective Studies; Tomography, X-Ray Computed | 2014 |
Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged | 2014 |
Baseline serum albumin is a predictive biomarker for patients with advanced pancreatic cancer treated with bevacizumab: a pooled analysis of 7 prospective trials of gemcitabine-based therapy with or without bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Serum Albumin; Survival Analysis | 2014 |
Intensified chemotherapy and simultaneous treatment with heparin in outpatients with pancreatic cancer - the CONKO 004 pilot trial.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Enoxaparin; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Thromboembolism | 2014 |
Insulin-like growth factor 1 receptor (IGF-1R) as a target of MiR-497 and plasma IGF-1R levels associated with TNM stage of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation; Humans; Male; MicroRNAs; Neoplasm Proteins; Neoplasm Staging; Pancreatic Neoplasms; Receptor, IGF Type 1; RNA, Neoplasm; Tumor Cells, Cultured | 2014 |
Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis.
Topics: Adenocarcinoma; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Catheter-Related Infections; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2014 |
A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Prognosis; Quality of Life; Survival Analysis | 2014 |
Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Republic of Korea; Retrospective Studies; Survival Rate; Taxoids | 2014 |
A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Prodrugs; Proportional Hazards Models; Taxoids; Treatment Outcome; Tubulin Modulators | 2014 |
A phase I study of concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine-cetuximab in patients with stage III non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Precision Medicine; Radiotherapy Dosage; Remission Induction; Vinblastine; Vinorelbine | 2014 |
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Piperidines; Placebos; Quinazolines; Survival Rate | 2014 |
Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Genotype; Humans; Induction Chemotherapy; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Prospective Studies; Radiotherapy, Intensity-Modulated; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Thrombocytopenia; Treatment Outcome | 2014 |
A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines | 2014 |
Phase I trial of everolimus, gemcitabine and cisplatin in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Everolimus; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Sirolimus | 2014 |
Phase 1 dose escalation and pharmacokinetic evaluation of oral gemcitabine prodrug (LY2334737) in combination with docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Prodrugs; Taxoids; Treatment Outcome | 2014 |
Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Blood Glucose; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gemcitabine; Glycolysis; Humans; Induction Chemotherapy; Liver; Male; Middle Aged; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Prospective Studies; Radiopharmaceuticals; Radiosurgery; Regression Analysis; Tomography, X-Ray Computed; Tumor Burden | 2014 |
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Failure | 2011 |
A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Safety, tolerability, pharmacokinetics and antitumor activity of ganitumab, an investigational fully human monoclonal antibody to insulin-like growth factor type 1 receptor, combined with gemcitabine as first-line therapy in patients with metastatic pancr
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drugs, Investigational; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Pancreatic Neoplasms; Receptor, IGF Type 1; Thrombocytopenia; Treatment Outcome | 2014 |
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Receptor, ErbB-2; Taxoids; Trastuzumab | 2014 |
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Transitional Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Proportional Hazards Models; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
A correlative biomarker analysis of the combination of bevacizumab and carboplatin-based chemotherapy for advanced nonsquamous non-small-cell lung cancer: results of the phase II randomized ABIGAIL study (BO21015).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; E-Selectin; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Male; Neuropilins; Paclitaxel; Placenta Growth Factor; Platelet Endothelial Cell Adhesion Molecule-1; Pregnancy Proteins; Prospective Studies; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
A randomized phase II trial of gemcitabine plus carboplatin: biweekly versus standard schedules in patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2013 |
Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunomagnetic Separation; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Taxoids | 2014 |
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Topics: Adult; Aged; Alanine Transaminase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma; Cetuximab; Cholangiocarcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Mutation; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Peripheral Nervous System Diseases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); ras Proteins | 2014 |
Human equilibrative nucleoside transporter 1 is not predictive for gemcitabine efficacy in advanced pancreatic cancer: translational results from the AIO-PK0104 phase III study with the clone SP120 rabbit antibody.
Topics: Adolescent; Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Drug Administration Schedule; Equilibrative Nucleoside Transporter 1; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Prospective Studies; Quinazolines; Rabbits; Survival Analysis; Treatment Outcome; Young Adult | 2014 |
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.
Topics: Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Drug Eruptions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
MM-398 achieves primary endpoint of overall survival in phase III study in patients with gemcitabine refractory metastatic pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Sucrose | 2014 |
Clinical efficacy of bevacizumab concomitant with pemetrexed in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Treatment Outcome | 2014 |
TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Denmark; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome | 2014 |
Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liposomes; Lung Neoplasms; Male; Middle Aged; Nanoparticles; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2014 |
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms | 2014 |
Prognostic and predictive value of metabolic tumor volume on (18)F-FDG PET/CT in advanced biliary tract cancer treated with gemcitabine/oxaliplatin with or without erlotinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gemcitabine; Glycolysis; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Prognosis; Quinazolines; Survival Analysis; Tomography, X-Ray Computed; Tumor Burden | 2014 |
A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2014 |
Is there a role for second-line platinum re-challenge in advanced biliary tract cancers?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Survival Analysis | 2014 |
Phase II clinical trial of ex vivo-expanded cytokine-induced killer cells therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Cytokine-Induced Killer Cells; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2014 |
A randomized phase II/III trial of perioperative chemotherapy with adriamycin plus ifosfamide versus gemcitabine plus docetaxel for high-grade soft tissue sarcoma: Japan Clinical Oncology Group Study JCOG1306.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Japan; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Sarcoma; Soft Tissue Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Treatment Outcome | 2014 |
Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Risk; Survival Rate; Tegafur; Treatment Outcome | 2014 |
Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Broadly Neutralizing Antibodies; Carboplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Paclitaxel; Polyethylene Glycols; Taxoids | 2015 |
Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate | 2014 |
Prognostic and predictive role of ERCC1 protein expression in locally advanced stage III non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2014 |
Combined chemoradiotherapy with gemcitabine in patients with locally advanced inoperable transitional cell carcinoma of the urinary bladder and/or in patients ineligible for surgery: a phase I trial.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Radiation-Sensitizing Agents; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Phthalazines; Prognosis; Pyridines; Survival Rate | 2014 |
[Effect of integrated Chinese medical treatment (as maintenance therapy) on the survival time of patients with advanced non-small-cell lung cancer: a clinical study].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Gemcitabine; Humans; Pemetrexed; Prospective Studies; Taxoids | 2014 |
Phase II trial of gemcitabine plus UFT as salvage treatment in oxaliplatin, irinotecan and fluoropyrimidine-refractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Republic of Korea; Salvage Therapy; Tegafur; Treatment Outcome; Uracil | 2014 |
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Fatigue; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pain; Pancreatic Ducts; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2014 |
Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2014 |
Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2014 |
Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Cyclophosphamide; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Topotecan; Young Adult | 2014 |
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Phase I study and preclinical efficacy evaluation of the mTOR inhibitor sirolimus plus gemcitabine in patients with advanced solid tumours.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasms; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Quinolones; Thromboembolism; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2014 |
Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Everolimus; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Insulin-Like Growth Factor I; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome | 2014 |
Phase Ib/II trial of gemcitabine, cisplatin, and lenalidomide as first-line therapy in patients with metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Lenalidomide; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Thalidomide; Urothelium | 2014 |
Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cholangiocarcinoma; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Epitopes; Female; Follow-Up Studies; Gemcitabine; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Peptide Fragments; Prognosis; Survival Rate; T-Lymphocytes, Cytotoxic; Vaccination; WT1 Proteins | 2014 |
Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hypertension; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Risk Assessment; Single-Blind Method; Survival Rate; Treatment Outcome | 2016 |
Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Drug Screening Assays, Antitumor; Female; Gemcitabine; Hepatectomy; Humans; Male; Neutropenia; Postoperative Care; Pyridines; Tegafur; Treatment Outcome | 2014 |
Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Risk Factors; Treatment Outcome | 2014 |
Quality of life in a prospective, multicenter phase 2 trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Patient Compliance; Prospective Studies; Quality of Life; Radiotherapy, Conformal | 2014 |
Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutropenia; Republic of Korea; Severity of Illness Index; Taxoids; Treatment Outcome | 2014 |
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Paclitaxel; Prognosis; Receptor, Angiotensin, Type 1; Receptor, ErbB-2; Survival Rate; Translational Research, Biomedical | 2015 |
Timing of thoracic radiotherapy in limited stage small cell lung cancer: results of early versus late irradiation from a single institution in Turkey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Time Factors | 2014 |
A phase II randomized study evaluating the addition of iniparib to gemcitabine plus cisplatin as first-line therapy for metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2014 |
Phase I study of sunitinib in combination with gemcitabine and capecitabine for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib; Treatment Outcome | 2014 |
A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Stomatitis; Survival Analysis; Tegafur; Treatment Outcome; Venous Thrombosis | 2014 |
Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; China; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; Male; Middle Aged; Nuclear Proteins; Taxoids; Treatment Outcome; White People | 2014 |
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Hydrazines; Male; Middle Aged; Neoplasm Staging; Neoplasms; Platelet Count; Pyrazoles; Treatment Outcome | 2015 |
Concurrent gemcitabine and 3D radiotherapy in patients with stage III unresectable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Treatment Outcome; Vinblastine | 2014 |
A phase II trial of Endostar combined with gemcitabine and cisplatin chemotherapy in patients with metastatic nasopharyngeal carcinoma (NCT01612286).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Endostatins; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Recombinant Proteins; Treatment Outcome | 2013 |
Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Drug Dosage Calculations; Female; Gemcitabine; Humans; Lumbosacral Region; Lung Neoplasms; Male; Middle Aged; Muscle, Skeletal; Palliative Care; Pilot Projects; Radiography; Sarcopenia; Sex Factors; Vinblastine; Vinorelbine | 2015 |
Expression of ERCC1, RRM1 and LRP in non-small cell lung cancers and their influence on chemotherapeutic efficacy of gemcitabine concomitant with nedaplatin.
Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Nausea; Organoplatinum Compounds; Ribonucleoside Diphosphate Reductase; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Proteins; Vault Ribonucleoprotein Particles; Vomiting | 2014 |
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cell Separation; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon alpha-2; Interferon-alpha; Interleukin-2; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Recombinant Proteins; T-Lymphocytes, Regulatory; Time Factors; Treatment Outcome | 2015 |
Duodenal ischemia and upper GI bleeding are dose-limiting toxicities of 24-h continuous intra-arterial pancreatic perfusion of gemcitabine following vascular isolation of the pancreatic head: early results from the Regional Chemotherapy in Locally Advance
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Catheterization; Deoxycytidine; Duodenal Diseases; Duodenum; Female; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Ischemia; Male; Maximum Tolerated Dose; Middle Aged; Pancreas; Pancreatic Neoplasms; Perfusion; Splenic Artery; Treatment Outcome | 2015 |
A randomized phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in locally advanced or metastatic squamous cell carcinoma of lung.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Prospective Studies; Treatment Outcome; Young Adult | 2014 |
Gemcitabine plus cisplatin versus chemoradiotherapy in locally advanced biliary tract cancer: Fédération Francophone de Cancérologie Digestive 9902 phase II randomised study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Medication Adherence; Middle Aged; Treatment Outcome | 2014 |
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2014 |
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.
Topics: Adult; Age Distribution; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prevalence; Prospective Studies; Risk Factors; Sex Distribution; Survival Rate; Switzerland; Treatment Outcome | 2015 |
An innovative, multi-arm, complete phase 1b study of the novel anti-cancer agent tasisulam in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Sulfonamides; Taxoids; Temozolomide; Young Adult | 2015 |
S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, multicenter, phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2014 |
Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Deoxycytidine; Female; Gemcitabine; Hedgehog Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Pyridines; Signal Transduction; Treatment Outcome | 2014 |
Survivin as prognostic and predictive factor in patients treated with gemcitabine, dexamethasone, and cisplatin for relapsed or refractory aggressive NHL.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Dexamethasone; Female; Follow-Up Studies; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lymphoma, Non-Hodgkin; Male; Middle Aged; Predictive Value of Tests; Prognosis; Recurrence; Survival Rate; Survivin; Treatment Outcome; Young Adult | 2014 |
α-Smooth muscle actin expression and desmoplastic stromal reaction in pancreatic cancer: results from the CONKO-001 study.
Topics: Actins; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Stromal Cells; Survival Rate; Tissue Array Analysis; Tumor Microenvironment | 2014 |
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dimethyl Sulfoxide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Organometallic Compounds; Ruthenium; Ruthenium Compounds; Treatment Outcome | 2015 |
Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms; United States | 2014 |
Docetaxel, gemcitabine and bevacizumab as salvage chemotherapy for HER-2-negative metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast; Breast Neoplasms; Cohort Studies; Deoxycytidine; Docetaxel; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Salvage Therapy; Survival Analysis; Taxoids | 2015 |
Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prodrugs; Survival Analysis; Tegafur | 2015 |
Intratumoral chemotherapy with paclitaxel liposome combined with systemic chemotherapy: a new method of neoadjuvant chemotherapy for stage III unresectable non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intralesional; Kaplan-Meier Estimate; Liposomes; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel | 2015 |
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Quinazolines; Treatment Outcome | 2014 |
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; Chemokine CXCL12; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality of Life; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2014 |
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Treatment Outcome | 2014 |
Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Platinum; Receptor, ErbB-2; Trastuzumab | 2015 |
A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2015 |
Phase II study of gemcitabine and vinorelbine as second- or third-line therapy in patients with primary refractory or platinum-resistant recurrent ovarian and primary peritoneal cancer by the Korean Cancer Study Group (KCSG)_KCSG GY10-10.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Republic of Korea; Vinblastine; Vinorelbine | 2015 |
SUCCINCT: an open-label, single-arm, non-randomised, phase 2 trial of gemcitabine and cisplatin chemotherapy in combination with sunitinib as first-line treatment for patients with advanced urothelial carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Pyrroles; Sunitinib; Treatment Outcome; Urologic Neoplasms | 2015 |
Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a Phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Positron-Emission Tomography; Retreatment; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Survival Analysis; Tegafur; Treatment Outcome | 2015 |
Neoadjuvant gemcitabine, docetaxel, and capecitabine followed by gemcitabine and capecitabine/radiation therapy and surgery in locally advanced, unresectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Taxoids; Treatment Outcome | 2015 |
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Europe; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Lymph Node Excision; Male; Methotrexate; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Time Factors; Time-to-Treatment; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2015 |
Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cancer Vaccines; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Peptide Fragments; Survival Analysis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Health Care Costs; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Prospective Studies; Quality-Adjusted Life Years; Quinazolines; Survival Analysis | 2014 |
Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Nitroimidazoles; Pancreatic Neoplasms; Phosphoramide Mustards; Proportional Hazards Models; Time Factors; Treatment Outcome; United States | 2015 |
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Radiosurgery; Survival Rate | 2015 |
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Piperidines; Quinazolines | 2015 |
Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2014 |
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Pancreatic Neoplasms; Phthalazines; Piperazines; Prognosis; Survival Rate | 2015 |
Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis | 2015 |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Quinazolines; Survival Rate | 2015 |
Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Drug Therapy, Combination; Female; Gemcitabine; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Sarcoma; Tetrahydroisoquinolines; Thrombocytopenia; Trabectedin; Transaminases | 2015 |
Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Penile Neoplasms; Treatment Outcome | 2016 |
Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Checkpoint Kinase 1; Cohort Studies; Cytarabine; Deoxycytidine; Female; Gemcitabine; Histones; Humans; Infusions, Intravenous; K562 Cells; Male; Melanoma; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Sarcoma; Time Factors | 2015 |
A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Time Factors; Treatment Outcome | 2015 |
Single-Agent versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase II Trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Hepatic Artery; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Single-Blind Method; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Cancer Vaccines; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Interleukin-8; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Pilot Projects; Treatment Outcome; Vaccination; WT1 Proteins | 2015 |
Histopathological effects of preoperative chemoradiotherapy for pancreatic cancer: an analysis for the impact of radiation and gemcitabine doses.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Preoperative Care; Prospective Studies; Radiation Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2015 |
nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; International Cooperation; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2015 |
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Deoxycytidine; Disease-Free Survival; European Union; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Japan; Kaplan-Meier Estimate; Male; Middle Aged; North America; Odds Ratio; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-s
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Failure | 2015 |
Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Mice; Nitroimidazoles; Paclitaxel; Phosphoramide Mustards; Xenograft Model Antitumor Assays | 2015 |
Phase I trial of oral S-1 combined with hepatic arterial infusion of gemcitabine in unresectable biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Oxonic Acid; Tegafur | 2015 |
Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer.
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Treatment Outcome | 2015 |
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Randomized phase III trial of gemcitabine plus docetaxel plus bevacizumab or placebo as first-line treatment for metastatic uterine leiomyosarcoma: an NRG Oncology/Gynecologic Oncology Group study.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Middle Aged; Neoplasm Metastasis; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Uterine Neoplasms | 2015 |
Pemetrexed and gemcitabine versus carboplatin and gemcitabine in non-small cell lung cancer: a randomized noninferiority phase II study in one center.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Pemetrexed; Treatment Outcome | 2015 |
Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Drug Administration Schedule; Endonucleases; Gemcitabine; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Pemetrexed; Precision Medicine; Predictive Value of Tests; Prospective Studies; Ribonucleoside Diphosphate Reductase; Thymidylate Synthase; Tumor Suppressor Proteins | 2015 |
A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; France; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Quality of Life; Surveys and Questionnaires; Taxoids; Time Factors; Treatment Outcome | 2015 |
Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Quality-Adjusted Life Years; Survival Rate; Tegafur; Young Adult | 2015 |
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Treatment Outcome | 2015 |
Measuring treatment response to systemic therapy and predicting outcome in biliary tract cancer: comparing tumor size, volume, density, and metabolism.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Contrast Media; Deoxycytidine; Disease Progression; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron-Emission Tomography; Radiographic Image Interpretation, Computer-Assisted; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
A phase I pilot study of the insulin-like growth factor 1 receptor pathway modulator AXL1717 in combination with gemcitabine HCl and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pilot Projects; Podophyllotoxin; Prognosis; Receptor, IGF Type 1; Tissue Distribution | 2015 |
Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Switch maintenance treatment with oral vinorelbine and bevacizumab after induction chemotherapy with cisplatin, gemcitabine and bevacizumab in patients with advanced non-squamous non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Vinblastine; Vinorelbine | 2015 |
A phase II study of adjuvant gemcitabine plus docetaxel followed by concurrent chemoradation in resected pancreaticobiliary carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Carcinoma; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Genome-Wide Association Study; Humans; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Prognosis; Quantitative Trait Loci; Survival Analysis; Taxoids; Young Adult | 2015 |
A randomized trial comparing concurrent chemoradiotherapy with single-agent cisplatin versus cisplatin plus gemcitabine in patients with advanced cervical cancer: An Asian Gynecologic Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Uterine Cervical Neoplasms | 2015 |
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Erlotinib Hydrochloride; Female; Gemcitabine; Genes, erbB-1; Humans; Intercalating Agents; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum Compounds; Treatment Outcome | 2015 |
Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Patient Compliance; Quality of Life; Radiation-Sensitizing Agents | 2015 |
Randomized clinical trial of adjuvant chemotherapy with S-1 versus gemcitabine after pancreatic cancer resection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome; Young Adult | 2015 |
A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Humans; Injections, Intravenous; Lenalidomide; Leukopenia; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreas; Pancreatic Neoplasms; Thalidomide | 2015 |
A multicenter, open-label, Phase 1 study evaluating the safety and tolerability of pegaspargase in combination with gemcitabine in advanced metastatic solid tumors and lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Polyethylene Glycols | 2015 |
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; BRCA1 Protein; BRCA2 Protein; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Profiling; Genomic Instability; Humans; Mastectomy, Segmental; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Oxidoreductases; Pancreatic Neoplasms; Pharmacogenetics; Piperidines; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Risk Factors; Thiazoles; Time Factors; Treatment Outcome; United States | 2015 |
Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Adenosquamous; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Phase I study of gemcitabine, cisplatin, and S-1 combination therapy for patients with untreated advanced biliary tract cancer.
Topics: Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2015 |
Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur | 2015 |
Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Republic of Korea; Taxoids; Time Factors; Treatment Outcome | 2015 |
Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antirheumatic Agents; Autophagy; Biomarkers; CA-19-9 Antigen; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxychloroquine; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Safety; Survival Rate | 2015 |
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Receptor, ErbB-2; Salvage Therapy; Trastuzumab | 2015 |
Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma.
Topics: Adult; Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; DNA, Viral; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunoglobulin A; Immunoglobulin G; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; T-Lymphocytes; Valproic Acid; Virus Latency | 2015 |
Impact of hand-foot skin reaction on treatment outcome in patients receiving capecitabine plus erlotinib for advanced pancreatic cancer: a subgroup analysis from AIO-PK0104.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Middle Aged; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor A | 2015 |
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung Cancer.
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quality of Life; Quinazolines; Treatment Outcome | 2015 |
Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Integrin alphaVbeta3; Lung Neoplasms; Male; Middle Aged; Prognosis; Proportional Hazards Models; Receptors, Vitronectin; Snake Venoms; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Phase II trial of gemcitabine and tanespimycin (17AAG) in metastatic pancreatic cancer: a Mayo Clinic Phase II Consortium study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Deoxycytidine; Female; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2015 |
Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols | 2015 |
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Capecitabine; Chemoradiotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Survival Rate | 2015 |
RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients.
Topics: Absorbable Implants; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Implants; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; RNAi Therapeutics | 2015 |
Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Liver Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Quality of Life; Research Design; Surveys and Questionnaires; Survival Analysis | 2015 |
Phase I trial of combination chemotherapy with gemcitabine, cisplatin, and S-1 in patients with advanced biliary tract cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Prospective Studies; Tegafur; Time Factors; Treatment Outcome | 2015 |
Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Taxoids | 2015 |
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Neoplasm Metastasis; Paclitaxel; Quality of Life; Treatment Outcome | 2015 |
Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Male; Neutrophils | 2015 |
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Pancreatic Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Taiwan; Time Factors; Treatment Outcome | 2015 |
Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine - Results from the CONKO-001 trial.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prospective Studies; Rabbits; Survival Analysis; Watchful Waiting | 2015 |
Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Proportional Hazards Models; Salvage Therapy; Treatment Outcome | 2015 |
Gemcitabine plus cisplatin for patients with recurrent or metastatic nasopharyngeal carcinoma in Taiwan: a multicenter prospective Phase II trial.
Topics: Adult; Aged; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Prospective Studies; Survival Analysis; Taiwan; Treatment Outcome | 2015 |
Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Agents; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Panitumumab; Radiation-Sensitizing Agents | 2015 |
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Pyrroles; Sunitinib | 2015 |
A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Michigan; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Radiotherapy, Adjuvant; Sarcoma; Soft Tissue Neoplasms; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2015 |
Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial.
Topics: Academic Medical Centers; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Metformin; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Netherlands; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transition
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2016 |
Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Hydroxamic Acids; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Vorinostat | 2015 |
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glycine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Sulfones; Tumor Suppressor Protein p53 | 2015 |
Sequential Cytokine-Induced Killer Cell Immunotherapy Enhances the Efficacy of the Gemcitabine Plus Cisplatin Chemotherapy Regimen for Metastatic Nasopharyngeal Carcinoma.
Topics: Adult; Antineoplastic Agents; Antineoplastic Protocols; Carcinoma; Cisplatin; Cytokine-Induced Killer Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2015 |
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2015 |
Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multivariate Analysis; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Time Factors; Transplantation, Autologous | 2015 |
Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Electroporation; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Hydroxamic Acids; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Vorinostat | 2015 |
Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Pemetrexed; Predictive Value of Tests; Thymidylate Synthase; Treatment Outcome | 2015 |
Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Somatostatin | 2015 |
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Survival Analysis; Treatment Outcome | 2015 |
The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Organoplatinum Compounds; Pemetrexed; Pleural Neoplasms; Survival Analysis | 2015 |
Definitive Chemoradiation With Full-dose Gemcitabine for Unresectable Pancreatic Cancer: Efficacy of Involved-Field Radiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2017 |
SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mice, Knockout; Neoplasm Metastasis; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma.
Topics: Adult; Bayes Theorem; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Extremities; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Radiation-Sensitizing Agents; Sarcoma; Survival Analysis; Torso; Treatment Outcome | 2015 |
Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Time Factors; Treatment Outcome; United Kingdom | 2015 |
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mucins; Pancreatic Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome; United States; Yttrium Radioisotopes | 2015 |
Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome; Tumor Burden | 2015 |
Influence of infusion method on gemcitabine pharmacokinetics: a controlled randomized multicenter trial.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Half-Life; Humans; Infusion Pumps; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Occupational Exposure; Sodium Chloride; Time Factors | 2015 |
Low muscle mass is associated with chemotherapy-induced haematological toxicity in advanced non-small cell lung cancer.
Topics: Administration, Intravenous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cross-Sectional Studies; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Muscle, Skeletal; Neoplasm Staging; Vinblastine; Vinorelbine | 2015 |
Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Predictive Value of Tests; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins; Urologic Neoplasms | 2015 |
Impact of TG4010 Vaccine on Health-Related Quality of Life in Advanced Non-Small-Cell Lung Cancer: Results of a Phase IIB Clinical Trial.
Topics: Aged; Cancer Vaccines; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Quality of Life; Treatment Outcome | 2015 |
Intravenous ω-3 Fatty Acids Plus Gemcitabine.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Endpoint Determination; Fatty Acids, Omega-3; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Treatment Outcome | 2017 |
A phase I/II study of fixed-dose-rate gemcitabine and S-1 with concurrent radiotherapy for locally advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial
Topics: Australia; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Denmark; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Germany; Humans; Netherlands; Prognosis; Treatment Outcome; United Kingdom | 2015 |
Feasibility and efficacy of gemcitabine plus cisplatin combination therapy after curative resection for biliary tract cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Glasgow Prognostic Score Predicts Clinical Outcomes in Patients with Pancreatic Cancer Undergoing Adjuvant Gemcitabine Monotherapy After Curative Surgery.
Topics: Adult; Aged; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2015 |
A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Asian People; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Pyridones; Pyrimidinones | 2015 |
Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Survival Rate | 2015 |
Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial.
Topics: Adult; Aged; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Taxoids; United States | 2015 |
Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines | 2015 |
FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2015 |
Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Paclitaxel; Pain Measurement; Phenylurea Compounds; Quality of Life; Sorafenib; Urinary Bladder Neoplasms | 2015 |
A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cancer Vaccines; Cells, Cultured; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Interferon alpha-2; Interferon-alpha; Lymphocytes, Tumor-Infiltrating; Middle Aged; Netherlands; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Recombinant Proteins; T-Lymphocytes; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nitriles; Pancreatic Neoplasms; Prognosis; Pyrazoles; Pyrimidines; Survival Rate | 2015 |
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Fatigue; Female; Gemcitabine; Humans; Lapatinib; Middle Aged; Quinazolines | 2015 |
Gemcitabine, capecitabine and oxaliplatin with or without cetuximab in advanced biliary tract carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cetuximab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Prospective Studies; Survival Rate; Young Adult | 2016 |
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Deoxyuridine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Prodrugs | 2015 |
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Body Mass Index; Bridged-Ring Compounds; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Obesity; Overweight; Prognosis; Receptor, ErbB-2; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms; Young Adult | 2015 |
Metformin Addition to Chemotherapy in Stage IV Non-Small Cell Lung Cancer: an Open Label Randomized Controlled Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Nausea; Neoplasm Staging; Pilot Projects; Prospective Studies; Survival Rate; Treatment Outcome | 2015 |
A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Clinical Protocols; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Translational Research, Biomedical | 2015 |
A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoadjuvant Therapy; Pyrimidines; Sarcoma; Sulfonamides; Taxoids; Treatment Outcome | 2015 |
(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Metformin; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Results from a Phase I Study of Lapatinib with Gemcitabine and Cisplatin in Advanced or Metastatic Bladder Cancer: EORTC Trial 30061.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Febrile Neutropenia; Female; Gemcitabine; Humans; International Cooperation; Lapatinib; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Receptor, ErbB-2; Renal Insufficiency; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cells, Cultured; Chemotherapy, Adjuvant; Dendritic Cells; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Immunologic Tests; Immunotherapy; Interleukin-6; Interleukin-8; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; WT1 Proteins | 2015 |
A Phase II Study of Gemcitabine, Vincristine, and Cisplatin As Second-Line Treatment for Patients with Advanced Soft Tissue Sarcoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome; Vincristine; Young Adult | 2015 |
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hedgehog Proteins; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Mice; Middle Aged; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Pyridines; Signal Transduction; Treatment Outcome | 2015 |
Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Drug Administration Schedule; Fatigue; Feeding and Eating Disorders; Female; Follow-Up Studies; Gastrointestinal Diseases; Gemcitabine; Health Status; Humans; Induction Chemotherapy; Male; Pancreatic Neoplasms; Quality of Life; Statistics, Nonparametric; Surveys and Questionnaires; United Kingdom | 2015 |
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Prognosis; Risk Assessment; Survival Analysis; Treatment Outcome | 2018 |
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2016 |
Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Constipation; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Thrombocytopenia; Treatment Outcome | 2015 |
A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Endometrial Neoplasms; Female; Furans; Gemcitabine; Humans; Ketones; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Neutropenia; Ontario; Ovarian Neoplasms; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2015 |
Optimal dose of gemcitabine for the treatment of biliary tract or pancreatic cancer in patients with liver dysfunction.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Liver; Liver Diseases; Male; Middle Aged; Pancreatic Neoplasms | 2016 |
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2016 |
Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lapatinib; Lymph Node Excision; Male; Maximum Tolerated Dose; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
A Phase II Randomized Study of Lapatinib Combined With Capecitabine, Vinorelbine, or Gemcitabine in Patients With HER2-Positive Metastatic Breast Cancer With Progression After a Taxane (Latin American Cooperative Oncology Group 0801 Study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lapatinib; Middle Aged; Quinazolines; Receptor, ErbB-2; Salvage Therapy; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2016 |
Development of peripheral neuropathy and its association with survival during treatment with nab-paclitaxel plus gemcitabine for patients with metastatic adenocarcinoma of the pancreas: A subset analysis from a randomised phase III trial (MPACT).
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Risk Assessment; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome | 2016 |
Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Deoxycytidine; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Conformal | 2015 |
Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Research Design; Survival Analysis; Time Factors; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
Phase I clinical trial of oral administration of S-1 in combination with intravenous gemcitabine and cisplatin in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Consolidation Chemotherapy; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Paclitaxel; Prospective Studies; Radiotherapy Dosage; Remission Induction; Salvage Therapy; Urinary Bladder Neoplasms | 2016 |
A Phase 2 Randomized, Double-Blind, Multicenter Trial of Imexon Plus Gemcitabine Versus Gemcitabine Plus Placebo in Patients With Metastatic Chemotherapy-naïve Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Hexanones; Humans; Male; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival | 2018 |
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Quinazolines; Treatment Outcome | 2016 |
Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney; Male; Middle Aged; Paclitaxel; Polyethylene Glycols; Recombinant Proteins; Renal Insufficiency; Urologic Neoplasms | 2016 |
RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alleles; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genotype; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Polymorphism, Genetic; RecQ Helicases; Reproducibility of Results | 2016 |
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Topics: Aged; Anemia; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Cancer Vaccines; Carboplatin; Carcinoma, Non-Small-Cell Lung; CD56 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Erlotinib Hydrochloride; Fatigue; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Lung Neoplasms; Lymphocyte Activation; Lymphocytes; Male; Membrane Glycoproteins; Middle Aged; Mucin-1; Neutropenia; Paclitaxel; Pemetrexed; Predictive Value of Tests; Receptors, IgG | 2016 |
Clinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, or gemcitabine alone: Subgroup analysis of a randomised phase III trial, GEST study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Oxonic Acid; Pancreatic Neoplasms; Proportional Hazards Models; Risk Factors; Tegafur; Time Factors; Treatment Outcome | 2016 |
Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment of Patients With Advanced Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2016 |
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Treatment Outcome | 2016 |
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Biomarkers, Pharmacological; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Risk factors for vertebral compression fractures in preoperative chemoradiotherapy with gemcitabine for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Epidemiologic Methods; Female; Fractures, Compression; Fractures, Spontaneous; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Complications; Preoperative Care; Spinal Fractures | 2016 |
A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Double-Blind Method; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Placebos | 2016 |
A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Rate; Taxoids; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine; Vinorelbine; Young Adult | 2016 |
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Hyaluronoglucosaminidase; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Russia; Treatment Outcome; United States | 2016 |
Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2016 |
Alleviating Effect of Active Hexose Correlated Compound (AHCC) on Chemotherapy-Related Adverse Events in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polysaccharides; Survival Analysis; Treatment Outcome | 2016 |
Radiochemotherapy with Gemcitabine in Unresectable Extrahepatic Cholangiocarcinoma: Long-term Results of a Phase II Study.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Time Factors; Treatment Outcome | 2016 |
Gemcitabine Plus Radiation Therapy for High-Grade Glioma: Long-Term Results of a Phase 1 Dose-Escalation Study.
Topics: Adult; Aged; Brain Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Radiation-Sensitizing Agents; Radiotherapy Dosage; Young Adult | 2016 |
Gemcitabine and Capecitabine Combination Chemotherapy in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and/or Taxanes.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Remission Induction; Taxoids; Tomography, X-Ray Computed | 2016 |
Concurrent gemcitabine+S-1 neoadjuvant chemotherapy contributes to the improved survival of patients with small borderline-resectable pancreatic cancer tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2016 |
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2016 |
Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiosurgery | 2016 |
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Staging; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2016 |
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quality of Life; Survival Rate; Taxoids | 2016 |
A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic Oncology GI Cancer Consortium study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2016 |
A Phase I Study of S-1 and Gemcitabine with Concurrent Radiotherapy in Patients with Non-Metastatic Advanced Pancreatic Cancer.
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Radiation Pneumonitis; Tegafur; Treatment Outcome | 2015 |
A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cause of Death; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Treatment Outcome | 2016 |
Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; C-Reactive Protein; CA-19-9 Antigen; Cancer Vaccines; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Hypersensitivity, Delayed; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; T-Lymphocytes; Telomerase | 2016 |
Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Netherlands; Pancreatectomy; Pancreatic Neoplasms; Radiation Dose Hypofractionation; Research Design; Time Factors; Treatment Outcome; Tumor Burden | 2016 |
Biweekly dose-dense gemcitabine-oxaliplatin and dexamethasone for relapsed/refractory aggressive non-Hodgkin lymphoma: A multicenter, single-arm, phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Salvage Therapy; Treatment Outcome | 2016 |
A multicenter randomized controlled open-label trial to assess the efficacy of compound kushen injection in combination with single-agent chemotherapy in treatment of elderly patients with advanced non-small cell lung cancer: study protocol for a randomiz
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Paclitaxel; Proportional Hazards Models; Quality of Life; Research Design; Taxoids; Time Factors; Treatment Outcome | 2016 |
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quality of Life; Survival Rate | 2016 |
A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging | 2016 |
Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pain; Pain Measurement; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome | 2016 |
Randomized Phase III study of gemcitabine plus S-1 versus gemcitabine plus cisplatin in advanced biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1113, FUGA-BT).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Oxonic Acid; Patient Selection; Tegafur; Treatment Outcome | 2016 |
Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Klatskin Tumor; Male; Middle Aged; Oxonic Acid; Tegafur | 2016 |
DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; China; Cisplatin; Deoxycytidine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Male; Methotrexate; Middle Aged; Natural Killer T-Cells; Neoplasm Recurrence, Local; Polyethylene Glycols; Remission Induction; Young Adult | 2016 |
Impact of Chemotherapy on Retroperitoneal Lymph Nodes in Ovarian Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Deoxycytidine; Female; Fibrosis; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Retroperitoneal Space; Taxoids | 2016 |
A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2016 |
nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Isoquinolines; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Research Design; Rituximab | 2016 |
Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Gemcitabine; Humans; Models, Biological; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Survival Analysis | 2016 |
Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer.
Topics: Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cetuximab; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Treatment Outcome | 2016 |
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms | 2016 |
Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan | 2016 |
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with st
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Treatment Outcome | 2016 |
Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation | 2016 |
Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01).
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Tegafur | 2016 |
Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur | 2016 |
A phase 1, dose-finding and pharmacokinetic study of gemcitabine with nab-paclitaxel in patients with metastatic breast cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Paclitaxel | 2016 |
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Australia; Biliary Tract Neoplasms; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Panitumumab; Patient Selection; Prospective Studies; Proto-Oncogene Proteins p21(ras); Survival Rate; Treatment Outcome | 2016 |
Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Decision Making; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quality of Life; Surveys and Questionnaires; Time Factors; Vinblastine; Vinorelbine | 2016 |
Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites.
Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Infusions, Parenteral; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2016 |
Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Panitumumab; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Signal Transduction; Treatment Outcome; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53 | 2016 |
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2016 |
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Topics: Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Pemetrexed; Proto-Oncogene Proteins p21(ras); Survival Rate | 2016 |
Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study.
Topics: Adolescent; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Transplantation, Autologous; Vinblastine; Vinorelbine; Young Adult | 2016 |
Efficacy and safety of cisplatin, dexamethasone, gemcitabine and pegaspargase (DDGP) regimen in newly diagnosed, advanced-stage extranodal natural killer/T-cell lymphoma: interim analysis of a phase 4 study NCT01501149.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Polyethylene Glycols; Young Adult | 2016 |
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Treatment Outcome | 2016 |
Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2016 |
A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Pyridines; Survival Rate | 2016 |
Preoperative Gemcitabine-based Chemoradiation Therapy for Borderline Resectable Pancreatic Cancer: Impact of Venous and Arterial Involvement Status on Surgical Outcome and Pattern of Recurrence.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Treatment Outcome; Vascular Neoplasms | 2016 |
Chemoradiation for Locally Advanced Unresectable Pancreatic Cancer-What Now?
Topics: Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Mortality; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2017 |
Combination gemcitabine/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a Phase II prospective trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Therapy, Combination; Endonucleases; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Prospective Studies; Treatment Outcome | 2016 |
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Middle Aged; Neoplasms; Neutropenia; Phenylurea Compounds; Pyrazines; Thrombocytopenia; Young Adult | 2016 |
Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Europe; Female; Gemcitabine; Humans; Immunotherapy, Active; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2016 |
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prevalence; Risk Factors; Survival Rate; Treatment Outcome | 2016 |
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Quality of Life | 2016 |
Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mucin-1; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Taxoids | 2016 |
Phase I trial of GBS-01 for advanced pancreatic cancer refractory to gemcitabine.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Deoxycytidine; Drug Monitoring; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Microbubbles; Middle Aged; Pancreatic Neoplasms; Survival Rate; Treatment Outcome; Ultrasonic Therapy | 2016 |
Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Precision Medicine; Tumor Suppressor Proteins | 2016 |
Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Quality of Life; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
[The results of the LAP07 trial should not be misunderstood as the end of chemoradiotherapy in pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; International Agencies; Male; Middle Aged; Pancreatic Neoplasms; Prevalence; Risk Factors; Survival Rate; Treatment Outcome | 2016 |
Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Nivolumab; Paclitaxel; Pemetrexed; Taxoids | 2016 |
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Survival Analysis; Treatment Outcome | 2016 |
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; HLA-A24 Antigen; Humans; Kinesins; Male; Middle Aged; Pancreatic Neoplasms; Peptides; Prognosis; T-Lymphocytes, Cytotoxic; Time Factors; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Quality of Life; Topotecan | 2016 |
Tumor Reduction in Primary and Metastatic Pancreatic Cancer Lesions With nab-Paclitaxel and Gemcitabine: An Exploratory Analysis From a Phase 3 Study.
Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2017 |
A Multicenter Phase II Study of Gemcitabine, Capecitabine, and Bevacizumab for Locally Advanced or Metastatic Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2018 |
Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epitopes; Female; Gemcitabine; HLA-A24 Antigen; Humans; Immunotherapy, Active; Kaplan-Meier Estimate; Kinesins; Male; Middle Aged; Neoplasm Proteins; Pancreatectomy; Pancreatic Neoplasms; Peptide Fragments; T-Cell Antigen Receptor Specificity; T-Lymphocytes, Cytotoxic; Vaccines, Subunit; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cytoplasm; Deoxycytidine; Disease-Free Survival; ELAV-Like Protein 1; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Tissue Array Analysis; Treatment Outcome | 2018 |
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Diphenylamine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sulfonamides; Treatment Outcome | 2017 |
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Niacinamide; Peptides, Cyclic; Phenylurea Compounds; Prospective Studies; Sorafenib; Young Adult | 2017 |
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dasatinib; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Treatment Outcome | 2017 |
Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate | 2016 |
Gemcitabine and S-1 Induction Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2017 |
A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Republic of Korea; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adenocarcinoma; Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2017 |
Dosimetric parameters correlate with duodenal histopathologic damage after stereotactic body radiotherapy for pancreatic cancer: Secondary analysis of a prospective clinical trial.
Topics: Aged; Deoxycytidine; Duodenum; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiosurgery; Radiotherapy Dosage | 2017 |
Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lenalidomide; Leukocytes, Mononuclear; Male; Middle Aged; Pancreatic Neoplasms; Thalidomide | 2017 |
Efficacy and Safety of First-Line Necitumumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in East Asian Patients with Stage IV Squamous Non-small Cell Lung Cancer: A Subgroup Analysis of the Phase 3, Open-Label, Randomized SQUIRE Study
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Treatment Outcome | 2017 |
Nimotuzumab Combined with Chemotherapy is a Promising Treatment for Locally Advanced and Metastatic Esophageal Cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Remission Induction; Retrospective Studies | 2017 |
Measurement of health-related quality of life during chemotherapy - the importance of timing.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Time Factors; Vinblastine; Vinorelbine | 2017 |
Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Interferon-alpha; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; Missouri; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Phase I Study of Nab-Paclitaxel plus Gemcitabine as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer.
Topics: Aged; Albumins; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2017 |
A Multicenter Phase II Study of Gemcitabine plus S-1 Chemotherapy for Advanced Biliary Tract Cancer.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Tegafur; Treatment Outcome; Vomiting | 2017 |
Adjuvant combination therapy with gemcitabine and autologous γδ T-cell transfer in patients with curatively resected pancreatic cancer.
Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Transplantation, Autologous | 2017 |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2017 |
Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer.
Topics: Aged; Antineoplastic Agents; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Tolerance; Female; Follow-Up Studies; Gemcitabine; Humans; Longitudinal Studies; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Radiation Dose Hypofractionation; Radiation Injuries; Radiation Tolerance; Survival Rate; Treatment Outcome; United Kingdom; Urinary Bladder Neoplasms | 2017 |
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab or Placebo in Combination with Gemcitabine for the First-Line Treatment of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Oxidoreductases; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Extracellular Matrix; Female; Gemcitabine; Humans; Immunoglobulin G; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Treatment Outcome | 2017 |
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Piperidines; Prognosis; Quinazolines; Survival Rate | 2017 |
Considerable interobserver variation in delineation of pancreatic cancer on 3DCT and 4DCT: a multi-institutional study.
Topics: Aged; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Four-Dimensional Computed Tomography; Gemcitabine; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Neoadjuvant Therapy; Observer Variation; Pancreatic Neoplasms; Radiation Oncology | 2017 |
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Pancreatic Neoplasms; Quality of Life; Retreatment; Survival Rate | 2017 |
Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Agents; Body Image; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Cancer Pain; Deoxycytidine; Docetaxel; Dyspnea; Epothilones; Fatigue; Female; Furans; Gemcitabine; Health Status; Heterocyclic Compounds, 4 or More Rings; Humans; Ketones; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nausea; Paclitaxel; Polyethylene Glycols; Quality of Life; Reproductive Health; Sleep Initiation and Maintenance Disorders; Taxoids; Vinblastine; Vinorelbine; Vomiting | 2017 |
A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteries; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Radiotherapy, Intensity-Modulated; Survival Rate; Tegafur; Tomography, X-Ray Computed | 2017 |
Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2017 |
Neoadjuvant Chemotherapy with Gemcitabine plus Cisplatin in Patients with Locally Advanced Bladder Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Clinical-pharmacogenetic models for personalized cancer treatment: application to malignant mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Models, Biological; Multidrug Resistance-Associated Protein 2; Neoplasm Proteins; Pemetrexed; Pharmacogenomic Testing; Polymorphism, Genetic; Precision Medicine; Survival Rate | 2017 |
Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Asian People; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Quinolines | 2017 |
Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retreatment; Treatment Outcome | 2017 |
Salvage chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: a subset analysis of the Canadian Cancer Trials Group LY.12 randomized phase 3 study
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, T-Cell, Peripheral; Salvage Therapy; Transplantation, Autologous | 2017 |
The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Smad4 Protein; Treatment Outcome | 2017 |
Exposure-Response Analysis of Necitumumab Efficacy in Squamous Non-Small Cell Lung Cancer Patients.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Models, Theoretical; Survival Analysis; Treatment Outcome; Tumor Burden | 2017 |
Thyroid V40 Predicts Primary Hypothyroidism After Intensity Modulated Radiation Therapy for Nasopharyngeal Carcinoma.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Hypothyroidism; Incidence; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Pituitary Gland; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Regression Analysis; Thyroid Gland; Time Factors | 2017 |
A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus).
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diarrhea; Docetaxel; Doxorubicin; Drug Eruptions; Fatigue; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasms; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Sarcoma; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2017 |
Phase II study of induction gemcitabine and S-1 followed by chemoradiotherapy and systemic chemotherapy using S-1 for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2017 |
The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prednisolone; Prednisone; Prospective Studies; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Thalidomide; Treatment Outcome; Vincristine; Young Adult | 2017 |
Gemcitabine and Vinorelbine Combination Chemotherapy in Taxane-Pretreated Patients with Metastatic Breast Cancer: A Phase II Study of the Kinki Multidisciplinary Breast Oncology Group (KMBOG) 1015.
Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neutropenia; Prognosis; Receptor, ErbB-2; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2017 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor, Cholecystokinin B; Survival Rate | 2017 |
Ethanol-induced symptoms in patients receiving gemcitabine diluted from a concentrate for solution for infusion containing ethanol.
Topics: Aged; Blood Alcohol Content; Breath Tests; Cross-Over Studies; Deoxycytidine; Double-Blind Method; Ethanol; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Pharmaceutical Solutions | 2018 |
Axitinib for Gemcitabine-refractory Advanced Biliary Tract Cancer: Report of 5 Cases.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Biliary Tract Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Lymph Nodes; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2017 |
Histology-based Combination Induction Chemotherapy for Elderly Patients with Clinical Stage III Non-small Cell Lung Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Treatment Outcome | 2017 |
Adjuvant chemoradiotherapy (gemcitabine-based) in pancreatic adenocarcinoma: the Pisa University experience.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis | 2017 |
Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial).
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Young Adult | 2017 |
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases, 70-kDa | 2017 |
Phase II study of paclitaxel associated with lipid core nanoparticles (LDE) as third-line treatment of patients with epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lipids; Nanoparticles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols | 2017 |
Phase I study of veliparib in combination with gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasms | 2017 |
GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS).
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Kaplan-Meier Estimate; Odds Ratio; Prognosis; Prospective Studies; Sarcoma, Ewing; Spain; Survival Rate; Taxoids | 2017 |
INST OX-05-024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Analysis; Treatment Outcome | 2017 |
The Safety and Efficacy of an Alcohol-Free Pancreatic Cyst Ablation Protocol.
Topics: Ablation Techniques; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Endosonography; Ethanol; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Pancreatic Cyst; Pancreatic Neoplasms; Pennsylvania; Postoperative Complications; Prospective Studies; Risk Factors; Therapeutic Irrigation; Time Factors; Treatment Outcome | 2017 |
Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Smokers | 2017 |
CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors; Treatment Outcome; Young Adult | 2017 |
Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Dioxoles; Disease Progression; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Early Termination of Clinical Trials; Europe; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Prospective Studies; Tetrahydroisoquinolines; Time Factors; Topotecan; Trabectedin; Treatment Outcome | 2017 |
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Deoxycytidine; Female; Gemcitabine; Humans; Hydrazines; Male; Middle Aged; Neoplasms; Pyrazoles; Thrombocytosis | 2017 |
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
Efficacy and Safety of Capecitabine, Irinotecan, Gemcitabine, and Bevacizumab as Second-Line Treatment in Advanced Biliary Tract Cancer: A Phase II Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biliary Tract Neoplasms; Camptothecin; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Prospective Studies | 2018 |
Response to FOLFIRINOX by gender in patients with metastatic pancreatic cancer: Results from the PRODIGE 4/ ACCORD 11 randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Quality of Life; Sex Factors; Survival Rate | 2017 |
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oligonucleotides, Antisense; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2017 |
Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Young Adult | 2017 |
SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Deoxycytidine; Diarrhea; Epistaxis; Fatigue; Female; Gemcitabine; Humans; Lethargy; Lung Neoplasms; Male; Middle Aged; Nausea; Pemetrexed; Protein Kinase Inhibitors; Thrombocytopenia; Vomiting | 2017 |
Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Proto-Oncogene Proteins p21(ras); Survival Rate | 2017 |
Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Chaperones; Oligonucleotides, Antisense; Urologic Neoplasms | 2017 |
Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Pemetrexed; Radiosurgery; Radiotherapy, Adjuvant; Treatment Outcome | 2018 |
Phase I study of a chloroquine-gemcitabine combination in patients with metastatic or unresectable pancreatic cancer.
Topics: Aged; Antimalarials; Antimetabolites, Antineoplastic; Chloroquine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2017 |
Retrospective Analysis of CA19-9 Decrease in Patients with Metastatic Pancreatic Carcinoma Treated with FOLFIRINOX or Gemcitabine in a Randomized Phase III Study (ACCORD11/PRODIGE4).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2017 |
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2018 |
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Osteosarcoma; Recurrence; Sirolimus; Young Adult | 2017 |
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Margins of Excision; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Analysis | 2019 |
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Furans; Gemcitabine; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Neoplasm Metastasis; Paclitaxel; Proportional Hazards Models; Prospective Studies; Receptor, ErbB-2; Republic of Korea; Time Factors; Treatment Outcome; Young Adult | 2017 |
Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prospective Studies | 2018 |
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis | 2018 |
"HEATPAC" - a phase II randomized study of concurrent thermochemoradiotherapy versus chemoradiotherapy alone in locally advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Hyperthermia, Induced; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome; Young Adult | 2017 |
Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy: A Randomized Phase 2 Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Urinary Bladder Neoplasms | 2018 |
High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascorbic Acid; Cell Proliferation; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Parenteral; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Prospective Studies; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enoxaparin; Female; Fibrinolytic Agents; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Thromboembolism; Time Factors | 2018 |
HALO-109-301: a Phase III trial of PEGPH20 (with gemcitabine and nab-paclitaxel) in hyaluronic acid-high stage IV pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Tumor Microenvironment | 2018 |
Phase I/II study of mocetinostat in combination with gemcitabine for patients with advanced pancreatic cancer and other advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Deoxycytidine; Endpoint Determination; Female; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Pyrimidines; Treatment Outcome | 2018 |
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Damage; DNA Mutational Analysis; Female; Gemcitabine; Humans; Ipilimumab; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Prospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2018 |
PEGPH20 for metastatic pancreatic ductal adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Hyaluronoglucosaminidase; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; San Francisco; Survival Rate; Treatment Outcome | 2018 |
p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.
Topics: Adult; Aged; Cancer Vaccines; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; T-Lymphocytes; Treatment Outcome; Tumor Suppressor Protein p53 | 2018 |
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cisplatin; Cohort Studies; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Germ-Line Mutation; Heterozygote; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Rate | 2018 |
Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Treatment Outcome | 2018 |
Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gallbladder Neoplasms; Gemcitabine; Gene Amplification; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis | 2018 |
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bayes Theorem; Benzimidazoles; Bile Duct Neoplasms; Breast Neoplasms; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Induction Chemotherapy; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Maintenance Chemotherapy; Male; Maximum Tolerated Dose; Mesothelioma; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Skin Neoplasms; Thrombocytopenia; Treatment Outcome | 2018 |
Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Vaccines, Subunit; WT1 Proteins | 2018 |
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Quinolones; Treatment Outcome | 2018 |
Pharmacometabonomics Analysis Reveals Serum Formate and Acetate Potentially Associated with Varying Response to Gemcitabine-Carboplatin Chemotherapy in Metastatic Breast Cancer Patients.
Topics: Acetates; Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Pharmacological; Breast Neoplasms; Carboplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Formates; Gemcitabine; Humans; Lymphatic Metastasis; Magnetic Resonance Spectroscopy; Middle Aged; Prognosis; ROC Curve; Taxoids | 2018 |
Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Surgical Procedures; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2018 |
CHK1 inhibition in soft-tissue sarcomas: biological and clinical implications.
Topics: Animals; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Genes, p53; Heterografts; Humans; Mice; Mice, Knockout; Mice, Nude; Mutation; Piperidines; Pyridines; Pyrroles; Soft Tissue Neoplasms; Tumor Suppressor Protein p53 | 2018 |
A phase I trial of the γ-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Amyloid Precursor Protein Secretases; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzene Derivatives; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Propionates; Receptors, Notch; Signal Transduction; Sulfones | 2018 |
Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
Topics: Activation, Metabolic; Antimetabolites, Antineoplastic; Breast Neoplasms; Cytidine Triphosphate; Deamination; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Leukocytes, Mononuclear; Phosphorylation; Uridine Triphosphate | 2018 |
Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Prognostic Factors and the Role of Adjuvant Treatment in Periampullary Carcinoma: a Single-Centre Experience of 95 Patients.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Common Bile Duct Neoplasms; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Health-related quality of life of adjuvant chemotherapy with S-1 versus gemcitabine for resected pancreatic cancer: Results from a randomised phase III trial (JASPAC 01).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Quality of Life; Survival Rate; Tegafur | 2018 |
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Proto-Oncogene Proteins p21(ras); Pyrrolidinones; Quinolines; Survival Analysis; Treatment Outcome | 2018 |
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Young Adult | 2018 |
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Drug Eruptions; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Prospective Studies; Young Adult | 2018 |
WT1-pulsed Dendritic Cell Vaccine Combined with Chemotherapy for Resected Pancreatic Cancer in a Phase I Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Tegafur; WT1 Proteins | 2018 |
Expression of Estrogen Receptor-α and Survival in Advanced-stage Non-small Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Estrogen Receptor alpha; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Retrospective Studies | 2018 |
Effects of ω-3 Fatty Acid Supplementation in Patients with Bile Duct or Pancreatic Cancer Undergoing Chemotherapy.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cachexia; Camptothecin; Combined Modality Therapy; Deoxycytidine; Dietary Supplements; Drug Combinations; Fatty Acids, Omega-3; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nutritional Support; Organoplatinum Compounds; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur | 2018 |
Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711).
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Pemetrexed; Prospective Studies; Survival Rate; Time-to-Treatment; Treatment Failure | 2018 |
Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Complementary Therapies; Curcumin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phospholipids; Treatment Outcome | 2018 |
Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Progression-Free Survival | 2018 |
Trimodalities for bladder cancer in elderly: Transurethral resection, hypofractionated radiotherapy and gemcitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Prospective Studies; Radiation Dose Hypofractionation; Urethra; Urinary Bladder Neoplasms | 2018 |
Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Genotype; Genotyping Techniques; Humans; Lung Neoplasms; Male; Polymorphism, Single Nucleotide; Precision Medicine; Singapore; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Progression-Free Survival | 2018 |
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Fatigue; Female; Gemcitabine; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Thrombocytopenia; Treatment Outcome | 2018 |
Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial.
Topics: Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Sodium Chloride; Urinary Bladder Neoplasms; Urothelium | 2018 |
A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Endosonography; Erlotinib Hydrochloride; Female; Gemcitabine; Herpesvirus 1, Human; Humans; Injections, Intralesional; Male; Middle Aged; Mutation; Oncolytic Virotherapy; Oncolytic Viruses; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Survival Rate; Treatment Outcome; Ultrasonography, Interventional; Young Adult | 2018 |
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Receptor, IGF Type 1; Receptors, Somatomedin; Survival Analysis; Treatment Outcome | 2018 |
Change in plasma lactate concentration during arctigenin administration in a phase I clinical trial in patients with gemcitabine-refractory pancreatic cancer.
Topics: Antineoplastic Agents, Phytogenic; Arctium; Area Under Curve; Biomarkers; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Furans; Gemcitabine; Gluconeogenesis; Humans; Kaplan-Meier Estimate; Kidney; Lactic Acid; Lignans; Liver; Mitochondria; Oxidative Phosphorylation; Pancreatic Neoplasms; Plant Extracts | 2018 |
Outcomes of radiosensitisation in elderly patients with advanced bladder cancer.
Topics: Aged; Aged, 80 and over; Deoxycytidine; Female; Gemcitabine; Humans; Male; Radiation-Sensitizing Agents; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Mastectomy; Middle Aged; Paclitaxel; Progression-Free Survival; Triple Negative Breast Neoplasms | 2018 |
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Middle Aged; Neoplasm Metastasis; Neutrophils; Paclitaxel; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms | 2018 |
Biomarker assessment of the CBCSG006 trial: a randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Models, Biological; Paclitaxel; Patient Selection; Progression-Free Survival; Prospective Studies; Risk Assessment; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2018 |
Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Keratin-18; Male; Middle Aged; Neoplasm Proteins; Neoplastic Cells, Circulating; Quinazolines; Treatment Outcome; United Kingdom; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
nab-Paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: Australian subset analyses of the phase III MPACT trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Australia; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
A multicenter phase 4 geriatric assessment directed trial to evaluate gemcitabine +/- nab-paclitaxel in elderly pancreatic cancer patients (GrantPax).
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Geriatric Assessment; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Pemetrexed; Quality of Life; Treatment Outcome | 2018 |
Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan clinical oncology group study (JCOG1407).
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2018 |
Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study.
Topics: Adult; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Staging; Radiotherapy, Intensity-Modulated; Recurrence; Risk; Safety; Treatment Outcome | 2018 |
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Janus Kinase 1; Janus Kinase 2; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Pyrimidines; Tissue Distribution | 2019 |
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Bevacizumab; Cell Line, Tumor; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Receptors, Calcitriol; RNA, Messenger; Vitamin D | 2018 |
Salvage Chemotherapy With Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin for Relapsed Germ Cell Cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Ifosfamide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure; Young Adult | 2018 |
Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin's lymphoma (AHOD1221): a Children's Oncology Group, multicentre single-arm, phase 1-2 trial.
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Canada; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Immunoconjugates; Male; Recurrence; Time Factors; Treatment Outcome; United States | 2018 |
Phase I Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Febrile Neutropenia; Female; Gemcitabine; Humans; Infections; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Preoperative Period | 2018 |
Subclinical cancer cell dissemination in peritoneal lavage fluid detected by reverse-transcription polymerase chain reaction identifies patients at high risk for peritoneal recurrence and consequent impaired survival in the setting of preoperative chemora
Topics: Aged; Antimetabolites, Antineoplastic; Ascitic Fluid; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Lavage; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment | 2018 |
A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Time Factors; Young Adult | 2018 |
[A Phase I Combination Dose-Escalation Study of Eribulin Mesylate and Gemcitabine in Japanese Patients with Metastatic Breast Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Furans; Gemcitabine; Humans; Ketones; Middle Aged; Neoplasm Metastasis | 2018 |
Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Platinum Compounds; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Urologic Neoplasms | 2018 |
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Sorafenib; Survival Analysis; Urologic Neoplasms | 2018 |
Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Treatment Outcome | 2018 |
A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neutropenia; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Survival Rate; Tegafur | 2019 |
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Ki-67 Antigen; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tumor Suppressor Protein p53 | 2019 |
Gemcitabine, cisplatin, and dexamethasone (GDP) in combination with methotrexate and pegaspargase is active in newly diagnosed peripheral T cell lymphoma patients: a phase 2, single-center, open-label study in China.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; China; Cisplatin; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Methotrexate; Middle Aged; Polyethylene Glycols; Survival Rate | 2019 |
Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Animals; Ascorbic Acid; Cell Line, Tumor; Cell Proliferation; Cell Survival; Collagen; Deoxycytidine; Disease-Free Survival; DNA Damage; Female; Gemcitabine; Glutathione; Humans; Male; Mice; Mice, Nude; Middle Aged; Oxidative Stress; Pancreatic Neoplasms; Radiation Tolerance; Radiotherapy; Recombinant Proteins; Treatment Outcome | 2018 |
Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nitriles; Paclitaxel; Pancreatic Neoplasms; Phenylthiohydantoin; Prognosis; Survival Rate; Tissue Distribution | 2019 |
Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Prognosis; Survival Rate; Treatment Outcome | 2019 |
A phase 1, open-label, dose escalation study of intravenous paricalcitol in combination with gemcitabine in patients with advanced malignancies.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Ergocalciferols; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2018 |
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Placebos; Pyrazoles; Quinolines; Signal Transduction; Transforming Growth Factor beta | 2018 |
Protocol for the STRONG trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma, a phase I feasibility study.
Topics: Bile Duct Neoplasms; Cisplatin; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Klatskin Tumor; Netherlands; Quality of Life; Radiosurgery; Treatment Outcome | 2018 |
A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Postoperative Care; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2019 |
Clinical assessment of palliative radiotherapy for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiosurgery; Surveys and Questionnaires; Treatment Outcome | 2018 |
A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Survival Rate; Tegafur | 2019 |
Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Middle Aged; Pancreatic Neoplasms; Polyethylene Glycols; Progression-Free Survival; Proportional Hazards Models | 2018 |
A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pancreatic Neoplasms; Prognosis; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Vascular Endothelial Growth Factor; Survival Rate; Tissue Distribution | 2019 |
Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2019 |
TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer: a randomised, open-label, phase 3 study (GRAPE trial).
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Republic of Korea; Tegafur; Time Factors | 2019 |
Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf | 2019 |
Mogamulizumab
Topics: Adult; Aged; Aged, 80 and over; Aminopterin; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; International Agencies; Leukemia-Lymphoma, Adult T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Oxaliplatin; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2019 |
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lung Diseases, Interstitial; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies | 2018 |
Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma; Cisplatin; Deoxycytidine; Drug Monitoring; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin | 2019 |
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Leucovorin; Middle Aged; Multicenter Studies as Topic; Neoadjuvant Therapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Young Adult | 2018 |
An Open-Label Phase II Trial of Bevacizumab plus Docetaxel and Gemcitabine in Advanced, Previously Untreated Nonsquamous Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Rate | 2019 |
Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2019 |
The Benefit-Risk Balance of Nab-Paclitaxel in Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2019 |
Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Signal Transduction; Translational Research, Biomedical; Treatment Outcome | 2019 |
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Microsatellite Instability; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prognosis; Radiotherapy; Treatment Outcome | 2019 |
Highlights of the NCCN Oncology Research Program.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Female; Folate Receptor 1; Gemcitabine; Humans; Immunoconjugates; Male; Maytansine; Neoplasm Recurrence, Local; Neoplasms; Progression-Free Survival; Young Adult | 2019 |
Chemoimmunotherapy with brentuximab vedotin combined with ifosfamide, gemcitabine, and vinorelbine is highly active in relapsed or refractory classical Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Immunotherapy; Male; Middle Aged; Recurrence; Survival Rate; Vinorelbine | 2019 |
Combination of weekly topotecan and gemcitabine as a salvage treatment in patients with recurrent ovarian cancer: a phase I study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Salvage Therapy; Topotecan | 2019 |
A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2019 |
CanStem111P trial: a Phase III study of napabucasin plus nab-paclitaxel with gemcitabine.
Topics: Administration, Oral; Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Multicenter Studies as Topic; Naphthoquinones; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Randomized Controlled Trials as Topic; Young Adult | 2019 |
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Oxaliplatin; Progression-Free Survival; Survival Rate | 2019 |
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Nelfinavir; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiosurgery | 2019 |
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; Cholangiocarcinoma; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Staging; Niacinamide; Protein Kinase Inhibitors; Ramucirumab; Squamous Cell Carcinoma of Head and Neck | 2019 |
A Phase 2 Study of PCI-27483, a Factor VIIa Inhibitor in Combination with Gemcitabine for Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Benzimidazoles; Blood Coagulation; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Factor VIIa; Female; Gemcitabine; Hemorrhage; Humans; International Normalized Ratio; Male; Middle Aged; Pancreatic Neoplasms; Progression-Free Survival; Time Factors | 2019 |
Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cross-Over Studies; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2019 |
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Inflammation; Male; MicroRNAs; Pancreatic Neoplasms; Prognosis; Pyrazoles; Quinolines; Receptors, Transforming Growth Factor beta; Survival Rate | 2019 |
An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Topics: Administration, Intravenous; Aged; Cytidine Deaminase; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Prospective Studies | 2019 |
Quality of life during and after adjuvant anthracycline-taxane-based chemotherapy with or without Gemcitabine in high-risk early breast cancer: results of the SUCCESS A trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Patient Compliance; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2019 |
Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Survival Rate; Tegafur; Young Adult | 2019 |
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Placebos; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome | 2019 |
Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Prospective Studies; Young Adult | 2019 |
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Hydroxychloroquine; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Treatment Outcome | 2019 |
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Can
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Receptor, ErbB-2; Republic of Korea; Surveys and Questionnaires | 2019 |
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Leukopenia; Male; Middle Aged; Nasopharyngeal Carcinoma; Survival Analysis; Young Adult | 2019 |
Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cancer Vaccines; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Interferon-beta; Male; Middle Aged; Pancreatic Neoplasms; Peptides; Prognosis; Progression-Free Survival; Survivin; Vaccination; Vaccines, Subunit | 2019 |
Efficacy of R-GCVP in patients with late relapse of diffuse large B-cell lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisolone; Recurrence; Retrospective Studies; Rituximab; Survival Rate; Vincristine | 2019 |
A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2019 |
A new pragmatic design for dose escalation in phase 1 clinical trials using an adaptive continual reassessment method.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Repositioning; Gemcitabine; Humans; Maximum Tolerated Dose; Paclitaxel; Pancreas; Pancreatic Neoplasms; Patient Selection; Research Design; Response Evaluation Criteria in Solid Tumors; Tretinoin | 2019 |
Phase I/II Study: Experience with the Late Onset of Acute Pancreatitis after the Start of Chemotherapy with Gemcitabine Plus nab-Paclitaxel for Metastatic Pancreatic Cancer.
Topics: Acute Disease; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Pancreatitis; Tomography, X-Ray Computed | 2019 |
A clinical trial to assess the feasibility and efficacy of nab-paclitaxel plus gemcitabine for elderly patients with unresectable advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prospective Studies; Treatment Outcome | 2019 |
Impact on health-related quality of life deterioration-free survival of a first-line therapy combining nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomiz
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Quality of Life; Treatment Outcome | 2019 |
Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nadroparin; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Pneumonectomy; Positron-Emission Tomography | 2019 |
A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Wnt Signaling Pathway | 2020 |
A randomized phase II trial of nab-paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Disease Management; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Receptor, Notch2; Receptor, Notch3; Treatment Outcome | 2019 |
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones; Survival Rate | 2019 |
A Phase II Study of Cisplatin Plus Gemcitabine followed by Maintenance Gemcitabine for Advanced Squamous Non-Small-Cell Lung Cancer: Kyoto Thoracic Oncology Research Group 1302.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2019 |
Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2019 |
Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Reported Outcome Measures; Progression-Free Survival; Receptor, ErbB-3; RNA, Messenger; Topotecan | 2019 |
A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Intention to Treat Analysis; Male; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2019 |
Neoadjuvant Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation Versus Chemoradiation for Locally Advanced Cervical Cancer: A Randomized Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Patient Compliance; Progression-Free Survival; Uterine Cervical Neoplasms; Young Adult | 2019 |
Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2019 |
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Radiotherapy, Intensity-Modulated | 2020 |
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Nausea; Oxonic Acid; Tegafur; Vomiting | 2019 |
S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Tegafur | 2020 |
Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD36 Antigens; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Non-Randomized Controlled Trials as Topic; Pancreatic Neoplasms; Prognosis; Retrospective Studies; RNA, Small Interfering; Survival Rate; Tumor Cells, Cultured | 2020 |
Phase II Trial Using Romidepsin after Gemcitabine, Dexamethasone, and Cisplatin Therapy in Elderly Transplant-Ineligible Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Study Protocol.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Depsipeptides; Dexamethasone; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral | 2019 |
Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxaliplatin; Treatment Outcome | 2020 |
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Patient Safety; Treatment Outcome | 2020 |
Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Laparotomy; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate | 2019 |
Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Intention to Treat Analysis; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Survival Rate; Treatment Outcome | 2019 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin in the first-line setting for Chinese patients with metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Markov Chains; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Quality-Adjusted Life Years | 2020 |
Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ipilimumab; Male; Pancreatic Neoplasms; Tumor Microenvironment | 2020 |
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biopsy; Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Pancreas; Pancreatic Neoplasms; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors | 2020 |
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Progression-Free Survival; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2019 |
R-GEM-Lenalidomide versus R-GEM-P as second-line treatment of diffuse large B-cell lymphoma: results of the UK NRCI phase II randomised LEGEND trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Rituximab; Survival Rate | 2020 |
A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Imidazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Progression-Free Survival; Pyridines; Young Adult | 2020 |
Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Carrier Proteins; Clustered Regularly Interspaced Short Palindromic Repeats; Cohort Studies; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Genome-Wide Association Study; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Internal Ribosome Entry Sites; Male; Middle Aged; RNA Processing, Post-Transcriptional; RNA, Transfer; Tumor Suppressor Protein p53 | 2019 |
A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Safety; Polyethylene Glycols; Survival Rate; Topotecan; Treatment Outcome | 2020 |
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Leiomyosarcoma; Male; Middle Aged; Pyrimidines; Sulfonamides | 2020 |
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma.
Topics: Aged; Albumins; Anilides; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Pyridines; Treatment Outcome | 2020 |
Pilot study of docetaxel combined with lobaplatin or gemcitabine for recurrent and metastatic breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclobutanes; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Pilot Projects; Survival Analysis | 2019 |
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbolines; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Research Design; Sarcoma | 2020 |
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE).
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2020 |
Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Progression-Free Survival; Salvage Therapy | 2020 |
Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Autografts; Child; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Ifosfamide; Male; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Vinorelbine | 2020 |
Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Deoxycytidine; Disease-Free Survival; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Recurrence; Transplantation, Autologous | 2020 |
Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2020 |
First Line Gemcitabine/Pazopanib in Locally Advanced and/or Metastatic Biliary Tract Carcinoma. A Hellenic Cooperative Oncology Group Phase II Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Neoplasm Metastasis; Pyrimidines; Sulfonamides; Treatment Outcome | 2020 |
Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Paclitaxel; Pemetrexed; Progression-Free Survival; Prospective Studies; Radiofrequency Ablation; Treatment Outcome; Vinorelbine | 2020 |
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms | 2020 |
Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy o
Topics: Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Incidental Findings; Male; Neoadjuvant Therapy; Treatment Outcome | 2020 |
TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial.
Topics: Adenocarcinoma; Aged; Deoxycytidine; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2020 |
A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Imatinib Mesylate; Male; Mesothelioma, Malignant; Pemetrexed; Pleural Neoplasms; Prognosis; Salvage Therapy; Survival Rate | 2020 |
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Netherlands; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors | 2020 |
A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids; Urinary Bladder Neoplasms | 2020 |
Phase II Study of Second-line Chemotherapy With Paclitaxel, Gemcitabine, and Cisplatin for Advanced Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urologic Neoplasms | 2020 |
A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Deoxycytidine; Female; Gemcitabine; Humans; Hydroxychloroquine; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Preoperative Care; Recurrence; Survival Analysis; Treatment Outcome | 2020 |
Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Treatment Outcome | 2020 |
A randomized evaluation of vinorelbine versus gemcitabine chemotherapy mobilization of stem cells in myeloma patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Mobilization; Humans; Multiple Myeloma; Stem Cells; Vinorelbine | 2020 |
Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gemcitabine alone: AX-PANC-SY001, a randomized phase-2 study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 2020 |
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Ovarian Epithelial; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Indazoles; Middle Aged; Peritoneal Neoplasms; Pyrimidines; Sulfonamides | 2020 |
Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated | 2020 |
Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Paclitaxel; Pemetrexed; Progression-Free Survival; Treatment Outcome | 2020 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor Proteins, Signal Transducing; Adenine; Adenocarcinoma; Adipogenesis; Administration, Cutaneous; Administration, Ophthalmic; Adolescent; Adsorption; Adult; Aeromonas hydrophila; Aerosols; Aged; Aged, 80 and over; Aging; Agriculture; Air Pollutants; Air Pollution; Airway Remodeling; Alanine Transaminase; Albuminuria; Aldehyde Dehydrogenase 1 Family; Algorithms; AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase; Alzheimer Disease; Amino Acid Sequence; Ammonia; Ammonium Compounds; Anaerobiosis; Anesthetics, Dissociative; Anesthetics, Inhalation; Animals; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Anti-Inflammatory Agents; Antibiotics, Antineoplastic; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antigens, Bacterial; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antitubercular Agents; Antiviral Agents; Apolipoproteins E; Apoptosis; Arabidopsis; Arabidopsis Proteins; Arsenic; Arthritis, Rheumatoid; Asthma; Atherosclerosis; ATP-Dependent Proteases; Attitude of Health Personnel; Australia; Austria; Autophagy; Axitinib; Bacteria; Bacterial Outer Membrane Proteins; Bacterial Proteins; Bacterial Toxins; Bacterial Typing Techniques; Bariatric Surgery; Base Composition; Bayes Theorem; Benzoxazoles; Benzylamines; beta Catenin; Betacoronavirus; Betula; Binding Sites; Biological Availability; Biological Oxygen Demand Analysis; Biomarkers; Biomarkers, Tumor; Biopsy; Bioreactors; Biosensing Techniques; Birth Weight; Blindness; Blood Chemical Analysis; Blood Gas Analysis; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Blood-Brain Barrier; Blotting, Western; Body Mass Index; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Borates; Brain; Brain Infarction; Brain Injuries, Traumatic; Brain Neoplasms; Breakfast; Breast Milk Expression; Breast Neoplasms; Bronchi; Bronchoalveolar Lavage Fluid; Buffaloes; Cadherins; Calcification, Physiologic; Calcium Compounds; Calcium, Dietary; Cannula; Caprolactam; Carbon; Carbon Dioxide; Carboplatin; Carcinogenesis; Carcinoma, Ductal; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Cardiovascular Diseases; Carps; Carrageenan; Case-Control Studies; Catalysis; Catalytic Domain; Cattle; CD8-Positive T-Lymphocytes; Cell Adhesion; Cell Cycle Proteins; Cell Death; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Phone Use; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cell Transformation, Viral; Cells, Cultured; Cellulose; Chemical Phenomena; Chemoradiotherapy; Child; Child Development; Child, Preschool; China; Chitosan; Chlorocebus aethiops; Cholecalciferol; Chromatography, Liquid; Circadian Clocks; Circadian Rhythm; Circular Dichroism; Cisplatin; Citric Acid; Clinical Competence; Clinical Laboratory Techniques; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clostridioides difficile; Clostridium Infections; Coculture Techniques; Cohort Studies; Cold Temperature; Colitis; Collagen Type I; Collagen Type I, alpha 1 Chain; Collagen Type XI; Color; Connective Tissue Diseases; Copper; Coronary Angiography; Coronavirus 3C Proteases; Coronavirus Infections; Cost of Illness; Counselors; COVID-19; COVID-19 Testing; Creatine Kinase; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Cryoelectron Microscopy; Cryosurgery; Crystallography, X-Ray; Cues; Cultural Competency; Cultural Diversity; Curriculum; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p21; Cycloparaffins; Cysteine Endopeptidases; Cytokines; Cytoplasm; Cytoprotection; Databases, Factual; Denitrification; Deoxycytidine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diagnosis, Differential; Diatoms; Diet; Diet, High-Fat; Dietary Exposure; Diffusion Magnetic Resonance Imaging; Diketopiperazines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Disease Progression; Disease-Free Survival; DNA; DNA Damage; DNA Glycosylases; DNA Repair; DNA-Binding Proteins; DNA, Bacterial; DNA, Viral; Docetaxel; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drosophila; Drosophila melanogaster; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Repositioning; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Edema; Edible Grain; Education, Graduate; Education, Medical, Graduate; Education, Pharmacy; Ehlers-Danlos Syndrome; Electron Transport Complex III; Electron Transport Complex IV; Electronic Nicotine Delivery Systems; Emergency Service, Hospital; Empathy; Emulsions; Endothelial Cells; Endurance Training; Energy Intake; Enterovirus A, Human; Environment; Environmental Monitoring; Enzyme Assays; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Epoxide Hydrolases; Epoxy Compounds; Erythrocyte Count; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagectomy; Estrogens; Etanercept; Ethiopia; Ethnicity; Ethylenes; Exanthema; Exercise; Exercise Test; Exercise Tolerance; Extracellular Matrix; Extracorporeal Membrane Oxygenation; Eye Infections, Fungal; False Negative Reactions; Fatty Acids; Fecal Microbiota Transplantation; Feces; Female; Femur Neck; Fermentation; Ferritins; Fetal Development; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Fibroblasts; Fibroins; Fish Proteins; Flavanones; Flavonoids; Focus Groups; Follow-Up Studies; Food Handling; Food Supply; Food, Formulated; Forced Expiratory Volume; Forests; Fractures, Bone; Fruit and Vegetable Juices; Fusobacteria; G1 Phase Cell Cycle Checkpoints; G2 Phase Cell Cycle Checkpoints; Gamma Rays; Gastrectomy; Gastrointestinal Microbiome; Gastrointestinal Stromal Tumors; Gefitinib; Gels; Gemcitabine; Gene Amplification; Gene Expression; Gene Expression Regulation; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Gene-Environment Interaction; Genotype; Germany; Glioma; Glomerular Filtration Rate; Glucagon; Glucocorticoids; Glycemic Control; Glycerol; Glycogen Synthase Kinase 3 beta; Glycolipids; Glycolysis; Goblet Cells; Gram-Negative Bacterial Infections; Granulocyte Colony-Stimulating Factor; Graphite; Greenhouse Effect; Guanidines; Haemophilus influenzae; HCT116 Cells; Health Knowledge, Attitudes, Practice; Health Personnel; Health Services Accessibility; Health Services Needs and Demand; Health Status Disparities; Healthy Volunteers; Heart Failure; Heart Rate; Heart Transplantation; Heart-Assist Devices; HEK293 Cells; Heme; Heme Oxygenase-1; Hemolysis; Hemorrhage; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Hepatocytes; Hexoses; High-Throughput Nucleotide Sequencing; Hippo Signaling Pathway; Histamine; Histamine Agonists; Histidine; Histone Deacetylase 2; HIV Infections; HIV Reverse Transcriptase; HIV-1; Homebound Persons; Homeodomain Proteins; Homosexuality, Male; Hospice and Palliative Care Nursing; HSP70 Heat-Shock Proteins; Humans; Hyaluronan Receptors; Hydrogen; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrolysis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemia; Hypoglycemic Agents; Hypoxia; Idiopathic Interstitial Pneumonias; Imaging, Three-Dimensional; Imatinib Mesylate; Immunotherapy; Implementation Science; Incidence; INDEL Mutation; Induced Pluripotent Stem Cells; Industrial Waste; Infant; Infant, Newborn; Inflammation; Inflammation Mediators; Infliximab; Infusions, Intravenous; Inhibitory Concentration 50; Injections; Insecticides; Insulin-Like Growth Factor Binding Protein 5; Insulin-Secreting Cells; Interleukin-1; Interleukin-17; Interleukin-8; Internship and Residency; Intestines; Intracellular Signaling Peptides and Proteins; Ion Transport; Iridaceae; Iridoid Glucosides; Islets of Langerhans Transplantation; Isodon; Isoflurane; Isotopes; Italy; Joint Instability; Ketamine; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Neoplasms; Kinetics; Klebsiella pneumoniae; Knee Joint; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lactate Dehydrogenase 5; Laparoscopy; Laser Therapy; Lasers, Semiconductor; Lasers, Solid-State; Laurates; Lead; Leukocyte L1 Antigen Complex; Leukocytes, Mononuclear; Light; Lipid Peroxidation; Lipopolysaccharides; Liposomes; Liver; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Locomotion; Longitudinal Studies; Lopinavir; Lower Urinary Tract Symptoms; Lubricants; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Lymphoma, Mantle-Cell; Lysosomes; Macrophages; Male; Manganese Compounds; MAP Kinase Kinase 4; Mass Screening; Maternal Health; Medicine, Chinese Traditional; Melanoma, Experimental; Memantine; Membrane Glycoproteins; Membrane Proteins; Mesenchymal Stem Cell Transplantation; Metal Nanoparticles; Metalloendopeptidases; Metalloporphyrins; Methadone; Methane; Methicillin-Resistant Staphylococcus aureus; Mexico; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Knockout; Mice, Nude; Mice, SCID; Mice, Transgenic; Microarray Analysis; Microbial Sensitivity Tests; Microbiota; Micronutrients; MicroRNAs; Microscopy, Confocal; Microsomes, Liver; Middle Aged; Milk; Milk, Human; Minority Groups; Mitochondria; Mitochondrial Membranes; Mitochondrial Proteins; Models, Animal; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Molecular Epidemiology; Molecular Structure; Molecular Weight; Multilocus Sequence Typing; Multimodal Imaging; Muscle Strength; Muscle, Skeletal; Muscular Diseases; Mutation; Mycobacterium tuberculosis; Myocardial Stunning; Myristates; NAD(P)H Dehydrogenase (Quinone); Nanocomposites; Nanogels; Nanoparticles; Nanotechnology; Naphthalenes; Nasal Cavity; National Health Programs; Necrosis; Needs Assessment; Neoadjuvant Therapy; Neonicotinoids; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm Transplantation; Neoplasms; Neoplastic Stem Cells; Netherlands; Neuroblastoma; Neuroprotective Agents; Neutrophils; NF-kappa B; NFATC Transcription Factors; Nicotiana; Nicotine; Nitrates; Nitrification; Nitrites; Nitro Compounds; Nitrogen; Nitrogen Dioxide; North Carolina; Nuclear Magnetic Resonance, Biomolecular; Nuclear Proteins; Nucleic Acid Hybridization; Nucleosomes; Nutrients; Obesity; Obesity, Morbid; Oceans and Seas; Oncogene Protein v-akt; Oncogenes; Oocytes; Open Reading Frames; Osteoclasts; Osteogenesis; Osteoporosis; Osteoporosis, Postmenopausal; Outpatients; Ovarian Neoplasms; Ovariectomy; Overweight; Oxazines; Oxidants; Oxidation-Reduction; Oxidative Stress; Oxides; Oxidoreductases; Oxygen; Oxygen Inhalation Therapy; Oxygenators, Membrane; Ozone; Paclitaxel; Paenibacillus; Pain Measurement; Palliative Care; Pancreatic Neoplasms; Pandemics; Parasympathetic Nervous System; Particulate Matter; Pasteurization; Patient Preference; Patient Satisfaction; Pediatric Obesity; Permeability; Peroxiredoxins; Peroxynitrous Acid; Pharmaceutical Services; Pharmacists; Pharmacy; Phaseolus; Phenotype; Phoeniceae; Phosphates; Phosphatidylinositol 3-Kinases; Phospholipid Transfer Proteins; Phospholipids; Phosphorus; Phosphorylation; Photoperiod; Photosynthesis; Phylogeny; Physical Endurance; Physicians; Pilot Projects; Piperidines; Pituitary Adenylate Cyclase-Activating Polypeptide; Plant Extracts; Plant Leaves; Plant Proteins; Plant Roots; Plaque, Atherosclerotic; Pneumonia; Pneumonia, Viral; Point-of-Care Testing; Polyethylene Glycols; Polymers; Polysorbates; Pore Forming Cytotoxic Proteins; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Postprandial Period; Poverty; Pre-Exposure Prophylaxis; Prediabetic State; Predictive Value of Tests; Pregnancy; Pregnancy Trimester, First; Pregnancy, High-Risk; Prenatal Exposure Delayed Effects; Pressure; Prevalence; Primary Graft Dysfunction; Primary Health Care; Professional Role; Professionalism; Prognosis; Progression-Free Survival; Prolactin; Promoter Regions, Genetic; Proof of Concept Study; Proportional Hazards Models; Propylene Glycol; Prospective Studies; Prostate; Protein Binding; Protein Biosynthesis; Protein Isoforms; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Proteoglycans; Proteome; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins c-ret; Proto-Oncogene Proteins p21(ras); Proton Pumps; Protons; Protoporphyrins; Pseudomonas aeruginosa; Pseudomonas fluorescens; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Pulmonary Gas Exchange; Pulmonary Veins; Pyrazoles; Pyridines; Pyrimidines; Qualitative Research; Quinoxalines; Rabbits; Random Allocation; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Histamine H3; Receptors, Immunologic; Receptors, Transferrin; Recombinant Proteins; Recurrence; Reference Values; Referral and Consultation; Regional Blood Flow; Registries; Regulon; Renal Insufficiency, Chronic; Reperfusion Injury; Repressor Proteins; Reproducibility of Results; Republic of Korea; Research Design; Resistance Training; Respiration, Artificial; Respiratory Distress Syndrome; Respiratory Insufficiency; Resuscitation; Retinal Dehydrogenase; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Ribosomal Proteins; Ribosomes; Risk Assessment; Risk Factors; Ritonavir; Rivers; RNA Interference; RNA-Seq; RNA, Messenger; RNA, Ribosomal, 16S; RNA, Small Interfering; Rosuvastatin Calcium; Rural Population; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salivary Ducts; Salivary Gland Neoplasms; San Francisco; SARS-CoV-2; Satiation; Satiety Response; Schools; Schools, Pharmacy; Seasons; Seawater; Selection, Genetic; Sequence Analysis, DNA; Serine-Threonine Kinase 3; Sewage; Sheep; Sheep, Domestic; Shock, Hemorrhagic; Signal Transduction; Silver; Silymarin; Single Photon Emission Computed Tomography Computed Tomography; Sirolimus; Sirtuin 1; Skin; Skin Neoplasms; Skin Physiological Phenomena; Sleep Initiation and Maintenance Disorders; Social Class; Social Participation; Social Support; Soil; Soil Microbiology; Solutions; Somatomedins; Soot; Specimen Handling; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis; Spinal Fractures; Spirometry; Staphylococcus aureus; STAT1 Transcription Factor; STAT3 Transcription Factor; Streptomyces coelicolor; Stress, Psychological; Stroke; Stroke Volume; Structure-Activity Relationship; Students, Medical; Students, Pharmacy; Substance Abuse Treatment Centers; Sulfur Dioxide; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Analysis; Survival Rate; Survivin; Sweden; Swine; Swine, Miniature; Sympathetic Nervous System; T-Lymphocytes, Regulatory; Talaromyces; Tandem Mass Spectrometry; tau Proteins; Telemedicine; Telomerase; Telomere; Telomere Homeostasis; Temperature; Terminally Ill; Th1 Cells; Thiamethoxam; Thiazoles; Thiophenes; Thioredoxin Reductase 1; Thrombosis; Thulium; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Time Factors; Titanium; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Transcription Factor AP-1; Transcription Factors; Transcription, Genetic; Transcriptional Activation; Transcriptome; Transforming Growth Factor beta1; Transistors, Electronic; Translational Research, Biomedical; Transplantation Tolerance; Transplantation, Homologous; Transportation; Treatment Outcome; Tretinoin; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Tubulin Modulators; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Twins; Ultrasonic Therapy; Ultrasonography; Ultraviolet Rays; United States; Up-Regulation; Uranium; Urethra; Urinary Bladder; Urodynamics; Uromodulin; Uveitis; Vasoconstrictor Agents; Ventricular Function, Left; Vero Cells; Vesicular Transport Proteins; Viral Nonstructural Proteins; Visual Acuity; Vital Capacity; Vitamin D; Vitamin D Deficiency; Vitamin K 2; Vitamins; Volatilization; Voriconazole; Waiting Lists; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Whole Genome Sequencing; Wine; Wnt Signaling Pathway; Wound Healing; Wounds and Injuries; WW Domains; X-linked Nuclear Protein; X-Ray Diffraction; Xanthines; Xenograft Model Antitumor Assays; YAP-Signaling Proteins; Yogurt; Young Adult; Zebrafish; Zebrafish Proteins; Ziziphus | 2016 |
Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
Topics: Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Frail Elderly; Gemcitabine; Germany; Humans; Immunotherapy; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Staging; Paclitaxel; Progression-Free Survival; Prospective Studies; Randomized Controlled Trials as Topic; Vinorelbine | 2020 |
Quality of life of locally advanced cervical cancer patients after neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation alone (CIRCE trial): a randomized phase II trial.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Quality of Life; Uterine Cervical Neoplasms | 2020 |
A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first-line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Double-Blind Method; Drug Combinations; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Piperidines; Quinazolines; Treatment Outcome | 2020 |
Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival | 2020 |
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Double-Blind Method; Female; Follow-Up Studies; Gemcitabine; Heparitin Sulfate; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Survival Rate | 2020 |
Relapse and Prognosis of Non-Muscle Invasive Bladder Cancer After Combined HOLRBT with Sunitinib and TGC Perfusion Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Lasers, Solid-State; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Sunitinib; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non-Small Cell Lung Cancer: LOGIK0801.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Treatment Outcome | 2020 |
Combined gemcitabine, cisplatin, dexamethasone, methotrexate, and pegaspargase (GDP-ML) for patients with newly diagnosed extranodal natural killer/T cell lymphoma, nasal type: a single arm, single center, prospective phase 2 study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Methotrexate; Middle Aged; Nose Neoplasms; Polyethylene Glycols; Prospective Studies; Survival Rate; Young Adult | 2020 |
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Global Health; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Survival Analysis | 2020 |
Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Phenylurea Compounds; Platinum; Pyridines; Treatment Outcome | 2020 |
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Interleukin-8; Irinotecan; Male; MAP Kinase Kinase Kinases; Mice; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Transcriptional Activation; Xenograft Model Antitumor Assays | 2020 |
[Prevention effect of transcutaneous electrical acupoint stimulation for chemotherapy-related myelosuppression in non-small cell lung cancer].
Topics: Acupuncture Points; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Humans; Lung Neoplasms; Transcutaneous Electric Nerve Stimulation | 2020 |
A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Postoperative Period; Ribonucleoside Diphosphate Reductase; Treatment Outcome | 2020 |
Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Platinum; Retrospective Studies; Salvage Therapy; Survival Analysis; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.
Topics: Adenocarcinoma of Lung; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; DNA-Binding Proteins; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Gene Rearrangement; Humans; Lung Neoplasms; Male; Matched-Pair Analysis; Middle Aged; Mutation; Pemetrexed; Prognosis; Propensity Score; Retrospective Studies; Survival Rate; Transcription Factors | 2020 |
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Drug Substitution; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2020 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with pancreatic cancer treated with gemcitabine plus nab-paclitaxel: a retrospective cohort study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2020 |
Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals | 2021 |
Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Electrochemotherapy; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunoglobulin Fc Fragments; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Recombinant Fusion Proteins; Wnt Proteins | 2020 |
Surgical Outcome Results From SWOG S1505: A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Perioperative Care; Prospective Studies; Treatment Outcome | 2020 |
Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome; Tumor Microenvironment | 2020 |
Integration of Antiangiogenic Therapy with Cisplatin and Gemcitabine Chemotherapy in Patients with Nasopharyngeal Carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Sunitinib | 2020 |
Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer.
Topics: Adolescent; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreas; Pancreatic Neoplasms; Tomography, X-Ray Computed; Young Adult | 2020 |
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Seconda
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Perioperative Period; Prospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2021 |
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Sorafenib; Time Factors; Treatment Outcome | 2020 |
R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007± trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Survival Analysis | 2021 |
First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Cross-Over Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Genes, erbB-1; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Programmed Cell Death 1 Receptor; Progression-Free Survival; Treatment Outcome | 2020 |
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Male; Middle Aged; Progression-Free Survival; Survival Analysis; Urologic Neoplasms; Urothelium | 2020 |
Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study.
Topics: Adenocarcinoma; Aged; Albumins; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Neutropenia; Paclitaxel; Prognosis; Progression-Free Survival; Radiation-Sensitizing Agents; Thrombocytopenia; Treatment Outcome | 2020 |
Dendritic Cell-based Immunotherapy Pulsed With Wilms Tumor 1 Peptide and Mucin 1 as an Adjuvant Therapy for Pancreatic Ductal Adenocarcinoma After Curative Resection: A Phase I/IIa Clinical Trial.
Topics: Adenocarcinoma; Aged; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Dendritic Cells; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunotherapy; Male; Middle Aged; Mucin-1; WT1 Proteins | 2020 |
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Survival Analysis | 2020 |
Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study).
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bile Duct Neoplasms; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Treatment Outcome; Vascular Endothelial Growth Factor A | 2021 |
Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chemoradiotherapy; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Polyethylene Glycols; Progression-Free Survival; Young Adult | 2021 |
Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer-results from the randomized phase III SUCCESS-A trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Prognosis; Survival Rate; Treatment Outcome | 2020 |
nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Liposomes; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2020 |
A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Tegafur | 2020 |
Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer.
Topics: Aged; Biomarkers, Tumor; Capecitabine; Chemokine CCL5; Chemoradiotherapy; Cytokines; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Pancreatic Neoplasms; Regression Analysis; ROC Curve; Treatment Outcome | 2021 |
Predicting Chemotherapy-Induced Neutropenia and Granulocyte Colony-Stimulating Factor Response Using Model-Based In Vitro to Clinical Translation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplatin; Cells, Cultured; Deoxycytidine; Doxorubicin; Filgrastim; Gemcitabine; Humans; Incidence; Models, Biological; Myelopoiesis; Neoplasms; Neutropenia; Paclitaxel; Polyethylene Glycols; Primary Cell Culture; Risk Assessment; Treatment Outcome | 2020 |
Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2020 |
Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group trial, JCOG1106.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Japan; Kaplan-Meier Estimate; Male; Medical Oncology; Middle Aged; Multivariate Analysis; Neoplasm Staging; Pancreatic Neoplasms; Progression-Free Survival; Treatment Outcome | 2021 |
Tailored-dose chemotherapy with gemcitabine and irinotecan in patients with platinum-refractory/resistant ovarian or primary peritoneal cancer: a phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Ovarian Neoplasms; Platinum | 2021 |
Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur | 2021 |
A Phase Ib multicenter, dose-escalation study of the polyamine analogue PG-11047 in combination with gemcitabine, docetaxel, bevacizumab, erlotinib, cisplatin, 5-fluorouracil, or sunitinib in patients with advanced solid tumors or lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Lymphoma; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Spermine; Sunitinib | 2021 |
Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Phosphoinositide-3 Kinase Inhibitors; Precision Medicine; Progression-Free Survival; PTEN Phosphohydrolase; Pyrimidines; Quinazolines | 2021 |
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Pyrimidines; Quinazolines; Treatment Outcome | 2021 |
Efficacy of Pazopanib With or Without Gemcitabine in Patients With Anthracycline- and/or Ifosfamide-Refractory Soft Tissue Sarcoma: Final Results of the PAPAGEMO Phase 2 Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Indazoles; Middle Aged; Pyrimidines; Quality of Life; Sarcoma; Sulfonamides; Treatment Outcome; Young Adult | 2021 |
Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Time Factors | 2021 |
Phase II study evaluating the association of gemcitabine, trastuzumab and erlotinib as first-line treatment in patients with metastatic pancreatic adenocarcinoma (GATE 1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome | 2021 |
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Care; Prognosis; Survival Rate; Young Adult | 2021 |
Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Salvage Therapy; Young Adult | 2021 |
Randomized Phase II Study of Gemcitabine Monotherapy vs. Gemcitabine with an EPA-Enriched Oral Supplement in Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Eicosapentaenoic Acid; Gemcitabine; Humans; Male; Pancreas; Pancreatic Neoplasms | 2022 |
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial.
Topics: Antimetabolites, Antineoplastic; Canada; Deoxycytidine; Double-Blind Method; Enzyme Inhibitors; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Pyrazoles; Pyrimidinones; Survival; United States | 2021 |
Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients.
Topics: Carcinoma, Pancreatic Ductal; CD40 Antigens; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms | 2021 |
Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesothelioma, Malignant; Netherlands; Pemetrexed; Prospective Studies; Treatment Outcome | 2021 |
Ultrasound and microbubble assisted drug delivery - A clinical pharmacological perspective.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Microbubbles; Pancreatic Neoplasms; Pharmacology, Clinical; Ultrasonic Therapy | 2021 |
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Interleukin-10; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Pancreatic Neoplasms; Polyethylene Glycols; Thrombocytopenia | 2021 |
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Progression-Free Survival; Survival Rate | 2021 |
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2021 |
Neoadjuvant Chemotherapy-Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Prognosis; Prospective Studies; Quality of Life; Remission Induction; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2021 |
A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Standard of Care; Survival Analysis | 2022 |
A randomized, double-blind, phase II study of oral histone deacetylase inhibitor resminostat plus S-1 versus placebo plus S-1 in biliary tract cancers previously treated with gemcitabine plus platinum-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Hydroxamic Acids; Japan; Male; Middle Aged; Oxonic Acid; Placebos; Platinum Compounds; Progression-Free Survival; Sulfonamides; Tegafur; Young Adult | 2021 |
Combination of HAI-FUDR and Systemic Gemcitabine and Cisplatin in Unresectable Cholangiocarcinoma: A Dose Finding Single Center Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Non-Randomized Controlled Trials as Topic; Prognosis; Prospective Studies; Survival Rate | 2021 |
Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled t
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2021 |
Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asia; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Follow-Up Studies; Furans; Gemcitabine; Germ-Line Mutation; Humans; Ketones; Middle Aged; Phthalazines; Prognosis; Receptor, ErbB-2; Survival Rate; Vinorelbine | 2021 |
Phase II Study of Adjuvant Chemotherapy With Gemcitabine and Nafamostat Mesilate for Pancreatic Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Exanthema; Female; Gemcitabine; Guanidines; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Postoperative Period; Treatment Outcome | 2021 |
A genetically defined signature of responsiveness to erlotinib in early-stage pancreatic cancer patients: Results from the CONKO-005 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; DNA Copy Number Variations; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Signal Transduction; Treatment Outcome; Young Adult | 2021 |
Gemcitabine maintenance therapy after gemcitabine and platinum drug chemotherapy for naive stage IIIB/IV squamous cell lung cancer: a phase II study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival | 2021 |
Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance).
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Neovascularization, Pathologic; Survival Analysis; Urinary Bladder Neoplasms; Urologic Neoplasms | 2021 |
A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Prospective Studies; Survival Rate; Treatment Outcome | 2021 |
The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine.
Topics: Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Prospective Studies; Retrospective Studies; Tumor Microenvironment | 2021 |
Efficacy and safety of two different adjuvant chemotherapy regimens in combination with concurrent chemoradiotherapy in treating patients with advanced nasopharyngeal carcinoma: A protocol for randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Progression-Free Survival; Radiotherapy, Intensity-Modulated; Randomized Controlled Trials as Topic | 2021 |
Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Lung Neoplasms; Platinum | 2021 |
Gemcitabine, carboplatin and veliparib in multiple relapsed/refractory germ cell tumours: The GCT-SK-004 phase II trial.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Young Adult | 2021 |
Equivalent Efficacy but Different Safety Profiles of Gemcitabine Plus Nab-Paclitaxel and FOLFIRINOX in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Rate | 2021 |
Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; CA-125 Antigen; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Progression-Free Survival; Survival Rate; Treatment Outcome | 2021 |
Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers; Deoxycytidine; Disease Management; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Kidney Diseases; Kidney Function Tests; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Treatment Outcome | 2021 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Pancreatic Ductal; China; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Radiosurgery | 2021 |
Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Middle Aged; Neoplasm Staging; Ovarian Neoplasms | 2021 |
Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2021 |
A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds | 2021 |
Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Treatment Outcome | 2021 |
A phase I study of the anaplastic lymphoma kinase inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients with advanced solid tumors.
Topics: Adult; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrimidines; Sulfones | 2021 |
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Neoplasm Recurrence, Local; Progression-Free Survival | 2021 |
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Central Serous Chorioretinopathy; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Dry Eye Syndromes; Fatigue; Female; Gemcitabine; Humans; Hyperphosphatemia; Male; Middle Aged; Neoplasm Metastasis; Phenylurea Compounds; Pyrimidines; Radiation-Sensitizing Agents; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Retinal Detachment; Safety; Stomatitis; Treatment Outcome | 2021 |
A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high-risk or relapsed/refractory non-Hodgkin's lymphomas.
Topics: Adolescent; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Busulfan; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Progression-Free Survival; Transplantation Conditioning; Transplantation, Autologous; Young Adult | 2021 |
Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma: A Phase 2 Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Isoxazoles; Male; Pyrazines; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Furans; Gemcitabine; Humans; Ketones; Nuclear Proteins; Paclitaxel; Pharmacogenomic Testing; Polymorphism, Genetic; Prospective Studies; Repressor Proteins | 2021 |
Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-G
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; GTP-Binding Proteins; Humans; Membrane Proteins; Nanoparticles; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2021 |
Phase III study of adjuvant gemcitabine compared with adjuvant uracil-tegafur in patients with completely resected pathological stage IB-IIIA non-small cell lung cancer (WJTOG0101).
Topics: Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Tegafur; Uracil | 2021 |
Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Humans; Italy; Male; Mesothelioma, Malignant; Middle Aged; Pleural Neoplasms; Progression-Free Survival; Ramucirumab; Time Factors | 2021 |
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Biomarkers, Tumor; Deoxycytidine; DNA Replication; Female; Gemcitabine; Humans; Isoxazoles; Mutation; Oncogenes; Ovarian Neoplasms; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Recombinational DNA Repair; Retinoblastoma Binding Proteins | 2021 |
Cost-effectiveness analysis of FOLFIRINOX vs gemcitabine with nab-paclitaxel as adjuvant treatment for resected pancreatic cancer in the United States based on PRODIGE-24 and APACT trials.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Markov Chains; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; United States | 2021 |
A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Macrophage Colony-Stimulating Factor; Treatment Outcome; Triple Negative Breast Neoplasms | 2022 |
Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Fluorouracil; France; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Progression-Free Survival; Time Factors | 2022 |
Paclitaxel liposome for injection (Lipusu) plus cisplatin versus gemcitabine plus cisplatin in the first-line treatment of locally advanced or metastatic lung squamous cell carcinoma: A multicenter, randomized, open-label, parallel controlled clinical stu
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liposomes; Lung; Lung Neoplasms; Middle Aged; Paclitaxel; Young Adult | 2022 |
Phase I Study of Preoperative Chemoradiotherapy Using Gemcitabine Plus Nab-Paclitaxel for Patients Who Have Localized Pancreatic Ductal Adenocarcinoma With Contact or Invasion to Major Arteries.
Topics: Aged; Aged, 80 and over; Albumins; Arteries; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Vascular Neoplasms | 2021 |
Cost-Effectiveness of Nab-Paclitaxel and Gemcitabine Versus Gemcitabine Monotherapy for Patients with Unresectable Metastatic Pancreatic Cancer in Japan.
Topics: Adenocarcinoma; Albumins; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Japan; Markov Chains; Paclitaxel; Pancreatic Neoplasms | 2022 |
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2021 |
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Methotrexate; Neoadjuvant Therapy; Paclitaxel; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Analysis of the Mechanism and Safety of Bisphosphonates in Patients with Lung Cancer and Bone Metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Cisplatin; Computational Biology; Deoxycytidine; Diphosphonates; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Safety; Young Adult; Zoledronic Acid | 2021 |
Impact of Gemcitabine Plus S1 Neoadjuvant Chemotherapy on Borderline Resectable Perihilar Cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Gemcitabine; Humans; Klatskin Tumor; Neoadjuvant Therapy; Pancreatic Neoplasms | 2022 |
Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma with peritoneal metastasis (SP study).
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms | 2022 |
Neoadjuvant concurrent chemoradiotherapy using infusional gemcitabine in locally advanced rectal cancer: A phase II trial.
Topics: Adolescent; Adult; Chemoradiotherapy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Rectal Neoplasms; Treatment Outcome | 2022 |
VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects.
Topics: Adenoviridae; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesocricetus; Mice; Mice, Inbred C57BL; Oncolytic Virotherapy; Paclitaxel; Pancreatic Neoplasms; Prognosis; Stromal Cells | 2021 |
Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: a phase I trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Rituximab; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2022 |
Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stroma.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Biomarkers, Tumor; Cancer-Associated Fibroblasts; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Repositioning; Female; Gemcitabine; Humans; Immunoglobulins; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Tetrahydronaphthalenes; Treatment Outcome; Tumor Microenvironment; Young Adult | 2022 |
Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Radiosurgery | 2022 |
Neoadjuvant chemotherapy with gemcitabine and cisplatin followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of bladder.
Topics: Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Muscles; Neoadjuvant Therapy; Prospective Studies; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Muscles; Neoadjuvant Therapy; Urinary Bladder Neoplasms; Vinblastine | 2022 |
Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Middle Aged; Ramucirumab; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
A study on the antitumor effect of gemcitabine polybutylcy- anoacrylate nanoparticles coupled with Mucin 1 monoclonal antibody on pancreatic cancer
Topics: Animals; Antibodies, Monoclonal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Mucin-1; Nanoparticles; Pancreatic Neoplasms | 2021 |
Gemcitabine and cisplatin plus immunotherapy in advanced biliary tract cancer: a phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Immunotherapy; Treatment Outcome | 2022 |
The safety, tolerability, and efficacy of a neoadjuvant gemcitabine intravesical drug delivery system (TAR-200) in muscle-invasive bladder cancer patients: a phase I trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Urinary Bladder Neoplasms | 2022 |
Efficacy of Bevacizumab and Gemcitabine in Combination with Cisplatin in the Treatment of Esophageal Cancer and the Effect on the Incidence of Adverse Reactions.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Gemcitabine; Humans; Incidence; Keratin-19; Lung Neoplasms; Vascular Endothelial Growth Factor A | 2022 |
Re: Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2022 |
Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamidines; Deoxycytidine; Female; Gemcitabine; Guanidines; Humans; Male; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Phase II Clinical Trial of Eribulin-Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma.
Topics: Deoxycytidine; Furans; Gemcitabine; Humans; Ketones; Leiomyosarcoma; Liposarcoma; Treatment Outcome | 2022 |
Drug-Eluting Bead, Irinotecan Therapy of Unresectable Intrahepatic Cholangiocarcinoma (DELTIC) with Concomitant Systemic Gemcitabine and Cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Prospective Studies; Treatment Outcome | 2022 |
The efficacy of trimodal chemoradiotherapy with gemcitabine and cisplatin as a bladder-preserving strategy for the treatment of muscle-invasive bladder cancer: a single-arm phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoplasm Invasiveness; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Re: Ekaterina Laukhtina, Shahrokh F. Shariat. Phase II Study of Gemcitabine and Split-dose Cisplatin plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer. Eur Urol. 2022;82:242-3.
Topics: Antibodies, Monoclonal, Humanized; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Urinary Bladder Neoplasms | 2022 |
A Phase II Study of Nivolumab plus Gemcitabine in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma (KCSG HN17-11).
Topics: Antineoplastic Combined Chemotherapy Protocols; Artificial Intelligence; B7-H1 Antigen; Chromatin; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Nivolumab; Programmed Cell Death 1 Receptor | 2022 |
A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chromatin Assembly and Disassembly; Deoxycytidine; Gemcitabine; Humans; Nivolumab | 2022 |
Randomised, Phase II study of selumetinib, an oral inhibitor of MEK, in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Mitogen-Activated Protein Kinase Kinases | 2022 |
Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Febrile Neutropenia; Gemcitabine; Humans; Ifosfamide; Sarcoma; Soft Tissue Neoplasms | 2022 |
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT-01.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ipilimumab; Male; Middle Aged; Nivolumab | 2022 |
A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Azepines; Deoxycytidine; Gemcitabine; Humans; Maximum Tolerated Dose; Neoplasms; Pancreatic Neoplasms; Pyrimidines | 2022 |
Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: a prospective, randomized, open-label, single center trial.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies | 2022 |
The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2022 |
A phase 1b study of crenigacestat (LY3039478) in combination with gemcitabine and cisplatin or gemcitabine and carboplatin in patients with advanced or metastatic solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Neoplasms, Second Primary | 2022 |
Effects of Gemcitabine and Oxaliplatin Combined with Apatinib on Immune Function and Levels of SIL-2R and sicAM-1 in Patients with Gallbladder Cancer.
Topics: Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Immunity; Oxaliplatin; Pyridines; Retrospective Studies | 2022 |
Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Head and Neck Neoplasms; Humans; Immune Checkpoint Inhibitors; Neoadjuvant Therapy; Programmed Cell Death 1 Receptor; Receptors, Death Domain; Squamous Cell Carcinoma of Head and Neck | 2022 |
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms | 2022 |
Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
A Phase II Study of Nab-Paclitaxel and Gemcitabine as First-Line Therapy in Patients with Cholangiocarcinoma Ineligible for Cisplatin-Based Chemotherapy (NACHO).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Pilot Projects; Prospective Studies; Treatment Outcome | 2023 |
A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms | 2023 |
Tislelizumab with gemcitabine and oxaliplatin in patients with relapsed or refractory classic Hodgkin lymphoma: a multicenter phase II trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Oxaliplatin; Prospective Studies; Treatment Outcome | 2023 |
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Sirolimus; TOR Serine-Threonine Kinases; Tumor Microenvironment; Urinary Bladder Neoplasms | 2023 |
Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms | 2023 |
[GEM plus CDDP Combination Therapy for Unresectable Biliary Tract Cancer-A Single Institution Experience].
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Neutropenia; Thrombocytopenia; Treatment Outcome | 2023 |
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans | 2023 |
Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04).
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Neutropenia | 2023 |
Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Prospective Studies; Treatment Outcome | 2023 |
Study protocol of an open-label, single arm phase II trial investigating the efficacy and safety of Trifluridine/Tipiracil combined with irinotecan as a second line therapy in patients with cholangiocarcinoma (TRITICC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Frontotemporal Dementia; Gemcitabine; Humans; Irinotecan; Prospective Studies; Trifluridine | 2023 |
A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01).
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic | 2023 |
Topics: Acetogenins; Acute Disease; Acute Kidney Injury; Administration, Intravenous; Aged; Albumins; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase, Mitochondrial; alpha-Glucosidases; Anemia; Animals; Anthozoa; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bacterial; Antigens, Bacterial; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Ascites; Asthma; Bacteria; beta-Lactamases; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Binding Sites; Biological Availability; Biomass; Borderline Personality Disorder; Brain; Brucella abortus; Brucella melitensis; Brucellosis; Calcium; Carbapenems; Case-Control Studies; Caseins; Cattle; CD8-Positive T-Lymphocytes; Ceftaroline; Cell Line; Cell Line, Tumor; Cell Physiological Phenomena; Cell Proliferation; Cephalosporins; Chemotherapy, Adjuvant; China; Chitin; Chlorella; Chlorophyll; Chlorophyll A; Chlorophyta; Cholangiocarcinoma; Cisplatin; Conotoxins; Contrast Media; Conus Snail; Cross-Sectional Studies; Cytokines; Decapodiformes; Deoxycytidine; Diagnostic and Statistical Manual of Mental Disorders; Dietary Fiber; Diterpenes; DNA Methylation; Dogs; Double-Blind Method; Drug Design; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Enzyme-Linked Immunosorbent Assay; Epidermis; Escherichia coli; Escherichia coli Infections; Extraintestinal Pathogenic Escherichia coli; Fatty Acids; Fatty Acids, Unsaturated; Fatty Acids, Volatile; Feasibility Studies; Feces; Female; Ferritins; Fluorodeoxyglucose F18; Gastrectomy; Gastrointestinal Microbiome; Gemcitabine; Glomerular Filtration Rate; Glucose; Glycerol; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Immunoassay; Immunoglobulin G; India; Infant, Newborn; Infertility; Inflammation; Intensive Care Units; Iron; Iron Deficiencies; Kidney; Lacticaseibacillus rhamnosus; Laurencia; Leukocytes; Lipids; Liver Cirrhosis; Long Interspersed Nucleotide Elements; Longitudinal Studies; Male; Mesenchymal Stem Cells; Methicillin-Resistant Staphylococcus aureus; Mice; Microalgae; Microbial Sensitivity Tests; Microscopy; Middle Aged; Minerals; Molecular Conformation; Molecular Docking Simulation; Molecular Structure; Mycobacterium tuberculosis; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephropidae; Nicotinic Antagonists; Nitrogen; Obesity; Oxaliplatin; Paclitaxel; Panax; Pancreatic Neoplasms; Pancreatitis; Personality; Personality Disorders; Personality Inventory; Photobioreactors; Plant Extracts; Plasmalogens; Plasmids; Polymorphism, Genetic; Polynesia; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Prebiotics; Predictive Value of Tests; Prognosis; Prolyl-Hydroxylase Inhibitors; Rabbits; Radiopharmaceuticals; Rats; Rats, Wistar; Receptors, Nicotinic; Recombinant Proteins; Retrospective Studies; Rifampin; Risk Factors; RNA, Ribosomal, 16S; Salinity; Seaweed; Sensitivity and Specificity; Sepsis; Sesquiterpenes; Severity of Illness Index; Shock, Septic; Silicones; Single Photon Emission Computed Tomography Computed Tomography; Skin; Snails; Solubility; Solvents; Sputum; Staphylococcal Infections; Stomach Neoplasms; Stramenopiles; Structure-Activity Relationship; Technetium Tc 99m Exametazime; Technology; Terpenes; Tuberculosis; Tuberculosis, Multidrug-Resistant; Urinary Catheters; Urinary Tract Infections; Vascular Endothelial Growth Factor A; Virulence Factors; Water; Wound Healing | 2023 |
A phase II study of gemcitabine and docetaxel combination in relapsed metastatic or unresectable locally advanced synovial sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neutropenia; Prospective Studies; Quality of Life; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Treatment Outcome | 2023 |
Letter to the Editor: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Nivolumab; Urinary Bladder Neoplasms; Xeroderma Pigmentosum Group D Protein | 2023 |
Clinical Effect of the Combination of Compound Kushen Injection and Gemcitabine on Postoperative Patients with Non-Muscle Invasive Bladder Cancer and Its Influence on Serum-Related Factors.
Topics: Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Non-Muscle Invasive Bladder Neoplasms; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2023 |
7269 other study(ies) available for gemcitabine and deoxycytidine
| Article | Year |
|---|---|
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
Topics: Antiviral Agents; Catalysis; Deoxycytidine; Hepacivirus; Hepatitis C; Humans; Mutation; Phosphorylation; RNA-Dependent RNA Polymerase; RNA, Viral; Structure-Activity Relationship; Viral Nonstructural Proteins; Virus Replication | 2007 |
Deoxyribonucleoside kinases activate nucleoside antibiotics in severely pathogenic bacteria.
Topics: Animals; Anti-Bacterial Agents; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Sequence Data; Nucleosides; Phosphotransferases (Alcohol Group Acceptor); Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus pyogenes | 2007 |
Increased deoxycytidine kinase activity in cancer cells and inhibition by difluorodeoxycytidine.
Topics: Animals; Cell Division; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Humans; In Vitro Techniques; Kinetics; Neoplasms; Rats; Tumor Cells, Cultured | 1992 |
Synergistic action of tiazofurin and difluorodeoxycytidine on differentiation and cytotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; IMP Dehydrogenase; Kinetics; Leukemia, Promyelocytic, Acute; Liver Neoplasms, Experimental; Models, Biological; Ovarian Neoplasms; Pancreatic Neoplasms; Rats; Ribavirin; Tetradecanoylphorbol Acetate; Tretinoin; Tumor Stem Cell Assay | 1992 |
Modulation of deoxycytidylate deaminase in intact human leukemia cells. Action of 2',2'-difluorodeoxycytidine.
Topics: Antimetabolites, Antineoplastic; Carbon Radioisotopes; Cell Extracts; Chromatography, High Pressure Liquid; Cytidine Deaminase; DCMP Deaminase; Deoxycytidine; Deoxycytosine Nucleotides; Gemcitabine; Humans; Leukemia, Lymphoid; Leukemia, Myeloid; Thymine Nucleotides; Tumor Cells, Cultured | 1992 |
A quantitative assay for fragmented DNA in apoptotic cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; DNA; DNA, Circular; Ethidium; Gemcitabine; Humans; Microchemistry; Phosphorus Radioisotopes; Plasmids; T-Lymphocytes; Time Factors; Vidarabine | 1992 |
Effect of 2',2'-difluorodeoxycytidine on the viability and radiosensitivity of EMT6 cells in vitro.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Division; Cell Line; Cell Survival; Deoxycytidine; Dose-Response Relationship, Radiation; Gemcitabine; Mammary Neoplasms, Experimental; Mice; Tumor Cells, Cultured; X-Rays | 1992 |
Activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human tumor colony forming units.
Topics: Antimetabolites, Antineoplastic; Deamination; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Neoplasms, Experimental; Tetrahydrouridine; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1992 |
[Pharmacokinetic studies of dFdC (2',2'-difluorodeoxycytidine), ara-C and BH-AC (N4-behenoyl ara-C) in experimental animals].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytarabine; Deoxycytidine; Gemcitabine; Half-Life; Liver; Mice; Rabbits; Sarcoma, Experimental | 1992 |
Synthesis and restriction enzyme analysis of oligodeoxyribonucleotides containing the anti-cancer drug 2',2'-difluoro-2'-deoxycytidine.
Topics: Antimetabolites, Antineoplastic; Base Composition; Base Sequence; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Molecular Sequence Data; Oligodeoxyribonucleotides; Restriction Mapping; Temperature | 1992 |
Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Bone Marrow Cells; Cisplatin; Cystadenocarcinoma; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Glutathione Transferase; Humans; Injections, Intraperitoneal; Injections, Intravenous; Ovarian Neoplasms; RNA, Messenger; Stem Cells; Tumor Cells, Cultured | 1992 |
[Clinical application of enzyme inhibitors--hematologic malignancies].
Topics: Cytarabine; Deoxycytidine; DNA Topoisomerases, Type I; Etoposide; Gemcitabine; Humans; Leukemia; Mercaptopurine; Methotrexate; Purines; Pyrimidines; Thioguanine; Topoisomerase I Inhibitors | 1991 |
Action of 2',2'-difluorodeoxycytidine on DNA synthesis.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Cells, Cultured; Cytarabine; Deoxycytidine; Deoxycytidine Monophosphate; Deoxycytosine Nucleotides; DNA; Gemcitabine; Humans; Molecular Sequence Data; RNA | 1991 |
Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.
Topics: Antimetabolites, Antineoplastic; Cell Line; Cytidine Triphosphate; DCMP Deaminase; Deoxycytidine; Deoxyribonucleotides; Gemcitabine; Humans; Kinetics; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Ribonucleotides | 1992 |
Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity.
Topics: Arabinofuranosylcytosine Triphosphate; Base Sequence; Cell Line; Cell Survival; DCMP Deaminase; Deoxycytidine; Deoxycytosine Nucleotides; Deoxyribonucleotides; DNA Polymerase II; Gemcitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Oligodeoxyribonucleotides; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Stem Cell Assay | 1991 |
Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Carcinoma, Squamous Cell; Cell Division; Cell Line; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Kinetics; Mice; Ovarian Neoplasms | 1991 |
Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells.
Topics: Antimetabolites, Antineoplastic; Cell Division; Cytarabine; Deoxycytidine; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Leukemia, Experimental; Leukemia, Lymphoid; Leukemia, Myeloid; Phenotype; Tumor Cells, Cultured | 1991 |
Preclinical in vivo activity of 2',2'-difluorodeoxycytidine (Gemcitabine) against human head and neck cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation | 1991 |
Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cytidine Triphosphate; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Leukemia; Male; Middle Aged; Neoplastic Cells, Circulating | 1990 |
Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.
Topics: Cell Line; Cytidine; Deoxycytidine; Deoxycytosine Nucleotides; DNA; Gemcitabine; Humans; Hydroxyurea; Oxidation-Reduction; Ribonucleoside Diphosphate Reductase; Ribonucleotides; Thymine Nucleotides | 1990 |
Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.
Topics: Arabinonucleosides; Arabinonucleotides; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Leukemia; Phosphorylation; Tumor Cells, Cultured; Vidarabine | 1990 |
Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Survival; Deoxycytidine; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Leukemia L1210; Leukemia P388; Leukemia, Experimental; Male; Mice; Mice, Inbred ICR; Mice, Inbred Strains; Neoplasms, Experimental; Tumor Cells, Cultured | 1990 |
Cytotoxicity and antitumor activity of 2',2'-difluorodeoxycytidine (Gemcitabine).
Topics: Animals; Antimetabolites, Antineoplastic; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice | 1990 |
Comparison of the cellular pharmacokinetics and toxicity of 2',2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine.
Topics: Animals; Arabinofuranosylcytosine Triphosphate; Cell Line; Cell Survival; Clone Cells; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; DNA Replication; Drug Evaluation, Preclinical; Gemcitabine; Kinetics | 1988 |
Gemcitabine--status of preclinical studies and perspectives for future clinical applications of this novel nucleoside analog. Symposium proceedings. Amsterdam, The Netherlands, March 15, 1994.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; DNA, Neoplasm; Drug Interactions; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplasms; Ribonucleotide Reductases; RNA, Neoplasm; Tumor Cells, Cultured | 1995 |
Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carbon-Nitrogen Ligases; CHO Cells; Cricetinae; Cytidine Triphosphate; Deoxycytidine; Deoxycytosine Nucleotides; Dinucleoside Phosphates; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gemcitabine; Ligases; Phosphorylation; Ribonucleotide Reductases; Ribonucleotides; RNA; Tissue Distribution | 1995 |
Induction of apoptosis by gemcitabine.
Topics: Aphidicolin; Apoptosis; Calcium; Carcinogens; Chelating Agents; Clone Cells; Deoxycytidine; DNA; Egtazic Acid; Enzyme Inhibitors; Flow Cytometry; Gemcitabine; Humans; Ribonucleotide Reductases; S Phase; Tetradecanoylphorbol Acetate | 1995 |
Consequences of 2',2'-difluorodeoxycytidine (gemcitabine) on replicative DNA synthesis in intact HL-60 cells.
Topics: Antimetabolites, Antineoplastic; Cytarabine; Cytidine Triphosphate; Deoxycytidine; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Gemcitabine; Guanosine Triphosphate; Half-Life; HL-60 Cells; Humans; Nucleosides; Peptide Chain Elongation, Translational; Thymine | 1995 |
Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Base Sequence; Cell Division; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Molecular Sequence Data; Nucleoside Deaminases; Ovarian Neoplasms; Phenotype; Ribonucleotide Reductases; RNA, Messenger; Tumor Cells, Cultured; Vincristine | 1995 |
Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Squamous Cell; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Injections, Intraperitoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms | 1995 |
Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cladribine; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; In Vitro Techniques; Leukemia; Lung Neoplasms; Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured; Urogenital Neoplasms | 1995 |
Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Arabinonucleosides; Base Sequence; Cricetinae; Deoxycytidine; Deoxyguanosine; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Gemcitabine; Humans; Leukemia; Molecular Sequence Data; Nucleotides; Peptide Chain Elongation, Translational; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); RNA, Neoplasm; Structure-Activity Relationship; Tumor Cells, Cultured | 1995 |
Radiosensitization of human tumor cells by gemcitabine in vitro.
Topics: Cell Cycle; Cells, Cultured; Chromatography, High Pressure Liquid; Deoxycytidine; Deoxycytosine Nucleotides; Deoxyribonucleotides; Gemcitabine; HT29 Cells; Humans; Radiation-Sensitizing Agents | 1995 |
Interaction between cisplatin and gemcitabine in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Colonic Neoplasms; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Drug Tolerance; Female; Fluorometry; Gemcitabine; Head and Neck Neoplasms; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Tumor Cells, Cultured | 1995 |
Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells.
Topics: Adenosine Triphosphate; Animals; Base Sequence; Cell Division; CHO Cells; Cricetinae; Deoxycytidine; DNA; Drug Screening Assays, Antitumor; Gemcitabine; Guanosine Triphosphate; Molecular Sequence Data; Phosphorylation; Purine-Nucleoside Phosphorylase; RNA; Substrate Specificity | 1995 |
Ovarian cancer--new insights into systemic therapy.
Topics: Antimetabolites, Antineoplastic; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel | 1995 |
Topoisomerase I inhibitors and other new cytotoxic drugs.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aziridines; Camptothecin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Organoplatinum Compounds; Quinazolines; Thiophenes; Thymidylate Synthase; Topoisomerase I Inhibitors | 1995 |
FDA expands access to gemcitabine for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drugs, Investigational; Gemcitabine; Humans; Pancreatic Neoplasms; United States; United States Food and Drug Administration | 1995 |
Metabolism of gemcitabine in rat and dog.
Topics: Animals; Antimetabolites, Antineoplastic; Carbon Radioisotopes; Deoxycytidine; Dogs; Feces; Gemcitabine; Injections, Intravenous; Kidney; Liver; Lung; Male; Rats; Rats, Inbred F344 | 1995 |
Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line; Cisplatin; Colonic Neoplasms; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Kinetics; Mice; Nucleoside Deaminases; Ovarian Neoplasms; Time Factors; Tumor Cells, Cultured | 1994 |
Effect of hyperthermia on the cytotoxicity of 2',2'-difluorodeoxycytidine (gemcitabine) in cultured SW1573 cells.
Topics: Carcinoma, Squamous Cell; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; In Vitro Techniques; Lung Neoplasms; Tumor Cells, Cultured | 1995 |
Fludarabine- and gemcitabine-induced apoptosis: incorporation of analogs into DNA is a critical event.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Aphidicolin; Apoptosis; Cell Cycle; Cell Line; Cell Membrane; Deoxycytidine; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; T-Lymphocytes; Time Factors; Tumor Cells, Cultured; Vidarabine | 1995 |
Validated assays for the determination of gemcitabine in human plasma and urine using high-performance liquid chromatography with ultraviolet detection.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Reproducibility of Results; Spectrophotometry, Ultraviolet | 1995 |
Disposition of gemcitabine in rat and dog after single and multiple dosings.
Topics: Animals; Antimetabolites, Antineoplastic; Autoradiography; Deoxycytidine; Dogs; Dose-Response Relationship, Drug; Feces; Female; Gemcitabine; Injections, Intravenous; Male; Rats; Rats, Inbred F344; Sex Characteristics; Species Specificity; Tissue Distribution | 1994 |
From the Food and Drug Administration.
Topics: Abciximab; Acquired Immunodeficiency Syndrome; Angioplasty; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Deoxycytidine; Drugs, Investigational; Gemcitabine; Growth Hormone; Humans; Immunoglobulin Fab Fragments; Nonprescription Drugs; Pancreatic Neoplasms; Platelet Aggregation Inhibitors; Recombinant Proteins; Spermatocidal Agents; United States; United States Food and Drug Administration | 1995 |
Placental transfer, lacteal transfer and plasma protein binding of gemcitabine.
Topics: Animals; Autoradiography; Blood Proteins; Carbon Radioisotopes; Deoxycytidine; Dogs; Female; Fetus; Gemcitabine; Gestational Age; Kidney; Kinetics; Liver; Lung; Maternal-Fetal Exchange; Milk; Placenta; Pregnancy; Rats | 1994 |
[Synergistic cytotoxic effects of chemotherapy in colon tumor cells by simultaneous inhibition of de novo and salvage energy metabolism pathways].
Topics: Allopurinol; Antimetabolites, Antineoplastic; Benzamidines; Cell Line; Cell Survival; Colonic Neoplasms; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Hypoxanthine; Hypoxanthines; Ribavirin; Ribonucleotide Reductases; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1994 |
Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Mice; Ovarian Neoplasms; Phosphates; Ribonucleotides; Tumor Cells, Cultured | 1994 |
Fluorodeoxyglucose uptake in vitro: aspects of method and effects of treatment with gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Deoxyglucose; Fluorodeoxyglucose F18; Gemcitabine; In Vitro Techniques; Male; Prostatic Neoplasms; Rats; Tomography, Emission-Computed; Tumor Cells, Cultured | 1994 |
[Antitumor activity of combination treatment combining gemcitabine with cisplatin or vindesine against human lung cancer xenografted in nude mice].
Topics: Adenocarcinoma, Papillary; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Vindesine | 1994 |
Molecular effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells.
Topics: Antimetabolites, Antineoplastic; Cell Death; Cytarabine; Deoxycytidine; Deoxycytosine Nucleotides; Deoxyguanine Nucleotides; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Stability; Gemcitabine; Humans; Hydrogen-Ion Concentration; Tumor Cells, Cultured | 1994 |
General pharmacology of gemcitabine hydrochloride in animals.
Topics: Animals; Antimetabolites, Antineoplastic; Autonomic Nervous System; Central Nervous System; Deoxycytidine; Digestive System; Dogs; Female; Gemcitabine; Guinea Pigs; Hemodynamics; Male; Mice; Rats; Rats, Sprague-Dawley; Respiratory System; Water-Electrolyte Balance | 1994 |
[Acquired resistance and cross-resistance of gemcitabine to cisplatin or vindesine in human lung cancer xenografted in nude mice].
Topics: Adenocarcinoma, Papillary; Animals; Cell Division; Cisplatin; Deoxycytidine; Drug Resistance; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Transplantation, Heterologous; Vindesine | 1994 |
Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.
Topics: Animals; Antimetabolites, Antineoplastic; Base Sequence; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance; Female; Gemcitabine; Humans; Mice; Mice, Nude; Molecular Sequence Data; Ovarian Neoplasms; RNA, Messenger; Tumor Cells, Cultured | 1994 |
Gemcitabine: current status of phase I and II trials.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Research | 1994 |
Degradation chemistry of gemcitabine hydrochloride, a new antitumor agent.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Gemcitabine; Hydrogen-Ion Concentration; Isomerism; Magnetic Resonance Spectroscopy; Mass Spectrometry; Solutions | 1994 |
Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cells, Cultured; Cytidine; Deoxycytidine; Gemcitabine; Humans; Hydroxyurea; In Vitro Techniques; Prodrugs; Ribonucleotide Reductases; Zidovudine | 1994 |
Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Sulfonylurea Compounds; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
[Antitumor activity of LY 188011, a new deoxycytidine analog, against human cancers xenografted into nude mice].
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomycin; Neoplasm Transplantation; Stomach Neoplasms | 1994 |
Metabolism of 2',2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Deoxyribonucleotides; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1994 |
Determination of the antimetabolite Gemcitabine (2',2'-difluoro-2'-deoxycytidine) and of 2',2'-difluoro-2'-deoxyuridine by 19F nuclear magnetic resonance spectroscopy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Floxuridine; Fluorine; Gemcitabine; Humans; Magnetic Resonance Spectroscopy | 1993 |
Developmental toxicity of gemcitabine, an antimetabolite oncolytic, administered during gestation to CD-1 mice.
Topics: Abnormalities, Drug-Induced; Animals; Antimetabolites, Antineoplastic; Behavior, Animal; Body Weight; Deoxycytidine; Dose-Response Relationship, Drug; Eating; Erythropoiesis; Female; Fetal Resorption; Gemcitabine; Gestational Age; Hematopoiesis; Male; Mice; Mice, Inbred Strains; Organ Size; Pregnancy; Pregnancy, Animal; Reproduction; Spleen; Thymus Gland | 1993 |
Gemcitabine: novel combination of efficacy and tolerability.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 1993 |
The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Sarcoma; Soft Tissue Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1993 |
Regulation of deoxycytidine kinase activity and inhibition by DFDC.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cycloheximide; Dactinomycin; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Humans; Neoplasms; Pyrimidine Nucleotides; Rats; Tumor Cells, Cultured | 1993 |
2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; DNA, Neoplasm; Gemcitabine; Humans; Mice; RNA, Neoplasm; Tumor Cells, Cultured | 1993 |
Effects of 2',2'-difluorodeoxycytidine (Gemcitabine) on wild type and variant mouse leukemia L1210 cells.
Topics: Animals; Antimetabolites, Antineoplastic; Carbon Radioisotopes; Cytidine; Deoxycytidine; Gemcitabine; Leukemia L1210; Mice; Ribonucleotide Reductases; Tumor Cells, Cultured | 1993 |
Intratumoral pharmacokinetic analysis by 19F-magnetic resonance spectroscopy and cytostatic in vivo activity of gemcitabine (dFdC) in two small cell lung cancer xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Deoxycytidine; Fluorine; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Neoplasm Transplantation | 1993 |
Effect of a template-located 2',2'-difluorodeoxycytidine on the kinetics and fidelity of base insertion by Klenow (3'-->5'exonuclease-) fragment.
Topics: Antimetabolites, Antineoplastic; Base Composition; Base Sequence; Cloning, Molecular; Deoxycytidine; Deoxyribonucleotides; DNA Polymerase I; DNA Primers; Exodeoxyribonuclease V; Exodeoxyribonucleases; Gemcitabine; Kinetics; Molecular Sequence Data; Recombinant Proteins; Substrate Specificity; Templates, Genetic | 1993 |
Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
Topics: Antimetabolites, Antineoplastic; Azepines; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Deoxycytosine Nucleotides; Gemcitabine; Half-Life; Humans; Kinetics; Tetrahydrouridine | 1993 |
Comparison of the induction of apoptosis in human leukemic cell lines by 2',2'-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Northern; Cytarabine; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Gene Expression; Genes, fos; Genes, jun; HL-60 Cells; Humans; Leukemia, T-Cell; Protein Kinase C; Staurosporine; Tumor Cells, Cultured | 1995 |
ODAC recommends full approval for Gemzar for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Approval; Gemcitabine; Humans; Pancreatic Neoplasms; United States; United States Food and Drug Administration | 1995 |
Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine.
Topics: Adenosine Triphosphate; Cell Cycle; Cell Survival; Cytidine Triphosphate; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Guanosine Triphosphate; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Thymine Nucleotides; Tumor Cells, Cultured | 1996 |
Gemcitabine in the treatment of non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms | 1995 |
Lack of in vivo crossresistance with gemcitabine against drug-resistant murine P388 leukemias.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Leukemia P388; Mice; Molecular Structure | 1996 |
Inhibitory effects of the nucleoside analogue gemcitabine on prostatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Division; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cells; Humans; Male; Prostatic Neoplasms; Tumor Cells, Cultured | 1996 |
Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Receptor, ErbB-2; Regression Analysis; Tumor Cells, Cultured | 1996 |
Effects of fludarabine and gemcitabine on human acute myeloid leukemia cell line HL 60: direct comparison of cytotoxicity and cellular Ara-C uptake enhancement.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell Survival; Cytarabine; Deoxycytidine; Drug Interactions; Gemcitabine; HL-60 Cells; Humans; Thymidine; Vidarabine | 1996 |
Regulation of phosphorylation of deoxycytidine and 2',2'-difluorodeoxycytidine (gemcitabine); effects of cytidine 5'-triphosphate and uridine 5'-triphosphate in relation to chemosensitivity for 2',2'-difluorodeoxycytidine.
Topics: Cytidine Deaminase; Cytidine Triphosphate; Deoxycytidine; Deoxycytidine Kinase; Enzyme Inhibitors; Female; Gemcitabine; Humans; Kinetics; Nucleoside Deaminases; Ovarian Neoplasms; Phosphorylation; Tumor Cells, Cultured; Uridine Triphosphate | 1996 |
The influence of BIBW22BS, a dipyridamole derivative, on the antiproliferative effects of 5-fluorouracil, methotrexate and gemcitabine in vitro and in human tumour xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dipyridamole; Doxorubicin; Drug Resistance; Female; Floxuridine; Fluorouracil; Gemcitabine; Humans; Methotrexate; Mice; Mice, Nude; Morpholines; Neoplasms; Neoplasms, Experimental; Protein Binding; Transplantation, Heterologous; Triamterene; Tumor Cells, Cultured; Vincristine | 1995 |
Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
Antitumor activity of prolonged as compared with bolus administration of 2',2'-difluorodeoxycytidine in vivo against murine colon tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Infusions, Intravenous; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL | 1996 |
Drug resistance against gemcitabine and topotecan mediated by constitutive hsp70 overexpression in vitro: implication of quercetin as sensitiser in chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Division; Deoxycytidine; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fibrosarcoma; Gemcitabine; HSP70 Heat-Shock Proteins; Humans; Mice; Quercetin; Topotecan; Transfection; Tumor Cells, Cultured | 1996 |
Gemcitabine hydrochloride: combination of activity and tolerability. Proceedings of a symposium. Jerusalem, Israel, November 14, 1993.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasms | 1995 |
Gemcitabine: clinical and economic impact in inoperable non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Deoxycytidine; Etoposide; Gemcitabine; Germany; Humans; Ifosfamide; Lung Neoplasms; Neoplasm Staging | 1995 |
Gemcitabine in advanced breast cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Neoplasm Staging; Quality of Life; United States | 1995 |
2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).
Topics: 2-Chloroadenosine; Antimetabolites, Antineoplastic; Apoptosis; Biotin; Deoxyadenosines; Deoxycytidine; Deoxyuracil Nucleotides; Dexamethasone; DNA Damage; Drug Resistance; Gemcitabine; Glucocorticoids; Hematopoietic Stem Cells; Humans; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sensitivity and Specificity; Staining and Labeling; Steroids; Tumor Cells, Cultured | 1996 |
Treatment of metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 1996 |
Ab initio quantum mechanical and X-ray crystallographic studies of gemcitabine and 2'-deoxy cytosine.
Topics: Antimetabolites, Antineoplastic; Chemical Phenomena; Chemistry, Physical; Crystallography, X-Ray; Cytosine; Deoxycytidine; Gemcitabine; Models, Molecular | 1996 |
Gemcitabine for pancreatic cancer: how hard to look for clinical benefit? An American perspective.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Approval; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 1996 |
Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Monophosphate; DNA; DNA Ligases; DNA Primers; DNA-Directed DNA Polymerase; Exodeoxyribonucleases; Gemcitabine | 1996 |
Clinical trials referral resource. Clinical trials using gemcitabine.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytidine Deaminase; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Neoplasms; Nucleic Acid Synthesis Inhibitors; Nucleoside Deaminases | 1996 |
Docetaxel and gemcitabine released for cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Approval; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Taxoids; United States; United States Food and Drug Administration | 1996 |
Forced expression of cytidine deaminase confers resistance to cytosine arabinoside and gemcitabine.
Topics: 3T3 Cells; Animals; Antimetabolites, Antineoplastic; Cytarabine; Cytidine Deaminase; Deoxycytidine; Drug Resistance; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Humans; Mice | 1996 |
Activity of gemcitabine in platinum-resistant ovarian germ cell cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Germinoma; Humans; Ovarian Neoplasms; Platinum Compounds | 1996 |
Gemcitabine for lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Lung Neoplasms; Survival Rate | 1996 |
Gemcitabine: a case study for clinical benefit.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 1996 |
An estimate of the cost effectiveness of gemcitabine in stage IV non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Neoplasm Staging | 1996 |
Gemcitabine: we've reached the end of the beginning.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 1996 |
Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; Cytarabine; Daunorubicin; Deoxycytidine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Software; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1996 |
Comment: vinorelbine and gemcitabine--new antineoplastic drugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Vinblastine; Vinorelbine | 1996 |
Gemcitabine for treatment of pancreatic cancer.
Topics: Adenocarcinoma; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 1996 |
Gemcitabine concentration lower than cited in package insert.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Compounding; Drug Labeling; Gemcitabine; Humans | 1996 |
Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Models, Biological; Molecular Structure; Pancreatic Neoplasms; Transplantation, Heterologous; Treatment Outcome | 1996 |
Activity of gemcitabine in a human tumor cloning assay as a basis for clinical trials with gemcitabine. San Antonio Drug Development Team.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Ovarian Neoplasms; Tumor Stem Cell Assay | 1996 |
Seeking the nucleoside transporter.
Topics: Animals; Antimetabolites, Antineoplastic; Carrier Proteins; Cell Membrane; Cladribine; Cloning, Molecular; Cytarabine; Deoxycytidine; Erythrocytes; Gemcitabine; Glucose Transporter Type 1; Humans; Leukemia; Lymphoma; Membrane Proteins; Monosaccharide Transport Proteins; Nucleosides; Oocytes; Recombinant Proteins; Uridine; Vidarabine; Xenopus | 1997 |
Gemcitabine: safety profile unaffected by starting dose.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Kidney Function Tests; Liver Function Tests; Lung Neoplasms; Nausea; Pancreatic Neoplasms; Ribonucleotide Reductases; Vomiting | 1996 |
[Oncology--a common language, new perspectives. Lilly Oncology Global Medical Conference, Indianapolis, 1996].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bronchial Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Medical Oncology; Pancreatic Neoplasms; Urinary Bladder Neoplasms | 1996 |
Gemcitabine shows promise as combination agent in NSCLC.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Survival Rate | 1996 |
Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Treatment Outcome | 1997 |
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione; Humans; Lung Neoplasms; Neoplasm Proteins; Paclitaxel; Taxoids; Topotecan; Tumor Cells, Cultured | 1997 |
More is better but ... how is best: are milligrams over hours better than grams over minutes? The case of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms | 1997 |
The emerging role of gemcitabine in lung cancer: part I.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Ribonucleotide Reductases | 1997 |
In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Models, Theoretical; Ribonucleotide Reductases; Tumor Cells, Cultured | 1997 |
Cost-effectiveness of gemcitabine in stage IV non-small cell lung cancer: an estimate using the Population Health Model lung cancer module.
Topics: Antimetabolites, Antineoplastic; Canada; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Health Care Costs; Health Resources; Humans; Lung Neoplasms; Models, Economic; Neoplasm Staging; Ribonucleotide Reductases; Survival Rate | 1997 |
Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Palliative Care; Taxoids; Topoisomerase I Inhibitors | 1997 |
The emerging role of gemcitabine in lung cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Ribonucleotide Reductases | 1997 |
Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.
Topics: Antineoplastic Agents; Binding Sites; Cytarabine; Deoxycytidine; DNA Repair; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Leukemia; Tumor Cells, Cultured; Vidarabine | 1997 |
New drugs for the treatment of lung cancer. The Tokyo Cooperative Oncology Group.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Organoplatinum Compounds; Taxoids; Vinca Alkaloids | 1997 |
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Hypoxia; Lung Diseases; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Pulmonary Edema; Respiratory Distress Syndrome | 1997 |
PET 2-fluoro-2-deoxyglucose uptake in rat prostate adenocarcinoma during chemotherapy with gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Transport; Deoxycytidine; Deoxyglucose; DNA, Neoplasm; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Male; Neoplasm Transplantation; Prostatic Neoplasms; Radiopharmaceuticals; Rats; Ribonucleotide Reductases; Thymidine; Tomography, Emission-Computed; Tritium; Tumor Cells, Cultured | 1997 |
Delayed anemia and thrombocytopenia after treatment with gemcitabine.
Topics: Anemia; Antimetabolites, Antineoplastic; Bone Marrow; Carcinoma, Squamous Cell; Deoxycytidine; Erythropoiesis; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Thrombocytopenia; Time Factors | 1997 |
Biochemical characterization of the protein activity responsible for high molecular weight DNA fragmentation during drug-induced apoptosis.
Topics: Antineoplastic Agents; Aphidicolin; Apoptosis; Cell Fusion; Cell Line; Cysteine Endopeptidases; Deoxycytidine; DNA Fragmentation; DNA, Neoplasm; Electrophoresis, Gel, Pulsed-Field; Gemcitabine; Humans; In Vitro Techniques; Molecular Weight; Nucleosomes; Vidarabine | 1997 |
Weekly short infusions of gemcitabine are not associated with suppression of lymphatic activity in patients with solid tumors.
Topics: Antimetabolites, Antineoplastic; CD4-CD8 Ratio; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Killer Cells, Natural; Lymphocytes; Male; Neoplasms | 1997 |
Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model.
Topics: Animals; Apoptosis; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Administration Schedule; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Transplantation, Heterologous | 1997 |
New drugs for small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Vincristine | 1997 |
Characterisation of genotoxic properties of 2',2'-difluorodeoxycytidine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Division; Cell Line, Transformed; Cells, Cultured; Chromosome Aberrations; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Micronucleus Tests; Mutagens; Sister Chromatid Exchange | 1997 |
Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Tolerance; Edema; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Safety | 1997 |
Kinetics of mouse jejunum radiosensitization by 2',2'-difluorodeoxycytidine (gemcitabine) and its relationship with pharmacodynamics of DNA synthesis inhibition and cell cycle redistribution in crypt cells.
Topics: Animals; Cell Cycle; Deoxycytidine; DNA; Gemcitabine; Jejunum; Kinetics; Male; Mice; Mice, Inbred C3H; Radiation Tolerance; Radiation-Sensitizing Agents | 1997 |
Gemcitabine-induced hemolytic uremic syndrome: a case report.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney; Kidney Failure, Chronic; Lung Neoplasms; Male; Middle Aged | 1997 |
Analgesic effects of chemotherapy?
Topics: Analgesics; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Pain; Pancreatic Neoplasms | 1998 |
Clinical benefit as a primary efficacy endpoint.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 1998 |
Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Krukenberg Tumor; Liver Neoplasms; Peritoneal Neoplasms; Tomography, X-Ray Computed | 1998 |
Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured | 1998 |
Gemcitabine-associated autonomic neuropathy.
Topics: Antimetabolites, Antineoplastic; Autonomic Nervous System Diseases; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1998 |
The antiproliferative activity of DMDC is modulated by inhibition of cytidine deaminase.
Topics: Animals; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Growth Inhibitors; Humans; Male; Mice; Mice, Nude; Substrate Specificity; Tumor Cells, Cultured | 1998 |
High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'-methylidenecytidine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cytidine Deaminase; Deoxycytidine; Disease Susceptibility; Enzyme Inhibitors; Female; Gemcitabine; Humans; Kinetics; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1998 |
Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; Enzyme Activation; Female; Gemcitabine; Humans; Microscopy, Electron, Scanning; Ovarian Neoplasms; Protein Kinase C; Tumor Cells, Cultured | 1998 |
[Disseminated intravascular coagulation (DIG) with massive hyperfibrinolysis in metastatic uterine cancer. Observations on the effects on the coagulopathy of various treatments (a case report)].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Deoxycytidine; Disseminated Intravascular Coagulation; Endometrial Neoplasms; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Fibrinolysis; Gemcitabine; Humans; Middle Aged; Thrombolytic Therapy; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 1998 |
Gemcitabine 5'-triphosphate is a stoichiometric mechanism-based inhibitor of Lactobacillus leichmannii ribonucleoside triphosphate reductase: evidence for thiyl radical-mediated nucleotide radical formation.
Topics: Cytosine; Deoxyadenosines; Deoxycytidine; Electron Spin Resonance Spectroscopy; Enzyme Activation; Enzyme Inhibitors; Enzyme Stability; Fluorides; Free Radicals; Gemcitabine; Lactobacillus; Peptides; Protein Denaturation; Ribonucleotide Reductases; Spectrophotometry, Ultraviolet; Sulfhydryl Compounds; Vitamin B 12 | 1998 |
Antitumor effect of the nucleoside analogs 2-chlorodeoxyadenosine and 2',2'-difluorodeoxycytidine on human hepatoma HepG2 cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cladribine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Liver Neoplasms; Nucleosides; Tumor Cells, Cultured | 1998 |
Diffuse alveolar damage in a patient treated with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Pulmonary Alveoli; Radiography, Thoracic; Respiratory Insufficiency | 1998 |
An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Mice; Mice, Inbred ICR; Mice, SCID; Oligopeptides; Pancreatic Neoplasms; Transplantation, Heterologous | 1998 |
Unresectable pancreatic adenocarcinoma treated with palladium-103 implant and chemoradiation.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy, Needle; Brachytherapy; Deoxycytidine; Fatal Outcome; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Palladium; Pancreatic Neoplasms; Radioisotopes; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 1998 |
Detection of a new substrate-derived radical during inactivation of ribonucleotide reductase from Escherichia coli by gemcitabine 5'-diphosphate.
Topics: Chromatography, High Pressure Liquid; Cytidine Diphosphate; Deoxycytidine; Dithiothreitol; Electron Spin Resonance Spectroscopy; Enzyme Inhibitors; Free Radicals; Gemcitabine; Ribonucleotide Reductases; Spectrophotometry, Ultraviolet | 1998 |
Fatal pulmonary toxicity resulting from treatment with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Fatal Outcome; Gemcitabine; Humans; Infusions, Intravenous; Lung Diseases; Male | 1998 |
The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) combined with interferon in human renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Gemcitabine; Humans; Interferons; Kidney Neoplasms; Time Factors; Treatment Outcome; Tumor Cells, Cultured; Vinblastine | 1998 |
The efficacy of 2',2'-difluorodeoxycytidine (gemcitabine) and vinblastine combined with interferon in nude mice xenografts of human renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Division; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Interferons; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Remission Induction; Survival Analysis; Transplantation, Heterologous; Treatment Outcome; Tumor Cells, Cultured; Vinblastine | 1998 |
Similar changes were induced by Cladribine and by gemcitabine, in the deoxypyrimidine salvage, during short-term treatments.
Topics: Antimetabolites, Antineoplastic; Cell Line; Cladribine; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Deoxyuracil Nucleotides; Enzyme Inhibitors; Fluorodeoxyuridylate; Gemcitabine; Humans; In Vitro Techniques; Kinetics; Lymphocytes; Palatine Tonsil; Thymidine; Thymidine Kinase | 1998 |
Cross-resistance of the gemcitabine resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Division; Clone Cells; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured | 1998 |
Increased sensitivity to gemcitabine of P-gP and MRP overexpressing human non-small cell lung cancer cell lines.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Daunorubicin; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Gemcitabine; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Tumor Cells, Cultured | 1998 |
Induction of in vivo resistance against gemcitabine (dFdC, 2',2'-difluoro-deoxycytidine).
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line; Colonic Neoplasms; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Kinetics; Mice; Mice, Inbred BALB C; Thymidine Kinase; Tumor Cells, Cultured | 1998 |
Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Mice; Nucleoside Deaminases; Pancreatic Neoplasms; Thymidine Kinase; Transplantation, Heterologous | 1998 |
Differential effects of gemcitabine on nucleotide pools of 19 solid tumor cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Kinetics; Nucleotides; Ribonucleotides; Tumor Cells, Cultured | 1998 |
There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Eflornithine; Gemcitabine; Humans; Mitoguazone; Neoplasms; Research Design | 1998 |
Interactions of 2',2'-diflurodeoxycytidine (gemcitabine) with tumor necrosis factor alpha or its mutein VI in murine leukemias L1210 and P388.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Interactions; Gemcitabine; Leukemia L1210; Leukemia P388; Male; Mice; Tumor Necrosis Factor-alpha | 1998 |
Effective intrahepatic administration of gemcitabine after failure of doxorubicin in metastatic breast cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Treatment Failure | 1997 |
Effects of gemcitabine on renal function in patients with non-small cell lung cancer.
Topics: Adult; Aged; Albuminuria; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erythrocytes; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Renal Plasma Flow, Effective | 1998 |
Radiosensitization of mouse sarcoma cells by fludarabine (F-ara-A) or gemcitabine (dFdC), two nucleoside analogues, is not mediated by an increased induction or a repair inhibition of DNA double-strand breaks as measured by pulsed-field gel electrophoresi
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; DNA Damage; DNA Repair; DNA, Neoplasm; Electrophoresis, Gel, Pulsed-Field; Fibrosarcoma; Gemcitabine; Mice; Mice, Inbred C3H; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Vidarabine | 1998 |
Radiosensitizing potential of gemcitabine (2',2'-difluoro-2'-deoxycytidine) within the cell cycle in vitro.
Topics: Animals; Cell Cycle; Cell Line; Cell Survival; Combined Modality Therapy; Cricetinae; Cricetulus; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Radiation Dosage; Radiation-Sensitizing Agents; S Phase; Tumor Cells, Cultured | 1998 |
New prospects in the treatment of indolent lymphomas with purine analogues.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Pentostatin; Vidarabine | 1998 |
Veno-occlusive disease of the liver induced by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Budd-Chiari Syndrome; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hepatic Encephalopathy; Humans; Lung Neoplasms; Middle Aged | 1998 |
[New cytostatics in the therapy of non-small cell bronchial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 1998 |
Interaction of gallium nitrate with other inhibitors of ribonucleotide reductase: effects on the proliferation of human leukemic cells.
Topics: Antineoplastic Agents; Benzamidines; Cell Division; Deoxycytidine; Drug Synergism; Enzyme Inhibitors; Gallium; Gemcitabine; Humans; Hydroxamic Acids; Hydroxyurea; Oximes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Ribonucleotide Reductases; Tumor Cells, Cultured | 1998 |
Lung Cancer Experts' Symposium. Proceedings. Stresa, Italy, October 1997.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 1998 |
Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1998 |
Interaction of 2',2'-difluorodeoxycytidine (gemcitabine) and formycin B with the Na+-dependent and -independent nucleoside transporters of Ehrlich ascites tumor cells.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Ehrlich Tumor; Carrier Proteins; Deoxycytidine; Formycins; Gemcitabine; Male; Membrane Proteins; Mice; Nucleoside Transport Proteins; Sodium; Thioinosine; Uridine | 1998 |
Bcl-2 overexpression is associated with resistance to paclitaxel, but not gemcitabine, in multiple myeloma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Deoxycytidine; Drug Resistance; Gemcitabine; Humans; Multiple Myeloma; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Transport; Carrier Proteins; Cell Division; Cell Survival; Deoxycytidine; Dipyridamole; DNA, Complementary; Gemcitabine; HeLa Cells; Humans; K562 Cells; Kinetics; Membrane Proteins; Membrane Transport Proteins; Nucleoside Transport Proteins; Recombinant Proteins; Thioinosine; Transfection; Tumor Cells, Cultured | 1998 |
Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells.
Topics: 3T3 Cells; Animals; Antimetabolites; Antimetabolites, Antineoplastic; Azacitidine; Colony-Forming Units Assay; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; DNA, Complementary; Drug Resistance; Enzyme Inhibitors; Fibroblasts; Gemcitabine; Gene Transfer Techniques; Genetic Vectors; Humans; Mice; Phenotype; Retroviridae; Tetrahydrouridine | 1998 |
Cell cycle arrest in ovarian cancer cell lines does not depend on p53 status upon treatment with cytostatic drugs.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Gemcitabine after bone marrow transplantation for refractory juvenile granulosa cell tumor.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Deoxycytidine; Female; Gemcitabine; Granulosa Cell Tumor; Humans; Ovarian Neoplasms | 1998 |
Economic evaluation of gemcitabine single agent therapy compared with standard treatment in stage IIIB and IV non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Sweden; Treatment Outcome | 1998 |
Postconfluent multilayered cell line cultures for selective screening of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Nucleotides; Ovarian Neoplasms; Tumor Cells, Cultured | 1998 |
Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2',2'-difluoro-2'-deoxycytidine (Gemcitabine).
Topics: Antimetabolites, Antineoplastic; Cell Survival; Cobalt Radioisotopes; Colonic Neoplasms; Deoxycytidine; DNA Damage; DNA Fragmentation; DNA, Neoplasm; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Electrophoresis, Gel, Pulsed-Field; Gemcitabine; Humans; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1997 |
High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Apoptosis; Chelating Agents; Deoxycytidine; DNA Fragmentation; DNA, Neoplasm; Egtazic Acid; Enzyme Inhibitors; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Weight; Tumor Cells, Cultured; Vidarabine | 1995 |
Intratumor pharmacokinetics, flow resistance, and metabolism during gemcitabine infusion in ex vivo perfused human small cell lung cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lactic Acid; Lung Neoplasms; Mice; Mice, Nude; Oxygen Consumption | 1996 |
Synergistic interaction between cisplatin and gemcitabine in vitro.
Topics: Antineoplastic Agents; Cell Division; Cisplatin; Deoxycytidine; DNA; DNA Damage; Drug Synergism; Gemcitabine; Humans; Tumor Cells, Cultured | 1996 |
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1998 |
Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Colonic Neoplasms; Deoxycytidine; DNA Damage; DNA Fragmentation; DNA, Neoplasm; Floxuridine; Gemcitabine; HT29 Cells; Humans; Thymidylate Synthase | 1998 |
Cancer treatment in Sweden--costs of drugs, inpatient and outpatient care from 1985 to 1996 and cost effectiveness of new drugs.
Topics: Ambulatory Care; Androgen Antagonists; Antineoplastic Agents; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Filgrastim; Gemcitabine; Gonadotropin-Releasing Hormone; Granulocyte Colony-Stimulating Factor; Humans; Neoplasms; Paclitaxel; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Recombinant Proteins; Sweden | 1998 |
Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans | 1998 |
Lack of cross-resistance with gemcitabine and cytarabine in cladribine-resistant HL60 cells with elevated 5'-nucleotidase activity.
Topics: 5'-Nucleotidase; Adenosine Triphosphate; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Northern; Cladribine; Cytarabine; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; HL-60 Cells; Humans; RNA, Messenger | 1998 |
Palliative effect of gemcitabine in osteosarcoma resistant to standard chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Osteosarcoma; Palliative Care; Thyroid Neoplasms | 1998 |
Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Middle Aged; Pleural Neoplasms; Prednisolone; Ribonucleotide Reductases; Treatment Outcome | 1998 |
Enhancement of tumor radioresponse in vivo by gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Combined Modality Therapy; Deoxycytidine; DNA Replication; Dose-Response Relationship, Drug; Gemcitabine; Mice; Neoplasms, Experimental; Radiation-Sensitizing Agents | 1999 |
Gemcitabine--a major advance?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; DNA Replication; DNA, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Neoplasms; Pancreatic Neoplasms | 1998 |
Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cytarabine; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; DNA; Drug Resistance; Gemcitabine; Leukemia L1210; Mice; Nucleoside Deaminases; Polyphosphates; Rats; Rats, Inbred BN; Substrate Specificity; Thymidine Kinase; Tumor Cells, Cultured | 1999 |
Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Deoxycytosine Nucleotides; DNA Damage; Drug Synergism; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Ovarian Neoplasms; Tumor Cells, Cultured | 1999 |
Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Interactions; Female; Flow Cytometry; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone.
Topics: Antimetabolites, Antineoplastic; Antioxidants; Cell Survival; Deoxycytidine; Dexamethasone; Drug Interactions; Gemcitabine; Genes, p53; Glioma; Humans; In Vitro Techniques; Proto-Oncogene Proteins c-bcl-2; Transfection; Tumor Cells, Cultured | 1999 |
[3H]gemcitabine uptake by nucleoside transporters in a human head and neck squamous carcinoma cell line.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Carrier Proteins; Deoxycytidine; Drug Resistance; Formycins; Gemcitabine; Head and Neck Neoplasms; Humans; Membrane Proteins; Nucleoside Transport Proteins; Time Factors; Tritium; Tumor Cells, Cultured; Uridine | 1999 |
Increased sensitivity of hydroxyurea-resistant leukemic cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Division; Deoxycytidine; DNA, Neoplasm; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hydroxyurea; Leukemia, Lymphoid; Ribonucleotide Reductases; Tumor Cells, Cultured | 1999 |
Anal pruritus after cancer chemotherapy with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Dexamethasone; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Pruritus Ani | 1999 |
The effects of gemcitabine and TPA on PKC signaling in BG-1 human ovarian cancer cells.
Topics: Alkaline Phosphatase; Antimetabolites, Antineoplastic; Blotting, Western; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Isoenzymes; Mitogen-Activated Protein Kinase 1; Ovarian Neoplasms; Protein Kinase C; Subcellular Fractions; Tetradecanoylphorbol Acetate; Time Factors; Tumor Cells, Cultured | 1998 |
[Non-clinical studies of gemcitabine--the mode of action and antitumor activities].
Topics: Animals; Antimetabolites, Antineoplastic; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Tumor Cells, Cultured | 1999 |
[The intensification of the radiotherapeutic effect on HeLa cells by gemcitabine].
Topics: Cell Division; Cell Survival; Colony-Forming Units Assay; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Gemcitabine; HeLa Cells; Humans; Linear Models; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors | 1999 |
[Compassionate use of gemcitabine in advanced pancreatic cancer: a French multicentric study].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Quality of Life; Survival Analysis | 1999 |
Thrombotic microangiopathy as a complication of long-term therapy with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Creatinine; Deoxycytidine; Female; Gemcitabine; Haptoglobins; Hemoglobins; Hemolytic-Uremic Syndrome; Humans; Kidney; Male; Microcirculation; Pancreatic Neoplasms; Thrombosis | 1999 |
Additive action of gemcitabine (2',2'-difluorodeoxycytidine) and 2-chlorodeoxyadenosine on murine leukemias L1210 and P388.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Leukemia L1210; Leukemia P388; Male; Mice | 1999 |
The effect of 2'-2' difluorodeoxycytidine (dFdC, gemcitabine) on radiation-induced cell lethality in two human head and neck squamous carcinoma cell lines differing in intrinsic radiosensitivity.
Topics: Carcinoma, Squamous Cell; Cell Death; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Head and Neck Neoplasms; Humans; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 1999 |
Inhibition of [3H]thymidine incorporation into DNA of rat regenerating liver by 2',2'-difluorodeoxycytidine coupled to lactosaminated poly-L-lysine.
Topics: Amino Sugars; Animals; Antimetabolites, Antineoplastic; Asialoglycoprotein Receptor; Cell Line; Deoxycytidine; DNA; DNA, Neoplasm; Gemcitabine; Humans; Liver Regeneration; Male; Models, Biological; Nucleic Acid Synthesis Inhibitors; Polylysine; Rats; Rats, Wistar; Receptors, Cell Surface; Thymidine; Tritium; Tumor Cells, Cultured | 1999 |
Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Choroid Neoplasms; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Melanoma; Paclitaxel; Tumor Stem Cell Assay | 1999 |
Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report.
Topics: Adult; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Duodenal Neoplasms; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Pancreatic Neoplasms; Reticulocyte Count; Thrombocytopenia | 1999 |
An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Drugs, Investigational; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 1999 |
Impressive remission in a patient with locally advanced malignant pleural mesothelioma treated with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Deoxycytidine; Dexamethasone; Fever; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Nausea; Pleural Neoplasms; Remission Induction; Tomography | 1999 |
Effect of vesnarinone in combination with anti-cancer drugs on lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cell Division; Cisplatin; Coloring Agents; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Pyrazines; Quinolines; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1999 |
Introduction: the emerging roles of gemcitabine and MTA in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed | 1999 |
The Gynecologic Oncology Group experience in ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Decision Making; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Treatment Outcome | 1999 |
A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Confounding Factors, Epidemiologic; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Incidence; Male; Middle Aged; Retrospective Studies; Risk Factors; Treatment Outcome; United States | 1999 |
Induction of growth inhibition and apoptosis in pancreatic cancer cells by auristatin-PE and gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Cycle; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Deoxycytidine; Flow Cytometry; Gemcitabine; Gene Expression; Humans; Oligopeptides; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Effect of gemcitabine on the tolerance of the lung to single-dose irradiation in C3H mice.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Radiation; Gemcitabine; Lung; Male; Mice; Mice, Inbred C3H; Radiation Tolerance | 1999 |
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Deoxycytidine; DNA; DNA Adducts; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorometry; Gemcitabine; Humans; Intracellular Fluid; Lung Neoplasms; Mice; Ovarian Neoplasms; Platinum; RNA; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Diagnosis and treatment of leptomeningeal metastases in a patient with renal carcinoma responding to 5-fluorouracil and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arachnoid; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Meningeal Neoplasms; Middle Aged | 1999 |
Commentary on "Gemcitabine: single-agent and combination therapy in non-small cell lung cancer". The Oncologist 1999;4:241-251.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Practice Guidelines as Topic; Research; Treatment Outcome | 1999 |
Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bryostatins; Cell Cycle Proteins; Cell Differentiation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cytarabine; Deoxycytidine; Drug Interactions; Enzyme Activation; Gemcitabine; Humans; Lactones; Leukemia; Macrolides; Microtubule-Associated Proteins; Mitogens; Protein Kinase C; Tetradecanoylphorbol Acetate; Tumor Suppressor Proteins; U937 Cells | 1999 |
Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Deoxycytidine; DNA; Gemcitabine; Humans; Leukemia; Organoplatinum Compounds; Oxaliplatin; Tumor Cells, Cultured | 1999 |
Gemcitabine: a real major advance?
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans | 1999 |
Effect of loss of DNA mismatch repair on development of topotecan-, gemcitabine-, and paclitaxel-resistant variants after exposure to cisplatin.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; DNA Repair; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Paclitaxel; Topotecan; Tumor Cells, Cultured | 1999 |
Maximizing therapeutic gain with gemcitabine and fractionated radiation.
Topics: Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Gemcitabine; Intestinal Mucosa; Jejunum; Mice; Mice, Inbred C3H; Radiation-Sensitizing Agents; Sarcoma, Experimental; Specific Pathogen-Free Organisms | 1999 |
Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562.
Topics: Antineoplastic Agents; Cladribine; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; K562 Cells; Leukemia, Erythroblastic, Acute; Phenotype; Vidarabine | 1999 |
Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Death; Cell Division; Colonic Neoplasms; Deoxycytidine; DNA Replication; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; HT29 Cells; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pemetrexed | 1999 |
Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterization of the human enzyme.
Topics: Amino Acid Sequence; Antimetabolites, Antineoplastic; Base Sequence; Blotting, Northern; Chromosome Mapping; Chromosomes, Human, Pair 1; Cloning, Molecular; Cytarabine; Deoxycytidine; DNA, Complementary; Gemcitabine; Humans; Molecular Sequence Data; Nucleoside-Phosphate Kinase; Phosphorylation; Recombinant Proteins; Sequence Homology, Amino Acid; Subcellular Fractions | 1999 |
Gemcitabine--a new agent in the treatment of non-small cell lung cancer. A commentary.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Quality of Life | 1999 |
Increased levels of vascular endothelial growth factor in bronchoalveolar lavage of patients with bronchial carcinoma effect of tumour activity and oxidative stress due to radio-chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Albumins; Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Endothelial Growth Factors; Epidermal Growth Factor; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphokines; Male; Middle Aged; Neoplasm Proteins; Neovascularization, Pathologic; Oxidative Stress; Proteins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vindesine | 1999 |
Selective cell kill of the combination of gemcitabine and cisplatin in multilayered postconfluent tumor cell cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Tumor Cells, Cultured | 1999 |
In vitro study of the combination gemcitabine + fludarabine on freshly isolated chronic lymphocytic leukemia cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Leukemic; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Neoplastic Stem Cells; Proto-Oncogene Proteins c-bcl-2; Vidarabine | 1999 |
Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line.
Topics: Antimetabolites, Antineoplastic; Deoxyadenine Nucleotides; Deoxycytidine; Deoxycytosine Nucleotides; Drug Resistance, Neoplasm; Gemcitabine; Humans; KB Cells; Ribonucleotide Reductases | 1999 |
Pre-clinical evaluation of new antineoplastic agents in NSCLC cell lines: evidence of histological subtype-dependent cytotoxicity.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Cisplatin; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Sensitivity and Specificity; Taxoids; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured | 1999 |
Toxicology and pharmacokinetics of intravesical gemcitabine: a preclinical study in dogs.
Topics: Absorption; Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Dogs; Drug Evaluation, Preclinical; Gemcitabine; Humans; Infusions, Intravenous; Urinary Bladder | 1999 |
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Immunohistochemistry; Lung Neoplasms; Topotecan; Tumor Cells, Cultured | 1999 |
Scheduling of gemcitabine and cisplatin in Lewis lung tumour bearing mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Lung Neoplasms; Mice; Neoplasm Transplantation | 1999 |
Vancomycin-induced thrombocytopenia.
Topics: Aged; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Bacteremia; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Platelet Count; Staphylococcal Infections; Thrombocytopenia; Vancomycin | 1999 |
Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gemcitabine; Heart; Humans; Liver Neoplasms; Lung; Male; Pancreatic Neoplasms; Respiratory Distress Syndrome; Ventricular Fibrillation | 1999 |
Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
Topics: 3T3 Cells; Adenocarcinoma; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Division; Cisplatin; Deoxycytidine; Enzyme Inhibitors; Farnesyltranstransferase; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Structure; Oligopeptides; Paclitaxel; rap1 GTP-Binding Proteins; ras Proteins; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
[In vitro evaluation of potentially effective gemcitabine combination therapy for exocrine pancreatic carcinoma].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Division; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Cells, Cultured | 1999 |
Gemcitabine salvage chemotherapy for patients with gynecologic malignancies of the ovary, fallopian tube, and peritoneum.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Hematologic Diseases; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; United States | 1999 |
[Contribution of gemcitabine in the treatment of advanced pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Multicenter Studies as Topic; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 1999 |
Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bronchopneumonia; Deoxycytidine; Fatal Outcome; Gemcitabine; Glomerulonephritis, Membranoproliferative; Humans; Male; Mesothelioma; Peritoneal Neoplasms; Vinblastine; Vinorelbine | 1999 |
Haemolytic uraemic syndrome after gemcitabine treatment for pancreatic carcinoma.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Pancreatic Neoplasms | 1999 |
Comparison of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)cytosine with gemcitabine in its antitumor activity.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Cytarabine; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Stomach Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Gemcitabine--a novel immunosuppressive agent--prevents rejection in a rat cardiac transplantation model.
Topics: Animals; Deoxycytidine; Gemcitabine; Graft Rejection; Heart Transplantation; Immunosuppressive Agents; Lymphocyte Activation; Male; Phytohemagglutinins; Rats; Rats, Inbred BN; Rats, Inbred Lew; T-Lymphocytes | 1999 |
Severe non-haematological toxicity after treatment with gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases; Male; Middle Aged; Neoplasms; Retrospective Studies; Tomography, X-Ray Computed; Ventricular Dysfunction | 1999 |
Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Bryostatins; Deoxycytidine; DNA Mutational Analysis; Ethers, Cyclic; Gemcitabine; Genes, p53; Genes, ras; Humans; Karyotyping; Lactones; Macrolides; Male; Mice; Mice, SCID; Neoplasm Transplantation; Oligopeptides; Pancreatic Neoplasms; Tumor Cells, Cultured | 1999 |
Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters.
Topics: Animals; Antimetabolites, Antineoplastic; Biological Transport; Carrier Proteins; Cell Membrane; Deoxycytidine; Electrophysiology; Gemcitabine; Membrane Proteins; Neoplasms; Nucleosides; Oocytes; Recombinant Proteins; Sodium Channels; Uridine; Xenopus laevis | 1999 |
Identification of a gemcitabine-warfarin interaction.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Interactions; Gemcitabine; Half-Life; Humans; Liver; Male; Middle Aged; Warfarin | 1999 |
Gemcitabine toxicity.
Topics: Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Immunosuppressive Agents; Male; Pulmonary Alveoli; Respiratory Distress Syndrome; Ribonucleotide Reductases | 1999 |
Gemcitabine and cisplatin: second-line chemotherapy for malignant mesothelioma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome | 1999 |
Gemcitabine is active in relapsed Hodgkin's disease.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Deoxycytidine; Doxorubicin; Gemcitabine; Hodgkin Disease; Humans; Male; Mechlorethamine; Neoplasm Recurrence, Local; Prednisone; Procarbazine; Tomography, X-Ray Computed; Vinblastine; Vincristine | 1999 |
Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Taxoids; Tumor Cells, Cultured | 1999 |
Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy, Needle; Cholangiocarcinoma; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney Failure, Chronic; Kidney Glomerulus; Male; Middle Aged; Pancreatic Neoplasms; Renal Dialysis; Ribonucleotide Reductases | 1999 |
A brief historical review of the development of chemotherapy for the treatment of advanced non-small cell lung cancer: why we should look beyond platinum.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy; Gemcitabine; History, 20th Century; Humans; Irinotecan; Lung Neoplasms; Medical Oncology; Paclitaxel; Vinblastine; Vinorelbine | 1999 |
Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Germany; Germinoma; Humans; Male; Testicular Neoplasms; Treatment Failure | 1999 |
Acute myocardial infarction following gemcitabine therapy--a case report.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Electrocardiography; Gemcitabine; Humans; Male; Middle Aged; Myocardial Infarction; Pancreatic Neoplasms | 1999 |
Differential effects of cladribine and gemcitabine on erythroid and granulocytic progenitors from patients with chronic myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Bone Marrow Cells; Bone Marrow Purging; Cells, Cultured; Cladribine; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplastic Stem Cells | 1999 |
Elevation of urinary porphyrin levels following gemcitabine administration.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Male; Porphyrins | 1999 |
Interaction between gemcitabine and mitomycin-C in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mitomycin; Tumor Cells, Cultured | 2000 |
Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Radiodermatitis | 2000 |
Side effects of chemotherapy. Case 2. Radiation recall reaction induced by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Radiodermatitis | 2000 |
Side effects of chemotherapy. Case 3. Acute interstitial pneumonitis related to gemcitabine.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged | 2000 |
Drug-induced apoptosis in lung cnacer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Caspase 8; Caspase 9; Caspases; Cisplatin; Deoxycytidine; Fas Ligand Protein; fas Receptor; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Lung Neoplasms; Membrane Glycoproteins; Paclitaxel; Recombinant Proteins; Signal Transduction; Topotecan; Transfection; Tumor Cells, Cultured | 2000 |
Histology and sensitivity to anticancer drugs of two human non-small cell lung carcinomas implanted in the pleural cavity of nude mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Doxorubicin; Ellipticines; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Pleural Neoplasms; Topotecan; Transplantation, Heterologous; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospitalization; Humans; Incidence; Liver; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy Dosage; Retrospective Studies; Stents | 2000 |
Gemcitabine and the blood brain barrier.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 1999 |
Gemcitabine-containing regimens in non-small cell lung cancer: are these standard therapies or not?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2000 |
Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Leukemia; Lung Neoplasms; Mice; Ovarian Neoplasms; Rats; Ribonucleotide Reductases; Ribonucleotides; Tumor Cells, Cultured | 2000 |
Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer.
Topics: Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prospective Studies; Sex Factors; Survival Analysis; Time Factors | 2000 |
Expression of ERCC1 antisense RNA abrogates gemicitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair.
Topics: Antineoplastic Agents; Base Pair Mismatch; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxycytidine; Deoxycytosine Nucleotides; DNA; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Endonucleases; Gemcitabine; Gene Expression; Humans; Mutation; Proteins; RNA, Antisense; Tumor Cells, Cultured | 2000 |
Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome.
Topics: Antigens, Polyomavirus Transforming; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Breast Neoplasms; Cloning, Molecular; Cytarabine; Deoxycytidine; DNA Polymerase I; DNA Polymerase III; DNA, Neoplasm; Gemcitabine; Humans; Replicon; Tumor Cells, Cultured | 2000 |
Time- and dose-limiting erysipeloid rash confined to areas of lymphedema following treatment with gemcitabine--a report of three cases.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Eruptions; Erysipeloid; Exanthema; Female; Gemcitabine; Humans; Lymphedema; Middle Aged; Neoplasms | 2000 |
Virulizin-2gamma, a novel immunotherapeutic agent, in treatment of human pancreatic cancer xenografts.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; Bile; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; Immunologic Factors; In Vitro Techniques; Mice; Mice, Nude; Pancreatic Neoplasms; Spleen; T-Lymphocytes; Tissue Extracts | 2000 |
The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
Topics: Animals; Antineoplastic Agents; Body Weight; Cytosine; Deoxycytidine; Dioxolanes; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
In vitro sensitivity of normal human mesothelial and malignant mesothelioma cell lines to four new chemotherapeutic agents.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Transformed; Cell Survival; Comet Assay; Deoxycytidine; DNA Damage; Docetaxel; Epithelial Cells; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2000 |
The role of p53 in gemcitabine-mediated cytotoxicity and radiosensitization.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Deoxycytidine; Gemcitabine; Humans; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; beta-Galactosidase; Cell Cycle; Cell Survival; Cisplatin; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Gemcitabine; Genes, p53; Genetic Vectors; Humans; Recombinant Fusion Proteins; Transfection; Tumor Cells, Cultured | 2000 |
Role of p53 in cellular response to anticancer nucleoside analog-induced DNA damage.
Topics: Antineoplastic Agents; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Deoxycytidine; DNA Damage; Gemcitabine; Thymidine; Tumor Suppressor Protein p53; Vidarabine | 2000 |
Purtscher retinopathy and necrotizing vasculitis with gemcitabine therapy.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fingers; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Necrosis; Retinal Diseases; Skin Diseases, Vascular; Vasculitis | 2000 |
Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cetuximab; Deoxycytidine; Endothelial Growth Factors; Epidermal Growth Factor; ErbB Receptors; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines.
Topics: Antineoplastic Agents; Cell Cycle; Cisplatin; Deoxycytidine; DNA; Dose-Response Relationship, Drug; Drug Interactions; Drug Synergism; Gemcitabine; Humans; Thyroid Neoplasms; Time Factors; Tumor Cells, Cultured | 2000 |
Severe acute lung injury induced by gemcitabine.
Topics: Acute Disease; Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Lung; Lung Injury; Middle Aged; Pancreatic Neoplasms; Pulmonary Edema; Severity of Illness Index | 2000 |
Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2000 |
Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine).
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Gemcitabine; Head and Neck Neoplasms; Lip; Mice; Mice, Inbred C3H; Mouth Mucosa; Radiation Tolerance; Radiation-Sensitizing Agents; Weight Loss | 2000 |
Solitary cutaneous metastasis on the buttock: a disclosing sign of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Buttocks; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Skin Neoplasms | 2000 |
Gemcitabine-induced atrial fibrillation: a hitherto unreported manifestation of drug toxicity.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Atrial Fibrillation; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2000 |
Successful modulation of high-dose cytosine arabinoside metabolism in acute myeloid leukaemia by haematopoietic growth factors: no effect of ribonucleotide reductase inhibitors fludarabine and gemcitabine.
Topics: Arabinofuranosylcytosine Triphosphate; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Administration Schedule; Enzyme Inhibitors; Gemcitabine; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Ribonucleotide Reductases; Vidarabine | 2000 |
Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Deoxycytidine; Down-Regulation; Endothelium; ErbB Receptors; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2000 |
In vitro synergistic effects of vinflunine, a novel fluorinated vinca alkaloid, in combination with other anticancer drugs.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Etoposide; Fluorouracil; Gemcitabine; Humans; Mitomycin; Models, Chemical; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Cell Line; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Interleukin-6; Irinotecan; Mesothelioma | 2000 |
The degradation of the antitumor agent gemcitabine hydrochloride in an acidic aqueous solution at pH 3.2 and identification of degradation products.
Topics: Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Hydrogen-Ion Concentration; Kinetics; Magnetic Resonance Spectroscopy; Mass Spectrometry; Solutions; Spectrophotometry, Ultraviolet | 2000 |
Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Chromatography, Affinity; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pancreatic Neoplasms; Phenylalanine; Thiophenes; Time Factors; Tumor Cells, Cultured | 2000 |
The interaction of gemcitabine and cytarabine on murine leukemias L1210 or P388 and on human normal and leukemic cell growth in vitro.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Leukemia, Experimental; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mice; Mice, Inbred Strains; Stem Cells; Tumor Cells, Cultured | 2000 |
Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Blood Cell Count; Blood Platelets; Bone Marrow; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neutropenia; Neutrophils; Phenylenediamines; Random Allocation; Stem Cells; Time Factors | 2000 |
Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Ovarian Neoplasms | 1999 |
Quality of life and cisplatin-gemcitabine chemotherapy.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Quality of Life | 2000 |
Favorable outcome of gemcitabine-induced respiratory distress syndrome.
Topics: Aged; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Lung Neoplasms; Prognosis; Respiratory Distress Syndrome; Steroids; Tomography, X-Ray Computed | 2000 |
[Splenic vascular occlusion in the course of pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Arterial Occlusive Diseases; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Infarction; Middle Aged; Pancreatic Neoplasms; Spleen; Tomography, X-Ray Computed | 2000 |
Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms | 2000 |
Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Colonic Neoplasms; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Mice; Mice, Nude; Mitomycin; Neoplasms, Experimental; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2000 |
Schedule dependent toxicity and efficacy of combined gemcitabine/paclitaxel treatment in mouse adenocarcinoma.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Mammary Neoplasms, Experimental; Mice; Mice, Inbred Strains; Paclitaxel; Statistics, Nonparametric | 2000 |
Squamous cell carcinoma of the pancreas with cystic degeneration.
Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Cell; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Jaundice; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pancreatic Cyst; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2000 |
Gemcitabine-induced severe extremity edema with muscle contractures and subsequent prevention with prednisone.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Contracture; Deoxycytidine; Drug Interactions; Edema; Gemcitabine; Glucocorticoids; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prednisone; Ribonucleotide Reductases | 2000 |
Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cell Survival; Deoxycytidine; DNA, Neoplasm; Gemcitabine; Humans; Kinetics; Lung Neoplasms; Mice; Paclitaxel; RNA, Neoplasm; Tumor Cells, Cultured | 2000 |
Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antiviral Agents; Arabinonucleosides; Bromodeoxyuridine; Catalysis; Cell Division; Cell Nucleus; Cladribine; Cytarabine; Deoxycytidine; Drosophila melanogaster; Gemcitabine; Humans; Inhibitory Concentration 50; Kinetics; Osteosarcoma; Pancreatic Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Promoter Regions, Genetic; Retroviridae; Substrate Specificity; Thymidine; Thymidine Kinase; Transduction, Genetic; Tumor Cells, Cultured | 2000 |
Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in Xenopus laevis oocytes.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antiviral Agents; Carrier Proteins; Cytidine; Deoxycytidine; Electric Conductivity; Gemcitabine; Gene Expression; Humans; Membrane Potentials; Membrane Proteins; Nucleoside Transport Proteins; Nucleosides; Oocytes; Sodium; Substrate Specificity; Uridine; Vidarabine; Xenopus laevis | 2000 |
Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs.
Topics: Antineoplastic Agents, Phytogenic; Cell Division; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drugs, Investigational; Female; Flow Cytometry; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured | 2000 |
Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Death; Deoxycytidine; Gemcitabine; Humans; In Situ Nick-End Labeling; Lung Neoplasms; NF-kappa B; Tumor Cells, Cultured | 2000 |
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
Topics: Abdominal Pain; Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Catheters, Indwelling; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Floxuridine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Urinary Tract Infections | 2000 |
Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells.
Topics: Adenocarcinoma; Androstadienes; Antimetabolites, Antineoplastic; Apoptosis; Chromones; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Humans; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured; Wortmannin | 2000 |
Pre-clinical evaluation of the activity of gemcitabine as a basis for regional chemotherapy of pancreatic and colorectal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Division; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kinetics; Liver Neoplasms; Male; Middle Aged; Neoplastic Stem Cells; Pancreatic Neoplasms; Tumor Cells, Cultured | 2000 |
Induction of apoptosis using 2',2' difluorodeoxycytidine (gemcitabine) in combination with antimetabolites or anthracyclines on malignant lymphatic and myeloid cells. Antagonism or synergism depends on incubation schedule and origin of neoplastic cells.
Topics: Anthracyclines; Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; HL-60 Cells; Humans; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic System; Lymphoma; Myeloid Cells | 2000 |
[A case of docetaxel-resistant lung cancer effectively treated with chemotherapy of gemcitabine and vinorelbine].
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2000 |
Effect of nucleoside analogues and oligonucleotides on hydrolysis of liposomal phospholipids.
Topics: Anions; Antimetabolites, Antineoplastic; Buffers; Deoxycytidine; Gemcitabine; Hydrogen-Ion Concentration; Hydrolysis; Lipid Bilayers; Liposomes; Lysophospholipids; Nucleosides; Oligonucleotides | 2000 |
Distal ischemic changes related to combination chemotherapy with cisplatin and gemcitabine: description of four cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Ischemia; Lung Neoplasms; Male; Middle Aged; Peripheral Vascular Diseases | 2000 |
Cytotoxic activity of 2',2'-difluorodeoxycytidine (gemcitabine) in poorly differentiated thyroid carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Cell Differentiation; Cell Division; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Mutation; Thyroid Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carrier Proteins; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transport Proteins; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; Purine Nucleosides; Quinazolines; Thiophenes; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2000 |
The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine.
Topics: Adenosine Triphosphate; Apoptosis; Bromodeoxyuridine; Cell Cycle; Deoxyadenine Nucleotides; Deoxycytidine; Gemcitabine; Glioblastoma; Humans; Nuclear Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2000 |
[Severe ischemic myopathy localized in an irradiated area following gemcitabine therapy].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Ischemia; Lung Neoplasms; Male; Middle Aged; Muscular Diseases; Pancreatic Neoplasms; Radiotherapy | 2000 |
Influence of gemcitabine (2',2'-difluoro-deoxycytidine) and 2-chlorodeoxyadenosine on growth of normal and leukemic cells in vitro.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Cell Division; Cladribine; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Stem Cells | 2000 |
Schedule-dependent pharmacodynamic effects of gemcitabine and cisplatin in mice bearing Lewis lung murine non-small cell lung tumours.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Carcinoma, Lewis Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Kidney; Mice; Mice, Inbred C57BL | 2000 |
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Pancreatic Neoplasms | 2000 |
Rapid reduction of platelet numbers in thrombocytosis.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Platelet Count; Plateletpheresis; Thrombocytosis; Time Factors | 2000 |
Resolution of psoriatic skin lesions after chemotherapy with gemcitabine and vinorelbine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dermatologic Agents; Gemcitabine; Humans; Lung Neoplasms; Male; Psoriasis; Vinblastine; Vincristine; Vinorelbine | 2000 |
Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support.
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lymphatic Metastasis; Paclitaxel; Pulmonary Edema; Radiography; Taxoids | 2000 |
Chemotherapy with gemcitabine in patients with advanced gallbladder carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2000 |
Human cytosolic 5'-nucleotidase I: characterization and role in nucleoside analog resistance.
Topics: 5'-Nucleotidase; Amino Acid Sequence; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Baculoviridae; Blotting, Northern; Blotting, Western; Cell Line; Cell Survival; Cladribine; Cloning, Molecular; Cytosol; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance; Gemcitabine; Humans; Inhibitory Concentration 50; Insecta; Jurkat Cells; Kinetics; Molecular Sequence Data; Muscle, Skeletal; Myocardium; Phosphorylation; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Substrate Specificity; Tissue Distribution; Transfection | 2001 |
The role of laparoscopy in second-look evaluations for ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Injections, Intravenous; Laparoscopy; Middle Aged; Mitoxantrone; Ovarian Neoplasms; Paclitaxel; Reoperation; Retrospective Studies | 2001 |
Effects of gemcitabine on cell proliferation and apoptosis in non-small-cell lung cancer (NSCLC) cell lines.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Deoxycytidine; DNA Fragmentation; fas Receptor; Gemcitabine; Humans; Lung Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |
Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Division; Cell Survival; CHO Cells; Cisplatin; Cricetinae; Cytarabine; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Genes, bcl-2; Humans; In Situ Nick-End Labeling; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Transfection; Tumor Cells, Cultured | 2001 |
A fatal case of cholestatic liver failure probably related to gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cholestasis, Intrahepatic; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Failure; Lung Neoplasms; Male; Multiple Organ Failure | 2000 |
The ex vivo effect of high concentrations of doxorubicin on recurrent ovarian carcinoma.
Topics: Adenosine Triphosphate; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Tumor Cells, Cultured | 2000 |
Intravenous cereport (RMP-7) enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain.
Topics: Animals; Antineoplastic Agents; Autoradiography; Blood-Brain Barrier; Bradykinin; Brain; Brain Neoplasms; Carboplatin; Carmustine; Deoxycytidine; Gemcitabine; Male; Rats; Rats, Inbred F344; Vinblastine; Vinorelbine | 2000 |
Derivation and initial characterization of a mouse mammary tumor cell line carrying the polyomavirus middle T antigen: utility in the development of novel cancer therapeutics.
Topics: Adenoviridae; Alkyl and Aryl Transferases; Animals; Antigens, Polyomavirus Transforming; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Western; Bridged-Ring Compounds; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Farnesyltranstransferase; Female; Gemcitabine; Gene Transfer Techniques; Genes, p53; Mammary Neoplasms, Animal; Mice; Mice, Transgenic; Nucleic Acid Synthesis Inhibitors; Paclitaxel; Phosphoric Monoester Hydrolases; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sequence Analysis, DNA; Taxoids; Time Factors; Transduction, Genetic; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2000 |
Chemotherapy triggers apoptosis in a caspase-8-dependent and mitochondria-controlled manner in the non-small cell lung cancer cell line NCI-H460.
Topics: Adaptor Proteins, Signal Transducing; Amino Acid Chloromethyl Ketones; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cisplatin; Cytochrome c Group; Cytosol; Deoxycytidine; DNA, Complementary; Fas-Associated Death Domain Protein; Gemcitabine; Genes, Dominant; Humans; Inhibitory Concentration 50; Jurkat Cells; Lung Neoplasms; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Spectrometry, Fluorescence; Topotecan; Transfection; Tumor Cells, Cultured | 2000 |
Fatal pulmonary veno-occlusive disease possibly related to gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Dyspnea; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pulmonary Veno-Occlusive Disease | 2001 |
Preclinical in vivo antitumor efficacy of nedaplatin with gemcitabine against human lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Tumor Cells, Cultured | 2001 |
Gemcitabine and cisplatin for advanced, metastatic bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Metastasis; Urinary Bladder Neoplasms; Vinblastine | 2001 |
[Refractory non-small-cell lung cancer responding to combination chemotherapy with docetaxel, gemcitabine and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Taxoids | 2001 |
[Experience with chemotherapy for advanced pancreatic carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2000 |
Radiation myositis: the possible role of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Buttocks; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Myositis; Pain; Radiotherapy; Tomography, X-Ray Computed | 2000 |
S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine.
Topics: Alkaloids; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Leukemia, Myeloid, Acute; S Phase; Staurosporine; Tumor Cells, Cultured | 2001 |
The clinical implications of gemcitabine radiosensitization.
Topics: Apoptosis; Caspases; Cell Survival; Cobalt Radioisotopes; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Radiation-Sensitizing Agents | 2001 |
The role of apoptosis in 2',2'-difluoro-2'-deoxycytidine (gemcitabine)-mediated radiosensitization.
Topics: Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cell Survival; Cobalt Radioisotopes; Colonic Neoplasms; Coumarins; Deoxycytidine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Radiation; Electrophoresis, Gel, Pulsed-Field; Enzyme Activation; Gemcitabine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Oligopeptides; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2001 |
Effects of gemcitabine on cisplatin-induced nephrotoxicity in rats: schedule-dependent study.
Topics: Animals; Antineoplastic Agents; Blood Urea Nitrogen; Cisplatin; Creatinine; Deoxycytidine; Drug Interactions; Enzyme Inhibitors; Gemcitabine; Glutathione; Kidney; Lipid Peroxidation; Male; Platinum; Rats; Rats, Wistar | 2001 |
End-joining deficiency and radiosensitization induced by gemcitabine.
Topics: Animals; Antigens, Nuclear; Cell Cycle; Cell Survival; CHO Cells; Chromosomes, Artificial, Yeast; Cricetinae; Deoxycytidine; Deoxyribonucleotides; DNA; DNA Damage; DNA Helicases; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; Gemcitabine; Humans; Ku Autoantigen; Mutation; Nuclear Proteins; Protein Serine-Threonine Kinases; Radiation Tolerance; Radiation-Sensitizing Agents; Transfection | 2001 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2001 |
2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; Chromosome Breakage; Cyclin B; Cyclin B1; Cytarabine; Deoxycytidine; DNA, Neoplasm; G2 Phase; Gemcitabine; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Phosphorylation; RNA; Tumor Cells, Cultured | 2001 |
[A case of primary malignant hemangiopericytoma of the lung with marked response to combination chemotherapy with cisplatin, ifosfamide and gemcitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Hemangiopericytoma; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged | 2001 |
Latent hematopoietic stem cell toxicity associated with protracted drug administration.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzamides; Bone Marrow; Colony-Forming Units Assay; Crosses, Genetic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematopoiesis; Hematopoietic Stem Cells; Injections, Intraperitoneal; Male; Melphalan; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Phenylenediamines; Time Factors | 2001 |
Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition.
Topics: Apoptosis; Chromones; Deoxycytidine; Enzyme Inhibitors; Flavonoids; Gemcitabine; Humans; Morpholines; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Receptor Protein-Tyrosine Kinases; Tumor Cells, Cultured | 2001 |
Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Deoxycytidine; Deoxycytidine Kinase; Dexamethasone; Drug Interactions; Drug Resistance, Multiple; Gemcitabine; Humans; Hydrocortisone; Tumor Cells, Cultured; Verapamil | 2001 |
Unexpected severe myelotoxicity of gemcitabine in pretreated breast cancer patients.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Hematologic Tests; Humans; Male; Middle Aged; Myeloid Cells | 2001 |
Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Bone Marrow; Deoxycytidine; Disease-Free Survival; Drug Evaluation; Gemcitabine; Hodgkin Disease; Humans; Infusions, Intravenous; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome | 2001 |
Excellent response to gemcitabine in a massively pre-treated woman with extensive cutaneous involvement after recurrence of breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms | 2001 |
Gemcitabine-associated posterior reversible encephalopathy syndrome: MR imaging and MR spectroscopy findings.
Topics: Antimetabolites, Antineoplastic; Brain; Brain Injuries; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Middle Aged; Syndrome | 2001 |
Treatment of progressive metastatic glomus jugulare tumor (paraganglioma) with gemcitabine.
Topics: Adolescent; Antimetabolites, Antineoplastic; Brain Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Paraganglioma; Tomography, X-Ray Computed | 2000 |
Cotton-wool spots associated with pancreatic carcinoma.
Topics: Adrenal Gland Neoplasms; Biomarkers, Tumor; Bone Neoplasms; Deoxycytidine; Eye Neoplasms; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Vision Disorders | 2001 |
Gemcitabine as single agent therapy in advanced non small cell lung cancer and quality of life in the elderly.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Quality of Life | 2001 |
Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Ascitic Fluid; Chromatography, High Pressure Liquid; Deoxycytidine; Fluorouracil; Gemcitabine; Hypertonic Solutions; Hypotonic Solutions; Infusions, Parenteral; Isotonic Solutions; Male; Molecular Weight; Pharmaceutical Vehicles; Random Allocation; Rats | 2001 |
A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Mucous Membrane; Neutropenia; Thrombocytopenia; Treatment Outcome | 2001 |
Collateral sensitivity to gemcitabine (2',2'-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Carcinoma, Small Cell; Cell Survival; Cytarabine; Cytidine Deaminase; Daunorubicin; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Guanosine Triphosphate; Humans; Lung Neoplasms; Nucleoside Deaminases; Teniposide; Thymidine Kinase; Tumor Cells, Cultured; Uridine Triphosphate | 2001 |
Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Survival Rate; Urinary Bladder Neoplasms | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Gemcitabine demonstrates in vitro activity against human B-cell chronic lymphocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Deoxycytidine; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53 | 2001 |
Neoadjuvant chemoradiation treatment of locally advanced adenocarcinoma of the duodenum.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Duodenal Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Preoperative Care; Radiotherapy, Adjuvant; Tomography, X-Ray Computed; Treatment Outcome | 2000 |
[Efficacy of gemcitabine in the gallbladder cancer. Initial experience in 4 cases].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Tomography, X-Ray Computed; Treatment Outcome | 2000 |
Intestinal permeability in patients with chemotherapy-induced stomatitis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Digestive System Neoplasms; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Intestinal Absorption; Intestinal Mucosa; Lactulose; Leucovorin; Male; Mannitol; Middle Aged; Paclitaxel; Permeability; Stomatitis; Tegafur; Treatment Outcome; Xylose | 2001 |
Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine.
Topics: 3-O-Methylglucose; Animals; Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; DNA, Neoplasm; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Immunohistochemistry; Liver Neoplasms, Experimental; Neoplasm Transplantation; Phosphorylation; Radiopharmaceuticals; Rats; Rats, Inbred Strains; Thymidine; Tomography, Emission-Computed; Tumor Cells, Cultured | 2001 |
[Gemcitabine and cisplatin as induction therapy for patients with histologically proven stage IIIA-N2 non-small-cell bronchial cancer: a phase-II study of the EORTC Cooperative Group (EORTC 08955)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction; Treatment Outcome | 2001 |
Preliminary evaluation of influence of gemcitabine (Gemzar) on proliferation and neuroendocrine activity of human TT cell line: immunocytochemical investigations.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Medullary; Cell Division; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Immunohistochemistry; Neurosecretory Systems; Thyroid Neoplasms; Tumor Cells, Cultured | 2001 |
The antitumor mechanism of 1-(2-deoxy-2-fluoro-4-thio-beta-D-arabinofuranosyl)-cytosine: effects of its triphosphate on mammalian DNA polymerases.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Death; Cell Division; Cytarabine; Deoxycytidine; DNA Polymerase I; Drug Interactions; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Kinetics; Mouth Neoplasms; Nucleic Acid Synthesis Inhibitors; Tumor Cells, Cultured | 2001 |
Inhibitor of apoptosis-1 (IAP-1) expression and apoptosis in non-small-cell lung cancer cells exposed to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Drosophila Proteins; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Insect Proteins; Lung Neoplasms; Tumor Cells, Cultured | 2001 |
[Non-small cell lung cancer with liver metastasis responsive to gemcitabine--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged | 2001 |
Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Infusions, Intravenous; Macaca mulatta; Male | 2001 |
Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2001 |
Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2001 |
Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Deoxyribonucleotides; DNA-Directed DNA Polymerase; DNA, Neoplasm; Gemcitabine; Humans; Nucleic Acid Synthesis Inhibitors; Tumor Cells, Cultured | 2001 |
Cell cycle effects of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Survival; Deoxycytidine; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Flow Cytometry; Gemcitabine; Humans; Ovarian Neoplasms; S Phase; Tumor Cells, Cultured | 2001 |
Chemotherapy and quality of life in advanced NSCLC.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Placebos; Quality of Life; Randomized Controlled Trials as Topic | 2001 |
Evaluating new treatments for advanced cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasms; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2001 |
Neoadjuvant chemotherapy with docetaxel in non--small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Paclitaxel; Survival Rate; Taxoids | 2001 |
Pancreatic adenocarcinoma cell lines show variable susceptibility to TRAIL-mediated cell death.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Arabidopsis Proteins; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Caspase 3; Caspases; Computer Systems; Deoxycytidine; Fas Ligand Protein; fas Receptor; Fatty Acid Desaturases; Flow Cytometry; Gemcitabine; GPI-Linked Proteins; HeLa Cells; Humans; Jurkat Cells; Membrane Glycoproteins; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Cell Surface; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Receptors, Tumor Necrosis Factor, Member 6b; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2001 |
Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine susceptibility in human bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Blotting, Western; Cell Death; Cell Line; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Immunohistochemistry; Mutation; Paclitaxel; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2001 |
Bladder tumor markers, intravesical therapy and systemic chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Biomarkers, Tumor; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Green Fluorescent Proteins; Humans; Luminescent Proteins; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatic Neoplasms; Tumor Cells, Cultured | 2000 |
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Base Pair Mismatch; Breast Neoplasms; Carrier Proteins; Colorectal Neoplasms; Deoxycytidine; DNA Repair; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endometrial Neoplasms; Enzyme Inhibitors; Epirubicin; Female; Gemcitabine; Humans; Intercalating Agents; Mitoxantrone; MutL Protein Homolog 1; MutS Homolog 2 Protein; Neoplasm Proteins; Nuclear Proteins; Paclitaxel; Proto-Oncogene Proteins; Taxoids; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2001 |
Gemcitabine in pre-treated advanced renal carcinoma: a feasibility study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged | 2001 |
Gemcitabine in the treatment of ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Treatment Outcome | 2001 |
Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle Proteins; Cyclin D1; Cyclin E; Cysteine Endopeptidases; Cytochrome c Group; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; E2F Transcription Factors; E2F1 Transcription Factor; Enzyme Inhibitors; Flavonoids; Gastrointestinal Neoplasms; Gemcitabine; Gene Expression Regulation, Enzymologic; Humans; Mitochondria; Multienzyme Complexes; Phosphorylation; Piperidines; Poly(ADP-ribose) Polymerases; Proteasome Endopeptidase Complex; Protein Subunits; Retinoblastoma Protein; Ribonucleotide Reductases; RNA, Messenger; Thymidine; Transcription Factors; Tritium; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2001 |
Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyrimidines; Pyrroles; Ribonucleotide Reductases; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2001 |
Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines.
Topics: Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Survival; Deoxyadenine Nucleotides; Deoxycytidine; Dose-Response Relationship, Radiation; Gemcitabine; Genotype; Humans; Mutation; Radiation-Sensitizing Agents; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
CaSm/gemcitabine chemo-gene therapy leads to prolonged survival in a murine model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Gemcitabine; Genetic Therapy; Humans; In Situ Nick-End Labeling; Mice; Neoplasm Proteins; Pancreatic Neoplasms; Survival Rate; Tumor Cells, Cultured | 2001 |
Nuclear factor-kappa B is upregulated in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Caspase 3; Caspases; Colon; Colorectal Neoplasms; Cysteine Proteinase Inhibitors; Deoxycytidine; DNA; Gemcitabine; Humans; Intestinal Mucosa; Leupeptins; NF-kappa B; Protein Binding; Rectum; Tumor Cells, Cultured | 2001 |
Gemcitabine active in patients with metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Multicenter Studies as Topic; Treatment Outcome | 2001 |
Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Division; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Isoenzymes; Male; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Sulindac; Tumor Cells, Cultured | 2001 |
Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Peptide Hydrolases; Poly(ADP-ribose) Polymerases; Protease Inhibitors; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Transfection; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Sustained complete remission in a patient with platinum-resistant ovarian yolk sac tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Endodermal Sinus Tumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Taxoids; Thalidomide | 2001 |
Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pilot Projects; Prognosis; Treatment Outcome; Urologic Neoplasms; Urothelium | 2001 |
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lung Neoplasms; Mitomycin; Neoplasm Metastasis; Paclitaxel; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2001 |
WR-2721 reduces intestinal toxicity from concurrent gemcitabine and radiation treatment.
Topics: Amifostine; Animals; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Jejunum; Mice; Mice, Inbred C3H; Radiation-Protective Agents; Radiation-Sensitizing Agents; Whole-Body Irradiation | 2001 |
Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Radiotherapy; Survival Analysis | 2001 |
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Screening Assays, Antitumor; Epirubicin; Female; Gemcitabine; Humans; Paclitaxel; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Genes, p53; Genes, Retinoblastoma; Humans; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured | 2001 |
Targeted delivery of a peripheral benzodiazepine receptor ligand-gemcitabine conjugate to brain tumors in a xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Glioma; Humans; Isoquinolines; Male; Rats; Rats, Nude; Rats, Sprague-Dawley; Receptors, GABA-A; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Thrombocytopenia; Treatment Outcome | 2001 |
Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Prognosis | 2001 |
Therapeutic efficacy of E2F1 in pancreatic cancer correlates with TP73 induction.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Proteins; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; E2F Transcription Factors; E2F1 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Nude; Nuclear Proteins; Pancreatic Neoplasms; Signal Transduction; Transcription Factors; Tumor Protein p73; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2001 |
Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Topics: Amino Acid Sequence; Antineoplastic Agents; Biological Transport; Carrier Proteins; Cytarabine; Cytidine Deaminase; Cytosine; Deoxycytidine; Deoxycytidine Kinase; Dioxolanes; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia; Male; Membrane Proteins; Molecular Sequence Data; Nucleoside Transport Proteins; Phosphorylation; Prostatic Neoplasms; Sequence Homology, Amino Acid; Sodium; Stereoisomerism; Tritium; Tumor Cells, Cultured; Uridine | 2001 |
Bystander effects of nucleoside analogs phosphorylated in the cytosol or mitochondria.
Topics: Animals; CHO Cells; Cricetinae; Cytarabine; Cytosol; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Genetic Therapy; Mitochondria; Neoplasms; Nucleosides; Phosphorylation | 2001 |
Retinoic acid enhances the cytotoxic effects of gemcitabine and cisplatin in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Alitretinoin; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Tretinoin; Tumor Cells, Cultured | 2001 |
Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2001 |
Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response.
Topics: Animals; Cell Division; Chromatography, High Pressure Liquid; Cytidine Triphosphate; Deoxycytidine; Deoxycytidine Kinase; Female; Fluorine; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Transfer Techniques; HT29 Cells; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2001 |
Wortmannin inhibits pkb/akt phosphorylation and promotes gemcitabine antitumor activity in orthotopic human pancreatic cancer xenografts in immunodeficient mice.
Topics: Androstadienes; Animals; Antimetabolites, Antineoplastic; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Receptor, ErbB-2; Tumor Cells, Cultured; Wortmannin; Xenograft Model Antitumor Assays | 2001 |
Bcl-x(L) antisense oligonucleotides induce apoptosis and increase sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Blotting, Northern; Blotting, Western; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Oligonucleotides, Antisense; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Tumor Cells, Cultured | 2001 |
Chemotherapy for non-small-cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Taxoids | 2001 |
Gemcitabine and small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Vincristine | 2001 |
Gemcitabine-associated diffuse alveolar hemorrhage.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Deoxycytidine; Fatal Outcome; Gemcitabine; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Male; Pulmonary Alveoli; Steroids | 2001 |
Antagonistic effect of the combination gemcitabine/topotecan in ovarian cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Flow Cytometry; Gemcitabine; Humans; Inhibitory Concentration 50; Ovarian Neoplasms; Time Factors; Topotecan; Tumor Cells, Cultured; Tumor Protein, Translationally-Controlled 1 | 2000 |
Gemcitabine-associated CD8+ CD30+ pseudolymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; CD8 Antigens; Deoxycytidine; Drug Eruptions; Gemcitabine; Humans; Ki-1 Antigen; Male; Pseudolymphoma | 2001 |
Durable complete remission of metastatic sarcomatoid carcinoma of the bladder with cisplatin and gemcitabine in an 80-year-old man.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Remission Induction; Urinary Bladder Neoplasms | 2001 |
Drug resistance in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Proteins; Survival Analysis | 2001 |
Combination chemotherapy of the taxanes and antimetabolites: its use and limitations.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Methotrexate; Paclitaxel | 2001 |
Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2001 |
Interaction of p53 and DNA-PK in response to nucleoside analogues: potential role as a sensor complex for DNA damage.
Topics: Antigens, Nuclear; Antimetabolites, Antineoplastic; Apoptosis; Binding, Competitive; Deoxycytidine; DNA Damage; DNA Helicases; DNA Repair; DNA Replication; DNA-Activated Protein Kinase; DNA-Binding Proteins; DNA, Neoplasm; Gemcitabine; Humans; Ku Autoantigen; Leukemia, Myeloid; Nuclear Proteins; Phosphorylation; Protein Serine-Threonine Kinases; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2001 |
Intraoperative and early postoperative chemotherapy into the abdominal cavity using gemcitabine may prevent postoperative occurence of peritoneal carcinomatosis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Models, Animal; Drug Administration Schedule; Gemcitabine; Infusions, Parenteral; Intraoperative Care; Male; Neoplasm Seeding; Peritoneal Neoplasms; Postoperative Care; Rats; Rats, Wistar | 2002 |
Gemcitabine (Gemzar) and radiotherapy--is it feasible?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Retrospective Studies | 2002 |
Intraoperative saline and gemcitabine irrigation improves tumour control in human squamous cell carcinoma-contaminated surgical wounds.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Deoxycytidine; Gemcitabine; Head and Neck Neoplasms; Humans; Intraoperative Care; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Seeding; Neoplasm Transplantation; Sodium Chloride; Therapeutic Irrigation; Transplantation, Heterologous; Water | 2001 |
Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Time Factors; Tissue Distribution; Tumor Cells, Cultured | 2002 |
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
A novel type of metastatically spreading subcutaneous aspergillosis without epidermal lesions following allogeneic stem cell transplantation.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Aspergillosis; Bleomycin; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunocompromised Host; Klebsiella Infections; Klebsiella pneumoniae; Lung Diseases, Fungal; Male; Melphalan; Neoplasm Recurrence, Local; Opportunistic Infections; Pneumonia, Bacterial; Pneumonia, Pneumocystis; Prednisone; Procarbazine; Salvage Therapy; Skin; Transplantation, Homologous; Vinblastine; Vincristine | 2001 |
The role of deoxycytidine kinase in gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Colorectal Neoplasms; Deoxycytidine; Deoxycytidine Kinase; Dexamethasone; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression; Glucocorticoids; HL-60 Cells; Humans; Protein Kinase C; Ribonucleotide Reductases; RNA, Messenger; Staurosporine; Tumor Cells, Cultured; U937 Cells | 2000 |
[Prognosis of pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Patient Selection; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Sex Factors; Time Factors | 2001 |
NMR structure of a gemcitabine-substituted model Okazaki fragment.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Deoxycytidine; DNA; DNA Replication; Gemcitabine; Magnetic Resonance Spectroscopy; Models, Molecular; Nucleic Acid Conformation; Oligodeoxyribonucleotides; Spectrophotometry, Ultraviolet; Static Electricity; Thermodynamics | 2002 |
Gemcitabine activity in cervical cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Survival; Cisplatin; Deoxycytidine; DNA Damage; Drug Interactions; Female; Gemcitabine; HeLa Cells; Humans; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2001 |
In Vitro schedule-dependent interactions between the multitargeted antifolate LY231514 and gemcitabine in human colon adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; Deoxycytidine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Flow Cytometry; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; In Situ Nick-End Labeling; Pemetrexed; Thymidylate Synthase; Tumor Cells, Cultured | 2002 |
Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Breast Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Deoxycytidine; DNA Damage; DNA Replication; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; G1 Phase; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Genes, Dominant; Genes, p53; Humans; Neoplasm Proteins; Neoplastic Stem Cells; Phenotype; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; S Phase; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Biological basis for chemo-radiotherapy interactions.
Topics: Antineoplastic Agents; Apoptosis; Cell Transformation, Neoplastic; Cisplatin; Combined Modality Therapy; Deoxycytidine; DNA Adducts; DNA Repair; Docetaxel; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Neovascularization, Pathologic; Paclitaxel; Radiotherapy; Taxoids | 2002 |
Use of 5-[(76)Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model.
Topics: Animals; Autoradiography; Bromodeoxyuridine; Carbon Radioisotopes; Cell Division; Cimetidine; Deoxycytidine; DNA, Neoplasm; Fibrosarcoma; Flow Cytometry; Floxuridine; Gamma Cameras; Gemcitabine; Mice; Mice, Inbred C3H; Radionuclide Imaging; Radiopharmaceuticals; Scintillation Counting; Thymidine | 2002 |
[Successful outpatient treatment with chemotherapy of weekly gemcitabine and vinorelbine for a patient with recurrent lung cancer].
Topics: Adenocarcinoma; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Quality of Life; Vinblastine; Vinorelbine | 2002 |
Gemcitabine-induced systemic capillary leak syndrome.
Topics: Antimetabolites, Antineoplastic; Capillary Leak Syndrome; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2001 |
Severe pulmonary toxicity in a patient treated with gemcitabine.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dyspnea; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male | 2002 |
Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cytochrome c Group; Deoxycytidine; DNA Fragmentation; Enzyme Activation; Gemcitabine; Humans; Lung Neoplasms; NF-kappa B; Tumor Cells, Cultured | 2002 |
The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Topics: Actins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Caveolin 1; Caveolins; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesol; Gemcitabine; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phalloidine; ras Proteins; Rats; Salicylates; Time Factors; Tumor Cells, Cultured; Up-Regulation | 2002 |
Hand-foot syndrome associated with short infusions of combination chemotherapy with gemcitabine and vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Eruptions; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2001 |
Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cisplatin; Deoxycytidine; Diffusion; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Membranes, Artificial; Mice; Neoplasm Staging; Paclitaxel; Polytetrafluoroethylene; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock!
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Indoles; Pyrroles | 2002 |
Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Monitoring; Epirubicin; Female; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Humans; Liver Neoplasms; Lung Neoplasms; Paclitaxel; Predictive Value of Tests; Radiopharmaceuticals; Remission Induction; Soft Tissue Neoplasms; Survival Analysis; Time Factors; Tomography, Emission-Computed; Treatment Outcome | 2000 |
Eradication of osteosarcoma lung metastasis using intranasal gemcitabine.
Topics: Administration, Intranasal; Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Mice; Mice, Nude; Osteosarcoma; Tumor Cells, Cultured | 2002 |
Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Treatment Failure | 2002 |
Gemcitabine-related pulmonary toxicity.
Topics: Aged; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Dyspnea; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Mediastinal Neoplasms; Prednisone; Pulmonary Edema | 2002 |
Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bronchi; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Transformed; Cisplatin; Cyclin-Dependent Kinases; Deoxycytidine; DNA; DNA, Neoplasm; Drug Interactions; Enzyme Inhibitors; Epithelial Cells; Fibroblasts; Flavonoids; Gemcitabine; Humans; Lung Neoplasms; Piperidines; S Phase; Tumor Cells, Cultured | 2002 |
[An elderly patient with advanced non-small-cell lung cancer that responded remarkably to combination chemotherapy of vinorelbine and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Quality of Life; Vinblastine; Vinorelbine | 2002 |
[Phase III clinical trials concerning non-small-cell lung carcinoma (NSCLC) presented at the ASCO 2001].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2001 |
[An autopsy case of pulmonary and central nervous system metastatic osteosarcoma treated with thirty-six courses of chemotherapy over four years].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carboplatin; Cisplatin; Dacarbazine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Methotrexate; Osteosarcoma; Paclitaxel; Spinal Cord Neoplasms; Survivors; Taxoids; Vincristine; Vindesine | 2002 |
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phthalazines; Pyridines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2002 |
Enhancement of DNA ligase I level by gemcitabine in human cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Cycle; Cytarabine; Deoxycytidine; DNA Ligase ATP; DNA Ligases; Dose-Response Relationship, Drug; Enzyme Activation; Fluorouracil; Gemcitabine; Humans; Hydroxyurea; Tumor Cells, Cultured | 2002 |
[Regional intra-arterial infusion chemotherapy for pancreatic cancer: an experimental study].
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Models, Animal; Dogs; Gemcitabine; Infusions, Intra-Arterial; Kidney; Male; Pancreatic Neoplasms; Tissue Distribution | 2002 |
Vasculitis due to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Muscles; Muscular Diseases; Necrosis; Treatment Outcome; Vasculitis | 2002 |
Is long term gemcitabine useful in small cell lung cancer?
Topics: Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Prognosis | 2002 |
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis | 2002 |
Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.
Topics: Animals; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; B-Lymphocyte Subsets; B-Lymphocytes; Combined Modality Therapy; Deoxycytidine; Epitopes, B-Lymphocyte; Gemcitabine; Immunosuppressive Agents; Immunotherapy; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Mice, Transgenic; Spleen | 2002 |
Conjugates of nucleoside analogs with lactosaminated human albumin to selectively increase the drug levels in liver blood: requirements for a regional chemotherapy.
Topics: Animals; Deoxycytidine; Drug Delivery Systems; Floxuridine; Gemcitabine; Liver; Male; Models, Animal; Nucleosides; Rats; Rats, Wistar; Serum Albumin; Vidarabine | 2002 |
[Therapy of gallbladder carcinoma. Experience of a central hospital].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Palliative Care; Postoperative Care; Regression Analysis; Survival Analysis; Time Factors | 2002 |
Change in pharmacokinetic and pharmacodynamic behavior of gemcitabine in human tumor xenografts upon entrapment in vesicular phospholipid gels.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Docetaxel; Gels; Gemcitabine; Half-Life; Humans; Liposomes; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Phospholipids; Sarcoma; Taxoids; Tissue Distribution; Transplantation, Heterologous; Urinary Bladder Neoplasms; Vindesine | 2002 |
[Antitumor activity of combination treatment combining gemcitabine with topotecin against human lung cancer xenografted in nude mice].
Topics: Adenocarcinoma, Papillary; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Transplantation, Heterologous | 2002 |
Human ribonucleotide reductase M2 subunit gene amplification and transcriptional regulation in a homogeneous staining chromosome region responsible for the mechanism of drug resistance.
Topics: Chromosome Banding; Chromosomes, Human, Pair 2; Deoxycytidine; DNA; Drug Resistance; Electrophoretic Mobility Shift Assay; Gemcitabine; Gene Amplification; Gene Expression Regulation, Enzymologic; Humans; Hydroxyurea; In Situ Hybridization, Fluorescence; Karyotyping; Promoter Regions, Genetic; Protein Subunits; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Staining and Labeling; Transcription Factors; Transcription, Genetic; Translocation, Genetic; Tumor Cells, Cultured | 2001 |
[Interstitial lung disease in a patient given gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Disease Progression; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Staging; Pulmonary Fibrosis; Tomography, X-Ray Computed | 2002 |
Induction of apoptosis by cladribine (2-CdA), gemcitabine and other chemotherapeutic drugs on CD34+/CD38+ and CD34+/CD38- hematopoietic progenitor cells: selective effects of doxorubicin and 2-CdA with protection of immature cells.
Topics: Antigens, CD34; Antineoplastic Agents; Apoptosis; Cladribine; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Hematologic Neoplasms; Hematopoietic Stem Cells; Humans; Mitoxantrone | 2002 |
Barriers to winning the battle with head-and-neck cancer.
Topics: Clinical Trials, Phase I as Topic; Deglutition; Deglutition Disorders; Deoxycytidine; Gemcitabine; Head and Neck Neoplasms; Humans; Radiation-Sensitizing Agents | 2002 |
Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: from the laboratory to the clinic.
Topics: Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2002 |
Effect of gemcitabine on acute and late radiation toxicity of skin and underlying soft tissues to single-dose irradiation in a nude mice model.
Topics: Animals; Connective Tissue; Deoxycytidine; Dose-Response Relationship, Radiation; Fibrosis; Gemcitabine; Mice; Mice, Nude; Radiation-Sensitizing Agents; Skin; Time Factors | 2002 |
Recurrent ovarian cancer as chronic disease.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Chronic Disease; Deoxycytidine; Doxorubicin; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Ovarian Neoplasms; Recurrence; Topotecan; Trastuzumab | 2002 |
Durable control of small cell carcinoma of the urinary bladder by gemcitabine and paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Urinary Bladder Neoplasms | 2002 |
Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Division; Cell Survival; Clinical Trials as Topic; Dactinomycin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Flow Cytometry; Gemcitabine; Humans; Paclitaxel; Time Factors; Tumor Cells, Cultured | 2002 |
Combination effects of alkylphosphocholines and gemcitabine in malignant and normal hematopoietic cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Survival; Cell-Free System; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Hematopoietic Stem Cells; HL-60 Cells; Humans; K562 Cells; Phosphorylcholine; Reference Values; Tumor Cells, Cultured | 2002 |
Cytotoxic activity of 2',2'-difluorodeoxycytidine, 5-aza-2'-deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene.
Topics: 3T3 Cells; Animals; Azacitidine; Cell Death; Cell Line; Cytarabine; Cytidine Deaminase; Decitabine; Deoxycytidine; Deoxycytidine Kinase; DNA, Complementary; Dose-Response Relationship, Drug; Gemcitabine; Genetic Vectors; Humans; Mice; Phenotype; Phosphorylation; Retroviridae; Thymidine Kinase; Tumor Cells, Cultured | 2002 |
Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Salvage Therapy; Taxoids | 2002 |
Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents.
Topics: Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Division; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Indoles; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retroviridae; Ribonucleotide Reductases; Tetracyclines; Transfection; Tumor Cells, Cultured | 2002 |
Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Outcome Assessment, Health Care; Paclitaxel; Practice Guidelines as Topic; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine; Vinorelbine; World Health Organization | 2002 |
Bayesian two-stage designs for phase II clinical trials.
Topics: Antimetabolites, Antineoplastic; Bayes Theorem; Carcinoma; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Nasopharyngeal Neoplasms; Sample Size; Singapore | 2002 |
Pharmacokinetics of intrathecal gemcitabine in nonhuman primates.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Cerebrospinal Fluid; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Injections, Intraventricular; Macaca mulatta; Male; Metabolic Clearance Rate | 2002 |
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Survival Rate | 2002 |
3'-Azido-2',3'-dideoxythymidine induced deficiency of thymidine kinases 1, 2 and deoxycytidine kinase in H9 T-lymphoid cells.
Topics: Adenosine Triphosphate; Anti-HIV Agents; Blotting, Western; Cytidine Triphosphate; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Microbial; Gemcitabine; HIV-1; Humans; RNA, Messenger; T-Lymphocytes; Thymidine Kinase; Uridine Triphosphate; Zidovudine | 2002 |
Fixed erythrodysaesthesia plaque due to gemcitabine and epirubicin treatment.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Eruptions; Epirubicin; Erythema; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Paresthesia; Skin; Taxoids | 2002 |
Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; In Vitro Techniques; Inhibitory Concentration 50; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-bcl-2; Rhodamines; Ribonuclease, Pancreatic; Tumor Cells, Cultured | 2002 |
Gemcitabine and vascular toxicity.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hepatic Veno-Occlusive Disease; Humans; Lung Neoplasms; Treatment Outcome; Vasculitis | 2002 |
Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Flow Cytometry; Gemcitabine; Humans; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Topotecan; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
Topics: Animals; Deoxycytidine; Deoxycytidine Kinase; Fibrosarcoma; Gemcitabine; Humans; Mice; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2002 |
[Refractory non-small-cell lung cancer responding to combination chemotherapy with gemcitabine and cisplatin].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Pneumonectomy | 2002 |
Gemcitabine and the interaction with anticoagulants.
Topics: Anticoagulants; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Male; Monitoring, Physiologic; Registries; Risk Assessment; Warfarin | 2002 |
[Chemotherapy of advanced non-small cell lung cancer with the combination of gemcitabine and cisplatin].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quality of Life; Remission Induction; Survival Analysis; Time Factors; Treatment Outcome | 2002 |
[Renal toxicity with a gemcitabine-cisplatin combination in lung cancer].
Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney; Lung Neoplasms; Male | 2002 |
Salvage chemotherapy for advanced sarcoma patients: a single-institution experience survey.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Sarcoma; Soft Tissue Neoplasms; Treatment Outcome | 2002 |
Intravesical therapy for superficial cancer: need for more options.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2002 |
Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gemcitabine; Humans; Mice; Models, Chemical; Oligonucleotides; Time Factors; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2002 |
Selective cytotoxicity of gemcitabine in bladder cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Survival; Coculture Techniques; Coloring Agents; Deoxycytidine; Fibroblasts; Gemcitabine; Humans; Immunohistochemistry; Rats; Spheroids, Cellular; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured; Tumor Stem Cell Assay; Urinary Bladder Neoplasms | 2002 |
Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma. Carboplatin and gemcitabine followed by paclitaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2002 |
[Ureteroplasty using the appendix: apropos of a case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendix; Carcinoma, Transitional Cell; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Laparotomy; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrostomy, Percutaneous; Paclitaxel; Prostatectomy; Retroperitoneal Space; Transplantation, Autologous; Transplantation, Heterotopic; Ureter; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2002 |
Preclinical combination chemotherapy of nedaplatin with gemcitabine against gemcitabine-refractory human lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Transplantation, Heterologous; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles | 2002 |
Gemcitabine in models of acute and accelerated rejection.
Topics: Acute Disease; Animals; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Time Factors; Transplantation, Homologous | 2002 |
Sensitivity to ionizing radiation and chemotherapeutic agents in gemcitabine-resistant human tumor cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Radiation Tolerance; Tumor Cells, Cultured | 2002 |
Gemcitabine-induced erysipeloid skin lesions in a patient with malignant mesothelioma.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Eruptions; Erysipeloid; Gemcitabine; Humans; Liver Neoplasms; Male; Mesothelioma; Middle Aged | 2002 |
Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Case-Control Studies; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Proteins; Ribonucleotide Reductases; Vidarabine | 2002 |
A report on serious pulmonary toxicity associated with gemcitabine-based therapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases; Male; Middle Aged; Radiotherapy; Retrospective Studies; Risk Factors | 2002 |
Treatment of advanced non-small-cell lung cancer with two-drug combinations.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Patient Selection | 2002 |
Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Paclitaxel; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured | 2002 |
[Successful salvage chemotherapy with gemcitabine, etoposide and cisplatin for metastatic ureteral cancer: a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Lymphatic Metastasis; Male; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Treatment Outcome; Ureteral Neoplasms | 2002 |
Unusual radiation response of gemcitabine-treated HeLa cells: reduced and enhanced survival.
Topics: Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Gemcitabine; HeLa Cells; Humans; Radiation Protection; Radiation Tolerance; Radiation-Sensitizing Agents | 2002 |
An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy.
Topics: 3T3 Cells; Animals; Carboplatin; Cytokines; Deoxycytidine; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Neoplasms; Paclitaxel; Transforming Growth Factor beta; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Disseminated pagetoid reticulosis presenting as cytotoxic CD4/CD8 double negative cutaneous T-cell lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; CD4 Antigens; CD8 Antigens; Deoxycytidine; Gemcitabine; Humans; Lymphatic Diseases; Lymphoma, T-Cell, Cutaneous; Male; Skin Neoplasms | 2002 |
Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cells; Deoxycytidine; Gemcitabine; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2002 |
[Gemcitabine in the treatment of advanced non-small cell lung cancer: report of one case].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Treatment Outcome | 2002 |
[Effect of preoperative concurrent chemo-radiotherapy for thymic carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Etoposide; Gemcitabine; Humans; Male; Middle Aged; Preoperative Care; Radiotherapy Dosage; Remission Induction; Thymoma; Thymus Neoplasms | 2002 |
Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Division; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Interferon-beta; Lung Neoplasms; Paclitaxel; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2002 |
Early changes in [18F]FLT uptake after chemotherapy: an experimental study.
Topics: Antineoplastic Agents; Artifacts; Carcinoma, Squamous Cell; Cell Survival; Cisplatin; Deoxycytidine; Dideoxynucleosides; Dose-Response Relationship, Drug; Esophageal Neoplasms; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Humans; Methotrexate; Radionuclide Imaging; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Statistics as Topic; Tumor Cells, Cultured | 2002 |
Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells.
Topics: Chromatography, Ion Exchange; Deoxycytidine; Gemcitabine; Humans; Leukocytes; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2002 |
Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Cycle; Cell Division; Cell Survival; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Blockade of the epidermal growth factor receptor signaling inhibits angiogenesis leading to regression of human renal cell carcinoma growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Deoxycytidine; DNA-Binding Proteins; Down-Regulation; Endothelial Growth Factors; Enzyme Inhibitors; ErbB Receptors; Gemcitabine; Immunohistochemistry; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Kidney; Lung; Lymphokines; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Time Factors; Trans-Activators; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Healthcare outcomes: gemcitabine cost-effectiveness in the treatment of non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cost Savings; Cost-Benefit Analysis; Decision Making; Deoxycytidine; Disease Progression; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Quality of Life | 2002 |
[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Retreatment | 2002 |
Chemoradiation protocols offer only incremental gains for pancreatic cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Feasibility Studies; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2002 |
Pancreatic cancer in vitro toxicity mediated by Chinese herbs SPES and PC-SPES: implications for monotherapy and combination treatment.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Division; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Drugs, Chinese Herbal; Gemcitabine; Humans; Pancreatic Neoplasms; Plant Extracts; Tumor Cells, Cultured | 2003 |
[Updates on gemcitabine at the American Society of Clinical Oncology congress (ASCO, 2002) ].
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Docetaxel; Enzyme Inhibitors; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunotherapy; Lung Neoplasms; Mitomycins; Multicenter Studies as Topic; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Radiotherapy; Remission Induction; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2002 |
Early detection and successful treatment of drug-induced pneumonitis with corticosteroids.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Paclitaxel; Pneumonia; Prednisone; Radiography, Thoracic; Tomography, X-Ray Computed; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[A case of vulval extramammary Paget's disease associated with pancreatic cancer that was successfully treated with chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Paget Disease, Extramammary; Pancreatic Neoplasms; Vulvar Neoplasms | 2002 |
[A case of pancreatic tail cancer with peritoneal carcinosis treated with gemcitabine hydrochloride].
Topics: Antimetabolites, Antineoplastic; Ascitic Fluid; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Peritonitis | 2002 |
Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hematologic Diseases; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Rate; Treatment Outcome | 2002 |
Combined platinum containing treatment in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Prognosis | 2002 |
The role of chemotherapy (CT) and supportive care (SC) in advanced non-small cell lung cancer (NSCLC).
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Palliative Care; Quality of Life | 2002 |
Effect of gemcitabine and cis-platinum combinations on ribonucleotide and deoxyribonucleotide pools in ovarian cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Deoxyribonucleotides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Ovarian Neoplasms; Ribonucleotides; Tumor Cells, Cultured | 2003 |
[Severe interstitial pneumonitis related to Gemcitabine].
Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Respiratory Distress Syndrome | 2002 |
Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; DNA Primers; Female; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Skin Neoplasms | 2002 |
Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Cycle; Cell Division; Deoxycytidine; Drug Combinations; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Interleukin-6; Membrane Potentials; Mitochondria; Multiple Myeloma; Poly(ADP-ribose) Polymerases; Tumor Cells, Cultured | 2002 |
[Intra-arterial chemotherapy with gemcitabine (GEM) for unresectable pancreatic cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms | 2002 |
Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Androstadienes; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique, Indirect; Gemcitabine; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, SCID; Microscopy, Fluorescence; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Wortmannin | 2002 |
DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.
Topics: Animals; Antineoplastic Agents; CHO Cells; Cisplatin; Cricetinae; Deoxycytidine; DNA Adducts; DNA Repair; Drug Synergism; Gemcitabine | 2003 |
[Weekly administration of gemcitabine in outpatient clinic for non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Ambulatory Care; Ambulatory Care Facilities; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Rate | 2002 |
[Gemcitabine in elderly patients with unresectable pancreas cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Karnofsky Performance Status; Male; Pancreatic Neoplasms | 2002 |
Efficacy of camptothecin analog DX-8951f (Exatecan Mesylate) on human pancreatic cancer in an orthotopic metastatic model.
Topics: Animals; Camptothecin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured | 2003 |
Measurement of the anti-cancer agent gemcitabine in human plasma by high-performance liquid chromatography.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Reference Standards; Reproducibility of Results; Sensitivity and Specificity | 2003 |
Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma, B-Cell; Paclitaxel; Rituximab; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2002 |
[New data presented at ASCO 2002 concerning non-small cell bronchial cancers].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
[New data presented at ASCO 2002 concerning small cell bronchial cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Quinolones; Smoking; Smoking Prevention; Survival Analysis; Treatment Outcome | 2002 |
[New therapeutic options for mesothelioma].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Folic Acid Antagonists; France; Gemcitabine; Humans; Mesothelioma; Mitomycin; Neoplasm Staging; Patient Selection; Pneumonectomy; Prognosis; Quinazolines; Radiotherapy, Adjuvant; Risk Factors; Survival Analysis; Thiophenes; Treatment Outcome; Vindesine | 2002 |
[Therapeutic strategies in advanced non-small cell bronchial cancers: platin-based combinations].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Patient Selection; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2002 |
Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Fatal Outcome; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Palliative Care | 2003 |
[Two cases of complete response to combination chemotherapy of gemcitabine and docetaxel for recurrent ovarian cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Pelvic Neoplasms; Taxoids | 2003 |
Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Division; Cetuximab; Deoxycytidine; DNA; Electrophoretic Mobility Shift Assay; ErbB Receptors; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Protein Binding; Signal Transduction; Tumor Cells, Cultured | 2003 |
Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged | 2003 |
Antineoplastic therapy in colorectal cancer through proteasome inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Caspase 3; Caspases; Colorectal Neoplasms; Cysteine Endopeptidases; Deoxycytidine; DNA, Neoplasm; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Enzyme Precursors; Gemcitabine; Gene Transfer Techniques; Humans; Leupeptins; Luciferases; Multienzyme Complexes; NF-kappa B; Proteasome Endopeptidase Complex; Rats; Transcriptional Activation; Tumor Cells, Cultured; Up-Regulation | 2003 |
In vitro schedule-dependent interaction between docetaxel and gemcitabine in human gastric cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Survival; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Radiation enhancement by gemcitabine-mediated cell cycle modulations.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Cycle; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; HeLa Cells; Humans; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2003 |
Usage of the NF-kappaB inhibitor sulfasalazine as sensitizing agent in combined chemotherapy of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Sulfasalazine; Tumor Cells, Cultured | 2003 |
27th ESMO Congress, Nice, 18-22 October 2002. Iressa disappoints in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Congresses as Topic; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Treatment Failure | 2003 |
Timing is everything, or could be.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2003 |
Extensive cutaneous metastasis of transitional cell carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Immunohistochemistry; Male; Neoplasm Staging; Severity of Illness Index; Skin Neoplasms; Treatment Refusal; Urinary Bladder Neoplasms | 2003 |
[Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pilot Projects; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Time Factors; Tomography, X-Ray Computed | 2003 |
Significant increase in residual DNA damage as a possible mechanism of radiosensitization by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; DNA; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Radiation; Electrophoresis; Gemcitabine; Humans; Models, Theoretical; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Time Factors; Tumor Cells, Cultured | 2003 |
Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells.
Topics: Animals; Apoptosis; Carcinoma, Transitional Cell; Cell Division; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Flow Cytometry; Gemcitabine; Genes, p53; Humans; In Situ Nick-End Labeling; Mutation; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2003 |
[A case of liver metastasis of pancreatic duct carcinoma successfully treated with gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Quality of Life | 2003 |
[Preclinical studies of concomitant chemoradiation].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Child; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Radiation Tolerance; Time Factors; Topotecan; Transplantation, Heterologous | 2003 |
Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigens, Neoplasm; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Adenosquamous; Deoxycytidine; Female; Gemcitabine; Humans; Life Tables; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2002 |
Circulating nucleosomes and response to chemotherapy: an in vitro, in vivo and clinical study on cervical cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA, Neoplasm; DNA, Viral; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; HeLa Cells; Humans; In Vitro Techniques; Mice; Mice, Nude; Middle Aged; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nucleosomes; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Papillomaviridae; Papillomavirus Infections; Prognosis; Rats; Rats, Wistar; Tumor Virus Infections; Uterine Cervical Neoplasms | 2003 |
Isolated lung perfusion with gemcitabine in a rat: pharmacokinetics and survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Survival; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Infusions, Intravenous; Lung Neoplasms; Male; Models, Animal; Rats; Survival Analysis; Tumor Cells, Cultured | 2003 |
Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; DNA Adducts; DNA Damage; DNA Repair; Drug Synergism; Female; Gemcitabine; Humans; Ovarian Neoplasms; Tetrahydrofolate Dehydrogenase; Tumor Cells, Cultured | 2003 |
Gemcitabine therapy in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Survival Rate | 2002 |
Sustained partial response of an intra-abdominal desmoid tumor treated with gemcitabine, 5-fluorouracil and leucovorin.
Topics: Abdominal Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fibromatosis, Aggressive; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Treatment Outcome | 2003 |
The radiosensitising effect of gemcitabine and the influence of the rescue agent amifostine in vitro.
Topics: Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Humans; Lethal Dose 50; Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2003 |
Comparison of the sulforhodamine B assay and the clonogenic assay for in vitro chemoradiation studies.
Topics: Breast Neoplasms; Colonic Neoplasms; Colony-Forming Units Assay; Colorimetry; Combined Modality Therapy; Deoxycytidine; Fluorescent Dyes; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Rhodamines; Sensitivity and Specificity; Tumor Cells, Cultured | 2003 |
Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Kidney Failure, Chronic; Male; Middle Aged; Pancreatic Neoplasms; Renal Dialysis | 2003 |
Intrathecal gemcitabine chemotherapy for non-small cell lung cancer patients with meningeal carcinomatosis--a case report.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Injections, Spinal; Lung Neoplasms; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Middle Aged; Ribonucleotide Reductases; Tomography, X-Ray Computed | 2003 |
[Gemcitabine in the treatment of relapsed or refractory non-Hodgkin's lymphoma].
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Salvage Therapy; Secondary Prevention | 2002 |
In vitro studies on the immunosuppressive effect of 2',2'-difluorodeoxycytidine (dFdC) and its metabolite 2',2'-difluorodeoxyuridine (dFdU).
Topics: Adrenal Cortex Hormones; Antigens, CD34; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Therapy, Combination; Floxuridine; Gemcitabine; HL-60 Cells; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Phytohemagglutinins; Stem Cells | 2003 |
Effect of metal-based anticancer drugs on wild type and metallothionein null cell lines.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cadmium Chloride; Carboplatin; Cell Division; Cell Line; Chlorides; Cisplatin; Copper Sulfate; Deoxycytidine; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Ferrous Compounds; Fibroblasts; Gemcitabine; Inhibitory Concentration 50; Metallothionein; Metals, Heavy; Mice; Mice, Knockout; Paclitaxel; Spectrophotometry, Atomic; Survival Analysis; Survival Rate; Vinblastine; Zinc Compounds | 2003 |
Efficacy of gemcitabine in heavily pretreated advanced ovarian cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2003 |
Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[Combination chemotherapy with Hemzar (gemcitabine) and cisplatin for relapsing and cisplatin-resistant ovarian cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Recurrence; Treatment Outcome | 2003 |
[Successful treatment with chemotherapy of vinorelbine and gemcitabine for an elderly patient with advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Quality of Life; Vinblastine; Vinorelbine | 2003 |
[Gemcitabine improved QOL and survival in a case of diffuse malignant pleural mesothelioma].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Mesothelioma; Pleural Neoplasms; Prognosis; Quality of Life; Survivors | 2003 |
[Pancreatic carcinoma--overcome technically but not oncologically].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Risk Factors | 2003 |
[Clinical case of the month. Pulmonary toxicity due to gemcitabine for NSCLC with brain metastasis].
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases; Lung Neoplasms; Middle Aged; Ribonucleotide Reductases | 2003 |
Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia.
Topics: Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Drug Screening Assays, Antitumor; Fibrosarcoma; Gemcitabine; Hyperthermia, Induced; Irinotecan; Melphalan; Mice; Mice, Inbred C3H; Organoplatinum Compounds; Oxaliplatin; Paclitaxel | 2003 |
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells.
Topics: Animals; Antigen Presentation; Antigen-Presenting Cells; Antigens, Neoplasm; Apoptosis; CD8-Positive T-Lymphocytes; Clonal Anergy; Clonal Deletion; Cytotoxicity, Immunologic; Deoxycytidine; Dose-Response Relationship, Immunologic; Epitopes, T-Lymphocyte; Gemcitabine; Growth Inhibitors; Hemagglutinin Glycoproteins, Influenza Virus; Immunization; Injections, Intraperitoneal; Mesothelioma; Mice; Mice, Inbred BALB C; Mice, Transgenic; Tumor Cells, Cultured; Up-Regulation | 2003 |
Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Deoxycytidine; Dose-Response Relationship, Drug; Endothelium, Vascular; Fibroblast Growth Factor 2; Gemcitabine; Humans; Implants, Experimental; Interferon-alpha; Interleukin-8; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Survival Rate; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2003 |
Genotoxicity of two anticancer drugs, gemcitabine and topotecan, in mouse bone marrow in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Marrow Cells; Chromosome Aberrations; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Gemcitabine; Mice; Micronucleus Tests; Mitosis; Regression Analysis; Time Factors; Topotecan | 2003 |
Delayed addition of deoxycytidine protects normal CD34+ cells against cytotoxicity of gemcitabine without compromising its activity against human leukemic cells.
Topics: Antigens, CD34; Antineoplastic Agents; Bone Marrow Cells; Cell Division; Coculture Techniques; Cytotoxins; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gemcitabine; Hematopoietic Stem Cells; HL-60 Cells; Humans; Immunosuppressive Agents; Leukemia; T-Lymphocytes | 2003 |
Synergistic effect of sequential administration of mitoguazone (MGBG) and gemcitabine in treating tissue cultured human breast cancer cells and mammary rat tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Mitoguazone; Rats; Survival Analysis; Tumor Cells, Cultured | 2003 |
High-resolution magnetic resonance imaging of the efficacy of the cytosine analogue 1-[2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl]-N(4)-palmitoyl cytosine (CS-682) in a liver-metastasis athymic nude mouse model.
Topics: Animals; Antineoplastic Agents; Arabinonucleosides; Cell Division; Colonic Neoplasms; Cytosine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2003 |
Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Etoposide; Gemcitabine; Humans; Morpholines; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured | 2003 |
In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Organoplatinum Compounds; Tumor Cells, Cultured | 2003 |
Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis.
Topics: Antineoplastic Agents; Carboplatin; Deoxycytidine; Drug Therapy, Combination; Female; Fingers; Gangrene; Gemcitabine; Humans; Immunosuppressive Agents; Infarction; Middle Aged; Necrosis; Scleroderma, Systemic | 2003 |
The radioenhancement of two human head and neck squamous cell carcinomas by 2'-2' difluorodeoxycytidine (gemcitabine; dFdC) is mediated by an increase in radiation-induced residual chromosome aberrations but not residual DNA DSBs.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chromosome Aberrations; Combined Modality Therapy; Deoxycytidine; DNA Damage; DNA, Neoplasm; Gemcitabine; Head and Neck Neoplasms; Humans; Radiation Tolerance; Radiation-Sensitizing Agents; Radiation, Ionizing; Time Factors; Tumor Cells, Cultured | 2003 |
The recent past and future of adjuvant therapy for pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant | 2003 |
Fatal hepatic failure due to gemcitabine and vinorelbine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Failure, Acute; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2003 |
Simultaneous determination of gemcitabine and its metabolite in human plasma by high-performance liquid chromatography.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Urinary Bladder Neoplasms | 2003 |
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Multidrug Resistance-Associated Proteins; Neoplasms; Phosphorylation; Tumor Cells, Cultured | 2003 |
Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-X Protein; Blotting, Western; Caspases; Cell Division; Cisplatin; Combined Modality Therapy; Deoxycytidine; DNA Primers; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Potentials; Mesothelioma; Mitochondria; Oligonucleotides, Antisense; Pleural Neoplasms; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Ribonucleotide Reductases; Tumor Cells, Cultured | 2003 |
Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bryostatins; Cell Survival; Cytosol; Deoxycytidine; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gemcitabine; Humans; Isoenzymes; Lactones; Macrolides; Protein Kinase C; Tumor Cells, Cultured | 2003 |
The role of DNA synthesis inhibition in the cytotoxicity of 2',2'-difluoro-2'-deoxycytidine.
Topics: Antineoplastic Agents; Aphidicolin; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; DNA, Neoplasm; Enzyme Inhibitors; Gemcitabine; Glioblastoma; Humans; Hydroxyurea; Nucleic Acid Synthesis Inhibitors; Pyrimidine Nucleosides; Ribonucleotide Reductases | 2003 |
[Pancreatic cancer--diagnostics and therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Neoadjuvant Therapy; Pancreatic Neoplasms | 2003 |
Peripheral neuropathy due to therapy with paclitaxel, gemcitabine, and cisplatin in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neurologic Examination; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases | 2003 |
In vitro cytotoxicity of aplidin and crossresistance with other cytotoxic drugs in childhood leukemic and normal bone marrow and blood samples: a rational basis for clinical development.
Topics: Antineoplastic Agents; Blood Cells; Bone Marrow; Carnitine; Case-Control Studies; Cell Survival; Child; Deoxycytidine; Depsipeptides; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Interactions; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia; Peptides, Cyclic; Podophyllotoxin | 2003 |
A new therapeutical approach: topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy with paclitaxel and platinum.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Leukopenia; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Paclitaxel; Platinum Compounds; Survival Rate; Thrombocytopenia; Topotecan; Treatment Failure | 2003 |
[Acute pulmonary toxicity due to gemcitabine: a role for asbestos exposure?].
Topics: Acute Disease; Aged; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Asbestos; Asbestosis; Causality; Deoxycytidine; Diagnosis, Differential; Diuretics; Dyspnea; Female; Gemcitabine; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Occupational Exposure; Oxygen Inhalation Therapy; Respiratory Insufficiency; Retrospective Studies; Smoking; Steroids | 2003 |
Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cell Division; Cetuximab; Cobalt Radioisotopes; Deoxycytidine; Electrophoresis, Polyacrylamide Gel; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; GRB2 Adaptor Protein; Humans; Immunosorbent Techniques; Iodine Radioisotopes; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2003 |
[Combination therapy with vinorelbine and gemcitabine in unresectable non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2003 |
[Effective treatment with the additional administration of UFT for refractory malignant pleural effusion secondary to adenocarcinoma of the lung after the treatment regimen of gemcitabine and vinorelbine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Tegafur; Uracil; Vinblastine; Vinorelbine | 2003 |
Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines.
Topics: Antigens, Neoplasm; Blotting, Northern; Calcium-Binding Proteins; Cell Cycle Proteins; Cell Line, Tumor; Chromosomes, Human, X; Cluster Analysis; Deoxycytidine; DNA Primers; DNA, Complementary; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunotherapy; Male; Multigene Family; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Oligonucleotides; Paclitaxel; Phenotype; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Testis; Time Factors; Transfection | 2003 |
Systemic capillary leak syndrome resulting from gemcitabine treatment in renal cell carcinoma: a case report.
Topics: Biopsy, Needle; Capillary Leak Syndrome; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Pulmonary Edema; Risk Assessment; Severity of Illness Index | 2003 |
Low-dose gemcitabine plus cisplatin in previously treated, relapsed non-Hodgkin's lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Salvage Therapy | 2003 |
It's what's inside that counts.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Pancreatic Neoplasms | 2003 |
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Division; Cell Line; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Screening Assays, Antitumor; Fenretinide; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Mesothelioma; Paclitaxel; Taxoids; Topotecan | 2003 |
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; CD4-Positive T-Lymphocytes; CD40 Antigens; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Hemagglutinins; Immunotherapy; Lymphocytes, Tumor-Infiltrating; Mesothelioma; Mice; Mice, Inbred BALB C; Neoplasms, Experimental | 2003 |
Rituximab in combination with vinorelbine/gemcitabine chemotherapy in patients with primary refractory or early relapsed T cell rich B cell lymphoma. A pilot study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Remission Induction; Rituximab; Salvage Therapy; T-Lymphocytes; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
Sensitization of ara-C-resistant lymphoma cells by a pronucleotide analogue.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Cell Division; Chromatography, High Pressure Liquid; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma, Follicular; Nucleic Acid Synthesis Inhibitors; Prodrugs; Tumor Cells, Cultured | 2003 |
Lung function changes and pulmonary complications in patients with stage III non-small cell lung cancer treated with gemcitabine/cisplatin as part of combined modality treatment.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Pulmonary Disease, Chronic Obstructive; Respiratory Function Tests; Retrospective Studies; Smoking | 2003 |
[Remission rate of mediastinal lymph nodes after multimodal therapy of lung cancer--is it a prognostic factor?].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Etoposide; Feasibility Studies; Female; Gemcitabine; Hospital Mortality; Humans; Lung; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Prognosis; Radiotherapy Dosage; Survival Analysis | 2003 |
[A case of advanced pancreatic cancer treated with gemcitabine hydrochloride].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2003 |
Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Cell Cycle Proteins; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2003 |
A novel red fluorescent protein orthotopic pancreatic cancer model for the preclinical evaluation of chemotherapeutics.
Topics: Animals; Antineoplastic Agents; Camptothecin; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Luminescent Proteins; Male; Mice; Mice, Nude; Models, Animal; Neoplasm Metastasis; Pancreatic Neoplasms; Predictive Value of Tests; Red Fluorescent Protein; Transduction, Genetic; Tumor Cells, Cultured | 2003 |
Synthesis and cytotoxic activity of two novel 1-dodecylthio-2-decyloxypropyl-3-phosphatidic acid conjugates with gemcitabine and cytosine arabinoside.
Topics: Antineoplastic Agents; Buffers; Cell Line; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Inhibitory Concentration 50; Phosphatidic Acids; Ribonucleotide Reductases; Solubility | 2003 |
Selective targeting of homologous DNA recombination repair by gemcitabine.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Cell Survival; CHO Cells; Cricetinae; Deoxycytidine; DNA Damage; DNA Repair; DNA-Binding Proteins; Gemcitabine; Hyperthermia, Induced; Mitomycin; Rad51 Recombinase; Radiation Tolerance; Radiation-Sensitizing Agents; Radiobiology; Tumor Cells, Cultured | 2003 |
Supportive care in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quality of Life; Randomized Controlled Trials as Topic; Survival Rate; Vinblastine; Vinorelbine | 2003 |
Changes of mitochondrial respiration, mitochondrial content and cell size after induction of apoptosis in leukemia cells.
Topics: Apoptosis; Cell Respiration; Cell Size; Cell Survival; Cytosol; Deoxycytidine; Dexamethasone; Electron Transport; G1 Phase; Gemcitabine; Genes, cdc; Humans; Intracellular Membranes; Membrane Potentials; Mitochondria; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; S Phase; Tumor Cells, Cultured | 2003 |
[Gemcitabine-cisplatin combination in the first line treatment of non-small cell lung cancer. Our experience and analysis of safety].
Topics: Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arrhythmias, Cardiac; Carcinoma, Non-Small-Cell Lung; Cisplatin; Constipation; Creatinine; Deoxycytidine; Diarrhea; Drug Administration Schedule; Drug Eruptions; Dyspnea; Female; Gemcitabine; Hemoglobins; Humans; Hyponatremia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Retrospective Studies; Severity of Illness Index; Taste Disorders; Thrombocytopenia; Treatment Outcome | 2003 |
Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient receiving concurrent radiation and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Radiography; Skin Neoplasms; Stevens-Johnson Syndrome | 2003 |
Unusual response to gemcitabine in a case of peritoneal malignant fibrous histiocytoma.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Histiocytoma, Benign Fibrous; Humans; Peritoneal Neoplasms | 2003 |
Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gefitinib; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Lung; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2003 |
Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Neoplasm Staging | 2003 |
Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy.
Topics: Animals; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Bromodeoxyuridine; Cell Cycle; Colonic Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Ligands; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Genetic; Neoplasm Transplantation; Radioimmunotherapy; Recombinant Fusion Proteins; Time Factors; Tissue Distribution | 2003 |
Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Radioimmunotherapy; Time Factors; Tissue Distribution; Yttrium Radioisotopes | 2003 |
Establishment of gemcitabine-resistant human pancreatic cancer cells and effect of brefeldin-a on the resistant cell line.
Topics: Brefeldin A; Cell Division; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2003 |
An expedient assay for determination of gemcitabine and its metabolite in human plasma using isocratic ion-pair reversed-phase high-performance liquid chromatography.
Topics: Calibration; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Sensitivity and Specificity | 2003 |
Colour junctions as predictors of radiosensitivity: X-irradiation combined with gemcitabine in a lung carcinoma cell line.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chromosome Aberrations; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Flow Cytometry; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents | 2003 |
Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity.
Topics: Animals; Antimetabolites, Antineoplastic; Base Sequence; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Nucleus; Chromatin; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; DNA-Binding Proteins; Drosophila; Gemcitabine; Gene Deletion; Gene Expression Regulation, Enzymologic; Humans; Molecular Sequence Data; Mutagenesis, Site-Directed; Plasmids; Precipitin Tests; Promoter Regions, Genetic; Protein Binding; Protein Structure, Tertiary; Sp1 Transcription Factor; Transcription Factors; Transfection; Upstream Stimulatory Factors | 2003 |
[A case of advanced pancreatic cancer showing remarkable response to gemcitabine treatment].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Karnofsky Performance Status; Liver Neoplasms; Pancreatic Neoplasms | 2003 |
Synergistic activity of gamma-linolenic acid and cytotoxic drugs against pancreatic adenocarcinoma cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Fluorouracil; gamma-Linolenic Acid; Gemcitabine; Pancreatic Neoplasms | 2003 |
Pharmacokinetics after pulmonary artery perfusion with gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Survival; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Gemcitabine; In Vitro Techniques; Lung; Lung Neoplasms; Male; Pulmonary Circulation; Rats; Rats, Inbred Strains; Tumor Cells, Cultured | 2003 |
Large cell neuroendocrine carcinoma of the urinary bladder with lymphoepithelioma-like features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Epithelial Cells; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Surgical Procedures | 2003 |
Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy-proven Stage IIIA(N2) nonsmall cell lung carcinoma: a Phase II multicenter study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Extensive palliative surgery for advanced mesothelioma of the tunica vaginalis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Debridement; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Neoplasm Recurrence, Local; Palliative Care; Penis; Scrotum; Testicular Neoplasms; Urethra | 2003 |
Gemcitabine with cyclosporine or with tacrolimus exerts a synergistic effect and induces tolerance in the rat.
Topics: Acute Disease; Animals; Cyclosporine; Deoxycytidine; Drug Synergism; Gemcitabine; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Isoantigens; Male; Rats; Rats, Inbred Lew; Tacrolimus; Tissue Donors; Transplantation Tolerance | 2003 |
Adenovirus type 5 E1A sensitizes hepatocellular carcinoma cells to gemcitabine.
Topics: Adenovirus E1A Proteins; Adenoviruses, Human; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; NF-kappa B; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Transfection | 2003 |
Fatal cholestatic liver failure associated with gemcitabine therapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Cholestasis, Intrahepatic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Liver; Liver Failure, Acute; Liver Neoplasms; Middle Aged; Necrosis | 2003 |
Combination chemotherapy with topotecan for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Vinblastine; Vinorelbine | 2003 |
Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.
Topics: Antimetabolites, Antineoplastic; Benzoquinones; cdc25 Phosphatases; Cell Line; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; Gemcitabine; HeLa Cells; HSP90 Heat-Shock Proteins; Humans; Immunoblotting; Lactams, Macrocyclic; Precipitin Tests; Protein Binding; Protein Kinases; Protein Serine-Threonine Kinases; Rifabutin; S Phase; Signal Transduction; Time Factors | 2003 |
Pharmacokinetics of intravesical gemcitabine: a preclinical study in pigs.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Evaluation, Preclinical; Female; Gemcitabine; Swine; Urinary Bladder; Urinary Bladder Neoplasms | 2003 |
Rapid in vitro chemosensitivity analysis of human colon tumor cell lines.
Topics: Antineoplastic Agents; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Culture Media; Deoxycytidine; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Humans; Hydrogen-Ion Concentration; Organoplatinum Compounds; Oxaliplatin; Reproducibility of Results; Tetrazolium Salts | 2003 |
Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro.
Topics: Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Radiation Tolerance; Radiation-Sensitizing Agents; S Phase; Time Factors | 2003 |
Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B.
Topics: Annexin A5; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Northern; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chromatin; Coloring Agents; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; Detergents; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Epothilones; Flow Cytometry; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Multienzyme Complexes; Phosphorylation; Precipitin Tests; Proteasome Endopeptidase Complex; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sepharose; Taxoids; Tetrazolium Salts; Thiazoles; Time Factors; Trastuzumab | 2003 |
Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cell Membrane; Deoxycytidine; DNA, Complementary; Dose-Response Relationship, Drug; Gemcitabine; Humans; Inhibitory Concentration 50; Kinetics; Membrane Transport Proteins; Pancreatic Neoplasms; Poly A; Polymerase Chain Reaction; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Messenger; Time Factors; Transfection | 2003 |
Enhanced radiosensitization with gemcitabine in mismatch repair-deficient HCT116 cells.
Topics: Base Pair Mismatch; Cell Cycle; Deoxyadenine Nucleotides; Deoxycytidine; DNA Repair; DNA, Neoplasm; Gemcitabine; HCT116 Cells; Humans; Nucleotides; Radiation Tolerance; Radiation-Sensitizing Agents | 2003 |
[Two cases of radiation myositis probably induced by recall phenomenon].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Myositis; Radiation-Sensitizing Agents; Radiotherapy | 2003 |
Effects of intraperitoneal administration of gemcitabine and paclitaxel on hepatic regeneration in rats.
Topics: Animals; Biopsy, Needle; Deoxycytidine; Disease Models, Animal; Gemcitabine; Hepatectomy; Immunohistochemistry; Injections, Intraperitoneal; Liver; Liver Function Tests; Liver Regeneration; Male; Paclitaxel; Rats; Rats, Inbred Strains; Sensitivity and Specificity | 2003 |
Special patients, special treatments.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Fever; Gemcitabine; Health Status; Humans; Lung Neoplasms; Middle Aged; Neutropenia; Population Dynamics; Taxoids | 2003 |
Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Fingers; Gangrene; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Iloprost; Male; Middle Aged; Pancreatic Neoplasms; Urinary Bladder Neoplasms; Vasodilator Agents | 2003 |
Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Stevens-Johnson Syndrome; Urinary Bladder Neoplasms | 2003 |
Gemcitabine-induced radiation recall dermatitis following whole pelvic radiation therapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Radiation-Sensitizing Agents; Radiodermatitis | 2003 |
Dose-finding with two agents in Phase I oncology trials.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Biometry; Clinical Trials, Phase I as Topic; Cyclophosphamide; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Models, Statistical; Neoplasms | 2003 |
Unusual response to second-line single-agent gemcitabine in locally advanced primary leiomyosarcoma of the lung: a case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged | 2003 |
Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prognosis; Survival Rate; Tomography, X-Ray Computed | 2003 |
Fanconi's anemia and clinical radiosensitivity report on two adult patients with locally advanced solid tumors treated by radiotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Anus Neoplasms; Carboplatin; Carcinoma, Squamous Cell; Cobalt Radioisotopes; Combined Modality Therapy; Cytogenetics; Deoxycytidine; Dose Fractionation, Radiation; Fanconi Anemia; Flow Cytometry; Gemcitabine; Humans; Lymphatic Metastasis; Male; Mouth Neoplasms; Mutation; Neoplasms, Second Primary; Oropharyngeal Neoplasms; Radiation Tolerance; Radioisotope Teletherapy; Radiotherapy Dosage; Salvage Therapy; Time Factors; Tongue Neoplasms | 2003 |
Enhancement of effects of irradiation by gemcitabine in a glioblastoma cell line and cell line spheroids.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Glioblastoma; Humans; Radiation-Sensitizing Agents; Spheroids, Cellular | 2004 |
Re: a multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Costs; Endpoint Determination; Gemcitabine; Humans; Mesothelioma; Organoplatinum Compounds; Oxaliplatin; Patient Care Planning; Pleural Neoplasms; Treatment Outcome | 2003 |
Safety and efficacy of convection-enhanced delivery of gemcitabine or carboplatin in a malignant glioma model in rats.
Topics: Animals; Antineoplastic Agents; Basal Ganglia; Brain Neoplasms; Brain Stem; Carboplatin; Convection; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Glioma; Injections, Intralesional; Male; Rats; Rats, Inbred F344 | 2003 |
[Chemoradiation therapy for stage IV pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Intraoperative Care; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy Dosage; Survival Rate | 2003 |
[Novel chemoradiotherapy for locally advanced pancreatic cancer using arterial infusion chemotherapy following the alteration of peripancreatic blood flow].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Intraoperative Care; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Survival Rate | 2003 |
[Gemcitabine infusion via splenic artery for advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Pancreatic Neoplasms; Quality of Life; Remission Induction; Splenic Artery | 2003 |
A novel biweekly schedule with cisplatin and gemcitabine in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Confidence Intervals; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Survival Rate | 2003 |
RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Northern; Blotting, Western; Caspases; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreas; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA; RNA Interference; RNA, Small Interfering; Transfection | 2003 |
[Chemotherapy of bladder cancer. Systemic therapy with reduced toxicity].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Clinical Trials as Topic; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Palliative Care; Urinary Bladder Neoplasms | 2003 |
[Home chemotherapy for lung cancer: a five year retrospective study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hospital Bed Capacity; Humans; Lung Neoplasms; Male; Medication Errors; Middle Aged; Quality of Life; Retrospective Studies; Safety; Treatment Outcome; Vinblastine; Vinorelbine | 2003 |
[Non-platinum induction chemotherapy for stage III non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2003 |
Trans-tissue, sustained release of gemcitabine from photocured gelatin gel inhibits the growth of heterotopic human pancreatic tumor in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Gelatin; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Tissue Distribution; Transplantation, Heterologous | 2003 |
Gemcitabine suppresses malignant ascites of human pancreatic cancer: correlation with VEGF expression in ascites.
Topics: Animals; Antimetabolites, Antineoplastic; Ascites; Ascitic Fluid; Cell Division; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Random Allocation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
Forced expression of cytidine deaminase confers sensitivity to capecitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Cell Survival; Cytidine Deaminase; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease Models, Animal; DNA, Complementary; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Thymidine Phosphorylase; Thymidylate Synthase; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2003 |
RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Time Factors; Transplantation, Heterologous | 2004 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Survival Rate; Treatment Outcome | 2003 |
Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Division; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Remission Induction; Time Factors; Tomography, X-Ray Computed | 2003 |
Domiciliary chemotherapy with gemcitabine is safe and acceptable to advanced non-small-cell lung cancer patients: results of a feasibility study.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Home Care Services; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Treatment Outcome | 2003 |
Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gemcitabine; Humans; Middle Aged; Mitomycin; Neoplasm Staging | 2003 |
A novel cell line and xenograft model of ampulla of Vater adenocarcinoma.
Topics: Adenocarcinoma; Ampulla of Vater; Animals; Cell Adhesion; Common Bile Duct Neoplasms; Deoxycytidine; DNA Methylation; Fluorouracil; Gemcitabine; Genes, p16; Genes, p53; Genes, ras; Humans; Immunophenotyping; Interferon-gamma; Karyotyping; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Ploidies; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
[Arterial oil chemoembolization: a new method of treatment for pancreatic cancer].
Topics: Adult; Aged; Angiography; Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Iodized Oil; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
[Combined gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2003 |
Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Facial Neoplasms; Gemcitabine; Humans; Jaw Neoplasms; Male; Middle Aged; Snake Venoms | 2004 |
Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Costs and Cost Analysis; Deoxycytidine; Drug Costs; Europe; Gemcitabine; Hospital Costs; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies | 2004 |
[New: gemzar plus taxan in metastatic breast carcinoma. Optimal combination].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Taxoids | 2003 |
[A case of undifferentiated bladder carcinoma with axilla lymph node metastasis successfully treated with gemcitabine and cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Carcinoma; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Urinary Bladder Neoplasms | 2003 |
Mistletoe and gemcitabine in patients with advanced cancer: a model for the phase I study of botanicals and botanical-drug interactions in cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Complementary Therapies; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Models, Theoretical; Neoplasms; Phytotherapy; Plant Extracts; Plant Proteins; Research Design; Viscum album | 2003 |
Gemcitabine and reactivation of hepatitis B.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hepatitis B; Hepatitis B Surface Antigens; Humans; Liver Function Tests; Pleural Neoplasms; Recurrence | 2003 |
Retrospective analysis of adverse drug reactions induced by gemcitabine treatment in patients with non-small cell lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies | 2004 |
An evaluation of gemcitabines differential radiosensitising effect in related bladder cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Colony-Forming Units Assay; Deoxycytidine; Gemcitabine; Humans; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2004 |
Gemcitabine-induced vasculitis in advanced transitional cell carcinoma of the bladder.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms; Urinary Diversion; Vasculitis | 2004 |
Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.
Topics: Animals; Antibiotics, Antineoplastic; Antiviral Agents; B-Lymphocytes; Cell Line, Transformed; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Epstein-Barr Virus Infections; Ganciclovir; Gemcitabine; Herpesvirus 4, Human; Humans; Lymphoma, B-Cell; Mice; Mice, SCID; Signal Transduction; Tumor Cells, Cultured; Virus Activation | 2004 |
Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Carrier Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Caspase 9; Caspases; Cytochromes c; Deoxycytidine; Drug Resistance, Neoplasm; fas Receptor; Female; Gemcitabine; Intracellular Signaling Peptides and Proteins; Membrane Potentials; Mice; Mice, Inbred BALB C; Mice, SCID; Mitochondria; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retroviridae; Tumor Cells, Cultured | 2004 |
An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; Female; Gemcitabine; Humans; Inhibitory Concentration 50 | 2004 |
Radiosensitization of vinorelbine and gemcitabine in NCI-H460 non-small-cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Radiation-Sensitizing Agents; Vinblastine; Vinorelbine | 2004 |
Dexamethasone as a chemoprotectant in cancer chemotherapy: hematoprotective effects and altered pharmacokinetics and tissue distribution of carboplatin and gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Bone Marrow; Carboplatin; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Antagonism; Gemcitabine; Glucocorticoids; Injections, Intravenous; Injections, Subcutaneous; Longevity; Male; Mice; Mice, Inbred Strains | 2004 |
New perspectives with antimetabolites in the management of breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans | 2004 |
Gemcitabine associated vasculitis leading to necrotizing enterocolitis and death in women undergoing primary treatment for epithelial ovarian/peritoneal cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Enterocolitis, Necrotizing; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Vasculitis | 2004 |
Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Female; Flow Cytometry; Gemcitabine; Lipopeptides; Macrophage Activation; Male; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oligopeptides; Pancreas; Pancreatic Neoplasms; Spleen; Survival Analysis; Ultrasonography | 2004 |
In response to Li et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. IJROBP 2003;57:98-104.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Lymphatic Irradiation; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2004 |
Suppression of human pancreatic cancer cell proliferation by AGN194204, an RXR-selective retinoid.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; CDC2-CDC28 Kinases; Cell Cycle; Cell Division; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Deoxycytidine; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Interferon-gamma; Ligands; Pancreatic Neoplasms; Plasmids; Protein Binding; Proto-Oncogene Proteins; Receptors, Retinoic Acid; Retinoid X Receptors; Retinoids; Tetrahydronaphthalenes; Time Factors; Transcription Factors | 2004 |
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA; DNA Repair; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA, Messenger; Time Factors; Treatment Outcome; Tumor Suppressor Proteins | 2004 |
Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Clinical Trials as Topic; Comet Assay; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Epirubicin; Flow Cytometry; Gemcitabine; Humans; Inhibitory Concentration 50; Mutation; Rhodamines; Time Factors; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2004 |
Combined 90Yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Body Weight; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Heterocyclic Compounds; Humans; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms, Experimental; Organometallic Compounds; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2004 |
[Outcomes of treatment with gemcitabine for unresectable pancreatic cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2004 |
Management of primary resistance to gemcitabine and cisplatin (G-C) chemotherapy in metastatic bladder cancer with HER2 over-expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Receptor, ErbB-2; Urinary Bladder Neoplasms | 2004 |
Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Imidazoles; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerases; Pyridines | 2004 |
Recurrent ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retreatment; Topotecan; Treatment Failure | 2004 |
Gestational choriocarcinoma: an unusual presentation with response to gemcitabine and surgery.
Topics: Adult; Antimetabolites, Antineoplastic; Choriocarcinoma; Chorionic Gonadotropin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Uterine Neoplasms | 2004 |
Pretreatment with dexamethasone increases antitumor activity of carboplatin and gemcitabine in mice bearing human cancer xenografts: in vivo activity, pharmacokinetics, and clinical implications for cancer chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Carboplatin; Colonic Neoplasms; Deoxycytidine; Dexamethasone; Drug Synergism; Gemcitabine; Glioma; Half-Life; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms; Transplantation, Heterologous | 2004 |
Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Liposomes; Male; Mice; Mice, Nude; Mitoxantrone; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-raf; Taxoids; Xenograft Model Antitumor Assays | 2004 |
Measurement of the anticancer agent gemcitabine and its deaminated metabolite at low concentrations in human plasma by liquid chromatography-mass spectrometry.
Topics: Adult; Antimetabolites, Antineoplastic; Deamination; Deoxycytidine; Gemcitabine; Humans; Mass Spectrometry; Reproducibility of Results; Sensitivity and Specificity | 2004 |
Right pneumonectomy for adenocarcinoma stage IIIA-N2 in a heart transplant patient after induction chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Heart Transplantation; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Postoperative Complications; Ribonucleotide Reductases | 2004 |
Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Northern; Cell Line, Tumor; Clusterin; Coloring Agents; Deoxycytidine; DNA; DNA Fragmentation; Dose-Response Relationship, Drug; Gemcitabine; Glycoproteins; Humans; Immunohistochemistry; In Vitro Techniques; Lung Neoplasms; Mice; Molecular Chaperones; Nucleotides; Oligonucleotide Array Sequence Analysis; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Double-Stranded; RNA, Small Interfering; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; CDC2-CDC28 Kinases; Cell Death; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-8; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Multienzyme Complexes; Neoplasm Transplantation; Neovascularization, Pathologic; Proteasome Endopeptidase Complex; Pyrazines; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2004 |
Role of 2'-2' difluorodeoxycytidine (gemcitabine)-induced cell cycle dysregulation in radio-enhancement of human head and neck squamous cell carcinomas.
Topics: Carcinoma, Squamous Cell; Cell Cycle; Deoxycytidine; Flow Cytometry; Gemcitabine; Head and Neck Neoplasms; Humans; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2004 |
Nuclear factor Y regulation and promoter transactivation of human ribonucleotide reductase subunit M2 gene in a Gemcitabine resistant KB clone.
Topics: Antimetabolites, Antineoplastic; Biological Transport; CCAAT-Binding Factor; CCAAT-Enhancer-Binding Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Hydroxamic Acids; KB Cells; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Ribonucleoside Diphosphate Reductase; Transcription Factors; Transcriptional Activation | 2004 |
Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Blood Flow Velocity; Cell Death; Cell Division; Deoxycytidine; Endothelium, Vascular; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Sirolimus; Transplantation, Heterologous | 2004 |
[A case of inoperable advanced gallbladder cancer that has maintained stable disease status for a long period with gemcitabine and cisplatin therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Middle Aged; Quality of Life; Survivors; Tomography, X-Ray Computed | 2004 |
Costs of treatment and outcomes associated with second-line therapy and greater for relapsed ovarian cancer.
Topics: Adolescent; Adult; Aged; Deoxycytidine; Drug Costs; Drug Resistance, Neoplasm; Female; Gemcitabine; Health Care Costs; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Salvage Therapy; Topotecan | 2004 |
Inhibition of AKT abrogates chemotherapy-induced NF-kappaB survival mechanisms: implications for therapy in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Genes, bcl-2; Humans; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Phospholipid Ethers; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Signal Transduction | 2004 |
Screening for supra-additive effects of cytotoxic drugs and gamma irradiation in an in vitro model for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gamma Rays; Gemcitabine; Humans; Liver Neoplasms; Radiation-Sensitizing Agents; Spheroids, Cellular; Time Factors | 2004 |
Treatment with alemtuzumab in a case of refractory primary cutaneous CD30-negative CD8-positive cytotoxic large T-cell lymphoma.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CD8 Antigens; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunophenotyping; Lymphoma, T-Cell, Cutaneous; Organoplatinum Compounds; Oxaliplatin; Pentostatin; Prednisone; Remission Induction; Salvage Therapy; Skin Neoplasms; Vincristine | 2004 |
[Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Chemoembolization of rat liver metastasis with microspheres and gemcitabine followed by evaluation of tumor cell load by chemiluminescence.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chemoembolization, Therapeutic; Colonic Neoplasms; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Liver Neoplasms; Male; Microspheres; Neoplasm Transplantation; Organ Size; Rats; Rats, Inbred Strains; Tumor Burden | 2004 |
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Butadienes; Cell Division; Cell Line, Tumor; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gemcitabine; Humans; Hypoxia; Mitogen-Activated Protein Kinases; Morpholines; Neovascularization, Pathologic; NF-kappa B; Nitriles; Oxygen; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Signal Transduction; Sp1 Transcription Factor; Time Factors; Tyrosine | 2004 |
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Northern; Blotting, Western; Caspases; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; E2F Transcription Factors; E2F1 Transcription Factor; Gemcitabine; Genes, Dominant; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Pyrimidines; Ribonucleoside Diphosphate Reductase; src-Family Kinases; Transcription Factors; Tyrosine | 2004 |
Gemcitabine plus carboplatin; and gemcitabine, docetaxel, and carboplatin combined chemotherapy regimens in patients with metastatic urothelial carcinoma previously treated with a platinum-based regimen: preliminary report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pilot Projects; Taxoids; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2004 |
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Interactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Taxoids | 2004 |
Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Mycosis Fungoides; Ribonucleotide Reductases; Skin Neoplasms | 2004 |
Comparison of zero- and second-order derivative spectrophotometric and HPLC methods for the determination of gemcitabine in human plasma.
Topics: Calibration; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2004 |
High body mass index correlates with increased risk of venous irritation by vinorelbine infusion.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Mitomycins; Phlebitis; Retrospective Studies; Risk Factors; Vinblastine; Vinorelbine | 2004 |
Synergistic antitumor activity by combined treatment with gemcitabine and antisense oligodeoxynucleotide targeting clusterin gene in an intravesical administration model against human bladder cancer kotcc-1 cells.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Clusterin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Glycoproteins; Humans; Mice; Mice, Inbred BALB C; Molecular Chaperones; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Urinary Bladder Neoplasms | 2004 |
Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Pancreatic Neoplasms; Pemetrexed; Ribonucleotide Reductases | 2004 |
Multidisciplinary management of lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Vinblastine; Vinorelbine | 2004 |
Effects of gemcitabine on cell survival and chromosome aberrations after pulsed low dose-rate irradiation.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Chromosome Aberrations; Chromosomes; Deoxycytidine; Dose-Response Relationship, Radiation; Gemcitabine; Humans; Lung Neoplasms; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents; X-Rays | 2004 |
In vitro assessment of nucleoside analogs in multiple myeloma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Multiple Myeloma; Nucleosides; Tumor Cells, Cultured | 2004 |
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Transfer Techniques; Genetic Vectors; Humans; Pancreatic Neoplasms; Retinoblastoma Protein; Tumor Suppressor Protein p53 | 2004 |
Experimental study on the toxicity and the local and systemic tolerability of gemcitabine after topical treatment of the rabbit bladder.
Topics: Absorption; Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Body Weight; Bone Marrow; Deoxycytidine; Drinking; Drug Evaluation, Preclinical; Eating; Gemcitabine; Male; Maximum Tolerated Dose; Muscles; Rabbits; Spleen; Testis; Thymus Gland; Urinary Bladder | 2004 |
Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine.
Topics: Antineoplastic Agents; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Models, Chemical; Molecular Conformation; Molecular Structure; Ribonucleotide Reductases; Structure-Activity Relationship; Thermodynamics | 2004 |
High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Incidence; Lung Diseases; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Taxoids | 2004 |
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Prodrugs; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies | 2004 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
Validated procedure for simultaneous trace level determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high-performance liquid chromatography with tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Mass Spectrometry | 2004 |
Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Heart Neoplasms; Humans; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Remission Induction | 2004 |
Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene.
Topics: Animals; Apoptosis; Cell Cycle; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Gene Deletion; Gene Expression Regulation, Enzymologic; Humans; Lymphoma, Follicular; Mice; Mice, Nude; Neoplasm Transplantation; Nucleic Acids; Reverse Transcriptase Polymerase Chain Reaction; Transplantation, Heterologous; Tritium; Tumor Cells, Cultured | 2004 |
Gemcitabine and vinorelbine as a salvage regimen for relapse in Hodgkin lymphoma after autologous hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
[Bronchiolitis obliterans organizing pneumonia induced by chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bronchoalveolar Lavage; Cryptogenic Organizing Pneumonia; Deoxycytidine; Female; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Paclitaxel; Treatment Outcome | 2004 |
Cytotoxic chemotherapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Neoplasm Metastasis; Survival Rate | 2004 |
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Time Factors; Xenograft Model Antitumor Assays | 2004 |
Effect of LY293111 in combination with gemcitabine in colonic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Body Weight; Colonic Neoplasms; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Receptors, Leukotriene B4; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Carbon-Nitrogen Ligases; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytosine Deaminase; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2004 |
A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antigens, CD; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Caspase 3; Caspases; Cell Adhesion Molecules; Cell Line, Tumor; CSK Tyrosine-Protein Kinase; Cytochromes c; Deoxycytidine; Drug Resistance, Viral; Enzyme Activation; Gemcitabine; Gene Silencing; GPI-Linked Proteins; Humans; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; src-Family Kinases; Transfection | 2004 |
[Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Methotrexate; Middle Aged; Taxoids; Urinary Bladder Neoplasms; Vinblastine | 2004 |
[Development and characterization of a gemcitabine-resistant variant of human lung adenocarcinoma cell line A549].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Survival; Colony-Forming Units Assay; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Vincristine | 2004 |
siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Small Interfering; src-Family Kinases; Tumor Cells, Cultured | 2004 |
[Mechanistic study of radiosensitization by gemcitabine on human squamous carcinoma cell line of the cervix].
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Deoxycytidine; Dose-Response Relationship, Drug; Female; Flow Cytometry; Gemcitabine; HeLa Cells; Humans; Radiation Tolerance; Radiation-Sensitizing Agents; Time Factors; Tumor Suppressor Protein p53 | 2004 |
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Bridged-Ring Compounds; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Topotecan | 2004 |
Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Protease Inhibitors; Pyrazines; Tumor Cells, Cultured | 2004 |
Gemcitabine-associated thrombotic microangiopathy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Hypertension; Incidence; Male; Microcirculation; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Retrospective Studies; Vascular Diseases | 2004 |
Promising combination therapies with gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; DNA, Neoplasm; Docetaxel; Drug Synergism; Gemcitabine; Histones; Humans; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Taxoids; Tumor Stem Cell Assay | 2004 |
Cellular response of X-ray sensitive hamster mutant cell lines to gemcitabine, cisplatin and 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line; CHO Cells; Cisplatin; Cricetinae; Deoxycytidine; DNA; DNA Repair; Dose-Response Relationship, Drug; Fluorouracil; Gemcitabine; X-Rays | 2004 |
Non-allergic nature of docetaxel-induced acute hypersensitivity reactions.
Topics: Administration, Oral; Adult; Blood Pressure; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Histamine; Histamine Antagonists; Humans; Hypersensitivity, Immediate; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Paclitaxel; Premedication; Serine Endopeptidases; Tachycardia; Taxoids; Time Factors; Tryptases | 2004 |
[Concurrent chemoradiotherapy using full-dose gemcitabine for patients with unresectable pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2004 |
Setting the record straight: activity of gemcitabine monotherapy for breast cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Neutropenia; Palliative Care; Randomized Controlled Trials as Topic; Treatment Outcome | 2004 |
Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Leukopenia; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms | 2004 |
Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Pancreatic Neoplasms | 2004 |
Mechanism for induction of hydroxyurea resistance and loss of latent EBV genome in hydroxyurea-treated Burkitt's lymphoma cell line Raji.
Topics: Antiviral Agents; Burkitt Lymphoma; Cell Line, Transformed; Cell Line, Tumor; Clone Cells; Deoxycytidine; Drug Resistance, Viral; Enzyme Inhibitors; Gemcitabine; Genome, Viral; Herpesvirus 4, Human; Humans; Hydroxyurea; Ribonucleotide Reductases; Virus Latency | 2004 |
[Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cholestasis; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Heart Failure; Humans; Jaundice, Obstructive; Liver Neoplasms; Lymphatic Metastasis; Male; Pancreatic Neoplasms; Stents; Survivors; Tegafur; Uracil | 2004 |
[A case of advanced pancreatic cancer with remarkable response to thalidomide, celecoxib and gemcitabine].
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Infusions, Intravenous; Isoenzymes; Male; Membrane Proteins; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Sulfonamides; Thalidomide | 2004 |
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.
Topics: Abdominal Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Contraindications; Deoxycytidine; Diaphragm; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Mesothelioma; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pericardium; Pleural Neoplasms; Pneumonectomy; Prognosis; Prostheses and Implants; Radiotherapy, Adjuvant; Surgical Mesh; Survival Analysis; Thoracic Surgery, Video-Assisted; Treatment Outcome | 2004 |
Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.
Topics: Antimetabolites, Antineoplastic; Chi-Square Distribution; Databases, Genetic; Deoxycytidine; Gemcitabine; Gene Frequency; Genetic Variation; Humans; Polymorphism, Single Nucleotide | 2004 |
Our experience with 23 consecutive patients on gemcitabine/carboplatin chemotherapy for treatment of metastasized transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urologic Neoplasms; Urothelium | 2004 |
Long-term disease-free survival effected by gemcitabine in a heavily pretreated patient with recurrent ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gynecologic Surgical Procedures; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Treatment Outcome | 2005 |
Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Decorin; Deoxycytidine; Drug Interactions; Extracellular Matrix; Extracellular Matrix Proteins; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Proteoglycans; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2004 |
HER2 overexpression as a prognostic factor in metastatic breast cancer patients treated with high-dose chemotherapy and autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Paclitaxel; Prognosis; Receptor, ErbB-2; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Neoplasms, Unknown Primary; Prognosis; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2004 |
Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Topics: Alternative Splicing; Amino Acid Sequence; Animals; Antimetabolites, Antineoplastic; Base Sequence; Cell Line; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Molecular Sequence Data; Ovarian Neoplasms; Rats; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured | 2004 |
Gemcitabine-associated scleroderma-like changes of the lower extremities.
Topics: Acetaminophen; Amitriptyline; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Neoplasms; Carcinoma, Transitional Cell; Cisplatin; Clonazepam; Deoxycytidine; Dermis; Doxorubicin; Edema; Gemcitabine; Humans; Infusions, Intravenous; Leg; Lung Neoplasms; Male; Methotrexate; Middle Aged; Morphine; Scleroderma, Diffuse; Vinblastine | 2004 |
Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; Endpoint Determination; Feasibility Studies; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Patient Compliance; Pleural Neoplasms; Predictive Value of Tests; Quality of Life; Reproducibility of Results; Surveys and Questionnaires; Treatment Outcome | 2004 |
Gemcitabine in heavily pretreated patients with recurrent ovarian, peritoneal and fallopian tube carcinoma.
Topics: Adult; Aged; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Registries; Retrospective Studies; Risk Assessment; Salvage Therapy; Survival Analysis; Treatment Outcome | 2004 |
Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2004 |
Increased expression of pro-inflammatory cytokines as a cause of lung toxicity after combined treatment with gemcitabine and thoracic irradiation.
Topics: Animals; Biomarkers; Combined Modality Therapy; Cytokines; Deoxycytidine; Female; Gemcitabine; Hemibody Irradiation; Interleukin-1; Interleukin-6; Lung; Mice; Mice, Inbred C57BL; Radiation-Sensitizing Agents; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2004 |
Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: A novel therapeutic strategy in pancreatic cancer.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Matrix Metalloproteinase 9; NF-kappa B; Pancreatic Neoplasms; Retroviridae; Ribonucleoside Diphosphate Reductase; RNA Interference | 2004 |
[Predictive value of drug resistance-related genes expression in neoadjuvant chemotherapy in patients with non-small cell lung cancer of stage III].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Resistance, Multiple; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasm Staging; Predictive Value of Tests; Survival Rate; Vault Ribonucleoprotein Particles; Vinblastine; Vinorelbine | 2004 |
Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Lewis Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; In Vitro Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Tumor Cells, Cultured; Vesicular stomatitis Indiana virus | 2004 |
The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA, Antisense; Docetaxel; Gastrins; Gemcitabine; Gene Expression; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Precursors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Taxoids; Transfection | 2004 |
Effects of gemcitabine on APE/ref-1 endonuclease activity in pancreatic cancer cells, and the therapeutic potential of antisense oligonucleotides.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA-(Apurinic or Apyrimidinic Site) Lyase; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Kinetics; Oligonucleotides, Antisense; Pancreatic Neoplasms; Transfection | 2004 |
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
Topics: Aged; BRCA1 Protein; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; RNA, Messenger | 2004 |
Retroviral IFN-alpha gene transfer combined with gemcitabine acts synergistically via cell cycle alteration in human pancreatic carcinoma cells implanted orthotopically in nude mice.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA, Complementary; Female; Gemcitabine; Gene Expression; Genetic Therapy; Humans; Interferon-alpha; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Retroviridae; Transgenes | 2004 |
Investigation of the pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in human plasma by liquid chromatography.
Topics: Aged; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Floxuridine; Gemcitabine; Humans; Molecular Structure | 2004 |
Quantitative real time PCR of deoxycytidine kinase mRNA by Light Cycler PCR in relation to enzyme activity and gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Kinase; DNA, Complementary; Esophageal Neoplasms; Gemcitabine; Gene Expression Profiling; Humans; Light; Phosphorylation; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Transplantation, Heterologous; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
Characterization of a gemcitabine-resistant murine leukemic cell line: reversion of in vitro resistance by a mononucleotide prodrug.
Topics: Animals; Antimetabolites, Antineoplastic; Base Sequence; Cell Survival; Deoxycytidine; Disease Models, Animal; DNA Primers; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Kinetics; Leukemia L1210; Mice; Polymerase Chain Reaction; Time Factors | 2004 |
[Role of postoperative adjuvant chemotherapy with gemcitabine for pancreatic cancer: feasibility and anti-tumor effect].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Retrospective Studies; Survival Rate; Vomiting, Anticipatory | 2004 |
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Fatal Outcome; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Incidence; Lymphoma; Male; Middle Aged | 2005 |
Selenoprotein P, as a predictor for evaluating gemcitabine resistance in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Humans; Interferon-gamma; Muscle Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Protein Biosynthesis; Proteins; Reactive Oxygen Species; Selenoprotein P; Selenoproteins; Tumor Cells, Cultured | 2004 |
Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy | 2004 |
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fibrosis; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2003 |
Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Cell Survival; Chemistry, Pharmaceutical; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Liposomes; Thyroid Neoplasms; Tumor Cells, Cultured | 2004 |
Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Division; Cell Line; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Endothelial Cells; Female; Gemcitabine; Humans; Immunohistochemistry; Indoles; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta; Pregnancy; Protein Kinase Inhibitors; Pyrroles; Time Factors; Tissue Culture Techniques; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |
Gemcitabine and haemolytic-uraemic syndrome.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2004 |
Severe neurotoxicity caused by gemcitabine treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Central Nervous System Diseases; Confusion; Deoxycytidine; Female; Gemcitabine; Headache; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Seizures; Urinary Bladder Neoplasms | 2004 |
Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KoTCC-1 model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; Cell Survival; Cyclohexanes; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Lymphatic Metastasis; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Sesquiterpenes; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2004 |
Microregional effects of gemcitabine in HCT-116 xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; HCT116 Cells; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Recombinant Proteins; Sarcoma | 2004 |
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Dipyridamole; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Neoplasm Staging; Pancreatic Neoplasms | 2004 |
[Clinical study of gemcitabine therapy for recurrent or metastatic pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Remission Induction; Retrospective Studies; Survival Rate | 2004 |
Therapeutic effects of gemcitabine on cutaneous manifestations in an Adamantiades-Behçet's disease-like mouse model.
Topics: Alanine Transaminase; Animals; Behcet Syndrome; Cytokines; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Herpes Simplex; Immunosuppressive Agents; Mice; Mice, Inbred ICR; Skin Ulcer | 2004 |
[Synergistic effects of paclitaxel and gemcitabine on androgen-independent prostate cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms | 2004 |
Economic evaluation of gemcitabine in the treatment of pancreatic cancer in the UK. How important is quality of life?
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; United Kingdom | 2004 |
Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Proteins; NF-kappa B; Proteasome Inhibitors; Pyrazines; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor RelA; Transcription, Genetic; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2004 |
Gemcitabine and cisplatin combination chemotherapy in intrahepatic cholangiocarcinoma as second-line treatment: report of four cases.
Topics: Adenocarcinoma; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2004 |
Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
Topics: Affinity Labels; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lung Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Thioinosine; Tumor Cells, Cultured | 2004 |
Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Genes, bcl-2; Genes, p53; Humans; Signal Transduction | 2004 |
Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter.
Topics: Adenoviridae; Animals; Apoptosis Regulatory Proteins; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Gemcitabine; Genetic Therapy; Humans; Liver; Liver Neoplasms; Membrane Glycoproteins; Mice; Mice, Nude; Oligopeptides; Pancreatic Neoplasms; Promoter Regions, Genetic; Telomerase; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2005 |
Synchronous solitary metastasis of transitional cell carcinoma of the bladder to the testis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Cystitis; Deoxycytidine; Gemcitabine; Hematuria; Humans; Incidental Findings; Male; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Orchiectomy; Positron-Emission Tomography; Prostatectomy; Prostatic Neoplasms; Radiation Injuries; Testicular Neoplasms; Transurethral Resection of Prostate; Ultrasonography; Urinary Bladder Neoplasms; Urinary Diversion | 2004 |
Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cystitis; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fibrosis; Gemcitabine; Hyperplasia; Injections, Intraperitoneal; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Organ Size; Single-Blind Method; Urinary Bladder Neoplasms; Urothelium | 2004 |
Targeting metastatic leiomyosarcoma by rapamycin plus gemcitabine: an intriguing clinical observation.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diabetic Nephropathies; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Kidney Transplantation; Leiomyosarcoma; Liver Neoplasms; Male; Middle Aged; Sirolimus; Tomography, X-Ray Computed; Treatment Outcome | 2004 |
Non-toxic and short treatment with gemcitabine inhibits in vitro migration of HT-1080 cells.
Topics: Cell Cycle; Cell Division; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Fibrosarcoma; France; Gemcitabine; Humans; Inhibitory Concentration 50; Neoplasms, Experimental; Time Factors | 2004 |
[The synergistic effects of paclitaxel and gemcitabine on prostate cancer cell line PC-3].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms | 2004 |
[Hypertrophic myopathy due to muscular metastasis of a signet cell adenocarcinoma of the bladder].
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Buttocks; Carcinoma, Signet Ring Cell; Deoxycytidine; Gemcitabine; Humans; Hypertrophy; Male; Muscle Neoplasms; Muscle, Skeletal; Muscular Diseases; Neoplasm Recurrence, Local; Thigh; Treatment Outcome; Urinary Bladder Neoplasms | 2004 |
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2004 |
[Histoculture drug response assay for solitary fibrous tumor--a case report].
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Diaphragm; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Muscle Neoplasms; Neoplasms, Fibrous Tissue; Taxoids | 2004 |
[A case of successful management of nonresectable pancreas cancer with liver metastasis by intra-arterial infusion chemotherapy with gemcitabine hydrochloride, 5-FU, CDDP and administration of tegafur/uracil].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Male; Pancreatic Neoplasms; Quality of Life; Tegafur; Uracil | 2004 |
[Multimodality therapy for diffuse malignant pleural mesothelioma].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Mesothelioma; Pleural Neoplasms; Pneumonectomy | 2004 |
Delayed-type hypersensitivity reaction with iscador M given in combination with cytotoxic chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypersensitivity, Delayed; Methotrexate; Plant Extracts; Plant Proteins | 2004 |
[Pancreatic carcinoma: progress in therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Survival Rate | 2004 |
Combination chemotherapy of gemcitabine and vinorelbine in patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Health Status; Humans; Lung Neoplasms; Quality of Life; Reproducibility of Results; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2004 |
Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; NF-kappa B; Pancreatic Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrazoles; RNA, Messenger; Sulfonamides | 2004 |
Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Radiation Dosage; Retrospective Studies; Survival Analysis; Time Factors | 2004 |
Polymerization of the triphosphates of AraC, 2',2'-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase.
Topics: Arabinonucleosides; Cytarabine; Deoxycytidine; DNA Polymerase I; DNA Primase; Gemcitabine; Humans; Polymers; Polyphosphates | 2004 |
Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer.
Topics: Apoptosis; Cell Line, Tumor; Ceramides; Deoxycytidine; Drug Synergism; Enzyme Activation; Gemcitabine; Glucosyltransferases; Humans; Pancreatic Neoplasms; Sphingomyelin Phosphodiesterase; Sphingomyelins | 2004 |
[A case of successful treatment with combined 5-fluorouracil, adriamycin, cisplatin (FAP) therapy followed by Gemcitabine, UFT therapy and intra-arterial FAP therapy for unresectable advanced gallbladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Middle Aged; Tegafur; Uracil | 2004 |
[Intra-arterial cellular immunochemotherapy for unresectable pancreatic cancer with liver metastasis].
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Transfusion, Autologous; Deoxycytidine; Gemcitabine; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Killer Cells, Natural; Liver Neoplasms; Male; Pancreatic Neoplasms; Treatment Outcome | 2004 |
[The QOL of the patient with advanced pancreatic carcinoma was changed for the better with combination therapy consisting of arterial chemotherapy and injection of interferon].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Pancreatectomy; Pancreatic Neoplasms; Quality of Life | 2004 |
[A case of unresectable pancreatic cancer showing tumor dormancy treated with gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Palliative Care; Pancreatic Neoplasms; Treatment Outcome | 2004 |
Development of a green fluorescent protein metastatic-cancer chick-embryo drug-screen model.
Topics: Animals; Carcinoma, Lewis Lung; Chick Embryo; Deoxycytidine; Disease Models, Animal; Drug Screening Assays, Antitumor; Gemcitabine; Green Fluorescent Proteins; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Streptokinase | 2004 |
Activity of bortezomib in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Protease Inhibitors; Pyrazines; Taxoids | 2004 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
[Initial results of intra-arterial chemotherapy for poorly differentiated bladder transitional cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Urinary Bladder Neoplasms | 2004 |
Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.
Topics: Animals; Antimetabolites, Antineoplastic; Calorimetry, Differential Scanning; Cathepsin B; Cathepsin D; Cell Line, Tumor; Deoxycytidine; Drug Compounding; Drug Delivery Systems; Drug Stability; Female; Gemcitabine; Half-Life; Hydrogen-Ion Concentration; Indicators and Reagents; Liposomes; Mice; Mice, Inbred BALB C; Neoplasm Proteins; Prodrugs; Protein Synthesis Inhibitors | 2004 |
Determination of gemcitabine and its metabolite in human plasma using high-pressure liquid chromatography coupled with a diode array detector.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Middle Aged; Neoplasms | 2004 |
Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small cell lung cancer: a prospective observational study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies | 2004 |
[Clinical problems in gemcitabine treatment for unresectable pancreatic cancer in the elderly--a multicentric retrospective study of 53 cases].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Surveys and Questionnaires | 2004 |
Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Carbon; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; DNA; DNA Damage; Fatty Acids; Gemcitabine; Humans; Inhibitory Concentration 50; Leukemia; Melanoma; Mice; Mice, Nude; Models, Chemical; Neoplasm Transplantation; Nucleoside Deaminases; Phosphorylation; Rats; Time Factors | 2004 |
Fluorescence studies of substrate binding to human recombinant deoxycytidine kinase.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Humans; Kinetics; Ligands; Microscopy, Fluorescence; Neoplasms; Phosphates; Phosphorylation; Protein Binding; Protein Conformation; Recombinant Proteins; Spectrometry, Fluorescence; Substrate Specificity; Uridine Triphosphate | 2004 |
Modulation of cytarabine induced cytotoxicity using novel deoxynucleoside analogs in the HL60 cell line.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Cladribine; Coloring Agents; Cytarabine; Deoxycytidine; DNA; Gemcitabine; HL-60 Cells; Humans; Inhibitory Concentration 50; Nucleosides; Tetrazolium Salts; Thiazoles; Vidarabine | 2004 |
Increased cytotoxicity of 2',2'-difluoro-2'-deoxycytidine in human leukemic cell-lines after a preincubation with cyclopentenyl cytosine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carbon-Nitrogen Ligases; Cell Line, Tumor; Cell Separation; Clinical Trials as Topic; Cytidine; Deoxycytidine; DNA; Dose-Response Relationship, Drug; Flow Cytometry; Gemcitabine; HL-60 Cells; Humans; Necrosis; Neoplasms; Time Factors | 2004 |
Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinosylcytosine (ara-C) in leukemia and solid tumor cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatty Acids; Gemcitabine; Humans; Inhibitory Concentration 50; Leukemia; Mice; Neoplasms; Rats; Time Factors | 2004 |
Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy, Conformal | 2004 |
Vascular administration of adenoviral vector soaked in absorbable gelatin sponge particles (GSP) prolongs the transgene expression in hepatocytes.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; beta-Galactosidase; Deoxycytidine; Dogs; Gelatin Sponge, Absorbable; Gemcitabine; Genetic Vectors; Hepatic Artery; Hepatocyte Growth Factor; Hepatocytes; Humans; Infusions, Intra-Arterial; Liver; Rats; Rats, Sprague-Dawley; Transduction, Genetic; Transgenes | 2005 |
Gemcitabine does not prevent acute rejection of the transplanted liver in rats.
Topics: Acute Disease; Animals; Creatinine; Cyclosporine; Deoxycytidine; Gemcitabine; Graft Rejection; Immunosuppressive Agents; Liver; Liver Transplantation; Male; Rats; Rats, Inbred Lew; Rats, Inbred Strains; Treatment Failure; Urea | 2005 |
Chemotherapeutic response with single agent gemcitabine in metastatic Bellini duct tumor.
Topics: Adrenal Gland Neoplasms; Adult; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Heart Neoplasms; Humans; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Tomography, X-Ray Computed | 2004 |
Gemcitabine-induced apoptosis in a drug-resistant mouse leukemia L1210 cell line that does not express p53.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Deoxyadenosines; Deoxycytidine; Drug Resistance, Neoplasm; Flavonoids; Gemcitabine; Leukemia L1210; Methotrexate; Mice; Piperidines; Tumor Suppressor Protein p53 | 2004 |
Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Survival Analysis | 2004 |
Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Gemcitabine; Genes, erbB; Humans; Immunoblotting; Mice; Pancreatic Neoplasms; Phosphorylation; Rabbits; Radiation-Sensitizing Agents; Receptor, ErbB-4; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Boronic Acids; Bortezomib; Caspase 3; Caspases; Cell Line; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; Immunoblotting; Pancreatic Neoplasms; Protease Inhibitors; Pyrazines; Ribonucleotide Reductases; Tumor Cells, Cultured | 2004 |
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Apoptosis; Cell Movement; Cell Proliferation; Cells, Cultured; Deoxycytidine; Drug Therapy, Combination; Enzyme Inhibitors; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Ki-67 Antigen; Male; Mice; Mice, Nude; NIH 3T3 Cells; Pancreatic Neoplasms; Ribonucleotide Reductases; src-Family Kinases | 2004 |
Chemoradiation may prolong survival of patients with non-bulky unresectable extrahepatic biliary carcinoma. A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Germany; Humans; Male; Middle Aged; Palliative Care; Prevalence; Prognosis; Radiotherapy, Conformal; Retrospective Studies; Risk Assessment; Risk Factors; Stents; Survival Analysis; Survival Rate; Treatment Outcome | 2004 |
[Efficacy of selective continuous transarterial infusion chemotherapy on advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2004 |
[Short-term efficacy of combined chemotherapy of gemcitabine and cisplatin on advanced hormone refractory prostate cancer].
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Ribonucleotide Reductases; Survival Rate | 2004 |
Impact of gemcitabine on the treatment of metastatic pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2005 |
In vitro chemosensitivity to gemcitabine, oxaliplatin and zoledronic acid predicts treatment response in metastatic gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Deoxycytidine; Diphosphonates; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Imidazoles; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Remission Induction; Stomach Neoplasms; Tumor Cells, Cultured; Zoledronic Acid | 2005 |
Relative Bcl-2 independence of drug-induced cytotoxicity and resistance in 518A2 melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Melanoma; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Small Interfering; Skin Neoplasms; Taxoids; Thapsigargin; Thionucleotides; Tumor Cells, Cultured | 2004 |
New infusion device for trans-tissue, sustained local delivery of anticancer agent to surgically resected tissue: potential use for suppression of local recurrence of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Elastomers; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Polyurethanes; Prognosis; Secondary Prevention; Time Factors | 2005 |
Symptom-free T4 lung cancer with bilateral pulmonary artery infiltration.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diagnosis, Differential; Gemcitabine; Heart Neoplasms; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Pulmonary Artery; Radiography | 2005 |
Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capillary Leak Syndrome; Coronary Artery Disease; Deoxycytidine; Diagnosis, Differential; Gemcitabine; Heart Failure; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pulmonary Edema | 2004 |
Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2'-deoxycytidine treatment is associated with activation of the interferon signalling pathway.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Decitabine; Deoxycytidine; DNA Methylation; DNA Modification Methylases; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; Interferons; Pancreatic Neoplasms; Signal Transduction | 2005 |
Antiangiogenic therapy for human pancreatic carcinoma xenografts in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cyclohexanes; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; O-(Chloroacetylcarbamoyl)fumagillol; Pancreatic Neoplasms; Sesquiterpenes; Transplantation, Heterologous | 2005 |
FOLFOX-4 in pre-treated patients with advanced transitional cell carcinoma of the bladder.
Topics: Aged; Aged, 80 and over; Agranulocytosis; Anemia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Transitional Cell; Deoxycytidine; Drug Administration Schedule; Energy Intake; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomatitis; Taxoids; Tissue Polypeptide Antigen; Urinary Bladder Neoplasms | 2004 |
Acetaminophen and DMSO modulate growth and gemcitabine cytotoxicity in FM3A breast cancer cells in vitro.
Topics: Acetaminophen; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Breast Neoplasms; Cell Division; Cyclooxygenase Inhibitors; Deoxycytidine; Dimethyl Sulfoxide; Gemcitabine; Humans; Ribonucleotide Reductases; S Phase; Time Factors; Tumor Cells, Cultured | 2004 |
Induction of apoptosis in non-small lung carcinoma cell line (H1299) by combination of anti-asthma drugs with gemcitabine and cisplatin.
Topics: Anti-Asthmatic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Separation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Flow Cytometry; G1 Phase; Gemcitabine; Humans; Lung Neoplasms; Propidium; Proto-Oncogene Proteins c-bcl-2; Resting Phase, Cell Cycle; Theophylline | 2005 |
Growth inhibition of human pancreatic cancer cells by human interferon-beta gene combined with gemcitabine.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cations; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; Combined Modality Therapy; Culture Media, Conditioned; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gemcitabine; Gene Transfer Techniques; Genetic Therapy; Humans; Immunoprecipitation; Interferon-beta; Liposomes; Pancreatic Neoplasms; Plasmids; ras GTPase-Activating Proteins; Signal Transduction; SOS1 Protein; Time Factors; Transfection | 2005 |
Combination treatment of CC531-lac-Z rat liver metastases by chemoembolization with pemetrexed disodium and gemcitabine.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemoembolization, Therapeutic; Colorectal Neoplasms; Combined Modality Therapy; Death; Deoxycytidine; Disease Models, Animal; Gemcitabine; Glutamates; Guanine; Liver Neoplasms; Male; Neoplasm Metastasis; Pemetrexed; Rats; Rats, Inbred Strains | 2005 |
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma: is it safe?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hemorrhage; Humans; Mesothelioma; Morbidity; Pleural Neoplasms; Pneumonectomy; Thromboembolism | 2005 |
Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Topotecan; Xenograft Model Antitumor Assays | 2005 |
Biweekly administration of gemcitabine and vinorelbine as first line therapy in elderly advanced breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Quality of Life; Vinblastine; Vinorelbine | 2005 |
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Embolism; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Thrombosis; Time Factors | 2005 |
Noninvasive assessment of tumor vascularity by contrast-enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma.
Topics: Adult; Aged; Contrast Media; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neovascularization, Pathologic; Oxonic Acid; Pancreatic Neoplasms; Polysaccharides; Prognosis; Pyridines; Survival Analysis; Survival Rate; Tegafur; Ultrasonography | 2005 |
Gemcitabine, pemetrexed, and novel agents in the treatment of thoracic cancer. Selected presentations from the 10th World Congress on Lung Cancer. Vancouver, Canada.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed | 2004 |
[A new therapy standard in metastatic breast cancer--gemzar/paclitaxel. Longer survival by optimized combination therapy].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Multicenter Studies as Topic; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate | 2004 |
[Cisplatin schedule in combination with gemcitabine in unresectable non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Length of Stay; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia | 2005 |
[A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Survivors | 2005 |
Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines | 2005 |
Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA Fragmentation; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Polymerase Chain Reaction; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Topoisomerase I Inhibitors; Topotecan | 2005 |
Treosulfan and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Gemcitabine; Humans; Melanoma; Reproducibility of Results; Uveal Neoplasms | 2005 |
Unusual liver abscess.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Abscess; Liver Neoplasms; Male; Pancreatic Neoplasms; Seminoma; Testicular Neoplasms; Tomography, X-Ray Computed | 2005 |
[Experimental study on effect of chemotherapy combined ginsengnoside Rg3 in treating pulmonary carcinoma].
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Ginsenosides; Lung Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Transplantation | 2005 |
[Second-line treatment of malignant pleural mesothelioma with Pemetrexed (Alimta) -- a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Forced Expiratory Volume; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Organoplatinum Compounds; Pemetrexed; Pleural Neoplasms; Pyridines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Apoptosis by gemcitabine in non-small cell lung cancer cell line KNS62 is induced downstream of caspase 8 and is profoundly blocked by Bcl-xL over-expression.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Caspase 8; Caspases; Cell Line, Tumor; Deoxycytidine; DNA Fragmentation; fas Receptor; Female; Gemcitabine; Humans; Immunoblotting; Lung Neoplasms; Mice; Mice, SCID; Transplantation, Heterologous | 2005 |
Sonography and CT of vasculitis during gemcitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Tomography, X-Ray Computed; Ultrasonography; Vasculitis | 2005 |
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow Cells; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials as Topic; Cytochromes c; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Activation; Farnesyltranstransferase; Flow Cytometry; Fluorouracil; G2 Phase; Gemcitabine; Homozygote; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, SCID; Mitosis; Multiple Myeloma; Paclitaxel; Quinolones; Taxoids; Tetrazolium Salts; Thiazoles | 2005 |
Successful treatment of chemo-refractory pulmonary metastases of renal pelvic cancer by second-line chemotherapy including gemcitabine followed by salvage surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Lung Neoplasms; Middle Aged; Salvage Therapy | 2005 |
Automated nanospray using chip-based emitters for the quantitative analysis of pharmaceutical compounds.
Topics: Deoxycytidine; Gemcitabine; Microchip Analytical Procedures; Nanotechnology; Pharmaceutical Preparations; Receptors, G-Protein-Coupled; Receptors, Ghrelin; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization | 2005 |
Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenograf
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Mice; Mice, SCID; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2005 |
Primary alveolar soft part sarcoma (ASPS) of the breast: report of a deceptive case with xanthomatous features confirmed by TFE3 immunohistochemistry and electron microscopy.
Topics: Adult; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Biomarkers, Tumor; Breast Neoplasms; Cytoplasmic Vesicles; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Humans; Microscopy, Electron, Transmission; Sarcoma; Soft Tissue Neoplasms; Transcription Factors; Treatment Outcome; Xanthomatosis | 2005 |
Preoperative gemcitabine for unresectable, solid pseudopapillary tumour of the pancreas.
Topics: Adult; Carcinoma, Papillary; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tomography, X-Ray Computed | 2005 |
[The effect of gemcitabine on proliferation and telomerase activity of Tca8113 cell lines].
Topics: Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Telomerase | 2005 |
[A case of recurrence and systemic metastasis of oral cancer successfully treated with combination chemotherapy of cisplatin and gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Salvage Therapy | 2005 |
[Local recurrence of pancreatic cancer successfully treated with gemcitabine].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Period; Quality of Life; Remission Induction; Stomach Neoplasms | 2005 |
[A case of unresectable advanced pancreatic tail cancer successfully treated with gemcitabine hydrochloride].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Peritoneal Neoplasms; Quality of Life | 2005 |
[Two-year survivor in response to gemcitabine-based chemotherapy for advanced pancreatic cancer with multiple lung metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms; Quality of Life; Survivors | 2005 |
[Acute myocardial infarction induced by lung cancer chemotherapy after radiation of left lung].
Topics: Angioplasty, Balloon, Coronary; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Infarction | 2005 |
Assessment of quality of life in patients with rectal cancer treated by preoperative radiotherapy: a longitudinal prospective study.
Topics: Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Preoperative Care; Prospective Studies; Quality of Life; Radiation-Sensitizing Agents; Radiotherapy; Rectal Neoplasms | 2005 |
Dexamethasone-induced cisplatin and gemcitabine resistance in lung carcinoma samples treated ex vivo.
Topics: Aged; Apoptosis; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2005 |
Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aziridines; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Combined Modality Therapy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Hyperthermia, Induced; Indolequinones; Mitomycin; Tetrazolium Salts; Thiazoles; Urinary Bladder Neoplasms | 2005 |
Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Leukopenia; Male; Middle Aged; Prospective Studies; Recombinant Proteins; Thrombocytopenia | 2005 |
Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Flavonoids; Gemcitabine; Humans; Piperidines | 2005 |
[Low-dose gemcitabine promotes radiation-induced apoptosis of human hepatoma cell line SMMC-7721].
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Radiation; Radiation-Sensitizing Agents | 2005 |
In vitro genotoxic effects of the anticancer drug gemcitabine in human lymphocytes.
Topics: Antineoplastic Agents; Cells, Cultured; Chromosome Aberrations; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphocytes; Male; Sister Chromatid Exchange | 2005 |
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antigen-Presenting Cells; Antimetabolites, Antineoplastic; B-Lymphocytes; CD4-CD8 Ratio; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Killer Cells, Natural; Lymphocyte Activation; Male; Middle Aged; Pancreatic Neoplasms; Ribonucleotide Reductases; T-Lymphocytes | 2005 |
A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Phospholipids; Prodrugs; Solubility; Tumor Cells, Cultured | 2005 |
Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Ovarian Neoplasms | 2005 |
Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Glutamates; Growth Inhibitors; Guanine; Humans; Lung Neoplasms; Pemetrexed | 2005 |
A mechanistic study of the permeation kinetics through biomembrane models: gemcitabine-phospholipid bilayer interaction.
Topics: Aniline Compounds; Calorimetry, Differential Scanning; Deoxycytidine; Dimyristoylphosphatidylcholine; Gemcitabine; Kinetics; Lipid Bilayers; Models, Biological; Permeability; Phospholipids; Radiation-Sensitizing Agents | 2005 |
Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer.
Topics: Adenocarcinoma; Adenovirus E1A Proteins; Adenoviruses, Human; Animals; Antiviral Agents; Bone Marrow Cells; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Genetic Therapy; Liver; Mice; Neoplasms, Experimental; Oncolytic Virotherapy; Oncolytic Viruses; Ovarian Neoplasms; Virus Replication | 2005 |
Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases.
Topics: Aerosols; Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Disease Models, Animal; fas Receptor; Gemcitabine; Lung Neoplasms; Mice; Mice, Nude; Osteosarcoma; Tumor Cells, Cultured | 2005 |
[Antitumor effects of interferon-gamma-inducible protein 10 combined with gemcitabine].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Lewis Lung; Chemokine CXCL10; Chemokines, CXC; Deoxycytidine; Drug Synergism; Escherichia coli; Female; Gemcitabine; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microcirculation; Neovascularization, Pathologic; Plasmids; Transfection | 2005 |
Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cluster Analysis; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger | 2005 |
Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Male; Mice; Mice, Inbred C57BL; Osteosarcoma | 2005 |
Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Patient Satisfaction; Urinary Bladder Neoplasms; Vinblastine | 2005 |
Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Endostatins; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Injections, Intralesional; Injections, Intraperitoneal; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Recombinant Proteins; Xenograft Model Antitumor Assays | 2005 |
[Active combination immunochemotherapy with interferon-alpha, interleukin-2 and gemcitabine for four patients with metastatic renal cell carcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged | 2005 |
Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins; RNA, Messenger; RNA, Small Interfering; Survival Rate | 2005 |
Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lipids; Mice; Mice, SCID | 2005 |
RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glycogen Synthase Kinases; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Serine; Transfection | 2005 |
Sensitivity to gemcitabine and its metabolizing enzymes in neuroblastoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Gemcitabine; HeLa Cells; Humans; Mice; Mice, Nude; Neuroblastoma; RNA, Messenger; Xenograft Model Antitumor Assays | 2005 |
Enhanced apoptotic reaction correlates with suppressed tumor glucose utilization after cytotoxic chemotherapy: use of 99mTc-Annexin V, 18F-FDG, and histologic evaluation.
Topics: Animals; Annexin A5; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclophosphamide; Deoxycytidine; Fluorodeoxyglucose F18; Gemcitabine; Glucose; Liver Neoplasms; Male; Metabolic Clearance Rate; Organ Specificity; Organotechnetium Compounds; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Statistics as Topic; Tissue Distribution | 2005 |
Cisplatin and gemcitabine induction chemotherapy followed by concurrent chemoradiotherapy or surgery for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage | 2005 |
Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Muller S, Schütt P, Bojko P, Nowrousian MR, Hense J, Seeber S, Moritz T. Ann. Hematol. 2005 Feb; 84(2):110-4.
Topics: Adult; Deoxycytidine; Fatal Outcome; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney Neoplasms; Male; Multiple Organ Failure | 2005 |
Possible antitumor activity of 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytidine; Deoxycytidine; Deoxyribonucleotides; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Ribonucleotides; RNA, Messenger; Xenograft Model Antitumor Assays | 2005 |
Antagonistic effects of sequential administration of BL1521, a histone deacetylase inhibitor, and gemcitabine to neuroblastoma cells.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Differentiation; Deoxycytidine; Drug Combinations; Enzyme Inhibitors; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neuroblastoma; Tumor Cells, Cultured | 2006 |
[Gemcitabine plus cisplatin therapy in breast cancer refractory to anthracyclines, docetaxel and capecitabine].
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Neoplasm Metastasis; Taxoids | 2005 |
cN-II expression predicts survival in patients receiving gemcitabine for advanced non-small cell lung cancer.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Time Factors; Treatment Outcome | 2005 |
Mismatch repair proficiency is not required for radioenhancement by gemcitabine.
Topics: Base Pair Mismatch; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA; DNA Repair; Gemcitabine; Humans; Neoplasm Proteins; Nuclear Proteins; Radiation Tolerance; Radiation-Sensitizing Agents; Transcription Factors | 2005 |
Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 7; Caspases; Cell Cycle; Chlorambucil; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; Irinotecan; Leukemia, Myeloid; Mitoxantrone; Paclitaxel; U937 Cells; Vidarabine | 2005 |
["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Remission Induction; Retroperitoneal Neoplasms; Tomography, X-Ray Computed | 2005 |
Impact of different treatment methods on survival in advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Palliative Care; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Stents; Survival Analysis; Time Factors | 2005 |
Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and Cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Mitomycin; Oligonucleotides, Antisense; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2005 |
Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Enkephalin, Methionine; Fluorouracil; Gemcitabine; Growth Substances; Humans; Male; Mice; Mice, Nude; Naloxone; Narcotics; Pancreatic Neoplasms; Receptors, Opioid; Tumor Burden; Xenograft Model Antitumor Assays | 2005 |
Combination chemotherapy for advanced pancreatic cancer--has its time finally come?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2005 |
Neoadjuvant chemotherapy in malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Mesothelioma; Neoadjuvant Therapy; Neoplasm Staging; Pleural Neoplasms | 2005 |
Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Neoadjuvant Therapy; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Pneumonectomy; Radiotherapy, Adjuvant | 2005 |
Cisplatin plus vinorelbine or gemcitabine in patients with advanced non-small cell lung cancer: pharmacoeconomic considerations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Randomized Controlled Trials as Topic; Vinblastine; Vinorelbine | 2005 |
Sp1/Sp3-dependent regulation of human telomerase reverse transcriptase promoter activity by the bioactive sphingolipid ceramide.
Topics: Base Sequence; Cell Line, Tumor; Ceramides; Chromatin Immunoprecipitation; Chromatography, High Pressure Liquid; Deoxycytidine; DNA; DNA-Binding Proteins; Enzyme Inhibitors; Gemcitabine; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunoprecipitation; Luciferases; Mass Spectrometry; Molecular Sequence Data; Mutagenesis, Site-Directed; Plasmids; Promoter Regions, Genetic; Protein Structure, Tertiary; Protein Synthesis Inhibitors; RNA Polymerase II; RNA, Small Interfering; Sp1 Transcription Factor; Sp3 Transcription Factor; Sphingolipids; Telomerase; Transcription Factors; Transfection | 2005 |
Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Blotting, Western; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Profiling; Humans; Mitogen-Activated Protein Kinases; Neuropilin-1; Pancreatic Neoplasms; Phenotype; Signal Transduction; Transfection; Tumor Cells, Cultured; Up-Regulation | 2005 |
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Coagulation; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Endothelial Cells; Gemcitabine; Humans; Indoles; Oxindoles; Piperidines; Propionates; Pyrroles; Quinazolines; Thromboplastin | 2005 |
Evaluation of the combined effect of p53 codon 72 polymorphism and hotspot mutations in response to anticancer drugs.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Cell Line, Tumor; Cell Survival; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gemcitabine; Genes, Tumor Suppressor; Humans; Mutation, Missense; Nuclear Proteins; Paclitaxel; Plasmids; Polymorphism, Genetic; Transfection; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Vinblastine | 2005 |
Safety of pulmonary administration of gemcitabine in rats.
Topics: Administration, Inhalation; Administration, Oral; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Delivery Systems; Feasibility Studies; Female; Gemcitabine; Lung; Maximum Tolerated Dose; Radionuclide Imaging; Rats; Rats, Wistar | 2005 |
LY293111 improves efficacy of gemcitabine therapy on pancreatic cancer in a fluorescent orthotopic model in athymic mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Female; Gemcitabine; Green Fluorescent Proteins; Humans; Image Processing, Computer-Assisted; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Random Allocation; Time Factors | 2005 |
Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Deoxycytidine; Female; Gemcitabine; Humans; Interferon-alpha; Male; Middle Aged; Mycosis Fungoides; Neoplasm Staging; Pentostatin; PUVA Therapy; Sezary Syndrome; Treatment Outcome | 2005 |
Major response and clinical benefit following third-line treatment for Bellini duct carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Palliative Care; Thalidomide; Treatment Failure; Treatment Outcome | 2005 |
[Chemotherapy of pancreatic carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2005 |
Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm, Abdominal; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiotherapy; Smoking; Tomography, X-Ray Computed | 2005 |
The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Paclitaxel; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2005 |
Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pilot Projects; Survival Analysis | 2005 |
Posterior reversible encephalopathy syndrome: a possible late interaction between cytotoxic agents and general anaesthesia.
Topics: Anesthesia, General; Antimetabolites, Antineoplastic; Blood Pressure; Brain; Brain Diseases; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Gemcitabine; Gestational Trophoblastic Disease; Humans; Middle Aged; Pregnancy; Syndrome; Water-Electrolyte Balance | 2005 |
Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Male; Melphalan; Rats; Rats, Inbred Strains; Tumor Cells, Cultured | 2005 |
Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Marrow Cells; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Time Factors; Treatment Outcome | 2005 |
Cisplatin and gemcitabine in malignant mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Drug Industry; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Reproducibility of Results; Treatment Outcome | 2005 |
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Coculture Techniques; Colonic Neoplasms; Cross-Priming; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Drug Evaluation, Preclinical; Fluorouracil; Gemcitabine; HLA-A Antigens; HLA-A2 Antigen; HT29 Cells; Humans; Leucovorin; Leukocytes, Mononuclear; Organoplatinum Compounds; Oxaliplatin; T-Lymphocytes, Cytotoxic | 2005 |
Chemotherapy for non-small cell lung cancer in elderly patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2005 |
Streptokinase increases the sensitivity of colon cancer cells to chemotherapy by gemcitabine and cis-platine in vitro.
Topics: Antineoplastic Agents; Cell Proliferation; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Fibrinolytic Agents; Gemcitabine; HT29 Cells; Humans; Streptokinase; Time Factors | 2006 |
Triplet chemotherapy with cisplatin, gemcitabine and vinorelbine for malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Pleural Neoplasms; Pneumonectomy; Survival Rate; Vinblastine; Vinorelbine | 2005 |
Enhancement of gemcitabine-induced apoptosis by restoration of p53 function in human pancreatic tumors.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; beta-Galactosidase; Colorimetry; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Suppressor Protein p53 | 2005 |
Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Thrombosis | 2005 |
The impact of practice guidelines and funding policies on the use of new drugs in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Utilization; Drugs, Investigational; Evidence-Based Medicine; Female; Financing, Government; Gemcitabine; Humans; Male; Middle Aged; National Health Programs; Ontario; Practice Guidelines as Topic; Vinblastine; Vinorelbine | 2005 |
New drugs for cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Serotonin Antagonists | 1998 |
Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Thyroid Neoplasms; Topotecan; Vinblastine; Vinorelbine | 2005 |
Gemcitabine inhibits viability, growth, and metastasis of osteosarcoma cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bone Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA; Fibroblasts; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Osteosarcoma | 2005 |
Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; CpG Islands; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Female; Gemcitabine; Humans; Immunotherapy; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Oligonucleotides; Pancreatic Neoplasms; Receptors, Cell Surface; Toll-Like Receptor 9; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2005 |
Induction of apoptosis in tumor-associated endothelial cells and therapy of orthotopic human pancreatic carcinoma in nude mice.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; ErbB Receptors; Exons; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Microcirculation; Microscopy, Fluorescence; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Purines; Receptors, Vascular Endothelial Growth Factor | 2005 |
Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Polymerase Chain Reaction; Quinazolines | 2005 |
Preoperative chemotherapy does not increase complications after nonsmall cell lung cancer resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymph Node Excision; Male; Mediastinum; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; Postoperative Complications; Radiotherapy, Adjuvant; Survival Analysis; Thoracotomy; Vinblastine; Vinorelbine | 2005 |
[Cut-off level of docetaxel, paclitaxel and gemcitabine in histoculture drug response assay for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Taxoids; Tumor Cells, Cultured | 2005 |
The effect of gemcitabine in the treatment of rejection in experimental small intestine transplantation.
Topics: Animals; Deoxycytidine; Gemcitabine; Graft Rejection; Immunosuppression Therapy; Intestine, Small; Male; Rats; Rats, Inbred BN; Transplantation, Homologous | 2005 |
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells.
Topics: 5'-Nucleotidase; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Gemcitabine; Genes, ras; Humans; Immunoblotting; Immunohistochemistry; Indoles; Male; Mevalonic Acid; Mice; Mitogen-Activated Protein Kinase 1; Mutation; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins p21(ras); rho GTP-Binding Proteins | 2005 |
[Enhancing effects of celecoxib on the growth inhibition of pancreatic carcinoma by gemcitabine treatment].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Celecoxib; Cell Cycle; Cyclooxygenase Inhibitors; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2005 |
Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.
Topics: cdc25 Phosphatases; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; DNA, Neoplasm; Gemcitabine; Humans; Mitosis; Protein Kinases; Protein Serine-Threonine Kinases; Radiation-Sensitizing Agents; RNA, Small Interfering; Transfection | 2005 |
Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model.
Topics: Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; Female; Flow Cytometry; Gemcitabine; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, SCID; Microcirculation; Microscopy, Fluorescence; Molecular Sequence Data; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Protein Structure, Tertiary; Recombinant Proteins; Thrombospondin 1; Time Factors | 2005 |
Cisplatin and gemcitabine for small cell carcinoma of the gall bladder.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged | 2005 |
[Effect of full-length cyclin B1 antisense cDNA on chemosensitivity of lewis lung carcinoma cells to gemicitabine in vitro and in vivo].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Lewis Lung; Cell Cycle; Cyclin B; Cyclin B1; Deoxycytidine; DNA, Antisense; DNA, Complementary; Drug Synergism; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Random Allocation; Ribonucleotide Reductases | 2005 |
[Application of adenosine triphosphate tumor chemosensitive assay system to individual chemotherapy for hepatocellular carcinoma].
Topics: Adenosine Triphosphate; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Postoperative Period; Remission Induction; Sensitivity and Specificity; Survival Rate | 2005 |
Combination of low-dose gemcitabine and recombinant quail vascular endothelial growth factor receptor-2 as a vaccine induces synergistic antitumor activities.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Lewis Lung; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; In Situ Nick-End Labeling; Liver Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Quail; Random Allocation; Vaccines, Synthetic; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Protein Subunits; Ribonucleotide Reductases; Up-Regulation | 2005 |
Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Cell Division; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Neoplasm Seeding; Neoplasm Transplantation; Tumor Cells, Cultured; Urinary Bladder; Urinary Bladder Neoplasms | 2005 |
In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Deoxycytidine; Docetaxel; Erythrocytes; Female; Gemcitabine; Humans; In Vitro Techniques; Male; Taxoids | 2005 |
A phase I study of moderate-dose radiation therapy and weekly gemcitabine in patients with locally advanced non-small cell lung cancer not suitable for radical chemoradiation therapy.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Radiation Pneumonitis; Radiotherapy; Radiotherapy Dosage; Time Factors | 2005 |
Importance of rational pre-clinical development: gemcitabine comes of age.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Mice; Xenograft Model Antitumor Assays | 2005 |
In vitro and in vivo enhancement of ganciclovir-mediated bystander cytotoxicity with gemcitabine.
Topics: Animals; Antiviral Agents; Cell Line; Cell Line, Tumor; Deoxycytidine; DNA; Drug Synergism; Female; Ganciclovir; Gemcitabine; Genetic Therapy; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasm Transplantation; Phosphorylation; Simplexvirus; Thymidine Kinase | 2005 |
Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Coloring Agents; Combined Modality Therapy; Deoxycytidine; Gemcitabine; In Vitro Techniques; Inhibitory Concentration 50; Lymphoma, Non-Hodgkin; Mice; Mice, SCID; Neoplasm Transplantation; Poly(ADP-ribose) Polymerases; Rituximab; Tetrazolium Salts; Thiazoles; Translocation, Genetic | 2005 |
Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation.
Topics: Adult; Cardiac Tamponade; Deoxycytidine; Female; Gemcitabine; Heart; Humans; Lymphoma; Male; Mediastinum; Middle Aged; Pericardial Effusion; Radiation Injuries | 2005 |
Predictive value of heparanase expression in the palliative therapy of pancreatic cancer.
Topics: Adenocarcinoma; Aged; Biomarkers; Deoxycytidine; Female; Gemcitabine; Germany; Glucuronidase; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Predictive Value of Tests; Retrospective Studies; Survival Rate | 2005 |
Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspase 8; Caspases; Deoxycytidine; Enzyme Activation; fas Receptor; Fas-Associated Death Domain Protein; Flow Cytometry; Gemcitabine; Genes, Dominant; Humans; Pancreatic Neoplasms; Retroviridae; Ribonucleotide Reductases; Transfection; Tumor Cells, Cultured | 2005 |
Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Culture Media; Cyclin D1; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Mice, Transgenic; NF-kappa B; Pancreatic Elastase; Pancreatic Neoplasms; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2005 |
Treatment cost of pancreatic cancer in Japan: analysis of the difference after the introduction of gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2005 |
[Survey of gemcitabine treatment for advanced pancreatic cancer in 20 hospitals of Nagano Prefecture].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2005 |
Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Cytarabine; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Gemcitabine; Humans; Protein Kinases; Protein Serine-Threonine Kinases; Signal Transduction; Tumor Suppressor Proteins | 2005 |
Cyclopentenyl cytosine-induced activation of deoxycytidine kinase increases gemcitabine anabolism and cytotoxicity in neuroblastoma.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Survival; Cytidine; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Gemcitabine; Humans; Immunoblotting; N-Myc Proto-Oncogene Protein; Neuroblastoma; Nuclear Proteins; Oncogene Proteins | 2006 |
Is the tolerance to MIP chemotherapy different between English and other European populations?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Clinical Trials, Phase III as Topic; Decision Making; Deoxycytidine; England; Europe; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Mitomycin; Randomized Controlled Trials as Topic; Reproducibility of Results | 2005 |
[An orbital metastasis as the presentation of lung adenocarcinoma].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biopsy; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gadolinium; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Orbit; Orbital Neoplasms; Radiography, Thoracic; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Synergistic interaction of hyperthermia and Gemcitabine in lung cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspases; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms | 2005 |
Gemcitabine-induced radiation recall dermatitis in a patient with resistant Hodgkin lymphoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dermatitis; Female; Gemcitabine; Hodgkin Disease; Humans; Mechlorethamine; Prednisone; Procarbazine; Radionuclide Imaging; Vincristine | 2005 |
Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy.
Topics: Animals; Antibodies; Antimetabolites, Antineoplastic; CD40 Antigens; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Immunization, Passive; Immunologic Memory; Mesothelioma; Mice; Mice, Inbred BALB C | 2005 |
Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy.
Topics: Agar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Recombinant Proteins; Taxoids; Time Factors; Trastuzumab | 2005 |
The evolution of cancer research and drug discovery at Lilly Research Laboratories.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Drug Industry; Gemcitabine; Glutamates; Guanine; History, 20th Century; Humans; Indoles; Neoplasms; Pemetrexed; United States | 2005 |
A case of diffuse pleural mesothelioma in which contralateral exploratory thoracoscopy assisted the selection of therapy.
Topics: Aged; Biopsy, Needle; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Mesothelioma; Neoplasm Invasiveness; Neoplasm Staging; Pleural Effusion, Malignant; Pleural Neoplasms; Risk Assessment; Thoracoscopy; Tomography, X-Ray Computed | 2005 |
Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autoantigens; Carcinoma, Lewis Lung; Cell Line, Tumor; Collagen Type IV; Colonic Neoplasms; Deoxycytidine; Disease Models, Animal; Endothelial Cells; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Plasmids; Recombinant Proteins; Treatment Outcome | 2005 |
Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
Topics: Acetylation; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Chromatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Hydroxamic Acids; Lung Neoplasms; NF-kappa B; Transcription, Genetic; Vorinostat | 2005 |
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria.
Topics: bcl-2-Associated X Protein; bcl-X Protein; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Deoxycytidine; DNA-Binding Proteins; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression; Genes, Tumor Suppressor; Humans; Inhibitory Concentration 50; Leiomyosarcoma; Melanoma; Mitochondria; Morpholines; Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
Current and future strategies for treating metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Management; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Forecasting; Gemcitabine; Humans; Neoplasm Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2004 |
[Treatment of Bacillus Calmette-Guerin refractory superficial bladder cancer: further intravesical therapy].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma in Situ; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Salvage Therapy; Urinary Bladder Neoplasms | 2005 |
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Topics: Adenoviridae; Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; B-Lymphocytes; CD11b Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line; Cell Line, Tumor; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Genetic Therapy; Genetic Vectors; Immunotherapy; Interferon-beta; Killer Cells, Natural; Lymphocyte Count; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Necrosis; Neoplasms, Experimental; Receptors, Chemokine; Spleen; T-Lymphocytes, Cytotoxic; Time Factors | 2005 |
In focus: advanced pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Meta-Analysis as Topic; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2005 |
Pre-exenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Pelvic Exenteration; Pilot Projects; Recurrence; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Uterine Cervical Neoplasms | 2005 |
Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Complementary Therapies; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Genistein; Glucuronides; Humans; Isoflavones; Middle Aged; Ovarian Neoplasms; Paclitaxel; Soy Milk; Topotecan | 2006 |
Vanilloids in pancreatic cancer: potential for chemotherapy and pain management.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Chronic Disease; Deoxycytidine; Diterpenes; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Mitochondria; Oxidative Stress; Pain; Pancreas; Pancreatic Neoplasms; Pancreatitis; Prospective Studies; TRPV Cation Channels | 2006 |
[Two cases of advanced gallbadder cancer with para-aortic lymph node metastasis responding to intra-aortic infusion of gemcitabine and low-dose CDDP/5-FU].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2005 |
[Experience of gemcitabine therapy after non-curative resection for biliary tract cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male | 2005 |
Pancreatic cancer combo treatment promising.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Italy; Pancreatic Neoplasms; Treatment Outcome | 2005 |
Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly s
Topics: Activities of Daily Living; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Lung Neoplasms; Male; Prognosis; Quality of Life; Vinblastine; Vinorelbine | 2005 |
Double diagnosis in cancer patients and cutaneous reaction related to gemcitabine: CASE 3. Photo therapy recall with gemcitabine following ultraviolet B treatment.
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Inflammation; Keratinocytes; Male; Photosensitivity Disorders; Phototherapy; Ultraviolet Rays; Urinary Bladder Neoplasms | 2005 |
Gemcitabine-induced respiratory failure associated with elevated erythrocyte sedimentation rate (ESR).
Topics: Adrenal Cortex Hormones; Antimetabolites, Antineoplastic; Blood Sedimentation; Breast Neoplasms; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Respiratory Distress Syndrome; Treatment Outcome | 2006 |
Induction chemotherapy with cisplatin and gemcitabine followed by reirradiation for locally recurrent nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Survival Rate | 2005 |
518A2 melanoma cells are protected by G3139 and other antineoplastic agents against the cytotoxic effects of DTIC.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Dacarbazine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Guanine; Humans; Melanoma; Oligonucleotides, Antisense; Thionucleotides | 2005 |
Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma.
Topics: Adolescent; Adult; Alkaline Phosphatase; Analgesics, Non-Narcotic; Antigens, CD34; Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Image Processing, Computer-Assisted; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Osteosarcoma; Pain; Positron-Emission Tomography; Radiation-Sensitizing Agents; Radiopharmaceuticals; Remission Induction; Samarium; Sarcoma; Stem Cells; Time Factors | 2005 |
Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Female; Gemcitabine; Genistein; Humans; Mice; Mice, Inbred ICR; Mice, Nude; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Random Allocation; Xenograft Model Antitumor Assays | 2005 |
Aerosol delivery of chemotherapy in an orthotopic model of lung cancer.
Topics: Administration, Inhalation; Animals; Antineoplastic Agents; Carcinoma, Large Cell; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude | 2005 |
Potentiation of the antitumoral activity of gemcitabine and paclitaxel in combination on human breast cancer cells.
Topics: Animals; Anthracyclines; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Paclitaxel; Taxoids; Xenograft Model Antitumor Assays | 2005 |
Serum amyloid A as a tumor marker in sera of nude mice with orthotopic human pancreatic cancer and in plasma of patients with pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Staging; Neoplasms, Experimental; Pancreatic Neoplasms; Random Allocation; Sensitivity and Specificity; Serum Amyloid A Protein; Transplantation, Heterologous | 2005 |
Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms | 2005 |
Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Irinotecan; Male; Mandibular Diseases; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Osteoradionecrosis; Paclitaxel; Prognosis; Radiotherapy Dosage; Treatment Failure; Treatment Outcome | 2006 |
[A case report of chemotherapy with thalidomide, celecoxib and gemcitabine in the treatment of patients with brain metastases from lung cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cranial Irradiation; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Pyrazoles; Sulfonamides; Thalidomide | 2005 |
Nucleoside ester prodrug substrate specificity of liver carboxylesterase.
Topics: Animals; Benzimidazoles; Caco-2 Cells; Carboxylesterase; Cytosol; Deoxycytidine; Esters; Floxuridine; Gemcitabine; Humans; Hydrolysis; Liver; Models, Molecular; Molecular Structure; Nucleosides; Prodrugs; Ribonucleosides; Substrate Specificity; Swine | 2006 |
[Locally advanced pancreatic cancer that enlarged after administration of gemcitabine and responded to oral TS-1--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Jaundice, Obstructive; Male; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Stents; Tegafur | 2005 |
[Combined systemic and intraarterial chemotherapy with gemcitabine and concomitant external-beam radiotherapy in patients with liver metastasis from pancreatic cancer--report of two cases].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage | 2005 |
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
Topics: Animals; Blotting, Western; Colonic Neoplasms; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Deoxycytosine Nucleotides; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Mice; Mice, Inbred BALB C; Nucleoside Deaminases; Oligonucleotide Array Sequence Analysis; Protein Subunits; Ribonucleotide Reductases | 2005 |
Gallbladder cancer, a different disease that needs individual trials.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gallbladder Neoplasms; Gallstones; Gemcitabine; Hemorrhage; Humans; Research Design; Treatment Outcome | 2005 |
Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53.
Topics: Cell Cycle; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53 | 2005 |
Vascular targeting in pancreatic cancer: the novel tubulin-binding agent ZD6126 reveals antitumor activity in primary and metastatic tumor models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cells, Cultured; Coloring Agents; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Immunohistochemistry; Liver; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Chemical; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Organophosphorus Compounds; Pancreatic Neoplasms; Tetrazolium Salts; Thiazoles; Tubulin; Umbilical Veins | 2005 |
In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; BRCA2 Protein; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Chlorambucil; Cisplatin; Cross-Linking Reagents; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Fanconi Anemia Complementation Group C Protein; Fanconi Anemia Complementation Group G Protein; Fanconi Anemia Complementation Group Proteins; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Melphalan; Mice; Mice, Nude; Mitomycin; Mutation; Paclitaxel; Pancreatic Neoplasms; Time Factors; Vinblastine; Xenograft Model Antitumor Assays | 2005 |
Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Transplantation Conditioning; Transplantation, Autologous | 2006 |
Rob Ashley of AmpliMed discusses the discovery and development of Imexon. Interview by Steve Carney.
Topics: Antineoplastic Agents; Chemistry, Pharmaceutical; Deoxycytidine; Doxycycline; Drug Industry; Drug Synergism; Gemcitabine; Hexanones; Humans; Neoplasms; Tetracyclines | 2005 |
Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Cancer mouse models and other techniques for improved prediction of efficacy.
Topics: Angiogenesis Inhibitors; Animals; Boronic Acids; Bortezomib; Camptothecin; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Forecasting; Gemcitabine; Green Fluorescent Proteins; Humans; Image Enhancement; Irinotecan; Luminescent Proteins; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Pyrazines; Red Fluorescent Protein; Technology, Pharmaceutical; Treatment Outcome | 2005 |
Durable local responses with subtherapeutic doses of concurrent radiation and gemcitabine in a patient with refractory Hodgkin's disease.
Topics: Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Male; Treatment Outcome | 2003 |
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
Role of gross tumor volume on outcome and of dose parameters on toxicity of patients undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prognosis; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Survival Rate | 2005 |
Achieving cure for early stage pediatric Hodgkin disease with minimal morbidity: are we there yet?
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Failure | 2006 |
Which should be added to cisplatin for advanced non-small-cell lung cancer--vinorelbine or gemcitabine?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Vinblastine | 2005 |
Gemcitabine and carboplatin in the treatment of locally advanced and metastatic non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Malaysia; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Rate | 2005 |
5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Herpesvirus 1, Human; Humans; Oncolytic Viruses; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Virus Replication | 2005 |
[Drug resistance and activity changes of thioredoxin reductase in pancreatic cancer cells strain SW1990 induced by gemcitabine].
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Thioredoxin-Disulfide Reductase | 2005 |
Determination of the importance of the stereochemistry of psorospermin in topoisomerase II-induced alkylation of DNA and in vitro and in vivo biological activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Line; Cell Line, Tumor; Deoxycytidine; DNA; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Epoxy Compounds; Gemcitabine; In Vitro Techniques; Inhibitory Concentration 50; Leukemia; Lymphoma; Mice; Mice, Nude; Models, Chemical; Models, Molecular; Pancreatic Neoplasms; Stereoisomerism; Time Factors; Xanthones | 2005 |
Economic evaluation of three two-drug chemotherapy regimens in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost of Illness; Deoxycytidine; Gemcitabine; Hospitalization; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Prospective Studies | 2005 |
North Central Cancer Treatment Group N0531: Phase II Trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caveolin 1; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel | 2005 |
[A case of pancreatic cancer complicated by gemcitabine-induced peripheral edema].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Diuretics; Drug Administration Schedule; Drug Therapy, Combination; Edema; Furosemide; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prednisolone; Spironolactone | 2005 |
Gemcitabine in intravesical treatment of Ta-T1 transitional cell carcinoma of the bladder.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Urinary Bladder Neoplasms | 2005 |
What's happening in PHARMAC--where do all the submissions go? On the trail of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Drug Approval; Gemcitabine; Humans; National Health Programs; New Zealand; Urinary Bladder Neoplasms | 2005 |
PHARMAC's response on gemcitabine and transparency.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Drug Approval; Gemcitabine; Humans; National Health Programs; New Zealand; Urinary Bladder Neoplasms | 2005 |
Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations.
Topics: Animals; Antimetabolites, Antineoplastic; Chromosome Aberrations; Colonic Neoplasms; Deoxycytidine; DNA Replication; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Mice; Nucleic Acid Hybridization; Oligonucleotide Array Sequence Analysis | 2005 |
Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Endothelial Cells; ErbB Receptors; Gemcitabine; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Purines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2005 |
Improving outcomes in the treatment of locally-advanced NSCLC with gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Survival Rate; Treatment Outcome | 2005 |
Using translational research to tailor the use of chemotherapy in the treatment of NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Drug Delivery Systems; Endonucleases; Gemcitabine; Genetic Markers; Humans; Lung Neoplasms; Pharmacogenetics; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2005 |
The development of gemcitabine and carboplatin in the treatment of non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms | 2005 |
Incorporating novel agents with gemcitabine-based treatment of NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms | 2005 |
Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Health Status Indicators; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2005 |
Folate-mediated targeting of polymeric conjugates of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carrier Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Folate Receptors, GPI-Anchored; Folic Acid; Gemcitabine; Humans; Hydrogen-Ion Concentration; Polyhydroxyethyl Methacrylate; Prodrugs; Receptors, Cell Surface; Succinates; Time Factors | 2006 |
Resistance to cytarabine and gemcitabine and in vitro selection of transduced cells after retroviral expression of cytidine deaminase in human hematopoietic progenitor cells.
Topics: Cells, Cultured; Cytarabine; Cytidine Deaminase; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Erythroid Precursor Cells; Gemcitabine; Hematopoietic Stem Cells; Humans; Myeloid Progenitor Cells; Retroviridae; Transduction, Genetic | 2005 |
Myelopathy after radiation therapy and chemotherapy with capecitabine and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Middle Aged; Radiation Injuries; Radiation-Sensitizing Agents; Spinal Cord Diseases | 2005 |
Activation of c-Jun NH2-terminal kinase is required for gemcitabine's cytotoxic effect in human lung cancer H1299 cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Resistance; Enzyme Activation; Gemcitabine; Humans; JNK Mitogen-Activated Protein Kinases | 2005 |
Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine | 2006 |
A case of advanced Hodgkin lymphoma with breast involvement treated with a combination of gemcitabine and pegylated liposomal doxorubicin.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Breast Neoplasms, Male; Deoxycytidine; Doxorubicin; Gemcitabine; Hodgkin Disease; Humans; Male; Radiography; Recurrence | 2005 |
Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; DNA Mutational Analysis; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Analysis; Survival Rate; Treatment Outcome | 2005 |
[A study of recurrent pancreatic cancer with metastatic liver tumors after pancreatectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2005 |
[Intraperitoneal and intrapleural gemcitabine in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Infusions, Parenteral; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pleural Cavity; Pleural Neoplasms | 2005 |
[Gemcitabine concurrent with radiation for locally advanced pancreatic cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2005 |
[A case of advanced pancreatic cancer treated with chemoradiation].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Tegafur; Uracil | 2005 |
In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate.
Topics: Animals; Antineoplastic Agents; Body Weight; Cardiolipins; Cell Proliferation; Deoxycytidine; Dipyridamole; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; HT29 Cells; Humans; Leukemia P388; Leukocyte Count; Mice; Mice, SCID; Neutropenia; Nucleoside Transport Proteins; Pancreatic Neoplasms; Thioinosine; Xenograft Model Antitumor Assays | 2006 |
Gemcitabine-related radiation recall in a patient with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation Injuries | 2006 |
Effects of gemcitabine on cis-platinum-DNA adduct formation and repair in a panel of gemcitabine and cisplatin-sensitive or -resistant human ovarian cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Cisplatin; Deoxycytidine; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Ovarian Neoplasms; Tumor Cells, Cultured | 2006 |
Combined modality therapy of gemcitabine and irradiation on human glioma spheroids derived from cell lines and biopsy tissue.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Glioma; Humans; Immunohistochemistry; Ki-67 Antigen; Microscopy, Confocal; Proto-Oncogene Proteins p21(ras); Radiation-Sensitizing Agents; Spheroids, Cellular; Tumor Suppressor Protein p53 | 2006 |
Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons.
Topics: Aerosols; Animals; Deoxycytidine; Female; Gemcitabine; Lung Neoplasms; Models, Animal; Neoplasms, Experimental; Papio; Radionuclide Imaging | 2006 |
Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Cytarabine; Deoxycytidine; Dexamethasone; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome | 2006 |
In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinases; Signal Transduction; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2006 |
Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Carcinoma; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Genetic Therapy; Genetic Vectors; Hepatocyte Growth Factor; Humans; Injections; Liver Neoplasms; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; RNA, Messenger; Xenograft Model Antitumor Assays | 2006 |
4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Hymecromone; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Gemcitabine doublets in advanced pancreatic cancer: should we move on?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Treatment Outcome | 2006 |
Bayesian sample size calculations in phase II clinical trials using a mixture of informative priors.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Clinical Trials, Phase II as Topic; Computer Simulation; Deoxycytidine; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Leiomyosarcoma; Organoplatinum Compounds; Oxaliplatin; Sample Size; Taxoids | 2006 |
[An outpatient with unresectable pancreatic cancer treated with gemcitabine showing prolonged NC (22 months)].
Topics: Adenocarcinoma; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Pancreatic Neoplasms | 2005 |
Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylserines; Transplantation, Heterologous | 2006 |
14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
Topics: 14-3-3 Proteins; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; DNA Methylation; Drug Administration Schedule; Exonucleases; Exoribonucleases; Female; Gemcitabine; Gene Silencing; Genes, cdc; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Prospective Studies | 2005 |
Symptoms in cancer patients and an unusual tumor: Case 3. Follicular dendritic cell sarcoma.
Topics: Abdominal Pain; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dendritic Cells; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Liver Neoplasms; Male; Prednisone; Sarcoma; Tomography, X-Ray Computed; Vinblastine; Vincristine; Vinorelbine | 2005 |
Re: "Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival".
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy | 2006 |
Prolonged gemcitabine infusion in advanced non-small-cell lung cancer with stable disease after gemcitabine 30-min infusion.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged | 2006 |
Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carboplatin; Carcinoma; Caspase 2; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Interactions; Enzyme Activation; Female; Gemcitabine; Humans; Isoflavones; Mice; Ovarian Neoplasms; Paclitaxel; Proteasome Endopeptidase Complex; Transplantation, Heterologous | 2006 |
Monitoring of cell growth and assessment of cytotoxicity using electrochemical impedance spectroscopy.
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Electric Impedance; Electrochemistry; Gemcitabine; Humans; Liver Neoplasms; Mercuric Chloride; Spectrum Analysis | 2006 |
Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Female; Gemcitabine; Glucocorticoids; Humans; Immediate-Early Proteins; Mice; Ovarian Neoplasms; Phosphoprotein Phosphatases; Protein Phosphatase 1; Protein Serine-Threonine Kinases; Protein Tyrosine Phosphatases | 2006 |
Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fibrosarcoma; Gemcitabine; Lymphoma; Mice; Neoplasm Transplantation; Neoplasms; Paclitaxel; Tumor Necrosis Factor-alpha | 2006 |
p8 is a new target of gemcitabine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Gene Expression; Humans; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA Repair; Gemcitabine; Genotype; Humans; Lung Neoplasms; Polymorphism, Genetic; Survival Analysis | 2006 |
Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreas; Pancreatic Neoplasms; Radiotherapy, Conformal; Remission Induction; Retrospective Studies; Survival Analysis; Thrombocytopenia; Time Factors; Treatment Outcome | 2006 |
Squamous cell carcinoma of the pancreas: report of a case and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Gemcitabine; Humans; Incidence; Male; Neoplasm Staging; Pancreatic Neoplasms; Prognosis | 2006 |
Radiotherapy and chemotherapy in pancreatic cancer. Topical issues and future perspectives.
Topics: Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Male; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Radiotherapy, Computer-Assisted; Survival Rate | 2006 |
[A 65-year-old man with liver metastases after lung cancer resection that responded to concomitant use of gemcitabine and carboplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Node Excision; Male; Pneumonectomy; Postoperative Period; Quality of Life | 2006 |
[A case of drug-induced interstitial pneumonitis after gemcitabine treatment for advanced pancreatic cancer].
Topics: Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Methylprednisolone Hemisuccinate; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Prednisolone; Pulse Therapy, Drug; Tomography, X-Ray Computed | 2006 |
Putting the chemo in chemoradiation for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Maximum Tolerated Dose; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiation Dosage | 2006 |
Study of the interaction of an anticancer drug with human and bovine serum albumin: spectroscopic approach.
Topics: Antimetabolites, Antineoplastic; Circular Dichroism; Deoxycytidine; Energy Transfer; Fluorescence Resonance Energy Transfer; Gemcitabine; Models, Chemical; Protein Binding; Protein Structure, Secondary; Serum Albumin; Serum Albumin, Bovine; Spectrophotometry, Ultraviolet | 2006 |
Gemcitabine in the first and second-line chemotherapy of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Croatia; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Survival Rate | 2005 |
Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Deoxycytidine; Drug Administration Schedule; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Quinazolines; Tumor Cells, Cultured | 2006 |
MSX2 overexpression inhibits gemcitabine-induced caspase-3 activity in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA-Binding Proteins; Enzyme Activation; Gemcitabine; Homeodomain Proteins; Humans; Pancreatic Neoplasms | 2005 |
Bullous dermatosis associated with gemcitabine therapy for non-small-cell lung carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Blister; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Eruptions; Gemcitabine; Humans; Lung Neoplasms; Male | 2006 |
[Experience of gemcitabine plus cisplatin chemotherapy in 52 patients with head and neck cancer].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis | 2005 |
Electrophysiological characterization and modeling of the structure activity relationship of the human concentrative nucleoside transporter 3 (hCNT3).
Topics: Algorithms; Animals; Deoxycytidine; Electrophysiology; Female; Gemcitabine; Humans; Kinetics; Membrane Potentials; Membrane Transport Proteins; Nucleosides; Oocytes; Purines; Pyrimidines; Quantitative Structure-Activity Relationship; Transfection; Xenopus laevis | 2006 |
A structurally optimized celecoxib derivative inhibits human pancreatic cancer cell growth.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Ribonucleotide Reductases; Sulfonamides; Tetrazolium Salts; Thiazoles | 2006 |
[Arterial infusion chemotherapy and radiotherapy after vascular supply distribution for pancreatic carcinoma].
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Retrospective Studies; Treatment Outcome | 2006 |
Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA, Neoplasm; Drosophila melanogaster; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Phosphotransferases (Alcohol Group Acceptor); Sarcoma; Transfection | 2006 |
Response of pseudomyxoma peritonei to gemcitabine.
Topics: Aged; Antineoplastic Agents; Cystadenocarcinoma, Mucinous; Deoxycytidine; Gemcitabine; Humans; Male; Peritoneal Neoplasms; Pseudomyxoma Peritonei | 2006 |
The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma.
Topics: Aminopterin; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cytarabine; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Evaluation, Preclinical; Gemcitabine; Humans; In Vitro Techniques; Lymphoma, Non-Hodgkin; Methotrexate; Mice; Mice, SCID; Time Factors; Xenograft Model Antitumor Assays | 2006 |
Gemcitabine-induced radiation necrosis of the pectoralis major muscle.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Necrosis; Palliative Care; Pectoralis Muscles | 2006 |
Gemcitabine-induced chronic systemic capillary leak syndrome: a life-threatening disease.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capillary Leak Syndrome; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2006 |
[A case of salvage combination chemotherapy of gemcitabine plus nedaplatin for squamous cell carcinoma of the ureter].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Salvage Therapy; Ureteral Neoplasms | 2006 |
Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vindesine | 2006 |
Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcit
Topics: Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Cytosine; Deoxycytidine; Dioxolanes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; RNA, Small Interfering; Transfection | 2006 |
[The mechanism of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer cell line].
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Proteins; Naphthoquinones; Pancreatic Neoplasms; RNA, Messenger | 2005 |
Relationship between cisplatin administration and the development of ototoxicity.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Audiometry; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hearing; Hearing Loss; Hearing Loss, High-Frequency; Humans; Lung Neoplasms; Male; Middle Aged; Randomized Controlled Trials as Topic | 2006 |
[Clinical features of long time survivors with unresectable pancreatic cancer treated by gemcitabine alone].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis; Survivors | 2006 |
[A case report of unresectable gallbladder cancer that responded remarkably to the combination of thalidomide, celecoxib, and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Deoxycytidine; Drug Administration Schedule; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Peritoneal Neoplasms; Prognosis; Pyrazoles; Remission Induction; Sulfonamides; Thalidomide | 2006 |
Interferon receptors and the caspase cascade regulate the antitumor effects of interferons on human pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Interferons; Pancreatic Neoplasms; Receptors, Interferon | 2006 |
Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fistula; Gemcitabine; Glutamates; Guanine; Humans; Intraoperative Period; Length of Stay; Male; Mesothelioma; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pemetrexed; Pleural Diseases; Pleural Neoplasms; Pneumonectomy; Prognosis; Retrospective Studies; Risk Factors; Severity of Illness Index | 2006 |
Dual-color imaging of nascent blood vessels vascularizing pancreatic cancer in an orthotopic model demonstrates antiangiogenesis efficacy of gemcitabine.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Endothelium, Vascular; Gemcitabine; Green Fluorescent Proteins; Humans; Immunohistochemistry; Intermediate Filament Proteins; Mice; Mice, Nude; Mice, Transgenic; Microscopy, Fluorescence; Neoplasm Transplantation; Neovascularization, Pathologic; Nerve Tissue Proteins; Nestin; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Transfection; Transplantation, Heterologous | 2006 |
Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bioreactors; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lactic Acid | 2006 |
Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cohort Studies; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
c-Abl-independent p73 stabilization during gemcitabine- or 4'-thio-beta-D-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells.
Topics: Apoptosis; Arabinonucleosides; Carcinoma; Caspase 3; Caspases; Colorectal Neoplasms; Deoxycytidine; DNA-Binding Proteins; Gemcitabine; Gene Deletion; Genes, Tumor Suppressor; Humans; Nuclear Proteins; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-abl; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation | 2006 |
Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cations; Cell Line, Tumor; Cell Proliferation; Ceramides; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Head and Neck Neoplasms; Humans; Inactivation, Metabolic; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasms, Squamous Cell; Pyridinium Compounds; Tissue Distribution; Xenograft Model Antitumor Assays | 2006 |
Response to paclitaxel, gemcitabine, and cisplatin in renal medullary carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Kidney Medulla; Kidney Neoplasms; Male; Paclitaxel | 2006 |
Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous bolus dosing and its in vitro pharmacodynamics.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Dogs; Female; Floxuridine; Gemcitabine; Half-Life; Metabolic Clearance Rate; Tumor Cells, Cultured | 2006 |
Pharmacokinetics of gemcitabine and its primary metabolite in dogs after intravenous infusion.
Topics: Animals; Antimetabolites, Antineoplastic; Area Under Curve; Deoxycytidine; Dogs; Female; Floxuridine; Gemcitabine; Half-Life; Infusions, Intravenous; Tissue Distribution | 2006 |
Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity.
Topics: Aged; Atrial Fibrillation; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms | 2006 |
Analysis of mannitol in pharmaceutical formulations using hydrophilic interaction liquid chromatography with evaporative light-scattering detection.
Topics: Chromatography, High Pressure Liquid; Deoxycytidine; Drug Compounding; Drug Stability; Excipients; Gemcitabine; Light; Mannitol; Scattering, Radiation; Sensitivity and Specificity; Solvents | 2006 |
Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation.
Topics: Animals; Antineoplastic Agents; Carbon; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Doxorubicin; Esophageal Neoplasms; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Rats; Taxoids; Treatment Outcome; X-Rays; Xenograft Model Antitumor Assays | 2006 |
Is thrombotic microangiopathy associated with antitumoral activity?
Topics: Acute Kidney Injury; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney; Middle Aged; Ovarian Neoplasms | 2006 |
With a little help from small friends: Enhanced chemotherapeutic effects with imatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines | 2006 |
Triplet chemotherapy for malignant pericardial mesothelioma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drainage; Drug Administration Schedule; Female; Gemcitabine; Heart Neoplasms; Humans; Mesothelioma; Middle Aged; Neutropenia; Pericardial Effusion; Remission Induction; Survivors; Vinblastine; Vinorelbine | 2006 |
[Is there a nonsurgical therapeutic approach to cholangiocellular carcinomas?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Brachytherapy; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholestasis; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hepatic Duct, Common; Humans; Jejunostomy; Neoadjuvant Therapy; Palliative Care; Photochemotherapy; Radiotherapy, Adjuvant; Stents; Survival Rate | 2006 |
Aggressive multimodality treatment in transitional cell carcinoma of the parafallopian tube: report of 2 cases and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel | 2006 |
Structures of eukaryotic ribonucleotide reductase I define gemcitabine diphosphate binding and subunit assembly.
Topics: Amino Acid Sequence; Animals; Catalytic Domain; Crystallography, X-Ray; Deoxycytidine; Deoxycytosine Nucleotides; Dimerization; Escherichia coli; Gemcitabine; Humans; Mice; Models, Molecular; Molecular Sequence Data; Protein Structure, Quaternary; Protein Subunits; Ribonucleotide Reductases; Saccharomyces cerevisiae; Sequence Homology, Amino Acid; Static Electricity; Substrate Specificity | 2006 |
Toxicity and efficacy of isolated lung perfusion with gemcitabine in a rat model of pulmonary metastases.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Lung; Lung Neoplasms; Male; Random Allocation; Rats; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Novel orthotopic implantation model of human malignant pleural mesothelioma (EHMES-10 cells) highly expressing vascular endothelial growth factor and its receptor.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Immunohistochemistry; Male; Mesothelioma; Mice; Mice, SCID; Neoplasm Transplantation; Pleural Neoplasms; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor A | 2006 |
Adjuvant treatment of pancreatic carcinoma in a clinically adapted mouse resection model.
Topics: Adenocarcinoma; Animals; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
SUMOylation plays a role in gemcitabine- and bortezomib-induced cytotoxicity in human oropharyngeal carcinoma KB gemcitabine-resistant clone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; NF-kappa B; Oropharyngeal Neoplasms; Pyrazines; SUMO-1 Protein | 2006 |
Low doses of cisplatin or gemcitabine plus Photofrin/photodynamic therapy: Disjointed cell cycle phase-related activity accounts for synergistic outcome in metastatic non-small cell lung cancer cells (H1299).
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dihematoporphyrin Ether; Dose-Response Relationship, Drug; G1 Phase; Gemcitabine; Humans; Lung Neoplasms; Photochemotherapy; Photosensitizing Agents; Resting Phase, Cell Cycle | 2006 |
Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics.
Topics: Animals; Black or African American; Chlorocebus aethiops; COS Cells; Cytidine Deaminase; DCMP Deaminase; Deoxycytidine; Gemcitabine; Genomics; Haplotypes; Humans; Kinetics; Linkage Disequilibrium; Pharmacogenetics; Polymorphism, Single Nucleotide; Recombinant Proteins; Sequence Analysis, DNA; Transfection; White People | 2006 |
Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; HCT116 Cells; Hedgehog Proteins; Humans; Paclitaxel; Pancreatic Neoplasms; Radiation, Ionizing; Time Factors; Veratrum Alkaloids | 2006 |
Erlotinib or capecitabine with gemcitabine in pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2006 |
[Is the frequency of hemolytic uremic syndrome as a complication of gemcitabine underestimated? The role of systematic screening].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Mass Screening; Mesothelioma; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms | 2006 |
Clinical features and correlates of gemcitabine-associated lung injury: findings from the RADAR project.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Male; Respiratory Distress Syndrome | 2006 |
Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Fragmentation; DNA, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Heat-Shock Proteins; Humans; Lectins, C-Type; Pancreatic Neoplasms; Pancreatitis-Associated Proteins; RNA, Messenger | 2006 |
High-performance liquid chromatographic method for the determination of gemcitabine and 2',2'-difluorodeoxyuridine in plasma and tissue culture media.
Topics: Bioreactors; Chromatography, High Pressure Liquid; Culture Media; Deoxycytidine; Drug Stability; Floxuridine; Gemcitabine; Humans; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2006 |
Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; RNA Splicing; RNA, Messenger; RNA, Small Interfering; Transfection | 2006 |
Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression; Humans; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Transcriptional Activation; Treatment Outcome; Tumor Suppressor Proteins | 2006 |
Nicotine inhibits apoptosis induced by chemotherapeutic drugs by up-regulating XIAP and survivin.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatin Immunoprecipitation; Cisplatin; Deoxycytidine; Dihydro-beta-Erythroidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Nicotine; Paclitaxel; Promoter Regions, Genetic; Receptors, Nicotinic; Retinoblastoma Protein; Survivin; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein | 2006 |
Does postoperative chemotherapy have a survival benefit for patients with pancreatic cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Survival Rate | 2006 |
[A case of non-small cell lung cancer accompanied with hemorrhage after chemotherapy including gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Radiography, Thoracic; Tomography, X-Ray Computed | 2006 |
Targeting oncogenes to improve breast cancer chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Breast Neoplasms; Cell Adhesion; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; Gene Expression; Genes, myc; Humans; Molecular Sequence Data; Oligonucleotides; Transcription, Genetic | 2006 |
Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Mice; Phosphoproteins; Protein Biosynthesis; RNA Caps; Transfection | 2006 |
Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Gene Expression Profiling; Humans; Immunohistochemistry; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2006 |
Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.
Topics: Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Data Interpretation, Statistical; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Radiotherapy Dosage; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis; Time Factors | 2006 |
XIAP is related to the chemoresistance and inhibited its expression by RNA interference sensitize pancreatic carcinoma cells to chemotherapeutics.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; X-Linked Inhibitor of Apoptosis Protein | 2006 |
Bronchiolitis obliterans organizing pneumonia simulating progression in bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Cryptogenic Organizing Pneumonia; Deoxycytidine; Diagnosis, Differential; Disease Progression; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Respiratory Insufficiency; Taxoids; Tomography, X-Ray Computed | 2006 |
Subcutaneous metastasis as the first manifestation of a solid-pseudopapillary tumor of the pancreas.
Topics: Adenocarcinoma, Clear Cell; Aged; Antimetabolites, Antineoplastic; Arm; Biomarkers; Biomarkers, Tumor; Deoxycytidine; Diagnostic Errors; Female; Gemcitabine; Humans; Keratins; Neoplasm Proteins; Neprilysin; Neuroendocrine Tumors; Pancreatic Neoplasms; Phosphopyruvate Hydratase; Soft Tissue Neoplasms; Subcutaneous Tissue; Vimentin | 2006 |
Primary carcinoid tumour of the pancreas.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Cisplatin; Combined Modality Therapy; Deoxycytidine; Diagnostic Errors; Gemcitabine; Humans; Liver Neoplasms; Liver Transplantation; Male; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction | 2006 |
Cerebellar metastasis from pancreatic adenocarcinoma. A case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cerebellar Neoplasms; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence; Tomography, X-Ray Computed | 2006 |
Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA Methylation; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Pancreatic Neoplasms; Survival Analysis | 2006 |
Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Survival; Cells, Cultured; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gemcitabine; Gene Expression; GPI-Linked Proteins; Hepatocytes; Humans; Immunohistochemistry; Irinotecan; Membrane Glycoproteins; Organoplatinum Compounds; Oxaliplatin; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Member 10c; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor Decoy Receptors; Tumor Necrosis Factor-alpha | 2006 |
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Costs and Cost Analysis; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; National Health Programs; Paclitaxel; Portugal; Taxoids | 2006 |
Pelvic chemoradiotherapy after chemotherapy for metastatic bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Combined Modality Therapy; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pelvic Neoplasms; Prognosis; Radiotherapy Dosage; Urinary Bladder Neoplasms | 2006 |
Gemcitabine-induced rectus abdominus radiation recall.
Topics: Abdominal Muscles; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Myositis; Pancreatic Neoplasms; Radiation Injuries; Radiation-Sensitizing Agents; Radiodermatitis; Tomography, X-Ray Computed | 2006 |
[Present and future home therapy in advanced stage of pancreatic cancer].
Topics: Ambulatory Care; Analgesics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fluorouracil; Forecasting; Gemcitabine; Home Care Services, Hospital-Based; Humans; Neoplasm Staging; Pain; Pancreatic Neoplasms; Quality of Life | 2006 |
Pulmonary toxicity in patients treated with gemcitabine and a combination of gemcitabine and a taxane: investigation of a signal using postmarketing data.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Taxoids | 2006 |
Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cisplatin; Comorbidity; Deoxycytidine; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Pyrazines; Risk Factors; Ventricular Dysfunction, Left | 2006 |
Determination of the mechanism of gemcitabine modulation of cisplatin drug resistance in panel of human endometrial cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endometrial Neoplasms; Female; Gemcitabine; Glutathione; Humans | 2006 |
Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Humans; Ifosfamide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Remission Induction; Rituximab; Salvage Therapy; Stem Cell Transplantation; Survival Rate; Transplantation, Autologous; Treatment Outcome | 2006 |
Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Colorectal Neoplasms; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Stomach Neoplasms; Tumor Suppressor Proteins | 2006 |
Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Pair Mismatch; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; MutL Protein Homolog 1; MutL Proteins; Neoplasm Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate | 2006 |
[Maintenance chemotherapy in advanced NSCLC].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Karnofsky Performance Status; Lung; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Time Factors; Vinblastine; Vinorelbine | 2006 |
[From ASCO and WCLC 2005 to clinical practice: "conventional" treatments].
Topics: Administration, Oral; Age Factors; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung; Lung Neoplasms; Mediastinoscopy; Meta-Analysis as Topic; Middle Aged; Neoplasm Staging; Palliative Care; Pneumonectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids; Time Factors; Topotecan | 2006 |
Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Quality of Life; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Simultaneous determination of gemcitabine di- and triphosphate in human blood mononuclear and cancer cells by RP-HPLC and UV detection.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Monocytes; Ovarian Neoplasms; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2006 |
Gemcitabine-cisplatin chemotherapy before lung resection: a case-matched analysis of early outcome.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Critical Care; Deoxycytidine; Drug Evaluation; Female; Gemcitabine; Humans; Length of Stay; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; Postoperative Complications; Retrospective Studies; Selection Bias; Statistics, Nonparametric; Treatment Outcome | 2006 |
The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.
Topics: Cell Survival; Deoxycytidine; Deoxycytidine Kinase; DNA Repair; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2006 |
Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort Studies; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Intestinal Perforation; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies; Taxoids; Tomography Scanners, X-Ray Computed; Treatment Outcome | 2006 |
Surgery is an essential part of salvage treatment in refractory germ cell tumors.
Topics: Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Failure | 2006 |
Cardiac metastasis from uterine leiomyosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Diagnostic Errors; Docetaxel; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Heart Neoplasms; Humans; Hysterectomy; Ifosfamide; Kidney Neoplasms; Leiomyoma; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Ovariectomy; Taxoids; Temozolomide; Thoracic Surgery, Video-Assisted; Uterine Neoplasms | 2006 |
Heavily pretreated ovarian cancer patients treated by single-agent gemcitabine. A retrospective outcome comparison between platinum-sensitive and platinum-resistant patients.
Topics: Adenocarcinoma, Clear Cell; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Salvage Therapy; Survival Rate | 2006 |
High activity of salvage treatment with biweekly paclitaxel-gemcitabine combination in heavily pretreated breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Neoplasm Metastasis; Paclitaxel; Salvage Therapy; Treatment Outcome | 2006 |
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.
Topics: Animals; Apoptosis; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; MicroRNAs; Oligonucleotide Array Sequence Analysis; Probability; Reverse Transcriptase Polymerase Chain Reaction; Sampling Studies; Sensitivity and Specificity; Transfection; Transplantation, Heterologous | 2006 |
Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Deoxycytidine; Disease Progression; Docetaxel; Female; Fibrin Fibrinogen Degradation Products; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Patient Compliance; Predictive Value of Tests; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2006 |
Gemcitabine plus cisplatin (GC): a salvage regimen for advanced breast cancer patients who have failed anthracycline and/or taxane therapy.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Remission Induction; Salvage Therapy; Survival Rate; Taxoids; Treatment Failure | 2006 |
[A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Jaundice, Obstructive; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Quality of Life; Remission Induction; Tegafur; Uracil | 2006 |
Model-based drug development: the road to quantitative pharmacology.
Topics: Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Biomarkers; Clinical Trials as Topic; Computer Simulation; Decision Making; Deoxycytidine; Dose-Response Relationship, Drug; Drug Industry; Female; Gemcitabine; Humans; Male; Middle Aged; Models, Biological; Osteocalcin; Osteoporosis, Postmenopausal; Pharmacology; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Treatment Outcome | 2006 |
Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; src-Family Kinases | 2006 |
Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Europe; Gemcitabine; Humans; Japan; Lung Neoplasms; Platinum; Retrospective Studies; Survival Rate; Taxoids; United States; Vinblastine; Vinorelbine | 2006 |
Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Mammary Glands, Animal; Mice; Paclitaxel; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Cells, Cultured | 2006 |
Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Treatment Outcome | 2006 |
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase Inhibitors; Deoxycytidine; Electrophoretic Mobility Shift Assay; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; Laser Scanning Cytometry; Luciferases; Mice; Mice, Nude; Neovascularization, Pathologic; ortho-Aminobenzoates; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sp Transcription Factors; Sp1 Transcription Factor; Sp3 Transcription Factor; Sp4 Transcription Factor; Vascular Endothelial Growth Factor A | 2006 |
Intramedullary metastases due to non microcytic lung carcinoma.
Topics: Adenocarcinoma; Bone Marrow Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cervical Vertebrae; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Craniotomy; Deoxycytidine; Docetaxel; Frontal Lobe; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Spinal Neoplasms; Taxoids; Thoracic Vertebrae; Vinblastine; Vinorelbine | 2006 |
Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: A cost-effectiveness analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Humans; Models, Economic; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum | 2006 |
In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Deoxycytidine; DNA Topoisomerases; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Topoisomerase Inhibitors; Treatment Outcome | 2006 |
Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Databases, Factual; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Tumor Cells, Cultured | 2006 |
Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Brain Neoplasms; Cetuximab; Cholangiocarcinoma; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Organoplatinum Compounds; Oxaliplatin | 2006 |
Correlation of hENT1 expression and function with gemcitabine cytotoxicity in mantle cell lymphoma lines and clinical samples.
Topics: Cell Line, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Nucleosides; RNA, Messenger | 2006 |
Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma.
Topics: Cell Line, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lymphoma, Mantle-Cell; Nucleosides; RNA, Messenger | 2006 |
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies | 2006 |
Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Drug Tolerance; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunologic Factors; Lung Neoplasms; Male; Mice; Mice, Nude; Oligonucleotides; Pemetrexed; RNA, Messenger; Toll-Like Receptor 9; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Growth inhibition and apoptosis induction in ovarian cancer cells.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Genes, p53; Humans; Ovarian Neoplasms; Paclitaxel; Tetrazolium Salts; Thiazoles; Tumor Suppressor Protein p53 | 2006 |
Cytidine is a novel substrate for wild-type concentrative nucleoside transporter 2.
Topics: Amino Acid Substitution; Animals; Antimetabolites, Antineoplastic; Biological Transport; Chlorocebus aethiops; COS Cells; Cytarabine; Cytidine; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Genotype; Kinetics; Male; Membrane Transport Proteins; Mice; Thymidine; Transfection; Tritium; Uridine | 2006 |
Serum tumor markers for pancreatic cancer: the dawn of new era?
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteomics; Quinazolines; Sensitivity and Specificity; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2006 |
Pancreatic cancer: highlights from the 42nd annual meeting of the American Society of Clinical Oncology, 2006.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Staging; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate | 2006 |
Gene transfer of cytidine deaminase protects myelopoiesis from cytidine analogs in an in vivo murine transplant model.
Topics: 3T3 Cells; Animals; Bone Marrow Transplantation; Colony-Forming Units Assay; Cytarabine; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Gene Transfer Techniques; Graft Survival; Leukocyte Count; Mice; Models, Animal; Platelet Count; Recombinant Fusion Proteins | 2006 |
[Interferon-alpha+cisplatin+5-FU therapy for gemcitabine-refractory unresectable and recurrent pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Pancreatic Neoplasms; Thrombocytopenia | 2006 |
Erysipeloid skin toxicity induced by gemcitabine.
Topics: Aged; Ankle; Antimetabolites, Antineoplastic; Deoxycytidine; Erysipeloid; Gemcitabine; Humans; Kidney Neoplasms; Leg; Male; Skin | 2006 |
Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cetuximab; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Palliative Care; Quality of Life; Survival Analysis | 2006 |
Vitamin D receptor agonists, cancer and the immune system: an intricate relationship.
Topics: Calcitriol; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Synergism; Epirubicin; Gemcitabine; Humans; Molecular Structure; Receptors, Calcitriol; Structure-Activity Relationship; Urinary Bladder Neoplasms | 2006 |
Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; I-kappa B Kinase; Mitosis; Ovarian Neoplasms; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2006 |
Strategy for prevention of local recurrence of pancreatic cancer after pancreatectomy: antitumor effect of gemcitabine mixed with fibrin glue in an orthotopic nude mouse model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Fibrin Tissue Adhesive; Fluorescent Dyes; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatectomy; Pancreatic Neoplasms; Rhodamines; Transplantation, Heterologous | 2006 |
Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1).
Topics: 5' Flanking Region; 5' Untranslated Regions; Amino Acid Substitution; Antimetabolites, Antineoplastic; Asian People; Deoxycytidine; DNA Mutational Analysis; Equilibrative Nucleoside Transporter 1; Exons; Gemcitabine; Genetic Variation; Haplotypes; Humans; Japan; Linkage Disequilibrium; Neoplasms; Polymorphism, Single Nucleotide | 2006 |
Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinomas and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Gemcitabine and radiotherapy in the treatment of uterine cervical cancer patients at Phramongkutklao Hospital.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Retrospective Studies; Survival Rate; Thailand; Treatment Outcome; Uterine Cervical Neoplasms | 2005 |
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Successful resection of advanced pancreatic tail cancer after neoadjuvant gemcitabine chemotherapy: report of a case.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2006 |
Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; RNA, Messenger; Tegafur; Uracil; Xenograft Model Antitumor Assays | 2006 |
Preparation of poly epsilon-caprolactone nanoparticles containing magnetite for magnetic drug carrier.
Topics: Cisplatin; Deoxycytidine; Drug Carriers; Gemcitabine; Magnetics; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Polyesters; Solubility; Spectroscopy, Fourier Transform Infrared | 2006 |
[Changes and clinical significance of serum soluble Apo-1/Fas in pancreatic cancer].
Topics: Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; Disease Progression; fas Receptor; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Remission Induction | 2006 |
Long-term survival under maintenance gemcitabine chemotherapy for metastatic transitional cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Retroperitoneal Neoplasms; Ribonucleotide Reductases; Survival Rate; Time Factors; Urinary Bladder Neoplasms | 2006 |
Something old, something new....
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Prednisone; Procarbazine; Recurrence; Stem Cell Transplantation; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Hungarian laboratory scientist use gene therapy to improve gemcitabine chemotherapy in glioma tumours.
Topics: Antimetabolites, Antineoplastic; Brain Neoplasms; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Genetic Therapy; Glioma; Humans | 2006 |
The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Glutamates; Guanine; Humans; Lung Neoplasms; Multidrug Resistance-Associated Proteins; Pemetrexed; Phosphodiesterase Inhibitors; Purinones; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Tumor Suppressor Proteins | 2006 |
An in vivo platform for translational drug development in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Injections, Subcutaneous; Kinetics; Mice; Mice, Nude; Pancreatic Neoplasms; Predictive Value of Tests; Sirolimus; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |
Malignant acanthosis nigricans and tripe palms associated with pancreatic adenocarcinoma.
Topics: Acanthosis Nigricans; Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Hand Dermatoses; Humans; Pancreatic Neoplasms | 2006 |
Intrapericardial instillation of mitomycin C in recurrent cardiac tamponade due to malignant pericardial effusion.
Topics: Adenocarcinoma; Antineoplastic Agents; Cardiac Tamponade; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Instillation, Drug; Lung Neoplasms; Middle Aged; Mitomycin; Pericardial Effusion; Recurrence | 2006 |
Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice.
Topics: Adult; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Deoxycytidine; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Hodgkin Disease; Homeodomain Proteins; Humans; Immunoglobulin Heavy Chains; Lymph Nodes; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Male; Mice; Mice, Knockout; Mice, SCID; Nucleic Acid Hybridization; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Transplantation, Heterologous; Tumor Cells, Cultured | 2006 |
Gemcitabine and cisplatin after radical cystectomy for bladder cancer in an adjuvant setting: feasibility study from the Genito-Urinary Group of the French Federation of Cancer Centers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Immunologic Factors; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Oligonucleotides; Phosphatidylethanolamines; Prostatic Neoplasms; RNA, Messenger; Taxoids; Toll-Like Receptor 9 | 2006 |
Modified approach of administering cytostatics to the lung: more efficient isolated lung perfusion.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Chromatography, High Pressure Liquid; Deoxycytidine; Diffusion; Gemcitabine; Lung; Lung Neoplasms; Male; Models, Biological; Rats; Rats, Wistar; Spectrophotometry, Ultraviolet; Therapeutic Irrigation | 2006 |
Enhanced killing of pancreatic cancer cells by expression of fusogenic membrane glycoproteins in combination with chemotherapy.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Female; Gemcitabine; Genetic Vectors; Humans; Membrane Fusion Proteins; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Pancreatic Neoplasms; Survival Rate; Transduction, Genetic; Tumor Cells, Cultured | 2006 |
Antagonistic interactions between gemcitabine and 5-fluorouracil in the human pancreatic carcinoma cell line Capan-2.
Topics: Antimetabolites, Antineoplastic; Caspase 2; Caspase Inhibitors; Cell Cycle; Cell Division; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Kinetics; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; Floxuridine; Gemcitabine; Histones; Humans; Mitosis; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; RNA Interference | 2006 |
A 99mTc-labeled gemcitabine bisphosphonate drug conjugate as a probe to assess the potential for targeted chemotherapy of metastatic bone cancer.
Topics: Animals; Bone Neoplasms; Deoxycytidine; Diphosphonates; Female; Gemcitabine; Kidney; Liver; Mice; Mice, Inbred BALB C; Technetium; Tissue Distribution | 2006 |
Effects of low-dose warfarin and regional chemotherapy on survival in patients with pancreatic carcinoma.
Topics: Antibiotics, Antineoplastic; Anticoagulants; Carcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Injections, Intra-Arterial; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; Warfarin | 2006 |
Combined gemcitabine and alpha-interferon therapy for pancreatic cancer: report of a case.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Interferon-alpha; Liver Neoplasms; Male; Pancreatic Neoplasms | 2006 |
Vitamins C and K3 sensitize human urothelial tumors to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Ascorbic Acid; Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Urinary Bladder Neoplasms; Urothelium; Vitamin K 3; Vitamins | 2006 |
Advanced non-small-cell lung cancer: 'triplets' better than 'doublets'?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel | 2006 |
[Analysis of antineoplastic drugs used in Cancer Center, Sun Yat-sen University, during the period of 1996-2005].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Drug Utilization Review; Gemcitabine; Humans; Neoplasms; Paclitaxel; Rituximab; Vinblastine; Vinorelbine | 2006 |
[Tailored-dose chemotherapy using gemcitabine for advanced pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms | 2006 |
[Gemcitabine versus combined chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2006 |
[A patient with pancreatic cancer and multiple liver metastases after total pancreatectomy who showed a partial response to combination chemotherapy with gemcitabine and UFT].
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Pancreatectomy; Pancreatic Neoplasms; Quality of Life; Remission Induction; Tegafur; Uracil | 2006 |
[Myositis as a 'radiation-recall phenomenon' following palliative chemotherapy with carboplatin-gemcitabin for non-small-cell pulmonary carcinoma].
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Myositis; Palliative Care; Radiation-Sensitizing Agents | 2006 |
Inhibition of expression of vascular endothelial growth factor and its receptors in pulmonary adenocarcinoma cell by TNP-470 in combination with gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cyclohexanes; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Metastasis; O-(Chloroacetylcarbamoyl)fumagillol; Protein Structure, Tertiary; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
[Experience with gemcitabine-carboplatin chemotherapy in relapsed ovarian cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; ErbB Receptors; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Tumor Suppressor Proteins | 2006 |
Pifithrin-alpha enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzothiazoles; Bile Duct Neoplasms; Cell Count; Cell Cycle; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Eukaryotic Initiation Factor-4E; Gemcitabine; Humans; Immunoblotting; Oligonucleotide Array Sequence Analysis; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Receptors, Aryl Hydrocarbon; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Toluene | 2006 |
Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Pelvic Neoplasms; Prostatic Neoplasms; Taxoids | 2006 |
Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Carboplatin; Cerebral Ventricle Neoplasms; Combined Modality Therapy; Consciousness Disorders; Cranial Irradiation; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Etoposide; Female; Gemcitabine; Germinoma; Hematopoietic Stem Cell Transplantation; Humans; Hypophysectomy; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pituitary Neoplasms; Temozolomide; Thiotepa; Topotecan | 2008 |
Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Cricetinae; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Genetic Therapy; Genetic Vectors; Male; Mesocricetus; Neoplasms, Experimental; Nucleoside-Phosphate Kinase; Pancreatic Neoplasms | 2006 |
RP101 improves the efficacy of chemotherapy in pancreas carcinoma cell lines and pancreatic cancer patients.
Topics: Adult; Aged; Bromodeoxyuridine; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Humans; Killer Cells, Natural; Middle Aged; Pancreatic Neoplasms | 2006 |
Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Laryngeal Neoplasms; Male; Middle Aged; Mouth Neoplasms; Neoplasm Recurrence, Local; Neutropenia; Pharyngeal Neoplasms; Stomatitis | 2006 |
Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Genome, Human; Humans; Pancreatic Neoplasms; Phosphotransferases; RNA, Small Interfering | 2006 |
Diverse resveratrol sensitization to apoptosis induced by anticancer drugs in sensitive and resistant leukemia cells.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Busulfan; Cell Cycle; Cell Line, Tumor; Cycloheximide; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Leukemia; Paclitaxel; Resveratrol; Stilbenes | 2006 |
Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: a monocenter prospective study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cytarabine; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Prospective Studies; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation, Autologous; Vinblastine; Vinorelbine | 2007 |
[The use of gemcitabine in the treatment of patients with mesothelioma].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Mesothelioma; Pleural Effusion, Malignant; Treatment Outcome | 2006 |
[Gemcitabine and cisplatin therapy in advanced or metastatic urothelial cancer: comparison of side effect with MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin)].
Topics: Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Staging; Quality of Life; Urologic Neoplasms; Vinblastine | 2006 |
A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Failure; Treatment Outcome | 2006 |
[A case of adenocarcinoma of unknown primary site successfully treated with gemcitabine monotherapy].
Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasms, Unknown Primary; Pancreatic Neoplasms; Pleural Effusion, Malignant; Tomography, X-Ray Computed | 2006 |
[A case of stage IVA intrahepatic biliary tract cancer successfully treated with gemcitabine].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Drug Administration Routes; Floxuridine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Tomography, X-Ray Computed | 2006 |
[Chemotherapy-naïve advanced pancreatic cancer with multiple liver metastases successfully treated by S-1 monotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2006 |
A new, simple method for quantifying gemcitabine triphosphate in cancer cells using isocratic high-performance liquid chromatography.
Topics: Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Chromatography, High Pressure Liquid; Cytarabine; Deoxycytidine; Gemcitabine; HL-60 Cells; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Sensitivity and Specificity | 2006 |
Gene expression profiling of breast cancer cells in response to gemcitabine: NF-kappaB pathway activation as a potential mechanism of resistance.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; NF-kappa B; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Signal Transduction; Tissue Array Analysis; Tumor Cells, Cultured | 2007 |
[Second-line chemotherapy with gemcitabine and cisplatin for urothelial cancer previously treated with or resistant to M-VAC therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Prognosis; Remission Induction; Urologic Neoplasms; Vinblastine | 2006 |
[A case of leiomyosarcoma of the scrotum: chemotherapy with anti-cancer agents was effective for the lung metastasis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Genital Neoplasms, Male; Humans; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pneumonectomy; Scrotum | 2006 |
Large topographic variability of upper abdominal lymphatics and the consequences for radiation treatment planning.
Topics: Adenocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Imaging, Three-Dimensional; Lymph Nodes; Lymphatic Vessels; Male; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiography, Abdominal; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Haematological toxicity in patients treated with cisplatin and gemcitabine for bladder cancer: the Weston Park Hospital, Sheffield, experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Thrombocytopenia; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Gemcitabine; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt | 2006 |
The determination of gemcitabine and 2'-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry.
Topics: Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; Reproducibility of Results; Tandem Mass Spectrometry; Tissue Distribution | 2007 |
Management dilemmas due to a paratracheal follicular dendritic cell tumor.
Topics: Adult; Airway Obstruction; Antineoplastic Agents; Bronchoscopy; Dendritic Cells, Follicular; Deoxycytidine; Female; Gemcitabine; Humans; Radiotherapy; Respiration, Artificial; Sarcoma; Stents; Tracheal Neoplasms | 2006 |
[Apoptosis of breast cancer cell line MCF-7 cells induced by gemcitabine and radiation].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Radiation; Radiation-Sensitizing Agents; Tumor Cells, Cultured | 2006 |
Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells.
Topics: Antineoplastic Agents; Catalysis; Cell Line, Tumor; Cladribine; Cytosine; Deoxycytidine; Dioxolanes; Drug Resistance, Neoplasm; Gemcitabine; HeLa Cells; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Models, Chemical; Nucleosides | 2006 |
Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Cladribine; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Inhibitory Concentration 50; Oligonucleotide Array Sequence Analysis; Pemetrexed; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases | 2006 |
Enhanced activity of deoxycytidine kinase after pulsed low dose rate and single dose gamma irradiation.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA; DNA Repair; Dose-Response Relationship, Radiation; Gamma Rays; Gemcitabine; Humans; Lung Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Radiation-Sensitizing Agents; Time Factors | 2006 |
Analysis of deoxycytidine accumulation in gemcitabine treated patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Chemistry, Clinical; Chromatography; Deoxycytidine; Gemcitabine; Humans; Mass Spectrometry; Models, Biological; Models, Chemical; Sensitivity and Specificity; Time Factors | 2006 |
[A pilot study on the impact of the drug resistance on the radioresistance in human pancreatic cancer cell lines].
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation Tolerance | 2006 |
Early detection of Richter's transformation: stable disease with dose-reduced gemcitabine and local radiation.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Radiation-Sensitizing Agents; Treatment Outcome | 2006 |
Tannic acid synergizes the cytotoxicity of chemotherapeutic drugs in human cholangiocarcinoma by modulating drug efflux pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Down-Regulation; Drug Interactions; Fluoresceins; Fluorouracil; Gemcitabine; Humans; Membrane Transport Proteins; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Tannins | 2007 |
Metastatic non-small-cell lung carcinoma successfully treated with pre-operative chemotherapy and bilateral adrenalectomy.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Splenectomy | 2006 |
Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Neoplasm Metastasis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
[Treatment of squamous cell carcinoma of the pancreas with gemcitabine].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Time Factors; Treatment Outcome | 2006 |
Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Cytoprotection; Deoxycytidine; DNA, Neoplasm; Doxorubicin; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Imidazoles; Keratinocytes; Mutation; Piperazines; Proto-Oncogene Proteins c-mdm2; S Phase | 2006 |
Increased expression of tissue transglutaminase in pancreatic ductal adenocarcinoma and its implications in drug resistance and metastasis.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; GTP-Binding Proteins; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Glutamine gamma Glutamyltransferase 2; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Transglutaminases | 2006 |
Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Genistein; Humans; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis | 2006 |
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms | 2006 |
Basal cell carcinoma metastatic to cervical lymph nodes and lungs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Basal Cell; Carcinoma, Papillary; Deoxycytidine; Diagnostic Errors; Docetaxel; Gemcitabine; Head and Neck Neoplasms; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Radiotherapy; Seminoma; Skin Neoplasms; Taxoids; Testicular Neoplasms; Thyroid Neoplasms; Thyroidectomy; Unnecessary Procedures | 2006 |
Molecular features linked to the growth-inhibitory effects of gemcitabine on human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2006 |
Effective use of multi-arterial infusion chemotherapy for advanced non-small cell lung cancer patients: four clinical specified cases.
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Middle Aged; Taxoids; Tomography, X-Ray Computed | 2007 |
Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneal Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy | 2006 |
Exatecan and gemcitabine: no better than gemcitabine only.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Rate | 2006 |
[A case of gemcitabine-based chemo-radiation therapy for locally advanced unresectable pancreatic cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Radiotherapy Dosage; Survivors; Tegafur; Uracil | 2006 |
[A case of intrahepatic cholangiocarcinoma effectively treated by hepatic arterial infusion chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bone Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2006 |
[Pancreatic cancer].
Topics: Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Palliative Care; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Smad4 Protein; Tomography, X-Ray Computed; Tumor Suppressor Protein p53 | 2006 |
Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGA Proteins; Humans; Lentivirus; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference | 2006 |
Treatment with gemcitabine and TRA-8 anti-death receptor-5 mAb reduces pancreatic adenocarcinoma cell viability in vitro and growth in vivo.
Topics: Animals; Annexin A5; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Flow Cytometry; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2006 |
Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
Topics: Anions; Antimetabolites, Antineoplastic; Calibration; Chromatography, Liquid; Deoxycytidine; Gemcitabine; Humans; Leukocyte Count; Leukocytes, Mononuclear; Proteins; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2006 |
The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy.
Topics: Aged; Analysis of Variance; Anemia; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Europe; False Positive Reactions; Female; Gemcitabine; Hemoglobins; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Palliative Care; Platinum Compounds; Predictive Value of Tests; Prospective Studies; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2007 |
Mediastinal follicular dendritic cell sarcoma involving bone marrow: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Dendritic Cells, Follicular; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Immunoenzyme Techniques; Mediastinal Neoplasms; Methotrexate; Middle Aged; Sarcoma; Taxoids; Treatment Outcome | 2006 |
A case of Guillain-Barré syndrome in a patient with non small cell lung cancer treated with chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Guillain-Barre Syndrome; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Middle Aged | 2006 |
Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA, Antisense; RNA, Messenger; Transfection; Tumor Suppressor Proteins; Up-Regulation | 2007 |
A step in the right direction.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Approval; Endpoint Determination; Female; Gemcitabine; Humans; Neoplasms; Ovarian Neoplasms; Survival Analysis; United States; United States Food and Drug Administration | 2006 |
Endoscopic biliary drainage for patients with unresectable pancreatic cancer with obstructive jaundice who are to undergo gemcitabine chemotherapy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drainage; Gemcitabine; Humans; Jaundice, Obstructive; Lower Body Negative Pressure; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Stents; Survival Analysis | 2006 |
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Deoxycytidine Kinase; Disease Models, Animal; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Gene Expression Profiling; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Piperidines; Polymerase Chain Reaction; Predictive Value of Tests; Quinazolines; Radiation, Ionizing; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Transplantation, Heterologous | 2006 |
Consistent liver metastases in a rat model by portal injection of microencapsulated cancer cells.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Injections, Intravenous; Irinotecan; Liver Neoplasms, Experimental; Mice; Mice, Nude; Microspheres; Neoplasm Transplantation; Pancreatic Neoplasms; Portal Vein; Rats; Rats, Nude; Transplantation, Heterologous | 2006 |
Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity.
Topics: Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; Cytotoxins; Deoxycytidine; Down-Regulation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Lysosomes; Phosphorylation; Proteasome Endopeptidase Complex; Protein Processing, Post-Translational; RNA, Messenger; Transcription, Genetic; Ubiquitin | 2007 |
An unusual case of gemcitabine-induced radiation recall.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Myositis; Palliative Care; Radiodermatitis | 2006 |
Gemcitabine-induced apoptosis in 5637 cell line: an in-vitro model for high-risk superficial bladder cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Carcinoma, Transitional Cell; Caspases; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Fragmentation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Fluorescent Antibody Technique; Gemcitabine; Humans; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Urinary Bladder Neoplasms | 2007 |
Reversible posterior leukoencephalopathy syndrome after carboplatin therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neurotoxicity Syndromes; Pleural Neoplasms | 2007 |
Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells.
Topics: Anthracenes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 8; Cell Communication; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Gap Junctions; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Phenylbutyrates; Time Factors; Tumor Cells, Cultured | 2007 |
Combination therapy with gemcitabine and 5-Fluorouracil: unblocking the pathways to survivin?
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survivin | 2006 |
Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Chromatography, Affinity; Cromolyn Sodium; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Reporter; Immunoprecipitation; Luciferases; Mice; Neoplasm Invasiveness; NF-kappa B; Pancreatic Neoplasms; Receptor for Advanced Glycation End Products; Receptors, Immunologic; S100 Proteins | 2006 |
The histone deacetylase inhibitors depsipeptide and MS-275, enhance TRAIL gene therapy of LNCaP prostate cancer cells without adverse effects in normal prostate epithelial cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Caspases; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Deoxycytidine; Depsipeptides; Doxorubicin; Gemcitabine; Genetic Therapy; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Male; Prostate; Prostatic Neoplasms; Pyridines; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Markov Chains; Medicare; Models, Economic; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis | 2007 |
Adjuvant therapy for pancreatic cancer: a time that has not yet come.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy Dosage | 2007 |
Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Infusions, Intravenous; Japan; Linkage Disequilibrium; Male; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2007 |
Prognostic significance of RASSF1A promoter methylation on survival of non-small cell lung cancer patients treated with gemcitabine.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Deoxycytidine; DNA Methylation; DNA Primers; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Promoter Regions, Genetic; Proportional Hazards Models; Tumor Suppressor Proteins | 2007 |
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Leukopenia; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Taxoids; Vascular Neoplasms | 2006 |
[A case of small cell carcinoma in the urinary bladder responding to gemcitabine/cisplatin combination therapy as neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Urinary Bladder Neoplasms; Urinary Diversion | 2006 |
ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma.
Topics: Adult; Alpha-Globulins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Platelet Factor 4; Protein Array Analysis; Protein Precursors; Salvage Therapy | 2007 |
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Deoxycytidine; Flow Cytometry; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Up-Regulation; Vorinostat | 2007 |
Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; MAP Kinase Kinase 4; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2007 |
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.
Topics: Adoptive Transfer; Animals; Antigen Presentation; Antigen-Presenting Cells; Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Immunization; In Vitro Techniques; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms, Experimental; Receptors, Antigen, T-Cell; Stromal Cells; T-Lymphocytes, Cytotoxic | 2007 |
[Low-dose gemcitabine concurrent with radiation therapy for locally advanced pancreatic carcinoma].
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy Dosage | 2006 |
A case report--The marked response to gemcitabine combined with irinotecan and low-dose cisplatin chemotherapy for advanced gastric cancer with multiple liver metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Male; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2006 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
Assessment of supra-additive effects of cytotoxic drugs and low dose rate irradiation in an in vitro model for hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cobalt Radioisotopes; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Radiation; Fluorouracil; Gamma Rays; Gemcitabine; Glucose Transporter Type 1; Humans; Rhenium; Topotecan | 2006 |
Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arm; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Ovarian Neoplasms; Respiratory Distress Syndrome; Severity of Illness Index; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Biomarkers; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2007 |
Adjuvant therapy for pancreatic cancer: one small step forward.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2007 |
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Caveolin 1; Cisplatin; Databases as Topic; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Time Factors; Treatment Outcome; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2007 |
Antitumor effect of gemcitabine on orthotopically inoculated human gallbladder cancer cells in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Cell Proliferation; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Proliferating Cell Nuclear Antigen; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Cells, Cultured; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Genes, cdc; Mice; Mice, Nude; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Xenograft Model Antitumor Assays | 2007 |
Transcleral orbital invasion by a radiation and chemotherapy-resistant choroidal metastasis of a pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Choroid Neoplasms; Deoxycytidine; Drug Resistance; Eye Enucleation; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Invasiveness; Orbital Neoplasms; Radiation Tolerance; Radiotherapy Dosage; Sclera | 2007 |
Data acquisition for the histoculture drug response assay in lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Probability; Retrospective Studies; Sensitivity and Specificity; Tumor Cells, Cultured | 2007 |
Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Male; Oncogenes; Ploidies; Probability; Sensitivity and Specificity; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Vinblastine | 2007 |
Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?
Topics: Antineoplastic Agents; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Humans; Kinetics; Metabolic Clearance Rate; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Sensitivity and Specificity; Treatment Outcome | 2007 |
Effects of lipid composition and preparation conditions on physical-chemical properties, technological parameters and in vitro biological activity of gemcitabine-loaded liposomes.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Caco-2 Cells; Cell Survival; Cholesterol; Colloids; Deoxycytidine; Gemcitabine; Humans; Hydrogen-Ion Concentration; Lipids; Liposomes; Oleic Acid; Particle Size; Phosphatidylethanolamines; Polyethylene Glycols; Prodrugs; Static Electricity; Technology, Pharmaceutical | 2007 |
Prognostic factors in patients with gemcitabine-refractory pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Remission Induction; Survival Analysis; Treatment Failure | 2007 |
Estrogen receptor beta/alpha ratio predicts response of pancreatic cancer cells to estrogens and phytoestrogens.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Coumestrol; Deoxycytidine; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens, Non-Steroidal; Gemcitabine; Genistein; Humans; In Vitro Techniques; Pancreatic Neoplasms; Predictive Value of Tests; Tamoxifen | 2007 |
Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Topics: 5'-Nucleotidase; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Proliferation; Cell Survival; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunophenotyping; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2007 |
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone; Middle Aged; Prognosis; Remission Induction; Treatment Outcome | 2007 |
[A case of advanced large cell lung carcinoma for whom fourth-line chemotherapy of cisplatin and gemcitabine proved effective for the first time].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Remission Induction; Taxoids; Tegafur; Vinblastine; Vinorelbine | 2007 |
Prediction of drug combination chemosensitivity in human bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Paclitaxel; Predictive Value of Tests; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2007 |
Role of human longevity assurance gene 1 and C18-ceramide in chemotherapy-induced cell death in human head and neck squamous cell carcinomas.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Caspases; Cell Line, Tumor; Ceramides; Chromatography, High Pressure Liquid; Chromatography, Liquid; Deoxycytidine; Doxorubicin; Fluorescent Antibody Technique; Gemcitabine; Head and Neck Neoplasms; Humans; Membrane Proteins; Mice; Mice, SCID; Oxidoreductases; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sphingosine N-Acyltransferase; Survival Rate | 2007 |
Preliminary data suggestive of a novel translational approach to mesothelioma treatment: imatinib mesylate with gemcitabine or pemetrexed.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Death; Deoxycytidine; Gemcitabine; Genes, fms; Glutamates; Guanine; Humans; Imatinib Mesylate; Mesothelioma; Pemetrexed; Piperazines; Pleural Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Tumor Cells, Cultured | 2007 |
Chemotherapy induced reversible posterior leukoencephalopathy syndrome.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diagnosis, Differential; Drug Therapy, Combination; Electroencephalography; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Neoplasms; Middle Aged; Ribonucleotide Reductases; Tomography, X-Ray Computed | 2007 |
Operative complications and early mortality after induction therapy for lung cancer.
Topics: Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Postoperative Complications; Preoperative Care; Radiation-Sensitizing Agents; Remission Induction; Retrospective Studies; Risk Factors; Treatment Outcome | 2007 |
Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens--evidence of schedule-dependent synergy.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Urinary Bladder Neoplasms | 2007 |
The synergistic interaction of gemcitabine and cytosine arabinoside with the ribonucleotide reductase inhibitor triapine is schedule dependent.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinofuranosylcytosine Triphosphate; Cytarabine; Deoxycytidine; DNA; Drug Synergism; Gemcitabine; Humans; Pyridines; Ribonucleotide Reductases; Thiosemicarbazones; Tumor Cells, Cultured | 2007 |
Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin | 2007 |
Treatment options for patients with pretreated metastatic breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Retreatment; Taxoids; Vinblastine; Vinorelbine | 2007 |
Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Vinblastine; Vinorelbine | 2007 |
Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Hedgehog Proteins; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Signal Transduction; Tumor Cells, Cultured; Veratrum Alkaloids; Xenograft Model Antitumor Assays | 2007 |
Electrolyte abnormalities and progressive renal failure in a cancer patient.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Creatinine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Docetaxel; Drug Administration Schedule; Fibrosarcoma; Follow-Up Studies; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Ifosfamide; Inflammation; Kidney; Kidney Glomerulus; Kidney Tubules; Male; Middle Aged; Renal Insufficiency; Taxoids; Treatment Outcome; Water-Electrolyte Imbalance | 2007 |
Thrombotic microangiopathy in a sirolimus-treated renal transplant patient receiving gemcitabine for lung cancer.
Topics: Anemia, Hemolytic; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Lung Neoplasms; Male; Middle Aged; Sirolimus; Thrombocytopenia | 2007 |
Targeting the apoptotic machinery in pancreatic cancers using small-molecule antagonists of the X-linked inhibitor of apoptosis protein.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Immunoenzyme Techniques; Ligands; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phenylurea Compounds; TNF-Related Apoptosis-Inducing Ligand; Tumor Stem Cell Assay; X-Linked Inhibitor of Apoptosis Protein; X-Rays | 2007 |
Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Docetaxel; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Patient attitudes towards chemotherapy as assessed by patient versus physician: a prospective observational study in advanced non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Attitude to Health; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Outcome Assessment, Health Care; Patient Compliance; Patient Satisfaction; Physician-Patient Relations; Prospective Studies; Ribonucleotide Reductases; Surveys and Questionnaires | 2007 |
Synergistic antitumor activity of oxaliplatin in combination with gemcitabine in pancreatic tumor-bearing mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Male; Mice; Mice, Inbred C57BL; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2007 |
Integrating Chinese and conventional medicine in colorectal cancer treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Drugs, Chinese Herbal; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Medicine, Chinese Traditional; Middle Aged | 2007 |
Delayed posterior encephalopathy syndrome following chemotherapy with oxaliplatin and gemcitabine.
Topics: Antineoplastic Agents; Brain Diseases; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Urinary Bladder Neoplasms | 2007 |
Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cell
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclooxygenase 2; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Interferon-alpha; Membrane Proteins; NF-kappa B; Paclitaxel; Poly(ADP-ribose) Polymerases; Smoking; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
Potentiation of high-LET radiation by gemcitabine: targeting HER2 with trastuzumab to treat disseminated peritoneal disease.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Lead Radioisotopes; Linear Energy Transfer; Mice; Mice, Nude; Peritoneal Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Receptor, ErbB-2; Survival Analysis; Trastuzumab; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2007 |
Gemcitabine plus cisplatin in advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome | 2007 |
Improved survival with single-agent paclitaxel consolidation/maintenance therapy in advanced ovarian carcinoma.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2006 |
Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Proportional Hazards Models; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
Editorial comment on: Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
Gemcitabine radiosensitizes multiple myeloma cells to low let, but not high let, irradiation.
Topics: Alpha Particles; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Gamma Rays; Gemcitabine; Humans; Linear Energy Transfer; Multiple Myeloma; Radiation Dosage; Radiation Tolerance; Radiation-Sensitizing Agents | 2007 |
Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2007 |
Pancreatic cancer: an update on a 'stealth' cancer. Treatment advances have been slow in coming. What makes this cancer so intractable?
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Early Diagnosis; Family Health; Gemcitabine; Humans; Mice; Pancreas; Pancreatic Neoplasms | 2007 |
Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Disease Models, Animal; Gemcitabine; Immunologic Memory; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Survival Analysis; T-Lymphocytes, Cytotoxic; Treatment Outcome; Vaccination | 2007 |
Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.
Topics: Adenocarcinoma; Aged; Animals; Antibodies, Monoclonal; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; CD8-Positive T-Lymphocytes; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Lymphocytes, Tumor-Infiltrating; Male; Mice; Mice, Inbred C57BL; Middle Aged; Pancreatic Neoplasms; Peptides; Prognosis; Programmed Cell Death 1 Ligand 2 Protein; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Digital ischemic changes after gemcitabine therapy in a patient with metastatic non-small-cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fingers; Gemcitabine; Humans; Ischemia; Lung Neoplasms; Male; Middle Aged | 2007 |
H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.
Topics: Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Replication; DNA-Binding Proteins; DNA, Neoplasm; Gemcitabine; Histones; Humans; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases; S Phase; Tumor Suppressor Proteins | 2007 |
Radiation recall pneumonitis induced by gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Pneumonia; Radionuclide Imaging; Treatment Outcome | 2007 |
Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma.
Topics: Animals; Deoxycytidine; Disease Models, Animal; Gallbladder Neoplasms; Gemcitabine; Humans; Keratin-7; Keratin-8; Ki-67 Antigen; Neoplasm Transplantation; Transplantation, Heterologous | 2007 |
Efficacy of vinorelbine in the second-line setting and beyond in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Probability; Retrospective Studies; Salvage Therapy; Survival Analysis; Vinblastine; Vinorelbine | 2007 |
Pick the winner designs in phase II cancer clinical trials.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Randomized Controlled Trials as Topic; Ribonucleotide Reductases; Treatment Outcome | 2006 |
Gemcitabine and carboplatin chemotherapy safely administered to a patient with homocystinuria.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Homocystinuria; Humans; Lung Neoplasms; Male; Middle Aged | 2006 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Taiwan; Taxoids; Treatment Outcome | 2006 |
Image-guided convection-enhanced delivery of gemcitabine to the brainstem.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Stem; Contrast Media; Convection; Deoxycytidine; Gadolinium DTPA; Gemcitabine; Infusions, Intralesional; Macaca mulatta; Magnetic Resonance Imaging; Therapy, Computer-Assisted | 2007 |
Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2007 |
Acute tubulointerstitial nephritis associated with long-term gemcitabine therapy.
Topics: Acute Kidney Injury; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Nephritis, Interstitial; Pancreatic Neoplasms | 2007 |
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Piperidines; Quinazolines; Regional Blood Flow; Signal Transduction; Skin; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2007 |
Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line: preliminary results of an in vitro study.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Diphosphonates; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Imidazoles; Lung Neoplasms; Zoledronic Acid | 2007 |
An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB clone.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Blotting, Western; Clone Cells; Deoxycytidine; DNA; Drug Resistance, Neoplasm; Electron Transport Complex IV; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; KB Cells; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; RNA, Messenger; Sodium Azide | 2007 |
A case of drug resistant clear cell ovarian cancer showing responsiveness to gemcitabine at first administration and at re-challenge.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Treatment Outcome | 2007 |
Pharmacodynamic characterization of gemcitabine cytotoxicity in an in vitro cell culture bioreactor system.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bioreactors; Cell Cycle; Cell Death; Cell Line, Tumor; Deoxycytidine; DNA, Neoplasm; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Tetrazolium Salts; Thiazoles | 2008 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Mice; Mice, Nude; Quinazolines; Rats; Transplantation, Heterologous | 2007 |
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-kappaB-regulated gene products.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Curcumin; Cyclooxygenase 2; Deoxycytidine; Down-Regulation; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 9; Mice; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2007 |
Circadian physiology is a toxicity target of the anticancer drug gemcitabine in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Body Temperature; Circadian Rhythm; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Male; Mice; Motor Activity | 2007 |
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Synergism; Female; Fluorouracil; Gemcitabine; Hematologic Diseases; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Tissue transglutaminase induces the release of apoptosis inducing factor and results in apoptotic death of pancreatic cancer cells.
Topics: Apoptosis; Apoptosis Inducing Factor; Calcimycin; Calcium Channels; Carcinoma, Pancreatic Ductal; Cell Death; Cell Differentiation; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Humans; Ionophores; Models, Biological; Pancreatic Neoplasms; Protein Glutamine gamma Glutamyltransferase 2; Transglutaminases; Tumor Cells, Cultured | 2007 |
Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.
Topics: Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Japan; Male; Middle Aged; Orotate Phosphoribosyltransferase; Pancreatic Neoplasms; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; RNA, Messenger; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome | 2007 |
Pharmacokinetics of gemcitabine in tumor and non-tumor extracellular fluid of brain: an in vivo assessment in rats employing intracerebral microdialysis.
Topics: Analysis of Variance; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Brain; Brain Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Extracellular Fluid; Gemcitabine; Glioma; Injections, Intravenous; Male; Microdialysis; Neoplasm Transplantation; Rats; Rats, Sprague-Dawley | 2008 |
Combination therapy of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, Nude; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Time Factors | 2007 |
Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Evaluation; Female; Gemcitabine; Humans; Immunotherapy; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Survival Rate; Treatment Outcome | 2007 |
Atrial fibrillation induced by gemcitabine treatment in a 65-year-old man.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Atrial Fibrillation; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Electrocardiography; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Risk Factors | 2007 |
3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
Topics: Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Deoxycytidine; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; p21-Activated Kinases; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptors, Thyroid Hormone; Triiodothyronine | 2007 |
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; ErbB Receptors; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2007 |
O(2/3) exposure inhibits cell progression affecting cyclin B1/cdk1 activity in SK-N-SH while induces apoptosis in SK-N-DZ neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin B; Cyclin B1; Cytoplasm; Deoxycytidine; Etoposide; Gemcitabine; Humans; Neuroblastoma; Oxygen; Ozone; Reactive Oxygen Species | 2007 |
Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Amplification; Humans; Lung Neoplasms; Mice; Mice, Nude; Retinoid X Receptors; Tetrahydronaphthalenes; Xenograft Model Antitumor Assays | 2007 |
Interaction of lipophilic gemcitabine prodrugs with biomembrane models studied by Langmuir-Blodgett technique.
Topics: Chemistry; Chemistry, Pharmaceutical; Deoxycytidine; Dimyristoylphosphatidylcholine; Gemcitabine; Liposomes; Membranes, Artificial; Models, Chemical; Permeability; Pressure; Prodrugs; Surface Properties; Technology, Pharmaceutical; Temperature | 2007 |
K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Silencing; Genes, ras; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Plasmids; RNA, Messenger; RNA, Small Interfering; Transcription, Genetic; Transfection; Transplantation, Heterologous | 2007 |
[A case of lung adenocarcinoma with Marie-Bamberger syndrome that improved by chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Male; Osteoarthropathy, Secondary Hypertrophic; Remission Induction | 2007 |
[New therapeutics in the suppression of superficial bladder carcinoma].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Carcinoma, Papillary; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Mitomycin; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
[The not-infrequent story of a superficial bladder carcinoma...Discussion of clinical case no.1].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
[The not-infrequent story of a superficial bladder carcinoma...Discussion of clinical case no.2].
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Agmatine; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Papillary; Deoxycytidine; Gemcitabine; Humans; Male; Mitomycin; Succinates; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Metastatic urothelial carcinoma of upper urinary tract.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Hematologic Diseases; Humans; Hypercalcemia; Kidney Neoplasms; Male; Middle Aged; Ureteral Neoplasms | 2007 |
[A resected case of effective treatment with gemcitabine for advanced pancreatic cancer with peritoneal metastasis].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lymph Node Excision; Male; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Neoplasms; Splenectomy; Tomography, X-Ray Computed | 2007 |
The cumulative incidence of gemcitabine-induced thrombotic microangiopathy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Iceland; Incidence; Middle Aged; Neoplasms; Peripheral Vascular Diseases; Thrombocytopenia | 2007 |
Concurrent chemoradiotherapy for advanced pancreatic cancer: 1,000 mg/m2 gemcitabine can be administered using limited-field radiotherapy.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Planning, Computer-Assisted; Survival Rate | 2007 |
Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prospective Studies; Protein Subunits; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis | 2007 |
Column selection for pharmaceutical analyses based on a column classification using four test parameters.
Topics: 2,2'-Dipyridyl; Antidepressive Agents, Second-Generation; Antimetabolites, Antineoplastic; Chromatography, Liquid; Deoxycytidine; Europe; Fluoxetine; Gemcitabine; Indicators and Reagents; Particle Size; Pharmaceutical Preparations; Pharmacopoeias as Topic; Porosity; Solvents; United States | 2007 |
Chemotherapeutic stress selectively activates NF-kappa B-dependent AKT and VEGF expression in liver cancer-derived endothelial cells.
Topics: Animals; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Cell Movement; Cells, Cultured; Deoxycytidine; Diethylnitrosamine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endothelial Cells; Gemcitabine; Liver; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Microcirculation; Neovascularization, Pathologic; NF-kappa B; Phenotype; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-akt; Receptors, Cell Surface; Time Factors; Transfection; Vascular Endothelial Growth Factor A | 2007 |
Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2007 |
Moving forward in advanced bladder cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; ErbB Receptors; Gemcitabine; Humans; Methotrexate; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Urinary Bladder Neoplasms; Vinblastine | 2007 |
Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiation Dosage; Survival Analysis; Time Factors; Treatment Outcome | 2007 |
Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Recombinant Proteins; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Expression of orotate phosphoribosyl transferase in human pancreatic cancer: implication for the efficacy of uracil and tegafur-based adjuvant chemotherapy.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Orotate Phosphoribosyltransferase; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur | 2007 |
Molecular impacts of rapamycin-based drug combinations: combining rapamycin with gemcitabine or imatinib mesylate (Gleevec) in a human leiomyosarcoma model.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Imatinib Mesylate; Leiomyosarcoma; Membrane Potential, Mitochondrial; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Piperazines; Pyrimidines; Signal Transduction; Sirolimus | 2007 |
Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cancer Vaccines; Cell Proliferation; Chickens; Colonic Neoplasms; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Fibroblast Growth Factor 1; Gemcitabine; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Random Allocation; Recombinant Proteins; Survival Rate | 2007 |
A new liposomal formulation of Gemcitabine is active in an orthotopic mouse model of pancreatic cancer accessible to bioluminescence imaging.
Topics: Animals; Antimetabolites, Antineoplastic; Capillary Permeability; Cell Line, Tumor; Chemistry, Pharmaceutical; Deoxycytidine; Drug Carriers; Drug Compounding; Evans Blue; Gemcitabine; Liposomes; Luciferases; Luminescence; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Permeability | 2008 |
Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine.
Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Glycoproteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Membrane Proteins; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins; Reactive Oxygen Species | 2007 |
Androgen receptor blockade in experimental combination therapy of pancreatic cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Cell Division; Cell Line, Tumor; Deoxycytidine; Dihydrotestosterone; Drug Therapy, Combination; Flutamide; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Pancreatic Neoplasms; Receptors, Androgen; Testosterone; Xenograft Model Antitumor Assays | 2007 |
The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Colonic Neoplasms; Cytosine; Deoxycytidine; Dioxolanes; DNA-(Apurinic or Apyrimidinic Site) Lyase; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Phosphoglycerate Kinase; Rhabdomyosarcoma | 2007 |
Shortness of breath and hypoxemia after chemotherapy with carboplatin and gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchiolitis Obliterans; Carboplatin; Deoxycytidine; Dyspnea; Gemcitabine; Humans; Hypoxia; Male; Pneumonia; Urinary Bladder Neoplasms | 2007 |
[Biliary tract carcinoma in elderly patients in whom gemcitabine chemotherapy induced complete remission - a report of two cases].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Remission Induction | 2007 |
A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Proliferation; Cells, Cultured; Deoxycytidine; DNA; Drug Resistance; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; In Vitro Techniques; Lung Neoplasms; Tissue Survival; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Experience with gemcitabine and cisplatin in the therapy of inoperable and metastatic cholangiocarcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Platelet Aggregation Inhibitors; Retrospective Studies; Survival Analysis; Treatment Outcome | 2007 |
Mismatched nucleotides as the lesions responsible for radiosensitization with gemcitabine: a new paradigm for antimetabolite radiosensitizers.
Topics: Base Pair Mismatch; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mutation; Radiation-Sensitizing Agents; RNA, Small Interfering | 2007 |
Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Death; Cell Line, Tumor; Ceramides; Deoxycytidine; Doxorubicin; Gemcitabine; Gene Expression Regulation, Neoplastic; Glioma; Humans; Sphingomyelin Phosphodiesterase | 2007 |
A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine.
Topics: Adenocarcinoma, Clear Cell; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritonitis; Salvage Therapy | 2008 |
Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer.
Topics: Aged; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Linear Models; Lung Neoplasms; Male; Middle Aged; Organotechnetium Compounds; Prognosis; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon | 2007 |
Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry.
Topics: Antineoplastic Agents; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Complex Mixtures; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2007 |
Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms | 2007 |
Adjuvant chemotherapy with gemcitabine for patients with resectable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Analysis | 2007 |
Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Immunotherapy; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; T-Lymphocytes; T-Lymphocytes, Cytotoxic | 2007 |
Gemcitabine plus bevacizumab no better than gemcitabine alone in clinical study of 600 patients with pancreatic cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Treatment Outcome | 2007 |
Collecting duct carcinoma producing granulocyte-colony-stimulating factor (G-CSF).
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Male; Nephrectomy; Organoplatinum Compounds; Radiography | 2007 |
An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cells, Cultured; DCMP Deaminase; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Haplotypes; Humans; Middle Aged; Neutropenia; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Tumor Suppressor Proteins | 2007 |
Synthesis and biological activity of a gemcitabine phosphoramidate prodrug.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine Monophosphate; Deoxycytidine; Deoxycytidine Kinase; Dipyridamole; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Nucleoside Transport Proteins; Prodrugs; Structure-Activity Relationship | 2007 |
Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytosine; Deoxycytidine; Dioxolanes; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Treatment Outcome; Tritium; Tumor Cells, Cultured; Uridine; Xenograft Model Antitumor Assays | 2007 |
Magnetic poly epsilon-caprolactone nanoparticles containing Fe3O4 and gemcitabine enhance anti-tumor effect in pancreatic cancer xenograft mouse model.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Female; Ferrosoferric Oxide; Gemcitabine; Humans; Magnetics; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Polyesters; Tissue Distribution; Xenograft Model Antitumor Assays | 2007 |
Nucleoside analogues are activated by bacterial deoxyribonucleoside kinases in a species-specific manner.
Topics: Anti-Bacterial Agents; Bacteria; Biotransformation; Cloning, Molecular; Deoxycytidine; DNA, Bacterial; Escherichia coli; Gemcitabine; Kinetics; Microbial Sensitivity Tests; Nucleosides; Phosphotransferases (Alcohol Group Acceptor); Phylogeny; Recombinant Proteins; Species Specificity; Thymidine Kinase; Zidovudine | 2007 |
[MMW drug award for gemcitabine. Cytostatic drug with growing indications].
Topics: Antimetabolites, Antineoplastic; Awards and Prizes; Deoxycytidine; Drug Approval; Gemcitabine; Germany; Neoplasms; Pancreatic Neoplasms; Treatment Outcome | 2006 |
The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2007 |
Pancreatic cancer: is this bleak landscape finally changing? Highlights from the '43rd ASCO Annual Meeting'. Chicago, IL, USA. June 1-5, 2007.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; ErbB Receptors; Farnesyltranstransferase; Gemcitabine; Humans; Matrix Metalloproteinase Inhibitors; Models, Biological; Pancreatic Neoplasms; Platinum Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Gemcitabine-induced liver fibrosis in a patient with pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Liver Cirrhosis; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms | 2007 |
In vitro simulation study of individualized chemotherapy in lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2007 |
Endoscopic ultrasound-guided fine-needle injection of immature dendritic cells into advanced pancreatic cancer refractory to gemcitabine: a pilot study.
Topics: Adult; Antimetabolites, Antineoplastic; Dendritic Cells; Deoxycytidine; Drug Resistance, Neoplasm; Endoscopy; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Pilot Projects | 2007 |
A pure invasive micropapillary carcinoma of the pancreatic head: long disease-free survival after pancreatoduodenectomy and adjuvant chemotherapy with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Duodenum; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms | 2007 |
Developmental chemotherapy and management of recurrent ovarian cancer.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drugs, Investigational; Enzyme Inhibitors; Etoposide; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Recurrence; Research Design; Taxoids; Topoisomerase I Inhibitors; Topotecan; Treatment Outcome | 2003 |
Understanding ribonucleotide reductase inactivation by gemcitabine.
Topics: Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Models, Molecular; Protein Conformation; Ribonucleotide Reductases | 2007 |
[A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine as second-line chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Quality of Life; Tegafur; Tomography, X-Ray Computed | 2007 |
Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Cytarabine; Cytosine; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids | 2007 |
Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC.
Topics: Animals; Antimetabolites, Antineoplastic; Blood Chemical Analysis; Calibration; Chemistry, Clinical; Chromatography, High Pressure Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Male; Rats; Rats, Wistar; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Serum | 2007 |
S100A4 contributes to the suppression of BNIP3 expression, chemoresistance, and inhibition of apoptosis in pancreatic cancer.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cell Survival; Deoxycytidine; Enzyme Activation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Proto-Oncogene Proteins; RNA Interference; S100 Calcium-Binding Protein A4; S100 Proteins; Time Factors; Transfection | 2007 |
Pancreatic cancer: new studies, new treatments. "Periodontal disease,", "gemcitabine" and "adjuvant therapy" are the new buzzwords.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Periodontal Diseases; Radiotherapy, Adjuvant; Smoking | 2007 |
[Establishment of a multi drug-resistant human lung adenocarcinoma cell line and biological characteristics there of].
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Microscopy, Electron; Vinblastine | 2007 |
Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system.
Topics: Apoptosis; Bioreactors; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Time Factors; Tumor Stem Cell Assay | 2007 |
Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules.
Topics: Antimetabolites, Antineoplastic; Calorimetry, Differential Scanning; Cell Line, Tumor; Cyanoacrylates; Deoxycytidine; Drug Compounding; Drug Delivery Systems; Gemcitabine; Humans; Nanocapsules; Nanospheres; Polymers; Prodrugs; Structure-Activity Relationship | 2007 |
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Topics: Adenocarcinoma; Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Neoplasm Proteins; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2007 |
The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2007 |
2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity.
Topics: Acetamides; Adenine; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Camptothecin; Cell Line, Tumor; Cellular Senescence; Deoxycytidine; Drug Screening Assays, Antitumor; Erythrocyte Count; Female; Gemcitabine; Humans; Imides; Irinotecan; Isoquinolines; Leukocyte Count; Maximum Tolerated Dose; Mice; Naphthalimides; Neoplasm Transplantation; Organophosphonates; Platelet Count; Structure-Activity Relationship; Topoisomerase I Inhibitors; Urea | 2007 |
Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Biomedical Research; Breast Neoplasms; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Imidazoles; Indazoles; Male; Molecular Structure; Neoplasms; Organoplatinum Compounds; Pancreatic Neoplasms; Piperidines; Prednisolone; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine.
Topics: Aerosols; Animals; Apoptosis; Blotting, Western; Bone Neoplasms; Deoxycytidine; fas Receptor; Flow Cytometry; Gemcitabine; Lung Neoplasms; Mice; Mice, Inbred BALB C; Osteosarcoma; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Up-Regulation | 2007 |
A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
Topics: Adenoviridae; Animals; Antigens, CD; Antigens, Differentiation; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Combined Modality Therapy; CTLA-4 Antigen; Cyclophosphamide; Dendritic Cells; Deoxycytidine; Docetaxel; Doxorubicin; Female; Flow Cytometry; Galactosylceramides; Gemcitabine; Genetic Vectors; Glucocorticoid-Induced TNFR-Related Protein; Humans; Immunization; Immunotherapy; Mice; Myeloid Cells; Peptide Fragments; Receptor, ErbB-2; Receptors, Nerve Growth Factor; Receptors, Tumor Necrosis Factor; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Taxoids; Transfection; Vaccines, DNA | 2007 |
The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Carcinoma; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Separation; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras) | 2007 |
Regulation of DR-5 protein and mitochondrial transmembrane potential by gemcitabine, a possible mechanism of gemcitabine-enhanced TRAIL-induced apoptosis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Deoxycytidine; DNA Fragmentation; Gastrointestinal Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Potentials; Mitochondrial Membranes; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand | 2007 |
siRNA directed against TrkA sensitizes human pancreatic cancer cells to apoptosis induced by gemcitabine through an inactivation of PI3K/Akt-dependent pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Proto-Oncogene Mas; Receptor, trkA; RNA, Small Interfering; Transfection | 2007 |
[Consideration of preventive free-flowing IV infusion method for vinorelbine].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Phlebitis; Trastuzumab; Vinblastine; Vinorelbine | 2007 |
Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Diagnosis, Differential; Docetaxel; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Infant, Newborn; Lung Neoplasms; Neoplasm Staging; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pregnancy Trimester, First; Pregnancy Trimester, Second; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Taxoids; Tomography, X-Ray Computed | 2008 |
Chemotherapy improves low performance status lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis | 2007 |
[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2007 |
Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: a novel adjunct to standard chemotherapy?
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Collagen Type I; Deoxycytidine; Drug Synergism; Everolimus; Gemcitabine; Humans; Immunosuppressive Agents; Mycophenolic Acid; Pancreatic Neoplasms; Sirolimus | 2007 |
Superiority of extended neoadjuvant chemotherapy with gemcitabine in pancreatic cancer: a comparative analysis in a clinically adapted orthotopic xenotransplantation model in SCID beige mice.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Models, Animal; Gemcitabine; Mice; Mice, SCID; Neoadjuvant Therapy; Neoplasm Transplantation; Pancreatectomy; Pancreatic Neoplasms; Transplantation, Heterologous | 2007 |
Gemcitabine and cisplatin for advanced urothelial carcinomas: the Ehime University Hospital experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hospitals, University; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Survival Analysis; Urologic Neoplasms | 2007 |
Pharmacokinetics and pharmacodynamics of paclitaxel with carboplatin or gemcitabine, and effects of CYP3A5 and MDR1 polymorphisms in patients with urogenital cancers.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Deoxycytidine; Gemcitabine; Genotype; Humans; Male; Metabolic Clearance Rate; Middle Aged; Paclitaxel; Polymorphism, Genetic; Prostate-Specific Antigen; Urogenital Neoplasms | 2007 |
Pancreatic acinar cell carcinoma with excessive alpha-fetoprotein expression.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Acinar Cell; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mitomycin; Pancreatic Neoplasms | 2007 |
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Exanthema; Gemcitabine; Glucocorticoids; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prednisolone; Quinazolines; Radiography | 2007 |
Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Tumor Suppressor Protein p53 | 2008 |
[Peak concentration of gemcitabine at fixed-dose-rate and its hematological toxicity profile].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neutropenia; Thrombocytopenia | 2007 |
Enhanced efficacy in anti-tumour activity by combined therapy of recombinant FGFR-1 related angiogenesis and low-dose cytotoxic agent.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Cancer Vaccines; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Receptor, Fibroblast Growth Factor, Type 1; Recombinant Proteins | 2007 |
[Lung cancer treatment in elderly patients].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2007 |
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Gemcitabine; Histone Deacetylase Inhibitors; Humans; L-Lactate Dehydrogenase; Niacinamide; Phenylurea Compounds; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyridines; Sorafenib | 2007 |
Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases.
Topics: Cysteine; Cytidine Diphosphate; Deoxycytidine; Enzyme Activation; Escherichia coli; Gemcitabine; Humans; Molecular Structure; Molecular Weight; Protein Binding; Protein Subunits; Ribonucleotide Reductases; Time Factors | 2007 |
Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Oncolytic Viruses; Pancreatic Neoplasms; Simplexvirus; Virus Replication | 2008 |
Cutaneous metastasis as the first clinical manifestation of pancreatic adenocarcinoma: a case treated with gemcitabine.
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Skin Neoplasms | 2007 |
Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
Topics: Animals; Apoptosis; Biliary Tract Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Enzyme Inhibitors; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Mice, Nude; Panobinostat; Xenograft Model Antitumor Assays | 2007 |
Elucidation of the relationship of BNIP3 expression to gemcitabine chemosensitivity and prognosis.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins; RNA, Messenger; Treatment Outcome | 2007 |
[Clinical characteristics and chemotherapy of advanced-stage bronchioloalveolar carcinoma of the lung: report of 53 patients].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Remission Induction; Retrospective Studies; Sex Factors; Smoking; Vinblastine; Vinorelbine | 2007 |
Locally advanced leiomyosarcoma of the urinary bladder: near-complete pathologic response to neoadjuvant gemcitabine and docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Taxoids; Urinary Bladder Neoplasms | 2007 |
Causes of thrombotic thrombocytopenic purpura.
Topics: Deoxycytidine; Endothelial Cells; Gemcitabine; Humans; Neoplasms; Purpura, Thrombotic Thrombocytopenic | 2007 |
Enhancement of gemcitabine affinity for biomembranes by conjugation with squalene: differential scanning calorimetry and Langmuir-Blodgett studies using biomembrane models.
Topics: Calorimetry, Differential Scanning; Deoxycytidine; Dimyristoylphosphatidylcholine; Gemcitabine; Hot Temperature; Lipid Bilayers; Models, Biological; Molecular Structure; Phase Transition; Squalene; Surface Properties | 2007 |
A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo.
Topics: Alkylating Agents; Animals; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Glucose; Ifosfamide; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphoramide Mustards; Xenograft Model Antitumor Assays | 2007 |
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Contraindications; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prodrugs; Prospective Studies; Radiation-Sensitizing Agents; Ribonucleotide Reductases; Survival Rate; Treatment Outcome; United States | 2008 |
Retrospective case series of gemcitabine plus cisplatin in the treatment of recurrent and metastatic nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
[Gemcitabine and pemetrexed update].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Neoplasms; Pemetrexed | 2007 |
Successful amelioration of oxaliplatin-induced hyperexcitability syndrome with the antiepileptic pregabalin in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Anticonvulsants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Calcium Gluconate; Deoxycytidine; Diphenhydramine; Female; gamma-Aminobutyric Acid; Gemcitabine; Histamine H1 Antagonists; Humans; Magnesium Sulfate; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pregabalin; Psychomotor Agitation | 2008 |
Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caveolin 1; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis | 2008 |
Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma.
Topics: Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Molecular Structure; Reproducibility of Results; Squalene; Tandem Mass Spectrometry | 2007 |
Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Chemoembolization, Therapeutic; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Contraindications; Deoxycytidine; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Hepatectomy; Hepatic Artery; Humans; Injections, Intra-Arterial; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Drug Costs; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Quality of Life | 2007 |
[A case of unresectable advanced pancreatic cancer with peritoneal dissemination responding to continuous dose S-1 monotherapy after chemo-radiation therapy].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Cavity; Peritonitis; Quality of Life; Tegafur | 2007 |
Curcumin augments gemcitabine cytotoxic effect on pancreatic adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Curcumin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms | 2007 |
Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation.
Topics: Aged; Cytidine Deaminase; Deoxycytidine; Down-Regulation; Fatal Outcome; Female; Gemcitabine; Humans; Phenotype; Polymorphism, Single Nucleotide; Reference Values | 2007 |
Structure-based design and synthesis of (5-arylamino-2H-pyrazol-3-yl)-biphenyl-2',4'-diols as novel and potent human CHK1 inhibitors.
Topics: Antineoplastic Agents; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Checkpoint Kinase 1; Crystallography, X-Ray; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Indazoles; Male; Models, Molecular; Molecular Structure; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Structure-Activity Relationship | 2007 |
Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC).
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Retrospective Studies | 2007 |
Dissociation of gemcitabine sensitivity and protein kinase B signaling in pancreatic ductal adenocarcinoma models.
Topics: Androstadienes; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Wortmannin; Xenograft Model Antitumor Assays | 2007 |
Successful management of multiple liver metastases from pancreatic neuroendocrine tumor by hepatic arterial administration of cisplatin powder.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Drug Carriers; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Iodized Oil; Liver Neoplasms; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Pancreaticoduodenectomy; Powders; Remission Induction | 2007 |
Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Fatty Acids, Omega-3; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Tumor Cells, Cultured | 2007 |
Trial of adjuvant gemcitabine for pancreatic cancer: the jury is still out.
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Pancreatic Neoplasms | 2007 |
Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Female; Gastrins; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, Cholecystokinin B; Survival Rate; Xenograft Model Antitumor Assays | 2008 |
The characteristics of Hep-2 cell with multiple drug resistance induced by Taxol.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Dyes; Fluorouracil; Gemcitabine; Humans; Laryngeal Neoplasms; Multidrug Resistance-Associated Proteins; Paclitaxel; Rhodamine 123 | 2007 |
Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Electrocoagulation; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Nephrectomy; Paclitaxel; Taxoids; Ureteroscopy | 2007 |
Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quality-Adjusted Life Years; Quinazolines; Survival Analysis; United States | 2007 |
[Lung adenocarcinoma feigning an interstitial lung disease in a 30-year-old man].
Topics: Adenocarcinoma, Papillary; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Cardiomegaly; Cisplatin; Deoxycytidine; Dyspnea; Fibrosis; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Lymphatic Metastasis; Male; Radiography | 2007 |
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Chromatography, Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Farnesol; Gemcitabine; Injections, Intraperitoneal; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; ras Proteins; Salicylates; Solvents; Survival Rate; Tandem Mass Spectrometry | 2008 |
Development and characterization of gemcitabine-resistant pancreatic tumor cells.
Topics: Antimetabolites, Antineoplastic; beta Catenin; Cadherins; Cell Adhesion; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Epithelium; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Immunoblotting; Membrane Proteins; Mesoderm; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Tumor Cells, Cultured | 2007 |
Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami/Braman Family Breast Cancer Institute.
Topics: Albumin-Bound Paclitaxel; Albumins; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genes, erbB-2; Humans; Paclitaxel; Retrospective Studies | 2007 |
Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Kidney Neoplasms; Tumor Lysis Syndrome | 2007 |
[Non-small-cell bronchial carcinoma--induction--combined with radiochemotherapy--a more certain alternative].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Survival Analysis; Treatment Outcome | 2007 |
Gemcitabine-induced hemolytic uremic syndrome in ovarian carcinoma.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged; Ovarian Neoplasms; Treatment Outcome | 2007 |
Surgery combined with intra-arterial chemotherapy for stage iv advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2007 |
Prognostic relevance of carbohydrate antigen 19-9 levels in patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Drainage; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Predictive Value of Tests; Stents; Treatment Outcome | 2007 |
Gemcitabine plus paclitaxel may be a promising chemotherapy regimen for metastatic granular cell tumour.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Granular Cell Tumor; Humans; Male; Middle Aged; Paclitaxel; Positron-Emission Tomography | 2008 |
Palliative hepatic intraarterial chemotherapy (HIC) using a novel combination of gemcitabine and mitomycin C: results in hepatic metastases.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Breast Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Mitomycin; Palliative Care; Treatment Outcome | 2008 |
A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Oxonic Acid; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tegafur | 2007 |
Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Green Fluorescent Proteins; Humans; Interleukin-4; Leukocidins; Mice; Mice, Nude; Pancreatic Neoplasms; Receptors, Interleukin-4; Recombinant Fusion Proteins; Transfection; Xenograft Model Antitumor Assays | 2007 |
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2007 |
Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results.
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; False Negative Reactions; Gemcitabine; Genotype; Humans; Neoplasms; Polymorphism, Genetic; Ribonucleotide Reductases | 2007 |
[Transarterial chemoperfusion with gemcitabine and mitomycin C in pancreatic carcinoma: results in locally recurrent tumors and advanced tumor stages].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Injections, Intra-Arterial; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Outpatients; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2007 |
Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Mice; Mice, SCID; Oncolytic Virotherapy; Ovarian Neoplasms; Virus Replication; Xenograft Model Antitumor Assays | 2008 |
Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Cross-Over Studies; Deoxycytidine; Drug Interactions; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Neoplasms; Organoplatinum Compounds; Oxaliplatin | 2008 |
Enhanced anti-tumor effect of combination therapy with gemcitabine and apigenin in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2008 |
Gemcitabine combination in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Taxoids | 2007 |
Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; RNA, Small Interfering; Transfection | 2007 |
Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Needle; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Immunohistochemistry; Molecular Chaperones; Neoplasm Proteins; Pancreatic Neoplasms; Proteomics | 2007 |
Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer.
Topics: Adenoviridae; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Mice; Models, Genetic; Pancreatic Neoplasms; Promoter Regions, Genetic; Telomerase; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic | 2008 |
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pharmacogenetics; Survival Analysis; Thymidine Phosphorylase; Treatment Outcome | 2007 |
Bilateral renal infarction in a patient with lung carcinoma treated with cisplatin and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infarction; Kidney; Lung Neoplasms; Middle Aged; Tomography, X-Ray Computed | 2007 |
Clinical potential of an antitumor drug sensitivity test and diffusion-weighted MRI in a patient with a recurrent solid pseudopapillary tumor of the pancreas.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiography | 2007 |
Synergistic effects of deuterium oxide and gemcitabine in human pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Deuterium Oxide; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Hematopoietic Stem Cells; Humans; Inhibitory Concentration 50; Neoplastic Stem Cells; Pancreatic Neoplasms; Tumor Stem Cell Assay | 2008 |
[Preparation of gemcitabine polybutylcyanoacrylate nanoparticles].
Topics: Chemistry, Pharmaceutical; Deoxycytidine; Drug Delivery Systems; Enbucrilate; Gemcitabine; Nanoparticles | 2007 |
[A long-term survivor case with good quality of life due to biliary bypass and gemcitabine for advanced pancreatic cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biliary Tract Surgical Procedures; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Survivors | 2007 |
Carbohydrate antigen 19-9-positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Agents; CA-19-9 Antigen; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Male; Middle Aged; Prostatic Neoplasms | 2007 |
Pancreatic cancer cell genetics and signaling response to treatment correlate with efficacy of gemcitabine-based molecular targeting strategies.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Chromones; Curcumin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Gemcitabine; Humans; MAP Kinase Signaling System; Morpholines; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Tumor Cells, Cultured | 2008 |
19F NMR in vivo spectroscopy reflects the effectiveness of perfusion-enhancing vascular modifiers for improving gemcitabine chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Botulinum Toxins, Type A; Carcinoma, Hepatocellular; Deoxycytidine; Drug Synergism; Fluorine Radioisotopes; Gemcitabine; Magnetic Resonance Spectroscopy; Male; Mice; Neoplasms, Experimental; Peptides, Cyclic; Thalidomide | 2008 |
CXCL14 expression and potential function in pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Chemokines, CXC; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 2; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Messenger; Time Factors; Transcription Factor RelA; Up-Regulation; Vascular Endothelial Growth Factor A | 2008 |
Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Brain; Central Nervous System; Deoxycytidine; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Medical Oncology; Neoplasms; Posterior Leukoencephalopathy Syndrome; Risk Factors; Treatment Outcome | 2007 |
Anti-mesothelin immunotoxin SS1P in combination with gemcitabine results in increased activity against mesothelin-expressing tumor xenografts.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; GPI-Linked Proteins; Humans; Membrane Glycoproteins; Mesothelin; Mice; Mice, Nude; Neoplasms; Remission Induction; Xenograft Model Antitumor Assays | 2007 |
Finding clinical meaning in cancer data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Data Interpretation, Statistical; Deoxycytidine; Diarrhea; Erlotinib Hydrochloride; Evidence-Based Medicine; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sample Size; Survival Analysis | 2007 |
Vinorelbine and gemcitabine as salvage treatment in advanced and very poor prognosis non-Hodgkin's lymphoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Prognosis; Salvage Therapy; Treatment Failure; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Inhibition of Src reduces gemcitabine-induced cytotoxicity in human pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Serum; Signal Transduction; src-Family Kinases; Transfection | 2008 |
[A case undergoing repeated anaphylactic shock after systemic administration of vinorelbine].
Topics: Adenocarcinoma; Anaphylaxis; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Food Hypersensitivity; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pistacia; Vinblastine; Vinorelbine | 2007 |
Carbon beam therapy in recurrent ovarian cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Carboplatin; Carcinoma, Endometrioid; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Irinotecan; Lymph Node Excision; Neoplasm Recurrence, Local; Omentum; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Radiotherapy, High-Energy; Remission Induction; Salvage Therapy | 2008 |
Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Rate; Uveal Neoplasms | 2008 |
Re: The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy.
Topics: Administration, Intravesical; Antineoplastic Agents; Combined Modality Therapy; Cystectomy; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2008 |
Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Methotrexate; Middle Aged; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome; Vinblastine | 2008 |
Ureterovesical malignancy following renal transplantation: a case report.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Incidence; Kidney Transplantation; Male; Peritoneal Dialysis, Continuous Ambulatory; Radiography; Time Factors; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2007 |
TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Immunoprecipitation; Mice; Mice, SCID; Pancreatic Neoplasms; Radiography | 2007 |
Questions about gemcitabine dose rate: answered or unanswered?
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Neoplasms | 2007 |
Survival and prognostic factors of unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hospitals, Teaching; Humans; Injections, Intravenous; Korea; Male; Medical Records; Middle Aged; Multivariate Analysis; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Prognosis; Radiotherapy; Retrospective Studies; Social Support; Survival Rate; Treatment Outcome | 2008 |
Sequence-dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Humans; Paclitaxel; Poly(ADP-ribose) Polymerases | 2008 |
Development of thrombotic thrombocytopenic purpura after a single dose of gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Renal Dialysis | 2008 |
[A rare primary tumor of the mediastinum: pleomorphic liposarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chest Pain; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liposarcoma; Male; Mediastinal Neoplasms | 2007 |
[Favorable outcome of gemcitabine-induced acute respiratory distress syndrome].
Topics: Adrenal Cortex Hormones; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Respiratory Distress Syndrome; Urinary Bladder Neoplasms | 2007 |
Combined systemic therapy and radiotherapy for bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Salvage Therapy; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2007 |
A multi-centre retrospective review of second-line therapy in advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Failure | 2008 |
[Anasarca, a complication of chemotherapy with gemcitabine in two patients with pancreatic cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Deoxycytidine; Edema; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Peritoneal Neoplasms; Radiotherapy, Adjuvant; Ribonucleotide Reductases | 2007 |
Inoperable pancreatic cancer: standard of care.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Platinum Compounds; Tomography, X-Ray Computed | 2007 |
Bevacizumab: optimal dose, schedule, and duration of therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2007 |
Pharmacokinetics of gemcitabine when delivered by selective pulmonary artery perfusion for the treatment of lung cancer.
Topics: Animals; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Infusions, Intra-Arterial; Lung; Lung Neoplasms; Pulmonary Artery; Swine | 2008 |
Adenoviral vector transduction of the human deoxycytidine kinase gene enhances the cytotoxic and radiosensitizing effect of gemcitabine on experimental gliomas.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Genetic Therapy; Genetic Vectors; Glioma; Male; Mice; Mice, Inbred C57BL; Radiotherapy; Rats; Rats, Wistar; Xenograft Model Antitumor Assays | 2008 |
Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Care; Retrospective Studies; Survival Rate; Treatment Outcome | 2008 |
Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests.
Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Bleomycin; Carcinoma; Cell Count; Cell Culture Techniques; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Gemcitabine; Humans; Thyroid Neoplasms; Tumor Cells, Cultured | 2008 |
[Irinotecan plus gemcitabine(IRINOGEM)in the treatment of biliary malignancies].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Survival Rate; Tomography, X-Ray Computed | 2008 |
[Short-term outcome of neoadjuvant gemcitabine-carboplatin therapy for muscle-invasive bladder cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
[A case of drug-induced interstitial pneumonitis after adjuvant chemotherapy with gemcitabine for pancreatic cancer].
Topics: Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2008 |
[A case of salvage chemotherapy with gemcitabine hydrochloride and nedaplatin for gemcitabine-refractory pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Organoplatinum Compounds; Pancreatic Neoplasms; Salvage Therapy; Treatment Failure | 2008 |
[Fatal liver failure associated with gemcitabine hydrochloride therapy].
Topics: Aged; Deoxycytidine; Gemcitabine; Humans; Liver Failure; Male; Pancreatic Neoplasms; Treatment Failure | 2008 |
Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Retrospective Studies; Taxoids | 2007 |
Anti-apoptotic and growth-stimulatory functions of CK1 delta and epsilon in ductal adenocarcinoma of the pancreas are inhibited by IC261 in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Casein Kinase 1 epsilon; Casein Kinase Idelta; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; fas Receptor; Gemcitabine; Humans; Indoles; Lymphatic Metastasis; Mice; Mice, SCID; Neoplasm Transplantation; Pancreatic Neoplasms; Phloroglucinol; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma; Cell Proliferation; Deoxycytidine; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Etoposide; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; Idarubicin; Immunohistochemistry; Male; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Up-Regulation | 2008 |
[Transhepatic arterial chemoembolization with gemcitabine and carboplatin for the treatment of stage III hepatocellular carcinoma].
Topics: Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Male; Middle Aged; Nausea; Neoplasm Staging; Quality of Life; Remission Induction; Survival Rate; Young Adult | 2007 |
A case of gemcitabine-refractory pancreatic cancer responsive to second-line chemotherapy using S-1.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Failure; Treatment Outcome | 2007 |
CXCR7 transcription in human non-small cell lung cancer and tumor-free lung tissues; possible regulation upon chemotherapy.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Lung Neoplasms; Macrophages, Alveolar; Receptors, CXCR; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic | 2008 |
[A case of gemcitabine-based chemo-radiation therapy for unresectable pancreatic cancer with liver metastases].
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed | 2007 |
[Assessment of efficacy of arterial infusion chemotherapy with gemcitabine for four cases of advanced pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Neoplasm Staging; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed | 2007 |
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Humans; Imatinib Mesylate; Mesothelioma; Mice; Mice, Nude; Mice, SCID; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Xenograft Model Antitumor Assays | 2008 |
Synergy of Irofulven in combination with various anti-metabolites, enzyme inhibitors, and miscellaneous agents in MV522 lung carcinoma cells: marked interaction with gemcitabine and 5-fluorouracil.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Enzyme Inhibitors; Female; Fluorouracil; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Random Allocation; Sesquiterpenes; Xenograft Model Antitumor Assays | 2008 |
Persistence of side population cells with high drug efflux capacity in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Cell Line, Tumor; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms | 2008 |
Complete radiographic response of primary pulmonary angiosarcomas following gemcitabine and taxotere.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Hemangiosarcoma; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Taxoids; Tomography, X-Ray Computed | 2008 |
Cancer-associated stromal fibroblasts promote pancreatic tumor progression.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Culture Media, Conditioned; Deoxycytidine; Disease Progression; Enzyme Activation; Fibroblasts; Gemcitabine; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Stromal Cells | 2008 |
Discovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogue.
Topics: Animals; Antineoplastic Agents; Cryoelectron Microscopy; Deoxycytidine; Gemcitabine; Leukemia P388; Macromolecular Substances; Mice; Mice, Inbred DBA; Models, Molecular; Nanostructures; Nanotechnology; Scattering, Small Angle; Squalene; X-Ray Diffraction | 2008 |
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis | 2008 |
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Salvage Therapy; Trastuzumab; Treatment Failure | 2008 |
Preclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicine.
Topics: Animals; Antineoplastic Agents; Cytarabine; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Leukemia; Mice; Mice, Inbred DBA; Nanomedicine; Nanostructures; Squalene; Treatment Outcome | 2008 |
Recombinant human endostatin-associated acute left heart failure.
Topics: Acute Disease; Adenocarcinoma; Aged; Antineoplastic Agents; Deoxycytidine; Dyspnea; Endostatins; Female; Gemcitabine; Heart Failure; Humans; Lung Neoplasms; Receptor, ErbB-2; Recombinant Proteins | 2008 |
Clinical efficacy of intra-arterial pharmacokinetic chemotherapy with 5-fluorouracil, CDDP, gemcitabine, and angiotensin-II in patients with advanced pancreatic cancer.
Topics: Angiotensin II; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2007 |
188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.
Topics: Animals; Bone and Bones; Bone Neoplasms; Cattle; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Durapatite; Etidronic Acid; Female; Gemcitabine; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Rhenium; Tissue Distribution | 2008 |
RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Base Sequence; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering | 2008 |
Trial methodology in soft tissue sarcomas; the 'one plus one is three or zero' phenomenon.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bias; Deoxycytidine; Disease Progression; Docetaxel; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Research Design; Sarcoma; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Staging; Palliative Care; Retrospective Studies; Sarcoma; Survival Analysis; Taxoids; Uterine Neoplasms | 2008 |
Measurement of plasma concentration of gemcitabine and its metabolite dFdU in hemodialysis patients with advanced urothelial cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Bone Neoplasms; Cystectomy; Deoxycytidine; Fatal Outcome; Floxuridine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Renal Dialysis; Renal Insufficiency; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2008 |
[Non-small cell lung neoplasms--weekly taxane combinations are possible].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Treatment Failure; Treatment Outcome | 2007 |
Tumor resensitization to erlotinib following brief substitution of cetuximab.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Bone Neoplasms; Cetuximab; Deoxycytidine; Drug Eruptions; Drug Interactions; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
The importance of schedule in whole body thermochemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hyperthermia, Induced; Mammary Neoplasms, Animal; Neoadjuvant Therapy; Rats; Rats, Sprague-Dawley | 2008 |
Comparison of two column characterisation systems based on pharmaceutical applications.
Topics: Amlodipine; Bisacodyl; Chromatography, Liquid; Deoxycytidine; Erythromycin; Fluoxetine; Gemcitabine; Pharmaceutical Preparations; Tetracaine; Tetracycline | 2008 |
Inducing apoptosis and enhancing chemosensitivity to gemcitabine via RNA interference targeting Mcl-1 gene in pancreatic carcinoma cell.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Genetic Vectors; Humans; Inverted Repeat Sequences; Mice; Mice, Nude; Molecular Sequence Data; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Specific Pathogen-Free Organisms; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2008 |
An iatrogenic hepatic subcapsular biloma successfully treated by percutaneous drainage and endoscopic biliary stenting.
Topics: Adenocarcinoma; Aged; Bile; Cholangiopancreatography, Endoscopic Retrograde; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Drainage; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Iatrogenic Disease; Magnetic Resonance Imaging; Male; Risk Assessment; Stents; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Weekly full-dose gemcitabine and single-dose cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Conformal; Survival Rate | 2008 |
A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes.
Topics: Animals; Antibodies; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Docetaxel; Female; Gemcitabine; Hepatocytes; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Receptors, TNF-Related Apoptosis-Inducing Ligand; Taxoids | 2008 |
The feasibility of using topotecan, vinorelbine, thiotepa and gemcitabine (TVTG) in adult patients with relapsed/refractory acute lymphoblastic leukaemia/lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Thiotepa; Topotecan; Vinblastine; Vinorelbine | 2008 |
Does saturable formation of gemcitabine triphosphate occur in patients?
Topics: Adipose Tissue; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Body Weight; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Creatinine; Cytidine Triphosphate; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Prodrugs; Prospective Studies; Randomized Controlled Trials as Topic | 2008 |
Polyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugs.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cells, Cultured; Chromatography, Gel; Chromatography, High Pressure Liquid; Colonic Neoplasms; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Flow Cytometry; Gemcitabine; Humans; Magnetic Resonance Spectroscopy; Molecular Structure; Peptides; Polymers; Thyroid Neoplasms; Tumor Cells, Cultured | 2008 |
Repetitive transarterial chemoembolization (TACE) of liver metastases from renal cell carcinoma: local control and survival results.
Topics: Adult; Aged; Carcinoma, Renal Cell; Chemoembolization, Therapeutic; Contrast Media; Deoxycytidine; Female; Gemcitabine; Humans; Iodized Oil; Kidney Neoplasms; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Prospective Studies; Statistics, Nonparametric; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Introduction. Gemcitabine: ten years of clinical experience.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2006 |
Gemcitabine: ten years of clinical experience. Proceedings of a workshop. September 19-21, 2005. Monastier di Treviso, Italy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2006 |
Second-line therapy in gemcitabine-pretreated patients with advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy | 2008 |
Gemcitabine resistance in pancreatic cancer: picking the key players.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGA Proteins; Humans; Pancreatic Neoplasms | 2008 |
HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Caspase 3; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; HMGA1a Protein; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Tumor Cells, Cultured | 2008 |
Adjuvant therapy for surgically resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2008 |
Localized malignant mesenteric mesothelioma causing small bowel obstruction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Endoscopy, Gastrointestinal; Epithelioid Cells; Gemcitabine; Humans; Intestinal Obstruction; Male; Mesentery; Middle Aged; Peritoneal Neoplasms; Solitary Fibrous Tumor, Pleural; Treatment Outcome | 2008 |
Is there a standard of care for the management of advanced pancreatic cancer?. Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2008 |
Effectiveness of gemcitabine as second-line chemotherapy in non-small cell lung cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome | 2008 |
Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Gene Dosage; Gene Expression Profiling; Genetic Variation; Haplotypes; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide | 2008 |
Pseudocirrhosis in a pancreatic cancer patient with liver metastases: a case report of complete resolution of pseudocirrhosis with an early recognition and management.
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Deoxycytidine; Diuretics; Drug Therapy, Combination; Female; Gemcitabine; Humans; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2008 |
[Unresectable pancreatic cancer in the Hokuriku area].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Drug Utilization; Female; Gemcitabine; Humans; Japan; Male; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Surveys and Questionnaires; Survival Rate | 2008 |
Prognostic factors and prognostic index for chemonaïve and gemcitabine-refractory patients with advanced pancreatic cancer.
Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Weight Loss | 2007 |
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cetuximab; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Gemcitabine; Gold; Humans; Immunoconjugates; Metal Nanoparticles; Pancreatic Neoplasms | 2008 |
[National study of adjuvant treatments of resected cholangiocarcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; France; Gemcitabine; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Organoplatinum Compounds; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2008 |
Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cytidine Deaminase; Deoxycytidine; Drug Carriers; Drug Stability; Female; Folic Acid; Gemcitabine; HeLa Cells; Humans; Mice; Mice, Inbred BALB C; Neoplasms; Polyethylene Glycols; Prodrugs | 2008 |
Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cells, Cultured; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Pancreatic Neoplasms | 2008 |
Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytidine Deaminase; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2008 |
[Combination of carboplatin and gemcitabine is a safe and feasible regimen in adjuvant therapy for stage II and IIIA NSCLC].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging | 2008 |
NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Nitrobenzenes; Sulfonamides; Up-Regulation | 2008 |
Cyclopentenyl cytosine increases gemcitabine radiosensitisation in human pancreatic cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Cytidine; Cytidine Triphosphate; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents | 2008 |
Inhibition of proliferation to omega-3 fatty acids in chemoresistant pancreatic cancer cells: mechanism of action may be more complex.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Fatty Acids, Omega-3; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; STAT3 Transcription Factor | 2008 |
Inhibition of c-Myc down-regulation by sustained extracellular signal-regulated kinase activation prevents the antimetabolite methotrexate- and gemcitabine-induced differentiation in non-small-cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Down-Regulation; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Lung Neoplasms; Methotrexate; Transcription Factors | 2008 |
[Elevation of CA 19.9 in urothelial bladder cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Time Factors; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2008 |
Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Drug Tolerance; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2008 |
Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Rate; Tegafur | 2008 |
[Acral necrosis in metastatic ovarian carcinoma. A single episode of Moschowitz syndrome during gemcitabine chemotherapy].
Topics: Deoxycytidine; Female; Fingers; Gemcitabine; Hand Dermatoses; Humans; Middle Aged; Necrosis; Ovarian Neoplasms; Purpura, Thrombotic Thrombocytopenic; Treatment Outcome | 2008 |
Characterization of intestinal absorption of mizoribine mediated by concentrative nucleoside transporters in rats.
Topics: Animals; Antimetabolites; Bile Acids and Salts; Biological Availability; Carrier Proteins; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gemcitabine; In Vitro Techniques; Intestinal Absorption; Male; Membrane Transport Proteins; Nucleosides; Rats; Rats, Sprague-Dawley; Ribavirin; Ribonucleosides | 2008 |
Palliative pancreatectomy with postoperative gemcitabine for patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Hospitals, University; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Survival Rate | 2008 |
Sublethal concentrations of gemcitabine (2',2'-difluorodeoxycytidine) alter mitochondrial ultrastructure and function without reducing mitochondrial DNA content in BxPC-3 human pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Polymerase gamma; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Inhibitory Concentration 50; Lactic Acid; Mitochondria; Pancreatic Neoplasms; Reverse Transcriptase Inhibitors; Zalcitabine | 2007 |
Real-time high-resolution compound imaging allows percutaneous initiation and surveillance in an orthotopic murine pancreatic cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neoplasms, Experimental; Pancreatic Neoplasms; Time Factors; Ultrasonography, Interventional | 2008 |
Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; DNA Polymerase gamma; DNA Replication; DNA-Directed DNA Polymerase; DNA, Mitochondrial; Gemcitabine; Humans; Kinetics; Mitochondrial Diseases; Neoplasms | 2008 |
Neoadjuvant chemotherapy with reduced-dose carboplatin and gemcitabine for non-small cell lung cancer in a patient with Fanconi anemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bronchial Neoplasms; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Fanconi Anemia; Gemcitabine; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Pulmonary Artery; Whole-Body Irradiation | 2008 |
Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Remission Induction; Tomography Scanners, X-Ray Computed | 2008 |
The analgesic effect of gemcitabine in mice.
Topics: Acetic Acid; Animals; Behavior, Animal; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Hot Temperature; Male; Mice; Pain Threshold; Reaction Time | 2006 |
Synthesis of gemcitabine triphosphate (dFdCTP) as a tris(triethylammonium) salt.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Deoxycytidine; Gemcitabine; Humans; Models, Chemical; Polyphosphates; Quaternary Ammonium Compounds; Salts; Tromethamine; Tumor Cells, Cultured | 2008 |
Compassionate approval process for experimental gene-based products.
Topics: Adult; Aged; Cancer Vaccines; Deoxycytidine; Drug Approval; Empathy; Female; Gemcitabine; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Humans; Li-Fraumeni Syndrome; Male; Pancreatic Neoplasms; Terminal Care; Therapies, Investigational; Time Factors; United States; United States Food and Drug Administration; Viral Vaccines | 2008 |
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cytarabine; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrazines; Idarubicin; Irinotecan; Leukemia; Lymphoma; Sulfonamides; Topotecan | 2008 |
A phase II study of oxaliplatin and gemcitabine in advanced inoperable stage IIIB/IV non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin | 2008 |
[A case of HER2-positive metastatic breast cancer responding to trastuzumab plus gemcitabine combination therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Carcinoembryonic Antigen; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radiography; Receptor, ErbB-2; Tomography Scanners, X-Ray Computed; Trastuzumab | 2008 |
LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis.
Topics: Animals; Anoikis; Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Ribonucleotide Reductases; Signal Transduction; Smad2 Protein; Survival Rate; Transforming Growth Factor beta; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
[A 42 year old patient with bilateral loss of sight and hypertension. Gemcitabine-associated thrombotic microangiopathy (TMA)].
Topics: Adrenal Cortex Neoplasms; Adult; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Biopsy; Blindness; Deoxycytidine; Diagnosis, Differential; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Hypertension, Malignant; Kidney; Male; Purpura, Thrombotic Thrombocytopenic | 2008 |
Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM).
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Indoles; Pancreatic Neoplasms; Receptors, Thrombin; Signal Transduction; Up-Regulation | 2008 |
Synergy of gemcitabine and lidamycin associated with NF-kappaB downregulation in pancreatic carcinoma cells.
Topics: Aminoglycosides; Antimetabolites, Antineoplastic; Apoptosis; Benzimidazoles; Carbocyanines; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Synergism; Enediynes; Fluorescent Dyes; Gemcitabine; Humans; Membrane Potential, Mitochondrial; NF-kappa B; Pancreatic Neoplasms; RNA, Messenger | 2008 |
Liposomal delivery improves the growth-inhibitory and apoptotic activity of low doses of gemcitabine in multiple myeloma cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Gemcitabine; Humans; Liposomes; Multiple Myeloma | 2008 |
Pulmonary gemcitabine delivery for treating lung cancer: pharmacokinetics and acute lung injury aspects in animals.
Topics: Administration, Inhalation; Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Bronchoalveolar Lavage Fluid; Deoxycytidine; Gemcitabine; Injections, Intravenous; Intubation, Gastrointestinal; Intubation, Intratracheal; Lung; Male; Proteins; Rats; Rats, Sprague-Dawley; Respiratory Distress Syndrome; Tumor Necrosis Factor-alpha | 2008 |
Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arabinonucleosides; Deoxycytidine; Diphtheria Toxin; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-2; Lymphoma, T-Cell, Peripheral; Practice Guidelines as Topic; Protease Inhibitors; Purine Nucleosides; Purine-Nucleoside Phosphorylase; Pyrimidinones; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2008 |
Protein kinase C: a target for therapy in pancreatic cancer.
Topics: Adenocarcinoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Isoenzymes; Pancreatic Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Reference Values | 2008 |
Dose enhancement effect of anticaner drugs associated with increased temperature in vitro.
Topics: Antineoplastic Agents; Carboplatin; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Gemcitabine; HeLa Cells; Humans; Hyperthermia, Induced; Ifosfamide; Organoplatinum Compounds; Oxaliplatin; Taxoids; Temperature; Vinblastine; Vinorelbine | 2008 |
Systemic gemcitabine combined with intra-arterial low-dose cisplatin and 5-fluorouracil for advanced hepatocellular carcinoma: seven cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Patient Selection; Survival Analysis; Survivors; Treatment Outcome | 2008 |
Predictive value of individualized tumor response testing by ATP-based chemotherapy response assay in ovarian cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Sensitivity and Specificity; Single-Blind Method; Treatment Outcome; Tumor Cells, Cultured | 2008 |
Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2008 |
Preparation of pH-sensitive, long-circulating and EGFR-targeted immunoliposomes.
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; Chemistry, Pharmaceutical; Deoxycytidine; Dose-Response Relationship, Drug; Drug Compounding; ErbB Receptors; Flow Cytometry; Fluoresceins; Fluorescent Dyes; Gemcitabine; Humans; Hydrogen-Ion Concentration; Lipids; Liposomes; Lung Neoplasms; Particle Size; Tumor Stem Cell Assay | 2008 |
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlati
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Hodgkin Disease; Humans; Liposomes; Male; Middle Aged; Neoplasm Recurrence, Local; Reed-Sternberg Cells; Survival Rate; Treatment Failure; Vinblastine; Vinorelbine | 2008 |
The effect of HIF-1alpha siRNA on growth and chemosensitivity of MIA-paca cell line.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Random Allocation; RNA Interference; RNA, Small Interfering; Transfection | 2008 |
Remarkable shrinkage of sarcomatoid renal cell carcinoma with single-agent gemcitabine.
Topics: Antimetabolites, Antineoplastic; Buttocks; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Muscle Neoplasms; Tomography, X-Ray Computed | 2008 |
Unilateral blindness as a presenting symptom of lung cancer treated with erlotinib.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2008 |
A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols | 2008 |
Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Autoimmunity; Colonic Neoplasms; Deoxycytidine; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Interleukin-2; Leucovorin; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin | 2008 |
Highly elevated serum CA 125 in a lady with ascites and retroperitoneal mass--a diagnostic dilemma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-125 Antigen; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Paclitaxel; Prednisone; Radiography, Abdominal; Retroperitoneal Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Vincristine | 2008 |
Squalenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in mice.
Topics: Animals; Antineoplastic Agents; Chromatography, Liquid; Deoxycytidine; Female; Gemcitabine; Magnetic Resonance Spectroscopy; Mice; Mice, Inbred DBA; Squalene; Tandem Mass Spectrometry; Tissue Distribution | 2008 |
Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Deoxycytidine; Doxorubicin; Gemcitabine; Hodgkin Disease; Immunoconjugates; Ki-1 Antigen; Mice; Mice, SCID; Neoplasm Transplantation; Oligopeptides; Tubulin Modulators; Vinblastine | 2008 |
Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: report of efficacy, quality of life and geriatric assessment.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Patient Selection; Quality of Life; Survival Analysis; Treatment Outcome; Urologic Neoplasms | 2007 |
Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2008 |
Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Osteosarcoma; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
[A long-term survival case of unresectable malignant pancreatic endocrine tumor successfully treated with systemic chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiography; Tegafur | 2008 |
[Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Neoplasm Recurrence, Local; Oxonic Acid; Tegafur | 2008 |
Single agent gemcitabine in the second-line treatment of advanced non-small cell lung cancer after treatment with taxane + platinum regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Retrospective Studies; Taxoids | 2008 |
Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Deoxycytidine; Female; Gemcitabine; Infusions, Intravenous; Kidney; Liver; Mice | 2008 |
Laser microdissection and primary cell cultures improve pharmacogenetic analysis in pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cells, Cultured; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lasers; Male; Microdissection; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; RNA, Messenger; Tetrazolium Salts; Thiazoles | 2008 |
mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Endonucleases; Gemcitabine; Gene Expression Profiling; Humans; In Vitro Techniques; Inhibitory Concentration 50; Lung Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2008 |
Short time to progression under first-line chemotherapy is a negative prognostic factor for time to progression and residual survival under second-line chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Prognosis; Survival Rate; Time Factors | 2007 |
Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Carcinoma, Squamous Cell; Cell Survival; Cetuximab; Cisplatin; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Myeloid Cell Leukemia Sequence 1 Protein; Oligonucleotides, Antisense; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2008 |
Budget impact model of adding erlotinib to a regimen of gemcitabine for the treatment of locally advanced, nonresectable or metastatic pancreatic cancer.
Topics: Aged; Budgets; Deoxycytidine; Drug Costs; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Models, Economic; Neoplasm Staging; Outcome Assessment, Health Care; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Ribonucleotide Reductases; Severity of Illness Index; Survival Rate; United States | 2008 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with advanced non-small cell lung cancer treated with front-line docetaxel-gemcitabine chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Time Factors; Treatment Outcome | 2008 |
Pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Male; Naturopathy; Pancreatic Neoplasms; Pastoral Care; Physical Therapy Modalities | 2008 |
Overcoming S-phase checkpoint-mediated resistance: sequence-dependent synergy of gemcitabine and 7-ethyl-10-hydroxycamptothecin (SN-38) in human carcinoma cell lines.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Irinotecan; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; RNA, Small Interfering; S Phase; Tumor Stem Cell Assay | 2008 |
A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Hemoglobins; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Remission Induction; Retrospective Studies; Treatment Outcome | 2008 |
Efficacy of alemtuzumab and gemcitabine in a patient with enteropathy-type T-cell lymphoma.
Topics: Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Celiac Disease; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Recurrence | 2008 |
[Chemotherapy and renal toxicity].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carboplatin; Carmustine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney; Kidney Diseases; Lomustine; Methotrexate; Organoplatinum Compounds; Oxaliplatin | 2008 |
mTOR mediates survival signals in malignant mesothelioma grown as tumor fragment spheroids.
Topics: Cell Line, Tumor; Cell Survival; Chromones; Cycloheximide; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mesothelioma; Morpholines; Phosphorylation; Protein Kinases; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; RNA, Small Interfering; Signal Transduction; Sirolimus; Spheroids, Cellular; TNF-Related Apoptosis-Inducing Ligand; TOR Serine-Threonine Kinases | 2008 |
Targeting angiogenesis in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Axitinib; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Imidazoles; Indazoles; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor | 2008 |
Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Biological Availability; Deoxycytidine; Drug Interactions; Gemcitabine; Male; Mice; Tetrahydrouridine | 2008 |
Response of a patient with pleural and peritoneal mesothelioma after second-line chemotherapy with lipoplatin and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Palliative Care; Peritoneal Neoplasms; Pleural Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Pulmonary strongyloidiasis mimicking cancer symptoms: a case of hyperinfection in a patient with metastatic lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchoalveolar Lavage Fluid; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dexamethasone; Diagnosis, Differential; Diphosphonates; Gemcitabine; Humans; Imidazoles; Immunocompromised Host; Lung Diseases, Parasitic; Lung Neoplasms; Male; Strongyloidiasis; Superinfection; Zoledronic Acid | 2008 |
The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectro
Topics: Acetylcysteine; Antineoplastic Agents; Blood Proteins; Chromatography, High Pressure Liquid; Cisplatin; Deoxycytidine; DNA; Gemcitabine; Glutathione; Humans; Mass Spectrometry; Protein Binding; Thiosulfates | 2008 |
Gemcitabine/docetaxel--welcome to a new standard.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Leiomyosarcoma; Taxoids; Uterine Neoplasms | 2008 |
Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Carcinoma, Non-Small-Cell Lung; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Retrospective Studies; Singapore; Treatment Outcome | 2009 |
Magnetoresponsive squalenoyl gemcitabine composite nanoparticles for cancer active targeting.
Topics: Antineoplastic Agents; Deoxycytidine; Electrons; Gemcitabine; Kinetics; Magnetics; Microscopy, Electron, Transmission; Molecular Structure; Nanoparticles; Spectrophotometry, Infrared; Squalene; Surface Properties; Thermodynamics; X-Ray Diffraction | 2008 |
[Outpatient chemotherapy and oncology network : Onco Pays-de-la-Loire experiment].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Home Care Services; Humans; Male; Methotrexate; Middle Aged; Neoplasms; Trastuzumab | 2008 |
Inhibition of activation of dsRNA-dependent protein kinase and tumour growth inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Proliferation; Deoxycytidine; eIF-2 Kinase; Electrophoretic Mobility Shift Assay; Enzyme Activation; Fluorouracil; Gemcitabine; Mice; Neoplasms, Experimental; NF-kappa B; Phosphorylation; Proteasome Endopeptidase Complex; Protein Biosynthesis; Protein Kinase Inhibitors; Ribonucleotide Reductases; RNA, Double-Stranded | 2009 |
Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics.
Topics: Antineoplastic Agents; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Haplotypes; Humans; Kinetics; Linkage Disequilibrium; Models, Molecular; Nucleoside-Phosphate Kinase; Pharmacogenetics | 2008 |
[Hemolytic uremic syndrome following gemcitabine treatment].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Middle Aged | 2008 |
Oxaliplatin plus gemcitabine as a salvage schedule for hormone-refractory prostate adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Tomography, X-Ray Computed | 2008 |
Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Pemetrexed; Peptide Synthases; Pleural Neoplasms; Reduced Folate Carrier Protein; RNA, Messenger; Thymidylate Synthase; Time Factors | 2008 |
Nonmetastatic pancreatic cancer: many trials, little progress.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms | 2008 |
Synthesis and antitumor activity of a heterodinucleotide of BVDU and gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Bromodeoxyuridine; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Rats; Sarcoma, Experimental | 2008 |
Improved in vitro anti-tumoral activity, intracellular uptake and apoptotic induction of gemcitabine-loaded pegylated unilamellar liposomes.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Polyethylene Glycols; Thyroid Neoplasms; Unilamellar Liposomes | 2008 |
Establishment of combined immuno-chemotherapy with systemically administered gemcitabine and intra-portal administration of interleukin-2 in murine models of liver metastases of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gemcitabine; Interleukin-2; Liver Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Portal Vein; T-Lymphocytes | 2008 |
Gemcitabine-induced retinopathy in a diabetic patient.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Diabetes Mellitus, Type 1; Fluorescein Angiography; Gemcitabine; Humans; Male; Middle Aged; Retinal Neovascularization; Urinary Bladder Neoplasms; Visual Acuity | 2009 |
Survival for patients with pancreatic cancer after addition of gemcitabine to fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Survival Analysis | 2008 |
Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Pancreatic Neoplasms; Survival Analysis | 2008 |
Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer.
Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Genetic Vectors; Humans; Injections, Intralesional; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Protein Biosynthesis; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Uridine; Xenograft Model Antitumor Assays | 2008 |
siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Pancreatic Neoplasms; Plasmids; RNA, Small Interfering; Survivin; Transfection | 2009 |
Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Ki-67 Antigen; Mice; Mice, Nude; Pancreatic Neoplasms; Panobinostat; Time Factors | 2008 |
Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples.
Topics: Antineoplastic Agents; Cytidine Deaminase; Deamination; Deoxycytidine; Gemcitabine; Genotype; Humans; Polymorphism, Genetic | 2008 |
Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cattle; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transport Proteins; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Imatinib Mesylate; Mice; Nucleoside Transport Proteins; Piperazines; Pyrimidines; RNA, Messenger; Time Factors | 2008 |
[Economic evaluation of gemcitabine-cisplatin chemotherapy for non small-cell lung cancer patient in an outpatient setting].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost Allocation; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Outpatients | 2008 |
Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells.
Topics: Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Hexanones; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Protein Synthesis Inhibitors | 2009 |
Gemcitabine based combination chemotherapy in advanced pancreatic cancer-indirect comparison.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Pancreatic Neoplasms; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2008 |
Gemcitabine pulmonary toxicity in ovarian cancer.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Papillary; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Palliative Care; Pneumonia | 2008 |
Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Paclitaxel; Prognosis; Quality of Life; Survival Rate | 2008 |
Tumor heterogeneity in ovarian cancer as demonstrated by in vitro chemoresistance assays.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prospective Studies; Taxoids; Topotecan | 2008 |
[Feasibility and anti-tumor activity of postoperative adjuvant chemotherapy with gemcitabine for resected pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2008 |
[A case of advanced pancreatic cancer responding to combination chemotherapy with the individual maximum repeatable dose of gemcitabine and oral S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[Ethnic differences of genetic polymorphisms in cancer chemotherapy].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Polymorphism, Genetic | 2008 |
[Chemotherapy with gemcitabine after non-curative resection of bile duct cancer--a case report].
Topics: Aged; Bile Duct Neoplasms; Deoxycytidine; Gemcitabine; Humans; Male; Tomography, X-Ray Computed | 2008 |
[Usefulness of S-1/gemcitabine combination therapy for advanced pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[A case of advanced pancreatic cancer successfully treated by combined chemotherapy of S-1 and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2008 |
Clinical trials probe new therapies for some difficult-to-treat cancers.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Renal Cell; Clinical Trials as Topic; Deoxycytidine; Endometrial Neoplasms; Everolimus; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Pancreatic Neoplasms; Sirolimus | 2008 |
New developments in the treatment of pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2008 |
Translational research in pancreatic cancer. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Topics: Antineoplastic Agents; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Meta-Analysis as Topic; Mucin-1; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Survival Rate | 2008 |
Is there a role for herbal medicine in the treatment of pancreatic cancer?. Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30 - June 3, 2008.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Curcumin; Deoxycytidine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Fluorouracil; Gemcitabine; Herbal Medicine; Humans; Multicenter Studies as Topic; Pancreatic Neoplasms; Plant Preparations | 2008 |
The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Base Sequence; Blotting, Western; Cell Line, Tumor; Cystine; Deoxycytidine; DNA Primers; Drug Resistance, Neoplasm; Gemcitabine; Glutathione; Humans; Immunohistochemistry; Microscopy, Fluorescence; Oxidative Stress; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases.
Topics: Animals; Apoptosis; Azacitidine; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Nucleus; Coculture Techniques; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Etoposide; Female; Fibroblasts; Gemcitabine; Humans; Mice; Mice, SCID; Pancreatic Neoplasms; STAT1 Transcription Factor; Transfection | 2008 |
Selective pulmonary artery perfusion followed by blood flow occlusion: new challenge for the treatment of pulmonary malignancies.
Topics: Animals; Antimetabolites, Antineoplastic; Catheterization; Deoxycytidine; Dose-Response Relationship, Drug; Embolization, Therapeutic; Female; Gemcitabine; Infusions, Intra-Arterial; Lung Neoplasms; Neoplasms, Experimental; Perfusion; Pulmonary Artery; Ribonucleotide Reductases; Swine; Treatment Outcome | 2009 |
The combined effect of fludarabine monophosphate and radiation as well as gemcitabine and radiation on squamous carcinoma tumor cell lines in vitro.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Radiation-Sensitizing Agents; Vidarabine Phosphate | 2008 |
Cytotoxic effects of haplamine and its major metabolites on human cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Digestive System Neoplasms; Fluorouracil; Gemcitabine; Humans; Pyrans; Quinolones; Rutaceae | 2008 |
Weekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Salvage Therapy; Taxoids | 2008 |
Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Neoplasms; Octreotide; Radiation-Sensitizing Agents; Radiopharmaceuticals; Receptors, Somatostatin; Up-Regulation | 2008 |
Low copy number and low oxidative damage of mitochondrial DNA are associated with tumor progression in lung cancer tissues after neoadjuvant chemotherapy.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Deoxyguanosine; Disease Progression; DNA Damage; DNA, Mitochondrial; Down-Regulation; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Oxidative Stress; Pneumonectomy; Retrospective Studies; Treatment Outcome | 2008 |
Efficacy of gemcitabine for locally advanced pancreatic cancer: comparison with 5-fluorouracil-based chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2008 |
FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer.
Topics: Acid Anhydride Hydrolases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53 | 2008 |
Significant antitumor activity of cationic multilamellar liposomes containing human interferon-beta gene in combination with 5-fluorouracil against human renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cations; Cisplatin; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon-beta; Irinotecan; Kidney Neoplasms; Liposomes; Mice; Mice, SCID; Paclitaxel; Thymidine Phosphorylase; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2008 |
Long-term effects of multimodal treatment for patients with resectable carcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Time Factors | 2008 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy; Xenograft Model Antitumor Assays | 2008 |
Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2008 |
[A case of recurrent gall bladder cancer responding to chemotherapy with gemcitabine after endoscopic metallic biliary stent implantation].
Topics: Aged; Deoxycytidine; Endoscopes; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Metals; Recurrence; Stents; Tomography, X-Ray Computed | 2008 |
[A case of left urothelial carcinoma with multiple bone metastasis, liver metastasis and right adrenal metastasis successfully treated with combination chemotherapy of gemcitabine and carboplatin].
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Tomography, X-Ray Computed; Urethral Neoplasms | 2008 |
Impact of adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for adenocarcinoma of the body or tail of the pancreas.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Tegafur; Treatment Outcome | 2009 |
Annexin II overexpression predicts rapid recurrence after surgery in pancreatic cancer patients undergoing gemcitabine-adjuvant chemotherapy.
Topics: Adenocarcinoma; Aged; Annexin A2; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Cell Survival; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Tumor Cells, Cultured | 2008 |
Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1.
Topics: Animals; Apoptosis; Benzodiazepinones; Cell Line; Checkpoint Kinase 1; Chromatography, Liquid; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Female; Gemcitabine; Histones; Humans; Male; Mice; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Rats; Rats, Sprague-Dawley; S Phase; Tandem Mass Spectrometry | 2008 |
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
Topics: Animals; Antineoplastic Agents; Biotransformation; Cell Line; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Phosphorylation | 2008 |
Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Gene Expression Profiling; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymerase Chain Reaction | 2008 |
The antitumor activity of an anti-CD54 antibody in SCID mice xenografted with human breast, prostate, non-small cell lung, and pancreatic tumor cell lines.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Prostatic Neoplasms; Transplantation, Heterologous | 2008 |
Nutritional and pharmacologic support in patients with pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Appetite Stimulants; Deoxycytidine; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Megestrol Acetate; Middle Aged; Nutritional Support; Pancreatic Neoplasms; Weight Loss | 2008 |
Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Lymphocytes; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2008 |
Docetaxel as second line therapy in advanced non-small cell lung cancer-the dose and combination may matter!
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Salvage Therapy; Taxoids; Treatment Outcome | 2008 |
Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Movement; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
[Three-dimensional conformal radiation therapy concurrent with full dose Gemcitabine for locally advanced inoperable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Conformal; Registries; Retrospective Studies; Survival Analysis | 2008 |
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Drug Therapy, Combination; Endothelial Cells; Female; Gemcitabine; Humans; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms; Paclitaxel; Stem Cells; Tumor Burden; Vascular Endothelial Growth Factor A | 2008 |
Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Galectin 3; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Tissue Array Analysis; Tumor Suppressor Protein p53 | 2008 |
CA 19-9 response as an early indicator of the effectiveness of gemcitabine in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome | 2008 |
Synergistic effects of acyclic retinoid and gemcitabine on growth inhibition in pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Oncogene Protein p21(ras); Pancreatic Neoplasms; Retinoids | 2009 |
Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, SCID; Pancreatic Neoplasms; Protein Transport; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Topics: Animals; Biological Assay; Cell Cycle Proteins; Cell Death; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Synergism; G2 Phase; Gemcitabine; HCT116 Cells; HT29 Cells; Humans; Male; Mice; Mutation; Protein Kinase Inhibitors; Protein Kinases; Rats; Thiophenes; Topotecan; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2008 |
Gemcitabine plus UFT combination chemotherapy as second- or third-line therapy in non-small cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Evidence-Based Medicine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Salvage Therapy; Tegafur; Uracil | 2008 |
Breathless beyond obvious.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diagnosis, Differential; Docetaxel; Dyspnea; Endometrial Neoplasms; Female; Gemcitabine; Humans; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Taxoids | 2008 |
[A case of elderly non-small cell lung cancer effectively treated by combined chemotherapy of gemcitabine and S-1].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lung Neoplasms; Oxonic Acid; Positron-Emission Tomography; Tegafur; Tomography, X-Ray Computed | 2008 |
Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Cholecystectomy, Laparoscopic; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Incidental Findings; Male; Middle Aged; Neoplasm, Residual; Neuroendocrine Tumors; Radiotherapy, Adjuvant; Retrospective Studies; Sarcoma; Survival Analysis | 2008 |
Acinar cell carcinoma--a rare tumour of the pancreas.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Laparotomy; Male; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Splenectomy; Tomography, X-Ray Computed | 2008 |
Craniocervical paraganglioma with numerous pulmonary metastases--case report.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cervical Vertebrae; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Glomus Jugulare Tumor; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Paclitaxel; Paraganglioma; Treatment Outcome | 2008 |
The growth inhibition of hepatocellular and cholangiocellular carcinoma cells by gemcitabine and the roles of extracellular signal-regulated and checkpoint kinases.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cholangiocarcinoma; Deoxycytidine; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Liver Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases | 2008 |
Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Down-Regulation; Gemcitabine; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Pancreatic Neoplasms; Radiography; Retrospective Studies; Time Factors; Treatment Outcome | 2008 |
S-phase cell-specific modification by gemcitabine of PFGE-analyzed radiation-induced DNA fragmentation and rejoining.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; DNA; DNA Fragmentation; DNA Repair; Dose-Response Relationship, Drug; Electrophoresis, Gel, Pulsed-Field; Gemcitabine; Humans; S Phase; Sensitivity and Specificity | 2008 |
Neoadjuvant gemcitabine and cisplatin: another step on the path toward improving the outcomes of patients with high-risk, invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Risk Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2008 |
Patient challenges trust's right to deprive her of NHS treatment for buying drugs privately.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Patient Acceptance of Health Care; Patient Rights; Prescription Fees; State Medicine; United Kingdom | 2008 |
Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Leukemia, Experimental; Nanomedicine; Rats; Rats, Inbred F344; Squalene | 2008 |
Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; CA-125 Antigen; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies | 2008 |
Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Pancreatic Neoplasms; Proteins; RNA Interference; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Prospective study on warfarin and regional chemotherapy in patients with pancreatic carcinoma.
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Prospective Studies; Warfarin | 2008 |
Results of surgical treatment after neoadjuvant chemotherapy for stage III non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Pneumonectomy; Retrospective Studies; Treatment Outcome; Vinblastine | 2008 |
Postoperative adjuvant treatments for biliary tract cancer.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2008 |
[An autopsy case of pancreatic cancer with poor performance status due to peritonitis carcinomatosa treated successfully with continuous infusion of low-dose 5-FU with octreotide].
Topics: Antimetabolites, Antineoplastic; Ascites; Autopsy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Octreotide; Pancreatic Neoplasms; Peritonitis | 2008 |
Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Molecular Structure; Pancreatic Neoplasms; Ribonucleotide Reductases; Stilbenes; Tumor Cells, Cultured | 2009 |
Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome | 2008 |
Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines.
Topics: Animals; Antineoplastic Agents; Arabinofuranosylcytosine Triphosphate; Breast Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Colorectal Neoplasms; Cytarabine; Deoxycytidine; Drug Carriers; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Humans; Mice; Nanogels; Nucleosides; Polyethylene Glycols; Polyethyleneimine; Polymers; Polyphosphates | 2008 |
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Xenograft Model Antitumor Assays | 2008 |
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2008 |
Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Early Growth Response Transcription Factors; Gemcitabine; Humans; Kruppel-Like Transcription Factors; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases; RNA, Messenger; RNA, Small Interfering; Stathmin; Transforming Growth Factor beta; Tumor Cells, Cultured | 2009 |
[Two cases of advanced biliary tract cancer successfully treated with gemcitabine combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Tomography, X-Ray Computed | 2008 |
Personalized medicine in advanced non-small-cell lung cancer: reality or wishful thinking?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic; Research Design | 2008 |
[Neoadjuvant intra-arterial oil chemoembolization and adjuvant selective intra-arterial chemoinfusion in the combined treatment of pancreatic cancer].
Topics: Actuarial Analysis; Adult; Aged; Antimetabolites, Antineoplastic; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Iodized Oil; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Treatment Outcome | 2008 |
Prometheus' spirit: quality survival in advanced hepatocellular carcinoma after gemcitabine and cisplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quality of Life; Remission Induction; Treatment Outcome | 2008 |
Efficacy and safety of metallic stents in patients with unresectable pancreatic cancer receiving gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Surgical Procedures; Cholangitis; Cholecystitis; Cholestasis; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Neutropenia; Palliative Care; Pancreatic Neoplasms; Prosthesis Design; Prosthesis-Related Infections; Retrospective Studies; Stents; Time Factors; Treatment Outcome | 2008 |
Quantitative analysis of vascular endothelial growth factor in liver metastases from pancreatic carcinoma as a predictor of chemotherapeutic effect and prognosis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK).
Topics: Antimetabolites, Antineoplastic; Asian People; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Haplotypes; Humans; Japan; Neoplasms; Polymorphism, Single Nucleotide | 2008 |
[Combination therapy consisting of gemcitabine, docetaxel and carboplatin as a second-line chemotherapy for patients with MVAC-treated metastatic urothelial carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Gemcitabine; Hematologic Diseases; Humans; Methotrexate; Neoplasm Metastasis; Retrospective Studies; Taxoids; Urologic Neoplasms; Vinblastine | 2008 |
Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Health Care Costs; Humans; Lung Neoplasms; Male; Population Surveillance; Retrospective Studies; Taxoids; United States | 2009 |
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Humans; Lung; Male; Oxygen Inhalation Therapy; Pancreatic Neoplasms; Pneumonia; Tomography, X-Ray Computed | 2008 |
Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Blood Coagulation; Capecitabine; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Drug Interactions; Female; Fluorouracil; Gemcitabine; Humans; International Normalized Ratio; Pancreatic Neoplasms; Prothrombin Time; Stents; Warfarin | 2008 |
Radiation recall phenomenon secondary to bevacizumab in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Bevacizumab; Deoxycytidine; Duodenitis; Female; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Pancreatic Neoplasms; Radiodermatitis; Stomach Ulcer | 2008 |
Antitumor efficacy of combination of interferon-gamma-inducible protein 10 gene with gemcitabine, a study in murine model.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Apoptosis; Chemokine CXCL10; Chlorocebus aethiops; Combined Modality Therapy; COS Cells; Deoxycytidine; Gemcitabine; Genetic Therapy; Mice; Models, Animal; Neovascularization, Pathologic; Plasmids; Transfection | 2008 |
Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Volume; Combined Modality Therapy; Contrast Media; Deoxycytidine; Extracellular Fluid; Female; Fluid Shifts; Follow-Up Studies; Gemcitabine; Humans; Iopamidol; Male; Middle Aged; Pancreatic Neoplasms; Plasma Volume; Portography; Prospective Studies; Radiotherapy Dosage; ROC Curve; Tomography, Spiral Computed; Treatment Outcome | 2009 |
Resection of gallbladder cancer with hepatic metastasis after chemotherapy with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemotherapy, Adjuvant; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Tomography, X-Ray Computed | 2008 |
Effective chemotherapy based on a chemosensitivity test for malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fatal Outcome; Female; Gemcitabine; Humans; Mesothelioma; Middle Aged; Neoplasm Staging; Palliative Care; Patient Selection; Pleural Neoplasms; Tomography, X-Ray Computed; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2008 |
In vivo chemotherapeutic profile of human gallbladder small cell carcinoma.
Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Organoplatinum Compounds; Taxoids; Xenograft Model Antitumor Assays | 2008 |
[Efficacy of whole body gamma-knife radiotherapy combined with thermochemotherapy on locally advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Radiosurgery; Remission Induction; Survival Rate; Tegafur | 2008 |
Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Pyrazines; RGS Proteins; Vascular Endothelial Growth Factor A | 2008 |
Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Taxoids; Tumor Suppressor Proteins | 2008 |
Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Cisplatin; Clinical Trials, Phase II as Topic; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Platinum; Pleural Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2009 |
Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Clusterin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasm Metastasis; Oligonucleotides, Antisense; Thionucleotides; Urinary Bladder Neoplasms | 2009 |
Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Still's Disease, Adult-Onset | 2009 |
[Remarkable effect of gemcitabine-oxaliplatin (GEMOX) therapy in a patient with advanced metastatic mucinous cystic neoplasm of the pancreas].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cystadenoma, Mucinous; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Radiography | 2008 |
Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Ribonucleotide Reductases; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dyspnea; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Statistics, Nonparametric; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Adrenal metastasis of breast cancer with involvement of the inferior vena cava.
Topics: Adrenal Gland Neoplasms; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Mastectomy, Radical; Neoplasm Invasiveness; Radiography; Radiotherapy, Adjuvant; Renal Veins; Vena Cava, Inferior; Venous Thrombosis | 2008 |
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; California; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Doxorubicin; Feasibility Studies; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Retrospective Studies; Universities; Urinary Bladder Neoplasms; Vinblastine | 2009 |
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; cdc25 Phosphatases; Cell Line, Tumor; Cyclin B; Cyclin B1; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Glycine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Predictive Value of Tests; Sulfones; Xenograft Model Antitumor Assays | 2009 |
Adjuvant chemoradiation for pancreatic cancer: few good data, much debate.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Deoxycytidine; Europe; Fluorouracil; Gemcitabine; Humans; Incidence; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate; Treatment Outcome; United States | 2008 |
CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines.
Topics: Cell Line, Tumor; Cell Membrane; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma | 2009 |
The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Necrosis; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
Personalized medicine for pancreatic cancer: a step in the right direction.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Humans; Membrane Transport Proteins; Pancreatic Neoplasms | 2009 |
The role of amifostine on late normal tissue damage induced by pelvic radiotherapy with concomitant gemcitabine: an in vivo study.
Topics: Amifostine; Animals; Colitis; Collagen; Combined Modality Therapy; Cystitis; Deoxycytidine; Fibrosis; Gemcitabine; Male; Neoplasm Staging; Pelvic Neoplasms; Radiation-Protective Agents; Radiotherapy Dosage; Rats; Rats, Wistar; Ribonucleotide Reductases; Survival Rate; Treatment Outcome | 2009 |
Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Outcome and Process Assessment, Health Care; Paclitaxel; Radiography; Retrospective Studies; Vascular Endothelial Growth Factor A | 2009 |
Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy.
Topics: Adoptive Transfer; Animals; Antigens, Differentiation, T-Lymphocyte; CD8-Positive T-Lymphocytes; Cyclophosphamide; Deoxycytidine; Gemcitabine; Immunosuppressive Agents; Inducible T-Cell Co-Stimulator Protein; Kaplan-Meier Estimate; Ki-67 Antigen; L-Selectin; Lymphocyte Depletion; Mesothelioma; Mice; Mice, Inbred BALB C; Mice, Nude; Receptors, Tumor Necrosis Factor, Type II; T-Lymphocytes, Regulatory | 2009 |
A patient with unresectable advanced pancreatic cancer achieving long-term survival with gemcitabine chemotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cell Differentiation; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Digestive System Surgical Procedures; Drug Administration Schedule; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
S-1 and gemcitabine as an outpatient-based regimen in patients with advanced or metastatic pancreatic cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur | 2009 |
Gemcitabine-induced acute coronary syndrome: a case report.
Topics: Antimetabolites, Antineoplastic; Aspirin; Bundle-Branch Block; Clopidogrel; Coronary Artery Disease; Coronary Vasospasm; Deoxycytidine; Electrocardiography; Fatal Outcome; Female; Gemcitabine; Humans; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Ticlopidine | 2009 |
[Investigation into the controlled release behavior of gemcitabine-loaded nanovesicles].
Topics: Delayed-Action Preparations; Deoxycytidine; Drug Design; Gemcitabine; Immunosuppressive Agents; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles | 2008 |
[Use of diffusion-weighted MRI in monitoring response of lymph node metastatic bladder cancer treated with chemotherary].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Gemcitabine; Humans; Lymphatic Metastasis; Male; Urinary Bladder Neoplasms | 2008 |
[Metastases from urethelial carcinoma: role of chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Urinary Bladder Neoplasms; Vinblastine | 2008 |
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase-inhibition with sunitinib.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Protein-Tyrosine Kinases; Pyrroles; Sunitinib | 2008 |
Cutaneous vasculitis associated with gemcitabine therapy.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Lung Neoplasms; Male; Skin Diseases, Vascular | 2009 |
[Salvage chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer: survival benefit in selected patients].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Salvage Therapy; Survival Analysis; Treatment Failure | 2008 |
Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Male; Mice; Pancreatic Neoplasms; RNA, Small Interfering; Transcription Factor RelA | 2008 |
CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; CA-19-9 Antigen; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Palliative Care; Pyrimidinones; Retrospective Studies; Tegafur; Treatment Outcome; Uracil | 2008 |
Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Palliative Care; Prospective Studies; Survival Rate; Tomography, Spiral Computed | 2009 |
Gemcitabine and paclitaxel chemotherapy for advanced urothelial carcinoma in patients who have received prior cisplatin-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2008 |
Advanced pancreatic cancer: the use of the apparent diffusion coefficient to predict response to chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Selective pulmonary artery perfusion for the treatment of primary lung cancer: Improved drug exposure of the lung.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Female; Gemcitabine; Lung Neoplasms; Swine | 2009 |
[Gemcitabine treatment in patients with stage IV pancreatic cancer and prognostic factors for survival of patients with stage IVb(a retrospective survey at 15 hospitals in Niigata Prefecture)].
Topics: Adult; Aged; Aged, 80 and over; Data Collection; Deoxycytidine; Female; Gemcitabine; Hospitals; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2008 |
[A long survival case of unresectable pancreatic cancer by chemoradiotherapy with gemcitabine as key drug].
Topics: Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2008 |
Genetic transfer of PNAS-4 induces apoptosis and enhances sensitivity to gemcitabine in lung cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Carbon-Nitrogen Lyases; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Gene Transfer Techniques; Humans; Lung Neoplasms; Mice; Mice, Nude; Transplantation, Heterologous | 2009 |
Fixed-dose rate infusion of gemcitabine and weekly cisplatin in elderly or poor performance status patients with unresectable non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2009 |
[A case report of intra-operative radiotherapy and gemcitabine for unresectable pancreatic body cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Middle Aged; Pancreatic Neoplasms | 2008 |
[S-1+gemcitabine (GEM) therapy was effective in a case of unresectable pancreatic head carcinoma].
Topics: Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Prohibitins; Tegafur; Tomography, X-Ray Computed | 2008 |
[Effective combination chemotherapy with gemcitabine hydrochloride, S-1 and nedaplatin for recurrent pancreatic cancer--a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Pancreatic Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed | 2008 |
Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition.
Topics: Adenocarcinoma; Animals; Antibodies; Cancer Vaccines; Carcinoma, Pancreatic Ductal; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Disease Progression; Drug Evaluation, Preclinical; Drug Therapy, Combination; Gemcitabine; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice; Mice, Transgenic; Mucin-1; Pancreatic Neoplasms; Pyrazoles; Sulfonamides; Vaccines, Subunit | 2009 |
Metastatic non-small-cell lung cancer and the use of gemcitabine during pregnancy.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Infant, Newborn; Infant, Newborn, Diseases; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic | 2009 |
Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Glucocorticoids; Hemolytic-Uremic Syndrome; Humans; Immunologic Factors; Middle Aged; Pancreatic Neoplasms; Plasmapheresis; Retrospective Studies; Rituximab; Vincristine | 2009 |
Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B.
Topics: Acrylates; Animals; Antineoplastic Agents; Cell Line; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Epothilones; Fibroblasts; Gemcitabine; Humans; Mice; Multidrug Resistance-Associated Proteins; Polymers; Pyrimidine Nucleosides | 2009 |
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Combined Modality Therapy; Cystectomy; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Methotrexate; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Risk Factors; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2009 |
Concurrent chemoradiotherapy with gemcitabine plus regional hyperthermia for locally advanced pancreatic carcinoma: initial experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Hyperthermia, Induced; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Outcome | 2008 |
Challenge of high polarity and low concentrations in analysis of cytostatics and metabolites in wastewater by hydrophilic interaction chromatography/tandem mass spectrometry.
Topics: Adsorption; Chromatography, Liquid; Cytostatic Agents; Deoxycytidine; Drug Residues; Floxuridine; Fluorouracil; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Linear Models; Models, Molecular; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Water; Water Pollutants, Chemical | 2009 |
Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
Topics: Biocatalysis; Carbazoles; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Rad51 Recombinase | 2009 |
Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68.
Topics: Animals; Cell Line, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Viral; Genetic Markers; Humans; Inflammation; Injections, Intravenous; Male; Mice; Mice, Nude; Oncolytic Virotherapy; Pancreatic Neoplasms; Vaccinia; Vaccinia virus; Viral Proteins; Virus Replication; Xenograft Model Antitumor Assays | 2009 |
Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies; Survival Analysis | 2009 |
Antimetastatic effects of liposomal gemcitabine and empty liposomes in an orthotopic mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Liposomes; Luciferases; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Peritoneal Neoplasms; Transduction, Genetic | 2009 |
The flavonoid apigenin potentiates the growth inhibitory effects of gemcitabine and abrogates gemcitabine resistance in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apigenin; Apoptosis; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; G2 Phase; Gemcitabine; Humans; Mitosis; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; S Phase | 2009 |
Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Oncolytic Viruses; Pancreatic Neoplasms; Parvovirus; Rats; Rats, Inbred Lew | 2009 |
INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Doxorubicin; Female; Gemcitabine; Humans; Hydrazones; Inhibitory Concentration 50; Mice; Pancreatic Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Pleural Effusion, Malignant; Prognosis; Proto-Oncogene Proteins c-bcl-2; Recurrence; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2009 |
[Feasibility and response of gemcitabine and carboplatin biweekly combination chemotherapy for patients with postoperative recurrence non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Time Factors | 2009 |
Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase.
Topics: Adenosine Diphosphate; Biocatalysis; Crystallography, X-Ray; Cytarabine; Deoxyadenosines; Deoxycytidine; Deoxycytidine Kinase; Deoxyguanosine; Gemcitabine; Humans; Kinetics; Mutant Proteins; Mutation; Protein Structure, Secondary; Static Electricity; Substrate Specificity; Thymidine; Thymidine Kinase | 2009 |
[Inhibitory effects of a combination of rmhTRAIL and gemcitabine on human non-small cell lung cancer cell line NCI-H460 cells in vitro and in vivo].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Tumor Burden | 2008 |
A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Biomarkers, Tumor; CD24 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Hyaluronan Receptors; Immunohistochemistry; Isoenzymes; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Retinal Dehydrogenase; Xenograft Model Antitumor Assays | 2009 |
Adjuvant gemcitabine after surgical removal of aggressive malignant mammary tumours in dogs.
Topics: Animals; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Dog Diseases; Dogs; Female; Gemcitabine; Infusions, Intravenous; Mammary Neoplasms, Animal; Neoplasm Metastasis; Prospective Studies; Quality of Life; Treatment Outcome | 2008 |
Gemicitabine resistence and mesenchymal phenotype.
Topics: Antimetabolites, Antineoplastic; Cadherins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplasms; Phenotype | 2009 |
Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography.
Topics: Animals; Antineoplastic Agents; Cytosine; Deoxycytidine; Gemcitabine; Humans; Leukemia; Mice; Positron-Emission Tomography | 2009 |
Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cause of Death; Creatinine; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Hypertension, Renal; L-Lactate Dehydrogenase; Male; Middle Aged; Thrombocytopenia | 2009 |
Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cytosine; Deoxycytidine; Dioxolanes; Dose-Response Relationship, Drug; Gemcitabine; Hemodynamics; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Proteins; Phosphoglycerate Kinase; Response Elements; Transcription, Genetic; Xenograft Model Antitumor Assays | 2009 |
Schedule-dependent synergistic interaction between gemcitabine and oxaliplatin in human gallbladder adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gallbladder Neoplasms; Gemcitabine; Humans; Inhibitory Concentration 50; Organoplatinum Compounds; Oxaliplatin; Time Factors | 2009 |
Cyclopentenyl cytosine has biological and anti-tumour activity, but does not enhance the efficacy of gemcitabine and radiation in two animal tumour models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Cytidine; Cytidine Triphosphate; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Rats; Rats, Inbred BN | 2009 |
Carcinoma of the collecting ducts of Bellini of the kidney: adjuvant chemotherapy followed by multikinase inhibition with sunitinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Middle Aged; Prospective Studies; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Recurrence; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome | 2009 |
Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hysterectomy; Lymph Nodes; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 2009 |
Synergetic anticancer effect of combined gemcitabine and photodynamic therapy on pancreatic cancer in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Pancreatic Neoplasms; Photochemotherapy | 2009 |
Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Topics: Adenocarcinoma; Adenoviridae; Adenovirus E1B Proteins; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Gene Deletion; Genetic Therapy; Genetic Vectors; Humans; Immunoblotting; Mice; Mice, Inbred C57BL; Mice, Nude; Mutation; Oncolytic Viruses; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; S Phase; Virus Replication; Xenograft Model Antitumor Assays | 2009 |
[Retrospective analysis of uracil/tegafur, cyclophosphamide and gemcitabine compared with gemcitabine monotherapy in unresectable pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
[Effective gemcitabine plus S-1 treatment in elderly non-small cell lung cancer patients with multiple bone metastases].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Positron-Emission Tomography; Tegafur | 2009 |
[A case of metastatic pancreatic cancer after combination chemotherapy with uracil-tegafur and gemcitabine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Uracil | 2009 |
Adjuvant chemoradiotherapy for high-risk pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Ovarian Neoplasms; Paclitaxel; Topotecan; Treatment Failure | 2009 |
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Pleural Neoplasms; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Remission Induction; Retrospective Studies; Thiophenes; Vinblastine; Vinorelbine | 2009 |
Epigallocatechin-gallate modulates chemotherapy-induced apoptosis in human cholangiocarcinoma cells.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Camellia sinensis; Catechin; Cell Line, Tumor; Cholangiocarcinoma; Cytochromes c; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Mitomycin; Plant Extracts | 2009 |
[Chemotherapy, chemoradiotherapy or observation after complete resection of pancreatic adenocarcinoma?].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic | 2009 |
Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method.
Topics: Acetonitriles; Bicarbonates; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Graphite; Hydrogen Peroxide; Hydrogen-Ion Concentration; Oxidation-Reduction; Porosity; Pyrimidines; Tandem Mass Spectrometry | 2009 |
MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy.
Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Linear Models; MicroRNAs; Ovarian Neoplasms; Paclitaxel; RNA, Messenger; Taxoids; Topotecan | 2009 |
Interferon-gamma down-regulates heat shock protein 27 of pancreatic cancer cells and helps in the cytotoxic effect of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Interferon-gamma; Molecular Chaperones; Pancreatic Neoplasms | 2009 |
Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy.
Topics: Acrylamides; Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Gadolinium; Gemcitabine; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Nanomedicine; Prostatic Neoplasms; Radiation Tolerance; Rats; Ribonucleotide Reductases; Tissue Distribution | 2008 |
Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Epidemiologic Methods; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Remission Induction; Salvage Therapy; Survivors; Testicular Neoplasms; Treatment Outcome | 2009 |
Re: Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dyspnea; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Radiotherapy Dosage; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Chemotherapy synergizes with radioimmunotherapy targeting La autoantigen in tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Autoantigens; Carcinoma, Lewis Lung; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Etoposide; Gemcitabine; Heterocyclic Compounds, 1-Ring; Immunohistochemistry; Mice; Mice, Inbred C57BL; Radioimmunotherapy; Ribonucleoproteins; SS-B Antigen | 2009 |
Chemotherapy-related posterior reversible leukoencephalopathy syndrome.
Topics: Anticonvulsants; Antineoplastic Agents; Brain; Carboplatin; Deoxycytidine; Diagnosis, Differential; Electroencephalography; Female; Gemcitabine; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Posterior Leukoencephalopathy Syndrome; Small Cell Lung Carcinoma; Status Epilepticus; Tomography, X-Ray Computed | 2009 |
In vivo activity of gemcitabine-loaded PEGylated small unilamellar liposomes against pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Gemcitabine; Half-Life; Humans; Liposomes; Mice; Mice, SCID; Microscopy, Confocal; Pancreatic Neoplasms; Polyethylene Glycols; Xenograft Model Antitumor Assays | 2009 |
Patient attitudes towards chemotherapy and survival: a prospective observational study in advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Attitude to Health; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Observation; Platinum; Prospective Studies | 2009 |
Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Biliary Tract Neoplasms; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Floxuridine; Gemcitabine; Humans; Infusions, Intravenous; Liver Diseases; Liver Function Tests; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Tandem Mass Spectrometry | 2009 |
Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.
Topics: Antimetabolites, Antineoplastic; Calcium-Binding Proteins; Cell Movement; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial Cells; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Jagged-1 Protein; Membrane Proteins; Mesoderm; NF-kappa B; Pancreatic Neoplasms; Phenotype; Proto-Oncogene Proteins; Receptor, Notch2; Receptor, Notch4; Receptors, Notch; RNA, Messenger; RNA, Small Interfering; Serrate-Jagged Proteins; Signal Transduction; Transfection | 2009 |
[Thrombotic microangiopathy under an effective treatment with gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Deoxycytidine; Erythrocytes; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Liver Neoplasms; Male; Palliative Care; Pancreatic Neoplasms; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Treatment Outcome | 2009 |
Drosophila melanogaster deoxyribonucleoside kinase activates gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drosophila melanogaster; Drug Resistance, Neoplasm; Gemcitabine; Humans; Phosphotransferases (Alcohol Group Acceptor); Protein Conformation; Structure-Activity Relationship; Substrate Specificity | 2009 |
Pancreatic cancer: translating lessons from mouse models.
Topics: Animals; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Gemcitabine; Genotype; Humans; Mice; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Ribonucleotide Reductases | 2009 |
Advancements in the management of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Treatment Outcome | 2009 |
Therapeutic tools in pancreatic cancer.
Topics: Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Haptoglobins; Humans; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Sensitivity and Specificity | 2009 |
Identification of a predictive biomarker for hematologic toxicities of gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Proteins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Haptoglobins; Humans; Logistic Models; Male; Mass Spectrometry; Middle Aged; Neutropenia; Pancreatic Neoplasms; Phenotype; Thrombocytopenia | 2009 |
Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Survivors | 2009 |
Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Asian People; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2009 |
Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers.
Topics: Acrylamides; Animals; Antineoplastic Agents; Apoptosis; Biocompatible Materials; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Male; Materials Testing; Molecular Structure; Neoplasm Transplantation; Neoplasms; Neovascularization, Physiologic; Polymers; Rats; Tissue Distribution | 2009 |
Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Membrane Transport Proteins; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2009 |
Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Interphase; Ligands; Mice; Mice, Inbred C57BL; Paclitaxel; Pancreatic Neoplasms; Receptors, sigma; Survival Analysis | 2009 |
The effect of adjuvant and neoadjuvant chemo(radio)therapy on survival in 1,679 resected pancreatic carcinoma cases in Japan: report of the national survey in the 34th annual meeting of Japanese Society of Pancreatic Surgery.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Health Surveys; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis | 2009 |
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
Topics: Animals; Antigens, Neoplasm; Carcinoma; Cell Growth Processes; Deoxycytidine; Drug Therapy; Female; Gemcitabine; Immune Tolerance; Immunotherapy, Adoptive; Lymphocyte Activation; Mammary Neoplasms, Animal; Mice; Mice, Inbred BALB C; T-Lymphocytes; Tumor Burden; Tumor Escape | 2009 |
Experimental study of combination therapy with S-1 against pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Doxorubicin; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Inhibitory Concentration 50; Irinotecan; Mice; Mice, Inbred BALB C; Mitomycin; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Pyridines; Tegafur; Xenograft Model Antitumor Assays | 2009 |
Long-term disease stabilization during second-line gemcitabine in a refractory metastatic haemangioendothelioma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Doxorubicin; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans; Ifosfamide; Liver Neoplasms; Lung Neoplasms; Male; Scapula; Time Factors; Treatment Outcome | 2009 |
Downregulation of neutral ceramidase by gemcitabine: Implications for cell cycle regulation.
Topics: Animals; Cell Cycle; Cell Line; Ceramides; Deoxycytidine; Down-Regulation; Endothelial Cells; Gemcitabine; Gene Knockdown Techniques; Mice; Neutral Ceramidase; Phosphorylation; Retinoblastoma Protein; RNA, Small Interfering; Sphingomyelin Phosphodiesterase | 2009 |
Quantitative phosphorus metabolomics using nanoflow liquid chromatography-tandem mass spectrometry and culture-derived comprehensive global internal standards.
Topics: Cell Line, Tumor; Chromatography, Liquid; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Metabolomics; Methotrexate; Phosphorus; Reference Standards; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2009 |
FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Doxorubicin; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoadjuvant Therapy; Positron-Emission Tomography; Prospective Studies; Sarcoma; Sensitivity and Specificity; Soft Tissue Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Binding; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Generating genome-scale candidate gene lists for pharmacogenomics.
Topics: Anticoagulants; Antineoplastic Agents; Area Under Curve; Carboplatin; Deoxycytidine; Gefitinib; Gemcitabine; Gene Expression Regulation; Genes; Genome, Human; Humans; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Quinazolines; Warfarin | 2009 |
Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug.
Topics: Blotting, Western; Cell Proliferation; Cell Survival; Ceramides; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Lysophospholipids; Pancreatic Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases; RNA, Messenger; Sphingosine; Tumor Cells, Cultured | 2009 |
Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenovirus E1A Proteins; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Large Cell; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Evaluation, Preclinical; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Ribonucleotide Reductases; S Phase; Signal Transduction; Telomerase; Tumor Cells, Cultured; Virus Replication; Xenograft Model Antitumor Assays | 2009 |
Gemcitabine plus vinorelbine as an effective salvage chemotherapeutic regimen in cisplatin-refractory germ cell tumor.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Humans; Male; Mediastinal Neoplasms; Neoplasms, Germ Cell and Embryonal; Salvage Therapy; Vinblastine; Vinorelbine; Young Adult | 2009 |
[A case of drug induced interstitial pneumonitis after gemcitabine treatment for pancreatic carcinoma].
Topics: Aged; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2009 |
Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Interferons; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2009 |
Cisplatin plus gemcitabine chemotherapy in taxane/anthracycline-resistant metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Survival Rate; Taxoids | 2009 |
Polyethylene glycosylated curcumin conjugate inhibits pancreatic cancer cell growth through inactivation of Jab1.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; COP9 Signalosome Complex; Curcumin; Deoxycytidine; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Male; Pancreatic Neoplasms; Peptide Hydrolases; Polyethylene Glycols | 2009 |
Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Prognosis; Treatment Outcome | 2009 |
Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies | 2009 |
Impact of rhenium-188, gemcitabine, and 5-fluorouracil on cholangiocellular carcinoma cells: an in vitro study.
Topics: Analysis of Variance; Antimetabolites, Antineoplastic; Cell Cycle; Cholangiocarcinoma; Deoxycytidine; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; In Vitro Techniques; Palliative Care; Radioisotopes; Rhenium; Stents; Tumor Cells, Cultured | 2009 |
Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Liposomes; Liver Neoplasms; Luciferases; Male; Mice; Mice, Nude; Prostatic Neoplasms; Splenic Neoplasms; Transplantation, Heterologous | 2009 |
Antitumor effects of polysorbate-80 coated gemcitabine polybutylcyanoacrylate nanoparticles in vitro and its pharmacodynamics in vivo on C6 glioma cells of a brain tumor model.
Topics: Analysis of Variance; Animals; Brain; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Deoxycytidine; Flow Cytometry; Gemcitabine; Glioma; Male; Nanoparticles; Neoplasm Transplantation; Polysorbates; Rats; Rats, Sprague-Dawley; Staining and Labeling; Survival Rate | 2009 |
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Vinblastine; Vinorelbine | 2009 |
Final overall results of a study with a novel triplet induction chemotherapy regimen (PACCAGE) followed by consolidation radiotherapy in locally advanced inoperable non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Feasibility Studies; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspases; Deoxycytidine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Immunoenzyme Techniques; In Situ Nick-End Labeling; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Nude; Pancreatic Neoplasms; Peptide Fragments; Phosphorylation; Proto-Oncogene Proteins c-akt; Radiation Tolerance; tat Gene Products, Human Immunodeficiency Virus; Thiolester Hydrolases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Treatment of disseminated paraganglioma with gemcitabine and docetaxel.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Paraganglioma; Taxoids | 2009 |
Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Gemcitabine; Glycogen Synthase Kinase 3; Humans; NF-kappa B; Pancreatic Neoplasms; Protein Kinase Inhibitors; Tumor Necrosis Factor-alpha | 2009 |
Identification of genomic alterations associated with the aggressiveness of pancreatic cancer using an ultra-high-resolution CGH array.
Topics: Adenocarcinoma; Cell Line, Tumor; Chromosome Mapping; Chromosomes, Human; Chromosomes, Human, X; Comparative Genomic Hybridization; Deoxycytidine; Drug Resistance; Gemcitabine; Genetic Variation; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phenotype; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Survival Rate | 2009 |
[Effects of magnetic gemcitabine stealth nano-liposomes on the characteristics of breast cancer cell line MCF-7].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Gemcitabine; Humans; Liposomes; Magnetics; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasm Transplantation; Tissue Distribution; Tumor Burden | 2009 |
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Regression Analysis; Retrospective Studies; Treatment Outcome | 2009 |
The "win-win" initiative: a global, scientifically based approach to resource sparing treatment for systemic breast cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lapatinib; Pharmacogenetics; Quinazolines; Trastuzumab | 2009 |
Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Patient Selection; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2009 |
Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cisplatin; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Drug Evaluation; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Methylprednisolone; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Salvage Therapy; Transplantation, Autologous; Young Adult | 2009 |
Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Differentiation; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Proteins; Pancreatic Neoplasms; Piperazines; Pyrazoles; Signal Transduction; Tumor Stem Cell Assay; Vorinostat | 2009 |
Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Hepatectomy; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Postoperative Care; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD8-Positive T-Lymphocytes; Cisplatin; Combined Modality Therapy; Cytotoxicity, Immunologic; Deoxycytidine; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Interferon-gamma; Interleukin-12 Subunit p40; Killer Cells, Lymphokine-Activated; Lipopolysaccharides; Liver Neoplasms; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pilot Projects; Prognosis; Survival Rate; T-Lymphocytes; Treatment Outcome | 2009 |
Potentiation of the effect of gemcitabine by emodin in pancreatic cancer is associated with survivin inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Caspase 3; Cell Division; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Primers; Drug Synergism; Emodin; Gemcitabine; Gene Expression Regulation; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Muscle, Skeletal; Pancreatic Neoplasms; Rats; Reverse Transcriptase Polymerase Chain Reaction; Suppression, Genetic; Survivin | 2009 |
XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Endonucleases; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein | 2009 |
Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lenalidomide; Pancreatic Neoplasms; Thalidomide | 2010 |
Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Taxoids | 2009 |
MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance.
Topics: Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A | 2009 |
Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Apoptosis; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Nude; Neovascularization, Pathologic; Xenograft Model Antitumor Assays | 2009 |
Effect of hyperthermia combined with gemcitabine on apoptotic cell death in cultured human pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; NF-kappa B; Pancreatic Neoplasms | 2009 |
Gallbladder carcinoma presenting as a pelvic mass with elevated serum testosterone: a case report.
Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Agents; CA-125 Antigen; Cholecystectomy; Cisplatin; Deoxycytidine; Diagnosis, Differential; Fallopian Tubes; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Hysterectomy; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Ovariectomy; Testosterone; Tomography, X-Ray Computed; Ultrasonography | 2009 |
Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Retrospective Studies; Skin Neoplasms; Vinblastine; Vinorelbine | 2009 |
Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Hedgehog Proteins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Proteins; Pancreatic Neoplasms; Piperazines; Pyrazoles; Signal Transduction; Vorinostat | 2009 |
Cap-dependent translation blockade and fixed dose-rate gemcitabine: interaction in an in vitro bioreactor system.
Topics: Antimetabolites, Antineoplastic; Bioreactors; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Eukaryotic Initiation Factor-4E; Gemcitabine; Humans; Microscopy, Electron; Protein Biosynthesis; RNA, Messenger | 2009 |
Sonochemically prepared BSA microspheres containing Gemcitabine, and their potential application in renal cancer therapeutics.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Renal Cell; Cell Line; Cell Proliferation; Deoxycytidine; Diffusion; Drug Carriers; Drug Compounding; Feasibility Studies; Gemcitabine; Microspheres; Rats; Serum Albumin, Bovine; Sonication | 2009 |
Combination of human tumor necrosis factor-alpha (hTNF-alpha) gene delivery with gemcitabine is effective in models of pancreatic cancer.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2009 |
Metastatic acinar cell carcinoma of the pancreas responding to gemcitabine, 5-fluorouracil and leucovorin therapy: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome; Vitamin B Complex | 2009 |
[Sudden blindness following combination chemotherapy with Cisplatin and Gemcitabine].
Topics: Adult; Antineoplastic Agents; Blindness; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Male | 2009 |
A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Smoking | 2009 |
Quantification of mouse pulmonary cancer models by microcomputed tomography imaging.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Gemcitabine; Genes, ras; Lentivirus; Luciferases; Luminescent Measurements; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Random Allocation; Time Factors; Tumor Suppressor Protein p53; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2009 |
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Stromal Cells; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2009 |
[Seven cases of gemcitabine-induced lung injury during treatment for pancreatic or biliary tract cancers].
Topics: Aged; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung Injury; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2009 |
Suppression of ErbB-2 in androgen-independent human prostate cancer cells enhances cytotoxic effect by gemcitabine in an androgen-reduced environment.
Topics: Androgens; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzothiazoles; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gemcitabine; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Time Factors; Tyrphostins | 2009 |
Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease Progression; Endometrial Neoplasms; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Prognosis; Prospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Structural lung damage after chemotherapy fact or fiction?
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Lung Injury; Lung Neoplasms; Male; Middle Aged; Pneumonectomy; Pneumonia; Preoperative Period | 2010 |
Acute rhabdomyolysis as a complication of paclitaxel-gemcitabine chemotherapy for ovarian cancer.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Rhabdomyolysis | 2009 |
Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Glucocorticoids; Humans; Lymphoma, Non-Hodgkin; Male; Methylprednisolone; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy | 2009 |
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.
Topics: Antigens, Surface; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; ELAV Proteins; ELAV-Like Protein 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inactivation, Metabolic; Pancreatic Neoplasms; RNA-Binding Proteins; Time Factors; Treatment Outcome; Tumor Cells, Cultured; Up-Regulation | 2009 |
Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Vinblastine; Vinorelbine | 2009 |
High frequency of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent radiotherapy and gemcitabine after induction with gemcitabine and carboplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mexico; Middle Aged; Neoplasm Staging; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate | 2009 |
Gemcitabine induced digital ischaemia and necrosis.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Fingers; Gemcitabine; Humans; Iloprost; Ischemia; Magnetic Resonance Angiography; Necrosis; Urinary Bladder Neoplasms; Vasodilator Agents | 2010 |
Characterizing DNA methylation patterns in pancreatic cancer genome.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line; Cluster Analysis; CpG Islands; Deoxycytidine; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reproducibility of Results; Transplantation, Heterologous | 2009 |
Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Gene Expression Regulation, Enzymologic; Humans; Lung Neoplasms; Paclitaxel; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2009 |
Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression Profiling; Humans; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Protein-Tyrosine Kinases; Rats; Rats, Nude; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Skin; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2009 |
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Glycoproteins; Hedgehog Proteins; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Protein Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Veratrum Alkaloids | 2009 |
Thrombotic microangiopathy associated with gemcitabine: rare but real.
Topics: Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Purpura, Thrombotic Thrombocytopenic | 2009 |
Enhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Pancreatic Neoplasms; RNA Interference; Survivin; Time Factors; X-Linked Inhibitor of Apoptosis Protein | 2009 |
[Phalanges necrosis--a rare manifestation of "hand-foot" syndrome induced by gemcitabine used in the second--line therapy for progressive ovarian cancer. A case report].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Finger Phalanges; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Necrosis; Ovarian Neoplasms; Syndrome | 2009 |
Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunoenzyme Techniques; Indoles; Mice; Mice, Nude; Protein Kinase C; Protein Kinase C beta; Proto-Oncogene Proteins c-akt; Ribonucleotide Reductases | 2009 |
Antiangiogenic versus cytotoxic therapeutic approaches in a mouse model of pancreatic cancer: an experimental study with a multitarget tyrosine kinase inhibitor (sunitinib), gemcitabine and radiotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Epidermal Growth Factor; fas Receptor; Gemcitabine; Indoles; Male; Mice; Microvessels; Neovascularization, Pathologic; Pancreatic Neoplasms; Placenta Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Pyrroles; Radiotherapy, Adjuvant; Sunitinib; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
[Case of malignant pleural mesothelioma with long-term disease control after 4 different lines of systemic chemotherapy and pleurodesis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drainage; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Pemetrexed; Pleural Neoplasms; Pleurodesis; Quality of Life; Time Factors; Vinblastine; Vinorelbine | 2009 |
Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
Topics: Aged; Alkaloids; Antimetabolites, Antineoplastic; Carbazoles; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; Dose-Response Relationship, Drug; Electric Impedance; Enzyme Inhibitors; Female; Gemcitabine; Gene Silencing; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinases; Reproducibility of Results; RNA Interference; RNA, Small Interfering; Transfection | 2009 |
Cancer. Breaching the cancer fortress.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Fibroblasts; Gemcitabine; Hedgehog Proteins; Humans; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Signal Transduction; Stromal Cells | 2009 |
Carboplatin-gemcitabine in the therapy of advanced ovarian cancer: dose reduction consideration.
Topics: Adenocarcinoma; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Epistaxis; Fatigue; Female; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Pelvic Neoplasms; Remission Induction; Splenic Neoplasms; Thrombocytopenia | 2010 |
Recurrent cutaneous toxic erythema induced by gemcitabine in a patient with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy; Cellulitis; Deoxycytidine; Diagnosis, Differential; Erythema Nodosum; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Recurrence; Vasculitis, Leukocytoclastic, Cutaneous | 2009 |
Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Suppressor Proteins; Ultrasonography | 2009 |
Sarcoidosis as a diagnostic pitfall of pancreatic cancer.
Topics: Abdominal Pain; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Carcinoma; Deoxycytidine; Diagnosis, Differential; Fatal Outcome; Female; Gallium Radioisotopes; Gemcitabine; Granuloma; Humans; Laparotomy; Lymph Nodes; Middle Aged; Neoplasm Invasiveness; Palliative Care; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Sarcoidosis; Trigeminal Neuralgia | 2009 |
Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cellular Senescence; Ceramides; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Sphingomyelins | 2009 |
3,3'-Diindolylmethane enhances chemosensitivity of multiple chemotherapeutic agents in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Cytochromes c; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Indoles; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2009 |
Malignant solitary fibrous tumor with superior vena cava syndrome.
Topics: Adult; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Lung Neoplasms; Mediastinal Neoplasms; Neoplasm Invasiveness; Pleural Neoplasms; Radiotherapy, Adjuvant; Solitary Fibrous Tumors; Sternum; Superior Vena Cava Syndrome; Tomography, X-Ray Computed; Treatment Outcome; Vascular Surgical Procedures | 2009 |
Statins inhibit Akt/PKB signaling via P2X7 receptor in pancreatic cancer cells.
Topics: Apoptosis; Atorvastatin; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrroles; Receptors, Purinergic P2; Receptors, Purinergic P2X7; RNA, Small Interfering; Signal Transduction | 2009 |
[Local recurrence after surgical resection of pancreatic cancer effectively treated with combined chemoradiotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Uracil | 2009 |
A case of advanced mucinous cystadenocarcinoma of the pancreas with peritoneal dissemination responding to gemcitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9 Antigen; Cystadenocarcinoma, Mucinous; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Peritoneum; Tomography, X-Ray Computed | 2009 |
[A case of advanced ampullary carcinoma successfully resected after primary chemotherapy with s-1 and gemcitabine].
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Duodenal Neoplasms; Gemcitabine; Humans; Jaundice, Obstructive; Male; Middle Aged; Oxonic Acid; Tegafur | 2009 |
Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreas; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2009 |
Development of a sensitive and selective LC-MS/MS method for simultaneous determination of gemcitabine and 2,2-difluoro-2-deoxyuridine in human plasma.
Topics: Antineoplastic Agents; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Neoplasms; Sensitivity and Specificity; Tandem Mass Spectrometry | 2009 |
Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
The usefulness of perfusion-weighted magnetic resonance imaging in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2009 |
Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Cytochromes c; Deoxycytidine; Dinoprostone; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Inbred ICR; Mice, SCID; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2009 |
"The best-laid plans ... often go awry ...".
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Radiation Pneumonitis; Radiation-Sensitizing Agents; Radiotherapy Dosage; Survival Rate | 2009 |
Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Follow-Up Studies; Gemcitabine; Germany; Health Care Surveys; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Quinazolines; Radiotherapy Dosage; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Infusion Pumps, Implantable; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Perfusion; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Treatment Outcome | 2009 |
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dacarbazine; Deoxycytidine; Deoxyguanosine; DNA Adducts; DNA Methylation; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Piperidines; Pyridines; Temozolomide | 2009 |
Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Gene Expression; Gene Expression Profiling; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Nude; Nucleoside-Phosphate Kinase; Pancreatic Neoplasms; Prodrugs; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA Interference; RNA, Small Interfering; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2009 |
A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
Topics: Aniline Compounds; Animals; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2009 |
A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Bayes Theorem; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Gene Expression; Genetic Variation; Humans; Models, Statistical; Pharmacogenetics | 2009 |
Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Survival Rate; Treatment Outcome | 2009 |
Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities.
Topics: Angiogenesis Inhibitors; Animals; Deoxycytidine; Drug Synergism; Gemcitabine; Losartan; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2009 |
Pharmacogenetics in pancreatic cancer. Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: alpha 1-Antichymotrypsin; alpha 1-Antitrypsin; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide | 2009 |
Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Platinum; Quinazolines; Treatment Outcome | 2009 |
Sirolimus can reverse resistance to gemcitabine, capecitabine and docetaxel combination therapy in pancreatic cancer.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatal Outcome; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Sirolimus; Treatment Outcome | 2009 |
Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Confidence Intervals; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Probability; Prognosis; Proportional Hazards Models; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Statistics, Nonparametric; Survival Analysis | 2009 |
Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer.
Topics: Antineoplastic Agents; Blotting, Western; Cadherins; Cell Line, Tumor; Cisplatin; Cluster Analysis; Deoxycytidine; Drug Resistance, Neoplasm; Epithelium; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Immunohistochemistry; Mesoderm; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcription Factors; Zinc Finger E-box-Binding Homeobox 1 | 2009 |
Concurrent chemo-radiotherapy following neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Combination chemotherapy with cisplatin and gemcitabine in malignant peritoneal mesothelioma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesothelioma; Peritoneal Neoplasms; Tomography, X-Ray Computed | 2009 |
Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Enzyme Activation; Gemcitabine; Humans; Lung Neoplasms; Mammalian orthoreovirus 3; Oncolytic Virotherapy; Paclitaxel; Poly(ADP-ribose) Polymerases; ras Proteins; Vinblastine; Virion | 2009 |
Cisplatin-Ifosfamide-gemcitabine as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and Paclitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Middle Aged; Ovarian Neoplasms; Paclitaxel; Patient Compliance; Salvage Therapy | 2009 |
Hydrophilic multi-walled carbon nanotubes decorated with magnetite nanoparticles as lymphatic targeted drug delivery vehicles.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Delivery Systems; Ferrosoferric Oxide; Gemcitabine; Lymph Nodes; Microscopy, Electron, Scanning; Molecular Structure; Nanoparticles; Nanotubes, Carbon; Rats; Rats, Sprague-Dawley; Water | 2009 |
CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Colony-Forming Units Assay; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronan Receptors; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Survival Rate; Xenograft Model Antitumor Assays | 2009 |
Cucurbitacin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Gemcitabine; Giant Cells; Humans; Janus Kinases; Mice; Molecular Structure; Pancreatic Neoplasms; Signal Transduction; STAT Transcription Factors; Time Factors; Triterpenes; Xenograft Model Antitumor Assays | 2009 |
Effects of the anti-VEGF monoclonal antibody bevacizumab in a preclinical model and in patients with refractory and multiple relapsed Hodgkin lymphoma.
Topics: Adult; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Growth Processes; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Immunotherapy; Male; Mice; Mice, SCID; Neoplasm Transplantation; Tumor Burden; Vascular Endothelial Growth Factor A | 2009 |
Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; ErbB Receptors; Gemcitabine; Humans; Hydrogen-Ion Concentration; Immunohistochemistry; In Situ Nick-End Labeling; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Particle Size; Proliferating Cell Nuclear Antigen; Random Allocation; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
[Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy].
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Remission Induction; Survival Rate | 2009 |
[A squamous cell lung cancer patient who developed immune hemolytic anemia after gemcitabine and docetaxel administration].
Topics: Aged; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Gemcitabine; Glucocorticoids; Humans; Lung Neoplasms; Male; Prednisone; Taxoids | 2009 |
[A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur | 2009 |
Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics.
Topics: 5'-Nucleotidase; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Cytarabine; Deoxycytidine; DNA; Gemcitabine; Genetic Variation; Glycoproteins; Haplotypes; Humans; Kinetics; Models, Genetic; Pharmacogenetics | 2009 |
Inhibitory effect of ginsenoside Rg3 combined with gemcitabine on angiogenesis and growth of lung cancer in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Growth Processes; Deoxycytidine; Female; Gemcitabine; Ginsenosides; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Random Allocation; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2009 |
An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; RNA-Binding Proteins; Xenograft Model Antitumor Assays | 2009 |
Gemcitabine impacts histological structure of mice testis and embryonic organs.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Embryo, Mammalian; Female; Fertility; Gemcitabine; Humans; Male; Mice; Pregnancy; Testis | 2009 |
Gemcitabine: cutaneous, hepatic and vascular disorders.
Topics: Antimetabolites, Antineoplastic; Cellulitis; Chemical and Drug Induced Liver Injury; Cytotoxins; Deoxycytidine; Drug Approval; France; Gemcitabine; Humans; Ischemia; Necrosis; Skin Diseases; Stevens-Johnson Syndrome; Vascular Diseases | 2009 |
Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Membrane Transport Proteins; Middle Aged; Nucleoside Transport Proteins; Ovarian Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2010 |
Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Topics: Anticarcinogenic Agents; Cell Dedifferentiation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial Cells; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Indoles; Isoflavones; Mesoderm; MicroRNAs; Pancreatic Neoplasms; Tumor Cells, Cultured; Up-Regulation | 2009 |
A non-randomized comparison of gemcitabine-based chemoradiation with or without induction chemotherapy for locally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Radiation-Sensitizing Agents; Treatment Outcome | 2009 |
Cytotoxic activity of gemcitabine in cultured cell lines derived from histologically different types of bladder cancer: role of thymidine kinase 2.
Topics: Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Thymidine Kinase; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2010 |
Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pilot Projects; Prognosis; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2009 |
Combination chemotherapy of nafamostat mesilate with gemcitabine for pancreatic cancer targeting NF-kappaB activation.
Topics: Animals; Antimetabolites, Antineoplastic; Benzamidines; Cell Cycle; Deoxycytidine; Drug Therapy, Combination; Electrophoretic Mobility Shift Assay; Gemcitabine; Guanidines; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Ribonucleotide Reductases; Serine Proteinase Inhibitors; Tumor Cells, Cultured | 2009 |
Placement of an expandable metallic stent improves the efficacy of chemoradiotherapy for pancreatic cancer with malignant portal vein stenosis or obstruction.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Constriction, Pathologic; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Hypertension, Portal; Liver Diseases; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Stents; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoided.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Contraindications; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pneumonectomy; Retrospective Studies; Survival Analysis | 2010 |
Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Acinar Cell; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Sex Factors; Treatment Outcome | 2009 |
The role of apoptotic cell death in the radiosensitising effect of gemcitabine.
Topics: Apoptosis; BH3 Interacting Domain Death Agonist Protein; Blotting, Western; Caspase 8; Caspase 9; Cell Line, Tumor; Deoxycytidine; Enzyme Activation; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Polymerase Chain Reaction; Radiation-Sensitizing Agents | 2009 |
Tumour growth and resistance to gemcitabine of pancreatic cancer cells are decreased by AP-2alpha overexpression.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Mice; Mice, Nude; Microscopy, Confocal; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Transcription Factor AP-2; Transfection; Xenograft Model Antitumor Assays | 2009 |
Mass flows of X-ray contrast media and cytostatics in hospital wastewater.
Topics: Contrast Media; Cytostatic Agents; Deoxycytidine; Environmental Monitoring; Floxuridine; Fluorouracil; Gemcitabine; Hospitals; Medical Waste Disposal; Waste Disposal, Fluid; Water Pollutants; Water Pollution, Chemical; Water Purification; X-Rays | 2009 |
The relationship between response to previous systemic treatment and the efficacy of subsequent pemetrexed therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Curcumin potentiates the antitumor effects of gemcitabine in an orthotopic model of human bladder cancer through suppression of proliferative and angiogenic biomarkers.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Cell Line, Tumor; Cell Proliferation; Curcumin; Deoxycytidine; DNA Primers; Drug Synergism; Gemcitabine; Humans; Models, Biological; Neovascularization, Pathologic; Urinary Bladder Neoplasms | 2010 |
Enterocolitis related to chemotherapy with gemcitabine and cisplatin in patient with transitional cell carcinoma of ureter.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Enterocolitis; Gemcitabine; Humans; Male; Tomography, X-Ray Computed; Ureteral Neoplasms | 2009 |
Gemcitabine and pemetrexed combination: the key role of the sequence of drugs administration.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Treatment Outcome | 2009 |
[A case of unresectable advanced pancreatic cancer treated by gemcitabine-based chemotherapy following cancer pain alleviation by low-dose matrix-type transdermal fentanyl].
Topics: Administration, Cutaneous; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fentanyl; Gemcitabine; Humans; Pain, Intractable; Pancreatic Neoplasms | 2009 |
Polymeric nanoparticulate system augmented the anticancer therapeutic efficacy of gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Cyanoacrylates; Deoxycytidine; Drug Carriers; Gemcitabine; Hydrogen-Ion Concentration; Injections, Intravenous; Leukemia L1210; Mice; Mice, Inbred DBA; Nanoparticles; Polymers | 2009 |
Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cisplatin; Cricetinae; Deoxycytidine; Drug Administration Schedule; Drug Delivery Systems; Gemcitabine; Humans; Immunohistochemistry; Lipopeptides; Liposomes; Lung Neoplasms; Male; Mice; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms | 2010 |
Clinical impact of radiotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy; Treatment Outcome | 2009 |
Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry.
Topics: Antimetabolites, Antineoplastic; Chromatography; Deoxycytidine; Gemcitabine; Humans; Leukocytes; Nucleosides; Nucleotides; Tandem Mass Spectrometry | 2009 |
Ceramide metabolism determines glioma cell resistance to chemotherapy.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Ceramides; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Glioma; Glucosylceramides; Glucosyltransferases; Mice; Mice, Inbred Strains; Mitochondria; Morpholines; RNA, Small Interfering; Sphingolipids; Sphingomyelin Phosphodiesterase; Tumor Stem Cell Assay | 2009 |
Medullary thyroid carcinoma with poor differentiation and atypical radiographic pattern of metastasis.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Calcitonin; Carcinoma, Medullary; Chromogranin A; Deoxycytidine; Diagnosis, Differential; Gemcitabine; Humans; Lung Neoplasms; Male; Radiography, Thoracic; Synaptophysin; Thyroid Neoplasms; Thyroidectomy | 2009 |
Gemcitabine combined with uracil-tegafur in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2009 |
Adaptive group sequential design for phase II clinical trials: a Bayesian decision theoretic approach.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bayes Theorem; Bevacizumab; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Models, Biological; Models, Statistical; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Research Design | 2009 |
OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemoembolization, Therapeutic; Cholangiocarcinoma; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Microspheres; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Treatment Outcome | 2009 |
Do recurrent and metastatic pancreatic cancer patients have the same outcomes with gemcitabine treatment?
Topics: Adult; Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2009 |
Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Line; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; G1 Phase; Gemcitabine; Humans; MicroRNAs; Oligonucleotides, Antisense; Pancreatic Neoplasms; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; Transfection | 2009 |
Preparation of albumin nanospheres loaded with gemcitabine and their cytotoxicity against BXPC-3 cells in vitro.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Nanocapsules; Nanospheres; Pancreatic Neoplasms; Serum Albumin, Bovine; Tumor Cells, Cultured | 2009 |
Metastatic pancreatic adenocarcinoma and renal cell carcinoma treated with gemcitabine and sunitinib malate. A case report.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pyrroles; Sunitinib; Treatment Outcome | 2009 |
Gemcitabine-induced hepatitis in a pancreatic cancer patient receiving adjuvant therapy following metastasectomy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Metastasis; Pancreatic Neoplasms | 2009 |
Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Drug Approval; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors; United States; United States Food and Drug Administration | 2009 |
Pancreatic cancer cells resistance to gemcitabine: the role of MUC4 mucin.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Cell Line, Tumor; Cytosol; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Mucin-4; Pancreatic Neoplasms; Receptor, ErbB-2; Signal Transduction | 2009 |
Is pneumonectomy after induction chemotherapy for non-small cell lung cancer a reasonable procedure? A multicenter retrospective study of 228 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Gemcitabine: new indication. Relapsed ovarian cancer: simply more toxic. Increases haematologic toxicity but not overall survival.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Approval; Europe; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Randomized Controlled Trials as Topic; Ribonucleotide Reductases | 2009 |
Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Unknown Primary; Pancreatic Neoplasms | 2009 |
Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin's lymphoma: a consortium for improving survival of lymphoma (CISL) trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Treatment Outcome; Young Adult | 2011 |
Lysosomal ceramide mediates gemcitabine-induced death of glioma cells.
Topics: Animals; Antimetabolites, Antineoplastic; bcl-2-Associated X Protein; Cathepsin D; Cell Death; Cell Line, Tumor; Ceramides; Deoxycytidine; Gemcitabine; Glioma; Humans; Lysosomes; Mice; Sphingomyelin Phosphodiesterase | 2009 |
Effects of taxane-based chemotherapy on inhibin B and gonadotropins as biomarkers of spermatogenesis.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Deoxycytidine; Docetaxel; Fertility; Follicle Stimulating Hormone; Gemcitabine; Humans; Infertility, Male; Inhibins; Luteinizing Hormone; Male; Middle Aged; Neoplasms; Paclitaxel; Spermatogenesis; Taxoids; Testis; Ultrasonography; Young Adult | 2010 |
Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Deoxycytidine; Female; Gemcitabine; Hemostatics; Humans; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neuroendocrine Tumors; Retrospective Studies; Treatment Outcome | 2009 |
Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer.
Topics: Absorption; Administration, Intravesical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urethra; Urinary Bladder Neoplasms | 2009 |
Gemcitabine, paclitaxel, and cisplatin as combined adjuvant approach in transitional cell carcinoma of the urothelium.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Paclitaxel; Retrospective Studies; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2009 |
A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Postoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Radiography | 2009 |
Disulfiram/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Colonic Neoplasms; Copper; Deoxycytidine; Disulfiram; Drug Resistance, Neoplasm; Drug Synergism; Electrophoretic Mobility Shift Assay; Female; Fluorouracil; Gemcitabine; Humans; NF-kappa B; Ribonucleoside Diphosphate Reductase; Thymidylate Synthase; Tumor Suppressor Proteins | 2010 |
Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Capillary Permeability; Cell Line, Tumor; Cells, Cultured; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; Liposomes; Luciferases; Male; Mice; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Transduction, Genetic; Xenograft Model Antitumor Assays | 2009 |
Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3'-deoxy-3'-fluorothymidine.
Topics: Biological Transport; Cell Line, Tumor; Deoxycytidine; Dideoxynucleosides; Fluorine Radioisotopes; Gemcitabine; Humans; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Protein Binding | 2010 |
The effects of Gemcitabine and Vinorelbine on inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) distribution of MCF-7 breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Nitric Oxide; Nitric Oxide Synthase Type II; Nitric Oxide Synthase Type III; Vinblastine; Vinorelbine | 2011 |
Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Cancer Vaccines; CD11c Antigen; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Interferon-gamma; Interleukin-4; Killer Cells, Natural; Lipopolysaccharide Receptors; Lymphocyte Activation; Male; Middle Aged; Monocytes; Pancreatic Neoplasms | 2009 |
IR spectroscopy reveals effect of non-cytotoxic doses of anti-tumour drug on cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Spectrophotometry, Infrared | 2009 |
Direct binding of glyceraldehyde 3-phosphate dehydrogenase to telomeric DNA protects telomeres against chemotherapy-induced rapid degradation.
Topics: Amino Acid Substitution; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Deoxycytidine; DNA, Single-Stranded; Doxorubicin; Electrophoretic Mobility Shift Assay; Gemcitabine; Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+); Humans; Kinetics; Mutation, Missense; Protein Binding; Telomere | 2009 |
Aerosol gemcitabine: preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs.
Topics: Aerosols; Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Dogs; Fas Ligand Protein; fas Receptor; Gemcitabine; Lung Neoplasms; Osteosarcoma | 2010 |
[The inhibition of the Sonic Hedgehog (SHh) pathway improves the effects of chemotherapy in a model of ductal carcinoma of the pancreas in mice].
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Hedgehog Proteins; Mice; Neoplasm Proteins; Pancreatic Neoplasms; Veratrum Alkaloids | 2009 |
A case of progressive hypertension preceding gemcitabine-associated thrombotic microangiopathy complicated by acute kidney injury and stroke.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Hypertension; Pancreatic Neoplasms; Stroke; Thrombotic Microangiopathies | 2009 |
Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Neoplasm Proteins; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, Notch3; Receptors, Notch; RNA Interference; RNA, Small Interfering; Signal Transduction | 2010 |
Radiological assessment following thermoradiation therapy for primary pleural synovial sarcoma: case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Deoxycytidine; Doxorubicin; Etoposide; Fatal Outcome; Gemcitabine; Humans; Hyperthermia, Induced; Ifosfamide; Neoplasm Proteins; Oncogene Proteins, Fusion; Pleural Neoplasms; Radiotherapy, Adjuvant; Sarcoma, Synovial; Tomography, X-Ray Computed; Vincristine | 2010 |
Toxicity and efficacy of 5-fluorouracil and capecitabine in a patient with TYMS gene polymorphism: A challenge or a dilemma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Foot Dermatoses; Gemcitabine; Hand Dermatoses; Humans; Liver Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Thymidylate Synthase; Treatment Outcome | 2009 |
Preclinical studies of apogossypolone, a novel pan inhibitor of bcl-2 and mcl-1, synergistically potentiates cytotoxic effect of gemcitabine in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gossypol; Humans; Membrane Proteins; Mice; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2010 |
HuR modulates gemcitabine efficacy: new perspectives in pancreatic cancer treatment.
Topics: Antigens, Surface; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; ELAV Proteins; ELAV-Like Protein 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Prodrugs; RNA-Binding Proteins; Treatment Outcome | 2009 |
The reg4 gene, amplified in the early stages of pancreatic cancer development, is a promising therapeutic target.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Dosage; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Lectins, C-Type; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Pancreatitis-Associated Proteins | 2009 |
[Gemcitabine in combination with S-1 or UFT in patients with advanced pancreatic cancer].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Uracil | 2009 |
[A case of recurrent pancreatic cancer with lung metastasis responding to S-1 combined gemcitabine chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Recurrence; Tegafur; Tomography, X-Ray Computed | 2009 |
[A case of unresectable hilar bile duct cancer responding to chemo-radiotherapy by gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biomarkers, Tumor; Combined Modality Therapy; Deoxycytidine; Duodenal Neoplasms; Fatal Outcome; Female; Gemcitabine; Humans; Lymphatic Metastasis; Neoplasm Invasiveness; Radiography | 2009 |
Downsizing to resectability of a large solid and cystic papillary tumor of the pancreas by single-agent chemotherapy.
Topics: Adolescent; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Papillary; Cystadenoma, Papillary; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Treatment Outcome | 2009 |
Successful treatment of metastatic pancreatic adenocarcinoma with combination chemotherapy regimens.
Topics: Adenocarcinoma, Mucinous; Adult; Albumins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Mycosis Fungoides; Skin Neoplasms | 2009 |
Acute aortic dissection during sorafenib-containing therapy.
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aortic Dissection; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Call for clarity in the reporting of benefit associated with anticancer therapies.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Deoxycytidine; Editorial Policies; Fluorouracil; Gemcitabine; Humans; Neoplasms; Pancreatic Neoplasms; Periodicals as Topic; Sensitivity and Specificity; Survival Analysis; Total Quality Management; Treatment Outcome | 2009 |
What does similarity mean in clinical trials?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Prognosis; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Taxoids | 2009 |
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Forecasting; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Patient Selection; Randomized Controlled Trials as Topic; Survival Analysis; Time Factors | 2009 |
Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Colonic Neoplasms; Crystallization; Crystallography, X-Ray; Cytidine; Deoxycytidine; Gemcitabine; Humans; Mice; Models, Molecular; Molecular Conformation; Prodrugs; Solubility | 2009 |
Evidence linking CD44-positive cells and gemcitabine resistance in pancreatic cancer cells: need for further substantiation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronan Receptors; Pancreatic Neoplasms | 2010 |
Patterns of radiotherapy practice for pancreatic cancer in Japan: results of the Japanese Radiation Oncology Study Group (JROSG) survey.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Surveys; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Practice Patterns, Physicians'; Radiation Oncology; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal | 2010 |
Downregulation of nuclear factor-kappaB p65 subunit by small interfering RNA synergizes with gemcitabine to inhibit the growth of pancreatic cancer.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; DNA; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Transcription Factor RelA | 2010 |
Editorial comment.
Topics: Absorption; Administration, Intravesical; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Urethra; Urinary Bladder Neoplasms | 2009 |
Chemotherapy-associated toxicity in a large cohort of elderly patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Incidence; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; SEER Program; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Small Cell Lung Carcinoma; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Weekly cetuximab and gemcitabine plus cisplatin as salvage therapy for unresectable non-small cell lung cancer.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Salvage Therapy; Treatment Outcome | 2009 |
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Pancreatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2010 |
Premedication with 20 mg dexamethasone effectively prevents relapse of extensive skin rash associated with gemcitabine monotherapy.
Topics: Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Deoxycytidine; Dexamethasone; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Premedication; Secondary Prevention | 2010 |
A case of advanced intrahepatic cholangiocarcinoma successfully treated with chemosensitivity test-guided systemic chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Combinations; Drug Therapy; Female; Gemcitabine; Humans; Oxonic Acid; Tegafur; Treatment Outcome | 2009 |
Features of gemcitabine-related severe pulmonary toxicity: patients with pancreatic or biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung; Lung Diseases; Male; Middle Aged; Pancreatic Neoplasms; Pneumonia | 2009 |
Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Cytarabine; Deoxycytidine; Ethnicity; Gemcitabine; Genetic Variation; Genome-Wide Association Study; Humans; Inhibitory Concentration 50; Linkage Disequilibrium; Neoplasms; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Polymorphism, Single Nucleotide; RNA, Messenger | 2009 |
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Survival Rate; Treatment Outcome | 2010 |
[Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis].
Topics: Deoxycytidine; Drug Eruptions; Gemcitabine; Hodgkin Disease; Humans; Ichthyosis; Ifosfamide; Male; Middle Aged; Recurrence; Vinblastine; Vinorelbine | 2009 |
Ultrasonic nanotherapy of pancreatic cancer: lessons from ultrasound imaging.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; Luminescent Proteins; Mice; Mice, Nude; Micelles; Microbubbles; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Recombinant Proteins; Red Fluorescent Protein; Transfection; Ultrasonography; Xenograft Model Antitumor Assays | 2010 |
Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.
Topics: 5'-Nucleotidase; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; DNA-Binding Proteins; Endonucleases; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Tumor Suppressor Proteins | 2010 |
Multimodal approach for treatment of peritoneal surface malignancies in a tumour-bearing rat model.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chemotherapy, Adjuvant; Colonic Neoplasms; Deoxycytidine; Disease Models, Animal; Gemcitabine; Hypothermia, Induced; Infusions, Parenteral; Male; Mitomycin; Neoplasm Transplantation; Peritoneal Neoplasms; Photochemotherapy; Rats; Taurine; Therapeutic Irrigation; Thiadiazines; Time Factors; Tumor Burden | 2010 |
Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Neoplasm Metastasis | 2010 |
Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Proliferation; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Humans; Immunoenzyme Techniques; In Vitro Techniques; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Resveratrol; Stilbenes; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Drug compendia in oncology: are they flawed?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Conflict of Interest; Deoxycytidine; Gemcitabine; Humans; Medicaid; Medical Oncology; Medicare; Pharmacopoeias as Topic; United States; Urinary Bladder Neoplasms | 2009 |
A case of unresectable gallbladder cancer responding to gemcitabine after metallic biliary stent implantation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drainage; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Metals; Radiography; Stents | 2009 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
[Two cases of inoperable advanced bileduct cancer treated effectively with a gemcitabine/cisplatin combination].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoembryonic Antigen; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Stents | 2009 |
ABC transporter gene expression in benign and malignant ovarian tissue.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Carboplatin; Cyclophosphamide; Cystadenoma; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Multidrug Resistance-Associated Protein 2; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; ROC Curve; Up-Regulation | 2010 |
A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pilot Projects; Tegafur | 2009 |
Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Biomarkers; Child; Child, Preschool; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mice | 2010 |
Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Comorbidity; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Quality of Life; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
The effect of endostatin and gemcitabine combined with HIFU on the animal xenograft model of human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Endostatins; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Microvessels; Pancreatic Neoplasms; Random Allocation; Ultrasonic Therapy; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine.
Topics: Amino Acid Sequence; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Heterocyclic Compounds, 1-Ring; Humans; Mice; Oligopeptides; Pancreatic Neoplasms; Radioimmunotherapy; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2009 |
Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Hepatectomy; Humans; Immunosuppressive Agents; Japan; Male; Oxonic Acid; Pancreaticoduodenectomy; Postoperative Care; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2009 |
Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cytokines; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitins | 2010 |
Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Aspirin; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2010 |
A case report of gemcitabine treatment for duodenal cancer: the good (a sustained response) and the bad (life threatening refractory thrombotic thrombocytopenic purpura).
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Duodenal Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Omentum; Pancreas; Peritoneal Neoplasms; Purpura, Thrombotic Thrombocytopenic | 2010 |
In situ protein expression of RRM1, ERCC1, and BRCA1 in metastatic breast cancer patients treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; BRCA1 Protein; Breast Neoplasms; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2010 |
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses.
Topics: Animals; Antigen Presentation; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Colonic Neoplasms; Culture Media, Conditioned; Cyclophosphamide; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HLA-A1 Antigen; Humans; Lymphocyte Activation; Male; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Premedication; T-Lymphocytes, Cytotoxic | 2010 |
[Analysis of factors associated with quality of life for older adult patients with non-small cell lung cancer receiving outpatient gemcitabine therapy as an alternative inpatient therapy].
Topics: Aged; Aged, 80 and over; Ambulatory Care; Antimetabolites, Antineoplastic; Data Collection; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Quality of Life; Small Cell Lung Carcinoma | 2009 |
[Clinical evaluation of calculating carboplatin doses using modification of diet in renal disease (MDRD) estimate and adverse events].
Topics: Age Factors; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Lung Neoplasms; Male; Middle Aged; Sex Factors; Thrombocytopenia | 2009 |
High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Base Sequence; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Genetic Variation; Genotype; Humans; Male; Mutation; Neoplasms; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Reproducibility of Results; Transition Temperature | 2010 |
Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Blotting, Western; Calcium-Binding Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Proteomics; Spectrometry, Mass, Electrospray Ionization; Survival Rate; Tandem Mass Spectrometry; Tumor Cells, Cultured | 2010 |
Functional analysis of LOXL2 in pancreatic carcinoma.
Topics: Amino Acid Oxidoreductases; Cell Death; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; E2F5 Transcription Factor; Epithelium; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Mesoderm; Pancreatic Neoplasms; RNA, Small Interfering; Stress, Physiological; Transfection | 2010 |
Antitumour activity of NK012, SN-38-incorporating polymeric micelles, in hypovascular orthotopic pancreatic tumour.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Deoxycytidine; Drug Delivery Systems; Enzyme Inhibitors; Female; Gemcitabine; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Pancreatic Neoplasms; Topoisomerase I Inhibitors; Xenograft Model Antitumor Assays | 2010 |
Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Blotting, Western; Cell Line, Tumor; Deoxycytidine; DNA Primers; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescent Antibody Technique; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Laminin; Pancreatic Neoplasms; Phosphorylation; RNA Interference | 2009 |
[Relationship between the level of RRM1 expression and the sensitivity to gemcitabine in the esophageal squamous cell carcinoma cell lines].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Esophageal Neoplasms; Gemcitabine; Humans; Ribonucleoside Diphosphate Reductase; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transfection; Tumor Suppressor Proteins | 2009 |
Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage iv breast cancer: case reports and review of the literature.
Topics: Angiography; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mastectomy; Middle Aged; Obesity; Paclitaxel; Skin Ulcer | 2011 |
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Treatment Outcome | 2010 |
[The possibility of local control of cancer by neoadjuvant chemoradiation therapy with gemcitabine and surgical resection for advanced cholangiocarcinoma].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy | 2009 |
[A case of postoperative multiple liver metastases of pancreatic cancer successfully treated by combination chemotherapy with weekly high-dose 5-FU hepatic arterial infusion plus systemic infusion of gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Liver Neoplasms; Male; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Period | 2009 |
[A case of long-term survival for advanced gallbladder cancer].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged | 2009 |
[The effectiveness of reduction surgery and gemcitabine for multiple bowel obstructions due to peritoneal dissemination of pancreatic carcinoma with liver metastasis--a case report].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Intestinal Obstruction; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms | 2009 |
[A long-term survival case of pancreatic cancer with hepatic metastasis after pancreaticoduodenectomy successfully treated by s-1 and gemcitabine combination chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2009 |
[A partial response to S-1 as second-line chemotherapy in a patient with unresectable pancreatic cancer].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Tegafur | 2009 |
[A case report of un-resectable pancreas body carcinoma successfully treated by chemoradiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms | 2009 |
[A case of locally advanced pancreatic cancer with superior membrane artery invasion successfully resected after gemcitabine-based chemoradiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Pancreatic Neoplasms; Radiotherapy | 2009 |
[A case report-neoadjuvant chemoradiotherapy with combination of S-1 and gemcitabine in a patient with locally advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy; Tegafur | 2009 |
Analytical strategies for characterizing chemotherapy diffusion with patient-level population-based data.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Deoxycytidine; Diffusion of Innovation; Drug Approval; Drug Utilization; Gemcitabine; Humans; Models, Statistical; Pancreatic Neoplasms; Quality of Health Care; SEER Program; United States; United States Food and Drug Administration | 2010 |
Enhanced anticancer effect of gemcitabine by genistein in osteosarcoma: the role of Akt and nuclear factor-kappaB.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Genistein; Humans; NF-kappa B; Osteosarcoma; Proto-Oncogene Proteins c-akt | 2010 |
Second and third line treatment in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Paclitaxel; Pemetrexed; Taxoids | 2009 |
EMAP II-based antiangiogenic-antiendothelial in vivo combination therapy of pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cytokines; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Immunoenzyme Techniques; Mice; Mice, Nude; Neoplasm Proteins; Neovascularization, Pathologic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; RNA-Binding Proteins; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Remission Induction; Skin Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Separation; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; ortho-Aminobenzoates; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases | 2010 |
Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Nucleoside Deaminases; Pancreatic Neoplasms; Tetrahydrouridine; Transfection; Up-Regulation | 2010 |
Biweekly gemcitabine (GEM) in combination with erlotinib (ERL): an active and convenient regimen for advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quinazolines; Survival Rate; Time Factors | 2009 |
Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene.
Topics: Alleles; Antimetabolites, Antineoplastic; Antirheumatic Agents; Asian People; Black or African American; Black People; Cytarabine; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; White People | 2009 |
High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Survival Rate; Time Factors; Treatment Outcome | 2011 |
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Drug Synergism; G2 Phase; Gemcitabine; Humans; Irinotecan; Isoquinolines; Mice; Mice, Nude; Mutagens; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Xenograft Model Antitumor Assays | 2010 |
18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Disease-Free Survival; Fluorodeoxyglucose F18; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Positron-Emission Tomography; Radiopharmaceuticals; Radiosurgery; Radiotherapy Dosage; Retrospective Studies | 2010 |
Pancreatic cancer: progress made.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Early Detection of Cancer; Endosonography; Fluorouracil; Gemcitabine; Humans; Jejunostomy; Laparoscopy; Magnetic Resonance Imaging; Neoplasm Staging; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Radiotherapy, Adjuvant; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Survival prediction for pancreatic cancer patients receiving gemcitabine treatment.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Calibration; Carcinoma, Pancreatic Ductal; Deoxycytidine; Early Detection of Cancer; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2010 |
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Death; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Dogs; Fatty Acids; Gemcitabine; Humans; Mice; Nucleoside Deaminases; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Proto-Oncogene Proteins c-akt; Pteridines; Pyrimidines; Pyrroles; Receptor, IGF Type 1 | 2010 |
Vesicular phospholipid gels.
Topics: Cytostatic Agents; Delayed-Action Preparations; Deoxycytidine; Freeze Drying; Gels; Gemcitabine; Phospholipids; Pressure | 2010 |
Combination of bilateral metal stenting and trans-stent photodynamic therapy for palliative treatment of hilar cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Cholestasis, Intrahepatic; Combined Modality Therapy; Deoxycytidine; Duodenoscopy; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Hematoporphyrins; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Photochemotherapy; Photosensitizing Agents; Stents; Treatment Outcome | 2010 |
Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?
Topics: Adult; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib | 2010 |
Development of quantitative and high-throughput assays of polyomavirus and papillomavirus DNA replication.
Topics: Antigens, Viral, Tumor; Antiviral Agents; Blotting, Southern; Blotting, Western; Cell Line, Tumor; Deoxycytidine; DNA Replication; Fluorescence Polarization; Gemcitabine; High-Throughput Screening Assays; Humans; Luciferases; Papillomaviridae; Polyomavirus; Reverse Transcriptase Polymerase Chain Reaction; Simian virus 40; Virus Replication | 2010 |
Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Humans; Mice; Mice, SCID; Microtubule-Associated Proteins; Neoplasm Proteins; Specific Pathogen-Free Organisms | 2010 |
A patient of situs ambiguus with pancreatic head cancer successfully treated with gemcitabine and erlotinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines; Situs Inversus; Treatment Outcome | 2011 |
Memoirs of differential radiation doses: Gemcitabine induced radiation recall.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carboplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Mastectomy; Radiodermatitis; Radiotherapy; Radiotherapy Dosage | 2010 |
A fine-needle aspirate-based vulnerability assay identifies polo-like kinase 1 as a mediator of gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Biopsy, Fine-Needle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Treatment Outcome | 2010 |
Silencing of RON receptor signaling promotes apoptosis and gemcitabine sensitivity in pancreatic cancers.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Immunoblotting; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
[Combination chemotherapy with gemcitabine and paclitaxel in a hemodialysis patient with metastatic urothelial carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Urinary Bladder Neoplasms | 2010 |
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Therapy; Gemcitabine; Humans; Italy; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
[Digital ischemia in two patients treated with gemcitabine].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Fingers; Gemcitabine; Humans; Ischemia; Male | 2010 |
[Effects of gemcitabine and pemetrexed on the proliferation of pancreatic cancer cell lines BXPC-3 and PANC-1 in vitro].
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Pancreatic Neoplasms; Pemetrexed | 2010 |
Gemcitabine plus vinorelbine as an effective salvage chemotherapeutic regimen in advanced Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Hodgkin Disease; Humans; Salvage Therapy; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Z-360, a novel cholecystokinin-2/gastrin receptor antagonist, inhibits gemcitabine-induced expression of the vascular endothelial growth factor gene in human pancreatic cancer cells.
Topics: Animals; Benzodiazepinones; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Receptor, Cholecystokinin B; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Rapid and complete resolution of chemotherapy-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS) with rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Blood Cell Count; Blood Platelets; Creatinine; Deoxycytidine; Gemcitabine; Hemoglobins; Hemolytic-Uremic Syndrome; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Purpura, Thrombotic Thrombocytopenic; Rituximab | 2010 |
Renal atrophy secondary to chemoradiotherapy of abdominal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Atrophy; Capecitabine; Cisplatin; Combined Modality Therapy; Creatinine; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Neoplasms; Gemcitabine; Humans; Kidney; Male; Middle Aged; Organ Size; Radiation Injuries; Radiography; Regression Analysis; Retrospective Studies; ROC Curve | 2010 |
Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival.
Topics: Aged; Algorithms; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Preoperative Care; Retrospective Studies; Survival Rate | 2010 |
[Effect of human telomerase reverse transcriptase gene antisense oligonucleotide on sensitivity of gemcitabine in pancreatic cancer cell].
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Oligonucleotides, Antisense; Pancreatic Neoplasms; RNA, Messenger; Telomerase | 2009 |
Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Cell Growth Processes; Cell Survival; Deoxycytidine; DNA, Neoplasm; Down-Regulation; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Fluorouracil; Gemcitabine; Histones; Humans; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tissue Array Analysis | 2010 |
Effects of alphavbeta6 gene silencing by RNA interference in PANC-1 pancreatic carcinoma cells.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Division; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; G2 Phase; Gemcitabine; Gene Silencing; Humans; Integrins; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Transfection | 2010 |
Management of borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Care; Radiotherapy, Adjuvant; Tomography, X-Ray Computed | 2010 |
Update on adjuvant trials for pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2010 |
Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Comet Assay; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; DNA-Activated Protein Kinase; DNA-Binding Proteins; G1 Phase; Gemcitabine; Histones; Humans; Mitosis; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; S Phase; Thiophenes; Tumor Suppressor Proteins; Urea | 2010 |
[A case of refractory pulmonary peripheral T cell lymphoma successfully treated with Cisplatin Plus Gemcitabine Plus Solumedrol].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, T-Cell, Peripheral; Male; Methylprednisolone Hemisuccinate; Middle Aged; Recurrence | 2010 |
Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antimetabolites, Antineoplastic; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Genetic Vectors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Pancreatic Neoplasms; Promoter Regions, Genetic; RNA, Messenger; Telomerase; Transfection; Virus Replication; Xenograft Model Antitumor Assays | 2010 |
Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cetuximab; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Survival Rate | 2010 |
Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Duodenum; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Movement; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed | 2010 |
Transverse leukonychia (Mees' lines) associated with docetaxel.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Nails; Nails, Malformed; Taxoids | 2010 |
Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Precision Medicine; Taxoids; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2010 |
Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles.
Topics: Antimetabolites, Antineoplastic; Biocompatible Materials; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Emulsions; Gemcitabine; Humans; Materials Testing; Nanostructures; Particle Size; Polyesters; Polyethylene Glycols; Polymers | 2010 |
Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.
Topics: Administration, Oral; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Interactions; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Bacterial deoxyribonucleoside kinases are poor suicide genes in mammalian cells.
Topics: Animals; Antimetabolites, Antineoplastic; Bacteria; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Genes, Transgenic, Suicide; Humans; Inhibitory Concentration 50; Phosphotransferases (Alcohol Group Acceptor); Transfection | 2009 |
Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR: biodistribution, pharmacokinetic features and in vivo antitumor activity.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Deoxycytidine; Floxuridine; Gemcitabine; Half-Life; Liposomes; Mice; Mice, Inbred NOD; Mice, SCID; Polyethylene Glycols; Raloxifene Hydrochloride; Tissue Distribution; Unilamellar Liposomes | 2010 |
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged | 2010 |
S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Survival Rate; Tegafur | 2010 |
Chemotherapy: Gemcitabine remains the standard of care for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2010 |
[Gemcitabine therapy for unresectable pancreatic cancer in elderly patients].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2010 |
Can CDA deficiency explain tumour lysis syndrome in a child with neuroblastoma receiving gemcitabine?
Topics: Antimetabolites, Antineoplastic; Child, Preschool; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Humans; Neuroblastoma; Tumor Lysis Syndrome | 2010 |
Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Colonic Neoplasms; Deoxycytidine; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Gemcitabine-induced pulmonary toxicity in a patient with pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Pneumonia; Radiography | 2010 |
Pulmonary toxicity associated with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Pneumonia; Severity of Illness Index | 2010 |
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Piperidines; Pyridines; Thiazoles | 2010 |
[Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Humans; Lung Neoplasms; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; PTEN Phosphohydrolase; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2010 |
Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Indoles; Mice; Mice, SCID; NF-kappa B; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2010 |
[Cerebral vasculitis associated with gemcitabine].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cerebral Cortex; Cisplatin; Cognition Disorders; Deoxycytidine; Epilepsy, Tonic-Clonic; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Urinary Bladder Neoplasms; Vasculitis, Central Nervous System | 2010 |
Improved plasma stability and sustained release profile of gemcitabine via polypeptide conjugation.
Topics: Animals; Cell Line; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Stability; Female; Gemcitabine; Humans; Polyglutamic Acid; Prodrugs | 2010 |
Retrospective analysis of the efficacy of gemcitabine for previously treated AIDS-associated Kaposi's sarcoma in western Kenya.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kenya; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Sarcoma, Kaposi; Treatment Failure; Treatment Outcome; Vinblastine | 2010 |
Unresectable locally advanced pancreatic cancer: a multimodal treatment using neoadjuvant chemoradiotherapy (gemcitabine plus stereotactic radiosurgery) and subsequent surgical exploration.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pain Measurement; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Radiosurgery; Survival Rate; Treatment Outcome | 2010 |
RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2010 |
Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cohort Studies; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome | 2010 |
Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Toxicities of gemcitabine in patients with severe hepatic dysfunction.
Topics: Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bilirubin; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Liver Diseases; Male; Neoplasms; Pancreatic Neoplasms; Platelet Count; Retrospective Studies | 2010 |
Efficacy of adjuvant gemcitabine-cisplatin chemotherapy: a comparative study between locally advanced transitional cell carcinoma of the bladder and upper urinary tract.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2010 |
Chitosan and glyceryl monooleate nanostructures containing gemcitabine: potential delivery system for pancreatic cancer treatment.
Topics: Cell Survival; Chitosan; Deoxycytidine; Emulsions; Gemcitabine; Glycerides; Humans; Inhibitory Concentration 50; Nanostructures; Pancreas; Pancreatic Neoplasms | 2010 |
Gemcitabine induces the VMP1-mediated autophagy pathway to promote apoptotic death in human pancreatic cancer cells.
Topics: Adenine; Apoptosis; Autophagy; Caspase 3; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Knockdown Techniques; Humans; Membrane Proteins; Pancreatic Neoplasms; Vacuoles | 2010 |
Gemcitabine and cisplatin in patients with carcinoma of unknown primary site.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Retrospective Studies | 2011 |
[An experimental study of gemcitabine inducing pancreatic cancer cell apoptosis potentiated by nuclear factor-kappa B P65 siRNA].
Topics: Animals; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; RNA, Small Interfering; Transcription Factor RelA; Transfection; Xenograft Model Antitumor Assays | 2010 |
MUC4 down-regulation reverses chemoresistance of pancreatic cancer stem/progenitor cells and their progenies.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mucin-4; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms | 2010 |
Conventional and complementary therapies: a tale of two research standards?
Topics: Acupuncture Therapy; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Complementary Therapies; Cyclohexanols; Deoxycytidine; Dietary Supplements; Evidence-Based Medicine; Gemcitabine; Hot Flashes; Humans; Neoplasms; Peptide Hydrolases; Risk Assessment; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride | 2010 |
Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Biomimetic Materials; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Mice, Transgenic; Mitochondrial Proteins; Pancreatic Neoplasms; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; X-Linked Inhibitor of Apoptosis Protein | 2010 |
[Current status of adjuvant chemotherapy for resected lung cancer at our institute--focus on clinical trial enrollment].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Selection; Small Cell Lung Carcinoma; Tegafur; Uracil; Vinblastine; Vinorelbine | 2010 |
[A case of metastatic pancreatic cancer with a remarkable response to combination therapy of gemcitabine and adoptive immune cell therapy].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Middle Aged; Mucin-1; Pancreatic Neoplasms; Treatment Outcome | 2010 |
Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Prospective Studies; Salvage Therapy; Survival Rate; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2010 |
Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Saliva | 2010 |
Stromal depletion goes on trial in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Hedgehog Proteins; Humans; Off-Label Use; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Survival Analysis; United States | 2010 |
Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Hexanones; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Pancreatic Neoplasms; Ribonucleotide Reductases; Xenograft Model Antitumor Assays | 2011 |
Long-term results of combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Time Factors; Treatment Outcome; Urologic Neoplasms; Urothelium | 2010 |
Interaction between DNA Polymerase lambda and anticancer nucleoside analogs.
Topics: Animals; Antineoplastic Agents; Cytarabine; Deoxycytidine; DNA; DNA Polymerase beta; DNA Repair; DNA Replication; DNA-Directed DNA Polymerase; Dose-Response Relationship, Drug; Gemcitabine; Humans; Kinetics; Mice; Models, Molecular; Nucleosides; Nucleotides | 2010 |
Impact of cytidine deaminase polymorphisms on toxicity after gemcitabine: the question is still ongoing.
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Genotype; Humans; Neoplasms; Patient Selection; Phenotype; Polymorphism, Genetic; Treatment Outcome | 2010 |
Gemcitabine and cisplatin chemotherapy induced reversible posterior leukoencephalopathy syndrome in a bladder cancer patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Posterior Leukoencephalopathy Syndrome; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2010 |
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Improved survival of left-sided pancreas cancer after surgery.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatectomy; Pancreatic Neoplasms; Survival Rate | 2010 |
Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma.
Topics: Antigens, Neoplasm; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Hodgkin Disease; Humans; Immunoenzyme Techniques; Immunotherapy; Prognosis; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured | 2010 |
In vitro anti-mesothelioma activity of cisplatin-gemcitabine combinations: evidence for sequence-dependent effects.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; DNA Breaks, Double-Stranded; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Inhibitory Concentration 50; Mesothelioma; Pleural Neoplasms | 2011 |
Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
Topics: Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Humans; Immunoprecipitation; Indoles; Ku Autoantigen; Mice; Mice, Inbred ICR; Mice, SCID; Pancreatic Neoplasms; Protein Binding; Proto-Oncogene Proteins c-mdm2; RNA Interference; Sirtuin 1; Spiro Compounds; Surface Plasmon Resonance; Time Factors; Transfection; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2010 |
Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; CD24 Antigen; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Separation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hyaluronan Receptors; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
A step forward in the treatment of advanced biliary tract cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Research Design | 2010 |
Silencing of Tousled-like kinase 1 sensitizes cholangiocarcinoma cells to cisplatin-induced apoptosis.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Cisplatin; Deoxycytidine; DNA Repair; DNA Replication; Fibroblasts; Foreskin; Gemcitabine; Gene Knockdown Techniques; Gene Silencing; Humans; In Situ Nick-End Labeling; Male; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2010 |
Tubulin binding cofactor C (TBCC) suppresses tumor growth and enhances chemosensitivity in human breast cancer cells.
Topics: Adenocarcinoma; Animals; Breast Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, SCID; Microbial Sensitivity Tests; Microtubules; Molecular Chaperones; Paclitaxel; Transfection; Tubulin; Tubulin Modulators; Vinblastine; Vinorelbine | 2010 |
Outcome of patients receiving chemotherapy for advanced biliary tract or gallbladder carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2010 |
A ribonucleotide reductase inhibitor reverses burn-induced inflammatory defects.
Topics: Animals; Burns; Concanavalin A; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Interleukin-10; Interleukin-6; Leukocyte Count; Lipopolysaccharides; Lymphocyte Activation; Macrophages; Male; Mice; Mice, Inbred C57BL; Monocytes; Myeloid Cells; Nitric Oxide; Peptidoglycan; Pseudomonas Infections; Ribonucleotide Reductases; Spleen; T-Lymphocyte Subsets; Tumor Necrosis Factor-alpha | 2010 |
[A case of a pulmonary pleomorphic carcinoma with fever which responded well to chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Docetaxel; Fever; Gemcitabine; Humans; Lung Neoplasms; Male; Taxoids | 2010 |
Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Curcumin; Deoxycytidine; Dinoprostone; DNA, Complementary; DNA, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; MicroRNAs; NF-kappa B; Oligonucleotides, Antisense; Pancreatic Neoplasms; PTEN Phosphohydrolase; Transfection; Triterpenes; Vascular Endothelial Growth Factor A | 2010 |
5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Deoxycytidine; Flow Cytometry; Fluorouracil; Gemcitabine; Immune System; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; T-Lymphocytes | 2010 |
Efficient syntheses of clofarabine and gemcitabine from 2-deoxyribonolactone.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Chemistry, Organic; Clofarabine; Deoxycytidine; Gemcitabine; Stereoisomerism; Sugar Acids | 2010 |
Establishment and characterization of multidrug-resistant gastric cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Cell Cycle; Cell Line, Tumor; Death-Associated Protein Kinases; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms | 2010 |
Gemcitabine synergistically enhances the effect of adenovirus gene therapy through activation of the CMV promoter in pancreatic cancer cells.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Cytomegalovirus; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Hepatocyte Growth Factor; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Promoter Regions, Genetic; Transgenes | 2010 |
Any progress in pancreatic cancer? Well, but progress for Acta Oncologica.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Congresses as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Journalism, Medical; Pancreatic Neoplasms; Quinazolines; Research Design; Treatment Failure | 2010 |
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chi-Square Distribution; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies | 2011 |
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Line, Tumor; Cetuximab; Colonic Neoplasms; Deoxycytidine; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Genes, ras; Humans; Irinotecan; Killer Cells, Lymphokine-Activated; Mutation; Panitumumab; Up-Regulation | 2010 |
Gemcitabine-associated large vessel vasculitis presenting as fever of unknown origin.
Topics: Antimetabolites, Antineoplastic; Aortitis; Deoxycytidine; Female; Fever of Unknown Origin; Fluorodeoxyglucose F18; Gemcitabine; Humans; Middle Aged; Positron-Emission Tomography | 2010 |
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
[Cost-effectiveness analysis of chemotherapy with GEM or S-1 for patients with non-resectable pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2010 |
[Influence of gemcitabine on expression of C-myc gene and its apoptosis-inducing effect on HL-60 cells].
Topics: Apoptosis; Cell Proliferation; Deoxycytidine; Gemcitabine; HL-60 Cells; Humans; Proto-Oncogene Proteins c-myc; RNA, Messenger | 2010 |
Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, SCID; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prostaglandins E; Structure-Activity Relationship | 2010 |
Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Imidazoles; Immunoprecipitation; Mutation; Nuclear Proteins; Piperazines; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
Potentiation of gemcitabine by Turmeric Force in pancreatic cancer cell lines.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclooxygenase 2; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunoblotting; Interleukin-8; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; STAT3 Transcription Factor | 2010 |
Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Immunoglobulins, Intravenous; Incidental Findings; Magnetic Resonance Imaging; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Staging; Receptor, IGF Type 1; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Interaction of a new anticancer prodrug, gemcitabine-squalene, with a model membrane: coupled DSC and XRD study.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; Calorimetry, Differential Scanning; Deoxycytidine; Gemcitabine; Lipid Bilayers; Membranes, Artificial; Phase Transition; Prodrugs; Scattering, Radiation; Scattering, Small Angle; Squalene; Transition Temperature; X-Ray Diffraction | 2010 |
Staurosporine increases toxicity of gemcitabine in non-small cell lung cancer cells: role of protein kinase C, deoxycytidine kinase and ribonucleotide reductase.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Protein Kinase C; Ribonucleotide Reductases; Staurosporine | 2010 |
First case report associating gemcitabine with hypersensitivity reaction in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms | 2010 |
Options for the treatment of gemcitabine-resistant advanced pancreatic cancer: are we there yet?
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2010 |
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Area Under Curve; Biocatalysis; Biological Availability; Blood; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Injections, Intravenous; Male; Mice; Mice, Inbred Strains; Models, Biological; Prodrugs; Recombinant Proteins; Specific Pathogen-Free Organisms; Tetrahydrouridine; Urine | 2011 |
[Oncological treatment of patients with pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Survival Rate | 2010 |
Bladder cancer: can we move beyond chemotherapy?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Genetic Therapy; Humans; Immunotherapy; Urinary Bladder Neoplasms | 2010 |
Chemotherapy-induced reversible posterior leucoencephalopathy syndrome.
Topics: Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Posterior Leukoencephalopathy Syndrome | 2010 |
The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Insulin; Metformin; Neoplasms; Pancreatic Neoplasms; Rosiglitazone; Thiazolidinediones | 2011 |
Resveratrol enhances the sensitivity of cholangiocarcinoma to chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cholangiocarcinoma; Cytochrome P-450 Enzyme System; Deoxycytidine; Fluorouracil; Gemcitabine; Mice; Mice, Nude; Mitomycin; Resveratrol; Stilbenes | 2010 |
Incorporation of gemcitabine and cytarabine into DNA by DNA polymerase beta and ligase III/XRCC1.
Topics: Antimetabolites, Antineoplastic; Catalysis; Cytarabine; Deoxycytidine; DNA Damage; DNA Ligase ATP; DNA Ligases; DNA Polymerase beta; DNA Repair; DNA-Binding Proteins; Gemcitabine; Humans; Kinetics; Poly-ADP-Ribose Binding Proteins; Signal Transduction; Substrate Specificity; X-ray Repair Cross Complementing Protein 1; Xenopus Proteins | 2010 |
MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Retrospective Studies; RNA, Messenger; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Hand-foot hyperpigmentation skin lesions associated with combination gemcitabine-carboplatin (GemCarbo) therapy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Foot; Gemcitabine; Hand; Humans; Hyperpigmentation; Lung Neoplasms; Male | 2011 |
Immunoglobulin E-mediated severe anaphylaxis to paclitaxel.
Topics: Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Asthma; Cisplatin; Deoxycytidine; Drug Hypersensitivity; Dyspnea; Epitopes; Female; Gemcitabine; Humans; Hypersensitivity, Immediate; Hypotension; Immunoglobulin E; Middle Aged; Neoplasms; Paclitaxel; Pulmonary Atelectasis; Remission Induction; Skin Tests | 2010 |
Haemolytic uraemic syndrome associated with gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Urinary Bladder Neoplasms; Urothelium | 2010 |
Impact of S-1 on the survival of patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2010 |
Sensitization of SiHa cell to gemcitabine by CD40 activation and its overexpression in cervical carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; CD40 Antigens; Cell Line, Tumor; Cell Proliferation; Cell Separation; Deoxycytidine; Enzyme Activation; Female; Flow Cytometry; Gemcitabine; Humans; Immunohistochemistry; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Uterine Cervical Neoplasms | 2011 |
CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system.
Topics: ADP-ribosyl Cyclase 1; Antimetabolites, Antineoplastic; Biomarkers; Blotting, Western; Cells, Cultured; Cytarabine; Deoxycytidine; Electrophoretic Mobility Shift Assay; Gemcitabine; Gene Expression Profiling; Humans; Lymphocytes; Models, Biological; Oligonucleotide Array Sequence Analysis; Polymorphism, Single Nucleotide; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |
Targeting IL-13Rα2 in human pancreatic ductal adenocarcinoma with combination therapy of IL-13-PE and gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Interleukin-13; Interleukin-13 Receptor alpha2 Subunit; Mice; Mice, Nude; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
Dicoumarol enhances gemcitabine-induced cytotoxicity in high NQO1-expressing cholangiocarcinoma cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Dicumarol; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Glutathione; Humans; Membrane Potential, Mitochondrial; NAD(P)H Dehydrogenase (Quinone); NF-kappa B; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; RNA, Messenger; Tumor Suppressor Protein p53 | 2010 |
In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents.
Topics: Antineoplastic Agents; Artemisinins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Inhibitory Concentration 50; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Thalidomide | 2011 |
[A case of drug-induced interstitial pneumonitis after adjuvant chemotherapy with gemcitabine for bile duct cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Methylprednisolone; Tomography, X-Ray Computed | 2010 |
Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cells, Cultured; Cytokines; Deoxycytidine; Endothelium, Vascular; Female; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; RNA-Binding Proteins; Survival Rate; Xenograft Model Antitumor Assays | 2010 |
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Erlotinib Hydrochloride; Gemcitabine; Genetic Engineering; Humans; Lung Neoplasms; Mice; Mutation; Neoplasms; Proto-Oncogene Proteins p21(ras); Quinazolines; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Topics: Adenocarcinoma; Animals; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; DNA Damage; DNA Repair; Drug Therapy, Combination; Flow Cytometry; Fluorescent Antibody Technique; G2 Phase; Gamma Rays; Gemcitabine; Humans; Immunoblotting; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Rad51 Recombinase; Radiation-Sensitizing Agents; Recombination, Genetic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2010 |
[Gemcitabine combined with cisplatin and methylprednisolone sodium succinate in chemotherapy for relapsed or refractory T cell non-Hodgkin lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Methylprednisolone Hemisuccinate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 2010 |
Analysis of chemiotherapeutic protocols efficiency in therapy of advanced non small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Vinblastine; Vinorelbine | 2010 |
Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Flow Cytometry; Gemcitabine; Genes, bcl-2; Growth Inhibitors; Humans; I-kappa B Proteins; Mastic Resin; NF-kappa B; Pancreatic Neoplasms; Resins, Plant | 2010 |
Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach.
Topics: Antineoplastic Agents; Base Sequence; Cell Line; Cell Transformation, Viral; Cytarabine; Deoxycytidine; DNA Copy Number Variations; Female; Gemcitabine; Genome-Wide Association Study; Herpesvirus 4, Human; Histone-Lysine N-Methyltransferase; Humans; Inhibitory Concentration 50; Male; Nucleic Acid Amplification Techniques; Polymorphism, Single Nucleotide; Reproducibility of Results | 2010 |
Two lung masses with different responses to pemetrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasms, Second Primary; Pemetrexed | 2010 |
Ovarian metastasis following gallbladder carcinoma: a case report.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Incidental Findings; Lymph Node Excision; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Oxaliplatin; Treatment Outcome | 2010 |
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; Gemcitabine; Humans; Male; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Pemetrexed; Peritoneal Neoplasms; Pleural Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Reversible neuropathy after chemotherapy for metastatic adenocarcinoma from an unknown primary tumor to the sural nerve.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Unknown Primary; Peripheral Nervous System Neoplasms; Polyneuropathies; Sural Nerve | 2011 |
Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy.
Topics: Antimetabolites, Antineoplastic; Antiviral Agents; Bystander Effect; Cell Line, Tumor; Deoxycytidine; Fluorescent Antibody Technique; Gap Junctions; Gemcitabine; Humans; Neoplasms | 2010 |
Pasteurella multocida thymidine kinase 1 efficiently activates pyrimidine nucleoside analogs.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Deoxyuridine; Escherichia coli; Gemcitabine; Microbial Sensitivity Tests; Pasteurella multocida; Pyrimidine Nucleosides; Thymidine Kinase; Zidovudine | 2010 |
Induction of resistance to the lipophilic cytarabine prodrug elacytarabine (CP-4055) in CEM leukemic cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Cytidine Deaminase; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia; Nucleoside Deaminases; Polymerase Chain Reaction | 2010 |
Study of apoptosis induction and deoxycytidine kinase/cytidine deaminase modulation in the synergistic interaction of a novel ceramide analog and gemcitabine in pancreatic cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Ceramides; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Enzyme Activation; Gemcitabine; Humans; Pancreatic Neoplasms | 2010 |
Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Marrow; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Localizing putative markers in genetic association studies by incorporating linkage disequilibrium into bayesian hierarchical models.
Topics: Antineoplastic Agents; Bayes Theorem; Deoxycytidine; Female; Gemcitabine; Genetic Markers; Genome-Wide Association Study; Humans; Linkage Disequilibrium; Male; Models, Genetic; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide | 2010 |
Cell cycle arrest and apoptosis in TP53 subtypes of bladder carcinoma cell lines treated with cisplatin and gemcitabine.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Urinary Bladder Neoplasms | 2010 |
Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
Topics: Adenine; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Confounding Factors, Epidemiologic; Cytidine Deaminase; Cytosine; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Research Design | 2010 |
Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Palliative Care; Prognosis; Survival Rate; Tegafur; Tumor Burden; Young Adult | 2011 |
Combinatorial drug conjugation enables nanoparticle dual-drug delivery.
Topics: Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Hydrolysis; Lipids; Magnetic Resonance Spectroscopy; Nanoparticles; Paclitaxel | 2010 |
1,25D3 enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Calcitriol; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Mice; Mice, Nude; Nuclear Proteins; Receptors, Calcitriol; Tumor Protein p73; Tumor Suppressor Proteins; Urinary Bladder Neoplasms; Vitamin D; Xenograft Model Antitumor Assays | 2010 |
Analysis of multi-arm tumor growth trials in xenograft animals using phase change adaptive piecewise quadratic models.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Computer Simulation; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Immunoglobulin G; Lung Neoplasms; Mice; Mice, Nude; Models, Statistical; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Five-year survival of stage IIIA-IIIB (non-N3) non-small cell lung cancer patients after platinum/gemcitabine induction chemotherapy and surgery.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Prospective Studies; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2010 |
[A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Remission Induction; Tegafur | 2010 |
[A case of abdominal wall metastasis from pancreatic cancer].
Topics: Abdominal Neoplasms; Abdominal Wall; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
Radiation myelopathy after 36 Gy in 12 fractions palliative chest radiotherapy for squamous cell cancer of the lung: case report and review of published studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Squamous Cell; Palliative Care; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Spinal Cord; Spinal Cord Diseases; Thorax; Tomography, X-Ray Computed | 2010 |
Treatment of metachronous and simultaneous liver metastases of pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Time Factors | 2010 |
Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Silencing; Humans; Male; Middle Aged; Neoplasm, Residual; Pancreatectomy; Pancreatic Neoplasms; Pancreatitis, Chronic; Pennsylvania; Polycomb Repressive Complex 2; Survival Rate; Transcription Factors | 2010 |
Adjuvant chemoradiation therapy in gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis | 2011 |
Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biological Transport; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Resistance; Drug Resistance, Neoplasm; Gels; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Nanotechnology; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 22; Technology, Pharmaceutical; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Leveraging combinatorial chemotherapy to improve outcomes in patients with pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cytokines; Deoxycytidine; Gemcitabine; Humans; Neoplasm Proteins; Pancreatic Neoplasms; RNA-Binding Proteins; Survival Rate | 2010 |
Volumetric modulated arc therapy for advanced pancreatic cancer.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Film Dosimetry; Gemcitabine; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Intestines; Kidney; Liver; Neoplasm Staging; Pancreatic Neoplasms; Radiation Injuries; Radiation Tolerance; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Computer-Assisted; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Spinal Cord; Stomach; Tomography, X-Ray Computed | 2010 |
Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-myc; Stem Cells; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Complications; Radiotherapy, Adjuvant | 2010 |
Biological activity of gemcitabine against canine osteosarcoma cell lines in vitro.
Topics: Animals; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Deoxycytidine; Diphosphonates; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gemcitabine; Osteosarcoma; Pamidronate | 2010 |
Outcomes of concurrent chemoradiotherapy in patients with stage III non-small-cell lung cancer and significant comorbidity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Comorbidity; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Rate; Treatment Outcome | 2011 |
[Suppression of renin-angiotensin system and cancer therapy (discussion)].
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Cimetidine; Cyclooxygenase 2 Inhibitors; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Gemcitabine; Humans; Hypertension; Interferon-alpha; Life Style; Neoplasms; Oxonic Acid; Renin-Angiotensin System; Tegafur; Tetrazoles | 2010 |
Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers; Blood Cell Count; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleural mesothelioma patient previously treated with pemetrexed.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Mesothelioma; Pemetrexed; Pleural Neoplasms; Retroperitoneal Neoplasms; Salvage Therapy; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; United Kingdom | 2010 |
Metronomic gemcitabine in combination with sunitinib inhibits multisite metastasis and increases survival in an orthotopic model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Indoles; Inhibitory Concentration 50; Kaplan-Meier Estimate; Luminescent Proteins; Mice; Mice, Nude; Neoplasm Metastasis; Pancreatic Neoplasms; Pyrroles; Red Fluorescent Protein; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Asian People; Computer Simulation; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Floxuridine; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Polymorphism, Genetic; Polymorphism, Single Nucleotide | 2010 |
Folate-targeted supramolecular vesicular aggregates based on polyaspartyl-hydrazide copolymers for the selective delivery of antitumoral drugs.
Topics: Antineoplastic Agents; Azides; Biocompatible Materials; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Folic Acid; Gemcitabine; Humans; Materials Testing; Microscopy, Confocal; Molecular Structure; Peptides; Polymers; Tissue Distribution | 2010 |
Exploiting drug repositioning for discovery of a novel HIV combination therapy.
Topics: Anti-HIV Agents; Azacitidine; Decitabine; Deoxycytidine; Drug Interactions; Drug Therapy, Combination; Gemcitabine; HIV; HIV Infections; Humans; Mutation | 2010 |
Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands.
Topics: Animals; Antibodies; Antibodies, Monoclonal; Antibody Specificity; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Heparin-binding EGF-like Growth Factor; Humans; Immunotherapy; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Pancreatic Neoplasms; Transforming Growth Factor alpha | 2010 |
Novel therapies for pancreatic cancer: setbacks and progress.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Pancreatic Neoplasms; Signal Transduction | 2010 |
Ecotoxicity and genotoxicity assessment of cytotoxic antineoplastic drugs and their metabolites.
Topics: Animals; Antineoplastic Agents; Arabinofuranosyluracil; beta-Alanine; Chlorophyta; Cytarabine; Daphnia; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Growth Inhibitors; Mutagenicity Tests; Mutagens; Pseudomonas; Salmonella; Toxicity Tests | 2010 |
Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
[Experimental study of the function and mechanism combining dihydroartemisinin and gemcitabine in treating pancreatic cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Cisplatin plus gemcitabine for biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Neoplasms, Squamous Cell; Pemetrexed | 2010 |
Systemic administration of polymeric nanoparticle-encapsulated curcumin (NanoCurc) blocks tumor growth and metastases in preclinical models of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Line, Tumor; Cell Proliferation; Curcumin; Cyclin D1; Deoxycytidine; Disease Models, Animal; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Matrix Metalloproteinase 9; Mice; Nanoparticles; Neoplasm Metastasis; NF-kappa B; Pancreatic Neoplasms; Polymers; Subcutaneous Tissue; Xenograft Model Antitumor Assays | 2010 |
[A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2010 |
Small interfering RNA against the apurinic or apyrimidinic endonuclease enhances the sensitivity of human pancreatic cancer cells to gemcitabine in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA-(Apurinic or Apyrimidinic Site) Lyase; Down-Regulation; Gemcitabine; Humans; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering | 2010 |
Survival analysis of pancreatic and periampullary collision cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
Inhibition of heme oxygenase-1 enhances the cytotoxic effect of gemcitabine in urothelial cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cytoprotection; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Heme Oxygenase-1; Humans; Mice; Mice, Inbred BALB C; Protoporphyrins; Radiation Tolerance; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Cisplatin plus gemcitabine for biliary tract cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans | 2010 |
Prevalence of in vitro chemotherapeutic drug resistance in primary malignant pleural mesothelioma: result in a cohort of 203 resection specimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Proliferation; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Feasibility Studies; Gemcitabine; Humans; Mesothelioma; Middle Aged; Neoadjuvant Therapy; Patient Selection; Pleural Neoplasms; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2010 |
Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Cancer Vaccines; Cell Cycle Proteins; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Dermatitis; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Injections, Intradermal; Liver Neoplasms; Lymphocytes; Nuclear Proteins; Palliative Care; Radiotherapy, Adjuvant; RNA Splicing Factors; Skin | 2010 |
Small-animal PET/CT for monitoring the development and response to chemotherapy of thymic lymphoma in Trp53-/- mice.
Topics: Aging; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Proliferation; Deoxycytidine; Disease Progression; Fluorodeoxyglucose F18; Gemcitabine; Image Processing, Computer-Assisted; Lymphoma; Mice; Mice, Knockout; Mitotic Index; Positron-Emission Tomography; Radiopharmaceuticals; Thymus Neoplasms; Tomography, Emission-Computed; Tumor Suppressor Protein p53 | 2010 |
A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2010 |
Gemcitabine-induced acute eosinophilic pneumonia.
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Pulmonary Eosinophilia; Radiation Tolerance | 2010 |
Comparison of cisplatin- and carboplatin-based third-generation chemotherapy in 1,014 Chinese patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.
Topics: Aged; Deoxycytidine; Disease-Free Survival; Eukaryotic Initiation Factor-3; Female; Gemcitabine; Gene Expression Profiling; Genotype; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2010 |
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2010 |
Combinations of mTORC1 inhibitor RAD001 with gemcitabine and paclitaxel for treating non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Everolimus; Gemcitabine; Humans; Immunosuppressive Agents; Jurkat Cells; Lymphoma, Non-Hodgkin; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2010 |
The value of clinical prognostic factors for survival in patients with invasive urinary bladder cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Particle Accelerators; Prognosis; Proportional Hazards Models; Prospective Studies; Radiotherapy Dosage; Retrospective Studies; Time Factors; Urinary Bladder Neoplasms; Young Adult | 2010 |
Heat-shock protein 27 is phosphorylated in gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Isoforms; Up-Regulation | 2010 |
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Quinazolines; Retrospective Studies; Salvage Therapy; Taxoids | 2010 |
Role of pregabalin in treatment of oxaliplatin-induced sensory neuropathy.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; gamma-Aminobutyric Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Pregabalin | 2010 |
Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Blotting, Western; Cancer Vaccines; CD8-Positive T-Lymphocytes; Chemokines; Cisplatin; Combined Modality Therapy; Cross-Priming; Cytokines; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Immunotherapy; Interferons; Lung Neoplasms; Memory, Short-Term; Mesothelioma; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-kappa B; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidine Kinase; Tumor Cells, Cultured; Tumor Microenvironment | 2010 |
Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells.
Topics: AC133 Antigen; Animals; Antigens, CD; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cadherins; CD24 Antigen; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplastic Stem Cells; Octamer Transcription Factor-3; Pancreatic Neoplasms; Peptides; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Survivin; Vimentin | 2011 |
Low dose fractionated cisplatin plus gemcitabine for elderly patients with advanced non small cell lung cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Retrospective Studies | 2010 |
Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells.
Topics: Alternative Splicing; Annexin A2; Antimetabolites, Antineoplastic; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Recombinant Proteins; RNA, Small Interfering; Tenascin; Transcription Factor RelA | 2010 |
Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathway.
Topics: Antimetabolites, Antineoplastic; Autoradiography; Cell Line, Tumor; Cell Membrane; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Carriers; Drug Compounding; Gemcitabine; Humans; Nanoparticles; Particle Size; Prodrugs; Squalene; Subcellular Fractions; Surface-Active Agents; Tandem Mass Spectrometry; Tissue Distribution | 2010 |
[Vertigo as a symptom of psychosocial pain].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hospices; Humans; Lung Neoplasms; Neoplasm Staging; Palliative Care; Quality of Life; Radiotherapy, Adjuvant; Sick Role; Social Isolation; Somatoform Disorders; Vertigo | 2010 |
Poorly differentiated endocrine carcinoma of the pancreas responded to gemcitabine: Case report.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Differentiation; Cisplatin; Deoxycytidine; Drug Administration Schedule; Endocrine Gland Neoplasms; Etoposide; Gemcitabine; Humans; Ileus; Irinotecan; Male; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2010 |
Quantification of gemcitabine incorporation into human DNA by LC/MS/MS as a surrogate measure for target engagement.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxycytidine; Deoxyguanosine; DNA; Dogs; Gemcitabine; Humans; Spectrometry, Mass, Electrospray Ionization | 2010 |
Calcitriol enhances gemcitabine anti-tumor activity in vitro and in vivo by promoting apoptosis in a human pancreatic carcinoma model system.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Calcitriol; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Synergism; Enzyme Activation; Gemcitabine; Humans; Liver; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Ovarian Neoplasms; Topotecan | 2010 |
A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germ-Line Mutation; Humans; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2010 |
[Primary urothelial carcinoma with sarcomatous transformation of the prostate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Sarcoma; Treatment Outcome; Urethral Neoplasms | 2010 |
[A dialysis patient with advanced lung adenocarcinoma who was safely given biweekly gemcitabine therapy].
Topics: Adenocarcinoma; Aged, 80 and over; Deoxycytidine; Gemcitabine; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Neoplasm Staging; Radiography; Renal Dialysis | 2010 |
[Response in a case of inoperable bile duct cancer treated by combined chemotherapy of S-1 and gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Tegafur; Tomography, X-Ray Computed | 2010 |
[An effective case of gemcitabine therapy with post-operative peritoneal recurrence of intrahepatic cholangiocarcinoma].
Topics: Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Liver; Male; Middle Aged; Peritoneal Neoplasms; Recurrence; Remission Induction; Tomography, X-Ray Computed | 2010 |
Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Treatment Outcome | 2011 |
Improved syntheses of 5'-S-(2-aminoethyl)-6-N-(4-nitrobenzyl)-5'-thioadenosine (SAENTA), analogues, and fluorescent probe conjugates: analysis of cell-surface human equilibrative nucleoside transporter 1 (hENT1) levels for prediction of the antitumor effi
Topics: Adenosine; Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Gemcitabine; Humans; Mice; Oocytes; Protein Binding; Stereoisomerism; Structure-Activity Relationship; Thioinosine; Thionucleosides; Xenopus; Yeasts | 2010 |
Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2010 |
In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Interactions; Drug Synergism; Flow Cytometry; Gemcitabine; Glutamates; Guanine; Head and Neck Neoplasms; Humans; In Vitro Techniques; Lung Neoplasms; Pemetrexed; Radiotherapy Dosage; Tumor Cells, Cultured | 2010 |
[Rituximab-mediated sensitization of B-NHL cell lines to apoptosis induced by gemcitabine and Navelbine in vitro].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cell Line, Tumor; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Lymphoma, T-Cell; Proto-Oncogene Proteins c-bcl-2; Rituximab; Vinblastine; Vinorelbine | 2010 |
Amphiregulin regulates the activation of ERK and Akt through epidermal growth factor receptor and HER3 signals involved in the progression of pancreatic cancer.
Topics: Amphiregulin; Antibodies; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; EGF Family of Proteins; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Glycoproteins; Humans; Immunoblotting; Intercellular Signaling Peptides and Proteins; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Gemcitabine; Glutamates; Guanine; Humans; Italy; Lung Neoplasms; Markov Chains; Models, Economic; Pemetrexed; Quality of Life | 2010 |
Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Costs; Gemcitabine; Germany; Glutamates; Guanine; Humans; Italy; Lung Neoplasms; Pemetrexed | 2010 |
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost of Illness; Deoxycytidine; European Union; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Paclitaxel | 2010 |
The differential expression of hCNT1 and hENT1 i n breast cancer and the possible impact on breast cancer therapy.
Topics: Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Membrane Transport Proteins; RNA, Messenger | 2010 |
Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Gemcitabine; Humans; Models, Biological; Ovarian Neoplasms; Paclitaxel; Topotecan | 2010 |
HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients.
Topics: Adenocarcinoma; Biomarkers, Tumor; Combined Modality Therapy; Cyclooxygenase 2; Deoxycytidine; ELAV Proteins; ELAV-Like Protein 2; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Microarray Analysis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Survival Analysis; Vascular Endothelial Growth Factor A | 2010 |
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Colony-Forming Units Assay; Deoxycytidine; DNA Repair; Drug Synergism; Female; Gemcitabine; Histones; Humans; Rad51 Recombinase | 2010 |
Fatal thrombotic microangiopathy after a single dose of gemcitabine as fourth-line palliative treatment for metastasized ductal breast carcinoma.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Deoxycytidine; Dose-Response Relationship, Drug; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care; Salvage Therapy; Thrombotic Microangiopathies | 2011 |
The SV2 variant of KLF6 is down-regulated in hepatocellular carcinoma and displays anti-proliferative and pro-apoptotic functions.
Topics: Alternative Splicing; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Down-Regulation; Gemcitabine; Hep G2 Cells; Humans; Kruppel-Like Factor 6; Kruppel-Like Transcription Factors; Liver Neoplasms; Protein Isoforms; Proto-Oncogene Proteins; Tumor Suppressor Protein p53 | 2010 |
Chemoradiation for unresectable gall bladder cancer: time to review historic nihilism?
Topics: Adult; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Middle Aged; Prospective Studies; Treatment Outcome | 2011 |
Novel bladder preservation therapy for locally invasive bladder cancer: combined therapy using balloon-occluded arterial infusion of anticancer agent and hemodialysis with concurrent radiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Balloon Occlusion; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Odds Ratio; Proportional Hazards Models; Radiotherapy, Adjuvant; Renal Dialysis; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2010 |
The role of autophagy in the treatment of pancreatic cancer with gemcitabine and ionizing radiation.
Topics: Adenine; Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Gemcitabine; Humans; Immunohistochemistry; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Scanning; Microtubule-Associated Proteins; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Time Factors; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2010 |
Ribonucleotide reductase subunit M1 assessed by quantitative double-fluorescence immunohistochemistry predicts the efficacy of gemcitabine in biliary tract carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Inhibitory Concentration 50; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Patient Selection; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Treatment Outcome; Tumor Suppressor Proteins | 2010 |
Assessment of pancreatic carcinoma cell chemosensitivity using a three-dimensional culture system.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Spheroids, Cellular | 2010 |
Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation.
Topics: Animals; Antimetabolites, Antineoplastic; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Deoxycytidine; Gemcitabine; Leukemia; Liposomes; Mice; Particle Size; Polyethylene Glycols; Prodrugs; Scattering, Small Angle; Squalene; X-Ray Diffraction | 2010 |
Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Boronic Acids; Bortezomib; Cytarabine; Deoxycytidine; Dexamethasone; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Lenalidomide; Lymphoma, Large-Cell, Immunoblastic; Male; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Pyrazines; Recombinant Proteins; Thalidomide; Young Adult | 2010 |
Finding the tumor copycat: approximating a human cancer.
Topics: Adenocarcinoma; Animals; Animals, Genetically Modified; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Division; Deoxycytidine; Disease Models, Animal; Gemcitabine; Mice; Neoplasms | 2010 |
Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Time Factors; Up-Regulation | 2010 |
Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine-resistant pancreatic cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Gemcitabine; Immunohistochemistry; In Vitro Techniques; Mice; Mice, Inbred ICR; Mice, SCID; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
A novel arylethynyltriazole acyclonucleoside inhibits proliferation of drug-resistant pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nucleosides; Pancreatic Neoplasms; Triazoles | 2010 |
Induction chemotherapy for unresectable urothelial carcinoma of the bladder.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cystectomy; Deoxycytidine; Epidemiologic Methods; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Remission Induction; Urinary Bladder Neoplasms | 2011 |
[A case of gallbladder cancer which completely responded to gemcitabine].
Topics: Aged; Combined Modality Therapy; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoplasm Staging; Remission Induction; Tomography, X-Ray Computed | 2010 |
[S-1+gemcitabine (GEM) therapy effective in a case of pancreatic body cancer with multiple liver metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Ultrasonography | 2010 |
[Acute liver injury with hepatic encephalopathy associated with gemcitabine administration for adjuvant chemotherapy in an HBV carrier with pancreatic cancer].
Topics: Acute Disease; Aged; Amino Acids, Branched-Chain; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hepatic Encephalopathy; Hepatitis B; Humans; Lactulose; Liver; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2010 |
Clinical observations on safety of fixed dose rate gemcitabine chemotherapy by intravenous infusion.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatic Neoplasms; Prognosis | 2010 |
[Digital necrosis related to gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Fingers; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Necrosis; Paclitaxel; Palliative Care | 2010 |
Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms | 2010 |
Interaction of fused-pyrimidine nucleoside analogs with human concentrative nucleoside transporters: High-affinity inhibitors of human concentrative nucleoside transporter 1.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Proliferation; Cytoprotection; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Leukemia; Membrane Transport Proteins; Molecular Structure; Oocytes; Pyrimidine Nucleosides; Saccharomyces cerevisiae; Xenopus laevis | 2011 |
Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Gemcitabine; Gene Expression; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rad51 Recombinase; RNA, Small Interfering; Transfection; Ubiquitin | 2010 |
Factors for hematopoietic toxicity of carboplatin: refining the targeting of carboplatin systemic exposure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Blood Platelets; Carboplatin; Cell Proliferation; Deoxycytidine; Etoposide; Female; France; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Models, Biological; Neutropenia; Neutrophils; Paclitaxel; Platelet Count; Prospective Studies; Risk Assessment; Risk Factors; Thrombocytopenia; Young Adult | 2010 |
Conditions causing gemcitabine crystallization.
Topics: Administration, Intravesical; Chromatography, High Pressure Liquid; Cold Temperature; Crystallization; Deoxycytidine; Drug Storage; Gemcitabine; Hydrogen-Ion Concentration; Urinary Bladder Neoplasms | 2011 |
Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorodeoxyglucose F18; Gemcitabine; Hodgkin Disease; Humans; Positron-Emission Tomography; Recurrence; Research Report; Retrospective Studies; Survival Analysis; Vinblastine; Vinorelbine | 2010 |
Hypoxia inducible BHLHB2 is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Homeodomain Proteins; Humans; Male; Pancreas; Pancreatic Neoplasms; Prognosis; RNA Interference | 2010 |
{Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Chromans; Cyclooxygenase 2; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inflammation; Inflammation Mediators; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases; RNA, Messenger; Tumor Cells, Cultured; Vitamin E; Xenograft Model Antitumor Assays | 2010 |
[Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
Human SMG-1 is involved in gemcitabine-induced primary microRNA-155/BIC up-regulation in human pancreatic cancer PANC-1 cells.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; MicroRNAs; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Tumor Suppressor Proteins; Up-Regulation; Wortmannin | 2011 |
Chemotherapy: Gemcitabine alone or plus cisplatin for biliary tract cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Survival Rate | 2010 |
Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Floxuridine; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Middle Aged; Radiation-Sensitizing Agents | 2011 |
Intertriginous lymphomatoid drug eruption.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Intertrigo; Lung Neoplasms; Male | 2010 |
The antimalarial agent artesunate possesses anticancer properties that can be enhanced by combination strategies.
Topics: Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Artesunate; Blotting, Western; Breast Neoplasms; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lenalidomide; Lung Neoplasms; Organoplatinum Compounds; Oxaliplatin; Thalidomide; Tumor Cells, Cultured | 2011 |
Evaluation of the mTOR inhibitor, everolimus, in combination with cytotoxic antitumor agents using human tumor models in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Epothilones; Everolimus; Female; Fluorouracil; Gemcitabine; HCT116 Cells; Humans; Mice; Mice, Nude; Paclitaxel; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Outcomes and tolerability of systemic chemotherapy for pancreatic or biliary cancer patients aged 75 years or older.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Comorbidity; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2011 |
Specific targeting of tumor endothelial cells by a shiga-like toxin-vascular endothelial growth factor fusion protein as a novel treatment strategy for pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Movement; Cell Proliferation; Cells, Cultured; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Endothelium, Vascular; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Shiga Toxins; Signal Transduction; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Carcinoma, Adenosquamous; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Feasibility Studies; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Middle Aged; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Rate; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2010 |
Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report.
Topics: Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Citrates; Deoxycytidine; Energy Metabolism; Female; Gemcitabine; Humans; Methotrexate; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Pancreatic Neoplasms; Thioctic Acid; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
[Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Disease Progression; Feasibility Studies; Female; France; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Pemetrexed; Pleural Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
[A case of leiomyosarcoma of prostate: multimodality therapy suppressed disease progression for long term].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Male; Prostatic Neoplasms; Taxoids | 2010 |
Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Genotype; Humans; Irinotecan; Neoplasm Metastasis; Pharmacogenetics; Survival Analysis; Time Factors; Vascular Endothelial Growth Factor A | 2010 |
Simultaneous breast and ovarian metastasis from gallbladder carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Mastectomy; Middle Aged; Ovarian Neoplasms; Ovariectomy; Salpingectomy | 2010 |
Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; Humans; Mass Spectrometry; Pancreatic Neoplasms; Proteomics; Up-Regulation | 2010 |
Modulation of gemcitabine accumulation by DNA-damaging agents: mechanisms and specificity in an in vitro model.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; HCT116 Cells; Humans; In Vitro Techniques; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2010 |
Combined chemotherapy with gemcitabine and cisplatin for metastatic urothelial carcinomas in patients 80 years of age and over.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Retrospective Studies; Urinary Bladder Neoplasms | 2010 |
Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Cell Survival; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Inhibitory Concentration 50; Male; Middle Aged; Orotate Phosphoribosyltransferase; Pancreatic Neoplasms; RNA Interference; Thymidylate Synthase | 2010 |
[A case of malignant peritoneal mesothelioma treated effectively with cisplatin and gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Tomography, X-Ray Computed | 2010 |
[A long-term survivor treated with S-1 and gemcitabine for recurrence following an operation for advanced gall bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Staging; Oxonic Acid; Recurrence; Tegafur; Time Factors; Tomography, X-Ray Computed | 2010 |
CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma.
Topics: AC133 Antigen; Animals; Antigens, CD; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Glycoproteins; Humans; Hyaluronan Receptors; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Oncogene Proteins; Peptides; Spheroids, Cellular; Trans-Activators; Up-Regulation; Zinc Finger Protein GLI1 | 2010 |
Pilot study to relate clinical outcome in pancreatic carcinoma and angiogenic plasma factors/circulating mature/progenitor endothelial cells: Preliminary results.
Topics: Aged; Angiopoietins; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Deoxycytidine; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Pilot Projects; Stem Cells; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor D | 2010 |
Anti-carcinogenic effects of sulforaphane in association with its apoptosis-inducing and anti-inflammatory properties in human cervical cancer cells.
Topics: Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Apoptosis; Cell Survival; Cyclooxygenase 2; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Inflammation; Interleukin-1beta; Isothiocyanates; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Sulfoxides; Thiocyanates; Uterine Cervical Neoplasms | 2011 |
Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Cancer Vaccines; CD11b Antigen; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Genetic Vectors; Inhibitor of Apoptosis Proteins; Interferon-gamma; Lymphocyte Activation; Mice; Mice, Inbred C57BL; Myeloid Cells; Pancreatic Neoplasms; Peptide Fragments; Peptide Library; Receptors, Cell Surface; Remission Induction; Repressor Proteins; Survivin; Vaccination; Vaccinia virus | 2011 |
Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Mutation; Positron-Emission Tomography; Quinazolines; Treatment Outcome | 2010 |
Mifepristone (RU486) restores humoral and T cell-mediated immune response in endotoxin immunosuppressed mice.
Topics: Animals; Antigens, CD; Cyclophosphamide; Deoxycytidine; Forkhead Transcription Factors; Gemcitabine; Immunity, Cellular; Immunity, Humoral; Immunosuppression Therapy; Immunosuppressive Agents; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Mifepristone; Receptors, Glucocorticoid; T-Lymphocytes; T-Lymphocytes, Regulatory | 2010 |
Treatment effect or secret nature: long-term remissions in metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Longitudinal Studies; Lymphatic Metastasis; Mistletoe; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Treatment Outcome | 2010 |
Sustained partial remission of metastatic pancreatic cancer following systemic chemotherapy with gemcitabine and oxaliplatin plus adjunctive treatment with mistletoe extract.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Mistletoe; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Treatment Outcome | 2010 |
Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2010 |
Complete response to carboplatin, gemcitabine, and paclitaxel in a patient with advanced metastatic renal medullary carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Renal Cell; Child; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Male; Paclitaxel; Sickle Cell Trait; Treatment Outcome | 2010 |
Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Deoxycytidine; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2010 |
Methylation-mediated silencing of TMS1 in pancreatic cancer and its potential contribution to chemosensitivity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Cytoskeletal Proteins; Deoxycytidine; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Silencing; Humans; Pancreatic Neoplasms; Promoter Regions, Genetic; Taxoids; Transfection | 2010 |
Inhibition of GST-pi nuclear transfer increases mantle cell lymphoma sensitivity to cisplatin, cytarabine, gemcitabine, bortezomib and doxorubicin.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cytarabine; Deoxycytidine; Doxorubicin; Drug Screening Assays, Antitumor; Gemcitabine; Glutathione S-Transferase pi; Humans; Lectins; Lymphoma, Mantle-Cell; Pyrazines | 2010 |
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Piperidines; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
E phage gene transfection enhances sensitivity of lung and colon cancer cells to chemotherapeutic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Carcinoma; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genetic Therapy; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Paclitaxel; Transfection; Viral Proteins | 2010 |
Evaluation of the effectiveness of a chemoprevention model of pancreatic adenocarcinoma using protein chip technology.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Chemoprevention; Deoxycytidine; Diagnostic Techniques, Endocrine; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protein Array Analysis; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2010 |
Treatment trends in metastatic pancreatic cancer patients: Is it time to change?
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2011 |
Current status of adjuvant therapy for pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2010 |
CXCL12-CXCR4 signalling axis confers gemcitabine resistance to pancreatic cancer cells: a novel target for therapy.
Topics: Antimetabolites, Antineoplastic; Benzylamines; beta Catenin; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Heterocyclic Compounds; Humans; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, CXCR4; Signal Transduction | 2010 |
Perioperative intra-arterial and systemic chemotherapy for pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Injections, Intra-Arterial; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Perioperative Period; Survival Rate; Treatment Outcome | 2011 |
Microemulsions for intravesical delivery of gemcitabine.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Emulsions; Female; Gemcitabine; Humans; Rats; Rats, Sprague-Dawley; Urinary Bladder; Urinary Bladder Neoplasms | 2010 |
Chronic anemia resistant to erythropoietin in a patient treated with gemcitabine showing a hemolytic uremic syndrome (HUS).
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Chronic Disease; Deoxycytidine; Erythropoietin; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Liver Neoplasms; Male; Pancreatic Neoplasms; Treatment Failure | 2010 |
[Establish a gemcitabine-resistant pancreatic cancer cell line SW1990/GZ and research the relationship between SW1990/GZ and pancreatic cancer stem cell].
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2010 |
Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; BCG Vaccine; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Ki-67 Antigen; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Urinary Bladder Neoplasms | 2010 |
Treatment efficacy/safety and prognostic factors in patients with advanced biliary tract cancer receiving gemcitabine monotherapy: an analysis of 100 cases.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; C-Reactive Protein; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Retrospective Studies; Serum Albumin; Treatment Outcome | 2010 |
The expression of interferon receptor α/β in human pancreatic cancer in nude mice is essential for tumor response to interferon α treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunologic Factors; Interferon-alpha; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Receptor, Interferon alpha-beta | 2012 |
Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Hodgkin Disease; Humans; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines | 2011 |
Myelinoid bodies in a patient with membranoproliferative glomerulonephritis.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Glomerulonephritis, Membranoproliferative; Humans; Inclusion Bodies; Kidney Glomerulus; Male; Microscopy, Electron, Transmission; Middle Aged | 2010 |
Modular polymer-caged nanobins as a theranostic platform with enhanced magnetic resonance relaxivity and pH-responsive drug release.
Topics: Antineoplastic Agents; Contrast Media; Deoxycytidine; Gadolinium; Gemcitabine; Magnetic Resonance Imaging; Polymers | 2010 |
[Prediction of gemcitabine treatment discontinuation based on platelet count before first administration].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Platelet Count; Thrombocytopenia | 2010 |
Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; China; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Paclitaxel; Pharmacogenetics; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-akt; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2011 |
Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gallbladder Neoplasms; Gemcitabine; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor, ErbB-2; Signal Transduction | 2010 |
The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.
Topics: Animals; Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Receptors, sigma | 2010 |
The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Utility of the novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen), for elderly patients with invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Neoplasm Staging; Risk Factors; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Granulomatous mycosis fungoides with large cell transformation misdiagnosed as leprosy.
Topics: Antimetabolites, Antineoplastic; Cell Transformation, Neoplastic; Deoxycytidine; Diagnostic Errors; Disease Progression; Gemcitabine; Granuloma; Humans; Leprosy; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Weakness; Mycosis Fungoides; Skin Neoplasms; Treatment Outcome | 2010 |
Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Introns; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Minisatellite Repeats; Neoplasm Staging; Nitric Oxide Synthase Type III; Paclitaxel; Polymorphism, Single Nucleotide; Survival Rate; Treatment Outcome | 2010 |
Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arteries; Bevacizumab; Deoxycytidine; Gemcitabine; Humans; Ischemia; Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Thrombosis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Survival Rate; Tumor Cells, Cultured | 2010 |
Analysis of the cytotoxic activity of carboplatin and gemcitabine combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2010 |
Additive growth inhibition after combined treatment of 2-methoxyestradiol and conventional chemotherapeutic agents in human pancreatic cancer cells.
Topics: 2-Methoxyestradiol; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Cisplatin; Deoxycytidine; Drug Synergism; Estradiol; Female; Flow Cytometry; Fluorescent Antibody Technique; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Tubulin Modulators | 2010 |
A pilot study of gemcitabine in combination with oxaliplatin and vinorelbine in patients with metastatic bladder cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vinorelbine | 2010 |
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Efficiency and tolerance of aranose combinations with cisplatin and gemcitabine in experimental lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL | 2009 |
Superior preclinical efficacy of gemcitabine developed as chitosan nanoparticulate system.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Kinetics; Mice; Mice, Inbred DBA; Nanoparticles; Neoplasms, Experimental | 2011 |
Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Benzhydryl Compounds; Deoxycytidine; Down-Regulation; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Pancreatic Neoplasms; Pyrrolidinones; Tumor Cells, Cultured | 2011 |
Gemcitabine functions epigenetically by inhibiting repair mediated DNA demethylation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; DNA Methylation; DNA Repair; Epigenesis, Genetic; Female; Gemcitabine; Gene Expression Regulation; HCT116 Cells; HEK293 Cells; Humans; MutL Protein Homolog 1; Nuclear Proteins; Oocytes; Reverse Transcriptase Polymerase Chain Reaction; Xenopus; Xenopus Proteins | 2010 |
[Effect of gemcitabine on granulocyte colony-stimulating factor receptor and bcr/abl mRNA in patients with chronic myeloid leukemia].
Topics: Adolescent; Adult; Bone Marrow; Case-Control Studies; Deoxycytidine; Fusion Proteins, bcr-abl; Gemcitabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Receptors, Granulocyte Colony-Stimulating Factor; RNA, Messenger; Tumor Cells, Cultured; Young Adult | 2010 |
Bayesian hierarchical changepoint methods in modeling the tumor growth profiles in xenograft experiments.
Topics: Animals; Bayes Theorem; Cell Proliferation; Confidence Intervals; Deoxycytidine; Gemcitabine; Mice; Models, Biological; Models, Statistical; Neoplasms; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2011 |
Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Bile; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreas; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Tegafur; Treatment Failure | 2011 |
Cytotoxic effects of new trans-2,4-diaryl-r-3-methyl-1,2,3,4-tetrahydroquinolines and their interaction with antitumoral drugs gemcitabine and paclitaxel on cellular lines of human breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Paclitaxel; Quinolines | 2011 |
Pancreatic cancer: will incremental advances begin to make a difference?
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Failure | 2010 |
[Case of intrahepatic cholangiocarcinoma drained through a fistula of the duodenal bulb].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Duodenal Diseases; Duodenal Neoplasms; Female; Gemcitabine; Humans; Intestinal Fistula; Liver Neoplasms; Neoplasm Invasiveness | 2010 |
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Health Care Surveys; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy, Adjuvant; Vinblastine; Vinorelbine | 2011 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Collagen Type I; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Matrix; Gemcitabine; HMGA2 Protein; Humans; Matrix Metalloproteinase 14; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Targeted Therapy; Pancreatic Neoplasms; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
pp32 (ANP32A) expression inhibits pancreatic cancer cell growth and induces gemcitabine resistance by disrupting HuR binding to mRNAs.
Topics: Antigens, Surface; Antimetabolites, Antineoplastic; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance; ELAV Proteins; ELAV-Like Protein 1; Gemcitabine; HEK293 Cells; Humans; Pancreatic Neoplasms; Protein Binding; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA-Binding Proteins; RNA, Messenger | 2010 |
Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; DNA, Neoplasm; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2011 |
Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neuroblastoma; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2011 |
Interstitial lung disease under erlotinib plus gemcitabine for pancreatic carcinoma: a therapeutic dilemma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Middle Aged; Pancreatic Neoplasms; Quinazolines | 2011 |
Targeted combined aerosol chemotherapy in dogs and radiologic toxicity grading.
Topics: Administration, Inhalation; Aerosols; Animals; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Cisplatin; Deoxycytidine; Dogs; Dose-Response Relationship, Drug; Drug Delivery Systems; Gemcitabine; Lung; Nebulizers and Vaporizers; Radiography; Time Factors; Tissue Distribution | 2011 |
The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
How do carbon nanotubes serve as carriers for gemcitabine transport in a drug delivery system?
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Models, Molecular; Molecular Dynamics Simulation; Nanotubes, Carbon | 2011 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma.
Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Genes, erbB-2; Humans; Immunoconjugates | 2011 |
Impact of adjuvant chemotherapy on patients with lymph node metastasis at the time of radical cystectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Multivariate Analysis; Regression Analysis; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Burden; Urinary Bladder Neoplasms; Vinblastine | 2010 |
Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Remission Induction; Time Factors; Tomography, X-Ray Computed; Treatment Failure | 2011 |
[Successful long-term management of hepatic and lymph nodes metastases of ureteral cancer by multimodal treatment including radiofrequency ablation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Catheter Ablation; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Multiple Primary; Quality of Life; Treatment Outcome; Ureteral Neoplasms | 2010 |
Repeated chemoembolization followed by laser-induced thermotherapy for liver metastasis of breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoembolization, Therapeutic; Combined Modality Therapy; Contrast Media; Deoxycytidine; Female; Gadolinium DTPA; Gemcitabine; Humans; Laser Therapy; Liver Neoplasms; Magnetic Resonance Imaging, Interventional; Middle Aged; Mitomycin; Prospective Studies; Radiography, Interventional; Retreatment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2011 |
Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; CA-125 Antigen; Carcinoma; Carcinoma, Ovarian Epithelial; Cisplatin; Cytotoxins; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Targeting the IL-6 dependent phenotype can identify novel therapies for cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Drug Design; Felodipine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Interleukin-6; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Phenotype | 2010 |
Congenital retroperitoneal vascular anomalies: impact on pelvic surgery.
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Ovarian Neoplasms; Pelvis; Radiography; Treatment Outcome; Vascular Malformations; Vena Cava, Inferior | 2011 |
Adenovirus-mediated Drosophila melanogaster deoxyribonucleoside kinase mutants combined with gemcitabine harbor a safe cancer treatment profile.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cells, Cultured; Combined Modality Therapy; Deoxycytidine; Drosophila melanogaster; Female; Gemcitabine; Genes, Transgenic, Suicide; Genetic Therapy; Genetic Vectors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mutant Proteins; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Prohibitins; Xenograft Model Antitumor Assays | 2011 |
Gender differences in gemcitabine (Gemzar) efficacy in cancer cells: effect of indole-3-carbinol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; DNA Modification Methylases; Drug Synergism; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, p16; Humans; Indoles; Male; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Sex Factors | 2010 |
Weekly paclitaxel combining with gemcitabine is an effective and safe treatment for advanced breast cancer patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Gemcitabine and cisplatin salvage regimen in heavily pretreated metastatic breast cancer: a Brazilian experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Retrospective Studies; Salvage Therapy; Survival Rate | 2011 |
Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Membrane; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Gemcitabine; Humans; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms | 2011 |
A rare case of thyroid metastasis from pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Palliative Care; Pancreatic Neoplasms; Pancreaticoduodenectomy; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome | 2011 |
Medical therapy for advanced pancreatic cancer: work in progress.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Agents; Biomedical Research; Chemokine CXCL12; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gemcitabine; Humans; Hydrogen-Ion Concentration; Losartan; Lovastatin; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Silencing of tubulin binding cofactor C modifies microtubule dynamics and cell cycle distribution and enhances sensitivity to gemcitabine in breast cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Deoxycytidine; Female; Gemcitabine; Gene Silencing; GTP-Binding Proteins; Humans; Mice; Mice, SCID; Microtubules; Molecular Chaperones; Protein Transport; Tubulin; Xenograft Model Antitumor Assays | 2011 |
The promise of a personalized genomic approach to pancreatic cancer and why targeted therapies have missed the mark.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Forecasting; Gemcitabine; Genetic Association Studies; Human Genome Project; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Precision Medicine; Risk Factors; Sequence Analysis, DNA; Survival Rate; Treatment Failure | 2011 |
[Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Endometrioid; Cystadenocarcinoma, Serous; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Luminescent Measurements; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Sensitivity and Specificity; Survival Rate; Topotecan | 2010 |
[Locally advanced pancreatic cancer successfully treated by arterial infusion chemotherapy combined with stereotactic radiotherapy--a case report].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Middle Aged; Pancreatic Neoplasms; Radiosurgery | 2010 |
[Two cases of pancreatic cancer with fairly good prognosis].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Duodenum; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2010 |
[A 6-year survival case of locally advanced unresectable pancreatic tail cancer treated with chemo-radiation therapy].
Topics: Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Tegafur | 2010 |
[The case of a person who let to umbilicus metastasis at a year after PD].
Topics: Abdominal Neoplasms; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Lymph Node Excision; Pancreatic Neoplasms; Pancreaticoduodenectomy; Time Factors; Umbilicus | 2010 |
[A case of liver metastasis of pancreatic cancer that was resistant to S-1 and gemcitabine successfully treated by 5-FU and cisplatin hepatic arterial infusion].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lymph Node Excision; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2010 |
[Evaluation of systemic chemotherapy for unresectable gallbladder carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Survival Analysis; Tegafur | 2010 |
[A case of unresectable advanced gallbladder cancer successfully treated by a combined administration of gemcitabine + CDDP].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged | 2010 |
[A long-term survival case of unresectable intrahepatic cholangiocarcinoma treated with chemotherapy].
Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Tegafur; Treatment Outcome | 2010 |
Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Caspase 3; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; Genetic Vectors; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Matrix Metalloproteinase 1; Pancreatic Neoplasms; Proto-Oncogene Protein c-ets-1; RNA Interference; RNA, Small Interfering; Time Factors; Urokinase-Type Plasminogen Activator | 2011 |
A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Treatment Outcome | 2011 |
Smac mimetic-derived augmentation of chemotherapeutic response in experimental pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic Materials; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Gemcitabine; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Mice; Mice, SCID; Mitochondrial Proteins; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Survival Analysis; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Angiosarcoma of the scalp with complete response to a biweekly gemcitabine and docetaxel (GEMDOC) chemotherapy regimen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Scalp; Skin Neoplasms; Taxoids | 2011 |
Cost-effectiveness of gemcitabine + cisplatin vs. gemcitabine monotherapy in advanced biliary tract cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decision Support Techniques; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2012 |
Gemcitabine response in pancreatic adenocarcinoma cells is synergistically enhanced by dithiocarbamate derivatives.
Topics: Adenocarcinoma; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Thiocarbamates | 2011 |
Smac modulates chemosensitivity in head and neck cancer cells through the mitochondrial apoptotic pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Biomimetic Materials; Blotting, Western; Caspase 3; Cell Line, Tumor; Cytochromes c; Deoxycytidine; Drug Synergism; Enzyme Activation; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mice, Nude; Mitochondria; Mitochondrial Proteins; RNA Interference; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; RNA, Messenger; Survival Analysis; Up-Regulation | 2011 |
Microcystic/reticular schwannoma of the pancreas: a potential diagnostic pitfall.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy, Fine-Needle; Deoxycytidine; Diagnostic Errors; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neurilemmoma; Pancreatectomy; Pancreatic Neoplasms; Quinazolines | 2011 |
Pulmonary cryptococcus infection after mono-chemotherapy with gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Cryptococcosis; Cryptococcus neoformans; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Fungal; Male; Urinary Bladder Neoplasms | 2011 |
Analysis of the ex vivo and in vivo antiretroviral activity of gemcitabine.
Topics: Animals; Anti-Retroviral Agents; Cells, Cultured; Deoxycytidine; Disease Progression; Gemcitabine; Immunoglobulin M; Leukemia Virus, Murine; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Ribonucleotide Reductases; Spleen; Viral Load | 2011 |
Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Retrospective Studies; Salvage Therapy; Statistics, Nonparametric; Treatment Outcome | 2012 |
Fatal interstitial lung disease associated with gemcitabine and erlotinib therapy for lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2012 |
Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2011 |
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; src-Family Kinases; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
Response to combined molecular targeting: defining the role of P-STAT3.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; STAT3 Transcription Factor; Thiazoles; Xenograft Model Antitumor Assays | 2011 |
The human immunodeficiency virus protease inhibitor ritonavir inhibits lung cancer cells, in part, by inhibition of survivin.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cisplatin; Cyclin D1; Deoxycytidine; DNA Breaks, Double-Stranded; Drug Therapy, Combination; Gemcitabine; HIV Protease Inhibitors; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Messenger; RNA, Small Interfering; Survivin; Tumor Cells, Cultured | 2011 |
Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Magnetic Resonance Imaging; Magnetics; Magnetite Nanoparticles; Mice; Nanocomposites; Nanomedicine; Neoplasms; Prodrugs; Squalene; Xenograft Model Antitumor Assays | 2011 |
ERK phosphorylation predicts synergism between gemcitabine and the epidermal growth factor receptor inhibitor AG1478.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Mutation; Nitriles; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; RNA, Small Interfering; Tyrphostins | 2011 |
Combinatorial pharmacologic effects of gemcitabine and its metabolite dFdU.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combinatorial Chemistry Techniques; Deoxycytidine; Deoxyuridine; Embryo, Nonmammalian; Embryonic Development; Floxuridine; Gemcitabine; Humans; Tumor Stem Cell Assay; Zebrafish | 2011 |
Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Young Adult | 2011 |
Equilibrative nucleoside transporter 1 genotype, cytidine deaminase activity and age predict gemcitabine plasma clearance in patients with solid tumours.
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Genotype; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasms; Polymorphism, Genetic; White People | 2011 |
Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor.
Topics: Animals; Blotting, Western; BRCA2 Protein; Cell Line; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; HEK293 Cells; Humans; Mice; Mutation; Pancreatic Neoplasms; Protein Kinases; ras Proteins; RNA Interference; Transfection; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2011 |
Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells.
Topics: Deamination; Deoxycytidine; Floxuridine; Gemcitabine; HeLa Cells; Humans | 2011 |
Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Resistance; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Leukopenia; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum Compounds; Pleural Neoplasms; Thrombocytopenia | 2011 |
Peritoneal fibrosis leading to small bowel obstruction two years after first-line intraperitoneal chemotherapy for optimally debulked ovarian cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Intestinal Obstruction; Intestine, Small; Liver Neoplasms; Membrane Proteins; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Fibrosis; Treatment Outcome | 2011 |
Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase B; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Nude; Organophosphates; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Quinazolines; Xenograft Model Antitumor Assays | 2011 |
Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Deoxycytidine; Drug Synergism; Emodin; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2011 |
Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms | 2011 |
How fast can pancreatic cancer grow? A case of pancreatic carcinoma developed within 5 months after a negative examination to the advanced stage with multiple liver and bone metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Neoplasms, Cystic, Mucinous, and Serous; Pancreatic Neoplasms; Positron-Emission Tomography; Time Factors; Tomography, X-Ray Computed | 2011 |
Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cloning, Molecular; Deoxycytidine; DNA Transposable Elements; Drug Resistance, Neoplasm; Gemcitabine; Genome-Wide Association Study; Humans; Mutagenesis; Pancreatic Neoplasms; Proteins; RNA, Long Noncoding | 2011 |
Curative surgical treatment after preoperative chemotherapy for primarily inoperable locally advanced pancreatic carcinoma: report of a case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Addition of gemcitabine at the time of sunitinib resistance in metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Pyrroles; Retrospective Studies; Sunitinib | 2011 |
Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclic N-Oxides; Cyclin-Dependent Kinases; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Replication; Drug Screening Assays, Antitumor; Gemcitabine; Histones; Humans; Immunoblotting; Indolizines; Mice; Mice, Nude; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazoles; Pyridinium Compounds; Pyrimidines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Progressive multifocal leukoencephalopathy following chemotherapy for lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Immunocompromised Host; Leukoencephalopathy, Progressive Multifocal; Lung Neoplasms; Magnetic Resonance Imaging; Male; Tomography, X-Ray Computed | 2011 |
Transient silencing of galectin-3 expression promotes both in vitro and in vivo drug-induced apoptosis of human pancreatic carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Galectin 3; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; RNA Interference; Transfection; Tumor Cells, Cultured | 2011 |
ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration.
Topics: Adenosine Triphosphate; Adult; Aged; Antimetabolites, Antineoplastic; Biopsy, Fine-Needle; Cell Survival; Cells, Cultured; Deoxycytidine; Disease-Free Survival; Endosonography; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Sensitivity and Specificity; Treatment Outcome | 2011 |
Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Deoxycytidine; Dog Diseases; Dogs; Doxorubicin; Drug Synergism; Gemcitabine; Inhibitory Concentration 50; Piperidines; Protein Kinase Inhibitors; Pyridines; Sarcoma; Thiazoles; Vinblastine | 2012 |
An acetylated polysaccharide-PTFE membrane-covered stent for the delivery of gemcitabine for treatment of gastrointestinal cancer and related stenosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Constriction, Pathologic; Deoxycytidine; Drug-Eluting Stents; Gastrointestinal Neoplasms; Gemcitabine; Male; Mice; Mice, Inbred BALB C; Polysaccharides; Polytetrafluoroethylene | 2011 |
Optimizing pemetrexed-gemcitabine combination in patients with advanced non-small cell lung cancer: a pharmacogenetic approach.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2011 |
Multidisciplinary approach and multimodal therapy in resected pancreatic cancer. Observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Colectomy; Combined Modality Therapy; Deoxycytidine; Diagnostic Imaging; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Patient Care Team; Prospective Studies; Stents; Survival Rate | 2011 |
Mestastatic gastric cancer from malignant fibrous histiocytoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dioxoles; Docetaxel; Epirubicin; Fatal Outcome; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Ifosfamide; Lung Neoplasms; Male; Soft Tissue Neoplasms; Spinal Neoplasms; Stomach Neoplasms; Taxoids; Tetrahydroisoquinolines; Thigh; Thoracic Vertebrae; Trabectedin | 2011 |
Synergistic antitumor effect of interferon-ß with gemcitabine in interferon-α-non-responsive pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Interferon-alpha; Interferon-beta; Pancreatic Neoplasms; Receptor, Interferon alpha-beta; RNA, Messenger | 2011 |
MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Humans; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured | 2011 |
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Care Facilities; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Epidemiologic Methods; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Treatment Outcome | 2011 |
Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cancer Care Facilities; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Treatment Outcome | 2011 |
Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Canada; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Practice Guidelines as Topic; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prospective Studies; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Genotype; Humans; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2011 |
Metachronous multiple adenocarcinomas of the pancreas.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gastrectomy; Gemcitabine; Hepatitis C; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Pancreatic Neoplasms | 2011 |
[Effectiveness of adjuvant chemotherapy using gemcitabine for resected pancreatic cancer].
Topics: Aged; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2011 |
[A case of complete response of gemcitabine (GEM) monotherapy-refractive liver metastatic pancreatic cancer treated with GEM+S-1 combined chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[A case of coexisting malignant mesothelioma and squamous cell carcinoma of the lung].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Neoplasms, Multiple Primary; Neovascularization, Pathologic; Tomography, X-Ray Computed | 2011 |
[Two cases of curatively resected intrahepatic cholangiocellular carcinomas through effective response to neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Tegafur; Tomography Scanners, X-Ray Computed | 2011 |
[A case of pancreatic acinar cell carcinoma with a giant liver metastasis successfully treated with combination of gemcitabine and peroral S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Acinar Cell; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Tegafur | 2011 |
RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum.
Topics: Adult; Aged; Antineoplastic Agents; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, BRCA1; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Screening Assays, Antitumor; Excipients; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Polyethylene Glycols; Stearic Acids; Time Factors | 2011 |
Histone deacetylase inhibitor MGCD0103 synergizes with gemcitabine in human pancreatic cells.
Topics: Apoptosis; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Histone Deacetylase Inhibitors; Humans; Immunoblotting; Pancreas; Pancreatic Neoplasms; Pyrimidines | 2011 |
Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Up-Regulation | 2011 |
Gemcitabine-induced acute myositis in a patient with duodenal cancer.
Topics: Deoxycytidine; Duodenal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Myositis | 2011 |
Retention of the in vitro radiosensitizing potential of gemcitabine under anoxic conditions, in p53 wild-type and p53-deficient non-small-cell lung carcinoma cells.
Topics: Analysis of Variance; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Necrosis; Radiation Tolerance; Radiation-Sensitizing Agents; Resting Phase, Cell Cycle; S Phase; Tumor Suppressor Protein p53 | 2011 |
[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Deoxycytidine; Disease Models, Animal; Disease Progression; Doxorubicin; Drug Monitoring; Gemcitabine; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Rats; Rats, Inbred ACI; Sorafenib; Survival Analysis; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2011 |
Concurrent sulforaphane and eugenol induces differential effects on human cervical cancer cells.
Topics: Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Deoxycytidine; Down-Regulation; Drug Synergism; Eugenol; Female; Gemcitabine; HeLa Cells; Humans; Interleukin-1beta; Isothiocyanates; Proto-Oncogene Proteins c-bcl-2; Sulfoxides; Thiocyanates; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2012 |
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2011 |
Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Radiotherapy; Treatment Outcome | 2011 |
Adjuvant therapy of pancreatic cancer: beyond gemcitabine. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Leucovorin; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Treatment Outcome | 2011 |
Treatment for refractory pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Novel agents in the management of pancreatic adenocarcinoma: phase I studies. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Connective Tissue Growth Factor; Deoxycytidine; Enzyme Inhibitors; Factor VIIa; Gemcitabine; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Treatment Outcome | 2011 |
Ampullary and periampullary tumors: translational efforts to meet a challenge in diagnosis and treatment. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Common Bile Duct Neoplasms; Deoxycytidine; Diagnosis, Differential; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Mutation; Pancreatic Neoplasms; Translational Research, Biomedical; Treatment Outcome | 2011 |
Overall survival of patients with advanced pancreatic cancer improved with an increase in second-line chemotherapy after gemcitabine-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Linear Models; Male; Meta-Analysis as Topic; Middle Aged; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome | 2011 |
Multidisciplinary treatment with chemotherapy, targeted drug, and high-intensity focused ultrasound in advanced pancreatic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Liver Neoplasms; Middle Aged; Pancreatic Neoplasms; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Connexin-26 is a key factor mediating gemcitabine bystander effect.
Topics: Animals; Bystander Effect; Cell Communication; Cell Line, Tumor; Cell Proliferation; Connexin 26; Connexin 43; Connexins; Deoxycytidine; Gap Junction beta-1 Protein; Gap Junctions; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Phosphorylation; RNA, Messenger | 2011 |
MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Female; Gemcitabine; Genes, p53; Humans; Mice; Mice, Nude; Mutation; Neoplasms; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Chimeric Trop2 virus-like particles: a potential immunotherapeutic approach against pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antibodies; Antigens, Neoplasm; Cancer Vaccines; Cell Adhesion Molecules; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunization; Immunotherapy, Active; Interferon-gamma; Interleukin-10; Macrophages; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Proteins; Recombinant Proteins; Survival Rate; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Transforming Growth Factor beta; Vaccines, Virus-Like Particle | 2011 |
Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Carcinoma; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Cell Aggregation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clone Cells; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Mice; MicroRNAs; Neoplasm Invasiveness; Neoplasm Proteins; NF-kappa B; Pancreatic Neoplasms; PTEN Phosphohydrolase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2011 |
Chronic thrombotic microangiopathy secondary to chemotherapy for urothelial carcinoma in a patient with a history of Wegener granulomatosis.
Topics: Antimetabolites, Antineoplastic; Chronic Disease; Deoxycytidine; Gemcitabine; Granulomatosis with Polyangiitis; Humans; Male; Middle Aged; Thrombotic Microangiopathies; Urinary Bladder Neoplasms | 2011 |
Interaction of self-assembled squalenoyl gemcitabine nanoparticles with phospholipid-cholesterol monolayers mimicking a biomembrane.
Topics: Cell Membrane; Cholesterol; Deoxycytidine; Gemcitabine; Membranes, Artificial; Models, Biological; Nanoparticles; Phosphatidylcholines; Phospholipids; Squalene | 2011 |
Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Nanomedicine; Nanoparticles; Pancreas; Pancreatic Neoplasms; Squalene | 2011 |
Genetically modified tumour vaccines producing IL-12 augment chemotherapy of HPV16-associated tumours with gemcitabine.
Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Cell Separation; Combined Modality Therapy; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gemcitabine; Genetic Therapy; Human papillomavirus 16; Interleukin-12; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Papillomavirus Infections | 2011 |
A novel method for quantification of gemcitabine and its metabolites 2',2'-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC-MS/MS: comparison with (19)F NMR spectroscopy.
Topics: Animals; Antineoplastic Agents; Calibration; Cytidine Triphosphate; Deoxycytidine; Disease Models, Animal; Floxuridine; Fluorine; Gemcitabine; Humans; Magnetic Resonance Spectroscopy; Mice; Reference Standards; Tandem Mass Spectrometry | 2011 |
[Emodin enhances antitumor effect of gemcitabine in model of SW1990 cell xenograft on athymic mouse].
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Transformation, Neoplastic; Cytochromes c; Deoxycytidine; Drug Synergism; Emodin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Are we making progress in curing advanced cervical cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Developing Countries; Female; Gemcitabine; Humans; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Uterine Cervical Neoplasms | 2011 |
[Collecting duct renal cell carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Incidental Findings; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Neoplasm Staging; Nephrectomy; Prognosis; Retrospective Studies; Sirolimus; Survival Analysis | 2011 |
Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Cycle Proteins; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Real-Time Polymerase Chain Reaction; Ribonucleotide Reductases; RNA, Neoplasm | 2011 |
[Cerebral infarction after cisplatin-gemcitabine chemotherapy: probable cause-effect].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cerebral Infarction; Cisplatin; Deoxycytidine; Electrocardiography; Gemcitabine; Humans; Intracranial Thrombosis; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Radiography; Seizures | 2012 |
Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Biomarkers, Pharmacological; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Salvage Therapy | 2011 |
Comment on "Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer," i.e., all we are saying is, give C a chance.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Injections, Intravenous; Mice; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; GATA6 Transcription Factor; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Pancreatic Neoplasms; Pharmacogenetics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
[Nephropathy following administration of angiogenesis inhibitors].
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bowman Capsule; Dacarbazine; Deoxycytidine; Disease Progression; Docetaxel; Doxorubicin; Endothelium, Vascular; Fibrosarcoma; Gemcitabine; Glomerulonephritis, Membranoproliferative; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna; Muscle Neoplasms; Podocytes; Proteinuria; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
Exploring palliative treatment outcomes in women with advanced or recurrent ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Palliative Care; Topotecan; Treatment Outcome | 2011 |
Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Gemcitabine; Hemangiosarcoma; Humans; Middle Aged; Retrospective Studies; Survival Analysis | 2012 |
Tamoxifen enhances therapeutic effects of gemcitabine on cholangiocarcinoma tumorigenesis.
Topics: Animals; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cytochromes c; Deoxycytidine; Drug Therapy, Combination; Enzyme Activation; Gemcitabine; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Tamoxifen | 2011 |
Pancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Glucocorticoids; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymyositis; Quinazolines; Radionuclide Imaging | 2011 |
UBE2M-mediated p27(Kip1) degradation in gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Chromones; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Drug Screening Assays, Antitumor; Elafin; Formazans; Gemcitabine; Gene Expression Regulation; Gene Silencing; Humans; Morpholines; RNA, Small Interfering; Spectrometry, Mass, Electrospray Ionization; Tetrazolium Salts; Ubiquitins; Urinary Bladder Neoplasms | 2011 |
Occupational exposure to antineoplastic drugs in four Italian health care settings.
Topics: Antineoplastic Agents; Cyclophosphamide; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Italy; Nursing Staff, Hospital; Occupational Exposure; Personnel, Hospital; Pharmacy Service, Hospital; Surveys and Questionnaires | 2012 |
A case of progressive digital ischemia after early withdrawal of gemcitabine and S-1 in a patient with systemic sclerosis.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Administration Schedule; Drug Combinations; Fatal Outcome; Fingers; Gangrene; Gemcitabine; Humans; Ischemia; Male; Necrosis; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Raynaud Disease; Scleroderma, Systemic; Tegafur; Toes | 2011 |
Concomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Retrospective Studies | 2011 |
Angiotensin-converting enzyme 2 acts as a potential molecular target for pancreatic cancer therapy.
Topics: Adenoviridae; Angiotensin-Converting Enzyme 2; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Adhesion; Cell Movement; Cell Proliferation; Colony-Forming Units Assay; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Hypoxia; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Peptidyl-Dipeptidase A; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Endonucleases; Etoposide; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinolines; Receptor, Fibroblast Growth Factor, Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
Topics: Animals; Biomarkers; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Gemcitabine; Histones; Humans; Mice; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Thiophenes; Transplantation, Heterologous; Urea; Xenograft Model Antitumor Assays | 2011 |
EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer.
Topics: Antibodies, Monoclonal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Compounding; ErbB Receptors; Gemcitabine; Humans; Lactic Acid; Nanocapsules; Pancreatic Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Treatment Outcome | 2011 |
Acute transverse myelopathy probably related to intravenous gemcitabine plus cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Myelitis, Transverse; Neoplasms, Squamous Cell | 2011 |
Gemcitabine combined with cisplatin as neoadjuvant chemotherapy in stage IB-IIIA non-small cell lung cancer.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Survival Analysis; Tomography, X-Ray Computed; Young Adult | 2011 |
Effects and mechanisms of the combination of suberoylanilide hydroxamic acid and bortezomib on the anticancer property of gemcitabine in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Vorinostat; Xenograft Model Antitumor Assays | 2011 |
Increased expression of transcription factor TFAP2α correlates with chemosensitivity in advanced bladder cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Proliferation; Chlorocebus aethiops; Cisplatin; COS Cells; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Neoplasm Staging; Protein Isoforms; Survival Analysis; Transcription Factor AP-2; Urinary Bladder Neoplasms | 2011 |
Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Carriers; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Lymph Nodes; Lymphatic Metastasis; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Microscopy, Electron, Transmission; Nanotubes, Carbon; Necrosis; Pancreatic Neoplasms | 2011 |
(18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.
Topics: Adenosine Triphosphate; Animals; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Basigin; Cell Death; Cell Line, Tumor; Contrast Media; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Injections, Intravenous; Mice; Mice, SCID; Multimodal Imaging; Pancreatic Neoplasms; Positron-Emission Tomography; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
[Relations between RRM1 protein expression levels and effects of gemcitabine and cisplatin chemotherapy in advanced non-small cell lung cancer patients].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Doxorubicin; Endonucleases; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Polymorphism, Single Nucleotide; Topotecan | 2011 |
Multicystic mesothelioma of the pericardium.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Diagnosis, Differential; Fatal Outcome; Gemcitabine; Humans; Immunohistochemistry; Liver; Lung; Male; Mediastinum; Mesothelioma, Cystic; Middle Aged; Pericardium; Peritoneal Neoplasms; Pleural Cavity; Tomography, X-Ray Computed | 2011 |
Novel approaches to treatment of leiomyosarcomas.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Doxorubicin; Enzyme Inhibitors; Gemcitabine; Humans; Ifosfamide; Leiomyosarcoma; Molecular Targeted Therapy; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Taxoids | 2011 |
Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells.
Topics: Adenoviridae; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genetic Therapy; Green Fluorescent Proteins; Hepatocyte Growth Factor; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transgenes | 2011 |
Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Radiotherapy Dosage; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids | 2011 |
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma.
Topics: Age Factors; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Time Factors | 2011 |
Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cannabinoids; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Endoplasmic Reticulum; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Reactive Oxygen Species; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Stress, Physiological; Transcription, Genetic; Transplantation, Heterologous | 2011 |
Tubulin, BRCA1, ERCC1, Abraxas, RAP80 mRNA expression, p53/p21 immunohistochemistry and clinical outcome in patients with advanced non small-cell lung cancer receiving first-line platinum-gemcitabine chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Disease Progression; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Histone Chaperones; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nuclear Proteins; Platinum; Predictive Value of Tests; RNA, Messenger; Treatment Outcome; Tubulin; Tumor Suppressor Protein p53 | 2011 |
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2011 |
Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and anti-VEGF treatment.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Blood Platelets; Bone Marrow; Cell Movement; Chemokine CXCL12; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Monocytes; Neoadjuvant Therapy; Neovascularization, Physiologic; Pancreatic Neoplasms; Stem Cells; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Fetal Proteins; Gemcitabine; Gene Silencing; High-Throughput Screening Assays; Humans; Pancreatic Neoplasms; Protein-Tyrosine Kinases; RNA, Small Interfering | 2011 |
Urothelial cancer cell response to combination therapy of gemcitabine and TRAIL.
Topics: Apoptosis; Carcinoma, Transitional Cell; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms | 2011 |
Treatment of borderline cases for curative resection of biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Brachytherapy; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
[Role of nuclear factor-kappaB on emodin-induced sensitization of pancreatic cancer to gemcitabine].
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Emodin; Female; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Repressor Proteins; Survivin; Tumor Burden | 2011 |
Silencing of high mobility group A1 enhances gemcitabine chemosensitivity of lung adenocarcinoma cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Calcium-Transporting ATPases; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Genetic Vectors; HMGA Proteins; Humans; Lentivirus; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2011 |
E1A, E1B double-restricted adenovirus enhances the cytotoxicity and antitumor activity of gemcitabine to renal cell carcinoma.
Topics: Adenoviridae; Adenovirus E1A Proteins; Adenovirus E1B Proteins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Coxsackie and Adenovirus Receptor-Like Membrane Protein; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Oncolytic Virotherapy; Receptors, Virus; Xenograft Model Antitumor Assays | 2011 |
Targeting of pancreatic and prostate cancer stem cell characteristics by Crambe crambe marine sponge extract.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cells, Cultured; Crambe Sponge; Deoxycytidine; Endothelial Cells; Female; Fibroblasts; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Prostatic Neoplasms | 2012 |
Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate | 2011 |
Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chitosan; Deoxycytidine; Drug Delivery Systems; Gemcitabine; HEK293 Cells; Humans; Nanoparticles; Pancreas; Pancreatic Neoplasms; Trastuzumab | 2011 |
AACR highlights: promise for treating pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Anilides; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Clinical Trials as Topic; Delayed Diagnosis; Deoxycytidine; Disease Progression; Gemcitabine; Genes, ras; Humans; Mice; Molecular Targeted Therapy; Mutation; Off-Label Use; Paclitaxel; Pancreatic Neoplasms; Pyridines; Signal Transduction; Transcription Factors; United States | 2011 |
Modulation in concentrative nucleoside transporters-mediated intestinal absorption of mizoribine, an immunosuppressive agent, in lipopolysaccharide-treated rats.
Topics: Animals; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antiviral Agents; Bile; Biological Availability; Cephalexin; Cholestasis; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Immunosuppressive Agents; In Vitro Techniques; Inflammation; Intestinal Absorption; Lipopolysaccharides; Male; Nucleoside Transport Proteins; Rats; Rats, Sprague-Dawley; Ribavirin; Ribonucleosides | 2011 |
Reversible posterior leukoencephalopathy syndrome associated with concurrent bevacizumab, gemcitabine, and oxaliplatin for cholangiocarcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Hypertension; Magnetic Resonance Imaging; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Posterior Leukoencephalopathy Syndrome; Prognosis; Seizures | 2012 |
Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Interactions; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interferon alpha-2; Interferon-alpha; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Repressor Proteins; Trans-Activators; Valproic Acid | 2011 |
Raman imaging of single living cells: probing effects of non-cytotoxic doses of an anti-cancer drug.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Intracellular Space; Molecular Imaging; Principal Component Analysis; Proteins; Quartz; RNA; Single-Cell Analysis; Spectrum Analysis, Raman | 2011 |
Identification of genes associated to 2',2'-difluorodeoxycytidine resistance in HeLa cells with a lentiviral short-hairpin RNA library.
Topics: Antimetabolites, Antineoplastic; Base Sequence; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Library; HeLa Cells; Humans; RNA, Small Interfering; RNA, Viral | 2011 |
Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Biphenyl Compounds; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Nitrophenols; Piperazines; Protein Binding; Proto-Oncogene Proteins c-bcl-2; RNA Interference; Sulfonamides; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2011 |
[A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Salvage Therapy; Tegafur | 2011 |
β2-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction.
Topics: Adrenergic beta-2 Receptor Antagonists; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Propanolamines; Proto-Oncogene Proteins c-bcl-2; Receptors, Adrenergic, beta-2 | 2011 |
Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Central Nervous System Neoplasms; Cerebellar Neoplasms; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neuroblastoma; Organoplatinum Compounds; Osteosarcoma; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2011 |
[Relationship between the protein expression of ERCC1, BRCA, β-tubulin and K-ras and the efficacy and prognosis in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; ras Proteins; Remission Induction; Survival Rate; Taxoids; Tubulin; Vinblastine; Vinorelbine | 2011 |
[The prognostic significance of human equilibrative nucleoside transporter1 (hENT1) expression in metastatic bladder cancer patients treated with gemcitabine-cisplatin based combination chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms | 2011 |
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Gene Deletion; Glutathione Transferase; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies | 2012 |
Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.
Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Death; Cell Line, Tumor; Cytotoxicity, Immunologic; Deoxycytidine; DNA Damage; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression; Histocompatibility Antigens Class I; Humans; Kaplan-Meier Estimate; Killer Cells, Natural; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Uric Acid; Xanthine Dehydrogenase | 2011 |
Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Topics: Animals; Antigen Presentation; Antimetabolites, Antineoplastic; Cell Growth Processes; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Deoxycytidine; Gemcitabine; Gene Expression; Genes, T-Cell Receptor; HLA-A24 Antigen; Humans; Mice; Mice, SCID; Pancreatic Neoplasms; RNA, Messenger; T-Lymphocytes; T-Lymphocytes, Cytotoxic; Transduction, Genetic; Up-Regulation; WT1 Proteins | 2011 |
Gemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluation.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chitosan; Deoxycytidine; Dextran Sulfate; Drug Carriers; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Microscopy, Electron, Scanning; Microspheres; Particle Size | 2011 |
[Effect of emodin combined gemcitabine on the growth and apoptosis of pancreatic cancer cell line BxPC-3 in vitro].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Emodin; Gemcitabine; Humans; Pancreatic Neoplasms | 2011 |
Clusterin confers gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Clusterin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Cisplatin; Deoxycytidine; Gemcitabine; Germ-Line Mutation; Heterozygote; Humans; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2011 |
A novel 3-dimensional culture system uncovers growth stimulatory actions by TGFβ in pancreatic cancer cells.
Topics: Animals; Benzamides; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cisplatin; Culture Media; Deoxycytidine; Dioxoles; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gemcitabine; Humans; Mice; Mice, Transgenic; Pancreatic Neoplasms; Quinazolines; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Transforming Growth Factor beta1; Tumor Microenvironment | 2011 |
Experimental study of the anticancer effect of gemcitabine combined with sirolimus on chemically induced urothelial lesions.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Butylhydroxybutylnitrosamine; Deoxycytidine; Gemcitabine; Male; Mice; Mice, Inbred ICR; Neoplasm Invasiveness; Sirolimus; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Off-label use of oxaliplatin in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Off-Label Use; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Skin Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Pancreatic Neoplasms; RNA, Messenger | 2011 |
Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chi-Square Distribution; Cholangiocarcinoma; Combined Modality Therapy; Contrast Media; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Hepatic Duct, Common; Humans; Klatskin Tumor; Lymphatic Metastasis; Male; Middle Aged; Radiosurgery; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer.
Topics: Antimetabolites, Antineoplastic; Chi-Square Distribution; Combined Modality Therapy; Contrast Media; Deoxycytidine; Dose Fractionation, Radiation; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiography, Interventional; Radiotherapy, Conformal; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2011 |
Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.
Topics: Aged; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crizotinib; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Amplification; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Treatment Outcome | 2011 |
Lack of any relationship between chemotherapy toxicity in non-small cell lung cancer cases and polymorphisms in XRCC1 codon 399 or XPD codon 751.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Codon; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Survival Rate; Taxoids; Treatment Outcome; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2011 |
Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Blotting, Western; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Coatomer Protein; Deoxycytidine; Fluorouracil; Gemcitabine; Golgi Apparatus; Humans; Lysosomal Membrane Proteins; Lysosomes; Magnetic Resonance Spectroscopy; Male; Microscopy, Electron, Transmission; Microscopy, Fluorescence; Omeprazole; Pancreatic Neoplasms; Ultracentrifugation | 2011 |
Regulation of chemosensitivity and migration by clusterin in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Clusterin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Neoplasm Metastasis; RNA Interference; Taxoids; Transcription, Genetic | 2012 |
Cyclopamine reverts acquired chemoresistance and down-regulates cancer stem cell markers in pancreatic cancer cell lines.
Topics: AC133 Antigen; Antigens, CD; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Glycoproteins; Hedgehog Proteins; Humans; Hyaluronan Receptors; Neoplasm Proteins; Neoplastic Stem Cells; Oncogene Proteins; Pancreatic Neoplasms; Patched Receptors; Peptides; Receptors, Cell Surface; Receptors, G-Protein-Coupled; RNA, Messenger; Signal Transduction; Smoothened Receptor; Trans-Activators; Tumor Cells, Cultured; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2011 |
Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytokines; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Humans; Midkine; Pancreatic Neoplasms; Receptor, Notch2; RNA Interference; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2011 |
Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Deoxycytidine; DNA Repair; ErbB Receptors; Female; Gemcitabine; Glutathione; Glutathione Peroxidase; Humans; Lung Neoplasms; Male; Platinum; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-raf; Taxoids | 2011 |
A man with a testicular mass and a colon stenosis. Diagnosis: Metastatic pancreatic adenocarcinoma to the gonads.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Colonic Diseases; Colonoscopy; Constriction, Pathologic; Deoxycytidine; Endoscopy, Digestive System; Gemcitabine; Humans; Immunohistochemistry; Intestinal Obstruction; Krukenberg Tumor; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Testicular Neoplasms; Tomography, X-Ray Computed | 2011 |
Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cohort Studies; Deoxycytidine; DNA, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Nucleoside-Phosphate Kinase; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2011 |
[Gemcitabine in RRM1-negative advanced refractory non-small cell lung cancer (NSCLC): a case report].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2011 |
In vitro screening of synergistic ascorbate-drug combinations for the treatment of malignant mesothelioma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Catechin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coloring Agents; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; L-Lactate Dehydrogenase; Lung Neoplasms; Mesothelioma; Neutral Red | 2011 |
Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27.
Topics: Adenocarcinoma, Clear Cell; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Deoxycytidine; Doxorubicin; Enzyme Activation; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation | 2011 |
Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Neoplasm Staging; Platinum Compounds; Polymorphism, Genetic; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; ROC Curve | 2012 |
Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.
Topics: Adult; Aged; Aged, 80 and over; CA-19-9 Antigen; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiosurgery; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Retrospective Studies | 2011 |
Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Muscle Neoplasms; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
Triphendiol (NV-196), development of a novel therapy for pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Flow Cytometry; Gemcitabine; Humans; Isoflavones; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Intravenous fluid therapy successfully prevents renal injury by gemcitabine in patients with pancreatic cancer.
Topics: Acute Kidney Injury; Antineoplastic Agents; Crystallization; Deoxycytidine; Fluid Therapy; Gemcitabine; Humans; Infusions, Intravenous; Pancreatic Neoplasms | 2011 |
Cancer stem-like cells enriched in Panc-1 spheres possess increased migration ability and resistance to gemcitabine.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cadherins; CD24 Antigen; Cell Line; Cell Movement; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Hyaluronan Receptors; Neoplasm Proteins; Neoplastic Stem Cells; Pancreatic Neoplasms; Polycomb Repressive Complex 1; Vimentin | 2011 |
Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy.
Topics: Adult; Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Repair; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Polymorphism, Single Nucleotide; Proportional Hazards Models; Regression Analysis; Survival Rate; Taxoids | 2012 |
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.
Topics: Adenocarcinoma; Animals; CD11b Antigen; Coculture Techniques; Colonic Neoplasms; Deoxycytidine; Female; Gemcitabine; Interferon gamma Receptor; Interferon Type I; Interferon-gamma; Interferons; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, Knockout; Myeloid Cells; Neoplasm Proteins; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase Type II; Phosphorylation; Protein Processing, Post-Translational; Receptors, Cell Surface; Receptors, Interferon; Recombinant Proteins; Spleen; STAT1 Transcription Factor; Tumor Escape | 2011 |
Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Sensitivity and Specificity; Survival Rate; Taxoids; Treatment Outcome; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2011 |
[Postoperative adjuvant treatment for pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Postoperative Period | 2011 |
A prognostic model to predict clinical outcomes with first-line gemcitabine-based chemotherapy in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Ascites; Biomarkers, Tumor; C-Reactive Protein; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; ROC Curve; Serum Albumin; Survival Rate; Treatment Outcome | 2011 |
Wipe sampling procedure coupled to LC-MS/MS analysis for the simultaneous determination of 10 cytotoxic drugs on different surfaces.
Topics: Antineoplastic Agents; Camptothecin; Chromatography, Liquid; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Epirubicin; Etoposide; Gemcitabine; Ifosfamide; Irinotecan; Methotrexate; Organophosphorus Compounds; Surface Properties; Tandem Mass Spectrometry; Vincristine | 2012 |
[Therapeutic perspectives of cutaneous T-cell lymphoma].
Topics: Antineoplastic Agents; Bexarotene; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Interferons; Lymphoma, T-Cell, Cutaneous; Retinoids; Skin Neoplasms; Tetrahydronaphthalenes | 2011 |
Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Retrospective Studies; Salvage Therapy; Testicular Neoplasms; Treatment Outcome; Young Adult | 2011 |
Different combination schedules of gemcitabine with endostar affect antitumor efficacy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Deoxycytidine; Drug Administration Schedule; Endostatins; Gemcitabine; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Recombinant Proteins; Vascular Endothelial Growth Factor A | 2012 |
Subamolide A, a component isolated from Cinnamomum subavenium, induces apoptosis mediated by mitochondria-dependent, p53 and ERK1/2 pathways in human urothelial carcinoma cell line NTUB1.
Topics: 4-Butyrolactone; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Shape; Cell Survival; Cinnamomum; Cisplatin; Cytochromes c; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Membrane Potential, Mitochondrial; Mitochondria; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Plant Preparations; Plant Stems; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Time Factors; Tumor Suppressor Protein p53; Urologic Neoplasms; Urothelium | 2011 |
Successful management of metastatic urothelial carcinoma with gemcitabine and Paclitaxel chemotherapy in a hemodialysis patient.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Paclitaxel; Renal Dialysis; Time Factors; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Urothelium | 2011 |
Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cancer Vaccines; CD4-Positive T-Lymphocytes; Deoxycytidine; Female; Gemcitabine; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasms; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory | 2011 |
Combination of gemcitabine and doxorubicin in rapidly progressive metastatic renal cell carcinoma and/or sarcomatoid renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Biphenyl Compounds; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; G1 Phase; Gemcitabine; Humans; Lignans; NF-kappa B; Pancreatic Neoplasms; Protein Transport | 2011 |
Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Urinary Bladder Neoplasms | 2012 |
Circulating tumor cells count and characterization in a male breast cancer patient.
Topics: Breast Neoplasms, Male; Carboplatin; Carcinoma, Ductal, Breast; Cell Count; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2011 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Preoperative chemotherapy for bladder cancer: a standard waits to be optimally deployed.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Urinary Bladder Neoplasms | 2012 |
Response of recurrent urachal cancer to gemcitabine and cisplatin therapy: a case report and literature review.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Pelvic Neoplasms; Urinary Bladder Neoplasms | 2011 |
[Advanced gallbladder cancer that showed complete response to gemcitabine plus S-1 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Tegafur | 2011 |
Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer.
Topics: Animals; Animals, Genetically Modified; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Mice; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras) | 2011 |
Feasibility of intravenous gemcitabine and an intraperitoneal platinum agent in the treatment of ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Ovarian Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2011 |
Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Humans; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Prognosis; Smad4 Protein; Transplantation, Heterologous; Treatment Outcome | 2011 |
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Gemcitabine; Gene Silencing; Humans; Irinotecan; MAP Kinase Kinase Kinases; Mice; Mice, Nude; NF-kappa B; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Signal Transduction; Transforming Growth Factor beta; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; Emodin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Tumor Burden; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2011 |
Expression of CD147 in advanced non-small cell lung cancer correlated with cisplatin-based chemotherapy resistance.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Basigin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Thalidomide; Vascular Endothelial Growth Factor A | 2012 |
The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.
Topics: Acetylation; Apoptosis; Apoptosis Regulatory Proteins; Benzamides; Biphenyl Compounds; Boronic Acids; Bortezomib; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Hodgkin Disease; Humans; Indoles; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Nitrophenols; Piperazines; Protein Processing, Post-Translational; Pyrazines; Pyridines; Pyrroles; Sulfonamides; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclic N-Oxides; Cyclin-Dependent Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Indolizines; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Pyridinium Compounds; ral GTP-Binding Proteins; Receptors, Notch; Retinoblastoma Protein; Signal Transduction; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2011 |
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.
Topics: Animals; Antineoplastic Agents; Cisplatin; Deoxycytidine; DNA Damage; DNA Repair; Epithelial Cells; Female; Gemcitabine; Genes, BRCA1; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice | 2011 |
Cost-effectiveness of modern radiotherapy techniques in locally advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Radiosurgery; Radiotherapy; Radiotherapy, Intensity-Modulated; Severity of Illness Index; Survival Rate; Treatment Outcome | 2012 |
Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Capecitabine; Chemotherapy, Adjuvant; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Radiotherapy, Adjuvant; Survival Rate; Tegafur; Treatment Outcome; Uracil | 2011 |
In vitro and in vivo anti-tumor effects of gemcitabine loaded with a new drug delivery system.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Materials Testing; Nanocapsules; Rats; Treatment Outcome | 2011 |
A conjugate of gemcitabine with bisphosphonate (Gem/BP) shows potential as a targeted bone-specific therapeutic agent in an animal model of human breast cancer bone metastases.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Breast Neoplasms; Calcium; Creatinine; Deoxycytidine; Diphosphonates; Disease Models, Animal; Drug Delivery Systems; Female; Gemcitabine; Humans; Injections, Intralesional; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Technetium; Tumor Cells, Cultured | 2011 |
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Records; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure; Treatment Outcome | 2011 |
Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Fluorodeoxyglucose F18; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Positron-Emission Tomography; Prospective Studies; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma; Chemotherapy, Adjuvant; Dendritic Cells; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Killer Cells, Lymphokine-Activated; Male; Middle Aged; Multimodal Imaging; Oxonic Acid; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Aerosolized gemcitabine in patients with carcinoma of the lung: feasibility and safety study.
Topics: Aerosols; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Feasibility Studies; Female; Forced Expiratory Volume; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged | 2011 |
Safety evaluation of self-expanding metallic biliary stents eluting gemcitabine in a porcine model.
Topics: Animals; Antimetabolites, Antineoplastic; Bile Ducts; Biomarkers; Decompression; Deoxycytidine; Drug-Eluting Stents; Equipment Safety; Gemcitabine; Materials Testing; Metals; Models, Animal; Palliative Care; Prosthesis Design; Risk Assessment; Solubility; Swine; Time Factors | 2012 |
Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Pancreatic Neoplasms; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2011 |
Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Ceramides; Deoxycytidine; Drug Carriers; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Gemcitabine; Glucosyltransferases; Humans; Liposomes; MAP Kinase Signaling System; Mice; Mice, Nude; Morpholines; Nanoparticles; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Xenograft Model Antitumor Assays | 2011 |
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Synergism; Epigenomics; Gemcitabine; Gene Expression Profiling; Gene Regulatory Networks; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Microarray Analysis; Valproic Acid | 2011 |
[Investigation of gemcitabine plus lomustine treatment in mice with transplantable lymphosarcoma LIO-1].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Lomustine; Lymphoma, Non-Hodgkin; Maximum Tolerated Dose; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Random Allocation | 2011 |
Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review.
Topics: Adenocarcinoma; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pancreatic Neoplasms; Radiotherapy; Thigh | 2012 |
New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cancer Vaccines; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Ipilimumab; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Pancreatic Neoplasms; Risk Factors | 2011 |
Combination chemotherapy for older adults with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Paclitaxel; Vinblastine; Vinorelbine | 2011 |
The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
Topics: Antineoplastic Agents; Biological Transport; Deamination; Deoxycytidine; Deoxycytidine Kinase; Floxuridine; Gemcitabine; HeLa Cells; Humans; Inactivation, Metabolic; Phosphorylation; Polyphosphates; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
[Granulocyte colony stimulating factor-producing spindle cell renal cell carcinoma successfully treated by chemotherapy consisting of gemcitabine and doxorubicin].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Middle Aged | 2011 |
Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer.
Topics: Adenoviruses, Human; Animals; Antibodies, Neutralizing; Capsid; Capsid Proteins; Cell Line, Tumor; Combined Modality Therapy; Cricetinae; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Silica Gel; Transfection | 2012 |
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Topics: Adenocarcinoma; Adenoviruses, Human; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cytopathogenic Effect, Viral; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Deletion; Gene Expression Regulation, Viral; Humans; Kaplan-Meier Estimate; Mice; Mice, Inbred C57BL; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Receptors, Virus; Retinoblastoma Protein; Virus Replication; Xenograft Model Antitumor Assays | 2011 |
CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Benzodiazepinones; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Isoforms; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Receptor, Cholecystokinin B; Signal Transduction; Vascular Endothelial Growth Factor A | 2011 |
Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Ethnicity; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Review Literature as Topic | 2011 |
A novel effective therapy for refractory angiosarcoma of the face and scalp.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Face; Female; Gemcitabine; Hemangiosarcoma; Humans; Methotrexate; Paclitaxel; Radiotherapy; Salvage Therapy; Scalp; Skin Neoplasms | 2011 |
Antitumour activity of sunitinib in combination with gemcitabine in experimental pancreatic cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
The C-terminal region of Bfl-1 sensitizes non-small cell lung cancer to gemcitabine-induced apoptosis by suppressing NF-κB activity and down-regulating Bfl-1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Minor Histocompatibility Antigens; NF-kappa B; Protein Structure, Tertiary; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2011 |
HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Drug Synergism; G1 Phase; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lymphoma, Mantle-Cell; Mice; Proto-Oncogene Proteins c-mdm2; Ribonucleoside Diphosphate Reductase; S Phase; Spiro Compounds; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Hospitalization; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Retrospective Studies; Taxoids; Thrombocytopenia; Treatment Failure | 2012 |
Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.
Topics: Animals; Cell Line, Tumor; Chemistry, Pharmaceutical; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Humans; Mice; Mice, Nude; Nanoparticles; Random Allocation; Ribonucleoside Diphosphate Reductase; Stearates; Tumor Suppressor Proteins | 2012 |
Prognostic value of lymph-node dissection in patients undergoing radical cystectomy following previous oncological treatment for bladder cancer.
Topics: Abdomen; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2011 |
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
c-Met is a marker of pancreatic cancer stem cells and therapeutic target.
Topics: Adenocarcinoma; Anilides; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Therapy, Combination; Flow Cytometry; Gemcitabine; Humans; Immunoblotting; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyridines | 2011 |
The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Salvage Therapy | 2011 |
Gene set analysis of purine and pyrimidine antimetabolites cancer therapies.
Topics: Antimetabolites; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Genes, Neoplasm; Humans; Neoplasms; Phenotype; Purines; Pyrimidines; Reproducibility of Results; Thioguanine | 2011 |
EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Epidermal Growth Factor; ErbB Receptors; Gemcitabine; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Nanoparticles; Neoplasms; Ovalbumin; Tumor Burden | 2012 |
Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Combined Modality Therapy; Cytotoxicity, Immunologic; Deoxycytidine; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class I; Humans; In Vitro Techniques; Interleukin-2; Liver Neoplasms; Monocytes, Activated Killer; Muromonab-CD3; NK Cell Lectin-Like Receptor Subfamily K; Recombinant Proteins | 2011 |
Inactivation of mirk/dyrk1b kinase targets quiescent pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cisplatin; Deoxycytidine; DNA Damage; Drug Synergism; Dyrk Kinases; Exons; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Resting Phase, Cell Cycle | 2011 |
Acute digital ischemia complicating gemcitabine and carboplatin combination chemotherapy for ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Hand; Humans; Ischemia; Middle Aged; Ovarian Neoplasms | 2011 |
Modulation of the ribonucleotide reductase M1-gemcitabine interaction in vivo by N-ethylmaleimide.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Pharmacological; Catalytic Domain; Cell Line, Tumor; Deoxycytidine; Drug Design; Drug Resistance, Neoplasm; Enzyme Inhibitors; Ethylmaleimide; Gemcitabine; Humans; Mice; Mice, Inbred Strains; Protein Conformation; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2011 |
Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mass Spectrometry; Pancreatic Neoplasms; Protein Interaction Mapping; Proteome; Proteomics; Two-Dimensional Difference Gel Electrophoresis | 2011 |
FOLFIRINOX: a small step or a great leap forward?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2011 |
Livedo reticularis as an initial clinical manifestation of gemcitabine-induced hemolytic uremic syndrome.
Topics: Antineoplastic Agents; Deoxycytidine; Drug Eruptions; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Livedo Reticularis; Middle Aged; Pancreatic Neoplasms | 2012 |
Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models | 2012 |
Sarcomatoid peritoneal malignant mesothelioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Calbindin 2; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Mesothelioma; Peritoneal Neoplasms; Peritoneum; S100 Calcium Binding Protein G | 2011 |
Hypoxia-inducible factor-1α expression and gemcitabine chemotherapy for pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kaplan-Meier Estimate; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Sequence Analysis, DNA | 2011 |
Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
Topics: Antigens, CD; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Hydroxyurea; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleotide Reductases; RNA Interference; Snail Family Transcription Factors; Transcription Factors; Vimentin; Zinc Finger E-box-Binding Homeobox 1 | 2012 |
Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Plant Extracts; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Eugenol enhances the chemotherapeutic potential of gemcitabine and induces anticarcinogenic and anti-inflammatory activity in human cervical cancer cells.
Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Eugenol; Female; Gemcitabine; HeLa Cells; Humans; Uterine Cervical Neoplasms | 2011 |
Gemcitabine in elderly patients with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Induction of caspase mediated apoptosis and down-regulation of nuclear factor-κB and Akt signaling are involved in the synergistic antitumor effect of gemcitabine and the histone deacetylase inhibitor trichostatin A in human bladder cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; NF-kappa B; Proto-Oncogene Proteins c-akt; Signal Transduction; Urinary Bladder Neoplasms | 2011 |
Ultraviolet enhances the sensitivity of pancreatic cancer cells to gemcitabine by activation of 5' AMP-activated protein kinase.
Topics: AMP-Activated Protein Kinases; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Pancreatic Neoplasms; Ultraviolet Rays | 2011 |
MicroRNA miR-548d is a superior regulator in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Computational Biology; Databases, Genetic; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; MicroRNAs; Pancreatic Neoplasms; Transfection | 2012 |
Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Cell Movement; Cell Proliferation; Deoxycytidine; Diphosphonates; Drug Therapy, Combination; Female; Gemcitabine; Humans; Imidazoles; Immunoenzyme Techniques; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tumor Cells, Cultured; Zoledronic Acid | 2012 |
Implications of delayed initiation of radiotherapy: accelerated repopulation after induction chemotherapy for stage III non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Time Factors; Tomography, X-Ray Computed | 2011 |
Enhanced efficacy of gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrative nucleoside transporter 1.
Topics: Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Indoles; Pancreatic Neoplasms; RNA, Messenger; Treatment Outcome | 2011 |
Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.
Topics: Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrimidines; Pyrroles; RNA, Messenger | 2011 |
Locally advanced pancreatic cancer: where should we go from here?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2011 |
Vitamin E δ-tocotrienol augments the antitumor activity of gemcitabine and suppresses constitutive NF-κB activation in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Carcinoma; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, SCID; Models, Biological; NF-kappa B; Pancreatic Neoplasms; Up-Regulation; Vitamin E; Xenograft Model Antitumor Assays | 2011 |
Liver metastases of pancreatic cancer: role of repetitive transarterial chemoembolization (TACE) on tumor response and survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Pyridines; Retrospective Studies; Treatment Outcome; Tumor Burden | 2011 |
Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemoembolization, Therapeutic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Survival Rate; Treatment Outcome | 2012 |
Surviving cells after treatment with gemcitabine or 5-fluorouracil for the study of de novo resistance of pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2012 |
Dickkopf3 overexpression inhibits pancreatic cancer cell growth in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; beta Catenin; Cell Line, Tumor; Cell Proliferation; Chemokines; Deoxycytidine; DNA Methylation; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; RNA, Messenger | 2011 |
ZSTK474, a PI3K inhibitor, suppresses proliferation and sensitizes human pancreatic adenocarcinoma cells to gemcitabine.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Triazines | 2012 |
Phosphorylation status of heat shock protein 27 plays a key role in gemcitabine-induced apoptosis of pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Intracellular Signaling Peptides and Proteins; Molecular Chaperones; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Serine | 2011 |
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.
Topics: Antineoplastic Agents; Cell Line; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Dipyridamole; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia; Nucleoside Transport Proteins; Nucleotidases | 2012 |
Synchronous bilateral urothelial cancer in a kidney recipient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Kidney Transplantation; Male; Neoplasms, Multiple Primary; Ureteral Neoplasms; Urothelium | 2011 |
Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Heat-Shock Proteins; Heat-Shock Response; HSP27 Heat-Shock Proteins; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Chaperones; Multivariate Analysis; Pancreas; Prognosis; Tissue Array Analysis | 2012 |
High-grade invasive urothelial carcinoma with focal plasmacytoid differentiation successfully treated by transurethral resection followed by chemoradiotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Organoplatinum Compounds; Urinary Bladder Neoplasms; Urothelium | 2011 |
OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Synergism; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Molecular Chaperones; Oligonucleotides, Antisense; Pancreatic Neoplasms; Phosphorylation; Prognosis; Xenograft Model Antitumor Assays | 2011 |
Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Tumor Burden | 2012 |
The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Enzyme Inhibitors; Female; Fibroblasts; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Imidazoles; Mice; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinolines; RNA-Binding Proteins; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases | 2012 |
Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatic Neoplasms; Recurrence; Treatment Outcome | 2012 |
PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; fas Receptor; Gemcitabine; Histone Deacetylases; Humans; Ligands; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Pioglitazone; PPAR gamma; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; Rosiglitazone; Thiazolidinediones; Valproic Acid; Xenograft Model Antitumor Assays | 2012 |
Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Coculture Techniques; Cytokines; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Macrophages; Pancreatic Neoplasms; Phagocytosis; Phenylbutyrates | 2012 |
Factors predicting the appearance of neutropenia in patients with advanced pancreatic cancer undergoing gemcitabine therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neutropenia; Odds Ratio; Pancreatic Neoplasms; Risk Assessment; Risk Factors; Severity of Illness Index; Treatment Outcome | 2012 |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Republic of Korea; Treatment Outcome | 2011 |
A polymeric nanoparticle encapsulated small-molecule inhibitor of Hedgehog signaling (NanoHHI) bypasses secondary mutational resistance to Smoothened antagonists.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Hedgehog Proteins; Humans; Male; Medulloblastoma; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Patched Receptors; Patched-1 Receptor; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Transcription Factors; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2012 |
Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Glycoproteins; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Pyrans; Xenograft Model Antitumor Assays | 2011 |
HMGA-targeted phosphorothioate DNA aptamers increase sensitivity to gemcitabine chemotherapy in human pancreatic cancer cell lines.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aptamers, Nucleotide; Cell Line, Tumor; Deoxycytidine; Gemcitabine; HMGA Proteins; Humans; Pancreatic Neoplasms; Phosphorothioate Oligonucleotides; Transfection; Xenograft Model Antitumor Assays | 2012 |
The relationship between treatment time of gemcitabine and development of hematologic toxicity in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Circadian Rhythm; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Leukocyte Count; Male; Middle Aged; Neoplasms; Odds Ratio; Retrospective Studies | 2011 |
Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; Thiazoles; Urea; Xenograft Model Antitumor Assays | 2012 |
[MicroRNA expression pattern in intraductal papillary mucinous neoplasm].
Topics: Adenocarcinoma, Mucinous; Adenoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Papillary; Cell Line; Deoxycytidine; Female; Gemcitabine; Humans; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Up-Regulation | 2011 |
SMAC mimetic (JP1201) sensitizes non-small cell lung cancers to multiple chemotherapy agents in an IAP-dependent but TNF-α-independent manner.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondrial Proteins; Molecular Mimicry; Paclitaxel; RNA Interference; Tumor Burden; Tumor Necrosis Factor-alpha; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2011 |
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Proportional Hazards Models; Retrospective Studies; Xeroderma Pigmentosum Group D Protein | 2011 |
Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Chondroitin Sulfates; Deoxycytidine; Drug Synergism; Enzyme Activation; Gemcitabine; Humans; Mitomycin; Urinary Bladder Neoplasms | 2012 |
Metastatic clear cell adenocarcinoma of the urethra in a male patient: report of a case.
Topics: Adenocarcinoma, Clear Cell; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Treatment Outcome; Urethral Neoplasms | 2012 |
[Effectiveness of systemic chemotherapy of GEM+CBDCA+5-FU/LV and hepatic arterial infusion of CDDP in a case of advanced, combined hepatocellular-cholangiocarcinoma with multiple lung metastases].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carboplatin; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male | 2011 |
Bevacizumab-induced laryngeal necrosis.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Laryngeal Diseases; Lung Neoplasms; Middle Aged; Necrosis; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Tubulin Modulators | 2012 |
Verteporfin-based photodynamic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Blotting, Western; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mitochondria; Pancreatic Neoplasms; Photochemotherapy; Photosensitizing Agents; Porphyrins; Verteporfin | 2011 |
Gemcitabine-induced posterior reversible encephalopathy syndrome: a case report.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Posterior Leukoencephalopathy Syndrome | 2012 |
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Dissection; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2012 |
Boswellic acid suppresses growth and metastasis of human pancreatic tumors in an orthotopic nude mouse model through modulation of multiple targets.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Metastasis; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Triterpenes; Xenograft Model Antitumor Assays | 2011 |
Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.
Topics: Adult; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Exotoxins; Gemcitabine; Hodgkin Disease; Humans; Immunotoxins; Interleukin-2 Receptor alpha Subunit; Mice; Mice, Nude; Plasmacytoma; Tumor Cells, Cultured | 2012 |
Pancreaticoduodenectomy with resection of the splenic artery and splenectomy for pancreatic double cancers after total gastrectomy. Preservation of the pancreatic function via the blood supply from the posterior epiploic artery: report of a case.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Chemotherapy, Adjuvant; Deoxycytidine; Gastrectomy; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Splenectomy; Splenic Artery; Stomach Neoplasms | 2012 |
Predictive value of metabolic 18FDG-PET response on outcomes in patients with locally advanced pancreatic carcinoma treated with definitive concurrent chemoradiotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Multimodal Imaging; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2011 |
Combination of hedgehog signaling blockage and chemotherapy leads to tumor reduction in pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Genes, Reporter; Hedgehog Proteins; Humans; Mice; Mice, Nude; Middle Aged; Mutation; Pancreatic Neoplasms; Patched Receptors; Patched-1 Receptor; Polymorphism, Single Nucleotide; Receptors, Cell Surface; Signal Transduction; Time Factors; Transcription Factors; Transfection; Tumor Burden; Veratrum Alkaloids; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2012 |
Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Transformation, Neoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Karyotype; Mice; Mice, SCID; Microsatellite Repeats; Neoplastic Stem Cells; Pancreatic Neoplasms; Transplantation, Heterologous | 2012 |
Single-agent gemcitabine chemotherapy in dogs with hepatocellular carcinomas.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Dog Diseases; Dogs; Female; Gemcitabine; Liver Neoplasms; Male; Survival Analysis; Treatment Outcome; Ultrasonography | 2011 |
Initial experience with repetitive transarterial chemoembolization (TACE) as a third line treatment of ovarian cancer metastasis to the liver: indications, outcomes and role in patient's management.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Mitomycin; Ovarian Neoplasms; Palliative Care; Survival Rate; Treatment Outcome | 2012 |
Taxane doublets for metastatic breast cancer: do we need another cytotoxic pair or another approach?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Receptor, ErbB-2; Taxoids | 2011 |
Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Disease-Free Survival; Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Predictive Value of Tests; Proportional Hazards Models; Tegafur | 2012 |
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Metformin; Mice; Mice, SCID; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Polycomb Repressive Complex 2; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Tumor Stem Cell Assay | 2012 |
Evaluation of a UCMK/dCK fusion enzyme for gemcitabine-mediated cytotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; CHO Cells; Cricetinae; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Nucleoside-Phosphate Kinase; Protein Engineering; Recombinant Fusion Proteins; Transfection | 2011 |
Gemcitabine and tamoxifen-loaded liposomes as multidrug carriers for the treatment of breast cancer diseases.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Cholesterol; Colloids; Deoxycytidine; Dose-Response Relationship, Drug; Drug Compounding; Fatty Acids, Monounsaturated; Female; Gemcitabine; Humans; Kinetics; Lipids; Liposomes; Particle Size; Phosphatidylethanolamines; Phosphatidylglycerols; Polyethylene Glycols; Quaternary Ammonium Compounds; Selective Estrogen Receptor Modulators; Solubility; Tamoxifen; Technology, Pharmaceutical | 2012 |
Dose-volume analysis of predictors for gastrointestinal toxicity after concurrent full-dose gemcitabine and radiotherapy for locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Area Under Curve; Combined Modality Therapy; Deoxycytidine; Duodenum; Erlotinib Hydrochloride; Female; Gastrointestinal Tract; Gemcitabine; Humans; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Quinazolines; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Retrospective Studies; Risk Factors | 2012 |
Pharmacodynamic modeling of sequence-dependent antitumor activity of insulin-like growth factor blockade and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Imidazoles; Models, Biological; Pyrazines; Receptor, IGF Type 1; Signal Transduction; Somatomedins | 2012 |
Enhanced anticancer activity of gemcitabine in combination with noscapine via antiangiogenic and apoptotic pathway against non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antitussive Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cells, Cultured; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Noscapine; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2011 |
Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Evaluation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neutropenia; Receptors, Estrogen; Receptors, Progesterone; Salvage Therapy; Taxoids; Thrombocytopenia | 2012 |
Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD™ lenalidomide.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Blotting, Western; Butadienes; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Lenalidomide; Nitriles; Pancreatic Neoplasms; Phosphorylation; Thalidomide; Tumor Cells, Cultured | 2011 |
Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2011 |
Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy.
Topics: Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Differentiation; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; Enzyme Inhibitors; Female; Fluorescent Antibody Technique; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Protein Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Silencing of X-linked inhibitor of apoptosis decreases resistance to cisplatin and paclitaxel but not gemcitabine in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Lung Neoplasms; Paclitaxel; RNA Interference; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Evaluation of the efficacy and safety of the combination of gemcitabine and nedaplatin for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Survival Analysis; Survival Rate; Treatment Outcome | 2011 |
Radiotherapy: the importance of local control in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy; Smad4 Protein | 2011 |
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Control Studies; Chemoradiotherapy; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Length of Stay; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Quinazolines; Survival Rate; Taxoids | 2012 |
Combination effects of digalloylresveratrol with arabinofuranosylcytosine and difluorodeoxycytidine in human leukemia and pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cytarabine; Deoxycytidine; Gallic Acid; Gemcitabine; HL-60 Cells; Humans; Leukemia; Pancreatic Neoplasms; Stilbenes; Tumor Stem Cell Assay | 2011 |
Determination of the phosphorylated metabolites of gemcitabine and of difluorodeoxyuridine by LCMSMS.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chromatography, Liquid; Cytosol; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Mass Spectrometry; Nucleotides; Phosphorylation | 2011 |
Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.
Topics: Base Composition; Base Sequence; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA Methylation; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MicroRNAs; Molecular Sequence Data; Neoplasms; Promoter Regions, Genetic; Protein Binding; RNA, Messenger | 2011 |
The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; Female; Gemcitabine; Genetic Association Studies; Genotype; Haplotypes; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; Treatment Outcome | 2012 |
[Gemcitabine plus S-1 combination therapy (GS therapy) for pancreatic cancer patients with high-grade hepatic metastasis].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2011 |
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
Topics: Adenocarcinoma; Aged; Amino Acid Substitution; Antimetabolites, Antineoplastic; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Genome-Wide Association Study; Humans; Interleukin-17; Kaplan-Meier Estimate; Linkage Disequilibrium; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Randomized Controlled Trials as Topic | 2012 |
Local control of experimental malignant pancreatic tumors by treatment with a combination of chemotherapy and intratumoral 224radium-loaded wires releasing alpha-emitting atoms.
Topics: Alpha Particles; Animals; Antimetabolites, Antineoplastic; Brachytherapy; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Pancreas; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radium | 2012 |
Targeting quiescent tumor cells via oxygen and IGF-I supplementation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Culture Techniques; Cell Hypoxia; Cell Proliferation; Cell Survival; Colonic Neoplasms; Deoxycytidine; Drug Synergism; Gemcitabine; HCT116 Cells; HT29 Cells; Humans; Insulin; Insulin-Like Growth Factor I; Mice; Mice, Inbred NOD; Mice, SCID; Oxygen; Paclitaxel; Receptor, IGF Type 1; Xenograft Model Antitumor Assays | 2012 |
Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Emodin; Gemcitabine; Humans; Mitochondria; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2012 |
Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2013 |
Neo-adjuvant chemoradiation therapy using S-1 followed by surgical resection in patients with pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Dose Fractionation, Radiation; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Statistics, Nonparametric; Tegafur | 2012 |
Double-targeted and double-enhanced suicide gene therapy mediated by generation 5 polyamidoamine dendrimers for prostate cancer.
Topics: Animals; Apoptosis; Bystander Effect; Connexin 43; Dendrimers; Deoxycytidine; Ganciclovir; Gemcitabine; Genes, Transgenic, Suicide; Genetic Therapy; Humans; Lipids; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Polyamines; Promoter Regions, Genetic; Prostatic Neoplasms; Simplexvirus; Thymidine Kinase; Transfection; Xenograft Model Antitumor Assays | 2013 |
Targeted silencing of TRPM7 ion channel induces replicative senescence and produces enhanced cytotoxicity with gemcitabine in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Exodeoxyribonucleases; Gemcitabine; Humans; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; RecQ Helicases; RNA Interference; RNA, Messenger; RNA, Small Interfering; Werner Syndrome Helicase | 2012 |
Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Janus Kinases; Signal Transduction; STAT Transcription Factors | 2012 |
Prognostic factors for survival and resection in patients with initial nonresectable locally advanced pancreatic cancer treated with chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Leucovorin; Logistic Models; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur; Tumor Burden; Uracil | 2012 |
Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Genotype; HapMap Project; Humans; Lung Neoplasms; Polymorphism, Genetic; Signal Transduction | 2012 |
Taxane-based mono- or combination therapy for managing metastatic breast cancer (MBC) in routine practice: a multinational prospective observational study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2; Regression Analysis; Taxoids; Trastuzumab | 2012 |
Cutaneous presentation of a distant metastasis of malignant phyllodes tumor.
Topics: Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Phyllodes Tumor; Skin Neoplasms; Treatment Outcome | 2012 |
Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Humans; Neuroblastoma; Spheroids, Cellular; Tumor Cells, Cultured | 2012 |
Video-assisted thoracoscopic surgery is more favorable than thoracotomy for administration of adjuvant chemotherapy after lobectomy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Patient Compliance; Pneumonectomy; Postoperative Complications; Psychosurgery; Retrospective Studies; Thoracic Surgery, Video-Assisted; Thoracotomy; Treatment Outcome | 2011 |
Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Blood Vessels; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Endothelial Cells; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasms; Neovascularization, Pathologic; Prodrugs; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
[Safety profiles of gemcitabine hydrochloride(GEMZAR®)in Japanese clinical studies].
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Japan; Lung Diseases, Interstitial; Myeloid Cells; Neoplasms | 2011 |
[Results of chemotherapy for gynecologic cancer patients in ambulatory care].
Topics: Ambulatory Care; Ambulatory Care Facilities; Anemia, Hypochromic; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Deoxycytidine; Doxorubicin; Endometrial Neoplasms; Female; Gemcitabine; Genital Neoplasms, Female; Hospitalization; Humans; Middle Aged; Neutropenia; Outpatients; Ovarian Neoplasms; Paclitaxel; Quality of Life; Russia; Thrombocytopenia; Treatment Outcome; Uterine Cervical Neoplasms | 2011 |
[Experience with gemcitabine monotherapy in three patients with metastatic urothelial carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2011 |
Biliary-tract cancer: improving therapy by adding molecularly targeted agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2012 |
Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Doxorubicin; Drug Evaluation; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Proportional Hazards Models; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2012 |
Intensity-modulated radiotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate | 2012 |
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; MAP Kinase Signaling System; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolinones; Receptors, Growth Factor; STAT3 Transcription Factor | 2012 |
Carboplatin-gemcitabine combination chemotherapy upregulates AKR1B10 expression in bladder cancer.
Topics: Aged; Aged, 80 and over; Aldehyde Reductase; Aldo-Keto Reductases; Carboplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Urinary Bladder Neoplasms | 2013 |
Effect of maintenance chemotherapy with gemcitabine and paclitaxel on recurrent squamous cell carcinoma of the bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Gemcitabine; Humans; Japan; Male; Methotrexate; Middle Aged; Paclitaxel; Prognosis; Recurrence; Remission Induction; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2011 |
[Effect of gemcitabine in enhancing the radiosensitivity of HepG2 hepatoma cells and the possible mechanism].
Topics: Apoptosis; Cell Cycle Checkpoints; Deoxycytidine; Gemcitabine; Hep G2 Cells; Humans; Radiation Tolerance; Radiation-Sensitizing Agents | 2011 |
A humanized anti-IGF-1R monoclonal antibody (R1507) and/or metformin enhance gemcitabine-induced apoptosis in pancreatic cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Metformin; Pancreatic Neoplasms; Receptor, IGF Type 1; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Synergistic antitumor interactions between gemcitabine and clofarabine in human pancreatic cancer cell lines.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Cell Line, Tumor; Clofarabine; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; S Phase Cell Cycle Checkpoints | 2012 |
[A case of locally advanced pancreas cancer effectively treated by multidisciplinary strategy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
[An example case that chemoradiotherapy was succeeded for unresectable pancreas cancer].
Topics: Antimetabolites, Antineoplastic; Biopsy; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2011 |
[A case of peritoneal recurrence of invasive carcinoma derived from IPMN after distal pancreatectomy].
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Neoplasms; Recurrence; Tegafur; Tomography, X-Ray Computed | 2011 |
[An operated case of metastasis to the small intestine from lung cancer].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Jejunal Neoplasms; Lung Neoplasms; Male; Positron-Emission Tomography; Tomography, X-Ray Computed | 2011 |
[Curative resection of gallbladder cancer with simultaneous liver metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Tegafur | 2011 |
[A novel gemcitabine delivery system].
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Pharmaceutical Solutions | 2011 |
[Re-resection for local recurrence in the remnant pancreas after pancreaticoduodenectomy for pancreatic cancer- a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Recurrence; Tomography, X-Ray Computed | 2011 |
[A case of intrahepatic recurrence of intrahepatic cholangiocarcinoma treated with repeated hepatectomy].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Oxonic Acid; Recurrence; Tegafur; Tomography, X-Ray Computed | 2011 |
Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
Topics: Antimetabolites; Antineoplastic Agents; Blotting, Western; Camptothecin; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Hydroxyurea; Irinotecan; Molecular Structure; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Staurosporine | 2012 |
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytostatic Agents; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Mice; Mice, SCID; Neural Cell Adhesion Molecule L1; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms | 2012 |
Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Quinazolines; Signal Transduction | 2012 |
Gemcitabine with or without docetaxel and resection for recurrent osteosarcoma: the experience at Children's Memorial Hospital.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neurosurgical Procedures; Osteosarcoma; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Novel immunocompetent murine models representing advanced local and metastatic pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Immunocompetence; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Pancreas; Pancreatic Neoplasms; Severity of Illness Index; Spleen; Survival Rate | 2012 |
Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Luminescent Measurements; Mice; Mice, Nude; Microscopy, Fluorescence; Myxoma virus; Oncolytic Viruses; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Langerhans/dendritic cell sarcoma arising from hairy cell leukemia: a rare phenomenon.
Topics: Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cell Transdifferentiation; Chromosome Aberrations; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Gene Rearrangement, B-Lymphocyte; Humans; Hypopharyngeal Neoplasms; Immunophenotyping; Karyotyping; Langerhans Cell Sarcoma; Leukemia, Hairy Cell; Mutation; Neoplastic Stem Cells; Pyriform Sinus; Taxoids | 2012 |
[A case of adenosquamous carcinoma of lower extrahepatic bile duct].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Carcinoma, Adenosquamous; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Staging; Remission Induction | 2012 |
[A case of curatively resected locally advanced cancer of the pancreatic body treated by distal pancreatectomy with en bloc celiac axis resection after neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
Requirement of nuclear factor κB for Smac mimetic-mediated sensitization of pancreatic carcinoma cells for gemcitabine-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mitochondrial Proteins; Molecular Mimicry; NF-kappa B; Pancreatic Neoplasms; Tumor Necrosis Factor-alpha | 2011 |
Multicellular tumor spheroid model to evaluate spatio-temporal dynamics effect of chemotherapeutics: application to the gemcitabine/CHK1 inhibitor combination in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinolines; Quinuclidines; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment | 2012 |
Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Isoquinolines; Organoplatinum Compounds; Oxaliplatin; Radiation, Ionizing; Tubulin | 2012 |
Survivin-mediated therapeutic efficacy of gemcitabine through glucose-regulated protein 78 in hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Flow Cytometry; Gemcitabine; Heat-Shock Proteins; Humans; In Situ Nick-End Labeling; Inhibitor of Apoptosis Proteins; Liver Neoplasms; RNA, Small Interfering; Survivin; Tumor Cells, Cultured | 2012 |
Defined clinical classifications are associated with outcome of patients with anatomically resectable pancreatic adenocarcinoma treated with neoadjuvant therapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2012 |
Discovery of drugs that possess activity against feline leukemia virus.
Topics: Adenine; Animals; Antiviral Agents; Azacitidine; Cat Diseases; Cats; Decitabine; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Leukemia Virus, Feline; Leukemia, Feline; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Retroviridae Infections; Tenofovir; Tumor Virus Infections | 2012 |
Genistein potentiates the anti-cancer effects of gemcitabine in human osteosarcoma via the downregulation of Akt and nuclear factor-κB pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genistein; Humans; Mice; Mice, Inbred BALB C; NF-kappa B; Osteosarcoma; Proto-Oncogene Proteins c-akt; Signal Transduction | 2012 |
Mutagen-mediated enhancement of HIV-1 replication in persistently infected cells.
Topics: Cell Line; Deoxycytidine; Fluorouracil; Gemcitabine; HIV Infections; HIV-1; Humans; Mutagens; Mutation; Mutation Rate; RNA, Viral; Virus Replication | 2012 |
Retrospective study on the use of different protocols for repeated transarterial chemoembolization in the treatment of patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Liver Neoplasms; Male; Mitomycin; Prevalence; Retrospective Studies; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome | 2012 |
Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Carcinoma, Pancreatic Ductal; Caspase 12; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Electrophoretic Mobility Shift Assay; Endoplasmic Reticulum; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Membrane Potential, Mitochondrial; Mitochondria; Mucins; NF-kappa B; Pancreatic Neoplasms; Polymerase Chain Reaction; Protease Inhibitors; Pyrazines; Regulatory Factor X Transcription Factors; RNA Interference; Time Factors; Transcription Factor CHOP; Transcription Factors; Transfection; Unfolded Protein Response; X-Box Binding Protein 1 | 2012 |
Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Drug Combinations; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Oxonic Acid; Prognosis; Proportional Hazards Models; Tegafur | 2012 |
Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-κB and nuclear factor-κB-regulated gene products in pancreatic cancer both in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Down-Regulation; Drug Synergism; Escin; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; NF-kappa B; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1.
Topics: Animals; Anti-HIV Agents; Azacitidine; Body Weight; Cells, Cultured; Chemical and Drug Induced Liver Injury; Decitabine; Deoxycytidine; Drug Combinations; Drug Synergism; Female; Flow Cytometry; Gemcitabine; HIV-1; Humans; Liver; Lymph Nodes; Mice; Mice, Inbred C57BL; Murine Acquired Immunodeficiency Syndrome; Proviruses; Spleen; T-Lymphocytes; Transfection | 2012 |
Analysis of local control in patients receiving IMRT for resected pancreatic cancers.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Failure | 2012 |
In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbon; Cell Line, Tumor; Chemoradiotherapy; Cisplatin; Deoxycytidine; Dose-Response Relationship, Radiation; Gemcitabine; Glioblastoma; Humans; In Vitro Techniques; Paclitaxel; Photons; Tumor Stem Cell Assay | 2012 |
High-dose helical tomotherapy with concurrent full-dose chemotherapy for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Retrospective Studies; Tegafur; Treatment Outcome | 2012 |
Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Line, Tumor; Chromones; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Morpholines; Ovarian Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinoxalines; Signal Transduction; Topotecan | 2012 |
A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy.
Topics: Aged; Apoptosis Regulatory Proteins; Biomarkers, Pharmacological; Calcium-Calmodulin-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 4; Death-Associated Protein Kinases; Deoxycytidine; Female; Gemcitabine; Genome-Wide Association Study; Genotype; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Risk Factors | 2012 |
Adjuvant chemotherapy decreases and postpones distant metastasis in extremity stage IIB/III synovial sarcoma patients.
Topics: Adult; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug Administration Schedule; Extremities; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Mesna; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Remission Induction; Sarcoma, Synovial; Soft Tissue Neoplasms; Taxoids | 2012 |
Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Immunohistochemistry; Ovarian Neoplasms; Paclitaxel; Sulfonamides | 2012 |
Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Topics: Adenine Nucleotides; Animals; Arabinonucleosides; Cell Line, Tumor; Clofarabine; Cytarabine; Cytidine Deaminase; Cytosine; Deoxycytidine; Deoxycytidine Kinase; Fluorine Radioisotopes; Gemcitabine; Gene Expression Regulation, Neoplastic; Leukemia, Lymphoid; Mice; Positron-Emission Tomography; Treatment Outcome | 2012 |
High-pressure intrapleural chemotherapy: feasibility in the pig model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Neoplasms; Pleural Neoplasms; Pressure; Swine; Tumor Cells, Cultured | 2012 |
Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Deoxycytidine; Electrophoretic Mobility Shift Assay; Female; Gemcitabine; Humans; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine.
Topics: AC133 Antigen; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glycoproteins; Humans; Interferon-alpha; Mice; Mice, Nude; Mice, SCID; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides | 2012 |
Mechanisms of TRAIL and gemcitabine induction of pancreatic cancer cell apoptosis.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Mitochondrial Proteins; Pancreatic Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein | 2011 |
Prognostic significance of telomerase activity and human telomerase reverse transcriptase expression in ampullary carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Tegafur; Telomerase; Young Adult | 2012 |
Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, SCID; Neoplasm Transplantation; NF-kappa B; NM23 Nucleoside Diphosphate Kinases; Pancreatic Neoplasms | 2012 |
The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice.
Topics: Animals; Antimetabolites, Antineoplastic; Benzofurans; Carcinoma; Carrier Proteins; Cell Division; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Mice; Mice, Mutant Strains; Mucin-4; Phosphorylation; RNA, Messenger | 2012 |
Gemcitabine alone versus combination of gemcitabine and cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a retrospective analysis of multicenter study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
[A case of pancreatic cancer with celiac trunk and common hepatic artery invasion successfully resected after gemcitabine+S-1therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Liver; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2012 |
[A case of a patient with bladder cancer who received warfarin and showed a significantly prolonged PT-INR after gemcitabine and cisplatin combination therapy].
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Edema; Female; Gemcitabine; Humans; International Normalized Ratio; Leg; Prothrombin; Thrombophlebitis; Urinary Bladder Neoplasms; Warfarin | 2012 |
Effect of a combination of S-1 and gemcitabine on cell cycle regulation in pancreatic cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclins; Deoxycytidine; Drug Combinations; Drug Synergism; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; S Phase; Tegafur | 2012 |
Chemotherapy-induced toxicity is highly heritable in Drosophila melanogaster.
Topics: Animals; Carboplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drosophila melanogaster; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Fertility; Floxuridine; Gemcitabine; High-Throughput Screening Assays; Humans; Methotrexate; Mitomycin; Models, Animal; Neoplasms; Topotecan | 2012 |
Isolated lung perfusion with gemcitabine combined with radiotherapy: no additional lung toxicity in an experimental model.
Topics: Animals; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Hemosiderosis; Infusions, Intravenous; Logistic Models; Lung; Male; Models, Animal; Pulmonary Fibrosis; Random Allocation; Rats; Rats, Inbred Strains | 2012 |
EGCG enhances the therapeutic potential of gemcitabine and CP690550 by inhibiting STAT3 signaling pathway in human pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Catechin; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Piperidines; Pyrimidines; Pyrroles; Signal Transduction; STAT3 Transcription Factor | 2012 |
Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes.
Topics: Aged; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Receptor, ErbB-2; Survival Analysis | 2013 |
Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma.
Topics: Amyloid Precursor Protein Secretases; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclic S-Oxides; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Endothelial Cells; Gemcitabine; Humans; Hypoxia; Mice; Mice, Mutant Strains; Necrosis; Pancreatic Neoplasms; Protease Inhibitors; Receptors, Notch; Signal Transduction; Thiadiazoles; Translational Research, Biomedical | 2012 |
Involvement of p53 in gemcitabine mediated cytotoxicity and radiosensitivity in breast cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; Electrophoresis, Gel, Pulsed-Field; Epithelial Cells; Female; Gemcitabine; Humans; Mutation; Radiation-Sensitizing Agents; Tumor Suppressor Protein p53 | 2012 |
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Etoposide; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neovascularization, Pathologic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Clinical course of plasmacytoid urothelial carcinoma of the upper urinary tract: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carboplatin; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Lymph Node Excision; Lymphatic Metastasis; Male; Nephrectomy; Treatment Failure; Urothelium | 2012 |
Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine.
Topics: Animals; Azacitidine; Carbon Radioisotopes; Decitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Membrane Transport Proteins; Oocytes; Saccharomyces cerevisiae; Tritium; Xenopus | 2012 |
Haemolytic uremic syndrome and gemcitabine: jaundice is not always progression in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Jaundice; Male; Middle Aged; Prognosis | 2012 |
MDM2 309 polymorphism predicts outcome in platinum-treated locally advanced head and neck cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Genes, p53; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-mdm2; Treatment Outcome; Young Adult | 2012 |
DPEP1 inhibits tumor cell invasiveness, enhances chemosensitivity and predicts clinical outcome in pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cohort Studies; Deoxycytidine; Dipeptidases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Association Studies; GPI-Linked Proteins; Humans; Male; MAP Kinase Signaling System; Maryland; Microtubule-Associated Proteins; Middle Aged; Neoplasm Invasiveness; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Proportional Hazards Models; Reproducibility of Results; Treatment Outcome | 2012 |
Accelerated MVAC chemotherapy in patients with advanced bladder cancer previously treated with a platinum-gemcitabine regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Urinary Bladder Neoplasms; Vinblastine | 2012 |
Gemcitabine-releasing polymeric films for covered self-expandable metallic stent in treatment of gastrointestinal cancer.
Topics: Alloys; Animals; Antimetabolites, Antineoplastic; Cell Count; Cell Proliferation; Cell Survival; Colonic Neoplasms; Constriction, Pathologic; Cytokines; Deoxycytidine; Drug-Eluting Stents; Gastrointestinal Neoplasms; Gemcitabine; Humans; Membranes, Artificial; Mice; p38 Mitogen-Activated Protein Kinases; Poloxamer; Polymers; Polytetrafluoroethylene; Polyurethanes | 2012 |
Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: experience at Sindh Institute of Urology & Transplantation (SIUT).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Cystectomy; Cystoscopy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Radiotherapy Dosage; Treatment Outcome; Urinary Bladder Neoplasms | 2011 |
Pathological responses to gemcitabine/platinum-based neoadjuvant chemotherapy for muscle-invasive urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2012 |
The T393C polymorphism of GNAS1 as a predictor for chemotherapy sensitivity and survival in advanced non-small-cell lung cancer patients treated with gemcitabine plus platinum.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chromogranins; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Genotype; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prognosis; Proportional Hazards Models | 2012 |
Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Synergism; Emodin; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Survivin; Tumor Burden; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2012 |
Analysis of dosimetric parameters associated with acute gastrointestinal toxicity and upper gastrointestinal bleeding in locally advanced pancreatic cancer patients treated with gemcitabine-based concurrent chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Duodenum; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Intestine, Small; Male; Middle Aged; Organs at Risk; Pancreatic Neoplasms; Radiation Injuries; Radiography; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Conformal; Retrospective Studies; Stomach; Tumor Burden | 2012 |
TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Hypoxia; Cell Line, Tumor; Cisplatin; Deoxycytidine; Docetaxel; Drug Evaluation, Preclinical; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Mice; Mice, SCID; Nitroimidazoles; Pemetrexed; Phosphoramide Mustards; Prodrugs; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms | 2012 |
Transforming growth factor beta receptor I inhibitor sensitizes drug-resistant pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Imidazoles; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Quinoxalines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta | 2012 |
Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Cytosine; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Nucleosides | 2012 |
Effect of biliary drainage on chemotherapy in patients with biliary tract cancer: an exploratory analysis of the BT22 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangitis; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Disease-Free Survival; Drainage; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neoadjuvant Therapy; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2012 |
The effect of gemcitabine/paclitaxel chemotherapy on the survival of patients with metastatic urothelial cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
Right atrial angiosarcoma: rupture and tamponade.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cardiac Surgical Procedures; Cardiac Tamponade; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Gemcitabine; Heart Atria; Heart Neoplasms; Heart Rupture; Hemangiosarcoma; Humans; Male; Taxoids; Tomography, X-Ray Computed | 2012 |
Exploring protein kinase inhibitors: potentiating gemcitabine efficacy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Inhibitory Concentration 50; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2012 |
[Synergism of antitumor activity of gemcitabine and dioxadet in mice with ascitic Ehrlich's tumor].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ehrlich Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Gemcitabine; Maximum Tolerated Dose; Mice; Mice, Inbred Strains; Time Factors; Triazines; Weight Gain | 2011 |
Attenuation of phosphorylation by deoxycytidine kinase is key to acquired gemcitabine resistance in a pancreatic cancer cell line: targeted proteomic and metabolomic analyses in PK9 cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metabolomics; Pancreas; Pancreatic Neoplasms; Phosphorylation; Proteomics | 2012 |
Survival after chemoradiation in resected pancreatic cancer: the impact of adjuvant gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Analysis | 2012 |
[A case of pancreatic cancer with liver metastasis controlled effectively by chemotherapy based on chemosensitivity test and stereotactic body radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Radiosurgery; Tomography, X-Ray Computed | 2012 |
Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Salvage Therapy; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipids; Mice; Nanoparticles; Neoplasms; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2012 |
Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Ribonucleotide Reductases | 2012 |
CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells.
Topics: Basigin; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Monocarboxylic Acid Transporters; Muscle Proteins; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Symporters | 2012 |
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib | 2012 |
DNA methylation-independent reversion of gemcitabine resistance by hydralazine in cervical cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Chromatin Immunoprecipitation; Deoxycytidine; DNA Primers; Drug Resistance, Neoplasm; Epigenesis, Genetic; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens; Histone Deacetylases; Histone-Lysine N-Methyltransferase; Humans; Hydralazine; Reverse Transcriptase Polymerase Chain Reaction; Uterine Cervical Neoplasms | 2012 |
Analysis of gemcitabine liposome injection by HPLC with evaporative light scattering detection.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Light; Liposomes; Scattering, Radiation; Spectrophotometry, Ultraviolet | 2012 |
Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Tumor Suppressor Proteins | 2012 |
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Animals, Genetically Modified; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Deoxycytidine; Drug Evaluation, Preclinical; Extracellular Fluid; Gemcitabine; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Microvessels; Pancreatic Neoplasms; Polyethylene Glycols; Stromal Cells; Tumor Microenvironment | 2012 |
Gemcitabine is active against clinical multiresistant Staphylococcus aureus strains and is synergistic with gentamicin.
Topics: Anti-Bacterial Agents; Deoxycytidine; Drug Resistance, Multiple, Bacterial; Drug Synergism; Gemcitabine; Gentamicins; Humans; Microbial Sensitivity Tests; Staphylococcal Infections; Staphylococcus aureus | 2012 |
Routine administration of a single dose of cisplatin ≥ 75 mg/m2 after short hydration in an outpatient lung-cancer clinic.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Etoposide; Female; Fluid Therapy; Gemcitabine; Humans; Kidney; Kidney Diseases; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2012 |
Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Deoxycytidine; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
Neoadjuvant therapy for resectable and borderline resectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Pancreatic Neoplasms; Patient Selection; Survival Rate | 2012 |
Conventional chemotherapy of advanced pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
A Bayesian integrative genomic model for pathway analysis of complex traits.
Topics: Algorithms; Antimetabolites, Antineoplastic; Bayes Theorem; Cell Line; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Genomics; Humans; Markov Chains; Models, Statistical; Models, Theoretical; Monte Carlo Method; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Reproducibility of Results; RNA, Messenger; Stochastic Processes | 2012 |
Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Hyaluronic Acid; Hyaluronoglucosaminidase; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Transgenic; Pancreatic Neoplasms; Recombinant Proteins; Tissue Array Analysis; Treatment Outcome | 2013 |
Poorly differentiated neuroendocrine carcinoma of the pancreas responsive to combination therapy with gemcitabine and S-1.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Prognostic significance of aquaporins in human biliary tract carcinoma.
Topics: Aged; Aged, 80 and over; Aquaporin 1; Aquaporin 4; Aquaporin 5; Aquaporins; Bile Duct Neoplasms; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Prognosis; Tegafur | 2012 |
Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Lysosomes; Melanoma; Mice; Mice, Inbred C57BL; Micelles; Polyethylene Glycols; Prodrugs; Stearic Acids | 2012 |
HADHA is a potential predictor of response to platinum-based chemotherapy for lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Electrophoresis, Gel, Two-Dimensional; Etoposide; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Mitochondrial Trifunctional Protein; Mitochondrial Trifunctional Protein, alpha Subunit; Multienzyme Complexes; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Small Cell Lung Carcinoma; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2011 |
High-dose chemotherapy in relapsed or refractory Hodgkin lymphoma patients: a reappraisal of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cisplatin; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Disease-Free Survival; Etoposide; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Methylprednisolone; Middle Aged; Neoplasm Staging; Peripheral Blood Stem Cell Transplantation; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2013 |
Rituximab, gemcitabine, cisplatin, and dexamethasone in patients with refractory or relapsed aggressive B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Middle Aged; Recurrence; Rituximab | 2012 |
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cross-Sectional Studies; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate | 2012 |
ErbB3 expression predicts sensitivity to elisidepsin treatment: in vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitogen-Activated Protein Kinases; Paclitaxel; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4 | 2012 |
Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic conditions in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Fluorouracil; Gemcitabine; Hedgehog Proteins; Humans; Immunoblotting; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; RNA Interference; Smoothened Receptor; Transcription Factors; Veratrum Alkaloids; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2012 |
Noxa enhances the cytotoxic effect of gemcitabine in human ovarian cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Genetic Therapy; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Plasmids; Proto-Oncogene Proteins c-bcl-2; Transfection | 2012 |
DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Gene Silencing; Histones; Humans; Pancreatic Neoplasms; Phosphorylation; RNA, Small Interfering | 2012 |
Phosphorylation of deoxycytidine kinase on Ser-74: impact on kinetic properties and nucleoside analog activation in cancer cells.
Topics: Antineoplastic Agents; Aphidicolin; Biotransformation; Cell Line, Tumor; Cell Survival; Cladribine; Deoxycytidine; Deoxycytidine Kinase; Enzyme Activation; Gemcitabine; HCT116 Cells; HT29 Cells; Humans; Kinetics; Mutation; Phosphorylation; Purine Nucleosides; Pyrimidine Nucleosides; Serine; Structure-Activity Relationship; Substrate Specificity; Vidarabine | 2012 |
Portal vein infusion chemotherapy with gemcitabine after surgery for pancreatic cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Prospective Studies; Treatment Outcome | 2013 |
Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Retrospective Studies | 2012 |
Genetic association studies of copy-number variation: should assignment of copy number states precede testing?
Topics: Algorithms; Computer Simulation; Data Interpretation, Statistical; Deoxycytidine; DNA Copy Number Variations; Gemcitabine; Genetic Markers; Genetic Variation; Genome-Wide Association Study; Genome, Human; Genotype; Humans; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide | 2012 |
A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Benzene Derivatives; Clinical Trials, Phase II as Topic; Computer Simulation; Deoxycytidine; Gemcitabine; Humans; Models, Statistical; Pancreatic Neoplasms; Propionates; Research Design; Sample Size; Sulfones | 2012 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
Unprecedented case of tumor lysis syndrome in a patient with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Tumor Lysis Syndrome | 2012 |
[The evaluation of chemotherapy for patients over eighty-years-old].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2012 |
Enhanced antitumor effect of combination therapy with gemcitabine and guggulsterone in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA; Drug Synergism; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Pregnenediones; Xenograft Model Antitumor Assays | 2012 |
Crucial role of heme oxygenase-1 on the sensitivity of cholangiocarcinoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Cytoprotection; Deoxycytidine; Doxorubicin; Gemcitabine; Heme Oxygenase-1; Humans; Protoporphyrins; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA, Small Interfering | 2012 |
Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Survival Rate; Urinary Bladder Neoplasms | 2012 |
Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Prognosis; Retrospective Studies; Salvage Therapy; Sarcoma; Survival Rate; Taxoids; Young Adult | 2012 |
Outcome of single agent generic gemcitabine in platinum-resistant ovarian cancer, fallopian tube cancer and primary peritoneal adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antimetabolites, Antineoplastic; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Fallopian Tube Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2012 |
Analytical detection and method development of anticancer drug Gemcitabine HCl using gold nanoparticles.
Topics: Antineoplastic Agents; Chemistry Techniques, Analytical; Deoxycytidine; Gemcitabine; Gold; Injections; Light; Limit of Detection; Metal Nanoparticles; Nanotechnology; Particle Size; Pharmaceutical Preparations; Reproducibility of Results; Scattering, Radiation; Solutions; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared | 2012 |
DJ-1, a novel biomarker and a selected target gene for overcoming chemoresistance in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Oncogene Proteins; Pancreatic Neoplasms; Protein Deglycase DJ-1; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Young Adult | 2012 |
Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Doxorubicin; Erythema; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Polyethylene Glycols; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2012 |
Advanced Pancreatic Adenocarcinoma: Complete Histological Response After Palliative Therapy with Gemcitabine and Cisplatin.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Palliative Care; Pancreatic Neoplasms; Prognosis; Remission Induction; Tomography, X-Ray Computed | 2012 |
CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Oncogenes; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Osteosarcoma; Prospective Studies; Taxoids | 2013 |
A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma.
Topics: Animals; Apoptosis; Aurora Kinase A; Aurora Kinases; Cell Line, Tumor; Cell Proliferation; Centrosome; Cyclohexanecarboxylic Acids; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Profiling; Humans; Leiomyoma; Leiomyosarcoma; M Phase Cell Cycle Checkpoints; Mice; Mice, Nude; Myometrium; Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Taxoids; Thiazoles; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2012 |
DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Biomarkers; Brain Neoplasms; Cell Line; Chemoradiotherapy; Dacarbazine; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Drug Screening Assays, Antitumor; Gemcitabine; Glioblastoma; Humans; Kaplan-Meier Estimate; Mice; Mice, Transgenic; Neoplasms, Experimental; Radiation-Sensitizing Agents; Temozolomide; Treatment Outcome; Tumor Burden | 2012 |
Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Docetaxel; Drug Evaluation, Preclinical; Drug Synergism; Female; Fibroblasts; Flavonoids; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Leiomyosarcoma; Phytotherapy; Plant Extracts; Survivin; Taxoids; Uterine Neoplasms | 2012 |
Incorporation and controlled release of silyl ether prodrugs from PRINT nanoparticles.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Dasatinib; Delayed-Action Preparations; Deoxycytidine; Ethers; Gemcitabine; Humans; Nanoparticles; Neoplasms; Prodrugs; Pyrimidines; Silanes; Thiazoles | 2012 |
High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation.
Topics: Adult; Aged; Asian People; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Gene Frequency; Humans; Male; Middle Aged; Mutation; Neoplasms; Neutropenia; Polymorphism, Genetic | 2012 |
Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
Topics: Animals; Antineoplastic Agents; Binding Sites; Camptothecin; Checkpoint Kinase 1; Crystallography, X-Ray; Deoxycytidine; DNA Damage; Drug Design; Drug Synergism; Gemcitabine; High-Throughput Screening Assays; Irinotecan; Mice; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Rats; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Urea; Xenograft Model Antitumor Assays | 2012 |
Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymerase Chain Reaction; Polymorphism, Genetic; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Taiwan; Treatment Outcome; X-ray Repair Cross Complementing Protein 1 | 2012 |
Involvement of the mitochondrial pathway in bruceine D-induced apoptosis in Capan-2 human pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Brucea; Camptothecin; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Damage; Drugs, Chinese Herbal; Gemcitabine; Hepatocytes; Humans; Membrane Potential, Mitochondrial; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quassins; Stem Cells | 2012 |
The O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Biosynthetic Pathways; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Glycosylation; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Polysaccharides; Principal Component Analysis; Protein Processing, Post-Translational; Signal Transduction; Transcription, Genetic | 2012 |
Transactivation of the human NME5 gene by Sp1 in pancreatic cancer cells.
Topics: Base Sequence; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; NM23 Nucleoside Diphosphate Kinases; Pancreatic Neoplasms; Promoter Regions, Genetic; Regulatory Sequences, Nucleic Acid; Sequence Analysis, DNA; Sp1 Transcription Factor; Sp3 Transcription Factor; Transcription Initiation Site; Transcription, Genetic; Transcriptional Activation | 2012 |
Label-free Raman spectroscopy for accessing intracellular anticancer drug release on gold nanoparticles.
Topics: Antineoplastic Agents; Deoxycytidine; Gemcitabine; Glutathione; Gold; HeLa Cells; Humans; Intracellular Space; Metal Nanoparticles; Spectrum Analysis, Raman; Thioguanine | 2012 |
Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Liver; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Retrospective Studies; Survival Analysis | 2012 |
Induction of pancreatic cancer cell apoptosis and enhancement of gemcitabine sensitivity by RAP80 siRNA.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carrier Proteins; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Gemcitabine; Gene Expression; Histone Chaperones; Humans; Nuclear Proteins; Pancreatic Neoplasms; RNA, Small Interfering; Transfection | 2012 |
Complications and toxicity after abdominal and pelvic hypoxic stop-flow perfusion chemotherapy: incidence and assessment of risk factors.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Mitomycin; Nausea; Pelvic Neoplasms; Risk Factors; Surgical Wound Infection; Vomiting | 2012 |
Tumor macrophages as a target for Capsaicin mediated immunotherapy.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Apoptosis; Capsaicin; CD11b Antigen; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Forkhead Transcription Factors; Gemcitabine; Immunologic Factors; Immunotherapy; Interleukin-2 Receptor alpha Subunit; Macrophages; Mice; Mice, Inbred BALB C; Neoplasms; Stromal Cells; T-Lymphocytes; T-Lymphocytes, Regulatory; Tumor Microenvironment | 2012 |
The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Membrane Transport Proteins; Middle Aged; Models, Biological; Mucin-4; Multigene Family; Pancreatic Neoplasms | 2013 |
Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Hepatectomy; Humans; Immunohistochemistry; Male; Middle Aged; Pancreaticoduodenectomy; Prognosis; Survival Analysis | 2012 |
[Analysis of risk factors of drug-induced lung injury in patients receiving gemcitabine treatment].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Injury; Male; Middle Aged; Neoplasms; Risk Factors | 2012 |
Drug interactions: the importance of looking inside cancer cells.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Paclitaxel; Pancreatic Neoplasms | 2012 |
nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Drug Synergism; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms | 2012 |
FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Ribonucleosides; Tacrolimus Binding Proteins; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2012 |
The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Mice; Mice, Inbred BALB C; Naphthoquinones; Pancreatic Neoplasms; RNA, Small Interfering; Survivin | 2012 |
Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Pancreatic Neoplasms; Quinazolines | 2012 |
Chitosan-Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study.
Topics: Cell Survival; Chitosan; Deoxycytidine; Drug Carriers; Gemcitabine; HT29 Cells; Humans; Mucins; Nanoparticles; Particle Size; Poloxamer | 2012 |
Malignant fibrous histiocytoma of the ovary: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Ovarian Neoplasms; Taxoids | 2012 |
Gemcitabine-associated livedoid thrombotic microangiopathy with associated sclerema neonatorum-like microscopic changes.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Fibrin; Gemcitabine; Humans; Leukocytes; Male; Middle Aged; Skin; Thrombotic Microangiopathies | 2012 |
[Efficacy of gemcitabine and vinorelbine in first-line treatment with advanced non-small cell lung cancer: a multicentre retrospective study].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Constipation; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Retrospective Studies; Stomatitis; Vinblastine; Vinorelbine | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
[First case in Spain of bacteremia by Methylobacterium thiocyanatum from Hickmann catheter in an immunosuppressed patient with Hodgkin's lymphoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Biofilms; Bleomycin; Carmustine; Catheter-Related Infections; Central Venous Catheters; Cisplatin; Cross Infection; Cytarabine; Dacarbazine; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple, Bacterial; Equipment Contamination; Etoposide; Female; Gemcitabine; Gram-Negative Bacterial Infections; Hodgkin Disease; Humans; Immunocompromised Host; Melphalan; Methylobacterium; Prednisone; Ribotyping; Spain; Vinblastine | 2012 |
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Topics: Alleles; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Colonic Neoplasms; Deoxycytidine; DNA Topoisomerases, Type I; GATA2 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mutation; Nuclear Proteins; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; ras Proteins; RNA Interference; RNA, Small Interfering; Topoisomerase I Inhibitors; Topotecan; Transcriptional Activation | 2012 |
Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Topics: Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms; Tetrahydrouridine | 2012 |
SL-01, an oral gemcitabine derivative, inhibited human cancer growth more potently than gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Enzyme Activation; Female; Gemcitabine; Humans; In Situ Nick-End Labeling; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation | 2012 |
Triptolide cooperates with Cisplatin to induce apoptosis in gemcitabine-resistant pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Diterpenes; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Epoxy Compounds; Female; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Mitochondria; Neoplasm Transplantation; Pancreatic Neoplasms; Phenanthrenes; RNA, Small Interfering; Transfection | 2012 |
A feasibility study on gene therapy of pancreatic carcinoma with Ad-PUMA.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Combined Modality Therapy; Deoxycytidine; Feasibility Studies; Fluorouracil; Gemcitabine; Gene Expression; Genetic Therapy; Genetic Vectors; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Proto-Oncogene Proteins; Tumor Burden; Tumor Suppressor Protein p53 | 2012 |
Dimethylamino parthenolide enhances the inhibitory effects of gemcitabine in human pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Sesquiterpenes | 2012 |
Is renal thrombotic angiopathy an emerging problem in the treatment of ovarian cancer recurrences?
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Creatinine; Deoxycytidine; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Quality of Life; Recurrence; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Taxoids; Thrombosis; Topotecan | 2012 |
Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells.
Topics: AC133 Antigen; Adenosine; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Membrane Transport Proteins; Pancreatic Neoplasms; Peptides; Polycomb Repressive Complex 2; Spheroids, Cellular; Tumor Cells, Cultured | 2012 |
Unresectable pancreatic cancer: arterial embolization to achieve a single blood supply for intraarterial infusion of 5-fluorouracil and full-dose IV gemcitabine.
Topics: Antimetabolites, Antineoplastic; Contrast Media; Deoxycytidine; Embolization, Therapeutic; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Radiography, Interventional; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Chemotherapy-related thrombocytosis: does it increase the risk of thromboembolism?.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Platelet Count; Risk Factors; Thrombocytosis; Thromboembolism | 2012 |
Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Checkpoint Kinase 1; Cyclins; Deoxycytidine; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Mitosis; Nuclear Proteins; Polycomb Repressive Complex 2; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Quinolines; S Phase; Thiazoles; Thiophenes; Transcription Factors; Tumor Burden; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2012 |
Gemcitabine for advanced endometrial cancer: a retrospective study of the Memorial sloan-Kettering Cancer Center experience.
Topics: Adenocarcinoma, Clear Cell; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-125 Antigen; Cystadenocarcinoma, Serous; Deoxycytidine; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2012 |
High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemokine CX3CL1; Chemotherapy, Adjuvant; CX3C Chemokine Receptor 1; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Receptors, Chemokine; Retrospective Studies; Survival Analysis; Tissue Array Analysis; Up-Regulation | 2012 |
Inferring biochemical reaction pathways: the case of the gemcitabine pharmacokinetics.
Topics: Biotransformation; Computational Biology; Deoxycytidine; Gemcitabine; Kinetics; Metabolic Networks and Pathways; Protein Interaction Maps | 2012 |
Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-κB pathways.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Nude; NF-kappa B; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Random Allocation; Signal Transduction; Triterpenes; Ursolic Acid; Xenograft Model Antitumor Assays | 2012 |
Synthesis and biological evaluation of oral prodrugs based on the structure of gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Carcinoma, Hepatocellular; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Mice; Neoplasms; Prodrugs | 2012 |
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Lymphoma; Male; Melphalan; Middle Aged; Mucositis; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome | 2012 |
Variability of gemcitabine accumulation and its relationship to expression of nucleoside transporters in peripheral blood mononuclear cells.
Topics: Adult; Cells, Cultured; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation; Humans; Leukocytes, Mononuclear; Male; Membrane Transport Proteins; Nucleoside Transport Proteins | 2012 |
Combined modality treatment for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Complications; Treatment Outcome | 2012 |
Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.
Topics: Animals; Antibodies, Monoclonal; Antigen Presentation; Carcinoma, Squamous Cell; CD11b Antigen; Cell Differentiation; Cell Proliferation; Cells, Cultured; Deoxycytidine; Female; Gemcitabine; Immune Tolerance; Interferon-gamma; Lymphocyte Activation; Lymphocytes, Tumor-Infiltrating; Macrophages; Mice; Mice, Inbred BALB C; Myeloid Cells; Neutrophils; Receptors, Interleukin-6; Skin Neoplasms; Spleen; T-Lymphocytes | 2012 |
Tumor cavitation in patients with stage III non-small-cell lung cancer undergoing concurrent chemoradiotherapy: incidence and outcomes.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hemorrhage; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Pulmonary Embolism; Retrospective Studies; Risk Factors; Survival Rate | 2012 |
Improving drug delivery to pancreatic cancer: breaching the stromal fortress by targeting hyaluronic acid.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Adhesion Molecules; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Mice; Pancreatic Neoplasms; Recombinant Proteins | 2012 |
Preparation and evaluation of polymeric microparticulates for improving cellular uptake of gemcitabine.
Topics: Acrylic Resins; Adsorption; Caco-2 Cells; Calorimetry, Differential Scanning; Cell Survival; Chitosan; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Intestinal Secretions; Models, Biological; Mucins; Nanomedicine; Surface Properties | 2012 |
Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Ohio; Pancreatectomy; Pancreatic Neoplasms; Paraffin Embedding; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Risk Assessment; Risk Factors; Time Factors; Tissue Array Analysis; Treatment Outcome | 2012 |
Gemcitabine-induced severe peripheral edema in a patient with lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Edema; Gemcitabine; Humans; Lung Neoplasms; Male; Severity of Illness Index | 2012 |
Validity of the FACT Hepatobiliary (FACT-Hep) questionnaire for assessing disease-related symptoms and health-related quality of life in patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Patient Outcome Assessment; Psychometrics; Quality of Life; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires; Symptom Assessment | 2013 |
[Emodin combined gemcitabine inhibited the growth of pancreatic cancer in vitro and in vivo and its mechanisms study].
Topics: Animals; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Emodin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Xenograft Model Antitumor Assays | 2012 |
Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Mice; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Paclitaxel; Retrospective Studies | 2012 |
[Basic investigation for classification of anticancer drugs by pharmacological effects].
Topics: Antineoplastic Agents; Carboplatin; Cell Survival; Cisplatin; Deoxycytidine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; MCF-7 Cells; Paclitaxel; Time Factors; Tumor Cells, Cultured | 2012 |
Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
Topics: Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Azacitidine; Busulfan; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 2; Cytotoxins; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; DNA Methyltransferase 3B; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Hydroxamic Acids; Lymphoma; Melphalan; Protein Serine-Threonine Kinases; Transplantation Conditioning; Transplantation, Homologous; Tumor Suppressor Proteins | 2012 |
Cholangiocarcinoma in a young woman with perinatally acquired HIV.
Topics: Adult; Antimetabolites, Antineoplastic; Antiretroviral Therapy, Highly Active; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; HIV Infections; Humans; Jaundice; Treatment Outcome; Young Adult | 2013 |
BOOP as a rare complication of gemcitabine therapy.
Topics: Antimetabolites, Antineoplastic; Cryptogenic Organizing Pneumonia; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged | 2011 |
Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Remission Induction; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2012 |
Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases | 2012 |
Gemcitabine associated pseudocellulitis.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Diagnosis, Differential; Follow-Up Studies; Gemcitabine; Humans; Lower Extremity; Male; Pancreatic Neoplasms; Risk Assessment | 2012 |
The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Community Health Services; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Tennessee; Time Factors; Treatment Outcome | 2013 |
Guggulsterone enhances antitumor activity of gemcitabine in gallbladder cancer cells through suppression of NF-κB.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Matrix Metalloproteinase 2; Neoplasm Invasiveness; NF-kappa B; Pregnenediones; Vascular Endothelial Growth Factor C | 2012 |
Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cholangitis; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Peripheral Nervous System Diseases; Retrospective Studies; Sarcopenia; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2012 |
Gemcitabine causes telomere attrition by stabilizing TRF2.
Topics: Antimetabolites, Antineoplastic; Cell Division; Chromatin Immunoprecipitation; Deoxycytidine; DNA-Binding Proteins; DNA, Neoplasm; Endonucleases; Gemcitabine; Gene Expression Regulation, Neoplastic; Half-Life; HeLa Cells; Humans; In Vitro Techniques; Neoplasm Proteins; Polymorphism, Restriction Fragment Length; Protein Binding; Protein Interaction Mapping; Protein Processing, Post-Translational; Protein Stability; Recombinant Fusion Proteins; Telomere; Telomeric Repeat Binding Protein 2; Ubiquitination; Up-Regulation | 2012 |
Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Biotransformation; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Chi-Square Distribution; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; France; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Multivariate Analysis; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Risk Assessment; Risk Factors; Time Factors; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Gemcitabine; Humans; Hydrazines; Liposomes; MCF-7 Cells; Mice; Mice, Inbred NOD; Mice, SCID; Nylons; Xenograft Model Antitumor Assays | 2012 |
Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine.
Topics: Acetylcysteine; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ion Channels; Iridoids; Mitochondrial Proteins; Neoplasms; Poly(ADP-ribose) Polymerases; RNA, Messenger; Superoxide Dismutase; Superoxides; Uncoupling Agents; Uncoupling Protein 2 | 2012 |
Lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase driven by the hTERT promoter combined with gemcitabine: a potential strategy for cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drosophila melanogaster; Female; Gemcitabine; Gene Expression; Gene Order; Genetic Therapy; Genetic Vectors; Humans; Lentivirus; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Phosphotransferases (Alcohol Group Acceptor); Prohibitins; Promoter Regions, Genetic; Telomerase | 2012 |
Aldehyde dehydrogenase 1A1 confers intrinsic and acquired resistance to gemcitabine in human pancreatic adenocarcinoma MIA PaCa-2 cells.
Topics: Adenocarcinoma; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Retinal Dehydrogenase; RNA Interference; RNA, Small Interfering | 2012 |
Oridonin enhances antitumor activity of gemcitabine in pancreatic cancer through MAPK-p38 signaling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diterpenes, Kaurane; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Random Allocation; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Antineoplastic Agents; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; Deoxycytidine; Epitopes; Female; Gemcitabine; Histocompatibility Antigens Class I; Interferon-gamma; Interleukin-2; Mesothelioma; Mice; Mice, Inbred C57BL; Ovalbumin; T-Lymphocytes, Cytotoxic; Transfection | 2012 |
Intervention of mirtazapine on gemcitabine-induced mild cachexia in nude mice with pancreatic carcinoma xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Body Weight; Cachexia; Carcinoma; Cell Line, Tumor; Deoxycytidine; Eating; Gemcitabine; Humans; Mianserin; Mice; Mice, Inbred BALB C; Mice, Nude; Mirtazapine; Nutritional Status; Pancreatic Neoplasms; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Significant response to gemcitabine monotherapy in primary pleural epithelioid angiosarcoma.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Epithelioid Cells; Gemcitabine; Hemangiosarcoma; Humans; Male; Pleural Neoplasms; Prognosis; Tomography, X-Ray Computed | 2012 |
Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bevacizumab; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Pyrroles; Sunitinib; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Akt/mTOR signaling pathway is crucial for gemcitabine resistance induced by Annexin II in pancreatic cancer cells.
Topics: Aged; Annexin A2; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Cell Survival; Deoxycytidine; Drug Stability; Female; Gemcitabine; Half-Life; Humans; Linoleic Acid; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Nucleoside Transport Proteins; Prodrugs; Rats; Rats, Sprague-Dawley | 2012 |
Coadministration of 5% glucose solution relieves vascular pain in the patients administered gemcitabine immediately.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Glucose; Humans; Male; Middle Aged; Neoplasms; Pain; Treatment Outcome | 2013 |
Acute liver failure secondary to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Liver Failure, Acute; Liver Function Tests; Male; Middle Aged; Neoplasm Staging | 2010 |
Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Ribonucleoside Diphosphate Reductase; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Inhibitor of Apoptosis Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2012 |
Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Topics: Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; CHO Cells; Cricetinae; Cricetulus; Cytarabine; Cytosine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; DNA-Binding Proteins; Gemcitabine; Homologous Recombination; Inhibitory Concentration 50; Prodrugs | 2012 |
The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cyclic S-Oxides; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Receptor, Notch1; Thiadiazoles; Transcriptome; Xenograft Model Antitumor Assays | 2012 |
hTERT-siRNA could potentiate the cytotoxic effect of gemcitabine to pancreatic cancer cells Bxpc-3.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Colorimetry; Cytomegalovirus; Deoxycytidine; Down-Regulation; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Messenger; RNA, Small Interfering; Telomerase; Time Factors; Transfection | 2012 |
UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Ubiquitin-Conjugating Enzymes | 2012 |
Paraneoplastic Raynaud's phenomenon manifesting before the diagnosis of lung cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Raynaud Disease | 2012 |
Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.
Topics: Antibodies, Viral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Line, Tumor; Deoxycytidine; DNA, Viral; Dose-Response Relationship, Drug; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunoglobulin G; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Treatment Outcome; Valproic Acid; Viral Load; Virus Activation | 2012 |
Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Targeting the MAGE A3 antigen in pancreatic cancer.
Topics: Adenocarcinoma; Antigens, Neoplasm; Azacitidine; Cell Line, Tumor; Chromatin Assembly and Disassembly; Cytokines; Decitabine; Deoxycytidine; DNA Methylation; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Male; Neoplasm Proteins; Pancreas; Pancreatic Neoplasms; Receptors, Antigen, T-Cell; T-Lymphocytes; Testis; Valproic Acid | 2012 |
Recurrent lower extremity pseudocellulitis.
Topics: Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Drug Eruptions; Gemcitabine; Humans; Inflammation; Lower Extremity; Lung Neoplasms; Lymphedema; Male; Middle Aged | 2012 |
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Pilot Projects; Recurrence; Rituximab; Treatment Outcome | 2013 |
Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Treatment Outcome | 2013 |
Gemcitabine-induced pleuropericardial effusion in a patient with pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Pericardial Effusion; Pleural Effusion | 2012 |
Surface-modified gemcitabine with mucoadhesive polymer for oral delivery.
Topics: Acrylic Resins; Administration, Oral; Antimetabolites, Antineoplastic; Caco-2 Cells; Chitosan; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Microspheres; Particle Size; Polyethylene Glycols; Polyvinyls | 2012 |
The antitumor activity of recombinant antitumor antiviral protein and the associated molecular mechanism in pancreatic tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; Interferons; Mice; Mice, Nude; Pancreatic Neoplasms; Recombinant Proteins; Xenograft Model Antitumor Assays | 2012 |
HuR's post-transcriptional regulation of Death Receptor 5 in pancreatic cancer cells.
Topics: 5' Untranslated Regions; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytoplasm; Deoxycytidine; ELAV Proteins; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Pancreatic Neoplasms; Protein Transport; Proteolysis; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA Processing, Post-Transcriptional; RNA, Messenger | 2012 |
Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Mice; Neoplasms; Ribonucleoside Diphosphate Reductase; RNA Interference; RNA, Small Interfering; Tumor Suppressor Proteins | 2012 |
Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.
Topics: Animals; Antimetabolites, Antineoplastic; Checkpoint Kinase 1; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Everolimus enhances gemcitabine-induced cytotoxicity in bladder-cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Comet Assay; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Gemcitabine; Humans; Mutagens; Neoplasm Invasiveness; Osmolar Concentration; S Phase; Sirolimus; Urinary Bladder Neoplasms | 2012 |
Study on effectiveness of gemcitabine, dexamethasone, and cisplatin (GDP) for relapsed or refractory AIDS-related non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; HIV-1; Humans; Lymphoma, AIDS-Related; Male; Middle Aged; Myelopoiesis; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Analysis; Virus Replication; Young Adult | 2012 |
Localized delivery of chemotherapy to the cervix for radiosensitization.
Topics: Antimetabolites, Antineoplastic; Cervix Uteri; Deoxycytidine; Diazepam; Drug Delivery Systems; Drug Interactions; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Radiation-Sensitizing Agents | 2012 |
Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Eukaryotic Initiation Factor-4E; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Isoenzymes; Kaplan-Meier Estimate; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; RNA Splicing; RNA-Binding Proteins; Serine-Arginine Splicing Factors; Signal Transduction | 2013 |
Novel agents and new combination treatments on phase I studies on solid tumors and pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Neoplasms; Pancreatic Neoplasms; Sirolimus | 2012 |
Hypersensitivity reactions to oxaliplatin: clinical features and risk factors in Koreans.
Topics: Aged; Anaphylaxis; Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dexamethasone; Drug Eruptions; Drug Hypersensitivity; Female; Fluorouracil; Gemcitabine; Glucocorticoids; Histamine H1 Antagonists; Humans; Hydrocortisone; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prevalence; Republic of Korea; Retrospective Studies; Risk Factors | 2012 |
First-line combination of gemcitabine, oxaliplatin, and L-asparaginase (GELOX) followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma.
Topics: Adult; Aged; Aluminum Hydroxide; Antineoplastic Combined Chemotherapy Protocols; Bentonite; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphoma, Extranodal NK-T-Cell; Magnesium Hydroxide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Treatment Outcome; Young Adult | 2013 |
Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cluster Analysis; Deoxycytidine; Disease Models, Animal; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mice; Protein Kinase Inhibitors; Protein Kinases; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA Interference; RNA, Small Interfering; Staurosporine; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2012 |
Bendamustine salvage for the treatment of relapsed Hodgkin's lymphoma after allogeneic bone marrow transplantation.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bleomycin; Bone Marrow Transplantation; Chemical and Drug Induced Liver Injury; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Deoxycytidine; Doxorubicin; Etoposide; Fatal Outcome; Female; Gemcitabine; Graft vs Host Disease; Hodgkin Disease; Humans; Ifosfamide; Male; Nitrogen Mustard Compounds; Prednisolone; Prednisone; Procarbazine; Recurrence; Reoperation; Rituximab; Salvage Therapy; Transplantation, Autologous; Transplantation, Homologous; Vinblastine; Vincristine; Vinorelbine; Young Adult | 2013 |
Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Macrophage Migration-Inhibitory Factors; Male; Mice, Nude; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; RNA Interference; Transplantation, Heterologous | 2013 |
The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Hypoxia; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Pyrazines; Radiation-Sensitizing Agents; Signal Transduction; Sulfones | 2012 |
Assessment of gemcitabine, cisplatin and methylprednisolone (GEM-P) combination treatment for non-Hodgkin T cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphoma, T-Cell; Male; Methylprednisolone; Middle Aged; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Young Adult | 2012 |
A retrospective study of S-1 monotherapy as second-line treatment for patients with advanced biliary tract cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Tegafur; Treatment Outcome | 2012 |
Cancer cell-derived supernatants that support the carcinogenic process: a future cancer therapy target?
Topics: Antineoplastic Agents; Cyclophosphamide; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Tumor Microenvironment | 2012 |
Synergic effect of photodynamic therapy using talaporfin sodium with conventional anticancer chemotherapy for the treatment of bile duct carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Organoplatinum Compounds; Oxaliplatin; Photochemotherapy; Photosensitizing Agents; Porphyrins; Proliferating Cell Nuclear Antigen; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
sVEGF R1 and Tie-2 levels during chemotherapy of lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Pulmonary Disease, Chronic Obstructive; Receptor, TIE-2; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Can pharmacogenomics guide effective anticancer therapy in pancreatic ductal adenocarcinoma?
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pharmacogenetics | 2012 |
Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Floxuridine; Gemcitabine; Genetic Association Studies; Humans; Male; Metabolic Networks and Pathways; Middle Aged; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide | 2012 |
Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease Progression; Female; Gemcitabine; Genetic Association Studies; Haplotypes; Humans; Male; Metabolic Networks and Pathways; Middle Aged; Nucleoside-Phosphate Kinase; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Treatment Outcome | 2012 |
Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A degradation and cell-cycle attenuation in pancreatic carcinoma cells.
Topics: Benzoquinones; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Novobiocin; Pancreatic Neoplasms; Protein Kinases; Protein Serine-Threonine Kinases; Proteolysis; Proto-Oncogene Mas | 2012 |
Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; C-Reactive Protein; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Inflammation; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Urinary Bladder Neoplasms | 2012 |
Effects of gemcitabine and gemcitabine in combination with carboplatin on five canine transitional cell carcinoma cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Transitional Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dog Diseases; Dogs; Drug Synergism; Drug Therapy, Combination; Gemcitabine | 2012 |
Role of heat shock protein 27 in gemcitabine-resistant human pancreatic cancer: comparative proteomic analyses.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Female; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; Male; Mass Spectrometry; Middle Aged; Pancreatic Neoplasms; Proteome | 2012 |
Rosiglitazone and Gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pioglitazone; Rosiglitazone; T-Lymphocytes; Thiazolidinediones; Xenograft Model Antitumor Assays | 2013 |
Use of low-dose combined therapy with gemcitabine and paclitaxel for advanced urothelial cancer patients with resistance to cisplatin-containing therapy: a retrospective analysis.
Topics: Aged; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pain; Pain Measurement; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urologic Neoplasms; Urothelium | 2012 |
Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers.
Topics: Base Sequence; Cell Line, Tumor; Cyclin-Dependent Kinases; Deoxycytidine; DNA Primers; Flavones; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
Cavitary pulmonary metastases of pancreas cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Pancreatic Neoplasms | 2013 |
[Combined effect of gemcitabine and lomustine in mice with intracranial transplanted lymphosarcoma LIO-1].
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Gemcitabine; Injections, Intraperitoneal; Lomustine; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Mice; Survival Analysis | 2012 |
Effective use of gemcitabine in the treatment of undifferentiated carcinoma with osteoclast-like giant cells of the pancreas with portal vein tumor thrombus.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Disease Progression; Female; Gemcitabine; Giant Cells; Humans; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Remission Induction; Thrombectomy; Tomography, X-Ray Computed; Venous Thrombosis | 2012 |
Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chlortetracycline; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins | 2012 |
Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine.
Topics: Aged; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Humans; Male; Mice; Mice, SCID; Middle Aged; Pancreatic Neoplasms; Statistics, Nonparametric; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Long term survivors with metastatic pancreatic cancer treated with gemcitabine alone or plus cisplatin: a retrospective analysis of an Anatolian Society of Medical Oncology multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Survivors | 2012 |
Triplet platinum-based combination sequential chemotherapy improves survival outcome and quality of life of advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Quality of Life; Survival Rate; Vinblastine; Vinorelbine; Young Adult | 2012 |
Gemcitabine-based concurrent chemoradiotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Retrospective Studies; Survival Rate | 2012 |
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Stomach Neoplasms; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Vinblastine; Vinorelbine | 2012 |
[A case of unresectable hilar cholangiocarcinoma successfully treated by gemcitabine and S-1 combination chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Stents; Tegafur | 2012 |
sMEK1 enhances gemcitabine anti-cancer activity through inhibition of phosphorylation of Akt/mTOR.
Topics: Carcinoma, Ovarian Epithelial; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphoprotein Phosphatases; Phosphorylation; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2012 |
Role of chitosan nanoparticles in the oral absorption of Gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Calorimetry, Differential Scanning; Chitosan; Deoxycytidine; Drug Carriers; Gemcitabine; Intestinal Mucosa; Male; Microscopy, Electron, Scanning; Nanoparticles; Rats; Rats, Wistar; Spectroscopy, Fourier Transform Infrared | 2012 |
Obatoclax, saliphenylhalamide, and gemcitabine inhibit influenza a virus infection.
Topics: Amides; Animals; Antiviral Agents; Chlorocebus aethiops; Deoxycytidine; Dogs; Gemcitabine; Humans; Indoles; Influenza A Virus, H3N2 Subtype; Influenza, Human; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrroles; RNA, Viral; Salicylates; Vero Cells; Virus Replication | 2012 |
Randomization and statistical power: paramount in trial reproducibility (even for rare cancers).
Topics: Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Male; Taxoids | 2012 |
Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
Topics: Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Arginase; CD11b Antigen; Cell Line, Tumor; Cyclophosphamide; Deoxycytidine; Female; Forkhead Transcription Factors; Gemcitabine; Interferon-gamma; Leukocyte Common Antigens; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Neoplasms; Receptors, Chemokine; T-Lymphocytes; T-Lymphocytes, Regulatory; Tumor Escape | 2013 |
Retrovolution: HIV-driven evolution of cellular genes and improvement of anticancer drug activation.
Topics: Amino Acid Sequence; Animals; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Targeting; Genetic Variation; HIV-1; Humans; Models, Molecular; Molecular Sequence Data; Mutation; Neoplasms; Protein Serine-Threonine Kinases; Sequence Alignment; Vesiculovirus | 2012 |
Synergistic effects of nanosecond pulsed electric fields combined with low concentration of gemcitabine on human oral squamous cell carcinoma in vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Gemcitabine; Humans; Mouth Neoplasms; Necrosis; Neoplasm Invasiveness; Time Factors | 2012 |
Curcumin-cyclodextrin complexes potentiate gemcitabine effects in an orthotopic mouse model of lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Curcumin; Cyclodextrins; Deoxycytidine; Drug Synergism; G2 Phase; Gemcitabine; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Tumor Cells, Cultured | 2012 |
Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Ascites; Blotting, Western; Carboplatin; Cell Line, Tumor; Cisplatin; Cystadenocarcinoma, Serous; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, SCID; Middle Aged; Ovarian Neoplasms; Paclitaxel; Topotecan; Xenograft Model Antitumor Assays | 2012 |
Polyisoprenoyl gemcitabine conjugates self assemble as nanoparticles, useful for cancer therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; MCF-7 Cells; Melanoma, Experimental; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Random Allocation; Terpenes; Xenograft Model Antitumor Assays | 2013 |
Combined chemotherapy with gemcitabine and carboplatin for metastatic urothelial carcinomas in patients with high renal insufficiency.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Renal Insufficiency; Urologic Neoplasms; Urothelium | 2013 |
Development of a unique mouse model for pancreatic cancer lymphatic metastasis.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cluster Analysis; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymph Nodes; Lymphatic Metastasis; Mice; Pancreatic Neoplasms; Transplantation, Heterologous | 2012 |
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Treatment Failure; Vinblastine; Vinorelbine | 2012 |
Expression of the antiapoptotic protein BAG3 is a feature of pancreatic adenocarcinoma and its overexpression is associated with poorer survival.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Aged; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Proportional Hazards Models; Survival Analysis | 2012 |
Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models.
Topics: Animals; Antigen Presentation; Antimetabolites, Antineoplastic; Chlorocebus aethiops; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Herpes Simplex; Injections, Intralesional; Interferon-gamma; Mice; Mice, Inbred BALB C; Oncolytic Virotherapy; Simplexvirus; Spleen; T-Lymphocytes; Vero Cells | 2013 |
Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-Notch signaling in both tumor and vasculature cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Anti-Idiotypic; Calcium-Binding Proteins; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2012 |
Pristimerin causes G1 arrest, induces apoptosis, and enhances the chemosensitivity to gemcitabine in pancreatic cancer cells.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Pentacyclic Triterpenes; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Triterpenes | 2012 |
Efficacy of minimally invasive therapies on unresectable pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Brachytherapy; Catheter Ablation; Chemoembolization, Therapeutic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Remission Induction; Survival Rate | 2013 |
The cellular level of histone H3 lysine 4 dimethylation correlates with response to adjuvant gemcitabine in Japanese pancreatic cancer patients treated with surgery.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Histones; Humans; Immunohistochemistry; Lysine; Male; Methylation; Middle Aged; Pancreatic Neoplasms | 2012 |
Characterization of proteins secreted by pancreatic cancer cells with anticancer drug treatment in vitro.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Lactoferrin; Neoplasm Proteins; Pancreatic Neoplasms; Proteomics; S100 Proteins; Transferrin | 2012 |
Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Clusterin; Deoxycytidine; Flavonoids; Gemcitabine; Gene Knockdown Techniques; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms; Thionucleotides | 2012 |
Role of taxanes in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Radiotherapy; Salvage Therapy; Taxoids; Treatment Outcome | 2012 |
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Platinum; Retrospective Studies; Survival Rate; Treatment Failure; Treatment Outcome | 2012 |
Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromatography, Liquid; Crizotinib; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Mass Spectrometry; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines | 2013 |
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Dose-Response Relationship, Radiation; Female; Fluorouracil; Gemcitabine; Genetic Therapy; Genetic Vectors; Humans; Kaplan-Meier Estimate; Male; Metalloporphyrins; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha | 2012 |
Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Survival Analysis; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2012 |
DNA repair polymorphisms and treatment outcomes of patients with malignant mesothelioma treated with gemcitabine-platinum combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cell Cycle Proteins; Deoxycytidine; DNA; DNA Repair; DNA-Binding Proteins; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Nuclear Proteins; Peritoneal Neoplasms; Platinum; Pleural Effusion, Malignant; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Rad51 Recombinase; Survival Rate; X-ray Repair Cross Complementing Protein 1 | 2012 |
Bronchoesophageal fistula in a patient with stage IIIB non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Fistula; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Esophageal Fistula; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Tomography, X-Ray Computed | 2012 |
Treatment of advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Platinum | 2012 |
Salvage chemotherapy using gemcitabine for taxane/platinum-resistant recurrent ovarian cancer: a single institutional experience.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bridged-Ring Compounds; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Retrospective Studies; Salvage Therapy; Taxoids | 2012 |
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Control Studies; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2012 |
Gemcitabine-induced pulmonary toxicity.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pneumonia | 2012 |
Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Treatment Outcome | 2012 |
Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cholesterol; Deoxycytidine; Gemcitabine; Humans; Lactic Acid; Liposomes; Microscopy, Electron, Transmission; Nanotechnology; Pancreatic Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2012 |
Adenocarcinoma of the lung with miliary brain and pulmonary metastases with echinoderm microtubule-associated protein like 4-anaplastic lymphoma kinase translocation treated with crizotinib: a case report.
Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Cisplatin; Crizotinib; Deoxycytidine; DNA Mutational Analysis; Fatal Outcome; Female; Gemcitabine; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Oncogene Proteins, Fusion; Pyrazoles; Pyridines; Translocation, Genetic | 2012 |
Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Comorbidity; Deoxycytidine; Diabetes Mellitus; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Tegafur; Time Factors; Treatment Outcome | 2013 |
The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Luciferases, Firefly; Luminescent Measurements; Mice; Mice, Nude; Pancreatic Neoplasms; Quercetin; Time Factors; Transduction, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
miR-17-5p inhibitor enhances chemosensitivity to gemcitabine via upregulating Bim expression in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Caspase 3; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation; Gene Silencing; Humans; Membrane Proteins; MicroRNAs; Proto-Oncogene Proteins; Transfection; Up-Regulation | 2012 |
Preclinical combination therapy of clofarabine plus radiation.
Topics: Adenine Nucleotides; Animals; Antineoplastic Agents; Arabinonucleosides; Cell Line, Tumor; Clofarabine; Combined Modality Therapy; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasms, Experimental; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Sarcoma; Taxoids; Vascular Endothelial Growth Factor A | 2012 |
Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cell Line, Tumor; CpG Islands; Decitabine; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Enzyme Stability; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Histone Deacetylase 1; Humans; Promoter Regions, Genetic; Tumor Suppressor Proteins; Vascular Endothelial Growth Factor Receptor-1 | 2012 |
Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; ErbB Receptors; Fluorouracil; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Survivin | 2012 |
Tumor size as measured at initial X-ray examination, not length of bile duct stricture, predicts survival in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Bile Ducts; Cholangiopancreatography, Endoscopic Retrograde; Constriction, Pathologic; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tomography, X-Ray Computed | 2012 |
Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carcinoma; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies | 2012 |
Aquaporin 3 (AQP3) participates in the cytotoxic response to nucleoside-derived drugs.
Topics: Antineoplastic Agents; Apoptosis; Aquaporin 3; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Size; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; fas Receptor; Floxuridine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; MCF-7 Cells; Nucleosides; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Up-Regulation | 2012 |
Synergistic effects of photodynamic therapy with HPPH and gemcitabine in pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Chlorophyll; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Photochemotherapy; Photosensitizing Agents | 2012 |
Evidence for different mechanisms of 'unhooking' for melphalan and cisplatin-induced DNA interstrand cross-links in vitro and in clinical acquired resistant tumour samples.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA; DNA Damage; DNA Repair; DNA Replication; Drug Resistance, Neoplasm; Female; Gemcitabine; Histones; Homologous Recombination; Humans; Melphalan; Multiple Myeloma; Ovarian Neoplasms; Rad51 Recombinase; Signal Transduction | 2012 |
Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Middle Aged; Neoplasm Staging; Recurrence; Salvage Therapy; Transplantation, Autologous; Treatment Outcome; Young Adult | 2013 |
Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Reproducibility of Results; RNA Interference; RNA, Messenger; Wound Healing | 2012 |
Progress in pancreatic cancer: moving beyond gemcitabine?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2012 |
Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Aptamers, Nucleotide; Base Sequence; Cell Death; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Screening Assays, Antitumor; Endocytosis; ErbB Receptors; Fluorescent Dyes; Gemcitabine; Humans; Microscopy, Fluorescence; Molecular Sequence Data; Pancreatic Neoplasms; Staining and Labeling | 2012 |
Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells.
Topics: Aldehyde Dehydrogenase; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Copper; Cytotoxicity, Immunologic; Deoxycytidine; Disulfiram; Drug Synergism; Gemcitabine; Glioblastoma; Humans; MAP Kinase Kinase 4; MAP Kinase Signaling System; Neoplastic Stem Cells; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Reactive Oxygen Species | 2012 |
Lack of association of genetic variations of deoxycytidine kinase with toxicity or survival of non-small-cell lung cancer patients treated with gemcitabine plus cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Gene Frequency; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenetics; Polymorphism, Single Nucleotide; Proportional Hazards Models; Survival Rate | 2012 |
CD133(+)/CD44(+)/Oct4(+)/Nestin(+) stem-like cells isolated from Panc-1 cell line may contribute to multi-resistance and metastasis of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Multiple; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Intermediate Filament Proteins; Mice; Mice, SCID; Neoplasm Metastasis; Nerve Tissue Proteins; Nestin; Octamer Transcription Factor-3; Pancreatic Neoplasms; Polymerase Chain Reaction; Stem Cells | 2013 |
Paclitaxel plus doxorubicin chemotherapy as second-line therapy in patients with advanced urothelial carcinoma pretreated with platinum plus gemcitabine chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Platinum; Premedication; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Young Adult | 2012 |
Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Ascites; Ascitic Fluid; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Endostatins; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Neoplasm Staging; Pleural Effusion, Malignant; Recombinant Proteins; Secondary Prevention; Severity of Illness Index; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Antimetabolites, Antineoplastic; Aspartate Aminotransferases; Benzamides; Cell Line, Tumor; Chitosan; Deoxycytidine; Drug Carriers; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Polyethylene Glycols; Tissue Distribution; Urea | 2012 |
Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Enzyme Activation; Female; Gemcitabine; Humans; MAP Kinase Kinase 4; Mice; Mice, Nude; Pancreatic Neoplasms; Tetradecanoylphorbol Acetate; Xenograft Model Antitumor Assays | 2012 |
Use of gemcitabine with multi-stage surgical resection as successful second-line treatment of metastatic pancreatoblastoma.
Topics: Antimetabolites, Antineoplastic; Child; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Salvage Therapy; Tomography, X-Ray Computed | 2013 |
Safety and effectiveness of gemcitabine in 260 patients with biliary tract cancer in a Japanese clinical practice based on post-marketing surveillance in Japan.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Asian People; Biliary Tract Neoplasms; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Exanthema; Female; Fever; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Liver Function Tests; Male; Middle Aged; Product Surveillance, Postmarketing; Treatment Outcome; Young Adult | 2012 |
Effect analysis of chemoradiotherapy after operation in patients with stage III A non-small cell lung cancer.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Postoperative Period; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
Alternating chemotherapy: gemcitabine and cisplatin with concurrent radiotherapy for treatment of advanced head and neck cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deglutition Disorders; Deoxycytidine; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Leukopenia; Male; Middle Aged; Neoplasm Staging; Radiation-Sensitizing Agents; Radiodermatitis; Radiotherapy Dosage; Remission Induction; Safety; Stomatitis; Survival Rate; Treatment Outcome; Xerostomia | 2013 |
BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Immunohistochemistry; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Pyrazoles; Random Allocation; Receptor, IGF Type 1; Signal Transduction; Triazines; Xenograft Model Antitumor Assays | 2012 |
[The effect of presurgical gemcitabine cisplatin chemotherapy for urothelial carcinoma].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urologic Neoplasms | 2012 |
[A case of renal salt wasting syndrome progressing to severe hyponatremia after gemcitabine-cisplatin chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Diagnosis, Differential; Gemcitabine; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Diseases; Male; Sodium; Urinary Bladder Neoplasms | 2012 |
Toxicogenomic activity of gemcitabine in two TP53-mutated bladder cancer cell lines: special focus on cell cycle-related genes.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Transcriptome; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2012 |
Photodynamic therapy for pancreatic and biliary tract cancer: the United Kingdom experience.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Photochemotherapy; Survival Rate; Treatment Outcome; United Kingdom | 2012 |
Lipocalin2 promotes invasion, tumorigenicity and gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunohistochemistry; In Vitro Techniques; Lipocalins; Mice; Pancreatic Neoplasms | 2012 |
Endoscopic self-expandable metallic stent placement in malignant pyloric or duodenal obstruction: does chemotherapy affect stent patency?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Deoxycytidine; Duodenal Obstruction; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Intestinal Obstruction; Male; Palliative Care; Pancreatic Neoplasms; Prognosis; Pylorus; Stents; Stomach Neoplasms | 2013 |
Gemcitabine, oxaliplatin and dexamethasone as salvage treatment for elderly patients with refractory and relapsed peripheral T-cell lymphoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pilot Projects; Recurrence; Salvage Therapy; Treatment Outcome | 2013 |
Here it comes....the role of cost-effective analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Uterine Cervical Neoplasms | 2012 |
Serum biomarkers analyzed by LC-MS/MS as predictors for short outcome of non-small cell lung cancer patients treated with chemoradiotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Chromatography, Liquid; Cisplatin; Deoxycytidine; Docetaxel; Electrophoresis, Gel, Two-Dimensional; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Prognosis; Proteomics; Radiotherapy, Intensity-Modulated; Tandem Mass Spectrometry; Taxoids; Vinblastine; Vinorelbine | 2013 |
miRNA profiling in pancreatic cancer and restoration of chemosensitivity.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreatic Neoplasms | 2013 |
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids | 2012 |
LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzimidazoles; Blotting, Western; Carbocyanines; Cell Death; Cell Line, Tumor; Ceramides; Chromatography, High Pressure Liquid; Coloring Agents; Cytochromes c; Deoxycytidine; Female; Gemcitabine; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Mitochondria; Oxygen Consumption; Pancreatic Neoplasms; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Spectrum Analysis; Xenograft Model Antitumor Assays | 2013 |
Intrahepatic cholangiocarcinoma arising 28 years after excision of a type IV-A congenital choledochal cyst: report of a case.
Topics: Adult; Anastomosis, Roux-en-Y; Antimetabolites, Antineoplastic; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Choledochal Cyst; Deoxycytidine; Duodenum; Female; Follow-Up Studies; Gemcitabine; Hepatectomy; Humans; Jejunostomy; Liver Neoplasms; Pancreatectomy; Pancreatic Juice; Time Factors; Treatment Outcome | 2014 |
Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biliary Tract Neoplasms; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Cisplatin-gemcitabine as palliative chemotherapy in advanced squamous vulvar carcinoma: report of two cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Palliative Care; Vulvar Neoplasms | 2012 |
Gemcitabine-loaded biocompatible nanocapsules for the effective treatment of human cancer.
Topics: Animals; Cell Line; Cell Survival; Deoxycytidine; Gemcitabine; HEK293 Cells; Humans; Lactic Acid; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Confocal; Nanocapsules; Nanomedicine; Polyesters; Polymers; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Modelling non-homogeneous stochastic reaction-diffusion systems: the case study of gemcitabine-treated non-small cell lung cancer growth.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Diffusion; Gemcitabine; Humans; Lung Neoplasms; Models, Biological; Viscosity | 2012 |
Knockdown of Ezrin by RNA interference reverses malignant behavior of human pancreatic cancer cells in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2012 |
Retrospective study of gemcitabine based chemotherapy for unresectable or recurrent esophagus squamous cell carcinoma refractory to first line chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2012 |
Enhancement of gene gun-induced vaccine-specific cytotoxic T-cell response by administration of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Biolistics; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Spleen; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Vaccination; Vaccines | 2013 |
Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Nose Neoplasms; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Skin Neoplasms; Survival Rate | 2013 |
Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Cell Movement; Cell Proliferation; Cyclohexanones; Deoxycytidine; Disease Models, Animal; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunoenzyme Techniques; Interleukin-8; Liver Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; DNA Damage; Doxorubicin; Drug Synergism; Etoposide; Gemcitabine; Imidazoles; Immunohistochemistry; Immunoprecipitation; Indoles; Mice; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins c-mdm2; Pyrrolidinones; Topoisomerase II Inhibitors | 2013 |
IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Chromatin Immunoprecipitation; Cohort Studies; Deoxycytidine; DNA Modification Methylases; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation; Histone Deacetylase Inhibitors; Humans; Interleukin-23; Lung Neoplasms; Macrophages; Neoplasm Staging; Tumor Cells, Cultured | 2013 |
Involvement of phosphatidylinositol 3-kinase/Akt pathway in gemcitabine-induced apoptosis-like cell death in insulinoma cell line INS-1.
Topics: Androstadienes; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Death; Cell Line, Tumor; Chromones; Deoxycytidine; Gemcitabine; Insulinoma; Morpholines; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Wortmannin | 2012 |
High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survivin; Up-Regulation | 2013 |
Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Platinum; Prognosis; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Signet ring cell adenocarcinoma of the ampulla of Vater: a rare pathology.
Topics: Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Diagnostic Imaging; Female; Gemcitabine; Humans; Lymphatic Metastasis; Pancreaticoduodenectomy | 2012 |
Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy.
Topics: Adenocarcinoma; Adipose Tissue; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fibrosis; Gemcitabine; Humans; Length of Stay; Male; Middle Aged; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Fistula; Pancreatic Neoplasms; Pancreaticoduodenectomy; Postoperative Hemorrhage; Time Factors; Treatment Outcome | 2013 |
Long term survival after trimodal therapy in malignant pleural mesothelioma.
Topics: Adult; Aged; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Length of Stay; Male; Mesothelioma; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum Compounds; Pleural Neoplasms; Pneumonectomy; Postoperative Complications; Retrospective Studies | 2012 |
Preparation and characterization of gemcitabine liposome injections.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Delivery Systems; Electrochemistry; Gemcitabine; Injections; Liposomes; Microscopy, Electron, Transmission; Pancreatic Neoplasms; Particle Size | 2012 |
Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Proportional Hazards Models; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
Therapy of Smac mimetic SM-164 in combination with gemcitabine for pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Caspase 3; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Triazoles; Xenograft Model Antitumor Assays | 2013 |
In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chemistry, Pharmaceutical; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Xenograft Model Antitumor Assays | 2013 |
Disease volumes as a marker for patient response in malignant pleural mesothelioma.
Topics: Aged; Aged, 80 and over; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Prognosis; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Chronic nicotine inhibits the therapeutic effects of gemcitabine on pancreatic cancer in vitro and in mouse xenografts.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Administration Schedule; Drug Antagonism; Drug Evaluation, Preclinical; Gemcitabine; Humans; Male; Mice; Mice, Nude; Nicotine; Pancreatic Neoplasms; Time Factors; Xenograft Model Antitumor Assays | 2013 |
Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Deoxycytidine; Gemcitabine; Humans; Indoles; Pancreas; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors | 2013 |
Surgical resection after downsizing chemotherapy for initially unresectable locally advanced biliary tract cancer: a retrospective single-center study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Carcinoma; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome | 2013 |
Nonselective transarterial chemoperfusion: a palliative treatment for malignant pleural mesothelioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Mesothelioma; Middle Aged; Mitomycin; Pain Measurement; Palliative Care; Pleural Neoplasms; Retrospective Studies; Statistics, Nonparametric; Surveys and Questionnaires; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
[Effective multidisciplinary therapy mainly using S-1+ gemcitabine (GEM) for a case of pancreatic body cancer with multiple liver metastases].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Remission Induction; Tegafur | 2012 |
Establishment and characterization of a highly tumourigenic and cancer stem cell enriched pancreatic cancer cell line as a well defined model system.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Alleles; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Genomic Instability; Glycoproteins; GPI-Linked Proteins; Humans; Isoenzymes; Keratins; Male; Mesothelin; Mice; Middle Aged; Mutation; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Polyploidy; Retinal Dehydrogenase; Transplantation, Heterologous; Tumor Microenvironment | 2012 |
Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Transfer Techniques; Genetic Therapy; Humans; Immunohistochemistry; Liposomes; Lung Neoplasms; Mice; Mice, Nude; Plasmids; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2012 |
Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Taxoids | 2013 |
[Chemotherapy for recurrent ovarian cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum Compounds; Polyethylene Glycols; Topotecan | 2012 |
[Treatment of recurrent ovarian cancer].
Topics: Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyethylene Glycols; Reoperation; Topotecan | 2012 |
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cytarabine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Drugs, Investigational; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Organoplatinum Compounds; Polyethylene Glycols; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vinblastine; Vinorelbine | 2013 |
The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Bone Marrow Cells; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Synergism; Female; Gemcitabine; Humans; Mice; Taxoids; Triterpenes; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Impact of chemotherapy on hypercalcemia in breast and lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Calcium; Chi-Square Distribution; Cisplatin; Cyclophosphamide; Deoxycytidine; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Hypercalcemia; Imidazoles; Linear Models; Logistic Models; Lung Neoplasms; Male; Middle Aged; Pamidronate; Parathyroid Hormone-Related Protein; Retrospective Studies; Severity of Illness Index; Statistics, Nonparametric; Taxoids; Young Adult; Zoledronic Acid | 2012 |
Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Glutathione S-Transferase pi; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Prospective Studies; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2012 |
Gemcitabine-induced gouty arthritis attacks.
Topics: Aged; Antimetabolites, Antineoplastic; Arthritis, Gouty; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2013 |
Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; CHO Cells; Cisplatin; Combined Modality Therapy; Cricetinae; Cricetulus; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Glutamates; Guanine; Humans; Hyperthermia, Induced; Mesothelioma; Pemetrexed; Pleural Neoplasms; Time Factors; Tumor Stem Cell Assay | 2013 |
Monogalactosyl diacylglycerol, a replicative DNA polymerase inhibitor, from spinach enhances the anti-cell proliferation effect of gemcitabine in human pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cattle; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Directed DNA Polymerase; Drug Synergism; Enzyme Inhibitors; Galactolipids; Gemcitabine; Humans; Isoenzymes; Kinetics; Neoplasm Proteins; Nucleic Acid Synthesis Inhibitors; Pancreatic Neoplasms; Plant Extracts; Rats; Spinacia oleracea | 2013 |
FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Proportional Hazards Models; RNA, Messenger; Taxoids; Vinblastine; Vinorelbine | 2013 |
The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Fas Ligand Protein; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Pancreas; Pancreatic Neoplasms; Prognosis | 2013 |
MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Kruppel-Like Transcription Factors; MAP Kinase Kinase Kinases; Nuclear Proteins; Pancreatic Neoplasms; Transcription Factors; Up-Regulation; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2013 |
Early initiation of adjuvant chemotherapy improves survival of patients with pancreatic carcinoma after surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Postoperative Complications; Prognosis; Retrospective Studies; Survival Rate; Tegafur; Time Factors | 2013 |
Activation of alpha-smooth muscle actin-positive myofibroblast-like cells after chemotherapy with gemcitabine in a rat orthotopic pancreatic cancer model.
Topics: Actins; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cell Proliferation; Deoxycytidine; Gemcitabine; Immunohistochemistry; Male; Myofibroblasts; Neoplasms, Experimental; Pancreatic Neoplasms; Rats; Rats, Inbred Lew; Ribonucleotide Reductases; Transforming Growth Factor beta1; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Ectoenzymes and cholinesterase activity and biomarkers of oxidative stress in patients with lung cancer.
Topics: Acetylcholinesterase; Adenosine Deaminase; Aged; Antineoplastic Agents; Biomarkers, Tumor; Butyrylcholinesterase; Catalase; Cholinesterases; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Inflammation; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Nucleoside-Triphosphatase; Oxidative Stress; Smoking; Sulfhydryl Compounds; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances | 2013 |
Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; DNA Replication; Drug Resistance, Neoplasm; Female; Gemcitabine; Histone Acetyltransferases; Humans; Inhibitory Concentration 50; Mice; Mice, Nude; Origin Recognition Complex; Pancreatic Neoplasms; Phosphorylation; Polo-Like Kinase 1; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-fos; Pteridines; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2013 |
Toxic erythema of chemotherapy with periorbital and perioral involvement.
Topics: Antineoplastic Agents; Axilla; Bone Neoplasms; Child; Deoxycytidine; Docetaxel; Erythema; Female; Femur; Gemcitabine; Humans; Hyperpigmentation; Lung Neoplasms; Mouth; Orbit; Osteosarcoma; Taxoids; Treatment Outcome | 2012 |
Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Prognosis; Survival Rate; Young Adult | 2012 |
Sensitization of tumor to ²¹²Pb radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; Chromatin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; DNA Repair; Drug Synergism; Female; G2 Phase; Gemcitabine; Heterocyclic Compounds; Humans; In Situ Nick-End Labeling; Isothiocyanates; Lead Radioisotopes; Linear Energy Transfer; Mice; Mice, Nude; Mitosis; Peritoneal Neoplasms; Phosphorylation; Protein Kinases; Rad51 Recombinase; Radiation-Sensitizing Agents; Radioimmunotherapy; Trastuzumab; Xenograft Model Antitumor Assays | 2013 |
[Perforation of the nasal septum: a rare complication of bevacizumab].
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Middle Aged; Nasal Septal Perforation; Neoplasm Proteins; Pemetrexed; Quinazolines; Respiratory Insufficiency; Salvage Therapy; Vascular Endothelial Growth Factor A | 2012 |
Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth.
Topics: Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Carrier Proteins; Caspase 1; Cathepsin B; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Dendritic Cells; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Inflammasomes; Interleukin-17; Interleukin-1beta; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; NLR Family, Pyrin Domain-Containing 3 Protein; Receptors, Interleukin-1; RNA Interference; RNA, Small Interfering; Signal Transduction | 2013 |
Biliary tract cancer: a survey regarding the current oncological daily care practice in Germany.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Endoscopy; Female; Fluorouracil; Gemcitabine; Germany; Health Care Surveys; Humans; Male; Medical Oncology; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Practice Patterns, Physicians'; Treatment Outcome; Young Adult | 2012 |
Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Achieving the best of both worlds.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Quality of Life | 2013 |
Synergistic effect between Juzen-taiho-to, a Japanese traditional herbal medicine, and gemcitabine single-agent chemotherapy for advanced biliary tract cancer.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Synergism; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Medicine, Kampo | 2013 |
Inhibition of nuclear factor kappa-B enhances the antitumor effect of combination treatment with tumor necrosis factor-alpha gene therapy and gemcitabine for pancreatic cancer in mice.
Topics: Adenoviridae; Analysis of Variance; Animals; Benzamidines; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Gene Transfer Techniques; Genetic Therapy; Genetic Vectors; Guanidines; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2013 |
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Biopsy; CA-125 Antigen; Capecitabine; Carcinoembryonic Antigen; Carrier Proteins; CDX2 Transcription Factor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cytokines; Deoxycytidine; Female; Fluorodeoxyglucose F18; Fluorouracil; Gemcitabine; Glycoproteins; Hepatectomy; Homeodomain Proteins; Humans; Immunohistochemistry; Keratin-20; Keratins; Liver; Liver Neoplasms; Lymph Node Excision; Magnetic Resonance Imaging; Membrane Transport Proteins; Phenotype; Portal Vein; Pregnancy; Receptors, Estrogen; Receptors, Progesterone | 2012 |
Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses.
Topics: Animals; Cell Communication; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Tolerance; Macrophages; Mice; Neoplasm Metastasis; Neoplasms; Neoplastic Stem Cells; Receptor, Macrophage Colony-Stimulating Factor; Receptors, CCR2; STAT3 Transcription Factor; T-Lymphocytes, Cytotoxic | 2013 |
Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro.
Topics: Antineoplastic Agents; Cells, Cultured; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Forkhead Transcription Factors; Gemcitabine; Humans; Immunosuppressive Agents; Leukocytes, Mononuclear; T-Lymphocytes, Regulatory | 2012 |
Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Interactions; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Gossypol; Humans; Inhibitory Concentration 50; Multigene Family; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reproducibility of Results; Signal Transduction; Up-Regulation | 2012 |
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Topics: Antimetabolites, Antineoplastic; Biotransformation; Catalysis; Cytarabine; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Genetic Variation; Genotype; Humans; Kinetics; Models, Biological; Nonlinear Dynamics; Pharmacogenetics; Phenotype; Phosphorylation; Recombinant Proteins; Substrate Specificity | 2013 |
Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Chromatography, Liquid; Deoxycytidine; Female; Gemcitabine; Humans; Liposarcoma; Metabolomics; Mice; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2012 |
Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer.
Topics: Administration, Metronomic; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Lymphocyte Count; Mice; Neoplasms, Experimental; Pancreatic Neoplasms; Survival Analysis; T-Lymphocytes, Regulatory | 2013 |
H-gemcitabine: a new gemcitabine prodrug for treating cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Binding Sites; Cell Line, Tumor; Deoxycytidine; DNA; Drug Delivery Systems; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasms; Prodrugs | 2013 |
Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacy.
Topics: Algorithms; Computer Simulation; Deoxycytidine; Deoxycytidine Kinase; Deoxycytosine Nucleotides; DNA; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Models, Theoretical; Neoplasms; Ribonucleotide Reductases | 2012 |
Pancreatic cancer - cost for overtreatment with gemcitabine.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nucleoside Transport Proteins; Pancreatic Neoplasms; Precision Medicine; Retrospective Studies; Sweden | 2013 |
Melatonin is involved in the apoptosis and necrosis of pancreatic cancer cell line SW-1990 via modulating of Bcl-2/Bax balance.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Melatonin; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2013 |
Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Hyperthermia, Induced; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gem
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2013 |
Nanoparticles with in vivo anticancer activity from polymer prodrug amphiphiles prepared by living radical polymerization.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Free Radicals; Gemcitabine; Humans; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Polymerization; Polymers; Prodrugs; Transplantation, Heterologous | 2013 |
Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Tegafur; Treatment Outcome | 2012 |
Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Capecitabine; Cell Survival; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Fluorouracil; Gemcitabine; Glycation End Products, Advanced; HMGB1 Protein; Humans; Pancreatic Neoplasms; Prospective Studies; Statistics, Nonparametric; Treatment Outcome | 2013 |
In vitro study on the binding of gemcitabine to bovine serum albumin.
Topics: Animals; Antimetabolites, Antineoplastic; Binding Sites; Cattle; Circular Dichroism; Deoxycytidine; Fluorescence Resonance Energy Transfer; Gemcitabine; Kinetics; Models, Molecular; Molecular Conformation; Molecular Docking Simulation; Protein Binding; Serum Albumin, Bovine; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Thermodynamics; Titrimetry; Tryptophan | 2013 |
Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Deoxycytidine; Diabetes Mellitus, Type 2; Female; Gemcitabine; Glucose; Glucose Tolerance Test; Humans; Insulin; Lipid Metabolism; Male; Metabolic Syndrome; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Pilot Projects; Prognosis | 2013 |
[Three cases of recurrent bile duct cancer diagnosed and treated by double-balloon endoscopy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Endoscopy; Female; Gemcitabine; Humans; Male; Middle Aged; Recurrence | 2012 |
[Combination therapy for inoperable cholangiocellular carcinoma-systemic chemotherapy and hepatic arterial injection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Middle Aged | 2012 |
[Resection of the remnant pancreas for recurrent pancreatic cancer after distal pancreatectomy-a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Pancreatectomy; Pancreatic Neoplasms | 2012 |
[A case of recurrent breast cancer in which gemcitabine-docetaxel therapy was successful for a long period].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Recurrence; Taxoids; Time Factors | 2012 |
[A case of advanced cholangiolocellular carcinoma successfully treated by neoadjuvant chemotherapy with gemcitabine followed by radical resection].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging | 2012 |
[Long-term survival in 2 cases with unresectable hilar bile duct cancer and sclerosing cholangitis].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangitis, Sclerosing; Deoxycytidine; Female; Gemcitabine; Humans; Male; Time Factors; Treatment Outcome | 2012 |
[Total pancreatectomy for pancreatic head cancer accompanied with multiple lesions].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Jaundice; Male; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms | 2012 |
[A case of simultaneous resection of pancreatic tail and transverse hematogenous metastasis].
Topics: Antimetabolites, Antineoplastic; Colonic Neoplasms; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms | 2012 |
[A case of interstitial lung disease associated with gemcitabine treatment in a patient with locally advanced pancreatic cancer following proton beam radiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hemorrhage; Humans; Lung Diseases, Interstitial; Pancreatic Neoplasms; Proton Therapy | 2012 |
Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, T-Cell, Peripheral; Male; Methotrexate; Middle Aged; Neoplasm Staging; Retrospective Studies; Young Adult | 2013 |
A child with gemcitabine-induced severe radiation recall myositis resulting in a compartment syndrome.
Topics: Adolescent; Antimetabolites, Antineoplastic; Combined Modality Therapy; Compartment Syndromes; Deoxycytidine; Female; Gemcitabine; Humans; Radiodermatitis; Sarcoma, Synovial | 2013 |
Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-κB.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Drugs, Chinese Herbal; Female; Flavonoids; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; NF-kappa B | 2013 |
Safety and effectiveness of gemcitabine in 855 patients with pancreatic cancer under Japanese clinical practice based on post-marketing surveillance in Japan.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Observation; Pancreatic Neoplasms; Product Surveillance, Postmarketing; Prospective Studies; Treatment Outcome | 2013 |
Neoadjuvant gemcitabine plus carboplatin for locally advanced bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Nausea; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Vomiting | 2013 |
Self-assembly of thermally responsive nanoparticles of a genetically encoded peptide polymer by drug conjugation.
Topics: Amino Acid Sequence; Deoxycytidine; Drug Carriers; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Oxycodone; Paclitaxel; Peptides; Pharmaceutical Preparations; Polymers; Temperature | 2013 |
[Hodgkin lymphoma with hepatic involvement treated with dexametasone, gemcitabine and cisplatin as a bridge to standard therapy: report of one case].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hodgkin Disease; Humans; Liver Diseases; Middle Aged; Salvage Therapy | 2012 |
Treatment of breast and lung cancer cells with a N-7 benzyl guanosine monophosphate tryptamine phosphoramidate pronucleotide (4Ei-1) results in chemosensitization to gemcitabine and induced eIF4E proteasomal degradation.
Topics: Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Crystallography, X-Ray; Deoxycytidine; Eukaryotic Initiation Factor-4E; Gemcitabine; Guanosine Monophosphate; Humans; Lung Neoplasms; Models, Chemical; Proteasome Endopeptidase Complex; Spectrometry, Mass, Electrospray Ionization | 2013 |
Adjuvant chemotherapy seems beneficial for invasive intraductal papillary mucinous neoplasms.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Italy; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2013 |
Replica exchange molecular dynamics simulation of chitosan for drug delivery system based on carbon nanotube.
Topics: Biopolymers; Chitosan; Deoxycytidine; Drug Delivery Systems; Epidermal Growth Factor; Gemcitabine; Molecular Conformation; Molecular Dynamics Simulation; Nanotubes, Carbon | 2013 |
Suppressive oligodeoxynucleotides synergistically enhance antiproliferative effects of anticancer drugs in A549 human lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Oligodeoxyribonucleotides; Paclitaxel; Proto-Oncogene Proteins c-akt; Repetitive Sequences, Nucleic Acid | 2013 |
Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspases; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Interleukin-8; Matrix Metalloproteinase 9; Microarray Analysis; MicroRNAs; NF-kappa B; Pancreatic Neoplasms; Phenotype; Signal Transduction; Terpenes; Vascular Endothelial Growth Factor A; Wound Healing | 2013 |
Potential use of drug loaded nano composite pectin scaffolds for the treatment of ovarian cancer.
Topics: Antimetabolites, Antineoplastic; Cell Adhesion; Cell Line, Tumor; Cell Survival; Chitosan; Deoxycytidine; Drug Delivery Systems; Female; Fibrin; Gemcitabine; Humans; Nanocomposites; Ovarian Neoplasms; Pectins; Porosity; Tissue Scaffolds | 2013 |
Dual role of immunomodulation by anticancer chemotherapy.
Topics: Animals; Carrier Proteins; Caspase 1; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Inflammasomes; Neoplasms; NLR Family, Pyrin Domain-Containing 3 Protein | 2013 |
Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer.
Topics: Aged; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interleukin-6; Male; Middle Aged; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Smad4 Protein; Transforming Growth Factor beta1 | 2013 |
Biocompatible gemcitabine-based nanomedicine engineered by Flow Focusing for efficient antitumor activity.
Topics: Antimetabolites, Antineoplastic; Biocompatible Materials; Cell Survival; Colloids; Deoxycytidine; Drug Carriers; Drug Compounding; Female; Gemcitabine; Humans; Lactic Acid; MCF-7 Cells; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Technology, Pharmaceutical | 2013 |
Naringenin decreases invasiveness and metastasis by inhibiting TGF-β-induced epithelial to mesenchymal transition in pancreatic cancer cells.
Topics: Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Estrogen Antagonists; Flavanones; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta; Tumor Cells, Cultured; Wound Healing | 2012 |
Effects of a non thermal plasma treatment alone or in combination with gemcitabine in a MIA PaCa2-luc orthotopic pancreatic carcinoma model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Tracking; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Luciferases, Firefly; Mice; Pancreatic Neoplasms; Plasma Gases; Tumor Burden; Whole Body Imaging; Xenograft Model Antitumor Assays | 2012 |
Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients' quality of life.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Quality of Life; Retrospective Studies; Survival Rate | 2013 |
[Questions on "gemcitabine plus S-1 combination therapy (G-S therapy) for pancreatic cancer with accentuated hepatic metastasis" (by Matsumoto, T. et al) published on Japanese Journal of Gastro-enterology Vol. 108, N0. 12].
Topics: Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Inhibitor of Differentiation Protein 1; Kaplan-Meier Estimate; Mice; Mice, SCID; Nicotine; Pancreatic Neoplasms; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transcription, Genetic | 2012 |
ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells.
Topics: ADAM Proteins; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Pancreatic Neoplasms; Protein Structure, Tertiary; RNA Interference; RNA, Messenger; RNA, Small Interfering | 2013 |
Early detection and gemcitabine/cisplatin combination positively effect survival in sarcomatoid carcinoma of the urinary bladder.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Early Diagnosis; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Urinary Bladder; Urinary Bladder Neoplasms | 2012 |
Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Inflammation; Male; Middle Aged; Neoplasm Invasiveness; Postoperative Complications; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Human carboxylesterase-2 hydrolyzes the prodrug of gemcitabine (LY2334737) and confers prodrug sensitivity to cancer cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Bystander Effect; Carboxylesterase; Deoxycytidine; Deoxyuridine; Female; Gemcitabine; Humans; Hydrolysis; Molecular Structure; Neoplasms; Prodrugs; Recombinant Proteins; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Improvement of prognosis for unresectable biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Skin equivalents: a tool for the discovery and validation of pharmacodynamic biomarkers.
Topics: 3T3 Cells; Animals; Biomarkers; CDC2 Protein Kinase; Cell Cycle Proteins; Cells, Cultured; Cyclin B; Cyclin-Dependent Kinases; Deoxycytidine; Drug Screening Assays, Antitumor; Fibroblasts; Gemcitabine; Humans; Keratinocytes; Mice; Nuclear Proteins; Phosphorylation; Protein-Tyrosine Kinases; Skin | 2013 |
Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Time; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Up-regulation of MBD1 promotes pancreatic cancer cell epithelial-mesenchymal transition and invasion by epigenetic down-regulation of E-cadherin.
Topics: Adult; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Cadherins; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Nuclear Proteins; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; RNA Interference; RNA, Small Interfering; Sirtuin 1; Survival; Transcription Factors; Transcriptional Activation; Twist-Related Protein 1; Up-Regulation | 2013 |
Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
Topics: Antineoplastic Agents; Cell Line; Cells, Cultured; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Chaperones; Humans; MicroRNAs; Oncogene Proteins; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA Interference; RNA-Binding Proteins; Transcription Factors | 2013 |
[Percutaneous cryoablation and (125)I seed implantation combined with chemotherapy for advanced pancreatic cancer: report of 67 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Cisplatin; Combined Modality Therapy; Cryosurgery; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate; Young Adult | 2012 |
Highly lymphatic metastatic pancreatic cancer cells possess stem cell-like properties.
Topics: AC133 Antigen; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Glycoproteins; Hedgehog Proteins; Humans; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Receptors, CXCR4; Veratrum Alkaloids | 2013 |
ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
An integrative network inference approach to predict mechanisms of cancer chemoresistance.
Topics: Algorithms; Antineoplastic Agents; Bayes Theorem; Biotransformation; Cell Line, Tumor; Computational Biology; Computer Simulation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Markov Chains; Metabolic Networks and Pathways; Models, Statistical; Pancreatic Neoplasms; Stochastic Processes; Time Factors | 2013 |
Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma.
Topics: Acute Disease; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Indoles; Male; Neoplasm Metastasis; Neutropenia; Pancreatitis; Pyrroles; Sunitinib; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2013 |
[Hemolytic uremic syndrome induced by gemcitabine. A poorly recognized complication?].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Neoplasms; Renal Dialysis; Renal Insufficiency; Time Factors | 2012 |
The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate.
Topics: Anticarcinogenic Agents; Antimicrobial Cationic Peptides; Apoptosis; Biocompatible Materials; Biodegradation, Environmental; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Synergism; Fluorescent Antibody Technique; Gemcitabine; HeLa Cells; HT29 Cells; Humans; Inhibitory Concentration 50; Microscopy, Confocal; Polyhydroxyalkanoates; Taxoids | 2013 |
Preclinical pharmacokinetic/pharmacodynamic models to predict schedule-dependent interaction between erlotinib and gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Protein Kinase Inhibitors; Quinazolines | 2013 |
Old drugs: new complications.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Infarction; Kidney; Lung Neoplasms; Male; Middle Aged; Ribonucleotide Reductases; Splenic Infarction; Tomography, X-Ray Computed | 2013 |
Pirfenidone inhibits pancreatic cancer desmoplasia by regulating stellate cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Deoxycytidine; Female; Fibrosis; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Platelet-Derived Growth Factor; Pyridones; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stromal Cells; Tumor Cells, Cultured | 2013 |
Double inhibition of NF-κB and XIAP via RNAi enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Apoptosis; Carrier Proteins; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Stearoyl gemcitabine nanoparticles overcome obesity-induced cancer cell resistance to gemcitabine in a mouse postmenopausal breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Nanoparticles; Obesity; Postmenopause; Random Allocation | 2013 |
Neuroendocrine tumor of the gallbladder.
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Catheter Ablation; Cisplatin; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Indoles; Middle Aged; Pyrroles; Sunitinib; Taxoids; Ultrasonography | 2013 |
Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Survival Rate | 2013 |
Combination of gemcitabine and carboplatin as first line treatment in elderly patients or those unfit for cisplatin-based chemotherapy with advanced transitional cell carcinoma of the urinary tract.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Urinary Bladder Neoplasms | 2013 |
Efficacy of low-dose oral metronomic dosing of the prodrug of gemcitabine, LY2334737, in human tumor xenografts.
Topics: Administration, Metronomic; Administration, Oral; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxyuridine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression; HCT116 Cells; Humans; Lung Neoplasms; Mice; Prodrugs; Valproic Acid; Xenograft Model Antitumor Assays | 2013 |
Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gemcitabine; Immunoenzyme Techniques; Immunoprecipitation; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Tumor Cells, Cultured | 2013 |
Neoadjuvant chemoradiation therapy for borderline pancreatic adenocarcinoma: report of two cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
The rescue of miR-148a expression in pancreatic cancer: an inappropriate therapeutic tool.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Mice; MicroRNAs; Pancreatic Neoplasms; Proteome; Proteomics; Xenograft Model Antitumor Assays | 2013 |
Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cholesterol; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Hyaluronic Acid; Liposomes; Mice; Mice, Nude; Microscopy, Confocal; Pancreatic Neoplasms; Phosphatidylethanolamines; Prodrugs; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Application of activated nucleoside analogs for the treatment of drug-resistant tumors by oral delivery of nanogel-drug conjugates.
Topics: Administration, Oral; Alkaline Phosphatase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cholesterol; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Hydrolysis; Mice; Mice, Nude; Nanostructures; Neoplasms; Particle Size; Permeability; Phosphoric Diester Hydrolases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Glycine; Humans; Lysine; Male; Middle Aged; Pancreatic Neoplasms; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Xeroderma Pigmentosum Group D Protein | 2013 |
LY294002 enhances inhibitory effect of gemcitabine on proliferation of human pancreatic carcinoma PANC-1 cells.
Topics: Adult; Antimetabolites, Antineoplastic; Cell Proliferation; Chromones; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Female; Gemcitabine; Humans; Male; Middle Aged; Morpholines; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Treatment Outcome; Tumor Cells, Cultured | 2013 |
VEGF-C ShRNA inhibits pancreatic cancer growth and lymphangiogenesis in an orthotopic fluorescent nude mouse model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Gene Silencing; Green Fluorescent Proteins; Humans; Immunohistochemistry; Lymphangiogenesis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Vascular Endothelial Growth Factor C; Xenograft Model Antitumor Assays | 2013 |
Severe or lethal toxicities with nucleosidic analogs: time for action.
Topics: Animals; Capecitabine; Cytidine Deaminase; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Nucleosides | 2013 |
Multicellular tumor spheroid models to explore cell cycle checkpoints in 3D.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Culture Techniques; Cell Cycle Checkpoints; Cytotoxins; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |
Determination of gemcitabine and its metabolite in extracellular fluid of rat brain tumor by ultra performance liquid chromatography-tandem mass spectrometry using microdialysis sampling after intralesional chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Chemistry; Brain Neoplasms; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Floxuridine; Gemcitabine; Glioma; Limit of Detection; Linear Models; Male; Microdialysis; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tandem Mass Spectrometry | 2013 |
Theranostic nanoparticles with controlled release of gemcitabine for targeted therapy and MRI of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice; Mice, Nude; Nanocapsules; Nanotechnology; Pancreatic Neoplasms; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays | 2013 |
Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Tetrahydronaphthalenes; Tumor Burden; Tumor Cells, Cultured; Valine; Xenograft Model Antitumor Assays | 2013 |
The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.
Topics: Aneuploidy; Animals; Apoptosis; Aurora Kinase A; Aurora Kinases; Azepines; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cluster Analysis; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; M Phase Cell Cycle Checkpoints; Mice; Neoplasm Invasiveness; Paclitaxel; Phenotype; Protein Serine-Threonine Kinases; Pyrimidines; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to therapy.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Deoxycytidine; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Immunohistochemistry; Mice; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Xenograft Model Antitumor Assays | 2013 |
Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Kidney Neoplasms; Male; Middle Aged; Nomograms; Paclitaxel; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome; Urothelium | 2013 |
[A case of inoperable advanced bile duct cancer treated effectively with combined chemotherapy of gemcitabine and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Tegafur | 2013 |
[Remarkable tumor response to cisplatin plus gemcitabine therapy in a patient with recurrent gallbladder cancer - a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Staging; Recurrence | 2013 |
[Gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) in patients with metastatic urothelial cancer].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Treatment Outcome; Urologic Neoplasms | 2013 |
Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Gemcitabine; Humans; Mitochondria; Paclitaxel; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor | 2012 |
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Docetaxel; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Panobinostat; Receptor, ErbB-2; Survivin; Taxoids | 2012 |
Atypical posterior reversible encephalopathy syndrome associated with chemotherapy with Bevacizumab, Gemcitabine and Cisplatin.
Topics: Adult; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunologic Factors; Magnetic Resonance Imaging; Posterior Leukoencephalopathy Syndrome | 2013 |
Bmi1 enhances tumorigenicity and cancer stem cell function in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinoma in Situ; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Polycomb Repressive Complex 1; Xenograft Model Antitumor Assays | 2013 |
miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Transfection; Xenograft Model Antitumor Assays | 2013 |
Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets.
Topics: Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Cell Shape; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Emodin; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Inhibitory Concentration 50; NF-kappa B; Protein Binding; Survivin; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Human concentrative nucleoside transporter 3 transfection with ultrasound and microbubbles in nucleoside transport deficient HEK293 cells greatly increases gemcitabine uptake.
Topics: Animals; Biological Transport; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression; HEK293 Cells; Humans; Membrane Transport Proteins; Mice; Microbubbles; Oocytes; Transfection; Xenopus laevis | 2013 |
[Pathological complete response to gemcitabine and cisplatin chemotherapy for advanced upper tract urothelial carcinoma: a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Ureteral Neoplasms; Urothelium | 2013 |
Novel role of VMP1 as modifier of the pancreatic tumor cell response to chemotherapeutic drugs.
Topics: Animals; Autophagy; Biomarkers, Pharmacological; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Gemcitabine-coumarin-biotin conjugates: a target specific theranostic anticancer prodrug.
Topics: Antineoplastic Agents; Biotin; Cell Line, Tumor; Cell Survival; Coumarins; Deoxycytidine; Drug Delivery Systems; Fluorescent Dyes; Gemcitabine; Humans; Neoplasms; Prodrugs; Sulfhydryl Compounds | 2013 |
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hand-Foot Syndrome; Humans; Lethargy; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
CacyBP/SIP enhances multidrug resistance of pancreatic cancer cells by regulation of P-gp and Bcl-2.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium-Binding Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Organ Specificity; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2013 |
Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Female; Gemcitabine; Genetic Markers; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Prevalence; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2013 |
Evaluation of the effect of gemcitabine on cochlea by otoacoustic emission in experimental animal model.
Topics: Animals; Antimetabolites, Antineoplastic; Cochlea; Data Interpretation, Statistical; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Injections, Intraperitoneal; Male; Otoacoustic Emissions, Spontaneous; Rats; Rats, Wistar; Signal-To-Noise Ratio | 2013 |
Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Liver Neoplasms; Mice; Mice, Inbred C57BL; Nanomedicine; Nanoparticles; Neoplasm Transplantation; Pancreatic Neoplasms; Receptors, Transferrin; Single-Chain Antibodies; Tumor Burden | 2013 |
Chemoradiotherapy for locally advanced pancreatic cancer.
Topics: Antineoplastic Agents; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2013 |
Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Fluids; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Designer Drugs; Disease Models, Animal; Gemcitabine; Gold; Humans; Immunohistochemistry; Light; Male; Metal Nanoparticles; Mice; Mice, Nude; Molecular Targeted Therapy; Nanoconjugates; Pancreatic Neoplasms; Scattering, Radiation; Static Electricity; Treatment Outcome | 2013 |
A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
Topics: Animals; Cattle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Small Molecule Libraries; Thiophenes; Treatment Outcome; Tumor Suppressor Proteins; Urea | 2013 |
Gemcitabine-loaded smart carbon nanotubes for effective targeting to cancer cells.
Topics: Cell Line, Tumor; Chemistry, Pharmaceutical; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Folic Acid; Gemcitabine; Humans; MCF-7 Cells; Nanotubes, Carbon; Neoplasms; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2013 |
Complete pathological remission of locally advanced, unresectable pancreatic cancer (LAPC) after intensified neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Remission Induction; Treatment Outcome | 2013 |
Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Receptor, Notch3; Receptors, Notch; Retrospective Studies; RNA, Messenger | 2013 |
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cytokines; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, SCID; Neoplasm Proteins; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Random Allocation; RNA-Binding Proteins; Sorafenib; Survival Analysis; Xenograft Model Antitumor Assays | 2013 |
Gastropleural fistula in a patient with recurrent ovarian cancer receiving combination therapy with Carboplatin, gemcitabine, and bevacizumab.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Female; Gastric Fistula; Gemcitabine; Humans; Intestinal Fistula; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms | 2013 |
Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cystectomy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Recurrence; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Molecular analysis of the inhibitory effect of N-acetyl-L-cysteine on the proliferation and invasiveness of pancreatic cancer cells.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, myc; Humans; Mitomycin; Pancreatic Neoplasms; Reactive Oxygen Species | 2013 |
Antibody targeting of CD24 efficiently retards growth and influences cytokine milieu in experimental carcinomas.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; CD24 Antigen; Cell Growth Processes; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Macrophages; Mice; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
A three-drug induction chemotherapy with gemcitabine, carboplatin, and paclitaxel for stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel | 2013 |
A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
[Optimizing good use and costs of anticancer drugs: A French inter regional study of the Observatory of Cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cost Savings; Deoxycytidine; Drug Costs; France; Gemcitabine; Humans; Neoplasms; Quality Improvement | 2013 |
Vitamin D receptor genetic variants are associated with chemotherapy response and prognosis in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA, Neoplasm; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Prognosis; Receptors, Calcitriol; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
Preclinical demonstration of synergistic Active Nutrients/Drug (AND) combination as a potential treatment for malignant pleural mesothelioma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Catechin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Inbred NOD; Mice, SCID; Pleural Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Isolated lung perfusion as an adjuvant treatment of colorectal cancer lung metastases: a preclinical study in a pig model.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Hemodynamics; Humans; Lung Neoplasms; Perfusion; Swine; Treatment Outcome; Vasoconstriction | 2013 |
Common variations of DNA repair genes are associated with response to platinum-based chemotherapy in NSCLCs.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Confidence Intervals; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Docetaxel; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1; Xeroderma Pigmentosum Group D Protein | 2013 |
Clinicopathological features of patients with malignant mesothelioma in a multicenter, case-control study: no role for ABO-Rh blood groups.
Topics: ABO Blood-Group System; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplatin; Confidence Intervals; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Pemetrexed; Retrospective Studies; Rh-Hr Blood-Group System; Turkey | 2013 |
Perioperative chemotherapy: when to use it, what to use, and why.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Randomized Controlled Trials as Topic; Urinary Bladder Neoplasms | 2013 |
New agents for bacillus Calmette-Guérin-refractory bladder cancer.
Topics: Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Agents; BCG Vaccine; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
Neoadjuvant chemotherapy improves survival rate in advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2013 |
Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells.
Topics: Aminopyridines; Antimetabolites, Antineoplastic; Benzamides; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Up-Regulation | 2013 |
Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Biopsy; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Immunohistochemistry; Leucine; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Unknown Primary; Point Mutation; Quinazolines; Tomography, X-Ray Computed | 2013 |
Evolving panorama of treatment for metastatic pancreas adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2013 |
Juxtaglomerular cell tumor: multicentric synchronous disease associated with paraneoplastic syndrome.
Topics: Antidiuretic Hormone Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzazepines; Dacarbazine; Deoxycytidine; Diagnosis, Differential; Disease Progression; Doxorubicin; Gemcitabine; Humans; Hyponatremia; Ifosfamide; Immunohistochemistry; Immunophenotyping; Inappropriate ADH Syndrome; Juxtaglomerular Apparatus; Kidney Neoplasms; Luminescent Measurements; Male; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel; Paraneoplastic Syndromes; Renin; Tolvaptan; Vinblastine; Vinorelbine | 2013 |
ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; BRCA1 Protein; BRCA2 Protein; cdc25 Phosphatases; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Immunoblotting; Ovarian Neoplasms; Phosphorylation; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Protein Kinases; Protein Serine-Threonine Kinases; Pyrazines; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction; Sulfones; Topotecan | 2013 |
Covered self-expandable metal stent deployment promises safe neoadjuvant chemoradiation therapy in patients with borderline resectable pancreatic head cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Protocols; Deoxycytidine; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Care; Prosthesis Design; Sphincterotomy, Endoscopic; Stents | 2014 |
Efficacy comparison of traditional Chinese medicine LQ versus gemcitabine in a mouse model of pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Humans; Medicine, Chinese Traditional; Mice; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2013 |
[A case of pancreatic neuroendocrine tumor with excessively-advanced liver metastasis treated with S-1/GEM combination chemotherapy plus the long-acting somatostatin analogue octreotide].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2013 |
Preclinical analyses of intravesical chemotherapy for prevention of bladder cancer progression.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Cycloleucine; Deoxycytidine; Disease Models, Animal; Disease Progression; Docetaxel; Drug Screening Assays, Antitumor; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Random Allocation; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Pharmacokinetics and metabolism of SL-01, a prodrug of gemcitabine, in rats.
Topics: Administration, Oral; Animals; Biological Availability; Biotransformation; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Injections, Intravenous; Male; Molecular Structure; Prodrugs; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry | 2013 |
Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Randomized Controlled Trials as Topic; SEER Program; Survival Analysis; Taxoids; Treatment Outcome; United States | 2013 |
Chemosensitivity induced by down-regulation of microRNA-21 in gemcitabine-resistant pancreatic cancer cells by indole-3-carbinol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Cell Cycle; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Indoles; MicroRNAs; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Acute oesophageal toxicity related to paclitaxel-based concurrent chemoradiotherapy for non-small cell lung cancer.
Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Comorbidity; Deoxycytidine; Docetaxel; Esophageal Diseases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Risk Factors; Survival Rate; Taxoids | 2013 |
F14512, a polyamine-vectorized anti-cancer drug, currently in clinical trials exhibits a marked preclinical anti-leukemic activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cytarabine; Deoxycytidine; Doxorubicin; Fetal Blood; Flow Cytometry; Gemcitabine; Humans; Hydroxamic Acids; Immunoenzyme Techniques; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Podophyllotoxin; Pyrazines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Tumor Cells, Cultured; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
Notch1 contributes to chemoresistance to gemcitabine and serves as an unfavorable prognostic indicator in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Survival Analysis; Treatment Outcome | 2013 |
ERK1/2 activity contributes to gemcitabine resistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Butadienes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Nitriles; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Tumor Burden | 2013 |
[Analysis of drug therapy of lung cancer in Hungary].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Etoposide; Gemcitabine; Glutamates; Guanine; Humans; Hungary; Inpatients; Insurance, Health; Lung Neoplasms; Paclitaxel; Pemetrexed; Prescription Drugs; Quinazolines; Retrospective Studies; Taxoids; Topotecan | 2013 |
BLU enhances the effects of anti-angiogenic activity in combination with gemcitabine-based chemotherapeutic agents.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Deoxycytidine; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neovascularization, Pathologic; NF-kappa B; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; rho GTP-Binding Proteins; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Curative resection of hilar cholangiocarcinoma in a 25-year-old woman: report of a case.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Hepatectomy; Humans; Lymphatic Metastasis; Mutation; Neoplasm Staging; Pancreatic Ducts; Portal Vein; Treatment Outcome; Tumor Suppressor Protein p53 | 2014 |
Sleeve lobectomy compared with pneumonectomy after induction therapy for non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pneumonectomy; Proportional Hazards Models; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Synergistic targeting/prodrug strategies for intravesical drug delivery--lectin-modified PLGA microparticles enhance cytotoxicity of stearoyl gemcitabine by contact-dependent transfer.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Lactic Acid; Lectins; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prodrugs; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium | 2013 |
Interplay between autophagy and apoptosis in pancreatic tumors in response to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Transfection; Xenograft Model Antitumor Assays | 2014 |
Insulin-like growth factor 1 receptor promotes the growth and chemoresistance of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Lentivirus; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2013 |
Complete remission of recurrent and refractory ovarian cancers using weekly administration of bevacizumab and gemcitabine/oxaliplatin: report of two cases.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin | 2013 |
Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Deoxycytidine; Disease Models, Animal; Gemcitabine; Immunohistochemistry; Mice; Mice, Mutant Strains; NF-kappa B; Pancreatic Neoplasms; Sesquiterpenes | 2013 |
Drug combination extends late-stage pancreatic cancer survival in Phase III clinical trial.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | 2013 |
Relapse in medulloblastoma: what can be done after abandoning high-dose chemotherapy? A mono-institutional experience.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cerebellar Neoplasms; Child; Child, Preschool; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cranial Irradiation; Dacarbazine; Deoxycytidine; Disease Progression; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Irinotecan; Male; Medulloblastoma; Melphalan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Patient Selection; Quality of Life; Radiotherapy; Retrospective Studies; Salvage Therapy; Temozolomide; Young Adult | 2013 |
[Regional chemotherapy in locally advanced and metastatic gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Docetaxel; Drug Administration Schedule; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2012 |
[Possibilities of epigenetic anti-tumor therapy in in-vitro models].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butyric Acid; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Neoplasms; Radiotherapy, Adjuvant; Salts; Sodium; Time Factors; Valproic Acid | 2012 |
Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Carcinoma; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Mice; Pancreatic Neoplasms; T-Lymphocytes, Regulatory; Tumor Burden | 2013 |
TL-118-anti-angiogenic treatment in pancreatic cancer: a case report.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cimetidine; Cyclophosphamide; Deoxycytidine; Diclofenac; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Sulfasalazine; Tomography, X-Ray Computed | 2013 |
Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Deoxycytidine; Drug Utilization; Female; Gemcitabine; Humans; Male; Medicare; Multivariate Analysis; Neoplasm Staging; Pancreatic Neoplasms; SEER Program; United States | 2013 |
Enhanced antitumor efficacy of gemcitabine-loaded temperature-sensitive liposome by hyperthermia in tumor-bearing mice.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Chromatin; Colonic Neoplasms; Combined Modality Therapy; Deoxycytidine; DNA Fragmentation; Dose-Response Relationship, Drug; Gemcitabine; Hyperthermia, Induced; Inhibitory Concentration 50; Liposomes; Mice; Mice, Inbred BALB C; Temperature | 2014 |
Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Predictive effect of XPA and XPD polymorphisms on survival of advanced NSCLC patients treated with platinum-based chemotherapy: a three-dimensional (3-D), polyacrylamide gel-based DNA microarray method.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2013 |
XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Polymorphism, Single Nucleotide; Transcription Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Survival of mesothelioma in a palliative medical care unit in egypt.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Egypt; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Morphine; Pain; Palliative Care; Pleural Neoplasms; Quality of Life; Retrospective Studies; Survival; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Acute generalized exanthematous pustulosis caused by gemcitabine.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2014 |
A pilot study: sequential gemcitabine/cisplatin and icotinib as induction therapy for stage IIB to IIIA non-small-cell lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crown Ethers; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
Centromere fragmentation is a common mitotic defect of S and G2 checkpoint override.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Centromere; Checkpoint Kinase 1; CHO Cells; Comet Assay; Cricetinae; Cricetulus; Deoxycytidine; DNA Damage; DNA Topoisomerases, Type II; Doxorubicin; Etoposide; G2 Phase Cell Cycle Checkpoints; Gemcitabine; HeLa Cells; Humans; Kinetochores; Mitosis; Protein Kinases; S Phase Cell Cycle Checkpoints; Staurosporine; Topoisomerase II Inhibitors | 2013 |
Effect of a novel bladder preservation therapy, BOAI-CDDP-radiation (OMC-regimen).
Topics: Adult; Aged; Aged, 80 and over; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Urinary Bladder; Urinary Bladder Neoplasms | 2013 |
Lithium inhibits tumorigenic potential of PDA cells through targeting hedgehog-GLI signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Lithium Chloride; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Signal Transduction; Transcription Factors; Zinc Finger Protein GLI1 | 2013 |
Synergistic effect of CTLA-4 blockade and cancer chemotherapy in the induction of anti-tumor immunity.
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Lewis Lung; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Immunity, Innate; Immunologic Factors; Lung Neoplasms; Lymphocyte Depletion; Mesothelioma; Mice; Mice, Transgenic; Neoplasm Transplantation; Survival Analysis; Tumor Burden | 2013 |
UPEC biomimickry at the urothelial barrier: lectin-functionalized PLGA microparticles for improved intravesical chemotherapy.
Topics: Administration, Intravesical; Antineoplastic Agents; Biomimetic Materials; Cell Adhesion; Cell Line, Tumor; Cell Survival; Deoxycytidine; Doxorubicin; Drug Carriers; Gemcitabine; Humans; Lactic Acid; Mitomycin; Phosphatidylcholines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prodrugs; Stearic Acids; Urinary Bladder Neoplasms; Urothelium; Wheat Germ Agglutinins | 2013 |
18F-fluorothymidine PET is a potential predictive imaging biomarker of the response to gemcitabine-based chemotherapeutic treatment for recurrent ovarian cancer: preliminary results in three patients.
Topics: Aged; Biomarkers, Tumor; Deoxycytidine; Dideoxynucleosides; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Positron-Emission Tomography; Recurrence; Tomography, X-Ray Computed | 2013 |
Which regimen is better for stem cell mobilization of lymphoma patients?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Methylprednisolone; Methylprednisolone Hemisuccinate; Middle Aged; Procarbazine; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Preparation and characterization of folate-chitosan-gemcitabine core-shell nanoparticles for potential tumor-targeted drug delivery.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Deoxycytidine; Diffusion; Folic Acid; Gemcitabine; Humans; Materials Testing; Nanocapsules; Pancreatic Neoplasms; Porosity; Treatment Outcome | 2013 |
Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Base Sequence; Cell Line, Tumor; Clofarabine; Deoxycytidine; DNA Damage; DNA Primers; DNA Repair; Drug Synergism; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Phosphorylation; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Suppressor Protein p53 | 2013 |
Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells.
Topics: Adenocarcinoma; Administration, Metronomic; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Ovarian Neoplasms; Pancreatic Neoplasms; Random Allocation; Thrombospondin 1; Xenograft Model Antitumor Assays | 2013 |
Towards a tailored therapy in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Precision Medicine; Receptors, CXCR4 | 2013 |
A tissue-engineered subcutaneous pancreatic cancer model for antitumor drug evaluation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Mice, Nude; Nanofibers; Nanotechnology; Neoplasms, Experimental; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Tissue Scaffolds; Tumor Cells, Cultured | 2013 |
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.
Topics: Anilides; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyridines; Signal Transduction; SOXB1 Transcription Factors; Stem Cells | 2013 |
Loss of runt-related transcription factor 3 induces gemcitabine resistance in pancreatic cancer.
Topics: Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunoblotting; Pancreatic Neoplasms; Pancreaticoduodenectomy; RNA, Small Interfering | 2013 |
Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Remission Induction | 2013 |
Intravesical gemcitabine for high risk, nonmuscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Risk Assessment; Treatment Failure; Urinary Bladder Neoplasms | 2013 |
Gemcitabine induced skin rash.
Topics: Antineoplastic Agents; Child; Deoxycytidine; Exanthema; Gemcitabine; Hodgkin Disease; Humans; Male | 2013 |
Intraarterial chemotherapy with gemcitabine and cisplatin in locally advanced or recurrent penile squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease Progression; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Penile Neoplasms; Survival Rate | 2013 |
Inhibition of pancreatic cancer and potentiation of gemcitabine effects by the extract of Pao Pereira.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Neoplasm Transplantation; Pancreatic Neoplasms; Plant Extracts; Trees; Xenograft Model Antitumor Assays | 2013 |
Drug-induced thrombotic thrombocytopenic purpura successfully treated with recombinant human soluble thrombomodulin.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Hypertension; Lung Neoplasms; Middle Aged; Oxonic Acid; Pemetrexed; Plasma; Purpura, Thrombotic Thrombocytopenic; Pyridines; Quinazolines; Recombinant Proteins; Solubility; Taxoids; Tegafur; Thrombomodulin | 2013 |
Salvage therapy of gemcitabine plus endostar significantly improves progression-free survival (PFS) with platinum-resistant recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endostatins; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Ovarian Neoplasms; Platinum; Prognosis; Recombinant Proteins; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Triplex-forming oligonucleotides targeting c-MYC potentiate the anti-tumor activity of gemcitabine in a mouse model of human cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatin Immunoprecipitation; Colonic Neoplasms; Deoxycytidine; DNA, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Oligonucleotides; Proto-Oncogene Proteins c-myc; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Current therapy and future directions in biliary tract malignancies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Retrospective Studies | 2013 |
Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Gemcitabine; Hepatectomy; Mice; Mice, Inbred Strains; Mice, Knockout; Neoplasm Recurrence, Local; Proto-Oncogene Proteins p21(ras); Risk Factors; Survival Rate; Tumor Suppressor Protein p53 | 2013 |
Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; RNA, Small Interfering; Signal Transduction | 2013 |
In vivo and in vitro liver cancer metabolism observed with hyperpolarized [5-(13)C]glutamine.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carbon Isotopes; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Glutaminase; Glutamine; Liver Neoplasms, Experimental; Magnetic Resonance Spectroscopy; Rats | 2013 |
Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Predictive Value of Tests; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Intrahepatic cholangiocarcinoma with sarcomatous change producing granulocyte-colony stimulating factor.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fatal Outcome; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Liver Failure; Middle Aged | 2013 |
Gemcitabine in patients with intraductal papillary mucinous neoplasm with an associated invasive carcinoma of the pancreas.
Topics: Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Carcinoma, Papillary; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2013 |
Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival.
Topics: Antineoplastic Agents; Benzimidazoles; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; Gemcitabine; Gene Silencing; High-Throughput Screening Assays; Humans; Mitoxantrone; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Thiolester Hydrolases | 2013 |
Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression.
Topics: Cell Line, Tumor; Collagen Type I; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Histone Acetyltransferases; HMGA2 Protein; Humans; p300-CBP Transcription Factors; Pancreatic Neoplasms | 2013 |
Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Endometrial Neoplasms; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Genital Neoplasms, Female; Humans; Irinotecan; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Pelvic Exenteration; Prognosis; Retrospective Studies; Survival Rate; Topotecan | 2013 |
A retrospective study of ampullary adenocarcinomas: overall survival and responsiveness to fluoropyrimidine-based chemotherapy.
Topics: Adenocarcinoma; Ampulla of Vater; Antimetabolites, Antineoplastic; Common Bile Duct Neoplasms; Deoxycytidine; Duodenal Neoplasms; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Pyrimidines; Retrospective Studies; Survival; Treatment Outcome | 2013 |
NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Practice Guidelines as Topic; Quality-Adjusted Life Years; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
HMGB1 recruits myeloid derived suppressor cells to promote peritoneal dissemination of colon cancer after resection.
Topics: Animals; Antimetabolites, Antineoplastic; Ascitic Fluid; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gemcitabine; HMGB1 Protein; Mice; Mice, Inbred BALB C; Myeloid Cells; Peritoneal Neoplasms; Recombinant Proteins | 2013 |
The method of GFR determination impacts the estimation of cisplatin eligibility in patients with advanced urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cohort Studies; Creatinine; Deoxycytidine; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Linear Models; Male; Patient Selection; Renal Insufficiency; Retrospective Studies | 2014 |
Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2013 |
Retrospective analysis of survival benefits of chemotherapy for metastatic or non-resectable intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies | 2013 |
Sequence‑dependent effect of gemcitabine and cisplatin on A549 non‑small‑cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Lung Neoplasms | 2013 |
Is the progression free survival advantage of concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin in patients with advanced cervical cancer worth the additional cost? A cost-effectiveness analysis.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hospitalization; Humans; Models, Econometric; Neutropenia; Uterine Cervical Neoplasms | 2013 |
[Relative efficacy of neoadjuvant gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management for muscle-invasive bladder cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2013 |
[Cardiorespiratory arrest due to acute pulmonary thromboembolism during chemotherapy for female urothelial carcinoma of urethra: a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Heart Arrest; Humans; Pulmonary Embolism; Urethral Neoplasms | 2013 |
Validated RP-HPLC method for the simultaneous analysis of gemcitabine and LY-364947 in liposomal formulations.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cattle; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Gemcitabine; Liposomes; Pancreatic Neoplasms; Pyrazoles; Pyrroles | 2013 |
A report of a rare case of autoimmune haemolytic anaemia in a patient with Hodgkin's disease in whom routine serology was negative.
Topics: Adult; Anemia, Hemolytic, Autoimmune; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Coombs Test; Deoxycytidine; Dexamethasone; Gemcitabine; Hodgkin Disease; Humans; Male; Recurrence | 2014 |
An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.
Topics: Cell Line, Tumor; Cell Movement; Deoxycytidine; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasm Invasiveness; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Receptors, CXCR4; Transcription Factor RelA; Transcription, Genetic; Up-Regulation | 2013 |
A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bioengineering; Camptothecin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Tissue Scaffolds; Xenograft Model Antitumor Assays | 2013 |
BSA-PLGA-based core-shell nanoparticles as carrier system for water-soluble drugs.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Lactic Acid; Nanoparticles; Osteosarcoma; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Serum Albumin, Bovine; Solubility; Water | 2013 |
Self-assembling, amphiphilic polymer-gemcitabine conjugate shows enhanced antitumor efficacy against human pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Polymers; Xenograft Model Antitumor Assays | 2013 |
Prognostic potential of ERCC1 protein expression and clinicopathologic factors in stage III/N2 non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Chi-Square Distribution; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-Associated Death Protein; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; Imidazoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyridazines; RNA, Small Interfering | 2013 |
Small cell gall bladder carcinoma complicated by syndrome of inappropriate secretion of antidiuretic hormone (SIADH) treated with mozavaptan.
Topics: Antidiuretic Hormone Receptor Antagonists; Antimetabolites, Antineoplastic; Benzazepines; Carcinoma, Small Cell; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Inappropriate ADH Syndrome; Middle Aged; Treatment Outcome | 2013 |
Tolerability and toxicity of adjuvant cisplatin and gemcitabine for treating non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies | 2013 |
Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup.
Topics: Antineoplastic Agents; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Equipment Design; Gemcitabine; Nebulizers and Vaporizers; Paclitaxel; Taxoids | 2013 |
Anti-cancer activity of gemcitabine against natural killer cell leukemia/lymphoma.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Inhibitory Concentration 50; Lymphoma, Extranodal NK-T-Cell; Male; Mice; Xenograft Model Antitumor Assays | 2014 |
Aggressive secondary surgery for local recurrence of pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Reoperation; Tomography, X-Ray Computed | 2013 |
Codelivery of VEGF siRNA and gemcitabine monophosphate in a single nanoparticle formulation for effective treatment of NSCLC.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Transfer Techniques; Genetic Therapy; Humans; Lung Neoplasms; Mice; Nanoparticles; Neovascularization, Pathologic; RNA, Small Interfering; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Gemcitabine with paclitaxel therapy against mesocolic leiomyosarcoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Leiomyosarcoma; Male; Mesocolon; Neoplasm Recurrence, Local; Paclitaxel; Prognosis | 2013 |
Patients treated with platinum-doublet chemotherapy for advanced non--small-cell lung cancer have inferior outcomes if previously treated with platinum-based chemoradiation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Genes, bcl-2; Heterografts; Humans; Intracellular Signaling Peptides and Proteins; Mice, Nude; Mitochondrial Proteins; Molecular Mimicry; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Urothelium | 2013 |
Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Oxonic Acid; Peripheral Nerves; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tegafur; Treatment Outcome | 2013 |
miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Transcription Factors; Transfection | 2013 |
SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analgesics; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiosurgery | 2013 |
Inhibitory effect of geraniol in combination with gemcitabine on proliferation of BXPC-3 human pancreatic cancer cells.
Topics: Acyclic Monoterpenes; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Terpenes; Time Factors | 2013 |
An insight into potential of nanoparticles-assisted chemotherapy of cancer using gemcitabine and its fatty acid prodrug:a comparative study.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Fatty Acids; Female; Gemcitabine; Humans; Male; Mice; Nanoparticles; Neoplasms; Prodrugs; Rats; Rats, Wistar | 2013 |
Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Docetaxel; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Neoplasms, Experimental; Paclitaxel; Pancreatic Neoplasms; Stathmin; Stromal Cells; Taxoids; Tubulin; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.
Topics: Animals; Cell Line, Tumor; Checkpoint Kinase 1; Chemoradiotherapy; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyrimidines; Radiation-Sensitizing Agents; Recombinational DNA Repair; Xenograft Model Antitumor Assays | 2013 |
A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
Topics: Algorithms; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Neoplasm Transplantation; Neoplasms, Experimental; Xenograft Model Antitumor Assays | 2013 |
[Metastatic micropapillary variant of urothelial carcinoma of the urinary bladder responding to gemcitabine and cisplatin chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lymphatic Metastasis; Male; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell line.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzodiazepinones; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pyrazoles; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Spheroids, Cellular; Tumor Cells, Cultured | 2013 |
Treatment of human pancreatic cancer using combined ultrasound, microbubbles, and gemcitabine: a clinical case study.
Topics: Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Microbubbles; Middle Aged; Pancreatic Neoplasms; Ultrasonic Therapy | 2013 |
In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Carbon; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Heavy Ion Radiotherapy; Humans; Pancreatic Neoplasms; Photons; Relative Biological Effectiveness | 2013 |
Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Survival Rate; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Functionalized magnetic nanoparticles as vehicles for the delivery of the antitumor drug gemcitabine to tumor cells. Physicochemical in vitro evaluation.
Topics: Acrylic Resins; Adsorption; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chemical Phenomena; Deoxycytidine; Drug Delivery Systems; Electrophoresis; Folic Acid; Gemcitabine; Humans; Hydrogen-Ion Concentration; Magnetite Nanoparticles; Microscopy, Confocal; Neoplasms; Optical Imaging; Particle Size | 2013 |
Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cathepsin B; Cell Line, Tumor; Cell Survival; Chemistry, Pharmaceutical; Deoxycytidine; Drug Carriers; Drug Stability; Drug Synergism; Female; Gemcitabine; Humans; Hydrogen-Ion Concentration; Hydrolysis; Kinetics; Male; Molecular Weight; Ovarian Neoplasms; Paclitaxel; Polymerization; Polymethacrylic Acids; Solubility; Technology, Pharmaceutical | 2013 |
Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; C-Reactive Protein; Cell Line, Tumor; Cell Movement; Deoxycytidine; Female; Gemcitabine; Humans; Inflammation Mediators; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Prospective Studies; Serum Amyloid P-Component; Transfection; Treatment Outcome | 2013 |
Adjuvant chemotherapy in resectable cholangiocarcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Evaluation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Neoplasm Grading; Neoplasm Staging; Retrospective Studies; Survival Analysis; Treatment Outcome | 2013 |
Polymer prodrug nanoparticles based on naturally occurring isoprenoid for anticancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colloids; Deoxycytidine; Gemcitabine; Humans; Mice; Nanocapsules; Nanoparticles; Neoplasms; Polyethylene Glycols; Polymerization; Polymethacrylic Acids; Prodrugs; Squalene; Terpenes | 2013 |
Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzamidines; Carcinoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gallbladder Neoplasms; Gemcitabine; Guanidines; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Serine Proteinase Inhibitors; Xenograft Model Antitumor Assays | 2013 |
High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC-MS/MS.
Topics: Antimetabolites, Antineoplastic; Chromatography, Liquid; Deoxycytidine; Deoxyuridine; Floxuridine; Gemcitabine; Humans; Prodrugs; Sensitivity and Specificity; Tandem Mass Spectrometry | 2013 |
A fluorescence off-on reporter for real time monitoring of gemcitabine delivery to the cancer cells.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Monitoring; Fluorescent Dyes; Gemcitabine; Humans; Microscopy, Confocal; Molecular Structure; Prodrugs | 2013 |
Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Time Factors | 2013 |
Antagonistic effects of anti-EMMPRIN antibody when combined with chemotherapy against hypovascular pancreatic cancers.
Topics: Animals; Antibodies, Neoplasm; Basigin; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Drug Delivery Systems; Female; Gemcitabine; Mice; Pancreatic Neoplasms; Positron-Emission Tomography; Tumor Burden | 2014 |
CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Connective Tissue Growth Factor; Deoxycytidine; Gemcitabine; Liver Neoplasms; Mice; Pancreatic Neoplasms; Survival Analysis; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytidine Deaminase; Deoxycytidine; Disease Progression; Gemcitabine; Genotype; Humans; Pancreatic Neoplasms; Polymorphism, Single Nucleotide | 2013 |
Variation in drug sensitivity of malignant mesothelioma cell lines with substantial effects of selenite and bortezomib, highlights need for individualized therapy.
Topics: Amino Acid Transport System y+; Antineoplastic Agents; Biomarkers, Tumor; Boronic Acids; Bortezomib; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Multidrug Resistance-Associated Proteins; Pemetrexed; Pyrazines; Selenious Acid | 2013 |
Anti-tumour efficacy of capecitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Mice; Mice, Transgenic; Neoplasm Transplantation; Pancreatic Neoplasms; Prodrugs; Tissue Distribution | 2013 |
Drug-induced subacute cutaneous lupus erythematosus--filling the gap in knowledge: comment on "subacute cutaneous lupus erythematosus induced by chemotherapy".
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Eruptions; Female; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous | 2013 |
The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cystectomy; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Proportional Hazards Models; Retrospective Studies; Smoking; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Andrographolide causes apoptosis via inactivation of STAT3 and Akt and potentiates antitumor activity of gemcitabine in pancreatic cancer.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Count; Cell Cycle; Cell Line, Tumor; Coloring Agents; Cytochromes c; Deoxycytidine; Diterpenes; Drug Synergism; Flow Cytometry; Gemcitabine; Gentian Violet; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2013 |
Upper gastrointestinal complications associated with gemcitabine-concurrent proton radiotherapy for inoperable pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Endoscopy, Gastrointestinal; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Incidence; Japan; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies; Proton Therapy; Radiation Injuries | 2014 |
Is S-1 a potential game changer in adjuvant therapy of pancreatic cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
Locally advanced pancreatic cancer. Looking beyond traditional chemotherapy and radiation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Peptide Fragments; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Telomerase; Treatment Outcome; Vaccines | 2013 |
First line therapy for metastatic pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Administration Schedule; Fatigue; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2013 |
Update on phase I studies in advanced pancreatic adenocarcinoma. Hunting in darkness?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Furans; Gemcitabine; Humans; Hyaluronoglucosaminidase; Lignans; Mutation; Pancreatic Neoplasms; Polyethylene Glycols; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Recombinant Proteins; RNA Interference; Treatment Outcome | 2013 |
Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Osteonectin; Pancreatic Neoplasms; Pharmacogenetics; Transcriptome; Treatment Outcome | 2013 |
Preclinical research in treatment of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Imidazoles; Mice; Paclitaxel; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Novel agents and future prospects in the treatment of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Anilides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Indoles; Niacinamide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sunitinib; Treatment Outcome | 2013 |
Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Nucleoside Transport Proteins; Platinum Compounds; Predictive Value of Tests; Urinary Bladder Neoplasms | 2014 |
An efficient and robust method for analyzing population pharmacokinetic data in genome-wide pharmacogenomic studies: a generalized estimating equation approach.
Topics: Antimetabolites, Antineoplastic; Computer Simulation; Data Interpretation, Statistical; Deoxycytidine; Gemcitabine; Genome-Wide Association Study; Humans; Models, Statistical; Pancreatic Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide | 2013 |
Inhibition of checkpoint kinase 2 (CHK2) enhances sensitivity of pancreatic adenocarcinoma cells to gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Tumor; Checkpoint Kinase 2; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Reactive Oxygen Species | 2013 |
Nuclear expression of glioma-associated oncogene homolog 1 and nuclear factor-κB is associated with a poor prognosis of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Nucleus; Deoxycytidine; Female; Gemcitabine; Hedgehog Proteins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Transcription Factor RelA; Transcription Factors; Treatment Outcome; Zinc Finger Protein GLI1 | 2013 |
Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; T-Lymphocytes, Regulatory | 2014 |
[A case of triple-negative breast cancer achieved pCR by epirubicin and cyclophosphamide(EC)therapy followed by gemcitabine plus paclitaxel combination preoperative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Remission Induction | 2013 |
[Clinical benefit of full-dose gemcitabine for advanced pancreatic cancer refractory to S-1+gemcitabine].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed | 2013 |
[A case of pancreatic body cancer with multiple liver metastases experiencing long-term response by gemcitabine plus erlotinib therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Time Factors | 2013 |
Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; LIM-Homeodomain Proteins; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms; Side-Population Cells; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urokinase-Type Plasminogen Activator | 2013 |
Folate-based near-infrared fluorescent theranostic gemcitabine delivery.
Topics: Animals; Antimetabolites, Antineoplastic; Carbocyanines; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Fluorescent Dyes; Folic Acid; Gemcitabine; Humans; KB Cells; Mice; Neoplasms; Optical Imaging; Sulfhydryl Compounds | 2013 |
Comparative outcomes of elderly and non-elderly patients receiving first-line palliative chemotherapy for advanced biliary tract cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Retrospective Studies; Tegafur; Treatment Outcome; Uracil | 2014 |
Gemcitabine therapy-associated cutaneous vasculitis with a polyarteritis nodosa-like pattern.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Ovarian Neoplasms; Polyarteritis Nodosa; Vasculitis, Leukocytoclastic, Cutaneous | 2013 |
Interactions between dietary flavonoids apigenin or luteolin and chemotherapeutic drugs to potentiate anti-proliferative effect on human pancreatic cancer cells, in vitro.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Luteolin; Pancreatic Neoplasms; Signal Transduction; Transcription Factor RelA | 2013 |
Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; HEK293 Cells; Homeodomain Proteins; Humans; Kaplan-Meier Estimate; Mice; Mice, Inbred BALB C; Mice, Nude; Nanog Homeobox Protein; Neoplasm Invasiveness; Neoplasm Transplantation; Neoplastic Stem Cells; Octamer Transcription Factor-3; Pancreatic Neoplasms; RNA Interference; Tumor Burden | 2013 |
Synergy between chemotherapeutic agents and CTLA-4 blockade in preclinical tumor models.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; CTLA-4 Antigen; Deoxycytidine; Drug Synergism; Epothilones; Etoposide; Female; Gemcitabine; Ipilimumab; Mice; Mice, Inbred BALB C; Neoplasms, Experimental | 2013 |
CHFR silencing or microsatellite instability is associated with increased antitumor activity of docetaxel or gemcitabine in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Base Sequence; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; DNA Methylation; DNA Primers; Docetaxel; Female; Gemcitabine; Gene Silencing; Humans; Mice; Microsatellite Instability; Neoplasm Proteins; Poly-ADP-Ribose Binding Proteins; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Taxoids; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2014 |
Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; Gemcitabine; Humans; Mitosis; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles | 2013 |
Combination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Gene Expression; Genes, Reporter; Lung Neoplasms; Mice; Neovascularization, Pathologic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Tumor Burden | 2013 |
Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Mice; Mice, SCID; Microbubbles; Pancreatic Neoplasms; Reproducibility of Results; Sonication; Survival Analysis; Transducers; Tumor Burden; Ultrasonics; Xenograft Model Antitumor Assays | 2014 |
Severe eosinophilic pneumonia presenting during gemcitabine adjuvant chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Prognosis; Pulmonary Eosinophilia; Tomography, X-Ray Computed | 2013 |
Treatment outcome of palliative chemotherapy in inoperable cholangiocarcinoma in Thailand.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases; a preferential option for triple negative patients?
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Carcinoma, Medullary; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Rate | 2013 |
Secondline chemotherapy versus best supportive care in patient with malignant pleural mesothelioma: a retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Palliative Care; Pemetrexed; Platinum; Pleural Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
The safety and efficacy of cisplatin plus gemcitabine in recurrent ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms | 2014 |
Up-regulation of DDX39 in human pancreatic cancer cells with acquired gemcitabine resistance compared to gemcitabine-sensitive parental cells.
Topics: Blotting, Western; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Up-Regulation | 2013 |
Inhibition of SIRT1 combined with gemcitabine therapy for pancreatic carcinoma.
Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Electrophoresis, Polyacrylamide Gel; Gemcitabine; Immunohistochemistry; Mice; Mice, Nude; Naphthols; Pancreatic Neoplasms; Sirtuin 1; Survival Analysis | 2013 |
SL-01, an oral derivative of gemcitabine, inhibited human breast cancer growth through induction of apoptosis.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Design; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Xenograft Model Antitumor Assays | 2013 |
MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells.
Topics: Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Signal Transduction; Wnt Signaling Pathway | 2013 |
[Experimental study of remaxol as a drug for supportive therapy in traditional and high-dose treatment of tumors].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Etoposide; Gemcitabine; Methotrexate; Mice; Neoplasms, Experimental; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Succinates | 2013 |
A spheroid-based 3-D culture model for pancreatic cancer drug testing, using the acid phosphatase assay.
Topics: Acid Phosphatase; Antimetabolites, Antineoplastic; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Spheroids, Cellular | 2013 |
Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Collagen; Deoxycytidine; Disease Models, Animal; Elasticity Imaging Techniques; Endosonography; Female; Fibroblasts; Gemcitabine; Humans; Male; Mice; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography | 2013 |
Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Docetaxel; Female; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Retrospective Studies; Taxoids; Vinblastine; Vinorelbine | 2013 |
[Acute pain at tumor recurrence site induced by vinorelbine infusion].
Topics: Acute Disease; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Oxycodone; Pain; Vinblastine; Vinorelbine | 2013 |
Chemotherapy counteracts metastatic dissemination induced by antiangiogenic treatment in mice.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Movement; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Indoles; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Topotecan | 2013 |
A large primary vaginal leiomyosarcoma diagnosed postoperatively and uterine leiomyomas treated with surgery and chemotherapy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyoma; Leiomyosarcoma; Middle Aged; Taxoids; Uterine Neoplasms; Vagina; Vaginal Neoplasms | 2013 |
Regression of choroidal neovascularization in response to systemic chemotherapy for cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Choroidal Neovascularization; Cisplatin; Deoxycytidine; Docetaxel; Fatal Outcome; Fluorescein Angiography; Gemcitabine; Humans; Male; Remission Induction; Taxoids; Tomography, Optical Coherence; Urethral Neoplasms; Urinary Bladder Neoplasms | 2013 |
In vitro effects of lapatinib with gemcitabine for pancreatic cancer cells.
Topics: Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lapatinib; Pancreatic Neoplasms; Quinazolines; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2013 |
A great option for elderly patients with locally invasive bladder cancer, BOAI-CDDP-radiation (OMC regimen).
Topics: Age Factors; Aged; Aged, 80 and over; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Radiotherapy Dosage; Treatment Outcome; Urinary Bladder Neoplasms | 2013 |
Bayseian genomic models for the incorporation of pathway topology knowledge into association studies.
Topics: 5'-Nucleotidase; Algorithms; Antimetabolites, Antineoplastic; Bayes Theorem; Cell Line, Tumor; Computer Simulation; Data Interpretation, Statistical; Deoxycytidine; Gemcitabine; Gene Expression; Gene Regulatory Networks; Genetic Association Studies; Genomics; Glycoproteins; Humans; Membrane Transport Proteins; Mercaptopurine; Models, Genetic; Phenotype | 2013 |
Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genotype; HEK293 Cells; Humans; Pancreatic Neoplasms; Pharmacogenetics; Phenotype; Polymorphism, Single Nucleotide; Receptors, Glucocorticoid; Sequence Analysis, DNA; Survival Analysis; Tacrolimus Binding Proteins | 2013 |
Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies.
Topics: Adenosine; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Delayed-Action Preparations; Deoxycytidine; DNA Methylation; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Nanoparticles; Nucleosides; Pancreatic Neoplasms; Xenopus | 2013 |
Simultaneous knock-down of Bcl-xL and Mcl-1 induces apoptosis through Bax activation in pancreatic cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspases; Cell Line, Tumor; Cytochromes c; Deoxycytidine; Enzyme Activation; Gemcitabine; Gene Knockdown Techniques; Humans; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms | 2013 |
Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Staging; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Vitamin E δ-tocotrienol prolongs survival in the LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) transgenic mouse model of pancreatic cancer.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Biomarkers, Tumor; Body Weight; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Genes, ras; Genotype; Immunohistochemistry; Male; Mice; Mice, Transgenic; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Poly(ADP-ribose) Polymerases; Random Allocation; Signal Transduction; Treatment Outcome; Vitamin E | 2013 |
Pulsed high-intensity focused ultrasound enhances apoptosis of pancreatic cancer xenograft with gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Treatment Outcome | 2013 |
Attenuation of nucleoside and anti-cancer nucleoside analog drug uptake in prostate cancer cells by Cimicifuga racemosa extract BNO-1055.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; Cell Line; Cell Proliferation; Cimicifuga; Deoxycytidine; Dose-Response Relationship, Drug; Equilibrative Nucleoside Transport Proteins; Fluorouracil; Gemcitabine; Humans; Male; Nucleosides; Phytotherapy; Plant Extracts; Prostate; Prostatic Neoplasms; RNA, Small Interfering; Saponins; Thymidine; Vidarabine | 2013 |
Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India.
Topics: Camptothecin; Cost Savings; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Drugs, Generic; Gemcitabine; Humans; India; Irinotecan; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Poverty; Taxoids | 2013 |
Re-challenge chemotherapy with gemcitabine plus carboplatin in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Remission Induction; Retrospective Studies; Survival Rate | 2013 |
Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Single Nucleotide; Prognosis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2013 |
Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Aspirin; Carcinoma, Pancreatic Ductal; Cyclooxygenase Inhibitors; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Forkhead Transcription Factors; Gemcitabine; Mice; Mice, Transgenic; Pancreatic Neoplasms; T-Lymphocytes, Regulatory | 2013 |
Gemcitabine eliminates double minute chromosomes from human ovarian cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; DNA, Neoplasm; Eukaryotic Translation Initiation Factor 5A; Female; Gemcitabine; Gene Amplification; Histones; Humans; Hydroxyurea; In Situ Hybridization, Fluorescence; Micronuclei, Chromosome-Defective; Myeloid Cell Leukemia Sequence 1 Protein; N-Myc Proto-Oncogene Protein; Nuclear Proteins; Oncogene Proteins; Ovarian Neoplasms; Peptide Initiation Factors; Real-Time Polymerase Chain Reaction; RNA-Binding Proteins | 2013 |
Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.
Topics: Anti-HIV Agents; Azacitidine; Biological Availability; Caco-2 Cells; Cell Proliferation; Decitabine; Deoxycytidine; Drug Stability; Gemcitabine; Half-Life; HEK293 Cells; HIV-1; Humans; Hydrogen-Ion Concentration; Permeability; Prodrugs | 2014 |
[Long-term survival with gemcitabine and docetaxel for renal leiomyosarcoma : a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kidney Neoplasms; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Pancreatic Neoplasms; Taxoids | 2013 |
Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Macrophages; Mice; Mice, Knockout; Pancreatic Neoplasms; Receptors, Granulocyte-Macrophage Colony-Stimulating Factor; Xenograft Model Antitumor Assays | 2014 |
Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Taxoids; Treatment Outcome; Tumor Suppressor Protein p53 | 2013 |
Gemcitabine-mediated tumour regression and p53-dependent gene expression: implications for colon and pancreatic cancer therapy.
Topics: 14-3-3 Proteins; Animals; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Cell Line, Tumor; Chromium; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; DNA Damage; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; Models, Biological; Pancreatic Neoplasms; Protein Biosynthesis; Proto-Oncogene Proteins; Remission Induction; Transcription, Genetic; Tumor Suppressor Protein p53 | 2013 |
The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Melanoma; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Uveal Neoplasms | 2014 |
Does adjuvant chemotherapy improve survival for women with early-stage uterine leiomyosarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy, Adjuvant; Retrospective Studies; Taxoids; Uterine Neoplasms | 2013 |
Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Survival; Deoxycytidine; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mitotane; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2014 |
Inhibition of amyloid precursor protein processing enhances gemcitabine-mediated cytotoxicity in pancreatic cancer cells.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Deoxycytidine; Dipeptides; Gemcitabine; Humans; Hydroxamic Acids; Membrane Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Protein Structure, Tertiary; Thiophenes | 2013 |
Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies | 2013 |
Propofol induces apoptosis and increases gemcitabine sensitivity in pancreatic cancer cells in vitro by inhibition of nuclear factor-κB activity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Drug Synergism; Gemcitabine; Humans; Hypnotics and Sedatives; NF-kappa B; Pancreatic Neoplasms; Propofol | 2013 |
Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Tyrphostins; Xenograft Model Antitumor Assays | 2013 |
Genetic inactivation of Nupr1 acts as a dominant suppressor event in a two-hit model of pancreatic carcinogenesis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cadherins; Carcinogenesis; Caspase 3; Cell Survival; Claudin-1; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Disease Models, Animal; DNA-Binding Proteins; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression; Genes, Suppressor; Heterozygote; Immediate-Early Proteins; Life Expectancy; Mice; Mice, Knockout; Mucin-1; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Transforming Growth Factor beta1; Tumor Cells, Cultured | 2014 |
A retrospective study of gemcitabine and cisplatin combination therapy as second-line treatment for advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Severity of Illness Index; Survival Rate | 2013 |
Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Immunoblotting; Microscopy, Fluorescence; Phosphorylation; Proto-Oncogene Proteins c-akt; Sirolimus; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms | 2014 |
Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carbolines; Cell Cycle Checkpoints; Checkpoint Kinase 1; Dacarbazine; Deoxycytidine; DNA Damage; Gemcitabine; HCT116 Cells; High-Throughput Nucleotide Sequencing; HT29 Cells; Humans; Irinotecan; Mice; Mice, Nude; Neoplasms; Neoplasms, Experimental; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Temozolomide; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
In vitro evaluation of HPMA-copolymers targeted to HER2 expressing pancreatic tumor cells for image guided drug delivery.
Topics: Acrylamides; Animals; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrogen-Ion Concentration; Indium Radioisotopes; Inhibitory Concentration 50; Mice; Molecular Targeted Therapy; Pancreatic Neoplasms; Polymers; Receptor, ErbB-2 | 2014 |
In vivo activity and pharmacokinetics of nemorosone on pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Agents; Benzophenones; Biological Availability; Biotransformation; Carcinoma; Caspase 3; Cytochrome P-450 CYP3A; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Gene Expression; Half-Life; Hepatocytes; Humans; Injections, Subcutaneous; Ki-67 Antigen; Mice; Mice, Nude; Pancreatic Neoplasms; Phloroglucinol; Primary Cell Culture; Terpenes; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2013 |
Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genotype; Humans; Inhibitory Concentration 50; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Patient Selection; Phenotype; RNA, Messenger | 2013 |
Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2013 |
Erlotinib-induced thrombocytosis in patients with recurrence of pancreatic cancer after distal pancreatectomy.
Topics: Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Platelet Count; Quinazolines; Splenectomy; Thrombocytosis | 2013 |
[Outcomes of chemotherapy in patients with EGFR mutation-negative non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Remission Induction; Survival Rate; Vinblastine; Vinorelbine | 2013 |
Downregulation of LIMK1 level inhibits migration of lung cancer cells and enhances sensitivity to chemotherapy drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lim Kinases; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Respiratory Mucosa; RNA, Small Interfering | 2013 |
Predictive modeling of in vivo response to gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, SCID; Pancreatic Neoplasms | 2013 |
A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Cycle; Cell Proliferation; Chromatography, High Pressure Liquid; Computer Simulation; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Flow Cytometry; Gemcitabine; Half-Life; Humans; Hydroxyurea; Interleukin-2 Receptor alpha Subunit; Mice; Mice, Inbred NOD; Mice, SCID; Mutagenesis, Site-Directed; Mutation; Neoplasms; Protein Conformation; Ribonucleotide Reductases; Small Molecule Libraries; Structure-Activity Relationship; Surface Plasmon Resonance; Tandem Mass Spectrometry; Thiazoles | 2013 |
Micellar nanoparticles loaded with gemcitabine and doxorubicin showed synergistic effect.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Doxorubicin; Drug Carriers; Gemcitabine; Hep G2 Cells; Humans; Micelles; Nanoparticles | 2014 |
Sequential gemcitabine and platinum versus first-line combination of gemcitabine and platinum for advanced pancreatic cancer treatment: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Platinum; Retrospective Studies | 2014 |
Cigarette smoking and gemcitabine-induced neutropenia in advanced solid tumors.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Retrospective Studies; Smoking | 2013 |
PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Liposomes; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanoparticles; Paclitaxel; Polyethylene Glycols; Time Factors; Treatment Outcome; Tumor Burden | 2013 |
Damage-induced DNA replication stalling relies on MAPK-activated protein kinase 2 activity.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; DNA, Single-Stranded; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Knockdown Techniques; Histones; Humans; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Mice; Mice, Knockout; p38 Mitogen-Activated Protein Kinases; Protein Kinases; Protein Serine-Threonine Kinases; Ultraviolet Rays | 2013 |
Expression of hENTl and ERCC1 genes in tumor tissues non-small cell lung cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Equilibrative Nucleoside Transporter 1; Gemcitabine; Lung Neoplasms; Mice; RNA, Messenger; Survival Rate; Tumor Burden | 2013 |
Effectivity of long antigen exposition dendritic cell therapy (LANEXDC®) in the palliative treatment of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell- and Tissue-Based Therapy; Cytokines; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Recombinant Proteins; Retrospective Studies; Treatment Outcome | 2013 |
Survival analysis in advanced non small cell lung cancer treated with platinum based chemotherapy in combination with paclitaxel, gemcitabine and etoposide.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Crizotinib; Deoxycytidine; Female; Gemcitabine; Humans; Inactivation, Metabolic; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways.
Topics: Animals; Carcinoma, Lewis Lung; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Immune Tolerance; Immunosuppressive Agents; Immunotherapy, Adoptive; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C57BL; Myeloid Cells; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
Carboplatin-containing regimens as front-line treatment for advanced non-small-cell lung cancer in two groups of elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Retrospective Studies; Vinblastine; Vinorelbine | 2014 |
Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasms; Retrospective Studies; Thrombotic Microangiopathies | 2014 |
Angiotensin-(1-7) synergizes with colony-stimulating factors in hematopoietic recovery.
Topics: Angiotensin I; Animals; Antimetabolites, Antineoplastic; Bone Marrow Cells; Cell Proliferation; Deoxycytidine; Drug Synergism; Epoetin Alfa; Erythroid Precursor Cells; Erythropoietin; Female; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematinics; Megakaryocytes; Mice; Mice, Inbred C57BL; Myeloid Progenitor Cells; Peptide Fragments; Recombinant Proteins; Stem Cells; Time Factors | 2013 |
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers, Tumor; Chemokine CXCL12; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Vascular Endothelial Growth Factor D; Vesicular Transport Proteins | 2013 |
[Clinical experience with gemcitabine treatment for metastatic breast cancer].
Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quality of Life; Recurrence | 2013 |
Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cellular Senescence; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Neoplasm Grading; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-raf; Retinoblastoma Protein; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Doxorubicin; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Tumor Suppressor Protein p53 | 2014 |
Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells.
Topics: 1-Methyl-3-isobutylxanthine; Amides; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colforsin; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphodiesterase Inhibitors; Pyridines; Quinolones; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; rhoC GTP-Binding Protein; Vasodilator Agents | 2015 |
Manipulation of olfactory tight junctions using papaverine to enhance intranasal delivery of gemcitabine to the brain.
Topics: Administration, Intranasal; Animals; Antimetabolites, Antineoplastic; Blood-Brain Barrier; Blotting, Western; Brain; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Male; Microdialysis; Occludin; Olfactory Mucosa; Papaverine; Permeability; Phosphorylation; Rats; Rats, Sprague-Dawley; Tight Junctions; Tissue Distribution | 2014 |
[Double-mutated oncolytic adenovirus combined with gemcitabine for treating an orthotopic nude mouse model of bladder cancer].
Topics: Adenoviridae; Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Galactosides; Gemcitabine; Indoles; Mice; Mice, Nude; Models, Animal; Urinary Bladder Neoplasms | 2013 |
[Hemolytic-uremic syndrome associated with gemcitabine use: report of one case].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2013 |
Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Proteome; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2013 |
USANZ: Time-trends in use and impact on outcomes of perioperative chemotherapy in patients treated with radical cystectomy for urothelial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Perioperative Period; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2013 |
Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 8; Cell Line, Tumor; Cytotoxicity, Immunologic; Deoxycytidine; Fas Ligand Protein; fas Receptor; Gemcitabine; Humans; Killer Cells, Lymphokine-Activated; Lung Neoplasms | 2014 |
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Fusion Regulatory Protein-1; Gemcitabine; Humans; Kaplan-Meier Estimate; Large Neutral Amino Acid-Transporter 1; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Prognosis; Retrospective Studies; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
The effect of photochemical internalization of bleomycin in the treatment of urothelial carcinoma of the bladder: an in vitro study.
Topics: Animals; Antibiotics, Antineoplastic; Bleomycin; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Epirubicin; Gemcitabine; Humans; Light; Mitomycin; Photochemotherapy; Photosensitizing Agents; Porphyrins; Rats; Time Factors; Urinary Bladder Neoplasms | 2014 |
uPAR-controlled oncolytic adenoviruses eliminate cancer stem cells in human pancreatic tumors.
Topics: AC133 Antigen; Adenoviridae; Adenovirus E1A Proteins; Animals; Antigens, CD; Antigens, Neoplasm; Antimetabolites, Antineoplastic; CD24 Antigen; Cell Adhesion Molecules; Deoxycytidine; Epithelial Cell Adhesion Molecule; Gemcitabine; Glycoproteins; Humans; Hyaluronan Receptors; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Oncolytic Virotherapy; Pancreatic Neoplasms; Peptides; Promoter Regions, Genetic; Receptors, Urokinase Plasminogen Activator; Transplantation, Heterologous; Tumor Cells, Cultured | 2014 |
Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice.
Topics: Animals; Cell Line, Tumor; Collagen; Deoxycytidine; Drug Carriers; Drug Combinations; Endothelial Cells; Female; Gemcitabine; Humans; Laminin; Liposomes; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanomedicine; Nanoparticles; Neoplasm Transplantation; Pancreatic Neoplasms; Polyethylene Glycols; Polyethyleneimine; Proteoglycans; Signal Transduction; Silicon Dioxide; Smad2 Protein; Transforming Growth Factor beta | 2013 |
miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Caspase 3; Caspase 7; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Transcriptome | 2013 |
Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Pemetrexed; Pleural Neoplasms; RNA Interference; Transfection; Tumor Burden | 2013 |
Feasibility study of gemcitabine plus docetaxel in advanced or recurrent uterine leiomyosarcoma and undifferentiated endometrial sarcoma in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Feasibility Studies; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Japan; Leiomyosarcoma; Middle Aged; Sarcoma, Endometrial Stromal; Taxoids; Uterine Neoplasms | 2014 |
Thermosensitive liposomes for the delivery of gemcitabine and oxaliplatin to tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry, Pharmaceutical; Deoxycytidine; Female; Gemcitabine; Liposomes; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Organoplatinum Compounds; Oxaliplatin; Phospholipids; Polyethylene Glycols; Surface-Active Agents; Temperature; Tissue Distribution | 2013 |
Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
Erythropoietin receptor expression is a potential prognostic factor in human lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Biomarkers, Tumor; Bronchoscopy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Middle Aged; Multivariate Analysis; Prognosis; Receptors, Erythropoietin; Recombinant Proteins; Xenograft Model Antitumor Assays | 2013 |
Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine.
Topics: Adoptive Transfer; Animals; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Administration Schedule; Drug Synergism; Gemcitabine; Immunologic Memory; Lymphocyte Depletion; Lymphocytes, Tumor-Infiltrating; Melphalan; Mice; Myeloid Cells; Neoplasms; Recombinant Fusion Proteins; T-Lymphocytes, Regulatory | 2013 |
GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Methylprednisolone; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Survival Analysis; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome | 2014 |
Chemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathway.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Growth Processes; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lymphokines; Phenotype; Platelet-Derived Growth Factor; Signal Transduction; Transfection | 2013 |
Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asbestos; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoplasm Staging; Pemetrexed; Pleural Neoplasms; Vinblastine; Vinorelbine | 2014 |
The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity.
Topics: Adenosine; Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Survival; Central Nervous System Depressants; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Ethanol; Gemcitabine; Humans; Mice; Mice, Knockout; Myocytes, Cardiac; Protein Kinase C-epsilon | 2014 |
Safety and pharmacology of gemcitabine and capecitabine in patients with advanced pancreatico-biliary cancer and hepatic dysfunction.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hyperbilirubinemia; Liver Diseases; Male; Middle Aged; Pancreatic Neoplasms | 2014 |
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Quinazolinones; Random Allocation; Receptor, ErbB-2; Receptor, ErbB-4; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Inhibitory Concentration 50; Nucleoside Transport Proteins; Piperidines; Quinazolines; Saccharomyces cerevisiae; Uridine | 2014 |
Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2013 |
Concurrent chemoradiation with weekly gemcitabine and cisplatin for locally advanced cervical cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cobalt Radioisotopes; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Uterine Cervical Neoplasms; Young Adult | 2013 |
Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Time Factors; Treatment Outcome | 2013 |
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gemcitabine; Glycoproteins; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Metalloproteases; Pancreatic Neoplasms; Peptides; Polycomb Repressive Complex 2; RNA, Messenger; Spheroids, Cellular; Tumor Cells, Cultured | 2014 |
Feasibility of pre- and postoperative gemcitabine-plus-cisplatin systemic chemotherapy for the treatment of locally advanced urothelial carcinoma in kidney transplant patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Kidney Transplantation; Male; Middle Aged; Urinary Bladder Neoplasms | 2013 |
The combination of gemcitabine and carboplatin shows similar efficacy in the treatment of platinum-resistant and platinum-sensitive recurrent epithelial ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Endometrioid; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Retrospective Studies | 2014 |
Multifunctional squalene-based prodrug nanoparticles for targeted cancer therapy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Nanomedicine; Nanoparticles; Neoplasms; Prodrugs; Squalene; Tumor Cells, Cultured | 2014 |
Adjuvant surgery for advanced extrahepatic cholangiocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Lymph Node Excision; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreaticoduodenectomy; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response.
Topics: Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cisplatin; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Liposomes; Liver Neoplasms; Models, Theoretical; Nanomedicine; Nanoparticles | 2013 |
Bevacizumab-induced transient sixth nerve palsy in ovarian cancer: A case report.
Topics: Abducens Nerve Diseases; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2016 |
Triple combination of bevacizumab, gemcitabine and platinum salt in metastatic collecting duct carcinoma.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Maintenance Chemotherapy; Middle Aged; Treatment Outcome | 2013 |
Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carbon; Cell Cycle; Cell Line, Tumor; Cell Separation; Chemoradiotherapy; Cisplatin; Colonic Neoplasms; Deoxycytidine; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Glioblastoma; Humans; Ions; Lung Neoplasms; Paclitaxel; Pancreatic Neoplasms; Photons; Propidium; Radiotherapy; Relative Biological Effectiveness; Time Factors | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Reversing the intractable nature of pancreatic cancer by selectively targeting ALDH-high, therapy-resistant cancer cells.
Topics: Aldehyde Dehydrogenase; Analysis of Variance; Animals; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disulfiram; Drug Delivery Systems; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Immunohistochemistry; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction | 2013 |
Combination of ascorbate/epigallocatechin-3-gallate/gemcitabine synergistically induces cell cycle deregulation and apoptosis in mesothelioma cells.
Topics: Apoptosis; Ascorbic Acid; Catechin; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Combinations; Drug Synergism; Gemcitabine; Humans; Mesothelioma | 2014 |
Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model.
Topics: Adjuvants, Immunologic; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; CD40 Antigens; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Immunotherapy; Macrophages; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nitrites; Oligodeoxyribonucleotides; Skin Neoplasms; Tumor Burden | 2013 |
Antiprotease strategy in pancreatic cancer treatment: emergence from a preclinical study.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Evaluation, Preclinical; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gabexate; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Serine Proteinase Inhibitors; Vascular Endothelial Growth Factor A | 2014 |
CKD-516 displays vascular disrupting properties and enhances anti-tumor activity in combination with chemotherapy in a murine tumor model.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzophenones; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Deoxycytidine; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Mice, Mutant Strains; Microtubules; Neoplasms; Neovascularization, Pathologic; Tubulin; Tumor Burden; Valine; Xenograft Model Antitumor Assays | 2014 |
Reduction of decoy receptor 3 enhances TRAIL-mediated apoptosis in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Pancreatic Neoplasms; Protein Binding; Receptors, Tumor Necrosis Factor, Member 6b; RNA Interference; TNF-Related Apoptosis-Inducing Ligand; Tumor Burden; Tumor Necrosis Factor Ligand Superfamily Member 14; Xenograft Model Antitumor Assays | 2013 |
Locoregional radiotherapy in patients with distant metastases of nasopharyngeal carcinoma at diagnosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Palliative Care; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Young Adult | 2013 |
Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Deoxycytidine; Drug Synergism; Fluorescent Antibody Technique; Gemcitabine; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Inositol Phosphates; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Oxygen; Pancreatic Neoplasms; Rats; Rats, Inbred Lew; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2014 |
Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle Proteins; Deoxycytidine; Disease Progression; DNA Copy Number Variations; Docetaxel; Female; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Neoplasm Staging; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Taxoids; Treatment Outcome; Tumor Suppressor Proteins | 2013 |
Separate episodes of capillary leak syndrome and pulmonary hypertension after adjuvant gemcitabine and three years later after nab-paclitaxel for metastatic disease.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capillary Leak Syndrome; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Hypertension, Pulmonary; Paclitaxel; Pancreatic Neoplasms; Time Factors; Tomography, X-Ray Computed; Ultrasonography, Doppler | 2013 |
Chin tremors associated with paroxetine in a patient with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anxiety; Chemotherapy, Adjuvant; Chin; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tremor; Withholding Treatment | 2013 |
U.S. Food and Drug Administration approves paclitaxel protein-bound particles (Abraxane®) in combination with gemcitabine as first-line treatment of patients with metastatic pancreatic cancer.
Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration | 2013 |
MiR-365 induces gemcitabine resistance in pancreatic cancer cells by targeting the adaptor protein SHC1 and pro-apoptotic regulator BAX.
Topics: 3' Untranslated Regions; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1 | 2014 |
Bleeding from gastrointestinal tract recurrence of non-seminomatous germ cell tumour testis, showing temporary response to gemcitabine and oxaliplatin chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Radiography; Testicular Neoplasms; Thalidomide; Thrombocytopenia | 2013 |
Human pancreatic cancer cells with acquired gemcitabine resistance exhibit significant up-regulation of peroxiredoxin-2 compared to sensitive parental cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Peroxiredoxins; Tumor Cells, Cultured | 2013 |
Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Hyperbaric Oxygenation; In Vitro Techniques; Pancreatic Neoplasms; Tumor Cells, Cultured | 2013 |
Genetic factors associated with gemcitabine pharmacokinetics, disposition, and toxicity.
Topics: 5-Lipoxygenase-Activating Proteins; Antimetabolites, Antineoplastic; Asian People; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Gene-Environment Interaction; Genetic Markers; Genome-Wide Association Study; Genome, Human; Genotype; Humans; Models, Genetic; Neoplasms; Neutropenia; Polymorphism, Single Nucleotide; Signal Transduction | 2014 |
[Gemcitabine-induced tumor lysis syndrome caused by recurrent breast cancer in a patient without hemodialysis].
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Recurrence; Tumor Lysis Syndrome | 2013 |
Gemcitabine-induced thrombotic microangiopathy.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Thrombotic Microangiopathies | 2013 |
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2014 |
Clinical outcome of paclitaxel and carboplatin as second-line chemotherapy for advanced urothelial carcinoma resistant to first-line therapy with gemcitabine and cisplatin.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2014 |
Insights into the selective binding and toxic mechanism of microcystin to catalase.
Topics: Catalase; Circular Dichroism; Deoxycytidine; Energy Transfer; Gemcitabine; Hydrogen-Ion Concentration; Microcystins; Protein Binding; Protein Structure, Secondary; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared; Temperature | 2014 |
Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death.
Topics: Carbolines; Caspases; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Checkpoint Kinase 1; Chromosomes, Human; Deoxycytidine; DNA Fragmentation; Enzyme Activation; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mitosis; Nuclear Proteins; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Rad51 Recombinase; S Phase Cell Cycle Checkpoints; Tumor Suppressor Protein p53 | 2014 |
Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide.
Topics: Actins; Antineoplastic Agents; Apoptosis; Cell Count; Cell Line, Tumor; Deoxycytidine; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4F; Gemcitabine; Gene Expression; Glutamates; Guanine; Humans; Mesothelioma; Molecular Targeted Therapy; Oligonucleotides, Antisense; Ornithine Decarboxylase; Pemetrexed; Poly(ADP-ribose) Polymerases; Protein Binding; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Transfection | 2013 |
[Non-muscle invasive bladder cancer with multiple bone metastasis without local invasion : a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2013 |
Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Time Factors | 2014 |
Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
Topics: Adult; Aged; Breast Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease Progression; Female; Gemcitabine; Health Services Needs and Demand; Health Status; Humans; Longitudinal Studies; Middle Aged; Pancreatic Neoplasms; Quality of Life; Response Evaluation Criteria in Solid Tumors | 2015 |
The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
Topics: Apoptosis; Blotting, Western; Brentuximab Vedotin; Cell Line, Tumor; Cells, Cultured; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gemcitabine; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Interferon-gamma; Ki-1 Antigen; Lymphocytes; Microscopy, Fluorescence; Panobinostat; Reverse Transcriptase Polymerase Chain Reaction; Tumor Necrosis Factor-alpha | 2013 |
Identification of a novel subpopulation of tumor-initiating cells from gemcitabine-resistant pancreatic ductal adenocarcinoma patients.
Topics: AC133 Antigen; Aged; Aged, 80 and over; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Gemcitabine; Gene Expression; Glycoproteins; Humans; Immunophenotyping; Male; Mice; Middle Aged; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Phenotype; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2013 |
Gemcitabine enhances the efficacy of reovirus-based oncotherapy through anti-tumour immunological mechanisms.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Mice; Mice, Inbred C57BL; Oncolytic Virotherapy; Ovarian Neoplasms; Reoviridae; T-Lymphocytes; Virus Replication | 2014 |
MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Everolimus; Female; Gemcitabine; Humans; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, ErbB-3; Receptor, IGF Type 1; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Formulation and evaluation of gemcitabine-loaded solid lipid nanoparticles.
Topics: Animals; Antimetabolites, Antineoplastic; Chemistry, Pharmaceutical; Deoxycytidine; Gemcitabine; Glycine max; Lecithins; Lipids; Nanoparticles; Rats; Stearic Acids; Taurocholic Acid | 2015 |
Gemcitabine-induced radiation recall myositis in a patient with dermatomyositis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antimetabolites, Antineoplastic; Anus Neoplasms; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Dermatomyositis; Female; Gemcitabine; Humans; Immunosuppressive Agents; Lung Neoplasms; Magnetic Resonance Imaging; Myositis; Neoplasms, Multiple Primary; Radiation Injuries; Treatment Outcome | 2014 |
Managing overfill during preparation and delivery of intravenous medications.
Topics: Antineoplastic Combined Chemotherapy Protocols; Canada; Cyclophosphamide; Deoxycytidine; Drug Compounding; Gemcitabine; Humans; Infusions, Intravenous; Medication Errors | 2013 |
Sulforaphane inhibits growth of human breast cancer cells and augments the therapeutic index of the chemotherapeutic drug, gemcitabine.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclooxygenase 2; Deoxycytidine; Down-Regulation; Drug Synergism; Female; Gemcitabine; Humans; Isothiocyanates; MCF-7 Cells; Proto-Oncogene Proteins c-bcl-2; Sulfoxides | 2013 |
No relationship between the amount of DNA damage and the level of hMLH1 and RASSF1A gene expression in bladder cancer cells treated with cisplatin and gemcitabine.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cisplatin; Comet Assay; Deoxycytidine; DNA Damage; DNA Methylation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MutL Protein Homolog 1; Nuclear Proteins; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2013 |
The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; CD11b Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-6; Myeloid Cells; Pancreatic Neoplasms; Peptide Fragments; Telomerase; Vaccination | 2014 |
Diagnosis of brainstem involvement in NK/T cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Brain Stem; Cerebrospinal Fluid; Cisplatin; Deoxycytidine; Dexamethasone; DNA, Viral; Etoposide; Gemcitabine; Herpesvirus 4, Human; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Male; Methotrexate; Neoplastic Stem Cells; Nose Neoplasms; Ophthalmoplegia; Trigeminal Nerve Diseases; Viral Load | 2014 |
Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells.
Topics: Adenine; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; DNA Fragmentation; Drug Resistance, Neoplasm; Everolimus; Gemcitabine; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Ki-67 Antigen; Microtubule-Associated Proteins; Naphthoquinones; Proto-Oncogene Proteins c-bcl-2; Securin; Sirolimus; Survivin; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms; Urothelium | 2014 |
Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cisplatin; Deoxycytidine; Dexamethasone; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Polyethylene Glycols; Remission Induction | 2014 |
SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
Topics: 5'-Nucleotidase; Adult; Aged; Aged, 80 and over; Alleles; Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Membrane Transport Proteins; Middle Aged; Neoplasms; Young Adult | 2014 |
Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphocytes, Tumor-Infiltrating; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Survival Rate; Tegafur; Tumor Microenvironment | 2014 |
Expression of heat shock protein 70 modulates the chemoresponsiveness of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Caspase 3; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HSP70 Heat-Shock Proteins; Humans; Microtubule-Associated Proteins; Pancreatic Neoplasms; Quercetin | 2013 |
Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.
Topics: Amyloid Precursor Protein Secretases; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Notch; Signal Transduction | 2014 |
Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells.
Topics: Biocompatible Materials; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Synergism; Gemcitabine; Humans; Methacrylates; Molecular Structure; Molecular Weight; Organoplatinum Compounds | 2014 |
Efficacy of concurrent chemoradiotherapy with 5-fluorouracil or gemcitabine in locally advanced biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies | 2014 |
[Granulocyte-colony stimulating factor-producing urothelial carcinoma of right renal pelvis : a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Kidney Pelvis; Urothelium | 2013 |
A case of NUT midline carcinoma with complete response to gemcitabine following cisplatin and docetaxel.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Child; Cisplatin; Deoxycytidine; Docetaxel; Fatal Outcome; Female; Gemcitabine; Humans; Nuclear Proteins; Oncogene Proteins, Fusion; Remission Induction; Taxoids; Thoracic Neoplasms | 2014 |
Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neovascularization, Pathologic; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Gemcitabine for the treatment of classic Kaposi's Sarcoma: a case series.
Topics: Aged; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Male; Middle Aged; Sarcoma, Kaposi; Treatment Outcome | 2013 |
Curcumin inhibits tumor growth and angiogenesis in an orthotopic mouse model of human pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Curcumin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms | 2013 |
RC-3095, a gastrin-releasing peptide receptor antagonist, synergizes with gemcitabine to inhibit the growth of human pancreatic cancer CFPAC-1 in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Bombesin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Peptide Fragments; Receptors, Bombesin; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
ERCC1 in advanced biliary tract cancer patients treated with chemotherapy: prognostic and predictive roles.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Male; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Inhibition of cell proliferation and increase of chemosensitivity by simultaneous knockdown of XIAP and survivin in pancreatic carcinoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression; Humans; Inhibitor of Apoptosis Proteins; Pancreatic Neoplasms; RNA, Small Interfering; Survivin; Transfection; X-Linked Inhibitor of Apoptosis Protein | 2013 |
Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Topics: Adenosine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; DNA Methylation; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Epigenesis, Genetic; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Polycomb Repressive Complex 2; RNA Interference; RNA, Small Interfering | 2014 |
Synergistic induction of apoptosis in A549 cells by dihydroartemisinin and gemcitabine.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Deoxycytidine; Drug Synergism; fas Receptor; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Reactive Oxygen Species; Signal Transduction | 2014 |
Synthesis and cytostatic evaluation of 4-N-alkanoyl and 4-N-alkyl gemcitabine analogues.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Structure-Activity Relationship | 2014 |
Efficacy and feasibility of gemcitabine and carboplatin as first-line chemotherapy in elderly patients with advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Retrospective Studies; Treatment Outcome | 2013 |
Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Sex Factors; Time Factors; Treatment Outcome | 2016 |
Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Cohort Studies; Deoxycytidine; Drug Therapy, Combination; Female; Fluorouracil; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Nausea; Neoplasm Staging; Retrospective Studies; Treatment Outcome | 2013 |
Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Diffusion MRI and novel texture analysis in osteosarcoma xenotransplants predicts response to anti-checkpoint therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Cycle Checkpoints; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Gemcitabine; Humans; Mice; Mice, SCID; Middle Aged; Molecular Targeted Therapy; Osteosarcoma; Prognosis; Pyrazoles; Pyrimidines; Pyrimidinones; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Sensitization of human cancer cells to gemcitabine by the Chk1 inhibitor MK-8776: cell cycle perturbation and impact of administration schedule in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Pyrazoles; Pyrimidines; Recombinational DNA Repair; S Phase Cell Cycle Checkpoints; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
PAM50 breast cancer intrinsic subtypes and effect of gemcitabine in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Messenger; Taxoids | 2014 |
The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stability.
Topics: Administration, Oral; Amino Acids; Animals; Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Membrane Permeability; Deoxycytidine; Enzyme Stability; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Prodrugs; Stereoisomerism | 2014 |
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2014 |
Intratumoral Mistletoe (Viscum album L) Therapy in Patients With Unresectable Pancreas Carcinoma: A Retrospective Analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Endosonography; Erlotinib Hydrochloride; Female; Fever; Fluorouracil; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Retrospective Studies; Survival Rate; Ultrasonography, Interventional; Viscum album | 2014 |
Inhibition of NRF2 by PIK-75 augments sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hydrazones; Mice; NF-E2-Related Factor 2; Pancreatic Neoplasms; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
[Effect of high-intensity focused ultrasound combined with gemcitabine on subcutaneous pancreatic cancer in nude mice].
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Immunohistochemistry; Mice; Mice, Nude; Pancreatic Neoplasms; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2013 |
Potential of adenovirus-mediated REIC/Dkk-3 gene therapy for use in the treatment of pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Chemokines; Deoxycytidine; Disease Models, Animal; Drug Synergism; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Genetic Therapy; Genetic Vectors; Humans; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms | 2014 |
Expression of DNA translesion synthesis polymerase η in head and neck squamous cell cancer predicts resistance to gemcitabine and cisplatin-based chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Male; Middle Aged; Prognosis; Squamous Cell Carcinoma of Head and Neck | 2013 |
Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8(+) T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model.
Topics: Adenocarcinoma; Animals; Antibody Specificity; Antimetabolites, Antineoplastic; B-Lymphocytes; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Immunity, Cellular; Immunity, Humoral; Immunosuppression Therapy; Mice; Mice, Inbred C57BL; Mice, Transgenic; Ovalbumin; Pancreatic Neoplasms; Peptide Fragments; Tumor Escape | 2014 |
Gemcitabine-induced myopathy.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Magnetic Resonance Imaging; Muscle, Skeletal; Muscular Diseases; Pancreatic Neoplasms; Quadriceps Muscle; Thigh | 2014 |
Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells.
Topics: Antimetabolites, Antineoplastic; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media; Dendritic Cells; Deoxycytidine; Gemcitabine; HSP70 Heat-Shock Proteins; Humans; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic | 2014 |
Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gemcitabine; Giant Cell Tumors; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2013 |
[Gemcitabine augments major histocompatibility complex class I-related chain A expression in pancreatic cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; T-Lymphocytes | 2013 |
[Examination of resectable and borderline pancreatic cancer treated with neoadjuvant chemoradiation therapy].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2013 |
[Hepatic arterial infusion chemotherapy with gemcitabine for patients with postoperative liver metastases from pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Pancreatic Neoplasms; Treatment Outcome | 2013 |
[A case of initially unresectable gallbladder cancer with surgical resection after chemotherapy with gemcitabine].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Staging; Remission Induction | 2013 |
[A case of effective multidisciplinary treatment for advanced gallbladder carcinoma with distant lymph node metastases].
Topics: Antineoplastic Agents; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Oxonic Acid; Quality of Life; Tegafur | 2013 |
[A case of long-term survival after aggressive surgery for Stage IV gallbladder carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Staging | 2013 |
[A surgical case of peritoneal dissemination metastasis of bile duct carcinoma after pancreaticoduodenectomy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Pancreaticoduodenectomy; Peritoneal Neoplasms; Recurrence | 2013 |
[A case of locally advanced pancreatic cancer with hepatic artery invasion treated with neoadjuvant chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2013 |
[A case of successful R0 resection after neoadjuvant therapy for locally advanced unresectable pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome | 2013 |
[A case of curatively resected locally advanced pancreatic cancer with combined resection of the portal vein and common hepatic artery after neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatic Artery; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Tegafur | 2013 |
[Long-term survival of a patient with locally advanced unresectable pancreatic cancer treated with gemcitabine after chemoradiation therapy].
Topics: Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2013 |
[Erlotinib plus gemcitabine combination therapy in patients with unresectable advanced pancreatic cancer - a single-institution experience].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines | 2013 |
[A case of effective trastuzumab plus gemcitabine therapy for human epidermal growth factor receptor 2-positive breast cancer].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Receptor, ErbB-2; Trastuzumab | 2013 |
Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytostatic Agents; Deoxycytidine; Docetaxel; Doxorubicin; Gemcitabine; Herb-Drug Interactions; Humans; Male; Mitoxantrone; Neoplasms; Plant Extracts; Plants, Medicinal; Taxoids; Viscum album | 2014 |
MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells.
Topics: Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; NF-kappa B; Pancreatic Neoplasms; Transcription Factors; Tumor Suppressor Proteins | 2014 |
Non-invasive quantification of 5 fluorouracil and gemcitabine in aqueous matrix by direct measurement through glass vials using near-infrared spectroscopy.
Topics: Antineoplastic Agents; Calibration; Deoxycytidine; Flow Injection Analysis; Fluorouracil; Gemcitabine; Glass; Limit of Detection; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Spectroscopy, Near-Infrared; Water | 2014 |
Extraskeletal Osteosarcoma: An International Rare Cancer Network Study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Ifosfamide; Lower Extremity; Male; Methotrexate; Middle Aged; Mitomycin; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Osteosarcoma; Pelvic Neoplasms; Prognosis; Radiotherapy; Rare Diseases; Retroperitoneal Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Tumor Burden; Young Adult | 2016 |
Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bias; Carboplatin; Clinical Trials as Topic; Deoxycytidine; Drugs, Investigational; Female; Gemcitabine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Ovarian Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Research Design; Treatment Failure; Triple Negative Breast Neoplasms | 2014 |
Active hexose-correlated compound down-regulates HSP27 of pancreatic cancer cells, and helps the cytotoxic effect of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Molecular Chaperones; Pancreatic Neoplasms; Polysaccharides; Tumor Cells, Cultured | 2014 |
Design, synthesis and ex-vivo release studies of colon-specific polyphosphazene-anticancer drug conjugates.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colon; Colorectal Neoplasms; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Design; Gemcitabine; HT29 Cells; Humans; Methotrexate; Organophosphorus Compounds; Polymers; Rats | 2014 |
Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Dasatinib; Deoxycytidine; Docetaxel; Doxorubicin; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gemcitabine; Humans; Paxillin; Pyrimidines; Signal Transduction; src-Family Kinases; Taxoids; Thiazoles; Topotecan | 2014 |
DUSP1 is a novel target for enhancing pancreatic cancer cell sensitivity to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cisplatin; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Neovascularization, Pathologic; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Signal Transduction; Transcription, Genetic; Xenograft Model Antitumor Assays | 2014 |
Hypofractionated intensity modulated radiation therapy in combined modality treatment for bladder preservation in elderly patients with invasive bladder cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Organ Sparing Treatments; Radiation-Sensitizing Agents; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2014 |
Management of advanced pancreatic cancer with gemcitabine plus erlotinib: efficacy and safety results in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Eruptions; Drug Evaluation; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2014 |
Gemcitabine as salvage treatment in patients with poorly differentiated pancreatic neuroendocrine tumors: a case series.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Differentiation; Deoxycytidine; Drug Evaluation; Fatal Outcome; Female; Gemcitabine; Humans; Male; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Salvage Therapy; Treatment Outcome | 2014 |
Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Protein Kinases; Thiophenes; Urea | 2014 |
PI3K/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Induction Chemotherapy; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Pemetrexed; Phosphatidylinositol 3-Kinase; Pleural Neoplasms; Pneumonectomy; Prognosis; PTEN Phosphohydrolase; Remission Induction; Signal Transduction; Survival Rate; Tissue Array Analysis; TOR Serine-Threonine Kinases | 2014 |
Antitumor activity of gemcitabine can be potentiated in pancreatic cancer through modulation of TLR4/NF-κB signaling by 6-shogaol.
Topics: Animals; Antineoplastic Agents; Apoptosis; Catechols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Toll-Like Receptor 4; Xenograft Model Antitumor Assays | 2014 |
The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.
Topics: Adenoviridae; Animals; Cell Line, Tumor; Cricetinae; Deoxycytidine; DNA Primers; Fluorescence; Gemcitabine; HEK293 Cells; Humans; Immunohistochemistry; Mesocricetus; Mice; Mutation, Missense; Neoplasms; Oncolytic Virotherapy; Protein Sorting Signals; Statistics, Nonparametric; Virus Release | 2014 |
Efficacy of Salmonella typhimurium A1-R versus chemotherapy on a pancreatic cancer patient-derived orthotopic xenograft (PDOX).
Topics: Animals; Antimetabolites, Antineoplastic; Cisplatin; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Humans; Luminescent Proteins; Mice; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Red Fluorescent Protein; Salmonella Infections; Salmonella typhimurium; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2014 |
Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunoenzyme Techniques; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Knockout; Neovascularization, Pathologic; Pancreatic Neoplasms; Prognosis; Receptor, PAR-1; Signal Transduction; Stromal Cells; Tumor Cells, Cultured | 2014 |
A single center experience: post-transplantation adjuvant chemotherapy impacts the prognosis of hepatocellular carcinoma patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Liver Neoplasms; Liver Transplantation; Male | 2014 |
Effects of chemotherapy on global gene expression in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Oligonucleotide Array Sequence Analysis | 2014 |
5-Fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have progressed on gemcitabine-based therapy.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome; Young Adult | 2013 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Young Adult | 2013 |
MiR-21 upregulation induced by promoter zone histone acetylation is associated with chemoresistance to gemcitabine and enhanced malignancy of pancreatic cancer cells.
Topics: Acetylation; Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Movement; Cell Proliferation; Chromatin Immunoprecipitation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Histones; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Real-Time Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Suppression of NAD(P)H-quinone oxidoreductase 1 enhanced the susceptibility of cholangiocarcinoma cells to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; NAD(P)H Dehydrogenase (Quinone); RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |
Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancer.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Synergism; Gemcitabine; Glycosides; Mice; Mice, Nude; Pancreatic Neoplasms; Triterpenes | 2014 |
Science to practice: Can we turn the undesired heating effects of MR imaging into effective cancer therapies?
Topics: Animals; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging | 2014 |
Intrabiliary RF heat-enhanced local chemotherapy of a cholangiocarcinoma cell line: monitoring with dual-modality imaging--preclinical study.
Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Chromatography, High Pressure Liquid; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hyperthermia, Induced; Magnetic Resonance Imaging; Mice; Radio Waves; Swine | 2014 |
Application of ProTide technology to gemcitabine: a successful approach to overcome the key cancer resistance mechanisms leads to a new agent (NUC-1031) in clinical development.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine Monophosphate; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans | 2014 |
Survival outcomes in patients with early stage, resected pancreatic cancer - a comparison of gemcitabine- and 5-fluorouracil-based chemotherapy and chemoradiation regimens.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
An absolute obstacle: cardiac metastasis of synovial sarcoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Disease Progression; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Heart Atria; Heart Neoplasms; Humans; Ifosfamide; Male; Polyethylene Glycols; Sarcoma, Synovial; Shoulder; Treatment Failure; Treatment Refusal; Vascular Neoplasms; Vena Cava, Superior | 2014 |
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Ampulla of Vater; Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Glycogen; Glypicans; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; RNA, Messenger; Transplantation, Heterologous; Tumor Cells, Cultured | 2014 |
Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term fol
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Deoxycytidine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prednisone; Prognosis; Retrospective Studies; Survival Rate; Vincristine; Young Adult | 2014 |
Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cytarabine; Deoxycytidine; Gemcitabine; Genetic Markers; Genome-Wide Association Study; Genotype; Humans; Linkage Disequilibrium; Mannosyltransferases; Polymorphism, Single Nucleotide; Regulatory Elements, Transcriptional; RNA Interference; RNA, Small Interfering | 2014 |
Sirtuin 1 facilitates chemoresistance of pancreatic cancer cells by regulating adaptive response to chemotherapy-induced stress.
Topics: Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Forkhead Box Protein O3; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; rho GTP-Binding Proteins; RNA Interference; Sirtuin 1; Tumor Suppressor Protein p53 | 2014 |
Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Down-Regulation; Drug Synergism; Enzyme Activation; Gemcitabine; Glaucarubin; Humans; Mice; Mice, Nude; p21-Activated Kinases; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Noninvasive quantification of solid tumor microstructure using VERDICT MRI.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Gemcitabine; Humans; Mice; Models, Theoretical; Neoplasms | 2014 |
Autophagy and enhanced chemosensitivity in experimental pancreatic cancers induced by noninvasive radiofrequency field treatment.
Topics: Adenocarcinoma; Animals; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Radio Waves; Xenograft Model Antitumor Assays | 2014 |
Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs.
Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferation; Chloroquine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Microtubule-Associated Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Wortmannin | 2014 |
Antitumor activity of the c-Myc inhibitor KSI-3716 in gemcitabine-resistant bladder cancer.
Topics: 4-Quinolones; Aniline Compounds; Animals; Antimetabolites, Antineoplastic; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Macromolecular bipill of gemcitabine and methotrexate facilitates tumor-specific dual drug therapy with higher benefit-to-risk ratio.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Kidney; Liver; Macromolecular Substances; Mammary Neoplasms, Experimental; MCF-7 Cells; Methotrexate; Mice; Molecular Structure; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Risk Factors; Structure-Activity Relationship | 2014 |
Oligo(ethylene glycol)-based thermosensitive dendrimers and their tumor accumulation and penetration.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Dendrimers; Deoxycytidine; Drug Carriers; Female; Flow Cytometry; Gemcitabine; Mice; Microscopy, Electron, Transmission; Polyethylene Glycols; Positron-Emission Tomography | 2014 |
Redox-responsive targeted gelatin nanoparticles for delivery of combination wt-p53 expressing plasmid DNA and gemcitabine in the treatment of pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Female; Gelatin; Gemcitabine; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Humans; Mice; Mice, SCID; Nanoparticles; Oxidation-Reduction; Pancreatic Neoplasms; Plasmids; Random Allocation; Xenograft Model Antitumor Assays | 2014 |
Mass spectrometry-based metabolic profiling of gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Discriminant Analysis; Drug Resistance, Neoplasm; Gemcitabine; Humans; Least-Squares Analysis; Mass Spectrometry; Metabolic Networks and Pathways; Metabolome; Metabolomics; Pancreatic Neoplasms; Principal Component Analysis | 2014 |
Perifosine inhibits S6K1-Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Knockdown Techniques; Humans; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Random Allocation; Ribosomal Protein S6 Kinases, 70-kDa; RNA, Small Interfering; Signal Transduction; Survival Analysis; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2014 |
Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lymphocytes; Male; Neutrophils; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Prospective Studies; Quinazolines; Survival Analysis; Tegafur; Treatment Outcome | 2014 |
Thyroid malignancies in survivors of Hodgkin lymphoma.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Dacarbazine; Databases, Factual; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Mechlorethamine; Middle Aged; Neoplasms, Second Primary; Poisson Distribution; Prednisone; Procarbazine; Radiotherapy Dosage; Retrospective Studies; Risk Assessment; Risk Factors; Sex Factors; Survivors; Thyroid Neoplasms; Vinblastine; Vincristine; Young Adult | 2014 |
Shikonin suppresses tumor growth and synergizes with gemcitabine in a pancreatic cancer xenograft model: Involvement of NF-κB signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Microvessels; Naphthoquinones; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Genomic polymorphisms of SLC29A3 associated with overall survival in advanced non-small-cell lung cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genotype; Humans; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Nucleoside Transport Proteins; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Potential biomarkers for sensitivity of gallbladder cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gallbladder Neoplasms; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Oligonucleotide Array Sequence Analysis; Real-Time Polymerase Chain Reaction; Signal Transduction | 2014 |
Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Drug Carriers; Drug Design; Gemcitabine; Humans; Intracellular Space; Mice; Nanocomposites; Squalene; Stilbenes; Xenograft Model Antitumor Assays | 2014 |
Anticancer effects of gemcitabine are enhanced by co-administered iRGD peptide in murine pancreatic cancer models that overexpressed neuropilin-1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Humans; Male; Mice; Middle Aged; Neuropilin-1; Oligopeptides; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2014 |
The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Histones; Humans; Intracellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Phosphorylation; Protein Kinases; Protein Serine-Threonine Kinases | 2014 |
Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Failure | 2014 |
Gemcitabine and Cisplatin followed by chemo-radiation for advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2014 |
What outcome after the prescription of neoadjuvant chemotherapy in lung cancer?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Pneumonectomy; Retrospective Studies; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
Temperature-sensitive magnetic drug carriers for concurrent gemcitabine chemohyperthermia.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cellulose; Deoxycytidine; Drug Carriers; Gemcitabine; Hyperthermia, Induced; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tissue Distribution; Xenograft Model Antitumor Assays | 2014 |
Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Deoxycytidine; Epithelial Cells; Gemcitabine; HMGB1 Protein; Humans; Oncolytic Viruses; Parvovirus; Signal Transduction | 2014 |
Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Neoplasm Invasiveness; Neoplasm Proteins; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Up-Regulation | 2014 |
Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles.
Topics: Animals; Antimetabolites, Antineoplastic; Cathepsin B; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Humans; Mice; Micelles; Phosphatidylethanolamines; Polyethylene Glycols; Vitamin E; Xenograft Model Antitumor Assays | 2014 |
Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; Disease Models, Animal; Gemcitabine; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred C3H; Mouth Neoplasms; Phenotype; T-Lymphocytes | 2014 |
Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Calcium; Calcium Channels; Calcium Signaling; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Neoplasm Proteins; ORAI1 Protein; Pancreatic Neoplasms; RNA, Small Interfering; Stromal Interaction Molecule 1 | 2014 |
Gemcitabine-induced hemolytic uremic syndrome mimicking scleroderma renal crisis presenting with Raynaud's phenomenon, positive antinuclear antibodies and hypertensive emergency.
Topics: Antibodies, Antinuclear; Blood Pressure; Deoxycytidine; Diagnosis, Differential; Emergencies; Female; Gallbladder Neoplasms; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Hypertension, Malignant; Immunosuppressive Agents; Kidney Glomerulus; Middle Aged; Raynaud Disease; Ribonucleotide Reductases; Scleroderma, Systemic | 2014 |
Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect.
Topics: Antimetabolites, Antineoplastic; Aorta, Thoracic; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gemcitabine; Humans; Iliac Artery; Middle Aged; Positron-Emission Tomography; Tomography, X-Ray Computed; Vasculitis | 2014 |
The identification of novel 5'-amino gemcitabine analogs as potent RRM1 inhibitors.
Topics: Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; High-Throughput Screening Assays; Humans; Magnetic Resonance Spectroscopy; Molecular Structure; Ribonucleoside Diphosphate Reductase; Structure-Activity Relationship; Tumor Suppressor Proteins | 2014 |
Development and characterization of nanoparticles for the delivery of gemcitabine hydrochloride.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Hepatocytes; Humans; Inhibitory Concentration 50; Nanoparticles; Starch | 2014 |
[Honokiol combined with Gemcitabine synergistically inhibits the proliferation of human Burkitt lymphoma cells and induces their apoptosis].
Topics: Apoptosis; Biphenyl Compounds; Burkitt Lymphoma; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lignans; Proto-Oncogene Proteins c-bcl-2 | 2014 |
Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pain Measurement; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Radiotherapy Dosage; Tegafur | 2014 |
Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Doxorubicin; Gemcitabine; Half-Life; Hyperthermia, Induced; Liposomes; Male; Phosphatidylglycerols; Rats; Sarcoma | 2014 |
In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Topics: Antineoplastic Agents; Ascites; Carboplatin; Carcinoma, Ovarian Epithelial; Coloring Agents; Deoxycytidine; Disease Progression; Drug Screening Assays, Antitumor; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Predictive Value of Tests; Retrospective Studies; Survival Rate; Tetrazolium Salts; Thiazoles; Time Factors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2013 |
TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cimetidine; Cyclophosphamide; Deoxycytidine; Diclofenac; Drug Administration Schedule; Drug Combinations; Drug Synergism; Gemcitabine; Gene Amplification; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Male; Mice, Inbred NOD; Mice, SCID; N-Myc Proto-Oncogene Protein; Neovascularization, Pathologic; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Platelet Endothelial Cell Adhesion Molecule-1; Sulfasalazine; Treatment Outcome; Tretinoin; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Replication-competent adenovirus expressing TRAIL synergistically potentiates the antitumor effect of gemcitabine in bladder cancer cells.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Genetic Therapy; Humans; Male; Mice; Mice, Inbred BALB C; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms; Virus Replication; Xenograft Model Antitumor Assays | 2014 |
Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; CD24 Antigen; Cell Line, Tumor; Cisplatin; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Mice; Mice, Nude; Neoplastic Stem Cells | 2014 |
Patients with advanced disease: the value of patient reported outcomes.
Topics: Capecitabine; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Karnofsky Performance Status; Male; Pain; Pancreatic Neoplasms; Quality of Life | 2014 |
Ubiquitination and degradation of ribonucleotide reductase M1 by the polycomb group proteins RNF2 and Bmi1 and cellular response to gemcitabine.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Polycomb Repressive Complex 1; Polyubiquitin; Proteasome Endopeptidase Complex; Protein Binding; Proteolysis; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Ubiquitination | 2014 |
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Therapy; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
Is there a role for second line therapy in advanced pancreatic cancer?
Topics: Albumins; Antineoplastic Agents; Deoxycytidine; Disease Progression; Drug Therapy; Drug Therapy, Combination; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2014 |
dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Nucleus; Chemoradiotherapy; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; ELAV Proteins; ELAV-Like Protein 1; Fluorouracil; Follow-Up Studies; Gemcitabine; Gene Expression; Humans; Kaplan-Meier Estimate; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Protein Transport; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Berbamine enhances the antineoplastic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-β/Smad signaling.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzylisoquinolines; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Interactions; Gemcitabine; Humans; Pancreatic Neoplasms; Signal Transduction; Smad Proteins; Transforming Growth Factor beta | 2014 |
A comparison of toxicity and health care resource use between eribulin, capecitabine, gemcitabine, and vinorelbine in patients with metastatic breast cancer treated in a community oncology setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Community Mental Health Centers; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Medical Oncology; Middle Aged; Retrospective Studies; Vinblastine; Vinorelbine | 2015 |
Long-term management of gemcitabine in a patient with advanced pancreatic cancer undergoing haemodialysis.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Renal Dialysis; Tomography, X-Ray Computed | 2014 |
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; CA-19-9 Antigen; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Pancreatic Neoplasms; Proportional Hazards Models | 2014 |
Gemcitabine-based chemoradiotherapy followed by surgery for borderline resectable and locally unresectable pancreatic ductal adenocarcinoma: significance of the CA19-9 reduction rate and intratumoral human equilibrative nucleoside transporter 1 expression
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Outcome Assessment, Health Care; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models | 2014 |
(125)I particle implantation combined with chemoradiotherapy to treat advanced pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate | 2014 |
CHD7 expression predicts survival outcomes in patients with resected pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA Helicases; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Mice; Pancreatic Neoplasms; Proportional Hazards Models; Random Allocation; Survival Analysis; Xenograft Model Antitumor Assays | 2014 |
N-Acyl-phosphoramidates as potential novel form of gemcitabine prodrugs.
Topics: Amides; Deoxycytidine; DNA Polymerase I; Dose-Response Relationship, Drug; Enzyme Inhibitors; Escherichia coli; Gemcitabine; HeLa Cells; Humans; K562 Cells; Molecular Structure; Phosphoric Acids; Prodrugs; Structure-Activity Relationship | 2014 |
The roles of interferon regulatory factors 1 and 2 in the progression of human pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Interferon Regulatory Factor-1; Interferon Regulatory Factor-2; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neutropenia; Pemetrexed; Pleural Neoplasms; Retrospective Studies; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
The synthesis of gemcitabine.
Topics: Carbohydrates; Deoxycytidine; Fluorine; Gemcitabine; Halogenation; Humans; Molecular Structure; Neoplasms; Stereoisomerism | 2014 |
Synergistic anti-tumor effects of combined gemcitabine and cisplatin nanoparticles in a stroma-rich bladder carcinoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; Female; Fibroblasts; Gemcitabine; Humans; Mice; Mice, Nude; Nanoparticles; NIH 3T3 Cells; Urinary Bladder Neoplasms | 2014 |
Development of high-content gemcitabine PEGylated liposomes and their cytotoxicity on drug-resistant pancreatic tumour cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Drug Resistance, Neoplasm; Drug Stability; Gemcitabine; Humans; Liposomes; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Surface Properties; Technology, Pharmaceutical | 2014 |
Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Nomograms; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2014 |
Incidence of venous thromboembolism (VTE) in ambulatory pancreatic cancer patients receiving chemotherapy and analysis of Khorana's predictive model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Incidence; Male; Middle Aged; Models, Statistical; Pancreatic Neoplasms; Platinum Compounds; Pulmonary Embolism; Retrospective Studies; Risk Assessment; Venous Thromboembolism; Venous Thrombosis | 2014 |
Response to first-line chemotherapy in patients with non-small cell lung cancer according to RRM1 expression.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Taxoids; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
Salvage chemotherapy with gemcitabine plus oxaliplatin for patients with testicular germ cell cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothecin; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Salvage Therapy; Testicular Neoplasms | 2014 |
Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Lactate Dehydrogenases; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2014 |
Gold nanoparticles and radiofrequency in experimental models for hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Gold; Humans; Hyperthermia, Induced; Liver; Liver Neoplasms; Metal Nanoparticles; Mice, Inbred BALB C; Nanoconjugates | 2014 |
MRE11A and SKP2 genes are associated with the increased cytotoxicity induced by the synergistic effects of cisplatin and gemcitabine in bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line, Tumor; Cisplatin; Cytotoxins; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; MRE11 Homologue Protein; S-Phase Kinase-Associated Proteins; Signal Transduction; Urinary Bladder | 2014 |
Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Urothelium | 2014 |
An innovative hydrogel of gemcitabine-loaded lipid nanocapsules: when the drug is a key player of the nanomedicine structure.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Hydrogel, Polyethylene Glycol Dimethacrylate; Lipids; Nanocapsules; Nanomedicine; Nanoparticles | 2014 |
Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis.
Topics: Adenocarcinoma; Age Factors; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Multicenter Studies as Topic; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic | 2014 |
Identification of new mechanisms of cellular response to chemotherapy by tracking changes in post-translational modifications by ubiquitin and ubiquitin-like proteins.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chromatography, Liquid; Deoxycytidine; Gemcitabine; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Microscopy, Fluorescence; NEDD8 Protein; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protein Processing, Post-Translational; Proteins; Proteome; Proteomics; Proto-Oncogene Proteins c-akt; RNA-Binding Proteins; Signal Transduction; SUMO-1 Protein; Tandem Mass Spectrometry; TOR Serine-Threonine Kinases; Ubiquitin; Ubiquitins; Wnt1 Protein | 2014 |
GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery.
Topics: Animals; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Molecular Structure; Prostatic Neoplasms, Castration-Resistant; Receptors, LHRH; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Topics: Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Glutamates; Guanine; Hospitalization; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Registries; Retrospective Studies; Survival Rate; Taxoids; United States; United States Department of Veterans Affairs; Vinblastine; Vinorelbine | 2014 |
Paraneoplastic focal segmental glomerulosclerosis in sarcomatoid renal cell cancer.
Topics: Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Deoxycytidine; Diagnosis, Differential; Drug Administration Schedule; Fluorodeoxyglucose F18; Gemcitabine; Glomerulosclerosis, Focal Segmental; Humans; Hypertension; Kidney Neoplasms; Lymph Node Excision; Male; Nephrectomy; Obesity; Paraneoplastic Syndromes; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Whole Body Imaging | 2015 |
Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Bacterial Proteins; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mammary Neoplasms, Experimental; Mice; Mycoplasma hyorhinis; Mycoplasma Infections; Pyrimidine Phosphorylases; Tetrahydrouridine; Thymidine; Tumor Microenvironment | 2014 |
Downregulating sCLU enhances the sensitivity of hepatocellular carcinoma cells to gemcitabine by activating the intrinsic apoptosis pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Proteins; Clusterin; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Nuclear Proteins | 2014 |
Combination of dasatinib and gemcitabine reduces the ALDH1A1 expression and the proliferation of gemcitabine-resistant pancreatic cancer MIA PaCa-2 cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Pyrimidines; Retinal Dehydrogenase; Thiazoles | 2014 |
A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Deoxycytidine; Dexamethasone; Etoposide; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Neoplasm Recurrence, Local; Treatment Outcome | 2014 |
Anti-tumor efficacy of a therapeutic peptide based on thermo-responsive elastin-like polypeptide in combination with gemcitabine.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell-Penetrating Peptides; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Elastin; Feasibility Studies; Female; Gemcitabine; Humans; Hypothermia, Induced; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Recombinant Fusion Proteins; Retinoblastoma Protein; S Phase Cell Cycle Checkpoints; Time Factors; Xenograft Model Antitumor Assays | 2014 |
Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cerebellar Neoplasms; Deoxycytidine; Gemcitabine; Glutamates; Guanine; High-Throughput Screening Assays; Humans; Medulloblastoma; Mice; Mice, Transgenic; Pemetrexed; Prognosis | 2014 |
The low chamber pancreatic cancer cells had stem-like characteristics in modified transwell system: is it a novel method to identify and enrich cancer stem-like cells?
Topics: AC133 Antigen; Animals; Antigens, CD; Biomarkers, Tumor; Carcinogenesis; Cell Count; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glycoproteins; Humans; Hyaluronan Receptors; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Spheroids, Cellular; Up-Regulation | 2014 |
Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pleural Neoplasms; Retrospective Studies; Salvage Therapy; Vinblastine; Vinorelbine | 2014 |
Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Busulfan; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Antagonism; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2014 |
Surgical treatment and adjuvant chemotherapy for patients with biliary tract cancer: single institution experience of 100 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Tegafur; Time Factors; Treatment Outcome | 2013 |
Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Survival Rate | 2014 |
Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystectomy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2014 |
Efficacy of radical cystectomy plus adjuvant intraarterial chemotherapy with gemcitabine and cisplatin on locally advanced bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Urinary Bladder Neoplasms | 2014 |
Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 9; Mice; Neoplasm Metastasis; Neovascularization, Pathologic; Ovarian Neoplasms; Platinum; Proto-Oncogene Proteins c-akt; Signal Transduction; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis.
Topics: Aged; Antibiotic Prophylaxis; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Australia; Deoxycytidine; Female; Gemcitabine; Humans; Immunocompromised Host; Male; Middle Aged; Neoplasms; Pneumocystis carinii; Pneumonia, Pneumocystis | 2015 |
Antitumor effect of angiotensin II type 1 receptor blocker losartan for orthotopic rat pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Immunohistochemistry; Losartan; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Rats, Inbred Lew; Receptor, Angiotensin, Type 1; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): a new treatment option for invasive bladder cancer patients with lymph node metastasis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy Dosage; Renal Dialysis; Urinary Bladder Neoplasms | 2014 |
Recurrent low-dose chemotherapy to inhibit and oxygenate head and neck tumors.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Dose-Response Relationship, Drug; Electron Spin Resonance Spectroscopy; Gemcitabine; Head and Neck Neoplasms; Heterografts; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Oxygen | 2014 |
Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; DNA Glycosylases; DNA-(Apurinic or Apyrimidinic Site) Lyase; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; X-ray Repair Cross Complementing Protein 1 | 2014 |
Gemcitabine-induced pancreatic cancer cell death is associated with MST1/cyclophilin D mitochondrial complexation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cyclophilins; Cyclosporine; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Pancreatic Neoplasms; Peptidyl-Prolyl Isomerase F; Protein Conformation; Protein Serine-Threonine Kinases; Protein Transport; Reactive Oxygen Species | 2014 |
Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Communication; Cell Proliferation; Connexin 43; Deoxycytidine; Drug Resistance, Neoplasm; Gap Junctions; Gemcitabine; Humans; Immunoenzyme Techniques; Isothiocyanates; Microscopy, Electron; Pancreas; Pancreatic Neoplasms; Phosphorylation; RNA, Small Interfering; Spheroids, Cellular; Sulfoxides; Tumor Cells, Cultured | 2014 |
Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deglutition Disorders; Deoxycytidine; Gemcitabine; Humans; Interpersonal Relations; Lung Neoplasms; Multicenter Studies as Topic; Nausea; Paclitaxel; Pain; Palliative Care; Prognosis; Proportional Hazards Models; Quality of Life; Randomized Controlled Trials as Topic; Risk; Severity of Illness Index; Surveys and Questionnaires; Survival Analysis | 2014 |
[Outcomes of treatment of 32 cases of advanced or relapsed post-surgery pulmonary sarcomatoid carcinoma].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Postoperative Period; Survival Rate | 2014 |
Axitinib (AG-013736), an oral specific VEGFR TKI, shows potential therapeutic utility against cholangiocarcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Axitinib; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Imidazoles; Immunohistochemistry; Indazoles; Male; Middle Aged; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Antitumor Activities of Rauwolfia vomitoria Extract and Potentiation of Gemcitabine Effects Against Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Plant Extracts; Rauwolfia; Tumor Burden | 2014 |
Suppression of pancreatic cancer by sulfated non-anticoagulant low molecular weight heparin.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Chick Embryo; Chorioallantoic Membrane; Deoxycytidine; Enzyme Inhibitors; Female; Fibrinolytic Agents; Gemcitabine; Heparin, Low-Molecular-Weight; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Tinzaparin; Xenograft Model Antitumor Assays | 2014 |
Recurrent pseudocellulitis due to gemcitabine: underrecognized and underreported?
Topics: Aged; Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Metastasis; Pancreatic Neoplasms; Recurrence | 2015 |
Development of a 'mouse and human cross-reactive' affinity-matured exosite inhibitory human antibody specific to TACE (ADAM17) for cancer immunotherapy.
Topics: ADAM Proteins; ADAM17 Protein; Allosteric Regulation; Animals; Antibody Specificity; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; HEK293 Cells; Humans; Immunotherapy; Inhibitory Concentration 50; Kinetics; Mice; Protein Binding; Single-Chain Antibodies | 2014 |
Dismal outcome of T-cell lymphoma patients failing first-line treatment: results of a population-based study from the Modena Cancer Registry.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Italy; Lymphoma, T-Cell; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Recurrence; Registries; Regression Analysis; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Treatment Outcome; Young Adult | 2015 |
Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2014 |
Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis.
Topics: Animals; Antineoplastic Agents, Alkylating; B7-H1 Antigen; CD4-Positive T-Lymphocytes; Cell Line, Tumor; Cell- and Tissue-Based Therapy; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Immunosuppression Therapy; Immunosuppressive Agents; Immunotherapy, Adoptive; Lymphocyte Activation; Lymphoma; Melphalan; Mice; Mice, Inbred BALB C; Myeloid Cells; Programmed Cell Death 1 Receptor; Receptors, CCR2 | 2014 |
[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2014 |
cRGD grafted siRNA nano-constructs for chemosensitization of gemcitabine hydrochloride in lung cancer treatment.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Genetic Therapy; Humans; Inhibitory Concentration 50; Lung Neoplasms; Nanoparticles; Particle Size; Peptides, Cyclic; Ribonucleoside Diphosphate Reductase; RNA Interference; RNA Stability; RNA, Small Interfering; Time Factors; Transfection; Tumor Suppressor Proteins | 2015 |
Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells.
Topics: Acoustics; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Survival; Chromatography, Gel; Cytosol; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Fluoresceins; Fluorescence; Gemcitabine; Humans; Hydrogen-Ion Concentration; Liposomes; Microscopy, Atomic Force; Microscopy, Confocal; Neoplasms; Oxidation-Reduction; Particle Size; Polymers; Reducing Agents; Spectrophotometry, Ultraviolet; Spheroids, Cellular; Ultrasonics | 2014 |
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Cohort Studies; Deoxycytidine; Disease Progression; DNA; Enhancer of Zeste Homolog 2 Protein; Female; Gemcitabine; Humans; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Polycomb Repressive Complex 2; Polymorphism, Genetic; Promoter Regions, Genetic; Survival Analysis; Treatment Outcome | 2014 |
Transarterial infusion with gemcitabine and oxaliplatin for the treatment of unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Femoral Artery; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoplasm Grading; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2014 |
In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer.
Topics: Adenosine Triphosphate; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Ki-67 Antigen; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2014 |
The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mammary Glands, Human; Proto-Oncogene Proteins c-bcl-2; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2014 |
MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine.
Topics: Animals; Antibodies; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; Doxycycline; Drug Therapy; Enediynes; ErbB Receptors; Female; Gemcitabine; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Neoplasms, Experimental; Recombinant Fusion Proteins; Treatment Outcome; Xenograft Model Antitumor Assays | 2014 |
Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Lactic Acid; Membrane Potential, Mitochondrial; Nucleoside Transport Proteins; Poly(ADP-ribose) Polymerases; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2014 |
Enhanced bioavailability and intestinal uptake of Gemcitabine HCl loaded PLGA nanoparticles after oral delivery.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Caco-2 Cells; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Intestinal Absorption; Intestinal Mucosa; K562 Cells; Lactic Acid; Male; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats, Wistar | 2014 |
Interfacial behavior of PEGylated lipids and their effect on the stability of squalenoyl-drug nanoassemblies.
Topics: Adsorption; Cholesterol; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Stability; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Microscopy, Electron, Transmission; Nanoparticles; Particle Size; Polyethylene Glycols; Prodrugs; Squalene; Surface Tension; Zalcitabine | 2014 |
The emerging role of gemcitabine in conditioning regimens for hematopoietic stem cell transplantation.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Male; Transplantation Conditioning; Transplantation, Homologous | 2014 |
DNA microarray reveals ZNF195 and SBF1 are potential biomarkers for gemcitabine sensitivity in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Head and Neck Neoplasms; Humans; Intracellular Signaling Peptides and Proteins; Kruppel-Like Transcription Factors; Oligonucleotide Array Sequence Analysis; Treatment Outcome; Zinc Fingers | 2014 |
HS-104, a PI3K inhibitor, enhances the anticancer efficacy of gemcitabine in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Hepatic arterial infusion of gemcitabine plus oxaliplatin as second-line treatment for locally advanced intrahepatic cholangiocarcinoma: preliminary experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Survival Rate; Treatment Outcome | 2013 |
Long-term outcome of photodynamic therapy with systemic chemotherapy compared to photodynamic therapy alone in patients with advanced hilar cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Photochemotherapy; Treatment Outcome | 2014 |
Mmp-9 responsive PEG cleavable nanovesicles for efficient delivery of chemotherapeutics to pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Extracellular Matrix; Female; Gemcitabine; Glutathione; Humans; Hydrolysis; Lipid Bilayers; Lipopeptides; Matrix Metalloproteinase 9; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Phosphatidylcholines; Polyethylene Glycols; Transport Vesicles | 2014 |
E2F inhibition synergizes with paclitaxel in lung cancer cell lines.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; E2F3 Transcription Factor; Gemcitabine; Humans; Hydroxyquinolines; Inhibitory Concentration 50; Lung Neoplasms; Paclitaxel; RNA, Small Interfering; Small Cell Lung Carcinoma | 2014 |
Self-assembly of polyisoprenoyl gemcitabine conjugates: influence of supramolecular organization on their biological activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Microscopy, Confocal; Nanoparticles; Squalene | 2014 |
Targeting the thyroid gland with thyroid-stimulating hormone (TSH)-nanoliposomes.
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; CHO Cells; Chromatography, Liquid; Cricetulus; Deoxycytidine; Female; Gemcitabine; Liposomes; Microscopy, Confocal; Nanostructures; Rats; Rats, Wistar; Receptors, Thyrotropin; Tandem Mass Spectrometry; Thyroid Gland; Thyrotropin | 2014 |
Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Drug Stability; Gemcitabine; Humans; Immunohistochemistry; Ligands; Male; Mice, Nude; Micelles; MicroRNAs; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Polymers; Transfection; Xenograft Model Antitumor Assays | 2014 |
Differential effect of buffering agents on the crystallization of gemcitabine hydrochloride in frozen solutions.
Topics: Buffers; Calorimetry, Differential Scanning; Citric Acid; Crystallization; Deoxycytidine; Excipients; Freeze Drying; Freezing; Gemcitabine; Malates; Solutions; Succinic Acid; Tartrates; Transition Temperature; X-Ray Diffraction | 2014 |
Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Benzodiazepinones; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Proliferation; Checkpoint Kinase 1; Combined Modality Therapy; Deoxycytidine; DNA Damage; Drug Synergism; ErbB Receptors; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Protein Kinases; Pyrazoles; Radioimmunotherapy; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |
Association of xeroderma pigmentosum group D (Asp312Asn, Lys751Gln) and cytidine deaminase (Lys27Gln, Ala70Thr) polymorphisms with outcome in Chinese non-small cell lung cancer patients treated with cisplatin-gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Xeroderma Pigmentosum Group D Protein | 2014 |
Study of gemcitabine-sensitive/resistant cancer cells by cell cloning and synchrotron FTIR microspectroscopy.
Topics: Cell Line, Tumor; Clone Cells; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Principal Component Analysis; Spectroscopy, Fourier Transform Infrared; Synchrotrons | 2014 |
δ-Aminolevulinate dehydratase activity in lung cancer patients and its relationship with oxidative stress.
Topics: Aged; Ascorbic Acid; Blood Platelets; Case-Control Studies; Catalase; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oxidative Stress; Porphobilinogen Synthase; Reactive Oxygen Species; Sulfhydryl Compounds; Superoxide Dismutase; Thiobarbituric Acid Reactive Substances; Vitamin E | 2014 |
Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospital Mortality; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Topics: Active Transport, Cell Nucleus; Animals; Antibiotics, Antineoplastic; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Smad4 Protein; Time Factors; Transfection; Up-Regulation | 2014 |
Carboplatin-based combination chemotherapy for elderly patients with advanced bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cystectomy; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway.
Topics: Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Cell Line, Tumor; Deoxycytidine; Epithelial Cell Adhesion Molecule; Epithelial-Mesenchymal Transition; Female; Flow Cytometry; Gemcitabine; Hepatocyte Growth Factor; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Micrometastasis; Neoplastic Cells, Circulating; Pilot Projects; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2014 |
Development and bioorthogonal activation of palladium-labile prodrugs of gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carbamates; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Damage; Drug Carriers; Drug Screening Assays, Antitumor; Embryo, Nonmammalian; Gemcitabine; Humans; Nanoparticles; Palladium; Polystyrenes; Prodrugs; Rhodamines; Structure-Activity Relationship; Zebrafish | 2014 |
Profiling and targeting of cellular bioenergetics: inhibition of pancreatic cancer cell proliferation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Celecoxib; Cell Culture Techniques; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Doxorubicin; Energy Metabolism; Gemcitabine; Glycolysis; Humans; Hydrogen; Metformin; Mitochondria; Oxygen Consumption; Pancreatic Neoplasms; Pyrazoles; Sulfonamides | 2014 |
Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Choline; Deoxycytidine; Diphosphates; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tumor Cells, Cultured | 2014 |
Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Female; Gemcitabine; Glucose; Glucose Transport Proteins, Facilitative; Humans; Mice; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Thiazolidinediones; Xenograft Model Antitumor Assays | 2014 |
Cholangiocarcinoma cell line TK may be useful for the pharmacokinetic study of the chemotherapeutic agent gemcitabine.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans | 2014 |
Berberine diminishes side population and down-regulates stem cell-associated genes in the pancreatic cancer cell lines PANC-1 and MIA PaCa-2.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Berberine; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Nanog Homeobox Protein; Neoplastic Stem Cells; Octamer Transcription Factor-3; Pancreatic Neoplasms; Receptor, Notch1; RNA, Messenger; Side-Population Cells; Signal Transduction; SOXB1 Transcription Factors | 2014 |
Chemometrics meets cytometry. Analysis of multivariate spectral data to organize and discriminate biological information.
Topics: Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Spectroscopy, Fourier Transform Infrared; Synchrotrons | 2014 |
Effects of microwave exposure and Gemcitabine treatment on apoptotic activity in Burkitt's lymphoma (Raji) cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Deoxycytidine; DNA; Flow Cytometry; Gemcitabine; Humans; Microwaves; Propidium; Radiation, Nonionizing | 2015 |
Phenoxodiol enhances the antitumor activity of gemcitabine in gallbladder cancer through suppressing Akt/mTOR pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gallbladder Neoplasms; Gemcitabine; Humans; Isoflavones; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Resting Phase, Cell Cycle; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Retrospective Studies; Skin Neoplasms; Time Factors; Treatment Outcome | 2014 |
[Marked efficacy of multimodality therapy for ureteral cancer producing granulocyte colony-stmimulating factor].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Male; Taxoids; Ureteral Neoplasms | 2014 |
Delivery of perioperative chemotherapy for bladder cancer in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine; Young Adult | 2014 |
Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate | 2014 |
[Radical resection of a locally advanced pancreatic tail adenosquamous carcinoma treated with S-1 and gemcitabine as neoadjuvant chemotherapy - a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.
Topics: Aged; Antimetabolites, Antineoplastic; Cancer Vaccines; Combined Modality Therapy; Cytokines; Deoxycytidine; Female; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Middle Aged; Pancreatic Neoplasms; Peptide Fragments; Telomerase | 2014 |
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Deoxycytidine; Drug Therapy, Combination; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mice; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Retinoblastoma Protein; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Human ovarian cancer multicellular spheroids: a model for testing antiproliferation activity of Devil's club (Oplopanax horridus) and anticancer agents.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Proliferation; Chromatography, High Pressure Liquid; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Oplopanax; Ovarian Neoplasms; Paclitaxel; Plant Bark; Plant Extracts; Plants, Medicinal; Proteome; Spheroids, Cellular; Tumor Cells, Cultured | 2014 |
Gemcitabine-based adjuvant chemotherapy for patients with advanced gallbladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2014 |
Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cisplatin; Cohort Studies; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Recurrence, Local; Polyethylene Glycols; Recurrence; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2014 |
Involvement of p38 mitogen-activated protein kinase in acquired gemcitabine-resistant human urothelial carcinoma sublines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Flavonoids; Gemcitabine; Humans; Imidazoles; p38 Mitogen-Activated Protein Kinases; Pyridines; Urinary Bladder Neoplasms | 2014 |
Multifunctionalization of magnetic nanoparticles for controlled drug release: a general approach.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Magnetite Nanoparticles; MCF-7 Cells; Structure-Activity Relationship | 2014 |
Gemcitabine, capecitabine and oxaliplatin in advanced biliary tract carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Capecitabine; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Severity of Illness Index | 2014 |
ERCC1 as a biological marker guiding management in malignant pleural mesothelioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; Female; Folic Acid Antagonists; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Pemetrexed; Pleural Neoplasms; Retrospective Studies; Treatment Outcome | 2014 |
Multiplex real-time PCR for RRM1, XRCC1, TUBB3 and TS mRNA for prediction of response of non-small cell lung cancer to chemoradiotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Ribonucleoside Diphosphate Reductase; Thymidylate Synthase; Treatment Outcome; Tubulin; Tumor Suppressor Proteins; X-ray Repair Cross Complementing Protein 1 | 2014 |
Glasgow prognostic score in patients receiving chemotherapy for non-small-cell lung cancer in stages IIIb and IV.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Predictive Value of Tests; Prognosis; Prospective Studies; Quality of Life; Survival Rate | 2014 |
Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients.
Topics: Adult; Aged; Aged, 80 and over; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Recurrence; Treatment Outcome | 2015 |
miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase | 2014 |
Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment.
Topics: Adult; Cost-Benefit Analysis; Cytarabine; Cytidine Deaminase; Deoxycytidine; Enzyme Assays; Female; Gemcitabine; Humans; Male; Middle Aged; Reproducibility of Results; Young Adult | 2014 |
Paclitaxel and gemcitabine combinational drug-loaded mucoadhesive delivery system in the treatment of colon cancers.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cell Survival; Chitosan; Colonic Neoplasms; Deoxycytidine; Drug Carriers; Drug Liberation; Drug Therapy, Combination; Gemcitabine; Humans; Mice; Nanoparticles; Paclitaxel; Succinic Anhydrides; Survival Rate; Xenograft Model Antitumor Assays | 2015 |
Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Male; Middle Aged; Mucin-1; Pancreatic Neoplasms; RNA, Messenger; T-Lymphocytes, Cytotoxic; Transfection | 2014 |
Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cell Separation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phenotype; Side-Population Cells; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2015 |
[Toxicity of intravesical gemcitabine in superficial bladder cancer treatment].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2014 |
Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.
Topics: Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Endoribonucleases; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, SCID; Naphthalenes; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Pyrazines; Regulatory Factor X Transcription Factors; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA Splicing; Sulfonamides; Thiophenes; Toyocamycin; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2014 |
BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; DNA Helicases; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Male; Mice; Mice, Nude; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Transcription Factors; Transfection; Xenograft Model Antitumor Assays | 2014 |
Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cytokines; Deoxycytidine; Disease Models, Animal; Gemcitabine; Genes, p53; Genes, ras; Homeodomain Proteins; Mice; Mice, Transgenic; NF-kappa B; Pancreatic Neoplasms; Pancreatitis, Chronic; Phosphorylation; STAT3 Transcription Factor; Systemic Inflammatory Response Syndrome; Trans-Activators; Treatment Outcome | 2014 |
Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; DNA Replication; Dose-Response Relationship, Drug; Doxorubicin; Drug Repositioning; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, Inbred C57BL; Mice, SCID; Models, Molecular; Nitriles; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Quinolines; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2014 |
Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy.
Topics: Adenocarcinoma; Administration, Metronomic; Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Models, Animal; Female; Gastrointestinal Hormones; Gemcitabine; Humans; Mice; Neoplasm Metastasis; Neuropeptides; Pancreatic Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Urologic Neoplasms | 2014 |
Challenges in using ¹⁸F-fluorodeoxyglucose-PET-CT to define a biological radiotherapy boost volume in locally advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Fluorodeoxyglucose F18; Follow-Up Studies; Gemcitabine; Humans; Multimodal Imaging; Neoplasm Staging; Pancreatic Neoplasms; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Tomography, X-Ray Computed | 2014 |
Dynamic contrast-enhanced ultrasonographic (DCE-US) assessment of the early response after combined gemcitabine and HIFU with low-power treatment for the mouse xenograft model of human pancreatic cancer.
Topics: Animals; Contrast Media; Deoxycytidine; Gemcitabine; Heterografts; High-Intensity Focused Ultrasound Ablation; Humans; Immunosuppressive Agents; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pancreatic Neoplasms; Ribonucleotide Reductases; Transplantation, Heterologous; Treatment Outcome; Ultrasonography | 2014 |
Bone metastases from bladder perivascular epithelioid cell tumor - an unusual localization of a rare tumor: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Bone Neoplasms; Deoxycytidine; Gemcitabine; Humans; Ilium; Male; Perivascular Epithelioid Cell Neoplasms; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2014 |
Renal toxicity associated with weekly cisplatin and gemcitabine combination therapy for treatment of advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Kaplan-Meier Estimate; Kidney; Male; Middle Aged; Renal Insufficiency; Retrospective Studies | 2014 |
The novel mTORC1/2 dual inhibitor INK-128 suppresses survival and proliferation of primary and transformed human pancreatic cancer cells.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Apoptosis; Benzoxazoles; Cell Line, Transformed; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Necrosis; Pancreatic Neoplasms; Pyrimidines; TOR Serine-Threonine Kinases | 2014 |
The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Calreticulin; Camptothecin; Carcinoma, Lewis Lung; CD3 Complex; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunomodulation; Lymphocyte Count; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mitomycin; Mitoxantrone; Neoplasm Transplantation; Neoplasms, Experimental; Protein Transport; T-Lymphocytes; Tumor Microenvironment | 2015 |
Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cladribine; Clone Cells; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Down-Regulation; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Mantle-Cell; Mass Spectrometry; Mice; Proteomics; Rituximab; Vidarabine; Xenograft Model Antitumor Assays | 2014 |
Serum cytokine profile in patients with pancreatic cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Pancreatic Ductal; Comorbidity; Cytokines; Deoxycytidine; Diabetes Mellitus, Type 2; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking; Tumor Microenvironment | 2014 |
Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Inflammatory Breast Neoplasms; Itraconazole; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Triple Negative Breast Neoplasms | 2014 |
Peptide-functionalized nanoparticles for selective targeting of pancreatic tumor.
Topics: Amino Acid Sequence; Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Male; Mice, Inbred C57BL; Nanoparticles; Pancreatic Neoplasms; Peptides; Prodrugs; Squalene | 2014 |
In situ evaluation of gemcitabine-DNA interaction using a DNA-electrochemical biosensor.
Topics: Antimetabolites, Antineoplastic; Biosensing Techniques; Deoxycytidine; DNA; Electrochemical Techniques; Gemcitabine; Humans; Neoplasms; Nucleic Acid Conformation; Oxidation-Reduction | 2014 |
Comparison of gemcitabine, oxaliplatin and L-asparaginase and etoposide, vincristine, doxorubicin, cyclophosphamide and prednisone as first-line chemotherapy in patients with stage IE to IIE extranodal natural killer/T-cell lymphoma: a multicenter retrosp
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cyclophosphamide; Deoxycytidine; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prednisone; Remission Induction; Retrospective Studies; Treatment Outcome; Vincristine; Young Adult | 2015 |
Clinical characteristics of long-term survivors of inoperable pancreatic cancer: an 8-year cohort analysis in Korea.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Proportional Hazards Models; Quinazolines; Republic of Korea; Retrospective Studies; Survivors; Treatment Outcome | 2014 |
[Down-regulation of Notch1 by small interfering RNA enhances chemosensitivity to gemcitabine in pancreatic cancer cells through activating apoptosis activity].
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; Pancreatic Neoplasms; Receptor, Notch1; RNA, Small Interfering; Signal Transduction | 2014 |
Development of a gradient high performance liquid chromatography assay for simultaneous analysis of hydrophilic gemcitabine and lipophilic curcumin using a central composite design and its application in liposome development.
Topics: Biological Assay; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Curcumin; Deoxycytidine; Gemcitabine; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Limit of Detection; Liposomes | 2014 |
Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cost-Benefit Analysis; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Quality of Life; Retrospective Studies; Survival Rate; United States; Urinary Bladder Neoplasms | 2014 |
The effect of neoadjuvant chemoradiation on pancreatic cancer-associated diabetes mellitus.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy; Deoxycytidine; Diabetes Mellitus; Docetaxel; Fasting; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Paraneoplastic Syndromes; Retrospective Studies; Single-Blind Method; Taxoids; Treatment Outcome; Tumor Burden | 2014 |
Novel role of pancreatic differentiation 2 in facilitating self-renewal and drug resistance of pancreatic cancer stem cells.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Mice, Transgenic; Neoplastic Stem Cells; Nuclear Proteins; Pancreatic Neoplasms; Side-Population Cells; Transcription Factors | 2014 |
The targeting mechanism of DHA ligand and its conjugate with Gemcitabine for the enhanced tumor therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Docosahexaenoic Acids; Female; Gemcitabine; Hep G2 Cells; Humans; Ligands; Liver Neoplasms; MCF-7 Cells; Mice; Mice, Nude; Molecular Targeted Therapy; Phosphatidylethanolamines; Random Allocation; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Malignant peritoneal mesothelioma in a child: chemotherapy with gemcitabine and platinum was effective for the disease unresponsive to other treatments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Ascites; Child; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Peritoneal Neoplasms | 2014 |
Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis.
Topics: Adolescent; Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Chick Embryo; Deoxycytidine; Female; Gemcitabine; Glucose; Glycolysis; Humans; Immunohistochemistry; Isoenzymes; L-Lactate Dehydrogenase; Mice, Inbred Strains; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Pyruvates; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Potent proapoptotic actions of dihydroartemisinin in gemcitabine-resistant A549 cells.
Topics: Antineoplastic Agents; Apoptosis; Artemisinins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Caspase 3; Caspase 8; Caspase 9; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Membrane Potential, Mitochondrial; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering | 2014 |
Clobenpropit enhances anti-tumor effect of gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Histamine Agonists; Histamine H3 Antagonists; Humans; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H4; Thiourea; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
[Mechanism of SPARC-enhanced chemosensitivity of pancreatic cancer cells to gemcitabine].
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 2; Caspase 8; Caspase 9; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cysteine Endopeptidases; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Osteonectin; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Time Factors | 2014 |
Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cross-Sectional Studies; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2014 |
Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Endothelium, Vascular; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Prospective Studies; ROC Curve; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2015 |
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2015 |
Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an effective regimen in relapsed diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Substitution; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Methylprednisolone; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Rituximab; Salvage Therapy; Survival Analysis; Thrombocytopenia; Treatment Outcome | 2015 |
Treatment outcomes of gemcitabine in refractory or recurrent epithelial ovarian cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Treatment Outcome | 2014 |
Cordycepin down-regulates multiple drug resistant (MDR)/HIF-1α through regulating AMPK/mTORC1 signaling in GBC-SD gallbladder cancer cells.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxyadenosines; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
BRCA2 and RAD51 promote double-strand break formation and cell death in response to gemcitabine.
Topics: Antimetabolites, Antineoplastic; BRCA2 Protein; Cell Death; Cell Survival; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Replication; Gemcitabine; Humans; MCF-7 Cells; Neoplasms; Rad51 Recombinase | 2014 |
Neutralizing murine TGFβR2 promotes a differentiated tumor cell phenotype and inhibits pancreatic cancer metastasis.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; NIH 3T3 Cells; Pancreatic Neoplasms; Random Allocation; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2014 |
Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax.
Topics: bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Histones; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Tumor Suppressor Protein p53 | 2014 |
NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therapy; Cytokine-Induced Killer Cells; Cytotoxicity, Immunologic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Retrospective Studies | 2014 |
[Lung cancer: is surgery an option for persisting N2 after induction therapy?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Neoplasm Staging; Pneumonectomy; Postoperative Complications; Prognosis; Reoperation; Retrospective Studies; Treatment Outcome | 2015 |
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Quinazolines; Taxoids; Treatment Outcome | 2014 |
Phase 1 trials in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Locally advanced unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Pancreatic Neoplasms; Radiotherapy; Survival Analysis; Treatment Outcome | 2014 |
Pharmacogenetics in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Genotype; Glucuronosyltransferase; Humans; Pancreatic Neoplasms; Pharmacogenetics; Survival Analysis; Treatment Outcome | 2014 |
PARP-inhibitors in BRCA-associated pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Survival Analysis; Treatment Outcome | 2014 |
Second-line treatment for pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Leucovorin; Metformin; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Adjuvant treatment for pancreatic cancer.
Topics: Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Role of neoadjuvant therapy in management of pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Predictive role of RRM1 and BRCA1 mRNA expression on the clinical outcome of advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Survival Analysis; Treatment Outcome; Tumor Suppressor Proteins; Vinblastine; Vinorelbine | 2014 |
A predictive model for evaluating responsiveness to pemetrexed treatment in patients with advanced colorectal cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Cyclobutanes; Deoxycytidine; Female; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Prognosis | 2014 |
Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters.
Topics: Animals; Bacterial Proteins; Binding Sites; Biological Transport; Crystallography, X-Ray; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Kinetics; Membrane Transport Proteins; Molecular Docking Simulation; Nucleoside Transport Proteins; Oocytes; Protein Binding; Quantitative Structure-Activity Relationship; Recombinant Proteins; Ribavirin; Substrate Specificity; Thermodynamics; Uridine; Vibrio cholerae; Xenopus laevis | 2014 |
CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Lectins, C-Type; Macrophage Colony-Stimulating Factor; Macrophages; Mannose Receptor; Mannose-Binding Lectins; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Random Allocation; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Cell Surface; Signal Transduction; T-Lymphocytes; Tissue Array Analysis; Tumor Microenvironment | 2014 |
Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Survival Analysis | 2015 |
Sequential combination therapy of ovarian cancer with degradable N-(2-hydroxypropyl)methacrylamide copolymer paclitaxel and gemcitabine conjugates.
Topics: Acrylamides; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2014 |
25-Hydroxyvitamin D levels and survival in advanced pancreatic cancer: findings from CALGB 80303 (Alliance).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Black or African American; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Prevalence; Randomized Controlled Trials as Topic; United States; Vitamin D; Vitamin D Deficiency; White People | 2014 |
Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Heterozygote; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Polymorphism, Genetic; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Topics: Benzodiazepinones; Biomarkers, Tumor; Cell Line, Tumor; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Indoles; MCF-7 Cells; Ovarian Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridones; Thiophenes; Triple Negative Breast Neoplasms; Urea | 2014 |
S-1 vs. gemcitabine as an adjuvant therapy after surgical resection for ductal adenocarcinoma of the pancreas.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm, Residual; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Tegafur | 2014 |
Effect of gemcitabine and retinoic acid loaded PAMAM dendrimer-coated magnetic nanoparticles on pancreatic cancer and stellate cell lines.
Topics: Antineoplastic Agents; Cell Line; Dendrimers; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Gemcitabine; Humans; Magnetite Nanoparticles; Pancreatic Neoplasms; Pancreatic Stellate Cells; Tretinoin; Tumor Cells, Cultured | 2014 |
Monitoring oxygen levels in orthotopic human glioma xenograft following carbogen inhalation and chemotherapy by implantable resonator-based oximetry.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carbon Dioxide; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Glioma; Humans; Hypoxia; Inhalation; Magnetic Resonance Imaging; Male; Mice; Oximetry; Oxygen; Oxygen Consumption; Pyrazoles; Pyrimidines; Xenograft Model Antitumor Assays | 2015 |
Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.
Topics: Biomarkers, Tumor; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Molecular Targeted Therapy; Neoplasm Staging; Pancreatic Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2014 |
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Capecitabine; Carboplatin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2014 |
MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cyclin G2; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms | 2014 |
A prospective study of biomarker-guided chemotherapy in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Endonucleases; Feasibility Studies; Female; Gemcitabine; Humans; Image-Guided Biopsy; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Ribonucleoside Diphosphate Reductase; Tomography, X-Ray Computed; Treatment Outcome; Tubulin; Tumor Suppressor Proteins | 2014 |
Adjuvant Gemcitabine and Gemcitabine-based Chemoradiotherapy Versus Gemcitabine Alone After Pancreatic Cancer Resection: The Indiana University Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Indiana; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Universities | 2017 |
Inhibition of endoglin-GIPC interaction inhibits pancreatic cancer cell growth.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antigens, CD; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Endoglin; Gemcitabine; Humans; Ligands; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Pancreatic Neoplasms; Peptides; Random Allocation; Receptors, Cell Surface; RNA, Small Interfering; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2014 |
The radiosensitising effect of gemcitabine and its main metabolite dFdU under low oxygen conditions is in vitro not dependent on functional HIF-1 protein.
Topics: Breast Neoplasms; Cell Cycle; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Deoxyuridine; Female; Gemcitabine; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; In Vitro Techniques; Radiation-Sensitizing Agents | 2014 |
Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Cycle; Cell Survival; Deoxycytidine; Disease Models, Animal; DNA Replication; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Exonucleases; Gemcitabine; Humans; Hyperthermia, Induced; Liver Neoplasms; Mice; Mice, SCID; MRE11 Homologue Protein; Neoplasms, Experimental; Radio Waves; Radiofrequency Therapy; Recombinational DNA Repair | 2014 |
Prognostic value of cyclooxygenase-2 gene polymorphisms in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.
Topics: Adult; Aged; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Prototype of biliary drug-eluting stent with photodynamic and chemotherapy using electrospinning.
Topics: Deoxycytidine; Drug-Eluting Stents; Equipment Design; Gemcitabine; Microscopy, Electron, Scanning; Photochemotherapy; Polymers | 2014 |
DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; DNA-Activated Protein Kinase; Enzyme Activation; Gemcitabine; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2014 |
Chemotherapy for transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Deoxycytidine; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2014 |
[The study of clinical value of transarterial chemical perfusion as second-line therapy for late stage pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging; Pancreatic Neoplasms; Salvage Therapy | 2014 |
Treatment of experimental pancreatic cancer with 213-Bismuth-labeled chimeric antibody to single-strand DNA.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Bismuth; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Radioimmunotherapy; Radioisotopes; Xenograft Model Antitumor Assays | 2014 |
Measles vaccine strains for virotherapy of non-small-cell lung carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cell Adhesion Molecules; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; Epithelial Cells; Eukaryotic Initiation Factor-4E; Gemcitabine; Green Fluorescent Proteins; Humans; Hydrazones; Lung; Lung Neoplasms; Measles Vaccine; Measles virus; Membrane Cofactor Protein; Mice; Oncolytic Virotherapy; Phosphoproteins; Sirolimus; Thiazoles; Tumor Burden; Virus Replication | 2014 |
Less toxic chemotherapy improves uptake of all lines of chemotherapy in advanced non-small-cell lung cancer: a 10-year retrospective population-based review.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; British Columbia; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Therapy; Erlotinib Hydrochloride; Female; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum Compounds; Quinazolines; Retrospective Studies; Sex Factors; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2014 |
pH-sensitive stearoyl-PEG-poly(methacryloyl sulfadimethoxine) decorated liposomes for the delivery of gemcitabine to cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Culture Techniques; Cell Survival; Deoxycytidine; Drug Carriers; Drug Stability; Gemcitabine; Humans; Hydrogen-Ion Concentration; Liposomes; MCF-7 Cells; Microscopy, Confocal; Microscopy, Electron, Transmission; Molecular Structure; Particle Size; Polyethylene Glycols; Polymethacrylic Acids; Spectrometry, Fluorescence; Sulfonamides; Surface Properties | 2014 |
[Successful combination chemotherapy of gemcitabine plus nedaplatin for invasive ureteral squamous cell carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Organoplatinum Compounds; Ureteral Neoplasms | 2014 |
Gemcitabine-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Murine-Derived; Antihypertensive Agents; Antimetabolites, Antineoplastic; Blood Component Transfusion; Deoxycytidine; Disease Management; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Hypertension; Kidney Failure, Chronic; Nursing Assessment; Pancreatic Neoplasms; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Renal Dialysis; Rituximab | 2014 |
dNTP pool modulation dynamics by SAMHD1 protein in monocyte-derived macrophages.
Topics: Deoxycytidine; Gemcitabine; HIV-1; Humans; Macrophages; Monocytes; Monomeric GTP-Binding Proteins; Nucleotides; SAM Domain and HD Domain-Containing Protein 1; Tandem Mass Spectrometry; Viral Regulatory and Accessory Proteins; Virion | 2014 |
PharmGKB summary: gemcitabine pathway.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Pharmacogenetics | 2014 |
Anticancer effects of brucine and gemcitabine combination in MCF-7 human breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Cycle; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; MCF-7 Cells; Strychnine | 2015 |
Novel bladder preservation therapy with Osaka Medical College regimen.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Balloon Occlusion; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Radiotherapy, Adjuvant; Renal Dialysis; Survival Rate; Urinary Bladder Neoplasms | 2015 |
Oncological outcomes of advanced muscle-invasive bladder cancer with a micropapillary variant after radical cystectomy and adjuvant platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Papillary; Carcinoma, Transitional Cell; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Male; Methotrexate; Middle Aged; Multivariate Analysis; Muscle, Smooth; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Benzoates; Benzylamines; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Liver X Receptors; Male; Microarray Analysis; Middle Aged; Neoplasm Proteins; Orphan Nuclear Receptors; Pancreatic Neoplasms; Signal Transduction | 2014 |
A miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer.
Topics: Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mesoderm; MicroRNAs; Molecular Targeted Therapy; Neoplasm Proteins; Neuraminidase; Proto-Oncogene Proteins | 2014 |
Cutaneous Langerhans cell sarcoma relapsing systemically: Complete remission with the EPIG regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Langerhans Cell Sarcoma; Male; Recurrence; Remission Induction; Skin Neoplasms; Young Adult | 2015 |
Acquired resistance to gemcitabine and cross-resistance in human pancreatic cancer clones.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clone Cells; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2015 |
Reversible epigenetic regulation of 14-3-3σ expression in acquired gemcitabine resistance by uhrf1 and DNA methyltransferase 1.
Topics: 14-3-3 Proteins; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Cytarabine; Deoxycytidine; DNA; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Pancreatic Neoplasms; Ribonucleotide Reductases; Ubiquitin-Protein Ligases; Up-Regulation | 2014 |
Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Benzoquinones; Betulinic Acid; Carrier Proteins; Cell Proliferation; Deoxycytidine; Drug Synergism; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Membrane Potential, Mitochondrial; Membrane Proteins; Pancreatic Neoplasms; Pentacyclic Triterpenes; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Triterpenes; Tumor Cells, Cultured | 2014 |
Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to predict clinical outcomes in pancreatic ductal adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Disease Progression; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; RNA, Messenger; Survival Rate; Transcription Factor CHOP | 2014 |
Decreased miR-206 expression in BRCA1 wild-type triple-negative breast cancer cells after concomitant treatment with gemcitabine and a Poly(ADP-ribose) polymerase-1 inhibitor.
Topics: Antineoplastic Agents; Apoptosis; BRCA1 Protein; Cell Line, Tumor; Cell Survival; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms | 2014 |
Incidence of hematologic toxicity in older adults treated with gemcitabine or a gemcitabine-containing regimen in routine clinical practice: a multicenter retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Aging; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Health Services for the Aged; Humans; Incidence; Male; Middle Aged; Netherlands; Neutropenia; Retrospective Studies | 2014 |
A gemcitabine sensitivity screen identifies a role for NEK9 in the replication stress response.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; Female; Gemcitabine; Humans; NIMA-Related Kinases; Protein Kinases; Protein Serine-Threonine Kinases; Replication Protein A; Stress, Physiological; Triple Negative Breast Neoplasms | 2014 |
Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
Topics: 3T3 Cells; Animals; Antimetabolites, Antineoplastic; Cell Line; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Humans; Mice; Mice, Nude; Radiation-Sensitizing Agents; RNA, Messenger; RNA, Small Interfering; Urinary Bladder Neoplasms | 2014 |
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxaloacetates; Pancreatic Neoplasms; Retrospective Studies; Vomiting | 2014 |
Cytotoxicity of gemcitabine enhanced by polyphenolics from Aronia melanocarpa in pancreatic cancer cell line AsPC-1.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Colorimetry; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Pancreatic Neoplasms; Photinia; Phytotherapy; Plants, Medicinal; Polyphenols | 2014 |
PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carrier Proteins; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutamates; Guanine; Humans; Immunoenzyme Techniques; Lung Neoplasms; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Taxoids; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2014 |
Using Drosophila melanogaster to identify chemotherapy toxicity genes.
Topics: Animals; Antineoplastic Agents; Carboplatin; Deoxycytidine; DNA Transposable Elements; Drosophila melanogaster; Drosophila Proteins; Fertility; Gemcitabine; Mitomycin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Quantitative Trait Loci; Repressor Proteins; Ribonucleoside Diphosphate Reductase; Trans-Activators | 2014 |
Luteolin and Gemcitabine Protect Against Pancreatic Cancer in an Orthotopic Mouse Model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Luteolin; Male; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Topics: Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Argininosuccinate Synthase; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Hydrolases; Male; Mice; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Signal Transduction; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Deoxycytidine; Diterpenes, Kaurane; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction | 2014 |
Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small-cell lung cancer patients.
Topics: Adult; Aged; Asian People; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Treatment Outcome | 2014 |
[Two cases of pancreatic cancer with multiple liver metastases treated with radical treatment after successful treatment with gemcitabine plus S-1 therapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
Pseudogene PTENP1 functions as a competing endogenous RNA to suppress clear-cell renal cell carcinoma progression.
Topics: Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; MicroRNAs; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Pseudogenes; PTEN Phosphohydrolase; RNA Interference; RNA, Messenger; Tumor Burden | 2014 |
Silencing of STRN4 suppresses the malignant characteristics of cancer cells.
Topics: Animals; Anoikis; Calmodulin-Binding Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; Humans; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms, Experimental; Nerve Tissue Proteins; Pancreatic Neoplasms; RNA, Small Interfering | 2014 |
A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Densitometry; Deoxycytidine; Drug Resistance, Neoplasm; Free Radical Scavengers; Gemcitabine; Homeostasis; Humans; Inhibitory Concentration 50; MAP Kinase Kinase Kinase 5; MAP Kinase Signaling System; Organogold Compounds; Oxidation-Reduction; p38 Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Protein Binding; Reactive Oxygen Species; Thioredoxin-Disulfide Reductase; Thioredoxins | 2014 |
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Europe; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; North America; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
N-acetyl-L-cysteine sensitizes pancreatic cancers to gemcitabine by targeting the NFκB pathway.
Topics: Acetylcysteine; Animals; Apoptosis; Cell Line, Tumor; Cysteine; Deoxycytidine; Gemcitabine; Glutathione; Humans; Male; Mice; Mice, Nude; NF-kappa B; Oxidative Stress; Pancreatic Neoplasms; Signal Transduction; X-Linked Inhibitor of Apoptosis Protein | 2014 |
Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Ribonucleotide Reductases; Survival Rate; Taiwan; Treatment Outcome | 2014 |
Differential modulation of nicotine-induced gemcitabine resistance by GABA receptor agonists in pancreatic cancer cell xenografts and in vitro.
Topics: Animals; Baclofen; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; GABA Agonists; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Male; Mice; Mice, Nude; Nicotine; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2014 |
A hypusine-eIF5A-PEAK1 switch regulates the pathogenesis of pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Ciclopirox; Deoxycytidine; Eukaryotic Translation Initiation Factor 5A; Female; Gemcitabine; Humans; Lysine; Mice; Pancreatic Neoplasms; Peptide Initiation Factors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridones; ras Proteins; RNA-Binding Proteins | 2014 |
A2A Adenosine Receptor Regulates the Human Blood-Brain Barrier Permeability.
Topics: Adenosine A2 Receptor Agonists; Adherens Junctions; Animals; Antineoplastic Agents; Blood-Brain Barrier; Cell Death; Cell Line; Cell Membrane Permeability; Cell Movement; Deoxycytidine; Down-Regulation; Electric Impedance; Endothelial Cells; Focal Adhesions; Gemcitabine; Glioblastoma; Humans; Jurkat Cells; Mice, Inbred C57BL; Phosphorylation; Receptors, Adenosine A2; rhoA GTP-Binding Protein; Signal Transduction; Stress Fibers; T-Lymphocytes; Tight Junctions | 2015 |
A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Polypropylenes; Repressor Proteins; RNA Interference; Ubiquitin-Protein Ligases | 2015 |
Effects of doxorubicin and gemcitabine on the induction of apoptosis in breast cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; MCF-7 Cells; Mice; Neoplastic Stem Cells | 2014 |
Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1) degradation through autophagy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Autophagy; Culture Media, Serum-Free; Deoxycytidine; Gemcitabine; Humans; Poly(ADP-ribose) Polymerases; Proteolysis | 2014 |
Apicidin sensitizes pancreatic cancer cells to gemcitabine by epigenetically regulating MUC4 expression.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Mucin-4; Pancreatic Neoplasms; Peptides, Cyclic; Small Molecule Libraries | 2014 |
One-electron oxidation of gemcitabine and analogs: mechanism of formation of C3' and C2' sugar radicals.
Topics: Carbohydrates; Deoxycytidine; Electron Spin Resonance Spectroscopy; Electrons; Free Radicals; Gemcitabine; Oxidation-Reduction | 2014 |
Human equilibrative nucleoside transporter 1 testing in pancreatic ductal adenocarcinoma: a comparison between murine and rabbit antibodies.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Mice; Pancreatic Neoplasms; Rabbits; Sensitivity and Specificity; Tissue Array Analysis | 2015 |
Clinical trials in thoracic radiation oncology: as easy as 1, 2, 3.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Organs at Risk; Radiation-Sensitizing Agents; Research Design; Survival Rate; Treatment Failure | 2014 |
WNT5A modulates cell cycle progression and contributes to the chemoresistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D; Deoxycytidine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Male; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Retinoblastoma Protein; RNA, Messenger; Wnt Proteins; Wnt-5a Protein | 2014 |
Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mutation; Pancreatic Neoplasms; Phosphorylation; Pyrimidines; Tumor Suppressor Protein p53 | 2015 |
Peptide conjugation: before or after nanoparticle formation?
Topics: Amino Acid Sequence; Animals; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Design; Gemcitabine; Humans; Ligands; Mice; Nanoparticles; NIH 3T3 Cells; Oligopeptides; Particle Size; Proto-Oncogene Proteins | 2014 |
Is pancreatic fistula associated with worse overall survival in patients with pancreatic carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Oxonic Acid; Pancreatectomy; Pancreatic Fistula; Pancreatic Neoplasms; Severity of Illness Index; Survival Rate; Tegafur | 2015 |
Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.
Topics: Animals; Antigen Presentation; Antigens, Neoplasm; Antimetabolites, Antineoplastic; CD11b Antigen; CD4-Positive T-Lymphocytes; Cell Movement; Coculture Techniques; Cross-Priming; Dendritic Cells; Deoxycytidine; Gemcitabine; Gene Expression; Hemagglutinins; Lymph Nodes; Mesothelioma; Mice; Mice, Transgenic; Neoplasm Transplantation; Skin Neoplasms; T-Lymphocytes, Cytotoxic; Tumor Microenvironment | 2015 |
Prototype development of an electrical impedance based simultaneous respiratory and cardiac monitoring system for gated radiotherapy.
Topics: Cholangiocarcinoma; Deoxycytidine; Drug Delivery Systems; Drug-Eluting Stents; Electric Impedance; Gemcitabine; Hematoporphyrins; Humans; Membranes, Artificial; Microscopy, Electron, Scanning; Monitoring, Physiologic; Movement; Photochemotherapy; Polyesters; Polyethylene Glycols; Polymers; Radiotherapy; Solubility; Time Factors | 2014 |
S-1 plus gemcitabine chemotherapy followed by concurrent radiotherapy and maintenance therapy with S-1 for unresectable pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Radiosurgery; Radiotherapy, Conformal; Survival Analysis; Tegafur; Time Factors; Treatment Outcome | 2014 |
Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biliary Tract Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Platinum Compounds; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
A report of sarcomatoid carcinoma of the gallbladder treated with palliative deocetaxel and gemcitabine chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Radiography; Taxoids | 2014 |
[Relationship between the efficacy of gemcitabine/cisplatin adjuvant chemotherapy and RRM1 protein expression in postoperative NSCLC patients].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Immunohistochemistry; Postoperative Period; Prognosis; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2014 |
[Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome | 2014 |
GEMOX as the best hope for combined hepatocellular carcinoma and cholangiocarcinoma?
Topics: Carcinoma, Hepatocellular; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Treatment Outcome | 2014 |
Overexpression of heat shock protein 27 (HSP27) increases gemcitabine sensitivity in pancreatic cancer cells through S-phase arrest and apoptosis.
Topics: Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Molecular Chaperones; Pancreas; Pancreatic Neoplasms; S Phase | 2015 |
Prognostic significance and therapeutic implications of peroxisome proliferator-activated receptor γ overexpression in human pancreatic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Deoxycytidine; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms; PPAR gamma; Prognosis; Retrospective Studies; Tumor Cells, Cultured; Up-Regulation | 2015 |
Metronomic gemcitabine targeted tumor vascular microenvironment decreases the population of CD133(+) cells in hepatocarcinoma xenografts.
Topics: AC133 Antigen; Angiogenesis Inhibitors; Animals; Antigens, CD; Carcinoma, Hepatocellular; Deoxycytidine; Endothelial Cells; Gemcitabine; Glycoproteins; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; Peptides; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Chemotherapy and targeted therapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma; Databases, Factual; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Neoplasm Staging; Survival Rate; Treatment Outcome | 2014 |
Small molecule inhibitor YM155-mediated activation of death receptor 5 is crucial for chemotherapy-induced apoptosis in pancreatic carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Mice; Mice, SCID; Naphthoquinones; Pancreatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Survivin; Xenograft Model Antitumor Assays | 2015 |
Thymoquinone Pretreatment Overcomes the Insensitivity and Potentiates the Antitumor Effect of Gemcitabine Through Abrogation of Notch1, PI3K/Akt/mTOR Regulated Signaling Pathways in Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Mice, Inbred BALB C; Mice, Nude; Nigella sativa; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-akt; Receptor, Notch1; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Rat N-ERC/mesothelin as a marker for in vivo screening of drugs against pancreas cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Female; Gemcitabine; GPI-Linked Proteins; Male; Mesothelin; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Rats; Rats, Sprague-Dawley; Rats, Wistar | 2014 |
Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Caspase 3; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Proto-Oncogene Proteins c-cbl; Quinazolines; RNA, Small Interfering | 2015 |
Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodiazepinones; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Mutation; Protein Kinases; Pyrazoles; Thiophenes; Tumor Suppressor Protein p53; Urea; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Involvement of FoxQ1 in NSCLC through regulating EMT and increasing chemosensitivity.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Glutamates; Guanine; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pemetrexed; RNA, Messenger; Taxoids | 2014 |
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Survival Rate | 2015 |
Intermittent chemotherapy can retain the therapeutic potential of anti-CD137 antibody during the late tumor-bearing state.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Mice, Inbred BALB C; Mice, Nude; Myeloid Cells; Neoplasm Transplantation; T-Lymphocytes, Cytotoxic; Tumor Burden; Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2015 |
Curative resection of gallbladder cancer with liver invasion and hepatic metastasis after chemotherapy with gemcitabine plus S-1: report of a case.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Tegafur | 2014 |
Response to nab-paclitaxel plus gemcitabine in a patient with primary resistance to FOLFIRINOX.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Gastrointestinal Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel | 2014 |
Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Dendritic Cells; Deoxycytidine; Female; Fluorouracil; Gemcitabine; HLA-DR Antigens; Humans; Immunotherapy; Interferon-gamma; Lymphatic Metastasis; Middle Aged; Mucin-1; Peritoneal Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; WT1 Proteins | 2014 |
Concurrent chemoradiotherapy with or without induction chemotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Gemcitabine associated retinopathy and nephropathy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Failure, Chronic; Middle Aged; Retinal Diseases; Retrospective Studies; Vision Disorders | 2014 |
Efficacy of permanent iodine-125 seed implants and gemcitabine chemotherapy in patients with platinum- resistant recurrent ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Brachytherapy; Chemoradiotherapy; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Prognosis; Tomography, X-Ray Computed | 2014 |
Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azetidines; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Indazoles; MAP Kinase Kinase 1; Mice; Models, Biological; Mutation; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Standard of Care; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Poor outcomes after liver transplantation in patients with incidental cholangiocarcinoma irrespective of tumor localization.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Calcineurin Inhibitors; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Doxorubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Incidental Findings; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Prognosis; Sirolimus; Survival Analysis; Treatment Outcome | 2014 |
Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaloacetates; Palliative Care; Pancreatic Neoplasms; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2014 |
Impact of tert-butyl alcohol on crystallization kinetics of gemcitabine hydrochloride in frozen aqueous solutions.
Topics: Algorithms; Antimetabolites, Antineoplastic; Calorimetry, Differential Scanning; Cold Temperature; Crystallization; Crystallography, X-Ray; Deoxycytidine; Energy Transfer; Entropy; Freeze Drying; Gemcitabine; Kinetics; Microscopy, Electron, Scanning; Models, Molecular; Particle Size; Solubility; Solvents; tert-Butyl Alcohol; Thermodynamics | 2015 |
Selective efficacy of zoledronic acid on metastasis in a patient-derived orthotopic xenograph (PDOX) nude-mouse model of human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Deoxycytidine; Diphosphonates; Gemcitabine; Humans; Imidazoles; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zoledronic Acid | 2015 |
Establishment of human pancreatic cancer gemcitabine‑resistant cell line with ribonucleotide reductase overexpression.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Odds Ratio; Pancreatic Neoplasms; Proportional Hazards Models; Renin-Angiotensin System; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Long-term complete response in a patient with disseminated pulmonary pleomorphic carcinoma induced by cisplatin and gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 2014 |
Curaxin CBL0137 eradicates drug resistant cancer stem cells and potentiates efficacy of gemcitabine in preclinical models of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Cost-effectiveness of gemcitabine versus PEGylated liposomal doxorubicin for recurrent or progressive ovarian cancer: comparing chemotherapy with nanotherapy.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Nanomedicine; Ovarian Neoplasms; Polyethylene Glycols; Quality-Adjusted Life Years | 2014 |
Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs.
Topics: Acute Disease; Acute Lung Injury; Anesthesia, General; Animals; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Gemcitabine; Lung; Lung Neoplasms; Sus scrofa | 2015 |
Targeted oncolytic herpes simplex virus type 1 eradicates experimental pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression Regulation; Genetic Engineering; Herpesvirus 1, Human; Humans; Injections, Intralesional; Mice; Mice, Nude; Neoplasm Transplantation; Oncolytic Virotherapy; Pancreas; Pancreatic Neoplasms; Promoter Regions, Genetic; Trans-Activators; Tumor Burden; Viral Proteins | 2015 |
Neoadjuvant gemcitabine-based accelerated hyperfractionation chemoradiotherapy for patients with borderline resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neutropenia; Pancreatic Neoplasms | 2014 |
Transport Oncophysics in silico, in vitro, and in vivo. Preface.
Topics: Biophysics; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Medical Oncology; Nanomedicine; Pancreatic Neoplasms | 2014 |
Intra-tumoral heterogeneity of gemcitabine delivery and mass transport in human pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Deoxycytidine; DNA Adducts; DNA, Neoplasm; Drug Delivery Systems; Gemcitabine; Humans; Injections, Intravenous; Pancreatectomy; Pancreatic Neoplasms; Tissue Distribution; Tomography Scanners, X-Ray Computed; Tumor Microenvironment | 2014 |
Intravenous 3-weekly paclitaxel and metronomic oral cyclophosphamide in patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prognosis; Salvage Therapy; Survival Analysis; Treatment Failure; Treatment Outcome; Urologic Neoplasms | 2015 |
Gemcitabine plus capecitabine (Gem-Cape) biweekly in chemorefractory metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Capecitabine; Colonic Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Rectal Neoplasms; Retreatment; Retrospective Studies; Survival Rate | 2015 |
Nuclear FAM21 participates in NF-κB-dependent gene regulation in pancreatic cancer cells.
Topics: Cell Line, Tumor; Cell Nucleus; Chromatin; Cytoplasm; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Microfilament Proteins; NF-kappa B; Nuclear Localization Signals; Pancreatic Neoplasms; Phosphate-Binding Proteins; Protein Binding; Proteins; Transcription Factor RelA | 2015 |
Gemcitabine and γ-cyclodextrin/docetaxel inclusion complex-loaded liposome for highly effective combinational therapy of osteosarcoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Deoxycytidine; Docetaxel; Drug Combinations; Drug Liberation; gamma-Cyclodextrins; Gemcitabine; Humans; Liposomes; Mice, Nude; Nanostructures; Osteosarcoma; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Cytotoxins; Deoxycytidine; Disease-Free Survival; Female; Furans; Gemcitabine; Humans; Ketones; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2015 |
Preoperative gemcitabine-based chemoradiation therapy for pancreatic ductal adenocarcinoma of the body and tail: impact of splenic vessels involvement on operative outcome and pattern of recurrence.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Splenic Artery; Splenic Vein | 2015 |
Counter-intuitive effect of non-crystallizing sugars on the crystallization of gemcitabine HCl in frozen solutions.
Topics: Calorimetry, Differential Scanning; Crystallization; Deoxycytidine; Freezing; Fructose; Gemcitabine; Raffinose; Solutions; Sucrose; Trehalose; Water; X-Ray Diffraction | 2015 |
Gemcitabine-based therapy for pancreatic cancer using the squalenoyl nucleoside monophosphate nanoassemblies.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Ki-67 Antigen; Mice; Nanomedicine; Nanoparticles; Neoplasm Invasiveness; Pancreatic Neoplasms; Prodrugs; Squalene; Xenograft Model Antitumor Assays | 2015 |
Cisplatin-based first-line therapy for advanced urothelial carcinoma after previous perioperative cisplatin-based therapy.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Perioperative Care; Proportional Hazards Models; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
A PAUF-neutralizing antibody targets both carcinoma and endothelial cells to impede pancreatic tumor progression and metastasis.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neutralizing; Antineoplastic Agents; beta Catenin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combined Modality Therapy; Cyclin D1; Deoxycytidine; Disease Progression; Endothelial Cells; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Lectins; Mice; Mice, Nude; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells.
Topics: Analysis of Variance; Cell Line, Tumor; Deoxycytidine; DNA Primers; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation; Humans; Hypoxia-Inducible Factor 1; Image Processing, Computer-Assisted; Immunoblotting; Interleukin-6; Interleukin-8; Kaplan-Meier Estimate; Luciferases; Microscopy; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Triple Negative Breast Neoplasms | 2014 |
Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1.
Topics: Administration, Oral; Animals; Aza Compounds; Carbazoles; Carbolines; Checkpoint Kinase 1; Crystallography, X-Ray; Deoxycytidine; Drug Discovery; Drug Synergism; Gemcitabine; Humans; Mice; Protein Conformation; Protein Kinase Inhibitors; Protein Kinases; Rats; Structure-Activity Relationship; Tissue Distribution | 2014 |
Aqueous-core PEG-coated PLA nanocapsules for an efficient entrapment of water soluble anticancer drugs and a smart therapeutic response.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Female; Gemcitabine; HT29 Cells; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Nanocapsules; Particle Size; Polyethylene Glycols; Solubility; Water | 2015 |
GAIP interacting protein C-terminus regulates autophagy and exosome biogenesis of pancreatic cancer through metabolic pathways.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Autophagy; Autophagy-Related Protein 7; Beclin-1; Biological Transport; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Expression; Glucose; Humans; Membrane Proteins; Metabolic Networks and Pathways; Neoplasm Proteins; Pancreatic Neoplasms; Stress, Physiological; Ubiquitin-Activating Enzymes | 2014 |
Differences in the recurrence pattern after neoadjuvant chemotherapy compared to surgery alone in patients with muscle-invasive bladder cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2015 |
JNK suppression of chemotherapeutic agents-induced ROS confers chemoresistance on pancreatic cancer stem cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Humans; Immunoblotting; MAP Kinase Kinase 4; Neoplastic Stem Cells; Pancreatic Neoplasms; Reactive Oxygen Species; RNA, Small Interfering; Transfection | 2015 |
PBI-05204, a supercritical CO₂ extract of Nerium oleander, inhibits growth of human pancreatic cancer via targeting the PI3K/mTOR pathway.
Topics: Animals; Cardiac Glycosides; Cell Cycle; Cell Line, Tumor; Class Ib Phosphatidylinositol 3-Kinase; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Nerium; Pancreatic Neoplasms; Plant Extracts; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2015 |
Two-dimensional culture of human pancreatic adenocarcinoma cells results in an irreversible transition from epithelial to mesenchymal phenotype.
Topics: Animals; Blotting, Western; Cell Culture Techniques; Cell Cycle; Cell Proliferation; Colony-Forming Units Assay; Deoxycytidine; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Heterografts; Humans; Immunohistochemistry; Mice; Neoplasm Invasiveness; Pancreatic Neoplasms; Phenotype; Protein Array Analysis; Proteomics; Tumor Cells, Cultured | 2015 |
Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Chromatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Pancreatic Neoplasms; Phenotype | 2015 |
Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; In Vitro Techniques; Lactic Acid; Microscopy, Confocal; Microscopy, Electron, Scanning; Nanospheres; Pancreatic Neoplasms; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2015 |
The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms, Unknown Primary; Prognosis; Slovakia; Survival Analysis; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2014 |
Gemcitabine and vinorelbine treatment in cutaneous T-cell lymphoma in four patients.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Male; Retreatment; Skin Neoplasms; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; E2F1 Transcription Factor; Gemcitabine; Humans; Hydrolases; Mice, Nude; Pancreatic Neoplasms; Polyethylene Glycols; Ribonucleoside Diphosphate Reductase; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2014 |
Hispidulin inhibits proliferation and enhances chemosensitivity of gallbladder cancer cells by targeting HIF-1α.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Flavones; Fluorouracil; G1 Phase Cell Cycle Checkpoints; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Inbred BALB C; Mice, Nude; Signal Transduction; Transcriptional Activation; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cytidine; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; HCT116 Cells; HT29 Cells; Humans; Mice; Mice, Nude; Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Congestive heart failure secondary to gemcitabine nab-paclitaxel in patients with pancreatic cancer.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diuretics; Female; Gemcitabine; Heart Failure; Humans; Paclitaxel; Pancreatic Neoplasms | 2014 |
Quality of life in advanced non-small cell lung cancer receiving chemotherapy of platinum combination in old versus new standard chemotherapy regimen.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Disease-Free Survival; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Prospective Studies; Quality of Life | 2014 |
Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice.
Topics: Antineoplastic Agents; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Health Surveys; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Treatment Outcome; United Kingdom; Urinary Bladder Neoplasms | 2015 |
The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Matrix Metalloproteinase 13; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mucin-1; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2015 |
Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Berberine; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Flow Cytometry; G1 Phase; Gemcitabine; Humans; Pancreatic Neoplasms; Reactive Oxygen Species; Time Factors | 2015 |
Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Mass Spectrometry; Pancreatic Neoplasms; Proteomics | 2014 |
Interactions of multitargeted kinase inhibitors and nucleoside drugs: Achilles heel of combination therapy?
Topics: Axitinib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Nucleoside Transport Proteins; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib | 2015 |
Characterization of Anthropometric Changes that Occur During Neoadjuvant Therapy for Potentially Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Weight; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Deoxycytidine; Follow-Up Studies; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia; Survival Rate | 2015 |
Prognostic factors and adjuvant treatments for surgically treated cancers of the biliary tract: a multicentre study of the Anatolian Society of Medical Oncology (ASMO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemoradiotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2014 |
Novel SNP improves differential survivability and mortality in non-small cell lung cancer patients.
Topics: Active Transport, Cell Nucleus; Adult; Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Computational Biology; Deoxycytidine; DNA Polymerase I; Female; Gemcitabine; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Models, Molecular; Mutation; Polymorphism, Single Nucleotide; Prognosis; Protein Conformation; Survival Analysis | 2014 |
Can thymidine phosphorylase be a predictive marker for gemcitabine and doxifluridine combination chemotherapy in cholangiocarcinoma?: case series.
Topics: Adult; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Therapy, Combination; Fatal Outcome; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Middle Aged; Thymidine Phosphorylase; Tomography, X-Ray Computed | 2014 |
Nintedanib, a triple angiokinase inhibitor, enhances cytotoxic therapy response in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Indoles; Neoplasms, Experimental; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2015 |
Mechanisms of Overcoming Intrinsic Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma through the Redox Modulation.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutathione; Humans; Isothiocyanates; Mice; Mice, Inbred NOD; Mice, SCID; NF-E2-Related Factor 2; NF-kappa B; Oxidation-Reduction; Pancreatic Neoplasms; Reactive Oxygen Species; RNA Interference; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
[Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Blood Urea Nitrogen; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Logistic Models; Male; Middle Aged; Neoplasm Staging; Odds Ratio; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Sex Factors; Survival Rate | 2014 |
Tubulocystic carcinoma of the kidney with fatal outcome in an adolescent male.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Male; Nephrectomy; Pleural Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Time Factors; Treatment Outcome | 2015 |
A bioengineered murine model using CD24⁺CD44⁺ pancreatic cancer stem cells for chemotherapy study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomedical Engineering; Camptothecin; CD24 Antigen; Cell Proliferation; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Irinotecan; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Tissue Scaffolds | 2014 |
Onconase induces autophagy sensitizing pancreatic cancer cells to gemcitabine and activates Akt/mTOR pathway in a ROS-dependent manner.
Topics: Adenocarcinoma; Antineoplastic Agents; Autophagy; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Oncogene Protein v-akt; Pancreatic Neoplasms; Reactive Oxygen Species; Ribonucleases; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation | 2015 |
Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Death; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Gemcitabine; HMGB1 Protein; Hypoxia-Inducible Factor 1, alpha Subunit; Immunization; Mice, Inbred C57BL; Mice, Nude; Microscopy, Fluorescence; Mustard Compounds; Pancreatic Neoplasms; Phenylpropionates; Phosphorylation; Survival Analysis; T-Lymphocytes; Transcription Factors; Tumor Burden | 2015 |
Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer: inflammation-based prognostic score predicts survival.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Inflammation; Infusions, Intravenous; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Tegafur; Treatment Outcome | 2015 |
KML001 enhances anticancer activity of gemcitabine against pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Arsenites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gemcitabine; Humans; Matrix Metalloproteinase 2; Pancreatic Neoplasms; Sodium Compounds; Vascular Endothelial Growth Factor C | 2015 |
Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cancer Vaccines; Cells, Cultured; Combined Modality Therapy; Cytokines; Dendritic Cells; Deoxycytidine; Female; Gemcitabine; Histocompatibility Antigens Class I; Histocompatibility Antigens Class II; Humans; Lymphocyte Count; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Peptide Fragments; Prognosis; Treatment Outcome; Vaccination; WT1 Proteins | 2015 |
A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Damage; Gemcitabine; Gene Library; Histones; Homologous Recombination; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Rad51 Recombinase; Receptors, Calcitriol; RNA Interference; RNA, Small Interfering; Tumor Suppressor p53-Binding Protein 1 | 2014 |
Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Humans; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Tumor Suppressor Proteins | 2015 |
Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine.
Topics: Cell Line, Tumor; Deoxycytidine; DNA Damage; Enzyme Activation; Floxuridine; Gemcitabine; Humans; Thymidylate Synthase | 2015 |
A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dexamethasone; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Male; Methotrexate; Middle Aged; Neoplasm Staging; Pilot Projects; Prognosis; Young Adult | 2015 |
Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine.
Topics: Animals; Cell Cycle; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Deoxycytidine; DNA-Binding Proteins; Gemcitabine; Humans; Phosphates; Radiation-Sensitizing Agents; Recombinational DNA Repair | 2015 |
Time and concentration dependency of P-gp, MRP1 and MRP5 induction in response to gemcitabine uptake in Capan-2 pancreatic cancer cells.
Topics: Adenosine Triphosphatases; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Death; Cell Line, Tumor; Cell Membrane; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Messenger; Time Factors | 2015 |
Expression of oncogenic HMGN5 increases the sensitivity of prostate cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HMGN Proteins; Humans; Male; MAP Kinase Signaling System; Neoplasm Invasiveness; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Sequence Analysis, DNA; Trans-Activators | 2015 |
Third-line chemotherapy with carboplatin, gemcitabine and liposomised doxorubicin for malignant pleural mesothelioma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Mesothelioma; Middle Aged; Neoplasms, Mesothelial; Pleural Neoplasms; Polyethylene Glycols; Retrospective Studies; Salvage Therapy | 2015 |
A Novel CDC25B Promoter-Based Oncolytic Adenovirus Inhibited Growth of Orthotopic Human Pancreatic Tumors in Different Preclinical Models.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; cdc25 Phosphatases; Cricetinae; Deoxycytidine; Gemcitabine; Humans; Mesocricetus; Mice; Mice, Nude; Oncolytic Virotherapy; Pancreatic Neoplasms; Promoter Regions, Genetic; Xenograft Model Antitumor Assays | 2015 |
Vascular-promoting therapy reduced tumor growth and progression by improving chemotherapy efficacy.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Lewis Lung; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Snake Venoms; Verapamil | 2015 |
Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Lewis Lung; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Snake Venoms; Verapamil | 2015 |
Sirolimus plus gemcitabine: a new therapeutic combination for resistant sarcomas?
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Prognosis; Sarcoma; Sirolimus; TOR Serine-Threonine Kinases | 2015 |
Evaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Gemcitabine; Humans; Isotopes; Mice; Mice, Nude; Peritoneal Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy | 2015 |
Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Preoperative Care; Renal Insufficiency; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Screening analysis of ubiquitin ligases reveals G2E3 as a potential target for chemosensitizing cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Synergism; Gemcitabine; Gene Knockdown Techniques; HCT116 Cells; Histones; Humans; Molecular Targeted Therapy; Neoplasms; Phosphorylation; Protein Kinases; RNA, Small Interfering; Transfection; Ubiquitin-Protein Ligases | 2015 |
Initial safety and efficacy of cisplatin and gemcitabine combination chemotherapy for unresectable biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies | 2014 |
[Outpatient reinduction therapy with gemcitabine, dexamethasone, Cisplatin (GDP) for patients with relapsed and refractory lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Induction Chemotherapy; Lymphoma; Male; Middle Aged; Outpatients; Recurrence | 2015 |
Defective hCNT1 transport contributes to gemcitabine chemoresistance in ovarian cancer subtypes: overcoming transport defects using a nanoparticle approach.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Membrane Transport Proteins; Nanocapsules; Ovarian Neoplasms | 2015 |
Gemcitabine interacts with carbonate apatite with concomitant reduction in particle diameter and enhancement of cytotoxicity in breast cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apatites; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Resistance, Neoplasm; Endocytosis; Female; Gemcitabine; Humans; MCF-7 Cells; Nanoparticles; Particle Size | 2015 |
Irinotecan as a palliative therapy for metastatic breast cancer patients after previous chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Meta-Analysis as Topic; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Salvage Therapy; Survival Rate | 2014 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Autocrine Communication; Cell Line, Tumor; Chemokine CXCL12; Culture Media, Conditioned; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Receptors, CXCR4; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2015 |
Intracellular annexin A2 regulates NF-κB signaling by binding to the p50 subunit: implications for gemcitabine resistance in pancreatic cancer.
Topics: Annexin A2; Calcium; Cell Line, Tumor; Cell Nucleus; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genes, Neoplasm; Humans; Intracellular Space; Pancreatic Neoplasms; Protein Binding; Protein Structure, Tertiary; Protein Subunits; Protein Transport; Signal Transduction; Structure-Activity Relationship; Transcription Factor RelA; Transcription, Genetic; Tumor Necrosis Factor-alpha; Up-Regulation | 2015 |
Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; HSP27 Heat-Shock Proteins; Humans; Male; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreas; Pancreatic Neoplasms; Phosphorylation | 2015 |
Development of gemcitabine-adsorbed magnetic gelatin nanoparticles for targeted drug delivery in lung cancer.
Topics: Animals; Deoxycytidine; Drug Delivery Systems; Gelatin; Gemcitabine; Humans; Lung Neoplasms; Magnetite Nanoparticles | 2016 |
Self-assembled nanoscale coordination polymers carrying oxaliplatin and gemcitabine for synergistic combination therapy of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Liberation; Gemcitabine; Humans; Mice, Nude; Nanoparticles; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polymers; Tumor Burden | 2015 |
Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Patient Selection; Retrospective Studies; Survival Analysis; Urinary Bladder Neoplasms | 2015 |
Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy.
Topics: Animals; Antineoplastic Agents; Bleomycin; Deoxycytidine; Dogs; Electroporation; Female; Gemcitabine; Genetic Therapy; Interleukin-12; Male; Neoplasms; Plasmids; Treatment Outcome | 2015 |
Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Urinary Bladder Neoplasms | 2015 |
Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Synergism; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; NF-kappa B; Random Allocation; Signal Transduction; Triterpenes; Xenograft Model Antitumor Assays | 2015 |
Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms | 2015 |
Drug-induced thrombotic microangiopathy: Experience of the Oklahoma Registry and the BloodCenter of Wisconsin.
Topics: Ambulatory Care Facilities; Antibodies; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Oklahoma; Organoplatinum Compounds; Oxaliplatin; Pentostatin; Purpura, Thrombotic Thrombocytopenic; Quinine; Registries; Thrombotic Microangiopathies; Vancomycin; Wisconsin | 2015 |
Validation of a hydrophilic interaction ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of gemcitabine in human plasma with tetrahydrouridine.
Topics: Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Tandem Mass Spectrometry; Tetrahydrouridine | 2015 |
Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer.
Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Cell Cycle; Cell Proliferation; Cyclin E; Cyclin-Dependent Kinase 2; Cytidine Deaminase; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; MCF-7 Cells; MicroRNAs; Proportional Hazards Models; RNA Interference | 2015 |
[Concurrent chemoradiotherapy for locally advanced unresectable extrahepatic cholangiocarcinoma: a report of 19 cases].
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Survival Rate | 2014 |
Gemcitabine-induced CXCL8 expression counteracts its actions by inducing tumor neovascularization.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Pancreatic Neoplasms; Reactive Oxygen Species; Treatment Outcome; Up-Regulation | 2015 |
BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial Cells; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Male; Mice; Mice, Nude; Neoplasm Proteins; Nuclear Proteins; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Signal Transduction; Transcription Factors; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2015 |
Successful treatment of metastatic urothelial carcinoma arising in a transplanted renal allograft with paclitaxel, cisplatin, and gemcitabine combination therapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Hematuria; Humans; Kidney Transplantation; Lung Neoplasms; Male; Paclitaxel; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
Local iontophoretic administration of cytotoxic therapies to solid tumors.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Dogs; Drug Delivery Systems; Equipment Design; Female; Gemcitabine; Humans; Injections, Intravenous; Iontophoresis; Mice, Inbred BALB C; Neoplasms; Skin; Survival Analysis; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Endoribonucleases; Gemcitabine; Gene Expression; Genetic Variation; Hepatocyte Nuclear Factor 1-alpha; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Protein Serine-Threonine Kinases; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunosuppression Therapy; Killer Cells, Natural; Lung Neoplasms; Male; Middle Aged; T-Lymphocytes, Regulatory | 2015 |
Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Liberation; Drug Resistance, Neoplasm; Endocytosis; Endosomes; Gemcitabine; Humans; Hydrogen-Ion Concentration; Liposomes; Macrophages; Particle Size; Polyethylene Glycols; Rats, Sprague-Dawley; Surface Properties | 2015 |
[Neoadjuvant chemotherapy for urothelial tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoadjuvant Therapy; Preoperative Care; Treatment Outcome; Urologic Neoplasms; Vinblastine | 2014 |
[Management of metastatic bladder cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Neoplasm Staging; Prognosis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2014 |
The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Biomimetic Materials; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; Saponins; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2015 |
Bitter melon juice targets molecular mechanisms underlying gemcitabine resistance in pancreatic cancer cells.
Topics: Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Momordica charantia; Oxygen Consumption; Pancreatic Neoplasms; Plant Extracts | 2015 |
HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer.
Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Coculture Techniques; Culture Media, Conditioned; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Pancreatic Stellate Cells; Prognosis; Proportional Hazards Models; Rats; Receptors, Notch; RNA Interference; RNA, Small Interfering; Signal Transduction; Transcription Factor HES-1 | 2015 |
3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.
Topics: Aged; Aged, 80 and over; Deoxycytidine; Dideoxynucleosides; Female; Gemcitabine; Humans; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Pancreatic Neoplasms; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Tomography, X-Ray Computed | 2015 |
Salvage pancreaticoduodenectomy after complete response to chemoradiotherapy for a previously unresectable pancreatic adenosquamous carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Adenosquamous; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Salvage Therapy | 2015 |
Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Compartmentation; Cell Line, Tumor; Cell Proliferation; Cholesterol; Clone Cells; Deoxycytidine; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lipoproteins; MAP Kinase Signaling System; Metabolic Networks and Pathways; Mice; Pancreatic Neoplasms; Phenotype; Prognosis; Receptors, LDL; Up-Regulation | 2015 |
[Chemo-sensitivity study in pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Pancreatic Neoplasms | 2014 |
Co-delivery of HIF1α siRNA and gemcitabine via biocompatible lipid-polymer hybrid nanoparticles for effective treatment of pancreatic cancer.
Topics: Animals; Biocompatible Materials; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Delivery Systems; Endocytosis; Female; Gemcitabine; Gene Knockdown Techniques; Gene Transfer Techniques; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interferon-alpha; Interleukin-6; Kaplan-Meier Estimate; Lipids; Lysosomes; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polymers; RNA, Small Interfering; Serum; Static Electricity | 2015 |
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; CD40 Antigens; Cell Line, Tumor; Combined Modality Therapy; CTLA-4 Antigen; Deoxycytidine; Female; Gemcitabine; Genetic Engineering; Humans; Immune Tolerance; Immunity, Cellular; Interferon-gamma; Lymphocyte Activation; Mice, Inbred C57BL; Pancreatic Neoplasms; T-Lymphocyte Subsets; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
Prognostic score for recurrence after Whipple's pancreaticoduodenectomy for ampullary carcinomas; results of an AGEO retrospective multicenter cohort.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Health Status; Humans; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Pancreaticoduodenectomy; Retrospective Studies; Risk Assessment; Survival Rate | 2015 |
A linear synthesis of gemcitabine.
Topics: Acylation; Antimetabolites, Antineoplastic; Catalysis; Cyclization; Deoxycytidine; Gemcitabine; Urea | 2015 |
Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Mitomycin; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Predictive role of neutrophil gelatinase-associated lipocalin in early diagnosis of platin-induced renal injury.
Topics: Acute Kidney Injury; Acute-Phase Proteins; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lipocalin-2; Lipocalins; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Proto-Oncogene Proteins; Taxoids | 2015 |
Establishment of a pancreatic cancer stem cell model using the SW1990 human pancreatic cancer cell line in nude mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Piperazine and its carboxylic acid derivatives-functionalized mesoporous silica as nanocarriers for gemcitabine: adsorption and release study.
Topics: Antineoplastic Agents; Carboxylic Acids; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Piperazine; Piperazines; Silicon Dioxide | 2015 |
Efficacy of prophylactic minocycline treatment for skin toxicities induced by erlotinib plus gemcitabine in patients with advanced pancreatic cancer: a retrospective study.
Topics: Acneiform Eruptions; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dermatologic Agents; Drug Eruptions; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Minocycline; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Will targeting Chk1 have a role in the future of cancer therapy?
Topics: Checkpoint Kinase 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasms; Protein Kinases; Pyrazoles; Pyrimidines | 2015 |
Radical Resection of a Primarily Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy Using Gemcitabine, TS-1, and Nafamostat Mesilate; Report of a Case.
Topics: Antimetabolites, Antineoplastic; Benzamidines; Deoxycytidine; Gemcitabine; Guanidines; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Silicates; Titanium; Tomography, X-Ray Computed | 2015 |
Outcome of recurrent uterine papillary serous carcinoma treated with platinum-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Papillary; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Paclitaxel; Retrospective Studies; Survival Rate; Treatment Outcome; Uterine Neoplasms | 2015 |
Repression of Nrf2 enhances antitumor effect of 5-fluorouracil and gemcitabine on cholangiocarcinoma cells.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Knockdown Techniques; Glutamate-Cysteine Ligase; Glutathione S-Transferase pi; Heme Oxygenase-1; Humans; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; RNA, Messenger; RNA, Small Interfering | 2015 |
Gemcitabine + platinum combination chemotherapy in patients with metastatic cancer who suffer from severe and irreversible hepatic impairment: a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Diseases; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Turkey | 2014 |
Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; CD47 Antigen; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Hybridomas; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Mild hyperthermia enhances transport of liposomal gemcitabine and improves in vivo therapeutic response.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Fever; Gemcitabine; Gold; Hyperthermia, Induced; Liposomes; Mice; Nanotubes; Pancreatic Neoplasms | 2015 |
Role of topotecan, vinorelbine, thiotepa and gemcitabine chemotherapy in relapsed/refractory adult acute leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retreatment; Thiotepa; Topotecan; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Identifying microRNA-mRNA regulatory network in gemcitabine-resistant cells derived from human pancreatic cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Messenger; Signal Transduction | 2015 |
Manganoporphyrins and ascorbate enhance gemcitabine cytotoxicity in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Ascorbic Acid; Catalase; Catalysis; Deoxycytidine; Drug Synergism; Fluorescent Antibody Technique; Free Radical Scavengers; Gemcitabine; Histones; Humans; Hydrogen Peroxide; Metalloporphyrins; Mice; Mice, Nude; Oxidation-Reduction; Oxidative Stress; Oxygen Consumption; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Maintenance monotherapy with gemcitabine after standard platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2015 |
[A case of curative resection after downsizing chemotherapy in initially unresectable locally advanced intrahepatic cholangiocarcinoma].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Invasiveness | 2014 |
[A case of initially unresectable pancreatic cancer with arterial invasion successfully resected after chemotherapy].
Topics: Antimetabolites, Antineoplastic; Arteries; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2014 |
[A case of advanced gallbladder cancer with mediastinum lymph node metastasis successfully treated with multimodality therapy].
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Mediastinal Neoplasms; Tegafur; Uracil | 2014 |
[A long term survival case of hilar cholangiocarcinoma with multiple metastases treated with chemotherapy and operation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Catheter Ablation; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Oxonic Acid; Tegafur | 2014 |
[Long-term survivor of unresectable bile duct cancer complicated with sclerosing cholangitis treated with chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans | 2014 |
[A case of curatively resected advanced intrahepatic cholangiocellular carcinoma through effective response to neoadjuvant chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Surgical Procedures; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Hepatectomy; Humans; Male; Neoadjuvant Therapy | 2014 |
[A case of intrahepatic cholangiocarcinoma with peritoneal dissemination treated successfully with surgical resection and adjuvant chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Lymph Node Excision; Oxonic Acid; Peritoneal Neoplasms; Tegafur | 2014 |
[A case of radical resection for pancreatic head cancer with peritoneal dissemination treated with combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Multimodal Imaging; Oxonic Acid; Pancreatic Neoplasms; Peritoneal Neoplasms; Positron-Emission Tomography; Tegafur; Tomography, X-Ray Computed | 2014 |
[A case of locally advanced pancreatic cancer successfully resected after gemcitabine+S-1 therapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur; Treatment Outcome | 2014 |
[A case of resection for a huge pancreatic acinar cell carcinoma with tumor thrombus in the portal vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Acinar Cell; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Prognosis; Tegafur; Thrombosis | 2014 |
[A case report of hepatic arterial infusion chemotherapy and RFA for liver metastasis from pancreatic cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Laser Therapy; Liver Neoplasms; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2014 |
[A case of pancreatic pseudocyst associated with pancreatic cancer successfully treated with endoscopic pseudocyst drainage, which allowed continuation of chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drainage; Endoscopy, Digestive System; Fatal Outcome; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreatic Pseudocyst; Stents | 2014 |
Increased expression of endoplasmic reticulum protein 29 in lung adenocarcinoma is associated with chemosensitivity to gemcitabine.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Heat-Shock Proteins; Humans; Lung Neoplasms; Male; Middle Aged | 2015 |
BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.
Topics: AC133 Antigen; Aged; Antigens, CD; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; BRCA2 Protein; CD24 Antigen; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group D2 Protein; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hyaluronan Receptors; Male; Metabolic Networks and Pathways; Middle Aged; Peptides; Rad51 Recombinase; RNA, Small Interfering | 2015 |
Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Mouth Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA, Messenger; RNA, Small Interfering | 2015 |
[A case of advanced pancreas cancer successfully treated by using combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2015 |
[A case of pleomorphic malignant fibrous histiocytoma with multiple lung metastases with bilateral pneumothorax after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Histiocytoma, Malignant Fibrous; Humans; Lung Neoplasms; Male; Pneumothorax; Taxoids; Treatment Outcome | 2015 |
Anti-mutagenic activity of Salvia merjamie extract against gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antimutagenic Agents; Bone Marrow; Camphanes; Cells, Cultured; Chromosome Aberrations; Deoxycytidine; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Female; Gemcitabine; Male; Mice; Mitosis; Mitotic Index; Panax notoginseng; Salvia miltiorrhiza | 2015 |
Enhanced cellular uptake and intracellular drug controlled release of VESylated gemcitabine prodrug nanocapsules.
Topics: Antineoplastic Agents; Biological Transport; Buffers; Cathepsin B; Cell Line, Tumor; Cell Survival; Cytidine Deaminase; Delayed-Action Preparations; Deoxycytidine; Drug Liberation; Drug Stability; Gemcitabine; Humans; Hydrogen-Ion Concentration; Lysosomes; Microscopy, Electron, Transmission; Nanocapsules; Pancreas; Particle Size; Prodrugs; Tocopherols | 2015 |
Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Europe; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Prospective Studies; Taxoids; Vinblastine; Vinorelbine | 2015 |
Cleaning Efficiencies of Three Cleaning Agents on Four Different Surfaces after Contamination by Gemcitabine and 5-fluorouracile.
Topics: Alcohols; Antineoplastic Agents; Decontamination; Deoxycytidine; Equipment Contamination; Fluorouracil; Gemcitabine; Glass; Occupational Exposure; Polyvinyl Chloride; Stainless Steel; Surface-Active Agents; Water; Wood | 2015 |
Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Cancer Vaccines; Cell Line, Tumor; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; fas Receptor; Female; Gemcitabine; Gene Expression; Gene Silencing; Humans; Immunotherapy; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA Interference; T-Lymphocyte Subsets; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Effect evaluation of cisplatin-gemcitabine combination chemotherapy for advanced non-small cell lung cancer patients using microarray data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Microarray Analysis; Neoadjuvant Therapy | 2015 |
Overexpression of serine/threonine-protein kinase-1 in pancreatic cancer tissue: Serine/threonine-protein kinase-1 knockdown increases the chemosensitivity of pancreatic cancer cells.
Topics: Adult; Aged; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Serine-Threonine Kinases | 2015 |
The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells.
Topics: Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Hep G2 Cells; Humans; Immunohistochemistry; Liver Neoplasms; Lymphokines; MicroRNAs; Molecular Sequence Data; Neoplasm Invasiveness; Nuclear Proteins; Platelet-Derived Growth Factor; Twist-Related Protein 1; Wound Healing | 2015 |
Final analysis of a randomized phase II study with prednisone, vinblastine, doxorubicin, and gemcitabine in patients with early unfavorable Hodgkin lymphoma-PVAG-14 pilot.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Prednisone; Randomized Controlled Trials as Topic; Vinblastine; Young Adult | 2014 |
Molecularly targeted gemcitabine-loaded nanoparticulate system towards the treatment of EGFR overexpressing lung cancer.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; ErbB Receptors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nanoparticles; Particle Size; Treatment Outcome | 2015 |
Use of a lipid-coated mesoporous silica nanoparticle platform for synergistic gemcitabine and paclitaxel delivery to human pancreatic cancer in mice.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Transformation, Neoplastic; Cytidine Deaminase; Deoxycytidine; Drug Carriers; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipid Bilayers; Mice; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Porosity; Silicon Dioxide | 2015 |
Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: a single institutional experience.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Treatment Failure | 2015 |
Safe lipid nanocapsule-based gel technology to target lymph nodes and combat mediastinal metastases from an orthotopic non-small-cell lung cancer model in SCID-CB17 mice.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Humans; Lipids; Lung; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mediastinum; Mice, Nude; Mice, SCID; Nanocapsules | 2015 |
Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer.
Topics: Adult; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Middle Aged; Models, Economic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis; United Kingdom | 2015 |
A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Models, Statistical; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Tegafur; Treatment Outcome | 2015 |
Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Growth Processes; Deoxycytidine; Gemcitabine; Humans; Hyaluronan Receptors; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Recurrence; Xenograft Model Antitumor Assays | 2015 |
Icotinib plus gemcitabine for metastatic pancreatic cancer: a case report.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Crown Ethers; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Molecular Targeted Therapy; Pancreatic Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
[Promotive effect and its molecular mechanism of KLF5 on gemcitabine-induced apoptosis in human lung adenocarcinoma cell line H441].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; fas Receptor; Gemcitabine; Humans; Kruppel-Like Transcription Factors; Lung Neoplasms; Transfection | 2015 |
Three-weekly oxaliplatin combined with gemcitabine and capecitabine in the first-line treatment of patients with advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis | 2015 |
[A three-week regimen of S-1 monotherapy reduced gastrointestinal toxicity and maintained efficacy in patients with gemcitabine-refractory advanced pancreatic cancer].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Female; Gastrointestinal Diseases; Gemcitabine; Humans; Male; Middle Aged; Nausea; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome; Vomiting | 2015 |
Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Outcome Assessment, Health Care; Survival Rate; Urologic Neoplasms | 2015 |
Photochemical tissue penetration via photosensitizer for effective drug penetration in a non-vascular tumor.
Topics: Animals; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Deoxycytidine; Drug Delivery Systems; Fluorescein; Gemcitabine; Light; Male; Materials Testing; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Photochemotherapy; Photosensitizing Agents; Polyurethanes; Singlet Oxygen; Surface Properties | 2015 |
A retrospective clinical study of bevacizumab combined with gemcibabine or paclitaxel in the treatment of recurrent ovarian cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Bevacizumab combined with chemotherapy in the treatment of recurrence or platinum-refractory ovarian cancer: a retrospective study of 37 cases.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Transitional Cell; Cystadenocarcinoma, Serous; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2014 |
Histomorphologic and molecular phenotypes predict gemcitabine response and overall survival in adenocarcinoma of the ampulla of Vater.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Common Bile Duct Neoplasms; Databases, Factual; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Phenotype; Survival Analysis; Tissue Array Analysis | 2015 |
The complex morphology of acute kidney injury with microangiopathic hemolytic anemia and hyposplenism.
Topics: Acute Kidney Injury; Adenocarcinoma, Mucinous; Anemia, Hemolytic; Antimetabolites, Antineoplastic; Blood Cells; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Microscopy; Middle Aged; Pancreatic Neoplasms; Splenectomy | 2015 |
Platelet VEGF and serum TGF-β1 levels predict chemotherapy response in non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Transforming Growth Factor beta; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Severe ischemic colitis after treatment of bile-duct cancer using gemcitabine and cisplatin.
Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Cisplatin; Colitis, Ischemic; Deoxycytidine; Gemcitabine; Humans; Male | 2015 |
Posterior segment toxicity after gemcitabine and docetaxel chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Staging; Neoplasms, Unknown Primary; Photoreceptor Cells, Vertebrate; Sarcoma; Taxoids; Tomography, Optical Coherence; Uveal Diseases; Vision Disorders; Visual Acuity | 2015 |
Genome-wide association study of myelosuppression in non-small-cell lung cancer patients with platinum-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Blood Platelets; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Genome-Wide Association Study; Hemoglobins; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Polymorphism, Single Nucleotide; Taxoids; Vinblastine; Vinorelbine | 2016 |
Full-dose gemcitabine is a more effective chemotherapeutic agent than 5-fluorouracil for concurrent chemoradiotherapy as first-line treatment in locally advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2014 |
Gemcitabine plus nedaplatin as salvage therapy is a favorable option for patients with progressive metastatic urothelial carcinoma after two lines of chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Prognosis; Salvage Therapy; Survival Rate; Urologic Neoplasms | 2015 |
Locally Advanced Intrahepatic Cholangiocarcinoma: Complete Pathologic Response to Neoadjuvant Chemotherapy Followed by Left Hepatic Trisectionectomy and Caudate Lobectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biopsy; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Hepatectomy; Humans; Male; Neoadjuvant Therapy; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
[Therapy in pancreatic cancer - and still it moves along!].
Topics: Albumins; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2015 |
[Cytidine].
Topics: Antineoplastic Agents; Arabinonucleosides; Cytarabine; Cytidine; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2015 |
[Supportive management of cisplatin and gemcitabine combination therapy for advanced biliary tract cancer].
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Neoplasm Staging | 2015 |
[Side effect and supportive care to combination of gemcitabine and cisplatin chemotherapy for the advanced urothelial cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Urologic Neoplasms | 2015 |
Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; India; Insecticide-Treated Bednets; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
The transformation of a nonfunctioning islet cell tumor of the pancreas into a proinsulinoma under conditions of lung metastasis.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Islet Cell; Colectomy; Deoxycytidine; Diazoxide; Disease Progression; Fatal Outcome; Female; Fluorouracil; Gastrectomy; Gemcitabine; Humans; Hypoglycemia; Lung Neoplasms; Mitomycin; Nephrectomy; Octreotide; Pancreatectomy; Pancreatic Neoplasms | 2015 |
Gemcitabine impacts differentially on bladder and kidney cancer cells: distinct modulations in the expression patterns of apoptosis-related microRNAs and BCL2 family genes.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gene Expression; Humans; Kidney Neoplasms; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Urinary Bladder Neoplasms | 2015 |
Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cells, Cultured; Deoxycytidine; Disease Models, Animal; Drug Resistance; Fibroblasts; Gemcitabine; Heterografts; Humans; Mice, Nude; Phosphoproteins; Somatostatin; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Pancreatic Neoplasms; Ribonucleotide Reductases; Tumor Cells, Cultured | 2015 |
Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory Hodgkin lymphoma.
Topics: Adolescent; Adult; Anemia; Antineoplastic Agents; Brentuximab Vedotin; Deoxycytidine; Doxorubicin; Drug Administration Schedule; Drug Hypersensitivity; Female; Gemcitabine; Hodgkin Disease; Humans; Immunoconjugates; Male; Neutropenia; Polyethylene Glycols; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Importance of excision repair cross-complementation group 1 and ribonucleotide reductase M1 as prognostic biomarkers in malignant pleural mesothelioma treated with platinum-based induction chemotherapy followed by surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Glutamates; Guanine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Platinum Compounds; Pleural Neoplasms; Pneumonectomy; Predictive Value of Tests; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Risk Factors; Time Factors; Tissue Array Analysis; Treatment Outcome; Tumor Suppressor Proteins | 2015 |
Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Apoptosis; Benzopyrans; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Combined effect of microRNA, nutraceuticals and drug on pancreatic cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Benzoquinones; Betulinic Acid; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dietary Supplements; Drug Synergism; Gemcitabine; Humans; MicroRNAs; Pancreas; Pancreatic Neoplasms; Pentacyclic Triterpenes; Transfection; Triterpenes | 2015 |
SIRT1 inhibition in pancreatic cancer models: contrasting effects in vitro and in vivo.
Topics: Animals; Apoptosis; Carbazoles; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Deoxycytidine; Disease Models, Animal; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Male; Mice; Micronucleus Tests; Pancreatic Neoplasms; Sirtuin 1 | 2015 |
Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Deoxycytidine; Eligibility Determination; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Pancreatic Neoplasms | 2017 |
p85α is a microRNA target and affects chemosensitivity in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Class Ia Phosphatidylinositol 3-Kinase; Deoxycytidine; Gemcitabine; HEK293 Cells; Humans; MicroRNAs; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt | 2015 |
Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
Topics: Antineoplastic Agents; Apoptosis; Benzylamines; Bile Ducts; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclams; Deoxycytidine; Drug Synergism; Epithelial Cells; Gallbladder; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Receptors, CXCR4; Signal Transduction | 2015 |
Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chick Embryo; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cells.
Topics: Albumins; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Pancreatic Neoplasms | 2015 |
δ-tocotrienol induces human bladder cancer cell growth arrest, apoptosis and chemosensitization through inhibition of STAT3 pathway.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Protein-Tyrosine Kinases; Signal Transduction; STAT3 Transcription Factor; Urinary Bladder Neoplasms; Vitamin E | 2015 |
Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo.
Topics: Animals; Carbon; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemoradiotherapy; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; Heavy Ion Radiotherapy; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Pancreatic Neoplasms; Transcriptome; Xenograft Model Antitumor Assays | 2015 |
Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Cytarabine; Cytidine Deaminase; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Inactivation, Metabolic; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide | 2015 |
Fucosylation is a common glycosylation type in pancreatic cancer stem cell-like phenotypes.
Topics: Antimetabolites, Antineoplastic; CD24 Antigen; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fucose; Fucosyltransferases; Galactoside 2-alpha-L-fucosyltransferase; Gemcitabine; Glycosylation; Humans; Hyaluronan Receptors; Neoplastic Stem Cells; Pancreatic Neoplasms; RNA Interference; Spheroids, Cellular; Transfection | 2015 |
[Efficacy of neoadjuvant chemotherapy for pancreatic carcinoma planned resection].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
[FOLFIRINOX, nab-paclitaxel + gemcitabine].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms | 2015 |
[hENT1, dCK, RRM, WFA-MY.1E12].
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Early Detection of Cancer; Gemcitabine; Humans; Prognosis | 2015 |
[Current status and future directions in chemotherapy for biliary tract carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Molecular Targeted Therapy | 2015 |
IMP-GMP specific cytosolic 5'-nucleotidase regulates nucleotide pool and prodrug metabolism.
Topics: 5'-Nucleotidase; Antineoplastic Agents; Cell Survival; Cytarabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance; Gemcitabine; Green Fluorescent Proteins; Guanosine Monophosphate; HEK293 Cells; Humans; Immunoblotting; Inosine Monophosphate; Nucleotides; Phosphorylation; Prodrugs; Substrate Specificity; Vidarabine | 2015 |
Salvage therapy with gemcitabine, vinorelbine, and pegylated liposomal doxorubicin for relapsed or refractory pediatric Hodgkin lymphoma. Results of a retrospective series of four children.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Neoplasm Recurrence, Local; Polyethylene Glycols; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Metformin; Molecular Chaperones; Pancreatic Neoplasms; Phosphorylation | 2015 |
Anticancer drug detection using a highly sensitive molecularly imprinted electrochemical sensor based on an electropolymerized microporous metal organic framework.
Topics: Aniline Compounds; Antimetabolites, Antineoplastic; Biosensing Techniques; Deoxycytidine; Electrochemical Techniques; Electrodes; Gemcitabine; Gold; Graphite; Humans; Metal Nanoparticles; Molecular Imprinting; Polymers; Reproducibility of Results; Sulfhydryl Compounds | 2015 |
[Nab-paclitaxel use in pancreatic cancer: practical aspects and consequences in a French oncology day-care unit].
Topics: Adenocarcinoma; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2015 |
Gemcitabine, navelbine, and doxorubicin as treatment for patients with refractory or relapsed T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Middle Aged; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2015 |
Gemcitabine/dexamethasone/cisplatin vs cytarabine/dexamethasone/cisplatin for relapsed or refractory aggressive-histology lymphoma: cost-utility analysis of NCIC CTG LY.12.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Cisplatin; Clinical Trials as Topic; Cost Savings; Cost-Benefit Analysis; Cytarabine; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hospital Charges; Hospital Costs; Humans; Lymphoma; Male; Middle Aged; Quality-Adjusted Life Years; Recurrence | 2015 |
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Multicenter Studies as Topic; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
Regioselective chemical and rapid enzymatic synthesis of a novel redox – Antiproliferative molecular hybrid.
Topics: Antineoplastic Agents; Biocatalysis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Enzymes, Immobilized; Fungal Proteins; Gemcitabine; Humans; Lipase; Molecular Structure; Oxidation-Reduction; Stereoisomerism; Structure-Activity Relationship | 2015 |
Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glycoproteins; Glycosylation; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polysaccharides; Prognosis; Retrospective Studies; Survival Analysis | 2015 |
MGMT inhibition suppresses survivin expression in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Deoxycytidine; DNA Modification Methylases; DNA Repair Enzymes; Down-Regulation; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine; Humans; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Random Allocation; RNA Interference; Survivin; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2015 |
pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Tumor Cells, Cultured | 2015 |
Gemcitabine Plus Nab-Paclitaxel as Second-Line and Beyond Treatment for Metastatic Pancreatic Cancer: a Single Institution Retrospective Analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Targeting cMET with INC280 impairs tumour growth and improves efficacy of gemcitabine in a pancreatic cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mice; Molecular Targeted Therapy; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Signal Transduction; Triazines; Xenograft Model Antitumor Assays | 2015 |
Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101).
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gossypol; Humans; Membrane Proteins; Peptide Fragments; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Urinary Bladder Neoplasms | 2015 |
Nanoparticle albumin-bound-paclitaxel: a limited improvement under the current therapeutic paradigm of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Paclitaxel; Pancreatic Neoplasms | 2015 |
The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells.
Topics: Activins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Self Renewal; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p57; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Mice; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; Nodal Protein; Pancreatic Neoplasms; RNA, Long Noncoding; Signal Transduction; T-Box Domain Proteins; Transcriptome; Transforming Growth Factor beta1 | 2015 |
Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD40 Antigens; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Immunohistochemistry; Immunotherapy; Macrophages; Mice; Pancreatic Neoplasms | 2015 |
The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Long Noncoding; Survival Analysis | 2015 |
Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate | 2015 |
The oncogenic receptor ErbB2 modulates gemcitabine and irinotecan/SN-38 chemoresistance of human pancreatic cancer cells via hCNT1 transporter and multidrug-resistance associated protein MRP-2.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Death; Cell Line, Tumor; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Irinotecan; Male; Membrane Transport Proteins; Mice, SCID; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Receptor, ErbB-2; RNA Interference; RNA, Messenger; Signal Transduction; Transfection; Xenograft Model Antitumor Assays | 2015 |
Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Hyaluronan Receptors; Nanoparticles; Paclitaxel | 2015 |
Pancreatectomy with major arterial resection after neoadjuvant chemoradiotherapy gemcitabine and S-1 and concurrent radiotherapy for locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Vascular Neoplasms | 2015 |
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; France; Gemcitabine; Health Resources; Hospice Care; Humans; Irinotecan; Leucovorin; Long-Term Care; Male; Middle Aged; Molecular Targeted Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Practice Patterns, Physicians'; Retreatment; Retrospective Studies; United Kingdom | 2015 |
Ampulla of Vater carcinoma in real-world clinical practice: a case series.
Topics: Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Carcinoma; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organ Sparing Treatments; Organoplatinum Compounds; Pancreaticoduodenectomy; Pylorus; Retrospective Studies; Treatment Outcome | 2015 |
Pachymic acid inhibits growth and induces apoptosis of pancreatic cancer in vitro and in vivo by targeting ER stress.
Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Mice; Mice, Nude; Pancreas; Pancreatic Neoplasms; Poria; Regulatory Factor X Transcription Factors; Signal Transduction; Taurochenodeoxycholic Acid; Transcription Factor CHOP; Transcription Factors; Triterpenes; Unfolded Protein Response; X-Box Binding Protein 1; Xenograft Model Antitumor Assays | 2015 |
Increased B7H4 tissue expression correlates with high CA19.9 serum levels and a worse prognosis of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Serum; Survival Analysis; Treatment Outcome; V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 2016 |
Integrin β1, Osmosensing, and Chemoresistance in Mouse Ehrlich Carcinoma Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Ehrlich Tumor; Caspases; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Size; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Fibronectins; Gemcitabine; Integrin beta1; Mice; Osmosis; Taurine | 2015 |
Gemcitabine plus vinorelbine as the second-line treatment and beyond in elderly patients with platinum-pretreated advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Platinum Compounds; Retrospective Studies; Survival Rate; Treatment Outcome; Vinblastine; Vinorelbine | 2014 |
Optimal indication of neoadjuvant chemoradiotherapy for pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Pancreatic Neoplasms; Preoperative Period; Prognosis; Retrospective Studies | 2015 |
Cytoreductive Surgery for Pancreatic Cancer Improves Overall Outcome of Gemcitabine-Based Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Matched-Pair Analysis; Middle Aged; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2015 |
Non small cell carcinoma of lung with metachronous breast metastasis and cardiac tamponade: Unusual presentation of a common cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasms, Second Primary; Quinazolines; Radiography | 2015 |
Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; Gemcitabine; Humans; Hydrazines; Mice, Nude; Microscopy, Confocal; Pancreatic Neoplasms; Triazoles; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
A Validated Prediction Model for Overall Survival From Stage III Non-Small Cell Lung Cancer: Toward Survival Prediction for Individual Patients.
Topics: Age Factors; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Nomograms; Probability; Radiotherapy Dosage; Regression Analysis; Severity of Illness Index; Sex Factors; Vinblastine; Vinorelbine | 2015 |
Combined treatment with tamoxifen and a fusicoccin derivative (ISIR-042) to overcome resistance to therapy and to enhance the antitumor activity of 5-fluorouracil and gemcitabine in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diterpenes; Drug Resistance, Neoplasm; Drug Synergism; Female; Fluorouracil; Gemcitabine; Glycosides; Humans; Lipid Peroxidation; Mice; Mice, Nude; Pancreatic Neoplasms; Tamoxifen; Xenograft Model Antitumor Assays | 2015 |
The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Histones; Humans; Pancreatic Neoplasms; Valproic Acid | 2015 |
Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; MCF-7 Cells; MicroRNAs; Mutation; Neoplasms; Paclitaxel; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Ribonucleoside Diphosphate Reductase; Signal Transduction; Transfection; Tubulin | 2015 |
[Safety and efficacy evaluation of gemcitabine combined with oxaliplatin for the treatment of patients with lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Organoplatinum Compounds; Oxaliplatin | 2015 |
Chemotherapy-Derived Inflammatory Responses Accelerate the Formation of Immunosuppressive Myeloid Cells in the Tissue Microenvironment of Human Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; HeLa Cells; Humans; Lymphocyte Activation; MAP Kinase Signaling System; Monocytes; Myeloid Cells; NF-kappa B; Pancreatic Neoplasms; T-Lymphocytes; Tissue Array Analysis; Tumor Microenvironment | 2015 |
Homology modelling and molecular docking of MDR1 with chemotherapeutic agents in non-small cell lung cancer.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Binding Sites; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Mice; Molecular Docking Simulation; Molecular Sequence Data; Paclitaxel; Sequence Alignment; Structural Homology, Protein; Taxoids; Thermodynamics | 2015 |
Gemcitabine Induces Radiosensitization Through Inhibition of RAD51-dependent Repair for DNA Double-strand Breaks.
Topics: Cell Line, Tumor; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Repair; Gamma Rays; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents | 2015 |
Recurrence 11 years after complete response to gemcitabine, 5-Fluorouracil, and Cisplatin chemotherapy followed by radiotherapy in a patient with advanced pancreatic cancer: a case report.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2015 |
Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Signal Transduction | 2015 |
Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Chemistry, Pharmaceutical; Chromatography, Gel; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Combinations; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice, Inbred BALB C; Pemetrexed; Pinocytosis; Polyethylene Glycols; Proton Magnetic Resonance Spectroscopy; Spectroscopy, Fourier Transform Infrared; Technology, Pharmaceutical | 2015 |
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Ifosfamide; Kaplan-Meier Estimate; Male; Middle Aged; Mitomycin; Neoadjuvant Therapy; Paclitaxel; Perioperative Care; Retrospective Studies; Urethra; Urethral Neoplasms; Urinary Diversion | 2015 |
Gemcitabine triggers angiogenesis-promoting molecular signals in pancreatic cancer cells: Therapeutic implications.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endothelial Cells; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Pancreatic Neoplasms; Signal Transduction; Survival Analysis; Tumor Microenvironment | 2015 |
MicroRNA-33a-mediated downregulation of Pim-3 kinase expression renders human pancreatic cancer cells sensitivity to gemcitabine.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Deoxycytidine; Down-Regulation; Gemcitabine; Genes, Tumor Suppressor; Humans; MicroRNAs; Middle Aged; Prognosis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Signal Transduction; Treatment Outcome | 2015 |
Estimation of Tumor Size Evolution Using Particle Filters.
Topics: Algorithms; Antimetabolites, Antineoplastic; Computer Simulation; Deoxycytidine; Diagnosis, Computer-Assisted; Gemcitabine; Half-Life; Humans; Models, Biological; Monte Carlo Method; Neoplasms; Tumor Burden | 2015 |
[Sequential Treatment of Advanced Squamous Lung Cancer:
First-line Gemcitabine +/- platinum Followed by Second-line Taxanes +/- platinum Versus Reverse Sequence].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids | 2015 |
Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine.
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Maytansine; MCF-7 Cells; Paclitaxel; Receptor, ErbB-2; Trastuzumab; Up-Regulation | 2015 |
[A case of stage IV b pancreatic head cancer that was resected because of a good response to chemotherapy].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Fatal Outcome; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
Neurotensin branched peptide as a tumor-targeting agent for human bladder cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Cell Death; Cell Line, Tumor; Deoxycytidine; Endocytosis; Female; Fluorescence; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neurotensin; Protein Binding; Urinary Bladder Neoplasms | 2015 |
Sensitization of Radiation or Gemcitabine-Based Chemoradiation Therapeutic Effect by Nimotuzumab in Pancreatic Cancer Cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2016 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Models, Economic; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Spain | 2015 |
Use of Adjuvant Cisplatin-Based Versus Carboplatin-Based Chemotherapy in Non-Small-Cell Lung Cancer: Findings From the Florida Initiative for Quality Cancer Care.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Etoposide; Female; Florida; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Audit; Middle Aged; Paclitaxel; Pneumonectomy; Practice Patterns, Physicians'; Quality of Health Care; Taxoids; Time Factors; Vinblastine; Vinorelbine | 2015 |
Multidisciplinary management of pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2015 |
Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells.
Topics: AC133 Antigen; Antigens, CD; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glycoproteins; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Peptides; Snail Family Transcription Factors; Transcription Factors | 2015 |
Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness.
Topics: Bile Duct Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Paclitaxel | 2015 |
Gemcitabine plus split-dose cisplatin could be a promising alternative to gemcitabine plus carboplatin for cisplatin-unfit patients with advanced urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Urologic Neoplasms | 2015 |
A case of metastatic renal cell carcinoma and bile duct carcinoma treated with a combination of sunitinib and gemcitabine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Renal Cell; Cholangiopancreatography, Magnetic Resonance; Deoxycytidine; Female; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Neoplasms, Second Primary; Polymorphism, Single Nucleotide; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; BRCA1 Protein; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Paclitaxel; Prognosis; Survival Analysis; Treatment Outcome | 2015 |
[Nab-Paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma: experience of use].
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Creatinine; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Urologic Neoplasms | 2015 |
PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
Topics: Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Caspase 8; Caspase 9; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Histones; Humans; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; S Phase | 2015 |
Association of TERT Polymorphisms with Clinical Outcome of Non-Small Cell Lung Cancer Patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Polymorphism, Single Nucleotide; Prognosis; Survival Analysis; Telomerase; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Biocompatible Glycopolymer Nanocapsules via Inverse Miniemulsion Periphery RAFT Polymerization for the Delivery of Gemcitabine.
Topics: Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Hydrophobic and Hydrophilic Interactions; Nanocapsules; Particle Size; Polymers | 2015 |
Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Genotype; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Response Evaluation Criteria in Solid Tumors; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2015 |
In vitro Study of the Antagonistic Effect of Low-dose Liquiritigenin on Gemcitabine-induced Capillary Leak Syndrome in Pancreatic Adenocarcinoma via Inhibiting ROS- Mediated Signalling Pathways.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Capillary Leak Syndrome; Cell Line, Tumor; Cell Survival; Deoxycytidine; Electric Impedance; Flavanones; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; In Vitro Techniques; Intercellular Adhesion Molecule-1; Matrix Metalloproteinase 9; Pancreatic Neoplasms; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; rac1 GTP-Binding Protein; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Tumor Suppressor Protein p53; Vascular Cell Adhesion Molecule-1 | 2015 |
Analysis on clinical characteristics and influencing factors of patients with locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Risk Factors | 2015 |
Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cation Transport Proteins; Cisplatin; Copper-Transporting ATPases; Deoxycytidine; DNA-Binding Proteins; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Glutathione S-Transferase pi; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Taxoids; Vinblastine; Vinorelbine; X-ray Repair Cross Complementing Protein 1 | 2015 |
Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Hepatectomy; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Positron-Emission Tomography; Remission Induction; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2015 |
Retinoic Acid Reduces Stem Cell-Like Features in Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Signal Transduction; Time Factors; Transcription Factors; Tretinoin | 2015 |
Saturable Hepatic Extraction of Gemcitabine Involves Biphasic Uptake Mediated by Nucleoside Transporters Equilibrative Nucleoside Transporter 1 and 2.
Topics: Animals; Binding Sites; Biological Transport; Carrier Proteins; Cell Membrane; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Female; Gemcitabine; Hepatic Artery; Hepatocytes; Humans; Infusion Pumps; Male; Membrane Proteins; Middle Aged; Rats; Rats, Wistar; Thioinosine | 2015 |
Critical Roles of Chemoresistant Effector and Regulatory T Cells in Antitumor Immunity after Lymphodepleting Chemotherapy.
Topics: Adoptive Transfer; Animals; Cisplatin; Cyclophosphamide; Cytotoxins; Deoxycytidine; Drug Resistance; Etoposide; Female; Fibrosarcoma; Gemcitabine; Lymph Nodes; Lymphocyte Depletion; Lymphopenia; Methylcholanthrene; Mice; Mice, Inbred C57BL; Mice, Knockout; Paclitaxel; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Vidarabine; Whole-Body Irradiation | 2015 |
Chemotherapy-associated anemia in patients with lung cancer: an epidemiological, retrospective and multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Transfusion; Bridged-Ring Compounds; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Etoposide; Female; Gemcitabine; Hematinics; Hemoglobins; Humans; Incidence; Iron; Lung Neoplasms; Male; Middle Aged; Observational Studies as Topic; Prevalence; Retrospective Studies; Small Cell Lung Carcinoma; Spain; Taxoids; Vinblastine; Vinorelbine; Young Adult | 2015 |
Trabectedin clinical cases: use according to indication in diverse clinical scenarios.
Topics: Anthracyclines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Contraindications; Dacarbazine; Deoxycytidine; Dioxoles; Female; Femoral Neoplasms; Gemcitabine; Humans; Hysterectomy; Ifosfamide; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Radionuclide Imaging; Remission Induction; Salvage Therapy; Sarcoma; Sarcoma, Synovial; Soft Tissue Neoplasms; Tetrahydroisoquinolines; Thigh; Tomography, X-Ray Computed; Trabectedin; Treatment Outcome; Uterine Neoplasms | 2015 |
Molecular dynamics simulation study of chitosan and gemcitabine as a drug delivery system.
Topics: Antimetabolites, Antineoplastic; Chitosan; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Gemcitabine; Hydrogen-Ion Concentration; Kinetics; Molecular Dynamics Simulation; Thermodynamics; Water | 2015 |
Quercetin Enhances Chemosensitivity to Gemcitabine in Lung Cancer Cells by Inhibiting Heat Shock Protein 70 Expression.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Biomarkers, Pharmacological; Caspases; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation; HSP70 Heat-Shock Proteins; Humans; Lung Neoplasms; Quercetin | 2015 |
Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cohort Studies; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Male; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2015 |
WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Nuclear Proteins; Organoplatinum Compounds; Polymorphism, Genetic; Protein-Tyrosine Kinases | 2015 |
Gemcitabine and oxaliplatin or alkylating agents for neuroendocrine tumors: Comparison of efficacy and search for predictive factors guiding treatment choice.
Topics: Adult; Aged; Aged, 80 and over; Alkylating Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neuroendocrine Tumors; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2015 |
Suppression of Reserve MCM Complexes Chemosensitizes to Gemcitabine and 5-Fluorouracil.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane Permeability; Deoxycytidine; DNA Replication; Etoposide; Fluorouracil; Gemcitabine; Humans; Minichromosome Maintenance Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms | 2015 |
A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Oligopeptides | 2015 |
Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Bilirubin; Biomarkers; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Jaundice; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Patient Selection; Proportional Hazards Models; Retrospective Studies; Risk Factors; Stents; Time Factors; Treatment Outcome; United Kingdom; Young Adult | 2015 |
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Pancreatic Neoplasms; Survival Analysis | 2015 |
Five-year follow-up of concomitant accelerated hypofractionated radiation in advanced squamous cell carcinoma of the buccal mucosa: a retrospective cohort study.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Mouth Mucosa; Mouth Neoplasms; Radiotherapy Dosage; Retrospective Studies; Survival Rate | 2015 |
Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug efficacy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Hypoxia; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Protein-Lysine 6-Oxidase; Treatment Outcome | 2015 |
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cells, Cultured; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gemcitabine; Glutathione; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Protein Folding; Quinuclidines; Random Allocation; Taxoids; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Gemcitabine; Gene Knockdown Techniques; HeLa Cells; Humans; MCF-7 Cells; Mitochondria; Neoplasms; RNA, Small Interfering; Thymidine Kinase; Transfection | 2015 |
[Systemic therapy of soft tissue sarcomas].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2015 |
[Therapeutic activity of gemcitabine in intracranial tumors].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Ehrlich Tumor; Carmustine; Cisplatin; Cyclophosphamide; Deoxycytidine; Gemcitabine; Injections, Intraperitoneal; Male; Mice; Neoplasm Transplantation | 2015 |
Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dexamethasone; Drug Therapy, Combination; Female; Gemcitabine; Granisetron; Humans; Isoquinolines; Kidney Neoplasms; Male; Middle Aged; Morpholines; Nausea; Ondansetron; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vomiting | 2015 |
Natural polysaccharide functionalized gold nanoparticles as biocompatible drug delivery carrier.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Deoxycytidine; Drug Carriers; Drug Screening Assays, Antitumor; Drug Stability; Gemcitabine; Gold; Humans; Karaya Gum; Materials Testing; Metal Nanoparticles; Particle Size; Reactive Oxygen Species | 2015 |
Ki-67 Can Predict the Response to the Gemcitabine, Oxaliplatin And L-asparaginase Regimen (GELOX) and Prognosis in Patients with Nasal Natural Killer/T-cell Lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Staging; Nose Neoplasms; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Circulating endothelial cells for evaluation of tumor response in non-small cell lung cancer patients receiving first-line chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Endothelial Cells; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Paclitaxel; Prospective Studies; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Snail Family Transcription Factors; Transcription Factors; Up-Regulation; Xenograft Model Antitumor Assays; Zidovudine | 2015 |
Pyruvate kinase isoenzyme M2 is a therapeutic target of gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carrier Proteins; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Pancreatic Neoplasms; Phosphorylation; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Tumor Cells, Cultured | 2015 |
miR-33a suppresses the nuclear translocation of β-catenin to enhance gemcitabine sensitivity in human pancreatic cancer cells.
Topics: Apoptosis; beta Catenin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Proteins; Pancreatic Neoplasms; Wnt Signaling Pathway | 2015 |
Establishment and Characterization of Two Novel Human Pancreatic Carcinoma Cell Lines.
Topics: Aged, 80 and over; Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mutation; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; ras Proteins; RNA, Messenger; Tumor Suppressor Protein p53 | 2015 |
High-mobility Group Box 1 and Mitogen-activated Protein Kinase activated Protein Kinase-2 Are Up-regulated in Gemcitabine-resistant Pancreatic Cancer Cells.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGB1 Protein; Humans; Intracellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Up-Regulation | 2015 |
Combination Chemotherapy with Itraconazole for Treating Metastatic Pancreatic Cancer in the Second-line or Additional Setting.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Itraconazole; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
Curative Resection After Gemcitabine, Cisplatin and S-1 Chemotherapy for Initially Unresectable Biliary Duct Cancer: A Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase I as Topic; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Oxonic Acid; Tegafur | 2015 |
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Radiography; Retrospective Studies; Treatment Outcome | 2015 |
Pancreatic Adenocarcinoma Treated With Irreversible Electroporation Case Report: First Experience and Outcome.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Electrochemotherapy; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2015 |
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Disease Progression; Duodenal Ulcer; Erlotinib Hydrochloride; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Intensity-Modulated; Retrospective Studies; Thrombocytopenia; Treatment Outcome | 2016 |
EMX2 Is a Predictive Marker for Adjuvant Chemotherapy in Lung Squamous Cell Carcinomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Movement; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pneumonectomy; Prognosis; RNA Interference; RNA, Small Interfering; Transcription Factors; Vinblastine; Vinorelbine | 2015 |
Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Exons; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Pemetrexed; Quinazolines; Receptor, ErbB-2; Trastuzumab; Vinblastine; Vinorelbine | 2015 |
Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2015 |
CHK1 Inhibition Synergizes with Gemcitabine Initially by Destabilizing the DNA Replication Apparatus.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA Replication; Drug Synergism; G2 Phase; Gemcitabine; Humans; Mitosis; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Tumor Suppressor Protein p53 | 2015 |
Molecular self-assembly of amphiphilic cyclic phosphoryl gemcitabine with different N-fatty acyl tails and enhanced anticancer effects of the self-assembled nanostructures.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Hep G2 Cells; Humans; Microscopy, Electron, Transmission; Nanostructures | 2015 |
Comparison of bevacizumab alone or with chemotherapy in recurrent ovarian cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Doxorubicin; Fallopian Tube Neoplasms; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Polyethylene Glycols; Radiography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate; Taxoids; Topotecan; Young Adult | 2015 |
Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hemoglobins; Humans; Lung Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Staging; Prognosis; Taxoids; Treatment Outcome | 2015 |
1‑O‑acetylbritannilactone combined with gemcitabine elicits growth inhibition and apoptosis in A549 human non‑small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Combinations; Drug Synergism; Epithelial Cells; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Proteins; Lactones; NF-kappa B; NF-KappaB Inhibitor alpha; Proto-Oncogene Proteins c-bcl-2; Respiratory Mucosa; Signal Transduction | 2015 |
The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer.
Topics: Antineoplastic Agents; Deoxycytidine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Humans; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Reoviridae | 2015 |
Development and evaluation of folate functionalized albumin nanoparticles for targeted delivery of gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Folic Acid; Gemcitabine; Hemolysis; Humans; Male; Mice; Nanoparticles; Serum Albumin, Bovine | 2015 |
miR-15b promotes epithelial-mesenchymal transition by inhibiting SMURF2 in pancreatic cancer.
Topics: Cell Line; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Metastasis; Pancreatic Neoplasms; Promoter Regions, Genetic; Transforming Growth Factor beta; Ubiquitin-Protein Ligases | 2015 |
Consensus conference on hilar cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biopsy; Cholangiopancreatography, Endoscopic Retrograde; Cisplatin; Deoxycytidine; Embolization, Therapeutic; Gemcitabine; Humans; Klatskin Tumor; Liver Transplantation; Magnetic Resonance Imaging; Neoplasm Staging; Portal Vein; Tomography, Spiral Computed; Treatment Outcome | 2015 |
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2014 |
Clinical Significance of Adjuvant Surgical Resection for Initially Unresectable Pancreatic Cancer Responsive to Arterial Infusion Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Survival Analysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
Topics: Animals; Antimetabolites, Antineoplastic; Cattle; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Culture Media; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fasting; Female; Fetal Blood; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Mice, Nude; Microscopy, Fluorescence; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Progression of Large Lymphoma Is Significantly Impeded with a Combination of Gemcitabine Chemotherapy and Dendritic Cells Intra-Tumor Vaccination.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Combined Modality Therapy; Cytotoxicity, Immunologic; Dendritic Cells; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Immunotherapy; Injections, Intralesional; Killer Cells, Natural; Lymphoma, B-Cell; Male; Mice; Mice, Inbred BALB C; Myeloid Cells; Survival Analysis; T-Lymphocytes, Cytotoxic; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Uncoupling protein 2 mediates resistance to gemcitabine-induced apoptosis in hepatocellular carcinoma cell lines.
Topics: Apoptosis; Carcinoma, Hepatocellular; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Hep G2 Cells; Humans; Ion Channels; Liver Neoplasms; Mitochondrial Proteins; Neoplasm Proteins; Uncoupling Protein 2 | 2015 |
Neoadjuvant induction dose-dense MVAC for muscle invasive bladder cancer: efficacy and safety compared with classic MVAC and gemcitabine/cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Leiomyosarcoma of the vagina in pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cyclophosphamide; Delayed Diagnosis; Deoxycytidine; Doxorubicin; Fatal Outcome; Female; Gemcitabine; Humans; Leiomyosarcoma; Pregnancy; Pregnancy Complications, Neoplastic; Vaginal Neoplasms; Vincristine | 2015 |
Expression of XB130 in human ductal breast cancer.
Topics: Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Movement; Cell Proliferation; Chi-Square Distribution; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mastectomy; MCF-7 Cells; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Proportional Hazards Models; Risk Factors; RNA Interference; Signal Transduction; Time Factors; Transfection; Treatment Outcome; Up-Regulation | 2015 |
Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Methotrexate; Neoadjuvant Therapy; Risk Assessment; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK.
Topics: Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; DNA Damage; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; Exons; Gallbladder Neoplasms; Gemcitabine; Gene Deletion; Humans; Mutation, Missense | 2015 |
Near-infrared fluorescence heptamethine carbocyanine dyes mediate imaging and targeted drug delivery for human brain tumor.
Topics: Animals; Blood-Brain Barrier; Brain Neoplasms; Carbocyanines; Cell Line, Tumor; Deoxycytidine; Diagnostic Imaging; Drug Delivery Systems; Fluorescent Dyes; Gemcitabine; HEK293 Cells; Humans; Hypoxia; Male; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Organic Anion Transporters; Prostatic Neoplasms; Spectroscopy, Near-Infrared; Xenograft Model Antitumor Assays | 2015 |
[A Patient with Recurrent Ovarian Cancer Who Was Hypersensitive to Carboplatin Exhibited Complete Response to Gemcitabine and Nedaplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Ovarian Neoplasms; Recurrence | 2015 |
Carotid artery inflammation associated with gemcitabine-based therapy: a special report.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteritis; Carotid Arteries; Carotid Artery Diseases; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Taxoids; Tomography, X-Ray Computed; Urinary Bladder Neoplasms; Vasculitis | 2015 |
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Child; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Prognosis; Retroperitoneal Neoplasms; Salvage Therapy; Survival Rate; Testicular Neoplasms; Transplantation, Autologous; Young Adult | 2015 |
Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non-Small Cell Lung Cancer Patient.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Osteoarthritis; Protein Kinase Inhibitors; Pyrazoles; Pyridines | 2015 |
Synergistic antitumor effect of adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase and nucleoside analogs for human breast carcinoma in vitro and in vivo.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Deoxycytidine; Drosophila Proteins; Female; Gemcitabine; Genes, Transgenic, Suicide; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Phosphotransferases (Alcohol Group Acceptor); Time Factors; Transduction, Genetic; Virus Replication; Xenograft Model Antitumor Assays | 2015 |
Distribution of Gemcitabine Is Nearly Homogenous in Two Orthotopic Murine Models of Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Pancreatic Ductal; Cell Division; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Progression; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Specific Pathogen-Free Organisms; Warfarin; Xenograft Model Antitumor Assays | 2015 |
Targeted nuclear factor-kappaB suppression enhances gemcitabine response in human pancreatic tumor cell line murine xenografts.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Humans; I-kappa B Proteins; Male; Mice; Mice, Nude; NF-kappa B; NF-KappaB Inhibitor alpha; Pancreatic Neoplasms; Random Allocation; Xenograft Model Antitumor Assays | 2015 |
OSI-027 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine both in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitory Concentration 50; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice, Inbred BALB C; Mice, Nude; Multiprotein Complexes; Pancreatic Neoplasms; Protein Kinase Inhibitors; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection; Triazines; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Topics: alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Longitudinal Studies; Lung Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Remission Induction; Retroperitoneal Neoplasms; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Testicular Neoplasms; Treatment Outcome | 2015 |
Prognostic value of CA 19-9 kinetics during gemcitabine-based chemotherapy in patients with advanced cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoembryonic Antigen; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Survival Rate | 2016 |
Inhibition of Human Pancreatic Cancer Cell Proliferation by Devil's Club Oplopanax horridus and Its Polyacetylene Bioactive Compound.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Inhibitory Concentration 50; Oplopanax; Paclitaxel; Pancreatic Neoplasms; Plant Extracts; Plant Roots; Polyynes; Signal Transduction | 2015 |
AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; NF-kappa B; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Receptors, Urokinase Plasminogen Activator; Virus Replication; Xenograft Model Antitumor Assays | 2015 |
Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Eukaryotic Initiation Factor-4E; Gemcitabine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Oligonucleotides, Antisense; Osteopontin; Vascular Endothelial Growth Factor A | 2015 |
Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Carriers; Drug Liberation; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Micelles; NIH 3T3 Cells; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Pyrans; Solubility; Surface Properties; Xenograft Model Antitumor Assays | 2015 |
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Knockdown Techniques; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Niacinamide; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Transplantation, Isogeneic; Tumor Burden; Tumor Suppressor Proteins; Ubiquitination | 2015 |
Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; RNA, Messenger; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2015 |
Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells.
Topics: Alternative Splicing; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Pancreatic Neoplasms; Polypyrimidine Tract-Binding Protein; Pyruvate Kinase | 2016 |
Tumor-Targeting Salmonella typhimurium A1-R Arrests a Chemo-Resistant Patient Soft-Tissue Sarcoma in Nude Mice.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Disease Models, Animal; Gemcitabine; Indazoles; Mice; Mice, Nude; Pyrimidines; Salmonella Infections; Salmonella typhimurium; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Downsizing Chemotherapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Patients Treated with Gemcitabine Plus Cisplatin Combination Therapy Followed by Radical Surgery.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Case-Control Studies; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Postoperative Complications; Prognosis; Survival Rate | 2015 |
[A Retrospective Study of Chinese Herbal Medicine Combined with Systemic Chemotherapy and/or Regional Arterial Perfusion for Pancreatic Cancer with Liver Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Complementary Therapies; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Humans; Liver Neoplasms; Pancreatic Neoplasms; Retrospective Studies | 2015 |
Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Progression; Drosophila Proteins; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Nerve Tissue Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Survival Rate; Transcription Factors; Treatment Outcome | 2016 |
The Role of Neoadjuvant Chemoradiation Therapy in Patients With Borderline Resectable Pancreatic Cancer With Isolated Venous Vascular Involvement.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Treatment Outcome; Veins | 2015 |
Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Transcriptome | 2015 |
Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Dipeptides; Gemcitabine; Humans; Indoles; Models, Theoretical; Pancreatic Neoplasms | 2015 |
Triciribine Phosphate Monohydrate, an AKT Inhibitor, Enhances Gemcitabine Activity in Pancreatic Cancer Cells.
Topics: Acenaphthenes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Ribonucleotides; Staining and Labeling; Trypan Blue | 2015 |
The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Urologic Neoplasms; Vinblastine | 2015 |
Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Lung Neoplasms; Male; Mice, Nude; Ribonucleoside Diphosphate Reductase; RNA Interference; RNA, Small Interfering; RNAi Therapeutics; Time Factors; Transfection; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2015 |
Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Collagen; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Molecular Targeted Therapy; Neoplasm Staging; Osteonectin; Pancreatic Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyrimidines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; STAT3 Transcription Factor; Stromal Cells; Time Factors; Transcription Factors; Transfection; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
MicroRNA-200c overexpression inhibits chemoresistance, invasion and colony formation of human pancreatic cancer stem cells.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Transfection; Up-Regulation | 2015 |
Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Survival Analysis | 2016 |
Changing trends in utilization of neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carboplatin; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Lymphatic Metastasis; Lymphatic Vessels; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Renal Insufficiency, Chronic; Retrospective Studies; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2015 |
Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proteomics; Survival Rate; Tandem Mass Spectrometry; Tumor Cells, Cultured | 2015 |
Liquid chromatography/tandem mass spectrometry method for simultaneous quantification of eight endogenous nucleotides and the intracellular gemcitabine metabolite dFdCTP in human peripheral blood mononuclear cells.
Topics: Chromatography, Liquid; Deoxycytidine; Gemcitabine; Humans; Monocytes; Nucleotides; Tandem Mass Spectrometry | 2015 |
The Antipancreatic Cancer Activity of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Imidazoles; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Membrane Proteins; Mice, SCID; Multiprotein Complexes; Pancreatic Neoplasms; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays | 2015 |
Quercetin Mediates β-Catenin in Pancreatic Cancer Stem-Like Cells.
Topics: Antimetabolites, Antineoplastic; Antioxidants; beta Catenin; Biomarkers, Tumor; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Microscopy, Confocal; Neoplastic Stem Cells; Pancreatic Neoplasms; Quercetin; Spheroids, Cellular | 2015 |
Stem cell mobilization chemotherapy with gemcitabine is effective and safe in myeloma patients with bortezomib-induced neurotoxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Polyneuropathies; Transplantation, Autologous; Treatment Outcome | 2016 |
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Topics: 4-Aminopyridine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Checkpoint Kinase 2; Cyclin-Dependent Kinases; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; HT29 Cells; Humans; Irinotecan; Lung Neoplasms; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, Transgenic; Proto-Oncogene Proteins c-myc; Proto-Oncogene Proteins p21(ras); Pyrazines; Xenograft Model Antitumor Assays | 2016 |
Leukemia inhibitory factor protects cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation.
Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Cell Line, Tumor; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Leukemia Inhibitory Factor; Leukemia Inhibitory Factor Receptor alpha Subunit; Microscopy, Fluorescence; Myeloid Cell Leukemia Sequence 1 Protein; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction | 2015 |
Biweekly gemcitabine therapy induces complete remission in cutaneous angiosarcoma resistant to multiple anticancer drugs.
Topics: Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Hemangiosarcoma; Humans; Middle Aged; Remission Induction; Skin Neoplasms | 2015 |
Inclusion of functional information from perfusion SPECT improves predictive value of dose-volume parameters in lung toxicity outcome after radiotherapy for non-small cell lung cancer: A prospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Radiation; Etoposide; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Radiation Pneumonitis; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2015 |
Thiophene-expanded guanosine analogues of Gemcitabine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Guanosine; Humans; Molecular Conformation; Structure-Activity Relationship; Thiophenes | 2015 |
A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Neoplasm Staging; Organoplatinum Compounds; Prognosis | 2015 |
[A Case of Gastrointestinal Metastases of Breast Cancer Effectively Treated with Gemcitabine and Paclitaxel Combination Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Intestinal Obstruction; Middle Aged; Paclitaxel; Stomach Neoplasms | 2015 |
Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Deoxycytidine; Drug Synergism; Estrogen Receptor alpha; Estrogen Receptor beta; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Tamoxifen; Urinary Bladder Neoplasms | 2015 |
Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Cancer Care Facilities; Chemoradiotherapy; Cohort Studies; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Hematologic Diseases; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Radiation Injuries; Radiotherapy, Intensity-Modulated; Regression Analysis; Retrospective Studies; Risk Assessment; Survival Analysis | 2018 |
Systemic Administration of Small Interfering RNA Targeting Human Nestin Inhibits Pancreatic Cancer Cell Proliferation and Metastasis.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotherapy, Adjuvant; Deoxycytidine; Epigenesis, Genetic; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Nestin; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; RNAi Therapeutics; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2016 |
Tumor priming by Apo2L/TRAIL reduces interstitial fluid pressure and enhances efficacy of liposomal gemcitabine in a patient derived xenograft tumor model.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Deoxycytidine; Extracellular Fluid; Gemcitabine; Humans; Liposomes; Mice, SCID; Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2015 |
Chlorambucil gemcitabine conjugate nanomedicine for cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Chlorambucil; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Nanoconjugates; Nanomedicine; Neoplasm Transplantation; Neoplasms | 2015 |
Semi-Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for the Combination Use of Dexamethasone and Gemcitabine in Breast Cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Dexamethasone; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Gemcitabine; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays | 2015 |
Voltage/pH-Driven Mechanized Silica Nanoparticles for the Multimodal Controlled Release of Drugs.
Topics: Calorimetry; Cell Death; Cell Survival; Delayed-Action Preparations; Deoxycytidine; Doxorubicin; Electricity; Gemcitabine; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Nanoparticles; Silicon Dioxide; Spectroscopy, Fourier Transform Infrared | 2015 |
The Effects of HSP27 on Gemcitabine-Resistant Pancreatic Cancer Cell Line Through Snail.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Gemcitabine; HSP27 Heat-Shock Proteins; Humans; MicroRNAs; Pancreatic Neoplasms; RNA Interference; Snail Family Transcription Factors; Transcription Factors | 2015 |
Piceatannol Enhances the Antitumor Efficacy of Gemcitabine in Human A549 Non-Small Cell Lung Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-Associated Death Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Inhibitory Concentration 50; Lung Neoplasms; Stilbenes; Up-Regulation | 2014 |
New mouse xenograft model modulated by tumor-associated fibroblasts for human multi-drug resistance in cancer.
Topics: Actins; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fibroblasts; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; NIH 3T3 Cells; Paclitaxel; Xenograft Model Antitumor Assays | 2015 |
Impact of Smoking on Pancreatic Cancer Patients Receiving Current Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blood Cell Count; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hemoglobins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Smoking; Treatment Outcome | 2015 |
Secreted protein acidic and rich in cysteine enhances the chemosensitivity of pancreatic cancer cells to gemcitabine.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Flow Cytometry; Gemcitabine; Humans; Osteonectin; Pancreatic Neoplasms | 2016 |
Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer.
Topics: AC133 Antigen; Animals; Antigens, CD; Antigens, Ly; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CD24 Antigen; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Gemcitabine; Glycoproteins; Luciferases; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms, Experimental; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Peptides; Phenotype; Proto-Oncogene Proteins p21(ras); Pyrans; Spheroids, Cellular; Staining and Labeling; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2015 |
Acquired Type II von Willebrand Syndrome in Locally Advanced Bladder Cancer Successfully Treated With Intravenous Immunoglobulin and Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Immunoglobulins, Intravenous; Lymphatic Metastasis; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Radiography; Urinary Bladder Neoplasms; von Willebrand Disease, Type 2 | 2016 |
Development and validation of a stability indicating isocratic HPLC method for gemcitabine with application to drug release from poly lactic-co-glycolic acid nanoparticles and enzymatic degradation studies.
Topics: Antimetabolites, Antineoplastic; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Carriers; Drug Liberation; Drug Stability; Drug Storage; Gemcitabine; Lactic Acid; Limit of Detection; Nanoparticles; Oxidation-Reduction; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Time Factors | 2015 |
Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Machine Learning; Paclitaxel; Support Vector Machine | 2016 |
Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome | 2015 |
Preanalytical Stability of Gemcitabine and its Metabolite 2', 2'-Difluoro-2'-Deoxyuridine in Whole Blood-Assessed by Liquid Chromatography Tandem Mass Spectrometry.
Topics: Antimetabolites, Antineoplastic; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Tandem Mass Spectrometry | 2015 |
Codelivery of dual drugs from polymeric micelles for simultaneous targeting of both cancer cells and cancer stem cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Synergism; Female; Gemcitabine; Humans; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Micelles; Neoplastic Stem Cells; Phenformin; Polycarboxylate Cement; Polyethylene Glycols; Urea | 2015 |
Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Exome; Female; Gemcitabine; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Polymorphism, Single Nucleotide; Thrombocytopenia | 2016 |
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Taxoids; Time Factors; Topotecan | 2015 |
Metformin Increases Sensitivity of Pancreatic Cancer Cells to Gemcitabine by Reducing CD133+ Cell Populations and Suppressing ERK/P70S6K Signaling.
Topics: AC133 Antigen; Animals; Antigens, CD; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Gemcitabine; Gene Knockdown Techniques; Glycoproteins; Humans; Metformin; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptides; Phosphorylation; Prognosis; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Gemcitabine-Related Pneumonitis in Pancreas Adenocarcinoma--An Infrequent Event: Elucidation of Risk Factors and Management Implications.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alcohol Drinking; Alcohol-Related Disorders; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort Studies; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Peritoneal Neoplasms; Pneumonia; Retrospective Studies; Risk Factors; Severity of Illness Index; Smoking | 2016 |
DKK3 blocked translocation of β-catenin/EMT induced by hypoxia and improved gemcitabine therapeutic effect in pancreatic cancer Bxpc-3 cell.
Topics: Active Transport, Cell Nucleus; Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; beta Catenin; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Proliferation; Chemokines; Deoxycytidine; DNA Methylation; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Male; Mice, Nude; Microscopy, Confocal; Middle Aged; Pancreatic Neoplasms; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
The flavonoid p-hydroxycinnamic acid exhibits anticancer effects in human pancreatic cancer MIA PaCa-2 cells in vitro: Comparison with gemcitabine.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Coumaric Acids; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Radiation Tolerance; Signal Transduction | 2015 |
Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer.
Topics: Animals; Apoptosis; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Neovascularization, Pathologic; NF-kappa B; Thalidomide; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Cantharidin and norcantharidin impair stemness of pancreatic cancer cells by repressing the β-catenin pathway and strengthen the cytotoxicity of gemcitabine and erlotinib.
Topics: Apoptosis; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Cantharidin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Phosphorylation; Signal Transduction | 2015 |
[EFFICACY OF NEOADJUVANT GEMCITABINE AND CISPLATIN IN THE MANAGEMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA OF THE BLADDER].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle, Skeletal; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Urinary Bladder; Urologic Neoplasms | 2015 |
Preparation of intravenous injection nanoformulation of VESylated gemcitabine by co-assembly with TPGS and its anti-tumor activity in pancreatic tumor-bearing mice.
Topics: alpha-Tocopherol; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Stability; Drug Storage; Female; Gemcitabine; Humans; Injections, Intravenous; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Microscopy, Electron, Transmission; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Prodrugs; Vitamin E | 2015 |
Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Prognosis; ras Proteins; Retrospective Studies; Taxoids | 2015 |
Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Topics: Animals; Anticonvulsants; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Carcinoma; Cell Proliferation; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Epstein-Barr Virus Infections; Ganciclovir; Gemcitabine; Gene Expression Profiling; Herpesvirus 4, Human; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred NOD; Mice, SCID; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Oncolytic Virotherapy; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Valproic Acid; Viral Load; Virus Activation; Xenograft Model Antitumor Assays | 2015 |
Local bacteria affect the efficacy of chemotherapeutic drugs.
Topics: Animals; Antineoplastic Agents; Aziridines; Biotransformation; Cladribine; Colonic Neoplasms; Deoxycytidine; Escherichia coli; Female; Gemcitabine; Injections, Intralesional; Injections, Subcutaneous; Listeria; Mice; Neoplasm Transplantation; Skin; Treatment Outcome; Vidarabine | 2015 |
Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Cytidine Deaminase; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Membrane Transport Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Tumor Suppressor Proteins | 2015 |
[A CASE OF HEPATIC METASTASECTOMY FOR RENAL PELVIS CARCINOMA].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Kidney Neoplasms; Laparoscopy; Liver Neoplasms; Metastasectomy; Nephrectomy; Pelvic Neoplasms; Recurrence | 2015 |
Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Second Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2015 |
Expression of the Stem Cell Factor Nestin in Malignant Pleural Mesothelioma Is Associated with Poor Prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Nestin; Pemetrexed; Platinum; Pleural Neoplasms; Pneumonectomy; Prognosis; Sarcoma; Stem Cell Factor | 2015 |
Downstream mediators of the intratumoral interferon response suppress antitumor immunity, induce gemcitabine resistance and associate with poor survival in human pancreatic cancer.
Topics: Adaptive Immunity; Cell Line, Tumor; Chemokine CXCL10; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; HLA Antigens; Humans; Interferon-gamma; Interferons; Pancreatic Neoplasms; Receptors, CXCR3; Tumor Cells, Cultured; Tumor Microenvironment | 2015 |
Fatal acute cardiac vasculopathy during cisplatin-gemcitabine-bevacizumab (CGB) chemotherapy for advanced urothelial carcinoma.
Topics: Acute Disease; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Heart Diseases; Humans; Male; Urologic Neoplasms; Urothelium | 2016 |
Targeted therapy for Epstein-Barr virus-associated gastric carcinoma using low-dose gemcitabine-induced lytic activation.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Repositioning; Enzyme Induction; Epstein-Barr Virus Infections; Female; Ganciclovir; Gemcitabine; Herpesvirus 4, Human; Humans; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Protein Kinases; RNA Interference; Signal Transduction; Stomach Neoplasms; Thymidine Kinase; Time Factors; Transfection; Tumor Burden; Viral Proteins; Virus Activation; Xenograft Model Antitumor Assays | 2015 |
An Effective and Well Tolerated Strategy of Bladder Preservation Therapy in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.
Topics: Caspases; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Enzyme Activation; Flow Cytometry; Gemcitabine; HCT116 Cells; Histones; Humans; Imidazoles; Immunoblotting; Microscopy, Confocal; Mitosis; Mutation; Nuclear Proteins; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-mdm2; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Suppressor Protein p53 | 2015 |
Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cyclobutanes; Deoxycytidine; Docetaxel; Drug Administration Schedule; Endostatins; Female; Gemcitabine; Humans; Injections, Intravenous; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Perfusion Imaging; Recombinant Proteins; Taxoids; Tomography, Emission-Computed | 2015 |
Downregulation of ASPP2 in pancreatic cancer cells contributes to increased resistance to gemcitabine through autophagy activation.
Topics: Adult; Aged; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Humans; In Vitro Techniques; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Small Interfering | 2015 |
Folate-Conjugated pH-Responsive Nanocarrier Designed for Active Tumor Targeting and Controlled Release of Gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Folic Acid; Gemcitabine; Graphite; Humans; Hydrogen-Ion Concentration; Nanoparticles; Polyethylene Glycols; Silicon Dioxide | 2016 |
A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Biological Assay; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Genes, Reporter; Green Fluorescent Proteins; Humans; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Receptor Protein-Tyrosine Kinases; RGS Proteins | 2015 |
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Killer Cells, Natural; Lung Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Quinazolines | 2015 |
Melatonin overcomes gemcitabine resistance in pancreatic ductal adenocarcinoma by abrogating nuclear factor-κB activation.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Melatonin; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Proteins; NF-kappa B; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Lack of significant intraoperative coagulopathy in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) indicates that epidural anaesthesia is a safe option.
Topics: Adult; Aged; Analgesia, Epidural; Antineoplastic Agents; Blood Coagulation; Cisplatin; Combined Modality Therapy; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Fibrinogen; Gemcitabine; Humans; Hyperthermia, Induced; Integrin beta3; Male; Melphalan; Middle Aged; Mitomycin; Peritoneal Neoplasms; Platelet Count; Platelet Glycoprotein GPIb-IX Complex; Young Adult | 2015 |
Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.
Topics: Aged; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Immunity, Innate; Male; Middle Aged; Neoadjuvant Therapy; NK Cell Lectin-Like Receptor Subfamily K; Pancreas; Pancreatic Neoplasms; Receptors, Antigen, T-Cell, gamma-delta; Receptors, IgG; Signal Transduction; T-Lymphocytes, Cytotoxic | 2017 |
In vitro immunomodulatory properties of gemcitabine alone and in combination with interferon-alpha.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B7-1 Antigen; B7-2 Antigen; CD4-CD8 Ratio; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dendritic Cells; Deoxycytidine; Flow Cytometry; Gemcitabine; Interferon-alpha; Mice, Inbred C57BL; Pancreatic Neoplasms; Spleen; T-Lymphocytes; T-Lymphocytes, Regulatory | 2015 |
Efficient "green" encapsulation of a highly hydrophilic anticancer drug in metal-organic framework nanoparticles.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Crystallization; Deoxycytidine; Drug Liberation; Drug Stability; Drug Storage; Ferric Compounds; Gemcitabine; Humans; Hydrophobic and Hydrophilic Interactions; Metal Nanoparticles; Organometallic Compounds; Pancreatic Neoplasms; Phosphates; Polymers; Prodrugs | 2015 |
Inhalable liposomal dry powder of gemcitabine-HCl: Formulation, in vitro characterization and in vivo studies.
Topics: Aerosols; Cell Line, Tumor; Chemistry, Pharmaceutical; Deoxycytidine; Drug Stability; Dry Powder Inhalers; Gemcitabine; Humans; Liposomes; Solubility | 2015 |
Combinatorial treatment of CD95L and gemcitabine in pancreatic cancer cells induces apoptotic and RIP1-mediated necroptotic cell death network.
Topics: Adenosine Triphosphate; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Fas Ligand Protein; fas Receptor; Gemcitabine; Humans; Necrosis; Nuclear Pore Complex Proteins; Pancreatic Neoplasms; RNA-Binding Proteins; Signal Transduction; Tumor Cells, Cultured | 2015 |
Take-home message in times of crisis: Is it really better to treat with cisplatin & pemetrexed than cisplatin & gemcitabine in first line NSCLC? The power of statistical considerations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Pemetrexed; Treatment Outcome | 2015 |
Blockade of autophagy reduces pancreatic cancer stem cell activity and potentiates the tumoricidal effect of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Tumor Cells, Cultured | 2015 |
A novel assay revealed that ribonucleotide reductase is functionally important for interstrand DNA crosslink repair.
Topics: Antigens, Polyomavirus Transforming; Cell Line, Tumor; Cisplatin; Comet Assay; Deoxycytidine; DNA Repair; DNA Replication; Enzyme Inhibitors; Gemcitabine; Genes, Reporter; HEK293 Cells; Humans; Plasmids; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA Interference; RNA, Small Interfering; Ubiquitination | 2015 |
Tolerability of Gemcitabine Plus Cisplatin for Treatment of Urothelial Cancer in the Elderly Population.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2016 |
[Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2015 |
The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Male; Mice, Nude; Pancreatic Neoplasms; Proteasome Endopeptidase Complex; Proteolysis; Proto-Oncogene Proteins c-met; Receptor, ErbB-3; Retinoids; Signal Transduction; Transcriptional Activation; Tretinoin; Tumor Burden; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2015 |
The magnitude of gonadotoxicity of chemotherapy drugs on ovarian follicles and granulosa cells varies depending upon the category of the drugs and the type of granulosa cells.
Topics: Animals; Anti-Mullerian Hormone; Antineoplastic Agents; Apoptosis; Caspase 3; Cisplatin; Cyclophosphamide; Deoxycytidine; Estradiol; Female; Gemcitabine; Granulosa Cells; Ovarian Follicle; Progesterone; Rats; Rats, Sprague-Dawley | 2015 |
The rational design of a gemcitabine prodrug with AIE-based intracellular light-up characteristics for selective suppression of pancreatic cancer cells.
Topics: Amino Acid Sequence; Antineoplastic Agents; Buthionine Sulfoximine; Cathepsin B; Cell Line, Tumor; Cysteine Proteinase Inhibitors; Deoxycytidine; Dipeptides; Endocytosis; Fluorescent Dyes; Gemcitabine; Glutathione; Humans; Integrin alphaVbeta3; Oxidation-Reduction; Pancreatic Neoplasms; Prodrugs | 2015 |
Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Acetamides; Activating Transcription Factor 4; Animals; Antimetabolites, Antineoplastic; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cyclohexylamines; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Mice, Nude; Neoplasm Proteins; Oxidative Stress; Pancreatic Neoplasms; Protein Biosynthesis; Protein Phosphatase 1; Signal Transduction; Transcriptome; Xenograft Model Antitumor Assays | 2015 |
Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Pancreatic Neoplasms; Transcription Factors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2015 |
Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells.
Topics: Adenocarcinoma; Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Maytansine; Mice; Pancreatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2015 |
Gemcitabine-releasing mesenchymal stromal cells inhibit in vitro proliferation of human pancreatic carcinoma cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Mesenchymal Stem Cells; Paclitaxel; Pancreatic Neoplasms | 2015 |
Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; HEK293 Cells; Humans; Mutation; Promoter Regions, Genetic | 2015 |
[Gemcitabine in Combination with Cisplatin in Patients with Unresectable Advanced or Recurrent Biliary Tract Cancer--A Multicenter Prospective Observational Study in Fukuoka].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Recurrence; Treatment Outcome | 2015 |
Maspin mediates the gemcitabine sensitivity of hormone-independent prostate cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Prostatic Neoplasms, Castration-Resistant; Serpins; Signal Transduction | 2016 |
SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pancreatic Neoplasms; Vorinostat | 2016 |
Interplay Between Gemcitabine and Erlotinib Over Pancreatic Adenocarcinoma Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Drug Interactions; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2016 |
Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate | 2016 |
The MRTF-A/B function as oncogenes in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Trans-Activators; Transcription Factors | 2016 |
IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation.
Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1alpha; Male; Mice; NF-kappa B; Pancreatic Neoplasms; Receptors, Interleukin-1; Xenograft Model Antitumor Assays | 2016 |
Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice; Models, Biological; Mutation; Organoids; Pancreas; Pancreatic Neoplasms; Pluripotent Stem Cells; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; SOX9 Transcription Factor; Tissue Culture Techniques; Tumor Suppressor Protein p53 | 2015 |
Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Cullin Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Matrix Proteins; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2015 |
Active Hexose-correlated Compound Down-regulates Heat Shock Factor 1, a Transcription Factor for HSP27, in Gemcitabine-resistant Human Pancreatic Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gemcitabine; Heat Shock Transcription Factors; Heat-Shock Proteins; HMGB1 Protein; HSP27 Heat-Shock Proteins; Humans; Molecular Chaperones; Pancreatic Neoplasms; Polysaccharides; Transcription Factors; Tumor Cells, Cultured | 2015 |
Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer.
Topics: Aged; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Male; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Prognosis; Sequence Analysis, RNA; Up-Regulation | 2015 |
Predicting the response of patients with advanced urothelial cancer to methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC) after the failure of gemcitabine and platinum (GP).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Platinum; Predictive Value of Tests; Treatment Failure; Urologic Neoplasms; Urothelium; Vinblastine | 2015 |
Design and evaluation of an intravesical delivery system for superficial bladder cancer: preparation of gemcitabine HCl-loaded chitosan-thioglycolic acid nanoparticles and comparison of chitosan/poloxamer gels as carriers.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Chemistry, Pharmaceutical; Chitosan; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Design; Gels; Gemcitabine; Humans; Nanoparticles; Poloxamer; Thioglycolates; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2015 |
The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Biological Availability; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cellular Senescence; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Indoles; Lung Neoplasms; Mice, Nude; Morpholines; Protein Kinase Inhibitors; Pyrimidines; RNA Interference; Sulfonamides; Sulfoxides; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Prognosis; Retrospective Studies; Survival Rate; Vinblastine; Vinorelbine | 2016 |
Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses.
Topics: Animals; Antiviral Agents; Cell Proliferation; Deoxycytidine; Drug Synergism; Enterovirus; Enterovirus A, Human; Enterovirus Infections; Gemcitabine; HEK293 Cells; HeLa Cells; Humans; Replicon; Ribavirin; Vero Cells; Virus Replication | 2015 |
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Case-Control Studies; Clonal Evolution; Deoxycytidine; DNA, Neoplasm; Female; Gemcitabine; Humans; Lapatinib; Liver Neoplasms; Lung Neoplasms; Mutation; Neoplasm Metastasis; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sequence Analysis, DNA; Spinal Neoplasms; Tamoxifen; Trastuzumab | 2015 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
Synergistic Effect of Immunoliposomal Gemcitabine and Bevacizumab in Glioblastoma Stem Cell-Targeted Therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Drug Delivery Systems; Drug Synergism; Gemcitabine; Glioblastoma; Human Umbilical Vein Endothelial Cells; Humans; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Xenograft Model Antitumor Assays | 2015 |
Gemcitabine upregulates ABCG2/BCRP and modulates the intracellular pharmacokinetic profiles of bioluminescence in pancreatic cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzothiazoles; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Intracellular Space; Luciferases, Firefly; Luminescence; Luminescent Measurements; Mitoxantrone; Neoplasm Proteins; Pancreatic Neoplasms; Up-Regulation | 2016 |
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Nucleoside Transport Proteins; Pancreatic Neoplasms; Snail Family Transcription Factors; Survival Analysis; Transcription Factors; Twist-Related Protein 1 | 2015 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies | 2015 |
[The Combination Therapy of Gemcitabine Plus Paclitaxel Induced Complete Response in a Tongue Skin Brain Metastasis of Bladder Carcinoma: A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Skin Neoplasms; Tongue Neoplasms; Urinary Bladder Neoplasms | 2015 |
C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; C-Reactive Protein; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Reproducibility of Results; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden | 2016 |
Metastatic cardiac tumor from urothelial carcinoma detected by transthoracic echocardiography: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Echocardiography; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Male; Multiple Organ Failure; Paclitaxel; Tomography, X-Ray Computed; Treatment Outcome; Urothelium | 2015 |
Sensitivity of Human Intrahepatic Cholangiocarcinoma Subtypes to Chemotherapeutics and Molecular Targeted Agents: A Study on Primary Cell Cultures.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Fluorouracil; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Molecular Targeted Therapy; Mucins; Neoplasm Transplantation; Phthalazines; Pyridines | 2015 |
[Intraperitoneal chemotherapy--a method of improving treatment effectiveness in ovarian cancer].
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Female; Gemcitabine; Infusions, Intravenous; Infusions, Parenteral; Maximum Tolerated Dose; Melphalan; Mitomycin; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Rats; Rats, Wistar; Triazines | 2015 |
YAP overexpression promotes the epithelial-mesenchymal transition and chemoresistance in pancreatic cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Phenotype; Phosphoproteins; Proto-Oncogene Proteins c-akt; Signal Transduction; Transcription Factors; Up-Regulation; YAP-Signaling Proteins | 2016 |
IDO Downregulation Induces Sensitivity to Pemetrexed, Gemcitabine, FK866, and Methoxyamine in Human Cancer Cells.
Topics: Acrylamides; Animals; BRCA2 Protein; Cell Line, Tumor; Clone Cells; Deoxycytidine; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Induction; Floxuridine; Gemcitabine; Gene Knockdown Techniques; Humans; Hydroxylamines; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice, SCID; NAD; Pemetrexed; Piperidines; RNA, Small Interfering; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2015 |
An indeterminate mucin-producing cystic neoplasm containing an undifferentiated carcinoma with osteoclast-like giant cells: a case report of a rare association of pancreatic tumors.
Topics: Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Giant Cells; Humans; Neoplasms, Multiple Primary; Osteoclasts; Pancreatectomy; Pancreatic Neoplasms; Splenectomy; Ultrasonography | 2015 |
Antitumor potential of a synthetic interferon-alpha/PLGF-2 positive charge peptide hybrid molecule in pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Interferon-alpha; Models, Molecular; Pancreatic Neoplasms; Peptides; Placenta Growth Factor; Pregnancy Proteins; Protein Conformation; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT1 Transcription Factor | 2015 |
Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle Proteins; Cell Proliferation; Chemoradiotherapy; Deoxycytidine; DNA Damage; Female; Flow Cytometry; Fluorescent Antibody Technique; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Nuclear Proteins; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Radiation-Sensitizing Agents; Recombinational DNA Repair; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line.
Topics: Animals; Cell Death; Cell Line, Tumor; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; In Situ Nick-End Labeling; Mice, Inbred BALB C; Nanoparticles; Pancreatic Neoplasms; Particle Size; Serum Albumin; Subcutaneous Tissue | 2015 |
Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine resistant urothelial carcinoma cells via suppression of TG-interacting factor.
Topics: Aged; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Hydroxamic Acids; Male; Proto-Oncogene Proteins c-akt; Repressor Proteins; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2016 |
Predictive factors for survival and correlation to toxicity in advanced Stage III non-small cell lung cancer patients with concurrent chemoradiation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Proportional Hazards Models; Radiation Injuries; Radiotherapy, Conformal; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Synergism; Gemcitabine; Humans; Niacinamide; Organoplatinum Compounds; Paclitaxel; Phenylurea Compounds; Pyridines; Radiation Tolerance; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes | 2015 |
[A Long-Term Survival Case of Unresectable Hilar Bile Duct Cancer Treated with Gemcitabine].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiopancreatography, Endoscopic Retrograde; Cholecystectomy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Time Factors; Treatment Outcome | 2015 |
Targeting pancreatic cancer using a combination of gemcitabine with the omega-3 polyunsaturated fatty acid emulsion, Lipidem™.
Topics: Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Deoxycytidine; Fatty Acids, Omega-3; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreatic Stellate Cells; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Receptors, Platelet-Derived Growth Factor | 2016 |
FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Platinum Compounds; Treatment Failure; Treatment Outcome | 2016 |
Pharmacodynamic modeling of combined chemotherapeutic effects predicts synergistic activity of gemcitabine and trabectedin in pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dioxoles; Drug Synergism; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Tetrahydroisoquinolines; Trabectedin | 2016 |
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cluster Analysis; Computational Biology; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Genes, p53; Humans; MicroRNAs; Mutation; Pancreatic Neoplasms; Reproducibility of Results; RNA Interference; RNA, Messenger | 2015 |
Theranostic reduction-sensitive gemcitabine prodrug micelles for near-infrared imaging and pancreatic cancer therapy.
Topics: Animals; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Nude; Micelles; Pancreatic Neoplasms; Prodrugs; Xenograft Model Antitumor Assays | 2016 |
LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Checkpoint Kinase 1; Colonic Neoplasms; Deoxycytidine; DNA Damage; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyrazines; Xenograft Model Antitumor Assays | 2016 |
The high incidence of vascular thromboembolic events in patients with metastatic or unresectable urothelial cancer treated with platinum chemotherapy agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Kidney Neoplasms; Kidney Pelvis; Logistic Models; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Retrospective Studies; Stroke; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Venous Thromboembolism | 2016 |
Comparison of Single Agent Gemcitabine and Docetaxel in Second-Line Therapy for Advanced Stage Non-Small Cell Lung Cancer in a University Hospital in Turkey.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Hospitals, University; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Retrospective Studies; Taxoids; Turkey | 2015 |
EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Carriers; ErbB Receptors; Gemcitabine; Humans; Mice; Micelles; Pancreatic Neoplasms; Peptides; Polyesters; Polyethylene Glycols; Polymers | 2016 |
Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Hepatectomy; Humans; Male; Middle Aged; Treatment Outcome | 2015 |
Chemotherapy with Gemcitabine and Cisplatin for Advanced Ductal Adenocarcinoma of the Prostate: Clinical Courses of Two Patients.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Prostatic Neoplasms | 2015 |
Effects of gemcitabine on radiosensitization, apoptosis, and Bcl-2 and Bax protein expression in human pancreatic cancer xenografts in nude mice.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Cancer drugs can be four times more costly in some wealthy countries than in others.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Australia; Cost of Illness; Deoxycytidine; Developed Countries; Drug Industry; European Union; Gemcitabine; Humans; Neoplasms; New Zealand | 2015 |
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Deoxycytidine; Depsipeptides; Diphtheria Toxin; Disease Progression; Doxorubicin; Electrons; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Incidence; Interleukin-2; Lenalidomide; Lymphoma, T-Cell; Mycosis Fungoides; Pentostatin; Photopheresis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Stem Cell Transplantation; Thalidomide; United States; Vorinostat | 2015 |
[The progress of chemotherapy for advanced pancreatic cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
The effect of PI3K inhibitor LY294002 and gemcitabine hydrochloride combined with ionizing radiation on the formation of vasculogenic mimicry of Panc-1 cells in vitro and in vivo.
Topics: Antineoplastic Agents; Apoptosis; Chromones; Deoxycytidine; Gemcitabine; Humans; Morpholines; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Radiation-Sensitizing Agents; Radiation, Ionizing; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Changes of Lymphocyte Subgroups in Non-Small Cell Lung Cancer Patients Before and During Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; CD28 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cisplatin; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Paclitaxel; Time Factors | 2015 |
Adenovirus-Mediated E2F-1 Gene Transfer Augments Gemcitabine-Induced Apoptosis in Human Colon Cancer Cells.
Topics: Adenoviridae; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Deoxycytidine; DNA Fragmentation; E2F1 Transcription Factor; Gemcitabine; Gene Transfer Techniques; Humans; Inhibitory Concentration 50; Microscopy, Fluorescence; Mutation; Tumor Suppressor Protein p53 | 2015 |
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gemcitabine; Gene Deletion; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Taxoids | 2016 |
Gemcitabine in patients previously treated with platinum-containing chemotherapy for refractory thymic carcinoma: radiographic assessment using the RECIST criteria and the ITMIG recommendations.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Platinum Compounds; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Thymoma; Thymus Neoplasms; Treatment Outcome | 2016 |
The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Proportional Hazards Models; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2016 |
SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway.
Topics: Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Lysosomes; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Sirtuin 1; Thiazoles | 2016 |
EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Gelatin; Gemcitabine; Humans; Mice; Mice, SCID; Nanoparticles; Pancreas; Pancreatic Neoplasms | 2016 |
Do metastatic upper tract urothelial carcinoma and bladder carcinoma have similar clinical responses to systemic chemotherapy? A Japanese multi-institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2016 |
A Potent Chemotherapeutic Strategy with Eg5 Inhibitor against Gemcitabine Resistant Bladder Cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cluster Analysis; Cysteine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Kinesins; Mice, Inbred BALB C; Oligonucleotide Array Sequence Analysis; Reverse Transcriptase Polymerase Chain Reaction; Ribonucleoside Diphosphate Reductase; RNA Interference; Trityl Compounds; Tumor Burden; Tumor Suppressor Proteins; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Gemcitabine and mitomycin induced autophagy regulates cancer stem cell pool in urothelial carcinoma cells.
Topics: Adult; Aged; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Blotting, Western; Carcinoma, Transitional Cell; Deoxycytidine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Male; Middle Aged; Mitomycin; Neoplastic Stem Cells; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Cells, Cultured; Ubiquitin-Activating Enzymes; Urinary Bladder Neoplasms; Young Adult | 2016 |
Outcomes of a Clinical Pathway for Borderline Resectable Pancreatic Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Therapy; Critical Pathways; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Radiosurgery; Retrospective Studies; Survival Rate; Taxoids | 2016 |
MiRNA-21 induces epithelial to mesenchymal transition and gemcitabine resistance via the PTEN/AKT pathway in breast cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Piperlongumine Suppresses Growth and Sensitizes Pancreatic Tumors to Gemcitabine in a Xenograft Mouse Model by Modulating the NF-kappa B Pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Proliferation; Deoxycytidine; Dioxolanes; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Nicotine Reduces Survival via Augmentation of Paracrine HGF-MET Signaling in the Pancreatic Cancer Microenvironment.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Hepatocyte Growth Factor; Humans; Inhibitor of Differentiation Protein 1; Mice; Neoplasm Metastasis; Nicotine; Pancreatic Neoplasms; Paracrine Communication; Phosphorylation; Proto-Oncogene Proteins c-met; Signal Transduction; Smoking; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Synthesis of a Gemcitabine Prodrug for Remote Loading into Liposomes and Improved Therapeutic Effect.
Topics: Animals; Cell Line, Tumor; Chemistry Techniques, Synthetic; Deoxycytidine; Drug Delivery Systems; Drug Stability; Female; Gemcitabine; Inhibitory Concentration 50; Liposomes; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Prodrugs; Solubility | 2016 |
HuR mediated post-transcriptional regulation as a new potential adjuvant therapeutic target in chemotherapy for pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cyclooxygenase 2; Deoxycytidine; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Enzyme Activation; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Pancreatic Neoplasms; RNA Interference; RNA Processing, Post-Transcriptional; Transfection | 2015 |
HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice, Nude; Minor Histocompatibility Antigens; Oncogene Protein v-akt; Pancreatic Neoplasms; Phosphorylation; Random Allocation; Ribonucleosides; RNA-Binding Proteins; Xenograft Model Antitumor Assays | 2016 |
Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; HEK293 Cells; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Survivin; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2016 |
Silencing pancreatic adenocarcinoma upregulated factor (PAUF) increases the sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Deoxycytidine; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Immunoenzyme Techniques; Intercellular Signaling Peptides and Proteins; Lectins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Osteosarcoma; Radiotherapy Dosage; Radiotherapy, Adjuvant; Republic of Korea; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2015 |
Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Floxuridine; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Male; Middle Aged; Mitomycin; Retrospective Studies; Survival Rate | 2016 |
Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies | 2016 |
Efficacy and safety of gemcitabine, oxaliplatin, and paclitaxel in cisplatin-refractory germ cell cancer in routine care--Registry data from an outcomes research project of the German Testicular Cancer Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Registries; Retrospective Studies; Survival Analysis; Testicular Neoplasms | 2016 |
TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Topics: Animals; Antigens, Surface; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice; Mice, Nude; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pancreatic Neoplasms; RNA Interference; RNA, Messenger; RNA, Small Interfering; Signal Transduction | 2015 |
Evolution of a Lung-Sparing Strategy with Sleeve Lobectomy and Induction Therapy for Non-small Cell Lung Cancer: 20-Year Experience at a Single Institution.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Organ Sparing Treatments; Oxonic Acid; Paclitaxel; Platinum Compounds; Pneumonectomy; Remission Induction; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2016 |
[Efficacy and safety evaluation of gemcitabine combined with ifosfamide in patients with advanced nasopharyngeal carcinoma after failure of platinum-based chemotherapy].
Topics: Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Ifosfamide; Induction Chemotherapy; Kaplan-Meier Estimate; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neutropenia; Platinum; Remission Induction; Salvage Therapy; Survival Rate; Thrombocytopenia; Treatment Failure | 2015 |
Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Neoadjuvant Therapy; Pemetrexed; Pleural Neoplasms; Pneumonectomy; Proportional Hazards Models; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Treatment Outcome | 2015 |
Establishment of a novel method to evaluate peritoneal microdissemination and therapeutic effect using luciferase assay.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Luciferases; Mice, Inbred BALB C; Neoplasm Micrometastasis; Neoplasm Transplantation; Optical Imaging; Peritoneal Neoplasms; Whole Body Imaging; Xenograft Model Antitumor Assays | 2016 |
Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Monitoring; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2015 |
A Rare Pancreatic Tumor That Underwent a Change in Morphology and Histopathologic Features During Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Fine-Needle; Carcinoma, Acinar Cell; Carcinoma, Neuroendocrine; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasms, Complex and Mixed; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Signal Transduction | 2016 |
Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; RNA, Messenger; S100 Calcium-Binding Protein A4; S100 Proteins | 2015 |
Haem oxygenase 1 expression is associated with prognosis in cholangiocarcinoma patients and with drug sensitivity in xenografted mice.
Topics: Adult; Aged; Animals; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Female; Gemcitabine; Heme Oxygenase-1; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Multivariate Analysis; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins c-mdm2; Protoporphyrins; Signal Transduction; Survival Analysis; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Initial Characterization of Integrase-Defective Lentiviral Vectors for Pancreatic Cancer Gene Therapy.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Genes, Reporter; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; HIV-1; Humans; Injections, Subcutaneous; Integrases; Lentivirus; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Pancreatic Neoplasms; Transplantation, Heterologous; Viral Proteins | 2016 |
Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine.
Topics: Amides; Antineoplastic Agents; Antiviral Agents; Cells, Cultured; Coinfection; Cytokines; Deoxycytidine; Gemcitabine; Humans; Immunity, Innate; Immunologic Factors; Indoles; Influenza A virus; Influenza, Human; Interferon-alpha; Lipopolysaccharides; Macrophages; Oxazoles; Phosphoproteins; Pyrroles; RNA, Viral; Salicylates; Thiazoles; Virus Replication | 2016 |
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies.
Topics: Adult; Aged; Deoxycytidine; DNA Damage; DNA Repair; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematologic Neoplasms; Humans; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Prospective Studies | 2016 |
Cost-Utility of "Doxorubicin and Cyclophosphamide" versus "Gemcitabine and Paclitaxel" for Treatment of Patients with Breast Cancer in Iran.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cross-Sectional Studies; Cyclophosphamide; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Iran; Neoplasm Staging; Paclitaxel; Prognosis; Quality of Life | 2015 |
S-phase-specific radiosensitization by gemcitabine for therapeutic carbon ion exposure in vitro.
Topics: Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Heavy Ion Radiotherapy; Humans; Radiation Tolerance; S Phase; Tumor Stem Cell Assay | 2016 |
Influence of PEG Molecular Weight on the Drug Release and In vitro Cytotoxicity of Single-Walled Carbon Nanotubes-PEG-Gemcitabine Conjugates.
Topics: Acylation; Calorimetry, Differential Scanning; Carbon Dioxide; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Liberation; Gemcitabine; Humans; Molecular Weight; Nanotubes, Carbon; Particle Size; Polyethylene Glycols | 2016 |
Survival effects of adjuvant gemcitabine plus S-1 chemotherapy on pancreatic carcinoma stratified by preoperative resectability status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2016 |
Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells.
Topics: Cell Line, Tumor; Chemistry, Pharmaceutical; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Ferric Compounds; Gemcitabine; Humans; Hyaluronan Receptors; Magnetics; Nanomedicine; Nanoparticles; Neoplastic Cells, Circulating; Neoplastic Stem Cells; Tissue Distribution | 2016 |
MiR-125a regulates chemo-sensitivity to gemcitabine in human pancreatic cancer cells through targeting A20.
Topics: 3' Untranslated Regions; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; MicroRNAs; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; RNA, Messenger; RNA, Neoplasm; Tumor Necrosis Factor alpha-Induced Protein 3 | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Pancreatic Ductal; Cetuximab; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Silicates; Singapore; Titanium | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Singapore; Urinary Bladder Neoplasms; Vinblastine | 2015 |
Singapore Cancer Network (SCAN) Guidelines for Front-Line Systemic Therapy of Newly Diagnosed Advanced Epithelial Ovarian Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Chemotherapy, Adjuvant; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Infusions, Parenteral; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Ovariectomy; Paclitaxel; Polyethylene Glycols; Singapore | 2015 |
Identification of pancreatic tumors in vivo with ligand-targeted, pH responsive mesoporous silica nanoparticles by multispectral optoacoustic tomography.
Topics: Animals; Cell Line, Tumor; Chitosan; Deoxycytidine; Drug Liberation; Female; Gemcitabine; Humans; Hydrogen-Ion Concentration; Indocyanine Green; Ligands; Mice; Nanoparticles; Pancreatic Neoplasms; Particle Size; Photoacoustic Techniques; Porosity; Rats, Nude; Silicon Dioxide; Surface Properties; Theranostic Nanomedicine; Tissue Distribution; Tomography; Urokinase-Type Plasminogen Activator | 2016 |
Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Predictive Value of Tests; Prognosis; Retrospective Studies; Survival Rate; X-ray Repair Cross Complementing Protein 1 | 2016 |
Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Hepatocyte Growth Factor; Humans; In Vitro Techniques; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Pancreatic Neoplasms; Pancreatic Stellate Cells; Proto-Oncogene Proteins c-met; Xenograft Model Antitumor Assays | 2016 |
FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Neoplasm Invasiveness; p21-Activated Kinases; Pancreatic Ducts; Pancreatic Neoplasms; Pyridones; Pyrimidines; Xenograft Model Antitumor Assays | 2016 |
Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study.
Topics: Age Factors; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Smoking | 2016 |
Monitoring vascular normalization induced by antiangiogenic treatment with (18)F-fluoromisonidazole-PET.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Benzimidazoles; Breast; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Female; Fluorine Radioisotopes; Gemcitabine; Humans; Mice; Mice, Nude; Misonidazole; Neovascularization, Pathologic; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Quinolones | 2016 |
Complete and Durable Remission of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Urothelial Carcinoma Following Third-Line Treatment with Trastuzumab and Gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Receptor, ErbB-2; Remission Induction; Trastuzumab | 2018 |
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition.
Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Cyclic S-Oxides; Deoxycytidine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Ligands; MAP Kinase Signaling System; Mutation; Pancreatic Neoplasms; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor | 2016 |
Herceptin-conjugated temperature-sensitive immunoliposomes encapsulating gemcitabine for breast cancer.
Topics: Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Liposomes; Particle Size; Polyethylene Glycols; Surface Properties; Temperature; Trastuzumab | 2016 |
Hypoxia regulates ABCG2 activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Pancreatic Neoplasms; Tumor Microenvironment | 2016 |
An open-label, dose-escalation study to evaluate the safety and pharmacokinetics of CEP-9722 (a PARP-1 and PARP-2 inhibitor) in combination with gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbazoles; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Melanoma; Middle Aged; Neoplasms; Ovarian Neoplasms; Phthalimides; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases | 2016 |
Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer.
Topics: Antineoplastic Agents; Apoptosis; Biological Transport; Carboplatin; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Adducts; DNA Damage; DNA Repair; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Glutathione; Humans; Mass Spectrometry; Methotrexate; Organoplatinum Compounds; Oxaliplatin; Urinary Bladder Neoplasms; Vinblastine | 2016 |
[Long Term Survival in a Case of Hilar Cholangiocarcinoma Treated with Chemotherapy and Surgery].
Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Male; Oxonic Acid; Pancreatectomy; Tegafur; Time Factors; Treatment Outcome | 2015 |
[Resection of Initially Unresectable Gallbladder Cancer with Multiple Liver Metastases after Chemotherapy with Gemcitabine plus Cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Prognosis | 2015 |
[A Patient with Three-Year Relapse-Free Survival after Surgical Resection for Lung and Liver Metastases of Cholangiocarcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreaticoduodenectomy; Recurrence; Tegafur | 2015 |
[A Case of Gemcitabine Refractory Lung Metastasis after Distal Pancreatectomy for Pancreatic Cancer, Effectively Treated with S -1 as Second Line Chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Recurrence; Tegafur | 2015 |
[R0 Resection of Locally Advanced Pancreatic Cancer after Combination Chemotherapy with Gemcitabine and S-1].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Grading; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[Unresectable Gallbladder Cancer Successfully Treated with Gemcitabine Chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Hepatic Artery; Humans; Jaundice, Obstructive; Male; Stents; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
[A Case of Successful Curative Resection Following Downsizing Chemotherapy in Initially Unresectable Locally Advanced Gallbladder Carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Treatment Outcome | 2015 |
[Surgical Resection after Chemotherapy for Ampullary Carcinoma with Synchronous Liver Metastasis--Report of a Case].
Topics: Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Duodenal Neoplasms; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Oxonic Acid; Pancreaticoduodenectomy; Tegafur | 2015 |
[A Case of Invasive Ductal Carcinoma in the Fat Replacement of the Pancreatic Body and Tail].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Fats; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Splenectomy | 2015 |
[Nab-Paclitaxel plus Gemcitabine for Metastatic Pancreatic Cancer].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2015 |
[A Case of Pancreatic Head Cancer Treated with Pancreaticoduodenectomy Combined with Hepatic Artery Resection Following Neoadjuvant Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[Adjuvant Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer following Gemcitabine and S-1 Chemotherapy--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Jaundice, Obstructive; Male; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[The Clinical Efficacy of Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Carcinoma--Report of Two Cases Treated by Curative Pancreatectomy with Portal Vein Resection after Neoadjuvant Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Portal Vein; Tegafur; Treatment Outcome | 2015 |
[A Case of Radical Resection for Locally Advanced Pancreatic Cancer with Positive Peritoneal Cytology Treated with Chemoradiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2015 |
[Two Cases of Liver Metastasis from Pancreatic Cancer with a Complete Response Owing to Chemotherapy].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2015 |
[A Case of Invasive Intraductal Papillary Mucinous Carcinoma, Penetrating the Stomach, Colon, and Jejunum].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Colon; Deoxycytidine; Drug Combinations; Duodenum; Fatal Outcome; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Stomach; Tegafur | 2015 |
Synthesis, Characterization, and In Vitro and In Vivo Evaluations of 4-(N)-Docosahexaenoyl 2', 2'-Difluorodeoxycytidine with Potent and Broad-Spectrum Antitumor Activity.
Topics: Animals; Antimetabolites, Antineoplastic; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Stability; Female; Gemcitabine; Humans; Mice; Mice, Transgenic; Solubility; X-Ray Diffraction; Xenograft Model Antitumor Assays | 2016 |
Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Survival Rate; Topotecan; Treatment Outcome; Young Adult | 2016 |
The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cystadenocarcinoma, Serous; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Endometrial Neoplasms; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Pilot Projects; Polyethylene Glycols; Prognosis; Remission Induction; Retrospective Studies; Survival Rate | 2016 |
Gemcitabine and Docetaxel Compared With Observation, Radiation, or Other Chemotherapy Regimens as Adjuvant Treatment for Stage I-to-IV Uterine Leiomyosarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Leiomyosarcoma; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Taxoids; Uterine Neoplasms | 2016 |
Photodynamic Therapy Plus Chemotherapy Compared with Photodynamic Therapy Alone in Hilar Nonresectable Cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Endoscopy, Digestive System; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Photochemotherapy; Randomized Controlled Trials as Topic; Stents; Treatment Outcome | 2016 |
MiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Invasiveness; Smad4 Protein | 2016 |
Quercetin-3-O-glucoside suppresses pancreatic cancer cell migration induced by tumor-deteriorated growth factors in vitro.
Topics: Cell Line, Tumor; Cell Movement; Databases, Genetic; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Fibroblast Growth Factor 2; Flavonoids; Gemcitabine; Gene Expression Regulation, Neoplastic; Glucosides; Humans; In Vitro Techniques; Pancreatic Neoplasms; Quercetin; Transforming Growth Factor beta; Vascular Endothelial Growth Factor A | 2016 |
Thermosensitive gemcitabine-magnetoliposomes for combined hyperthermia and chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Survival; Delayed-Action Preparations; Deoxycytidine; Drug Compounding; Drug Liberation; Drug Stability; Ferrosoferric Oxide; Gemcitabine; Hyperthermia, Induced; Light; Liposomes; Magnetic Fields; Magnetite Nanoparticles; Mesenchymal Stem Cells; Particle Size; Photochemotherapy; Primary Cell Culture; Rats; Rats, Inbred Lew | 2016 |
Self-assembled gemcitabine-gadolinium nanoparticles for magnetic resonance imaging and cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gadolinium; Gemcitabine; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Mice, Nude; Nanoparticles; Neoplasms; Solutions | 2016 |
[Chronic alveolar condensations with erythematous cutaneous lesions].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Deoxycytidine; Diagnosis, Differential; Doxorubicin; Erythema; Female; Gemcitabine; Humans; Lung Neoplasms; Mycosis Fungoides; Pulmonary Alveoli; Skin Neoplasms; Vidarabine | 2016 |
MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Topics: 3' Untranslated Regions; Antimetabolites, Antineoplastic; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA Interference; Time Factors; Transfection; Tumor Suppressor Proteins; Up-Regulation | 2016 |
Lauroyl-gemcitabine-loaded lipid nanocapsule hydrogel for the treatment of glioblastoma.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Deoxycytidine; Drug Liberation; Female; Gemcitabine; Glioblastoma; Humans; Hydrogels; Injections; Lipids; Mice, Nude; Nanocapsules; Needles; Rheology; Tumor Burden | 2016 |
SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts.
Topics: Albumins; Animals; Antineoplastic Agents, Phytogenic; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Humans; Mice; Microcirculation; Osteonectin; Paclitaxel; Pancreatic Neoplasms; Stromal Cells; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
[Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: A case report].
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Thrombotic Microangiopathies; Treatment Outcome | 2016 |
Novel microspheres based on triterpene saponins from the roots of Physospermum verticillatum (Waldst & Kit) (Apiaceae) for the improvement of gemcitabine release.
Topics: Antimetabolites, Antineoplastic; Apiaceae; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Gemcitabine; Hydrogen-Ion Concentration; Microspheres; Plant Roots; Saponins; Spectroscopy, Fourier Transform Infrared; Surface Properties; Triterpenes | 2016 |
CEST theranostics: label-free MR imaging of anticancer drugs.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Contrast Media; Deoxycytidine; Drug Delivery Systems; Female; Fluorescence; Gemcitabine; Humans; Image Interpretation, Computer-Assisted; Immunoenzyme Techniques; Liposomes; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Nude; Theranostic Nanomedicine; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Mesoporous silica nanoparticles with bilayer coating of poly(acrylic acid-co-itaconic acid) and human serum albumin (HSA): A pH-sensitive carrier for gemcitabine delivery.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Hydrogen-Ion Concentration; Magnetic Resonance Spectroscopy; Mice; Microscopy, Atomic Force; Polymers; Porosity; Serum Albumin; Silicon Dioxide; Spectroscopy, Fourier Transform Infrared; Static Electricity | 2016 |
Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Aptamers, Nucleotide; Deoxycytidine; Diterpenes; Drug Resistance, Neoplasm; Epoxy Compounds; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Oligodeoxyribonucleotides; Pancreatic Neoplasms; Phenanthrenes; Polyethylene Glycols; Polymers; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Acridine Orange Conjugated Polymersomes for Simultaneous Nuclear Delivery of Gemcitabine and Doxorubicin to Pancreatic Cancer Cells.
Topics: Acridine Orange; Antineoplastic Agents; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Microscopy, Electron, Transmission; Pancreatic Neoplasms; Polymers | 2016 |
Hypoxic Conditions Promote Gemcitabine Sensitivity in a Pancreatic Cancer Stem Cell Line.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Hypoxia; Immunoenzyme Techniques; Leukemia Inhibitory Factor; Mediator Complex; Neoplastic Stem Cells; Pancreatic Neoplasms; Tumor Cells, Cultured | 2016 |
Relevance of Sp Binding Site Polymorphism in WWOX for Treatment Outcome in Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxidoreductases; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Predictive Value of Tests; Prognosis; Sp Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins; WW Domain-Containing Oxidoreductase | 2016 |
Massive malignant pleural effusion due to lung adenocarcinoma in 13-year-old boy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Mucinous; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Deoxycytidine; Drainage; Gemcitabine; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Tomography, X-Ray Computed | 2016 |
The Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms | 2016 |
Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Quinazolines; Urinary Bladder Neoplasms | 2016 |
Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
Topics: Adrenergic alpha-1 Receptor Antagonists; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Interactions; ets-Domain Protein Elk-1; Gemcitabine; Gene Silencing; Humans; Indoles; Male; Neoplasm Invasiveness; Phosphorylation; Prostate; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Mas; Receptors, Androgen | 2016 |
Predictors of Locoregional Failure and Impact on Overall Survival in Patients With Resected Exocrine Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreas, Exocrine; Pancreatectomy; Pancreatic Neoplasms; Postoperative Care; Propensity Score; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Retrospective Studies | 2016 |
Interleukin-27 inhibits malignant behaviors of pancreatic cancer cells by targeting M2 polarized tumor associated macrophages.
Topics: Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Interleukins; Macrophages; Neoplasm Proteins; Pancreatic Neoplasms; U937 Cells | 2017 |
GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Middle Aged; Natural Killer T-Cells; Neoplasm Recurrence, Local; Neoplasm Staging; Nose Neoplasms; Retrospective Studies; Treatment Outcome | 2016 |
The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoviridae; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Deoxycytidine; DNA Damage; Down-Regulation; Gemcitabine; Genes, Viral; Humans; Irinotecan; MRE11 Homologue Protein; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms | 2016 |
Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Lumican; Mice; Microtubule-Associated Proteins; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Atorvastatin (Lipitor) attenuates the effects of aspirin on pancreatic cancerogenesis and the chemotherapeutic efficacy of gemcitabine on pancreatic cancer by promoting M2 polarized tumor associated macrophages.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antimetabolites, Antineoplastic; Aspirin; Atorvastatin; Cell Line; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Macrophages; Male; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Carbon Ion Radiation Therapy With Concurrent Gemcitabine for Patients With Locally Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Heavy Ion Radiotherapy; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pancreatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage | 2016 |
Overcoming chemo/radio-resistance of pancreatic cancer by inhibiting STAT3 signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemoradiotherapy; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Radiation Tolerance; Random Allocation; Signal Transduction; STAT3 Transcription Factor; Survival Analysis | 2016 |
Methylisoindigo preferentially kills cancer stem cells by interfering cell metabolism via inhibition of LKB1 and activation of AMPK in PDACs.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Humans; Indoles; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Protein Serine-Threonine Kinases | 2016 |
Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Line, Tumor; Checkpoint Kinase 1; Cyclin B1; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mitosis; Nocodazole; Pancreatic Neoplasms; Thiophenes; Urea | 2016 |
Plk1 inhibition enhances the efficacy of gemcitabine in human pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; S Phase; Thiophenes; Xenograft Model Antitumor Assays | 2016 |
CIP2A down regulation enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Autoantigens; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Intracellular Signaling Peptides and Proteins; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Pancreas; Pancreatic Neoplasms; Prognosis; Survival Rate; Tumor Cells, Cultured | 2016 |
14-3-3σ regulation of and interaction with YAP1 in acquired gemcitabine resistance via promoting ribonucleotide reductase expression.
Topics: 14-3-3 Proteins; Adaptor Proteins, Signal Transducing; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Pancreatic Neoplasms; Phosphoproteins; Ribonucleotide Reductases; Transcription Factors; Transfection; Up-Regulation; YAP-Signaling Proteins | 2016 |
The significance of phosphorylated heat shock protein 27 on the prognosis of pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Male; Middle Aged; Molecular Chaperones; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Phosphorylation; Prognosis; Retrospective Studies; Survival Rate | 2016 |
Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Prospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2016 |
Ursolic acid inhibits the growth of human pancreatic cancer and enhances the antitumor potential of gemcitabine in an orthotopic mouse model through suppression of the inflammatory microenvironment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Inflammation; Mice; Mice, Nude; Pancreatic Neoplasms; Triterpenes; Tumor Microenvironment; Ursolic Acid; Xenograft Model Antitumor Assays | 2016 |
Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Models, Theoretical; Pancreatic Neoplasms | 2016 |
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation.
Topics: Antigens, CD20; Azacitidine; Cell Line, Tumor; Complement System Proteins; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; NF-kappa B; Rituximab; Thalidomide; Up-Regulation | 2016 |
Gemcitabine-induced myositis in a diabetes mellitus patient on hemodialysis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Deoxycytidine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gemcitabine; Humans; Kidney Failure, Chronic; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Myositis; Pancreatic Neoplasms; Renal Dialysis | 2017 |
Sirolimus induces apoptosis and reverses multidrug resistance in human osteosarcoma cells in vitro via increasing microRNA-34b expression.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; HEK293 Cells; Humans; Methotrexate; MicroRNAs; Osteosarcoma; Sirolimus | 2016 |
Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Polyethylene Glycols; Prognosis; Quality-Adjusted Life Years; Salvage Therapy; Survival Rate; Topotecan | 2016 |
Gemcitabine-Induced Subacute Cutaneous Lupus Erythematosus: A Case Report.
Topics: Administration, Oral; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Positron Emission Tomography Computed Tomography; Prednisone; Skin; Treatment Outcome | 2016 |
Cyclic RGDfK Peptide Functionalized Polymeric Nanocarriers for Targeting Gemcitabine to Ovarian Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Membrane Potential, Mitochondrial; Nanoparticles; Ovarian Neoplasms; Peptides; Peptides, Cyclic; Polymers; Reactive Oxygen Species | 2016 |
Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Shape; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Peptides, Cyclic | 2016 |
A Case of Gemcitabine and Cisplatin Chemotherapy in a Patient With Metastatic Urothelial Carcinoma Receiving Hemodialysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Renal Dialysis; Urologic Neoplasms | 2016 |
Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Gemcitabine; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heat-Shock Proteins; Humans; Immunohistochemistry; Male; Middle Aged; Proto-Oncogene Proteins c-akt; Survival Analysis; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2016 |
Optimizing initial chemotherapy for metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Organoplatinum Compounds; Pancreatic Neoplasms | 2016 |
Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data.
Topics: Antimetabolites, Antineoplastic; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Models, Theoretical; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tumor Burden | 2016 |
Insights from HuR biology point to potential improvement for second-line ovarian cancer therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Deoxycytidine; Deoxycytidine Kinase; ELAV-Like Protein 1; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Nuclear Proteins; Ovarian Neoplasms; Protein Transport; Protein-Tyrosine Kinases; Retrospective Studies | 2016 |
A rash diagnosis: Gemcitabine-associated pseudocellulitis.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Cellulitis; Creatinine; Deoxycytidine; Diagnosis, Differential; Erythema; Exanthema; Female; Gemcitabine; Humans; Leg; Leukocytosis; Middle Aged; Pancreatic Neoplasms; Withholding Treatment | 2017 |
[Effective palliative chemotherapy in a patient with collecting duct carcinoma of a unilateral kidney associated with anuria. Case report].
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Anuria; Carcinoma, Renal Cell; Cisplatin; Creatinine; Deoxycytidine; Disease Progression; Female; Gemcitabine; Hematuria; Humans; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Palliative Care; Renal Dialysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Invasive urothelial carcinoma, lymphoma-like/plasmacytoid variant, successfully treated by radical cystectomy with adjuvant chemotherapy: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2016 |
In vivo drug delivery of gemcitabine with PEGylated single-walled carbon nanotubes.
Topics: Animals; Antimetabolites, Antineoplastic; Calorimetry, Differential Scanning; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Microscopy, Electron, Transmission; Nanotubes, Carbon; Neoplasms; Polyethylene Glycols; Spectroscopy, Fourier Transform Infrared; Transplantation, Heterologous | 2016 |
Therapy of pancreatic cancer via an EphA2 receptor-targeted delivery of gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Receptor, EphA2; Xenograft Model Antitumor Assays | 2016 |
The differential effects of metronomic gemcitabine and antiangiogenic treatment in patient-derived xenografts of pancreatic cancer: treatment effects on metabolism, vascular function, cell proliferation, and tumor growth.
Topics: Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Male; Mice, SCID; Microvessels; Necrosis; Neovascularization, Pathologic; Pancreatic Neoplasms; Perfusion; Xenograft Model Antitumor Assays | 2016 |
Human malignant mesothelioma is recapitulated in immunocompetent BALB/c mice injected with murine AB cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; Female; Gemcitabine; HMGB1 Protein; Humans; Immunocompetence; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice, Inbred BALB C; Neoplasm Transplantation; Pemetrexed; Survival Analysis | 2016 |
Penile cancer metastasizing to the breast: a case report.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms, Male; Carcinoma, Squamous Cell; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Penile Neoplasms | 2016 |
dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Deoxycytidine Kinase; Female; Gemcitabine; Genotype; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Drug Resistance, Neoplasm; Gemcitabine; Half-Life; Hydrogen-Ion Concentration; Liposomes; Pancreas; Pancreatic Neoplasms; Particle Size; Pharmaceutical Solutions; Rats; Rats, Sprague-Dawley | 2016 |
Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cullin Proteins; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice, Inbred BALB C; Neoplasm Proteins; RNA, Small Interfering; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm.
Topics: Adult; Brain Diseases; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Hyperammonemia; Liver Neoplasms; Male; Organoplatinum Compounds; Ornithine Carbamoyltransferase Deficiency Disease; Oxaliplatin | 2016 |
Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Busulfan; Cell Line, Tumor; Cell Membrane Permeability; Cladribine; Deoxycytidine; DNA Damage; Drug Synergism; Gemcitabine; Hematopoietic Stem Cell Transplantation; Histones; Humans; Hydroxamic Acids; Intracellular Membranes; Lymphoma; Mitochondria; Signal Transduction; Transplantation Conditioning; Vorinostat | 2016 |
Locked Nucleic Acid In Situ Hybridization Analysis of MicroRNA-21 Predicts Clinical Outcome in Patients After Resection for Pancreatic Cancer Treated with Adjuvant Gemcitabine Monotherapy.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; In Situ Hybridization; Male; MicroRNAs; Middle Aged; Oligonucleotides; Pancreatic Neoplasms; Prognosis; Survival Analysis; Treatment Outcome | 2016 |
Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK.
Topics: Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Culture Media, Conditioned; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inflammation; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Tumor Cells, Cultured | 2016 |
Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
Topics: Adult; Antineoplastic Agents; Apoptosis; Bortezomib; Busulfan; Cell Line, Tumor; Cell Survival; Chromatin Assembly and Disassembly; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Melphalan; Membrane Potential, Mitochondrial; Middle Aged; Panobinostat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2016 |
Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer.
Topics: Adenocarcinoma; Anilides; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dodecanol; Gemcitabine; Humans; Male; Mice; Mice, Nude; Micelles; Pancreatic Neoplasms; Polyethylene Glycols; Polymers; Propane; Pyridines; Signal Transduction | 2016 |
Gemcitabine-Based Regional Intra-Arterial Infusion Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; China; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Pancreatic Neoplasms | 2016 |
Correlation of Early Recurrence With In Vitro Adenosine Triphosphate Based Chemotherapy Response Assay in Pancreas Cancer With Postoperative Gemcitabine Chemotherapy.
Topics: Adenosine Triphosphate; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Immunosuppressive Agents; Longitudinal Studies; Male; Middle Aged; Pancreatic Neoplasms; Pancreaticoduodenectomy; Predictive Value of Tests; Republic of Korea; Retrospective Studies; Tumor Cells, Cultured | 2016 |
Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Esters; Female; Gemcitabine; Humans; Injections, Intraperitoneal; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prodrugs; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2016 |
Classification of Gemcitabine resistant Cholangiocarcinoma cell lines using synchrotron FTIR microspectroscopy.
Topics: Animals; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Microscopy; Neoplasm Transplantation; Phenotype; Sensitivity and Specificity; Spectroscopy, Fourier Transform Infrared; Synchrotrons | 2017 |
[Klatskin tumor - a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Remission Induction; Stents | 2016 |
Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genes, p53; Humans; Janus Kinase 2; Mice; Mutation; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; STAT3 Transcription Factor | 2016 |
Glucose regulated protein 78 (GRP78) inhibits apoptosis and attentinutes chemosensitivity of gemcitabine in breast cancer cell via AKT/mitochondrial apoptotic pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Endoplasmic Reticulum Chaperone BiP; Gemcitabine; Heat-Shock Proteins; Humans; MCF-7 Cells; Mitochondria; Proto-Oncogene Proteins c-akt; Signal Transduction | 2016 |
A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Taxoids; Treatment Outcome | 2016 |
Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging.
Topics: A549 Cells; Antineoplastic Agents; Cell Line; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Liberation; Gemcitabine; Gold; Humans; Nanocomposites; Nanoparticles; Neoplasms; Porosity; Serum Albumin, Bovine; Silicon Dioxide | 2016 |
Gemcitabine and Paclitaxel for Primary Bladder Carcinoma in Renal Transplant Recipients: A Case Report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney Transplantation; Male; Paclitaxel; Urinary Bladder; Urinary Bladder Neoplasms; Young Adult | 2016 |
S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Blood Proteins; Calgranulin B; Deoxycytidine; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Multivariate Analysis; Orosomucoid; Outcome Assessment, Health Care; Polyethylene Glycols; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Proteome; Proteomics; Young Adult | 2016 |
Prospective Study Delivering Simultaneous Integrated High-dose Tumor Boost (≤70 Gy) With Image Guided Adaptive Radiation Therapy for Radical Treatment of Localized Muscle-Invasive Bladder Cancer.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Feasibility Studies; Follow-Up Studies; Gemcitabine; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Sparing Treatments; Organs at Risk; Prospective Studies; Radiation Injuries; Radiation-Sensitizing Agents; Radiography; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Proliferation; Deoxycytidine; Dioxoles; Doxorubicin; Female; Gemcitabine; Humans; Mice; Middle Aged; Neoadjuvant Therapy; Ovarian Neoplasms; Polyethylene Glycols; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Glaucarubin; Mice; Neoplasms, Experimental; Pancreatic Neoplasms | 2016 |
Membrane Localization of Human Equilibrative Nucleoside Transporter 1 in Tumor Cells May Predict Response to Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged | 2016 |
Enriched environment housing enhances the sensitivity of mouse pancreatic cancer to chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Deoxycytidine; Fluorouracil; Gemcitabine; Housing, Animal; Male; Mice, Inbred C57BL; Pancreas; Pancreatic Neoplasms; Stress, Psychological | 2016 |
Cost-effectiveness of Gemcitabine Plus Modern Radiotherapy in Locally Advanced Pancreatic Cancer.
Topics: Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Monte Carlo Method; Pancreatic Neoplasms; Quality-Adjusted Life Years; Radiosurgery; Taiwan | 2016 |
Prognostic Factors for Risk Stratification of Patients with Recurrent or Metastatic Pancreatic Adenocarcinoma Who Were Treated with Gemcitabine-Based Chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models | 2016 |
Suppression of STAT5b in pancreatic cancer cells leads to attenuated gemcitabine chemoresistance, adhesion and invasion.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; bcl-X Protein; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; RNA, Small Interfering; STAT5 Transcription Factor | 2016 |
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Statistical; Niacinamide; Oxonic Acid; Phenylurea Compounds; Random Allocation; Sorafenib; Tegafur; Xenograft Model Antitumor Assays | 2016 |
AS1411 Aptamer-Decorated Biodegradable Polyethylene Glycol-Poly(lactic-co-glycolic acid) Nanopolymersomes for the Targeted Delivery of Gemcitabine to Non-Small Cell Lung Cancer In Vitro.
Topics: A549 Cells; Animals; Antimetabolites, Antineoplastic; Aptamers, Nucleotide; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lung Neoplasms; Nanoparticles; Oligodeoxyribonucleotides; Polyesters; Polyethylene Glycols; Polymers | 2016 |
A Case of Severe Rectal Hemorrhage Possibly Caused by Radiation Recall after Administration of Gemcitabine.
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gamma Rays; Gastrointestinal Hemorrhage; Gemcitabine; Humans; Radiation-Sensitizing Agents; Radiodermatitis; Rectum; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 2016 |
Long-circulating and liver-targeted nanoassemblies of cyclic phosphoryl N-dodecanoyl gemcitabine for the treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Hydrogen-Ion Concentration; Injections, Intravenous; Liver; Liver Neoplasms; Male; Mice; Nanoparticles; Solutions; Tissue Distribution; Tumor Burden | 2016 |
The necrosome promotes pancreatic oncogenesis via CXCL1 and Mincle-induced immune suppression.
Topics: Adenocarcinoma; Animals; Apoptosis; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GTPase-Activating Proteins; Humans; Immune Tolerance; Lectins, C-Type; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Necrosis; Pancreatic Neoplasms; Receptor-Interacting Protein Serine-Threonine Kinases; Signal Transduction; Up-Regulation | 2016 |
Lysyl oxidase family activity promotes resistance of pancreatic ductal adenocarcinoma to chemotherapy by limiting the intratumoral anticancer drug distribution.
Topics: Amino Acid Oxidoreductases; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Diffusion; Drug Resistance, Neoplasm; Female; Fibrillar Collagens; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Pancreatic Neoplasms; Protein-Lysine 6-Oxidase; Tissue Distribution; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Cost-effectiveness analysis of treatments for metastatic pancreatic cancer based on PRODIGE and MPACT trials.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Support Techniques; Deoxycytidine; Drug Costs; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Analysis | 2016 |
Adenocarcinoma of the ampulla of Vater metastasising into the right ventricle.
Topics: Adenocarcinoma; Adult; Albumins; Ampulla of Vater; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Heart Neoplasms; Heart Ventricles; Humans; Neoplasm Recurrence, Local; Paclitaxel | 2016 |
Anti-stromal treatment together with chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Pancreatic Stellate Cells; Signal Transduction | 2016 |
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Retrospective Studies; ROC Curve; Severity of Illness Index; Treatment Outcome | 2016 |
Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma.
Topics: Adult; Brentuximab Vedotin; Deoxycytidine; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lung Diseases; Male; Melphalan; Middle Aged; Nausea; Remission Induction; Salvage Therapy; Skin Diseases; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2016 |
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Costs and Cost Analysis; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2016 |
[Comparison of the Four-Week and Three-Week Regimens of GC Therapy for Urothelial Cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Urologic Neoplasms; Urothelium | 2016 |
[A Case of Bilateral Pneumothorax after Chemotherapy for Uterine Leiomyosarcoma with Multiple Lung Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Hysterectomy; Leiomyosarcoma; Lung Neoplasms; Middle Aged; Ovariectomy; Pneumothorax; Taxoids | 2016 |
[A Case of Primary Cancer of the Pancreas and Colon Treated with the Combination of Gemcitabine and TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Silicates; Titanium; Treatment Outcome | 2016 |
Prognostic Significance of a Minute Amount of Ascites During Chemoradiotherapy for Locally Advanced Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; CA-19-9 Antigen; Chemoradiotherapy; Cisplatin; Deoxycytidine; Drug Combinations; Etoposide; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur; Tomography, X-Ray Computed | 2016 |
Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
ALDH1A3, the Major Aldehyde Dehydrogenase Isoform in Human Cholangiocarcinoma Cells, Affects Prognosis and Gemcitabine Resistance in Cholangiocarcinoma Patients.
Topics: Adult; Aged; Aldehyde Oxidoreductases; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Survival; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Protein Isoforms; Proto-Oncogene Proteins c-met | 2016 |
Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Deoxycytidine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prednisone; Retrospective Studies; Survival Analysis; Vincristine | 2016 |
The Role of Oxygen in Avascular Tumor Growth.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Models, Theoretical; Neoplasms; Oxygen; Oxygen Consumption; Tumor Cells, Cultured | 2016 |
Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Germany; Humans; Irinotecan; Male; Middle Aged; Palliative Care; Retrospective Studies; Treatment Outcome | 2016 |
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bendamustine Hydrochloride; Brentuximab Vedotin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Immunoconjugates; Male; Middle Aged; Treatment Outcome | 2016 |
Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Efficacy Screening of Gloriosa Superba Extracts in a Murine Pancreatic Cancer Model Using (18)F-FDG PET/CT for Monitoring Treatment Response.
Topics: Animals; Antimetabolites, Antineoplastic; Colchicine; Deoxycytidine; Drug Synergism; Female; Fluorodeoxyglucose F18; Gemcitabine; High-Throughput Screening Assays; Humans; Immunoenzyme Techniques; Liliaceae; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Plant Extracts; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Seeds; Toxicity Tests, Acute; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.
Topics: Adolescent; Adult; Aged; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Osteosarcoma; Recurrence; Sarcoma; Taxoids; Treatment Outcome | 2016 |
In vitro and in vivo efficacy of afatinib as a single agent or in combination with gemcitabine for the treatment of nasopharyngeal carcinoma.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms, Experimental; Quinazolines; Structure-Activity Relationship | 2016 |
The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Frequency; HLA-B27 Antigen; HLA-DRB1 Chains; Humans; Infusions, Intravenous; Japan; Lung Diseases, Interstitial; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Prospective Studies; Young Adult | 2016 |
Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Half-Life; Humans; Hyaluronic Acid; Liposomes; MCF-7 Cells; Mice; Mice, Nude; Neoplastic Stem Cells; Xenograft Model Antitumor Assays | 2016 |
PLAG (1-palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol) augments the therapeutic effect of pegfilgrastim on gemcitabine-induced neutropenia.
Topics: Animals; Biomarkers; Cell Movement; Deoxycytidine; Diglycerides; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Filgrastim; Gemcitabine; Granulocyte Colony-Stimulating Factor; Leukocyte Count; Mice, Inbred BALB C; Neutropenia; Neutrophils; Polyethylene Glycols; Receptors, Interleukin-8B; Recombinant Proteins; Time Factors | 2016 |
Anoikis-resistant cholangiocarcinoma cells display aggressive characteristics and increase STAT3 activation.
Topics: Anoikis; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Phosphorylation; Reference Values; Signal Transduction; STAT3 Transcription Factor; Tyrphostins | 2016 |
Delivery of Gemcitabine Prodrugs Employing Mesoporous Silica Nanoparticles.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Nanoparticles; Particle Size; Porosity; Prodrugs; Silicon Dioxide | 2016 |
Hypofractionated Conformal Radiotherapy with Concurrent Full-Dose Gemcitabine Versus Standard Fractionation Radiotherapy with Concurrent Fluorouracil for Unresectable Pancreatic Cancer: a Multi-Institution Experience.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Radiotherapy, Conformal; Retrospective Studies; Survival Analysis | 2016 |
P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; p21-Activated Kinases; Pancreatic Stellate Cells; Xenograft Model Antitumor Assays | 2016 |
Comment on: 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2016 |
Reply to the comment on 'Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prospective Studies | 2016 |
Livedo racemosa and hemolytic uremic syndrome induced by gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Eruptions; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Leg Ulcer; Male | 2016 |
A Prospective Observational Study of Adoptive Immunotherapy for Cancer Using Zoledronate-Activated Killer (ZAK) Cells - An Analysis for Patients with Incurable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Combined Modality Therapy; Deoxycytidine; Diphosphonates; Drug Combinations; Female; Gemcitabine; Humans; Imidazoles; Immunotherapy, Adoptive; Interleukin-2; Kaplan-Meier Estimate; Killer Cells, Lymphokine-Activated; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Salvage Therapy; Tegafur; Treatment Outcome; Zoledronic Acid | 2016 |
Combining the Glasgow Prognostic Score and Serum Carbohydrate Antigen 19-9 Level Improves the Ability to Predict Early Recurrence in Resected Pancreatic Cancer Patients Receiving Adjuvant Gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2016 |
Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy.
Topics: Animals; Cell Death; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Gemcitabine; Humans; Immunosuppression Therapy; Immunotherapy; Immunotherapy, Adoptive; Lipids; Mice, Inbred C57BL; Mice, Transgenic; Monocytes; Myeloid-Derived Suppressor Cells; Nanocapsules; Neoplasms; Pinocytosis; Spleen; T-Lymphocytes | 2016 |
Electrochemical DNA biosensor based on poly(2,6-pyridinedicarboxylic acid) modified glassy carbon electrode for the determination of anticancer drug gemcitabine.
Topics: Antimetabolites, Antineoplastic; Biosensing Techniques; Carbon; Deoxycytidine; DNA; Electrochemical Techniques; Electrodes; Gemcitabine; Humans; Picolinic Acids; Reproducibility of Results | 2016 |
[IgG1 antibody allows the first targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Approval; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy | 2016 |
Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists.
Topics: Aminoquinolines; Animals; Antimetabolites, Antineoplastic; Apoptosis; Benzimidazoles; Butylamines; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Female; Fibroblasts; Gemcitabine; Heterocyclic Compounds, 1-Ring; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptors, CXCR4; Stromal Cells; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Role of TFEB-driven autophagy regulation in pancreatic cancer treatment.
Topics: Animals; Apoptosis; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Lysosomes; Male; Mice; Proto-Oncogene Proteins p21(ras); RNA Interference | 2016 |
Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Fluorescent Antibody Technique; Gemcitabine; Gene Knockdown Techniques; Humans; Intracellular Membranes; Membrane Potential, Mitochondrial; Mice, Nude; Mitochondria; NF-kappa B; Oxidative Stress; Pancreas; Pancreatic Neoplasms; Polycomb Repressive Complex 1; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Letter.
Topics: Deoxycytidine; Gemcitabine; Humans; Niacinamide; Protein Kinase Inhibitors | 2016 |
The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy-Response.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Niacinamide; Protein Kinase Inhibitors | 2016 |
Loading of Gemcitabine on chitosan magnetic nanoparticles increases the anti-cancer efficacy of the drug.
Topics: Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Chitosan; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Magnetic Fields; Magnetite Nanoparticles; MCF-7 Cells | 2016 |
Glucocorticoid Receptor-Targeted Liposomal Codelivery of Lipophilic Drug and Anti-Hsp90 Gene: Strategy to Induce Drug-Sensitivity, EMT-Reversal, and Reduced Malignancy in Aggressive Tumors.
Topics: Animals; Cell Line, Tumor; Cell Survival; Chlorocebus aethiops; COS Cells; Deoxycytidine; DNA; Doxorubicin; Epithelial-Mesenchymal Transition; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Liposomes; Mice; Polymerase Chain Reaction; Receptors, Glucocorticoid | 2016 |
Biased Expression of the FOXP3Δ3 Isoform in Aggressive Bladder Cancer Mediates Differentiation and Cisplatin Chemotherapy Resistance.
Topics: Animals; Cell Differentiation; Cell Line; Cell Line, Tumor; Cisplatin; Cystectomy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Forkhead Transcription Factors; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred NOD; Mice, SCID; Protein Isoforms; RNA, Small Interfering; Urinary Bladder; Urinary Bladder Neoplasms | 2016 |
Adjuvant gemcitabine monotherapy for resectable perihilar cholangiocarcinoma with lymph node involvement: a propensity score matching analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Klatskin Tumor; Lymphatic Metastasis; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2017 |
Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel Chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Osteosarcoma; Retrospective Studies; Taxoids | 2016 |
A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intramolecular Oxidoreductases; Macrophage Migration-Inhibitory Factors; Mice; Mice, Knockout; MicroRNAs; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Receptors, Mineralocorticoid; Signal Transduction; Survival Rate; Tumor Cells, Cultured | 2016 |
Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Busulfan; Child; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Female; Follow-Up Studies; Gemcitabine; Humans; Hydroxamic Acids; Lymphoma; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Vorinostat; Young Adult | 2016 |
Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells.
Topics: Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Berberine; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; NF-kappa B; Pancreas; Pancreatic Neoplasms; Phellodendron; Plant Extracts; Signal Transduction; STAT3 Transcription Factor | 2017 |
The combination use of 1-O-acetylbritannilactone (ABL) and gemcitabine inhibits cell growth and induces cell apoptosis in lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; I-kappa B Proteins; Lactones; Lung Neoplasms; Signal Transduction | 2016 |
Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Disease Models, Animal; Gemcitabine; Killer Cells, Natural; Mice; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2016 |
Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Hydrocarbons, Chlorinated; Male; Middle Aged; Palliative Care; Prognosis; Prospective Studies; Retrospective Studies | 2016 |
Sarcomatoid Carcinoma of the Bladder in a Child: Case Report of a Successful Treatment Including Gemcitabine and Cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Child, Preschool; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Organ Sparing Treatments; Radiotherapy, Adjuvant; Urinary Bladder Neoplasms | 2016 |
Anti-CCR4 Monoclonal Antibody Mogamulizumab Followed by the GDP (Gemcitabine, Dexamethasone and Cisplatin) Regimen in Primary Refractory Angioimmunoblastic T-Cell Lymphoma.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Lymphadenopathy; Lymphatic Metastasis; Lymphoma, T-Cell; Receptors, CCR4; Salvage Therapy; Tomography, X-Ray Computed | 2017 |
Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Topics: 3' Untranslated Regions; Acrylamides; Animals; Antimetabolites, Antineoplastic; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gemcitabine; Glycolysis; Humans; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; MicroRNAs; NAD; Nicotinamide Phosphoribosyltransferase; Pancreatic Neoplasms; Piperidines; RNA Interference; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Gemcitabine-oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Platinum | 2016 |
Efficacy and tolerance of pegaspargase, gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer (NK)/T cell lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Remission Induction; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Hospitals, University; Humans; Immunohistochemistry; Japan; Kaplan-Meier Estimate; Lymph Nodes; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Patient Selection; Precision Medicine; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Rate; Tegafur | 2016 |
Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Humans; Liposomes; Magnetite Nanoparticles; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Xenograft Model Antitumor Assays | 2016 |
Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Cell Survival; Clone Cells; Deoxycytidine; Diet; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phytochemicals; Quercetin; Sulfoxides | 2016 |
Neoadjuvant chemotherapy in urothelial bladder cancer: impact of regimen and variant histology.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Disease-Free Survival; Female; Gemcitabine; Heterografts; Humans; Irinotecan; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Retrospective Studies; Xenograft Model Antitumor Assays | 2016 |
Clinical outcomes of pancreatic ductal adenocarcinoma resection following neoadjuvant chemoradiation therapy vs. chemotherapy.
Topics: Adult; Aged; Ascites; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Diarrhea; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Tegafur; Treatment Outcome | 2017 |
CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Prognosis; Receptors, Interleukin-8B; Signal Transduction; Small Molecule Libraries; Survival Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
CD44 Expression Level and Isoform Contributes to Pancreatic Cancer Cell Plasticity, Invasiveness, and Response to Therapy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Pancreatic Neoplasms; Protein Isoforms; RNA, Small Interfering | 2016 |
Hypoxia-inducible factor-targeting prodrug TOP3 combined with gemcitabine or TS-1 improves pancreatic cancer survival in an orthotopic model.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hypoxia-Inducible Factor 1; Male; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Prodrugs; Recombinant Fusion Proteins; Silicates; Survival Analysis; Titanium; Tumor Hypoxia; Xenograft Model Antitumor Assays | 2016 |
Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Dipeptides; DNA Repair; Female; Gemcitabine; Humans; Indoles; Phosphorylation; Thiophenes; Triple Negative Breast Neoplasms; Urea | 2016 |
Expression of Bcl-2 19-kDa interacting protein 3 predicts prognosis after ampullary carcinoma resection.
Topics: Adult; Aged; Aged, 80 and over; Ampulla of Vater; Biliary Tract Surgical Procedures; Biomarkers, Tumor; Biopsy, Needle; Chemotherapy, Adjuvant; Cohort Studies; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Genes, bcl-2; Humans; Immunohistochemistry; Japan; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Oxonic Acid; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Rare Diseases; Retrospective Studies; Risk Assessment; Survival Analysis; Tegafur; Thymidylate Synthase | 2016 |
Cationic Supramolecular Vesicular Aggregates for Pulmonary Tissue Selective Delivery in Anticancer Therapy.
Topics: Animals; Antineoplastic Agents; Cations; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Macromolecular Substances; Molecular Structure; Rats; Rats, Wistar; Structure-Activity Relationship; Tissue Distribution; Tumor Cells, Cultured | 2016 |
Terpinen-4-ol: A Novel and Promising Therapeutic Agent for Human Gastrointestinal Cancers.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Mice; Organoplatinum Compounds; Oxaliplatin; Tea Tree Oil; Terpenes; Xenograft Model Antitumor Assays | 2016 |
RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4.
Topics: Adenocarcinoma; Aged; Angiopoietin-Like Protein 4; Angiopoietins; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; RNA, Messenger; ROC Curve; Sequence Analysis, RNA; Survival Analysis; Time Factors | 2016 |
GEMOX: An Active Regimen for the Treatment of Luminal and Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Receptor, ErbB-2; Retrospective Studies; Salvage Therapy; Taxoids; Treatment Outcome | 2017 |
Integrinβ1 modulates tumour resistance to gemcitabine and serves as an independent prognostic factor in pancreatic adenocarcinomas.
Topics: Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Pancreatic Ductal; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Integrin beta1; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Cells, Cultured | 2016 |
CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.
Topics: Albumins; Animals; Antibodies; Antigen-Presenting Cells; Carcinoma, Pancreatic Ductal; CD40 Antigens; CD8-Positive T-Lymphocytes; Clone Cells; Deoxycytidine; Gemcitabine; Immunity, Innate; Interferon-gamma; Lymphocyte Subsets; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Paclitaxel; Pancreatic Neoplasms; T-Lymphocytes; Treatment Outcome; Tumor Microenvironment | 2016 |
Gemcitabine Plus Vinorelbine as Second-Line Therapy in Patients With Metastatic Esophageal Cancer Previously Treated With Platinum-Based Chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Esophageal Neoplasms; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Platinum; Retreatment; Survival Analysis; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Primary Poorly Differentiated Squamous Cell Carcinoma of the Extrahepatic Bile Duct.
Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local | 2016 |
Hypoxia-Responsive Polymersomes for Drug Delivery to Hypoxic Pancreatic Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Hypoxia; Pancreatic Neoplasms; Polymers; Tumor Cells, Cultured | 2016 |
Integrin-Targeting Knottin Peptide-Drug Conjugates Are Potent Inhibitors of Tumor Cell Proliferation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cystine-Knot Miniproteins; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Integrins; Molecular Conformation; Structure-Activity Relationship | 2016 |
[Resection of Advanced Intrahepatic Cholangiocarcinoma after an Effective Response to S-1 and Gemcitabine Combination Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Lymphatic Metastasis; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
Pancreatic Cancer: Multicenter Prospective Data Collection and Analysis by the Hungarian Pancreatic Study Group.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Drinking; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cholangiopancreatography, Endoscopic Retrograde; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Humans; Hungary; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Neuroendocrine Tumors; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Pancreatitis, Chronic; Prognosis; Proportional Hazards Models; Prospective Studies; Registries; Risk Factors; Smoking; Stents; Young Adult | 2016 |
Gemcitabine induces cell senescence in human pancreatic cancer cell lines.
Topics: Cellular Senescence; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2016 |
Primary osteosarcoma of the uterine corpus: A case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Hysterectomy; Lung Neoplasms; Middle Aged; Osteosarcoma; Taxoids; Treatment Outcome; Uterine Neoplasms | 2016 |
P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; E1A-Associated p300 Protein; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; RNA, Small Interfering | 2016 |
Repeated Hepatectomy for Recurrent Intrahepatic Cholangiolocellular Carcinoma: Report of a Case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Reoperation; Survival; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Gemcitabine Induced Cutaneous Collagenous Vasculopathy in a Breast Cancer Patient.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Skin Diseases, Vascular; Telangiectasis | 2016 |
[Overexpression of Keap1 inhibits the cell proliferation and metastasis and overcomes the drug resistance in human lung cancer A549 cells].
Topics: A549 Cells; Antineoplastic Agents; Carboplatin; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; NF-E2-Related Factor 2; Transfection | 2016 |
Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Recurrence; Retreatment; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2017 |
An evaluation of Minor Groove Binders as anti-lung cancer therapeutics.
Topics: Antineoplastic Agents, Phytogenic; Biological Products; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Distamycins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Molecular Structure; Structure-Activity Relationship | 2016 |
Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Drug Monitoring; Female; Gemcitabine; Humans; Japan; Kidney Function Tests; Male; Medication Therapy Management; Methotrexate; Retrospective Studies; Survival Rate; Urologic Neoplasms; Urothelium; Vinblastine | 2016 |
Re: Vinflunine-gemcitabine Versus Vinflunine-carboplatin as First-line Chemotherapy in Cisplatin-unfit Patients with Advanced Urothelial Carcinoma: Results of an International Randomized Phase II Trial (JASINT1).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Treatment Outcome; Vinblastine | 2016 |
Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Macrophage-Activating Factors; Male; Pemetrexed; Treatment Outcome; Ultrasonic Therapy; Vitamin D-Binding Protein | 2016 |
Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms | 2016 |
Regression of experimental NIS-expressing breast cancer brain metastases in response to radioiodide/gemcitabine dual therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; HEK293 Cells; Humans; Iodine Radioisotopes; Mice, Nude; Symporters; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Pancreatic Cancer Survival Increases with Chemo Combo.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2016 |
Capsaicin triggers autophagic cell survival which drives epithelial mesenchymal transition and chemoresistance in bladder cancer cells in an Hedgehog-dependent manner.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Autophagy; Beclin-1; Capsaicin; Cell Line, Tumor; Cell Survival; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Hedgehog Proteins; Homeostasis; Humans; Mitomycin; Oxidation-Reduction; Oxidative Stress; Patched-2 Receptor; Phenotype; Reactive Oxygen Species; Signal Transduction; Urinary Bladder Neoplasms | 2016 |
Knockdown delta-5-desaturase promotes the formation of a novel free radical byproduct from COX-catalyzed ω-6 peroxidation to induce apoptosis and sensitize pancreatic cancer cells to chemotherapy drugs.
Topics: 8,11,14-Eicosatrienoic Acid; Antineoplastic Agents; Apoptosis; Biocatalysis; Caprylates; Cell Line, Tumor; Cyclooxygenase 2; Delta-5 Fatty Acid Desaturase; Deoxycytidine; Drug Resistance, Neoplasm; Fatty Acid Desaturases; Free Radicals; Gemcitabine; Gene Knockdown Techniques; Humans; Lipid Peroxidation; Pancreatic Neoplasms | 2016 |
The alteration of pharmacokinetics of erlotinib and OSI420 in type 1 diabetic rabbits.
Topics: Animals; Antineoplastic Agents; Blood Glucose; Deoxycytidine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Erlotinib Hydrochloride; Female; Gemcitabine; Male; Protein Kinase Inhibitors; Rabbits | 2016 |
Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Killer Cells, Natural; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2016 |
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Topics: Aminopyridines; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Disease Progression; Fibrosis; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Immunoblotting; Immunohistochemistry; Immunotherapy; Immunotherapy, Adoptive; Mice; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Reverse Transcriptase Polymerase Chain Reaction; Tumor Escape; Tumor Microenvironment | 2016 |
Carcinoma of Gall bladder with distant metastasis to breast parenchyma. Report of a case and review of literature.
Topics: Adult; Breast Neoplasms; Carboplatin; Carcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Neoplasm Metastasis; Palliative Medicine | 2016 |
Inhibition of ERα/ERK/P62 cascades induces "autophagic switch" in the estrogen receptor-positive breast cancer cells exposed to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Autophagy; Beclin-1; Breast Neoplasms; Cytoprotection; Deoxycytidine; Estrogen Receptor alpha; Female; Flavonoids; Gemcitabine; Humans; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Prohibitins; RNA Interference; RNA, Small Interfering; Sequestosome-1 Protein; Signal Transduction | 2016 |
Microvesicle removal of anticancer drugs contributes to drug resistance in human pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell-Derived Microparticles; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Tumor Microenvironment | 2016 |
Effectiveness of a Closed-System Transfer Device in Reducing Surface Contamination in a New Antineoplastic Drug-Compounding Unit: A Prospective, Controlled, Parallel Study.
Topics: Antineoplastic Agents; Camptothecin; Cyclophosphamide; Cytarabine; Deoxycytidine; Drug Compounding; Drug Contamination; Fluorouracil; Ganciclovir; Gemcitabine; Humans; Ifosfamide; Irinotecan; Methotrexate; Occupational Exposure; Prospective Studies | 2016 |
Irreversible electroporation enhances delivery of gemcitabine to pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Deoxycytidine; Electrochemotherapy; Gemcitabine; Immunocompromised Host; Mice; Mice, Nude; Pancreatic Neoplasms | 2016 |
Pancreatic cancer: cause for optimism?
Topics: Clinical Trials, Phase III as Topic; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Surveys and Questionnaires | 2016 |
Sézary Syndrome in a 17-Year-Old Boy: Clinicopathologic Features and Genomic Profile.
Topics: Adolescent; Antineoplastic Agents; Biopsy, Needle; Deoxycytidine; Gemcitabine; Genomics; Humans; Immunohistochemistry; Italy; Male; Prognosis; Severity of Illness Index; Sezary Syndrome; Skin Neoplasms; Treatment Outcome | 2016 |
GFRα2 prompts cell growth and chemoresistance through down-regulating tumor suppressor gene PTEN via Mir-17-5p in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Kaplan-Meier Estimate; Male; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; PTEN Phosphohydrolase; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden | 2016 |
Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Republic of Korea; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Endothelial Nitric Oxide Synthase Traffic Inducer (NOSTRIN) is a Negative Regulator of Disease Aggressiveness in Pancreatic Cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Gene Expression; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Male; Nitric Oxide; Nitric Oxide Synthase Type III; Pancreatic Neoplasms | 2016 |
Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Young Adult | 2016 |
A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.
Topics: Animals; Antineoplastic Agents; Benzylidene Compounds; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Progression; Drug Compounding; Drug Therapy, Combination; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Kinase; Injections, Subcutaneous; Liposomes; Mice; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Piperidones; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Long-circulatory nanoparticles for gemcitabine delivery: Development and investigation of pharmacokinetics and in-vivo anticancer efficacy.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Ehrlich Tumor; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Liberation; Erythrocytes; Female; Gemcitabine; Hemolysis; Humans; Male; Mice, Inbred BALB C; Nanoparticles; Polyesters; Polyethylene Glycols; Rats; Tumor Burden | 2016 |
GPRC5A is a potential oncogene in pancreatic ductal adenocarcinoma cells that is upregulated by gemcitabine with help from HuR.
Topics: Antimetabolites, Antineoplastic; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; ELAV-Like Protein 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Binding; Receptors, G-Protein-Coupled; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Tissue Array Analysis | 2016 |
Neutrophil-lymphocyte ratio as a prognostic marker for chemotherapy in advanced lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Paclitaxel; Pemetrexed; Prognosis; Retrospective Studies; Survival Analysis | 2016 |
Selective GPR55 antagonism reduces chemoresistance in cancer cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; beta Catenin; Biomarkers, Tumor; Carrier Proteins; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Fenoterol; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; MCF-7 Cells; Membrane Proteins; Mitogen-Activated Protein Kinase Kinases; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Cannabinoid; Receptors, G-Protein-Coupled; Signal Transduction; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2016 |
Efficacy and safety of extended use of platinum-based doublet chemotherapy plus endostatin in patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Endostatins; Female; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Pemetrexed; Retrospective Studies; Survival Rate; Treatment Outcome | 2016 |
Nutlin-3 reverses the epithelial-mesenchymal transition in gemcitabine-resistant hepatocellular carcinoma cells.
Topics: Apoptosis; Cadherins; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Imidazoles; Liver Neoplasms; Neoplasm Invasiveness; Piperazines; Smad2 Protein; Snail Family Transcription Factors; Tumor Suppressor Protein p53; Vimentin | 2016 |
Bufalin suppresses cancer stem-like cells in gemcitabine-resistant pancreatic cancer cells via Hedgehog signaling.
Topics: Animals; Bufanolides; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hedgehog Proteins; Humans; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
The safety and effect of chemotherapy with short hydration for urothelial cancer on patients' quality of life.
Topics: Adult; Aged; Aged, 80 and over; Cisplatin; Creatinine; Deoxycytidine; Drug Therapy, Combination; Female; Fluid Therapy; Gemcitabine; Glomerular Filtration Rate; Humans; Kidney; Linear Models; Male; Middle Aged; Quality of Life; Treatment Outcome; Urologic Neoplasms | 2016 |
Antitumor gemcitabine conjugated micelles from amphiphilic comb-like random copolymers.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Polyethylene Glycols; Polymers; Rats, Sprague-Dawley; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Hemolytic uremic syndrome due to gemcitabine in a young woman with cholangiocarcinoma.
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Hemolytic-Uremic Syndrome; Humans | 2016 |
A case report of metastasis of malignant mesothelioma to the retromolar trigone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Calbindin 2; Cisplatin; Deoxycytidine; Diagnosis, Differential; Fatal Outcome; Fluorodeoxyglucose F18; Gemcitabine; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Mouth Neoplasms; Pemetrexed; Pleural Neoplasms; Positron Emission Tomography Computed Tomography; Radiography, Panoramic; Radiotherapy, Adjuvant | 2016 |
Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Splenic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Deubiquitinating Enzyme CYLD; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Tumor Suppressor Proteins; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2016 |
A retrospective analysis of survival factors of high intensity focused ultrasound (HIFU) treatment for unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Amylases; Antimetabolites, Antineoplastic; Deoxycytidine; Feasibility Studies; Female; Fever; Fluorouracil; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Injections, Intra-Arterial; Intestinal Obstruction; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Postoperative Complications; Retrospective Studies; Treatment Outcome | 2016 |
Large intergenic non-coding RNA-ROR reverses gemcitabine-induced autophagy and apoptosis in breast cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Humans; Methylation; MicroRNAs; Promoter Regions, Genetic; RNA, Long Noncoding | 2016 |
Augmented delivery of gemcitabine in lung cancer cells exploring mannose anchored solid lipid nanoparticles.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Gemcitabine; Humans; Lipids; Lung Neoplasms; Mannose; Nanoparticles; Structure-Activity Relationship | 2016 |
Coix seed emulsion synergistically enhances the antitumor activity of gemcitabine in pancreatic cancer through abrogation of NF-κB signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Coix; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Drugs, Chinese Herbal; Emulsions; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Seeds; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Ki-67 Antigen; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Survival Rate; Treatment Outcome; Tumor Suppressor Protein p53; Up-Regulation | 2016 |
FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Camptothecin; Carcinoma, Pancreatic Ductal; Cisplatin; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Drug Substitution; Female; Fluorouracil; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Sepsis; Treatment Outcome | 2016 |
Cell Killing Mechanisms and Impact on Gene Expression by Gemcitabine and 212Pb-Trastuzumab Treatment in a Disseminated i.p. Tumor Model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lead Radioisotopes; Mice; Trastuzumab | 2016 |
Cell-cycle-controlled radiation therapy was effective for treating a murine malignant melanoma cell line in vitro and in vivo.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Epithelial Cells; Gemcitabine; Humans; Melanocytes; Melanoma; Mice; Radiation-Sensitizing Agents; Treatment Outcome | 2016 |
Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Endoscopy, Digestive System; Erlotinib Hydrochloride; Female; Gastritis; Gemcitabine; Humans; Maintenance Chemotherapy; Middle Aged; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Recapitulating epithelial tumor microenvironment in vitro using three dimensional tri-culture of human epithelial, endothelial, and mesenchymal cells.
Topics: Cell Line, Tumor; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Endothelial Cells; Epithelial Cells; Gemcitabine; HEK293 Cells; Humans; Keratin-18; Mesenchymal Stem Cells; Paclitaxel; Reactive Oxygen Species; Spheroids, Cellular; Tumor Microenvironment; Vimentin | 2016 |
Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hydrogen-Ion Concentration; Male; Metformin; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pancreatic Stellate Cells; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Next-generation sequencing survey of biliary tract cancer reveals the association between tumor somatic variants and chemotherapy resistance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cyclin-Dependent Kinases; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Mutation; Organoplatinum Compounds; Prognosis; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2016 |
Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Humans; Hypoglycemic Agents; Metformin; Mice, Nude; Pancreas; Pancreatic Neoplasms | 2016 |
Cost-effectiveness analysis of pemetrexed and gemcitabine treatment for advanced nonsmall cell lung cancer in Turkey.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Pemetrexed; Turkey | 2016 |
Enhanced tumor targeting of cRGD peptide-conjugated albumin nanoparticles in the BxPC-3 cell line.
Topics: Albumins; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms; Peptides, Cyclic | 2016 |
The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cisplatin; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Natural Killer T-Cells; Nose Neoplasms; Polyethylene Glycols; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640.
Topics: Acetylation; Adamantane; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Histones; Humans; Pancreatic Neoplasms; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Proto-Oncogene Proteins c-myc; Pyridines; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase | 2016 |
In vitro investigation of multidrug nanoparticles for combined therapy with gemcitabine and a tyrosine kinase inhibitor: Together is not better.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Indoles; Microscopy, Electron, Transmission; Nanoparticles; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib | 2016 |
PEGylated squalenoyl-gemcitabine nanoparticles for the treatment of glioblastoma.
Topics: Absorption, Physicochemical; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Diffusion; Dose-Response Relationship, Drug; Gemcitabine; Glioblastoma; Humans; Molecular Imaging; Nanocapsules; Polyethylene Glycols; Rats; Squalene; Treatment Outcome | 2016 |
[Radiation therapy of pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Dose Fractionation, Radiation; Gemcitabine; Humans; Neoadjuvant Therapy; Organs at Risk; Pancreatectomy; Pancreatic Neoplasms; Radiation Injuries; Radiotherapy; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Adjuvant; Radiotherapy, Image-Guided | 2016 |
Selective single cell isolation for genomics using microraft arrays.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cells, Cultured; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genomics; Humans; Mice; Microarray Analysis; Reproducibility of Results; Sequence Analysis, RNA; Tumor Stem Cell Assay | 2016 |
The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HEK293 Cells; Histocompatibility Antigens; Histone Demethylases; Histone-Lysine N-Methyltransferase; Humans; Interleukin-8; Male; Mice; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, Interleukin-8A; RNA, Small Interfering | 2016 |
The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Survival Rate; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Pulmonary metastases from low grade sarcoma in a patient with pulmonary sarcoidosis. Sarcoidosis or sarcoid-like reaction?
Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Deoxycytidine; Diagnosis, Differential; Drainage; Gemcitabine; Humans; Lung Neoplasms; Male; Multiple Pulmonary Nodules; Neoplasm Grading; Pleural Effusion, Malignant; Predictive Value of Tests; Sarcoidosis, Pulmonary; Sarcoma; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
The Evolving Context of Driver Mutations: ROS1 Rearrangement in Metastatic Non-Small Cell Lung Cancer.
Topics: Adult; Antineoplastic Agents; Asian People; Canada; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Mutation; Neoplasm Metastasis; Pemetrexed; Philippines; Reactive Oxygen Species; Treatment Outcome | 2016 |
Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Prognosis; Randomized Controlled Trials as Topic; Taxoids; Tumor Burden | 2016 |
Hyaluronic acid-coated, prodrug-based nanostructured lipid carriers for enhanced pancreatic cancer therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Flavanones; Gemcitabine; Humans; Hyaluronic Acid; Lipids; Mice; Mice, Inbred C57BL; Nanostructures; Pancreatic Neoplasms; Prodrugs; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Adjuvant Chemotherapy After Radical Cystectomy for Urothelial Bladder Cancer: Outcome and Prognostic Factors for Survival in a French Multicenter, Contemporary Cohort.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; France; Gemcitabine; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2017 |
Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Cytarabine; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mice, Transgenic; Mitosis; Mutation; Nucleosides; Pyrazoles; Pyrimidines; Signal Transduction; Tumor Suppressor Protein p53; Vidarabine | 2016 |
Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Basigin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gemcitabine; HEK293 Cells; Humans; Immunohistochemistry; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Invasiveness; Pancreas; Pancreatic Neoplasms; Phosphorylation; RNA Interference; RNA, Small Interfering; Signal Transduction; STAT3 Transcription Factor; Tissue Array Analysis; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Cell Transformation, Neoplastic; Ciclopirox; Cloning, Molecular; Deoxycytidine; DNA Damage; Down-Regulation; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice; Neoplasm Transplantation; Nuclear Proteins; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; Pyridones; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; RNA-Binding Protein EWS; RNA, Small Interfering; S Phase; Sarcoma, Ewing; Transcriptome | 2016 |
Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carbodiimides; Cell Line, Tumor; Chemistry Techniques, Synthetic; Deoxycytidine; Drug Design; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Immunoglobulin G; Immunoglobulins; Lung Neoplasms; Polymerization; Receptor, IGF Type 1 | 2017 |
Clinical Implications of Hepatocyte Growth Factor, Interleukin-20, and Interleukin-22 in Serum and Bronchoalveolar Fluid of Patients with Non-Small Cell Lung Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Hepatocyte Growth Factor; Humans; Interleukin-22; Interleukins; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Prognosis; Treatment Outcome | 2016 |
Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice, Nude; NADPH Oxidases; Nanog Homeobox Protein; Neoplasm Invasiveness; Neoplastic Stem Cells; NF-kappa B; Pancreatic Neoplasms; Phenotype; Polycomb Repressive Complex 1; Reactive Oxygen Species; Signal Transduction; SOXB1 Transcription Factors; STAT3 Transcription Factor; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Preoperative chemoradiotherapy does not compromise the feasibility of adjuvant chemotherapy for patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Preoperative Period; Radiotherapy Dosage; Retrospective Studies; Tegafur | 2017 |
[S‑1 versus gemcitabine for adjuvant therapy in pancreatic cancer].
Topics: Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2016 |
A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Pilot Projects; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-sma
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Haplotypes; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Staging; Organic Cation Transport Proteins; Organic Cation Transporter 2; Pemetrexed; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Survival Rate; Taxoids; Young Adult | 2016 |
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Compassionate Use Trials; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
Long non-coding RNA UCA1 promotes cisplatin/gemcitabine resistance through CREB modulating miR-196a-5p in bladder cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Cyclic AMP Response Element-Binding Protein; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Promoter Regions, Genetic; RNA Interference; RNA, Long Noncoding; Signal Transduction; Time Factors; Transfection; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Promising in vivo efficacy of the BET bromodomain inhibitor OTX015/MK-8628 in malignant pleural mesothelioma xenografts.
Topics: Acetanilides; Aged; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Down-Regulation; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Mice; Middle Aged; Pemetrexed; Proto-Oncogene Proteins c-myc; Xenograft Model Antitumor Assays | 2017 |
PIM-1 contributes to the malignancy of pancreatic cancer and displays diagnostic and prognostic value.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enhancer of Zeste Homolog 2 Protein; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Male; Neoplasm Proteins; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-pim-1; Signal Transduction; Survival Analysis | 2016 |
Gemcitabine inhibits immune escape of pancreatic cancer by down regulating the soluble ULBP2 protein.
Topics: ADAM10 Protein; Adult; Aged; Amyloid Precursor Protein Secretases; Antimetabolites, Antineoplastic; Deoxycytidine; Down-Regulation; Female; Gemcitabine; GPI-Linked Proteins; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Male; Membrane Proteins; Middle Aged; Pancreatic Neoplasms; Tumor Escape | 2016 |
Gemcitabine-Induced Autophagy Protects Human Lung Cancer Cells from Apoptotic Death.
Topics: A549 Cells; Adenine; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Autophagy-Related Protein 5; bcl-2-Associated X Protein; Beclin-1; Caspase 3; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Membrane Proteins; Microtubule-Associated Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Tumor Suppressor Proteins | 2016 |
Primary Tumor Resection Following Favorable Response to Systemic Chemotherapy in Stage IV Pancreatic Adenocarcinoma with Synchronous Metastases: a Bi-institutional Analysis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Peritoneal Neoplasms; Retrospective Studies; Survival Analysis | 2016 |
TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Line, Tumor; Coculture Techniques; Cysteine-Rich Protein 61; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Membrane Transport Proteins; Pancreatic Neoplasms; Pancreatic Stellate Cells; Signal Transduction; Statistics, Nonparametric; Survival Analysis; Transforming Growth Factor beta; Tumor Microenvironment | 2016 |
Population Pharmacodynamic Model for Bayesian Prediction of Myelosuppression Profiles Based on Routine Clinical Data after Gemcitabine and Carboplatin Treatment.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bayes Theorem; Blood Cell Count; Carboplatin; Deoxycytidine; Erythrocytes; Female; Forecasting; Gemcitabine; Humans; Leukocytes; Male; Middle Aged; Models, Biological; Neoplasms; Retrospective Studies; Treatment Outcome | 2016 |
Gemcitabine-based polymer-drug conjugate for enhanced anticancer effect in colon cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Survival; Colonic Neoplasms; Delayed-Action Preparations; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; HT29 Cells; Humans; Mice, Nude; Micelles; Polyesters; Polyethylene Glycols; Rats; Tumor Burden | 2016 |
Survival variability of controls and definition of imaging endpoints for longitudinal follow-up of pancreatic ductal adenocarcinoma in rats.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Follow-Up Studies; Gemcitabine; Longitudinal Studies; Male; Pancreatic Neoplasms; Rats, Inbred Lew; Survival Rate; X-Ray Microtomography | 2017 |
Repeated iodine-125 seed implantations combined with external beam radiotherapy for the treatment of locally recurrent or metastatic stage III/IV non-small cell lung cancer: a retrospective study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Radiotherapy; Radiotherapy Dosage; Remission Induction; Retrospective Studies; Treatment Outcome | 2016 |
Will gemcitabine monotherapy be dethroned as the adjuvant chemotherapy in pancreatic adenocarcinoma?
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2017 |
Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential.
Topics: Autophagy; Autophagy-Related Proteins; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Membrane Proteins; MicroRNAs; Neoplasm Invasiveness; Pancreatic Neoplasms; Vesicular Transport Proteins | 2016 |
A Case of Mixed Germ Cell Tumor in the Intramedullary Spinal-cord.
Topics: Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Bleomycin; Chorionic Gonadotropin; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Guillain-Barre Syndrome; Humans; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Neoplasms, Germ Cell and Embryonal; Organoplatinum Compounds; Paclitaxel; Paraplegia; Spinal Cord Neoplasms; Tomography, X-Ray Computed | 2016 |
Neutrophil-to-lymphocyte ratio as a prognostic marker in locally advanced nasopharyngeal carcinoma: A pooled analysis of two randomised controlled trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA, Viral; Epstein-Barr Virus Infections; Female; Fluorouracil; Gemcitabine; Herpesvirus 4, Human; Humans; Leukocyte Count; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Neutrophils; Prognosis; Proportional Hazards Models; Radiotherapy; Randomized Controlled Trials as Topic; Singapore; Survival Rate | 2016 |
Evidence of a clinically significant interaction between warfarin and intravesical gemcitabine.
Topics: Administration, Intravesical; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Drug Interactions; Enoxaparin; Gemcitabine; Humans; International Normalized Ratio; Male; Urinary Bladder Neoplasms; Venous Thrombosis; Warfarin | 2016 |
The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Gemcitabine; Humans; Male; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Peptide Fragments; Telomerase; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Diagnostic Microdosing Approach to Study Gemcitabine Resistance.
Topics: Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Deoxycytidine; DNA Repair; Dose-Response Relationship, Drug; Gemcitabine; Humans | 2016 |
The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo.
Topics: Adenine Nucleotide Translocator 1; Adenosine Monophosphate; Adenosine Triphosphate; Adult; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Cyclophilins; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; In Vitro Techniques; Mice; Mice, Nude; Middle Aged; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Pancreatic Neoplasms; Peptidyl-Prolyl Isomerase F; Reactive Oxygen Species; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Immature myeloid cells are critical for enhancing bone fracture healing through angiogenic cascade.
Topics: Adoptive Transfer; Animals; Cell Differentiation; Cell Movement; Cell Separation; Deoxycytidine; Female; Fracture Healing; Fractures, Bone; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Immunosuppression Therapy; Mice, Inbred C57BL; Myeloid Cells; Myeloid-Derived Suppressor Cells; Neovascularization, Physiologic; Osteogenesis; Up-Regulation | 2016 |
[The poor chemotherapeutic efficacy in lung adenocarcinoma overexpressing c-Src and nucleophosmin/B23(NPM1)].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cisplatin; CSK Tyrosine-Protein Kinase; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Nucleophosmin; src-Family Kinases; Treatment Outcome | 2016 |
YAP Inhibition by Resveratrol via Activation of AMPK Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Enzymologic; Humans; Pancreatic Neoplasms; Phosphoproteins; Resveratrol; RNA Interference; Signal Transduction; Stilbenes; Transcription Factors; YAP-Signaling Proteins | 2016 |
Cancer-associated fibroblast exosomes regulate survival and proliferation of pancreatic cancer cells.
Topics: Actins; Antimetabolites, Antineoplastic; Biomarkers; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Humans; MicroRNAs; Models, Biological; Pancreatic Neoplasms; Signal Transduction; Snail Family Transcription Factors; Vimentin | 2017 |
Discovery of a novel chimeric ubenimex-gemcitabine with potent oral antitumor activity.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta, Thoracic; Apoptosis; CD13 Antigens; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Discovery; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Leucine; Molecular Structure; Rats; Structure-Activity Relationship; Swine | 2016 |
Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Transitional Cell; Choriocarcinoma; Cisplatin; Cyclophosphamide; Dactinomycin; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pelvic Neoplasms; Remission Induction; Ureteral Neoplasms | 2017 |
Mastoparan is a membranolytic anti-cancer peptide that works synergistically with gemcitabine in a mouse model of mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Circular Dichroism; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Peptides; Wasp Venoms | 2016 |
Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cell Adhesion Molecules; Cell Cycle; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Nanoscale Coordination Polymers Codeliver Carboplatin and Gemcitabine for Highly Effective Treatment of Platinum-Resistant Ovarian Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms; Platinum; Polymers; Treatment Outcome | 2016 |
[Anti-PLD1 and anti-PD1 in advanced urothelial cancers: promises from early phase trials].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Programmed Cell Death 1 Receptor; Urologic Neoplasms; Vinblastine | 2016 |
Depletion of pro-oncogenic RUNX2 enhances gemcitabine (GEM) sensitivity of p53-mutated pancreatic cancer Panc-1 cells through the induction of pro-apoptotic TAp63.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genes, p53; Humans; Membrane Proteins; Mutation; Pancreatic Neoplasms | 2016 |
Concurrent gemcitabine and radiotherapy for the treatment of muscle-invasive bladder cancer: A pooled individual data analysis of eight phase I-II trials.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Statistics as Topic; Urinary Bladder Neoplasms | 2016 |
Early chemotherapy discontinuation and mortality in older patients with metastatic bladder cancer: The AGEVIM multicenter cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Health Status; Humans; Male; Neoplasm Metastasis; Prospective Studies; Serum Albumin; Survival Rate; Time Factors; Tumor Burden; Urinary Bladder Neoplasms; Withholding Treatment | 2017 |
Gemcitabine inhibits proliferation and induces apoptosis in human pancreatic cancer PANC-1 cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enzyme Activation; Gemcitabine; Gene Expression Regulation; Humans; Inhibitor of Apoptosis Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2016 |
Improvement in advanced pancreatic cancer survival with novel chemotherapeutic strategies - experience of a community based hospital.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, Community; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prevalence; Retrospective Studies; Risk Factors; Survival Rate | 2016 |
Self-Delivery Nanoparticles of Amphiphilic Methotrexate-Gemcitabine Prodrug for Synergistic Combination Chemotherapy via Effect of Deoxyribonucleotide Pools.
Topics: Antineoplastic Agents; Apoptosis; Biological Transport; Caspase 3; Cell Cycle; Cell Survival; Deoxycytidine; Drug Carriers; Drug Resistance, Multiple; Drug Synergism; Gemcitabine; Humans; Hydrophobic and Hydrophilic Interactions; Methotrexate; Models, Molecular; Molecular Conformation; Nanoparticles; Prodrugs | 2016 |
Half generations magnetic PAMAM dendrimers as an effective system for targeted gemcitabine delivery.
Topics: Antineoplastic Agents; Cations; Cell Line, Tumor; Dendrimers; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Half-Life; Humans; Magnetite Nanoparticles; MCF-7 Cells; Particle Size; Polyamines | 2016 |
Nab-paclitaxel+gemcitabine therapy for adenosquamous carcinoma of the pancreas: an autopsy case.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Carcinoma, Adenosquamous; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2016 |
Cell-Based High-Throughput Screening Assay Identifies 2',2'-Difluoro-2'-deoxycytidine Gemcitabine as a Potential Antipoliovirus Agent.
Topics: Antiviral Agents; Deoxycytidine; Gemcitabine; HeLa Cells; High-Throughput Screening Assays; Humans; Poliovirus; Viral Plaque Assay; Virus Replication | 2017 |
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Male; Pneumonia; Protein Kinase Inhibitors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Late DNA Damage Mediated by Homologous Recombination Repair Results in Radiosensitization with Gemcitabine.
Topics: Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; DNA-Binding Proteins; Dose-Response Relationship, Drug; Gamma Rays; Gemcitabine; Histones; Humans; MCF-7 Cells; Rad51 Recombinase; Radiation-Sensitizing Agents; Recombinational DNA Repair; Time Factors | 2016 |
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Induction Chemotherapy; Intraoperative Care; Laparotomy; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
microRNA-520a-3p inhibits proliferation and cancer stem cell phenotype by targeting HOXD8 in non-small cell lung cancer.
Topics: 3' Untranslated Regions; A549 Cells; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Lung Neoplasms; MicroRNAs; Neoplastic Stem Cells; Phenotype; RNA Interference; Transcription Factors; Up-Regulation | 2016 |
Genetic variations associated with gemcitabine treatment outcome in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cadherins; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Genetic Association Studies; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pharmacogenomic Variants; Survival Analysis; Treatment Outcome | 2016 |
DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Calcium-Binding Proteins; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Immunohistochemistry; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Prognosis; Receptor, Notch1; Receptor, Notch3 | 2016 |
Unstable Angina: A Serious Adverse Event following Gemcitabine-Cisplatin Based Chemotherapy.
Topics: Adenocarcinoma; Adult; Angina, Unstable; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Male | 2016 |
Coadministration of a Gloriosa superba extract improves the in vivo antitumoural activity of gemcitabine in a murine pancreatic tumour model.
Topics: Alkaloids; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Colchicine; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Glycosides; Herb-Drug Interactions; Humans; Liliaceae; Mice, Inbred C57BL; Pancreas; Pancreatic Neoplasms; Phytotherapy; Plant Extracts; Seeds | 2016 |
MiRNA-145 increases therapeutic sensibility to gemcitabine treatment of pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; MicroRNAs; Pancreatic Neoplasms; Ribosomal Protein S6 Kinases, 70-kDa | 2016 |
Comparison of gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2017 |
Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Cytokines; Deoxycytidine; Disease Progression; Enzyme Activation; Enzyme Activators; Female; Fibrosis; Gemcitabine; Humans; Metformin; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Phosphorylation; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Granulocyte Colony-Stimulating Factor-Producing Gallbladder Cancer.
Topics: Adenocarcinoma, Papillary; Antimetabolites, Antineoplastic; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged | 2016 |
Metformin potentiates the anticancer activities of gemcitabine and cisplatin against cholangiocarcinoma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Male; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Xenograft Model Antitumor Assays | 2016 |
Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma mouse models.
Topics: Adenocarcinoma; Animals; Apoptosis; Carbolines; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; DNA Damage; Down-Regulation; Drug Synergism; Enzyme Activation; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Macrophages; Mice, Nude; Pancreatic Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Gemcitabine Mechanism of Action Confounds Early Assessment of Treatment Response by 3'-Deoxy-3'-[18F]Fluorothymidine in Preclinical Models of Lung Cancer.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Dideoxynucleosides; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Female; Flow Cytometry; Gemcitabine; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Nude; Positron-Emission Tomography; Radiopharmaceuticals; Xenograft Model Antitumor Assays | 2016 |
Linc-ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR-124/PTBP1/PKM2 axis.
Topics: Autophagy; Carrier Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Heterogeneous-Nuclear Ribonucleoproteins; Humans; Membrane Proteins; MicroRNAs; Pancreatic Neoplasms; Polypyrimidine Tract-Binding Protein; RNA, Long Noncoding; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2016 |
A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male | 2017 |
Tissue Transglutaminase Activates Cancer-Associated Fibroblasts and Contributes to Gemcitabine Resistance in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Coculture Techniques; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Enzyme Activation; Fibroblasts; Gemcitabine; Gene Expression; GTP-Binding Proteins; Humans; Laminin; Mice; Models, Biological; Pancreatic Neoplasms; Protein Glutamine gamma Glutamyltransferase 2; Transglutaminases; Xenograft Model Antitumor Assays | 2016 |
Antitumor Effects of Eribulin Mesylate in Gemcitabine-resistant Pancreatic Cancer Cell Lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Furans; Gemcitabine; Humans; Ketones; Pancreatic Neoplasms | 2016 |
Fisetin Reduces Cell Viability Through Up-Regulation of Phosphorylation of ERK1/2 in Cholangiocarcinoma Cells.
Topics: Cell Line, Tumor; Cell Survival; Cholangiocarcinoma; Deoxycytidine; Flavonoids; Flavonols; Gemcitabine; Humans; MAP Kinase Signaling System; Phosphorylation; Up-Regulation | 2016 |
Impact of the Copper Transporter Protein 1 (CTR1) Polymorphism on Adverse Events among Advanced NonSmall Cell Lung Cancer Patients Treated with a Carboplatin/Gemcitabine Regimen.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cation Transport Proteins; Copper Transporter 1; Deoxycytidine; Female; Gemcitabine; Gene Frequency; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Polymorphism, Single Nucleotide | 2016 |
hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Treatment Outcome | 2016 |
PEG Grafted-Nanodiamonds for the Delivery of Gemcitabine.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Nanodiamonds; Pancreatic Neoplasms; Polyethylene Glycols | 2016 |
Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Anti-Inflammatory Agents; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Complement Activation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Etanercept; Female; Gemcitabine; Humans; Infliximab; Kaplan-Meier Estimate; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Pancreatic Stellate Cells; Proportional Hazards Models; Stromal Cells; Time Factors; Tumor Microenvironment; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2016 |
Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Connective Tissue Growth Factor; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HMGB1 Protein; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macrophages; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Simvastatin; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2017 |
Profiling ribonucleotide and deoxyribonucleotide pools perturbed by gemcitabine in human non-small cell lung cancer cells.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Deoxyribonucleotides; Dose-Response Relationship, Drug; G1 Phase; Gemcitabine; Humans; Lung Neoplasms; Resting Phase, Cell Cycle; Ribonucleotides; S Phase Cell Cycle Checkpoints | 2016 |
Bisdemethoxycurcumin exerts pro-apoptotic effects in human pancreatic adenocarcinoma cells through mitochondrial dysfunction and a GRP78-dependent pathway.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Curcumin; Deoxycytidine; Diarylheptanoids; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Eukaryotic Initiation Factor-2; Gemcitabine; Heat-Shock Proteins; Humans; Mitochondria; Pancreatic Neoplasms; Prohibitins; Protein Deglycase DJ-1; Protein Interaction Maps; Repressor Proteins; RNA Interference; Signal Transduction; Transcription Factor CHOP; Transfection | 2016 |
Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2017 |
Combination of 125I brachytherapy and chemotherapy for unresectable recurrent breast cancer: A retrospective control study.
Topics: Aged; Antimetabolites, Antineoplastic; Brachytherapy; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Iodine Radioisotopes; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies | 2016 |
Photo- and thermo-responsive multicompartment hydrogels for synergistic delivery of gemcitabine and doxorubicin.
Topics: Antineoplastic Agents; Delayed-Action Preparations; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Combinations; Drug Liberation; Gemcitabine; Hydrogels; Micelles; Polymers; Temperature; Ultraviolet Rays | 2017 |
Gemcitabine treatment enhanced the anti-tumor effect of cytokine induced killer cells by depletion of CD4
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytokine-Induced Killer Cells; Cytokines; Cytotoxicity, Immunologic; Deoxycytidine; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Gemcitabine; Humans; Immunomodulation; Immunosuppressive Agents; Lymphocyte Depletion; Male; Mice; Neoplasms; Phenotype; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory | 2017 |
Involvement of bleomycin hydrolase and poly(ADP-ribose) polymerase-1 in Ubc9-mediated resistance to chemotherapy agents.
Topics: Antineoplastic Agents; Bleomycin; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Cysteine Endopeptidases; Deoxycytidine; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Enbucrilate; Etoposide; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Poly (ADP-Ribose) Polymerase-1; Ubiquitin; Ubiquitin-Conjugating Enzymes; Vincristine | 2017 |
Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tegafur | 2017 |
HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
Topics: Adenocarcinoma; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Molecular Targeted Therapy; Neoplasm Proteins; Pancreatic Neoplasms; Recurrence | 2017 |
Gemcitabine-induced hemolytic-uremic syndrome treated with eculizumab or plasmapheresis: two case reports
.
Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Kidney Function Tests; Male; Pancreatic Neoplasms; Plasmapheresis; Purpura, Thrombotic Thrombocytopenic; Renal Dialysis; Treatment Outcome | 2017 |
ASP5878, a selective FGFR inhibitor, to treat FGFR3-dependent urothelial cancer with or without chemoresistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Body Weight; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Fusion; Humans; Molecular Targeted Therapy; Point Mutation; Pyrazoles; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Transcription Factors; Urologic Neoplasms | 2017 |
EUS-guided fine-needle injection of gemcitabine for locally advanced and metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Endosonography; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate; Ultrasonography, Interventional | 2017 |
Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Kaplan-Meier Estimate; Mice, Transgenic; Muscle, Skeletal; Pancreatic Neoplasms; Phenylbutyrates; Tumor Burden; Wasting Syndrome; Xenograft Model Antitumor Assays | 2016 |
Development and characterization of folic acid-conjugated chitosan nanoparticles for targeted and controlled delivery of gemcitabinein lung cancer therapeutics.
Topics: A549 Cells; Animals; Biological Transport; Chitosan; Delayed-Action Preparations; Deoxycytidine; Drug Carriers; Drug Liberation; Folic Acid; Gemcitabine; Humans; Lung Neoplasms; Mice; Nanoparticles; Particle Size; Polyethylene Glycols; Tissue Distribution | 2017 |
Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy; Retrospective Studies; Survival Rate | 2017 |
A SPATIOTEMPORAL MODEL TO SIMULATE CHEMOTHERAPY REGIMENS FOR HETEROGENEOUS BLADDER CANCER METASTASES TO THE LUNG.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Computational Biology; Computer Simulation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Models, Biological; Urinary Bladder Neoplasms | 2017 |
[Two Cases of Unresectable Advanced Gallbladder Cancer in Which Gemcitabine and Cisplatin Therapy Improved the QOL].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Fatal Outcome; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Treatment Outcome | 2016 |
Microdose-Induced Drug-DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carboplatin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; DNA Adducts; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mass Spectrometry; Mice; Mutation; Neoplasms; Platinum; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Sensitive liquid chromatography mass spectrometry (LC-MS) assay reveals novel insights on DNA methylation and incorporation of gemcitabine, its metabolite difluorodeoxyuridine, deoxyuridine, and RX-3117 into DNA.
Topics: Cell Line, Tumor; Chromatography, Liquid; Cytidine; Deoxycytidine; DNA; DNA Methylation; Floxuridine; Gemcitabine; Humans; Limit of Detection; Mass Spectrometry; RNA | 2016 |
Extended exposure to substrate regulates the human equilibrative nucleoside transporter 1 (hENT1).
Topics: Antimetabolites, Antineoplastic; Binding Sites; Cytidine; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; HEK293 Cells; Humans; Protein Transport; Thioinosine | 2016 |
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1.
Topics: Antimetabolites, Antineoplastic; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression; Humans; Indoles; Inhibitory Concentration 50; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Mesothelioma | 2016 |
Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Genotype; Humans; Immunoenzyme Techniques; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Ribonucleoside Diphosphate Reductase; Survival Rate; Taxoids; Tumor Suppressor Proteins; Xeroderma Pigmentosum Group D Protein | 2017 |
Enzalutamide inhibits proliferation of gemcitabine-resistant bladder cancer cells with increased androgen receptor expression.
Topics: Androgens; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Nitriles; Phenylthiohydantoin; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Urinary Bladder Neoplasms | 2017 |
New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamidines; Biomarkers; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Guanidines; Humans; Injections, Intraperitoneal; Injections, Intravenous; Male; Mice; Mice, Inbred BALB C; NF-kappa B; Paclitaxel; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Radiotherapy; Recurrence; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Economic evaluation for the US of nab-paclitaxel plus gemcitabine versus FOLFIRINOX versus gemcitabine in the treatment of metastatic pancreas cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Markov Chains; Models, Econometric; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; United States | 2017 |
Rho-Associated Protein Kinase (ROCK) Inhibitors Inhibit Survivin Expression and Sensitize Pancreatic Cancer Stem Cells to Gemcitabine.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Inhibitor of Apoptosis Proteins; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Kinase Inhibitors; rho-Associated Kinases; Survivin | 2016 |
Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Disease-Free Survival; Docetaxel; Feasibility Studies; Gemcitabine; Humans; Japan; Middle Aged; Neutropenia; Osteosarcoma; Pneumonia; Retrospective Studies; Sarcoma; Taxoids; Treatment Outcome; Tubulin Modulators; Young Adult | 2016 |
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.
Topics: Adenocarcinoma; Animals; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Deoxycytidine; Disease Models, Animal; Gemcitabine; Mice; Models, Theoretical; Radiation-Sensitizing Agents; Treatment Outcome | 2017 |
Quality-of-life evaluation during platinum-based neoadjuvant chemotherapies for urothelial carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prospective Studies; Quality of Life; Urologic Neoplasms | 2017 |
Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Ovarian Neoplasms | 2017 |
Neoadjuvant Gemcitabine Chemotherapy followed by Concurrent IMRT Simultaneous Boost Achieves High R0 Resection in Borderline Resectable Pancreatic Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colitis; Deoxycytidine; Feasibility Studies; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Thrombocytopenia; Treatment Outcome | 2016 |
microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Transfection | 2017 |
Gemcitabine and Antisense-microRNA Co-encapsulated PLGA-PEG Polymer Nanoparticles for Hepatocellular Carcinoma Therapy.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Lactic Acid; Liver Neoplasms; MicroRNAs; Nanoparticles; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2016 |
Effective targeting of gemcitabine to pancreatic cancer through PEG-cored Flt-1 antibody-conjugated dendrimers.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dendrimers; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Gemcitabine; Humans; Male; Mice, Nude; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Surface Properties; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2017 |
Survival prognostic factors for metachronous second primary head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Head and Neck Neoplasms; Humans; Hydroxyurea; Male; Methotrexate; Middle Aged; Neoplasm Staging; Neoplasms, Second Primary; Paclitaxel; Prognosis; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Taxoids; Treatment Outcome; Young Adult | 2017 |
micorRNA-101 silences DNA-PKcs and sensitizes pancreatic cancer cells to gemcitabine.
Topics: Antagomirs; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Chromones; Deoxycytidine; DNA-Activated Protein Kinase; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; MicroRNAs; Morpholines; Nuclear Proteins; Pancreatic Neoplasms; Phosphorylation | 2017 |
Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemothera
Topics: Abdomen; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Deoxycytidine; Dermatofibrosarcoma; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Fatal Outcome; Gemcitabine; Humans; Ifosfamide; Indazoles; Male; Mesna; Middle Aged; Pyrimidines; Skin Neoplasms; Sulfonamides | 2017 |
Designing geriatric-specific trials in advanced lung cancer: What, who and how to study?
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Gemcitabine; Geriatric Assessment; Humans; Lung Neoplasms; Paclitaxel; Vinorelbine | 2017 |
MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Glycosylases; Dose-Response Relationship, Drug; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Paclitaxel; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Tumor Hypoxia; Tumor Microenvironment; Vincristine; Xenograft Model Antitumor Assays | 2017 |
Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Retrospective Studies; Survival Analysis; Urinary Bladder Neoplasms; Venous Thromboembolism | 2017 |
PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells.
Topics: Androstadienes; Cell Line, Tumor; Cell Survival; Chromones; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Wortmannin | 2017 |
Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Survival Analysis; Young Adult | 2016 |
Gemcitabine: Selective cytotoxicity, induction of inflammation and effects on urothelial function.
Topics: Antimetabolites, Antineoplastic; Cell Line; Cell Survival; Cytotoxins; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Inflammation; Urologic Neoplasms; Urothelium | 2017 |
Gemcitabine-induced thrombocytosis as a potential predictive factor in non-small cell lung cancer: analysis of 318 patients.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Retrospective Studies; Thrombocytosis; Treatment Outcome | 2017 |
Prognostic Differences: Epstein-Barr Virus-Associated Primary Leiomyosarcoma of the Spine Versus Spinal Leiomyosarcoma Metastases.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Docetaxel; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunocompromised Host; Leiomyosarcoma; Male; Mediastinal Neoplasms; Middle Aged; Neoplasm Metastasis; Prognosis; Retroperitoneal Neoplasms; Spinal Neoplasms; Taxoids | 2017 |
Ultrasound and microbubble enhanced treatment of inoperable pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Contrast Media; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Microbubbles; Pancreas; Pancreatic Neoplasms; Sonication; Ultrasonography | 2016 |
Stimuli-Sensitive Biodegradable and Amphiphilic Block Copolymer-Gemcitabine Conjugates Self-Assemble into a Nanoscale Vehicle for Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Delivery Systems; Gemcitabine; Mice; Polymers | 2017 |
Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Topics: Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Erlotinib Hydrochloride; Europe; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Surveys and Questionnaires | 2016 |
CYFRA 21-1 is an early predictor of chemotherapeutic effectiveness in advanced nonsmall cell lung cancer: An observational study.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Docetaxel; Female; Gemcitabine; Humans; Keratin-19; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Taxoids; Weight Loss | 2016 |
MiR-216a decreases MALAT1 expression, induces G2/M arrest and apoptosis in pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MicroRNAs; Pancreatic Neoplasms; RNA Processing, Post-Transcriptional; RNA, Long Noncoding | 2017 |
Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Young Adult | 2017 |
Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Benzodioxoles; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Focal Adhesion Kinase 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Inhibitor of Apoptosis Proteins; JNK Mitogen-Activated Protein Kinases; Matrix Metalloproteinase 3; Octamer Transcription Factor-3; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; RNA, Small Interfering; src-Family Kinases; Survivin; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2016 |
A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Constipation; Deoxycytidine; Diarrhea; Disease Progression; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neutropenia; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Influence of Statins and Cholesterol on Mortality Among Patients With Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; California; Carcinoma, Pancreatic Ductal; Cholesterol, LDL; Deoxycytidine; Drug Prescriptions; Female; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Middle Aged; Pancreatic Neoplasms; Pravastatin; Proportional Hazards Models; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Survival Rate | 2017 |
Obatoclax, saliphenylhalamide and gemcitabine inhibit Zika virus infection in vitro and differentially affect cellular signaling, transcription and metabolism.
Topics: Amides; Antiviral Agents; Brain; Caspases; Deoxycytidine; Drug Combinations; Enzyme Inhibitors; Fetus; Gemcitabine; Humans; Indoles; Metabolic Networks and Pathways; Pyrroles; Retinal Pigment Epithelium; RNA, Viral; Salicylates; Signal Transduction; Virus Replication; Zika Virus | 2017 |
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; RNA, Small Interfering; Thiophenes; Urea; Urinary Bladder Neoplasms | 2017 |
Time-Series Modeling and Simulation for Comparative Cost-Effective Analysis in Cancer Chemotherapy: An Application to Platinum-Based Regimens for Advanced Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Irinotecan; Lung Neoplasms; Models, Economic; Paclitaxel; Quality-Adjusted Life Years; Vinblastine; Vinorelbine | 2017 |
Platinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.
Topics: Adolescent; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carcinoma, Medullary; Child; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Paclitaxel | 2017 |
Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2017 |
Gemcitabine Enhances Kras-MEK-Induced Matrix Metalloproteinase-10 Expression Via Histone Acetylation in Gemcitabine-Resistant Pancreatic Tumor-initiating Cells.
Topics: Acetylation; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Histones; Humans; MAP Kinase Kinase Kinases; Matrix Metalloproteinase 10; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer.
Topics: Aged; Apoptosis; Biopsy; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Glucose Transporter Type 1; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phosphoproteins; Prognosis; Proto-Oncogene Proteins c-akt; RNA, Messenger; Spheroids, Cellular; Tumor Cells, Cultured | 2017 |
Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Mice; Neoplastic Stem Cells; Organoplatinum Compounds; Oxaliplatin; p21-Activated Kinases; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Databases, Factual; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Analysis; Tumor Suppressor Proteins; Urinary Bladder Neoplasms | 2017 |
Dual Enzymatic Reaction-Assisted Gemcitabine Delivery Systems for Programmed Pancreatic Cancer Therapy.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Matrix Metalloproteinase 9; Nanoparticles; Pancreatic Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.
Topics: Animals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Lymphocyte Activation; Mammary Neoplasms, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Transplantation; Tumor Burden; V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 2017 |
[Recommendations for the management of pancreatic cancer type adenocarcinoma: A consensus statement reached during the 2015 Latin American Symposium on Gastroenterological Oncology].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Consensus Development Conferences as Topic; Deoxycytidine; Disease Management; Gemcitabine; Humans; Latin America; Pancreatic Neoplasms; Practice Guidelines as Topic | 2016 |
Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer.
Topics: 5'-Nucleotidase; Actins; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Triphosphate; Deoxycytidine; Fibroblasts; Floxuridine; Gemcitabine; Humans; Liver; Liver Neoplasms; Mice; Pancreatic Neoplasms; Primary Cell Culture; Tumor Microenvironment | 2018 |
Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Interleukin-18; L-Lactate Dehydrogenase; Male; Middle Aged; Pancreatic Neoplasms; Prognosis | 2017 |
The telomere-binding protein TRF2 is required for metronomic therapeutic effects of gemcitabine and capecitabine.
Topics: Administration, Metronomic; Animals; Capecitabine; Cell Line, Tumor; Deoxycytidine; Drug Resistance; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Proteins; Ovarian Neoplasms; Telomere Homeostasis; Telomeric Repeat Binding Protein 2 | 2017 |
Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capsaicin; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Resveratrol; Signal Transduction; Stilbenes | 2017 |
Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Positron Emission Tomography Computed Tomography; Recurrence; Retrospective Studies; Rituximab; Tomography, X-Ray Computed; Young Adult | 2017 |
Cisplatin can be safely administered to ovarian cancer patients with hypersensitivity to carboplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Drug Hypersensitivity; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Retrospective Studies | 2017 |
Backbone Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts.
Topics: Acrylamides; Animals; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Polymers; Xenograft Model Antitumor Assays | 2017 |
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azabicyclo Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Oligopeptides; Pancreatic Neoplasms; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2017 |
Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy.
Topics: Animals; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Peptides; Prodrugs; Prostatic Neoplasms, Castration-Resistant; Rats, Wistar; Receptors, LHRH; Tissue Distribution; Tumor Cells, Cultured | 2017 |
A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biliary Tract Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Klatskin Tumor; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreaticoduodenectomy; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2017 |
Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Deoxycytidine; Erlotinib Hydrochloride; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Tertiary Care Centers | 2017 |
Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine for Locally Advanced Unresectable Pancreatic Cancer: Results from a Feasibility Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Survival Analysis; Treatment Outcome | 2017 |
Second-Line Combination Therapies in Pancreatic Cancer: Where Are We Now?
Topics: Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2017 |
Palliative Chemotherapy for Bladder Cancer: Treatment Delivery and Outcomes in the General Population.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine; Young Adult | 2017 |
BAP1 dependent expression of long non-coding RNA NEAT-1 contributes to sensitivity to gemcitabine in cholangiocarcinoma.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mutation; RNA, Long Noncoding; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2017 |
Gemcitabine and S-1 versus gemcitabine and cisplatin treatment in patients with advanced biliary tract cancer: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Tegafur; Young Adult | 2017 |
The Value of Survival Gains in Pancreatic Cancer from Novel Treatment Regimens.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Survival Analysis | 2017 |
HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells.
Topics: Activating Transcription Factor 4; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Death; Cell Line, Tumor; Deoxycytidine; Endoplasmic Reticulum Chaperone BiP; Gemcitabine; Glutathione Peroxidase; Heat-Shock Proteins; Humans; Lipid Peroxidation; Mice; Pancreatic Neoplasms; Phospholipid Hydroperoxide Glutathione Peroxidase | 2017 |
[Radical Resection of cT3a Gallbladder Cancer after Neoadjuvant Chemotherapy - A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholecystitis, Acute; Cisplatin; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Neoplasm Staging | 2016 |
[A Case of Surgical Resection for Gallbladder Cancer with Para-Aortic Lymph Node Metastasis Following Neoadjuvant Chemotherapy with Gemcitabine, Cisplatin, and TS-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Silicates; Titanium | 2016 |
[Antitumor Effects of a Combined Treatment with Bortezomib and Gemcitabine in Bile Duct Cancer Cell Lines].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bortezomib; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; NF-kappa B; Signal Transduction | 2016 |
[Long-Term Survival after Locally Advanced Pancreatic Ductal Adenocarcinoma Treated with Multidisciplinary Therapy - A Case Report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Endoscopic Ultrasound-Guided Fine Needle Aspiration; Gemcitabine; Humans; Male; Oxonic Acid; Pancreaticoduodenectomy; Tegafur; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
[Experience with Gemcitabine plus Nab-Paclitaxel Therapy for Advanced Metastatic Pancreatic Cancer in Our Hospital].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Multimodal Imaging; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
[Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Recurrence; Treatment Outcome | 2016 |
[A Study of Gemctabine plus Nab-Paclitaxel Therapy for Advanced Local Progressive Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
[Surgical Resection after Gemcitabine plus Cisplatin Chemotherapy for Intrahepatic Cholangiocarcinoma with Multiple Lymph Node Metastases - Report of a Case].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Hepatectomy; Humans; Lymphatic Metastasis; Male; Neoadjuvant Therapy | 2016 |
[A Case of Successful Stomach-Preserving Pancreaticoduodenectomy with Celiac Artery Resection after Neoadjuvant Chemoradiation Therapy for Pancreatic Cancer with Hepatic Arterial Variation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Hepatic Artery; Humans; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tegafur | 2016 |
[A Case of Borderline Resectable Pancreatic Cancer Responding to Preoperative GEM plus Nab-PTX Combination Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2016 |
[A Case of Remnant Pancreatic Cancer after Pancreatoduodenectomy Successfully Treated Using Chemotherapy and Carbon-Ion Radiotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Heavy Ion Radiotherapy; Humans; Pancreatic Neoplasms; Pancreaticoduodenectomy; Treatment Outcome | 2016 |
[Long-Term Survival in Response to Multimodality Therapy in a Patient with Invasive Pancreatic Cancer with Cyst Formation].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cysts; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Pancreatectomy; Pancreatic Neoplasms; Time Factors | 2016 |
[A Case of Curatively Resected Locally Advanced Cancer of the Pancreatic Body Treated by Distal Pancreatectomy with En Bloc Celiac Axis Resection after Preoperative Intensive Treatment].
Topics: Aged; Albumins; Celiac Artery; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms | 2016 |
[A Case of Liver Metastasis of Ampullary Carcinoma That Developed Postoperatively That Was Effectively Treated with Gemcitabine plus Cisplatin].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Common Bile Duct Neoplasms; Deoxycytidine; Duodenal Neoplasms; Fatal Outcome; Gemcitabine; Humans; Liver Neoplasms; Male; Pancreaticoduodenectomy | 2016 |
[A Case of Locally Advanced Gallbladder Cancer That Developed Early Multiple Liver Metastasis after Curative Resection, and Achieved Long-TermPartial Remission Using S-1 and Gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Oxonic Acid; Tegafur; Treatment Outcome | 2016 |
[A Long-Surviving Case of Unresectable Gall Bladder Carcinoma Treated with Gemcitabine-Based Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Time Factors | 2016 |
[A Case of Metachronous Liver Metastases of Gall Bladder Cancer Successfully Treated by Liver Resection].
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cholecystectomy; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms | 2016 |
[Regrowth of Isolated Local Residual Tumor Effectively Treated with Chemoradiotherapy More Than Five Years after a Resection for Pancreatic Cancer with an Involvement of the Portal Vein].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Neoplasm, Residual; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Portal Vein; Tegafur | 2016 |
[Pancreatic Adenosquamous Carcinoma That Developed after Resection of IPMA in the Pancreatic Tail].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Tegafur | 2016 |
[Two Year Recurrence Free Survival after Resection of Cutaneous Metastasis from Pancreatic Cancer - A Case Report].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Recurrence; Skin Neoplasms; Thalamus; Time Factors | 2016 |
[A Case of Peritoneal Dissemination of Hilar Cholangiocarcinoma Presenting with Hematuria Six Years after Radical Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Hematuria; Humans; Klatskin Tumor; Male; Peritoneal Neoplasms; Time Factors | 2016 |
[A Case of Lymph Node Metastasis of Intrahepatic Bile Duct Cancer Successfully Treated Using Multidisciplinary Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lymphatic Metastasis; Male; Oxonic Acid; Recurrence; Tegafur; Treatment Outcome | 2016 |
A novel HDAC inhibitor, CG200745, inhibits pancreatic cancer cell growth and overcomes gemcitabine resistance.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Mice; Naphthalenes; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Ras-MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Signaling System; Mice; Osteosarcoma; Ovarian Neoplasms; Piperidines; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2017 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
Plasmonic nanocarrier grid-enhanced Raman sensor for studies of anticancer drug delivery.
Topics: Antineoplastic Agents; Biosensing Techniques; Delayed-Action Preparations; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Equipment Design; Folic Acid; Gemcitabine; Glutathione; Gold; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Spectrum Analysis, Raman | 2017 |
The marine triterpene glycoside frondoside A induces p53-independent apoptosis and inhibits autophagy in urothelial carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Glycosides; Humans; Sea Cucumbers; Triterpenes; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms | 2017 |
Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.
Topics: 3' Untranslated Regions; Catalase; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Dynamic Light Scattering; Exosomes; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Reactive Oxygen Species; Superoxide Dismutase | 2017 |
Ku70 inhibits gemcitabine-induced DNA damage and pancreatic cancer cell apoptosis.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Ku Autoantigen; Mice; Mice, SCID; Pancreatic Neoplasms | 2017 |
Knockdown of POLA2 increases gemcitabine resistance in lung cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Chromosome Mapping; Computational Biology; Deoxycytidine; DNA Polymerase I; Drug Resistance, Neoplasm; Epistasis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Polymorphism, Single Nucleotide | 2016 |
Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Michaelson MD, McKay RR, Werner L, Atkins MB, Van Allen EM, Olivier KM, Song J, Signoretti S, McDermott DF, Choueiri TK.Cancer. 2015
Topics: Carcinoma, Renal Cell; Deoxycytidine; Gemcitabine; Humans; Kidney Neoplasms; Sunitinib | 2017 |
Multifunctionalized iron oxide nanoparticles for selective targeting of pancreatic cancer cells.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; CD47 Antigen; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Gemcitabine; Humans; Magnetics; Magnetite Nanoparticles; Nanomedicine; Neoplastic Stem Cells; Pancreatic Neoplasms; Surface Properties; Tumor Cells, Cultured | 2017 |
The Detection of Urinary Podocytes from Drug-Induced Glomerular Thrombotic Microangiopathy in Advanced Cancer Patients.
Topics: Acute Kidney Injury; Aged; Antineoplastic Agents; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Nephrotic Syndrome; Podocytes; Predictive Value of Tests; Protein Kinase Inhibitors; Retrospective Studies; Thrombotic Microangiopathies; Time Factors; Urinalysis; Urine | 2016 |
Everolimus Inhibits Growth of Gemcitabine-Resistant Pancreatic Cancer Cells via Induction of Caspase-Dependent Apoptosis and G
Topics: Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; M Phase Cell Cycle Checkpoints; Neoplasm Proteins; Pancreatic Neoplasms | 2017 |
Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma.
Topics: Animals; Antibodies, Monoclonal; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Molecular Targeted Therapy; Neural Cell Adhesion Molecule L1; Tissue Distribution; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
PARP inhibitor increases chemosensitivity by upregulating miR-664b-5p in BRCA1-mutated triple-negative breast cancer.
Topics: Base Sequence; BRCA1 Protein; Carboplatin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclins; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; MicroRNAs; Middle Aged; Mutation; Neoplasm Invasiveness; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms; Up-Regulation | 2017 |
Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder
.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Genotype; Humans; Introns; Logistic Models; Male; Middle Aged; Models, Genetic; N-Acetylgalactosaminyltransferases; Pharmacogenetics; Pharmacogenomic Variants; Phenotype; Polymorphism, Single Nucleotide; Polypeptide N-acetylgalactosaminyltransferase; Prospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2017 |
Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Deoxycytidine; Endoplasmic Reticulum Stress; Female; Gemcitabine; Genes, myc; Genes, ras; Humans; Male; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mesoderm; Mice; Mosaicism; Oncogene Protein p55(v-myc); Pancreatic Neoplasms; Proteolysis; Proto-Oncogene Proteins p21(ras); SMARCB1 Protein; Transcriptome | 2017 |
Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins.
Topics: Aged; alpha Karyopherins; Antineoplastic Agents; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; DNA Repair; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Transport; RNA Interference; Tumor Burden | 2017 |
Thrombotic Microangiopathy in a Patient Treated With Gemcitabine.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Thrombotic Microangiopathies | 2017 |
A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
Topics: Adenoviridae; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplastic Stem Cells; Oncolytic Virotherapy; Paclitaxel; Pancreatic Neoplasms; Receptors, Notch; Receptors, Urokinase Plasminogen Activator; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Biomimetic nanoassemblies of 1-O-octodecyl-2-conjugated linoleoyl-sn-glycero-3-phosphatidyl gemcitabine with phospholipase A
Topics: Animals; Antineoplastic Agents; Biomimetics; Cholesterol Esters; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms; Mice; Nanomedicine; Nanostructures; Phospholipases A2; Polyethylene Glycols; Polymers; Prodrugs | 2017 |
Current Status of Uterine Leiomyosarcoma in the Tohoku Region: Results of the Tohoku Translational Center Development Network Survey.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Health Surveys; Humans; Japan; Leiomyosarcoma; Lymph Node Excision; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Taxoids; Uterine Neoplasms | 2017 |
Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC): Results from a National Multi-Center Study on Safety and Efficacy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carboplatin; Chemoembolization, Therapeutic; Cholangiocarcinoma; Cisplatin; Cohort Studies; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Mitomycin; Starch | 2017 |
Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.
Topics: Antineoplastic Agents; Carboplatin; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Damage; DNA Repair; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Neuroblastoma; Organoplatinum Compounds; Oxaliplatin; Ploidies; Ultraviolet Rays | 2017 |
Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Immunosuppressive Agents; India; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Survival Rate; Time Factors; Treatment Outcome | 2017 |
MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Microdissection; MicroRNAs; Pancreatic Neoplasms; Prognosis; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
OCTN1 Is a High-Affinity Carrier of Nucleoside Analogues.
Topics: Animals; Antimetabolites, Antineoplastic; Child; CHO Cells; Cohort Studies; Cricetulus; Cytarabine; Deoxycytidine; Dipyridamole; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; HEK293 Cells; HeLa Cells; Humans; Leukemia, Myeloid, Acute; Organic Cation Transport Proteins; Symporters | 2017 |
Elevated interferon-induced protein with tetratricopeptide repeats 3 (IFIT3) is a poor prognostic marker in pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Tumor Cells, Cultured; Up-Regulation | 2017 |
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Failure; Treatment Outcome | 2017 |
All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase.
Topics: Catalysis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Tretinoin; Up-Regulation | 2017 |
[Conversion Surgery for Initially Unresectable Locally Advanced Pancreatic Cancer Following Gemcitabine plus Nab-Paclitaxel - A Case Report].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Gemcitabine and docetaxel as a novel treatment regimen for blastic plasmacytoid dendritic cell neoplasm.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dendritic Cells; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Hematologic Neoplasms; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Taxoids | 2017 |
A case report of posterior reversible encephalopathy syndrome in a patient receiving gemcitabine and cisplatin.
Topics: Antineoplastic Agents; Brain; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Posterior Leukoencephalopathy Syndrome | 2017 |
Clinical efficacy and safety of gemcitabine plus nedaplatin in the treatment of advanced nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Case-Control Studies; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Grading; Neoplasm Staging; Organoplatinum Compounds; Treatment Outcome | 2016 |
Clinical impact of circulating tumor cells and therapy response in pancreatic cancer.
Topics: Antineoplastic Agents; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Multivariate Analysis; Neoplasm Staging; Neoplastic Cells, Circulating; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Tegafur | 2017 |
Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2017 |
Combination of l-Carnitine with Lipophilic Linkage-Donating Gemcitabine Derivatives as Intestinal Novel Organic Cation Transporter 2-Targeting Oral Prodrugs.
Topics: Animals; Antimetabolites, Antineoplastic; Caco-2 Cells; Carnitine; Deoxycytidine; Gemcitabine; HEK293 Cells; Humans; Mice; Molecular Docking Simulation; Organic Cation Transport Proteins; Prodrugs; Solute Carrier Family 22 Member 5; Tissue Distribution | 2017 |
Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Aorta; Apoptosis; Cattle; Cell Proliferation; Cells, Cultured; Ceramides; Deoxycytidine; Endothelial Cells; Gemcitabine; Signal Transduction; Sphingomyelin Phosphodiesterase | 2017 |
Metabolic profiling of gemcitabine- and paclitaxel-treated immortalized human pancreatic cell lines with K-RAS
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, ras; Glycolysis; Humans; Metabolome; Mutation; Paclitaxel; Pancreatic Neoplasms | 2017 |
Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells.
Topics: Aerobiosis; Carcinogenesis; Cell Line, Tumor; Deoxycytidine; Doublecortin-Like Kinases; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glycolysis; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Up-Regulation | 2017 |
Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; France; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2017 |
Difference in toxicity reporting between patients and clinicians during systemic chemotherapy in patients with urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Constipation; Deoxycytidine; Diarrhea; Feeding and Eating Disorders; Female; Gemcitabine; Humans; Male; Nausea; Patient Reported Outcome Measures; Prospective Studies; Quality of Life; Retrospective Studies; Treatment Outcome; Urologic Neoplasms | 2017 |
Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Delayed-Action Preparations; Dendrimers; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Peptides; Xenograft Model Antitumor Assays | 2017 |
Sclareolide enhances gemcitabine‑induced cell death through mediating the NICD and Gli1 pathways in gemcitabine‑resistant human pancreatic cancer.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diterpenes; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Pancreatic Neoplasms; Phenotype; Receptors, Notch; Ribonucleoside Diphosphate Reductase; Signal Transduction; Tumor Suppressor Proteins; Up-Regulation; Zinc Finger Protein GLI1 | 2017 |
Low MUC4 expression is associated with survival benefit in patients with resectable pancreatic cancer receiving adjuvant gemcitabine.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Mucin-4; Pancreas; Pancreatic Neoplasms; Survival Analysis; Sweden | 2017 |
Ecological Factors in Human Development.
Topics: Capecitabine; Deoxycytidine; Friends; Gemcitabine; Humans; Pancreatic Neoplasms; Social Identification | 2017 |
Modulation of chemotherapy-induced cytotoxicity in SH-SY5Y neuroblastoma cells by caffeine and chlorogenic acid.
Topics: Antineoplastic Agents; Apoptosis; Caffeine; Cell Line, Tumor; Cell Survival; Chlorogenic Acid; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Interactions; Gemcitabine; Humans; Paclitaxel; Reactive Oxygen Species | 2017 |
Development of Optimized, Inhalable, Gemcitabine-Loaded Gelatin Nanocarriers for Lung Cancer.
Topics: A549 Cells; Administration, Inhalation; Aerosols; Calorimetry, Differential Scanning; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chemistry, Pharmaceutical; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Gelatin; Gemcitabine; Humans; Lung Neoplasms; Nanoparticles; Particle Size; Viscosity; X-Ray Diffraction | 2017 |
Lymph cancer chemotherapy: delivery of doxorubicin-gemcitabine prodrug and vincristine by nanostructured lipid carriers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Lipids; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanostructures; Tissue Distribution; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays | 2017 |
Tumor-targeted polymeric nanostructured lipid carriers with precise ratiometric control over dual-drug loading for combination therapy in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Stability; Endocytosis; Galactose; Gemcitabine; Humans; Inhibitory Concentration 50; Lipids; Lung Neoplasms; Mice; Nanostructures; Paclitaxel; Polymers | 2017 |
Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Delivery of Health Care; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Length of Stay; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Time Factors | 2017 |
Cholangiocellular Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Incidence; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Staging; Palliative Care; Precision Medicine; Survival Rate | 2017 |
Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing.
Topics: Adenocarcinoma; Animals; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Chickens; Chorioallantoic Membrane; Crizotinib; Deoxycytidine; DNA Mutational Analysis; Drug Evaluation, Preclinical; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 6; Luminescent Measurements; MicroRNAs; Models, Biological; Pancreatic Neoplasms; Sequence Analysis, DNA; SOX9 Transcription Factor; Tumor Cells, Cultured | 2017 |
Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer.
Topics: Aged; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
New Interventional Treatment Model for Pancreatic Neoplasms Using Gemcitabine-Eluting Hydrogel Devices: In Vitro and In Vivo Results.
Topics: Adenocarcinoma; Animals; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Equipment Design; Gemcitabine; Hydrogel, Polyethylene Glycol Dimethacrylate; In Vitro Techniques; Injections, Intravenous; Pancreas; Pancreatic Neoplasms; Swine; Vascular Access Devices | 2017 |
The effect of adjuvant chemotherapy in patients with intrahepatic cholangiocarcinoma: a matched pair analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Male; Matched-Pair Analysis; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Prognosis; Survival Rate; Treatment Outcome | 2017 |
Prognostic impact of normalization of serum tumor markers following neoadjuvant chemotherapy in patients with borderline resectable pancreatic carcinoma with arterial contact.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteries; Biomarkers, Tumor; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Regional Blood Flow; Retrospective Studies; Survival Analysis; Tegafur | 2017 |
Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; HEK293 Cells; Humans; Male; Mice; Mice, Nude; Oncolytic Virotherapy; Pancreatic Neoplasms; Random Allocation; Relaxin; Xenograft Model Antitumor Assays | 2017 |
Silencing of ATF2 inhibits growth of pancreatic cancer cells and enhances sensitivity to chemotherapy.
Topics: Activating Transcription Factor 2; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; RNA, Small Interfering | 2017 |
Genotoxicity kinetics in murine normoblasts as an approach for the in vivo action of difluorodeoxycytidine.
Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Cell Survival; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Erythroblasts; Erythrocytes; Gemcitabine; Kinetics; Male; Mice; Mice, Inbred BALB C; Micronucleus Tests; Mutagens | 2017 |
Tailoring the properties of mPEG-PLLA nanoparticles for better encapsulation and tuned release of the hydrophilic anticancer drug.
Topics: Animals; Antineoplastic Agents; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Fluorescent Dyes; Gemcitabine; Hep G2 Cells; Humans; Hydrophobic and Hydrophilic Interactions; Male; MCF-7 Cells; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Polyesters; Polyethylene Glycols; Rats, Wistar; Rhodamines | 2017 |
Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
Topics: Angiogenic Proteins; Animals; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Mice; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Protein Binding; Proto-Oncogene Mas; Proto-Oncogene Proteins c-jun; Ribonucleoside Diphosphate Reductase; Transcriptional Activation; Xenograft Model Antitumor Assays | 2017 |
Atypical lymphoproliferative disorder-clinical and pathological features.
Topics: Aged; Antineoplastic Agents; Deoxycytidine; Depsipeptides; Female; Gemcitabine; Humans; Lymphoproliferative Disorders; Mycosis Fungoides; Radiotherapy; Skin Neoplasms | 2016 |
Improvement in the prognosis of ovarian cancer in the era before addition of molecular targeting therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Demography; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Polyethylene Glycols; Prognosis | 2017 |
Impact of Secreted Protein Acidic and Rich in Cysteine (SPARC) Expression on Prognosis After Surgical Resection for Biliary Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Carcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; Osteonectin; Prognosis; Retrospective Studies; Risk Factors; Survival Analysis | 2017 |
Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy.
Topics: Antimetabolites, Antineoplastic; Blood Cell Count; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Lymphocyte Count; Male; Palliative Care; Pancreatic Neoplasms; Platelet Count; Prognosis; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2017 |
Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.
Topics: Antimetabolites, Antineoplastic; Cytidine Deaminase; Deoxycytidine; Drug Monitoring; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Deoxycytidine; Gemcitabine; Humans; NAD(P)H Dehydrogenase (Quinone); Naphthoquinones; Paclitaxel; Pancreatic Neoplasms | 2017 |
In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models.
Topics: Animals; Cell Line, Tumor; Cytosine; Deoxycytidine; Female; Gemcitabine; Humans; Mice, Nude; Mice, Transgenic; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells.
Topics: A549 Cells; ATP Binding Cassette Transporter, Subfamily B, Member 1; Calcium-Binding Proteins; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; EGF Family of Proteins; Endothelial Growth Factors; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; RNA Interference; RNA, Small Interfering | 2017 |
Preclinical Evaluation of the Short-Term Toxicity of 4-(N)-Docosahexaenoyl 2´, 2´- Difluorodeoxycytidine (DHA-dFdC).
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Compounding; Female; Gemcitabine; Humans; Leukemia L1210; Maximum Tolerated Dose; Mice, Inbred DBA | 2017 |
Fluorescent Immortalized Human Adipose Derived Stromal Cells (hASCs-TS/GFP+) for Studying Cell Drug Delivery Mediated by Microvesicles.
Topics: Adipose Tissue; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; Fluorescence; Gemcitabine; Green Fluorescent Proteins; Humans; Mesenchymal Stem Cells; Molecular Structure; Paclitaxel; Simian virus 40; Structure-Activity Relationship; Telomerase | 2017 |
Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study.
Topics: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Sarcoma; Taxoids; Young Adult | 2018 |
USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling.
Topics: Antimetabolites, Antineoplastic; Carcinogenesis; Cell Line; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Phosphoprotein Phosphatases; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Signal Transduction; Tacrolimus Binding Proteins; Tissue Array Analysis; Ubiquitin Thiolesterase | 2017 |
Curcumin and its cyclohexanone analogue inhibited human Equilibrative nucleoside transporter 1 (ENT1) in pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Curcumin; Cyclohexanones; Deoxycytidine; Drug Interactions; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms; Uridine | 2017 |
Gemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of Gemcitabine and Inhibit Proliferation and Metastasis In Human SW1990 Pancreatic Cancer Cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Chitosan; Cytoplasm; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Nanoparticles; Neoplasm Metastasis; Pancreatic Neoplasms | 2017 |
miR-202 Diminishes TGFβ Receptors and Attenuates TGFβ1-Induced EMT in Pancreatic Cancer.
Topics: Adenosine; Animals; Capecitabine; Cell Line, Tumor; Deoxycytidine; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lentivirus; Mice; MicroRNAs; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2017 |
Comparison of Efficacy of Adjuvant MEC (Methotrexate, Epirubicin and Cisplatin) and GC (Gemcitabine and Cisplatin) in Advanced Upper Tract Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Survival Rate; Urologic Neoplasms | 2017 |
Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Prognosis; Survival Rate | 2017 |
Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.
Topics: Adenocarcinoma; Aged; AMP-Activated Protein Kinase Kinases; Carbamoyl-Phosphate Synthase (Ammonia); Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metabolic Networks and Pathways; Metabolome; Middle Aged; Pemetrexed; Prognosis; Proportional Hazards Models; Protein Serine-Threonine Kinases; Proteome; RNA, Messenger; Signal Transduction; Survival Rate; Thiophenes; Tissue Array Analysis; Urea | 2017 |
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Actin Cytoskeleton; Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Biosensing Techniques; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Collagen; Deoxycytidine; Disease Progression; Extracellular Matrix; Gemcitabine; Humans; Liver; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; Protein Kinase Inhibitors; rho-Associated Kinases; Signal Transduction; src-Family Kinases; Treatment Outcome | 2017 |
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cancer Pain; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Health Status; Humans; Irinotecan; Jaundice; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Nomograms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Prospective Studies; Retreatment; Risk Factors; Smoking; Survival Rate | 2017 |
YWHAE-rearranged high-grade endometrial stromal sarcoma: Two-center case series and response to chemotherapy.
Topics: 14-3-3 Proteins; Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Endometrial Stromal Tumors; Female; Gemcitabine; Gene Rearrangement; Humans; Middle Aged; Neoplasm Grading; Retrospective Studies; Taxoids | 2017 |
The impact of a solitary kidney on tolerability to gemcitabine plus cisplatin chemotherapy in urothelial carcinoma patients: a retrospective study.
Topics: Acute Kidney Injury; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Male; Middle Aged; Nephrectomy; Neutropenia; Retrospective Studies; Urinary Bladder Neoplasms | 2017 |
The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Damage; DNA Repair; Drug Synergism; Gemcitabine; Humans; Lymphoma; Male; Melphalan; Middle Aged; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Reactive Oxygen Species; Tumor Cells, Cultured | 2017 |
Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatectomy; Pancreatic Neoplasms | 2017 |
Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; Butylhydroxybutylnitrosamine; Cytokines; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mitomycin; Neoplasms, Experimental; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Proto-Oncogene Proteins p21(ras); Republic of Korea; Retrospective Studies; Treatment Outcome | 2017 |
Extra-pancreatic invasion induces lipolytic and fibrotic changes in the adipose microenvironment, with released fatty acids enhancing the invasiveness of pancreatic cancer cells.
Topics: Adipose Tissue; Adiposity; Animals; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Fatty Acids; Gemcitabine; Humans; Lipolysis; Mice; Neoplasm Invasiveness; Pancreatic Neoplasms | 2017 |
Validated UHPLC-MS/MS assay for quantitative determination of etoposide, gemcitabine, vinorelbine and their metabolites in patients with lung cancer.
Topics: Aged; Antineoplastic Agents; Chromatography, High Pressure Liquid; Cohort Studies; Deoxycytidine; Etoposide; Gemcitabine; Humans; Linear Models; Lung Neoplasms; Middle Aged; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Vinblastine; Vinorelbine | 2017 |
Advanced penile cancer with iliac lymph node involvement treated with radiation and concurrent gemcitabine.
Topics: Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Male; Pelvis; Penile Neoplasms | 2017 |
Hippo pathway mediates resistance to cytotoxic drugs.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Line; Cytotoxins; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Hippo Signaling Pathway; Humans; Mice; Neoplasms; Phosphoproteins; Protein Serine-Threonine Kinases; Signal Transduction; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2017 |
Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Canada; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Pancreatic Neoplasms; Retrospective Studies | 2017 |
Gemcitabine-induced coronary vasospasm: A case report.
Topics: Coronary Vasospasm; Deoxycytidine; Female; Gemcitabine; Humans | 2017 |
Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Proliferation; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Imaging, Three-Dimensional; Leiomyosarcoma; Luminescent Proteins; Mice, Nude; Mice, Transgenic; Neoplasm Invasiveness; Red Fluorescent Protein; Stomach Neoplasms; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Melittin inhibits tumor growth and decreases resistance to gemcitabine by downregulating cholesterol pathway gene CLU in pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cholesterol; Clusterin; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; Melitten; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
[Comparison of Preparation Efficiency and Therapeutic Safety between Generic Products of Gemcitabine].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drugs, Generic; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms | 2017 |
Activation of a c-Jun N-terminal kinase-mediated autophagy pathway attenuates the anticancer activity of gemcitabine in human bladder cancer cells.
Topics: Anthracenes; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Enzyme Activation; Gemcitabine; Humans; JNK Mitogen-Activated Protein Kinases; Urinary Bladder Neoplasms | 2017 |
Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin Lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Child; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphocyte Count; Male; Melphalan; Recurrence; Retrospective Studies; Young Adult | 2017 |
Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Pancreatic Neoplasms; Pyrimidines; Ribonucleotide Reductases; Tumor Suppressor Protein p53 | 2017 |
Gemcitabine Integrated Nano-Prodrug Carrier System.
Topics: Amyloid; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Nanofibers; Nanostructures; Prodrugs; Tumor Cells, Cultured | 2017 |
Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy.
Topics: Animals; Deoxycytidine; Drug Carriers; Female; Ferric Compounds; Gemcitabine; Genetic Therapy; Humans; Hyaluronan Receptors; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Molecular Targeted Therapy; Nanomedicine; Oligonucleotides, Antisense; Pancreatic Neoplasms; Polyethylene Glycols; Polyethyleneimine; Precision Medicine; Single-Chain Antibodies; Xenograft Model Antitumor Assays | 2017 |
Toward Better Predictions of Chemosensitivity: Comparative Study of Conventional and Simulated Chemosensitivity Tests for Bladder Cancer Cell Lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Epirubicin; Gemcitabine; Humans; Mitomycin; Urinary Bladder Neoplasms | 2017 |
Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gemcitabine; GTP Phosphohydrolases; Humans; Male; Membrane Proteins; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Randomized Controlled Trials as Topic; Survival Rate | 2017 |
miR-153 enhances the therapeutic effect of gemcitabine by targeting Snail in pancreatic cancer.
Topics: 3' Untranslated Regions; Animals; Antimetabolites, Antineoplastic; Apoptosis; Base Sequence; Cell Line; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Sequence Homology, Nucleic Acid; Snail Family Transcription Factors; Survival Analysis; Xenograft Model Antitumor Assays | 2017 |
Tumor regression is mediated via the induction of HER263-71- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control.
Topics: Animals; Antigens, Neoplasm; Biomarkers; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Immunoglobulin G; Interferon-gamma; Mice; Mice, Knockout; Neoplasms; Receptor, ErbB-2; T-Cell Antigen Receptor Specificity; T-Lymphocyte Subsets; T-Lymphocytes, Cytotoxic; Th1 Cells; Tumor Burden | 2017 |
High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Bile Duct Neoplasms; Carcinogenesis; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HMGA Proteins; Humans; Male; Mice; Middle Aged; Oligonucleotide Array Sequence Analysis; RNA, Messenger; Time Factors | 2017 |
Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Pemetrexed; Platinum; Retrospective Studies; Taxoids | 2017 |
Effect of nucleoside analogue antimetabolites on the structure of PEO-PPO-PEO micelles investigated by SANS.
Topics: Antimetabolites; Deoxycytidine; Floxuridine; Fluorouracil; Gemcitabine; Micelles; Neutron Diffraction; Poloxamer; Polyethylene Glycols; Propylene Glycols; Scattering, Small Angle; Transition Temperature; Water | 2017 |
Prognostic Index for Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Third-Generation Agents.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Rate; Taxoids; Vinblastine; Vinorelbine | 2017 |
Efficacy and safety of gemcitabine plus S-1 in pancreatic cancer: a pooled analysis of individual patient data.
Topics: Aftercare; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Diarrhea; Drug Combinations; Drug Eruptions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tegafur; Thrombocytopenia; Vomiting | 2017 |
Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Chemoradiotherapy; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Thymidylate Synthase | 2017 |
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Decision Making; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; United States | 2017 |
Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; MicroRNAs; Pancreatic Neoplasms; Prognosis; RNA-Binding Proteins; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Chemotherapy-induced neutropenia as a prognostic factor in patients with metastatic pancreatic cancer treated with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Prognosis; Survival Analysis; Young Adult | 2017 |
Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2017 |
Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring.
Topics: Antibodies, Monoclonal; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Monitoring; Gemcitabine; Humans; Immunoassay; Limit of Detection; Nanoparticles; Plasma; Reproducibility of Results; Tandem Mass Spectrometry | 2017 |
miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Neoplasm Proteins; Protein Kinase C-epsilon; RNA, Neoplasm; Up-Regulation | 2017 |
Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Meningeal Carcinomatosis; Middle Aged; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Gemcitabine anti-proliferative activity significantly enhanced upon conjugation with cell-penetrating peptides.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell-Penetrating Peptides; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Molecular Structure; Structure-Activity Relationship | 2017 |
[Gemcitabine-induced thrombotic microangiopathy: Can we improve screening and treatment?]
Topics: Adult; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Plasma Exchange; Severity of Illness Index; Thrombotic Microangiopathies | 2017 |
Peritoneal metastasis from pancreatic cancer treated with pressurized intraperitoneal aerosol chemotherapy (PIPAC).
Topics: Aerosols; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Administration Routes; Drug Delivery Systems; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Peritoneal Neoplasms; Pressure; Prospective Studies; Treatment Outcome | 2017 |
Gemcitabine, busulfan, and melphalan conditioning for autologous stem-cell transplants in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Multiple Myeloma; Transplantation Conditioning; Transplantation, Autologous | 2017 |
The renal safety and efficacy of combined gemcitabine plus cisplatin and gemcitabine plus carboplatin chemotherapy in Chinese patients with a solitary kidney after nephroureterectomy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Creatinine; Deoxycytidine; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Retrospective Studies; Risk Factors; Ureteral Neoplasms | 2017 |
Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; NEDD8 Protein; Pyrimidines; Ubiquitin-Activating Enzymes; Ubiquitins; Xenograft Model Antitumor Assays | 2017 |
Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Caveolin 1; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Injections, Intravenous; Ki-67 Antigen; Male; Mice; Micelles; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Pancreatic Neoplasms; Polymers; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX).
Topics: Animals; Antineoplastic Agents; Azetidines; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Piperidines; Protein Kinase Inhibitors; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2017 |
Establishment of patient-derived tumor xenograft (PDTX) models using samples from CT-guided percutaneous biopsy.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Deoxycytidine; Disease Models, Animal; Feasibility Studies; Female; Gemcitabine; Humans; Image-Guided Biopsy; Liver Neoplasms; Lung Neoplasms; Male; Mice, Inbred Strains; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Tomography, X-Ray Computed; Xenograft Model Antitumor Assays | 2017 |
Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Japan; Male; Pancreatic Neoplasms; Risk Factors; Survival Rate | 2017 |
Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions.
Topics: Adult; Aged; Albumins; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cisplatin; Deoxycytidine; Docetaxel; Drug Hypersensitivity; Female; Gemcitabine; Genital Neoplasms, Female; Humans; Middle Aged; Nervous System Diseases; Neutropenia; Paclitaxel; Retreatment; Retrospective Studies; Taxoids; Thrombocytopenia | 2017 |
Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Pancreaticoduodenectomy; Proto-Oncogene Proteins p21(ras); Translational Research, Biomedical | 2017 |
Conjugation of squalene to gemcitabine as unique approach exploiting endogenous lipoproteins for drug delivery.
Topics: A549 Cells; Animals; Calorimetry; Cell Line; Cell Line, Tumor; Cholesterol; Deoxycytidine; Drug Delivery Systems; Fluorescence Resonance Energy Transfer; Gemcitabine; Humans; Ligands; Lipoproteins; Liposomes; MCF-7 Cells; Nanoparticles; Neoplasms; Rats; Receptors, LDL; Squalene | 2017 |
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Nerve Sheath Neoplasms; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Reproducibility of Results; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2017 |
Induction Chemotherapy Followed by Resection or Irreversible Electroporation in Locally Advanced Pancreatic Cancer (IMPALA): A Prospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Electrochemotherapy; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2017 |
Micro-RNA-130a-3p Regulates Gemcitabine Resistance via PPARG in Cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Expression Profiling; Humans; Male; MicroRNAs; Middle Aged; PPAR gamma; Prognosis; Survival Rate; Tumor Cells, Cultured; Up-Regulation | 2017 |
Chemotherapy for pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Etoposide; Female; Gemcitabine; Humans; Male; Middle Aged; Netherlands; Paclitaxel; Pemetrexed; Registries; Small Cell Lung Carcinoma; Taxoids; Vinblastine; Vinorelbine | 2017 |
[Gemcitabine and capecitabine as new standard of care for adjuvant therapy in pancreatic cancer].
Topics: Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Standard of Care | 2017 |
Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Transitional Cell; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinase Inhibitor p15; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mutation; Nuclear Proteins; Trans-Activators; Transcription Factors; Tumor Suppressor Protein p53; Up-Regulation; Urinary Bladder Neoplasms | 2018 |
Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Repair; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Retrospective Studies; Signal Transduction; Smad4 Protein; Topoisomerase I Inhibitors; Transforming Growth Factor beta | 2017 |
Pancreatic cancer heterogeneity and response to Mek inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Methylation; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Gemcitabine; Genetic Heterogeneity; Humans; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase Kinases; Mutation; Paclitaxel; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Xenograft Model Antitumor Assays | 2017 |
Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Republic of Korea; Retrospective Studies; Sex Factors; Treatment Outcome | 2017 |
Time to Initiation of Adjuvant Chemotherapy in Pancreas Cancer: A Multi-Institutional Experience.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Retrospective Studies; Serum Albumin; Survival Rate; Time Factors | 2017 |
BRM/SMARCA2 promotes the proliferation and chemoresistance of pancreatic cancer cells by targeting JAK2/STAT3 signaling.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; DNA Helicases; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Janus Kinase 2; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Nuclear Proteins; Pancreatic Neoplasms; Phosphorylation; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transcription Factors; Transfection; Xenograft Model Antitumor Assays | 2017 |
Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipoproteins, LDL; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Mice, SCID; Nanoparticles; Receptors, LDL; Squalene; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
[Posterior reversible encephalopathy syndrome associated to chemotherapy. Gemcitabine as the causative agent].
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Posterior Leukoencephalopathy Syndrome | 2017 |
Pancreatic adenocarcinoma response to chemotherapy enhanced with non-invasive radio frequency evaluated via an integrated experimental/computational approach.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Computer Simulation; Deoxycytidine; Drug Therapy; Gemcitabine; Humans; Imaging, Three-Dimensional; Mice; Mice, SCID; Pancreatic Neoplasms; Radiofrequency Therapy | 2017 |
Antiinflammatory and antioxidant effects of gemcitabine in collagen-induced arthritis model.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arthritis, Experimental; Arthritis, Rheumatoid; Bone and Bones; Collagen; Cytokines; Deoxycytidine; Gemcitabine; Inflammation; Oxidoreductases; Rats; Rats, Wistar | 2017 |
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Topotecan | 2017 |
Gemcitabine-vitamin E conjugates: Synthesis, characterization, entrapment into nanoemulsions, and in-vitro deamination and antitumor activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromans; Deamination; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Tocotrienols; Vitamin E | 2017 |
Unique cellular interactions between pancreatic cancer cells and the omentum.
Topics: Adipocytes; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Cells, Cultured; Chromatography, High Pressure Liquid; Culture Media, Conditioned; Deoxycytidine; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Omentum; Pancreatic Neoplasms; Tandem Mass Spectrometry; Transplantation, Heterologous | 2017 |
miR-509-5p and miR-1243 increase the sensitivity to gemcitabine by inhibiting epithelial-mesenchymal transition in pancreatic cancer.
Topics: Aged; Cadherins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms | 2017 |
Design and fabrication of dual-targeted delivery system based on gemcitabine-conjugated human serum albumin nanoparticles.
Topics: Antineoplastic Agents; Apoptosis; Cell Membrane Permeability; Cell Proliferation; Deoxycytidine; Drug Compounding; Drug Liberation; Folic Acid; Folic Acid Transporters; Gemcitabine; Glutathione; Humans; Hydrogen-Ion Concentration; Molecular Targeted Therapy; Nanocapsules; Serum Albumin, Human | 2020 |
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression; Hemangiosarcoma; Humans; Kaplan-Meier Estimate; Leiomyosarcoma; Male; Middle Aged; Retrospective Studies; Survival Rate | 2017 |
The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cytarabine; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Glycerophosphates; Humans; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Transplantation; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase C; Random Allocation; Tumor Burden | 2017 |
Posttranscriptional Upregulation of IDH1 by HuR Establishes a Powerful Survival Phenotype in Pancreatic Cancer Cells.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; ELAV-Like Protein 1; Gemcitabine; Humans; Isocitrate Dehydrogenase; Mice; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phenotype; Protein Processing, Post-Translational; Survival Analysis; Transcriptional Activation; Transfection; Up-Regulation | 2017 |
Wnt/β-catenin signaling pathway activation reverses gemcitabine resistance by attenuating Beclin1-mediated autophagy in the MG63 human osteosarcoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Proteins; Beclin-1; Bone Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cyclin D1; Deoxycytidine; Gemcitabine; Genes, bcl-2; Humans; Lysosomal Membrane Proteins; Osteosarcoma; Wnt Signaling Pathway | 2017 |
Fabrication and Cytotoxicity of Gemcitabine-Functionalized Magnetite Nanoparticles.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erythrocytes; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Magnetite Nanoparticles; Nanotechnology | 2017 |
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Mucositis; Multivariate Analysis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Radiation Injuries; Radiosurgery; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Thrombocytopenia | 2017 |
Does "OPTINAB" strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel-gemcitabine?
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Retrospective Studies; Survival Rate | 2017 |
Effective encapsulation and biological activity of phosphorylated chemotherapeutics in calcium phosphosilicate nanoparticles for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Calcium Compounds; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Phosphorylation; Silicates; Xenograft Model Antitumor Assays | 2017 |
Neoadjuvant chemotherapy by bronchial arterial infusion in patients with unresectable stage III squamous cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Staging; Quality of Life; Retrospective Studies; Survival Rate | 2017 |
Association of MDM2 expression with shorter progression-free survival and overall survival in patients with advanced pancreatic cancer treated with gemcitabine-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins c-mdm2; Survival Analysis | 2017 |
Analysis of Perioperative Chemotherapy in Resected Pancreatic Cancer: Identifying the Number and Sequence of Chemotherapy Cycles Needed to Optimize Survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymph Node Excision; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Pancreatic Neoplasms; Perioperative Period; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tumor Burden | 2017 |
Gemcitabine-camptothecin conjugates: a hybrid prodrug for controlled drug release and synergistic therapeutics.
Topics: Animals; Antineoplastic Agents; Biological Transport; Camptothecin; Delayed-Action Preparations; Deoxycytidine; Disulfides; Drug Synergism; Gemcitabine; HeLa Cells; Humans; Hydrophobic and Hydrophilic Interactions; Materials Testing; MCF-7 Cells; Mice; Prodrugs | 2017 |
Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Albumin-Bound Paclitaxel; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Pancreatic Ductal; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Time Factors; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Hospitals, High-Volume; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Pancreatic Neoplasms; Positron-Emission Tomography; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2017 |
Successful pregnancy after mucinous cystic neoplasm with invasive carcinoma of the pancreas in a patient with polycystic ovarian syndrome: a case report.
Topics: Adenocarcinoma; Adult; Chemoradiotherapy; Cystadenocarcinoma, Mucinous; Deoxycytidine; Female; Gemcitabine; Humans; Infertility, Female; Magnetic Resonance Imaging; Ovary; Ovulation; Pancreatic Neoplasms; Pancreaticoduodenectomy; Polycystic Ovary Syndrome; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Radiation-Sensitizing Agents; Ultrasonography | 2017 |
Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy, Adoptive; Kaplan-Meier Estimate; Leukopenia; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Postoperative Period | 2017 |
MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer.
Topics: Carbon; Deoxycytidine; Digoxin; Drug Resistance, Neoplasm; Gemcitabine; Glucose; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mucin-1; Pancreatic Neoplasms; Pentose Phosphate Pathway; Prognosis; Pyrimidines; Signal Transduction | 2017 |
Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Age Factors; Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Preoperative Period; Radiation-Sensitizing Agents; Retrospective Studies; Survival Analysis | 2017 |
Linc-DYNC2H1-4 promotes EMT and CSC phenotypes by acting as a sponge of miR-145 in pancreatic cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cytoplasmic Dyneins; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; Pancreatic Neoplasms; Phenotype; RNA, Long Noncoding; Transplantation, Heterologous; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Radiotherapy, Adjuvant | 2017 |
Antiviral activity of gemcitabine against human rhinovirus in vitro and in vivo.
Topics: Animals; Antiviral Agents; Cytokines; Deoxycytidine; Disease Models, Animal; Drug Repositioning; Gemcitabine; Humans; Inflammation; Lung; Mice; Picornaviridae Infections; Rhinovirus; RNA, Viral; Viral Load; Virus Replication | 2017 |
Gemcitabine associated pseudocellulitis: A missed diagnosis.
Topics: Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Biopsy; Cellulitis; Deoxycytidine; Erythema; Gemcitabine; Humans; Lower Extremity; Male; Middle Aged | 2018 |
Nuclear expression of Y box binding-1 is important for resistance to chemotherapy including gemcitabine in TP53-mutated bladder cancer.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Nucleus; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; HeLa Cells; Humans; Male; MCF-7 Cells; Mutation; Tumor Suppressor Protein p53; Urinary Bladder Neoplasms; Y-Box-Binding Protein 1 | 2017 |
Circulating regulatory T cell subsets predict overall survival of patients with unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Interleukin-17; Interleukin-6; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Survival Analysis; T-Lymphocytes, Regulatory; Transforming Growth Factor beta1; Treatment Outcome | 2017 |
Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreatoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm, Residual; Neoplasms, Second Primary; Pancreatic Neoplasms; Pancreaticoduodenectomy; Positron Emission Tomography Computed Tomography; Time Factors | 2017 |
EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer.
Topics: Cell Line, Tumor; Cell Survival; Cetuximab; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Gemcitabine; Humans; Micelles; MicroRNAs; Pancreatic Neoplasms; Polyethylene Glycols; Polymers | 2017 |
Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fructose-Bisphosphatase; Gemcitabine; Humans; MAP Kinase Signaling System; Pancreatic Neoplasms; ras GTPase-Activating Proteins; Signal Transduction; Transfection | 2017 |
TS-1 (tegafur/gimeracil/oteracil)-induced systemic lupus erythematosus with skin lesions and anti-Sm antibody.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Systemic; Male; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Renal Insufficiency; Tegafur | 2017 |
Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Synergism; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metformin; Mice; Thymidine Kinase; Thymidylate Synthase; Thymine Nucleotides; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Gemcitabine hydrochloride-loaded liposomes and nanoparticles: comparison of encapsulation efficiency, drug release, particle size, and cytotoxicity.
Topics: Cell Line, Tumor; Chemistry, Pharmaceutical; Deoxycytidine; Drug Liberation; Gemcitabine; Humans; Lactic Acid; Liposomes; MCF-7 Cells; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2018 |
Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: a multi-institutional analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Australia; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Chi-Square Distribution; Cholangiocarcinoma; Databases, Factual; Deoxycytidine; Europe; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Logistic Models; Middle Aged; Multivariate Analysis; Neoplasm Staging; North America; Odds Ratio; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Enhanced antitumor activity of gemcitabine by polysaccharide-induced NK cell activation and immune cytotoxicity reduction in vitro/vivo.
Topics: Animals; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Hep G2 Cells; Histocompatibility Antigens Class I; Humans; Killer Cells, Natural; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; NK Cell Lectin-Like Receptor Subfamily K; Polysaccharides; Proto-Oncogene Proteins c-akt; RAW 264.7 Cells; Reactive Oxygen Species; Receptors, Immunologic; Spleen; Strongylocentrotus | 2017 |
Improved metabolic stability and therapeutic efficacy of a novel molecular gemcitabine phospholipid complex.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Drug Stability; Gemcitabine; Humans; Male; Mice; Pancreatic Neoplasms; Phospholipids; Rats, Sprague-Dawley; Spectroscopy, Fourier Transform Infrared; Toxicity Tests | 2017 |
Z-360 Suppresses Tumor Growth in MIA PaCa-2-bearing Mice
Topics: Animals; Apoptosis; Benzodiazepinones; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Endopeptidases; Gastrins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Receptor, Cholecystokinin B; Survivin; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2017 |
Exosomes derived from gemcitabine-resistant cells transfer malignant phenotypic traits via delivery of miRNA-222-3p.
Topics: 3' Untranslated Regions; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Exosomes; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Middle Aged; Neoplasm Recurrence, Local | 2017 |
Role of eculizumab in a pediatric refractory gemcitabine-induced thrombotic microangiopathy: a case report.
Topics: Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cerebellar Neoplasms; Child, Preschool; Complement Inactivating Agents; Deoxycytidine; Fatal Outcome; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Medulloblastoma | 2017 |
Adjuvant gemcitabine-docetaxel chemotherapy for stage I uterine leiomyosarcoma: Trends and survival outcomes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Leiomyosarcoma; Middle Aged; Neoplasm Recurrence, Local; Proportional Hazards Models; Retrospective Studies; Taxoids; Uterine Neoplasms | 2017 |
Platinum-based Neoadjuvant Chemotherapy Improves Oncological Outcomes in Patients with Locally Advanced Upper Tract Urothelial Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Prognosis; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies; Survival Rate; Ureter; Ureteral Neoplasms; Urologic Surgical Procedures | 2018 |
Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Topics: Adenocarcinoma; AMP-Activated Protein Kinase Kinases; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Female; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Knockout; Mice, Nude; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Thiophenes; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2017 |
Cholesterol derivative-based liposomes for gemcitabine delivery: preparation, in vitro, and in vivo characterization.
Topics: Antineoplastic Agents; Cholesterol; Deoxycytidine; Drug Liberation; Gemcitabine; Half-Life; Humans; Liposomes | 2017 |
FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; F-Box-WD Repeat-Containing Protein 7; Gemcitabine; Humans; Lysosomes; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; Up-Regulation | 2017 |
A cascade enzymatic reaction activatable gemcitabine prodrug with an AIE-based intracellular light-up apoptotic probe for in situ self-therapeutic monitoring.
Topics: Apoptosis; Caspase 3; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Fluorescent Dyes; Gemcitabine; Humans; Microscopy, Fluorescence; Molecular Structure; Pancreatic Neoplasms; Prodrugs; Protein Aggregates; Stilbenes; Structure-Activity Relationship | 2017 |
Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD3 Complex; CD8-Positive T-Lymphocytes; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Integrin beta4; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; T-Lymphocytes, Cytotoxic | 2017 |
Therapeutic Tumor Control of HER2 DNA Vaccines Is Achieved by an Alteration of Tumor Cells and Tumor Microenvironment by Gemcitabine and Anti-Gr-1 Ab Treatment in a HER2-Expressing Tumor Model.
Topics: Animals; Antibodies; B7-H1 Antigen; Cancer Vaccines; Deoxycytidine; Female; Gemcitabine; Mice, Inbred BALB C; Neoplasms, Experimental; Receptor, ErbB-2; Receptors, Chemokine; T-Lymphocytes, Cytotoxic; Tumor Microenvironment; Vaccines, DNA | 2017 |
Primary Cardiac Leiomyosarcoma: A 27-Month Survival with Surgery and Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Docetaxel; Doxorubicin; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Ifosfamide; Indoles; Leiomyosarcoma; Life Support Care; Male; Mesna; Pyrroles; Sunitinib; Taxoids | 2017 |
ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Deoxycytidine; DNA Damage; Fluorouracil; Gemcitabine; Gene Expression; Genomic Instability; Humans; Immunohistochemistry; Male; Mice; Mice, SCID; Pancreatic Neoplasms; Phthalazines; Piperazines | 2017 |
Novel Gemcitabine Conjugated Albumin Nanoparticles: a Potential Strategy to Enhance Drug Efficacy in Pancreatic Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cattle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Liberation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms; Particle Size; Serum Albumin, Bovine; Surface Properties | 2017 |
Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
Topics: Aged; Albumins; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Cost of Illness; Deoxycytidine; Drug Costs; Female; Filgrastim; Fluorouracil; Gemcitabine; Granulocyte Colony-Stimulating Factor; Health Care Costs; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Time Factors | 2017 |
Potential Development of Tumor-Targeted Oral Anti-Cancer Prodrugs: Amino Acid and Dipeptide Monoester Prodrugs of Gemcitabine.
Topics: Amino Acids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Dipeptides; Drug Delivery Systems; Drug Liberation; Drug Stability; Enzyme Activation; Esters; Gemcitabine; Humans; Pancreatic Neoplasms; Permeability; Prodrugs; Thymidine Phosphorylase | 2017 |
Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
Topics: Animals; Apoptosis; Caspase 3; Caspase 9; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Xanthones; Xenograft Model Antitumor Assays | 2017 |
An in vivo high-throughput screening for riboswitch ligands using a reverse reporter gene system.
Topics: Anti-Bacterial Agents; Bacillus subtilis; Deoxycytidine; Dose-Response Relationship, Drug; Drug Discovery; Gemcitabine; Gene Expression; Gene Expression Regulation, Bacterial; Genes, Reporter; High-Throughput Screening Assays; Ligands; Luminescent Measurements; Riboswitch | 2017 |
Enzyme-sensitive gemcitabine conjugated albumin nanoparticles as a versatile theranostic nanoplatform for pancreatic cancer treatment.
Topics: Albumins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Liberation; Floxuridine; Fluorescent Dyes; Gemcitabine; Heterografts; Humans; Indoles; Mice, Inbred BALB C; Nanoparticles; Oligopeptides; Pancreatic Neoplasms; Particle Size; Surface Properties; Theranostic Nanomedicine; Tissue Distribution | 2017 |
Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Diazooxonorleucine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glutamine; Humans; Metabolic Networks and Pathways; Oxidation-Reduction; Pancreatic Neoplasms; Proteomics | 2017 |
Designing Liposomes To Suppress Extracellular Matrix Expression To Enhance Drug Penetration and Pancreatic Tumor Therapy.
Topics: Animals; Antineoplastic Agents; Deoxycytidine; Extracellular Matrix; Gemcitabine; Humans; Liposomes; Matrix Metalloproteinase 2; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Peptides; Pyridones; Tumor Cells, Cultured | 2017 |
Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Medical Records; Middle Aged; Patient Reported Outcome Measures; Pemetrexed; Proportional Hazards Models; Prospective Studies; Quality of Life; Registries | 2017 |
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Female; Gemcitabine; Humans; Lipids; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
A hyaluronic acid conjugate engineered to synergistically and sequentially deliver gemcitabine and doxorubicin to treat triple negative breast cancer.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Drug Carriers; Drug Liberation; Drug Synergism; Gemcitabine; Humans; Hyaluronic Acid; Mice; Mice, Inbred BALB C; Prodrugs; Triple Negative Breast Neoplasms | 2017 |
Positively charged cyclodextrins as effective molecular transporters of active phosphorylated forms of gemcitabine into cancer cells.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Breast Neoplasms; Cyclodextrins; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lymphoma, T-Cell; Models, Theoretical; Phosphorylation; Tumor Cells, Cultured | 2017 |
Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Gemcitabine; Glioblastoma; Humans; Hydrogels; Injections; Lipids; Mice; Nanocapsules; Nanomedicine; Xenograft Model Antitumor Assays | 2017 |
Bilateral macular infarction after gemcitabine and carboplatin chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Carboplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Infarction; Macula Lutea; Retinal Diseases; Uterine Cervical Neoplasms; Visual Acuity | 2018 |
Targeted Delivery System Based on Gemcitabine-Loaded Silk Fibroin Nanoparticles for Lung Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Fibroins; Gemcitabine; Lung Neoplasms; Mice; Nanoparticles | 2017 |
TGFβ1 Promotes Gemcitabine Resistance through Regulating the LncRNA-LET/NF90/miR-145 Signaling Axis in Bladder Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance; Gemcitabine; Humans; Kruppel-Like Factor 4; Male; Mice, Nude; MicroRNAs; Neoplastic Stem Cells; Nuclear Factor 90 Proteins; RNA, Long Noncoding; Signal Transduction; Transforming Growth Factor beta1; Urinary Bladder Neoplasms | 2017 |
Biodistribution study of
Topics: A549 Cells; Animals; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Stability; Gemcitabine; Humans; In Vitro Techniques; Lung Neoplasms; Microscopy, Electron, Transmission; Organotechnetium Compounds; Radionuclide Imaging; Rats; Rats, Sprague-Dawley; Tissue Distribution | 2017 |
Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; Heterografts; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Cytolytic virus activation therapy and treatment monitoring for Epstein-Barr virus associated nasopharyngeal carcinoma in a mouse tumor model.
Topics: Animals; Antiviral Agents; Carcinoma; Deoxycytidine; Disease Models, Animal; DNA, Viral; Epstein-Barr Virus Infections; Ganciclovir; Gemcitabine; Herpesvirus 4, Human; Humans; Mice; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome; Tumor Cells, Cultured; Valproic Acid; Viral Load; Virus Activation | 2017 |
Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs).
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Heat-Shock Proteins; Humans; Mitochondria; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Pyrimidines; Tumor Suppressor Protein p53; Urokinase-Type Plasminogen Activator | 2017 |
Gemcitabine-induced chronic systemic capillary leak syndrome.
Topics: Antimetabolites, Antineoplastic; Capillary Leak Syndrome; Deoxycytidine; Edema; Female; Gemcitabine; Humans; Hypoalbuminemia; Hypotension; Middle Aged; Pancreatic Neoplasms | 2017 |
ITGA1 is a pre-malignant biomarker that promotes therapy resistance and metastatic potential in pancreatic cancer.
Topics: Adenocarcinoma; Aldehyde Dehydrogenase 1 Family; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Collagen; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Integrin alpha Chains; Isoenzymes; Pancreatic Neoplasms; Prognosis; Retinal Dehydrogenase; RNA, Small Interfering; Signal Transduction; Tissue Array Analysis; Transforming Growth Factor beta; Tumor Microenvironment | 2017 |
Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Liposomes; Nanostructures; Prodrugs; Taxoids; Triple Negative Breast Neoplasms | 2017 |
[Efficacy of GC Therapy for the Patient of iTNBC with Resistance to TAC Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Middle Aged; Taxoids; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2017 |
Dual Inhibition of Hedgehog and c-Met Pathways for Pancreatic Cancer Treatment.
Topics: Adenocarcinoma; Animals; Benzamides; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Hepatocyte Growth Factor; Humans; Imidazoles; Mice; Mice, Transgenic; Neoplasm Metastasis; Proto-Oncogene Proteins c-met; Pyridines; Triazines; Tumor Microenvironment | 2017 |
Ternary cocktail nanoparticles for sequential chemo-photodynamic therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Carriers; Gemcitabine; Humans; Nanoparticles; Neoplasms; Photochemotherapy; Taxoids | 2017 |
Preparation and Evaluation of
Topics: Animals; Deoxycytidine; Fibrosarcoma; Gemcitabine; Humans; Lutetium; Mice; Molecular Targeted Therapy; Muscles; Radioisotopes; Radiopharmaceuticals; Tissue Distribution | 2017 |
Efficacy of Gemcitabine and S-1 for Patients with Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Gemcitabine; Humans; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Tegafur; Treatment Outcome | 2017 |
Calcitriol Reverses Induced Expression of Efflux Proteins and Potentiates Cytotoxic Activity of Gemcitabine in Capan-2 Pancreatic Cancer Cells.
Topics: Adenosine Triphosphatases; Antimetabolites, Antineoplastic; Butylated Hydroxyanisole; Butylated Hydroxytoluene; Calcitriol; Calcium Channel Agonists; Carrier Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Silybin; Silymarin | 2017 |
MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Cytidine Deaminase; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Luciferases; MicroRNAs; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Transfection; Tumor Suppressor Proteins; Up-Regulation | 2017 |
Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biological Availability; Biotransformation; Deoxycytidine; Drug Administration Schedule; Drug Interactions; Erlotinib Hydrochloride; Gemcitabine; Male; Plant Extracts; Plants, Medicinal; Protective Agents; Quinazolines; Rats; Rats, Sprague-Dawley | 2017 |
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemoradiotherapy, Adjuvant; Deoxycytidine; Disease Progression; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Male; Mesenteric Artery, Superior; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Neoplasms, Second Primary; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Radiosurgery; Radiotherapy, Intensity-Modulated; Survival Rate | 2018 |
Gemcitabine, Pyrrologemcitabine, and 2'-Fluoro-2'-Deoxycytidines: Synthesis, Physical Properties, and Impact of Sugar Fluorination on Silver Ion Mediated Base Pairing.
Topics: Base Pairing; Deoxycytidine; Gemcitabine; Halogenation; Ions; Magnetic Resonance Spectroscopy; Oligonucleotides; Ribose; Silver; Spectrometry, Fluorescence | 2017 |
Percutaneous intratumoral injection of gemcitabine plus cisplatin mixed with fibrin glue for advanced pancreatic carcinoma: Case Report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Fibrin Tissue Adhesive; Gemcitabine; Humans; Injections, Intralesional; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms | 2017 |
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Gammaproteobacteria; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mycoplasma hyorhinis; Neoplasms, Experimental; Pancreatic Neoplasms | 2017 |
PEGylated thermosensitive lipid-coated hollow gold nanoshells for effective combinational chemo-photothermal therapy of pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Gemcitabine; Gold; Humans; Hydrophobic and Hydrophilic Interactions; Infrared Rays; Lipids; Nanoshells; Pancreatic Neoplasms; Phototherapy; Polyethylene Glycols; Temperature | 2017 |
Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Hyaluronic Acid; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Polymers; Prodrugs; Xenograft Model Antitumor Assays | 2017 |
Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metal Nanoparticles; Ovarian Neoplasms; Resveratrol; Silver; Stilbenes | 2017 |
Synergistic chemo-photodynamic therapy by "big & small combo nanoparticles" sequential release system.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Female; Gemcitabine; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Photochemotherapy; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Smart thermosensitive liposomes for effective solid tumor therapy and in vivo imaging.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Contrast Media; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Female; Gadolinium; Gemcitabine; Hot Temperature; Liposomes; Magnetic Resonance Imaging; Mice, Nude; Models, Biological; Nanoparticles; Neoplasm Transplantation; Pancreatic Neoplasms; Particle Size; Phantoms, Imaging; Viscosity | 2017 |
ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy.
Topics: ADAMTS13 Protein; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Middle Aged; Plasma Exchange; Practice Guidelines as Topic; Purpura, Thrombotic Thrombocytopenic; Thrombocytopenia; Thrombotic Microangiopathies | 2018 |
Antifibrotic effects of pentoxifylline improve the efficacy of gemcitabine in human pancreatic tumor xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pentoxifylline; Phosphodiesterase Inhibitors; Tissue Distribution; Xenograft Model Antitumor Assays | 2017 |
Diels Alder-mediated release of gemcitabine from hybrid nanoparticles for enhanced pancreatic cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Liberation; Female; Gemcitabine; Hot Temperature; Humans; Lasers; Maleimides; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Tumor Burden | 2017 |
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Maintenance Chemotherapy; Neoplasm Metastasis; Peritoneal Neoplasms; Splenic Neoplasms; Time Factors; Treatment Outcome | 2017 |
HINT2 triggers mitochondrial Ca
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Calcium Channels; Deoxycytidine; Gemcitabine; Heterografts; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Mitochondrial Proteins; Pancreatic Neoplasms | 2017 |
NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; I-kappa B Kinase; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Peptide Fragments; Peptides; Protein Domains; Random Allocation; Xenograft Model Antitumor Assays | 2017 |
Acinar Cell Carcinoma in the Background of Chronic Calcific Pancreatitis.
Topics: Carcinoma, Acinar Cell; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Pancreatitis, Chronic; Treatment Outcome; Viscera | 2019 |
CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HMGA2 Protein; Humans; Mice, Nude; MicroRNAs; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms; Receptors, CXCR4 | 2017 |
Efficacy and Safety of Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin for Treatment of Metastatic Triple-Negative Breast Cancer After Failure with Anthracyclines and Taxanes.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Demography; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2017 |
Synergistic effect of a drug loaded electrospun patch and systemic chemotherapy in pancreatic cancer xenograft.
Topics: Administration, Cutaneous; Animals; Antineoplastic Combined Chemotherapy Protocols; Biocompatible Materials; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Polyesters; Survival Rate; Transdermal Patch; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression.
Topics: AC133 Antigen; Aged; Animals; Anoikis; Antimetabolites, Antineoplastic; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Plasticity; Cell Proliferation; Cell Survival; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression; Gene Silencing; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Pancreatic Neoplasms; Phenotype; RNA, Messenger; Spheroids, Cellular; Transcription Factors; Vimentin | 2017 |
Gemcitabine-Induced Retinopathy.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Fluorescein Angiography; Gemcitabine; Humans; Intravitreal Injections; Middle Aged; Neoplasm Staging; Retinal Diseases; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Vision Disorders | 2017 |
Mixed Liposome Approach for Ratiometric and Sequential Delivery of Paclitaxel and Gemcitabine.
Topics: Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Liposomes; Paclitaxel | 2018 |
The Pharmacological Costs of Second-Line Treatments for Recurrent Ovarian Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Dioxoles; Disease-Free Survival; Doxorubicin; Drug Costs; European Union; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Polyethylene Glycols; Randomized Controlled Trials as Topic; Survival Rate; Tetrahydroisoquinolines; Trabectedin | 2017 |
Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2.
Topics: Adaptor Proteins, Signal Transducing; Annexin A2; Anti-Bacterial Agents; Antineoplastic Agents; Azithromycin; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoroquinolones; Gemcitabine; Humans; Liver Neoplasms; Mitoxantrone; Moxifloxacin; Mycoplasma hyorhinis; Protein Binding; Real-Time Polymerase Chain Reaction | 2017 |
Variations in gene expression of lung macromolecules after induction chemotherapy for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Extracellular Matrix Proteins; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Induction Chemotherapy; Lung Neoplasms; Membrane Proteins; Pneumonectomy; Preoperative Care; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm | 2017 |
Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lymphatic Metastasis; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Photochemotherapy; Serum Albumin, Human; Xenograft Model Antitumor Assays | 2017 |
Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CCL5; Chemokine CXCL1; Chemotaxis, Leukocyte; Deoxycytidine; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-12 Subunit p35; Interleukin-8; Interleukins; Macrophages; Mice, SCID; Microvessels; Minor Histocompatibility Antigens; Monocytes; Neovascularization, Pathologic; Pancreatic Neoplasms; Paracrine Communication; RNA Interference; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Multifaceted peptide assisted one-pot synthesis of gold nanoparticles for plectin-1 targeted gemcitabine delivery in pancreatic cancer.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Gold; Humans; Metal Nanoparticles; Pancreatic Neoplasms; Peptides; Plectin | 2017 |
Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; C-Reactive Protein; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Retrospective Studies | 2018 |
Mechanistic Evaluation and Translational Signature of Gemcitabine-induced Chemoresistance by Quantitative Phosphoproteomics Analysis with iTRAQ Labeling Mass Spectrometry.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Ontology; Humans; Isotope Labeling; Neoplastic Stem Cells; Pancreatic Neoplasms; Phosphoproteins; Proteomics; Signal Transduction; Tandem Mass Spectrometry; Translational Research, Biomedical | 2017 |
Pancreatic cancer: Intra-tumour bacteria promote gemcitabine resistance in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Bacteria; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2017 |
Formulation and Pharmacokinetics of HSA-core and PLGA-shell Nanoparticles for Delivering Gemcitabine.
Topics: Delayed-Action Preparations; Deoxycytidine; Diffusion; Drug Carriers; Drug Liberation; Gemcitabine; Lactic Acid; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Serum Albumin, Human | 2018 |
Network modeling of kinase inhibitor polypharmacology reveals pathways targeted in chemical screens.
Topics: Algorithms; Cell Line, Tumor; Cell Proliferation; Databases, Genetic; Deoxycytidine; DNA Repair; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Protein Kinase Inhibitors; Transcription, Genetic | 2017 |
ANO9/TMEM16J promotes tumourigenesis via EGFR and is a novel therapeutic target for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Anoctamins; Anti-Bacterial Agents; Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease-Free Survival; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Gene Knockdown Techniques; HEK293 Cells; Humans; Male; Membrane Proteins; Mice; Middle Aged; Neoplasm Transplantation; Pancreatic Neoplasms; Phospholipid Transfer Proteins; Prognosis; RNA, Messenger; Survival Rate; Tumor Stem Cell Assay | 2017 |
Monitoring Surface Contamination by Antineoplastic Drugs in Italian Hospitals: Performance-Based Hygienic Guidance Values (HGVs) Project.
Topics: Antineoplastic Agents; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Packaging; Environmental Monitoring; Equipment Contamination; Fluorouracil; Gemcitabine; Hospitals; Humans; Occupational Exposure | 2017 |
The effects of novel chitosan-targeted gemcitabine nanomedicine mediating cisplatin on epithelial mesenchymal transition, invasion and metastasis of pancreatic cancer cells.
Topics: Animals; Cell Line, Tumor; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Neoplasm Invasiveness; Pancreatic Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Synergistic effects of baicalein with gemcitabine or docetaxel on the proliferation, migration and apoptosis of pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Synergism; Flavanones; Gemcitabine; Humans; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Taxoids | 2017 |
Establishment of a human primary pancreatic cancer mouse model to examine and investigate gemcitabine resistance.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Primary Cell Culture; Prognosis; Rho Guanine Nucleotide Exchange Factors; Xenograft Model Antitumor Assays | 2017 |
Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Kidney Failure, Chronic; Kidney Transplantation; Middle Aged; Programmed Cell Death 1 Receptor; Urinary Bladder Neoplasms | 2017 |
miR-3656 expression enhances the chemosensitivity of pancreatic cancer to gemcitabine through modulation of the RHOF/EMT axis.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Nuclear Proteins; Pancreatic Neoplasms; rho GTP-Binding Proteins; Twist-Related Protein 1 | 2017 |
Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; RNA, Long Noncoding; Xenograft Model Antitumor Assays | 2017 |
Enhancement of cytotoxic effects of gemcitabine by Dclk1 inhibition through suppression of Chk1 phosphorylation in human pancreatic cancer cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Benzodiazepinones; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Doublecortin-Like Kinases; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Pyrimidines; Signal Transduction | 2017 |
Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Dose Fractionation, Radiation; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Organometallic Compounds; Organoplatinum Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2017 |
Development and
Topics: Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; In Vitro Techniques; Liposomes; Mucin-4; Pancreatic Neoplasms; Tumor Cells, Cultured | 2017 |
Effect of Adjuvant Gemcitabine Combined with Low-dose 5-Fluorouracil and Cisplatin Chemotherapy for Advanced Biliary Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Hepatectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
Bladder Urothelial Carcinoma with Peritoneal Involvement: Benefit of Continuous Maintenance Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemoradiotherapy; Cisplatin; Cystectomy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Maintenance Chemotherapy; Male; Middle Aged; Peritoneal Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Feasibility Studies; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Prognostic Factors and Patterns of Locoregional Failure After Surgical Resection in Patients With Cholangiocarcinoma Without Adjuvant Radiation Therapy: Optimal Field Design for Adjuvant Radiation Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Confidence Intervals; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Time Factors | 2017 |
Redox active metals and H
Topics: Animals; Antimetabolites, Antineoplastic; Ascorbic Acid; Cell Line, Tumor; Deoxycytidine; DNA Damage; Female; Gemcitabine; Humans; Hydrogen Peroxide; Iron; Mice, Nude; Oxidation-Reduction; Radiation-Sensitizing Agents; Sarcoma | 2018 |
[Analysis of Clinical Efficacy and Influencing Factors of Gemcitabine-L-Asparaginase-Oxaliplatin Chemotherapy Scheme and Radiotherapy for Treatment of Early ENKTL Patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Deoxycytidine; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Retrospective Studies; Treatment Outcome | 2017 |
A successful case of locally advanced pancreatic cancer undergoing curative distal pancreatectomy with en bloc celiac axis resection after combination chemotherapy of nab-paclitaxel with gemcitabine.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Celiac Artery; Deoxycytidine; Gemcitabine; Hepatic Artery; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Splenic Artery | 2017 |
Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |
Skin Necrosis Due to the Extravasation of Irritant Anticancer Agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Injection Site Reaction; Irritants; Lymphoma; Male; Necrosis; Skin | 2018 |
Comment on: MicroRNA Expression as a Predictive Marker for Gemcitabine Response After Surgical Resection of Pancreatic Cancer.
Topics: Deoxycytidine; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms | 2017 |
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gefitinib; Gemcitabine; Humans; Piperidones; Proteasome Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine | 2017 |
Significance of sarcopenia as a prognostic factor for metastatic urothelial carcinoma patients treated with systemic chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Carboplatin; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle, Skeletal; Prognosis; Retrospective Studies; Sarcopenia; Tomography, X-Ray Computed; Urologic Neoplasms | 2018 |
Nivolumab in HIV-related non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD4 Lymphocyte Count; Cisplatin; Darunavir; Deoxycytidine; Docetaxel; Gemcitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lung Neoplasms; Male; Middle Aged; Nivolumab; Oxazines; Piperazines; Pyridones; Ritonavir; Vinorelbine | 2017 |
Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Pancreatic Ductal; Caspase Inhibitors; Cell Line, Tumor; Cell Movement; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Humans; Hyaluronan Receptors; Limonins; Mitochondria; Mutation; Neoplastic Stem Cells; Pancreatic Neoplasms; Reactive Oxygen Species; Time Factors; Tumor Suppressor Protein p53 | 2018 |
A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Rate | 2017 |
Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrroles; Random Allocation | 2018 |
DNA methyltransferase 3a modulates chemosensitivity to gemcitabine and oxaliplatin via CHK1 and AKT in p53‑deficient pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; Drug Resistance, Neoplasm; Gemcitabine; Humans; Organoplatinum Compounds; Oxaliplatin; Proto-Oncogene Proteins c-akt; Tumor Suppressor Protein p53 | 2018 |
4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma.
Topics: Adaptor Proteins, Signal Transducing; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Eukaryotic Initiation Factor-4E; Eukaryotic Initiation Factor-4F; Eukaryotic Initiation Factor-4G; Gemcitabine; Genome, Human; Humans; Hydrazones; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Phosphoproteins; Phosphorylation; Pleural Neoplasms; Polyribosomes; Protein Binding; Protein Biosynthesis; Proteome; Reproducibility of Results; RNA Caps; Thiazoles | 2018 |
Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.
Topics: A549 Cells; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Fanconi Anemia Complementation Group Proteins; Gemcitabine; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; RNA Interference; Signal Transduction | 2017 |
Alternative polyadenylation of ZEB1 promotes its translation during genotoxic stress in pancreatic cancer cells.
Topics: 3' Untranslated Regions; Base Sequence; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Polyadenylation; Polyribosomes; Ribonucleoproteins; Up-Regulation; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Surface-enhanced Raman scattering investigation of targeted delivery and controlled release of gemcitabine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Female; Folic Acid; Gemcitabine; Gold; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Molecular Targeted Therapy; Spectrum Analysis, Raman; Transferrin; Triple Negative Breast Neoplasms | 2017 |
Dual protein kinase and nucleoside kinase modulators for rationally designed polypharmacology.
Topics: A549 Cells; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Crystallography, X-Ray; Deoxycytidine; Deoxycytidine Kinase; Drug Design; Drug Resistance, Neoplasm; Enzyme Activation; Gemcitabine; Humans; Imatinib Mesylate; Models, Biological; Models, Molecular; Phosphorylation; Piperidines; Polypharmacology; Protein Kinase Inhibitors; Proteomics; Pyridines; Thiazoles | 2017 |
A case report of mixed acinar-endocrine carcinoma of the pancreas treated with S-1 chemotherapy: Does it work or induce endocrine differentiation?
Topics: Aged; Antineoplastic Agents; Carcinoma, Acinar Cell; Cisplatin; Deoxycytidine; Drug Combinations; Etoposide; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2017 |
Differentially expressed proteins in the human esophageal cancer cell line Eca‑109, in the presence and absence of gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; bcl-2-Associated X Protein; CARD Signaling Adaptor Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Esophageal Neoplasms; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein | 2018 |
Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Contraindications, Procedure; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Hepatic Artery; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Survival Rate; Tomography, X-Ray Computed | 2018 |
Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen.
Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Deoxycytidine; Dexamethasone; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Gemcitabine; Humans; Molecular Structure; Structure-Activity Relationship; Tumor Cells, Cultured; Vidarabine | 2018 |
A Real-World Comparison of FOLFIRINOX, Gemcitabine Plus nab-Paclitaxel, and Gemcitabine in Advanced Pancreatic Cancers.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2019 |
[Clinical analysis of 36 cases of advanced non-small cell lung cancer (NSCLC) with performance status (PS) scores between 2 and 4].
Topics: Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Humans; Hypoxia; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Remission Induction; Response Evaluation Criteria in Solid Tumors; Severity of Illness Index; Taxoids | 2017 |
A Favorable Response to Levetiracetam in a Patient with Metastatic Adenoid Cystic Carcinoma.
Topics: Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cystic; Cisplatin; Deoxycytidine; Epilepsy; Gemcitabine; Humans; Levetiracetam; Lung Neoplasms; Male; Middle Aged; Piracetam; Tomography, X-Ray Computed | 2018 |
Co-treatment with a C1B5 peptide of protein kinase Cγ and a low dose of gemcitabine strongly attenuated pancreatic cancer growth in mice through T cell activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Peptide Fragments; Protein Kinase C; T-Lymphocytes | 2018 |
Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bilirubin; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease Progression; Female; France; Gemcitabine; Hepatitis B Antibodies; Hepatitis C Antibodies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms, Complex and Mixed; Oxaliplatin; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Survival Rate | 2018 |
MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Heterografts; Humans; Keratins; Male; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Transplantation; Neuroendocrine Cells; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-myc; Synaptophysin | 2017 |
Monophosphorylation by deoxycytidine kinase affects apparent cellular uptake of decitabine in HCT116 colon cancer cells.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Camptothecin; Colonic Neoplasms; Cytarabine; Decitabine; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Etoposide; Gemcitabine; HCT116 Cells; Humans; Irinotecan; Phosphorylation | 2017 |
YAP1 and COX2 Coordinately Regulate Urothelial Cancer Stem-like Cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclooxygenase 2; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Neoplastic Stem Cells; Phosphoproteins; SOXB1 Transcription Factors; Transcription Factors; Urinary Bladder Neoplasms; Urothelium; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2018 |
Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Triazoles; Xenograft Model Antitumor Assays | 2018 |
Perioperative, Spatiotemporally Coordinated Activation of T and NK Cells Prevents Recurrence of Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Killer Cells, Natural; Lymphocyte Activation; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Perioperative Care; Prognosis; Survival Rate; Tumor Cells, Cultured | 2018 |
Mocetinostat combined with gemcitabine for the treatment of leiomyosarcoma: Preclinical correlates.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Leiomyosarcoma; Pyrimidines | 2017 |
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Fibroblast Growth Factors; Gemcitabine; Humans; Immunohistochemistry; Mice; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
3D collagen fibrillar microstructure guides pancreatic cancer cell phenotype and serves as a critical design parameter for phenotypic models of EMT.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Collagen; Deoxycytidine; Dose-Response Relationship, Drug; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Protein Conformation; S Phase | 2017 |
ST6Gal-I sialyltransferase promotes chemoresistance in pancreatic ductal adenocarcinoma by abrogating gemcitabine-mediated DNA damage.
Topics: Antimetabolites, Antineoplastic; beta-D-Galactoside alpha 2-6-Sialyltransferase; Cell Line, Tumor; Comet Assay; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Immunoblotting; Neuraminidase; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; RNA, Messenger; Sialyltransferases; Tumor Suppressor Proteins | 2018 |
Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Inflammation; Male; Middle Aged; Multivariate Analysis; Prognosis; Progression-Free Survival; Treatment Outcome | 2018 |
Efficacy and tolerance of GELOXD/P-GEMOXD in newly diagnosed nasal-type extranodal NK/T-cell lymphoma: A multicenter retrospective study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Deoxycytidine; Female; Gemcitabine; Humans; Killer Cells, Natural; Leukopenia; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Multivariate Analysis; Nausea; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Prognosis; Remission Induction; Survival Analysis; T-Lymphocytes; Treatment Outcome; Vomiting | 2018 |
Metabolomic prediction of treatment outcome in pancreatic ductal adenocarcinoma patients receiving gemcitabine.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Female; Gas Chromatography-Mass Spectrometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lactic Acid; Male; Metabolomics; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; ROC Curve; Survival Analysis; Treatment Outcome | 2018 |
Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Palliative Care; Receptor, ErbB-2; Receptors, Estrogen; Retreatment; Trastuzumab; Treatment Outcome | 2018 |
Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors.
Topics: Animals; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; B7-H1 Antigen; Carboxymethylcellulose Sodium; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; Humans; Immunity, Cellular; Mice; Mice, Transgenic; Mucin-1; Pancreatic Neoplasms; Poly I-C; Polylysine; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Pseudolaric Acid B Inhibits Proliferation, Invasion and Epithelial-to-Mesenchymal Transition in Human Pancreatic Cancer Cell.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytokines; Deoxycytidine; Diterpenes; Epithelial-Mesenchymal Transition; Female; Fibronectins; Gemcitabine; Humans; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Signal Transduction; Vimentin | 2018 |
Implication of 4E-BP1 protein dephosphorylation and accumulation in pancreatic cancer cell death induced by combined gemcitabine and TRAIL.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Drug Combinations; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreas; Phosphoproteins; Phosphorylation; Rapamycin-Insensitive Companion of mTOR Protein; Regulatory-Associated Protein of mTOR; RNA, Small Interfering; Signal Transduction; Time-Lapse Imaging; TNF-Related Apoptosis-Inducing Ligand; TOR Serine-Threonine Kinases | 2017 |
Metastatic Collecting (Bellini) Duct Carcinoma Presented in a Young Patient: A Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Ductal; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Iliac Vein; Immunohistochemistry; Kidney Neoplasms; Kidney Tubules, Collecting; Male; Neoplasm Metastasis; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Radiography, Abdominal; Spleen; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2017 |
Demethylzeylasteral (ZST93) inhibits cell growth and enhances cell chemosensitivity to gemcitabine in human pancreatic cancer cells via apoptotic and autophagic pathways.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Growth Processes; Cell Line, Tumor; Cyclin A2; Cyclin D1; Deoxycytidine; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Random Allocation; RNA, Messenger; Triterpenes; Xenograft Model Antitumor Assays | 2018 |
Nrf2 promotes mutant K-ras/p53-driven pancreatic carcinogenesis.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Genes, p53; Male; Mice; Mutation; NF-E2-Related Factor 2; Oxidative Stress; Pancreatic Neoplasms; Precancerous Conditions; Proto-Oncogene Proteins p21(ras) | 2017 |
β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer.
Topics: Adrenergic Agents; Animals; Carcinoma in Situ; Catecholamines; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice, Transgenic; Nerve Growth Factors; Pancreatic Neoplasms | 2018 |
Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Treatment Outcome | 2018 |
Microchannel system for rate-controlled, sequential, and pH-responsive drug delivery.
Topics: Cell Survival; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Drug Liberation; Finite Element Analysis; Gemcitabine; HeLa Cells; Humans; Hydrogen-Ion Concentration; Microfluidics; Optical Imaging | 2018 |
PEGPH20 May Improve Standard-of-Care Therapy in Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Breast Neoplasms; Deoxycytidine; Gemcitabine; Humans; Hyaluronic Acid; Hyaluronoglucosaminidase; Paclitaxel; Pancreatic Neoplasms | 2018 |
Interstitial lung disease secondary to Cetuximab in bladder cancer: an Oncologist's perspective.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Neoadjuvant Therapy; Noninvasive Ventilation; Prednisolone; Respiratory Insufficiency; Steroids; Treatment Outcome; Urinary Bladder Neoplasms | 2017 |
Gemcitabine directly inhibits effector CD4 T cell activation and prevents experimental autoimmune encephalomyelitis.
Topics: Animals; CD4-Positive T-Lymphocytes; Deoxycytidine; Encephalomyelitis, Autoimmune, Experimental; Female; Gemcitabine; Immunosuppressive Agents; Lymphocyte Activation; Mice; Mice, Inbred C57BL | 2018 |
Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liposomes; Mice; Precision Medicine; Ribonucleotide Reductases; RNA, Small Interfering | 2018 |
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-paclitaxel Reduces the Number of Cancer-associated Fibroblasts Through Depletion of Pancreatic Stroma.
Topics: Actins; Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; CA-19-9 Antigen; Cancer-Associated Fibroblasts; Collagen; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreas; Pancreatic Neoplasms; Positron-Emission Tomography; Retrospective Studies; Stromal Cells | 2018 |
Re-irradiation with 36 Gy (1.5 Gy Twice Daily) Plus Paclitaxel for Advanced Recurrent and Previously Irradiated SCCHN is Feasible.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Head and Neck Neoplasms; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Re-Irradiation; Squamous Cell Carcinoma of Head and Neck | 2018 |
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bile Duct Neoplasms; Camptothecin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Docetaxel; Endometrial Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Middle Aged; Ovarian Neoplasms; Retrospective Studies; Taxoids | 2018 |
CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; CDC2 Protein Kinase; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Ribonucleoside Diphosphate Reductase; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2018 |
Ultra-sensitive LC-MS/MS method for the quantification of gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma for a microdose clinical trial.
Topics: Chromatography, Liquid; Clinical Trials, Phase I as Topic; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Reproducibility of Results; Tandem Mass Spectrometry | 2018 |
The high stromal SPARC expression is independently associated with poor survival of patients with resected pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine in combination with S-1 or adjuvant gemcitabine alone.
Topics: Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Osteonectin; Oxonic Acid; Retrospective Studies; Survival Analysis; Tegafur | 2018 |
Bladder cancer: Chemotherapy and checkpoint blockade.
Topics: Cisplatin; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Ipilimumab; Mutation; Urinary Bladder Neoplasms | 2018 |
Low-Density Lipoproteins and Human Serum Albumin as Carriers of Squalenoylated Drugs: Insights from Molecular Simulations.
Topics: Adenine; Binding Sites; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Compounding; Gemcitabine; Humans; Hydrophobic and Hydrophilic Interactions; Lipoproteins, LDL; Molecular Docking Simulation; Molecular Dynamics Simulation; Nanoparticles; Protein Binding; Serum Albumin, Human; Squalene | 2018 |
Difluoromethylornithine Combined with a Polyamine Transport Inhibitor Is Effective against Gemcitabine Resistant Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biological Transport; Biosynthetic Pathways; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Eflornithine; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Ornithine Decarboxylase; Ornithine Decarboxylase Inhibitors; Pancreas; Pancreatic Neoplasms; Polyamines; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Proliferation; Cell Transformation, Neoplastic; Chemokine CXCL10; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesenchymal Stem Cells; Mice; Mice, SCID; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, CXCR3; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Establishing a Preclinical Multidisciplinary Board for Brain Tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; Mice; Mice, Nude; Treatment Outcome | 2018 |
When Lightning Strikes Twice.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cholangiopancreatography, Endoscopic Retrograde; Common Bile Duct; Deoxycytidine; Dissection; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Second Primary; Pancreaticoduodenectomy; Reoperation; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Blood Glucose; China; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Hyperglycemia; Incidence; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Registries; Sorafenib | 2017 |
Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephroureterectomy; Retrospective Studies; Ureter; Ureteral Neoplasms | 2018 |
Long non-coding RNA MEG3 functions as a tumour suppressor and has prognostic predictive value in human pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; Pancreatic Neoplasms; Prognosis; RNA, Long Noncoding; Survival Rate; Tumor Cells, Cultured | 2018 |
Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Janus Kinase 1; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pancreatic Neoplasms; STAT Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
MicroRNA-200a confers chemoresistance by antagonizing TP53INP1 and YAP1 in human breast cancer.
Topics: Breast Neoplasms; Carrier Proteins; Cell Cycle Proteins; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; MCF-7 Cells; MicroRNAs; Nuclear Proteins; Prognosis; Transcription Factors | 2018 |
Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2018 |
Thymidylate synthase prompts metastatic progression through the dTMP associated EMT process in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Thymidine Monophosphate; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2018 |
The absence of class III β-tubulin is predictive of a favorable response to nab-paclitaxel and gemcitabine in patients with unresectable pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Treatment Outcome; Tubulin | 2018 |
A Nanoparticle Carrier for Co-Delivery of Gemcitabine and Small Interfering RNA in Pancreatic Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Physiological Phenomena; Deoxycytidine; Female; Gemcitabine; Humans; Hyaluronan Receptors; Magnetite Nanoparticles; Mice; Mice, Inbred BALB C; Nanoconjugates; Pancreatic Neoplasms; Particle Size; Polycomb Repressive Complex 1; Proto-Oncogene Proteins; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2016 |
Analysis of the prolonged infusion of DFP-10917, a deoxycytidine analog, as a therapeutic strategy for the treatment of human tumor xenografts in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytarabine; Deoxycytidine; DNA Breaks, Double-Stranded; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Infusions, Intravenous; Isoflurophate; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Neoplasms; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Effect of midkine on gemcitabine resistance in biliary tract cancer.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Midkine | 2018 |
Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Survival Rate | 2018 |
The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Ontology; Humans; Methyltransferases; Pancreatic Neoplasms; Radiation Tolerance | 2018 |
Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; China; Deoxycytidine; DNA Mismatch Repair; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2018 |
miR-34 increases in vitro PANC-1 cell sensitivity to gemcitabine via targeting Slug/PUMA.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins; Snail Family Transcription Factors | 2018 |
Targeting Multiple Effector Pathways in Pancreatic Ductal Adenocarcinoma with a G-Quadruplex-Binding Small Molecule.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Computational Biology; Computer Simulation; Deoxycytidine; DNA Damage; Down-Regulation; Drug Design; Drug Resistance, Neoplasm; G-Quadruplexes; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Tumor-Stroma IL1β-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Fibrosis; Gemcitabine; Humans; Interleukin-1 Receptor-Associated Kinases; Interleukin-1beta; Mice; Mice, Knockout; NF-kappa B; Pancreatic Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines.
Topics: Aminoquinolines; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Lung Neoplasms; Mice; Paclitaxel; Thiosemicarbazones; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2018 |
Predicting tumour growth and its impact on survival in gemcitabine-treated patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Proliferation; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2018 |
Depletion of HDAC1, 7 and 8 by Histone Deacetylase Inhibition Confers Elimination of Pancreatic Cancer Stem Cells in Combination with Gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Neoplastic Stem Cells; Pancreatic Neoplasms | 2018 |
Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report.
Topics: Antineoplastic Agents; Ascites; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Assessment of Anticancer Drug Effects on Pancreatic Cancer Cells under Glucose-Depleted Conditions Using Intracellular and Extracellular Amino Acid Metabolomics.
Topics: Amino Acids; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Glucose; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; Discriminant Analysis; Extracellular Fluid; Gemcitabine; Glucose; Humans; Hydrophobic and Hydrophilic Interactions; Hypoglycemia; Intracellular Fluid; Least-Squares Analysis; Metabolomics; Pancreatic Neoplasms; Principal Component Analysis; Pyrvinium Compounds; Reproducibility of Results; Tandem Mass Spectrometry | 2018 |
S-1 (Teysuno) and gemcitabine in Caucasian patients with unresectable pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Diarrhea; Drug Combinations; Fatigue; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Treatment Outcome; White People | 2018 |
Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Hepatocyte Growth Factor; Humans; Male; Mice; Mice, Nude; Oligopeptides; Pancreatic Neoplasms; Proto-Oncogene Proteins; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Recurrence, Local; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2018 |
[Multidisciplinary Therapy with Gemcitabine and Nab-Paclitaxel for Unresectable Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2017 |
[Long-Term Survival after Resection for Repeated Abdominal Wall Recurrence of Gallbladder Cancer].
Topics: Abdominal Neoplasms; Abdominal Wall; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Recurrence; Time Factors | 2017 |
[Long-Term Survival Due to Combination Therapy in a Patient with Locally Advanced Body-Tail Pancreatic Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Tegafur; Time Factors | 2017 |
[A Case of Gemcitabine and Nab-Paclitaxel Therapy for Multiple Metastatic Pancreatic Cancer].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2017 |
[A Case of Unresectable Locally Advanced Pancreatic Cancer Resulted in R0 Surgery after Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2017 |
[A Case of Successful Adjuvant Surgery for the Pancreas Head Cancer with Peritoneal Metastasis].
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peritoneal Neoplasms | 2017 |
[Long-Term Survival after Multidisciplinary Treatment for Resected Pancreatic Adenocarcinoma with Recurrence of Pulmonary Metastases - A Case Report].
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Fatal Outcome; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Paclitaxel; Pancreaticoduodenectomy; Pneumonectomy; Recurrence; Tegafur; Time Factors | 2017 |
[A Case Report of Curative Surgery for Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination after Gemcitabine Chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Peritoneal Neoplasms; Treatment Outcome | 2017 |
Hyaluronic Acid-Modified Micelles Encapsulating Gem-C
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Brain Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Compounding; Gemcitabine; Glioblastoma; Humans; Hyaluronan Receptors; Hyaluronic Acid; Lignans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Rats; Rats, Sprague-Dawley; Spheroids, Cellular; Survival Rate; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
A Case of Small Cell Lung Carcinoma in a 15-Year-Old Boy and Literature Review.
Topics: Adolescent; Deoxycytidine; Gemcitabine; Humans; Male; Pediatrics; Prognosis; Small Cell Lung Carcinoma | 2018 |
The Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Prognostic Factors in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Platelet Count; Prognosis; Retrospective Studies; Tegafur; Tumor Burden; Uracil | 2018 |
Contrasting roles of H3K4me3 and H3K9me3 in regulation of apoptosis and gemcitabine resistance in human pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Histones; Humans; Indoles; Lysine; Methylation; Pancreatic Neoplasms | 2018 |
Effective light-triggered contents release from helper lipid-incorporated liposomes co-encapsulating gemcitabine and a water-soluble photosensitizer.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Deoxycytidine; Drug Compounding; Drug Liberation; Female; Gemcitabine; Infrared Rays; Kinetics; Lipids; Liposomes; Mice; Photosensitizing Agents; Porphyrins; Solubility; Technology, Pharmaceutical; Water | 2018 |
Compatibility and Stability of Nab-Paclitaxel in Combination with Other Drugs.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Combinations; Drug Incompatibility; Drug Stability; Female; Gemcitabine; Granisetron; Humans; Infusions, Intravenous; Male; Paclitaxel; Risk Factors | 2017 |
Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Fatty Acids, Omega-3; Gemcitabine; Humans; Lung Neoplasms; Tumor Cells, Cultured | 2018 |
Follicular dendritic cell sarcoma of the porta hepatis.
Topics: Abdominal Pain; Antineoplastic Combined Chemotherapy Protocols; Bilirubin; Biomarkers, Tumor; Cholangiopancreatography, Endoscopic Retrograde; Dendritic Cell Sarcoma, Follicular; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Taxoids | 2018 |
CQ sensitizes human pancreatic cancer cells to gemcitabine through the lysosomal apoptotic pathway via reactive oxygen species.
Topics: Animals; Apoptosis; Cell Line, Tumor; Chloroquine; Deoxycytidine; Gemcitabine; Humans; Lysosomes; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2018 |
The effects of intra-arterial chemotherapy on bladder preservation in patients with T1 stage bladder cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Injections, Intra-Arterial; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Organ Sparing Treatments; Progression-Free Survival; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy.
Topics: Animals; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Hydrogel, Polyethylene Glycol Dimethacrylate; Immunotherapy; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Programmed Cell Death 1 Receptor | 2018 |
The 4-N-acyl and 4-N-alkyl gemcitabine analogues with silicon-fluoride-acceptor: Application to
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Fluorides; Fluorine Radioisotopes; Gastrointestinal Tract; Gemcitabine; HEK293 Cells; Humans; Kidney; Liver; Mice; Positron-Emission Tomography; Silicon Compounds; Tissue Distribution | 2018 |
Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Metabolomics; Mice; Mice, Nude; Microbiota; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.
Topics: Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Inhibitory Concentration 50; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyridines; Quinolones; Signal Transduction; TOR Serine-Threonine Kinases | 2018 |
Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Klatskin Tumor; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Prognosis; Prospective Studies; Survival Rate | 2018 |
[A Resected Case of Long-Term Survival of Pancreatic Cancer with Simultaneous Multiple Lung Metastasis with Systemic Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Tegafur; Time Factors | 2018 |
Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Deoxycytidine; Enzyme Inhibitors; Esterification; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Sterol O-Acyltransferase | 2018 |
The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Tegafur; Treatment Outcome | 2018 |
Cytoplasmic Hu-Antigen R (HuR) Expression is Associated with Poor Survival in Patients with Surgically Resected Cholangiocarcinoma Treated with Adjuvant Gemcitabine-Based Chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Nucleus; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cytoplasm; Deoxycytidine; Disease-Free Survival; Drug Combinations; ELAV-Like Protein 1; Female; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Survival Rate; Tegafur | 2018 |
Circulating Microvesicles from Pancreatic Cancer Accelerate the Migration and Proliferation of PANC-1 Cells.
Topics: Antimetabolites, Antineoplastic; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell-Derived Microparticles; Deoxycytidine; Gemcitabine; Gene Expression Regulation; Humans; Hyaluronan Receptors; Pancreatic Neoplasms; Protein Phosphatase 2; Proteome; Tumor Suppressor Protein p53 | 2018 |
Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Margins of Excision; Middle Aged; Multivariate Analysis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Pancreaticoduodenectomy; Prognosis; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Young Adult | 2018 |
Acceptance of Adjuvant and Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer in Germany: A Survey of Current Practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Germany; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Practice Patterns, Physicians'; Surveys and Questionnaires; Urinary Bladder Neoplasms; Urology | 2018 |
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Dihydrouracil Dehydrogenase (NADP); Equilibrative Nucleoside Transporter 1; Female; Fluorouracil; Gemcitabine; Humans; Immunohistochemistry; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Tissue Array Analysis | 2018 |
LncRNA AB209630 inhibits gemcitabine resistance cell proliferation by regulating PI3K/AKT signaling in pancreatic ductal adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prognosis; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; Up-Regulation | 2018 |
Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Germ-Line Mutation; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Maintenance Chemotherapy; Resorcinols; Treatment Outcome | 2018 |
You cannot miss it: Pancreatic mucoepidermoid carcinoma: A case report and literature review.
Topics: Antineoplastic Agents; Carcinoma, Mucoepidermoid; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Diagnosis, Differential; Drug Monitoring; Gemcitabine; Humans; Male; Middle Aged; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Breast Neoplasms; Caco-2 Cells; Cell Survival; Chitosan; Deoxycytidine; Female; Gemcitabine; HT29 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Peptide Fragments; Rats; Rats, Sprague-Dawley; Swine; Treatment Outcome | 2018 |
Sensitive analysis and pharmacokinetic study of a novel gemcitabine carbamate prodrug and its active metabolite gemcitabine in rats using LC-ESI-MS/MS.
Topics: Animals; Carbamates; Chromatography, Liquid; Deoxycytidine; Gemcitabine; Linear Models; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2018 |
Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
Topics: Animals; Chromatography, High Pressure Liquid; Deoxycytidine; Drug Stability; Floxuridine; Gemcitabine; Linear Models; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2018 |
Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mast Cells; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prognosis; Proportional Hazards Models; T-Lymphocyte Subsets; Tissue Array Analysis | 2018 |
Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Retrospective Studies | 2018 |
Hyperthermia inhibits the motility of gemcitabine-resistant pancreatic cancer PANC-1 cells through the inhibition of epithelial-mesenchymal transition.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Hyperthermia, Induced; Pancreatic Neoplasms | 2018 |
The encapsulation of the gemcitabine anticancer drug into grapheme nest: a theoretical study.
Topics: Adsorption; Algorithms; Antineoplastic Agents; Deoxycytidine; Drug Compounding; Gemcitabine; Graphite; Models, Chemical; Models, Molecular; Models, Theoretical; Molecular Conformation | 2018 |
Nucleoside-Based Self-Assembling Drugs for Localized Drug Delivery.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gels; Gemcitabine; Humans; Lamivudine; Microscopy, Electron, Transmission; Rheology; Viscoelastic Substances | 2018 |
Gemcitabine induces apoptosis and autophagy via the AMPK/mTOR signaling pathway in pancreatic cancer cells.
Topics: Adenylate Kinase; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Pancreatic Neoplasms; Signal Transduction; Survival Analysis; TOR Serine-Threonine Kinases | 2018 |
Selective Activation of a Prodrug by Thioredoxin Reductase Providing a Strategy to Target Cancer Cells.
Topics: Antineoplastic Agents; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; HeLa Cells; Humans; Molecular Structure; Prodrugs; Structure-Activity Relationship; Thioredoxin-Disulfide Reductase | 2018 |
Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; United States | 2019 |
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyridones; Pyrimidinones | 2018 |
Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer.
Topics: Administration, Metronomic; Carcinoma, Non-Small-Cell Lung; Cisplatin; Computer Simulation; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Maximum Tolerated Dose; Models, Theoretical; Pharmacokinetics | 2018 |
MiR-10a-5p targets TFAP2C to promote gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Glycoproteins; Mice; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Receptors, Immunologic; RNA Interference; Transcription Factor AP-2; Xenograft Model Antitumor Assays | 2018 |
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2018 |
Zein Microneedles for Localized Delivery of Chemotherapeutic Agents to Treat Breast Cancer: Drug Loading, Release Behavior, and Skin Permeation Studies.
Topics: Administration, Cutaneous; Animals; Antineoplastic Agents; Breast Neoplasms; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Excipients; Female; Gemcitabine; Humans; Microinjections; Needles; Organ Culture Techniques; Skin; Skin Absorption; Solubility; Swine; Tamoxifen; Zein | 2018 |
The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hedgehog Proteins; Heme Oxygenase-1; Humans; Pancreatic Neoplasms; Protoporphyrins; Signal Transduction; Up-Regulation; Veratrum Alkaloids | 2018 |
Impact of RUNX2 gene silencing on the gemcitabine sensitivity of p53‑mutated pancreatic cancer MiaPaCa‑2 spheres.
Topics: Cell Culture Techniques; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Gene Silencing; Humans; Mutation; Pancreatic Neoplasms; Signal Transduction; Spheroids, Cellular; Transcription Factors; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2018 |
Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur Lyases; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Injections, Intraperitoneal; Male; Methionine; Mice; Mice, Nude; Molecular Targeted Therapy; Pancreatic Neoplasms; Recombinant Proteins; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chick Embryo; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; Simvastatin | 2018 |
Efficacy and Tolerability of Second-line Nab-paclitaxel and Gemcitabine After Failure of First-line FOLFIRINOX for Advanced Pancreas Cancer: A Single-institution Experience.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2018 |
Co-delivery of docetaxel and gemcitabine by anacardic acid modified self-assembled albumin nanoparticles for effective breast cancer management.
Topics: Albumins; Anacardic Acids; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Clathrin; Deoxycytidine; Docetaxel; Drug Carriers; Female; Gemcitabine; Hemolysis; Humans; Macromolecular Substances; MCF-7 Cells; Nanoparticles; Neoplasm Transplantation; Particle Size; Polymers; Protein Conformation; Rats; Rats, Sprague-Dawley | 2018 |
[A Case of Locally Advanced Intrahepatic Cholangiocarcinoma Successfully Treated by Conversion Surgery after Hepatic Arterial Infusion Chemotherapy and Radiation Therapy].
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Male; Middle Aged | 2018 |
[A Case of Successful Treatment with Gemcitabine plus Nab-Paclitaxel Therapy for Nonresected Pancreatic Body Cancer(Stage IVb)].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
ZH-1 enhances the anticancer activity of gemcitabine via deoxyribonucleotide synthesis and apoptotic pathway against A549 cells.
Topics: A549 Cells; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Proliferation; Deoxycytidine; Deoxyribonucleotides; Gemcitabine; Humans | 2018 |
Gemcitabine loaded microbubbles for targeted chemo-sonodynamic therapy of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Humans; Male; Mice, SCID; Microbubbles; Pancreatic Neoplasms; Rose Bengal; Ultrasonic Therapy; Xenograft Model Antitumor Assays | 2018 |
FF-10502, an Antimetabolite with Novel Activity on Dormant Cells, Is Superior to Gemcitabine for Targeting Pancreatic Cancer Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxycytidine; Gemcitabine; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms | 2018 |
A mixed treatment comparison of toxicity of gemcitabine combined with different targeted drugs in the treatment of advanced or metastatic pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Pancreatic Neoplasms | 2018 |
Synergistic antiproliferative effects of an mTOR inhibitor (rad001) plus gemcitabine on cholangiocarcinoma by decreasing choline kinase activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Choline; Choline Kinase; Deoxycytidine; Drug Synergism; Everolimus; Fluorodeoxyglucose F18; Gemcitabine; Humans; Male; Metabolome; Mice; Positron-Emission Tomography; Proton Magnetic Resonance Spectroscopy; Rats, Sprague-Dawley; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2018 |
Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?
Topics: Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2018 |
Long noncoding RNA FOXD2-AS1 accelerates the gemcitabine-resistance of bladder cancer by sponging miR-143.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; RNA, Long Noncoding; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2018 |
The Combination of Gemcitabine, Cisplatin, and Paclitaxel as Salvage Chemotherapy for Advanced Urothelial Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Retrospective Studies; Salvage Therapy; Treatment Outcome; Urologic Neoplasms | 2018 |
Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biopsy; Bronchoscopy; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Immunohistochemistry; Leukocytes, Mononuclear; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Programmed Cell Death 1 Receptor | 2018 |
Factors that Predict Neutropenia in Korean Patients with Advanced Urothelial Cancer after Cisplatin- Based Systemic Chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Leukocyte Count; Methotrexate; Middle Aged; Neutropenia; Neutrophils; Republic of Korea; Risk Factors; Urologic Neoplasms; Vinblastine | 2018 |
Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Equilibrative-Nucleoside Transporter 2; Gemcitabine; Hepatocytes; Humans; Pancreatic Neoplasms | 2018 |
Co-delivery of docetaxel and gemcitabine using PEGylated self-assembled stealth nanoparticles for improved breast cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Micelles; Nanoparticles; Polyethylene Glycols; Rats; Rats, Sprague-Dawley; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
[Novel Palliative Chemotherapy in Patients with Metastatic Pancreatic Cancer: PEGPH20].
Topics: Albumins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
An onco-geriatric approach to select older patients for optimal treatments of pancreatic adenocarcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Female; Gemcitabine; Geriatric Assessment; Humans; Male; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Weight Loss | 2018 |
Survival of patients with non-resectable, chemotherapy-resistant colorectal cancer liver metastases undergoing conventional lipiodol-based transarterial chemoembolization (cTACE) palliatively versus neoadjuvantly prior to percutaneous thermal ablation.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Cisplatin; Colonic Neoplasms; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Ethiodized Oil; Female; Gemcitabine; Humans; Hyperthermia, Induced; Irinotecan; Laser Therapy; Liver Neoplasms; Male; Microwaves; Middle Aged; Mitomycin; Neoadjuvant Therapy; Palliative Care; Prognosis; Rectal Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Gastrointestinal: CT and PET/CT imaging of splenic littoral cell angiosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Diagnosis, Differential; Docetaxel; Gemcitabine; Hemangioma; Hemangiosarcoma; Humans; Male; Middle Aged; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Splenectomy; Splenic Neoplasms | 2018 |
Suppression of
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Interleukin-6; Pancreatic Neoplasms; RNA, Small Interfering | 2018 |
Hypoxia-induced autophagy promotes gemcitabine resistance in human bladder cancer cells through hypoxia-inducible factor 1α activation.
Topics: Aged; Aged, 80 and over; Apoptosis; Autophagy; Beclin-1; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Membrane Proteins; Middle Aged; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Hypoxia; Urinary Bladder Neoplasms | 2018 |
Comment on: Yohshino et al.: combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer: a multicenter phase I/II trial (GOGO-Ov 6). Cancer Chemother Pharmacol (2017) 80:1239-124
Topics: Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Irinotecan; Platinum; Taxoids | 2018 |
dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
Topics: Acetylcysteine; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Glutamate-Cysteine Ligase; Glutathione; Humans; Kelch-Like ECH-Associated Protein 1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NF-E2-Related Factor 2; Pancreatic Neoplasms; Plasmids; Reactive Oxygen Species; Up-Regulation | 2018 |
Inhibition of MAPKAPK2/MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Replication; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Intracellular Signaling Peptides and Proteins; Mitomycin; Pancreatic Neoplasms; Peptides; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Signal Transduction | 2018 |
Anticancer activity of arborinine from Glycosmis parva leaf extract in human cervical cancer cells.
Topics: Acridines; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Bleomycin; Caspase 3; Caspase 7; Cell Line, Transformed; Cell Proliferation; Cisplatin; Deoxycytidine; Dermis; Epithelial-Mesenchymal Transition; Female; Fibroblasts; Gemcitabine; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Plant Extracts; Plant Leaves; Proto-Oncogene Proteins c-bcl-2; Rutaceae; Spheroids, Cellular | 2018 |
Combined Gemcitabine and Metronidazole Is a Promising Therapeutic Strategy for Cancer Stem-like Cholangiocarcinoma.
Topics: Aldehyde Dehydrogenase; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Line, Tumor; Cell Transdifferentiation; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Metronidazole; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Spheroids, Cellular | 2018 |
TMSOTf assisted synthesis of 2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosylcytosine ([18F]FAC).
Topics: Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Fluorine Radioisotopes; Gemcitabine; Mesylates; Radiochemistry; Radiopharmaceuticals; Trimethylsilyl Compounds | 2018 |
Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Patient Compliance; Proportional Hazards Models; Retrospective Studies; Tegafur; Treatment Outcome | 2018 |
Induced PTF1a expression in pancreatic ductal adenocarcinoma cells activates acinar gene networks, reduces tumorigenic properties, and sensitizes cells to gemcitabine treatment.
Topics: Acinar Cells; Adenocarcinoma; Animals; Basic Helix-Loop-Helix Transcription Factors; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Gene Silencing; Genetic Loci; Mice; Neoplastic Stem Cells; Rats; Transcription Factors | 2018 |
Frondoside A Enhances the Anti-Cancer Effects of Oxaliplatin and 5-Fluorouracil on Colon Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Deoxycytidine; Drug Synergism; Fluorouracil; Gemcitabine; Glycosides; HCT116 Cells; HT29 Cells; Humans; Organoplatinum Compounds; Oxaliplatin; Triterpenes | 2018 |
Metastasis from pancreatic adenocarcinoma to the cheekbone.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Exophthalmos; Female; Gemcitabine; Humans; Middle Aged; Orbital Neoplasms; Pancreatectomy; Pancreatic Neoplasms; Plastic Surgery Procedures; Tomography, X-Ray Computed; Vinorelbine; Vision Disorders; Zygoma | 2018 |
Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Failure | 2018 |
Mechanism Comparison of Gemcitabine and Dasatinib-Resistant Pancreatic Cancer by Integrating mRNA and miRNA Expression Profiles.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Dasatinib; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Messenger | 2018 |
Identification of inhibitors synergizing gemcitabine sensitivity in the squamous subtype of pancreatic ductal adenocarcinoma (PDAC).
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cell Line, Tumor; Datasets as Topic; Deoxycytidine; Drug Delivery Systems; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Gemcitabine; Humans; Mitogen-Activated Protein Kinase Kinases; Proto-Oncogene Mas; Proto-Oncogene Proteins pp60(c-src); Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Transcriptome | 2018 |
Widespread Skin Necrosis Secondary to Gemcitabine Therapy.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Middle Aged; Skin Neoplasms; Stevens-Johnson Syndrome | 2018 |
Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; High-Throughput Screening Assays; Humans; Models, Molecular; Molecular Conformation; Protein Kinase Inhibitors; Protein Kinases; Structure-Activity Relationship; Workflow | 2018 |
Modification of sterculia gum polysaccharide via network formation by radiation induced crosslinking polymerization for biomedical applications.
Topics: Antioxidants; Deoxycytidine; Diffusion; Drug Delivery Systems; Drug Liberation; Gemcitabine; Graphite; Hydrogels; Karaya Gum; Oxides; Polymerization; Polymers; Polysaccharides; Sterculia | 2018 |
Natural compound Oblongifolin C confers gemcitabine resistance in pancreatic cancer by downregulating Src/MAPK/ERK pathways.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Terpenes; Xenograft Model Antitumor Assays | 2018 |
Effects of obatoclax combined with gemcitabine on the biological activity of pancreatic cancer cells under hypoxic conditions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Indoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Pyrroles; Tumor Suppressor Protein p53 | 2018 |
Gemcitabine-loaded gold nanospheres mediated by albumin for enhanced anti-tumor activity combining with CT imaging.
Topics: A549 Cells; Animals; Antimetabolites, Antineoplastic; Cattle; Cell Survival; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Gold; Humans; Hydrogen-Ion Concentration; Nanospheres; Neoplasms; Serum Albumin, Bovine; Tomography, X-Ray Computed | 2018 |
Antibody fragment-conjugated gemcitabine and paclitaxel-based liposome for effective therapeutic efficacy in pancreatic cancer.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Gemcitabine; Humans; Immunoglobulin Fragments; Liposomes; Microscopy, Confocal; Microscopy, Electron, Transmission; Paclitaxel; Pancreatic Neoplasms; Particle Size; Proto-Oncogene Proteins c-bcl-2 | 2018 |
[Pulmonary Pleomorphic Carcinoma Relapsed after Surgery Surviving Long-term by Chemotherapy and Nivolumab].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nivolumab | 2018 |
How Do We "Validate" a QSP Model?
Topics: Deoxycytidine; Dipeptides; Gemcitabine; Humans; Indoles; Pancreatic Neoplasms; Proteomics | 2018 |
Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; Mitochondria; NF-E2-Related Factor 2; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Resveratrol; Ribonucleoproteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Stilbenes | 2018 |
Gemcitabine-induced thrombotic microangiopathy with nephrotic syndrome.
Topics: Acute Kidney Injury; Aftercare; Antimetabolites, Antineoplastic; Conservative Treatment; Deoxycytidine; Female; Gemcitabine; Humans; Kidney; Middle Aged; Nephrotic Syndrome; Thrombotic Microangiopathies; Treatment Outcome | 2018 |
HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplasm Invasiveness; Valproic Acid; Vimentin | 2018 |
Platinum-Gemcitabine-Avastin (PGA) for platinum-resistant/refractory ovarian cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bevacizumab; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Middle Aged; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies | 2017 |
Striking a Balance between Carbonate/Carbamate Linkage Bond- and Reduction-Sensitive Disulfide Bond-Bearing Linker for Tailored Controlled Release: In Situ Covalent-Albumin-Binding Gemcitabine Prodrugs Promote Bioavailability and Tumor Accumulation.
Topics: Animals; Biological Availability; Carbamates; Carbonates; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Disulfides; Endocytosis; Female; Gemcitabine; Humans; Intracellular Space; Mice; Oxidation-Reduction; Prodrugs; Rats; Serum Albumin, Bovine | 2018 |
The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Precision Medicine; Retrospective Studies; Risk Factors; Survival Rate; Tegafur | 2018 |
Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas.
Topics: Adolescent; Albumins; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Hematologic Diseases; Humans; Infections; Kaplan-Meier Estimate; Male; Paclitaxel; Recurrence; Salvage Therapy; Sarcoma; Young Adult | 2018 |
miR-301a plays a pivotal role in hypoxia-induced gemcitabine resistance in pancreatic cancer.
Topics: Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; MicroRNAs; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Cells, Cultured; Tumor Hypoxia | 2018 |
Involvement of CYP4F2 in the Metabolism of a Novel Monophosphate Ester Prodrug of Gemcitabine and Its Interaction Potential In Vitro.
Topics: Animals; Benzamidines; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P450 Family 4; Deoxycytidine; Drug Interactions; Esters; Gemcitabine; Hepatocytes; Humans; Male; Microsomes, Liver; Molecular Structure; NADP; Prodrugs; Rats | 2018 |
Multifunctional Tumor-Targeting Cathepsin B-Sensitive Gemcitabine Prodrug Covalently Targets Albumin in Situ and Improves Cancer Therapy.
Topics: Animals; Cathepsin B; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Male; Mice; Neoplasms; Prodrugs; Rats, Sprague-Dawley; Serum Albumin | 2018 |
Analysis of the cytotoxic effects of combined ultrasound, microbubble and nucleoside analog combinations on pancreatic cells in vitro.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Flow Cytometry; Fluorocarbons; Gemcitabine; Humans; In Vitro Techniques; Microbubbles; Pancreatic Neoplasms; Ultrasonic Therapy | 2018 |
Microarray analysis of circular RNA expression profiles associated with gemcitabine resistance in pancreatic cancer cells.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Microarray Analysis; Pancreatic Neoplasms; RNA; RNA, Circular; RNA, Messenger; Signal Transduction | 2018 |
Specific inhibitor of Notch‑3 enhances the sensitivity of NSCLC cells to gemcitabine.
Topics: A549 Cells; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Diamines; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Receptor, Notch3; Signal Transduction; Thiazoles | 2018 |
Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways.
Topics: Animals; Antimetabolites, Antineoplastic; Benzopyrans; Bone Neoplasms; Caspase 3; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Osteosarcoma; Proto-Oncogene Proteins c-akt; Signal Transduction; Transplantation, Heterologous | 2018 |
Comparison of efficacy and toxicity of second-line combination chemotherapy regimens in patients with advanced urothelial carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate; Taxoids; Urologic Neoplasms | 2018 |
Metabolic and Physiologic Imaging Biomarkers of the Tumor Microenvironment Predict Treatment Outcome with Radiation or a Hypoxia-Activated Prodrug in Mice.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Hypoxia; Mice; Mice, Nude; Oxygen; Pancreatic Neoplasms; Prodrugs; Treatment Outcome; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2018 |
Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro.
Topics: Antiviral Agents; Benzodioxoles; Cell Line; Cross Infection; Deoxycytidine; DNA Replication; Drug Discovery; Enzyme Inhibitors; Gemcitabine; Humans; Middle East Respiratory Syndrome Coronavirus; Quinazolines; Small Molecule Libraries; src-Family Kinases; Virus Replication | 2018 |
The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Commerce; Decision Making, Organizational; Deoxycytidine; Drug Costs; Gemcitabine; Health Policy; Humans; Incidence; Insurance, Health; Lung Neoplasms; Medicare; Models, Economic; Treatment Outcome; United States | 2018 |
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pyrimidines; Remission Induction; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sarcoma; Sulfonamides; Young Adult | 2018 |
The BET inhibitor I-BET762 inhibits pancreatic ductal adenocarcinoma cell proliferation and enhances the therapeutic effect of gemcitabine.
Topics: Animals; Bcl-2-Like Protein 11; Benzodiazepines; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice, Nude; Neoplasm Invasiveness; Xenograft Model Antitumor Assays | 2018 |
Salvage topical therapy for upper tract urothelial carcinoma.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG Vaccine; Carcinoma in Situ; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Kidney Neoplasms; Kidney Pelvis; Male; Mitomycin; Nephrostomy, Percutaneous; Retrospective Studies; Salvage Therapy; Treatment Outcome; Ureteral Neoplasms; Urinary Catheterization | 2018 |
Total pancreatoduodenectomy en bloc with superior mesenteric artery and vein resection after gemcitabine and nab-paclitaxel neoadjuvancy.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Mesenteric Veins; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis | 2017 |
MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy.
Topics: 3' Untranslated Regions; Animals; Antagomirs; Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Mice, Nude; MicroRNAs; Microtubule-Associated Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Thiolester Hydrolases; Transplantation, Heterologous; Ubiquitin Thiolesterase | 2018 |
Co-delivery of paclitaxel and gemcitabine by methoxy poly(ethylene glycol)-poly(lactide-coglycolide)-polypeptide nanoparticles for effective breast cancer therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Female; Gemcitabine; Humans; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Transplantation; Paclitaxel; Particle Size; Peptides; Polyesters; Polyethylene Glycols; Surface Properties | 2018 |
Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2018 |
Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).
Topics: Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prospective Studies | 2018 |
Fisetin Enhances the Cytotoxicity of Gemcitabine by Down-regulating ERK-MYC in MiaPaca-2 Human Pancreatic Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Flavonols; Gemcitabine; Humans; Pancreatic Neoplasms; Proto-Oncogene Proteins c-myc | 2018 |
Gemcitabine reduces recurrence.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2018 |
Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Adducts; DNA Breaks, Double-Stranded; DNA Repair; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Humans; Proliferating Cell Nuclear Antigen; Ubiquitination; Up-Regulation | 2018 |
Brusatol Enhances the Chemotherapy Efficacy of Gemcitabine in Pancreatic Cancer via the Nrf2 Signalling Pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-E2-Related Factor 2; Pancreatic Neoplasms; Quassins; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Gemcitabine resistance mediated by ribonucleotide reductase M2 in lung squamous cell carcinoma is reversed by GW8510 through autophagy induction.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Carcinoma, Squamous Cell; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Indoles; Lung Neoplasms; Male; Mice, Inbred NOD; Ribonucleoside Diphosphate Reductase; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2018 |
Assessment of response to chemotherapy in pancreatic ductal adenocarcinoma: Comparison between diffusion-weighted MR quantitative parameters and RECIST.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Female; Gemcitabine; Humans; Male; Middle Aged; Prospective Studies; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Treatment Outcome | 2018 |
Commentary on "A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience."
Topics: BCG Vaccine; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
Enhanced taxane uptake into bladder tissues following co-administration with either mitomycin C, doxorubicin or gemcitabine: association to exfoliation processes.
Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Cations; Deoxycytidine; Doxorubicin; Gemcitabine; Male; Mitomycin; Nanoparticles; Swine; Taxoids; Urinary Bladder; Urothelium | 2018 |
A carbon nanotube-gemcitabine-lentinan three-component composite for chemo-photothermal synergistic therapy of cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Delivery Systems; Female; Gemcitabine; Humans; Laser Therapy; Lasers; Lentinan; MCF-7 Cells; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Nanotubes, Carbon; Neoplasms, Experimental; Phototherapy; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Thermogravimetry; Xenograft Model Antitumor Assays | 2018 |
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bilirubin; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hepatitis B; Humans; Male; Middle Aged; Prognosis; Retrospective Studies | 2018 |
The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Electrochemotherapy; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Laparotomy; Oxonic Acid; Pancreatic Neoplasms; Pyridines; Survival Rate; Tegafur | 2018 |
PEGylation of Carbonate Apatite Nanoparticles Prevents Opsonin Binding and Enhances Tumor Accumulation of Gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Apatites; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Mice; Mice, Inbred BALB C; Nanoparticles; Opsonin Proteins; Polyethylene Glycols; Protein Binding; Tumor Burden | 2018 |
The ATR Inhibitor AZD6738 Synergizes with Gemcitabine
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Indoles; Mice; Morpholines; Pyrimidines; Sulfonamides; Sulfoxides | 2018 |
The contribution of DNA replication stress marked by high-intensity, pan-nuclear γH2AX staining to chemosensitization by CHK1 and WEE1 inhibitors.
Topics: Analysis of Variance; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Replication; Gemcitabine; Histones; Humans; Nucleosides; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones; Roscovitine; Staining and Labeling | 2018 |
Isodon eriocalyx and its bioactive component Eriocalyxin B enhance cytotoxic and apoptotic effects of gemcitabine in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Deoxycytidine; Diterpenes; Gemcitabine; Humans; Isodon; MAP Kinase Signaling System; Pancreatic Neoplasms; Phosphorylation; Plant Extracts; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyruvate Dehydrogenase Acetyl-Transferring Kinase | 2018 |
A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2018 |
Comparing first-line treatment patterns and clinical outcomes of patients with pan-negative advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pemetrexed; Platinum; Retrospective Studies; Survival Analysis; Treatment Outcome; Vinorelbine | 2018 |
Oral recombinant methioninase (o-rMETase) is superior to injectable rMETase and overcomes acquired gemcitabine resistance in pancreatic cancer.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Apoptosis; Carbon-Sulfur Lyases; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Injections, Intraperitoneal; Mice; Mice, Nude; Pancreatic Neoplasms; Recombinant Proteins; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Oncogenic TRIM31 confers gemcitabine resistance in pancreatic cancer via activating the NF-κB signaling pathway.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Profiling; Heterografts; Humans; Male; Mice, Inbred BALB C; Middle Aged; Neoplasm Transplantation; NF-kappa B; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Signal Transduction; Tripartite Motif Proteins; Tumor Cells, Cultured; Ubiquitin-Protein Ligases | 2018 |
Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Basic-Leucine Zipper Transcription Factors; Blotting, Western; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Genetic Predisposition to Disease; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Male; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Survival Analysis; Treatment Outcome | 2018 |
Efficacy and treatment-related adverse events of gemcitabine plus nab-paclitaxel for treatment of metastatic pancreatic cancer "in a Korean" population: A single-center cohort study.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nervous System Diseases; Neurotoxicity Syndromes; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Peritoneal Neoplasms; Progression-Free Survival; Republic of Korea; Survival Rate; Treatment Outcome | 2017 |
Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Immunoconjugates; Mice; Mice, Nude; Oligopeptides; Oxaliplatin; Pancreatic Neoplasms; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2018 |
Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans; Markov Chains; Models, Economic; Pancreatic Neoplasms; Quality-Adjusted Life Years; United States | 2018 |
Gemcitabine and cisplatin for treatment of lung cancer in vitro and vivo.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Survival Rate; Vascular Endothelial Growth Factor A | 2018 |
Assessment of Three-Drug Combination Pharmacodynamic Interactions in Pancreatic Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Gemcitabine; Humans; Inhibitory Concentration 50; Models, Biological; Neoplastic Stem Cells; Paclitaxel; Pancreatic Neoplasms; Trifluoperazine | 2018 |
Role and timing of second-line therapies for patients with recurrent platinum-resistant ovarian epithelial cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cisplatin; Cytoreduction Surgical Procedures; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; Retreatment; Retrospective Studies; Survival Rate; Topotecan | 2017 |
Stereocomplex Prodrugs of Oligo(lactic acid)
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Lactates; Lactic Acid; Mice; Mice, Nude; Micelles; Molecular Structure; Neoplasms, Experimental; Polyethylene Glycols; Prodrugs; Stereoisomerism | 2018 |
LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Survival; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Indazoles; Neoplasm Invasiveness; Pancreatic Neoplasms; Piperazines; RNA, Long Noncoding | 2018 |
Nab-paclitaxel in combination with gemcitabine for the treatment of metastatic pancreas cancer: the South Wales experience.
Topics: Adult; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome; United Kingdom; Venous Thromboembolism | 2018 |
Tissue-Penetrating, Hypoxia-Responsive Echogenic Polymersomes For Drug Delivery To Solid Tumors.
Topics: Animals; Antineoplastic Agents; Azo Compounds; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Heterografts; Humans; Lactates; Male; Mice, Nude; Microsomes, Liver; Nanoparticles; Oligopeptides; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols; Rats; Tumor Hypoxia | 2018 |
Development and characterization of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs) using central composite design.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Stability; Gemcitabine; Lactic Acid; Nanoparticles; Particle Size; Phosphatidylethanolamines; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer | 2018 |
Combination Effects of Hispidin and Gemcitabine
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Pyrones | 2018 |
Neoadjuvant
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
A population-based analysis of urban-rural disparities in advanced pancreatic cancer management and outcomes.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; British Columbia; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Healthcare Disparities; Humans; Irinotecan; Leucovorin; Male; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Rural Health; Rural Population; Urban Health; Urban Population | 2018 |
Development of angiotensin II (1-7) analog as an oral therapeutic for the treatment of chemotherapy-induced myelosuppression.
Topics: Administration, Oral; Angiotensin I; Animals; Deoxycytidine; Gemcitabine; Humans; Immunosuppressive Agents; Mice; Myelopoiesis; Peptide Fragments | 2018 |
Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.
Topics: Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3; Humans; Irinotecan; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Signal Transduction | 2018 |
Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Glutathione Peroxidase; Glutathione Peroxidase GPX1; Glycogen Synthase Kinase 3 beta; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Snail Family Transcription Factors; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2018 |
A Critical Comparison of Rejection-Based Algorithms for Simulation of Large Biochemical Reaction Networks.
Topics: Algorithms; Biochemical Phenomena; Colloids; Computer Simulation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Kinetics; Linear Models; Mathematical Concepts; Models, Biological; Receptors, IgE; Stochastic Processes | 2019 |
Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Network Meta-Analysis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Quality-Adjusted Life Years; United Kingdom | 2018 |
Implication of linker length on cell cytotoxicity, pharmacokinetic and toxicity profile of gemcitabine-docetaxel combinatorial dual drug conjugate.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Drug Combinations; Female; Gemcitabine; Hemolysis; Humans; Polyethylene Glycols; Rats, Sprague-Dawley; Taxoids | 2018 |
The Strategy of Treatment for Mid to Distal Cholangiocarcinoma after Surgical Resection.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2018 |
Selecting patients with triple negative breast cancer for platinum-based therapy: we still haven't found what we're looking for.
Topics: Biomarkers; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum | 2018 |
Five Cases of Interstitial Pneumonitis Due to Gemcitabine and Nab-Paclitaxel Combination Treatment in Pancreatic Cancer Patients.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fatigue; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms | 2018 |
Inhibition of endoplasmic-reticulum-stress-mediated autophagy enhances the effectiveness of chemotherapeutics on pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Gemcitabine; Heat-Shock Proteins; Humans; Ki-67 Antigen; Mice, Inbred C57BL; Multivesicular Bodies; Pancreatic Neoplasms; Sunitinib; Survival Analysis; Tumor Burden; Unfolded Protein Response; X-Box Binding Protein 1 | 2018 |
miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins c-fyn; Signal Transduction; Time Factors | 2018 |
Simultaneous quantification of Gemcitabine and Irinotecan hydrochloride in rat plasma by using high performance liquid chromatography-diode array detector.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Chemistry Techniques, Analytical; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Injections, Intravenous; Irinotecan; Rats; Rats, Sprague-Dawley | 2018 |
[Impact of neoadjuvant chemotherapy on the peri-operative morbidity of radical cystectomy for muscle invasive bladder cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Postoperative Complications; Retrospective Studies; Risk Factors; Urinary Bladder Neoplasms | 2018 |
Gemcitabine hydrochloride microspheres used for intravesical treatment of superficial bladder cancer: a comprehensive in vitro/ex vivo/in vivo evaluation.
Topics: Administration, Intravesical; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Compounding; Gemcitabine; Humans; In Vitro Techniques; Microscopy, Electron, Scanning; Microspheres; Neoplasms, Experimental; Particle Size; Rats; Rats, Sprague-Dawley; Rheology; Urinary Bladder Neoplasms; Viscosity | 2018 |
GATA3 as a master regulator and therapeutic target in ovarian high-grade serous carcinoma stem cells.
Topics: Alkaline Phosphatase; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Deoxycytidine; Female; GATA3 Transcription Factor; Gemcitabine; Histone Demethylases; Humans; Neoplastic Stem Cells; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Prognosis; Protein Binding; Spheroids, Cellular | 2018 |
A gel system for single instillation of non-muscle-invasive bladder Cancer: A "divide-and-rule" strategy.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Dendrimers; Deoxycytidine; Dextrans; Doxorubicin; Drug Delivery Systems; Female; Gels; Gemcitabine; Mice; Mice, Inbred BALB C; Mice, Nude; Polyethylene Glycols; Urinary Bladder Neoplasms | 2018 |
Safety and efficacy of Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer suffering from cholestatic hyperbilirubinaemia-A retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cholestasis; Databases, Factual; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Hyperbilirubinemia; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2018 |
Guided chemotherapy based on patient-derived mini-xenograft models improves survival of gallbladder carcinoma patients.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Oxaliplatin; Paclitaxel; Xenograft Model Antitumor Assays | 2018 |
Design, characterization, and in vitro antiproliferative efficacy of gemcitabine conjugates based on carboxymethyl glucan.
Topics: Antineoplastic Agents; beta-Glucans; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Gemcitabine; HeLa Cells; Humans; Lung Neoplasms; Molecular Structure; Structure-Activity Relationship | 2018 |
MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells.
Topics: Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Cyclin D2; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms | 2018 |
Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Contraindications, Procedure; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Laparotomy; Leucovorin; Lymph Nodes; Male; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome; Withholding Treatment | 2019 |
[Two Case Reports of Chemotherapy-Induced Radiation Myositis].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Drug Combinations; Gemcitabine; Humans; Male; Middle Aged; Myositis; Oxonic Acid; Pancreatic Neoplasms; Tegafur | 2018 |
[Retrospective Analysis of Weekly Paclitaxel Chemotherapy for Gemcitabine- and S-1-Resistant Pancreatic Cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2018 |
[Maintenance strategies for advanced pancreatic cancer: Rationale and issues].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Maintenance Chemotherapy; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Randomized Controlled Trials as Topic | 2018 |
Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Platinum; Republic of Korea; Survival Analysis; Treatment Outcome | 2018 |
A density functional theory-based analysis of the structural, topological and electronic properties of gemcitabine drug adsorption on the pyrrolidine functionalized single-walled carbon nanotube.
Topics: Adsorption; Algorithms; Antimetabolites, Antineoplastic; Density Functional Theory; Deoxycytidine; Drug Carriers; Gemcitabine; Models, Chemical; Models, Molecular; Molecular Conformation; Molecular Structure; Nanotubes, Carbon; Pyrrolidines; Solubility | 2019 |
A case of gemcitabine-related acute lipodermatosclerosis.
Topics: Acute Disease; Antimetabolites, Antineoplastic; Deoxycytidine; Dermatitis; Female; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Scleroderma, Localized | 2019 |
Transfer of miRNA in Macrophage-Derived Exosomes Induces Drug Resistance in Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Transfer Techniques; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Mice, Knockout; MicroRNAs; Pancreatic Neoplasms; rab27 GTP-Binding Proteins; Tumor Microenvironment; Up-Regulation | 2018 |
TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage.
Topics: A549 Cells; Acetylation; Apoptosis; Camptothecin; Cell Proliferation; Chromatin Assembly and Disassembly; Deoxycytidine; DNA Damage; DNA-Binding Proteins; E1A-Associated p300 Protein; Etoposide; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nuclear Proteins; Protein Processing, Post-Translational; Sirtuin 1; Transcriptional Activation; Tumor Suppressor Protein p53 | 2019 |
Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Homeodomain Proteins; Hypoglycemic Agents; Male; Metformin; Mice; Mice, Knockout; Mutation; Neovascularization, Pathologic; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Trans-Activators; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2018 |
A drug-repositioning screen for primary pancreatic ductal adenocarcinoma cells identifies 6-thioguanine as an effective therapeutic agent for TPMT-low cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; Humans; MAP Kinase Signaling System; Methyltransferases; Pancreatic Neoplasms; Proto-Oncogene Proteins B-raf; Signal Transduction; Thioguanine; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
RBPJ and MAML3: Potential Therapeutic Targets for Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Gemcitabine; Hedgehog Proteins; Humans; Immunoglobulin J Recombination Signal Sequence-Binding Protein; Lung Neoplasms; Matrix Metalloproteinases; Neoplasm Invasiveness; Nuclear Proteins; Pancreatic Neoplasms; Receptors, Notch; Signal Transduction; Small Cell Lung Carcinoma; Trans-Activators; Transcription Factors | 2018 |
Localized Controlled Delivery of Gemcitabine via Microsol Electrospun Fibers to Prevent Pancreatic Cancer Recurrence.
Topics: Animals; Apoptosis; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms | 2018 |
Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Models, Biological; Neoplastic Stem Cells; Pancreatic Neoplasms; Transcriptome | 2018 |
Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Endonucleases; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Prognosis; Survival Rate; Transcription Factors; Xeroderma Pigmentosum Group A Protein; Xeroderma Pigmentosum Group D Protein | 2019 |
2,3,7,8‑Tetrachlorodibenzo‑p‑dioxin suppresses the growth of human liver cancer HepG2 cells in vitro: Involvement of cell signaling factors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Cell Proliferation; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Polychlorinated Dibenzodioxins; Receptors, Aryl Hydrocarbon; Signal Transduction | 2018 |
Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Dipeptides; Female; Gemcitabine; Heterografts; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Models, Biological; Pancreatic Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Nivolumab-induced cold agglutinin syndrome successfully treated with rituximab.
Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell, Marginal Zone; Neoplasms, Second Primary; Nivolumab; Rituximab; Syndrome | 2018 |
Optimal resection area for superior mesenteric artery nerve plexuses after neoadjuvant chemoradiotherapy for locally advanced pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Celiac Plexus; Chemoradiotherapy; Deoxycytidine; Dissection; Female; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2018 |
Multi-Scale Network Model Supported by Proteomics for Analysis of Combined Gemcitabine and Birinapant Effects in Pancreatic Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dipeptides; Gemcitabine; Humans; Indoles; Models, Biological; Pancreatic Neoplasms; Proteomics; Signal Transduction | 2018 |
Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma: A retrospective observational study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Central Venous Catheters; Cisplatin; Deoxycytidine; Disease-Free Survival; Endostatins; Female; Gemcitabine; Humans; Infusion Pumps; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Recombinant Proteins; Retrospective Studies | 2018 |
Self-Healing pH- and Enzyme Stimuli-Responsive Hydrogels for Targeted Delivery of Gemcitabine To Treat Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Female; Gemcitabine; Histidine; Humans; Hydrogels; Hydrogen-Ion Concentration; Male; Mice; Mice, Inbred NOD; Pancreatic Neoplasms; Polyglutamic Acid | 2018 |
Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages.
Topics: Cell Differentiation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytokines; Deoxycytidine; Gemcitabine; Humans; Immunomodulation; Macrophage Activation; Macrophages; Pancreatic Neoplasms; Tumor Microenvironment | 2018 |
A facile route to heterotelechelic polymer prodrug nanoparticles for imaging, drug delivery and combination therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Female; Fluorescent Dyes; Gemcitabine; Humans; MCF-7 Cells; Nanoparticles; Optical Imaging; Polymers; Prodrugs; Rhodamines | 2018 |
Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biomarkers, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Follow-Up Studies; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Male; Neoplasm Recurrence, Local; Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase; Prognosis; Survival Rate | 2018 |
Identification of lncRNAs and Their Functional Network Associated with Chemoresistance in SW1990/GZ Pancreatic Cancer Cells by RNA Sequencing.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; High-Throughput Nucleotide Sequencing; Humans; Insulin-Secreting Cells; MicroRNAs; Molecular Sequence Annotation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; Signal Transduction | 2018 |
Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Dose-Response Relationship, Radiation; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Diseases; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Radiation Injuries; Radiotherapy Dosage; Radiotherapy, High-Energy; Radiotherapy, Intensity-Modulated; Retrospective Studies; Treatment Outcome; Ulcer | 2018 |
Real-Time Monitoring of Cancer Cells in Live Mouse Bone Marrow.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Marrow; Cell Movement; Cell Survival; Cell Tracking; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Immune Tolerance; Intravital Microscopy; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Microscopy, Fluorescence, Multiphoton; Models, Animal; Neoplasms; Statistics, Nonparametric; Tumor Microenvironment | 2018 |
miR-129-5p inhibits gemcitabine resistance and promotes cell apoptosis of bladder cancer cells by targeting Wnt5a.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Inhibitory Concentration 50; Male; MicroRNAs; Middle Aged; Urinary Bladder Neoplasms; Wnt-5a Protein | 2018 |
USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy.
Topics: Animals; Autophagy; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyanoacrylates; Deoxycytidine; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Pyridines; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2018 |
Synergistic antitumour effects of triptolide plus gemcitabine in bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Diterpenes; Dose-Response Relationship, Drug; Drug Synergism; Epoxy Compounds; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Glycogen Synthase Kinase 3 beta; Humans; Phenanthrenes; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; Urinary Bladder Neoplasms | 2018 |
Brentuximab vedotin-based salvage treatment in Hodgkin's lymphoma.
Topics: Brentuximab Vedotin; Child; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Immunoconjugates; Salvage Therapy; Young Adult | 2018 |
Poor treatment outcomes with palliative gemcitabine and docetaxel chemotherapy in advanced and metastatic synovial sarcoma.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Retrospective Studies; Sarcoma, Synovial; Treatment Outcome; Young Adult | 2018 |
Carrier-free Janus nano-prodrug based on camptothecin and gemcitabine: Reduction-triggered drug release and synergistic in vitro antiproliferative effect in multiple cancer cells.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Janus Kinases; Nanoparticles; Neoplasms; Oxidation-Reduction; Prodrugs | 2018 |
Poly (l-glutamic acid)-g-methoxy poly (ethylene glycol)-gemcitabine conjugate improves the anticancer efficacy of gemcitabine.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Neoplasms, Experimental; Polyethylene Glycols; Polyglutamic Acid; Tissue Distribution | 2018 |
GnT-V promotes chemosensitivity to gemcitabine in bladder cancer cells through β1,6 GlcNAc branch modification of human equilibrative nucleoside transporter 1.
Topics: Acetylglucosamine; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; N-Acetylglucosaminyltransferases; Urinary Bladder Neoplasms | 2018 |
An Inhibitor of GSK3B and HDACs Kills Pancreatic Cancer Cells and Slows Pancreatic Tumor Growth and Metastasis in Mice.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Histone Deacetylase Inhibitors; Humans; Mice; Pancreas; Pancreatic Neoplasms | 2018 |
PARP inhibitors synergize with gemcitabine by potentiating DNA damage in non-small-cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Synergism; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Recombinational DNA Repair; Xenograft Model Antitumor Assays | 2019 |
Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients.
Topics: Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Biopsy; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression; Humans; Immunomodulation; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice; Positron Emission Tomography Computed Tomography; Prognosis; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
BH3 Mimetic ABT-199 Enhances the Sensitivity of Gemcitabine in Pancreatic Cancer in vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression; Genes, bcl-2; Humans; Mice; Pancreatic Neoplasms; Sulfonamides; Xenograft Model Antitumor Assays | 2018 |
Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms; Young Adult | 2018 |
Gemcitabine-loaded DSPE-PEG-PheoA liposome as a photomediated immune modulator for cholangiocarcinoma treatment.
Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor; Cell Survival; Chlorophyll; Cholangiocarcinoma; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Heterografts; Humans; Immunomodulation; Lasers; Liposomes; Mice, Inbred BALB C; Mice, Nude; Phosphatidylethanolamines; Photochemotherapy; Photosensitizing Agents; Polyethylene Glycols | 2018 |
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Electronic Health Records; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Progression-Free Survival; Quality of Life; Retrospective Studies | 2019 |
Gallbladder Carcinosarcoma with Mirizzi Syndrome: a Rare Presentation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cholecystectomy, Laparoscopic; Cisplatin; Deoxycytidine; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Mirizzi Syndrome; Treatment Outcome | 2019 |
Gemcitabine delivered by fucoidan/chitosan nanoparticles presents increased toxicity over human breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; Chitosan; Deoxycytidine; Drug Delivery Systems; Endothelial Cells; Gemcitabine; Humans; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Polymers; Polysaccharides | 2018 |
Pectoralis major radiation recall.
Topics: Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pectoralis Muscles; Radiation Injuries | 2019 |
Gemcitabine induced cytotoxicity, DNA damage and hepatic injury in laboratory mice.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Chemical and Drug Induced Liver Injury; Deoxycytidine; DNA Damage; DNA Fragmentation; Gemcitabine; In Situ Nick-End Labeling; Liver; Male; Mice; Time Factors | 2020 |
Evaluation of lauroyl-gemcitabine-loaded hydrogel efficacy in glioblastoma rat models.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Glioblastoma; Hydrogels; Magnetic Resonance Imaging; Nanomedicine; Rats; Rats, Sprague-Dawley | 2018 |
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome; United States | 2018 |
Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Dexamethasone; DNA-Binding Proteins; Female; Gemcitabine; Gene Rearrangement; Humans; Lymphoma, B-Cell; Middle Aged; Salvage Therapy; Treatment Outcome | 2019 |
Camrelizumab for nasopharyngeal carcinoma: a new hope?
Topics: Carcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2018 |
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Deoxycytidine; DNA Repair; DNA Replication; Female; Follow-Up Studies; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Organ Culture Techniques; Organoids; Ovarian Neoplasms; Prognosis; Pyrazines; Pyrazoles | 2018 |
Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.
Topics: Albumins; Animals; Antineoplastic Agents; Apoptosis; Body Weight; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Mice; Nanoparticles; Pancreatic Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Chemotherapy for pancreatic cancer: the rise of multidrug regimens.
Topics: Adenocarcinoma; Albumins; Capecitabine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.
Topics: Animals; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Mutation; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calcineurin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Discovery; Drug Screening Assays, Antitumor; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Mice; Mice, Nude; Neoplasm Transplantation; NFATC Transcription Factors; Pancreatic Neoplasms; Protein Binding; Proto-Oncogene Proteins c-mdm2; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2018 |
Optimized Gemcitabine Therapy in Combination with E7 Peptide Immunization Elicits Tumor Cure by Preventing Ag-Specific CTL Inhibition in Animals with Large Established Tumors.
Topics: Adenocarcinoma; Animals; Antibodies; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Cytotoxicity, Immunologic; Deoxycytidine; Drug Therapy; Epithelial Cells; Female; Gemcitabine; Humans; Immunization; Immunotherapy; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Oligodeoxyribonucleotides; Peptides; T-Lymphocytes, Cytotoxic; Tumor Burden; Tumor Necrosis Factor Receptor Superfamily, Member 9 | 2018 |
Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HMGA2 Protein; Humans; Mice; Mice, Knockout; Pancreatic Neoplasms; Prognosis; Survival Rate; Tissue Array Analysis; Tumor Cells, Cultured | 2018 |
Efficacy of S-1 monotherapy for older patients with unresectable pancreatic cancer: A retrospective cohort study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Databases, Factual; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Oxonic Acid; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Tegafur | 2019 |
Integrin β1 promotes gemcitabine resistance in pancreatic cancer through Cdc42 activation of PI3K p110β signaling.
Topics: Animals; Antimetabolites, Antineoplastic; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Survival; Class Ia Phosphatidylinositol 3-Kinase; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Integrin beta1; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; RNA Interference; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Tumor-stromal cross-talk modulating the therapeutic response in pancreatic cancer.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Survival; Coculture Techniques; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Risk Factors; Sensitivity and Specificity; Stromal Cells; Tumor Cells, Cultured | 2018 |
Evaluation of the use of nab-paclitaxel and gemcitabine in clinical practice.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2018 |
A biocompatible and cathepsin B sensitive nanoscale system of dendritic polyHPMA-gemcitabine prodrug enhances antitumor activity markedly.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biocompatible Materials; Cathepsin B; Cell Line, Tumor; Dendrimers; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Mice; Nanostructures; Optical Imaging; Phagocytosis; Polymethacrylic Acids; Prodrugs | 2018 |
Dihydroartemisinin increases gemcitabine therapeutic efficacy in ovarian cancer by inducing reactive oxygen species.
Topics: Animals; Antimetabolites, Antineoplastic; Artemisinins; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Female; Gemcitabine; Heme Oxygenase-1; Humans; Inhibitory Concentration 50; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Reactive Oxygen Species; Signal Transduction; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Hospitalization by cytotoxic chemotherapy regimen among older women with stage IV breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Hospitalization; Humans; Linear Models; Neoplasm Staging; Retrospective Studies; SEER Program; Survival Analysis | 2018 |
Hesperidin Induces ROS-Mediated Apoptosis along with Cell Cycle Arrest at G2/M Phase in Human Gall Bladder Carcinoma.
Topics: Acetylcysteine; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Gallbladder Neoplasms; Gemcitabine; Hesperidin; Humans; Macrophages; Membrane Potential, Mitochondrial; Mice; Reactive Oxygen Species; Tumor Cells, Cultured | 2019 |
Rab14 overexpression regulates gemcitabine sensitivity through regulation of Bcl-2 and mitochondrial function in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Membrane Potential, Mitochondrial; Middle Aged; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; rab GTP-Binding Proteins; Signal Transduction; Up-Regulation | 2019 |
Dietary Garcinol Arrests Pancreatic Cancer in p53 and K-ras Conditional Mutant Mouse Model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Deoxycytidine; Dietary Supplements; Gemcitabine; Genes, p53; Genes, ras; Humans; Magnetic Resonance Imaging; Male; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; S100 Calcium Binding Protein beta Subunit; Smad4 Protein; Survival Rate; Terpenes | 2018 |
Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with
Topics: Animals; Antibodies, Monoclonal; Basigin; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Radioimmunotherapy; Yttrium Radioisotopes | 2018 |
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin.
Topics: Aged; Biliary Tract Neoplasms; Case-Control Studies; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Maintenance Chemotherapy; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Survival Analysis; Treatment Outcome; Watchful Waiting | 2019 |
mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Phosphoproteins; Phosphorylation; Protein Biosynthesis; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Sarcoma, Ewing; Xenograft Model Antitumor Assays | 2018 |
Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Differentiation; Cells, Cultured; Deoxycytidine; Ferric Compounds; Fibrosis; Gemcitabine; Humans; Male; Mice, SCID; Nanoparticles; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, G-Protein-Coupled; Receptors, Peptide; Relaxin; Transforming Growth Factor beta; Treatment Outcome | 2018 |
Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Doxorubicin; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; MAP Kinase Signaling System; Mice, Nude; Protein Kinase Inhibitors; Protein Kinases; RNA, Small Interfering; Urologic Neoplasms | 2018 |
Mutant p53 prevents GAPDH nuclear translocation in pancreatic cancer cells favoring glycolysis and 2-deoxyglucose sensitivity.
Topics: AMP-Activated Protein Kinase Kinases; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Nucleus; Cytosol; Deoxycytidine; Deoxyglucose; Gemcitabine; Glyceraldehyde-3-Phosphate Dehydrogenases; Glycolysis; Humans; Mutation; Pancreatic Neoplasms; Protein Kinases; Protein Transport; Signal Transduction; Sirtuin 1; Tumor Suppressor Protein p53 | 2018 |
A Comparison Between Plastic and Metallic Biliary Stent Placement in Patients Receiving Preoperative Neoadjuvant Chemoradiotherapy for Resectable Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drainage; Female; Gemcitabine; Health Care Costs; Humans; Male; Metals; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Plastics; Retrospective Studies; Stents; Treatment Outcome | 2019 |
ASO Author Reflections: Neoadjuvant Treatment of Resectable and Borderline-Resectable Pancreatic Head Adenocarcinoma: Is FOLFIRINOX Better than Gem/Nab-Paclitaxel?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2018 |
The antioxidant transcription factor Nrf2 modulates the stress response and phenotype of malignant as well as premalignant pancreatic ductal epithelial cells by inducing expression of the ATF3 splicing variant ΔZip2.
Topics: Activating Transcription Factor 3; Adenocarcinoma; Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Epithelial Cells; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; NF-E2-Related Factor 2; Pancreatic Ducts; Precancerous Conditions; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2019 |
Comprehensive analysis of microRNA-messenger RNA regulatory network in gemcitabine-resistant bladder cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Gene Regulatory Networks; Humans; MicroRNAs; Protein Interaction Maps; RNA, Messenger; Small Molecule Libraries; Urinary Bladder Neoplasms | 2019 |
Melatonin and its metabolite N1-acetyl-N2-formyl-5-methoxykynuramine (afmk) enhance chemosensitivity to gemcitabine in pancreatic carcinoma cells (PANC-1).
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Kynuramine; Melatonin; Pancreatic Neoplasms | 2018 |
Gemcitabine plus S-1 for metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; China; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Pancreatic Neoplasms; Prospective Studies; Tegafur | 2018 |
Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
Topics: Amino Acids; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemistry Techniques, Synthetic; Chromatography, Liquid; Chromatography, Thin Layer; Deoxycytidine; Disease Models, Animal; Drug Monitoring; Drug Stability; Gemcitabine; Humans; Magnetic Resonance Spectroscopy; Pancreatic Neoplasms; Prodrugs; Tandem Mass Spectrometry; Threonine; Xenograft Model Antitumor Assays | 2018 |
p53 modeling as a route to mesothelioma patients stratification and novel therapeutic identification.
Topics: Cell Line, Tumor; Cell Survival; Deoxycytidine; Etoposide; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Models, Biological; Neoplasm Staging; Pleural Neoplasms; Proportional Hazards Models; Transcriptome; Tumor Suppressor Protein p53; Wound Healing | 2018 |
Silencing of TRPM8 inhibits aggressive tumor phenotypes and enhances gemcitabine sensitivity in pancreatic cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Calcium; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Silencing; Humans; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; RNA, Small Interfering; TRPM Cation Channels | 2018 |
Resistin effects on pancreatic cancer progression and chemoresistance are mediated through its receptors CAP1 and TLR4.
Topics: Animals; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytoskeletal Proteins; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Humans; Interleukin-6; Mice, SCID; Neoplasm Grading; Neoplasm Invasiveness; Pancreatic Neoplasms; Resistin; STAT3 Transcription Factor; Toll-Like Receptor 4 | 2019 |
Co-operation of ABT-199 and gemcitabine in impeding DNA damage repair and inducing cell apoptosis for synergistic therapy of T-cell acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Case-Control Studies; Cell Proliferation; Deoxycytidine; DNA Damage; DNA Repair; Drug Synergism; Gemcitabine; Humans; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Sulfonamides; Tumor Cells, Cultured | 2019 |
Overall survival in patients with relapsed/refractory high grade B-cell lymphomas treated with gemcitabine, oxaliplatin with or without rituximab.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Oxaliplatin; Retrospective Studies; Rituximab | 2019 |
Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Platelets; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Inflammation; Liver Neoplasms; Lymphatic Metastasis; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neutrophils; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Improving Plasma Stability and Bioavailability In Vivo of Gemcitabine Via Nanoparticles of mPEG-PLG-GEM Complexed with Calcium Phosphate.
Topics: Animals; Antimetabolites, Antineoplastic; Calcium Phosphates; Deoxycytidine; Drug Stability; Gemcitabine; Humans; Nanoconjugates; Polyethylene Glycols; Polyglutamic Acid; Rats, Sprague-Dawley | 2018 |
Combination therapy for the treatment of pancreatic cancer through hyaluronic acid-decorated nanoparticles loaded with quercetin and gemcitabine: A preliminary in vitro study.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Synergism; Gemcitabine; Humans; Hyaluronic Acid; Nanoparticles; Pancreatic Neoplasms; Quercetin | 2019 |
Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Indazoles; Male; Middle Aged; Pyrimidines; Retrospective Studies; Soft Tissue Neoplasms; Sulfonamides; Young Adult | 2019 |
Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; Matrix Attachment Region Binding Proteins; Mice; Mice, Nude; Middle Aged; Pancreatic Neoplasms; RNA, Small Interfering; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Lipids; Mice; Mice, Transgenic; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Resveratrol; RNA Interference; RNA, Small Interfering; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Xenograft Model Antitumor Assays | 2019 |
Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreas; Pancreatic Neoplasms; Proto-Oncogene Mas; RNA, Long Noncoding | 2018 |
Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Circulating Tumor DNA; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Palliative Care; Pancreas; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Prospective Studies; Proto-Oncogene Proteins p21(ras); Response Evaluation Criteria in Solid Tumors | 2018 |
Genetic Variants in the Wingless Antagonist Genes (
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axin Protein; Carboplatin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Docetaxel; Epistasis, Genetic; Female; Gemcitabine; Genetic Variation; Genotype; Humans; India; Intercellular Signaling Peptides and Proteins; Irinotecan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pemetrexed; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Prognosis; Proportional Hazards Models; Smoking; Wnt Proteins | 2018 |
Depletion of SIRT7 sensitizes human non-small cell lung cancer cells to gemcitabine therapy by inhibiting autophagy.
Topics: Animals; Autophagy; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Mice; Sirtuins | 2018 |
Conophylline suppresses pancreatic cancer desmoplasia and cancer-promoting cytokines produced by cancer-associated fibroblasts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cancer-Associated Fibroblasts; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Pancreatic Stellate Cells; Tumor Burden; Vinca Alkaloids; Xenograft Model Antitumor Assays | 2019 |
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Early Growth Response Protein 1; Erlotinib Hydrochloride; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Internet; National Cancer Institute (U.S.); Oligonucleotide Array Sequence Analysis; Signal Transduction; Translational Research, Biomedical; United States; Vorinostat | 2018 |
Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Neutralizing; Autocrine Communication; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemokines; Deoxycytidine; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Immunotherapy; Intercellular Signaling Peptides and Proteins; Mice, Inbred C57BL; Mice, Nude; Neutralization Tests; NF-kappa B; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Survival Analysis | 2018 |
Topics: Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2018 |
Risk-dependent curability of radiotherapy for elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma: A multicenter study from the China Lymphoma Collaborative Group (CLCG).
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Asparaginase; Combined Modality Therapy; Deoxycytidine; Etoposide; Female; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Neoplasm Staging; Prognosis; Risk; Survival Analysis | 2018 |
Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphocytes; Neutrophils; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2020 |
Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Survival; Deoxycytidine; Drug Liberation; Female; Folic Acid; Gemcitabine; HeLa Cells; Humans; Liposomes; Mice; Phosphatidylethanolamines; Polyethylene Glycols; Tissue Distribution | 2019 |
Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer.
Topics: Animals; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mice; Mitochondrial Proteins; Oncolytic Virotherapy; Oncolytic Viruses; Pancreatic Neoplasms; Vaccinia virus; Xenograft Model Antitumor Assays | 2019 |
Inactivation of ATF-2 enhances epithelial-mesenchymal transition and gemcitabine sensitivity in human pancreatic cancer cells.
Topics: Activating Transcription Factor 2; Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Survival Rate; Up-Regulation | 2019 |
Designing Two-Dimensional Nanosheets for Improving Drug Delivery to Fucose-Receptor-Overexpressing Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Deoxycytidine; Drug Liberation; Fucose; Gemcitabine; Graphite; Humans; Hydrogen-Ion Concentration; Molecular Targeted Therapy; Nanostructures; Receptors, Cell Surface | 2018 |
Pancreatic Microtumors: A Novel 3D Ex Vivo Testing Platform.
Topics: Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Macrophages; Pancreatic Neoplasms; Spheroids, Cellular; Tumor Microenvironment | 2019 |
The role of GLI-SOX2 signaling axis for gemcitabine resistance in pancreatic cancer.
Topics: Animals; Binding Sites; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Transplantation; Nuclear Proteins; Pancreatic Neoplasms; Signal Transduction; SOXB1 Transcription Factors; Survival Analysis; Up-Regulation; Zinc Finger Protein GLI1; Zinc Finger Protein Gli2 | 2019 |
Dihomo-γ-linolenic acid inhibits growth of xenograft tumors in mice bearing human pancreatic cancer cells (BxPC-3) transfected with delta-5-desaturase shRNA.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Proliferation; Delta-5 Fatty Acid Desaturase; Deoxycytidine; Disease Models, Animal; Drug Synergism; Fatty Acid Desaturases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2019 |
Tetramodal therapy using balloon-occluded arterial infusion of anticancer agents, the Azuma regimen, for lymph node-involved bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Balloon Occlusion; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Pelvis; Remission Induction; Retrospective Studies; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
Gemcitabine nanoparticles promote antitumor immunity against melanoma.
Topics: Animals; Antineoplastic Agents; Calcium Phosphates; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Female; Gemcitabine; Immune Tolerance; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Nanoparticles; Tumor Microenvironment | 2019 |
Bioengineered miRNA-1291 prodrug therapy in pancreatic cancer cells and patient-derived xenograft mouse models.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Mice, Transgenic; MicroRNAs; Paclitaxel; Pancreatic Neoplasms; Prodrugs; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Engineering Lineage Potency and Plasticity of Stem Cells using Epigenetic Molecules.
Topics: Aged; Aminopyridines; Benzamides; Cell Engineering; Cell Line; Cell Lineage; Cell Plasticity; Cell Proliferation; Deoxycytidine; Epigenesis, Genetic; Gemcitabine; Humans; Mesenchymal Stem Cells; Osteogenesis; Primary Cell Culture; Small Molecule Libraries | 2018 |
Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-grade Non-muscle-invasive Bladder Cancer on Tumor Recurrence.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2019 |
The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine.
Topics: Aggregatibacter actinomycetemcomitans; Animals; Chronic Periodontitis; Cytidine Deaminase; Deoxycytidine; Drug Resistance, Neoplasm; Gammaproteobacteria; Gemcitabine; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Neoplastic; Humans; Inactivation, Metabolic; Mice; Pancreatic Neoplasms; Pathology, Molecular; Porphyromonas gingivalis; Receptor, Notch1 | 2018 |
Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; France; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Pharmacovigilance; Retrospective Studies; Thrombotic Microangiopathies | 2019 |
Hyaluronic Acid-Based Multilayer Films Regulate Hypoxic Multicellular Aggregation of Pancreatic Cancer Cells with Distinct Cancer Stem-Cell-like Properties.
Topics: Cell Aggregation; Cell Cycle; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronic Acid; Nanostructures; Neoplastic Stem Cells; Pancreatic Neoplasms; Polyamines | 2018 |
CUB Domain-containing Protein 1 (CDCP1) Is Down-regulated by Active Hexose-correlated Compound in Human Pancreatic Cancer Cells.
Topics: Actins; Antigens, CD; Antigens, Neoplasm; Blotting, Western; Cell Adhesion Molecules; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Neoplasm Proteins; Pancreatic Neoplasms; Polysaccharides | 2018 |
Synchronous Adeno-squamous Carcinoma of Gallbladder and Adenocarcinoma of Common Bile Duct: Twin Trouble.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cholecystectomy, Laparoscopic; Cisplatin; Common Bile Duct; Deoxycytidine; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Multiple Primary; Pancreaticojejunostomy; Treatment Outcome; Ultrasonography | 2019 |
Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-кB pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Fibrinolytic Agents; Gemcitabine; Ginkgolides; HEK293 Cells; Humans; Lactones; Mice; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Xenograft Model Antitumor Assays | 2019 |
Efficacy of Nab-Paclitaxel Plus Gemcitabine and Prognostic Value of Peripheral Neuropathy in Patients with Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Linear Models; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Prognosis; Proportional Hazards Models; Retrospective Studies; Treatment Outcome | 2018 |
Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
Topics: Algorithms; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Computational Biology; Databases, Factual; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genome, Human; Humans; Machine Learning; Neoplasms; Ovarian Neoplasms; Precision Medicine; Predictive Value of Tests; Support Vector Machine; Transcriptome | 2018 |
Co-Delivery of Gemcitabine and Paclitaxel in cRGD-Modified Long Circulating Nanoparticles with Asymmetric Lipid Layers for Breast Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Delivery Systems; Gemcitabine; Lipids; Mice; Nanoparticles; Oligopeptides; Paclitaxel; Tissue Distribution | 2018 |
Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Retrospective Studies | 2018 |
The Long Noncoding RNA HOST2 Promotes Gemcitabine Resistance in Human Pancreatic Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Long Noncoding | 2020 |
Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Analysis; Tumor Burden | 2018 |
Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Deoxycytidine; Drug Delivery Systems; ErbB Receptors; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Nanoparticles; Neoplasms, Experimental; Pancreatic Neoplasms; Peptides; Phthalazines; Piperazines | 2018 |
[Adjuvant chemotherapy with cisplatin and gemcitabine after radiochemotherapy with curative intent does not improve relapse-free survival in nasopharyngeal cancer patients with persistently detectable EBV DNA].
Topics: Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; DNA; Gemcitabine; Herpesvirus 4, Human; Humans; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local | 2019 |
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gemcitabine; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Nestin; Phosphoric Monoester Hydrolases; Prognosis; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies | 2019 |
Efficacy and toxicities of gemcitabine and cisplatin combined with endostar in advanced thymoma and thymic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Endostatins; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Recombinant Proteins; Thymoma; Thymus Neoplasms; Uganda | 2019 |
Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.
Topics: Adenocarcinoma; Adenosine Triphosphate; Animals; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cell Survival; Clonal Evolution; Deoxycytidine; Elafin; Gemcitabine; Glycolysis; Heterografts; Humans; Mice; Oncogene Protein v-akt; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y2; RNA, Small Interfering; Sequence Analysis, RNA; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2019 |
SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Proliferation; Cholangiocarcinoma; Chronic Disease; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liver Diseases; SOX9 Transcription Factor; Survival Analysis; Treatment Outcome | 2018 |
Prognostic Value of Patient Knowledge of Cancer on Quality of Life in Advanced Lung Cancer During Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Health Knowledge, Attitudes, Practice; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quality of Life; Surveys and Questionnaires; Survival Rate | 2020 |
Pancreatic ductal adenocarcinoma: Role of chemotherapy & future perspectives.
Topics: Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2018 |
Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Monitoring; Female; Gemcitabine; Humans; India; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2018 |
Hyaluronic acid conjugated multi-walled carbon nanotubes for colon cancer targeting.
Topics: Animals; Cell Line, Tumor; Colonic Neoplasms; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Liberation; Folic Acid; Gemcitabine; Humans; Hyaluronic Acid; Nanotubes, Carbon; Rats | 2019 |
PEG-b-poly (carbonate)-derived nanocarrier platform with pH-responsive properties for pancreatic cancer combination therapy.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Hydrogen-Ion Concentration; Mice; Mice, Nude; Micelles; Nanoparticles; Pancreatic Neoplasms; Polycarboxylate Cement; Polyethylene Glycols; Polymers; Pyridines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Successful Bridging Chemotherapy with Gemcitabine, Carboplatin, and Dexamethasone before Unrelated Stem Cell Transplantation for Hepatosplenic T-cell Lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Liver Neoplasms; Lymphoma, T-Cell, Peripheral; Middle Aged; Splenic Neoplasms | 2019 |
[Microwave Hyperthermia Combined with Gemcitabine Inhibits Proliferation
and Induces Apoptosis of Human Lung Squamous Carcinoma Cells].
Topics: Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms; Microwaves | 2018 |
Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Margins of Excision; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
Drug-free albumin-triggered sensitization of cancer cells to anticancer drugs.
Topics: Antigens, CD20; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Pyrimidines; Serum Albumin, Human | 2019 |
CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane; Cell Survival; Cisplatin; Class I Phosphatidylinositol 3-Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Heat-Shock Proteins; Humans; Membrane Proteins; Neoplasm Proteins; Pancreatic Neoplasms; Phosphorylation; Primary Cell Culture; Protein Domains; Signal Transduction; Unfolded Protein Response | 2019 |
Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate | 2019 |
HIF1α-siRNA and gemcitabine combination-based GE-11 peptide antibody-targeted nanomedicine for enhanced therapeutic efficacy in pancreatic cancers.
Topics: Animals; Annexin A5; Antibodies; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Nanostructures; Neoplasms, Experimental; Pancreatic Neoplasms; Peptides; RNA, Small Interfering | 2019 |
Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptor, Notch1; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Predictable Resistance and Overall Survival of Gemcitabine/Cisplatin by Platelet Activation Index in Non-Small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Platelet Activation; Prognosis; Retrospective Studies | 2018 |
Comment on "Interpreting Clinical Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer (BRPC)".
Topics: Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2019 |
Long-term clinical response of advanced lung adenocarcinoma to maintenance treatment of gemcitabine: A case report.
Topics: Adenocarcinoma of Lung; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Progression-Free Survival; Time Factors; Treatment Outcome | 2018 |
A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Doxorubicin; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Prednisolone; Progression-Free Survival; Retrospective Studies; Thrombocytopenia; Vincristine; Young Adult | 2019 |
Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; GTP Phosphohydrolases; Humans; Male; Membrane Proteins; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Radiotherapy; Reoperation; Retrospective Studies; Survival Rate | 2019 |
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Circulating Tumor DNA; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Multicenter Studies as Topic; Mutation; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2018 |
Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells.
Topics: Adenocarcinoma; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreas; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Retinoblastoma Protein; RNA, Small Interfering; STAT3 Transcription Factor | 2019 |
Gemcitabine anticancer activity enhancement by water soluble celecoxib/sulfobutyl ether-β-cyclodextrin inclusion complex.
Topics: A549 Cells; Antineoplastic Agents; beta-Cyclodextrins; Celecoxib; Deoxycytidine; Drug Compounding; Drug Synergism; Gemcitabine; Humans; Molecular Dynamics Simulation; Powders; Solubility; Water | 2019 |
Primary hepatic squamous cell carcinoma with abdominal incision metastasis after hepatectomy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Fatal Outcome; Gemcitabine; Hepatectomy; Humans; Liver Neoplasms; Male; Neoplasm Seeding; Oxaliplatin; Treatment Outcome | 2019 |
ADAM9 contributes to vascular invasion in pancreatic ductal adenocarcinoma.
Topics: ADAM Proteins; Adenocarcinoma; Animals; Basement Membrane; Biocatalysis; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cohort Studies; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Lymphangiogenesis; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Grading; Neoplasm Invasiveness; Neovascularization, Pathologic; Paracrine Communication; Signal Transduction | 2019 |
LncRNA SNHG8 promotes the development and chemo-resistance of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms; RNA, Long Noncoding; Up-Regulation | 2018 |
Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Biliary Tract Neoplasms; Biomarkers; Cell Line, Tumor; Cell Survival; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Middle Aged; Prognosis; RNA, Small Interfering | 2018 |
Early venous thromboembolism at the beginning of palliative chemotherapy is a poor prognostic factor in patients with metastatic pancreatic cancer: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Sodium; Survival Analysis; Treatment Outcome; Venous Thromboembolism | 2018 |
Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Male; Mice; Mice, Nude; Monensin; Pancreas; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Xenograft Model Antitumor Assays | 2018 |
Value of adjuvant chemotherapy in patients with resected stage IB solid predominant and solid non-predominant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pemetrexed; Retrospective Studies; Survival Rate; Vinorelbine | 2019 |
Gemcitabine-induced pseudocellulitis.
Topics: Antimetabolites, Antineoplastic; Cellulitis; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Leg; Lymphoma, T-Cell, Peripheral; Middle Aged | 2018 |
Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2019 |
Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
Topics: Cell Cycle Proteins; Checkpoint Kinase 1; Cyclin-Dependent Kinase 2; Deoxycytidine; DNA Replication; DNA, Single-Stranded; Gemcitabine; Humans; PC-3 Cells; Protein Serine-Threonine Kinases; Pyrazoles; Pyrimidines; S Phase Cell Cycle Checkpoints | 2019 |
A Glimmer of Hope for Pancreatic Cancer.
Topics: Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2018 |
Dual delivery nanoscale device for miR-345 and gemcitabine co-delivery to treat pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Mice, Nude; MicroRNAs; Nanostructures; Pancreatic Neoplasms | 2019 |
Gemcitabine Induces Microvesicle Particle Release in a Platelet-Activating Factor-Receptor-Dependent Manner via Modulation of the MAPK Pathway in Pancreatic Cancer Cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell-Derived Microparticles; Deoxycytidine; Gemcitabine; Humans; MAP Kinase Signaling System; Pancreatic Neoplasms; Platelet Membrane Glycoproteins; Receptors, G-Protein-Coupled; Sphingomyelin Phosphodiesterase | 2018 |
Antipancreatic cancer effect of DNT cells and the underlying mechanism.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Transplantation; Coculture Techniques; Deoxycytidine; Fas Ligand Protein; fas Receptor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Pancreatic Neoplasms; T-Lymphocyte Subsets | 2019 |
Adenovirus-Mediated CRM197 Sensitizes Human Glioma Cells to Gemcitabine by the Mitochondrial Pathway.
Topics: Adenoviridae; Animals; Apoptosis; Bacterial Proteins; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Genetic Vectors; Glioma; Humans; Mice; Mice, Nude; Mitochondria; Xenograft Model Antitumor Assays | 2019 |
A new therapeutic combination for osteosarcoma: Gemcitabine and Clofazimine co-loaded liposomal formulation.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Clofazimine; Deoxycytidine; Drug Combinations; Drug Synergism; Gemcitabine; Humans; Liposomes; Osteosarcoma | 2019 |
Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Sarcoma; Treatment Outcome | 2019 |
Oxaliplatin regulates myeloid-derived suppressor cell-mediated immunosuppression via downregulation of nuclear factor-κB signaling.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Immune Tolerance; Mice, Inbred BALB C; Myeloid-Derived Suppressor Cells; Neoplasms; NF-kappa B; Oxaliplatin; T-Lymphocytes | 2019 |
Ultrasonic cavitation induces necrosis and impairs growth in three-dimensional models of pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Mice; Mice, Transgenic; Microscopy, Fluorescence; Models, Biological; Necrosis; Oxidative Stress; Pancreatic Neoplasms; Sonication; Spheroids, Cellular | 2018 |
Retrospective Analysis of Taxane-Based Therapy in Small Bowel Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Paclitaxel; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Heterotelechelic polymer prodrug nanoparticles: Adaptability to different drug combinations and influence of the dual functionalization on the cytotoxicity.
Topics: Breast Neoplasms; Cell Survival; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Combinations; Drug Synergism; Female; Gemcitabine; Humans; Lapatinib; MCF-7 Cells; Nanoparticles; Polymerization; Prodrugs | 2019 |
KML001, an arsenic compound, as salvage chemotherapy in refractory biliary tract cancers: A prospective study.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenites; Biliary Tract Neoplasms; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Prospective Studies; Salvage Therapy; Sodium Compounds; Time Factors; Tomography, X-Ray Computed | 2019 |
Chemoresistance Transmission via Exosome-Mediated EphA2 Transfer in Pancreatic Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Humans; Pancreatic Neoplasms; Proteome; Receptor, EphA2 | 2018 |
The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Paclitaxel; Sarcoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Paclitaxel; Pancreas; Sweden; Treatment Outcome | 2019 |
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organometallic Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2019 |
Rg3 inhibits gemcitabine-induced lung cancer cell invasiveness through ROS-dependent, NF-κB- and HIF-1α-mediated downregulation of PTX3.
Topics: A549 Cells; C-Reactive Protein; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Ginsenosides; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; MAP Kinase Signaling System; Neoplasm Invasiveness; NF-kappa B; NF-KappaB Inhibitor alpha; Phosphorylation; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Serum Amyloid P-Component; Signal Transduction | 2019 |
MicroRNA-200b and -301 are associated with gemcitabine response as biomarkers in pancreatic carcinoma cells.
Topics: Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; MicroRNAs; Pancreatic Neoplasms | 2019 |
Comparative Study Between Gemcitabine-Based and Gemcitabine Plus S1-Based Preoperative Chemoradiotherapy for Localized Pancreatic Ductal Adenocarcinoma, With Special Attention to Initially Locally Advanced Unresectable Tumor.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis | 2019 |
Gemcitabine: End of a Chemotherapy's Era?
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Salvage Therapy | 2019 |
Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Positron Emission Tomography Computed Tomography; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Young Adult | 2019 |
Chemo-immunotherapy improves long-term survival in a preclinical model of MMR-D-related cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cancer Vaccines; Cell Line, Tumor; Colorectal Neoplasms; Cyclophosphamide; Dendritic Cells; Deoxycytidine; Gastrointestinal Neoplasms; Gemcitabine; Immunotherapy; Mice; Myeloid-Derived Suppressor Cells; Neoplastic Syndromes, Hereditary; Spleen; T-Lymphocytes, Regulatory | 2019 |
Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Emulsions; Gemcitabine; Humans; Inhibitory Concentration 50; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Wistar; Simvastatin | 2019 |
Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Photochemotherapy; Retrospective Studies; Treatment Outcome | 2019 |
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies.
Topics: Adult; Antibodies, Monoclonal, Humanized; Deoxycytidine; Gemcitabine; Humans; Male; Sezary Syndrome; Time Factors | 2019 |
Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Factor 6; Leptin; Male; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Up-Regulation | 2019 |
Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD20; Apoptosis; Cell Cycle; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Membrane Potential, Mitochondrial; Microscopy, Confocal; Middle Aged; Nanomedicine; Young Adult | 2019 |
Acoustic disruption of tumor endothelium and on-demand drug delivery for cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Endothelium; Gemcitabine; Liposomes; Mice; Nanoparticles | 2019 |
Attempts to strengthen and simplify the tumor vascular normalization strategy using tumor vessel normalization promoting nanomedicines.
Topics: Angiogenesis Inhibitors; Animals; Cell Survival; Deoxycytidine; Gemcitabine; Hep G2 Cells; Heparin, Low-Molecular-Weight; Human Umbilical Vein Endothelial Cells; Humans; Lipids; Liver Neoplasms; Mice; Microscopy, Fluorescence; Nanomedicine; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Transplantation, Heterologous | 2019 |
How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
Topics: Deoxycytidine; Gemcitabine; Humans; Indazoles; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Sarcoma; Soft Tissue Neoplasms; Sulfonamides | 2019 |
Enhancing responsiveness of pancreatic cancer cells to gemcitabine treatment under hypoxia by heme oxygenase-1 inhibition.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Glutathione; Heme Oxygenase-1; Humans; Male; Mice, Nude; Models, Biological; Neoplastic Stem Cells; Pancreatic Neoplasms; Reactive Oxygen Species; Stromal Cells | 2019 |
Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Interferon Type I; Killer Cells, Natural; Mice; Mice, Inbred C57BL; Myeloid Cells; Pancreatic Neoplasms; Transcriptome; Xenograft Model Antitumor Assays | 2019 |
FOLFIRINOX goes adjuvant.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms; Prognosis; Random Allocation; Survival Analysis; Treatment Outcome | 2019 |
Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Gemcitabine; Heterografts; Humans; Leiomyosarcoma; Mice; Mice, Nude; Neoplasm Metastasis; Peritoneal Neoplasms; Recurrence; Salvage Therapy; Treatment Outcome; Tumor Burden | 2019 |
lncRNAPVT1 targets miR-152 to enhance chemoresistance of osteosarcoma to gemcitabine through activating c-MET/PI3K/AKT pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Osteosarcoma; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; RNA, Long Noncoding; Signal Transduction | 2019 |
Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Methotrexate; Retrospective Studies; SEER Program; United States; Urologic Neoplasms; Venous Thromboembolism; Vinblastine | 2019 |
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Gene Silencing; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mutation; Tumor Suppressor Proteins; Ubiquitin Thiolesterase | 2019 |
Modified FOLFIRINOX superior to gemcitabine in resected pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2019 |
Enhanced anti-tumor efficiency of gemcitabine prodrug by FAPα-mediated activation.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Endopeptidases; Gelatinases; Gemcitabine; Humans; Lung Neoplasms; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; PC-3 Cells; Prodrugs; Rats, Sprague-Dawley; Serine Endopeptidases; Tumor Microenvironment | 2019 |
EBV-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma Response to PD-L1 Blockade.
Topics: Adenocarcinoma of Lung; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Deoxycytidine; Docetaxel; Drug Resistance; Drug Substitution; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Immunotherapy; Lung Neoplasms; Neoplasm Staging; Treatment Outcome | 2019 |
Carcinoma of Unknown Primary with
Topics: Adult; Anaplastic Lymphoma Kinase; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Neoplasms, Unknown Primary; Oncogene Proteins, Fusion; Prognosis | 2019 |
Quantification of gemcitabine intravenous drugs by direct measurement in chemotherapy plastic bags using a handheld Raman spectrometer.
Topics: Administration, Intravenous; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Packaging; Gemcitabine; Humans; Plastics; Spectrum Analysis, Raman | 2019 |
A Polymeric Nanogel-Based Treatment Regimen for Enhanced Efficacy and Sequential Administration of Synergistic Drug Combination in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Gels; Gemcitabine; Humans; Mice; Mice, Nude; Nanostructures; Pancreatic Neoplasms; Platinum; Polymers | 2019 |
S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Janus Kinase 2; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; S-Adenosylmethionine; Signal Transduction; STAT3 Transcription Factor; Tumor Burden | 2019 |
Patterns of Local Failure After Stereotactic Body Radiation Therapy and Sequential Chemotherapy as Initial Treatment for Pancreatic Cancer: Implications of Target Volume Design.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Celiac Artery; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Mesenteric Artery, Superior; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Radiosurgery; Radiotherapy Dosage; Splenic Artery; Time Factors; Treatment Failure; Tumor Burden | 2019 |
[A Case of Advanced Gallbladder Cancer with Paraaortic Lymph Node Metastases Successfully Treated by Chemotherapy and Conversion Surgery].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Positron Emission Tomography Computed Tomography | 2018 |
[A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemodialysis].
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Renal Dialysis | 2018 |
[A Case of Long-Term Survival of a Patient with Cholangiocarcinoma and Liver Metastatic Recurrence Who Responded to Gemcitabine plus Cisplatin Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Neoplasm Recurrence, Local | 2018 |
[Treatment Outcomes of Gemcitabine and Cisplatin Combination Therapy for Unresectable and Recurrent Biliary Tract Cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Treatment Outcome | 2018 |
[A Case of Unresectable Pancreas Cancer with 32 Months Survival after Chemotherapy].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2018 |
Clinical efficacy of concurrent bevacizumab for malignant ascites in nonsquamous cell carcinoma of the lung.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Prognosis | 2019 |
Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Topics: Aged; Antimetabolites, Antineoplastic; Biological Variation, Population; Biomarkers, Tumor; Cytidine Deaminase; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Inflammation; Male; Malnutrition; Middle Aged; Neutrophils; Nutritional Status; Pancreatic Neoplasms; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Prospective Studies | 2019 |
Drug combination using an injectable nanomedicine hydrogel for glioblastoma treatment.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Combinations; Drug Liberation; Gemcitabine; Glioblastoma; Hydrogels; Injections; Lipids; Mice; Nanocapsules; Nanomedicine; Paclitaxel; Rats | 2019 |
PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; DNA Damage; DNA Repair; Epithelial-Mesenchymal Transition; Etoposide; Forkhead Box Protein M1; Gemcitabine; HEK293 Cells; Homeodomain Proteins; Humans; Liver Neoplasms; Mice; Mice, Knockout; Pancreas; Pancreatic Neoplasms; Protein Isoforms; Transcription, Genetic | 2019 |
Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.
Topics: Animals; Antimetabolites, Antineoplastic; Data Interpretation, Statistical; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Mice; Models, Biological; Ovarian Neoplasms; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Long term oncologic outcome in patients with bladder cancer after radical cystectomy: Impact of carcinoma in situ in the era of neoadjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasms, Multiple Primary; Survival Rate; Time Factors; Urinary Bladder Neoplasms; Vinblastine | 2019 |
Cytosolic 5'-nucleotidase 1A is overexpressed in pancreatic cancer and mediates gemcitabine resistance by reducing intracellular gemcitabine metabolites.
Topics: 5'-Nucleotidase; Animals; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Humans; Mice; Mice, Transgenic; Models, Biological; Pancreatic Neoplasms; Prognosis; Xenograft Model Antitumor Assays | 2019 |
Second-line chemotherapy in biliary tract cancer: Outcome and prognostic factors.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2019 |
Development of bioactive gemcitabine-D-Lys
Topics: Animals; Cell Proliferation; Deoxycytidine; Drug Liberation; Drug Stability; Gemcitabine; Gonadotropin-Releasing Hormone; Humans; Intracellular Space; Lysine; MCF-7 Cells; Mice; Prodrugs; Receptors, LHRH | 2019 |
Glucose-Regulated Protein 94 Modulates the Response of Osteosarcoma to Chemotherapy.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epirubicin; Gemcitabine; Humans; Membrane Glycoproteins; Osteosarcoma; Paclitaxel | 2019 |
Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotherapy, Adjuvant; Cullin Proteins; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; MicroRNAs; Pneumonectomy | 2019 |
Comparison of Gemcitabine monotherapy with Gemcitabine and Cisplatin combination in metastatic pancreatic cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2018 |
Serine/arginine protein-specific kinase 2 promotes the development and progression of pancreatic cancer by downregulating Numb and p53.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasm Staging; Nerve Tissue Proteins; Oxaliplatin; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2019 |
Pre-existing Functional Heterogeneity of Tumorigenic Compartment as the Origin of Chemoresistance in Pancreatic Tumors.
Topics: Aged; Animals; Antimetabolites, Antineoplastic; Cells, Cultured; Clonal Evolution; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Genetic Heterogeneity; Humans; Male; Mice; Middle Aged; Neoplastic Stem Cells; Pancreatic Neoplasms; Transcriptome | 2019 |
Long non-coding RNA LINC00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; MicroRNAs; Middle Aged; Molecular Targeted Therapy; Nuclear Proteins; Pancreatic Neoplasms; RNA, Long Noncoding; Transcription Factors | 2019 |
Light-Cross-linked Enediyne Small-Molecule Micelle-Based Drug-Delivery System.
Topics: A549 Cells; Cell Survival; Deoxycytidine; Drug Carriers; Enediynes; Gemcitabine; Humans; Light; Micelles; Microscopy, Confocal; Polymerization | 2019 |
In vitro culture with gemcitabine augments death receptor and NKG2D ligand expression on tumour cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; fas Receptor; Gemcitabine; GPI-Linked Proteins; Histocompatibility Antigens Class I; Humans; Intercellular Signaling Peptides and Proteins; Protein Kinase Inhibitors; Receptor Activator of Nuclear Factor-kappa B; Signal Transduction; Up-Regulation | 2019 |
Effects of Chemotherapy-Induced Neutropenia on Overall Survival in Patients With Unresectable or Metastatic Urothelial Carcinoma to Gemcitabine Plus Cisplatin Combination Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Retrospective Studies; Treatment Outcome; Urologic Neoplasms; Urothelium | 2019 |
Digoxin sensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine via inhibiting Nrf2 signaling pathway.
Topics: Animals; Apoptosis; Cell Line, Tumor; Deoxycytidine; Digoxin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Gene Expression Profiling; Germ Cells; Humans; Mice; Models, Biological; NF-E2-Related Factor 2; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Transcriptome; Xenograft Model Antitumor Assays | 2019 |
SNHG14 enhances gemcitabine resistance by sponging miR-101 to stimulate cell autophagy in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Long Noncoding | 2019 |
[Gemcitabine and capecitabine as new standard of care for adjuvant therapy in pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Standard of Care | 2019 |
Re: Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: .
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2019 |
EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Eukaryotic Translation Initiation Factor 5A; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Peptide Initiation Factors; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1 | 2019 |
Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Cyclophosphamide; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Hospitalization; Humans; Incidence; Induction Chemotherapy; Length of Stay; Retrospective Studies; Risk; Thrombocytopenia; United States | 2019 |
[Postoperative Recurrence of Pancreatic Cancer Successfully Treated with the Gemcitabine plus Oxaliplatin Regimen Resulting in Long-Term Survival-ACase Report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms | 2019 |
MiR-30a regulates cancer cell response to chemotherapy through SNAI1/IRS1/AKT pathway.
Topics: Aged; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Female; Gemcitabine; Humans; Insulin Receptor Substrate Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Snail Family Transcription Factors; Survival Rate; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Efficient anticorrelated variance reduction for stochastic simulation of biochemical reactions.
Topics: Algorithms; Analysis of Variance; Deoxycytidine; Gemcitabine; Gene Expression Regulation; Models, Biological; Receptors, IgE; Signal Transduction; Stochastic Processes | 2019 |
MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
Topics: 3' Untranslated Regions; Albumins; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Sequence Homology, Nucleic Acid | 2019 |
STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Gemcitabine; Humans; Interferon-gamma; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; STAT1 Transcription Factor; Xenograft Model Antitumor Assays | 2019 |
Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mixed Function Oxygenases; Proto-Oncogene Proteins; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta-Arrestin 1; beta-Arrestin 2; Cell Line, Tumor; Cisplatin; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Phenotype; Prognosis; Stem Cells; Transfection; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Enhancement of gemcitabine cytotoxicity in pancreatic adenocarcinoma through controlled release of nitric oxide.
Topics: Adenocarcinoma; Cell Line, Tumor; Cytotoxins; Delayed-Action Preparations; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Nitric Oxide; Pancreatic Neoplasms | 2019 |
A Case of Heavily Pretreated Metastatic Germ Cell Tumor With Ongoing Long-term Complete Response After Gemcitabine Treatment.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasms, Germ Cell and Embryonal; Prognosis; Remission Induction; Salvage Therapy; Young Adult | 2019 |
Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Cycle Proteins; Clofarabine; Colorectal Neoplasms; Deoxycytidine; DNA Damage; DNA Repair; Gemcitabine; HCT116 Cells; Histones; HT29 Cells; Humans; Mice; Mice, Nude; Nuclear Proteins; Rad51 Recombinase; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates.
Topics: Animals; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Deoxycytidine; Drug Design; Female; Gemcitabine; Humans; Immunoconjugates; Immunoglobulin Fab Fragments; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, SCID; Mice, Transgenic; Models, Molecular; Protein Structure, Tertiary; Receptors, CXCR4; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Local release of gemcitabine via in situ UV-crosslinked lipid-strengthened hydrogel for inhibiting osteosarcoma.
Topics: Animals; Antimetabolites, Antineoplastic; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Implants; Gelatin; Gemcitabine; Humans; Hydrogels; In Vitro Techniques; Liposomes; Mice; Osteosarcoma; Ultraviolet Rays; Xenograft Model Antitumor Assays | 2018 |
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2018 |
New guideline-sanctioned and emerging interventions for pancreatic cancer.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Histone Acetyltransferases; Humans; Hyaluronoglucosaminidase; Irinotecan; Leucovorin; Neoplasm Metastasis; Oxaliplatin; Pancreas; Pancreatic Neoplasms | 2018 |
Adjuvant Therapy for Early Uterine High-Grade Leiomyosarcoma.
Topics: Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Leiomyosarcoma; Uterine Neoplasms | 2019 |
Reply to F. Tomao et al.
Topics: Deoxycytidine; Docetaxel; Doxorubicin; Female; Gemcitabine; Humans; Leiomyosarcoma | 2019 |
Gemcitabine and betulinic acid co-encapsulated PLGA-PEG polymer nanoparticles for improved efficacy of cancer chemotherapy.
Topics: Apoptosis; Betulinic Acid; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Nanoparticles; Particle Size; Pentacyclic Triterpenes; Polyesters; Polyethylene Glycols; Reactive Oxygen Species; Triterpenes | 2019 |
Antitumoral effect of maintained neutrophilia induced by rhG-CSF in a murine model of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukocytosis; Mice; Mice, Nude; Neutrophils; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
A novel liver-specific fluorescent anti-cancer drug delivery system using indocyanine green.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Fluorescent Dyes; Gemcitabine; Hepatocytes; Human Umbilical Vein Endothelial Cells; Humans; Indocyanine Green; Injections, Intravenous; Liver; Liver Neoplasms; Male; Mice; Microscopy, Fluorescence; Xenograft Model Antitumor Assays | 2019 |
Re: Bladder Preservation with Twice-a-day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2019 |
aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1.
Topics: Animals; Antioxidants; Cell Line, Tumor; Cell Transformation, Neoplastic; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gallbladder Neoplasms; Gemcitabine; Gene Knockdown Techniques; Humans; Kelch-Like ECH-Associated Protein 1; Mice; Models, Biological; NF-E2-Related Factor 2; Prognosis; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase C; Reactive Oxygen Species; Signal Transduction | 2019 |
Emerging new predictive biomarkers in metastatic breast cancer: Caveolin-1 and weekly nab-paclitaxel plus gemcitabine, are we on for tomorrow?
Topics: Albumins; Biomarkers; Breast Neoplasms; Caveolin 1; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Paclitaxel | 2019 |
Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cells, Cultured; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pancreatic Neoplasms; Pyrimidines; RAW 264.7 Cells; Xenograft Model Antitumor Assays | 2019 |
Insights into gemcitabine resistance and the potential for therapeutic monitoring.
Topics: Antimetabolites, Antineoplastic; Biomarkers; Deoxycytidine; Drug Monitoring; Drug Resistance, Neoplasm; Gemcitabine; Humans; Metabolome; Pancreatic Neoplasms; Tumor Cells, Cultured | 2018 |
Current Real-Life Results and Future Options of Gemcitabine-Based Salvage Therapy for Relapsed or Refractory Non-Hodgkin Lymphoma.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Salvage Therapy | 2019 |
Macrophages throw tumour cells a lifeline.
Topics: Deoxycytidine; Gemcitabine; Humans; Macrophages; Pancreatic Neoplasms; Pyrimidines | 2019 |
Combination or single-agent chemotherapy as adjuvant treatment for pancreatic cancer?
Topics: Capecitabine; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2019 |
Antitumor effects of all-trans retinoic acid and its synergism with gemcitabine are associated with downregulation of p21-activated kinases in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Synergism; Gemcitabine; Humans; Mice; p21-Activated Kinases; Pancreatic Neoplasms; Treatment Outcome; Tretinoin; Xenograft Model Antitumor Assays | 2019 |
[FOLFIRINOX after resection of pancreatic cancer sets new standards-systemic therapy providing an impulse for local treatment in resectable pancreatic cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms | 2019 |
Topics: Animals; Cell Line, Tumor; Cetuximab; Combined Modality Therapy; Copper Radioisotopes; Deoxycytidine; Disease Models, Animal; ErbB Receptors; Female; Gemcitabine; HCT116 Cells; Humans; Injections, Intraperitoneal; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Pancreatic Neoplasms; Radioimmunotherapy; Radiotherapy, Adjuvant; Treatment Outcome | 2019 |
WT1 associated protein promotes metastasis and chemo-resistance to gemcitabine by stabilizing Fak mRNA in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; Pancreatic Neoplasms; RNA, Messenger; Signal Transduction; WT1 Proteins | 2019 |
Emergence, development, and future of cardio-oncology in China: cardiohypersensitivity, cardiotoxicity and the Kounis syndrome.
Topics: Afatinib; Carcinoma, Squamous Cell; Cardiotoxicity; China; Cisplatin; Coronary Artery Disease; Deoxycytidine; Gemcitabine; Humans; Kounis Syndrome; Male; Medical Oncology; Middle Aged | 2019 |
Can cytidine deaminase be used as predictive biomarker for gemcitabine toxicity and response?
Topics: Biomarkers; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2019 |
Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dasatinib; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Signal Transduction; STAT3 Transcription Factor | 2019 |
Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2019 |
RNAi-Mediated PD-L1 Inhibition for Pancreatic Cancer Immunotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Carriers; Drug Evaluation, Preclinical; Drug Monitoring; Female; Gemcitabine; Humans; Immunotherapy; Magnetic Resonance Imaging; Magnetite Nanoparticles; Maximum Tolerated Dose; Mice; Pancreas; Pancreatic Neoplasms; RNA Interference; RNA, Small Interfering; Tumor Microenvironment | 2019 |
Co-Delivery of Gemcitabine and Mcl-1 SiRNA via Cationic Liposome-Based System Enhances the Efficacy of Chemotherapy in Pancreatic Cancer.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liposomes; Myeloid Cell Leukemia Sequence 1 Protein; Pancreatic Neoplasms; RNA, Small Interfering | 2019 |
FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms | 2019 |
Bilateral leiomyosarcoma of kidneys with pericardial metastases: a double whammy.
Topics: Administration, Intravenous; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Heart Neoplasms; Humans; Kidney Neoplasms; Leiomyosarcoma; Magnetic Resonance Imaging; Male; Middle Aged; Positron-Emission Tomography | 2019 |
Recombinant deoxyribonucleoside kinase from Drosophila melanogaster can improve gemcitabine based combined gene/chemotherapy for targeting cancer cells.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Drosophila melanogaster; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Gemcitabine; Genetic Therapy; Genetic Vectors; HCT116 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; MCF-7 Cells; Phosphotransferases (Alcohol Group Acceptor); Recombinant Proteins; Substrate Specificity; Transfection | 2019 |
Survival benefit of first-generation epidermal growth factor receptor-tyrosine kinase inhibitors in female with advanced lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Female; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Staging; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors | 2019 |
[Successful R0 Resection of Hilar Cholangiocarcinoma by Extrahepatic Bile Duct Resection Due to Accompanying Liver Dysfunction after Neoadjuvant Gemcitabine/Cisplatin/S-1 Combination Chemotherapy-A Case Report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Klatskin Tumor; Male; Neoadjuvant Therapy; Positron Emission Tomography Computed Tomography | 2019 |
[A Case of Liver Metastasis of Intrahepatic Cholangiocarcinoma That Achieved Clinical Complete Response after Gemcitabine and Cisplatin Combination Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local | 2019 |
The role of lncRNA MSC-AS1/miR-29b-3p axis-mediated CDK14 modulation in pancreatic cancer proliferation and Gemcitabine-induced apoptosis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinases; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; RNA, Antisense; RNA, Long Noncoding | 2019 |
Low doses of decitabine improve the chemotherapy efficacy against basal-like bladder cancer by targeting cancer stem cells.
Topics: Animals; Antimetabolites, Antineoplastic; Cisplatin; Decitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gemcitabine; Humans; Male; Mice; Neoplastic Stem Cells; Urinary Bladder Neoplasms | 2019 |
Expression profile and prognostic value of SFN in human ovarian cancer.
Topics: 14-3-3 Proteins; Aged; Aged, 80 and over; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Exoribonucleases; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prognosis; RNA, Messenger | 2019 |
Metabolite crosstalk could modulate chemotherapy response in pancreatic cancer.
Topics: Deoxycytidine; Gemcitabine; Humans; Macrophages; Pancreatic Neoplasms; Pyrimidines | 2019 |
The distinct role of CD73 in the progression of pancreatic cancer.
Topics: 5'-Nucleotidase; Animals; Apoptosis; Base Sequence; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Progression; Female; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Male; Mice, Nude; MicroRNAs; Middle Aged; Models, Biological; Pancreatic Neoplasms; Receptors, Tumor Necrosis Factor, Type II; RNA, Messenger; Signal Transduction | 2019 |
Unresectable pancreatic ductal adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting outcomes of patients treated with chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Contrast Media; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
The combination of olaratumab with gemcitabine and docetaxel arrests a chemotherapy-resistant undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Nude; Middle Aged; Sarcoma; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Longitudinal Studies; Models, Statistical; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate | 2019 |
Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
Topics: 14-3-3 Proteins; Animals; Antimetabolites, Antineoplastic; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Pancreatic Ductal; Cell Polarity; Cell Proliferation; Culture Media, Conditioned; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Macrophages; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2019 |
The phenotype of target pancreatic cancer cells influences cell death by magnetic hyperthermia with nanoparticles carrying gemicitabine and the pseudo-peptide NucAnt.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; JNK Mitogen-Activated Protein Kinases; Ki-67 Antigen; Magnetite Nanoparticles; Mice, Nude; Pancreatic Neoplasms; Peptides; Phenotype; S Phase; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
A case of extrahepatic bile duct cancer with distant metastases showing pathological complete response to treatment combining gemcitabine and cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Pancreaticoduodenectomy; Positron-Emission Tomography; Tomography, X-Ray Computed | 2019 |
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Propensity Score; Time Factors; Treatment Outcome | 2019 |
Ocoxin Oral Solution Exerts an Antitumoral Effect in Pancreatic Cancer and Reduces the Stromal-Mediated Chemoresistance.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Ascorbic Acid; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Folic Acid; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred C57BL; Neoplasms, Experimental; Paclitaxel; Pancreatic Neoplasms; Pantothenic Acid; Plant Extracts; Solutions; Vitamin B 12; Vitamin B 6; Zinc Sulfate | 2019 |
RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment.
Topics: Animals; Benzoxazines; Cell Line, Tumor; Chemokine CCL2; Deoxycytidine; Female; Gemcitabine; Humans; Male; Mice; Middle Aged; Monocytes; Myeloid-Derived Suppressor Cells; Spiro Compounds; Survival Analysis; T-Lymphocytes; Tumor Microenvironment; Urinary Bladder Neoplasms | 2019 |
The Efficacy and Limitations of Postoperative Adjuvant Chemotherapy in Patients With Extrahepatic Cholangiocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Oxonic Acid; Plastic Surgery Procedures; Pyridines; Recurrence; Tegafur | 2019 |
Polyethylenimine (PEI)-Mediated E1A Increases the Sensitivity of Hepatocellular Carcinoma Cells to Chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Docetaxel; Epirubicin; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Polyethyleneimine; Viral Proteins | 2019 |
Radiofrequency deep hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms; Male; Middle Aged; Retrospective Studies | 2019 |
Gemcitabine-induced haemolytic uraemic syndrome in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Glucocorticoids; Hemolytic-Uremic Syndrome; Humans; Methylprednisolone; Paclitaxel; Pancreatic Neoplasms | 2019 |
Gastrointestinal Cancers: Management of Rectal, Hepatocellular, Pancreatic, and Esophageal Cancers.
Topics: Carcinoma, Hepatocellular; Deoxycytidine; Esophageal Neoplasms; Gastrointestinal Neoplasms; Gemcitabine; Humans; Liver Neoplasms; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2019 |
PARP14 promotes the proliferation and gemcitabine chemoresistance of pancreatic cancer cells through activation of NF-κB pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Pancreas; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; RNA Interference; RNA, Small Interfering | 2019 |
Treatment of Metastatic Urothelial Cancer in 2018.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Carboplatin; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Programmed Cell Death 1 Receptor; Taxoids; Urologic Neoplasms; Urothelium | 2019 |
Microwave hyperthermia enhances the sensitivity of lung cancer cells to gemcitabine through reactive oxygen species‑induced autophagic death.
Topics: Adenine; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyperthermia, Induced; Lung Neoplasms; Microwaves; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Kidney Failure, Chronic; Liver Neoplasms; Male; Paclitaxel; Pancreatic Neoplasms; Peritoneal Dialysis; Tomography, X-Ray Computed | 2019 |
Gemcitabine, Cisplatin, and nab-Paclitaxel for Patients With Advanced Biliary Tract Cancer: Closing the GAP.
Topics: Albumins; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel | 2019 |
Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Curcumin; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Ferric Compounds; Gemcitabine; Humans; Magnetite Nanoparticles; Mice; Microscopy, Confocal; Nanoparticles; Pancreatic Neoplasms; Receptors, CXCR4 | 2019 |
Acquisition of gemcitabine resistance enhances angiogenesis via upregulation of IL‑8 production in pancreatic cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-8; Neovascularization, Pathologic; Pancreatic Neoplasms | 2019 |
Antiproliferative Effects of Matricine in Gemcitabine-Resistant Human Pancreatic Carcinoma Cells Are Mediated via Mitochondrial-Mediated Apoptosis, Inhibition of Cell Migration, Invasion Suppression, and Mammalian Target of Rapamycin (mTOR)-TOR/PI3K/AKT S
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lactones; Mitochondria; Neoplasm Invasiveness; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sesquiterpenes; Sesquiterpenes, Guaiane; Signal Transduction; TOR Serine-Threonine Kinases | 2019 |
A novel gemcitabine derivative-loaded liposome with great pancreas-targeting ability.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Diamines; Drug Carriers; Drug Delivery Systems; Gemcitabine; Liposomes; Mice, Inbred C57BL; Pancreas; Pancreatic Neoplasms; Phosphatidylethanolamines; Polyethylene Glycols | 2019 |
Impact of adjuvant chemotherapy on oncologic outcomes following radical nephroureterectomy for patients with pT3NanyM0 upper tract urothelial carcinoma: A retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Nephroureterectomy; Proportional Hazards Models; Retrospective Studies; Urologic Neoplasms | 2019 |
Degree of
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Gene Amplification; Humans; Liposarcoma; Mice; Neoplasm Recurrence, Local; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-mdm2; Retrospective Studies; Surgical Procedures, Operative; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Pretreatment with Gemcitabine/5-Fluorouracil Enhances the Cytotoxicity of Trastuzumab to HER2-Negative Human Gallbladder Cancer Cells In Vitro and In Vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2019 |
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Clinical Decision-Making; Computer Simulation; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Models, Biological; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Remission Induction; Tumor Burden | 2019 |
The Water Extract of
Topics: A549 Cells; Cell Death; Cell Survival; Cytostatic Agents; Deoxycytidine; Fluorouracil; Gemcitabine; Hep G2 Cells; Humans; Juniperus; Nuclear Proteins; Phosphoprotein Phosphatases; Plant Extracts; Proto-Oncogene Proteins c-akt; Tumor Suppressor Protein p53 | 2019 |
A novel low molecular weight nanocomposite hydrogel formulation for intra-tumoural delivery of anti-cancer drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Liberation; Gemcitabine; Humans; Hyaluronic Acid; Hydrogels; Injections; Molecular Weight; Nanocomposites; Neoplasms; Polyglutamic Acid; Rheology | 2019 |
Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Taxoids | 2019 |
Undifferentiated Carcinoma of the Pancreas - a Case Report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Deoxycytidine; Fatal Outcome; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2018 |
The economic impact of the transition from branded to generic oncology drugs.
Topics: Antineoplastic Agents; Cetuximab; Cisplatin; Cost-Benefit Analysis; Cytarabine; Deoxycytidine; Dexamethasone; Drug Costs; Drugs, Generic; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphoma; Randomized Controlled Trials as Topic; Vinorelbine | 2019 |
Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Treatment Outcome; Urologic Neoplasms; Urothelium | 2019 |
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Hydroxyurea; Lung Neoplasms; Melanoma; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors | 2019 |
Body weight loss after surgery affects the continuity of adjuvant chemotherapy for pancreatic cancer.
Topics: Aged; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Logistic Models; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Survival Analysis; Tegafur; Treatment Outcome; Weight Loss | 2019 |
Macrophage manipulation.
Topics: Deoxycytidine; Gemcitabine; Humans; Macrophages; Pancreatic Neoplasms; Pyrimidines | 2019 |
Codelivery Nanosystem Targeting the Deep Microenvironment of Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Humans; Mice; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2019 |
Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Muscle Neoplasms; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Can intracellular drug delivery using hyaluronic acid functionalised pH-sensitive liposomes overcome gemcitabine resistance in pancreatic cancer?
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronic Acid; Hydrogen-Ion Concentration; Liposomes; Male; Mice, SCID; Pancreatic Neoplasms; Rats | 2019 |
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Cell Line, Tumor; Child; Child, Preschool; Cytarabine; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; High-Throughput Screening Assays; Humans; Infant; Janus Kinase Inhibitors; Leukemia, Experimental; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Taxoids; Whole-Body Irradiation; Xenograft Model Antitumor Assays; Young Adult | 2019 |
Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinogens; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Fendiline; Gemcitabine; Humans; Inhibitory Concentration 50; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Phosphoproteins; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Signal Transduction; Verteporfin; YAP-Signaling Proteins | 2019 |
Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combination.
Topics: Adenocarcinoma; Albumins; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Deoxycytidine; Duodenal Neoplasms; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Tomography, X-Ray Computed; Treatment Outcome | 2019 |
Combined use of DDGP and IMRT has a good effect on extranodal natural killer/T-cell lymphoma, nasal type.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Chemoradiotherapy; Child; Cisplatin; Deoxycytidine; Dexamethasone; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Nose Neoplasms; Polyethylene Glycols; Prognosis; Retrospective Studies; Survival Rate; Young Adult | 2020 |
HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Hepatocyte Nuclear Factor 1-alpha; Humans; Immunohistochemistry; Male; Mice; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Prognosis; Promoter Regions, Genetic; Protein Binding | 2019 |
Nivolumab with gemcitabine plus cisplatin for biliary cancers: as easy as ABC?
Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Japan; Neoplasm Recurrence, Local; Nivolumab | 2019 |
Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors.
Topics: Animals; Arginine; Argininosuccinate Synthase; Cell Line, Tumor; Cell Membrane; Deoxycytidine; Disease Models, Animal; Docetaxel; Equilibrative Nucleoside Transporter 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Models, Biological; Neoplasms; Protein Binding; Protein Transport; Proto-Oncogene Proteins c-myc; Xenograft Model Antitumor Assays | 2019 |
Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Clinical Trials, Phase I as Topic; CRISPR-Cas Systems; Cytidine Monophosphate; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; HEK293 Cells; Humans; Ovarian Neoplasms; Pancreatic Neoplasms | 2019 |
Neoadjuvant therapy versus upfront surgery for borderline-resectable pancreatic cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy Dosage; Radiotherapy, Adjuvant; Retrospective Studies; Selection Bias; Survival Analysis; Survival Rate; Treatment Outcome | 2020 |
Long non-coding RNA GHET1 contributes to chemotherapeutic resistance to Gemcitabine in bladder cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Male; Middle Aged; Multidrug Resistance-Associated Proteins; RNA, Long Noncoding; Up-Regulation; Urinary Bladder Neoplasms | 2019 |
sCLU as prognostic biomarker and therapeutic target in osteosarcoma.
Topics: Animals; Antimetabolites, Antineoplastic; Apolipoproteins; Biomarkers; Cell Line, Tumor; Cell Proliferation; Clusterin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Mice; Osteosarcoma; Prognosis; Xenograft Model Antitumor Assays | 2019 |
Polygemcitabine nanogels with accelerated drug activation for cancer therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Gels; Gemcitabine; Humans; Mice, Nude; Nanoparticles; Neoplasms; Polymers; Prodrugs; Xenograft Model Antitumor Assays | 2019 |
Reduced expression of annexin A1 promotes gemcitabine and 5-fluorouracil drug resistance of human pancreatic cancer.
Topics: Animals; Annexin A1; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Fluorouracil; Gemcitabine; Humans; Male; MAP Kinase Kinase 4; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protein Kinase C; Signal Transduction | 2020 |
One-step preparation of reduction-responsive cross-linked gemcitabine prodrug micelles for intracellular drug delivery.
Topics: Antineoplastic Agents; Cell Proliferation; Cross-Linking Reagents; Deoxycytidine; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Methacrylates; Micelles; Molecular Structure; Oxidation-Reduction; Particle Size; Polyethylene Glycols; Prodrugs; Surface Properties; Tumor Cells, Cultured | 2019 |
Danggui Buxue Decoction Sensitizes the Response of Non-Small-Cell Lung Cancer to Gemcitabine via Regulating Deoxycytidine Kinase and P-glycoprotein.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Deoxycytidine Kinase; Drugs, Chinese Herbal; Enzyme-Linked Immunosorbent Assay; Female; Gemcitabine; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Rats | 2019 |
Concentration changes in gemcitabine and its metabolites after hyperthermia in pancreatic cancer cells assessed using RP-HPLC.
Topics: Calibration; Cell Line, Tumor; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Deoxycytidine; Gemcitabine; Humans; Hyperthermia, Induced; Limit of Detection; Linear Models; Metabolome; Pancreatic Neoplasms; Reference Standards | 2019 |
Cellular context-dependent interaction between cancer and stellate cells in hetero-type multicellular spheroids of pancreatic tumor.
Topics: Antimetabolites, Antineoplastic; Cadherins; Carcinoma, Pancreatic Ductal; Cell Communication; Cell Line, Tumor; Cell Survival; Coculture Techniques; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreatic Stellate Cells; Spheroids, Cellular; Tumor Microenvironment; Vimentin | 2019 |
Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Palliative Care; Prognosis; Republic of Korea; Retrospective Studies | 2019 |
Development of Liposomal Gemcitabine with High Drug Loading Capacity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Therapy, Combination; Gemcitabine; Humans; Liposomes; Liver Neoplasms; Male; Mice; Mice, Nude; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Common Bile Duct Neoplasms; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Staging; Pancreaticoduodenectomy; Prognosis; Propensity Score; Retrospective Studies; Survival Rate; United States | 2019 |
Qingyihuaji formula reverses gemcitabine resistant human pancreatic cancer through regulate lncRNA AB209630/miR-373/EphB2-NANOG signals.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Gemcitabine; Homeodomain Proteins; Humans; MicroRNAs; Neoplasm Proteins; Pancreatic Neoplasms; Receptor, EphB2; RNA, Long Noncoding; RNA, Neoplasm; Signal Transduction; Transcription Factors | 2019 |
Drug-Initiated Synthesis of Heterotelechelic Polymer Prodrug Nanoparticles for in Vivo Imaging and Cancer Cell Targeting.
Topics: A549 Cells; Animals; Antineoplastic Agents; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Heterografts; Humans; Lung Neoplasms; Mice; Nanoparticles; Optical Imaging; Prodrugs | 2019 |
Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridones; Pyrimidinones; Xenograft Model Antitumor Assays | 2019 |
[A Case of Boderline Resectable Pancreatic Cancer Curatively Resected after Chemotherapy with Gemcitabine and Nab-Paclitaxel].
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2019 |
Yeast (1 → 3)-(1 → 6)-β-d-glucan alleviates immunosuppression in gemcitabine-treated mice.
Topics: Animals; beta-Glucans; Bone Marrow Cells; Cell Line, Tumor; Cytokines; Deoxycytidine; Gemcitabine; Hematopoiesis; Immunosuppression Therapy; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Pancytopenia; Spleen; Yeasts | 2019 |
Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle Checkpoints; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Immunohistochemistry; Mice; Microtubules; Paclitaxel; Pancreatic Neoplasms; Protein Multimerization; Tubulin Modulators; Xenograft Model Antitumor Assays | 2019 |
Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Brachytherapy; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose Fractionation, Radiation; Female; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Retrospective Studies; Risk Factors; Time Factors | 2019 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Health Care Costs; Humans; Male; Markov Chains; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Brief Psychiatric Rating Scale; Deoxycytidine; Diabetes Mellitus; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Time Factors; Treatment Outcome | 2019 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community Health Planning; Deoxycytidine; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Saskatchewan | 2019 |
Dendritic Polyglycerol-Derived Nano-Architectures as Delivery Platforms of Gemcitabine for Pancreatic Cancer.
Topics: Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Endocytosis; Gemcitabine; Glycerol; Humans; Hydrogen-Ion Concentration; Nanoparticles; Pancreatic Neoplasms; Polycarboxylate Cement; Polymers; Proton Magnetic Resonance Spectroscopy; Spheroids, Cellular; Tissue Scaffolds | 2019 |
FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Standard of Care | 2019 |
Reply to I. Pecora et al.
Topics: Albumin-Bound Paclitaxel; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms | 2019 |
Combination Chemotherapy in Patients With Advanced Pancreatic Cancer With an Eastern Cooperative Oncology Group Performance Status of 2: Lights and Shadows of a Frail Route.
Topics: Aged; Albumin-Bound Paclitaxel; Deoxycytidine; Drug Therapy, Combination; Frail Elderly; Gemcitabine; Group Processes; Humans; Nanoparticles; Pancreatic Neoplasms | 2019 |
Induction chemotherapy improves efficacy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2019 |
Microvascular invasion is a major prognostic factor after pancreatico-duodenectomy for adenocarcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Microvessels; Neovascularization, Pathologic; Oxaliplatin; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Retrospective Studies | 2019 |
The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Heterografts; Humans; Indazoles; Liposarcoma; Male; Mice; Mice, Nude; Neoplasm Recurrence, Local; Pyrimidines; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
A Hydrogen Peroxide Activatable Gemcitabine Prodrug for the Selective Treatment of Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Humans; Hydrogen Peroxide; Mice; Mice, Nude; Pancreatic Neoplasms; Prodrugs; Reactive Oxygen Species; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Mechanisms of gemcitabine oral absorption as determined by in situ intestinal perfusions in mice.
Topics: Administration, Oral; Animals; Cell Membrane; Cell Membrane Permeability; Deoxycytidine; Dilazep; Equilibrative Nucleoside Transport Proteins; Female; Gemcitabine; Inhibitory Concentration 50; Intestinal Absorption; Male; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Oral Mucosal Absorption; Perfusion; Thymidine | 2019 |
Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Coculture Techniques; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Extracellular Matrix; Fibronectins; Flavonoids; Gemcitabine; Humans; MAP Kinase Signaling System; Oligopeptides; Pancreatic Neoplasms; Pancreatic Stellate Cells; Phosphorylation; Proteome; Proto-Oncogene Proteins c-akt | 2019 |
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Failure | 2019 |
Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Genes, Neoplasm; Humans; Male; Middle Aged; Mutation; Prognosis; Republic of Korea; Retrospective Studies; RNA, Neoplasm; United States; Up-Regulation | 2019 |
Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Everolimus; Female; Gemcitabine; Humans; Indazoles; International Agencies; Male; Middle Aged; Perivascular Epithelioid Cell Neoplasms; Prognosis; Pyrimidines; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-1 | 2019 |
The efficacy and safety of nab paclitaxel plus gemcitabine in elderly patients over 75 years with unresectable pancreatic cancer compared with younger patients.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Patient Safety; Peritoneal Neoplasms; Prognosis; Retrospective Studies; Survival Rate; Treatment Outcome | 2019 |
Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasm Staging; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Overcoming Cancer Cell Drug Resistance by a Folic Acid Targeted Polymeric Conjugate of Buthionine Sulfoximine.
Topics: A549 Cells; Antimetabolites, Antineoplastic; Buthionine Sulfoximine; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Folate Receptors, GPI-Anchored; Folic Acid; Gemcitabine; HeLa Cells; Humans; Molecular Structure; Polyethylene Glycols; Structure-Activity Relationship; Tumor Cells, Cultured | 2019 |
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Chemotherapy, Adjuvant; Circulating Tumor DNA; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liquid Biopsy; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras) | 2019 |
Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Topotecan; Treatment Outcome; Young Adult | 2019 |
Dual-Responsive Micelles with Aggregation-Induced Emission Feature and Two-Photon Aborsption for Accurate Drug Delivery and Bioimaging.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Female; Fluorescent Dyes; Gemcitabine; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Micelles; Neoplasms; Optical Imaging; Polymers | 2019 |
p110γ deficiency protects against pancreatic carcinogenesis yet predisposes to diet-induced hepatotoxicity.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinogenesis; Carcinoma, Pancreatic Ductal; Class Ia Phosphatidylinositol 3-Kinase; Class Ib Phosphatidylinositol 3-Kinase; Deoxycytidine; Diet, High-Fat; Disease Models, Animal; Drug Resistance, Neoplasm; Fatty Acids, Omega-6; Female; Gemcitabine; Glucose; Humans; Lipid Metabolism; Liver; Male; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Obesity; Pancreas; Pancreatic Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Signal Transduction; Up-Regulation | 2019 |
Alternate Week Gemcitabine and Capecitabine: An Effective Treatment for Patients With Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Administration Schedule; Fatigue; Female; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
PLAC8 overexpression correlates with PD-L1 upregulation and acquired resistance to chemotherapies in gallbladder carcinoma.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; B7-H1 Antigen; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial Cells; Gallbladder; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Proteins; Oxaliplatin; Proteins; RNA, Small Interfering; Signal Transduction | 2019 |
FF-10832 enables long survival via effective gemcitabine accumulation in a lethal murine peritoneal dissemination model.
Topics: Animals; Antimetabolites, Antineoplastic; Ascites; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Stability; Female; Gemcitabine; Humans; Injections, Intravenous; Kaplan-Meier Estimate; Liposomes; Mice; Mice, Inbred BALB C; Peritoneal Neoplasms; Peritoneum; Tissue Distribution; Treatment Outcome | 2019 |
Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer.
Topics: Academic Medical Centers; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cause of Death; Combined Modality Therapy; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Logistic Models; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome | 2019 |
Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.
Topics: Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Female; Gemcitabine; Humans; Immunotherapy; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Survival Analysis; Treatment Outcome | 2019 |
Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retreatment; Retrospective Studies | 2020 |
DNA-SWCNT Biosensors Allow Real-Time Monitoring of Therapeutic Responses in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Biosensing Techniques; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Monitoring; Female; Gemcitabine; Humans; Hydrogen Peroxide; Irinotecan; Luminescence; Mice, SCID; Nanotubes, Carbon; Pancreatic Neoplasms; Spectrum Analysis, Raman; Xenograft Model Antitumor Assays | 2019 |
Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Gene Knockout Techniques; Humans; Interleukin-6; Leukemia Inhibitory Factor; Mice; Mutation; Pancreatic Neoplasms; Phosphoproteins; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Signal Transduction; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2019 |
Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Proliferation; Computational Biology; Deoxycytidine; Early Detection of Cancer; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Pancreatic Neoplasms; Prognosis; Protein Interaction Maps; Survival Rate; Tumor Cells, Cultured | 2019 |
Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Dexamethasone; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, Extranodal NK-T-Cell; Male; Middle Aged; Nose Neoplasms; Prognosis; Radiotherapy, Intensity-Modulated; Retrospective Studies; Survival Rate; Young Adult | 2019 |
Tumor-specific delivery of gemcitabine with activatable liposomes.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Female; Gemcitabine; Humans; Hyperthermia, Induced; Liposomes; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Temperature | 2019 |
Tailoring the Chemical Modification of Chitosan Hydrogels to Fine-Tune the Release of a Synergistic Combination of Chemotherapeutics.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chitosan; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Liberation; Drug Synergism; Female; Gemcitabine; Humans; Hydrogels; Polymers | 2019 |
Effectiveness and safety of nab-paclitaxel/gemcitabine in locally advanced or metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies | 2020 |
The efficacy of drug-eluting beads bronchial arterial chemoembolization loaded with gemcitabine for treatment of non-small cell lung cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Bronchial Arteries; Carcinoma, Non-Small-Cell Lung; Chemoembolization, Therapeutic; Deoxycytidine; Drug Delivery Systems; Female; Follow-Up Studies; Gemcitabine; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Survival Rate | 2019 |
Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hodgkin Disease; Humans; Male; Middle Aged; Recurrence; Retreatment; Salvage Therapy; Treatment Outcome; Vinorelbine; Young Adult | 2019 |
Chemotherapy Toxicity Confirms Diagnosis of Urachal Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystoscopy; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Image-Guided Biopsy; Leucovorin; Male; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2019 |
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Survival Analysis | 2019 |
RRM1 predicts clinical outcome of high-and intermediate-risk non-muscle-invasive bladder cancer patients treated with intravesical gemcitabine monotherapy.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Predictive Value of Tests; Random Allocation; Retrospective Studies; Ribonucleoside Diphosphate Reductase; Risk Factors; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
Efficient Click Synthesis of a Protonized and Reduction-Sensitive Amphiphilic Small-Molecule Prodrug Containing Camptothecin and Gemcitabine for a Drug Self-Delivery System.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Survival; Click Chemistry; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Drug Stability; Gemcitabine; Half-Life; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Male; Nanoparticles; Prodrugs; Rats; Rats, Sprague-Dawley; Tissue Distribution; Triazoles | 2019 |
Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-dense Gemcitabine Plus Cisplatin in Patients with Muscle-invasive Bladder Cancer.
Topics: Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Prospective Studies; Urinary Bladder Neoplasms | 2019 |
Gemcitabine-induced epithelial-mesenchymal transition-like changes sustain chemoresistance of pancreatic cancer cells of mesenchymal-like phenotype.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MAP Kinase Signaling System; Pancreas; Pancreatic Neoplasms; Phenotype; Zinc Finger E-box-Binding Homeobox 1 | 2019 |
Outcome of postoperative radiation therapy for cholangiocarcinoma and analysis of dose-volume histogram of remnant liver.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Diseases; Liver Neoplasms; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Radiation Injuries; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Adjuvant; Tegafur; Tomography, X-Ray Computed | 2019 |
Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Carrier Proteins; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; MicroRNAs; Pancreatic Neoplasms; Signal Transduction | 2019 |
Induction chemotherapy in pancreatic cancer: CA 19-9 may predict resectability and survival.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Predictive Value of Tests; Retrospective Studies; Survival Rate | 2020 |
KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bridged-Ring Compounds; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; Paclitaxel; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Taxoids; Transcriptome | 2019 |
Gemcitabine, vinorelbine and cyclooxygenase inhibitors in the treatment of glioblastoma. Ultrastructural analyses in C6 glioma in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagic Cell Death; Cyclooxygenase Inhibitors; Deoxycytidine; Gemcitabine; Glioblastoma; Humans; Vinorelbine | 2019 |
Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.
Topics: Animals; Antineoplastic Agents, Immunological; B7-H1 Antigen; Cell Line, Tumor; Cisplatin; Combined Modality Therapy; Cystectomy; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Margins of Excision; Mice; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Random Allocation; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Validation and application of a prognostic model for patients with advanced pancreatic cancer receiving palliative chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Models, Theoretical; Oxonic Acid; Palliative Care; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Survival Analysis; Tegafur; Treatment Outcome; Young Adult | 2019 |
Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Crown Ethers; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; RNA, Small Interfering | 2019 |
Synthesis and in vitro anticancer activity of new gemcitabine-nucleoside analogue dimers containing methyltriazole or ester-methyltriazole linker.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Click Chemistry; Deoxycytidine; Dimerization; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Esters; Gemcitabine; Humans; Molecular Structure; Nucleosides; Structure-Activity Relationship; Triazoles | 2019 |
Epigallocatechin-3-Gallate (EGCG) Suppresses Pancreatic Cancer Cell Growth, Invasion, and Migration partly through the Inhibition of Akt Pathway and Epithelial-Mesenchymal Transition: Enhanced Efficacy when Combined with Gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Catechin; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Enzyme Stability; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Mice, Inbred C57BL; Neoplasm Invasiveness; Pancreatic Neoplasms; Proteolysis; Proto-Oncogene Proteins c-akt; Signal Transduction; Tumor Burden | 2019 |
Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas - are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies; Survival Rate; Treatment Outcome | 2020 |
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Kaplan-Meier Estimate; Ketones; Middle Aged; Multicenter Studies as Topic; Mutation; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Risk Factors; Treatment Outcome; Young Adult | 2019 |
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Computer Simulation; Cost-Benefit Analysis; Deoxycytidine; Drug Costs; Gemcitabine; Humans; Models, Economic; Progression-Free Survival; Quality-Adjusted Life Years; Sweden; Urologic Neoplasms | 2019 |
Irisin Enhances Doxorubicin-Induced Cell Apoptosis in Pancreatic Cancer by Inhibiting the PI3K/AKT/NF-κB Pathway.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Deoxycytidine; Doxorubicin; Drug Synergism; Fibronectins; Gemcitabine; Humans; Myocytes, Cardiac; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction | 2019 |
Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2019 |
Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Dimerization; Drug Resistance, Neoplasm; Gemcitabine; Hexokinase; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Voltage-Dependent Anion Channels | 2019 |
Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy.
Topics: Adipogenesis; Antimetabolites; Bone Marrow Cells; Cell Adhesion; Cell Differentiation; Cell Survival; Cells, Cultured; Deoxycytidine; Fibroblasts; Fluorouracil; Gemcitabine; Humans; Mesenchymal Stem Cells; Multidrug Resistance-Associated Proteins | 2019 |
Editorial About: "A Prospective, Open-Label, Multicenter Phase II Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma".
Topics: Adenocarcinoma; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2019 |
The DNA repair helicase RECQ1 has a checkpoint-dependent role in mediating DNA damage responses induced by gemcitabine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; DNA Breaks, Double-Stranded; DNA Damage; DNA Repair; DNA-Binding Proteins; Endonucleases; Gemcitabine; Humans; RecQ Helicases | 2019 |
Nab-paclitaxel plus gemcitabine as first line therapy in metastatic pancreatic cancer patients relapsed after gemcitabine adjuvant treatment.
Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2019 |
Black phosphorus nanosheets and gemcitabine encapsulated thermo-sensitive hydrogel for synergistic photothermal-chemotherapy.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Hydrogels; Hyperthermia, Induced; Mice; Mice, Inbred BALB C; Nanocapsules; Neoplasms, Experimental; Phosphorus; Phototherapy | 2019 |
WEE1 kinase inhibitor shows promise.
Topics: Cell Cycle Proteins; Deoxycytidine; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Pyrimidinones | 2019 |
Antineoplastic drug occupational exposure: a new integrated approach to evaluate exposure and early genotoxic and cytotoxic effects by no-invasive Buccal Micronucleus Cytome Assay biomarker.
Topics: Adult; Antineoplastic Agents; Biomarkers; Case-Control Studies; Deoxycytidine; DNA Glycosylases; Environmental Monitoring; Female; Fluorouracil; Gemcitabine; Humans; Italy; Male; Micronuclei, Chromosome-Defective; Micronucleus Tests; Middle Aged; Mouth Mucosa; Nursing Staff, Hospital; Occupational Exposure; Occupational Health; Oncology Nursing; Polymorphism, Genetic; Risk Assessment; Risk Factors; Urinalysis; X-ray Repair Cross Complementing Protein 1 | 2019 |
Cyanine-Gemcitabine Conjugates as Targeted Theranostic Agents for Glioblastoma Tumor Cells.
Topics: Animals; Antineoplastic Agents; Carbocyanines; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Stability; Female; Gemcitabine; Glioblastoma; Humans; Mice; Mice, Nude; Theranostic Nanomedicine; Tissue Distribution; Transplantation, Heterologous | 2019 |
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC.
Topics: Administration, Oral; Animals; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Heterocyclic Compounds, 4 or More Rings; Humans; Immunotherapy; Lung Neoplasms; Mice; Programmed Cell Death 1 Receptor; Small Cell Lung Carcinoma; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2019 |
Targeting WEE1 in Pancreatic Cancer.
Topics: Adenocarcinoma; Cell Cycle Proteins; Deoxycytidine; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones | 2019 |
An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Male; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.
Topics: Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Inhibitory Concentration 50 | 2019 |
Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; HEK293 Cells; Humans; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Pancreatic Stellate Cells; Xenograft Model Antitumor Assays | 2019 |
Targeting myeloid-derived suppressor cells in combination with primary mammary tumor resection reduces metastatic growth in the lungs.
Topics: Animals; Antigens, Ly; Antineoplastic Agents; CD11b Antigen; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Eosinophils; Female; Gemcitabine; Killer Cells, Natural; Lung Neoplasms; Macrophages; Mammary Neoplasms, Experimental; Mastectomy; Mice; Mice, Inbred BALB C; Myeloid-Derived Suppressor Cells | 2019 |
Hsa_circ_0035483 sponges hsa-miR-335 to promote the gemcitabine-resistance of human renal cancer cells by autophagy regulation.
Topics: Animals; Autophagy; Base Sequence; Cell Line, Tumor; Cyclin B1; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; RNA, Circular | 2019 |
Sarcomas and old age: few options for such a large patient population.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Geriatric Assessment; Humans; Ifosfamide; Male; Prognosis; Sarcoma; Survival Rate; Trabectedin | 2019 |
Treatment of advanced soft tissue sarcoma by histological subtype: wish, prediction or reality?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Furans; Gemcitabine; Humans; Ifosfamide; Indazoles; Ketones; Liposarcoma; Middle Aged; Prognosis; Pyrimidines; Sulfonamides; Survival Rate; Trabectedin | 2019 |
Which goals should we pursue in each line of treatment for advanced soft tissue sarcoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Ifosfamide; Male; Middle Aged; Prognosis; Sarcoma; Survival Rate; Trabectedin | 2019 |
Computational modeling of therapy on pancreatic cancer in its early stages.
Topics: Anisotropy; Cell Death; Cell Division; Cell Line, Tumor; Cell Movement; Computer Simulation; Deoxycytidine; Extracellular Matrix; Gemcitabine; Humans; Hyaluronoglucosaminidase; Injections; Monte Carlo Method; Neoplasm Staging; Numerical Analysis, Computer-Assisted; Pancreatic Neoplasms; Stochastic Processes | 2020 |
In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues.
Topics: Aged; Antineoplastic Agents; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Tissue Culture Techniques; Toxicity Tests | 2019 |
Anti-tumor activity of cediranib, a pan-vascular endothelial growth factor receptor inhibitor, in pancreatic ductal adenocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Cadherins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Pancreatic Neoplasms; Quinazolines; Radiation Tolerance; Snail Family Transcription Factors; Survivin; Vascular Endothelial Growth Factor A; X-Linked Inhibitor of Apoptosis Protein; Zinc Finger E-box-Binding Homeobox 1 | 2020 |
Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; RNA, Long Noncoding; Scavenger Receptors, Class E; Transcriptome; Up-Regulation | 2019 |
Chemogenomic study of gemcitabine using Saccharomyces cerevisiae as model cell-molecular insights about chemoresistance.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Fungal; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Intracellular Signaling Peptides and Proteins; Mutation; Protein-Arginine N-Methyltransferases; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2020 |
ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Integrins; Male; Mice; Mice, SCID; Neoplasm Proteins; Pancreatic Neoplasms; Pancreatic Stellate Cells; Peptidomimetics; Xenograft Model Antitumor Assays | 2019 |
Development and validation of a liquid chromatography tandem mass spectrometry quantification method for 14 cytotoxic drugs in environmental samples.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Environmental Pollutants; Gemcitabine; Occupational Exposure; Paclitaxel; Sensitivity and Specificity; Tandem Mass Spectrometry | 2020 |
Sarcopenia as a significant predictive factor of neutropenia and overall survival in urothelial carcinoma patients underwent gemcitabine and cisplatin or carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Retrospective Studies; Sarcopenia; Thrombocytopenia; Tomography, X-Ray Computed; Urologic Neoplasms | 2020 |
The synergism of Clinacanthus nutans Lindau extracts with gemcitabine: downregulation of anti-apoptotic markers in squamous pancreatic ductal adenocarcinoma.
Topics: Acanthaceae; Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Plant Extracts; Proto-Oncogene Proteins c-bcl-2 | 2019 |
Polysaccharide enhanced NK cell cytotoxicity against pancreatic cancer via TLR4/MAPKs/NF-κB pathway in vitro/vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunosuppressive Agents; Killer Cells, Natural; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Polysaccharides; Strongylocentrotus; Toll-Like Receptor 4 | 2019 |
Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Lactate Dehydrogenase 5; Liver Neoplasms; Male; Mice; Middle Aged; Prognosis; Real-Time Polymerase Chain Reaction; Tumor Suppressor Proteins | 2019 |
Alantolactone enhances gemcitabine sensitivity of lung cancer cells through the reactive oxygen species-mediated endoplasmic reticulum stress and Akt/GSK3β pathway.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Gemcitabine; Glycogen Synthase Kinase 3 beta; Humans; Lactones; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sesquiterpenes, Eudesmane; Signal Transduction | 2019 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Diet, Ketogenic; Female; Fluorouracil; Gemcitabine; Humans; Hyperbaric Oxygenation; Hyperthermia, Induced; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Survivors | 2020 |
[A Case of an Elderly Patient with Multiple Lung Metastases of Postoperative Pancreatic Cancer in Whom Lung Metastases Were Controlled by Biweekly Dose-Down Administration of Gemcitabine].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms | 2019 |
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response.
Topics: Adenocarcinoma; Animals; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA-Binding Proteins; Flow Cytometry; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Maleimides; Mice; Nuclear Proteins; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction | 2019 |
Biodegradable, pH-Sensitive Hollow Mesoporous Organosilica Nanoparticle (HMON) with Controlled Release of Pirfenidone and Ultrasound-Target-Microbubble-Destruction (UTMD) for Pancreatic Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Carriers; Extracellular Matrix; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Hydrogen-Ion Concentration; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microbubbles; Nanoparticles; Pancreatic Neoplasms; Pyridones; Silicon Dioxide | 2019 |
Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Deoxycytidine; Female; Gemcitabine; Heart Neoplasms; Humans; Indazoles; Male; Middle Aged; Prognosis; Progression-Free Survival; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Sarcoma; Sulfonamides; Treatment Outcome; Tunica Intima | 2020 |
ASO Author Reflections: Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer on Surgical Outcomes.
Topics: Albumins; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2019 |
Metabolomic profiling identifies novel biomarkers and mechanisms in human bladder cancer treated with submucosal injection of gemcitabine.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Transitional Cell; Deoxycytidine; Female; Gemcitabine; Humans; Male; Metabolic Networks and Pathways; Metabolome; Metabolomics; Middle Aged; Neoplasm Recurrence, Local; Principal Component Analysis; Urinary Bladder; Urinary Bladder Neoplasms | 2019 |
A unique multidrug nanomedicine made of squalenoyl-gemcitabine and alkyl-lysophospholipid edelfosine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Lysophospholipids; Microscopy, Electron, Transmission; Nanomedicine; Particle Size; Phospholipid Ethers; Prodrugs; Squalene | 2019 |
Combination of Doxorubicin with Gemcitabine-Incorporated G-Quadruplex Aptamer Showed Synergistic and Selective Anticancer Effect in Breast Cancer Cells.
Topics: Antineoplastic Agents; Aptamers, Nucleotide; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Delivery Systems; Drug Synergism; Female; Gemcitabine; Humans; MCF-7 Cells; Nucleolin; Phosphoproteins; RNA-Binding Proteins | 2019 |
Interstitial Flow Recapitulates Gemcitabine Chemoresistance in A 3D Microfluidic Pancreatic Ductal Adenocarcinoma Model by Induction of Multidrug Resistance Proteins.
Topics: ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Intestine, Small; Lab-On-A-Chip Devices; Microfluidic Analytical Techniques; Models, Biological; Neoplasm Proteins; Pancreatic Neoplasms | 2019 |
Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication.
Topics: Biosensing Techniques; Deoxycytidine; DNA; Electrochemical Techniques; ErbB Receptors; Exons; Gemcitabine; Humans; Limit of Detection; Lung Neoplasms; Metal Nanoparticles; Nanotubes, Carbon; Point Mutation; Siloxanes; Silver | 2019 |
Percutaneous stenting and chemotherapy for unresectable pancreatic cancer: Comparison of irradiation stents vs conventional metal stents.
Topics: Adult; Aged; Antineoplastic Agents; Biliary Tract; Biliary Tract Surgical Procedures; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Stents | 2019 |
The Upregulation of OCT4 in Acidic Extracellular pH is Associated with Gemcitabine Resistance in Cholangiocarcinoma Cell Lines.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Biomarkers, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Octamer Transcription Factor-3; Tumor Cells, Cultured; Tumor Microenvironment | 2019 |
Efficacy of Gemcitabine on Intracranial Erlich Tumor and its Determinants.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Ehrlich Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Male; Mice; Mice, Inbred BALB C; Permeability; Tissue Distribution | 2020 |
4-Carboxyphenylboronic acid-decorated, redox-sensitive rod-shaped nano-micelles fabricated through co-assembling strategy for active targeting and synergistic co-delivery of camptothecin and gemcitabine.
Topics: Antineoplastic Agents; Boronic Acids; Camptothecin; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Hydrophobic and Hydrophilic Interactions; MCF-7 Cells; Micelles; Nanoparticles; Oxidation-Reduction; Polyethylene Glycols | 2019 |
Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2020 |
Exercise during preoperative therapy increases tumor vascularity in pancreatic tumor patients.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Exercise; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Physical Conditioning, Animal; Vascular Remodeling; Xenograft Model Antitumor Assays | 2019 |
Clinical candidate and genistein analogue AXP107-11 has chemoenhancing functions in pancreatic adenocarcinoma through G protein-coupled estrogen receptor signaling.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Synergism; Female; Gemcitabine; Genistein; Humans; Mice; Models, Biological; Mucin-1; Pancreatic Neoplasms; Protein Kinase Inhibitors; Receptors, Estrogen; Signal Transduction; Xenograft Model Antitumor Assays | 2019 |
First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Platinum; Prognosis; Retrospective Studies; Survival Rate; Taxoids | 2019 |
Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Topics: Antibiotics, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Computational Biology; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Deletion; Humans; Pancreatic Neoplasms; Smad4 Protein; Tumor Cells, Cultured | 2019 |
Induction of Metastasis by Low-dose Gemcitabine in a Pancreatic Cancer Orthotopic Mouse Model: An Opposite Effect of Chemotherapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Green Fluorescent Proteins; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Pancreas; Pancreatic Neoplasms | 2019 |
Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cancer-Associated Fibroblasts; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Membrane Glycoproteins; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Platelet Activation; Platelet Glycoprotein GPIb-IX Complex; Tegafur | 2019 |
Gemcitabine-loaded RGD modified liposome for ovarian cancer: preparation, characterization and pharmacodynamic studies.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; China; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Female; Gemcitabine; Humans; Liposomes; Mice; Mice, Inbred BALB C; Nanoparticles; Oligopeptides; Ovarian Neoplasms; Particle Size; Rats | 2019 |
Optimal first-line treatment for advanced thymic carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Retrospective Studies; Survival Analysis; Thymoma; Thymus Neoplasms; Treatment Outcome; Young Adult | 2019 |
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Keratins, Hair-Specific; Keratins, Type II; Leucovorin; Machine Learning; Male; Middle Aged; Neoplasm Proteins; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies; Sensitivity and Specificity; Survival Rate | 2019 |
Design and Evaluation of PEGylated Liposomal Formulation of a Novel Multikinase Inhibitor for Enhanced Chemosensitivity and Inhibition of Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Compounding; Drug Design; ErbB Receptors; Female; Gemcitabine; Humans; Liposomes; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Polyethylene Glycols; Protein Kinase Inhibitors; Proteolysis; Xenograft Model Antitumor Assays | 2019 |
Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine.
Topics: Abnormalities, Multiple; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Keratoconus; Mice; Organophosphates; Pancreatic Neoplasms; Signal Transduction; Valproic Acid; Xenograft Model Antitumor Assays | 2020 |
IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Female; Gemcitabine; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Progression-Free Survival; Receptors, Interleukin-17; Tissue Array Analysis; Vascular Endothelial Growth Factor A | 2019 |
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Celecoxib; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Immunoglobulin G; Inflammation; Interleukin-1beta; Macrophages; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Pancreatic Neoplasms; THP-1 Cells; Xenograft Model Antitumor Assays | 2019 |
Expanding the Arsenal of Pt
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carbonates; Carcinoma, Lewis Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Screening Assays, Antitumor; Estramustine; Female; Gemcitabine; Humans; Ligands; Male; Mice, Inbred C57BL; Organoplatinum Compounds; Paclitaxel; Prodrugs; Prohibitins; Structure-Activity Relationship | 2019 |
Targeting SREBP1 chemosensitizes colorectal cancer cells to gemcitabine by caspase-7 upregulation.
Topics: Adult; Aged; Antineoplastic Agents; Caspase 7; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Middle Aged; Sterol Regulatory Element Binding Protein 1; Up-Regulation; Young Adult | 2019 |
Oncogenic ADAM28 induces gemcitabine resistance and predicts a poor prognosis in pancreatic cancer.
Topics: ADAM Proteins; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Survival; Datasets as Topic; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Sequence Analysis, RNA; Up-Regulation | 2019 |
pH-Responsive and Gemcitabine-Containing DNA Nanogel To Facilitate the Chemodrug Delivery.
Topics: A549 Cells; Antimetabolites, Antineoplastic; Apoptosis; Carbocyanines; Deoxycytidine; DNA; Drug Carriers; Drug Liberation; Endodeoxyribonucleases; Fluorescence Resonance Energy Transfer; Gemcitabine; Humans; Hydrogen-Ion Concentration; Microscopy, Confocal; Nanogels | 2019 |
Prognostic value of post-induction chemotherapy 18F-FDG PET-CT in stage II/III non-small cell lung cancer before (chemo-) radiation.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Fluorodeoxyglucose F18; Gamma Rays; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival; Proportional Hazards Models; Radiopharmaceuticals; Remission Induction; Retrospective Studies; Taxoids; Tumor Burden; Vinorelbine | 2019 |
Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Female; Gemcitabine; Gene Knockout Techniques; HCT116 Cells; HEK293 Cells; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Middle Aged; Nuclear Proteins; Ovarian Neoplasms; Random Allocation; Transcription Factors; Xenograft Model Antitumor Assays | 2019 |
Hepatitis B-associated hepatocellular carcinoma in a young Haitian man: a review of screening guidelines.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Deoxycytidine; Diagnosis, Differential; Fatal Outcome; Gemcitabine; Haiti; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Mass Screening; Oxaliplatin; Practice Guidelines as Topic; Sorafenib; Tomography, X-Ray Computed | 2019 |
Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Case-Control Studies; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Germ-Line Mutation; Humans; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Paclitaxel; Phthalazines; Piperazines | 2019 |
Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; ErbB Receptors; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic | 2019 |
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Treatment Failure | 2020 |
Comparison of gemcitabine and anthracycline antibiotics in prevention of superficial bladder cancer recurrence.
Topics: Aged; Anthracyclines; Antineoplastic Agents; Deoxycytidine; Doxorubicin; Epirubicin; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2019 |
Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA; Female; Gemcitabine; Genome-Wide Association Study; Hematopoiesis; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Thrombocytopenia | 2020 |
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.
Topics: Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Proto-Oncogene Proteins p21(ras); Sequence Analysis, DNA; Tomography, X-Ray Computed; Tumor Suppressor Protein p53 | 2019 |
Long non-coding SBF2-AS1 acting as a competing endogenous RNA to sponge microRNA-142-3p to participate in gemcitabine resistance in pancreatic cancer via upregulating TWF1.
Topics: Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Microfilament Proteins; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Protein-Tyrosine Kinases; RNA, Long Noncoding; Up-Regulation | 2019 |
YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Aporphines; Cell Cycle Proteins; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Hydroxymethylglutaryl CoA Reductases; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Transcription Factors; Tumor Cells, Cultured | 2019 |
Gemcitabine loaded autologous exosomes for effective and safe chemotherapy of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Liberation; Endocytosis; Exosomes; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Tissue Distribution | 2020 |
[Ⅰ.Adverse Effects of Gemcitabine/CDDP Therapy for Initially Unresectable Locally Advanced Biliary Tract Cancer Followed by Conversion Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Gemcitabine; Humans | 2019 |
Development of Mesoporous Silica Nanoparticles of Tunable Pore Diameter for Superior Gemcitabine Drug Delivery in Pancreatic Cancer Cells.
Topics: Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms; Porosity; Silicon Dioxide | 2020 |
Systemic treatment of biliary tract cancer: now we have the evidence.
Topics: Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2019 |
Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled for lead time bias and waiting time paradox.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time-to-Treatment; Treatment Outcome | 2020 |
Coix Seed Extract Enhances the Anti-Pancreatic Cancer Efficacy of Gemcitabine through Regulating ABCB1- and ABCG2-Mediated Drug Efflux: A Bioluminescent Pharmacokinetic and Pharmacodynamic Study.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Coix; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Plant Extracts | 2019 |
Inhibitory Effect of Oat Bran Ethanol Extract on Survival and Gemcitabine Resistance of Pancreatic Cancer Cells.
Topics: Avena; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Ethanol; Gemcitabine; Humans; Pancreatic Neoplasms; Plant Extracts | 2019 |
Skeletal Muscle Mass Reduction Velocity as a Simple Prognostic Indicator for Patients with Metastatic Urothelial Carcinoma Receiving Second-Line Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Muscle, Skeletal; Prognosis; Retrospective Studies; Sarcopenia; Survival Rate; Urologic Neoplasms | 2019 |
ASO Author Reflections: Regulation of Chemoresistance in Pancreatic Ductal Adenocarcinoma by Scavenger Receptor CD36.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; CD36 Antigens; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis | 2020 |
Sample preparation strategies for high-throughput mass spectrometry imaging of primary tumor organoids.
Topics: Centrifugation; Collagen; Deoxycytidine; Drug Combinations; Extracellular Matrix; Fluorouracil; Gemcitabine; Humans; Laminin; Neoplasms; Organoids; Proteoglycans; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Array Analysis; Workflow | 2020 |
Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Radiosurgery; Retrospective Studies | 2020 |
Inhibition of miR30a-3p by sulforaphane enhances gap junction intercellular communication in pancreatic cancer.
Topics: Adult; Aged; Animals; Cell Communication; Cell Line, Tumor; Connexin 43; Deoxycytidine; Female; Gap Junctions; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterografts; Humans; In Situ Hybridization; Isothiocyanates; Male; Mice; MicroRNAs; Middle Aged; Pancreatic Neoplasms; Signal Transduction; Sulfoxides | 2020 |
Another disappointment in treating relapsed, refractory high-risk aggressive B-cell lymphomas.
Topics: B-Lymphocytes; Deoxycytidine; Gemcitabine; Humans; Isoquinolines; Lymphoma, B-Cell; Rituximab | 2020 |
A Study Comparing the Effects of Targeted Intra-Arterial and Systemic Chemotherapy in an Orthotopic Mouse Model of Pancreatic Cancer.
Topics: Administration, Intravenous; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gemcitabine; Humans; Infusions, Intra-Arterial; Male; Mice; Mice, Nude; Neoplasm, Residual; Pancreatic Neoplasms; Transplantation, Heterologous | 2019 |
RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Bone Marrow; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Half-Life; Humans; Inhibitory Concentration 50; Male; Mice, Inbred ICR; Nanomedicine; Oligopeptides; Particle Size; Static Electricity | 2019 |
Optimization of nanoemulsion containing gemcitabine and evaluation of its cytotoxicity towards human fetal lung fibroblast (MRC5) and human lung carcinoma (A549) cells.
Topics: A549 Cells; Analysis of Variance; Cell Death; Cell Line; Deoxycytidine; Emulsions; Fetus; Fibroblasts; Gemcitabine; Humans; Inhibitory Concentration 50; Kinetics; Lung; Lung Neoplasms; Nanoparticles; Particle Size; Phase Transition; Polysorbates; Surface-Active Agents | 2019 |
Glycolysis promotes the progression of pancreatic cancer and reduces cancer cell sensitivity to gemcitabine.
Topics: Animals; Cell Death; Cell Line, Tumor; Deoxycytidine; Deoxyglucose; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Mice; Mice, Inbred BALB C; Pancreas; Pancreatic Neoplasms; Prognosis | 2020 |
Combination of Gemcitabine with Cell-Penetrating Peptides: A Pharmacokinetic Approach Using In Silico Tools.
Topics: Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell-Penetrating Peptides; Computer Simulation; Deoxycytidine; Gemcitabine; Humans; Kinetics | 2019 |
Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Analysis | 2020 |
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; Cohort Studies; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retreatment; Retrospective Studies; Risk Assessment; Survival Analysis; Tertiary Care Centers; Treatment Failure; Treatment Outcome | 2019 |
MiR-760 enhances sensitivity of pancreatic cancer cells to gemcitabine through modulating Integrin β1.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Integrin beta1; MicroRNAs; Pancreas; Pancreatic Neoplasms; PC-3 Cells; RNA Helicases; RNA, Messenger | 2019 |
The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cell-Free Nucleic Acids; Deoxycytidine; Etoposide; Female; Gemcitabine; Genomics; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Organoplatinum Compounds; Pemetrexed; Prognosis; Survival Rate; Taxoids | 2020 |
Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Doxorubicin; Fluorouracil; Gemcitabine; HSP90 Heat-Shock Proteins; Humans; Neoplasm Proteins; Pancreatic Neoplasms | 2019 |
Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2019 |
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Gene Knockdown Techniques; Humans; Integrin alpha3; Integrin beta1; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphorylation; Signal Transduction; Spheroids, Cellular; STAT3 Transcription Factor; Survival Rate; Zinc Finger E-box-Binding Homeobox 1 | 2020 |
Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Microscopy, Electron, Transmission; Neoplastic Stem Cells; Pancreatic Neoplasms; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Deoxycytidine; Emergency Service, Hospital; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Hospitalization; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score; Treatment Outcome | 2020 |
Gemcitabine, paclitaxel, and oxaliplatin (GEMPOX) in the treatment of relapsed/refractory intracranial nongerminomatous germ cell tumors.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Salvage Therapy; Testicular Neoplasms | 2020 |
Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer.
Topics: Animals; Carcinoma, Neuroendocrine; Deoxycytidine; Gemcitabine; Humans; Immunohistochemistry; Mice; Octreotide; Radiation-Sensitizing Agents; Radiometry; Radiotherapy; Thyroid Neoplasms | 2019 |
Clinicopathological features and prognosis of surgical resected cases of biliary cancer with pancreaticobiliary maljunction.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cholecystectomy; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Male; Middle Aged; Pancreaticobiliary Maljunction; Pancreaticoduodenectomy; Prognosis | 2020 |
Encapsulated microRNA by gemcitabine prodrug for cancer treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Nanoparticles; Oleic Acid; Particle Size; Prodrugs; Xenograft Model Antitumor Assays | 2019 |
Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Size; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; STAT3 Transcription Factor; Sulfones; Xenograft Model Antitumor Assays | 2020 |
Pralatrexate Induces Long-Term Remission in Relapsed Subcutaneous Panniculitis-Like T-Cell Lymphoma.
Topics: Adult; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin; Cyclophosphamide; Deoxycytidine; Dexamethasone; Doxorubicin; Folic Acid Antagonists; Gemcitabine; Humans; Lymphohistiocytosis, Hemophagocytic; Lymphoma, T-Cell, Peripheral; Male; Neoplasm Recurrence, Local; Panniculitis; Prednisone; Remission Induction; Subcutaneous Fat, Abdominal; Vincristine | 2019 |
Quantitative dynamic contrast-enhanced MR imaging for the preliminary prediction of the response to gemcitabine-based chemotherapy in advanced pancreatic ductal carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Contrast Media; Deoxycytidine; Evaluation Studies as Topic; Female; Gemcitabine; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Pancreas; Pancreatic Neoplasms; Retrospective Studies | 2019 |
Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Curvature increases permeability of the plasma membrane for ions, water and the anti-cancer drugs cisplatin and gemcitabine.
Topics: Animals; Antineoplastic Agents; Cell Membrane; Cell Membrane Permeability; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Ions; Lipid Bilayers; Molecular Dynamics Simulation; Water | 2019 |
Conversion surgery for positive peritoneal washing cytology in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Cytodiagnosis; Deoxycytidine; Gemcitabine; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Peritoneum; Treatment Outcome | 2019 |
A facile di-acid mono-amidation strategy to prepare cyclization-activating mono-carboxylate transporter 1-targeting gemcitabine prodrugs for enhanced oral delivery.
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Biological Availability; Caco-2 Cells; Cyclization; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Monocarboxylic Acid Transporters; Prodrugs; Rats; Rats, Wistar; Symporters | 2020 |
Effect of Chemotherapeutic Agents on the Expression of Retinoid Receptors and Markers of Cancer Stem Cells and Epithelial-Mesenchymal Transition.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cadherins; Cell Line, Tumor; Deoxycytidine; Epithelial-Mesenchymal Transition; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplastic Stem Cells; Retinoid X Receptor beta; S Phase Cell Cycle Checkpoints | 2019 |
α-Mangostin suppresses the de novo lipogenesis and enhances the chemotherapeutic response to gemcitabine in gallbladder carcinoma cells via targeting the AMPK/SREBP1 cascades.
Topics: AMP-Activated Protein Kinases; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Cycle Checkpoints; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipogenesis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Sterol Regulatory Element Binding Protein 1; Tumor Cells, Cultured; Xanthones; Xenograft Model Antitumor Assays | 2020 |
Highly Porous Hybrid Metal-Organic Nanoparticles Loaded with Gemcitabine Monophosphate: a Multimodal Approach to Improve Chemo- and Radiotherapy.
Topics: Antineoplastic Agents; Deoxycytidine; DNA Repair; Gemcitabine; HeLa Cells; Humans; Metal-Organic Frameworks; Nanoparticles; Neoplasms; Particle Size; Porosity; Surface Properties | 2020 |
GEM + nab-PTX Therapy for Pancreatic Body Cancer cStage IVb for Conversion Surgery: A Case Report.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Treatment Outcome | 2019 |
A study of effect of lncRNA MVIH on sensitivity of gastric cancer cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; RNA, Long Noncoding; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured | 2019 |
Tumor Microenvironment following Gemcitabine Treatment Favors Differentiation of Immunosuppressive Ly6C
Topics: Animals; Antigens, Ly; Antimetabolites, Antineoplastic; Apoptosis; Cell Differentiation; Cell Proliferation; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Immunosuppressive Agents; Injections, Intraperitoneal; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloid Cells; Neoplasms, Experimental; Tumor Cells, Cultured; Tumor Microenvironment | 2020 |
MiR-512-3p regulates malignant tumor behavior and multi-drug resistance in breast cancer cells via targeting Livin.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epirubicin; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; MicroRNAs; Neoplasm Proteins | 2020 |
Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells.
Topics: Antineoplastic Agents; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Dendritic Cells; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; T-Lymphocytes, Cytotoxic | 2020 |
HEATR1 deficiency promotes pancreatic cancer proliferation and gemcitabine resistance by up-regulating Nrf2 signaling.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Kelch-Like ECH-Associated Protein 1; Minor Histocompatibility Antigens; NF-E2-Related Factor 2; Pancreatic Neoplasms; RNA-Binding Proteins | 2020 |
The efficacy and toxicity of chemotherapy in the elderly with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Rituximab-Mediated Complement-Dependent Cytotoxicity Enhanced by Gemcitabine in Older Patients with Previously Rituximab-Treated Diffuse Large B-Cell Lymphoma: Study Protocol.
Topics: Activities of Daily Living; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Remission Induction; Rituximab; Salvage Therapy; Transplantation, Autologous | 2020 |
Loss of Mitochondrial DNA by Gemcitabine Triggers Mitophagy and Cell Death.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Cell Death; Cell Line, Tumor; Deoxycytidine; DNA, Mitochondrial; Gemcitabine; Mitochondria; Mitophagy; Rats | 2019 |
Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Carcinoma, Pancreatic Ductal; Case-Control Studies; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Germ-Line Mutation; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies | 2020 |
Prexasertib increases the sensitivity of pancreatic cancer cells to gemcitabine and S‑1.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Combinations; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Oxonic Acid; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyrazoles; Tegafur | 2020 |
Combination of a novel microtubule inhibitor MBRI-001 and gemcitabine synergistically induces cell apoptosis by increasing DNA damage in pancreatic cancer cell lines.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line; Cell Survival; Deoxycytidine; Diketopiperazines; DNA Damage; Drug Synergism; Female; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Rats, Wistar; Tubulin Modulators | 2020 |
EMERGING-CTONG 1103: For Achieving High-Quality Evidence in a Randomized Phase II Trial.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy | 2020 |
Reply to A. Tateishi et al.
Topics: Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Neoadjuvant Therapy | 2020 |
Long non-coding RNA SSTR5-AS1 facilitates gemcitabine resistance via stabilizing NONO in gallbladder carcinoma.
Topics: Animals; Apoptosis; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; RNA-Binding Proteins; RNA, Long Noncoding; Up-Regulation | 2020 |
UCP2 promotes proliferation and chemoresistance through regulating the NF-κB/β-catenin axis and mitochondrial ROS in gallbladder cancer.
Topics: Animals; Antineoplastic Agents; beta Catenin; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Iridoids; Male; Mice; Mice, Nude; Mitochondria; Neoplasms, Experimental; NF-kappa B; Reactive Oxygen Species; Uncoupling Protein 2; Up-Regulation | 2020 |
CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzothiazoles; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; DNA Damage; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Naphthyridines; Pancreatic Neoplasms; RNA, Messenger; Spheroids, Cellular | 2019 |
Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Canada; Cystoscopy; Deoxycytidine; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Invasiveness; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; United States; Urinary Bladder Neoplasms | 2020 |
Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Pancreatic Neoplasms; Ribonucleoproteins; Ribonucleoside Diphosphate Reductase; RNA-Seq; RNA, Messenger; Stromal Interaction Molecule 1; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Programmed co-delivery of platinum nanodrugs and gemcitabine by a clustered nanocarrier for precision chemotherapy for NSCLC tumors.
Topics: A549 Cells; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Lung Neoplasms; Metal Nanoparticles; Platinum | 2020 |
Ultrasound-induced Cavitation enhances the efficacy of Chemotherapy in a 3D Model of Pancreatic Ductal Adenocarcinoma with its microenvironment.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Mice, Transgenic; Neoplasms, Experimental; Pancreatic Neoplasms; Spheroids, Cellular; Tumor Microenvironment; Ultrasonic Therapy | 2019 |
Preoperative chemoradiotherapy using gemcitabine for pancreatic ductal adenocarcinoma in patients with impaired renal function.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Preoperative Care; Prognosis; Prospective Studies; Renal Insufficiency; Survival Rate | 2020 |
Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; CA-19-9 Antigen; Deoxycytidine; Drug Combinations; Electroporation; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Proportional Hazards Models; Pyridines; Tegafur; Young Adult | 2020 |
Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Metformin; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Tumor Stem Cell Assay | 2019 |
Risk factors of grade ≥ 2 radiation pneumonitis after gemcitabine induction chemotherapy for patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Lung Neoplasms; Male; Middle Aged; Prognosis; Radiation Pneumonitis; Radiotherapy, Conformal; Retrospective Studies; Risk Factors; ROC Curve; Survival Rate | 2019 |
A genome-scale CRISPR/Cas9 knockout screening reveals SH3D21 as a sensitizer for gemcitabine.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line; Cell Line, Tumor; CRISPR-Cas Systems; Deoxycytidine; DNA Replication; Drug Resistance, Neoplasm; Gemcitabine; HEK293 Cells; Humans; Pancreatic Neoplasms | 2019 |
Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma.
Topics: 2-Acetylaminofluorene; Animals; Antimetabolites, Antineoplastic; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Chitosan; Deoxycytidine; Gemcitabine; Liver Neoplasms; Male; Nanoparticles; Rats; Xenograft Model Antitumor Assays | 2019 |
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Male; Molecular Typing; Oxaliplatin; Pancreatic Neoplasms; Proteome; Proteomics; Survival Rate; Treatment Outcome | 2020 |
Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child, Preschool; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence, Local; Neoplasms, Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate | 2020 |
Heterogeneity of Treg/Th17 According to Cancer Progression and Modification in Biliary Tract Cancers via Self-Producing Cytokines.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Cell Differentiation; Cells, Cultured; Coculture Techniques; Cytokines; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Forkhead Transcription Factors; Gemcitabine; Humans; Interleukin-17; Interleukin-6; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Phenotype; Retrospective Studies; T-Lymphocytes, Regulatory; Th17 Cells; Transforming Growth Factor beta1; Tumor Microenvironment | 2020 |
Targetoid erythema surrounding multiple seborrheic keratoses induced by chemotherapy with gemcitabine.
Topics: Adenocarcinoma of Lung; Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Eruptions; Female; Gemcitabine; Humans; Keratosis, Seborrheic | 2019 |
Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells.
Topics: Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclic AMP; Deoxycytidine; Flow Cytometry; Gemcitabine; Glucagon-Like Peptide-1 Receptor; Humans; Immunohistochemistry; Liraglutide; Pancreatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2020 |
ATM-Mutated Pancreatic Cancer: Clinical and Molecular Response to Gemcitabine/Nab-Paclitaxel After Genome-Based Therapy Resistance.
Topics: Adult; Albumins; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Germ-Line Mutation; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma?
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Hepatic artery infusion pump for nasopharyngeal carcinoma with liver metastasis.
Topics: Adult; Aged; Angiography, Digital Subtraction; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Floxuridine; Follow-Up Studies; Gemcitabine; Hepatic Artery; Humans; Infusion Pumps; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Treatment Outcome; Vascular Access Devices | 2020 |
Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cisplatin; Deoxycytidine; Depsipeptides; Drug Compounding; Female; Gemcitabine; Humans; Mice; Mice, Nude; Triple Negative Breast Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Identification of novel compounds against Tat-mediated human immunodeficiency virus-1 transcription by high-throughput functional screening assay.
Topics: 3-Deazauridine; Anti-HIV Agents; Cell Line; Cytidine; Deoxycytidine; Drug Repositioning; Gemcitabine; High-Throughput Screening Assays; HIV-1; Humans; Roscovitine; Small Molecule Libraries; tat Gene Products, Human Immunodeficiency Virus; Transcription, Genetic; Virus Replication | 2020 |
Increased clinical and plasma EBV DNA responses to platinum-gemcitabine after nivolumab in patients with heavily platinum-pretreated nasopharyngeal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; DNA, Viral; Epstein-Barr Virus Infections; Gemcitabine; Herpesvirus 4, Human; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Nivolumab; Organoplatinum Compounds | 2020 |
Exosomes as a Surrogate Marker for Autophagy in Peripheral Blood, Correlative Data from Phase I Study of Chloroquine in Combination with Carboplatin/Gemcitabine in Advanced Solid Tumors.
Topics: Antimalarials; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers; Carboplatin; Chloroquine; Deoxycytidine; Drug Therapy, Combination; Exosomes; Gemcitabine; Humans; Neoplasms; Tumor Cells, Cultured | 2019 |
Tumor Cell-Intrinsic USP22 Suppresses Antitumor Immunity in Pancreatic Cancer.
Topics: Albumins; Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Knockout Techniques; Humans; Interferon-gamma; Killer Cells, Natural; Lung Neoplasms; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C57BL; Myeloid-Derived Suppressor Cells; Paclitaxel; Pancreatic Neoplasms; T-Lymphocytes, Cytotoxic; Tumor Cells, Cultured; Tumor Microenvironment; Ubiquitin Thiolesterase | 2020 |
Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Self-Assembled Gemcitabine Prodrug Nanoparticles Show Enhanced Efficacy against Patient-Derived Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Xenograft Model Antitumor Assays | 2020 |
Modulation of Biliary Cancer Chemo-Resistance Through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells.
Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Cisplatin; CRISPR-Cas Systems; Deoxycytidine; Drug Discovery; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; High-Throughput Screening Assays; Humans; MicroRNAs; Xenograft Model Antitumor Assays | 2020 |
Circular RNA SMARCA5 correlates with favorable clinical tumor features and prognosis, and increases chemotherapy sensitivity in intrahepatic cholangiocarcinoma.
Topics: Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Factor Analysis, Statistical; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Prognosis; RNA, Circular; Up-Regulation | 2020 |
Prognostic Predicting Role of Contrast-Enhanced Computed Tomography for Locally Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Nomograms; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed; Tumor Burden | 2019 |
Anti-tumor Activities of 3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors and Bisphosphonates in Pancreatic Cell Lines Which Show Poor Responses to Gemcitabine.
Topics: Alendronate; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pancreatic Neoplasms; Zoledronic Acid | 2020 |
Novel Mechanistic Insight into the Anticancer Activity of Cucurbitacin D against Pancreatic Cancer (Cuc D Attenuates Pancreatic Cancer).
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation; Humans; Mice; Models, Molecular; Mucins; Pancreatic Neoplasms; Structure-Activity Relationship; Triterpenes; Xenograft Model Antitumor Assays | 2019 |
Dexamethasone enhances the antitumor efficacy of Gemcitabine by glucocorticoid receptor signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Deoxycytidine; Dexamethasone; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Receptors, Glucocorticoid; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutaminase; Glutamine; Heterografts; Humans; Mice; Mice, Nude; Mutation; Neoplasm Proteins; NF-E2-Related Factor 2; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Random Allocation; Tissue Array Analysis; Up-Regulation | 2020 |
Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
Topics: Animals; Bone and Bones; Bone Marrow; Bone Neoplasms; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Deoxycytidine; Disease Models, Animal; Female; Fluorouracil; Gemcitabine; Humans; Male; Mice; Mice, Knockout; Multiple Myeloma; Myeloid-Derived Suppressor Cells; Osteoblasts; Tumor Microenvironment | 2020 |
FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor.
Topics: Antineoplastic Agents; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; Deoxycytidine; Drug Synergism; Fibroblast Growth Factor 2; Gemcitabine; Humans; Magnetite Nanoparticles; Pancreatic Neoplasms; Pancreatic Stellate Cells; Spheroids, Cellular | 2020 |
Key necroptotic proteins are required for Smac mimetic-mediated sensitization of cholangiocarcinoma cells to TNF-α and chemotherapeutic gemcitabine-induced necroptosis.
Topics: Biliary Tract Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Caspase Inhibitors; Cell Cycle Checkpoints; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Necroptosis; Protein Kinases; Receptor-Interacting Protein Serine-Threonine Kinases; RNA Interference; RNA, Small Interfering; Triazoles; Tumor Necrosis Factor-alpha | 2020 |
Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T-cell therapy for relapsed diffuse large B-cell lymphoma.
Topics: Adrenal Cortex Hormones; Allografts; Anemia, Aplastic; Antibodies, Monoclonal, Humanized; Antigens, CD19; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Deoxycytidine; Doxorubicin; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Oxaliplatin; Prednisone; Recurrence; Rituximab; Salvage Therapy; Transplantation, Autologous; Vincristine | 2020 |
International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Capecitabine; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical Decision Rules; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Internationality; Lymph Nodes; Male; Margins of Excision; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy; Reproducibility of Results; Retrospective Studies | 2020 |
High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer.
Topics: Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Interferon-gamma; Lymphocytes, Tumor-Infiltrating; Male; Mast Cells; Middle Aged; Prognosis; Signal Transduction | 2020 |
Re: Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine plus Cisplatin in Patients with Muscle-Invasive Bladder Cancer.
Topics: Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Prospective Studies; Urinary Bladder Neoplasms | 2020 |
Ibrutinib resistance in a patient with transformed diffuse large B-cell lymphoma from primary pulmonary mucosa-associated lymphoid tissue lymphoma.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cyclophosphamide; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Oxaliplatin; Piperidines; Prognosis; Rituximab; Vincristine | 2020 |
Early relapse on adjuvant gemcitabine associated with an exceptional response to 2nd line capecitabine chemotherapy in a patient with pancreatic adenosquamous carcinoma with strong intra-tumoural expression of cytidine deaminase: a case report.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Cytidine Deaminase; Deoxycytidine; Female; Gemcitabine; Gene Expression; Humans; Immunohistochemistry; Magnetic Resonance Imaging; Middle Aged; Pancreatic Neoplasms; Recurrence; Retreatment; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Biodegradable Polymeric Multilayer Capsules for Therapy of Lung Cancer.
Topics: Animals; Antineoplastic Agents; Capsules; Deoxycytidine; Drug Compounding; Drug Delivery Systems; Gemcitabine; Lung Neoplasms; Macrophages; Mice; Mice, Inbred C57BL; Mice, Transgenic; Polymers; Tissue Distribution | 2020 |
Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Dasatinib; Deoxycytidine; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Stromal Cells; Survival Analysis; Xenograft Model Antitumor Assays | 2020 |
Charging forward in locally advanced pancreatic cancer.
Topics: Albumins; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2020 |
Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Cell Line, Tumor; Cytotoxins; Deoxycytidine; DNA Fragmentation; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Humans; Melphalan; Membrane Potential, Mitochondrial; Multiple Myeloma; Neoplasm Proteins; Panobinostat; Signal Transduction; Sulfonamides | 2020 |
The performance of the single-walled carbon nanotube covalently modified with polyethylene glycol to delivery of Gemcitabine anticancer drug in the aqueous environment.
Topics: Antineoplastic Agents; Deoxycytidine; Gemcitabine; Nanotubes, Carbon; Polyethylene Glycols | 2021 |
Survival improvement and prognostic factors in recent management of extrahepatic cholangiocarcinoma: A single-center study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Palliative Care; Prognosis; Retrospective Studies; Risk Factors; Survival Rate | 2020 |
Drug-loaded implantable surgical cavity-adaptive hydrogels for prevention of local tumor recurrence.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chitosan; Delayed-Action Preparations; Deoxycytidine; Doxorubicin; Drug Implants; Drug Synergism; Female; Gemcitabine; Hyaluronic Acid; Hydrogels; Mice; Mice, Inbred BALB C; Neoplasm Recurrence, Local; Xenograft Model Antitumor Assays | 2020 |
Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Japan; L-Lactate Dehydrogenase; Leiomyosarcoma; Middle Aged; Neoplasm Staging; Prognosis; Progression-Free Survival; Retrospective Studies; Uterine Neoplasms; Young Adult | 2020 |
Editorial Comment.
Topics: Deoxycytidine; Docetaxel; Gemcitabine; Health Facilities; Humans; Urinary Bladder Neoplasms | 2020 |
PTBP3 promotes malignancy and hypoxia-induced chemoresistance in pancreatic cancer cells by ATG12 up-regulation.
Topics: 3' Untranslated Regions; Adenocarcinoma; Animals; Autophagy; Autophagy-Related Protein 12; Base Sequence; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Polypyrimidine Tract-Binding Protein; Stress, Physiological; Tumor Hypoxia; Up-Regulation | 2020 |
Polymeric modification of gemcitabine via cyclic acetal linkage for enhanced anticancer potency with negligible side effects.
Topics: Acetals; Animals; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Pancreatic Neoplasms; Polymers | 2020 |
Acid-Triggered Release of Native Gemcitabine Conjugated in Polyketal Nanoparticles for Enhanced Anticancer Therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Liberation; Female; Gemcitabine; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Prodrugs; Rabbits; Xenograft Model Antitumor Assays | 2020 |
Gemcitabine induces Parkin-independent mitophagy through mitochondrial-resident E3 ligase MUL1-mediated stabilization of PINK1.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; HeLa Cells; Humans; Immunoblotting; Mitochondria; Mitochondrial Membranes; Mitophagy; Protein Kinases; Ubiquitin-Protein Ligases | 2020 |
Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Liberation; Enzyme Inhibitors; Female; Gemcitabine; Imidazoles; Immunity; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Isoindoles; Mice, Inbred BALB C; Micelles; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols; Prodrugs | 2020 |
Imidazo[2,1-b] [1,3,4]thiadiazoles with antiproliferative activity against primary and gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Pancreatic Neoplasms; Thiadiazoles; Thiophenes; Tumor Cells, Cultured | 2020 |
A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Exanthema; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
Gemcitabine inhibits cisplatin resistance in cisplatin-resistant A549 cells by upregulating trx-interacting protein and inducing cell cycle arrest.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Cycle Checkpoints; Cell Death; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; G1 Phase; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Resting Phase, Cell Cycle; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Is it time to redefine cisplatin ineligibility in metastatic urothelial cancer?
Topics: Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Urologic Neoplasms; Vinblastine | 2020 |
Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; RNA, Messenger | 2020 |
Identification of a C3'-nitrile nucleoside analogue inhibitor of pancreatic cancer cell line growth.
Topics: Amides; Antineoplastic Agents; Apoptosis; Benzylamines; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Glycosylation; Humans; Mutation; Nitriles; Pancreatic Neoplasms; Phosphoric Acids; Proto-Oncogene Proteins p21(ras); Purines; Structure-Activity Relationship | 2020 |
Tumor necrosis factor‑related apoptosis‑inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first‑line chemotherapy.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Caspase 3; Caspase Inhibitors; Cell Line, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Signal Transduction; Thiazoles; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms; Urothelium; X-Linked Inhibitor of Apoptosis Protein | 2020 |
Encapsulation of gemcitabine in RGD-modified nanoliposomes improves breast cancer inhibitory activity.
Topics: Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Drug Stability; Emulsions; Female; Gemcitabine; Humans; Liposomes; Male; Mice; Nanoparticles; Oligopeptides; Particle Size; Rats; Rats, Sprague-Dawley; Surface Properties; Xenograft Model Antitumor Assays | 2020 |
Aggregation of chitosan nanoparticles in cell culture: Reasons and resolutions.
Topics: Cell Culture Techniques; Cell Line, Tumor; Chitosan; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gels; Gemcitabine; Humans; Hydrogen-Ion Concentration; Nanoparticles; Particle Size; Polymers; Temperature | 2020 |
Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
Topics: Adaptor Proteins, Signal Transducing; Amyloid Precursor Protein Secretases; Animals; Benzazepines; Bile Duct Neoplasms; Calcium-Binding Proteins; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Disease Progression; Female; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 13; Mice, Nude; Microvessels; Neovascularization, Pathologic; Receptor, Notch1; Reproducibility of Results; RNA, Messenger; Signal Transduction; Transcriptome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2020 |
Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Area Under Curve; Cell Line, Tumor; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Metabolic Networks and Pathways; Models, Biological; Pancreatic Neoplasms | 2020 |
[Erlotinib plus Gemcitabine in metastatic pancreatic cancer: Results from a non-interventional trial].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Medical Staff, Hospital; Middle Aged; Netherlands; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Regression Analysis; Young Adult | 2020 |
Targeting of immunosuppressive myeloid cells from glioblastoma patients by modulation of size and surface charge of lipid nanocapsules.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Membrane Permeability; Deoxycytidine; Drug Compounding; Endocytosis; Gemcitabine; Glioblastoma; Humans; Immunosuppressive Agents; Immunotherapy; Leukocytes; Lipids; Macrophages; Myeloid-Derived Suppressor Cells; Nanocapsules; Particle Size; Signal Transduction; Surface Properties | 2020 |
Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy.
Topics: Adenocarcinoma; Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Magnetite Nanoparticles; Male; Metformin; Mice, Inbred BALB C; Pancreatic Neoplasms; Pancreatic Stellate Cells; Peptides | 2020 |
Complete Response of a Pleural, Hepatic, and Splenic Metastatic Primary Breast Angiosarcoma Using Gemcitabine Monotherapy.
Topics: Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Hemangiosarcoma; Humans; Splenic Neoplasms | 2020 |
Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Markov Chains; Middle Aged; Multicenter Studies as Topic; Nasopharyngeal Carcinoma; Randomized Controlled Trials as Topic; Young Adult | 2020 |
Gemcitabine Co-Encapsulated with Curcumin in Folate Decorated PLGA Nanoparticles; a Novel Approach to Treat Breast Adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Curcumin; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Folic Acid; Gemcitabine; Humans; Mice, Nude; Nanoparticles; Polylactic Acid-Polyglycolic Acid Copolymer | 2020 |
The combination of artesunate and carboplatin exerts a synergistic anti-tumour effect on non-small cell lung cancer.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Artesunate; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; G2 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Lung Neoplasms; Mitochondria; Signal Transduction | 2020 |
Chemotherapy-induced pneumonitis associated with transient CA 15-3 elevation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Pneumonia; Tomography, X-Ray Computed | 2020 |
The preparation of cell-containing microbubble scaffolds to mimic alveoli structure as a 3D drug-screening system for lung cancer.
Topics: A549 Cells; Antineoplastic Agents; Biocompatible Materials; Cell Culture Techniques; Cell Proliferation; Cell Survival; Compressive Strength; Deoxycytidine; Gelatin; Gemcitabine; Humans; Lung Neoplasms; Microbubbles; Proto-Oncogene Proteins c-bcl-2; Tissue Scaffolds | 2020 |
Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Pancreatic Neoplasms; Survival Rate | 2020 |
Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Female; Fluorescent Dyes; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Organoids; Pancreatic Neoplasms; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
The effect of gemcitabine, dexamethasone, and cisplatin chemotherapy in relapsed/refractory NHL and HL patients: A single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Young Adult | 2020 |
Theranostic nanoparticles enabling the release of phosphorylated gemcitabine for advanced pancreatic cancer therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice; Mice, Nude; Molecular Structure; Nanoparticles; Neoplasms, Experimental; Optical Imaging; Pancreatic Neoplasms; Particle Size; Photothermal Therapy; Surface Properties; Theranostic Nanomedicine; Tumor Cells, Cultured | 2020 |
A NAG-Guided Nano-Delivery System for Redox- and pH-Triggered Intracellularly Sequential Drug Release in Cancer Cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Hydrogen-Ion Concentration; Lung Neoplasms; Male; Mice, Inbred BALB C; Nanostructures; Oxidation-Reduction; Paclitaxel; Polymers; Xenograft Model Antitumor Assays | 2020 |
Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cetuximab; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; Gold; Humans; Metal Nanoparticles; Nanoconjugates; Pancreatic Neoplasms; Pancreatic Stellate Cells; Polyethylene Glycols; Tumor Microenvironment | 2020 |
Ginsenoside Rg3 suppresses the growth of gemcitabine-resistant pancreatic cancer cells by upregulating lncRNA-CASC2 and activating PTEN signaling.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Ginsenosides; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Transfection; Tumor Burden; Tumor Suppressor Proteins; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation.
Topics: Animals; Antigens, CD; Cadherins; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Cyclin B; Cyclin D1; Deoxycytidine; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Pancreas; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-cbl; Signal Transduction; Ubiquitin-Protein Ligases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2020 |
Gemcitabine Plus Cisplatin Chemotherapy Prolongs the Survival in Advanced Hilar Cholangiocarcinoma: A Large Multicenter Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Drainage; Female; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Time Factors | 2020 |
PROM2 promotes gemcitabine chemoresistance via activating the Akt signaling pathway in pancreatic cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Gemcitabine; Humans; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Doxorubicin; Gemcitabine; Humans; Lab-On-A-Chip Devices; MCF-7 Cells; Microfluidic Analytical Techniques; Models, Biological; Perfusion; Proof of Concept Study; Tissue Culture Techniques | 2020 |
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Retrospective Studies; SEER Program; Survival Rate; United States | 2020 |
Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; PC-3 Cells; Prostatic Neoplasms, Castration-Resistant; RNA, Small Interfering; Transcriptome; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2020 |
Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Deoxycytidine; Dose-Response Relationship, Drug; Drug Compounding; Drug Synergism; Female; Gemcitabine; Lung Neoplasms; Mice; Mice, Inbred C57BL; Nanoparticles; Paclitaxel; Treatment Outcome | 2020 |
Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
Topics: Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Oncogene Proteins, Fusion; Paclitaxel; Pemetrexed; Prognosis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Retrospective Studies; Survival Rate | 2020 |
Treatment strategies for recurrent ovarian cancer in older adult patients in Japan: a study based on real-world data.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Deoxycytidine; Drug Resistance, Neoplasm; Evidence-Based Medicine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Survival Rate | 2020 |
Mitochondria as target to inhibit proliferation and induce apoptosis of cancer cells: the effects of doxycycline and gemcitabine.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Respiration; Cell Survival; Deoxycytidine; DNA Copy Number Variations; DNA, Mitochondrial; Doxycycline; Gemcitabine; Gene Expression Regulation, Enzymologic; Glycolysis; Humans; Membrane Potential, Mitochondrial; Mitochondria; Oxidative Stress; Protein Biosynthesis; Reactive Oxygen Species | 2020 |
Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Denmark; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Gemcitabine; Humans; Imidazoles; Longitudinal Studies; Male; Middle Aged; Patient Reported Outcome Measures; Prognosis; Prospective Studies; Quality of Life; Surveys and Questionnaires; Urinary Bladder Neoplasms | 2020 |
Characterization of Gemcitabine Loaded Polyhydroxybutyrate Coated Magnetic Nanoparticles for Targeted Drug Delivery.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrogen-Ion Concentration; Hydroxybutyrates; Magnetite Nanoparticles; Molecular Structure; Particle Size; Polyesters; Prohibitins; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
[A Case of Liver Metastases of Ampullary Carcinoma with Clinical Complete Response Treated with Gemcitabine plus Cisplatin].
Topics: Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Treatment Outcome | 2019 |
Liquid Formulation of Gemcitabine Increases Venous Pain in Patients With Cancer: A Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Drug Compounding; Female; Freeze Drying; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Pain; Retrospective Studies; Risk Factors | 2020 |
Low-Dose Gemcitabine Treatment Enhances Immunogenicity and Natural Killer Cell-Driven Tumor Immunity in Lung Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calreticulin; Cell Line, Tumor; Cisplatin; Cytotoxicity, Immunologic; Deoxycytidine; Gemcitabine; HMGB1 Protein; Humans; Immunotherapy; Interferon-gamma; Killer Cells, Natural; Lung Neoplasms; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; NK Cell Lectin-Like Receptor Subfamily K | 2020 |
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Pancreatic Neoplasms; Prospective Studies; Survival Analysis; Treatment Outcome | 2020 |
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Evaluation, Preclinical; Female; Fluorouracil; Gemcitabine; Heterografts; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Jejunal Neoplasms; Leucovorin; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peritoneal Neoplasms; Treatment Failure; Trifluridine; Xenograft Model Antitumor Assays | 2020 |
Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; Deoxycytidine; Docetaxel; Female; Gemcitabine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Oncogene Fusion; Paclitaxel; Pemetrexed; Platinum Compounds; Progression-Free Survival; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Retrospective Studies; Treatment Outcome | 2020 |
Synthesis and Characterization of Folic Acid Conjugated Gemcitabine Tethered Silver Nanoparticles (FA-GEM-AgNPs) for Targeted Delivery.
Topics: Deoxycytidine; Folic Acid; Gemcitabine; Humans; Metal Nanoparticles; Plant Extracts; Silver | 2020 |
Targeting MYC-driven replication stress in medulloblastoma with AZD1775 and gemcitabine.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cerebellar Neoplasms; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Genes, myc; Humans; Medulloblastoma; Mice, Transgenic; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones | 2020 |
Antibacterial Use Is Associated with an Increased Risk of Hematologic and Gastrointestinal Adverse Events in Patients Treated with Gemcitabine for Stage IV Pancreatic Cancer.
Topics: Adenocarcinoma; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Controlled drug release from polyelectrolyte-drug conjugate nanoparticles.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Liberation; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrogen-Ion Concentration; Molecular Structure; Nanoparticles; Optical Imaging; Particle Size; Polyelectrolytes; Rhodamines; Surface Properties | 2020 |
hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Fluorodeoxyglucose F18; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Pancreatic Neoplasms; Positron-Emission Tomography; Proto-Oncogene Proteins c-myc; Xenograft Model Antitumor Assays | 2020 |
Significance of unphosphorylated and phosphorylated heat shock protein 27 as a prognostic biomarker in pancreatic ductal adenocarcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Heat-Shock Proteins; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Chaperones; Pancreatic Neoplasms; Phosphorylation; Prognosis; Survival Rate | 2020 |
Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Muscles; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2020 |
LncRNA AGAP2-AS1 augments cell viability and mobility, and confers gemcitabine resistance by inhibiting miR-497 in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Oncogenes; Prognosis; RNA, Long Noncoding; Up-Regulation | 2020 |
Targeting the HGF/c-MET pathway in advanced pancreatic cancer: a key element of treatment that limits primary tumour growth and eliminates metastasis.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doublecortin-Like Kinases; Gemcitabine; Hepatocyte Growth Factor; Humans; Immunoglobulin G; Intracellular Signaling Peptides and Proteins; Mice; Neoplasm Metastasis; Neoplasm Staging; Neoplastic Stem Cells; Pancreas; Pancreatic Neoplasms; Pancreatic Stellate Cells; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-met; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Type 2 diabetes induced microbiome dysbiosis is associated with therapy resistance in pancreatic adenocarcinoma.
Topics: Animals; Deoxycytidine; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Dysbiosis; Gastrointestinal Microbiome; Gemcitabine; Hyperglycemia; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Pancreatic Neoplasms | 2020 |
Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades - A meta-regression.
Topics: Bias; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Regression Analysis | 2020 |
Antitumor activity of gemcitabine hydrochloride loaded lipid polymer hybrid nanoparticles (LPHNs): In vitro and in vivo.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Gemcitabine; Humans; Lipids; Lung Neoplasms; MCF-7 Cells; Nanoparticles; Pancreatic Neoplasms; Particle Size; Polymers; Rats; Rats, Sprague-Dawley | 2020 |
An Unusual Gastric Lesion during Chemotherapy for Pancreatic Cancer.
Topics: Abdominal Pain; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Endoscopy, Gastrointestinal; Female; Gastritis; Gemcitabine; Humans; Pancreatic Neoplasms; Radiation Injuries; Tomography, X-Ray Computed | 2020 |
Treatment patterns and outcomes in pancreatic cancer: Retrospective claims analysis.
Topics: Aged; Aged, 80 and over; Albumins; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Duration of Therapy; Emergency Service, Hospital; Female; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Insurance, Health; Irinotecan; Leucovorin; Male; Medicare Part C; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate; Treatment Outcome; United States | 2020 |
Assessment of Anti-Tumor potential and safety of application of Glutathione stabilized Gold Nanoparticles conjugated with Chemotherapeutics.
Topics: Chromatography, High Pressure Liquid; Cytarabine; Deoxycytidine; Doxorubicin; Gemcitabine; Glutathione; Gold; Humans; MCF-7 Cells; Metal Nanoparticles; Microscopy, Electron, Transmission; Neoplasms; Osteoblasts; Telomerase | 2020 |
IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Interleukin-1; Male; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Severity of Illness Index; STAT3 Transcription Factor | 2020 |
Pediatric glioblastoma target-specific efficient delivery of gemcitabine across the blood-brain barrier via carbon nitride dots.
Topics: Animals; Antimetabolites, Antineoplastic; Blood-Brain Barrier; Brain Neoplasms; Cell Line; Cell Survival; Deoxycytidine; Drug Carriers; Gemcitabine; Glioblastoma; Humans; Larva; Nitriles; Quantum Dots; Transferrin; Zebrafish | 2020 |
Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Hexosamines; Humans; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Unfolded Protein Response; Xenograft Model Antitumor Assays | 2020 |
[Biliary tract cancer: on the way to a personalized therapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Immunotherapy; Leucovorin; Organoplatinum Compounds; Palliative Care; Precision Medicine | 2020 |
Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Mice; Pancreatic Neoplasms; Proteomics; Tumor Microenvironment | 2020 |
MUC1 promotes glycolysis through inhibiting BRCA1 expression in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Glucose; Glycolysis; Humans; Irinotecan; Lactic Acid; Leucovorin; Male; Mice, Nude; Mucin-1; Neoplasm Transplantation; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Nanomized tumor-microenvironment-active NIR fluorescent prodrug for ensuring synchronous occurrences of drug release and fluorescence tracing.
Topics: A549 Cells; Animals; Antineoplastic Agents; Cell Proliferation; Deoxycytidine; Drug Liberation; Gemcitabine; Glutathione; Humans; Lung Neoplasms; Mice; Microscopy, Fluorescence; Nanoparticles; Polymers; Prodrugs; Pyrans; Tumor Microenvironment | 2019 |
Gemcitabine-based adjuvant chemotherapy in subtypes of ampullary adenocarcinoma: international propensity score-matched cohort study.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pancreaticoduodenectomy; Propensity Score; Proportional Hazards Models; Retrospective Studies; Survival Analysis | 2020 |
Antitumor effect of VEGFR2-targeted microbubble destruction with gemcitabine using an endoscopic ultrasound probe: In vivo mouse pancreatic ductal adenocarcinoma model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Contrast Media; Deoxycytidine; Endosonography; Female; Ferric Compounds; Gemcitabine; Iron; Mice, Inbred C57BL; Microbubbles; Oxides; Pancreatic Neoplasms; Tumor Burden; Ultrasonic Therapy; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Oxaliplatin | 2020 |
Locoregional Therapy Plus Systemic Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma-Reply.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Floxuridine; Gemcitabine; Humans; Oxaliplatin | 2020 |
Re: Bladder Preservation with Twice-a-Day Radiation plus Fluorouracil/Cisplatin or Once Daily Radiation plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial.
Topics: Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2020 |
Neoadjuvant Gemcitabine-Cisplatin Plus Radical Cystectomy-Pelvic Lymph Node Dissection for Muscle-invasive Bladder Cancer: A 12-year Experience.
Topics: Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Muscles; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Pharmacological; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Disease Progression; Drug Monitoring; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Predictive Value of Tests; Prognosis; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor B | 2020 |
Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Pancreatic Neoplasms; Quercetin; Tumor Suppressor Protein p53 | 2020 |
FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Substitution; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Salvage Therapy | 2020 |
Combined blockade of TGf-β1 and GM-CSF improves chemotherapeutic effects for pancreatic cancer by modulating tumor microenvironment.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Proliferation; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lymphangiogenesis; Male; Mice; Mice, Inbred C57BL; Middle Aged; Neoplastic Stem Cells; Neovascularization, Pathologic; Pancreatic Neoplasms; Prognosis; Survival Rate; Transforming Growth Factor beta1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Role of Conversion Surgery for Unresectable Pancreatic Cancer After Long-Term Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Oxaliplatin; Oxonic Acid; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Prognosis; Pyridines; Radiotherapy; Retrospective Studies; Tegafur; Time Factors | 2020 |
Functional and genomic characterization of three novel cell lines derived from a metastatic gallbladder cancer tumor.
Topics: Animals; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Ascitic Fluid; Carcinogenesis; Carcinogenicity Tests; Cell Line, Tumor; Chile; Cisplatin; Clone Cells; Deoxycytidine; DNA Fingerprinting; Epithelial Cells; Gallbladder Neoplasms; Gemcitabine; Gene Expression Profiling; Genes, erbB-2; Humans; Indians, South American; Keratin-19; Keratin-7; Male; Mice, Inbred NOD; Middle Aged; Receptor, ErbB-2; Sequence Analysis, RNA; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2020 |
[42-year-old patient with renal insufficience, anemia and thrombocytopenia during chemotherapy].
Topics: Adult; Anemia; Antineoplastic Agents; Deoxycytidine; Erythrocytes; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Male; Pancreatic Neoplasms; Renal Insufficiency; Thrombocytopenia | 2020 |
Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Pancreatic Ductal; Cell Hypoxia; Deoxycytidine; Diagnostic Techniques, Radioisotope; Disease Models, Animal; Fluorouracil; Gemcitabine; Mice; Mice, Inbred C57BL; Organoids; Pancreatic Neoplasms | 2020 |
Physicochemical and in vitro cytotoxicity studies of inclusion complex between gemcitabine and cucurbit[7]uril host.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Imidazoles; Molecular Structure; Structure-Activity Relationship | 2020 |
Probing the effect of polyethene glycol on the adsorption mechanisms of Gem on the hexagonal boron nitride as a highly efficient polymer-based drug delivery system: DFT, classical MD and Well-tempered Metadynamics simulations.
Topics: Adsorption; Boron Compounds; Deoxycytidine; Drug Carriers; Gemcitabine; Polyethylene Glycols; Polymers | 2020 |
Targeted deep sequencing contributes to guiding personalized targeted therapy for advanced biliary tract cancer patients with non‑radical resection: A real‑world study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Class I Phosphatidylinositol 3-Kinases; Dasatinib; Deoxycytidine; ErbB Receptors; Everolimus; Female; Gemcitabine; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Lapatinib; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Organoplatinum Compounds; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Survival Rate; Treatment Outcome | 2020 |
Cardiac Masses in a Patient With Pancreatic Adenocarcinoma and a History of Breast Carcinoma.
Topics: Adenocarcinoma; Albumins; Anticoagulants; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Heart Ventricles; Humans; Magnetic Resonance Imaging; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Thrombosis; Warfarin | 2020 |
Recurrent Bladder Cancer in a Teenage Male.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adolescent; Antimetabolites, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Cystectomy; Cystoscopy; Deoxycytidine; Gemcitabine; Humans; Male; Monitoring, Physiologic; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
De novo perihilar cholangiocarcinoma arising in the allograft liver 15 years post-transplantation for biliary atresia.
Topics: Adenocarcinoma; Allografts; Bile Duct Neoplasms; Biliary Atresia; Child; Cholangiocarcinoma; Cisplatin; Constriction, Pathologic; Deoxycytidine; Female; Gemcitabine; Humans; Immunosuppressive Agents; Liver; Liver Transplantation; Neoplasm Recurrence, Local; Postoperative Complications; Young Adult | 2020 |
Polymer Coated Iron Nanoparticles: Radiolabeling & In vitro Studies.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; In Vitro Techniques; Magnetic Iron Oxide Nanoparticles; Polymers; Radiopharmaceuticals; Technetium | 2021 |
Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.
Topics: Anilides; Animals; Antimetabolites, Antineoplastic; Benzylamines; Cell Communication; Cell Survival; Coculture Techniques; Cyclams; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Hedgehog Proteins; Heterocyclic Compounds; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Pancreatic Stellate Cells; Pyridines; Reactive Oxygen Species; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; Signal Transduction | 2020 |
Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; China; Cisplatin; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Treatment Outcome | 2020 |
Pterostilbene Enhances Cytotoxicity and Chemosensitivity in Human Pancreatic Cancer Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor for Advanced Glycation End Products; Signal Transduction; Stilbenes | 2020 |
Re: Multi-institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
Topics: Administration, Intravesical; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2020 |
The yield of chest computed tomography in patients with locally advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lung Neoplasms; Male; Middle Aged; Multiple Pulmonary Nodules; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Radiosurgery; Retrospective Studies; Tomography, X-Ray Computed | 2020 |
Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreatic cancer cells.
Topics: Amino Acid Transport Systems; Amino Acids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Metabolomics; Pancreatic Neoplasms; Tryptophan | 2020 |
Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; DNA Methylation; Down-Regulation; Female; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Phosphoglycerate Dehydrogenase; Promoter Regions, Genetic; RNA, Messenger; Urinary Bladder Neoplasms | 2020 |
Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Depsipeptides; Gemcitabine; Humans; MAP Kinase Signaling System; Mice; Neoplasm Recurrence, Local; Reactive Oxygen Species; Urinary Bladder Neoplasms; Urothelium; Xenograft Model Antitumor Assays | 2020 |
Development of Gemcitabine Loaded PLGA/Lecithin Nanoparticles for Non-Small Cell Lung Cancer Therapy.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Gemcitabine; Humans; Lecithins; Lung Neoplasms; Nanoparticles; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer | 2020 |
Coaxial mussel-inspired biofibers: making of a robust and efficacious depot for cancer drug delivery.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Proliferation; Cell Survival; Deoxycytidine; Doxorubicin; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrogels; Male; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Optical Imaging; Particle Size; Proteins; Surface Properties; Tumor Cells, Cultured | 2020 |
Cisplatin Plus Gemcitabine as Standard of Care for Germline
Topics: Adenocarcinoma; Benzimidazoles; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Gemcitabine; Germ Cells; Humans; Mutation; Pancreas; Pancreatic Neoplasms; Standard of Care | 2020 |
Reply to N. Fazio.
Topics: Adenocarcinoma; Benzimidazoles; Cisplatin; Deoxycytidine; Fanconi Anemia Complementation Group N Protein; Gemcitabine; Germ Cells; Humans; Mutation; Pancreas | 2020 |
Self-assembled multifunctional nanotheranostics loading GEM for targeted lung cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Endocytosis; ErbB Receptors; Female; Gemcitabine; Hemolysis; Humans; Lung Neoplasms; Mice; Mice, Nude; Nanoparticles; Polyethylene Glycols; Polyethyleneimine; Prodrugs; Tissue Distribution; Transplantation, Heterologous | 2020 |
Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Taiwan | 2020 |
Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Linear Models; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Adjuvant; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tumor Burden | 2020 |
Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin.
Topics: Carboplatin; Cell Cycle; Cells, Cultured; Deoxycytidine; Gemcitabine; Gene Expression; Gene Ontology; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; RNA-Seq; Sequence Alignment; Single-Cell Analysis | 2020 |
Blockade of endothelin receptor A enhances the therapeutic efficacy of gemcitabine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bosentan; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Endothelin A Receptor Antagonists; Gemcitabine; Humans; Pancreatic Neoplasms; Receptor, Endothelin A | 2020 |
Drug repurposing of pyrimidine analogs as potent antiviral compounds against human enterovirus A71 infection with potential clinical applications.
Topics: Animals; Antiviral Agents; Deoxycytidine; Drug Repositioning; Enterovirus A, Human; Enterovirus Infections; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Pyrimidines; RNA, Viral; Virus Replication | 2020 |
Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Casein Kinase Idelta; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Gemcitabine, lycorine and oxysophoridine inhibit novel coronavirus (SARS-CoV-2) in cell culture.
Topics: Alkaloids; Amaryllidaceae Alkaloids; Animals; Antiviral Agents; Betacoronavirus; Cell Survival; Chlorocebus aethiops; Chloroquine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Gemcitabine; Phenanthridines; SARS-CoV-2; Vero Cells; Virus Replication | 2020 |
Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biliary Tract Neoplasms; Cell Proliferation; Cisplatin; Cytidine Monophosphate; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Multi-stimuli responsive polymeric prodrug micelles for combined chemotherapy and photodynamic therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chlorophyllides; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Micelles; Molecular Structure; Particle Size; Photochemotherapy; Photosensitizing Agents; Polymers; Porphyrins; Prodrugs; Surface Properties | 2020 |
Targeted drug delivery systems: synthesis and in vitro bioactivity and apoptosis studies of gemcitabine-carbon dot conjugates.
Topics: Apoptosis; Biocompatible Materials; Carbon; Cell Adhesion; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Gemcitabine; HeLa Cells; Humans; Inhibitory Concentration 50; MCF-7 Cells; Nanomedicine; Solubility | 2020 |
Comparative clinical study on microwave ablation combined with gemcitabine and cisplatin or combined with pemetrexed and cisplatin in treatment of advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Microwaves; Neoplasm Staging; Pemetrexed; Treatment Outcome | 2020 |
Determination of Gemcitabine in Plasma of Bladder Cancer Patients by Hydrophilic Interaction Chromatography with Ultraviolet Detection.
Topics: Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Hydrophobic and Hydrophilic Interactions; Linear Models; Reproducibility of Results; Spectrophotometry, Ultraviolet; Urinary Bladder Neoplasms | 2020 |
Sarcomatoid carcinoma of the pancreas with rare long-term survival: a case report.
Topics: Carcinosarcoma; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Time Factors; Treatment Outcome | 2020 |
Damage-associated molecular patterns (DAMPs) related to immunogenic cell death are differentially triggered by clinically relevant chemotherapeutics in lung adenocarcinoma cells.
Topics: A549 Cells; Adenocarcinoma of Lung; Adenosine Triphosphate; Alarmins; Antineoplastic Agents; Apoptosis; Autophagy; Calreticulin; Carboplatin; Caspase 3; Cell Survival; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; HMGB1 Protein; Humans; Immunogenic Cell Death; Lung Neoplasms; Paclitaxel; Prognosis | 2020 |
CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer.
Topics: Animals; Ataxia Telangiectasia Mutated Proteins; Basigin; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytoplasm; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Genomic Instability; Humans; Mice; Pancreatic Neoplasms; Prognosis; Signal Transduction; Survival Analysis; Tumor Suppressor Protein p53 | 2020 |
Regioselective synthesis and anticancer evaluation of H
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Deoxycytidine; Drug Design; Gemcitabine; Humans; Hydrogen Peroxide; Nucleosides; Prodrugs; Stereoisomerism | 2020 |
Editorial Comment.
Topics: BCG Vaccine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Taxoids; Urinary Bladder | 2020 |
Association of Jagged1 expression with malignancy and prognosis in human pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Jagged-1 Protein; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Prognosis; RNA, Messenger; Signal Transduction | 2020 |
[Neoajuvant Chemotherapy with Gemcitabine and Cisplatin Plus S-1 for Primary Female Urethral Adenocarcinoma].
Topics: Adenocarcinoma; Aged; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Recurrence, Local; Urethra; Urethral Neoplasms; Urinary Bladder Neoplasms | 2020 |
Drug screening identifies gemcitabine inhibiting rotavirus through alteration of pyrimidine nucleotide synthesis pathway.
Topics: Animals; Antiviral Agents; Biosynthetic Pathways; Caco-2 Cells; Deoxycytidine; Drug Evaluation, Preclinical; Gemcitabine; High-Throughput Screening Assays; Humans; Intestines; Macaca mulatta; Organoids; Pyrimidines; Rotavirus; Rotavirus Infections; Small Molecule Libraries | 2020 |
Efficacy of a Newly Modified Short Hydration Method for Gemcitabine and Cisplatin Combination Chemotherapy in Patients with Urothelial Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studies; Creatinine; Deoxycytidine; Female; Fluid Therapy; Gemcitabine; Humans; Hyponatremia; Kidney Diseases; Male; Middle Aged; Retrospective Studies; Sodium; Urinary Bladder Neoplasms; Urologic Neoplasms | 2020 |
Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Management; Disease Models, Animal; Drug Evaluation, Preclinical; Gemcitabine; Gene Rearrangement; Genetic Predisposition to Disease; Humans; Infant; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2020 |
Prolonged response to liposomal irinotecan in a patient with stage IV pancreatic/bile duct cancer previously treated with FOLFIRINOX and gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Staging; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2020 |
Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds.
Topics: Animals; Antigens, Neoplasm; Carbonic Anhydrase IX; Cell Culture Techniques; Cell Hypoxia; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; L-Lactate Dehydrogenase; Mesothelioma, Malignant; Mice; Pemetrexed; Peritoneal Neoplasms; Pleural Neoplasms; Proton-Coupled Folate Transporter; Xenograft Model Antitumor Assays | 2020 |
Advanced Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin (GEMCIS) and Novel Inflammatory Markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Inflammation; Kaplan-Meier Estimate; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Prognosis; Progression-Free Survival; Retrospective Studies | 2021 |
Regulation of pancreatic cancer microenvironment by an intelligent gemcitabine@nanogel system via in vitro 3D model for promoting therapeutic efficiency.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Nanogels; Pancreatic Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
Adjuvant treatments in biliary tract cancer: an analysis based on restricted mean survival time.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Case-Control Studies; Chemotherapy, Adjuvant; Cohort Studies; Deoxycytidine; Gemcitabine; Humans; Oxaliplatin; Survival Analysis | 2020 |
Combination of cyclin-dependent kinase and immune checkpoint inhibitors for the treatment of bladder cancer.
Topics: Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Deoxycytidine; Gemcitabine; Humans; Mice; Piperazines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyridines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2020 |
NEPA as antiemetic prophylaxis after failure of 5HT
Topics: Adult; Antiemetics; Carboplatin; Deoxycytidine; Dexamethasone; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Palonosetron; Pre-Exposure Prophylaxis; Pyridines; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Treatment Failure; Vomiting | 2021 |
Synergistic effects of piperlongumine and gemcitabine against KRAS mutant lung cancer.
Topics: A549 Cells; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Cell Survival; Deoxycytidine; Dioxolanes; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Proto-Oncogene Proteins p21(ras); Reactive Oxygen Species | 2021 |
Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Flow Cytometry; Gemcitabine; Gene Expression; Humans; Mice; Nanoparticles; Pancreatic Neoplasms; Phosphatidylserines; Xenograft Model Antitumor Assays | 2020 |
TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Small Interfering; Tissue Inhibitor of Metalloproteinase-1 | 2021 |
Mre11 exonuclease activity removes the chain-terminating nucleoside analog gemcitabine from the nascent strand during DNA replication.
Topics: Deoxycytidine; DNA; DNA Replication; DNA-Binding Proteins; Exonucleases; Gemcitabine | 2020 |
[Induction Chemotherapy with Gemcitabine and Cisplatin followed by Radiochemotherapy in locally advanced Nasopharyngeal Carcinoma].
Topics: Chemoradiotherapy; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2020 |
Temozolomide, Gemcitabine, and Decitabine Hybrid Nanoconjugates: From Design to Proof-of-Concept (PoC) of Synergies toward the Understanding of Drug Impact on Human Glioblastoma Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Decitabine; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Glioblastoma; Gold; Humans; Magnetic Resonance Spectroscopy; Metal Nanoparticles; Nanoconjugates; Proof of Concept Study; Spectrophotometry, Ultraviolet; Temozolomide | 2020 |
Deoxyelephantopin induces apoptosis via oxidative stress and enhances gemcitabine sensitivity
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Oxidative Stress; Pancreatic Neoplasms; Sesquiterpenes; Signal Transduction; Transcription Factor RelA; Xenograft Model Antitumor Assays | 2020 |
Challenges of pancreatic cancer chemotherapy in the COVID-19 era.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Betacoronavirus; Capecitabine; Coronavirus Infections; COVID-19; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Pandemics; Pneumonia, Viral; Romania; SARS-CoV-2 | 2020 |
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; High-Throughput Screening Assays; Humans; Keratin-17; Mice, Inbred C57BL; Microtubules; Paclitaxel; Pancreatic Neoplasms; Podophyllotoxin; Tumor Burden | 2020 |
pH and singlet oxygen dual-responsive GEM prodrug micelles for efficient combination therapy of chemotherapy and photodynamic therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chlorophyllides; Combined Modality Therapy; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Hydrogen-Ion Concentration; Lasers; Mammary Neoplasms, Experimental; Mice; Micelles; Molecular Structure; Optical Imaging; Particle Size; Photochemotherapy; Photosensitizing Agents; Polymers; Porphyrins; Prodrugs; Singlet Oxygen; Surface Properties | 2020 |
Nomogram for Estimating Overall Survival in Patients With Metastatic Pancreatic Cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Nomograms; Outcome Assessment, Health Care; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proportional Hazards Models; Reproducibility of Results | 2020 |
Biomimetic Gemcitabine-Lipid Prodrug Nanoparticles for Pancreatic Cancer.
Topics: Animals; Biomimetic Materials; Carboxylesterase; Cell Line, Tumor; Deoxycytidine; Dimyristoylphosphatidylcholine; Gemcitabine; Liposomes; Mice, Inbred NOD; Mice, SCID; Nanoparticles; Pancreas; Pancreatic Neoplasms; Prodrugs; Swine | 2020 |
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; Drug Carriers; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liposomes; Male; Middle Aged; Nanoparticles; Retrospective Studies; Treatment Outcome | 2020 |
Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Self Renewal; Deoxycytidine; Doxorubicin; Female; Gemcitabine; HEK293 Cells; Heterografts; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Neoplastic Stem Cells; Pancreatic Neoplasms; Protein Methyltransferases; Proto-Oncogene Proteins p21(ras); Trans-Activators; Transcriptional Coactivator with PDZ-Binding Motif Proteins | 2020 |
Clinical implications of the serum CA19-9 level in "biological borderline resectability" and "biological downstaging" in the setting of preoperative chemoradiation therapy for pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; CA-19-9 Antigen; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Preoperative Care; Radiation-Sensitizing Agents; Survival Analysis | 2020 |
MicroRNA-7 as a Potential Biomarker for Prognosis in Pancreatic Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Circulating MicroRNA; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms | 2020 |
Reaching out beyond first-line treatments in advanced biliary tract cancers.
Topics: Biliary Tract Neoplasms; Deoxycytidine; Double-Blind Method; Gemcitabine; Humans; Phenylurea Compounds; Platinum; Pyridines | 2020 |
Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; B7-H1 Antigen; Carcinoma, Lewis Lung; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Drug Synergism; Gemcitabine; Immune Checkpoint Inhibitors; Lymphocytes, Tumor-Infiltrating; Mice, Inbred C57BL; Neoplasm Recurrence, Local; Programmed Cell Death 1 Receptor; Tumor Microenvironment; Up-Regulation | 2020 |
Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Mice; Mice, Inbred C57BL; Mutation; Nanoparticles; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Tumor Burden | 2020 |
Gemcitabine plus nab-paclitaxel with initial dose reduction for older patients with advanced pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Tapering; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
NLRP3 augmented resistance to gemcitabine in triple-negative breast cancer cells via EMT/IL-1β/Wnt/β-catenin signaling pathway.
Topics: Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inflammasomes; Interleukin-1beta; Nigericin; NLR Family, Pyrin Domain-Containing 3 Protein; Thiazolidines; Thiones; Triple Negative Breast Neoplasms; Up-Regulation; Wnt Signaling Pathway | 2020 |
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, SCID; Mitosis; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyrimidines; S Phase; Xenograft Model Antitumor Assays | 2020 |
(3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Pyrones | 2020 |
Characterization of a dual BET/HDAC inhibitor for treatment of pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Agents; Azepines; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Protein Domains; Proto-Oncogene Proteins c-fos; Transcription Factors; Triazoles | 2020 |
Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice.
Topics: Administration, Oral; Amino Acids; Animals; Antimetabolites, Antineoplastic; Biological Availability; Deoxycytidine; Drug Stability; Esters; Gemcitabine; Injections, Intravenous; Jejunum; Mice; Mice, Inbred C57BL; Molecular Structure; Prodrugs | 2020 |
[Evaluation of the Tolerability of Gemcitabine and Cisplatin Combination Chemotherapy with a Small Quantity of Replacement Fluid for Biliary Tract Cancer].
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Fluid Therapy; Gemcitabine; Humans; Male; Middle Aged; Retrospective Studies | 2020 |
LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytoskeletal Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gemcitabine; Humans; Male; Middle Aged; Oncostatin M Receptor beta Subunit; Pancreatic Neoplasms; Sp1 Transcription Factor; Transcriptome; Young Adult | 2020 |
Clinical impact of irreversible electroporation ablation for unresectable hilar cholangiocarcinoma.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts; Chemotherapy, Adjuvant; Combined Modality Therapy; Constriction, Pathologic; Deoxycytidine; Electroporation; Female; Follow-Up Studies; Gemcitabine; Humans; Klatskin Tumor; Laparotomy; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Treatment Outcome | 2020 |
Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Infusions, Intralesional; Infusions, Intravenous; Male; Mice; Pancreas; Pancreatic Neoplasms; Pressure; Tissue Distribution | 2020 |
FOLFIRINOX
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms | 2020 |
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Pretreatment biomarkers as prognostic predictors of survival in patients with Pancreatic Cancer treated with Gemcitabine-based Therapy and 5-Fluorouracil: Neutrophil-to-lymphocyte ratio
Topics: Aged; Biomarkers, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Lymphocytes; Male; Middle Aged; Neutrophils; Pancreatic Neoplasms; Prognosis | 2020 |
Electrochemotherapy of cholangiocellular carcinoma at hepatic hilum: a case report.
Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Electrochemotherapy; Gemcitabine; Humans; Male; Tomography, X-Ray Computed | 2020 |
Cisplatin, Gemcitabine, and Paclitaxel as a Salvage Second-Line Therapy for Metastatic Germ-Cell Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Ifosfamide; Neoplasms, Germ Cell and Embryonal; Paclitaxel; Salvage Therapy; Treatment Outcome | 2021 |
Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Calcium channel blockers in pancreatic cancer: increased overall survival in a retrospective cohort study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcium Channel Blockers; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Survival Rate; United Kingdom | 2020 |
Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; China; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Female; Gemcitabine; Humans; Markov Chains; Middle Aged; Neoplasm Metastasis; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Bevacizumab in recurrent ovarian cancer: could it be particularly effective in patients with clear cell carcinoma?
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Confidence Intervals; Cystadenocarcinoma, Serous; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Odds Ratio; Ovarian Neoplasms; Paclitaxel; Progression-Free Survival; Retrospective Studies | 2021 |
Inhibition of autophagy by chloroquine enhances the antitumor activity of gemcitabine for gallbladder cancer.
Topics: Animals; Antimalarials; Antimetabolites, Antineoplastic; Apoptosis; Autophagy; Cell Proliferation; Chloroquine; Deoxycytidine; Drug Synergism; Drug Therapy, Combination; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
A Novel E2F1-EP300-VMP1 Pathway Mediates Gemcitabine-Induced Autophagy in Pancreatic Cancer Cells Carrying Oncogenic KRAS.
Topics: Antimetabolites, Antineoplastic; Autophagy; Biomarkers, Tumor; Deoxycytidine; E1A-Associated p300 Protein; E2F1 Transcription Factor; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Tumor Cells, Cultured | 2020 |
The Complexity of Neoadjuvant Therapy for Operable Pancreatic Cancer: Lessons Learned From SWOG S1505.
Topics: Adenocarcinoma; Albumins; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2020 |
Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Diagnostic Imaging; Dose Fractionation, Radiation; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Middle Aged; Neoadjuvant Therapy; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreas; Pancreatic Neoplasms; Radiosurgery | 2020 |
Chitosan Hydrogels for Synergistic Delivery of Chemotherapeutics to Triple Negative Breast Cancer Cells and Spheroids.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Chitosan; Deoxycytidine; Doxorubicin; Drug Carriers; Drug Compounding; Drug Liberation; Drug Synergism; Female; Gemcitabine; Humans; Hydrogels; Kinetics; Spheroids, Cellular; Triple Negative Breast Neoplasms | 2020 |
Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Dendritic Cells; Deoxycytidine; Drug Interactions; Gemcitabine; Histocompatibility Antigens Class I; Humans; Immunomodulation; Interferon-gamma; Lymphocyte Activation; Oxaliplatin; Pancreatic Neoplasms; Thalidomide; Zoledronic Acid | 2021 |
Comparative efficacy of Chinese herbal injections combined with GP regimen chemotherapy for patients with advanced NSCLC: A protocol for systematic review and network meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drugs, Chinese Herbal; Gemcitabine; Humans; Lung Neoplasms; Meta-Analysis as Topic; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Systematic Review as Topic | 2020 |
Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2020 |
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Radiography; Survival Rate; Treatment Outcome | 2020 |
Risk Associated with Severe Hematological Toxicity in Patients with Urothelial Cancer Receiving Combination Chemotherapy of Gemcitabine and Cisplatin.
Topics: Aged; Antineoplastic Agents; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Neutropenia; Odds Ratio; Retrospective Studies; Risk Factors; Severity of Illness Index; Thrombocytopenia; Urologic Neoplasms | 2020 |
Human equilibrative nucleoside transporter-1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Cross-Sectional Studies; Deoxycytidine; Deoxycytidine Kinase; Egypt; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Real-Time Polymerase Chain Reaction; Treatment Outcome | 2020 |
Efficacy of S-1 in second-line chemotherapy after nab-paclitaxel plus gemcitabine for patients with advanced pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tegafur | 2020 |
Precise engineering of Gemcitabine prodrug cocktails into single polymeric nanoparticles delivery for metastatic thyroid cancer cells.
Topics: Adenocarcinoma, Follicular; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Linoleic Acid; Microscopy, Electron; Nanoconjugates; Nanoparticles; Polymers; Prodrugs; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2020 |
Multiple Liver Metastases Rather Than the Presence of Liver Metastasis Is a Significantly Poor Prognostic Factor for Patients With Advanced Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Pancreatic Neoplasms; Prognosis; Tomography Scanners, X-Ray Computed | 2020 |
Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Exome Sequencing; Gemcitabine; Genome-Wide Association Study; Humans; Leukopenia; Lung Neoplasms; Neutropenia | 2020 |
Targeting Myeloid-Derived Suppressor Cells Is a Novel Strategy for Anti-Psoriasis Therapy.
Topics: Adult; Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Cells, Cultured; Deoxycytidine; Female; Flow Cytometry; Gemcitabine; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Middle Aged; Myeloid-Derived Suppressor Cells; Psoriasis; Receptors, Interleukin-21; T-Lymphocytes, Regulatory; Th17 Cells; Young Adult | 2020 |
A G-quadruplex-binding compound shows potent activity in human gemcitabine-resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; G-Quadruplexes; Gemcitabine; Gene Expression Profiling; Humans; Imides; Ligands; Naphthalenes; Pancreatic Neoplasms; Repressor Proteins; Up-Regulation | 2020 |
One Two Punch: Combination Chemotherapy Knocks Out Pancreatic Cancer.
Topics: Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylserines | 2020 |
Low‑intensity low‑frequency ultrasound enhances the chemosensitivity of gemcitabine‑resistant ASPC‑1 cells via PI3K/AKT/NF‑κB pathway‑mediated ABC transporters.
Topics: Animals; Apoptosis; ATP-Binding Cassette Transporters; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Ultrasonic Therapy; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2020 |
Proteomic Characterization of Circulating Molecular Perturbations Associated With Pancreatic Adenocarcinoma Following Intravenous ω-3 Fatty Acid and Gemcitabine Administration: A Pilot Study.
Topics: Adenocarcinoma; Deoxycytidine; Fatty Acids, Omega-3; Gemcitabine; Humans; Pancreatic Neoplasms; Pilot Projects; Proteomics | 2021 |
Outcomes of neoadjuvant chemotherapy using gemcitabine and cisplatin in muscle invasive bladder cancer: A retrospective analysis of the patient and treatment factors in a single institute.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gemcitabine; Humans; Middle Aged; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Progression-Free Survival; Retrospective Studies; Urinary Bladder; Urinary Bladder Neoplasms | 2019 |
MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Cell Movement; Cell Proliferation; Deoxycytidine; DNA Modification Methylases; DNA Repair Enzymes; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Purines; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2020 |
Enhancement of Soft Tissue Sarcoma Response to Gemcitabine through Timed Administration of a Short-Acting Anti-Angiogenic Agent.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Deoxycytidine; Endothelial Cells; Gemcitabine; Male; Mice; Neovascularization, Pathologic; Phenylurea Compounds; Quinolines; Sarcoma; Soft Tissue Neoplasms; Sphingomyelin Phosphodiesterase; Vascular Endothelial Growth Factor Receptor-2 | 2020 |
Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma.
Topics: Adult; Albumin-Bound Paclitaxel; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Progression-Free Survival; Retrospective Studies; Sarcoma; Treatment Outcome | 2020 |
LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt/β-catenin and autophagy pathway through modulating the miR-619-5p/Pygo2 and miR-619-5p/ATG14 axes.
Topics: Adaptor Proteins, Vesicular Transport; Animals; Autophagy; Autophagy-Related Proteins; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mice; MicroRNAs; Pancreatic Neoplasms; Protein Binding; RNA Interference; RNA, Long Noncoding; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2020 |
Clinical significance of circPVT1 in patients with non-small cell lung cancer who received cisplatin combined with gemcitabine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; RNA, Circular; RNA, Long Noncoding | 2021 |
Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidine; Europe; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Postoperative Complications; Prognosis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2020 |
TGF-β downregulation overcomes gemcitabine resistance in oral squamous cell carcinoma.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice; Mouth Neoplasms; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2020 |
Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Knockout Techniques; Humans; Indoles; Mice; Mice, 129 Strain; Mice, Inbred C57BL; Morpholines; Pancreatic Neoplasms; Pyridines; Pyrimidines; Quinolines; RNA, Small Interfering; Sulfonamides; Sulfoxides; Xenograft Model Antitumor Assays | 2020 |
Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Taxoids; Time Factors | 2020 |
First-line gemcitabine plus nab-paclitaxel for elderly patients with metastatic pancreatic cancer: Crossing the frontier of age?
Topics: Aged; Aged, 80 and over; Albumins; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms | 2020 |
Targeting the Microenvironment to Overcome Gemcitabine Resistance in Pancreatic Cancer.
Topics: Animals; Carcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Immunotherapy; Mice; Pancreatic Neoplasms; Tumor Microenvironment | 2020 |
Clear cell adenocarcinoma presenting as acute pancreatitis: A rare form of primary pancreatic malignancy.
Topics: Adenocarcinoma, Clear Cell; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Deoxycytidine; Diagnosis, Differential; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreas; Pancreatic Neoplasms; Pancreatitis; Tomography, X-Ray Computed | 2020 |
Development and In Vitro Evaluation of Long Circulating Liposomes for Targeted Delivery of Gemcitabine and Irinotecan in Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Irinotecan; Liposomes; Pancreatic Neoplasms; Particle Size; Polyethylene Glycols | 2020 |
Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Male; Margins of Excision; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Proportional Hazards Models; Radiotherapy, Conformal; Retrospective Studies; Survival Rate | 2020 |
Gambogic acid potentiates gemcitabine induced anticancer activity in non-small cell lung cancer.
Topics: A549 Cells; Adult; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Male; Mice, Nude; Middle Aged; Pilot Projects; Tumor Cells, Cultured; Xanthones; Xenograft Model Antitumor Assays | 2020 |
Co-delivery of gemcitabine prodrug along with anti NF-κB siRNA by tri-layer micelles can increase cytotoxicity, uptake and accumulation of the system in the cancers.
Topics: Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Liver Neoplasms; Micelles; NF-kappa B; Polyethylene Glycols; Prodrugs; RNA, Small Interfering | 2020 |
Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine.
Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Female; Furans; Gemcitabine; Humans; Ketones; Liver; Lung Neoplasms; Retrospective Studies; Survival Analysis | 2020 |
Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice; Mice, Nude; Momordica charantia; Neoplasm Invasiveness; Pancreatic Neoplasms; Plant Extracts; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
The clinicopathological and prognostic implications of tyrosine phosphatase SHP2 and ankyrin Hook1 gene expression in non- small cell lung cancer patients treated with gemcitabine plus platinum as first-line chemotherapy.
Topics: Ankyrins; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Expression; Humans; Lung Neoplasms; Neoplasm Staging; Platinum; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Small Cell Lung Carcinoma; Tyrosine | 2020 |
GDC-0980 (apitolisib) treatment with gemcitabine and/or cisplatin synergistically reduces cholangiocarcinoma cell growth by suppressing the PI3K/Akt/mTOR pathway.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2020 |
In vitro affinity maturation to improve the efficacy of a hypoxia-inducible factor 1α single-domain intrabody.
Topics: Algorithms; Antibody Affinity; Antibody Specificity; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Binding Sites; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Pancreatic Ducts; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Single-Domain Antibodies; Structural Homology, Protein; User-Computer Interface | 2020 |
Combination of thermally ablative focused ultrasound with gemcitabine controls breast cancer via adaptive immunity.
Topics: Adaptive Immunity; Deoxycytidine; Female; Gemcitabine; High-Intensity Focused Ultrasound Ablation; Humans; Immunosuppressive Agents; Triple Negative Breast Neoplasms | 2020 |
Important roles of estrogen receptor alpha in tumor progression and anti-estrogen therapy of pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Gemcitabine; Gene Expression; Gene Knockout Techniques; Humans; Letrozole; Leuprolide; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2020 |
MRP5 nitration by NO-releasing gemcitabine encapsulated in liposomes confers sensitivity in chemoresistant pancreatic adenocarcinoma cells.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Liposomes; Multidrug Resistance-Associated Proteins; Nitric Oxide; Pancreatic Neoplasms | 2020 |
[A Case of a Huge, Mixed-Type IPMC with Suspected Rupture of the Omental Bursa That Was Effectively Treated with Gemcitabine plus Nab-Paclitaxel].
Topics: Adenocarcinoma, Mucinous; Albumins; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Peritoneal Cavity; Positron Emission Tomography Computed Tomography | 2020 |
Insulin-like growth factor binding protein 3 chemosensitizes pancreatic ductal adenocarcinoma through its death receptor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Pancreatic Neoplasms; Receptors, Cell Surface; Receptors, Death Domain; RNA, Small Interfering | 2020 |
Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer - translational results from the AIO-PK0104 Phase 3 study.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Cohort Studies; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immunohistochemistry; Lipopolysaccharides; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Randomized Controlled Trials as Topic; Survival Analysis; Translational Research, Biomedical; Treatment Outcome | 2020 |
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients.
Topics: Bone Marrow; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Gene Regulatory Networks; Humans; Lung Neoplasms; Whole Genome Sequencing | 2020 |
Topics: Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2020 |
Klatskin tumor diagnosed concurrently with IgG4 related sclerosing cholangitis: A case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Cholangiopancreatography, Endoscopic Retrograde; Cholangitis, Sclerosing; Cisplatin; Common Bile Duct; Deoxycytidine; Diagnosis, Differential; Gemcitabine; Humans; Immunoglobulin G; Immunoglobulin G4-Related Disease; Jaundice; Klatskin Tumor; Male; Pruritus; Steroids; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
Overexpression of microRNA-205-5p exerts suppressive effects on stem cell drug resistance in gallbladder cancer by down-regulating PRKCE.
Topics: Adult; Aged; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Cholecystectomy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gallbladder; Gallbladder Neoplasms; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Healthy Volunteers; HEK293 Cells; Humans; Male; Mice; MicroRNAs; Middle Aged; Neoplastic Stem Cells; Protein Kinase C-epsilon; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma.
Topics: Aged; Antineoplastic Agents; Bortezomib; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Drug Tapering; Fibroma; Gemcitabine; Humans; Loss of Function Mutation; Male; Neoplasm Invasiveness; Neurofibromin 1; PTEN Phosphohydrolase; Topotecan | 2021 |
New Imidazo[2,1-
Topics: Antineoplastic Agents; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Equilibrative Nucleoside Transporter 1; Focal Adhesion Kinase 1; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Mesothelioma; Molecular Structure; Peritoneal Neoplasms; Phosphorylation; Thiadiazoles; Tumor Cells, Cultured | 2020 |
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brucea; Deoxycytidine; Drug Synergism; Drugs, Chinese Herbal; Female; Gemcitabine; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Plant Oils; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2020 |
Feasibility and efficacy evaluation of metallic biliary stents eluting gemcitabine and cisplatin for extrahepatic cholangiocarcinoma.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug-Eluting Stents; Feasibility Studies; Gemcitabine; Humans; Mice; Mice, Nude; Stents; Swine | 2020 |
Comparison of FOLFIRINOX and Gemcitabine Plus Nab-paclitaxel for Treatment of Metastatic Pancreatic Cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cross-Over Studies; Deoxycytidine; Febrile Neutropenia; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Peritoneal Neoplasms; Progression-Free Survival; Registries; Republic of Korea; Survival Rate; Treatment Outcome | 2020 |
Two cycles of neoadjuvant chemotherapy improves survival in patients with high-risk upper tract urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Methotrexate; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Nephroureterectomy; Proportional Hazards Models; Retrospective Studies; Sex Factors; Survival Rate; Ureteral Neoplasms; Vinblastine | 2021 |
Gemcitabine potentiates anti-tumor effect of resveratrol on pancreatic cancer via down-regulation of VEGF-B.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Resveratrol; Tumor Cells, Cultured; Vascular Endothelial Growth Factor B; Xenograft Model Antitumor Assays | 2021 |
Inhibitory effects of canagliflozin on pancreatic cancer are mediated via the downregulation of glucose transporter‑1 and lactate dehydrogenase A.
Topics: Animals; Apoptosis; Canagliflozin; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Gemcitabine; Glucose Transporter Type 1; Glycolysis; Humans; Lactate Dehydrogenase 5; Male; Mice; Mice, Inbred BALB C; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Gemcitabine-retinoid prodrug loaded nanoparticles display in vitro antitumor efficacy towards drug-resilient human PANC-1 pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Nanoparticles; Pancreatic Neoplasms; Prodrugs; Retinoids | 2020 |
Combination of DN604 with gemcitabine led to cell apoptosis and cell motility inhibition via p38 MAPK signaling pathway in NSCLC.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Signal Transduction; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Response rates, long term outcomes and toxicity profile of gemcitabine and vinorelbine based outpatient chemotherapy regimen in primary progressive and relapsed childhood Hodgkin lymphoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Gemcitabine; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Outpatients; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vinorelbine | 2020 |
Ultrahigh-Throughput and Chromatography-Free Bioanalysis of Polar Analytes with Acoustic Ejection Mass Spectrometry.
Topics: Acoustics; Deoxycytidine; Ephedrine; Ethambutol; Gemcitabine; HEK293 Cells; High-Throughput Screening Assays; Humans; Isoniazid; Mass Spectrometry | 2020 |
Aloe-emodin induces autophagy and apoptotic cell death in non-small cell lung cancer cells via Akt/mTOR and MAPK signaling.
Topics: A549 Cells; Anthraquinones; Antineoplastic Agents, Phytogenic; Antioxidants; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Caspase Inhibitors; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinases; Oncogene Protein v-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Serum IL6 as a Prognostic Biomarker and IL6R as a Therapeutic Target in Biliary Tract Cancers.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Biomarkers, Tumor; Cell Proliferation; Chitinase-3-Like Protein 1; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Interleukin-6; Male; Mice; Middle Aged; Palliative Care; Prognosis; Progression-Free Survival; Receptors, Interleukin-6 | 2020 |
Curcumin enhances anti‑cancer efficacy of either gemcitabine or docetaxel on pancreatic cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cadherins; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Curcuma; Curcumin; Deoxycytidine; Docetaxel; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Pancreatic Neoplasms; Plant Extracts; Poly (ADP-Ribose) Polymerase-1; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2020 |
sATP‑binding cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer/T cell lymphoma side population cells.
Topics: Antineoplastic Agents; Asparaginase; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Extranodal NK-T-Cell; Neoplasm Proteins | 2020 |
TNNC1 Reduced Gemcitabine Sensitivity of Nonsmall-Cell Lung Cancer by Increasing Autophagy.
Topics: A549 Cells; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Troponin C | 2020 |
Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.
Topics: Administration, Intravenous; Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Bone Marrow; Carboplatin; Contrast Media; Creatinine; Cytochrome P-450 Enzyme System; Deoxycytidine; Drug Dosage Calculations; Drug Interactions; Female; Gemcitabine; Glomerular Filtration Rate; Glucuronosyltransferase; Humans; Iohexol; Kidney; Metabolic Clearance Rate; Mice; Microsomes, Liver; Models, Animal; Paclitaxel; Specific Pathogen-Free Organisms; Tandem Mass Spectrometry; Tissue Distribution | 2020 |
Pancreatic adenocarcinoma preferentially takes up and is suppressed by synthetic nanoparticles carrying apolipoprotein A-II and a lipid gemcitabine prodrug in mice.
Topics: Animals; Apolipoprotein A-II; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Lipoproteins, HDL; Male; Mice; Nanoparticles; Pancreatic Neoplasms; Particle Size; Prodrugs; Scavenger Receptors, Class B; Xenograft Model Antitumor Assays | 2020 |
Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Italy; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2020 |
Right supernumerary kidney with urothelial carcinoma: A case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Nephroureterectomy; Ureter | 2020 |
Thyroid Follicle-Like Cholangiocarcinoma in Liver: a Novel Variant and What We Know So Far?
Topics: Adult; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Fatal Outcome; Female; Gemcitabine; Humans; Immunohistochemistry; India | 2021 |
High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Blood Platelets; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lymphocytes; Male; Middle Aged; Prognosis; Retrospective Studies | 2020 |
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Interferon-beta; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2020 |
The economic burden of metastatic pancreatic cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cost of Illness; Costs and Cost Analysis; Databases, Factual; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Health Care Costs; Health Resources; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Needs Assessment; Neoplasm Metastasis; Oxaliplatin; Pancreatic Neoplasms; Retrospective Studies | 2020 |
A multiple drug loaded, functionalized pH-sensitive nanocarrier as therapeutic and epigenetic modulator for osteosarcoma.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Deoxycytidine; Drug Combinations; Epigenesis, Genetic; Epirubicin; Gemcitabine; Hydrogen-Ion Concentration; Male; Nanocapsules; Osteosarcoma; Particle Size; Rats; Rats, Sprague-Dawley | 2020 |
Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules.
Topics: Animals; Breast Neoplasms; Deoxycytidine; Drug Combinations; Drug Delivery Systems; Female; Gemcitabine; Kidney; Liver; Lung; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Paclitaxel; Spleen; Tissue Distribution | 2020 |
Predictive implications of decreased CA19-9 at 8 weeks during nab-paclitaxel plus gemcitabine for the induction of second-line chemotherapy for patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms | 2020 |
Cost-effectiveness analysis of nab-paclitaxel plus gemcitabine versus folfirinox in the treatment of metastatic pancreatic cancer in china.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Deoxycytidine; Disease Progression; Fluorouracil; Gemcitabine; Health Care Costs; Hospitalization; Humans; Irinotecan; Leucovorin; Markov Chains; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Quality-Adjusted Life Years; Survival Rate | 2021 |
Exploring the action of RGDV-gemcitabine on tumor metastasis, tumor growth and possible action pathway.
Topics: A549 Cells; Animals; Cell Adhesion; Cell Line, Tumor; Cell Movement; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Inbred C57BL; Microscopy, Atomic Force; Oligopeptides; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2020 |
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Comparative Effectiveness Research; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nephroureterectomy; Proportional Hazards Models; Retrospective Studies; Survival Rate; Treatment Outcome; Ureteral Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Glycogen synthase kinase-3β participates in acquired resistance to gemcitabine in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Deoxycytidine; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Gemcitabine; Glycogen Synthase Kinase 3 beta; Heterografts; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Retinoblastoma Protein; Ribonucleoside Diphosphate Reductase; Thymidine Kinase; Thymidylate Synthase; Transcription, Genetic | 2020 |
A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Fluorouracil; Gemcitabine; Humans; Liver Neoplasms; Mice; Oxaliplatin; Stomach; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Primary Bone Marrow Epithelioid Hemangioendothelioma Treated With Gemcitabine and Docetaxel.
Topics: Bone Marrow; Bone Neoplasms; Deoxycytidine; Docetaxel; Gemcitabine; Hemangioendothelioma, Epithelioid; Humans | 2021 |
Association between the use of antibiotics and efficacy of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2020 |
Role of sphingomyelin on the interaction of the anticancer drug gemcitabine hydrochloride with cell membrane models.
Topics: Antineoplastic Agents; Cell Membrane; Deoxycytidine; Gemcitabine; Glycerol; Phosphorylcholine; Sphingomyelins | 2020 |
Leveraging TCGA gene expression data to build predictive models for cancer drug response.
Topics: Antineoplastic Agents; Area Under Curve; Cluster Analysis; Databases, Genetic; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Machine Learning; Neoplasms; ROC Curve | 2020 |
Dual Delivery of Gemcitabine and Paclitaxel by Wet-Spun Coaxial Fibers Induces Pancreatic Ductal Adenocarcinoma Cell Death, Reduces Tumor Volume, and Sensitizes Cells to Radiation.
Topics: Adenocarcinoma; Animals; Cell Death; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms; Tumor Burden | 2020 |
Hypofractionated sequential radiotherapy boost: a promising strategy in inoperable locally advanced pancreatic cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Radiation Dose Hypofractionation; Retrospective Studies; Survival Rate | 2021 |
Enhanced gemcitabine cytotoxicity with knockdown of multidrug resistance protein genes in human cholangiocarcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression; Gene Knockdown Techniques; Humans; Liver; Liver Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2021 |
Clinical Utility of Pancreatic Cancer Circulating Tumor DNA in Predicting Disease Progression, Prognosis, and Response to Chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Circulating Tumor DNA; Deoxycytidine; Disease Progression; Female; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Mutation; Paclitaxel; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins p21(ras); Survival Analysis | 2020 |
Clinical outcomes of chemotherapy in patients with undifferentiated carcinoma of the pancreas: a retrospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Tegafur; Treatment Outcome | 2020 |
Chemotherapy combined with apatinib for the treatment of desmoplastic small round cell tumors: A case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Deoxycytidine; Desmoplastic Small Round Cell Tumor; Epirubicin; Gemcitabine; Humans; Male; Neoplasm Metastasis; Oncogene Proteins, Fusion; Pyridines; RNA-Binding Protein EWS; Treatment Outcome; Vincristine; WT1 Proteins | 2020 |
Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Prognosis; Treatment Outcome | 2020 |
Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Calcium Channel Blockers; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Deoxycytidine; Diltiazem; Drug Synergism; Fluorouracil; Gemcitabine; Humans; Pancreatic Neoplasms | 2020 |
Perioperative Treatment in Muscle-invasive Bladder Cancer: Analysis of Secondary Endpoints in a Randomized Trial Comparing Gemcitabine and Cisplatin Versus Dose-dense Methotrexate, Vinblastine, Adriamycin, and Cisplatin.
Topics: Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Muscles; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Mechanical Control of Cell Proliferation Increases Resistance to Chemotherapeutic Agents.
Topics: Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Models, Biological; Pancreatic Neoplasms; Stress, Mechanical | 2020 |
Clinical benefits of adjuvant chemotherapy with carboplatin and gemcitabine in patients with non-small cell lung cancer: a single-center retrospective study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies | 2020 |
Identification of human adenovirus replication inhibitors from a library of small molecules targeting cellular epigenetic regulators.
Topics: Adenovirus Infections, Human; Adenoviruses, Human; Antiviral Agents; Carbazoles; Deoxycytidine; Furans; Gemcitabine; Humans; Piperazines; Virus Replication | 2021 |
Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: Real-life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Transla
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Registries; Treatment Outcome | 2021 |
Paracrine HGF promotes EMT and mediates the effects of PSC on chemoresistance by activating c-Met/PI3K/Akt signaling in pancreatic cancer in vitro.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Pancreatic Neoplasms; Pancreatic Stellate Cells; Paracrine Communication; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Tumor Cells, Cultured | 2020 |
Real world experience on maintenance chemotherapy with gemcitabine in second line setting for advanced non-small cell lung carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Platinum Compounds; Retrospective Studies | 2020 |
Precise and efficient silencing of mutant Kras
Topics: Amino Acid Substitution; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; CRISPR-Cas Systems; Deoxycytidine; Dependovirus; Disease Progression; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Knockdown Techniques; Genetic Therapy; Genetic Vectors; Humans; Mice; Mutation; Pancreatic Neoplasms; Proof of Concept Study; Proto-Oncogene Proteins p21(ras); RNA, Guide, Kinetoplastida; Xenograft Model Antitumor Assays | 2020 |
Quercetin potentializes the respective cytotoxic activity of gemcitabine or doxorubicin on 3D culture of AsPC-1 or HepG2 cells, through the inhibition of HIF-1α and MDR1.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; ATP Binding Cassette Transporter, Subfamily B; Cell Hypoxia; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Pancreatic Neoplasms; Quercetin; Tumor Microenvironment | 2020 |
Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Leukopenia; Male; Mesothelioma, Malignant; Middle Aged; Neutropenia; Pemetrexed; Platinum; Progression-Free Survival; Retrospective Studies; Thrombocytopenia | 2021 |
Toxic erythema of chemotherapy secondary to gemcitabine and paclitaxel.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Deoxycytidine; Erythema; Female; Gemcitabine; Humans; Intertrigo; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2020 |
Recurrence patterns after bevacizumab in platinum-sensitive, recurrent epithelial ovarian cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carboplatin; Carcinoma, Ovarian Epithelial; Cisplatin; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Topotecan | 2020 |
Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Intention to Treat Analysis; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Atorvastatin Augments Gemcitabine-Mediated Anti-Cancer Effects by Inhibiting Yes-Associated Protein in Human Cholangiocarcinoma Cells.
Topics: Animals; Anticholesteremic Agents; Antimetabolites, Antineoplastic; Apoptosis; Atorvastatin; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Connective Tissue Growth Factor; Contractile Proteins; Cysteine-Rich Protein 61; Deoxycytidine; Drug Combinations; Drug Interactions; Gemcitabine; Humans; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Muscle Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Nuclear Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-yes; Repressor Proteins | 2020 |
In Regard to Mell et al.
Topics: Carcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Radiotherapy, Image-Guided | 2020 |
In Reply to Sari et al.
Topics: Carcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Tumor Suppressor Proteins | 2020 |
JMJD1C knockdown affects myeloid cell lines proliferation, viability, and gemcitabine/carboplatin-sensitivity.
Topics: Carboplatin; Cell Proliferation; Cell Survival; Deoxycytidine; Gemcitabine; Gene Knockdown Techniques; Humans; Jumonji Domain-Containing Histone Demethylases; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cells; Oxidoreductases, N-Demethylating | 2021 |
First case of classical Hodgkin-like EBV-positive lymphoproliferative disorder under ruxolitinib therapy.
Topics: Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Deoxycytidine; DNA, Viral; Doxorubicin; Epstein-Barr Virus Infections; Gemcitabine; Humans; Immunocompromised Host; Lymph Nodes; Lymphoproliferative Disorders; Male; Middle Aged; Nitriles; PAX5 Transcription Factor; Prednisone; Primary Myelofibrosis; Pyrazoles; Pyrimidines; Reed-Sternberg Cells; RNA, Viral; Thrombocythemia, Essential; Vinblastine | 2021 |
Targeting interleukin-17 receptor B enhances gemcitabine sensitivity through downregulation of mucins in pancreatic cancer.
Topics: Antibodies, Blocking; Antineoplastic Agents; Antineoplastic Agents, Immunological; Deoxycytidine; Down-Regulation; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Molecular Targeted Therapy; Mucins; Neoplastic Stem Cells; Pancreatic Neoplasms; Receptors, Interleukin-17; Tumor Cells, Cultured | 2020 |
Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Caveolin 1; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Administration Schedule; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred NOD; Mice, Knockout; Mice, Nude; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; CRISPR-Cas Systems; Deoxycytidine; Drug Development; Gemcitabine; Gene Knockout Techniques; Humans; Mice, Nude; Pancreatic Neoplasms; Protein-Arginine N-Methyltransferases; Xenograft Model Antitumor Assays | 2020 |
Combinational dual drug delivery system to enhance the care and treatment of gastric cancer patients.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Delivery Systems; Gemcitabine; Humans; Irinotecan; Stomach Neoplasms; Treatment Outcome | 2020 |
Detection of risk factors related to administration suspension and severe neutropenia in gemcitabine and nab-paclitaxel treatment.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors | 2021 |
Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: comparison of multiple tumor regression grading systems.
Topics: Aged; Carcinoma, Pancreatic Ductal; Chemoradiotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Reproducibility of Results; Survival Analysis; Tegafur; Treatment Outcome | 2020 |
Squamous cell carcinoma of the colon - a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Colonic Neoplasms; Deoxycytidine; Gemcitabine; Humans; Male | 2020 |
Metabolic programming of distinct cancer stem cells promotes metastasis of pancreatic ductal adenocarcinoma.
Topics: AC133 Antigen; Aldehyde Dehydrogenase 1 Family; Animals; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Lung Neoplasms; Metabolomics; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Neoplastic Stem Cells; Pancreatic Neoplasms; Retinal Dehydrogenase | 2021 |
Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Topics: Animals; Apoptosis; bcl-X Protein; Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Cyclic N-Oxides; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 5; Cyclin-Dependent Kinase 9; Deoxycytidine; Gastrointestinal Neoplasms; Gemcitabine; Histones; Humans; Indolizines; Inhibitory Concentration 50; Ki-67 Antigen; Male; Mice; Mice, Inbred NOD; Proto-Oncogene Proteins c-bcl-2; Pyridinium Compounds; Xenograft Model Antitumor Assays | 2020 |
Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Carriers; Drug Delivery Systems; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Molecular Structure; Nanoparticles; Pancreatic Neoplasms; Particle Size; Rats; Rats, Wistar; Structure-Activity Relationship | 2020 |
Assessment of efficacy of postinfusion tubing flushing in reducing risk of cytotoxic contamination.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Cytarabine; Decontamination; Deoxycytidine; Gemcitabine; Health Personnel; Humans; Infusions, Parenteral; Occupational Exposure; Paclitaxel | 2020 |
Antimicrobial Peptide Induced-Stress Renders
Topics: Anti-Bacterial Agents; Antimetabolites; Antimicrobial Cationic Peptides; Bacterial Proteins; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Microbial Viability; Nucleosides; Proteome; Staphylococcus aureus; Stress, Physiological; Thioguanine; Uracil | 2020 |
Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation.
Topics: Antiviral Agents; Cell Line; Deoxycytidine; Drug Evaluation, Preclinical; Drug Repositioning; Drug Synergism; Gemcitabine; Gene Expression Regulation; Hepatitis E; Hepatitis E virus; Host Microbial Interactions; Humans; Interferon-alpha; Janus Kinases; Mycophenolic Acid; Phosphorylation; Pyrimidine Nucleosides; Response Elements; Ribavirin; Signal Transduction; STAT1 Transcription Factor; Virus Replication | 2020 |
Treatment patterns in pancreatic cancer patients based on a hospital claims database in Japan.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Databases as Topic; Deoxycytidine; Female; Gemcitabine; Hospitals; Humans; Insurance; Japan; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Efficacy and toxicity of pegylated liposomal doxorubicin as therapy for recurrent ovarian cancer in relation to the number of previous chemotherapy regimens: Comparison with gemcitabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Polyethylene Glycols; Retrospective Studies | 2021 |
New Mechanism of Gemcitabine and Its Phosphates: DNA Polymerization Disruption via 3'-5' Exonuclease Inhibition.
Topics: Base Sequence; Deoxycytidine; DNA; Enzyme Inhibitors; Exonucleases; Gemcitabine; Phosphates; Polymerization | 2020 |
Nicotinamide combined with gemcitabine is an immunomodulatory therapy that restrains pancreatic cancer in mice.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Disease Models, Animal; Female; Gemcitabine; Humans; Immunomodulation; Mice; Niacinamide; Vitamin B Complex | 2020 |
MicroRNA-136-5p regulates gemcitabine resistance in pancreatic cancer via down-regulating ZNF32.
Topics: Antimetabolites, Antineoplastic; Cell Line; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kruppel-Like Transcription Factors; Male; MicroRNAs; Middle Aged; Pancreatic Neoplasms | 2020 |
Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cell- and Tissue-Based Therapy; Cisplatin; Deoxycytidine; Epithelial Cells; Gemcitabine; Humans; Immunotherapy; Lymphocyte Activation; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Microspheres; Swine; T-Lymphocytes; Transplantation, Heterologous; Tumor Burden; Urinary Bladder Neoplasms; Urothelium | 2021 |
The RNA-binding protein MEX3A is a prognostic factor and regulator of resistance to gemcitabine in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Mice, Knockout; Neoplasm Proteins; Neoplasms, Experimental; Pancreatic Neoplasms; Phosphoproteins; Prognosis; RNA-Binding Proteins | 2021 |
Risk factors for gemcitabine plus nab-paclitaxel-induced interstitial lung disease in pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Risk Factors | 2021 |
Characteristic distribution of maculopapular rash caused by gemcitabine-based chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Exanthema; Gemcitabine; Humans | 2021 |
ATM Inhibitor Suppresses Gemcitabine-Resistant BTC Growth in a Polymerase θ Deficiency-Dependent Manner.
Topics: Ataxia Telangiectasia Mutated Proteins; Biliary Tract Neoplasms; Cell Line, Tumor; Deoxycytidine; DNA Polymerase theta; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gemcitabine; Gene Knockdown Techniques; Humans; Protein Kinase Inhibitors | 2020 |
ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Ribonuclease III; Signal Transduction; Sp1 Transcription Factor; Transcriptional Activation; Xenograft Model Antitumor Assays | 2021 |
Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Macrophages; Mice; Neoplasm Metastasis; Pancreatic Neoplasms; Tumor Microenvironment | 2020 |
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Retrospective Studies; Transcriptome | 2021 |
Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blood Platelets; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Leukocyte Count; Lymphocytes; Male; Neoplasm Invasiveness; Neutrophils; Platelet Count; Predictive Value of Tests; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Chemotherapy-induced changes in bronchoalveolar lavage fluid CD4 + and CD8 + cells of the opposite lung to the cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchoalveolar Lavage Fluid; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; Cisplatin; Deoxycytidine; Etoposide; Female; Follow-Up Studies; Gemcitabine; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Prognosis; Prospective Studies; Vinorelbine | 2020 |
Regulation of ABCG2 expression by Wnt5a through FZD7 in human pancreatic cancer cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Correlation of Data; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Female; Frizzled Receptors; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Proteins; Pancreatic Neoplasms; Up-Regulation; Wnt Signaling Pathway; Wnt-5a Protein | 2021 |
Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma.
Topics: Antineoplastic Agents; Bortezomib; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Drug Screening Assays, Antitumor; Gemcitabine; Gene Deletion; Genes, Neoplasm; Humans; Liposarcoma; Male; Middle Aged; Neoplasm Invasiveness | 2021 |
Poly(anhydride-ester) gemcitabine: Synthesis and particle engineering of a high payload hydrolysable polymeric drug for cancer therapy.
Topics: Anhydrides; Animals; Deoxycytidine; Drug Delivery Systems; Esters; Gemcitabine; Humans; Mice; Neoplasms; Pharmaceutical Preparations; Polymers | 2021 |
Chitinase 3-like-1 and fibronectin in the cargo of extracellular vesicles shed by human macrophages influence pancreatic cancer cellular response to gemcitabine.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chitinase-3-Like Protein 1; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Vesicles; Fibronectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Macrophages; Pancreatic Neoplasms; Pentoxifylline; Proteomics; Pyridones; Survival Analysis; Up-Regulation | 2021 |
Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Topics: Animals; Antimetabolites, Antineoplastic; Apolipoprotein E3; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Drug Compounding; Gemcitabine; Gene Transfer Techniques; Humans; Lipids; Liposomes; Male; Mice, Inbred BALB C; Mice, Nude; Mutation; Nanoparticles; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Receptors, LDL; RNA, Small Interfering; RNAi Therapeutics; Xenograft Model Antitumor Assays | 2020 |
Anti-tumor effects and cell motility inhibition of the DN604-gemcitabine combined treatment in human bladder cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Movement; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Structure-Activity Relationship; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2021 |
Pancreatic cancer transcriptomes: molecular stratification in the adjuvant setting.
Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Transcriptome | 2021 |
A G-Quadruplex-Binding Small Molecule and the HDAC Inhibitor SAHA (Vorinostat) Act Synergistically in Gemcitabine-Sensitive and Resistant Pancreatic Cancer Cells.
Topics: Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; G-Quadruplexes; Gemcitabine; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Pancreatic Neoplasms; Small Molecule Libraries; Vorinostat | 2020 |
4Ei-10 interdiction of oncogenic cap-mediated translation as therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Interactions; Eukaryotic Initiation Factor-4E; Gemcitabine; Humans; Lung Neoplasms; Nucleotides; Prodrugs | 2021 |
Antibiotics and Adverse Events in Patients with Pancreatic Cancer Treated with Gemcitabine: Looking for Novel Clinical and Preclinical Insights.
Topics: Anti-Bacterial Agents; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2021 |
pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Hydrogen-Ion Concentration; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Nanoparticles; Pancreatic Neoplasms; Polyethylene Glycols; Polymers; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2021 |
Assessment of the Chemosensitivity of Uveal Melanoma Cells Ex Vivo.
Topics: Adult; Aged; Antineoplastic Agents; Benzeneacetamides; Busulfan; Cell Proliferation; Cell Survival; Choroid Neoplasms; Deoxycytidine; Diterpenes; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Female; Gemcitabine; Humans; Male; Melanoma; Middle Aged; Phenylacetates; Primary Cell Culture; Retinyl Esters; Tumor Cells, Cultured; Uveal Neoplasms; Valproic Acid | 2020 |
Zinc oxide nanoparticles (ZnO NPs) combined with cisplatin and gemcitabine inhibits tumor activity of NSCLC cells.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Lung Neoplasms; Metal Nanoparticles; Mice; Xenograft Model Antitumor Assays; Zinc Oxide | 2020 |
Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Gemcitabine, dexamethasone and cisplatin (GDP) is an effective and well-tolerated mobilization regimen for relapsed and refractory lymphoma: a single center experience
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Transplantation, Autologous; Treatment Outcome | 2021 |
Concerted cell and in vivo screen for pancreatic ductal adenocarcinoma (PDA) chemotherapeutics.
Topics: Acinar Cells; Adenocarcinoma; Animals; Antineoplastic Agents; Calcium; Carcinogenesis; Carcinoma, Pancreatic Ductal; Cell Dedifferentiation; Cell Transformation, Neoplastic; Cells, Cultured; Ceruletide; Deoxycytidine; Disease Progression; Gemcitabine; GTP-Binding Proteins; Histone Deacetylase Inhibitors; Mice; Pancreatic Ducts; Pancreatic Neoplasms; Pancreatitis; Proto-Oncogene Proteins p21(ras); RGS Proteins; Signal Transduction | 2020 |
Checkpoint Kinase 1 Pharmacological Inhibition Synergizes with DNA-Damaging Agents and Overcomes Platinum Resistance in Basal-Like Breast Cancer.
Topics: Apoptosis; Breast Neoplasms; Carboplatin; Caspases; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Cisplatin; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Humans; Neoplasm Invasiveness; Platinum | 2020 |
Midterm follow-up (3 years) confirms and extends short-term results of intravesical gemcitabine as bladder-preserving treatment for non-muscle-invasive bladder cancer after BCG failure.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Retreatment; Time Factors; Treatment Failure; Urinary Bladder Neoplasms | 2021 |
Soluble VCAM-1 promotes gemcitabine resistance via macrophage infiltration and predicts therapeutic response in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Macrophages; Mice; Pancreatic Neoplasms; Prognosis; Vascular Cell Adhesion Molecule-1; Xenograft Model Antitumor Assays | 2020 |
CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; CD40 Antigens; Cell Line, Tumor; Cholangiocarcinoma; Cisplatin; Dendritic Cells; Deoxycytidine; Drug Collateral Sensitivity; Gemcitabine; Immune Checkpoint Inhibitors; Liver Neoplasms; Lymphocytes, Tumor-Infiltrating; Macrophage Activation; Macrophage-Activating Factors; Mice; Mice, Knockout; Tumor Microenvironment | 2021 |
Thermosensitive and biodegradable hydrogel encapsulating targeted nanoparticles for the sustained co-delivery of gemcitabine and paclitaxel to pancreatic cancer cells.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Hydrogels; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Polyethylene Glycols | 2021 |
Decreased drug resistance of bladder cancer using phytochemicals treatment.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Multidrug Resistance-Associated Protein 2; Phytochemicals; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatectomy; Pancreatic Neoplasms; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Survival Rate | 2021 |
Signal transducer and activator of transcription 3 mediates apoptosis inhibition through reducing mitochondrial ROS and activating Bcl-2 in gemcitabine-resistant lung cancer A549 cells.
Topics: A549 Cells; Apoptosis; Cell Nucleus; Cytosol; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Mitochondria; Models, Biological; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; STAT3 Transcription Factor; Up-Regulation | 2021 |
Gemcitabine, cisplatin, and dexamethasone and ifosfamide, carboplatin, and etoposide regimens have similar efficacy as salvage treatment for relapsed/refractory aggressive lymphoma: A retrospectively comparative study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Dexamethasone; Etoposide; Female; Gemcitabine; Hodgkin Disease; Humans; Ifosfamide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Salvage Therapy; Young Adult | 2020 |
Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue.
Topics: Adult; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Sarcoma, Clear Cell; Soft Tissue Neoplasms | 2020 |
Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis.
Topics: Afatinib; Animals; Cell Line, Tumor; Deoxycytidine; ErbB Receptors; Gemcitabine; Hepatocyte Nuclear Factor 3-beta; Humans; Mice; Neoplasm Metastasis; Neoplastic Stem Cells; Pancreatic Neoplasms; SOX9 Transcription Factor | 2021 |
Targeting Mitochondrial Complex I Overcomes Chemoresistance in High OXPHOS Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cell Respiration; Deoxycytidine; Drug Resistance, Neoplasm; Electron Transport Complex I; Female; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mitochondria; Oxidative Phosphorylation; Pancreatic Neoplasms; PC-3 Cells; Phenformin; Xenograft Model Antitumor Assays | 2020 |
Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Deoxycytidine; Female; Gemcitabine; Health Records, Personal; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Pyrimidines; Retrospective Studies; Sarcoma; Sulfonamides; Treatment Outcome; United States; Young Adult | 2021 |
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms | 2021 |
EMT-Induced Gemcitabine Resistance in Pancreatic Cancer Involves the Functional Loss of Equilibrative Nucleoside Transporter 1.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Epithelial-Mesenchymal Transition; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Mice | 2021 |
Pristimerin synergizes with gemcitabine through abrogating Chk1/53BP1-mediated DNA repair in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Repair; Drug Synergism; Gemcitabine; Humans; Pancreatic Neoplasms; Pentacyclic Triterpenes; Tumor Suppressor p53-Binding Protein 1 | 2021 |
High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Pancreatic Neoplasms | 2021 |
Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Genes, ras; Lung Neoplasms; Mice; Molecular Targeted Therapy; Mutation; Neoplasm Transplantation; Pancreatic Neoplasms; Peptides; Rats | 2020 |
Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Galactosyltransferases; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycosylation; Humans; Neoplasm Recurrence, Local; Organoids; Transcription Factor RelA | 2021 |
p38β (MAPK11) mediates gemcitabine-associated radiosensitivity in sarcoma experimental models.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mitogen-Activated Protein Kinase 11; Models, Theoretical; Radiation Tolerance; Sarcoma | 2021 |
Chemotherapy for biliary tract cancer: real-world experience in a single institute.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Practice Patterns, Physicians'; Progression-Free Survival; Retrospective Studies | 2020 |
Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Impact of immunohistochemistry-based molecular subtype on predicting chemotherapy response and survival in patients with T1 stage bladder cancer after bladder-preserving treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Deoxycytidine; Epirubicin; Female; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoplasm Staging; Organ Sparing Treatments; Prognosis; Progression-Free Survival; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Birinapant Enhances Gemcitabine's Antitumor Efficacy in Triple-Negative Breast Cancer by Inducing Intrinsic Pathway-Dependent Apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Dipeptides; Enzyme Inhibitors; Female; Gemcitabine; Humans; Indoles; Mice; Mice, Nude; Triple Negative Breast Neoplasms | 2021 |
Downregulation of GSTM2 enhances gemcitabine chemosensitivity of pancreatic cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic Markers; Glutathione Transferase; Humans; Pancreatic Neoplasms; RNA Interference | 2021 |
Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report.
Topics: Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Acinar Cell; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Male; Mutation; Paclitaxel; Pancreatic Neoplasms | 2021 |
Combined ablation-chemotherapy versus chemotherapy alone for pancreatic cancer with liver metastasis: a propensity score matching study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microwaves; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Propensity Score; Radiofrequency Ablation; Retrospective Studies; Survival Rate; Tegafur; Tumor Burden | 2021 |
S100A16 induces epithelial-mesenchymal transition in human PDAC cells and is a new therapeutic target for pancreatic cancer treatment that synergizes with gemcitabine.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Coculture Techniques; Combined Modality Therapy; Deoxycytidine; Drug Delivery Systems; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Targeting; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; S100 Proteins; Xenograft Model Antitumor Assays | 2021 |
Perihilar clear cell cholangiocarcinoma: an often-diagnostic challenge.
Topics: Adenocarcinoma, Clear Cell; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biopsy; Cholangiography; Cholangiopancreatography, Magnetic Resonance; Cisplatin; Deoxycytidine; Diffusion Magnetic Resonance Imaging; Fatal Outcome; Gemcitabine; Hepatic Duct, Common; Humans; Klatskin Tumor; Male; Palliative Care; Positron Emission Tomography Computed Tomography | 2020 |
Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progression; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Intention to Treat Analysis; Leucovorin; Male; Middle Aged; Oxonic Acid; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Taiwan; Tegafur; Treatment Failure | 2020 |
Social and Clinical Correlates of Neoadjuvant Chemotherapy in Medicare Beneficiaries With Muscle Invasive Bladder Cancer From 2004-2015.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Medicare; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Social Class; United States; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Disease-Free Survival; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Risk Assessment; Risk Factors; Survival Rate | 2020 |
Novel Nonsecosteroidal Vitamin D Receptor Modulator Combined with Gemcitabine Enhances Pancreatic Cancer Therapy through Remodeling of the Tumor Microenvironment.
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Pancreatic Stellate Cells; Receptors, Calcitriol; Tumor Microenvironment | 2021 |
Takotsubo syndrome early after treatment due to non cardiotoxic chemotherapy agents.
Topics: Aged; Antineoplastic Agents; Carcinoma; Cardiotoxicity; Deoxycytidine; Echocardiography; Electrocardiography; Female; Gemcitabine; Humans; Kidney Neoplasms; Myocardial Infarction; Takotsubo Cardiomyopathy; Vinorelbine | 2021 |
Utilization of circulating cell-free DNA profiling to guide first-line chemotherapy in advanced lung squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell-Free Nucleic Acids; Circulating Tumor DNA; Cisplatin; Deoxycytidine; DNA Copy Number Variations; Female; Gemcitabine; Humans; Lung Neoplasms; Machine Learning; Male; Middle Aged; Paclitaxel; Prognosis; Progression-Free Survival; Survival Rate; Treatment Outcome | 2021 |
FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Double-Blind Method; Drug Approval; Gemcitabine; Humans; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Paclitaxel; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms; United States; United States Food and Drug Administration | 2020 |
Synergistic Interactions between GW8510 and Gemcitabine in an In Vitro Model of Pancreatic Cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cell Survival; Computational Biology; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Indoles; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Tumor Cells, Cultured | 2021 |
CC Chemokine Receptor 2-Targeting Copper Nanoparticles for Positron Emission Tomography-Guided Delivery of Gemcitabine for Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Cell Line, Tumor; Copper; Deoxycytidine; Gemcitabine; Mice; Nanoparticles; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, CCR2; Tumor Microenvironment | 2021 |
Effects of ER-resident and secreted AGR2 on cell proliferation, migration, invasion, and survival in PANC-1 pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Endoplasmic Reticulum Stress; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mucoproteins; Neoplasm Invasiveness; Oncogene Proteins; Pancreatic Neoplasms; Proto-Oncogene Mas; Tumor Cells, Cultured | 2021 |
HDAC6 inhibitor, ACY1215 suppress the proliferation and induce apoptosis of gallbladder cancer cells and increased the chemotherapy effect of gemcitabine and oxaliplatin.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Gallbladder Neoplasms; Gemcitabine; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Humans; Oxaliplatin; Tumor Cells, Cultured | 2021 |
[A case of advanced pancreatic cancer with oculomotor nerve palsy caused by herpes zoster after introduction of gemcitabine plus nab-paclitaxel].
Topics: Acyclovir; Aged; Albumins; Antiviral Agents; Deoxycytidine; Female; Gemcitabine; Humans; Oculomotor Nerve Diseases; Paclitaxel; Pancreatic Neoplasms | 2021 |
Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma.
Topics: Bone Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Humans; Neoplasm Proteins; Osteosarcoma | 2021 |
STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Calcium; Calcium Signaling; Carcinoma, Pancreatic Ductal; Cell Nucleus; Cell Proliferation; Cytosol; Deoxycytidine; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Epigenesis, Genetic; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Stromal Interaction Molecule 1; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Long non-coding RNA LINC00665 promotes gemcitabine resistance of Cholangiocarcinoma cells via regulating EMT and stemness properties through miR-424-5p/BCL9L axis.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; MicroRNAs; Middle Aged; Neoplastic Stem Cells; RNA, Long Noncoding; Transcription Factors | 2021 |
Investigations of potent biocompatible metal-organic framework for efficient encapsulation and delivery of Gemcitabine: biodistribution, pharmacokinetic and cytotoxicity study.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biocompatible Materials; Cell Proliferation; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Male; Metal-Organic Frameworks; Pancreatic Neoplasms; Rats, Wistar; Tissue Distribution; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
A MET Targeting Antibody-Drug Conjugate Overcomes Gemcitabine Resistance in Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunoconjugates; Male; Mice; Pancreatic Neoplasms; Proto-Oncogene Proteins c-met; Xenograft Model Antitumor Assays | 2021 |
KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer.
Topics: Apoptosis; Carcinogenesis; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Microtubule-Associated Proteins; Oncogene Protein v-akt; Phosphorylation; Urinary Bladder Neoplasms | 2021 |
Design, synthesis, and evaluation of liver-specific gemcitabine prodrugs for potential treatment of hepatitis C virus infection and hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Gemcitabine; Hepacivirus; Hepatitis C; Humans; Liver Neoplasms; Microbial Sensitivity Tests; Molecular Structure; Prodrugs; Structure-Activity Relationship; Virus Replication | 2021 |
Clinical significance of skeletal muscle density and sarcopenia in patients with pancreatic cancer undergoing first-line chemotherapy: a retrospective observational study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Muscle, Skeletal; Palliative Care; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies; Sarcopenia; Tomography, X-Ray Computed | 2021 |
Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Adult; Aged; Albumins; Alleles; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Cytidine Deaminase; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Genotype; Glucuronosyltransferase; Humans; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Pancreatic Neoplasms; Pharmacogenomic Testing; Polymorphism, Genetic | 2021 |
[Nab-Paclitaxel plus Gemcitabine for Patients with Recurrence after Resection for Adenocarcinoma of the Pancreas].
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2021 |
[A Case of Ipsilateral Breast Tumor Recurrence(IBTR)after Breast-Conserving Surgery Which Successfully Resected after Chemotherapy Using Carboplatin plus Gemcitabine].
Topics: Adult; Breast Neoplasms; Carboplatin; Deoxycytidine; Female; Gemcitabine; Humans; Mastectomy; Mastectomy, Segmental; Neoplasm Recurrence, Local | 2020 |
[A Case of Gallbladder Cancer with Para-Aortic Lymph Node Metastasis Successfully Treated by Gemcitabine plus Cisplatin Combination Chemotherapy and Conversion Surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2020 |
[A Case of Initially Locally Advanced Pancreatic Cancer Curatively Resected after Carbon-Ion Radiotherapy with Gemcitabine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carbon; Deoxycytidine; Gemcitabine; Humans; Male; Neoadjuvant Therapy; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography | 2020 |
The impact of body composition on short-term outcomes of neoadjuvant chemotherapy with gemcitabine plus S-1 in patients with resectable pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Pancreatic Neoplasms; Retrospective Studies; Risk Factors; Sarcopenia; Tegafur; Treatment Outcome | 2021 |
Injectable Hyaluronic Acid Hydrogel for the Co-Delivery of Gemcitabine Nanoparticles and Cisplatin for Malignant Ascites Therapy.
Topics: Animals; Ascites; Cell Line, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Hyaluronic Acid; Hydrogels; Mice; Mice, Inbred BALB C; Nanoparticles; Quality of Life | 2020 |
A source of hope for platinum-resistant ovarian cancer?
Topics: Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Pyrazoles; Pyrimidinones | 2021 |
MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; ErbB Receptors; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Membrane Transport Proteins; Mice; Mucin-4; Neoplasm Transplantation; Pancreatic Neoplasms; Polysaccharides | 2021 |
Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Gene Silencing; Humans; Mice; Pancreatic Neoplasms; Pancreatic Stellate Cells; RNA-Binding Proteins; RNA, Small Interfering; Stromal Cells; Tumor Cells, Cultured | 2021 |
Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinom
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Induction Chemotherapy; Male; Middle Aged; Nasopharyngeal Carcinoma; Progression-Free Survival; Prospective Studies; Treatment Outcome; Young Adult | 2021 |
New and old treatments for malignant mesothelioma: not just immunotherapy.
Topics: Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Mesothelioma, Malignant; Pleural Neoplasms | 2021 |
Immune monitoring in mesothelioma patients identifies novel immune-modulatory functions of gemcitabine associating with clinical response.
Topics: Antimetabolites, Antineoplastic; Cytokines; Deoxycytidine; Gemcitabine; Humans; Immunomodulation; Immunosuppressive Agents; Killer Cells, Natural; Leukocytes, Mononuclear; Lymphocyte Activation; Mesothelioma; Monitoring, Immunologic; Myeloid-Derived Suppressor Cells; Prognosis; Treatment Outcome | 2021 |
Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Fanconi Anemia Complementation Group N Protein; Female; Fluorouracil; Gemcitabine; Genes, BRCA1; Genes, BRCA2; Genomic Instability; Germ-Line Mutation; Homologous Recombination; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Recombinational DNA Repair; Sensitivity and Specificity; Survival Rate; Tumor Suppressor Protein p53; Whole Genome Sequencing | 2021 |
[Intravesical Gemcitabine instillations following BCG failure and allergy to Mitomycin: A unique case of a patient with an inverted papilloma of the bladder].
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Gemcitabine; Humans; Hypersensitivity; Mitomycin; Papilloma, Inverted; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
Externally Triggered Novel Rapid-Release Sonosensitive Folate-Modified Liposomes for Gemcitabine: Development and Characteristics.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Drug Liberation; Endocytosis; Female; Folic Acid; Gemcitabine; Humans; Liposomes; Ovarian Neoplasms; Particle Size; Rats, Sprague-Dawley; Tissue Distribution; Ultrasonics | 2021 |
Clinical relevance of CD70 expression in resected pancreatic cancer: Prognostic value and therapeutic potential.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; CD27 Ligand; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Real-Time Polymerase Chain Reaction; Retrospective Studies; Survival Analysis | 2021 |
Co-encapsulation of gemcitabine and tocotrienols in nanovesicles enhanced efficacy in pancreatic cancer.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms; Tocotrienols | 2021 |
mTOR modulates resistance to gemcitabine in lung cancer in an MTORC2 dependent mechanism.
Topics: A549 Cells; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; MAP Kinase Signaling System; MCF-7 Cells; Mechanistic Target of Rapamycin Complex 2; Neoplasm Proteins; TOR Serine-Threonine Kinases | 2021 |
WEE1 inhibition after platinum resistance.
Topics: Cell Cycle Proteins; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Ovarian Neoplasms; Platinum; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidinones | 2021 |
Surface peptide functionalization of zeolitic imidazolate framework-8 for autonomous homing and enhanced delivery of chemotherapeutic agent to lung tumor cells.
Topics: Antineoplastic Agents; Cell Line; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Imidazoles; Lung Neoplasms; Metal-Organic Frameworks; Nanoparticles; Oligopeptides; Surface Properties; Zeolites | 2021 |
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Deoxycytidine Kinase; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Meningeal Neoplasms; Meningioma; Pancreatic Neoplasms | 2021 |
Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Animals; Antiviral Agents; Cell Line; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Inhibitory Concentration 50; SARS-CoV-2; Vero Cells; Virus Replication | 2021 |
Gemcitabine-Containing Chemotherapy for the Treatment of Metastatic Myxofibrosarcoma Refractory to Doxorubicin: A Case Series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Neoplasm Recurrence, Local; Retrospective Studies | 2021 |
PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer.
Topics: Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Membrane Proteins; MicroRNAs; Pancreatic Neoplasms; RNA, Long Noncoding; Signal Transduction | 2021 |
Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Curcumin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; PTEN Phosphohydrolase; RNA, Long Noncoding; Signal Transduction; Tumor Cells, Cultured | 2021 |
Fam83D promotes tumorigenesis and gemcitabine resistance of pancreatic adenocarcinoma through the Wnt/β-catenin pathway.
Topics: Adenocarcinoma; Aged; Animals; Carcinogenesis; Cell Cycle Proteins; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Microtubule-Associated Proteins; Middle Aged; Pancreatic Neoplasms; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2021 |
Identification of PARP-1 in cancer stem cells of gastrointestinal cancers: A preliminary study.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gastrointestinal Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Irinotecan; Liver Neoplasms; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Xenograft Model Antitumor Assays | 2021 |
S100A14 promotes progression and gemcitabine resistance in pancreatic cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blotting, Western; Calcium-Binding Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Staging; Pancreatic Neoplasms; Random Allocation; Reverse Transcriptase Polymerase Chain Reaction; S100 Proteins; Tissue Array Analysis; Up-Regulation | 2021 |
Evaluation of the significance of adjuvant chemotherapy in patients with stage ⅠA pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Retrospective Studies; Tegafur; Treatment Outcome | 2021 |
Calreticulin: a potential diagnostic and therapeutic biomarker in gallbladder cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Calreticulin; Cell Line, Tumor; Cholecystitis; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Oncogenes; Prognosis; Random Allocation; Xenograft Model Antitumor Assays | 2021 |
Engineering of gemcitabine coated nano-graphene oxide sheets for efficient near-infrared radiation mediated in vivo lung cancer photothermal therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Deoxycytidine; Female; Gemcitabine; Graphite; Humans; Infrared Rays; Lung Neoplasms; Male; Mice; Neoplasms, Experimental; Photothermal Therapy | 2021 |
Long-Term Survival Outcomes of Metabolically Supported Chemotherapy with Gemcitabine-Based or FOLFIRINOX Regimen Combined with Ketogenic Diet, Hyperthermia, and Hyperbaric Oxygen Therapy in Metastatic Pancreatic Cancer: A Letter to the Editor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diet, Ketogenic; Fluorouracil; Gemcitabine; Humans; Hyperbaric Oxygenation; Hyperthermia; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2021 |
Targeting B cells in pancreatic adenocarcinoma: does RESOLVE resolve the question?
Topics: Adenine; Adenocarcinoma; Albumins; B-Lymphocytes; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Piperidines | 2021 |
Identification of laminin γ2 as a prognostic and predictive biomarker for determining response to gemcitabine-based therapy in pancreatic ductal adenocarcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Gene Expression Profiling; Humans; Laminin; Male; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2021 |
Quality control of cytostatic drug preparations-comparison of workflow and performance of Raman/UV and high-performance liquid chromatography coupled with diode array detection (HPLC-DAD).
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Cyclophosphamide; Cytostatic Agents; Deoxycytidine; Drug Compounding; Drug Stability; Drug Storage; Fluorouracil; Gemcitabine; Irinotecan; Quality Control; Spectrophotometry, Ultraviolet; Spectrum Analysis, Raman; Workflow | 2021 |
LAMC2 promotes cancer progression and gemcitabine resistance through modulation of EMT and ATP-binding cassette transporters in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Apoptosis; ATP-Binding Cassette Transporters; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Laminin; Male; Middle Aged; Prognosis | 2021 |
Bladder cancer cell-intrinsic PD-L1 signals promote mTOR and autophagy activation that can be inhibited to improve cytotoxic chemotherapy.
Topics: Animals; Antibiotics, Antineoplastic; Autophagy; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Neoplasm Metastasis; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Sirolimus; Urinary Bladder Neoplasms | 2021 |
H2A.Z overexpression suppresses senescence and chemosensitivity in pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aging; Animals; beta-Galactosidase; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Cyclin-Dependent Kinase Inhibitor p16; Deoxycytidine; DNA Damage; DNA Methylation; DNA Repair; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Heterografts; Histones; Humans; Mice | 2021 |
TRIM11 suppresses ferritinophagy and gemcitabine sensitivity through UBE2N/TAX1BP1 signaling in pancreatic ductal adenocarcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Female; Ferroptosis; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Pancreatic Neoplasms; Signal Transduction; Tripartite Motif Proteins; Tumor Burden; Ubiquitin-Conjugating Enzymes; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2021 |
A bladder cancer patient-derived xenograft displays aggressive growth dynamics in vivo and in organoid culture.
Topics: Animals; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Male; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Organoids; Urinary Bladder Neoplasms | 2021 |
Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cell Adhesion; Cell Aggregation; Cell Division; Cell Movement; Cell Self Renewal; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; GPI-Linked Proteins; Humans; Mesothelin; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Proteins; Neoplastic Stem Cells; Organ Size; Pancreatic Neoplasms; Peritoneal Neoplasms; Peritoneum; Peritonitis | 2021 |
Danggui Buxue Decoction enhances the anticancer activity of gemcitabine and alleviates gemcitabine-induced myelosuppression.
Topics: A549 Cells; Animals; Antineoplastic Agents; Bone Marrow; Cytokines; Deoxycytidine; Drug Synergism; Drugs, Chinese Herbal; Gemcitabine; Gene Expression Regulation; Humans; Mice; Mice, Nude; Neoplasms, Experimental | 2021 |
Catechol enhances chemo‑ and radio‑sensitivity by targeting AMPK/Hippo signaling in pancreatic cancer cells.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Apoptosis; Catechols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphorylation; Radiation Tolerance; Signal Transduction; Transcription Factors; YAP-Signaling Proteins | 2021 |
GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer.
Topics: Aged; Animals; B7-H1 Antigen; Biomarkers, Tumor; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Lymphocytes, Tumor-Infiltrating; Male; Mice; Middle Aged; Nuclear Proteins; Prognosis; Signal Transduction; Zinc Finger Protein Gli2 | 2021 |
Suppression of Wnt/β-catenin and RAS/ERK pathways provides a therapeutic strategy for gemcitabine-resistant pancreatic cancer.
Topics: beta Catenin; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Deoxycytidine; Gemcitabine; Humans; MAP Kinase Signaling System; Neoplasm Metastasis; Pancreatic Neoplasms; Proteolysis; Proto-Oncogene Proteins p21(ras); ras Proteins; Thiazolidines; Wnt Signaling Pathway | 2021 |
Trimetazidine alone or in combination with gemcitabine and/or abraxane decreased cell viability, migration and ATP levels and induced apoptosis of human pancreatic cells.
Topics: Adenosine Triphosphate; Albumin-Bound Paclitaxel; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome; Trimetazidine | 2021 |
Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft Models.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Ketoglutarate Dehydrogenase Complex; Mice; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases | 2021 |
Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Glomerular Filtration Rate; Humans; Male; Middle Aged; Prognosis; Renal Insufficiency, Chronic; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms | 2021 |
Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; Chemotherapy, Adjuvant; Cisplatin; Dendritic Cells; Deoxycytidine; Gemcitabine; Gene Expression Profiling; Humans; Immune Checkpoint Inhibitors; Immunohistochemistry; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Lymphocytes, Tumor-Infiltrating; Male; Middle Aged; Neoadjuvant Therapy; Pneumonectomy; RNA-Seq; Transcriptome; Treatment Outcome; Tumor Burden; Tumor Microenvironment; Tumor-Associated Macrophages | 2021 |
pH-Sensitive Nanoparticles Composed Solely of Membrane-Disruptive Macromolecules for Treating Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Delayed-Action Preparations; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Hydrogen-Ion Concentration; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; NIH 3T3 Cells; Pancreatic Neoplasms | 2021 |
Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution.
Topics: Albumins; China; Deoxycytidine; Gemcitabine; Humans; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2020 |
Neoadjuvant chemotherapy is associated with improved survival in patients undergoing hepatic resection for intrahepatic cholangiocarcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Graft Survival; Hepatectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Retrospective Studies | 2021 |
Evaluation of Loading Strategies to Improve Tumor Uptake of Gemcitabine in a Murine Orthotopic Bladder Cancer Model Using Ultrasound and Microbubbles.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Disease Models, Animal; Drug Delivery Systems; Female; Gemcitabine; Mice; Mice, Nude; Microbubbles; Tumor Cells, Cultured; Ultrasonic Therapy; Urinary Bladder Neoplasms | 2021 |
Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; JNK Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; RNA-Binding Proteins | 2021 |
The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
Topics: Adenosylhomocysteinase; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Proliferation; Cell Transformation, Neoplastic; Cholangiocarcinoma; Co-Repressor Proteins; Cyclic AMP Response Element-Binding Protein A; Deoxycytidine; Fetal Proteins; Gemcitabine; Gene Fusion; Liver Neoplasms, Experimental; Mice; Microtubule-Associated Proteins; Mutation; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrimidines; Receptor, Fibroblast Growth Factor, Type 2; Vesicular Transport Proteins | 2021 |
Ultrasound-Mediated Gemcitabine Delivery Reduces the Normal-Tissue Toxicity of Chemoradiation Therapy in a Muscle-Invasive Bladder Cancer Model.
Topics: Animals; Antimetabolites, Antineoplastic; Biotinylation; Cell Line, Tumor; Chemoradiotherapy; Contrast Media; Deoxycytidine; Female; Gemcitabine; Humans; Intestines; Mice; Mice, Nude; Microbubbles; Neoplasm Invasiveness; Organs at Risk; Radiation Injuries; Tumor Burden; Ultrasonography; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Veterans | 2021 |
Comparison of clinical outcomes in patients with localized or locally advanced urothelial carcinoma treated with neoadjuvant chemotherapy involving gemcitabine-cisplatin and high dose-intensity MVAC.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2021 |
Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy.
Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult | 2021 |
Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; Platinum; Polymorphism, Single Nucleotide | 2021 |
Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bile Duct Neoplasms; Biomarkers, Tumor; Cholangiocarcinoma; Deoxycytidine; Female; Gallbladder Neoplasms; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Palliative Care; Platinum; Prognosis; Survival Analysis; Treatment Outcome | 2021 |
A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patients.
Topics: Aged; Databases, Nucleic Acid; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Male; Middle Aged; Pancreatic Neoplasms; Survival Rate | 2021 |
Chk1 inhibition induces a DNA damage bystander effect in cocultured tumour cells.
Topics: Ataxia Telangiectasia Mutated Proteins; Bystander Effect; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 1; Coculture Techniques; Deoxycytidine; DNA; DNA Damage; DNA-Activated Protein Kinase; Gemcitabine; Histones; HT29 Cells; Humans; Jurkat Cells; Neoplasms; Protein Kinase Inhibitors; Signal Transduction | 2021 |
Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Endocytosis; Endosomes; Epithelial Cell Adhesion Molecule; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Tumor Burden; Xenograft Model Antitumor Assays | 2021 |
LC-MS/MS method for quantitation of gemcitabine and its metabolite 2',2'-difluoro-2'-deoxyuridine in mouse plasma and brain tissue: Application to a preclinical pharmacokinetic study.
Topics: Animals; Brain; Chromatography, High Pressure Liquid; Chromatography, Liquid; Deoxycytidine; Floxuridine; Gemcitabine; Mice; Reproducibility of Results; Tandem Mass Spectrometry | 2021 |
Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
Topics: Deoxycytidine; Gemcitabine; Kinetics; Pancreatic Neoplasms; Protein Kinase Inhibitors | 2021 |
Synergistic effect of the herbal mixture C5E on gemcitabine treatment in PANC‑1 cells.
Topics: Annexin A5; Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Fluorescein-5-isothiocyanate; Gemcitabine; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Herbal Medicine; Humans; Pancreatic Neoplasms; Plant Extracts | 2021 |
Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Oxaliplatin; Retrospective Studies; Rituximab; Transplantation, Autologous; Treatment Outcome; Young Adult | 2021 |
Dual Gate-Controlled Therapeutics for Overcoming Bacterium-Induced Drug Resistance and Potentiating Cancer Immunotherapy.
Topics: Animals; Anti-Bacterial Agents; Antimetabolites, Antineoplastic; Cell Line; Ciprofloxacin; Colonic Neoplasms; Deoxycytidine; Drug Resistance, Bacterial; Escherichia coli; Gemcitabine; Humans; Mice | 2021 |
Structural Effects of Incorporation of 2'-Deoxy-2'2'-Difluorodeoxycytidine (Gemcitabine) in A- and B-Form Duplexes.
Topics: Deoxycytidine; DNA; Gemcitabine; Nucleic Acid Conformation; RNA | 2021 |
Impact of paclitaxel, cisplatin, and gemcitabine as first-line chemotherapy in cisplatin-fit and -unfit patients with advanced/metastatic urothelial carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Retrospective Studies; Survival Analysis; Urinary Bladder Neoplasms | 2021 |
Cancer-associated fibroblasts-mediated ATF4 expression promotes malignancy and gemcitabine resistance in pancreatic cancer via the TGF-β1/SMAD2/3 pathway and ABCC1 transactivation.
Topics: Activating Transcription Factor 4; Cancer-Associated Fibroblasts; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Transforming Growth Factor beta1; Tumor Microenvironment | 2021 |
Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26.
Topics: Aged; Antigens, CD; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Karyotyping; Mutation; Octamer Transcription Factor-3; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Tumor Suppressor Protein p53 | 2021 |
First-line Gemcitabine
Topics: Adult; Aged; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Metastasis; Physicians; Prospective Studies; Quality of Life; Treatment Failure | 2021 |
[Clinical Application of Gemcitabine plus Cisplatin plus Bevacizumab Combination Chemotherapy for Ovarian Clear Cell Carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms | 2021 |
Tailored adjuvant gemcitabine versus 5-fluorouracil/folinic acid based on hENT1 immunohistochemical staining in resected pancreatic ductal adenocarcinoma: A biomarker stratified prospective trial.
Topics: Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Fluorouracil; Gemcitabine; Humans; Leucovorin; Pancreatic Neoplasms; Prospective Studies; Staining and Labeling | 2021 |
Gemcitabine Lipid Prodrugs: The Key Role of the Lipid Moiety on the Self-Assembly into Nanoparticles.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colloids; Deoxycytidine; Gemcitabine; Humans; Hydrophobic and Hydrophilic Interactions; Lipids; Nanoparticles; Powder Diffraction; Prodrugs | 2021 |
AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer.
Topics: Animals; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Plasticity; Deoxycytidine; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Male; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Pancreatic Neoplasms; Proto-Oncogene Proteins; Receptor Protein-Tyrosine Kinases; Tumor Microenvironment | 2021 |
Treatment and Visualization of Pancreatic Ductal Adenocarcinoma through Actively Targeted Copper 64 Nanoparticles.
Topics: Copper Radioisotopes; Deoxycytidine; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms; Positron-Emission Tomography; Receptors, CCR2; Tomography, X-Ray Computed | 2021 |
Impact of adverse events of adjuvant and neoadjuvant chemotherapies on outcomes of patients with pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Survival Rate | 2021 |
Drug-eluting bead bronchial arterial chemoembolization vs. chemotherapy in treating advanced non-small cell lung cancer: comparison of treatment efficacy, safety and quality of life.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemoembolization, Therapeutic; Cohort Studies; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quality of Life; Retrospective Studies; Surveys and Questionnaires | 2021 |
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Tegafur | 2021 |
Abdominal Wall Metastasis of Pancreatic Cancer: The Tip of the Iceberg-Case Report.
Topics: Abdominal Wall; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasm Metastasis; Paclitaxel; Pancreatic Neoplasms; Tomography, X-Ray Computed | 2021 |
Everolimus regulates the activity of gemcitabine-resistant pancreatic cancer cells by targeting the Warburg effect via PI3K/AKT/mTOR signaling.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Everolimus; Gemcitabine; Glucose; Humans; Lactic Acid; Male; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy.
Topics: Aged; Aged, 80 and over; Deoxycytidine; Disease Progression; Dose-Response Relationship, Radiation; Female; Gemcitabine; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Radiation Pneumonitis; Radiotherapy; Retrospective Studies; Risk Factors; Thorax; Treatment Outcome | 2021 |
Noncovalent molecular interactions between antineoplastic drug gemcitabine and a carrier protein identified through spectroscopic and in silico methods.
Topics: Antineoplastic Agents; Binding Sites; Deoxycytidine; Gemcitabine; Molecular Docking Simulation; Muramidase; Protein Binding | 2021 |
The prognostic impact of circulating miRNAs in patients with advanced esophagogastric cancer during palliative chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II as Topic; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Female; Folic Acid; Gemcitabine; Humans; Male; MicroRNAs; Middle Aged; Palliative Care; Prognosis; Progression-Free Survival; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate | 2021 |
Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Clinical Decision-Making; Deoxycytidine; Disease Progression; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Logistic Models; Lymphocytes; Male; Middle Aged; Neutrophils; Oxaliplatin; Oxaloacetates; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Time Factors | 2021 |
Precise engineering of hybrid molecules-loaded macromolecular nanoparticles shows
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Chemistry, Pharmaceutical; Cisplatin; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Nanoparticles; Nasopharyngeal Neoplasms; Polylactic Acid-Polyglycolic Acid Copolymer; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
An Amphiphilic PEGylated Peptide Dendron-Gemcitabine Prodrug-Based Nanoagent for Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Dendrimers; Deoxycytidine; Gemcitabine; Nanoparticles; Neoplasms; Peptides; Polyethylene Glycols; Prodrugs | 2021 |
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Deoxycytidine; Female; Fluorouracil; Forkhead Transcription Factors; Gemcitabine; Hepatitis A Virus Cellular Receptor 2; Humans; Immune Checkpoint Proteins; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pilot Projects; Programmed Cell Death 1 Receptor; Progression-Free Survival; Prospective Studies; T-Lymphocytes, Regulatory | 2021 |
CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Quinazolines; Signal Transduction | 2021 |
Micelle-contained and PEGylated hybrid liposomes of combined gemcitabine and cisplatin delivery for enhancing antitumor activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liposomes; Micelles; Polyethylene Glycols | 2021 |
Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Deoxycytidine; Drug Synergism; Gemcitabine; Liver Neoplasms; Male; Mesothelin; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Internationality; Kaplan-Meier Estimate; Male; Methotrexate; Middle Aged; Muscle, Smooth; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Risk Factors; Time Factors; Urinary Bladder; Urinary Bladder Neoplasms; Vinblastine | 2021 |
Inhibition of the Receptor for Advanced Glycation End Products Enhances the Cytotoxic Effect of Gemcitabine in Murine Pancreatic Tumors.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Autophagy; Cell Line, Tumor; Cell Survival; Deoxycytidine; Gemcitabine; HMGB1 Protein; Mice; Microtubule-Associated Proteins; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerases; Receptor for Advanced Glycation End Products; Transplantation, Homologous | 2021 |
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compounds; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Diabetes Mellitus; Dietary Supplements; Disease Progression; Doxorubicin; Female; Fluorouracil; Gemcitabine; Glycogen Synthase Kinase 3 beta; Glycolysis; Humans; Inhibitory Concentration 50; Malaria; MCF-7 Cells; Metformin; Molecular Targeted Therapy; Neoplasm Metastasis; Nitrophenols; Pancreatic Neoplasms; Piperazines; Protein Kinase Inhibitors; Signal Transduction; Sulfonamides; Thiadiazoles; Tumor Stem Cell Assay | 2021 |
Knockdown of RRM1 with Adenoviral shRNA Vectors to Inhibit Tumor Cell Viability and Increase Chemotherapeutic Sensitivity to Gemcitabine in Bladder Cancer Cells.
Topics: Adenoviridae; Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genetic Vectors; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Ribonucleoside Diphosphate Reductase; RNA, Small Interfering; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2021 |
The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Adhesion; Cell Proliferation; Cisplatin; Deoxycytidine; DNA Methylation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Basal Cell; Prognosis; Promoter Regions, Genetic; Proteinase Inhibitory Proteins, Secretory; Retrospective Studies; Survival Rate; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2021 |
Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels.
Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Prognosis | 2021 |
Polymer coated gold nanoshells for combinational photochemotherapy of pancreatic cancer with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Screening Assays, Antitumor; Gemcitabine; Gold; Humans; Nanoshells; Pancreatic Neoplasms; Photochemotherapy; Polymers | 2021 |
Suppression of lysosomal acid alpha-glucosidase impacts the modulation of transcription factor EB translocation in pancreatic cancer.
Topics: alpha-Glucosidases; Animals; Autophagy; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Lysosomes; Male; Mice; Mice, Nude; Pancreatic Neoplasms; RNA, Small Interfering; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Zebularine suppressed gemcitabine-induced senescence and improved the cellular and plasma pharmacokinetics of gemcitabine, augmented by liposomal co-delivery.
Topics: Animals; Cell Line, Tumor; Cytidine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Liposomes; Pancreatic Neoplasms; Rats | 2021 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Neoplasm Recurrence, Local; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Treatment Outcome | 2021 |
Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Topics: Adult; Aged; Aged, 80 and over; Antigens, Tumor-Associated, Carbohydrate; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Young Adult | 2021 |
Procaspase-Activating Compound-1 Synergizes with TRAIL to Induce Apoptosis in Established Granulosa Cell Tumor Cell Line (KGN) and Explanted Patient Granulosa Cell Tumor Cells In Vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Female; Gemcitabine; Granulosa Cell Tumor; Humans; Hydrazones; In Vitro Techniques; Mathematical Concepts; Models, Biological; Ovarian Neoplasms; Piperazines; TNF-Related Apoptosis-Inducing Ligand | 2021 |
PEG-PEI-modified gated N-doped mesoporous carbon nanospheres for pH/NIR light-triggered drug release and cancer phototherapy.
Topics: Antineoplastic Agents; Apoptosis; Biocompatible Materials; Carbon; Cell Line, Tumor; Click Chemistry; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Humans; Hydrogen-Ion Concentration; Infrared Rays; Nanospheres; Nitrobenzenes; Oxidation-Reduction; Photochemotherapy; Photolysis; Photosensitizing Agents; Polyethylene Glycols; Polyethyleneimine; Porosity; Reactive Oxygen Species; Surface Properties; Temperature; Time Factors | 2021 |
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Austria; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Progression-Free Survival; Propensity Score; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors | 2021 |
Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Lymph Nodes; Male; Middle Aged; Neoadjuvant Therapy; Oxaliplatin; Pancreatectomy; Pancreatic Neoplasms; Pancreaticoduodenectomy; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Survival Rate; Tumor Burden | 2021 |
A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Compounding; Drug Delivery Systems; Drug Stability; Female; Gemcitabine; Humans; Liposomes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Pancreatic Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2021 |
Impact of histological response after neoadjuvant therapy on podocalyxin as a prognostic marker in pancreatic cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gemcitabine; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm, Residual; Pancreas; Pancreatectomy; Pancreatic Neoplasms; Prognosis; Progression-Free Survival; Retrospective Studies; Risk Assessment; Sialoglycoproteins | 2021 |
Gene-Gene Interactions of Gemcitabine Metabolizing-Enzyme Genes hCNT3 and WEE1 for Preventing Severe Gemcitabine-Induced Hematological Toxicity.
Topics: Aged; Antimetabolites, Antineoplastic; Cell Cycle Proteins; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Logistic Models; Male; Membrane Transport Proteins; Middle Aged; Patient Acuity; Polymorphism, Single Nucleotide; Protein-Tyrosine Kinases | 2021 |
Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Propensity Score | 2021 |
[Gemcitabine and Docetaxel for the Treatment of Relapsed and Refractory Malignant Rhabdoid Tumor of Kidney and Atypical Teratoid Rhabdoid Tumor].
Topics: Deoxycytidine; Docetaxel; Gemcitabine; Humans; Kidney; Rhabdoid Tumor; SMARCB1 Protein; Teratoma | 2021 |
Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Female; Gemcitabine; Humans; Kidney; Lymphoma, T-Cell; Middle Aged; Thrombotic Microangiopathies | 2021 |
Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; Gemcitabine; Humans; Mice, Inbred BALB C; Mice, Nude; Necrosis; Pyrazoles; Pyrimidines; Tumor Stem Cell Assay; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2021 |
A gemcitabine-based conjugate with enhanced antitumor efficacy by suppressing HIF-1α expression under hypoxia.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Female; Gemcitabine; Hepatocytes; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Oxygen | 2021 |
MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Up-Regulation | 2021 |
Exosomes secreted from cancer-associated fibroblasts elicit anti-pyrimidine drug resistance through modulation of its transporter in malignant lymphoma.
Topics: Animals; Antimetabolites, Antineoplastic; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Proliferation; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative-Nucleoside Transporter 2; Exosomes; Gemcitabine; Humans; Lymphoma; Male; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Primary Cell Culture; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Groin Pain After Gemcitabine for Lung Cancer.
Topics: Deoxycytidine; Gemcitabine; Groin; Humans; Lung Neoplasms; Pain | 2021 |
Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer.
Topics: Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Chondroitinases and Chondroitin Lyases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Histone Acetyltransferases; Humans; Hyaluronoglucosaminidase; Mice; Prognosis; Treatment Failure; Urinary Bladder Neoplasms | 2021 |
Synthesis of a gemcitabine-modified phospholipid and its subsequent incorporation into a single microbubble formulation loaded with paclitaxel for the treatment of pancreatic cancer using ultrasound-targeted microbubble destruction.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Female; Gemcitabine; Humans; Male; Mice; Microbubbles; Nanoparticles; Paclitaxel; Pancreatic Neoplasms; Phospholipids; Ultrasonic Waves; Xenograft Model Antitumor Assays | 2021 |
A triple combination gemcitabine + romidepsin + cisplatin to effectively control triple-negative breast cancer tumor development, recurrence, and metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Depsipeptides; Epithelial-Mesenchymal Transition; Female; Gemcitabine; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Reactive Oxygen Species; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Proliferation; Deoxycytidine; DNA Replication; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Isoxazoles; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Pyrazines; Pyrazoles; Small Cell Lung Carcinoma; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
In vitro assessment of a synergistic combination of gemcitabine and zebularine in pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cytidine; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Pancreas; Pancreatic Neoplasms | 2021 |
Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach.
Topics: Cell Culture Techniques; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; HeLa Cells; High-Throughput Screening Assays; Humans; MCF-7 Cells; Neoplasms; Nocodazole; Piperazines; Pyridines; Small Molecule Libraries; Time Factors; Tubulin Modulators | 2021 |
Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Immunological; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Lung Neoplasms; Magnesium; Magnesium Deficiency; Male | 2021 |
Novel Seleno-Aspirinyl Compound AS-10 Induces Apoptosis, G1 Arrest of Pancreatic Ductal Adenocarcinoma Cells, Inhibits Their NF-κB Signaling, and Synergizes with Gemcitabine Cytotoxicity.
Topics: Acetylcysteine; Adenocarcinoma; Apoptosis; Aspirin; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Cell Proliferation; Cytokines; Deoxycytidine; Enzyme Activation; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inflammation Mediators; NF-kappa B; Pancreatic Neoplasms; Signal Transduction; Transcriptome | 2021 |
Plasmalemma vesicle-associated protein promotes angiogenesis in cholangiocarcinoma via the DKK1/CKAP4/PI3K signaling pathway.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cisplatin; Cytoskeleton; Deoxycytidine; Endothelial Cells; Female; Gemcitabine; Human Umbilical Vein Endothelial Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Membrane Proteins; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2021 |
Gemcitabine-loaded microbubble system for ultrasound imaging and therapy.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Microbubbles; Pancreatic Neoplasms; Ultrasonography | 2021 |
Nutritional impact of active hexose-correlated compound for patients with resectable or borderline-resectable pancreatic cancer treated with neoadjuvant therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Nutrition Assessment; Nutrition Therapy; Nutritional Status; Oxonic Acid; Pancreatic Neoplasms; Phytotherapy; Polysaccharides; Shiitake Mushrooms; Tegafur; Treatment Outcome | 2021 |
Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma: A propensity score-adjusted analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Klatskin Tumor; Propensity Score; Retrospective Studies | 2021 |
Hypericin-mediated photodynamic therapy enhances gemcitabine induced Capan-2 cell apoptosis via inhibiting NADPH level.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; NADP; Pancreatic Neoplasms; Perylene; Photochemotherapy; Reactive Oxygen Species | 2022 |
Intravesical sequential gemcitabine and docetaxel versus bacillus calmette-guerin (BCG) plus interferon in patients with recurrent non-muscle invasive bladder cancer following a single induction course of BCG.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Adult; Aged; Antineoplastic Agents; BCG Vaccine; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Induction Chemotherapy; Interferon alpha-2; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Preclinical efficacy of prexasertib in acute lymphoblastic leukemia.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrazines; Pyrazoles | 2021 |
A sulfobetaine zwitterionic polymer-drug conjugate for multivalent paclitaxel and gemcitabine co-delivery.
Topics: Animals; Betaine; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Mice; Paclitaxel; Pharmaceutical Preparations; Polymers | 2021 |
Heat shock protein 47 confers chemoresistance on pancreatic cancer cells by interacting with calreticulin and IRE1α.
Topics: Animals; Antimetabolites, Antineoplastic; Calcium; Calreticulin; Carcinoma, Pancreatic Ductal; Caspases; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Endoribonucleases; Gemcitabine; Gene Knockout Techniques; Gene Silencing; Heterografts; HSP47 Heat-Shock Proteins; Humans; Inositol 1,4,5-Trisphosphate Receptors; Mice; NADPH Oxidases; Neoplasm Transplantation; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Unfolded Protein Response | 2021 |
Cytoplasmic RRM1 activation as an acute response to gemcitabine treatment is involved in drug resistance of pancreatic cancer cells.
Topics: Aged; Cell Line, Tumor; Cell Survival; Cytoplasm; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Hydroxyurea; Male; Middle Aged; Pancreatic Neoplasms; Prognosis; Ribonucleoside Diphosphate Reductase; Survival Analysis; Up-Regulation | 2021 |
Combination of Gemcitabine and Thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer/T-cell lymphoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Epstein-Barr Virus Infections; Gemcitabine; Herpesvirus 4, Human; Humans; Inhibitory Concentration 50; Lymphoma, Extranodal NK-T-Cell; Mice; Thymalfasin; Viral Load; Xenograft Model Antitumor Assays | 2021 |
Safety and Efficacy of Gemcitabine Plus Nab-Paclitaxel for Metastatic Pancreatic Cancer Patients Undergoing Biliary Stent Placement.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Stents; Treatment Outcome | 2022 |
mTORC2 regulates ribonucleotide reductase to promote DNA replication and gemcitabine resistance in non-small cell lung cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; DNA Damage; DNA Replication; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histones; Humans; Mechanistic Target of Rapamycin Complex 2; Phosphorylation; Protein Binding; Ribonucleoside Diphosphate Reductase; Ribonucleotide Reductases; Signal Transduction | 2021 |
[Fever after Gemcitabine Administration is a Poor Prognostic Factor in Patients with Metastatic Urothelial Carcinoma : Multicenter Retrospective Study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Prognosis; Retrospective Studies; Treatment Outcome | 2021 |
Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Mesenteric Artery, Superior; Middle Aged; Neoplasm Recurrence, Local; Organ Sparing Treatments; Oxonic Acid; Pancreatic Neoplasms; Pancreaticoduodenectomy; Peripheral Nerves; Retrospective Studies; Survival Rate; Tegafur | 2021 |
Treatment outcomes of erlotinib plus gemcitabine as late-line chemotherapy in unresectable pancreatic cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2021 |
Treatment Outcome of Nab-paclitaxel Plus Gemcitabine for Leptomeningeal Carcinomatosis from Pancreatic Ductal Adenocarcinoma: An Autopsy Case Report.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Deoxycytidine; Female; Gemcitabine; Humans; Meningeal Carcinomatosis; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
MCL1 participates in leptin-promoted mitochondrial fusion and contributes to drug resistance in gallbladder cancer.
Topics: Adipocytes; Animals; Antimetabolites, Antineoplastic; Apoptosis Regulatory Proteins; CCAAT-Enhancer-Binding Protein-delta; Deoxycytidine; Drug Discovery; Drug Resistance, Neoplasm; Gallbladder Neoplasms; Gemcitabine; Leptin; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondrial Dynamics; Myeloid Cell Leukemia Sequence 1 Protein; STAT3 Transcription Factor | 2021 |
An experimental study on the malignant characteristics of gemcitabine resistant cells by Transferring MiRNA-222-3p via exosomes.
Topics: A549 Cells; Deoxycytidine; Drug Resistance, Neoplasm; Exosomes; Gemcitabine; Humans; MicroRNAs | 2021 |
An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Delivery of Health Care; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Prospective Studies; Retrospective Studies; Urinary Bladder Neoplasms; Vinblastine | 2021 |
miRNA-93-5p Promotes Gemcitabine Resistance in Pancreatic Cancer Cells by Targeting the PTEN-Mediated PI3K/Akt Signaling Pathway.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Tumor Cells, Cultured | 2021 |
The effect of gemcitabine combined with AMD3100 applying to cholangiocarcinoma RBE cell lines to CXCR4/CXCL12 axis.
Topics: Benzylamines; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chemokine CXCL12; Cholangiocarcinoma; Cyclams; Deoxycytidine; Gemcitabine; Humans; Neoplasm Invasiveness; Receptors, CXCR4 | 2021 |
Intralesional injection of rose bengal augments the efficacy of gemcitabine chemotherapy against pancreatic tumors.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Rose Bengal | 2021 |
Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Curcumin; Deoxycytidine; Drug Liberation; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Hydrogen-Ion Concentration; Liposomes; Male; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Polyethylene Glycols; Rats | 2021 |
PMEPA1 interference activates PTEN/PI3K/AKT, thereby inhibiting the proliferation, invasion and migration of pancreatic cancer cells and enhancing the sensitivity to gemcitabine and cisplatin.
Topics: Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Membrane Proteins; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase | 2022 |
Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Gemcitabine; Histones; Humans; Pancreatic Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents | 2021 |
Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Tinzaparin; Xenograft Model Antitumor Assays | 2021 |
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Comparison of Side Effects and Tolerability Between Intravesical Bacillus Calmette-Guerin, Reduced-Dose BCG and Gemcitabine for Non-Muscle Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Aged; Antimetabolites, Antineoplastic; BCG Vaccine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Monitoring; Drug Tapering; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasm Invasiveness; Neoplasm Staging; Patient Reported Outcome Measures; Prevalence; Symptom Assessment; Urinary Bladder Neoplasms | 2021 |
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nanoparticles; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Nausea; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Vomiting | 2021 |
Cytotoxic effects and tolerability of gemcitabine and axitinib in a xenograft model for c-myc amplified medulloblastoma.
Topics: Animals; Antineoplastic Agents; Axitinib; Cell Line, Tumor; Cell Survival; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Gene Amplification; Gene Expression; Humans; Medulloblastoma; Mice; Neovascularization, Pathologic; Proto-Oncogene Proteins c-myc; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2021 |
Gemcitabine-induced Gli-dependent activation of hedgehog pathway resists to the treatment of urothelial carcinoma cells.
Topics: Cell Line, Tumor; Cell Movement; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glycogen Synthase Kinase 3 beta; Hedgehog Proteins; Humans; Models, Biological; Neoplasm Invasiveness; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Urinary Bladder Neoplasms; Urothelium; Zinc Finger Protein Gli2 | 2021 |
Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer.
Topics: Annexin A6; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Exosomes; Gemcitabine; Humans; Lapatinib; Proteolysis; Triple Negative Breast Neoplasms; Ubiquitination | 2021 |
Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2021 |
Editorial Comment to Combination therapy with paclitaxel and gemcitabine after platinum-based chemotherapy in patients with advanced urothelial cancer.
Topics: Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Platinum | 2021 |
Chemotherapy with gemcitabine for unresectable intrahepatic cholangiocarcinoma in a patient undergoing maintenance hemodialysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Renal Dialysis | 2021 |
Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferase, Cytoplasmic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Disease Progression; Energy Metabolism; Enzyme Activation; Enzyme Activators; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mutation; Pancreatic Neoplasms; Proto-Oncogene Proteins p21(ras); Signal Transduction; Sirtuins; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2021 |
Development of Ag nanoparticle-carbon quantum dot nanocomplex as fluorescence sensor for determination of gemcitabine.
Topics: Carbon; Deoxycytidine; Gemcitabine; Humans; Metal Nanoparticles; Quantum Dots; Silver | 2021 |
Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; Carcinoma, Pancreatic Ductal; Deoxycytidine; Epidemiologic Methods; Female; Fluorouracil; Gastrointestinal Microbiome; Gemcitabine; Humans; Male; Middle Aged; Multivariate Analysis; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Time Factors; Treatment Outcome | 2021 |
A case of necrotic enteritis during neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms | 2021 |
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Venous Thromboembolism | 2022 |
Building and behavior of a pH-stimuli responsive chitosan nanoparticles loaded with folic acid conjugated gemcitabine silver colloids in MDA-MB-453 metastatic breast cancer cell line and pharmacokinetics in rats.
Topics: Animals; Breast Neoplasms; Cell Line; Cell Line, Tumor; Chitosan; Deoxycytidine; Female; Folic Acid; Gemcitabine; Humans; Hydrogen-Ion Concentration; Metal Nanoparticles; Nanoparticles; Particle Size; Rats; Silver | 2021 |
Activation of autophagy reverses gemcitabine-induced immune inhibition of RAW264.7 macrophages by promoting TNF-α, IL-6 and MHC-II expression.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Cell Cycle; Deoxycytidine; Gemcitabine; Histocompatibility Antigens Class II; Immunosuppressive Agents; Interferon-gamma; Interleukin-6; Lipopolysaccharides; Mice; Phagocytosis; RAW 264.7 Cells; Reactive Oxygen Species; Tumor Necrosis Factor-alpha | 2021 |
Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy.
Topics: Adult; Aged; Albumins; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Risk Factors | 2021 |
Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Retrospective Studies | 2021 |
BMI1 activates P-glycoprotein via transcription repression of
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Histones; Humans; Male; MicroRNAs; Polycomb Repressive Complex 1; Urinary Bladder Neoplasms | 2021 |
[A Rare Case of Non-small Cell Lung Carcinoma Squamous Phenotype with Epstein-Barr Virus Positivity with Prolonged Response to both Chemotherapy and Radiotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Antitubercular Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; Epstein-Barr Virus Infections; Female; Gemcitabine; Herpesvirus 4, Human; Humans; Lung Neoplasms; Lupus Erythematosus, Systemic; Middle Aged; Neck Dissection; Neoplasm Recurrence, Local; Radiotherapy; Tuberculosis, Pulmonary | 2021 |
Biotinylated Mn
Topics: Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Carriers; Drug Delivery Systems; Female; Gemcitabine; Humans; Magnetic Resonance Imaging; Nanoparticles; Polyethylene Glycols | 2021 |
Gemcitabine Plus Nab-Paclitaxel as Second-Line Chemotherapy following FOLFIRINOX in Patients with Unresectable Pancreatic Cancer: A Single-Institution, Retrospective Analysis.
Topics: Adult; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fluid Therapy; Gemcitabine; Humans; Male; Middle Aged; Prognosis; Progression-Free Survival; Retrospective Studies; Survival Rate; Ureteral Neoplasms; Urinary Bladder Neoplasms | 2021 |
Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.
Topics: Acute Kidney Injury; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Blood Transfusion; Complement Inactivating Agents; Deoxycytidine; Female; France; Gemcitabine; Humans; Kidney Function Tests; Male; Middle Aged; Recovery of Function; Remission Induction; Renal Replacement Therapy; Thrombotic Microangiopathies; Treatment Outcome | 2021 |
Development and evaluation of a multi-functional organic-inorganic nanotheranostic hybrid for pancreatic cancer therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitosan; Contrast Media; Deoxycytidine; Gemcitabine; Gold; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Pancreas; Pancreatic Neoplasms; Theranostic Nanomedicine | 2021 |
New In Vitro-In Silico Approach for the Prediction of In Vivo Performance of Drug Combinations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Computer Simulation; Deoxycytidine; Drug Combinations; Fluorouracil; Gemcitabine; Humans; Models, Biological; Neoplasms | 2021 |
CD73 induces gemcitabine resistance in pancreatic ductal adenocarcinoma: A promising target with non-canonical mechanisms.
Topics: 5'-Nucleotidase; Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; HEK293 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Troglitazone; Xenograft Model Antitumor Assays | 2021 |
The Cisplatin, 5-fluorouracil, Irinotecan, and Gemcitabine Treatment in Resistant 2D and 3D Model Triple Negative Breast Cancer Cell Line: ABCG2 Expression Data.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Proliferation; Cell Survival; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorouracil; Gemcitabine; Humans; Irinotecan; Neoplasm Proteins; Structure-Activity Relationship; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2022 |
The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation.
Topics: Animals; Apoptosis; Cell Line, Tumor; Coumarins; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pancreatic Neoplasms; Reactive Oxygen Species; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2021 |
Nuclear Factor Erythroid 2-Related Factor 2 Depletion Sensitizes Pancreatic Cancer Cells to Gemcitabine via Aldehyde Dehydrogenase 3a1 Repression.
Topics: Aldehyde Dehydrogenase; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Gemcitabine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; NF-E2-Related Factor 2; Pancreatic Neoplasms; Piperidines; Quinazolinones | 2021 |
Axially slanted laser illumination scheme for direct and accurate Raman spectroscopic determination of gemcitabine concentration in freeze-dried gemcitabine injection powder housed in a glass container.
Topics: Deoxycytidine; Gemcitabine; Glass; Lasers; Lighting; Powders; Spectrum Analysis, Raman | 2021 |
MASTL regulates EGFR signaling to impact pancreatic cancer progression.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Disease Progression; ErbB Receptors; Gain of Function Mutation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Loss of Function Mutation; Mice; Microtubule-Associated Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Protein Stability; Signal Transduction; Up-Regulation | 2021 |
Evaluation of renal function using cystatin C-based estimated glomerular filtration rate in patients with urothelial carcinoma treated with gemcitabine and cisplatin chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Cystatin C; Deoxycytidine; Female; Gemcitabine; Glomerular Filtration Rate; Humans; Male; Middle Aged; Reproducibility of Results; Retrospective Studies; Urologic Neoplasms | 2021 |
Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies | 2021 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diarrhea; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Outcome Assessment, Health Care; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2021 |
Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Neoplasm Metastasis; Phenotype | 2021 |
Treatment and Outcomes of Metastatic Pancreatic Cancer in Elderly Patients.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Comorbidity; Deoxycytidine; Female; Gemcitabine; Humans; Male; Neoplasm Metastasis; Palliative Care; Pancreatic Neoplasms; Proportional Hazards Models; Survival Rate; Treatment Outcome | 2021 |
Minimal PK/PD model for simultaneous description of the maximal tolerated dose and metronomic treatment outcomes in mouse tumor models.
Topics: Administration, Metronomic; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Deoxycytidine; Female; Gemcitabine; Maximum Tolerated Dose; Mice; Models, Theoretical; Reproducibility of Results | 2021 |
Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; bcl-X Protein; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Janus Kinase 2; Models, Biological; Myeloid Cell Leukemia Sequence 1 Protein; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Piperidines; Signal Transduction; Small Molecule Libraries; STAT3 Transcription Factor | 2021 |
An exploratory study of body composition as a predictor of dose-limiting toxicity in metastatic pancreatic cancer treated with gemcitabine plus nab-paclitaxel.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Body Mass Index; Body Surface Area; Canada; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lumbar Vertebrae; Male; Maximum Tolerated Dose; Middle Aged; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Predictive Value of Tests; Reference Values; Retrospective Studies; Tomography, X-Ray Computed | 2021 |
In Vitro Evaluation of Rigosertib Antitumoral and Radiosensitizing Effects against Human Cholangiocarcinoma Cells.
Topics: Antineoplastic Agents; Autophagy; Bile Duct Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Glycine; Humans; Radiation-Sensitizing Agents; Sulfones | 2021 |
A therapeutic DNA vaccine and gemcitabine act synergistically to eradicate HPV-associated tumors in a preclinical model.
Topics: Alphapapillomavirus; Animals; CD8-Positive T-Lymphocytes; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Papillomaviridae; Papillomavirus Infections; Papillomavirus Vaccines; Uterine Cervical Neoplasms; Vaccines, DNA | 2021 |
lncRNA ANRIL aggravates the chemoresistance of pancreatic cancer cells to gemcitabine by targeting inhibition of miR-181a and targeting HMGB1-induced autophagy.
Topics: Apoptosis; Autophagy; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; HMGB1 Protein; Humans; MicroRNAs; Pancreatic Neoplasms; RNA, Long Noncoding | 2021 |
T Cell-Mediated Antitumor Immunity Cooperatively Induced By TGFβR1 Antagonism and Gemcitabine Counteracts Reformation of the Stromal Barrier in Pancreatic Cancer.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; CD8-Positive T-Lymphocytes; Cell Proliferation; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Receptor, Transforming Growth Factor-beta Type I; Stromal Cells; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Effectiveness of Concomitant Chemoradiotherapy with Gemcitabine in Locally Advanced Cervical Cancer Patients with Comorbidities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Uterine Cervical Neoplasms | 2022 |
Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Allografts; Amino Acid Motifs; Animals; Apoptosis; B7-H1 Antigen; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Membrane; Deoxycytidine; Drug Synergism; Endocytosis; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Immunosuppression Therapy; Immunotherapy; Lysosomes; Mice; Microfilament Proteins; Molecular Targeted Therapy; NIMA-Interacting Peptidylprolyl Isomerase; Oncogenes; Organoids; Pancreatic Neoplasms; Signal Transduction; Survival Analysis; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Molecular Targeted Therapy; Pancreatic Neoplasms; Prognosis; Survival Analysis; Toll-Like Receptor 2; Xenograft Model Antitumor Assays | 2021 |
Synergistic combination of cytotoxic chemotherapy and cyclin-dependent kinase 4/6 inhibitors in biliary tract cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Biliary Tract Neoplasms; Cisplatin; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Mice; Protein Kinase Inhibitors; Xenograft Model Antitumor Assays | 2022 |
The enhancement of Tetrandrine to gemcitabine-resistant PANC-1 cytochemical sensitivity involves the promotion of PI3K/Akt/mTOR-mediated apoptosis and AMPK-regulated autophagy.
Topics: AMP-Activated Protein Kinases; Apoptosis; Autophagy; Benzylisoquinolines; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases | 2021 |
Synthesis and characterization of hybrid nanocarrier layered double hydroxide grafted by polyethylene glycol and gemcitabine.
Topics: Deoxycytidine; Drug Delivery Systems; Gemcitabine; Hydroxides; Polyethylene Glycols; Spectroscopy, Fourier Transform Infrared | 2021 |
Establishment of Pancreatobiliary Cancer Zebrafish Avatars for Chemotherapy Screening.
Topics: Albumins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Zebrafish | 2021 |
Enhancement of gemcitabine efficacy by K73-03 via epigenetically regulation of miR-421/SPINK1 in gemcitabine resistant pancreatic cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Oleanolic Acid; Pancreatic Neoplasms; Trypsin Inhibitor, Kazal Pancreatic | 2021 |
Improved tumor control with antiangiogenic therapy after treatment with gemcitabine and nab-paclitaxel in pancreatic cancer.
Topics: Adenocarcinoma; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Bevacizumab; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Combination of anlotinib and gemcitabine promotes the G0/G1 cell cycle arrest and apoptosis of intrahepatic cholangiocarcinoma in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Therapy, Combination; G1 Phase Cell Cycle Checkpoints; Gemcitabine; Humans; Indoles; Quinolines | 2021 |
Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma: A Retrospective Cohort Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Cohort Studies; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Preoperative Period; Retrospective Studies; Treatment Outcome | 2021 |
Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network.
Topics: Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Retrospective Studies; Skin Neoplasms; Treatment Outcome | 2022 |
Gemcitabine synergizes with cisplatin to inhibit nasopharyngeal carcinoma cell proliferation and tumor growth.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cisplatin; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Xenograft Model Antitumor Assays | 2021 |
Gemcitabine lipid prodrug nanoparticles: Switching the lipid moiety and changing the fate in the bloodstream.
Topics: Animals; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lipids; Male; Nanoparticles; Prodrugs; Rats, Sprague-Dawley | 2021 |
Cell-specific activation of gemcitabine by endogenous H
Topics: Antimetabolites, Antineoplastic; Cell Proliferation; Deoxycytidine; Drug Screening Assays, Antitumor; Fluorescence; Gemcitabine; HeLa Cells; Humans; Hydrogen Sulfide; Ligands; Prodrugs; Theranostic Nanomedicine | 2021 |
Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Surgical Procedures; Chemotherapy, Adjuvant; Common Bile Duct Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Combinations; Female; Follow-Up Studies; Gallbladder Neoplasms; Gemcitabine; Humans; Klatskin Tumor; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Propensity Score; Survival Rate; Tegafur | 2021 |
Dosing Schedules of Gemcitabine and nab-Paclitaxel for Older Adults With Metastatic Pancreatic Cancer.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Databases as Topic; Deoxycytidine; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Paclitaxel; Pancreatic Neoplasms; Racial Groups; Retrospective Studies; Sex Factors; Treatment Outcome | 2021 |
Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell Line, Tumor; Databases, Genetic; Deoxycytidine; Drug Resistance, Neoplasm; Energy Metabolism; Enzyme Inhibitors; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Glutaminase; Glutamine; Humans; Male; Mice, Knockout; Mice, Nude; Mucin 5AC; Pancreatic Neoplasms; Proto-Oncogene Proteins c-myc; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2022 |
Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Deoxycytidine; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphoma, T-Cell, Peripheral; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Platinum; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2021 |
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for Bacillus Calmette-Guérin-unresponsive Non-muscle invasive Bladder Cancer: Con.
Topics: BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Injectable Micelle-Incorporated Hydrogels for the Localized Chemo-Immunotherapy of Breast Tumors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Chondroitin Sulfates; Delayed-Action Preparations; Deoxycytidine; Enzyme Inhibitors; Female; Gemcitabine; Hydrogels; Immunotherapy; Indoleamine-Pyrrole 2,3,-Dioxygenase; Mice, Inbred BALB C; Micelles; Neoplasm Metastasis; Poloxamer; Tryptophan; Tumor Microenvironment | 2021 |
MiR-9-3p regulates the biological functions and drug resistance of gemcitabine-treated breast cancer cells and affects tumor growth through targeting MTDH.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Gene Silencing; HEK293 Cells; Humans; Male; Membrane Proteins; Mice, Inbred BALB C; MicroRNAs; Neoplasm Invasiveness; Neoplasm Proteins; Prognosis; RNA-Binding Proteins | 2021 |
N-trimethyl chitosan coated nano-complexes enhance the oral bioavailability and chemotherapeutic effects of gemcitabine.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chitosan; Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Polylactic Acid-Polyglycolic Acid Copolymer; Rats, Sprague-Dawley; Vitamin E | 2021 |
Histone acetyltransferase 1 promotes gemcitabine resistance by regulating the PVT1/EZH2 complex in pancreatic cancer.
Topics: Animals; Calmodulin-Binding Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Chitosan; Deoxycytidine; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Humans; Male; Mice, Nude; Pancreatic Neoplasms; Promoter Regions, Genetic; Protein Binding; Protein Domains; Protein Stability; RNA, Long Noncoding; Transcription Factors; Ubiquitin-Protein Ligases | 2021 |
ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Movement; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immune Tolerance; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid-Derived Suppressor Cells; Neoplasm Invasiveness; Neoplastic Stem Cells; Prognosis; Recombinant Proteins; Retinal Dehydrogenase; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2021 |
Decoration of Squalenoyl-Gemcitabine Nanoparticles with Squalenyl-Hydroxybisphosphonate for the Treatment of Bone Tumors.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Molecular Structure; Nanoparticles; Organophosphonates; Osteosarcoma; Squalene; Structure-Activity Relationship | 2021 |
Sequential Gemcitabine plus Docetaxel Is the Standard Second-line Intravesical Therapy for BCG-unresponsive Non-muscle-invasive bladder cancer: Pro.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2022 |
Efficacy and Feasibility of Adjuvant Gemcitabine Plus Cisplatin Chemotherapy After Major Hepatectomy for Biliary Tract Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Hepatectomy; Humans; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate | 2021 |
LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Prognosis; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; Survival Rate; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1 | 2021 |
Fabrication of polymer-based self-assembly nanocarriers loaded with a crizotinib and gemcitabine: potential therapeutics for the treatment of endometrial cancer.
Topics: Crizotinib; Deoxycytidine; Drug Carriers; Endometrial Neoplasms; Female; Gemcitabine; Humans; Nanoparticles; Polyesters; Polyethylene Glycols; Polymers | 2022 |
Use of
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Colony-Stimulating Factors; Deoxycytidine; Gemcitabine; Granulocytes; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Combination of PD-1 inhibitor with GVD (gemcitabine, vinorelbine, liposomal doxorubicin) versus GVD regimen as second-line therapy for relapsed/refractory classical Hodgkin lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Management; Doxorubicin; Drug Resistance, Neoplasm; Female; Gemcitabine; Hodgkin Disease; Humans; Immune Checkpoint Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Polyethylene Glycols; Prognosis; Programmed Cell Death 1 Receptor; Recurrence; Retreatment; Treatment Outcome; Vinorelbine; Young Adult | 2022 |
Silencing GS Homeobox 2 Alleviates Gemcitabine Resistance in Pancreatic Cancer Cells by Activating SHH/GLI1 Signaling Pathway.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Gene Silencing; Genes, Homeobox; Hedgehog Proteins; Homeodomain Proteins; Humans; Mice; Pancreatic Neoplasms; Signal Transduction; Zinc Finger Protein GLI1 | 2022 |
Effects of ribosomal associated protein hnRNP D in gemcitabine-resistant pancreatic cancer.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Flow Cytometry; Gemcitabine; Gene Silencing; Heterogeneous Nuclear Ribonucleoprotein D0; Humans; Inhibitory Concentration 50; MicroRNAs; Pancreas; Pancreatic Neoplasms; Ploidies; Proto-Oncogene Proteins c-akt; Transcription Factor RelA | 2021 |
Gemcitabine and nab-paclitaxel induced interstitial pneumonia.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Lung Diseases, Interstitial; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2021 |
Reviewing the Outcomes of Different Treatment Approaches in Elderly Pancreatic Cancer Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Neoplasm Staging; Outcome Assessment, Health Care; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Analysis | 2021 |
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Supramolecular Organization of Polymer Prodrug Nanoparticles Revealed by Coarse-Grained Simulations.
Topics: Deoxycytidine; Drug Carriers; Drug Liberation; Gemcitabine; Hydrophobic and Hydrophilic Interactions; Molecular Dynamics Simulation; Nanoparticles; Paclitaxel; Polymers; Prodrugs | 2021 |
Role of biliary stent and neoadjuvant chemotherapy in the pancreatic tumor microbiome.
Topics: Aged; Carcinoma, Pancreatic Ductal; Deoxycytidine; Enterobacteriaceae; Female; Gemcitabine; Humans; Male; Microbiota; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Stents; Tumor Microenvironment | 2021 |
Development of a KRAS-Associated Metabolic Risk Model for Prognostic Prediction in Pancreatic Cancer.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Mutation; Pancreatic Neoplasms; Phenotype; Prognosis; Proto-Oncogene Proteins p21(ras); Reproducibility of Results; Risk Factors; ROC Curve; Survival Analysis | 2021 |
Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells.
Topics: Alcohol Oxidoreductases; Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cytosol; Deoxycytidine; Drug Delivery Systems; Drug Resistance, Neoplasm; Ferroptosis; Flavonoids; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lipid Peroxidation; Male; Mice; Mice, Nude; Molecular Docking Simulation; Oxidative Stress; Pancreatic Neoplasms; Reactive Oxygen Species; Up-Regulation; Xenograft Model Antitumor Assays | 2021 |
Persistent Postoperative Vasoplegia After Ureteronephrectomy Due To Suspected Intravesical Gemcitabine Toxicity.
Topics: Deoxycytidine; Gemcitabine; Humans; Nephroureterectomy; Vasoconstrictor Agents; Vasoplegia | 2021 |
Photoacoustic imaging of elevated glutathione in models of lung cancer for companion diagnostic applications.
Topics: Animals; Arylsulfonates; Biomarkers, Tumor; Cell Line, Tumor; Coloring Agents; Deoxycytidine; Drug Design; Female; Gemcitabine; Glutathione; HEK293 Cells; Humans; Indoles; Light; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Photoacoustic Techniques; Prodrugs; Single-Blind Method; Xenograft Model Antitumor Assays | 2021 |
Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Infusions, Parenteral; Male; Mice; Mice, Inbred C57BL; Nanoparticles; Pancreatic Neoplasms; Polo-Like Kinase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Receptors, CXCR4; RNA, Small Interfering; Tissue Distribution | 2021 |
Management of first-line palliative chemotherapy for post-treatment metastasis after gemcitabine plus cisplatin induction chemotherapy: Gemcitabine plus cisplatin and non-gemcitabine plus cisplatin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Liposomes; Male; Middle Aged; Nanoconjugates; Neutropenia; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Proportional Hazards Models; Retrospective Studies | 2021 |
Response to Platinum-based Chemotherapy Rechallenge for Patients With Pembrolizumab-refractory Urothelial Carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2021 |
Reply to comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma".
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Klatskin Tumor | 2022 |
Comment on "Adjuvant S-1 vs gemcitabine for node-positive perihilar cholangiocarcinoma".
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Klatskin Tumor | 2022 |
Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155-5p to regulate WEE1 expression.
Topics: Animals; Cell Cycle Proteins; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Mice; MicroRNAs; Protein-Tyrosine Kinases; RNA, Long Noncoding; Urinary Bladder Neoplasms | 2021 |
Advanced Nanoengineering Approach for Target-Specific, Spatiotemporal, and Ratiometric Delivery of Gemcitabine-Cisplatin Combination for Improved Therapeutic Outcome in Pancreatic Cancer.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Mice; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Male; Neoplasm Metastasis; Outcome Assessment, Health Care; Pancreatic Neoplasms; Proportional Hazards Models; Retrospective Studies; Taiwan; Topoisomerase I Inhibitors | 2022 |
The Association of Drug-Funding Reimbursement With Survival Outcomes and Use of New Systemic Therapies Among Patients With Advanced Pancreatic Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Ontario; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Retrospective Studies; Survival Rate | 2021 |
Fabrication of dopamine conjugated with protein @metal organic framework for targeted drug delivery: A biocompatible pH-Responsive nanocarrier for gemcitabine release on MCF‑7 human breast cancer cells.
Topics: Animals; Antimetabolites, Antineoplastic; Biocompatible Materials; Cattle; Cell Proliferation; Deoxycytidine; Dopamine; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Metal-Organic Frameworks; Molecular Structure; Serum Albumin, Bovine; Structure-Activity Relationship; Tumor Cells, Cultured | 2022 |
Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer.
Topics: Albumins; Antineoplastic Agents; CA-19-9 Antigen; Carcinoembryonic Antigen; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Karnofsky Performance Status; Male; Middle Aged; Nomograms; Oxonic Acid; Paclitaxel; Pancreatic Neoplasms; Probability; Proportional Hazards Models; ROC Curve; Sex Factors; Survival Rate; Tegafur | 2021 |
Curcumin enhances drug sensitivity of gemcitabine-resistant lung cancer cells and inhibits metastasis.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Curcumin; Deoxycytidine; Gemcitabine; Lung Neoplasms; Mice; Mice, Nude | 2021 |
MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Cluster Analysis; Cohort Studies; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Glucose; Humans; Molecular Targeted Therapy; Monocarboxylic Acid Transporters; Muscle Proteins; Pancreatic Neoplasms; Prognosis | 2021 |
R-GCD regimen in elderly patients with relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma: a retrospective single-center analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Disease-Free Survival; Female; Gemcitabine; Humans; Lymphoma, B-Cell; Male; Retrospective Studies; Survival Rate | 2022 |
Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy.
Topics: Animals; Antimetabolites, Antineoplastic; Deoxycytidine; Epigenomics; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Mice; Mice, Nude | 2021 |
Cutting Edge Research for Exploration of Biomolecules for Gemcitabine-Based Chemo-Resistant Advanced Bile Duct Cancer: From Basic Study to Clinical Trial.
Topics: Aged; Bile Duct Neoplasms; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Middle Aged | 2021 |
Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis.
Topics: Animals; Cells, Cultured; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; RNA-Binding Proteins; RNA, Circular; Signal Transduction; Xenograft Model Antitumor Assays | 2021 |
Tuning gut microbiota through a probiotic blend in gemcitabine-treated pancreatic cancer xenografted mice.
Topics: Animals; Deoxycytidine; Gastrointestinal Microbiome; Gemcitabine; Mice; Pancreatic Neoplasms; Probiotics; Transplantation, Heterologous | 2021 |
MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
Topics: Animals; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Movement; Cell Self Renewal; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice, Nude; MicroRNAs; Pancreatic Neoplasms; Receptor, Notch1; Signal Transduction; Xenograft Model Antitumor Assays | 2021 |
Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs.
Topics: Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Evaluation, Preclinical; Early Detection of Cancer; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Sequence Therapy with FOLFIRINOX and Gemcitabine/Nab-Paclitaxel for Patients with Advanced Pancreatic Cancer: A Monocentre Retrospective Cohort Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin in Patients With Platinum-Resistant Ovarian Cancer.
Topics: Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Nivolumab; Ovarian Neoplasms; Polyethylene Glycols | 2022 |
Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biliary Tract Neoplasms; Bridged-Ring Compounds; Cholangiocarcinoma; Deoxycytidine; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Practice Patterns, Physicians'; Pyrimidines; Registries; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2022 |
Co-delivery of gemcitabine and cisplatin via Poly (L-glutamic acid)-g-methoxy poly (ethylene glycol) micelle to improve the in vivo stability and antitumor effect.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxycytidine; Drug Carriers; Drug Compounding; Drug Liberation; Gemcitabine; Glutamic Acid; Humans; Male; Mice; Micelles; Polyethylene Glycols; Prodrugs; Rats; Xenograft Model Antitumor Assays | 2021 |
Imiquimod-gemcitabine nanoparticles harness immune cells to suppress breast cancer.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Imiquimod; Mice; Nanoparticles | 2022 |
Analysis of the CONKO-001 trial: Is the validity of the study sufficient to recommend adjuvant chemotherapy for pancreatic cancer?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Response to Pembrolizumab After Dose-Reduced Cisplatin Plus Gemcitabine Chemotherapy Is Inferior to That After Carboplatin Plus Gemcitabine Chemotherapy in Cisplatin-Unfit Patients With Advanced Urothelial Carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2022 |
Inhibition of TRIM32 by ibr-7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Ribosomal Protein S6 Kinases, 70-kDa; TOR Serine-Threonine Kinases; Transcription Factors; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2022 |
Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
Topics: Animals; B7-H1 Antigen; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Mice; Neoplasm Recurrence, Local; Programmed Cell Death 1 Receptor; Transforming Growth Factor beta; Tumor Microenvironment | 2022 |
Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Berberine; Carrier Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Down-Regulation; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, Inbred BALB C; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rad51 Recombinase; Up-Regulation; Urinary Bladder Neoplasms | 2022 |
Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
Synergistic Effect of Baculovirus-Mediated Endostatin and Angiostatin Combined with Gemcitabine in Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Baculoviridae; Carcinoma, Hepatocellular; Deoxycytidine; Endostatins; Gemcitabine; Humans; Liver Neoplasms; Mice; Mice, Nude | 2022 |
Permeability of Gemcitabine and PBPK Modeling to Assess Oral Administration.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Area Under Curve; Biological Transport; Cell Culture Techniques; Cell Line, Tumor; Cells, Cultured; Chromatography, High Pressure Liquid; Deoxycytidine; Gemcitabine; Humans; Models, Biological; Permeability; Tissue Distribution | 2021 |
Self-Delivery Janus-Prodrug for Precise Immuno-Chemotherapy of Colitis-Associated Colorectal Cancer.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Budesonide; Cell Line; Colitis-Associated Neoplasms; Colorectal Neoplasms; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Materials Testing; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Molecular Structure; Prodrugs | 2022 |
Integrin-Mediated Targeted Cancer Therapy Using c(RGDyK)-Based Conjugates of Gemcitabine.
Topics: A549 Cells; Animals; Antimetabolites, Antineoplastic; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Integrins; Lung Neoplasms; Mice; Mice, Inbred C57BL; Peptides, Cyclic | 2022 |
A 5% Glucose Solution for the Liquid Formulation Gemcitabine Solvent Decreases Gemcitabine-induced Vascular Pain.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Blood Vessels; Deoxycytidine; Female; Gemcitabine; Glucose; Humans; Male; Middle Aged; Pain; Pancreatic Neoplasms | 2022 |
MiR-206 suppresses the deterioration of intrahepatic cholangiocarcinoma and promotes sensitivity to chemotherapy by inhibiting interactions with stromal CAFs.
Topics: Animals; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Down-Regulation; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; MicroRNAs; Xenograft Model Antitumor Assays | 2022 |
Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: A post-hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study).
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Male; Middle Aged; Nomograms; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Treatment Outcome | 2022 |
Taxane/gemcitabine-containing chemotherapy plus locoregional IMRT for patients with de novo metastatic nasopharyngeal carcinoma: the treatment outcomes and prognostic factors analysis.
Topics: Carcinoma; Deoxycytidine; Disease-Free Survival; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Radiotherapy, Intensity-Modulated; Retrospective Studies; Taxoids; Treatment Outcome | 2022 |
Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo.
Topics: Adenocarcinoma of Lung; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Xenograft Model Antitumor Assays | 2022 |
Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Ovarian Neoplasms; Platinum | 2022 |
[A Case of Advanced Bladder Carcinoma Treated by Third-Line Gemcitabine and Paclitaxel Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Paclitaxel; Urinary Bladder; Urinary Bladder Neoplasms | 2021 |
ASO Author Reflections: ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer.
Topics: Biliary Tract Neoplasms; Cholesterol Esters; Deoxycytidine; Gemcitabine; Humans | 2022 |
ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer.
Topics: Acyltransferases; Biliary Tract Neoplasms; Cholesterol Esters; Deoxycytidine; Gemcitabine; Humans; RNA, Small Interfering | 2022 |
ITGA5 is an independent prognostic biomarker and potential therapeutic target for laryngeal squamous cell carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cohort Studies; Deoxycytidine; Docetaxel; Female; Gemcitabine; Humans; Integrins; Laryngeal Neoplasms; Male; Middle Aged; Nomograms; Prognosis; Proportional Hazards Models; Survival Analysis | 2022 |
Arterial enhancement pattern predicts survival in patients with resectable and unresectable intrahepatic cholangiocarcinoma.
Topics: Aged; Antineoplastic Agents; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Hepatectomy; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed | 2022 |
Real-World Outcomes of Gemcitabine, Cisplatin, and Nab-Paclitaxel Chemotherapy Regimen for Advanced Biliary Tract Cancer: A Propensity Score-Matched Analysis.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Propensity Score | 2022 |
m6A Modification Patterns With Distinct Immunity, Metabolism, and Stemness Characteristics in Soft Tissue Sarcoma.
Topics: Adenosine; Antineoplastic Agents; Deoxycytidine; DNA Copy Number Variations; DNA Methylation; Docetaxel; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy; Kaplan-Meier Estimate; Sarcoma | 2021 |
Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Multimodal Imaging; Pancreatic Neoplasms; Tumor Microenvironment | 2022 |
PD-1 inhibitor toripalimab with gemcitabine as a neoadjuvant therapy for muscle-invasive bladder urothelial carcinoma: A case report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Male; Middle Aged; Muscles; Neoadjuvant Therapy; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms | 2022 |
Impact of sarcopenia on prediction of progression-free survival and overall survival of patients with pancreatic ductal adenocarcinoma receiving first-line gemcitabine and nab-paclitaxel chemotherapy.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival; Sarcopenia | 2022 |
circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis.
Topics: Animals; Cancer-Associated Fibroblasts; Caveolin 1; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Leukemia Inhibitory Factor; Mice; MicroRNAs; Models, Biological; Pancreatic Neoplasms; Rho Guanine Nucleotide Exchange Factors; RNA Interference; RNA, Circular; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2022 |
Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cholangiocarcinoma; Cholangitis; Cholestasis; Cisplatin; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Progression-Free Survival; Radiofrequency Ablation; Retrospective Studies; Survival Rate; Treatment Outcome | 2022 |
The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Male; Middle Aged; Oxonic Acid; Tegafur; Treatment Outcome | 2022 |
Olive Mill Wastewater Inhibits Growth and Proliferation of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro by Down-Regulating the Akt/mTOR-Signaling Pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Olea; Polyphenols; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms; Wastewater | 2022 |
Cisplatin Loaded Poly(L-glutamic acid)-g-Methoxy Polyethylene Glycol Complex Nanoparticles Combined with Gemcitabine Presents Improved Safety and Lasting Anti-Tumor Efficacy in a Murine Xenograft Model of Human Aggressive B Cell Lymphoma.
Topics: Animals; Animals, Outbred Strains; Cisplatin; Deoxycytidine; Gemcitabine; Glutamic Acid; Heterografts; Humans; Lymphoma, B-Cell; Mice; Mice, SCID; Nanoparticles; Polyethylene Glycols | 2021 |
Deregulation of the CD44-NANOG-MDR1 associated chemoresistance pathways of breast cancer stem cells potentiates the anti-cancer effect of Kaempferol in synergism with Verapamil.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Female; Gemcitabine; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Kaempferols; Nanog Homeobox Protein; Neoplastic Stem Cells; Verapamil | 2022 |
Identification of Ferroptosis-Related Gene Prognostic Signature and HSF1 for Reversing Doxorubicin and Gemcitabine Resistance in Uterine Carcinosarcoma.
Topics: Carcinosarcoma; Deoxycytidine; Doxorubicin; Ferroptosis; Gemcitabine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Prognosis | 2022 |
Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Nausea; Oxaliplatin; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Treatment Outcome; Vomiting | 2022 |
Postoperative Treatment of Resectable Pancreatic Cancer With Positive Peritoneal Lavage Cytology: A Multicentre Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Deoxycytidine; Drug Combinations; Female; Gemcitabine; Humans; Japan; Male; Middle Aged; Oxonic Acid; Pancreatectomy; Pancreatic Neoplasms; Peritoneal Lavage; Peritoneal Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2022 |
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Effectiveness and safety of R-GCD (rituximab, gemcitabine, carboplatin, and dexamethasone) for transplant-ineligible relapse/refractory diffuse large B-cell lymphoma and grade 3a follicular lymphoma: a retrospective analysis comparing with R-GDP (rituxima
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Deoxycytidine; Dexamethasone; Gemcitabine; Humans; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Retrospective Studies; Rituximab; Salvage Therapy | 2022 |
Progressive digital necrosis during gemcitabine/nab-paclitaxel chemotherapy in a patient with pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Necrosis; Paclitaxel; Pancreatic Neoplasms | 2022 |
The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression.
Topics: Animals; Anthelmintics; beta Catenin; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Glycogen Synthase Kinase 3 beta; Humans; Immune Evasion; Mice; Niclosamide; Pancreatic Neoplasms; Wnt Signaling Pathway | 2022 |
Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable/locally advanced pancreatic cancer patients.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
MiR-624-5p enhances NLRP3 augmented gemcitabine resistance via EMT/IL-1β/Wnt/β-catenin signaling pathway in ovarian cancer.
Topics: beta Catenin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; NLR Family, Pyrin Domain-Containing 3 Protein; Ovarian Neoplasms; Wnt Signaling Pathway | 2022 |
The association of four genetic variants with myelosuppression in gemcitabine-treated Japanese is not evident in gemcitabine/carboplatin-treated Swedes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Gemcitabine; Humans; Japan; Lung Neoplasms; Neutropenia; Sweden | 2022 |
Factors associated with long-term survival in gemcitabine-concurrent proton radiotherapy for non-metastatic locally advanced pancreatic cancer: a single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Proton Therapy; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Time Factors | 2022 |
microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1.
Topics: Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Chromosomal Proteins, Non-Histone; Deoxycytidine; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Urinary Bladder Neoplasms | 2022 |
Synergistic ferroptosis-gemcitabine chemotherapy of the gemcitabine loaded carbonaceous nanozymes to enhance the treatment and magnetic resonance imaging monitoring of pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Ferroptosis; Gemcitabine; Glutathione Peroxidase; Humans; Magnetic Resonance Imaging; Pancreatic Neoplasms; Peroxidase; Reactive Oxygen Species | 2022 |
Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Heat-Shock Response; Mice; Neoplastic Stem Cells; Pancreatic Neoplasms | 2022 |
Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Deoxycytidine; Drug Synergism; Epithelial-Mesenchymal Transition; ERRalpha Estrogen-Related Receptor; Gemcitabine; Humans; MAP Kinase Signaling System; Nitriles; Pancreatic Neoplasms; Receptors, Estrogen; Thiazoles; Xenograft Model Antitumor Assays | 2022 |
Complementary effects of Orthosiphon stamineus standardized ethanolic extract and rosmarinic acid in combination with gemcitabine on pancreatic cancer.
Topics: Apoptosis; Cell Line, Tumor; Cinnamates; Deoxycytidine; Depsides; Gemcitabine; Humans; Orthosiphon; Pancreatic Neoplasms; Plant Extracts; Rosmarinic Acid | 2021 |
Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
Topics: Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Models, Animal; Feasibility Studies; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Mice; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
Optimal Relative Dose Intensity in the First 4 Weeks During Nab-Paclitaxel Plus Gemcitabine for Older Patients With Advanced Pancreatic Cancer in Japan.
Topics: Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Japan; Male; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Inhibition of FGFR2 enhances chemosensitivity to gemcitabine in cholangiocarcinoma through the AKT/mTOR and EMT signaling pathways.
Topics: Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Neovascularization, Pathologic; Proto-Oncogene Proteins c-akt; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; TOR Serine-Threonine Kinases | 2022 |
Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Glucose; Humans | 2022 |
IL-10 contributes to gemcitabine resistance in extranodal NK/T-cell lymphoma cells via ABCC4.
Topics: Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Interleukin-10; Lymphoma, Extranodal NK-T-Cell; Multidrug Resistance-Associated Proteins | 2022 |
Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Early Detection of Cancer; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Venous Thromboembolism | 2022 |
Anticancer effect of locally applicable aptamer-conjugated gemcitabine-loaded atelocollagen patch in pancreatic cancer patient-derived xenograft models.
Topics: Animals; Cell Line, Tumor; Collagen; Deoxycytidine; Disease Models, Animal; Gemcitabine; Heterografts; Humans; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2022 |
Replication stress induced by the ribonucleotide reductase inhibitor guanazole, triapine and gemcitabine in fission yeast.
Topics: Cell Cycle Proteins; Checkpoint Kinase 2; Deoxycytidine; DNA Replication; Enzyme Inhibitors; Gemcitabine; Guanazole; Humans; Hydroxyurea; Pyridines; Ribonucleotide Reductases; Schizosaccharomyces; Schizosaccharomyces pombe Proteins; Thiosemicarbazones | 2022 |
[A case of thrombotic microangiopathy during chemotherapy with gemcitabine in a patient with pancreatic cancer].
Topics: Deoxycytidine; Gemcitabine; Humans; Male; Pancreatic Neoplasms; Renal Dialysis; Thrombotic Microangiopathies | 2022 |
Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Mice; Mice, Nude; NF-E2-Related Factor 2; Pancreatic Neoplasms; Quassins; Survival Analysis; Transfection | 2022 |
Inhibiting nonhomologous end-joining repair would promote the antitumor activity of gemcitabine in nonsmall cell lung cancer cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line; Deoxycytidine; DNA; DNA Repair; Gemcitabine; Humans; Lung Neoplasms; RNA, Messenger | 2022 |
Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Japan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.
Topics: Animals; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Immunotherapy; Mice; Pancreatic Neoplasms; Receptors, Transforming Growth Factor beta; Transforming Growth Factor beta; Tumor Microenvironment | 2022 |
Redox-responsive self-assembled polymeric nanoprodrug for delivery of gemcitabine in B-cell lymphoma therapy.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lymphoma; Lymphoma, B-Cell; Mice; Micelles; Nanoparticles; Neoplasms; Oxidation-Reduction; Polymers; Prodrugs; Tumor Microenvironment | 2022 |
Durable remission for four pediatric patients with high-risk relapsed classical Hodgkin lymphoma treated with brentuximab vedotin plus gemcitabine but without autologous stem cell transplantation: A report from the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Child; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Neoplasm Recurrence, Local; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous | 2022 |
Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification.
Topics: Administration, Intravesical; Anthracyclines; Antibiotics, Antineoplastic; Deoxycytidine; Doxorubicin; Epirubicin; Gemcitabine; Humans; Immunohistochemistry; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Urinary Bladder Neoplasms | 2022 |
Suppression of Endothelial Cell FAK Expression Reduces Pancreatic Ductal Adenocarcinoma Metastasis after Gemcitabine Treatment.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Endothelial Cells; Focal Adhesion Protein-Tyrosine Kinases; Gemcitabine; Humans; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms | 2022 |
The immune modulation effects of gemcitabine plus cisplatin induction chemotherapy in nasopharyngeal carcinoma.
Topics: Cisplatin; Deoxycytidine; Gemcitabine; HLA-DR Antigens; Humans; Induction Chemotherapy; Interleukin-2; Interleukin-5; Interleukin-6; Interleukin-8; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms | 2022 |
Gemcitabine cationic polymeric nanoparticles against ovarian cancer: formulation, characterization, and targeted drug delivery.
Topics: Chitosan; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms | 2022 |
ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Lung Neoplasms; MicroRNAs; Neoplasm Proteins; RNA, Long Noncoding | 2022 |
Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study.
Topics: Deoxycytidine; Gemcitabine; Humans; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides; Retrospective Studies; Sezary Syndrome; Skin Neoplasms | 2022 |
lncRNA DLG1-AS1 promotes cervical cancer cell gemcitabine resistance by regulating miR-16-5p/HDGF.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Discs Large Homolog 1 Protein; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Mice; Mice, Nude; MicroRNAs; RNA, Long Noncoding; Uterine Cervical Neoplasms | 2022 |
Pathological complete response of liver metastases of cholangiocarcinoma using hepatic intra-arterial gemcitabine-oxaliplatin.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Oxaliplatin | 2022 |
A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous | 2022 |
A mild case of acute generalized exanthematous pustulosis caused by gemcitabine.
Topics: Acute Generalized Exanthematous Pustulosis; Deoxycytidine; Gemcitabine; Humans | 2022 |
Sarcopenia: Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Male; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2022 |
Balanitoside as a Natural Adjuvant to Gemcitabine in Lung Cancer Experimental Model.
Topics: Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Models, Theoretical; Saponins; Steroids | 2022 |
Ataxia telangiectasia and Rad3-related inhibition by AZD6738 enhances gemcitabine-induced cytotoxic effects in bladder cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpoint Kinase 1; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Indoles; Morpholines; Protein Kinase Inhibitors; Pyrimidines; Sulfonamides; Sulfoxides; Urinary Bladder Neoplasms | 2022 |
Gemcitabine-Associated Retinopathy With Bilateral Exudative Retinal Detachment and Elschnig's Spots.
Topics: Deoxycytidine; Female; Fundus Oculi; Gemcitabine; Humans; Middle Aged; Retinal Detachment; Retinal Diseases | 2022 |
Combination gemcitabine and PD-L1xCD3 bispecific T cell engager (BiTE) enhances T lymphocyte cytotoxicity against cholangiocarcinoma cells.
Topics: B7-H1 Antigen; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; CD3 Complex; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; T-Lymphocytes, Cytotoxic | 2022 |
Is age just a number? A population pharmacokinetic study of gemcitabine.
Topics: Aged; Antimetabolites, Antineoplastic; Deoxycytidine; Gemcitabine; Humans; Infusions, Intravenous; Research Design | 2022 |
Gemcitabine-induced renal thrombotic microangiopathy.
Topics: Deoxycytidine; Gemcitabine; Humans; Kidney; Thrombotic Microangiopathies | 2022 |
CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Deoxycytidine; Disulfides; Gemcitabine; Humans; Hyaluronan Receptors; Lung; Lung Neoplasms; Methoxyhydroxyphenylglycol; Micelles; Prodrugs | 2022 |
Prognosis following an extended duration of adjuvant gemcitabine plus S-1 chemotherapy in patients with pancreatic ductal adenocarcinoma: Analysis using inverse probability of treatment weighting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Probability; Prognosis; Retrospective Studies | 2022 |
Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Endosonography; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2022 |
[Successful R0 Resection of Hilar Cholangiocarcinoma Invading the Inferior Vena Cava through Left Trisegmentectomy with Combined Resection of the Portal Vein and Inferior Vena Cava after Gemcitabine/Cisplatin Combination Chemotherapy-A Case Report].
Topics: Aged; Bile Duct Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Female; Gemcitabine; Hepatectomy; Humans; Klatskin Tumor; Portal Vein; Vena Cava, Inferior | 2022 |
Endobiliary Radiofrequency Ablation Combined with Gemcitabine and Cisplatin in Patients with Unresectable Extrahepatic Cholangiocarcinoma.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cholestasis; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Radiofrequency Ablation; Retrospective Studies; Treatment Outcome | 2022 |
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Resu
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Potential efficacy of hepatic arterial infusion chemotherapy using gemcitabine, cisplatin, and 5-fluorouracil for intrahepatic cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Neoplasm Recurrence, Local; Retrospective Studies; Treatment Outcome | 2022 |
Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Methylenetetrahydrofolate Dehydrogenase (NADP); MicroRNAs; Minor Histocompatibility Antigens; Pancreatic Neoplasms; RNA, Circular | 2022 |
Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer.
Topics: Amlodipine; Animals; Antineoplastic Agents; Calcium Channel Blockers; Calmodulin; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; United States | 2022 |
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Neoplasms; Nivolumab | 2022 |
Gemcitabine Combined with Cisplatin Has a Better Effect in the Treatment of Recurrent/Metastatic Advanced Nasopharyngeal Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Quality of Life; Retrospective Studies; Treatment Outcome | 2022 |
GAS41 mediates proliferation and GEM chemoresistance via H2A.Z.2 and Notch1 in pancreatic cancer.
Topics: Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Histones; Humans; Pancreatic Neoplasms; Receptor, Notch1; Transcription Factors | 2022 |
[Intravesical gemcitabine for non-muscle invasive bladder cancer].
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2022 |
Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review.
Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Interactions; Gemcitabine; Humans; Mice; Paclitaxel; Pancreatic Neoplasms; Thrombotic Microangiopathies | 2022 |
Hsa-miR-3178/RhoB/PI3K/Akt, a novel signaling pathway regulates ABC transporters to reverse gemcitabine resistance in pancreatic cancer.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Molecular Docking Simulation; Neoplasm Proteins; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; rhoB GTP-Binding Protein; Signal Transduction | 2022 |
SRSF3-mediated regulation of N6-methyladenosine modification-related lncRNA ANRIL splicing promotes resistance of pancreatic cancer to gemcitabine.
Topics: Adenosine; Alternative Splicing; Deoxycytidine; DNA; Gemcitabine; Humans; Pancreatic Neoplasms; RNA, Long Noncoding; Serine-Arginine Splicing Factors | 2022 |
Sequential Chemotherapy with Gemcitabine and Docetaxel: Breaking the Chains of bacillus Calmette-Guérin.
Topics: Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; Carcinoma, Transitional Cell; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Mycobacterium bovis; Urinary Bladder Neoplasms | 2022 |
Risk Factors for Nab-Paclitaxel and Gemcitabine-Induced Peripheral Neuropathy in Patients with Pancreatic Cancer.
Topics: Albumins; Antineoplastic Agents; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Peripheral Nervous System Diseases; Quality of Life; Risk Factors | 2022 |
The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Baseline Factors Predictive of the Receipt of Second-Line Chemotherapy After Nab-Paclitaxel Plus Gemcitabine for Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Hypoalbuminemia; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Sarcopenia | 2022 |
Bacterial Lipopolysaccharide as a Negative Predictor of Adjuvant Gemcitabine Efficacy in Pancreatic Cancer.
Topics: Bacteria; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Lipopolysaccharides; Pancreatic Neoplasms | 2022 |
Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine.
Topics: Deoxycytidine; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Gemcitabine; Genomics; Humans; Urinary Bladder Neoplasms | 2022 |
Biodegradable gemcitabine-loaded microdevice with sustained local drug delivery and improved tumor recurrence inhibition abilities for postoperative pancreatic tumor treatment.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Lactic Acid; Mice; Neoplasm Recurrence, Local; Pancreatic Neoplasms; Polyethylene Glycols | 2022 |
FAT10 promotes chemotherapeutic resistance in pancreatic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gemcitabine; Humans; Pancreatic Neoplasms; Signal Transduction; Ubiquitins | 2022 |
Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report.
Topics: Acute Generalized Exanthematous Pustulosis; Adenocarcinoma of Lung; Aged; Deoxycytidine; Female; Gemcitabine; Humans; Neoplasms; Nivolumab | 2022 |
Progesterone receptor expression contributes to gemcitabine resistance at higher ECM stiffness in breast cancer cell lines.
Topics: Breast Neoplasms; Cell Line; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Progesterone; Receptors, Progesterone | 2022 |
Butyrate, a postbiotic of intestinal bacteria, affects pancreatic cancer and gemcitabine response in in vitro and in vivo models.
Topics: Animals; Bacteria; Butyrates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Mice; Pancreatic Neoplasms | 2022 |
Gemcitabine and Cisplatin as Neo-Adjuvant for Cholangiocarcinoma Patients Prior to Liver Transplantation: Case-Series.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Liver Transplantation; Male; Neoadjuvant Therapy | 2022 |
Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy.
Topics: Animals; Annexin A5; Breast Neoplasms; Cell Line, Tumor; Deoxycytidine; Female; Fluorescein-5-isothiocyanate; Gemcitabine; Humans; Mice; Mucin-1; Nanoparticles; Polyesters; Polyethylene Glycols | 2022 |
Correlation of gemcitabine sensitization by Chk1 inhibition with p53 status.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Protein Kinase Inhibitors; Protein Kinases; Tumor Suppressor Protein p53 | 2023 |
Electrocatalytic enhancement of [Ru(bpy)
Topics: Deoxycytidine; Electrochemical Techniques; Gemcitabine; Gold; Luminescent Measurements; Metal Nanoparticles; Ruthenium | 2022 |
Quality of Life, Efficacy, and Safety of Sequential Intravesical Gemcitabine + Docetaxel versus BCG for Non-Muscle Invasive Urinary Bladder Cancer: A Pilot Study.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Quality of Life; Urinary Bladder Neoplasms | 2022 |
Are there differences in the characteristics of patients who respond to gemcitabine plus cisplatin chemotherapy and those who respond to pembrolizumab therapy for metastatic urothelial carcinoma? Multicenter retrospective study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
HIF-1-dependent heme synthesis promotes gemcitabine resistance in human non-small cell lung cancers via enhanced ABCB6 expression.
Topics: Animals; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Catalase; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heme; Humans; Hypoxia-Inducible Factor 1; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Mice | 2022 |
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Photochemical Internalization of Gemcitabine Is Safe and Effective in Locally Advanced Inoperable Cholangiocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans; Photochemotherapy | 2022 |
Glycolysis addiction compensating for a defective pentose phosphate pathway confers gemcitabine sensitivity in SETD2-deficient pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Glycolysis; Humans; Pancreatic Neoplasms; Pentose Phosphate Pathway | 2022 |
Pancreatic cancer cells spectral library by DIA-MS and the phenotype analysis of gemcitabine sensitivity.
Topics: Antimetabolites, Antineoplastic; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mass Spectrometry; Pancreatic Neoplasms; Proteomics | 2022 |
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Flavonoids; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Tubulin | 2022 |
Ursolic acid restores sensitivity to gemcitabine through the RAGE/NF-κB/MDR1 axis in pancreatic cancer cells and in a mouse xenograft model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heterografts; Humans; Mice; NF-kappa B; Pancreatic Neoplasms; Receptor for Advanced Glycation End Products; Triterpenes; Ursolic Acid | 2021 |
Application of Nab-paclitaxel combined with gemcitabine in neoadjuvant chemotherapy laparoscopic followed by pancreatoduodenectomy to a patient with pancreas head cancer invading to protal vein.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Laparoscopy; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms; Pancreaticoduodenectomy | 2022 |
Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma.
Topics: Aminopyridines; Animals; Cerebellar Neoplasms; Child; Deoxycytidine; Gemcitabine; Humans; Medulloblastoma; Mice; Purines | 2022 |
Implication of methylselenocysteine in combination chemotherapy with gemcitabine for improved anticancer efficacy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Selenocysteine | 2022 |
E2F2 enhances the chemoresistance of pancreatic cancer to gemcitabine by regulating the cell cycle and upregulating the expression of RRM2.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; E2F2 Transcription Factor; Gemcitabine; Humans; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Up-Regulation | 2022 |
Serum IL-6 level is associated with clinical outcome of intravesical gemcitabine therapy in T1 non-muscle-invasive bladder cancer.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Interleukin-6; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Evaluation of risk factors for chemotherapy-induced nausea and vomiting in cisplatin and gemcitabine treatment for biliary tract cancer: acid suppressants do not prevent nausea.
Topics: Anorexia; Antiemetics; Antineoplastic Agents; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Nausea; Risk Factors; Vomiting | 2022 |
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms | 2022 |
HIF-1α-regulated stanniocalcin-1 mediates gemcitabine resistance in pancreatic ductal adenocarcinoma via PI3K/AKT signaling pathway.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glycoproteins; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction | 2022 |
A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Prospective Studies | 2023 |
Efficacy of Gemcitabine, Paclitaxel, and Oxaliplatin Protocol in the Treatment of Relapsed or Refractory Germ Cell Tumours.
Topics: Adult; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Male; Neoplasms, Germ Cell and Embryonal; Observational Studies as Topic; Oxaliplatin; Paclitaxel | 2022 |
Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases | 2022 |
Design, synthesis and antitumor activity study of a gemcitabine prodrug conjugated with a HDAC6 inhibitor.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Histone Deacetylase 6; Humans; Mice; Prodrugs; Xenograft Model Antitumor Assays | 2022 |
Comparative analysis of three vs. four cycles of neoadjuvant gemcitabine and cisplatin for muscle invasive bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Invasiveness; Retrospective Studies; Treatment Outcome; Urinary Bladder Neoplasms | 2022 |
Use and outcomes from neoadjuvant chemotherapy in borderline resectable pancreatic ductal adenocarcinoma in an Australasian population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Middle Aged; Neoadjuvant Therapy; Pancreatic Neoplasms; Retrospective Studies | 2023 |
GITR Antibodies in Cancer: Not Ready for Prime Time.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Glucocorticoid-Induced TNFR-Related Protein; Humans; Neoplasms; Nivolumab; T-Lymphocytes, Regulatory | 2022 |
Gemcitabine induces polarization of mouse peritoneal macrophages towards M1-like and confers antitumor property by inducing ROS production.
Topics: Animals; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Macrophages; Macrophages, Peritoneal; Mice; Reactive Oxygen Species | 2022 |
[Efficacy of Combination Chemotherapy of Gemcitabine and Nedaplatin for Squamous Cell Carcinoma of the Urinary Tract : Experience of Four Cases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Deoxycytidine; Gemcitabine; Humans; Organoplatinum Compounds; Treatment Outcome; Urinary Tract | 2022 |
Promotion of tumor progression induced by continuous low-dose administration of antineoplastic agent gemcitabine or gemcitabine combined with cisplatin.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cell Line, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2022 |
Mild forms of thrombotic microangiopathy in patients with advanced pancreatic cancer receiving gemcitabine and nab-paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Purpura, Thrombotic Thrombocytopenic; Thrombotic Microangiopathies | 2023 |
Extracellular Vesicles Inhibit the Response of Pancreatic Ductal Adenocarcinoma Cells to Gemcitabine and TRAIL Treatment.
Topics: Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Culture Media, Conditioned; Deoxycytidine; Drug Resistance, Neoplasm; Extracellular Vesicles; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
Gemcitabine Resistance in Pancreatic Ductal Carcinoma Cell Lines Stems from Reprogramming of Energy Metabolism.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Energy Metabolism; Gemcitabine; Humans; Pancreatic Neoplasms; Reactive Oxygen Species | 2022 |
Sequential Intravesical Gemcitabine and Docetaxel for bacillus Calmette-Guérin-Naïve High-Risk Nonmuscle-Invasive Bladder Cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Bacillus; BCG Vaccine; Carcinoma in Situ; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
microRNA-497 prevents pancreatic cancer stem cell gemcitabine resistance, migration, and invasion by directly targeting nuclear factor kappa B 1.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Neoplastic Stem Cells; NF-kappa B; Pancreatic Neoplasms | 2022 |
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Effectiveness and safety of gemcitabine plus nab-paclitaxel in elderly patients with advanced pancreatic cancer: a single-center retrospective cohort study.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Middle Aged; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2022 |
Combination of Low-Dose Gemcitabine and PD-1 Inhibitors for Treatment in Patients With Advanced Malignancies.
Topics: Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Neoplasms; Retrospective Studies | 2022 |
CASC9 potentiates gemcitabine resistance in pancreatic cancer by reciprocally activating NRF2 and the NF-κB signaling pathway.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; NF-E2-Related Factor 2; NF-kappa B; Pancreatic Neoplasms; Signal Transduction | 2023 |
Antitumour effects of a solid lipid nanoparticle loaded with gemcitabine and oxaliplatin on the viability, apoptosis, autophagy, and Hsp90 of ovarian cancer cells.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Female; Gemcitabine; Humans; Liposomes; Nanoparticles; Ovarian Neoplasms; Oxaliplatin | 2022 |
Novel intravesical gemcitabine delivery system (TAR-200) for neoadjuvant treatment of MIBC: context is everything.
Topics: Administration, Intravesical; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2022 |
A Novel Delivery System of RGD-HSA Loaded GEM/CUR Nanoparticles for the Treatment of Pancreatic Cancer Therapy.
Topics: Animals; Cell Line, Tumor; Curcumin; Deoxycytidine; Drug Carriers; Gemcitabine; Humans; Mice; Nanoparticles; Oligopeptides; Pancreatic Neoplasms; Particle Size; Serum Albumin, Human | 2022 |
Amphiphilic Dendritic Nanomicelle-Mediated Delivery of Gemcitabine for Enhancing the Specificity and Effectiveness.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dendrimers; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Pancreatic Neoplasms; Prodrugs | 2022 |
Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Dexamethasone; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Neoplasm Recurrence, Local; Outpatients; Retrospective Studies; Salvage Therapy; Stem Cell Transplantation; Transplantation, Autologous | 2022 |
M1 macrophage-derived exosomes synergistically enhance the anti- bladder cancer effect of gemcitabine.
Topics: Animals; Antineoplastic Agents; bcl-2-Associated X Protein; Caspase 3; Cytokines; Deoxycytidine; Disease Models, Animal; Exosomes; Gemcitabine; Macrophages; Mice; Urinary Bladder Neoplasms | 2022 |
Sustained delivery of gemcitabine
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hydrogels; Pancreatic Neoplasms | 2022 |
Gemcitabine resistance of pancreatic cancer cells is mediated by IGF1R dependent upregulation of CD44 expression and isoform switching.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hyaluronan Receptors; Pancreatic Neoplasms; Protein Isoforms; Receptor, IGF Type 1; Transcription Factors; Up-Regulation | 2022 |
Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2022 |
Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Topics: Antibodies; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Quinolines; Retrospective Studies | 2022 |
Single-agent gemcitabine in patients with advanced, pre-treated angiosarcoma: A multicenter, retrospective study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Hemangiosarcoma; Humans; Retrospective Studies; Taxoids | 2023 |
Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Carrier Proteins; Cell Line, Tumor; Colchicine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; LIM Domain Proteins; Mice; Neoplasm Proteins; NF-kappa B; Nucleosomes; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2022 |
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Registries | 2022 |
Chemotherapeutic resistant cholangiocarcinoma displayed distinct intratumoral microbial composition and metabolic profiles.
Topics: Acetylcholine; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Metabolome; RNA, Ribosomal, 16S | 2022 |
Phosphomimetic Dicer S1016E triggers a switch to glutamine metabolism in gemcitabine-resistant pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamate-Ammonia Ligase; Glutaminase; Glutamine; Humans; MicroRNAs; Pancreatic Neoplasms; Ribonuclease III; RNA, Small Interfering | 2022 |
Gemcitabine combined with apatinib and toripalimab in recurrent or metastatic nasopharyngeal carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Circulating Tumor DNA; Clinical Trials as Topic; Deoxycytidine; Endothelial Growth Factors; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Necrosis; Neoplasm Recurrence, Local; Pyridines | 2022 |
Optimal treatment occasion for ultrasound stimulated microbubbles in promoting gemcitabine delivery to VX2 tumors.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Microbubbles; Rabbits; Ultrasonography | 2022 |
[Evaluation of Prognostic Factors in Patients with Relapse and Unresectable Biliary Tract Cancer, Treated with S-1 after Failure of Gemcitabine].
Topics: Biliary Tract Neoplasms; Deoxycytidine; Gemcitabine; Humans; Oxonic Acid; Prognosis; Pyridines; Recurrence; Retrospective Studies; Tegafur | 2022 |
Long non-coding RNA SNHG16 decreased SMAD4 to induce gemcitabine resistance in pancreatic cancer via EZH2-mediated epigenetic modification.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA, Long Noncoding; RNA, Small Nucleolar; Smad4 Protein | 2022 |
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Prognosis; Quality of Life | 2023 |
Is Weight Loss During Chemotherapy for Pancreatic Cancer Prognostic?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Prognosis; Prospective Studies; Retrospective Studies; Weight Loss | 2023 |
Artemisia argyi extract induces apoptosis in human gemcitabine-resistant lung cancer cells via the PI3K/MAPK signaling pathway.
Topics: Annexin A5; Apoptosis; Artemisia; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Plant Extracts; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction | 2022 |
Re-challenging chemotherapy after pembrolizumab in platinum-refractory urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Methotrexate; Platinum; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 2023 |
Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immunologic Factors; Immunotherapy; Lung Neoplasms; Mice; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins p21(ras) | 2022 |
RETSAT associates with DDX39B to promote fork restarting and resistance to gemcitabine based chemotherapy in pancreatic ductal adenocarcinoma.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; DEAD-box RNA Helicases; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Hypoxia; Mice; Oxidoreductases Acting on CH-CH Group Donors; Pancreatic Neoplasms; Tumor Microenvironment | 2022 |
Clinical Study of Anti-PD-1 Immunotherapy Combined with Gemcitabine Chemotherapy in Multiline Treatment of Advanced Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Carcinoembryonic Antigen; Deoxycytidine; Fatigue; Gemcitabine; Humans; Immunotherapy; Pancreatic Neoplasms; Retrospective Studies | 2022 |
An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms.
Topics: Aminoglycosides; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Enediynes; ErbB Receptors; Gemcitabine; Humans; Ligands; NF-kappa B; Pancreatic Neoplasms; Smad4 Protein; TOR Serine-Threonine Kinases | 2022 |
Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment.
Topics: Antineoplastic Agents; Asparaginase; Brain Diseases; Cisplatin; Cytarabine; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Hyperammonemia; Neurotoxicity Syndromes | 2022 |
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Retrospective Studies; Urinary Bladder Neoplasms | 2022 |
Anti-tumour activity and toxicological studies of combination treatment of
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Eosine Yellowish-(YS); Gemcitabine; Heterografts; Humans; Ki-67 Antigen; Mice; Mice, Nude; Necrosis; Orthosiphon; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2022 |
Fluorogenic gemcitabine based light up sensor for serum albumin detection in complex biological matrices.
Topics: Deoxycytidine; Gemcitabine; Humans; Serum Albumin | 2022 |
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity.
Topics: Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence.
Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Recombinant Thrombomodulin Has Anti-tumor Effects and Enhances the Effects of Gemcitabine for Pancreatic Cancer Through G-protein Coupled Receptor 15.
Topics: Anti-Inflammatory Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms; Receptors, G-Protein-Coupled; Receptors, Peptide; RNA, Small Interfering; Thrombomodulin | 2022 |
ARID1A promotes chemosensitivity to gemcitabine in pancreatic cancer through epigenetic silencing of RRM2.
Topics: Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Epigenesis, Genetic; Gemcitabine; Humans; Pancreatic Neoplasms; Ribonucleoside Diphosphate Reductase; Transcription Factors | 2022 |
Remarkable response to gemcitabine rechallenge in advanced urothelial carcinoma: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Deoxycytidine; Gemcitabine; Humans; Male; Urinary Bladder Neoplasms | 2022 |
High Glucose Promotes Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance and Invasion through Modulating ROS/MMP-3 Signaling Pathway.
Topics: Animals; Blood Glucose; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Matrix Metalloproteinase 3; Mice; Pancreatic Neoplasms; Reactive Oxygen Species; Signal Transduction; Streptozocin | 2022 |
Neoadjuvant Nivolumab Plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder.
Topics: Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Muscles; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nivolumab; Prospective Studies; Urinary Bladder; Urinary Bladder Neoplasms | 2023 |
Allyl-, Butyl- and Phenylethyl-Isothiocyanate Modulate Akt-mTOR and Cyclin-CDK Signaling in Gemcitabine- and Cisplatin-Resistant Bladder Cancer Cell Lines.
Topics: Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; Cisplatin; Cyclin-Dependent Kinases; Cyclins; Deoxycytidine; Gemcitabine; Humans; Isothiocyanates; Proto-Oncogene Proteins c-akt; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Urinary Bladder Neoplasms | 2022 |
Micro-lymph node metastasis in intrahepatic cholangiocarcinoma showing pathological complete response to primary tumor and intrahepatic metastasis treated by gemcitabine plus cisplatin chemotherapy and radical surgery.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Lymph Node Excision; Lymphatic Metastasis; Male | 2023 |
Comparison of adjuvant gemcitabine plus S-1 with S-1 monotherapy for pancreatic ductal adenocarcinoma: Retrospective real-world data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Middle Aged; Pancreatic Neoplasms; Retrospective Studies | 2022 |
ATAD2 suppression enhances the combinatorial effect of gemcitabine and radiation in pancreatic cancer cells.
Topics: ATPases Associated with Diverse Cellular Activities; Cell Line, Tumor; Deoxycytidine; DNA-Binding Proteins; Gemcitabine; Humans; Pancreatic Neoplasms | 2022 |
Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with elevated pre-chemotherapy CA19-9 levels.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis | 2023 |
Gemcitabine-induced digital ischaemia in a patient with metastatic breast cancer.
Topics: Breast Neoplasms; Carcinoma, Ductal, Breast; Deoxycytidine; Female; Gemcitabine; Humans; Ischemia; Middle Aged | 2022 |
Functional metabolomics revealed the dual-activation of cAMP-AMP axis is a novel therapeutic target of pancreatic cancer.
Topics: Cell Line, Tumor; Cyclic AMP; Deoxycytidine; Gemcitabine; Humans; Metabolomics; Pancreatic Neoplasms | 2023 |
LogP of N-acyl-gemcitabine and lectin-corona emerge as key parameters in nanoparticulate intravesical cancer therapy.
Topics: Administration, Intravesical; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Nanoparticle Drug Delivery System; Polylactic Acid-Polyglycolic Acid Copolymer; Urinary Bladder Neoplasms; Wheat Germ Agglutinins | 2023 |
Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Imatinib Mesylate; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Signal Transduction | 2023 |
Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis.
Topics: Apoptosis; Arsenic Trioxide; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; TOR Serine-Threonine Kinases | 2023 |
Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Feasibility Studies; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Co-delivery of gemcitabine and salinomycin in PEGylated liposomes for enhanced anticancer efficacy against colorectal cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Deoxycytidine; Gemcitabine; Humans; Liposomes; Polyethylene Glycols | 2023 |
Pharmacoinformatic screening of phytoconstituent and evaluation of its anti-PDAC effect using
Topics: Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Deoxycytidine; Gemcitabine; Humans; Ligands; Pancreatic Neoplasms | 2023 |
Influence of antidiabetic drugs on glucose metabolism and immune response in patients with metastatic pancreatic ductal adenocarcinoma receiving gemcitabine plus nab-paclitaxel as first-line treatment.
Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Diabetes Mellitus, Type 2; Female; Gemcitabine; Glucose; Humans; Hypoglycemic Agents; Immunity; Insulins; Male; Metformin; Pancreatic Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |
Serum thrombospondin-1 serves as a novel biomarker and agonist of gemcitabine-based chemotherapy in intrahepatic cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Thrombospondins | 2023 |
WRQ-2, a gemcitabine prodrug, reverses gemcitabine resistance caused by hENT1 inhibition.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; HeLa Cells; Humans; Pancreatic Neoplasms; Prodrugs | 2022 |
Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Male; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2023 |
Head-to-head comparison of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in advanced pancreatic cancer: a target trial emulation using real-world data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Oxaliplatin; Pancreatic Neoplasms | 2023 |
Tumor volume reduction after induction chemotherapy with gemcitabine plus cisplatin in nasopharyngeal carcinoma.
Topics: Cisplatin; Deoxycytidine; Gemcitabine; Humans; Induction Chemotherapy; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Retrospective Studies; Tumor Burden | 2023 |
Preclinical evaluation of pentagamavunone-1 as monotherapy and combination therapy for pancreatic cancer in multiple xenograft models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Heterografts; Humans; Mice; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2022 |
Combined chemotherapy based on bioactive black phosphorus for pancreatic cancer therapy.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Enhanced Glutaminolysis Drives Hypoxia-Induced Chemoresistance in Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glutamine; Humans; Hypoxia; Pancreatic Neoplasms | 2023 |
Efficacy and Safety of First-line Carboplatin-paclitaxel and Carboplatin-gemcitabine in Patients With Advanced Triple-negative Breast Cancer: A Monocentric, Retrospective Comparison.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2023 |
Case report: A report of the complete pathological response of intrahepatic cholangiocarcinoma after conversion therapy.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Deoxycytidine; Gemcitabine; Humans | 2022 |
A biomimetic nanodrug for enhanced chemotherapy of pancreatic tumors.
Topics: Animals; Biomimetics; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mice; Nanoparticles; Pancreatic Neoplasms; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2023 |
Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Retrospective Studies; Treatment Outcome | 2023 |
Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model.
Topics: Alginates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
The efficacy and safety of Nab-paclitaxel plus gemcitabine versus mFOLFIRINOX in the first-line treatment of metastatic pancreatic cancer: a retrospective study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Deoxycytidine; Gemcitabine; Humans; Lymphoma, Non-Hodgkin; Oxaliplatin; Retrospective Studies; Rituximab; Treatment Outcome | 2023 |
The Predictive Value of ERCC1, RRM1, and Thymidylate Synthase in Advanced Malignant Pleural Mesothelioma Patients Treated with Platinum-Based Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Endonucleases; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Pemetrexed; Platinum; Prospective Studies; Thymidylate Synthase; Treatment Outcome | 2023 |
Elevated PAF1-RAD52 axis confers chemoresistance to human cancers.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lung Neoplasms; Rad52 DNA Repair and Recombination Protein; Transcription Factors | 2023 |
Clinical Outcome and Treatment Sequences of Patients with Advanced Pancreatic Cancer Treated with Contemporary Chemotherapy Protocols.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Prospective Studies | 2023 |
[A Case of an Advanced Intrahepatic Cholangiocarcinoma Effectively Treated by Conversion Surgery after Neoadjuvant Chemotherapy of Gemcitabine, Cisplatin and S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography | 2022 |
Evolved bacterial resistance to the chemotherapy gemcitabine modulates its efficacy in co-cultured cancer cells.
Topics: Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Escherichia coli; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Partial response in non-resectable adenosquamous carcinoma of the pancreas with high tumour mutation burden treated with gemcitabine, nab-paclitaxel and pembrolizumab.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Deoxycytidine; Gemcitabine; Humans; Male; Mutation; Paclitaxel; Pancreas; Pancreatic Neoplasms | 2023 |
hENT1's role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, Adjuvant; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine Resistance.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Gemcitabine; Glutamine; Humans; Pancreatic Neoplasms | 2023 |
CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoadjuvant Therapy; Paclitaxel; Pancreatic Neoplasms | 2023 |
Implication of Skeletal Muscle Loss in the Prognosis of Patients with Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Muscle, Skeletal; Paclitaxel; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Sarcopenia | 2023 |
Prognostic impact of osteosarcopenia in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Pancreatic Neoplasms; Prognosis; Retrospective Studies | 2023 |
Efficacy of gemcitabine in combination with nanoparticle albumin-bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review.
Topics: Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Treatment Outcome | 2023 |
Rubicon can predict prognosis in patients with pancreatic ductal adenocarcinoma after neoadjuvant chemoradiotherapy.
Topics: Carcinoma, Pancreatic Ductal; Chemoradiotherapy; Deoxycytidine; Gemcitabine; Humans; Neoadjuvant Therapy; Pancreatic Neoplasms; Prognosis; RNA, Small Interfering | 2023 |
Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Irinotecan; Leucovorin; Male; Ontario; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Association of Antibiotic Receipt With Survival Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Receiving Chemotherapy.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort Studies; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Male; Medicare; Pancreatic Neoplasms; Retrospective Studies; United States | 2023 |
In Situ Formed ROS-Responsive Hydrogel with STING Agonist and Gemcitabine to Intensify Immunotherapy against Pancreatic Ductal Adenocarcinoma.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Hydrogels; Immunotherapy; Membrane Proteins; Pancreatic Neoplasms; Reactive Oxygen Species; Tumor Microenvironment | 2023 |
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Neoplasm Recurrence, Local; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
A tumor microenvironment-stimuli responsive nano-prodrug for overcoming gemcitabine chemoresistance by co-delivered miRNA-21 modulator.
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Prodrugs; RNA, Small Interfering; Tumor Microenvironment | 2023 |
Nonrisk-adapted Sequential Intravesical Gemcitabine and Docetaxel for Nonmuscle-invasive Bladder Cancer: The Time Is Now.
Topics: Administration, Intravesical; BCG Vaccine; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Neoplasm Invasiveness; Urinary Bladder Neoplasms | 2023 |
Targeting mitochondrial transcription factor A sensitizes pancreatic cancer cell to gemcitabine.
Topics: Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Mitochondrial Proteins; Pancreatic Neoplasms | 2023 |
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs.
Topics: Animals; Cancer-Associated Fibroblasts; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Coenzyme A Ligases; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Exosomes; Ferroptosis; Gemcitabine; Humans; Mice; MicroRNAs; Pancreatic Neoplasms | 2023 |
Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer.
Topics: Artificial Intelligence; Biomarkers; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Evofosfamide and Gemcitabine Act Synergistically in Pancreatic Cancer Xenografts by Dual Action on Tumor Vasculature and Inhibition of Homologous Recombination DNA Repair.
Topics: Animals; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Heterografts; Humans; Hypoxia; Mice; Pancreatic Neoplasms; Prodrugs; Recombinational DNA Repair | 2023 |
The Efficacy and Safety of Treatment Regimens Used in the First-Line Setting in Metastatic Pancreatic Cancer Patients: A Multicenter Real-Life Study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Progression-Free Survival | 2022 |
Characterization and treatment of gemcitabine- and cisplatin-resistant bladder cancer cells with a pan-RAS inhibitor.
Topics: Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Urinary Bladder Neoplasms | 2023 |
Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Cost-Benefit Analysis; Deoxycytidine; Gemcitabine; Humans | 2023 |
Vactosertib, TGF-β receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Gemcitabine; Humans; Pancreatic Neoplasms; Transforming Growth Factor beta | 2023 |
A Novel Gemcitabine-Resistant Gallbladder Cancer Model Provides Insights into Molecular Changes Occurring during Acquired Resistance.
Topics: Carcinoma in Situ; Cell Line, Tumor; Deoxycytidine; Gallbladder Neoplasms; Gemcitabine; Humans; Proteomics | 2023 |
Identification and Clinical Significance of Pancreatic Cancer Stem Cells and Their Chemotherapeutic Drug Resistance.
Topics: Cell Line, Tumor; Clinical Relevance; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Male; Neoplastic Stem Cells; Pancreatic Neoplasms | 2023 |
Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma.
Topics: Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; DNA, Mitochondrial; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Reactive Oxygen Species | 2023 |
ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; DNA-Binding Proteins; Gemcitabine; High-Throughput Nucleotide Sequencing; Humans; Mutation; Prospective Studies; Transcription Factors | 2023 |
Real-world outcomes of first-line chemotherapy for unresectable stage III and IV bladder cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Treatment Outcome; Urinary Bladder Neoplasms | 2023 |
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Nutritional Support; Paclitaxel; Pancreatic Neoplasms; Quality of Life; Retrospective Studies; Weight Loss | 2023 |
Clinical outcome and safety profile of metastatic pancreatic cancer patients treated with more than six cycles of nab-paclitaxel plus gemcitabine.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; Gemcitabine; Heterografts; Humans; Mice; Nanoparticles; Pancreatic Neoplasms; Xenograft Model Antitumor Assays | 2023 |
Petite Integration Factor 1 knockdown enhances gemcitabine sensitivity in pancreatic cancer cells via increasing DNA damage.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Deoxycytidine; DNA Damage; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Silencing of IGHG1 reverses the resistance of pancreatic cancer to multidrug chemotherapy by modulating autophagy.
Topics: Animals; Apoptosis; Autophagy; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Mice; Mice, Nude; Oxaliplatin; Pancreatic Neoplasms | 2023 |
Treatment patterns and cost estimations of systemic chemotherapy for pancreatic cancer in Japan: A retrospective database study.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Japan; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies; Serum Albumin | 2023 |
Chemoresistance in pancreatic ductal adenocarcinoma: Overcoming resistance to therapy.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Tumor Microenvironment | 2023 |
Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance.
Topics: Angiopoietin-Like Protein 4; Apolipoprotein L1; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Pancreatic Neoplasms; Transcriptome | 2023 |
Bromo- and Extra-Terminal Domain Inhibitors Induce Mitochondrial Stress in Pancreatic Ductal Adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; Mice; Mitochondria; Paclitaxel; Pancreatic Neoplasms; Tumor Microenvironment | 2023 |
Gemcitabine-associated digital necrosis in metastatic breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Necrosis; Thrombosis | 2023 |
Reversible promoter demethylation of PDGFD confers gemcitabine resistance through STAT3 activation and RRM1 upregulation.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Demethylation; Deoxycytidine; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gemcitabine; Humans; Lymphokines; Pancreatic Neoplasms; Platelet-Derived Growth Factor; Ribonucleoside Diphosphate Reductase; Up-Regulation | 2023 |
Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation.
Topics: Afatinib; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Gemcitabine; Humans; Mucin-4; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt | 2023 |
Efficacy of second and third lines of treatment in advanced soft tissue sarcomas: a real-world study.
Topics: Dacarbazine; Deoxycytidine; Gemcitabine; Humans; Ifosfamide; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms | 2023 |
Sitravatinib and Acquired Immune Checkpoint Inhibitor Resistance: A Gem for the Future?
Topics: Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms | 2023 |
Trends in treatment patterns and survival outcomes in pancreatic cancer: A nationwide population-based study in Korea.
Topics: Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Infant; Leucovorin; Middle Aged; Paclitaxel; Pancreatic Neoplasms; Republic of Korea; Retrospective Studies | 2023 |
A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; BRCA2 Protein; Cicatrix; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Leucovorin; Paclitaxel; Pancreatic Neoplasms; Retrospective Studies | 2023 |
Nuclear PLD1 combined with NPM1 induces gemcitabine resistance through tumorigenic IL7R in pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Nuclear Proteins; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Interleukin-7; RNA, Guide, CRISPR-Cas Systems; STAT5 Transcription Factor | 2023 |
Resistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Gemcitabine; Heat-Shock Response; Humans; Pancreatic Neoplasms; Pyruvaldehyde | 2023 |
Co-delivery of three synergistic chemotherapeutics in a core-shell nanoscale coordination polymer for the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcitabine; Mice; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Polymers | 2023 |
Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-pac
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease Progression; Gemcitabine; Humans; Pancreatic Hormones; Pancreatic Neoplasms | 2023 |
Reply: Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: The STAMP randomized trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans | 2023 |
Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma.
Topics: Animals; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mice; Pancreatic Neoplasms; Thalidomide; Xenograft Model Antitumor Assays | 2023 |
STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage.
Topics: B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Epithelial-Mesenchymal Transition; Gemcitabine; Humans; Oxidative Stress; Pancreatic Neoplasms; STAT3 Transcription Factor | 2023 |
hENT1 as a Predictive Biomarker in PDAC-Response.
Topics: Biomarkers; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
An age-group analysis on the efficacy of chemotherapy in older adult patients with metastatic biliary tract cancer: a Japanese cancer registry cohort study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biliary Tract Neoplasms; Cisplatin; Cohort Studies; Deoxycytidine; East Asian People; Gemcitabine; Humans | 2023 |
Flashback Foreword: Gemcitabine/Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Transitional Cell Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Doxorubicin; Gemcitabine; Humans; Methotrexate; Urinary Bladder Neoplasms; Vinblastine | 2023 |
Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance.
Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Coculture Techniques; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Macrophages; Mice; Organoids; Pancreatic Neoplasms; Plicamycin; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Tumor Microenvironment | 2023 |
High-Load Gemcitabine Inorganic-Organic Hybrid Nanoparticles as an Image-Guided Tumor-Selective Drug-Delivery System to Treat Pancreatic Cancer.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gemcitabine; Humans; Nanoparticles; Pancreatic Neoplasms | 2023 |
Efficacy and safety of gemcitabine plus S-1
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms; Treatment Outcome | 2023 |
Cytidine deaminase enzyme activity is a predictive biomarker in gemcitabine-treated cancer patients.
Topics: Anemia; Biomarkers; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Humans; Neoplasms | 2023 |
Increased mitochondria are responsible for the acquisition of gemcitabine resistance in pancreatic cancer cell lines.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Mitochondria; Pancreatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2023 |
The role of LOXL2 induced by glucose metabolism-activated NF-κB in maintaining drug resistance through EMT and cancer stemness in gemcitabine-resistant PDAC.
Topics: Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Glucose; Mice; NF-kappa B; Pancreatic Neoplasms | 2023 |
Matrix stiffness triggers chemoresistance through elevated autophagy in pancreatic ductal adenocarcinoma.
Topics: Autophagy; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Chloroquine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Pancreatic Neoplasms | 2023 |
Gemcitabine with Cisplatin Versus Hepatic Arterial Infusion Pump Chemotherapy for Liver-Confined Unresectable Intrahepatic Cholangiocarcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Infusion Pumps; Liver; Male; Retrospective Studies; Treatment Outcome | 2024 |
Immunization with a multi-antigen targeted DNA vaccine eliminates chemoresistant pancreatic cancer by disrupting tumor-stromal cell crosstalk.
Topics: Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Immunization; Pancreatic Neoplasms; Stromal Cells; Tumor Microenvironment; Vaccines, DNA | 2023 |
Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract.
Topics: Carcinoma, Neuroendocrine; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Urinary Bladder Neoplasms; Urinary Tract | 2023 |
Flashback Foreword: Erlotinib and Gemcitabine in Pancreatic Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Pancreatic Neoplasms; Quinazolines | 2023 |
SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer.
Topics: Amino Acid Transport Systems, Neutral; Animals; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Ferroptosis; Gemcitabine; Glutamine; Humans; Mice; Pancreatic Neoplasms | 2023 |
Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer.
Topics: Animals; Cytokines; Deoxycytidine; Gemcitabine; Humans; Immunotherapy, Adoptive; Mice; Myeloid-Derived Suppressor Cells; Tumor Microenvironment; Urinary Bladder Neoplasms | 2023 |
Inhibitory effect of liriopesides B in combination with gemcitabine on human pancreatic cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Gemcitabine; Humans; NF-kappa B; Pancreatic Neoplasms | 2024 |
FTO-mediated LINC01134 stabilization to promote chemoresistance through miR-140-3p/WNT5A/WNT pathway in PDAC.
Topics: Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; MicroRNAs; Pancreatic Neoplasms; Wnt Signaling Pathway; Wnt-5a Protein | 2023 |
Multidrug resistance protein 5 affects cell proliferation, migration and gemcitabine sensitivity in pancreatic cancer MIA Paca‑2 and PANC‑1 cells.
Topics: Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Molecular Docking Simulation; Pancreatic Neoplasms; RNA, Messenger; Tumor Microenvironment | 2024 |
[Nationwide multidisciplinary developments in pancreatic cancer care in the Netherlands].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Humans; Netherlands; Pancreatic Neoplasms | 2023 |
[Resection of locally advanced pancreatic cancer: careful selection and shared decision making].
Topics: Antineoplastic Combined Chemotherapy Protocols; Decision Making, Shared; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Paclitaxel; Pancreatic Neoplasms | 2023 |
Development of a nomogram to predict survival in advanced biliary tract cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytidine; Gemcitabine; Humans; Nomograms; Prognosis | 2023 |